<SEC-DOCUMENT>0000885590-22-000027.txt : 20220511
<SEC-HEADER>0000885590-22-000027.hdr.sgml : 20220511
<ACCEPTANCE-DATETIME>20220510175327
ACCESSION NUMBER:		0000885590-22-000027
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		152
CONFORMED PERIOD OF REPORT:	20220510
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220511
DATE AS OF CHANGE:		20220510

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bausch Health Companies Inc.
		CENTRAL INDEX KEY:			0000885590
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14956
		FILM NUMBER:		22911314

	BUSINESS ADDRESS:	
		STREET 1:		2150 ST. ELZEAR BLVD. WEST
		STREET 2:		LAVAL
		CITY:			QUEBEC
		STATE:			A8
		ZIP:			H7L 4A8
		BUSINESS PHONE:		514-744-6792

	MAIL ADDRESS:	
		STREET 1:		2150 ST. ELZEAR BLVD. WEST
		STREET 2:		LAVAL
		CITY:			QUEBEC
		STATE:			A8
		ZIP:			H7L 4A8

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Valeant Pharmaceuticals International, Inc.
		DATE OF NAME CHANGE:	20100928

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOVAIL Corp
		DATE OF NAME CHANGE:	20100416

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOVAIL CORP INTERNATIONAL
		DATE OF NAME CHANGE:	19960522
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>bhc-20220510.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:9acca3cc-2386-49dd-bd2b-e67723848b1a,g:d4f0cfd5-5dd4-484a-81ac-21ef5810b617,d:ff28e15b560342ab8a38d1fdf8fb627f--><html xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:bhc="http://www.bauschhealth.com/20220510" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bhc-20220510</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl80L2ZyYWc6MWUxMTM3MGUzZDY3NDg2ZTllZmVjNjQzZDg5MGJiNjMvdGFibGU6Yjc0OGRhZGFhYmI4NDI0Y2ExYjM5ZTliMjY3Zjc2YzAvdGFibGVyYW5nZTpiNzQ4ZGFkYWFiYjg0MjRjYTFiMzllOWIyNjdmNzZjMF8yLTEtMS0xLTk5MDc5_9005b654-7bce-4584-981d-0c4323d8eedc">0000885590</ix:nonNumeric><ix:nonNumeric contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl80L2ZyYWc6MWUxMTM3MGUzZDY3NDg2ZTllZmVjNjQzZDg5MGJiNjMvdGFibGU6Yjc0OGRhZGFhYmI4NDI0Y2ExYjM5ZTliMjY3Zjc2YzAvdGFibGVyYW5nZTpiNzQ4ZGFkYWFiYjg0MjRjYTFiMzllOWIyNjdmNzZjMF81LTEtMS0xLTk5MDc5_3af1d405-1deb-4520-b841-edee6ec198fe">false</ix:nonNumeric><ix:nonNumeric contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzExLTAtMS0xLTk0ODMx_04eaaa0c-20bb-457c-924e-608518b46f23">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member</ix:nonNumeric><ix:nonNumeric contextRef="if18ed4a9db4c4141bfff00c96c8d6997_D20210101-20211231" name="bhc:RevenuePerformanceObligationPaymentTerms" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzM5OTI3_716494a0-facf-44b6-8b49-d8fd0a7992d6">P30D</ix:nonNumeric><ix:nonNumeric contextRef="ie389482f874b41c39bfff2d72239425b_I20211231" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzQwMDc5_7eac39f6-be77-4d3e-9e6c-f409097e05ab">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="ie389482f874b41c39bfff2d72239425b_I20211231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzQwMTcz_d3eef5e1-5571-4a30-b1f7-7d9902542a6b">P1Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i85cf29296fb442daae3551dbbb86810d_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDMvZnJhZzo1NTQ1ODA5YmYyNzg0YjMwYTgwODYxYWVkZmNiZDIxNS90YWJsZTphMTlkNDc5MmViZmU0YmZiYWEwYzZkODAyN2RhN2I3YS90YWJsZXJhbmdlOmExOWQ0NzkyZWJmZTRiZmJhYTBjNmQ4MDI3ZGE3YjdhXzAtMS0xLTEtOTQ4MzE_80d37567-8b0c-4a46-9755-f1473d16ae0e">0.5</ix:nonFraction><ix:nonNumeric contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzItMC0xLTEtOTQ4MzE_4bf2464d-f080-463a-b82a-fe3327a6ffe8">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzItMC0xLTEtOTQ4MzE_ce76341b-5893-4112-b76b-f4aed3b43dcf">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzQtMC0xLTEtOTQ4MzE_4bf64393-afaa-455f-a448-662b6f9a6f45">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzQtMC0xLTEtOTQ4MzE_4de59f41-dcca-4036-87e1-e7e98c16d228">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzUtMC0xLTEtOTQ4MzE_339c676d-41f8-49e5-86a9-b2e8149fc1fd">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzUtMC0xLTEtOTQ4MzE_c6eaab40-e3c8-4b6a-afe4-21b28ab4bf11">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bhc-20220510.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-10</xbrli:startDate><xbrli:endDate>2022-05-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5393601523d4ba3bef1b785065c95b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="idc87f78bc74d4e43ab17c35afb0f8079_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8771372c3b94462beccdbc52f82e2b4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ff468ead247475a82ce446740f1f83a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32509de5461547988d9730878e48539c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib332d58601bd454bb89ede6b79782526_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3a6d276415e419fb9288f1aa64070ba_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i9065a4b181534b6ab3a847b07fb47561_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1d1a33a09fa48859e7e47fd030be3fd_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7651c2a37e9f49e9915cd978a12d1e8f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if72905c016ef4f1494ae44900f94a9fd_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbcfed5f24544ab594fad1395b2ed82b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c139d1926cf4e6c9d1ee8a32ee091d3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18439fe8345c481db53c486667ac6940_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6adf3d44da584f02a9de432de2320ed5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id70a674e2be94ffd85bbca114010b4f0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15c0150c538f487cb6591cfcbe5f75f1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i261c4af1d70b4e2395fbc9f9f1d94e47_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id967574fda7e4ceabaf0455646739979_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i119d0f73c7f74fc9bb4f33a268f1733a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i473f77fb1af344a29eab4fdfd6d3dd2b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3596f3678c0497483ac196ed8bec2eb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a73edc85bf74e808a3aec728f72c249_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9aca61c7e88b46d19ad0b86e6d3a2ecf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia032d22b364945dd81a246b3994295ed_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if43bfad251bd4331a051f408c738cf0b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10dd5d5cf93949878c6cc5089859a3bd_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f5bb32797ed4025b477232d70d05dd7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i052b9590a90c45a9b05e3dd474e6d8d6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d81998e18d049a795cb319c580e68df_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dca8f6ac26c452fa7d59299882a0097_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ff42e3612b54f43abc128d492dcd6b7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9eb6e474c66a4666bf7e3a85d9c998a9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f36a5753643489d88a4e0f82c989bd6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i086e5920df794c1bb867ec98391c2996_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia496362f6d164947b1a2ae170da89d4c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bcb5947fed543afb53cd6a3b48f336b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8bec50dbaed4dbea096a71456e733f9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i923a3743995f408db8308a2d12856422_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib105e1aee9db4b46ae7d9e203dadfad7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3206e4462f2f44e9860f3d0294412da9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b49661c9941455eb0cd3e84d7fac743_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b938a0322254b5aaab41c8892322507_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if33956ad61204d93933927de0fdb82c7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a6553baa7a24ea0992e7694bf3ada46_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28ab1aeb8c054aa1a4603d09d2ee8fc7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19f72ec10a1846be8c55a1dd70f9a9a2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11f91c7cdb5e4652b3582c04a13bbd0c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0aec0a6b31ac49f8b1539442f4d1de2a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69270432269b42208da3ba0a5f6c0c8d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i525200ba6a35425892b9fb1f4c0c7eeb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff498ebdd499404a95f12abea2bd55e9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e55e9853c474101a26d48d5ad7d46b6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19c82921041f4fa6b0c1e1a12a9800a1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="country"><xbrli:measure>bhc:country</xbrli:measure></xbrli:unit><xbrli:unit id="company"><xbrli:measure>bhc:company</xbrli:measure></xbrli:unit><xbrli:context id="ia62208ce4dc846f1ba9f111c31435582_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:ThreeLargestUSWholesalerCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="wholesaler"><xbrli:measure>bhc:wholesaler</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="iedf6d2b80161425e9e29520cc751a2f1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0a435d217a0443898aeb95a619d60b2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00e7a4ba81a046a790930dda41d3956b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0043ca6c60b448469dd9c10b6369a160_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic50c129d307b456db8bd6d0a3572b5cf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c6ea96094f24f6aa4162dcd33584114_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id111070c09c44a9f836bd940a8c401b1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5d7287ea6164d739cdd4537fbbcf93b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71d4507094c54c61a828a4ba28c456f8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i300d1bbfb1584998a64def9a1e591494_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcb50c382a0f41abb2ebb51d91d43a1c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bhc:EquipmentOnOperatingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbd918087d4845c1890cc471931bf4ee_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id51447b7e78f425bafc98f09b85f21fd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i975464f279ce4238b86edce4c77ddbe8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie756de63eaaf4535abb5aeced45c5b18_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia21b8496153c42c087eeb45cea371ca7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i490b2ed3d24b48e583bcdcad19e43866_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibeae95de06d24f9696ad1c74d3eee5f4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic53aa697e1c24a5896e49065797f9b0d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i589f537dbee5471e9bfcdc450bd648fd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b9398fd67264ccbab689da594b22ed4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36b171d0ac0f4d8ba4064dc0477f6b5d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie888db196c4b4c7da3187745b2f5d4b8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25b840b91a804c71b49368c35927a054_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1c4cad2abfd4049a17a50ff205cdabc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i775805d9c3154ad285c4fa424c1e815b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43f8e7fcb97b444098dc083e79b1b3cc_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5df68fab41b644118a6a79ca3701e13c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23a4bf59c23544509ffad0bea04a9270_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13a9ccb3dbd94a549431fe94a821e396_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4e09033a34c4a888cda3e4a5656b5bf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1941a9e694f34f33978cf055adb0230f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3abe2f197384a5faf80cf8970b4f6e1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb7a5a9f654c44d88f30b125fda3dd93_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id38abec1faf94c6a8cb3456db066aea3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if02ec4ff710b412386b75c6474100d94_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40cfa45466644cff8b8dc0f3298dfb6a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fc0bea60f3d4043bab8518cf76f48fa_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if231ab941291433d88b5f479ceaaaab9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i056b23d864094b3a8805bbf7eae8f62d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifac9a0ee97354de5ad0790a506ffc752_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f5af18d5ed449a39d9cf011a2c82598_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i968f181cf55f432d8b88feaea1bfdebb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i024019b8dc9d47e9a40e0391dd2811f6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic252586b20d24ab2b1f4c1e7d2d0216a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45c7461bce0f4ce88d5a315b0d9016b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77cd717b81fc4051b53b2ba09fbc08d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3217dc4fc80f4a868a33e3af520f1ca4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bc559ab6ace4d47880bb10942e52a2d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if642d30e99ba413e98c7c9fa16c98d58_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8f30533812f49bdb16ff48c59ebaf7a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if18ed4a9db4c4141bfff00c96c8d6997_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb0e80397f6a447584308760a43131cd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie389482f874b41c39bfff2d72239425b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65c560b8d709448ebce15c3e5d971fa8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7ab09da936244e1bea7e8bf2554b541_D20190306-20190306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:SynergyPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-06</xbrli:startDate><xbrli:endDate>2019-03-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3228597eb86549919c150d017affe6c9_I20190306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:SynergyPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieaf743deafab4bc2bccd438cce5fc248_D20190306-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:SynergyPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-06</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaffb0ddf4f849c6b6a4167f5b18f584_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:SynergyPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="businesscombination"><xbrli:measure>bhc:businessCombination</xbrli:measure></xbrli:unit><xbrli:context id="ic9f191dca8cb406ead6fbd0a27981bb3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">bhc:AllegroOphthalmicsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie23b3d96ce1248c98d46a1440bd6d937_D20210623-20210623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-23</xbrli:startDate><xbrli:endDate>2021-06-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id741d32018d54352affe7795fbf6464e_D20210726-20210726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-26</xbrli:startDate><xbrli:endDate>2021-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e7cb1daba9744fc8e55c867cd1d063f_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id21d49c675e3425b871866e8870406fc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b13ca98db8c463aaeed70c3abe4f348_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id64abf2e66454ecb8393494a9d2a34a1_D20200101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9dae4cbf28945e690c15be6b4c2db5e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:ACertainInternationalBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e08237054f64594815ad5013a5aa9e4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a1258a2943a4cd69dc73c01e660d449_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i405dec7379e74ca38494473ae3975347_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc79228c9dac48f29a1d9bd8078aa0c4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i813493bb33fc46b7a7a4c4b6aa9f0252_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationAndInitialPublicOfferingCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10381b45a049401593f3912db2562a03_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationAndInitialPublicOfferingCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f6583316fc34f2ebde02bee82fce983_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifadbfa9e788b43cba3cad3e76ae5d807_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7aec1240743845078358d61e36c809cf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2abe9143f14849f1bc9dd6da011f2cf4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3319185b216a47d3b6da5be2dc91b570_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia48dede4a3424904945186832465d56a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie64c787ebb9447d0a92c7295f0f6d419_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia04ea7b71bd04c6d9cf8679abe9ec99e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e44595ee4a14fcabb69571771959535_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78ba78cf61414c25a16502d502d685c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70b47e80f74944c99ac1f1b1f772d335_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie46f9e499c3b4367a00f89844e5b3e05_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia18f0da75a394809a608e7d0eae6fa53_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ecd69567c0b46f5b506f1e4c711298e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i440fa512b3bd4579bb8d93cc9d65ddd0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1313267327e41edacf2aecaa695623a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a6ca21431734f2b82ccc26320d115b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if285ca9b8419448ca0ecfe732b387fab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7727cda61cec499488b86e1b280aba86_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic622a69d05a04c3da2e6c078832136fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff786c33709b42768b27ac83294252fa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2ec169a70624d1a9715b177b9eed016_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3c641a323124a5e909b2269cea5b838_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if60700f229f0413882411855a4cc706a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ad175767e714adb952f1fc81f92fc67_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic25e35c549a54c708a26494e39477c78_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2313e85fce74e5aae451d3654b4cc63_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2543b8697622497798f72858198a9b4e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bhc:CrossCurrencyFinalSettlementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6236fa286e14aeabadb9f150267531f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d8c9c1bfdd840429f53aab587d9c839_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b510358d6854ed28e6f46e5f58ded33_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6beec5955f640bf84cf335c76410fb7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ac58aeb82cb4d5da0dc54736de89480_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cd1bac2236840fd955596ca631b176d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9eb64f96a45e4870872718cc8df9421a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c82f3651439499c885ddce82e4834ce_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i457c889b626f42869ba8488dbeeb08d6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22478da08d664decbeccb00e9738fd08_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dc84dac17cc43a3984fc9929fd5e294_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e1566b2fa444f9281a88fe587091171_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad637097d6f449b982fcf6ea6c568da3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bdd18e14d804d67a4f34d683bfa58ea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if472041674414bdeb5fb73f64f380506_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib426ea78162c4c489b291c4a5ef1bda1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida0fa648d576472480251eb6eb22d85b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71801473f3324db7b4ad384aae92fc76_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c9863c6c02148b280910bb43a45b30b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0159699620b14a238fdfa5d3fe9aea70_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic984dc5f62ec4772bc9ece326f420058_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="rate"><xbrli:measure>bhc:rate</xbrli:measure></xbrli:unit><xbrli:context id="i680eb79e17184399ba8ff57eb89e8ab8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafdb511725c04b449bc18c9f41f1c601_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bhc:MeasurementInputWeightedAverageDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98d1e9065dbc434ca6fa39e4ee7397d4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fa8c12aacc74d6b91c15b886f0f76d8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if32e75dc65d54621a38196e180c5052b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4908569b3b44a878e5d419525405804_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15d7424af8b443409563957178d9f029_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8453f3b3b4c743129918b8a8465d47e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica46ac5deb7f4bca98fd1442ab972fe1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00e41fe3c6f64b2289dbd0cd45fde7ea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0703b0cf397f477687f950dbbe23e831_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ca97df2856842dfbaf44ca3f738a575_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib66efd6818984bf8b7ee621516776ce1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia03371e98c434dabab65c558c26cca83_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03f09b98a2794ea19b27978f0c0a73fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i794b0cd648154358b5f12e82f9710bbf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55bc00875c13421c8e7ef466a6e806e2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5486904f53c94726b49a9232f4dcb0d0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i802908ddd2fd4486afb3bf31d0d9edd9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2600359d03bf4008a75ebdf90c246dfc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b77fdc1142642a0acda999683173c6e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bhc:OtherEquipmentAndLeaseholdImprovementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38dbc214d6144a758e35f77291e56b5c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bhc:OtherEquipmentAndLeaseholdImprovementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida44475894334e22b76c358bb055a53a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bhc:EquipmentOnOperatingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6649875e397846f2945b7974a238e07a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bhc:EquipmentOnOperatingLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied26b295528f43e08d519d8a4f061068_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e5b883341944b8591f5c00136de5e09_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7db43bf7c3c4b4186ebf9e2d3d12935_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iead8c960de884ed6a2da68f1c9212534_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i118c693b1f954748862447902a5683db_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a7c179df5a84846a54bcfeb13c293e4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8d0b9bcbcff47528293434664f12031_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0141b3d37c034975b5525cda87681171_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c05dc4d9b434c80a5cbd4af3c7c9d01_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie35bf5d8694c4774974b0abc32f8fb13_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idabeb53d68674574be9e8bc3a04fc023_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03fe969473114a429bbf4edf40c1b1b5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d77acb3fa444b01a7222031f5d4d6ea_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b81638d52a34a33a0380c8dc68c21d6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i240a15f4864f40c195868e118ea13730_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ba67417f7694417880945ef3a458823_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ac6cd5788244ea0b4e00e55c970a88b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4357b8c2815049e2916abd0dd4c84a5e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bhc:AcquiredInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68da001337c24191a51c93ad8d98f64a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bhc:AcquiredInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c9e8270f510440cafaaadcad18b83e9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46550d37e139414ebc038a9317b297af_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdc79af88d674986aa0a6ba7cb0f5f09_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i846ec01236d9492bac74fd5461000270_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:UnutilizedITInfrastructureImprovementProjectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80296fd237314f53b6c594ed566c42d6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:ACertainInternationalBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e1691abab7e45ce93d9c7cf06722945_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i993b35454ff842d7806cb59a463ffa34_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d17c5bf6d9841eba3706e1d48dc6848_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bhc:AcquiredInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5392c04784e4d69b6bc3a708883efda_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20a958bbcf974985879a206eeec09656_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:CertainProductsForDisposalSeptemberTwoThousandNineteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3596e67486c490b9d96f6e6a4bf73bb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i525a2c44053046a38066e353d995cc61_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bhc:AcquiredInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29a1b1fb5e7d43a0a5704750d1336b1f_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c3d9b6375104575a0b650fb85f1b280_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94cb38fd73a64df9bcbf981da8f70e3c_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id466e6e6ca4d4b5cbde067689c3faef3_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i417dcef94a21464c8f3e70b1b83c913c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba8428875eb04c3490fd83250b59b893_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3dfd5b244cf486d987b952dbf744f29_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba148d40c69f47e983b912769213931c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f812afa0f2f46a5a00813ce760a5ac1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53ea644df00c4c18a3c89f1915121a44_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25de128371b34a1f9d25e80a34d0887d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i305ad186f05a46689ddd955b46c78817_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9106cb312b894b4fb0e6e25a1c2f3229_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e7e6c0540534603be58b450ccc6ebd2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb7488e0749d446eabef23fd482eb625_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cbcad2018a947ad8f38faccb79805c0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i414fba28824c413593139a2e4ef76d21_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied7527e9c7f3438db93389c0a1768d2a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a5a9e6c49d742aca8267ceb1bf314d3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3328d4d641274769857018f609cda173_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea2db51516f74749bd5cb23d69094522_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bc870f8e27c47c28a8e424dee7145fe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9aac4f4658b94a079f835ab8b92e3d71_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1d8a07e1c514b0588c2be7cad93ca17_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5279cba8f1f4e03838c2449f0a36169_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ccf39e3c6294658af0ff9fe475686ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf7ffc6e85884b44bb020321c2fcfd9b_D20191001-20191001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib12ef9337a854b11b31304b6e0c0205c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7127e175a3854e52bc0c75d9ff20c0a3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1987990ae2747de8eb8993bcdd37868_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cb87466591741d69c11218eca97afee_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:ReportingUnitsExcludingOrthoDermatologicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98b90ee22470425788f2889f17244951_D20200331-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-31</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i699a9e7d09c64c9c88f463de1d97f137_D20200630-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-30</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30a1d9b6c3d84763be8ecc3f1d79f317_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d5b8f902e834dda885bb99a7a2bb489_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6080875e0e1f4486a08e3dc0c2dc6319_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21115bf566934307b8091d4d727aa2c3_D20201001-20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86c894299d29409ead4b863813550b86_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a2dd9a9a7d04b008adc3046b51f7059_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6202fe446ad4ef9a31cbf50a8342593_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icded4b5feb5b4918af206e2655141f49_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice067f6010c74048bd8841e74a7cef86_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47d8b26934ee4498a7ab3ff3fecbfed7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ea718d72ec4448ba2219818acc2f6f2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe79965a558440f68c2f201ffc977e8e_D20210331-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-31</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd4661795c6d477dae3ccd804bc808e8_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d4cdd25b2984038a1406bacb8cdc3dd_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90bbe44e848c4111942574f93f21895e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b861d276efc40a681c82e2398b819a7_D20210630-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-30</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75ce7fc0f0264a0f904c3a8cde7de3fd_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfae6f80e7694be08e982fe5786bd632_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if40967e6d4d3497cb45e304881c2d2d3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>bhc:segment</xbrli:measure></xbrli:unit><xbrli:context id="i711dcf2b52cb48f98fc1cf3d97a987ec_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i969d616487264ae4b3b65d39984bbeda_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22c93f5e835048719e869de028b61cc3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc44ed8e69bb43ea954db330ec970a6a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie889e70e297a454da84ecd8e61e4957d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="reporting_unit"><xbrli:measure>bhc:reporting_unit</xbrli:measure></xbrli:unit><xbrli:context id="i707a0a1b00b141a28c29e5d5fd1faa7a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fd6185a911a4065809d6e0b5f61c3b9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib49f81a33d864365851ef46a13cca29f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fd3df09e61d4c56a4826cfa2060c2f1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i537bc84d95f240518063d4d8d3b870e2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d40e1f7a1c14a28b74752dcba680ada_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6eb226ab9604bf188531181e371079e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes7.00PercentDueMarch2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3248199cb70749178b2c7c4fb4982735_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes7.00PercentDueMarch2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06ec3dd3dcb0438eaf3aebc8db3d319e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a77d52d62824a7cadf4ab72fa8e094b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i557d4dca2ccb47e682e75358f752e842_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40edb907b7044d23b89c96ffb68d67e9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fe84f0ae9724529bf29568dbbffd5a3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bb8d72e3c074630bbceb17545ec7261_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2db39af25b1445a1b1d39932a08c5fc7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfeed60331fb49708cf75fb16367305e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3daa9b4fd734cb7af4bf16715ab23b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e861b64daed45ebbe70114675bf535f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8827aaaa75144f59a8e1bb3dccf8fe3d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad0d1a99b6ec42b9aaee8785c8cb6f79_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a929eccb9e64e0b88c64d38a28ef190_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a25feedc2bd4f438e6d127ea650e095_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03f92fc0786847c3b0c496e8d1603888_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c0dad67e3784bcdb5a6e6f002cd9ee7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4315b5a6bf3449c790d05b0d6ad5b10b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43b03fff47d14db7bcc1ddf661a8dc92_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46a9772e12364383a02b198038550550_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic87200a1dc2742999c99925809369c99_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55ad7bb0a54347dd9a4596d8be5b8dca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f0cd0c7bcda47b38d01957e2a3bc327_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c5faf2607ad4637a05e98dc5c8875c4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19dcb028ec1d4e60aa66dbeb559a420a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0249a1288b1649bdbb249d5ea07218db_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1627b94e1a9a4cca93a1bbe3b864cf4d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06254af032384d79944c4fbf0358b2a1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f9e33e485084fff9d0c81867c005c16_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4e37ee467534e15bb29330c819bd784_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic10baeef95084b95a40fdf0c4c004831_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27fc8076f1bb4e4fac0065b5495211c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c884d2a677c46099dc4bf036009410a_I20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e81a6b0b4494ea99594e7ae61d6e7e2_D20180601-20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ac7b4fdfdf54cca97131f28525e6edc_I20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b48943d62f64d77bf275084b850c10b_D20180601-20180601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icca812a26f644f92a7e1f4a986e51c00_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bba7bbfcfef401787d57a665a8baaab_D20181127-20181127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-27</xbrli:startDate><xbrli:endDate>2018-11-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i122eb939c38343d79b07091d8c902050_I20181127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ee961e3429c4173bd50b3e41367ad7c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia998a2f7b86b483b983a8b3498ae44fc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i388ac421c82b49c48346643fa2ca8a0c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i984c72f35f464a9f992e3b3b631f4b0d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6084b059746d44c2acce81065d562b57_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:CanadaBankersAcceptanceRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7840f0b2e2b48f5833d3f0adc12fa7e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:CanadaBankersAcceptanceRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2fc98102d394e23ab05be5028d334b8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredTermCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27aa31be484b4e9b951df5511db3cc35_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateOrPrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d1c850c7eb04b9a9236112505ccf265_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateOrPrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i084241e0c0984f30b029369bd43fb499_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a3693985875498082ba11e282f4e79b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a7a975faf994c36a88b4e0e0eb6800f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e2ae2d598fc4a64a6dd097539edef68_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateOrPrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd51dd72613243c68aa536db0dc3c70f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateOrPrimeRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i302db430cde9461f934b806767f52349_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b262c356e2e4aef8c99010988af7e67_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77d8c4f932f64c7ab48f7c0ff10b8a3a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76d8b3b4ed87466eab6f101ddcb61ba9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i558d07c8b64a40c8b3072a4379c5db37_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3089f6878ad144f5971f1a990ab34d3a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9abd9fd4a3d4f839584c60b7f287d72_I20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes6.50PercentDueMarch2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd735e6d7a4a49c4a31ba11a3b55d3c5_I20170331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes7.00PercentDueMarch2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i449725090bcb4e129cd4dff2677ce289_I20171017"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17ca0b3ae0a14541b95a0029b74fc81f_I20171121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i426ecf59adef4723a9464ff7dd035235_I20190308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4d5b348d3924c7286e27eb049dcb072_I20190308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A8.50SeniorNotesDueJanuary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i234da319c3ef47c291bbc91d590a7fc6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5875SeniorNotesDueMay2023March2019RefinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b7290e999a74c9f84f1e1f0dc4acadf_I20190308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.875SeniorNotesdueMay2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60523f26c0cc421995caf64823d36f89_D20190308-20190308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5.625PercentDueDecember2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-08</xbrli:startDate><xbrli:endDate>2019-03-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7107764faeb3461fb0c3e1558afa09a0_I20190308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5.625PercentDueDecember2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia554f95ec9dd4a30af67e386976e2ee4_D20190308-20190308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.50SeniorNotesdueMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-08</xbrli:startDate><xbrli:endDate>2019-03-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c3fe314a07b49f5a24c68a78aa7c617_I20190308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.50SeniorNotesdueMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4a78928619a4fbdbb34836a1b0fe3dd_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5.625PercentDueDecember2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55f45e1ec8754cce8219f906d738aa2d_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotesAndSeniorUnsecuredNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefa733ef7c794dbaaf6199d058362bd6_D20190308-20190308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-08</xbrli:startDate><xbrli:endDate>2019-03-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64a0081e7f7a480c9031042be2e2e776_D20190308-20190308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-08</xbrli:startDate><xbrli:endDate>2019-03-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eb18dd3d80f4b20be43d6f02dd8ec59_I20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide09659430754a848ded8babd4ea06b0_D20210608-20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueMarch2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88ac47eb607d48dda7da8b2ce778805a_D20210608-20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c34aa862974483ea57b2b1d0e3c0f03_D20210608-20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7d99baf53a5465bbbfe961490f008dc_D20210608-20210608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fc30bcb84e44522a8af652f8f8ce17c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd5fa5a50ddb47ce943d25e5158d7fa4_I20150130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.50SeniorNotesdueMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-01-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6d83e37326d4725bc725486444bd866_D20190523-20190523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.50SeniorNotesdueMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-23</xbrli:startDate><xbrli:endDate>2019-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dd5787480294fa2b679e5d4885e9821_D20200101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.50SeniorNotesdueMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc9c834100a744ec86cca979fb7b31ec_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.50SeniorNotesdueMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fdd4332ca4c43c99f6dab6dd5f1e32f_I20150327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.375SeniorNotesdueMarch2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia903bb7aea2a44119bda10563a043e40_I20150327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.875SeniorNotesdueMay2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedce2bbbaab64fc79908a3e30f8e6c65_I20150327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes4.502023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7040cce3fb9b4eeba357b284b09231e2_I20150327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A6.125SeniorNotesdueApril2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="id9f599c080f5467ea5baebd9fac485a0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5875SeniorNotesDueMay2023May2019RefinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if99807b8eead4d89b01d9fb9a37fc251_D20191003-20191003"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorUnsecuredNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-03</xbrli:startDate><xbrli:endDate>2019-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic53f9efb99aa4ccda95f61d26890a343_I20200116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorUnsecuredNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if94fac52f3f54b40b4fdd01288bf1861_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorUnsecuredNotesDue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6298e5d16674dff95b3e998b6c37203_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4177e1b635b74d889574e58be568dee6_I20171218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.00SeniorNotesdueDecember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a8941f15dfb40e2ad916e87ad8d78c1_I20171218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.375SeniorNotesdueMarch2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i719d98863d0149828286447cfc21c537_D20171218-20171218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.00SeniorNotesdueDecember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-18</xbrli:startDate><xbrli:endDate>2017-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5f75d74fcd94b378a67e51f53cdb29a_D20171218-20171218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.00SeniorNotesdueDecember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-18</xbrli:startDate><xbrli:endDate>2017-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7a91ae9c014412285210f2ad632343e_I20180326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.25SeniorNotesDueApril2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2277d8eefa0b44fba997881be7afffec_D20180326-20180326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.25SeniorNotesDueApril2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-26</xbrli:startDate><xbrli:endDate>2018-03-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i177b63c1f7f747e3b7ccc3613e2fcaa8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A8.50SeniorNotesDueJanuary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4c76c9931404817acf913b8360dbb5e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A8.50SeniorNotesDueJanuary2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i797b2df10ff44b2aa71c461fc27b30ef_I20190523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A7.00SeniorUnsecuredNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc2d2ee34b9d4af8aaed19ac1ff2667c_I20190523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A7.25SeniorUnsecuredNotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c71c44fc4c34b9bae672a9f56dfd653_D20190523-20190523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-23</xbrli:startDate><xbrli:endDate>2019-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c637f283ab04dfbbbfee6141ea6b782_D20190523-20190523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A7.25SeniorUnsecuredNotesDue2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-23</xbrli:startDate><xbrli:endDate>2019-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if78fcb7d67eb418892f72d087ada3247_D20190523-20190523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A7.00SeniorUnsecuredNotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-23</xbrli:startDate><xbrli:endDate>2019-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b69c2b55c9f49159ba0241d1da3b1b6_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.00SeniorNotesDueJanuary2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i707c6ada63c346a9b3799fb37f228dee_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.25SeniorNotesDueJanuary2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11d7dcdeb76f46a1ac2fb260dc29bf23_D20200116-20200116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.875SeniorNotesdueMay2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-16</xbrli:startDate><xbrli:endDate>2020-01-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ba274da5cb54b1daae13438db70ae34_D20191216-20191216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-16</xbrli:startDate><xbrli:endDate>2019-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f688b41850c4d0fba418cbe194ccfbe_D20191230-20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.25SeniorNotesDueJanuary2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2019-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b0d3caab19d43358c37172b00a1d73e_D20191230-20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.00SeniorNotesDueJanuary2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2019-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23b34418de5747bc96ac966e1bad4561_I20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39f28d2202204cc1b5a777f81170474c_I20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes6.50PercentDueMarch2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0649a2ad7e34fdd9c9aaacf95248fea_D20200526-20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025AndNovember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-26</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79078ef3ff22478e8ad56dbe5a19750d_D20200526-20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-26</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80f3eb0d6a794c4dbf060750dbc6dc48_D20200526-20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-26</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a0f2471e7f44074809037b78de94990_D20200526-20200526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-26</xbrli:startDate><xbrli:endDate>2020-05-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d4effd4ca8849688cd2273c89e716e3_I20201203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i374367eeb97946bcb6cacd5888eb32f6_I20201203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id77d7960c24b4e4a865ddd716f13ec49_I20201203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes4.502023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd85aaaa25cc479b99bd4e886b1c3240_I20201203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes550DueMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i356651edb41c4b0a8e39c4bd624b498e_D20201203-20201203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes550DueMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-03</xbrli:startDate><xbrli:endDate>2020-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id78465b77ff94c179049b8f8da315bc7_D20201203-20201203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-03</xbrli:startDate><xbrli:endDate>2020-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f524b83d2a14769b88a62af6ce78e47_D20201203-20201203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-03</xbrli:startDate><xbrli:endDate>2020-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85ca12bc72e84e42b58ea2d217fa1aaa_D20220211-20220211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-11</xbrli:startDate><xbrli:endDate>2022-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e619b455ff146759a2117b1f93fefb2_I20220118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.00SeniorNotesdueDecember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib440abcc71694fa09f8e1ad1955b47b3_I20220210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85cf29296fb442daae3551dbbb86810d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredTermCreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f9960dff77240d28dd966ea114e1dc3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09794c3bfd084a82b2a8672bfec8f4ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:IE</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="defined_benefit_plan"><xbrli:measure>bhc:defined_benefit_plan</xbrli:measure></xbrli:unit><xbrli:context id="i0da6a354b78d46da85ab05e0768ba4cf_D20141201-20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:IE</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-12-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fe9a8f118334aab8ff6bd90e126b597_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14b494ef22db47cbaaccc4668e7c1b84_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icac9bfd5e8d54c0689a02e2e251a39cd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8813f768a6d40a090aaffec2d906007_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if38262082aca4b1ca51d9de262b48c77_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6a73441ba534c4aac153b012771c389_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5d47857632948b3953696f970672168_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b7fae28641143098c895dc923ecf268_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60dd7747d8e84735ad54cdac6b306397_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75033e6771e2462a948d8f02b08289cd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i463e7100cf0447ed909a1b0e9a750265_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77e60ffa0a7048b3bc6ab71dd3ff10d2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idea50cd734984c47856762240b1f1a02_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d64985a4d524a32b742dc7857f893e4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a24ca36ef784ec8aca560e12794804b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56ca37936bae4988b7fe9d7260b0cb9e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72013f8a77a84d8ab1b6625f3d57d1a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i180a6063ed294b858f6f1b7f8889f355_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:IE</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9fef24732ce40f1b0ecd84c613bcf34_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ed8db4899e1486f9838d297668a6b15_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:IE</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75d6d22fe7ca49c89901fff21f7ad775_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69b3efe62ce6415a85977af860ad298b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c0ee6030b5c47b0a466a9c0070795c1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id92890a272ad4d899e7c6ca96512a97e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i149842c6f40f4c6b98cbccfc257a922e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i564973e386674c78ba408d13105b6bb9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia227b3e9ab7d47569890495351afa79e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba0dcccaa1ae4b01bba40ab426ba276d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fd2da8ac3ce4d44bbccc6dac3b7d322_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib00d5eeb7e7c4827bda09db46a2b4b1d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36fefdbf2cff4913b1f038b13bc2cb55_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id521934ae5cd453d9101134d84a1626d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie612fd61a6d44af9a15649aaa2d9324a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bc3ec72daa042338987d5ace9cc9c8d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i508b730bcd0045f397f719f04005991d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e4425ac2c7e4b668baf3cbbb7ae8f68_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89055898a93c470ba50888d0e49f6b0d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8ab04904aed47918dfa94bfb170c6d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2650274c9924895bc8990f8ebdac630_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06afb70ae6a84cb4ba00bb19a81c46b5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i719bfb4f085d4c0687d6a46f624c525d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66914e16e0af429cbb73c75ef6994478_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37752c8772ad4c29a5c583152fb1b1b2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c903c7579724e20ba48c46c10b81489_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89938cca48aa4028b0c54c7484178623_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93955a18cd3641cdb2827cd853fc1b10_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa2bba98ed41466c8eba7b037cea18ab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a9940f2b3284c0aa162120bf8b40dfe_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5229d9d0142d45cdb60d7849d3a88d6e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3c37ec3412c46a4893efcd62fe0f8fb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c6eb4a0a10d45f7a7eac6ac330e192a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ada422ea708495daf471908c27e5f60_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ea389b2765d4a4fafbd53999a35bb35_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74064a651ca64c52b9baa2296bd46b02_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieac386533ed94ed9a1fef188636cdbb6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ea8ab4572664d2591c8cb715411dd99_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bdce432423c43a8a10a88bf483dc5c8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4956f9b1dfe045249f6c89ed5e3c029e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab7cb7f147434baa9c2c29c45db60a33_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i924b51a174a64385823aa357a0e7d2d6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86b804a160e24122a58d7bdb3e3fbf73_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife79e98052444bd79079d82129a7420a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4826dfe3433b4c8db9be32ccbebd4288_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32bbe248bdd14f98b8a37a069861c416_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica87f2077d3b4d10a04094762892a8b9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica23a5188b6f4261abc044904c51cb8b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a607fbcafdf4f8f9686e30cf1341551_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i485c30c6aa2a43eab8ca4aca9b70a7d6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2fe2902fe4c41e5a9916ee6a7bd0a90_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9547b54812bf44caaa56e89c1c450612_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23a29524779046dbb6c442615652d8ec_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i734a347aebdf40829771a9719601c1a2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b1173f2365141c1815363160c16b76b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26f1f9b48f334ed1a02e13e365598828_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifae30c4aff3d4a04be56aae506f89f0f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbf7a924becb4619aca1895ebcae9add_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1912d789a0c46d991c0a3481ca5f6a1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52de4cf8c1b0450fad0734be23582658_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i573fd8e898604de1858ab39ea3a2f4dd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac7f5ab099cd40b592114ecfb3acc77b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac4d46a037ab47089459af1054a64149_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26d6737e6a7a4e638bdb45c231ed9fd5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41d69b7357c9455081525dab7d356749_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64de5046767046de88a2974a3167af0f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee2f17c2a4204c139a5cb4c3ea8be354_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd8d218140314ef584532f8f6d286341_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i235dff73cd944ced95f474c54f791c38_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1613dfe248574162a0b44c0c9a6b5c54_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b79635c2ffe49ca916192dec4f287c6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib51448370c174e5ca94ba98d05fc89d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac7d05a36d0e406b93de498c08fff242_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5829e60e9724608908829f25ab1d7d2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d0c98de7cf64efd96dfbe09aeb5ee81_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32e3ecbd002a4e80a35abbbbdc4463e7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90565c4f71694e28b3ea6de13e2a5891_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie31761652b084de784cd258f75f2ab5c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5dbb70148a946ea9172055a4c675214_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2b24c259bf14e85a565ed910de3fe12_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i848b70ed1bbc4567bfd96cad2f56686b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80d8aa205290445f8909c5d756177c51_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia47563e74c594e7b94af08bf1c408bfa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd5049ff38de4a8c965af08e2994ca04_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd8ab02c4da8460891761a7202ea7fbb_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccd41ef2d6e64a15b9d909ae1d8e22fd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96121b9d867041058111f2cfd46930a1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1798ff527d09475a9e91083ed73cef87_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac0b4c1d18854f90b18c3b8d1b65c5d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i341cd2bb05814777ac5eb1149ac11deb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a3d63af67894f27abf02eb5401cbe40_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1498ce58934451fa75a98f7dcbb17dd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a556e59b8bd4005a138e1541662bb46_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebfe537a4e7b4899829b3ce5a6812386_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i122fb437432445bb8b94f66c1352498c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d8ae058e10b42b19b2b7a51fe102286_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9920661ad081431584fffee6621bedd1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0debe97407a4a29ac76598d242abe70_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3f9511b3ce84767b0cd5dda4878a1d8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0d196db8de044f7b096a26f568bcc2e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7166c1867db42a59946692d872ca487_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77e48c2c77094705a53af852b1a9d72f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifef414e1cacc4427af5c130c1dfb7069_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i562a1c1d813143b387a1386991ee371c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dd6ff8969cd46219034eaa9f922cc63_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67a8b38165f445a29651dd0163d7b97e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fc0e0e6cfd34b848a4329f6b2d4eef1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85a230e5f81a48c78ac96f0556ba1bcd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55a8a69189ab41e4a27cb0653b591709_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01a935b5313744c69b2134f0706843b3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia283fca771744c269e37b513966bcfca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib78c157abc13457fb3c2ffeeabc6887c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib31507c35e284e299c5a447d87eb3bad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief04c0c77f754c4e8773310d3f3f995d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4abe5fa288434acba436f3607616486a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a1c231876b24515b9cf5290b20d8497_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4091e0935746423e802930a0a249f3ab_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icced8c77467a439ab94442205659b698_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie78131bdf4944cb4b7835bfd51e69c57_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d6663b8d3354af0836780f9a3ccb7d8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i819974f0d173482a87f6215140f5cd12_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a4ba4ae2f084135b4c3396a39a9e4d5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a1a9199b6b3495db74904db30ace49f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90b3621ef3a04a7e80b74c2ea9544924_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9b498085ab54167830633419e66f3ce_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if783dd84203d4097828a5dfcf36b9360_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3617a1ce43f34e31b97e8612dceb1bc9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fdf60201168414184b8e02445c9a52f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38f0c1c6c791466996e0e14977fb3043_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27c4a253513c4ac885cb55c4a07909d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieabf485ffa9b4b01ac91c9afed822bd0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i991e579e87be40ff91924707db6a6553_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e76b4972fd740e69b695e357d4e25c2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if13b91c47c564e65a71a7033d532765d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2043342d86cd4a6280d52ee1ce7e996a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9788e7d7947465a8b5827eb980e4f3c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6361735a69df45b5bec1a681fbc6e116_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:IE</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id943b700697244c1a9af35217a5014fc_I20140531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6006b5cfb8f34c728d0575646bfaa31c_D20180430-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-30</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9c449e903f04beb9f713f2df4efd6ca_D20180430-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonemployeeDirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-30</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d0c600ff58f4f0da9f1d4e553efd25b_D20200428-20200428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-28</xbrli:startDate><xbrli:endDate>2020-04-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e2ddff148e045819b4c2a2baecf7de3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f3083202c7e4f36ada3cfe487b44863_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69f7d41ce4b642209bb25ea9c478625f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00aeb13ceebf48e891b516a2d0c221d3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c0144ad2365471881ed18f7ced989f8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dcf40ad82c34f11ac4a925dd47873ab_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b764cf71454461b9ae558f095cef352_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i169ce44b8b6147b5af92c163ff58f3e3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25d8a1ce6eb4407f92324a3e68f2013f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbd1e5635e5040f3a9121f39e9238a50_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bhc:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib100363bb61344be9b5ce0d1f32e9248_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bhc:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb7848e770bf4984a2093c22786e7db8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bhc:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id87fa13c036e497faecb209787ce467e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecd38b28e9a84d1880313b43be4e32a2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7384f8f25998459682939a04e6a9c33f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if57561008d804ce4b03b997a95d4d41e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d3ab00f203a4abdb121762625a88c8a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01666d0d4a034ebbb396a9f3c3378737_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if15c6a218d7d43c38c67bf323a224454_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45c56aa08db349ad9a3b4168267b7511_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cd01c5e13964b01922532131f0e6d49_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89368b0fb9454b688b6e6dde554c44e1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29af68bd8dac4b57b173b5f3c801e3b7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42196f5311924fb28aae7927e03f4954_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i071c8dec838c4bb88915169735766953_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5e547542b4b4e4db07d76b12dbfa958_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i403b5b7721914e66b5361779547ecaef_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54c4a51199e24aa0a3d6a1ec87ede263_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if92bc6c46d244c3788aeab448cab0a64_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TSRPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b9e26fe691746ed9f535f3800019b25_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ROTCPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf752be0eda64aa790f9f6d3442bf3f5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:OtherPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3c11e633ca64c359eb1f4e64ed9945e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76387c207f8f42439a9c69184bef25d1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66760525c1824001967bb86d988a25bf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ddbf83e6ad54de686a53b50675cf560_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cdfe5b964b94b969e2829780c73f7e9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bhc:MilestonePaymentRelatedToCertainProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibffc30cecb9c4ef0b327417dbb601c42_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f6b4de2972a45b48db5cc52d91b1a88_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if84d1523bc1740e9b7b6df3d57e513ef_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i915068d30e9c465eb1028aff329712ac_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic055386399994346ad881ca91aeba458_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67ba81224f654cb2b0f2010018455b61_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id379e27a083f4bb1879222afc10f82f9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i187c9f9f5937400ba090ce33c5c46259_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie80a8d41d8154b9fa08ad7c9d7849024_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27ecb8e5fdeb4e02bde51b102f8143fc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib41b4897f8fc4d62a5af15ed7e0950d0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1d46f5c753c4613a41c0b24b7215d74_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">bhc:PooledScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64fcc3a1ff2b47af8fa496e471287739_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">bhc:PooledScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a91733048244e1caf9bc10fed86c62d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie95a42cdf2a44bae88536d5e9143a530_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6d550dbbfda46bf82a16f8ce10ebe0b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:RevenueCommissionersIrelandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i541042590f234b388cebba5a8ab708be_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:RevenueCommissionersIrelandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="subsidiary"><xbrli:measure>bhc:subsidiary</xbrli:measure></xbrli:unit><xbrli:context id="i3981d7a177af492eb4fbd78ea657ad8f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a701334d8d94a828739c539bfb11dbf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic261bd3e9bfd4d98ae7b58e6abadcb92_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c2e628003764836a5a04489d83647f6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90867327964d4767846d8c36adbc2e43_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4e269c5fff94bdba040ffb57118494d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65523828a01044e59ade22a5ccb853d2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c327fe5449c48c48e8d5f0372ae6137_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib902cbf8a7fe4328a5114bf1cab23702_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c126541a8a74e41a63df4a34dfd968a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96392c49eef14e5988d30ce53b0250b0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:IE</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i031396881a4b4914914165e52a669249_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5eb8fe6d6da478c96fbec9cb03cc330_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:NL</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie47ed3dfd2114787b382d6779d753245_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:NL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i966ab6abce524555a38770e32731ec1b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id73c90871edb496a8acded32a4868495_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5656a30a453e4f61bee5ce805d141aa0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:LuxembourgInlandRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf6683fc8f2a4c7681664da8552f7c19_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:LuxembourgInlandRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ad0eba196ab4a07a56009d4610284f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">bhc:TaxYear2005ThroughTaxYear2009Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:context id="i3a2b5c5adebc4e62b7d64a5d6bcca25d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a6621a8c1674dbc9a844087860a0e82_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bb9780df86a4065b01b2469abd59faf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">bhc:TaxYear2015AndTaxYear2016Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if92917964a2f48fc8d583659d90471f8_D20170808-20170808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-08-08</xbrli:startDate><xbrli:endDate>2017-08-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i794db5d83c3641aa853ac4acaa8182e9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i426b648515c34755bb623ee81a4f1ae9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0aaea235b331445aa69d79ccdb7823d4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd3e00426ff44f65af5c22541ee8cb9a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84aa0d0a4fea4c29a4fea75d90ed7794_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5998f35e4ed44ab4a12b43f529e4ee2e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i647e97c259b643fcb29ab0bf3ac45e1a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i574ece8cc22045c08b39e4da379ec989_D20151001-20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="case"><xbrli:measure>bhc:case</xbrli:measure></xbrli:unit><xbrli:context id="i546776d7d59544bda0c885c5725afaef_D20211231-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:RestrictedCashAndOtherSettlementDepositsCurrentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-31</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a8688d163da4bddb3dfdc9ef920e0fb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="group"><xbrli:measure>bhc:group</xbrli:measure></xbrli:unit><xbrli:context id="i721131c964b147fab4e1a6b8f95b4460_D20150101-20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i522c83d185a3433eb7ebdb03a1574f39_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="action"><xbrli:measure>bhc:action</xbrli:measure></xbrli:unit><xbrli:context id="i3d14d3034bc54cf58ac8ef0977e6b643_D20200804-20200804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-04</xbrli:startDate><xbrli:endDate>2020-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0288b667636240ca9edb0931e9570cbf_I20190215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="entity"><xbrli:measure>bhc:entity</xbrli:measure></xbrli:unit><xbrli:context id="i7a3cc564cfa54644914c3dd2984b2e99_I20210317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="numberofbusiness"><xbrli:measure>bhc:numberOfBusiness</xbrli:measure></xbrli:unit><xbrli:context id="ic99388c5fb8449b4b2899f64833edd24_D20160527-20160916"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:RICOClassActionsLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-05-27</xbrli:startDate><xbrli:endDate>2016-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib788085ae68b43f5be26854e2e649395_D20171207-20171207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-07</xbrli:startDate><xbrli:endDate>2017-12-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="insurance_policy_period"><xbrli:measure>bhc:insurance_policy_period</xbrli:measure></xbrli:unit><xbrli:context id="ia2292d9d54a74b14a40833c7ee03e2c0_I20210720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="insured"><xbrli:measure>bhc:insured</xbrli:measure></xbrli:unit><xbrli:context id="i10b5c7db69ef4006bcb53437d3aa06b8_D20210720-20210720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-20</xbrli:startDate><xbrli:endDate>2021-07-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d3399dca8844555b1a0224ee52572bb_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:SandozLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i416608f63c8f48baa9c46a05acc57dba_D20200828-20200828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PerrigoIsraelPharmaceuticalsLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-28</xbrli:startDate><xbrli:endDate>2020-08-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20d7a644460c4ab7b2d3fc7e95d5d3c7_D20200501-20200501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PadagisLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad566679ccb740d78397815ac12d9b44_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:MSNLaboratoriesPrivateLtdLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9d5c1c1399a4c59b08e7d331695b3a6_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5f2cff0c15c4497abb7c0bb38853653_D20220202-20220202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LupinPharmaceuticalsIncLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-02</xbrli:startDate><xbrli:endDate>2022-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bdbb266b2064e05970e5019800e2253_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ApotexIncLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8167d807dd934310925525373a61a11f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowertoShowerProductLiabilityLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b8fdb21d7d648d59dfb6f5b8647cf38_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7ca0340304c47edaa88616e036f7daf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowertoShowerProductLiabilityLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2a61b2c466048d7a44cf2f37e6f9067_D20211216-20211216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowertoShowerProductLiabilityLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-BC</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-16</xbrli:startDate><xbrli:endDate>2021-12-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4161ab534a444089a14221908e89ca6b_I20211215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowertoShowerProductLiabilityLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-BC</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic25fde520f434990aec8bc4ef672935d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-QC</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowertoShowerProductLiabilityLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cee0c4f1d894fc3aa19e2148d91bb12_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:DoctorsAllergyFormulaLLCLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fa7f1086a9a45249ac683ef177587c9_D20190128-20190128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LitigationwithFormerSalixCEOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-28</xbrli:startDate><xbrli:endDate>2019-01-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c84bf2f503a48bcbda0eee28745f465_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic39bb939c10e450dbd36a0e824f2720b_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cb1b7f540294b49ad9ef73316d882e6_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e52d3146d5a487e9ca0aeaadf2b0915_D20190801-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35ef7917c4e846cdb1959043a03d5bca_D20210726-20210726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-26</xbrli:startDate><xbrli:endDate>2021-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff2a848fa15e484ba0fd1a37bd47732e_I20190910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:DerivativeLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shareholder"><xbrli:measure>bhc:shareholder</xbrli:measure></xbrli:unit><xbrli:context id="i6efe4500a1e94445a37235d0071dbc71_I20190913"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:DerivativeLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45d0ac640df44b65a4bc4c22c9500429_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5496c79fe37f42a9a6ed6ceefc84608e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76cbbad47b514c08a436d4d6576f412a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:NovaliqGmbHMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bdf942d40b54fefaef817509211ad3e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:CedarsSinaiMedicalCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4268c1a55cd4a2e89570ee83827d90d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:EyenoviaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff7c3f276277409b964a030bb9ddf9bc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i899638122b1443aea3cf842ccf65501f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cd37c585bfd45c29417f050b1fb96e7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b94206c32884a8fa83f6929a2cb28d7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6899a304edb44929422d6afaf6cef0a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icda72308df944034b125cc6838172395_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8df850998cb6487c8f0b80f71254800b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98f0b0d400a84364ac143e0c73a45029_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42a14ea9b3e84273aeea86db5027a7ef_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff3b9d2f71d648e191dab78cdfc14a22_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bcc7f02716c496789da6644b328c014_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59a5f333092b47d6b10bcf6f866713da_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabb641d02a434242909814412771e876_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if09045f9cc464856be5eee85d720e168_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if27684da78ec405a8823766a077e4e59_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8c2fffa98a84f4785e561d53fa2ad78_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20c9332693f549f3a5029b30f65e69d5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0629a7489a0e43599cf635c5af5d5370_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9327c2fc153040b99cb89cd74f8b0c52_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied28eb131a9d4f14930f4e4a0f0d7abd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia29f4c57d8b542cbafe1450ba688c6b5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>bhc:product</xbrli:measure></xbrli:unit><xbrli:context id="icc8c408b488a4ea2a66ad4c5e2951610_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72654cd7063243f1a8df8bc3a4f0195d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85db686e88084b1daeb7d9f72f4f05ad_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i418a04d4e056401399ccd4b61b80c49e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i208a6bf939c242978d7d9ccc2fc10274_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i183660041cad45ea8dd6de8f87fb3352_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e9b099c602241aea11206441f010b8a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85426466f4c3491594754c3f8fc926ab_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica7446f3b2c9467380385861ab7f846c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97a39f300bde49ca9fc43dfa11399cca_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6cb2a068a1c48d2ace685a569e695c1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dfbabd3f8ad4b34a103357fe12fcfcd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fb12fface6c4c7e82b18336a7a67376_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iada6d354701043aa8ed66ad26387df2c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefe6d8b686a343d78914861cca583670_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie68fa27569a84628a38c78ec3c373351_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaee7f42c5a6e468eb8cc29e3ccdff123_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd994066bcd8437a9238a565a38135fd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9083205e195d456097ba2cf0d7d660c7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a89853896aa43c787ccc01b19d26a52_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdef7aa1a0f744b2a4b78007975133bd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dbb383514c346138c6f03e2442cf299_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cfbdc3f3475470493bc0b06e113623c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie646b8a4d77c437591b1f253ad1ce98c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b09688e27584c5c8598014546598fc6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93bb05eba3ba4b89973b0e8adec86826_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cd4d9c52b49420b9fd755ecae1f6e34_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i449241e47dc94783a4ce61ebe70a084c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i945b3a4ecfe946f49fd0768311efb98e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c41e1b8ff6243bea499531336ad49f3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9565df56092f4004881389c04df25c93_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8a16169eb2d4f67b89fdacefbd0662d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a0ba16f9629426fbbc2da84a05d2fd5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if72021acf180458a8e22ca22a9fa4b7c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10c6872a04d24bdd87a47a8fcff435f5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01141cbdbc294de9a69e8742d0ac0103_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a2b29c602cd4b958959f3a523a03952_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30e3835f2cc243289f8661e3a751167e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fa10e66f5ca4afbb367c4f716dbdb6f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i035f8ab24ddb4f03a63105201f52a080_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f1a89016aaa44f1b9b7cbf14bcc530f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07e9e47444534ef380cd91916978cc8e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ea3465f6a0045f59c3e4d358fade4ea_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic174d4e74321475a84d00d558435391e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f3a113a586047de86a5ff20c4cad591_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d52437e494a45f5b5d81fd921f506ea_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba2bfdb91306432787e6d119f24c9aa6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccf8163c97e441b695eed7ad4118029e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id931ecb1d5924adc9990fe3880f43991_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b3b9253b89e4ba5af70da5f568580ee_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ce0e8c5792746c4898df7b4b795738b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6b7d530488142ca89ab8ee239e906ac_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87499fcd581e451e8b4380c27a63aa69_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i090b17bc8edc432898c155379a09ffbc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i675b1f36cfd84e78bd9e49edeea02d3d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79f443d6034b41279b6e32600dfad1dc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99f4c2a755d74f6782eeac0e0d29ccd5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e35c309da054713ba96e1155984e51e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2daf7c9c3709441a96dee7e2be490687_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i827e4d3a675249bd9a863b2b7df083b6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c401d26917e40768b5d281285429ae5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe1dab615a544098b3eb8dab58113a92_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd1357104df74efbb0da5b76bc89c115_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6331eae27614b90855cfb5b25b9acd0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92793a91c9c747858dd71f6a9a0a9d23_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida777483b4584d87a6cf2850e419fdd4_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7999bb21b9045d28a73afe96f2eb35b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i672bff69a6fc4ef3aebe3725cc29e40e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i626b9ba57ccd4f46b64c17f382055091_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i936342f03a8e4fa2b1e39321ca993106_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24cd510cf43d4f998e635afc20c956b2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55bf18e767ee4fbd8771bf6350d26aff_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00e2f75f8e8a4e30a276c3033c8f9971_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i087b26d2da5842a783ce0a89063cf3f2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7af7813bfb2b41168f468df55e46c835_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic113e26dc8a943e3bcb1595fc30166d4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0ca740d21c34ec1a4f67ff1a0624db4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9186a43c41842cca559fad18f9be2a6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc4e1ec44690405aa82469ba14ebe09c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25dddfae7e964bdfac0c22c5bd9b8197_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f5298b1c6b04825936c29a9867976f9_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if179cdcb08a0401481a1219768254267_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8664af0b79840da9709c1622bb9ddf2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3e3f60c68704a709d886a22a7a0625c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieecb00ddf1e346c497a7a3939fd11cb7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i546306a3ad4f430786457eae18ef4185_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b77d4f86e5b4d38a20c7bda0feef351_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a4ec44e96e44217afae2275f04e02cb_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02ace42c02c2429cb5f9a01e0cdfb82c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia05135846e24408ea51ac1a000116fc6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i654644a806dc4e4c810f174fd6c3d5d7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14f7e763fe5647bc92cbfc644aadf9e5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdd6fed0918446febaeb315df0545125_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80e98cb6ebeb4ac595398dcd45214e1a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id42bd5ff7402461eae15a600bbe77743_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c6ab8b8553d4be6bb88ba2a97705892_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd261e8b9f2d458587ab145f0b01027b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i835dafddf9254e80881be0cd65ee190b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58a96cd4d49841fba044c42410080076_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16d6de8cde05443f89914d40cf8374a2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0536a549f4e94235a4c555bc2d5aa85d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i551031e418e04e92a28afd201e2a7815_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e0b639594e4483fa2e3d9eaa57f0c52_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6a213bd75514daebf43eb6d93a109f3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5464eb24d31a4be0beb852ba387bade8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ba444e2ab994ca1a3c530ace04d6dc6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe8e8f4ff47f48599e5fcab4fe291d47_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id15ad738c4a24f2db24b34a5a0710ae4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c2d9ba589c34635af841f55fabca3a3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9cd10e388d948f69faaa2a13ee4e9a3_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9548d7cc49134168aac65b53c630d341_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08b753376f4946ee869fca342eb74772_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibad2ef89232a4629aad3bf5d2c272019_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21a132fe24e747f0a5b421bc7f0ac7e7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i920bf658665d471ba624c241f037cab0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbd946703e614d71b6d50b2f7ef7c141_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id50f4cab02f148edb0f275c887c08c1a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2af93ee9adb74fed8865c912c5df1f30_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54515e5b9a1540f28363106924361f49_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5566c138571140a6b83afaef74940706_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id01f277d70d744e19dc9ac68d075ef8e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia51b7a120b6d4bfaaac2e2f5d62cd956_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67e2a75f81a2442e98999a9c1a2cd7a8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb566fc6694e418b911114af24372afe_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c64023910d940d280c4372028887834_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0cffeeeada484c5982be5b0d0fba6d27_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36510dcee9304e688d7fe55e6e0cdada_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7458902eaa074c759452bcd57083fefa_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2524acb5669c4f46b137c163c7500bb8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:EG</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea6f1abfde62479a85a276b00644bbda_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:EG</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d19db7ffad34988952acdbe5de7846c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:EG</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0667b68241574742a0864172124b2604_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26ae9e62be7441c196757ba308583044_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i516a86604ef14c82b80390e67af470ba_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4339bb0ca24249ba8ca9d3aacc1e7a0a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e8cb0908b5141feae7cceed8fb1fbf6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfa55d1cb36c454c8ec5fda74ab99db4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47f75495e622462aaff82bf298f1f418_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8280a4a6ac8459590c2dcaa41f23220_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i530e4f0186a947ecbd4d27d49cb0e1dd_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic43dc8234c6a4dceabd306a0a1c1fe32_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16c4e15aae264f818da6ace454e9fbec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a5eeb906ad94c799a42264f6d5855ed_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fffa5927ecf4eb5b8a70faa07450b99_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib537ff890e5e4cec8f7b9df78020e5c0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fc8256f50d840ac85eb640d6f16ba43_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8965029593294a24adc5e0c5daccbfbd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c135788a091404aa9a7b000b712ebb3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc3f5d1fae4241ef94326581b829bff7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc53a771e452444ea4bc5759cdd083db_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe7ac3c028a54540be9b808a17416a89_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ab3fadee1424d2b9a667a9b07eac40a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34d52e2c9af34f2eba8ae6242e32285b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7fa6fc30bf5449caf063162224cd090_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3f2d957c7234a77b712ff75e65b792e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie327497372b349d3a51955d6959df2f5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69ea4eb4471f4aae9d2a35f42e82ace9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c536f8e7b6c4bdc94cd38d6eef8e2e3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i872f81fbc9ba4c60a97667b7432c52c3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if846fad239254513bf3cca0ba1935da3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie66e6133905345078ee7cb9899b48d33_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d19b0b4d54a4b8cad166f0ef7a625c7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbf66cd972eb4b26b35c2652ab001028_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic83a5702808c4b7889dca0da3411ecf7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1597a3574967438391767431a634b19a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idde75edf275b41fb8ca106bbac1cc51f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb3cfed9c9f746829c13cb94a536f2e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2183ac8cb0c24b26a214e41ab91d3425_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3630993f4ba446f9a740bd6e81c5a6ad_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18e3409174504c54b7800e5ee44a1e49_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18eef1a898514fe0a4faf29152835a3a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36636d2e771b4f25a4bb954e3f474155_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35cef2f6062b462484e17c3d2b33a715_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idad1bbd9ef07469495ba41c98fade794_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaff05b11cfdd4a25ba35f7b6f554d5c4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23b4bebac662486b914059dbbda7d89e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie831ea955b1b4600b7818bcbb63030ae_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74d4a550bdbc4a13ac94ac84a9361ccb_I20220118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityNewRestatedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c8a1f0a665d43229d899da271c970a6_I20220118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityNewRestatedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if17269c4e45643c89336bb79651ea5eb_D20220118-20220118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:NewRestatedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-18</xbrli:startDate><xbrli:endDate>2022-01-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d0ad67661d948d99c4ae13e0a3670a2_D20220210-20220210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-10</xbrli:startDate><xbrli:endDate>2022-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c6a7f652a6543c78115ce45b38d0293_D20220210-20220210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000885590</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-10</xbrli:startDate><xbrli:endDate>2022-02-10</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iff28e15b560342ab8a38d1fdf8fb627f_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:45.00pt 45.00pt 45.00pt 45.00pt"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGV4dHJlZ2lvbjo0NzljNDViN2I5M2E0N2NhYTI2ZmE0N2IyNDkxMzBmM18xNzY1_9c419fe8-5839-43c7-9fb8-fb8fa935e7be">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGV4dHJlZ2lvbjo0NzljNDViN2I5M2E0N2NhYTI2ZmE0N2IyNDkxMzBmM18xNzQ_ec51d375-713a-4a58-903e-f624ccb7f033">May 10, 2022</ix:nonNumeric></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of report (Date of earliest event reported)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGV4dHJlZ2lvbjo0NzljNDViN2I5M2E0N2NhYTI2ZmE0N2IyNDkxMzBmM18xNzYx_9aa51e4c-9c63-47aa-a5b4-e04c004b0878">Bausch Health Companies Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.729%"><tr><td style="width:1.0%"></td><td style="width:29.399%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.771%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGFibGU6ZDUyMDcxZGIyZjhhNGE5N2I2N2NjMWUxNTU5OWQ3M2MvdGFibGVyYW5nZTpkNTIwNzFkYjJmOGE0YTk3YjY3Y2MxZTE1NTk5ZDczY18wLTAtMS0xLTk5MDc5_6bcb3518-4d6b-422c-ac17-1b3e57220fde">British Columbia</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGFibGU6ZDUyMDcxZGIyZjhhNGE5N2I2N2NjMWUxNTU5OWQ3M2MvdGFibGVyYW5nZTpkNTIwNzFkYjJmOGE0YTk3YjY3Y2MxZTE1NTk5ZDczY18wLTItMS0xLTk5MDc5_fc84b31a-36e5-49bd-8006-3fbeaf4f9a00">Canada</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGFibGU6ZDUyMDcxZGIyZjhhNGE5N2I2N2NjMWUxNTU5OWQ3M2MvdGFibGVyYW5nZTpkNTIwNzFkYjJmOGE0YTk3YjY3Y2MxZTE1NTk5ZDczY18wLTMtMS0xLTk5MDc5_46ccb226-811f-4a93-a8f6-c7bf4cb8bb7e">001-14956</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGFibGU6ZDUyMDcxZGIyZjhhNGE5N2I2N2NjMWUxNTU5OWQ3M2MvdGFibGVyYW5nZTpkNTIwNzFkYjJmOGE0YTk3YjY3Y2MxZTE1NTk5ZDczY18wLTUtMS0xLTk5MDc5_c38af265-835e-4019-bdd6-b8e0b07a113a">98-0448205</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation)</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission file number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(IRS Employer Identification No.)</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGV4dHJlZ2lvbjo0NzljNDViN2I5M2E0N2NhYTI2ZmE0N2IyNDkxMzBmM18xNzYy_61c00c47-114a-4889-ac9b-9242b2e683e7">2150 St. Elz&#233;ar Blvd. West</ix:nonNumeric>, <ix:nonNumeric contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGV4dHJlZ2lvbjo0NzljNDViN2I5M2E0N2NhYTI2ZmE0N2IyNDkxMzBmM18xNzY2_848bc109-1b44-4c8e-b913-b95cbc01193a">Laval</ix:nonNumeric>, <ix:nonNumeric contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGV4dHJlZ2lvbjo0NzljNDViN2I5M2E0N2NhYTI2ZmE0N2IyNDkxMzBmM18xNzYz_8b5e855b-f39e-40a3-acab-7ba49794374d">Qu&#233;bec</ix:nonNumeric>, <ix:nonNumeric contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGV4dHJlZ2lvbjo0NzljNDViN2I5M2E0N2NhYTI2ZmE0N2IyNDkxMzBmM18xNzU3_3e54cff7-909e-4fa9-b3b9-75085bcc597e">Canada</ix:nonNumeric> <ix:nonNumeric contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGV4dHJlZ2lvbjo0NzljNDViN2I5M2E0N2NhYTI2ZmE0N2IyNDkxMzBmM18xNzU4_e9f9425f-b6d9-41ec-abbe-1d1576a4db5f">H7L 4A8</ix:nonNumeric></span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices) (Zip Code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGV4dHJlZ2lvbjo0NzljNDViN2I5M2E0N2NhYTI2ZmE0N2IyNDkxMzBmM18xNzU5_bd8d7e60-8d4e-4a61-be39-532f66b05245">514</ix:nonNumeric>) <ix:nonNumeric contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGV4dHJlZ2lvbjo0NzljNDViN2I5M2E0N2NhYTI2ZmE0N2IyNDkxMzBmM18xNzY3_d4375829-914c-4286-b960-165512641df3">744-6792</ix:nonNumeric> </span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant's telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGV4dHJlZ2lvbjo0NzljNDViN2I5M2E0N2NhYTI2ZmE0N2IyNDkxMzBmM18xNzY5_5d8a81d9-c962-408a-8407-5740494bf821">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGV4dHJlZ2lvbjo0NzljNDViN2I5M2E0N2NhYTI2ZmE0N2IyNDkxMzBmM18xNzcw_e1424fc0-4ab8-4bfa-bf1f-e240537488f8">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGV4dHJlZ2lvbjo0NzljNDViN2I5M2E0N2NhYTI2ZmE0N2IyNDkxMzBmM18xNzY4_8dc4780a-da17-4080-95b4-e276097f3ad8">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGV4dHJlZ2lvbjo0NzljNDViN2I5M2E0N2NhYTI2ZmE0N2IyNDkxMzBmM18xNzYw_670d22fb-f96b-4104-a295-660a28ea9da6">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.913%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="6" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGFibGU6ZThjODg2NjQ1YWQ5NGE1N2E2ZTU2MDlkMDIwY2UyN2EvdGFibGVyYW5nZTplOGM4ODY2NDVhZDk0YTU3YTZlNTYwOWQwMjBjZTI3YV8xLTAtMS0xLTk5MDc5_590c7893-1bd8-44cb-a174-e06d3f844e7b">Common Shares, No Par Value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGFibGU6ZThjODg2NjQ1YWQ5NGE1N2E2ZTU2MDlkMDIwY2UyN2EvdGFibGVyYW5nZTplOGM4ODY2NDVhZDk0YTU3YTZlNTYwOWQwMjBjZTI3YV8xLTEtMS0xLTk5MDc5_4bd5dc01-e1d3-43b5-b963-9e3eaf84db9e">BHC</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGFibGU6ZThjODg2NjQ1YWQ5NGE1N2E2ZTU2MDlkMDIwY2UyN2EvdGFibGVyYW5nZTplOGM4ODY2NDVhZDk0YTU3YTZlNTYwOWQwMjBjZTI3YV8xLTItMS0xLTk5MDc5_ca4baf7f-f5e8-4b54-8a57-d37ee6efc58e">New York Stock Exchange</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Toronto Stock Exchange</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company     </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGV4dHJlZ2lvbjo0NzljNDViN2I5M2E0N2NhYTI2ZmE0N2IyNDkxMzBmM18xNzY0_7cbe8cec-d9aa-45ab-8d52-1e5e6db8b7af">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:45.00pt 45.00pt 45.00pt 45.00pt"><div style="margin-top:5pt"><span><br/></span></div><div id="iff28e15b560342ab8a38d1fdf8fb627f_7"></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 8.01 &#160;&#160;&#160;&#160;Other Events.</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except where the context otherwise requires, all references in this Current Report on Form 8-K (&#8220;Form 8-K&#8221;) and the related exhibits attached hereto to&#160;the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221; or similar words or phrases are to Bausch Health Companies Inc. and its subsidiaries, taken together. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 3, 2021, the Company announced its intentions to conduct an initial public offering (&#8220;IPO&#8221;) of its aesthetic medical device business, Global Solta (&#8220;Solta&#8221;) (the &#8220;Solta IPO&#8221;). In connection with the planned separation of its Solta business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., the Company has begun managing its operations in a manner which is consistent with the organizational structure of the two separate entities as proposed by the Solta IPO. As a result, during the first quarter of 2022, the Company&#8217;s Chief Executive Officer (&#8220;CEO&#8221;), who is the Company&#8217;s Chief Operating Decision Maker, commenced managing the business differently through changes in its operating and reportable segments, which necessitated a realignment of the Company&#8217;s historical segment structure. This realignment is consistent with how the Company&#8217;s CEO currently: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports. Pursuant to these changes, effective in the first quarter of 2022, the Company operates in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International (formerly International Rx), (iv) Solta Medical and (v) Diversified Products. The new segment structure does not impact the Company&#8217;s reporting units but realigns the two reporting units of the former Ortho Dermatologics segment whereby its medical dermatology reporting unit (Ortho Dermatologics) is now part of the current Diversified Products segment and the Solta reporting unit is now the sole reporting unit of the new Solta Medical segment.  All segment revenues and segment profits for the periods presented have been recast to conform to the 2022 reportable segment structure.</span></div><div style="margin-bottom:8pt;margin-top:5pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began to report under our new structure effective with the filing of our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022, filed with the United States Securities and Exchange Commission (&#8220;SEC&#8221;) and with the Canadian Securities Administrators on SEDAR at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.sedar.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on May&#160;10, 2022. This Form 8-K updates and supersedes the information in Items 7 and 15(a)(1) of our Annual Report on Form 10-K for the year ended December 31, 2021 ("2021 Form 10-K") to reflect retrospective application of the new segments and reclassified historical results to conform to the new segment presentation. These adjustments had no impact on the Company&#8217;s consolidated operating results, cash flows or equity. Except as specifically provided, the information in this Form 8-K does not reflect any event or development occurring after February 23, 2022, the date we filed the 2021 Form 10-K. For a discussion of events and developments subsequent to the filing of the Form 10-K, please refer to our filings with the SEC and the Canadian Securities Administrators on SEDAR since that date. In our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022, we adjusted the unaudited consolidated financial statements as of and for the three months ended March 31, 2022 and 2021 to reflect the retrospective application of our new segments. Accordingly, we are filing this Form 8-K so that our annual financial statement information for the three (3) years prior to January 1, 2022 incorporated by reference in any document that we have filed or may file from time to time with the SEC or with the Canadian Securities Administrators on SEDAR would reflect our current segment presentation.</span></div><div id="iff28e15b560342ab8a38d1fdf8fb627f_123"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statements and Exhibits.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibits</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.141%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.941%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit No.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="bhc8-k542022ex23.htm">23*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="bhc8-k542022ex23.htm">Consent of Independent Registered Public Accounting Firm</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="bhc5422-ex991.htm">99.1*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="bhc5422-ex991.htm">Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations with Retrospective Segment Changes of the 2021 Form 10-K</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="bhc-20220510_d2.htm">99.2*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="bhc-20220510_d2.htm">Item 15.(a)(1) The consolidated financial statements required to be filed in the Annual Report on Form 10-K with Retrospective Segment Changes of the 2021 Form 10-K</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:174%">____________________________________</span></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:45.00pt 45.00pt 45.00pt 45.00pt"><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">*     Filed herewith.</span></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div></div><div id="iff28e15b560342ab8a38d1fdf8fb627f_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="border-color:#000000;border-style:solid;border-width:0.00pt;padding:45.00pt 45.00pt 45.00pt 45.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: May&#160;10, 2022</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;padding-left:198pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.873%"><tr><td style="width:1.0%"></td><td style="width:10.041%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.759%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BAUSCH HEALTH COMPANIES INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Tom Vadaketh</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name: Tom Vadaketh</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title: Executive Vice President, Chief Financial Officer</span></td></tr></table></div><div style="margin-top:5pt;padding-left:198pt"><span><br/></span></div><div><span><br/></span></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>2
<FILENAME>bhc8-k542022ex23.htm
<DESCRIPTION>EX-23
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ibce44b4d0b6d4165a375291f6c6ece05_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (Nos. 333-238084, 333-226786, 333-196120, 333-176205, 333-168254, 333-168629, and 333-138697 as amended, where applicable) of Bausch Health Companies Inc. of our report dated February 23, 2022, except with respect to our opinion on the consolidated financial statements insofar as it relates to the change in composition of reportable segments discussed in Note 22 in the consolidated financial statements, as to which the date is May 10, 2022 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Current Report on Form 8-K.</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; PricewaterhouseCoopers LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Florham Park, New Jersey</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 10, 2022</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>bhc5422-ex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_97"></div><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:5pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Explanatory Note</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 3, 2021, the Company announced its intentions to conduct an initial public offering (&#8220;IPO&#8221;) of its aesthetic medical device business, Global Solta (&#8220;Solta&#8221;) (the &#8220;Solta IPO&#8221;). See See &#8220;Separation of the Bausch + Lomb Eye-Health Business and the Solta Medical Business&#8221; below for further details regarding the Solta IPO. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the planned separation of its Solta business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., the Company has begun managing its operations in a manner which is consistent with the organizational structure of the two separate entities as proposed by the Solta IPO. As a result, during the first quarter of 2022, the Company&#8217;s Chief Executive Officer (&#8220;CEO&#8221;), who is the Company&#8217;s Chief Operating Decision Maker, commenced managing the business differently through changes in its operating and reportable segments, which necessitated a realignment of the Company&#8217;s historical segment structure. This realignment is consistent with how the Company&#8217;s CEO currently&#58; (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports. Pursuant to these changes, effective in the first quarter of 2022, the Company operates in the following reportable segments&#58; (i) Bausch + Lomb, (ii) Salix, (iii) International (formerly International Rx), (iv) Solta Medical and (v) Diversified Products. The new segment structure does not impact the Company&#8217;s reporting units but realigns the two reporting units of the former Ortho Dermatologics segment whereby its medical dermatology reporting unit (Ortho Dermatologics) is now part of the current Diversified Products segment and the Solta reporting unit is now the sole reporting unit of the new Solta Medical segment.  All segment revenues and segment profits for the periods presented have been recast to conform to the 2022 reportable segment structure.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations with Retrospective Segment Changes of the 2021 Form 10-K&#8221; set forth in this Exhibit 99.1 has been revised from the &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in Part II to the Company's Annual Report on Form 10-K for the year ended December 31, 2021 (the &#8220;2021 Form 10-K&#8221;) to reflect retrospective application of the new reporting structure and recast our historical results to conform to the new segment presentation. &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations with Retrospective Segment Changes of the 2021 Form 10-K&#8221; set forth below has not been revised to reflect events or developments subsequent to February 23, 2022, the date that we filed the 2021 Form 10-K.  For a discussion of events and developments subsequent to the filing date of the 2021 Form 10-K, please refer to the reports and other information the Company has filed with the Securities and Exchange Commission at www.sec.gov and with the Canadian Securities Administrators on SEDAR at www.sedar.com since that date, including the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022 filed on May&#160;10, 2022.</font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_136"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7.&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations with Retrospective Segment Changes of the 2021 Form 10-K</font></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_139"></div><div style="margin-bottom:8pt;margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTRODUCTION</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; has been updated through February&#160;23, 2022 and for the subsequent retrospective reflection of the segment change and should be read in conjunction with the audited Consolidated Financial Statements and the related notes thereto included elsewhere in this Annual Report on Form 10-K. The matters discussed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that may be forward-looking information within the meaning defined under applicable Canadian securities laws (collectively, &#8220;Forward-Looking Statements&#8221;). See &#8220;Forward-Looking Statements&#8221; at the end of this discussion. Additional company information, including this Form&#160;10-K, is available on SEDAR at </font><font style="color:#0027ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.sedar.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> and on the U.S.&#160;Securities and Exchange Commission (the&#160;&#8220;SEC&#8221;) website at&#160;</font><font style="color:#0027ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">www.sec.gov</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  All currency amounts are expressed in U.S.&#160;dollars, unless otherwise noted.</font></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_142"></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bausch Health Companies&#160;Inc. (&#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221; or the&#160;&#8220;Company&#8221;) is a global company whose mission is to improve people&#8217;s lives with our health care products. We develop, manufacture and market, primarily in the therapeutic areas of eye-health, gastroenterology (&#8220;GI&#8221;) and dermatology, a broad range of&#58; (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) over-the-counter (&#8220;OTC&#8221;) products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in approximately 100 countries. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generated revenues for 2021, 2020 and 2019, of $8,434 million, $8,027 million and $8,601 million, respectively. Our portfolio of products falls into five operating and reportable segments&#58; (i) Bausch + Lomb, (ii) Salix, (iii) International (formerly International Rx), (iv) Solta Medical and (v) Diversified Products. These segments are discussed in detail in Note 22, &#8220;SEGMENT INFORMATION&#8221; to our audited Consolidated Financial Statements. The following is a brief description of the Company&#8217;s segments&#58;  </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Bausch + Lomb segment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Bausch + Lomb Vision Care, Consumer, Surgical and Ophthalmic Pharmaceuticals products. </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Salix segment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of GI products.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The International segment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists of sales, with the exception of sales of Bausch +Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Solta Medical segment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Solta aesthetic medical devices.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Diversified Products segment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of&#58; (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products, (iii) Ortho Dermatologics (dermatological) products and (iv) dentistry products. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional discussion of our reportable segments, see the discussion in Note 22, &#8220;SEGMENT INFORMATION&#8221; to our audited Consolidated Financial Statements for further details on these reportable segments.</font></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_145"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Focus on Value</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, we retained a new executive team which implemented a multi-year plan designed to transform and bring out value in our Company. The multi-year plan increased our focus on, among other factors, our&#58; product portfolio, infrastructure, geographic footprint, capital structure and risk management.  Since that time, we have been executing and continue to execute on our commitments to transform the Company and generate value. As discussed below, under the multi-year plan, we have taken actions that among other things included&#58; (i) divesting non-core assets, (ii) making strategic investments in our core businesses and (iii) making measurable progress in improving our capital structure.  These measures gave us operating flexibility and put us in a strong position to unlock the additional value to be found in our specific businesses. We believe that these and other positive actions we took to transform our Company, have helped to focus our operations, and improve our capital structure. These positive actions also presented us with an opportunity to unlock potential value across our portfolio of assets by separating our pharmaceutical, eye-health and skincare businesses, and, in 2020 and 2021, we set out to create three highly attractive but dissimilar businesses. Although management believes these transactions will bring out additional value, there can be no assurance that either the B+L Separation or the Solta IPO will be successful in doing so.</font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_148"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Separation of the Bausch + Lomb Eye-Health Business and the Solta Medical Business</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, we announced our plan to separate our eye-health business consisting of our Bausch + Lomb Global Vision Care, Global Consumer, Global Surgical and Global Ophthalmic Pharmaceuticals businesses into an independent publicly traded entity, Bausch + Lomb  from the remainder of Bausch Health Companies Inc (the &#8220;B+L Separation&#8221;). </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time of our announcement, we have previously emphasized that it is important that the post-separation entities be well capitalized, with appropriate leverage and with access to additional capital, if and when needed, to provide each entity with the ability to independently allocate capital to areas that will strengthen their own competitive positions in their respective lines of business and position each entity for sustainable growth. Therefore, we see the appropriate capitalization and leverage of these businesses post-separation as a key to maximizing value across our portfolio of assets and, so, it is a primary objective of our plan of separation. We also previously stated that all options for achieving the appropriate capitalization and leverage for these entities post-separation were being considered. Management remains focused on the capitalizations of the post-separation entities and has considered and continues to consider alternative means of achieving the appropriate outcome, including dispositions in our business that we believe represent attractive opportunities for the Company and are in line with our plan of separation. This informed our decision to divest Amoun Pharmaceutical Company S.A.E. (&#8220;Amoun&#8221;) on July 26, 2021 and, as discussed below, use the net proceeds to repay certain debt obligations. It has also informed, in part, our decision to pursue an initial public offering of our Solta aesthetic medical device business (&#8220;Solta Medical&#8221;) (the &#8220;Solta IPO&#8221;), which we announced on August 3, 2021. We believe that the Solta IPO, when and if complete, will allow us to unlock the value of this high-growth business and give us ownership of a valuable financial asset that would compare more favorably to other aesthetic medical device companies. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since announcing the B+L Separation and Solta IPO, we began executing on those plans and, at the end of 2021, had substantially completed the internal objectives necessary to facilitate the IPOs and related separation of those businesses.  We continue to monitor market conditions and aim to launch the B+L IPO and the Solta IPO when financial market conditions are favorable (subject to receipt of regulatory, stock exchange and other approvals). However, there can be no assurance as to when we will complete either IPO, if at all. Until such time, we continue to manage these businesses along with our diverse portfolio of gastrointestinal, dermatology, neurology and other therapeutics, with our commitment to bring out additional value for our shareholders. Following the B+L IPO, we expect to complete the separation of Bausch + Lomb following the expiry of customary lockups related to the B+L IPO and achievement of targeted debt leverage ratios, subject to the receipt of applicable shareholder and other necessary approvals and market conditions.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to use the proceeds from the B+L Separation and the Solta IPO to repay, to the extent possible, a portion of our existing debt, thereby improving our capitalization and leverage. We believe the B+L Separation and the Solta IPO provide us with an attractive opportunity for liquidity to support the appropriate capitalization and leverage of the Bausch + Lomb entity, the Solta Medical entity and the remainder of Bausch Health Companies Inc., which we refer to as &#8220;Bausch Pharma&#8221; and will assume a new name upon completion of the B+L Separation. However, management continues to consider the forms of the B+L Separation and the Solta IPO and is exploring a number of alternative capitalization structures in order to properly capitalize the three entities. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The B+L Separation and the Solta IPO will establish three separate companies that include&#58;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Bausch + Lomb</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - a fully integrated, pure play eye-health company built on the iconic Bausch + Lomb brand and long history of innovation&#59; </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Solta Medical</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - a leading global aesthetic medical device company focused on the development, manufacture and sale of innovative technologies that provide aesthetic and therapeutic benefits&#59; and</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Bausch Pharma</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - a diversified pharmaceutical company with leading positions in gastroenterology, dermatology, neurology and international pharmaceuticals. The remaining pharmaceutical entity will comprise a diversified portfolio of our leading durable brands across the Salix, International, dentistry, neurology, medical dermatology and generics businesses. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe these transactions will result in three highly attractive but dissimilar businesses. As separate entities, management believes that each company will be better positioned to individually focus on its core businesses to drive additional growth, more effectively allocate capital and better manage its respective capital needs.  Further, these transactions allow us and the market to compare the operating results of each entity with other &#8220;pure play&#8221; peer companies. Although management believes these transactions will bring out additional value, there can be no assurance that either the B+L Separation or the Solta IPO will be successful in doing so.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January and February 2022, we took certain actions to, and announced others that we believe will, bring us closer in reaching our targeted capitalization of the post-separation entities. These actions are discussed in more detail in Item &#8220;&#8212; </font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidity and Capital Resources &#8212; Liquidity and Debt &#8212; Long-term Debt&#8221; and Note 23, &#8220;SUBSEQUENT EVENTS&#8221; to our audited Consolidated Financial Statements.  Although an IPO of the Bausch + Lomb and Solta Medical businesses are among the alternate capital structures being considered, this Form 10-K does not constitute an offer to sell, or the solicitation of an offer to buy, any securities of the Bausch + Lomb or Solta Medical entities. As of February 23, 2022, the determination of the capitalization of the three entities continues to evolve, and we do not have a definitive timetable to finalize the respective capital structures. We continue to monitor market conditions and aim to launch the B+L IPO and Solta IPO when financial market conditions are favorable (and subject to receipt of regulatory, stock exchange, and other regulatory approvals). </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the capitalization and leverage ratios of each entity, there are considerations, approvals and conditions, including market conditions, that will determine the ultimate timing and structure of these transactions, including regulatory approvals, final approval by our board of directors, any shareholder vote requirements that may be applicable, compliance with U.S. and Canadian securities laws and stock exchange rules, receipt of any applicable opinions and&#47;or rulings with respect to the Canadian and U.S. federal income tax treatment of such transactions and determination of the pro forma capitalization of each of the three entities. The failure to satisfy all of the required conditions could delay the completion of these transactions for a significant period of time or prevent them from occurring at all. In addition to our internal organization and structure work, we will need to complete a number of additional steps that will depend on the ultimate structure of the transactions (in addition to obtaining the regulatory approvals and satisfying the conditions described above) before we can launch the B+L IPO, complete the B+L Separation and&#47;or launch the Solta IPO. As a result, there can be no assurance as to the timing of the completion of any of these transactions or their terms, and the information in this Form 10-K relating to each transaction is preliminary and may change as the transactions progress and any such changes and their impact on the Company, or any of the companies that result from the consummation of any of these transactions, may be material.  </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item&#160;1A. &#8220;Risk Factors &#8212;&#160;Risk Relating to the B+L Separation&#8221; of this Form 10-K for additional risks relating to the B+L Separation and the Solta IPO.</font></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_151"></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Setting Up Our Company to Unlock Value</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To position ourselves to unlock the value we see in our individual businesses, we have sought to right-size our portfolio of assets and provide financial flexibility. The Company has focused on the following growth drivers, that remain a focus of our growth strategies today&#58;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">divested non-core assets in order to narrow the Company's activities to our core businesses where we believe we have an existing and sustainable competitive edge and the ability to generate operational efficiencies. As of February 23, 2022, we received approximately $4,100 million in net proceeds from these divestitures, which includes the sale of Amoun (the &#8220;Amoun Sale&#8221;) which we divested on July 26, 2021, as discussed below&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">made strategic investments in our core businesses in order to support recent revenue growth and prepare for additional growth opportunities we plan to capitalize on for our core businesses&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">made measurable progress in improving our capital structure as we have repaid approximately $10,000&#160;million in debt obligations (net of additional borrowings, amounts refinanced and excluding the $1,210 million financing of the U.S. Securities Litigation settlement discussed below) during the period of January 1, 2016 through December 31, 2021 using the proceeds from the divestiture of non-core assets, cash generated from our operations and improved working capital management. This includes approximately $1,300 million of repayments (net of additional borrowings) during 2021 using cash on hand, cash generated from operations and the net proceeds from the Amoun Sale&#59; and</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:40.5pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">resolved many of the Company's legacy litigation matters originating back to 2015 and prior, including the most significant legacy legal matter, the U.S. Securities Litigation settlement discussed below, significantly reducing related possible disruptions and other uncertainties to our operations. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that these and other positive actions we have taken to transform our Company have helped focus our operations, unlocked value across our product portfolios, improved our capital structure and mitigated certain risks associated with legacy litigation matters.  We believe that these measures, along with our continued commitment to improving people's lives through our health products, help position us to unlock potential value across our portfolio of assets by separating our pharmaceutical, eye-health and skincare businesses.</font></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_154"></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divest Assets to Improve Our Capital Structure and Simplify Our Business</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to better focus on our core businesses, we continue to evaluate opportunities to simplify our operations and improve our capital structure, including dispositions of various assets. For example, on July 26, 2021, we completed the sale of Amoun for total gross consideration of approximately $740&#160;million, subject to certain adjustments. Amoun, which was part of </font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the International segment, manufactures, markets and distributes branded generics of human and animal health products. Revenues associated with Amoun were $157&#160;million for the period of January 1, 2021 through July 26, 2021 and were $247&#160;million and $220&#160;million for the years 2020 and 2019, respectively. Following the completion of the Amoun Sale, the Company made aggregate payments of $600&#160;million, to repay $469&#160;million of its June 2025 Term Loan B Facility and $131&#160;million of its November 2025 Term Loan B Facility, using the net proceeds from the Amoun Sale and cash on hand.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to consider further dispositions of various assets in line with this strategy. While we anticipate that any future divestiture activities will be on non-core assets, consistent with our duties to our shareholders and other stakeholders, we will consider dispositions in core areas that we believe represent attractive opportunities for the Company. See Note 3, &#8220;ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE&#8221; to our audited Consolidated Financial Statements for additional information.</font></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_157"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impacts of COVID-19 Pandemic</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unprecedented nature of the COVID-19 pandemic has, and continues to, adversely impact the global economy. The COVID-19 pandemic and the reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and&#47;or address its impacts have had significant direct and indirect effects on businesses and commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facility closures and production suspensions. We believe we responded quickly to these and other human and commercial challenges brought on by the COVID-19 pandemic and that our actions allowed us to&#58; (i) maintain a reliable supply of our products, (ii) protect the health, safety and well-being of our employees, (iii) reduce operating expenses and preserve cash through profit protection measures initiated in response to the COVID-19 pandemic, (iv) limit the disruptions to our product development pipeline and (v) ensure affordability of and access to our products. We will continue to monitor the impacts of the COVID-19 pandemic and related responses from governments and private sector participants on the Company, our customers, supply chain, third-party suppliers, project development timelines, costs, revenue, margins, liquidity and financial condition and our planned actions and responses to this pandemic. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2020 revenues were most negatively impacted during our second quarter by certain social restrictions and other precautionary measures taken in response to the COVID-19 pandemic. However, as governments began lifting social restrictions, allowing offices of certain health care providers to reopen and certain surgeries and elective medical procedures to proceed, the negative trend in the revenues of certain businesses began to level off and stabilize prior to our third quarter of 2020. After the launch of effective vaccines in December 2020, infection rates began to decline, signaling the beginning of a recovery from the COVID-19 pandemic.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues were $8,434 million for 2021, as compared to $8,027 million for 2020, a year-over-year increase of $407 million, or 5%, and primarily reflects the positive impacts of the recovery from the COVID-19 pandemic, partially offset by the impact of our divestiture of Amoun on July 26, 2021. The increase in revenue also represents an improving trend over the decreases in year-over-year revenues for the three-month periods ended June 30, 2020, September 30, 2020 and December 31, 2020 of 23%, 3% and less than 1%, respectively. Presuming there continues to be increased availability of effective vaccines and any resurgence of the COVID-19 virus and variant strains thereof, such as the delta and omicron variants, do not have a material adverse impact on efforts to contain the COVID-19 virus, the Company anticipates an ongoing, gradual global recovery from the significant macroeconomic and health care impacts of the pandemic. Our revenues returned to pre-pandemic levels for many of our businesses and geographies in 2021 and, at the current pace of recovery, we anticipate the COVID-19 pandemic to have a minimal impact on the remaining businesses and geographies in 2022.  However, the rates of recovery for each business will vary by geography and will be dependent upon, among other things, the availability and effectiveness of vaccines for the COVID-19 virus and variant strains thereof, government responses, rates of economic recovery, precautionary measures taken by patients and customers, the rate at which remaining social restrictions are lifted and, once lifted, the presumption that social restrictions will not be materially reenacted in the event of a resurgence of the virus or variant strains thereof and other actions taken in response to the COVID-19 pandemic.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we put in place procedures to mitigate the risks associated with closures and disruptions at our manufacturing facilities, the COVID-19 pandemic temporarily impacted the manner in which we managed our inventories and inventory levels. The negative impact of the COVID-19 pandemic on the demand for many of our products necessitated that we, among other things, shorten production runs during 2020 to reduce inventories and mitigate inventory losses. The shorter production runs, the costs associated with idling certain facilities during government mandated lockdowns and the costs of the precautionary measures taken at our manufacturing facilities in response to the COVID-19 pandemic resulted in manufacturing variances, which temporarily depressed our contribution margins in 2020. However, in 2021, as demand increased and our retailers and distributors replenished their inventories, the pressures on our manufacturing processes experienced during 2020 have been alleviated and we have avoided many of the COVID-19 pandemic-induced manufacturing variances during 2021. </font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we monitor the direction and pace of the recovery in each business and geography, we are also continually monitoring the effectiveness of the profit protection measures we initiated to manage and reduce our operating expenses and preserve cash during the COVID-19 pandemic. These profit protection measures were successful in expanding the profit margins in many of our businesses, as referenced in the discussion of our operating results below. In 2021, we began allocating more resources to selling and other promotional activities in support of our existing products, product launches and products in development. As a result, our SG&#38;A and R&#38;D expenses increased 11% and 3% during 2021 as compared to 2020, respectively.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our diverse portfolio of durable products and strong brands has served us well through the COVID-19 pandemic and we continue to be well-positioned to grow market share and return to growth as the world recovers. However, this situation remains fluid and we continue to monitor the availability and effectiveness of vaccines and any resurgence of the COVID-19 virus and outbreaks of variant strains thereof, such as the delta and omicron variants, on our operations, businesses and primary goals.  Given these circumstances, we continue to focus on&#58; (i) revising our go-to-market and sales force strategies to address the changing business dynamics created by the COVID-19 pandemic, (ii) building out our e-commerce presence to enable us to reach customers in new ways, (iii) investing in our key promoted brands and product launches to increase market share, (iv) optimizing our cost structure and (v) looking for key trends in the market to meet changing consumer&#47;patient needs and identify areas for investment and growth. We believe focusing on these priorities will best enable us to effectively manage the changing business dynamics created by the COVID-19 pandemic, prepare us for a possible resurgence of the virus and any variant strains thereof and return us to growth during the recovery from the COVID-19 pandemic.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a further discussion of these and other COVID-19 related risks, see Item 1A. &#8220;Risk Factors&#8212; Risks Relating to COVID-19&#8221; of this Form 10-K.</font></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_160"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Focus on Core Businesses</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to focus on our core businesses we have&#58; (i) directed capital allocation to drive growth within our core businesses, (ii) made measurable progress in effectively managing our capital structure, (iii) increased our efforts to improve patient access and (iv) continued to invest in sustainable growth drivers to position us for long-term growth.</font></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_163"></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Direct Capital Allocation to Drive Growth Within Our Core Businesses</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our capital allocation is driven by our long-term growth strategies. We have been aggressively allocating resources to promote our core businesses globally through&#58; (i) strategic acquisitions, (ii) R&#38;D investment, (iii) strategic licensing agreements and (iv) strategic investments in our infrastructure. The outcome of this process allows us to better drive value in our product portfolio and generate operational efficiencies.</font></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_166"></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Strategic Acquisitions</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We remain very selective when considering any acquisition and pursue only those opportunities that we believe align well with our current organization and strategic plan. We sometimes refer to these opportunities as &#8220;bolt on&#8221; acquisitions.  In being selective, we seek to enter into only those acquisitions that provide us with significant synergies with our existing business, thereby minimizing risks to our core businesses and providing long-term growth opportunities. Recently, we have entered into transactions that although not immediately impactful to our operating results, are expected to be accretive to our bottom line in future years and contribute to our long-term growth strategies. </font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, we completed the acquisition of certain assets of Synergy whereby we acquired the worldwide rights to the Trulance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) product, a once-daily tablet for adults with chronic idiopathic constipation, or CIC, and irritable bowel syndrome with constipation, or IBS-C. We believe that the Trulance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product complements our existing Salix products and allows us to effectively leverage our existing GI sales force. In order to drive growth of the Trulance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product, we have increased the number of sales force representatives for the Trulance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product. We believe this has been successful as Trulance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues were $103 million and $82 million for the years 2021 and 2020, respectively.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we acquired the U.S. rights to EM-100 (an investigational preservative-free formulation eye drop) from Eton Pharmaceuticals, Inc. On September 25, 2020, the Company announced that the FDA had approved Alaway</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Preservative Free (ketotifen fumarate) ophthalmic solution, 0.035%, antihistamine eye drops (EM-100) as the first OTC preservative-free formulation eye drop approved to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair and dander. Alaway</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Preservative Free was launched in February 2021 and is expected to complement our broad range of Bausch + Lomb integrated eye-health products.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are considering further acquisition opportunities within our core therapeutic areas, some of which could be material in size.</font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_169"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">R&#38;D Investment</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continuously search for new product opportunities through internal development and strategic licensing agreements, that if successful, will allow us to leverage our commercial footprint, particularly our sales force, and supplement our existing product portfolio and address specific unmet needs in the market. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal R&#38;D organization focuses on the development of products through clinical trials. As of December 31, 2021, approximately 1,300 dedicated R&#38;D and quality assurance employees in 25 R&#38;D facilities were involved in our R&#38;D efforts internally.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have approximately 200 projects in our global pipeline. Certain core internal R&#38;D projects that have received a significant portion of our R&#38;D investment in current and prior periods are listed below. However, due to the challenges of the COVID-19 pandemic, most notably those attributable to &#8220;stay at home&#8221; orders and travel restrictions, certain of our R&#38;D activities were forced to pause in 2020. Clinical trials that started prior to governmental shutdowns remained enrolled and existing patients progressed, while new patient enrollments were paused as most trial sites were not able to accept new patients. However, during our third quarter of 2020, we saw the pace of new patient enrollments increase, and, although certain of our projects are moving slower than we would like due to the impacts of the COVID-19 pandemic, through the date of this filing we have not had to make changes to our development timelines that would have a material impact on our current or future operating results.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor the timing and completion of our ongoing and anticipated clinical trial programs. As of February 23, 2022, the delays in our clinical trials have not had a material impact on our operating results&#59; however, a resurgence of the virus significant enough to necessitate reenacting certain social restrictions could result in unanticipated delays in our ability to conduct new patient enrollments. Other possible COVID-19 pandemic and resurgence related challenges include, but are not limited to, facility closures, delays by third-party service providers, deferrals of doctor visits, postponement of elective medical procedures and surgeries and changes in prioritization by the FDA and other regulatory authorities. Delays, if any, caused by the COVID-19 pandemic and a possible resurgence of the virus or variant strains thereof such as these and others will likely adversely affect the timely approval, launch and commercialization and the commercial success of our products, particularly those in early stage clinical trials. As a result, our estimates regarding the timing and success of our R&#38;D efforts (some of which are set out below), including as it relates to study initiation, enrollment and completion, availability of study results, regulatory submissions, regulatory approvals and commercial launches, may change.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">SiHy Daily - A silicone hydrogel daily disposable contact lens designed to provide clear vision throughout the day. In September 2018, we launched SiHy Daily in Japan under the branded name AQUALOX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY.&#160; In August 2020, we launched SiHy Daily in the U.S. under the branded name Bausch + Lomb INFUSE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SiHy Daily Disposable contact lens.  In the fourth quarter of 2020, SiHy Daily was launched in Australia, Hong Kong and Canada under the branded name Bausch + Lomb Ultra</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY. SiHy Daily has also received regulatory approval in China, New Zealand, Japan, South Korea, Europe, Singapore and Malaysia, where it will be branded as Bausch + Lomb Ultra</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY, and, in the second quarter of 2021, we launched SiHy Daily in South Korea and Singapore as Bausch + Lomb Ultra</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Lumify</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (brimonidine tartrate ophthalmic solution, 0.025%) - An OTC eye drop developed as an ocular redness reliever. We launched this product in the U.S. in May 2018. Currently, we have several line extensions under development and expect Phase 3 clinical studies to commence in 2022.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Biotrue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday for Astigmatism - A daily disposable contact lens for astigmatic patients. The Biotrue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday contact lens incorporates Surface Active Technology</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to provide a dehydration barrier.&#160; The Biotrue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday for Astigmatism also includes evolved peri-ballast geometry to deliver stability and comfort for the astigmatic patient.&#160;We launched this product in December 2016 and launched an extended power range and further extended power ranges in each of the years 2017 through 2020. Biotrue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday for Astigmatism has also received regulatory approval in China.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">New Ophthalmic Viscosurgical Device (&#8220;OVD&#8221;) product - A formulation to protect corneal endothelium during phacoemulsification process during a cataract surgery and to help chamber maintenance and lubrication during intraocular lens delivery.  In January 2020, we commenced an FDA clinical study for the cohesive OVD product which has now achieved its enrollment target, despite COVID-19-related slowdowns, and we expect results in the first quarter of 2022. In addition, in March 2021, we received Premarket Approval from the FDA for Clearvisc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> dispersive OVD, which we launched in the U.S. in June 2021.</font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">enVista</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Trifocal intraocular lens - An innovative lens design.  We initiated an investigative device exemption study for this product in May 2018 and initiated the last phase of this three phase study in the fourth quarter of 2020. We completed enrollment during the first quarter of 2022 for the Canadian study and expect to complete enrollment during the first half of 2022 for the U.S. study.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10pt">SimplifEYE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> preloaded intraocular lens injector platform for enVista intraocular lens - We have received approvals from the European Union and Canada and received FDA clearance for the injector and launched this platform in October 2020.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Extended depth of focus intraocular lens - Currently under development, however, the timing and completion of which has been delayed due to COVID-19 pandemic related matters.  Once development is completed, and if approved, we anticipate that this product could be launched in 2024.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Bausch + Lomb ULTRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> monthly silicone hydrogel lens - Specifically designed to address the lifestyle and vision needs of patients with MoistureSeal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology which maintains 95% of contact lens moisture for a full 16 hours. In the second quarter of 2020, Bausch + Lomb ULTRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> received a seven day extended wear indication approval from the European Union and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">received regulatory approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from the National</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical Products Administration in China.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Bausch + Lomb ULTRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Multifocal for Astigmatism contact lens - The first and only multifocal toric lens available as a standard offering in the eye care professional's fit set. The new monthly silicone hydrogel lens, which was specifically designed to address the lifestyle and vision needs of patients with both astigmatism and presbyopia, combines the Company's unique 3-Zone Progressive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;multifocal design with the stability of its OpticAlign</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;toric with MoistureSeal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology to provide eye care professionals and their patients an advanced contact lens technology that offers the convenience of same-day fitting during the initial lens exam.&#160;Bausch + Lomb ULTRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Multifocal for Astigmatism was launched in June 2019 and received European Union regulatory approval in the second quarter of 2020.  In July 2021, we launched an extended parameter range of this product.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Renu</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advanced Multi-Purpose Solution (&#8220;MPS&#8221;) - Contains a triple disinfectant system that kills 99.9% of germs, and has a dual surfactant system that provides up to 20 hours of moisture.  Renu</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advanced MPS is FDA cleared with indications for use to condition, clean, remove protein, disinfect, rinse and store soft contact lenses including those composed of silicone hydrogels.  Renu</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advanced MPS has gained regulatory approvals in Korea, India, Mexico, Indonesia, Malaysia, Singapore and, during the second quarter of 2020, the European Union. In 2021, Renu</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Advanced MPS was launched in Greece and gained regulatory approvals in China and Taiwan.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Zen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Multifocal Scleral Lens for presbyopia - In January 2019, we launched this product exclusively available with Zenlens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Zen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> RC scleral lenses and will allow eye care professionals to fit presbyopic patients with regular and irregular corneas and those with ocular surface disease, such as dry eye.  The Zen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Multifocal Scleral Lens incorporates decentered optics, enabling the near power to be positioned over the visual axis.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Tangible</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hydra-PEG</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - A high-water polymer coating that is bonded to the surface of a contact lens and designed to address contact lens discomfort and dry eye. We launched this product in March 2019. Tangible</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Hydra-PEG</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> coating technology in combination with our Boston</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> materials and Zenlens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> family of scleral lenses will help eye care professionals provide a better lens wearing experience for their patients with challenging vision needs.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gastrointestinal</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10pt">Rifaximin - Top line results from a Phase 2 study for the treatment of overt hepatic encephalopathy with a new formulation (SSD IR) of rifaximin showed a treatment benefit. Patients receiving 40 mg twice daily showed a statistically significant separation from placebo. The top line results from this Phase 2 study will help inform further research on potential new indications for rifaximin&#59; this included the commencement of a Phase 3 study (RED-C) in 2021 to seek an indication for the prevention of the first episode of Hepatic Encephalopathy. </font></div><div style="text-align:justify;text-indent:4.5pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10pt">Rifaximin - Rifaximin recently received orphan drug designation for sickle cell anemia. A novel dosage formulation is planned to be studied for the treatment of sickle cell anemia and clinical sites began enrolling into the trial at the end of 2021.</font></div><div style="text-align:justify;text-indent:4.5pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10pt">Rifaximin - Development of a fit for purpose Patient Reported Outcomes tool for small intestinal bacterial overgrowth, or &#8220;SIBO&#8221;, is continuing in 2022.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10pt">Rifaximin - We have entered into an agreement with Cedars Sinai Medical Center to evaluate a new formulation of rifaximin for the treatment of IBS-D.  Two preclinical studies have been completed. A Proof of Concept study that was paused due to COVID-19 pandemic related factors, has recommenced and is fully enrolled. Based on recent FDA comments dated February 10, 2022, the program is being assessed and related timelines reviewed.</font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10pt">Envive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> - In October 2020, we launched, on a limited basis, a probiotic supplement that was developed to address gastrointestinal disturbances. In April 2021, we expanded the launch to additional territories in the U.S.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10pt">Amiselimod (S1P modulator) - We commenced a Phase 2 study during the first half of 2021 to evaluate Amiselimod (S1P modulator) for the treatment of mild to moderate ulcerative colitis.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dermatology</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Arazlo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(tazarotene) Lotion, 0.045% (formerly Internal Development Project (&#8220;IDP&#8221;) 123) - In June 2020, we launched this acne product containing lower concentration of tazarotene in a lotion form to help reduce irritation while maintaining efficacy. </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">IDP-120 - An acne product with a fixed combination of mutually incompatible ingredients&#58; benzoyl peroxide and tretinoin.  Phase 3 clinical studies have been completed and met the primary endpoints. We are currently evaluating next steps for this project.  </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">IDP-126 - An acne product with a fixed combination of benzoyl peroxide, clindamycin phosphate and adapalene. Phase 3 clinical studies initiated in December 2019 were paused due to COVID-19 pandemic related factors, but resumed in June 2020. Both Phase 3 studies have been completed and have met their primary endpoints. A comparative bridging safety and efficacy study was delayed until 2021 due to COVID-19. The bridging study is ongoing. We anticipate filing a New Drug Application (&#8220;NDA&#8221;) in the second half of 2022.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Clear + Brilliant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Touch - Next generation Clear + Brilliant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> laser that is designed to deliver a customized and more comprehensive treatment protocol by providing patients of all ages and skin types the benefits of two wavelengths. This product was launched in the U.S. in March 2021.</font></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_172"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Strategic Licensing Agreements</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To supplement our internal R&#38;D initiatives and to build-out and refresh our product portfolio, we also search for opportunities to augment our pipeline through arrangements that allow us to gain access to unique products and investigational treatments, by strategically aligning ourselves with other innovative product solutions.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company will enter into select licensing and collaborative agreements for the commercialization and&#47;or development of unique products primarily in the U.S. and Canada. These products are sometimes investigational treatments in early stage development that target unique conditions.  The ultimate outcome, including whether the product will be&#58; (i) fully developed, (ii) approved by the FDA or other regulators, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain. Under certain agreements, the Company may be required to make payments contingent upon the achievement of specific developmental, regulatory, or commercial milestones.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we announced that we had entered into two exclusive license agreements which present us with unique developmental opportunities to address the unmet need of treatment for myopia in children. The first of these two licensing agreements is with Eyenovia, Inc. for the development and commercialization in the United States and Canada of an investigational microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression, also known as nearsightedness, in children ages 3-12. We expect to complete enrollment for a Phase 3 study during the second half of 2022. If approved by the FDA, we believe this investigational product could potentially change the treatment paradigm for the reduction of myopia progression in children. The second is an exclusive global licensing agreement with BHVI for a myopia control contact lens design developed by BHVI. The Company plans to pair BHVI's novel contact lens design with our leading contact lens technologies to develop potential contact lens treatments designed to slow the progression of myopia in children.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we announced that we had acquired an exclusive license from Novaliq GmbH for the commercialization and development in the U.S. and Canada of the investigational treatment NOV03 (perfluorohexyloctane), a first-in-class investigational drug with a novel mechanism of action to treat dry eye disease (&#8220;DED&#8221;) associated with Meibomian gland dysfunction (&#8220;MGD&#8221;). In an Open Label Safety study, NOV03 has achieved its enrollment target.  In April 2021, we announced statistically significant topline data from the first of two Phase 3 studies and, in September 2021, we announced statistically significant topline data from the second Phase 3 study. We anticipate filing an NDA in the first half of 2022. If approved by the FDA, we believe the addition of this investigational treatment for DED will help build upon our strong portfolio of integrated eye- health products.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, we acquired an exclusive license from Clearside Biomedical, Inc. (&#8220;Clearside&#8221;) for the commercialization and development of Xipere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (triamcinolone acetonide suprachoroidal injectable suspension) in the U.S. and Canada. Xipere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for suprachoroidal </font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">administration via Clearside's proprietary SCS Microinjector. In October 2021, the FDA approved Xipere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for suprachoroidal use for the treatment of macular edema associated with uveitis. We launched Xipere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the first quarter of 2022.</font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, we entered into two licensing agreements which presented us with unique developmental opportunities to address unmet needs of individuals suffering with certain GI and liver diseases. The first of these two licensing agreements was with the University of California for certain intellectual property relating to an investigational compound targeting the pituitary adenylate cyclase receptor 1 in non-alcoholic fatty liver disease (&#8220;NAFLD&#8221;), nonalcoholic steatohepatitis (&#8220;NASH&#8221;) and other GI and liver diseases. However, as some early non-clinical (in-vitro) development work did not meet our internal expectations, in September 2021, we made the decision to terminate this license agreement and notified the University of California accordingly. The second is an exclusive licensing agreement with Mitsubishi Tanabe Pharma Corporation to develop and commercialize MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate receptor that plays a role in autoimmune diseases, such as inflammatory bowel disease and ulcerative colitis. We have completed a thorough QTC study, which evaluated the cardiac safety profile of the compound. Topline results were positive, and we commenced a Phase 2 study in the first half of 2021.</font></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_175"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Strategic Investments in our Infrastructure</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In support of our core businesses, we have and continue to make strategic investments in our infrastructure, the most significant of which are at our Waterford facility in Ireland, our Rochester facility in New York and our Lynchburg facility in Virginia. </font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To meet the forecasted demand for our Biotrue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday range of contact lenses, in July 2017, we placed into service a $175 million multi-year strategic expansion project of the Waterford facility.  The emphasis of the expansion project was to&#58; (i) develop new technology to manufacture, automatically inspect and package contact lenses, (ii) bring that technology to full validation and (iii) increase the size of the Waterford facility.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To address the expected global demand for our Bausch + Lomb ULTRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> range of contact lenses, in December 2017, we completed a multi-year, $220 million strategic upgrade to our Rochester facility.  The upgrade increased production capacity in support of our Bausch + Lomb Ultra</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and SiHy Daily AQUALOX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product lines and better supports the production of other well-established contact lenses, such as our PureVision</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, PureVision</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 (SVS, Toric, and Multifocal), SofLens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38 and SilSoft</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To address the expected global demand for our SiHy Daily disposable contact lenses, in November 2018, we initiated $300 million of additional projects to add multiple production lines to our Rochester and Waterford facilities. These production lines have recently been completed and we expect to start production of our latest contact lenses, Bausch + Lomb INFUSE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Bausch + Lomb ULTRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY, at these facilities in early 2022.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further help us meet the anticipated demand of our contact lenses, in 2020, we initiated an expansion of the Company's Lynchburg distribution center. The new facility is expected to create new jobs over the next five years and expand the overall site to 200,000 square feet, which will provide distribution capabilities for medical devices, primarily contact lens products, and be the main point of distribution for these products in the U.S. This expansion program is expected to be completed in the first half of 2022.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In</font><font style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">July 2021, we announced plans to invest an additional $90 million to increase capacity at our Waterford facility to meet the expected demand for our Biotrue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday range of daily disposable contact lenses.  The new production lines are expected to be completed in 2023.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If completed as planned, the recently announced expansion of our Waterford facility will be the fifth major expansion of our Bausch + Lomb manufacturing facilities in support of our efforts to increase market share in the contact lens market in the seven years ending 2023. We believe the investments in our Waterford, Rochester and Lynchburg facilities and related expansion of labor forces further demonstrates the growth potential we see in our Bausch + Lomb products and our eye- health business.</font></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_178"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effectively Managing Our Capital Structure  </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to effectively manage our capital structure by&#58; (i) executing on our plan for the B+L Separation and Solta IPO, (ii) reducing our debt through repayments, (iii) extending the maturities of debt through refinancing and (iv) improving our credit ratings.  </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since announcing our plans for the B+L Separation and the Solta IPO, we emphasized that it is important that the post-separation entities be well capitalized, with appropriate leverage and with access to additional capital, if and when needed, to provide each entity with the ability to independently allocate capital to areas that will strengthen their own competitive positions in their respective lines of business and position each entity for sustainable growth. Therefore, we see the appropriate </font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capitalization and leverage of these businesses post-separation as a key to maximizing value across our portfolio of assets and, so, it is a primary objective of our plan of separation.  </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Repayments and Other Financing Transactions &#8212; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, our new executive team committed to improving our Company's capital structure and since that time we have been executing and continue to execute on that commitment.  As a result of a series of debt repayments and transactions since making that commitment, the Company positioned itself to add value through the B+L Separation and Solta IPO while at the same time providing for the appropriate capitalization and leverage of these businesses post-separation.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the impact of the $1,210 million financing of the U.S. Securities Litigation settlement (discussed in the subsequent section titled &#8220;OFF-BALANCE SHEET ARRANGEMENTS AND CONTRACTUAL OBLIGATIONS&#8221;), we have repaid (net of additional borrowings) approximately $10,000&#160;million of long-term debt during the period January 1, 2016 through December 31, 2021 using the net cash proceeds from divestitures of non-core assets, cash generated from operations and cash generated from tighter working capital management. This includes approximately $1,300&#160;million of repayments (net of additional borrowings) during 2021 using cash on hand, cash generated from operations and the net proceeds from the Amoun Sale.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Focus on Capitalization of the Post-separation Entities</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the B+L Separation and Solta IPO, we have emphasized that it is important that the post-separation entities be well capitalized, with appropriate leverage and with access to additional capital, if and when needed, to provide each entity with the ability to independently allocate capital to areas that will strengthen their own competitive positions in their respective lines of business and position each entity for sustainable growth. Therefore, we see the appropriate capitalization and leverage of these new entities post-separation as a key to bringing out the maximum value across our portfolio of assets and, so, it is a primary objective of our plan of separation. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor market conditions and aim to launch the B+L IPO and Solta IPO when financial market conditions are favorable, subject to receipt of regulatory, stock exchange and other approvals and, in January and February 2022, took certain actions to, and announced others that we believe will, bring us closer in reaching our targeted capitalizations of the post-separation entities.  These actions are discussed in more detail in Item &#8220;&#8212; Liquidity and Capital Resources &#8212; Liquidity and Debt &#8212; Long-term Debt&#8221; and Note 23, &#8220;SUBSEQUENT EVENTS&#8221; to our audited Consolidated Financial Statements.  </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Continue to Manage our Capital Structure</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor our capital structure and to evaluate other opportunities to simplify our business and improve our capital structure, giving us the ability to better focus on our core businesses. Also, the Company regularly evaluates market conditions, its liquidity profile and various financing alternatives for opportunities to enhance its capital structure. If the Company determines that conditions are favorable, the Company may refinance or repurchase existing debt or issue additional debt, equity or equity-linked securities.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; and Note 23, &#8220;SUBSEQUENT EVENTS&#8221; to our audited Consolidated Financial Statements and Item &#8220;&#8212; Liquidity and Capital Resources &#8212; Liquidity and Debt &#8212; Long-term Debt&#8221; for further details and additional discussion regarding these matters. Cash requirements for future debt repayments including interest can be found in this Item &#8220;&#8212; Off-Balance Sheet Arrangements and Contractual Obligations.&#8221;</font></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_181"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improve Patient Access</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Improving patient access to our products, as well as making them more affordable, is a key element of our business strategy.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient Access and Pricing Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In 2016, we formed the Patient Access and Pricing Committee which is responsible for setting, changing and monitoring the pricing of our products and evaluating contract arrangements that determine the placement of our products on drug formularies. The Patient Access and Pricing Committee considers new to market product pricing, price changes and their impact across channels on patient accessibility and affordability. Since its inception, the Patient Access and Pricing Committee has limited the average annual price increase for our branded prescription pharmaceutical products to single digits. Future pricing changes and programs could affect the average realized pricing for our products and may have a significant impact on our revenues and profits.</font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch Health Patient Assistance Program - </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to supporting patients who have lost employment health benefits due to the COVID-19 pandemic, and because it is essential that our patients continue their prescribed treatments, we are proud to offer certain of our prescription medicines through our Bausch Health Patient Assistance Program.  In the face of the COVID-19 pandemic, some people have financial obstacles that keep them from obtaining and continuing their prescribed treatments. The purpose of the Bausch Health Patient Assistance Program is to provide eligible unemployed patients in the U.S., who meet stated qualifications and have lost their health insurance due to the COVID-19 pandemic, with certain of our prescription products where their financial circumstances or insurance status would otherwise interfere with their ability to access such products. If approved, patients receive their Bausch Health Companies Inc. prescription product(s) at no cost to them for up to one year, and may be able to reapply to the program annually if they continue to meet eligibility requirements and have a valid prescription.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash-pay Prescription Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In February 2019, we launched Dermatology.com, a cash-pay product acquisition program offering certain branded Ortho Dermatologics products directly to patients. In March 2020, the name Dermatology.com was removed as the cash-pay product program name, with the name Dermatology.com limited to only online usage, including future digital teledermatology and e-commerce offerings. The cash-pay program is designed to address the affordability and availability of certain branded dermatology products, when insurers and pharmacy benefit managers are no longer offering those branded prescription pharmaceutical products under their designated pharmacy benefit offerings.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Walgreens Fulfillment Arrangements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In the beginning of 2016, we launched a brand fulfillment arrangement with Walgreen Co. (&#8220;Walgreens&#8221;). Under the terms of the brand fulfillment arrangement, as amended in July 2019, we made certain dermatology and ophthalmology products available to eligible patients through patient access and co-pay assistance programs at Walgreens U.S. retail pharmacy locations, as well as participating independent retail pharmacies. </font></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_184"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invest in Sustainable Growth Drivers to Position us for Long-Term Growth</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are constantly challenged by the changing dynamics of our industry to innovate and bring new products to market.  We have divested certain businesses where we saw limited growth opportunities, so that we can be more aggressive in redirecting our R&#38;D spend and other corporate investments to innovate within our core businesses where we believe we can be most profitable and where we aim to be an industry leader. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we have a well-established product portfolio that is diversified within our core businesses and provides a sustainable revenue stream to fund our operations. However, our future success is also dependent upon our ability to continually refresh our pipeline, to provide a rotation of product launches that meet new and changing demands and replace other products that have lost momentum.  We believe we have a robust pipeline that not only provides for the next generation of our existing products, but is also poised to bring new products to market.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Invest in our Eye- Health Business - </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our global Bausch + Lomb business strategy, we continually look for key trends in the eye-health market to meet changing consumer&#47;patient needs and identify areas for investment to extend our market share through new launches and effective pricing. For instance, there is an increasing rate of myopia, and importantly, myopia as a potential risk factor for glaucoma, macular degeneration and retinal detachment. We continue to see increased demand for new eye- health products that address conditions brought on by factors such as increased screen time, lack of outdoor activities and academic pressures, as well as conditions brought on by an aging population (for example, as more and more baby-boomers in the U.S. are reaching the age of 65).  To extend our market share in eye- health, we continually seek to identify new products tailored to address these key trends for development internally with our own R&#38;D team to generate organic growth. Recent product launches include Biotrue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday daily disposable contact lenses, the next generation of Bausch + Lomb ULTRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contact lenses, SiHy Daily contact lenses (branded as AQUALOX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY in Japan, Bausch + Lomb INFUSE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SiHy Daily Disposable in the U.S. and Bausch + Lomb Ultra</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY in Australia, Hong Kong and Canada), Lumify</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (an eye redness treatment), Vyzulta</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (a pressure lowering eye drop for patients with angle glaucoma or ocular hypertension), Ocuvite</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Eye Performance (vitamins to protect the eye from stressors such as sunlight and blue light emitted from digital devices) and SimplifEYE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (preloaded intraocular lens injector platform for enVista intraocular lens). </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also license selective molecules or technology in leveraging our own R&#38;D expertise through development, as well as seek out external product development opportunities. As previously discussed, we acquired a global exclusive license for a myopia control contact lens design developed by BHVI, which we plan to pair with our leading contact lens technologies to develop potential contact lens treatments designed to slow the progression of myopia in children, and exclusive licenses for the commercialization and development in the U.S. and Canada of&#58; a microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression in children ages 3-12&#59; Xipere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which was approved by the FDA in October 2021 and launched in the first quarter of 2022, and is the first treatment available in the U.S. that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis&#59; and NOV03, an investigational drug with a novel mechanism of action to treat DED associated with MGD. which has demonstrated statistically significant topline data in two Phase 3 studies. We also acquired the U.S. rights to EM-100, which was launched as Alaway</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Preservative-</font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Free and is the first OTC preservative-free formulation eye drop for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair, and dander in adults and children 3 years of age and older. We believe investments in these investigational treatments, if approved by the FDA, will complement, and help build upon, our strong portfolio of integrated eye-health products.</font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, we have also made strategic investments in our infrastructure, the most significant of which were at our Waterford facility in Ireland to meet the forecasted demand for our Biotrue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONEday lenses, our Rochester facility in New York to address the expected global demand for our Bausch + Lomb ULTRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contact lens and our Lynchburg facility in Virginia to be our main point of distribution for medical devices in the U.S. During late 2018, we began investing in additional expansion projects at the Waterford and Rochester facilities in order to address the expected global demand for our SiHy Daily disposable contact lenses, which we launched in Japan in September 2018, under the branded name AQUALOX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY, in the U.S. in August 2020, under the branded name Bausch + Lomb INFUSE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SiHy Daily Disposable contact lens, and in Australia, Hong Kong and Canada in the fourth quarter of 2020, under the branded name Bausch + Lomb Ultra</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ONE DAY.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our recent product launches, licensing arrangements and the investments in our Waterford, Rochester and Lynchburg facilities demonstrate the growth potential we see in our Bausch + Lomb products and our eye-health business and that these investments will position us to further extend our market share in the eye- health market.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leveraging our Salix Infrastructure - </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strongly believe in our GI product portfolio and we have implemented initiatives, including increasing our marketing presence and identifying additional opportunities outside our existing GI portfolio, to further capitalize on the value of the infrastructure we built around these products to extend our market share. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2017, we hired approximately 250 trained and experienced sales force representatives and managers to create, bolster and sustain deep relationships with primary care physicians (&#8220;PCP&#8221;). With approximately 70% of IBS-D patients initially presenting symptoms to a PCP, we continue to believe that the dedicated PCP sales force is better positioned to reach more patients in need of IBS-D treatment. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This initiative provided us with positive results, as we experienced consistent growth in demand for our GI products throughout 2017 through 2021 which was evident by our growth in Salix revenues of 32% when comparing 2021 to 2017. These results encouraged us to seek out ways to bring out further value through leveraging our existing sales force and, in the later portion of 2018 and in 2019, we identified and executed on certain opportunities which we describe below.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Strategic Acquisition - </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, in March 2019, we completed the acquisition of certain assets of Synergy, whereby we acquired the worldwide rights to the Trulance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product, a once-daily tablet for adults with chronic idiopathic constipation, or CIC and irritable bowel syndrome with constipation, or IBS-C. We believe that the Trulance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product complements our existing Salix products and allows us to effectively leverage our existing GI sales force.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licensing Arrangements - </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, in April 2019, we entered into a licensing agreement to develop and commercialize MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate receptor that plays a role in autoimmune diseases, such as inflammatory bowel disease and ulcerative colitis.  This license presents a unique developmental opportunity to address unmet needs of individuals suffering with certain GI and liver diseases and if developed and approved by the FDA, will allow us to further utilize our existing sales force and infrastructure to extend our market share in the future and create value.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Next Generation Formulations - </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from our Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product increased approximately 11%, 2% and 22% in 2021, 2020 and 2019, respectively. In order to extend the growth in Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we continue to directly invest in next generation formulations of Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and rifaximin, the principal semi-synthetic antibiotic used in our Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product.  In addition to three R&#38;D programs in progress, we have another R&#38;D program planned for a next generation formulation of Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) which would address a new indication.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the acquisition and licensing opportunities discussed above will be accretive to our business by providing us access to products and investigational compounds that are a natural pairing to our Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> business, allowing us to effectively leverage our existing infrastructure and sales force. We believe these opportunities, coupled with our investment in next generation formulations, will allow our GI franchise to continue to further extend market share.</font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reposition the Ortho Dermatologics Business to Generate Additional Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - As of January 2022, we have positioned the Solta Medical business to move forward with the Solta IPO.  We continue to monitor market conditions and aim to launch the Solta IPO when financial market conditions are favorable subject to receipt of regulatory, stock exchange and other approvals. However, there can be no assurance as to when we will complete the Solta IPO, if at all. Until such time, we continue to manage our Solta business and our medical dermatology business with our continued commitment to bring out additional value for our shareholders. We continue to make investments in our Solta portfolio and anticipate building out our Solta sales force, </font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">particularly in Europe, to address the growing demand for our Solta aesthetic medical devices. Our Ortho Dermatologics business continues to work towards improving the treatment options for medical dermatology patients needing topical acne and psoriasis products. We also continue to explore additional strategic e-commerce and partnership expansion opportunities which can enable increased accessibility for patients and we continue to invest in our on-market products and evaluate various opportunities for our key medical dermatology pipeline products. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In support of the complete dermatology portfolio, we continue to take a number of actions that we believe will help our efforts to stabilize our dermatology business. These actions include&#58; (i) building on our legacy brands to improve and meet today&#8217;s physician relevance and customer service, (ii) appointing new leadership, (iii) making key investments in our core medical device and dermatological products portfolios, (iv) optimizing our go to market strategy by building on our relationships with prescribers of our products to balance our sales portfolio with the business' profitability, (v) refocusing our operational and promotional resources and (vi) improving patient access to our Ortho Dermatologics products through our cash-pay prescription program previously discussed. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, we identified launches of certain Ortho Dermatologics products which were not going to achieve their trajectories as forecasted once the social restrictions associated with the COVID-19 pandemic began to ease in the U.S. and offices of health care professionals could reopen. In addition, insurance coverage pressures within the U.S. continued to persist, limiting patient access to topical acne and psoriasis products.  In light of these developments, during the first quarter of 2021, the Company began taking steps to&#58; (i) redirect its R&#38;D spend to eliminate projects it has identified as high cost and high risk, (ii) redirect a portion of its marketing and product development outside the U.S. to geographies where there is better patient access and (iii) reduce its cost structure to be more competitive.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment in Our Core Dermatology Portfolio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - We have made significant investments to build out our aesthetics, psoriasis and acne product portfolios, which are the markets within dermatology where we see the greatest opportunities to extend our market share.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Aesthetics</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In 2017, we launched our next generation Thermage FLX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product in the U.S., a fourth-generation non-invasive treatment option using a radiofrequency platform designed to optimize key functional characteristics and improve patient outcomes. Next generation Thermage FLX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was launched in the U.S., Hong Kong, Japan, Korea, Chinese Taipei, Philippines, Singapore, Indonesia, Malaysia, China, Thailand, Vietnam, Australia and various parts of Europe as part of our Solta aesthetic medical devices portfolio. These launches have been successful as next generation Thermage FLX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues were $154 million, $142 million and $77 million for the years ended December 31, 2021, 2020 and 2019, respectively. We plan to continue to expand into other regions, paced by country-specific regulatory registrations. Consistent with our business strategy to continually update and improve our technology, in 2021, we launched, our next generation Clear + Brilliant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Touch</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> system in the U.S., which is designed to deliver a customized and more comprehensive treatment protocol by providing patients of all ages and skin types the benefits of two wavelengths. The launch of our next generation Clear + Brilliant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Touch</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> system in the U.S. is expected to serve as a foundation for future launches in Asia and Europe.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Psoriasis</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In response to the increasing number of reported cases of psoriasis in the U.S., we launched Duobrii</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in June 2019 and launched Bryhali</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in November 2018, which align well with our topical portfolio of psoriasis treatments. Although, we continue to support a diverse portfolio of topical and injectable biologics, in order to provide a diverse choice of psoriasis treatments to doctors and patients&#59; we believe some patients prefer topical products as an alternative to injectable biologics.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acne</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In support of our established acne product portfolio, we have developed and launched several products, which include Arazlo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(tazarotene) Lotion (launched in the U.S. in June 2020), Altreno</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(launched in the U.S. in October 2018), the first lotion (rather than a gel or cream) product containing tretinoin for the treatment of acne, and Retin-A Micro</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 0.06% (launched in the U.S. in January 2018). We also have a unique acne project in our pipeline that, if approved by the FDA, we believe will further innovate and advance the treatment of acne.</font></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_187"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Trends</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the actions previously outlined, the events described below have affected and may affect our business trends.  The matters discussed in this section contain Forward-Looking Statements.  Please see &#8220;Forward-Looking Statements&#8221; for additional information.</font></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_190"></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Tax Reform</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, U.S. President Joseph Biden proposed changes to the U.S. tax system. Since that date, both houses of Congress have released their own proposals for changes to the U.S. tax system, which differ in a number of respects from the President&#8217;s proposal. The proposals under discussion have included changes to the U.S. corporate tax system that would </font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase U.S. corporate tax rates, although the most recent proposals do not include any such rate increase, and changes that would raise the tax rate on and make other changes to the taxation of Global Intangible Low Tax Income earned by foreign subsidiaries. Also under consideration are modifications to the Base Erosion and Anti-Abuse Tax, which would tax certain payments, including some that are related to inventory, made to affiliates that are subject to an effective tax rate of less than specified rates. Certain proposals also include limitations on the participation exemption for foreign dividends received and interest expense. In addition, certain proposals include limitations on the deduction of interest expense and carryforwards of unused interest expense, as well as an excise tax on certain pharmaceutical products that are non-compliant with the proposed drug pricing legislation.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict which, if any, U.S. tax reform proposals will be enacted into law, and what effects any enacted legislation might have on our liability for U.S. corporate tax. However, it is possible that the enactment of changes in the U.S. corporate tax system could have a material adverse effect on our liability for U.S. corporate tax and our consolidated effective tax rate.</font></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_193"></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Global Minimum Corporate Tax Rate</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8, 2021, the Organisation for Economic Co-operation and Development (&#8220;OECD&#8221;)&#47;G20 inclusive framework on Base Erosion and Profit Shifting (the &#8220;Inclusive Framework&#8221;) published a statement updating and finalizing the key components of a two-pillar plan on global tax reform originally agreed on July 1, 2021, and a timetable for implementation by 2023. The Inclusive Framework plan has now been agreed to by 141 OECD members, including several countries which did not agree to the initial plan. Under pillar one, a portion of the residual profits of multinational businesses with global turnover above &#8364;20 billion and a profit margin above 10% will be allocated to market countries where such allocated profits would be taxed. Under pillar two, the Inclusive Framework has agreed on a global minimum corporate tax rate of 15% for companies with revenue above &#8364;750 million, calculated on a country-by-country basis. On October 30, 2021, the G20 formally endorsed the new global minimum corporate tax rate rules. The Inclusive Framework agreement must now be implemented by the OECD Members who have agreed to the plan, effective in 2023. On December 20, 2021, the OECD published model rules to implement the pillar two rules, which are generally consistent with the agreement reached by the Inclusive Framework in October 2021.  Additional guidance is expected to be published in 2022. We will continue to monitor the implementation of the Inclusive Framework agreement by the countries in which we operate. While we are unable to predict when and how the Inclusive Framework agreement will be enacted into law in these countries, and it is possible that the implementation of the Inclusive Framework agreement, including the global minimum corporate tax rate could have a material effect on our liability for corporate taxes and our consolidated effective tax rate.</font></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_196"></div><div style="margin-bottom:8pt;margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Care Reform</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal and state governments continue to propose and pass legislation designed to regulate the health care industry. In March&#160;2010, the Patient Protection and Affordable Care Act (the &#8220;ACA&#8221;) was enacted in the U.S.&#160;The ACA contains several provisions that impact our business, including&#58; (i) an increase in the minimum Medicaid rebate to states participating in the Medicaid program, (ii) the extension of the Medicaid rebates to Managed Care Organizations that dispense drugs to Medicaid beneficiaries, (iii) the expansion of the 340(B) Public Health Services drug pricing program, which provides outpatient drugs at reduced rates, to include additional hospitals, clinics and health care centers and (iv) a fee payable to the federal government based on our prior-calendar-year share relative to other companies of branded prescription drug sales to specified government programs.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in 2013 federal subsidies began to be phased in for brand-name prescription drugs filled in the Medicare Part D coverage gap. The ACA also included provisions designed to increase the number of Americans covered by health insurance. In 2014, the ACA's private health insurance exchanges began to operate. The ACA also allows states to expand Medicaid coverage with most of the expansion&#8217;s cost paid for by the federal government.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2021, 2020 and 2019, we incurred costs of $13 million, $21 million and $20 million, respectively, related to the annual fee assessed on prescription drug manufacturers and importers that sell branded prescription drugs to specified U.S.&#160;government programs (e.g.,&#160;Medicare and Medicaid). For 2021, 2020 and 2019, we also incurred costs of $94 million, $131 million and $137 million, respectively, on Medicare Part&#160;D utilization incurred by beneficiaries whose prescription drug costs cause them to be subject to the Medicare Part&#160;D coverage gap (i.e.,&#160;the &#8220;donut&#160;hole&#8221;). </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial impact of the ACA will be affected by certain additional developments over the next few years, including pending implementation guidance and certain health care reform proposals. Additionally, policy efforts designed specifically to reduce patient out-of-pocket costs for medicines could result in new mandatory rebates and discounts or other pricing restrictions. Also, it is possible, as discussed further below, that legislation will be passed by Congress repealing the ACA in whole or in part.  Adoption of legislation at the federal or state level could materially affect demand for, or pricing of, our products.</font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2011, the law imposed a significant annual fee on companies that manufacture or import branded prescription drug products. More recently, the Bipartisan Budget Act of 2018 amended the Patient Protection and Affordable Care Act, effective January 1, 2019, to close the donut hole in most Medicare drug plans. In addition, in April 2018, the Centers for Medicare &#38; Medicaid Services published a final rule that gives states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the Patient Protection and Affordable Care Act for plans sold through such marketplaces.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we faced uncertainties due to federal legislative and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the ACA. However, we believe there is low likelihood of repeal of the ACA, given the recent failure of the Senate&#8217;s multiple attempts to repeal various combinations of ACA provisions and the recent change in administration. There is no assurance that any replacement or administrative modifications of the ACA will not adversely affect our business and financial results, particularly if the replacing legislation reduces incentives for employer-sponsored insurance coverage, and we cannot predict how future federal or state legislative or administrative changes relating to the reform will affect our business.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the U.S. Department of Health and Human Services announced a preliminary plan to allow for the importation of certain lower-cost drugs from Canada. The preliminary plan excludes insulin, biological drugs, controlled substances and intravenous drugs. The preliminary plan relies on individual states to develop proposals for safe importation of those drugs from Canada and submit those proposals to the federal government for approval. Although the preliminary plan has some support from the prior administration, at this time, studies to evaluate the related costs and benefits, evaluate the reasonableness of the logistics, and measure the public reaction of such a plan have not been performed. While we do not believe this will have a significant impact on our future cash flows, we cannot provide assurance as to the effect or impact of such a plan.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Government of Canada (Health Canada) published in the Canada Gazette the new pricing regulation for patented drugs. These regulations were scheduled to become effective on July 1, 2021, but have been delayed until July 1, 2022. The new regulations will, among other things, change the mechanics of establishing the pricing for products submitted for approval after August 21, 2019 and the number and composition of reference countries used to determine if a drug&#8217;s price is excessive. While we do not believe this will have a significant impact on our future cash flows, as additional facts materialize, we cannot provide assurance as to the ultimate content, timing, effect or impact of such regulations.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, former U.S. President Donald Trump signed four Executive Orders related to drug pricing, including orders addressing&#58; (i) Part D rebate reform, (ii) the provision of deeply discounted insulin and&#47;or an EpiPen to patients of Federally Qualified Health Centers, (iii) drug importation from Canada and (iv) most favored nation pricing for Medicare. In November 2020, former U.S. President Donald Trump announced the Most Favored Nation Model for Medicare Part B Payment which was to be implemented by the Centers for Medicare &#38; Medicaid Services Innovation Center on January 1, 2021&#59; however, it has not been implemented, as it is currently being challenged in court. It is also uncertain whether the Biden administration intends to reverse these measures or adopt similar policy initiatives. However, U.S. President Joseph Biden and several members of the current U.S. Congress have indicated that lowering drug prices is a legislative and political priority, and some have introduced proposals that seek to address drug pricing. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, as part of a series of drug pricing-related rules issued by the Trump Administration, the Center for Medicare &#38; Medicaid Services issued a Final Rule that makes significant modifications to the Medicaid Drug Rebate Program regulations in several areas, including with respect to the definition of key terms &#8220;line extension&#8221; and &#8220;new formulation&#8221; and best price reporting relating to certain value-based purchasing arrangements (which took effect on January 1, 2022) and the price reporting treatment of manufacturer-sponsored patient benefit programs (which take effect on January 1, 2023). </font></div><div style="text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the U.S. Congress enacted the American Rescue Plan Act of 2021. One of the provisions included within the American Rescue Plan Act of 2021 eliminated the Maximum Rebate Amount for Single Source drugs and Innovator Multiple Source drugs in the Medicaid Drug Rebate Program.  We are currently reviewing this legislation, the impact of which is uncertain at this time.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative efforts relating to drug pricing have been enacted and others have been proposed at the U.S. federal and state levels. For instance, certain states have enacted legislation related to prescription drug pricing transparency. Several states have passed importation legislation and Florida is working with the U.S. government to implement an importation program from Canada. We also anticipate that Congress, state legislatures and third-party payors may continue to review and assess alternative health care delivery and payment systems and may in the future propose and adopt legislation or policy changes or implementations affecting additional fundamental changes in the health care delivery system. We continually review newly enacted and proposed U.S. federal and state legislation, as well as proposed rulemaking and guidance published by the U.S. Department of Health and Human Services and the FDA&#59; however, at this time, it is unclear the effect these matters may have on our businesses.</font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_199"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Competition and Loss of Exclusivity</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our products face the expiration of their patent or regulatory exclusivity in 2022 or in later years, following which we anticipate generic competition of these products. In addition, in certain cases, as a result of negotiated settlements of some of our patent infringement proceedings against generic competitors, we have granted licenses to such generic companies, which will permit them to enter the market with their generic products prior to the expiration of our applicable patent or regulatory exclusivity. Finally, for certain of our products that lost patent or regulatory exclusivity in prior years, we anticipate that generic competitors may launch in 2022 or in later years. Following a loss of exclusivity (&#8220;LOE&#8221;) of and&#47;or generic competition for a product, we would anticipate that product sales for such product would decrease significantly shortly following the LOE or entry of a generic competitor. Where we have the rights, we may elect to launch an authorized generic of such product (either ourselves or through a third-party) prior to, upon or following generic entry, which may mitigate the anticipated decrease in product sales&#59; however, even with launch of an authorized generic, the decline in product sales of such product would still be expected to be significant, and the effect on our future revenues could be material.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of our products already face generic competition.  Prior to and during 2021, in the U.S., these products include, among others, Ammonul</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Apriso</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Benzaclin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bepreve</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bupap</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cuprimine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Demser</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Edecrin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Elidel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Glumetza</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Istalol</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Isuprel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Locoid</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lotion, Lotemax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gel, Lotemax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Suspension, Mephyton</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Migranal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MoviPrep</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Nitropress</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Solodyn</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Syprine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Timoptic</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Ocudose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Uceris</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tablet, Virazole</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Wellbutrin&#160;XL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Xenazine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zegerid</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Zovirax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cream.  In Canada, these products include, among others, Glumetza</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Wellbutrin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;XL and Zovirax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ointment.</font></div><div style="text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">2021 LOE Branded Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">- Branded products that began facing generic competition in the U.S. during 2021 included Lotemax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Gel, Bepreve</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, Clindagel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and certain other products. These products accounted for less than 1% of our total revenues in 2020. We believe the entry into the market of generic competition generally would have an adverse impact on the volume and&#47;or pricing of the affected products, however we are unable to predict the magnitude or timing of this impact.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 through 2026 LOE Branded Products</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Based on current patent expiration dates, settlement agreements and&#47;or competitive information, we have identified branded products that we believe could begin facing potential LOE and&#47;or generic competition in the U.S. during the years 2022 through 2026.  These products and year of expected LOE include, but are not limited to, Noritate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (2022), Targretin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gel (2022), Xerese</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2022)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and certain other products that are subject to settlement agreements which could impact their exclusivity during the years 2022 through 2026.&#160;In aggregate, these products accounted for 2% of our total revenues in 2021. These dates may change based on, among other things, successful challenge to our patents, settlement of existing or future patent litigation and at-risk generic launches. We believe the entry into the market of generic competition generally would have an adverse impact on the volume and&#47;or pricing of the affected products, however we are unable to predict the magnitude or timing of this impact.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, for a number of our products (including Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 550mg, Bryhali</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trulance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lumify</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Relistor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Injection in the U.S and Jublia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Canada.), we have commenced (or anticipate commencing) and have (or may have) ongoing infringement proceedings against potential generic competitors in the U.S. and Canada. If we are not successful in these proceedings, we may face increased generic competition for these products.  </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bryhali</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Lotion, 0.01% (Glenmark)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In December 2019, the Company announced that it had reached an agreement to resolve&#160;the&#160;outstanding&#160;intellectual&#160;property&#160;litigation&#160;with&#160;Glenmark&#160;Pharmaceuticals,&#160;Ltd. (&#8220;Glenmark&#8221;). Under the terms of the agreement, the Company will grant Glenmark a non-exclusive license to its intellectual property relating to Bryhali</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. and, beginning in 2026 (or earlier under certain circumstances), Glenmark will have the option to market a royalty-free generic version of Bryhali</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lotion, should it receive approval from the FDA. The parties have agreed to dismiss all litigation related to Bryhali</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lotion, and all intellectual property protecting Bryhali</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lotion remains intact.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bryhali</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Lotion, 0.01% (Padagis) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-  On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (now Padagis LLC) (&#8220;Padagis&#8221;), in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Bryhali</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and&#47;or will not be infringed by the commercial manufacture, use or sale of Padagis' generic halobetasol propionate lotion, for which an Abbreviated New Drug Application (&#8220;ANDA&#8221;) has been filed by Padagis.&#160; On May 1, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Bryhali</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA for halobetasol propionate lotion.&#160;On September 3, 2020, this action was consolidated with the action between the Company and Padagis described below, regarding Padagis' ANDA for generic Duobrii</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotine) lotion. The Company remains confident in the strength of the Bryhali</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously pursue this matter and defend its intellectual property.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Duobrii</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Lotion (Padagis) - </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2020, the Company received a Notice of Paragraph IV Certification from Padagis, in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA's Orange Book for Duobrii</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotine) lotion, are either invalid, unenforceable and&#47;or will not be infringed by the commercial </font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacture, use or sale of Padagis' generic lotion, for which an ANDA has been filed by Padagis.  On August 28, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Duobrii</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA.  On September 3, 2020, this action was consolidated with the action between the Company and Padagis described above, regarding Padagis' ANDA for generic Bryhali</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion. We remain confident in the strength of the Duobrii</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will vigorously defend our intellectual property.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> 550mg Patent Litigation (Actavis) - </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2016, the Company initiated litigation against Actavis Laboratories FL, Inc.&#8217;s (&#8220;Actavis&#8221;), which alleged infringement by Actavis of one or more claims of each of the Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents. On September 12, 2018, we announced that we had reached an agreement with Actavis that resolved the existing litigation and eliminated the pending challenges to our intellectual property protecting Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets. As part of the agreement, the parties agreed to dismiss all litigation related to Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin), Actavis acknowledged the validity of the licensed patents for Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets and all intellectual property protecting Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets will remain intact and enforceable until expiry in 2029. The agreement also grants Actavis a non-exclusive license to the intellectual property relating to Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets in the United States beginning January 1, 2028 (or earlier under certain circumstances). The Company will not make any financial payments or other transfers of value as part of the agreement. In addition, under the terms of the agreement, beginning January 1, 2028 (or earlier under certain circumstances), Actavis will have the option to&#58; (1) market a royalty-free generic version of Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tablets, 550 mg, should it receive approval from the FDA on its ANDA, or (2) market an authorized generic version of Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tablets, 550 mg, in which case, we will receive a share of the economics from Actavis on its sales of such an authorized generic. Actavis will be able to commence such marketing earlier if another generic rifaximin product is granted approval and such other generic rifaximin product begins to be sold or distributed before January 1, 2028.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">550mg Patent Litigation (Sandoz) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-  In October 2019, the Company announced that it and its licensor, Alfasigma had commenced litigation against Sandoz Inc. (&#8220;Sandoz&#8221;), a Novartis division, alleging patent infringement of 14 patents by Sandoz's filing of its ANDA for Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 550 mg tablets. On May 6, 2020, the Company announced that an agreement had been reached with Sandoz that resolved this litigation. Under the terms of the agreement, </font><font style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the parties agreed to dismiss all litigation related to Xifaxan</font><font style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(rifaximin), Sandoz acknowledged the validity of the licensed patents for Xifaxan</font><font style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(rifaximin) 550 mg tablets and all intellectual property protecting Xifaxan</font><font style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(rifaximin) 550 mg tablets will remain intact and enforceable until expiry in October 2029. The agreement also grants Sandoz a non-exclusive license to the intellectual property relating to Xifaxan</font><font style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(rifaximin) 550 mg tablets in the United States beginning January 1, 2028 (or earlier under certain circumstances).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the terms of the agreement, beginning January 1, 2028 (or earlier under certain circumstances), Sandoz will have the right to market a royalty-free generic version of </font><font style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xifaxan</font><font style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(rifaximin)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 550 mg tablets, should it receive approval from the FDA on its ANDA. </font><font style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sandoz will be able to commence such marketing earlier if another generic rifaximin product is granted approval and such other generic rifaximin product begins to be sold or distributed in the U.S. before January 1, 2028.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not make any financial payments or other transfers of value as part of this agreement with Sandoz.</font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">550mg Patent Litigation (Norwich) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">- On March 26, 2020, the Company and its licensor Alfasigma filed suit against Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;), alleging infringement by Norwich of one or more claims of the 23 Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> patents by Norwich&#8217;s filing of its ANDA for Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (rifaximin) 550 mg tablets.  On November 13, 2020, an additional three patents alleged to be infringed by Norwich were added to the suit.  Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> 550mg is protected by 26 patents covering the composition of matter and the use of Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange&#160;Book. A 3-day bench trial is scheduled to begin March 21, 2022. The Company remains confident in the strength of the Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> patents and will continue to vigorously pursue this matter and defend its intellectual property.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">200mg and 550mg Patent Litigation (Sun) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- In April 2019, the Company and its licensor, Alfasigma, commenced litigation against Sun Pharmaceutical Industries Ltd. (&#8220;Sun&#8221;), alleging patent infringement by Sun&#8217;s filing of its ANDA for Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from Sun, in which Sun asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 200 mg, were either invalid, unenforceable and&#47;or would not be infringed by the commercial manufacture, use or sale of Sun&#8217;s generic rifaximin tablets, 200 mg. Subsequently, on August 10, 2020, the Company received an additional Notice of Paragraph IV Certification from Sun, in which Sun asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 550 mg, were either invalid, unenforceable and&#47;or would not be infringed by the commercial manufacture, use or sale of Sun&#8217;s generic rifaximin tablets, 550 mg, for which an ANDA had been filed by Sun. On September 22, 2020, the Company announced that an agreement had been reached with Sun that resolved the outstanding intellectual property disputes with Sun regarding Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets. Under the terms of the agreement, the parties agreed to dismiss all litigation related to Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) and all intellectual property protecting Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets will remain intact and enforceable until expiry in July and October 2029, respectively. </font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement also grants Sun a non-exclusive license to the intellectual property relating to Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets in the U.S. beginning January 1, 2028 (or earlier under certain circumstances). Under the terms of the agreement, beginning January 1, 2028 (or earlier under certain circumstances), Sun will have the right to market royalty-free generic versions of Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (rifaximin) 200 mg and 550 mg tablets, should it receive approval from the FDA on its ANDAs. Sun will be able to commence such marketing earlier if another generic rifaximin product is granted approval and such other generic rifaximin product begins to be sold or distributed in the U.S. before January 1, 2028. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Relistor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Tablets Patent Litigation (Actavis)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - On December 6, 2016, the Company initiated litigation against Actavis, which alleged infringement by Actavis of one or more claims of U.S.&#160;Patent No. 8,524,276 (the &#8220;&#8216;276 Patent&#8221;), which protects the formulation of RELISTOR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets. Actavis had challenged the validity of such patent and alleged non-infringement by its generic version of such product. In July 2019, we announced that the U.S. District Court of New Jersey had upheld the validity of and determined that Actavis infringed the &#8216;276 Patent, expiring in March 2031.  Actavis has appealed this decision to the U.S. Court of Appeals for the Federal Circuit. In March 2021, the Company and Actavis reached a settlement agreement and the appeal was dismissed.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Relistor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Injection Patent Litigation (Gland)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - On February 22, 2022, the Company commenced litigation against Gland Pharma Limited (&#8220;Gland&#8221;) alleging patent infringement by Gland&#8217;s filing of its ANDA No. 216836, referencing Relistor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (methynaltrexone bromide injection, vials) and its ANDA No. 216965, referencing Relistor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (methynaltrexone bromide injection, pre-filled syringes).  This suit had been filed following receipt of two Notices of Paragraph IV Certification from Gland, in which it had asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Relistor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> methynaltrexone bromide injection, were either invalid, unenforceable and&#47;or would not be infringed by the commercial manufacture, use or sale of its generic methynaltrexone bromide injection.  The filing of this suit triggered a 30-month stay of the approval of the Gland ANDA for its methynaltrexone bromide injection. The Company remains confident in the strength of the Relistor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will continue to vigorously pursue this matter and defend its intellectual property.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trulance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> 3mg Tablets Patent Litigation (MSN and Mylan)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> -  In March 2021, the Company received Notices of Paragraph IV Certification from MSN Laboratories Private Ltd. (&#8220;MSN&#8221;) and Mylan Pharmaceuticals Inc., (&#8220;Mylan&#8221;) in which MSN and Mylan asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Trulance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) 3mg tablets, are either invalid, unenforceable and&#47;or will not be infringed by the commercial manufacture, use or sale of their generic plecanatide tablets, for which each of MSN and Mylan had filed an ANDA.  In April 2021, the Company filed suit against MSN and Mylan, alleging infringement of one or more claims of the patents listed for Trulance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. The Company remains confident in the strength of the Trulance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will continue to vigorously pursue this matter and defend its intellectual property.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lumify</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Ophthalmic Solution Patent Litigation (Slayback)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In September 2021, the Company commenced litigation against Slayback Pharma LLC and Slayback Pharma India LLP (together, &#8220;Slayback&#8221;) alleging patent infringement by Slayback Pharma LLC&#8217;s filing of its ANDA No. 216361, referencing Lumify</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (0.025% brimonidine tartrate ophthalmic solution). This suit had been filed following receipt of a Notice of Paragraph IV Certification from Slayback Pharma LLC, in which it had asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Lumify</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brimonidine tartrate ophthalmic solution, were either invalid, unenforceable and&#47;or would not be infringed by the commercial manufacture, use or sale of its generic brimonidine tartrate solution.  The filing of this suit triggered a 30-month stay of the approval of the Slayback ANDA for its brimonidine tartrate solution. The Company remains confident in the strength of the Lumify</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will continue to vigorously pursue this matter and defend its intellectual property.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lumify</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Ophthalmic Solution Patent Litigation (Lupin)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; On February 2, 2022 the Company commenced litigation against Lupin Pharmaceuticals, Inc. (&#8220;Lupin&#8221;) alleging patent infringement by Lupin&#8217;s filing of its ANDA No. 216716, referencing Lumify</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (0.025% brimonidine tartrate ophthalmic solution). This suit had been filed following receipt of a Notice of Paragraph IV Certification from Lupin, in which it had asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Lumify</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brimonidine tartrate ophthalmic solution, were either invalid, unenforceable and&#47;or would not be infringed by the commercial manufacture, use or sale of its generic brimonidine tartrate solution.  The filing of this suit triggered a 30-month stay of the approval of the Lupin ANDA for its brimonidine tartrate solution. The Company remains confident in the strength of the Lumify</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will continue to vigorously pursue this matter and defend its intellectual property.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Competition to Uceris</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> - </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, a generic competitor launched a product which will directly compete with our Uceris</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tablet product. As disclosed in our prior filings, the Company initiated various infringement proceedings against this generic competitor. The Court construed the claims of the asserted patents on August 2, 2019 and, on October 24, 2019, the Company agreed to a judgment that the asserted patents did not cover the generic tablets under the Court&#8217;s claim construction, while reserving its right to appeal the claim construction. On November 22, 2019, the Company filed a Notice of Appeal with respect to the claim construction in the Court of Appeals for the Federal Circuit.  On December 18, 2020, the Court of Appeals for the Federal Circuit affirmed the District Court&#8217;s claim construction. The ultimate impact of this generic competitor on our </font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future revenues cannot be predicted&#59; however, Uceris</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tablet revenues for 2021, 2020 and 2019 were approximately $10&#160;million, $15&#160;million and $20&#160;million, respectively.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Competition to Jublia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> - </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2018, the U.S. Patent and Trial Appeal Board (&#8220;PTAB&#8221;) completed its inter partes review for an Orange Book-listed patent covering Jublia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (U.S. Patent No 7,214,506 (the &#8220;506 Patent&#8221;)) and issued a written determination invalidating such patent.&#160; On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings.&#160; As a result of a settlement, a joint motion to terminate the proceedings was filed on November 12, 2020 and, on January 8, 2021, the PTAB granted this motion.   The &#8216;506 Patent, therefore, remains valid and enforceable and expires in 2026. Jublia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> revenues for 2021, 2020 and 2019 were approximately $100&#160;million, $111&#160;million and $110&#160;million, respectively. &#160;Jublia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is covered by fourteen additional Orange Book-listed patents owned by the Company or its licensor, which expire in the years 2028 through 2035. In August and September 2018, the Company received notices of the filing of a number of ANDAs with paragraph IV certification, and has timely filed patent infringement suits against these ANDA filers, and, in addition, the Company has also commenced certain patent infringement proceedings in Canada against four separate defendants. All cases in the U.S. regarding Jublia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been settled. In Canada, two lawsuits remain pending against Apotex, Inc.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PreserVision</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Litigation -  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PreserVision</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AREDS and PreserVision</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AREDS 2 are OTC eye vitamin and mineral supplements containing nutrient formulas recommended by the National Eye Institute to reduce the risk of progression of intermediate to advanced AMD. PreserVision</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products accounted for 3% of our total revenues in 2021.  The PreserVision</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> U.S. formulation patent expired in March 2021, but a patent covering methods of using the formulation remains in force into 2026. The Company has filed patent infringement proceedings against 16 defendants claiming infringement of these patents and, in certain circumstances, related unfair competition and false advertising causes of action. Eleven of these proceedings were subsequently settled&#59; two resulted in entry of a default. One defendant filed a declaratory judgment action after the Company filed its suit, seeking declaratory judgment related to patent claims as well as false advertising and unfair competition claims. As of February 23, 2022, there are four unresolved actions. The Company remains confident in the strength of these patents and will continue to vigorously pursue these matters and defend its intellectual property. While the Company cannot predict the magnitude or timing of the impact from the PreserVision</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patent expiry, this is an OTC product and thus, the impact is not expected to be as significant as the LOE of a branded pharmaceutical product. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 20, &#8220;LEGAL PROCEEDINGS&#8221; to our audited Consolidated Financial Statements for further details regarding certain infringement proceedings.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risks of generic competition are a fact of the health care industry and are not specific to our operations or product portfolio.  These risks are not avoidable, but we believe they are manageable.  To manage these risks, our leadership team continually evaluates the impact that generic competition may have on future profitability and operations.  In addition to aggressively defending the Company's patents and other intellectual property, our leadership team makes operational and investment decisions regarding these products and businesses at risk, not the least of which are decisions regarding our pipeline. Our leadership team actively manages the Company's pipeline in order to identify innovative and realizable projects aligned with our core businesses that are expected to provide incremental and sustainable revenues and growth into the future.  We believe that our current pipeline is strong enough to meet these objectives and provide future sources of revenues, in our core businesses, sufficient enough to sustain our growth and corporate health as other products in our established portfolio face generic competition and lose momentum.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we have a well-established product portfolio that is diversified within our core businesses. We also believe that we have a robust pipeline that not only provides for the next generation of our existing products, but also brings new solutions into the market.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 1A. &#8220;Risk Factors&#8221; of this Form 10-K for additional information on our competition risks. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Matters</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, our products, devices and facilities are the subject of ongoing oversight and review by regulatory and governmental agencies, including general, for cause and pre-approval inspections by the relevant competent authorities where we have business operations. Through the date of this filing, all of our global operations and facilities have the relevant operational good manufacturing practices certificates and all Company products and operating sites are in good compliance standing with all relevant notified bodies and global health authorities. Further, all sites under FDA jurisdiction are rated as either No Action Indicated (where there was no Form 483 observation) or Voluntary Action Indicated (&#8220;VAI&#8221;) (where there was a Form 483 with one or more observations). In the case of VAI inspection outcomes, the FDA has accepted our responses to the issues cited, which will be verified when the agency makes its next inspection of those specific facilities.</font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_202"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL PERFORMANCE HIGHLIGHTS </font></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides financial performance highlights for each of the last three&#160;years&#58; </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.461%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share data)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 to 2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019 to 2020</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,434&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,027&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,601&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(574)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(226)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">879&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before benefit from income taxes</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,024)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,837)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">903&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(937)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(559)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,783)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(378)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,224&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(948)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(560)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,788)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share attributable to Bausch Health Companies Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.64)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.58)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.08)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.06)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.64)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.58)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.08)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.06)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Performance </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of 2021 Compared with 2020</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for 2021 and 2020 were $8,434 million and $8,027 million, respectively, an increase of $407 million, or 5%. The increase was primarily driven by&#58; (i) a net increase in volumes and (ii) the favorable impact of foreign currencies, primarily in Europe, Asia and Canada. These increases were partially offset by&#58; (i) our divestiture of Amoun on July 26, 2021 and (ii) a decrease in net realized pricing. The net increase in volumes was primarily due to the positive impacts from the recovery from the COVID-19 pandemic and the easing of certain social restrictions, as previously discussed, primarily during the three months ended June 30, 2021, partially offset by the impact of the loss of exclusivity of certain products. The changes in our segment revenues and segment profits are discussed in further detail in the subsequent section titled &#8220;Reportable Segment Revenues and Profits&#8221;.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income was $450 million and $676 million for 2021 and 2020, respectively, a decrease in our operating results of $226 million which reflects, among other factors&#58;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in contribution (product sales revenue less cost of goods sold, exclusive of amortization and impairments of intangible assets) of $259 million. The increase was primarily driven by&#58; (i) the increase in volumes, as previously discussed, and (ii) the favorable impact of foreign currencies, partially offset by&#58; (i) the impact of our divestiture of Amoun on July 26, 2021 and (ii) the decrease in net realized pricing&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in Selling, general, and administrative (&#8220;SG&#38;A&#8221;) expenses of $257 million, primarily attributable to&#58; (i) the impacts of the non-recurrence of certain profit protection measures taken in 2020 to manage and reduce operating expenses during the COVID-19 pandemic, as previously discussed, (ii) Separation-related and IPO-related costs incurred in 2021 and (iii) the impact of foreign currencies&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in R&#38;D of $13 million primarily attributable to the non-recurrence of the temporary suspension in certain R&#38;D activities and clinical trials in 2020, partially offset by a rebalancing of our portfolio within the Ortho Dermatologics business&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Amortization of intangible assets of $270 million primarily attributable to fully amortized intangible assets no longer being amortized in 2021&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Goodwill impairments of $469 million related to the impairment to the goodwill of the Ortho Dermatologics reporting unit during the three months ended March 31, 2021 as a result of revised forecasts due to&#58; (i) certain products that continued to experience longer launch cycles than originally anticipated, in part due to COVID-19 pandemic factors, and (ii) other changes to its product pipeline&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in Asset impairments, including loss on assets held for sale of $120 million, primarily attributable to&#58; (i) higher impairments to certain products and (ii) additional losses during 2021 related to assets classified as held for sale&#59; and</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Other expense, net of $129 million, primarily attributable&#58; (i) higher insurance recoveries related to certain litigation matters in 2021 as compared to 2020 and (ii) decreases in charges for Acquisition-related contingent consideration and Acquired in-process research and development costs.</font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income was $450 million and $676 million for 2021 and 2020, respectively, and includes non-cash charges for Depreciation and amortization of intangible assets of $1,552 million and $1,825 million, Asset impairments, including loss on assets held for sale of $234 million and $114 million, Goodwill impairments of $469 million and $0 and Share-based compensation of $128 million and $105&#160;million for 2021 and 2020, respectively.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Loss before benefit from income taxes for 2021 and 2020 was $1,024 million and $934 million, respectively, an increase in our Loss before benefit from income taxes of $90 million. The increase in our Loss before benefit from income taxes is primarily attributable to the decrease in our operating results of $226 million, as previously discussed, partially offset by&#58; (i) a decrease in Interest expense of $108 million and (ii) the favorable net change in Foreign exchange and other of $37 million.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to Bausch Health Companies Inc. for 2021 and 2020 was $948 million and $560 million, respectively, a decrease in our results of $388 million.  The decrease in our results was primarily due to&#58; (i)  a decrease in the Benefit from income taxes of $288 million, primarily attributable to the release of a portion of our valuation allowance against deferred tax assets in 2020 and (ii) the increase in Loss before benefit from income taxes of $90 million, as previously discussed. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of 2020 Compared with 2019</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for 2020 and 2019 were $8,027 million and $8,601 million, respectively, a decrease of $574 million, or 7%. The decrease was primarily driven by&#58; (i) lower volumes driven by&#58; (a) social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed, and (b) the impact of the LOE of certain products, (ii) the unfavorable effect of foreign currencies, primarily in Latin America, and (iii) the impact of divestitures and discontinuations. These decreases in our revenues were partially offset by the incremental sales of our Trulance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy. Net realized pricing was flat with increases in our International, Diversified Products, Bausch + Lomb and Solta Medical segments being offset by decreases in our Salix segment. The changes in our segment revenues and segment profits are discussed in further detail in the subsequent section titled &#8220;Reportable Segment Revenues and Profits&#8221;.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income for 2020 was $676 million compared to Operating loss for 2019 of $203 million, an increase in our operating results of $879 million which reflects, among other factors&#58;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in contribution (product sales revenue less cost of goods sold, exclusive of amortization and impairments of intangible assets) of $470 million. The decrease was primarily driven by&#58; (i) the decrease in revenues, as previously discussed and (ii) higher manufacturing variances primarily due to the impacts of the COVID-19 pandemic. The decrease was partially offset by lower third-party royalty costs&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in SG&#38;A expenses of $187 million, primarily attributable to profit protection measures taken to manage and reduce operating expenses during the COVID-19 pandemic&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in R&#38;D of $19 million primarily attributable to social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Amortization of intangible assets of $252 million primarily attributable to fully amortized intangible assets no longer being amortized in 2020&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in Asset impairments, including loss on assets held for sale of $39 million. Asset impairments, including loss on assets held for sale in 2020 were primarily related to&#58; (i) reclassifying a business within our International segment as held for sale and (ii) certain product lines as a result of changes to forecasted sales. Impairments during 2019 were primarily related to&#58; (i) certain product lines as a result of changes to forecasted sales due to generic competition and other factors and (ii) impairments related to assets being classified as held for sale&#59; and</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease in Other expense, net of $924 million, primarily attributable the decrease in net charges to Litigation and other matters.  The decrease in Litigation and other matters was primarily related to the settlement of a legacy U.S. securities class action matter (which is subject to an objector's appeal of the final court approval) in 2019, to which the Company and the other settling defendants admitted no liability as to the claims against it and denied all allegations of wrongdoing.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income for 2020 was $676 million compared to Operating loss for 2019 of $203 million and includes non-cash charges for Depreciation and amortization of intangible assets of $1,825 million and $2,075 million, Asset impairments, including loss on assets held for sale of $114 million and $75 million and Share-based compensation of $105 million and $102&#160;million for 2020 and 2019, respectively.</font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Loss before benefit from income taxes for 2020 and 2019 was $934 million and $1,837 million, respectively, an increase in our results before benefit from income taxes of $903 million. The decrease in our Loss before benefit from income taxes is primarily attributable to&#58; (i) the increase in our operating results of $879 million, as previously discussed, and (ii) a decrease in Interest expense of $78 million as a result of&#58; (a) a lower weighted average stated rate of interest, (b) lower interest as a result of debt repayments during the year and (c) a benefit related to the Company's cross-currency swaps. These decreases in Interest expense were partially offset by the interest associated with $1,210 million of additional financing in December 2019 relating to the U.S. Securities Litigation. The decrease in our Loss before benefit from income taxes was partially offset by&#58; (i) an unfavorable net change in Foreign exchange and other of $38 million and (ii) an increase in the Loss on extinguishment of debt of $17 million.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to Bausch Health Companies Inc. for 2020 and 2019 was $560 million and $1,788 million, respectively, an increase in our results of $1,228 million.  The increase in our results was primarily due to&#58; (i) the decrease in Loss before benefit from income taxes of $903 million, as previously discussed, and (ii) the favorable net change in the Benefit from income taxes of $321 million, primarily attributable to the release of a portion of our valuation allowance against deferred tax assets in 2020. </font></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_205"></div><div style="margin-bottom:8pt;margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS  </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results for the years 2021, 2020 and 2019 were as follows&#58; </font></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:58.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 to 2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019 to 2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product sales</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,342&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,924&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,489&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">418&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(565)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenues</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,434&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,027&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,601&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">407&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(574)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expenses</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of goods sold (excluding amortization and impairments of intangible assets)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,361&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,202&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,297&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(95)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of other revenues</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,624&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,367&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,554&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">257&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(187)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">465&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">452&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">471&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,375&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,645&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,897&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(270)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(252)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill impairments</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">469&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">469&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">234&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">373&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">502&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,426&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(129)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(924)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,984&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,351&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,804&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">633&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,453)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating income (loss)</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">676&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(203)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(226)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">879&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,426)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,534)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,612)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign exchange and other</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Loss before benefit from income taxes</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,024)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(934)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,837)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(90)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">903&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefit from income taxes</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">375&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(288)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">321&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(937)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(559)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,783)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(378)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,224&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interest</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(948)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(560)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,788)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(388)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,228&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_208"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 Compared with 2020</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues are primarily generated from product sales, principally in the therapeutic areas of eye-health, GI and dermatology, that consist of&#58; (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material.  See Note 22, &#8220;SEGMENT INFORMATION&#8221; to our audited Consolidated Financial Statements for the disaggregation of revenues which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues were $8,434 million and $8,027 million for 2021 and 2020, respectively, an increase of $407 million, or 5%.  The increase was due to&#58; (i) a net increase in volumes of $471 million primarily in our Bausch + Lomb, Salix, International and Solta Medical segments and (ii) the favorable impact of foreign currencies of $95 million primarily in Europe, Asia and Canada. These increases were partially offset by&#58; (i) the impact of divestitures and discontinuations of $132 million, primarily attributable to our divestiture of Amoun on July 26, 2021 and (ii) a decrease in net realized pricing of $27 million primarily the result of higher sales deductions. The net increase in volumes was primarily due to the positive impacts of the recovery from the COVID-19 pandemic and the easing of certain social restrictions, as previously discussed, partially offset by&#58; (i) the impact of the loss of exclusivity of certain products primarily in our Diversified Products and Bausch + Lomb segments and (ii) the impacts of a quality issue at a third-party supplier on the revenues of certain Consumer products included in our Bausch + Lomb segment, as discussed below. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our 2020 revenues were most negatively impacted during our second quarter by the social restrictions and other precautionary measures taken in response to the COVID-19 pandemic. However, as governments began lifting social restrictions, allowing offices of certain health care providers to reopen and certain surgeries and elective medical procedures to proceed, the negative trend in the revenues of certain businesses began to level off and stabilize prior to our third quarter of 2020. Our revenues returned to pre-pandemic levels for many of our businesses and geographies in 2021 and, at the current pace of recovery, we anticipate the COVID-19 pandemic to have a minimal impact on the remaining businesses and geographies in 2022.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The changes in our segment revenues and segment profits, including the impacts of COVID-19 pandemic related matters, are discussed in further detail in the respective subsequent section &#8220; &#8212; Reportable Segment Revenues and Profits&#8221;.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Discounts and Allowances, Chargebacks and Distribution Fees</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at net product sales.&#160;Provisions for these deductions are recognized concurrently with the recognition of gross product sales. These provisions include cash discounts and allowances, chargebacks, and distribution fees, which are paid or credited to direct customers, as well as rebates and returns, which can be paid or credited to direct and indirect customers. As more fully discussed in Note 2, &#8220;SIGNIFICANT ACCOUNTING POLICIES&#8221; to our audited Consolidated Financial Statements, the Company continually monitors the provisions for these deductions and evaluates the estimates used as additional information becomes available.  Price appreciation credits are generated when we increase a product&#8217;s wholesaler acquisition cost (&#8220;WAC&#8221;) under our contracts with certain wholesalers. Under such contracts, we are entitled to credits from such wholesalers for the impact of that WAC increase on inventory on hand at the wholesalers. In wholesaler contracts, such credits are offset against the total distribution service fees we pay on all of our products to each such wholesaler. In addition, some payor contracts require discounting if a price increase or series of price increases in a contract period exceeds a negotiated threshold. Provision balances relating to amounts payable to direct customers are netted against trade receivables and balances relating to indirect customers are included in accrued liabilities.&#160; </font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively manage these offerings, focusing on the incremental costs of our patient assistance programs, the level of discounting to non-retail accounts and identifying opportunities to minimize product returns. We also concentrate on managing our relationships with our payors and wholesalers, reviewing the ranges of our offerings and being disciplined as to the amount and type of incentives we negotiate.  </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions recorded to reduce gross product sales to net product sales and revenues for 2021 and 2020 were as follows&#58; </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product sales</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,770&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,960&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions to reduce gross product sales to net product sales</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Returns</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,462&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,174&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chargebacks</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,999&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,925&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distribution service fees</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,428&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.4&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,036&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.9&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,342&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.6&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,924&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.1&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts and allowances, returns, rebates, chargebacks and distribution service fees as a percentage of gross product sales were</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 39.4% and 38.9% in 2021 and 2020, respectively, an increase of 0.5% percentage points and includes&#58;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discounts and allowances as a percentage of gross product sales were lower primarily due to lower discount rates and gross product sales for certain generic products, such as Migranal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG, Elidel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG and Diastat</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG, partially offset by the impact of higher discount rates for and lower sales of Glumetza</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">returns as a percentage of gross product sales were higher and represent the impacts of&#58; (i) higher sales of certain products, primarily Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and (ii) returns associated with a quality issue at a third-party supplier on the revenues of certain Consumer products included in our Bausch + Lomb segment, as discussed below, offset by improving sales returns experience in 2021 as compared to 2020. Over the last several years, the Company has increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including, but not limited to&#58; (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving the sales return experience, related to branded and generic products. Included in the product returns provision for 2021 and 2020 are reductions in variable consideration for sales returns related to past sales of approximately $28 million and $38 million, respectively. See Note 2, &#8220;SIGNIFICANT ACCOUNTING POLICIES&#8221; to our audited Consolidated Financial Statements regarding further details related to product sales provisions&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">rebates as a percentage of gross product sales were higher primarily due the impact of&#58; (i) an increase in gross product sales of certain branded products with higher rebate rates, such as Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Prolensa</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Jublia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Trulance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and  (ii) an increase in rebates due to the launch of Arazlo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (June 2020) and was partially offset by lower gross product sales for certain branded products, such as Duobrii</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Apriso</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Lotemax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gel&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">chargebacks as a percentage of gross product sales were lower primarily due to the impacts of&#58; (i) lower chargeback rates and gross product sales for certain products, such as Glumetza</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG and Wellbutrin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and (ii) lower gross product sales for certain products, such as Targretin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG, partially offset by higher chargeback rates and gross product sales for certain products, such as Glumetza</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SLX, Syprine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AG and Mysoline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59; and</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distribution service fees as a percentage of gross product sales were unchanged. Price appreciation credits were offset against the distribution service fees we paid wholesalers and were $17 million and $15 million for 2021 and 2020, respectively.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Expenses </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold (excluding amortization and impairments of intangible assets)</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold primarily includes&#58; manufacturing and packaging&#59; the cost of products we purchase from third parties&#59; royalty payments we make to third parties&#59; depreciation of manufacturing facilities and equipment&#59; and lower of cost or net </font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">realizable value adjustments to inventories. Cost of goods sold typically vary between periods as a result of product mix, volume, royalties, changes in foreign currency and inflation. Cost of goods sold excludes the amortization and impairments of intangible assets.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold was $2,361 million and $2,202 million for 2021 and 2020, respectively, an increase of $159 million, or 7%. The increase was primarily driven by&#58; (i) the net increase in volumes, as previously discussed, (ii) the unfavorable impact of foreign currencies and (iii) higher manufacturing variances, primarily the result of&#58; (a) charges related to a quality issue at a third-party supplier, as discussed below, and (b) inflationary pressures related to certain manufacturing costs. These increases were partially offset by&#58; (i) the impact of the divestiture of Amoun on July 26, 2021 and (ii) a reduction in third party royalties.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the recovery from the COVID-19 pandemic continues and businesses reopen, many companies are reporting increases for certain costs, such as labor, materials, shipping and utilities. The increased costs have resulted in additional manufacturing variances and have had a negative impact on our contribution margins during 2021. Through the date of this filing, we are unable to determine if these inflationary factors are transitory or should be expected to continue over a medium or long term. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold as a percentage of Product sales revenue was 28.3% and 27.8% for 2021 and 2020, respectively, an increase of 0.5 percentage points primarily attributable to the year-over-year changes in product mix.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were notified by a third-party supplier of sterilization services for our lens care solution bottles and caps at our Milan, Italy facility, of inconsistencies in the sterilization data versus certificates of conformance previously submitted to us by that supplier. Based on our internal Health and Safety Analysis, it was determined that this issue did not affect the safety or performance of any of our products and is limited to a specific number of lots for certain Consumer products within our Bausch + Lomb segment. However, out of an abundance of caution and working with the appropriate notified body and responsible health authorities, we have contained and&#47;or recalled down to the consumer level the limited number of affected lots of products resulting in $8&#160;million of manufacturing variances and $6 million of returns. Further, although our Greenville, South Carolina facility increased production to support some of the demand in the near term, due to the limited availability of qualified materials, production at the Milan facility could not keep up with demand, which negatively impacted our sales for the affected products in this region during 2021. At this time, we have removed this supplier from our Approved Supplier List and qualified another sterilization supplier, who, along with an existing secondary supplier, have and will provide bottle sterilization, thereby allowing our Milan facility to return to full production capacity. Although it is possible additional charges may be incurred, at this time we believe no additional charges will be necessary.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&#38;A expenses primarily include&#58; employee compensation associated with sales and marketing, finance, legal, information technology, human resources and other administrative functions&#59; certain outside legal fees and consultancy costs&#59; product promotion expenses&#59; overhead and occupancy costs&#59; depreciation of corporate facilities and equipment&#59; separation-related and IPO-related costs&#59; and other general and administrative costs. The Company has incurred, and will incur, Separation-related and IPO-related costs which are incremental costs indirectly related to the B+L Separation and Solta IPO. Separation-related and IPO-related costs include, but are not limited to&#58; (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and&#47;or modification.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&#38;A expenses were $2,624 million and $2,367 million for 2021 and 2020, respectively, an increase of $257 million, or 11%. The increase was primarily attributable to&#58; (i) the impacts of the non-recurrence of certain profit protection measures taken in 2020 to manage and reduce operating expenses during the COVID-19 pandemic, (ii) an increase in Separation-related and IPO-related costs of $111 million and (iii) the impact of foreign currencies. These increases were partially offset by the impact of the Amoun Sale on July 26, 2021.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the Company took certain profit protection measures to manage and reduce operating expenses during the COVID-19 pandemic, which resulted in year-over-year increases primarily in selling expenses and advertising and promotion expenses. These profit protection measures were successful in expanding the profit margins in many of our businesses as previously discussed. As the pace of recovery in each geography accelerated, we continued to allocate more resources to selling and other promotional activities to drive our return to sustainable revenue and profit growth and as a result our operating expenses for 2021 exceeded our operating expenses in 2020.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Research and development are costs related to our product development and quality assurance programs. Expenses related to product development include&#58; employee compensation costs&#59; overhead and occupancy costs&#59; depreciation of research and development facilities and equipment&#59; clinical trial costs&#59; clinical manufacturing and scale-up costs&#59; and other </font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">third-party development costs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards and include&#58; employee compensation costs&#59; overhead and occupancy costs&#59; amortization of software&#59; and other third-party costs. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&#38;D expenses were $465 million and $452 million for 2021 and 2020, respectively, an increase of $13 million, or 3%. The increase was primarily attributable to the non-recurrence of the temporary suspension in certain R&#38;D activities and clinical trials in 2020 due to social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed, partially offset by the impact of rebalancing our portfolio within the Ortho Dermatologics business. R&#38;D expenses as a percentage of Product sales were approximately 6% and 6% for 2021 and 2020, respectively. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, certain of our R&#38;D activities were limited and others, including new patient enrollments in clinical trials, were temporarily paused primarily during our second quarter, as most trial sites were not able to accept new patients due to government-mandated shutdowns. However, during our third quarter of 2020, many of these trial sites began to reopen and we saw the pace of new patient enrollments increase, although at this time certain of our projects are moving slower than we would like due to the impacts of the COVID-19 pandemic. As of February 23, 2022, we have not had to make material changes to our development timelines and the pause in our clinical trials has not had a material impact on our operating results&#59; however, a resurgence of the virus could result in unanticipated delays in our ability to conduct new patient enrollments and create other delays, which could have a significant adverse effect on our future operating results. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization of Intangible Assets</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives are amortized using the straight-line method over their estimated useful lives, generally 2 to 20 years. Management continually assesses the useful lives related to the Company's long-lived assets to reflect the most current assumptions. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets was $1,375 million and $1,645 million for 2021 and 2020, respectively, a decrease of $270 million, or 16%.  The decrease was primarily attributable to fully amortized intangible assets no longer being amortized in 2021. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our audited Consolidated Financial Statements for further details related to our intangible assets.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill Impairments</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is tested for impairment at least annually at the reporting unit level. An interim goodwill impairment test in advance of the annual impairment assessment may be required if events occur that indicate an impairment might be present. A reporting unit is the same as, or one level below, an operating segment. The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair values of all reporting units using a discounted cash flow model, which utilizes Level 3 unobservable inputs.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill impairments were $469 million and $0 for 2021 and 2020, respectively. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, management identified launches of certain Ortho Dermatologics products which were not going to achieve their trajectories as forecasted once the social restrictions associated with the COVID-19 pandemic began to ease in the U.S. and offices of health care professionals could reopen. In addition, insurance coverage pressures within the U.S. continued to persist limiting patient access to topical acne and psoriasis products.  In light of these developments, during the first quarter of 2021, the Company began taking steps to&#58; (i) redirect its R&#38;D spend to eliminate projects it has identified as high cost and high risk, (ii) redirect a portion of its marketing and product development outside the U.S. to geographies where there is better patient access and (iii) reduce its cost structure to be more competitive. As a result, during the three months ended March 31, 2021, the Company revised its long-term forecasts for the Ortho Dermatologics reporting unit. Management believed that these events were indicators that there is less headroom as of March 31, 2021 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2020). Therefore, a quantitative fair value test for the Ortho Dermatologics reporting unit was performed. The quantitative fair value test utilized the Company's most recent cash flow projections as revised in the first quarter of 2021 to reflect the business changes previously discussed, including a range of potential outcomes, along with a long-term growth rate of 1.0% and a range of discount rates between 9.0% and 10.0%. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at March 31, 2021, and the Company recognized a goodwill impairment of $469&#160;million.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our audited Consolidated Financial Statements regarding further details related to our goodwill impairment analysis.</font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Asset impairments, including loss on assets held for sale </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments in the Consolidated Statement of Operations. The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale were $234 million and $114 million for 2021 and 2020, respectively, an increase of $120 million. Asset impairments, including loss on assets held for sale for 2021 includes&#58; (i) impairments of $105&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines, (ii) an $88&#160;million loss on assets held for sale in connection with the Amoun Sale, (iii) impairments of $23&#160;million, in aggregate, related to the discontinuance of certain product lines and (iv) $18&#160;million related to a portion of an IT infrastructure improvement project no longer being utilized.  Asset impairments, including loss on assets held for sale for 2020 includes&#58; (i) a $96&#160;million adjustment to reduce the carrying value of the Amoun business to its estimated fair value less costs to sell due to classifying the business as held for sale, (ii) $16&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines, (iii) $1&#160;million, in aggregate, related to the discontinuance of certain product lines not aligned with the focus of the Company's core businesses and (iv) $1&#160;million related to Acquired in-process research and development not in service.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our audited Consolidated Financial Statements for further details related to our intangible assets.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring, Integration, Separation and IPO Costs</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, integration, separation and IPO costs were $50 million and $22 million for 2021 and 2020, respectively, an increase of $28 million. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring and integration costs</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with&#58; (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and integration costs were $18&#160;million and $11&#160;million for 2021 and 2020, respectively, an increase of $7&#160;million. The Company continues to evaluate opportunities to streamline its operations and identify additional cost savings globally. Although a specific plan does not exist at this time, the Company may identify and take additional exit and cost-rationalization restructuring actions in the future, the costs of which could be material.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation and IPO costs</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Separation-related and IPO-related costs, which are incremental costs indirectly related to the B+L Separation and Solta IPO and included in Selling, general and administrative expenses, as previously discussed, the Company has incurred, and will incur, costs directly associated with activities to effectuate the B+L Separation and the Solta IPO. These activities include&#58; (i) separating the Bausch + Lomb and Solta Medical businesses from the remainder of the Company and (ii) registering the Bausch + Lomb and Solta Medical businesses as independent publicly traded entities. Separation and IPO costs are incremental costs directly related to the B+L Separation and Solta IPO and include, but are not limited to&#58; (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing a new board of directors and related board committees for the Bausch + Lomb and Solta Medical entities. Separation and IPO costs were  $32&#160;million and $11&#160;million for 2021 and 2020, respectively.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of 2021, we had substantially completed the internal objectives necessary to facilitate the B+L Separation and Solta IPO and related separation of these businesses. We continue to monitor market conditions and aim to launch the B+L IPO and the Solta IPO when financial market conditions become favorable (subject to receipt of regulatory, stock exchange and other approvals). Until such time, we continue to manage these businesses along with our pharmaceutical portfolio of gastrointestinal, dermatology, neurology and other therapeutics, with our continued commitment to bring out additional value for our shareholders.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See Note 4, &#8220;RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS&#8221; to our audited Consolidated Financial Statements for further details regarding these actions. </font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other expense, net </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net for 2021 and 2020 consists of the following&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:77.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.711%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain on sales of assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation and other matters for 2021, includes adjustments related to the Glumetza Antitrust Litigation, partially offset by insurance recoveries of $213 million related to certain litigation matters. See Note 20, &#8220;LEGAL PROCEEDINGS&#8221; to our audited Consolidated Financial Statements for further details regarding these matters.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation and other matters for 2020, includes adjustments related to an SEC investigation into the Company and its former relationship with Philidor Rx Services, LLC, its accounting practices and policies, its public disclosures and other matters (which investigation has now been settled) (the &#8220;SEC Investigation&#8221;) and the U.S. Securities Litigation and the Canadian Securities Litigation and related opt-outs of each. Litigation and other matters also includes an insurance recovery related to a certain litigation matter. See Note 20, &#8220;LEGAL PROCEEDINGS&#8221; to our audited Consolidated Financial Statements for further details regarding certain of these matters.</font></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired in-process research and development costs primarily consists of costs associated with the upfront payments to enter into certain exclusive licensing agreements. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Operating Income and Expense</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense primarily consists of interest payments due, amortization of debt premiums, discounts and deferred issuance costs on indebtedness under our credit facilities and notes and the amortization of amounts excluded from the assessment of hedge effectiveness over the term of the Company's cross-currency swaps. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense was $1,426 million and $1,534 million and included non-cash amortization and write-offs of debt discounts and deferred financing costs of $55 million and $61 million for 2021 and 2020, respectively. Interest expense decreased $108 million, or 7%, in 2021 as compared to 2020, primarily due to lower outstanding principal balances. The weighted average stated rate of interest as of December 31, 2021 and 2020 was 5.88% and 6.02%, respectively.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our audited Consolidated Financial Statements for further details. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss on Extinguishment of Debt</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on extinguishment of debt represents the differences between the amounts paid to settle extinguished debts and the carrying value of the related extinguished debt. Loss on extinguishment of debt was $62 million and $59 million for 2021 and 2020, respectively, primarily associated with certain refinancing transactions that occurred each year. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our audited Consolidated Financial Statements for further details. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange and Other </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange and other was a gain of $7&#160;million for 2021 as compared to a loss of $30 million for 2020, a favorable net change of $37 million primarily due to&#58; (i) translation gains&#47;losses on intercompany loans and third-party liabilities and (ii) the gain&#47;loss due to foreign currency exchange contracts.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the temporary differences between the financial statement and income tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. Deferred tax assets for outside basis differences in investments in subsidiaries are only recognized if the difference will be realized in the foreseeable future. Benefit from income taxes was $87 million and $375 million in 2021 and 2020, respectively, an unfavorable net change of $288 million, primarily attributable to the release of a portion of the </font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company's valuation allowance against deferred tax assets in 2020 in excess of the release of its valuation allowance in 2021. In 2021, the Company's valuation allowance decreased by $30 million primarily attributable to the impact of book taxable income in Canada, change in deferred tax assets in Canada and use of deferred tax assets in the U.S. in connection with internal restructurings.  In 2020, our valuation allowance decreased by $579 million primarily attributable to the impact of taxable losses in Canada, partially offset by the impact of internal restructurings which resulted in reductions to our deferred tax assets.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated foreign rate differential reflects the net total tax cost or benefit on income earned or losses incurred in jurisdictions outside of Canada as compared to the net total tax cost or benefit of such income (on a jurisdictional basis) at the Canadian statutory rate of 26.9%.  Tax costs below the Canadian statutory rate generate a beneficial foreign rate differential as do tax benefits generated in jurisdictions where the statutory tax rate exceeds the Canadian statutory tax rate.  The net total foreign rate differentials generated in each jurisdiction in which we operate is not expected to bear a direct relationship to the net total amount of foreign income (or loss) earned outside of Canada. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021 and 2020, our effective tax rate differs from the statutory Canadian income tax rate primarily due to&#58; (i) the recording of valuation allowance on entities for which no tax benefit of losses is expected, (ii) the tax benefit generated from our annualized mix of earnings by jurisdiction and (iii) the discrete treatment of certain tax matters, primarily related to&#58; (a) changes in uncertain tax positions, (b) impairment of United&#160;States generally accepted accounting principles (&#8220;U.S.&#160;GAAP&#8221;) goodwill, (c) internal restructurings, and (d) changes in the manner in which an outside basis difference will be recovered in future periods.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record a valuation allowance against our deferred tax assets to reduce their net carrying value to an amount that we believe is more likely than not to be realized. In determining our deferred tax asset valuation allowance, we estimate our ability to utilize future sources of income to realize the benefits of our temporary income tax differences including&#58; (i) net operating loss carryforwards in each jurisdiction, primarily in Canada, the U.S. and Ireland, (ii) research and development tax credit carryforwards, (iii) scientific research and experimental development pool carryforwards and (iv) investment tax credit carryforwards. When we establish&#47;increase or reduce&#47;decrease the valuation allowance, the provision for income taxes will increase or decrease, respectively, in the period such determination is made. Our valuation allowance against deferred tax assets as of December 31, 2021 and 2020 was $2,222 million and $2,252 million, respectively, a decrease of $30 million, as discussed above.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 17, &#8220;INCOME TAXES&#8221; to our audited Consolidated Financial Statements for further details.</font></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_211"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segment Revenues and Profits</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the planned separation of its Solta business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., the Company has begun managing its operations in a manner which is consistent with the organizational structure of the two separate entities as proposed by the Solta IPO. As a result, during the first quarter of 2022, the Company&#8217;s Chief Executive Officer (&#8220;CEO&#8221;), who is the Company&#8217;s Chief Operating Decision Maker, commenced managing the business differently through changes in its operating and reportable segments, which necessitated a realignment of the Company&#8217;s historical segment structure. This realignment is consistent with how the Company&#8217;s CEO currently&#58; (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports. Pursuant to these changes, effective in the first quarter of 2022, the Company operates in the following reportable segments&#58; (i) Bausch + Lomb, (ii) Salix, (iii) International (formerly International Rx), (iv) Solta Medical and (v) Diversified Products. The new segment structure does not impact the Company&#8217;s reporting units but realigns the two reporting units of the former Ortho Dermatologics segment whereby its medical dermatology reporting unit (Ortho Dermatologics) is now part of the current Diversified Products segment and the Solta reporting unit is now the sole reporting unit of the new Solta Medical segment. All segment revenues and segment profits for the periods presented have been recast to conform to the 2022 reportable segment structure.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a brief description of our segments&#58; </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Bausch + Lomb segment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Bausch + Lomb Vision Care, Consumer, Surgical and Ophthalmic Pharmaceuticals products. </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Salix segment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of GI products.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The International segment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales, with the exception of sales of Bausch +Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products.</font></div><div style="margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Solta Medical segment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Solta aesthetic medical devices.</font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Diversified Products segment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of&#58; (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products, (iii) Ortho Dermatologics (dermatological) products and (iv) dentistry products. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment profit is based on operating income after the elimination of intercompany transactions.  Certain costs, such as Amortization of intangible assets, Asset impairments, including loss on assets held for sale, Restructuring, integration, separation and IPO costs, and Other expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance. See Note 22, &#8220;SEGMENT INFORMATION&#8221; to our audited Consolidated Financial Statements for a reconciliation of segment profit to Loss before benefit from income taxes.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment revenues, segment revenues as a percentage of total revenues and the year over year changes in segment revenues for 2021 and 2020. The following table also presents segment profits, segment profits as a percentage of segment revenues and the year-over-year changes in segment profits for 2021 and 2020. </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.193%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 to 2021</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Segment Revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,765&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,415&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,074&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,434&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,027&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Segment Profits &#47; Segment Profit Margins</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,493&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(92)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,743&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,578&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Organic Revenues and Organic Growth Rates (non-GAAP)</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organic growth, a non-GAAP metric, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of recent acquisitions, divestitures and discontinuations. Organic revenue growth (non-GAAP) is growth in GAAP Revenue (its most directly comparable GAAP financial measure), adjusted for certain items, of businesses that have been owned for one or more years. Organic revenue (non-GAAP) is impacted by changes in product volumes and price. The price component is made up of two key drivers&#58; (i) changes in product gross selling price and (ii) changes in sales deductions. The Company uses organic revenue (non-GAAP) and organic revenue growth (non-GAAP) to assess performance of its reportable segments, and the Company in total, without the impact of foreign currency exchange fluctuations and recent acquisitions, divestitures and product discontinuations. The Company believes that such measures are useful to investors as they provide a supplemental period-to-period comparison.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP measures are not standardized measures under the financial reporting framework used to prepare the Company&#8217;s financial statements and might not be comparable to similar financial measures disclosed by other issuers.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Organic revenue growth (non-GAAP) reflects adjustments for&#58; (i) the impact of period-over-period changes in foreign currency exchange rates on revenues and (ii) the revenues associated with acquisitions, divestitures and discontinuations of businesses divested and&#47;or discontinued.  These adjustments are determined as follows&#58;</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency exchange rates&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Although changes in foreign currency exchange rates are part of our business, they are not within management&#8217;s control. Changes in foreign currency exchange rates, however, can mask positive or negative trends in the underlying business performance. The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.</font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions, divestitures and discontinuations&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In order to present period-over-period organic revenues (non-GAAP) on a comparable basis, revenues associated with acquisitions, divestitures and discontinuations are adjusted to include only revenues from those businesses and assets owned during both periods. Accordingly, organic revenue growth (non-GAAP) excludes from the current period, all revenues attributable to each acquisition for twelve months subsequent to the day of acquisition, as there are no revenues from those businesses and assets included in the comparable prior period. Organic revenue growth (non-GAAP) excludes from the prior period (but not the current period), all revenues attributable to each divestiture and discontinuance during the twelve months prior to the day of divestiture or discontinuance, as there are no revenues from those businesses and assets included in the comparable current period. There were no acquisitions during 2021.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of GAAP revenues to organic revenues (non-GAAP) and presents organic revenue (Non-GAAP) and the year over year changes in organic revenue (Non-GAAP) for 2021 and 2020 by segment.</font></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.907%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31, 2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change in<br>Organic Revenue (Non-GAAP)</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue<br>as<br>Reported</font></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Changes in Exchange Rates</font></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Organic Revenue (Non-GAAP)</font></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue<br>as<br>Reported</font></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Divestitures and Discontinuations</font></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Organic Revenue (Non-GAAP)</font></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pct.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bausch + Lomb</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,765&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,707&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,415&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,405&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">302&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salix</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,074&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,074&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,904&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,904&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">International</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,166&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,138&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,181&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(113)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,068&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solta Medical</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diversified Products</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,121&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,121&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,274&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,265&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(144)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,434&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(95)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,339&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,027&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(132)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,895&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">444&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Bausch + Lomb Segment&#58;</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb Segment Revenue</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bausch + Lomb segment has a diversified product line with no single product group representing 10% or more of its segment revenues. The Bausch + Lomb segment revenue was $3,765 million and $3,415&#160;million for 2021 and 2020, respectively, an increase of $350 million, or 10%. The increase was primarily attributable to&#58; (i) an increase in volumes across all of our Bausch + Lomb businesses of $337 million primarily due to the positive impacts from the recovery from the COVID-19 pandemic and the easing of certain social restrictions, as previously discussed, partially offset by&#58; (a) the impact of generic competition as certain products, primarily Lotemax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Gel, lost exclusivity and (b) the impacts of a third-party supplier quality issue on the revenues of certain Consumer products, as previously discussed, and (ii) the favorable impact of foreign currencies of $58 million, primarily in Europe and Asia.  These increases were partially offset by&#58; (i) a decrease in net realized pricing of $35 million primarily due to higher sales deductions in our Ophthalmic Pharmaceuticals business and (ii) the impact of divestitures and discontinuations of $10 million, related to several products. The increase in volumes was across all Bausch + Lomb businesses, most notably seen in our Surgical and Vision Care businesses, and across all geographies, most notably in the U.S., Asia and Europe.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, the volumes of our Bausch + Lomb segment were most negatively impacted by the social restrictions and other precautionary measures taken in response to the COVID-19 pandemic during the second quarter of 2020. However, as governments began lifting social restrictions, the negative trend in the revenues began to level off and stabilize prior to our third quarter and continued into our fourth quarter of 2020 and first quarter of 2021. Our revenues returned to pre-pandemic levels for many of our Bausch + Lomb businesses and geographies in 2021 and, at the current pace of recovery, we anticipate the COVID-19 pandemic to have a minimal impact on the remaining businesses and geographies in 2022. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb Segment Profit</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bausch + Lomb segment profit was $958 million and $909 million for 2021 and 2020, respectively, an increase of $49 million, or 5%. The increase was primarily driven by an increase in contribution primarily attributable to the net increase in revenues, as previously discussed. This increase was partially offset by&#58; (i) the impacts of the non-recurrence of certain profit protection measures taken in 2020 to manage and reduce operating expenses during the COVID-19 pandemic, as previously discussed, which resulted in year-over-year increases primarily in selling expenses and advertising and promotion expenses, (ii) the non-recurrence of the temporary suspension in certain R&#38;D activities and clinical trials in 2020 due to social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed and (iii) inflationary pressures related to certain manufacturing costs.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 13, 2022, in connection with the B+L Separation, Bausch + Lomb Corporation filed a Registration Statement on Form S-1 with the SEC (the &#8220;Registration Statement&#8221;), which as of February 23, 2022 has not been declared effective.  As the Bausch + Lomb business has historically operated as part of the Company, Bausch + Lomb Corporation relied on the </font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s corporate and other support functions. Therefore, certain corporate and shared costs have been allocated to Bausch + Lomb Corporation in the financial results and other financial information as presented by Bausch + Lomb in its filings with the SEC, including expenses related to the support functions that are provided on a centralized basis by the Company and not included in the measurement of segment profit for any segment in the table above. This includes expenses for executive oversight, treasury, accounting, legal, human resources, shared services, compliance, procurement, information technology and other corporate functions.  Therefore, any measurement of Bausch + Lomb Corporation's net operating results, as presented in Bausch + Lomb Corporation's filings with the SEC, will not agree to Bausch + Lomb's segment profit as presented in the table above.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Salix Segment&#58;</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salix Segment Revenue</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Salix segment includes the Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product line, which accounted for approximately 79% and 78% of the Salix segment revenues and approximately 19% and 18% of the Company's revenues for 2021 and 2020, respectively. No other single product group represents 10% or more of the Salix segment revenues. The Salix segment revenue was $2,074&#160;million and $1,904 million for 2021 and 2020, respectively, an increase of $170 million, or 9%. The increase was primarily attributable to increases in&#58; (i) volume of $101 million, primarily attributable to increased volumes for our Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Trulance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product lines driven in part by the positive impacts of the recovery from the COVID-19 pandemic and the easing of certain social restrictions, as previously discussed, and (ii) net realized pricing of $69 million, primarily attributable to our Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product line, partially offset by higher sales adjustments for Glumetza</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SLX.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salix Segment Profit</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Salix segment profit was $1,493 million and $1,338 million for 2021 and 2020, respectively, an increase of $155&#160;million, or 12%. The increase was primarily driven by the increase in contribution as a result of&#58; (i) the increase in revenue, as previously discussed, and (ii) a reduction in third party royalties. This increase was partially offset by the impacts of the non-recurrence of certain profit protection measures taken in 2020 to manage and reduce operating expenses during the COVID-19 pandemic, as previously discussed, which resulted in year-over-year increases primarily in selling expenses and advertising and promotion expenses.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">International Segment&#58;</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Segment Revenue</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The International segment has a diversified product line with no single product group representing 10% or more of its product sales. The International segment revenue was $1,166 million and $1,181 million for 2021 and 2020, respectively, a decrease of $15 million, or 1%. The decrease was primarily attributable to the impact of divestitures and discontinuations of $113 million, primarily attributable to our divestiture of Amoun on July 26, 2021. Amoun revenues were $157 million for the period of January 1, 2021 through July 26,2021 and were $247 million for the full year 2020. The decreases were partially offset by&#58; (i) an increase in volumes of $51 million, (ii) the favorable impact of foreign currencies of $28 million, primarily in Canada and Latin America, and (iii) an increase in net realized pricing of $19 million. The increase in volumes is primarily due to the positive impacts from the recovery from the COVID-19 pandemic and the easing of certain social restrictions, as previously discussed.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we experienced COVID-19 pandemic related declines in year-over-year revenues in certain products and geographies during 2021, at the current pace of recovery, we anticipate the COVID-19 pandemic to have a minimal impact on the remaining businesses and geographies in 2022. .</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Segment Profit</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The International segment profit for 2021 and 2020 was $403 million and $386 million, respectively, an increase of $17 million, or 4%. The increase was primarily driven by a decrease in SG&#38;A expenses, partially offset by the decrease in contribution primarily attributable to our divestiture of Amoun on July 26, 2021.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Solta Medical Segment&#58;</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Solta Medical Segment Revenue</font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Solta Medical segment includes the Thermage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> product lines, which accounted for approximately 78% of the Solta Medical segment revenues for 2021. No other single product group represents 10% or more of the Solta Medical segment revenues. The Solta Medical segment revenue was $308 million and $253 million for 2021 and 2020, respectively, an increase of $55 million, or 22%. The increase was primarily attributable to&#58; (i) an increase in volume of $47 million and (ii) the </font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">favorable impact of foreign currencies of $9&#160;million, partially offset by a decrease in net realized pricing of $1&#160;million. The increase in volume was primarily due to&#58; (i) an increase in Thermage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> tips and other consumables sales and (ii) an increase in systems sold driven by the U.S. launch of the next generation Clear + Brilliant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Touch laser system in March 2021.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Solta Medical Segment Profit</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Solta Medical segment profit was $167 million and $131 million for 2021 and 2020, respectively, an increase of $36 million, or 27%. The increase was primarily due to an increase in contribution primarily attributable to the net increase in revenues, as previously discussed, partially offset by an increase in SG&#38;A expenses to support the growth in sales.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Diversified Products Segment&#58;</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversified Products Segment Revenue</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the Diversified Products segment revenues by product and product revenues as a percentage of segment revenue for 2021 and 2020. </font></div><div style="margin-bottom:8pt;margin-top:13pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.461%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020 to 2021</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wellbutrin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Franchise</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aplenzin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arestin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jublia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ativan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Franchise</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retin-A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Franchise</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Siliq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Targretin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardizem</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Franchise</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mysoline</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Franchise</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other product revenues</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Diversified Products revenues </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)%</font></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Diversified Products segment revenue was $1,121 million and $1,274 million for 2021 and 2020, respectively, a decrease of $153 million, or 12%. The decrease was driven by&#58; (i) a decrease in net realized pricing of $79 million, (ii) a decrease in volume of $65 million and (iii) the impact of divestitures and discontinuations of $9 million. The decrease in net realized pricing was primarily due to higher sales deductions in our Generics and Ortho Dermatologics business units. The decrease in volume was primarily attributable to the impact of generic competition as certain products in our Neurology and Other business, such as Migranal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Xenazine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Mephyton</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Isuprel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Syprine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cuprimine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Demser</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, lost exclusivity.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversified Products Segment Profit</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Diversified Products segment profit was $722 million and $814 million for 2021 and 2020, respectively, a decrease of $92 million, or 11% and was primarily driven by the decrease in revenues, as previously discussed, partially offset by a decrease in selling expenses within our Ortho Dermatologics business.</font></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_2823"></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Compared with 2019</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A detailed discussion of the year-over-year changes of the Company&#8217;s 2020 results compared with that of 2019 can be found under &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations with Retrospective Segment Changes of the 2020 Form 10-K&#8221; in Exhibit 99.1 of our Form 8-K filed on May 4, 2021. The following only contains sections which have been revised from the Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations with Retrospective Segment Changes of the 2020 Form 10-K&#8221; included in Exhibit 99.1 of our Form 8-K filed on May 4, 2021 to reflect retrospective application of the new reporting structure which occurred in the first quarter of 2022 and recast our historical segment revenues and profits to conform to the new segment presentation as more fully discussed in the &#8220;Explanatory Note&#8221; at the beginning of this Exhibit 99.1.</font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues were $8,027 million and $8,601 million for 2020 and 2019, respectively, a decrease of $574 million, or 7%.   The decrease was primarily driven by&#58; (i) lower volumes of $528 million primarily in our Bausch + Lomb and Diversified Products segments primarily due to social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed, (ii) the unfavorable effect of foreign currencies of $39 million primarily in Latin America and (iii) the impact of divestitures and discontinuations of $20 million. The decreases in our revenues were partially offset by the incremental product sales of our Trulance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy of $13&#160;million. Net realized pricing was flat with increases in our International, Diversified Products, Bausch + Lomb and Solta Medical segments being offset by decreases in our Salix segment.</font></div><div style="margin-bottom:0.8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our 2020 revenues were most negatively impacted during our second quarter by the social restrictions and other precautionary measures taken in response to the COVID-19 pandemic. However, as governments began lifting social restrictions, allowing offices of certain health care providers to reopen and certain surgeries and elective medical procedures to proceed, the negative trend in the revenues of certain businesses began to level off and stabilize prior to our third quarter of 2020. Our revenues for the three months ended December 31, 2020 and 2019 were $2,213 million and $2,224 million, respectively, a decrease of $11 million.  This decrease of less than 1% represents a continuing improving trend over the decreases in our year-over-year revenues for the three month periods ended June 30, 2020 and September 30, 2020 of 23% and 3%, respectively, and suggests that a recovery is underway. Presuming there continues to be increased availability of effective vaccines and any resurgence of the COVID-19 virus and variant strains thereof do not have a material adverse impact on efforts to contain the COVID-19 virus, the Company anticipates an ongoing, gradual global recovery from the significant macroeconomic and health care impacts of the pandemic that occurred during the first-half of 2020 and anticipates that its affected businesses could return to pre-pandemic levels during 2021. However, the rates of recovery for each business will vary by geography and will be dependent upon, among other things, the availability and effectiveness of vaccines for the COVID-19 virus, government responses, rates of economic recovery, precautionary measures taken by patients and customers, the rate at which remaining social restrictions are lifted and once lifted, the presumption that social restrictions will not be materially reenacted in the event of a resurgence of the virus and other actions taken in response to the COVID-19 pandemic.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our year over year segment revenues and segment profits, including the impacts of COVID-19 pandemic related matters for 2020, are discussed in further detail in the respective subsequent sections &#8220; &#8212; Reportable Segment Revenues and Profits&#8221;.</font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_2830"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segment Revenues and Profits</font></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents segment revenues, segment revenues as a percentage of total revenues and the year over year changes in segment revenues for 2020 and 2019. The following table also presents segment profits, segment profits as a percentage of segment revenues and the year over year changes in segment profits for 2020 and 2019. </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.193%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019 to 2020</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Segment Revenue</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,415&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,778&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(363)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,453&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,027&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,601&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(574)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Segment Profits &#47; Segment Profit Margins</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(208)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment profit </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,578&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,835&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(257)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Organic Revenues and Organic Growth Rates (non-GAAP)</font></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of GAAP revenues to organic revenues (non-GAAP) and presents organic revenue (Non-GAAP) and the year over year changes in organic revenue (Non-GAAP) for 2020 and 2019 by segment.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:19.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.652%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Year ended December 31, 2019</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Change in<br>Organic Revenue</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Revenue<br>as<br>Reported</font></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Changes in Exchange Rates</font></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Acquisition</font></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Organic Revenue (Non-GAAP)</font></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Revenue<br>as<br>Reported</font></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Divestitures and Discontinuations</font></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Organic Revenue (Non-GAAP)</font></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Pct.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bausch + Lomb</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,415&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,431&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,778&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,763&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(332)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Salix</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,904&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,891&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,022&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,022&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(131)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,181&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,207&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,154&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,150&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Solta Medical</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">253&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">250&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diversified Products</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,274&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,274&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,453&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,452&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(178)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,027&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,053&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,601&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,581&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(528)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Bausch + Lomb Segment&#58;</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb Segment Revenue</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bausch + Lomb segment revenue was $3,415 million and $3,778 million for 2020 and 2019, respectively, a decrease of $363 million, or 10%. The decrease was primarily attributable to&#58; (i) a decrease in volume of $353&#160;million, as discussed below, (ii) the unfavorable effect of foreign currencies of $16 million, primarily in Latin America, and (iii) the impact of divestitures and discontinuations of $15 million. These decreases were partially offset by an increase in net realized pricing of $21 million, primarily driven by our Global Consumer business.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The volumes of our Bausch + Lomb were negatively impacted, primarily in Europe, Asia and the U.S., by social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed. The postponement of certain surgical and elective medical procedures related to the COVID-19 pandemic, and associated declines in pre- and post-operative prescriptions, negatively impacted the volumes of our Global Ophthalmology and Global Surgical businesses. The reduction in the consumption of contact lenses worldwide due to limited social interactions and in some regions government recommended use of frames, negatively impacted the volumes of our Global Vision Care business. During our first quarter of 2020, certain customers engaged in &#8220;pantry-loading&#8221;, which, along with stay-at-home orders, negatively impacted the volumes of our Global Consumer business for our second quarter of 2020. However, as governments began lifting social restrictions, the negative trend in the revenues of these businesses began to level off and stabilize prior to our third quarter of </font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020 and continued in the fourth quarter of 2020.  Therefore, our revenues for the year 2020 were most impacted by the COVID-19 pandemic in our second quarter of 2020. Presuming the increased availability of effective vaccines, and any resurgence of the COVID-19 virus and variant strains thereof or reenactment of social restrictions are not significant, we anticipate that our affected businesses could possibly return to pre-pandemic levels in 2021.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bausch + Lomb Segment Profit</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bausch + Lomb segment profit was $909 million and $1,117 million for 2020 and 2019, respectively, a decrease of $208 million, or 19%. The decrease was primarily driven by the decrease in contribution as a result of social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed, partially offset by lower SG&#38;A expenses.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Salix Segment&#58;</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salix Segment Revenue</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Salix segment revenue was $1,904&#160;million and $2,022&#160;million for 2020 and 2019, respectively, a decrease of $118&#160;million, or 6%. The decrease includes&#58; (i) a decrease in net realized pricing of $96 million, primarily attributable to higher sales deductions for Glumetza</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SLX, partially offset by higher gross selling prices for Xifaxan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and (ii) a decrease in volume of $35 million primarily attributable to the decrease in demand for Apriso</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> due to LOE. The decrease in revenue was partially offset by sales of our Trulance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy, of $13&#160;million.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain branded pharmaceutical products within our Salix segment were negatively impacted by social restrictions and other precautionary measures taken in response to the COVID-19 pandemic, as previously discussed. Although we experienced  COVID-19 pandemic related declines in year-over-year revenues in 2020, Salix segment revenues for the three months ended December 31, 2020 and 2019 were $527 million and $517 million, respectively, an increase of $10 million.  This increase of 2% represents a continuing improving trend over the decreases in our year-over-year revenues for the three month periods ended June 30, 2020 and September 30, 2020 of 21% and 10%, respectively, and suggests that a recovery is underway. Presuming the increased availability of effective vaccines, and any resurgence of the COVID-19 virus and variant strains thereof or reenactment of social restrictions are not significant, we anticipate that our affected Salix businesses could possibly return to pre-pandemic levels in 2021.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salix Segment Profit</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Salix segment profit was $1,338&#160;million and $1,349&#160;million for 2020 and 2019, respectively, a decrease of $11&#160;million, or 1%. The decrease was primarily driven by the decrease in contribution as a result of the decrease in revenue, as previously discussed, partially offset by lower third-party royalty costs. The decrease in segment profit was partially offset by&#58; (i) decreases in SG&#38;A expenses due to&#58; (a) COVID-19 pandemic related matters, as previously discussed, and (b) a charge associated with the termination of a certain co-promotional agreement during 2019 and (ii) the contribution from the sales of our Trulance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product, which we added to our portfolio in March 2019 as part of the acquisition of certain assets of Synergy.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">International Segment&#58;</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Segment Revenue</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The International segment revenue was $1,181 million and $1,154 million for 2020 and 2019, respectively, an increase of $27 million, or 2%. The increase was primarily attributable to&#58; (i) an increase in net realized pricing of $46&#160;million primarily in Latin America and (ii) an increase in volume of $11&#160;million primarily in Egypt. These increases were partially offset by&#58; (i) the unfavorable effect of foreign currencies of $26 million, primarily in Latin America, and (ii) the impact of divestitures and discontinuations of $4&#160;million.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain branded pharmaceutical products, branded generic pharmaceutical products and OTC products within our International segment were negatively impacted by social restrictions and other precautionary measures taken in response to the COVID-19 pandemic. However, presuming the increased availability of effective vaccines, and any resurgence of the COVID-19 virus and variant strains thereof or reenactment of social restrictions are not significant, we anticipate that our affected businesses could possibly return to pre-pandemic levels in 2021.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">International Segment Profit</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The International segment profit was $386 million and $352 million for 2020 and 2019, respectively, an increase of $34&#160;million, or 10%. The increase was primarily driven by&#58; (i) an increase in contribution primarily due to the increase in revenue, as previously discussed, and (ii) lower selling, advertising and promotion expenses.</font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Solta Medical Segment&#58;</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Solta Medical Segment Revenue</font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Solta Medical segment revenue was $253 million and $194 million for 2020 and 2019, respectively, an increase of $59 million, or 30%. The increase was due to&#58; (i) an increase in volume of $50 million, (ii) an increase in net realized pricing of $6 million and (iii) the favorable effect of foreign currencies of $3 million. The increase in volume was primarily due to increased demand for Thermage FLX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, primarily in China. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Solta Medical Segment Profit</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Solta Medical segment profit was $131 million and $84 million for 2020 and 2019, respectively, an increase of $47 million, or 56%. The increase was primarily due to an increase in contribution as a result of the increase in revenue, as previously discussed, partially offset by an increase in selling expense.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Diversified Products Segment&#58;</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversified Products Segment Revenue</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the Diversified Products segment revenues by product and product revenues as a percentage of segment revenue for 2020 and 2019. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.461%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019 to 2020</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pct.</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wellbutrin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Franchise</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aplenzin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jublia</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arestin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ativan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Franchise</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Siliq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardizem</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Franchise</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pepcid</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,450%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Targretin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diastat</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Franchise</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Diversified Products revenues </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,453&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)%</font></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Diversified Products segment revenue was $1,274 million and $1,453 million for 2020 and 2019, respectively, a decrease of $179 million, or 12%. The decrease was driven by&#58; (i) a decrease in volume of $201 million and (ii) the impact of divestitures and discontinuations of $1 million. The decrease was partially offset by an increase in net realized pricing of $23 million due to lower sales deductions and higher gross selling prices, primarily within the Wellbutrin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Franchise, partially offset by higher sales deductions in our medical dermatology products. The decrease in volume was primarily attributable to&#58; (i) the impact of generic competition as certain products in our Neurology and Other and Ortho Dermatologics businesses lost exclusivity, such as Cuprimine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Migranal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Syprine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Isuprel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Xenazine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Elidel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Zovirax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Solodyn</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and (ii) the postponement of certain surgeries and elective medical procedures in response to the COVID-19 pandemic primarily impacting our Dentistry business. The decrease in volume was partially offset by an increase in volumes for Pepcid</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> due to a competitor recall in 2020.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversified Products Segment Profit</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Diversified Products segment profit was $814 million and $933 million for 2020 and 2019, respectively, a decrease of $119 million, or 13%. The decrease was primarily driven by the decrease in revenue, partially offset by a decrease in selling and advertising and promotional expenses.</font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_214"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized cash flow information for the years 2021, 2020 and 2019 is as follows&#58; </font></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.367%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.368%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020 to 2021</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019 to 2020</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(937)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(559)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,783)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(378)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,224&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile Net loss to net cash provided by operating activities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,491&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,036&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,602&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">455&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,566)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash provided by operating activities before changes in operating assets and liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,554&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,477&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,819&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(342)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(128)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(366)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(318)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(48)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by operating activities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,426&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,111&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,501&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">315&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(390)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(261)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(419)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">670&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,513)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,294)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,443&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">781&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,737)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in Cash and cash equivalents and Restricted cash and other settlement deposits</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,428)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,521&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,731&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,949)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents and Restricted cash and other settlement deposits, beginning of year</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,816&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,244&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">723&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,428)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,521&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents and Restricted cash and other settlement deposits, end of year</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,119&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,816&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,244&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,428)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A detailed discussion of the year-over-year changes of the Company&#8217;s 2020 results compared with that of 2019 can be found under &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations with Retrospective Segment Changes of the 2020 Form 10-K&#8221; in Exhibit 99.1 of our Form 8-K filed on May 4, 2021. There was no impact to such detailed discussion based on the change in reporting segment structure that occurred in 2022.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities was $1,426 million and $1,111 million in 2021 and 2020, respectively, an increase of $315 million. The increase was attributable to the year-over-year increases in&#58; (i) Changes in operating assets and liabilities of $238 million and (ii) Cash provided by operating activities before changes in operating assets and liabilities of $77 million.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities before changes in operating assets and liabilities for the years 2021 and 2020 was $1,554 million and $1,477 million, respectively, an increase of $77 million.  The increase was primarily attributable to&#58; (i) the positive impacts on our operating results of the recovery from the COVID-19 pandemic and the easing of certain social restrictions, as previously discussed, and (ii) higher insurance recoveries during 2021 as compared to 2020 associated with certain litigation matters.  These increases were partially offset by&#58; (i) higher payments of accrued legal settlements during 2021 as compared to 2020, (ii) higher payments for Separation and IPO costs and Separation-related and IPO-related costs during 2021 as compared to 2020 and (iii) the impacts of the non-recurrence of certain profit protection measures taken in 2020 to manage and reduce operating expenses during the COVID-19 pandemic, as previously discussed, which resulted in year-over-year increases in payments primarily for selling expenses and advertising and promotion expenses. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities resulted in a net decrease in cash of $128 million and $366 million in 2021 and 2020, respectively, a favorable change of $238 million. During 2021, Changes in operating assets and liabilities was negatively impacted by&#58; (i) the increase in trade receivables of $229&#160;million, (ii) an increase in inventories of $16&#160;million and (iii) lower interest payable due to the timing of payments of $13 million, partially offset by the positive impact of the timing of other payments in the ordinary course of business of $130&#160;million. During 2020, Changes in operating assets and liabilities was negatively impacted by&#58; (i) the timing of other payments in the ordinary course of business of $495&#160;million and (ii) an increase in inventories of $77&#160;million and was partially offset by&#58; (i) the collection of trade receivables of $170&#160;million and (ii) an increase in accrued interest due to timing of payments of $36&#160;million.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $409 million in 2021 and was primarily driven by&#58; (i) Proceeds from sale of assets and businesses, net of costs to sell of $669 million, which is primarily attributable to the Amoun Sale and (ii) Settlements from cross-currency swaps of $27 million, partially offset by Purchases of property, plant and equipment of $269 million. </font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $261 million in 2020 and was primarily driven by Purchases of property, plant and equipment of $302 million partially offset by&#58; (i) Interest settlements from cross-currency swaps of $23 million and (ii) Proceeds from sale of assets and businesses, net of costs to sell of $21 million, primarily related to the receipt of a milestone payment associated with a prior year divestiture. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities during 2021 was $1,513 million and was primarily driven by the repayments of debt of $3,440 million which consisted of&#58; (i) $1,600 million of 7.000% Senior Secured Notes due 2024 as part of the 2021 Refinancing Transactions (as defined below), (ii) the aggregate prepayments of $1,600&#160;million using cash on hand, cash generated from operations and the net proceeds from the Amoun Sale and (iii) the repayment of $240 million previously drawn under our 2023 Revolving Credit Facility. Issuance of long-term debt  (net of discounts) of $2,100 million primarily includes&#58; (i) the proceeds of $1,575 million from the issuance of $1,600 million in principal amount of 4.875% Senior Secured Notes due June 2028 and (ii) draw downs of $525 million under our 2023 Revolving Credit Facility which we used primarily to make deposits of approximately $300&#160;million, in the aggregate, into escrow funds under the terms of settlement agreements regarding the Glumetza Antitrust Litigation and to pay interest and other business expenses.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities during 2020 was $2,294 million and was primarily driven by repayments of long-term debt, net of issuances and related discounts, of $2,187 million. These repayments primarily include&#58; (i) $1,240 million of 5.875% Senior Unsecured Notes due 2023 (the &#8220;May 2023 Unsecured Notes&#8221;), which was previously financed as part of the December 2019 Financing and Refinancing Transactions and (ii) debt repayments of $902 million using cash on hand and cash generated from operations.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; to our audited Consolidated Financial Statements for further details regarding the financing activities previously described.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Debt</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Sources of Liquidity</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity are our cash and cash equivalents, cash collected from customers, funds as available from our revolving credit facility, issuances of long-term debt and issuances of equity and equity-linked securities. We believe these sources will be sufficient to meet our current liquidity needs for the next twelve months.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously discussed, at the end of 2021, we had substantially completed the internal objectives to facilitate the IPOs and related separation of the B+L and Solta Medical businesses. We continue to monitor market conditions and aim to launch the B+L IPO and the Solta IPO when financial market conditions are favorable (subject to receipt of regulatory, stock exchange and other approvals). However, there can be no assurance as to when we will complete either IPO, if at all. Until such time, we continue to manage these businesses along with our diverse portfolio of gastrointestinal, dermatology, neurology and other therapeutics, with our continued commitment to bring out additional value for our shareholders. Following the B+L IPO, we expect to complete the separation of Bausch + Lomb after the expiry of customary lockups related to the B+L IPO and achievement of targeted debt leverage ratios, subject to the receipt of applicable shareholder and other necessary approvals and market conditions. Nothing in the Form 10-K shall constitute an offer to sell or the solicitation of an offer to buy any securities of the Bausch + Lomb or Solta entities.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly evaluates market conditions, its liquidity profile, and various financing alternatives for opportunities to enhance its capital structure. If opportunities are favorable, the Company may refinance or repurchase existing debt or issue equity or equity-linked securities.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-term Debt</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt, net of unamortized premiums, discounts and issuance costs was $22,654 million and $23,925 million as of December 31, 2021 and 2020, respectively. Aggregate contractual principal amounts due under our debt obligations were $22,870 million and $24,185 million as of December 31, 2021 and 2020, respectively, a decrease of $1,315 million. The decrease during 2021 was attributable to the debt repayments previously discussed under &#8220; - Cash Flows - Financing Activities&#8221;. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Credit Facilities</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the &#8220;Senior Secured Credit Facilities&#8221; under the Company&#8217;s Fourth Amended and Restated Credit and Guaranty Agreement, as amended by the First Incremental Amendment to the Restated Credit Agreement, dated as of November 27, 2018 (the &#8220;Restated Credit Agreement&#8221;) with a syndicate of financial institutions and investors as lenders. </font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restated Credit Agreement provides for a revolving credit facility of $1,225 million, which matures on the earlier of June 1, 2023 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company and Bausch Health Americas, Inc. (&#8220;BHA&#8221;) in an aggregate principal amount in excess of $1,000 million (the &#8220;2023 Revolving Credit Facility&#8221;) and term loan facilities of original principal amounts of $4,565 million and $1,500 million, maturing in June 2025 (the &#8220;June 2025 Term Loan B Facility&#8221;) and November 2025 (the &#8220;November 2025 Term Loan B Facility&#8221;), respectively. Both the Company and BHA are borrowers under the 2023 Revolving Credit Facility, borrowings under which may be made in U.S. dollars or Canadian dollars (or if an amendment to the Restated Credit Agreement is made to replace LIBOR with an alternative benchmark rate with respect to borrowings under the Revolving Credit Facility denominated in euros, euros).</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Current Description of Senior Secured Credit Facilities</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Senior Secured Credit Facilities in U.S. dollars bear interest at a rate per annum equal to, at the Company's option, either&#58; (i) a base rate determined by reference to the highest of&#58; (a) the prime rate (as defined in the Restated Credit Agreement), (b) the federal funds effective rate plus 1&#47;2 of 1.00% or (c) the eurocurrency rate (as defined in the Restated Credit Agreement) for a period of one month plus 1.00% (or if such eurocurrency rate shall not be ascertainable, 1.00%) or (ii) a eurocurrency rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing adjusted for certain additional costs (provided however, that the eurocurrency rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2023 Revolving Credit Facility in euros, when available, are expected to bear interest at a term benchmark rate determined by reference to the costs of funds for euro deposits for the interest period relevant to such borrowing (provided however, that the eurocurrency rate is at no time expected to be less than 0.00% per annum), plus an applicable margin. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2023 Revolving Credit Facility in Canadian dollars bear interest at a rate per annum equal to, at the Company's option, either&#58; (i) a prime rate determined by reference to the higher of&#58; (a) the rate of interest last quoted by The Wall Street Journal as the &#8220;Canadian Prime Rate&#8221; or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Bank of Canada as its prime rate and (b) the 1 month BA rate (as defined below) calculated daily plus 1.00% (provided however, that the prime rate shall at no time be less than 0.00%) or (ii) the bankers&#8217; acceptance rate for Canadian dollar deposits in the Toronto interbank market (the &#8220;BA rate&#8221;) for the interest period relevant to such borrowing (provided however, that the BA rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the Restated Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from&#58; (i)&#160;100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii)&#160;100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the Restated Credit Agreement), (iii)&#160;50% of Excess Cash Flow (as&#160;defined in the Restated Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv)&#160;100% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility are 2.00% and 1.75%, respectively, with respect to base rate and prime rate borrowings and 3.00% and 2.75%, respectively, with respect to eurocurrency rate and BA rate borrowings. As of December 31, 2021, the stated rates of interest on the Company&#8217;s borrowings under the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility were 3.09% and 2.84% per annum, respectively.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for both the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility is 5.00% per annum. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of December&#160;31, 2021, there were no remaining mandatory quarterly amortization payments for the Senior Secured Credit Facilities. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for borrowings under the 2023 Revolving Credit Facility are 1.50% - 2.00% with respect to base rate or prime rate borrowings and 2.50% - 3.00% with respect to eurocurrency rate or BA rate borrowings.&#160; As of December 31, 2021, the stated rate of interest on the 2023 Revolving Credit Facility was 2.84% per annum. As of December 31, 2021, the Company had $285 million outstanding borrowings, $54 million of issued and outstanding letters of credit, and remaining availability of $886 million under its 2023 Revolving Credit Facility. In addition, the Company is required to pay commitment fees of 0.25% - 0.50% per annum with respect to the unutilized commitments under the 2023 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay&#58; (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on eurocurrency rate </font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">borrowings under the 2023 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency&#160;fees.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restated Credit Agreement permits the incurrence of incremental credit facility borrowings, up to the greater of $1,000 million and 28.5% of Consolidated Adjusted EBITDA (non-GAAP) (as defined in the Restated Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to, in the case of secured debt, a secured leverage ratio of not greater than 3.50&#58;1.00, and, in the case of unsecured debt, either a total leverage ratio of not greater than 6.50&#58;1.00 or an interest coverage ratio of not less than 2.00&#58;1.00.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Secured Notes</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes are guaranteed by each of the Company&#8217;s subsidiaries that is a guarantor under the Restated Credit Agreement and existing Senior Unsecured Notes (together, the &#8220;Note Guarantors&#8221;). The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#8217;s obligations under the Restated Credit Agreement under the terms of the indentures governing the Senior Secured Notes. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#8217;s and Note Guarantors&#8217; respective existing and future unsubordinated indebtedness and senior to the Company&#8217;s and Note Guarantors&#8217; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pari passu</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to&#58; (i) all liabilities of any of the Company&#8217;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#8217;s debt that is secured by assets that are not collateral.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#8217;s notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate principal amount of our Senior Secured Notes as of December 31, 2021 and 2020 was $3,850&#160;million and $4,250&#160;million, respectively, a decrease of $400&#160;million representing the prepayment of $400 million 7.00% Senior Secured Notes due 2024 using cash on hand and cash generated from operations during 2021.  Additionally, in June 2021, we accessed the credit markets and completed a series of transactions, whereby we&#58; (i) extended $1,600 million in aggregate maturities of certain debt obligations due to mature in 2024 out to 2028 and (ii) refinanced $1,600 million in aggregate of existing 7.00% Senior Secured Notes due 2024 with $1,600 million in aggregate of 4.875% Senior Secured Notes due 2028 (the &#8220;2021 Refinancing Transactions&#8221;).</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Unsecured Notes</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Unsecured Notes issued by the Company are the Company&#8217;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the Senior Secured Credit Facilities. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the Senior Secured Credit Facilities. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate principal amount of our Senior Unsecured Notes as of December 31, 2021 and 2020 was $14,900 million and $15,500 million, respectively, a decrease of $600 million, representing the prepayment of $600 million 6.125% Senior Unsecured Notes due 2025 (the &#8220;6.125% Notes due 2025&#8221;) using cash on hand and cash generated from operations during 2021.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Covenant Compliance</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any inability to comply with the covenants under the terms of our Restated Credit Agreement, Senior Secured Notes indentures or Senior Unsecured Notes indentures could lead to a default or an event of default for which we may need to seek relief from our lenders and noteholders in order to waive the associated default or event of default and avoid a potential </font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acceleration of the related indebtedness or cross-default or cross-acceleration to other debt. There can be no assurance that we would be able to obtain such relief on commercially reasonable terms or otherwise and we may be required to incur significant additional costs. In addition, the lenders under our Restated Credit Agreement, holders of our Senior Secured Notes and holders of our Senior Unsecured Notes may impose additional operating and financial restrictions on us as a condition to granting any such waiver.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2017 through the date of this filing, the Company completed several actions which included repaying debt with proceeds from divestitures and cash flows from operations, as well as refinancing debt with near term maturities. These actions have reduced the Company&#8217;s debt balance and positively affected the Company&#8217;s ability to comply with its financial maintenance covenant. As of December&#160;31, 2021, the Company was in compliance with the financial maintenance covenant related to its outstanding debt. The Company, based on its current forecast for the next twelve months from the date of issuance of this Form 10-K, expects to remain in compliance with the financial maintenance covenant and meet its debt service obligations over that same period. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to take steps to improve its operating results to ensure continual compliance with its financial maintenance covenant and take other actions to reduce its debt levels to align with the Company&#8217;s long-term strategy. The Company may consider taking other actions, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities including secondary offerings of the common stock of Bausch + Lomb and Solta Medical, as deemed appropriate, to provide additional coverage in complying with the financial maintenance covenant and meeting its debt service obligations.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Notes and Secured Notes are guaranteed by a substantial portion of the Company&#8217;s subsidiaries. On a non-consolidated basis, the non-guarantor subsidiaries had total assets of $2,161 million and $2,442 million and total liabilities of $942 million and $1,804 million as of December&#160;31, 2021 and 2020, respectively. On a non-consolidated basis, the non-guarantor subsidiaries had revenues of $1,755 million and $1,320&#160;million for 2021 and 2020, respectively. On a non-consolidated basis, the non-guarantor subsidiaries had operating income of $116 million for 2021 and an operating loss of $38&#160;million for 2020.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Focus on Capitalization of the Post-separation Entities</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the B+L Separation and Solta IPO, we have emphasized that it is important that the post-separation entities be well-capitalized, with appropriate leverage and with access to additional capital, if and when needed, to provide each entity with the ability to independently allocate capital to areas that will strengthen their own competitive positions in their respective lines of business and position each entity for sustainable growth. Therefore, we see the appropriate capitalization and leverage of these businesses post-separation as a key to bringing out the maximum value across our portfolio of assets and, it is a primary objective of our plan of separation. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, in connection with the anticipated B+L IPO and Solta IPO, the Company issued conditional notices of redemption to redeem in full all of its outstanding 6.125% Notes due 2025 and to redeem $370 million aggregate principal amount of its outstanding 9.000% Notes due 2025. The redemption and discharge of the indenture governing the 6.125% Notes due 2025 will be conditioned upon the completion of the Credit Agreement Refinancing, as defined below. The redemption of the 9.000% Notes due 2025 will be conditioned upon the receipt of aggregate gross proceeds from the B+L IPO, the B+L Debt Financing as defined below, the Credit Agreement Refinancing and the offering of the February 2027 Secured Notes, as defined below, of at least $7,000 million. The foregoing redemptions are subject to the conditions described above, and there can be no assurance that such conditions will be satisfied and that such redemptions will occur.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, the Company announced its intention to refinance its existing Restated Credit Agreement with an amended Restated Credit Agreement (the &#8220;New Restated Credit Agreement&#8221; and such refinancing, the &#8220;Credit Agreement Refinancing&#8221;). The New Restated Credit Agreement is expected to consist of approximately $2,500 million of term B loans and a $975 million revolving credit facility. The Credit Agreement Refinancing is expected to occur only upon completion of the B+L IPO and a related debt financing by Bausch + Lomb (the &#8220;B+L Debt Financing&#8221;). At the time of the B+L IPO, the Credit Agreement Refinancing will provide that Bausch + Lomb initially be a &#8220;restricted&#8221; subsidiary subject to the terms of the Credit Agreement covenants, however the Credit Agreement Refinancing is expected to permit the Company to designate Bausch + Lomb as an &#8220;unrestricted&#8221; subsidiary under the New Restated Credit Agreement covenants upon achievement of a 7.6x pro forma &#8220;Remainco Total Leverage Ratio.&#8221; Such designation could take place at any time after the B+L IPO (including as soon as the closing of the B+L IPO). The Credit Agreement Refinancing is designed to facilitate the separation and distribution of Bausch + Lomb. The Credit Agreement Refinancing will not be consummated until completion of the B+L IPO and related B+L Debt Financing. There can be no assurance that the Credit Agreement Refinancing will occur on the terms described above, or at all.</font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2022, the Company issued $1,000 million aggregate principal amount of 6.125% Senior Secured Notes due February 2027 (the &#8220;February 2027 Secured Notes&#8221;). The February 2027 Secured Notes accrue interest at a rate of 6.125% per year, payable semi-annually in arrears on each February and August. The February 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after February 2024, at the redemption prices set forth in the indenture. The Company may redeem some or all of the February 2027 Secured Notes prior to February 2024 at a price equal to 100% of the principal amount thereof plus a &#8220;make-whole&#8221; premium. Prior to February 2024, the Company may redeem up to 40% of the aggregate principal amount of the February 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture. If the B+L IPO does not occur on or prior to August 15, 2022, the Company will be required to redeem the February 2027 Secured Notes at such time at a redemption price equal to the issue price of the February 2027 Secured Notes plus accrued and unpaid interest.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Weighted Average Interest Rate</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average stated rate of interest of the Company's debt  as of December 31, 2021 and 2020 was 5.88% and 6.02%, respectively.</font></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10, &#8220;FINANCING ARRANGEMENTS&#8221; and Note 23, &#8220;SUBSEQUENT EVENTS&#8221; to our audited Consolidated Financial Statements for further details.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Ratings </font></div><div style="text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During 2021, Moody's, Standard &#38; Poor's and Fitch maintained our credit ratings but changed our outlook from Stable to Negative. As of February&#160;23, 2022, the credit ratings and outlook from Moody's, Standard &#38; Poor's and Fitch for certain outstanding obligations of the Company were as follows&#58;</font></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.349%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rating Agency</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Corporate Rating</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Rating&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Rating</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outlook</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Moody&#8217;s&#160;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B2</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ba2&#47;Ba3</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B3</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Negative</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standard &#38; Poor&#8217;s</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B+</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BB</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Negative</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fitch</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BB</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Negative</font></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a part of the financing transactions launched in January 2022 discussed above, Moody&#8217;s assigned a Ba3 rating to the $2,500 million of term B loans and the $975 million revolving credit facility as anticipated by the Credit Agreement Refinancing and to the newly issued February 2027 Secured Notes. The Ba3 rating is one notch lower than Moody&#8217;s rating of Ba2 for our existing senior secured debt. As the Credit Agreement Refinancing will not be consummated until completion of the B+L IPO and related B+L Debt Financing, there can be no assurance that the Credit Agreement Refinancing will occur on the terms described above, or at all. Should the Credit Agreement Refinancing be completed as described above, Moody's anticipates downgrading its ratings on our existing senior secured notes to Ba3 from Ba2, consistent with the Ba3 rating assigned to the $2,500 million of term B loans and the $975 million revolving credit facility as anticipated by the Credit Agreement Refinancing and to the newly issued February 2027 Secured Notes.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any downgrade in our corporate credit ratings or other credit ratings may increase our cost of borrowing and may negatively impact our ability to raise additional debt capital.</font></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_217"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OFF-BALANCE SHEET ARRANGEMENTS AND CONTRACTUAL OBLIGATIONS </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no off-balance sheet arrangements that have a material current effect or that are reasonably likely to have a material future effect on our results of operations, financial condition, capital expenditures, liquidity, or capital resources. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other future cash requirements relate to working capital, capital expenditures, business development transactions (contingent consideration), restructuring, integration, separation and IPO costs, benefit obligations and litigation settlements. In addition, we may use cash to enter into licensing arrangements and&#47;or to make strategic acquisitions. We are considering further acquisition opportunities within our core therapeutic areas, some of which could be sizable.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our working capital requirements, as of December&#160;31, 2021, we expect our primary cash requirements for 2022 to include&#58;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Debt repayments and interest payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;On February 11, 2022, we repaid $285 million representing all amounts outstanding under our 2023 Revolving Credit Facility as of December 31, 2021, and, therefore as a result of prepayments and a series of refinancing transactions we have reduced and extended the maturities of a substantial portion of our long-term debt and have no debt maturities until 2025 (other than our obligation to redeem the February 2027 Secured Notes if the B+L IPO does not occur on or prior to August 15, 2022 as discussed above) and have no mandatory amortization payments. Based on our debt portfolio as of December 31, 2021, which does not reflect changes in our capitalization in </font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">connection with the B+L Separation and the Solta IPO if and when they occur, we anticipate making interest payments of approximately $1,350 million during 2022. Further, in connection with the conditional notices of redemption discussed above, we anticipate&#58; (i) redeeming in full all of our outstanding 6.125% Notes due 2025 conditioned upon the completion of the Credit Agreement Refinancing, as discussed above, and (ii) redeeming $370 million aggregate principal amount of our 9.000% Notes due 2025 conditioned upon the receipt of aggregate gross proceeds from the B+L IPO, the B+L Debt Financing, the Credit Agreement Refinancing and the February 2027 Secured Notes of at least $7,000 million, as discussed above. The foregoing redemptions are subject to the conditions described above, and there can be no assurance that such conditions will be satisfied and that such redemptions will occur. We may also elect to make additional principal payments under certain circumstances. Further, in the ordinary course of business, we may borrow and repay additional amounts under our credit facilities using cash on hand, cash generated from operations and cash provided from the sale of common stock and additional debt financings in connection with the B+L Separation and the Solta IPO&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">IT Infrastructure Investment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make payments of approximately $65&#160;million for licensing, maintenance and capitalizable costs associated with our IT infrastructure improvement projects during 2022&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Capital expenditures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make payments of approximately $275&#160;million for property, plant and equipment during 2022&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Contingent consideration payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make contingent consideration and other development&#47;approval&#47;sales-based milestone payments of approximately $64&#160;million during 2022&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Restructuring and integration payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make payments of $8&#160;million during 2022 for employee separation costs and lease termination obligations associated with restructuring and integration actions we have taken through December&#160;31, 2021&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Benefit obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;We expect to make aggregate payments under our pension and postretirement obligations of $13&#160;million during 2022. See Note 11, &#8220;PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS&#8221; to our audited Consolidated Financial Statements for further details of our benefit obligations&#59; and</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Litigation Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;In the ordinary course of business, the Company is involved in litigation, claims, government inquiries, investigations, charges and proceedings.  As of December&#160;31, 2021, the Company's Consolidated Balance Sheet includes accrued current loss contingencies of $1,890 million related to matters which are both probable and reasonably estimable, of which $1,567 million, has been paid or is expected to be payable during 2022&#59; however, no assurance can be provided as to when such amount will be payable, if&#160;at all. The amounts which can be expected to be payable during 2022 include among other agreements to resolve&#58; </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:42.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation for $1,210&#160;million </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- The Company reached an agreement to resolve the U.S. Securities Litigation for $1,210 million.  Final court approval of this settlement was granted in January 2021 but is subject to an objector's appeal of the Court's final approval order. The settlement resolves and discharges all claims against the Company in the class action. As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against them and deny all allegations of wrongdoing. This settlement resolves the most significant of the Company's remaining legacy legal matters and eliminates a material uncertainty regarding our Company. As of December&#160;31, 2021, Restricted cash and other settlement deposits includes $1,210&#160;million of payments into an escrow fund under the terms of a settlement agreement regarding the U.S. Securities Litigation. </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:42.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza Antitrust Litigation for $300 million</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - On September 14, 2021, the Company executed a final settlement agreement to resolve the class plaintiffs&#8217; claims in the Glumetza Antitrust Litigation for $300 million, subject to court approval. On February 3, 2022, the court granted final approval of the class settlement and ordered dismissal of the class plaintiffs&#8217; claims. Subject to appeal of the final approval of the class settlement, the settlement will resolve and discharge all asserted class claims against the Company. As part of the settlement, the Company admitted no liability as to the claims against it and denied all allegations of wrongdoing. As of December&#160;31, 2021, Restricted cash and other settlement deposits includes approximately $300&#160;million of payments into an escrow fund under the terms of a settlement agreement regarding the class plaintiffs' claims in the Glumetza Antitrust Litigation.</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:24.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 20, &#8220;LEGAL PROCEEDINGS&#8221; to our audited interim Consolidated Financial Statements for further details of these and other matters. Our ability to successfully defend the Company against pending and future litigation may impact future cash flows.</font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Costs of B+L Separation and Solta IPO</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred, and will incur, costs associated with activities to complete the B+L Separation and the Solta IPO. These activities include the costs of&#58; (i) separating the Bausch + Lomb and the Solta Medical businesses from the remainder of the Company and (ii) registering the Bausch + Lomb and the Solta Medical businesses as independent publicly traded entities. Separation and IPO costs are incremental costs directly related to the B+L Separation and Solta IPO and include, but are not limited to&#58; (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing new boards of directors and related board committees for the Bausch + Lomb and Solta Medical entities. The Company has also incurred, and will incur, Separation-related and IPO-related costs which are incremental costs indirectly related to the B+L Separation and Solta IPO. These costs include, but are not limited to&#58; (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and&#47;or modification. The extent and timing of future charges for these costs cannot be reasonably estimated at this time and could be material.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Cost Savings Programs </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate opportunities to improve our operating results and may initiate additional cost savings programs to streamline our operations and eliminate&#160;redundant processes and expenses. These cost savings programs may include, but are not limited to&#58; (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The expenses associated with the implementation of these cost savings programs could be material and may impact our cash flows.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future Licensing Payments</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and&#47;or development of unique products primarily in the U.S. and Canada. In connection with these agreements, the Company may pay an upfront fee to secure the agreement. See Note 3, &#8220;ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our audited Consolidated Financial Statements. Payments associated with the upfront fee for these agreements cannot be reasonably estimated at this time and could be material</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unrecognized Tax Benefits</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company had unrecognized tax benefits totaling $104 million which are expected to be realized within the next twelve months.</font></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_220"></div><div style="margin-bottom:8pt;margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUTSTANDING SHARE DATA</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common shares are listed on the TSX and the NYSE under the ticker symbol&#160;&#8220;BHC&#8221;.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At February&#160;17, 2022, we had 359,646,496 issued and outstanding common shares. In addition, as of February&#160;17, 2022, we had 8,734,135 stock options and 5,150,139 time-based restricted share units (&#8220;RSUs&#8221;) that each represent the right of a holder to receive one of the Company&#8217;s common shares, and 2,625,722 performance-based RSUs that represent the right of a holder to receive a number of the Company's common shares up to a specified maximum. A maximum of 3,937,844 common shares could be issued upon vesting of the performance-based RSUs outstanding.</font></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_223"></div><div style="margin-bottom:8pt;margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business and financial results are affected by fluctuations in world financial markets, including the impacts of foreign currency exchange rate and interest rate movements. We evaluate our exposure to such risks on an ongoing basis, and seek ways to manage these risks to an acceptable level, based on management&#8217;s judgment of the appropriate trade-off between risk, opportunity and cost. We may use derivative financial instruments from time to time as a risk management tool and not for trading or speculative purposes. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inflation&#59; Seasonality </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to price control restrictions on our pharmaceutical products in a number of countries in which we now operate. As a result, our ability to raise prices in a timely fashion in anticipation of inflation may be limited in some&#160;markets. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, revenues from our business tend to be weighted toward the second half of the year.  Sales in the first quarter tend to be lower as patient co-pays and deductibles reset at the beginning of each year.&#160;&#160;Sales in the fourth quarter tend to be higher based on consumer and customer purchasing patterns associated with health care reimbursement programs.  However, there are no assurances that these historical trends will continue in the future.</font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Risk</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, a majority of our revenue and expense activities and capital expenditures were denominated in U.S.&#160;dollars.&#160; We have exposure to multiple foreign currencies, including, among others, the Euro, Chinese yuan, Polish zloty, Canadian dollar and Mexican peso. Our operations are subject to risks inherent in conducting business abroad, including price and currency exchange controls and fluctuations in the relative values of currencies. In addition, to the extent that we require, as a source of debt repayment, earnings and cash flows from some of our operations located in foreign countries, we are subject to risk of changes in the value of the U.S.&#160;dollar, relative to all other currencies in which we operate, which may materially affect our results of operations. Where possible, we manage foreign currency risk by managing same currency revenues in relation to same currency expenses. Further strengthening of the U.S. dollar and&#47;or further devaluation of foreign currencies will have a negative impact on our reported revenue and reported results.  As of December 31, 2021, a 1% change in foreign currency exchange rates would have impacted our shareholders&#8217; deficit by approximately $39 million.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the unrealized foreign exchange gain on the translation of the remaining principal amount of U.S. denominated senior secured and unsecured notes was $285 million, for Canadian income tax purposes. Additionally, as of December&#160;31, 2021, the unrealized foreign exchange loss on certain intercompany balances was equal to $197 million. One-half of any realized foreign exchange gain or loss will be included in our Canadian taxable income. Any resulting gain will result in a corresponding reduction in our available Canadian Losses, Scientific Research and Experimental Development Pool, and&#47;or Investment Tax Credit carryforward balances. However, the repayment of the senior notes and the intercompany loans denominated in U.S. dollars does not result in a foreign exchange gain or loss being recognized in our Consolidated Financial Statements, as these statements are prepared in U.S. dollars.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not hold financial instruments for speculative purposes. Our financial assets are not subject to significant interest rate risk due to their short duration. The primary objective of our policy for the investment of temporary cash surpluses is the protection of principal, and accordingly, we generally invest in high quality, money market investments and time deposits with varying maturities, but typically less than three months. As it is our intent and policy to hold these investments until maturity, we do not have a material exposure to interest rate&#160;risk. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, we had $18,762 million and $4,108 million principal amount of issued fixed rate debt and variable rate debt, respectively. The estimated fair value of our issued fixed rate debt as of December&#160;31, 2021 was $18,599 million. If interest rates were to increase by 100 basis-points, the fair value of our issued fixed rate debt would decrease by approximately $561 million. If interest rates were to decrease by 100 basis-points, the fair value of our issued fixed rate debt would increase by approximately $478 million. We are subject to interest rate risk on our variable rate debt as changes in interest rates could adversely affect earnings and cash flows. A 100 basis-points increase in interest rates, would have an annualized pre-tax effect of approximately $41 million in our Consolidated Statements of Operations and Consolidated Statements of Cash Flows, based on current outstanding borrowings and effective interest rates on our variable rate debt. While our variable-rate debt may impact earnings and cash flows as interest rates change, it is not subject to changes in fair value. </font></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_226"></div><div style="margin-bottom:8pt;margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING POLICIES AND ESTIMATES</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical accounting policies and estimates are those policies and estimates that are most important and material to the preparation of our Consolidated Financial Statements, and which require management&#8217;s most subjective and complex judgments due to the need to select policies from among alternatives available, and to make estimates about matters that are inherently uncertain. We base our estimates on historical experience and other factors that we believe to be reasonable under the circumstances. On an ongoing basis, we review our estimates to ensure that these estimates appropriately reflect changes in our business and new information as it becomes available. If historical experience and other factors we use to make these estimates do not reasonably reflect future activity, our results of operations and financial condition could be materially impacted.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are primarily generated from product sales, primarily in the therapeutic areas of eye-health, GI and dermatology that consist of&#58; (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. </font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when the customer obtains control of promised goods or services and in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services.  To achieve this core principle, the Company applies the five-step revenue model to contracts within its scope&#58; (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.  The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future period.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers.  </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and application of the critical accounting policies associated with the revenue recognition guidance, including the policies associated with each of our product sales provisions and the table showing the activity and ending balances for our product sales provisions, are discussed in more detail in Note 2, &#8220;SIGNIFICANT ACCOUNTING POLICIES&#8221; to our audited Consolidated Financial Statements.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition-Related Contingent Consideration </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the business combinations that we have consummated include contingent consideration to be potentially paid based upon the occurrence of future events, such as sales performance and the achievement of certain future development, regulatory and sales milestones. Acquisition-related contingent consideration associated with a business combination is initially recognized at fair value and remeasured each reporting period, with changes in fair value recorded in the Consolidated Statements of Operations. The estimates of fair value involve the use of acceptable valuation methods, such as probability-weighted discounted cash flow analysis and Monte Carlo Simulation (when appropriate), and contain uncertainties as they require assumptions about the likelihood of achieving specified milestone criteria, projections of future financial performance and assumed discount rates. Changes in the fair value of the acquisition-related contingent consideration result from several factors including changes in the timing and amount of revenue estimates, changes in probability assumptions with respect to the likelihood of achieving specified milestone criteria and changes in discount rates.  A change in any of these assumptions could produce a different fair value, which could have a material impact on our results of&#160;operations.  At December&#160;31, 2021, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from 6% to 18%.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate potential impairments of amortizable intangible assets acquired through asset acquisitions or business combinations if events or changes in circumstances indicate that the carrying amounts of these assets may not be recoverable. Our evaluation is based on an assessment of potential indicators of impairment, such&#160;as&#58;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an adverse change in legal factors or in the business climate that could affect the value of an asset. For example, a successful challenge of our patent rights resulting in earlier than expected generic competition&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an adverse change in the extent or manner in which an asset is used or is expected to be used. For example, a decision not to pursue a product line-extension strategy to enhance an existing product due to changes in market conditions and&#47;or technological advances&#59;&#160;or</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">current or forecasted reductions in revenue, operating income, or cash flows associated with the use of an asset. For example, the introduction of a competing product that results in a significant loss of market&#160;share.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment exists when the carrying value of the asset exceeds the related estimated undiscounted future cash flows expected to be derived from the asset, which include the amount and timing of the projected future cash flows. If impairment exists, the carrying value of the asset is adjusted to its fair value. A discounted cash flow analysis is typically used to determine an asset's fair value, using estimates and assumptions that market participants would apply. Some of the estimates and assumptions inherent in a discounted cash flow model include the amount and timing of the projected future cash flows, and the discount rate used to reflect the risks inherent in the future cash flows. A change in any of these estimates and assumptions </font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">could produce a different fair value, which could have a material impact on our results of operations. In addition, an intangible asset&#8217;s expected useful life can increase estimation risk, as longer-lived assets necessarily require longer-term cash flow forecasts, which for some of our intangible assets can be up to 20&#160;years. In connection with an impairment evaluation, we also reassess the remaining useful life of the intangible asset and modify it, as&#160;appropriate.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management continually assesses the useful lives of the Company's long-lived assets. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets, including Acquired in-process research and development and the B&#38;L corporate trademark, are tested for impairment annually, or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based solely on a comparison of their fair value to carrying value, without consideration of any recoverability test. In particular, we will continue to monitor closely the progression of our R&#38;D programs as their likelihood of success is contingent upon the achievement of future milestones.  See Item&#160;7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212;&#160;Overview &#8212;&#160;Focus on Core Business&#8221; for additional information regarding our R&#38;D&#160;programs.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill </font></div><div style="padding-right:4.5pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is tested for impairment at least annually on October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment.  The Company performs its annual impairment test by first assessing qualitative factors. Where the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed for that reporting unit (Step 1). </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair values of a reporting unit using a discounted cash flow model which utilizes Level 3 unobservable inputs. The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The quantitative fair value test is performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit's terminal value. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To forecast a reporting unit's cash flows the Company takes into consideration economic conditions and trends, estimated future operating results, management's and a market participant's view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts are based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected LOE to the Company's product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company&#8217;s control could have a positive or negative impact on achieving its targets.  Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Annual Goodwill Impairment Test</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2019 by first assessing qualitative factors. Where the qualitative assessment suggested that it was more likely than not that the fair value of a reporting unit was less than its carrying amount, a quantitative fair value test was performed for that reporting unit. In each quantitative fair value test performed, the fair value was greater than the carrying value of the reporting unit.  As a result, there was no impairment to the goodwill of any reporting unit.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Interim Goodwill Impairment Assessment</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the interim periods of 2020, after giving consideration to the nature and timing of the negative impacts of the COVID-19 pandemic on the Company's forecasted cash flows, with the exception of the Ortho Dermatologics reporting unit, no events occurred, or circumstances changed that would indicate that the fair value of any other reporting unit might be below its carrying value and therefore, no impairments were recorded. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2020 and June 30, 2020, the operating results for the Ortho Dermatologics reporting unit were less than forecasted primarily due to certain products experiencing longer launch cycles than originally anticipated as a result of the COVID-19 pandemic. The Company revised its long-term forecasts as of March 31, 2020 and as of </font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2020 for these matters. Management believed that these events were indicators that there was less headroom as of March 31, 2020 and June 30, 2020 as compared to the headroom calculated on the date the Ortho Dermatologics reporting unit goodwill was previously tested for impairment. Therefore, a quantitative fair value test for impairment to the goodwill of the Ortho Dermatologics reporting unit was performed at March 31, 2020 and at June 30, 2020. Based on the quantitative fair value tests, the fair value of the Ortho Dermatologics reporting unit continued to be greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit at March 31, 2020 or at June 30, 2020.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Annual Goodwill Impairment Test</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2020 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2020, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required.  </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2020, the Company considered, among other matters, a range of potential impacts of COVID-19 pandemic related matters and the limited headroom calculated on the date Ortho Dermatologics goodwill was last tested for impairment (June 30, 2020).  The Company believed that these factors may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2020, utilizing a long-term growth rate of 2.0% and a range of discount rates between 9.50% and 9.75%, in estimation of the fair value of this reporting unit.  Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately 10% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Interim Goodwill Impairment Test</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, management identified launches of certain Ortho Dermatologics products which were not going to achieve their trajectories as forecasted once the social restrictions associated with the COVID-19 pandemic began to ease in the U.S. and offices of health care professionals could reopen. In addition, insurance coverage pressures within the U.S. continued to persist limiting patient access to topical acne and psoriasis products.  In light of these developments, during the first quarter of 2021, the Company began taking steps to&#58; (i) redirect its R&#38;D spend to eliminate projects it has identified as high cost and high risk, (ii) redirect a portion of its marketing and product development outside the U.S. to geographies where there is better patient access and (iii) reduce its cost structure to be more competitive. As a result, during the three months ended March 31, 2021, the Company revised its long-term forecasts for the Ortho Dermatologics reporting unit. Management believed that these events were indicators that there is less headroom as of March 31, 2021 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2020). Therefore, a quantitative fair value test for the Ortho Dermatologics reporting unit was performed. The quantitative fair value test utilized the Company's most recent cash flow projections as revised in the first quarter of 2021 to reflect the business changes previously discussed, including a range of potential outcomes, along with a long-term growth rate of 1.0% and a range of discount rates between 9.0% and 10.0%. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at March 31, 2021, and the Company recognized a goodwill impairment of $469&#160;million.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Annual Goodwill Impairment Test</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2021 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2021, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required.  </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2021, the Company considered, among other matters, the limited headroom as a result of the impairment to the goodwill of the Ortho Dermatologics reporting unit when last tested (March 31, 2021) and macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The Company believed that these facts and circumstances may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit.</font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2021, utilizing a long-term growth rate of 1.0% and a discount rate of 9.0%, in estimation of the fair value of this reporting unit.  Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately 10% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, &#8220;INTANGIBLE ASSETS AND GOODWILL&#8221; to our audited Consolidated Financial Statements for further details on the goodwill impairments recognized in 2021.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we are subject to loss contingencies, such as claims and assessments arising from litigation and other legal proceedings, contractual indemnities, product and environmental liabilities and tax matters. Other than loss contingencies that are assumed in business combinations for which we can reliably estimate the fair value, we are required to accrue for such loss contingencies if it is probable that the outcome will be unfavorable and if the amount of the loss can be reasonably estimated. We evaluate our exposure to loss based on the progress of each contingency, experience in similar contingencies and consultation with our legal counsel. We re-evaluate all contingencies as additional information becomes available. Given the uncertainties inherent in complex litigation and other contingencies, these evaluations can involve significant judgment about future events. The ultimate outcome of any litigation or other contingency may be material to our results of operations, financial condition and cash flows. See Note 20, &#8220;LEGAL PROCEEDINGS&#8221; to our audited Consolidated Financial Statements for further details regarding our current legal proceedings. If no accrual is made for a loss contingency because the amount of loss cannot be reasonably estimated, the Company will disclose contingent liabilities when there is at least a reasonable possibility that a loss or an additional loss may have been incurred. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operations in various countries that have differing tax laws and rates. Our tax structure is supported by current domestic tax laws in the countries in which we operate and the application of tax treaties between the various countries in which we operate. Our income tax reporting is subject to audit by domestic and foreign tax authorities. Our effective tax rate may change from year to year based on changes in the mix of activities and income earned under our intercompany arrangements among the different jurisdictions in which we operate, changes in tax laws in these jurisdictions, changes in tax treaties between various countries in which we operate, changes in our eligibility for benefits under those tax treaties and changes in the estimated values of deferred tax assets and liabilities. Such changes could result in an increase in the effective tax rate on all or a portion of our income and&#47;or any of our subsidiaries. </font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our provision for income taxes is based on a number of estimates and assumptions made by management. Our consolidated income tax rate is affected by the amount of income earned in our various operating jurisdictions, the availability of benefits under tax treaties and the rates of taxes payable in respect of that income. We enter into many transactions and arrangements in the ordinary course of business in which the tax treatment is not entirely certain. We must therefore make estimates and judgments based on our knowledge and understanding of applicable tax laws and tax treaties, and the application of those tax laws and tax treaties to our business, in determining our consolidated tax provision. For example, certain countries could seek to tax a greater share of income than has been provided for by us. The final outcome of any audits by taxation authorities may differ from the estimates and assumptions we have used in determining our consolidated income tax provisions and accruals. This could result in a material effect on our consolidated income tax provision, results of operations, and financial condition for the period in which such determinations are&#160;made.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax returns are subject to audit in various jurisdictions. Existing and future audits by, or other disputes with, tax authorities may not be resolved favorably for us and could have a material adverse effect on our reported effective tax rate and after-tax cash flows. We record liabilities for uncertain tax positions, which involve significant management judgment. New laws and new interpretations of laws and rulings by tax authorities may affect the liability for uncertain tax positions. Due to the subjectivity and complex nature of the underlying issues, actual payments or assessments may differ from our estimates. To the extent that our estimates differ from amounts eventually assessed and paid our income and cash flows may be materially and adversely affected.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether it is more likely than not that we will realize the tax benefits associated with our deferred tax assets and establish a valuation allowance for assets that are not expected to result in a realized tax benefit. A significant amount of judgment is used in this process, including preparation of forecasts of future taxable income and evaluation of tax planning initiatives. If we revise these forecasts or determine that certain planning events will not occur, an adjustment to the valuation allowance will be made to tax expense in the period such determination is&#160;made.</font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_229"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NEW ACCOUNTING STANDARDS</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the recently issued new accounting guidance (adopted and not adopted as of December 31, 2021) is contained in Note 2, &#8220;SIGNIFICANT ACCOUNTING POLICIES&#8221; to our audited Consolidated Financial Statements.</font></div><div id="i0b544a4c0bfd46c2b158aa1a39e8f831_232"></div><div style="margin-bottom:8pt;margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Caution regarding forward-looking information and statements and &#8220;Safe-Harbor&#8221; statements under the U.S.&#160;Private Securities Litigation Reform Act of&#160;1995 and applicable Canadian securities laws&#58;</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent any statements made in this Form&#160;10-K contain information that is not historical, these statements are forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, and may be forward-looking information within the meaning defined under applicable Canadian securities laws (collectively, &#8220;forward-looking statements&#8221;).</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements relate to, among other things&#58; our business strategy, business plans and prospects and forecasts and changes thereto&#59; product pipeline, prospective products and product approvals, expected launches of new products, product development and future performance and results of current and anticipated products&#59; anticipated revenues for our products&#59; expected R&#38;D and marketing spend&#59; our expected primary cash and working capital requirements for 2022 and beyond&#59; the Company's plans for continued improvement in operational efficiency and the anticipated impact of such plans&#59; our liquidity and our ability to satisfy our debt maturities as they become due&#59; our ability to reduce debt levels&#59; our ability to comply with the financial and other covenants contained in the Restated Credit Agreement, and senior notes indentures&#59; the impact of our distribution, fulfillment and other third-party arrangements&#59; proposed pricing actions&#59; exposure to foreign currency exchange rate changes and interest rate changes&#59; the outcome of contingencies, such as litigation, subpoenas, investigations, reviews, audits and regulatory proceedings&#59; the anticipated impact of the adoption of new accounting standards&#59; general market conditions&#59; our expectations regarding our financial performance, including revenues, expenses, gross margins and income taxes&#59; our impairment assessments, including the assumptions used therein and the results thereof&#59; the anticipated impact of the evolving COVID-19 pandemic and related responses from governments and private sector participants on the Company, its supply chain, third-party suppliers, project development timelines, costs, revenues, margins, liquidity and financial condition, the anticipated timing, speed and magnitude of recovery from these COVID-19 pandemic related impacts and the Company&#8217;s planned actions and responses to this pandemic&#59; the Company&#8217;s plan to separate its eye- health business, including the structure and timing of completing such separation transaction&#59; and the proposed initial public offering (&#8220;IPO&#8221;) of the Company&#8217;s Solta aesthetic medical device business, including the timing of such IPO.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements can generally be identified by the use of words such as &#8220;believe&#8221;, &#8220;anticipate&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;estimate&#8221;, &#8220;plan&#8221;, &#8220;continue&#8221;, &#8220;will&#8221;, &#8220;may&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;should&#8221;, &#8220;target&#8221;, &#8220;potential&#8221;, &#8220;opportunity&#8221;, &#8220;designed&#8221;, &#8220;create&#8221;, &#8220;predict&#8221;, &#8220;project&#8221;, &#8220;forecast&#8221;, &#8220;seek&#8221;, &#8220;strive&#8221;, &#8220;ongoing&#8221;, &#8220;decrease&#8221; or &#8220;increase&#8221; and variations or other similar expressions. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements may not be appropriate for other purposes. Although we have previously indicated certain of these statements set out herein, all of the, statements in this Form&#160;10-K that contain forward-looking statements are qualified by these cautionary statements. These statements are based upon the current expectations and beliefs of management. Although we believe that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making such forward-looking statements, including, but not limited to, factors and assumptions regarding the items previously outlined, those factors, risks and uncertainties outlined below and the assumption that none of these factors, risks and uncertainties will cause actual results or events to differ materially from those described in such forward-looking statements. Actual results may differ materially from those expressed or implied in such statements. Important factors, risks and uncertainties that could cause actual results to differ materially from these expectations include, among other things, the&#160;following&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">the risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, the fear of that pandemic, the availability and effectiveness of vaccines for COVID-19 (including with respect to current or future variants), COVID-19 vaccine immunization rates, the emergence of variant strains of COVID-19, the evolving reaction of governments, private sector participants and the public to that pandemic, and the potential effects and economic impact of the pandemic and the reaction to it, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a significant adverse impact on the Company, including but not limited to its supply chain, third-party suppliers, project development timelines, employee base, liquidity, stock price, financial condition and costs (which may increase) and revenue and margins (both of which may decrease)&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">with respect to the proposed separation of the Company&#8217;s eye-health business, the risks and uncertainties include, but are not limited to, the expected benefits and costs of the separation transaction, the expected timing of completion of the separation transaction and its terms, (including the Company&#8217;s expectation that it will launch the IPO of the Bausch </font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+ Lomb entity when financial market conditions are favorable, subject to receipt of regulatory, stock exchange and other approvals, and the Company&#8217;s expectation that the separation transaction will be completed following the expiry of customary lockups related to the B+L IPO and achievement of targeted debt leverage ratios, subject to receipt of applicable shareholder and other necessary approvals), the Company&#8217;s ability to complete the separation transaction considering the various conditions to the completion of the separation transaction (some of which are outside the Company&#8217;s control, including conditions related to regulatory matters and a possible shareholder vote, if applicable), that market or other conditions are no longer favorable to completing the transaction, that any shareholder, stock exchange, regulatory or other approval (if required) is not obtained on the terms or timelines anticipated or at all, business disruption during the pendency of or following the separation transaction, diversion of management time on separation transaction-related issues, retention of existing management team members, the reaction of customers and other parties to the separation transaction, the qualification of the separation transaction as a tax-free transaction for Canadian and&#47;or U.S. federal income tax purposes (including whether or not an advance ruling from the Canada Revenue Agency will be sought or obtained), the ability of the Company and the separated entity to satisfy the conditions required to maintain the tax-free status of the separation transaction (some of which are beyond their control), the ability of the Company and the separated entity to satisfy the conditions required to maintain the tax-free status of the separation transaction (some of which are beyond their control), the potential dissynergy costs resulting from the separation transaction, the impact of the separation transaction on relationships with customers, suppliers, employees and other business counterparties, general economic conditions, conditions in the markets the Company is engaged in, behavior of customers, suppliers and competitors, technological developments, as well as legal and regulatory rules affecting the Company&#8217;s business. In particular, the Company can offer no assurance that any IPO or separation will occur at all, or that any such transaction will occur on the timelines anticipated by the Company&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">with respect to the proposed IPO of the Company&#8217;s Solta aesthetic medical device business, the risks and uncertainties include, but are not limited to, risks relating to the expected timing of completion of such transaction (including the Company&#8217;s expectation that it will launch such IPO when financial market conditions are favorable, subject to receipt of regulatory, stock exchange and other approvals) and the Company&#8217;s ability to complete such transaction, that market or other conditions are no longer favorable to completing the transaction on a timely basis or at all, the receipt of (or failure to receive) any stock exchange, regulatory and other approvals required in connection with the transaction and the timing of receipt of such approvals, business disruption during the pendency of or following such transaction, diversion of management time on transaction-related issues, retention of Solta aesthetic medical device management team members, the reaction of customers and other parties to such transaction, the impact of such transaction on relationships with customers, suppliers, employees and other business counterparties, and other events that could adversely impact the completion of such transaction, including industry or economic conditions outside of Bausch Health&#8217;s control. In particular, the Company can offer no assurance that any IPO will occur at all, or that any such transaction will occur on the timelines anticipated by the Company&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expense, timing and outcome of legal and governmental proceedings, investigations and information requests relating to, among other matters, our past distribution, marketing, pricing, disclosure and accounting practices (including with respect to our former relationship with Philidor Rx Services, LLC (&#8220;Philidor&#8221;)), including a number of pending non-class securities litigations (including certain pending opt-out actions in the U.S. related to the previously settled securities class action (which remains subject to an objector's appeal of the Court's final approval order) and certain opt-out actions in Canada relating to the recently settled class action in Canada), certain pending lawsuits and other claims, investigations or proceedings that may be initiated or that may be asserted&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential additional litigation and regulatory investigations (and any costs, expenses, use of resources, diversion of management time and efforts, liability and damages that may result therefrom), negative publicity and reputational harm on our Company, products and business that may result from the past and ongoing public scrutiny of our past distribution, marketing, pricing, disclosure and accounting practices and from our former relationship with Philidor&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the past and ongoing scrutiny of our legacy business practices, including with respect to pricing, and any pricing controls or price adjustments that may be sought or imposed on our products as a result thereof&#59; </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing decisions that we have implemented, or may in the future elect to implement, such as the Patient Access and Pricing Committee&#8217;s historic practice of limiting the average annual price increase for our branded prescription pharmaceutical products to single digits, or any future pricing actions we may take in 2022 or beyond following review by our Patient Access and Pricing Committee (which is responsible for the pricing of our drugs)&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">legislative or policy efforts, including those that may be introduced and passed by the U.S. Congress, designed to reduce patient out-of-pocket costs for medicines, which could result in new mandatory rebates and discounts or other pricing restrictions, controls or regulations (including mandatory price reductions)&#59;</font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ongoing oversight and review of our products and facilities by regulatory and governmental agencies, including periodic audits by the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) and equivalent agencies outside of the U.S. and the results thereof&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actions by the FDA or other regulatory authorities with respect to our products or facilities&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with the legal and regulatory requirements of our marketed products&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our substantial debt (and potential additional future indebtedness) and current and future debt service obligations, our ability to reduce our outstanding debt levels and the resulting impact on our financial condition, cash flows and results of operations&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with the financial and other covenants contained in our Restated Credit Agreement, senior notes indentures, 2023 Revolving Credit Facility (as defined below) and other current or future credit and&#47;or debt agreements and the limitations, restrictions and prohibitions such covenants impose or may impose on the way we conduct our business, including prohibitions on incurring additional debt if certain financial covenants are not met, limitations on the amount of additional obligations we are able to incur pursuant to other covenants, our ability to draw under our 2023 Revolving Credit Facility and restrictions on our ability to make certain investments and other restricted payments&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any default under the terms of our senior notes indentures or Restated Credit Agreement (and other current or future credit and&#47;or debt agreements) and our ability, if any, to cure or obtain waivers of such default&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any downgrade by rating agencies in our credit ratings, which may impact, among other things, our ability to raise debt and the cost of capital for additional debt issuances&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any reductions in, or changes in the assumptions used in, our forecasts for fiscal year 2022 or beyond, including as a result of the impacts of the COVID-19 pandemic on our business and operations, which could lead to, among other things&#58; (i) a failure to meet the financial and&#47;or other covenants contained in our Restated Credit Agreement and&#47;or senior notes indentures (and other current or future credit and&#47;or debt agreements) and&#47;or (ii) impairment in the goodwill associated with certain of our reporting units or impairment charges related to certain of our products or other intangible assets, which impairments could be material&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the assumptions used in connection with our impairment analyses or assessments, which would lead to a change in such impairment analyses and assessments and which could result in an impairment in the goodwill associated with any of our reporting units or impairment charges related to certain of our products or other intangible assets&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the uncertainties associated with the acquisition and launch of new products, assets and businesses, including, but not limited to, our ability to provide the time, resources, expertise and funds required for the commercial launch of new products, the acceptance and demand for new products, and the impact of competitive products and&#160;pricing, which could lead to material impairment charges&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability or inability to extend the profitable life of our products, including through line extensions and other life-cycle programs&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to retain, motivate and recruit executives and other key&#160;employees&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to implement effective succession planning for our executives and key employees&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to stabilize and reposition our Ortho Dermatologics business to generate additional value, including the success of recently launched products  and the approval of pipeline products (and the timing of such approvals)&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to achieve anticipated revenues for our products, including changes in anticipated marketing spend on such products and launch of competing products&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">factors impacting our ability to achieve anticipated market acceptance for our products, including acceptance of the pricing, effectiveness of promotional efforts, reputation of our products and launch of competing products&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the challenges and difficulties associated with managing a large complex business, which has, in the past, grown rapidly&#59;</font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to compete against companies that are larger and have greater financial, technical and human resources than we do, as well as other competitive factors, such as technological advances achieved, patents obtained and new products introduced by our competitors&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively operate and grow our businesses in light of the challenges that the Company has faced and market conditions, including with respect to its substantial debt, pending investigations and legal proceedings, scrutiny of our past pricing and other practices, limitations on the way we conduct business imposed by the covenants contained in our Restated Credit Agreement, senior notes indentures and the agreements governing our other indebtedness, and the impacts of the COVID-19 pandemic&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which our products are reimbursed by government authorities, pharmacy benefit managers (&#8220;PBMs&#8221;) and other third-party payors&#59; the impact our distribution, pricing and other practices may have on the decisions of such government authorities, PBMs and other third-party payors to reimburse our products&#59; and the impact of obtaining or maintaining such reimbursement on the price and sales of our products&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inclusion of our products on formularies or our ability to achieve favorable formulary status, as well as the impact on the price and sales of our products in connection therewith&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the consolidation of wholesalers, retail drug chains and other customer groups and the impact of such industry consolidation on our business&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain strong relationships with physicians and other healthcare professionals&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">our eligibility for benefits under tax treaties and the continued availability of low effective tax rates for the business profits of certain of our subsidiaries&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the implementation of the Organisation for Economic Co-operation and Development inclusive framework on Base Erosion and Profit Shifting, including the global minimum corporate tax rate, by the countries in which we operate&#59; </font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of any audits by taxation authorities, which outcomes may differ from the estimates and assumptions that we may use in determining our consolidated tax provisions and accruals&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the actions of our third-party partners or service providers of research, development, manufacturing, marketing, distribution or other services, including their compliance with applicable laws and contracts, which actions may be beyond our control or influence, and the impact of such actions on our Company&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risks associated with the international scope of our operations, including our presence in emerging markets and the challenges we face when entering and operating in new and different geographic markets (including the challenges created by new and different regulatory regimes in such countries and the need to comply with applicable anti-bribery and economic sanctions laws and regulations)&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse global economic conditions and credit markets and foreign currency exchange uncertainty and volatility in certain of the countries in which we do&#160;business&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the trade conflict between the United States and China&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential conflict between Russia and Ukraine and any restrictive actions that may be taken by the U.S. and&#47;or other countries in response thereto, such as sanctions or export controls&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, maintain and license sufficient intellectual property rights over our products and enforce and defend against challenges to such intellectual property (such as in connection with the filing by Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;) of its Abbreviated New Drug Application (&#8220;ANDA&#8221;) for Xifaxan&#174; (rifaximin) 550 mg tablets and the Company&#8217;s related lawsuit filed against Norwich in connection therewith)&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the introduction of generic, biosimilar or other competitors of our branded products and other products, including the introduction of products that compete against our products that do not have patent or data exclusivity rights&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to identify, finance, acquire, close and integrate acquisition targets successfully and on a timely basis and the difficulties, challenges, time and resources associated with the integration of acquired companies, businesses and products&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any divestitures of our assets or businesses and our ability to successfully complete any such divestitures on commercially reasonable terms and on a timely basis, or at all, and the impact of any such divestitures on our Company, including the reduction in the size or scope of our business or market share, loss of revenue, any loss on </font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sale, including any resultant impairments of goodwill or other assets, or any adverse tax consequences suffered as a result of any such divestitures&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expense, timing and outcome of pending or future legal and governmental proceedings, arbitrations, investigations, subpoenas, tax and other regulatory audits, examinations, reviews and regulatory proceedings against us or relating to us and settlements thereof&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to negotiate the terms of or obtain court approval for the settlement of certain legal and regulatory proceedings&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain components, raw materials or finished products supplied by third&#160;parties (some of which may be single-sourced) and other manufacturing and related supply difficulties, interruptions and delays&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the disruption of delivery of our products and the routine flow of manufactured goods&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic factors over which the Company has no control, including changes in inflation, interest rates, foreign currency rates, and the potential effect of such factors on revenues, expenses and resulting margins&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interest rate risks associated with our floating rate debt borrowings&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively distribute our products and the effectiveness and success of our distribution arrangements&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively promote our own products and those of our co-promotion partners&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our fulfillment arrangements with Walgreen Co. including market acceptance of, or market reaction to, such arrangements (including by customers, doctors, patients, PBMs, third-party payors and governmental agencies), and the continued compliance of such arrangements with applicable laws&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to secure and maintain third-party research, development, manufacturing, licensing, marketing or distribution arrangements&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that our products could cause, or be alleged to cause, personal injury and adverse effects, leading to potential lawsuits, product liability claims and damages and&#47;or recalls or withdrawals of products from the&#160;market&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the mandatory or voluntary recall or withdrawal of our products from the market and the costs associated therewith&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of, and our ability to obtain and maintain, adequate insurance coverage and&#47;or our ability to cover or insure against the total amount of the claims and liabilities we face, whether through third-party insurance or self-insurance&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our indemnity agreements, which may result in an obligation to indemnify or reimburse the relevant counterparty, which amounts may be material&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the difficulty in predicting the expense, timing and outcome within our legal and regulatory environment, including with respect to approvals by the FDA, Health Canada, European Medicines Agency (&#8220;EMA&#8221;) and similar agencies in other countries, legal and regulatory proceedings and settlements thereof, the protection afforded by our patents and other intellectual and proprietary property, successful generic challenges to our products and infringement or alleged infringement of the intellectual property of&#160;others&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of continuing safety and efficacy studies by industry and government agencies&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of preclinical and clinical trials for our drug development pipeline or delays in clinical trials that adversely impact the timely commercialization of our pipeline products, as well as other factors impacting the commercial success of our products, which could lead to material impairment charges&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainties around the successful improvement and modification of our existing products and development of new products, which may require significant expenditures and efforts&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">the results of management reviews of our research and development portfolio (including following the receipt of clinical results or feedback from the FDA or other regulatory authorities), which could result in terminations of specific projects which, in turn, could lead to material impairment charges&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the seasonality of sales of certain of our products&#59;</font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">declines in the pricing and sales volume of certain of our products that are distributed or marketed by third parties, over which we have no or limited control&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance by the Company or our third-party partners and service providers (over whom we may have limited influence), or the failure of our Company or these third parties to comply, with health care &#8220;fraud and abuse&#8221; laws and other extensive regulation of our marketing, promotional and business practices (including with respect to pricing), worldwide anti-bribery laws (including the U.S. Foreign Corrupt Practices Act and the Canadian Corruption of Foreign Public Officials Act), worldwide economic sanctions and&#47;or export laws, worldwide environmental laws and regulation and privacy and security regulations&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impacts of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 and potential amendment thereof and other legislative and regulatory health care reforms in the countries in which we operate, including with respect to recent government inquiries on pricing&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of any changes in or reforms to the legislation, laws, rules, regulation and guidance that apply to the Company and its businesses and products or the enactment of any new or proposed legislation, laws, rules, regulations or guidance that will impact or apply to the Company or its businesses or products&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of changes in federal laws and policy that may be undertaken under the Biden administration&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">illegal distribution or sale of counterfeit versions of our products&#59;</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruptions, breakdowns or breaches in our information technology systems&#59; and</font></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks in Item 1A. &#8220;Risk Factors&#8221; in this Form 10-K.</font></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found elsewhere in this Form 10-K, under Item 1A. &#8220;Risk Factors&#8221; and in the Company's other filings with the SEC and the CSA. When relying on our forward-looking statements to make decisions with respect to the Company, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. These forward-looking statements speak only as of the date made. We undertake no obligation to update or revise any of these forward-looking statements to reflect events or circumstances after the date of this Form&#160;10-K or&#160;to reflect actual outcomes, except as required by law. We caution that, as it is not possible to predict or identify all relevant factors that may impact forward-looking statements, the foregoing list of important factors that may affect future results is not exhaustive and should not be considered a complete statement of all potential risks and uncertainties.</font></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>4
<FILENAME>bhc-20220510_d2.htm
<DESCRIPTION>EX-99.2
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:9acca3cc-2386-49dd-bd2b-e67723848b1a,g:d4f0cfd5-5dd4-484a-81ac-21ef5810b617,d:8256f225f07d49409c31f7443adffdbf--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:bhc="http://www.bauschhealth.com/20220510" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bhc-20220510_d2</title></head><body><div id="i8256f225f07d49409c31f7443adffdbf_271"></div><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:5pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.2</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Explanatory Note</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 3, 2021, the Company announced its intentions to conduct an initial public offering  (&#8220;IPO&#8221;) of its aesthetic medical device business, Global Solta (&#8220;Solta&#8221;) (the &#8220;Solta IPO&#8221;). See Note 2, &#8220;SIGNIFICANT ACCOUNTING POLICIES - Basis of Presentation and Use of Estimates - Separation of the Bausch + Lomb Eye-Health Business and Initial Public Offering of Solta Medical Business&#8221; to our audited Consolidated Financial Statements included herein for further details regarding the Solta IPO. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the planned separation of its Solta business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., the Company has begun managing its operations in a manner which is consistent with the organizational structure of the two separate entities as proposed by the Solta IPO. As a result, during the first quarter of 2022, the Company&#8217;s Chief Executive Officer (&#8220;CEO&#8221;), who is the Company&#8217;s Chief Operating Decision Maker, commenced managing the business differently through changes in its operating and reportable segments, which necessitated a realignment of the Company&#8217;s historical segment structure. This realignment is consistent with how the Company&#8217;s CEO currently: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports. Pursuant to these changes, effective in the first quarter of 2022, the Company operates in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International (formerly International Rx), (iv) Solta Medical and (v) Diversified Products. The new segment structure does not impact the Company&#8217;s reporting units but realigns the two reporting units of the former Ortho Dermatologics segment whereby its medical dermatology reporting unit (Ortho Dermatologics) is now part of the current Diversified Products segment and the Solta reporting unit is now the sole reporting unit of the new Solta Medical segment. All segment revenues and segment profits for the periods presented have been recast to conform to the 2022 reportable segment structure.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Item 15.(a)(1) The consolidated financial statements required to be filed in the Annual Report on Form 10-K with Retrospective Segment Changes of the 2021 Form 10-K&#8221; set forth in this Exhibit 99.2 have been revised from the &#8220;Item 15.(a)(1) The consolidated financial statements required to be filed in the Annual Report on Form 10-K&#8221; included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021  (&#8220;2021 Form 10-K&#8221;) to reflect retrospective application of the new reporting structure and recast the Company's historical results to conform to the new segment presentation. &#8220;Item 15.(a)(1) The consolidated financial statements required to be filed in the Annual Report on Form 10-K with Retrospective Segment Changes of the 2021 Form 10-K&#8221; set forth below have not been revised to reflect events or developments subsequent to February 23, 2022, the date that the Company filed the 2021 Form 10-K. For a discussion of events and developments subsequent to the filing date of the 2021 Form 10-K, please refer to the reports and other information the Company has filed with the Securities and Exchange Commission and the Canadian Securities Administrators since that date, including the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022 filed on May&#160;10, 2022.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div></div><div id="i8256f225f07d49409c31f7443adffdbf_283"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15.(a)(1) The consolidated financial statements required to be filed in the Annual Report on Form 10-K with Retrospective Segment Changes of the 2021 Form 10-K</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:92.705%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Report of Management on Financial Statements </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8256f225f07d49409c31f7443adffdbf_286">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8256f225f07d49409c31f7443adffdbf_286">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Report of Independent Registered Public Accounting Firm (PCAOB ID 238)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8256f225f07d49409c31f7443adffdbf_289">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8256f225f07d49409c31f7443adffdbf_289">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Balance Sheets as of December&#160;31, 2021 and 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8256f225f07d49409c31f7443adffdbf_295">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8256f225f07d49409c31f7443adffdbf_295">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Operations for the years ended December&#160;31, 2021, 2020 and 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8256f225f07d49409c31f7443adffdbf_298">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8256f225f07d49409c31f7443adffdbf_298">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Comprehensive Loss for the years ended December 31, 2021, 2020 and 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8256f225f07d49409c31f7443adffdbf_301">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8256f225f07d49409c31f7443adffdbf_301">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Shareholders&#8217; Equity (Deficit) for the years ended December&#160;31, 2021, 2020 and 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8256f225f07d49409c31f7443adffdbf_304">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8256f225f07d49409c31f7443adffdbf_304">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Cash Flows for the years ended December&#160;31, 2021, 2020 and 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8256f225f07d49409c31f7443adffdbf_307">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8256f225f07d49409c31f7443adffdbf_307">11</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Consolidated Financial Statements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8256f225f07d49409c31f7443adffdbf_310">F-</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i8256f225f07d49409c31f7443adffdbf_310">12</a></span></div></td></tr></table></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i8256f225f07d49409c31f7443adffdbf_286"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF MANAGEMENT ON FINANCIAL STATEMENTS</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for preparing the accompanying consolidated financial statements in conformity with United&#160;States generally accepted accounting principles (&#8220;U.S.&#160;GAAP&#8221;). In preparing these consolidated financial statements, management selects appropriate accounting policies and uses its judgment and best estimates to report events and transactions as they occur. Management has determined such amounts on a reasonable basis in order to ensure that the consolidated financial statements are presented fairly, in all material respects. Financial information included throughout this Annual Report is prepared on a basis consistent with that of the accompanying consolidated financial statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PricewaterhouseCoopers&#160;LLP has been engaged by the Company to audit the consolidated financial statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors is responsible for ensuring that management fulfills its responsibility for financial reporting and is ultimately responsible for reviewing and approving the consolidated financial statements. The Board of Directors carries out this responsibility principally through its Audit and Risk Committee. The members of the Audit and Risk Committee are outside Directors. The Audit and Risk Committee considers, for review by the Board of Directors and approval by the shareholders, the engagement or reappointment of the external auditors. PricewaterhouseCoopers&#160;LLP has full and free access to the Audit and Risk&#160;Committee.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:29.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ JOSEPH C. PAPA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ SAM ELDESSOUKY</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph C. Papa<br/>Chief Executive Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sam Eldessouky<br/>Executive Vice President and<br/>Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">February&#160;23, 2022, except with respect to the change in composition of reportable segments discussed in Note 22, as to which the date is May 10, 2022.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:3pt;margin-top:8pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:29.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.208%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ THOMAS J. APPIO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ TOM VADAKETH</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas J. Appio<br/>Chief Executive Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ton Vadaketh<br/>Executive Vice President and<br/>Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">May&#160;10, 2022, with respect to the change in composition of reportable segments discussed in Note 22.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="i8256f225f07d49409c31f7443adffdbf_289"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Shareholders of Bausch Health Companies Inc.</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Bausch Health Companies Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December 31, 2021 and 2020, and the related consolidated statements of operations, of comprehensive loss, of shareholders' equity (deficit) and of cash flows for each of the three years in the period ended December 31, 2021, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). We also have audited the Company's internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Opinions</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in Management&#8217;s Annual Report on Internal Control Over Financial Reporting (not presented herein) appearing under Item 9A of the Company&#8217;s 2021 Annual Report on Form 10-K. Our responsibility is to express opinions on the Company&#8217;s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicaid Rebates and Sales Returns Allowances</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 2 to the consolidated financial statements, gross product sales are subject to a variety of deductions in arriving at reported net product sales. The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. The provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue as a reduction in revenue. The variable consideration provisions, either recognized within accrued and other current liabilities or as a reduction of trade receivables, included $482 million related to returns allowances and $944 million related to rebates, including Medicaid rebates as of December 31, 2021. For certain rebate programs, such as Medicaid, provisions recognized by management are based on the terms of state government-managed programs, estimates of outstanding and future claims for end-customer sales and the sales mix. As disclosed by management, for sales returns, management estimates provisions utilizing existing return policies with customers, historical return and exchange levels, external data with respect to inventory levels in the wholesale distribution channel, external data with respect to prescription demand for products, remaining shelf lives of products at the date of sale, and estimated returns liability to be processed by year of sale based on an analysis of lot information related to actual historical returns.</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal considerations for our determination that performing procedures relating to Medicaid rebates and sales returns allowances is a critical audit matter are the significant judgment by management when developing the estimate of Medicaid rebates and allowances for sales returns as the estimates are based on assumptions developed using terms of state government-managed Medicaid programs, existing return policies with customers, and projected estimated outstanding and future claims for end-customer sales. This in turn led to a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating audit evidence relating to these assumptions.</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to provisions for Medicaid rebates and allowances for sales returns, including controls over the assumptions used to estimate these rebates and allowances. These procedures also included, among others (i) developing an independent estimate of Medicaid rebates by utilizing third-party information on inventory levels in the distribution channel, the terms of the specific Medicaid rebate programs, and the historical trends of actual Medicaid rebate claims paid, adjusted for price and projected market conditions, (ii) comparing the independent estimate for these Medicaid rebates to management&#8217;s estimates, (iii) evaluating management&#8217;s process for developing the estimate of the allowance for sales returns and the reasonableness of management&#8217;s assumptions related to existing return policies, (iv) evaluating management&#8217;s assumptions related to existing return policies involved comparing to historical trends and considering whether these assumptions were consistent with evidence obtained in other areas of the audit, (v) evaluating the appropriateness of the method for estimating the allowance for sales returns and testing the completeness and accuracy of underlying data used in the model, and (vi) testing Medicaid rebate and sales returns claims processed by the Company, including evaluating those claims for consistency with the contractual terms of the Company&#8217;s arrangements and policies.</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Finite-Lived Intangible Assets Impairment Assessment</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Notes 2 and 8 to the consolidated financial statements, the Company&#8217;s consolidated finite-lived net intangible assets balance was $5,250 million as of December 31, 2021, which consists of product and corporate brands, product rights/patents, partner relationships and technology and other assets. Finite-lived intangible assets are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset, which include the amount and timing of the projected future cash flows.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal considerations for our determination that performing procedures relating to the finite- lived intangible assets impairment assessment is a critical audit matter are the significant judgment by management in the identification of events that suggest an asset group might not be recoverable and in developing the assumptions used in the impairment testing assessment. This in turn led to a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating audit evidence related to management&#8217;s undiscounted future cash flow projections.</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management&#8217;s finite-lived intangible assets impairment assessment, including controls over the development of assumptions used to estimate recoverability and controls over the identification of events that suggest an asset group might not be recoverable. These procedures also included, among others (i) testing management&#8217;s process for identifying potential impairment events and determining the recoverability of the intangible assets, (ii) evaluating the appropriateness of the undiscounted cash flow model used in the impairment testing assessment, (iii) testing the completeness and accuracy of underlying data used in the model, and (iv) evaluating the reasonableness of the significant assumptions used by management related to the undiscounted future cash flow projections. Evaluating the reasonableness of management's assumptions for undiscounted future cash flow projections involved evaluating whether the assumptions used by management were reasonable considering the current and past performance of the asset group and whether these assumptions were consistent with evidence obtained in other areas of the audit. </span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill Impairment Assessments &#8211; Ortho Dermatologics Reporting Unit</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 2 and 8 to the consolidated financial statements, the Company&#8217;s consolidated goodwill balance was $12,457 million as of December 31, 2021, and the goodwill associated with the Ortho Dermatologics segment was $798 million, inclusive of a goodwill impairment of $469 million. The Ortho Dermatologics segment consists of the Ortho Dermatologics and Global Solta reporting units. Goodwill is not amortized but is tested for impairment at least annually as of October 1st at the reporting unit level. An interim goodwill impairment test in advance of the annual impairment assessment may be required if events occur that indicate an impairment might be present. Where the qualitative assessment suggested that it was more likely than not that the fair value of a reporting unit was less than its carrying amount, a quantitative fair value test was performed for that reporting unit. Goodwill impairment is measured by the amount the carrying value exceeds the fair value. Fair value of each reporting unit is estimated by management using a discounted cash flow model. During the quarter ended March 31, 2021, the Company revised its long-term forecasts for the Ortho Dermatologics reporting unit and thus Management conducted an interim quantitative fair value test for this reporting unit and recognized a goodwill impairment of $469 million. Management also conducted its annual goodwill impairment test on October 1, 2021 and determined that there was no additional impairment of goodwill. Management&#8217;s discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates.</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal considerations for our determination that performing procedures relating to the goodwill impairment assessments of the Ortho Dermatologics reporting unit is a critical audit matter are the significant judgment by management when developing the fair value estimates of the reporting unit. This in turn led to a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating management&#8217;s significant assumptions related to revenue growth rates, gross profit, discount rates, and terminal growth rates. Also, the audit effort involved the use of professionals with specialized skill and knowledge.</span></div><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management&#8217;s goodwill impairment assessments, including controls over the valuation of the Company&#8217;s Ortho Dermatologics reporting unit. These procedures also included, among others (i) testing management&#8217;s process for developing the fair value estimates of the Ortho Dermatologics reporting unit, (ii) evaluating the appropriateness of the discounted cash flow models, (iii) testing the completeness and accuracy of underlying data used in the models, and (iv) evaluating the reasonableness of the significant assumptions used by management related to the revenue growth rates, gross profit, discount rates, and terminal growth rates. Evaluating management&#8217;s assumptions related to revenue growth rates and gross profit involved evaluating whether the assumptions used by management were reasonable considering (i) the current and past performance of the reporting unit, (ii) the consistency with external market and industry data, and (iii) whether these assumptions were consistent with evidence obtained in other areas of the audit. Professionals with specialized skill and knowledge were used to assist in the evaluation of the Company&#8217;s discounted cash flow models and discount rate and terminal growth rate assumptions. </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:9.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ PricewaterhouseCoopers LLP</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Florham Park, New Jersey</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">February&#160;23, 2022, except with respect to our opinion on the consolidated financial statements insofar as it relates to the change in composition of reportable segments discussed in Note 22 in the consolidated financial statements, as to which the date is May 10, 2022</span></div><div style="margin-top:9.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2012. </span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i8256f225f07d49409c31f7443adffdbf_292"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div><span><br/></span></div><div id="i8256f225f07d49409c31f7443adffdbf_295"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions, except share amounts)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:75.620%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.711%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzQtMi0xLTEtOTQ4MzE_9794ada4-cb09-4a10-b6ce-0db69830db03">582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzQtNC0xLTEtOTQ4MzE_1389602c-657a-4ba2-ac09-06651910dbfb">605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and other settlement deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="bhc:RestrictedCashAndOtherSettlementDepositsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzUtMi0xLTEtOTQ4MzE_5d847b4f-9a3b-488b-9256-128176ddb57c">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="bhc:RestrictedCashAndOtherSettlementDepositsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzUtNC0xLTEtOTQ4MzE_279d634b-1530-4bdf-a60a-68a6997d4407">1,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzYtMi0xLTEtOTQ4MzE_686a45ac-366d-4d27-bb60-904c39a81dd3">1,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzYtNC0xLTEtOTQ4MzE_24fcd4ac-e357-4e93-ac67-4d6acf4d80eb">1,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzctMi0xLTEtOTQ4MzE_549f841a-6413-48db-bc81-5ac9d4514885">993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzctNC0xLTEtOTQ4MzE_0163be90-217f-4d98-a4d7-eb908dc43681">1,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzgtMi0xLTEtOTQ4MzE_c00ef405-6e32-41fb-b52d-b5c8479436de">720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzgtNC0xLTEtOTQ4MzE_1bb23c15-396e-4416-885b-894f25d9bb25">855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzktMi0xLTEtOTQ4MzE_5bbbfe07-3e40-41b6-8c57-65889496aaf6">5,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzktNC0xLTEtOTQ4MzE_20dc0bbc-708d-40b2-87fa-d179b930766c">5,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzEwLTItMS0xLTk0ODMx_c3788717-f3a5-4d5a-b3d8-12ee20e41dd4">1,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzEwLTQtMS0xLTk0ODMx_10384676-da77-483f-b2ce-1e6d3332d799">1,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzExLTItMS0xLTk0ODMx_999d5cec-4495-40b2-a649-2088b845505d">6,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzExLTQtMS0xLTk0ODMx_2e87171d-5e2b-4850-b955-def9bddcd49d">8,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzEyLTItMS0xLTk0ODMx_7a6494cd-cfc1-4e87-9ed9-a6e37ca90864">12,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzEyLTQtMS0xLTk0ODMx_e985d5a4-1fba-476f-9396-516d8ecc2ed6">13,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzEzLTItMS0xLTk0ODMx_41633dcd-73e3-49b9-9dd0-0e57273b61b4">2,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzEzLTQtMS0xLTk0ODMx_57049148-661e-4e03-86b1-420886d3a15a">2,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzE0LTItMS0xLTk0ODMx_f7563753-c7bb-4d9a-80d6-3ca5838ec873">340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzE0LTQtMS0xLTk0ODMx_15ec21bb-78cb-4b82-98d5-8eb700f0c19a">664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzE1LTItMS0xLTk0ODMx_5428772b-3d6a-4578-bde3-c1686cbc23ba">29,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzE1LTQtMS0xLTk0ODMx_c0c6028d-b31c-4557-a672-099090591702">31,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzE4LTItMS0xLTk0ODMx_576dde1a-5662-4179-b126-0947e736e54c">407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzE4LTQtMS0xLTk0ODMx_e4e6f33a-1a60-4c42-853f-07ae86324a1c">337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzE5LTItMS0xLTk0ODMx_9e0888fb-cc0a-46b8-9499-a99b384b5cc8">4,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzE5LTQtMS0xLTk0ODMx_8d3fdfee-e1aa-44d6-8015-f1c5c2511d9f">4,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzIwLTItMS0xLTk0ODMx_1dde74bf-3637-4648-bad2-8b91d0a36602">5,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzIwLTQtMS0xLTk0ODMx_6b5dad94-d7d9-4aba-9ad3-ee2623f49088">4,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationNoncurrentLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzIxLTItMS0xLTk0ODMx_a4d7e1cb-5986-4e5d-8b62-f4cd3f0a4f79">202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationNoncurrentLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzIxLTQtMS0xLTk0ODMx_4b43f868-fd07-4080-8e25-afa3e454c6ee">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzIyLTItMS0xLTk0ODMx_18db40f8-be0c-4ec1-b876-1471f7d4e70e">22,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzIyLTQtMS0xLTk0ODMx_99681720-a322-4efb-ac2c-8806215d7d43">23,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzIzLTItMS0xLTk0ODMx_1e609a24-c4e3-48bd-8e43-d3e8bc63233c">529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzIzLTQtMS0xLTk0ODMx_22b8fcd9-60e5-4079-9aeb-ebbf50e695a3">528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzI0LTItMS0xLTk0ODMx_efff87cf-dde6-4f04-9078-2046a5502508">653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzI0LTQtMS0xLTk0ODMx_de4496a2-28c1-40e0-a797-b0df63923844">1,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzI1LTItMS0xLTk0ODMx_3023989a-98ca-467e-8c1d-d8b7dfc7abc2">29,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzI1LTQtMS0xLTk0ODMx_35754e54-ca43-47e7-860f-885b8e7e90a7">30,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Notes&#160;20 and 21)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzI2LTItMS0xLTk0ODMx_9d6a9c1f-58f6-40a6-ac58-92d1714d61f3"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzI2LTQtMS0xLTk0ODMx_5931381f-567e-4e22-a9c0-5a19c7745743"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares, no par value, unlimited shares authorized, <ix:nonFraction unitRef="shares" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzI4LTAtMS0xLTk0ODMxL3RleHRyZWdpb246ZTRmNDk1NzQ4MGYyNGMzYzllMjJlN2MwZjE5OTliY2JfNjI_12b8e4de-4313-4296-9aad-f6f54ab22add"><ix:nonFraction unitRef="shares" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzI4LTAtMS0xLTk0ODMxL3RleHRyZWdpb246ZTRmNDk1NzQ4MGYyNGMzYzllMjJlN2MwZjE5OTliY2JfNjI_9bf430c4-7210-46d3-9d1f-151e6ca8b723">359,405,748</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzI4LTAtMS0xLTk0ODMxL3RleHRyZWdpb246ZTRmNDk1NzQ4MGYyNGMzYzllMjJlN2MwZjE5OTliY2JfNjk_3baac1f1-72cf-4463-bc60-a235eb7b4187"><ix:nonFraction unitRef="shares" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzI4LTAtMS0xLTk0ODMxL3RleHRyZWdpb246ZTRmNDk1NzQ4MGYyNGMzYzllMjJlN2MwZjE5OTliY2JfNjk_4df45541-3b33-4f5e-a32c-a6ff463775ce">355,422,347</ix:nonFraction></ix:nonFraction>&#160;issued and outstanding at December&#160;31, 2021 and 2020, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzI4LTItMS0xLTk0ODMx_3be2c208-6352-479f-9733-ab0018231782">10,317</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzI4LTQtMS0xLTk0ODMx_e257e637-eab1-42dc-b4b6-1017bbea0a4d">10,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzI5LTItMS0xLTk0ODMx_8a3b98ce-3f96-46a6-aeb0-dad46dc16ae8">462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzI5LTQtMS0xLTk0ODMx_9ec07e09-ad2c-465f-a45e-2d8ca9adc944">454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzMwLTItMS0xLTk0ODMx_e2802f49-c0f5-4f08-88bb-01c2b5150b89">8,961</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzMwLTQtMS0xLTk0ODMx_7ea3cdfb-e713-472b-b2ac-cfa17c2d4b17">8,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzMxLTItMS0xLTk0ODMx_45a4ba3b-2204-45ab-97f9-4916dbfc3dde">1,924</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzMxLTQtMS0xLTk0ODMx_59d8d103-940d-4735-98e6-05e3ef1255c9">2,133</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Bausch Health Companies Inc. shareholders&#8217; (deficit) equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzMyLTItMS0xLTk0ODMx_ff324f21-06fe-49de-a4f4-8bb7daea38e7">106</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzMyLTQtMS0xLTk0ODMx_284f4b8f-5ac2-4aec-9b49-da8e5e6bd68a">535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzMzLTItMS0xLTk0ODMx_ff0a8a33-46ee-4a32-ab84-d03d30899128">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzMzLTQtMS0xLTk0ODMx_f3504c7f-71cd-429d-8b7c-0e5807ea5442">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (deficit) equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzM0LTItMS0xLTk0ODMx_c9e9af4b-1346-4dad-9d07-2656390ba65c">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzM0LTQtMS0xLTk0ODMx_3b91614d-1d7b-4ea6-a422-228495474d78">605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and (deficit) equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzM1LTItMS0xLTk0ODMx_ce8d75b8-1df4-4919-9dbc-02b12c08a03f">29,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzM1LTQtMS0xLTk0ODMx_421ab523-8665-4d9b-a735-771daf2ad07b">31,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On behalf of the Board:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:46.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.778%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;JOSEPH C. PAPA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;RUSSEL C. ROBERTSON</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph C. Papa</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russel C. Robertson</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairperson, Audit and Risk Committee</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="i8256f225f07d49409c31f7443adffdbf_298"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 36.00pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions, except per share&#160;amounts)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.866%"><tr><td style="width:1.0%"></td><td style="width:67.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.311%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.315%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc87f78bc74d4e43ab17c35afb0f8079_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzMtMS0xLTEtOTQ4MzE_7803e3ae-4210-45e8-8c81-1e217ad60987">8,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8771372c3b94462beccdbc52f82e2b4_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzMtMy0xLTEtOTQ4MzE_d29a36bb-2581-447a-9ff3-74ed003644f5">7,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ff468ead247475a82ce446740f1f83a_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzMtNS0xLTEtOTQ4MzE_301e6723-3f5a-4a8e-9bbe-3717700576d6">8,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32509de5461547988d9730878e48539c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzQtMS0xLTEtOTQ4MzE_3eb50b05-72a3-4a2f-b3fe-acad80b6825a">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib332d58601bd454bb89ede6b79782526_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzQtMy0xLTEtOTQ4MzE_be7272b6-10fa-444e-9f2a-e9dd77638900">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3a6d276415e419fb9288f1aa64070ba_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzQtNS0xLTEtOTQ4MzE_c92ca5f5-71db-44dc-b76d-b72d816c32a3">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzUtMS0xLTEtOTQ4MzE_b90525f9-10a2-4cd0-b3e7-aed1121fb5e0">8,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzUtMy0xLTEtOTQ4MzE_d63563cd-004a-4bd8-ac7a-6c18c3dafb8b">8,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzUtNS0xLTEtOTQ4MzE_dc2d6f87-be78-400f-81b6-6990144ee35c">8,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold (excluding amortization and impairments of intangible assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc87f78bc74d4e43ab17c35afb0f8079_D20210101-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzctMS0xLTEtOTQ4MzE_9c696e45-228a-4856-a7a7-eccc24de94f4">2,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8771372c3b94462beccdbc52f82e2b4_D20200101-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzctMy0xLTEtOTQ4MzE_eab2e367-41f6-4883-8fc1-d5467274cb6a">2,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ff468ead247475a82ce446740f1f83a_D20190101-20191231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzctNS0xLTEtOTQ4MzE_e92f9041-591e-4bcf-872c-d2d2960adff4">2,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32509de5461547988d9730878e48539c_D20210101-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzgtMS0xLTEtOTQ4MzE_fed38e0a-97f1-4800-bde7-b15021b39f0a">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib332d58601bd454bb89ede6b79782526_D20200101-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzgtMy0xLTEtOTQ4MzE_d51bccad-1a5c-4055-858b-7fc22976c942">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3a6d276415e419fb9288f1aa64070ba_D20190101-20191231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzgtNS0xLTEtOTQ4MzE_692bc07a-681a-452b-82e0-827d65a09f4d">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzktMS0xLTEtOTQ4MzE_a177e430-ccd9-4ac5-9108-37a9858a3f28">2,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzktMy0xLTEtOTQ4MzE_671582a9-a81f-4f33-aea3-7eab9218a778">2,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzktNS0xLTEtOTQ4MzE_8c69224d-a1da-4eb9-833b-17a1a24504c8">2,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzEwLTEtMS0xLTk0ODMx_e0dc0b6d-765e-43c2-b8ea-406ea2806f7c">465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzEwLTMtMS0xLTk0ODMx_9603fde2-7592-4a8f-91ec-9627ea654d42">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzEwLTUtMS0xLTk0ODMx_c34d03dc-deb5-41c7-9c9c-a2c0ec329b84">471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzExLTEtMS0xLTk0ODMx_d5f60881-882b-44bf-80c4-df4f12aa6593">1,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzExLTMtMS0xLTk0ODMx_a8859627-66a7-4ec2-b49a-bbf0bcf383f7">1,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzExLTUtMS0xLTk0ODMx_cde27e80-b7f8-4061-b0c7-1bc92c564621">1,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzEyLTEtMS0xLTk0ODMx_f44230fd-aa19-4bf5-97d6-bafc0c17d742">469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzEyLTMtMS0xLTk0ODMx_20a531b3-04d5-46d1-aa45-73f2ab2b2fdb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzEyLTUtMS0xLTk0ODMx_04a2ef35-eeb0-41a9-9639-e5cb2ade050b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzEzLTEtMS0xLTk0ODMx_358bf3c9-c18b-4d5f-aafb-90ee1b84b940">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzEzLTMtMS0xLTk0ODMx_fbe987db-8996-4bff-810e-d61c98bbdc80">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzEzLTUtMS0xLTk0ODMx_d972c677-90db-45dd-b8bf-5aaff1ed8393">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE0LTEtMS0xLTk0ODMx_434c9702-122a-4d83-b52a-3abd603209e1">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE0LTMtMS0xLTk0ODMx_b6601a6b-8afd-4ffe-88e2-56548ff451c4">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE0LTUtMS0xLTk0ODMx_286f0936-0709-434d-9d4c-9cf251271f3f">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE1LTEtMS0xLTk0ODMx_dbcdf5c4-5808-4e18-8ccd-24f303d4583a">373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE1LTMtMS0xLTk0ODMx_d01d36ce-d109-4361-b1be-fe437729a28b">502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE1LTUtMS0xLTk0ODMx_af28a5c6-7d62-4b2b-b5f1-beb34c8cd722">1,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE2LTEtMS0xLTk0ODMx_f20053d6-e163-4141-9a89-276d62204019">7,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE2LTMtMS0xLTk0ODMx_24459a5a-284b-402a-9efc-8e6123c41a38">7,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE2LTUtMS0xLTk0ODMx_ce5a8e3f-6f7d-4e9e-8336-6385e44f3fb2">8,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE3LTEtMS0xLTk0ODMx_37e961ef-e977-47c5-aaea-28f54c870ff9">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE3LTMtMS0xLTk0ODMx_adddd037-8cf6-45bf-9461-35a848d9252d">676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE3LTUtMS0xLTk0ODMx_fb2ee83d-9527-4d4a-b22c-80f6ad570137">203</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE4LTEtMS0xLTk0ODMx_327e0e65-9e5b-49c9-9d40-f15f00a93538">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE4LTMtMS0xLTk0ODMx_e38eef94-fe3d-4500-a35c-b147c7697c65">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE4LTUtMS0xLTk0ODMx_c62182d4-6eac-4262-a8d1-b4d18c037266">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE5LTEtMS0xLTk0ODMx_1b0c3a3a-4fa6-434c-a39d-9dfc3aebbc9d">1,426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE5LTMtMS0xLTk0ODMx_edc67937-8d64-4818-a506-b54878223e83">1,534</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE5LTUtMS0xLTk0ODMx_1ab50fda-72cc-4f27-b8b4-5abb8464f9da">1,612</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzIwLTEtMS0xLTk0ODMx_ea02bbbf-aff1-447d-b21d-3aec04e5f3a1">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzIwLTMtMS0xLTk0ODMx_44a8b6c4-de64-4923-be33-b3e281595987">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzIwLTUtMS0xLTk0ODMx_f03a88cd-594b-4ceb-bc16-c0eca588dacb">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzIxLTEtMS0xLTk0ODMx_97f078f2-3922-410e-9ac8-16a6cd568bb2">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzIxLTMtMS0xLTk0ODMx_9c033080-2c4b-460f-9bd3-d15deed68c7b">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzIxLTUtMS0xLTk0ODMx_63b6d40c-37fc-4330-949b-a11fb8f7ac98">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before benefit from income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzIyLTEtMS0xLTk0ODMx_1c4ac6ed-6ed8-4b05-94b8-877bdaee5260">1,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzIyLTMtMS0xLTk0ODMx_84acde4f-e5ef-4b0d-8259-63e5dedd73d8">934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzIyLTUtMS0xLTk0ODMx_5dd578d4-fc93-478e-bbf9-596e6887e287">1,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzIzLTEtMS0xLTk0ODMx_6305edc3-86dd-4dc5-98f1-90acb7d747da">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzIzLTMtMS0xLTk0ODMx_0701442c-d785-4c6d-931b-c55363d8dd8e">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzIzLTUtMS0xLTk0ODMx_c0961863-b5ea-4fd7-9f02-485a65dd3fdd">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzI0LTEtMS0xLTk0ODMx_cc8e9e6c-eec8-463b-ac59-dfe33d594170">937</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzI0LTMtMS0xLTk0ODMx_45823ac2-9c2e-4ca8-85d9-5f146891a299">559</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzI0LTUtMS0xLTk0ODMx_5b4b35b2-8ce7-4693-b4c6-e9795acedd5b">1,783</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzI1LTEtMS0xLTk0ODMx_783d9df5-0b2d-4346-805f-1742092ab3b2">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzI1LTMtMS0xLTk0ODMx_1fe94743-e4a7-4048-80bf-7fb891c51850">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzI1LTUtMS0xLTk0ODMx_38a54c30-65c4-4128-bb95-fd53a8668c0a">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzI2LTEtMS0xLTk0ODMx_b5000712-fe80-4137-81fb-64a4f77c5742">948</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzI2LTMtMS0xLTk0ODMx_decb28db-2f84-4020-9eca-586e3c49a0d2">560</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzI2LTUtMS0xLTk0ODMx_df8aaa3f-449b-4cfe-ab45-9193ac3384c1">1,788</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted loss per share attributable to Bausch Health Companies Inc.</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzI4LTEtMS0xLTk0ODMx_af1c6f61-5cae-4d7f-9435-d4033c24f650"><ix:nonFraction unitRef="usdPerShare" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzI4LTEtMS0xLTk0ODMx_f3ee7061-3fb4-4970-ae54-631555a9baa2">2.64</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzI4LTMtMS0xLTk0ODMx_dde9f557-1e13-49ee-a7b2-10d16c070965"><ix:nonFraction unitRef="usdPerShare" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzI4LTMtMS0xLTk0ODMx_fffeb972-dbc7-46c1-a923-584601c42fd1">1.58</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzI4LTUtMS0xLTk0ODMx_8c86d686-2659-4f12-bb67-b853a27d08d3"><ix:nonFraction unitRef="usdPerShare" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzI4LTUtMS0xLTk0ODMx_dbedc38b-86d2-483d-aea2-925f0693174e">5.08</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted weighted-average common shares</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzMwLTEtMS0xLTk0ODMx_2701e3a8-d81d-4782-9165-ce4da81f0a7b"><ix:nonFraction unitRef="shares" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzMwLTEtMS0xLTk0ODMx_cb0f8c67-bc0d-4ad0-a350-a28f056d9952">358.9</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzMwLTMtMS0xLTk0ODMx_255c37d6-4f9e-4511-b578-326f6a6b9269"><ix:nonFraction unitRef="shares" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzMwLTMtMS0xLTk0ODMx_9ec93fe0-8896-4d07-a063-abf74c47a980">355.0</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzMwLTUtMS0xLTk0ODMx_2997b533-f22a-4403-95d9-280971affe40"><ix:nonFraction unitRef="shares" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzMwLTUtMS0xLTk0ODMx_b630f35d-3c36-453d-8940-8b8ab0a32202">352.1</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="i8256f225f07d49409c31f7443adffdbf_301"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions)</span></div><div style="margin-bottom:16pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzItMS0xLTEtOTQ4MzE_eefe108e-982a-45c1-b0c3-6896ba424e73">937</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzItMy0xLTEtOTQ4MzE_7c3152b3-110b-46fc-b354-267fdb5c902c">559</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzItNS0xLTEtOTQ4MzE_30cd79a8-2610-4b63-b880-31fc45fb1e2e">1,783</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and postretirement benefit plan adjustments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial gain (loss) arising during the year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzUtMS0xLTEtOTQ4MzE_eadba2b4-2ebe-46fe-ae0a-15f7cecf9428">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzUtMy0xLTEtOTQ4MzE_1301463d-b019-4fdc-b418-b14871328240">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzUtNS0xLTEtOTQ4MzE_905a68d3-a7e7-4f0b-9475-d6a2aa9aec12">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service credit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzYtMS0xLTEtOTQ4MzE_a1375195-6ded-4561-8bad-82f0ae1acacd">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzYtMy0xLTEtOTQ4MzE_628169cd-ad7f-4966-ab02-9e4371ee60cd">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzYtNS0xLTEtOTQ4MzE_e4a9d14a-1dee-40f8-948b-0a956bc693c1">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization or settlement recognition of net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="bhc:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzctMS0xLTEtOTQ4MzE_12f8769f-6f16-4609-8326-1b79bb68e983">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="bhc:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzctMy0xLTEtOTQ4MzE_097a540f-b101-43c9-9866-a5dc40bdc073">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="bhc:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzctNS0xLTEtOTQ4MzE_8c55edeb-42c2-40de-b2ef-e5d3283626dd">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzgtMS0xLTEtOTQ4MzE_feabce6c-87a3-4e00-864e-4bd619336da7">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzgtMy0xLTEtOTQ4MzE_177896e4-b371-493d-9a53-fd3ed4271709">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzgtNS0xLTEtOTQ4MzE_85d36c1f-d26e-4ff4-b45a-35cad1844d5a">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="bhc:OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzktMS0xLTEtOTQ4MzE_b62c5329-db75-4a27-8607-aa794bb36ca6">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="bhc:OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzktMy0xLTEtOTQ4MzE_e4853c34-ef8b-48ff-9c3d-431a018cfe1a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="bhc:OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzktNS0xLTEtOTQ4MzE_ff0362eb-f38e-475f-b5b9-bb15c73e2637">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net pension and postretirement benefit plan adjustments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzEwLTEtMS0xLTk0ODMx_417d2606-ddc0-4a7e-833c-7fa2675d6461">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzEwLTMtMS0xLTk0ODMx_ed440ee9-5986-4a95-b6d5-50260193dc1e">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzEwLTUtMS0xLTk0ODMx_b55bbed1-cfc9-435b-8133-c94c3a8eeb69">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzExLTEtMS0xLTk0ODMx_b8c38e1d-c6e5-4f24-b078-849d6c96a1e1">158</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzExLTMtMS0xLTk0ODMx_9a305891-003c-4920-ad3f-c772f82ffc6b">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzExLTUtMS0xLTk0ODMx_d586dc96-72b9-46ba-a4a2-3e0ce8c119df">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzEyLTEtMS0xLTk0ODMx_f72fe79a-9522-437d-8daf-13740bd01650">130</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzEyLTMtMS0xLTk0ODMx_0afc2821-8f6b-4a47-8a6f-9ddec5d66827">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzEyLTUtMS0xLTk0ODMx_e70a705a-8326-4454-8528-d92f6e6aebc3">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzEzLTEtMS0xLTk0ODMx_23812efd-ef11-43cd-b1c5-714fcf67ec3d">1,067</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzEzLTMtMS0xLTk0ODMx_8285bd35-d917-4a8e-83c2-a00b8a3e971d">604</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzEzLTUtMS0xLTk0ODMx_0f577559-542b-4d70-ae33-e81bc9517012">1,733</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzE0LTEtMS0xLTk0ODMx_82a686bc-b61c-4078-9624-e6eb317bf4e4">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzE0LTMtMS0xLTk0ODMx_fb7eec7b-e652-40b4-be2f-084ba18978a3">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzE0LTUtMS0xLTk0ODMx_c3208496-3cfa-4b92-b3df-1be45c266be1">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss attributable to Bausch Health Companies Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzE1LTEtMS0xLTk0ODMx_b0d48c96-17d9-47bd-98db-3b88bbcbe18d">1,079</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzE1LTMtMS0xLTk0ODMx_0a8b0fba-ce27-4e87-8f3b-ac21f7857881">607</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzE1LTUtMS0xLTk0ODMx_c29d8544-3701-452b-92ad-f9d984b229ed">1,737</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><div id="i8256f225f07d49409c31f7443adffdbf_304"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#8217; EQUITY (DEFICIT)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:28.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.389%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.717%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.543%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch Health Companies&#160;Inc. Shareholders' Equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Bausch Health<br/>Companies&#160;Inc.<br/>Shareholders'<br/>Equity (Deficit)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Total<br/>Equity (Deficit)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, January&#160;1, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9065a4b181534b6ab3a847b07fb47561_I20181231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzMtMi0xLTEtOTQ4MzE_e72c8401-e59a-4c63-b49a-537de4db4b05">349.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9065a4b181534b6ab3a847b07fb47561_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzMtNC0xLTEtOTQ4MzE_8761d188-3a97-4486-a3eb-4e69ca663de5">10,121</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1d1a33a09fa48859e7e47fd030be3fd_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzMtNi0xLTEtOTQ4MzE_ea2ffa4c-72cf-4253-b208-2e6a089c42c9">413</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7651c2a37e9f49e9915cd978a12d1e8f_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzMtOC0xLTEtOTQ4MzE_d21f7a77-fff4-4d71-bfdb-b4a53caa7566">5,664</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72905c016ef4f1494ae44900f94a9fd_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzMtMTAtMS0xLTk0ODMx_b9f024e3-9033-408b-8429-312fbb13f723">2,137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbcfed5f24544ab594fad1395b2ed82b_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzMtMTItMS0xLTk0ODMx_da694b4b-dfa6-40d4-a50c-64371512b5e6">2,733</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c139d1926cf4e6c9d1ee8a32ee091d3_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzMtMTQtMS0xLTk0ODMx_3739edfc-f705-4e26-9293-8291e6b64454">82</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18439fe8345c481db53c486667ac6940_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzMtMTYtMS0xLTk0ODMx_c95fc102-0136-4729-95c0-0d4a0cbd012b">2,815</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issued under share-based compensation plans</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6adf3d44da584f02a9de432de2320ed5_D20190101-20191231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzQtMi0xLTEtOTQ4MzE_a3af01d5-748a-4015-bb4e-a96a7c32499b">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6adf3d44da584f02a9de432de2320ed5_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzQtNC0xLTEtOTQ4MzE_f9947940-933f-4af5-975a-14f0a715c33d">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id70a674e2be94ffd85bbca114010b4f0_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzQtNi0xLTEtOTQ4MzE_4a50f0ec-c48b-465e-b428-97a316810068">46</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15c0150c538f487cb6591cfcbe5f75f1_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzQtMTItMS0xLTk0ODMx_3bae0398-782b-4041-a7b4-0653e276b1b8">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzQtMTYtMS0xLTk0ODMx_17391473-c0cf-4e16-b2c5-02ab1eed2151">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id70a674e2be94ffd85bbca114010b4f0_D20190101-20191231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzUtNi0xLTEtOTQ4MzE_a78de168-83db-4e7d-9ec0-139815f8c955">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15c0150c538f487cb6591cfcbe5f75f1_D20190101-20191231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzUtMTItMS0xLTk0ODMx_94340cf5-1329-4dcd-858b-7026ea447a37">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzUtMTYtMS0xLTk0ODMx_e0376acd-852d-4dd4-8b76-224b4eabff0f">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based awards tax withholding</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id70a674e2be94ffd85bbca114010b4f0_D20190101-20191231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzYtNi0xLTEtOTQ4MzE_ecc404f9-92f7-4916-a21d-0bd074a874a2">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15c0150c538f487cb6591cfcbe5f75f1_D20190101-20191231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzYtMTItMS0xLTk0ODMx_af8bf771-6e0d-4484-aa3f-ca82f49cb247">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzYtMTYtMS0xLTk0ODMx_96bdb609-7511-4764-b69b-350be25bb969">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interest distributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i261c4af1d70b4e2395fbc9f9f1d94e47_D20190101-20191231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzctMTQtMS0xLTk0ODMx_b95362c8-5790-42d3-b667-a5c97c8fed2e">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzctMTYtMS0xLTk0ODMx_ccd97c4f-adf4-4086-9853-da819aec3be0">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id967574fda7e4ceabaf0455646739979_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzgtOC0xLTEtOTQ4MzE_94f39ecf-3192-41ee-a425-a5d9767ac964">1,788</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i15c0150c538f487cb6591cfcbe5f75f1_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzgtMTItMS0xLTk0ODMx_0553b8cc-fe95-4fe0-9fd3-b7627596a7b3">1,788</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i261c4af1d70b4e2395fbc9f9f1d94e47_D20190101-20191231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzgtMTQtMS0xLTk0ODMx_9598812b-d9af-46e3-a87a-9cac0b75580e">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzgtMTYtMS0xLTk0ODMx_e1f92176-293a-40e9-a686-18f01302d3c0">1,783</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i119d0f73c7f74fc9bb4f33a268f1733a_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzktMTAtMS0xLTk0ODMx_b2acdede-06cb-4a4a-8cfb-aff8d48f0504">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15c0150c538f487cb6591cfcbe5f75f1_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzktMTItMS0xLTk0ODMx_57b5e6ed-c96d-4cb5-94da-9d60c1d2bd00">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i261c4af1d70b4e2395fbc9f9f1d94e47_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzktMTQtMS0xLTk0ODMx_d98ffe65-7641-40d6-986c-088355d61884">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzktMTYtMS0xLTk0ODMx_d99ce5f6-86b8-4da0-a0e5-1fa8e7edf211">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i473f77fb1af344a29eab4fdfd6d3dd2b_I20191231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEwLTItMS0xLTk0ODMx_601b5aac-959b-4afd-8c6e-2adaabcf8906">352.6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i473f77fb1af344a29eab4fdfd6d3dd2b_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEwLTQtMS0xLTk0ODMx_788e6267-5574-48c7-83c6-c2ebe2c1d79e">10,172</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3596f3678c0497483ac196ed8bec2eb_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEwLTYtMS0xLTk0ODMx_a6ba20ee-c703-4534-b1c5-a548a682787c">429</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a73edc85bf74e808a3aec728f72c249_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEwLTgtMS0xLTk0ODMx_33d65fd6-bfae-403d-9a19-e44379d52df9">7,452</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9aca61c7e88b46d19ad0b86e6d3a2ecf_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEwLTEwLTEtMS05NDgzMQ_788c3cb7-bb2a-4e50-b76f-03e56cf28545">2,086</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia032d22b364945dd81a246b3994295ed_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEwLTEyLTEtMS05NDgzMQ_43a2707d-05df-44f7-8713-232c70453cb4">1,063</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if43bfad251bd4331a051f408c738cf0b_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEwLTE0LTEtMS05NDgzMQ_3a8c4c9d-a492-4383-9026-a552abd67e9a">73</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEwLTE2LTEtMS05NDgzMQ_3eac9d46-a388-4be2-9aa6-fe1b7227d54c">1,136</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzExLTAtMS0xLTk0ODMx_04eaaa0c-20bb-457c-924e-608518b46f23">Effect of application of new accounting standard: financial instruments - credit losses</span></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f5bb32797ed4025b477232d70d05dd7_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzExLTgtMS0xLTk0ODMx_506a800c-000d-4d9c-a05b-e19f543af841">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i052b9590a90c45a9b05e3dd474e6d8d6_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzExLTEyLTEtMS05NDgzMQ_394534b7-cb55-4c4f-acc3-edd710166fe6">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d81998e18d049a795cb319c580e68df_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzExLTE2LTEtMS05NDgzMQ_8d61ebc0-59c7-40f7-9c60-08caddefc620">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issued under share-based compensation plans</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1dca8f6ac26c452fa7d59299882a0097_D20200101-20201231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEyLTItMS0xLTk0ODMx_59d7604e-3d8e-4ba5-b9f5-c0f676dc72b2">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dca8f6ac26c452fa7d59299882a0097_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEyLTQtMS0xLTk0ODMx_82eefb14-6a59-4653-ad69-3b4c810ff428">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ff42e3612b54f43abc128d492dcd6b7_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEyLTYtMS0xLTk0ODMx_3c09421b-d5f1-425f-b282-8d645882460a">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eb6e474c66a4666bf7e3a85d9c998a9_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEyLTEyLTEtMS05NDgzMQ_292655e6-65d6-4db2-8c53-8c8c4634b3d5">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEyLTE2LTEtMS05NDgzMQ_c3168ed7-77a5-4cd3-b815-fec1e4880ae7">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ff42e3612b54f43abc128d492dcd6b7_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEzLTYtMS0xLTk0ODMx_a08be976-c573-44c5-ad88-75886f10451c">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eb6e474c66a4666bf7e3a85d9c998a9_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEzLTEyLTEtMS05NDgzMQ_7b422d6d-b4df-43e5-9277-45108116eea6">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEzLTE2LTEtMS05NDgzMQ_8895d1d4-277d-46bd-af11-19b9ae250c69">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based awards tax withholding</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ff42e3612b54f43abc128d492dcd6b7_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE0LTYtMS0xLTk0ODMx_c66e72f0-9fbe-42fa-b033-3628f05eb42d">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9eb6e474c66a4666bf7e3a85d9c998a9_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE0LTEyLTEtMS05NDgzMQ_a6a059e2-f991-4cbc-8c11-7f36a94eb5a0">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE0LTE2LTEtMS05NDgzMQ_b9bc3551-1d97-4ff5-b584-d14fc75c735d">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interest distributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f36a5753643489d88a4e0f82c989bd6_D20200101-20201231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE1LTE0LTEtMS05NDgzMQ_048a9042-9fa9-43c5-a8cf-8f048f809935">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE1LTE2LTEtMS05NDgzMQ_2f9d8af4-ee25-4d90-81aa-4c7023a59112">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i086e5920df794c1bb867ec98391c2996_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE2LTgtMS0xLTk0ODMx_6c4eaec5-96f7-4f43-a36a-a51a65aa5ce3">560</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9eb6e474c66a4666bf7e3a85d9c998a9_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE2LTEyLTEtMS05NDgzMQ_aebc66aa-06db-4725-93ed-f872af2edfa7">560</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f36a5753643489d88a4e0f82c989bd6_D20200101-20201231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE2LTE0LTEtMS05NDgzMQ_12511f42-6a60-4c33-8616-0116ac8e225f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE2LTE2LTEtMS05NDgzMQ_890ec503-5550-4453-8dd1-27d28e49cfad">559</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia496362f6d164947b1a2ae170da89d4c_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE3LTEwLTEtMS05NDgzMQ_1c992e7c-cfc4-48d8-9d45-3611d64ba863">47</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9eb6e474c66a4666bf7e3a85d9c998a9_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE3LTEyLTEtMS05NDgzMQ_8b4d98a1-19d5-4e4d-9850-ee429ef4224b">47</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f36a5753643489d88a4e0f82c989bd6_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE3LTE0LTEtMS05NDgzMQ_bb80f1d3-b211-4b47-a919-5fc3e478eef5">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE3LTE2LTEtMS05NDgzMQ_86d31e04-d63e-4c3e-aebf-993a3e5e30e2">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3bcb5947fed543afb53cd6a3b48f336b_I20201231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE4LTItMS0xLTk0ODMx_ffacf82c-4a07-46b5-b113-eece69fc1627">355.4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bcb5947fed543afb53cd6a3b48f336b_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE4LTQtMS0xLTk0ODMx_01078642-65d6-42bc-b780-bf88c86e29fd">10,227</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8bec50dbaed4dbea096a71456e733f9_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE4LTYtMS0xLTk0ODMx_03818dd2-664d-4b9d-9929-eaec7ac54198">454</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i923a3743995f408db8308a2d12856422_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE4LTgtMS0xLTk0ODMx_92fed015-9946-43e7-b7c2-46e4812ecbb9">8,013</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib105e1aee9db4b46ae7d9e203dadfad7_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE4LTEwLTEtMS05NDgzMQ_289dd953-d994-49c9-baa7-fe1e2f3a8e8f">2,133</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3206e4462f2f44e9860f3d0294412da9_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE4LTEyLTEtMS05NDgzMQ_c538656e-df0d-42d8-8e35-2da28b7f6f91">535</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b49661c9941455eb0cd3e84d7fac743_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE4LTE0LTEtMS05NDgzMQ_8ce244e1-7939-4054-a494-ae347b85f929">70</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE4LTE2LTEtMS05NDgzMQ_7e2f543f-fcfd-46d8-aeb4-eadd5b8c5123">605</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common shares issued under share-based compensation plans</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b938a0322254b5aaab41c8892322507_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE5LTItMS0xLTk0ODMx_d38916ee-7e9a-4870-8b0b-8da66bc88e2d">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b938a0322254b5aaab41c8892322507_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE5LTQtMS0xLTk0ODMx_f1dac23f-54ef-45bc-b342-9cb60ee0481e">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if33956ad61204d93933927de0fdb82c7_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE5LTYtMS0xLTk0ODMx_5dc9eafa-e135-4dfc-9df7-d6a78fd7aca2">68</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a6553baa7a24ea0992e7694bf3ada46_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE5LTEyLTEtMS05NDgzMQ_5aef2618-6c09-4965-9a4f-c894a639d916">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE5LTE2LTEtMS05NDgzMQ_46ecb795-3fac-4ee5-8939-2fbef8afc9ee">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if33956ad61204d93933927de0fdb82c7_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzIwLTYtMS0xLTk0ODMx_5c96d5fe-ec54-441f-8682-4decd59527dc">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a6553baa7a24ea0992e7694bf3ada46_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzIwLTEyLTEtMS05NDgzMQ_e920ae3b-7455-4488-86e8-35fc60d6b7b3">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzIwLTE2LTEtMS05NDgzMQ_228ac2d5-063b-467f-bb63-12aece4eabc4">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based awards tax withholding</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if33956ad61204d93933927de0fdb82c7_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzIxLTYtMS0xLTk0ODMx_f1e546e9-eab1-4b23-8f2f-9570fa9885b7">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a6553baa7a24ea0992e7694bf3ada46_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzIxLTEyLTEtMS05NDgzMQ_300c183f-5190-4671-b9b3-f842df287a72">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzIxLTE2LTEtMS05NDgzMQ_527da8a6-3fa1-43bc-9bef-4991d05e0cd1">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Release of foreign currency translation losses upon disposal of assets           held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ab1aeb8c054aa1a4603d09d2ee8fc7_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzIyLTEwLTEtMS05NDgzMQ_cb34a76e-0809-45c6-b4b1-c8ba75e1952d">340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a6553baa7a24ea0992e7694bf3ada46_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzIyLTEyLTEtMS05NDgzMQ_a597f5f2-cd1f-4a4a-b820-2f4bcf2978e7">340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzIyLTE2LTEtMS05NDgzMQ_33b9f48e-c0b3-4105-836b-ce54d92294a4">340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interest distributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19f72ec10a1846be8c55a1dd70f9a9a2_D20210101-20211231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzIzLTE0LTEtMS05NDgzMQ_69849f5d-753c-48c8-a358-0c9a9fe8df06">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzIzLTE2LTEtMS05NDgzMQ_fb9aa2f8-39e9-45c0-bd95-6f707eae847c">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11f91c7cdb5e4652b3582c04a13bbd0c_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI0LTgtMS0xLTk0ODMx_5dbdb1ca-c5e6-43f8-8bef-ed4eb28be09a">948</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a6553baa7a24ea0992e7694bf3ada46_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI0LTEyLTEtMS05NDgzMQ_d7a7e0a0-d736-4ff1-9ccc-8e0d14dab3c9">948</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19f72ec10a1846be8c55a1dd70f9a9a2_D20210101-20211231" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI0LTE0LTEtMS05NDgzMQ_4ba1a2e0-74c5-4720-9890-b568b5e45cbe">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI0LTE2LTEtMS05NDgzMQ_9a172322-2211-4c08-b9c3-ce9bd867e56a">937</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ab1aeb8c054aa1a4603d09d2ee8fc7_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI1LTEwLTEtMS05NDgzMQ_c5fccc9a-3ace-457c-8c2b-51838e543251">131</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a6553baa7a24ea0992e7694bf3ada46_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI1LTEyLTEtMS05NDgzMQ_fce10e47-056b-4da3-9c6a-69391c3c5758">131</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19f72ec10a1846be8c55a1dd70f9a9a2_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI1LTE0LTEtMS05NDgzMQ_dd07b44e-0124-44b0-a912-6f033e7abeb1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI1LTE2LTEtMS05NDgzMQ_abf9adcf-a712-4d87-bf6c-e532ad11a8bc">130</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0aec0a6b31ac49f8b1539442f4d1de2a_I20211231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI2LTItMS0xLTk0ODMx_89cacb4b-8dc0-4334-889e-fbee5871e75f">359.4</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aec0a6b31ac49f8b1539442f4d1de2a_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI2LTQtMS0xLTk0ODMx_56cd63d5-bce8-4e2f-86b7-45da0cbf565c">10,317</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69270432269b42208da3ba0a5f6c0c8d_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI2LTYtMS0xLTk0ODMx_79b6deac-529f-4f88-b665-71a371350e9f">462</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i525200ba6a35425892b9fb1f4c0c7eeb_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI2LTgtMS0xLTk0ODMx_55804549-75af-4bf5-a6a9-ad9a723a954c">8,961</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff498ebdd499404a95f12abea2bd55e9_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI2LTEwLTEtMS05NDgzMQ_b0ad28fe-736c-41ac-a1c4-3a54f7f90858">1,924</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e55e9853c474101a26d48d5ad7d46b6_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI2LTEyLTEtMS05NDgzMQ_4b4f804b-517f-4d90-adb7-4db153d21c1a">106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19c82921041f4fa6b0c1e1a12a9800a1_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI2LTE0LTEtMS05NDgzMQ_dded9af4-2ada-41c8-8035-bae45cd15807">72</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI2LTE2LTEtMS05NDgzMQ_c4e579ca-4e22-4ebd-9e8a-91c95dbb9cc4">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><div id="i8256f225f07d49409c31f7443adffdbf_307"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in millions)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:73.716%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows From Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzMtMi0xLTEtOTQ4MzE_eefe108e-982a-45c1-b0c3-6896ba424e73">937</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzMtNC0xLTEtOTQ4MzE_7c3152b3-110b-46fc-b354-267fdb5c902c">559</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzMtNi0xLTEtOTQ4MzE_30cd79a8-2610-4b63-b880-31fc45fb1e2e">1,783</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization of intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzUtMi0xLTEtOTQ4MzE_05ea3879-7412-45b9-a4f4-95cf56fa314d">1,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzUtNC0xLTEtOTQ4MzE_4b605682-34b9-4596-afad-2dedee295c72">1,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzUtNi0xLTEtOTQ4MzE_c86eb6d9-077f-4b9d-b277-57cf091b22dc">2,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and write-off of debt discounts and debt issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzYtMi0xLTEtOTQ4MzE_9387213f-d9f8-451f-8ad2-fd4386c2bafa">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzYtNC0xLTEtOTQ4MzE_63fd2de0-dc17-4cf7-b148-0385f1a88772">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzYtNi0xLTEtOTQ4MzE_5e978029-9029-42f3-a286-c16f5811df96">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzctMi0xLTEtOTQ4MzE_358bf3c9-c18b-4d5f-aafb-90ee1b84b940">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzctNC0xLTEtOTQ4MzE_fbe987db-8996-4bff-810e-d61c98bbdc80">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzctNi0xLTEtOTQ4MzE_d972c677-90db-45dd-b8bf-5aaff1ed8393">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzgtMi0xLTEtOTQ4MzE_f44230fd-aa19-4bf5-97d6-bafc0c17d742">469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzgtNC0xLTEtOTQ4MzE_7027c8bb-cf82-466d-bbb4-44b67aa50a51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzgtNi0xLTEtOTQ4MzE_3123715d-6b25-4f65-88a3-32b992f13cdb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzktMi0xLTEtOTQ4MzE_c3daab34-d024-4ebf-b7c9-5d630549b580">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzktNC0xLTEtOTQ4MzE_5e8ef50b-e687-435c-a3cb-faac828b07ab">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzktNi0xLTEtOTQ4MzE_e3b1b5c9-ccb8-48a8-9e01-aa3d37561718">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allowances for losses on trade receivables and inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="bhc:AllowancesForLossesOnAccountsReceivableAndInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzEwLTItMS0xLTk0ODMx_012ab480-4f52-4228-84d0-e1b1c9a1dc2d">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="bhc:AllowancesForLossesOnAccountsReceivableAndInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzEwLTQtMS0xLTk0ODMx_d2b9a4ea-03f9-4684-96ca-517807350404">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="bhc:AllowancesForLossesOnAccountsReceivableAndInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzEwLTYtMS0xLTk0ODMx_ff574830-3155-4e0a-8a64-1c507f07b887">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="bhc:DeferredIncomeTaxNoncashExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzExLTItMS0xLTk0ODMx_f405f747-2d57-4189-aae2-958e34e297c2">225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="bhc:DeferredIncomeTaxNoncashExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzExLTQtMS0xLTk0ODMx_6feb7912-c065-4ee8-8111-baf3ff5d9222">475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="bhc:DeferredIncomeTaxNoncashExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzExLTYtMS0xLTk0ODMx_4f46d9fb-578b-4c06-9885-ca65e6d24dfb">230</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on disposal of assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzEyLTItMS0xLTk0ODMx_aa3c1e72-a374-463a-8e5b-253e29511cfd">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzEyLTQtMS0xLTk0ODMx_221a877f-12f3-40ae-aaac-25f6bfa04b7b">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzEyLTYtMS0xLTk0ODMx_9451d367-8fbd-4662-a6f7-378db732c8a5">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to accrued legal settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="bhc:GainLossRelatedToLitigationSettlementGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzEzLTItMS0xLTk0ODMx_a52ea0fd-fe48-49a9-8294-ae6ff1ae074c">569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="bhc:GainLossRelatedToLitigationSettlementGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzEzLTQtMS0xLTk0ODMx_4b1b8426-78b2-4c84-8078-07c50dcb12bb">442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="bhc:GainLossRelatedToLitigationSettlementGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzEzLTYtMS0xLTk0ODMx_6e54261a-f087-4e55-ac39-f10a2e5f23cd">1,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments of accrued legal settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE0LTItMS0xLTk0ODMx_4a5e1458-5b07-4bb3-954e-1452804c74de">351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE0LTQtMS0xLTk0ODMx_6a594e7c-8fa3-46d1-a5ee-661797a09470">168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE0LTYtMS0xLTk0ODMx_0a9fa05c-e332-43fb-bc1f-d7cef3b6da33">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE1LTItMS0xLTk0ODMx_3167d0b7-1fff-4afe-934e-0144fec4ba23">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE1LTQtMS0xLTk0ODMx_592f4b8f-de61-4254-a594-288ad8a25b47">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE1LTYtMS0xLTk0ODMx_4cf2d252-3a5a-4821-893d-26ad80bb88d1">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE2LTItMS0xLTk0ODMx_f4745b66-96ae-4250-b489-7b0135915ebf">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE2LTQtMS0xLTk0ODMx_18714798-1190-4b1c-ae30-22225d1686d6">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE2LTYtMS0xLTk0ODMx_5cb55d1d-039c-4a3c-b814-a0a20e1e8769">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain excluded from hedge effectiveness</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="bhc:DerivativeGainExcludedComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE3LTItMS0xLTk0ODMx_142fefb7-48bc-45e8-873f-70c07cbd6905">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="bhc:DerivativeGainExcludedComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE3LTQtMS0xLTk0ODMx_c15154fe-0607-4b04-b1c8-8125266dc19a">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="bhc:DerivativeGainExcludedComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE3LTYtMS0xLTk0ODMx_482630c0-d1b0-43f9-a6b3-eb03ce2e75f6">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE4LTItMS0xLTk0ODMx_fc714814-3094-4cae-848a-c1032a658511">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE4LTQtMS0xLTk0ODMx_a0ba7f51-a93e-416c-8465-63a655ae5a5d">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE4LTYtMS0xLTk0ODMx_1142d4f2-a651-46d3-a419-d6eadde8aac4">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments of contingent consideration adjustments, including accretion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE5LTItMS0xLTk0ODMx_27d2d1c8-3d79-493d-b786-1b1be9db6938">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE5LTQtMS0xLTk0ODMx_94b74dd7-ac16-405e-b6c2-eb4cd505c414">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE5LTYtMS0xLTk0ODMx_caad2782-1ec8-4623-9711-17ce631898ad">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzIwLTItMS0xLTk0ODMx_25f5e648-3f34-45c5-968f-8599fe140475">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzIwLTQtMS0xLTk0ODMx_e02bf204-f3fd-4acd-8cc0-da4a39e5bcad">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzIwLTYtMS0xLTk0ODMx_565f4319-f060-467b-aeca-026c715e5a4c">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade receivables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzIyLTItMS0xLTk0ODMx_5d0f73e0-fd03-468b-abb4-b4ebc7615fa6">229</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzIyLTQtMS0xLTk0ODMx_cd482e1b-43ac-4b72-ab1a-12c285725e26">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzIyLTYtMS0xLTk0ODMx_1a1fb927-6deb-42a8-84e5-f90a98142b9f">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzIzLTItMS0xLTk0ODMx_f1377e9b-d276-4be7-9f71-e37bd65ded5d">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzIzLTQtMS0xLTk0ODMx_543645c6-42b5-46aa-ad2f-5f66c04aa1ef">77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzIzLTYtMS0xLTk0ODMx_a58089ae-59c7-430b-a29b-eb431b2bf9d9">209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzI0LTItMS0xLTk0ODMx_79bff121-be83-4d74-bc1c-0f8f3c92b807">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzI0LTQtMS0xLTk0ODMx_3f3fe161-0d71-4c4f-8fb1-c6c84371ccb2">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzI0LTYtMS0xLTk0ODMx_eb5d2455-c94e-40f6-907e-62d84e9dbd45">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable, accrued and other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzI1LTItMS0xLTk0ODMx_d5403375-7eb6-418c-a76f-d9d1dd5ad4de">121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzI1LTQtMS0xLTk0ODMx_7b5123d6-0fbf-468d-872e-5a6d6a451014">471</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzI1LTYtMS0xLTk0ODMx_97448d85-fa4a-4035-8d2d-3f57b4a6c591">149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzI2LTItMS0xLTk0ODMx_c604a17e-9ffb-48d2-ae7c-0c51919657df">1,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzI2LTQtMS0xLTk0ODMx_fd950edb-0715-4b3b-853d-d7a114423b62">1,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzI2LTYtMS0xLTk0ODMx_51560238-e7a2-4bd1-8a01-4c73ee581e42">1,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows From Investing Activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of businesses, net of cash acquired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzI4LTItMS0xLTk0ODMx_9918c02e-04d8-4ac5-9da9-610696f291e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzI4LTQtMS0xLTk0ODMx_05e1deeb-24f7-4d52-b88b-feffb95328cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzI4LTYtMS0xLTk0ODMx_7aaae4ee-d2ce-472b-b18f-3c74b5bb4cfa">180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of intangible assets and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzI5LTItMS0xLTk0ODMx_8adb01ae-f0c5-445f-b320-6e7cbaf125e2">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzI5LTQtMS0xLTk0ODMx_e71a787e-a6b7-4584-843f-3b20f22790a1">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzI5LTYtMS0xLTk0ODMx_788e2357-b146-4441-828c-9634d8ee0140">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzMwLTItMS0xLTk0ODMx_f6f29cec-ea82-4bdd-aa6d-83fe7dcdfb65">269</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzMwLTQtMS0xLTk0ODMx_b0d0eb0a-be79-4a6a-b66d-b9c2f1c2996c">302</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzMwLTYtMS0xLTk0ODMx_b67fdf41-1663-4bab-8e90-6ca5d801f2f5">270</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzMxLTItMS0xLTk0ODMx_632c56c7-6c6b-4580-91eb-1e364b5654ad">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzMxLTQtMS0xLTk0ODMx_4fa9d07f-8bac-41c5-8738-adf62e7f6bba">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzMxLTYtMS0xLTk0ODMx_98ee0fd6-288a-4248-b875-7e00ba7159f3">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzMyLTItMS0xLTk0ODMx_55ac511f-a20d-4f65-a9d3-8d7984943e9a">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzMyLTQtMS0xLTk0ODMx_5acabd3e-a4fd-4069-bc92-5dd767f73338">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzMyLTYtMS0xLTk0ODMx_3e0cc5be-d8e6-4517-8d0e-5874238ad6a6">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of assets and businesses, net of costs to sell</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzMzLTItMS0xLTk0ODMx_c5c9347f-1308-40a6-ae10-dad7e566f555">669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzMzLTQtMS0xLTk0ODMx_61ec80c3-47ac-4625-bcfd-1ba365430355">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzMzLTYtMS0xLTk0ODMx_fcf152e3-9c1f-4cec-a4d4-0185445af825">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlements from cross-currency swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="bhc:InterestSettlementOnCrossCurrencySwaps" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzM0LTItMS0xLTk0ODMx_5a6eb238-045c-4a95-90b5-0df3c431a182">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="bhc:InterestSettlementOnCrossCurrencySwaps" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzM0LTQtMS0xLTk0ODMx_5fc83a47-6099-4c2b-861a-4fb613a79cd8">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="bhc:InterestSettlementOnCrossCurrencySwaps" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzM0LTYtMS0xLTk0ODMx_0f404b2d-1e7b-49bd-9af5-cbb87b5f28ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzM1LTItMS0xLTk0ODMx_241c9d43-698d-4aba-a2f7-1887e6997ea8">409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzM1LTQtMS0xLTk0ODMx_2153097b-46b4-499a-b36b-042724a1dfbe">261</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzM1LTYtMS0xLTk0ODMx_d72c86f0-f15c-4ae5-8c98-230a21248c2e">419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash Flows From Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of long-term debt, net of discounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzM3LTItMS0xLTk0ODMx_787e2bde-cbea-4690-b0ed-9d3048498cc9">2,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzM3LTQtMS0xLTk0ODMx_f4f314c0-a006-4e82-94c2-8df7cec17c80">3,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzM3LTYtMS0xLTk0ODMx_3e3633a4-3aaa-4861-8ce5-91ffda957530">5,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayments of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzM4LTItMS0xLTk0ODMx_2a286964-15bc-45ef-b133-017f0ebbc362">3,440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzM4LTQtMS0xLTk0ODMx_112e4430-69f9-4ce9-aa60-395f6f95962c">5,642</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzM4LTYtMS0xLTk0ODMx_404d491a-d44d-4869-88e9-48a86b0cc906">4,406</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings of short-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzM5LTItMS0xLTk0ODMx_2ad8cb49-2c1f-43e8-83f2-8ba20ca98def">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzM5LTQtMS0xLTk0ODMx_80240aec-8c67-4fe1-9f67-a95fdb4d0e55">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzM5LTYtMS0xLTk0ODMx_1284411a-c96c-4694-bd77-6e0378f2585e">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayments of short-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQwLTItMS0xLTk0ODMx_d4aeaf2a-c924-41df-9f54-9051308a34cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQwLTQtMS0xLTk0ODMx_e8ccbca7-a7a9-4495-99bd-50bd771778ea">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQwLTYtMS0xLTk0ODMx_f972a0f8-db39-48d6-b8c7-6133e847f934">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of employee withholding taxes related to share-based awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQxLTItMS0xLTk0ODMx_cad43166-9bde-4a1c-b7b3-18e320fce6fa">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQxLTQtMS0xLTk0ODMx_e69ccf24-9c70-4457-9c4a-6a3f2a9fefd4">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQxLTYtMS0xLTk0ODMx_5c1603e8-5792-4cb9-b9f4-2bcb4a81fdac">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments of acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQyLTItMS0xLTk0ODMx_95080ca1-f571-4a73-9af6-4680c63143bd">83</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQyLTQtMS0xLTk0ODMx_dd4a0078-ec12-4940-938c-fe46119c0583">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQyLTYtMS0xLTk0ODMx_18d8589f-005f-45f8-9bc6-bae4bbfd96a7">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments of financing costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQzLTItMS0xLTk0ODMx_ca6c01b1-2670-4aa2-a3f6-c80a50a6c14a">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQzLTQtMS0xLTk0ODMx_651f2f5c-f1cf-47ae-a03c-7a57e58ba0c0">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQzLTYtMS0xLTk0ODMx_65d2c062-254c-42f6-9e6d-e3e0b808755c">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ0LTItMS0xLTk0ODMx_c2276e93-fee2-498f-a1e2-ab4bad9d5e56">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ0LTQtMS0xLTk0ODMx_5337c692-e652-4807-8c0a-6649ba3bd44a">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ0LTYtMS0xLTk0ODMx_e34ae960-9c97-4a89-865d-30f0c97acf23">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ1LTItMS0xLTk0ODMx_26711d70-90bc-433f-a01e-bb50448c4105">1,513</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ1LTQtMS0xLTk0ODMx_0c39831b-a059-4cdd-b02d-bd62d3343086">2,294</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ1LTYtMS0xLTk0ODMx_6ac63cf0-fe43-4a3c-877b-febe0608571d">1,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ2LTItMS0xLTk0ODMx_07e50071-026f-471d-932d-07ed4ffe98ba">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ2LTQtMS0xLTk0ODMx_257f3944-6557-4e7b-b12e-a0ce48c1c1d0">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ2LTYtMS0xLTk0ODMx_040cdda7-e140-4e77-96c5-46cc4afc3089">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in Cash and cash equivalents and Restricted cash and other settlement deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ3LTItMS0xLTk0ODMx_a0c8f20e-ba31-4ab0-97d9-5ac14a6e5202">303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ3LTQtMS0xLTk0ODMx_a5de0651-3403-4def-a96e-01232c574bec">1,428</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ3LTYtMS0xLTk0ODMx_811fb20e-14cb-44a4-a15d-f3911904825a">2,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents and Restricted cash and other settlement deposits, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ4LTItMS0xLTk0ODMx_fee9de61-fed7-4449-a88d-7ecd30c1f4bb">1,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231" decimals="-6" name="bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ4LTQtMS0xLTk0ODMx_3c4ed8cc-79f6-4e47-836c-40f63365f521">3,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18439fe8345c481db53c486667ac6940_I20181231" decimals="-6" name="bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ4LTYtMS0xLTk0ODMx_c138cf32-3a81-442b-aa9e-ba9ad7038adc">723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and cash equivalents and Restricted cash and other settlement deposits, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ5LTItMS0xLTk0ODMx_ce86acb1-a91b-43a6-8ae7-b6a11b51b13a">2,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ5LTQtMS0xLTk0ODMx_876da0b6-82fa-4b9b-acc9-488d5d17eb12">1,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231" decimals="-6" name="bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ5LTYtMS0xLTk0ODMx_522f163a-df6a-43c7-bb23-6db3f9879fa9">3,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzUxLTItMS0xLTk0ODMx_9794ada4-cb09-4a10-b6ce-0db69830db03">582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzUxLTQtMS0xLTk0ODMx_1389602c-657a-4ba2-ac09-06651910dbfb">605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzUxLTYtMS0xLTk0ODMx_46b0b1d7-0994-4433-a37e-a30a55982050">3,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash and other settlement deposits, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="bhc:RestrictedCashAndOtherSettlementDepositsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzUyLTItMS0xLTk0ODMx_5d847b4f-9a3b-488b-9256-128176ddb57c">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="bhc:RestrictedCashAndOtherSettlementDepositsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzUyLTQtMS0xLTk0ODMx_279d634b-1530-4bdf-a60a-68a6997d4407">1,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231" decimals="-6" name="bhc:RestrictedCashAndOtherSettlementDepositsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzUyLTYtMS0xLTk0ODMx_89df046e-ecd1-4af6-a0c6-9b0daa1f7e9f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and cash equivalents and Restricted cash and other settlement deposits, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzUzLTItMS0xLTk0ODMx_25e6d296-abe1-4334-81b5-f46816083858">2,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzUzLTQtMS0xLTk0ODMx_d0234a40-5255-4702-993e-137669a6f110">1,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231" decimals="-6" name="bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzUzLTYtMS0xLTk0ODMx_eed12bca-89de-4c33-a8c3-bbf1fc4eb14d">3,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><div id="i8256f225f07d49409c31f7443adffdbf_310"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BAUSCH HEALTH COMPANIES&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="i8256f225f07d49409c31f7443adffdbf_313"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTMvZnJhZzplNzU5NWUwMGZiNmM0NjkzYmY3OGQ5NTg4ZWNiZjgyZi90ZXh0cmVnaW9uOmU3NTk1ZTAwZmI2YzQ2OTNiZjc4ZDk1ODhlY2JmODJmXzEwOTI_0b55899e-7683-47bb-8e97-9abebb3d4411" continuedAt="ibaa8f0a967fc410298984c2a472d036f" escape="true">DESCRIPTION OF BUSINESS</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibaa8f0a967fc410298984c2a472d036f">Bausch Health Companies Inc. (the &#8220;Company&#8221;), formerly known as Valeant Pharmaceuticals International, Inc.,  is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (&#8220;OTC&#8221;) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in approximately <ix:nonFraction unitRef="country" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-2" name="us-gaap:NumberOfCountriesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTMvZnJhZzplNzU5NWUwMGZiNmM0NjkzYmY3OGQ5NTg4ZWNiZjgyZi90ZXh0cmVnaW9uOmU3NTk1ZTAwZmI2YzQ2OTNiZjc4ZDk1ODhlY2JmODJmXzUwNg_058d8c36-8e4f-4b59-9187-3c1474636c60">100</ix:nonFraction> countries.  Effective August 9, 2013, the Company continued from the federal jurisdiction of Canada to the Province of British Columbia, meaning that the Company became a company registered under the laws of the Province of British Columbia as if it had been incorporated under the laws of the Province of British Columbia. As a result of this continuance, the legal domicile of the Company became the Province of British Columbia, the Canada Business Corporations Act ceased to apply to the Company and the Company became subject to the British Columbia Business Corporations Act.</ix:continuation></span></div><div id="i8256f225f07d49409c31f7443adffdbf_316"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MjQy_fbf277de-b2ad-4ce9-8869-2144f0799866" continuedAt="i742c0f1934e34145973ac6d3c18263f9" escape="true">SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i742c0f1934e34145973ac6d3c18263f9" continuedAt="iabcd9c80a47549cfbad28052073222a7"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MDI5_10cfbb5c-4ee0-4d3a-a194-b0847ff50de6" continuedAt="i0d606417ef304dcc9a896c282f3b5af6" escape="true">Basis of Presentation and Use of Estimates </ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0d606417ef304dcc9a896c282f3b5af6">The Consolidated Financial Statements have been prepared by the Company in United&#160;States (&#8220;U.S.&#8221;) dollars and in accordance with U.S.&#160;generally accepted accounting principles (&#8220;U.S. GAAP&#8221;), applied on a consistent basis. The Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.</ix:continuation> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation of the Bausch + Lomb Eye-Health Business and Initial Public Offering of Solta Medical Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, the Company announced its intentions to separate its eye-health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc. (the &#8220;B+L Separation&#8221;). On August 3, 2021, the Company announced its intentions to conduct an initial public offering  (&#8220;IPO&#8221;) of its aesthetic medical device business, Global Solta (the &#8220;Solta IPO&#8221;).  In January 2022, the Company completed the internal organizational design and structure of the new eye-health entity, Bausch + Lomb Corporation  (&#8220;Bausch + Lomb&#8221;), and the new Global Solta entity, Solta Medical Corporation  (&#8220;Solta&#8221;), as previously announced and aims to launch the B+L IPO and the Solta IPO when financial market conditions are favorable (and subject to receipt of regulatory, stock exchange and other approvals). Following the B+L IPO the Company expects to complete the separation of Bausch + Lomb after the expiry of customary lockups related to the B+L IPO and achievement of targeted debt leverage ratios, subject to the receipt of applicable shareholder and other necessary approvals. The B+L Separation and the proposed Solta IPO will establish <ix:nonFraction unitRef="company" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="INF" name="bhc:BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzE3ODk_053dea0b-63c8-4891-947b-9170c7759599">three</ix:nonFraction> separate companies that include: (i) a fully integrated eye-health company which will consist of the Company&#8217;s Bausch + Lomb Global Vision Care, Global Surgical, Global Consumer and Global Ophthalmic Pharmaceuticals businesses, (ii) a global provider of aesthetic medical devices which will consist of the Company&#8217;s Solta business and (iii) a diversified pharmaceutical company which will include the Company&#8217;s Salix, International (formerly International Rx), dentistry, neurology, medical dermatology and generics pharmaceutical businesses. These audited Consolidated Financial Statements do not include any adjustments to give effect to either the B+L Separation or the proposed Solta IPO.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impacts of COVID-19 Pandemic</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unprecedented nature of the COVID-19 pandemic has, and continues to, adversely impact the global economy. The COVID-19 pandemic and the reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have had significant direct and indirect effects on businesses and commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facility closures and production suspensions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which these events may continue to impact the Company's business, financial condition, cash flows and results of operations, in particular, will depend on future developments which are highly uncertain and many of which are outside the Company's control. Such developments include the availability and effectiveness of vaccines for the COVID-19 virus, COVID-19 vaccine immunization rates, the ultimate geographic spread and duration of the pandemic, the extent and duration of a resurgence of the COVID-19 virus and variant strains thereof, such as the delta and omicron variants, new information concerning the severity of the COVID-19 virus, the effectiveness and intensity of measures to contain the COVID-19 virus and the economic impact of the pandemic and the reactions to it. Such developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company's business, financial condition, cash flows and results of operations. </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="iabcd9c80a47549cfbad28052073222a7" continuedAt="ib430713ad8844768a700f15f66c41352"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has been able to continue its operations with limited disruptions in supply and manufacturing. Although it is difficult to predict the broad macroeconomic effects that the COVID-19 pandemic will have on industries or individual companies, the Company has assessed the possible effects and outcomes of the pandemic on, among other things, its supply chain, customers and distributors, discounts and rebates, employee base, product sustainability, research and development efforts, product pipeline and consumer demand and currently believes that its estimates are reasonable. </span></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MjE2_b5505187-2963-435a-b1e1-0f925d99a097" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the Company's Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows.  The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include: provisions for product returns, rebates, chargebacks, discounts and allowances and distribution fees paid to certain wholesalers; useful lives of amortizable intangible assets and property, plant and equipment; expected future cash flows used in evaluating intangible assets for impairment, assessing compliance with debt covenants and making going concern assessments; reporting unit fair values for testing goodwill for impairment and allocating goodwill to new reporting unit structure on a relative fair value basis; provisions for loss contingencies; provisions for income taxes, uncertain tax positions and realizability of deferred tax assets; fair value of cross-currency swaps; fair value of foreign currency exchange contracts; and the recognition of the fair value of assets and liabilities acquired in a business combination, including the fair value of contingent consideration. Under certain product manufacturing and supply agreements, management uses information from the Company&#8217;s commercialization counterparties to arrive at estimates for future returns, rebates and chargebacks. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#8217;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#8217;s Consolidated Financial Statements could be materially impacted.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MTk3_398c7778-029b-49f5-af48-4e5431fd5510" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2022, the Company operates in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International, (iv) Solta Medical and (v) Diversified Products. Prior to the first quarter of 2022, the Company operated in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International, (iv) Ortho Dermatologics and (v) Diversified Products. All segment revenues and profits for the periods presented have been recast to conform to the 2022 segment reporting structure. See Note 22, &#8220;SEGMENT INFORMATION&#8221; for additional information.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MDI0_9d4eb89c-fd3e-4a4e-be74-666a7749c6b8" continuedAt="i738ad707e1d6426d9f06270d3121d3e9" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Consolidated Financial Statements after the date of acquisition.  Acquired in-process research and development (&#8220;IPR&amp;D&#8221;) is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&amp;D has an alternative future use. If the acquired net assets do not constitute a business, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&amp;D with no alternative future use is charged to expense at the acquisition&#160;date and any future contingent consideration is not recorded until it becomes probable.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MjI5_a6737dc1-1f73-47c5-8f2e-8ad2cb91eb95" continuedAt="i3aeb704dd3484ed98aaecee05eda1efe" escape="true">Fair Value of Financial Instruments</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3aeb704dd3484ed98aaecee05eda1efe">The estimated fair values of cash and cash equivalents, trade receivables, accounts payable and accrued liabilities approximate their carrying values due to their short maturity periods. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows or Monte Carlo Simulation (when appropriate) analyses and assessment of the probability of occurrence of potential future events.</ix:continuation> </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ib430713ad8844768a700f15f66c41352" continuedAt="if47e5e6b7ef14a4e836227d72e808ae9"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MjMy_589e8572-89fe-4b32-8f82-93db23a6f145" continuedAt="i2dd85aa843284d47b99c7d54ef3e5fd2" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Derivative Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting for changes in the fair value of a derivative instrument depends on whether the instrument has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Consolidated Statements of Operations during the current period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cross-currency swaps qualified for and had been designated as an accounting hedge of the foreign currency exposure of a net investment in a foreign operation and were remeasured at each reporting date to reflect changes in their fair values.  The fair value was determined via a mark-to-market analysis, using observable (Level&#160;2) inputs. These inputs included: (i)&#160;the foreign currency exchange spot rate between the euro and U.S. dollar, (ii)&#160;the interest rate yield curves in the euro and U.S. dollar and (iii)&#160;the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps is reported as a gain or loss in the Consolidated Statements of Comprehensive Loss as part of Foreign currency translation adjustment to the extent they are effective, and remain in Accumulated other comprehensive loss until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps was ineffective. The Company uses the spot method of assessing hedge effectiveness. The Company had elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as a reduction of Interest expense in the Consolidated Statements of Operations.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2dd85aa843284d47b99c7d54ef3e5fd2">The Company uses foreign currency exchange contracts to economically hedge the foreign exchange exposure on certain of the Company&#8217;s intercompany and third party balances. The Company's foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other.</ix:continuation> </span></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MTk2_42ded05f-c867-46ec-bd69-24ab9d85fda0" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash in bank accounts and highly liquid investments with maturities of <ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="bhc:MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzEwNjAy_6739ce57-4ad6-4ffb-8f21-523438a0f96c">three months</ix:nonNumeric> or less when&#160;purchased.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MTkx_86c91f11-6c69-45e7-9e9c-cd63fb080a6d" continuedAt="i763e558ca55346c1abf540f4775f1dac" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables, cross-currency swaps and foreign currency exchange contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests its excess cash in high-quality, money market instruments and term deposits with varying maturities, but typically less than <ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="bhc:MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzExMDYy_0732fe1d-3269-469f-8089-6a8a92678e9d">three months</ix:nonNumeric>.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash deposited at banks may exceed the amount of insurance provided on such deposits. Generally, these cash deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate such risks by spreading its risk across multiple counterparties and monitoring the risk profiles of these counterparties.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i763e558ca55346c1abf540f4775f1dac">The Company&#8217;s trade receivables primarily represent amounts due from wholesale distributors, retail pharmacies, government entities and group purchasing organizations. Outside of the U.S., concentrations of credit risk with respect to trade receivables, which are typically unsecured, are limited due to the number of customers using the Company&#8217;s products, as well as their dispersion across many different geographic regions. The Company performs periodic credit evaluations of customers and does not require collateral. The Company monitors economic conditions, including volatility associated with international economies, and related impacts on the relevant financial markets and its business, especially in light of sovereign credit issues. The credit and economic conditions within Argentina, Brazil, Egypt, Greece, among other members of the European Union, Turkey, Ukraine and Venezuela have been weak in recent years.</ix:continuation> These conditions have increased, and may continue to increase, the average length of time that it takes to collect on the Company&#8217;s trade receivables outstanding in these countries. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company&#8217;s <ix:nonFraction unitRef="wholesaler" contextRef="ia62208ce4dc846f1ba9f111c31435582_D20210101-20211231" decimals="INF" name="bhc:NumberOfLargestWholesaleCustomers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzEyNjAx_3cd2da7f-1d75-430d-9f21-4dad516d1280">three</ix:nonFraction> largest U.S. wholesaler customers accounted for approximately <ix:nonFraction unitRef="number" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="2" name="bhc:ConcentrationRiskPercentageofNetTradeReceivables" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzEyNjY2_27977363-37b8-4886-a702-d100dd3799ea">44</ix:nonFraction>% of net trade receivables. In addition, as of December 31, 2021 and 2020, the Company&#8217;s net trade receivable balance from Argentina, Brazil, Egypt, Greece, Serbia, South Africa, Turkey, Ukraine, Venezuela and Vietnam amounted to $<ix:nonFraction unitRef="usd" contextRef="iedf6d2b80161425e9e29520cc751a2f1_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzEyODY3_4249c8b8-df21-40c8-87e6-2784431264dd">78</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic0a435d217a0443898aeb95a619d60b2_I20201231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzEyODc0_88a7500d-0b67-43d4-a72e-1408c38bcbe5">166</ix:nonFraction>&#160;million, respectively, the majority of which is current or less than <ix:nonNumeric contextRef="i00e7a4ba81a046a790930dda41d3956b_D20210101-20211231" name="bhc:PastDuePeriodForAccountsReceivableToBeNegligible" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzEyOTM4_0ca3c985-a7fa-4a84-8a59-eb3d6a65add8">90</ix:nonNumeric> days past due. The portion of the net trade receivable from these countries that is past due more than <ix:nonNumeric contextRef="i00e7a4ba81a046a790930dda41d3956b_D20210101-20211231" name="bhc:PeriodReceivableOutstanding" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzEzMDQ0_b5eb3a06-be2d-4908-8938-916c08285eb2">90</ix:nonNumeric>&#160;days amounted to $<ix:nonFraction unitRef="usd" contextRef="iedf6d2b80161425e9e29520cc751a2f1_I20211231" decimals="-6" name="bhc:TradeReceivableNetPortionPastDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzEzMDY0_6d408324-220c-4e05-a664-810a5b564e2e">2</ix:nonFraction> million, as of December 31, 2021, a portion of which is comprised of public hospitals.  Based on an analysis of credit risk, including an analysis of bad debt </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="if47e5e6b7ef14a4e836227d72e808ae9" continuedAt="iac00b545ea0348438228f46eeb817ee0"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">experience and assessment of historical payment patterns for such customers, the Company has established a reserve covering more than half of the balance past due more than <ix:nonNumeric contextRef="i00e7a4ba81a046a790930dda41d3956b_D20210101-20211231" name="bhc:PeriodReceivableOutstanding" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzEzMzcw_d322a533-ad0d-497e-aa79-70b804c65d55">90</ix:nonNumeric> days for such countries. Over the three-year period ended December&#160;31, 2021, the Company has not experienced any material losses from uncollectible accounts in excess of the established reserves.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not enter into financial instruments for trading or speculative purposes. Further, the Company has a policy of only entering into contracts with parties that have at least an investment grade credit rating. The Company enters into cross-currency swaps and foreign currency exchange contracts with high credit quality financial institutions. The counter-parties to the Company's cross-currency swaps and foreign currency exchange contracts are major financial institutions, and there is no significant concentration of exposure with any one counter-party. To date, no counterparty has failed to meet its obligations to the Company and management believes the risk of loss associated with these contracts is remote.  See Note 5, &#8220;FAIR VALUE MEASUREMENTS&#8221; for additional details regarding the Company's cross-currency swaps and foreign currency exchange contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MjM1_088e83b0-b356-4216-a13a-ba1a9f86b26d" continuedAt="i4a17d9ac0fd9405784c8fdf9e4316536" escape="true">Allowance for Credit Losses</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4a17d9ac0fd9405784c8fdf9e4316536">An allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.&#160; Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be&#160;collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses.</ix:continuation> Allowance for credit losses were $<ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzE1MTk1_9e7c1223-0578-4615-b29f-9ce92b2f6393">35</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzE1MTk5_9f2f2b58-da1c-4a43-8d9c-890a6fea2c99">39</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzE1MjA2_abaa0baf-3d6a-43c1-83ed-9c59df7e798f">48</ix:nonFraction>&#160;million as of December 31, 2021, 2020 and 2019, respectively. <ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MTM2_57130331-0679-495b-9c06-3761296b2abd" continuedAt="i683a7680025249bea835b2a17706a3ef" escape="true">The activity in the allowance for credit losses for trade receivables for the years 2021, 2020 and 2019 is as follows.</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><ix:continuation id="i683a7680025249bea835b2a17706a3ef"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:70.199%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.965%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzEtMS0xLTEtOTQ4MzE_824101f1-a0d9-40a9-bc93-f96287c5df31">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzEtMy0xLTEtOTQ4MzE_31fea177-5ec4-4bec-8d2e-a368a10355f3">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18439fe8345c481db53c486667ac6940_I20181231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzEtNS0xLTEtOTQ4MzE_1a97abe7-2d63-4fa5-a31a-e4d155cb997c">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retrospective effect of application of new accounting standard</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzItMS0xLTEtOTQ4MzE_56e5b909-69dd-427a-ac7e-be2f5ec71bd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzItMy0xLTEtOTQ4MzE_3a594caa-960f-4cbd-8245-fa610d0ea2be">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzItNS0xLTEtOTQ4MzE_714247d7-5e1c-43fc-937e-f572aabe02f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzMtMS0xLTEtOTQ4MzE_80cb4574-3c41-4d25-8b5a-daf8dccff3bb">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzMtMy0xLTEtOTQ4MzE_97da51b2-d81c-4bcc-81e5-9e8075cd0fd4">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzMtNS0xLTEtOTQ4MzE_4aba4f73-dc44-42e5-bd47-f16b11d01a8b">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzQtMS0xLTEtOTQ4MzE_254c7f18-22d7-48e7-955d-d659ec827203">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzQtMy0xLTEtOTQ4MzE_cad34110-6372-4095-9d68-adbd0a0a7af4">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzQtNS0xLTEtOTQ4MzE_ba91a831-a7be-4054-bb13-cc1e8d958854">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoveries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzUtMS0xLTEtOTQ4MzE_3ef1f5e7-4d35-484b-8327-cf7bce69eaf0">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzUtMy0xLTEtOTQ4MzE_226031e6-4c9c-4ac4-8780-ee5bd613fe75">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzUtNS0xLTEtOTQ4MzE_ae6baf3d-967a-4253-8ef4-54cff995a6b8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="bhc:AccountsReceivableAllowanceForForeignExchangeAndOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzYtMS0xLTEtOTQ4MzE_65976557-0d6a-48a4-b12f-7d3c8a247c22">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="bhc:AccountsReceivableAllowanceForForeignExchangeAndOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzYtMy0xLTEtOTQ4MzE_1d0ead6f-fa8b-4106-8092-baf31561315c">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="bhc:AccountsReceivableAllowanceForForeignExchangeAndOther" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzYtNS0xLTEtOTQ4MzE_942414ab-cf42-4eb8-9e91-1429a28ecfe4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzctMS0xLTEtOTQ4MzE_9e7c1223-0578-4615-b29f-9ce92b2f6393">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzctMy0xLTEtOTQ4MzE_736d4d6f-c4dc-47bb-a7a6-5d367485a4e5">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzctNS0xLTEtOTQ4MzE_f590c2fa-31b9-4754-810a-83c337cd311c">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MDQ0_ecfc17ff-40a4-48bb-9611-ff67eeb8c0e5" escape="true"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories comprise raw materials, work in process and finished goods, which are valued at the lower of cost or net realizable value, on a first-in, first-out basis. The cost value for work in process and finished goods inventories includes materials, direct labor and an allocation of overheads. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on&#160;hand.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MDg2_5355b98f-5eaa-4218-9b63-0c41082a4235" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are reported at cost, less accumulated depreciation. Costs incurred on assets under construction are capitalized as construction in progress. <ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="bhc:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MTA1_d5cb6bcb-bdc8-4396-8992-47db42315be3" continuedAt="i78dfaeae127b4e0ea1b8c1b1f8a8be71" escape="true">Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful&#160;lives: </ix:nonNumeric></span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><ix:continuation id="i78dfaeae127b4e0ea1b8c1b1f8a8be71"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:54.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0043ca6c60b448469dd9c10b6369a160_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpjZmNiNzYwM2ExODE0YTJiYTllZjRjZWE3MTdlYWExNi90YWJsZXJhbmdlOmNmY2I3NjAzYTE4MTRhMmJhOWVmNGNlYTcxN2VhYTE2XzAtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjoxNDA0MmQyODNiNmE0YWY3ODY1MmU5ZTE2NzkyN2RlYl80_3eb0ecea-47c6-4565-8f90-4b9e34a10985">15</ix:nonNumeric> - <ix:nonNumeric contextRef="ic50c129d307b456db8bd6d0a3572b5cf_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpjZmNiNzYwM2ExODE0YTJiYTllZjRjZWE3MTdlYWExNi90YWJsZXJhbmdlOmNmY2I3NjAzYTE4MTRhMmJhOWVmNGNlYTcxN2VhYTE2XzAtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjoxNDA0MmQyODNiNmE0YWY3ODY1MmU5ZTE2NzkyN2RlYl85_23db710b-14fd-4575-9045-fcebe4b1fb22">30</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to <ix:nonNumeric contextRef="i1c6ea96094f24f6aa4162dcd33584114_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpjZmNiNzYwM2ExODE0YTJiYTllZjRjZWE3MTdlYWExNi90YWJsZXJhbmdlOmNmY2I3NjAzYTE4MTRhMmJhOWVmNGNlYTcxN2VhYTE2XzEtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjpiZDcxMDIzMTQ5Zjk0OTFkYmE5ZWY4ZDVkOTc3ZjVmMV8xMA_51bb9843-96be-4da9-ac81-4cdb5a050e3b">40</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id111070c09c44a9f836bd940a8c401b1_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpjZmNiNzYwM2ExODE0YTJiYTllZjRjZWE3MTdlYWExNi90YWJsZXJhbmdlOmNmY2I3NjAzYTE4MTRhMmJhOWVmNGNlYTcxN2VhYTE2XzItMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo4MmRjZmJlMTBiYzc0YmEzYjc3MjA1MDE4MDgzYTJiYl80_3c98ef13-b2ec-47eb-80a7-3dbfb7c5806d">3</ix:nonNumeric>&#160;-&#160;<ix:nonNumeric contextRef="id5d7287ea6164d739cdd4537fbbcf93b_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpjZmNiNzYwM2ExODE0YTJiYTllZjRjZWE3MTdlYWExNi90YWJsZXJhbmdlOmNmY2I3NjAzYTE4MTRhMmJhOWVmNGNlYTcxN2VhYTE2XzItMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo4MmRjZmJlMTBiYzc0YmEzYjc3MjA1MDE4MDgzYTJiYl85_eb66779a-f5c6-4281-826b-3f92ef8c6230">20</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i71d4507094c54c61a828a4ba28c456f8_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpjZmNiNzYwM2ExODE0YTJiYTllZjRjZWE3MTdlYWExNi90YWJsZXJhbmdlOmNmY2I3NjAzYTE4MTRhMmJhOWVmNGNlYTcxN2VhYTE2XzMtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo2MTg4ZDQ3NzIwMDI0MGY5YjY5YjIwMWY4NDdjNWQwYV80_8f709766-2eed-4f68-9df8-e9a120dcf294">3</ix:nonNumeric>&#160;-&#160;<ix:nonNumeric contextRef="i300d1bbfb1584998a64def9a1e591494_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpjZmNiNzYwM2ExODE0YTJiYTllZjRjZWE3MTdlYWExNi90YWJsZXJhbmdlOmNmY2I3NjAzYTE4MTRhMmJhOWVmNGNlYTcxN2VhYTE2XzMtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo2MTg4ZDQ3NzIwMDI0MGY5YjY5YjIwMWY4NDdjNWQwYV85_f27fa2f2-ae1d-44ac-94e2-b57f702a7c36">10</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment on operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to <ix:nonNumeric contextRef="idcb50c382a0f41abb2ebb51d91d43a1c_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpjZmNiNzYwM2ExODE0YTJiYTllZjRjZWE3MTdlYWExNi90YWJsZXJhbmdlOmNmY2I3NjAzYTE4MTRhMmJhOWVmNGNlYTcxN2VhYTE2XzQtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjphZTA3ODdiODEzNzQ0ZWVlYTcxZWViY2I2YzUyMTYyM18xMA_70345585-7949-4e89-b81b-20882920888d">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of term of lease or <ix:nonNumeric contextRef="ifbd918087d4845c1890cc471931bf4ee_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpjZmNiNzYwM2ExODE0YTJiYTllZjRjZWE3MTdlYWExNi90YWJsZXJhbmdlOmNmY2I3NjAzYTE4MTRhMmJhOWVmNGNlYTcxN2VhYTE2XzUtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjozMzBkYTBjMTY3Yzc0OGU5YWNiY2JjOGQ4MTdhNjQyNl8zMQ_1370791c-3770-4668-8d82-0c056bd3edfb">10</ix:nonNumeric> years</span></div></td></tr></table></ix:continuation></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="iac00b545ea0348438228f46eeb817ee0" continuedAt="ie217c2ab6c494568963ee5d59eafcea3"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MDc0_d00f4199-a020-4135-acbe-755ad1d3a655" escape="true"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reported at cost, less accumulated amortization and impairments. Intangible assets with finite lives are amortized over their estimated useful lives. <ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="bhc:ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MjI1_be3f6b13-e10f-45b1-90b7-c1782f285691" continuedAt="id7427de51d8b4cf19d7433e33c906064" escape="true">Amortization is calculated primarily using the straight-line method based on the following estimated useful&#160;lives:</ix:nonNumeric></span></div><div style="margin-top:5pt;padding-left:18pt"><ix:continuation id="id7427de51d8b4cf19d7433e33c906064"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:54.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id51447b7e78f425bafc98f09b85f21fd_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTowNTk3MzE4MGEwODE0YWVkYmRlYzk3MDdjNmYzMDM4NC90YWJsZXJhbmdlOjA1OTczMTgwYTA4MTRhZWRiZGVjOTcwN2M2ZjMwMzg0XzAtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo3NjJjOGU5ZmZjM2E0OTE3ODczODc4YzQxYzAzMjg0Nl80_de7a19bd-4c51-459e-b03a-5ca8c4976c2c">2</ix:nonNumeric> - <ix:nonNumeric contextRef="i975464f279ce4238b86edce4c77ddbe8_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTowNTk3MzE4MGEwODE0YWVkYmRlYzk3MDdjNmYzMDM4NC90YWJsZXJhbmdlOjA1OTczMTgwYTA4MTRhZWRiZGVjOTcwN2M2ZjMwMzg0XzAtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo3NjJjOGU5ZmZjM2E0OTE3ODczODc4YzQxYzAzMjg0Nl85_a706822f-f481-4620-9c9d-a9e9b85bc041">20</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie756de63eaaf4535abb5aeced45c5b18_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTowNTk3MzE4MGEwODE0YWVkYmRlYzk3MDdjNmYzMDM4NC90YWJsZXJhbmdlOjA1OTczMTgwYTA4MTRhZWRiZGVjOTcwN2M2ZjMwMzg0XzEtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjoxNGUzMjg4YzQzMzQ0MmRmOWI0NGY0Zjg1ZDk0YTFiMF80_02ae2763-9ebb-424b-8685-2dce49bef81f">9</ix:nonNumeric> - <ix:nonNumeric contextRef="ia21b8496153c42c087eeb45cea371ca7_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTowNTk3MzE4MGEwODE0YWVkYmRlYzk3MDdjNmYzMDM4NC90YWJsZXJhbmdlOjA1OTczMTgwYTA4MTRhZWRiZGVjOTcwN2M2ZjMwMzg0XzEtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjoxNGUzMjg4YzQzMzQ0MmRmOWI0NGY0Zjg1ZDk0YTFiMF85_b7029e28-0ffe-42b8-9bfa-65a5d810b2ef">20</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i490b2ed3d24b48e583bcdcad19e43866_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTowNTk3MzE4MGEwODE0YWVkYmRlYzk3MDdjNmYzMDM4NC90YWJsZXJhbmdlOjA1OTczMTgwYTA4MTRhZWRiZGVjOTcwN2M2ZjMwMzg0XzItMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjpkMzQxOGJmNmU0MWY0MzRhODViYTExNTM3NWQ5ODRlY180_528739f3-6153-4986-b7df-11c132ecc234">4</ix:nonNumeric> - <ix:nonNumeric contextRef="ibeae95de06d24f9696ad1c74d3eee5f4_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTowNTk3MzE4MGEwODE0YWVkYmRlYzk3MDdjNmYzMDM4NC90YWJsZXJhbmdlOjA1OTczMTgwYTA4MTRhZWRiZGVjOTcwN2M2ZjMwMzg0XzItMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjpkMzQxOGJmNmU0MWY0MzRhODViYTExNTM3NWQ5ODRlY185_d720ad75-e8fc-48d9-9a14-6240dd90bd42">15</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic53aa697e1c24a5896e49065797f9b0d_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTowNTk3MzE4MGEwODE0YWVkYmRlYzk3MDdjNmYzMDM4NC90YWJsZXJhbmdlOjA1OTczMTgwYTA4MTRhZWRiZGVjOTcwN2M2ZjMwMzg0XzMtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjpiZjgyNzE5ZTlhZGM0MjE1YjAzYjUzNGZkYmI5NmI4Yl80_7b821bfb-4922-4621-975d-ef89848eec61">7</ix:nonNumeric> - <ix:nonNumeric contextRef="i589f537dbee5471e9bfcdc450bd648fd_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTowNTk3MzE4MGEwODE0YWVkYmRlYzk3MDdjNmYzMDM4NC90YWJsZXJhbmdlOjA1OTczMTgwYTA4MTRhZWRiZGVjOTcwN2M2ZjMwMzg0XzMtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjpiZjgyNzE5ZTlhZGM0MjE1YjAzYjUzNGZkYmI5NmI4Yl85_1ff3668d-20db-4839-b551-5019d4983e88">9</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Out-licensed technology and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2b9398fd67264ccbab689da594b22ed4_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTowNTk3MzE4MGEwODE0YWVkYmRlYzk3MDdjNmYzMDM4NC90YWJsZXJhbmdlOjA1OTczMTgwYTA4MTRhZWRiZGVjOTcwN2M2ZjMwMzg0XzQtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo3MjI5ODg3OWU2NWY0YjAyOGEwNGRjYzIwZWUxZDAxYV80_5cfd55bf-830f-47fb-91e5-dfbbdce2678a">8</ix:nonNumeric> - <ix:nonNumeric contextRef="i36b171d0ac0f4d8ba4064dc0477f6b5d_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTowNTk3MzE4MGEwODE0YWVkYmRlYzk3MDdjNmYzMDM4NC90YWJsZXJhbmdlOjA1OTczMTgwYTA4MTRhZWRiZGVjOTcwN2M2ZjMwMzg0XzQtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo3MjI5ODg3OWU2NWY0YjAyOGEwNGRjYzIwZWUxZDAxYV85_dac9f6b3-d068-479d-9e25-a9b76acc9b9b">9</ix:nonNumeric> years</span></div></td></tr></table></ix:continuation></div></ix:nonNumeric><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="bhc:DivestituresOfNoncoreProductsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MTQ4_7440ad1e-c14d-4681-b892-f2b98ad4cc50" escape="true"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Divestitures of Products</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds on the divestiture of products and the carrying amount of the related assets is recorded as a gain/loss on sale within Other expense, net. Any contingent payments that are potentially due to the Company as a result of these divestitures are recorded when realizable.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MTM3_7497380f-48cf-4d40-aa52-d8a25172ff97" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IPR&amp;D </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of IPR&amp;D acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset will be assigned a useful life and&#160;amortized. Acquired IPR&amp;D assets are tested for impairment at least annually or when triggering events are identified.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of an acquired IPR&amp;D intangible asset is typically determined using an income approach. This approach starts with a forecast of the net cash flows expected to be generated by the asset over its estimated useful life. The net cash flows reflect the asset&#8217;s stage of completion, the probability of technical success, the projected costs to complete, expected market competition and an assessment of the asset&#8217;s life-cycle. The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the expected cash flow&#160;streams.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MDg4_2ce0463a-61ff-4131-9257-000368c57b1c" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.  If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset, which include the amount and timing of the projected future cash flows. If the expected undiscounted cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash&#160;flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets, which includes acquired IPR&amp;D and the corporate trademark acquired in the acquisition of Bausch &amp; Lomb Holdings Incorporated (the &#8216;&#8216;B&amp;L Trademark&#8217;&#8217;), are tested for impairment annually or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based on a comparison of the fair value of the asset to its carrying value.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MDQ1_cc3d0246-bb9d-4063-b8b2-55f358fe5337" continuedAt="if5ca48f7ae304d08bcdab18d5425f975" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is recorded with the acquisition of a business and is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment at least annually as of October 1st at the reporting unit level. Goodwill impairment is measured as the amount by which a reporting unit's carrying value exceeds its fair value. A reporting unit is the same as, or one level below, an operating segment. A</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n entity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is permitted to first assess qualitatively whether it is necessary to perform a quantitative impairment test for any of its reporting units. The quantitative impairment test is required only when the Company concludes that it is more likely than not that a reporting unit&#8217;s fair value is less than its carrying amount. In evaluating whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company considers the totality of all relevant events or circumstances that affect the fair value or carrying amount of a reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An interim goodwill impairment test in advance of the annual impairment assessment may be required if events occur that indicate an impairment might be present. For example, a substantial decline in the Company&#8217;s market capitalization, changes in reportable segments, unexpected adverse business conditions, economic factors and unanticipated competitive activities may signal that an interim impairment test is needed. Accordingly, among other factors, the Company monitors </span></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ie217c2ab6c494568963ee5d59eafcea3" continuedAt="icec808a81fd64678bad0bab54b61199b"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if5ca48f7ae304d08bcdab18d5425f975">changes in its share price between annual impairment tests. The Company considers a decline in its share price that corresponds to an overall deterioration in stock market conditions to be less of an indicator of goodwill impairment than a unilateral decline in its share price reflecting adverse changes in its underlying operating performance, cash flows, financial condition and/or liquidity. In the event that the Company&#8217;s market capitalization does decline below its book value, the Company would consider the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. The Company believes that short-term fluctuations in share prices may not necessarily reflect underlying values.</ix:continuation></span></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:DeferredChargesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MjEz_704ac726-ee03-47c5-b40b-6874098c4c07" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt discounts, premiums and issuance costs are presented in the Consolidated Balance Sheets as a direct deduction from or addition to the carrying amount of the related debt and are amortized or accreted, using the effective interest method, as interest expense over the contractual lives of the related credit facilities or notes. Deferred financing costs associated with revolving credit facility arrangements are included in the balances of Prepaid expenses and other current assets and Other non-current assets in the Consolidated Balance Sheets and are amortized as interest expense over the contractual life of the related revolving credit facility.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MDEz_e3430b2b-6f13-4da3-a963-b6ffcb37de98" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities of the Company&#8217;s foreign operations having a functional currency other than the U.S.&#160;dollar are translated into U.S.&#160;dollars at the exchange rate prevailing at the balance sheet date, and at the average exchange rate for the reporting period for revenue and expense accounts. The cumulative foreign currency translation adjustment is recorded as a component of Accumulated other comprehensive loss in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange gains and losses on transactions occurring in a currency other than an operation&#8217;s functional currency are recognized as a component of Foreign exchange and other in the Consolidated Statements of Operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MTA5_e7bd812f-0d3a-422d-a0af-786891d26e75" continuedAt="ibe2a981846ee4f308c62c69eb643378a" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are primarily generated from product sales, primarily in the therapeutic areas of eye-health, gastroenterology  (&#8220;GI&#8221;) and dermatology that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 22, &#8220;SEGMENT INFORMATION&#8221; for the disaggregation of revenues which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when the customer obtains control of promised goods or services and in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services.  To achieve this core principle, the Company applies the five-step revenue model to contracts within its scope: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract with the Company&#8217;s customers exists for each product sale.  Where a contract with a customer contains more than one performance obligation, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The transaction price is adjusted for variable consideration which is discussed below.  The Company generally recognizes revenue for product sales at a point in time, when the customer obtains control of the products.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160; The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future period.</span></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="icec808a81fd64678bad0bab54b61199b" continuedAt="ie8626221cafa4dc0bd3f4cd28a99ab96"><ix:continuation id="ibe2a981846ee4f308c62c69eb643378a" continuedAt="i41d88e46b9674b3686deb32d6ce54541"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers.  Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.&#160;</span></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MTE2_a1dacf78-d3d5-4bbb-9ca8-dc56d3d9b8f9" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the activity and ending balances of the Company&#8217;s variable consideration provisions the years 2021 and 2020.</span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"></td><td style="width:28.625%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.881%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, January 1, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie888db196c4b4c7da3187745b2f5d4b8_I20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzEtMi0xLTEtOTQ4MzE_5c786abd-e7c5-4a53-b959-5136c8d4877b">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25b840b91a804c71b49368c35927a054_I20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzEtNC0xLTEtOTQ4MzE_3967f2ad-bc91-4ef6-bf69-b4e165423117">691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1c4cad2abfd4049a17a50ff205cdabc_I20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzEtNi0xLTEtOTQ4MzE_00feb8a0-483f-400b-9caf-cf7fcfd241e4">927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i775805d9c3154ad285c4fa424c1e815b_I20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzEtOC0xLTEtOTQ4MzE_f5e49573-dd4a-46b1-9dfe-4799b9dbd264">168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43f8e7fcb97b444098dc083e79b1b3cc_I20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzEtMTAtMS0xLTk0ODMx_92725c8c-36b7-4a9e-b655-37682b084d06">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzEtMTItMS0xLTk0ODMx_d2bd15ad-8ede-47d6-9d13-cd8d363e0a97">2,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5df68fab41b644118a6a79ca3701e13c_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzItMi0xLTEtOTQ4MzE_7ce48200-1e66-4342-b94f-9a2a08342d7e">621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23a4bf59c23544509ffad0bea04a9270_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzItNC0xLTEtOTQ4MzE_5ff39431-c150-4eed-b1f3-842a131b15f5">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a9ccb3dbd94a549431fe94a821e396_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzItNi0xLTEtOTQ4MzE_8097d622-11bd-4c4e-9569-3c2443d87d51">2,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4e09033a34c4a888cda3e4a5656b5bf_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzItOC0xLTEtOTQ4MzE_04da03da-15f4-4f48-a6a1-b783b9ba8c7b">1,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1941a9e694f34f33978cf055adb0230f_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzItMTAtMS0xLTk0ODMx_a2e06f53-ff15-4b92-83e2-eac1ab62cc41">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzItMTItMS0xLTk0ODMx_edf2cb45-503d-4f4f-aa1a-076065d8bb51">5,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5df68fab41b644118a6a79ca3701e13c_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzMtMi0xLTEtOTQ4MzE_58fee874-f967-481e-aafe-0977556e9324">613</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i23a4bf59c23544509ffad0bea04a9270_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzMtNC0xLTEtOTQ4MzE_54b30ad8-5988-48f2-babb-4c89bbe74a9b">236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13a9ccb3dbd94a549431fe94a821e396_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzMtNi0xLTEtOTQ4MzE_623c3715-cd48-488f-92f3-b54de627d7d0">2,322</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4e09033a34c4a888cda3e4a5656b5bf_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzMtOC0xLTEtOTQ4MzE_1c0bb306-dd1a-42af-a9cf-dd5ccf99b356">1,909</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1941a9e694f34f33978cf055adb0230f_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzMtMTAtMS0xLTk0ODMx_97f041c6-7b97-4ffe-a28e-11f4d6919aaa">193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzMtMTItMS0xLTk0ODMx_99073109-0187-4f94-ae3f-bf6b7fd2efc8">5,273</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3abe2f197384a5faf80cf8970b4f6e1_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzQtMi0xLTEtOTQ4MzE_a250845e-9ed1-479e-82b7-d4c2086a1a60">190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb7a5a9f654c44d88f30b125fda3dd93_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzQtNC0xLTEtOTQ4MzE_1de6c587-d0c2-4a6b-bfaf-87a479a330c1">575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id38abec1faf94c6a8cb3456db066aea3_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzQtNi0xLTEtOTQ4MzE_70d5594e-76b8-4c35-a0fc-0e2eb962212b">779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if02ec4ff710b412386b75c6474100d94_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzQtOC0xLTEtOTQ4MzE_27ae3fde-46ec-4b73-a160-34912eeb4b3f">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40cfa45466644cff8b8dc0f3298dfb6a_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzQtMTAtMS0xLTk0ODMx_cf435759-b49e-489b-8a4f-8a31762b97b7">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzQtMTItMS0xLTk0ODMx_a8fe9b22-5f43-4a9f-8ba8-d7d547039173">1,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fc0bea60f3d4043bab8518cf76f48fa_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzUtMi0xLTEtOTQ4MzE_6540ac12-07d8-4738-9423-1b9aa262ac45">625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if231ab941291433d88b5f479ceaaaab9_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzUtNC0xLTEtOTQ4MzE_1d61f288-5508-4505-b9a7-0e99280fe228">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i056b23d864094b3a8805bbf7eae8f62d_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzUtNi0xLTEtOTQ4MzE_cfbfeb44-43c7-4ae5-a9de-8369fd279892">2,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifac9a0ee97354de5ad0790a506ffc752_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzUtOC0xLTEtOTQ4MzE_78738bf2-12ac-4ff6-bf46-fa51cf54c57b">1,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f5af18d5ed449a39d9cf011a2c82598_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzUtMTAtMS0xLTk0ODMx_39c86854-0ad8-4e88-81d6-ee670df9990e">211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzUtMTItMS0xLTk0ODMx_4ed2af62-b427-428e-bfa9-dcc211010b81">5,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fc0bea60f3d4043bab8518cf76f48fa_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzYtMi0xLTEtOTQ4MzE_0401b0c4-0c4a-480b-be8e-43c4e5ddc878">593</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if231ab941291433d88b5f479ceaaaab9_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzYtNC0xLTEtOTQ4MzE_2b06dd70-1e3b-47ec-893c-d11791090811">224</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i056b23d864094b3a8805bbf7eae8f62d_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzYtNi0xLTEtOTQ4MzE_37abbe57-5298-40a3-9ff5-f833ac121dc3">2,297</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac9a0ee97354de5ad0790a506ffc752_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzYtOC0xLTEtOTQ4MzE_71f72481-5ce4-4a64-89c8-c41f8f6ff55f">2,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f5af18d5ed449a39d9cf011a2c82598_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzYtMTAtMS0xLTk0ODMx_6e037fd8-c6e1-43d6-86fd-a19c9e73520c">251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzYtMTItMS0xLTk0ODMx_ef363e12-8e9e-4d0c-b305-c24ebc1f118f">5,378</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i968f181cf55f432d8b88feaea1bfdebb_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzctMi0xLTEtOTQ4MzE_b2c263f2-4608-462d-a761-8f8201066906">222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i024019b8dc9d47e9a40e0391dd2811f6_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzctNC0xLTEtOTQ4MzE_6c1c68a7-982d-451a-8948-87b96bab1810">482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic252586b20d24ab2b1f4c1e7d2d0216a_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzctNi0xLTEtOTQ4MzE_3c185cc1-9d86-4b68-9755-42206c3415fb">944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c7461bce0f4ce88d5a315b0d9016b4_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzctOC0xLTEtOTQ4MzE_c6f23863-ed17-42d1-ac3e-bc305be7a8d7">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77cd717b81fc4051b53b2ba09fbc08d7_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzctMTAtMS0xLTk0ODMx_68a4a4d5-d50f-4584-9b32-f3bacfa62926">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzctMTItMS0xLTk0ODMx_25557c24-3793-4bf4-9fc8-e05e7a6530f9">1,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $<ix:nonFraction unitRef="usd" contextRef="i3217dc4fc80f4a868a33e3af520f1ca4_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzI2OTQ3_6ec96215-e446-4398-a840-028c6748a916">36</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3bc559ab6ace4d47880bb10942e52a2d_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzI2OTU0_88372f14-c092-4f9c-aee6-56e7ec25b360">32</ix:nonFraction> million as of December 31, 2021 and 2020, respectively, which are reflected as a reduction of Trade accounts receivable, net in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company's products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis.  This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#8217;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period.  The Company applies this method consistently for contracts with similar characteristics.  The following describes the major sources of variable consideration in the Company&#8217;s customer arrangements and the methodology, estimates and judgments applied to estimate each type of variable consideration.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Discounts and Allowances</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash discounts are offered for prompt payment and allowances for volume purchases. Provisions for cash discounts and allowances are estimated at the time of sale and recorded as direct reductions to trade receivables and revenue. Management estimates the provisions for cash discounts and allowances based on contractual sales terms with customers, an analysis of unpaid invoices and historical payment experience. Estimated cash discounts and allowances have historically been predictable and less subjective, due to the limited number of assumptions involved, the consistency of historical experience and the fact that these amounts are generally settled within <ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="bhc:CashDiscountsAndAllowancesSettlementPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzI5NDUz_5aaeb0f6-1544-485b-ba4f-280f6082433d">one month</ix:nonNumeric> of incurring the&#160;liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Returns</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, customers are generally allowed to return a product within a specified period of time before and after its expiration date, excluding European businesses which generally do not provide a right of return. The returns provision is estimated utilizing historical sales and return rates over the period during which customers have a right of return, taking into account available information on competitive products and contract changes. The information utilized to estimate the returns provision includes: (i) historical return and exchange levels, (ii) external data with respect to inventory levels in the wholesale distribution channel, (iii) external data with respect to prescription demand for products, (iv) remaining shelf lives of products at the date of sale and (v) estimated returns liability to be processed by year of sale based on an analysis of lot information related to actual historical returns.</span></div></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ie8626221cafa4dc0bd3f4cd28a99ab96" continuedAt="i9046cdac12cb422895d5961d9f2e1f82"><ix:continuation id="i41d88e46b9674b3686deb32d6ce54541" continuedAt="i53b6dd54db494de084ca0defaa7911fc"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the estimate for returns, management is required to make certain assumptions regarding the timing of the introduction of new products and the potential of these products to capture market share. In addition, certain assumptions with respect to the extent and pattern of decline associated with generic competition are necessary. These assumptions are formulated using market data for similar products, past experience and other available information.  These assumptions are continually reassessed, and changes to the estimates and assumptions are made as new information becomes available. A change of 1% in the estimated return rates would have impacted the Company&#8217;s pre-tax earnings by approximately $<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="bhc:SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzMxMTU3_c2fd3023-c3b5-4bfe-9728-6e942b82a609">81</ix:nonFraction> million for the year 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimate for returns may be impacted by a number of factors, but the principal factor relates to the inventory levels in the distribution channel. When management becomes aware of an increase in such inventory levels, it considers whether the increase may be temporary or other-than-temporary. Temporary increases in wholesaler inventory levels will not warrant revision to the provision for returns. Other-than-temporary increases in wholesaler inventory levels, however, may be an indication that future product returns could be higher than originally anticipated, and, as a result, estimates for returns may need to be adjusted. Factors that suggest increases in wholesaler inventory levels are temporary include: (i) recently implemented or announced price increases for certain products, (ii) new product launches or expanded indications for existing products and (iii) timing of purchases by wholesale customers. Conversely, factors that suggest increases in wholesaler inventory levels are other-than-temporary include: (i) declining sales trends based on prescription demand, (ii) introduction of new products or generic competition, (iii) increasing price competition from generic competitors and (iv) changes to the U.S.&#160;National Drug Codes (&#8220;NDC&#8221;) of products.  Changes in the NDC of products could result in a period of higher returns related to products with the old NDC, as U.S.&#160;customers generally permit only one NDC per product for identification and tracking within their inventory systems.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the last several years, the Company increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving sales return experience, primarily related to branded and generic products. Sales return provisions for 2021 and 2020 were $<ix:nonFraction unitRef="usd" contextRef="if231ab941291433d88b5f479ceaaaab9_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzMzMTc3_ff86c284-4864-43d9-8b53-ffe80fbbd634">131</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i23a4bf59c23544509ffad0bea04a9270_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzMzMTg0_14f8cd77-6717-4c37-bb2c-c1b6c1f7853d">120</ix:nonFraction>&#160;million, respectively, and includes reductions in variable consideration for sales return provisions related to past sales of approximately $<ix:nonFraction unitRef="usd" contextRef="if231ab941291433d88b5f479ceaaaab9_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzMzMzE5_91ec4653-9106-4088-b234-81c2b6d9a3c9">28</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i23a4bf59c23544509ffad0bea04a9270_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzMzMzI2_a4a30269-529e-4f51-a896-f4d9d5051b02">38</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates and Chargebacks</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales made under governmental and managed-care pricing programs in the U.S. are subject to rebates.&#160; The Company participates in state government-managed Medicaid programs, as well as certain other qualifying federal and state government programs whereby rebates are provided to participating government entities. Medicaid rebates are generally billed 45 days to 270&#160;days after the quarter in which the product is dispensed to the Medicaid participant.  As a result, the Medicaid rebate reserve includes an estimate of outstanding claims for end-customer sales that occurred, but for which the related claim has not been billed and/or paid, and an estimate for future claims that will be made when inventory in the distribution channel is sold through to plan participants. The calculation of the Medicaid rebate reserve also requires other estimates, such as estimates of sales mix, to determine which sales are subject to rebates and the amount of such rebates. A change of 1% in the estimated rates used in the Medicaid rebate reserve would have impacted the Company&#8217;s pre-tax earnings by approximately $<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="bhc:SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzM0NDgy_fef165e2-fba3-41d3-a981-768b3efa8c91">76</ix:nonFraction> million for 2021. Quarterly, the Medicaid rebate reserve is adjusted based on actual claims paid. Due to the delay in billing, adjustments to actual claims paid may incorporate revisions of that reserve for several periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed Care rebates relate to contractual agreements to sell products to managed care organizations and pharmacy benefit managers at contractual rebate percentages in exchange for volume and/or market&#160;share.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks relate to contractual agreements to sell products to government agencies, group purchasing organizations and other indirect customers at contractual prices that are lower than the list prices the Company charges wholesalers. When these group purchasing organizations or other indirect customers purchase products through wholesalers at these reduced prices, the wholesaler charges the Company for the difference between the prices they paid the Company and the prices at which they sold the products to the indirect customers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In estimating provisions for rebates and chargebacks, management considers relevant statutes with respect to governmental pricing programs and contractual sales terms with managed-care providers and group purchasing organizations. Management estimates the amount of product sales subject to these programs based on historical utilization levels. Changes in the level of utilization of products through private or public benefit plans and group purchasing organizations will affect the amount of rebates and chargebacks that the Company is obligated to pay. Management continually updates these factors based on new contractual or statutory requirements, and any significant changes in sales trends that may impact the percentage of products subject to rebates or&#160;chargebacks.</span></div></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i9046cdac12cb422895d5961d9f2e1f82" continuedAt="i5fb9dd3fcfe64c0ca920c10711acaf8f"><ix:continuation id="i53b6dd54db494de084ca0defaa7911fc" continuedAt="i4e31b3e164d3488b9a9a10c5a2f250ef"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of Managed Care, Medicaid and other rebates and chargebacks has become more significant as a result of a combination of deeper discounts implemented in each of the last three years, changes in the Company&#8217;s product portfolio due to recent acquisitions and increased Medicaid utilization due to expansion of government funding for these programs.&#160;Management&#8217;s estimate for rebates and chargebacks may be impacted by a number of factors, but the principal factor relates to the level of inventory in the distribution channel.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebate provisions are based on factors such as timing and terms of plans under contract, time to process rebates, product pricing, sales volumes, amount of inventory in the distribution channel and prescription trends. Adjustments to actual for the years 2021 and 2020 were not material to the Company&#8217;s revenues or earnings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient Co-Pay Assistance programs, Consumer Rebates and Loyalty Programs are rebates offered on many of the Company&#8217;s products.  Patient Co-Pay Assistance Programs are patient discount programs offered in the form of coupon cards or point of sale discounts, with which patients receive certain discounts off their prescription at participating pharmacies, as defined by the specific product program. An accrual for these programs is established, equal to management&#8217;s estimate of the discount, rebate and loyalty incentives attributable to a sale.  That estimate is based on historical experience and other relevant factors. The accrual is adjusted throughout each quarter based on actual experience and changes in other factors, if any.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution Fees</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells products primarily to wholesalers, and in some instances to large pharmacy chains such as CVS and Walmart.  The Company has Distribution Services Agreements  (&#8220;DSAs&#8221;) with several large wholesale customers such as McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Specialty.  Under the DSAs, the wholesalers agree to provide services, and the Company pays the contracted DSA distribution service fees for these services based on product volumes.  Additionally, price appreciation credits are generated when the Company increases a product&#8217;s wholesaler acquisition cost (&#8220;WAC&#8221;) under contracts with certain wholesalers. Under such contracts, the Company is entitled to credits from such wholesalers for the impact of that WAC increase on inventory currently on hand at the wholesalers. Such credits are offset against the total distribution service fees paid to each such wholesaler. The variable consideration associated with price appreciation credits is reflected in the transaction price of products sold when it is determined to be probable that a significant reversal will not occur. Included as a reduction of current period provisions for Distribution Fees in the table above are price appreciation credits of $<ix:nonFraction unitRef="usd" contextRef="if642d30e99ba413e98c7c9fa16c98d58_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzM5MTA5_fbe55789-9ffa-4731-99f1-43f893356dce">17</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie8f30533812f49bdb16ff48c59ebaf7a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzM5MTE2_a7d18a1b-c00e-4330-b1b4-252b88059645">15</ix:nonFraction> million for the years 2021 and 2020, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Assets and Contract Liabilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Commissions </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales commissions are generally attributed to periods shorter than one year and therefore are expensed when incurred. Sales commissions are included in selling, general and administrative expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Component</span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4e31b3e164d3488b9a9a10c5a2f250ef">The Company has elected not to adjust consideration for the effects of a significant financing component when the period between the transfer of a promised good or service to the customer and when the customer pays for that good or service will be one year or less.</ix:continuation> The Company's global payment terms are generally between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzM5OTI3_716494a0-facf-44b6-8b49-d8fd0a7992d6">thirty</span> to <ix:nonNumeric contextRef="idb0e80397f6a447584308760a43131cd_D20210101-20211231" name="bhc:RevenuePerformanceObligationPaymentTerms" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzM5OTMz_ad7a052c-4da5-45d6-8d51-f5e3cb7bb8b6">ninety days</ix:nonNumeric>.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain facilities, vehicles and equipment principally under multi-year agreements generally having a lease term of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzQwMDc5_7eac39f6-be77-4d3e-9e6c-f409097e05ab">one</span> to <ix:nonNumeric contextRef="i65c560b8d709448ebce15c3e5d971fa8_I20211231" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzQwMDg1_b8999fa2-df7c-4948-8c34-790db0719683">twenty years</ix:nonNumeric>, some of which include termination options and options to extend the lease term from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzQwMTcz_d3eef5e1-5571-4a30-b1f7-7d9902542a6b">one</span> to <ix:nonNumeric contextRef="i65c560b8d709448ebce15c3e5d971fa8_I20211231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzQwMTc5_235c9143-3320-4700-9bdc-56da414a78ce">five years</ix:nonNumeric> or on a month-to-month basis. The Company includes options that are reasonably certain to be exercised as part of the lease term. The Company may negotiate termination clauses in anticipation of changes in market conditions but generally, these termination options are not exercised. Certain lease agreements also include variable payments that are dependent on usage or may vary month-to-month such as insurance, taxes and maintenance costs. None of the Company's lease agreements contain material residual value guarantees or material restrictive covenants.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to record a right-of-use asset and corresponding lease liability, equal to the present value of the lease payments at the commencement date of each lease. For all asset classes, in determining future lease payments, the Company has elected to aggregate lease components, such as payments for rent, taxes and insurance costs with non-lease components such as maintenance costs, and account for these payments as a single lease component. In limited </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i5fb9dd3fcfe64c0ca920c10711acaf8f" continuedAt="if70d132991c2406481e259dec010a7d4"><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">circumstances, when the information necessary to determine the rate implicit in a lease is available, the present value of the lease payments is determined using the rate implicit in that lease. If the information necessary to determine the rate implicit in a lease is not available, the Company uses its incremental borrowing rate at the commencement of the lease, which represents the rate of interest that the Company would incur to borrow on a collateralized basis over a similar term.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All leases must be classified as either an operating lease or finance lease. The classification is determined based on whether substantive control has been transferred to the lessee.  The classification governs the pattern of lease expense recognition. For leases classified as operating leases, total lease expense over the term of the lease is equal to the undiscounted payments due in accordance with the lease arrangement. Fixed lease expense is recognized periodically on a straight-line basis over the term of each lease and includes: (i) imputed interest during the period on the lease liability determined using the effective interest rate method plus (ii) amortization of the right-of-use asset for that period. Amortization of the right-of-use asset during the period is calculated as the difference between the straight-line expense and the imputed interest on the lease liability for that period. Variable lease expense is recognized when the achievement of the specific target is considered probable.</span></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MDU0_2b515cc6-0b75-4626-a267-6080d6916111" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to internal research and development programs, including costs associated with the development of acquired IPR&amp;D, are expensed as goods are delivered or services are performed. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Milestone payments made to third parties before a product receives regulatory approval, but after the milestone is determined to be probable, are expensed and included in Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from third parties as reimbursement of development activities conducted under certain research and development arrangements are recognized as a reduction of Research and development expenses.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:LegalCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MTU0_aadb3aef-e3df-4087-8ba1-4526f194e8af" continuedAt="ib370171a90b5446c8386d7771ea6f7ff" escape="true">Legal Costs </ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib370171a90b5446c8386d7771ea6f7ff">Legal fees and other costs related to litigation and other legal proceedings or services are expensed as incurred and are included in Selling, general and administrative expenses. Certain legal costs associated with acquisitions are included in Acquisition-related costs and certain legal costs associated with divestitures, legal settlements and other business development activities are included in Litigation and other matters or Net gain on sales of assets within Other expense (income), net, as appropriate. Legal costs expensed are reported net of expected insurance recoveries. A claim for insurance recovery is recognized when realization becomes probable</ix:continuation>.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MDU2_911f0789-e23e-4937-a007-82e80ff716e5" continuedAt="i92389a62b35d4f5789937d1a411ed994" escape="true">Advertising Costs</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i92389a62b35d4f5789937d1a411ed994">Advertising costs comprise product samples, print media, promotional materials and television advertising and are expensed on the first use of the advertisement.</ix:continuation> Included in Selling, general and administrative expenses are advertising costs of $<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzQ0NjU3_cd4f8a9a-91be-4a71-8bcf-75a5328036cd">515</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzQ0NjYx_7a86cd8c-c696-4dcc-a3b2-9d672e002481">451</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzQ0NjY4_94da8b62-5926-4324-978f-2bbaeffdee4a">544</ix:nonFraction> million, for 2021, 2020 and 2019, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MTY4_bd1debf3-825c-4835-9d33-8fd913163ee0" continuedAt="i63d598741e234199adddc584be4272bf" escape="true">Share-Based Compensation </ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i63d598741e234199adddc584be4272bf">The Company recognizes all share-based payments to employees, including grants of employee stock options and restricted share units (&#8220;RSUs&#8221;), at estimated fair value. The Company amortizes the fair value of stock option or RSU grants on a straight-line basis over the requisite service period of the individual stock option or RSU grant, which generally equals the vesting period. Stock option and RSU forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Share-based compensation is recorded in Research and development expenses and Selling, general and administrative expenses, as&#160;appropriate.</ix:continuation> </span></div><ix:continuation id="i738ad707e1d6426d9f06270d3121d3e9"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition-Related Contingent Consideration </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related contingent consideration, which primarily consists of potential milestone payments and royalty obligations, is recorded in the Consolidated Balance Sheets at its acquisition date estimated fair value, in accordance with the acquisition method of accounting. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the Consolidated Statements of Operations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level&#160;3 measurement as defined in fair value measurement accounting.</span></div></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="if70d132991c2406481e259dec010a7d4" continuedAt="i598d3ed2de3948a4922694ea8bd26246"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:InterestExpensePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MDU4_a37ea6ad-4b20-4af1-95ea-c63bb8f49cc7" continuedAt="i1cca6b5194b64536b8348e8f186ce898" escape="true">Interest Expense </ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1cca6b5194b64536b8348e8f186ce898">Interest expense includes standby fees, the amortization of debt discounts and deferred financing costs, accretion of debt premiums and the amortization of amounts excluded from the assessment of effectiveness related to the Company's cross-currency swaps. Interest costs are expensed as incurred, except to the extent such interest is related to construction in progress, in which case interest is capitalized.</ix:continuation> Capitalized interest related to construction in progress as of December 31, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzQ2NTky_9cf42469-bf3c-430f-a4d9-cadd6357bfa0">60</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzQ2NTk5_38e91051-7ea5-4583-b1bc-502f31a87d17">45</ix:nonFraction>&#160;million, respectively, and is included in Property, plant and equipment, net. </span></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MTAx_2d9b2d45-da87-4292-9713-f6868ad4a832" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the temporary differences between the financial statement and income tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. A valuation allowance is provided for the portion of deferred tax assets that is more likely than not to remain unrealized. Deferred tax assets and liabilities are measured using enacted tax rates and&#160;laws.  Deferred tax assets for outside basis differences in investments in subsidiaries are only recognized if the difference will be realized in the foreseeable future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax benefit from an uncertain tax position is recognized only if it is more likely than not that the tax position will be sustained upon examination by the appropriate taxing authority, based on the technical merits of the position. The tax benefits recognized from such position are measured based on the amount for which there is a greater than <ix:nonFraction unitRef="number" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="INF" name="bhc:TaxBenefitRecognitionMeasurementPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzQ3Njgz_9d99d056-c0b6-4fc7-971e-ce08bbc8f0a2">50</ix:nonFraction>% likelihood of being realized upon settlement. Liabilities associated with uncertain tax positions are classified as long-term unless expected to be paid within <ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="bhc:MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzQ3ODQ2_aeb9eaf1-ab30-47ea-88d0-b0fdc592dd02">one year</ix:nonNumeric>. Interest and penalties related to uncertain tax positions, if any, are recorded in the provision for income taxes and classified with the related liability on the consolidated balance&#160;sheets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MjQ1_84785da1-40bc-40b6-9c76-2a463549454b" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Per Share Attributable to Bausch Health Companies Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period. Diluted loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period after giving effect to dilutive potential common shares for stock options and RSUs, determined using the treasury stock&#160;method.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MTk0_bd8d1e2e-f9f5-43ad-a602-d6faed618828" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss comprises Net loss and Other comprehensive (loss) income. Other comprehensive (loss) income includes items such as foreign currency translation adjustments, unrealized holding gains and losses on available-for-sale and other investments and certain pension and other postretirement benefit plan adjustments. Accumulated other comprehensive loss is recorded as a component of shareholders&#8217; equity.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MjQ2_e6880480-4aa4-457b-9996-45934ee825c9" continuedAt="i9fda5f2dfe8b4820bc03732cc4309691" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is subject to loss contingencies, such as claims and assessments arising from litigation and other legal proceedings, contractual indemnities, product and environmental liabilities and tax matters. Accruals for loss contingencies are recorded when the Company determines that it is both probable that a liability has been incurred and the amount of loss can be reasonably estimated. If the estimate of the amount of the loss is a range and some amount within the range appears to be a better estimate than any other amount within the range, that amount is accrued as a liability. If no amount within the range is a better estimate than any other amount, the minimum amount of the range is accrued as a&#160;liability. These accruals are adjusted periodically as assessments change or additional information becomes available.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9fda5f2dfe8b4820bc03732cc4309691">If no accrual is made for a loss contingency because the amount of loss cannot be reasonably estimated, the Company will disclose contingent liabilities when there is at least a reasonable possibility that a loss or an additional loss may have been incurred.</ix:continuation> </span></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:PensionAndOtherPostretirementPlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MjU3_ca6564d4-0c86-4b1b-bc24-ef0702964d02" continuedAt="i9376e890e9ce4e43bbfcae7707179350" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Benefit Plans </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors various retirement and pension plans, including defined benefit pension plans, defined contribution plans and a participatory defined benefit postretirement plan. The determination of defined benefit pension and postretirement plan obligations and their associated expenses requires the use of actuarial valuations to estimate the benefits employees earn while working, as well as the present value of those benefits. Net actuarial gains and losses that exceed <ix:nonFraction unitRef="number" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="INF" name="bhc:DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzUwNTY0_08eea9a7-632b-4045-a32a-137553d3cb14">10</ix:nonFraction> percent of the greater of the plan&#8217;s projected benefit obligations or the market-related value of assets are amortized to earnings over the shorter of the estimated average future service period of the plan participants (or the </span></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i598d3ed2de3948a4922694ea8bd26246"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9376e890e9ce4e43bbfcae7707179350">estimated average future lifetime of the plan participants if the majority of plan participants are inactive) or the period until any anticipated final plan settlements.</ix:continuation> </span></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MDU5_1701634e-5268-49bb-8714-d655961cb133" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New&#160;Accounting Standards</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board  (&#8220;FASB&#8221;) issued guidance on the impairment of financial instruments requiring an impairment model based on expected losses rather than incurred losses. Under this guidance, an entity recognizes as an allowance its estimate of expected credit losses.  The guidance was effective for the Company beginning January 1, 2020 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit, which resulted in an increase to Accumulated deficit of less than $<ix:nonFraction unitRef="usd" contextRef="i2f5bb32797ed4025b477232d70d05dd7_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzUxNTU1_8249bafe-5c63-4cbb-b558-f5a6c95603ef">1</ix:nonFraction>&#160;million. The application of this guidance did not have a material effect on the Company's results of operations and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued guidance modifying the disclosure requirements for fair value measurement.  The guidance was effective for the Company beginning January 1, 2020. The application of this guidance did not have a material effect on the Company's disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued guidance modifying the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans.  The guidance was effective for annual periods ending after December 15, 2020. The application of this guidance did not have a material effect on the Company's disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.&#160; The guidance is effective for the Company beginning with annual periods beginning January 1, 2021.&#160; The application of this guidance did not have a material effect on the Company's financial position, results of operations and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued guidance providing optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform.&#160; Optional expedients are provided for contract modification accounting within the areas of receivables, debt, leases, derivatives and hedging.&#160;The optional amendments are effective for all entities as of March 12, 2020, through December 31, 2022. During 2020 and 2021, the Company has not entered into any contract modifications in which the optional expedients were applied.&#160; However, if prior to December 31, 2022, the Company enters into a contract modification in which the optional expedients are applied, the Company will evaluate the impact of adoption of this guidance on its financial position, results of operations and cash flows.</span></div></ix:nonNumeric></ix:continuation><div id="i8256f225f07d49409c31f7443adffdbf_319"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzY2Mjg_63f901e2-d0b6-4adb-8e5a-32feef185c2d" continuedAt="ic73095be9d75497186f5a04b99b9a82e" escape="true">ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE</ix:nonNumeric></span></div><ix:continuation id="ic73095be9d75497186f5a04b99b9a82e" continuedAt="i60531994e59f40dead0ac76882fe4151"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition Agreement for Synergy Pharmaceuticals Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 6, 2019, the Company acquired certain assets of Synergy Pharmaceuticals Inc.  (&#8220;Synergy&#8221;) for a cash purchase price of approximately $<ix:nonFraction unitRef="usd" contextRef="ib7ab09da936244e1bea7e8bf2554b541_D20190306-20190306" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzIwNQ_2885afff-24ab-4480-afbc-f087079593ed">180</ix:nonFraction> million and the assumption of certain liabilities, pursuant to the terms approved by the U.S. Bankruptcy Court for the Southern District of New York on March 1, 2019. Among the assets acquired are the worldwide rights to the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) product, a once-daily tablet for adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. This acquired business is included in the Company's Salix segment and is expected to result in additional revenues and costs savings associated with business synergies.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of certain assets of Synergy has been accounted for as a business combination under the acquisition method of accounting since: (i) substantially all of the fair value of the assets acquired is not&#160;concentrated in a single identifiable asset or group of similar identifiable assets and (ii) substantive inputs and processes were acquired to contribute to the creation of outputs. <ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzY1NDQ_5b321517-be35-4901-8faf-8f3b4cbca08b" continuedAt="ie8c7bf5df6294157b3373ccbc0bf343d" escape="true">The following table summarizes the estimated fair values of the assets acquired and liabilities assumed related to the acquisition of certain assets of Synergy as of the acquisition date:</ix:nonNumeric></span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i60531994e59f40dead0ac76882fe4151" continuedAt="ibef48f7b9b654f33a65b40ec86062a6a"><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><ix:continuation id="ie8c7bf5df6294157b3373ccbc0bf343d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:89.795%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.005%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3228597eb86549919c150d017affe6c9_I20190306" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTo3NzE1ZGFjM2YwYmM0OWRiYmIzYzliYWRlMzEzNTFkMi90YWJsZXJhbmdlOjc3MTVkYWMzZjBiYzQ5ZGJiYjNjOWJhZGUzMTM1MWQyXzEtMS0xLTEtOTQ4MzE_6c539db0-3a05-412b-9b78-20505dff46a1">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3228597eb86549919c150d017affe6c9_I20190306" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTo3NzE1ZGFjM2YwYmM0OWRiYmIzYzliYWRlMzEzNTFkMi90YWJsZXJhbmdlOjc3MTVkYWMzZjBiYzQ5ZGJiYjNjOWJhZGUzMTM1MWQyXzItMS0xLTEtOTQ4MzE_a24e407a-9997-4149-abfb-93685f4dc496">24</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3228597eb86549919c150d017affe6c9_I20190306" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTo3NzE1ZGFjM2YwYmM0OWRiYmIzYzliYWRlMzEzNTFkMi90YWJsZXJhbmdlOjc3MTVkYWMzZjBiYzQ5ZGJiYjNjOWJhZGUzMTM1MWQyXzMtMS0xLTEtOTQ4MzE_226b1ab4-bcb3-4699-ac71-9a14d5ef8dc8">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product brand intangible assets (estimated useful life <ix:nonNumeric contextRef="ib7ab09da936244e1bea7e8bf2554b541_D20190306-20190306" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTo3NzE1ZGFjM2YwYmM0OWRiYmIzYzliYWRlMzEzNTFkMi90YWJsZXJhbmdlOjc3MTVkYWMzZjBiYzQ5ZGJiYjNjOWJhZGUzMTM1MWQyXzQtMC0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo2ODI4ODkwNDgzMWU0YTQ4OGQxODI3MDc1YzMzZmM1OF81OQ_cbb274d1-fba9-4f5f-a37a-c73061ed4580">7</ix:nonNumeric> years)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3228597eb86549919c150d017affe6c9_I20190306" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTo3NzE1ZGFjM2YwYmM0OWRiYmIzYzliYWRlMzEzNTFkMi90YWJsZXJhbmdlOjc3MTVkYWMzZjBiYzQ5ZGJiYjNjOWJhZGUzMTM1MWQyXzQtMS0xLTEtOTQ4MzE_b1e58c28-eda3-4c5b-a049-f86d99d4a91f">159</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3228597eb86549919c150d017affe6c9_I20190306" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTo3NzE1ZGFjM2YwYmM0OWRiYmIzYzliYWRlMzEzNTFkMi90YWJsZXJhbmdlOjc3MTVkYWMzZjBiYzQ5ZGJiYjNjOWJhZGUzMTM1MWQyXzUtMS0xLTEtOTQ4MzE_c2e228fd-847c-4e16-b7c5-22a631b63774">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3228597eb86549919c150d017affe6c9_I20190306" decimals="-6" name="bhc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTo3NzE1ZGFjM2YwYmM0OWRiYmIzYzliYWRlMzEzNTFkMi90YWJsZXJhbmdlOjc3MTVkYWMzZjBiYzQ5ZGJiYjNjOWJhZGUzMTM1MWQyXzYtMS0xLTEtOTQ4MzE_1f413b5e-01ec-4b5b-a53d-046c5e2e4123">17</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3228597eb86549919c150d017affe6c9_I20190306" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTo3NzE1ZGFjM2YwYmM0OWRiYmIzYzliYWRlMzEzNTFkMi90YWJsZXJhbmdlOjc3MTVkYWMzZjBiYzQ5ZGJiYjNjOWJhZGUzMTM1MWQyXzctMS0xLTEtOTQ4MzE_5ee43fd6-63f5-4036-99be-cffbe0f9ca24">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3228597eb86549919c150d017affe6c9_I20190306" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTo3NzE1ZGFjM2YwYmM0OWRiYmIzYzliYWRlMzEzNTFkMi90YWJsZXJhbmdlOjc3MTVkYWMzZjBiYzQ5ZGJiYjNjOWJhZGUzMTM1MWQyXzgtMS0xLTEtOTQ4MzE_b8406942-fed1-438d-9939-65f2a4141a5e">3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of consideration transferred</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3228597eb86549919c150d017affe6c9_I20190306" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTo3NzE1ZGFjM2YwYmM0OWRiYmIzYzliYWRlMzEzNTFkMi90YWJsZXJhbmdlOjc3MTVkYWMzZjBiYzQ5ZGJiYjNjOWJhZGUzMTM1MWQyXzktMS0xLTEtOTQ4MzE_654119a4-49ed-4f45-9d60-c29cb070e5b4">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill associated with the acquisition of certain assets of Synergy is not deductible for income tax purposes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue and Operating Results </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues associated with the acquired assets of Synergy during the period March 6, 2019 through December 31, 2019 were $<ix:nonFraction unitRef="usd" contextRef="ieaf743deafab4bc2bccd438cce5fc248_D20190306-20191231" decimals="-6" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzE2MzI_d0cba8d6-e315-45bc-8083-2b0136c95c54">55</ix:nonFraction> million. Operating results associated with the acquired assets of Synergy during the period March 6, 2019 through December 31, 2019 and pro-forma revenues and operating results for the year 2019 were <ix:nonFraction unitRef="usd" contextRef="ifaffb0ddf4f849c6b6a4167f5b18f584_D20190101-20191231" decimals="-6" name="bhc:BusinessAcquisitionProFormaOperatingIncomeLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzE4Mjc_597eb2f8-299f-4e30-9586-cae6c2c18869"><ix:nonFraction unitRef="usd" contextRef="ieaf743deafab4bc2bccd438cce5fc248_D20190306-20191231" decimals="-6" name="bhc:BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzE4Mjc_5a0288a8-5d0e-46a3-96f1-6f650ba18503"><ix:nonFraction unitRef="usd" contextRef="ifaffb0ddf4f849c6b6a4167f5b18f584_D20190101-20191231" decimals="-6" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzE4Mjc_e7a30ac1-1382-4bbf-9b22-fccdad3db981">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t material. Included in Other expense, net for 2019 are acquisition-related costs of $<ix:nonFraction unitRef="usd" contextRef="ifaffb0ddf4f849c6b6a4167f5b18f584_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzE4OTg_84d27ff6-64be-47db-b29c-5af033fd6b1a">8</ix:nonFraction> million directly related to the acquisition of certain assets of Synergy, which include expenditures for advisory, legal, valuation, accounting and other similar services.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="businesscombination" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="INF" name="bhc:NumberOfOtherBusinessesAcquired" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzIwNzY_4620f66a-30fa-4c71-b76b-b21c1758a579"><ix:nonFraction unitRef="businesscombination" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="INF" name="bhc:NumberOfOtherBusinessesAcquired" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzIwNzY_b86ce378-ec30-418e-a69c-266151bd20db"><ix:nonFraction unitRef="businesscombination" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="INF" name="bhc:NumberOfOtherBusinessesAcquired" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzIwNzY_df225f65-44aa-4a4e-99f8-79f53b83ea4c">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> other material business combinations in 2021, 2020 or 2019. The measurement period for all acquisitions has closed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Option to Purchase All Ophthalmology Assets of Allegro Ophthalmics, LLC  (&#8220;Allegro&#8221;)</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 21, 2020, the Company announced that it had entered into an agreement to acquire an option to purchase all of the ophthalmology assets of Allegro (the &#8220;Option&#8221;), a privately held biopharmaceutical company focused on the development of therapies that regulate integrin functions for the treatment of ocular diseases. Among the assets to be acquired if the Option was exercised, were the worldwide rights to risuteganib (Luminate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), Allegro's lead investigational compound in retina, which is believed to simultaneously act on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases such as intermediate dry Age-related Macular Degeneration.  During the three months ended September 30, 2020, the Company made and expensed as acquired IPR&amp;D included in Other expense, net, an initial upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ic9f191dca8cb406ead6fbd0a27981bb3_D20200701-20200930" decimals="-6" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzMxMTA_5278152f-8ebc-48ca-92a2-ab37f1addfcc">10</ix:nonFraction>&#160;million to acquire the Option.  However, on June 23, 2021, Allegro notified the Company that it did not raise the additional funding required under the option agreement.  Pursuant to the terms of the option agreement, the Option thereby terminated, and the Company exercised its right to convert the $<ix:nonFraction unitRef="usd" contextRef="ie23b3d96ce1248c98d46a1440bd6d937_D20210623-20210623" decimals="-6" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzM0MDU_5fb308a7-835f-4687-a488-b08d317d129d">10</ix:nonFraction>&#160;million upfront payment into a minor equity interest in Allegro.  The Company expects that it will make <ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="INF" name="bhc:AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzM1MDQ_6e5ef7c1-7a74-4d27-8cd6-08e9123b3c77">no</ix:nonFraction> additional payments pursuant to this option agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products. These products are sometimes investigational treatments in early stage development that target unique conditions.  The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by regulatory agencies, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain.  The commitment periods under these agreements vary and include customary termination provisions.  Expenses arising from commitments, if any, to fund the development and testing of these products and their promotion are recognized as incurred. Royalties due are recognized when earned and milestone payments are accrued when each milestone has been achieved and payment is probable and can be reasonably estimated.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestiture of Amoun Pharmaceutical Company S.A.E.  (&#8220;Amoun&#8221;)</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, the Company announced that it and certain of its affiliates had entered into a definitive agreement to sell all of its equity interests in Amoun for total gross consideration of approximately $<ix:nonFraction unitRef="usd" contextRef="id741d32018d54352affe7795fbf6464e_D20210726-20210726" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzQ3NzE_01e91e70-eeac-4920-a93e-78315530b053">740</ix:nonFraction>&#160;million (including the assignment to the purchasing entity of an intercompany loan granted by the Company to Amoun), subject to certain adjustments (the &#8220;Amoun Sale&#8221;). The Amoun Sale closed on July 26, 2021. As part of the Amoun Sale, cash generated by Amoun during the period from the locked-box date of January 1, 2021 through closing was for the benefit of the purchasing entity, subject to working capital during such period. Amoun manufactures, markets and distributes branded generics of human and animal health products. The Amoun business was part of the International segment (previously </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ibef48f7b9b654f33a65b40ec86062a6a"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included within the former Bausch + Lomb/International segment) and was reclassified as held for sale as of December 31, 2020. As a result of meeting the criteria for held for sale classification, the carrying value of the Amoun business, was adjusted to its estimated fair value, less costs to sell, and the Company recognized an impairment loss of $<ix:nonFraction unitRef="usd" contextRef="i6e7cb1daba9744fc8e55c867cd1d063f_D20201001-20201231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzU3MTY_c5a3b5fd-89ad-417e-8f90-a62b74f5e0ef">96</ix:nonFraction>&#160;million during the three months ended December 31, 2020 and an additional impairment loss of $<ix:nonFraction unitRef="usd" contextRef="id21d49c675e3425b871866e8870406fc_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzU4MDQ_7cd8b091-3984-4958-b4ed-8eaac1e1552e">88</ix:nonFraction>&#160;million during 2021, included within Asset impairments, including loss on assets held for sale in the Consolidated Statements of Operations. In connection with completing the Amoun Sale, the Company recognized an additional loss of $<ix:nonFraction unitRef="usd" contextRef="i5b13ca98db8c463aaeed70c3abe4f348_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzYwMzE_07dda7ad-5be2-4a11-b368-eb52503b9c6e">26</ix:nonFraction>&#160;million during 2021, included within Other (income) expense, net in the Combined Statements of Operations. The total loss of $<ix:nonFraction unitRef="usd" contextRef="id64abf2e66454ecb8393494a9d2a34a1_D20200101-20211231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzYxNTE_7928140c-5466-42b3-bb6c-1bdde88dfcfd">210</ix:nonFraction>&#160;million includes the release of non-cash cumulative foreign currency translation losses of $<ix:nonFraction unitRef="usd" contextRef="id64abf2e66454ecb8393494a9d2a34a1_D20200101-20211231" decimals="-6" name="bhc:NoncashCumulativeForeignCurrencyTranslationLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzYyMzc_d1f4a03f-0ef1-4aec-97eb-2d8d36b59b8b">340</ix:nonFraction>&#160;million, which were included as part of the carrying value of the Amoun business when measuring for impairment.</span></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzY1MzY_ee89df11-4628-4c3a-b8f4-5e3814254f89" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the Consolidated Balance Sheets as of December 31, 2020 are the following carrying amounts of the Amoun business' assets and liabilities held for sale.</span></div><div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:38.353%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.004%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.353%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.009%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9dae4cbf28945e690c15be6b4c2db5e_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTphNTlhNjU4ZTlhZWM0MTk5OWFlNWYyNGRkZGE1YWI2NC90YWJsZXJhbmdlOmE1OWE2NThlOWFlYzQxOTk5YWU1ZjI0ZGRkYTVhYjY0XzItMi0xLTEtOTQ4MzE_e88c6ffe-acdc-41fe-a0df-36352ea972b1">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9dae4cbf28945e690c15be6b4c2db5e_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTphNTlhNjU4ZTlhZWM0MTk5OWFlNWYyNGRkZGE1YWI2NC90YWJsZXJhbmdlOmE1OWE2NThlOWFlYzQxOTk5YWU1ZjI0ZGRkYTVhYjY0XzItNi0xLTEtOTQ4MzE_fd2729fb-6fe9-46a8-a04a-41a86230f724">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9dae4cbf28945e690c15be6b4c2db5e_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTphNTlhNjU4ZTlhZWM0MTk5OWFlNWYyNGRkZGE1YWI2NC90YWJsZXJhbmdlOmE1OWE2NThlOWFlYzQxOTk5YWU1ZjI0ZGRkYTVhYjY0XzMtMi0xLTEtOTQ4MzE_ecbdbf45-f476-4d49-a551-e84e06b28cf1">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9dae4cbf28945e690c15be6b4c2db5e_I20201231" decimals="-6" name="bhc:DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTphNTlhNjU4ZTlhZWM0MTk5OWFlNWYyNGRkZGE1YWI2NC90YWJsZXJhbmdlOmE1OWE2NThlOWFlYzQxOTk5YWU1ZjI0ZGRkYTVhYjY0XzMtNi0xLTEtOTQ4MzE_0da9ce33-e9c4-4a68-b8ba-18d038318d06">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9dae4cbf28945e690c15be6b4c2db5e_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTphNTlhNjU4ZTlhZWM0MTk5OWFlNWYyNGRkZGE1YWI2NC90YWJsZXJhbmdlOmE1OWE2NThlOWFlYzQxOTk5YWU1ZjI0ZGRkYTVhYjY0XzQtMi0xLTEtOTQ4MzE_0c02eceb-2617-42c4-94f6-b34cd9fa2c81">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9dae4cbf28945e690c15be6b4c2db5e_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTphNTlhNjU4ZTlhZWM0MTk5OWFlNWYyNGRkZGE1YWI2NC90YWJsZXJhbmdlOmE1OWE2NThlOWFlYzQxOTk5YWU1ZjI0ZGRkYTVhYjY0XzQtNi0xLTEtOTQ4MzE_121a1529-704c-40f3-887e-19546cd53e9c">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9dae4cbf28945e690c15be6b4c2db5e_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTphNTlhNjU4ZTlhZWM0MTk5OWFlNWYyNGRkZGE1YWI2NC90YWJsZXJhbmdlOmE1OWE2NThlOWFlYzQxOTk5YWU1ZjI0ZGRkYTVhYjY0XzUtMi0xLTEtOTQ4MzE_6ab4dbaa-1dae-4faf-b50a-bb0ff7fae8a1">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9dae4cbf28945e690c15be6b4c2db5e_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTphNTlhNjU4ZTlhZWM0MTk5OWFlNWYyNGRkZGE1YWI2NC90YWJsZXJhbmdlOmE1OWE2NThlOWFlYzQxOTk5YWU1ZjI0ZGRkYTVhYjY0XzctMi0xLTEtOTQ4MzE_c28325ad-b893-4b87-adc7-58c2293902eb">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9dae4cbf28945e690c15be6b4c2db5e_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTphNTlhNjU4ZTlhZWM0MTk5OWFlNWYyNGRkZGE1YWI2NC90YWJsZXJhbmdlOmE1OWE2NThlOWFlYzQxOTk5YWU1ZjI0ZGRkYTVhYjY0XzctNi0xLTEtOTQ4MzE_fcbc54e2-3e3d-4f0f-8971-341c49a6dac2">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9dae4cbf28945e690c15be6b4c2db5e_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTphNTlhNjU4ZTlhZWM0MTk5OWFlNWYyNGRkZGE1YWI2NC90YWJsZXJhbmdlOmE1OWE2NThlOWFlYzQxOTk5YWU1ZjI0ZGRkYTVhYjY0XzgtMi0xLTEtOTQ4MzE_23917ab4-09ad-47a9-bb18-bfb2e0f71678">245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9dae4cbf28945e690c15be6b4c2db5e_I20201231" decimals="-6" name="bhc:DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTphNTlhNjU4ZTlhZWM0MTk5OWFlNWYyNGRkZGE1YWI2NC90YWJsZXJhbmdlOmE1OWE2NThlOWFlYzQxOTk5YWU1ZjI0ZGRkYTVhYjY0XzgtNi0xLTEtOTQ4MzE_7c674408-e380-4f64-bc8e-063f336fa702">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9dae4cbf28945e690c15be6b4c2db5e_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTphNTlhNjU4ZTlhZWM0MTk5OWFlNWYyNGRkZGE1YWI2NC90YWJsZXJhbmdlOmE1OWE2NThlOWFlYzQxOTk5YWU1ZjI0ZGRkYTVhYjY0XzktMi0xLTEtOTQ4MzE_085b5774-8db7-4e24-9c4d-7ea42216cea5">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9dae4cbf28945e690c15be6b4c2db5e_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTphNTlhNjU4ZTlhZWM0MTk5OWFlNWYyNGRkZGE1YWI2NC90YWJsZXJhbmdlOmE1OWE2NThlOWFlYzQxOTk5YWU1ZjI0ZGRkYTVhYjY0XzktNi0xLTEtOTQ4MzE_bd3a70ed-c55b-404a-baa0-57896d81bb87">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9dae4cbf28945e690c15be6b4c2db5e_I20201231" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTphNTlhNjU4ZTlhZWM0MTk5OWFlNWYyNGRkZGE1YWI2NC90YWJsZXJhbmdlOmE1OWE2NThlOWFlYzQxOTk5YWU1ZjI0ZGRkYTVhYjY0XzEwLTItMS0xLTk0ODMx_28b2c95f-ab69-47af-ac9b-1ea5279d04a5">315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i8256f225f07d49409c31f7443adffdbf_322"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjIvZnJhZzo2YzE5YWE4MWIzNWQ0YzliOGYyZGQ3MjA0YzMwMWU3Ny90ZXh0cmVnaW9uOjZjMTlhYTgxYjM1ZDRjOWI4ZjJkZDcyMDRjMzAxZTc3XzIzODI_4313ae86-c018-4b43-a632-e9ea95214d2e" continuedAt="i7a709ed463464de6bb794e0821c8d004" escape="true">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</ix:nonNumeric></span></div><ix:continuation id="i7a709ed463464de6bb794e0821c8d004"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and integration costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The liability associated with restructuring and integration costs as of December 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i0e08237054f64594815ad5013a5aa9e4_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjIvZnJhZzo2YzE5YWE4MWIzNWQ0YzliOGYyZGQ3MjA0YzMwMWU3Ny90ZXh0cmVnaW9uOjZjMTlhYTgxYjM1ZDRjOWI4ZjJkZDcyMDRjMzAxZTc3XzY1OA_9552cd6a-efec-4c63-b686-62e6f6e5adaa">19</ix:nonFraction> million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $<ix:nonFraction unitRef="usd" contextRef="i8a1258a2943a4cd69dc73c01e660d449_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjIvZnJhZzo2YzE5YWE4MWIzNWQ0YzliOGYyZGQ3MjA0YzMwMWU3Ny90ZXh0cmVnaW9uOjZjMTlhYTgxYjM1ZDRjOWI4ZjJkZDcyMDRjMzAxZTc3XzY4Mw_d116bbcf-99dc-4c57-af34-c6c02ba701b3">18</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i405dec7379e74ca38494473ae3975347_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjIvZnJhZzo2YzE5YWE4MWIzNWQ0YzliOGYyZGQ3MjA0YzMwMWU3Ny90ZXh0cmVnaW9uOjZjMTlhYTgxYjM1ZDRjOWI4ZjJkZDcyMDRjMzAxZTc3XzY4Nw_5067a094-f4fc-450e-b17e-8caf23ea6e03">11</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="icc79228c9dac48f29a1d9bd8078aa0c4_D20190101-20191231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjIvZnJhZzo2YzE5YWE4MWIzNWQ0YzliOGYyZGQ3MjA0YzMwMWU3Ny90ZXh0cmVnaW9uOjZjMTlhYTgxYjM1ZDRjOWI4ZjJkZDcyMDRjMzAxZTc3XzY5NA_e8b67f66-f7e0-47ff-a66b-a398b37237f0">31</ix:nonFraction>&#160;million of restructuring and integration-related costs and made payments of $<ix:nonFraction unitRef="usd" contextRef="i8a1258a2943a4cd69dc73c01e660d449_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjIvZnJhZzo2YzE5YWE4MWIzNWQ0YzliOGYyZGQ3MjA0YzMwMWU3Ny90ZXh0cmVnaW9uOjZjMTlhYTgxYjM1ZDRjOWI4ZjJkZDcyMDRjMzAxZTc3Xzc2NQ_01705965-ac35-49cf-b697-0e103f91dad9">19</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i405dec7379e74ca38494473ae3975347_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjIvZnJhZzo2YzE5YWE4MWIzNWQ0YzliOGYyZGQ3MjA0YzMwMWU3Ny90ZXh0cmVnaW9uOjZjMTlhYTgxYjM1ZDRjOWI4ZjJkZDcyMDRjMzAxZTc3Xzc2OQ_4927d53c-9e4e-44d9-abbf-2707088065ba">18</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="icc79228c9dac48f29a1d9bd8078aa0c4_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjIvZnJhZzo2YzE5YWE4MWIzNWQ0YzliOGYyZGQ3MjA0YzMwMWU3Ny90ZXh0cmVnaW9uOjZjMTlhYTgxYjM1ZDRjOWI4ZjJkZDcyMDRjMzAxZTc3Xzc3Ng_321405d7-761e-47cb-9e4c-ff53cbb22311">31</ix:nonFraction> million during 2021, 2020 and 2019, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation costs, Separation-related costs, IPO Costs and IPO-related Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred, and will incur, costs associated with activities to effectuate the B+L Separation and the Solta IPO. These activities include: (i) separating the Bausch + Lomb and Solta Medical businesses from the remainder of the Company and (ii) registering the Bausch + Lomb and Solta Medical businesses as independent publicly traded entities. Separation and IPO costs are incremental costs directly related to the B+L Separation and Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing a new board of directors and related board committees for the Bausch + Lomb and Solta Medical entities. Included in Restructuring, integration, separation and IPO costs for the years ended December 31, 2021 and 2020 are Separation and IPO costs of $<ix:nonFraction unitRef="usd" contextRef="i813493bb33fc46b7a7a4c4b6aa9f0252_D20210101-20211231" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjIvZnJhZzo2YzE5YWE4MWIzNWQ0YzliOGYyZGQ3MjA0YzMwMWU3Ny90ZXh0cmVnaW9uOjZjMTlhYTgxYjM1ZDRjOWI4ZjJkZDcyMDRjMzAxZTc3XzE3MTU_b4280557-5cbc-472b-a583-537770f1d294">32</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i10381b45a049401593f3912db2562a03_D20200101-20201231" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjIvZnJhZzo2YzE5YWE4MWIzNWQ0YzliOGYyZGQ3MjA0YzMwMWU3Ny90ZXh0cmVnaW9uOjZjMTlhYTgxYjM1ZDRjOWI4ZjJkZDcyMDRjMzAxZTc3XzE3MjI_8ce9eccc-fbe5-4774-ad1a-5db9b3a33c8b">11</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also incurred, and will incur, Separation-related and IPO-related costs which are incremental costs indirectly related to the B+L Separation and Solta IPO. Separation-related and IPO-related costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. Included in Selling, general and administrative for years ended December 31, 2021 and 2020 are Separation-related and IPO-related costs of $<ix:nonFraction unitRef="usd" contextRef="i813493bb33fc46b7a7a4c4b6aa9f0252_D20210101-20211231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjIvZnJhZzo2YzE5YWE4MWIzNWQ0YzliOGYyZGQ3MjA0YzMwMWU3Ny90ZXh0cmVnaW9uOjZjMTlhYTgxYjM1ZDRjOWI4ZjJkZDcyMDRjMzAxZTc3XzIyMzY_e41b9c6d-a543-4ede-86b8-a20338be061c">132</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i10381b45a049401593f3912db2562a03_D20200101-20201231" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjIvZnJhZzo2YzE5YWE4MWIzNWQ0YzliOGYyZGQ3MjA0YzMwMWU3Ny90ZXh0cmVnaW9uOjZjMTlhYTgxYjM1ZDRjOWI4ZjJkZDcyMDRjMzAxZTc3XzIyNDM_3119ce75-1cec-4047-b4f5-02a1663f2b34">21</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent and timing of future charges for these costs cannot be reasonably estimated at this time and could be material.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><div id="i8256f225f07d49409c31f7443adffdbf_325"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzU4MzE_b20e4b4a-4db6-4698-97b5-aa9e2cc852e5" continuedAt="ic84d9efd51b849569b971ccde5f724a8" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="ic84d9efd51b849569b971ccde5f724a8" continuedAt="ifed305b3375e449fab09f5e0838512f6"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are estimated based on valuation techniques and inputs categorized as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1&#160;&#8212;&#160;Quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2&#160;&#8212;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;&#160;and </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or&#160;estimation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the&#160;instrument.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzU4MTM_8fdc2b76-6071-4769-9b84-a39c7a36af37" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis as of: </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:26.200%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.201%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f6583316fc34f2ebde02bee82fce983_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzMtMi0xLTEtOTQ4MzE_a5c155eb-8216-463d-bb51-7999eed32163">76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifadbfa9e788b43cba3cad3e76ae5d807_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzMtNC0xLTEtOTQ4MzE_8203bc6f-34b0-4166-8ddf-446f6816e937">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7aec1240743845078358d61e36c809cf_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzMtNi0xLTEtOTQ4MzE_d13bc5ac-e1f6-4b76-8fd1-df6f285505c7">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abe9143f14849f1bc9dd6da011f2cf4_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzMtOC0xLTEtOTQ4MzE_266852dd-fd79-41e8-9828-edc5f527450e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3319185b216a47d3b6da5be2dc91b570_I20201231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzMtMTAtMS0xLTk0ODMx_c73db9ad-05a9-479d-99f5-f0ae4dd98e0b">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia48dede4a3424904945186832465d56a_I20201231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzMtMTItMS0xLTk0ODMx_9682b81c-6a1a-41d9-85cb-992d4426e06b">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie64c787ebb9447d0a92c7295f0f6d419_I20201231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzMtMTQtMS0xLTk0ODMx_7ac8903f-52d2-48b9-8043-95adb5822a6f">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04ea7b71bd04c6d9cf8679abe9ec99e_I20201231" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzMtMTYtMS0xLTk0ODMx_d68cff4a-2a73-41af-b3ba-d3dee701d332">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash and other settlement deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f6583316fc34f2ebde02bee82fce983_I20211231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzQtMi0xLTEtOTQ4MzE_9bcf1318-f524-4a5d-8c83-c8ae507e6aa1">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifadbfa9e788b43cba3cad3e76ae5d807_I20211231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzQtNC0xLTEtOTQ4MzE_b503e69c-9ce6-4cec-893d-ff5d39a2f4a1">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7aec1240743845078358d61e36c809cf_I20211231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzQtNi0xLTEtOTQ4MzE_141d1677-085a-417f-b7b1-857d19a06fcc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abe9143f14849f1bc9dd6da011f2cf4_I20211231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzQtOC0xLTEtOTQ4MzE_85e62b12-dde3-4b35-bb91-15bec9ae0d28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3319185b216a47d3b6da5be2dc91b570_I20201231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzQtMTAtMS0xLTk0ODMx_c2ab82da-a509-49f2-a76e-3c0eaf78c95f">1,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia48dede4a3424904945186832465d56a_I20201231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzQtMTItMS0xLTk0ODMx_ef629ab8-68ad-47c8-84d2-182772d68e6f">1,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie64c787ebb9447d0a92c7295f0f6d419_I20201231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzQtMTQtMS0xLTk0ODMx_f2afcb89-15b5-453f-a0be-02bc0757d1d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04ea7b71bd04c6d9cf8679abe9ec99e_I20201231" decimals="-6" name="bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzQtMTYtMS0xLTk0ODMx_48470e93-b22c-410c-87ca-991d0dc29f5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e44595ee4a14fcabb69571771959535_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzUtMi0xLTEtOTQ4MzE_4a5849d2-10ea-4520-8bb2-2f539f35f097">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78ba78cf61414c25a16502d502d685c6_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzUtNC0xLTEtOTQ4MzE_c5e7edf8-b329-4df4-8334-d308b0b50515">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70b47e80f74944c99ac1f1b1f772d335_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzUtNi0xLTEtOTQ4MzE_37b2c69e-ebc2-4f59-9b15-93299cb3a546">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46f9e499c3b4367a00f89844e5b3e05_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzUtOC0xLTEtOTQ4MzE_5812db49-32be-4e3d-8b39-2ac64fa6e975">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia18f0da75a394809a608e7d0eae6fa53_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzUtMTAtMS0xLTk0ODMx_53f33fc6-14dd-4ca5-9749-2ccfa659d26a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ecd69567c0b46f5b506f1e4c711298e_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzUtMTItMS0xLTk0ODMx_9f4c53e8-0817-468b-9b3e-ca630bdebee4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i440fa512b3bd4579bb8d93cc9d65ddd0_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzUtMTQtMS0xLTk0ODMx_d9571f27-b560-4987-8844-f7ea5d05c2c1">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1313267327e41edacf2aecaa695623a_I20201231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzUtMTYtMS0xLTk0ODMx_550c05b2-807f-4815-a11b-7ab23f4f83e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f6583316fc34f2ebde02bee82fce983_I20211231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzctMi0xLTEtOTQ4MzE_a089a2f1-0ef4-4b15-afc7-80adafeda3e5">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifadbfa9e788b43cba3cad3e76ae5d807_I20211231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzctNC0xLTEtOTQ4MzE_65c725d0-8863-4d7b-894b-6fd6aa00fe2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7aec1240743845078358d61e36c809cf_I20211231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzctNi0xLTEtOTQ4MzE_7942d034-ba02-44dc-bbb2-5c80fda3384e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abe9143f14849f1bc9dd6da011f2cf4_I20211231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzctOC0xLTEtOTQ4MzE_4cf8c8b7-e696-4d91-b903-257836a34d7f">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3319185b216a47d3b6da5be2dc91b570_I20201231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzctMTAtMS0xLTk0ODMx_f80d1d0a-8c83-43ef-860e-1238d22bf149">328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia48dede4a3424904945186832465d56a_I20201231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzctMTItMS0xLTk0ODMx_1e65434b-02af-4d94-9d59-2981edf211c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie64c787ebb9447d0a92c7295f0f6d419_I20201231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzctMTQtMS0xLTk0ODMx_426bc45a-d813-4404-8d3c-336f392f6bc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia04ea7b71bd04c6d9cf8679abe9ec99e_I20201231" decimals="-6" name="bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzctMTYtMS0xLTk0ODMx_29b110f4-04ce-4fd5-a8ec-95cbb545c7d3">328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cross-currency swaps</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a6ca21431734f2b82ccc26320d115b4_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzgtMi0xLTEtOTQ4MzE_764f2331-a020-4af1-8496-4e42a2efa15f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if285ca9b8419448ca0ecfe732b387fab_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzgtNC0xLTEtOTQ4MzE_ea4cc7a6-ccd7-4f51-9bf4-605ccd3affad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7727cda61cec499488b86e1b280aba86_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzgtNi0xLTEtOTQ4MzE_1ef2202f-bc05-49ec-b6e4-bf96f453ce97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic622a69d05a04c3da2e6c078832136fb_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzgtOC0xLTEtOTQ4MzE_0e3b7943-24f4-4b9d-86a6-1c5a9c639625">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff786c33709b42768b27ac83294252fa_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzgtMTAtMS0xLTk0ODMx_6a784cb2-cf5e-4c45-9101-25b4f036fdb4">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2ec169a70624d1a9715b177b9eed016_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzgtMTItMS0xLTk0ODMx_f4f222fb-dd4e-49ec-835b-919a19642b11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3c641a323124a5e909b2269cea5b838_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzgtMTQtMS0xLTk0ODMx_63ada723-5d21-4a01-8d2c-30dd61f9ba65">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if60700f229f0413882411855a4cc706a_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzgtMTYtMS0xLTk0ODMx_467014da-4a95-462c-a325-2f10e704593a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e44595ee4a14fcabb69571771959535_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzktMi0xLTEtOTQ4MzE_144b6f4e-5d0a-44e9-935b-19ae4c4bc683">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78ba78cf61414c25a16502d502d685c6_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzktNC0xLTEtOTQ4MzE_7e9f815c-6ee3-4528-9561-cb50d268c1b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70b47e80f74944c99ac1f1b1f772d335_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzktNi0xLTEtOTQ4MzE_a3231062-cc63-4500-9824-90adc32e2b26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie46f9e499c3b4367a00f89844e5b3e05_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzktOC0xLTEtOTQ4MzE_b9a29cba-f7e3-4999-a015-058cd4d8d277">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia18f0da75a394809a608e7d0eae6fa53_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzktMTAtMS0xLTk0ODMx_d3fd8ff0-c04e-4c0d-9881-150139c54bcd">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ecd69567c0b46f5b506f1e4c711298e_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzktMTItMS0xLTk0ODMx_b6081996-afd5-4c83-9c5d-783f72b7de55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i440fa512b3bd4579bb8d93cc9d65ddd0_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzktMTQtMS0xLTk0ODMx_8b732d75-ef10-41ff-8498-969ba963f559">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1313267327e41edacf2aecaa695623a_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzktMTYtMS0xLTk0ODMx_90fb1d7d-36d2-4c12-acbe-f857833b836d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments, primarily money market funds, with maturities of <ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="bhc:HighlyLiquidInvestmentsMaturityPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzEzODk_e25e18b5-82a6-4082-8b81-7f21d32d8db2">three months</ix:nonNumeric> or less when&#160;purchased, and are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, Restricted cash and other settlement deposits includes $<ix:nonFraction unitRef="usd" contextRef="i6ad175767e714adb952f1fc81f92fc67_D20210101-20211231" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzE1NzI_e768c93c-282e-4a38-a7fc-103003d5b66a">1,510</ix:nonFraction>&#160;million of payments into escrow funds under the terms of settlement agreements regarding that certain U.S. securities litigation (subject to an objector's appeal of the final court approval) and the Glumetza Antitrust Litigation. These payments are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature.  These payments will remain in escrow until final approval of the settlements as discussed in Note 20, &#8220;LEGAL PROCEEDINGS&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers into or out of Level 3 during 2021 and 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cross-currency Swaps</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into cross-currency swaps, with aggregate notional amounts of $<ix:nonFraction unitRef="usd" contextRef="ic25e35c549a54c708a26494e39477c78_I20191231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzIyMjE_d98a7a44-11ce-406d-ab03-48caef4fd617">1,250</ix:nonFraction> million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its consolidated financial statements from adverse movements in exchange rates. The euro-denominated net investment being hedged was the Company&#8217;s investment in certain euro-denominated subsidiaries.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2021, the Company entered into a transaction to unwind its cross-currency swaps and received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="ia2313e85fce74e5aae451d3654b4cc63_D20211101-20211130" decimals="-6" name="us-gaap:ProceedsFromHedgeInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzI2NDI_c3c33cde-e0f9-4953-b186-47806c16a5f8">4</ix:nonFraction>&#160;million, which included interest income of $<ix:nonFraction unitRef="usd" contextRef="ia2313e85fce74e5aae451d3654b4cc63_D20211101-20211130" decimals="-6" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzI2ODA_a6c8fe54-723f-49c7-977d-d138f1a5a4a4">6</ix:nonFraction>&#160;million, offset by the amount owed by the Company upon the unwinding of $<ix:nonFraction unitRef="usd" contextRef="i2543b8697622497798f72858198a9b4e_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForProceedsFromHedgeInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzI3NDc_404b5977-489e-416d-aa3d-9db86aaade7a">2</ix:nonFraction>&#160;million. The gain arising from the transaction of the swaps has been included as a component of Other comprehensive loss.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ifed305b3375e449fab09f5e0838512f6" continuedAt="i1643ebecab55403aae2d34cf42a221e8"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzU4MTU_a6f8d7b5-2e74-406e-b6fd-ea953fffb41e" continuedAt="ic922af359b3e4804ab15cec901d0a664" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with the Company's cross-currency swaps as included in the Consolidated Balance Sheets as of December 31, 2021 and 2020 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:70.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.647%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6236fa286e14aeabadb9f150267531f_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTowODA1YjgwNjNjY2U0M2JkYTMyMjJmNjVkOWIwY2ZkNS90YWJsZXJhbmdlOjA4MDViODA2M2NjZTQzYmRhMzIyMmY2NWQ5YjBjZmQ1XzEtMS0xLTEtOTQ4MzE_ac4c8309-705a-447b-be7f-41dd9f808302">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d8c9c1bfdd840429f53aab587d9c839_I20201231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTowODA1YjgwNjNjY2U0M2JkYTMyMjJmNjVkOWIwY2ZkNS90YWJsZXJhbmdlOjA4MDViODA2M2NjZTQzYmRhMzIyMmY2NWQ5YjBjZmQ1XzEtMy0xLTEtOTQ4MzE_f1c474e9-77fa-4747-ac03-b6c1e9451c06">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b510358d6854ed28e6f46e5f58ded33_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTowODA1YjgwNjNjY2U0M2JkYTMyMjJmNjVkOWIwY2ZkNS90YWJsZXJhbmdlOjA4MDViODA2M2NjZTQzYmRhMzIyMmY2NWQ5YjBjZmQ1XzItMS0xLTEtOTQ4MzE_ce8c95b6-1091-4f71-83fb-63acb42d67a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6beec5955f640bf84cf335c76410fb7_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTowODA1YjgwNjNjY2U0M2JkYTMyMjJmNjVkOWIwY2ZkNS90YWJsZXJhbmdlOjA4MDViODA2M2NjZTQzYmRhMzIyMmY2NWQ5YjBjZmQ1XzItMy0xLTEtOTQ4MzE_d5fd2f3c-ed92-45df-b49c-f17461e2a194">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ac58aeb82cb4d5da0dc54736de89480_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTowODA1YjgwNjNjY2U0M2JkYTMyMjJmNjVkOWIwY2ZkNS90YWJsZXJhbmdlOjA4MDViODA2M2NjZTQzYmRhMzIyMmY2NWQ5YjBjZmQ1XzMtMS0xLTEtOTQ4MzE_ccb69d2c-9c8c-48be-9306-3dced472f2eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cd1bac2236840fd955596ca631b176d_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTowODA1YjgwNjNjY2U0M2JkYTMyMjJmNjVkOWIwY2ZkNS90YWJsZXJhbmdlOjA4MDViODA2M2NjZTQzYmRhMzIyMmY2NWQ5YjBjZmQ1XzMtMy0xLTEtOTQ4MzE_52841ece-cdd2-4e90-a830-fe2b7c556e0c">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzU4MzY_56ca2952-61df-4600-92e5-e585aaa6f534" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of hedging instruments on the Consolidated Statements of Operations and Consolidated Statements of Comprehensive Loss for 2021 and 2020: </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:70.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.647%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in Other comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9eb64f96a45e4870872718cc8df9421a_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNDcxMDE5M2I4MmY0NzIyYTZkMjM0ZDMyMzBjYzIxNy90YWJsZXJhbmdlOmY0NzEwMTkzYjgyZjQ3MjJhNmQyMzRkMzIzMGNjMjE3XzEtMS0xLTEtOTQ4MzE_792a52f2-6bad-45a9-a371-e5bae1451409">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c82f3651439499c885ddce82e4834ce_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNDcxMDE5M2I4MmY0NzIyYTZkMjM0ZDMyMzBjYzIxNy90YWJsZXJhbmdlOmY0NzEwMTkzYjgyZjQ3MjJhNmQyMzRkMzIzMGNjMjE3XzEtMy0xLTEtOTQ4MzE_aba0aee4-b740-44f9-96d8-bf65abd5cc9f">57</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain excluded from assessment of hedge effectiveness</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i457c889b626f42869ba8488dbeeb08d6_D20210101-20211231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNDcxMDE5M2I4MmY0NzIyYTZkMjM0ZDMyMzBjYzIxNy90YWJsZXJhbmdlOmY0NzEwMTkzYjgyZjQ3MjJhNmQyMzRkMzIzMGNjMjE3XzItMS0xLTEtOTQ4MzE_e39c298b-f84c-4faf-aa46-a10a04b8b589">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22478da08d664decbeccb00e9738fd08_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNDcxMDE5M2I4MmY0NzIyYTZkMjM0ZDMyMzBjYzIxNy90YWJsZXJhbmdlOmY0NzEwMTkzYjgyZjQ3MjJhNmQyMzRkMzIzMGNjMjE3XzItMy0xLTEtOTQ4MzE_7a132eff-e86c-443a-860a-7a84e0e9b00a">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location of gain of excluded component</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2021 and 2020, the Company received $<ix:nonFraction unitRef="usd" contextRef="i9dc84dac17cc43a3984fc9929fd5e294_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForProceedsFromHedgeInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzMyMTk_aebf6df2-414f-4f4e-beac-dfe467430bd1">27</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1e1566b2fa444f9281a88fe587091171_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForProceedsFromHedgeInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzMyMjY_4882c70b-344b-4a16-ae72-0299f3227eb8">23</ix:nonFraction>&#160;million, respectively, in settlements of its cross-currency swaps which are reported as Investing activities in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Contracts</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021 and 2020, the Company entered into foreign currency exchange contracts.  As of December&#160;31, 2021, these contracts had an aggregate outstanding notional amount of $<ix:nonFraction unitRef="usd" contextRef="iad637097d6f449b982fcf6ea6c568da3_I20211231" decimals="INF" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzM1NzE_7e26de50-432d-43df-b489-7ddbe1ed79e3">166</ix:nonFraction>&#160;million.</span></div><ix:continuation id="ic922af359b3e4804ab15cec901d0a664"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with the Company's foreign exchange contracts as included in the Consolidated Balance Sheets as of December 31, 2021 and 2020 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:70.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.647%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bdd18e14d804d67a4f34d683bfa58ea_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZToxNmVjMWFlZWVjYWE0ZWI1ODRmMTU3NjgzYWRhOGQ4MC90YWJsZXJhbmdlOjE2ZWMxYWVlZWNhYTRlYjU4NGYxNTc2ODNhZGE4ZDgwXzEtMS0xLTEtOTQ4MzE_936c94ae-8dc6-4a3b-8bff-db541106dbae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if472041674414bdeb5fb73f64f380506_I20201231" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZToxNmVjMWFlZWVjYWE0ZWI1ODRmMTU3NjgzYWRhOGQ4MC90YWJsZXJhbmdlOjE2ZWMxYWVlZWNhYTRlYjU4NGYxNTc2ODNhZGE4ZDgwXzEtMy0xLTEtOTQ4MzE_635da57b-a5bf-4cad-916f-6f6f87bfc6fe">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib426ea78162c4c489b291c4a5ef1bda1_I20211231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZToxNmVjMWFlZWVjYWE0ZWI1ODRmMTU3NjgzYWRhOGQ4MC90YWJsZXJhbmdlOjE2ZWMxYWVlZWNhYTRlYjU4NGYxNTc2ODNhZGE4ZDgwXzItMS0xLTEtOTQ4MzE_ea689996-37ea-4441-a214-7108b489286c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida0fa648d576472480251eb6eb22d85b_I20201231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZToxNmVjMWFlZWVjYWE0ZWI1ODRmMTU3NjgzYWRhOGQ4MC90YWJsZXJhbmdlOjE2ZWMxYWVlZWNhYTRlYjU4NGYxNTc2ODNhZGE4ZDgwXzItMy0xLTEtOTQ4MzE_5fa84962-cfff-4294-ad87-6adb0195d937">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad637097d6f449b982fcf6ea6c568da3_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZToxNmVjMWFlZWVjYWE0ZWI1ODRmMTU3NjgzYWRhOGQ4MC90YWJsZXJhbmdlOjE2ZWMxYWVlZWNhYTRlYjU4NGYxNTc2ODNhZGE4ZDgwXzMtMS0xLTEtOTQ4MzE_c85843d1-cfb9-40a5-8cfd-b8c3176a0931">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71801473f3324db7b4ad384aae92fc76_I20201231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZToxNmVjMWFlZWVjYWE0ZWI1ODRmMTU3NjgzYWRhOGQ4MC90YWJsZXJhbmdlOjE2ZWMxYWVlZWNhYTRlYjU4NGYxNTc2ODNhZGE4ZDgwXzMtMy0xLTEtOTQ4MzE_410b5e50-320b-4071-8d6c-0078970582a9">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzU4Mzc_ff465a6b-c63f-4296-8b91-aa3bc4abe5f8" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of the Company's foreign exchange contracts on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for 2021 and 2020:</span></div><div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:70.652%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.646%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.647%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) related to changes in fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c9863c6c02148b280910bb43a45b30b_D20210101-20211231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo4OWM4ZGQxMTYzN2E0NjFjOTAwNTEzODRiOTRlNGRhYy90YWJsZXJhbmdlOjg5YzhkZDExNjM3YTQ2MWM5MDA1MTM4NGI5NGU0ZGFjXzEtMS0xLTEtOTQ4MzE_a7cf8acb-f419-4d6c-b8c2-ae3e43589bb6">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0159699620b14a238fdfa5d3fe9aea70_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo4OWM4ZGQxMTYzN2E0NjFjOTAwNTEzODRiOTRlNGRhYy90YWJsZXJhbmdlOjg5YzhkZDExNjM3YTQ2MWM5MDA1MTM4NGI5NGU0ZGFjXzEtMy0xLTEtOTQ4MzE_bc706bb8-7585-48d9-b428-19d92670f7be">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss related to settlements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c9863c6c02148b280910bb43a45b30b_D20210101-20211231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo4OWM4ZGQxMTYzN2E0NjFjOTAwNTEzODRiOTRlNGRhYy90YWJsZXJhbmdlOjg5YzhkZDExNjM3YTQ2MWM5MDA1MTM4NGI5NGU0ZGFjXzItMS0xLTEtOTQ4MzE_ea23b725-be79-4283-a97f-d5d228363832">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0159699620b14a238fdfa5d3fe9aea70_D20200101-20201231" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo4OWM4ZGQxMTYzN2E0NjFjOTAwNTEzODRiOTRlNGRhYy90YWJsZXJhbmdlOjg5YzhkZDExNjM3YTQ2MWM5MDA1MTM4NGI5NGU0ZGFjXzItMy0xLTEtOTQ4MzE_9c1d93d1-a9f5-4743-b65e-099a87afdd44">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-related Contingent Consideration Obligations</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurement of contingent consideration obligations arising from business combinations is determined via a probability-weighted discounted cash flow analysis, using unobservable (Level&#160;3) inputs. These inputs may include: (i)&#160;the estimated amount and timing of projected cash flows, (ii)&#160;the probability of the achievement of the factor(s) on which the contingency is based and (iii)&#160;the risk-adjusted discount rate used to present value the probability-weighted cash&#160;flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly higher or lower fair value measurement. At December&#160;31, 2021, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from <ix:nonFraction unitRef="rate" contextRef="ic984dc5f62ec4772bc9ece326f420058_I20211231" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzQ3NTY_1a0a8a5c-cf9c-4208-8083-183290dbebee">6</ix:nonFraction>% to <ix:nonFraction unitRef="rate" contextRef="i680eb79e17184399ba8ff57eb89e8ab8_I20211231" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzQ3NjI_6db8d513-7376-4c9b-938b-c37845705f14">18</ix:nonFraction>%, and a weighted average risk-adjusted discount rate of <ix:nonFraction unitRef="rate" contextRef="iafdb511725c04b449bc18c9f41f1c601_I20211231" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzQ4MjA_d9c9e95a-81bb-41aa-848e-8bd32b90b43d">7</ix:nonFraction>%. The weighted average risk-adjusted discount rate was calculated by weighting each contract's relative fair value at December&#160;31, 2021.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i1643ebecab55403aae2d34cf42a221e8"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzU4MTg_a6ad28bf-039d-4dc3-99ee-a03307054731" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the years 2021 and 2020:</span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"></td><td style="width:63.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning balance, January 1, </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzEtNC0xLTEtOTQ4MzE_caf9dc76-102b-4cad-bcec-f3bab09bc8c9">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzEtOC0xLTEtOTQ4MzE_30f57215-2d42-4250-bdb2-e05e02c4c20c">316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to Acquisition-related contingent consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion for the time value of money</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98d1e9065dbc434ca6fa39e4ee7397d4_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzMtMi0xLTEtOTQ4MzE_b0125d9d-4cb2-4afb-ad84-bbf8d4b19521">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fa8c12aacc74d6b91c15b886f0f76d8_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzMtNi0xLTEtOTQ4MzE_a1122538-f44e-465d-ada0-ebd36372988f">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if32e75dc65d54621a38196e180c5052b_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzQtMi0xLTEtOTQ4MzE_cb6bdddc-e96e-4a02-b89e-54d845e31a59">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4908569b3b44a878e5d419525405804_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzQtNi0xLTEtOTQ4MzE_31da3cda-9e77-4c73-9738-e4526031451a">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzUtNC0xLTEtOTQ4MzE_54cdca53-c77b-4393-9f73-787f9b2791f8">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzUtOC0xLTEtOTQ4MzE_a3da7b8a-3456-463f-bb1a-098ec8b0caca">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments / Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzYtNC0xLTEtOTQ4MzE_806982c2-3975-47d0-9973-d850d634f8db">99</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzYtOC0xLTEtOTQ4MzE_0c77d0d2-fcf6-4401-870f-c59f403f2831">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment included in other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzctNC0xLTEtOTQ4MzE_cea22eae-ac8d-434d-8c2c-6c1ed2af418e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzctOC0xLTEtOTQ4MzE_5876cd45-c5d9-405c-b1b2-cc51f792ca30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance, December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzgtNC0xLTEtOTQ4MzE_a43db714-8de6-4b3c-a524-4236c8cbe135">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzgtOC0xLTEtOTQ4MzE_200dc661-508c-44f8-a325-cc34ca34cd2e">328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzktNC0xLTEtOTQ4MzE_f2c99a14-bfc3-4889-8388-ae8f5694958e">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzktOC0xLTEtOTQ4MzE_48448c97-739d-43b3-a43b-90269d73dace">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzEwLTQtMS0xLTk0ODMx_b6716af1-6d42-4665-82c7-8c1b5b79f6f1">202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzEwLTgtMS0xLTk0ODMx_e1f3db8c-f450-49cf-9812-eaf71e95cc2f">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis</span></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzU4MzU_6f3a4d2a-1e77-400b-980d-1e769e580fe9" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a non-recurring basis:</span></div><div style="margin-bottom:8pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:24.277%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.812%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.359%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.359%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.359%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.812%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.359%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.359%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.364%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current assets held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15d7424af8b443409563957178d9f029_I20211231" decimals="-6" name="us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo4OWQ0NWI5NjU0YWI0YzliODllZTMzZWRkZWY5YjVmOC90YWJsZXJhbmdlOjg5ZDQ1Yjk2NTRhYjRjOWI4OWVlMzNlZGRlZjliNWY4XzMtMi0xLTEtOTQ4MzE_d6ae8445-bf34-4405-8d98-208032d50c10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8453f3b3b4c743129918b8a8465d47e3_I20211231" decimals="-6" name="us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo4OWQ0NWI5NjU0YWI0YzliODllZTMzZWRkZWY5YjVmOC90YWJsZXJhbmdlOjg5ZDQ1Yjk2NTRhYjRjOWI4OWVlMzNlZGRlZjliNWY4XzMtNC0xLTEtOTQ4MzE_a2443bd3-ff06-430e-b4fb-49ceb9e875cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica46ac5deb7f4bca98fd1442ab972fe1_I20211231" decimals="-6" name="us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo4OWQ0NWI5NjU0YWI0YzliODllZTMzZWRkZWY5YjVmOC90YWJsZXJhbmdlOjg5ZDQ1Yjk2NTRhYjRjOWI4OWVlMzNlZGRlZjliNWY4XzMtNi0xLTEtOTQ4MzE_fab2b218-c4bc-4074-99bb-f3101f91d5e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00e41fe3c6f64b2289dbd0cd45fde7ea_I20211231" decimals="-6" name="us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo4OWQ0NWI5NjU0YWI0YzliODllZTMzZWRkZWY5YjVmOC90YWJsZXJhbmdlOjg5ZDQ1Yjk2NTRhYjRjOWI4OWVlMzNlZGRlZjliNWY4XzMtOC0xLTEtOTQ4MzE_946915f1-c2b6-4896-b1e6-8371cfc140a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0703b0cf397f477687f950dbbe23e831_I20201231" decimals="-6" name="us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo4OWQ0NWI5NjU0YWI0YzliODllZTMzZWRkZWY5YjVmOC90YWJsZXJhbmdlOjg5ZDQ1Yjk2NTRhYjRjOWI4OWVlMzNlZGRlZjliNWY4XzMtMTAtMS0xLTk0ODMx_c68c1850-eafc-4550-a228-e98d66559bae">245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ca97df2856842dfbaf44ca3f738a575_I20201231" decimals="-6" name="us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo4OWQ0NWI5NjU0YWI0YzliODllZTMzZWRkZWY5YjVmOC90YWJsZXJhbmdlOjg5ZDQ1Yjk2NTRhYjRjOWI4OWVlMzNlZGRlZjliNWY4XzMtMTItMS0xLTk0ODMx_3085f154-4b8f-468f-821a-cda1be598f59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib66efd6818984bf8b7ee621516776ce1_I20201231" decimals="-6" name="us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo4OWQ0NWI5NjU0YWI0YzliODllZTMzZWRkZWY5YjVmOC90YWJsZXJhbmdlOjg5ZDQ1Yjk2NTRhYjRjOWI4OWVlMzNlZGRlZjliNWY4XzMtMTQtMS0xLTk0ODMx_7112899c-6c84-4423-a3d9-c58fe46e80ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia03371e98c434dabab65c558c26cca83_I20201231" decimals="-6" name="us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo4OWQ0NWI5NjU0YWI0YzliODllZTMzZWRkZWY5YjVmOC90YWJsZXJhbmdlOjg5ZDQ1Yjk2NTRhYjRjOWI4OWVlMzNlZGRlZjliNWY4XzMtMTYtMS0xLTk0ODMx_073fff13-69a3-4409-a7a0-4fcd9ac15f8b">245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current assets held for sale of $<ix:nonFraction unitRef="usd" contextRef="ia03371e98c434dabab65c558c26cca83_I20201231" decimals="-6" name="us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzU0MDY_073fff13-69a3-4409-a7a0-4fcd9ac15f8b">245</ix:nonFraction>&#160;million as of December 31, 2020 were remeasured to estimated fair value, less costs to sell, which utilized Level 3 unobservable inputs. See Note 3, &#8220;ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE&#8221; for additional details regarding these assets held for sale.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Long-term Debt</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of long-term debt as of December&#160;31, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="ica46ac5deb7f4bca98fd1442ab972fe1_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzU2ODg_cb3632c2-75d5-4b19-8ad0-5a40a6d3166e">22,689</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib66efd6818984bf8b7ee621516776ce1_I20201231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzU2OTU_eae42820-09f3-4122-b3fb-de0e600f2731">25,378</ix:nonFraction> million, respectively, and was estimated using the quoted market prices for the same or similar debt issuances (Level 2).</span></div></ix:continuation><div id="i8256f225f07d49409c31f7443adffdbf_328"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjgvZnJhZzpiODdiNTkzOWQ3NGI0NTcwOTgyODU1YzRkZGU5MWM1Mi90ZXh0cmVnaW9uOmI4N2I1OTM5ZDc0YjQ1NzA5ODI4NTVjNGRkZTkxYzUyXzU0_de019526-f2b9-42fe-a1b6-454a4fac229d" continuedAt="iab0977fc2fdf4d07be524dfb0d4cba22" escape="true">INVENTORIES</ix:nonNumeric></span></div><ix:continuation id="iab0977fc2fdf4d07be524dfb0d4cba22"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjgvZnJhZzpiODdiNTkzOWQ3NGI0NTcwOTgyODU1YzRkZGU5MWM1Mi90ZXh0cmVnaW9uOmI4N2I1OTM5ZDc0YjQ1NzA5ODI4NTVjNGRkZTkxYzUyXzQ4_50187ff9-e4c1-4d87-810b-ee15b1e8dcf6" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net, as of December 31, 2021 and 2020 consist of: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:78.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:InventoryRawMaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjgvZnJhZzpiODdiNTkzOWQ3NGI0NTcwOTgyODU1YzRkZGU5MWM1Mi90YWJsZTo4NDBmNWUxYTlkMjk0ZDQyYTljNzdhYWExODY0OWI2My90YWJsZXJhbmdlOjg0MGY1ZTFhOWQyOTRkNDJhOWM3N2FhYTE4NjQ5YjYzXzEtMi0xLTEtOTQ4MzE_07893f60-b98e-46a4-abc3-0351fa9293dd">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:InventoryRawMaterials" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjgvZnJhZzpiODdiNTkzOWQ3NGI0NTcwOTgyODU1YzRkZGU5MWM1Mi90YWJsZTo4NDBmNWUxYTlkMjk0ZDQyYTljNzdhYWExODY0OWI2My90YWJsZXJhbmdlOjg0MGY1ZTFhOWQyOTRkNDJhOWM3N2FhYTE4NjQ5YjYzXzEtNC0xLTEtOTQ4MzE_ebed9ba8-36bd-4699-a020-418526d46881">286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:InventoryWorkInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjgvZnJhZzpiODdiNTkzOWQ3NGI0NTcwOTgyODU1YzRkZGU5MWM1Mi90YWJsZTo4NDBmNWUxYTlkMjk0ZDQyYTljNzdhYWExODY0OWI2My90YWJsZXJhbmdlOjg0MGY1ZTFhOWQyOTRkNDJhOWM3N2FhYTE4NjQ5YjYzXzItMi0xLTEtOTQ4MzE_272ff609-f643-4277-bbe8-36917410ffde">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:InventoryWorkInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjgvZnJhZzpiODdiNTkzOWQ3NGI0NTcwOTgyODU1YzRkZGU5MWM1Mi90YWJsZTo4NDBmNWUxYTlkMjk0ZDQyYTljNzdhYWExODY0OWI2My90YWJsZXJhbmdlOjg0MGY1ZTFhOWQyOTRkNDJhOWM3N2FhYTE4NjQ5YjYzXzItNC0xLTEtOTQ4MzE_d71d27e6-2099-484e-8734-6c54289c0fbc">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjgvZnJhZzpiODdiNTkzOWQ3NGI0NTcwOTgyODU1YzRkZGU5MWM1Mi90YWJsZTo4NDBmNWUxYTlkMjk0ZDQyYTljNzdhYWExODY0OWI2My90YWJsZXJhbmdlOjg0MGY1ZTFhOWQyOTRkNDJhOWM3N2FhYTE4NjQ5YjYzXzMtMi0xLTEtOTQ4MzE_87b55bab-c9ce-4590-a60c-061558fb218f">602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:InventoryFinishedGoods" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjgvZnJhZzpiODdiNTkzOWQ3NGI0NTcwOTgyODU1YzRkZGU5MWM1Mi90YWJsZTo4NDBmNWUxYTlkMjk0ZDQyYTljNzdhYWExODY0OWI2My90YWJsZXJhbmdlOjg0MGY1ZTFhOWQyOTRkNDJhOWM3N2FhYTE4NjQ5YjYzXzMtNC0xLTEtOTQ4MzE_f134079f-7502-49d6-9601-fd85b5709e23">665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjgvZnJhZzpiODdiNTkzOWQ3NGI0NTcwOTgyODU1YzRkZGU5MWM1Mi90YWJsZTo4NDBmNWUxYTlkMjk0ZDQyYTljNzdhYWExODY0OWI2My90YWJsZXJhbmdlOjg0MGY1ZTFhOWQyOTRkNDJhOWM3N2FhYTE4NjQ5YjYzXzQtMi0xLTEtOTQ4MzE_34baf053-ee71-44ce-88b2-d3d3b32ab13c">993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjgvZnJhZzpiODdiNTkzOWQ3NGI0NTcwOTgyODU1YzRkZGU5MWM1Mi90YWJsZTo4NDBmNWUxYTlkMjk0ZDQyYTljNzdhYWExODY0OWI2My90YWJsZXJhbmdlOjg0MGY1ZTFhOWQyOTRkNDJhOWM3N2FhYTE4NjQ5YjYzXzQtNC0xLTEtOTQ4MzE_336cc98a-bd2a-46ed-bcbe-b6dbafc2a61f">1,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><div id="i8256f225f07d49409c31f7443adffdbf_331"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90ZXh0cmVnaW9uOjc4N2I2ZWMwNzIyYjQ4YjliMjU1YTliZGU3MTY4YTdhXzE2Mg_8acc374f-6197-46ac-bf7c-9a7eb0622577" continuedAt="i10cb3d1c54304916afc0fa2509c38d81" escape="true">PROPERTY, PLANT AND EQUIPMENT</ix:nonNumeric></span></div><ix:continuation id="i10cb3d1c54304916afc0fa2509c38d81"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90ZXh0cmVnaW9uOjc4N2I2ZWMwNzIyYjQ4YjliMjU1YTliZGU3MTY4YTdhXzE1Mw_53e908ed-cbf4-4cb0-a5b4-e0e2e04c2828" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of property, plant and equipment as of December 31, 2021 and 2020 consist of: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:78.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03f09b98a2794ea19b27978f0c0a73fb_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzEtMi0xLTEtOTQ4MzE_f4c16bbc-e808-4f17-90f0-e416e4abcf5e">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i794b0cd648154358b5f12e82f9710bbf_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzEtNC0xLTEtOTQ4MzE_5febd3cd-1168-4453-8f67-098d04a77519">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55bc00875c13421c8e7ef466a6e806e2_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzItMi0xLTEtOTQ4MzE_0d4f1c1f-ec68-43e6-932c-a59179f9a8f5">675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5486904f53c94726b49a9232f4dcb0d0_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzItNC0xLTEtOTQ4MzE_54bd40db-c887-4f52-b997-01ab09c7e8b5">686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i802908ddd2fd4486afb3bf31d0d9edd9_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzMtMi0xLTEtOTQ4MzE_9e878865-64b7-4c7c-aaf9-3777b51d8564">1,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2600359d03bf4008a75ebdf90c246dfc_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzMtNC0xLTEtOTQ4MzE_33257df4-b996-4cdc-8f4d-4a3c4607c7f0">1,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equipment and leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b77fdc1142642a0acda999683173c6e_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzQtMi0xLTEtOTQ4MzE_4d7dbcce-fe66-4c90-813f-92af7d2c10ee">342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38dbc214d6144a758e35f77291e56b5c_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzQtNC0xLTEtOTQ4MzE_27f03cf5-66f0-42a0-8ced-66cd8f55a899">360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment on operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida44475894334e22b76c358bb055a53a_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzUtMi0xLTEtOTQ4MzE_56f2490c-fd6d-43f1-8c38-8f382c643e14">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6649875e397846f2945b7974a238e07a_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzUtNC0xLTEtOTQ4MzE_72269282-8bba-431c-9c48-36d78200de30">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied26b295528f43e08d519d8a4f061068_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzYtMi0xLTEtOTQ4MzE_3322b5b8-043c-4b1c-9d3b-a8fb44174eab">576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e5b883341944b8591f5c00136de5e09_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzYtNC0xLTEtOTQ4MzE_9a9625ac-bea8-40c3-a72a-b535791d351b">436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzctMi0xLTEtOTQ4MzE_cfe024b2-efa2-4f24-b88b-8ea5bceac56d">3,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzctNC0xLTEtOTQ4MzE_a45f93c1-b154-4c5d-978a-48d07b5d4e2d">3,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzgtMi0xLTEtOTQ4MzE_3fe43ae8-dce8-4cee-87a2-bcb025362095">1,820</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzgtNC0xLTEtOTQ4MzE_2dc3045e-64f2-4f3f-add8-6ff7913e366c">1,781</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzktMi0xLTEtOTQ4MzE_098622fa-25c4-462d-aff6-67263f8de474">1,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzktNC0xLTEtOTQ4MzE_89417b04-b1a9-47f8-a45c-3632e60a5966">1,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90ZXh0cmVnaW9uOjc4N2I2ZWMwNzIyYjQ4YjliMjU1YTliZGU3MTY4YTdhXzEwNg_c32a93f8-5da5-43cb-be15-f7a05331879b">177</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90ZXh0cmVnaW9uOjc4N2I2ZWMwNzIyYjQ4YjliMjU1YTliZGU3MTY4YTdhXzExMA_d5fe4a9e-db56-4ea1-abc4-6c43301d9546">180</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90ZXh0cmVnaW9uOjc4N2I2ZWMwNzIyYjQ4YjliMjU1YTliZGU3MTY4YTdhXzExNw_575d3d90-68a5-4f21-8e54-a3be09b60114">178</ix:nonFraction> million for 2021, 2020 and 2019, respectively.</span></div></ix:continuation><div id="i8256f225f07d49409c31f7443adffdbf_334"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzI0NDMw_0444af87-067c-41f9-b384-b2732afc4183" continuedAt="i8db4c70c303944aaa1d53de8e2044a85" escape="true">INTANGIBLE ASSETS AND GOODWILL</ix:nonNumeric></span></div><ix:continuation id="i8db4c70c303944aaa1d53de8e2044a85" continuedAt="i43634cda42ad42988abd909dde81bf17"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzI0NDMz_9c1c82cf-a162-48ad-a6bb-81cb07090fb6" escape="true"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzI0NDQ5_d9c5fb85-8493-436b-a77c-6563504cafcb" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets as of December&#160;31, 2021 and 2020 consist of:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"></td><td style="width:27.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.113%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.893%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.984%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Useful<br/>Lives<br/>(Years)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:36pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization and Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization and Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia7db43bf7c3c4b4186ebf9e2d3d12935_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzMtMS0xLTEtOTQ4MzE_9f5c909d-270a-4ed5-8277-27a36ce4f592">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iead8c960de884ed6a2da68f1c9212534_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzMtMy0xLTEtOTQ4MzE_6f31c74f-4ab6-44e5-b9c4-deb808a8bdd3">20,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iead8c960de884ed6a2da68f1c9212534_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzMtNS0xLTEtOTQ4MzE_f35dce6c-7362-4362-9b6d-7831fb893734">16,169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iead8c960de884ed6a2da68f1c9212534_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzMtNy0xLTEtOTQ4MzE_10fda4f6-6062-4014-a8fe-a74c9f4ecc7b">4,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i118c693b1f954748862447902a5683db_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzMtOS0xLTEtOTQ4MzE_62dc30e2-1684-45c3-90c2-37611dbfb313">20,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i118c693b1f954748862447902a5683db_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzMtMTEtMS0xLTk0ODMx_9536681b-e212-4832-82e1-e36059109f9f">14,914</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i118c693b1f954748862447902a5683db_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzMtMTMtMS0xLTk0ODMx_6d6570ee-3738-4d99-adb9-1351697bf57c">5,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7a7c179df5a84846a54bcfeb13c293e4_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzQtMS0xLTEtOTQ4MzE_74328f08-3b3a-411a-985e-46dbe1a5e1ef">6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8d0b9bcbcff47528293434664f12031_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzQtMy0xLTEtOTQ4MzE_a30802c3-7129-430a-b933-4101b1341a68">902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie8d0b9bcbcff47528293434664f12031_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzQtNS0xLTEtOTQ4MzE_1578c5fe-63d2-462c-a8c7-a410f7455bce">473</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8d0b9bcbcff47528293434664f12031_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzQtNy0xLTEtOTQ4MzE_5c60eb0d-2348-4009-b98f-b3ff8aa49119">429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0141b3d37c034975b5525cda87681171_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzQtOS0xLTEtOTQ4MzE_77961ebe-d77f-44ff-9fb6-a074327a57e0">907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0141b3d37c034975b5525cda87681171_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzQtMTEtMS0xLTk0ODMx_7afa5f93-c455-4020-8864-50b57005474f">404</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0141b3d37c034975b5525cda87681171_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzQtMTMtMS0xLTk0ODMx_5b936290-64c6-445d-a9ac-e85a3aa2f3ae">503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2c05dc4d9b434c80a5cbd4af3c7c9d01_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzUtMS0xLTEtOTQ4MzE_27a96377-95a1-43fe-8508-fa2a7c9ee56a">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie35bf5d8694c4774974b0abc32f8fb13_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzUtMy0xLTEtOTQ4MzE_af0a7078-b843-4693-8b0e-ddf2f7f36cbd">3,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie35bf5d8694c4774974b0abc32f8fb13_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzUtNS0xLTEtOTQ4MzE_9c72e337-d3fd-4f11-b0bc-4c27e03467cf">3,174</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie35bf5d8694c4774974b0abc32f8fb13_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzUtNy0xLTEtOTQ4MzE_8cd5e86d-8d44-4764-a879-6a797ea4e5e4">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idabeb53d68674574be9e8bc3a04fc023_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzUtOS0xLTEtOTQ4MzE_a42a60b1-e367-44da-949c-dbb7b2822dcc">3,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idabeb53d68674574be9e8bc3a04fc023_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzUtMTEtMS0xLTk0ODMx_d12acb76-c827-4fb6-b7b3-52f679e9e50b">3,055</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idabeb53d68674574be9e8bc3a04fc023_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzUtMTMtMS0xLTk0ODMx_b123e3e2-1171-475d-a3ad-bbcd86f29415">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03fe969473114a429bbf4edf40c1b1b5_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzYtMS0xLTEtOTQ4MzE_416af604-6ac0-4dec-85e9-6790470abf2e">0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d77acb3fa444b01a7222031f5d4d6ea_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzYtMy0xLTEtOTQ4MzE_b3a1cc68-e952-4532-bca1-293addfe733b">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d77acb3fa444b01a7222031f5d4d6ea_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzYtNS0xLTEtOTQ4MzE_231281cb-30d8-44cc-9acc-00bb7903bda9">158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d77acb3fa444b01a7222031f5d4d6ea_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzYtNy0xLTEtOTQ4MzE_1b8a48de-fd58-4524-88d5-d825b778a7c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b81638d52a34a33a0380c8dc68c21d6_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzYtOS0xLTEtOTQ4MzE_84576f90-596a-4a60-bee1-fa46e6461607">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b81638d52a34a33a0380c8dc68c21d6_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzYtMTEtMS0xLTk0ODMx_ecfd1a68-d94c-4fe7-92c4-26f706f78ac1">168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b81638d52a34a33a0380c8dc68c21d6_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzYtMTMtMS0xLTk0ODMx_8291c1c8-3b22-49e6-bdea-740b1a6d9c34">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i240a15f4864f40c195868e118ea13730_D20210101-20211231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzctMS0xLTEtOTQ4MzE_687431cd-65bb-4e17-84a6-88589f633105">1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ba67417f7694417880945ef3a458823_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzctMy0xLTEtOTQ4MzE_94154dfa-14ec-4102-b594-8ea47090d1a1">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ba67417f7694417880945ef3a458823_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzctNS0xLTEtOTQ4MzE_d027d420-16ac-4ca9-8605-3e93d4b23027">206</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ba67417f7694417880945ef3a458823_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzctNy0xLTEtOTQ4MzE_7a21975b-84a2-45c4-9c14-6564cb5dc283">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac6cd5788244ea0b4e00e55c970a88b_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzctOS0xLTEtOTQ4MzE_54d97206-7204-4e96-94eb-53eee880c029">210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ac6cd5788244ea0b4e00e55c970a88b_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzctMTEtMS0xLTk0ODMx_012d21d6-d9b5-4cb5-a15e-ba50a2bb0d43">200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac6cd5788244ea0b4e00e55c970a88b_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzctMTMtMS0xLTk0ODMx_07f63b13-5a0c-46d3-9e45-fafc63bcc6a0">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzgtMy0xLTEtOTQ4MzE_5e9f2227-91f2-4e90-972e-df551f752299">25,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzgtNS0xLTEtOTQ4MzE_8aabf777-3f09-4322-a1c4-b4858552003a">20,180</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzgtNy0xLTEtOTQ4MzE_1cfc9779-eb99-4e51-a3f3-53b7dcee96fc">5,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzgtOS0xLTEtOTQ4MzE_63d4d765-ef59-4b09-94ac-884c51897433">25,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzgtMTEtMS0xLTk0ODMx_33b58b79-7eab-4bdc-861a-183eb6aab5d9">18,741</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzgtMTMtMS0xLTk0ODMx_d86e7e70-c3f2-4188-8ad5-d1f054d8774a">6,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired IPR&amp;D not in service</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4357b8c2815049e2916abd0dd4c84a5e_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzktMy0xLTEtOTQ4MzE_9a88b054-d4de-48bf-8929-6cc4ad2c883f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4357b8c2815049e2916abd0dd4c84a5e_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzktNy0xLTEtOTQ4MzE_eef95bbd-9ba9-4ab3-9d95-aa285d6b66fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68da001337c24191a51c93ad8d98f64a_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzktOS0xLTEtOTQ4MzE_8387ffe3-b0fb-4f5c-8e1f-aae14ec8d18b">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68da001337c24191a51c93ad8d98f64a_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzktMTMtMS0xLTk0ODMx_8d793535-83d4-4f46-8a14-66ea83ce8895">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B&amp;L Trademark</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c9e8270f510440cafaaadcad18b83e9_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzEwLTMtMS0xLTk0ODMx_419bb543-e35b-4cb4-9fb5-ea7dfd2406d4">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c9e8270f510440cafaaadcad18b83e9_I20211231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzEwLTctMS0xLTk0ODMx_8c05a31c-4df1-4afd-bdf0-c1141ce8d587">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46550d37e139414ebc038a9317b297af_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzEwLTktMS0xLTk0ODMx_6acfb467-4ec6-44fa-a6bc-bdce23171958">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46550d37e139414ebc038a9317b297af_I20201231" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzEwLTEzLTEtMS05NDgzMQ_9ced6d83-8e9e-4fcd-9ca7-ad4208021d6a">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzExLTMtMS0xLTk0ODMx_c3d93440-4ede-4222-85b0-e89959a5d2af">27,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzExLTUtMS0xLTk0ODMx_b8e5a5b2-1ed7-4300-803a-57a172950adf">20,180</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzExLTctMS0xLTk0ODMx_d10fbfa9-7ae0-4e2f-8118-832f42d4510f">6,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzExLTktMS0xLTk0ODMx_1abbb223-1929-4b75-a0af-6e19340ec24e">27,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzExLTExLTEtMS05NDgzMQ_c9f97afe-5dc0-48a3-9d3b-a92a7185973f">18,741</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzExLTEzLTEtMS05NDgzMQ_8e85bfd5-902c-46f3-90e8-050c918c6e84">8,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments, including loss on assets held for sale in the Consolidated Statement of Operations.  The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale in 2021 included: (i) impairments of $<ix:nonFraction unitRef="usd" contextRef="ia7db43bf7c3c4b4186ebf9e2d3d12935_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzYwNg_e687bcd6-e54e-48e6-a017-307eb31ff11f">105</ix:nonFraction>&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines, (ii) an $<ix:nonFraction unitRef="usd" contextRef="i5b13ca98db8c463aaeed70c3abe4f348_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzY5NQ_d2489f7b-fb90-4d61-a582-bedc5930ee8e">88</ix:nonFraction>&#160;million loss on assets held for sale in connection with the Amoun Sale, (iii) impairments of $<ix:nonFraction unitRef="usd" contextRef="ibdc79af88d674986aa0a6ba7cb0f5f09_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzc4Mw_c41569ee-cca9-450d-a19e-d3fe5b465c23">23</ix:nonFraction>&#160;million, in aggregate, related to the discontinuance of certain product lines and (iv) $<ix:nonFraction unitRef="usd" contextRef="i846ec01236d9492bac74fd5461000270_D20210101-20211231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzg2NQ_ac29c259-8e49-4087-8a4c-76592384c1a3">18</ix:nonFraction>&#160;million related to a portion of an IT infrastructure improvement project no longer being utilized.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale in 2020 included impairments of: (i) $<ix:nonFraction unitRef="usd" contextRef="i80296fd237314f53b6c594ed566c42d6_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzk5OQ_837014c5-7333-4666-a261-84a0d8a3e60b">96</ix:nonFraction>&#160;million to reduce the carrying value of the Amoun business to its estimated fair value less costs to sell due to classifying the business as held for sale as discussed in Note 3, &#8220;ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE&#8221;, (ii) $<ix:nonFraction unitRef="usd" contextRef="i4e1691abab7e45ce93d9c7cf06722945_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzExNzQ_287fc4a3-e41d-4d12-9adf-e1d7e29dffaa">16</ix:nonFraction>&#160;million in aggregate, due to decreases in forecasted sales of certain product lines, (iii) $<ix:nonFraction unitRef="usd" contextRef="i993b35454ff842d7806cb59a463ffa34_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzEyNjA_a70c7789-8733-42c1-bd82-0d5581c87c5d">1</ix:nonFraction>&#160;million in aggregate, related to the discontinuance of certain product lines not aligned with the focus of the Company's core businesses and (iv) $<ix:nonFraction unitRef="usd" contextRef="i8d17c5bf6d9841eba3706e1d48dc6848_D20200101-20201231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE0MDE_db79e87c-ff0c-4768-99a7-ef5a7b6cd8b8">1</ix:nonFraction>&#160;million related to Acquired IPR&amp;D not in service.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i43634cda42ad42988abd909dde81bf17" continuedAt="i0305d63c52714c7eabbe3ec8f2efd283"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale in 2019 included impairments of: (i) $<ix:nonFraction unitRef="usd" contextRef="if5392c04784e4d69b6bc3a708883efda_D20190101-20191231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE0ODY_f57f456a-ac7c-4973-95c4-b76362f0d8ca">58</ix:nonFraction> million reflecting decreases in forecasted sales of certain product lines due to generic competition and other factors, (ii) $<ix:nonFraction unitRef="usd" contextRef="i20a958bbcf974985879a206eeec09656_D20190101-20191231" decimals="-6" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE2MDY_0aebb381-dbea-4e0d-a49d-2e473c8b0a34">8</ix:nonFraction> million related to assets being classified as held for sale, (iii) $<ix:nonFraction unitRef="usd" contextRef="ia3596e67486c490b9d96f6e6a4bf73bb_D20190101-20191231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE2Njg_492ebeda-9048-47da-82b6-6f3230f9df64">5</ix:nonFraction> million related to certain product/patent assets associated with the discontinuance of specific product lines not aligned with the focus of the Company's core businesses and (iv) $<ix:nonFraction unitRef="usd" contextRef="i525a2c44053046a38066e353d995cc61_D20190101-20191231" decimals="-6" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE4NDI_3aae49ea-4085-4fb4-8baa-e2b2aa653944">4</ix:nonFraction> million related to Acquired IPR&amp;D not in service. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impairments to assets reclassified as held for sale were measured as the difference of the carrying value of these assets as compared to the estimated fair values of these assets less costs to sell determined using a discounted cash flow analysis which utilized Level 3 unobservable inputs. The other impairments and adjustments to finite-lived intangible assets were measured as the difference of the historical carrying value of these finite-lived assets as compared to the estimated fair value as determined using a discounted cash flow analysis using Level 3 unobservable inputs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodically, the Company&#8217;s products face the expiration of their patent or regulatory exclusivity. The Company anticipates that product sales for such product would decrease shortly following a loss of exclusivity  (&#8220;LOE&#8221;), due to the possible entry of a generic competitor. Where the Company has the rights, it may elect to launch an authorized generic of such product (either as the Company&#8217;s own branded generic or through a third-party).  This may occur prior to, upon or following generic entry, which may mitigate the anticipated decrease in product sales; however, even with launch of an authorized generic, the decline in product sales of such product could still be significant, and the effect on future revenues could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management continually assesses the useful lives related to the Company's long-lived assets to reflect the most current assumptions.</span></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzI0NDQy_a1a719c1-050e-47c5-a657-b9a0ee3ebf9f" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense of finite-lived intangible assets for the five years ending December&#160;31 and thereafter are as&#160;follows: </span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"></td><td style="width:16.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.881%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTowYTBmN2JjZTdhNjA0YmRjOThmNGM4ZDI2MTQxOTBiZC90YWJsZXJhbmdlOjBhMGY3YmNlN2E2MDRiZGM5OGY0YzhkMjYxNDE5MGJkXzEtMi0xLTEtOTQ4MzE_1d4f47ec-adaa-4374-9cf5-3cda280188da">1,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTowYTBmN2JjZTdhNjA0YmRjOThmNGM4ZDI2MTQxOTBiZC90YWJsZXJhbmdlOjBhMGY3YmNlN2E2MDRiZGM5OGY0YzhkMjYxNDE5MGJkXzEtNC0xLTEtOTQ4MzE_179aafdb-b621-47fe-b0d2-dc22ef545da5">1,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTowYTBmN2JjZTdhNjA0YmRjOThmNGM4ZDI2MTQxOTBiZC90YWJsZXJhbmdlOjBhMGY3YmNlN2E2MDRiZGM5OGY0YzhkMjYxNDE5MGJkXzEtNi0xLTEtOTQ4MzE_fa7ce9fe-6e32-4d20-90ea-1c1dac44a091">902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTowYTBmN2JjZTdhNjA0YmRjOThmNGM4ZDI2MTQxOTBiZC90YWJsZXJhbmdlOjBhMGY3YmNlN2E2MDRiZGM5OGY0YzhkMjYxNDE5MGJkXzEtOC0xLTEtOTQ4MzE_422482a9-a263-42ce-90d5-4893fd5c699a">795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTowYTBmN2JjZTdhNjA0YmRjOThmNGM4ZDI2MTQxOTBiZC90YWJsZXJhbmdlOjBhMGY3YmNlN2E2MDRiZGM5OGY0YzhkMjYxNDE5MGJkXzEtMTAtMS0xLTk0ODMx_a7c17f1d-efd6-4b85-ba7b-291f3848345c">664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTowYTBmN2JjZTdhNjA0YmRjOThmNGM4ZDI2MTQxOTBiZC90YWJsZXJhbmdlOjBhMGY3YmNlN2E2MDRiZGM5OGY0YzhkMjYxNDE5MGJkXzEtMTItMS0xLTk0ODMx_41a35abc-c718-4425-81fe-579ed3531d6a">682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTowYTBmN2JjZTdhNjA0YmRjOThmNGM4ZDI2MTQxOTBiZC90YWJsZXJhbmdlOjBhMGY3YmNlN2E2MDRiZGM5OGY0YzhkMjYxNDE5MGJkXzEtMTQtMS0xLTk0ODMx_d8711f68-5e3b-4e6a-bb42-50a0b3875f03">5,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzI0NDQ2_f594bce6-406e-42a6-a186-0e786145c275" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill during the years ended December 31, 2021, 2020 and 2019 were as follows: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:31.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.611%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.408%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + <br/>Lomb/<br/>International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + <br/>Lomb</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, January 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a1b1fb5e7d43a0a5704750d1336b1f_I20181231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEtMi0xLTEtOTQ4MzE_fb0d3acc-7fb4-4005-bb6a-8cccc05a5193">5,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c3d9b6375104575a0b650fb85f1b280_I20181231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEtNi0xLTEtOTQ4MzE_57a64689-c619-4363-ac0a-7cce662e9665">3,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94cb38fd73a64df9bcbf981da8f70e3c_I20181231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEtMTAtMS0xLTk0ODMx_40b8cc7d-413e-472f-88e0-441092ca840b">1,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id466e6e6ca4d4b5cbde067689c3faef3_I20181231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEtMTItMS0xLTk0ODMx_12f2b128-df2d-4a86-b37e-7ca226a938ee">2,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18439fe8345c481db53c486667ac6940_I20181231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEtMTQtMS0xLTk0ODMx_7846e121-1015-4c01-a2e7-03e0896ccbcb">13,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of certain assets of Synergy </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i417dcef94a21464c8f3e70b1b83c913c_D20190101-20191231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzItNi0xLTEtOTQ4MzE_1d8fb209-e961-4c3a-8c9b-32f8c721415c">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzItMTQtMS0xLTk0ODMx_24eedca8-560c-47ee-bc9b-e8c539e38dbe">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill reclassified to assets held for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba8428875eb04c3490fd83250b59b893_D20190101-20191231" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzMtMi0xLTEtOTQ4MzE_d69461b1-d1fc-4b33-ae6d-81019ae8c901">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzMtMTQtMS0xLTk0ODMx_d49b5573-c117-4fbf-bdd1-8ee2746052a4">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba8428875eb04c3490fd83250b59b893_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzQtMi0xLTEtOTQ4MzE_117d8852-db8c-45af-893a-913cefd28df2">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzQtMTQtMS0xLTk0ODMx_be9221e5-fc43-4389-9614-882660182aeb">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3dfd5b244cf486d987b952dbf744f29_I20191231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzUtMi0xLTEtOTQ4MzE_aa7b0024-4999-41f7-9977-f8f29a657fd4">5,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba148d40c69f47e983b912769213931c_I20191231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzUtNi0xLTEtOTQ4MzE_0c23dcc8-2575-462e-aa03-f7538d87a7fe">3,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f812afa0f2f46a5a00813ce760a5ac1_I20191231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzUtMTAtMS0xLTk0ODMx_716193d8-01b0-4e9b-a06f-6e022c7bc563">1,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53ea644df00c4c18a3c89f1915121a44_I20191231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzUtMTItMS0xLTk0ODMx_3cf606b2-c8d7-4038-8e02-d1463c947a58">2,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzUtMTQtMS0xLTk0ODMx_d7d95163-6c95-40b1-b509-3addaffcb434">13,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets held for sale reclassified to goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25de128371b34a1f9d25e80a34d0887d_D20200101-20201231" decimals="-6" name="bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzYtMi0xLTEtOTQ4MzE_5877de6e-35d2-4e1c-84b0-6b6920b67e82">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzYtMTQtMS0xLTk0ODMx_1bbdad06-bde5-49f4-8a71-61940eb2146c">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill reclassified to assets held for sale (Note 3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i25de128371b34a1f9d25e80a34d0887d_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzctMi0xLTEtOTQ4MzE_985928d7-10f8-4e16-81e1-ed61c34d6a9b">217</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzctMTQtMS0xLTk0ODMx_2bc4ec48-e6a2-422e-8e31-129109581049">217</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25de128371b34a1f9d25e80a34d0887d_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzgtMi0xLTEtOTQ4MzE_d676ec4a-a31a-4917-92a4-b1f02f00e5f4">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzgtMTQtMS0xLTk0ODMx_5b385009-7c39-42b4-bb82-eefe4f6a29f5">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i305ad186f05a46689ddd955b46c78817_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzktMi0xLTEtOTQ4MzE_a5b7027c-32f6-433c-8a9c-3efe27b5ce00">5,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9106cb312b894b4fb0e6e25a1c2f3229_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzktNi0xLTEtOTQ4MzE_a647b0a1-82c7-4be6-b7c5-60156c8fea9e">3,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7e6c0540534603be58b450ccc6ebd2_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzktMTAtMS0xLTk0ODMx_c3875ffb-0cfe-48bc-a838-a0cd9a0797f4">1,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb7488e0749d446eabef23fd482eb625_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzktMTItMS0xLTk0ODMx_68c18c76-4fee-4bc4-a541-3b6c66b57aa5">2,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzktMTQtMS0xLTk0ODMx_5cd9aacd-cd71-4292-b58e-b4b699c1b81b">13,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cbcad2018a947ad8f38faccb79805c0_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEwLTItMS0xLTk0ODMx_bd171c30-de31-49cb-a1f6-11236bf19d27">5,704</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i414fba28824c413593139a2e4ef76d21_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEwLTQtMS0xLTk0ODMx_07f00c98-8568-490a-9c03-1cb4cdaa9493">5,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied7527e9c7f3438db93389c0a1768d2a_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEwLTgtMS0xLTk0ODMx_894a382c-a960-45a1-9015-31789bb1aecb">887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a5a9e6c49d742aca8267ceb1bf314d3_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEwLTEyLTEtMS05NDgzMQ_4604c6e0-057e-4109-b400-692defc8a221">578</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEwLTE0LTEtMS05NDgzMQ_48cece26-901e-44b3-8a7e-d18ea2c591a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cbcad2018a947ad8f38faccb79805c0_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzExLTItMS0xLTk0ODMx_7dcd3c5a-c27a-4faa-8fe7-7c04c686a04d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3328d4d641274769857018f609cda173_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzExLTEwLTEtMS05NDgzMQ_b8d34063-01ec-47e1-b974-fb6488fffa89">469</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzExLTE0LTEtMS05NDgzMQ_be37f6a0-ee6b-4a1b-ae8f-3c9331ca48c2">469</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cbcad2018a947ad8f38faccb79805c0_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEyLTItMS0xLTk0ODMx_78d40e9f-4915-49bf-b867-4a16610d6f79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i414fba28824c413593139a2e4ef76d21_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEyLTQtMS0xLTk0ODMx_d30d0907-604a-4f61-96b5-71ac12705055">77</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied7527e9c7f3438db93389c0a1768d2a_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEyLTgtMS0xLTk0ODMx_ac1df28b-ed09-4d2c-a76d-8965949dc05c">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a5a9e6c49d742aca8267ceb1bf314d3_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEyLTEyLTEtMS05NDgzMQ_ce51623c-9c14-4fc8-bdae-d3ceb40806f7">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEyLTE0LTEtMS05NDgzMQ_0d424611-b3e6-41cf-a4e8-627fb51394f9">118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea2db51516f74749bd5cb23d69094522_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEzLTItMS0xLTk0ODMx_36831202-69a2-48b6-8d39-755b85100a6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bc870f8e27c47c28a8e424dee7145fe_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEzLTQtMS0xLTk0ODMx_41993544-bfa1-46ae-8f0e-1a68f4b227ea">5,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9aac4f4658b94a079f835ab8b92e3d71_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEzLTYtMS0xLTk0ODMx_672e45de-be73-4eb2-b807-4758c5bf211d">3,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1d8a07e1c514b0588c2be7cad93ca17_I20211231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEzLTgtMS0xLTk0ODMx_87108737-77bd-4beb-bc7b-100beb5e3d77">825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5279cba8f1f4e03838c2449f0a36169_I20211231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEzLTEwLTEtMS05NDgzMQ_00a84818-8795-4c5c-91fb-a1d6ee243be8">798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ccf39e3c6294658af0ff9fe475686ff_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEzLTEyLTEtMS05NDgzMQ_a207ce1f-daa9-4e61-9ac9-e32d07ca7554">2,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEzLTE0LTEtMS05NDgzMQ_940b7e7a-a396-44b4-97b5-382f2be93568">12,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is tested for impairment at least annually on October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment.  The Company performs its annual impairment test by first assessing qualitative factors. Where the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed for that reporting unit (Step 1). </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i0305d63c52714c7eabbe3ec8f2efd283" continuedAt="ibd7759c0954446edaf7924605cbd8b47"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair values of a reporting unit using a discounted cash flow model which utilizes Level 3 unobservable inputs. The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The quantitative fair value test is performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit's terminal value. </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To forecast a reporting unit's cash flows the Company takes into consideration economic conditions and trends, estimated future operating results, management's and a market participant's view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts are based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected LOE to the Company's product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company&#8217;s control could have a positive or negative impact on achieving its targets.  Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2019</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Annual Goodwill Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2019 by first assessing qualitative factors. Where the qualitative assessment suggested that it was more likely than not that the fair value of a reporting unit was less than its carrying amount, a quantitative fair value test was performed for that reporting unit. In each quantitative fair value test performed, the fair value was greater than the carrying value of the reporting unit.  As a result, there was <ix:nonFraction unitRef="usd" contextRef="idf7ffc6e85884b44bb020321c2fcfd9b_D20191001-20191001" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzY5Mzc_ca3e7c77-e22f-4736-a58c-40db4ae6e038">no</ix:nonFraction> impairment to the goodwill of any reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2020</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The negative impacts of the COVID-19 pandemic on the global economy have led to significant volatility in the global equity markets. The Company has been able to continue its operations with limited disruptions and has assessed the potential impact that the COVID-19 pandemic is likely to have on its forecasted cash flows.  In performing its assessment, the Company considered the possible effects and outcomes of the COVID-19 pandemic on, among other things, its supply chain, customers and distributors, employee base, product sustainability, research and development activities, product pipeline and consumer demand and related rebates and discounts and has made adjustments, although not considered to be material, to its long-term forecasts used in its previous goodwill impairment assessments, for these and other matters. After completing this assessment, although not completely insulated from the negative effects of the COVID-19 pandemic, the Company believes that its long-term forecasted cash flows, as adjusted for the possible outcome of the COVID-19 pandemic and other matters, do not indicate that the fair value of any reporting unit may be below its carrying value. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2020 revenues were most negatively impacted during its second quarter by certain social restrictions and other precautionary measures taken in response to the COVID-19 pandemic. However, as governments began lifting social restrictions, allowing offices of certain health care providers to reopen and certain surgeries and elective medical procedures to proceed, the negative trend in the revenues of certain businesses began to level off and stabilize prior to the third quarter of 2020. Revenues for 2021 and 2020 were $<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzg3MTY_11953966-5649-4981-9e46-445bd8261b25">8,434</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzg3MjM_3fcc9e3a-b8cb-4f45-bc58-6556353b8201">8,027</ix:nonFraction>&#160;million, respectively. The increase of $<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="bhc:IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzg3NTc_42c471d1-c9e5-4398-877c-cda20e34b886">407</ix:nonFraction>&#160;million in revenue represents an improving trend over the decreases in year-over-year revenues for the three month periods ended June 30, 2020, September 30, 2020 and December 31, 2020 of <ix:nonFraction unitRef="number" contextRef="ib12ef9337a854b11b31304b6e0c0205c_D20200401-20200630" decimals="2" sign="-" name="bhc:IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzg5NDA_f12170a2-f042-4e2d-91bc-ef54cc88e0e4">23</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i7127e175a3854e52bc0c75d9ff20c0a3_D20200701-20200930" decimals="2" sign="-" name="bhc:IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzg5NDQ_39255933-b8d2-4829-8568-77a7e1a4be77">3</ix:nonFraction>% and less than <ix:nonFraction unitRef="number" contextRef="ic1987990ae2747de8eb8993bcdd37868_D20201001-20201231" decimals="2" sign="-" name="bhc:IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzg5NjE_e3fe7817-a50f-4bb8-a9ac-be2dd4513c3b">1</ix:nonFraction>%, respectively. The Company's revenues returned to pre-pandemic levels for many of its businesses and geographies in 2021 and, presuming there continues to be increased availability of effective vaccines and any further resurgence of the COVID-19 virus, the delta and omicron variants and other variant strains thereof do not have a material adverse impact on efforts to contain the COVID-19 virus, the Company anticipates the COVID-19 pandemic to have a minimal impact on its remaining businesses and geographies in 2022. However, the rates of recovery for each business will vary by geography and will be dependent upon, among other things, the availability and effectiveness of vaccines for the COVID-19 virus, government responses, rates of economic recovery, precautionary measures taken by patients and customers, the rate at which remaining social restrictions are lifted and once lifted, the presumption that social restrictions will not be materially reenacted in the event of a resurgence of the virus and other actions taken in response to the COVID-19 pandemic.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ibd7759c0954446edaf7924605cbd8b47" continuedAt="i790522a243434469ac237d31b0281421"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Interim Goodwill Impairment Assessment</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the interim periods of 2020, after giving consideration to the nature and timing of the negative impacts of the COVID-19 pandemic on the Company's forecasted cash flows, with the exception of the Ortho Dermatologics reporting unit, no events occurred, or circumstances changed that would indicate that the fair value of any other reporting unit might be below its carrying value and therefore, <ix:nonFraction unitRef="usd" contextRef="i7cb87466591741d69c11218eca97afee_D20200101-20201231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzEwNDgy_6d53d587-7a95-49b0-9acf-d2727e6a309a">no</ix:nonFraction> impairments were recorded. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2020 and June 30, 2020, the operating results for the Ortho Dermatologics reporting unit were less than forecasted primarily due to certain products experiencing longer launch cycles than originally anticipated as a result of the COVID-19 pandemic. The Company revised its long-term forecasts as of March 31, 2020 and as of June 30, 2020 for these matters. Management believed that these events were indicators that there was less headroom as of March 31, 2020 and June 30, 2020 as compared to the headroom calculated on the date Ortho Dermatologics goodwill was previously tested for impairment. Therefore, a quantitative fair value test for impairment to the goodwill of the Ortho Dermatologics reporting unit was performed at March 31, 2020 and at June 30, 2020. Based on the quantitative fair value tests, the fair value of the Ortho Dermatologics reporting unit continued to be greater than its carrying value and as a result there was <ix:nonFraction unitRef="usd" contextRef="i98b90ee22470425788f2889f17244951_D20200331-20200331" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzExNDk0_00753941-efca-4f9d-b6ea-608bc6712d1c"><ix:nonFraction unitRef="usd" contextRef="i699a9e7d09c64c9c88f463de1d97f137_D20200630-20200630" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzExNDk0_944d2b71-f51b-4436-8ec0-7fe93e021c50">no</ix:nonFraction></ix:nonFraction> impairment to the goodwill of the reporting unit at March 31, 2020 and at June 30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Annual Goodwill Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2020 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2020, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2020, the Company considered, among other matters, a range of potential impacts of COVID-19 pandemic related matters and the limited headroom calculated on the date Ortho Dermatologics goodwill was last tested for impairment (June 30, 2020).  The Company believed that these factors may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2020, utilizing a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="i30a1d9b6c3d84763be8ecc3f1d79f317_I20201001" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzEyODc5_a5f8ec8e-07b2-4b33-be90-5fe0b129cf82">2.0</ix:nonFraction>% and a range of discount rates between <ix:nonFraction unitRef="number" contextRef="i5d5b8f902e834dda885bb99a7a2bb489_I20201001" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzEyOTIw_36ff7d06-fbbe-4424-b713-6f26839426f3">9.50</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i6080875e0e1f4486a08e3dc0c2dc6319_I20201001" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzEyOTI3_ddb1e198-cd44-4cdc-9125-5b9219ff57a7">9.75</ix:nonFraction>%, in estimation of the fair value of this reporting unit.  Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately <ix:nonFraction unitRef="number" contextRef="i30a1d9b6c3d84763be8ecc3f1d79f317_I20201001" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzEzMTA2_8dee9861-a846-4009-82e8-6ebb98e61134">10</ix:nonFraction>% greater than its carrying value and as a result there was <ix:nonFraction unitRef="usd" contextRef="i21115bf566934307b8091d4d727aa2c3_D20201001-20201001" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzEzMTY3_526eb8ff-1a2c-4419-bbd4-e1bbabf175ff">no</ix:nonFraction> impairment to the goodwill of the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2021</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Quarter 2021 - Realignment of Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2021 through the fourth quarter of 2021, the Company operated in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International, (iv) Ortho Dermatologics and (v) Diversified Products. The Bausch + Lomb segment consists of the: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. The Salix segment consists of the Salix reporting unit. The International segment consists of the International (formerly International RX) reporting unit. The Ortho Dermatologics segment consisted of the: (i) Ortho Dermatologics and (ii) Global Solta reporting units. The Diversified Products segment consists of the: (i) Neurology and Other, (ii) Generics and (iii) Dentistry reporting units. This realignment in segment structure resulted in a change in the Company's former International reporting unit, which is now divided between the International Bausch + Lomb reporting unit and International reporting unit. In addition, as part of this realignment of segment structure, certain products historically included in the Generics reporting unit are now included in the U.S. Bausch + Lomb reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of this realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. Goodwill previously reported in the former International reporting unit was reassigned to the International Bausch + Lomb and International reporting units, and a portion of goodwill previously reported in the former Generics reporting unit was reassigned to the U.S. Bausch + Lomb reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the change in reporting units, the Company performed a qualitative fair value assessment for its former: (i) International and (ii) Generics reporting units. Based on the qualitative fair value assessment performed, management believed that it was more likely than not that the carrying values of its former: (i) International and (ii) </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i790522a243434469ac237d31b0281421" continuedAt="ifd1b307d6a4042ab829cfcbf2c6e9b47"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generics reporting units were less than their respective fair values and therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately following the change in reporting units, as a result of the change in composition of the net assets for its current: (i) International Bausch + Lomb, (ii) International and (iii) Generics reporting units, the Company performed a quantitative fair value test. The quantitative fair value test utilized a range of long-term growth rates of <ix:nonFraction unitRef="number" contextRef="i86c894299d29409ead4b863813550b86_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE1Njg3_40bb0a36-ee42-4717-a5b6-0ee80ba469eb">1.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i9a2dd9a9a7d04b008adc3046b51f7059_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE1Njkz_698f0d50-ee7c-4b38-8ef5-8ecfb6fd8b59">3.0</ix:nonFraction>% and a range of discount rates between <ix:nonFraction unitRef="number" contextRef="i86c894299d29409ead4b863813550b86_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE1NzM0_51d13418-166f-4640-8d44-14ebae97cc9d">11.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i9a2dd9a9a7d04b008adc3046b51f7059_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE1NzQx_4da77f05-9461-4f6e-b3f0-89658d3c7b3e">12.25</ix:nonFraction>%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than <ix:nonFraction unitRef="number" contextRef="ic6202fe446ad4ef9a31cbf50a8342593_I20210331" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE1OTIw_5580adc7-2f06-4024-a1b3-16c5cf660ec1">40</ix:nonFraction>%, and, therefore, there was <ix:nonFraction unitRef="usd" contextRef="icded4b5feb5b4918af206e2655141f49_D20210331-20210331" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE1OTUw_7995e29e-b24f-437a-86ba-7bba849e2e63">no</ix:nonFraction> impairment to goodwill. In addition, as the U.S. Bausch + Lomb reporting unit had a change in composition of its net assets related to certain products historically included in the Generics reporting unit now being included in the U.S. Bausch + Lomb reporting unit, the Company performed a qualitative assessment of this reporting unit. Based on the qualitative fair value assessment performed, management believed that it was more likely than not that the carrying value of its current U.S. Bausch + Lomb reporting unit was less than its fair value and therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">March 31, 2021 Impairment to Goodwill </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, management identified launches of certain Ortho Dermatologics products which were not going to achieve their trajectories as forecasted once the social restrictions associated with the COVID-19 pandemic began to ease in the U.S. and offices of health care professionals could reopen. In addition, insurance coverage pressures within the U.S. continued to persist limiting patient access to topical acne and psoriasis products.  In light of these developments, during the first quarter of 2021, the Company began taking steps to: (i) redirect its R&amp;D spend to eliminate projects it has identified as high cost and high risk, (ii) redirect a portion of its marketing and product development outside the U.S. to geographies where there is better patient access and (iii) reduce its cost structure to be more competitive. As a result, during the three months ended March 31, 2021, the Company revised its long-term forecasts for the Ortho Dermatologics reporting unit. Management believed that these events were indicators that there is less headroom as of March 31, 2021 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2020). Therefore, a quantitative fair value test for the Ortho Dermatologics reporting unit was performed. The quantitative fair value test utilized the Company's most recent cash flow projections as revised in the first quarter of 2021 to reflect the business changes previously discussed, including a range of potential outcomes, along with a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="ice067f6010c74048bd8841e74a7cef86_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE4MTk4_7df2c569-b2b5-493f-863b-d3ff4e4e5384">1.0</ix:nonFraction>% and a range of discount rates between <ix:nonFraction unitRef="number" contextRef="i47d8b26934ee4498a7ab3ff3fecbfed7_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE4MjM5_e5aed00f-3517-4c2a-b29a-a0b6a8c4347b">9.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i6ea718d72ec4448ba2219818acc2f6f2_I20210331" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE4MjQ2_369e07a8-6aca-4b6b-97b1-0947ac6815c3">10.0</ix:nonFraction>%. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at March 31, 2021, and the Company recognized a goodwill impairment of $<ix:nonFraction unitRef="usd" contextRef="ibe79965a558440f68c2f201ffc977e8e_D20210331-20210331" decimals="-6" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE4NDQ5_d1c46927-ad80-431d-8c38-cecbef5b1382">469</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Second Quarter 2021 - Realignment of Bausch + Lomb Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the second quarter of 2021, the Company changed the way it reviews the financial information of its Bausch + Lomb segment.  Beginning in the second quarter of 2021, management no longer reviews the financial information of its Bausch + Lomb segment on a geographic basis, but instead reviews this financial information on a business line basis.  This change created a change in the reporting units of the Bausch + Lomb segment. After the change, under its business line view, the Bausch + Lomb segment consists of the global: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units. Prior to the second quarter of 2021, under the geographic view, the Bausch + Lomb segment consisted of the former: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. As a result of this realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. The change in Bausch + Lomb reporting units does not impact the reported revenues and segment profits of the Bausch + Lomb segment for any prior periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the change in its Bausch + Lomb reporting units, the Company performed a qualitative fair value assessment for its former reporting units. Based on the qualitative fair value assessment, management believed that it was more likely than not that the carrying values of its former:  (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units were less than their respective fair values and, therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the change in composition of net assets, the Company performed a quantitative fair value test of its new: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units immediately following the change in the Bausch + Lomb segment. The quantitative fair value test utilized long-term growth rates of <ix:nonFraction unitRef="number" contextRef="icd4661795c6d477dae3ccd804bc808e8_I20210630" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzIwNTAw_ad2b2ac5-43bf-4f9e-8a57-6792eff31d4e">2.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i5d4cdd25b2984038a1406bacb8cdc3dd_I20210630" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzIwNTA3_5f89e579-1e13-4d31-acc6-8c74b7b07307">3.0</ix:nonFraction>% and a range of discount rates between <ix:nonFraction unitRef="number" contextRef="icd4661795c6d477dae3ccd804bc808e8_I20210630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzIwNTQ4_c364856c-30a9-4915-b076-bbd3c2e77427">7.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i5d4cdd25b2984038a1406bacb8cdc3dd_I20210630" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzIwNTU1_45c66b8f-36bb-4989-9e30-bc700a54a013">10.0</ix:nonFraction>%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than <ix:nonFraction unitRef="number" contextRef="i90bbe44e848c4111942574f93f21895e_I20210630" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzIwNzM0_181b3f2c-ba57-4ed8-a18e-06c52e774db7">45</ix:nonFraction>%, and, therefore, there was <ix:nonFraction unitRef="usd" contextRef="i4b861d276efc40a681c82e2398b819a7_D20210630-20210630" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzIwNzY0_e66d42f6-6850-48ce-b26a-cb89e114115a">no</ix:nonFraction> impairment to goodwill.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ifd1b307d6a4042ab829cfcbf2c6e9b47"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">June 30, 2021 and September 30, 2021 Interim Assessments of Goodwill</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to monitor the market conditions impacting the Ortho Dermatologics reporting unit. The  Company's latest forecasts for the Ortho Dermatologics reporting unit include a range of potential outcomes for, among other matters: (i) the impacts of the COVID-19 pandemic on operations, (ii) the impact of the loss of exclusivity of certain products, (iii) the impact of longer launch cycles for certain new products, (iv) progress of its product pipeline and (v) ongoing pricing pressures, which could negatively impact the reporting unit's results over the long term. The changes in the amounts and timing of revenues and expenses in the latest forecast as compared to the forecast used at March 31, 2021 (the last time goodwill of the Ortho Dermatologics reporting unit was tested), were not substantial enough to materially adversely affect the recoverability of the Ortho Dermatologics reporting unit's assets and are not material enough to indicate that the fair value of the Ortho Dermatologics reporting unit might be below its carrying value as last tested at March 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other events occurred or circumstances changed during the period October 1, 2020 (the earliest date goodwill was tested for all other reporting units) through December 31, 2021 that indicated that the fair value of any reporting unit, other than the Ortho Dermatologics reporting unit, might be below its carrying value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Annual Goodwill Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2021 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2021, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2021, the Company considered, among other matters, the limited headroom as a result of the impairment to the goodwill of the Ortho Dermatologics reporting unit when last tested (March 31, 2021) and macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The Company believed that these facts and circumstances may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2021, utilizing a long-term growth rate of <ix:nonFraction unitRef="number" contextRef="i75ce7fc0f0264a0f904c3a8cde7de3fd_I20211001" decimals="INF" name="bhc:ReportingUnitImpairmentTestLongTermGrowthRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzIzNzEx_33a5407d-2fa5-400c-abb0-9f8c811a7228">1.0</ix:nonFraction>% and a discount rate of <ix:nonFraction unitRef="number" contextRef="i75ce7fc0f0264a0f904c3a8cde7de3fd_I20211001" decimals="INF" name="bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzIzNzM3_908d9262-b42d-439e-a311-53397f24c650">9.0</ix:nonFraction>%, in estimation of the fair value of this reporting unit.  Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately <ix:nonFraction unitRef="number" contextRef="i75ce7fc0f0264a0f904c3a8cde7de3fd_I20211001" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzIzOTE2_1ef5f657-40e4-46b1-b44a-ee6bcfd802d9">10</ix:nonFraction>% greater than its carrying value and as a result there was <ix:nonFraction unitRef="usd" contextRef="idfae6f80e7694be08e982fe5786bd632_D20211001-20211001" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzIzOTc3_b0382a22-c585-44f8-b21c-5206c20c8584">no</ix:nonFraction> impairment to the goodwill of the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If market conditions deteriorate, if the factors and circumstances regarding the COVID-19 pandemic escalate beyond management&#8217;s current expectations, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and those charges could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated goodwill impairment charges through December 31, 2021 were $<ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzI0NDA2_0d419d8b-8a00-4391-b137-fce4709bc723">4,180</ix:nonFraction> million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Realignment of Segment Structure</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2022, the Company has realigned and has begun managing its operations in a manner consistent with the organizational structure of the two separate entities as proposed by the Solta IPO. Under the new reporting structure, the Company has <ix:nonFraction unitRef="segment" contextRef="if40967e6d4d3497cb45e304881c2d2d3_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE2NDkyNjc0NjgzODI_d79ff47a-9f0f-485f-aaed-466a5dbe510e">five</ix:nonFraction> reportable segments and has allocated goodwill to those segments as follows: (i) $<ix:nonFraction unitRef="usd" contextRef="i711dcf2b52cb48f98fc1cf3d97a987ec_I20220331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE2NDkyNjc0NjgzMDc_64416579-3f77-4dea-8ffe-4c7b81625535">5,318</ix:nonFraction>&#160;million to the Bausch + Lomb segment, (ii) $<ix:nonFraction unitRef="usd" contextRef="i969d616487264ae4b3b65d39984bbeda_I20220331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE2NDkyNjc0NjgzNTM_625e3039-4f9a-4531-8a2e-ac3953faf34f">3,159</ix:nonFraction>&#160;million to the Salix segment, (iii) $<ix:nonFraction unitRef="usd" contextRef="i22c93f5e835048719e869de028b61cc3_I20220331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE2NDkyNjc0NjgzNjk_3af9e7dc-8fd6-40c6-8710-deafa0fea35b">825</ix:nonFraction>&#160;million to the International segment, (iv) $<ix:nonFraction unitRef="usd" contextRef="ifc44ed8e69bb43ea954db330ec970a6a_I20220331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE2NDkyNjc0NjgzMjM_5ff78fe3-cf56-4823-98fd-df36ed94f552">115</ix:nonFraction>&#160;million to the Solta Medical segment and (v) $<ix:nonFraction unitRef="usd" contextRef="ie889e70e297a454da84ecd8e61e4957d_I20220331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE2NDkyNjc0NjgzMzc_18e5fd51-bd98-44e0-aa76-bca85603bfb3">3,040</ix:nonFraction>&#160;million to the Diversified Products segment. The new segment structure does not impact the Company&#8217;s reporting units but realigns the <ix:nonFraction unitRef="reporting_unit" contextRef="if40967e6d4d3497cb45e304881c2d2d3_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzk4OTU2MDQ2NzcwODg_26ff550b-c60a-4f92-93ed-619a03ebe12c">two</ix:nonFraction> reporting units of the former Ortho Dermatologics segment whereby the Ortho Dermatologics reporting unit is now part of the current Diversified Products segment and the Solta reporting unit is now its own operating and reportable segment.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div><div id="i8256f225f07d49409c31f7443adffdbf_337"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90ZXh0cmVnaW9uOjgxNjY1NDkyNjJhMjQzZWNiM2QwMTVmMjYxNzlkMmY2Xzcy_89d7ebbe-6384-4850-ada7-1c609baaedaf" continuedAt="i20e48a2adb624968b07a1fb3ed8ffb56" escape="true">ACCRUED AND OTHER CURRENT LIABILITIES</ix:nonNumeric></span></div><ix:continuation id="i20e48a2adb624968b07a1fb3ed8ffb56"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90ZXh0cmVnaW9uOjgxNjY1NDkyNjJhMjQzZWNiM2QwMTVmMjYxNzlkMmY2XzY5_a90d4e0b-d53f-4105-a8dc-9f37b7965783" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities as of December 31, 2021 and 2020 consist of: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:78.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal matters and related fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="bhc:Legalsettlementsandrelatedfees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzEtMi0xLTEtOTQ4MzE_6632df50-e56e-4967-a221-cc14bdea41e8">1,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="bhc:Legalsettlementsandrelatedfees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzEtNC0xLTEtOTQ4MzE_e6bcd93a-d61a-42cc-aa60-f088a074ef47">1,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="bhc:AccruedProductRebateCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzItMi0xLTEtOTQ4MzE_25cce1be-446b-4586-ad00-68cd69ae4ec3">908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="bhc:AccruedProductRebateCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzItNC0xLTEtOTQ4MzE_9036809c-648e-4fd6-a0ed-c7ec44a32d85">747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="bhc:AccruedProductReturnCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzMtMi0xLTEtOTQ4MzE_38305d81-f587-42aa-aa37-d8f6e225140a">482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="bhc:AccruedProductReturnCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzMtNC0xLTEtOTQ4MzE_2310fc2f-0c2f-4a50-8018-0871dde2f006">575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefit costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzQtMi0xLTEtOTQ4MzE_a2bb8dee-1ec4-4ab0-8cf2-14f9f171eca3">336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzQtNC0xLTEtOTQ4MzE_56730ebd-557f-4d8c-a64e-a5ad57a33cac">316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzUtMi0xLTEtOTQ4MzE_f6e12278-8021-42e7-806a-ca3d08587b42">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:InterestPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzUtNC0xLTEtOTQ4MzE_0590a5dc-a026-4ca3-9735-b2f45b22c175">341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzYtMi0xLTEtOTQ4MzE_07724153-ee7d-43bd-bda3-03d046205804">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzYtNC0xLTEtOTQ4MzE_90a6fa7e-9edf-421a-b634-dd5931385045">158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzctMi0xLTEtOTQ4MzE_7a44fce4-59f1-45fb-8fa8-2789947eadeb">749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzctNC0xLTEtOTQ4MzE_36dbdd45-063b-4dcf-8122-5a32914f9567">767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzgtMi0xLTEtOTQ4MzE_aca1f9d4-ed9d-488c-a192-61cac79985b1">4,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzgtNC0xLTEtOTQ4MzE_e12e3c72-1df2-486c-996f-e716b6735fed">4,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-35</span></div></div></div><div id="i8256f225f07d49409c31f7443adffdbf_340"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzM0MjUx_3201fc25-88f7-4fd0-ad31-cee5a68c5f89" continuedAt="i61f326a4f42c44ea813bebb7835aa27d" escape="true">FINANCING ARRANGEMENTS</ix:nonNumeric></span></div><ix:continuation id="i61f326a4f42c44ea813bebb7835aa27d" continuedAt="i4078d3162a094684aeed924ef5334343"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzM0MjYy_8309ef5f-9884-4695-a8b1-56007e0b258a" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs as of December 31, 2021 and 2020 consists of the following:</span></div><div style="margin-top:11pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:34.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.082%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.121%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.082%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.129%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707a0a1b00b141a28c29e5d5fd1faa7a_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzMtNC0xLTEtOTQ4MzE_e5bf967a-94ad-4b7d-8934-d01269a81287">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i707a0a1b00b141a28c29e5d5fd1faa7a_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzMtNi0xLTEtOTQ4MzE_9853262b-681f-4536-9338-66a08a38f8c5">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd6185a911a4065809d6e0b5f61c3b9_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzMtOC0xLTEtOTQ4MzE_0d66a31b-2594-4e8d-b1e7-874d0ce6a8f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fd6185a911a4065809d6e0b5f61c3b9_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzMtMTAtMS0xLTk0ODMx_5666a8b8-78b8-43ed-953d-7afd5023281a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib49f81a33d864365851ef46a13cca29f_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzQtNC0xLTEtOTQ4MzE_e21e90ae-0db0-44a5-9575-30e1d23a0a9d">2,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib49f81a33d864365851ef46a13cca29f_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzQtNi0xLTEtOTQ4MzE_a8a41cb4-fb3e-404a-8cc5-a35d74814fb1">2,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd3df09e61d4c56a4826cfa2060c2f1_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzQtOC0xLTEtOTQ4MzE_e818ba7d-4c73-40fe-bcac-2524dd5bb39e">3,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fd3df09e61d4c56a4826cfa2060c2f1_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzQtMTAtMS0xLTk0ODMx_36669060-2e9a-46ac-b829-1b1ffff5f90a">3,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i537bc84d95f240518063d4d8d3b870e2_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzUtNC0xLTEtOTQ4MzE_0c367710-d873-4d7f-a65d-f58cae8fc9d3">994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i537bc84d95f240518063d4d8d3b870e2_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzUtNi0xLTEtOTQ4MzE_055ece72-e281-4628-8edf-14f4e32be70a">984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d40e1f7a1c14a28b74752dcba680ada_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzUtOC0xLTEtOTQ4MzE_a2153145-c20a-4da2-ace2-e10ce9a4e727">1,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d40e1f7a1c14a28b74752dcba680ada_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzUtMTAtMS0xLTk0ODMx_ea64cf77-a5fa-437c-99c0-5552eabe61b6">1,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic6eb226ab9604bf188531181e371079e_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzctMC0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjpkMWZjZTdhNmRlYmI0ODFiOGVjMWZiMWUzMGRiNmQxMl80_4e2c51c5-da05-4f51-839f-cf895300c87d">7.000</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6eb226ab9604bf188531181e371079e_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzctNC0xLTEtOTQ4MzE_fa4f838e-f292-409d-9407-8d2dd8851e89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6eb226ab9604bf188531181e371079e_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzctNi0xLTEtOTQ4MzE_edaea50d-dc04-4880-9041-b3f489846d82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3248199cb70749178b2c7c4fb4982735_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzctOC0xLTEtOTQ4MzE_be931920-2888-427c-9053-2c32c10a4e00">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3248199cb70749178b2c7c4fb4982735_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzctMTAtMS0xLTk0ODMx_c189bdcf-f38a-426f-b221-1e3e6b98454c">1,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i06ec3dd3dcb0438eaf3aebc8db3d319e_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzgtMC0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjpiOGRkMWY2YWVmYmU0YmUyYTBiNDhlNzQ4M2M2MDM5Yl80_d95b9b75-dc00-4ce7-b014-bf7773ae2618">5.500</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ec3dd3dcb0438eaf3aebc8db3d319e_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzgtNC0xLTEtOTQ4MzE_8b0ea2af-e4ec-48b3-868f-93d269613b95">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ec3dd3dcb0438eaf3aebc8db3d319e_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzgtNi0xLTEtOTQ4MzE_c4c40cda-3407-4cda-a41e-5e0c2c5060bf">1,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a77d52d62824a7cadf4ab72fa8e094b_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzgtOC0xLTEtOTQ4MzE_913c013a-4a5e-4b47-810f-61641335197b">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a77d52d62824a7cadf4ab72fa8e094b_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzgtMTAtMS0xLTk0ODMx_64857746-7c95-40c9-bf15-abc40af9644d">1,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i557d4dca2ccb47e682e75358f752e842_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzktMC0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo4ZWEyNWM0NDZjYmM0MzExYjA3NzA4MGI4NjdlYTNmZF80_478a7805-236b-4909-8d88-02ab60a904ce">5.750</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557d4dca2ccb47e682e75358f752e842_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzktNC0xLTEtOTQ4MzE_4faeef3d-2265-4717-bad6-03e47f93a51a">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i557d4dca2ccb47e682e75358f752e842_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzktNi0xLTEtOTQ4MzE_6cd7501f-610d-4a0c-8bec-05f2bdd179ee">495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40edb907b7044d23b89c96ffb68d67e9_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzktOC0xLTEtOTQ4MzE_6350d5fd-9245-4d2c-97d8-745eecb07d37">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40edb907b7044d23b89c96ffb68d67e9_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzktMTAtMS0xLTk0ODMx_5f04e9d0-79d1-4cd1-88a7-01da5b4d9a03">494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4fe84f0ae9724529bf29568dbbffd5a3_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzEwLTAtMS0xLTk0ODMxL3RleHRyZWdpb246NjYwZmUxNGJmMDMwNGYwYmE4NmYzMTcwY2QzNWJiMGNfNA_0794558a-cb41-4e3b-8239-dc3a6051a52d">4.875</ix:nonFraction>% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fe84f0ae9724529bf29568dbbffd5a3_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzEwLTQtMS0xLTk0ODMx_7f61cf1c-2e35-45d3-bbb0-fa60eacfbeae">1,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fe84f0ae9724529bf29568dbbffd5a3_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzEwLTYtMS0xLTk0ODMx_bd90ad36-82ae-43b9-82d0-a7477a1cb079">1,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bb8d72e3c074630bbceb17545ec7261_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzEwLTgtMS0xLTk0ODMx_ab0b07e0-334c-4f58-8de7-022f58dbf5e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bb8d72e3c074630bbceb17545ec7261_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzEwLTEwLTEtMS05NDgzMQ_abaaa23c-8335-4738-b07a-c0ada75be6ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2db39af25b1445a1b1d39932a08c5fc7_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzEyLTAtMS0xLTk0ODMxL3RleHRyZWdpb246YTExNzE3YTAwZGEzNGNmN2IyM2Q3OTIwNmY5N2JjZTNfNA_10e38569-9cf8-433d-9169-59cbf0bddad2">6.125</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db39af25b1445a1b1d39932a08c5fc7_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzEyLTQtMS0xLTk0ODMx_258f4646-2255-470c-9023-2288fb14277a">2,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db39af25b1445a1b1d39932a08c5fc7_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzEyLTYtMS0xLTk0ODMx_2c0aedd8-e12a-4416-adf5-c24faacfa51c">2,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfeed60331fb49708cf75fb16367305e_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzEyLTgtMS0xLTk0ODMx_23b66636-5fa2-4613-bdd1-4944bd164605">3,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfeed60331fb49708cf75fb16367305e_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzEyLTEwLTEtMS05NDgzMQ_a5bb9504-d470-4576-91fd-67d8080c3d9e">3,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia3daa9b4fd734cb7af4bf16715ab23b1_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzEzLTAtMS0xLTk0ODMxL3RleHRyZWdpb246NzIwY2ZjYzg2MTBmNDY4YzlmMjcyNDQ2NmRkNGNiYmNfNA_80241282-1a55-4448-b62e-7d3449d3adc0">9.000</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3daa9b4fd734cb7af4bf16715ab23b1_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzEzLTQtMS0xLTk0ODMx_0b044bba-2123-4201-9390-403af9a7c037">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3daa9b4fd734cb7af4bf16715ab23b1_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzEzLTYtMS0xLTk0ODMx_b9237258-891d-4443-bc67-6bbaa0f279bc">1,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e861b64daed45ebbe70114675bf535f_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzEzLTgtMS0xLTk0ODMx_caa2e104-7a33-4a06-8f09-e0bb0efb0be6">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e861b64daed45ebbe70114675bf535f_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzEzLTEwLTEtMS05NDgzMQ_4d64b925-16e9-4000-a6a1-459ff95b8f3b">1,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8827aaaa75144f59a8e1bb3dccf8fe3d_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE0LTAtMS0xLTk0ODMxL3RleHRyZWdpb246ZGQ4MTg2NWQyNDExNDRmOTgwNjM4MGYzYTllN2M3MzdfNA_ee452e09-5f38-4309-a960-289847e06c3e">9.250</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8827aaaa75144f59a8e1bb3dccf8fe3d_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE0LTQtMS0xLTk0ODMx_dd629759-6eae-4180-a55e-fc3066dd7645">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8827aaaa75144f59a8e1bb3dccf8fe3d_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE0LTYtMS0xLTk0ODMx_1fc31b23-f2e2-43f7-a488-e79e967b305f">1,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad0d1a99b6ec42b9aaee8785c8cb6f79_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE0LTgtMS0xLTk0ODMx_7f5389b8-f0dc-42cb-910b-c4412f1a1d27">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad0d1a99b6ec42b9aaee8785c8cb6f79_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE0LTEwLTEtMS05NDgzMQ_19bf7612-e192-4577-996a-157c5f01d4e7">1,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5a929eccb9e64e0b88c64d38a28ef190_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE1LTAtMS0xLTk0ODMxL3RleHRyZWdpb246Mzg1Zjk0ODQ5OWRlNGZjNGIzNjMxYmExZTFmOTYzN2RfNA_0acfa3f0-30df-48d6-a7d3-f0797d728f50">8.500</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a929eccb9e64e0b88c64d38a28ef190_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE1LTQtMS0xLTk0ODMx_72ecab66-da9e-4704-a55d-d0244de2d402">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a929eccb9e64e0b88c64d38a28ef190_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE1LTYtMS0xLTk0ODMx_0d18ba87-ed94-4b23-b2c4-2f0623f4009e">1,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a25feedc2bd4f438e6d127ea650e095_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE1LTgtMS0xLTk0ODMx_448e3489-cb1c-4b8b-b8e7-97319ecfa3d5">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a25feedc2bd4f438e6d127ea650e095_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE1LTEwLTEtMS05NDgzMQ_9fe055c1-148c-4e6c-8cdb-5011cc0625f8">1,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i03f92fc0786847c3b0c496e8d1603888_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE2LTAtMS0xLTk0ODMxL3RleHRyZWdpb246YzQ5ZjBiMmE2NzFmNDczZTg4OTU0MTM3ZjQzNmQ3ZWFfNA_9b111029-0b9d-4371-ace9-59bd01c6199b">7.000</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03f92fc0786847c3b0c496e8d1603888_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE2LTQtMS0xLTk0ODMx_3a3069f6-a53f-420b-a8b1-97f1f2cb88f2">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03f92fc0786847c3b0c496e8d1603888_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE2LTYtMS0xLTk0ODMx_fcd524bf-d7a6-4c06-8c36-48ccf9c509ea">743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c0dad67e3784bcdb5a6e6f002cd9ee7_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE2LTgtMS0xLTk0ODMx_aac31b37-4789-458f-82fa-94ce185094e1">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c0dad67e3784bcdb5a6e6f002cd9ee7_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE2LTEwLTEtMS05NDgzMQ_4fa09e72-fb95-4dd0-8e84-6f5e71c32117">742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4315b5a6bf3449c790d05b0d6ad5b10b_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE3LTAtMS0xLTk0ODMxL3RleHRyZWdpb246YWRiYTAxOGMzNWE3NDBlY2E2NGEzMmE3ZWE3NWFjZTdfNA_94e7b346-cb5b-435d-b222-895ae23cce3e">5.000</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4315b5a6bf3449c790d05b0d6ad5b10b_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE3LTQtMS0xLTk0ODMx_f078d879-e7df-41ac-8f04-65816152e4ab">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4315b5a6bf3449c790d05b0d6ad5b10b_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE3LTYtMS0xLTk0ODMx_3389963d-d4fc-4eff-a900-b0e39befb825">1,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43b03fff47d14db7bcc1ddf661a8dc92_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE3LTgtMS0xLTk0ODMx_a4444fa4-988d-4eb2-8c79-7233ae5ef578">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43b03fff47d14db7bcc1ddf661a8dc92_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE3LTEwLTEtMS05NDgzMQ_e9f68ecc-7256-44b3-aadf-7fa220bb2e88">1,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i46a9772e12364383a02b198038550550_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE4LTAtMS0xLTk0ODMxL3RleHRyZWdpb246N2RhZjk2ZGE1MWNiNGFjNmI2MGQxYjQ3MWQ2NzFmYjdfNA_80a3cbef-0cbd-407f-ba20-3bc522e3a9d0">6.250</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46a9772e12364383a02b198038550550_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE4LTQtMS0xLTk0ODMx_98ad2d69-b9db-4037-8a9d-a5bc1f2489ee">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46a9772e12364383a02b198038550550_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE4LTYtMS0xLTk0ODMx_2ea3860a-39dd-438d-b757-bd643f11b02d">1,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87200a1dc2742999c99925809369c99_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE4LTgtMS0xLTk0ODMx_11b6a21f-fd40-4dab-8e41-aaa918f5f950">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic87200a1dc2742999c99925809369c99_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE4LTEwLTEtMS05NDgzMQ_d7fe91f4-4340-4cd8-bab1-57b7ee0e0bf6">1,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i55ad7bb0a54347dd9a4596d8be5b8dca_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE5LTAtMS0xLTk0ODMxL3RleHRyZWdpb246ZDVlMzc1YzBlZjVkNGMxZWJhMDM5MDBhNzRmM2RhNTZfNA_4b7d362d-4837-468b-865d-a952020ea858">5.000</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55ad7bb0a54347dd9a4596d8be5b8dca_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE5LTQtMS0xLTk0ODMx_c8ba464d-fa04-4db2-abce-5a9973c06aba">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55ad7bb0a54347dd9a4596d8be5b8dca_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE5LTYtMS0xLTk0ODMx_f7470c92-b62a-4915-ad9c-acbe173d785d">990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f0cd0c7bcda47b38d01957e2a3bc327_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE5LTgtMS0xLTk0ODMx_7a49125c-c445-4650-9b01-36b27867c3c7">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f0cd0c7bcda47b38d01957e2a3bc327_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE5LTEwLTEtMS05NDgzMQ_8454b9b8-cbfb-49c5-ace1-512fe132551f">988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5c5faf2607ad4637a05e98dc5c8875c4_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIwLTAtMS0xLTk0ODMxL3RleHRyZWdpb246NTE1NzkxZjBjNDMyNGIxNGJmMDdiOGZlZTEyN2VkYmRfNA_b27316b5-f164-49e8-88da-c82c61a4e775">7.250</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c5faf2607ad4637a05e98dc5c8875c4_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIwLTQtMS0xLTk0ODMx_fb23d92c-76aa-4992-87d3-d015f1d98236">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c5faf2607ad4637a05e98dc5c8875c4_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIwLTYtMS0xLTk0ODMx_84ab0d0f-ba22-46bc-877a-317a75f3e369">742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19dcb028ec1d4e60aa66dbeb559a420a_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIwLTgtMS0xLTk0ODMx_101346e7-cd19-4c5a-a3a5-f6bcaade744b">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19dcb028ec1d4e60aa66dbeb559a420a_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIwLTEwLTEtMS05NDgzMQ_92be6b1d-32de-4bf3-9322-46823358943b">741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0249a1288b1649bdbb249d5ea07218db_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIxLTAtMS0xLTk0ODMxL3RleHRyZWdpb246MGQ5YTlhNGU4NDQyNGY4YWEwYTZkOTU0MjVhOGMxNzdfNA_eaaf607a-624b-4bcb-ac6f-ed4a3ad5a620">5.250</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0249a1288b1649bdbb249d5ea07218db_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIxLTQtMS0xLTk0ODMx_0688d24e-18aa-4dcc-a000-8d0c9cc2c917">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0249a1288b1649bdbb249d5ea07218db_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIxLTYtMS0xLTk0ODMx_03fe1d39-7ea5-4dae-8dd8-d8491bbbfd3c">1,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1627b94e1a9a4cca93a1bbe3b864cf4d_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIxLTgtMS0xLTk0ODMx_4488d3b5-6951-425c-8f0e-a46009028e3e">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1627b94e1a9a4cca93a1bbe3b864cf4d_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIxLTEwLTEtMS05NDgzMQ_9e6a187f-c2c4-4e78-b4f7-9577bcba0ac2">1,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i06254af032384d79944c4fbf0358b2a1_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIyLTAtMS0xLTk0ODMxL3RleHRyZWdpb246YTFmYTljYmYzNmYzNGVmM2I0ODg0NWQ5OTE4MjEzYjdfNA_824b5aea-4783-40c9-89fc-f7a5cd654d89">5.250</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06254af032384d79944c4fbf0358b2a1_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIyLTQtMS0xLTk0ODMx_eee00ad4-b749-424b-af34-604e6ddc3190">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06254af032384d79944c4fbf0358b2a1_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIyLTYtMS0xLTk0ODMx_dc9794cd-e9bd-4185-be0d-72757337cc1e">989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9e33e485084fff9d0c81867c005c16_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIyLTgtMS0xLTk0ODMx_fa964be7-4ed1-49f8-964c-73fff6270d91">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9e33e485084fff9d0c81867c005c16_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIyLTEwLTEtMS05NDgzMQ_fb7327b9-c9ca-4dba-bdf8-825c75b1a088">988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4e37ee467534e15bb29330c819bd784_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIzLTQtMS0xLTk0ODMx_7ce6c019-335b-46ac-8a93-1849d89434f9">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4e37ee467534e15bb29330c819bd784_I20211231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIzLTYtMS0xLTk0ODMx_6f3fd2d4-e2f6-40ab-8040-e56ea159f7a6">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic10baeef95084b95a40fdf0c4c004831_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIzLTgtMS0xLTk0ODMx_37279e27-0f16-4b97-9866-a2d82d784ced">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic10baeef95084b95a40fdf0c4c004831_I20201231" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIzLTEwLTEtMS05NDgzMQ_3a8e4064-c0b4-43a7-a10e-f9661083e24c">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzI0LTQtMS0xLTk0ODMx_a22ca8c7-c4b1-45ce-96fc-40908b9d2f0e">22,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzI0LTYtMS0xLTk0ODMx_18644bca-6373-4833-b48e-967eddd0745c">22,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzI0LTgtMS0xLTk0ODMx_2665b15d-66fc-45fc-8923-e37a93bb3f53">24,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzI0LTEwLTEtMS05NDgzMQ_6c097a0d-b423-4027-9f88-3014655b6a67">23,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzI1LTYtMS0xLTk0ODMx_d053f199-82c5-4783-9856-a54c5c932685">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzI1LTEwLTEtMS05NDgzMQ_8734d831-7a50-4060-bb85-e809689e2a22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzI2LTYtMS0xLTk0ODMx_7489527c-0865-4d81-bce4-9fff8b227580">22,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzI2LTEwLTEtMS05NDgzMQ_99681720-a322-4efb-ac2c-8806215d7d43">23,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Covenant Compliance</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Credit Facilities (as defined below) and the indentures governing the Senior Secured Notes and Senior Unsecured Notes contain customary affirmative and negative covenants and specified events of default. These affirmative and negative covenants include, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company&#8217;s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends on capital stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates. As of December&#160;31, 2021, the amount available for restricted payments under the &#8220;builder basket&#8221; in the Company&#8217;s most restrictive indentures (as defined by those indentures) was approximately $<ix:nonFraction unitRef="usd" contextRef="i27fc8076f1bb4e4fac0065b5495211c5_I20211231" decimals="-6" name="bhc:DebtInstrumentAmountAvailableForRestrictedPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzExODQ_8e049cc5-edfb-40e2-a3e2-1176d7db8c58">13,800</ix:nonFraction>&#160;million (although such availability is subject to the Company's compliance with a <ix:nonFraction unitRef="number" contextRef="i27fc8076f1bb4e4fac0065b5495211c5_I20211231" decimals="INF" name="bhc:DebtInstrumentCovenantTermsFixedChargeCoverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEyNjE_5d68a941-f4aa-4f78-820c-966e1c8a2084">2.00</ix:nonFraction>:1.00 fixed charge coverage ratio). The 2023 Revolving Credit Facility (as defined below) also contains a financial maintenance covenant that requires the Company to maintain a first lien net leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="i27fc8076f1bb4e4fac0065b5495211c5_I20211231" decimals="INF" name="bhc:DebtInstrumentCovenantTermsSecuredLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE0OTA_d1e703b0-5162-4265-8e7f-dc7dbc8cc302">4.00</ix:nonFraction>:1.00. The financial maintenance covenant may be waived or amended without the consent of the term loan facility lenders and contains a customary term loan facility standstill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company was in compliance with its financial maintenance covenant related to its debt obligations. The Company, based on its current forecast for the next twelve months from the date of issuance of these financial statements, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations over that same period. </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i4078d3162a094684aeed924ef5334343" continuedAt="i2a17838e217541ceaf2998a9d2445b22"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to take steps to improve its operating results to ensure continual compliance with its financial maintenance covenant and may take other actions to reduce its debt levels to align with the Company&#8217;s long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the &#8220;Senior Secured Credit Facilities&#8221; under the Company's Fourth Amended and Restated Credit and Guaranty Agreement (the &#8220;Restated Credit Agreement&#8221;), with a syndicate of financial institutions and investors as lenders. The Restated Credit Agreement provides for a revolving credit facility of $<ix:nonFraction unitRef="usd" contextRef="i3c884d2a677c46099dc4bf036009410a_I20180601" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI4MTk_9404d8ad-b49b-4eba-ba4e-96e79272d2cc">1,225</ix:nonFraction> million (the &#8220;2023 Revolving Credit Facility&#8221;) and a <ix:nonNumeric contextRef="i3e81a6b0b4494ea99594e7ae61d6e7e2_D20180601-20180601" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzM0MjU5_427b6f5f-1efc-42f0-9258-e1b0c26d2483">seven year</ix:nonNumeric> Tranche B Term Loan Facility of $<ix:nonFraction unitRef="usd" contextRef="i3ac7b4fdfdf54cca97131f28525e6edc_I20180601" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI5MDc_253b7642-490e-4e86-bcaa-fa030c33290d">4,565</ix:nonFraction> million (the &#8220;June 2025 Term Loan B Facility&#8221;) borrowed by the Company&#8217;s subsidiary, Bausch Health Americas, Inc. (&#8220;BHA&#8221;). </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Revolving Credit Facility matures on the earlier of June 1, 2023 and the date that is <ix:nonNumeric contextRef="i1b48943d62f64d77bf275084b850c10b_D20180601-20180601" name="bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMxMjE_4772bc4f-ec15-40a6-96fc-7b6202e80d83">91</ix:nonNumeric> calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company or BHA in an aggregate principal amount in excess of $<ix:nonFraction unitRef="usd" contextRef="i3c884d2a677c46099dc4bf036009410a_I20180601" decimals="INF" name="bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMyNzM_36acbb61-f204-483a-b91f-427573695e27">1,000</ix:nonFraction> million. Both the Company and BHA are borrowers with respect to the 2023 Revolving Credit Facility. Borrowings under the 2023 Revolving Credit Facility may be made in U.S. dollars or Canadian dollars (or if an amendment to the Restated Credit Agreement is made to replace LIBOR with an alternative benchmark rate with respect to borrowings under the Revolving Credit Facility denominated in euros, euros).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="i707a0a1b00b141a28c29e5d5fd1faa7a_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzM3MDA_52e0709c-c5f0-4ed8-ae5c-2419fd960b17">285</ix:nonFraction> million of outstanding borrowings, $<ix:nonFraction unitRef="usd" contextRef="icca812a26f644f92a7e1f4a986e51c00_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzM3MzA_fedeadcf-0cc3-4beb-8206-1247b4db4e7b">54</ix:nonFraction> million of issued and outstanding letters of credit, and remaining availability of $<ix:nonFraction unitRef="usd" contextRef="i707a0a1b00b141a28c29e5d5fd1faa7a_I20211231" decimals="-6" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzM4MDg_6f6c6a8f-ab34-4aa6-a834-a85618eb8e9b">886</ix:nonFraction> million under its 2023 Revolving Credit Facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2018, the Company entered into the First Incremental Amendment to the Restated Credit Agreement, which provided an additional <ix:nonNumeric contextRef="i8bba7bbfcfef401787d57a665a8baaab_D20181127-20181127" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzM0Mjc4_fbc79a40-b403-446f-91b6-52a520bbdb65">seven year</ix:nonNumeric> Tranche B Term Loan Facility of $<ix:nonFraction unitRef="usd" contextRef="i122eb939c38343d79b07091d8c902050_I20181127" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzQwMzU_5c0b06ac-1c7a-4e5b-b10b-433bac75754a">1,500</ix:nonFraction>&#160;million (the &#8220;November 2025 Term Loan B Facility&#8221;).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Current Description of Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Senior Secured Credit Facilities in U.S. dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a base rate determined by reference to the highest of: (a) the prime rate (as defined in the Restated Credit Agreement), (b) the federal funds effective rate plus 1/2 of 1.00% or (c) the eurocurrency rate (as defined in the Restated Credit Agreement) for a period of one month plus <ix:nonFraction unitRef="number" contextRef="i0ee961e3429c4173bd50b3e41367ad7c_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzQ1Njg_1659c4ce-dafd-4b62-b84b-6b235558f553">1.00</ix:nonFraction>% (or if such eurocurrency rate shall not be ascertainable, <ix:nonFraction unitRef="number" contextRef="ia998a2f7b86b483b983a8b3498ae44fc_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzQ2Mjk_54417f87-8653-4723-906b-9cbfbb042822">1.00</ix:nonFraction>%) or (ii) a eurocurrency rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing adjusted for certain additional costs (provided however, that the eurocurrency rate shall at no time be less than <ix:nonFraction unitRef="number" contextRef="i388ac421c82b49c48346643fa2ca8a0c_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzQ4OTc_629f9de6-72ad-4977-b25b-e48c03bdc6fe">0.00</ix:nonFraction>% per annum), in each case plus an applicable margin.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2023 Revolving Credit Facility in euros, when available, are expected to bear interest at a term benchmark rate determined by reference to the costs of funds for euro deposits for the interest period relevant to such borrowing (provided however, that the eurocurrency rate is at no time expected to be less than <ix:nonFraction unitRef="number" contextRef="i984c72f35f464a9f992e3b3b631f4b0d_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzUyODU_78e21b45-b16f-41df-9b14-0c974c209ff9">0.00</ix:nonFraction>% per annum), plus an applicable margin. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2023 Revolving Credit Facility in Canadian dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a prime rate determined by reference to the higher of: (a) the rate of interest last quoted by The Wall Street Journal as the &#8220;Canadian Prime Rate&#8221; or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Bank of Canada as its prime rate and (b) the 1 month BA rate (as defined below) calculated daily plus <ix:nonFraction unitRef="number" contextRef="i6084b059746d44c2acce81065d562b57_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzU4NDI_e6253f5f-c860-4d78-bd94-9055b07bfecc">1.00</ix:nonFraction>% (provided however, that the prime rate shall at no time be less than <ix:nonFraction unitRef="number" contextRef="if7840f0b2e2b48f5833d3f0adc12fa7e_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzU5MTQ_e9086449-5bd2-49af-b030-8a313bf93c72">0.00</ix:nonFraction>%) or (ii) the bankers&#8217; acceptance rate for Canadian dollar deposits in the Toronto interbank market (the &#8220;BA rate&#8221;) for the interest period relevant to such borrowing (provided however, that the BA rate shall at no time be less than <ix:nonFraction unitRef="number" contextRef="if7840f0b2e2b48f5833d3f0adc12fa7e_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzYxNDk_d09d6dbd-4547-4168-a063-49d1e2fda141">0.00</ix:nonFraction>% per annum), in each case plus an applicable margin.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the Restated Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i)&#160;<ix:nonFraction unitRef="number" contextRef="ib2fc98102d394e23ab05be5028d334b8_D20210101-20211231" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzY0NTk_cd799bef-1289-471a-ad71-83e253a552c6">100</ix:nonFraction>% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii)&#160;<ix:nonFraction unitRef="number" contextRef="ib2fc98102d394e23ab05be5028d334b8_D20210101-20211231" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzY2NTY_2cdb61b6-293e-48db-8356-3d67c7d7df63">100</ix:nonFraction>% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the Restated Credit Agreement), (iii)&#160;<ix:nonFraction unitRef="number" contextRef="ib2fc98102d394e23ab05be5028d334b8_D20210101-20211231" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzY3OTM_aa15e4f2-5640-4ca4-b21c-f6f2c846a5ec">50</ix:nonFraction>% of Excess Cash Flow (as&#160;defined in the Restated Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv)&#160;<ix:nonFraction unitRef="number" contextRef="ib2fc98102d394e23ab05be5028d334b8_D20210101-20211231" decimals="INF" name="bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzY5NTA_30cec9eb-d51f-4968-bb35-fb0a26a6a58a">100</ix:nonFraction>% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility are <ix:nonFraction unitRef="number" contextRef="i27aa31be484b4e9b951df5511db3cc35_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzcyNTQ_d29a4a7e-7be0-491b-9450-79d25fb4fdf0">2.00</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i5d1c850c7eb04b9a9236112505ccf265_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzcyNjE_d55486b5-7857-4d2a-a257-958c24609f2c">1.75</ix:nonFraction>%, respectively, with respect to base rate and prime rate borrowings and <ix:nonFraction unitRef="number" contextRef="i084241e0c0984f30b029369bd43fb499_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzczMzU_62cea398-8fc1-4e24-b362-9d5db498711b">3.00</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i0a3693985875498082ba11e282f4e79b_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzczNDI_d92d8c95-e131-4cea-9620-c4590f0c211f">2.75</ix:nonFraction>%, </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i2a17838e217541ceaf2998a9d2445b22" continuedAt="id437d56c3a6444b7ad6b7197e563347f"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, with respect to eurocurrency rate and BA rate borrowings. As of December 31, 2021, the stated rates of interest on the Company&#8217;s borrowings under the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility were <ix:nonFraction unitRef="number" contextRef="ib49f81a33d864365851ef46a13cca29f_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzc1NDA_2a5dd090-35e0-4324-81ad-b39e287ee449">3.09</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i537bc84d95f240518063d4d8d3b870e2_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzc1NDc_1cbdeafb-7edf-4420-a16a-4292f3b4dc14">2.84</ix:nonFraction>% per annum, respectively.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for both the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility is <ix:nonFraction unitRef="number" contextRef="ib49f81a33d864365851ef46a13cca29f_I20211231" decimals="INF" name="bhc:DebtInstrumentAnnualAmortizationRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzc2NTk_10996344-f68b-41ef-8c02-6c584f069a41"><ix:nonFraction unitRef="number" contextRef="i537bc84d95f240518063d4d8d3b870e2_I20211231" decimals="INF" name="bhc:DebtInstrumentAnnualAmortizationRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzc2NTk_b787cb51-0a62-4bdd-9d4a-6c234fe9ee10">5.00</ix:nonFraction></ix:nonFraction>% per annum. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of December 31, 2021, there were <ix:nonFraction unitRef="usd" contextRef="i1a7a975faf994c36a88b4e0e0eb6800f_D20210101-20211231" decimals="INF" name="bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzc3OTE_81cdf3af-6e50-43af-9472-f9fff05b5a2f">no</ix:nonFraction> remaining mandatory quarterly amortization payments for the Senior Secured Credit Facilities. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for borrowings under the 2023 Revolving Credit Facility are <ix:nonFraction unitRef="number" contextRef="i6e2ae2d598fc4a64a6dd097539edef68_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzc5ODY_b9273739-f737-4ccb-aa3a-e89a7078270c">1.50</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="ifd51dd72613243c68aa536db0dc3c70f_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzc5ODk_16a90161-2167-40d1-8c92-6ac86b63a70e">2.00</ix:nonFraction>% with respect to base rate or prime rate borrowings and <ix:nonFraction unitRef="number" contextRef="i302db430cde9461f934b806767f52349_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzgwNDc_fe0ba08b-bc90-47ec-899e-757e5422ccbc">2.50</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="i9b262c356e2e4aef8c99010988af7e67_D20210101-20211231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzgwNTA_7d42946d-97e6-4013-a75c-5bba21a7972e">3.00</ix:nonFraction>% with respect to eurocurrency rate or BA rate borrowings.&#160; As of December 31, 2021, the stated rate of interest on the 2023 Revolving Credit Facility was <ix:nonFraction unitRef="number" contextRef="i707a0a1b00b141a28c29e5d5fd1faa7a_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzgxODU_24ad8271-5893-426e-88e4-1fafac58c2d4">2.84</ix:nonFraction>% per annum. In addition, the Company is required to pay commitment fees of <ix:nonFraction unitRef="number" contextRef="i77d8c4f932f64c7ab48f7c0ff10b8a3a_D20210101-20211231" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzgyNjI_e934835a-9018-456d-bff8-2631a575d615">0.25</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i76d8b3b4ed87466eab6f101ddcb61ba9_D20210101-20211231" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzgyNjc_41be03ee-6f85-4337-a89b-24b9c9e0f0ab">0.50</ix:nonFraction>% per annum with respect to the unutilized commitments under the 2023 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on eurocurrency rate borrowings under the 2023 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency&#160;fees.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restated Credit Agreement permits the incurrence of incremental credit facility borrowings, up to the greater of $<ix:nonFraction unitRef="usd" contextRef="i27fc8076f1bb4e4fac0065b5495211c5_I20211231" decimals="INF" name="bhc:LineOfCreditFacilityThresholdForIncrementalBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzg5MTg_23ba630c-98ab-4fde-8219-cfae83722069">1,000</ix:nonFraction> million and <ix:nonFraction unitRef="number" contextRef="i1a7a975faf994c36a88b4e0e0eb6800f_D20210101-20211231" decimals="INF" name="bhc:LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzg5MjU_bab4c450-f040-40df-951a-4bdf4e608f6c">28.5</ix:nonFraction>% of Consolidated Adjusted EBITDA (non-GAAP) (as defined in the Restated Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to, in the case of secured debt, a secured leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="i558d07c8b64a40c8b3072a4379c5db37_I20211231" decimals="INF" name="bhc:DebtInstrumentCovenantTermsSecuredLeverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzkyMjY_f42dd547-7518-4579-8ff8-985a7615cdcc">3.50</ix:nonFraction>:1.00, and, in the case of unsecured debt, either a total leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="i3089f6878ad144f5971f1a990ab34d3a_I20211231" decimals="INF" name="bhc:DebtInstrumentCovenantTotalLeverageRatioMaximum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzkzMjE_ccff3b1d-179e-4081-9bb9-4a4f79271cf3">6.50</ix:nonFraction>:1.00 or an interest coverage ratio of not less than <ix:nonFraction unitRef="number" contextRef="i27fc8076f1bb4e4fac0065b5495211c5_I20211231" decimals="INF" name="bhc:DebtInstrumentCovenantInterestCoverageRatioMinimum" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzkzNzY_af1976fd-2ecd-405a-900d-d84d92d49271">2.00</ix:nonFraction>:1.00.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes are guaranteed by each of the Company&#8217;s subsidiaries that is a guarantor under the Restated Credit Agreement and existing Senior Unsecured Notes (together, the &#8220;Note Guarantors&#8221;). The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#8217;s obligations under the Restated Credit Agreement under the terms of the indentures governing the Senior Secured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#8217;s and Note Guarantors&#8217; respective existing and future unsubordinated indebtedness and senior to the Company&#8217;s and Note Guarantors&#8217; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pari passu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company&#8217;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#8217;s debt that is secured by assets that are not collateral.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#8217;s notes, in whole or in part, at a purchase price equal to <ix:nonFraction unitRef="number" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="INF" name="bhc:DebtInstrumentRedemptionPricePercentageChangeinControl" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzExMzU1_c0d14a2b-4ff0-480c-9cad-cb92c4b475a6">101</ix:nonFraction>% of the principal amount thereof plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="id9abd9fd4a3d4f839584c60b7f287d72_I20170331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzExNDI0_a3582fa9-9771-40ab-88d3-39bc205cf6c2">6.500</ix:nonFraction>% Senior Secured Notes due 2022 and <ix:nonFraction unitRef="number" contextRef="idd735e6d7a4a49c4a31ba11a3b55d3c5_I20170331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzExNDYx_bfc56ce8-6206-4f15-9801-828a7b96c368">7.00</ix:nonFraction>% Senior Secured Notes due 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Company issued $<ix:nonFraction unitRef="usd" contextRef="id9abd9fd4a3d4f839584c60b7f287d72_I20170331" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzExNTI5_b23a52c4-cc72-4827-98ff-3111ed706409">1,250</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="id9abd9fd4a3d4f839584c60b7f287d72_I20170331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzExNTYy_a3582fa9-9771-40ab-88d3-39bc205cf6c2">6.500</ix:nonFraction>% senior secured notes due March 15, 2022 (the &#8220;March 2022 Secured Notes&#8221;) and $<ix:nonFraction unitRef="usd" contextRef="idd735e6d7a4a49c4a31ba11a3b55d3c5_I20170331" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzExNjQy_50900620-3850-432c-ad51-229f59b9d334">2,000</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="idd735e6d7a4a49c4a31ba11a3b55d3c5_I20170331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzExNjc1_bfc56ce8-6206-4f15-9801-828a7b96c368">7.000</ix:nonFraction>% senior secured notes due March 15, 2024 (the &#8220;March 2024 Secured Notes&#8221;), in a private placement. Interest on these notes is payable semi-annually in arrears on each March 15 and September 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The March 2022 Secured Notes were repaid in full as part of the May 2020 Refinancing Transactions (as defined below).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The March 2024 Secured Notes were repaid in full during 2021 with cash on hand and as part of the June 2021 Refinancing Transactions (as defined below).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i449725090bcb4e129cd4dff2677ce289_I20171017" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEyMTQy_4d0ce25d-dd77-4997-bef8-5b795d08b746">5.500</ix:nonFraction>% Senior Secured Notes due 2025</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;17, 2017, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i449725090bcb4e129cd4dff2677ce289_I20171017" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEyMjE1_cf7b8035-983c-4a36-85db-102d7b5c2aed">1,000</ix:nonFraction>&#160;million, and, on November 21, 2017, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i17ca0b3ae0a14541b95a0029b74fc81f_I20171121" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEyMjY1_96222aed-d108-45e3-8c8f-a8ec59061b0d">750</ix:nonFraction>&#160;million,  aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i449725090bcb4e129cd4dff2677ce289_I20171017" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEyMzAw_4d0ce25d-dd77-4997-bef8-5b795d08b746">5.500</ix:nonFraction>% Senior Secured Notes due November 2025 (the &#8220;November 2025 Secured Notes&#8221;), </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="id437d56c3a6444b7ad6b7197e563347f" continuedAt="id262f724486b43088185db8dc57ffc81"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in a private placement. Interest on the November 2025 Secured Notes is payable semi-annually in arrears on each May 1 and November 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The November 2025 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time, at the redemption prices set forth in the indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i426ecf59adef4723a9464ff7dd035235_I20190308" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEyNjc3_16a59dce-31d1-4551-b079-66379bdb647f">5.750</ix:nonFraction>% Senior Secured Notes due 2027 - March 2019 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2019, BHA and the Company issued: (i) $<ix:nonFraction unitRef="usd" contextRef="ic4d5b348d3924c7286e27eb049dcb072_I20190308" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEyNzk4_69a00a55-4fe7-4bb1-bc9b-a6cd0d10a9be">1,000</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="ic4d5b348d3924c7286e27eb049dcb072_I20190308" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEyODMx_79d899c1-b890-44a4-91b7-982abb15e63e">8.500</ix:nonFraction>% Senior Unsecured Notes due 2027 (the &#8220;January 2027 Unsecured Notes&#8221;) and (ii) $<ix:nonFraction unitRef="usd" contextRef="i426ecf59adef4723a9464ff7dd035235_I20190308" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEyOTEy_87b5db2c-910a-4715-9bf5-6c56ddbcf1ee">500</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i426ecf59adef4723a9464ff7dd035235_I20190308" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEyOTQ1_0218e345-3a79-4e3b-aa73-77b97e4c75a1">5.750</ix:nonFraction>% Senior Secured Notes due August 2027 (the &#8220;August 2027 Secured Notes&#8221;), respectively, in a private placement. A portion of the proceeds and cash on hand were used to: (i) repurchase $<ix:nonFraction unitRef="usd" contextRef="i234da319c3ef47c291bbc91d590a7fc6_D20190101-20191231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEzMTMw_ad149e92-1d00-4991-be97-c1557077de86">584</ix:nonFraction> million of <ix:nonFraction unitRef="number" contextRef="i1b7290e999a74c9f84f1e1f0dc4acadf_I20190308" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEzMTM2_5344af66-9549-44cb-983e-a6747b2727df">5.875</ix:nonFraction>% Senior Unsecured Notes due 2023 (the &#8220;May 2023 Unsecured Notes&#8221;), (ii) repurchase $<ix:nonFraction unitRef="usd" contextRef="i60523f26c0cc421995caf64823d36f89_D20190308-20190308" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEzMjIx_dc7577b7-cf1c-4073-b2a1-090c5e6e270f">518</ix:nonFraction> million of <ix:nonFraction unitRef="number" contextRef="i7107764faeb3461fb0c3e1558afa09a0_I20190308" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEzMjI3_7a9290e5-8980-4028-b3d3-db99c0b2870c">5.625</ix:nonFraction>% Senior Unsecured Notes due 2021 (the &#8220;December 2021 Unsecured Notes&#8221;), (iii) repurchase $<ix:nonFraction unitRef="usd" contextRef="ia554f95ec9dd4a30af67e386976e2ee4_D20190308-20190308" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEzMzE4_28604139-8b05-4d1e-af08-e4baf1fb690a">216</ix:nonFraction> million of <ix:nonFraction unitRef="number" contextRef="i8c3fe314a07b49f5a24c68a78aa7c617_I20190308" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEzMzI0_7ab4bcd2-a9ab-45ab-92bc-85803813446a">5.500</ix:nonFraction>% Senior Unsecured Notes due 2023 (the &#8220;March 2023 Unsecured Notes&#8221;) and (iv) pay all fees and expenses associated with these transactions (collectively, the &#8220;March 2019 Refinancing Transactions&#8221;). During April 2019, the Company redeemed $<ix:nonFraction unitRef="usd" contextRef="ia4a78928619a4fbdbb34836a1b0fe3dd_D20190401-20190430" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEzNTYz_61824fd3-87b5-4500-85bf-180adb5d2552">182</ix:nonFraction> million of the December 2021 Unsecured Notes, representing the remaining outstanding principal balance of the December 2021 Unsecured Notes and completing the refinancing of $<ix:nonFraction unitRef="usd" contextRef="i55f45e1ec8754cce8219f906d738aa2d_I20190430" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEzNzMy_c2945191-9a36-4cd8-a393-23517317e821">1,500</ix:nonFraction> million of debt in connection with the March 2019 Refinancing Transactions. The March 2019 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="iefa733ef7c794dbaaf6199d058362bd6_D20190308-20190308" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEzOTE5_d7fbb717-73d1-4fdd-837d-5993abddbbc9">8</ix:nonFraction> million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value. Interest on the August 2027 Secured Notes is payable semi-annually in arrears on each February 15 and August 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The August 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after August 15, 2022, at the redemption prices set forth in the indenture. The Company may redeem some or all of the August 2027 Secured Notes prior to August 15, 2022 at a price equal to <ix:nonFraction unitRef="number" contextRef="i64a0081e7f7a480c9031042be2e2e776_D20190308-20190308" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE0NDY2_28984433-2035-405b-b377-3e24d2668a27">100</ix:nonFraction>% of the principal amount thereof plus a &#8220;make-whole&#8221; premium. Prior to August 15, 2022, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="i64a0081e7f7a480c9031042be2e2e776_D20190308-20190308" decimals="INF" name="bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE0NTg1_20a6b576-f3ac-4c56-b431-1017f92552d9">40</ix:nonFraction>% of the aggregate principal amount of the August 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i8eb18dd3d80f4b20be43d6f02dd8ec59_I20210608" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE0NzU0_6c040f76-fe8b-401a-b6a5-8de578e9b40a">4.875</ix:nonFraction>% Senior Secured Notes due 2028 - June 2021 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2021, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i8eb18dd3d80f4b20be43d6f02dd8ec59_I20210608" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE0ODYw_870400e9-3f80-4829-a1b9-6329e17b003f">1,600</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i8eb18dd3d80f4b20be43d6f02dd8ec59_I20210608" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE0ODkz_6c040f76-fe8b-401a-b6a5-8de578e9b40a">4.875</ix:nonFraction>% Senior Secured Notes due June 2028 (the &#8220;June 2028 Secured Notes&#8221;) in a private placement. The proceeds and cash on hand were used to: (i) repurchase a portion and redeem the remainder of $<ix:nonFraction unitRef="usd" contextRef="ide09659430754a848ded8babd4ea06b0_D20210608-20210608" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE1MDg0_b63385f0-1b72-4a51-a3cb-d39f8fba47a2">1,600</ix:nonFraction>&#160;million of the March 2024 Secured Notes, representing the remaining outstanding principal balance of the March 2024 Secured Notes and (ii) pay all fees and expenses associated with these transactions (collectively, the &#8220;June 2021 Refinancing Transactions&#8221;). The June 2021 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i88ac47eb607d48dda7da8b2ce778805a_D20210608-20210608" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE1NDg1_2c7c903b-f49c-48ef-b124-f8e8c731780a">38</ix:nonFraction>&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value. Interest on the June 2028 Secured Notes is payable semi-annually in arrears on each June 1 and December 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2028 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after June 1, 2024, at the redemption prices set forth in the June 2028 Secured Notes indenture. The Company may redeem some or all of the June 2028 Secured Notes prior to June 1, 2024 at a price equal to <ix:nonFraction unitRef="number" contextRef="i9c34aa862974483ea57b2b1d0e3c0f03_D20210608-20210608" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE2MDQw_942adf78-bd7b-4c7e-b9eb-ba62c0a24d47">100</ix:nonFraction>% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of the redemption plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to June 1, 2024, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="if7d99baf53a5465bbbfe961490f008dc_D20210608-20210608" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE2MjY1_650a8c0b-22ac-4f85-b975-96bf0e87cc9b">40</ix:nonFraction>% of the aggregate principal amount of the June 2028 Secured Notes using the net proceeds of certain equity offerings at the redemption price set forth in the June 2028 Secured Notes indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Unsecured Notes issued by the Company are the Company&#8217;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the Senior Secured Credit Facilities. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the Senior Secured Credit Facilities. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to <ix:nonFraction unitRef="number" contextRef="i4fc30bcb84e44522a8af652f8f8ce17c_D20210101-20211231" decimals="INF" name="bhc:DebtInstrumentRedemptionPricePercentageChangeinControl" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE3MzIw_1e603f67-c841-4510-864f-ade814342ea7">101</ix:nonFraction>% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="id262f724486b43088185db8dc57ffc81" continuedAt="iedae0a67082c4ee28387f84d6bf65951"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="ibd5fa5a50ddb47ce943d25e5158d7fa4_I20150130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE3NDM0_5f2de05f-829e-4c8f-8925-b0f856a4b879">5.500</ix:nonFraction>% Senior Unsecured Notes due 2023</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 30, 2015, the Company issued $<ix:nonFraction unitRef="usd" contextRef="ibd5fa5a50ddb47ce943d25e5158d7fa4_I20150130" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE3NTA5_d8f6175b-b82c-49e0-9bcf-55850b2a5960">1,000</ix:nonFraction> million aggregate principal amount of March 2023 Unsecured Notes in a private placement. The March 2023 Unsecured Notes accrued interest at the rate of <ix:nonFraction unitRef="number" contextRef="ibd5fa5a50ddb47ce943d25e5158d7fa4_I20150130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE3NjU2_5f2de05f-829e-4c8f-8925-b0f856a4b879">5.500</ix:nonFraction>% per year, payable semi-annually in arrears. On March 8, 2019 and May 23, 2019, the Company repurchased $<ix:nonFraction unitRef="usd" contextRef="ia554f95ec9dd4a30af67e386976e2ee4_D20190308-20190308" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE3NzYy_28604139-8b05-4d1e-af08-e4baf1fb690a">216</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if6d83e37326d4725bc725486444bd866_D20190523-20190523" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE3NzY5_302ab4e8-d6ef-433d-851a-f13f771519eb">382</ix:nonFraction> million of March 2023 Unsecured Notes as part of the March 2019 Refinancing Transactions and the May 2019 Refinancing Transactions (as defined below), respectively. Throughout 2020, the Company repurchased, in aggregate, $<ix:nonFraction unitRef="usd" contextRef="i6dd5787480294fa2b679e5d4885e9821_D20200101-20201130" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE3ODk3_c8aaeb18-552b-47f4-89ff-3082e7765252">169</ix:nonFraction>&#160;million of March 2023 Unsecured Notes using cash on hand. The Company repurchased the remaining outstanding balance of $<ix:nonFraction unitRef="usd" contextRef="idc9c834100a744ec86cca979fb7b31ec_D20201201-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE4MDEx_d5ece080-ad15-43e1-97d7-f50a2607d7aa">233</ix:nonFraction>&#160;million in December 2020 as part of the December 2020 Refinancing Transactions (as defined below).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i9fdd4332ca4c43c99f6dab6dd5f1e32f_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE4MTA1_dedf23c6-0fe5-41fa-bb48-8441ea834f9e">5.375</ix:nonFraction>% Senior Unsecured Notes due 2020, <ix:nonFraction unitRef="number" contextRef="ia903bb7aea2a44119bda10563a043e40_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE4MTQx_ff18696a-d0fc-40cb-9828-d2339cf208db">5.875</ix:nonFraction>% Senior Unsecured Notes due 2023, <ix:nonFraction unitRef="number" contextRef="iedce2bbbaab64fc79908a3e30f8e6c65_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE4MTc3_899b1f37-6184-4d58-b5d0-58990e43cd44">4.500</ix:nonFraction>% Senior Unsecured Notes due 2023 and <ix:nonFraction unitRef="number" contextRef="i7040cce3fb9b4eeba357b284b09231e2_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE4MjE2_d29ef6f2-ba50-4ef4-aa44-7a25424167cf">6.125</ix:nonFraction>% Senior Unsecured Notes due 2025</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2015, VRX Escrow Corp. (the &#8220;VRX Issuer&#8221;), a newly formed wholly owned subsidiary of the Company, issued $<ix:nonFraction unitRef="usd" contextRef="i9fdd4332ca4c43c99f6dab6dd5f1e32f_I20150327" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE4MzY5_e32693f0-3164-43cd-a8a2-ecd4eb423207">2,000</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i9fdd4332ca4c43c99f6dab6dd5f1e32f_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE4NDAy_2f8d00c6-5dbe-4d74-8aa1-c166b9f6adc6">5.375</ix:nonFraction>% Senior Unsecured Notes due 2020 (the &#8220;March 2020 Unsecured Notes&#8221;), $<ix:nonFraction unitRef="usd" contextRef="ia903bb7aea2a44119bda10563a043e40_I20150327" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE4NDcz_c776e1b4-063f-40a7-a613-ed2c1c833e8f">3,250</ix:nonFraction> million aggregate principal amount of May 2023 Unsecured Notes, &#8364;<ix:nonFraction unitRef="eur" contextRef="iedce2bbbaab64fc79908a3e30f8e6c65_I20150327" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE4NTMy_adb57aa8-e0f8-4feb-83be-d3893c8939ac">1,500</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="iedce2bbbaab64fc79908a3e30f8e6c65_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE4NTY1_d018ada1-a7a5-4609-8338-f933b58dff79">4.500</ix:nonFraction>% Senior Unsecured Notes due 2023 (the &#8220;Euro Notes&#8221;) and $<ix:nonFraction unitRef="usd" contextRef="i7040cce3fb9b4eeba357b284b09231e2_I20150327" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE4NjIz_bf49642d-66a8-40d3-a534-365dde1d181b">3,250</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i7040cce3fb9b4eeba357b284b09231e2_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE4NjU2_427feabc-6c0b-4a97-a63f-f1a4e329d9cf">6.125</ix:nonFraction>% Senior Unsecured Notes due 2025 (the &#8220;April 2025 Unsecured Notes&#8221; and, together with the March 2020 Unsecured Notes&#8221;), the May 2023 Unsecured Notes and the Euro Notes, the &#8220;VRX Notes&#8221;) in a private placement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The March 2020 Unsecured Notes&#8221;) accrued interest at the rate of <ix:nonFraction unitRef="number" contextRef="i9fdd4332ca4c43c99f6dab6dd5f1e32f_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE4ODU5_3f68eee7-0380-48e0-8332-87b21e8e96a3">5.375</ix:nonFraction>% per year and were repaid in full as part of certain refinancing transactions completed in 2017 and 2018. The May 2023 Unsecured Notes and the Euro Notes accrued interest at the rate of <ix:nonFraction unitRef="number" contextRef="ia903bb7aea2a44119bda10563a043e40_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE5MDI1_8082628a-19da-419c-8637-73b66c3cf5bb">5.875</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="iedce2bbbaab64fc79908a3e30f8e6c65_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE5MDMy_1527a76a-6615-4237-8238-6d76ca553667">4.500</ix:nonFraction>%  per year, respectively and were each repaid in full as of December 31, 2020, as discussed below. The April 2025 Unsecured Notes accrue interest at the rate of <ix:nonFraction unitRef="number" contextRef="i7040cce3fb9b4eeba357b284b09231e2_I20150327" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE5MTk1_55f16d3e-f4b6-4576-8786-51eca8b387ba">6.125</ix:nonFraction>% per year, payable semi-annually in arrears. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of a refinancing transaction completed in June 2018, the Company repaid the remaining outstanding principal amounts of the March 2020 Unsecured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company repurchased $<ix:nonFraction unitRef="usd" contextRef="i234da319c3ef47c291bbc91d590a7fc6_D20190101-20191231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE5NDM5_ad149e92-1d00-4991-be97-c1557077de86">584</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id9f599c080f5467ea5baebd9fac485a0_D20190101-20191231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE5NDQ2_4c918951-cc70-4db4-81fc-af12c419bb2f">1,118</ix:nonFraction> million of May 2023 Unsecured Notes as part of the March 2019 Refinancing Transactions and the May 2019 Refinancing Transactions (as defined below), respectively, and on October 3, 2019, the Company repaid an additional $<ix:nonFraction unitRef="usd" contextRef="if99807b8eead4d89b01d9fb9a37fc251_D20191003-20191003" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE5NTc1_cbab03ec-c437-4d01-a4ff-96d68c16d97e">100</ix:nonFraction> million of May 2023 Unsecured Notes using cash on hand. On January 16, 2020, the Company redeemed $<ix:nonFraction unitRef="usd" contextRef="ic53f9efb99aa4ccda95f61d26890a343_I20200116" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE5NjQ2_f6f29e27-7d8f-4787-90b4-f4455fd862ff">1,240</ix:nonFraction> million aggregate principal amount of the May 2023 Unsecured Notes as part of the December 2019 Financing and Refinancing Transactions (as defined below). Throughout 2020, the Company repaid, in aggregate, $<ix:nonFraction unitRef="usd" contextRef="if94fac52f3f54b40b4fdd01288bf1861_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE5ODI1_5603c123-c23b-4474-a551-241862cbbc43">208</ix:nonFraction>&#160;million of the May 2023 Unsecured Notes, with the May 2023 Unsecured Notes having been fully repaid during November 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2020, the Company redeemed the remaining outstanding balance of the Euro Notes as part of the December 2020 Refinancing Transactions, as defined below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout 2021, the Company repaid, in aggregate, $<ix:nonFraction unitRef="usd" contextRef="id6298e5d16674dff95b3e998b6c37203_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIwMTYw_d79abc04-aa99-468f-9261-e99cf5a4dc12">600</ix:nonFraction>&#160;million of the April 2025 Unsecured Notes. The Company may redeem all or a portion of the April 2025 Unsecured Notes at the redemption prices set forth in the applicable indenture, plus accrued and unpaid interest to the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i4177e1b635b74d889574e58be568dee6_I20171218" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIwMzk2_2e6fc31b-df8a-45a9-b322-0407682735f9">9.000</ix:nonFraction>% Senior Unsecured Notes due 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;18, 2017, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i4177e1b635b74d889574e58be568dee6_I20171218" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIwNDcz_9d54d596-a2d9-4367-8e63-5a1da9f67637">1,500</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i4177e1b635b74d889574e58be568dee6_I20171218" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIwNTA2_a0f6c992-ed83-4325-a880-5d0ce3675401">9.000</ix:nonFraction>% Senior Unsecured Notes due 2025 (the &#8220;December 2025 Unsecured Notes&#8221;) in a private placement, the net proceeds of which were used to repurchase $<ix:nonFraction unitRef="usd" contextRef="i5a8941f15dfb40e2ad916e87ad8d78c1_I20171218" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIwNjUz_e90ad480-eae9-4b9b-8773-6f6a6fac4ef9">1,500</ix:nonFraction>&#160;million in aggregate principal amount of previously outstanding senior unsecured notes (the &#8220;December 2017 Refinancing Transactions&#8221;). The related fees and expenses were paid using cash on hand. The December 2025 Unsecured Notes accrue interest at the rate of <ix:nonFraction unitRef="number" contextRef="i4177e1b635b74d889574e58be568dee6_I20171218" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIwODgx_6ce58f17-a70d-4158-9cf5-af40b14c29d6">9.000</ix:nonFraction>% per year, payable semi-annually in arrears on each of June 15 and December 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the December 2025 Unsecured Notes at any time prior to December 15, 2021, at a price equal to <ix:nonFraction unitRef="number" contextRef="i719d98863d0149828286447cfc21c537_D20171218-20171218" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIxMTAw_838bb1d8-02f5-45ab-8a32-f46778ac1ca8">100</ix:nonFraction>% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to December 15, 2020, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="ib5f75d74fcd94b378a67e51f53cdb29a_D20171218-20171218" decimals="INF" name="bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIxMzE2_9cade36b-6040-4b7c-b971-d83fb2530992">40</ix:nonFraction>% of the aggregate principal amount of the outstanding December 2025 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the December 2025 Unsecured Notes indenture. On or after December 15, 2021, the Company may redeem all or a portion of the December 2025 Unsecured Notes at the applicable redemption prices set forth in the December 2025 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="iedae0a67082c4ee28387f84d6bf65951" continuedAt="i175591ffc71e44108441d1ca587261c1"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="ic7a91ae9c014412285210f2ad632343e_I20180326" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIxNzk2_9f0dca8c-e3bd-43de-b3c6-f0aeca631ed7">9.250</ix:nonFraction>% Senior Unsecured Notes due 2026</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 26, 2018, BHA issued $<ix:nonFraction unitRef="usd" contextRef="ic7a91ae9c014412285210f2ad632343e_I20180326" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIxODYx_722fe2c7-8f73-4849-946d-970e1b508a39">1,500</ix:nonFraction> million in aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="ic7a91ae9c014412285210f2ad632343e_I20180326" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIxODk3_9f0dca8c-e3bd-43de-b3c6-f0aeca631ed7">9.250</ix:nonFraction>% Senior Unsecured Notes due 2026 (the &#8220;April 2026 Unsecured Notes&#8221;) in a private placement, the net proceeds of which, and cash on hand, were used to repurchase $<ix:nonFraction unitRef="usd" contextRef="ic7a91ae9c014412285210f2ad632343e_I20180326" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIyMDYw_8ce0993d-fdfb-4337-ab02-27b26da77dfa">1,500</ix:nonFraction> million in aggregate principal amount of unsecured notes. All fees and expenses associated with these transactions were paid with cash on hand (collectively, the &#8220;March 2018 Refinancing Transactions&#8221;). The April 2026 Unsecured Notes accrue interest at the rate of <ix:nonFraction unitRef="number" contextRef="ic7a91ae9c014412285210f2ad632343e_I20180326" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIyMzE5_9f0dca8c-e3bd-43de-b3c6-f0aeca631ed7">9.250</ix:nonFraction>% per year, payable semi-annually in arrears on each of April 1 and October 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BHA may redeem all or a portion of the April 2026 Unsecured Notes at any time prior to April 1, 2022, at a price equal to <ix:nonFraction unitRef="number" contextRef="i2277d8eefa0b44fba997881be7afffec_D20180326-20180326" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIyNTIx_685536f0-5f46-4e99-90ea-d2e98d7ad4b5">100</ix:nonFraction>% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to April 1, 2021, BHA may redeem up to <ix:nonFraction unitRef="number" contextRef="i2277d8eefa0b44fba997881be7afffec_D20180326-20180326" decimals="INF" name="bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIyNzI1_452f7531-e359-4f0f-afe9-056ba5de198b">40</ix:nonFraction>% of the aggregate principal amount of the outstanding April 2026 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the April 2026 Unsecured Notes indenture. On or after April 1, 2022, BHA may redeem all or a portion of the April 2026 Unsecured Notes at the applicable redemption prices set forth in the April 2026 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i177b63c1f7f747e3b7ccc3613e2fcaa8_I20181231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIzMTgx_ac813477-de11-45f7-ae76-f4765066d548">8.500</ix:nonFraction>% Senior Unsecured Notes due 2027</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of a 2018 refinancing transaction, BHA issued $<ix:nonFraction unitRef="usd" contextRef="i177b63c1f7f747e3b7ccc3613e2fcaa8_I20181231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIzMjcw_1c649a78-25f7-4c4a-998c-a1c7c562b4a0">750</ix:nonFraction> million in aggregate principal amount of January 2027 Unsecured Notes in a private placement. The January 2027 Unsecured Notes accrue interest at the rate of <ix:nonFraction unitRef="number" contextRef="i177b63c1f7f747e3b7ccc3613e2fcaa8_I20181231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIzNDIz_ac813477-de11-45f7-ae76-f4765066d548">8.500</ix:nonFraction>% per year, payable semi-annually in arrears on each of January 31 and July 31. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the March 2019 Refinancing Transactions described above, BHA issued $<ix:nonFraction unitRef="usd" contextRef="ic4d5b348d3924c7286e27eb049dcb072_I20190308" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIzNTUx_69a00a55-4fe7-4bb1-bc9b-a6cd0d10a9be">1,000</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i177b63c1f7f747e3b7ccc3613e2fcaa8_I20181231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIzNTg0_ac813477-de11-45f7-ae76-f4765066d548">8.500</ix:nonFraction>% Senior Unsecured Notes due January 2027. These are additional notes and form part of the same series as BHA&#8217;s existing January 2027 Unsecured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BHA may redeem all or a portion of the January 2027 Unsecured Notes at any time prior to July 31, 2022, at a price equal to <ix:nonFraction unitRef="number" contextRef="ib4c76c9931404817acf913b8360dbb5e_D20180101-20181231" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIzODYw_a26b93b3-8ae9-41ed-a63c-3f0dc0479c1b">100</ix:nonFraction>% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to July 31, 2021, BHA may redeem up to <ix:nonFraction unitRef="number" contextRef="ib4c76c9931404817acf913b8360dbb5e_D20180101-20181231" decimals="INF" name="bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI0MDY0_1e3f1881-52e7-4d2a-8b68-8d3817a149c3">40</ix:nonFraction>% of the aggregate principal amount of the outstanding January 2027 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the January 2027 Unsecured Notes indenture. On or after July 31, 2022, BHA may redeem all or a portion of the January 2027 Unsecured Notes at the applicable redemption prices set forth in the January 2027 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i797b2df10ff44b2aa71c461fc27b30ef_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI0NTI4_9f4b7735-0a06-4590-b947-e56e49267136">7.000</ix:nonFraction>% Senior Unsecured Notes due 2028 and <ix:nonFraction unitRef="number" contextRef="ibc2d2ee34b9d4af8aaed19ac1ff2667c_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI0NTY3_a4c85980-5c1a-4d00-863e-16772573b60e">7.250</ix:nonFraction>% Senior Unsecured Notes due 2029 - May 2019 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 23, 2019, the Company issued: (i) $<ix:nonFraction unitRef="usd" contextRef="i797b2df10ff44b2aa71c461fc27b30ef_I20190523" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI0Njc5_9544e3ec-cf87-4491-9c17-92f3e8c55fe6">750</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i797b2df10ff44b2aa71c461fc27b30ef_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI0NzEy_9f4b7735-0a06-4590-b947-e56e49267136">7.000</ix:nonFraction>% Senior Unsecured Notes due January 2028 (the &#8220;<ix:nonFraction unitRef="number" contextRef="i797b2df10ff44b2aa71c461fc27b30ef_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI0NzYx_a712cfca-43d3-4b1b-acf0-5c747af2579d">7.000</ix:nonFraction>% January 2028 Unsecured Notes&#8221;) and (ii) $<ix:nonFraction unitRef="usd" contextRef="ibc2d2ee34b9d4af8aaed19ac1ff2667c_I20190523" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI0ODA0_414e4ded-39f7-4488-887d-9d552cac3de9">750</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="ibc2d2ee34b9d4af8aaed19ac1ff2667c_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI0ODM3_a4c85980-5c1a-4d00-863e-16772573b60e">7.250</ix:nonFraction>% Senior Unsecured Notes due May 2029 (the &#8220;May 2029 Unsecured Notes&#8221;), respectively, in a private placement. The proceeds and cash on hand were used to: (i) repurchase $<ix:nonFraction unitRef="usd" contextRef="id9f599c080f5467ea5baebd9fac485a0_D20190101-20191231" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI1MDA3_4c918951-cc70-4db4-81fc-af12c419bb2f">1,118</ix:nonFraction> million of May 2023 Unsecured Notes, (ii) repurchase $<ix:nonFraction unitRef="usd" contextRef="if6d83e37326d4725bc725486444bd866_D20190523-20190523" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI1MDU1_302ab4e8-d6ef-433d-851a-f13f771519eb">382</ix:nonFraction> million of March 2023 Unsecured Notes and (iii) pay all fees and expenses associated with these transactions (collectively, the &#8220;May 2019 Refinancing Transactions&#8221;). The May 2019 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i9c71c44fc4c34b9bae672a9f56dfd653_D20190523-20190523" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI1MzMy_816a167e-fbe4-4b2c-8686-4e24ce094e7a">32</ix:nonFraction> million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value. Interest on the <ix:nonFraction unitRef="number" contextRef="i797b2df10ff44b2aa71c461fc27b30ef_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI1NDc5_20801ae9-d0e8-49ef-bfb9-ee6eaffab1c1">7.000</ix:nonFraction>% January 2028 Unsecured Notes is payable semi-annually in arrears on each January 15 and July 15. Interest on the May 2029 Unsecured Notes is payable semi-annually in arrears on each May 30 and November 30. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The <ix:nonFraction unitRef="number" contextRef="i797b2df10ff44b2aa71c461fc27b30ef_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI1Njkz_c708cfbb-fd9b-400b-bae3-dac97678aeaf">7.000</ix:nonFraction>% January 2028 Unsecured Notes and the May 2029 Unsecured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after January 15, 2023 and May 30, 2024, respectively, at the redemption prices set forth in the respective indenture. The Company may redeem some or all of the <ix:nonFraction unitRef="number" contextRef="i797b2df10ff44b2aa71c461fc27b30ef_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI2MDAz_def56d2a-5f2e-4beb-8e13-493847060733">7.000</ix:nonFraction>% January 2028 Unsecured Notes or the May 2029 Unsecured Notes prior to January 15, 2023 and May 30, 2024, respectively, at a price equal to <ix:nonFraction unitRef="number" contextRef="i2c637f283ab04dfbbbfee6141ea6b782_D20190523-20190523" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI2MTQ1_78bc22e5-71b0-4878-8fc4-cc1becbd04fc"><ix:nonFraction unitRef="number" contextRef="if78fcb7d67eb418892f72d087ada3247_D20190523-20190523" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI2MTQ1_895fa434-a7ca-4ee1-ab36-3bd0d9f8759c">100</ix:nonFraction></ix:nonFraction>% of the principal amount thereof plus a &#8220;make-whole&#8221; premium. Prior to July 15, 2022, and May 30, 2022, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="if78fcb7d67eb418892f72d087ada3247_D20190523-20190523" decimals="INF" name="bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI2Mjgw_91adab12-9d39-4d74-b7a3-013b82b13177"><ix:nonFraction unitRef="number" contextRef="i2c637f283ab04dfbbbfee6141ea6b782_D20190523-20190523" decimals="INF" name="bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI2Mjgw_a5ef3700-8594-4e40-992a-e31d46ca66d9">40</ix:nonFraction></ix:nonFraction>% of the aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="i797b2df10ff44b2aa71c461fc27b30ef_I20190523" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI2MzI0_8cb1d3c3-f21d-4547-b10a-738741289ae3">7.000</ix:nonFraction>% January 2028 Unsecured Notes or the May 2029 Unsecured Notes, respectively, using the proceeds of certain equity offerings at the redemption price set forth in the respective indenture. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i8b69c2b55c9f49159ba0241d1da3b1b6_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI2NTE0_629806e7-0bbd-4c49-8c8c-cb89d2df3f33">5.000</ix:nonFraction>% Senior Unsecured Notes due 2028 and <ix:nonFraction unitRef="number" contextRef="i707c6ada63c346a9b3799fb37f228dee_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI2NTUz_e3f2fa2c-75e5-46ea-b1d8-00a89170d3dc">5.250</ix:nonFraction>% Senior Unsecured Notes due 2030 - December 2019 Financing and Refinancing Transactions</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i175591ffc71e44108441d1ca587261c1" continuedAt="i4efeff83fff24914852e200a4edd71e6"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, the Company issued: (i) $<ix:nonFraction unitRef="usd" contextRef="i8b69c2b55c9f49159ba0241d1da3b1b6_I20191230" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI2Njg5_05c7066e-c198-4b5f-9baf-e71a17232e23">1,250</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i8b69c2b55c9f49159ba0241d1da3b1b6_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI2NzIy_52a833f0-f124-4039-94c4-b14c273656a4">5.000</ix:nonFraction>% Senior Unsecured Notes due January 2028 (the &#8220;<ix:nonFraction unitRef="number" contextRef="i8b69c2b55c9f49159ba0241d1da3b1b6_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI2Nzcx_b5b81aea-e5a1-4658-9d34-d9e895449e78">5.000</ix:nonFraction>% January 2028 Unsecured Notes&#8221;) and (ii) $<ix:nonFraction unitRef="usd" contextRef="i707c6ada63c346a9b3799fb37f228dee_I20191230" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI2ODE0_501ff417-aed9-4d40-8001-0ed3f2aa1739">1,250</ix:nonFraction> million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i707c6ada63c346a9b3799fb37f228dee_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI2ODQ3_9211a149-b2f7-4788-9f69-7563d5afd0e6">5.250</ix:nonFraction>% Senior Unsecured Notes due January 2030 (the &#8220;January 2030 Unsecured Notes&#8221;) in a private placement. The proceeds and cash on hand were used to: (i) redeem $<ix:nonFraction unitRef="usd" contextRef="i11d7dcdeb76f46a1ac2fb260dc29bf23_D20200116-20200116" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI3MDA2_ca8bc690-15c6-4ec1-9c2d-8800bebc0053">1,240</ix:nonFraction> million of May 2023 Unsecured Notes on January 16, 2020, (ii) finance the $<ix:nonFraction unitRef="usd" contextRef="i6ba274da5cb54b1daae13438db70ae34_D20191216-20191216" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI3MDc1_e0ac410a-911e-4855-8b78-b9dac1dcb563">1,210</ix:nonFraction> million settlement of certain U.S. Securities litigation as discussed in Note 20, &#8220;LEGAL PROCEEDINGS&#8221; and (iii) pay all fees and expenses associated with these transactions (collectively, the &#8220;December 2019 Financing and Refinancing Transactions&#8221;). The redemption of $<ix:nonFraction unitRef="usd" contextRef="i11d7dcdeb76f46a1ac2fb260dc29bf23_D20200116-20200116" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI3MzEx_6642d215-c81e-4799-817a-552c63d1f014">1,240</ix:nonFraction>&#160;million of May 2023 Unsecured notes was accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i11d7dcdeb76f46a1ac2fb260dc29bf23_D20200116-20200116" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI3NDUw_7b8a94c2-1088-4f5e-8b1f-6d98bf738c54">24</ix:nonFraction>&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt's carrying value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on the <ix:nonFraction unitRef="number" contextRef="i8b69c2b55c9f49159ba0241d1da3b1b6_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI3NTk3_b5b81aea-e5a1-4658-9d34-d9e895449e78">5.000</ix:nonFraction>% January 2028 Unsecured Notes&#8221;) is payable semi-annually in arrears on each January 30 and July 30. Interest on the January 2030 Unsecured Notes&#8221;) is payable semi-annually in arrears on each January 30 and July 30. The <ix:nonFraction unitRef="number" contextRef="i8b69c2b55c9f49159ba0241d1da3b1b6_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI3NzYy_b5b81aea-e5a1-4658-9d34-d9e895449e78">5.000</ix:nonFraction>% January 2028 Unsecured Notes&#8221;) and the January 2030 Unsecured Notes&#8221;) are redeemable at the option of the Company, in whole or in part, at any time on or after January 30, 2023 and January 30, 2025, respectively, at the redemption prices set forth in the respective indenture. The Company may redeem some or all of the <ix:nonFraction unitRef="number" contextRef="i8b69c2b55c9f49159ba0241d1da3b1b6_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI4MDI4_b5b81aea-e5a1-4658-9d34-d9e895449e78">5.000</ix:nonFraction>% January 2028 Unsecured Notes&#8221;) or the January 2030 Unsecured Notes&#8221;) prior to January 30, 2023 and January 30, 2025, respectively, at a price equal to <ix:nonFraction unitRef="number" contextRef="i4f688b41850c4d0fba418cbe194ccfbe_D20191230-20191230" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI4MTI2_6f433409-67d4-47ca-a13e-d1ae30afb674"><ix:nonFraction unitRef="number" contextRef="i2b0d3caab19d43358c37172b00a1d73e_D20191230-20191230" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI4MTI2_db747253-52c6-47b7-8e2b-4aa13c1fec0e">100</ix:nonFraction></ix:nonFraction>% of the principal amount thereof plus a &#8220;make-whole&#8221; premium. Prior to January 30, 2023, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="i2b0d3caab19d43358c37172b00a1d73e_D20191230-20191230" decimals="INF" name="bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI4MjQ2_07e3403a-489a-488d-bd75-43f42cd35d48"><ix:nonFraction unitRef="number" contextRef="i4f688b41850c4d0fba418cbe194ccfbe_D20191230-20191230" decimals="INF" name="bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI4MjQ2_92059197-0a0d-4ec2-9a1a-4ded70d5c7c2">40</ix:nonFraction></ix:nonFraction>% of the aggregate principal amount of the <ix:nonFraction unitRef="number" contextRef="i8b69c2b55c9f49159ba0241d1da3b1b6_I20191230" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI4Mjkw_b5b81aea-e5a1-4658-9d34-d9e895449e78">5.000</ix:nonFraction>% January 2028 Unsecured Notes&#8221;) or the January 2030 Unsecured Notes&#8221;) using the proceeds of certain equity offerings at the redemption price set forth in the respective indenture. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i23b34418de5747bc96ac966e1bad4561_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI4NDE3_810619d3-98a8-4001-94e5-482f8f99f66a">6.250</ix:nonFraction>% Senior Unsecured Notes due 2029 - May 2020 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 26, 2020, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i23b34418de5747bc96ac966e1bad4561_I20200526" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI4NTI0_219af690-8ec1-4af7-ae3a-e5abf7df91c9">1,500</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i23b34418de5747bc96ac966e1bad4561_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI4NTU3_810619d3-98a8-4001-94e5-482f8f99f66a">6.250</ix:nonFraction>% Senior Unsecured Notes due February 2029 (the &#8220;<ix:nonFraction unitRef="number" contextRef="i23b34418de5747bc96ac966e1bad4561_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI4NjA3_810619d3-98a8-4001-94e5-482f8f99f66a">6.250</ix:nonFraction>% February 2029 Unsecured Notes&#8221;) in a private placement. The proceeds and cash on hand were used to: (i) repurchase $<ix:nonFraction unitRef="usd" contextRef="i39f28d2202204cc1b5a777f81170474c_I20200526" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI4NzI1_7ae4b391-7de3-4bf9-a226-3640cd6bb9a9">1,250</ix:nonFraction>&#160;million aggregate principal amount of the outstanding March 2022 Secured Notes, (ii) prepay $<ix:nonFraction unitRef="usd" contextRef="if0649a2ad7e34fdd9c9aaacf95248fea_D20200526-20200526" decimals="-6" name="bhc:PaymentForDebtAmortizationPrepaymentCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI4ODEy_761df073-5c79-4da7-91f7-c59f3dd8d03f">303</ix:nonFraction>&#160;million of mandatory amortization scheduled for payment in 2022 under the Company's June 2025 and November 2025 Term Loan B Facilities and (iii) pay all fees and expenses associated with these transactions (collectively, the &#8220;May 2020 Refinancing Transactions&#8221;). The May 2020 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i79078ef3ff22478e8ad56dbe5a19750d_D20200526-20200526" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI5MjE3_a3609d8f-d9d0-46c6-be0c-1f37cbcabe96">27</ix:nonFraction>&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt's carrying value. The <ix:nonFraction unitRef="number" contextRef="i23b34418de5747bc96ac966e1bad4561_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI5MzUy_810619d3-98a8-4001-94e5-482f8f99f66a">6.250</ix:nonFraction>% February 2029 Unsecured Notes accrue interest at the rate of <ix:nonFraction unitRef="number" contextRef="i23b34418de5747bc96ac966e1bad4561_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI5NDE2_810619d3-98a8-4001-94e5-482f8f99f66a">6.250</ix:nonFraction>% per year, payable semi-annually in arrears on each of February 15 and August 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the <ix:nonFraction unitRef="number" contextRef="i23b34418de5747bc96ac966e1bad4561_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI5NTQ3_810619d3-98a8-4001-94e5-482f8f99f66a">6.250</ix:nonFraction>% February 2029 Unsecured Notes at any time prior to February 15, 2024, at a price equal to <ix:nonFraction unitRef="number" contextRef="i80f3eb0d6a794c4dbf060750dbc6dc48_D20200526-20200526" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI5NjQw_748f8e60-c549-4408-97f6-44f5a89b4933">100</ix:nonFraction>% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to August 15, 2023, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="i7a0f2471e7f44074809037b78de94990_D20200526-20200526" decimals="INF" name="bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI5ODU0_78b336d3-a913-4046-81d5-1b5be8598c43">40</ix:nonFraction>% of the aggregate principal amount of the outstanding <ix:nonFraction unitRef="number" contextRef="i23b34418de5747bc96ac966e1bad4561_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI5OTEw_810619d3-98a8-4001-94e5-482f8f99f66a">6.250</ix:nonFraction>% February 2029 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the <ix:nonFraction unitRef="number" contextRef="i23b34418de5747bc96ac966e1bad4561_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMwMDM0_810619d3-98a8-4001-94e5-482f8f99f66a">6.250</ix:nonFraction>% February 2029 Unsecured Notes indenture. On or after February 15, 2024, the Company may redeem all or a portion of the <ix:nonFraction unitRef="number" contextRef="i23b34418de5747bc96ac966e1bad4561_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMwMTU2_810619d3-98a8-4001-94e5-482f8f99f66a">6.250</ix:nonFraction>% February 2029 Unsecured Notes at the applicable redemption prices set forth in the <ix:nonFraction unitRef="number" contextRef="i23b34418de5747bc96ac966e1bad4561_I20200526" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMwMjQy_810619d3-98a8-4001-94e5-482f8f99f66a">6.250</ix:nonFraction>% February 2029 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><ix:nonFraction unitRef="number" contextRef="i4d4effd4ca8849688cd2273c89e716e3_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMwMzY2_14e45b67-28ca-4572-bc98-a4d862cb11ed">5.000</ix:nonFraction>% Senior Unsecured Notes due 2029 and <ix:nonFraction unitRef="number" contextRef="i374367eeb97946bcb6cacd5888eb32f6_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMwNDA1_dea2ea85-8f33-4050-b3c7-0d393ccaaf06">5.250</ix:nonFraction>% Senior Unsecured Notes due 2031 &#8211; December 2020 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2020, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i4d4effd4ca8849688cd2273c89e716e3_I20201203" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMwNTIx_88b35f2f-54be-4ce6-9b2c-7286ff6c78f3">1,000</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i4d4effd4ca8849688cd2273c89e716e3_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMwNTU0_14e45b67-28ca-4572-bc98-a4d862cb11ed">5.000</ix:nonFraction>% Senior Unsecured Notes due February 2029 (the &#8220;<ix:nonFraction unitRef="number" contextRef="i4d4effd4ca8849688cd2273c89e716e3_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMwNjA0_14e45b67-28ca-4572-bc98-a4d862cb11ed">5.000</ix:nonFraction>% February 2029 Unsecured Notes&#8221;) and $<ix:nonFraction unitRef="usd" contextRef="i374367eeb97946bcb6cacd5888eb32f6_I20201203" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMwNjQz_dfd71b7b-2fc6-4088-8c78-3e423b0225b5">1,000</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="i374367eeb97946bcb6cacd5888eb32f6_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMwNjc2_dea2ea85-8f33-4050-b3c7-0d393ccaaf06">5.250</ix:nonFraction>% Senior Unsecured Notes due February 2031 (the &#8220;February 2031 Unsecured Notes&#8221;) in a private placement. The aggregate proceeds and cash on hand were used to repurchase the remaining outstanding principal amounts of: (i) &#8364;<ix:nonFraction unitRef="eur" contextRef="id77d7960c24b4e4a865ddd716f13ec49_I20201203" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMwODk4_04fcf269-9562-4fcf-b95c-a6c7957a6f50">1,500</ix:nonFraction>&#160;million of the Euro Notes, (ii) $<ix:nonFraction unitRef="usd" contextRef="idd85aaaa25cc479b99bd4e886b1c3240_I20201203" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMwOTI1_3b5c584c-6edf-4c0d-80f1-a88f77a936d1">233</ix:nonFraction>&#160;million of the March 2023 Unsecured Notes and (iii) pay all fees and expenses associated with these transactions (collectively, the &#8220;December 2020 Refinancing Transactions&#8221;). The December 2020 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i356651edb41c4b0a8e39c4bd624b498e_D20201203-20201203" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMxMjQ3_691090c3-7186-412d-9981-c1e77521268a">7</ix:nonFraction>&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt's carrying value. The <ix:nonFraction unitRef="number" contextRef="i4d4effd4ca8849688cd2273c89e716e3_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMxMzgy_14e45b67-28ca-4572-bc98-a4d862cb11ed">5.000</ix:nonFraction>% February 2029 Unsecured Notes accrue interest at the rate of <ix:nonFraction unitRef="number" contextRef="i4d4effd4ca8849688cd2273c89e716e3_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMxNDQ2_14e45b67-28ca-4572-bc98-a4d862cb11ed">5.000</ix:nonFraction>% per year, payable semi-annually in arrears on each of February 15 and August 15. The February 2031 Unsecured Notes accrue interest at the rate of <ix:nonFraction unitRef="number" contextRef="i374367eeb97946bcb6cacd5888eb32f6_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMxNTk1_dea2ea85-8f33-4050-b3c7-0d393ccaaf06">5.250</ix:nonFraction>% per year, payable semi-annually in arrears on each of February 15 and August 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the <ix:nonFraction unitRef="number" contextRef="i4d4effd4ca8849688cd2273c89e716e3_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMxNzI2_14e45b67-28ca-4572-bc98-a4d862cb11ed">5.000</ix:nonFraction>% February 2029 Unsecured Notes at any time prior to February 15, 2024, at a price equal to <ix:nonFraction unitRef="number" contextRef="id78465b77ff94c179049b8f8da315bc7_D20201203-20201203" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMxODE5_80fed3f2-b5d1-4365-842d-a3e855b00b7b">100</ix:nonFraction>% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i4efeff83fff24914852e200a4edd71e6"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to February 15, 2024, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="id78465b77ff94c179049b8f8da315bc7_D20201203-20201203" decimals="INF" name="bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMyMDM1_15391621-7b89-4d66-9d6b-0bf68376ce39">40</ix:nonFraction>% of the aggregate principal amount of the outstanding <ix:nonFraction unitRef="number" contextRef="i4d4effd4ca8849688cd2273c89e716e3_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMyMDkx_14e45b67-28ca-4572-bc98-a4d862cb11ed">5.000</ix:nonFraction>% February 2029 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the <ix:nonFraction unitRef="number" contextRef="i4d4effd4ca8849688cd2273c89e716e3_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMyMjE1_9d72a58c-1c76-487e-b30b-3d6edd8ff930">5.000</ix:nonFraction>% February 2029 Unsecured Notes indenture. On or after February 15, 2024, the Company may redeem all or a portion of the <ix:nonFraction unitRef="number" contextRef="i4d4effd4ca8849688cd2273c89e716e3_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMyMzM3_14e45b67-28ca-4572-bc98-a4d862cb11ed">5.000</ix:nonFraction>% February 2029 Unsecured Notes at the applicable redemption prices set forth in the <ix:nonFraction unitRef="number" contextRef="i4d4effd4ca8849688cd2273c89e716e3_I20201203" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMyNDIz_7cf92c41-8e1f-4853-939c-ee6721922ddc">5.000</ix:nonFraction>% February 2029 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the February 2031 Unsecured Notes at any time prior to February 15, 2026, at a price equal to <ix:nonFraction unitRef="number" contextRef="i4f524b83d2a14769b88a62af6ce78e47_D20201203-20201203" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMyNjg0_17ed9b4d-6b62-45e4-b4b3-152fcc08c3f3">100</ix:nonFraction>% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to February 15, 2024, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="i4f524b83d2a14769b88a62af6ce78e47_D20201203-20201203" decimals="INF" name="bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMyOTAw_6d56c6a2-9484-4d88-8b96-3c58b7204698">40</ix:nonFraction>% of the aggregate principal amount of the outstanding February 2031 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the February 2031 Unsecured Notes indenture. On or after February 15, 2026, the Company may redeem all or a portion of the February 2031 Unsecured Notes at the applicable redemption prices set forth in the February 2031 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Stated Rate of Interest</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average stated rate of interest for the Company's outstanding debt obligations as of December 31, 2021 and 2020 was <ix:nonFraction unitRef="number" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMzNTQw_f8a0ba4a-ba7b-479b-a5f6-db1c2cdbf592">5.88</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMzNTQ3_ed3c517b-58ac-487f-be51-6a31d2a2353e">6.02</ix:nonFraction>%, respectively.</span></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzM0MjY2_b4a77843-064f-4949-8c31-6a844def3e7a" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturities and Mandatory Payments</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities and mandatory payments of debt obligations for the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:88.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.067%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZToyNDhiYWNjNzA0MGM0OGYyYjdmNDU5MTEyYmQyYTNkNC90YWJsZXJhbmdlOjI0OGJhY2M3MDQwYzQ4ZjJiN2Y0NTkxMTJiZDJhM2Q0XzEtMS0xLTEtOTQ4MzE_845fddb6-158b-41ec-beef-f407344986a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZToyNDhiYWNjNzA0MGM0OGYyYjdmNDU5MTEyYmQyYTNkNC90YWJsZXJhbmdlOjI0OGJhY2M3MDQwYzQ4ZjJiN2Y0NTkxMTJiZDJhM2Q0XzItMS0xLTEtOTQ4MzE_f1e27b30-df86-469e-8e31-938376f46ac1">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZToyNDhiYWNjNzA0MGM0OGYyYjdmNDU5MTEyYmQyYTNkNC90YWJsZXJhbmdlOjI0OGJhY2M3MDQwYzQ4ZjJiN2Y0NTkxMTJiZDJhM2Q0XzMtMS0xLTEtOTQ4MzE_5bb124ee-5618-4d9e-b8c0-1f950d295748">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZToyNDhiYWNjNzA0MGM0OGYyYjdmNDU5MTEyYmQyYTNkNC90YWJsZXJhbmdlOjI0OGJhY2M3MDQwYzQ4ZjJiN2Y0NTkxMTJiZDJhM2Q0XzQtMS0xLTEtOTQ4MzE_09ae58db-486e-4074-828a-556658544bd8">9,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZToyNDhiYWNjNzA0MGM0OGYyYjdmNDU5MTEyYmQyYTNkNC90YWJsZXJhbmdlOjI0OGJhY2M3MDQwYzQ4ZjJiN2Y0NTkxMTJiZDJhM2Q0XzUtMS0xLTEtOTQ4MzE_13fac832-1a4b-4cc6-a842-cfa72c71cb6e">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZToyNDhiYWNjNzA0MGM0OGYyYjdmNDU5MTEyYmQyYTNkNC90YWJsZXJhbmdlOjI0OGJhY2M3MDQwYzQ4ZjJiN2Y0NTkxMTJiZDJhM2Q0XzYtMS0xLTEtOTQ4MzE_dc378bd1-9f80-40e4-a977-5cd05d291520">11,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross maturities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZToyNDhiYWNjNzA0MGM0OGYyYjdmNDU5MTEyYmQyYTNkNC90YWJsZXJhbmdlOjI0OGJhY2M3MDQwYzQ4ZjJiN2Y0NTkxMTJiZDJhM2Q0XzctMS0xLTEtOTQ4MzE_9a94e3cb-b4e0-4e57-bedc-5839afde3f9c">22,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZToyNDhiYWNjNzA0MGM0OGYyYjdmNDU5MTEyYmQyYTNkNC90YWJsZXJhbmdlOjI0OGJhY2M3MDQwYzQ4ZjJiN2Y0NTkxMTJiZDJhM2Q0XzgtMS0xLTEtOTQ4MzE_a3301d9b-6921-4818-9a43-311d97fbb27c">216</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZToyNDhiYWNjNzA0MGM0OGYyYjdmNDU5MTEyYmQyYTNkNC90YWJsZXJhbmdlOjI0OGJhY2M3MDQwYzQ4ZjJiN2Y0NTkxMTJiZDJhM2Q0XzktMS0xLTEtOTQ4MzE_18644bca-6373-4833-b48e-967eddd0745c">22,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Restated Credit Agreement, there is no Excess Cash Flow payment due for 2021.</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 11, 2022, the Company repaid its outstanding balance of $<ix:nonFraction unitRef="usd" contextRef="i85ca12bc72e84e42b58ea2d217fa1aaa_D20220211-20220211" decimals="-6" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMzODkx_7797c5f4-1cb5-44db-925f-abf81c654c54">285</ix:nonFraction>&#160;million under its 2023 Revolving Credit Facility.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As more fully discussed in Note 23, &#8220;SUBSEQUENT EVENTS&#8221;, during January 2022, the Company: (i) issued conditional notices of redemption to redeem in full all of its outstanding April 2025 Unsecured Notes&#8221;  and to redeem $<ix:nonFraction unitRef="usd" contextRef="i4e619b455ff146759a2117b1f93fefb2_I20220118" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzM0MTA0_a5f7f32e-eb93-4667-898c-f205fe522558">370</ix:nonFraction>&#160;million aggregate principal amount of its outstanding December 2025 Unsecured Notes and (ii) issued $<ix:nonFraction unitRef="usd" contextRef="ib440abcc71694fa09f8e1ad1955b47b3_I20220210" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzM0MTcy_a162e295-ca06-4715-9f7d-0a898ba35a97">1,000</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="ib440abcc71694fa09f8e1ad1955b47b3_I20220210" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzM0MjA1_588a6e93-7f54-42ca-a25e-29812b915be0">6.125</ix:nonFraction>% Senior Secured Notes due February 2027.</span></div></ix:continuation><div id="i8256f225f07d49409c31f7443adffdbf_346"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzkzODc_20e82d07-658e-4c4d-8d4f-9375014538d2" continuedAt="ia1170f7447d14fd49af5e7a614fd48bd" escape="true">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia1170f7447d14fd49af5e7a614fd48bd" continuedAt="i26a509f59133443b8f86349c027cc8d3">The Company has defined benefit plans and a participatory defined benefit postretirement medical and life insurance plan, which covers a closed grandfathered group of legacy Bausch &amp; Lomb Holdings Incorporated (&#8216;&#8216;B&amp;L&#8217;&#8217;) U.S. employees and employees in certain other countries. The U.S. defined benefit accruals were frozen as of December 31, 2004 and benefits that were earned up to December 31, 2004 were preserved. Participants continue to earn interest credits on their cash balance at an interest crediting rate that is equal to the greater of: (i) the average annual yield on 10-year treasury bonds in effect for the November preceding the plan year or (ii) <ix:nonFraction unitRef="number" contextRef="i2f9960dff77240d28dd966ea114e1dc3_I20211231" decimals="INF" name="bhc:DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzY3Mg_1d60d66f-a725-493c-9058-2293d90ab9b0">4.50</ix:nonFraction>%. The most significant non-U.S. plans are <ix:nonFraction unitRef="defined_benefit_plan" contextRef="i09794c3bfd084a82b2a8672bfec8f4ff_I20211231" decimals="INF" name="bhc:DefinedBenefitPlanNumberofDefinedBenefitPlans" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzcxNg_1a043f3c-6eba-492c-8e29-97e7a7bb0057">two</ix:nonFraction> defined benefit plans in Ireland. In 2011, both Ireland defined benefit plans were closed to future service benefit accruals; however, additional accruals related to annual salary increases continued. In December 2014, <ix:nonFraction unitRef="defined_benefit_plan" contextRef="i0da6a354b78d46da85ab05e0768ba4cf_D20141201-20141231" decimals="INF" name="bhc:DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzkzOA_6aec1255-96a3-471f-8aed-1a6fa59bbdc1">one</ix:nonFraction> of the Ireland defined benefit plans was amended effective August 2014 to eliminate future benefit accruals related to salary increases. All of the pension benefits accrued through the plan amendment date were preserved. As a result of the plan amendment, there are no active plan participants accruing benefits under the amended Ireland defined benefit plan.  The U.S. postretirement benefit </ix:continuation></span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i26a509f59133443b8f86349c027cc8d3" continuedAt="i6e8a7242d2a1492794213b57dced216d"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plan was amended effective January 1, 2005 to eliminate employer contributions after age <ix:nonNumeric contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231" name="bhc:DefinedBenefitPlanEmployerContributionMaximumAge" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzE0MjM_0a25672f-32c3-426e-a8f1-e62b6ca45ab3">65</ix:nonNumeric> for participants who did not meet the minimum requirements of age and service on that date. The employer contributions for medical and prescription drug benefits for participants retiring after March 1, 1989 were frozen effective January 1, 2010. Effective January 1, 2014, the Company no longer offers medical and life insurance coverage to new retirees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the B&amp;L benefit plans, outside of the U.S., a limited group of the Company's employees are covered by defined benefit pension plans. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses December 31 as the year-end measurement date for all of its defined benefit pension plans and the postretirement benefit plan. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Pension Benefit Plans and Postretirement Benefit Plan </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes in its Consolidated Balance Sheets an asset or liability equal to the over- or under-funded benefit obligation of each defined benefit pension plan and postretirement benefit plan. Actuarial gains or losses and prior service costs or credits that arise during the period but are not recognized as components of net periodic benefit cost are recognized, net of tax, as a component of Other comprehensive income (loss). </span></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2Xzk0MjE_afccc8f6-3d94-44a4-8927-02ee0f306f9d" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts included in Accumulated other comprehensive loss as of December 31, 2021 and 2020 were as follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:38.413%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.963%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized actuarial losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTMwOWMyODhjOTc0OWIxOTVhOWFhZTgyYTJjNDY0My90YWJsZXJhbmdlOmQ1MzA5YzI4OGM5NzQ5YjE5NWE5YWFlODJhMmM0NjQzXzMtMi0xLTEtOTQ4MzE_b6dfbfed-c1ef-44e8-82aa-309f4b01248e">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fe9a8f118334aab8ff6bd90e126b597_I20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTMwOWMyODhjOTc0OWIxOTVhOWFhZTgyYTJjNDY0My90YWJsZXJhbmdlOmQ1MzA5YzI4OGM5NzQ5YjE5NWE5YWFlODJhMmM0NjQzXzMtNC0xLTEtOTQ4MzE_489495ab-9f29-423e-a2c1-55cb96df5c69">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTMwOWMyODhjOTc0OWIxOTVhOWFhZTgyYTJjNDY0My90YWJsZXJhbmdlOmQ1MzA5YzI4OGM5NzQ5YjE5NWE5YWFlODJhMmM0NjQzXzMtNi0xLTEtOTQ4MzE_40461b73-b0f3-480b-8512-20063c4bf854">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icac9bfd5e8d54c0689a02e2e251a39cd_I20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTMwOWMyODhjOTc0OWIxOTVhOWFhZTgyYTJjNDY0My90YWJsZXJhbmdlOmQ1MzA5YzI4OGM5NzQ5YjE5NWE5YWFlODJhMmM0NjQzXzMtOC0xLTEtOTQ4MzE_8f99add9-d34a-44cd-a226-97ae69926d78">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTMwOWMyODhjOTc0OWIxOTVhOWFhZTgyYTJjNDY0My90YWJsZXJhbmdlOmQ1MzA5YzI4OGM5NzQ5YjE5NWE5YWFlODJhMmM0NjQzXzMtMTAtMS0xLTk0ODMx_48dbec28-0404-446e-af87-c669517756d0">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if38262082aca4b1ca51d9de262b48c77_I20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTMwOWMyODhjOTc0OWIxOTVhOWFhZTgyYTJjNDY0My90YWJsZXJhbmdlOmQ1MzA5YzI4OGM5NzQ5YjE5NWE5YWFlODJhMmM0NjQzXzMtMTItMS0xLTk0ODMx_661947cf-2a3e-421c-b05d-fcebd24db860">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized prior service credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTMwOWMyODhjOTc0OWIxOTVhOWFhZTgyYTJjNDY0My90YWJsZXJhbmdlOmQ1MzA5YzI4OGM5NzQ5YjE5NWE5YWFlODJhMmM0NjQzXzQtMi0xLTEtOTQ4MzE_7b90e87b-6136-46b0-bced-98a7f3ca1acb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fe9a8f118334aab8ff6bd90e126b597_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTMwOWMyODhjOTc0OWIxOTVhOWFhZTgyYTJjNDY0My90YWJsZXJhbmdlOmQ1MzA5YzI4OGM5NzQ5YjE5NWE5YWFlODJhMmM0NjQzXzQtNC0xLTEtOTQ4MzE_f4c611e1-55e1-485b-9f76-6b2041521a82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTMwOWMyODhjOTc0OWIxOTVhOWFhZTgyYTJjNDY0My90YWJsZXJhbmdlOmQ1MzA5YzI4OGM5NzQ5YjE5NWE5YWFlODJhMmM0NjQzXzQtNi0xLTEtOTQ4MzE_b7e245cf-1167-4849-a34a-8199f61175e4">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icac9bfd5e8d54c0689a02e2e251a39cd_I20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTMwOWMyODhjOTc0OWIxOTVhOWFhZTgyYTJjNDY0My90YWJsZXJhbmdlOmQ1MzA5YzI4OGM5NzQ5YjE5NWE5YWFlODJhMmM0NjQzXzQtOC0xLTEtOTQ4MzE_4f30173b-859e-4d31-9e66-af90e8526477">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTMwOWMyODhjOTc0OWIxOTVhOWFhZTgyYTJjNDY0My90YWJsZXJhbmdlOmQ1MzA5YzI4OGM5NzQ5YjE5NWE5YWFlODJhMmM0NjQzXzQtMTAtMS0xLTk0ODMx_5e6240fc-4ee5-4170-a059-492a2a676a98">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if38262082aca4b1ca51d9de262b48c77_I20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTMwOWMyODhjOTc0OWIxOTVhOWFhZTgyYTJjNDY0My90YWJsZXJhbmdlOmQ1MzA5YzI4OGM5NzQ5YjE5NWE5YWFlODJhMmM0NjQzXzQtMTItMS0xLTk0ODMx_0b284a75-0fef-43cc-a04e-f32176c49668">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Periodic (Benefit) Cost</span></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2Xzk0MjY_53741ddc-889b-4014-9dfb-33a8564c03f3" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the components of net periodic (benefit) cost for the Company&#8217;s defined benefit pension plans and postretirement benefit plan in 2021, 2020 and 2019:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:25.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.504%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzMtMi0xLTEtOTQ4MzE_7a818f45-208f-4e23-bdd5-4470307cb891">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzMtNC0xLTEtOTQ4MzE_1b8e4e84-bd87-4b85-b7f4-ccce884d43be">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5d47857632948b3953696f970672168_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzMtNi0xLTEtOTQ4MzE_f4de1a0e-190b-495a-be08-61f334952fed">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzMtOC0xLTEtOTQ4MzE_6e7865f6-fdfe-4245-a18a-cd85e87fce9f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzMtMTAtMS0xLTk0ODMx_136a2658-19ba-4349-ae1b-7f9d7a15377f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60dd7747d8e84735ad54cdac6b306397_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzMtMTItMS0xLTk0ODMx_4622373a-b94a-4b5c-b20d-9a948cab712d">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzMtMTQtMS0xLTk0ODMx_fd16fc9f-3329-4369-b356-3767a9a87143">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzMtMTYtMS0xLTk0ODMx_6e60a1b2-28e0-42c7-86ed-11c9a832e1bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75033e6771e2462a948d8f02b08289cd_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzMtMTgtMS0xLTk0ODMx_18f10f55-4eb3-4356-b519-2b8c79a09403">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzQtMi0xLTEtOTQ4MzE_547ab516-4f86-4b44-8fa8-b7a1b48f5729">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzQtNC0xLTEtOTQ4MzE_76ca2839-d91b-4759-a931-c9842db28c00">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5d47857632948b3953696f970672168_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzQtNi0xLTEtOTQ4MzE_5444d618-eabe-4831-b834-02ffd984a2a2">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzQtOC0xLTEtOTQ4MzE_c0ea6482-6b27-43af-aabc-e58c5f32b792">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzQtMTAtMS0xLTk0ODMx_3209e87b-3c74-439a-a6c9-01e0d1deb35e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60dd7747d8e84735ad54cdac6b306397_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzQtMTItMS0xLTk0ODMx_5e22b4e1-8161-4e0d-ba3a-d644473063da">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzQtMTQtMS0xLTk0ODMx_265a206f-f259-4c1f-ac5b-1dae5b94f09a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzQtMTYtMS0xLTk0ODMx_288719f7-33f7-429d-a405-fd8b681a9368">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75033e6771e2462a948d8f02b08289cd_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzQtMTgtMS0xLTk0ODMx_c31e9f79-257a-4dce-8ea1-bdb1b4a38ec4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzUtMi0xLTEtOTQ4MzE_d2dad0d1-ea6a-46bc-b435-7b37044a2732">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzUtNC0xLTEtOTQ4MzE_81f8ddad-8a1e-4b7b-ad7b-21ffc5ec98bc">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5d47857632948b3953696f970672168_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzUtNi0xLTEtOTQ4MzE_2f660d10-4dca-407d-b4fe-9154e0d09b1b">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzUtOC0xLTEtOTQ4MzE_a965104c-afd5-4d41-9bd3-29536bdf0753">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzUtMTAtMS0xLTk0ODMx_4ae6cd29-79ec-4cc0-a4eb-ae7c5aef4efe">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60dd7747d8e84735ad54cdac6b306397_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzUtMTItMS0xLTk0ODMx_57bb4a53-5d47-4df7-b451-e75e6e60dcba">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzUtMTQtMS0xLTk0ODMx_fa4b3790-36e6-4f27-b65b-cae646f166fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzUtMTYtMS0xLTk0ODMx_fdd7e16b-9bfe-47bd-8ad7-543ee01dc695">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75033e6771e2462a948d8f02b08289cd_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzUtMTgtMS0xLTk0ODMx_9497cebf-4626-40b4-8653-627c91512158">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzYtMi0xLTEtOTQ4MzE_1e6ad9a1-cb0b-4473-ae41-817df9519226">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzYtNC0xLTEtOTQ4MzE_88be7e78-d264-4ebd-be9a-27f5164f2a65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5d47857632948b3953696f970672168_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzYtNi0xLTEtOTQ4MzE_133c082a-bb29-455f-8242-c68a044a1ad6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzYtOC0xLTEtOTQ4MzE_6330015a-b93a-4bef-aa92-4e79a5989e26">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzYtMTAtMS0xLTk0ODMx_ec79e97d-a06e-4fd3-ac3f-ecf02191477c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60dd7747d8e84735ad54cdac6b306397_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzYtMTItMS0xLTk0ODMx_63f20367-330c-4cce-bea0-2d1c1f075441">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzYtMTQtMS0xLTk0ODMx_25aff60d-9e3f-4cc1-910a-b665f7f19818">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzYtMTYtMS0xLTk0ODMx_4efafa4b-6c43-40a1-b605-d33e083045f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75033e6771e2462a948d8f02b08289cd_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzYtMTgtMS0xLTk0ODMx_65dd63db-08c9-4d6f-9b9d-751c95d43360">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of prior service credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzctMi0xLTEtOTQ4MzE_06e516f4-0049-4293-a224-74a9bdf2664a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzctNC0xLTEtOTQ4MzE_a26934e7-0f9e-4212-b095-0645f6179a55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5d47857632948b3953696f970672168_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzctNi0xLTEtOTQ4MzE_66278974-99ba-41a8-b311-ab18824249b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzctOC0xLTEtOTQ4MzE_110c514b-098c-4275-99a2-0d3e8c41f308">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzctMTAtMS0xLTk0ODMx_298ae707-132d-4e5c-999b-120bd81c0f6a">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60dd7747d8e84735ad54cdac6b306397_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzctMTItMS0xLTk0ODMx_42ce521d-f1a4-4562-b336-d1c532276718">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzctMTQtMS0xLTk0ODMx_2cb374ef-9fb9-4309-845c-fb6577a7c467">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzctMTYtMS0xLTk0ODMx_3a84b45a-f3a0-460c-9840-9f27e52c31f3">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75033e6771e2462a948d8f02b08289cd_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzctMTgtMS0xLTk0ODMx_7bdd5e72-7a07-4475-b583-1c9ada6eb3ec">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement loss recognized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzgtMi0xLTEtOTQ4MzE_0e8f10fa-9f6f-4e81-8473-aa94ca39d1a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzgtNC0xLTEtOTQ4MzE_36e34b7f-64a9-435e-a188-ae6318b84eb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5d47857632948b3953696f970672168_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzgtNi0xLTEtOTQ4MzE_f7a04b76-36b5-4b01-83f7-6f03eec0ac21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzgtOC0xLTEtOTQ4MzE_e498f9ce-fe7f-4e0e-846d-843520c57624">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzgtMTAtMS0xLTk0ODMx_be193e92-48b9-4d8a-a9cd-6dda86a6fbb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60dd7747d8e84735ad54cdac6b306397_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzgtMTItMS0xLTk0ODMx_581baeec-1f9e-494e-8a1b-d37aaf297644">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzgtMTQtMS0xLTk0ODMx_683dbbbf-2e06-4a59-8ef0-b9242c417f7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzgtMTYtMS0xLTk0ODMx_3045915e-8665-4c48-888a-aff25f162c88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75033e6771e2462a948d8f02b08289cd_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzgtMTgtMS0xLTk0ODMx_c8abadeb-338d-4b64-824e-c51bc6d9dd3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzktMi0xLTEtOTQ4MzE_c3133afe-ac07-4d18-aee8-bc0211830342">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzktNC0xLTEtOTQ4MzE_9a8a2e1b-972f-4470-be2f-d52b44517867">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5d47857632948b3953696f970672168_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzktNi0xLTEtOTQ4MzE_e937c7a2-e1fd-45af-a9c0-b538d89a07d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzktOC0xLTEtOTQ4MzE_c79f172c-de6e-479c-9348-d7c5063356f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzktMTAtMS0xLTk0ODMx_67bbd354-b9fb-4206-844b-2475bb8ef7db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60dd7747d8e84735ad54cdac6b306397_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzktMTItMS0xLTk0ODMx_f4151f6e-f43d-48ef-b7c9-4948cb753f06">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzktMTQtMS0xLTk0ODMx_87dbd5e2-8858-496f-abca-17d5a24fa2bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzktMTYtMS0xLTk0ODMx_a5630b5d-1acc-4c8b-ad5d-da1c05ded3f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75033e6771e2462a948d8f02b08289cd_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanOtherCosts" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzktMTgtMS0xLTk0ODMx_2ab879ae-e107-4cb7-9779-575a42f9eaba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzEwLTItMS0xLTk0ODMx_bea87601-cbbd-4094-bf06-e11a2daa67d4">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzEwLTQtMS0xLTk0ODMx_b6abdf94-af1e-447d-9814-375c7b537d6d">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5d47857632948b3953696f970672168_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzEwLTYtMS0xLTk0ODMx_b12a3c40-e6ac-4b57-926e-2e38d999f4a7">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzEwLTgtMS0xLTk0ODMx_dcd4ef21-7c12-4028-9252-c6cbc1695b89">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzEwLTEwLTEtMS05NDgzMQ_dfd086ec-df24-4165-a60d-bd8171021577">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60dd7747d8e84735ad54cdac6b306397_D20190101-20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzEwLTEyLTEtMS05NDgzMQ_783c17f8-907c-4754-a628-6afa14cf01a1">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzEwLTE0LTEtMS05NDgzMQ_757556e0-c587-4ecd-9ac8-123801adb0d8">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzEwLTE2LTEtMS05NDgzMQ_9aa485b4-f265-4477-895a-cd820b9e8f21">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75033e6771e2462a948d8f02b08289cd_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzEwLTE4LTEtMS05NDgzMQ_37ff8d95-91a2-4034-a828-eefcdad0bc85">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><span><br/></span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i6e8a7242d2a1492794213b57dced216d" continuedAt="ie2441b5c18b2427d9b4c99541a4c6223"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Benefit Obligation, Change in Plan Assets and Funded Status </span></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2Xzk0MTY_76457e0b-f571-424d-81dd-22de01c22b83" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents components of the change in projected benefit obligation, change in plan assets and funded status for 2021 and 2020: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:40.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.025%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in Projected Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation, beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fe9a8f118334aab8ff6bd90e126b597_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzQtMi0xLTEtOTQ4MzE_8c2db1e4-5838-4cbf-8b9c-68d7cb3c3f55">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i463e7100cf0447ed909a1b0e9a750265_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzQtNC0xLTEtOTQ4MzE_c9593702-a13a-448a-81fc-9e67acb6eb13">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icac9bfd5e8d54c0689a02e2e251a39cd_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzQtNi0xLTEtOTQ4MzE_2f5d240a-2f7f-4daf-b9b4-642baa37a16e">294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77e60ffa0a7048b3bc6ab71dd3ff10d2_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzQtOC0xLTEtOTQ4MzE_1fcc679f-aafb-4c7b-bd8b-e92702b28b79">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if38262082aca4b1ca51d9de262b48c77_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzQtMTAtMS0xLTk0ODMx_d0a7009c-320e-492b-b51a-4c76929fa350">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idea50cd734984c47856762240b1f1a02_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzQtMTItMS0xLTk0ODMx_c5dff500-c098-4901-83a5-08d075e45413">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzUtMi0xLTEtOTQ4MzE_84b39927-1a42-4f25-a6f4-6d1a44b36a3c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzUtNC0xLTEtOTQ4MzE_3f745688-9610-44d2-a3a1-e7b7aaef7ab9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzUtNi0xLTEtOTQ4MzE_06e85864-42bd-483b-a9f4-2b8b410a901d">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzUtOC0xLTEtOTQ4MzE_71be263e-2e03-41ad-98ac-ede10b1d05ba">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzUtMTAtMS0xLTk0ODMx_fb34b2f1-aa3f-49c7-a5a8-01fb44b2a707">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzUtMTItMS0xLTk0ODMx_8deee005-1424-42e2-8723-612a10d795d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzYtMi0xLTEtOTQ4MzE_e042c060-c968-415d-b31b-0e8c6870f919">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzYtNC0xLTEtOTQ4MzE_9c27023f-5dd7-4aba-9ea3-0ce525fd8b43">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzYtNi0xLTEtOTQ4MzE_7a5b4f64-00ba-4be7-8a1d-d1465129a4f4">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzYtOC0xLTEtOTQ4MzE_e729c062-42df-49e7-b4f9-48a8947780f2">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzYtMTAtMS0xLTk0ODMx_3c572434-591b-4d91-a56d-995fb1d41357">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzYtMTItMS0xLTk0ODMx_3ceef61d-724c-42ca-854b-ea81e3fa5a80">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzgtMi0xLTEtOTQ4MzE_1b94de1e-a337-468a-b69f-92ddd51a3e69">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzgtNC0xLTEtOTQ4MzE_4ebb69ab-fc62-4032-85e5-851c78bd0559">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzgtNi0xLTEtOTQ4MzE_2ed4b22b-5aab-4d7e-b717-770540a72d04">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzgtOC0xLTEtOTQ4MzE_90d36e6e-441e-4e3a-ae9c-18cf5c8cb39e">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzgtMTAtMS0xLTk0ODMx_920f1df2-b8d1-4bd9-b521-f16a48da808c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzgtMTItMS0xLTk0ODMx_fc1bb800-f273-4a70-a690-58e6362bf036">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzktMi0xLTEtOTQ4MzE_2ebd6b06-ab99-4ba3-9fe3-565045690019">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzktNC0xLTEtOTQ4MzE_143fc5cd-9e89-4e97-982e-d415ed66d5b5">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzktNi0xLTEtOTQ4MzE_119fa506-ff1b-4651-9065-04dd76461d91">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzktOC0xLTEtOTQ4MzE_d0f0f3e6-06c5-44be-ab40-211ea4814aed">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzktMTAtMS0xLTk0ODMx_60f1c9ce-c9e1-4e4b-8f35-02181ccbb4f0">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzktMTItMS0xLTk0ODMx_233dcd1e-75cb-40ea-ba7c-25ddcd03e3ea">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial (gain) losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzEwLTItMS0xLTk0ODMx_013ade28-62e0-480b-b56a-cd79eb8093a1">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzEwLTQtMS0xLTk0ODMx_7349c10b-b693-4647-92c3-229d6796246b">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzEwLTYtMS0xLTk0ODMx_9c7dbf4c-6e29-442a-a650-ff6c6d7da09e">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzEwLTgtMS0xLTk0ODMx_0964fcad-7cb7-4f8d-a9f4-e205eb389b51">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzEwLTEwLTEtMS05NDgzMQ_d36cbe6d-e2a0-43e3-8ecb-752495df3935">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzEwLTEyLTEtMS05NDgzMQ_9fca6a33-67a5-40a8-96fd-e71972092ae3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzExLTItMS0xLTk0ODMx_e91b3cd8-52aa-48e3-aecd-46e0398c60b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzExLTQtMS0xLTk0ODMx_95fe4209-a7d9-4c3e-98a7-fe4ffc9eeb88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzExLTYtMS0xLTk0ODMx_153f2e9d-5e29-49f3-b341-b6ecf8f49411">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzExLTgtMS0xLTk0ODMx_34475cde-4fb9-4cb6-a19d-7899c40ec1ee">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzExLTEwLTEtMS05NDgzMQ_4ad47a59-3320-4e79-b31d-26ca7053640b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzExLTEyLTEtMS05NDgzMQ_eb7e35b1-d4a1-48a4-a9d6-80834f7304e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzEyLTItMS0xLTk0ODMx_a12e2823-5c44-4829-9317-f9c5367e3100">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fe9a8f118334aab8ff6bd90e126b597_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzEyLTQtMS0xLTk0ODMx_69209c55-7fee-4459-83fa-9c847160c5b3">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzEyLTYtMS0xLTk0ODMx_a578ac6a-7ecf-4120-b284-de15d7e71fd6">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icac9bfd5e8d54c0689a02e2e251a39cd_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzEyLTgtMS0xLTk0ODMx_0ec75ba7-4b0d-470b-aa5a-0a8119cdc1cf">294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzEyLTEwLTEtMS05NDgzMQ_4941e9fd-f46b-421e-bb8e-1c08239765aa">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if38262082aca4b1ca51d9de262b48c77_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzEyLTEyLTEtMS05NDgzMQ_f3e035bf-328a-4f75-ab49-dd856494858f">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets, beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fe9a8f118334aab8ff6bd90e126b597_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE1LTItMS0xLTk0ODMx_256f0282-e9a0-4c5a-ad87-4f7953958f8d">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i463e7100cf0447ed909a1b0e9a750265_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE1LTQtMS0xLTk0ODMx_e0634efe-85ea-42c7-82e1-03058df523ff">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icac9bfd5e8d54c0689a02e2e251a39cd_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE1LTYtMS0xLTk0ODMx_bdcb4d05-3126-4297-b18f-0d73aee229a1">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77e60ffa0a7048b3bc6ab71dd3ff10d2_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE1LTgtMS0xLTk0ODMx_41bb7314-e2d4-45a4-8878-b94c5f0a4b26">161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if38262082aca4b1ca51d9de262b48c77_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE1LTEwLTEtMS05NDgzMQ_e2402ad3-b63b-462e-bfa1-d2ba006995e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idea50cd734984c47856762240b1f1a02_I20191231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE1LTEyLTEtMS05NDgzMQ_9dbefc94-37b1-42fb-935c-cee566157017">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE2LTItMS0xLTk0ODMx_109bbe19-2056-48e8-bb14-53e7ade70d8e">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE2LTQtMS0xLTk0ODMx_c8d72abb-d887-4871-9dc3-ce1976c11ec3">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE2LTYtMS0xLTk0ODMx_2cd563c6-9d69-4a54-aecf-ad2a29c2de59">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE2LTgtMS0xLTk0ODMx_2f510673-f87f-445c-84a9-7d506b483e2b">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE2LTEwLTEtMS05NDgzMQ_5b738b52-b26c-4306-9583-0c86a954c24b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE2LTEyLTEtMS05NDgzMQ_2e987288-3193-49b3-8382-c24ed5f018ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE4LTItMS0xLTk0ODMx_8d40e7fb-a061-48bc-ab54-265598f022fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE4LTQtMS0xLTk0ODMx_99f1dc2b-5f64-4126-b658-1c248d6bdc7f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE4LTYtMS0xLTk0ODMx_2c2a5ee0-1b79-4edc-8bd7-2c2ea5ac7dec">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE4LTgtMS0xLTk0ODMx_2f9bef7b-3823-40d8-9366-c28ff2884339">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE4LTEwLTEtMS05NDgzMQ_1353a317-19a3-4f1c-95c3-85094db6d534">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE4LTEyLTEtMS05NDgzMQ_ccfdb5b7-33bd-46f1-9e67-dd5b3fdf8495">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE5LTItMS0xLTk0ODMx_b3015e06-489a-4df6-b286-83ca2cb52b63">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE5LTQtMS0xLTk0ODMx_019fd3df-43b7-4e83-be7c-d4d1a006d5b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE5LTYtMS0xLTk0ODMx_09564187-ff7d-4ab9-abcb-5f573354d84b">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE5LTgtMS0xLTk0ODMx_7cdbf7e3-4896-4fef-9401-3f0c5071de6a">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE5LTEwLTEtMS05NDgzMQ_aaada47f-91d4-4bf6-9b2d-f8b9ef6aa08e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE5LTEyLTEtMS05NDgzMQ_3dfa5576-0f04-4a4b-87a8-3082239eb6b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIwLTItMS0xLTk0ODMx_5452d54a-fcb7-4167-8dba-5bed1fb9cf2b">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIwLTQtMS0xLTk0ODMx_07834555-e581-4e1e-8287-63609108e9c8">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIwLTYtMS0xLTk0ODMx_c7221b26-bf55-4893-b5df-3d3bf1c0a9e5">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIwLTgtMS0xLTk0ODMx_1d2e2cd3-f02e-49a1-907e-705506a8da32">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIwLTEwLTEtMS05NDgzMQ_704fa223-61da-4ab0-ba24-77b4f396fc73">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIwLTEyLTEtMS05NDgzMQ_8e96bb9e-7b4e-4a7d-91e6-0be776d966b1">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIxLTItMS0xLTk0ODMx_a7300ae3-ce07-47db-b093-9af2a87e9780">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIxLTQtMS0xLTk0ODMx_7f73339c-de66-4861-b099-733e9e10c05f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIxLTYtMS0xLTk0ODMx_8813416c-3132-4d2e-8fe2-18d6586f8490">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIxLTgtMS0xLTk0ODMx_e6d79a87-9ae9-4599-9d3d-29ad0ea8c455">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIxLTEwLTEtMS05NDgzMQ_d9b30931-6de0-4d4a-a80c-9dad3e863b73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIxLTEyLTEtMS05NDgzMQ_e190d9e5-f585-4054-ac84-200912125756">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIyLTItMS0xLTk0ODMx_a25937f3-0145-421f-ab2c-3d548177d6a5">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fe9a8f118334aab8ff6bd90e126b597_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIyLTQtMS0xLTk0ODMx_b836fcec-7363-473e-9cec-3221d3bc9216">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIyLTYtMS0xLTk0ODMx_3da70e9d-5983-4aff-8e0c-e256885fe031">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icac9bfd5e8d54c0689a02e2e251a39cd_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIyLTgtMS0xLTk0ODMx_4d3f4fff-4175-4cf6-a2bd-1d0df4fc4398">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIyLTEwLTEtMS05NDgzMQ_65bad12e-f43b-45f7-a499-e79ad8d50bbd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if38262082aca4b1ca51d9de262b48c77_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIyLTEyLTEtMS05NDgzMQ_661d9d0b-814e-4459-b2bd-7d6c843960b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funded status, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIzLTItMS0xLTk0ODMx_2cd85f9f-00eb-4229-89f9-d958f0522f61">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7fe9a8f118334aab8ff6bd90e126b597_I20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIzLTQtMS0xLTk0ODMx_20b4f5b2-8ae9-41ff-a765-df283eb78bff">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIzLTYtMS0xLTk0ODMx_45984456-0495-4774-8404-03ebc37f3790">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icac9bfd5e8d54c0689a02e2e251a39cd_I20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIzLTgtMS0xLTk0ODMx_fd41eacd-ed5b-4236-b9d7-17ae0db52263">105</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIzLTEwLTEtMS05NDgzMQ_0ba78659-8aad-42e0-b202-fa16a7912361">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if38262082aca4b1ca51d9de262b48c77_I20201231" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIzLTEyLTEtMS05NDgzMQ_d6997f3e-92b4-43ea-a682-a959ff5ce339">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231" decimals="-6" name="bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI2LTItMS0xLTk0ODMx_216e3be7-079a-40bd-ad69-220d7d7ba035">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fe9a8f118334aab8ff6bd90e126b597_I20201231" decimals="-6" name="bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI2LTQtMS0xLTk0ODMx_2c4cc346-cfe4-47a7-b6a4-f12540a5816f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231" decimals="-6" name="bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI2LTYtMS0xLTk0ODMx_01f313a0-3f72-4f78-8f5f-0959a4608255">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icac9bfd5e8d54c0689a02e2e251a39cd_I20201231" decimals="-6" name="bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI2LTgtMS0xLTk0ODMx_52c01acb-2d8e-4270-8346-4b0274a05b6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231" decimals="-6" name="bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI2LTEwLTEtMS05NDgzMQ_750d0b9f-24d7-46a0-9e92-aa3cbbb17cdc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if38262082aca4b1ca51d9de262b48c77_I20201231" decimals="-6" name="bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI2LTEyLTEtMS05NDgzMQ_9909563d-ecaf-4521-8a52-b2efa64923aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231" decimals="-6" name="bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI3LTItMS0xLTk0ODMx_fb698997-5ec2-4bb5-996e-18d8d32a2e4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fe9a8f118334aab8ff6bd90e126b597_I20201231" decimals="-6" name="bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI3LTQtMS0xLTk0ODMx_284788d3-a6e3-486e-9f37-0c8a99daffe7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231" decimals="-6" name="bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI3LTYtMS0xLTk0ODMx_8a5aa689-35fc-4c79-b6a6-194e1a07885f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icac9bfd5e8d54c0689a02e2e251a39cd_I20201231" decimals="-6" name="bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI3LTgtMS0xLTk0ODMx_7d15d5f6-b962-4626-a71d-9419bd0ac5f6">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231" decimals="-6" name="bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI3LTEwLTEtMS05NDgzMQ_350aa1c9-97fa-4156-ab5e-43c9beb29176">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if38262082aca4b1ca51d9de262b48c77_I20201231" decimals="-6" name="bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI3LTEyLTEtMS05NDgzMQ_bfde52d7-f6b4-4880-bd13-7ac80e716e9a">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI4LTItMS0xLTk0ODMx_5e87994e-7bff-42e5-8475-e4124af458c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fe9a8f118334aab8ff6bd90e126b597_I20201231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI4LTQtMS0xLTk0ODMx_27305402-6a39-4eaf-a58a-3355edcc3e2b">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI4LTYtMS0xLTk0ODMx_cc06e466-8e9b-44d5-b8a6-024b3f69d7f8">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icac9bfd5e8d54c0689a02e2e251a39cd_I20201231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI4LTgtMS0xLTk0ODMx_79f48d35-67b1-44ea-adec-7c602a2d4b41">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI4LTEwLTEtMS05NDgzMQ_d111027b-ad84-4c06-9369-1bbe95889878">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if38262082aca4b1ca51d9de262b48c77_I20201231" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI4LTEyLTEtMS05NDgzMQ_871c02d3-7769-4f66-8d72-40d06240ba7f">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Settlement loss recognized and Settlements in the tables above are the costs and payments associated with the conversion of a portion of the Company&#8217;s defined benefit plan in Ireland to a defined contribution plan during the fourth quarter of 2021.</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of the Company&#8217;s pension benefit plans were underfunded as of December 31, 2021 and 2020, having accumulated benefit obligations exceeding the fair value of plan assets. There were <ix:nonFraction unitRef="usd" contextRef="i9d64985a4d524a32b742dc7857f893e4_I20211231" decimals="INF" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzM0OTU_2ce9bc95-9133-47d0-bef9-cc00f349a709">no</ix:nonFraction> U.S. pension benefit plans that were underfunded as of December 31, 2021, having accumulated benefit obligations exceeding the fair value of plan assets. <ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2Xzk0MTU_78512fbd-8123-4880-894e-d996323ce3cc" continuedAt="i9c506061a38a4640b8856209066e660b" escape="true">Information for the underfunded pension benefit plans is as follows:</ix:nonNumeric></span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><ix:continuation id="i9c506061a38a4640b8856209066e660b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:56.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.971%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d64985a4d524a32b742dc7857f893e4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxZGU2OTljZWU5MWM0YzcwODI5NTI3NTVjYzQ5ZTMwYi90YWJsZXJhbmdlOjFkZTY5OWNlZTkxYzRjNzA4Mjk1Mjc1NWNjNDllMzBiXzItMi0xLTEtOTQ4MzE_2cc56b1e-55ab-4bfc-9353-1f9b469eccbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a24ca36ef784ec8aca560e12794804b_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxZGU2OTljZWU5MWM0YzcwODI5NTI3NTVjYzQ5ZTMwYi90YWJsZXJhbmdlOjFkZTY5OWNlZTkxYzRjNzA4Mjk1Mjc1NWNjNDllMzBiXzItNC0xLTEtOTQ4MzE_de02f972-4c9f-413a-a4f5-9c2b438ce341">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxZGU2OTljZWU5MWM0YzcwODI5NTI3NTVjYzQ5ZTMwYi90YWJsZXJhbmdlOjFkZTY5OWNlZTkxYzRjNzA4Mjk1Mjc1NWNjNDllMzBiXzItNi0xLTEtOTQ4MzE_a578ac6a-7ecf-4120-b284-de15d7e71fd6">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56ca37936bae4988b7fe9d7260b0cb9e_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxZGU2OTljZWU5MWM0YzcwODI5NTI3NTVjYzQ5ZTMwYi90YWJsZXJhbmdlOjFkZTY5OWNlZTkxYzRjNzA4Mjk1Mjc1NWNjNDllMzBiXzItOC0xLTEtOTQ4MzE_84c06578-2e42-4edf-88ea-fa9fd7872a4a">294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d64985a4d524a32b742dc7857f893e4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxZGU2OTljZWU5MWM0YzcwODI5NTI3NTVjYzQ5ZTMwYi90YWJsZXJhbmdlOjFkZTY5OWNlZTkxYzRjNzA4Mjk1Mjc1NWNjNDllMzBiXzMtMi0xLTEtOTQ4MzE_df3b2605-31fd-4237-9a82-79be94ce249e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a24ca36ef784ec8aca560e12794804b_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxZGU2OTljZWU5MWM0YzcwODI5NTI3NTVjYzQ5ZTMwYi90YWJsZXJhbmdlOjFkZTY5OWNlZTkxYzRjNzA4Mjk1Mjc1NWNjNDllMzBiXzMtNC0xLTEtOTQ4MzE_1816c029-b53d-42de-ada0-c0e1a56c82b3">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72013f8a77a84d8ab1b6625f3d57d1a7_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxZGU2OTljZWU5MWM0YzcwODI5NTI3NTVjYzQ5ZTMwYi90YWJsZXJhbmdlOjFkZTY5OWNlZTkxYzRjNzA4Mjk1Mjc1NWNjNDllMzBiXzMtNi0xLTEtOTQ4MzE_6015b639-2080-426e-a3f9-bfae228e87a5">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56ca37936bae4988b7fe9d7260b0cb9e_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxZGU2OTljZWU5MWM0YzcwODI5NTI3NTVjYzQ5ZTMwYi90YWJsZXJhbmdlOjFkZTY5OWNlZTkxYzRjNzA4Mjk1Mjc1NWNjNDllMzBiXzMtOC0xLTEtOTQ4MzE_ac2c8ec6-bff7-456a-8f32-e507764c2cd3">286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d64985a4d524a32b742dc7857f893e4_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxZGU2OTljZWU5MWM0YzcwODI5NTI3NTVjYzQ5ZTMwYi90YWJsZXJhbmdlOjFkZTY5OWNlZTkxYzRjNzA4Mjk1Mjc1NWNjNDllMzBiXzQtMi0xLTEtOTQ4MzE_181e68d9-1478-49f3-8e78-5672c4fd7127">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a24ca36ef784ec8aca560e12794804b_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxZGU2OTljZWU5MWM0YzcwODI5NTI3NTVjYzQ5ZTMwYi90YWJsZXJhbmdlOjFkZTY5OWNlZTkxYzRjNzA4Mjk1Mjc1NWNjNDllMzBiXzQtNC0xLTEtOTQ4MzE_5b26824e-5580-41a1-80b9-1f0d2208ca1b">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxZGU2OTljZWU5MWM0YzcwODI5NTI3NTVjYzQ5ZTMwYi90YWJsZXJhbmdlOjFkZTY5OWNlZTkxYzRjNzA4Mjk1Mjc1NWNjNDllMzBiXzQtNi0xLTEtOTQ4MzE_3da70e9d-5983-4aff-8e0c-e256885fe031">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56ca37936bae4988b7fe9d7260b0cb9e_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxZGU2OTljZWU5MWM0YzcwODI5NTI3NTVjYzQ5ZTMwYi90YWJsZXJhbmdlOjFkZTY5OWNlZTkxYzRjNzA4Mjk1Mjc1NWNjNDllMzBiXzQtOC0xLTEtOTQ4MzE_16802146-055c-4489-bd1b-bcccd358a160">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy for funding its pension benefit plans is to make contributions that meet or exceed the minimum statutory funding requirements. These contributions are determined based upon recommendations made by the actuary under accepted actuarial principles. In 2022, the Company expects to contribute $<ix:nonFraction unitRef="usd" contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzQwMzE_c1c11ebe-24a1-49f6-85e7-8b7506f5231a">0</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzQwMzU_5f496e86-97d3-43bb-9b44-8368d3fe2e7d">9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzQwNDI_9202ec5d-aab9-4ae7-b0d1-f213ac8fe65f">4</ix:nonFraction> million to the U.S. pension benefit plan, the non-U.S. pension benefit plans and the U.S. postretirement benefit plan, respectively. The Company plans to use postretirement benefit plan assets and cash on hand, as necessary, to fund the U.S. postretirement benefit plan benefit payments in 2022.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ie2441b5c18b2427d9b4c99541a4c6223" continuedAt="i347cdc2eb3f54d85a331b5dd9aae3441"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Benefit Payments</span></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2Xzk0MTc_27d1d2ab-fd43-44d4-aae9-3c0aa922ff6b" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future benefit payments over the next <ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="bhc:DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzQ0MDM_8580cfa8-68d7-4a30-9952-8d4b813ce650">10</ix:nonNumeric> years for the pension benefit plans and the postretirement benefit plan, which reflect expected future service, as appropriate, are expected to be paid as follows: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:54.219%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.430%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>&#160;Benefit<br/>&#160;Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzItMi0xLTEtOTQ4MzE_2e065094-2b1a-4473-8c20-d6664088b652">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzItNC0xLTEtOTQ4MzE_434aca7c-c37f-474a-8ff0-bfa19bf9c23f">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzItNi0xLTEtOTQ4MzE_473a1a71-5819-47d0-a7bf-adc2ba5ab237">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzMtMi0xLTEtOTQ4MzE_7fb41768-8c5e-4b79-a5ea-11f56711d279">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzMtNC0xLTEtOTQ4MzE_fb2935c3-4b11-4389-bcee-da7730b19b84">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzMtNi0xLTEtOTQ4MzE_e39aba81-0763-47fe-b65c-9b24e607ae09">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzQtMi0xLTEtOTQ4MzE_d0915a60-f9ad-4ace-99f4-e94268b11499">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzQtNC0xLTEtOTQ4MzE_39fe23ec-d032-46bf-9538-78b3564f5708">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzQtNi0xLTEtOTQ4MzE_ab1cebf1-830f-4410-b7d1-945241db7c85">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzUtMi0xLTEtOTQ4MzE_66ab520d-cde2-4449-8248-f06ba150c3b2">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzUtNC0xLTEtOTQ4MzE_74cd438e-bc59-4677-bc0f-ef961f485298">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzUtNi0xLTEtOTQ4MzE_044f3cf7-1187-412b-bb96-716c9419bbb7">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzYtMi0xLTEtOTQ4MzE_bcf518fe-0315-4643-a2b6-b8233593701b">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzYtNC0xLTEtOTQ4MzE_3d0d33aa-8560-46a4-b344-f052539d45ec">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzYtNi0xLTEtOTQ4MzE_2d7fd0e1-f57a-4b81-90c5-4a8ce360ab0f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzctMi0xLTEtOTQ4MzE_86d81549-69a4-4bbd-9042-f88bbe6863be">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzctNC0xLTEtOTQ4MzE_805f2075-d0d5-4898-816b-f4e90f269382">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzctNi0xLTEtOTQ4MzE_a277af45-fef8-4da4-bb5d-e05a521b519d">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assumptions</span></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2Xzk0MTg_01fd3f9b-fdf2-403e-86e2-aaf5757072ed" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used to determine net periodic benefit costs and benefit obligations for 2021, 2020 and 2019 were as follows: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:43.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.427%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement Benefit Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For Determining Net Periodic (Benefit) Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzQtMi0xLTEtOTQ4MzE_db05aa52-f1f1-415f-8559-b0afb2cd5867">2.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzQtNC0xLTEtOTQ4MzE_3d016d4c-4e3d-4a03-a3b4-9fd6c8dd57ff">3.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie5d47857632948b3953696f970672168_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzQtNi0xLTEtOTQ4MzE_1641a2e4-54b2-42bf-be43-195cdfca3ec4">4.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzQtOC0xLTEtOTQ4MzE_0a982eeb-d4cb-4268-916e-1f565d5ec0d8">2.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzQtMTAtMS0xLTk0ODMx_f9709a36-6452-4fae-8800-da437398b128">3.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i75033e6771e2462a948d8f02b08289cd_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzQtMTItMS0xLTk0ODMx_513b667a-8e2f-4652-af14-f916929cf161">4.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzUtMi0xLTEtOTQ4MzE_1d8bb7c0-20bf-4dd4-8b60-06e2e2e71020">5.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzUtNC0xLTEtOTQ4MzE_758a4bd7-f9c9-41dd-a203-309eed93df03">6.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie5d47857632948b3953696f970672168_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzUtNi0xLTEtOTQ4MzE_e7e4ac48-214c-4132-8000-c1d5feba8185">7.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzUtOC0xLTEtOTQ4MzE_f9298377-3dcf-4f38-89fe-cd7852a25a0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzUtMTAtMS0xLTk0ODMx_5ed04096-0bd7-45c8-ad0f-380a0c9b7042">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i75033e6771e2462a948d8f02b08289cd_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzUtMTItMS0xLTk0ODMx_cb99388c-6de0-4373-a939-e29f8cf2c34b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzYtMi0xLTEtOTQ4MzE_989dac3a-e7a7-4cd5-9a35-7535ffd43176">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzYtNC0xLTEtOTQ4MzE_4e280dac-607f-45fb-b0e0-88ba3c2430e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie5d47857632948b3953696f970672168_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzYtNi0xLTEtOTQ4MzE_0b53fb91-020a-44de-872c-085d678b66ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzYtOC0xLTEtOTQ4MzE_b4dcc522-56b2-4f32-b70b-0da06de2f641">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzYtMTAtMS0xLTk0ODMx_3ef62917-c0a9-402e-809e-96da2f8041bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i75033e6771e2462a948d8f02b08289cd_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzYtMTItMS0xLTk0ODMx_36476697-94fd-4136-91a6-eeed78b02149">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzctMi0xLTEtOTQ4MzE_4b6beb85-69f6-415e-b546-1cbbbbaec1aa">4.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzctNC0xLTEtOTQ4MzE_f5b6439a-257b-48b1-8ccd-e388ff13d3ee">4.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie5d47857632948b3953696f970672168_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzctNi0xLTEtOTQ4MzE_34208d6a-c5ec-4c08-853a-4317cc4534da">5.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. Plans:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzktMi0xLTEtOTQ4MzE_0e07aa89-6bc3-4ef9-a0d4-622c6e5742f3">1.37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzktNC0xLTEtOTQ4MzE_aab695dc-9a6b-452b-8b87-01bd3ed66599">1.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i60dd7747d8e84735ad54cdac6b306397_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzktNi0xLTEtOTQ4MzE_64fae372-8de5-4021-aa65-255df1c5cab4">2.39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzEwLTItMS0xLTk0ODMx_68cac582-103c-471f-afba-c0d03a1d8763">2.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzEwLTQtMS0xLTk0ODMx_8e9a2d24-3868-427c-bd45-1ef7afa8fa1f">2.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i60dd7747d8e84735ad54cdac6b306397_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzEwLTYtMS0xLTk0ODMx_42b4fd5e-7dec-4db7-92e8-a2ea27b7e119">3.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzExLTItMS0xLTk0ODMx_d05ad309-eea9-4110-82a7-6b33c19fa25d">2.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzExLTQtMS0xLTk0ODMx_b1fb640f-b5e4-418e-a408-665df1f0ce07">3.05</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i60dd7747d8e84735ad54cdac6b306397_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzExLTYtMS0xLTk0ODMx_ce9b3d8c-1464-43da-8596-a4320426e9bc">2.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzEyLTItMS0xLTk0ODMx_84f83602-bf31-44fb-971e-b033464717e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzEyLTQtMS0xLTk0ODMx_a03a67e0-3358-4965-af81-bc5767ddb480">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i60dd7747d8e84735ad54cdac6b306397_D20190101-20191231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzEyLTYtMS0xLTk0ODMx_7da361b8-f7ae-47eb-af3e-9da6741b83eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:55.197%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.073%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement Benefit Plan</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For Determining Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzUtMi0xLTEtOTQ4MzE_e1dce046-0c8e-4e4d-b742-a314e7dd04a5">2.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7fe9a8f118334aab8ff6bd90e126b597_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzUtNC0xLTEtOTQ4MzE_053ae44e-ec19-4bc9-9f07-a9de54d39320">2.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzUtNi0xLTEtOTQ4MzE_bd53900d-13ae-4b2d-b144-f8ca7ac7a221">2.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if38262082aca4b1ca51d9de262b48c77_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzUtOC0xLTEtOTQ4MzE_8dc686f5-5aeb-440c-b654-ab5343ddf816">2.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzYtMi0xLTEtOTQ4MzE_ea4a4fea-dc5e-40e5-9120-5d836d37a445">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7fe9a8f118334aab8ff6bd90e126b597_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzYtNC0xLTEtOTQ4MzE_9c66cc61-9308-4ada-82f6-f1ece91bc7fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzYtNi0xLTEtOTQ4MzE_63b1bd76-5fb3-4cbf-8097-cdd4f4fcc367">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if38262082aca4b1ca51d9de262b48c77_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzYtOC0xLTEtOTQ4MzE_c57a5724-a73b-4884-a133-7d89cfe1dc48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzctMi0xLTEtOTQ4MzE_b7953aaf-1f5d-4904-9577-21669eaef917">4.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7fe9a8f118334aab8ff6bd90e126b597_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzctNC0xLTEtOTQ4MzE_00cba627-d840-4efe-8dd1-451880b711e8">4.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzktMi0xLTEtOTQ4MzE_16e89c1a-d689-403b-84b9-4f3cdfd6c9d5">1.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icac9bfd5e8d54c0689a02e2e251a39cd_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzktNC0xLTEtOTQ4MzE_a2fd86f7-7fce-4602-ac96-0aa824012ad4">1.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzEwLTItMS0xLTk0ODMx_1b672fe8-805a-4b64-8894-a08dcac7a28c">2.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icac9bfd5e8d54c0689a02e2e251a39cd_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzEwLTQtMS0xLTk0ODMx_e1324ee8-5043-4c9c-8a8b-20dcfbc4597e">2.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzExLTItMS0xLTk0ODMx_bc4b4c92-f713-4d2f-bdd7-8cfd744fd254">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icac9bfd5e8d54c0689a02e2e251a39cd_I20201231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzExLTQtMS0xLTk0ODMx_fc406ff4-b481-48df-938b-7c024ed53a9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected long-term rate of return on plan assets was developed based on a capital markets model that uses expected asset class returns, variance and correlation assumptions. The expected asset class returns were developed starting with current Treasury (for the U.S. pension plan) or Eurozone (for the Ireland pension plans) government yields and then adding corporate bond spreads and equity risk premiums to develop the return expectations for each asset class. The expected asset class returns are forward-looking. The variance and correlation assumptions are also forward-looking. They take into account historical relationships, but are adjusted to reflect expected capital market trends. The expected return on plan assets for the Company&#8217;s U.S. pension plan for 2021 was <ix:nonFraction unitRef="number" contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzU0OTI_1d8bb7c0-20bf-4dd4-8b60-06e2e2e71020">5.00</ix:nonFraction>%. The expected return on plan assets for the Company&#8217;s Ireland pension plans was <ix:nonFraction unitRef="number" contextRef="i180a6063ed294b858f6f1b7f8889f355_D20210101-20211231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzU1NzU_0f8af5df-54f6-4c67-886a-9e8e66c47a6a">2.75</ix:nonFraction>% for 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i347cdc2eb3f54d85a331b5dd9aae3441" continuedAt="ic99fe8608e3f4783bb4e418f315f7a29"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate used to determine benefit obligations represents the current rate at which the benefit plan liabilities could be effectively settled considering the timing of expected payments for plan participants.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 expected rate of return for the U.S. pension benefit plan will be <ix:nonFraction unitRef="number" contextRef="if9fef24732ce40f1b0ecd84c613bcf34_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzU4Nzg_2da0aad5-919d-4e36-a7f0-c75a945db4e5">4.50</ix:nonFraction>%. The 2022 expected rate of return for the Ireland pension benefit plans will be <ix:nonFraction unitRef="number" contextRef="i9ed8db4899e1486f9838d297668a6b15_D20220101-20221231" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzU5NTk_4a433342-0574-41d2-81af-5d2359e88a23">2.75</ix:nonFraction>%. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pension Benefit Plans Assets             </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pension benefit plan assets are invested in several asset categories. <ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2Xzk0MDg_22cc0734-c820-4686-8c5d-50ec959f584e" continuedAt="i5664e8cd5ca047e28efaa5887b219040" escape="true">The following presents the actual asset allocation as of December 31, 2021 and 2020:</ix:nonNumeric></span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><ix:continuation id="i5664e8cd5ca047e28efaa5887b219040"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:77.048%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.066%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i75d6d22fe7ca49c89901fff21f7ad775_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTo2MzFiZjA1NmIyOTk0NDNjOTAyMDI0NTQxYmJlMmEwZC90YWJsZXJhbmdlOjYzMWJmMDU2YjI5OTQ0M2M5MDIwMjQ1NDFiYmUyYTBkXzItMi0xLTEtOTQ4MzE_00a1045d-ff04-417f-8605-cda73eb8164f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69b3efe62ce6415a85977af860ad298b_I20201231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTo2MzFiZjA1NmIyOTk0NDNjOTAyMDI0NTQxYmJlMmEwZC90YWJsZXJhbmdlOjYzMWJmMDU2YjI5OTQ0M2M5MDIwMjQ1NDFiYmUyYTBkXzItNC0xLTEtOTQ4MzE_f5239707-0874-4240-9ec3-5ae3e9acb44f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8c0ee6030b5c47b0a466a9c0070795c1_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTo2MzFiZjA1NmIyOTk0NDNjOTAyMDI0NTQxYmJlMmEwZC90YWJsZXJhbmdlOjYzMWJmMDU2YjI5OTQ0M2M5MDIwMjQ1NDFiYmUyYTBkXzMtMi0xLTEtOTQ4MzE_7397c4f5-446b-4385-ab95-ff52b5126173">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id92890a272ad4d899e7c6ca96512a97e_I20201231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTo2MzFiZjA1NmIyOTk0NDNjOTAyMDI0NTQxYmJlMmEwZC90YWJsZXJhbmdlOjYzMWJmMDU2YjI5OTQ0M2M5MDIwMjQ1NDFiYmUyYTBkXzMtNC0xLTEtOTQ4MzE_44b1a67a-f9d6-4131-a352-8860091635fc">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i149842c6f40f4c6b98cbccfc257a922e_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTo2MzFiZjA1NmIyOTk0NDNjOTAyMDI0NTQxYmJlMmEwZC90YWJsZXJhbmdlOjYzMWJmMDU2YjI5OTQ0M2M5MDIwMjQ1NDFiYmUyYTBkXzQtMi0xLTEtOTQ4MzE_6bdcbf70-c75f-4536-853d-560ce3a16bcb">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i564973e386674c78ba408d13105b6bb9_I20201231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTo2MzFiZjA1NmIyOTk0NDNjOTAyMDI0NTQxYmJlMmEwZC90YWJsZXJhbmdlOjYzMWJmMDU2YjI5OTQ0M2M5MDIwMjQ1NDFiYmUyYTBkXzQtNC0xLTEtOTQ4MzE_c5803675-4b21-4fb1-9d28-297ed8de7135">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia227b3e9ab7d47569890495351afa79e_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTo2MzFiZjA1NmIyOTk0NDNjOTAyMDI0NTQxYmJlMmEwZC90YWJsZXJhbmdlOjYzMWJmMDU2YjI5OTQ0M2M5MDIwMjQ1NDFiYmUyYTBkXzYtMi0xLTEtOTQ4MzE_7b33db5b-49c8-48ed-9add-20ac370924e4">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iba0dcccaa1ae4b01bba40ab426ba276d_I20201231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTo2MzFiZjA1NmIyOTk0NDNjOTAyMDI0NTQxYmJlMmEwZC90YWJsZXJhbmdlOjYzMWJmMDU2YjI5OTQ0M2M5MDIwMjQ1NDFiYmUyYTBkXzYtNC0xLTEtOTQ4MzE_1cefa379-35d7-4902-823c-8071ba8560b4">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1fd2da8ac3ce4d44bbccc6dac3b7d322_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTo2MzFiZjA1NmIyOTk0NDNjOTAyMDI0NTQxYmJlMmEwZC90YWJsZXJhbmdlOjYzMWJmMDU2YjI5OTQ0M2M5MDIwMjQ1NDFiYmUyYTBkXzctMi0xLTEtOTQ4MzE_ffd7f5fc-92aa-4690-8ce9-70ace45b3751">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib00d5eeb7e7c4827bda09db46a2b4b1d_I20201231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTo2MzFiZjA1NmIyOTk0NDNjOTAyMDI0NTQxYmJlMmEwZC90YWJsZXJhbmdlOjYzMWJmMDU2YjI5OTQ0M2M5MDIwMjQ1NDFiYmUyYTBkXzctNC0xLTEtOTQ4MzE_bfe28f9a-e4c9-457f-8acb-31814c889c11">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i36fefdbf2cff4913b1f038b13bc2cb55_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTo2MzFiZjA1NmIyOTk0NDNjOTAyMDI0NTQxYmJlMmEwZC90YWJsZXJhbmdlOjYzMWJmMDU2YjI5OTQ0M2M5MDIwMjQ1NDFiYmUyYTBkXzgtMi0xLTEtOTQ4MzE_48039839-d48c-4d29-a294-107537ef262b">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id521934ae5cd453d9101134d84a1626d_I20201231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTo2MzFiZjA1NmIyOTk0NDNjOTAyMDI0NTQxYmJlMmEwZC90YWJsZXJhbmdlOjYzMWJmMDU2YjI5OTQ0M2M5MDIwMjQ1NDFiYmUyYTBkXzgtNC0xLTEtOTQ4MzE_a5f42b09-317f-499f-a8c8-81a15b779bef">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie612fd61a6d44af9a15649aaa2d9324a_I20211231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTo2MzFiZjA1NmIyOTk0NDNjOTAyMDI0NTQxYmJlMmEwZC90YWJsZXJhbmdlOjYzMWJmMDU2YjI5OTQ0M2M5MDIwMjQ1NDFiYmUyYTBkXzktMi0xLTEtOTQ4MzE_c728c794-3234-43ba-90db-fb6e0d5f3952">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8bc3ec72daa042338987d5ace9cc9c8d_I20201231" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTo2MzFiZjA1NmIyOTk0NDNjOTAyMDI0NTQxYmJlMmEwZC90YWJsZXJhbmdlOjYzMWJmMDU2YjI5OTQ0M2M5MDIwMjQ1NDFiYmUyYTBkXzktNC0xLTEtOTQ4MzE_f7055487-1df9-43e4-bf0f-0f03dc1395fc">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The investment strategy underlying pension plan asset allocation is to manage the assets of the plan to provide for the non-current liabilities while maintaining sufficient liquidity to pay current benefits. Pension plan assets are diversified to protect against large investment losses and to reduce the probability of excessive performance volatility. Diversification of assets is achieved by allocating funds to various asset classes and investment styles within asset classes, and retaining investment management firm(s) with complementary investment philosophies, styles and approaches.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s pension plan assets are managed by outside investment managers using a total return investment approach, whereby a mix of equity and debt securities investments are used to maximize the long-term rate of return on plan assets. A significant portion of the assets of the U.S. and Ireland pension plans have been invested in equity securities, as equity portfolios have historically provided higher returns than debt and other asset classes over extended time horizons. Correspondingly, equity investments also entail greater risks than other investments. Equity risks are balanced by investing a significant portion of plan assets in broadly diversified fixed income securities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Plan Assets </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measured the fair value of plan assets based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. See Note 5, &#8220;FAIR VALUE MEASUREMENTS&#8221; for details on the Company's fair value measurements based on a three-tier hierarchy.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ic99fe8608e3f4783bb4e418f315f7a29"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="bhc:ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2Xzk0MjQ_ee56a2dc-3436-4743-ad56-9735858c970d" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents total plan assets by investment category as of December 31, 2021 and 2020 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value. There were no transfers between Level 1 and Level 2 during 2021 and 2020.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.062%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.297%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans - U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i508b730bcd0045f397f719f04005991d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzMtMi0xLTEtOTQ4MzE_b566e599-1bf1-48d8-8789-3cdb1f828c17">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e4425ac2c7e4b668baf3cbbb7ae8f68_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzMtNC0xLTEtOTQ4MzE_314a84a2-b4a5-49c9-a9c2-41bd7624d45d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89055898a93c470ba50888d0e49f6b0d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzMtNi0xLTEtOTQ4MzE_7d9ee1c8-8d0e-4d96-9492-82241e601d37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8ab04904aed47918dfa94bfb170c6d0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzMtOC0xLTEtOTQ4MzE_aaad0104-895c-416e-ab80-c86809c63956">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2650274c9924895bc8990f8ebdac630_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzMtMTAtMS0xLTk0ODMx_c83a6511-7254-4f94-b7bf-f525b38d2a0b">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06afb70ae6a84cb4ba00bb19a81c46b5_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzMtMTItMS0xLTk0ODMx_7738af3c-65bd-4159-8a4b-cb5b038e5562">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719bfb4f085d4c0687d6a46f624c525d_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzMtMTQtMS0xLTk0ODMx_92996633-2175-4b3c-bd2b-6380973cd818">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66914e16e0af429cbb73c75ef6994478_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzMtMTYtMS0xLTk0ODMx_c1ec0308-b6dd-448d-950d-9c0744bf7930">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. broad market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37752c8772ad4c29a5c583152fb1b1b2_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzYtMi0xLTEtOTQ4MzE_9cc289f2-c8d4-4c62-bf90-49dfee91df2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c903c7579724e20ba48c46c10b81489_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzYtNC0xLTEtOTQ4MzE_9723fe4a-1ee8-415b-a35d-d66e6bd3c2f5">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89938cca48aa4028b0c54c7484178623_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzYtNi0xLTEtOTQ4MzE_e1d2e245-8979-4bc6-b5a7-6ca11b52c275">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93955a18cd3641cdb2827cd853fc1b10_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzYtOC0xLTEtOTQ4MzE_d8704c4a-d161-4901-b08b-6c4fbefe6f6d">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa2bba98ed41466c8eba7b037cea18ab_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzYtMTAtMS0xLTk0ODMx_2e2bf84c-cff0-4e80-bace-1f7458f9b80e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a9940f2b3284c0aa162120bf8b40dfe_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzYtMTItMS0xLTk0ODMx_7858fb32-0215-4fbd-a136-d61d8f3aaf29">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5229d9d0142d45cdb60d7849d3a88d6e_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzYtMTQtMS0xLTk0ODMx_6651767f-cc93-4648-bf37-dfd6963e109e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3c37ec3412c46a4893efcd62fe0f8fb_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzYtMTYtMS0xLTk0ODMx_ffd751f5-d49d-4867-b17f-110a9fe4d03e">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6eb4a0a10d45f7a7eac6ac330e192a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzctMi0xLTEtOTQ4MzE_f191c56e-8b1a-4447-8353-ff6bd5ce6029">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ada422ea708495daf471908c27e5f60_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzctNC0xLTEtOTQ4MzE_10b8d940-6e2b-4e7b-a5a8-fcf379dd9607">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ea389b2765d4a4fafbd53999a35bb35_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzctNi0xLTEtOTQ4MzE_3d250f76-e9e1-4087-8964-ae061191985f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74064a651ca64c52b9baa2296bd46b02_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzctOC0xLTEtOTQ4MzE_57391942-cc98-407c-8da0-78c7f846f879">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac386533ed94ed9a1fef188636cdbb6_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzctMTAtMS0xLTk0ODMx_d55d8d10-d817-4f9b-a310-2f06badebfba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ea8ab4572664d2591c8cb715411dd99_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzctMTItMS0xLTk0ODMx_dc6a9958-cd4f-47f0-9680-1dcfb383ea9b">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bdce432423c43a8a10a88bf483dc5c8_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzctMTQtMS0xLTk0ODMx_db516e71-4200-41fe-9950-9738eb5e68a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4956f9b1dfe045249f6c89ed5e3c029e_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzctMTYtMS0xLTk0ODMx_83e95fa0-f991-4c0e-8dc4-948da377200a">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide developed markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab7cb7f147434baa9c2c29c45db60a33_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzgtMi0xLTEtOTQ4MzE_0c4f4900-5434-4c4c-94c5-f5fbe346c76b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i924b51a174a64385823aa357a0e7d2d6_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzgtNC0xLTEtOTQ4MzE_a629db5f-8af0-4c28-9e83-6aa6ee4b2b3e">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86b804a160e24122a58d7bdb3e3fbf73_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzgtNi0xLTEtOTQ4MzE_36feeb1a-6a81-4cb7-849f-829c8e1c9133">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife79e98052444bd79079d82129a7420a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzgtOC0xLTEtOTQ4MzE_17299f8b-90a5-4a1c-83e3-b7dc09343da8">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4826dfe3433b4c8db9be32ccbebd4288_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzgtMTAtMS0xLTk0ODMx_cb91605f-36c3-48dd-83f1-9300cee4a61e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32bbe248bdd14f98b8a37a069861c416_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzgtMTItMS0xLTk0ODMx_90f32a46-ac7a-4b43-98c3-6be1384f1abe">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica87f2077d3b4d10a04094762892a8b9_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzgtMTQtMS0xLTk0ODMx_5fb8747a-ff8e-49ce-8210-a8f80685dfd1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica23a5188b6f4261abc044904c51cb8b_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzgtMTYtMS0xLTk0ODMx_016867cc-c359-4d2d-9fd7-3736eb0c8e77">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a607fbcafdf4f8f9686e30cf1341551_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzktMi0xLTEtOTQ4MzE_90c6d8a9-6d39-4365-b9bd-05d61a626f60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485c30c6aa2a43eab8ca4aca9b70a7d6_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzktNC0xLTEtOTQ4MzE_d30a4167-1ccf-4e7f-b892-4ca134ec6a12">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2fe2902fe4c41e5a9916ee6a7bd0a90_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzktNi0xLTEtOTQ4MzE_50b52736-47b1-41d6-9090-3daac70c6d3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9547b54812bf44caaa56e89c1c450612_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzktOC0xLTEtOTQ4MzE_2b3af8df-4613-4d17-90a9-ea4650f65457">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23a29524779046dbb6c442615652d8ec_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzktMTAtMS0xLTk0ODMx_2b3719b9-d511-48eb-b96e-b087d9311e43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i734a347aebdf40829771a9719601c1a2_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzktMTItMS0xLTk0ODMx_c48d6720-9003-476a-b2bd-e7fc3bd2b949">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1173f2365141c1815363160c16b76b_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzktMTQtMS0xLTk0ODMx_376a6ecb-e067-4c92-a68c-19b9ff7c3e72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f1f9b48f334ed1a02e13e365598828_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzktMTYtMS0xLTk0ODMx_9aed5523-b479-4a9e-9f0c-e57ee81ed502">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifae30c4aff3d4a04be56aae506f89f0f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzExLTItMS0xLTk0ODMx_ce0ae7d5-a594-4c93-bdbb-7786b8a8119e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbf7a924becb4619aca1895ebcae9add_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzExLTQtMS0xLTk0ODMx_61358a54-a89e-415a-8a2c-16e942519409">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1912d789a0c46d991c0a3481ca5f6a1_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzExLTYtMS0xLTk0ODMx_0687caef-399f-4e4b-a822-a1634a51cedf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52de4cf8c1b0450fad0734be23582658_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzExLTgtMS0xLTk0ODMx_56f04e6c-ff17-4e60-92bd-d9fe63635d05">155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i573fd8e898604de1858ab39ea3a2f4dd_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzExLTEwLTEtMS05NDgzMQ_461758fb-38aa-4a46-a740-e546de736cfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7f5ab099cd40b592114ecfb3acc77b_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzExLTEyLTEtMS05NDgzMQ_64047ad8-bd4c-4ac2-af94-2f13638cfc17">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac4d46a037ab47089459af1054a64149_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzExLTE0LTEtMS05NDgzMQ_31dc704d-0b96-40fe-83e9-8e7c89e151ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d6737e6a7a4e638bdb45c231ed9fd5_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzExLTE2LTEtMS05NDgzMQ_d2506fe2-721c-44ca-938c-b052379c3744">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41d69b7357c9455081525dab7d356749_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzEyLTItMS0xLTk0ODMx_4fd2e646-5de6-46ba-9003-f66e44336937">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64de5046767046de88a2974a3167af0f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzEyLTQtMS0xLTk0ODMx_ec0380ae-4bbe-469d-8a90-28968f2e8eca">223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee2f17c2a4204c139a5cb4c3ea8be354_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzEyLTYtMS0xLTk0ODMx_f7396cbc-92f4-45bf-933e-42d2ca8a07ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd8d218140314ef584532f8f6d286341_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzEyLTgtMS0xLTk0ODMx_12eda5bb-cabc-4a61-b330-2741cf013a0f">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i235dff73cd944ced95f474c54f791c38_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzEyLTEwLTEtMS05NDgzMQ_77a68ddd-9166-4ddf-8b80-a2cd648758bd">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1613dfe248574162a0b44c0c9a6b5c54_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzEyLTEyLTEtMS05NDgzMQ_c386bea9-1605-49ef-b80f-80f1f45b9122">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b79635c2ffe49ca916192dec4f287c6_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzEyLTE0LTEtMS05NDgzMQ_4eaa2da4-95f3-4d8f-bedc-56abf74bb02e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib51448370c174e5ca94ba98d05fc89d1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzEyLTE2LTEtMS05NDgzMQ_cea2ab62-9ca0-4808-afe8-c56733377664">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:31.624%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.083%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.360%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans - Non-U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac7d05a36d0e406b93de498c08fff242_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzMtMi0xLTEtOTQ4MzE_df41d189-be7c-46f8-afcf-5bb25b10381d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5829e60e9724608908829f25ab1d7d2_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzMtNC0xLTEtOTQ4MzE_d556c09a-267e-46c2-a22d-3f7931cc2061">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d0c98de7cf64efd96dfbe09aeb5ee81_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzMtNi0xLTEtOTQ4MzE_087c4c7f-fe54-400e-92c8-b278628c6cc5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32e3ecbd002a4e80a35abbbbdc4463e7_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzMtOC0xLTEtOTQ4MzE_caf99ed6-7a03-4473-b0df-f687478fbc6c">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90565c4f71694e28b3ea6de13e2a5891_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzMtMTAtMS0xLTk0ODMx_fd784408-56b3-4ff9-9422-9af29e3891af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie31761652b084de784cd258f75f2ab5c_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzMtMTItMS0xLTk0ODMx_f0650695-5dce-4958-9b52-870633f7c04f">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5dbb70148a946ea9172055a4c675214_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzMtMTQtMS0xLTk0ODMx_df192321-01b0-4fa1-97fb-8a1c8d95ba03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2b24c259bf14e85a565ed910de3fe12_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzMtMTYtMS0xLTk0ODMx_126d4ad3-0d5d-4006-93d8-edf6e32637b7">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i848b70ed1bbc4567bfd96cad2f56686b_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzYtMi0xLTEtOTQ4MzE_48901672-5036-4100-baa3-748507d2eadc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80d8aa205290445f8909c5d756177c51_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzYtNC0xLTEtOTQ4MzE_482126bf-2403-4144-84ee-bba82f78bdf3">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia47563e74c594e7b94af08bf1c408bfa_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzYtNi0xLTEtOTQ4MzE_10b01292-59d2-40b7-979f-47adb0925df4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd5049ff38de4a8c965af08e2994ca04_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzYtOC0xLTEtOTQ4MzE_d91c656f-a7aa-4082-ad77-6986bd45f76d">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd8ab02c4da8460891761a7202ea7fbb_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzYtMTAtMS0xLTk0ODMx_5eff9612-cb89-42d0-a5b8-3fb51c7154ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccd41ef2d6e64a15b9d909ae1d8e22fd_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzYtMTItMS0xLTk0ODMx_414b2dca-e396-4b68-8bc2-e61ebc2e2700">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96121b9d867041058111f2cfd46930a1_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzYtMTQtMS0xLTk0ODMx_d6823d18-a098-4467-afb3-a0d5f5aaba86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1798ff527d09475a9e91083ed73cef87_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzYtMTYtMS0xLTk0ODMx_fed96d14-d3d2-4861-850c-e9db845ba45b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide developed markets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac0b4c1d18854f90b18c3b8d1b65c5d1_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzctMi0xLTEtOTQ4MzE_ef02473b-e2a2-4edc-b333-dc646c865792">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i341cd2bb05814777ac5eb1149ac11deb_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzctNC0xLTEtOTQ4MzE_67c67421-b901-4ca4-991b-6f2f6b1c7d51">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a3d63af67894f27abf02eb5401cbe40_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzctNi0xLTEtOTQ4MzE_e9cf23b3-13c6-4ff3-9723-1a2ce1651ad6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1498ce58934451fa75a98f7dcbb17dd_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzctOC0xLTEtOTQ4MzE_f160c152-3520-41ec-ba21-7531fdc236e0">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a556e59b8bd4005a138e1541662bb46_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzctMTAtMS0xLTk0ODMx_59e9f8fe-a5d3-4137-abff-be7f5c529d23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebfe537a4e7b4899829b3ce5a6812386_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzctMTItMS0xLTk0ODMx_c370fde7-2384-4019-a63f-b8984149f512">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i122fb437432445bb8b94f66c1352498c_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzctMTQtMS0xLTk0ODMx_6209481e-8914-4888-9b49-ac3643906979">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d8ae058e10b42b19b2b7a51fe102286_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzctMTYtMS0xLTk0ODMx_0ab9f803-4de3-420d-acc5-d6a80c78dce3">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9920661ad081431584fffee6621bedd1_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzktMi0xLTEtOTQ4MzE_16001a0f-45cc-4bb7-ab71-11dc89a27601">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0debe97407a4a29ac76598d242abe70_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzktNC0xLTEtOTQ4MzE_40d73968-fb56-42ed-9fb3-e1ddef0e2203">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3f9511b3ce84767b0cd5dda4878a1d8_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzktNi0xLTEtOTQ4MzE_5c66803d-2741-43eb-b7d0-69ddfe3e27e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0d196db8de044f7b096a26f568bcc2e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzktOC0xLTEtOTQ4MzE_6c4e0494-2b8c-4416-b543-afc6b5e6a2bc">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7166c1867db42a59946692d872ca487_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzktMTAtMS0xLTk0ODMx_51b583f2-5ea6-4e4b-85d0-81012d8f6401">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77e48c2c77094705a53af852b1a9d72f_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzktMTItMS0xLTk0ODMx_ecb5ef79-f1f4-4b33-bd3b-4c565821c5fc">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifef414e1cacc4427af5c130c1dfb7069_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzktMTQtMS0xLTk0ODMx_006c2db1-a18d-4785-8ceb-59b9312c422c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i562a1c1d813143b387a1386991ee371c_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzktMTYtMS0xLTk0ODMx_b0a8f011-b141-44aa-9c01-844330b66254">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global high yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dd6ff8969cd46219034eaa9f922cc63_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEwLTItMS0xLTk0ODMx_db2bebc5-310c-4d54-8476-90f0d77b6dd4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67a8b38165f445a29651dd0163d7b97e_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEwLTQtMS0xLTk0ODMx_4fea558c-3851-4b43-b27c-d68bdd0e8806">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fc0e0e6cfd34b848a4329f6b2d4eef1_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEwLTYtMS0xLTk0ODMx_142b22c6-2632-4cfe-a5ac-aad7fa066439">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85a230e5f81a48c78ac96f0556ba1bcd_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEwLTgtMS0xLTk0ODMx_1fbe6116-acbd-4c83-b349-48ee3121bb87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55a8a69189ab41e4a27cb0653b591709_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEwLTEwLTEtMS05NDgzMQ_78475e6c-8406-4867-a184-57e1787d5d6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01a935b5313744c69b2134f0706843b3_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEwLTEyLTEtMS05NDgzMQ_42c09db4-f856-4aa2-a0fa-78f012c2a1bf">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia283fca771744c269e37b513966bcfca_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEwLTE0LTEtMS05NDgzMQ_1763dd0c-4cc8-417d-9895-00e59875ee49">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib78c157abc13457fb3c2ffeeabc6887c_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEwLTE2LTEtMS05NDgzMQ_1e5c4b4b-a776-4330-817b-6709a5346078">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government bond funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib31507c35e284e299c5a447d87eb3bad_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzExLTItMS0xLTk0ODMx_8adff5a0-5b87-4a8a-9860-f2799c624714">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief04c0c77f754c4e8773310d3f3f995d_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzExLTQtMS0xLTk0ODMx_1fa339b6-f39f-4bbe-8878-5a9611bc5dae">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4abe5fa288434acba436f3607616486a_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzExLTYtMS0xLTk0ODMx_5340981c-37a1-4ac7-89a8-32223970f2ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a1c231876b24515b9cf5290b20d8497_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzExLTgtMS0xLTk0ODMx_dbbf24ae-ece7-408a-8247-8ae3041b6cfe">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4091e0935746423e802930a0a249f3ab_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzExLTEwLTEtMS05NDgzMQ_7308133d-b4d5-4ae9-8784-c0b835b3f5d1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icced8c77467a439ab94442205659b698_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzExLTEyLTEtMS05NDgzMQ_57bb143c-84ca-4bd8-9c52-78d5db8a1aaf">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie78131bdf4944cb4b7835bfd51e69c57_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzExLTE0LTEtMS05NDgzMQ_9c05e36b-d569-4f05-9699-1c1e6d449c41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d6663b8d3354af0836780f9a3ccb7d8_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzExLTE2LTEtMS05NDgzMQ_53855344-5def-4ab1-bb30-bfafb21be744">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i819974f0d173482a87f6215140f5cd12_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEyLTItMS0xLTk0ODMx_01ba7108-1ce3-430e-bc0d-955d15281001">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a4ba4ae2f084135b4c3396a39a9e4d5_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEyLTQtMS0xLTk0ODMx_4a9614a2-3bbb-4445-a8c6-77de4a0a99f9">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a1a9199b6b3495db74904db30ace49f_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEyLTYtMS0xLTk0ODMx_7b2763f0-2696-4329-a6ce-c65dd50cee36">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90b3621ef3a04a7e80b74c2ea9544924_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEyLTgtMS0xLTk0ODMx_9662d827-68ec-443f-8fd3-0bde9c53c272">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9b498085ab54167830633419e66f3ce_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEyLTEwLTEtMS05NDgzMQ_e238b4d2-40f2-4428-9531-7470d98ace46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if783dd84203d4097828a5dfcf36b9360_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEyLTEyLTEtMS05NDgzMQ_923209e6-a943-46c5-8dd0-c08b3d840a4b">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3617a1ce43f34e31b97e8612dceb1bc9_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEyLTE0LTEtMS05NDgzMQ_86e580a4-464a-4d6b-bf61-105aebca33fb">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fdf60201168414184b8e02445c9a52f_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEyLTE2LTEtMS05NDgzMQ_8c1ea66c-33e7-4f8c-af55-a360a2a313d2">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f0c1c6c791466996e0e14977fb3043_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEzLTItMS0xLTk0ODMx_32351ebf-8d56-45cd-964b-1ad239c8f08e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27c4a253513c4ac885cb55c4a07909d1_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEzLTQtMS0xLTk0ODMx_d7bca388-c928-480b-8361-5bd74dcf32cf">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieabf485ffa9b4b01ac91c9afed822bd0_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEzLTYtMS0xLTk0ODMx_eeddf07b-b01d-4078-a040-906e5637087b">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i991e579e87be40ff91924707db6a6553_I20211231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEzLTgtMS0xLTk0ODMx_28dd52eb-e5c7-4748-8a9e-0eb16cc8818d">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e76b4972fd740e69b695e357d4e25c2_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEzLTEwLTEtMS05NDgzMQ_fd28fb30-ef21-4901-a046-fc27c404cdc5">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13b91c47c564e65a71a7033d532765d_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEzLTEyLTEtMS05NDgzMQ_5d80319e-7439-4c09-b516-10c2ba4b719a">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2043342d86cd4a6280d52ee1ce7e996a_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEzLTE0LTEtMS05NDgzMQ_6dbd433b-08db-47f6-a514-6afda1951220">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9788e7d7947465a8b5827eb980e4f3c_I20201231" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEzLTE2LTEtMS05NDgzMQ_37141cd9-35aa-40e4-86cf-b3df083f6cd1">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consisted primarily of term deposits and money market instruments. The fair value of the term deposits approximates their carrying amounts due to their short term maturities. The money market instruments also have short maturities and are valued using a market approach based on the quoted market prices of identical instruments. </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commingled funds are not publicly traded. The underlying assets in these funds are publicly traded on the exchanges and have readily available price quotes. The Ireland pension plans held approximately <ix:nonFraction unitRef="number" contextRef="i180a6063ed294b858f6f1b7f8889f355_D20210101-20211231" decimals="2" name="bhc:DefinedBenefitPlanPercentageAllocationofFund" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2Xzg1OTE_9cb5c86c-0076-4bd2-9c07-a4a6494cbb2a">95</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i6361735a69df45b5bec1a681fbc6e116_D20200101-20201231" decimals="2" name="bhc:DefinedBenefitPlanPercentageAllocationofFund" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2Xzg1OTg_7ad289d1-6b81-457f-b31c-9d974568f800">96</ix:nonFraction>% of the non-U.S. commingled funds in 2021 and 2020, respectively. The commingled funds held by the U.S. and Ireland pension plans are primarily invested in index funds.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The underlying assets in the fixed income funds are generally valued using the net asset value per fund share, which is derived using a market approach with inputs that include broker quotes, benchmark yields, base spreads and reported trades. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defined Contribution Plans </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors defined contribution plans in the U.S., Ireland and certain other countries.&#160;Under these plans, employees are allowed to contribute a portion of their salaries to the plans, and the Company matches a portion of the employee contributions. The Company contributed $<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzkzMjI_0a706106-dcd6-4758-a0d9-fcf4c8bbe946">44</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzkzMjY_00831136-3483-4b06-8080-1d5401b38c5f">43</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzkzMzM_d62e9b28-8286-4734-becd-2dee8c905f6d">41</ix:nonFraction> million to these plans during the years ended December 31, 2021, 2020 and 2019, respectively.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-48</span></div></div></div><div id="i8256f225f07d49409c31f7443adffdbf_349"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90ZXh0cmVnaW9uOjQyNTNmNzM2ZmM3YzRkMDk4NzhlYzM3ZjdhMTMwZDU0XzYwNA_a93a077d-726e-4f82-b46b-bd9f4cf58e11" continuedAt="i90dfc787b7554d1da49e6682e5d0d149" escape="true">LEASES </ix:nonNumeric></span></div><ix:continuation id="i90dfc787b7554d1da49e6682e5d0d149"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="bhc:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90ZXh0cmVnaW9uOjQyNTNmNzM2ZmM3YzRkMDk4NzhlYzM3ZjdhMTMwZDU0XzYwNQ_f9e7ac6d-64ec-41fc-9d5d-51900c261610" escape="true"><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets and lease liabilities associated with the Company's operating leases are included in the Consolidated Balance Sheet as of December 31, 2021 and 2020 as follows:</span></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:82.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets included in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzItMC0xLTEtOTQ4MzE_4bf2464d-f080-463a-b82a-fe3327a6ffe8"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzItMC0xLTEtOTQ4MzE_ce76341b-5893-4112-b76b-f4aed3b43dcf">Other non-current assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzItMS0xLTEtOTQ4MzE_2d90aff0-8db6-4079-ac85-15791442a7b9">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzItMy0xLTEtOTQ4MzE_29e8847b-c267-4a55-aaeb-34255f77b7f9">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities included in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzQtMC0xLTEtOTQ4MzE_4bf64393-afaa-455f-a448-662b6f9a6f45"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzQtMC0xLTEtOTQ4MzE_4de59f41-dcca-4036-87e1-e7e98c16d228">Accrued and other current liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzQtMS0xLTEtOTQ4MzE_4b103433-bee7-4f79-b6ef-3325957af88a">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzQtMy0xLTEtOTQ4MzE_2a4d6d7b-3833-4354-bffc-2df084b93120">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzUtMC0xLTEtOTQ4MzE_339c676d-41f8-49e5-86a9-b2e8149fc1fd"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzUtMC0xLTEtOTQ4MzE_c6eaab40-e3c8-4b6a-afe4-21b28ab4bf11">Other non-current liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzUtMS0xLTEtOTQ4MzE_3849e584-7582-46b9-9b46-f4fb0af28b8a">214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzUtMy0xLTEtOTQ4MzE_f0c247c7-eebe-45a5-b02f-fca1d907f98b">227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzYtMS0xLTEtOTQ4MzE_85085fb1-fe6d-4b76-9f74-da21592b845b">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzYtMy0xLTEtOTQ4MzE_4ae857e5-52be-472b-b157-731209605604">279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, 2020 and 2019 the Company's finance leases were <ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:FinanceLeaseLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90ZXh0cmVnaW9uOjQyNTNmNzM2ZmM3YzRkMDk4NzhlYzM3ZjdhMTMwZDU0XzIxNQ_19b66785-c1f5-4c39-9c2d-211243263736"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90ZXh0cmVnaW9uOjQyNTNmNzM2ZmM3YzRkMDk4NzhlYzM3ZjdhMTMwZDU0XzIxNQ_7c74e893-4c1e-449b-bc0f-6f0b18c56e4a"><ix:nonFraction unitRef="usd" contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231" decimals="-6" name="us-gaap:FinanceLeaseLiability" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90ZXh0cmVnaW9uOjQyNTNmNzM2ZmM3YzRkMDk4NzhlYzM3ZjdhMTMwZDU0XzIxNQ_e1d19bd4-dfa1-4547-a0c4-b081b30aa1b4">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t material and for the years 2021, 2020 and 2019 sub-lease income and short-term lease expense were <ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:SubleaseIncome" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90ZXh0cmVnaW9uOjQyNTNmNzM2ZmM3YzRkMDk4NzhlYzM3ZjdhMTMwZDU0XzMxMQ_1ea98294-fbe5-493b-b504-95a7c6826ac2"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90ZXh0cmVnaW9uOjQyNTNmNzM2ZmM3YzRkMDk4NzhlYzM3ZjdhMTMwZDU0XzMxMQ_22f3b3f6-4cb1-49e7-a8c3-d7beb4cf1c60"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90ZXh0cmVnaW9uOjQyNTNmNzM2ZmM3YzRkMDk4NzhlYzM3ZjdhMTMwZDU0XzMxMQ_25a182a3-14fa-4bec-a352-937298eb25b6"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90ZXh0cmVnaW9uOjQyNTNmNzM2ZmM3YzRkMDk4NzhlYzM3ZjdhMTMwZDU0XzMxMQ_c71c640e-cfc1-45f6-ae92-ffa6ae51ea52"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:SubleaseIncome" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90ZXh0cmVnaW9uOjQyNTNmNzM2ZmM3YzRkMDk4NzhlYzM3ZjdhMTMwZDU0XzMxMQ_cf15973f-2f03-4d64-99b5-decbf4b3fe8a"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:SubleaseIncome" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90ZXh0cmVnaW9uOjQyNTNmNzM2ZmM3YzRkMDk4NzhlYzM3ZjdhMTMwZDU0XzMxMQ_d48b7a78-33a3-4b68-aa05-2d8be1473694">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t material. <ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90ZXh0cmVnaW9uOjQyNTNmNzM2ZmM3YzRkMDk4NzhlYzM3ZjdhMTMwZDU0XzYwNg_80067e09-2481-480b-9855-f28fc5c1c0b6" continuedAt="i37c1cb470ed14b01b649aacc534921ae" escape="true">Lease expense for the years 2021, 2020 and 2019 include:</ix:nonNumeric></span></div><div style="margin-bottom:6.6pt;margin-top:5pt;padding-left:18pt;text-align:justify"><ix:continuation id="i37c1cb470ed14b01b649aacc534921ae"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:70.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpiMmMyNjc2NmYzZjY0YWIzOGFmOGM0NzUyZTQ0N2RkNS90YWJsZXJhbmdlOmIyYzI2NzY2ZjNmNjRhYjM4YWY4YzQ3NTJlNDQ3ZGQ1XzEtMS0xLTEtOTQ4MzE_f875c358-1851-4ef0-bbed-14727e57c680">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpiMmMyNjc2NmYzZjY0YWIzOGFmOGM0NzUyZTQ0N2RkNS90YWJsZXJhbmdlOmIyYzI2NzY2ZjNmNjRhYjM4YWY4YzQ3NTJlNDQ3ZGQ1XzEtMy0xLTEtOTQ4MzE_520c4a44-c303-4cbc-bf97-1f63b9ac8be3">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpiMmMyNjc2NmYzZjY0YWIzOGFmOGM0NzUyZTQ0N2RkNS90YWJsZXJhbmdlOmIyYzI2NzY2ZjNmNjRhYjM4YWY4YzQ3NTJlNDQ3ZGQ1XzEtNS0xLTEtOTQ4MzE_21c05f49-012e-4a90-8243-1dcca4302da9">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable operating lease costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpiMmMyNjc2NmYzZjY0YWIzOGFmOGM0NzUyZTQ0N2RkNS90YWJsZXJhbmdlOmIyYzI2NzY2ZjNmNjRhYjM4YWY4YzQ3NTJlNDQ3ZGQ1XzItMS0xLTEtOTQ4MzE_0a2826a6-a836-4c5d-bd60-64a1915eb8e2">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpiMmMyNjc2NmYzZjY0YWIzOGFmOGM0NzUyZTQ0N2RkNS90YWJsZXJhbmdlOmIyYzI2NzY2ZjNmNjRhYjM4YWY4YzQ3NTJlNDQ3ZGQ1XzItMy0xLTEtOTQ4MzE_5b4b41b9-0f54-4ef0-acc5-8dbf3818f578">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpiMmMyNjc2NmYzZjY0YWIzOGFmOGM0NzUyZTQ0N2RkNS90YWJsZXJhbmdlOmIyYzI2NzY2ZjNmNjRhYjM4YWY4YzQ3NTJlNDQ3ZGQ1XzItNS0xLTEtOTQ4MzE_e047bb5b-4b6e-4638-8c9a-2d15d8c5e68a">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="bhc:AdditionalOperatingLeaseInformationLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90ZXh0cmVnaW9uOjQyNTNmNzM2ZmM3YzRkMDk4NzhlYzM3ZjdhMTMwZDU0XzYwNw_b41bedd2-8e88-4476-8d7b-cbc4860890d4" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to operating leases for 2021, 2020 and 2019 is as follows:</span></div><div style="margin-bottom:6.6pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:70.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid from operating cash flows for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpjOGY5MzRjNmYwODI0Njg1YTRlY2Y5MzE1ZWQwZmYyNS90YWJsZXJhbmdlOmM4ZjkzNGM2ZjA4MjQ2ODVhNGVjZjkzMTVlZDBmZjI1XzEtMS0xLTEtOTQ4MzE_bc28460c-d3a4-4fb9-8842-63b2129eec8c">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpjOGY5MzRjNmYwODI0Njg1YTRlY2Y5MzE1ZWQwZmYyNS90YWJsZXJhbmdlOmM4ZjkzNGM2ZjA4MjQ2ODVhNGVjZjkzMTVlZDBmZjI1XzEtMy0xLTEtOTQ4MzE_b2c85188-c53b-4e31-80eb-b3bc4887a4bc">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpjOGY5MzRjNmYwODI0Njg1YTRlY2Y5MzE1ZWQwZmYyNS90YWJsZXJhbmdlOmM4ZjkzNGM2ZjA4MjQ2ODVhNGVjZjkzMTVlZDBmZjI1XzEtNS0xLTEtOTQ4MzE_a793bc17-c8bc-43e3-86af-01716e52f0a9">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="bhc:RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpjOGY5MzRjNmYwODI0Njg1YTRlY2Y5MzE1ZWQwZmYyNS90YWJsZXJhbmdlOmM4ZjkzNGM2ZjA4MjQ2ODVhNGVjZjkzMTVlZDBmZjI1XzItMS0xLTEtOTQ4MzE_0e03c663-7fe0-4df4-8ed5-fd35a5108771">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="bhc:RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpjOGY5MzRjNmYwODI0Njg1YTRlY2Y5MzE1ZWQwZmYyNS90YWJsZXJhbmdlOmM4ZjkzNGM2ZjA4MjQ2ODVhNGVjZjkzMTVlZDBmZjI1XzItMy0xLTEtOTQ4MzE_43a1a45c-a69e-4575-ab50-101def537b0e">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="bhc:RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpjOGY5MzRjNmYwODI0Njg1YTRlY2Y5MzE1ZWQwZmYyNS90YWJsZXJhbmdlOmM4ZjkzNGM2ZjA4MjQ2ODVhNGVjZjkzMTVlZDBmZjI1XzItNS0xLTEtOTQ4MzE_2c99d6c4-6d58-4d9d-8019-3008b81a282b">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpjOGY5MzRjNmYwODI0Njg1YTRlY2Y5MzE1ZWQwZmYyNS90YWJsZXJhbmdlOmM4ZjkzNGM2ZjA4MjQ2ODVhNGVjZjkzMTVlZDBmZjI1XzMtMS0xLTEtOTQ4MzE_1624ff9e-e460-4c93-b75f-fc34b59cdc90">7.2</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpjOGY5MzRjNmYwODI0Njg1YTRlY2Y5MzE1ZWQwZmYyNS90YWJsZXJhbmdlOmM4ZjkzNGM2ZjA4MjQ2ODVhNGVjZjkzMTVlZDBmZjI1XzMtMy0xLTEtOTQ4MzE_8dfb050f-99e3-4fbf-97c1-22891f945b0c">7.6</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpjOGY5MzRjNmYwODI0Njg1YTRlY2Y5MzE1ZWQwZmYyNS90YWJsZXJhbmdlOmM4ZjkzNGM2ZjA4MjQ2ODVhNGVjZjkzMTVlZDBmZjI1XzMtNS0xLTEtOTQ4MzE_fa8cc74f-9e78-4871-8988-8f991653f395">8.2</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpjOGY5MzRjNmYwODI0Njg1YTRlY2Y5MzE1ZWQwZmYyNS90YWJsZXJhbmdlOmM4ZjkzNGM2ZjA4MjQ2ODVhNGVjZjkzMTVlZDBmZjI1XzQtMS0xLTEtOTQ4MzE_cdf9e059-47d3-41a7-94ba-53430f2bb978">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpjOGY5MzRjNmYwODI0Njg1YTRlY2Y5MzE1ZWQwZmYyNS90YWJsZXJhbmdlOmM4ZjkzNGM2ZjA4MjQ2ODVhNGVjZjkzMTVlZDBmZjI1XzQtMy0xLTEtOTQ4MzE_fa33b715-1859-45c1-9c02-8a2705c6ea85">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpjOGY5MzRjNmYwODI0Njg1YTRlY2Y5MzE1ZWQwZmYyNS90YWJsZXJhbmdlOmM4ZjkzNGM2ZjA4MjQ2ODVhNGVjZjkzMTVlZDBmZjI1XzQtNS0xLTEtOTQ4MzE_a3005621-b7ef-4187-b087-375ae955d8da">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90ZXh0cmVnaW9uOjQyNTNmNzM2ZmM3YzRkMDk4NzhlYzM3ZjdhMTMwZDU0XzYwOA_9fc482f5-5714-4be3-ab0e-d660ee06851f" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, future payments under noncancelable operating leases for each of the five succeeding years ending December 31 and thereafter are as&#160;follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:91.594%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTo5MGNmZjU2MTJlNjU0MzhkODJkNTBjNjUwNTY2N2IzMy90YWJsZXJhbmdlOjkwY2ZmNTYxMmU2NTQzOGQ4MmQ1MGM2NTA1NjY3YjMzXzEtMi0xLTEtOTQ4MzE_8d6e6f83-f4c1-4906-89f8-c97b300f1dc6">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTo5MGNmZjU2MTJlNjU0MzhkODJkNTBjNjUwNTY2N2IzMy90YWJsZXJhbmdlOjkwY2ZmNTYxMmU2NTQzOGQ4MmQ1MGM2NTA1NjY3YjMzXzItMi0xLTEtOTQ4MzE_5caa0bef-372d-423b-87cf-836c35366840">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTo5MGNmZjU2MTJlNjU0MzhkODJkNTBjNjUwNTY2N2IzMy90YWJsZXJhbmdlOjkwY2ZmNTYxMmU2NTQzOGQ4MmQ1MGM2NTA1NjY3YjMzXzMtMi0xLTEtOTQ4MzE_91b7e9fb-a319-49cb-b4a1-d8f792ed9eb4">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTo5MGNmZjU2MTJlNjU0MzhkODJkNTBjNjUwNTY2N2IzMy90YWJsZXJhbmdlOjkwY2ZmNTYxMmU2NTQzOGQ4MmQ1MGM2NTA1NjY3YjMzXzQtMi0xLTEtOTQ4MzE_40ec6c2d-0706-4bd1-a11e-3a24f90913a2">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTo5MGNmZjU2MTJlNjU0MzhkODJkNTBjNjUwNTY2N2IzMy90YWJsZXJhbmdlOjkwY2ZmNTYxMmU2NTQzOGQ4MmQ1MGM2NTA1NjY3YjMzXzUtMi0xLTEtOTQ4MzE_2c4ce14c-da4c-47bb-bd71-55f5c9266290">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTo5MGNmZjU2MTJlNjU0MzhkODJkNTBjNjUwNTY2N2IzMy90YWJsZXJhbmdlOjkwY2ZmNTYxMmU2NTQzOGQ4MmQ1MGM2NTA1NjY3YjMzXzYtMi0xLTEtOTQ4MzE_b549ecbf-b99e-41f8-9978-0e8ca3881950">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTo5MGNmZjU2MTJlNjU0MzhkODJkNTBjNjUwNTY2N2IzMy90YWJsZXJhbmdlOjkwY2ZmNTYxMmU2NTQzOGQ4MmQ1MGM2NTA1NjY3YjMzXzctMi0xLTEtOTQ4MzE_13703995-d687-40cd-8ca9-df9a94301bf2">330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTo5MGNmZjU2MTJlNjU0MzhkODJkNTBjNjUwNTY2N2IzMy90YWJsZXJhbmdlOjkwY2ZmNTYxMmU2NTQzOGQ4MmQ1MGM2NTA1NjY3YjMzXzgtMi0xLTEtOTQ4MzE_9334f7a2-b574-4479-9045-29f5fc07188a">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of remaining lease payments</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTo5MGNmZjU2MTJlNjU0MzhkODJkNTBjNjUwNTY2N2IzMy90YWJsZXJhbmdlOjkwY2ZmNTYxMmU2NTQzOGQ4MmQ1MGM2NTA1NjY3YjMzXzktMi0xLTEtOTQ4MzE_2ec4db40-b910-4682-a5a7-7b48ec9da43d">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTo5MGNmZjU2MTJlNjU0MzhkODJkNTBjNjUwNTY2N2IzMy90YWJsZXJhbmdlOjkwY2ZmNTYxMmU2NTQzOGQ4MmQ1MGM2NTA1NjY3YjMzXzEwLTItMS0xLTk0ODMx_9b2019dc-1dd0-4135-85ce-c293a59b6a6b">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTo5MGNmZjU2MTJlNjU0MzhkODJkNTBjNjUwNTY2N2IzMy90YWJsZXJhbmdlOjkwY2ZmNTYxMmU2NTQzOGQ4MmQ1MGM2NTA1NjY3YjMzXzExLTItMS0xLTk0ODMx_3ae75631-3993-4793-be3c-afa743d1d8d1">214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i8256f225f07d49409c31f7443adffdbf_352"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzExMjI2_593321c3-c3eb-4653-bee6-3cd8e1ffc850" continuedAt="i5786ca702515423b850f0f4a596e175b" escape="true">SHARE-BASED COMPENSATION</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5786ca702515423b850f0f4a596e175b" continuedAt="id2d914d52f0c4b5ea8d0b480cdec5ae0">In May 2014, shareholders approved the Company&#8217;s 2014 Omnibus Incentive Plan (the &#8220;2014 Plan&#8221;), which replaced the Company&#8217;s 2011 Omnibus Incentive Plan (the &#8220;2011 Plan&#8221;) for future equity awards granted by the Company. The Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan was equal to <ix:nonFraction unitRef="shares" contextRef="id943b700697244c1a9af35217a5014fc_I20140531" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzQyMw_30d16b86-be77-4084-9419-3681c549db1d">18,000,000</ix:nonFraction> common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or </ix:continuation></span></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="id2d914d52f0c4b5ea8d0b480cdec5ae0" continuedAt="i8164fc82cf184c7d944f56eafe4423be"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">surrendered under the 2011 Plan and the Company&#8217;s 2007 Equity Compensation Plan. The Company registered <ix:nonFraction unitRef="shares" contextRef="id943b700697244c1a9af35217a5014fc_I20140531" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzc4Mw_d5b518ce-e12b-48cf-8c8c-56b139aecf38">20,000,000</ix:nonFraction> common shares of common stock for issuance under the 2014 Plan.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 30, 2018, the Company amended and restated the 2014 Plan (the &#8220;Amended and Restated 2014 Plan&#8221;). The Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Amended and Restated 2014 Plan has been increased by an additional <ix:nonFraction unitRef="shares" contextRef="i6006b5cfb8f34c728d0575646bfaa31c_D20180430-20180430" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzExNjg_b1c971d0-65a8-4f12-9aa6-b24091cbd275">11,900,000</ix:nonFraction> common shares, as approved by the requisite number of shareholders at the Company&#8217;s annual general meeting held on April 30, 2018, (ii) introduction of a $<ix:nonFraction unitRef="usd" contextRef="ia9c449e903f04beb9f713f2df4efd6ca_D20180430-20180430" decimals="INF" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzEzMjU_e489f5ab-7b8a-4ac8-8070-e5f315997dd4">750,000</ix:nonFraction> aggregate fair market value limit on awards (in either equity, cash or other compensation) that can be granted in any calendar year to a participant who is a non-employee director, (iii) housekeeping changes to address recent changes to Section 162(m) of the Internal Revenue Code, (iv) awards are expressly subject to the Company&#8217;s clawback policy and (v) awards not assumed or substituted in connection with a Change of Control (as defined in the Amended and Restated 2014 Plan) will only vest on a pro rata basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 28, 2020, the Company further amended and restated the Amended and Restated 2014 Plan (the &#8220;Further Amended and Restated 2014 Plan&#8221;). The Further Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Further Amended and Restated 2014 Plan has been increased by an additional <ix:nonFraction unitRef="shares" contextRef="i0d0c600ff58f4f0da9f1d4e553efd25b_D20200428-20200428" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzIyMTQ_1a12a6b1-62e9-4cb4-9a46-1942d1c1c499">13,500,000</ix:nonFraction> common shares, as approved by the requisite number of shareholders at the Company&#8217;s annual general meeting held on April 28, 2020, (ii) the exercise price of stock options and share appreciation rights (&#8220;SARs&#8221;) will be based on the closing price of the underlying common shares on the date such stock options or SARs are granted (rather than on the last preceding trading date), (iii)&#160;additional provisions clarifying that: (a)&#160;stock options and SARs will not be eligible for the payment of dividend or dividend equivalents and (b)&#160;the Talent and Compensation Committee of the Board of Directors of the Company cannot, without shareholder approval, seek to effect any repricing of any previously granted &#8220;underwater&#8221; stock option or SAR and (iv) other housekeeping and/or clerical changes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately <ix:nonFraction unitRef="shares" contextRef="i5e2ddff148e045819b4c2a2baecf7de3_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzMwMjE_59de7295-b1d6-4ffb-8efd-c67e6dad76c8">11,593,000</ix:nonFraction> common shares were available for future grants as of December&#160;31, 2021. The Company uses reserved and unissued common shares to satisfy its obligation under its share-based compensation plans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a long-term incentive program with the objective of aligning the share-based awards granted to senior management with the Company&#8217;s focus on improving its tangible capital usage and allocation, while maintaining focus on improving total shareholder return over the long-term.  The share-based awards granted under this long-term incentive program consist of time-based stock options, time-based RSUs and performance-based RSUs. Performance-based RSUs are comprised of: (i) awards that vest upon achievement of certain share price appreciation conditions that are based on total shareholder return (&#8220;TSR&#8221;), (ii) awards that vest upon attainment of certain performance targets that are based on the Company&#8217;s return on tangible capital (&#8220;ROTC&#8221;) and (iii) vest fully or partially upon attainment of certain goals that are linked to the B+L Separation.</span></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzExMjEy_3a86113c-a882-4f39-ae2f-458be43276d9" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components and classification of share-based compensation expense related to stock options and&#160;RSUs for the years 2021, 2020 and 2019 were as follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:67.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.934%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.934%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzEtMi0xLTEtOTQ4MzE_650098d4-1996-4b4c-bd6b-5a39a4dadadd">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f3083202c7e4f36ada3cfe487b44863_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzEtNC0xLTEtOTQ4MzE_cbba8c9b-3417-4352-a61e-e5a95a18572c">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69f7d41ce4b642209bb25ea9c478625f_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzEtNi0xLTEtOTQ4MzE_4845aafe-8c94-45ed-b59e-c62f086e367f">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00aeb13ceebf48e891b516a2d0c221d3_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzItMi0xLTEtOTQ4MzE_5d378fb9-44a2-4548-9a18-d983a49b1b2a">113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c0144ad2365471881ed18f7ced989f8_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzItNC0xLTEtOTQ4MzE_b48faedf-70b3-403e-9815-fb89bd8eae18">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dcf40ad82c34f11ac4a925dd47873ab_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzItNi0xLTEtOTQ4MzE_68d2c2f9-dbdb-4618-8740-4158a17b3624">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzMtMi0xLTEtOTQ4MzE_a0acef1e-aad6-41e8-b9c2-2c559f098909">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzMtNC0xLTEtOTQ4MzE_e2e9e578-fe6c-4b4b-b64a-110d43abcf63">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzMtNi0xLTEtOTQ4MzE_b0e27eda-b937-4fbc-9d37-74e5009f18ce">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b764cf71454461b9ae558f095cef352_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzUtMi0xLTEtOTQ4MzE_3491dafc-93f7-4736-89cf-a17dfde0f3ef">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i169ce44b8b6147b5af92c163ff58f3e3_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzUtNC0xLTEtOTQ4MzE_f79d0921-0492-4e9d-82e3-2896a7e28df2">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25d8a1ce6eb4407f92324a3e68f2013f_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzUtNi0xLTEtOTQ4MzE_cdc21aea-a185-43d3-9dc2-8539ff2bd232">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbd1e5635e5040f3a9121f39e9238a50_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzYtMi0xLTEtOTQ4MzE_07e99f25-d0fa-48bb-ae7a-5277d5131019">118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib100363bb61344be9b5ce0d1f32e9248_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzYtNC0xLTEtOTQ4MzE_d770af6a-86e7-4535-965e-9c0d5792c179">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb7848e770bf4984a2093c22786e7db8_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzYtNi0xLTEtOTQ4MzE_fc27e080-1a07-4d7c-a909-6c6d8731fe94">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzctMi0xLTEtOTQ4MzE_4d14c92a-a89e-4655-a632-e82f9d6582b4">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzctNC0xLTEtOTQ4MzE_46f2292e-cb1a-4ffa-8766-c7f44817828d">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzctNi0xLTEtOTQ4MzE_03d66f13-5095-4d85-a193-3a7d51f35241">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options granted under the 2011 Plan and the Amended and Restated 2014 Plan generally expire on the fifth or tenth anniversary of the grant date. The exercise price of any stock option granted under the 2011 Plan and the Amended and Restated 2014 Plan will not be less than the closing price per common share on the date of grant. Stock options generally vest <ix:nonFraction unitRef="number" contextRef="id87fa13c036e497faecb209787ce467e_D20210101-20211231" decimals="INF" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzQ1OTg_4adca589-10af-48fd-95d7-27bfe9d15c14">33</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="iecd38b28e9a84d1880313b43be4e32a2_D20210101-20211231" decimals="INF" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzQ2MDU_3e15c71b-6cb5-4a84-8e49-60a072e1ee61">25</ix:nonFraction>% each year over a <ix:nonNumeric contextRef="i7384f8f25998459682939a04e6a9c33f_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzExMjU5_008af08b-e30f-4572-afda-a8a4642b5ebe">three-year</ix:nonNumeric> and <ix:nonNumeric contextRef="if57561008d804ce4b03b997a95d4d41e_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzExMjIw_ff144dce-8c2e-4e1d-992f-105fc228f77c">four-year</ix:nonNumeric> period, respectively, on the anniversary of the date of&#160;grant.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i8164fc82cf184c7d944f56eafe4423be" continuedAt="i1fc6af286a3647e3ab2df4c20fe334a3"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzExMjIx_85aa30c8-0d84-4c01-8bf2-99184273029c" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of all stock options granted for the years 2021, 2020 and 2019 were estimated as of the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock option life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo4YzQzMTJjOTViMjI0YmIxOTFmNGVkOGVjNmI3NDEwNC90YWJsZXJhbmdlOjhjNDMxMmM5NWIyMjRiYjE5MWY0ZWQ4ZWM2Yjc0MTA0XzEtMi0xLTEtOTQ4MzE_dad0dff6-aaac-4183-b4e0-78a02d97e5a4">3.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2f3083202c7e4f36ada3cfe487b44863_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo4YzQzMTJjOTViMjI0YmIxOTFmNGVkOGVjNmI3NDEwNC90YWJsZXJhbmdlOjhjNDMxMmM5NWIyMjRiYjE5MWY0ZWQ4ZWM2Yjc0MTA0XzEtNC0xLTEtOTQ4MzE_141a1c81-1ab6-457e-9c3e-d1282fa52507">3.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i69f7d41ce4b642209bb25ea9c478625f_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo4YzQzMTJjOTViMjI0YmIxOTFmNGVkOGVjNmI3NDEwNC90YWJsZXJhbmdlOjhjNDMxMmM5NWIyMjRiYjE5MWY0ZWQ4ZWM2Yjc0MTA0XzEtNi0xLTEtOTQ4MzE_5e0c0a63-8bc2-4b25-a8be-cd2823ac912c">3.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo4YzQzMTJjOTViMjI0YmIxOTFmNGVkOGVjNmI3NDEwNC90YWJsZXJhbmdlOjhjNDMxMmM5NWIyMjRiYjE5MWY0ZWQ4ZWM2Yjc0MTA0XzItMi0xLTEtOTQ4MzE_1d4deba2-b582-458c-a6cd-7bf551ccf8d6">50.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f3083202c7e4f36ada3cfe487b44863_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo4YzQzMTJjOTViMjI0YmIxOTFmNGVkOGVjNmI3NDEwNC90YWJsZXJhbmdlOjhjNDMxMmM5NWIyMjRiYjE5MWY0ZWQ4ZWM2Yjc0MTA0XzItNC0xLTEtOTQ4MzE_649d26d9-cb2f-472d-a05a-24de0a980941">38.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69f7d41ce4b642209bb25ea9c478625f_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo4YzQzMTJjOTViMjI0YmIxOTFmNGVkOGVjNmI3NDEwNC90YWJsZXJhbmdlOjhjNDMxMmM5NWIyMjRiYjE5MWY0ZWQ4ZWM2Yjc0MTA0XzItNi0xLTEtOTQ4MzE_4cb9089c-9672-44b0-af64-bab91742c29d">46.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo4YzQzMTJjOTViMjI0YmIxOTFmNGVkOGVjNmI3NDEwNC90YWJsZXJhbmdlOjhjNDMxMmM5NWIyMjRiYjE5MWY0ZWQ4ZWM2Yjc0MTA0XzMtMi0xLTEtOTQ4MzE_86c2f65a-5153-449d-b8e9-a568af712cd2">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f3083202c7e4f36ada3cfe487b44863_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo4YzQzMTJjOTViMjI0YmIxOTFmNGVkOGVjNmI3NDEwNC90YWJsZXJhbmdlOjhjNDMxMmM5NWIyMjRiYjE5MWY0ZWQ4ZWM2Yjc0MTA0XzMtNC0xLTEtOTQ4MzE_295b0131-902b-4f1d-9488-615e6bea751a">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69f7d41ce4b642209bb25ea9c478625f_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo4YzQzMTJjOTViMjI0YmIxOTFmNGVkOGVjNmI3NDEwNC90YWJsZXJhbmdlOjhjNDMxMmM5NWIyMjRiYjE5MWY0ZWQ4ZWM2Yjc0MTA0XzMtNi0xLTEtOTQ4MzE_20d4265f-5995-4c12-9d0e-c0cd8617453b">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo4YzQzMTJjOTViMjI0YmIxOTFmNGVkOGVjNmI3NDEwNC90YWJsZXJhbmdlOjhjNDMxMmM5NWIyMjRiYjE5MWY0ZWQ4ZWM2Yjc0MTA0XzQtMi0xLTEtOTQ4MzE_74aecb7b-a79e-463d-b5e2-bd3a0a22e7fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f3083202c7e4f36ada3cfe487b44863_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo4YzQzMTJjOTViMjI0YmIxOTFmNGVkOGVjNmI3NDEwNC90YWJsZXJhbmdlOjhjNDMxMmM5NWIyMjRiYjE5MWY0ZWQ4ZWM2Yjc0MTA0XzQtNC0xLTEtOTQ4MzE_3a9414b3-fdf0-4d5e-b49f-ab1c573a3c86">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69f7d41ce4b642209bb25ea9c478625f_D20190101-20191231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo4YzQzMTJjOTViMjI0YmIxOTFmNGVkOGVjNmI3NDEwNC90YWJsZXJhbmdlOjhjNDMxMmM5NWIyMjRiYjE5MWY0ZWQ4ZWM2Yjc0MTA0XzQtNi0xLTEtOTQ4MzE_8a37e203-bc2c-4b62-b23d-69ea53568400">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected stock option life was determined based on historical exercise and forfeiture patterns. The expected volatility was determined based on implied volatility in the market traded options of the Company&#8217;s common stock. The risk-free interest rate was determined based on the rate at the time of grant for zero-coupon U.S. government bonds with maturity dates equal to the expected life of the stock&#160;option. The expected dividend yield was determined based on the stock option&#8217;s exercise price and expected annual dividend rate at the time of&#160;grant.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model used by the Company to calculate stock option values was developed to estimate the fair value of freely tradeable, fully transferable stock options without vesting restrictions, which significantly differ from the Company&#8217;s stock option awards. This model also requires highly subjective assumptions, including future stock price volatility and expected time until exercise, which greatly affect the calculated values.</span></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzExMjY1_bcdf91ff-842a-4bee-bf74-ddadcd01c105" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during 2021: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:56.633%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.706%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, January&#160;1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d3ab00f203a4abdb121762625a88c8a_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzEtMi0xLTEtOTQ4MzE_a92061ca-eb55-400b-a0fa-9f1157638e9f">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9d3ab00f203a4abdb121762625a88c8a_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzEtNC0xLTEtOTQ4MzE_52447dc3-ba4d-4b2a-9f25-32c6163a7a9a">25.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzItMi0xLTEtOTQ4MzE_0140f4a2-7c6d-4b68-a005-3b0cfc61c097">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzItNC0xLTEtOTQ4MzE_1d7af709-05a7-48d5-9553-ce0f74e6b0ed">32.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzMtMi0xLTEtOTQ4MzE_a9553a83-25f2-4660-b97a-54393d0c9083">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzMtNC0xLTEtOTQ4MzE_3cc6abea-7048-45b2-82e3-0a823be594ab">18.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired or forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzQtMi0xLTEtOTQ4MzE_89377c24-b5eb-4bec-8fe1-c802928397da">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzQtNC0xLTEtOTQ4MzE_8fd13a20-4888-4654-9155-e0ec58af43f7">29.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01666d0d4a034ebbb396a9f3c3378737_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzUtMi0xLTEtOTQ4MzE_08d57cc1-ddc1-47c9-9ce1-871f998877c4">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i01666d0d4a034ebbb396a9f3c3378737_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzUtNC0xLTEtOTQ4MzE_24973307-94e5-45f9-9e6b-5c94125b9531">27.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzUtNi0xLTEtOTQ4MzE_529725ed-0a1a-485f-81b5-bf7fe1adb7d0">6.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01666d0d4a034ebbb396a9f3c3378737_I20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzUtOC0xLTEtOTQ4MzE_c03540a9-7b44-4268-9674-52b703e293e9">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01666d0d4a034ebbb396a9f3c3378737_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzYtMi0xLTEtOTQ4MzE_090fe84f-05ca-4c8b-b0ee-941a0a96ee70">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i01666d0d4a034ebbb396a9f3c3378737_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzYtNC0xLTEtOTQ4MzE_74a5036d-8eb5-42ae-b98a-032c23ca2ed2">27.65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzYtNi0xLTEtOTQ4MzE_286ab90b-f479-45c1-98d4-324cb1e78c90">6.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01666d0d4a034ebbb396a9f3c3378737_I20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzYtOC0xLTEtOTQ4MzE_f252452a-6264-4148-84c1-bc191d4fbe4c">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01666d0d4a034ebbb396a9f3c3378737_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzctMi0xLTEtOTQ4MzE_62890023-a52f-4853-bbaa-f1727eb05c6a">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i01666d0d4a034ebbb396a9f3c3378737_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzctNC0xLTEtOTQ4MzE_be91e431-a9e3-457e-921a-5becca9e83ab">27.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzctNi0xLTEtOTQ4MzE_8e8d7c84-6dc3-4d1c-8194-30877b44cc14">5.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01666d0d4a034ebbb396a9f3c3378737_I20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzctOC0xLTEtOTQ4MzE_68c4db26-6a1e-4ed0-bbbb-20c56af61fb6">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair values of all stock options granted in 2021, 2020 and 2019 were $<ix:nonFraction unitRef="usdPerShare" contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzYwNzI_d85b981b-65ac-44ea-adab-60869cc30943">10.92</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i2f3083202c7e4f36ada3cfe487b44863_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzYwNzY_56048a78-5c1a-4e0c-99dd-8ae8231e4c63">6.60</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i69f7d41ce4b642209bb25ea9c478625f_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzYwODM_ee21e3b5-afc8-4fde-8f02-3a24f690e6e7">8.45</ix:nonFraction>, respectively. The total intrinsic values of stock options exercised in 2021, 2020 and 2019 were $<ix:nonFraction unitRef="usd" contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzYxNjY_1824f523-b503-42c0-b050-e607212f8278">15</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i2f3083202c7e4f36ada3cfe487b44863_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzYxNzA_aac11a73-97fd-408d-95c3-b2a2de99702b">2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i69f7d41ce4b642209bb25ea9c478625f_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzYxNzc_2be7d821-6e96-4c32-8993-62674f6e049c">3</ix:nonFraction> million, respectively. Proceeds received on the exercise of stock options in 2021, 2020 and 2019 were $<ix:nonFraction unitRef="usd" contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzYyNTc_b2ea46c2-5323-4ebf-996c-9c73aa7cdf32">22</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i2f3083202c7e4f36ada3cfe487b44863_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzYyNjE_a6873f3e-603a-4f58-8fd2-af6ab09e4af7">5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i69f7d41ce4b642209bb25ea9c478625f_D20190101-20191231" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzYyNjg_b8b89af1-d18c-4b77-9a9f-cd94935b2e86">5</ix:nonFraction> million,&#160;respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the total remaining unrecognized compensation expense related to non-vested stock options amounted to $<ix:nonFraction unitRef="usd" contextRef="i01666d0d4a034ebbb396a9f3c3378737_I20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzYzOTI_19df01ac-fd23-46fc-9a52-1de2625a9a11">10</ix:nonFraction> million, which will be amortized over the weighted-average remaining requisite service period of approximately <ix:nonNumeric contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzY0OTg_f349024c-c351-4d1d-9f98-1a1d12845b8a">1.6</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years. The total fair value of stock options vested in 2021, 2020 and 2019 were $<ix:nonFraction unitRef="usd" contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231" decimals="-6" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzY1NjQ_a4c01200-23b8-4b2d-87e1-8d243d0c3e30">15</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i2f3083202c7e4f36ada3cfe487b44863_D20200101-20201231" decimals="-6" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzY1Njg_1e348f48-6e3d-4ab9-bcf4-26f2ccc5d289">15</ix:nonFraction> million and&#160;$<ix:nonFraction unitRef="usd" contextRef="i69f7d41ce4b642209bb25ea9c478625f_D20190101-20191231" decimals="-6" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzY1NzU_9c48ab42-30f2-4e14-81b1-5f1455df2c09">18</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RSUs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs generally vest on the first or third anniversary date from the date of grant or <ix:nonFraction unitRef="number" contextRef="i00aeb13ceebf48e891b516a2d0c221d3_D20210101-20211231" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzY2ODM_cf7ac52f-7a0e-414c-a1c2-287732251aff">33</ix:nonFraction>% a year over a <ix:nonNumeric contextRef="i00aeb13ceebf48e891b516a2d0c221d3_D20210101-20211231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzExMjQ3_8eebbd2b-6ac4-4cb7-a162-90389f205961">three-year</ix:nonNumeric> period. Annual RSUs granted to non-management directors vest immediately prior to the next Annual Meeting of Shareholders. Pursuant to the applicable unit agreement, certain RSUs may be subject to the attainment of any applicable performance goals specified by the Board of Directors. If the vesting of the RSUs is conditional upon the attainment of performance goals, any RSUs that do not vest as a result of a determination that the prescribed performance goals failed to be attained will be forfeited immediately upon such determination. RSUs are credited with dividend equivalents, in the form of additional RSUs, when dividends are paid on the Company&#8217;s common shares. Such additional RSUs will have the same vesting dates and will vest under the same terms as the RSUs in respect of which such additional RSUs are&#160;credited.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent provided for in a RSU agreement, the Company may, in lieu of all or a portion of the common shares which would otherwise be provided to a holder, elect to pay a cash amount equivalent to the market price of the Company&#8217;s </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i1fc6af286a3647e3ab2df4c20fe334a3" continuedAt="i4dd15867186142fc88583d6ad5824097"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common shares on the vesting date for each vested RSU. The amount of cash payment will be determined based on the average market price of the Company&#8217;s common shares on the vesting date. The Company&#8217;s current intent is to settle vested RSUs through the issuance of common&#160;shares.   </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Time-Based RSUs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each vested time-based RSU represents the right of a holder to receive one of the Company&#8217;s common shares. The fair value of each RSU granted is estimated based on the trading price of the Company&#8217;s common shares on the date of&#160;grant.</span></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzExMjI5_421b2022-d83e-480b-b8d9-5ebd200586ca" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-vested time-based RSU activity during 2021: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:72.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Time-Based<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, January&#160;1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if15c6a218d7d43c38c67bf323a224454_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTozNzFkMTllZWJiYWY0ZjM0ODM2NGIzYTFhNTA3N2Y1MC90YWJsZXJhbmdlOjM3MWQxOWVlYmJhZjRmMzQ4MzY0YjNhMWE1MDc3ZjUwXzEtMi0xLTEtOTQ4MzE_d6f05561-72f1-4e83-a57e-2407fa6765bd">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if15c6a218d7d43c38c67bf323a224454_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTozNzFkMTllZWJiYWY0ZjM0ODM2NGIzYTFhNTA3N2Y1MC90YWJsZXJhbmdlOjM3MWQxOWVlYmJhZjRmMzQ4MzY0YjNhMWE1MDc3ZjUwXzEtNC0xLTEtOTQ4MzE_b136646e-16b1-4149-ac3f-4874f6b14874">21.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i45c56aa08db349ad9a3b4168267b7511_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTozNzFkMTllZWJiYWY0ZjM0ODM2NGIzYTFhNTA3N2Y1MC90YWJsZXJhbmdlOjM3MWQxOWVlYmJhZjRmMzQ4MzY0YjNhMWE1MDc3ZjUwXzItMi0xLTEtOTQ4MzE_d06237c7-98a0-4b02-ac46-5e2abdae2590">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i45c56aa08db349ad9a3b4168267b7511_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTozNzFkMTllZWJiYWY0ZjM0ODM2NGIzYTFhNTA3N2Y1MC90YWJsZXJhbmdlOjM3MWQxOWVlYmJhZjRmMzQ4MzY0YjNhMWE1MDc3ZjUwXzItNC0xLTEtOTQ4MzE_13b07e9c-3323-4017-ae4b-b33e059f8218">31.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i45c56aa08db349ad9a3b4168267b7511_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTozNzFkMTllZWJiYWY0ZjM0ODM2NGIzYTFhNTA3N2Y1MC90YWJsZXJhbmdlOjM3MWQxOWVlYmJhZjRmMzQ4MzY0YjNhMWE1MDc3ZjUwXzMtMi0xLTEtOTQ4MzE_75457dd8-2c6a-4038-b3e3-8376a4a68dda">3.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i45c56aa08db349ad9a3b4168267b7511_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTozNzFkMTllZWJiYWY0ZjM0ODM2NGIzYTFhNTA3N2Y1MC90YWJsZXJhbmdlOjM3MWQxOWVlYmJhZjRmMzQ4MzY0YjNhMWE1MDc3ZjUwXzMtNC0xLTEtOTQ4MzE_30ad54b9-a01a-4d19-bf03-5c7f5d76e1fc">21.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i45c56aa08db349ad9a3b4168267b7511_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTozNzFkMTllZWJiYWY0ZjM0ODM2NGIzYTFhNTA3N2Y1MC90YWJsZXJhbmdlOjM3MWQxOWVlYmJhZjRmMzQ4MzY0YjNhMWE1MDc3ZjUwXzQtMi0xLTEtOTQ4MzE_5f991abb-5f4e-48e0-a2c5-ba8176fcabda">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i45c56aa08db349ad9a3b4168267b7511_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTozNzFkMTllZWJiYWY0ZjM0ODM2NGIzYTFhNTA3N2Y1MC90YWJsZXJhbmdlOjM3MWQxOWVlYmJhZjRmMzQ4MzY0YjNhMWE1MDc3ZjUwXzQtNC0xLTEtOTQ4MzE_d96f727e-6644-4a1f-8e88-406be8498a0c">26.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5cd01c5e13964b01922532131f0e6d49_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTozNzFkMTllZWJiYWY0ZjM0ODM2NGIzYTFhNTA3N2Y1MC90YWJsZXJhbmdlOjM3MWQxOWVlYmJhZjRmMzQ4MzY0YjNhMWE1MDc3ZjUwXzUtMi0xLTEtOTQ4MzE_b956a90b-56c5-4d9a-8b67-c59a4aee96c6">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5cd01c5e13964b01922532131f0e6d49_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTozNzFkMTllZWJiYWY0ZjM0ODM2NGIzYTFhNTA3N2Y1MC90YWJsZXJhbmdlOjM3MWQxOWVlYmJhZjRmMzQ4MzY0YjNhMWE1MDc3ZjUwXzUtNC0xLTEtOTQ4MzE_0f200ccc-0241-45ff-8e6b-0abe1c9a285f">28.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the total remaining unrecognized compensation expense related to non-vested time-based RSUs amounted to $<ix:nonFraction unitRef="usd" contextRef="i5cd01c5e13964b01922532131f0e6d49_I20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzg0OTU_c03bd8be-7ac2-40d1-b4ee-81d1c4a987a8">68</ix:nonFraction> million, which will be amortized over the weighted-average remaining requisite service period of approximately <ix:nonNumeric contextRef="i45c56aa08db349ad9a3b4168267b7511_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzg2MDE_7395218b-db52-44d7-933c-abc269f1f812">1.6</ix:nonNumeric> years. The total fair value of time-based RSUs vested in 2021, 2020 and 2019 were $<ix:nonFraction unitRef="usd" contextRef="i45c56aa08db349ad9a3b4168267b7511_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzg2Njk_a2bf112a-fda7-46f9-8260-0fb9e2efb634">69</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i89368b0fb9454b688b6e6dde554c44e1_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzg2NzM_26c81986-1e26-42b6-9785-6da39d81a339">66</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i29af68bd8dac4b57b173b5f3c801e3b7_D20190101-20191231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzg2ODA_2afe8003-e7cc-42b5-b45b-aa29a5a7209e">34</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-Based RSUs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each vested performance-based RSU represents the right of a holder to receive a number of the Company&#8217;s common shares up to a specified maximum. Performance-based RSUs vest upon achievement of certain share price appreciation conditions or attainment of certain performance targets. If the Company&#8217;s performance is below a specified performance level, no common shares will be&#160;paid. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each TSR performance-based RSU granted during 2021, 2020 and 2019 was estimated using a Monte Carlo Simulation model, which utilizes multiple input variables to estimate the probability that the performance condition will be achieved.  The fair value of the ROTC performance-based RSUs is estimated based on the trading price of the Company&#8217;s common shares on the date of grant.  Expense recognized for the ROTC performance-based RSUs in each reporting period reflects the Company&#8217;s latest estimate of the number of ROTC performance-based RSUs that are expected to vest.  If the ROTC performance-based RSUs do not ultimately vest due to the ROTC targets not being met, no compensation expense is recognized and any previously recognized compensation expense is reversed. </span></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="bhc:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzExMjI0_51f147a1-cdb5-46c5-9a63-33e66caf3134" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of TSR performance-based RSUs granted during 2021, 2020 and 2019 were estimated with the following assumptions:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"></td><td style="width:58.136%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.727%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i42196f5311924fb28aae7927e03f4954_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo1NzhiNGNjMTk0MTg0Yjg5OWZlZTE3YTZkYzRkZmU3OC90YWJsZXJhbmdlOjU3OGI0Y2MxOTQxODRiODk5ZmVlMTdhNmRjNGRmZTc4XzEtMi0xLTEtOTQ4MzE_93187aa8-a7a5-4be9-a1e8-13f15879cafe">3.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i071c8dec838c4bb88915169735766953_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo1NzhiNGNjMTk0MTg0Yjg5OWZlZTE3YTZkYzRkZmU3OC90YWJsZXJhbmdlOjU3OGI0Y2MxOTQxODRiODk5ZmVlMTdhNmRjNGRmZTc4XzEtNC0xLTEtOTQ4MzE_e2a15963-a696-44ab-bc25-c1403ed27be5">3.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if5e547542b4b4e4db07d76b12dbfa958_D20190101-20191231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo1NzhiNGNjMTk0MTg0Yjg5OWZlZTE3YTZkYzRkZmU3OC90YWJsZXJhbmdlOjU3OGI0Y2MxOTQxODRiODk5ZmVlMTdhNmRjNGRmZTc4XzEtNi0xLTEtOTQ4MzE_9358d5ef-811f-4918-a7fb-6e4ded7824f6">3.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected Company share volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i42196f5311924fb28aae7927e03f4954_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo1NzhiNGNjMTk0MTg0Yjg5OWZlZTE3YTZkYzRkZmU3OC90YWJsZXJhbmdlOjU3OGI0Y2MxOTQxODRiODk5ZmVlMTdhNmRjNGRmZTc4XzItMi0xLTEtOTQ4MzE_12907647-d9e2-4bfa-bd94-6cb131899166">52</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i071c8dec838c4bb88915169735766953_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo1NzhiNGNjMTk0MTg0Yjg5OWZlZTE3YTZkYzRkZmU3OC90YWJsZXJhbmdlOjU3OGI0Y2MxOTQxODRiODk5ZmVlMTdhNmRjNGRmZTc4XzItNC0xLTEtOTQ4MzE_d54b7b64-a41c-4b1a-9574-793b6fbdaa75">38.6</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if5e547542b4b4e4db07d76b12dbfa958_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo1NzhiNGNjMTk0MTg0Yjg5OWZlZTE3YTZkYzRkZmU3OC90YWJsZXJhbmdlOjU3OGI0Y2MxOTQxODRiODk5ZmVlMTdhNmRjNGRmZTc4XzItNi0xLTEtOTQ4MzE_01a28984-7126-4151-b034-43f0c58442bb">46.5</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i42196f5311924fb28aae7927e03f4954_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo1NzhiNGNjMTk0MTg0Yjg5OWZlZTE3YTZkYzRkZmU3OC90YWJsZXJhbmdlOjU3OGI0Y2MxOTQxODRiODk5ZmVlMTdhNmRjNGRmZTc4XzMtMi0xLTEtOTQ4MzE_d2864922-7a63-4724-8a0d-4acda08d070d">0.4</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i071c8dec838c4bb88915169735766953_D20200101-20201231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo1NzhiNGNjMTk0MTg0Yjg5OWZlZTE3YTZkYzRkZmU3OC90YWJsZXJhbmdlOjU3OGI0Y2MxOTQxODRiODk5ZmVlMTdhNmRjNGRmZTc4XzMtNC0xLTEtOTQ4MzE_6f54454e-0632-4e78-9c62-a20bae1ff75d">1.2</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if5e547542b4b4e4db07d76b12dbfa958_D20190101-20191231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo1NzhiNGNjMTk0MTg0Yjg5OWZlZTE3YTZkYzRkZmU3OC90YWJsZXJhbmdlOjU3OGI0Y2MxOTQxODRiODk5ZmVlMTdhNmRjNGRmZTc4XzMtNi0xLTEtOTQ4MzE_6e842b66-af9c-4294-8c31-c027fd3818f4">2.5</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected company share volatility was determined based on implied volatility in the market traded options of the Company&#8217;s common stock. The risk-free interest rate was determined based on the rate at the time of grant for zero-coupon U.S.&#160;government bonds with maturity dates equal to the contractual term of the performance-based&#160;RSUs.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i4dd15867186142fc88583d6ad5824097"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzExMjYz_a437f2fe-5f29-4d96-9b69-80b639def481" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-vested performance-based RSU activity during 2021: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:72.799%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.587%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance-based <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, January&#160;1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i403b5b7721914e66b5361779547ecaef_I20201231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NzA3OGE4ODE0MTQ0YzM1OTQwYzIzNDI5MjY3ZGZmYi90YWJsZXJhbmdlOjc3MDc4YTg4MTQxNDRjMzU5NDBjMjM0MjkyNjdkZmZiXzEtMi0xLTEtOTQ4MzE_659b461a-1c5a-4127-b4af-b18d3a64dd21">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i403b5b7721914e66b5361779547ecaef_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NzA3OGE4ODE0MTQ0YzM1OTQwYzIzNDI5MjY3ZGZmYi90YWJsZXJhbmdlOjc3MDc4YTg4MTQxNDRjMzU5NDBjMjM0MjkyNjdkZmZiXzEtNC0xLTEtOTQ4MzE_ec9d5f6c-a47d-47bd-8641-7059b839c780">28.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i42196f5311924fb28aae7927e03f4954_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NzA3OGE4ODE0MTQ0YzM1OTQwYzIzNDI5MjY3ZGZmYi90YWJsZXJhbmdlOjc3MDc4YTg4MTQxNDRjMzU5NDBjMjM0MjkyNjdkZmZiXzItMi0xLTEtOTQ4MzE_daf529af-6e2b-4c4f-bf3b-ac38fc33c25b">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i42196f5311924fb28aae7927e03f4954_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NzA3OGE4ODE0MTQ0YzM1OTQwYzIzNDI5MjY3ZGZmYi90YWJsZXJhbmdlOjc3MDc4YTg4MTQxNDRjMzU5NDBjMjM0MjkyNjdkZmZiXzItNC0xLTEtOTQ4MzE_f63aec26-ec32-4ab7-b8db-57418a3555b2">40.42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i42196f5311924fb28aae7927e03f4954_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NzA3OGE4ODE0MTQ0YzM1OTQwYzIzNDI5MjY3ZGZmYi90YWJsZXJhbmdlOjc3MDc4YTg4MTQxNDRjMzU5NDBjMjM0MjkyNjdkZmZiXzMtMi0xLTEtOTQ4MzE_bf846ed0-48a6-47bc-bdf7-485cdf55f6c7">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i42196f5311924fb28aae7927e03f4954_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NzA3OGE4ODE0MTQ0YzM1OTQwYzIzNDI5MjY3ZGZmYi90YWJsZXJhbmdlOjc3MDc4YTg4MTQxNDRjMzU5NDBjMjM0MjkyNjdkZmZiXzMtNC0xLTEtOTQ4MzE_4405773e-f129-4630-afbf-4939aec62e55">27.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i54c4a51199e24aa0a3d6a1ec87ede263_I20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NzA3OGE4ODE0MTQ0YzM1OTQwYzIzNDI5MjY3ZGZmYi90YWJsZXJhbmdlOjc3MDc4YTg4MTQxNDRjMzU5NDBjMjM0MjkyNjdkZmZiXzQtMi0xLTEtOTQ4MzE_9d2f5f9d-6e88-4c85-ac84-b371007cb8d5">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i54c4a51199e24aa0a3d6a1ec87ede263_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NzA3OGE4ODE0MTQ0YzM1OTQwYzIzNDI5MjY3ZGZmYi90YWJsZXJhbmdlOjc3MDc4YTg4MTQxNDRjMzU5NDBjMjM0MjkyNjdkZmZiXzQtNC0xLTEtOTQ4MzE_f986b387-fdea-4514-8173-ee757699f28e">33.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company granted approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i42196f5311924fb28aae7927e03f4954_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzEwNDg3_2ea188b8-e12a-4a88-890c-740e9c326e13">1,035,000</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance-based RSUs, consisting of approximately <ix:nonFraction unitRef="shares" contextRef="if92bc6c46d244c3788aeab448cab0a64_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzEwNTQy_af3e6b16-250c-4663-b791-391cb62cef54">400,000</ix:nonFraction> units of TSR performance-based RSUs with an average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="if92bc6c46d244c3788aeab448cab0a64_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzEwNjIy_37ae5cfb-5726-4be1-b15c-ad1e15b71833">56.04</ix:nonFraction> per RSU, approximately <ix:nonFraction unitRef="shares" contextRef="i4b9e26fe691746ed9f535f3800019b25_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzEwNjQ4_87160cb6-bbe7-414d-9cd6-2aa17476f0d3">413,000</ix:nonFraction> units of ROTC performance-based RSUs with a weighted-average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i4b9e26fe691746ed9f535f3800019b25_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzEwNzM3_234b4f3d-6124-4439-a953-5529db2b6db2">31.72</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per RSU and approximately <ix:nonFraction unitRef="shares" contextRef="ibf752be0eda64aa790f9f6d3442bf3f5_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzEwNzY2_ce3953c0-1301-47a7-aaf0-ab05ff0aa4dd">222,000</ix:nonFraction> of other performance-based RSU's with a weighted-average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="ibf752be0eda64aa790f9f6d3442bf3f5_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzEwODUy_fac74819-7fe6-406e-a5a3-007db4e6f4ff">28.49</ix:nonFraction>. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the total remaining unrecognized compensation expense related to non-vested performance-based RSUs amounted to $<ix:nonFraction unitRef="usd" contextRef="i54c4a51199e24aa0a3d6a1ec87ede263_I20211231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzEwOTcy_9ad6a846-757b-4cb2-b9d2-d6b152362f43">32</ix:nonFraction> million, which will be amortized over the weighted-average remaining requisite service period of approximately <ix:nonNumeric contextRef="i42196f5311924fb28aae7927e03f4954_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzExMDc4_4f20400a-e10f-495d-b9fa-7f2ca4268f00">1.7</ix:nonNumeric> years.  A maximum of approximately <ix:nonFraction unitRef="shares" contextRef="i54c4a51199e24aa0a3d6a1ec87ede263_I20211231" decimals="INF" name="bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzExMTE2_f5b5d4eb-26cd-4789-9597-a6e69c2488ca">3,476,000</ix:nonFraction> common shares could be issued upon vesting of the performance-based RSUs outstanding as of December 31, 2021.</span></div></ix:continuation><div id="i8256f225f07d49409c31f7443adffdbf_355"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTUvZnJhZzphNWI3NGZhOTNkY2E0NDA5ODg3NTMzODE5ZjIzNzZiNy90ZXh0cmVnaW9uOmE1Yjc0ZmE5M2RjYTQ0MDk4ODc1MzM4MTlmMjM3NmI3XzQxOQ_53bc77da-d72b-4d37-af4d-d029fe7b4544" continuedAt="i8065f2c46cb84d0a920ebbf4d4664b76" escape="true">ACCUMULATED OTHER COMPREHENSIVE LOSS</ix:nonNumeric></span></div><ix:continuation id="i8065f2c46cb84d0a920ebbf4d4664b76"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTUvZnJhZzphNWI3NGZhOTNkY2E0NDA5ODg3NTMzODE5ZjIzNzZiNy90ZXh0cmVnaW9uOmE1Yjc0ZmE5M2RjYTQ0MDk4ODc1MzM4MTlmMjM3NmI3XzQyNA_f892e612-cbef-45d8-b7ca-dcfc729ab3a0" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss as of December&#160;31, 2021 and 2020 consists of: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:78.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie3c11e633ca64c359eb1f4e64ed9945e_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTUvZnJhZzphNWI3NGZhOTNkY2E0NDA5ODg3NTMzODE5ZjIzNzZiNy90YWJsZTozNGNjMDA4Y2YwZTU0NmIwYjAwZmVkN2UwNjFkYmMxYi90YWJsZXJhbmdlOjM0Y2MwMDhjZjBlNTQ2YjBiMDBmZWQ3ZTA2MWRiYzFiXzEtMi0xLTEtOTQ4MzE_c6b7a91b-c36d-4321-9534-1eb97d682702">1,905</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76387c207f8f42439a9c69184bef25d1_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTUvZnJhZzphNWI3NGZhOTNkY2E0NDA5ODg3NTMzODE5ZjIzNzZiNy90YWJsZTozNGNjMDA4Y2YwZTU0NmIwYjAwZmVkN2UwNjFkYmMxYi90YWJsZXJhbmdlOjM0Y2MwMDhjZjBlNTQ2YjBiMDBmZWQ3ZTA2MWRiYzFiXzEtNC0xLTEtOTQ4MzE_4c0b57b7-1d32-4fbc-8eac-f6ce0dc28516">2,077</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension adjustment, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66760525c1824001967bb86d988a25bf_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTUvZnJhZzphNWI3NGZhOTNkY2E0NDA5ODg3NTMzODE5ZjIzNzZiNy90YWJsZTozNGNjMDA4Y2YwZTU0NmIwYjAwZmVkN2UwNjFkYmMxYi90YWJsZXJhbmdlOjM0Y2MwMDhjZjBlNTQ2YjBiMDBmZWQ3ZTA2MWRiYzFiXzItMi0xLTEtOTQ4MzE_97c4e386-1ead-4e4b-9e9a-9c4abce0967b">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ddbf83e6ad54de686a53b50675cf560_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTUvZnJhZzphNWI3NGZhOTNkY2E0NDA5ODg3NTMzODE5ZjIzNzZiNy90YWJsZTozNGNjMDA4Y2YwZTU0NmIwYjAwZmVkN2UwNjFkYmMxYi90YWJsZXJhbmdlOjM0Y2MwMDhjZjBlNTQ2YjBiMDBmZWQ3ZTA2MWRiYzFiXzItNC0xLTEtOTQ4MzE_078abc69-e5a0-4d83-8fb3-6843e0a57515">56</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff498ebdd499404a95f12abea2bd55e9_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTUvZnJhZzphNWI3NGZhOTNkY2E0NDA5ODg3NTMzODE5ZjIzNzZiNy90YWJsZTozNGNjMDA4Y2YwZTU0NmIwYjAwZmVkN2UwNjFkYmMxYi90YWJsZXJhbmdlOjM0Y2MwMDhjZjBlNTQ2YjBiMDBmZWQ3ZTA2MWRiYzFiXzMtMi0xLTEtOTQ4MzE_e43fe811-1d4e-4ebc-ba04-69fd43bbfae5">1,924</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib105e1aee9db4b46ae7d9e203dadfad7_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTUvZnJhZzphNWI3NGZhOTNkY2E0NDA5ODg3NTMzODE5ZjIzNzZiNy90YWJsZTozNGNjMDA4Y2YwZTU0NmIwYjAwZmVkN2UwNjFkYmMxYi90YWJsZXJhbmdlOjM0Y2MwMDhjZjBlNTQ2YjBiMDBmZWQ3ZTA2MWRiYzFiXzMtNC0xLTEtOTQ4MzE_102ca691-948e-416d-a5c3-dad4d45862f2">2,133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company&#8217;s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to the Company&#8217;s retained earnings for foreign jurisdictions in which the Company is not considered to be permanently reinvested.</span></div></ix:continuation><div id="i8256f225f07d49409c31f7443adffdbf_358"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTgvZnJhZzo1ODQyNjcyNDQyNjg0N2Y2OWQ1YjA3MDY1OGRiMzA2ZS90ZXh0cmVnaW9uOjU4NDI2NzI0NDI2ODQ3ZjY5ZDViMDcwNjU4ZGIzMDZlXzI4OQ_f4831b35-b1f3-48d2-9eff-21cc626135c2" continuedAt="iae83c75c6bfc4848b47d554b3412eb04" escape="true">RESEARCH AND DEVELOPMENT</ix:nonNumeric></span></div><ix:continuation id="iae83c75c6bfc4848b47d554b3412eb04"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Research and development are costs related to product development and quality assurance programs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards. <ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTgvZnJhZzo1ODQyNjcyNDQyNjg0N2Y2OWQ1YjA3MDY1OGRiMzA2ZS90ZXh0cmVnaW9uOjU4NDI2NzI0NDI2ODQ3ZjY5ZDViMDcwNjU4ZGIzMDZlXzI4OA_0683eed8-bb32-4215-8185-e6588ddde073" continuedAt="i8068a5c7b21d4ad88e4ce745dd481e6d" escape="true">Research and development costs for the years 2021, 2020 and 2019 consists of:</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><ix:continuation id="i8068a5c7b21d4ad88e4ce745dd481e6d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product related research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseProductRelated" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTgvZnJhZzo1ODQyNjcyNDQyNjg0N2Y2OWQ1YjA3MDY1OGRiMzA2ZS90YWJsZTo0OWE3YzJkZmNlMzU0MjJlODRiYWJmZTNiMzcwN2ZmYi90YWJsZXJhbmdlOjQ5YTdjMmRmY2UzNTQyMmU4NGJhYmZlM2IzNzA3ZmZiXzEtMi0xLTEtOTQ4MzE_ae777afb-7fed-4679-a270-b7a758edb24e">440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseProductRelated" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTgvZnJhZzo1ODQyNjcyNDQyNjg0N2Y2OWQ1YjA3MDY1OGRiMzA2ZS90YWJsZTo0OWE3YzJkZmNlMzU0MjJlODRiYWJmZTNiMzcwN2ZmYi90YWJsZXJhbmdlOjQ5YTdjMmRmY2UzNTQyMmU4NGJhYmZlM2IzNzA3ZmZiXzEtNC0xLTEtOTQ4MzE_b90cb8ed-65ea-415a-9e22-4ab0f460a1cc">420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseProductRelated" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTgvZnJhZzo1ODQyNjcyNDQyNjg0N2Y2OWQ1YjA3MDY1OGRiMzA2ZS90YWJsZTo0OWE3YzJkZmNlMzU0MjJlODRiYWJmZTNiMzcwN2ZmYi90YWJsZXJhbmdlOjQ5YTdjMmRmY2UzNTQyMmU4NGJhYmZlM2IzNzA3ZmZiXzEtNi0xLTEtOTQ4MzE_8efa0c51-9431-4cd1-b2c7-2b3c83a2b3c7">434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseQualityAssurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTgvZnJhZzo1ODQyNjcyNDQyNjg0N2Y2OWQ1YjA3MDY1OGRiMzA2ZS90YWJsZTo0OWE3YzJkZmNlMzU0MjJlODRiYWJmZTNiMzcwN2ZmYi90YWJsZXJhbmdlOjQ5YTdjMmRmY2UzNTQyMmU4NGJhYmZlM2IzNzA3ZmZiXzItMi0xLTEtOTQ4MzE_45f61b26-790a-40fb-b760-13072779ac0a">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseQualityAssurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTgvZnJhZzo1ODQyNjcyNDQyNjg0N2Y2OWQ1YjA3MDY1OGRiMzA2ZS90YWJsZTo0OWE3YzJkZmNlMzU0MjJlODRiYWJmZTNiMzcwN2ZmYi90YWJsZXJhbmdlOjQ5YTdjMmRmY2UzNTQyMmU4NGJhYmZlM2IzNzA3ZmZiXzItNC0xLTEtOTQ4MzE_bb4a3109-35b7-4035-8e1e-24e5e366e530">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="bhc:ResearchAndDevelopmentExpenseQualityAssurance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTgvZnJhZzo1ODQyNjcyNDQyNjg0N2Y2OWQ1YjA3MDY1OGRiMzA2ZS90YWJsZTo0OWE3YzJkZmNlMzU0MjJlODRiYWJmZTNiMzcwN2ZmYi90YWJsZXJhbmdlOjQ5YTdjMmRmY2UzNTQyMmU4NGJhYmZlM2IzNzA3ZmZiXzItNi0xLTEtOTQ4MzE_b08cdee1-209b-418d-ad57-e4362f2bf796">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTgvZnJhZzo1ODQyNjcyNDQyNjg0N2Y2OWQ1YjA3MDY1OGRiMzA2ZS90YWJsZTo0OWE3YzJkZmNlMzU0MjJlODRiYWJmZTNiMzcwN2ZmYi90YWJsZXJhbmdlOjQ5YTdjMmRmY2UzNTQyMmU4NGJhYmZlM2IzNzA3ZmZiXzMtMi0xLTEtOTQ4MzE_3864b27f-4078-476c-8e5d-953015d2a160">465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTgvZnJhZzo1ODQyNjcyNDQyNjg0N2Y2OWQ1YjA3MDY1OGRiMzA2ZS90YWJsZTo0OWE3YzJkZmNlMzU0MjJlODRiYWJmZTNiMzcwN2ZmYi90YWJsZXJhbmdlOjQ5YTdjMmRmY2UzNTQyMmU4NGJhYmZlM2IzNzA3ZmZiXzMtNC0xLTEtOTQ4MzE_4405a517-dadc-4657-9873-8fda4bcf9db7">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTgvZnJhZzo1ODQyNjcyNDQyNjg0N2Y2OWQ1YjA3MDY1OGRiMzA2ZS90YWJsZTo0OWE3YzJkZmNlMzU0MjJlODRiYWJmZTNiMzcwN2ZmYi90YWJsZXJhbmdlOjQ5YTdjMmRmY2UzNTQyMmU4NGJhYmZlM2IzNzA3ZmZiXzMtNi0xLTEtOTQ4MzE_a72f3192-4f07-4d6d-8998-36219172cd18">471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="i8256f225f07d49409c31f7443adffdbf_361"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90ZXh0cmVnaW9uOjBlMWIzNGI5OGIwYTQyYzU5YWZhOTY2YTA4MDQ4Y2NlXzk4OQ_50f86dfc-4c3b-42e6-a4fd-e51ae6bfaa51" continuedAt="i30611bfe3f804b0faeaa165aad0c6f3c" escape="true">OTHER EXPENSE, NET</ix:nonNumeric></span></div><ix:continuation id="i30611bfe3f804b0faeaa165aad0c6f3c" continuedAt="i9abc02b7e68641dd96b8e47485f7de11"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90ZXh0cmVnaW9uOjBlMWIzNGI5OGIwYTQyYzU5YWZhOTY2YTA4MDQ4Y2NlXzk4NQ_5c0be3ba-b857-4464-a830-f838044fc2ea" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net for the years 2021, 2020 and 2019 consists of:</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzItMi0xLTEtOTQ4MzE_dee9c137-e4f1-4d12-8223-3e2ba1f6373f">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzItNC0xLTEtOTQ4MzE_28bef38e-5572-4df9-ae91-f8015e63fac1">422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzItNi0xLTEtOTQ4MzE_e93c3ea3-9e42-48e9-83b7-28ffd77b657e">1,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzMtMi0xLTEtOTQ4MzE_c1b6d87f-4a67-4a36-85cb-747935da7dc1">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzMtNC0xLTEtOTQ4MzE_e510e9da-be33-46ed-92c7-d34bea4c94f0">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzMtNi0xLTEtOTQ4MzE_acef8e2d-5ac8-40a3-b9da-b6d2c8e70ded">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain on sales of assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzQtMi0xLTEtOTQ4MzE_f0338fd5-0b05-4e46-9948-98395da8e8d0">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzQtNC0xLTEtOTQ4MzE_e1c5df5e-9e4e-44fb-9590-33ada62ae62b">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzQtNi0xLTEtOTQ4MzE_29d3f304-a94c-44a8-a089-cb990fb9baab">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzUtMi0xLTEtOTQ4MzE_fc7cdfcf-a2d4-4bac-aa36-24b426d1c7b4">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzUtNC0xLTEtOTQ4MzE_e4f0d6fd-edca-4b8c-9405-368495c8a33a">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzUtNi0xLTEtOTQ4MzE_d4526288-678f-4c33-b362-f1386ac0f4d2">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="bhc:OtherIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzYtMi0xLTEtOTQ4MzE_e8b526e4-65d9-4978-8cf4-4e3f8f166d2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="bhc:OtherIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzYtNC0xLTEtOTQ4MzE_404be505-aa2a-4245-8ffa-14a2bb3683e9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="bhc:OtherIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzYtNi0xLTEtOTQ4MzE_83828aba-fb99-4be6-8b1e-361655fbfa24">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzctMi0xLTEtOTQ4MzE_68788be2-61cd-4481-9b55-1bacc6d36a05">373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzctNC0xLTEtOTQ4MzE_d200a98b-ee9b-435d-80f2-dc72bf9e8f6a">502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzctNi0xLTEtOTQ4MzE_c5b0303e-764d-4335-984c-718eb14ca543">1,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i9abc02b7e68641dd96b8e47485f7de11"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, Litigation and other matters of $<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90ZXh0cmVnaW9uOjBlMWIzNGI5OGIwYTQyYzU5YWZhOTY2YTA4MDQ4Y2NlXzcw_dee9c137-e4f1-4d12-8223-3e2ba1f6373f">356</ix:nonFraction> million includes adjustments related to the Glumetza Antitrust Litigation, partially offset by insurance recoveries related to certain litigation matters. In 2020, Litigation and other matters of $<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90ZXh0cmVnaW9uOjBlMWIzNGI5OGIwYTQyYzU5YWZhOTY2YTA4MDQ4Y2NlXzI2MQ_28bef38e-5572-4df9-ae91-f8015e63fac1">422</ix:nonFraction> million includes net charges related to the U.S. Securities Litigation, the SEC Investigation and the Canadian Securities Litigation and related opt-outs. In 2020, Litigation and other matters also includes an insurance recovery related to a certain litigation matter. In 2019, Litigation and other matters of $<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90ZXh0cmVnaW9uOjBlMWIzNGI5OGIwYTQyYzU5YWZhOTY2YTA4MDQ4Y2NlXzU2Ng_e93c3ea3-9e42-48e9-83b7-28ffd77b657e">1,401</ix:nonFraction> million includes the settlement of a legacy U.S. securities class action matter. Certain of these matters and other significant matters are discussed in further detail in Note 20, &#8220;LEGAL PROCEEDINGS&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020 and 2019, Acquired in-process research and development costs of $<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90ZXh0cmVnaW9uOjBlMWIzNGI5OGIwYTQyYzU5YWZhOTY2YTA4MDQ4Y2NlXzc2MA_e510e9da-be33-46ed-92c7-d34bea4c94f0">32</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90ZXh0cmVnaW9uOjBlMWIzNGI5OGIwYTQyYzU5YWZhOTY2YTA4MDQ4Y2NlXzc2Nw_acef8e2d-5ac8-40a3-b9da-b6d2c8e70ded">41</ix:nonFraction>&#160;million, primarily consist of costs associated with the upfront payments to enter into certain exclusive licensing agreements. </span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, Net gain on sales of assets includes $<ix:nonFraction unitRef="usd" contextRef="i5cdfe5b964b94b969e2829780c73f7e9_D20190101-20191231" decimals="-6" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90ZXh0cmVnaW9uOjBlMWIzNGI5OGIwYTQyYzU5YWZhOTY2YTA4MDQ4Y2NlXzkxMQ_c0618355-398a-4536-9090-4fa16b4c40e6">20</ix:nonFraction> million related to the achievement of a milestone related to a certain product.</span></div></ix:continuation><div id="i8256f225f07d49409c31f7443adffdbf_364"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzEyNzg4_81794c93-e49b-4a82-8272-78a796c983e1" continuedAt="i0ea04d990dcb4636a0bf857cc7a52aac" escape="true">INCOME TAXES </ix:nonNumeric></span></div><ix:continuation id="i0ea04d990dcb4636a0bf857cc7a52aac" continuedAt="i7effec3479664c319b6a71074d4d4b2c"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzEyNzkz_48a0afec-5bbb-4a3a-ba64-810767af43f0" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Loss before benefit from income taxes for 2021, 2020 and 2019 consist of:  </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo3OGU2MGJhZDNmMjg0MmY2OTM4Mjk0NTE1YTRiOGIxMS90YWJsZXJhbmdlOjc4ZTYwYmFkM2YyODQyZjY5MzgyOTQ1MTVhNGI4YjExXzEtMi0xLTEtOTQ4MzE_44a58e39-77c8-490c-bbce-40e2e83c956e">323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo3OGU2MGJhZDNmMjg0MmY2OTM4Mjk0NTE1YTRiOGIxMS90YWJsZXJhbmdlOjc4ZTYwYmFkM2YyODQyZjY5MzgyOTQ1MTVhNGI4YjExXzEtNC0xLTEtOTQ4MzE_077ee069-7bcd-4d11-ae81-b755303d5a19">410</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo3OGU2MGJhZDNmMjg0MmY2OTM4Mjk0NTE1YTRiOGIxMS90YWJsZXJhbmdlOjc4ZTYwYmFkM2YyODQyZjY5MzgyOTQ1MTVhNGI4YjExXzEtNi0xLTEtOTQ4MzE_07684475-8cec-4adf-a16e-7cf77d0ed5b9">2,396</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo3OGU2MGJhZDNmMjg0MmY2OTM4Mjk0NTE1YTRiOGIxMS90YWJsZXJhbmdlOjc4ZTYwYmFkM2YyODQyZjY5MzgyOTQ1MTVhNGI4YjExXzItMi0xLTEtOTQ4MzE_e208f7c9-2ed3-4bd1-80e3-dbcb398a7c85">701</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo3OGU2MGJhZDNmMjg0MmY2OTM4Mjk0NTE1YTRiOGIxMS90YWJsZXJhbmdlOjc4ZTYwYmFkM2YyODQyZjY5MzgyOTQ1MTVhNGI4YjExXzItNC0xLTEtOTQ4MzE_e675393a-5406-4a77-8e14-09f892b1db4c">524</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo3OGU2MGJhZDNmMjg0MmY2OTM4Mjk0NTE1YTRiOGIxMS90YWJsZXJhbmdlOjc4ZTYwYmFkM2YyODQyZjY5MzgyOTQ1MTVhNGI4YjExXzItNi0xLTEtOTQ4MzE_e3f2a5da-7bd7-405a-bfa3-78978c54d41f">559</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo3OGU2MGJhZDNmMjg0MmY2OTM4Mjk0NTE1YTRiOGIxMS90YWJsZXJhbmdlOjc4ZTYwYmFkM2YyODQyZjY5MzgyOTQ1MTVhNGI4YjExXzMtMi0xLTEtOTQ4MzE_1c77bc36-b682-4933-820f-de684a4b8593">1,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo3OGU2MGJhZDNmMjg0MmY2OTM4Mjk0NTE1YTRiOGIxMS90YWJsZXJhbmdlOjc4ZTYwYmFkM2YyODQyZjY5MzgyOTQ1MTVhNGI4YjExXzMtNC0xLTEtOTQ4MzE_85e471b9-c468-470b-a7fd-79afa2893e3d">934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo3OGU2MGJhZDNmMjg0MmY2OTM4Mjk0NTE1YTRiOGIxMS90YWJsZXJhbmdlOjc4ZTYwYmFkM2YyODQyZjY5MzgyOTQ1MTVhNGI4YjExXzMtNi0xLTEtOTQ4MzE_e0eca1f6-f1aa-4b8d-b6c7-bd1dff1d6157">1,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzEyNzg0_58dacd67-1a85-48a5-9552-3a5f5dee9cd6" escape="true"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Benefit from income taxes for 2021, 2020 and 2019 consist of: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzItMi0xLTEtOTQ4MzE_a097bcde-e53f-4d22-84f9-09f1f561a24b">23</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzItNC0xLTEtOTQ4MzE_928708af-faa5-4bfc-9a0a-29acb7702c25">8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzItNi0xLTEtOTQ4MzE_41b77ac4-0aa1-4a70-b12e-21c381768a68">12</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzMtMi0xLTEtOTQ4MzE_56590b3f-d011-438d-854b-2919558cb59d">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzMtNC0xLTEtOTQ4MzE_a0cba2ac-669b-40a3-8137-11686653b403">216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzMtNi0xLTEtOTQ4MzE_5ff8e665-7aed-4fdc-82ca-124d82b72dbc">116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzQtMi0xLTEtOTQ4MzE_80c1820a-91c9-4378-9b47-7f95e7a2dfd8">51</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzQtNC0xLTEtOTQ4MzE_533bca2f-f728-4685-9371-0c7bbf3ebf4a">224</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzQtNi0xLTEtOTQ4MzE_208cbfc7-fdb8-4a69-92ca-8bcc3bcd8ebb">128</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzYtMi0xLTEtOTQ4MzE_c1d30500-5886-4ffd-bf39-36bd3603b431">20</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzYtNC0xLTEtOTQ4MzE_881ea8c8-070e-4296-ba38-54777a1023cb">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzYtNi0xLTEtOTQ4MzE_a6f29de1-43fe-4232-9c7d-16f428f9a66b">5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzctMi0xLTEtOTQ4MzE_1d539bbc-4d5b-4bef-b2f7-e8288c876fc3">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzctNC0xLTEtOTQ4MzE_f924f007-de81-4e67-97d0-0104fe20cbe9">590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzctNi0xLTEtOTQ4MzE_f22e6930-f0c3-4cc4-9551-14549f9fbe92">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzgtMi0xLTEtOTQ4MzE_5e1ebe03-68cd-4ddb-bab2-d6ab5d6b471d">36</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzgtNC0xLTEtOTQ4MzE_bd9195a0-302a-46f2-bc02-1130795d3da2">599</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzgtNi0xLTEtOTQ4MzE_3e94fd29-73b6-445d-880a-dac2ef0c8de4">182</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzktMi0xLTEtOTQ4MzE_3c8b5cf7-e519-4bdc-bc7c-f63d4bc29be7">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzktNC0xLTEtOTQ4MzE_90daf8de-441f-4dbd-b7ed-c87bc6a84efa">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzktNi0xLTEtOTQ4MzE_71abe0b2-fb21-4cfc-84f8-cba658c6d71a">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i7effec3479664c319b6a71074d4d4b2c" continuedAt="icdc1f7128dd346c3884854ea97bc5508"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzEyNzg1_e7d5f433-3f17-428d-892a-7b3cb1963131" escape="true"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Benefit from income taxes differs from the expected amount calculated by applying the Company&#8217;s Canadian statutory rate of <ix:nonFraction unitRef="number" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzIyMw_137620d8-b047-4d43-ac44-a78ac9db5963"><ix:nonFraction unitRef="number" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzIyMw_2feea97e-e592-41cc-98bb-8a7beabf0288"><ix:nonFraction unitRef="number" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzIyMw_fbc79e19-6ee6-4728-86d8-06b83e313bbe">26.9</ix:nonFraction></ix:nonFraction></ix:nonFraction>% to Loss before benefit from income taxes for 2021, 2020 and 2019 as follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before benefit from income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzEtMi0xLTEtOTQ4MzE_434eed2b-bfd0-4adf-8140-d45c4dc679e0">1,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzEtNC0xLTEtOTQ4MzE_83274b80-127d-4848-a027-27d30de8110b">934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzEtNi0xLTEtOTQ4MzE_587c1855-5487-427d-8efe-410e065325de">1,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected benefit from income taxes at Canadian statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzMtMi0xLTEtOTQ4MzE_71276c10-8ad9-4b60-85d2-30d97f75e124">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzMtNC0xLTEtOTQ4MzE_ecab016d-73db-4e12-bba6-6bb7c1c18991">251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzMtNi0xLTEtOTQ4MzE_1ab61b82-d00f-4663-9944-471314fcc92d">494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible amount of share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzQtMi0xLTEtOTQ4MzE_09fecb4a-c139-4e20-848c-13fcdcd150ca">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzQtNC0xLTEtOTQ4MzE_e856f76f-d5b3-4de8-8a7b-817399a54b42">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzQtNi0xLTEtOTQ4MzE_71d456ff-04eb-44c8-a8e0-01979c08f883">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to tax attributes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="bhc:EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzUtMi0xLTEtOTQ4MzE_0d9d17e0-06ab-4593-81ec-e81b409e1a40">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="bhc:EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzUtNC0xLTEtOTQ4MzE_d17f7c4b-dcf4-40a7-afbc-431f82ca9ac2">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="bhc:EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzUtNi0xLTEtOTQ4MzE_35b5c7cc-3c0e-4b0a-b198-5d9c1ce9bee1">99</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance related to foreign tax credits and NOLs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="bhc:IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzYtMi0xLTEtOTQ4MzE_9097cbcd-86a9-4b32-a997-d1eedccdcd6a">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="bhc:IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzYtNC0xLTEtOTQ4MzE_24f6ed05-2a42-4d25-9caf-f10d89534a67">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="bhc:IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzYtNi0xLTEtOTQ4MzE_2bf619a7-236f-4944-8853-48c559fdbadf">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance on Canadian deferred tax assets and tax rate changes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzctMi0xLTEtOTQ4MzE_353614ca-668e-4d9a-b9bd-60c5067d42b0">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzctNC0xLTEtOTQ4MzE_75744d6f-4eee-4ec8-b2cd-b6a5ba313ccf">687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzctNi0xLTEtOTQ4MzE_76b530e9-f2fb-46a6-ab6d-8a5c20dd90a6">142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in uncertain tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="bhc:IncomeTaxReconciliationUncertainTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzgtMi0xLTEtOTQ4MzE_c7a10253-0427-4875-8c66-59226381897b">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="bhc:IncomeTaxReconciliationUncertainTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzgtNC0xLTEtOTQ4MzE_2ca9dacf-e800-47b7-8ed4-95dd75799456">163</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="bhc:IncomeTaxReconciliationUncertainTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzgtNi0xLTEtOTQ4MzE_694d36c1-0c99-4cb0-9125-1ceeb01416de">350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzktMi0xLTEtOTQ4MzE_2934e825-1a72-4c77-9326-cb8809fda1de">198</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzktNC0xLTEtOTQ4MzE_bebc2ba0-8734-4da2-aa4b-d18f5a85530b">128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzktNi0xLTEtOTQ4MzE_a947e25e-7ed9-4cc1-8c67-cd6e7dd76b18">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible portion of Goodwill impairments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzEwLTItMS0xLTk0ODMx_307706cb-9e77-400b-820b-99745dccb82a">99</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzEwLTQtMS0xLTk0ODMx_1e45e6e8-662e-4861-a7fe-ba9785463f6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzEwLTYtMS0xLTk0ODMx_c4a4c0ca-645d-428b-8527-bd468f06ebaf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit on intra-entity transfers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="bhc:IncomeTaxReconciliationDeferredIntercompanyProfit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzExLTItMS0xLTk0ODMx_4f79a88d-5d69-41d5-8b45-5b9edceb83f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="bhc:IncomeTaxReconciliationDeferredIntercompanyProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzExLTQtMS0xLTk0ODMx_a970e31b-76d7-48ad-9545-a1d521b9e6d1">338</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="bhc:IncomeTaxReconciliationDeferredIntercompanyProfit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzExLTYtMS0xLTk0ODMx_d817f659-e1e2-4293-ab01-4c946a4b6d9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzEyLTItMS0xLTk0ODMx_f051ca52-8e55-42b1-839f-13a2de3cd513">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzEyLTQtMS0xLTk0ODMx_85c25e2c-7c2b-4740-8a27-4f13dc749b5c">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzEyLTYtMS0xLTk0ODMx_a896a901-8f69-4fdd-b917-cff57245c87b">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzEzLTItMS0xLTk0ODMx_b3885901-b88d-4d31-b211-1e7fb390f743">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzEzLTQtMS0xLTk0ODMx_4ce276db-1f4e-47e3-9e50-7ccf8d3562ac">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzEzLTYtMS0xLTk0ODMx_efba7445-665a-41a1-8471-5e6a8bb5a0df">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzEyNzk1_a36f5c09-507f-4878-b48e-45043177cd8f" continuedAt="ieb6aae7b5126442b9b6b5ddc3eb59080" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities as of December 31, 2021 and 2020 consist of: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:78.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="bhc:DeferredTaxAssetsTaxLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzItMi0xLTEtOTQ4MzE_8483eae4-8e3c-48d6-8312-ef8627d3dff7">2,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="bhc:DeferredTaxAssetsTaxLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzItNC0xLTEtOTQ4MzE_7884ec59-145e-4b09-91cd-a6db8c15b6c3">2,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzMtMi0xLTEtOTQ4MzE_1448a6a8-e652-44c4-a5cc-0fae3b62ebd7">991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzMtNC0xLTEtOTQ4MzE_8f1ff2ac-6888-41d4-9b24-430d2a18d381">1,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="bhc:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzQtMi0xLTEtOTQ4MzE_5c0b75cc-68d6-454d-968b-2a361299d4c0">173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="bhc:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzQtNC0xLTEtOTQ4MzE_4ed9e4cf-9cef-434a-91d2-a3a67f8ae0a0">172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific Research and Experimental Development pool</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="bhc:DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzUtMi0xLTEtOTQ4MzE_9bb77961-bdef-4d56-9a45-fb44941224c5">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="bhc:DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzUtNC0xLTEtOTQ4MzE_cdce10d4-6112-40bc-9312-b0636b7b85a5">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzYtMi0xLTEtOTQ4MzE_df2c39fc-128f-4355-a4ee-322bdb2eeeb9">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzYtNC0xLTEtOTQ4MzE_98f0763d-f6f2-4688-bf1a-8a8f5f5bc5a0">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzctMi0xLTEtOTQ4MzE_2c65af03-3332-473f-bfcc-beb3a7a111da">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzctNC0xLTEtOTQ4MzE_dfbe5117-5457-4b5c-ba69-13ae57a00e61">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="bhc:DeferredTaxAssetsPrepaidExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzgtMi0xLTEtOTQ4MzE_3868a2b0-1bad-43ea-9b4b-48d687abf81e">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="bhc:DeferredTaxAssetsPrepaidExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzgtNC0xLTEtOTQ4MzE_e9908c3e-63bc-44e9-8409-b598d32c757c">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzktMi0xLTEtOTQ4MzE_b49ac937-4cd8-4895-9a8a-e9e63db931b0">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzktNC0xLTEtOTQ4MzE_9dcb8d86-237c-40f1-a791-d26bc50f6697">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzEwLTItMS0xLTk0ODMx_c2850bb7-1d82-4785-b650-672347480c0b">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzEwLTQtMS0xLTk0ODMx_69fabca9-fb87-4e35-b4fb-0137efc3259f">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzExLTItMS0xLTk0ODMx_34b0732a-2574-4878-a2d5-22ad6cf3ea33">4,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzExLTQtMS0xLTk0ODMx_4e09c117-b4a9-4e07-8835-e293ba85b721">4,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzEyLTItMS0xLTk0ODMx_9c554600-ddc9-4175-ba32-9fae8bfe0031">2,222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzEyLTQtMS0xLTk0ODMx_d3bfa287-cb63-414f-b079-1ea08570b7ae">2,252</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets net of valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzEzLTItMS0xLTk0ODMx_6356e9e4-ddca-45c4-a8e4-ecea99ef332e">2,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzEzLTQtMS0xLTk0ODMx_ffaa8845-ab4f-4e7a-846f-485739d9f9ab">1,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzE1LTItMS0xLTk0ODMx_1404ee48-df0a-41c8-8203-4a70e66ac2b6">188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzE1LTQtMS0xLTk0ODMx_11c0214d-f29a-4ffa-9e33-e31e04274f65">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plant, equipment and technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="bhc:DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzE2LTItMS0xLTk0ODMx_febc9b55-7a4a-464a-8b34-2996a37ff37d">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="bhc:DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzE2LTQtMS0xLTk0ODMx_11e96dd0-b994-4b29-91d0-4f8e5cb936cc">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside basis differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzE3LTItMS0xLTk0ODMx_af0102c4-23cf-4464-aa33-aa045b133948">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzE3LTQtMS0xLTk0ODMx_2c8def22-c357-4494-a756-4c91deda4245">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized FX on U.S. dollar debt and other financing cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzE4LTItMS0xLTk0ODMx_c65daf2c-4335-49ba-8e2c-4768478d3281">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzE4LTQtMS0xLTk0ODMx_584524c6-cd51-43e1-801f-0f7afeda270b">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzE5LTItMS0xLTk0ODMx_be9defe1-6bd1-41e7-9c16-7b5156b7d1f6">342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzE5LTQtMS0xLTk0ODMx_0e9d90be-a923-485b-8147-843b3019e787">390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzIwLTItMS0xLTk0ODMx_3e102fae-3308-4791-8a86-800327133134">1,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzIwLTQtMS0xLTk0ODMx_35d081b9-a850-4e6c-b607-0785aca16f5a">1,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="icdc1f7128dd346c3884854ea97bc5508" continuedAt="i1b1dd0c22b13470891ec82671c91b477"><ix:continuation id="ieb6aae7b5126442b9b6b5ddc3eb59080"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the deferred tax asset valuation allowance for 2021, 2020 and 2019: </span></div><div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffc30cecb9c4ef0b327417dbb601c42_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo0YTMzYjZmM2U3YzE0NzQyYjQxMzhmYTlhOTAzN2YxYi90YWJsZXJhbmdlOjRhMzNiNmYzZTdjMTQ3NDJiNDEzOGZhOWE5MDM3ZjFiXzEtMi0xLTEtOTQ4MzE_e781b92f-7785-4dc8-afa6-8e6e10992074">2,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f6b4de2972a45b48db5cc52d91b1a88_I20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo0YTMzYjZmM2U3YzE0NzQyYjQxMzhmYTlhOTAzN2YxYi90YWJsZXJhbmdlOjRhMzNiNmYzZTdjMTQ3NDJiNDEzOGZhOWE5MDM3ZjFiXzEtNC0xLTEtOTQ4MzE_4ccf618c-9699-41a6-be45-861cd1fe91cc">2,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if84d1523bc1740e9b7b6df3d57e513ef_I20181231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo0YTMzYjZmM2U3YzE0NzQyYjQxMzhmYTlhOTAzN2YxYi90YWJsZXJhbmdlOjRhMzNiNmYzZTdjMTQ3NDJiNDEzOGZhOWE5MDM3ZjFiXzEtNi0xLTEtOTQ4MzE_6bacef1f-7980-4c43-95ef-0ad382029c1a">2,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to Benefit from income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i915068d30e9c465eb1028aff329712ac_D20210101-20211231" decimals="-6" sign="-" name="bhc:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo0YTMzYjZmM2U3YzE0NzQyYjQxMzhmYTlhOTAzN2YxYi90YWJsZXJhbmdlOjRhMzNiNmYzZTdjMTQ3NDJiNDEzOGZhOWE5MDM3ZjFiXzItMi0xLTEtOTQ4MzE_1b50c7d5-adea-4c53-9d37-0b778b512acb">63</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic055386399994346ad881ca91aeba458_D20200101-20201231" decimals="-6" sign="-" name="bhc:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo0YTMzYjZmM2U3YzE0NzQyYjQxMzhmYTlhOTAzN2YxYi90YWJsZXJhbmdlOjRhMzNiNmYzZTdjMTQ3NDJiNDEzOGZhOWE5MDM3ZjFiXzItNC0xLTEtOTQ4MzE_8b8d4be8-63da-4020-ab37-bb3492bbb07f">773</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba81224f654cb2b0f2010018455b61_D20190101-20191231" decimals="-6" name="bhc:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo0YTMzYjZmM2U3YzE0NzQyYjQxMzhmYTlhOTAzN2YxYi90YWJsZXJhbmdlOjRhMzNiNmYzZTdjMTQ3NDJiNDEzOGZhOWE5MDM3ZjFiXzItNi0xLTEtOTQ4MzE_fa1fa240-43e9-40a1-8e65-357bbdefbd04">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to other accounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i915068d30e9c465eb1028aff329712ac_D20210101-20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo0YTMzYjZmM2U3YzE0NzQyYjQxMzhmYTlhOTAzN2YxYi90YWJsZXJhbmdlOjRhMzNiNmYzZTdjMTQ3NDJiNDEzOGZhOWE5MDM3ZjFiXzMtMi0xLTEtOTQ4MzE_be03e754-8df8-4648-83bc-07bcfb64b2fe">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic055386399994346ad881ca91aeba458_D20200101-20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo0YTMzYjZmM2U3YzE0NzQyYjQxMzhmYTlhOTAzN2YxYi90YWJsZXJhbmdlOjRhMzNiNmYzZTdjMTQ3NDJiNDEzOGZhOWE5MDM3ZjFiXzMtNC0xLTEtOTQ4MzE_67adb9c4-0ff7-4bd3-8d45-36c6beeabb68">194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67ba81224f654cb2b0f2010018455b61_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo0YTMzYjZmM2U3YzE0NzQyYjQxMzhmYTlhOTAzN2YxYi90YWJsZXJhbmdlOjRhMzNiNmYzZTdjMTQ3NDJiNDEzOGZhOWE5MDM3ZjFiXzMtNi0xLTEtOTQ4MzE_a344f7fc-2f2b-43c6-8ca3-5bb911133da7">95</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id379e27a083f4bb1879222afc10f82f9_I20211231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo0YTMzYjZmM2U3YzE0NzQyYjQxMzhmYTlhOTAzN2YxYi90YWJsZXJhbmdlOjRhMzNiNmYzZTdjMTQ3NDJiNDEzOGZhOWE5MDM3ZjFiXzQtMi0xLTEtOTQ4MzE_f0b64635-b1de-4aed-b08a-5193712877ea">2,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibffc30cecb9c4ef0b327417dbb601c42_I20201231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo0YTMzYjZmM2U3YzE0NzQyYjQxMzhmYTlhOTAzN2YxYi90YWJsZXJhbmdlOjRhMzNiNmYzZTdjMTQ3NDJiNDEzOGZhOWE5MDM3ZjFiXzQtNC0xLTEtOTQ4MzE_7d6c1102-b191-4a9d-9766-9756bd722da7">2,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f6b4de2972a45b48db5cc52d91b1a88_I20191231" decimals="-6" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo0YTMzYjZmM2U3YzE0NzQyYjQxMzhmYTlhOTAzN2YxYi90YWJsZXJhbmdlOjRhMzNiNmYzZTdjMTQ3NDJiNDEzOGZhOWE5MDM3ZjFiXzQtNi0xLTEtOTQ4MzE_440e421a-1a7c-4323-95bf-e2598af58cc2">2,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. interest expense is subject to limitation rules which limit U.S. interest expense to 30% of adjusted taxable income, defined similar to EBITDA through 2021 and EBIT thereafter.  Disallowed interest can be carried forward indefinitely and any unused interest deduction assessed for recoverability. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) was signed into law.  The CARES Act also amended the annual limitation on the deduction of interest in the following respects: (i) increasing the limitation to 50% of adjusted taxable income (&#8220;ATI&#8221;), (ii) providing a rule for a partnership&#8217;s 2019 section 163(j)-disallowed interest expense and (iii) allowing an election to apply 2019 ATI to the 2020 section 163(j) computation.  For corporations, the increase to 50% of ATI applies to all taxable years beginning in 2019 or 2020 and permits taxpayers whose 2020 income will decrease from its 2019 level, an election to apply their 2019 ATI, rather than their 2020 ATI, to their 2020 computation. The Company considered such provisions and expects to fully utilize any interest carry forwards in future periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has provided for income taxes in accordance with guidance issued by accounting regulatory bodies, the U.S. Internal Revenue Service and state and local governments through the date of the issuance of these Consolidated Financial Statements. Additional guidance and interpretations can be expected and such guidance, if any, could impact future results.  While management continues to monitor these matters, the ultimate impact, if any, as a result of the application of any guidance issued in the future cannot be determined at this time.   </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The realization of deferred tax assets is dependent on the Company generating sufficient domestic and foreign taxable income in the years that the temporary differences become deductible. A valuation allowance has been provided for the portion of the deferred tax assets that the Company determined is more likely than not to remain unrealized based on estimated future taxable income and tax planning strategies.  In 2021, the valuation allowance decreased by $<ix:nonFraction unitRef="usd" contextRef="i187c9f9f5937400ba090ce33c5c46259_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzI2MDE_6f0d0a5d-6229-4703-9ab2-1fce0608170b">30</ix:nonFraction> million primarily due to book taxable income in Canada, the change in deferred tax assets in Canada and the use of deferred tax assets in the U.S. in connection with internal restructurings. In 2020, the valuation allowance decreased by $<ix:nonFraction unitRef="usd" contextRef="ie80a8d41d8154b9fa08ad7c9d7849024_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzI4MzM_5e8f61a7-344e-4500-9f8f-1aa85d4faa93">579</ix:nonFraction> million as a result of taxable losses in Canada as offset by a reduction of deferred tax assets due to internal restructurings. Given the Company&#8217;s history of pre-tax losses and expected future losses in Canada, the Company maintained that there was insufficient objective evidence to release the valuation allowance against Canadian tax loss carryforwards, International Tax Credits (&#8220;ITC&#8221;) and pooled Scientific Research and Experimental Development Tax Incentive (&#8220;SR&amp;ED&#8221;) expenditures.  The Canadian valuation allowance represents a material portion of the Company's total valuation allowance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, the Company had accumulated taxable losses available to offset future years&#8217; federal and provincial taxable income in Canada of approximately $<ix:nonFraction unitRef="usd" contextRef="i27ecb8e5fdeb4e02bde51b102f8143fc_I20211231" decimals="-6" name="bhc:AccumulatedLossesAvailableForFederalPurposes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzM1Nzg_7f80fda3-375e-41a0-be2d-08ece0850c2d">6,669</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib41b4897f8fc4d62a5af15ed7e0950d0_I20201231" decimals="-6" name="bhc:AccumulatedLossesAvailableForFederalPurposes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzM1ODU_a7f1f04f-fbfb-4f0d-978d-780f84ca5905">6,530</ix:nonFraction> million, respectively.&#160; As of December 31, 2021 and 2020, unclaimed ITCs available to offset future federal taxes in Canada were approximately $<ix:nonFraction unitRef="usd" contextRef="i27ecb8e5fdeb4e02bde51b102f8143fc_I20211231" decimals="-6" name="bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzM2OTk_ad20e31c-da1e-4029-9829-8f57e449f541">31</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib41b4897f8fc4d62a5af15ed7e0950d0_I20201231" decimals="-6" name="bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzM3MDY_ee153585-ac58-4a5f-88b4-287805af81ad">37</ix:nonFraction> million, respectively, which expire in the years 2022 through 2041.&#160; In addition, as of December 31, 2021 and 2020, pooled SR&amp;ED expenditures available to offset against future taxable income in Canada were approximately $<ix:nonFraction unitRef="usd" contextRef="ia1d46f5c753c4613a41c0b24b7215d74_I20211231" decimals="-6" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzM4OTg_656f69d6-0c38-4102-8483-e6ded75f4bd8">196</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i64fcc3a1ff2b47af8fa496e471287739_I20201231" decimals="-6" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzM5MDU_600c0d1e-f0c7-4a46-b58d-2ce394c6751e">206</ix:nonFraction> million, respectively, which may be carried forward indefinitely.  As of December 31, 2021 and 2020, a full valuation allowance against the net Canadian deferred tax assets on the parent company has been provided of $<ix:nonFraction unitRef="usd" contextRef="i27ecb8e5fdeb4e02bde51b102f8143fc_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzQwOTI_1f62dab4-66df-4ba4-bff8-58d0e96aff74">1,965</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib41b4897f8fc4d62a5af15ed7e0950d0_I20201231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzQwOTk_1305c4be-d5f2-4dd4-982d-0d7fa55d0080">1,966</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, the Company had accumulated taxable losses available to offset future years' federal taxable income in the U.S. of approximately $<ix:nonFraction unitRef="usd" contextRef="i3a91733048244e1caf9bc10fed86c62d_I20211231" decimals="-6" name="bhc:AccumulatedLossesAvailableForFederalPurposes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzQyNTY_60763c3b-c189-4ec9-be34-f4329734ea35">266</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie95a42cdf2a44bae88536d5e9143a530_I20201231" decimals="-6" name="bhc:AccumulatedLossesAvailableForFederalPurposes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzQyNjM_868368b6-f9ec-4bb5-8200-82926588a1e1">814</ix:nonFraction> million, respectively, including acquired losses which expire in the years 2022 through 2037. While the remaining taxable losses are subject to multiple annual loss limitations as a result of previous ownership changes, the Company believes that the recoverability of the deferred tax assets associated with these taxable losses are more likely than not to be realized. As of December 31, 2021 and 2020 U.S. research and development credits available to offset future years' federal income taxes in the U.S. were approximately $<ix:nonFraction unitRef="usd" contextRef="i3a91733048244e1caf9bc10fed86c62d_I20211231" decimals="-6" name="bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzQ3NjE_78f9a2e8-a4e6-4bf6-abe3-d4bdf702f420">119</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie95a42cdf2a44bae88536d5e9143a530_I20201231" decimals="-6" name="bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzQ3Njg_3b385be3-ab83-4baf-84f3-b7383853bbc6">110</ix:nonFraction> million, respectively, which includes acquired research and development credits and which expire in the years 2022 through 2042.  In the U.S. the Company has a capital loss of which is offset by a full valuation allowance since the benefit is not expected to be realized.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, the Company had accumulated taxable losses available to offset future years&#8217; taxable income in Ireland of approximately $<ix:nonFraction unitRef="usd" contextRef="id6d550dbbfda46bf82a16f8ce10ebe0b_I20211231" decimals="-6" name="bhc:AccumulatedLossesAvailableForFederalPurposes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzUxNjc_adbd8ec4-690d-4f04-b560-af8ed29a3a1f">10,040</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i541042590f234b388cebba5a8ab708be_I20201231" decimals="-6" name="bhc:AccumulatedLossesAvailableForFederalPurposes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzUxNzQ_be320d95-1cd0-4768-a6f9-38e0371a1b60">8,387</ix:nonFraction> million, respectively.&#160; As of  December&#160;31, 2021, the Company continues to have a capital loss which is offset by a valuation allowance on the portion of the loss for which a benefit is not expected to be realized.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i1b1dd0c22b13470891ec82671c91b477" continuedAt="i73794f2f97ac4663b3a0979be584c945"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for income taxes on the unremitted earnings of its direct foreign affiliates except for its direct U.S. subsidiaries.  The Company continues to assert that the unremitted earnings of its U.S.&#160;subsidiaries will be permanently reinvested and not repatriated.  As of December 31, 2021, the Company estimates that there will be no tax liability attributable to unremitted earnings of its U.S. subsidiaries. However, distribution of future earnings could be subject to U.S. withholding tax.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, unrecognized tax benefits (including interest and penalties) were $<ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzU5MzE_5d261528-1833-4a33-abad-80f440dc2752">927</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzU5Mzg_8eb568e0-f312-41dd-a6a0-a9c01a6323b2">1,025</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzU5NTE_26011e86-f35d-4edb-a2c1-37869efc7665">271</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzU5NTg_5e945755-fe86-41a8-b40d-b04babe1f1bd">414</ix:nonFraction> million would affect the effective income tax rate, respectively. In 2021 and 2020, the remaining unrecognized tax benefits would not impact the effective tax rate as the tax positions are offset against existing tax attributes or are timing in nature. In 2021 and 2020, the Company recognized net increases to unrecognized tax benefits for current year tax positions of $<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="bhc:UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzYzMTY_e6b68821-0450-4f93-880f-a9557cbf8218">79</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="bhc:UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzYzMjM_d707663f-df01-4430-a7f2-2d1582b07d06">66</ix:nonFraction> million, respectively.  The Company recognized a net reduction of $<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="bhc:UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzYzODQ_a1a92004-cab2-4e64-afe0-419ca3b502cf">177</ix:nonFraction> million during 2021 and a net reduction of $<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="bhc:UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzY0MjA_6233cace-b1a0-4d71-8654-269d5d4e0571">42</ix:nonFraction> million during 2020 in the unrecognized tax benefits related to tax positions taken in the prior years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for interest and penalties related to unrecognized tax benefits in the provision for income taxes. As of December 31, 2021 and 2020, accrued interest and penalties related to unrecognized tax benefits were approximately $<ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzY3MzQ_f2ec2f4e-b758-4969-8278-f37850b10c48">41</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzY3NDE_35bd3e8c-b44d-4216-9ad8-3a6577651d0f">49</ix:nonFraction> million, respectively. In 2021, the Company recognized a net decrease of approximately $<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzY4MjE_9be89a15-53f0-4c4e-b656-57f008b6b8c7">8</ix:nonFraction> million and, in 2020, recognized an increase of  $<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzY4NjM_055661c2-e86c-4d9d-9e8d-399162f0a447">4</ix:nonFraction> million of interest and&#160;penalties, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and <ix:nonFraction unitRef="subsidiary" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="INF" name="bhc:IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzY5MjM_91896c3d-7e26-4700-9c2c-4fbb079887d5">one</ix:nonFraction> or more of its subsidiaries file federal income tax returns in Canada, the U.S., and other foreign jurisdictions, as well as various provinces and states in Canada and the U.S.&#160;The Company and its subsidiaries have open tax years, primarily from 2012 to 2020, with significant taxing jurisdictions, respectively, including Canada and the U.S.&#160;These open years contain certain matters that could be subject to differing interpretations of applicable tax laws and regulations and tax treaties, as they relate to the amount, timing, or inclusion of revenues and expenses, or the sustainability of income tax positions of the Company and its subsidiaries. Certain of these tax years are expected to remain open indefinitely.</span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzEyNzky_c40f39e0-23dd-4a41-aa59-9665c9ec53c3" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"></td><td style="width:82.106%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.931%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jurisdiction:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Open Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States - Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3981d7a177af492eb4fbd78ea657ad8f_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzEtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjpkYzViNDAxODNmZDE0NGQwOWQ3OGM0NTAxZjdmODI0OF80_a78413a0-0978-4f3c-b8d8-9e10617430d8">2015</ix:nonNumeric> - <ix:nonNumeric contextRef="i0a701334d8d94a828739c539bfb11dbf_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzEtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjpkYzViNDAxODNmZDE0NGQwOWQ3OGM0NTAxZjdmODI0OF85_e9a79cc0-dfa7-41f4-93e2-c4b5bde19af2">2020</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic261bd3e9bfd4d98ae7b58e6abadcb92_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzItMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjowMmU5YjRhNTUwODQ0N2M1YTJkMjk1MjU4ZTY1NmEzMF80_a9140a37-0e74-4e45-89ca-8b594b45cd19">2012</ix:nonNumeric> - <ix:nonNumeric contextRef="i3c2e628003764836a5a04489d83647f6_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzItMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjowMmU5YjRhNTUwODQ0N2M1YTJkMjk1MjU4ZTY1NmEzMF85_482f6e1b-5214-4c39-8ebe-3c811d461cad">2020</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i90867327964d4767846d8c36adbc2e43_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzMtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjoxYTZmMjhjNWQ1Yjg0MDBiODFlNmVlMTQ5YzkzYTUzZl80_4302c183-31dc-4d98-8bf4-2baa75fb45d0">2014</ix:nonNumeric> - <ix:nonNumeric contextRef="if4e269c5fff94bdba040ffb57118494d_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzMtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjoxYTZmMjhjNWQ1Yjg0MDBiODFlNmVlMTQ5YzkzYTUzZl85_a8145d07-4442-41b5-9e64-40859d6b7866">2020</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i65523828a01044e59ade22a5ccb853d2_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzQtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjplNjdlNzczYzU3ODE0ZmZiODIzNDVmMjVlNDlkY2NkMl80_c7c7fa71-e905-4c61-bcfb-060c9be98643">2013</ix:nonNumeric> - <ix:nonNumeric contextRef="i5c327fe5449c48c48e8d5f0372ae6137_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzQtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjplNjdlNzczYzU3ODE0ZmZiODIzNDVmMjVlNDlkY2NkMl85_573a4d24-b81a-4e44-a70a-cd71cd5bf2c5">2020</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib902cbf8a7fe4328a5114bf1cab23702_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzUtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo3ZTgxZDgyYzg0OWQ0ZGFjOTU5MDcwMGUwNGI3NGU2Y180_e0588f5a-55ad-4871-8b39-dbf94dbb1521">2016</ix:nonNumeric> - <ix:nonNumeric contextRef="i1c126541a8a74e41a63df4a34dfd968a_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzUtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo3ZTgxZDgyYzg0OWQ0ZGFjOTU5MDcwMGUwNGI3NGU2Y185_a5b6bee7-b9df-4428-99c3-c8aa028ac944">2020</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i96392c49eef14e5988d30ce53b0250b0_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzYtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjowZGVhY2ExYjMwNDA0MzQ1YTE1MWFhYmU4NWRmZGNhMV80_43f6b47e-20a6-449c-aa00-e3e9f870d11f">2016</ix:nonNumeric> - <ix:nonNumeric contextRef="i031396881a4b4914914165e52a669249_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzYtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjowZGVhY2ExYjMwNDA0MzQ1YTE1MWFhYmU4NWRmZGNhMV85_55663b89-c38c-4818-9996-f60b51f5a740">2020</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie5eb8fe6d6da478c96fbec9cb03cc330_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzctMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjowNWU2YWJiYTA4NGY0NTQwOWJlMzA0ZDQxNDhmYjE0Zl80_8fd1619a-27f6-4ad3-9efa-0ff7f456f4e9">2017</ix:nonNumeric> - <ix:nonNumeric contextRef="ie47ed3dfd2114787b382d6779d753245_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzctMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjowNWU2YWJiYTA4NGY0NTQwOWJlMzA0ZDQxNDhmYjE0Zl85_5847044e-3e59-4506-ba7c-091aa1930bb5">2020</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i966ab6abce524555a38770e32731ec1b_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzgtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo0OWY0MjAwOWU3YTU0MmM5YjczNWU2Nzk1YzcyYWQyM180_0f53a362-adfc-4c8a-93b8-30f6169a1215">2011</ix:nonNumeric> - <ix:nonNumeric contextRef="id73c90871edb496a8acded32a4868495_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzgtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo0OWY0MjAwOWU3YTU0MmM5YjczNWU2Nzk1YzcyYWQyM185_4fadd04b-dc63-482e-aea9-ea80cfd36ee8">2020</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5656a30a453e4f61bee5ce805d141aa0_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzktMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo2ZjE3MjMyYjFjYTE0YzBmYmU2MDQwMjQ4Yjg4ZGIwNV80_33de5765-410c-4700-b26c-e5c788b55576">2017</ix:nonNumeric> - <ix:nonNumeric contextRef="iaf6683fc8f2a4c7681664da8552f7c19_D20210101-20211231" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzktMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo2ZjE3MjMyYjFjYTE0YzBmYmU2MDQwMjQ4Yjg4ZGIwNV85_5d10930d-3266-48ea-a758-aea4241f4a99">2020</ix:nonNumeric></span></div></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Internal Revenue Service (the &#8220;IRS&#8221;) completed its examinations of the Company&#8217;s U.S. consolidated federal income tax returns for the years 2013 and 2014. There were no material adjustments to the Company's taxable income as a result of these examinations.  However, the 2014 tax year remains open to the extent of a 2017 capital loss carried back to that year. Additionally, the IRS has selected for examination the Company's annual tax filings for 2015 and 2016 and the Company's short period tax return for the period ended September 8, 2017, which was filed as a result of the Company's internal restructuring efforts during 2017. In 2017, the Company undertook an internal restructuring in the form of what is commonly known as a Granite Trust transaction, which resulted in a recorded capital loss (the &#8220;2017 Capital Loss&#8221;). Recently, the Company has received a notice of proposed adjustment from the IRS that would disallow the 2017 Capital Loss and expects to receive a notice of proposed tax deficiency from the IRS, after which the Company intends to contest proposed tax deficiency through the IRS administrative appeals process. If the Company were ultimately unsuccessful in defending its position, and all or a substantial portion of the 2017 Capital Loss deduction were disallowed, the Company could be liable for additional taxes (excluding penalties and interest) of up to $<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzkwNDM_e64df7d0-b34c-4f36-b6b8-564695786d44">2,100</ix:nonFraction>&#160;million, which could have an adverse effect on the Company&#8217;s financial condition and results of operations. The Company intends to vigorously defend its position, including through appropriate litigation, if necessary, and ultimately believes it will sustain its deduction of the 2017 Capital Loss, and, accordingly, no income tax provision has been recorded.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is currently under examination by the Canada Revenue Agency (&#8220;CRA&#8221;) for three separate cycles: (a) years 2012 through 2013 (b) years 2014 through 2015, and (c) years 2016 through 2017.  The Company believes that the CRA will open an audit cycle for the years 2018 &#8211; 2019 in 2022.  The Company settled the tax years from 2005 through 2009 </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i73794f2f97ac4663b3a0979be584c945"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with the CRA. The Company had previously filed a Notice of Objection related to the assessment of these years and reduced net operating losses with a full valuation allowance by CAD <ix:nonFraction unitRef="cad" contextRef="i6ad0eba196ab4a07a56009d4610284f7_I20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzk5MzI_fd5e7106-c46d-4e7f-90de-17aaf4adc491">44</ix:nonFraction>&#160;million to close these years.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The adjustment did not result in a material change to the provision for income taxes.  The CRA audits of the 2010 and 2011 tax years were closed in 2016 and resulted in no material adjustments. The Company received an assessment for certain transfer pricing matters in 2012 and 2013 for CAD <ix:nonFraction unitRef="cad" contextRef="i3a2b5c5adebc4e62b7d64a5d6bcca25d_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzEwMjQ5_a7f7ee04-0411-45b0-ae02-029696402cbd">85</ix:nonFraction>&#160;million and CAD <ix:nonFraction unitRef="cad" contextRef="i5a6621a8c1674dbc9a844087860a0e82_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzEwMjYw_047f61b7-019c-4549-975a-91aadfcc04a0">90</ix:nonFraction>&#160;million, respectively.  The Company disagrees with the adjustments and has filed a Notice of Objection for 2012 and 2013.  The Company settled certain transfer pricing matters relating the 2015 and 2016 tax years resulting in a reduction to its NOLs of approximately CAD <ix:nonFraction unitRef="cad" contextRef="i0bb9780df86a4065b01b2469abd59faf_I20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzEwNTI2_7e3d89fa-75bb-4602-873e-3c0884149cd9">21</ix:nonFraction>&#160;million for 2015 and will receive a further adjustment for 2016.  The expected adjustment for 2016 will reduce NOLs currently offset by a full valuation allowance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s subsidiaries in Germany are under audit for tax years 2014 through 2016.  At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries in Australia are under audit by the Australian Tax Office for various years beginning in 2010. On August 8, 2017, the Australian Taxation Office issued a notice of assessment for the tax years 2011 through 2017 in the aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="if92917964a2f48fc8d583659d90471f8_D20170808-20170808" decimals="-6" name="us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzExMTg1_1fb169f9-0abb-41c8-8d6a-a56cc6acdf4f">117</ix:nonFraction> million, which includes penalties and interest.  The Company disagrees with the assessment and continues to believe that its tax positions are appropriate and supported by the facts, circumstances and applicable laws. The Company intends to defend its tax position in this matter vigorously and has filed a holding objection against the assessment by the Australian Taxation Office and has secured a bank guarantee to cover any potential cash outlays regarding this assessment. The bank guarantee has been reduced over time to now be an immaterial value.  Negotiations with the Australian Tax Office are ongoing and the Company expects to enter into a Settlement Deed in early 2022 with no material adverse results.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's U.S. affiliates remain under examination for various state tax audits in the U.S. for years 2015 through 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain affiliates of the Company in regions outside of Canada, the U.S., Germany, Luxembourg and Australia are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits.  At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's Consolidated Financial Statements.</span></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzEyODI3_98b60f16-523c-4402-bae3-a8934c3d269e" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the unrecognized tax&#160;benefits for 2021, 2020 and 2019: </span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzEtMi0xLTEtOTQ4MzE_8eb0b134-ab96-4587-b3df-4886e3314d73">1,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzEtNC0xLTEtOTQ4MzE_74cf11ec-df82-4e04-ad26-816941a1156a">1,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18439fe8345c481db53c486667ac6940_I20181231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzEtNi0xLTEtOTQ4MzE_a3149cd6-3567-4916-9438-bfef327d136a">654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzItMi0xLTEtOTQ4MzE_824d7b79-1245-4021-b222-e2e846c143ff">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzItNC0xLTEtOTQ4MzE_376b4b1e-c904-4582-8ddc-c4a78981657a">66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzItNi0xLTEtOTQ4MzE_dd996837-c101-46f6-b787-7aedb053826e">361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions of prior years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzMtMi0xLTEtOTQ4MzE_97278474-baf1-4b22-b7d6-f941959ee621">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzMtNC0xLTEtOTQ4MzE_948c5e13-f719-4d79-a384-6cd4fe2d86b4">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzMtNi0xLTEtOTQ4MzE_22bea28f-2268-494c-9df4-aefa30e201fd">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzQtMi0xLTEtOTQ4MzE_72b4c01f-f779-4db8-bb25-557447e29094">129</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzQtNC0xLTEtOTQ4MzE_5a8d0423-2cea-4c31-bdd4-1818bbcb497e">209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzQtNi0xLTEtOTQ4MzE_6da063ef-810f-4e34-8833-abf6e8aebbfd">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzUtMi0xLTEtOTQ4MzE_c485ccb1-f28f-4c63-b715-b1e6602744d1">169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzUtNC0xLTEtOTQ4MzE_9d726a10-a696-4cbd-bf34-d383ca26dbef">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzUtNi0xLTEtOTQ4MzE_bafe5534-79c8-4961-8a4b-a061e017158f">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzYtMi0xLTEtOTQ4MzE_2e76882a-9463-4f3f-8f80-8a2752705564">927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzYtNC0xLTEtOTQ4MzE_550ded15-6fcc-4403-a98d-1e6fd7939108">1,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzYtNi0xLTEtOTQ4MzE_fc0b85c6-2c1b-43c7-a4c1-d18b6a0f8ffc">1,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes it is reasonably possible that the total amount of unrecognized tax benefits at December 31, 2021 could decrease by approximately $<ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzEyNjYz_99e65db3-73d1-40a7-b7ce-6d29f8387bdb">104</ix:nonFraction> million in the next twelve months as a result of the resolution of certain tax and transfer pricing audits and other events.</span></div></ix:continuation><div id="i8256f225f07d49409c31f7443adffdbf_367"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90ZXh0cmVnaW9uOjQ5Yjk3YTVjMDMzODQ5NDZiYmRiNjkwOGJmZWQyMzA0XzEwMzI_6372277e-2345-4cc8-8d16-b4acdd3f995a" continuedAt="i2a9a145632c64b5a9800deb35cbaee67" escape="true">LOSS  PER SHARE</ix:nonNumeric></span></div><ix:continuation id="i2a9a145632c64b5a9800deb35cbaee67" continuedAt="if2370cac7cce4d37a06751df57b47b7f"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90ZXh0cmVnaW9uOjQ5Yjk3YTVjMDMzODQ5NDZiYmRiNjkwOGJmZWQyMzA0XzEwMjk_3f5b82a4-2637-4401-bfc3-09a776fe4720" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss per share attributable to Bausch Health Companies Inc. for 2021, 2020 and 2019 were calculated as&#160;follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90YWJsZTo0YTZlYzg1ZDg5NWY0YjY3YTc0YWMwMTJmNjAyZjMyOC90YWJsZXJhbmdlOjRhNmVjODVkODk1ZjRiNjdhNzRhYzAxMmY2MDJmMzI4XzEtMi0xLTEtOTQ4MzE_426ce37d-433f-4a0d-9166-023b8f653063">948</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90YWJsZTo0YTZlYzg1ZDg5NWY0YjY3YTc0YWMwMTJmNjAyZjMyOC90YWJsZXJhbmdlOjRhNmVjODVkODk1ZjRiNjdhNzRhYzAxMmY2MDJmMzI4XzEtNC0xLTEtOTQ4MzE_a678243c-c163-4200-b111-38c17983091b">560</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90YWJsZTo0YTZlYzg1ZDg5NWY0YjY3YTc0YWMwMTJmNjAyZjMyOC90YWJsZXJhbmdlOjRhNmVjODVkODk1ZjRiNjdhNzRhYzAxMmY2MDJmMzI4XzEtNi0xLTEtOTQ4MzE_2f1df46b-7da3-4041-b670-0956e8164a04">1,788</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic and diluted weighted-average common shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90YWJsZTo0YTZlYzg1ZDg5NWY0YjY3YTc0YWMwMTJmNjAyZjMyOC90YWJsZXJhbmdlOjRhNmVjODVkODk1ZjRiNjdhNzRhYzAxMmY2MDJmMzI4XzItMi0xLTEtOTQ4MzE_2701e3a8-d81d-4782-9165-ce4da81f0a7b"><ix:nonFraction unitRef="shares" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90YWJsZTo0YTZlYzg1ZDg5NWY0YjY3YTc0YWMwMTJmNjAyZjMyOC90YWJsZXJhbmdlOjRhNmVjODVkODk1ZjRiNjdhNzRhYzAxMmY2MDJmMzI4XzItMi0xLTEtOTQ4MzE_cb0f8c67-bc0d-4ad0-a350-a28f056d9952">358.9</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90YWJsZTo0YTZlYzg1ZDg5NWY0YjY3YTc0YWMwMTJmNjAyZjMyOC90YWJsZXJhbmdlOjRhNmVjODVkODk1ZjRiNjdhNzRhYzAxMmY2MDJmMzI4XzItNC0xLTEtOTQ4MzE_255c37d6-4f9e-4511-b578-326f6a6b9269"><ix:nonFraction unitRef="shares" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90YWJsZTo0YTZlYzg1ZDg5NWY0YjY3YTc0YWMwMTJmNjAyZjMyOC90YWJsZXJhbmdlOjRhNmVjODVkODk1ZjRiNjdhNzRhYzAxMmY2MDJmMzI4XzItNC0xLTEtOTQ4MzE_9ec93fe0-8896-4d07-a063-abf74c47a980">355.0</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90YWJsZTo0YTZlYzg1ZDg5NWY0YjY3YTc0YWMwMTJmNjAyZjMyOC90YWJsZXJhbmdlOjRhNmVjODVkODk1ZjRiNjdhNzRhYzAxMmY2MDJmMzI4XzItNi0xLTEtOTQ4MzE_2997b533-f22a-4403-95d9-280971affe40"><ix:nonFraction unitRef="shares" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90YWJsZTo0YTZlYzg1ZDg5NWY0YjY3YTc0YWMwMTJmNjAyZjMyOC90YWJsZXJhbmdlOjRhNmVjODVkODk1ZjRiNjdhNzRhYzAxMmY2MDJmMzI4XzItNi0xLTEtOTQ4MzE_b630f35d-3c36-453d-8940-8b8ab0a32202">352.1</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90YWJsZTo0YTZlYzg1ZDg5NWY0YjY3YTc0YWMwMTJmNjAyZjMyOC90YWJsZXJhbmdlOjRhNmVjODVkODk1ZjRiNjdhNzRhYzAxMmY2MDJmMzI4XzMtMi0xLTEtOTQ4MzE_d6832e65-792b-4c6e-b6bb-2bb1f92a61a1"><ix:nonFraction unitRef="usdPerShare" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90YWJsZTo0YTZlYzg1ZDg5NWY0YjY3YTc0YWMwMTJmNjAyZjMyOC90YWJsZXJhbmdlOjRhNmVjODVkODk1ZjRiNjdhNzRhYzAxMmY2MDJmMzI4XzMtMi0xLTEtOTQ4MzE_db472fbd-a24b-4172-93cb-5cfa14a4edba">2.64</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90YWJsZTo0YTZlYzg1ZDg5NWY0YjY3YTc0YWMwMTJmNjAyZjMyOC90YWJsZXJhbmdlOjRhNmVjODVkODk1ZjRiNjdhNzRhYzAxMmY2MDJmMzI4XzMtNC0xLTEtOTQ4MzE_46aefd65-8938-4ed4-9cc1-3615a5fb510f"><ix:nonFraction unitRef="usdPerShare" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90YWJsZTo0YTZlYzg1ZDg5NWY0YjY3YTc0YWMwMTJmNjAyZjMyOC90YWJsZXJhbmdlOjRhNmVjODVkODk1ZjRiNjdhNzRhYzAxMmY2MDJmMzI4XzMtNC0xLTEtOTQ4MzE_c10946fa-ff85-454d-acf6-ef71e1f4dad1">1.58</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90YWJsZTo0YTZlYzg1ZDg5NWY0YjY3YTc0YWMwMTJmNjAyZjMyOC90YWJsZXJhbmdlOjRhNmVjODVkODk1ZjRiNjdhNzRhYzAxMmY2MDJmMzI4XzMtNi0xLTEtOTQ4MzE_20db63a1-337a-432b-8291-66985ae5c4ea"><ix:nonFraction unitRef="usdPerShare" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90YWJsZTo0YTZlYzg1ZDg5NWY0YjY3YTc0YWMwMTJmNjAyZjMyOC90YWJsZXJhbmdlOjRhNmVjODVkODk1ZjRiNjdhNzRhYzAxMmY2MDJmMzI4XzMtNi0xLTEtOTQ4MzE_a5d3571f-9265-4ab6-8e60-4c016555b5fa">5.08</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="if2370cac7cce4d37a06751df57b47b7f"><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, 2020 and 2019, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive.  The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately <ix:nonFraction unitRef="shares" contextRef="i794db5d83c3641aa853ac4acaa8182e9_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90ZXh0cmVnaW9uOjQ5Yjk3YTVjMDMzODQ5NDZiYmRiNjkwOGJmZWQyMzA0XzQ5MA_337e9138-aa97-4e10-801a-3f99f2271959">4,932,000</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i426b648515c34755bb623ee81a4f1ae9_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90ZXh0cmVnaW9uOjQ5Yjk3YTVjMDMzODQ5NDZiYmRiNjkwOGJmZWQyMzA0XzQ5NA_f298bbce-9d18-452b-bc6b-78ff4e65693e">3,154,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i0aaea235b331445aa69d79ccdb7823d4_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90ZXh0cmVnaW9uOjQ5Yjk3YTVjMDMzODQ5NDZiYmRiNjkwOGJmZWQyMzA0XzUwMQ_3be0f562-7726-4b2c-8565-d8bac17be7c5">5,106,000</ix:nonFraction> common shares for 2021, 2020 and 2019, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in 2021, 2020 and 2019, stock options, time-based RSUs and performance-based RSUs to purchase approximately <ix:nonFraction unitRef="shares" contextRef="ifd3e00426ff44f65af5c22541ee8cb9a_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90ZXh0cmVnaW9uOjQ5Yjk3YTVjMDMzODQ5NDZiYmRiNjkwOGJmZWQyMzA0XzY0NQ_781a3560-7317-41f6-b73f-940c188526c5">3,428,000</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i84aa0d0a4fea4c29a4fea75d90ed7794_D20200101-20201231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90ZXh0cmVnaW9uOjQ5Yjk3YTVjMDMzODQ5NDZiYmRiNjkwOGJmZWQyMzA0XzY0OQ_02005b7a-fdf8-4b65-90e8-3d561ad8e055">9,551,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i5998f35e4ed44ab4a12b43f529e4ee2e_D20190101-20191231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90ZXh0cmVnaW9uOjQ5Yjk3YTVjMDMzODQ5NDZiYmRiNjkwOGJmZWQyMzA0XzY1Ng_7f9e5389-77e0-4218-b946-33d4907cde5a">2,598,000</ix:nonFraction> common shares of the Company, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During 2021, an additional <ix:nonFraction unitRef="shares" contextRef="i647e97c259b643fcb29ab0bf3ac45e1a_D20210101-20211231" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90ZXh0cmVnaW9uOjQ5Yjk3YTVjMDMzODQ5NDZiYmRiNjkwOGJmZWQyMzA0Xzg3OQ_da9a3ae2-f222-4774-932a-ca419ea8b188">156,000</ix:nonFraction> performance-based RSUs were not included in the computation of diluted earnings per share as the required performance conditions had not been met.</span></div></ix:continuation><div id="i8256f225f07d49409c31f7443adffdbf_370"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzAvZnJhZzoxNTYzMDI1Nzg3NTc0NWVkOGZkYzQ3OGY5ZGY5OTA2OS90ZXh0cmVnaW9uOjE1NjMwMjU3ODc1NzQ1ZWQ4ZmRjNDc4ZjlkZjk5MDY5XzY2_f70577ee-f0e9-49a4-b4e5-863c39a881b6" continuedAt="i20d85b930b9f46479df4e10d86b441d6" escape="true">SUPPLEMENTAL CASH FLOW DISCLOSURES </ix:nonNumeric></span></div><ix:continuation id="i20d85b930b9f46479df4e10d86b441d6"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzAvZnJhZzoxNTYzMDI1Nzg3NTc0NWVkOGZkYzQ3OGY5ZGY5OTA2OS90ZXh0cmVnaW9uOjE1NjMwMjU3ODc1NzQ1ZWQ4ZmRjNDc4ZjlkZjk5MDY5XzY4_0ccacab2-c16a-4f4b-8503-b9606cb19363" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow disclosures for 2021, 2020 and 2019 are as&#160;follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:67.849%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzAvZnJhZzoxNTYzMDI1Nzg3NTc0NWVkOGZkYzQ3OGY5ZGY5OTA2OS90YWJsZTpmM2NjMzgxNzE5MzQ0Y2UzOTc1MjcwOGMxYTNkOTYxMC90YWJsZXJhbmdlOmYzY2MzODE3MTkzNDRjZTM5NzUyNzA4YzFhM2Q5NjEwXzItMi0xLTEtOTQ4MzE_58f10011-9b7a-464b-8b81-a93f08635e6d">1,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzAvZnJhZzoxNTYzMDI1Nzg3NTc0NWVkOGZkYzQ3OGY5ZGY5OTA2OS90YWJsZTpmM2NjMzgxNzE5MzQ0Y2UzOTc1MjcwOGMxYTNkOTYxMC90YWJsZXJhbmdlOmYzY2MzODE3MTkzNDRjZTM5NzUyNzA4YzFhM2Q5NjEwXzItNC0xLTEtOTQ4MzE_b45b8254-aebd-4e7b-8130-cc7ecf68d4af">1,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzAvZnJhZzoxNTYzMDI1Nzg3NTc0NWVkOGZkYzQ3OGY5ZGY5OTA2OS90YWJsZTpmM2NjMzgxNzE5MzQ0Y2UzOTc1MjcwOGMxYTNkOTYxMC90YWJsZXJhbmdlOmYzY2MzODE3MTkzNDRjZTM5NzUyNzA4YzFhM2Q5NjEwXzItNi0xLTEtOTQ4MzE_8e7fb822-352f-4397-b334-cd62e769c4f1">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzAvZnJhZzoxNTYzMDI1Nzg3NTc0NWVkOGZkYzQ3OGY5ZGY5OTA2OS90YWJsZTpmM2NjMzgxNzE5MzQ0Y2UzOTc1MjcwOGMxYTNkOTYxMC90YWJsZXJhbmdlOmYzY2MzODE3MTkzNDRjZTM5NzUyNzA4YzFhM2Q5NjEwXzMtMi0xLTEtOTQ4MzE_8f77d593-b8c3-4deb-ac3f-62d588c5a384">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzAvZnJhZzoxNTYzMDI1Nzg3NTc0NWVkOGZkYzQ3OGY5ZGY5OTA2OS90YWJsZTpmM2NjMzgxNzE5MzQ0Y2UzOTc1MjcwOGMxYTNkOTYxMC90YWJsZXJhbmdlOmYzY2MzODE3MTkzNDRjZTM5NzUyNzA4YzFhM2Q5NjEwXzMtNC0xLTEtOTQ4MzE_61482c14-56bd-45af-bfdf-fe19ea469a0c">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzAvZnJhZzoxNTYzMDI1Nzg3NTc0NWVkOGZkYzQ3OGY5ZGY5OTA2OS90YWJsZTpmM2NjMzgxNzE5MzQ0Y2UzOTc1MjcwOGMxYTNkOTYxMC90YWJsZXJhbmdlOmYzY2MzODE3MTkzNDRjZTM5NzUyNzA4YzFhM2Q5NjEwXzMtNi0xLTEtOTQ4MzE_6c056d82-bd14-47b6-81cd-6b7985db27fa">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i8256f225f07d49409c31f7443adffdbf_373"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzU2MjQx_bc5c5ef6-a1ce-4365-834f-0ed2fdd640f6" continuedAt="i98dae3bbc06c4db9908f6bc5d718786a" escape="true">LEGAL PROCEEDINGS</ix:nonNumeric></span></div><ix:continuation id="i98dae3bbc06c4db9908f6bc5d718786a" continuedAt="i487913587fdf4d90bf2d78e7fb070eed"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described below. Going forward, in the Company's subsequent Quarterly Reports on Form 10-Q, the Company will only include a description of these matters to the extent there has been a material update with respect thereto during the applicable quarter or to the extent otherwise required by law.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, the Company evaluates developments in legal proceedings, potential settlements and other matters that could increase or decrease the amount of the liability accrued. As of December 31, 2021, the Company's Consolidated Balance Sheets includes accrued current loss contingencies of $<ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="bhc:Legalsettlementsandrelatedfees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzEyNjY_6632df50-e56e-4967-a221-cc14bdea41e8">1,890</ix:nonFraction> million related to matters which the Company believes a potential resolution or settlement is both probable and reasonably estimable. For all other matters, unless otherwise indicated, the Company cannot reasonably predict the outcome of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company&#8217;s business, financial condition and results of operations, and could cause the market value of its common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental and Regulatory Inquiries</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigation by the U.S. Attorney's Office for the District of Massachusetts - re OraPharma</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts, requesting materials including documents concerning the sales, marketing, coverage and reimbursement of Arestin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including related support services, and other matters.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is cooperating with this investigation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities and RICO Class Actions and Related Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2019, the Company announced that it had agreed to settle, subject to final court approval, the consolidated securities class action filed in the U.S. District Court for the District of New Jersey (In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658). On January 31, 2021, the District Court </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i487913587fdf4d90bf2d78e7fb070eed" continuedAt="id5f322fc76d14fd89aa17708756e4349"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued an order granting final approval of this settlement. On February 4, 2021, Timber Hill LLC filed a notice of appeal of the Court&#8217;s final approval order, which overruled its objections to the allocation of settlement proceeds as between common stock and options.  On March 1, 2021, Cathy Lochridge filed a notice of appeal of the Court&#8217;s final approval order, which overruled her objections as to the attorneys&#8217; fees awarded to class counsel. On October 14, 2021, Timber Hill dismissed its appeal of the final approval order. On December 20, 2021, the Third Circuit denied Lochridge&#8217;s appeal. On January 3, 2022, Lochridge filed a petition for rehearing of the appeal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">en banc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which remains pending.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2015, <ix:nonFraction unitRef="case" contextRef="i574ece8cc22045c08b39e4da379ec989_D20151001-20151031" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzM3MjY_aa46ab29-07f7-4cbd-b76e-53b2cddcb660">four</ix:nonFraction> putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. The allegations related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company&#8217;s business and prospects, including relating to drug pricing, the Company&#8217;s use of specialty pharmacies, and the Company&#8217;s relationship with Philidor. On May 31, 2016, the court entered an order consolidating the <ix:nonFraction unitRef="case" contextRef="i574ece8cc22045c08b39e4da379ec989_D20151001-20151031" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzQyNjc_182648f3-8cf7-4c70-9b65-9b47be6b283f">four</ix:nonFraction> actions under the caption In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658. On December 16, 2019, the Company, the current or former officers and directors, ValueAct, and the underwriters announced that they agreed to resolve the securities action for $<ix:nonFraction unitRef="usd" contextRef="i6ba274da5cb54b1daae13438db70ae34_D20191216-20191216" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzQ1Njc_e0ac410a-911e-4855-8b78-b9dac1dcb563">1,210</ix:nonFraction> million, subject to final court approval. This settlement received final approval from the court on January 31, 2021 and will resolve and discharge all claims against the Company in the class action.  As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. The settlement remains subject to an appeal of the final court approval (as such appeal is further described above). In order to qualify for a settlement payment all persons and entities that purchased or otherwise acquired the Company securities during the class period must have submitted a proof of claim and release form by May 6, 2020. The settlement payments have been paid into an escrow account in accordance with the payment schedule outlined in the settlement agreement. These payments, less certain settlement expenses and attorneys' fees, will remain in escrow until resolution of the appeal of the final court approval of the settlement agreement. The opt-out litigations discussed below remain ongoing. As of December 31, 2021, Restricted cash and other settlement deposits includes an aggregate $<ix:nonFraction unitRef="usd" contextRef="i546776d7d59544bda0c885c5725afaef_D20211231-20211231" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzU2OTM_2dad565c-e3ff-4460-9f0f-adf868414324">1,210</ix:nonFraction>&#160;million of: (i) payments in the escrow fund and (ii) certain disbursements for settlement expenses and attorney's fees. Disbursements for attorney's fees remain refundable until resolution of the appeal of the final court approval of the settlement agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2018, a putative class action was filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. This action, captioned Timber Hill LLC, v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 18-cv-10246) (&#8220;Timber Hill&#8221;), asserts securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons who purchased call options or sold put options on the Company&#8217;s common stock during the period January 4, 2013 through August 11, 2016.  On June 11, 2018, this action was consolidated with In re Valeant Pharmaceuticals International, Inc. Securities Litigation, (Case No. 15-cv-07658).  On January 14, 2019, the defendants filed a motion to dismiss the Timber Hill complaint. Briefing on that motion was completed on February 13, 2019. On August 15, 2019, the Court denied the motion to dismiss the Timber Hill action, holding that this complaint was a legal nullity as a result of the June 11, 2018 consolidation order.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the consolidated putative class action, <ix:nonFraction unitRef="group" contextRef="i0a8688d163da4bddb3dfdc9ef920e0fb_D20210101-20211231" decimals="INF" name="bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzcwNjc_59fb786d-26df-4412-ab31-5b86fcc26866">thirty-seven</ix:nonFraction> groups of individual investors in the Company&#8217;s stock and debt securities have chosen to opt out of the consolidated putative class action and filed securities actions in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. These actions are captioned: T. Rowe Price Growth Stock Fund, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-5034); Equity Trustees Limited as Responsible Entity for T. Rowe Price Global Equity Fund v. Valeant Pharmaceuticals International Inc. (Case No. 16-cv-6127); Principal Funds, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-6128); BloombergSen Partners Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7212); Discovery Global Citizens Master Fund, Ltd. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7321); MSD Torchlight Partners, L.P. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7324); BlueMountain Foinaven Master Fund, L.P. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7328) (&#8220;BlueMountain&#8221;); Incline Global Master LP v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7494); VALIC Company I v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7496); Janus Aspen Series v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7497) (&#8220;Janus Aspen&#8221;); Okumus Opportunistic Value Fund, LTD v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-6513) (&#8220;Okumus&#8221;); Lord Abbett Investment Trust- Lord Abbett Short Duration Income Fund, v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-6365) (&#8220;Lord Abbett&#8221;); Pentwater Equity Opportunities Master Fund LTD v. Valeant Pharmaceuticals International, Inc., et al. (Case No. 17-cv-7552) (&#8220;Pentwater&#8221;); Public Employees&#8217; Retirement System of Mississippi v. Valeant Pharmaceuticals International Inc. (Case No. 17-cv-7625) (&#8220;Mississippi&#8221;); The Boeing Company Employee Retirement Plans Master Trust v. Valeant Pharmaceuticals International Inc., et al., (Case No. 17-cv-7636) (&#8220;Boeing&#8221;); State Board of Administration of Florida v. Valeant Pharmaceuticals International Inc. (Case No. 17-cv-12808); The Regents of the University of California v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-13488); GMO Trust v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0089); F&#246;rsta AP Fonden v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-12088); New York City Employees&#8217; Retirement System v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0032) </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="id5f322fc76d14fd89aa17708756e4349" continuedAt="iab133336502148aeb5ddbc8becb8b8d5"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;NYCERS&#8221;); Hound Partners Offshore Fund, LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-08705) (&#8220;Hound Partners&#8221;); Blackrock Global Allocation Fund, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0343) (&#8220;Blackrock&#8221;); Colonial First State Investments Limited As Responsible Entity for Commonwealth Global Shares Fund 1 v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0383); Bharat Ahuja v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0846); Brahman Capital Corp. v. Valeant Pharmaceuticals International, Inc (Case No. 18-cv-0893); The Prudential Insurance Company of America v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-01223) (&#8220;Prudential&#8221;); Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) (&#8220;Senzar&#8221;); 2012 Dynasty UC LLC v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-08595) (&#8220;2012 Dynasty&#8221;); Catalyst Dynamic Alpha Fund v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-12673) (&#8220;Catalyst&#8221;); Northwestern Mutual Life Insurance Co., v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-15286) (&#8220;Northwestern Mutual&#8221;); Bahaa Aly, et al. v. Valeant Pharmaceuticals International, Inc., (Case No. 18-cv-17393) (&#8220;Aly&#8221;); Office of the Treasurer as Trustee for the Connecticut Retirement Plans and Trust Funds v. Valeant Pharmaceuticals International, Inc. (Case No. 19-cv-18473) (&#8220;Connecticut&#8221;); Delaware Public Employees&#8217; Retirement System v. Valeant Pharmaceuticals International, Inc. (Case No. 19-cv-18475) (&#8220;Delaware&#8221;); Maverick Neutral Levered Fund v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-02190) (&#8220;Maverick&#8221;), Templeton v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-05478) (&#8220;Templeton&#8221;), USAA Mutual Funds Trust, et al. v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 20-cv-07462) (&#8220;USAA&#8221;), and GIC Private Ltd. v. Valeant Pharmaceuticals International, Inc., (Case No. 20-cv-07460) (&#8220;GIC&#8221;). <ix:nonFraction unitRef="case" contextRef="i0a8688d163da4bddb3dfdc9ef920e0fb_D20210101-20211231" decimals="INF" name="us-gaap:LossContingencyClaimsDismissedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzExNzE2_fcdc282f-b32a-4935-b918-ce267321c631">Sixteen</ix:nonFraction> of the <ix:nonFraction unitRef="group" contextRef="i0a8688d163da4bddb3dfdc9ef920e0fb_D20210101-20211231" decimals="INF" name="bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzExNzI2_59fb786d-26df-4412-ab31-5b86fcc26866">thirty-seven</ix:nonFraction> opt-out actions have been dismissed; and the total number of remaining opt-out actions pending in the District of New Jersey is <ix:nonFraction unitRef="group" contextRef="i0a8688d163da4bddb3dfdc9ef920e0fb_D20210101-20211231" decimals="INF" name="bhc:LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzExODU3_1f65c35a-7736-4813-a61f-336d916f236b">twenty-one</ix:nonFraction> actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These individual shareholder actions assert claims under Sections 10(b), and 20(a) of the Exchange Act. Certain of these individual actions assert additional claims, including claims under Section 18 of the Exchange Act, Sections 11, 12(a)(2), and 15 of the Securities Act, common law fraud, negligent misrepresentation, and claims under the New Jersey Racketeer Influenced and Corrupt Organizations Act. These claims are based on alleged purchases of Company stock, options, and/or debt at various times between January 3, 2013 and August 10, 2016. The allegations in the complaints are similar to those made by plaintiffs in the putative class action. Motions to dismiss have been filed and in most cases decided in many of these individual actions. To date, the Court has dismissed state law claims including New Jersey Racketeer Influenced and Corrupt Organizations Act, common law fraud, and negligent misrepresentation claims in certain cases. On January 7, 2019, the Court entered a stipulation of voluntary dismissal in the Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) opt-out action, closing the case.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 10, 2019, the Court granted defendants&#8217; motion to dismiss all claims in the Bahaa Aly v. Valeant Pharmaceuticals International, Inc. (&#8220;Aly&#8221;) (Case No. 18-cv-17393) opt-out action. On October 9, 2019, the Aly Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Third Circuit. On June 16, 2021, the Court of Appeals granted plaintiffs&#8217; appeal in the Aly action. This action has been remanded to the District Court. On June 19, 2020, the Court entered stipulations of voluntary dismissal in the Catalyst, Mississippi, Connecticut, and Delaware actions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 13, 2020, the Court entered a stipulation of voluntary dismissal in the NYCERS action. On December 30, 2020, the Court entered a stipulation of voluntary dismissal in the BlueMountain action. On February 18, 2021, and March 10, 2021, the Court entered stipulations of voluntary dismissal in the T. Rowe, BloombergSen, Principal Funds, Pentwater, Lord Abbett, Equity Trustees, and UC Regents actions. On April 30, 2021, the Court entered a stipulation of voluntary dismissal in the Florida SBA action.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2021, the Court entered a stipulation of voluntary dismissal in the Janus action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims against it in the remaining individual opt-out complaints and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canadian Securities Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, <ix:nonFraction unitRef="case" contextRef="i721131c964b147fab4e1a6b8f95b4460_D20150101-20151231" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzE0NDA4_3a1669ad-3abf-4e32-bbcf-7566097f8352">six</ix:nonFraction> putative class actions were filed and served against the Company and certain current or former officers and directors in Canada in the provinces of British Columbia, Ontario and Quebec. These actions are captioned: (a) Alladina v. Valeant, et al. (Case No. S-1594B6) (Supreme Court of British Columbia) (filed November 17, 2015); (b) Kowalyshyn v. Valeant, et al. (CV-15-540593-00CP) (Ontario Superior Court) (filed November 16, 2015); (c) Kowalyshyn et al. v. Valeant, et al. (CV-15-541082-00CP) (Ontario Superior Court) (filed November 23, 2015); (d) O&#8217;Brien v. Valeant et al. (CV-15-543678-00CP) (Ontario Superior Court) (filed December 30, 2015); (e) Catucci v. Valeant, et al. (Court File No. 540-17-011743159, then Court File No. 500-06-000783-163) (Quebec Superior Court) (filed October 26, 2015); and (f) Rousseau-Godbout v. Valeant, et al. (Court File No. 500-06-000770-152) (Quebec Superior Court) (filed October 27, 2015). </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also aware of <ix:nonFraction unitRef="action" contextRef="i522c83d185a3433eb7ebdb03a1574f39_D20210101-20211231" decimals="INF" name="bhc:LossContingencyNewClaimsFiledButNotYetServedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzE1Mzc1_4da8c2fc-18aa-49ba-bbf6-16a65311bc20">two</ix:nonFraction> additional putative class actions that were filed with the applicable court but which have not been served on the Company. These actions are captioned: (i) Okeley v. Valeant, et al. (Case No. S-159991) (Supreme Court of British Columbia) (filed December 2, 2015); and (ii) Sukenaga v Valeant et al. (CV-15-540567-00CP) (Ontario </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="iab133336502148aeb5ddbc8becb8b8d5" continuedAt="i374567ffa6164395990c585587510262"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Superior Court) (filed November 16, 2015), and the factual allegations made in these actions are substantially similar to those outlined herein.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actions generally allege violations of Canadian provincial securities legislation on behalf of putative classes of persons who purchased or otherwise acquired securities of the Company for periods commencing as early as January 1, 2013 and ending as late as November 16, 2015. The alleged violations relate to the same matters described in the U.S. Securities Litigation description above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these putative class actions, other than the Catucci action in the Quebec Superior Court, was discontinued. In the Catucci action, on August 29, 2017, the judge granted the plaintiffs leave to proceed with their claims under the Quebec Securities Act and authorized the class proceeding.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 26, 2017, the plaintiffs issued their Judicial Application Originating Class Proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a hearing on November 11, 2019, the court approved a settlement in the Catucci action between the class members and the Company&#8217;s auditors and the action was dismissed as against them. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2020, the Company entered into a settlement agreement with the plaintiffs in Catucci, on behalf of the class, pursuant to which it agreed to resolve the Catucci action for the amount of CAD <ix:nonFraction unitRef="cad" contextRef="i3d14d3034bc54cf58ac8ef0977e6b643_D20200804-20200804" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzE3MDM4_1db2b7ab-40ff-4ca7-8bbd-9613177f7790">94</ix:nonFraction> million plus payment of an additional amount to cover notice and settlement administration costs and disbursements.  As part of the settlement, the Company and the other defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. Court approval of the settlement was granted after a hearing on November 16, 2020. The Catucci action has now been dismissed against the Company, its current and former directors and officers, its underwriters and its insurers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the class proceedings described above, on April 12, 2018, the Company was served with an application for leave filed in the Quebec Superior Court of Justice to pursue an action under the Quebec Securities Act against the Company and certain current or former officers and directors. This proceeding is captioned BlackRock Asset Management Canada Limited et al. v. Valeant, et al. (Court File No. 500-11-054155-185). The allegations in the proceeding are similar to those made by plaintiffs in the Catucci class action.  On June 18, 2018, the same BlackRock entities filed an originating application (Court File No. 500-17-103749-183) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is aware that certain other members of the Catucci class exercised their opt-out rights prior to the June 19, 2018 deadline. On February 15, 2019, <ix:nonFraction unitRef="entity" contextRef="i0288b667636240ca9edb0931e9570cbf_I20190215" decimals="INF" name="bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzE4NDY0_f8aac46e-4d34-4b59-ae0b-6477175c35bc">one</ix:nonFraction> of the entities which exercised its opt-out rights, the California State Teachers' Retirement System (&#8220;CalSTRS&#8221;), served the Company with an application in the Quebec Superior Court of Justice for leave to pursue an action under the Quebec Securities Act against the Company, certain current or former officers and directors of the Company and its auditor. That proceeding is captioned California State Teachers&#8217; Retirement System v. Bausch Health Companies Inc. et al. (Court File No. 500-11-055722-181). The allegations in the proceeding are similar to those made by the plaintiffs in the Catucci class action and in the BlackRock opt-out proceedings. On that same date, CalSTRS also served the Company with proceedings (Court File No. 500-17-106044-186) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2020, the Quebec Superior Court granted the applications of CalSTRS and BlackRock for leave to pursue their respective actions asserting claims under the Quebec Securities Act. On June 16, 2020, the Quebec Court of Appeal granted the defendants leave to appeal that decision. The appeal was heard on September 29, 2021 and, by judgment dated October 29, 2021, the appeals were dismissed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8 and 9, 2020, respectively, CalSTRS amended its proceedings to, among other things, include a new alleged misrepresentation concerning the accounting treatment of &#8220;price appreciation credits&#8221; in respect of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the period covered by the claims. A hearing was held on February 17, 2021 with respect to whether CalSTRS would be permitted to file the proposed amended proceedings. On June 9, 2021, the Quebec Superior Court granted the Company&#8217;s application to strike the new allegations from its Quebec Securities Act claim, but permitted the amendments to its claim under the Quebec Civil Code. On December 8, 2021, CalSTRS delivered its amended pleadings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2021, <ix:nonFraction unitRef="numberofbusiness" contextRef="i7a3cc564cfa54644914c3dd2984b2e99_I20210317" decimals="INF" name="bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzIwNDUw_749ba614-d108-4b98-9914-afdad924e890">four</ix:nonFraction> additional opt-outs from the Catucci class issued a Statement of Claim in the Ontario Superior Court of Justice. That proceeding is captioned The Bank of Korea et al. v. Valeant Pharmaceuticals International Inc. et al. (Court File No. 21-00658966-0000). In addition, these plaintiffs also served and filed a motion for leave to pursue claims under the Ontario Securities Act. The allegations in this proceeding are similar to those made by the plaintiffs in the Catucci class action and the plaintiffs in the opt-out actions described above. </span></div><div style="margin-top:7.5pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it has viable defenses in each of these actions. In each case, the Company intends to defend itself vigorously.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i374567ffa6164395990c585587510262" continuedAt="i6727919907704f528aa8856d9e2b3b4e"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RICO Class Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between May 27, 2016 and September 16, 2016, <ix:nonFraction unitRef="action" contextRef="ic99388c5fb8449b4b2899f64833edd24_D20160527-20160916" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzIxMTk5_fb7b2580-3098-4547-8398-b13004f38669">three</ix:nonFraction> actions were filed in the U.S. District Court for the District of New Jersey against the Company and various third-parties (these actions were subsequently consolidated), alleging claims under the federal Racketeer Influenced Corrupt Organizations Act (&#8220;RICO&#8221;) on behalf of a putative class of certain third-party payors that paid claims submitted by Philidor for certain Company-branded drugs between January 2, 2013 and November 9, 2015.&#160; The consolidated complaint alleges, among other things, that the defendants committed predicate acts of mail and wire fraud by submitting or causing to be submitted prescription reimbursement requests that misstated or omitted facts regarding: (1) the identity and licensing status of the dispensing pharmacy; (2) the resubmission of previously denied claims; (3) patient co-pay waivers; (4) the availability of generic alternatives; and (5) the insured&#8217;s consent to renew the prescription.&#160; The complaint further alleges that these acts constitute a pattern of racketeering or a racketeering conspiracy in violation of the RICO statute and caused plaintiffs and the putative class unspecified damages, which may be trebled under the RICO statute.  On August 4, 2021, the Company executed a stipulation of settlement for this action and, on August 17, 2021, the Court preliminarily approved the settlement.  On December 6, 2021 the Special Master overseeing this litigation issued a report and recommendation recommending final approval of the settlement, and on February 22, 2022 the settlement was approved by the district court. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Coverage Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2017, the Company filed a lawsuit against its insurance companies that issued insurance policies covering claims made against the Company, its subsidiaries, and its directors and officers during <ix:nonFraction unitRef="insurance_policy_period" contextRef="ib788085ae68b43f5be26854e2e649395_D20171207-20171207" decimals="INF" name="bhc:LossContingencyNumberOfInsurancePolicyPeriods" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzIzMDEz_6eb28166-4542-4b30-a299-5bd6c3984e0c">two</ix:nonFraction> distinct policy periods, (i) 2013-14 and (ii) 2015-16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lawsuit is currently pending in the United States District Court for the District of New Jersey (Valeant Pharmaceuticals International, Inc., et al. v. AIG Insurance Company of Canada, et al.; 3:18-CV-00493).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the lawsuit, the Company seeks coverage for: (i) the costs of defending and resolving claims brought by former shareholders and debtholders of Allergan, Inc. in In re Allergan, Inc. Proxy Violation Securities Litigation and Timber Hill LLC, individually and on behalf of all others similarly situated v. Pershing Square Capital Management, L.P., et al. (the &#8220;Allergan Securities Litigation&#8221;) (under the 2013-2014 coverage period), and (ii) costs incurred and to be incurred in connection with the securities class actions and opt-out cases described in this section and the SEC Investigation and certain of the other investigations described under &#8220;Complete or Inactive Matters&#8221; in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC and the CSA on February 24, 2021 and under &#8220;Governmental and Regulatory Inquiries&#8221; and &#8220;Complete or Inactive Matters&#8221; in Note 21, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC and the CSA on February 19, 2020 (under the 2015-2016 coverage period).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2021, the Company entered into settlement agreements with the insurers in the 2015-2016 coverage period in which the Company agreed to resolve its claims for insurance coverage in connection with the U.S. Securities Litigation and the Canadian Securities Litigation and related opt-out litigation and related investigations matters described above.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On that same day, the Company entered into settlement agreements with <ix:nonFraction unitRef="insured" contextRef="ia2292d9d54a74b14a40833c7ee03e2c0_I20210720" decimals="INF" name="bhc:LossContingencySettlementAgreementsNumberOfInsurers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzI0OTc4_63dd2055-3a41-4e84-8c9d-8bbaddc5802c">two</ix:nonFraction> of its insurers in the 2013-2014 coverage period in which the Company agreed to resolve its claims against those <ix:nonFraction unitRef="insured" contextRef="ia2292d9d54a74b14a40833c7ee03e2c0_I20210720" decimals="INF" name="bhc:LossContingencySettlementAgreementsNumberOfInsurers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzI1MDk0_cc6d1513-403d-427f-b7f8-f7eae0a6870d">two</ix:nonFraction> insurers only for insurance coverage in connection with the Allergan Securities Litigation. As a result of all of the settlement agreements entered into with the insurers on July 20, 2021, the Company has received an aggregate sum of $<ix:nonFraction unitRef="usd" contextRef="i10b5c7db69ef4006bcb53437d3aa06b8_D20210720-20210720" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzI1MzMx_af664376-a160-4038-af98-92909c57a39e">213</ix:nonFraction>&#160;million. The Company&#8217;s insurance claims with respect to the Allergan Securities Litigation against the remaining insurers in the 2013-2014 coverage period remain pending.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hound Partners Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, Hound Partners Offshore Fund, LP, Hound Partners Long Master, LP, and Hound Partners Concentrated Master, LP, filed a lawsuit against the Company in the Superior Court of New Jersey Law Division/Mercer County.  This action is captioned Hound Partners Offshore Fund, LP et al., v. Valeant Pharmaceuticals International, Inc., et al. (No. MER-L-002185-18).  This suit asserts claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act. The Company disputes the claims and intends to vigorously defend this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pricing Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's subsidiaries, Oceanside Pharmaceuticals, Inc. (&#8220;Oceanside&#8221;), Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) (&#8220;Bausch Health US&#8221;), and Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International) (&#8220;Bausch Health Americas&#8221;) (for the purposes of this paragraph, collectively, the &#8220;Company&#8221;), are defendants in multidistrict antitrust litigation (&#8220;MDL&#8221;) entitled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Generic Pharmaceuticals Pricing </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i6727919907704f528aa8856d9e2b3b4e" continuedAt="ic85c28883ec4413092167ce2b71e6dae"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, pending in the United States District Court for the Eastern District of Pennsylvania (MDL No. 2724, 16-MD-2724). The lawsuits seek damages under federal and state antitrust laws, state consumer protection and unjust enrichment laws and allege that the Company&#8217;s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals. The lawsuits, which have been brought as putative class actions by direct purchasers, end payers, and indirect resellers, and as direct actions by direct purchasers, end payers, insurers, States, and various Counties, Cities, and Towns, have been consolidated into the MDL. There are also additional, separate complaints which have been consolidated in the same MDL that do not name the Company or any of its subsidiaries as a defendant. There are cases pending in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed in the cases. The cases have been put in deferred status. The Company disputes the claims against it and continues to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Bausch Health Companies Inc. and certain U.S. and Canadian subsidiaries (for the purposes of this paragraph, collectively &#8220;the Company&#8221;) have been named as defendants in a proposed class proceeding entitled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kathryn Eaton v. Teva Canada Limited, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Federal Court in Toronto, Ontario, Canada (Court File No. T-607-20). The plaintiff seeks to certify a proposed class action on behalf of persons in Canada who purchased generic drugs in the private sector, alleging that the Company and other defendants violated the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Competition Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by conspiring to allocate the market, fix prices, and maintain the supply of generic drugs, and seeking damages under federal law. The proposed class action contains similar allegations to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Generic Pharmaceuticals Pricing Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> pending in the United States Court for the Eastern District of Pennsylvania. The Company disputes the claims against it and will defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza State-Law Insurer Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2021, the insurer plaintiff from the federal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822-WHA (N.D. Cal.) (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) (discussed in further detail below) filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#8220;State Court Action&#8221;).  The State Court Action alleges that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or grant any other company a license to do so.  The State Court Action alleges that the settlement agreement resulted in higher prices for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. On September 20, 2021, the parties stipulated that the insurer plaintiff&#8217;s direct opt-out claims from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, discussed below, were deemed asserted in the State Court Action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defendants&#8217; demurrer in the State Court Action was heard on September 22, 2021.  On November 11, 2021, the court denied the motion in part and granted it in part as to certain state law claims, with leave to amend.  The insurer plaintiff did not amend the complaint. Defendants&#8217; answers were filed on February 3, 2022. The Company disputes the claims and intends to vigorously defend this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Litigation/Paragraph IV Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company (and/or certain of its affiliates) is also party to certain patent infringement proceedings in the United States and Canada, including as arising from claims filed by the Company (or that the Company anticipates filing within the required time periods) in connection with Notices of Paragraph IV Certification (in the United States) and Notices of Allegation (in Canada) received from third-party generic manufacturers respecting their pending applications for generic versions of certain products sold by or on behalf of the Company, including Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 550mg, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Injection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States, and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Canada or other similar suits.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2020, the Company and Alfasigma S.p.A.  (&#8220;Alfasigma&#8221;) received a Notice of Paragraph IV Certification from Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;), in which Norwich asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Norwich&#8217;s generic rifaximin tablets, 550 mg, for which an Abbreviated New Drug Application (&#8220;ANDA&#8221;) has been filed by Norwich. The Company, through its subsidiaries Salix Pharmaceuticals, Inc. and Bausch Health Ireland Limited, holds the New Drug Application for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and owns or exclusively licenses (from Alfasigma) these patents.  On March 26, 2020, certain of the Company&#8217;s subsidiaries and Alfasigma filed suit against Norwich in the U.S. District Court for the District of Delaware (Case No. 20-cv-00430) pursuant to the Hatch-Waxman Act, alleging infringement by Norwich of one or more claims of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a <ix:nonNumeric contextRef="i8d3399dca8844555b1a0224ee52572bb_D20190901-20190930" name="bhc:LossContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzMyMDgy_538512f7-0f0e-450f-a83b-31d3fc5baad9">30</ix:nonNumeric>-month stay of the approval of Norwich&#8217;s ANDA for rifaximin tablets, 550 mg. Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is protected by 26 patents covering the composition of matter and the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. A 3-day bench trial is scheduled to begin March 21, 2022. The Company </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ic85c28883ec4413092167ce2b71e6dae" continuedAt="ib7d1220a7b074807960c098e22829a12"><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">remains confident in the strength of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will continue to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (now Padagis LLC) (&#8220;Padagis&#8221;), in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA's Orange Book for Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotine) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#8217; generic lotion, for which an ANDA has been filed by Padagis.  On August 28, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a <ix:nonNumeric contextRef="i416608f63c8f48baa9c46a05acc57dba_D20200828-20200828" name="bhc:LossContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzMzMjY2_e99dd0ba-a747-4aa4-b881-353dcd248238">30</ix:nonNumeric>-month stay of the approval of the Padagis ANDA.  On September 3, 2020, this action was consolidated with the action between the Company and Padagis described below, regarding Padagis&#8217; ANDA for generic Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion. The Company remains confident in the strength of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related patents and will vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Padagis, in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#8217; generic halobetasol propionate lotion, for which an ANDA has been filed by Padagis.  On May 1, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a <ix:nonNumeric contextRef="i20d7a644460c4ab7b2d3fc7e95d5d3c7_D20200501-20200501" name="bhc:LossContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzM0Mjg0_67da5d03-e833-4ca3-a2d7-b0c02d941737">30</ix:nonNumeric>-month stay of the approval of the Padagis ANDA for halobetasol propionate lotion. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described above, regarding Padagis&#8217; ANDA for generic Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotine) lotion. The Company remains confident in the strength of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company commenced litigation against MSN Laboratories Private Ltd. (&#8220;MSN&#8221;) and Mylan Pharmaceuticals Inc., (&#8220;Mylan&#8221;) alleging patent infringement by MSN&#8217;s and Mylan&#8217;s filing of their ANDA for generic Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) 3mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from each of MSN and Mylan, in which they had each asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 3 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of their respective generic plecanatide tablets, 3 mg.  The filing of these suits triggered a <ix:nonNumeric contextRef="iad566679ccb740d78397815ac12d9b44_D20210401-20210430" name="bhc:LossContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzM1NDMx_96181824-8fa3-4baf-84aa-087eb5acc71b">30</ix:nonNumeric>-month stay of the approval of the MSN and Mylan ANDAs for plecanatide tablets. The Company remains confident in the strength of the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company commenced litigation against Slayback Pharma LLC and Slayback Pharma India LLP (together, &#8220;Slayback&#8221;) alleging patent infringement by Slayback Pharma LLC&#8217;s filing of its ANDA No. 216361, referencing Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (0.025% brimonidine tartrate ophthalmic solution). This suit had been filed following receipt of a Notice of Paragraph IV Certification from Slayback Pharma LLC, in which it had asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brimonidine tartrate ophthalmic solution, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of its generic brimonidine tartrate solution.  The filing of this suit triggered a <ix:nonNumeric contextRef="id9d5c1c1399a4c59b08e7d331695b3a6_D20210901-20210930" name="bhc:LossContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzM2NDA1_7962c290-73de-44d9-8d8d-b5f220aeedcb">30</ix:nonNumeric>-month stay of the approval of the Slayback ANDA for its brimonidine tartrate solution.  The Company remains confident in the strength of the Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2022 the Company commenced litigation against Lupin Pharmaceuticals, Inc. (&#8220;Lupin&#8221;) alleging patent infringement by Lupin&#8217;s filing of its ANDA No. 216716, referencing Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (0.025% brimonidine tartrate ophthalmic solution). This suit had been filed following receipt of a Notice of Paragraph IV Certification from Lupin, in which it had asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brimonidine tartrate ophthalmic solution, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of its generic brimonidine tartrate solution.  The filing of this suit triggered a <ix:nonNumeric contextRef="ie5f2cff0c15c4497abb7c0bb38853653_D20220202-20220202" name="bhc:LossContingencyStayOfApprovalPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzM3MzAx_22b73222-aaf9-40fe-bb8c-0e74ac0bc253">30</ix:nonNumeric>-month stay of the approval of the Lupin ANDA for its brimonidine tartrate solution. The Company remains confident in the strength of the Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will continue to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jublia Patent Litigation</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, patents covering the Company's branded pharmaceutical products may be challenged in proceedings other than court proceedings, including inter partes review (&#8220;IPR&#8221;) at the U.S. Patent &amp; Trademark Office. The proceedings operate under different standards from district court proceedings, and are often completed within 18 months of institution. IPR challenges have been brought against patents covering the Company's branded pharmaceutical products. For example, following Acrux DDS&#8217;s IPR petition, the U.S. Patent and Trial Appeal Board  (&#8220;PTAB&#8221;), in May 2017, instituted inter partes review for an Orange Book-listed patent covering Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(U.S. Patent No. 7,214,506 (the &#8220;&#8216;506 Patent&#8221;)) and, on </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="ib7d1220a7b074807960c098e22829a12" continuedAt="i4c9795b2150549fdbf20f5c80b57b2f8"><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 6, 2018, issued a written determination invalidating such patent. An appeal of this decision was filed on August 7, 2018. On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings.  As a result of a settlement, a joint motion to terminate the proceedings was filed on November 12, 2020 and, on January 8, 2021, the PTAB granted this motion.   The &#8216;506 Patent, therefore, remains valid and enforceable and expires in 2026. Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is covered by fourteen Orange Book-listed patents owned by the Company or its licensor, which expire in the years 2028 through 2035. In August and September 2018, the Company received notices of the filing of a number of ANDAs with paragraph IV certification, and has timely filed patent infringement suits against these ANDA filers, and, in addition, the Company has also commenced certain patent infringement proceedings in Canada against four separate defendants.  All cases in the U.S. regarding Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been settled. In Canada, <ix:nonFraction unitRef="case" contextRef="i1bdbb266b2064e05970e5019800e2253_I20211231" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzM5MzQ3_7c16e61e-f98c-4510-92dc-409314519d84">two</ix:nonFraction> lawsuits remain pending against Apotex Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Products Liability Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2016, the Company has been named in a number of product liability lawsuits involving the Shower to Shower&#174; body powder product acquired in September 2012 from Johnson &amp; Johnson; due to dismissals, twenty-nine (<ix:nonFraction unitRef="case" contextRef="i8167d807dd934310925525373a61a11f_I20211231" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzM5Njc3_c586af71-0bae-45cd-be32-6ce58bce0bf0">29</ix:nonFraction>) of such product liability suits currently remain pending. Potential liability (including its attorneys&#8217; fees and costs) arising out of these remaining suits is subject to full indemnification obligations of Johnson &amp; Johnson owed to the Company and its affiliates, and legal fees and costs will be paid by Johnson &amp; Johnson. Twenty-eight (<ix:nonFraction unitRef="case" contextRef="i9b8fdb21d7d648d59dfb6f5b8647cf38_I20211231" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzQwMDIw_86156626-add2-4b00-a5e6-068778bf7cdb">28</ix:nonFraction>) of these lawsuits filed by individual plaintiffs allege that the use of Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> caused the plaintiffs to develop ovarian cancer, mesothelioma or breast cancer. The allegations in these cases include failure to warn, design defect, manufacturing defect, negligence, gross negligence, breach of express and implied warranties, civil conspiracy concert in action, negligent misrepresentation, wrongful death, loss of consortium and/or punitive damages. The damages sought include compensatory damages, including medical expenses, lost wages or earning capacity, loss of consortium and/or compensation for pain and suffering, mental anguish anxiety and discomfort, physical impairment and loss of enjoyment of life. Plaintiffs also seek pre- and post-judgment interest, exemplary and punitive damages, and attorneys&#8217; fees. Additionally, <ix:nonFraction unitRef="case" contextRef="ic7ca0340304c47edaa88616e036f7daf_I20211231" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzQwODY3_abaefb6f-ac93-4878-8e63-c6fb78c34cfc">two</ix:nonFraction> proposed class actions have been filed in Canada against the Company and various Johnson &amp; Johnson entities (<ix:nonFraction unitRef="case" contextRef="ib2a61b2c466048d7a44cf2f37e6f9067_D20211216-20211216" decimals="INF" name="us-gaap:LossContingencyClaimsDismissedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzQwOTc5_77aa1899-c0bb-4888-808f-4c0d1a49b2f8"><ix:nonFraction unitRef="case" contextRef="i4161ab534a444089a14221908e89ca6b_I20211215" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzQwOTc5_d700276a-cf85-490f-94c7-dc3fe5da5315">one</ix:nonFraction></ix:nonFraction> in the Supreme Court of British Columbia and <ix:nonFraction unitRef="case" contextRef="ic25fde520f434990aec8bc4ef672935d_I20211231" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzQxMDI3_7b0e98cf-f7d5-4162-a1de-21b5809cf45d">one</ix:nonFraction> in the Superior Court of Quebec), on behalf of persons who have purchased or used Johnson &amp; Johnson&#8217;s Baby Powder or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The class actions allege the use of the product increases certain health risks (British Columbia) or negligence in failing to properly test, failing to warn of health risks, and failing to remove the products from the market in a timely manner (Quebec). The plaintiffs in these actions are seeking awards of general, special, compensatory and punitive damages. On November 17, 2020, the British Columbia court issued a judgment declining to certify a class as to the Company or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and at this time no appeal of that judgment has been filed. On December 16, 2021, the plaintiff in the British Columbia class action filed a Second Amended Notice of Civil Claim and Application for Certification, removing the Company as a defendant; as a result, the British Columbia class action is concluded as to the Company. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson, through one or more subsidiaries has purported to have completed a Texas divisional merger with respect to any talc liabilities at Johnson &amp; Johnson Consumer, Inc. (&#8220;JJCI&#8221;). LTL Management, LLC (&#8220;LTL&#8221;), the resulting entity of the divisional merger, assumed JJCI&#8217;s talc liabilities and thereafter filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the Western District of North Carolina. Pursuant to a court order, the case was transferred to the United States District Court for the District of New Jersey. Notwithstanding the divisional merger and LTL&#8217;s bankruptcy case, the Company and its affiliates continue to have indemnification claims and rights against Johnson &amp; Johnson and LTL pursuant to the terms of the indemnification agreement entered into between JJCI and its affiliates and the Company and its affiliates, which indemnification agreement remains in effect. As a result, it is the Company's current expectation that it will not incur any material impairments with respect to its indemnification claims as a result of the divisional merger or the bankruptcy. Substantially all cases subject to the indemnification agreement related to Johnson &amp; Johnson&#8217;s talc liability are stayed through February 28, 2022, pursuant to a preliminary injunction issued by the bankruptcy court. Motions to dismiss the LTL bankruptcy, as well as extend the stay beyond February 28, 2022, were argued in the bankruptcy court in February 2022. A decision of the court is pending. To the extent that any cases subject to the indemnification agreement proceed during the pendency of the bankruptcy case, it is the Company's expectation that Johnson &amp; Johnson, in accordance with the indemnification agreement, will continue to vigorously defend the Company in each of the remaining actions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Civil Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Proposition 65 Related Matter</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2019, plaintiffs filed a proposed class action in California state court against Bausch Health US and Johnson &amp; Johnson (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gutierrez, et al. v. Johnson &amp; Johnson, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 37-2019-00025810-CU-NP-CTL), asserting claims for </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i4c9795b2150549fdbf20f5c80b57b2f8" continuedAt="i5090a2d4551c46e0bb6a71412e17c8b9"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">purported violations of the California Consumer Legal Remedies Act, False Advertising Law and Unfair Competition Law in connection with their sale of talcum powder products that the plaintiffs allege violated Proposition 65 and/or the California Safe Cosmetics Act. This lawsuit was served on Bausch Health US in June 2019 and was subsequently removed to the United States District Court for the Southern District of California, where it is currently pending. Plaintiffs seek damages, disgorgement of profits, injunctive relief, and reimbursement/restitution. The Company filed a motion to dismiss Plaintiffs&#8217; claims, which was granted in April 2020 without prejudice. In May 2020, Plaintiffs filed an amended complaint and in June 2020, filed a motion for leave to amend the complaint further, which was granted.  In August 2020, Plaintiffs filed the Fifth Amended Complaint. On January 22, 2021, the Court granted the motion to dismiss with prejudice. On February 19, 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit Court of Appeals. On July 1, 2021, Appellants (Plaintiffs) filed their opening brief; Appellees' response briefs were filed on October 8, 2021. This matter was stayed by the Ninth Circuit on December 7, 2021, due to the preliminary injunction entered by the bankruptcy court in the LTL bankruptcy proceeding. This stay included Appellants&#8217; reply brief deadline, which was previously due to be filed on or before December 2, 2021. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Mexico Attorney General Consumer Protection Action</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US were named in an action brought by State of New Mexico ex rel. Hector H. Balderas, Attorney General of New Mexico, in the County of Santa Fe New Mexico First Judicial District Court (New Mexico ex rel. Balderas v. Johnson &amp; Johnson, et al., Civil Action No. D-101-CV-2020-00013, filed on January 2, 2020), alleging consumer protection claims against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer Companies, Inc., the Company and Bausch Health US related to Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its alleged causal link to mesothelioma and other cancers.  In April 2020, Bausch Health US filed a motion to dismiss, which in September 2020, the Court granted in part as to the New Mexico Medicaid Fraud Act and New Mexico Fraud Against Taxpayers Act claims and denied as to all other claims. The State of New Mexico brings claims against all defendants under the New Mexico Unfair Practices Act and other common law and equitable causes of action, alleging defendants engaged in wrongful marketing, sale and promotion of talcum powder products. The lawsuit seeks to recover the cost of the talcum powder products as well as the cost of treating asbestos-related cancers allegedly caused by those products. Bausch Health US filed its answer on November 16, 2020. On December 30, 2020 Johnson &amp; Johnson filed a Motion for Partial Judgment on the Pleadings and on January 4, 2021, Bausch Health US filed a joinder to that motion, which was denied on March 8, 2021. Trial is scheduled to begin on January 18, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Doctors Allergy Formula Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, Doctors Allergy Formula, LLC (&#8220;Doctors Allergy&#8221;), filed a lawsuit against Bausch Health Americas in the Supreme Court of the State of New York, County of New York, asserting breach of contract and related claims under a 2015 Asset Purchase Agreement, which purports to include milestone payments that Doctors Allergy alleges should have been paid by Bausch Health Americas.  Doctors Allergy claims its damages are not less than $<ix:nonFraction unitRef="usd" contextRef="i8cee0c4f1d894fc3aa19e2148d91bb12_D20180401-20180430" decimals="-6" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzQ3ODgy_b233e803-35c1-418f-b7b8-df2fc5efa5b1">23</ix:nonFraction> million. Bausch Health Americas has asserted counterclaims against Doctors Allergy. Bausch Health Americas filed a motion seeking an order granting Bausch Health Americas summary judgment on its counterclaims against Plaintiff and dismissing Plaintiff&#8217;s claims against it. The motion was fully briefed as of May 2021. The Court held a hearing on the motion on January 25, 2022. The motion remains pending. Bausch Health Americas disputes the claims against it and will continue to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation with Former Salix CEO</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 28, 2019, former Salix Ltd. CEO and director Carolyn Logan filed a lawsuit in the Delaware Court of Chancery, Case No. 2019-0059, asserting claims for breach of contract and declaratory relief.  On November 19, 2021, Logan amended her complaint to add a claim for breach of the implied covenant of good faith and fair dealing. The lawsuit arises out of the contractual termination of approximately $<ix:nonFraction unitRef="usd" contextRef="i2fa7f1086a9a45249ac683ef177587c9_D20190128-20190128" decimals="-6" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzQ4ODI2_a294b7d4-8d9d-4098-be6e-f62aacd7a2de">30</ix:nonFraction> million in unvested equity awards following the determination by the Salix Ltd. Board of Directors that Logan intentionally engaged in wrongdoing that resulted, or would reasonably be expected to result, in material harm to Salix Ltd., or to the business or reputation of Salix Ltd.  Logan seeks the restoration of the unvested equity awards and a declaration regarding certain rights related to indemnification. On June 19, 2019, the Court entered an order staying the claim for declaratory relief pending the final resolution of the breach of contract claim. Trial is scheduled to commence on September 6, 2022. The Company disputes the claims and intends to vigorously defend the matter.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="i5090a2d4551c46e0bb6a71412e17c8b9" continuedAt="iafa7818ad8074733895ec707b3d65b31"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Completed or Inactive Matters</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following matters have concluded, have settled, are the subject of an agreement to settle or have otherwise been closed since January 1, 2021, have been inactive from the Company&#8217;s perspective for several quarters or the Company anticipates that no further material activity will take place with respect thereto. Due to the closure, settlement, inactivity or change in status of the matters referenced below, these matters will no longer appear in the Company's next public reports and disclosures, unless required. With respect to inactive matters, to the extent material activity takes place in subsequent quarters with respect thereto, the Company will provide updates as required or as deemed appropriate.</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza Antitrust Litigation</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between August 2019 and July 2020, eight (<ix:nonFraction unitRef="case" contextRef="i5c84bf2f503a48bcbda0eee28745f465_D20190801-20200730" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzUwMzI4_f9d14f5e-e5a1-47aa-8771-575c10829ed1">8</ix:nonFraction>) putative antitrust class actions and four (<ix:nonFraction unitRef="case" contextRef="ic39bb939c10e450dbd36a0e824f2720b_D20190801-20200730" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzUwMzc1_8ed6bc53-eea6-49a8-8783-1cfb99863d5e">4</ix:nonFraction>) non-class complaints naming Bausch Health Companies Inc., Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., and Santarus, Inc. (for purposes of this subsection, collectively, the &#8220;Company&#8221;), among other defendants, were filed or transferred to the Northern District of California. Three (<ix:nonFraction unitRef="case" contextRef="i7cb1b7f540294b49ad9ef73316d882e6_D20190801-20200730" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzUwNjc1_2131434d-047a-4df3-9cca-51f09745f235">3</ix:nonFraction>) of the class actions were filed by plaintiffs seeking to represent a class of direct purchasers. The purported classes of direct purchasers filed a consolidated first amended complaint and a motion for class certification in April 2020. The court certified a direct purchaser class in August 2020.  The putative class action complaints filed by end payer purchasers have all been voluntarily dismissed. Three (<ix:nonFraction unitRef="case" contextRef="i2e52d3146d5a487e9ca0aeaadf2b0915_D20190801-20200730" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzUxMDg5_ee0e5988-a7e5-460d-b5de-1c973420bb71">3</ix:nonFraction>) of the non-class complaints were filed by direct purchasers. The fourth non-class complaint, asserting claims based on both direct and indirect purchases, was filed by an insurer plaintiff in July 2020 and subsequently amended in September 2020.  In December 2020, the court denied the Company&#8217;s motion to dismiss as to the insurer plaintiff&#8217;s direct claims but dismissed the insurer plaintiff&#8217;s indirect claims. On February 2, 2021, the insurer plaintiff&#8217;s motion for leave to amend its complaint was denied.</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These actions were consolidated and coordinated in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822-WHA (N.D. Cal.) (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The lawsuits alleged that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or grant any other company a license to do so. The complaints alleged that the settlement agreement resulted in higher prices for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. Both the class and non-class plaintiffs sought damages under federal antitrust laws for claims based on direct purchases.</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 26, 2021, the Company reached an agreement in principle and, thereafter, on September 14, 2021, executed a final settlement agreement to resolve the class plaintiffs&#8217; claims for $<ix:nonFraction unitRef="usd" contextRef="i35ef7917c4e846cdb1959043a03d5bca_D20210726-20210726" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzUyNDc2_d0fe508c-7dd9-4441-b4e4-0475250aea8d">300</ix:nonFraction>&#160;million, subject to court approval. On August 1, 2021, the Company also reached an agreement in principle to resolve the non-class direct purchaser plaintiffs&#8217; claims, described above, for additional consideration.  A final settlement agreement with the non-class direct purchaser plaintiffs was executed on August 6, 2021. As part of the settlements, the Company admitted no liability as to the claims against it and denied all allegations of wrongdoing.  On September 20, 2021, the insurer plaintiff voluntarily dismissed its claims in the consolidated federal action. By stipulation, the insurer plaintiff has asserted its direct opt-out claims in the State Court Action, resulting in the consolidation of all of its opt-out claims in the State Court Action.</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 22, 2021, the court granted preliminary approval of the class settlement agreement and vacated the October 2021 trial date and all other pre-trial deadlines in the consolidated actions. On February 3, 2022, the court granted final  approval of the class settlement and ordered dismissal of the class plaintiffs' claims. Subject to appeal of the final approval of the class settlement, the settlements will resolve and discharge all asserted class and direct purchaser non-class claims against the Company in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Proposition 65 Related Matter</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 29, 2020, Plaintiff Jan Graham filed a lawsuit (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Graham v. Bausch Health Companies, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 20STCV03578) in Los Angeles County Superior Court against the Company, Bausch Health US and several other manufacturers, distributors and retailers of talcum powder products, alleging violations of California Proposition 65 by manufacturing and distributing talcum powder products containing chemicals listed under the statue, without a compliant warning on the label. On January 29, 2021, certain defendants including the Company and Bausch Health US filed a Motion for Summary Judgment or in the Alternative Motion for Summary Adjudication, which was granted with prejudice on May 26, 2021; Plaintiff waived the right to appeal.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Lawsuits</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 10, 2019 and September 13, 2019, <ix:nonFraction unitRef="shareholder" contextRef="iff2a848fa15e484ba0fd1a37bd47732e_I20190910" decimals="INF" name="bhc:LossContingencyNumberOfAllegedStockholdersFiledLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzU0NjUw_51c6042b-18c7-4b48-98a1-72deaf0e3b7e"><ix:nonFraction unitRef="shareholder" contextRef="i6efe4500a1e94445a37235d0071dbc71_I20190913" decimals="INF" name="bhc:LossContingencyNumberOfAllegedStockholdersFiledLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzU0NjUw_c862e7a2-465e-40db-bf48-2d9e8bbdb859">two</ix:nonFraction></ix:nonFraction> alleged stockholders filed derivative lawsuits purportedly on behalf of the Company against former Company board members and executives. On March 7, 2020, a consolidated amended derivative complaint was filed, captioned In re Bausch Health Companies Inc. F/K/A/ Valeant Pharmaceuticals International, Inc. Stockholder Derivative Litigation (Case No. 19-cv-17833). </span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><ix:continuation id="iafa7818ad8074733895ec707b3d65b31"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plaintiffs asserted claims for breach of fiduciary duty, waste of corporate assets, and unjust enrichment related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company&#8217;s business and prospects, including relating to drug pricing, the Company&#8217;s use of specialty pharmacies, and the Company&#8217;s relationship with Philidor. The consolidated complaint also asserted a claim for contribution and indemnification by the Defendants for any liability the Company ultimately faces as a result of the conduct alleged in the complaint. The claims alleged in these cases were based on the same purported conduct that is at issue in In re Valeant Pharmaceuticals International, Inc. Securities Litigation, all of which occurred prior to 2017. On April 21, 2020, the Defendants filed a motion to dismiss the consolidated amended complaint.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Briefing on this motion concluded on August 3, 2020. On November 24, 2020, the Special Master appointed by the Court issued a report recommending that the motion to dismiss be granted in full.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2021, the District Court adopted the report and recommendation of the Special Master and dismissed the action.</span></ix:continuation></div><div id="i8256f225f07d49409c31f7443adffdbf_376"></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">21.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzYvZnJhZzoyYmMyNDgwOTYzZDE0N2M2ODUxYzJiOWNkZDRiM2VmOS90ZXh0cmVnaW9uOjJiYzI0ODA5NjNkMTQ3YzY4NTFjMmI5Y2RkNGIzZWY5XzQ0MDU_30f818ee-b020-446b-a9b3-5776fdef845c" continuedAt="i191255f27ce547bd9e94291a00830773" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i191255f27ce547bd9e94291a00830773" continuedAt="id54e29787b9a44f28b923f57bc40a456"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has commitments related to capital expenditures of approximately $<ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:ContractualObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzYvZnJhZzoyYmMyNDgwOTYzZDE0N2M2ODUxYzJiOWNkZDRiM2VmOS90ZXh0cmVnaW9uOjJiYzI0ODA5NjNkMTQ3YzY4NTFjMmI5Y2RkNGIzZWY5Xzg2_29144e87-d681-42b0-92ad-d0a64c95a8ce">76</ix:nonFraction> million as of December&#160;31, 2021. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain agreements, the Company may be required to make payments contingent upon the achievement of specific developmental, regulatory, or commercial milestones. As of December&#160;31, 2021, the Company believes it is reasonably possible that it may potentially make milestone and license fee payments, including sales-based milestone payments, of approximately $<ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="bhc:CollaborativeAgreementMilestonePaymentsAggregate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzYvZnJhZzoyYmMyNDgwOTYzZDE0N2M2ODUxYzJiOWNkZDRiM2VmOS90ZXh0cmVnaW9uOjJiYzI0ODA5NjNkMTQ3YzY4NTFjMmI5Y2RkNGIzZWY5XzQ0OQ_884238e9-9a55-45a4-a964-7376ab2918b0">340</ix:nonFraction> million over time, in the aggregate, to third parties for products currently under development or being marketed, primarily consisting of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of a June 2013 distribution and supply agreement with Mylan Pharmaceuticals Inc. (as assignee of Spear Pharmaceuticals, Inc and Spear Dermatology Products Inc.), the Company may be required to make sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $<ix:nonFraction unitRef="usd" contextRef="i45d0ac640df44b65a4bc4c22c9500429_I20211231" decimals="INF" name="bhc:CollaborativeAgreementMilestonePaymentsAggregate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzYvZnJhZzoyYmMyNDgwOTYzZDE0N2M2ODUxYzJiOWNkZDRiM2VmOS90ZXh0cmVnaW9uOjJiYzI0ODA5NjNkMTQ3YzY4NTFjMmI5Y2RkNGIzZWY5XzkzNg_b86dab81-a141-4dc4-9ffc-07d97e0355df">70</ix:nonFraction> million, in the aggregate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of an April 2019 agreement with Mitsubishi Tanabe Pharma Corporation, the Company has acquired an exclusive license to develop and commercialize&#160;MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate receptor that plays a role in autoimmune diseases, such as Inflammatory Bowel Disease and ulcerative colitis. The Company may be required to make development and sales-based milestone payments over time of up to $<ix:nonFraction unitRef="usd" contextRef="i5496c79fe37f42a9a6ed6ceefc84608e_I20211231" decimals="INF" name="bhc:CollaborativeAgreementMilestonePaymentsAggregate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzYvZnJhZzoyYmMyNDgwOTYzZDE0N2M2ODUxYzJiOWNkZDRiM2VmOS90ZXh0cmVnaW9uOjJiYzI0ODA5NjNkMTQ3YzY4NTFjMmI5Y2RkNGIzZWY5XzE0MjE_2117ceab-1c81-417d-8432-bb7b96a81c35">60</ix:nonFraction> million, in the aggregate, as well as royalties on future sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of a December 2019 agreement with Novaliq GmbH, the Company has acquired an exclusive license for the commercialization and development in the U.S. and Canada of NOV03 (perfluorohexyloctane), an investigational drug to treat Dry Eye Disease associated with Meibomian gland dysfunction and may be required to make sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $<ix:nonFraction unitRef="usd" contextRef="i76cbbad47b514c08a436d4d6576f412a_I20211231" decimals="INF" name="bhc:CollaborativeAgreementMilestonePaymentsAggregate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzYvZnJhZzoyYmMyNDgwOTYzZDE0N2M2ODUxYzJiOWNkZDRiM2VmOS90ZXh0cmVnaW9uOjJiYzI0ODA5NjNkMTQ3YzY4NTFjMmI5Y2RkNGIzZWY5XzE5MzY_30c24375-e0d4-49f8-9c13-f10a28eaba35">48</ix:nonFraction> million, in the aggregate, as well as royalties on future sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of a November 2019 agreement with Cedars-Sinai Medical Center, to evaluate a new formulation of rifaximin for the treatment of irritable bowel syndrome, the Company may be required to make development and sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $<ix:nonFraction unitRef="usd" contextRef="i5bdf942d40b54fefaef817509211ad3e_I20211231" decimals="INF" name="bhc:CollaborativeAgreementMilestonePaymentsAggregate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzYvZnJhZzoyYmMyNDgwOTYzZDE0N2M2ODUxYzJiOWNkZDRiM2VmOS90ZXh0cmVnaW9uOjJiYzI0ODA5NjNkMTQ3YzY4NTFjMmI5Y2RkNGIzZWY5XzIzNDI_aa8abf5b-8db5-4630-88b8-29f4c11bb8ac">36</ix:nonFraction>&#160;million, in the aggregate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of an October 2020 agreement with Eyenovia, Inc., the Company has acquired an exclusive license in the U.S. and Canada for the development and commercialization of an investigational microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression, also known as nearsightedness, in children ages 3-12. Under the terms of the agreement, the Company may be required to make development and sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $<ix:nonFraction unitRef="usd" contextRef="if4268c1a55cd4a2e89570ee83827d90d_I20211231" decimals="INF" name="bhc:CollaborativeAgreementMilestonePaymentsAggregate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzYvZnJhZzoyYmMyNDgwOTYzZDE0N2M2ODUxYzJiOWNkZDRiM2VmOS90ZXh0cmVnaW9uOjJiYzI0ODA5NjNkMTQ3YzY4NTFjMmI5Y2RkNGIzZWY5XzI5NjI_9f172d5a-2c64-499f-90ca-3f2d70375d39">35</ix:nonFraction>&#160;million, in the aggregate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of a May 2020 agreement with STADA Arzneimittel AG and its development partner, Xbrane Biopharma AB, to commercialize in the U.S. and Canada a biosimilar candidate to Lucentis (ranibizumab), the Company may be required to make development and sales-based milestone payments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of these arrangements, the future potential payments related to the attainment of the specified milestones over a period of several years are inherently uncertain. As of December 31, 2021, no accruals related to the aforementioned agreements exist because the milestone targets are not yet probable of being achieved.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><ix:continuation id="id54e29787b9a44f28b923f57bc40a456"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into agreements that include indemnification provisions for product liability and other matters. These provisions are generally subject to maximum amounts, specified claim periods and other conditions and limits. In addition, the Company is obligated to indemnify its officers and directors in respect of any legal claims or actions initiated against them in their capacity as officers and directors of the Company in accordance with applicable law. Pursuant to such indemnities, the Company is indemnifying certain former officers and directors in respect of certain litigation and regulatory matters.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, no material amounts were accrued for the Company&#8217;s obligations under these indemnification provisions.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-70</span></div></div></div><div id="i8256f225f07d49409c31f7443adffdbf_379"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 67.50pt"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">22.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90ZXh0cmVnaW9uOjJmNDdlODBjMTIyNDQ0ZGQ5NzM3ZDQ1YzUzMWMzOTFkXzM0NTg_3cc0f96e-8213-47dd-9322-0c8585ce7b7a" continuedAt="if14f5a9b371549a4b57c121dc50dd54b" escape="true">SEGMENT INFORMATION</ix:nonNumeric></span></div><ix:continuation id="if14f5a9b371549a4b57c121dc50dd54b" continuedAt="ibf53f9fd0f4d48f9966ab3e4806f7cc6"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the planned separation of its Solta business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., the Company has begun managing its operations in a manner which is consistent with the organizational structure of the two separate entities as proposed by the Solta IPO. As a result, during the first quarter of 2022, the Company&#8217;s Chief Executive Officer  (&#8220;CEO&#8221;), who is the Company&#8217;s Chief Operating Decision Maker, commenced managing the business differently through changes in its operating and reportable segments, which necessitated a realignment of the Company&#8217;s historical segment structure. This realignment is consistent with how the Company&#8217;s CEO currently: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports. Pursuant to these changes, effective in the first quarter of 2022, the Company operates in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International (formerly International Rx), (iv) Solta Medical and (v) Diversified Products. The new segment structure does not impact the Company&#8217;s reporting units but realigns the <ix:nonFraction unitRef="reporting_unit" contextRef="i3328d4d641274769857018f609cda173_D20210101-20211231" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90ZXh0cmVnaW9uOjJmNDdlODBjMTIyNDQ0ZGQ5NzM3ZDQ1YzUzMWMzOTFkXzYwNDczMTM5NjIzNTc_975093b7-0787-44d9-a9da-32e6f99345b8">two</ix:nonFraction> reporting units of the former Ortho Dermatologics segment whereby its medical dermatology reporting unit (Ortho Dermatologics) is now part of the current Diversified Products segment and the Solta reporting unit is now the sole reporting unit of the new Solta Medical segment. All segment revenues and segment profits for the periods presented have been recast to conform to the 2022 reportable segment structure.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a brief description of the Company&#8217;s segments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Bausch + Lomb segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Bausch + Lomb Vision Care, Consumer, Surgical and Ophthalmic Pharmaceuticals products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of GI products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The International segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales, with the exception of sales of Bausch +Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Solta Medical segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Solta aesthetic medical devices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Diversified Products segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products, (iii) Ortho Dermatologics (dermatological) products and (iv) dentistry products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment profit is based on operating income after the elimination of intercompany transactions.  Certain costs, such as Amortization of intangible assets, Asset impairments, including loss on assets held for sale, Restructuring, integration, separation and IPO costs, and Other expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90ZXh0cmVnaW9uOjJmNDdlODBjMTIyNDQ0ZGQ5NzM3ZDQ1YzUzMWMzOTFkXzM0NTQ_acd0ce3b-b07a-48ea-953b-f89b7debfac5" escape="true">Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company&#8217;s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single&#160;segment.</ix:nonNumeric></span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 67.50pt"><ix:continuation id="ibf53f9fd0f4d48f9966ab3e4806f7cc6" continuedAt="ibed0a990e19f439daaf64e085e26f12c"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Revenues and Profit</span></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90ZXh0cmVnaW9uOjJmNDdlODBjMTIyNDQ0ZGQ5NzM3ZDQ1YzUzMWMzOTFkXzM0MjU_7af8863b-9013-42f8-b59d-6a964f63bb24" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenues and profits for the years 2021, 2020 and 2019 were as&#160;follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:68.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff7c3f276277409b964a030bb9ddf9bc_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzItMS0xLTEtOTQ4MzE_4357dfd2-0344-4973-8edb-c2794adf37b2">3,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i899638122b1443aea3cf842ccf65501f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzItMy0xLTEtOTQ4MzE_a510040a-798d-4e7c-b8c0-d92a9b072cd0">3,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cd37c585bfd45c29417f050b1fb96e7_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzItNS0xLTEtOTQ4MzE_bfb8bd3c-0465-4a70-9eb5-50857eea5279">3,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b94206c32884a8fa83f6929a2cb28d7_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzMtMS0xLTEtOTQ4MzE_2349c5da-5a76-4e77-b875-353f2fa02176">2,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6899a304edb44929422d6afaf6cef0a_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzMtMy0xLTEtOTQ4MzE_d1b296b1-746d-4e00-8640-a3c84828fb1f">1,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda72308df944034b125cc6838172395_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzMtNS0xLTEtOTQ4MzE_9602ac59-6a32-4da3-9f9b-73d4af61dc41">2,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8df850998cb6487c8f0b80f71254800b_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzQtMS0xLTEtOTQ4MzE_2dd3d18f-ce41-48ea-acd6-7c1c44aff1e8">1,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f0b0d400a84364ac143e0c73a45029_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzQtMy0xLTEtOTQ4MzE_fe75a9d6-641f-4d8c-aa4a-9448ec43cacb">1,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42a14ea9b3e84273aeea86db5027a7ef_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzQtNS0xLTEtOTQ4MzE_b2bf76c1-c754-49fc-85cc-a1bd725a6687">1,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3b9d2f71d648e191dab78cdfc14a22_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzUtMS0xLTEtOTQ4MzE_ae2f99cc-bd77-4048-b5a1-29e0aca7ca22">308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bcc7f02716c496789da6644b328c014_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzUtMy0xLTEtOTQ4MzE_33aff332-8a5c-4430-b55f-69571662a23b">253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59a5f333092b47d6b10bcf6f866713da_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzUtNS0xLTEtOTQ4MzE_c95c56b9-f4a5-4f1f-acb4-0f9dd6ec2ff7">194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabb641d02a434242909814412771e876_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzYtMS0xLTEtOTQ4MzE_90441763-32c3-4e09-b37b-17c5f38468fc">1,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if09045f9cc464856be5eee85d720e168_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzYtMy0xLTEtOTQ4MzE_b0eaaab8-7613-4ffb-9d8c-0daa88f647f4">1,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if27684da78ec405a8823766a077e4e59_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzYtNS0xLTEtOTQ4MzE_e19d2800-3ae2-4616-90f6-f178fdfdfaee">1,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8c2fffa98a84f4785e561d53fa2ad78_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzctMS0xLTEtOTQ4MzE_d1b792db-bb77-4f31-9163-18530cfcb82a">8,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20c9332693f549f3a5029b30f65e69d5_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzctMy0xLTEtOTQ4MzE_a1e1fd3d-95b8-4a1a-9a76-1e4187064c21">8,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0629a7489a0e43599cf635c5af5d5370_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzctNS0xLTEtOTQ4MzE_4b2fe399-997b-4b92-ba2f-199a5f986541">8,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profit:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff7c3f276277409b964a030bb9ddf9bc_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzktMS0xLTEtOTQ4MzE_3e9d2b93-b92d-4c7d-be53-6fc52f0c3128">958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i899638122b1443aea3cf842ccf65501f_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzktMy0xLTEtOTQ4MzE_970a7047-f9f5-4355-8e29-7d242b12a2f2">909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cd37c585bfd45c29417f050b1fb96e7_D20190101-20191231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzktNS0xLTEtOTQ4MzE_7f26ac45-2fd5-4612-8d37-48e99c881d56">1,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b94206c32884a8fa83f6929a2cb28d7_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzEwLTEtMS0xLTk0ODMx_8e742cbe-04ae-4109-b31a-c7411efd023a">1,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6899a304edb44929422d6afaf6cef0a_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzEwLTMtMS0xLTk0ODMx_bf5b1ff8-a44e-470f-bf95-12a61ac6473e">1,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda72308df944034b125cc6838172395_D20190101-20191231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzEwLTUtMS0xLTk0ODMx_b23ecf54-f383-4fef-a7fa-84d34895638e">1,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8df850998cb6487c8f0b80f71254800b_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzExLTEtMS0xLTk0ODMx_62c50723-750d-4895-85fd-8f0c9fe0d4fb">403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f0b0d400a84364ac143e0c73a45029_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzExLTMtMS0xLTk0ODMx_1ae1ce54-6872-48e2-9d7f-9e757cfbfe32">386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42a14ea9b3e84273aeea86db5027a7ef_D20190101-20191231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzExLTUtMS0xLTk0ODMx_7d1e59d8-4e58-4b68-8507-c667a1b9b84e">352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3b9d2f71d648e191dab78cdfc14a22_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzEyLTEtMS0xLTk0ODMx_8decf672-6d88-48f4-a26c-af1809193889">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bcc7f02716c496789da6644b328c014_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzEyLTMtMS0xLTk0ODMx_83d739b3-587e-4176-9c9e-bd98030416b4">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59a5f333092b47d6b10bcf6f866713da_D20190101-20191231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzEyLTUtMS0xLTk0ODMx_092ce28a-004a-4e56-a8d9-421931fb2536">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabb641d02a434242909814412771e876_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzEzLTEtMS0xLTk0ODMx_048d4303-c749-41d8-bd6b-6023cb87dbc8">722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if09045f9cc464856be5eee85d720e168_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzEzLTMtMS0xLTk0ODMx_b1239a28-65bb-41d7-b995-f74fc5ead140">814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if27684da78ec405a8823766a077e4e59_D20190101-20191231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzEzLTUtMS0xLTk0ODMx_7f238c69-d78c-4b6a-884a-7c1e466e5405">933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8c2fffa98a84f4785e561d53fa2ad78_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE0LTEtMS0xLTk0ODMx_c0a4edf4-6591-46c7-a012-5ca037f87950">3,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20c9332693f549f3a5029b30f65e69d5_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE0LTMtMS0xLTk0ODMx_afec34ad-8d2e-4d68-b8bc-2a03443803f8">3,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0629a7489a0e43599cf635c5af5d5370_D20190101-20191231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE0LTUtMS0xLTk0ODMx_5753d38b-d7bc-4140-b5c5-18f6a806ab50">3,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9327c2fc153040b99cb89cd74f8b0c52_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE1LTEtMS0xLTk0ODMx_75b476e8-58d9-420f-be5b-47fc02d8d510">792</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied28eb131a9d4f14930f4e4a0f0d7abd_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE1LTMtMS0xLTk0ODMx_77fe29e2-2e8c-4969-be9f-4e8695debca4">619</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia29f4c57d8b542cbafe1450ba688c6b5_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE1LTUtMS0xLTk0ODMx_8c1d0eb6-20d8-4499-98d6-49bdca1691a9">609</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE2LTEtMS0xLTk0ODMx_b7facf5a-aadd-484d-8ee6-cdd35f008eb9">1,375</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE2LTMtMS0xLTk0ODMx_7421f041-65cc-4ccd-bae7-7755a9330595">1,645</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE2LTUtMS0xLTk0ODMx_344091d9-9144-4dcf-a70e-76bc24594133">1,897</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE3LTEtMS0xLTk0ODMx_d159a2d4-4faf-4345-8b13-568ce5e3cff5">469</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE3LTMtMS0xLTk0ODMx_f08da81c-343a-4069-a9d3-cc3d9e5df0f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE3LTUtMS0xLTk0ODMx_09c6e2ca-c0a7-44fe-828e-18316dfd1686">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE4LTEtMS0xLTk0ODMx_32cd3aff-7ab7-499d-a48a-007baefc149f">234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE4LTMtMS0xLTk0ODMx_c44fbafa-e5ac-44dd-abfe-b44f472a6648">114</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE4LTUtMS0xLTk0ODMx_e39a1a0f-34e6-4258-8ebf-e96a35bc1a6c">75</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE5LTEtMS0xLTk0ODMx_543bc79e-37eb-4c61-a7a1-00517c0af12d">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE5LTMtMS0xLTk0ODMx_ef40161d-f6f1-415e-9e57-0ac8bdf5c552">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="bhc:RestructuringChargesAndInitialPublicOfferingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE5LTUtMS0xLTk0ODMx_627f9b31-8c77-4ffc-9760-d3f30a4082fd">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzIwLTEtMS0xLTk0ODMx_bade4f17-c5ae-486e-a7b0-544f07fc0f0f">373</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzIwLTMtMS0xLTk0ODMx_03dc9c35-d183-42c9-ab4c-9af691897561">502</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzIwLTUtMS0xLTk0ODMx_c3bfaddb-1a7d-4e70-a59b-70ad41e922ff">1,426</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzIxLTEtMS0xLTk0ODMx_b7c2440b-8790-42b7-a506-0f5d666a9520">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzIxLTMtMS0xLTk0ODMx_1b5764e0-dce8-46ad-b999-03ef8be9cf77">676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzIxLTUtMS0xLTk0ODMx_6bbb55ad-7929-4133-8367-1861092387da">203</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzIyLTEtMS0xLTk0ODMx_6307ef24-ae88-41fd-9e7d-f1a6d6a591f7">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzIyLTMtMS0xLTk0ODMx_d2aeadac-f909-4b69-9c07-f66540689347">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzIyLTUtMS0xLTk0ODMx_e6567242-38a6-4ea6-acf6-c4d2073c0c80">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:InterestAndDebtExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzIzLTEtMS0xLTk0ODMx_33ce6458-1218-4818-8946-64edf92d0239">1,426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:InterestAndDebtExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzIzLTMtMS0xLTk0ODMx_571fc66c-887c-47b7-a126-cea59d357492">1,534</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:InterestAndDebtExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzIzLTUtMS0xLTk0ODMx_223b4e39-3fde-4634-887e-e9f019c012fc">1,612</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzI0LTEtMS0xLTk0ODMx_8553c2c5-506a-405a-b9e5-ff888acac8ce">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzI0LTMtMS0xLTk0ODMx_2aa73fd2-79dc-4085-a73f-f64f2310c36f">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzI0LTUtMS0xLTk0ODMx_bb489af2-77d9-4447-b0a5-54b91d6b2790">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzI1LTEtMS0xLTk0ODMx_4b95da98-6cc4-4225-a72d-e8bc81be3cdf">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzI1LTMtMS0xLTk0ODMx_c5660489-41be-44d3-8e4b-edec13e49f11">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzI1LTUtMS0xLTk0ODMx_fa991619-b482-4a85-8583-0a4eee1aed43">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before benefit from income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzI2LTEtMS0xLTk0ODMx_c81b35d4-646b-4ce6-a73e-dcc8559890c2">1,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzI2LTMtMS0xLTk0ODMx_07cbe54b-d28d-4657-8c4e-e7b4a67e3cad">934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzI2LTUtMS0xLTk0ODMx_1d9fbd0c-586c-40b2-b1d2-0a19846801b5">1,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to segment revenue and profit in order for the prior years to conform to current year presentation. These reclassifications are not material.</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capital Expenditures</span></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90ZXh0cmVnaW9uOjJmNDdlODBjMTIyNDQ0ZGQ5NzM3ZDQ1YzUzMWMzOTFkXzM0MzI_6f3ddb2a-3b3c-4bd1-8f53-0e3265d0d431" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures by segment for the years 2021, 2020 and 2019 were as&#160;follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:68.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff7c3f276277409b964a030bb9ddf9bc_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzItMS0xLTEtOTQ4MzE_da692d23-fc6b-42c0-93bc-36e01d253db3">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i899638122b1443aea3cf842ccf65501f_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzItMy0xLTEtOTQ4MzE_4fbb6255-8ee7-422e-a5ce-4dec5578592e">253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cd37c585bfd45c29417f050b1fb96e7_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzItNS0xLTEtOTQ4MzE_30427701-0dfa-4058-b599-768fcf9d3f3f">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b94206c32884a8fa83f6929a2cb28d7_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzMtMS0xLTEtOTQ4MzE_b5529e84-074a-49fb-b10a-f59e9289e6ca">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6899a304edb44929422d6afaf6cef0a_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzMtMy0xLTEtOTQ4MzE_845fe6d0-85a1-4ff1-ac69-b2e992e1e1da">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icda72308df944034b125cc6838172395_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzMtNS0xLTEtOTQ4MzE_e08e86b1-fdfa-4c49-bf65-4967b276121f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8df850998cb6487c8f0b80f71254800b_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzQtMS0xLTEtOTQ4MzE_7eea3ede-f0c6-4139-a669-addde6fea0d1">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98f0b0d400a84364ac143e0c73a45029_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzQtMy0xLTEtOTQ4MzE_506567b2-1224-4404-ba4c-88ba83b471ab">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42a14ea9b3e84273aeea86db5027a7ef_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzQtNS0xLTEtOTQ4MzE_53a1eb9e-36b4-48fa-ba16-24a85c4daccf">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3b9d2f71d648e191dab78cdfc14a22_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzUtMS0xLTEtOTQ4MzE_235464b5-2d7e-453c-a627-b8a8a7d6a123">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bcc7f02716c496789da6644b328c014_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzUtMy0xLTEtOTQ4MzE_40e0b780-d138-415c-bcc8-0a582558327f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59a5f333092b47d6b10bcf6f866713da_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzUtNS0xLTEtOTQ4MzE_d4a3749e-c69f-457c-8eda-7e5e943747d2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabb641d02a434242909814412771e876_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzYtMS0xLTEtOTQ4MzE_47335e51-9195-41bc-9c94-055b46f86dea">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if09045f9cc464856be5eee85d720e168_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzYtMy0xLTEtOTQ4MzE_9ab802d9-22b4-4c87-860a-657ca00e74a5">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if27684da78ec405a8823766a077e4e59_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzYtNS0xLTEtOTQ4MzE_bf8490ac-88bf-4c2c-ac2c-f6064d5deada">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8c2fffa98a84f4785e561d53fa2ad78_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzctMS0xLTEtOTQ4MzE_73a0e880-75ab-4422-9ea6-a82be77169e8">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20c9332693f549f3a5029b30f65e69d5_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzctMy0xLTEtOTQ4MzE_b6271279-a032-4fad-8b51-5a36ea5e701a">289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0629a7489a0e43599cf635c5af5d5370_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzctNS0xLTEtOTQ4MzE_4cf04078-3715-4a3f-a74e-9edae0e0e71f">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9327c2fc153040b99cb89cd74f8b0c52_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzgtMS0xLTEtOTQ4MzE_02c1259e-eae3-49c4-a4c2-b468bf9f3171">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied28eb131a9d4f14930f4e4a0f0d7abd_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzgtMy0xLTEtOTQ4MzE_61ddfbba-4566-4ba2-a74d-d0ee61ee5d8a">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia29f4c57d8b542cbafe1450ba688c6b5_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzgtNS0xLTEtOTQ4MzE_9901ea77-49ab-4726-a83a-9913b8715a0d">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total capital expenditures</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzktMS0xLTEtOTQ4MzE_f92ceb1c-bd46-4284-a60c-fcbf07ccf285">269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzktMy0xLTEtOTQ4MzE_fdc33a7a-4c14-4bac-bbf6-6b89673ee2a6">302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzktNS0xLTEtOTQ4MzE_fd0d8ec8-78dc-4ff5-a937-a6b461112b50">270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 67.50pt"><ix:continuation id="ibed0a990e19f439daaf64e085e26f12c" continuedAt="i747d555c186d43fab35dbe490efe1d0f"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues by Product and by Product Category </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for the Company's top <ix:nonFraction unitRef="product" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="INF" name="bhc:ConcentrationRiskNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90ZXh0cmVnaW9uOjJmNDdlODBjMTIyNDQ0ZGQ5NzM3ZDQ1YzUzMWMzOTFkXzI3NDQ_3b9bccfa-aa7a-4cac-acad-64cf96800d0c"><ix:nonFraction unitRef="product" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="INF" name="bhc:ConcentrationRiskNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90ZXh0cmVnaW9uOjJmNDdlODBjMTIyNDQ0ZGQ5NzM3ZDQ1YzUzMWMzOTFkXzI3NDQ_5345d9bf-6f95-4612-88a7-5cbaf7003ba1"><ix:nonFraction unitRef="product" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="INF" name="bhc:ConcentrationRiskNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90ZXh0cmVnaW9uOjJmNDdlODBjMTIyNDQ0ZGQ5NzM3ZDQ1YzUzMWMzOTFkXzI3NDQ_d7da40fe-f8c8-4259-b2df-2442a84b963a">ten</ix:nonFraction></ix:nonFraction></ix:nonFraction> products for the years 2021, 2020 and 2019 represented <ix:nonFraction unitRef="number" contextRef="icc8c408b488a4ea2a66ad4c5e2951610_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90ZXh0cmVnaW9uOjJmNDdlODBjMTIyNDQ0ZGQ5NzM3ZDQ1YzUzMWMzOTFkXzI3ODU_12463edb-5f15-4efb-ac60-5f72a3dc7f70">43</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i72654cd7063243f1a8df8bc3a4f0195d_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90ZXh0cmVnaW9uOjJmNDdlODBjMTIyNDQ0ZGQ5NzM3ZDQ1YzUzMWMzOTFkXzI3ODk_c713d8bc-4762-42c9-a695-5635d86ec36b">41</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i85db686e88084b1daeb7d9f72f4f05ad_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90ZXh0cmVnaW9uOjJmNDdlODBjMTIyNDQ0ZGQ5NzM3ZDQ1YzUzMWMzOTFkXzI3OTY_ea6b772f-3f5c-4ec9-8b8d-467784226c3f">39</ix:nonFraction>% of total product sales, respectively. <ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90ZXh0cmVnaW9uOjJmNDdlODBjMTIyNDQ0ZGQ5NzM3ZDQ1YzUzMWMzOTFkXzM0NTA_2440d7ce-cf9a-40b8-8056-059212c3144c" continuedAt="i078edb8513ac481585c4ae25ebe4d74e" escape="true">Revenues by segment and product category were as&#160;follows: </ix:nonNumeric></span></div><ix:continuation id="i078edb8513ac481585c4ae25ebe4d74e"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"></td><td style="width:23.745%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i418a04d4e056401399ccd4b61b80c49e_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzItMS0xLTEtOTQ4MzE_99085bc9-c3f3-4b00-8669-129d68cb3143">514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i208a6bf939c242978d7d9ccc2fc10274_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzItMy0xLTEtOTQ4MzE_4305dc96-c211-4e8f-9896-278a6432e7d7">2,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i183660041cad45ea8dd6de8f87fb3352_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzItNS0xLTEtOTQ4MzE_520ae44b-2efa-46e9-9324-b34457901046">259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e9b099c602241aea11206441f010b8a_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzItNy0xLTEtOTQ4MzE_c7464bcc-0b2b-45d3-a227-c786fb422c93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85426466f4c3491594754c3f8fc926ab_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzItOS0xLTEtOTQ4MzE_43b1c645-fc51-4bae-a7ea-c9b415cf8963">923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica7446f3b2c9467380385861ab7f846c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzItMTEtMS0xLTk0ODMx_52140414-18cf-4fb6-907f-7e16384501d8">3,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97a39f300bde49ca9fc43dfa11399cca_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzMtMS0xLTEtOTQ4MzE_8e543822-692d-47b1-9209-4810e841aab7">1,596</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6cb2a068a1c48d2ace685a569e695c1_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzMtMy0xLTEtOTQ4MzE_940658ef-171c-47aa-8ed4-a5b4aa237d56">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6dfbabd3f8ad4b34a103357fe12fcfcd_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzMtNS0xLTEtOTQ4MzE_a382f980-0e1a-4b3c-ba78-322b577e3f95">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fb12fface6c4c7e82b18336a7a67376_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzMtNy0xLTEtOTQ4MzE_6fb436e8-7870-4b39-a53b-35922163b215">308</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iada6d354701043aa8ed66ad26387df2c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzMtOS0xLTEtOTQ4MzE_d49d4d94-0063-4c99-9174-abe50215004b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefe6d8b686a343d78914861cca583670_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzMtMTEtMS0xLTk0ODMx_b852d9ed-f745-4d7f-b6e2-128abac09f1a">1,904</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie68fa27569a84628a38c78ec3c373351_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzQtMS0xLTEtOTQ4MzE_47fe5ed7-4f44-4c77-adc9-bc53549903d4">1,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaee7f42c5a6e468eb8cc29e3ccdff123_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzQtMy0xLTEtOTQ4MzE_0d8cf900-b1f0-478b-9d28-282f872d354b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd994066bcd8437a9238a565a38135fd_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzQtNS0xLTEtOTQ4MzE_7e2ff5f2-cfb2-4f95-830a-1d0a02580c8c">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9083205e195d456097ba2cf0d7d660c7_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzQtNy0xLTEtOTQ4MzE_bdffe16c-859d-45c9-96fa-61621ff1039c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a89853896aa43c787ccc01b19d26a52_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzQtOS0xLTEtOTQ4MzE_fcf8a682-3fb3-482e-b9eb-14e46f273983">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdef7aa1a0f744b2a4b78007975133bd_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzQtMTEtMS0xLTk0ODMx_f53579bb-e8d0-4860-a99d-143cb08fc1f9">1,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dbb383514c346138c6f03e2442cf299_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzUtMS0xLTEtOTQ4MzE_6e001629-961d-4dc8-8e75-acc2a5c88c93">240</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cfbdc3f3475470493bc0b06e113623c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzUtMy0xLTEtOTQ4MzE_bd95d3c7-0609-49c1-b0c9-633cf043f71d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie646b8a4d77c437591b1f253ad1ce98c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzUtNS0xLTEtOTQ4MzE_d084ec7a-c743-4965-912d-03fffc64e01a">737</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b09688e27584c5c8598014546598fc6_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzUtNy0xLTEtOTQ4MzE_638cf024-e9cb-4941-9dc9-e2bba7981782">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93bb05eba3ba4b89973b0e8adec86826_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzUtOS0xLTEtOTQ4MzE_6ce2fcdb-8efb-4068-92d0-9ceaf090d89c">167</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cd4d9c52b49420b9fd755ecae1f6e34_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzUtMTEtMS0xLTk0ODMx_1ad70f85-0195-4fc8-adad-c489c5d7d5de">1,144</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i449241e47dc94783a4ce61ebe70a084c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzYtMS0xLTEtOTQ4MzE_03e9e5a1-1427-4156-9ce1-d515304573db">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i945b3a4ecfe946f49fd0768311efb98e_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzYtMy0xLTEtOTQ4MzE_af7ac0ed-4eb6-4474-b044-432190dcfedb">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c41e1b8ff6243bea499531336ad49f3_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzYtNS0xLTEtOTQ4MzE_10b00ec7-6047-4d70-aa5e-7026dc9135e8">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9565df56092f4004881389c04df25c93_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzYtNy0xLTEtOTQ4MzE_fb316d71-d4bc-4d1f-8a94-f874aa94e4c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8a16169eb2d4f67b89fdacefbd0662d_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzYtOS0xLTEtOTQ4MzE_a7c6d37a-9262-4879-bc33-8e0c226ec769">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a0ba16f9629426fbbc2da84a05d2fd5_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzYtMTEtMS0xLTk0ODMx_d4a74a1f-12c7-4f76-80d7-508c8d3e747a">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i414fba28824c413593139a2e4ef76d21_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzctMS0xLTEtOTQ4MzE_3a20ad0f-64d2-4e3c-9d77-24feb1be5481">3,765</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72021acf180458a8e22ca22a9fa4b7c_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzctMy0xLTEtOTQ4MzE_83710c9e-863a-4258-b004-41df10bcad1a">2,074</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied7527e9c7f3438db93389c0a1768d2a_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzctNS0xLTEtOTQ4MzE_fdcc1b15-8e74-46e9-89ea-2f296fcebbf6">1,166</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c6872a04d24bdd87a47a8fcff435f5_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzctNy0xLTEtOTQ4MzE_1e3dbdaa-fadd-4dd6-a0e9-517f29b10758">308</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a5a9e6c49d742aca8267ceb1bf314d3_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzctOS0xLTEtOTQ4MzE_a51278cf-f590-421d-b441-988f4d2a98a5">1,121</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzctMTEtMS0xLTk0ODMx_6ef34a92-a5df-4238-bace-1e6e3b1e1b6f">8,434</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"></td><td style="width:23.745%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01141cbdbc294de9a69e8742d0ac0103_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzItMS0xLTEtOTQ4MzE_c93127f0-b57b-4992-90bd-f29917ee923b">506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a2b29c602cd4b958959f3a523a03952_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzItMy0xLTEtOTQ4MzE_98a074ce-d78c-4ea1-a229-a8cb9777dd3c">1,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30e3835f2cc243289f8661e3a751167e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzItNS0xLTEtOTQ4MzE_57398410-19d1-4543-abcb-2955e891eff5">255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fa10e66f5ca4afbb367c4f716dbdb6f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzItNy0xLTEtOTQ4MzE_e1786e67-e358-461c-8b26-e4928596ec3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i035f8ab24ddb4f03a63105201f52a080_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzItOS0xLTEtOTQ4MzE_1b68c9dc-bbf3-4757-aca4-1e81347f2496">1,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1a89016aaa44f1b9b7cbf14bcc530f_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzItMTEtMS0xLTk0ODMx_0549f4d6-1aa4-44b6-bf23-9b86303daeeb">3,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e9e47444534ef380cd91916978cc8e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzMtMS0xLTEtOTQ4MzE_13634bb1-9974-4f64-bca8-576945c3eb58">1,313</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ea3465f6a0045f59c3e4d358fade4ea_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzMtMy0xLTEtOTQ4MzE_d5addd11-2f56-42d5-97bf-507d387295ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic174d4e74321475a84d00d558435391e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzMtNS0xLTEtOTQ4MzE_8cc124b5-cb0f-4d8f-98d8-cc53aa6f3837">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f3a113a586047de86a5ff20c4cad591_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzMtNy0xLTEtOTQ4MzE_5b219622-2a26-4423-96be-6916edb39232">253</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d52437e494a45f5b5d81fd921f506ea_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzMtOS0xLTEtOTQ4MzE_f7111ed7-f7fb-4263-b502-5c7d14ea4c63">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba2bfdb91306432787e6d119f24c9aa6_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzMtMTEtMS0xLTk0ODMx_dca457b8-d3fb-49c8-b59a-4ef8f146afe2">1,566</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccf8163c97e441b695eed7ad4118029e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzQtMS0xLTEtOTQ4MzE_6df16169-deea-4582-b389-ca7c977c5f7c">1,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id931ecb1d5924adc9990fe3880f43991_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzQtMy0xLTEtOTQ4MzE_52f43661-77ce-4f8d-9609-7b3dd3dae2bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b3b9253b89e4ba5af70da5f568580ee_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzQtNS0xLTEtOTQ4MzE_36786e46-2ff6-4462-b9b7-92a78ca8ede0">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ce0e8c5792746c4898df7b4b795738b_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzQtNy0xLTEtOTQ4MzE_4078afa7-204d-40bc-8026-6f3dc5b3dab0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6b7d530488142ca89ab8ee239e906ac_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzQtOS0xLTEtOTQ4MzE_e508aff3-0ba9-4abb-8daa-cc883c8c2d99">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87499fcd581e451e8b4380c27a63aa69_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzQtMTEtMS0xLTk0ODMx_51da16e6-5243-4d0b-8dc0-b28d94240ca3">1,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i090b17bc8edc432898c155379a09ffbc_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzUtMS0xLTEtOTQ4MzE_1a21dab9-1343-4a1d-9aad-77b5c950a33a">254</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i675b1f36cfd84e78bd9e49edeea02d3d_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzUtMy0xLTEtOTQ4MzE_2acb1902-4767-49e4-9587-0d3a950da81f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79f443d6034b41279b6e32600dfad1dc_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzUtNS0xLTEtOTQ4MzE_f6dfbe64-f7f6-403a-801e-7aecc0ab66cc">775</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f4c2a755d74f6782eeac0e0d29ccd5_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzUtNy0xLTEtOTQ4MzE_ab51c859-97e5-4348-b41f-336038c8c6c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e35c309da054713ba96e1155984e51e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzUtOS0xLTEtOTQ4MzE_f94beee9-2831-4365-add7-448bd0163315">219</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2daf7c9c3709441a96dee7e2be490687_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzUtMTEtMS0xLTk0ODMx_cb11f061-17b7-410b-a4bf-15fe9f183b16">1,248</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i827e4d3a675249bd9a863b2b7df083b6_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzYtMS0xLTEtOTQ4MzE_2d3a4418-a14d-4b65-9f1c-831e469aa81d">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c401d26917e40768b5d281285429ae5_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzYtMy0xLTEtOTQ4MzE_cc6ae831-9719-4509-ba56-68d92a8b5f9a">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe1dab615a544098b3eb8dab58113a92_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzYtNS0xLTEtOTQ4MzE_68644d4d-7cd1-413d-8275-0635a97239a0">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd1357104df74efbb0da5b76bc89c115_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzYtNy0xLTEtOTQ4MzE_ebdc0e10-46ed-4b91-b936-b7fa9f7ebbb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6331eae27614b90855cfb5b25b9acd0_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzYtOS0xLTEtOTQ4MzE_9b44a839-b7c8-4ba7-8c83-b43c3e9003fc">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92793a91c9c747858dd71f6a9a0a9d23_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzYtMTEtMS0xLTk0ODMx_522a23d5-2e65-4913-9a67-d751b59a175d">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida777483b4584d87a6cf2850e419fdd4_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzctMS0xLTEtOTQ4MzE_ad5a3f67-ff99-4ea7-a6e9-03f201a1e138">3,415</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7999bb21b9045d28a73afe96f2eb35b_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzctMy0xLTEtOTQ4MzE_58bf45d1-3e8d-4af1-b7f3-29e722fc8ca2">1,904</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i672bff69a6fc4ef3aebe3725cc29e40e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzctNS0xLTEtOTQ4MzE_9b0dc1c7-1501-4264-a404-f6030eb8574e">1,181</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i626b9ba57ccd4f46b64c17f382055091_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzctNy0xLTEtOTQ4MzE_473e3e28-d5c3-4a6c-8931-a7a693a7bcb5">253</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i936342f03a8e4fa2b1e39321ca993106_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzctOS0xLTEtOTQ4MzE_956aff85-3b9f-41b8-bdbd-0e44a4100604">1,274</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzctMTEtMS0xLTk0ODMx_59ec633f-75a4-4c62-8ffb-b59f8149cf3a">8,027</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"></td><td style="width:23.745%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.548%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.788%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24cd510cf43d4f998e635afc20c956b2_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzItMS0xLTEtOTQ4MzE_840cc8bc-6142-4b15-bbce-0c06589ca37b">623</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55bf18e767ee4fbd8771bf6350d26aff_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzItMy0xLTEtOTQ4MzE_b86d5bcb-e76f-4eec-b783-0ed485d6cbb0">2,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00e2f75f8e8a4e30a276c3033c8f9971_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzItNS0xLTEtOTQ4MzE_8df414d8-5c66-4efa-a759-62f9173cf114">268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i087b26d2da5842a783ce0a89063cf3f2_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzItNy0xLTEtOTQ4MzE_2086a2c8-1585-4144-ab99-ae6e7a2b84bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7af7813bfb2b41168f468df55e46c835_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzItOS0xLTEtOTQ4MzE_9d0b7018-a477-4f53-ab8e-bcb7e8246b5c">1,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic113e26dc8a943e3bcb1595fc30166d4_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzItMTEtMS0xLTk0ODMx_51100e84-e4f9-4cc2-b9dd-68abc44e631f">4,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0ca740d21c34ec1a4f67ff1a0624db4_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzMtMS0xLTEtOTQ4MzE_37be65ef-62f7-4939-bce2-b9a47ff98a50">1,524</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9186a43c41842cca559fad18f9be2a6_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzMtMy0xLTEtOTQ4MzE_a85028d0-4f02-4b2f-98a5-6e58d5dbb87d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc4e1ec44690405aa82469ba14ebe09c_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzMtNS0xLTEtOTQ4MzE_001cbe4d-cf7a-4ac3-b654-65d5f751d3d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25dddfae7e964bdfac0c22c5bd9b8197_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzMtNy0xLTEtOTQ4MzE_f22291a6-6d00-49ca-a085-a05aa777e983">194</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f5298b1c6b04825936c29a9867976f9_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzMtOS0xLTEtOTQ4MzE_98861ac9-3d82-4376-902f-423b237470ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if179cdcb08a0401481a1219768254267_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzMtMTEtMS0xLTk0ODMx_2eec6e2d-271a-4c63-936a-f7b54d4d1213">1,718</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8664af0b79840da9709c1622bb9ddf2_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzQtMS0xLTEtOTQ4MzE_d064e35a-7805-4283-b8db-17b2e5dcbd29">1,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3e3f60c68704a709d886a22a7a0625c_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzQtMy0xLTEtOTQ4MzE_374955f5-20f9-4cc5-ae85-a25e481e302c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieecb00ddf1e346c497a7a3939fd11cb7_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzQtNS0xLTEtOTQ4MzE_6b72f697-6a85-458c-81cd-c7efd90dde13">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i546306a3ad4f430786457eae18ef4185_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzQtNy0xLTEtOTQ4MzE_e4772f21-bf8b-403d-8343-86281d5cf154">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b77d4f86e5b4d38a20c7bda0feef351_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzQtOS0xLTEtOTQ4MzE_6749f4b4-d801-437e-8d7b-2df44ea27cb1">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a4ec44e96e44217afae2275f04e02cb_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzQtMTEtMS0xLTk0ODMx_3d0fe4ac-b1c2-4907-8b3a-acc7122bc605">1,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02ace42c02c2429cb5f9a01e0cdfb82c_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzUtMS0xLTEtOTQ4MzE_94fc5fec-4b0f-4886-833f-6e226eeba25b">260</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia05135846e24408ea51ac1a000116fc6_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzUtMy0xLTEtOTQ4MzE_055e5ba9-5248-46fc-a719-8db9a14553f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654644a806dc4e4c810f174fd6c3d5d7_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzUtNS0xLTEtOTQ4MzE_548e5ca0-9181-4663-a657-66418c62ae4b">730</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14f7e763fe5647bc92cbfc644aadf9e5_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzUtNy0xLTEtOTQ4MzE_864878f6-b04c-4877-ac15-92104e8a31ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdd6fed0918446febaeb315df0545125_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzUtOS0xLTEtOTQ4MzE_105f77b8-aa5c-46ac-85e4-35a3d29ff337">256</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80e98cb6ebeb4ac595398dcd45214e1a_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzUtMTEtMS0xLTk0ODMx_898a6948-2fe3-4c7c-91d7-a412754f9eef">1,246</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id42bd5ff7402461eae15a600bbe77743_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzYtMS0xLTEtOTQ4MzE_0ad428ee-228e-40fe-9a76-f1a9a74eb4dc">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c6ab8b8553d4be6bb88ba2a97705892_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzYtMy0xLTEtOTQ4MzE_9288c9c8-9628-4895-99e0-39872311f0da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd261e8b9f2d458587ab145f0b01027b_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzYtNS0xLTEtOTQ4MzE_01b83f39-132c-4b80-a086-ff23568a533b">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i835dafddf9254e80881be0cd65ee190b_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzYtNy0xLTEtOTQ4MzE_c4cf7873-2d82-4c2d-a2b8-824c3f4ac409">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58a96cd4d49841fba044c42410080076_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzYtOS0xLTEtOTQ4MzE_1a89eec8-36c8-4368-89a5-c15191d49294">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16d6de8cde05443f89914d40cf8374a2_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzYtMTEtMS0xLTk0ODMx_8337b56c-0ec6-4fee-9e6f-108fe05198f7">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0536a549f4e94235a4c555bc2d5aa85d_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzctMS0xLTEtOTQ4MzE_625a6780-c173-4ab0-94af-460931151404">3,778</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i417dcef94a21464c8f3e70b1b83c913c_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzctMy0xLTEtOTQ4MzE_bd9cbab5-fb76-46c0-8f78-51a99016f00a">2,022</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i551031e418e04e92a28afd201e2a7815_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzctNS0xLTEtOTQ4MzE_248bce84-0a54-4f21-b1a1-71fc1bd1abb8">1,154</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e0b639594e4483fa2e3d9eaa57f0c52_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzctNy0xLTEtOTQ4MzE_1c6380be-e30f-42dd-a1f8-c19e38cd67d7">194</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6a213bd75514daebf43eb6d93a109f3_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzctOS0xLTEtOTQ4MzE_16a1867e-a3a5-47f9-b377-a2cf13e47c46">1,453</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzctMTEtMS0xLTk0ODMx_454bf8a5-5d43-4172-ada8-28384e34bb6b">8,601</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 67.50pt"><ix:continuation id="i747d555c186d43fab35dbe490efe1d0f"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information</span></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90ZXh0cmVnaW9uOjJmNDdlODBjMTIyNDQ0ZGQ5NzM3ZDQ1YzUzMWMzOTFkXzM0NTM_51a41ea7-72bc-4de7-90d1-fede6cbba799" escape="true"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are attributed to a geographic region based on the location of the customer for the years 2021, 2020 and 2019 were as&#160;follows:</span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:68.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5464eb24d31a4be0beb852ba387bade8_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzEtMS0xLTEtOTQ4MzE_d4b5978e-f461-4207-941b-62de2c8725b0">4,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ba444e2ab994ca1a3c530ace04d6dc6_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzEtMy0xLTEtOTQ4MzE_c02b3143-d1b2-492d-b400-1160dbeef69d">4,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe8e8f4ff47f48599e5fcab4fe291d47_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzEtNS0xLTEtOTQ4MzE_eb0530fd-1de9-4396-959e-bcc3c70d7764">5,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id15ad738c4a24f2db24b34a5a0710ae4_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzItMS0xLTEtOTQ4MzE_5b295a79-af25-41b8-a4a4-9aa8886311b3">490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c2d9ba589c34635af841f55fabca3a3_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzItMy0xLTEtOTQ4MzE_ff51d5c4-d877-480b-8041-c8267cf19be4">341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9cd10e388d948f69faaa2a13ee4e9a3_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzItNS0xLTEtOTQ4MzE_7bdc3b06-f38e-4927-ad39-d50015867e8c">368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9548d7cc49134168aac65b53c630d341_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzMtMS0xLTEtOTQ4MzE_8d4aff22-b38d-44b5-909f-7276969f30b7">343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08b753376f4946ee869fca342eb74772_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzMtMy0xLTEtOTQ4MzE_19e0f85a-1756-44c6-9a7f-abd6ebdff95e">331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibad2ef89232a4629aad3bf5d2c272019_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzMtNS0xLTEtOTQ4MzE_f44bf0ae-f182-48d8-8435-b7910a248c3e">339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21a132fe24e747f0a5b421bc7f0ac7e7_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzQtMS0xLTEtOTQ4MzE_223774e5-b003-496c-a25e-21fc8d77b3a8">280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i920bf658665d471ba624c241f037cab0_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzQtMy0xLTEtOTQ4MzE_47980a55-d5a0-480d-adcc-3df6f4366c66">238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbd946703e614d71b6d50b2f7ef7c141_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzQtNS0xLTEtOTQ4MzE_9ac5e097-bee7-4fa5-9f68-39370492243b">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50f4cab02f148edb0f275c887c08c1a_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzUtMS0xLTEtOTQ4MzE_d43a8a94-1643-4cdd-ae83-abe1a9b0dc68">256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af93ee9adb74fed8865c912c5df1f30_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzUtMy0xLTEtOTQ4MzE_028a39c1-61b2-45d0-b954-6330f1ec4507">225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54515e5b9a1540f28363106924361f49_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzUtNS0xLTEtOTQ4MzE_26f525cb-d900-4279-bce5-d6bf0549b410">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5566c138571140a6b83afaef74940706_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzYtMS0xLTEtOTQ4MzE_8db5a6cf-7656-4fbc-a7dc-e78fe5eff6a3">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id01f277d70d744e19dc9ac68d075ef8e_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzYtMy0xLTEtOTQ4MzE_7b5c6671-377c-4c08-9ddf-8185b46732d5">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia51b7a120b6d4bfaaac2e2f5d62cd956_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzYtNS0xLTEtOTQ4MzE_f9408b72-9360-40e6-afba-17f6090fd077">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67e2a75f81a2442e98999a9c1a2cd7a8_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzctMS0xLTEtOTQ4MzE_91115ff6-3fe3-4f32-80c3-25cea6080f64">208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb566fc6694e418b911114af24372afe_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzctMy0xLTEtOTQ4MzE_fbcb6519-0870-41f8-b50d-5fb04fb440a9">179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c64023910d940d280c4372028887834_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzctNS0xLTEtOTQ4MzE_a49cf8d9-cfb1-49c5-a917-d27d105ffaf8">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cffeeeada484c5982be5b0d0fba6d27_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzgtMS0xLTEtOTQ4MzE_4d8a6425-294a-4833-ac90-438ef4c93ba9">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36510dcee9304e688d7fe55e6e0cdada_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzgtMy0xLTEtOTQ4MzE_f3233cc2-e5fd-4a71-946d-84dd2bd7ee84">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7458902eaa074c759452bcd57083fefa_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzgtNS0xLTEtOTQ4MzE_ace274ba-f116-46a1-bae7-fed180a4917c">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2524acb5669c4f46b137c163c7500bb8_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzktMS0xLTEtOTQ4MzE_cbdf7296-828e-40b0-bdc6-bab463d7db25">156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea6f1abfde62479a85a276b00644bbda_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzktMy0xLTEtOTQ4MzE_98a75a3e-bfaa-441a-95ba-20517cc24c79">243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d19db7ffad34988952acdbe5de7846c_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzktNS0xLTEtOTQ4MzE_35693f93-1aba-4231-87f2-ef15aa26f140">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0667b68241574742a0864172124b2604_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzEwLTEtMS0xLTk0ODMx_9dd9d1f6-8d81-4f89-aedd-95f35598136f">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26ae9e62be7441c196757ba308583044_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzEwLTMtMS0xLTk0ODMx_50f9afe5-99bb-4002-8248-538fdf4c6bba">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i516a86604ef14c82b80390e67af470ba_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzEwLTUtMS0xLTk0ODMx_6ba1cded-be9a-47e4-b57b-4a99fb74440b">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4339bb0ca24249ba8ca9d3aacc1e7a0a_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzExLTEtMS0xLTk0ODMx_2926b3f5-e8db-4a3c-ae73-66acc005ae97">116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8cb0908b5141feae7cceed8fb1fbf6_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzExLTMtMS0xLTk0ODMx_168c305c-95c0-48be-82b5-268c07efaaab">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfa55d1cb36c454c8ec5fda74ab99db4_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzExLTUtMS0xLTk0ODMx_09ec5ce9-5b05-486b-a694-697ed101130b">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47f75495e622462aaff82bf298f1f418_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzEyLTEtMS0xLTk0ODMx_7938de04-245c-41f0-aa0f-abc151517e26">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8280a4a6ac8459590c2dcaa41f23220_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzEyLTMtMS0xLTk0ODMx_66c64918-bacb-4819-ae13-8fd2dc179b09">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i530e4f0186a947ecbd4d27d49cb0e1dd_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzEyLTUtMS0xLTk0ODMx_d4543bed-9515-4408-a98b-74ce4a652e95">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic43dc8234c6a4dceabd306a0a1c1fe32_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzEzLTEtMS0xLTk0ODMx_bb52985c-03ee-4d1a-bf4d-63b1f5d4f4a8">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16c4e15aae264f818da6ace454e9fbec_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzEzLTMtMS0xLTk0ODMx_faa653f6-6676-4b3a-8d41-dd3dc89d5a9c">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a5eeb906ad94c799a42264f6d5855ed_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzEzLTUtMS0xLTk0ODMx_560deddd-fefe-45f1-afc7-a8f9cb94286c">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fffa5927ecf4eb5b8a70faa07450b99_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzE0LTEtMS0xLTk0ODMx_7cfe829e-478a-4107-bc4e-c584e49fa01d">986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib537ff890e5e4cec8f7b9df78020e5c0_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzE0LTMtMS0xLTk0ODMx_56e35605-042c-46f4-bb04-37cb7a6c12e4">937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fc8256f50d840ac85eb640d6f16ba43_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzE0LTUtMS0xLTk0ODMx_c2413109-f99b-44e4-956b-ac52c972259b">995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzE1LTEtMS0xLTk0ODMx_758c7c18-31df-4347-bc08-405818a85d9c">8,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzE1LTMtMS0xLTk0ODMx_ebe72e38-1944-4fe4-83c1-c189b0b65fe4">8,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzE1LTUtMS0xLTk0ODMx_99e4af40-43ce-4f4a-9517-8a5cb50cbb1c">8,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made and are reflected in the table above.</span></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90ZXh0cmVnaW9uOjJmNDdlODBjMTIyNDQ0ZGQ5NzM3ZDQ1YzUzMWMzOTFkXzM0Njg_dc964a36-3760-4d82-870e-86ccad8b73b3" escape="true"><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consisting of property, plant and equipment, net of accumulated depreciation, are attributed to geographic regions based on their physical location as of December&#160;31, 2021 and 2020 were as&#160;follows: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:79.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.956%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8965029593294a24adc5e0c5daccbfbd_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzEtMS0xLTEtOTQ4MzE_60e431ad-b186-4506-a733-734a2cc227fe">743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c135788a091404aa9a7b000b712ebb3_I20201231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzEtMy0xLTEtOTQ4MzE_942d4f86-c5b7-46d6-b2b5-65109b52fb92">725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc3f5d1fae4241ef94326581b829bff7_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzItMS0xLTEtOTQ4MzE_ef63eb1a-daf7-4b8f-9ce3-bd4c7f6f46c7">336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc53a771e452444ea4bc5759cdd083db_I20201231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzItMy0xLTEtOTQ4MzE_006bf58a-50d0-4f62-8f4f-670ce7ba58f6">328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe7ac3c028a54540be9b808a17416a89_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzMtMS0xLTEtOTQ4MzE_9112f4da-0717-4051-b109-f4e397d0b064">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab3fadee1424d2b9a667a9b07eac40a_I20201231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzMtMy0xLTEtOTQ4MzE_beecc5e3-766a-4e88-bcae-964d05024222">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34d52e2c9af34f2eba8ae6242e32285b_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzQtMS0xLTEtOTQ4MzE_64bea86c-bdcf-4cbf-a448-f4003b580986">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7fa6fc30bf5449caf063162224cd090_I20201231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzQtMy0xLTEtOTQ4MzE_abfe80f5-2b42-4e56-85f3-aec3e04212e8">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3f2d957c7234a77b712ff75e65b792e_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzUtMS0xLTEtOTQ4MzE_08a5c085-bcf9-438d-8681-d74c7e561462">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie327497372b349d3a51955d6959df2f5_I20201231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzUtMy0xLTEtOTQ4MzE_3495b80a-b642-4d30-a1f9-5d05444c4fd4">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69ea4eb4471f4aae9d2a35f42e82ace9_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzYtMS0xLTEtOTQ4MzE_8153c164-5b5b-4d07-b6ed-c25b20a0068b">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c536f8e7b6c4bdc94cd38d6eef8e2e3_I20201231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzYtMy0xLTEtOTQ4MzE_59afcb51-d539-48d0-a160-9df5d246240b">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i872f81fbc9ba4c60a97667b7432c52c3_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzctMS0xLTEtOTQ4MzE_69966e64-d31d-4a83-9cc0-928513df6804">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if846fad239254513bf3cca0ba1935da3_I20201231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzctMy0xLTEtOTQ4MzE_57e25b4b-4510-4aaa-8aa2-e8df42f7ae13">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie66e6133905345078ee7cb9899b48d33_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzgtMS0xLTEtOTQ4MzE_e8ff066b-d828-4cb5-ac86-0d9f24baadd3">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d19b0b4d54a4b8cad166f0ef7a625c7_I20201231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzgtMy0xLTEtOTQ4MzE_301173cd-77f6-4fe5-958b-dc3b2886c845">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serbia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbf66cd972eb4b26b35c2652ab001028_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzktMS0xLTEtOTQ4MzE_198a0114-bba7-458c-8c1c-22011e0a169c">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic83a5702808c4b7889dca0da3411ecf7_I20201231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzktMy0xLTEtOTQ4MzE_2bffd16a-c76e-4893-906c-3736d5837337">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1597a3574967438391767431a634b19a_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzEwLTEtMS0xLTk0ODMx_fd18f7b4-7e87-4e25-9e39-05873d895ab1">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idde75edf275b41fb8ca106bbac1cc51f_I20201231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzEwLTMtMS0xLTk0ODMx_4741c00f-d6d4-4ceb-8abb-11be4e3cabe2">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3cfed9c9f746829c13cb94a536f2e8_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzExLTEtMS0xLTk0ODMx_916c3a87-466e-445a-8fe0-e290d4037eb0">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2183ac8cb0c24b26a214e41ab91d3425_I20201231" decimals="-6" name="us-gaap:NoncurrentAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzExLTMtMS0xLTk0ODMx_024465b3-d8ab-4b87-a825-4ec802deebf2">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzEyLTEtMS0xLTk0ODMx_d33a5bda-ac5e-4629-8807-072a42888338">1,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzEyLTMtMS0xLTk0ODMx_03b7ba57-80d6-42fc-b17c-63a1eabf46fb">1,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers</span></div><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90ZXh0cmVnaW9uOjJmNDdlODBjMTIyNDQ0ZGQ5NzM3ZDQ1YzUzMWMzOTFkXzM0MzQ_2daef25f-a72b-4523-8d03-980ae925d09a" escape="true"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that accounted for 10% or more of total revenues were as&#160;follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:68.656%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.954%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3630993f4ba446f9a740bd6e81c5a6ad_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo1YTFlODg3NzZiMDk0YzNkYTJhZjRjODIyMzMwZDM3Yi90YWJsZXJhbmdlOjVhMWU4ODc3NmIwOTRjM2RhMmFmNGM4MjIzMzBkMzdiXzEtMS0xLTEtOTQ4MzE_5211187a-0696-4c1f-8580-5d22d36a4262">18</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i18e3409174504c54b7800e5ee44a1e49_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo1YTFlODg3NzZiMDk0YzNkYTJhZjRjODIyMzMwZDM3Yi90YWJsZXJhbmdlOjVhMWU4ODc3NmIwOTRjM2RhMmFmNGM4MjIzMzBkMzdiXzEtMy0xLTEtOTQ4MzE_e7618e48-efd9-432e-9da2-d9015df6ff9f">17</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i18eef1a898514fe0a4faf29152835a3a_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo1YTFlODg3NzZiMDk0YzNkYTJhZjRjODIyMzMwZDM3Yi90YWJsZXJhbmdlOjVhMWU4ODc3NmIwOTRjM2RhMmFmNGM4MjIzMzBkMzdiXzEtNS0xLTEtOTQ4MzE_8517283a-bb8f-4878-be74-40a2ccbc30c6">16</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i36636d2e771b4f25a4bb954e3f474155_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo1YTFlODg3NzZiMDk0YzNkYTJhZjRjODIyMzMwZDM3Yi90YWJsZXJhbmdlOjVhMWU4ODc3NmIwOTRjM2RhMmFmNGM4MjIzMzBkMzdiXzItMS0xLTEtOTQ4MzE_7f30ce58-9487-4309-a194-0ba1e9cd5b58">16</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i35cef2f6062b462484e17c3d2b33a715_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo1YTFlODg3NzZiMDk0YzNkYTJhZjRjODIyMzMwZDM3Yi90YWJsZXJhbmdlOjVhMWU4ODc3NmIwOTRjM2RhMmFmNGM4MjIzMzBkMzdiXzItMy0xLTEtOTQ4MzE_e5382aa1-dc83-4458-bed9-35ec0ac9b3af">17</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idad1bbd9ef07469495ba41c98fade794_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo1YTFlODg3NzZiMDk0YzNkYTJhZjRjODIyMzMwZDM3Yi90YWJsZXJhbmdlOjVhMWU4ODc3NmIwOTRjM2RhMmFmNGM4MjIzMzBkMzdiXzItNS0xLTEtOTQ4MzE_31649801-1fb0-4028-b9b6-87864aae2f71">17</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health,&#160;Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaff05b11cfdd4a25ba35f7b6f554d5c4_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo1YTFlODg3NzZiMDk0YzNkYTJhZjRjODIyMzMwZDM3Yi90YWJsZXJhbmdlOjVhMWU4ODc3NmIwOTRjM2RhMmFmNGM4MjIzMzBkMzdiXzMtMS0xLTEtOTQ4MzE_158a10eb-2223-4ef1-8009-9cf8eafda937">12</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i23b4bebac662486b914059dbbda7d89e_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo1YTFlODg3NzZiMDk0YzNkYTJhZjRjODIyMzMwZDM3Yi90YWJsZXJhbmdlOjVhMWU4ODc3NmIwOTRjM2RhMmFmNGM4MjIzMzBkMzdiXzMtMy0xLTEtOTQ4MzE_af176261-c79e-4f5f-9067-af8f5c7fad75">13</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie831ea955b1b4600b7818bcbb63030ae_D20190101-20191231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo1YTFlODg3NzZiMDk0YzNkYTJhZjRjODIyMzMwZDM3Yi90YWJsZXJhbmdlOjVhMWU4ODc3NmIwOTRjM2RhMmFmNGM4MjIzMzBkMzdiXzMtNS0xLTEtOTQ4MzE_8095df51-5700-426f-bb20-db2172555a48">14</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-74</span></div></div></div><div id="i8256f225f07d49409c31f7443adffdbf_382"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div></div><div style="border-color:#ffffff;border-style:solid;border-width:0.00pt;padding:42.75pt 49.50pt 42.75pt 49.50pt"><div style="margin-top:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">23.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zODIvZnJhZzozMDUwZjFhZDIxMGY0NjM2OGNhNDI3NzU0MzY1NzgyZS90ZXh0cmVnaW9uOjMwNTBmMWFkMjEwZjQ2MzY4Y2E0Mjc3NTQzNjU3ODJlXzIyNTk_152e8085-797f-4e72-a095-bcd4694eaec5" continuedAt="iab823344cbb9445091afed901e954dbf" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><ix:continuation id="iab823344cbb9445091afed901e954dbf"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, the Company issued conditional notices of redemption to redeem in full all of its outstanding April 2025 Unsecured Notes&#8221;  and to redeem $<ix:nonFraction unitRef="usd" contextRef="i4e619b455ff146759a2117b1f93fefb2_I20220118" decimals="INF" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zODIvZnJhZzozMDUwZjFhZDIxMGY0NjM2OGNhNDI3NzU0MzY1NzgyZS90ZXh0cmVnaW9uOjMwNTBmMWFkMjEwZjQ2MzY4Y2E0Mjc3NTQzNjU3ODJlXzE0MQ_a5f7f32e-eb93-4667-898c-f205fe522558">370</ix:nonFraction>&#160;million aggregate principal amount of its outstanding December 2025 Unsecured Notes. On February 10, 2022, the Company extended these conditional notices of redemption through March 15, 2022. The redemption and discharge of the indenture governing the April 2025 Unsecured Notes&#8221;  will be conditioned upon the completion of the Credit Agreement Refinancing, as defined below. The redemption of the December 2025 Unsecured Notes will be conditioned upon the receipt of aggregate gross proceeds from the B+L IPO, the B+L Debt Financing as defined below, the Credit Agreement Refinancing and the offering of the February 2027 Secured Notes, as defined below, of at least $<ix:nonFraction unitRef="usd" contextRef="i4e619b455ff146759a2117b1f93fefb2_I20220118" decimals="INF" name="bhc:DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zODIvZnJhZzozMDUwZjFhZDIxMGY0NjM2OGNhNDI3NzU0MzY1NzgyZS90ZXh0cmVnaW9uOjMwNTBmMWFkMjEwZjQ2MzY4Y2E0Mjc3NTQzNjU3ODJlXzcyNA_493e256e-9ed8-4b2a-97c8-d448f75f3347">7,000</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, the Company announced its intention to refinance its existing Restated Credit Agreement with a Fifth Amended Restated Credit Agreement (the &#8220;New Restated Credit Agreement&#8221; and such refinancing, the &#8220;Credit Agreement Refinancing&#8221;). The New Restated Credit Agreement is expected to consist of approximately $<ix:nonFraction unitRef="usd" contextRef="i74d4a550bdbc4a13ac94ac84a9361ccb_I20220118" decimals="-6" name="bhc:DebtInstrumentExpectedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zODIvZnJhZzozMDUwZjFhZDIxMGY0NjM2OGNhNDI3NzU0MzY1NzgyZS90ZXh0cmVnaW9uOjMwNTBmMWFkMjEwZjQ2MzY4Y2E0Mjc3NTQzNjU3ODJlXzEwNTQ_fbeaf781-8d15-464a-975a-eee1886c58e0">2,500</ix:nonFraction>&#160;million of term B loans and a $<ix:nonFraction unitRef="usd" contextRef="i2c8a1f0a665d43229d899da271c970a6_I20220118" decimals="-6" name="bhc:LineOfCreditFacilityExpectedMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zODIvZnJhZzozMDUwZjFhZDIxMGY0NjM2OGNhNDI3NzU0MzY1NzgyZS90ZXh0cmVnaW9uOjMwNTBmMWFkMjEwZjQ2MzY4Y2E0Mjc3NTQzNjU3ODJlXzEwNzk_5fe08cc4-3211-43f8-b467-fbb6a18fe7d8">975</ix:nonFraction>&#160;million revolving credit facility. The Credit Agreement Refinancing is expected to occur only upon completion of the B+L IPO and a related debt financing by Bausch + Lomb (the &#8220;B+L Debt Financing&#8221;). At the time of the B+L IPO, the Credit Agreement Refinancing will provide that Bausch + Lomb initially be a &#8220;restricted&#8221; subsidiary subject to the terms of the Credit Agreement covenants, however the Credit Agreement Refinancing is expected to permit the Company to designate Bausch + Lomb as an &#8220;unrestricted&#8221; subsidiary under the New Restated Credit Agreement covenants upon achievement of a <ix:nonFraction unitRef="number" contextRef="if17269c4e45643c89336bb79651ea5eb_D20220118-20220118" decimals="INF" name="bhc:DebtInstrumentCovenantTotalLeverageRatio" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zODIvZnJhZzozMDUwZjFhZDIxMGY0NjM2OGNhNDI3NzU0MzY1NzgyZS90ZXh0cmVnaW9uOjMwNTBmMWFkMjEwZjQ2MzY4Y2E0Mjc3NTQzNjU3ODJlXzExMTE_87b59f03-07de-4115-b2d8-f3ab4d925b6a">7.6</ix:nonFraction>x pro forma &#8220;Remainco Total Leverage Ratio.&#8221; Such designation could take place at any time after the B+L IPO (including as soon as the closing of the B+L IPO). The Credit Agreement Refinancing is designed to facilitate the separation and distribution of Bausch + Lomb. The Credit Agreement Refinancing will not be consummated until completion of the B+L IPO and related B+L Debt Financing. There can be no assurance that the Credit Agreement Refinancing will occur on the terms described above, or at all. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2022, the Company issued $<ix:nonFraction unitRef="usd" contextRef="ib440abcc71694fa09f8e1ad1955b47b3_I20220210" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zODIvZnJhZzozMDUwZjFhZDIxMGY0NjM2OGNhNDI3NzU0MzY1NzgyZS90ZXh0cmVnaW9uOjMwNTBmMWFkMjEwZjQ2MzY4Y2E0Mjc3NTQzNjU3ODJlXzExNjA_a162e295-ca06-4715-9f7d-0a898ba35a97">1,000</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="ib440abcc71694fa09f8e1ad1955b47b3_I20220210" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zODIvZnJhZzozMDUwZjFhZDIxMGY0NjM2OGNhNDI3NzU0MzY1NzgyZS90ZXh0cmVnaW9uOjMwNTBmMWFkMjEwZjQ2MzY4Y2E0Mjc3NTQzNjU3ODJlXzExOTM_588a6e93-7f54-42ca-a25e-29812b915be0">6.125</ix:nonFraction>% senior secured notes due February 2027 (the &#8220;February 2027 Secured Notes&#8221;). The February 2027 Secured Notes accrue interest at a rate of <ix:nonFraction unitRef="number" contextRef="ib440abcc71694fa09f8e1ad1955b47b3_I20220210" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zODIvZnJhZzozMDUwZjFhZDIxMGY0NjM2OGNhNDI3NzU0MzY1NzgyZS90ZXh0cmVnaW9uOjMwNTBmMWFkMjEwZjQ2MzY4Y2E0Mjc3NTQzNjU3ODJlXzEzMzM_588a6e93-7f54-42ca-a25e-29812b915be0">6.125</ix:nonFraction>% per year, payable semi-annually in arrears on each February and August. The February 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after February 2024, at the redemption prices set forth in the indenture. The Company may redeem some or all of the February 2027 Secured Notes prior to February 2024 at a price equal to <ix:nonFraction unitRef="number" contextRef="i4d0ad67661d948d99c4ae13e0a3670a2_D20220210-20220210" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zODIvZnJhZzozMDUwZjFhZDIxMGY0NjM2OGNhNDI3NzU0MzY1NzgyZS90ZXh0cmVnaW9uOjMwNTBmMWFkMjEwZjQ2MzY4Y2E0Mjc3NTQzNjU3ODJlXzE3MTE_c84b65ba-636f-4b60-a2fa-8e98fa4c055b">100</ix:nonFraction>% of the principal amount thereof plus a &#8220;make-whole&#8221; premium. Prior to February 2024, the Company may redeem up to <ix:nonFraction unitRef="number" contextRef="i6c6a7f652a6543c78115ce45b38d0293_D20220210-20220210" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zODIvZnJhZzozMDUwZjFhZDIxMGY0NjM2OGNhNDI3NzU0MzY1NzgyZS90ZXh0cmVnaW9uOjMwNTBmMWFkMjEwZjQ2MzY4Y2E0Mjc3NTQzNjU3ODJlXzE4Mjg_0f74805a-8ed2-4461-b96b-4b6dc46da484">40</ix:nonFraction>% of the aggregate principal amount of the February 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the B+L IPO does not occur on or prior to August 15, 2022, the Company will be required to redeem the February 2027 Secured Notes at such time at a redemption price equal to the issue price of the February 2027 Secured Notes plus accrued and unpaid interest.</span></div></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-75</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>bhc-20220510.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:9acca3cc-2386-49dd-bd2b-e67723848b1a,g:d4f0cfd5-5dd4-484a-81ac-21ef5810b617-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bhc="http://www.bauschhealth.com/20220510" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.bauschhealth.com/20220510">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20220510_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20220510_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20220510_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bhc-20220510_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Document" roleURI="http://www.bauschhealth.com/role/Document">
        <link:definition>000010001 - Document - Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>100010002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>100020003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>100030004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>100040005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT">
        <link:definition>100050006 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>100060007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESS" roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS">
        <link:definition>210011001 - Disclosure - DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESSNarrativeDetails" roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails">
        <link:definition>240024001 - Disclosure - DESCRIPTION OF BUSINESS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>210031002 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>220042001 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>230053001 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
        <link:definition>240064002 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails">
        <link:definition>240074003 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Concentrations of Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails">
        <link:definition>240084004 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Activity in Allowance for Credit Losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails">
        <link:definition>240094005 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails">
        <link:definition>240104006 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails">
        <link:definition>240114007 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Variable Consideration Provisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails">
        <link:definition>240124008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails">
        <link:definition>240134009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESAdvertisingCostsDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdvertisingCostsDetails">
        <link:definition>240144010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESInterestExpenseDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInterestExpenseDetails">
        <link:definition>240154011 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails">
        <link:definition>240164012 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESEmployeeBenefitPlansDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESEmployeeBenefitPlansDetails">
        <link:definition>240174013 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails" roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails">
        <link:definition>240184014 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Adoption of New Accounting Standards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURE" roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURE">
        <link:definition>210191003 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURETables" roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURETables">
        <link:definition>230203002 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails" roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails">
        <link:definition>240214015 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>240224016 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Estimated Fair Value Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails" roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails">
        <link:definition>240234017 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Assets and Liabilities Held For Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS" roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS">
        <link:definition>210241004 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails">
        <link:definition>240254018 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>210261005 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>230273003 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>240284019 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails">
        <link:definition>240294020 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails">
        <link:definition>240304021 - Disclosure - FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails">
        <link:definition>240314022 - Disclosure - FAIR VALUE MEASUREMENTS - Cross-currency Swaps Included in Consolidated Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails">
        <link:definition>240324023 - Disclosure - FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails">
        <link:definition>240334024 - Disclosure - FAIR VALUE MEASUREMENTS - Foreign Currency Exchange Contracts, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails">
        <link:definition>240344025 - Disclosure - FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails">
        <link:definition>240354026 - Disclosure - FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details">
        <link:definition>240364027 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level3) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails">
        <link:definition>240374028 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails">
        <link:definition>240384029 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails" roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails">
        <link:definition>240394030 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value of Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIES" roleURI="http://www.bauschhealth.com/role/INVENTORIES">
        <link:definition>210401006 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESTables" roleURI="http://www.bauschhealth.com/role/INVENTORIESTables">
        <link:definition>230413004 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESSummaryofInventoriesNetDetails" roleURI="http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails">
        <link:definition>240424031 - Disclosure - INVENTORIES - Summary of Inventories, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYPLANTANDEQUIPMENT" roleURI="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENT">
        <link:definition>210431007 - Disclosure - PROPERTY, PLANT AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYPLANTANDEQUIPMENTTables" roleURI="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTTables">
        <link:definition>230443005 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails" roleURI="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails">
        <link:definition>240454032 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Major Components of Property, Plant, and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYPLANTANDEQUIPMENTNarrativeDetails" roleURI="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails">
        <link:definition>240464033 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILL" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL">
        <link:definition>210471008 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLTables" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables">
        <link:definition>230483006 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails">
        <link:definition>240494034 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1">
        <link:definition>240494034 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLNarrativeDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails">
        <link:definition>240504035 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails">
        <link:definition>240514036 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails">
        <link:definition>240524037 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDANDOTHERCURRENTLIABILITIES" roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES">
        <link:definition>210531009 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDANDOTHERCURRENTLIABILITIESTables" roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables">
        <link:definition>230543007 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDANDOTHERCURRENTLIABILITIESDetails" roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails">
        <link:definition>240554038 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTS" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS">
        <link:definition>210561010 - Disclosure - FINANCING ARRANGEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSTables" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables">
        <link:definition>230573008 - Disclosure - FINANCING ARRANGEMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails">
        <link:definition>240584039 - Disclosure - FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSCovenantComplianceDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails">
        <link:definition>240594040 - Disclosure - FINANCING ARRANGEMENTS - Covenant Compliance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails">
        <link:definition>240604041 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails">
        <link:definition>240614042 - Disclosure - FINANCING ARRANGEMENTS - Current Description of Senior Secured Credit Facilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails">
        <link:definition>240624043 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails">
        <link:definition>240634044 - Disclosure - FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails">
        <link:definition>240644045 - Disclosure - FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails" roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails">
        <link:definition>240654046 - Disclosure - FINANCING ARRANGEMENTS - Maturities, Schedule of Maturities and Mandatory Payments of Debt Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS">
        <link:definition>210661011 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables">
        <link:definition>230673009 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails">
        <link:definition>240684047 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails">
        <link:definition>240694048 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails">
        <link:definition>240704049 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails">
        <link:definition>240714050 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Change in Benefit Obligation, Plan Assets and Funded Status (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1">
        <link:definition>240714050 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Change in Benefit Obligation, Plan Assets and Funded Status (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails">
        <link:definition>240724051 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Underfunded Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails">
        <link:definition>240734052 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Future Benefit Payments for the Pension Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails">
        <link:definition>240744053 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Weighted-Average Assumptions Used to Determine Net Periodic Benefit Costs and Benefit Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails">
        <link:definition>240754054 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Actual Asset Allocations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails" roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails">
        <link:definition>240764055 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with the Acquisition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.bauschhealth.com/role/LEASES">
        <link:definition>210771012 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://www.bauschhealth.com/role/LEASESTables">
        <link:definition>230783010 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESRightofuseAssetsandRightofuseLiabilitiesDetails" roleURI="http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails">
        <link:definition>240794056 - Disclosure - LEASES - Right-of-use Assets and Right-of-use Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESNarrativeDetails" roleURI="http://www.bauschhealth.com/role/LEASESNarrativeDetails">
        <link:definition>240804057 - Disclosure - LEASES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLeaseExpensesDetails" roleURI="http://www.bauschhealth.com/role/LEASESLeaseExpensesDetails">
        <link:definition>240814058 - Disclosure - LEASES - Lease Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLeaseAdditionalInformationDetails" roleURI="http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails">
        <link:definition>240824059 - Disclosure - LEASES - Lease Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLeaseFuturePaymentsDetails" roleURI="http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails">
        <link:definition>240834060 - Disclosure - LEASES - Lease Future Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLeaseFuturePaymentsDetails_1" roleURI="http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1">
        <link:definition>240834060 - Disclosure - LEASES - Lease Future Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATION" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION">
        <link:definition>210841013 - Disclosure - SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONTables" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables">
        <link:definition>230853011 - Disclosure - SHARE-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>240864061 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails">
        <link:definition>240874062 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONStockOptionsDetails" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails">
        <link:definition>240884063 - Disclosure - SHARE-BASED COMPENSATION - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONRSUsDetails" roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails">
        <link:definition>240894064 - Disclosure - SHARE-BASED COMPENSATION - RSUs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSS" roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS">
        <link:definition>210901014 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables">
        <link:definition>230913012 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails" roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails">
        <link:definition>240924065 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Accumulated Other Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESEARCHANDDEVELOPMENT" roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT">
        <link:definition>210931015 - Disclosure - RESEARCH AND DEVELOPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESEARCHANDDEVELOPMENTTables" roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables">
        <link:definition>230943013 - Disclosure - RESEARCH AND DEVELOPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails" roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails">
        <link:definition>240954066 - Disclosure - RESEARCH AND DEVELOPMENT - Schedule of Research and Development Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSENET" roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENET">
        <link:definition>210961016 - Disclosure - OTHER EXPENSE, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSENETTables" roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETTables">
        <link:definition>230973014 - Disclosure - OTHER EXPENSE, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails" roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails">
        <link:definition>240984067 - Disclosure - OTHER EXPENSE, NET - Schedule of Other Expense (Income), Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHEREXPENSENETNarrativeDetails" roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails">
        <link:definition>240994068 - Disclosure - OTHER EXPENSE, NET - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.bauschhealth.com/role/INCOMETAXES">
        <link:definition>211001017 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://www.bauschhealth.com/role/INCOMETAXESTables">
        <link:definition>231013015 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails" roleURI="http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails">
        <link:definition>241024069 - Disclosure - INCOME TAXES - Components of Benefit from Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails" roleURI="http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails">
        <link:definition>241034070 - Disclosure - INCOME TAXES - Schedule of Effective Income Tax Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>241044071 - Disclosure - INCOME TAXES - Tax Effect of Major Items Recorded as Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails" roleURI="http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails">
        <link:definition>241054072 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Deferred Tax Asset Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNarrativeDetails" roleURI="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails">
        <link:definition>241064073 - Disclosure - INCOME TAXES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails" roleURI="http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails">
        <link:definition>241074074 - Disclosure - INCOME TAXES - Federal Income Tax Returns by Jurisdiction (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails" roleURI="http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails">
        <link:definition>241084075 - Disclosure - INCOME TAXES - Reconciliation Schedule of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LOSSPERSHARE" roleURI="http://www.bauschhealth.com/role/LOSSPERSHARE">
        <link:definition>211091018 - Disclosure - LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LOSSPERSHARETables" roleURI="http://www.bauschhealth.com/role/LOSSPERSHARETables">
        <link:definition>231103016 - Disclosure - LOSS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails" roleURI="http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails">
        <link:definition>241114076 - Disclosure - LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LOSSPERSHARENarrativeDetails" roleURI="http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails">
        <link:definition>241124077 - Disclosure - LOSS PER SHARE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUPPLEMENTALCASHFLOWDISCLOSURES" roleURI="http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURES">
        <link:definition>211131019 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUPPLEMENTALCASHFLOWDISCLOSURESTables" roleURI="http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESTables">
        <link:definition>231143017 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails" roleURI="http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails">
        <link:definition>241154078 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES - Schedule of Supplemental Cash Flow Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGS" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGS">
        <link:definition>211161020 - Disclosure - LEGAL PROCEEDINGS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEGALPROCEEDINGSNarrativeDetails" roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails">
        <link:definition>241174079 - Disclosure - LEGAL PROCEEDINGS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>211181021 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESNarrativeDetails" roleURI="http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails">
        <link:definition>241194080 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATION" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATION">
        <link:definition>211201022 - Disclosure - SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONTables" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables">
        <link:definition>231213018 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails">
        <link:definition>241224081 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails">
        <link:definition>241234082 - Disclosure - SEGMENT INFORMATION - Segment Revenues and Profit, Assets and Capital Expenditures, Depreciation &amp; Amortization of Intangible Assets &amp; Asset Impairments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONRevenuesbyProductCategoryDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails">
        <link:definition>241244083 - Disclosure - SEGMENT INFORMATION - Revenues by Product Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONGeographicInformationRevenueDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails">
        <link:definition>241254084 - Disclosure - SEGMENT INFORMATION - Geographic Information, Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails">
        <link:definition>241264085 - Disclosure - SEGMENT INFORMATION - Geographical Information, Long-Lived Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTINFORMATIONMajorCustomersDetails" roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails">
        <link:definition>241274086 - Disclosure - SEGMENT INFORMATION - Major Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://www.bauschhealth.com/role/SUBSEQUENTEVENTS">
        <link:definition>211281023 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSNarrativeDetails" roleURI="http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails">
        <link:definition>241294087 - Disclosure - SUBSEQUENT EVENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" abstract="false" name="RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_CanadianSecuritiesLitigationMember" abstract="true" name="CanadianSecuritiesLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PerformanceBasedRestrictedStockUnitsMember" abstract="true" name="PerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_A5.375SeniorNotesdueMarch2020Member" abstract="true" name="A5.375SeniorNotesdueMarch2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_TSRPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="TSRPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_A5.00SeniorNotesDueJanuary2028Member" abstract="true" name="A5.00SeniorNotesDueJanuary2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_A5.875SeniorNotesdueMay2023Member" abstract="true" name="A5.875SeniorNotesdueMay2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember" abstract="true" name="ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions" abstract="false" name="UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions" abstract="false" name="UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_MeasurementInputWeightedAverageDiscountRateMember" abstract="true" name="MeasurementInputWeightedAverageDiscountRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ResearchAndDevelopmentExpenseProductRelated" abstract="false" name="ResearchAndDevelopmentExpenseProductRelated" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" abstract="false" name="AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_LossContingencySettlementAgreementsNumberOfInsurers" abstract="false" name="LossContingencySettlementAgreementsNumberOfInsurers" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_BaseRateOrPrimeRateMember" abstract="true" name="BaseRateOrPrimeRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RevenuePerformanceObligationPaymentTerms" abstract="false" name="RevenuePerformanceObligationPaymentTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_SeniorSecuredTermCreditFacilitiesMember" abstract="true" name="SeniorSecuredTermCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TaxYear2005ThroughTaxYear2009Member" abstract="true" name="TaxYear2005ThroughTaxYear2009Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_NoncashCumulativeForeignCurrencyTranslationLoss" abstract="false" name="NoncashCumulativeForeignCurrencyTranslationLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_A7.00SeniorUnsecuredNotesDue2028Member" abstract="true" name="A7.00SeniorUnsecuredNotesDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="ROTCPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes500DueFebruary2029Member" abstract="true" name="SeniorNotes500DueFebruary2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bhc_SeniorNotes525DueFebruary2031Member" abstract="true" name="SeniorNotes525DueFebruary2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LupinPharmaceuticalsIncLitigationMember" abstract="true" name="LupinPharmaceuticalsIncLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BauschLombInternationalMember" abstract="true" name="BauschLombInternationalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes900DueDecember2025Member" abstract="true" name="SeniorNotes900DueDecember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OvertheCounterProductsMember" abstract="true" name="OvertheCounterProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" abstract="false" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_DerivativeGainExcludedComponent" abstract="false" name="DerivativeGainExcludedComponent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_OtherEquipmentAndLeaseholdImprovementMember" abstract="true" name="OtherEquipmentAndLeaseholdImprovementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AmerisourceBergenCorporationMember" abstract="true" name="AmerisourceBergenCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ForeignCountryStateAndLocalMember" abstract="true" name="ForeignCountryStateAndLocalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract" abstract="true" name="CapitalExpenditureAndDepreciationAndAmortizationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" abstract="false" name="RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" abstract="false" name="DebtInstrumentPeriodicPaymentQuarterlyAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_EmergingMarketsMember" abstract="true" name="EmergingMarketsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_CollaborativeAgreementMilestonePaymentsAggregate" abstract="false" name="CollaborativeAgreementMilestonePaymentsAggregate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ACertainInternationalBusinessMember" abstract="true" name="ACertainInternationalBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_MilestonePaymentRelatedToCertainProductMember" abstract="true" name="MilestonePaymentRelatedToCertainProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" abstract="false" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SalixSegmentMember" abstract="true" name="SalixSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" abstract="false" name="LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" abstract="false" name="DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_ReserveForRebatesAdvertisingCreditsPortionMember" abstract="true" name="ReserveForRebatesAdvertisingCreditsPortionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" abstract="false" name="UnrecognizedTaxBenefitsIncludingInterestAndPenalties" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock" abstract="false" name="ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_SeniorSecured5.50NotesDueNovember2025Member" abstract="true" name="SeniorSecured5.50NotesDueNovember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ValeantUSSecuritiesLitigationMember" abstract="true" name="ValeantUSSecuritiesLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorSecuredCreditFacilitiesMember" abstract="true" name="SeniorSecuredCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AccumulatedLossesAvailableForFederalPurposes" abstract="false" name="AccumulatedLossesAvailableForFederalPurposes" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ReserveForRebatesMember" abstract="true" name="ReserveForRebatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_InvestmentGradeMember" abstract="true" name="InvestmentGradeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes525DueJanuary2030Member" abstract="true" name="SeniorNotes525DueJanuary2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ShowertoShowerProductLiabilityLitigationMember" abstract="true" name="ShowertoShowerProductLiabilityLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LitigationwithFormerSalixCEOMember" abstract="true" name="LitigationwithFormerSalixCEOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" abstract="false" name="IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ReportingUnitImpairmentTestLongTermGrowthRate" abstract="false" name="ReportingUnitImpairmentTestLongTermGrowthRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_SeniorNotes6125DueApril2025Member" abstract="true" name="SeniorNotes6125DueApril2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AssetsLesseeAbstract" abstract="true" name="AssetsLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" abstract="false" name="LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_UnitedStatesandPuertoRicoMember" abstract="true" name="UnitedStatesandPuertoRicoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DiversifiedProductsSegmentMember" abstract="true" name="DiversifiedProductsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember" abstract="true" name="RevolvingCreditFacilityNewRestatedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_HighlyLiquidInvestmentsMaturityPeriod" abstract="false" name="HighlyLiquidInvestmentsMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_LiabilitiesLesseeAbstract" abstract="true" name="LiabilitiesLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member" abstract="true" name="SeniorSecuredNotes7.00PercentDueMarch2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeparationAndInitialPublicOfferingCostsMember" abstract="true" name="SeparationAndInitialPublicOfferingCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit" abstract="false" name="GoodwillTransfersRelatedToSaleOfBusinessUnit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" abstract="false" name="LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_U.S.BroadMarketMember" abstract="true" name="U.S.BroadMarketMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TaxYear2015AndTaxYear2016Member" abstract="true" name="TaxYear2015AndTaxYear2016Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember" abstract="true" name="RestrictedCashAndOtherSettlementDepositsCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OtherLongTermDebtMember" abstract="true" name="OtherLongTermDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_CashDiscountsAndAllowancesSettlementPeriod" abstract="false" name="CashDiscountsAndAllowancesSettlementPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_SeniorNotes500DueJanuary2028Member" abstract="true" name="SeniorNotes500DueJanuary2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SoltaMedicalSegmentMember" abstract="true" name="SoltaMedicalSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DeviceProductsMember" abstract="true" name="DeviceProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" abstract="false" name="LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_OtherRevenuesMember" abstract="true" name="OtherRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DeferredTaxAssetsPrepaidExpenses" abstract="false" name="DeferredTaxAssetsPrepaidExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage" abstract="false" name="DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_SellingGeneralAndAdministrativeExpenseMember" abstract="true" name="SellingGeneralAndAdministrativeExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns" abstract="false" name="IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_A7.25SeniorUnsecuredNotesDue2029Member" abstract="true" name="A7.25SeniorUnsecuredNotesDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RevolvingCreditFacilityDueJune2023Member" abstract="true" name="RevolvingCreditFacilityDueJune2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReserveForChargebacksMember" abstract="true" name="ReserveForChargebacksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" abstract="false" name="LossContingencyNewClaimsFiledButNotYetServedNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_A9.00SeniorNotesdueDecember2025Member" abstract="true" name="A9.00SeniorNotesdueDecember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DeferredIncomeTaxNoncashExpenseBenefit" abstract="false" name="DeferredIncomeTaxNoncashExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_RICOClassActionsLitigationMember" abstract="true" name="RICOClassActionsLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_IncomeTaxLineItems" abstract="true" name="IncomeTaxLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" abstract="false" name="GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantTotalLeverageRatio" abstract="false" name="DebtInstrumentCovenantTotalLeverageRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance" abstract="false" name="DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_A5.25SeniorNotesDueJanuary2030Member" abstract="true" name="A5.25SeniorNotesDueJanuary2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_MSNLaboratoriesPrivateLtdLitigationMember" abstract="true" name="MSNLaboratoriesPrivateLtdLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BrandedandOtherGenericProductsMember" abstract="true" name="BrandedandOtherGenericProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DefinedBenefitPlanPercentageAllocationofFund" abstract="false" name="DefinedBenefitPlanPercentageAllocationofFund" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_AccretionForTimeValueOfMoneyMember" abstract="true" name="AccretionForTimeValueOfMoneyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" abstract="false" name="BusinessCombinationContingentConsiderationNoncurrentLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" abstract="false" name="ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock" abstract="false" name="ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_ReserveForDistributionFeesMember" abstract="true" name="ReserveForDistributionFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SynergyPharmaceuticalsInc.Member" abstract="true" name="SynergyPharmaceuticalsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_NonU.S.OtherAssetsMember" abstract="true" name="NonU.S.OtherAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AccruedAndOtherCurrentLiabilitiesMember" abstract="true" name="AccruedAndOtherCurrentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" abstract="true" name="GlumetzaAntitrustLitigationNonClassComplaintsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes625DueFebruary2029Member" abstract="true" name="SeniorNotes625DueFebruary2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax" abstract="false" name="IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_PriceAppreciationCreditMember" abstract="true" name="PriceAppreciationCreditMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes700DueMarch2024Member" abstract="true" name="SeniorNotes700DueMarch2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PerrigoIsraelPharmaceuticalsLitigationMember" abstract="true" name="PerrigoIsraelPharmaceuticalsLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_IncomeTaxTable" abstract="true" name="IncomeTaxTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bhc_OtherPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="OtherPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorSecured6125NotesDueFebruary2027Member" abstract="true" name="SeniorSecured6125NotesDueFebruary2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DeferredTaxAssetsTaxLossCarryforwards" abstract="false" name="DeferredTaxAssetsTaxLossCarryforwards" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember" abstract="true" name="A5875SeniorNotesDueMay2023March2019RefinancingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember" abstract="true" name="PooledScientificResearchAndExperimentalDevelopmentExpendituresMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DefinedBenefitPlanEmployerContributionMaximumAge" abstract="false" name="DefinedBenefitPlanEmployerContributionMaximumAge" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_ReportingUnitsExcludingOrthoDermatologicsMember" abstract="true" name="ReportingUnitsExcludingOrthoDermatologicsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ScheduleOfCommitmentsLineItems" abstract="true" name="ScheduleOfCommitmentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_DiscontinuedProductLinesMember" abstract="true" name="DiscontinuedProductLinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax" abstract="false" name="SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity" abstract="false" name="LineOfCreditFacilityExpectedMaximumBorrowingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_AmounPharmaceuticalCompanySAEMember" abstract="true" name="AmounPharmaceuticalCompanySAEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished" abstract="false" name="BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_MitsubishiTanabePharmaCorporationMember" abstract="true" name="MitsubishiTanabePharmaCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TradeReceivableNetPortionPastDue" abstract="false" name="TradeReceivableNetPortionPastDue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" abstract="true" name="ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_AccruedProductRebateCurrent" abstract="false" name="AccruedProductRebateCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_PadagisLitigationMember" abstract="true" name="PadagisLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OmnibusIncentivePlan2014Member" abstract="true" name="OmnibusIncentivePlan2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_CrossCurrencyFinalSettlementMember" abstract="true" name="CrossCurrencyFinalSettlementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_CustomerTopTenProductsMember" abstract="true" name="CustomerTopTenProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReserveForDiscountsAndAllowancesMember" abstract="true" name="ReserveForDiscountsAndAllowancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PaymentForDebtAmortizationPrepaymentCost" abstract="false" name="PaymentForDebtAmortizationPrepaymentCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantInterestCoverageRatioMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_AllowancesForLossesOnAccountsReceivableAndInventories" abstract="false" name="AllowancesForLossesOnAccountsReceivableAndInventories" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DerivativeLawsuitsMember" abstract="true" name="DerivativeLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_NumberOfLargestWholesaleCustomers" abstract="false" name="NumberOfLargestWholesaleCustomers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_ScheduleOfCommitmentsTable" abstract="true" name="ScheduleOfCommitmentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" abstract="false" name="AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_EyenoviaIncMember" abstract="true" name="EyenoviaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" abstract="true" name="ViolationofCanadianProvincialSecuritiesLegislationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OrthoDermatologicsReportingUnitMember" abstract="true" name="OrthoDermatologicsReportingUnitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TimeBasedRSUMember" abstract="true" name="TimeBasedRSUMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TermLoanBFacilityDueNovember2025Member" abstract="true" name="TermLoanBFacilityDueNovember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage" abstract="false" name="IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_ReserveForCustomerReturnsMember" abstract="true" name="ReserveForCustomerReturnsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" abstract="false" name="DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" abstract="false" name="DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ProductBrandsMember" abstract="true" name="ProductBrandsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorSecured4875NotesDueJune2028Member" abstract="true" name="SeniorSecured4875NotesDueJune2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" abstract="true" name="ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_TermLoanBFacilityDueJune2025Member" abstract="true" name="TermLoanBFacilityDueJune2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OtherCountriesMember" abstract="true" name="OtherCountriesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" abstract="false" name="DebtInstrumentCovenantTermsFixedChargeCoverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits" abstract="false" name="LossContingencyNumberOfAllegedStockholdersFiledLawsuits" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_LossContingencyStayOfApprovalPeriod" abstract="false" name="LossContingencyStayOfApprovalPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_A9.25SeniorNotesDueApril2026Member" abstract="true" name="A9.25SeniorNotesDueApril2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" abstract="false" name="SummaryOfValuationAndQualifyingAccountsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_SeniorNotes925DueApril2026Member" abstract="true" name="SeniorNotes925DueApril2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_TermLoanBFacilityNewRestatedCreditAgreementMember" abstract="true" name="TermLoanBFacilityNewRestatedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_NonU.S.DevelopedMarketsMember" abstract="true" name="NonU.S.DevelopedMarketsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" abstract="false" name="LineOfCreditFacilityThresholdForIncrementalBorrowings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_PartnerRelationshipsMember" abstract="true" name="PartnerRelationshipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BauschLombMember" abstract="true" name="BauschLombMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentAnnualAmortizationRatePercentage" abstract="false" name="DebtInstrumentAnnualAmortizationRatePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans" abstract="false" name="DefinedBenefitPlanNumberofDefinedBenefitPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_IncomeTaxReconciliationUncertainTaxPositions" abstract="false" name="IncomeTaxReconciliationUncertainTaxPositions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_PeriodReceivableOutstanding" abstract="false" name="PeriodReceivableOutstanding" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_SeniorNotes700DueJanuary2028Member" abstract="true" name="SeniorNotes700DueJanuary2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes550DueMarch2023Member" abstract="true" name="SeniorNotes550DueMarch2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RestructuringChargesAndInitialPublicOfferingCosts" abstract="false" name="RestructuringChargesAndInitialPublicOfferingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_A5.50SeniorNotesdueMarch2023Member" abstract="true" name="A5.50SeniorNotesdueMarch2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities" abstract="false" name="MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_EquipmentOnOperatingLeaseMember" abstract="true" name="EquipmentOnOperatingLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorUnsecuredNotesDue2023Member" abstract="true" name="SeniorUnsecuredNotesDue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" abstract="false" name="DebtInstrumentCovenantTotalLeverageRatioMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" abstract="false" name="AccountsReceivableAllowanceForForeignExchangeAndOther" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" abstract="false" name="AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" abstract="false" name="PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_CanadaBankersAcceptanceRateMember" abstract="true" name="CanadaBankersAcceptanceRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ApotexIncLitigationMember" abstract="true" name="ApotexIncLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" abstract="false" name="SummaryOfResearchAndDevelopmentExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_PlaintiffsDirectPurchasersMember" abstract="true" name="PlaintiffsDirectPurchasersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual" abstract="false" name="BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" abstract="false" name="OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_NovaliqGmbHMember" abstract="true" name="NovaliqGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DivestituresOfNoncoreProductsPolicyTextBlock" abstract="false" name="DivestituresOfNoncoreProductsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" abstract="false" name="PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ThreeLargestUSWholesalerCustomersMember" abstract="true" name="ThreeLargestUSWholesalerCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OtherIncomeExpenseNet" abstract="false" name="OtherIncomeExpenseNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes" abstract="false" name="DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_Legalsettlementsandrelatedfees" abstract="false" name="Legalsettlementsandrelatedfees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_InsuranceCoverageLawsuitMember" abstract="true" name="InsuranceCoverageLawsuitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" abstract="false" name="BusinessAcquisitionContingentConsiderationFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" abstract="false" name="LossContingencyPlaintiffsNumberofGroupsofInvestors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_A6.125SeniorNotesdueApril2025Member" abstract="true" name="A6.125SeniorNotesdueApril2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AccruedProductReturnCurrent" abstract="false" name="AccruedProductReturnCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock" abstract="false" name="AdditionalOperatingLeaseInformationLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_A8.50SeniorNotesDueJanuary2027Member" abstract="true" name="A8.50SeniorNotesDueJanuary2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DebtInstrumentExpectedFaceAmount" abstract="false" name="DebtInstrumentExpectedFaceAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ScheduleOfOtherIncomeAndExpensesLineItems" abstract="true" name="ScheduleOfOtherIncomeAndExpensesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_McKessonCorporationMember" abstract="true" name="McKessonCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DoctorsAllergyFormulaLLCLitigationMember" abstract="true" name="DoctorsAllergyFormulaLLCLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember" abstract="true" name="A5875SeniorNotesDueMay2023May2019RefinancingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate" abstract="false" name="LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_PharmaceuticalProductsMember" abstract="true" name="PharmaceuticalProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" abstract="false" name="UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" abstract="false" name="DebtInstrumentRedemptionPricePercentageChangeinControl" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_NonemployeeDirectorMember" abstract="true" name="NonemployeeDirectorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member" abstract="true" name="SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_ScheduleOfOtherIncomeAndExpensesTable" abstract="true" name="ScheduleOfOtherIncomeAndExpensesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="bhc_DebtInstrumentAmountAvailableForRestrictedPayments" abstract="false" name="DebtInstrumentAmountAvailableForRestrictedPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_CardinalHealthIncMember" abstract="true" name="CardinalHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" abstract="false" name="PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_GainLossRelatedToLitigationSettlementGross" abstract="false" name="GainLossRelatedToLitigationSettlementGross" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_FairValueAdjustmentsMember" abstract="true" name="FairValueAdjustmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ResearchAndDevelopmentExpenseQualityAssurance" abstract="false" name="ResearchAndDevelopmentExpenseQualityAssurance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" abstract="false" name="DebtInstrumentCovenantTermsSecuredLeverageRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bhc_UnutilizedITInfrastructureImprovementProjectMember" abstract="true" name="UnutilizedITInfrastructureImprovementProjectMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions" abstract="false" name="UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_NumberOfOtherBusinessesAcquired" abstract="false" name="NumberOfOtherBusinessesAcquired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_BusinessAcquisitionProFormaOperatingIncomeLoss" abstract="false" name="BusinessAcquisitionProFormaOperatingIncomeLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents" abstract="false" name="MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_PastDuePeriodForAccountsReceivableToBeNegligible" abstract="false" name="PastDuePeriodForAccountsReceivableToBeNegligible" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_SeniorNotes850DueJanuary2027Member" abstract="true" name="SeniorNotes850DueJanuary2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_GlobalHighYieldMember" abstract="true" name="GlobalHighYieldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member" abstract="true" name="SeniorSecuredNotes6.50PercentDueMarch2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OtherAssetsFixedIncomeSecuritiesMember" abstract="true" name="OtherAssetsFixedIncomeSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RestructuringAndIntegrationCostsMember" abstract="true" name="RestructuringAndIntegrationCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool" abstract="false" name="DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_AllegroOphthalmicsLLCMember" abstract="true" name="AllegroOphthalmicsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected" abstract="false" name="AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_ConcentrationRiskNumberOfProducts" abstract="false" name="ConcentrationRiskNumberOfProducts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_InternationalRxMember" abstract="true" name="InternationalRxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AcquiredInProcessResearchAndDevelopmentMember" abstract="true" name="AcquiredInProcessResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember" abstract="true" name="SeniorSecuredNotesAndSeniorUnsecuredNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ConcentrationRiskPercentageofNetTradeReceivables" abstract="false" name="ConcentrationRiskPercentageofNetTradeReceivables" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_InterestSettlementOnCrossCurrencySwaps" abstract="false" name="InterestSettlementOnCrossCurrencySwaps" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember" abstract="true" name="CertainProductsForDisposalSeptemberTwoThousandNineteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_RestrictedCashAndOtherSettlementDepositsCurrent" abstract="false" name="RestrictedCashAndOtherSettlementDepositsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" abstract="false" name="SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SandozLitigationMember" abstract="true" name="SandozLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OrthoDermatologicsSegmentMember" abstract="true" name="OrthoDermatologicsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_TermLoanBFacilityDueJune2025AndNovember2025Member" abstract="true" name="TermLoanBFacilityDueJune2025AndNovember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_NewRestatedCreditAgreementMember" abstract="true" name="NewRestatedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorNotes4.502023Member" abstract="true" name="SeniorNotes4.502023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_TaxBenefitRecognitionMeasurementPercentage" abstract="false" name="TaxBenefitRecognitionMeasurementPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax" abstract="false" name="SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_SeniorNotes725DueMay2029Member" abstract="true" name="SeniorNotes725DueMay2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended" abstract="false" name="DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_LossContingencyNumberOfInsurancePolicyPeriods" abstract="false" name="LossContingencyNumberOfInsurancePolicyPeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod" abstract="false" name="DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bhc_SeniorNotes5.625PercentDueDecember2021Member" abstract="true" name="SeniorNotes5.625PercentDueDecember2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_RevenuesNetMember" abstract="true" name="RevenuesNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_IncomeTaxReconciliationDeferredIntercompanyProfit" abstract="false" name="IncomeTaxReconciliationDeferredIntercompanyProfit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" abstract="false" name="DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_GlumetzaAntitrustLitigationMember" abstract="true" name="GlumetzaAntitrustLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" abstract="false" name="ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" abstract="false" name="LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember" abstract="true" name="SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_SeniorSecured5.75NotesDueAugust2027Member" abstract="true" name="SeniorSecured5.75NotesDueAugust2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" abstract="false" name="LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="bhc_CedarsSinaiMedicalCenterMember" abstract="true" name="CedarsSinaiMedicalCenterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bhc_OutLicensedTechnologyMember" abstract="true" name="OutLicensedTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>bhc-20220510_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:9acca3cc-2386-49dd-bd2b-e67723848b1a,g:d4f0cfd5-5dd4-484a-81ac-21ef5810b617-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bhc-20220510.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_98b8a87d-3d83-480b-a7f3-ff5fa36ba5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2a58225a-e922-4a58-b566-2dd27413f679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_98b8a87d-3d83-480b-a7f3-ff5fa36ba5e9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2a58225a-e922-4a58-b566-2dd27413f679" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_9ed7d620-71bb-4889-aa31-014a76944e6f" xlink:href="bhc-20220510.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_98b8a87d-3d83-480b-a7f3-ff5fa36ba5e9" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_9ed7d620-71bb-4889-aa31-014a76944e6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_0fe7139e-5ce9-43a0-8775-e5910c2ec2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_98b8a87d-3d83-480b-a7f3-ff5fa36ba5e9" xlink:to="loc_us-gaap_ReceivablesNetCurrent_0fe7139e-5ce9-43a0-8775-e5910c2ec2b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d299ebb0-d7c4-485c-958f-c2c8d2547a38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_98b8a87d-3d83-480b-a7f3-ff5fa36ba5e9" xlink:to="loc_us-gaap_InventoryNet_d299ebb0-d7c4-485c-958f-c2c8d2547a38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5b8fe110-ccdf-4b7d-a9a6-6fa6be8dce9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_98b8a87d-3d83-480b-a7f3-ff5fa36ba5e9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5b8fe110-ccdf-4b7d-a9a6-6fa6be8dce9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_617d8a52-ee3c-40b9-80bc-337146c78030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2bbfa8d3-052b-4f05-9ff4-eacc4811cb5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_617d8a52-ee3c-40b9-80bc-337146c78030" xlink:to="loc_us-gaap_AssetsCurrent_2bbfa8d3-052b-4f05-9ff4-eacc4811cb5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fb6a4a57-9877-4eb4-b344-5ede921533a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_617d8a52-ee3c-40b9-80bc-337146c78030" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fb6a4a57-9877-4eb4-b344-5ede921533a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_51b8ada2-8c6c-4cf0-bb8c-b0eba264113e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_617d8a52-ee3c-40b9-80bc-337146c78030" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_51b8ada2-8c6c-4cf0-bb8c-b0eba264113e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_149905d2-c37a-4658-ac1e-d16bd199d2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_617d8a52-ee3c-40b9-80bc-337146c78030" xlink:to="loc_us-gaap_Goodwill_149905d2-c37a-4658-ac1e-d16bd199d2f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_a4890db1-a6d1-491c-a54d-5d74de962185" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_617d8a52-ee3c-40b9-80bc-337146c78030" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_a4890db1-a6d1-491c-a54d-5d74de962185" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_cb28bddb-e329-4e59-89f5-db5fcd539769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_617d8a52-ee3c-40b9-80bc-337146c78030" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_cb28bddb-e329-4e59-89f5-db5fcd539769" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5ff79b5a-24c5-4df7-9432-b2e43a85e9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_94729ce6-bae1-474a-b8c6-c25c973a05bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5ff79b5a-24c5-4df7-9432-b2e43a85e9b1" xlink:to="loc_us-gaap_LiabilitiesCurrent_94729ce6-bae1-474a-b8c6-c25c973a05bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_cf490166-5b9b-4174-a5ba-910f08b038dc" xlink:href="bhc-20220510.xsd#bhc_BusinessCombinationContingentConsiderationNoncurrentLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5ff79b5a-24c5-4df7-9432-b2e43a85e9b1" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_cf490166-5b9b-4174-a5ba-910f08b038dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_17f1cda9-b4f5-46cd-b73f-e0de4ade1dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5ff79b5a-24c5-4df7-9432-b2e43a85e9b1" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_17f1cda9-b4f5-46cd-b73f-e0de4ade1dc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_13903436-ead6-4ccb-a25b-dcc5b219cf5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5ff79b5a-24c5-4df7-9432-b2e43a85e9b1" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_13903436-ead6-4ccb-a25b-dcc5b219cf5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_27962284-2344-46ae-a876-052d5d6745a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_5ff79b5a-24c5-4df7-9432-b2e43a85e9b1" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_27962284-2344-46ae-a876-052d5d6745a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_8881679a-8df7-415f-bf09-1f99e9bfd840" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_298caab2-6071-4bce-b92c-f5fe4a643d50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8881679a-8df7-415f-bf09-1f99e9bfd840" xlink:to="loc_us-gaap_Liabilities_298caab2-6071-4bce-b92c-f5fe4a643d50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9fc61211-2959-4109-9035-570d8d968c42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8881679a-8df7-415f-bf09-1f99e9bfd840" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9fc61211-2959-4109-9035-570d8d968c42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_9e5b8453-36c5-47c7-b618-26eecb887417" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_8881679a-8df7-415f-bf09-1f99e9bfd840" xlink:to="loc_us-gaap_CommitmentsAndContingencies_9e5b8453-36c5-47c7-b618-26eecb887417" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8b76cbe4-5d2d-4d84-8224-f24d83f33d16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_dff64875-d108-4d6f-b33b-e00c6cf3d213" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8b76cbe4-5d2d-4d84-8224-f24d83f33d16" xlink:to="loc_us-gaap_AccountsPayableCurrent_dff64875-d108-4d6f-b33b-e00c6cf3d213" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_41f4cf21-d79d-4694-966a-e5dd910261b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8b76cbe4-5d2d-4d84-8224-f24d83f33d16" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_41f4cf21-d79d-4694-966a-e5dd910261b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5bbebced-f151-46b5-ba2e-778f020fca7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_dc5f478f-abb3-4269-8440-85db104c70ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5bbebced-f151-46b5-ba2e-778f020fca7c" xlink:to="loc_us-gaap_CommonStockValue_dc5f478f-abb3-4269-8440-85db104c70ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_36d68b81-717f-4ef0-9560-4e2d177b9f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5bbebced-f151-46b5-ba2e-778f020fca7c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_36d68b81-717f-4ef0-9560-4e2d177b9f4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_248b5e28-02d9-431f-8354-ca07a3cc7214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5bbebced-f151-46b5-ba2e-778f020fca7c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_248b5e28-02d9-431f-8354-ca07a3cc7214" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_95168698-35cd-4cba-b881-4088391d9233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5bbebced-f151-46b5-ba2e-778f020fca7c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_95168698-35cd-4cba-b881-4088391d9233" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8d82d2ec-c846-4e4e-ae13-65fbcd201ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_03ade0fc-386d-4712-9fdc-7ec9a1bebd94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8d82d2ec-c846-4e4e-ae13-65fbcd201ece" xlink:to="loc_us-gaap_StockholdersEquity_03ade0fc-386d-4712-9fdc-7ec9a1bebd94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_568e0932-8288-4073-8336-dc0ec0d378a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_8d82d2ec-c846-4e4e-ae13-65fbcd201ece" xlink:to="loc_us-gaap_MinorityInterest_568e0932-8288-4073-8336-dc0ec0d378a8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bhc-20220510.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c983d1c9-1ca9-4347-833f-4666d67e358a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_65b41f1f-ad71-41cb-b04b-9135eea26603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c983d1c9-1ca9-4347-833f-4666d67e358a" xlink:to="loc_us-gaap_OperatingIncomeLoss_65b41f1f-ad71-41cb-b04b-9135eea26603" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_3a2ae7b8-f918-4088-a5e4-778695d78205" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c983d1c9-1ca9-4347-833f-4666d67e358a" xlink:to="loc_us-gaap_InvestmentIncomeInterest_3a2ae7b8-f918-4088-a5e4-778695d78205" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_acee124b-276c-4734-a4e1-c3593360e5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c983d1c9-1ca9-4347-833f-4666d67e358a" xlink:to="loc_us-gaap_InterestExpenseDebt_acee124b-276c-4734-a4e1-c3593360e5b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f075e6bc-831f-4309-8c13-09491a7555df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c983d1c9-1ca9-4347-833f-4666d67e358a" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_f075e6bc-831f-4309-8c13-09491a7555df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_c0d155a9-2163-4f10-8178-cf11091ce248" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c983d1c9-1ca9-4347-833f-4666d67e358a" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_c0d155a9-2163-4f10-8178-cf11091ce248" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_860b47d6-4a7d-46a8-8b15-232f181cf976" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fa5a0c8b-3c6f-46e0-8ad2-f73f6dd7395a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_860b47d6-4a7d-46a8-8b15-232f181cf976" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fa5a0c8b-3c6f-46e0-8ad2-f73f6dd7395a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_e114f45c-00fb-470f-af91-9a40f46523a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_860b47d6-4a7d-46a8-8b15-232f181cf976" xlink:to="loc_us-gaap_CostsAndExpenses_e114f45c-00fb-470f-af91-9a40f46523a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_94508197-0153-465e-9faf-1b0b35abd157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1898c9c7-f848-4c83-a34a-934d6ab83fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_94508197-0153-465e-9faf-1b0b35abd157" xlink:to="loc_us-gaap_ProfitLoss_1898c9c7-f848-4c83-a34a-934d6ab83fdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a091bc78-6b43-4acb-8349-0188df146906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_94508197-0153-465e-9faf-1b0b35abd157" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a091bc78-6b43-4acb-8349-0188df146906" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f15d06c0-0b8c-4386-9bb2-41752a9bee21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e2865a52-2215-4a52-8ed0-6122869c40ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f15d06c0-0b8c-4386-9bb2-41752a9bee21" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e2865a52-2215-4a52-8ed0-6122869c40ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f9e8b1cc-4f30-4485-ab27-022a1a4d9a28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f15d06c0-0b8c-4386-9bb2-41752a9bee21" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f9e8b1cc-4f30-4485-ab27-022a1a4d9a28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_7f414c48-7dcd-41ae-81da-9c3da54d94c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f15d06c0-0b8c-4386-9bb2-41752a9bee21" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_7f414c48-7dcd-41ae-81da-9c3da54d94c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_8cd81bea-f296-45e0-9a79-08215c10bd3d" xlink:href="bhc-20220510.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f15d06c0-0b8c-4386-9bb2-41752a9bee21" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_8cd81bea-f296-45e0-9a79-08215c10bd3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_ab26cde5-ad93-44d2-a333-7e8191ab3423" xlink:href="bhc-20220510.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f15d06c0-0b8c-4386-9bb2-41752a9bee21" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_ab26cde5-ad93-44d2-a333-7e8191ab3423" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_b0fcb957-69ac-4bd5-9895-9c1eb8148432" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f15d06c0-0b8c-4386-9bb2-41752a9bee21" xlink:to="loc_us-gaap_AssetImpairmentCharges_b0fcb957-69ac-4bd5-9895-9c1eb8148432" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_fc961e05-087d-48cf-9af3-cfc36f1ee6a6" xlink:href="bhc-20220510.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f15d06c0-0b8c-4386-9bb2-41752a9bee21" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_fc961e05-087d-48cf-9af3-cfc36f1ee6a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_9ed6b960-477c-4429-8002-1868c4c30f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f15d06c0-0b8c-4386-9bb2-41752a9bee21" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_9ed6b960-477c-4429-8002-1868c4c30f9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1af94561-bb47-4470-a1cc-fd5a9e514b35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a0fb8eef-9d63-4f87-80c3-f0030293c029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_1af94561-bb47-4470-a1cc-fd5a9e514b35" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a0fb8eef-9d63-4f87-80c3-f0030293c029" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2faab0e6-2c47-44eb-b118-2ec04d813ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_1af94561-bb47-4470-a1cc-fd5a9e514b35" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2faab0e6-2c47-44eb-b118-2ec04d813ec8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bhc-20220510.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b1227402-3d1e-4b5d-bfb0-8d4eee53fcb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_15924bbd-78ae-486c-a34a-bc7d3561b182" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b1227402-3d1e-4b5d-bfb0-8d4eee53fcb5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_15924bbd-78ae-486c-a34a-bc7d3561b182" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_c75f2748-d415-4a84-83bd-2109d55afb9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b1227402-3d1e-4b5d-bfb0-8d4eee53fcb5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_c75f2748-d415-4a84-83bd-2109d55afb9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a9a43f9a-4fce-49a6-9d6c-a7320db90d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_c5da3ab5-6efb-4ff8-bdf2-5bca54d059fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a9a43f9a-4fce-49a6-9d6c-a7320db90d2f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_c5da3ab5-6efb-4ff8-bdf2-5bca54d059fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_46bc2d2e-6016-4da3-902b-b3e371cbec73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a9a43f9a-4fce-49a6-9d6c-a7320db90d2f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_46bc2d2e-6016-4da3-902b-b3e371cbec73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2a58ecee-03fc-49e9-8d9b-c4fd55697d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f25e7eef-6a26-4047-9521-8566683392c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2a58ecee-03fc-49e9-8d9b-c4fd55697d3a" xlink:to="loc_us-gaap_ProfitLoss_f25e7eef-6a26-4047-9521-8566683392c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_09b78847-4376-4aca-97c8-245d55078564" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_2a58ecee-03fc-49e9-8d9b-c4fd55697d3a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_09b78847-4376-4aca-97c8-245d55078564" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_c520dfec-52b0-41ed-914d-fce323dd4fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_ac690f47-d0a5-4abd-8ca8-ff7dc52a2821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_c520dfec-52b0-41ed-914d-fce323dd4fc7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_ac690f47-d0a5-4abd-8ca8-ff7dc52a2821" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax_6b897dea-5887-4b95-967c-eea42916c044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_c520dfec-52b0-41ed-914d-fce323dd4fc7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax_6b897dea-5887-4b95-967c-eea42916c044" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition_ce6d0566-17f2-498f-83cd-211abd4f91eb" xlink:href="bhc-20220510.xsd#bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_c520dfec-52b0-41ed-914d-fce323dd4fc7" xlink:to="loc_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition_ce6d0566-17f2-498f-83cd-211abd4f91eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_e88f70a9-eb5b-4245-ae57-7ca65682b66f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_c520dfec-52b0-41ed-914d-fce323dd4fc7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_e88f70a9-eb5b-4245-ae57-7ca65682b66f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax_9253260c-3d08-4ecc-a997-c908a11f3ee6" xlink:href="bhc-20220510.xsd#bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_c520dfec-52b0-41ed-914d-fce323dd4fc7" xlink:to="loc_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax_9253260c-3d08-4ecc-a997-c908a11f3ee6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bhc-20220510.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_61564224-a915-4991-86d8-41028b310b02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_10cf3b1e-20d6-4f4d-8b22-a53e9d4e8c19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_61564224-a915-4991-86d8-41028b310b02" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_10cf3b1e-20d6-4f4d-8b22-a53e9d4e8c19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_72e3b85e-1574-4199-a5f3-1a8420569767" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_61564224-a915-4991-86d8-41028b310b02" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_72e3b85e-1574-4199-a5f3-1a8420569767" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7b5ee837-7f61-48d9-964c-6d041848cc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_61564224-a915-4991-86d8-41028b310b02" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7b5ee837-7f61-48d9-964c-6d041848cc1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_bc1c1972-1fc6-4449-bea3-c00d59c2c05c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_61564224-a915-4991-86d8-41028b310b02" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_bc1c1972-1fc6-4449-bea3-c00d59c2c05c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_141f1e6d-83c4-43b0-9e02-da75657265bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_61564224-a915-4991-86d8-41028b310b02" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_141f1e6d-83c4-43b0-9e02-da75657265bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_1fb39e73-447c-4874-92e5-5b6b6c247fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_61564224-a915-4991-86d8-41028b310b02" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_1fb39e73-447c-4874-92e5-5b6b6c247fd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InterestSettlementOnCrossCurrencySwaps_906b7502-73bf-4b6f-b75c-cff69ce92cfb" xlink:href="bhc-20220510.xsd#bhc_InterestSettlementOnCrossCurrencySwaps"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_61564224-a915-4991-86d8-41028b310b02" xlink:to="loc_bhc_InterestSettlementOnCrossCurrencySwaps_906b7502-73bf-4b6f-b75c-cff69ce92cfb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f5e9457d-2fc9-4d6e-8c09-04cc99893323" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9b27f9ac-d87e-4714-82b4-6ed559ef7efe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f5e9457d-2fc9-4d6e-8c09-04cc99893323" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_9b27f9ac-d87e-4714-82b4-6ed559ef7efe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_ead23e20-f69e-411b-983e-879e2c5ddf6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f5e9457d-2fc9-4d6e-8c09-04cc99893323" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_ead23e20-f69e-411b-983e-879e2c5ddf6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_1f678d4e-250f-45fe-a210-21d9891f1b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f5e9457d-2fc9-4d6e-8c09-04cc99893323" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_1f678d4e-250f-45fe-a210-21d9891f1b8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_926815db-439d-4749-84ee-ac378598ecba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f5e9457d-2fc9-4d6e-8c09-04cc99893323" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_926815db-439d-4749-84ee-ac378598ecba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_9ef66220-6fd0-408b-929a-dd91809bfa61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f5e9457d-2fc9-4d6e-8c09-04cc99893323" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_9ef66220-6fd0-408b-929a-dd91809bfa61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_30bbb902-dca5-4e11-b93e-85a690c17b27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f5e9457d-2fc9-4d6e-8c09-04cc99893323" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_30bbb902-dca5-4e11-b93e-85a690c17b27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_fabb4193-fe0a-428d-8b4d-c4d350b11580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f5e9457d-2fc9-4d6e-8c09-04cc99893323" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_fabb4193-fe0a-428d-8b4d-c4d350b11580" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_88be60f6-ea62-4ed9-a465-c4e7b4fed1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f5e9457d-2fc9-4d6e-8c09-04cc99893323" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_88be60f6-ea62-4ed9-a465-c4e7b4fed1ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d8dc3eb-2cee-4dbe-af7b-cc16a8445384" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_487ebf8d-22a6-424e-b1dc-09f4381fb165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d8dc3eb-2cee-4dbe-af7b-cc16a8445384" xlink:to="loc_us-gaap_ProfitLoss_487ebf8d-22a6-424e-b1dc-09f4381fb165" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_7a86d79f-17dc-4786-bef3-294eff635042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d8dc3eb-2cee-4dbe-af7b-cc16a8445384" xlink:to="loc_us-gaap_DepreciationAndAmortization_7a86d79f-17dc-4786-bef3-294eff635042" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_47389cdd-ae45-4e01-a5f6-c3e807b95155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d8dc3eb-2cee-4dbe-af7b-cc16a8445384" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_47389cdd-ae45-4e01-a5f6-c3e807b95155" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_6c2c4161-5d0d-4654-87bd-6da048c74fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d8dc3eb-2cee-4dbe-af7b-cc16a8445384" xlink:to="loc_us-gaap_AssetImpairmentCharges_6c2c4161-5d0d-4654-87bd-6da048c74fd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_762620ba-7bdd-47ab-bf8f-baef76add766" xlink:href="bhc-20220510.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d8dc3eb-2cee-4dbe-af7b-cc16a8445384" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_762620ba-7bdd-47ab-bf8f-baef76add766" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_a10b9b43-dd32-4356-8016-5035f34bab7e" xlink:href="bhc-20220510.xsd#bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d8dc3eb-2cee-4dbe-af7b-cc16a8445384" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_a10b9b43-dd32-4356-8016-5035f34bab7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_19ae0434-3478-4d4b-b367-91d9f86341a6" xlink:href="bhc-20220510.xsd#bhc_AllowancesForLossesOnAccountsReceivableAndInventories"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d8dc3eb-2cee-4dbe-af7b-cc16a8445384" xlink:to="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_19ae0434-3478-4d4b-b367-91d9f86341a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_e75dcc5e-2c09-4257-9d5d-8a0186755cec" xlink:href="bhc-20220510.xsd#bhc_DeferredIncomeTaxNoncashExpenseBenefit"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d8dc3eb-2cee-4dbe-af7b-cc16a8445384" xlink:to="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_e75dcc5e-2c09-4257-9d5d-8a0186755cec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_82cf5c66-22f2-4a8b-b760-0ec2edf0b5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d8dc3eb-2cee-4dbe-af7b-cc16a8445384" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_82cf5c66-22f2-4a8b-b760-0ec2edf0b5dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainLossRelatedToLitigationSettlementGross_2d542f9b-3475-4fff-815b-96b4f6804172" xlink:href="bhc-20220510.xsd#bhc_GainLossRelatedToLitigationSettlementGross"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d8dc3eb-2cee-4dbe-af7b-cc16a8445384" xlink:to="loc_bhc_GainLossRelatedToLitigationSettlementGross_2d542f9b-3475-4fff-815b-96b4f6804172" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_43bb8e65-8349-4174-ad88-4b0e17dd7c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d8dc3eb-2cee-4dbe-af7b-cc16a8445384" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_43bb8e65-8349-4174-ad88-4b0e17dd7c3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_be37ed01-a93c-4c07-bf44-642120ccbfad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d8dc3eb-2cee-4dbe-af7b-cc16a8445384" xlink:to="loc_us-gaap_ShareBasedCompensation_be37ed01-a93c-4c07-bf44-642120ccbfad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_81575da9-ff46-45a9-b0f7-dd58a03c75a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d8dc3eb-2cee-4dbe-af7b-cc16a8445384" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_81575da9-ff46-45a9-b0f7-dd58a03c75a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeGainExcludedComponent_6bb7e889-c9cf-407e-b80d-e506b922b905" xlink:href="bhc-20220510.xsd#bhc_DerivativeGainExcludedComponent"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d8dc3eb-2cee-4dbe-af7b-cc16a8445384" xlink:to="loc_bhc_DerivativeGainExcludedComponent_6bb7e889-c9cf-407e-b80d-e506b922b905" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d31a0970-fb86-41ad-be1a-f2c893082e17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d8dc3eb-2cee-4dbe-af7b-cc16a8445384" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d31a0970-fb86-41ad-be1a-f2c893082e17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_78d90a69-dd1f-422c-82db-20f1f6c97a59" xlink:href="bhc-20220510.xsd#bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d8dc3eb-2cee-4dbe-af7b-cc16a8445384" xlink:to="loc_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_78d90a69-dd1f-422c-82db-20f1f6c97a59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_da04f64b-9671-4c81-bff9-cc06d2e46e65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d8dc3eb-2cee-4dbe-af7b-cc16a8445384" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_da04f64b-9671-4c81-bff9-cc06d2e46e65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d8ac2270-27fa-4086-8ced-c19e145a13d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d8dc3eb-2cee-4dbe-af7b-cc16a8445384" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d8ac2270-27fa-4086-8ced-c19e145a13d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bb9f56d7-44fb-4b57-94ee-bdedfb85e00a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d8dc3eb-2cee-4dbe-af7b-cc16a8445384" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bb9f56d7-44fb-4b57-94ee-bdedfb85e00a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a8115659-3492-4397-ac81-fd5c6ae5d1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="20" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d8dc3eb-2cee-4dbe-af7b-cc16a8445384" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a8115659-3492-4397-ac81-fd5c6ae5d1ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_eaaa0394-8f38-42b8-8b05-9bd19c8d5349" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="21" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5d8dc3eb-2cee-4dbe-af7b-cc16a8445384" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_eaaa0394-8f38-42b8-8b05-9bd19c8d5349" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits_7ef2e441-29a3-4238-b693-3b17fb6c1899" xlink:href="bhc-20220510.xsd#bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_320a8619-d352-4c0b-ab90-8af0163cd2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits_7ef2e441-29a3-4238-b693-3b17fb6c1899" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_320a8619-d352-4c0b-ab90-8af0163cd2fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_b1bc0751-6cac-45a2-b613-a78d7a3913b0" xlink:href="bhc-20220510.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits_7ef2e441-29a3-4238-b693-3b17fb6c1899" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_b1bc0751-6cac-45a2-b613-a78d7a3913b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_067f74ae-b55b-4b44-9d43-72b283ed51b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9796697f-6dce-48d9-bd60-47d9abbc60e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_067f74ae-b55b-4b44-9d43-72b283ed51b2" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9796697f-6dce-48d9-bd60-47d9abbc60e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_543b0f72-ff0c-4246-b691-4f1257a7f913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_067f74ae-b55b-4b44-9d43-72b283ed51b2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_543b0f72-ff0c-4246-b691-4f1257a7f913" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0443209a-a85c-4463-a134-d0ccda580fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_067f74ae-b55b-4b44-9d43-72b283ed51b2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0443209a-a85c-4463-a134-d0ccda580fc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fef578d7-d147-463d-a921-fff90537cbb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_067f74ae-b55b-4b44-9d43-72b283ed51b2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fef578d7-d147-463d-a921-fff90537cbb3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_07f6ad3c-e2b0-4674-96d4-fac7abe89383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_c1b5b3e3-867d-4ad9-a021-86bd0860fe83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_07f6ad3c-e2b0-4674-96d4-fac7abe89383" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_c1b5b3e3-867d-4ad9-a021-86bd0860fe83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_1ea17326-6d10-4a2b-a121-06337138070d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_07f6ad3c-e2b0-4674-96d4-fac7abe89383" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_1ea17326-6d10-4a2b-a121-06337138070d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_f7b95f1b-1a38-4cb6-84d6-42863146e9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_07f6ad3c-e2b0-4674-96d4-fac7abe89383" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_f7b95f1b-1a38-4cb6-84d6-42863146e9ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_398c8afd-a0d8-4cc8-8445-8f02fe0aaaae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_07f6ad3c-e2b0-4674-96d4-fac7abe89383" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_398c8afd-a0d8-4cc8-8445-8f02fe0aaaae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_83909291-f75e-4dcc-a757-e8310b3ff50a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_07f6ad3c-e2b0-4674-96d4-fac7abe89383" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_83909291-f75e-4dcc-a757-e8310b3ff50a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses_84b59ccd-74bd-46e5-80ed-98ed55c1caed" xlink:href="bhc-20220510.xsd#bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_07f6ad3c-e2b0-4674-96d4-fac7abe89383" xlink:to="loc_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses_84b59ccd-74bd-46e5-80ed-98ed55c1caed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_79f8c3f4-695d-467b-b256-63e527571f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_06334343-8c47-45f9-a523-9441721528a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_79f8c3f4-695d-467b-b256-63e527571f9e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_06334343-8c47-45f9-a523-9441721528a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d2518d31-149c-42ed-a41f-04dd0c3f2171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_79f8c3f4-695d-467b-b256-63e527571f9e" xlink:to="loc_us-gaap_Goodwill_d2518d31-149c-42ed-a41f-04dd0c3f2171" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_6779dae6-70e0-4cd4-9d10-d23dc4b5f382" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_3f3f324d-7503-48f5-9f03-372336dbad38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_6779dae6-70e0-4cd4-9d10-d23dc4b5f382" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_3f3f324d-7503-48f5-9f03-372336dbad38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent_41e19c76-9311-4aab-ac08-c6b9e8aa57bf" xlink:href="bhc-20220510.xsd#bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_6779dae6-70e0-4cd4-9d10-d23dc4b5f382" xlink:to="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent_41e19c76-9311-4aab-ac08-c6b9e8aa57bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_dc94c225-0adc-4d00-a743-887e63d35e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_e57e317a-edcd-4031-a767-1dd0665f0b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_dc94c225-0adc-4d00-a743-887e63d35e6c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_e57e317a-edcd-4031-a767-1dd0665f0b6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_ee724f0b-e89a-4f76-bb43-0394d30abf92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_dc94c225-0adc-4d00-a743-887e63d35e6c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_ee724f0b-e89a-4f76-bb43-0394d30abf92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_b09c302e-572a-48f1-b7db-22a8a88cd5da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_dc94c225-0adc-4d00-a743-887e63d35e6c" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_b09c302e-572a-48f1-b7db-22a8a88cd5da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_45e10da6-9e7c-4221-a501-ff09ff3be666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_930f19aa-609f-4c07-83da-34fe03952fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_45e10da6-9e7c-4221-a501-ff09ff3be666" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_930f19aa-609f-4c07-83da-34fe03952fb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent_d00ce104-f124-4561-8b50-c879f63d03e3" xlink:href="bhc-20220510.xsd#bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_45e10da6-9e7c-4221-a501-ff09ff3be666" xlink:to="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent_d00ce104-f124-4561-8b50-c879f63d03e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_442624be-3b0a-4db1-9c44-17e63bb1d6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_208b0c98-ee4f-448c-98a3-072a651c2d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_442624be-3b0a-4db1-9c44-17e63bb1d6e2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_208b0c98-ee4f-448c-98a3-072a651c2d2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_fbab31bb-7ee7-4077-ad68-956e86889924" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_442624be-3b0a-4db1-9c44-17e63bb1d6e2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_fbab31bb-7ee7-4077-ad68-956e86889924" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_c7c0ed63-7882-4f0d-bd6c-766c7a9793be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_442624be-3b0a-4db1-9c44-17e63bb1d6e2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_c7c0ed63-7882-4f0d-bd6c-766c7a9793be" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_ac60021d-4bb1-43b8-a1ea-0a5f0d55e2af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_edd6b933-f11c-4ead-bd09-c78abce70a55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_ac60021d-4bb1-43b8-a1ea-0a5f0d55e2af" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_edd6b933-f11c-4ead-bd09-c78abce70a55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_70a2f1fe-7d1f-407b-ade5-136dfddef763" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_ac60021d-4bb1-43b8-a1ea-0a5f0d55e2af" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_70a2f1fe-7d1f-407b-ade5-136dfddef763" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" xlink:type="simple" xlink:href="bhc-20220510.xsd#FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3e52743d-f6ea-4a99-8389-a553ce33da8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_df2fec87-8728-460c-bd0b-45a6b509afdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3e52743d-f6ea-4a99-8389-a553ce33da8f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_df2fec87-8728-460c-bd0b-45a6b509afdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_61d05047-5303-4b57-be1f-f05c6404d6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3e52743d-f6ea-4a99-8389-a553ce33da8f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_61d05047-5303-4b57-be1f-f05c6404d6a6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#INVENTORIESSummaryofInventoriesNetDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7a1432c9-4a45-4bf1-9874-78afc3406502" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_99ba6801-052a-4276-b810-dda77059f97e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_7a1432c9-4a45-4bf1-9874-78afc3406502" xlink:to="loc_us-gaap_InventoryRawMaterials_99ba6801-052a-4276-b810-dda77059f97e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_5b4edfd9-b841-4fdf-aacc-c28b2fea7194" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_7a1432c9-4a45-4bf1-9874-78afc3406502" xlink:to="loc_us-gaap_InventoryWorkInProcess_5b4edfd9-b841-4fdf-aacc-c28b2fea7194" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_ba50aae0-0747-4b8c-8bc1-49aef30a980e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_7a1432c9-4a45-4bf1-9874-78afc3406502" xlink:to="loc_us-gaap_InventoryFinishedGoods_ba50aae0-0747-4b8c-8bc1-49aef30a980e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9438450b-fd2e-40f3-9543-da6ffe541b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c7bb1fcd-1af8-4a42-9058-6cdd6ee79ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_9438450b-fd2e-40f3-9543-da6ffe541b25" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c7bb1fcd-1af8-4a42-9058-6cdd6ee79ae1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2a21cb4f-2fa2-4995-8655-773ad33e0004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_9438450b-fd2e-40f3-9543-da6ffe541b25" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2a21cb4f-2fa2-4995-8655-773ad33e0004" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_86219672-9896-4462-befc-cff2f536d881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_79652a6d-8f82-40e6-8f59-b07936f7d6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_86219672-9896-4462-befc-cff2f536d881" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_79652a6d-8f82-40e6-8f59-b07936f7d6bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_205fa013-716d-4b01-9bd5-b77e6a26495a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_86219672-9896-4462-befc-cff2f536d881" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_205fa013-716d-4b01-9bd5-b77e6a26495a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_72868a04-11da-4343-8fbb-2bc278e49a51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_01b535bf-0957-4ef4-8159-c0ffd1d35453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_72868a04-11da-4343-8fbb-2bc278e49a51" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_01b535bf-0957-4ef4-8159-c0ffd1d35453" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c329cd65-5d21-4d46-8510-4a0b2cdf4f40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_72868a04-11da-4343-8fbb-2bc278e49a51" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c329cd65-5d21-4d46-8510-4a0b2cdf4f40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b41836ca-52b7-4e92-a894-f2ac40d35cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_06fe5147-02dd-4701-85dc-364b9975dd3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b41836ca-52b7-4e92-a894-f2ac40d35cd8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_06fe5147-02dd-4701-85dc-364b9975dd3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_75efc0d6-4059-4d9a-903e-a3b8376d723a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b41836ca-52b7-4e92-a894-f2ac40d35cd8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_75efc0d6-4059-4d9a-903e-a3b8376d723a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="bhc-20220510.xsd#INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7d8d4bf8-12b5-429a-acb6-01fcd5cb75d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1a4c58ad-9d82-4401-a225-e51cdfc0beca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7d8d4bf8-12b5-429a-acb6-01fcd5cb75d8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1a4c58ad-9d82-4401-a225-e51cdfc0beca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e2b12885-ff90-4781-aee0-8b9c3a05a22b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_7d8d4bf8-12b5-429a-acb6-01fcd5cb75d8" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_e2b12885-ff90-4781-aee0-8b9c3a05a22b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f150974d-a3e1-48ed-a752-c780acf0332b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_662fd11a-0223-46fd-8f7e-c9d91565609d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f150974d-a3e1-48ed-a752-c780acf0332b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_662fd11a-0223-46fd-8f7e-c9d91565609d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_dad23bae-2dd2-4540-8224-f6f30f4b5148" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f150974d-a3e1-48ed-a752-c780acf0332b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_dad23bae-2dd2-4540-8224-f6f30f4b5148" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_8e19b2e7-d2c9-48d2-b62a-fce74bf200e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f150974d-a3e1-48ed-a752-c780acf0332b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_8e19b2e7-d2c9-48d2-b62a-fce74bf200e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_13854e26-112c-435d-8b87-299ae35cedb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f150974d-a3e1-48ed-a752-c780acf0332b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_13854e26-112c-435d-8b87-299ae35cedb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_3c780c43-9bd1-4ed0-9193-e5a7a29f7d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f150974d-a3e1-48ed-a752-c780acf0332b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_3c780c43-9bd1-4ed0-9193-e5a7a29f7d5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_0ca91abd-2659-4357-b038-6fc89f6fa5e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f150974d-a3e1-48ed-a752-c780acf0332b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_0ca91abd-2659-4357-b038-6fc89f6fa5e1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#ACCRUEDANDOTHERCURRENTLIABILITIESDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_17cc652e-de30-4b61-9046-e05b171fb060" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_Legalsettlementsandrelatedfees_ffa15ea0-8e5e-49db-ad96-beb02e4bd13e" xlink:href="bhc-20220510.xsd#bhc_Legalsettlementsandrelatedfees"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_17cc652e-de30-4b61-9046-e05b171fb060" xlink:to="loc_bhc_Legalsettlementsandrelatedfees_ffa15ea0-8e5e-49db-ad96-beb02e4bd13e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductRebateCurrent_016360e7-b229-4962-9342-531feff49d3d" xlink:href="bhc-20220510.xsd#bhc_AccruedProductRebateCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_17cc652e-de30-4b61-9046-e05b171fb060" xlink:to="loc_bhc_AccruedProductRebateCurrent_016360e7-b229-4962-9342-531feff49d3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductReturnCurrent_b699b96f-b52e-4256-bb4d-fb82881e34bd" xlink:href="bhc-20220510.xsd#bhc_AccruedProductReturnCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_17cc652e-de30-4b61-9046-e05b171fb060" xlink:to="loc_bhc_AccruedProductReturnCurrent_b699b96f-b52e-4256-bb4d-fb82881e34bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_92f123cc-0eb7-46d0-9e54-8e271231879f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_17cc652e-de30-4b61-9046-e05b171fb060" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_92f123cc-0eb7-46d0-9e54-8e271231879f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_c3d4d0b1-67d6-415f-a683-7d58ef3515fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_17cc652e-de30-4b61-9046-e05b171fb060" xlink:to="loc_us-gaap_InterestPayableCurrent_c3d4d0b1-67d6-415f-a683-7d58ef3515fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_d23d023c-1e7c-4e31-9fa6-b5dd04c27e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_17cc652e-de30-4b61-9046-e05b171fb060" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_d23d023c-1e7c-4e31-9fa6-b5dd04c27e5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a1168c13-d9a9-47aa-ba74-aac95cbe6d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_17cc652e-de30-4b61-9046-e05b171fb060" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_a1168c13-d9a9-47aa-ba74-aac95cbe6d0b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ce3fec90-78e1-4d58-81f7-264ab672dc34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_4e85b76a-96d8-4469-afd6-1f5c9d315d96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_ce3fec90-78e1-4d58-81f7-264ab672dc34" xlink:to="loc_us-gaap_LongTermDebtCurrent_4e85b76a-96d8-4469-afd6-1f5c9d315d96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_79169ca5-f5c6-46ff-8aeb-ab61cae200d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_ce3fec90-78e1-4d58-81f7-264ab672dc34" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_79169ca5-f5c6-46ff-8aeb-ab61cae200d5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_77bb0ea8-b161-4f87-974d-1a02bba8185c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ee152c08-4550-4426-8ecc-b6ad9b0b8f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_77bb0ea8-b161-4f87-974d-1a02bba8185c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ee152c08-4550-4426-8ecc-b6ad9b0b8f8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_34a5e77c-9db4-4262-a718-7e4135be9fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_77bb0ea8-b161-4f87-974d-1a02bba8185c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_34a5e77c-9db4-4262-a718-7e4135be9fc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f029278c-558c-4437-9213-2e9601ee103e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_77bb0ea8-b161-4f87-974d-1a02bba8185c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f029278c-558c-4437-9213-2e9601ee103e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_38d2fd5b-f8da-4ca6-a8bc-c96ef260a196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_77bb0ea8-b161-4f87-974d-1a02bba8185c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_38d2fd5b-f8da-4ca6-a8bc-c96ef260a196" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_9beeeeef-f6be-4bdf-9de9-6c3b9f8f1cac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_77bb0ea8-b161-4f87-974d-1a02bba8185c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_9beeeeef-f6be-4bdf-9de9-6c3b9f8f1cac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_e2da2bd6-2dd9-46f7-a990-8690bd718a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_77bb0ea8-b161-4f87-974d-1a02bba8185c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_e2da2bd6-2dd9-46f7-a990-8690bd718a4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d11c6638-e4f6-4b13-9b2a-af24f69d2ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c3089994-39e9-470e-8cf3-d35af87127f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_d11c6638-e4f6-4b13-9b2a-af24f69d2ba9" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c3089994-39e9-470e-8cf3-d35af87127f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_a272e660-a232-42f1-88e2-236a2c6210b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_d11c6638-e4f6-4b13-9b2a-af24f69d2ba9" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_a272e660-a232-42f1-88e2-236a2c6210b3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7e171b1a-a29c-486e-b2ee-a5c05049a0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_c406ef35-b66d-45cb-9917-5d91c5be7370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7e171b1a-a29c-486e-b2ee-a5c05049a0c0" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_c406ef35-b66d-45cb-9917-5d91c5be7370" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_7f532108-db6c-4fa1-b3e0-9b494c7938ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7e171b1a-a29c-486e-b2ee-a5c05049a0c0" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_7f532108-db6c-4fa1-b3e0-9b494c7938ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_10ec0209-451b-4c94-a748-fa43af53d2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7e171b1a-a29c-486e-b2ee-a5c05049a0c0" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_10ec0209-451b-4c94-a748-fa43af53d2fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_e7faa66d-4bab-4a80-a94d-86b68457ff55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7e171b1a-a29c-486e-b2ee-a5c05049a0c0" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_e7faa66d-4bab-4a80-a94d-86b68457ff55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_75a1f632-bcc7-4b71-8596-80987715cf9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7e171b1a-a29c-486e-b2ee-a5c05049a0c0" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_75a1f632-bcc7-4b71-8596-80987715cf9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_4790a2b2-cdd9-4135-a064-d30c853d679d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7e171b1a-a29c-486e-b2ee-a5c05049a0c0" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_4790a2b2-cdd9-4135-a064-d30c853d679d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanOtherCosts_63d7343a-5fc6-4647-96ca-4ebf7e91bbc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanOtherCosts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_7e171b1a-a29c-486e-b2ee-a5c05049a0c0" xlink:to="loc_us-gaap_DefinedBenefitPlanOtherCosts_63d7343a-5fc6-4647-96ca-4ebf7e91bbc9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_e448a171-c33b-4b40-a241-dac927f6b4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent_68997f43-ab73-4667-958d-f02ef93129d3" xlink:href="bhc-20220510.xsd#bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_e448a171-c33b-4b40-a241-dac927f6b4b8" xlink:to="loc_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent_68997f43-ab73-4667-958d-f02ef93129d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities_36d2a25b-362a-47b0-95a1-29888580c8b4" xlink:href="bhc-20220510.xsd#bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_e448a171-c33b-4b40-a241-dac927f6b4b8" xlink:to="loc_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities_36d2a25b-362a-47b0-95a1-29888580c8b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_39ef15cf-2a4b-46ee-b32d-a416cef82d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_e448a171-c33b-4b40-a241-dac927f6b4b8" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_39ef15cf-2a4b-46ee-b32d-a416cef82d6b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1" xlink:type="simple" xlink:href="bhc-20220510.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_16a24936-78e8-485a-b527-211352e9ab8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_63092228-08cf-4a37-9088-39fc13a21e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_16a24936-78e8-485a-b527-211352e9ab8f" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_63092228-08cf-4a37-9088-39fc13a21e5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b0f7c236-860d-4daa-888f-524a34f4aff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_16a24936-78e8-485a-b527-211352e9ab8f" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_b0f7c236-860d-4daa-888f-524a34f4aff5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_10e2ead4-1ca4-44ca-9682-729ed2e31c64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3048d3eb-77fd-4e28-af26-d3ab3308847b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_10e2ead4-1ca4-44ca-9682-729ed2e31c64" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3048d3eb-77fd-4e28-af26-d3ab3308847b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_48e746ab-de46-4462-a7a3-4389188125d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_10e2ead4-1ca4-44ca-9682-729ed2e31c64" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_48e746ab-de46-4462-a7a3-4389188125d0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#LEASESLeaseFuturePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fc4b48d2-1e4a-4eca-be0f-a8b8a4f4b3e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4ab7c11b-1fca-4a8e-a926-60b7f3e13ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fc4b48d2-1e4a-4eca-be0f-a8b8a4f4b3e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4ab7c11b-1fca-4a8e-a926-60b7f3e13ee4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_99f83a75-0601-44f3-a29f-f7ab2812be17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fc4b48d2-1e4a-4eca-be0f-a8b8a4f4b3e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_99f83a75-0601-44f3-a29f-f7ab2812be17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c822ee4c-4429-428b-b80d-9a3bc4fa57e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fc4b48d2-1e4a-4eca-be0f-a8b8a4f4b3e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c822ee4c-4429-428b-b80d-9a3bc4fa57e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_021fa8e8-ada6-44b6-975e-db4949d0c2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fc4b48d2-1e4a-4eca-be0f-a8b8a4f4b3e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_021fa8e8-ada6-44b6-975e-db4949d0c2b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e92ed124-da0f-4278-81ab-b01186642118" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fc4b48d2-1e4a-4eca-be0f-a8b8a4f4b3e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e92ed124-da0f-4278-81ab-b01186642118" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4926dfc2-0b5b-41e2-802f-0bfd6923b88f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fc4b48d2-1e4a-4eca-be0f-a8b8a4f4b3e3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4926dfc2-0b5b-41e2-802f-0bfd6923b88f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1" xlink:type="simple" xlink:href="bhc-20220510.xsd#LEASESLeaseFuturePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a9453a66-2c46-4bd5-9cf2-da731226c4cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9ed120b5-4228-486b-8406-3801b15a67f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a9453a66-2c46-4bd5-9cf2-da731226c4cf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9ed120b5-4228-486b-8406-3801b15a67f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e911817f-bb92-4cc1-b860-fa58e3ccb521" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a9453a66-2c46-4bd5-9cf2-da731226c4cf" xlink:to="loc_us-gaap_OperatingLeaseLiability_e911817f-bb92-4cc1-b860-fa58e3ccb521" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8df9c792-b6cc-4948-ae4a-79676f4f10ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_f402c720-9109-417f-ae46-3153bac89fb8" xlink:href="bhc-20220510.xsd#bhc_ResearchAndDevelopmentExpenseProductRelated"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8df9c792-b6cc-4948-ae4a-79676f4f10ec" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_f402c720-9109-417f-ae46-3153bac89fb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_4eaa7542-5dab-437b-90da-fb1d8f4dd677" xlink:href="bhc-20220510.xsd#bhc_ResearchAndDevelopmentExpenseQualityAssurance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8df9c792-b6cc-4948-ae4a-79676f4f10ec" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_4eaa7542-5dab-437b-90da-fb1d8f4dd677" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0619a594-6a47-4069-a25c-a5655f9bd030" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_ed0b1a6e-152d-4318-bb33-aba862814c52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_0619a594-6a47-4069-a25c-a5655f9bd030" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_ed0b1a6e-152d-4318-bb33-aba862814c52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_84e4a299-ec4d-4c23-8e22-9137d6074c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_0619a594-6a47-4069-a25c-a5655f9bd030" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_84e4a299-ec4d-4c23-8e22-9137d6074c8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_bbd84704-e68d-450d-9e3d-204ea35a5b35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_0619a594-6a47-4069-a25c-a5655f9bd030" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_bbd84704-e68d-450d-9e3d-204ea35a5b35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_a12ae66a-701b-4856-819c-c88933592c91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_0619a594-6a47-4069-a25c-a5655f9bd030" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_a12ae66a-701b-4856-819c-c88933592c91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherIncomeExpenseNet_0a341ca1-8c00-414f-8bf0-7ebd35182cd7" xlink:href="bhc-20220510.xsd#bhc_OtherIncomeExpenseNet"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_0619a594-6a47-4069-a25c-a5655f9bd030" xlink:to="loc_bhc_OtherIncomeExpenseNet_0a341ca1-8c00-414f-8bf0-7ebd35182cd7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_84d4430d-cc8a-4bef-bba4-e90a3345a100" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0b5aeb41-7bbd-4116-a141-72f43c59b058" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_84d4430d-cc8a-4bef-bba4-e90a3345a100" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0b5aeb41-7bbd-4116-a141-72f43c59b058" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2a55e648-bcbe-4cb6-96da-d38dead869a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_84d4430d-cc8a-4bef-bba4-e90a3345a100" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2a55e648-bcbe-4cb6-96da-d38dead869a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_80a1c65c-c26b-416e-8a08-bc92f9a19855" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_97c5eb36-a6de-4d8c-8b05-e01a1ee8a438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_80a1c65c-c26b-416e-8a08-bc92f9a19855" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_97c5eb36-a6de-4d8c-8b05-e01a1ee8a438" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_797d6a67-b8d6-4e81-9bf5-9c9d3fb082e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_80a1c65c-c26b-416e-8a08-bc92f9a19855" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_797d6a67-b8d6-4e81-9bf5-9c9d3fb082e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_088a215a-fb4f-43fb-bd9c-abcde4cc90c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6a259b3d-7212-4db3-8856-800547601f34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_088a215a-fb4f-43fb-bd9c-abcde4cc90c4" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6a259b3d-7212-4db3-8856-800547601f34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_858673a3-ccd9-4a17-b5c8-8d746d4c572b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_088a215a-fb4f-43fb-bd9c-abcde4cc90c4" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_858673a3-ccd9-4a17-b5c8-8d746d4c572b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5e32fcd8-8734-482a-9e9a-5500a7c9a6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_004d0dac-227e-4bfb-844b-9e6e6d6443fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5e32fcd8-8734-482a-9e9a-5500a7c9a6f8" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_004d0dac-227e-4bfb-844b-9e6e6d6443fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_f2b41596-db29-428c-aa51-1c64ec87e715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5e32fcd8-8734-482a-9e9a-5500a7c9a6f8" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_f2b41596-db29-428c-aa51-1c64ec87e715" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_71ab6852-8148-4cec-81f6-9d6bb20f7330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_99c0ea1d-2561-4342-9e89-434e7bf885b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_71ab6852-8148-4cec-81f6-9d6bb20f7330" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_99c0ea1d-2561-4342-9e89-434e7bf885b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_7f89db55-65b9-4ea2-95c4-850ab32cb6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_71ab6852-8148-4cec-81f6-9d6bb20f7330" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_7f89db55-65b9-4ea2-95c4-850ab32cb6f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount_5adffbbe-06d8-4f96-8ac1-d46fae5a1678" xlink:href="bhc-20220510.xsd#bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_71ab6852-8148-4cec-81f6-9d6bb20f7330" xlink:to="loc_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount_5adffbbe-06d8-4f96-8ac1-d46fae5a1678" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance_67bcdbed-443c-4edf-893b-0e243d3d1f19" xlink:href="bhc-20220510.xsd#bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_71ab6852-8148-4cec-81f6-9d6bb20f7330" xlink:to="loc_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance_67bcdbed-443c-4edf-893b-0e243d3d1f19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_dcca1095-559b-4ed7-8777-f0764ddacbdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_71ab6852-8148-4cec-81f6-9d6bb20f7330" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_dcca1095-559b-4ed7-8777-f0764ddacbdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxReconciliationUncertainTaxPositions_e29f74a6-9bad-46f7-81f5-4d58c7829bdb" xlink:href="bhc-20220510.xsd#bhc_IncomeTaxReconciliationUncertainTaxPositions"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_71ab6852-8148-4cec-81f6-9d6bb20f7330" xlink:to="loc_bhc_IncomeTaxReconciliationUncertainTaxPositions_e29f74a6-9bad-46f7-81f5-4d58c7829bdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_395737ae-0f18-4564-838b-20aa0186c8df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_71ab6852-8148-4cec-81f6-9d6bb20f7330" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_395737ae-0f18-4564-838b-20aa0186c8df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_2783f6a8-08c6-41df-ab03-910d0be1c9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_71ab6852-8148-4cec-81f6-9d6bb20f7330" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_2783f6a8-08c6-41df-ab03-910d0be1c9c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit_e9a59207-b5a0-4e7f-8d64-f23221d1ec4a" xlink:href="bhc-20220510.xsd#bhc_IncomeTaxReconciliationDeferredIntercompanyProfit"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_71ab6852-8148-4cec-81f6-9d6bb20f7330" xlink:to="loc_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit_e9a59207-b5a0-4e7f-8d64-f23221d1ec4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_5081b54f-7f0f-43f6-95d0-e93cf6810dce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_71ab6852-8148-4cec-81f6-9d6bb20f7330" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_5081b54f-7f0f-43f6-95d0-e93cf6810dce" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_af8d6866-794e-45cf-82b6-f6d809e4d119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_368327a9-8be6-45f6-9e99-875985512e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_af8d6866-794e-45cf-82b6-f6d809e4d119" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_368327a9-8be6-45f6-9e99-875985512e9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes_1ae31348-e8bb-4374-a701-7dbd2b6d0f02" xlink:href="bhc-20220510.xsd#bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_af8d6866-794e-45cf-82b6-f6d809e4d119" xlink:to="loc_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes_1ae31348-e8bb-4374-a701-7dbd2b6d0f02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_a0a4f2ec-e5f2-416d-b792-a33c0b1ea70e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_af8d6866-794e-45cf-82b6-f6d809e4d119" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_a0a4f2ec-e5f2-416d-b792-a33c0b1ea70e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains_2a2fa199-e843-49d2-97bd-542de5564559" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_af8d6866-794e-45cf-82b6-f6d809e4d119" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains_2a2fa199-e843-49d2-97bd-542de5564559" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_987a10ef-bb2f-415c-ab1c-3013c894ef72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_39c3fbd4-8504-4df6-a975-ae17fe595ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_987a10ef-bb2f-415c-ab1c-3013c894ef72" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_39c3fbd4-8504-4df6-a975-ae17fe595ee7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_95fb4154-868f-4aad-9bca-e20725ad5983" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_987a10ef-bb2f-415c-ab1c-3013c894ef72" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_95fb4154-868f-4aad-9bca-e20725ad5983" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_b9fafefc-8f4b-41f1-95cf-134a530881fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_53e097d8-c9ef-48c4-8fd5-070f819c624b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_b9fafefc-8f4b-41f1-95cf-134a530881fd" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_53e097d8-c9ef-48c4-8fd5-070f819c624b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_45547636-c747-4628-8aad-3717848c176e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_b9fafefc-8f4b-41f1-95cf-134a530881fd" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_45547636-c747-4628-8aad-3717848c176e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_dd2c5075-1d1c-4b90-8ffd-c764baa4bffd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsTaxLossCarryforwards_ad643ee8-4835-4256-8129-1c4e5afe7890" xlink:href="bhc-20220510.xsd#bhc_DeferredTaxAssetsTaxLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_dd2c5075-1d1c-4b90-8ffd-c764baa4bffd" xlink:to="loc_bhc_DeferredTaxAssetsTaxLossCarryforwards_ad643ee8-4835-4256-8129-1c4e5afe7890" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_00ccdeb9-939b-4db2-b9d1-7f652562c2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_dd2c5075-1d1c-4b90-8ffd-c764baa4bffd" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_00ccdeb9-939b-4db2-b9d1-7f652562c2fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_ddd680a1-33d5-47e2-b91e-28b663719608" xlink:href="bhc-20220510.xsd#bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_dd2c5075-1d1c-4b90-8ffd-c764baa4bffd" xlink:to="loc_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_ddd680a1-33d5-47e2-b91e-28b663719608" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool_cd3f8805-78d2-43f1-8697-52c58beb7db0" xlink:href="bhc-20220510.xsd#bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_dd2c5075-1d1c-4b90-8ffd-c764baa4bffd" xlink:to="loc_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool_cd3f8805-78d2-43f1-8697-52c58beb7db0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_fac33431-99fa-4dcc-a5b0-760949820ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_dd2c5075-1d1c-4b90-8ffd-c764baa4bffd" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_fac33431-99fa-4dcc-a5b0-760949820ce1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_d5791145-86b6-456b-9345-b4818790fc44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_dd2c5075-1d1c-4b90-8ffd-c764baa4bffd" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_d5791145-86b6-456b-9345-b4818790fc44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsPrepaidExpenses_37035292-1822-47e2-8a2a-e4d1b189beca" xlink:href="bhc-20220510.xsd#bhc_DeferredTaxAssetsPrepaidExpenses"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_dd2c5075-1d1c-4b90-8ffd-c764baa4bffd" xlink:to="loc_bhc_DeferredTaxAssetsPrepaidExpenses_37035292-1822-47e2-8a2a-e4d1b189beca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_8abea59a-6e6d-420e-9982-3615fd91e219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_dd2c5075-1d1c-4b90-8ffd-c764baa4bffd" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_8abea59a-6e6d-420e-9982-3615fd91e219" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_55777cf5-720a-4138-b618-f0f6096fd842" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_dd2c5075-1d1c-4b90-8ffd-c764baa4bffd" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_55777cf5-720a-4138-b618-f0f6096fd842" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>bhc-20220510_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:9acca3cc-2386-49dd-bd2b-e67723848b1a,g:d4f0cfd5-5dd4-484a-81ac-21ef5810b617-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bhc-20220510.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="ie8596ab5862e47a3a649a6716d107b7a_CONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_071ba504-8e0b-467c-b520-7265412f95b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_RevenuesAbstract_071ba504-8e0b-467c-b520-7265412f95b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e7e436aa-0d4a-4d84-9f62-388897f14ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_071ba504-8e0b-467c-b520-7265412f95b9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e7e436aa-0d4a-4d84-9f62-388897f14ece" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_9d6db876-b7eb-4396-9d55-eddb2a91f790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_9d6db876-b7eb-4396-9d55-eddb2a91f790" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_948c37c5-f368-47b0-a153-a72691aa1ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9d6db876-b7eb-4396-9d55-eddb2a91f790" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_948c37c5-f368-47b0-a153-a72691aa1ba8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c6bb8a72-30fb-4c8e-96a7-4e113b28d325" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9d6db876-b7eb-4396-9d55-eddb2a91f790" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c6bb8a72-30fb-4c8e-96a7-4e113b28d325" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_f4b19837-f67e-4497-94e8-0882042344a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9d6db876-b7eb-4396-9d55-eddb2a91f790" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_f4b19837-f67e-4497-94e8-0882042344a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_152e1f23-12c7-400e-8e1c-786c3a4ea220" xlink:href="bhc-20220510.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9d6db876-b7eb-4396-9d55-eddb2a91f790" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_152e1f23-12c7-400e-8e1c-786c3a4ea220" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_44b375d3-c580-4e44-bf3a-e654638d3963" xlink:href="bhc-20220510.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9d6db876-b7eb-4396-9d55-eddb2a91f790" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_44b375d3-c580-4e44-bf3a-e654638d3963" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_97019eee-9c7e-42f0-be06-2110ac6871e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9d6db876-b7eb-4396-9d55-eddb2a91f790" xlink:to="loc_us-gaap_AssetImpairmentCharges_97019eee-9c7e-42f0-be06-2110ac6871e7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_e2a84e05-f8f3-445e-b60c-81fbb374352b" xlink:href="bhc-20220510.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9d6db876-b7eb-4396-9d55-eddb2a91f790" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_e2a84e05-f8f3-445e-b60c-81fbb374352b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_2d14a558-19a7-41aa-bbf3-38ee962df86d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9d6db876-b7eb-4396-9d55-eddb2a91f790" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_2d14a558-19a7-41aa-bbf3-38ee962df86d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a9bae5b5-b438-4078-a4bb-41f024907877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9d6db876-b7eb-4396-9d55-eddb2a91f790" xlink:to="loc_us-gaap_CostsAndExpenses_a9bae5b5-b438-4078-a4bb-41f024907877" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_83deea0a-615f-4323-a653-1d5a690401d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_OperatingIncomeLoss_83deea0a-615f-4323-a653-1d5a690401d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_6fb3a891-68e4-4c19-a531-7f1dc22ff69b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_InvestmentIncomeInterest_6fb3a891-68e4-4c19-a531-7f1dc22ff69b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_7fb803f4-c02e-4d36-a47f-0c3153adc720" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_InterestExpenseDebt_7fb803f4-c02e-4d36-a47f-0c3153adc720" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_dcc2400f-c489-43f3-907e-952f29b0b1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_dcc2400f-c489-43f3-907e-952f29b0b1a6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2bd82fbe-3172-45b7-9ba9-4293ef80d19f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2bd82fbe-3172-45b7-9ba9-4293ef80d19f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_32f0e39f-fff7-469e-9eda-103b755c4327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_32f0e39f-fff7-469e-9eda-103b755c4327" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4f4dac20-8d01-4b2c-aeee-4178e52933cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4f4dac20-8d01-4b2c-aeee-4178e52933cc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ba1c197b-1990-4e17-985d-fbebb90e1f88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_ProfitLoss_ba1c197b-1990-4e17-985d-fbebb90e1f88" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8d7a67ad-73b7-4814-917b-f3712dbbd124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8d7a67ad-73b7-4814-917b-f3712dbbd124" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e3a04aae-2b7c-468d-b712-5715884c4874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_NetIncomeLoss_e3a04aae-2b7c-468d-b712-5715884c4874" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d8bf0de0-c181-4827-b37f-d5a8c6dedc39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_EarningsPerShareBasic_d8bf0de0-c181-4827-b37f-d5a8c6dedc39" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_258376aa-559f-4c21-a89c-3bd8833a96ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_EarningsPerShareDiluted_258376aa-559f-4c21-a89c-3bd8833a96ab" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5cd49acb-0a1d-4c26-abbe-f972a5fcd215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5cd49acb-0a1d-4c26-abbe-f972a5fcd215" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1606e6b6-99b3-42fe-99a1-9c7cd62928c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1606e6b6-99b3-42fe-99a1-9c7cd62928c5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_593a1a48-74a2-4dbb-b826-1d14ab942793" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_StatementTable_593a1a48-74a2-4dbb-b826-1d14ab942793" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_72db89e6-840c-44f8-80a1-9843b60a8526" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_593a1a48-74a2-4dbb-b826-1d14ab942793" xlink:to="loc_srt_ProductOrServiceAxis_72db89e6-840c-44f8-80a1-9843b60a8526" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_72db89e6-840c-44f8-80a1-9843b60a8526_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_72db89e6-840c-44f8-80a1-9843b60a8526" xlink:to="loc_srt_ProductsAndServicesDomain_72db89e6-840c-44f8-80a1-9843b60a8526_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2fc34700-7185-4f47-8492-548ce407c8a5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_72db89e6-840c-44f8-80a1-9843b60a8526" xlink:to="loc_srt_ProductsAndServicesDomain_2fc34700-7185-4f47-8492-548ce407c8a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_6bddd85b-141c-4ce6-8b52-1f07bd8d8adf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2fc34700-7185-4f47-8492-548ce407c8a5" xlink:to="loc_us-gaap_ProductMember_6bddd85b-141c-4ce6-8b52-1f07bd8d8adf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_038cd057-ff15-481e-a3fb-d7e0f14d7c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2fc34700-7185-4f47-8492-548ce407c8a5" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_038cd057-ff15-481e-a3fb-d7e0f14d7c2d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="bhc-20220510.xsd#CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT" xlink:type="extended" id="icf1560829bbd4f998eeeb171ec6e0ab9_CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9f324018-d10e-4f8a-95a1-f56865e7825d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a9d738e0-eb5c-4c29-8a62-7c7a488b70fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9f324018-d10e-4f8a-95a1-f56865e7825d" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a9d738e0-eb5c-4c29-8a62-7c7a488b70fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_fb77db08-4307-494b-a00a-c4ff34a09e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a9d738e0-eb5c-4c29-8a62-7c7a488b70fc" xlink:to="loc_us-gaap_CommonStockSharesIssued_fb77db08-4307-494b-a00a-c4ff34a09e5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b5afe1e5-385c-4ea8-8f97-23efcaa3af05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a9d738e0-eb5c-4c29-8a62-7c7a488b70fc" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b5afe1e5-385c-4ea8-8f97-23efcaa3af05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_96c22c6a-b902-4aea-a844-4d872d61ad06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a9d738e0-eb5c-4c29-8a62-7c7a488b70fc" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_96c22c6a-b902-4aea-a844-4d872d61ad06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_9f280b08-57cf-464d-9149-f03ead824b04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a9d738e0-eb5c-4c29-8a62-7c7a488b70fc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_9f280b08-57cf-464d-9149-f03ead824b04" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7f58d391-2bec-4327-9624-cd0d0cfc8b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a9d738e0-eb5c-4c29-8a62-7c7a488b70fc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7f58d391-2bec-4327-9624-cd0d0cfc8b2c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1f6ba1ce-cb02-4a9a-b960-f1af9702b474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a9d738e0-eb5c-4c29-8a62-7c7a488b70fc" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1f6ba1ce-cb02-4a9a-b960-f1af9702b474" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_aaf26c05-9d52-460b-807a-76570833da75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a9d738e0-eb5c-4c29-8a62-7c7a488b70fc" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_aaf26c05-9d52-460b-807a-76570833da75" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_53445d67-5ff5-4a83-ae4f-ce57cee4e25a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a9d738e0-eb5c-4c29-8a62-7c7a488b70fc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_53445d67-5ff5-4a83-ae4f-ce57cee4e25a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_52997ecb-c7e4-4bcf-ba02-d822975f537e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a9d738e0-eb5c-4c29-8a62-7c7a488b70fc" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_52997ecb-c7e4-4bcf-ba02-d822975f537e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_fbf1b060-5114-4fde-8b5f-aa5828792bef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a9d738e0-eb5c-4c29-8a62-7c7a488b70fc" xlink:to="loc_us-gaap_ProfitLoss_fbf1b060-5114-4fde-8b5f-aa5828792bef" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_29a37505-cd9d-49fd-ad7e-93fe7b6c616f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a9d738e0-eb5c-4c29-8a62-7c7a488b70fc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_29a37505-cd9d-49fd-ad7e-93fe7b6c616f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b24b67df-b744-482d-b0a1-5a822c860cab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0846aa8b-7a50-486d-b4de-899889f914d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4ff6ad6a-c747-4375-8c86-c42c71527560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9f324018-d10e-4f8a-95a1-f56865e7825d" xlink:to="loc_us-gaap_StatementTable_4ff6ad6a-c747-4375-8c86-c42c71527560" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_32082fbd-2457-491c-86bf-39bcfb1a9138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4ff6ad6a-c747-4375-8c86-c42c71527560" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_32082fbd-2457-491c-86bf-39bcfb1a9138" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_32082fbd-2457-491c-86bf-39bcfb1a9138_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_32082fbd-2457-491c-86bf-39bcfb1a9138" xlink:to="loc_us-gaap_EquityComponentDomain_32082fbd-2457-491c-86bf-39bcfb1a9138_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d926c3da-9d71-4308-a8c5-d8b777a2133a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_32082fbd-2457-491c-86bf-39bcfb1a9138" xlink:to="loc_us-gaap_EquityComponentDomain_d926c3da-9d71-4308-a8c5-d8b777a2133a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_e5c8e787-3e6c-4fd5-a26d-df05981cf7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d926c3da-9d71-4308-a8c5-d8b777a2133a" xlink:to="loc_us-gaap_ParentMember_e5c8e787-3e6c-4fd5-a26d-df05981cf7e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_72f5188d-270a-411a-ad8c-e8c45384c631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_e5c8e787-3e6c-4fd5-a26d-df05981cf7e3" xlink:to="loc_us-gaap_CommonStockMember_72f5188d-270a-411a-ad8c-e8c45384c631" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_311ca4d8-436e-4ade-b69a-c277af622091" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_e5c8e787-3e6c-4fd5-a26d-df05981cf7e3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_311ca4d8-436e-4ade-b69a-c277af622091" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4a3db07d-f769-4a42-a0fd-fccdf76ca2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_e5c8e787-3e6c-4fd5-a26d-df05981cf7e3" xlink:to="loc_us-gaap_RetainedEarningsMember_4a3db07d-f769-4a42-a0fd-fccdf76ca2d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7789e0c4-80db-4941-9df0-031c152db20b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_e5c8e787-3e6c-4fd5-a26d-df05981cf7e3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7789e0c4-80db-4941-9df0-031c152db20b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_0f214d39-8961-4618-87f3-8f9ee4d3c6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d926c3da-9d71-4308-a8c5-d8b777a2133a" xlink:to="loc_us-gaap_NoncontrollingInterestMember_0f214d39-8961-4618-87f3-8f9ee4d3c6b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_9281a176-b740-4d9a-beda-1ea22783e2f3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4ff6ad6a-c747-4375-8c86-c42c71527560" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_9281a176-b740-4d9a-beda-1ea22783e2f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_9281a176-b740-4d9a-beda-1ea22783e2f3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_9281a176-b740-4d9a-beda-1ea22783e2f3" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_9281a176-b740-4d9a-beda-1ea22783e2f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_39c3c726-42fd-4352-a669-6804e3c29a67" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_9281a176-b740-4d9a-beda-1ea22783e2f3" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_39c3c726-42fd-4352-a669-6804e3c29a67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_0e8948f6-dca8-49e6-bc04-34b9bd2f5420" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_39c3c726-42fd-4352-a669-6804e3c29a67" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_0e8948f6-dca8-49e6-bc04-34b9bd2f5420" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" xlink:type="extended" id="ia2cdd9b24a7344a79cfebea0301f7615_SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_513a8d52-ee00-4273-9bbc-241e7272b3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents_68f0b4b9-8e4e-4482-a4a9-b463fd8e13fb" xlink:href="bhc-20220510.xsd#bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_513a8d52-ee00-4273-9bbc-241e7272b3bd" xlink:to="loc_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents_68f0b4b9-8e4e-4482-a4a9-b463fd8e13fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NumberOfLargestWholesaleCustomers_76e71dae-6a96-4208-a563-f47e75102308" xlink:href="bhc-20220510.xsd#bhc_NumberOfLargestWholesaleCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_513a8d52-ee00-4273-9bbc-241e7272b3bd" xlink:to="loc_bhc_NumberOfLargestWholesaleCustomers_76e71dae-6a96-4208-a563-f47e75102308" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskPercentageofNetTradeReceivables_318dbe7c-b63a-421e-a281-cbb413c4a055" xlink:href="bhc-20220510.xsd#bhc_ConcentrationRiskPercentageofNetTradeReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_513a8d52-ee00-4273-9bbc-241e7272b3bd" xlink:to="loc_bhc_ConcentrationRiskPercentageofNetTradeReceivables_318dbe7c-b63a-421e-a281-cbb413c4a055" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4cf492ca-7710-4436-b4c5-5fea22594424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_513a8d52-ee00-4273-9bbc-241e7272b3bd" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4cf492ca-7710-4436-b4c5-5fea22594424" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PastDuePeriodForAccountsReceivableToBeNegligible_8a11c1d2-8a14-4e0d-875f-592046aeb060" xlink:href="bhc-20220510.xsd#bhc_PastDuePeriodForAccountsReceivableToBeNegligible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_513a8d52-ee00-4273-9bbc-241e7272b3bd" xlink:to="loc_bhc_PastDuePeriodForAccountsReceivableToBeNegligible_8a11c1d2-8a14-4e0d-875f-592046aeb060" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PeriodReceivableOutstanding_7b08fe9a-6d05-4a54-8e9a-e4975d844fc4" xlink:href="bhc-20220510.xsd#bhc_PeriodReceivableOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_513a8d52-ee00-4273-9bbc-241e7272b3bd" xlink:to="loc_bhc_PeriodReceivableOutstanding_7b08fe9a-6d05-4a54-8e9a-e4975d844fc4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TradeReceivableNetPortionPastDue_b94ce3ff-a3d3-4f51-98ef-2f45816e7e78" xlink:href="bhc-20220510.xsd#bhc_TradeReceivableNetPortionPastDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_513a8d52-ee00-4273-9bbc-241e7272b3bd" xlink:to="loc_bhc_TradeReceivableNetPortionPastDue_b94ce3ff-a3d3-4f51-98ef-2f45816e7e78" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_606973bb-9156-4688-9409-647da0fa3001" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_513a8d52-ee00-4273-9bbc-241e7272b3bd" xlink:to="loc_us-gaap_ConcentrationRiskTable_606973bb-9156-4688-9409-647da0fa3001" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_10deead8-5bbe-4858-aa50-00c9e7b14885" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_606973bb-9156-4688-9409-647da0fa3001" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_10deead8-5bbe-4858-aa50-00c9e7b14885" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_10deead8-5bbe-4858-aa50-00c9e7b14885_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_10deead8-5bbe-4858-aa50-00c9e7b14885" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_10deead8-5bbe-4858-aa50-00c9e7b14885_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ce14e89-4b3a-4f64-8b55-8af79197bc53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_10deead8-5bbe-4858-aa50-00c9e7b14885" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ce14e89-4b3a-4f64-8b55-8af79197bc53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_beae0876-9357-4069-a28e-68eeeaf90853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ce14e89-4b3a-4f64-8b55-8af79197bc53" xlink:to="loc_us-gaap_AccountsReceivableMember_beae0876-9357-4069-a28e-68eeeaf90853" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_07dc1c95-8c9c-4dd8-87d2-b531c2ae15f3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_606973bb-9156-4688-9409-647da0fa3001" xlink:to="loc_srt_MajorCustomersAxis_07dc1c95-8c9c-4dd8-87d2-b531c2ae15f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_07dc1c95-8c9c-4dd8-87d2-b531c2ae15f3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_07dc1c95-8c9c-4dd8-87d2-b531c2ae15f3" xlink:to="loc_srt_NameOfMajorCustomerDomain_07dc1c95-8c9c-4dd8-87d2-b531c2ae15f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_55e9f807-e625-4ad8-8e51-9fb43c8edf9b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_07dc1c95-8c9c-4dd8-87d2-b531c2ae15f3" xlink:to="loc_srt_NameOfMajorCustomerDomain_55e9f807-e625-4ad8-8e51-9fb43c8edf9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ThreeLargestUSWholesalerCustomersMember_61ad24e2-1f2a-4cad-9ac6-8e27682d93d4" xlink:href="bhc-20220510.xsd#bhc_ThreeLargestUSWholesalerCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_55e9f807-e625-4ad8-8e51-9fb43c8edf9b" xlink:to="loc_bhc_ThreeLargestUSWholesalerCustomersMember_61ad24e2-1f2a-4cad-9ac6-8e27682d93d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5d00cd68-44eb-4996-af30-b5baaf92b410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_606973bb-9156-4688-9409-647da0fa3001" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5d00cd68-44eb-4996-af30-b5baaf92b410" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5d00cd68-44eb-4996-af30-b5baaf92b410_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5d00cd68-44eb-4996-af30-b5baaf92b410" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5d00cd68-44eb-4996-af30-b5baaf92b410_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c7dc1137-6e69-4bd8-8638-d2fc07a97026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5d00cd68-44eb-4996-af30-b5baaf92b410" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c7dc1137-6e69-4bd8-8638-d2fc07a97026" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_14bf81df-d64e-4209-8450-939d27b4a0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c7dc1137-6e69-4bd8-8638-d2fc07a97026" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_14bf81df-d64e-4209-8450-939d27b4a0b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_64642837-d776-4013-9a0d-5f77ab4af8b9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_606973bb-9156-4688-9409-647da0fa3001" xlink:to="loc_srt_StatementGeographicalAxis_64642837-d776-4013-9a0d-5f77ab4af8b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_64642837-d776-4013-9a0d-5f77ab4af8b9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_64642837-d776-4013-9a0d-5f77ab4af8b9" xlink:to="loc_srt_SegmentGeographicalDomain_64642837-d776-4013-9a0d-5f77ab4af8b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2b0aee8a-1cee-4c58-ab0d-d846d543ba18" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_64642837-d776-4013-9a0d-5f77ab4af8b9" xlink:to="loc_srt_SegmentGeographicalDomain_2b0aee8a-1cee-4c58-ab0d-d846d543ba18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember_a42b31f5-6849-46b1-b6f8-a8cc1fff3a55" xlink:href="bhc-20220510.xsd#bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2b0aee8a-1cee-4c58-ab0d-d846d543ba18" xlink:to="loc_bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember_a42b31f5-6849-46b1-b6f8-a8cc1fff3a55" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails" xlink:type="extended" id="i87f6b766715b4a06be77bd2581943df3_SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac8d290a-f50f-4779-910c-fb10fb12580d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_87c6d45e-ab07-4711-956f-3e1830196603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac8d290a-f50f-4779-910c-fb10fb12580d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_87c6d45e-ab07-4711-956f-3e1830196603" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3ce3048a-4c7a-420d-a544-4384bd47e441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac8d290a-f50f-4779-910c-fb10fb12580d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3ce3048a-4c7a-420d-a544-4384bd47e441" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c6f63d0b-9e4d-4a8d-b3b5-236ae94284eb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3ce3048a-4c7a-420d-a544-4384bd47e441" xlink:to="loc_srt_RangeAxis_c6f63d0b-9e4d-4a8d-b3b5-236ae94284eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c6f63d0b-9e4d-4a8d-b3b5-236ae94284eb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c6f63d0b-9e4d-4a8d-b3b5-236ae94284eb" xlink:to="loc_srt_RangeMember_c6f63d0b-9e4d-4a8d-b3b5-236ae94284eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cc8226fe-db63-4eaa-bc37-e4e12f7b96f0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c6f63d0b-9e4d-4a8d-b3b5-236ae94284eb" xlink:to="loc_srt_RangeMember_cc8226fe-db63-4eaa-bc37-e4e12f7b96f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_99503b1b-b7da-43fc-9bd7-140730bb2e1a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cc8226fe-db63-4eaa-bc37-e4e12f7b96f0" xlink:to="loc_srt_MinimumMember_99503b1b-b7da-43fc-9bd7-140730bb2e1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_463a1b0d-692d-47e8-ad43-d9734297298f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cc8226fe-db63-4eaa-bc37-e4e12f7b96f0" xlink:to="loc_srt_MaximumMember_463a1b0d-692d-47e8-ad43-d9734297298f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d7bebcbd-3c61-4a02-a08c-5061c3c7acbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3ce3048a-4c7a-420d-a544-4384bd47e441" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d7bebcbd-3c61-4a02-a08c-5061c3c7acbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d7bebcbd-3c61-4a02-a08c-5061c3c7acbb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d7bebcbd-3c61-4a02-a08c-5061c3c7acbb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d7bebcbd-3c61-4a02-a08c-5061c3c7acbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c16ba043-9c3b-4fc2-bf0c-73b47838f5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d7bebcbd-3c61-4a02-a08c-5061c3c7acbb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c16ba043-9c3b-4fc2-bf0c-73b47838f5c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandImprovementsMember_47f0343f-8abd-4acb-be1b-f648e18ad085" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c16ba043-9c3b-4fc2-bf0c-73b47838f5c8" xlink:to="loc_us-gaap_LandImprovementsMember_47f0343f-8abd-4acb-be1b-f648e18ad085" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_6a715471-afb3-4976-a136-fa13c288007a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c16ba043-9c3b-4fc2-bf0c-73b47838f5c8" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_6a715471-afb3-4976-a136-fa13c288007a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_5db6c40b-9536-4dbe-b5b3-1d26fb1a1b63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c16ba043-9c3b-4fc2-bf0c-73b47838f5c8" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_5db6c40b-9536-4dbe-b5b3-1d26fb1a1b63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember_61d817ab-d9c8-46f7-b710-0ada670c01c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherMachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c16ba043-9c3b-4fc2-bf0c-73b47838f5c8" xlink:to="loc_us-gaap_OtherMachineryAndEquipmentMember_61d817ab-d9c8-46f7-b710-0ada670c01c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EquipmentOnOperatingLeaseMember_1c44282f-a212-4328-bfd7-be90b70c6aa6" xlink:href="bhc-20220510.xsd#bhc_EquipmentOnOperatingLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c16ba043-9c3b-4fc2-bf0c-73b47838f5c8" xlink:to="loc_bhc_EquipmentOnOperatingLeaseMember_1c44282f-a212-4328-bfd7-be90b70c6aa6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_a0d3642f-cb67-49f7-a51a-b0ca220cc258" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c16ba043-9c3b-4fc2-bf0c-73b47838f5c8" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_a0d3642f-cb67-49f7-a51a-b0ca220cc258" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails" xlink:type="extended" id="ic6fbaf8e73c24ef08245a09c53cca7be_SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_caedd051-76f3-4230-a607-49eda891e1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_fc022721-a9ec-42b7-bd18-a39959bb027d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_caedd051-76f3-4230-a607-49eda891e1ac" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_fc022721-a9ec-42b7-bd18-a39959bb027d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_df71809c-beaa-45aa-8fd6-3d2d7e18a548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_caedd051-76f3-4230-a607-49eda891e1ac" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_df71809c-beaa-45aa-8fd6-3d2d7e18a548" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ba23508a-c7ed-45b2-9138-d860b29ac348" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_df71809c-beaa-45aa-8fd6-3d2d7e18a548" xlink:to="loc_srt_RangeAxis_ba23508a-c7ed-45b2-9138-d860b29ac348" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ba23508a-c7ed-45b2-9138-d860b29ac348_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ba23508a-c7ed-45b2-9138-d860b29ac348" xlink:to="loc_srt_RangeMember_ba23508a-c7ed-45b2-9138-d860b29ac348_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_899bbff5-1736-49f5-97f4-52bb97932888" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ba23508a-c7ed-45b2-9138-d860b29ac348" xlink:to="loc_srt_RangeMember_899bbff5-1736-49f5-97f4-52bb97932888" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_46d9ae31-b998-4aee-aea9-6014c5bd87b7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_899bbff5-1736-49f5-97f4-52bb97932888" xlink:to="loc_srt_MinimumMember_46d9ae31-b998-4aee-aea9-6014c5bd87b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0942116d-b7b4-40cc-80e8-f61c922f635a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_899bbff5-1736-49f5-97f4-52bb97932888" xlink:to="loc_srt_MaximumMember_0942116d-b7b4-40cc-80e8-f61c922f635a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dc363e23-8a50-44f7-b7dc-fa8db4aed5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_df71809c-beaa-45aa-8fd6-3d2d7e18a548" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dc363e23-8a50-44f7-b7dc-fa8db4aed5ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dc363e23-8a50-44f7-b7dc-fa8db4aed5ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dc363e23-8a50-44f7-b7dc-fa8db4aed5ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dc363e23-8a50-44f7-b7dc-fa8db4aed5ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fdbcceca-1e5e-4b92-90c2-f308345e0157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dc363e23-8a50-44f7-b7dc-fa8db4aed5ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fdbcceca-1e5e-4b92-90c2-f308345e0157" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_70336584-816b-47ac-84c3-c6a112962784" xlink:href="bhc-20220510.xsd#bhc_ProductBrandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fdbcceca-1e5e-4b92-90c2-f308345e0157" xlink:to="loc_bhc_ProductBrandsMember_70336584-816b-47ac-84c3-c6a112962784" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_332af8f0-b4d4-4183-8852-976629d04e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fdbcceca-1e5e-4b92-90c2-f308345e0157" xlink:to="loc_us-gaap_TradeNamesMember_332af8f0-b4d4-4183-8852-976629d04e9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_8dbb68a9-d0f4-4e04-be24-1cf5023f9dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fdbcceca-1e5e-4b92-90c2-f308345e0157" xlink:to="loc_us-gaap_ContractualRightsMember_8dbb68a9-d0f4-4e04-be24-1cf5023f9dc7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PartnerRelationshipsMember_ebff2956-b0b1-485c-93ae-042193dbf37a" xlink:href="bhc-20220510.xsd#bhc_PartnerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fdbcceca-1e5e-4b92-90c2-f308345e0157" xlink:to="loc_bhc_PartnerRelationshipsMember_ebff2956-b0b1-485c-93ae-042193dbf37a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OutLicensedTechnologyMember_58e95916-4029-4198-8ef6-479f4f1f40f7" xlink:href="bhc-20220510.xsd#bhc_OutLicensedTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fdbcceca-1e5e-4b92-90c2-f308345e0157" xlink:to="loc_bhc_OutLicensedTechnologyMember_58e95916-4029-4198-8ef6-479f4f1f40f7" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails" xlink:type="extended" id="i4c5719a3775d4b5eac6811efd93cd26f_SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c63e6faa-93ec-4992-99d2-87b2c2c1eb6c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5090ad5b-5ccf-40de-8bac-c291b883b22d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c63e6faa-93ec-4992-99d2-87b2c2c1eb6c" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5090ad5b-5ccf-40de-8bac-c291b883b22d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_ce0a17a6-5268-4a57-8777-e38a6ba50157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5090ad5b-5ccf-40de-8bac-c291b883b22d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_ce0a17a6-5268-4a57-8777-e38a6ba50157" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_2e6c5e53-5476-40ac-83ba-c175db6cdaa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5090ad5b-5ccf-40de-8bac-c291b883b22d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_2e6c5e53-5476-40ac-83ba-c175db6cdaa2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_eb1ddf90-61cc-4b5b-ad66-ba9b1fd0605b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5090ad5b-5ccf-40de-8bac-c291b883b22d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_eb1ddf90-61cc-4b5b-ad66-ba9b1fd0605b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_c130ecae-f07a-4c6a-9842-0a1219b0a5aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_beea758a-e50e-4b78-8497-09562e8d259f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c63e6faa-93ec-4992-99d2-87b2c2c1eb6c" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_beea758a-e50e-4b78-8497-09562e8d259f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_d95cfc30-d9bb-49ed-a074-899d44b041a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_beea758a-e50e-4b78-8497-09562e8d259f" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_d95cfc30-d9bb-49ed-a074-899d44b041a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_d95cfc30-d9bb-49ed-a074-899d44b041a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_d95cfc30-d9bb-49ed-a074-899d44b041a9" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_d95cfc30-d9bb-49ed-a074-899d44b041a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_2cfc3ab4-dcae-4cda-96b0-95d9d72b7ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_d95cfc30-d9bb-49ed-a074-899d44b041a9" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_2cfc3ab4-dcae-4cda-96b0-95d9d72b7ec6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDiscountsAndAllowancesMember_f635ef6c-41f3-452f-b483-a92d9bb3caf3" xlink:href="bhc-20220510.xsd#bhc_ReserveForDiscountsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2cfc3ab4-dcae-4cda-96b0-95d9d72b7ec6" xlink:to="loc_bhc_ReserveForDiscountsAndAllowancesMember_f635ef6c-41f3-452f-b483-a92d9bb3caf3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember_5ab6c0dc-2db2-402a-ac93-d23e3527a10a" xlink:href="bhc-20220510.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2cfc3ab4-dcae-4cda-96b0-95d9d72b7ec6" xlink:to="loc_bhc_ReserveForCustomerReturnsMember_5ab6c0dc-2db2-402a-ac93-d23e3527a10a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesMember_cedf6525-60b4-46d1-9361-f616e9e59fd3" xlink:href="bhc-20220510.xsd#bhc_ReserveForRebatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2cfc3ab4-dcae-4cda-96b0-95d9d72b7ec6" xlink:to="loc_bhc_ReserveForRebatesMember_cedf6525-60b4-46d1-9361-f616e9e59fd3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForChargebacksMember_8f8e89d1-4896-43df-b6fb-a596397b41c8" xlink:href="bhc-20220510.xsd#bhc_ReserveForChargebacksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2cfc3ab4-dcae-4cda-96b0-95d9d72b7ec6" xlink:to="loc_bhc_ReserveForChargebacksMember_8f8e89d1-4896-43df-b6fb-a596397b41c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDistributionFeesMember_8ce0dd03-a080-4fe1-a14a-563da9ef5106" xlink:href="bhc-20220510.xsd#bhc_ReserveForDistributionFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2cfc3ab4-dcae-4cda-96b0-95d9d72b7ec6" xlink:to="loc_bhc_ReserveForDistributionFeesMember_8ce0dd03-a080-4fe1-a14a-563da9ef5106" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="extended" id="i848544582b6c49248a60891d3796d09b_SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b54c5fea-39a4-4047-a127-0f537fd62635" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_250c73a5-35a5-4bc6-93b6-95c3022be964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b54c5fea-39a4-4047-a127-0f537fd62635" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_250c73a5-35a5-4bc6-93b6-95c3022be964" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CashDiscountsAndAllowancesSettlementPeriod_3623ce8d-e98f-4c46-b665-adbb529ae620" xlink:href="bhc-20220510.xsd#bhc_CashDiscountsAndAllowancesSettlementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b54c5fea-39a4-4047-a127-0f537fd62635" xlink:to="loc_bhc_CashDiscountsAndAllowancesSettlementPeriod_3623ce8d-e98f-4c46-b665-adbb529ae620" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax_345e1797-995b-4db1-8455-95d88bf32185" xlink:href="bhc-20220510.xsd#bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b54c5fea-39a4-4047-a127-0f537fd62635" xlink:to="loc_bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax_345e1797-995b-4db1-8455-95d88bf32185" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_79d717b9-fa96-47b0-a152-b645fecd0b27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b54c5fea-39a4-4047-a127-0f537fd62635" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_79d717b9-fa96-47b0-a152-b645fecd0b27" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_02220813-5c72-4441-a11a-98ec44871073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b54c5fea-39a4-4047-a127-0f537fd62635" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_02220813-5c72-4441-a11a-98ec44871073" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax_68ca22b2-4035-417d-b103-a2afb6f7a174" xlink:href="bhc-20220510.xsd#bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b54c5fea-39a4-4047-a127-0f537fd62635" xlink:to="loc_bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax_68ca22b2-4035-417d-b103-a2afb6f7a174" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3279cdb1-8d6a-4545-b353-941a92ed1a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b54c5fea-39a4-4047-a127-0f537fd62635" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3279cdb1-8d6a-4545-b353-941a92ed1a6d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuePerformanceObligationPaymentTerms_90683dd0-2e0a-47b0-b901-ddab112ce760" xlink:href="bhc-20220510.xsd#bhc_RevenuePerformanceObligationPaymentTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b54c5fea-39a4-4047-a127-0f537fd62635" xlink:to="loc_bhc_RevenuePerformanceObligationPaymentTerms_90683dd0-2e0a-47b0-b901-ddab112ce760" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_58d1a965-44df-43b7-800d-ecd851e8d780" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b54c5fea-39a4-4047-a127-0f537fd62635" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_58d1a965-44df-43b7-800d-ecd851e8d780" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_cda26ec9-2fd6-400d-aad8-b6f740c67348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_58d1a965-44df-43b7-800d-ecd851e8d780" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_cda26ec9-2fd6-400d-aad8-b6f740c67348" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_cda26ec9-2fd6-400d-aad8-b6f740c67348_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_cda26ec9-2fd6-400d-aad8-b6f740c67348" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_cda26ec9-2fd6-400d-aad8-b6f740c67348_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_db364f69-89ec-4708-a890-2caffd4f02af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_cda26ec9-2fd6-400d-aad8-b6f740c67348" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_db364f69-89ec-4708-a890-2caffd4f02af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_46026231-56f6-4884-9cee-fc1464aac429" xlink:href="bhc-20220510.xsd#bhc_ReserveForRebatesAdvertisingCreditsPortionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_db364f69-89ec-4708-a890-2caffd4f02af" xlink:to="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_46026231-56f6-4884-9cee-fc1464aac429" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember_cfedcd79-14e8-4259-815b-5655f980b487" xlink:href="bhc-20220510.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_db364f69-89ec-4708-a890-2caffd4f02af" xlink:to="loc_bhc_ReserveForCustomerReturnsMember_cfedcd79-14e8-4259-815b-5655f980b487" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_659ef397-99cc-44d3-b8c4-4d2f371bb9d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_58d1a965-44df-43b7-800d-ecd851e8d780" xlink:to="loc_srt_RangeAxis_659ef397-99cc-44d3-b8c4-4d2f371bb9d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_659ef397-99cc-44d3-b8c4-4d2f371bb9d7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_659ef397-99cc-44d3-b8c4-4d2f371bb9d7" xlink:to="loc_srt_RangeMember_659ef397-99cc-44d3-b8c4-4d2f371bb9d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_50832f7f-39b7-4204-b544-28e36969c063" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_659ef397-99cc-44d3-b8c4-4d2f371bb9d7" xlink:to="loc_srt_RangeMember_50832f7f-39b7-4204-b544-28e36969c063" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1ce9e934-12a7-4f78-a2d3-76fd5913cddf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_50832f7f-39b7-4204-b544-28e36969c063" xlink:to="loc_srt_MinimumMember_1ce9e934-12a7-4f78-a2d3-76fd5913cddf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f6aa81f0-51bb-4bc9-8554-a3e61fe23e23" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_50832f7f-39b7-4204-b544-28e36969c063" xlink:to="loc_srt_MaximumMember_f6aa81f0-51bb-4bc9-8554-a3e61fe23e23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5f67fd6a-f76e-4b33-a4de-04f927d3c21f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_58d1a965-44df-43b7-800d-ecd851e8d780" xlink:to="loc_srt_ProductOrServiceAxis_5f67fd6a-f76e-4b33-a4de-04f927d3c21f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5f67fd6a-f76e-4b33-a4de-04f927d3c21f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5f67fd6a-f76e-4b33-a4de-04f927d3c21f" xlink:to="loc_srt_ProductsAndServicesDomain_5f67fd6a-f76e-4b33-a4de-04f927d3c21f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_afc21235-62fe-43eb-8ec7-11e76c9baff6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5f67fd6a-f76e-4b33-a4de-04f927d3c21f" xlink:to="loc_srt_ProductsAndServicesDomain_afc21235-62fe-43eb-8ec7-11e76c9baff6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PriceAppreciationCreditMember_56c99bde-8ee9-4ded-88cc-f20dab03494a" xlink:href="bhc-20220510.xsd#bhc_PriceAppreciationCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_afc21235-62fe-43eb-8ec7-11e76c9baff6" xlink:to="loc_bhc_PriceAppreciationCreditMember_56c99bde-8ee9-4ded-88cc-f20dab03494a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" xlink:type="extended" id="ib8d50b4c600548258a051e6e50a3ecbc_SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a9e76d0a-19b9-4eac-a216-439353ec8353" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9f19292c-989e-44fa-94d0-80a170eb4633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a9e76d0a-19b9-4eac-a216-439353ec8353" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9f19292c-989e-44fa-94d0-80a170eb4633" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_abc60969-014e-4b25-bdee-524a65d14c26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a9e76d0a-19b9-4eac-a216-439353ec8353" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_abc60969-014e-4b25-bdee-524a65d14c26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_4f80524f-9777-4d07-903b-e32487c0df4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a9e76d0a-19b9-4eac-a216-439353ec8353" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_4f80524f-9777-4d07-903b-e32487c0df4c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0c95d262-88c8-49aa-b712-b849cdaa60dc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_4f80524f-9777-4d07-903b-e32487c0df4c" xlink:to="loc_srt_RangeAxis_0c95d262-88c8-49aa-b712-b849cdaa60dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0c95d262-88c8-49aa-b712-b849cdaa60dc_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0c95d262-88c8-49aa-b712-b849cdaa60dc" xlink:to="loc_srt_RangeMember_0c95d262-88c8-49aa-b712-b849cdaa60dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_92e697f0-9e1c-4869-91ca-5cdbf3fe4e0c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0c95d262-88c8-49aa-b712-b849cdaa60dc" xlink:to="loc_srt_RangeMember_92e697f0-9e1c-4869-91ca-5cdbf3fe4e0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2da377be-a966-4292-bcc7-3e9489b83ccb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_92e697f0-9e1c-4869-91ca-5cdbf3fe4e0c" xlink:to="loc_srt_MinimumMember_2da377be-a966-4292-bcc7-3e9489b83ccb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c7f9772c-01ae-4921-9d4a-88087f2617f6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_92e697f0-9e1c-4869-91ca-5cdbf3fe4e0c" xlink:to="loc_srt_MaximumMember_c7f9772c-01ae-4921-9d4a-88087f2617f6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails" xlink:type="extended" id="i928981f89d0c40a7b84fc69c64a90ff6_SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8fd48d3c-19ec-4839-8be0-ced2ce22d3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4fee4a69-6e00-4bde-b692-b528987d83da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8fd48d3c-19ec-4839-8be0-ced2ce22d3c6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4fee4a69-6e00-4bde-b692-b528987d83da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_19f9b51c-bd69-4fef-9c2f-1099f0f4e445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8fd48d3c-19ec-4839-8be0-ced2ce22d3c6" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_19f9b51c-bd69-4fef-9c2f-1099f0f4e445" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e6eebec9-22a9-4bd3-b36e-e928a9e977c6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_19f9b51c-bd69-4fef-9c2f-1099f0f4e445" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e6eebec9-22a9-4bd3-b36e-e928a9e977c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e6eebec9-22a9-4bd3-b36e-e928a9e977c6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e6eebec9-22a9-4bd3-b36e-e928a9e977c6" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e6eebec9-22a9-4bd3-b36e-e928a9e977c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_eee4026b-3d08-4802-84d5-a285a328d084" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e6eebec9-22a9-4bd3-b36e-e928a9e977c6" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_eee4026b-3d08-4802-84d5-a285a328d084" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_e1b3c62b-63ae-487c-9a87-1f019626e74a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_eee4026b-3d08-4802-84d5-a285a328d084" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_e1b3c62b-63ae-487c-9a87-1f019626e74a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1690d3a6-eb47-42ee-92c2-dac92e4fe758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_19f9b51c-bd69-4fef-9c2f-1099f0f4e445" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1690d3a6-eb47-42ee-92c2-dac92e4fe758" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1690d3a6-eb47-42ee-92c2-dac92e4fe758_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1690d3a6-eb47-42ee-92c2-dac92e4fe758" xlink:to="loc_us-gaap_EquityComponentDomain_1690d3a6-eb47-42ee-92c2-dac92e4fe758_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_25f65a11-8952-4f3b-a2a0-b769903520e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1690d3a6-eb47-42ee-92c2-dac92e4fe758" xlink:to="loc_us-gaap_EquityComponentDomain_25f65a11-8952-4f3b-a2a0-b769903520e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4e66bbb5-b255-4c3a-891a-7c6245d38197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_25f65a11-8952-4f3b-a2a0-b769903520e9" xlink:to="loc_us-gaap_RetainedEarningsMember_4e66bbb5-b255-4c3a-891a-7c6245d38197" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails" xlink:type="extended" id="i722b815391bd4641876e0ea2bf38e3cd_ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_910d42af-c6ee-41be-abc4-7f23f06185ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_a8d509f0-aa7c-4522-8fd6-8ab5c976a08c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_910d42af-c6ee-41be-abc4-7f23f06185ab" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_a8d509f0-aa7c-4522-8fd6-8ab5c976a08c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_41548330-b8f6-4d80-9c74-d94acdd5ba6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_910d42af-c6ee-41be-abc4-7f23f06185ab" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_41548330-b8f6-4d80-9c74-d94acdd5ba6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_a992836e-db32-45b8-8161-4ea641fce3b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_910d42af-c6ee-41be-abc4-7f23f06185ab" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_a992836e-db32-45b8-8161-4ea641fce3b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss_17d63777-6c79-4f13-8d03-5d0d44813696" xlink:href="bhc-20220510.xsd#bhc_BusinessAcquisitionProFormaOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_910d42af-c6ee-41be-abc4-7f23f06185ab" xlink:to="loc_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss_17d63777-6c79-4f13-8d03-5d0d44813696" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual_04b8b03e-c5ff-4e94-bcc2-983a3304004f" xlink:href="bhc-20220510.xsd#bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_910d42af-c6ee-41be-abc4-7f23f06185ab" xlink:to="loc_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual_04b8b03e-c5ff-4e94-bcc2-983a3304004f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_af41b7d4-0ad9-4f88-920e-feee607eb389" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_910d42af-c6ee-41be-abc4-7f23f06185ab" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_af41b7d4-0ad9-4f88-920e-feee607eb389" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NumberOfOtherBusinessesAcquired_ea206b54-4de8-4275-98db-f7c364d49620" xlink:href="bhc-20220510.xsd#bhc_NumberOfOtherBusinessesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_910d42af-c6ee-41be-abc4-7f23f06185ab" xlink:to="loc_bhc_NumberOfOtherBusinessesAcquired_ea206b54-4de8-4275-98db-f7c364d49620" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_adeb8a87-4c26-4f7d-8fee-148682c75774" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_910d42af-c6ee-41be-abc4-7f23f06185ab" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_adeb8a87-4c26-4f7d-8fee-148682c75774" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_b9753b2d-0842-42fb-be25-8c264406631d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_910d42af-c6ee-41be-abc4-7f23f06185ab" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_b9753b2d-0842-42fb-be25-8c264406631d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected_6650c48c-308e-4519-8601-a11a89dd22a1" xlink:href="bhc-20220510.xsd#bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_910d42af-c6ee-41be-abc4-7f23f06185ab" xlink:to="loc_bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected_6650c48c-308e-4519-8601-a11a89dd22a1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_5a631ad3-0712-4355-bad0-4f138c513d20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_910d42af-c6ee-41be-abc4-7f23f06185ab" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_5a631ad3-0712-4355-bad0-4f138c513d20" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_7640cba3-64a0-4e09-87a7-f21cfb9a4d62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_910d42af-c6ee-41be-abc4-7f23f06185ab" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_7640cba3-64a0-4e09-87a7-f21cfb9a4d62" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NoncashCumulativeForeignCurrencyTranslationLoss_259b0472-a6f3-4b22-a4e1-68cbcd757494" xlink:href="bhc-20220510.xsd#bhc_NoncashCumulativeForeignCurrencyTranslationLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_910d42af-c6ee-41be-abc4-7f23f06185ab" xlink:to="loc_bhc_NoncashCumulativeForeignCurrencyTranslationLoss_259b0472-a6f3-4b22-a4e1-68cbcd757494" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_963db72f-3618-456a-b2e0-932700c50c01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_910d42af-c6ee-41be-abc4-7f23f06185ab" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_963db72f-3618-456a-b2e0-932700c50c01" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b5b9a31e-2010-4eb8-a426-6d83ae723ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_963db72f-3618-456a-b2e0-932700c50c01" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b5b9a31e-2010-4eb8-a426-6d83ae723ed3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5b9a31e-2010-4eb8-a426-6d83ae723ed3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b5b9a31e-2010-4eb8-a426-6d83ae723ed3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b5b9a31e-2010-4eb8-a426-6d83ae723ed3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c567271-f788-46ce-98f1-e2b45ccc6013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b5b9a31e-2010-4eb8-a426-6d83ae723ed3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c567271-f788-46ce-98f1-e2b45ccc6013" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SynergyPharmaceuticalsInc.Member_72a59346-80b8-4473-8c1d-7c7f7b98a61e" xlink:href="bhc-20220510.xsd#bhc_SynergyPharmaceuticalsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c567271-f788-46ce-98f1-e2b45ccc6013" xlink:to="loc_bhc_SynergyPharmaceuticalsInc.Member_72a59346-80b8-4473-8c1d-7c7f7b98a61e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_92acf60c-5635-402e-8bea-db596bacb531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_963db72f-3618-456a-b2e0-932700c50c01" xlink:to="loc_us-gaap_AssetAcquisitionAxis_92acf60c-5635-402e-8bea-db596bacb531" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_92acf60c-5635-402e-8bea-db596bacb531_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_92acf60c-5635-402e-8bea-db596bacb531" xlink:to="loc_us-gaap_AssetAcquisitionDomain_92acf60c-5635-402e-8bea-db596bacb531_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_8ec13d68-de52-40ed-9b14-ffa95f544bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_92acf60c-5635-402e-8bea-db596bacb531" xlink:to="loc_us-gaap_AssetAcquisitionDomain_8ec13d68-de52-40ed-9b14-ffa95f544bfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllegroOphthalmicsLLCMember_098c912b-e9f1-4555-8bb3-409990104a9e" xlink:href="bhc-20220510.xsd#bhc_AllegroOphthalmicsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_8ec13d68-de52-40ed-9b14-ffa95f544bfb" xlink:to="loc_bhc_AllegroOphthalmicsLLCMember_098c912b-e9f1-4555-8bb3-409990104a9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_a2c3dbe9-1458-4e17-aa89-a61dbba4a94b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_963db72f-3618-456a-b2e0-932700c50c01" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_a2c3dbe9-1458-4e17-aa89-a61dbba4a94b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a2c3dbe9-1458-4e17-aa89-a61dbba4a94b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_a2c3dbe9-1458-4e17-aa89-a61dbba4a94b" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a2c3dbe9-1458-4e17-aa89-a61dbba4a94b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_1a2287ae-d15f-4f1a-9a00-a29d3f84a2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_a2c3dbe9-1458-4e17-aa89-a61dbba4a94b" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_1a2287ae-d15f-4f1a-9a00-a29d3f84a2f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_49a4c223-d19c-4b96-a58c-2c13cca7b68b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_1a2287ae-d15f-4f1a-9a00-a29d3f84a2f9" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_49a4c223-d19c-4b96-a58c-2c13cca7b68b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_7e64f341-8324-44cf-aa27-371fcffd00f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_1a2287ae-d15f-4f1a-9a00-a29d3f84a2f9" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_7e64f341-8324-44cf-aa27-371fcffd00f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_0aa8d92f-2a5e-4b11-866c-c71cd81e130f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_1a2287ae-d15f-4f1a-9a00-a29d3f84a2f9" xlink:to="loc_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_0aa8d92f-2a5e-4b11-866c-c71cd81e130f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_831abbbf-15dd-4a82-91f5-72713aabdca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_963db72f-3618-456a-b2e0-932700c50c01" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_831abbbf-15dd-4a82-91f5-72713aabdca9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_831abbbf-15dd-4a82-91f5-72713aabdca9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_831abbbf-15dd-4a82-91f5-72713aabdca9" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_831abbbf-15dd-4a82-91f5-72713aabdca9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e360a342-ebe9-47ae-90a3-970743c91a44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_831abbbf-15dd-4a82-91f5-72713aabdca9" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e360a342-ebe9-47ae-90a3-970743c91a44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember_11de04cd-7422-435a-888a-5845235eea63" xlink:href="bhc-20220510.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e360a342-ebe9-47ae-90a3-970743c91a44" xlink:to="loc_bhc_AmounPharmaceuticalCompanySAEMember_11de04cd-7422-435a-888a-5845235eea63" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="i570e6cb7644a46da96e0006f6662cf4b_ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_70ec8b49-d35b-406d-a75b-b5f2702e1eab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_98f0eedd-3361-424a-817c-64182e97361f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70ec8b49-d35b-406d-a75b-b5f2702e1eab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_98f0eedd-3361-424a-817c-64182e97361f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_9969affb-4588-41b6-84c8-93a633b05b56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70ec8b49-d35b-406d-a75b-b5f2702e1eab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_9969affb-4588-41b6-84c8-93a633b05b56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_930d4eef-f853-4baf-8c27-81c1db08fb23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70ec8b49-d35b-406d-a75b-b5f2702e1eab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_930d4eef-f853-4baf-8c27-81c1db08fb23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_274a9b57-ec6e-483f-96d0-d45c685a6bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70ec8b49-d35b-406d-a75b-b5f2702e1eab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_274a9b57-ec6e-483f-96d0-d45c685a6bdc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_e4cfea76-7654-4989-b528-c92f4ffff376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70ec8b49-d35b-406d-a75b-b5f2702e1eab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_e4cfea76-7654-4989-b528-c92f4ffff376" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses_5dcde453-6df8-4ab1-bb78-bcbea43da195" xlink:href="bhc-20220510.xsd#bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70ec8b49-d35b-406d-a75b-b5f2702e1eab" xlink:to="loc_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses_5dcde453-6df8-4ab1-bb78-bcbea43da195" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_6720dc50-45dd-45db-90af-37983b94bb98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70ec8b49-d35b-406d-a75b-b5f2702e1eab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_6720dc50-45dd-45db-90af-37983b94bb98" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_90c5b3ea-57a3-48b3-a2b2-ff966a45f964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70ec8b49-d35b-406d-a75b-b5f2702e1eab" xlink:to="loc_us-gaap_Goodwill_90c5b3ea-57a3-48b3-a2b2-ff966a45f964" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_ecbfc51f-f789-4eed-9cb7-95cdafe7096d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70ec8b49-d35b-406d-a75b-b5f2702e1eab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_ecbfc51f-f789-4eed-9cb7-95cdafe7096d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_879ab176-2fbe-4bd3-8282-b04000e0154c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70ec8b49-d35b-406d-a75b-b5f2702e1eab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_879ab176-2fbe-4bd3-8282-b04000e0154c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d0b79b28-e9cd-4939-a23e-4e4d111eaeb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70ec8b49-d35b-406d-a75b-b5f2702e1eab" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d0b79b28-e9cd-4939-a23e-4e4d111eaeb5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b65d0ead-3e23-4cec-b5f1-a26ba0c4b36b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d0b79b28-e9cd-4939-a23e-4e4d111eaeb5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b65d0ead-3e23-4cec-b5f1-a26ba0c4b36b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b65d0ead-3e23-4cec-b5f1-a26ba0c4b36b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b65d0ead-3e23-4cec-b5f1-a26ba0c4b36b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b65d0ead-3e23-4cec-b5f1-a26ba0c4b36b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e5b5bbe-4fc0-43cc-b830-0e12e7c75f52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b65d0ead-3e23-4cec-b5f1-a26ba0c4b36b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e5b5bbe-4fc0-43cc-b830-0e12e7c75f52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SynergyPharmaceuticalsInc.Member_45797853-4ebb-44fa-a8b8-89f94195732f" xlink:href="bhc-20220510.xsd#bhc_SynergyPharmaceuticalsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e5b5bbe-4fc0-43cc-b830-0e12e7c75f52" xlink:to="loc_bhc_SynergyPharmaceuticalsInc.Member_45797853-4ebb-44fa-a8b8-89f94195732f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails" xlink:type="extended" id="i54d7952f55a94d47b681cedebc08b26f_ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5c328517-190b-47b7-86fe-d85e04156033" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_6635bab6-9047-4a8e-9bc2-395b02331fab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5c328517-190b-47b7-86fe-d85e04156033" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_6635bab6-9047-4a8e-9bc2-395b02331fab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_0fa70b84-9e02-41a4-a8e6-ca127e04fb12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_6635bab6-9047-4a8e-9bc2-395b02331fab" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_0fa70b84-9e02-41a4-a8e6-ca127e04fb12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_0f3def9e-072b-4457-b327-a6f1a977da26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_6635bab6-9047-4a8e-9bc2-395b02331fab" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_0f3def9e-072b-4457-b327-a6f1a977da26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_8fb28364-d0f1-47a2-baff-65317bd54812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_6635bab6-9047-4a8e-9bc2-395b02331fab" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_8fb28364-d0f1-47a2-baff-65317bd54812" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_ca654fc7-8071-4708-9097-e51dc265f164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_6635bab6-9047-4a8e-9bc2-395b02331fab" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_ca654fc7-8071-4708-9097-e51dc265f164" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_1d356c52-1489-403c-a3fa-134b91b3b54d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5c328517-190b-47b7-86fe-d85e04156033" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_1d356c52-1489-403c-a3fa-134b91b3b54d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_4b84552e-89c0-4fb8-8833-505998d2158f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_1d356c52-1489-403c-a3fa-134b91b3b54d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_4b84552e-89c0-4fb8-8833-505998d2158f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_3cab0c0b-4aa5-4acb-98f3-171fcf990151" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_1d356c52-1489-403c-a3fa-134b91b3b54d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_3cab0c0b-4aa5-4acb-98f3-171fcf990151" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_90397337-014b-4bf4-9fce-80a0f501f20d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_1d356c52-1489-403c-a3fa-134b91b3b54d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_90397337-014b-4bf4-9fce-80a0f501f20d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_b995e7ce-8ff7-481b-9c9d-84846cb569a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_1d356c52-1489-403c-a3fa-134b91b3b54d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_b995e7ce-8ff7-481b-9c9d-84846cb569a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_6d9bf238-3d60-42f3-b9de-bc01c2289b49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5c328517-190b-47b7-86fe-d85e04156033" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_6d9bf238-3d60-42f3-b9de-bc01c2289b49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_bc58e447-e352-4559-bc25-5609bc803bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_6d9bf238-3d60-42f3-b9de-bc01c2289b49" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_bc58e447-e352-4559-bc25-5609bc803bdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent_04ed6261-f9ec-4250-b373-8e8e27837d1e" xlink:href="bhc-20220510.xsd#bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_6d9bf238-3d60-42f3-b9de-bc01c2289b49" xlink:to="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent_04ed6261-f9ec-4250-b373-8e8e27837d1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_ca5bb1b9-6562-4c81-88e5-8887db116d93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_6d9bf238-3d60-42f3-b9de-bc01c2289b49" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_ca5bb1b9-6562-4c81-88e5-8887db116d93" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_89407fdb-30f4-4ed5-9086-109c98ca4020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5c328517-190b-47b7-86fe-d85e04156033" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_89407fdb-30f4-4ed5-9086-109c98ca4020" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_da025681-daa1-4668-90ad-014ea691456f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_89407fdb-30f4-4ed5-9086-109c98ca4020" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_da025681-daa1-4668-90ad-014ea691456f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent_514b1584-ea1e-4faf-9de6-1b3e72a82ac7" xlink:href="bhc-20220510.xsd#bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_89407fdb-30f4-4ed5-9086-109c98ca4020" xlink:to="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent_514b1584-ea1e-4faf-9de6-1b3e72a82ac7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_2de8c4b1-d812-45c4-bc5b-3bdfb76039e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_89407fdb-30f4-4ed5-9086-109c98ca4020" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_2de8c4b1-d812-45c4-bc5b-3bdfb76039e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f67cd9aa-4c3b-4877-8009-ba715b3b8686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5c328517-190b-47b7-86fe-d85e04156033" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f67cd9aa-4c3b-4877-8009-ba715b3b8686" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6a062929-c553-4efe-b398-f25c233d25e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f67cd9aa-4c3b-4877-8009-ba715b3b8686" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6a062929-c553-4efe-b398-f25c233d25e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6a062929-c553-4efe-b398-f25c233d25e3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6a062929-c553-4efe-b398-f25c233d25e3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6a062929-c553-4efe-b398-f25c233d25e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2f57c801-0361-4c8a-b35f-b02376617d67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6a062929-c553-4efe-b398-f25c233d25e3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2f57c801-0361-4c8a-b35f-b02376617d67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ACertainInternationalBusinessMember_9e2104f2-3647-4f1d-88ce-1c2d5b8befdd" xlink:href="bhc-20220510.xsd#bhc_ACertainInternationalBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2f57c801-0361-4c8a-b35f-b02376617d67" xlink:to="loc_bhc_ACertainInternationalBusinessMember_9e2104f2-3647-4f1d-88ce-1c2d5b8befdd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_d4b39a56-5e2d-4346-a829-786d4f5e9c68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f67cd9aa-4c3b-4877-8009-ba715b3b8686" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_d4b39a56-5e2d-4346-a829-786d4f5e9c68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_d4b39a56-5e2d-4346-a829-786d4f5e9c68_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_d4b39a56-5e2d-4346-a829-786d4f5e9c68" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_d4b39a56-5e2d-4346-a829-786d4f5e9c68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0eae1074-dd7b-4062-88f8-5eed6cff875e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_d4b39a56-5e2d-4346-a829-786d4f5e9c68" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0eae1074-dd7b-4062-88f8-5eed6cff875e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_2d145273-9fbc-41df-afbe-8cadaf8128dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_0eae1074-dd7b-4062-88f8-5eed6cff875e" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_2d145273-9fbc-41df-afbe-8cadaf8128dc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" xlink:type="extended" id="if8764ca9a9a94240a454351252fbe1a8_RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_d2e8ac34-6ae7-4da7-8301-367892b96597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_0f7cebd9-6185-4ed8-9ead-936216684e97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d2e8ac34-6ae7-4da7-8301-367892b96597" xlink:to="loc_us-gaap_RestructuringReserve_0f7cebd9-6185-4ed8-9ead-936216684e97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_364830a9-c2be-42db-bd57-70314dfe36df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d2e8ac34-6ae7-4da7-8301-367892b96597" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_364830a9-c2be-42db-bd57-70314dfe36df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_882768da-34f8-49c6-885d-bd3ebef1d868" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d2e8ac34-6ae7-4da7-8301-367892b96597" xlink:to="loc_us-gaap_PaymentsForRestructuring_882768da-34f8-49c6-885d-bd3ebef1d868" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_a53c7884-6603-47b0-9a79-cd2f0cf6b2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d2e8ac34-6ae7-4da7-8301-367892b96597" xlink:to="loc_us-gaap_RestructuringCharges_a53c7884-6603-47b0-9a79-cd2f0cf6b2e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_fc1f0be8-825f-4add-a1b2-a9711ff44b28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d2e8ac34-6ae7-4da7-8301-367892b96597" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_fc1f0be8-825f-4add-a1b2-a9711ff44b28" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_44ab1c4a-ab7e-4ff6-8393-06df2e68bea5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d2e8ac34-6ae7-4da7-8301-367892b96597" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_44ab1c4a-ab7e-4ff6-8393-06df2e68bea5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_a8ceee5c-0d4e-4b71-8566-90a5318a1506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_44ab1c4a-ab7e-4ff6-8393-06df2e68bea5" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_a8ceee5c-0d4e-4b71-8566-90a5318a1506" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_a8ceee5c-0d4e-4b71-8566-90a5318a1506_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_a8ceee5c-0d4e-4b71-8566-90a5318a1506" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_a8ceee5c-0d4e-4b71-8566-90a5318a1506_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_bc95fe0f-fc44-4766-95a3-fc18e2e88b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_a8ceee5c-0d4e-4b71-8566-90a5318a1506" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_bc95fe0f-fc44-4766-95a3-fc18e2e88b0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndIntegrationCostsMember_accfafab-b23e-4496-95d4-67257baa0897" xlink:href="bhc-20220510.xsd#bhc_RestructuringAndIntegrationCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_bc95fe0f-fc44-4766-95a3-fc18e2e88b0c" xlink:to="loc_bhc_RestructuringAndIntegrationCostsMember_accfafab-b23e-4496-95d4-67257baa0897" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationAndInitialPublicOfferingCostsMember_e0d667aa-7676-4d2d-8574-f39c91d93d58" xlink:href="bhc-20220510.xsd#bhc_SeparationAndInitialPublicOfferingCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_bc95fe0f-fc44-4766-95a3-fc18e2e88b0c" xlink:to="loc_bhc_SeparationAndInitialPublicOfferingCostsMember_e0d667aa-7676-4d2d-8574-f39c91d93d58" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="i3bd5652ca4ac48bbac36f07eb7601004_FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a319deaa-e843-4445-b359-87078551bcd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_d3c48298-998a-41df-8e04-7150ad9f1e60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a319deaa-e843-4445-b359-87078551bcd7" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_d3c48298-998a-41df-8e04-7150ad9f1e60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c88e3f69-0d55-4166-bbda-f6836f16cd70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d3c48298-998a-41df-8e04-7150ad9f1e60" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c88e3f69-0d55-4166-bbda-f6836f16cd70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_12ba1ced-463d-4016-8b6d-911562174432" xlink:href="bhc-20220510.xsd#bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d3c48298-998a-41df-8e04-7150ad9f1e60" xlink:to="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_12ba1ced-463d-4016-8b6d-911562174432" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_958fffec-2b5f-4cdc-9223-11e73e95e24f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d3c48298-998a-41df-8e04-7150ad9f1e60" xlink:to="loc_us-gaap_DerivativeAssets_958fffec-2b5f-4cdc-9223-11e73e95e24f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_fe05f4c7-194e-4b1b-9e49-da3d70da253e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a319deaa-e843-4445-b359-87078551bcd7" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_fe05f4c7-194e-4b1b-9e49-da3d70da253e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_017009a6-6734-46c8-b04a-7deff28ddf56" xlink:href="bhc-20220510.xsd#bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_fe05f4c7-194e-4b1b-9e49-da3d70da253e" xlink:to="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_017009a6-6734-46c8-b04a-7deff28ddf56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_560f3445-2274-4f0d-859f-437cfc865d89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_fe05f4c7-194e-4b1b-9e49-da3d70da253e" xlink:to="loc_us-gaap_DerivativeLiabilities_560f3445-2274-4f0d-859f-437cfc865d89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fa5a531c-ed24-48ad-bc74-28242447874e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a319deaa-e843-4445-b359-87078551bcd7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fa5a531c-ed24-48ad-bc74-28242447874e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_409c9182-4de7-4d37-9074-9f9c63db9362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fa5a531c-ed24-48ad-bc74-28242447874e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_409c9182-4de7-4d37-9074-9f9c63db9362" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_409c9182-4de7-4d37-9074-9f9c63db9362_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_409c9182-4de7-4d37-9074-9f9c63db9362" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_409c9182-4de7-4d37-9074-9f9c63db9362_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c6e4a89b-b3fd-43df-b034-af1b55b391c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_409c9182-4de7-4d37-9074-9f9c63db9362" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c6e4a89b-b3fd-43df-b034-af1b55b391c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_dddf6227-d030-4f3f-95b1-e37f79f40d31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c6e4a89b-b3fd-43df-b034-af1b55b391c8" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_dddf6227-d030-4f3f-95b1-e37f79f40d31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_118afa9d-df01-4a38-b76a-0e0f46d2c1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fa5a531c-ed24-48ad-bc74-28242447874e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_118afa9d-df01-4a38-b76a-0e0f46d2c1bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_118afa9d-df01-4a38-b76a-0e0f46d2c1bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_118afa9d-df01-4a38-b76a-0e0f46d2c1bf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_118afa9d-df01-4a38-b76a-0e0f46d2c1bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92fd67f3-1c07-4aa4-8d49-d3f6c1c9e82c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_118afa9d-df01-4a38-b76a-0e0f46d2c1bf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92fd67f3-1c07-4aa4-8d49-d3f6c1c9e82c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b2d640d1-3d0c-43c8-81c9-f987495e50c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92fd67f3-1c07-4aa4-8d49-d3f6c1c9e82c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b2d640d1-3d0c-43c8-81c9-f987495e50c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2189d3e4-88e7-4f91-8e88-157cfcca6a14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92fd67f3-1c07-4aa4-8d49-d3f6c1c9e82c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2189d3e4-88e7-4f91-8e88-157cfcca6a14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9fdc9ed8-d378-4fe6-95c1-de8b58b89452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92fd67f3-1c07-4aa4-8d49-d3f6c1c9e82c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9fdc9ed8-d378-4fe6-95c1-de8b58b89452" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_adde38b2-41a2-452f-a409-13e2397831b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fa5a531c-ed24-48ad-bc74-28242447874e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_adde38b2-41a2-452f-a409-13e2397831b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_adde38b2-41a2-452f-a409-13e2397831b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_adde38b2-41a2-452f-a409-13e2397831b1" xlink:to="loc_us-gaap_HedgingRelationshipDomain_adde38b2-41a2-452f-a409-13e2397831b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_8a922b11-8b91-4df1-9082-be15dd498751" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_adde38b2-41a2-452f-a409-13e2397831b1" xlink:to="loc_us-gaap_HedgingRelationshipDomain_8a922b11-8b91-4df1-9082-be15dd498751" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_a20d7d72-9d5d-44b3-9bb4-163be8998ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_8a922b11-8b91-4df1-9082-be15dd498751" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_a20d7d72-9d5d-44b3-9bb4-163be8998ae9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4dda6d8c-f67c-4b35-9b35-4f8f30acc779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fa5a531c-ed24-48ad-bc74-28242447874e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4dda6d8c-f67c-4b35-9b35-4f8f30acc779" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4dda6d8c-f67c-4b35-9b35-4f8f30acc779_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4dda6d8c-f67c-4b35-9b35-4f8f30acc779" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4dda6d8c-f67c-4b35-9b35-4f8f30acc779_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4e4392e7-bdcc-40cb-94c5-658c217b249a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4dda6d8c-f67c-4b35-9b35-4f8f30acc779" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4e4392e7-bdcc-40cb-94c5-658c217b249a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_a649004a-e4f4-49aa-a279-283842fa330a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4e4392e7-bdcc-40cb-94c5-658c217b249a" xlink:to="loc_us-gaap_CurrencySwapMember_a649004a-e4f4-49aa-a279-283842fa330a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_47be04a8-2cc6-4f18-beb7-8fc280de68e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4e4392e7-bdcc-40cb-94c5-658c217b249a" xlink:to="loc_us-gaap_ForeignExchangeContractMember_47be04a8-2cc6-4f18-beb7-8fc280de68e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_dbd31134-e1ff-4c14-a92b-98030ab8edd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fa5a531c-ed24-48ad-bc74-28242447874e" xlink:to="loc_us-gaap_HedgingDesignationAxis_dbd31134-e1ff-4c14-a92b-98030ab8edd4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_dbd31134-e1ff-4c14-a92b-98030ab8edd4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_dbd31134-e1ff-4c14-a92b-98030ab8edd4" xlink:to="loc_us-gaap_HedgingDesignationDomain_dbd31134-e1ff-4c14-a92b-98030ab8edd4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_2f1d4d08-86c8-4e44-9083-562f4e5bbff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_dbd31134-e1ff-4c14-a92b-98030ab8edd4" xlink:to="loc_us-gaap_HedgingDesignationDomain_2f1d4d08-86c8-4e44-9083-562f4e5bbff8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_cfd7ef53-de4c-483f-8ebd-8153a1491dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_2f1d4d08-86c8-4e44-9083-562f4e5bbff8" xlink:to="loc_us-gaap_NondesignatedMember_cfd7ef53-de4c-483f-8ebd-8153a1491dcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_39f051d9-b0be-4a85-b389-ac45723c0878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_2f1d4d08-86c8-4e44-9083-562f4e5bbff8" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_39f051d9-b0be-4a85-b389-ac45723c0878" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" xlink:type="extended" id="i67d99347a3ab4155a807032e2003f5e2_FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_356779b0-7697-4b03-b289-51c4545522ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_f9472136-be0b-4d52-8421-d727ca169e4f" xlink:href="bhc-20220510.xsd#bhc_HighlyLiquidInvestmentsMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_356779b0-7697-4b03-b289-51c4545522ba" xlink:to="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_f9472136-be0b-4d52-8421-d727ca169e4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_c8ba8755-8c7f-4424-b487-3a450d0be675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_356779b0-7697-4b03-b289-51c4545522ba" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_c8ba8755-8c7f-4424-b487-3a450d0be675" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7e11dd1a-d247-49aa-9617-8378c9fdaabf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_356779b0-7697-4b03-b289-51c4545522ba" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7e11dd1a-d247-49aa-9617-8378c9fdaabf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_ab8b87d0-4624-4005-ab0c-e16a29be816c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7e11dd1a-d247-49aa-9617-8378c9fdaabf" xlink:to="loc_srt_LitigationCaseAxis_ab8b87d0-4624-4005-ab0c-e16a29be816c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ab8b87d0-4624-4005-ab0c-e16a29be816c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_ab8b87d0-4624-4005-ab0c-e16a29be816c" xlink:to="loc_srt_LitigationCaseTypeDomain_ab8b87d0-4624-4005-ab0c-e16a29be816c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a68ad7c9-a404-4604-81bc-ca9a68ba8eec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_ab8b87d0-4624-4005-ab0c-e16a29be816c" xlink:to="loc_srt_LitigationCaseTypeDomain_a68ad7c9-a404-4604-81bc-ca9a68ba8eec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_236ef1ff-82f1-41d3-afa3-bb60981bf325" xlink:href="bhc-20220510.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_a68ad7c9-a404-4604-81bc-ca9a68ba8eec" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_236ef1ff-82f1-41d3-afa3-bb60981bf325" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_331fdc41-de14-4717-8f90-bb2819ca5186" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7e11dd1a-d247-49aa-9617-8378c9fdaabf" xlink:to="loc_srt_StatementGeographicalAxis_331fdc41-de14-4717-8f90-bb2819ca5186" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_331fdc41-de14-4717-8f90-bb2819ca5186_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_331fdc41-de14-4717-8f90-bb2819ca5186" xlink:to="loc_srt_SegmentGeographicalDomain_331fdc41-de14-4717-8f90-bb2819ca5186_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_99b08438-215f-4468-a56d-b4235a9a11c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_331fdc41-de14-4717-8f90-bb2819ca5186" xlink:to="loc_srt_SegmentGeographicalDomain_99b08438-215f-4468-a56d-b4235a9a11c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_60b2c22a-2666-4c9f-8f18-a254c9a91d3c" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_99b08438-215f-4468-a56d-b4235a9a11c8" xlink:to="loc_stpr_NJ_60b2c22a-2666-4c9f-8f18-a254c9a91d3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_f4c03c8b-5806-4311-9bf3-e7ae1d637fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7e11dd1a-d247-49aa-9617-8378c9fdaabf" xlink:to="loc_us-gaap_LitigationStatusAxis_f4c03c8b-5806-4311-9bf3-e7ae1d637fd3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_f4c03c8b-5806-4311-9bf3-e7ae1d637fd3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_f4c03c8b-5806-4311-9bf3-e7ae1d637fd3" xlink:to="loc_us-gaap_LitigationStatusDomain_f4c03c8b-5806-4311-9bf3-e7ae1d637fd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_10d86143-0824-41a8-8872-c3c852aa0f21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_f4c03c8b-5806-4311-9bf3-e7ae1d637fd3" xlink:to="loc_us-gaap_LitigationStatusDomain_10d86143-0824-41a8-8872-c3c852aa0f21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_5959f0c9-dfe5-4e63-b666-53119014ab02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_10d86143-0824-41a8-8872-c3c852aa0f21" xlink:to="loc_us-gaap_SettledLitigationMember_5959f0c9-dfe5-4e63-b666-53119014ab02" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="extended" id="ic132e96791c8424cbcbf8cf63d256007_FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b0b6dd1-9907-4e5e-9253-5c84180f1df5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_83a81707-df18-4ded-b6ff-1208dbb98594" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b0b6dd1-9907-4e5e-9253-5c84180f1df5" xlink:to="loc_us-gaap_DerivativeNotionalAmount_83a81707-df18-4ded-b6ff-1208dbb98594" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities_ab7af6b8-ee1f-4deb-86cc-db15da6b86e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromHedgeInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b0b6dd1-9907-4e5e-9253-5c84180f1df5" xlink:to="loc_us-gaap_ProceedsFromHedgeInvestingActivities_ab7af6b8-ee1f-4deb-86cc-db15da6b86e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_06cdc053-d5f8-4cfc-9b1e-43cbd4c4d05f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b0b6dd1-9907-4e5e-9253-5c84180f1df5" xlink:to="loc_us-gaap_InvestmentIncomeInterest_06cdc053-d5f8-4cfc-9b1e-43cbd4c4d05f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_688ed763-7b8f-4eeb-b99c-bad193dc57c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b0b6dd1-9907-4e5e-9253-5c84180f1df5" xlink:to="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_688ed763-7b8f-4eeb-b99c-bad193dc57c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a6227724-b007-49de-9c48-2154e005989e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b0b6dd1-9907-4e5e-9253-5c84180f1df5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a6227724-b007-49de-9c48-2154e005989e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_74edbb9f-f8d8-4cee-9d4b-7f69ba6db725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a6227724-b007-49de-9c48-2154e005989e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_74edbb9f-f8d8-4cee-9d4b-7f69ba6db725" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_74edbb9f-f8d8-4cee-9d4b-7f69ba6db725_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_74edbb9f-f8d8-4cee-9d4b-7f69ba6db725" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_74edbb9f-f8d8-4cee-9d4b-7f69ba6db725_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ffb296c8-28cd-48be-96b9-d79ed4f1542d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_74edbb9f-f8d8-4cee-9d4b-7f69ba6db725" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ffb296c8-28cd-48be-96b9-d79ed4f1542d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_c9926ca2-13b8-47eb-a58f-c47e7ac79334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ffb296c8-28cd-48be-96b9-d79ed4f1542d" xlink:to="loc_us-gaap_CurrencySwapMember_c9926ca2-13b8-47eb-a58f-c47e7ac79334" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CrossCurrencyFinalSettlementMember_25f43906-cfdc-4d53-be66-e4274e345b7f" xlink:href="bhc-20220510.xsd#bhc_CrossCurrencyFinalSettlementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CurrencySwapMember_c9926ca2-13b8-47eb-a58f-c47e7ac79334" xlink:to="loc_bhc_CrossCurrencyFinalSettlementMember_25f43906-cfdc-4d53-be66-e4274e345b7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ea1f1381-f10e-455a-bbe5-bbad8c298371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a6227724-b007-49de-9c48-2154e005989e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ea1f1381-f10e-455a-bbe5-bbad8c298371" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_ea1f1381-f10e-455a-bbe5-bbad8c298371_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ea1f1381-f10e-455a-bbe5-bbad8c298371" xlink:to="loc_us-gaap_HedgingRelationshipDomain_ea1f1381-f10e-455a-bbe5-bbad8c298371_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_5fa9d520-ff03-45e9-9d21-f204306fc4a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ea1f1381-f10e-455a-bbe5-bbad8c298371" xlink:to="loc_us-gaap_HedgingRelationshipDomain_5fa9d520-ff03-45e9-9d21-f204306fc4a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_9bd88e9a-9861-40b5-ae64-01004a069a11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_5fa9d520-ff03-45e9-9d21-f204306fc4a5" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_9bd88e9a-9861-40b5-ae64-01004a069a11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_622fc8d0-ef9f-43a4-a11e-268e5285d1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a6227724-b007-49de-9c48-2154e005989e" xlink:to="loc_us-gaap_HedgingDesignationAxis_622fc8d0-ef9f-43a4-a11e-268e5285d1ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_622fc8d0-ef9f-43a4-a11e-268e5285d1ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_622fc8d0-ef9f-43a4-a11e-268e5285d1ca" xlink:to="loc_us-gaap_HedgingDesignationDomain_622fc8d0-ef9f-43a4-a11e-268e5285d1ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_c5bb8dde-a18b-4fe9-9d2a-4eb0b72a3f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_622fc8d0-ef9f-43a4-a11e-268e5285d1ca" xlink:to="loc_us-gaap_HedgingDesignationDomain_c5bb8dde-a18b-4fe9-9d2a-4eb0b72a3f6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_ed6bce50-340f-45a5-b5cd-bc28076b54b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_c5bb8dde-a18b-4fe9-9d2a-4eb0b72a3f6e" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_ed6bce50-340f-45a5-b5cd-bc28076b54b5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="extended" id="i5d24e09a1250474eb1bf2ad9e53fdd73_FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f11178db-fc1a-4f38-8ac1-31ec109f9d82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_98c32c03-d3e3-4004-aa06-56f27641ce34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f11178db-fc1a-4f38-8ac1-31ec109f9d82" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_98c32c03-d3e3-4004-aa06-56f27641ce34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_86439078-730b-4bb5-a1a1-7350fbd66fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f11178db-fc1a-4f38-8ac1-31ec109f9d82" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_86439078-730b-4bb5-a1a1-7350fbd66fbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_5fac646f-d5bd-49b1-8bbe-4890f2e2802b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f11178db-fc1a-4f38-8ac1-31ec109f9d82" xlink:to="loc_us-gaap_DerivativeLiabilities_5fac646f-d5bd-49b1-8bbe-4890f2e2802b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b8940a3-f85d-4c91-b068-da4254758969" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f11178db-fc1a-4f38-8ac1-31ec109f9d82" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b8940a3-f85d-4c91-b068-da4254758969" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c898a0be-9d3f-4963-8730-0b6892a0e1af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b8940a3-f85d-4c91-b068-da4254758969" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c898a0be-9d3f-4963-8730-0b6892a0e1af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c898a0be-9d3f-4963-8730-0b6892a0e1af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c898a0be-9d3f-4963-8730-0b6892a0e1af" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c898a0be-9d3f-4963-8730-0b6892a0e1af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0b917516-b33b-4bdb-b4ec-7f69460d7695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c898a0be-9d3f-4963-8730-0b6892a0e1af" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0b917516-b33b-4bdb-b4ec-7f69460d7695" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_a7c76b75-4273-488a-a6d5-a62ba40922ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0b917516-b33b-4bdb-b4ec-7f69460d7695" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_a7c76b75-4273-488a-a6d5-a62ba40922ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_71086a47-330c-4fa4-b71b-6761a88c731e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0b917516-b33b-4bdb-b4ec-7f69460d7695" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_71086a47-330c-4fa4-b71b-6761a88c731e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4c05da9b-b603-4a28-8aa0-6eedbb3b54cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b8940a3-f85d-4c91-b068-da4254758969" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4c05da9b-b603-4a28-8aa0-6eedbb3b54cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4c05da9b-b603-4a28-8aa0-6eedbb3b54cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4c05da9b-b603-4a28-8aa0-6eedbb3b54cc" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4c05da9b-b603-4a28-8aa0-6eedbb3b54cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_195a9b0a-591f-4cd3-ac67-bd7675b13156" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4c05da9b-b603-4a28-8aa0-6eedbb3b54cc" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_195a9b0a-591f-4cd3-ac67-bd7675b13156" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_a2049c9e-c09f-4156-afdd-f7942851e2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_195a9b0a-591f-4cd3-ac67-bd7675b13156" xlink:to="loc_us-gaap_CurrencySwapMember_a2049c9e-c09f-4156-afdd-f7942851e2e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c5dfe78f-36f5-44b6-9cf9-7d498f9576d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b8940a3-f85d-4c91-b068-da4254758969" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c5dfe78f-36f5-44b6-9cf9-7d498f9576d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_c5dfe78f-36f5-44b6-9cf9-7d498f9576d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c5dfe78f-36f5-44b6-9cf9-7d498f9576d0" xlink:to="loc_us-gaap_HedgingRelationshipDomain_c5dfe78f-36f5-44b6-9cf9-7d498f9576d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_52c68974-ec31-43b0-a33f-61d889258617" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c5dfe78f-36f5-44b6-9cf9-7d498f9576d0" xlink:to="loc_us-gaap_HedgingRelationshipDomain_52c68974-ec31-43b0-a33f-61d889258617" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_d5a761d0-c195-4f23-bf42-27c23248c592" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_52c68974-ec31-43b0-a33f-61d889258617" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_d5a761d0-c195-4f23-bf42-27c23248c592" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_4efa966b-4fb9-4e79-89ed-7bbe0f032ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b8940a3-f85d-4c91-b068-da4254758969" xlink:to="loc_us-gaap_HedgingDesignationAxis_4efa966b-4fb9-4e79-89ed-7bbe0f032ea1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_4efa966b-4fb9-4e79-89ed-7bbe0f032ea1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_4efa966b-4fb9-4e79-89ed-7bbe0f032ea1" xlink:to="loc_us-gaap_HedgingDesignationDomain_4efa966b-4fb9-4e79-89ed-7bbe0f032ea1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_29d40ed8-69e7-408b-a61a-ae01f6383722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_4efa966b-4fb9-4e79-89ed-7bbe0f032ea1" xlink:to="loc_us-gaap_HedgingDesignationDomain_29d40ed8-69e7-408b-a61a-ae01f6383722" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b8fb2eb3-c474-42d8-88d0-c52e628cd4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_29d40ed8-69e7-408b-a61a-ae01f6383722" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b8fb2eb3-c474-42d8-88d0-c52e628cd4d0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="extended" id="i5ecb083075524507924299e978ff36a7_FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_99035930-e492-40a6-a5cc-ec8b1d2c2fac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_e973a78f-bf65-43fb-8151-795c519e390b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_99035930-e492-40a6-a5cc-ec8b1d2c2fac" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_e973a78f-bf65-43fb-8151-795c519e390b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_adf1d0a5-55f6-49e5-a42d-142ffec922ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_99035930-e492-40a6-a5cc-ec8b1d2c2fac" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_adf1d0a5-55f6-49e5-a42d-142ffec922ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_d9c8b294-8682-4856-a2e6-4f1ed2e01a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_99035930-e492-40a6-a5cc-ec8b1d2c2fac" xlink:to="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_d9c8b294-8682-4856-a2e6-4f1ed2e01a9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e99b0998-6d6f-452b-8468-274209031f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_99035930-e492-40a6-a5cc-ec8b1d2c2fac" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e99b0998-6d6f-452b-8468-274209031f1e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_a0e11ae2-9c65-4559-b315-96b0083ac790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e99b0998-6d6f-452b-8468-274209031f1e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_a0e11ae2-9c65-4559-b315-96b0083ac790" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a0e11ae2-9c65-4559-b315-96b0083ac790_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a0e11ae2-9c65-4559-b315-96b0083ac790" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a0e11ae2-9c65-4559-b315-96b0083ac790_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b4f0d9da-1f38-4b4e-8457-ec0e6d844e35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a0e11ae2-9c65-4559-b315-96b0083ac790" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b4f0d9da-1f38-4b4e-8457-ec0e6d844e35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_1d9e6d8a-93f3-4429-b108-23beb0447518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b4f0d9da-1f38-4b4e-8457-ec0e6d844e35" xlink:to="loc_us-gaap_CurrencySwapMember_1d9e6d8a-93f3-4429-b108-23beb0447518" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CrossCurrencyFinalSettlementMember_354881b3-31d3-4034-b5d0-326386dd298e" xlink:href="bhc-20220510.xsd#bhc_CrossCurrencyFinalSettlementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b4f0d9da-1f38-4b4e-8457-ec0e6d844e35" xlink:to="loc_bhc_CrossCurrencyFinalSettlementMember_354881b3-31d3-4034-b5d0-326386dd298e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ea90e635-3e90-4f1c-81a4-d4029b116339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e99b0998-6d6f-452b-8468-274209031f1e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ea90e635-3e90-4f1c-81a4-d4029b116339" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_ea90e635-3e90-4f1c-81a4-d4029b116339_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ea90e635-3e90-4f1c-81a4-d4029b116339" xlink:to="loc_us-gaap_HedgingRelationshipDomain_ea90e635-3e90-4f1c-81a4-d4029b116339_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_cd24a93b-7b74-4ec7-9ef9-e24a623c247f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ea90e635-3e90-4f1c-81a4-d4029b116339" xlink:to="loc_us-gaap_HedgingRelationshipDomain_cd24a93b-7b74-4ec7-9ef9-e24a623c247f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_5b9d0139-5521-4bb1-92dc-824e32ec52ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_cd24a93b-7b74-4ec7-9ef9-e24a623c247f" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_5b9d0139-5521-4bb1-92dc-824e32ec52ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_741c8e92-ce3d-447b-8189-c90410d0eda6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e99b0998-6d6f-452b-8468-274209031f1e" xlink:to="loc_us-gaap_HedgingDesignationAxis_741c8e92-ce3d-447b-8189-c90410d0eda6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_741c8e92-ce3d-447b-8189-c90410d0eda6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_741c8e92-ce3d-447b-8189-c90410d0eda6" xlink:to="loc_us-gaap_HedgingDesignationDomain_741c8e92-ce3d-447b-8189-c90410d0eda6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_07eac5c1-6e79-4e7a-85e0-91c2cefc3bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_741c8e92-ce3d-447b-8189-c90410d0eda6" xlink:to="loc_us-gaap_HedgingDesignationDomain_07eac5c1-6e79-4e7a-85e0-91c2cefc3bbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b1f3b00a-f7a5-4149-9ac5-bb895743ceff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_07eac5c1-6e79-4e7a-85e0-91c2cefc3bbf" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b1f3b00a-f7a5-4149-9ac5-bb895743ceff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6dae0530-cacf-45ff-a48c-83050008d7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e99b0998-6d6f-452b-8468-274209031f1e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6dae0530-cacf-45ff-a48c-83050008d7b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6dae0530-cacf-45ff-a48c-83050008d7b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6dae0530-cacf-45ff-a48c-83050008d7b5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6dae0530-cacf-45ff-a48c-83050008d7b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a4e72712-6dd0-4ef1-ac82-8f9e61f1c7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6dae0530-cacf-45ff-a48c-83050008d7b5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a4e72712-6dd0-4ef1-ac82-8f9e61f1c7bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_7f88abac-9a8f-4c28-9689-4596910fc568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a4e72712-6dd0-4ef1-ac82-8f9e61f1c7bb" xlink:to="loc_us-gaap_InterestExpenseMember_7f88abac-9a8f-4c28-9689-4596910fc568" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="extended" id="i078678d746fe41c5bbc54fb98d7eb351_FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f86e6df0-5b7b-4983-bc3a-888c6726d91b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_164e60ad-be92-4d03-86a8-c64e6f6c3de4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f86e6df0-5b7b-4983-bc3a-888c6726d91b" xlink:to="loc_us-gaap_DerivativeNotionalAmount_164e60ad-be92-4d03-86a8-c64e6f6c3de4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85b0ba12-bcf9-44a9-bcf3-f55708726712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f86e6df0-5b7b-4983-bc3a-888c6726d91b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85b0ba12-bcf9-44a9-bcf3-f55708726712" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_f2089632-ca8a-4145-b4a6-627e40aa25f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85b0ba12-bcf9-44a9-bcf3-f55708726712" xlink:to="loc_us-gaap_HedgingDesignationAxis_f2089632-ca8a-4145-b4a6-627e40aa25f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_f2089632-ca8a-4145-b4a6-627e40aa25f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_f2089632-ca8a-4145-b4a6-627e40aa25f3" xlink:to="loc_us-gaap_HedgingDesignationDomain_f2089632-ca8a-4145-b4a6-627e40aa25f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_0e97efd8-7994-4e7c-a7b6-a9f41f73830b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_f2089632-ca8a-4145-b4a6-627e40aa25f3" xlink:to="loc_us-gaap_HedgingDesignationDomain_0e97efd8-7994-4e7c-a7b6-a9f41f73830b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_df41afe6-d13c-4057-a308-e34888995128" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_0e97efd8-7994-4e7c-a7b6-a9f41f73830b" xlink:to="loc_us-gaap_NondesignatedMember_df41afe6-d13c-4057-a308-e34888995128" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_22954db4-8d02-4c9a-b885-f27eb0483225" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85b0ba12-bcf9-44a9-bcf3-f55708726712" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_22954db4-8d02-4c9a-b885-f27eb0483225" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_22954db4-8d02-4c9a-b885-f27eb0483225_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_22954db4-8d02-4c9a-b885-f27eb0483225" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_22954db4-8d02-4c9a-b885-f27eb0483225_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a2b1ba0e-bcde-40f4-b552-acf8edd2cf0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_22954db4-8d02-4c9a-b885-f27eb0483225" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a2b1ba0e-bcde-40f4-b552-acf8edd2cf0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_430bb873-78e1-45e2-9adc-0b5b43ed1f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a2b1ba0e-bcde-40f4-b552-acf8edd2cf0b" xlink:to="loc_us-gaap_ForeignExchangeContractMember_430bb873-78e1-45e2-9adc-0b5b43ed1f6a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="extended" id="i3ef03a17802f4f1195f147701fac89a0_FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e1e7444-bdd7-418d-8237-e45ff25d39b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_e5ca727f-cd06-446b-a06d-bf32925c4b96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e1e7444-bdd7-418d-8237-e45ff25d39b6" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_e5ca727f-cd06-446b-a06d-bf32925c4b96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_44db15b8-5dfa-4a41-9275-33e97d4754a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e1e7444-bdd7-418d-8237-e45ff25d39b6" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_44db15b8-5dfa-4a41-9275-33e97d4754a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_7064b722-647e-49eb-b7bd-3c40b07214c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e1e7444-bdd7-418d-8237-e45ff25d39b6" xlink:to="loc_us-gaap_DerivativeLiabilities_7064b722-647e-49eb-b7bd-3c40b07214c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01948448-8b47-4038-b1f4-8b9e5ddf80e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e1e7444-bdd7-418d-8237-e45ff25d39b6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01948448-8b47-4038-b1f4-8b9e5ddf80e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e02b49cf-189a-4b2d-b7b7-f58adb3b5690" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01948448-8b47-4038-b1f4-8b9e5ddf80e8" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e02b49cf-189a-4b2d-b7b7-f58adb3b5690" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e02b49cf-189a-4b2d-b7b7-f58adb3b5690_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e02b49cf-189a-4b2d-b7b7-f58adb3b5690" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e02b49cf-189a-4b2d-b7b7-f58adb3b5690_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_987ba9be-dbe0-4d1d-b66d-841f1606f278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e02b49cf-189a-4b2d-b7b7-f58adb3b5690" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_987ba9be-dbe0-4d1d-b66d-841f1606f278" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember_f7680cb8-a2be-4a34-8e60-be6ac548b95a" xlink:href="bhc-20220510.xsd#bhc_AccruedAndOtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_987ba9be-dbe0-4d1d-b66d-841f1606f278" xlink:to="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember_f7680cb8-a2be-4a34-8e60-be6ac548b95a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_2cbb57eb-c452-4491-9a73-088e2197d813" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_987ba9be-dbe0-4d1d-b66d-841f1606f278" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_2cbb57eb-c452-4491-9a73-088e2197d813" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_a0ec8043-ded3-4c91-b52f-aac5fc59f6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01948448-8b47-4038-b1f4-8b9e5ddf80e8" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_a0ec8043-ded3-4c91-b52f-aac5fc59f6cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a0ec8043-ded3-4c91-b52f-aac5fc59f6cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a0ec8043-ded3-4c91-b52f-aac5fc59f6cc" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a0ec8043-ded3-4c91-b52f-aac5fc59f6cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4ca01bae-51dc-42fc-aa95-b1aaa4cdeb79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a0ec8043-ded3-4c91-b52f-aac5fc59f6cc" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4ca01bae-51dc-42fc-aa95-b1aaa4cdeb79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_ea536ae8-da48-4968-a99c-a5901dcabe2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4ca01bae-51dc-42fc-aa95-b1aaa4cdeb79" xlink:to="loc_us-gaap_ForeignExchangeContractMember_ea536ae8-da48-4968-a99c-a5901dcabe2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_a0ffca10-c895-40fc-b61c-24bc9f85a205" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01948448-8b47-4038-b1f4-8b9e5ddf80e8" xlink:to="loc_us-gaap_HedgingDesignationAxis_a0ffca10-c895-40fc-b61c-24bc9f85a205" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_a0ffca10-c895-40fc-b61c-24bc9f85a205_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_a0ffca10-c895-40fc-b61c-24bc9f85a205" xlink:to="loc_us-gaap_HedgingDesignationDomain_a0ffca10-c895-40fc-b61c-24bc9f85a205_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_2676a2e3-5f65-4718-b692-01636f12f268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_a0ffca10-c895-40fc-b61c-24bc9f85a205" xlink:to="loc_us-gaap_HedgingDesignationDomain_2676a2e3-5f65-4718-b692-01636f12f268" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_78b3bfd6-4ab0-4e91-bfbe-7f283e2c0092" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_2676a2e3-5f65-4718-b692-01636f12f268" xlink:to="loc_us-gaap_NondesignatedMember_78b3bfd6-4ab0-4e91-bfbe-7f283e2c0092" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" xlink:type="extended" id="iaab02769df594f8ba307bcdc41acda14_FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ccb4f676-0fe7-4ab0-a00e-0094c574f441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_2f180f63-bd01-426a-b650-f36d3766fcc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ccb4f676-0fe7-4ab0-a00e-0094c574f441" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_2f180f63-bd01-426a-b650-f36d3766fcc8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_3a63c2c6-dd67-493e-9e00-b9d955fffde5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ccb4f676-0fe7-4ab0-a00e-0094c574f441" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_3a63c2c6-dd67-493e-9e00-b9d955fffde5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8ab1d6f9-78b6-424e-8639-cb0cc627c646" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ccb4f676-0fe7-4ab0-a00e-0094c574f441" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8ab1d6f9-78b6-424e-8639-cb0cc627c646" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_38374562-7f31-4728-9256-ca00a29d94ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8ab1d6f9-78b6-424e-8639-cb0cc627c646" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_38374562-7f31-4728-9256-ca00a29d94ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_38374562-7f31-4728-9256-ca00a29d94ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_38374562-7f31-4728-9256-ca00a29d94ff" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_38374562-7f31-4728-9256-ca00a29d94ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a6ae9e6e-b502-417b-91f6-add259248fed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_38374562-7f31-4728-9256-ca00a29d94ff" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a6ae9e6e-b502-417b-91f6-add259248fed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_37458fb2-b5e4-4381-b890-4108ce914498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a6ae9e6e-b502-417b-91f6-add259248fed" xlink:to="loc_us-gaap_ForeignExchangeContractMember_37458fb2-b5e4-4381-b890-4108ce914498" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_7cdb21f5-9d86-4a7a-97bb-a728745d086c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8ab1d6f9-78b6-424e-8639-cb0cc627c646" xlink:to="loc_us-gaap_HedgingDesignationAxis_7cdb21f5-9d86-4a7a-97bb-a728745d086c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7cdb21f5-9d86-4a7a-97bb-a728745d086c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_7cdb21f5-9d86-4a7a-97bb-a728745d086c" xlink:to="loc_us-gaap_HedgingDesignationDomain_7cdb21f5-9d86-4a7a-97bb-a728745d086c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_788be721-1448-4443-b017-d1644a8a3a81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_7cdb21f5-9d86-4a7a-97bb-a728745d086c" xlink:to="loc_us-gaap_HedgingDesignationDomain_788be721-1448-4443-b017-d1644a8a3a81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_f1967334-0b87-4c6a-8ad9-176843921029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_788be721-1448-4443-b017-d1644a8a3a81" xlink:to="loc_us-gaap_NondesignatedMember_f1967334-0b87-4c6a-8ad9-176843921029" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" xlink:type="simple" xlink:href="bhc-20220510.xsd#FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" xlink:type="extended" id="i2deb130630dc40efab214e6b407eb09d_FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2e1f4510-47df-4360-8903-d42ac1725eff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_6c3a6d9f-adfd-430e-9783-a8ecc28cf51d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2e1f4510-47df-4360-8903-d42ac1725eff" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_6c3a6d9f-adfd-430e-9783-a8ecc28cf51d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0b3b44da-a9e6-4ec8-aebc-a2e5e4f60b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2e1f4510-47df-4360-8903-d42ac1725eff" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0b3b44da-a9e6-4ec8-aebc-a2e5e4f60b25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_78867297-977e-47fa-aa66-1e02e6fd192a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0b3b44da-a9e6-4ec8-aebc-a2e5e4f60b25" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_78867297-977e-47fa-aa66-1e02e6fd192a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d5a81b87-5667-461c-874b-9009aad7792f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0b3b44da-a9e6-4ec8-aebc-a2e5e4f60b25" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d5a81b87-5667-461c-874b-9009aad7792f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0a52a032-f558-474f-a2b6-fdbca56ee658" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0b3b44da-a9e6-4ec8-aebc-a2e5e4f60b25" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0a52a032-f558-474f-a2b6-fdbca56ee658" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_8950b799-adb7-47b5-a245-6b22887b370e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0b3b44da-a9e6-4ec8-aebc-a2e5e4f60b25" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_8950b799-adb7-47b5-a245-6b22887b370e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_194abda0-5397-45b3-bd7b-8e9f845d7221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_b0762731-f522-46bd-937f-5c0c079903aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2e1f4510-47df-4360-8903-d42ac1725eff" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_b0762731-f522-46bd-937f-5c0c079903aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_0c081d55-3a54-48af-99ed-ce59fa6d4298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2e1f4510-47df-4360-8903-d42ac1725eff" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_0c081d55-3a54-48af-99ed-ce59fa6d4298" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d6815b3b-06db-4036-99f8-2d7ed5ee3964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2e1f4510-47df-4360-8903-d42ac1725eff" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d6815b3b-06db-4036-99f8-2d7ed5ee3964" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4cb0b8f8-df34-4086-8b52-833ce36b88f9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d6815b3b-06db-4036-99f8-2d7ed5ee3964" xlink:to="loc_srt_RangeAxis_4cb0b8f8-df34-4086-8b52-833ce36b88f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4cb0b8f8-df34-4086-8b52-833ce36b88f9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4cb0b8f8-df34-4086-8b52-833ce36b88f9" xlink:to="loc_srt_RangeMember_4cb0b8f8-df34-4086-8b52-833ce36b88f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_50cbe6fd-40de-4c01-8d08-7478b9bb45e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4cb0b8f8-df34-4086-8b52-833ce36b88f9" xlink:to="loc_srt_RangeMember_50cbe6fd-40de-4c01-8d08-7478b9bb45e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b2363ed1-3f27-4ffc-9625-e002173f59b0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_50cbe6fd-40de-4c01-8d08-7478b9bb45e8" xlink:to="loc_srt_MinimumMember_b2363ed1-3f27-4ffc-9625-e002173f59b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b0957184-a57f-4e55-9ba5-3d1b03e1e97f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_50cbe6fd-40de-4c01-8d08-7478b9bb45e8" xlink:to="loc_srt_MaximumMember_b0957184-a57f-4e55-9ba5-3d1b03e1e97f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_0ea9dd42-3ce1-4bcb-bccc-985688c7bbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d6815b3b-06db-4036-99f8-2d7ed5ee3964" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_0ea9dd42-3ce1-4bcb-bccc-985688c7bbd5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0ea9dd42-3ce1-4bcb-bccc-985688c7bbd5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_0ea9dd42-3ce1-4bcb-bccc-985688c7bbd5" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0ea9dd42-3ce1-4bcb-bccc-985688c7bbd5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_6a6fa0b0-786d-4f7e-b0fb-63c5ef5a2375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_0ea9dd42-3ce1-4bcb-bccc-985688c7bbd5" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_6a6fa0b0-786d-4f7e-b0fb-63c5ef5a2375" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_cb11c888-ae86-4463-8466-069fc5eb83ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6a6fa0b0-786d-4f7e-b0fb-63c5ef5a2375" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_cb11c888-ae86-4463-8466-069fc5eb83ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_3d2f9452-d165-4941-8b41-ea8b82c10447" xlink:href="bhc-20220510.xsd#bhc_MeasurementInputWeightedAverageDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6a6fa0b0-786d-4f7e-b0fb-63c5ef5a2375" xlink:to="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_3d2f9452-d165-4941-8b41-ea8b82c10447" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_308b4bb2-d6dd-4dd5-955c-059ea7d367b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d6815b3b-06db-4036-99f8-2d7ed5ee3964" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_308b4bb2-d6dd-4dd5-955c-059ea7d367b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_308b4bb2-d6dd-4dd5-955c-059ea7d367b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_308b4bb2-d6dd-4dd5-955c-059ea7d367b0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_308b4bb2-d6dd-4dd5-955c-059ea7d367b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9829d6d3-1af6-4593-b6f3-c487860b804f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_308b4bb2-d6dd-4dd5-955c-059ea7d367b0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9829d6d3-1af6-4593-b6f3-c487860b804f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a89879ac-abb8-406f-a1b8-e4d29d4d3ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9829d6d3-1af6-4593-b6f3-c487860b804f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a89879ac-abb8-406f-a1b8-e4d29d4d3ac1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9dd8c312-cf1d-4a6f-abb4-e2a0e5572d50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d6815b3b-06db-4036-99f8-2d7ed5ee3964" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9dd8c312-cf1d-4a6f-abb4-e2a0e5572d50" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9dd8c312-cf1d-4a6f-abb4-e2a0e5572d50_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9dd8c312-cf1d-4a6f-abb4-e2a0e5572d50" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9dd8c312-cf1d-4a6f-abb4-e2a0e5572d50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2fde7fb5-3ce3-4004-bc94-677c8ab41d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9dd8c312-cf1d-4a6f-abb4-e2a0e5572d50" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2fde7fb5-3ce3-4004-bc94-677c8ab41d2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_3951eb2b-35db-4d36-827c-5421f86095e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2fde7fb5-3ce3-4004-bc94-677c8ab41d2c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_3951eb2b-35db-4d36-827c-5421f86095e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_da712105-51e5-4f3e-aa81-ea02b8741bab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d6815b3b-06db-4036-99f8-2d7ed5ee3964" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_da712105-51e5-4f3e-aa81-ea02b8741bab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_da712105-51e5-4f3e-aa81-ea02b8741bab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_da712105-51e5-4f3e-aa81-ea02b8741bab" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_da712105-51e5-4f3e-aa81-ea02b8741bab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_beb3efbb-f6fa-47ba-bdcc-7c2516a95e26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_da712105-51e5-4f3e-aa81-ea02b8741bab" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_beb3efbb-f6fa-47ba-bdcc-7c2516a95e26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccretionForTimeValueOfMoneyMember_a7c7f8d0-cab0-4b2e-8b08-ae60d040ccd9" xlink:href="bhc-20220510.xsd#bhc_AccretionForTimeValueOfMoneyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_beb3efbb-f6fa-47ba-bdcc-7c2516a95e26" xlink:to="loc_bhc_AccretionForTimeValueOfMoneyMember_a7c7f8d0-cab0-4b2e-8b08-ae60d040ccd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FairValueAdjustmentsMember_db33522e-121c-4ceb-9d0e-967fc56eb94e" xlink:href="bhc-20220510.xsd#bhc_FairValueAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_beb3efbb-f6fa-47ba-bdcc-7c2516a95e26" xlink:to="loc_bhc_FairValueAdjustmentsMember_db33522e-121c-4ceb-9d0e-967fc56eb94e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails" xlink:type="extended" id="i4d44a019aa334ad0922141323b7316e5_FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ade77934-6613-4b23-b255-2264804cbe79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiabilityAbstract_f258fd2e-eab5-4927-abd6-3d68ab29c766" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetAssetLiabilityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ade77934-6613-4b23-b255-2264804cbe79" xlink:to="loc_us-gaap_FairValueNetAssetLiabilityAbstract_f258fd2e-eab5-4927-abd6-3d68ab29c766" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_4066465c-30ba-4242-b931-224dd8386628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetAssetLiabilityAbstract_f258fd2e-eab5-4927-abd6-3d68ab29c766" xlink:to="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_4066465c-30ba-4242-b931-224dd8386628" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9aa5bc93-302f-4e50-867e-55b950fbb933" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ade77934-6613-4b23-b255-2264804cbe79" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9aa5bc93-302f-4e50-867e-55b950fbb933" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_73386d82-cd6e-43cf-9947-c5682d484a51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9aa5bc93-302f-4e50-867e-55b950fbb933" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_73386d82-cd6e-43cf-9947-c5682d484a51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_73386d82-cd6e-43cf-9947-c5682d484a51_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_73386d82-cd6e-43cf-9947-c5682d484a51" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_73386d82-cd6e-43cf-9947-c5682d484a51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_66e59ef4-32dd-4ec9-9a98-eac020838643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_73386d82-cd6e-43cf-9947-c5682d484a51" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_66e59ef4-32dd-4ec9-9a98-eac020838643" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_24b62518-4f5e-4d5f-9069-072fb39deee8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_66e59ef4-32dd-4ec9-9a98-eac020838643" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_24b62518-4f5e-4d5f-9069-072fb39deee8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50dedc3c-5537-4efb-a1d1-adf23c3b74da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9aa5bc93-302f-4e50-867e-55b950fbb933" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50dedc3c-5537-4efb-a1d1-adf23c3b74da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50dedc3c-5537-4efb-a1d1-adf23c3b74da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50dedc3c-5537-4efb-a1d1-adf23c3b74da" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50dedc3c-5537-4efb-a1d1-adf23c3b74da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e54d18ed-74ce-426e-acc7-3a2fef190127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50dedc3c-5537-4efb-a1d1-adf23c3b74da" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e54d18ed-74ce-426e-acc7-3a2fef190127" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6a2ceec1-59a2-40ca-b159-397ce8cb8794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e54d18ed-74ce-426e-acc7-3a2fef190127" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6a2ceec1-59a2-40ca-b159-397ce8cb8794" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_be164b56-4f53-427d-9d0c-54a9dd4f95ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e54d18ed-74ce-426e-acc7-3a2fef190127" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_be164b56-4f53-427d-9d0c-54a9dd4f95ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f18d95f5-b111-4b31-aedd-a61891a50cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e54d18ed-74ce-426e-acc7-3a2fef190127" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f18d95f5-b111-4b31-aedd-a61891a50cd7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails" xlink:type="extended" id="i812bd5d317f1432aa07063267b764d6f_FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3b8cf0db-668d-449e-a1e8-6e41f0fedf3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_016f6396-7b73-4146-b2aa-3fb650a3b00d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3b8cf0db-668d-449e-a1e8-6e41f0fedf3a" xlink:to="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_016f6396-7b73-4146-b2aa-3fb650a3b00d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_a12eee19-e4e5-428f-91b4-aea937f18dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3b8cf0db-668d-449e-a1e8-6e41f0fedf3a" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_a12eee19-e4e5-428f-91b4-aea937f18dff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_547e3caf-db95-463b-b061-8fa68afe9db8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3b8cf0db-668d-449e-a1e8-6e41f0fedf3a" xlink:to="loc_us-gaap_Assets_547e3caf-db95-463b-b061-8fa68afe9db8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e63334df-7887-4001-a497-87de803999e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3b8cf0db-668d-449e-a1e8-6e41f0fedf3a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e63334df-7887-4001-a497-87de803999e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6c186c32-51e1-44b1-9d73-2ad1940fc0c7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e63334df-7887-4001-a497-87de803999e2" xlink:to="loc_srt_ProductOrServiceAxis_6c186c32-51e1-44b1-9d73-2ad1940fc0c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6c186c32-51e1-44b1-9d73-2ad1940fc0c7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_6c186c32-51e1-44b1-9d73-2ad1940fc0c7" xlink:to="loc_srt_ProductsAndServicesDomain_6c186c32-51e1-44b1-9d73-2ad1940fc0c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_08214808-c6ea-499b-bc86-c5905a34956c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_6c186c32-51e1-44b1-9d73-2ad1940fc0c7" xlink:to="loc_srt_ProductsAndServicesDomain_08214808-c6ea-499b-bc86-c5905a34956c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_e23124bb-44de-4308-abcb-83d88d1c7ec1" xlink:href="bhc-20220510.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_08214808-c6ea-499b-bc86-c5905a34956c" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_e23124bb-44de-4308-abcb-83d88d1c7ec1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_12117b8e-295f-4460-bd79-0b3c1387e339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e63334df-7887-4001-a497-87de803999e2" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_12117b8e-295f-4460-bd79-0b3c1387e339" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_12117b8e-295f-4460-bd79-0b3c1387e339_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_12117b8e-295f-4460-bd79-0b3c1387e339" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_12117b8e-295f-4460-bd79-0b3c1387e339_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_33546501-a737-4d4d-9d9d-9c301d0a2acc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_12117b8e-295f-4460-bd79-0b3c1387e339" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_33546501-a737-4d4d-9d9d-9c301d0a2acc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_fa66ede1-9467-41d3-94cc-db3b1736bb4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_33546501-a737-4d4d-9d9d-9c301d0a2acc" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_fa66ede1-9467-41d3-94cc-db3b1736bb4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_930e5c36-d133-475c-ac54-68bd1bf38e74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e63334df-7887-4001-a497-87de803999e2" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_930e5c36-d133-475c-ac54-68bd1bf38e74" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_930e5c36-d133-475c-ac54-68bd1bf38e74_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_930e5c36-d133-475c-ac54-68bd1bf38e74" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_930e5c36-d133-475c-ac54-68bd1bf38e74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3b8f9fdb-3cfc-40ff-966b-045de43fd2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_930e5c36-d133-475c-ac54-68bd1bf38e74" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3b8f9fdb-3cfc-40ff-966b-045de43fd2fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_b36146aa-315f-46f0-86e6-955e492be0c4" xlink:href="bhc-20220510.xsd#bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3b8f9fdb-3cfc-40ff-966b-045de43fd2fa" xlink:to="loc_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_b36146aa-315f-46f0-86e6-955e492be0c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fdc821ed-b951-4927-8ce7-30089116feb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e63334df-7887-4001-a497-87de803999e2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fdc821ed-b951-4927-8ce7-30089116feb6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fdc821ed-b951-4927-8ce7-30089116feb6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fdc821ed-b951-4927-8ce7-30089116feb6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fdc821ed-b951-4927-8ce7-30089116feb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2c94faa4-2db5-413c-a278-db4ed0c68c70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fdc821ed-b951-4927-8ce7-30089116feb6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2c94faa4-2db5-413c-a278-db4ed0c68c70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c6d6781b-5f89-4363-9aa2-b30f3d1fb83b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2c94faa4-2db5-413c-a278-db4ed0c68c70" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c6d6781b-5f89-4363-9aa2-b30f3d1fb83b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_21152d4a-21c6-44d5-b0fd-486442ea7a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e63334df-7887-4001-a497-87de803999e2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_21152d4a-21c6-44d5-b0fd-486442ea7a6f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_21152d4a-21c6-44d5-b0fd-486442ea7a6f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_21152d4a-21c6-44d5-b0fd-486442ea7a6f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_21152d4a-21c6-44d5-b0fd-486442ea7a6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d6ae5e4d-5416-404a-b7c9-25c603c83e10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_21152d4a-21c6-44d5-b0fd-486442ea7a6f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d6ae5e4d-5416-404a-b7c9-25c603c83e10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_f2175efe-da64-4566-af80-5a6b8620f931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d6ae5e4d-5416-404a-b7c9-25c603c83e10" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_f2175efe-da64-4566-af80-5a6b8620f931" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails" xlink:type="extended" id="i83407f8c47c840a297a0d7d6a8115ab3_FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9421163b-a1bc-4aa6-84e9-1f6192735777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_4dde5503-44f0-4985-8bc6-5f2c5561e26b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9421163b-a1bc-4aa6-84e9-1f6192735777" xlink:to="loc_us-gaap_DebtInstrumentFairValue_4dde5503-44f0-4985-8bc6-5f2c5561e26b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_32f28c3f-ca9f-4b40-873f-68d8e57fb6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9421163b-a1bc-4aa6-84e9-1f6192735777" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_32f28c3f-ca9f-4b40-873f-68d8e57fb6a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_85947fae-30f6-4c2b-8254-35bf0e41380a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_32f28c3f-ca9f-4b40-873f-68d8e57fb6a3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_85947fae-30f6-4c2b-8254-35bf0e41380a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_85947fae-30f6-4c2b-8254-35bf0e41380a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_85947fae-30f6-4c2b-8254-35bf0e41380a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_85947fae-30f6-4c2b-8254-35bf0e41380a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e6cff71d-f40c-4635-9db2-4f67a7c8f5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_85947fae-30f6-4c2b-8254-35bf0e41380a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e6cff71d-f40c-4635-9db2-4f67a7c8f5e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_06bbd428-4538-478c-b7eb-5757ebce9806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e6cff71d-f40c-4635-9db2-4f67a7c8f5e2" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_06bbd428-4538-478c-b7eb-5757ebce9806" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_451c562f-2e44-413a-a181-f3d4c0e9cd32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_32f28c3f-ca9f-4b40-873f-68d8e57fb6a3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_451c562f-2e44-413a-a181-f3d4c0e9cd32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_451c562f-2e44-413a-a181-f3d4c0e9cd32_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_451c562f-2e44-413a-a181-f3d4c0e9cd32" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_451c562f-2e44-413a-a181-f3d4c0e9cd32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_01ccf604-7e64-47cf-90a4-2c8badc68342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_451c562f-2e44-413a-a181-f3d4c0e9cd32" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_01ccf604-7e64-47cf-90a4-2c8badc68342" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0898cfae-0fc4-4021-8b75-30769a21db48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_01ccf604-7e64-47cf-90a4-2c8badc68342" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0898cfae-0fc4-4021-8b75-30769a21db48" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails" xlink:type="extended" id="ib203afd8a2d4405798a6858436012a56_PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bd0a4c54-f18b-4b21-80ca-ee706b14b584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4c4a83a1-f4bf-477e-b91c-aeea60492b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bd0a4c54-f18b-4b21-80ca-ee706b14b584" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4c4a83a1-f4bf-477e-b91c-aeea60492b18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_91ddb2d8-e310-4149-b32a-ed470de8065a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bd0a4c54-f18b-4b21-80ca-ee706b14b584" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_91ddb2d8-e310-4149-b32a-ed470de8065a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_eeadcb20-8dc3-4f5a-9151-d397fe899664" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bd0a4c54-f18b-4b21-80ca-ee706b14b584" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_eeadcb20-8dc3-4f5a-9151-d397fe899664" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_15946ffc-4b52-4f29-bebb-cb56286f9a05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bd0a4c54-f18b-4b21-80ca-ee706b14b584" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_15946ffc-4b52-4f29-bebb-cb56286f9a05" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2396b5a3-8706-4c76-8cf9-19c8f9d3b27f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_15946ffc-4b52-4f29-bebb-cb56286f9a05" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2396b5a3-8706-4c76-8cf9-19c8f9d3b27f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2396b5a3-8706-4c76-8cf9-19c8f9d3b27f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2396b5a3-8706-4c76-8cf9-19c8f9d3b27f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2396b5a3-8706-4c76-8cf9-19c8f9d3b27f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d6ee19e5-f8c9-455e-97f3-e61df4fa7125" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2396b5a3-8706-4c76-8cf9-19c8f9d3b27f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d6ee19e5-f8c9-455e-97f3-e61df4fa7125" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_7b733a88-fe8a-4bb4-bdc7-748925a1d135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d6ee19e5-f8c9-455e-97f3-e61df4fa7125" xlink:to="loc_us-gaap_LandMember_7b733a88-fe8a-4bb4-bdc7-748925a1d135" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_05aecf2a-f635-4dae-9f7f-42ba05fbdbb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d6ee19e5-f8c9-455e-97f3-e61df4fa7125" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_05aecf2a-f635-4dae-9f7f-42ba05fbdbb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_756f3cc1-6d5f-4544-a0f3-21c476d213cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d6ee19e5-f8c9-455e-97f3-e61df4fa7125" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_756f3cc1-6d5f-4544-a0f3-21c476d213cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherEquipmentAndLeaseholdImprovementMember_77b1dbe6-5ca1-428c-a4f4-889739b4e866" xlink:href="bhc-20220510.xsd#bhc_OtherEquipmentAndLeaseholdImprovementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d6ee19e5-f8c9-455e-97f3-e61df4fa7125" xlink:to="loc_bhc_OtherEquipmentAndLeaseholdImprovementMember_77b1dbe6-5ca1-428c-a4f4-889739b4e866" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EquipmentOnOperatingLeaseMember_034741ad-bdc8-46a0-afa5-d9dd8cc881f2" xlink:href="bhc-20220510.xsd#bhc_EquipmentOnOperatingLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d6ee19e5-f8c9-455e-97f3-e61df4fa7125" xlink:to="loc_bhc_EquipmentOnOperatingLeaseMember_034741ad-bdc8-46a0-afa5-d9dd8cc881f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_b45d86e3-cfcd-4935-b8fd-19efd4302074" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d6ee19e5-f8c9-455e-97f3-e61df4fa7125" xlink:to="loc_us-gaap_ConstructionInProgressMember_b45d86e3-cfcd-4935-b8fd-19efd4302074" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" xlink:type="extended" id="i7fc732feb0224193bb807b77cc0a8c9a_INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8289f89e-ec0c-4db6-89a7-0995308cbf4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3564e350-fb3d-4afc-a5d3-56329cae25fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8289f89e-ec0c-4db6-89a7-0995308cbf4e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3564e350-fb3d-4afc-a5d3-56329cae25fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b770c65a-01e1-4ecd-8073-4280fd66d037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8289f89e-ec0c-4db6-89a7-0995308cbf4e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b770c65a-01e1-4ecd-8073-4280fd66d037" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_37b1fd48-7e03-4702-8cb3-519b1b7c12c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8289f89e-ec0c-4db6-89a7-0995308cbf4e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_37b1fd48-7e03-4702-8cb3-519b1b7c12c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7728a7a5-01e1-468f-a3a8-6b175a69c35e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8289f89e-ec0c-4db6-89a7-0995308cbf4e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7728a7a5-01e1-468f-a3a8-6b175a69c35e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d78251f5-2464-4a77-bb72-e943fb30f907" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8289f89e-ec0c-4db6-89a7-0995308cbf4e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d78251f5-2464-4a77-bb72-e943fb30f907" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1369ec7b-4c27-4612-8c9b-129bea4c49ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d78251f5-2464-4a77-bb72-e943fb30f907" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1369ec7b-4c27-4612-8c9b-129bea4c49ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1369ec7b-4c27-4612-8c9b-129bea4c49ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1369ec7b-4c27-4612-8c9b-129bea4c49ae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1369ec7b-4c27-4612-8c9b-129bea4c49ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_66a71c3a-56bf-4788-9f1a-9df26c126811" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1369ec7b-4c27-4612-8c9b-129bea4c49ae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_66a71c3a-56bf-4788-9f1a-9df26c126811" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_a5d7f19f-4592-4268-b3b1-49033397eddc" xlink:href="bhc-20220510.xsd#bhc_ProductBrandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_66a71c3a-56bf-4788-9f1a-9df26c126811" xlink:to="loc_bhc_ProductBrandsMember_a5d7f19f-4592-4268-b3b1-49033397eddc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_65774df6-2617-44a8-a62c-798942926fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_66a71c3a-56bf-4788-9f1a-9df26c126811" xlink:to="loc_us-gaap_TradeNamesMember_65774df6-2617-44a8-a62c-798942926fb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_cbe231b8-6217-4e73-a0f0-455f20c14b86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_66a71c3a-56bf-4788-9f1a-9df26c126811" xlink:to="loc_us-gaap_ContractualRightsMember_cbe231b8-6217-4e73-a0f0-455f20c14b86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PartnerRelationshipsMember_907729fa-5b22-4700-80f8-9fc11a3b560e" xlink:href="bhc-20220510.xsd#bhc_PartnerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_66a71c3a-56bf-4788-9f1a-9df26c126811" xlink:to="loc_bhc_PartnerRelationshipsMember_907729fa-5b22-4700-80f8-9fc11a3b560e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OutLicensedTechnologyMember_16607570-623e-4fbb-87d0-9a003ed84058" xlink:href="bhc-20220510.xsd#bhc_OutLicensedTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_66a71c3a-56bf-4788-9f1a-9df26c126811" xlink:to="loc_bhc_OutLicensedTechnologyMember_16607570-623e-4fbb-87d0-9a003ed84058" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_383015da-3a5f-434e-b408-d4a349130486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_47d1004d-4b69-4b29-9651-d0c93fa1830f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_383015da-3a5f-434e-b408-d4a349130486" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_47d1004d-4b69-4b29-9651-d0c93fa1830f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8ddfa4a3-87aa-491e-92c3-8b19768f3774" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_383015da-3a5f-434e-b408-d4a349130486" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8ddfa4a3-87aa-491e-92c3-8b19768f3774" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c188c9f6-f0ba-4d7e-a0fd-45760ad13c54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8ddfa4a3-87aa-491e-92c3-8b19768f3774" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c188c9f6-f0ba-4d7e-a0fd-45760ad13c54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c188c9f6-f0ba-4d7e-a0fd-45760ad13c54_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c188c9f6-f0ba-4d7e-a0fd-45760ad13c54" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c188c9f6-f0ba-4d7e-a0fd-45760ad13c54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c118360b-d3fa-45bf-8883-1bdc56cdc2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c188c9f6-f0ba-4d7e-a0fd-45760ad13c54" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c118360b-d3fa-45bf-8883-1bdc56cdc2e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember_54ad01d6-4291-492c-8b99-9834cb5798ef" xlink:href="bhc-20220510.xsd#bhc_AcquiredInProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c118360b-d3fa-45bf-8883-1bdc56cdc2e1" xlink:to="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember_54ad01d6-4291-492c-8b99-9834cb5798ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_49960772-3c35-4800-818b-2eaefaba1cff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c118360b-d3fa-45bf-8883-1bdc56cdc2e1" xlink:to="loc_us-gaap_TrademarksMember_49960772-3c35-4800-818b-2eaefaba1cff" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#INTANGIBLEASSETSANDGOODWILLNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="extended" id="i02039f69485247d391f724bee677f418_INTANGIBLEASSETSANDGOODWILLNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_a7adb00c-c13d-47aa-b7bd-2e3c17851172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_a7adb00c-c13d-47aa-b7bd-2e3c17851172" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_685a6d21-46be-4c48-ae80-b918f7e68644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_685a6d21-46be-4c48-ae80-b918f7e68644" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_20e50900-2736-436e-86b7-8cdd66332134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_20e50900-2736-436e-86b7-8cdd66332134" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_5067de1a-c388-4027-bf86-77359a1c2910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_5067de1a-c388-4027-bf86-77359a1c2910" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fe577782-ed5f-4178-801a-425104e78815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fe577782-ed5f-4178-801a-425104e78815" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax_f60f43d0-026c-410b-b6e7-fa9b2c3df87a" xlink:href="bhc-20220510.xsd#bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:to="loc_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax_f60f43d0-026c-410b-b6e7-fa9b2c3df87a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage_fbefdd69-caaf-434a-9487-3d9ab4377676" xlink:href="bhc-20220510.xsd#bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:to="loc_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage_fbefdd69-caaf-434a-9487-3d9ab4377676" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_cf32a977-a5c1-436a-bd7e-8ad6f5b75857" xlink:href="bhc-20220510.xsd#bhc_ReportingUnitImpairmentTestLongTermGrowthRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:to="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_cf32a977-a5c1-436a-bd7e-8ad6f5b75857" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_077167c5-6347-4b59-bc5e-cdfba626bcc8" xlink:href="bhc-20220510.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:to="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_077167c5-6347-4b59-bc5e-cdfba626bcc8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_c6bc04e5-72c3-4076-9974-068123b7a163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:to="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_c6bc04e5-72c3-4076-9974-068123b7a163" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_ecfdcc4d-7b76-4fc0-9055-6ff10b96daef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_ecfdcc4d-7b76-4fc0-9055-6ff10b96daef" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_06e07eaf-c6bf-450a-871c-06cbfd79ee9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:to="loc_us-gaap_NumberOfReportableSegments_06e07eaf-c6bf-450a-871c-06cbfd79ee9c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b1f466f6-e59b-48e2-a992-da07bd97bf2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:to="loc_us-gaap_Goodwill_b1f466f6-e59b-48e2-a992-da07bd97bf2f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_be1eb543-ceef-40d2-952f-fa5f81eb92cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:to="loc_us-gaap_NumberOfReportingUnits_be1eb543-ceef-40d2-952f-fa5f81eb92cc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_50ea566e-e424-4808-b847-d48e08687c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_50ea566e-e424-4808-b847-d48e08687c8d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7973174c-9e49-4773-95fa-d7c09765f0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_50ea566e-e424-4808-b847-d48e08687c8d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7973174c-9e49-4773-95fa-d7c09765f0a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7973174c-9e49-4773-95fa-d7c09765f0a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7973174c-9e49-4773-95fa-d7c09765f0a9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7973174c-9e49-4773-95fa-d7c09765f0a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_10fdd4e5-d99b-4fd4-8dea-82994190b143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7973174c-9e49-4773-95fa-d7c09765f0a9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_10fdd4e5-d99b-4fd4-8dea-82994190b143" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_302505d7-e30d-4087-ab0a-ea0c5e32d5bf" xlink:href="bhc-20220510.xsd#bhc_ProductBrandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_10fdd4e5-d99b-4fd4-8dea-82994190b143" xlink:to="loc_bhc_ProductBrandsMember_302505d7-e30d-4087-ab0a-ea0c5e32d5bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiscontinuedProductLinesMember_e716d203-7ca4-4b4c-9e97-85b829badac4" xlink:href="bhc-20220510.xsd#bhc_DiscontinuedProductLinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_10fdd4e5-d99b-4fd4-8dea-82994190b143" xlink:to="loc_bhc_DiscontinuedProductLinesMember_e716d203-7ca4-4b4c-9e97-85b829badac4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_ac63632f-4fae-4f37-a90d-fbf2ef013733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_10fdd4e5-d99b-4fd4-8dea-82994190b143" xlink:to="loc_us-gaap_ContractualRightsMember_ac63632f-4fae-4f37-a90d-fbf2ef013733" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnutilizedITInfrastructureImprovementProjectMember_40b00212-a426-4e44-b67c-c68a5276a740" xlink:href="bhc-20220510.xsd#bhc_UnutilizedITInfrastructureImprovementProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_10fdd4e5-d99b-4fd4-8dea-82994190b143" xlink:to="loc_bhc_UnutilizedITInfrastructureImprovementProjectMember_40b00212-a426-4e44-b67c-c68a5276a740" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_3e38b12b-1d47-484d-be21-5d741998ea1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_50ea566e-e424-4808-b847-d48e08687c8d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_3e38b12b-1d47-484d-be21-5d741998ea1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_3e38b12b-1d47-484d-be21-5d741998ea1d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_3e38b12b-1d47-484d-be21-5d741998ea1d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_3e38b12b-1d47-484d-be21-5d741998ea1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_19937db1-4d20-412d-8d46-70b73bf30221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_3e38b12b-1d47-484d-be21-5d741998ea1d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_19937db1-4d20-412d-8d46-70b73bf30221" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_db574417-1244-4c3d-8ebe-18fc00ba1ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_19937db1-4d20-412d-8d46-70b73bf30221" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_db574417-1244-4c3d-8ebe-18fc00ba1ae4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_e29e81d0-85fd-4f89-b0e3-06d68ef259a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_19937db1-4d20-412d-8d46-70b73bf30221" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_e29e81d0-85fd-4f89-b0e3-06d68ef259a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_13559b50-5221-41ba-92ee-4aed77a48ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_50ea566e-e424-4808-b847-d48e08687c8d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_13559b50-5221-41ba-92ee-4aed77a48ea1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_13559b50-5221-41ba-92ee-4aed77a48ea1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_13559b50-5221-41ba-92ee-4aed77a48ea1" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_13559b50-5221-41ba-92ee-4aed77a48ea1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1db7fc66-cbb5-41b5-bd00-25f3e2a6e0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_13559b50-5221-41ba-92ee-4aed77a48ea1" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1db7fc66-cbb5-41b5-bd00-25f3e2a6e0c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember_619233c6-2510-4bba-9d58-8ea06a7228db" xlink:href="bhc-20220510.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1db7fc66-cbb5-41b5-bd00-25f3e2a6e0c0" xlink:to="loc_bhc_AmounPharmaceuticalCompanySAEMember_619233c6-2510-4bba-9d58-8ea06a7228db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ACertainInternationalBusinessMember_d61347fc-381e-43b4-8d5e-bf4b4a0c2517" xlink:href="bhc-20220510.xsd#bhc_ACertainInternationalBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1db7fc66-cbb5-41b5-bd00-25f3e2a6e0c0" xlink:to="loc_bhc_ACertainInternationalBusinessMember_d61347fc-381e-43b4-8d5e-bf4b4a0c2517" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_59a2bc81-2ce7-4288-889d-6193ef36e8f4" xlink:href="bhc-20220510.xsd#bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1db7fc66-cbb5-41b5-bd00-25f3e2a6e0c0" xlink:to="loc_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_59a2bc81-2ce7-4288-889d-6193ef36e8f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ed333307-7069-437b-b669-7bc7391c3a82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_50ea566e-e424-4808-b847-d48e08687c8d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ed333307-7069-437b-b669-7bc7391c3a82" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ed333307-7069-437b-b669-7bc7391c3a82_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ed333307-7069-437b-b669-7bc7391c3a82" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_ed333307-7069-437b-b669-7bc7391c3a82_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_62c5886c-ee84-47d0-88fa-62b0b38059e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ed333307-7069-437b-b669-7bc7391c3a82" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_62c5886c-ee84-47d0-88fa-62b0b38059e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember_9622b12d-04a5-4a1d-ab74-57525f0f1bcf" xlink:href="bhc-20220510.xsd#bhc_AcquiredInProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_62c5886c-ee84-47d0-88fa-62b0b38059e3" xlink:to="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember_9622b12d-04a5-4a1d-ab74-57525f0f1bcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_eec86c1b-eed7-4578-85b7-4bc3de9128c2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_50ea566e-e424-4808-b847-d48e08687c8d" xlink:to="loc_srt_RangeAxis_eec86c1b-eed7-4578-85b7-4bc3de9128c2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eec86c1b-eed7-4578-85b7-4bc3de9128c2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_eec86c1b-eed7-4578-85b7-4bc3de9128c2" xlink:to="loc_srt_RangeMember_eec86c1b-eed7-4578-85b7-4bc3de9128c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e1319fa8-2d72-49ed-9472-477231472373" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_eec86c1b-eed7-4578-85b7-4bc3de9128c2" xlink:to="loc_srt_RangeMember_e1319fa8-2d72-49ed-9472-477231472373" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_50ef58df-a887-4552-90f3-90ca73f08332" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e1319fa8-2d72-49ed-9472-477231472373" xlink:to="loc_srt_MinimumMember_50ef58df-a887-4552-90f3-90ca73f08332" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_68ecdcff-9708-4c64-b901-8799d8733c75" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e1319fa8-2d72-49ed-9472-477231472373" xlink:to="loc_srt_MaximumMember_68ecdcff-9708-4c64-b901-8799d8733c75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_943710be-b60b-4411-8cd8-a271d8929dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_50ea566e-e424-4808-b847-d48e08687c8d" xlink:to="loc_us-gaap_ReportingUnitAxis_943710be-b60b-4411-8cd8-a271d8929dd8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_943710be-b60b-4411-8cd8-a271d8929dd8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_943710be-b60b-4411-8cd8-a271d8929dd8" xlink:to="loc_us-gaap_ReportingUnitDomain_943710be-b60b-4411-8cd8-a271d8929dd8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_3539e330-6d8e-480b-986d-2fc06e5b4726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_943710be-b60b-4411-8cd8-a271d8929dd8" xlink:to="loc_us-gaap_ReportingUnitDomain_3539e330-6d8e-480b-986d-2fc06e5b4726" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsReportingUnitMember_cf560f92-811b-4519-9cd7-593eb3fa1fbf" xlink:href="bhc-20220510.xsd#bhc_OrthoDermatologicsReportingUnitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_3539e330-6d8e-480b-986d-2fc06e5b4726" xlink:to="loc_bhc_OrthoDermatologicsReportingUnitMember_cf560f92-811b-4519-9cd7-593eb3fa1fbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_3383608a-ab34-4e9e-9697-7074323a1397" xlink:href="bhc-20220510.xsd#bhc_ReportingUnitsExcludingOrthoDermatologicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_3539e330-6d8e-480b-986d-2fc06e5b4726" xlink:to="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_3383608a-ab34-4e9e-9697-7074323a1397" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_56cf4eb9-8a9c-43e6-bcb0-cd3d08430b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_50ea566e-e424-4808-b847-d48e08687c8d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_56cf4eb9-8a9c-43e6-bcb0-cd3d08430b5d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_56cf4eb9-8a9c-43e6-bcb0-cd3d08430b5d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_56cf4eb9-8a9c-43e6-bcb0-cd3d08430b5d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_56cf4eb9-8a9c-43e6-bcb0-cd3d08430b5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d0a27e56-46b7-49df-97e7-becedeb519ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_56cf4eb9-8a9c-43e6-bcb0-cd3d08430b5d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d0a27e56-46b7-49df-97e7-becedeb519ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7972ed38-7d7e-4ca0-9137-ee727f1ae7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d0a27e56-46b7-49df-97e7-becedeb519ba" xlink:to="loc_us-gaap_SubsequentEventMember_7972ed38-7d7e-4ca0-9137-ee727f1ae7d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_53b48e38-a190-4bb0-ac84-2ac7683deaaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_50ea566e-e424-4808-b847-d48e08687c8d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_53b48e38-a190-4bb0-ac84-2ac7683deaaf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_53b48e38-a190-4bb0-ac84-2ac7683deaaf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_53b48e38-a190-4bb0-ac84-2ac7683deaaf" xlink:to="loc_us-gaap_SegmentDomain_53b48e38-a190-4bb0-ac84-2ac7683deaaf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_198b8752-4d65-45d5-bf6f-ec5bd4ce1986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_53b48e38-a190-4bb0-ac84-2ac7683deaaf" xlink:to="loc_us-gaap_SegmentDomain_198b8752-4d65-45d5-bf6f-ec5bd4ce1986" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_7541c877-6836-42a6-b410-ee5cf281d16c" xlink:href="bhc-20220510.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_198b8752-4d65-45d5-bf6f-ec5bd4ce1986" xlink:to="loc_bhc_BauschLombMember_7541c877-6836-42a6-b410-ee5cf281d16c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_8fd086bc-4772-4aaf-ae79-9d623aff5376" xlink:href="bhc-20220510.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_198b8752-4d65-45d5-bf6f-ec5bd4ce1986" xlink:to="loc_bhc_SalixSegmentMember_8fd086bc-4772-4aaf-ae79-9d623aff5376" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_ce72a476-70b1-4007-baed-572fef93df66" xlink:href="bhc-20220510.xsd#bhc_InternationalRxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_198b8752-4d65-45d5-bf6f-ec5bd4ce1986" xlink:to="loc_bhc_InternationalRxMember_ce72a476-70b1-4007-baed-572fef93df66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_430be8e4-97ec-4bd1-a5f2-1d132962d105" xlink:href="bhc-20220510.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_198b8752-4d65-45d5-bf6f-ec5bd4ce1986" xlink:to="loc_bhc_SoltaMedicalSegmentMember_430be8e4-97ec-4bd1-a5f2-1d132962d105" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_42131205-2f0e-424b-802b-dc50f29fb748" xlink:href="bhc-20220510.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_198b8752-4d65-45d5-bf6f-ec5bd4ce1986" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_42131205-2f0e-424b-802b-dc50f29fb748" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" xlink:type="extended" id="ic46ebddc4053474e9324062384a30d04_INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_8dd01427-ccf7-439e-9124-436a95a90979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_05e29c20-6a82-44e9-a45c-f5d16cab4d86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_8dd01427-ccf7-439e-9124-436a95a90979" xlink:to="loc_us-gaap_GoodwillRollForward_05e29c20-6a82-44e9-a45c-f5d16cab4d86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_02c1fb95-74cd-4b2c-b082-3eb5b83ea9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_05e29c20-6a82-44e9-a45c-f5d16cab4d86" xlink:to="loc_us-gaap_Goodwill_02c1fb95-74cd-4b2c-b082-3eb5b83ea9c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_b265b2ba-d6e2-4512-8ef2-e6288ce542f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_05e29c20-6a82-44e9-a45c-f5d16cab4d86" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_b265b2ba-d6e2-4512-8ef2-e6288ce542f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_721efb8d-9f88-4b64-96be-60b9cf26bc43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_05e29c20-6a82-44e9-a45c-f5d16cab4d86" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_721efb8d-9f88-4b64-96be-60b9cf26bc43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_9701f6c5-74ef-4599-bba2-2862e0d4f20c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_05e29c20-6a82-44e9-a45c-f5d16cab4d86" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_9701f6c5-74ef-4599-bba2-2862e0d4f20c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit_13683423-6c3d-4a1f-b3e6-049302e89a65" xlink:href="bhc-20220510.xsd#bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_05e29c20-6a82-44e9-a45c-f5d16cab4d86" xlink:to="loc_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit_13683423-6c3d-4a1f-b3e6-049302e89a65" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_99fe4118-145a-4e7b-af7f-c625e3377ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_05e29c20-6a82-44e9-a45c-f5d16cab4d86" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_99fe4118-145a-4e7b-af7f-c625e3377ef7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_cd7919dd-0535-4c55-82a5-3c0b517ce0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_05e29c20-6a82-44e9-a45c-f5d16cab4d86" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_cd7919dd-0535-4c55-82a5-3c0b517ce0e0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ac2c6ad3-ce97-46ef-8d0e-9b7c706cae8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_1dadcdc2-d181-43d3-bc2c-b024b1821c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_8dd01427-ccf7-439e-9124-436a95a90979" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_1dadcdc2-d181-43d3-bc2c-b024b1821c9c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_45831985-7b97-484c-83c8-3dd12618bbb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1dadcdc2-d181-43d3-bc2c-b024b1821c9c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_45831985-7b97-484c-83c8-3dd12618bbb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_45831985-7b97-484c-83c8-3dd12618bbb3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_45831985-7b97-484c-83c8-3dd12618bbb3" xlink:to="loc_us-gaap_SegmentDomain_45831985-7b97-484c-83c8-3dd12618bbb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9231340b-4d2c-4d84-ab36-ebe5a391c13b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_45831985-7b97-484c-83c8-3dd12618bbb3" xlink:to="loc_us-gaap_SegmentDomain_9231340b-4d2c-4d84-ab36-ebe5a391c13b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombInternationalMember_cb8c1269-de5f-45e6-8c57-dad66e46046b" xlink:href="bhc-20220510.xsd#bhc_BauschLombInternationalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9231340b-4d2c-4d84-ab36-ebe5a391c13b" xlink:to="loc_bhc_BauschLombInternationalMember_cb8c1269-de5f-45e6-8c57-dad66e46046b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_c2e03aed-763f-4df9-9819-cbc6fc07f649" xlink:href="bhc-20220510.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9231340b-4d2c-4d84-ab36-ebe5a391c13b" xlink:to="loc_bhc_BauschLombMember_c2e03aed-763f-4df9-9819-cbc6fc07f649" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_cac29ec3-0be9-4edc-8661-730615aca1fa" xlink:href="bhc-20220510.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9231340b-4d2c-4d84-ab36-ebe5a391c13b" xlink:to="loc_bhc_SalixSegmentMember_cac29ec3-0be9-4edc-8661-730615aca1fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_b562fa7f-80b2-43a3-b6cd-656ae9d5467c" xlink:href="bhc-20220510.xsd#bhc_InternationalRxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9231340b-4d2c-4d84-ab36-ebe5a391c13b" xlink:to="loc_bhc_InternationalRxMember_b562fa7f-80b2-43a3-b6cd-656ae9d5467c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_9f9de315-cb61-465e-a03a-5010e2c56f1d" xlink:href="bhc-20220510.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9231340b-4d2c-4d84-ab36-ebe5a391c13b" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_9f9de315-cb61-465e-a03a-5010e2c56f1d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_8882c7cf-5a48-498d-9852-045411a3766e" xlink:href="bhc-20220510.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9231340b-4d2c-4d84-ab36-ebe5a391c13b" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_8882c7cf-5a48-498d-9852-045411a3766e" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="extended" id="if7e17e33f3f94f47bb018b6b10c1e31f_FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_04594dca-7640-4dbc-bec3-3682a0046c87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7ff7ba57-989c-4c10-b6ca-06fcd18f41fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_04594dca-7640-4dbc-bec3-3682a0046c87" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7ff7ba57-989c-4c10-b6ca-06fcd18f41fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_9a3b75a9-d73e-4fb2-9e5c-7267498ea731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_04594dca-7640-4dbc-bec3-3682a0046c87" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_9a3b75a9-d73e-4fb2-9e5c-7267498ea731" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_93e4efeb-5773-4e8f-85f8-f909fe8b83c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_04594dca-7640-4dbc-bec3-3682a0046c87" xlink:to="loc_us-gaap_LongTermDebt_93e4efeb-5773-4e8f-85f8-f909fe8b83c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_c4a548ee-e03b-4e1e-a86b-e824ba3f65a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_04594dca-7640-4dbc-bec3-3682a0046c87" xlink:to="loc_us-gaap_LongTermDebtCurrent_c4a548ee-e03b-4e1e-a86b-e824ba3f65a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_2ccc8073-9c4c-49aa-8e86-cb975f018530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_04594dca-7640-4dbc-bec3-3682a0046c87" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_2ccc8073-9c4c-49aa-8e86-cb975f018530" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_335adb6d-6271-431f-9d76-16240f5ddbac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_04594dca-7640-4dbc-bec3-3682a0046c87" xlink:to="loc_us-gaap_DebtInstrumentTable_335adb6d-6271-431f-9d76-16240f5ddbac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_7b5faf71-973d-4f92-a308-82d548e0d831" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_335adb6d-6271-431f-9d76-16240f5ddbac" xlink:to="loc_us-gaap_CreditFacilityAxis_7b5faf71-973d-4f92-a308-82d548e0d831" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7b5faf71-973d-4f92-a308-82d548e0d831_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_7b5faf71-973d-4f92-a308-82d548e0d831" xlink:to="loc_us-gaap_CreditFacilityDomain_7b5faf71-973d-4f92-a308-82d548e0d831_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_dc38d36c-6a07-45a2-9c96-8da38ac306e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_7b5faf71-973d-4f92-a308-82d548e0d831" xlink:to="loc_us-gaap_CreditFacilityDomain_dc38d36c-6a07-45a2-9c96-8da38ac306e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_9fcc30f5-e31b-427e-9f0e-f0862a482346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_dc38d36c-6a07-45a2-9c96-8da38ac306e4" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_9fcc30f5-e31b-427e-9f0e-f0862a482346" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_990c8acd-29f7-43d3-b7c1-9f55ce93ce1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_335adb6d-6271-431f-9d76-16240f5ddbac" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_990c8acd-29f7-43d3-b7c1-9f55ce93ce1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_990c8acd-29f7-43d3-b7c1-9f55ce93ce1d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_990c8acd-29f7-43d3-b7c1-9f55ce93ce1d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_990c8acd-29f7-43d3-b7c1-9f55ce93ce1d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_97d1a98d-b749-48f6-8fda-a8a219ce4a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_990c8acd-29f7-43d3-b7c1-9f55ce93ce1d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_97d1a98d-b749-48f6-8fda-a8a219ce4a09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_82f97f7d-7ac8-4981-907c-d4b4a0ad218a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_97d1a98d-b749-48f6-8fda-a8a219ce4a09" xlink:to="loc_us-gaap_SecuredDebtMember_82f97f7d-7ac8-4981-907c-d4b4a0ad218a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_163bc677-4663-41e8-a606-bcfbd7feb565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_97d1a98d-b749-48f6-8fda-a8a219ce4a09" xlink:to="loc_us-gaap_UnsecuredDebtMember_163bc677-4663-41e8-a606-bcfbd7feb565" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fe9341ff-9e86-4059-8aa1-7beb7fefb959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_335adb6d-6271-431f-9d76-16240f5ddbac" xlink:to="loc_us-gaap_DebtInstrumentAxis_fe9341ff-9e86-4059-8aa1-7beb7fefb959" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fe9341ff-9e86-4059-8aa1-7beb7fefb959_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_fe9341ff-9e86-4059-8aa1-7beb7fefb959" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fe9341ff-9e86-4059-8aa1-7beb7fefb959_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_fe9341ff-9e86-4059-8aa1-7beb7fefb959" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_ac8f59e1-d853-4d58-8901-783085cda733" xlink:href="bhc-20220510.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_ac8f59e1-d853-4d58-8901-783085cda733" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_b02a7ea3-28de-4aa9-a3fb-09e3d6a5ca75" xlink:href="bhc-20220510.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_b02a7ea3-28de-4aa9-a3fb-09e3d6a5ca75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member_43cb982d-f2da-4492-87c7-0a3e28321e9f" xlink:href="bhc-20220510.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_TermLoanBFacilityDueNovember2025Member_43cb982d-f2da-4492-87c7-0a3e28321e9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_2f1bde28-f044-46ed-906f-132a2fa01ded" xlink:href="bhc-20220510.xsd#bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_2f1bde28-f044-46ed-906f-132a2fa01ded" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_d69ba5bb-8af3-4823-a278-986bf534c5d3" xlink:href="bhc-20220510.xsd#bhc_SeniorSecured5.50NotesDueNovember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_d69ba5bb-8af3-4823-a278-986bf534c5d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_d1e32dee-693d-4dc2-ac27-9d5b4baed11b" xlink:href="bhc-20220510.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_d1e32dee-693d-4dc2-ac27-9d5b4baed11b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member_30fd0db1-3f11-4678-8d2c-1a6b46095dce" xlink:href="bhc-20220510.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_SeniorSecured4875NotesDueJune2028Member_30fd0db1-3f11-4678-8d2c-1a6b46095dce" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_1e50d821-697b-4b69-983c-7fff750f8006" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_1e50d821-697b-4b69-983c-7fff750f8006" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes900DueDecember2025Member_5fbfa744-fbf2-4c1b-9ae3-42ac6def01b6" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes900DueDecember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_SeniorNotes900DueDecember2025Member_5fbfa744-fbf2-4c1b-9ae3-42ac6def01b6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member_4801d733-90e2-4814-9597-892116135b4a" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_SeniorNotes925DueApril2026Member_4801d733-90e2-4814-9597-892116135b4a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member_44df5156-d812-4635-a8b6-87f25a07ba8f" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_SeniorNotes850DueJanuary2027Member_44df5156-d812-4635-a8b6-87f25a07ba8f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member_755e2c59-6392-4b95-a14f-5da0e2156e32" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_SeniorNotes700DueJanuary2028Member_755e2c59-6392-4b95-a14f-5da0e2156e32" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member_1c1ce7db-fad3-4c44-adce-28bc9cebc401" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_SeniorNotes500DueJanuary2028Member_1c1ce7db-fad3-4c44-adce-28bc9cebc401" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member_1113e18f-dcd0-4601-94cc-ad3bd0a91328" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_SeniorNotes625DueFebruary2029Member_1113e18f-dcd0-4601-94cc-ad3bd0a91328" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member_5d636110-2e2b-42f7-b076-0eb738921d76" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_SeniorNotes500DueFebruary2029Member_5d636110-2e2b-42f7-b076-0eb738921d76" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member_a08e6ed9-f380-4a82-99bd-7e53376b35cb" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_SeniorNotes725DueMay2029Member_a08e6ed9-f380-4a82-99bd-7e53376b35cb" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueJanuary2030Member_b12832e1-0e9f-41df-ac47-eea00253766e" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes525DueJanuary2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_SeniorNotes525DueJanuary2030Member_b12832e1-0e9f-41df-ac47-eea00253766e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member_df27b0d2-4032-4147-a7f1-2b6ead3a113d" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_SeniorNotes525DueFebruary2031Member_df27b0d2-4032-4147-a7f1-2b6ead3a113d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherLongTermDebtMember_0468b0d5-d2cb-47bc-bf9b-6819d9776b5b" xlink:href="bhc-20220510.xsd#bhc_OtherLongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_OtherLongTermDebtMember_0468b0d5-d2cb-47bc-bf9b-6819d9776b5b" xlink:type="arc" order="18"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FINANCINGARRANGEMENTSCovenantComplianceDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="extended" id="ib85d464597074ce6923a75f02f299f71_FINANCINGARRANGEMENTSCovenantComplianceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_aac28205-979d-4516-afd2-466a301e57c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAmountAvailableForRestrictedPayments_bf3c85ed-ff2e-42ab-ba09-cc7298c02813" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentAmountAvailableForRestrictedPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aac28205-979d-4516-afd2-466a301e57c4" xlink:to="loc_bhc_DebtInstrumentAmountAvailableForRestrictedPayments_bf3c85ed-ff2e-42ab-ba09-cc7298c02813" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_d3d87cab-1256-419d-8e3a-a4bf4c6a9d35" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aac28205-979d-4516-afd2-466a301e57c4" xlink:to="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_d3d87cab-1256-419d-8e3a-a4bf4c6a9d35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_b4d249e6-43a7-4cc9-a0b8-d22111b082cd" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aac28205-979d-4516-afd2-466a301e57c4" xlink:to="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_b4d249e6-43a7-4cc9-a0b8-d22111b082cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6aa30612-3acf-45e6-ba28-b5cb2f8d22e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aac28205-979d-4516-afd2-466a301e57c4" xlink:to="loc_us-gaap_DebtInstrumentTable_6aa30612-3acf-45e6-ba28-b5cb2f8d22e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_c43e1ac1-256c-4218-aff3-767cfeb1e37e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6aa30612-3acf-45e6-ba28-b5cb2f8d22e2" xlink:to="loc_us-gaap_CreditFacilityAxis_c43e1ac1-256c-4218-aff3-767cfeb1e37e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c43e1ac1-256c-4218-aff3-767cfeb1e37e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_c43e1ac1-256c-4218-aff3-767cfeb1e37e" xlink:to="loc_us-gaap_CreditFacilityDomain_c43e1ac1-256c-4218-aff3-767cfeb1e37e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_4d646b81-5d4a-4a5a-a14e-fe8639f9e84f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_c43e1ac1-256c-4218-aff3-767cfeb1e37e" xlink:to="loc_us-gaap_CreditFacilityDomain_4d646b81-5d4a-4a5a-a14e-fe8639f9e84f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_04683eca-9ad4-48bf-9e0f-4eb8f77d7967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_4d646b81-5d4a-4a5a-a14e-fe8639f9e84f" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_04683eca-9ad4-48bf-9e0f-4eb8f77d7967" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="extended" id="i2706879479c24ec8ba43bf28451405f7_FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_37f75754-0bd9-4a7a-b5bc-718781d616e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_68208265-b2d6-4ac7-9e20-14f77e2311d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_37f75754-0bd9-4a7a-b5bc-718781d616e7" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_68208265-b2d6-4ac7-9e20-14f77e2311d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_174683cd-a829-4e1f-954f-7c14426948f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_37f75754-0bd9-4a7a-b5bc-718781d616e7" xlink:to="loc_us-gaap_DebtInstrumentTerm_174683cd-a829-4e1f-954f-7c14426948f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d03cf1d2-0d3a-4510-9b6d-e8e204f53dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_37f75754-0bd9-4a7a-b5bc-718781d616e7" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d03cf1d2-0d3a-4510-9b6d-e8e204f53dc2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_113319bb-7574-493f-8350-f1d3ff0d885b" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_37f75754-0bd9-4a7a-b5bc-718781d616e7" xlink:to="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_113319bb-7574-493f-8350-f1d3ff0d885b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_6d788d3d-a11e-493e-baff-ffd4275532f6" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_37f75754-0bd9-4a7a-b5bc-718781d616e7" xlink:to="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_6d788d3d-a11e-493e-baff-ffd4275532f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c1e7192c-b276-40cb-8fca-41de6508589b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_37f75754-0bd9-4a7a-b5bc-718781d616e7" xlink:to="loc_us-gaap_LongTermDebt_c1e7192c-b276-40cb-8fca-41de6508589b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_1b15a1e0-0f8e-463c-aa9b-7c2a9d665597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_37f75754-0bd9-4a7a-b5bc-718781d616e7" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_1b15a1e0-0f8e-463c-aa9b-7c2a9d665597" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e751c116-f164-4903-bdba-b29a4e87a74c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_37f75754-0bd9-4a7a-b5bc-718781d616e7" xlink:to="loc_us-gaap_DebtInstrumentTable_e751c116-f164-4903-bdba-b29a4e87a74c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_270ea6fb-9568-49cf-a577-34415fd1cd0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e751c116-f164-4903-bdba-b29a4e87a74c" xlink:to="loc_us-gaap_CreditFacilityAxis_270ea6fb-9568-49cf-a577-34415fd1cd0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_270ea6fb-9568-49cf-a577-34415fd1cd0a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_270ea6fb-9568-49cf-a577-34415fd1cd0a" xlink:to="loc_us-gaap_CreditFacilityDomain_270ea6fb-9568-49cf-a577-34415fd1cd0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_53276ff6-12d1-4b98-8cf9-afb493f8a774" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_270ea6fb-9568-49cf-a577-34415fd1cd0a" xlink:to="loc_us-gaap_CreditFacilityDomain_53276ff6-12d1-4b98-8cf9-afb493f8a774" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_8381898a-6e94-47ea-8cc1-9feeef471d04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_53276ff6-12d1-4b98-8cf9-afb493f8a774" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_8381898a-6e94-47ea-8cc1-9feeef471d04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_2726ec4e-cb0b-43f4-925f-104f349ed920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_53276ff6-12d1-4b98-8cf9-afb493f8a774" xlink:to="loc_us-gaap_LetterOfCreditMember_2726ec4e-cb0b-43f4-925f-104f349ed920" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_98fe3871-82f4-4135-8d5f-c44112dafd2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e751c116-f164-4903-bdba-b29a4e87a74c" xlink:to="loc_us-gaap_DebtInstrumentAxis_98fe3871-82f4-4135-8d5f-c44112dafd2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_98fe3871-82f4-4135-8d5f-c44112dafd2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_98fe3871-82f4-4135-8d5f-c44112dafd2e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_98fe3871-82f4-4135-8d5f-c44112dafd2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a74eb401-6ef9-49c2-b31f-2ee99ece2c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_98fe3871-82f4-4135-8d5f-c44112dafd2e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a74eb401-6ef9-49c2-b31f-2ee99ece2c8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_11b2ba92-81b7-4325-b65c-f23c822c5b38" xlink:href="bhc-20220510.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a74eb401-6ef9-49c2-b31f-2ee99ece2c8f" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_11b2ba92-81b7-4325-b65c-f23c822c5b38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_fd4135fe-2640-42da-8a82-740d5163c9a1" xlink:href="bhc-20220510.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a74eb401-6ef9-49c2-b31f-2ee99ece2c8f" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_fd4135fe-2640-42da-8a82-740d5163c9a1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" xlink:type="extended" id="i7ef246b135844e84960a14ad145a0d59_FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ef45e21e-f854-4456-875d-f98d4a62f86f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ef45e21e-f854-4456-875d-f98d4a62f86f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_20db5a64-b546-4f8e-bac1-8ceca5954686" xlink:href="bhc-20220510.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_20db5a64-b546-4f8e-bac1-8ceca5954686" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_8f7a1f20-1e5c-4a57-a4bc-e5c2b07b7b12" xlink:href="bhc-20220510.xsd#bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_8f7a1f20-1e5c-4a57-a4bc-e5c2b07b7b12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_a064f233-c938-4d1d-93a7-2a3922a354a9" xlink:href="bhc-20220510.xsd#bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_a064f233-c938-4d1d-93a7-2a3922a354a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_c5a09950-0808-4951-b882-2d26cb9e3610" xlink:href="bhc-20220510.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_c5a09950-0808-4951-b882-2d26cb9e3610" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_70d25448-67da-4314-93de-2d12df4b6023" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_70d25448-67da-4314-93de-2d12df4b6023" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_69767bfc-c64d-4dca-b679-d1fd4e25fcf5" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentAnnualAmortizationRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:to="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_69767bfc-c64d-4dca-b679-d1fd4e25fcf5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_af2bcd94-b226-485e-8c82-d8a2a7a24209" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:to="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_af2bcd94-b226-485e-8c82-d8a2a7a24209" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_cc2f906e-4863-4ba0-8032-c832b2398e32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_cc2f906e-4863-4ba0-8032-c832b2398e32" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_8ebcda11-ea32-4db3-95be-78bc34701646" xlink:href="bhc-20220510.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_8ebcda11-ea32-4db3-95be-78bc34701646" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate_a9c7dcba-5af5-4278-b4a3-d57208a5b75d" xlink:href="bhc-20220510.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate_a9c7dcba-5af5-4278-b4a3-d57208a5b75d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_c1b2ff3f-3032-44ac-911a-a7a716dd25ed" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:to="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_c1b2ff3f-3032-44ac-911a-a7a716dd25ed" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_1e59d570-845f-44d6-a76f-559ab094f1e8" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_1e59d570-845f-44d6-a76f-559ab094f1e8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_854f51f4-48b8-466b-a304-94fbebffa13f" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:to="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_854f51f4-48b8-466b-a304-94fbebffa13f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2e641d1e-0b59-49b1-9fe4-a691b15dde3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:to="loc_us-gaap_DebtInstrumentTable_2e641d1e-0b59-49b1-9fe4-a691b15dde3c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_ff1a519f-505b-4407-a437-523339511dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2e641d1e-0b59-49b1-9fe4-a691b15dde3c" xlink:to="loc_us-gaap_VariableRateAxis_ff1a519f-505b-4407-a437-523339511dfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_ff1a519f-505b-4407-a437-523339511dfb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_ff1a519f-505b-4407-a437-523339511dfb" xlink:to="loc_us-gaap_VariableRateDomain_ff1a519f-505b-4407-a437-523339511dfb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_a798bcda-fec1-40b2-a42a-b3e940aad501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_ff1a519f-505b-4407-a437-523339511dfb" xlink:to="loc_us-gaap_VariableRateDomain_a798bcda-fec1-40b2-a42a-b3e940aad501" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_a8303424-e154-4cfc-bf59-aad88992a669" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_a798bcda-fec1-40b2-a42a-b3e940aad501" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_a8303424-e154-4cfc-bf59-aad88992a669" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_bc0883a9-9fea-408e-87db-26746b0b8c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_a798bcda-fec1-40b2-a42a-b3e940aad501" xlink:to="loc_us-gaap_EurodollarMember_bc0883a9-9fea-408e-87db-26746b0b8c49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadaBankersAcceptanceRateMember_06c6c12c-0df0-406c-b55f-d54fa82ff6cd" xlink:href="bhc-20220510.xsd#bhc_CanadaBankersAcceptanceRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_a798bcda-fec1-40b2-a42a-b3e940aad501" xlink:to="loc_bhc_CanadaBankersAcceptanceRateMember_06c6c12c-0df0-406c-b55f-d54fa82ff6cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BaseRateOrPrimeRateMember_855c1f8e-8c00-4ee7-a9e7-0bc2bfb4e689" xlink:href="bhc-20220510.xsd#bhc_BaseRateOrPrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_a798bcda-fec1-40b2-a42a-b3e940aad501" xlink:to="loc_bhc_BaseRateOrPrimeRateMember_855c1f8e-8c00-4ee7-a9e7-0bc2bfb4e689" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6eefa541-3e1c-4c33-bb57-6b4c09e3527d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2e641d1e-0b59-49b1-9fe4-a691b15dde3c" xlink:to="loc_us-gaap_DebtInstrumentAxis_6eefa541-3e1c-4c33-bb57-6b4c09e3527d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6eefa541-3e1c-4c33-bb57-6b4c09e3527d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_6eefa541-3e1c-4c33-bb57-6b4c09e3527d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6eefa541-3e1c-4c33-bb57-6b4c09e3527d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_862fe0a4-286f-4ca2-b21c-5387488a29e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_6eefa541-3e1c-4c33-bb57-6b4c09e3527d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_862fe0a4-286f-4ca2-b21c-5387488a29e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilitiesMember_8e81487f-3e0b-408c-9210-011263e4ccd8" xlink:href="bhc-20220510.xsd#bhc_SeniorSecuredCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_862fe0a4-286f-4ca2-b21c-5387488a29e7" xlink:to="loc_bhc_SeniorSecuredCreditFacilitiesMember_8e81487f-3e0b-408c-9210-011263e4ccd8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_85cf51ab-b475-4fc6-be70-f5ade38e29c4" xlink:href="bhc-20220510.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_862fe0a4-286f-4ca2-b21c-5387488a29e7" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_85cf51ab-b475-4fc6-be70-f5ade38e29c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredTermCreditFacilitiesMember_70d70593-ec2e-4123-aea9-547c188a901c" xlink:href="bhc-20220510.xsd#bhc_SeniorSecuredTermCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_862fe0a4-286f-4ca2-b21c-5387488a29e7" xlink:to="loc_bhc_SeniorSecuredTermCreditFacilitiesMember_70d70593-ec2e-4123-aea9-547c188a901c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_55d44bb4-e338-4b5f-90e5-d5afb928488c" xlink:href="bhc-20220510.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_862fe0a4-286f-4ca2-b21c-5387488a29e7" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_55d44bb4-e338-4b5f-90e5-d5afb928488c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member_e712cc85-9d6e-4fab-8e0d-d89a8cd69a38" xlink:href="bhc-20220510.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_862fe0a4-286f-4ca2-b21c-5387488a29e7" xlink:to="loc_bhc_TermLoanBFacilityDueNovember2025Member_e712cc85-9d6e-4fab-8e0d-d89a8cd69a38" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_19c2f186-a226-4211-82ef-8aab26dbfdfa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2e641d1e-0b59-49b1-9fe4-a691b15dde3c" xlink:to="loc_srt_RangeAxis_19c2f186-a226-4211-82ef-8aab26dbfdfa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_19c2f186-a226-4211-82ef-8aab26dbfdfa_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_19c2f186-a226-4211-82ef-8aab26dbfdfa" xlink:to="loc_srt_RangeMember_19c2f186-a226-4211-82ef-8aab26dbfdfa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dd1bbb44-42a5-4c82-a745-2242be94cb96" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_19c2f186-a226-4211-82ef-8aab26dbfdfa" xlink:to="loc_srt_RangeMember_dd1bbb44-42a5-4c82-a745-2242be94cb96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4464b1d5-30a9-474f-bb98-cfc023724267" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_dd1bbb44-42a5-4c82-a745-2242be94cb96" xlink:to="loc_srt_MinimumMember_4464b1d5-30a9-474f-bb98-cfc023724267" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_87adc0e4-fb90-486f-bc8b-2a1d3a484040" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_dd1bbb44-42a5-4c82-a745-2242be94cb96" xlink:to="loc_srt_MaximumMember_87adc0e4-fb90-486f-bc8b-2a1d3a484040" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_1f579138-ab7a-42b0-b760-da954f2e7726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2e641d1e-0b59-49b1-9fe4-a691b15dde3c" xlink:to="loc_us-gaap_CreditFacilityAxis_1f579138-ab7a-42b0-b760-da954f2e7726" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_1f579138-ab7a-42b0-b760-da954f2e7726_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_1f579138-ab7a-42b0-b760-da954f2e7726" xlink:to="loc_us-gaap_CreditFacilityDomain_1f579138-ab7a-42b0-b760-da954f2e7726_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e1a47386-8079-4d9b-8ebb-473cac37a454" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_1f579138-ab7a-42b0-b760-da954f2e7726" xlink:to="loc_us-gaap_CreditFacilityDomain_e1a47386-8079-4d9b-8ebb-473cac37a454" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_cf7e649f-3146-42b4-b594-9f8a679a6917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_e1a47386-8079-4d9b-8ebb-473cac37a454" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_cf7e649f-3146-42b4-b594-9f8a679a6917" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f0f4aa02-8a85-4836-b7cd-3573236bb960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2e641d1e-0b59-49b1-9fe4-a691b15dde3c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f0f4aa02-8a85-4836-b7cd-3573236bb960" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f0f4aa02-8a85-4836-b7cd-3573236bb960_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f0f4aa02-8a85-4836-b7cd-3573236bb960" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f0f4aa02-8a85-4836-b7cd-3573236bb960_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_aa5d3a32-8e74-4db2-aec8-0ca4caa732c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f0f4aa02-8a85-4836-b7cd-3573236bb960" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_aa5d3a32-8e74-4db2-aec8-0ca4caa732c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_34351aba-fe94-4984-8c41-0844c9a5623b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_aa5d3a32-8e74-4db2-aec8-0ca4caa732c7" xlink:to="loc_us-gaap_SecuredDebtMember_34351aba-fe94-4984-8c41-0844c9a5623b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_2d6b3197-4fd4-4974-b50d-cab96ac4c2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_aa5d3a32-8e74-4db2-aec8-0ca4caa732c7" xlink:to="loc_us-gaap_UnsecuredDebtMember_2d6b3197-4fd4-4974-b50d-cab96ac4c2ff" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="extended" id="i4d608c34e2fa4acc8ca4760ac916c339_FINANCINGARRANGEMENTSSeniorSecuredNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c5a492ce-9573-455c-8c3d-cdd9ec8eefbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_481ee1ad-6904-47eb-aae1-0f3fbc102a69" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c5a492ce-9573-455c-8c3d-cdd9ec8eefbe" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_481ee1ad-6904-47eb-aae1-0f3fbc102a69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_13952f7f-0499-4c20-85ea-bc099df28b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c5a492ce-9573-455c-8c3d-cdd9ec8eefbe" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_13952f7f-0499-4c20-85ea-bc099df28b9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a5bede33-9db3-4722-8020-b7f7317e2596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c5a492ce-9573-455c-8c3d-cdd9ec8eefbe" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a5bede33-9db3-4722-8020-b7f7317e2596" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_c05a1497-bde9-45e7-b9bd-55ad362e77cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c5a492ce-9573-455c-8c3d-cdd9ec8eefbe" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_c05a1497-bde9-45e7-b9bd-55ad362e77cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6ce536e5-59d3-4768-ab40-a40999842b15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c5a492ce-9573-455c-8c3d-cdd9ec8eefbe" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6ce536e5-59d3-4768-ab40-a40999842b15" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_104731f3-2ccc-410e-8a95-05abb25b5f53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c5a492ce-9573-455c-8c3d-cdd9ec8eefbe" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_104731f3-2ccc-410e-8a95-05abb25b5f53" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds_31fecb17-524b-4927-9de0-084600b8ff07" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c5a492ce-9573-455c-8c3d-cdd9ec8eefbe" xlink:to="loc_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds_31fecb17-524b-4927-9de0-084600b8ff07" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_2f974ed5-52b3-4959-b375-00d079829636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c5a492ce-9573-455c-8c3d-cdd9ec8eefbe" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_2f974ed5-52b3-4959-b375-00d079829636" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_859ba741-60db-4459-97ec-0a5843044698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c5a492ce-9573-455c-8c3d-cdd9ec8eefbe" xlink:to="loc_us-gaap_DebtInstrumentTable_859ba741-60db-4459-97ec-0a5843044698" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_569d9da3-5290-4b91-9a85-73f0c3eafd55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_859ba741-60db-4459-97ec-0a5843044698" xlink:to="loc_us-gaap_DebtInstrumentAxis_569d9da3-5290-4b91-9a85-73f0c3eafd55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_569d9da3-5290-4b91-9a85-73f0c3eafd55_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_569d9da3-5290-4b91-9a85-73f0c3eafd55" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_569d9da3-5290-4b91-9a85-73f0c3eafd55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0b11e187-6160-41a0-b8cb-d08c74fa67c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_569d9da3-5290-4b91-9a85-73f0c3eafd55" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0b11e187-6160-41a0-b8cb-d08c74fa67c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_ee878083-cefa-419c-9fad-258d0d8d76b3" xlink:href="bhc-20220510.xsd#bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b11e187-6160-41a0-b8cb-d08c74fa67c3" xlink:to="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_ee878083-cefa-419c-9fad-258d0d8d76b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_b097dac6-871e-4697-a6d5-44f6557bc939" xlink:href="bhc-20220510.xsd#bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b11e187-6160-41a0-b8cb-d08c74fa67c3" xlink:to="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_b097dac6-871e-4697-a6d5-44f6557bc939" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_46fd449b-8581-4b23-9a34-e66b1c31c424" xlink:href="bhc-20220510.xsd#bhc_SeniorSecured5.50NotesDueNovember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b11e187-6160-41a0-b8cb-d08c74fa67c3" xlink:to="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_46fd449b-8581-4b23-9a34-e66b1c31c424" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_818fd486-6c11-453a-9bdf-c72c84c0cf73" xlink:href="bhc-20220510.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b11e187-6160-41a0-b8cb-d08c74fa67c3" xlink:to="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_818fd486-6c11-453a-9bdf-c72c84c0cf73" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A8.50SeniorNotesDueJanuary2027Member_ba820b43-99ec-4e63-b2b0-aa59ce0f1716" xlink:href="bhc-20220510.xsd#bhc_A8.50SeniorNotesDueJanuary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b11e187-6160-41a0-b8cb-d08c74fa67c3" xlink:to="loc_bhc_A8.50SeniorNotesDueJanuary2027Member_ba820b43-99ec-4e63-b2b0-aa59ce0f1716" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.875SeniorNotesdueMay2023Member_c140756a-bdb1-434a-ad0f-82f788ebd428" xlink:href="bhc-20220510.xsd#bhc_A5.875SeniorNotesdueMay2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b11e187-6160-41a0-b8cb-d08c74fa67c3" xlink:to="loc_bhc_A5.875SeniorNotesdueMay2023Member_c140756a-bdb1-434a-ad0f-82f788ebd428" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes5.625PercentDueDecember2021Member_f5048103-f3f3-418b-a2d0-c3b0712c9356" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes5.625PercentDueDecember2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b11e187-6160-41a0-b8cb-d08c74fa67c3" xlink:to="loc_bhc_SeniorNotes5.625PercentDueDecember2021Member_f5048103-f3f3-418b-a2d0-c3b0712c9356" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember_0ebe669c-5eed-4278-b006-a64ecb171b5d" xlink:href="bhc-20220510.xsd#bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b11e187-6160-41a0-b8cb-d08c74fa67c3" xlink:to="loc_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember_0ebe669c-5eed-4278-b006-a64ecb171b5d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member_1e416db2-59fd-471d-9a96-3b5514e5491a" xlink:href="bhc-20220510.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b11e187-6160-41a0-b8cb-d08c74fa67c3" xlink:to="loc_bhc_SeniorSecured4875NotesDueJune2028Member_1e416db2-59fd-471d-9a96-3b5514e5491a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueMarch2024Member_796df159-d301-4eaf-bbc9-319d80a1a85b" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes700DueMarch2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b11e187-6160-41a0-b8cb-d08c74fa67c3" xlink:to="loc_bhc_SeniorNotes700DueMarch2024Member_796df159-d301-4eaf-bbc9-319d80a1a85b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5485b3fa-e146-40aa-8497-3d8ae3ac308d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_859ba741-60db-4459-97ec-0a5843044698" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5485b3fa-e146-40aa-8497-3d8ae3ac308d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5485b3fa-e146-40aa-8497-3d8ae3ac308d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5485b3fa-e146-40aa-8497-3d8ae3ac308d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5485b3fa-e146-40aa-8497-3d8ae3ac308d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_497f1dcb-8a54-4f6a-9d9d-88c47cdad37a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5485b3fa-e146-40aa-8497-3d8ae3ac308d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_497f1dcb-8a54-4f6a-9d9d-88c47cdad37a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_25174a8a-f10e-427d-9a5c-6b98972867b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_497f1dcb-8a54-4f6a-9d9d-88c47cdad37a" xlink:to="loc_us-gaap_SecuredDebtMember_25174a8a-f10e-427d-9a5c-6b98972867b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_26e48f1c-3444-4184-8a93-33efd3443d27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_497f1dcb-8a54-4f6a-9d9d-88c47cdad37a" xlink:to="loc_us-gaap_UnsecuredDebtMember_26e48f1c-3444-4184-8a93-33efd3443d27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_6e25399a-0b2d-4b10-aaaa-6d26cb1aa5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_859ba741-60db-4459-97ec-0a5843044698" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_6e25399a-0b2d-4b10-aaaa-6d26cb1aa5b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_6e25399a-0b2d-4b10-aaaa-6d26cb1aa5b6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_6e25399a-0b2d-4b10-aaaa-6d26cb1aa5b6" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_6e25399a-0b2d-4b10-aaaa-6d26cb1aa5b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_74bdfed3-d781-418a-a4cd-3a505f85399f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_6e25399a-0b2d-4b10-aaaa-6d26cb1aa5b6" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_74bdfed3-d781-418a-a4cd-3a505f85399f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_b896d053-9133-436c-86dc-36b592785e71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_74bdfed3-d781-418a-a4cd-3a505f85399f" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_b896d053-9133-436c-86dc-36b592785e71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_459c287b-8882-4e16-81cb-b4f3b9c40170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_74bdfed3-d781-418a-a4cd-3a505f85399f" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_459c287b-8882-4e16-81cb-b4f3b9c40170" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a0757de1-afa5-4033-951f-e564058e04e7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_859ba741-60db-4459-97ec-0a5843044698" xlink:to="loc_srt_RangeAxis_a0757de1-afa5-4033-951f-e564058e04e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a0757de1-afa5-4033-951f-e564058e04e7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a0757de1-afa5-4033-951f-e564058e04e7" xlink:to="loc_srt_RangeMember_a0757de1-afa5-4033-951f-e564058e04e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_975316e8-a4c9-410f-a339-ec1e0fbed89d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a0757de1-afa5-4033-951f-e564058e04e7" xlink:to="loc_srt_RangeMember_975316e8-a4c9-410f-a339-ec1e0fbed89d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_58d99adf-af08-486e-aee5-d05e9e80b7e6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_975316e8-a4c9-410f-a339-ec1e0fbed89d" xlink:to="loc_srt_MaximumMember_58d99adf-af08-486e-aee5-d05e9e80b7e6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="extended" id="ia4037f6dbb0b45c6948c4ebfecc137a1_FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6babba29-33a2-4fe7-b633-0d631648129f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_e60558fb-b312-471c-9224-8eea8a82d3d8" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6babba29-33a2-4fe7-b633-0d631648129f" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_e60558fb-b312-471c-9224-8eea8a82d3d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d2c0a366-f62d-4717-99a1-5293292db490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6babba29-33a2-4fe7-b633-0d631648129f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d2c0a366-f62d-4717-99a1-5293292db490" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_45781087-f8f7-4509-b27c-c5d155fc9c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6babba29-33a2-4fe7-b633-0d631648129f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_45781087-f8f7-4509-b27c-c5d155fc9c0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_640238fa-cfdc-4b33-be9e-63e5c9039f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6babba29-33a2-4fe7-b633-0d631648129f" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_640238fa-cfdc-4b33-be9e-63e5c9039f3f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_21ef2233-c248-4bcc-8505-74a093e38c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6babba29-33a2-4fe7-b633-0d631648129f" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_21ef2233-c248-4bcc-8505-74a093e38c15" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_5264d6ae-dd86-43c5-97b1-65cccb91ba63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6babba29-33a2-4fe7-b633-0d631648129f" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_5264d6ae-dd86-43c5-97b1-65cccb91ba63" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds_fd0f02f5-b376-486f-89d3-a4ed0cc8a874" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6babba29-33a2-4fe7-b633-0d631648129f" xlink:to="loc_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds_fd0f02f5-b376-486f-89d3-a4ed0cc8a874" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_13fca7b0-e89f-4614-88e2-58cd09bff2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6babba29-33a2-4fe7-b633-0d631648129f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_13fca7b0-e89f-4614-88e2-58cd09bff2b0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_1ab5c4c6-1308-4f6d-90be-a2cf61675352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6babba29-33a2-4fe7-b633-0d631648129f" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_1ab5c4c6-1308-4f6d-90be-a2cf61675352" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForDebtAmortizationPrepaymentCost_851857b3-dbb6-46ed-92c8-9bffa8e3e33f" xlink:href="bhc-20220510.xsd#bhc_PaymentForDebtAmortizationPrepaymentCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6babba29-33a2-4fe7-b633-0d631648129f" xlink:to="loc_bhc_PaymentForDebtAmortizationPrepaymentCost_851857b3-dbb6-46ed-92c8-9bffa8e3e33f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f6214da5-1ebf-4c2e-ac99-ca313737046f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6babba29-33a2-4fe7-b633-0d631648129f" xlink:to="loc_us-gaap_DebtInstrumentTable_f6214da5-1ebf-4c2e-ac99-ca313737046f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a38c87a5-6dbf-4d4a-a803-21e48c9dc16e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f6214da5-1ebf-4c2e-ac99-ca313737046f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a38c87a5-6dbf-4d4a-a803-21e48c9dc16e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a38c87a5-6dbf-4d4a-a803-21e48c9dc16e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a38c87a5-6dbf-4d4a-a803-21e48c9dc16e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a38c87a5-6dbf-4d4a-a803-21e48c9dc16e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_064bca09-7809-462c-8186-615dc4b67f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a38c87a5-6dbf-4d4a-a803-21e48c9dc16e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_064bca09-7809-462c-8186-615dc4b67f0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_dcb2dcc3-f896-4a75-be9b-bd0c7dbf3d69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_064bca09-7809-462c-8186-615dc4b67f0a" xlink:to="loc_us-gaap_UnsecuredDebtMember_dcb2dcc3-f896-4a75-be9b-bd0c7dbf3d69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_5f4526e1-e554-442e-9fb4-c3659428b8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_064bca09-7809-462c-8186-615dc4b67f0a" xlink:to="loc_us-gaap_SecuredDebtMember_5f4526e1-e554-442e-9fb4-c3659428b8bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_eea7df83-c5d0-4bba-b50c-65aa0383ae16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f6214da5-1ebf-4c2e-ac99-ca313737046f" xlink:to="loc_us-gaap_DebtInstrumentAxis_eea7df83-c5d0-4bba-b50c-65aa0383ae16" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_eea7df83-c5d0-4bba-b50c-65aa0383ae16_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_eea7df83-c5d0-4bba-b50c-65aa0383ae16" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_eea7df83-c5d0-4bba-b50c-65aa0383ae16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_eea7df83-c5d0-4bba-b50c-65aa0383ae16" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.50SeniorNotesdueMarch2023Member_9234ce4d-5374-4abe-8b6e-79f521585cf7" xlink:href="bhc-20220510.xsd#bhc_A5.50SeniorNotesdueMarch2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_A5.50SeniorNotesdueMarch2023Member_9234ce4d-5374-4abe-8b6e-79f521585cf7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.375SeniorNotesdueMarch2020Member_fa1381e8-8001-4363-8860-2a6c6b5da764" xlink:href="bhc-20220510.xsd#bhc_A5.375SeniorNotesdueMarch2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_A5.375SeniorNotesdueMarch2020Member_fa1381e8-8001-4363-8860-2a6c6b5da764" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.875SeniorNotesdueMay2023Member_d3d8af89-78f6-4aaa-93ba-a4892c03dbef" xlink:href="bhc-20220510.xsd#bhc_A5.875SeniorNotesdueMay2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_A5.875SeniorNotesdueMay2023Member_d3d8af89-78f6-4aaa-93ba-a4892c03dbef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember_8ba68ec8-9477-4af3-a32e-96572b07cce6" xlink:href="bhc-20220510.xsd#bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_A5.875SeniorNotesdueMay2023Member_d3d8af89-78f6-4aaa-93ba-a4892c03dbef" xlink:to="loc_bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember_8ba68ec8-9477-4af3-a32e-96572b07cce6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember_ca039c6a-e390-4fc8-9f5a-bb27b6e91eeb" xlink:href="bhc-20220510.xsd#bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_A5.875SeniorNotesdueMay2023Member_d3d8af89-78f6-4aaa-93ba-a4892c03dbef" xlink:to="loc_bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember_ca039c6a-e390-4fc8-9f5a-bb27b6e91eeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes4.502023Member_7685340c-3796-47a9-9a55-dd1b8334ef0f" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes4.502023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_SeniorNotes4.502023Member_7685340c-3796-47a9-9a55-dd1b8334ef0f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A6.125SeniorNotesdueApril2025Member_8166b68b-2689-410d-a62d-c4d6283f2e84" xlink:href="bhc-20220510.xsd#bhc_A6.125SeniorNotesdueApril2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_A6.125SeniorNotesdueApril2025Member_8166b68b-2689-410d-a62d-c4d6283f2e84" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorUnsecuredNotesDue2023Member_12243e09-10c8-47b8-a11d-844b7ad909dd" xlink:href="bhc-20220510.xsd#bhc_SeniorUnsecuredNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_SeniorUnsecuredNotesDue2023Member_12243e09-10c8-47b8-a11d-844b7ad909dd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_53bbed08-89b9-4079-ac85-396fdd079505" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_53bbed08-89b9-4079-ac85-396fdd079505" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.00SeniorNotesdueDecember2025Member_f8a8b992-2121-40d3-9fcd-34fafd07393c" xlink:href="bhc-20220510.xsd#bhc_A9.00SeniorNotesdueDecember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_A9.00SeniorNotesdueDecember2025Member_f8a8b992-2121-40d3-9fcd-34fafd07393c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.25SeniorNotesDueApril2026Member_f2635fd8-c893-483a-8999-9c91b6e9fbbc" xlink:href="bhc-20220510.xsd#bhc_A9.25SeniorNotesDueApril2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_A9.25SeniorNotesDueApril2026Member_f2635fd8-c893-483a-8999-9c91b6e9fbbc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A8.50SeniorNotesDueJanuary2027Member_ff5e5eaa-f618-4e11-8f03-c8f0fefa981a" xlink:href="bhc-20220510.xsd#bhc_A8.50SeniorNotesDueJanuary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_A8.50SeniorNotesDueJanuary2027Member_ff5e5eaa-f618-4e11-8f03-c8f0fefa981a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A7.00SeniorUnsecuredNotesDue2028Member_8018f639-d475-46ff-976f-ce8b124f2267" xlink:href="bhc-20220510.xsd#bhc_A7.00SeniorUnsecuredNotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_A7.00SeniorUnsecuredNotesDue2028Member_8018f639-d475-46ff-976f-ce8b124f2267" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A7.25SeniorUnsecuredNotesDue2029Member_8422ff9b-0f6f-4efa-ba50-b9027aea4e5e" xlink:href="bhc-20220510.xsd#bhc_A7.25SeniorUnsecuredNotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_A7.25SeniorUnsecuredNotesDue2029Member_8422ff9b-0f6f-4efa-ba50-b9027aea4e5e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.00SeniorNotesDueJanuary2028Member_138f9d52-3d1d-4e01-9e51-cf35f98e0551" xlink:href="bhc-20220510.xsd#bhc_A5.00SeniorNotesDueJanuary2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_A5.00SeniorNotesDueJanuary2028Member_138f9d52-3d1d-4e01-9e51-cf35f98e0551" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.25SeniorNotesDueJanuary2030Member_0a1f1337-de51-41af-9bc0-bdac3ba2a857" xlink:href="bhc-20220510.xsd#bhc_A5.25SeniorNotesDueJanuary2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_A5.25SeniorNotesDueJanuary2030Member_0a1f1337-de51-41af-9bc0-bdac3ba2a857" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member_cc79b265-0832-4884-b048-dbec1871b456" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_SeniorNotes625DueFebruary2029Member_cc79b265-0832-4884-b048-dbec1871b456" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_31eab49f-054e-4f49-9950-f668b86badb1" xlink:href="bhc-20220510.xsd#bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_31eab49f-054e-4f49-9950-f668b86badb1" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member_9333fa8b-1aa8-4597-afb5-07b182aad1fd" xlink:href="bhc-20220510.xsd#bhc_TermLoanBFacilityDueJune2025AndNovember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member_9333fa8b-1aa8-4597-afb5-07b182aad1fd" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member_3328d49b-8011-4fa6-a5c9-0efc4211e772" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_SeniorNotes500DueFebruary2029Member_3328d49b-8011-4fa6-a5c9-0efc4211e772" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member_4bed9b3c-d48d-4659-8438-bd582c730943" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_SeniorNotes525DueFebruary2031Member_4bed9b3c-d48d-4659-8438-bd582c730943" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes550DueMarch2023Member_26e4d75e-1026-4a59-840a-ca2e0f110663" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes550DueMarch2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_SeniorNotes550DueMarch2023Member_26e4d75e-1026-4a59-840a-ca2e0f110663" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_38acd062-57af-4b91-b1ac-f187c08057bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f6214da5-1ebf-4c2e-ac99-ca313737046f" xlink:to="loc_us-gaap_LitigationStatusAxis_38acd062-57af-4b91-b1ac-f187c08057bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_38acd062-57af-4b91-b1ac-f187c08057bf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_38acd062-57af-4b91-b1ac-f187c08057bf" xlink:to="loc_us-gaap_LitigationStatusDomain_38acd062-57af-4b91-b1ac-f187c08057bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_197d3de8-92ed-4094-bb98-0e2e07cc4908" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_38acd062-57af-4b91-b1ac-f187c08057bf" xlink:to="loc_us-gaap_LitigationStatusDomain_197d3de8-92ed-4094-bb98-0e2e07cc4908" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_41b909f9-60b7-4065-acaf-7f55acb4104c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_197d3de8-92ed-4094-bb98-0e2e07cc4908" xlink:to="loc_us-gaap_SettledLitigationMember_41b909f9-60b7-4065-acaf-7f55acb4104c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_209ab76a-b36c-4871-b262-4b238f1bba9d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f6214da5-1ebf-4c2e-ac99-ca313737046f" xlink:to="loc_srt_StatementGeographicalAxis_209ab76a-b36c-4871-b262-4b238f1bba9d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_209ab76a-b36c-4871-b262-4b238f1bba9d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_209ab76a-b36c-4871-b262-4b238f1bba9d" xlink:to="loc_srt_SegmentGeographicalDomain_209ab76a-b36c-4871-b262-4b238f1bba9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b9695792-53a5-4e59-8c1c-379ada279bdc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_209ab76a-b36c-4871-b262-4b238f1bba9d" xlink:to="loc_srt_SegmentGeographicalDomain_b9695792-53a5-4e59-8c1c-379ada279bdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_e96d4572-4481-4d96-a61f-e7eed2f03cb2" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b9695792-53a5-4e59-8c1c-379ada279bdc" xlink:to="loc_stpr_NJ_e96d4572-4481-4d96-a61f-e7eed2f03cb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_8b921302-a9af-4812-91ef-b1f632e4183f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f6214da5-1ebf-4c2e-ac99-ca313737046f" xlink:to="loc_srt_LitigationCaseAxis_8b921302-a9af-4812-91ef-b1f632e4183f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_8b921302-a9af-4812-91ef-b1f632e4183f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_8b921302-a9af-4812-91ef-b1f632e4183f" xlink:to="loc_srt_LitigationCaseTypeDomain_8b921302-a9af-4812-91ef-b1f632e4183f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_04230d54-6360-461a-932f-0c53eef6312c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_8b921302-a9af-4812-91ef-b1f632e4183f" xlink:to="loc_srt_LitigationCaseTypeDomain_04230d54-6360-461a-932f-0c53eef6312c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_8ea45cb8-a049-400c-b24e-82ff0405a216" xlink:href="bhc-20220510.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_04230d54-6360-461a-932f-0c53eef6312c" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_8ea45cb8-a049-400c-b24e-82ff0405a216" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_c5db70a6-3529-4d56-b7d7-fb4898c77249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f6214da5-1ebf-4c2e-ac99-ca313737046f" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_c5db70a6-3529-4d56-b7d7-fb4898c77249" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c5db70a6-3529-4d56-b7d7-fb4898c77249_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_c5db70a6-3529-4d56-b7d7-fb4898c77249" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c5db70a6-3529-4d56-b7d7-fb4898c77249_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_f851e9c8-b07e-4913-8366-5e257547f0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_c5db70a6-3529-4d56-b7d7-fb4898c77249" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_f851e9c8-b07e-4913-8366-5e257547f0b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_1ebf76c4-0121-43a7-aef4-82694e78c6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_f851e9c8-b07e-4913-8366-5e257547f0b2" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_1ebf76c4-0121-43a7-aef4-82694e78c6c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_5d27ab5e-def9-4f52-bd5a-21269cc9c894" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_f851e9c8-b07e-4913-8366-5e257547f0b2" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_5d27ab5e-def9-4f52-bd5a-21269cc9c894" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" xlink:type="extended" id="i8f5320fb1f73440abeae54d404c44d18_FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e2b63df0-e72f-4184-8ed6-c76e0e5529b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_592112e9-7a86-47c5-993a-c41dafedb3e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e2b63df0-e72f-4184-8ed6-c76e0e5529b0" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_592112e9-7a86-47c5-993a-c41dafedb3e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_c063269b-da3e-4bcd-a9a6-346c4b5c59fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e2b63df0-e72f-4184-8ed6-c76e0e5529b0" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_c063269b-da3e-4bcd-a9a6-346c4b5c59fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_fc78c2bb-f534-4b66-b7fd-46c7d07f2b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e2b63df0-e72f-4184-8ed6-c76e0e5529b0" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_fc78c2bb-f534-4b66-b7fd-46c7d07f2b4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_888e4ba6-fab6-4b0a-92de-31003803d136" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e2b63df0-e72f-4184-8ed6-c76e0e5529b0" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_888e4ba6-fab6-4b0a-92de-31003803d136" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_31ea8548-4070-4c82-a439-4bbe6882a2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e2b63df0-e72f-4184-8ed6-c76e0e5529b0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_31ea8548-4070-4c82-a439-4bbe6882a2d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d1dff5e7-4cef-461f-ac29-f08a46213580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e2b63df0-e72f-4184-8ed6-c76e0e5529b0" xlink:to="loc_us-gaap_DebtInstrumentTable_d1dff5e7-4cef-461f-ac29-f08a46213580" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2a39b425-5958-4bf2-9249-f0ff33311be4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d1dff5e7-4cef-461f-ac29-f08a46213580" xlink:to="loc_us-gaap_DebtInstrumentAxis_2a39b425-5958-4bf2-9249-f0ff33311be4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2a39b425-5958-4bf2-9249-f0ff33311be4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2a39b425-5958-4bf2-9249-f0ff33311be4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2a39b425-5958-4bf2-9249-f0ff33311be4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_587c00f4-aa5c-43d3-bfb0-82f895394c27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2a39b425-5958-4bf2-9249-f0ff33311be4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_587c00f4-aa5c-43d3-bfb0-82f895394c27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_5dfec80c-5d17-413f-8878-20f2868b66e4" xlink:href="bhc-20220510.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_587c00f4-aa5c-43d3-bfb0-82f895394c27" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_5dfec80c-5d17-413f-8878-20f2868b66e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.00SeniorNotesdueDecember2025Member_b6b5d002-fd69-4b49-819a-815f3a325c15" xlink:href="bhc-20220510.xsd#bhc_A9.00SeniorNotesdueDecember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_587c00f4-aa5c-43d3-bfb0-82f895394c27" xlink:to="loc_bhc_A9.00SeniorNotesdueDecember2025Member_b6b5d002-fd69-4b49-819a-815f3a325c15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_b2fa26da-21e3-43a3-8aef-465f3d26dc7c" xlink:href="bhc-20220510.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_587c00f4-aa5c-43d3-bfb0-82f895394c27" xlink:to="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_b2fa26da-21e3-43a3-8aef-465f3d26dc7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_69f4ff25-b80c-44f7-8125-4bfeb0e3eabd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d1dff5e7-4cef-461f-ac29-f08a46213580" xlink:to="loc_us-gaap_CreditFacilityAxis_69f4ff25-b80c-44f7-8125-4bfeb0e3eabd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_69f4ff25-b80c-44f7-8125-4bfeb0e3eabd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_69f4ff25-b80c-44f7-8125-4bfeb0e3eabd" xlink:to="loc_us-gaap_CreditFacilityDomain_69f4ff25-b80c-44f7-8125-4bfeb0e3eabd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_cf2eb12b-1dfa-438a-8f57-841aaae086cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_69f4ff25-b80c-44f7-8125-4bfeb0e3eabd" xlink:to="loc_us-gaap_CreditFacilityDomain_cf2eb12b-1dfa-438a-8f57-841aaae086cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_c156db34-0652-47bf-bacb-a081a844537a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_cf2eb12b-1dfa-438a-8f57-841aaae086cf" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_c156db34-0652-47bf-bacb-a081a844537a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c70d3c76-4139-4018-ace8-aecffa6ee77b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d1dff5e7-4cef-461f-ac29-f08a46213580" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c70d3c76-4139-4018-ace8-aecffa6ee77b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c70d3c76-4139-4018-ace8-aecffa6ee77b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c70d3c76-4139-4018-ace8-aecffa6ee77b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c70d3c76-4139-4018-ace8-aecffa6ee77b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_042596f8-5d7c-4436-a720-2c8ff44ea959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c70d3c76-4139-4018-ace8-aecffa6ee77b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_042596f8-5d7c-4436-a720-2c8ff44ea959" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_0f6f65fa-fe2e-4a2a-a7e6-53aba533799f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_042596f8-5d7c-4436-a720-2c8ff44ea959" xlink:to="loc_us-gaap_UnsecuredDebtMember_0f6f65fa-fe2e-4a2a-a7e6-53aba533799f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_fafafb67-02dc-4271-9daf-33ca13bb7e73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_042596f8-5d7c-4436-a720-2c8ff44ea959" xlink:to="loc_us-gaap_SecuredDebtMember_fafafb67-02dc-4271-9daf-33ca13bb7e73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0ff527c3-f6c3-4ce3-9b7a-e58e0b291876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d1dff5e7-4cef-461f-ac29-f08a46213580" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0ff527c3-f6c3-4ce3-9b7a-e58e0b291876" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0ff527c3-f6c3-4ce3-9b7a-e58e0b291876_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0ff527c3-f6c3-4ce3-9b7a-e58e0b291876" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0ff527c3-f6c3-4ce3-9b7a-e58e0b291876_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_009fee0a-e21d-4964-ae25-623c4e2c41c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0ff527c3-f6c3-4ce3-9b7a-e58e0b291876" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_009fee0a-e21d-4964-ae25-623c4e2c41c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5acc61b2-618b-4f48-ac03-f1f60bab5f75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_009fee0a-e21d-4964-ae25-623c4e2c41c7" xlink:to="loc_us-gaap_SubsequentEventMember_5acc61b2-618b-4f48-ac03-f1f60bab5f75" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails" xlink:type="extended" id="i649991e596c84d86a22b34cb930955e5_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_8ff04f89-111f-46c4-9d29-91138d3a5103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance_dd126e3f-f961-4261-8e35-2e6d1c9df1a9" xlink:href="bhc-20220510.xsd#bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_8ff04f89-111f-46c4-9d29-91138d3a5103" xlink:to="loc_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance_dd126e3f-f961-4261-8e35-2e6d1c9df1a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans_360713c2-47c1-4198-b9db-e55bcf3b2c85" xlink:href="bhc-20220510.xsd#bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_8ff04f89-111f-46c4-9d29-91138d3a5103" xlink:to="loc_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans_360713c2-47c1-4198-b9db-e55bcf3b2c85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended_42c4769a-9ae8-43e0-8116-3e0a28f7ccdb" xlink:href="bhc-20220510.xsd#bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_8ff04f89-111f-46c4-9d29-91138d3a5103" xlink:to="loc_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended_42c4769a-9ae8-43e0-8116-3e0a28f7ccdb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanEmployerContributionMaximumAge_eddf6c32-132e-402b-b8ad-25f6a4dd7402" xlink:href="bhc-20220510.xsd#bhc_DefinedBenefitPlanEmployerContributionMaximumAge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_8ff04f89-111f-46c4-9d29-91138d3a5103" xlink:to="loc_bhc_DefinedBenefitPlanEmployerContributionMaximumAge_eddf6c32-132e-402b-b8ad-25f6a4dd7402" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_79af6dc8-083b-4ce4-b4da-de9888548410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_8ff04f89-111f-46c4-9d29-91138d3a5103" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_79af6dc8-083b-4ce4-b4da-de9888548410" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_e9830d93-e34a-4236-bfca-2c8a6794f3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_8ff04f89-111f-46c4-9d29-91138d3a5103" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_e9830d93-e34a-4236-bfca-2c8a6794f3ca" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod_5cd510fc-4f2a-497f-b2ff-c84c341b4724" xlink:href="bhc-20220510.xsd#bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_8ff04f89-111f-46c4-9d29-91138d3a5103" xlink:to="loc_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod_5cd510fc-4f2a-497f-b2ff-c84c341b4724" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_ff61a917-bf3f-4f51-afd1-51051f84ed75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_8ff04f89-111f-46c4-9d29-91138d3a5103" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_ff61a917-bf3f-4f51-afd1-51051f84ed75" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanPercentageAllocationofFund_85eabddf-b7d4-4cd2-8931-1bcbe127431d" xlink:href="bhc-20220510.xsd#bhc_DefinedBenefitPlanPercentageAllocationofFund"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_8ff04f89-111f-46c4-9d29-91138d3a5103" xlink:to="loc_bhc_DefinedBenefitPlanPercentageAllocationofFund_85eabddf-b7d4-4cd2-8931-1bcbe127431d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_6a798dc1-90a2-4260-9c13-5d392397f46c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_8ff04f89-111f-46c4-9d29-91138d3a5103" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_6a798dc1-90a2-4260-9c13-5d392397f46c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_f960eebc-03f8-4f64-8c1f-780ed1a0e273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_8ff04f89-111f-46c4-9d29-91138d3a5103" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_f960eebc-03f8-4f64-8c1f-780ed1a0e273" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_7c976396-959c-4060-b296-61d7119e0677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_f960eebc-03f8-4f64-8c1f-780ed1a0e273" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_7c976396-959c-4060-b296-61d7119e0677" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_7c976396-959c-4060-b296-61d7119e0677_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7c976396-959c-4060-b296-61d7119e0677" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_7c976396-959c-4060-b296-61d7119e0677_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_ffd9bda9-7b6c-4e5f-808c-5519da5c7066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7c976396-959c-4060-b296-61d7119e0677" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_ffd9bda9-7b6c-4e5f-808c-5519da5c7066" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_f498994e-979b-4ca0-bc30-7709c58ccada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_ffd9bda9-7b6c-4e5f-808c-5519da5c7066" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_f498994e-979b-4ca0-bc30-7709c58ccada" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_934d1ad0-5e46-4b4f-8630-ef80d15fc221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_ffd9bda9-7b6c-4e5f-808c-5519da5c7066" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_934d1ad0-5e46-4b4f-8630-ef80d15fc221" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_cb6fe15f-f35b-4579-a2c2-c32f85fe9603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_f960eebc-03f8-4f64-8c1f-780ed1a0e273" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_cb6fe15f-f35b-4579-a2c2-c32f85fe9603" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_cb6fe15f-f35b-4579-a2c2-c32f85fe9603_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_cb6fe15f-f35b-4579-a2c2-c32f85fe9603" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_cb6fe15f-f35b-4579-a2c2-c32f85fe9603_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_4096a7be-b9e7-447d-9cbb-7db3577f72cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_cb6fe15f-f35b-4579-a2c2-c32f85fe9603" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_4096a7be-b9e7-447d-9cbb-7db3577f72cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_a07a52c8-6141-495f-b259-50eebf7c59f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_4096a7be-b9e7-447d-9cbb-7db3577f72cd" xlink:to="loc_us-gaap_ForeignPlanMember_a07a52c8-6141-495f-b259-50eebf7c59f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_b1faf7cb-0c3a-4bd1-bbc6-88f4b75a1aa3" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ForeignPlanMember_a07a52c8-6141-495f-b259-50eebf7c59f2" xlink:to="loc_country_IE_b1faf7cb-0c3a-4bd1-bbc6-88f4b75a1aa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_b1cdc84f-faec-4813-b298-195115f7f464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_4096a7be-b9e7-447d-9cbb-7db3577f72cd" xlink:to="loc_us-gaap_DomesticPlanMember_b1cdc84f-faec-4813-b298-195115f7f464" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_3eb7059f-9da0-42c3-895b-00b72792ff34" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_b1cdc84f-faec-4813-b298-195115f7f464" xlink:to="loc_country_US_3eb7059f-9da0-42c3-895b-00b72792ff34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_8445c32b-afdf-4b8a-be69-f0f7c44dcf0a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_f960eebc-03f8-4f64-8c1f-780ed1a0e273" xlink:to="loc_srt_StatementScenarioAxis_8445c32b-afdf-4b8a-be69-f0f7c44dcf0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_8445c32b-afdf-4b8a-be69-f0f7c44dcf0a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_8445c32b-afdf-4b8a-be69-f0f7c44dcf0a" xlink:to="loc_srt_ScenarioUnspecifiedDomain_8445c32b-afdf-4b8a-be69-f0f7c44dcf0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_06ee79f1-91a8-427e-9106-c66e158d3fbd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_8445c32b-afdf-4b8a-be69-f0f7c44dcf0a" xlink:to="loc_srt_ScenarioUnspecifiedDomain_06ee79f1-91a8-427e-9106-c66e158d3fbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_fc7b57a5-47ae-4aa4-a004-7258811e9e13" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_06ee79f1-91a8-427e-9106-c66e158d3fbd" xlink:to="loc_srt_ScenarioForecastMember_fc7b57a5-47ae-4aa4-a004-7258811e9e13" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails" xlink:type="extended" id="i2556e6bfc6764d64bc564e07d56f0051_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_b73e4b90-c329-45d7-8a8b-3e4d9914c477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_db497d22-e23b-40f5-8f96-02ac63ec4da0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_b73e4b90-c329-45d7-8a8b-3e4d9914c477" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_db497d22-e23b-40f5-8f96-02ac63ec4da0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax_94058b63-1274-49ae-9af9-d5eb343348ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_b73e4b90-c329-45d7-8a8b-3e4d9914c477" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax_94058b63-1274-49ae-9af9-d5eb343348ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_41d453d1-c46f-4e67-afa6-0b8a2089d522" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_b73e4b90-c329-45d7-8a8b-3e4d9914c477" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_41d453d1-c46f-4e67-afa6-0b8a2089d522" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_b831d65b-2712-4649-9b13-c6fa039e2078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_41d453d1-c46f-4e67-afa6-0b8a2089d522" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_b831d65b-2712-4649-9b13-c6fa039e2078" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_b831d65b-2712-4649-9b13-c6fa039e2078_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_b831d65b-2712-4649-9b13-c6fa039e2078" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_b831d65b-2712-4649-9b13-c6fa039e2078_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_22ba916c-ccd7-4618-a2a3-c393a4f729e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_b831d65b-2712-4649-9b13-c6fa039e2078" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_22ba916c-ccd7-4618-a2a3-c393a4f729e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_82bb7eac-4e0d-418f-93e4-f545334675d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_22ba916c-ccd7-4618-a2a3-c393a4f729e7" xlink:to="loc_us-gaap_DomesticPlanMember_82bb7eac-4e0d-418f-93e4-f545334675d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2b1b6287-ab53-4668-80dd-4d9e91bf5a0a" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_82bb7eac-4e0d-418f-93e4-f545334675d6" xlink:to="loc_country_US_2b1b6287-ab53-4668-80dd-4d9e91bf5a0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_fe7c90f4-d1d6-41d7-b31b-e1e6cfcb80fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_22ba916c-ccd7-4618-a2a3-c393a4f729e7" xlink:to="loc_us-gaap_ForeignPlanMember_fe7c90f4-d1d6-41d7-b31b-e1e6cfcb80fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_4e98d54d-52d9-4d9e-a970-60737dbf5a54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_41d453d1-c46f-4e67-afa6-0b8a2089d522" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_4e98d54d-52d9-4d9e-a970-60737dbf5a54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_4e98d54d-52d9-4d9e-a970-60737dbf5a54_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_4e98d54d-52d9-4d9e-a970-60737dbf5a54" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_4e98d54d-52d9-4d9e-a970-60737dbf5a54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_51ad2b2a-b39e-440a-929e-a7a07444dbda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_4e98d54d-52d9-4d9e-a970-60737dbf5a54" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_51ad2b2a-b39e-440a-929e-a7a07444dbda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_b1eb889c-d06b-41ad-816e-0d831e301182" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_51ad2b2a-b39e-440a-929e-a7a07444dbda" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_b1eb889c-d06b-41ad-816e-0d831e301182" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_2d9aee09-daa9-46d9-9dc4-ce81db17bc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_51ad2b2a-b39e-440a-929e-a7a07444dbda" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_2d9aee09-daa9-46d9-9dc4-ce81db17bc6e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended" id="i856179db3c8a4acd93d3585adffeccce_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_19c7016a-a608-4d1d-bb80-2bb8ba517469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_564a0e7f-2116-475f-97c0-296abe7af786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_19c7016a-a608-4d1d-bb80-2bb8ba517469" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_564a0e7f-2116-475f-97c0-296abe7af786" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_92d85bcf-b9af-4993-91da-9fc7ed57c2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_19c7016a-a608-4d1d-bb80-2bb8ba517469" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_92d85bcf-b9af-4993-91da-9fc7ed57c2a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_1b6fb562-956f-45f9-a213-0ab6483624f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_19c7016a-a608-4d1d-bb80-2bb8ba517469" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_1b6fb562-956f-45f9-a213-0ab6483624f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_27de45d8-eafa-42fa-aaaf-76de58190bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_19c7016a-a608-4d1d-bb80-2bb8ba517469" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_27de45d8-eafa-42fa-aaaf-76de58190bc1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_80a99580-f902-4af7-9891-461cc2c4aa1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_19c7016a-a608-4d1d-bb80-2bb8ba517469" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_80a99580-f902-4af7-9891-461cc2c4aa1e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_a835f12f-e7b9-4c6a-aadf-1160f4756bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_19c7016a-a608-4d1d-bb80-2bb8ba517469" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_a835f12f-e7b9-4c6a-aadf-1160f4756bac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanOtherCosts_9e0ab437-abeb-4b93-804d-2e5cf744127e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanOtherCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_19c7016a-a608-4d1d-bb80-2bb8ba517469" xlink:to="loc_us-gaap_DefinedBenefitPlanOtherCosts_9e0ab437-abeb-4b93-804d-2e5cf744127e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e285e3f4-1fde-4330-96a1-351129c41fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_19c7016a-a608-4d1d-bb80-2bb8ba517469" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e285e3f4-1fde-4330-96a1-351129c41fdd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e5acbcdb-03b3-4ed5-8035-00751f36e2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_19c7016a-a608-4d1d-bb80-2bb8ba517469" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e5acbcdb-03b3-4ed5-8035-00751f36e2c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_c352abca-2d4d-4210-a929-5697d9f476ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e5acbcdb-03b3-4ed5-8035-00751f36e2c9" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_c352abca-2d4d-4210-a929-5697d9f476ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_c352abca-2d4d-4210-a929-5697d9f476ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_c352abca-2d4d-4210-a929-5697d9f476ba" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_c352abca-2d4d-4210-a929-5697d9f476ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_a687d319-71c1-4718-854e-237a854eaa79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_c352abca-2d4d-4210-a929-5697d9f476ba" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_a687d319-71c1-4718-854e-237a854eaa79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_fa6066ef-e426-4a09-9fec-ba8f7fc513d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_a687d319-71c1-4718-854e-237a854eaa79" xlink:to="loc_us-gaap_DomesticPlanMember_fa6066ef-e426-4a09-9fec-ba8f7fc513d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_035121eb-942e-4b95-9013-68adbf2d2226" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_fa6066ef-e426-4a09-9fec-ba8f7fc513d3" xlink:to="loc_country_US_035121eb-942e-4b95-9013-68adbf2d2226" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_158b361d-77d3-4e12-b96e-82cb28e6a24c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_a687d319-71c1-4718-854e-237a854eaa79" xlink:to="loc_us-gaap_ForeignPlanMember_158b361d-77d3-4e12-b96e-82cb28e6a24c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_7ed213eb-cc5b-477e-8f9c-dfc78e71829d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e5acbcdb-03b3-4ed5-8035-00751f36e2c9" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_7ed213eb-cc5b-477e-8f9c-dfc78e71829d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_7ed213eb-cc5b-477e-8f9c-dfc78e71829d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7ed213eb-cc5b-477e-8f9c-dfc78e71829d" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_7ed213eb-cc5b-477e-8f9c-dfc78e71829d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_00ae33f6-d0e8-450f-a907-d5a312cd5a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7ed213eb-cc5b-477e-8f9c-dfc78e71829d" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_00ae33f6-d0e8-450f-a907-d5a312cd5a4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_0f21ad1a-c8f9-4a2c-94a5-83cc549a9881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_00ae33f6-d0e8-450f-a907-d5a312cd5a4f" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_0f21ad1a-c8f9-4a2c-94a5-83cc549a9881" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_cee0ba5d-5a1c-4320-8d12-53e8a0cba9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_00ae33f6-d0e8-450f-a907-d5a312cd5a4f" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_cee0ba5d-5a1c-4320-8d12-53e8a0cba9cd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" xlink:type="extended" id="i137e8484308b40a8bc2da864f781ba11_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d61b6661-19dd-4b12-8229-99c1001da357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e2a4d12f-8819-4c00-81bc-92c1d279ea57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d61b6661-19dd-4b12-8229-99c1001da357" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e2a4d12f-8819-4c00-81bc-92c1d279ea57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_9e8bfa4a-85c6-4f86-8cec-8e38db78d454" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e2a4d12f-8819-4c00-81bc-92c1d279ea57" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_9e8bfa4a-85c6-4f86-8cec-8e38db78d454" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_da5ecc2f-8305-4261-adc8-e69e7ab3f69c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e2a4d12f-8819-4c00-81bc-92c1d279ea57" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_da5ecc2f-8305-4261-adc8-e69e7ab3f69c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_28d48546-f127-401d-8dce-0b3c11b8a771" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e2a4d12f-8819-4c00-81bc-92c1d279ea57" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_28d48546-f127-401d-8dce-0b3c11b8a771" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_28f54b81-b661-40bd-ada8-9ad6b86a33df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e2a4d12f-8819-4c00-81bc-92c1d279ea57" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_28f54b81-b661-40bd-ada8-9ad6b86a33df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_9105b36c-5b79-40ab-ae07-63065580bd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e2a4d12f-8819-4c00-81bc-92c1d279ea57" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_9105b36c-5b79-40ab-ae07-63065580bd4d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_3f2dc7e4-9217-4d94-941a-41b733ceb057" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e2a4d12f-8819-4c00-81bc-92c1d279ea57" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_3f2dc7e4-9217-4d94-941a-41b733ceb057" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_2499b4cc-8997-4169-b798-c1ef92e2554f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e2a4d12f-8819-4c00-81bc-92c1d279ea57" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_2499b4cc-8997-4169-b798-c1ef92e2554f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_ebc4a83a-effe-44c6-be9b-65aeb1f7cb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b8218252-ebc8-45b1-b89d-81b3ff647c82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d61b6661-19dd-4b12-8229-99c1001da357" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b8218252-ebc8-45b1-b89d-81b3ff647c82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_d22a6a83-851f-4385-b65d-020af9f76bee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b8218252-ebc8-45b1-b89d-81b3ff647c82" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_d22a6a83-851f-4385-b65d-020af9f76bee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_45629f40-b85c-443a-8606-8de7d0d64d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b8218252-ebc8-45b1-b89d-81b3ff647c82" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_45629f40-b85c-443a-8606-8de7d0d64d5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_5facfaec-e11c-4d79-8279-fbb7e7e74a17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b8218252-ebc8-45b1-b89d-81b3ff647c82" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_5facfaec-e11c-4d79-8279-fbb7e7e74a17" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_fdb7fcae-1a66-4f99-9a38-77806316dd25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b8218252-ebc8-45b1-b89d-81b3ff647c82" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_fdb7fcae-1a66-4f99-9a38-77806316dd25" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_4faf4759-0d18-45db-a515-05830b80a23e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b8218252-ebc8-45b1-b89d-81b3ff647c82" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_4faf4759-0d18-45db-a515-05830b80a23e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_f6eb72a7-6ba1-4cbb-85e2-fbf69f940354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b8218252-ebc8-45b1-b89d-81b3ff647c82" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_f6eb72a7-6ba1-4cbb-85e2-fbf69f940354" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_f87aac9f-9e1e-47c6-a09d-f1ca11f597f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_cfa49a4b-2450-4534-9291-768e581d529e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d61b6661-19dd-4b12-8229-99c1001da357" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_cfa49a4b-2450-4534-9291-768e581d529e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_2e7b3628-854f-4f90-a8f6-1256802e9c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d61b6661-19dd-4b12-8229-99c1001da357" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_2e7b3628-854f-4f90-a8f6-1256802e9c1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent_66a08477-3883-4da8-85f9-05c4cd82a22f" xlink:href="bhc-20220510.xsd#bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_2e7b3628-854f-4f90-a8f6-1256802e9c1f" xlink:to="loc_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent_66a08477-3883-4da8-85f9-05c4cd82a22f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities_75b1d0f5-e84d-4fdf-a083-a02014015cad" xlink:href="bhc-20220510.xsd#bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_2e7b3628-854f-4f90-a8f6-1256802e9c1f" xlink:to="loc_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities_75b1d0f5-e84d-4fdf-a083-a02014015cad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_82a18af1-0cef-41ee-8ed9-a0a7c4fd1816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_2e7b3628-854f-4f90-a8f6-1256802e9c1f" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_82a18af1-0cef-41ee-8ed9-a0a7c4fd1816" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f2b8fc13-1df6-4b42-b352-2f9c1da3e79f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d61b6661-19dd-4b12-8229-99c1001da357" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f2b8fc13-1df6-4b42-b352-2f9c1da3e79f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_fb14848c-2893-4d67-94f1-3d2ca297149e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f2b8fc13-1df6-4b42-b352-2f9c1da3e79f" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_fb14848c-2893-4d67-94f1-3d2ca297149e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_fb14848c-2893-4d67-94f1-3d2ca297149e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_fb14848c-2893-4d67-94f1-3d2ca297149e" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_fb14848c-2893-4d67-94f1-3d2ca297149e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_cadffd88-22ee-4d85-b3c2-38ce59f5369a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_fb14848c-2893-4d67-94f1-3d2ca297149e" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_cadffd88-22ee-4d85-b3c2-38ce59f5369a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_d38b9f7d-b2d7-4861-a7e1-522c99f53979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_cadffd88-22ee-4d85-b3c2-38ce59f5369a" xlink:to="loc_us-gaap_DomesticPlanMember_d38b9f7d-b2d7-4861-a7e1-522c99f53979" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_fddeb17f-75a0-4ad0-b3a4-ded78c86aeee" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_d38b9f7d-b2d7-4861-a7e1-522c99f53979" xlink:to="loc_country_US_fddeb17f-75a0-4ad0-b3a4-ded78c86aeee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_ff2b07dc-7d62-4b96-a0f1-4c9c6f407071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_cadffd88-22ee-4d85-b3c2-38ce59f5369a" xlink:to="loc_us-gaap_ForeignPlanMember_ff2b07dc-7d62-4b96-a0f1-4c9c6f407071" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_bf250bdd-4fba-4d93-a7c1-03e45a4ab0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f2b8fc13-1df6-4b42-b352-2f9c1da3e79f" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_bf250bdd-4fba-4d93-a7c1-03e45a4ab0a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_bf250bdd-4fba-4d93-a7c1-03e45a4ab0a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_bf250bdd-4fba-4d93-a7c1-03e45a4ab0a8" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_bf250bdd-4fba-4d93-a7c1-03e45a4ab0a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_b247ee25-be14-489c-b607-9fac6d461a20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_bf250bdd-4fba-4d93-a7c1-03e45a4ab0a8" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_b247ee25-be14-489c-b607-9fac6d461a20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_af588c5f-aac2-48a8-8df5-9a62df0b29c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_b247ee25-be14-489c-b607-9fac6d461a20" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_af588c5f-aac2-48a8-8df5-9a62df0b29c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_85e83372-4742-4dfa-a141-0f0b10e44eae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_b247ee25-be14-489c-b607-9fac6d461a20" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_85e83372-4742-4dfa-a141-0f0b10e44eae" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails" xlink:type="extended" id="ib1a9684a541047b8b0736ba8ac26f22e_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4252150f-96d4-4b6a-8b22-68f8b8c9234c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_4bf2b324-2189-4d72-bf8e-e102103851fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4252150f-96d4-4b6a-8b22-68f8b8c9234c" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_4bf2b324-2189-4d72-bf8e-e102103851fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_57a03bfe-0403-4f3f-9f6a-5f3fc95af4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_4bf2b324-2189-4d72-bf8e-e102103851fd" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_57a03bfe-0403-4f3f-9f6a-5f3fc95af4e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_5b2d752d-f04a-4ccc-9fa3-232ee330c5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_4bf2b324-2189-4d72-bf8e-e102103851fd" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_5b2d752d-f04a-4ccc-9fa3-232ee330c5dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_bee71353-8978-41f8-86a3-8cb976a5e627" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_4bf2b324-2189-4d72-bf8e-e102103851fd" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_bee71353-8978-41f8-86a3-8cb976a5e627" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_44cea9ea-3a9b-42fe-9072-005531e0b2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4252150f-96d4-4b6a-8b22-68f8b8c9234c" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_44cea9ea-3a9b-42fe-9072-005531e0b2ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_c000eee8-e9c7-4dca-9ab8-dec2edf61f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_44cea9ea-3a9b-42fe-9072-005531e0b2ed" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_c000eee8-e9c7-4dca-9ab8-dec2edf61f6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_c000eee8-e9c7-4dca-9ab8-dec2edf61f6e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_c000eee8-e9c7-4dca-9ab8-dec2edf61f6e" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_c000eee8-e9c7-4dca-9ab8-dec2edf61f6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_9c193dc4-28ce-4809-90c0-f3de9ebf808e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_c000eee8-e9c7-4dca-9ab8-dec2edf61f6e" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_9c193dc4-28ce-4809-90c0-f3de9ebf808e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_c078ff49-640f-427a-bed3-9eba5bf24d43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_9c193dc4-28ce-4809-90c0-f3de9ebf808e" xlink:to="loc_us-gaap_DomesticPlanMember_c078ff49-640f-427a-bed3-9eba5bf24d43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0f312417-f0cb-4b14-9be4-7801a72ab1fe" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_c078ff49-640f-427a-bed3-9eba5bf24d43" xlink:to="loc_country_US_0f312417-f0cb-4b14-9be4-7801a72ab1fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_38894763-8c74-478d-9cde-9e4960157d76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_9c193dc4-28ce-4809-90c0-f3de9ebf808e" xlink:to="loc_us-gaap_ForeignPlanMember_38894763-8c74-478d-9cde-9e4960157d76" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails" xlink:type="extended" id="icf6ffd687d754f1fac1de92f759c4576_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_0e54b61e-b33e-4ac8-8204-1735d56b5ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_b587b12b-f56d-425e-bcbc-1bfc79abd4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_0e54b61e-b33e-4ac8-8204-1735d56b5ab1" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_b587b12b-f56d-425e-bcbc-1bfc79abd4ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_02dbcf8e-c558-4f19-bab8-ad57319acbf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_0e54b61e-b33e-4ac8-8204-1735d56b5ab1" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_02dbcf8e-c558-4f19-bab8-ad57319acbf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_6f7367f4-ae83-4cd8-8c87-45da0acf20f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_0e54b61e-b33e-4ac8-8204-1735d56b5ab1" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_6f7367f4-ae83-4cd8-8c87-45da0acf20f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_fbaf3f80-87e6-404e-a65a-7b3c84f42a52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_0e54b61e-b33e-4ac8-8204-1735d56b5ab1" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_fbaf3f80-87e6-404e-a65a-7b3c84f42a52" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_58a21ac6-cb63-4944-957c-da8ff16eec66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_0e54b61e-b33e-4ac8-8204-1735d56b5ab1" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_58a21ac6-cb63-4944-957c-da8ff16eec66" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_ae3d2320-9036-4f56-971f-3f81bab5e36c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_0e54b61e-b33e-4ac8-8204-1735d56b5ab1" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_ae3d2320-9036-4f56-971f-3f81bab5e36c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7bc68ddf-bcc8-4860-a736-51ef47532435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_0e54b61e-b33e-4ac8-8204-1735d56b5ab1" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7bc68ddf-bcc8-4860-a736-51ef47532435" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_68d36885-c845-4d99-897b-5facd339cb76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7bc68ddf-bcc8-4860-a736-51ef47532435" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_68d36885-c845-4d99-897b-5facd339cb76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_68d36885-c845-4d99-897b-5facd339cb76_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_68d36885-c845-4d99-897b-5facd339cb76" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_68d36885-c845-4d99-897b-5facd339cb76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_72a01d2f-3418-4849-aca8-8f019ad83aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_68d36885-c845-4d99-897b-5facd339cb76" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_72a01d2f-3418-4849-aca8-8f019ad83aea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_141047f6-283b-47b5-8b18-3b9c66e27181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_72a01d2f-3418-4849-aca8-8f019ad83aea" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_141047f6-283b-47b5-8b18-3b9c66e27181" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_88df3ea4-147b-47de-9fbc-26e2d75856f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_72a01d2f-3418-4849-aca8-8f019ad83aea" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_88df3ea4-147b-47de-9fbc-26e2d75856f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_077fa40f-fe3e-431f-a6bb-323ab10999fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7bc68ddf-bcc8-4860-a736-51ef47532435" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_077fa40f-fe3e-431f-a6bb-323ab10999fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_077fa40f-fe3e-431f-a6bb-323ab10999fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_077fa40f-fe3e-431f-a6bb-323ab10999fb" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_077fa40f-fe3e-431f-a6bb-323ab10999fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_6a4120ef-cbf1-4f4f-8f3c-cee99d7b7faf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_077fa40f-fe3e-431f-a6bb-323ab10999fb" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_6a4120ef-cbf1-4f4f-8f3c-cee99d7b7faf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_6eb8632d-d922-4728-99c7-7cdcbd06af96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_6a4120ef-cbf1-4f4f-8f3c-cee99d7b7faf" xlink:to="loc_us-gaap_DomesticPlanMember_6eb8632d-d922-4728-99c7-7cdcbd06af96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0169cb29-6d72-4487-b58f-4f47d1b021ab" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_6eb8632d-d922-4728-99c7-7cdcbd06af96" xlink:to="loc_country_US_0169cb29-6d72-4487-b58f-4f47d1b021ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_ed95aa34-33c4-4838-9ff1-cbe535a3af31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_6a4120ef-cbf1-4f4f-8f3c-cee99d7b7faf" xlink:to="loc_us-gaap_ForeignPlanMember_ed95aa34-33c4-4838-9ff1-cbe535a3af31" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails" xlink:type="extended" id="i6616fd8c497e4e06958f39cb0220d84e_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ff459615-37a0-415f-aabb-a4b75cfc0c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_6a5b88b0-ee91-4010-805d-c6bf02a87d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ff459615-37a0-415f-aabb-a4b75cfc0c1a" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_6a5b88b0-ee91-4010-805d-c6bf02a87d1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_59b71b5e-86b1-414d-b742-54b3c68b8320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_6a5b88b0-ee91-4010-805d-c6bf02a87d1e" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_59b71b5e-86b1-414d-b742-54b3c68b8320" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_ddb68331-9879-4b13-8a5a-14344a88d1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_6a5b88b0-ee91-4010-805d-c6bf02a87d1e" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_ddb68331-9879-4b13-8a5a-14344a88d1d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_798551ad-6072-414a-a15e-80dcbffbca95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_6a5b88b0-ee91-4010-805d-c6bf02a87d1e" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_798551ad-6072-414a-a15e-80dcbffbca95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_bc6c3a68-73cb-4e49-be98-e45cac239fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_6a5b88b0-ee91-4010-805d-c6bf02a87d1e" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_bc6c3a68-73cb-4e49-be98-e45cac239fe7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_a46016f3-8931-4894-9d95-1a93b4b86c65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ff459615-37a0-415f-aabb-a4b75cfc0c1a" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_a46016f3-8931-4894-9d95-1a93b4b86c65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_8d321fb1-9aa5-4ab7-adb2-7f1cfea95e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_a46016f3-8931-4894-9d95-1a93b4b86c65" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_8d321fb1-9aa5-4ab7-adb2-7f1cfea95e1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_aa6269bb-f11d-47c4-b97b-a9b90e929279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_a46016f3-8931-4894-9d95-1a93b4b86c65" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_aa6269bb-f11d-47c4-b97b-a9b90e929279" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_d9d83d47-69c9-4c73-a0fc-271ee3d85def" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_a46016f3-8931-4894-9d95-1a93b4b86c65" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_d9d83d47-69c9-4c73-a0fc-271ee3d85def" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_50a282df-a7c1-4e2d-98d5-53bac037b649" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ff459615-37a0-415f-aabb-a4b75cfc0c1a" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_50a282df-a7c1-4e2d-98d5-53bac037b649" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_dd099264-4dd9-483a-9a87-d54f224a43e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_50a282df-a7c1-4e2d-98d5-53bac037b649" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_dd099264-4dd9-483a-9a87-d54f224a43e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_dd099264-4dd9-483a-9a87-d54f224a43e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_dd099264-4dd9-483a-9a87-d54f224a43e4" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_dd099264-4dd9-483a-9a87-d54f224a43e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_9aa4f797-8835-450f-ab06-1c3b5c0402ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_dd099264-4dd9-483a-9a87-d54f224a43e4" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_9aa4f797-8835-450f-ab06-1c3b5c0402ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_39a0756a-7579-4813-aca2-3ec63de928eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9aa4f797-8835-450f-ab06-1c3b5c0402ba" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_39a0756a-7579-4813-aca2-3ec63de928eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_e6f16dd8-4fd7-4a34-9297-eb417e8a9e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9aa4f797-8835-450f-ab06-1c3b5c0402ba" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_e6f16dd8-4fd7-4a34-9297-eb417e8a9e9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_94e25901-208f-461a-a0e2-a8ea3ac63e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_50a282df-a7c1-4e2d-98d5-53bac037b649" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_94e25901-208f-461a-a0e2-a8ea3ac63e6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_94e25901-208f-461a-a0e2-a8ea3ac63e6e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_94e25901-208f-461a-a0e2-a8ea3ac63e6e" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_94e25901-208f-461a-a0e2-a8ea3ac63e6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_140f9c4d-a92a-46a9-a1da-12cd06544d76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_94e25901-208f-461a-a0e2-a8ea3ac63e6e" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_140f9c4d-a92a-46a9-a1da-12cd06544d76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_e0f292db-92fb-4d15-847f-1a2cd03583ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_140f9c4d-a92a-46a9-a1da-12cd06544d76" xlink:to="loc_us-gaap_DomesticPlanMember_e0f292db-92fb-4d15-847f-1a2cd03583ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b82bebc8-7d26-43cd-8926-2a3497f801bb" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_e0f292db-92fb-4d15-847f-1a2cd03583ae" xlink:to="loc_country_US_b82bebc8-7d26-43cd-8926-2a3497f801bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_8cd5df5d-89cc-4098-b793-f86294e20c99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_140f9c4d-a92a-46a9-a1da-12cd06544d76" xlink:to="loc_us-gaap_ForeignPlanMember_8cd5df5d-89cc-4098-b793-f86294e20c99" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails" xlink:type="extended" id="i56f81a4ea68a48248a301945d88bd27e_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_438eb7dd-60cb-464a-92e1-e191044b176e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_4ef21b86-4504-4923-9c6b-24834408b175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_438eb7dd-60cb-464a-92e1-e191044b176e" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_4ef21b86-4504-4923-9c6b-24834408b175" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_3d8ce808-3971-4d96-9249-80a7d7d0342a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_438eb7dd-60cb-464a-92e1-e191044b176e" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_3d8ce808-3971-4d96-9249-80a7d7d0342a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_7b805b9f-776f-4819-93e7-222559342789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_3d8ce808-3971-4d96-9249-80a7d7d0342a" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_7b805b9f-776f-4819-93e7-222559342789" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_7b805b9f-776f-4819-93e7-222559342789_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7b805b9f-776f-4819-93e7-222559342789" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_7b805b9f-776f-4819-93e7-222559342789_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_f06c5936-be38-4823-b665-8f1064a6b82e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7b805b9f-776f-4819-93e7-222559342789" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_f06c5936-be38-4823-b665-8f1064a6b82e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_88249192-7f91-439d-aa41-6490aef83e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_f06c5936-be38-4823-b665-8f1064a6b82e" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_88249192-7f91-439d-aa41-6490aef83e77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_5fb2600b-b467-4104-b38c-604ebb4dfea6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_3d8ce808-3971-4d96-9249-80a7d7d0342a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_5fb2600b-b467-4104-b38c-604ebb4dfea6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_5fb2600b-b467-4104-b38c-604ebb4dfea6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_5fb2600b-b467-4104-b38c-604ebb4dfea6" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_5fb2600b-b467-4104-b38c-604ebb4dfea6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_c0e6efcc-e0a5-4a54-a543-5cbbd9c44efa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_5fb2600b-b467-4104-b38c-604ebb4dfea6" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_c0e6efcc-e0a5-4a54-a543-5cbbd9c44efa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_7c584534-c866-4b4e-a0d2-8172cd4e417b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c0e6efcc-e0a5-4a54-a543-5cbbd9c44efa" xlink:to="loc_us-gaap_DomesticPlanMember_7c584534-c866-4b4e-a0d2-8172cd4e417b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ec7a6f9b-0924-4aaf-9c5f-2244fee1a2a9" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_7c584534-c866-4b4e-a0d2-8172cd4e417b" xlink:to="loc_country_US_ec7a6f9b-0924-4aaf-9c5f-2244fee1a2a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_ffd45302-908d-48cb-a5c1-360b8c4bf247" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c0e6efcc-e0a5-4a54-a543-5cbbd9c44efa" xlink:to="loc_us-gaap_ForeignPlanMember_ffd45302-908d-48cb-a5c1-360b8c4bf247" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_f7cc2296-9c1e-4d42-8529-4fb6c8e59255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_3d8ce808-3971-4d96-9249-80a7d7d0342a" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_f7cc2296-9c1e-4d42-8529-4fb6c8e59255" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_f7cc2296-9c1e-4d42-8529-4fb6c8e59255_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_f7cc2296-9c1e-4d42-8529-4fb6c8e59255" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_f7cc2296-9c1e-4d42-8529-4fb6c8e59255_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_6ff92a7b-9162-4065-b849-e85dd534241c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_f7cc2296-9c1e-4d42-8529-4fb6c8e59255" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_6ff92a7b-9162-4065-b849-e85dd534241c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_d5aa96b0-27c0-4d5b-a051-e85efee33cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_6ff92a7b-9162-4065-b849-e85dd534241c" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_d5aa96b0-27c0-4d5b-a051-e85efee33cd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_2ec6d5a6-6a5b-49cd-b107-11290ce533ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_6ff92a7b-9162-4065-b849-e85dd534241c" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_2ec6d5a6-6a5b-49cd-b107-11290ce533ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeSecuritiesMember_b6bc27ce-53f2-4963-afb2-91679bb56a87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FixedIncomeSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_6ff92a7b-9162-4065-b849-e85dd534241c" xlink:to="loc_us-gaap_FixedIncomeSecuritiesMember_b6bc27ce-53f2-4963-afb2-91679bb56a87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_57a8929a-336b-4486-b508-8e4b88007d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_6ff92a7b-9162-4065-b849-e85dd534241c" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_57a8929a-336b-4486-b508-8e4b88007d9a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails" xlink:type="extended" id="i3b4e6d176d1c437f8086d7d2928a46b5_PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_b8aedcaa-2800-44aa-a4fd-6724ef6be8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_c814d3aa-fbe5-4f5b-8acb-fe79edc31808" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_b8aedcaa-2800-44aa-a4fd-6724ef6be8b4" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_c814d3aa-fbe5-4f5b-8acb-fe79edc31808" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2aa567e5-f71c-4ed8-b614-4466ce4afdfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_b8aedcaa-2800-44aa-a4fd-6724ef6be8b4" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2aa567e5-f71c-4ed8-b614-4466ce4afdfd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_2fb2b777-c0a5-4fb6-aa00-6c202f08f00e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2aa567e5-f71c-4ed8-b614-4466ce4afdfd" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_2fb2b777-c0a5-4fb6-aa00-6c202f08f00e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_2fb2b777-c0a5-4fb6-aa00-6c202f08f00e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_2fb2b777-c0a5-4fb6-aa00-6c202f08f00e" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_2fb2b777-c0a5-4fb6-aa00-6c202f08f00e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_ea6eaed0-dd9d-49c4-9c1e-b0e92a16a599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_2fb2b777-c0a5-4fb6-aa00-6c202f08f00e" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_ea6eaed0-dd9d-49c4-9c1e-b0e92a16a599" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_df9d6605-3728-4879-8987-8bb1b387b265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_ea6eaed0-dd9d-49c4-9c1e-b0e92a16a599" xlink:to="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_df9d6605-3728-4879-8987-8bb1b387b265" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_14c81246-9159-401b-a411-0519b7c4f357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_ea6eaed0-dd9d-49c4-9c1e-b0e92a16a599" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_14c81246-9159-401b-a411-0519b7c4f357" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_U.S.BroadMarketMember_51968391-5fea-4d5c-adf0-e7c1743429fc" xlink:href="bhc-20220510.xsd#bhc_U.S.BroadMarketMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_14c81246-9159-401b-a411-0519b7c4f357" xlink:to="loc_bhc_U.S.BroadMarketMember_51968391-5fea-4d5c-adf0-e7c1743429fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmergingMarketsMember_a35a91ac-bb37-48d9-a147-4a56549bf549" xlink:href="bhc-20220510.xsd#bhc_EmergingMarketsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_14c81246-9159-401b-a411-0519b7c4f357" xlink:to="loc_bhc_EmergingMarketsMember_a35a91ac-bb37-48d9-a147-4a56549bf549" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonU.S.DevelopedMarketsMember_75823986-4ac5-445d-987a-fb5d432cc68c" xlink:href="bhc-20220510.xsd#bhc_NonU.S.DevelopedMarketsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_14c81246-9159-401b-a411-0519b7c4f357" xlink:to="loc_bhc_NonU.S.DevelopedMarketsMember_75823986-4ac5-445d-987a-fb5d432cc68c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonU.S.OtherAssetsMember_c7860208-56c3-4fc2-a344-be925d8d8c14" xlink:href="bhc-20220510.xsd#bhc_NonU.S.OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_14c81246-9159-401b-a411-0519b7c4f357" xlink:to="loc_bhc_NonU.S.OtherAssetsMember_c7860208-56c3-4fc2-a344-be925d8d8c14" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeSecuritiesMember_e9fabdf1-9457-430c-9a7b-52a93e408889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FixedIncomeSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_ea6eaed0-dd9d-49c4-9c1e-b0e92a16a599" xlink:to="loc_us-gaap_FixedIncomeSecuritiesMember_e9fabdf1-9457-430c-9a7b-52a93e408889" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InvestmentGradeMember_6e74c39b-5db3-437d-9549-a73da25365ce" xlink:href="bhc-20220510.xsd#bhc_InvestmentGradeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FixedIncomeSecuritiesMember_e9fabdf1-9457-430c-9a7b-52a93e408889" xlink:to="loc_bhc_InvestmentGradeMember_6e74c39b-5db3-437d-9549-a73da25365ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlobalHighYieldMember_8da55feb-4fe1-48e7-980c-175a53bc7dbb" xlink:href="bhc-20220510.xsd#bhc_GlobalHighYieldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FixedIncomeSecuritiesMember_e9fabdf1-9457-430c-9a7b-52a93e408889" xlink:to="loc_bhc_GlobalHighYieldMember_8da55feb-4fe1-48e7-980c-175a53bc7dbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_9f07e8b4-3bc8-4f00-bb30-ad1bb1bd9a89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FixedIncomeSecuritiesMember_e9fabdf1-9457-430c-9a7b-52a93e408889" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_9f07e8b4-3bc8-4f00-bb30-ad1bb1bd9a89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherAssetsFixedIncomeSecuritiesMember_c9749f10-21db-41b3-9304-633944bbedf8" xlink:href="bhc-20220510.xsd#bhc_OtherAssetsFixedIncomeSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_ea6eaed0-dd9d-49c4-9c1e-b0e92a16a599" xlink:to="loc_bhc_OtherAssetsFixedIncomeSecuritiesMember_c9749f10-21db-41b3-9304-633944bbedf8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7ab18cad-fd6c-402f-ad7f-aa4c48ce65bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2aa567e5-f71c-4ed8-b614-4466ce4afdfd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7ab18cad-fd6c-402f-ad7f-aa4c48ce65bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7ab18cad-fd6c-402f-ad7f-aa4c48ce65bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7ab18cad-fd6c-402f-ad7f-aa4c48ce65bd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7ab18cad-fd6c-402f-ad7f-aa4c48ce65bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4d51e755-624d-4abc-8e15-276e1388aa7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7ab18cad-fd6c-402f-ad7f-aa4c48ce65bd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4d51e755-624d-4abc-8e15-276e1388aa7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7ca9df74-8d9f-4663-a9d6-a35f21eb9295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4d51e755-624d-4abc-8e15-276e1388aa7b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7ca9df74-8d9f-4663-a9d6-a35f21eb9295" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_baafa9a0-51ff-4aae-942b-f1345fbd0fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4d51e755-624d-4abc-8e15-276e1388aa7b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_baafa9a0-51ff-4aae-942b-f1345fbd0fd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e22990e7-bdcd-44c8-9f32-8735a3e2ed07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4d51e755-624d-4abc-8e15-276e1388aa7b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e22990e7-bdcd-44c8-9f32-8735a3e2ed07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_50995c53-0354-47a9-a8c0-93c7ba9e684c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2aa567e5-f71c-4ed8-b614-4466ce4afdfd" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_50995c53-0354-47a9-a8c0-93c7ba9e684c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_50995c53-0354-47a9-a8c0-93c7ba9e684c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_50995c53-0354-47a9-a8c0-93c7ba9e684c" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_50995c53-0354-47a9-a8c0-93c7ba9e684c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_5a9f616d-582c-447c-88fc-51774942f3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_50995c53-0354-47a9-a8c0-93c7ba9e684c" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_5a9f616d-582c-447c-88fc-51774942f3f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_18f7a420-d3bf-4269-8dab-42be1e020c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_5a9f616d-582c-447c-88fc-51774942f3f0" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_18f7a420-d3bf-4269-8dab-42be1e020c1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_39e2fe48-a24a-47aa-b8c4-609a6eba82db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2aa567e5-f71c-4ed8-b614-4466ce4afdfd" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_39e2fe48-a24a-47aa-b8c4-609a6eba82db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_39e2fe48-a24a-47aa-b8c4-609a6eba82db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_39e2fe48-a24a-47aa-b8c4-609a6eba82db" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_39e2fe48-a24a-47aa-b8c4-609a6eba82db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_09d7f70d-67e1-45cd-8fcb-fe55324da5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_39e2fe48-a24a-47aa-b8c4-609a6eba82db" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_09d7f70d-67e1-45cd-8fcb-fe55324da5a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_22bdd46b-9fa4-414e-925a-035a5b69eee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_09d7f70d-67e1-45cd-8fcb-fe55324da5a7" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_22bdd46b-9fa4-414e-925a-035a5b69eee2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_f1a4c208-8aca-4c83-8846-66966b35e6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2aa567e5-f71c-4ed8-b614-4466ce4afdfd" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_f1a4c208-8aca-4c83-8846-66966b35e6dc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_f1a4c208-8aca-4c83-8846-66966b35e6dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_f1a4c208-8aca-4c83-8846-66966b35e6dc" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_f1a4c208-8aca-4c83-8846-66966b35e6dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_df0831a6-aebf-451c-8455-3d0a0be1de4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_f1a4c208-8aca-4c83-8846-66966b35e6dc" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_df0831a6-aebf-451c-8455-3d0a0be1de4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_94a0165a-318f-4087-ae5c-06089150bc13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_df0831a6-aebf-451c-8455-3d0a0be1de4b" xlink:to="loc_us-gaap_DomesticPlanMember_94a0165a-318f-4087-ae5c-06089150bc13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_06453b4b-0cec-47eb-a8ff-27a75c7cfb6f" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_94a0165a-318f-4087-ae5c-06089150bc13" xlink:to="loc_country_US_06453b4b-0cec-47eb-a8ff-27a75c7cfb6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_50e55283-96d4-4537-afd5-93d947b8ebae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_df0831a6-aebf-451c-8455-3d0a0be1de4b" xlink:to="loc_us-gaap_ForeignPlanMember_50e55283-96d4-4537-afd5-93d947b8ebae" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended" id="ia9fa0a0f1c2143c1a553251c4c56e437_SHAREBASEDCOMPENSATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6e7a354-46e4-4201-bdf3-114cad18d3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e0372654-9aa9-4acf-8843-29c334fc4943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6e7a354-46e4-4201-bdf3-114cad18d3e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e0372654-9aa9-4acf-8843-29c334fc4943" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0b29049f-3ae9-4498-8063-f8264ae2e202" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6e7a354-46e4-4201-bdf3-114cad18d3e5" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0b29049f-3ae9-4498-8063-f8264ae2e202" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b432f1cc-64c9-48c3-90a4-a478f05ea699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6e7a354-46e4-4201-bdf3-114cad18d3e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b432f1cc-64c9-48c3-90a4-a478f05ea699" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant_235ebd7f-58fe-46ce-8960-8c806262f805" xlink:href="bhc-20220510.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6e7a354-46e4-4201-bdf3-114cad18d3e5" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant_235ebd7f-58fe-46ce-8960-8c806262f805" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_aa05c965-0882-42fb-af67-4b58164bb4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6e7a354-46e4-4201-bdf3-114cad18d3e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_aa05c965-0882-42fb-af67-4b58164bb4a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c61be85a-80aa-404c-8a00-c80bb323a632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6e7a354-46e4-4201-bdf3-114cad18d3e5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c61be85a-80aa-404c-8a00-c80bb323a632" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_c595073e-9ca8-4f79-aa04-284ab0f19e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c61be85a-80aa-404c-8a00-c80bb323a632" xlink:to="loc_us-gaap_PlanNameAxis_c595073e-9ca8-4f79-aa04-284ab0f19e2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c595073e-9ca8-4f79-aa04-284ab0f19e2a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_c595073e-9ca8-4f79-aa04-284ab0f19e2a" xlink:to="loc_us-gaap_PlanNameDomain_c595073e-9ca8-4f79-aa04-284ab0f19e2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b5c646e5-9b11-4679-b67a-7d796d60f867" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_c595073e-9ca8-4f79-aa04-284ab0f19e2a" xlink:to="loc_us-gaap_PlanNameDomain_b5c646e5-9b11-4679-b67a-7d796d60f867" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014Member_b495dadb-d239-49fe-902d-7eeb7f8458b9" xlink:href="bhc-20220510.xsd#bhc_OmnibusIncentivePlan2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b5c646e5-9b11-4679-b67a-7d796d60f867" xlink:to="loc_bhc_OmnibusIncentivePlan2014Member_b495dadb-d239-49fe-902d-7eeb7f8458b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_cf40e670-388c-450b-ba0c-b7cbd884798a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c61be85a-80aa-404c-8a00-c80bb323a632" xlink:to="loc_srt_TitleOfIndividualAxis_cf40e670-388c-450b-ba0c-b7cbd884798a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_cf40e670-388c-450b-ba0c-b7cbd884798a_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_cf40e670-388c-450b-ba0c-b7cbd884798a" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_cf40e670-388c-450b-ba0c-b7cbd884798a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ac1c769d-64eb-4574-a3c4-2b9fd8de8069" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_cf40e670-388c-450b-ba0c-b7cbd884798a" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ac1c769d-64eb-4574-a3c4-2b9fd8de8069" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonemployeeDirectorMember_22445c15-2dc4-46df-ae94-acd00f8939a3" xlink:href="bhc-20220510.xsd#bhc_NonemployeeDirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ac1c769d-64eb-4574-a3c4-2b9fd8de8069" xlink:to="loc_bhc_NonemployeeDirectorMember_22445c15-2dc4-46df-ae94-acd00f8939a3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="extended" id="ifa701348ea7e464c974f5cf213178669_SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31d61191-2236-412f-8b87-9b4476f01be5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d27f292c-c094-4948-84f0-54584fd69306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31d61191-2236-412f-8b87-9b4476f01be5" xlink:to="loc_us-gaap_ShareBasedCompensation_d27f292c-c094-4948-84f0-54584fd69306" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a8f0b622-9d81-4ea7-a28d-b09fface19c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31d61191-2236-412f-8b87-9b4476f01be5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a8f0b622-9d81-4ea7-a28d-b09fface19c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_90448cf6-3634-4663-9cc4-cdf71ab73cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a8f0b622-9d81-4ea7-a28d-b09fface19c3" xlink:to="loc_us-gaap_AwardTypeAxis_90448cf6-3634-4663-9cc4-cdf71ab73cb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90448cf6-3634-4663-9cc4-cdf71ab73cb6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_90448cf6-3634-4663-9cc4-cdf71ab73cb6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_90448cf6-3634-4663-9cc4-cdf71ab73cb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53ff4121-7c0f-41eb-99db-29cd1f23c5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_90448cf6-3634-4663-9cc4-cdf71ab73cb6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53ff4121-7c0f-41eb-99db-29cd1f23c5e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_84c9108a-e189-491e-aa4c-a12d5e36b0be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53ff4121-7c0f-41eb-99db-29cd1f23c5e0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_84c9108a-e189-491e-aa4c-a12d5e36b0be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_fe5b3dd6-9cd7-4909-b423-5bd1e94bafec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53ff4121-7c0f-41eb-99db-29cd1f23c5e0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_fe5b3dd6-9cd7-4909-b423-5bd1e94bafec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1b8b3504-9e34-4e4d-abbf-46850e21fef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a8f0b622-9d81-4ea7-a28d-b09fface19c3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1b8b3504-9e34-4e4d-abbf-46850e21fef1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1b8b3504-9e34-4e4d-abbf-46850e21fef1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1b8b3504-9e34-4e4d-abbf-46850e21fef1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1b8b3504-9e34-4e4d-abbf-46850e21fef1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_35d1ea5b-ee69-4d97-895e-68a8baef1ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1b8b3504-9e34-4e4d-abbf-46850e21fef1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_35d1ea5b-ee69-4d97-895e-68a8baef1ac6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2f00596e-a91d-4c23-bf57-24404a18ee49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_35d1ea5b-ee69-4d97-895e-68a8baef1ac6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2f00596e-a91d-4c23-bf57-24404a18ee49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SellingGeneralAndAdministrativeExpenseMember_25616d48-31b2-4bc3-9f09-0a7746775300" xlink:href="bhc-20220510.xsd#bhc_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_35d1ea5b-ee69-4d97-895e-68a8baef1ac6" xlink:to="loc_bhc_SellingGeneralAndAdministrativeExpenseMember_25616d48-31b2-4bc3-9f09-0a7746775300" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SHAREBASEDCOMPENSATIONStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" xlink:type="extended" id="i5d41210a0b5d4df0bd027aa4ca0570d1_SHAREBASEDCOMPENSATIONStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95ca2795-8500-4064-828a-02d750a1030f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_331e480f-4540-4f0c-ab1a-5bfef18e5c2f" xlink:href="bhc-20220510.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95ca2795-8500-4064-828a-02d750a1030f" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_331e480f-4540-4f0c-ab1a-5bfef18e5c2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b268bb25-6af3-4d2e-a173-4478f939a635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95ca2795-8500-4064-828a-02d750a1030f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b268bb25-6af3-4d2e-a173-4478f939a635" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_5f7b672b-2ff0-4315-a899-9a616bced5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95ca2795-8500-4064-828a-02d750a1030f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_5f7b672b-2ff0-4315-a899-9a616bced5e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_aeb5cd02-f786-457e-aa79-fdc51564cc21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_5f7b672b-2ff0-4315-a899-9a616bced5e7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_aeb5cd02-f786-457e-aa79-fdc51564cc21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_781a32a9-e938-4753-87d9-8f114e8c15bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_5f7b672b-2ff0-4315-a899-9a616bced5e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_781a32a9-e938-4753-87d9-8f114e8c15bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_42dea893-860f-4ae9-97cd-158c4123b3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_5f7b672b-2ff0-4315-a899-9a616bced5e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_42dea893-860f-4ae9-97cd-158c4123b3e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3dac2788-e510-4fee-b864-e2ab5bbc2a62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_5f7b672b-2ff0-4315-a899-9a616bced5e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3dac2788-e510-4fee-b864-e2ab5bbc2a62" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3a463edb-48f5-4ea4-ba42-11fba18b5f45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95ca2795-8500-4064-828a-02d750a1030f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3a463edb-48f5-4ea4-ba42-11fba18b5f45" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d4222579-70ff-4302-b281-06b5c47aea01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3a463edb-48f5-4ea4-ba42-11fba18b5f45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d4222579-70ff-4302-b281-06b5c47aea01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_21930af5-aaf8-4a86-8002-e5a3d345a494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3a463edb-48f5-4ea4-ba42-11fba18b5f45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_21930af5-aaf8-4a86-8002-e5a3d345a494" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_35bf13e4-ecea-4973-aa26-62c9d5924272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3a463edb-48f5-4ea4-ba42-11fba18b5f45" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_35bf13e4-ecea-4973-aa26-62c9d5924272" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_f82dc2bb-1922-471a-a6b3-8692c3146ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3a463edb-48f5-4ea4-ba42-11fba18b5f45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_f82dc2bb-1922-471a-a6b3-8692c3146ce4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_63bedb3b-da61-4294-bfaa-12f07ba3c394" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1281a542-70d5-4389-bfc6-e7cba0ab7162" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95ca2795-8500-4064-828a-02d750a1030f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1281a542-70d5-4389-bfc6-e7cba0ab7162" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_e6118991-fb79-4493-8658-406ab5b6b8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95ca2795-8500-4064-828a-02d750a1030f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_e6118991-fb79-4493-8658-406ab5b6b8cd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_75bd425a-8573-4978-8979-6d7d4b18b592" xlink:href="bhc-20220510.xsd#bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95ca2795-8500-4064-828a-02d750a1030f" xlink:to="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_75bd425a-8573-4978-8979-6d7d4b18b592" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_784de42c-3b84-4887-b8f0-6e347643d9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_75bd425a-8573-4978-8979-6d7d4b18b592" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_784de42c-3b84-4887-b8f0-6e347643d9f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_da2a8826-5030-4de5-9c2a-db9b4a3bb8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_75bd425a-8573-4978-8979-6d7d4b18b592" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_da2a8826-5030-4de5-9c2a-db9b4a3bb8a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_875b3f3d-8137-4a85-bd5d-ee39b80be02a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_75bd425a-8573-4978-8979-6d7d4b18b592" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_875b3f3d-8137-4a85-bd5d-ee39b80be02a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1ea1dcb9-eaf2-4af7-8017-b94ea0b21b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_75bd425a-8573-4978-8979-6d7d4b18b592" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1ea1dcb9-eaf2-4af7-8017-b94ea0b21b9e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5f0c5062-8bcd-40d8-9b7a-2600c807840d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_dbc072e6-6cdb-43e5-9152-1d8e8a679009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95ca2795-8500-4064-828a-02d750a1030f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_dbc072e6-6cdb-43e5-9152-1d8e8a679009" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_b18097d8-30d6-47ad-8ee0-4a433550039f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95ca2795-8500-4064-828a-02d750a1030f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_b18097d8-30d6-47ad-8ee0-4a433550039f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_73069328-c4fb-491f-8d8c-1ea77ad2c9c9" xlink:href="bhc-20220510.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95ca2795-8500-4064-828a-02d750a1030f" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_73069328-c4fb-491f-8d8c-1ea77ad2c9c9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0ae0e50d-17fd-4d3f-b9b5-07d303e0fcdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_73069328-c4fb-491f-8d8c-1ea77ad2c9c9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0ae0e50d-17fd-4d3f-b9b5-07d303e0fcdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_43e2dea6-15b5-4dc7-94be-911774100890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_73069328-c4fb-491f-8d8c-1ea77ad2c9c9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_43e2dea6-15b5-4dc7-94be-911774100890" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_10c2d2c0-02b2-4a9d-b49e-1fb0830c72fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_73069328-c4fb-491f-8d8c-1ea77ad2c9c9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_10c2d2c0-02b2-4a9d-b49e-1fb0830c72fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_e5bb4839-27a9-4369-af5e-8d6d26eeebb6" xlink:href="bhc-20220510.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95ca2795-8500-4064-828a-02d750a1030f" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_e5bb4839-27a9-4369-af5e-8d6d26eeebb6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7e3316ba-a2ed-4fb0-8148-1865416940dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_e5bb4839-27a9-4369-af5e-8d6d26eeebb6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7e3316ba-a2ed-4fb0-8148-1865416940dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_63585cdf-cdb3-4150-9163-c08c5f231b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_e5bb4839-27a9-4369-af5e-8d6d26eeebb6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_63585cdf-cdb3-4150-9163-c08c5f231b7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_5509e805-d06a-4c89-ae50-2a80ecde59c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_e5bb4839-27a9-4369-af5e-8d6d26eeebb6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_5509e805-d06a-4c89-ae50-2a80ecde59c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_700188e9-8d8c-4412-9bc8-d1280895497e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95ca2795-8500-4064-828a-02d750a1030f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_700188e9-8d8c-4412-9bc8-d1280895497e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fff182a4-8181-441e-82bf-ed17e71cf086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_700188e9-8d8c-4412-9bc8-d1280895497e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fff182a4-8181-441e-82bf-ed17e71cf086" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_3dcb8797-93a2-419e-9920-7b891d598044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_700188e9-8d8c-4412-9bc8-d1280895497e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_3dcb8797-93a2-419e-9920-7b891d598044" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_4f65ac92-a1a2-4b3c-8b25-383a596ca0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_700188e9-8d8c-4412-9bc8-d1280895497e" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_4f65ac92-a1a2-4b3c-8b25-383a596ca0b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d54ec739-50e6-4a93-9abd-2ec858c57883" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_700188e9-8d8c-4412-9bc8-d1280895497e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d54ec739-50e6-4a93-9abd-2ec858c57883" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_20c2b02d-2b8f-4776-842b-8e8902621761" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_700188e9-8d8c-4412-9bc8-d1280895497e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_20c2b02d-2b8f-4776-842b-8e8902621761" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue_c822a81c-c080-46c3-8590-9969015d6212" xlink:href="bhc-20220510.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_700188e9-8d8c-4412-9bc8-d1280895497e" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue_c822a81c-c080-46c3-8590-9969015d6212" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cd6fa236-3a09-43f3-8443-c0248e17b817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95ca2795-8500-4064-828a-02d750a1030f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cd6fa236-3a09-43f3-8443-c0248e17b817" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_e70f2253-bc28-4de3-8f75-24af6a1f6999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cd6fa236-3a09-43f3-8443-c0248e17b817" xlink:to="loc_us-gaap_VestingAxis_e70f2253-bc28-4de3-8f75-24af6a1f6999" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_e70f2253-bc28-4de3-8f75-24af6a1f6999_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_e70f2253-bc28-4de3-8f75-24af6a1f6999" xlink:to="loc_us-gaap_VestingDomain_e70f2253-bc28-4de3-8f75-24af6a1f6999_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_c8c30275-0c4a-45ee-87ae-3cf19a13bf6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_e70f2253-bc28-4de3-8f75-24af6a1f6999" xlink:to="loc_us-gaap_VestingDomain_c8c30275-0c4a-45ee-87ae-3cf19a13bf6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_b16441d7-c233-438b-aec6-d0fb96717fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_c8c30275-0c4a-45ee-87ae-3cf19a13bf6d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_b16441d7-c233-438b-aec6-d0fb96717fe0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e895ea6c-fd59-49b3-b063-8d8ce19f532c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_c8c30275-0c4a-45ee-87ae-3cf19a13bf6d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e895ea6c-fd59-49b3-b063-8d8ce19f532c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bb3339bb-b5de-486c-a5e5-3f7f140f0db6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cd6fa236-3a09-43f3-8443-c0248e17b817" xlink:to="loc_us-gaap_AwardTypeAxis_bb3339bb-b5de-486c-a5e5-3f7f140f0db6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb3339bb-b5de-486c-a5e5-3f7f140f0db6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_bb3339bb-b5de-486c-a5e5-3f7f140f0db6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb3339bb-b5de-486c-a5e5-3f7f140f0db6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61939580-34a5-4edf-936a-ac82ae30c754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_bb3339bb-b5de-486c-a5e5-3f7f140f0db6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61939580-34a5-4edf-936a-ac82ae30c754" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4b3ee6d3-e6cc-4d44-9476-a199f50b0202" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61939580-34a5-4edf-936a-ac82ae30c754" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4b3ee6d3-e6cc-4d44-9476-a199f50b0202" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SHAREBASEDCOMPENSATIONRSUsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" xlink:type="extended" id="i990cbc4e15b04770b4b2af98ebefc052_SHAREBASEDCOMPENSATIONRSUsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_982d2ca9-5fde-4141-b86f-218917909de9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_153d62f2-3574-498e-b05e-0b03a146c512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_982d2ca9-5fde-4141-b86f-218917909de9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_153d62f2-3574-498e-b05e-0b03a146c512" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6e91ca31-5d9d-45d0-a3f0-6c9f111d7f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_982d2ca9-5fde-4141-b86f-218917909de9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6e91ca31-5d9d-45d0-a3f0-6c9f111d7f9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1eb166d7-31b5-42e2-ac5d-9a34dfb8f9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_982d2ca9-5fde-4141-b86f-218917909de9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1eb166d7-31b5-42e2-ac5d-9a34dfb8f9b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_229ecbe3-5c3e-44b8-bace-3eee3d1282b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_982d2ca9-5fde-4141-b86f-218917909de9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_229ecbe3-5c3e-44b8-bace-3eee3d1282b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ca073d8f-cf7c-447b-b6ff-71ee83105d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_982d2ca9-5fde-4141-b86f-218917909de9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ca073d8f-cf7c-447b-b6ff-71ee83105d8d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued_5eea834f-dd38-42db-aa25-2622f11b1603" xlink:href="bhc-20220510.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_982d2ca9-5fde-4141-b86f-218917909de9" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued_5eea834f-dd38-42db-aa25-2622f11b1603" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3cd768b5-f66b-4854-8a01-7137061f8451" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_982d2ca9-5fde-4141-b86f-218917909de9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3cd768b5-f66b-4854-8a01-7137061f8451" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_eecc9baf-aca4-4931-9bfa-65f7fefaefae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3cd768b5-f66b-4854-8a01-7137061f8451" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_eecc9baf-aca4-4931-9bfa-65f7fefaefae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f22034cf-aee2-4635-b875-f274877dbeb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3cd768b5-f66b-4854-8a01-7137061f8451" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f22034cf-aee2-4635-b875-f274877dbeb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7ec9d4ac-3c53-48e9-bb24-94338db4f959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3cd768b5-f66b-4854-8a01-7137061f8451" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7ec9d4ac-3c53-48e9-bb24-94338db4f959" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_25716d8d-3ba9-4acf-812a-5afd987b415f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3cd768b5-f66b-4854-8a01-7137061f8451" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_25716d8d-3ba9-4acf-812a-5afd987b415f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2fd0a053-bd63-4a66-bb27-624917457cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c3736c32-8ea6-4654-b4b5-3895780e92d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_982d2ca9-5fde-4141-b86f-218917909de9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c3736c32-8ea6-4654-b4b5-3895780e92d0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c1503271-5020-41be-a883-7bca5018a865" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c3736c32-8ea6-4654-b4b5-3895780e92d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c1503271-5020-41be-a883-7bca5018a865" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bb50a22a-0d49-40e7-8436-967cbc2ba634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c3736c32-8ea6-4654-b4b5-3895780e92d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bb50a22a-0d49-40e7-8436-967cbc2ba634" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e9bffba0-0539-4b43-85ef-934812947781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c3736c32-8ea6-4654-b4b5-3895780e92d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e9bffba0-0539-4b43-85ef-934812947781" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d135937b-0075-4289-b387-c2f354af124b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c3736c32-8ea6-4654-b4b5-3895780e92d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d135937b-0075-4289-b387-c2f354af124b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a593541c-396f-4812-9a05-d36b3edc623e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_0642f347-0423-4984-98c8-9b3191546d79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_982d2ca9-5fde-4141-b86f-218917909de9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_0642f347-0423-4984-98c8-9b3191546d79" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_98704278-72e8-4e93-84b9-71592761c53c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_0642f347-0423-4984-98c8-9b3191546d79" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_98704278-72e8-4e93-84b9-71592761c53c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_796cd475-1c93-4671-9715-36732bdbd9d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_0642f347-0423-4984-98c8-9b3191546d79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_796cd475-1c93-4671-9715-36732bdbd9d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3d9b6c6f-cbd7-40ad-a412-d8d2502a3b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_0642f347-0423-4984-98c8-9b3191546d79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3d9b6c6f-cbd7-40ad-a412-d8d2502a3b6f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_af511a96-a649-43dc-b2cb-134e07572bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_982d2ca9-5fde-4141-b86f-218917909de9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_af511a96-a649-43dc-b2cb-134e07572bdf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f23b4a39-8601-4bc5-9c11-750cd47a1a24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_af511a96-a649-43dc-b2cb-134e07572bdf" xlink:to="loc_us-gaap_AwardTypeAxis_f23b4a39-8601-4bc5-9c11-750cd47a1a24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f23b4a39-8601-4bc5-9c11-750cd47a1a24_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f23b4a39-8601-4bc5-9c11-750cd47a1a24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f23b4a39-8601-4bc5-9c11-750cd47a1a24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1a9a29c5-6b68-4304-aaac-42fc05f380e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f23b4a39-8601-4bc5-9c11-750cd47a1a24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1a9a29c5-6b68-4304-aaac-42fc05f380e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a7577818-5daa-40c2-a279-8779d9e7f46f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1a9a29c5-6b68-4304-aaac-42fc05f380e7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a7577818-5daa-40c2-a279-8779d9e7f46f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TimeBasedRSUMember_455af49f-e03d-4b5a-97c0-a102e12efc8e" xlink:href="bhc-20220510.xsd#bhc_TimeBasedRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1a9a29c5-6b68-4304-aaac-42fc05f380e7" xlink:to="loc_bhc_TimeBasedRSUMember_455af49f-e03d-4b5a-97c0-a102e12efc8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_6568d460-f16e-48e2-badc-57db52d524bf" xlink:href="bhc-20220510.xsd#bhc_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1a9a29c5-6b68-4304-aaac-42fc05f380e7" xlink:to="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_6568d460-f16e-48e2-badc-57db52d524bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_96af9e3e-e960-4e62-a642-ef1e20d916a2" xlink:href="bhc-20220510.xsd#bhc_TSRPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_6568d460-f16e-48e2-badc-57db52d524bf" xlink:to="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_96af9e3e-e960-4e62-a642-ef1e20d916a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_a5c00bf1-6922-4ccd-afea-7fad9002eaed" xlink:href="bhc-20220510.xsd#bhc_ROTCPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_6568d460-f16e-48e2-badc-57db52d524bf" xlink:to="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_a5c00bf1-6922-4ccd-afea-7fad9002eaed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherPerformanceBasedRestrictedStockUnitsMember_a417264e-9096-44a7-9df8-6427d0b938c2" xlink:href="bhc-20220510.xsd#bhc_OtherPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_6568d460-f16e-48e2-badc-57db52d524bf" xlink:to="loc_bhc_OtherPerformanceBasedRestrictedStockUnitsMember_a417264e-9096-44a7-9df8-6427d0b938c2" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails" xlink:type="extended" id="iea2963315d204968aeef14bbd0011232_ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_52dc6ee2-36e7-4d93-939a-1227b583483d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2929d319-8f6b-4935-8f80-68d3031f78b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_52dc6ee2-36e7-4d93-939a-1227b583483d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2929d319-8f6b-4935-8f80-68d3031f78b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_84fffa95-80a3-4946-9a56-6ab23fdfee13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_52dc6ee2-36e7-4d93-939a-1227b583483d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_84fffa95-80a3-4946-9a56-6ab23fdfee13" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9a6df90d-572b-4164-9e99-0d028835c18e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_84fffa95-80a3-4946-9a56-6ab23fdfee13" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9a6df90d-572b-4164-9e99-0d028835c18e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9a6df90d-572b-4164-9e99-0d028835c18e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9a6df90d-572b-4164-9e99-0d028835c18e" xlink:to="loc_us-gaap_EquityComponentDomain_9a6df90d-572b-4164-9e99-0d028835c18e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f6507f33-dcb5-4857-84ec-068af07f5862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9a6df90d-572b-4164-9e99-0d028835c18e" xlink:to="loc_us-gaap_EquityComponentDomain_f6507f33-dcb5-4857-84ec-068af07f5862" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_7d805300-0827-4799-8efe-824d8f79d843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f6507f33-dcb5-4857-84ec-068af07f5862" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_7d805300-0827-4799-8efe-824d8f79d843" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_f12d5109-7879-43b0-8764-b58157a4b745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f6507f33-dcb5-4857-84ec-068af07f5862" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_f12d5109-7879-43b0-8764-b58157a4b745" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0b58e2f6-7110-4845-8351-94ff9c2d7e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f6507f33-dcb5-4857-84ec-068af07f5862" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0b58e2f6-7110-4845-8351-94ff9c2d7e7d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#OTHEREXPENSENETNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails" xlink:type="extended" id="i599e81b00be14c73b660478ce8628d0a_OTHEREXPENSENETNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_3c9b6712-9730-4630-9c5b-9301ee1baeb2" xlink:href="bhc-20220510.xsd#bhc_ScheduleOfOtherIncomeAndExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_615261b8-e328-43f4-b731-b984d646274f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_3c9b6712-9730-4630-9c5b-9301ee1baeb2" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_615261b8-e328-43f4-b731-b984d646274f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_8da6c408-77c6-4a3d-98f2-17fcae45b1c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_3c9b6712-9730-4630-9c5b-9301ee1baeb2" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_8da6c408-77c6-4a3d-98f2-17fcae45b1c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_11a5092a-a589-4283-9de8-2610829883f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_3c9b6712-9730-4630-9c5b-9301ee1baeb2" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_11a5092a-a589-4283-9de8-2610829883f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_e15d5680-47e6-4af1-92e4-9a2a416fa83e" xlink:href="bhc-20220510.xsd#bhc_ScheduleOfOtherIncomeAndExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_3c9b6712-9730-4630-9c5b-9301ee1baeb2" xlink:to="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_e15d5680-47e6-4af1-92e4-9a2a416fa83e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_65b251f6-ea31-472b-8c5d-573d4c4b6283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_e15d5680-47e6-4af1-92e4-9a2a416fa83e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_65b251f6-ea31-472b-8c5d-573d4c4b6283" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_65b251f6-ea31-472b-8c5d-573d4c4b6283_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_65b251f6-ea31-472b-8c5d-573d4c4b6283" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_65b251f6-ea31-472b-8c5d-573d4c4b6283_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a45301c8-e076-4f5e-9374-5fabedbd229e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_65b251f6-ea31-472b-8c5d-573d4c4b6283" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a45301c8-e076-4f5e-9374-5fabedbd229e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MilestonePaymentRelatedToCertainProductMember_1d4042f1-fea9-49ad-afdf-09f024ccbcf5" xlink:href="bhc-20220510.xsd#bhc_MilestonePaymentRelatedToCertainProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a45301c8-e076-4f5e-9374-5fabedbd229e" xlink:to="loc_bhc_MilestonePaymentRelatedToCertainProductMember_1d4042f1-fea9-49ad-afdf-09f024ccbcf5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails" xlink:type="extended" id="i5c801bc66cfa46e99788ff360939c9ff_INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a2f9d21b-a34b-4b36-9d72-8e36f672f29d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ff099e96-2c54-4d9b-894e-0218c111b780" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a2f9d21b-a34b-4b36-9d72-8e36f672f29d" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ff099e96-2c54-4d9b-894e-0218c111b780" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_9424e68d-12ed-4504-bb3f-f2b3a6563909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ff099e96-2c54-4d9b-894e-0218c111b780" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_9424e68d-12ed-4504-bb3f-f2b3a6563909" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes_9cdc9c72-51ba-4b43-bf38-a532541f3f38" xlink:href="bhc-20220510.xsd#bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ff099e96-2c54-4d9b-894e-0218c111b780" xlink:to="loc_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes_9cdc9c72-51ba-4b43-bf38-a532541f3f38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_6fcec8e1-0bed-4b04-a828-7fe4d7d45ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ff099e96-2c54-4d9b-894e-0218c111b780" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_6fcec8e1-0bed-4b04-a828-7fe4d7d45ae6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_00950fc8-c80b-47b7-bb10-978d1f5bf2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_ae791976-d80d-4496-b5ed-c186380d0fe6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a2f9d21b-a34b-4b36-9d72-8e36f672f29d" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_ae791976-d80d-4496-b5ed-c186380d0fe6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_57b39963-6726-4ce7-86b5-1503db6d5e32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_ae791976-d80d-4496-b5ed-c186380d0fe6" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_57b39963-6726-4ce7-86b5-1503db6d5e32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_57b39963-6726-4ce7-86b5-1503db6d5e32_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_57b39963-6726-4ce7-86b5-1503db6d5e32" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_57b39963-6726-4ce7-86b5-1503db6d5e32_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_e0271214-8000-47be-a538-293be7b5caa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_57b39963-6726-4ce7-86b5-1503db6d5e32" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_e0271214-8000-47be-a538-293be7b5caa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_dbec263b-b376-47f0-89e1-cd2fc1069564" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_e0271214-8000-47be-a538-293be7b5caa3" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_dbec263b-b376-47f0-89e1-cd2fc1069564" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#INCOMETAXESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended" id="i52f2a2e8b973462194f6c4b019cf0c0d_INCOMETAXESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:href="bhc-20220510.xsd#bhc_IncomeTaxLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_624b7208-1dca-4beb-bc42-c7230ca17aff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_624b7208-1dca-4beb-bc42-c7230ca17aff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccumulatedLossesAvailableForFederalPurposes_bfb00d34-96c9-4954-93cc-6f8a6b02f51a" xlink:href="bhc-20220510.xsd#bhc_AccumulatedLossesAvailableForFederalPurposes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_bhc_AccumulatedLossesAvailableForFederalPurposes_bfb00d34-96c9-4954-93cc-6f8a6b02f51a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits_f550a852-0464-4da6-bc4a-ce635dea1794" xlink:href="bhc-20220510.xsd#bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits_f550a852-0464-4da6-bc4a-ce635dea1794" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_ceea6f13-0cb3-4c11-a0e5-6824fe189289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_ceea6f13-0cb3-4c11-a0e5-6824fe189289" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_dcb7debc-cdef-492c-89f3-28b22d5b0bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_dcb7debc-cdef-492c-89f3-28b22d5b0bac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_4300c267-81f3-4cba-8712-7aa13c56e7db" xlink:href="bhc-20220510.xsd#bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_4300c267-81f3-4cba-8712-7aa13c56e7db" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_adc899dd-f12c-447f-8211-af1d8c36258d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_adc899dd-f12c-447f-8211-af1d8c36258d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions_6272c3bd-7dae-4339-8b8d-5568be98e97c" xlink:href="bhc-20220510.xsd#bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions_6272c3bd-7dae-4339-8b8d-5568be98e97c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions_7b924d81-f7fa-49ec-8619-9a0515084335" xlink:href="bhc-20220510.xsd#bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions_7b924d81-f7fa-49ec-8619-9a0515084335" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions_95db29e0-2c43-4fb3-b482-700017a2b78d" xlink:href="bhc-20220510.xsd#bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions_95db29e0-2c43-4fb3-b482-700017a2b78d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_baf1c37b-8c3a-4a95-8052-058d2915b8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_baf1c37b-8c3a-4a95-8052-058d2915b8c7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_fe77e8a6-70c4-4ac2-82a7-f6749e6742ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_fe77e8a6-70c4-4ac2-82a7-f6749e6742ad" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns_f895600a-cc22-4eba-86ea-c3d2382f9662" xlink:href="bhc-20220510.xsd#bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns_f895600a-cc22-4eba-86ea-c3d2382f9662" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear_5303c1a3-af27-457d-b058-52a46b1ace6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear_5303c1a3-af27-457d-b058-52a46b1ace6b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_c56d0bf0-4156-420d-81e9-1f2411e78427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_c56d0bf0-4156-420d-81e9-1f2411e78427" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_5fbe3b14-1181-476e-9108-e9286e32a7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_5fbe3b14-1181-476e-9108-e9286e32a7c0" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxTable_3bf6b472-a23f-41cc-8110-9806d8a6840c" xlink:href="bhc-20220510.xsd#bhc_IncomeTaxTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_bhc_IncomeTaxTable_3bf6b472-a23f-41cc-8110-9806d8a6840c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_0389e86c-aa18-4643-aa95-00ab569b0f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_IncomeTaxTable_3bf6b472-a23f-41cc-8110-9806d8a6840c" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_0389e86c-aa18-4643-aa95-00ab569b0f96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0389e86c-aa18-4643-aa95-00ab569b0f96_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0389e86c-aa18-4643-aa95-00ab569b0f96" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0389e86c-aa18-4643-aa95-00ab569b0f96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_82ea176c-4937-46a4-a5f0-c9f98da1a76e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0389e86c-aa18-4643-aa95-00ab569b0f96" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_82ea176c-4937-46a4-a5f0-c9f98da1a76e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ForeignCountryStateAndLocalMember_072f7bc5-2be8-42e8-a271-1c1b452291bb" xlink:href="bhc-20220510.xsd#bhc_ForeignCountryStateAndLocalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_82ea176c-4937-46a4-a5f0-c9f98da1a76e" xlink:to="loc_bhc_ForeignCountryStateAndLocalMember_072f7bc5-2be8-42e8-a271-1c1b452291bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_4478857e-edc5-4b2a-ab2a-776a6f12e4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_82ea176c-4937-46a4-a5f0-c9f98da1a76e" xlink:to="loc_us-gaap_DomesticCountryMember_4478857e-edc5-4b2a-ab2a-776a6f12e4f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_43728d1c-7623-40b2-a5c1-5deee8216fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_82ea176c-4937-46a4-a5f0-c9f98da1a76e" xlink:to="loc_us-gaap_ForeignCountryMember_43728d1c-7623-40b2-a5c1-5deee8216fb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_ccf1b727-22d1-4292-834d-dd669cba5c79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_IncomeTaxTable_3bf6b472-a23f-41cc-8110-9806d8a6840c" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_ccf1b727-22d1-4292-834d-dd669cba5c79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_ccf1b727-22d1-4292-834d-dd669cba5c79_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_ccf1b727-22d1-4292-834d-dd669cba5c79" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_ccf1b727-22d1-4292-834d-dd669cba5c79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_b9f07f15-1d87-469e-9d7f-f903efb422a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_ccf1b727-22d1-4292-834d-dd669cba5c79" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_b9f07f15-1d87-469e-9d7f-f903efb422a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember_f96383e0-3d4a-47f6-a4f4-594c64e643e1" xlink:href="bhc-20220510.xsd#bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_b9f07f15-1d87-469e-9d7f-f903efb422a1" xlink:to="loc_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember_f96383e0-3d4a-47f6-a4f4-594c64e643e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_e72f5fe1-2df0-49ab-9a0e-5863082efbad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_IncomeTaxTable_3bf6b472-a23f-41cc-8110-9806d8a6840c" xlink:to="loc_us-gaap_TaxPeriodAxis_e72f5fe1-2df0-49ab-9a0e-5863082efbad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_e72f5fe1-2df0-49ab-9a0e-5863082efbad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_e72f5fe1-2df0-49ab-9a0e-5863082efbad" xlink:to="loc_us-gaap_TaxPeriodDomain_e72f5fe1-2df0-49ab-9a0e-5863082efbad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_7f5ed113-3834-43ab-8b69-593c9ae9f59a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_e72f5fe1-2df0-49ab-9a0e-5863082efbad" xlink:to="loc_us-gaap_TaxPeriodDomain_7f5ed113-3834-43ab-8b69-593c9ae9f59a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2012Member_e4323266-a8ff-4176-8917-eb2d0535ba1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxYear2012Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_7f5ed113-3834-43ab-8b69-593c9ae9f59a" xlink:to="loc_us-gaap_TaxYear2012Member_e4323266-a8ff-4176-8917-eb2d0535ba1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2013Member_a971bf8d-9a4a-4e7a-8c1e-dd25de8c913f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxYear2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_7f5ed113-3834-43ab-8b69-593c9ae9f59a" xlink:to="loc_us-gaap_TaxYear2013Member_a971bf8d-9a4a-4e7a-8c1e-dd25de8c913f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaxYear2005ThroughTaxYear2009Member_1cc817f6-1f1c-4ca0-83bd-ff211f9c2083" xlink:href="bhc-20220510.xsd#bhc_TaxYear2005ThroughTaxYear2009Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_7f5ed113-3834-43ab-8b69-593c9ae9f59a" xlink:to="loc_bhc_TaxYear2005ThroughTaxYear2009Member_1cc817f6-1f1c-4ca0-83bd-ff211f9c2083" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaxYear2015AndTaxYear2016Member_f3fc83ed-838f-48df-9b0b-46570c8f5d2e" xlink:href="bhc-20220510.xsd#bhc_TaxYear2015AndTaxYear2016Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_7f5ed113-3834-43ab-8b69-593c9ae9f59a" xlink:to="loc_bhc_TaxYear2015AndTaxYear2016Member_f3fc83ed-838f-48df-9b0b-46570c8f5d2e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_1feaa2fd-aa46-4fef-998d-54f92d57b0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_IncomeTaxTable_3bf6b472-a23f-41cc-8110-9806d8a6840c" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_1feaa2fd-aa46-4fef-998d-54f92d57b0ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_1feaa2fd-aa46-4fef-998d-54f92d57b0ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_1feaa2fd-aa46-4fef-998d-54f92d57b0ba" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_1feaa2fd-aa46-4fef-998d-54f92d57b0ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_08cb6573-d68b-40db-9350-1ee95f5208c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_1feaa2fd-aa46-4fef-998d-54f92d57b0ba" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_08cb6573-d68b-40db-9350-1ee95f5208c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueCommissionersIrelandMember_324f29d9-6123-4fb1-a0ff-0672627d1c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueCommissionersIrelandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_08cb6573-d68b-40db-9350-1ee95f5208c4" xlink:to="loc_us-gaap_RevenueCommissionersIrelandMember_324f29d9-6123-4fb1-a0ff-0672627d1c5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CanadaRevenueAgencyMember_6fe14649-4dbe-4a96-ac44-0afa24bfb50c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CanadaRevenueAgencyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_08cb6573-d68b-40db-9350-1ee95f5208c4" xlink:to="loc_us-gaap_CanadaRevenueAgencyMember_6fe14649-4dbe-4a96-ac44-0afa24bfb50c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AustralianTaxationOfficeMember_238dbed3-9436-46dd-95a1-1b5b29301b63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AustralianTaxationOfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_08cb6573-d68b-40db-9350-1ee95f5208c4" xlink:to="loc_us-gaap_AustralianTaxationOfficeMember_238dbed3-9436-46dd-95a1-1b5b29301b63" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails" xlink:type="extended" id="i3806d00c572640688cf8bf25508085a4_INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_5e1ebe78-df09-40f1-8468-16a127931ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear_53c79279-26a3-4476-93c1-bd4673dd6e58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_5e1ebe78-df09-40f1-8468-16a127931ebd" xlink:to="loc_us-gaap_OpenTaxYear_53c79279-26a3-4476-93c1-bd4673dd6e58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_b1a427f5-0df8-41d3-a541-1f0b49f672cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_5e1ebe78-df09-40f1-8468-16a127931ebd" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_b1a427f5-0df8-41d3-a541-1f0b49f672cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_df4fa3bb-35ef-4c50-a311-e1c759db6c85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_b1a427f5-0df8-41d3-a541-1f0b49f672cc" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_df4fa3bb-35ef-4c50-a311-e1c759db6c85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_df4fa3bb-35ef-4c50-a311-e1c759db6c85_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_df4fa3bb-35ef-4c50-a311-e1c759db6c85" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_df4fa3bb-35ef-4c50-a311-e1c759db6c85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_831af75c-ae94-4634-965f-4fb2bbd74a48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_df4fa3bb-35ef-4c50-a311-e1c759db6c85" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_831af75c-ae94-4634-965f-4fb2bbd74a48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_11b358d1-4169-48bf-835a-29f336583222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_831af75c-ae94-4634-965f-4fb2bbd74a48" xlink:to="loc_us-gaap_DomesticCountryMember_11b358d1-4169-48bf-835a-29f336583222" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_fea764e0-d7d2-4db2-b06a-6b5d37b4ae21" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_831af75c-ae94-4634-965f-4fb2bbd74a48" xlink:to="loc_country_CA_fea764e0-d7d2-4db2-b06a-6b5d37b4ae21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_e5ec4812-64b6-4d67-a1e9-c0e1559b688a" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_831af75c-ae94-4634-965f-4fb2bbd74a48" xlink:to="loc_country_DE_e5ec4812-64b6-4d67-a1e9-c0e1559b688a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_fba444ec-5895-49c6-b457-ee40dc7293d6" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_831af75c-ae94-4634-965f-4fb2bbd74a48" xlink:to="loc_country_FR_fba444ec-5895-49c6-b457-ee40dc7293d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_b74e151b-e09a-4593-89d2-1941289f91ef" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_831af75c-ae94-4634-965f-4fb2bbd74a48" xlink:to="loc_country_CN_b74e151b-e09a-4593-89d2-1941289f91ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_bd0bc975-5932-4cbc-8fd1-bbb030e8c827" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_831af75c-ae94-4634-965f-4fb2bbd74a48" xlink:to="loc_country_IE_bd0bc975-5932-4cbc-8fd1-bbb030e8c827" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_NL_432fae80-326e-4a67-a2a6-9a53a795642e" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_NL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_831af75c-ae94-4634-965f-4fb2bbd74a48" xlink:to="loc_country_NL_432fae80-326e-4a67-a2a6-9a53a795642e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AustralianTaxationOfficeMember_a380aa83-c6f5-4984-b575-8d2aa6153eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AustralianTaxationOfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_831af75c-ae94-4634-965f-4fb2bbd74a48" xlink:to="loc_us-gaap_AustralianTaxationOfficeMember_a380aa83-c6f5-4984-b575-8d2aa6153eb5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LuxembourgInlandRevenueMember_f4c5ea87-c288-4f13-9724-c302a0e3ad97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LuxembourgInlandRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_831af75c-ae94-4634-965f-4fb2bbd74a48" xlink:to="loc_us-gaap_LuxembourgInlandRevenueMember_f4c5ea87-c288-4f13-9724-c302a0e3ad97" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e4ca961a-d2d5-4cbe-a404-8b619de66d10" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_b1a427f5-0df8-41d3-a541-1f0b49f672cc" xlink:to="loc_srt_RangeAxis_e4ca961a-d2d5-4cbe-a404-8b619de66d10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e4ca961a-d2d5-4cbe-a404-8b619de66d10_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e4ca961a-d2d5-4cbe-a404-8b619de66d10" xlink:to="loc_srt_RangeMember_e4ca961a-d2d5-4cbe-a404-8b619de66d10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_25b1ed42-0f10-4830-aa69-21a083ab5737" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e4ca961a-d2d5-4cbe-a404-8b619de66d10" xlink:to="loc_srt_RangeMember_25b1ed42-0f10-4830-aa69-21a083ab5737" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1fbc4189-acf7-4838-a3a7-e92eb8f9b141" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_25b1ed42-0f10-4830-aa69-21a083ab5737" xlink:to="loc_srt_MinimumMember_1fbc4189-acf7-4838-a3a7-e92eb8f9b141" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3de848aa-7d62-4fe1-bc16-5ce31ef1bae2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_25b1ed42-0f10-4830-aa69-21a083ab5737" xlink:to="loc_srt_MaximumMember_3de848aa-7d62-4fe1-bc16-5ce31ef1bae2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#LOSSPERSHARENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails" xlink:type="extended" id="i5410d0418a014ca0b64b7f371861f5aa_LOSSPERSHARENarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_63145cda-3f9a-4c09-a17b-df5b39cef7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_aceb7fbb-660b-4504-9d0c-e0f0590c1f66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_63145cda-3f9a-4c09-a17b-df5b39cef7b1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_aceb7fbb-660b-4504-9d0c-e0f0590c1f66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8b7db4c6-37ef-4db5-84ae-44047a2c9c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_63145cda-3f9a-4c09-a17b-df5b39cef7b1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8b7db4c6-37ef-4db5-84ae-44047a2c9c4b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ab78e02f-ef24-4d14-89ec-917bdf58c6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8b7db4c6-37ef-4db5-84ae-44047a2c9c4b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ab78e02f-ef24-4d14-89ec-917bdf58c6e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ab78e02f-ef24-4d14-89ec-917bdf58c6e9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ab78e02f-ef24-4d14-89ec-917bdf58c6e9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_ab78e02f-ef24-4d14-89ec-917bdf58c6e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4ceedc95-0d93-4039-993a-9d9611aa07ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ab78e02f-ef24-4d14-89ec-917bdf58c6e9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4ceedc95-0d93-4039-993a-9d9611aa07ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_9be1b6f6-ae1b-4c41-9917-fe5842132b82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4ceedc95-0d93-4039-993a-9d9611aa07ae" xlink:to="loc_us-gaap_StockCompensationPlanMember_9be1b6f6-ae1b-4c41-9917-fe5842132b82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_7cedb14b-4162-43a3-810d-05beecf41ec2" xlink:href="bhc-20220510.xsd#bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4ceedc95-0d93-4039-993a-9d9611aa07ae" xlink:to="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_7cedb14b-4162-43a3-810d-05beecf41ec2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_7ba33bf2-28fd-4ea9-bce2-628b05f15b3b" xlink:href="bhc-20220510.xsd#bhc_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_7cedb14b-4162-43a3-810d-05beecf41ec2" xlink:to="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_7ba33bf2-28fd-4ea9-bce2-628b05f15b3b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#LEGALPROCEEDINGSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" xlink:type="extended" id="i8726edc9146849acbbb4a2466c378588_LEGALPROCEEDINGSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_Legalsettlementsandrelatedfees_514ca020-83cc-4aa8-85f1-c9d5645c2a75" xlink:href="bhc-20220510.xsd#bhc_Legalsettlementsandrelatedfees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_bhc_Legalsettlementsandrelatedfees_514ca020-83cc-4aa8-85f1-c9d5645c2a75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_adcfe675-2eed-41dd-94d5-59708956f887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_adcfe675-2eed-41dd-94d5-59708956f887" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_8ddb5fe4-c911-4662-a2b7-4f1c9730bf0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_8ddb5fe4-c911-4662-a2b7-4f1c9730bf0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_a074ac66-24d5-482a-aabb-f998c4ca1a1b" xlink:href="bhc-20220510.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_a074ac66-24d5-482a-aabb-f998c4ca1a1b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_ce8f85b6-82c1-4ec7-9dea-43d1794ebbba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_ce8f85b6-82c1-4ec7-9dea-43d1794ebbba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_7dc26786-de4b-47e6-b98e-9d7c1cd1beff" xlink:href="bhc-20220510.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_7dc26786-de4b-47e6-b98e-9d7c1cd1beff" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_b0176889-c878-405f-81ec-5c85508d693f" xlink:href="bhc-20220510.xsd#bhc_LossContingencyNewClaimsFiledButNotYetServedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_b0176889-c878-405f-81ec-5c85508d693f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_ba7ca89a-50e9-4f5a-ba6f-7bee42bb9ad4" xlink:href="bhc-20220510.xsd#bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_ba7ca89a-50e9-4f5a-ba6f-7bee42bb9ad4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_2cdcd99b-5997-4a32-8266-35f9c7565e05" xlink:href="bhc-20220510.xsd#bhc_LossContingencyNumberOfInsurancePolicyPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_2cdcd99b-5997-4a32-8266-35f9c7565e05" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers_67835862-0146-4af0-ab4f-9ce771572377" xlink:href="bhc-20220510.xsd#bhc_LossContingencySettlementAgreementsNumberOfInsurers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers_67835862-0146-4af0-ab4f-9ce771572377" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_bdd3a85b-80b3-40f5-970b-4ded40ded5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_bdd3a85b-80b3-40f5-970b-4ded40ded5b6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalPeriod_a4c39e3a-94f0-4871-8d4f-6e187efe7762" xlink:href="bhc-20220510.xsd#bhc_LossContingencyStayOfApprovalPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_bhc_LossContingencyStayOfApprovalPeriod_a4c39e3a-94f0-4871-8d4f-6e187efe7762" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_e0231a05-1fd4-451b-adb6-fb25adc7b258" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_e0231a05-1fd4-451b-adb6-fb25adc7b258" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_1683e2d2-8127-4634-89ef-66d9e040793e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_1683e2d2-8127-4634-89ef-66d9e040793e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits_b24e684c-e2da-4260-8f28-55e7440e6cef" xlink:href="bhc-20220510.xsd#bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits_b24e684c-e2da-4260-8f28-55e7440e6cef" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_2e612f62-abb8-4df7-adbe-1795c67eefa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_us-gaap_LossContingenciesTable_2e612f62-abb8-4df7-adbe-1795c67eefa1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_da840fde-f4a6-4238-b135-fa23d67e542d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_2e612f62-abb8-4df7-adbe-1795c67eefa1" xlink:to="loc_srt_LitigationCaseAxis_da840fde-f4a6-4238-b135-fa23d67e542d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_da840fde-f4a6-4238-b135-fa23d67e542d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_da840fde-f4a6-4238-b135-fa23d67e542d" xlink:to="loc_srt_LitigationCaseTypeDomain_da840fde-f4a6-4238-b135-fa23d67e542d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_da840fde-f4a6-4238-b135-fa23d67e542d" xlink:to="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_840af22b-1b83-4874-a7a1-97ba8f238b9e" xlink:href="bhc-20220510.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_840af22b-1b83-4874-a7a1-97ba8f238b9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadianSecuritiesLitigationMember_5725aa93-51fa-4d10-9ecf-a351dc1e771e" xlink:href="bhc-20220510.xsd#bhc_CanadianSecuritiesLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_CanadianSecuritiesLitigationMember_5725aa93-51fa-4d10-9ecf-a351dc1e771e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RICOClassActionsLitigationMember_6eb09704-5f8e-401f-a1a2-87318ff32bd2" xlink:href="bhc-20220510.xsd#bhc_RICOClassActionsLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_RICOClassActionsLitigationMember_6eb09704-5f8e-401f-a1a2-87318ff32bd2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InsuranceCoverageLawsuitMember_cb729d9e-d72a-411f-b0c5-922d1c1372d4" xlink:href="bhc-20220510.xsd#bhc_InsuranceCoverageLawsuitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_InsuranceCoverageLawsuitMember_cb729d9e-d72a-411f-b0c5-922d1c1372d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SandozLitigationMember_bc0a7838-f709-4096-b36a-af6b35739202" xlink:href="bhc-20220510.xsd#bhc_SandozLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_SandozLitigationMember_bc0a7838-f709-4096-b36a-af6b35739202" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerrigoIsraelPharmaceuticalsLitigationMember_f9c4f008-aac0-4350-b5ac-f00af346bf33" xlink:href="bhc-20220510.xsd#bhc_PerrigoIsraelPharmaceuticalsLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_PerrigoIsraelPharmaceuticalsLitigationMember_f9c4f008-aac0-4350-b5ac-f00af346bf33" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PadagisLitigationMember_1847514f-1324-4a73-8dbe-82aeb9fc4809" xlink:href="bhc-20220510.xsd#bhc_PadagisLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_PadagisLitigationMember_1847514f-1324-4a73-8dbe-82aeb9fc4809" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_f15bed9e-ea86-40b9-ac59-24014b53f565" xlink:href="bhc-20220510.xsd#bhc_MSNLaboratoriesPrivateLtdLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_f15bed9e-ea86-40b9-ac59-24014b53f565" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember_4aab0b71-7520-42cf-bae7-e6f0c3536626" xlink:href="bhc-20220510.xsd#bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember_4aab0b71-7520-42cf-bae7-e6f0c3536626" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LupinPharmaceuticalsIncLitigationMember_18f2fb16-92c5-46c8-96eb-19b27ac0ceb5" xlink:href="bhc-20220510.xsd#bhc_LupinPharmaceuticalsIncLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_LupinPharmaceuticalsIncLitigationMember_18f2fb16-92c5-46c8-96eb-19b27ac0ceb5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowertoShowerProductLiabilityLitigationMember_a355adbc-d4ba-41e5-9ccd-c56d1a809592" xlink:href="bhc-20220510.xsd#bhc_ShowertoShowerProductLiabilityLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_ShowertoShowerProductLiabilityLitigationMember_a355adbc-d4ba-41e5-9ccd-c56d1a809592" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_cb43f7e6-613a-4d53-ae6b-36d7ed0a015a" xlink:href="bhc-20220510.xsd#bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ShowertoShowerProductLiabilityLitigationMember_a355adbc-d4ba-41e5-9ccd-c56d1a809592" xlink:to="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_cb43f7e6-613a-4d53-ae6b-36d7ed0a015a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_117dd036-0ae7-4422-aa99-7feba8581730" xlink:href="bhc-20220510.xsd#bhc_DoctorsAllergyFormulaLLCLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_117dd036-0ae7-4422-aa99-7feba8581730" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationwithFormerSalixCEOMember_ffd99770-edd9-4c3a-a18c-ea023b1c4cf6" xlink:href="bhc-20220510.xsd#bhc_LitigationwithFormerSalixCEOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_LitigationwithFormerSalixCEOMember_ffd99770-edd9-4c3a-a18c-ea023b1c4cf6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationMember_38912431-1181-48e6-bf87-03a7c09b00fb" xlink:href="bhc-20220510.xsd#bhc_GlumetzaAntitrustLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_GlumetzaAntitrustLitigationMember_38912431-1181-48e6-bf87-03a7c09b00fb" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_7357d7e3-df75-40c0-a2a9-f7a448e9031e" xlink:href="bhc-20220510.xsd#bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_GlumetzaAntitrustLitigationMember_38912431-1181-48e6-bf87-03a7c09b00fb" xlink:to="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_7357d7e3-df75-40c0-a2a9-f7a448e9031e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ApotexIncLitigationMember_b3c78c2e-4757-46a7-ae74-ee3b89d6f3f5" xlink:href="bhc-20220510.xsd#bhc_ApotexIncLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_ApotexIncLitigationMember_b3c78c2e-4757-46a7-ae74-ee3b89d6f3f5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeLawsuitsMember_5082a34e-f2fc-4c55-ad56-afe54687d5de" xlink:href="bhc-20220510.xsd#bhc_DerivativeLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_DerivativeLawsuitsMember_5082a34e-f2fc-4c55-ad56-afe54687d5de" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_3a09d78c-4093-4804-b9ef-0da6639a65b8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_2e612f62-abb8-4df7-adbe-1795c67eefa1" xlink:to="loc_srt_StatementGeographicalAxis_3a09d78c-4093-4804-b9ef-0da6639a65b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3a09d78c-4093-4804-b9ef-0da6639a65b8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_3a09d78c-4093-4804-b9ef-0da6639a65b8" xlink:to="loc_srt_SegmentGeographicalDomain_3a09d78c-4093-4804-b9ef-0da6639a65b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3289dcde-adf7-45e5-9568-a42b258d0bd7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_3a09d78c-4093-4804-b9ef-0da6639a65b8" xlink:to="loc_srt_SegmentGeographicalDomain_3289dcde-adf7-45e5-9568-a42b258d0bd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_1d14e3f6-48a2-4cd4-aeed-c7027cb3d744" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3289dcde-adf7-45e5-9568-a42b258d0bd7" xlink:to="loc_stpr_NJ_1d14e3f6-48a2-4cd4-aeed-c7027cb3d744" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_13892afb-901f-44c3-bffd-68a9450a967b" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3289dcde-adf7-45e5-9568-a42b258d0bd7" xlink:to="loc_country_CA_13892afb-901f-44c3-bffd-68a9450a967b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-BC_d641e86f-4977-41be-804b-bca72337b50d" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA-BC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_country_CA_13892afb-901f-44c3-bffd-68a9450a967b" xlink:to="loc_stpr_CA-BC_d641e86f-4977-41be-804b-bca72337b50d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-QC_52823629-7a6a-4e23-a306-fbd63c16819d" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA-QC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_country_CA_13892afb-901f-44c3-bffd-68a9450a967b" xlink:to="loc_stpr_CA-QC_52823629-7a6a-4e23-a306-fbd63c16819d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_2deb502f-be31-40ae-877d-3218393343b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_2e612f62-abb8-4df7-adbe-1795c67eefa1" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_2deb502f-be31-40ae-877d-3218393343b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_2deb502f-be31-40ae-877d-3218393343b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_2deb502f-be31-40ae-877d-3218393343b4" xlink:to="loc_us-gaap_LossContingencyNatureDomain_2deb502f-be31-40ae-877d-3218393343b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_ee873533-f94e-4d65-83f0-77cd612c8e99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_2deb502f-be31-40ae-877d-3218393343b4" xlink:to="loc_us-gaap_LossContingencyNatureDomain_ee873533-f94e-4d65-83f0-77cd612c8e99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_50a16105-58ec-4d46-b83a-5182a3d26294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_ee873533-f94e-4d65-83f0-77cd612c8e99" xlink:to="loc_us-gaap_UnfavorableRegulatoryActionMember_50a16105-58ec-4d46-b83a-5182a3d26294" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_849abe26-62cd-4e82-a5b0-d5fcf22c6c63" xlink:href="bhc-20220510.xsd#bhc_ViolationofCanadianProvincialSecuritiesLegislationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_ee873533-f94e-4d65-83f0-77cd612c8e99" xlink:to="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_849abe26-62cd-4e82-a5b0-d5fcf22c6c63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_adde6f3e-9343-4d0e-88a6-e2d97bb71bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_2e612f62-abb8-4df7-adbe-1795c67eefa1" xlink:to="loc_us-gaap_LitigationStatusAxis_adde6f3e-9343-4d0e-88a6-e2d97bb71bf6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_adde6f3e-9343-4d0e-88a6-e2d97bb71bf6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_adde6f3e-9343-4d0e-88a6-e2d97bb71bf6" xlink:to="loc_us-gaap_LitigationStatusDomain_adde6f3e-9343-4d0e-88a6-e2d97bb71bf6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_77c82c99-e605-4655-a7d9-fb71ae222ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_adde6f3e-9343-4d0e-88a6-e2d97bb71bf6" xlink:to="loc_us-gaap_LitigationStatusDomain_77c82c99-e605-4655-a7d9-fb71ae222ef7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_e338e94c-7467-4986-9497-81c49f08d16b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_77c82c99-e605-4655-a7d9-fb71ae222ef7" xlink:to="loc_us-gaap_PendingLitigationMember_e338e94c-7467-4986-9497-81c49f08d16b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_f03aa113-5297-4877-88f1-c1f0fd09d10c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_77c82c99-e605-4655-a7d9-fb71ae222ef7" xlink:to="loc_us-gaap_SettledLitigationMember_f03aa113-5297-4877-88f1-c1f0fd09d10c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8ecdf1c5-7447-43cc-b192-4adc60d22eab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_2e612f62-abb8-4df7-adbe-1795c67eefa1" xlink:to="loc_srt_CounterpartyNameAxis_8ecdf1c5-7447-43cc-b192-4adc60d22eab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8ecdf1c5-7447-43cc-b192-4adc60d22eab_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8ecdf1c5-7447-43cc-b192-4adc60d22eab" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8ecdf1c5-7447-43cc-b192-4adc60d22eab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95db7d64-8d70-489a-895b-d5bda93547ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8ecdf1c5-7447-43cc-b192-4adc60d22eab" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95db7d64-8d70-489a-895b-d5bda93547ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PlaintiffsDirectPurchasersMember_3c032ea5-20d2-487e-b78b-43d60a7783b2" xlink:href="bhc-20220510.xsd#bhc_PlaintiffsDirectPurchasersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95db7d64-8d70-489a-895b-d5bda93547ab" xlink:to="loc_bhc_PlaintiffsDirectPurchasersMember_3c032ea5-20d2-487e-b78b-43d60a7783b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fce1ae14-e893-43e3-a631-a0bce3ab956f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_2e612f62-abb8-4df7-adbe-1795c67eefa1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fce1ae14-e893-43e3-a631-a0bce3ab956f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fce1ae14-e893-43e3-a631-a0bce3ab956f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fce1ae14-e893-43e3-a631-a0bce3ab956f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fce1ae14-e893-43e3-a631-a0bce3ab956f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_53b4c750-1bb5-4acb-a351-6661de9a795c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fce1ae14-e893-43e3-a631-a0bce3ab956f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_53b4c750-1bb5-4acb-a351-6661de9a795c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_513d7223-47aa-4461-adc8-d8547c448a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_53b4c750-1bb5-4acb-a351-6661de9a795c" xlink:to="loc_us-gaap_SubsequentEventMember_513d7223-47aa-4461-adc8-d8547c448a9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_58fc3284-a9b8-4874-bcaa-db6c26ecbf34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_2e612f62-abb8-4df7-adbe-1795c67eefa1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_58fc3284-a9b8-4874-bcaa-db6c26ecbf34" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_58fc3284-a9b8-4874-bcaa-db6c26ecbf34_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_58fc3284-a9b8-4874-bcaa-db6c26ecbf34" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_58fc3284-a9b8-4874-bcaa-db6c26ecbf34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_aaef1f5f-1c62-4177-897b-72f2cc7689e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_58fc3284-a9b8-4874-bcaa-db6c26ecbf34" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_aaef1f5f-1c62-4177-897b-72f2cc7689e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember_01a248e9-15fd-4b83-a8ed-e5cbc901cd5d" xlink:href="bhc-20220510.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_aaef1f5f-1c62-4177-897b-72f2cc7689e2" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember_01a248e9-15fd-4b83-a8ed-e5cbc901cd5d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended" id="ief19f2c0308042bf837b182834a51ea6_COMMITMENTSANDCONTINGENCIESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfCommitmentsLineItems_49a14cf7-6795-470a-be5e-bb903176560a" xlink:href="bhc-20220510.xsd#bhc_ScheduleOfCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_0cb912fe-ef4c-414d-9cfc-532c340d4b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ScheduleOfCommitmentsLineItems_49a14cf7-6795-470a-be5e-bb903176560a" xlink:to="loc_us-gaap_ContractualObligation_0cb912fe-ef4c-414d-9cfc-532c340d4b25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CollaborativeAgreementMilestonePaymentsAggregate_8d127300-96e4-4ba2-b50f-62d448f23175" xlink:href="bhc-20220510.xsd#bhc_CollaborativeAgreementMilestonePaymentsAggregate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_ScheduleOfCommitmentsLineItems_49a14cf7-6795-470a-be5e-bb903176560a" xlink:to="loc_bhc_CollaborativeAgreementMilestonePaymentsAggregate_8d127300-96e4-4ba2-b50f-62d448f23175" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfCommitmentsTable_5af8cb5c-25ff-4260-acc4-7b99c8bf9200" xlink:href="bhc-20220510.xsd#bhc_ScheduleOfCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_bhc_ScheduleOfCommitmentsLineItems_49a14cf7-6795-470a-be5e-bb903176560a" xlink:to="loc_bhc_ScheduleOfCommitmentsTable_5af8cb5c-25ff-4260-acc4-7b99c8bf9200" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2966e0e8-cb46-4127-a151-b16cb1a28373" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_bhc_ScheduleOfCommitmentsTable_5af8cb5c-25ff-4260-acc4-7b99c8bf9200" xlink:to="loc_srt_CounterpartyNameAxis_2966e0e8-cb46-4127-a151-b16cb1a28373" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2966e0e8-cb46-4127-a151-b16cb1a28373_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2966e0e8-cb46-4127-a151-b16cb1a28373" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2966e0e8-cb46-4127-a151-b16cb1a28373_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_33c13532-e45a-4b77-9a69-9e4bc8a2e5c1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2966e0e8-cb46-4127-a151-b16cb1a28373" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_33c13532-e45a-4b77-9a69-9e4bc8a2e5c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member_fff9d7ee-1035-452e-9561-333f999c59c4" xlink:href="bhc-20220510.xsd#bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_33c13532-e45a-4b77-9a69-9e4bc8a2e5c1" xlink:to="loc_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member_fff9d7ee-1035-452e-9561-333f999c59c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MitsubishiTanabePharmaCorporationMember_150f3a3c-bae7-4ab1-b848-6426d313077e" xlink:href="bhc-20220510.xsd#bhc_MitsubishiTanabePharmaCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_33c13532-e45a-4b77-9a69-9e4bc8a2e5c1" xlink:to="loc_bhc_MitsubishiTanabePharmaCorporationMember_150f3a3c-bae7-4ab1-b848-6426d313077e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NovaliqGmbHMember_7243b6c9-030f-4d51-bfcc-7682b2095dc9" xlink:href="bhc-20220510.xsd#bhc_NovaliqGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_33c13532-e45a-4b77-9a69-9e4bc8a2e5c1" xlink:to="loc_bhc_NovaliqGmbHMember_7243b6c9-030f-4d51-bfcc-7682b2095dc9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CedarsSinaiMedicalCenterMember_9489aa0e-0e0a-4636-981e-32f4ebede059" xlink:href="bhc-20220510.xsd#bhc_CedarsSinaiMedicalCenterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_33c13532-e45a-4b77-9a69-9e4bc8a2e5c1" xlink:to="loc_bhc_CedarsSinaiMedicalCenterMember_9489aa0e-0e0a-4636-981e-32f4ebede059" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EyenoviaIncMember_852039f6-bf13-437e-968b-169a5f8eeb2f" xlink:href="bhc-20220510.xsd#bhc_EyenoviaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_33c13532-e45a-4b77-9a69-9e4bc8a2e5c1" xlink:to="loc_bhc_EyenoviaIncMember_852039f6-bf13-437e-968b-169a5f8eeb2f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended" id="i8102237693a447aa97e110373f70f03f_SEGMENTINFORMATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_ba8483af-65fe-449c-beee-60ebea946830" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_a2dafbc0-2aad-469d-b807-46c68ad9478c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ba8483af-65fe-449c-beee-60ebea946830" xlink:to="loc_us-gaap_NumberOfReportingUnits_a2dafbc0-2aad-469d-b807-46c68ad9478c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f93f1487-4d63-4345-be5d-d9c27e7dfef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ba8483af-65fe-449c-beee-60ebea946830" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f93f1487-4d63-4345-be5d-d9c27e7dfef7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3bb11057-b588-4fb4-8f09-141951ee6563" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f93f1487-4d63-4345-be5d-d9c27e7dfef7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3bb11057-b588-4fb4-8f09-141951ee6563" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3bb11057-b588-4fb4-8f09-141951ee6563_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3bb11057-b588-4fb4-8f09-141951ee6563" xlink:to="loc_us-gaap_SegmentDomain_3bb11057-b588-4fb4-8f09-141951ee6563_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b566c296-f1ee-4bdd-aa2a-56f39c3edb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3bb11057-b588-4fb4-8f09-141951ee6563" xlink:to="loc_us-gaap_SegmentDomain_b566c296-f1ee-4bdd-aa2a-56f39c3edb7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_7da3d316-10c3-48d8-ac46-6f891ced0727" xlink:href="bhc-20220510.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_b566c296-f1ee-4bdd-aa2a-56f39c3edb7f" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_7da3d316-10c3-48d8-ac46-6f891ced0727" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" xlink:type="extended" id="i502f4590e9f24655aa87571ac3309587_SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_97e450b6-20e7-452e-8830-04d1ee29de52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4bb6d09a-58fc-445d-80a0-7ddd80da48f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_97e450b6-20e7-452e-8830-04d1ee29de52" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4bb6d09a-58fc-445d-80a0-7ddd80da48f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ef4e04c6-4b3d-4615-adc7-0eb24ee42208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_97e450b6-20e7-452e-8830-04d1ee29de52" xlink:to="loc_us-gaap_OperatingIncomeLoss_ef4e04c6-4b3d-4615-adc7-0eb24ee42208" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_490e00cd-eab5-4250-be26-456da679cc66" xlink:href="bhc-20220510.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_97e450b6-20e7-452e-8830-04d1ee29de52" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_490e00cd-eab5-4250-be26-456da679cc66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_0989a6db-52ff-4cfd-bcbc-1590010854d2" xlink:href="bhc-20220510.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_97e450b6-20e7-452e-8830-04d1ee29de52" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_0989a6db-52ff-4cfd-bcbc-1590010854d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_ab9d7a3b-c7b1-44ab-8f41-75d8413a0902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_97e450b6-20e7-452e-8830-04d1ee29de52" xlink:to="loc_us-gaap_AssetImpairmentCharges_ab9d7a3b-c7b1-44ab-8f41-75d8413a0902" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_51199a46-f758-4ac6-b211-af638eb7c1b9" xlink:href="bhc-20220510.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_97e450b6-20e7-452e-8830-04d1ee29de52" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_51199a46-f758-4ac6-b211-af638eb7c1b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_2bb10c27-73b3-4ff0-816d-129c7e5c54d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_97e450b6-20e7-452e-8830-04d1ee29de52" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_2bb10c27-73b3-4ff0-816d-129c7e5c54d3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_244a0215-112d-400c-8bef-2c04afc31b67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_97e450b6-20e7-452e-8830-04d1ee29de52" xlink:to="loc_us-gaap_InvestmentIncomeInterest_244a0215-112d-400c-8bef-2c04afc31b67" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDebtExpense_48aaa656-54a6-44a6-b949-b2f45c0a4a45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndDebtExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_97e450b6-20e7-452e-8830-04d1ee29de52" xlink:to="loc_us-gaap_InterestAndDebtExpense_48aaa656-54a6-44a6-b949-b2f45c0a4a45" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_76880df1-a223-4743-9306-1790462aa1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_97e450b6-20e7-452e-8830-04d1ee29de52" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_76880df1-a223-4743-9306-1790462aa1ae" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ca69e6cd-9648-40d2-aefc-5f8f6354456a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_97e450b6-20e7-452e-8830-04d1ee29de52" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ca69e6cd-9648-40d2-aefc-5f8f6354456a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a4723209-8984-48f6-a287-2988a5066876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_97e450b6-20e7-452e-8830-04d1ee29de52" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a4723209-8984-48f6-a287-2988a5066876" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract_85f04cb3-7e8c-4f90-88fb-94cfe8e81716" xlink:href="bhc-20220510.xsd#bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_97e450b6-20e7-452e-8830-04d1ee29de52" xlink:to="loc_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract_85f04cb3-7e8c-4f90-88fb-94cfe8e81716" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_56eb8f35-9bba-4fdc-b4f0-3d897547b321" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract_85f04cb3-7e8c-4f90-88fb-94cfe8e81716" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_56eb8f35-9bba-4fdc-b4f0-3d897547b321" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b506cbd1-3734-445b-ac50-7926cba2f63b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_97e450b6-20e7-452e-8830-04d1ee29de52" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b506cbd1-3734-445b-ac50-7926cba2f63b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_84c21100-deee-47a3-b6bb-9a00dac328ae" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b506cbd1-3734-445b-ac50-7926cba2f63b" xlink:to="loc_srt_ConsolidationItemsAxis_84c21100-deee-47a3-b6bb-9a00dac328ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_84c21100-deee-47a3-b6bb-9a00dac328ae_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_84c21100-deee-47a3-b6bb-9a00dac328ae" xlink:to="loc_srt_ConsolidationItemsDomain_84c21100-deee-47a3-b6bb-9a00dac328ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_1a357e8d-2eaf-440f-a596-853e6bf41299" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_84c21100-deee-47a3-b6bb-9a00dac328ae" xlink:to="loc_srt_ConsolidationItemsDomain_1a357e8d-2eaf-440f-a596-853e6bf41299" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_d4b9e272-16d9-4a5c-826e-f02fd9015d44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_1a357e8d-2eaf-440f-a596-853e6bf41299" xlink:to="loc_us-gaap_OperatingSegmentsMember_d4b9e272-16d9-4a5c-826e-f02fd9015d44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_0ca8ba2f-24aa-44c4-a530-060fede49249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_1a357e8d-2eaf-440f-a596-853e6bf41299" xlink:to="loc_us-gaap_CorporateNonSegmentMember_0ca8ba2f-24aa-44c4-a530-060fede49249" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4c7bd71d-b2b2-4034-8f51-2f7265cf6cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b506cbd1-3734-445b-ac50-7926cba2f63b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4c7bd71d-b2b2-4034-8f51-2f7265cf6cc7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4c7bd71d-b2b2-4034-8f51-2f7265cf6cc7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4c7bd71d-b2b2-4034-8f51-2f7265cf6cc7" xlink:to="loc_us-gaap_SegmentDomain_4c7bd71d-b2b2-4034-8f51-2f7265cf6cc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_33686b80-7919-472e-8951-98db7a93451e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4c7bd71d-b2b2-4034-8f51-2f7265cf6cc7" xlink:to="loc_us-gaap_SegmentDomain_33686b80-7919-472e-8951-98db7a93451e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_323e29a6-6e7d-4fd1-ad9d-d604e1261035" xlink:href="bhc-20220510.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_33686b80-7919-472e-8951-98db7a93451e" xlink:to="loc_bhc_BauschLombMember_323e29a6-6e7d-4fd1-ad9d-d604e1261035" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_8d7bb267-7e51-4240-b224-9ffa46ed5bad" xlink:href="bhc-20220510.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_33686b80-7919-472e-8951-98db7a93451e" xlink:to="loc_bhc_SalixSegmentMember_8d7bb267-7e51-4240-b224-9ffa46ed5bad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_49d6b30a-9fec-4fdb-b601-35a89616bc3b" xlink:href="bhc-20220510.xsd#bhc_InternationalRxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_33686b80-7919-472e-8951-98db7a93451e" xlink:to="loc_bhc_InternationalRxMember_49d6b30a-9fec-4fdb-b601-35a89616bc3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_b6e490d5-60d8-4947-94de-27af3bedf25a" xlink:href="bhc-20220510.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_33686b80-7919-472e-8951-98db7a93451e" xlink:to="loc_bhc_SoltaMedicalSegmentMember_b6e490d5-60d8-4947-94de-27af3bedf25a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_ec7cdc16-354d-46b7-89ef-c581293169e7" xlink:href="bhc-20220510.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_33686b80-7919-472e-8951-98db7a93451e" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_ec7cdc16-354d-46b7-89ef-c581293169e7" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails" xlink:type="extended" id="i6b1b8213844c4acb94535863cd88601b_SEGMENTINFORMATIONRevenuesbyProductCategoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_98526be2-6a87-429c-bbd7-22d48b302ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskNumberOfProducts_17e4450c-ac73-470d-bdfd-6386c9c283ea" xlink:href="bhc-20220510.xsd#bhc_ConcentrationRiskNumberOfProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_98526be2-6a87-429c-bbd7-22d48b302ece" xlink:to="loc_bhc_ConcentrationRiskNumberOfProducts_17e4450c-ac73-470d-bdfd-6386c9c283ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_a09ee8b1-40be-4fc5-b32e-9b5196691964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_98526be2-6a87-429c-bbd7-22d48b302ece" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_a09ee8b1-40be-4fc5-b32e-9b5196691964" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1b62b43d-b98a-4dd1-b86b-f0051df249d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_98526be2-6a87-429c-bbd7-22d48b302ece" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1b62b43d-b98a-4dd1-b86b-f0051df249d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2d86df2a-3dcf-4948-b6d3-7d36169aa567" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_98526be2-6a87-429c-bbd7-22d48b302ece" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2d86df2a-3dcf-4948-b6d3-7d36169aa567" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8bb40399-21b9-41cf-9ba6-bc696eeb85a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2d86df2a-3dcf-4948-b6d3-7d36169aa567" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8bb40399-21b9-41cf-9ba6-bc696eeb85a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8bb40399-21b9-41cf-9ba6-bc696eeb85a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8bb40399-21b9-41cf-9ba6-bc696eeb85a7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8bb40399-21b9-41cf-9ba6-bc696eeb85a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9f678cd2-7d22-47ca-aa19-9230000af013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8bb40399-21b9-41cf-9ba6-bc696eeb85a7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9f678cd2-7d22-47ca-aa19-9230000af013" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_d605f214-0179-41f3-8b56-21b1fb6e6dcc" xlink:href="bhc-20220510.xsd#bhc_RevenuesNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9f678cd2-7d22-47ca-aa19-9230000af013" xlink:to="loc_bhc_RevenuesNetMember_d605f214-0179-41f3-8b56-21b1fb6e6dcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c1d451b0-5902-464f-ad80-face0dc7a02b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2d86df2a-3dcf-4948-b6d3-7d36169aa567" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c1d451b0-5902-464f-ad80-face0dc7a02b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c1d451b0-5902-464f-ad80-face0dc7a02b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c1d451b0-5902-464f-ad80-face0dc7a02b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c1d451b0-5902-464f-ad80-face0dc7a02b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ebd13227-0f33-4cf0-ac67-b258a7e36977" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c1d451b0-5902-464f-ad80-face0dc7a02b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ebd13227-0f33-4cf0-ac67-b258a7e36977" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_0cc73ea3-974f-482f-8540-d5a791150e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ebd13227-0f33-4cf0-ac67-b258a7e36977" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_0cc73ea3-974f-482f-8540-d5a791150e4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_fe2c3280-5d0f-4956-8f97-964ea6165792" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2d86df2a-3dcf-4948-b6d3-7d36169aa567" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_fe2c3280-5d0f-4956-8f97-964ea6165792" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fe2c3280-5d0f-4956-8f97-964ea6165792_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fe2c3280-5d0f-4956-8f97-964ea6165792" xlink:to="loc_us-gaap_SegmentDomain_fe2c3280-5d0f-4956-8f97-964ea6165792_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1b135ed5-bc80-4c58-a0f8-7637ce513c70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fe2c3280-5d0f-4956-8f97-964ea6165792" xlink:to="loc_us-gaap_SegmentDomain_1b135ed5-bc80-4c58-a0f8-7637ce513c70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_3497e2d4-8c07-4ecc-943a-7b735af444f4" xlink:href="bhc-20220510.xsd#bhc_BauschLombMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1b135ed5-bc80-4c58-a0f8-7637ce513c70" xlink:to="loc_bhc_BauschLombMember_3497e2d4-8c07-4ecc-943a-7b735af444f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_eac02964-7fad-4ad1-8342-69371f3d862b" xlink:href="bhc-20220510.xsd#bhc_SalixSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1b135ed5-bc80-4c58-a0f8-7637ce513c70" xlink:to="loc_bhc_SalixSegmentMember_eac02964-7fad-4ad1-8342-69371f3d862b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_02d7dabd-90ee-465d-85ce-f80eaabbe262" xlink:href="bhc-20220510.xsd#bhc_InternationalRxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1b135ed5-bc80-4c58-a0f8-7637ce513c70" xlink:to="loc_bhc_InternationalRxMember_02d7dabd-90ee-465d-85ce-f80eaabbe262" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_90f8d953-4a58-425f-a3cf-ed140d4bb2b8" xlink:href="bhc-20220510.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1b135ed5-bc80-4c58-a0f8-7637ce513c70" xlink:to="loc_bhc_SoltaMedicalSegmentMember_90f8d953-4a58-425f-a3cf-ed140d4bb2b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_6a58b7dc-3f15-4167-98e9-a4639807d48b" xlink:href="bhc-20220510.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1b135ed5-bc80-4c58-a0f8-7637ce513c70" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_6a58b7dc-3f15-4167-98e9-a4639807d48b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_988459cb-066b-4d26-be95-8eb833df34da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2d86df2a-3dcf-4948-b6d3-7d36169aa567" xlink:to="loc_srt_ProductOrServiceAxis_988459cb-066b-4d26-be95-8eb833df34da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_988459cb-066b-4d26-be95-8eb833df34da_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_988459cb-066b-4d26-be95-8eb833df34da" xlink:to="loc_srt_ProductsAndServicesDomain_988459cb-066b-4d26-be95-8eb833df34da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5ba0c06a-d651-43de-a70d-251eec43d37d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_988459cb-066b-4d26-be95-8eb833df34da" xlink:to="loc_srt_ProductsAndServicesDomain_5ba0c06a-d651-43de-a70d-251eec43d37d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PharmaceuticalProductsMember_e7b688d0-cf43-4d2b-a96e-d055c049a49d" xlink:href="bhc-20220510.xsd#bhc_PharmaceuticalProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ba0c06a-d651-43de-a70d-251eec43d37d" xlink:to="loc_bhc_PharmaceuticalProductsMember_e7b688d0-cf43-4d2b-a96e-d055c049a49d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeviceProductsMember_4af2255b-f7fa-4537-861b-d6c98c074ab1" xlink:href="bhc-20220510.xsd#bhc_DeviceProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ba0c06a-d651-43de-a70d-251eec43d37d" xlink:to="loc_bhc_DeviceProductsMember_4af2255b-f7fa-4537-861b-d6c98c074ab1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OvertheCounterProductsMember_b9a331e3-d405-4e6b-ae29-432992294234" xlink:href="bhc-20220510.xsd#bhc_OvertheCounterProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ba0c06a-d651-43de-a70d-251eec43d37d" xlink:to="loc_bhc_OvertheCounterProductsMember_b9a331e3-d405-4e6b-ae29-432992294234" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BrandedandOtherGenericProductsMember_3e4d4418-758e-4719-ba03-1f8321ee176f" xlink:href="bhc-20220510.xsd#bhc_BrandedandOtherGenericProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ba0c06a-d651-43de-a70d-251eec43d37d" xlink:to="loc_bhc_BrandedandOtherGenericProductsMember_3e4d4418-758e-4719-ba03-1f8321ee176f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherRevenuesMember_c2d09537-c3d7-49f4-b196-2d95a05e7f93" xlink:href="bhc-20220510.xsd#bhc_OtherRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5ba0c06a-d651-43de-a70d-251eec43d37d" xlink:to="loc_bhc_OtherRevenuesMember_c2d09537-c3d7-49f4-b196-2d95a05e7f93" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_657242c8-5c85-44ce-a78a-c4a7915a35ac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2d86df2a-3dcf-4948-b6d3-7d36169aa567" xlink:to="loc_srt_MajorCustomersAxis_657242c8-5c85-44ce-a78a-c4a7915a35ac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_657242c8-5c85-44ce-a78a-c4a7915a35ac_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_657242c8-5c85-44ce-a78a-c4a7915a35ac" xlink:to="loc_srt_NameOfMajorCustomerDomain_657242c8-5c85-44ce-a78a-c4a7915a35ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0a0a1204-a918-463e-8f40-287c1ead1356" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_657242c8-5c85-44ce-a78a-c4a7915a35ac" xlink:to="loc_srt_NameOfMajorCustomerDomain_0a0a1204-a918-463e-8f40-287c1ead1356" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CustomerTopTenProductsMember_b3c9b1b3-5a45-4f3a-8922-8f6764f39d72" xlink:href="bhc-20220510.xsd#bhc_CustomerTopTenProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_0a0a1204-a918-463e-8f40-287c1ead1356" xlink:to="loc_bhc_CustomerTopTenProductsMember_b3c9b1b3-5a45-4f3a-8922-8f6764f39d72" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SEGMENTINFORMATIONGeographicInformationRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails" xlink:type="extended" id="ieb490d8e5c3c41b1b56a977e75da7ed0_SEGMENTINFORMATIONGeographicInformationRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_b72771e1-9dfd-4786-8f3e-ca482dad52d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7de8d1de-e160-48ce-b5a2-f91733ebce94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_b72771e1-9dfd-4786-8f3e-ca482dad52d7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7de8d1de-e160-48ce-b5a2-f91733ebce94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1045f479-d675-4d49-af49-3d796f6b8090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_b72771e1-9dfd-4786-8f3e-ca482dad52d7" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1045f479-d675-4d49-af49-3d796f6b8090" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6ab67be7-35b1-43d2-bf47-8eee165a1429" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1045f479-d675-4d49-af49-3d796f6b8090" xlink:to="loc_srt_StatementGeographicalAxis_6ab67be7-35b1-43d2-bf47-8eee165a1429" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6ab67be7-35b1-43d2-bf47-8eee165a1429_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_6ab67be7-35b1-43d2-bf47-8eee165a1429" xlink:to="loc_srt_SegmentGeographicalDomain_6ab67be7-35b1-43d2-bf47-8eee165a1429_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_6ab67be7-35b1-43d2-bf47-8eee165a1429" xlink:to="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnitedStatesandPuertoRicoMember_00931089-3428-45fe-98a7-6a42b7ea0495" xlink:href="bhc-20220510.xsd#bhc_UnitedStatesandPuertoRicoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:to="loc_bhc_UnitedStatesandPuertoRicoMember_00931089-3428-45fe-98a7-6a42b7ea0495" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_3544fb78-992f-411f-b92a-f9f05b8933f0" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:to="loc_country_CN_3544fb78-992f-411f-b92a-f9f05b8933f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_9ae549b8-ba0d-47e1-b853-9cb7c87a1cb8" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:to="loc_country_CA_9ae549b8-ba0d-47e1-b853-9cb7c87a1cb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PL_d86fe157-8775-4687-b524-b6ada867f308" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_PL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:to="loc_country_PL_d86fe157-8775-4687-b524-b6ada867f308" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX_13f3d14d-4139-4069-81be-6624d750ed38" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_MX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:to="loc_country_MX_13f3d14d-4139-4069-81be-6624d750ed38" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_b9ed64b7-789b-4144-b2fc-5c85243c5cf9" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:to="loc_country_JP_b9ed64b7-789b-4144-b2fc-5c85243c5cf9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_a22af6f5-45ee-403c-8528-95490dc058ea" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:to="loc_country_FR_a22af6f5-45ee-403c-8528-95490dc058ea" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_RU_f0de7d08-7833-4e9d-8130-b681c1655464" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_RU"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:to="loc_country_RU_f0de7d08-7833-4e9d-8130-b681c1655464" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_EG_03cb3b90-6917-47c6-a64e-8493da2840fa" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_EG"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:to="loc_country_EG_03cb3b90-6917-47c6-a64e-8493da2840fa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_60fd0697-acbb-472e-b14f-6f527cad486f" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:to="loc_country_DE_60fd0697-acbb-472e-b14f-6f527cad486f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_05d9c539-dd2b-4873-8e6b-c95e16884105" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_GB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:to="loc_country_GB_05d9c539-dd2b-4873-8e6b-c95e16884105" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES_c9127d43-ebb8-4942-bf91-e4385c3e5782" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_ES"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:to="loc_country_ES_c9127d43-ebb8-4942-bf91-e4385c3e5782" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IT_601f1f4d-5f2e-4c80-abca-613289be82cd" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IT"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:to="loc_country_IT_601f1f4d-5f2e-4c80-abca-613289be82cd" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherCountriesMember_6d4dbbbd-1118-447e-9d6a-fa6209e62797" xlink:href="bhc-20220510.xsd#bhc_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:to="loc_bhc_OtherCountriesMember_6d4dbbbd-1118-447e-9d6a-fa6209e62797" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails" xlink:type="extended" id="i7ac0075c9cff47d780a9b2d35ee88c9f_SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_27b1d024-ffe5-4669-ae81-ccac74a36db3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_af34d30d-8b3f-4fc7-b00b-7bae3c56fbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_27b1d024-ffe5-4669-ae81-ccac74a36db3" xlink:to="loc_us-gaap_NoncurrentAssets_af34d30d-8b3f-4fc7-b00b-7bae3c56fbd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_fe4a9b59-8dd5-4d3d-a7eb-dc751f926464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_27b1d024-ffe5-4669-ae81-ccac74a36db3" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_fe4a9b59-8dd5-4d3d-a7eb-dc751f926464" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a9021bd9-6e8c-4551-a6b3-f5d39e8ddc5e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_fe4a9b59-8dd5-4d3d-a7eb-dc751f926464" xlink:to="loc_srt_StatementGeographicalAxis_a9021bd9-6e8c-4551-a6b3-f5d39e8ddc5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a9021bd9-6e8c-4551-a6b3-f5d39e8ddc5e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_a9021bd9-6e8c-4551-a6b3-f5d39e8ddc5e" xlink:to="loc_srt_SegmentGeographicalDomain_a9021bd9-6e8c-4551-a6b3-f5d39e8ddc5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_564c01d5-a9b5-4291-9f87-cff8937c58c0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_a9021bd9-6e8c-4551-a6b3-f5d39e8ddc5e" xlink:to="loc_srt_SegmentGeographicalDomain_564c01d5-a9b5-4291-9f87-cff8937c58c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnitedStatesandPuertoRicoMember_c80b7d8e-2366-45d1-a4ad-4b17675ee26b" xlink:href="bhc-20220510.xsd#bhc_UnitedStatesandPuertoRicoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_564c01d5-a9b5-4291-9f87-cff8937c58c0" xlink:to="loc_bhc_UnitedStatesandPuertoRicoMember_c80b7d8e-2366-45d1-a4ad-4b17675ee26b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_ac8831ba-3ab3-4171-9066-21661f493594" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_564c01d5-a9b5-4291-9f87-cff8937c58c0" xlink:to="loc_country_IE_ac8831ba-3ab3-4171-9066-21661f493594" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_e00cb90d-e724-4388-b11f-4d9eb86b8961" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_564c01d5-a9b5-4291-9f87-cff8937c58c0" xlink:to="loc_country_CA_e00cb90d-e724-4388-b11f-4d9eb86b8961" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PL_4e39fb8d-25ca-4a7b-af2a-e029ff5c2b54" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_PL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_564c01d5-a9b5-4291-9f87-cff8937c58c0" xlink:to="loc_country_PL_4e39fb8d-25ca-4a7b-af2a-e029ff5c2b54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_1ee9d8c9-7466-43e4-8858-c591b7a9d591" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_564c01d5-a9b5-4291-9f87-cff8937c58c0" xlink:to="loc_country_DE_1ee9d8c9-7466-43e4-8858-c591b7a9d591" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX_0541799e-1e92-4637-a240-fab39774f902" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_MX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_564c01d5-a9b5-4291-9f87-cff8937c58c0" xlink:to="loc_country_MX_0541799e-1e92-4637-a240-fab39774f902" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_9591ff25-7552-4a7f-b946-c5506ee59520" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_564c01d5-a9b5-4291-9f87-cff8937c58c0" xlink:to="loc_country_FR_9591ff25-7552-4a7f-b946-c5506ee59520" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_cffae110-88fc-46be-b7e4-3cd121836fb8" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_564c01d5-a9b5-4291-9f87-cff8937c58c0" xlink:to="loc_country_CN_cffae110-88fc-46be-b7e4-3cd121836fb8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_RS_40b3bf63-8973-46d8-a1f8-d84a486352c0" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_RS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_564c01d5-a9b5-4291-9f87-cff8937c58c0" xlink:to="loc_country_RS_40b3bf63-8973-46d8-a1f8-d84a486352c0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IT_d5c843ea-b694-4487-a8e7-9470507179b4" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IT"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_564c01d5-a9b5-4291-9f87-cff8937c58c0" xlink:to="loc_country_IT_d5c843ea-b694-4487-a8e7-9470507179b4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherCountriesMember_29c36e50-f9b1-4d8b-bfcd-f2bfd11bb44d" xlink:href="bhc-20220510.xsd#bhc_OtherCountriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_564c01d5-a9b5-4291-9f87-cff8937c58c0" xlink:to="loc_bhc_OtherCountriesMember_29c36e50-f9b1-4d8b-bfcd-f2bfd11bb44d" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SEGMENTINFORMATIONMajorCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="extended" id="i0040a85d18b94223b27ee40550f6eb7a_SEGMENTINFORMATIONMajorCustomersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_741147bc-e5ae-4e33-a940-6a4864e145c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_782884fd-17d8-4adf-ba8c-25bad9c38516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_741147bc-e5ae-4e33-a940-6a4864e145c3" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_782884fd-17d8-4adf-ba8c-25bad9c38516" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_fd83f75e-66c8-491b-9c04-a72432995cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_741147bc-e5ae-4e33-a940-6a4864e145c3" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_fd83f75e-66c8-491b-9c04-a72432995cb8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_4babe1ed-ee9d-488e-aa57-28686d1b1757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_fd83f75e-66c8-491b-9c04-a72432995cb8" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_4babe1ed-ee9d-488e-aa57-28686d1b1757" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4babe1ed-ee9d-488e-aa57-28686d1b1757_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_4babe1ed-ee9d-488e-aa57-28686d1b1757" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4babe1ed-ee9d-488e-aa57-28686d1b1757_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6f3194e6-682d-41f0-bd77-6e088dc2cb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_4babe1ed-ee9d-488e-aa57-28686d1b1757" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6f3194e6-682d-41f0-bd77-6e088dc2cb3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_c6717112-610d-4e94-a8eb-89cf9dbfc1a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_6f3194e6-682d-41f0-bd77-6e088dc2cb3c" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_c6717112-610d-4e94-a8eb-89cf9dbfc1a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c7db25d8-5866-4745-bcc6-1f1b842a12ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_fd83f75e-66c8-491b-9c04-a72432995cb8" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c7db25d8-5866-4745-bcc6-1f1b842a12ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c7db25d8-5866-4745-bcc6-1f1b842a12ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c7db25d8-5866-4745-bcc6-1f1b842a12ff" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c7db25d8-5866-4745-bcc6-1f1b842a12ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0e73c552-a0bf-4a34-a073-e537882047e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c7db25d8-5866-4745-bcc6-1f1b842a12ff" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0e73c552-a0bf-4a34-a073-e537882047e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_19048ff1-09bd-47cf-8e93-c237c82f0cbb" xlink:href="bhc-20220510.xsd#bhc_RevenuesNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0e73c552-a0bf-4a34-a073-e537882047e7" xlink:to="loc_bhc_RevenuesNetMember_19048ff1-09bd-47cf-8e93-c237c82f0cbb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_32a22493-b3de-4a1f-a6d4-3b0567d21d9f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_fd83f75e-66c8-491b-9c04-a72432995cb8" xlink:to="loc_srt_MajorCustomersAxis_32a22493-b3de-4a1f-a6d4-3b0567d21d9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_32a22493-b3de-4a1f-a6d4-3b0567d21d9f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_32a22493-b3de-4a1f-a6d4-3b0567d21d9f" xlink:to="loc_srt_NameOfMajorCustomerDomain_32a22493-b3de-4a1f-a6d4-3b0567d21d9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_9434a810-0f32-495b-a79a-56e6cc520505" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_32a22493-b3de-4a1f-a6d4-3b0567d21d9f" xlink:to="loc_srt_NameOfMajorCustomerDomain_9434a810-0f32-495b-a79a-56e6cc520505" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmerisourceBergenCorporationMember_350caaac-a8e5-4099-9f83-ca8b4de73059" xlink:href="bhc-20220510.xsd#bhc_AmerisourceBergenCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9434a810-0f32-495b-a79a-56e6cc520505" xlink:to="loc_bhc_AmerisourceBergenCorporationMember_350caaac-a8e5-4099-9f83-ca8b4de73059" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_McKessonCorporationMember_aa81e804-1c72-42d7-bf76-7c5d26daa825" xlink:href="bhc-20220510.xsd#bhc_McKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9434a810-0f32-495b-a79a-56e6cc520505" xlink:to="loc_bhc_McKessonCorporationMember_aa81e804-1c72-42d7-bf76-7c5d26daa825" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CardinalHealthIncMember_03a94cb2-0505-43a4-9620-6b5393255d99" xlink:href="bhc-20220510.xsd#bhc_CardinalHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_9434a810-0f32-495b-a79a-56e6cc520505" xlink:to="loc_bhc_CardinalHealthIncMember_03a94cb2-0505-43a4-9620-6b5393255d99" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SUBSEQUENTEVENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails" xlink:type="extended" id="i53514701d582426e978a846c53a50db1_SUBSEQUENTEVENTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_6fbd3252-9575-45b5-9822-e43b1df14e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_e5ae3817-7890-49da-bb57-53f1bfe80095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fbd3252-9575-45b5-9822-e43b1df14e5a" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_e5ae3817-7890-49da-bb57-53f1bfe80095" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_4771da95-a9bc-444b-b07d-760570a0553b" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fbd3252-9575-45b5-9822-e43b1df14e5a" xlink:to="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_4771da95-a9bc-444b-b07d-760570a0553b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentExpectedFaceAmount_a0b649dc-fec8-400b-b14d-458088e05974" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentExpectedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fbd3252-9575-45b5-9822-e43b1df14e5a" xlink:to="loc_bhc_DebtInstrumentExpectedFaceAmount_a0b649dc-fec8-400b-b14d-458088e05974" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity_28100316-df88-44b7-88cc-f716e28d8dd2" xlink:href="bhc-20220510.xsd#bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fbd3252-9575-45b5-9822-e43b1df14e5a" xlink:to="loc_bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity_28100316-df88-44b7-88cc-f716e28d8dd2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio_b0e315ec-b983-435e-a650-86d39f424e95" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fbd3252-9575-45b5-9822-e43b1df14e5a" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio_b0e315ec-b983-435e-a650-86d39f424e95" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_26d5b79c-2044-4259-8184-8e0726d19483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fbd3252-9575-45b5-9822-e43b1df14e5a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_26d5b79c-2044-4259-8184-8e0726d19483" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b0ea44b4-6b28-4212-9fae-b9c21e55b14f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fbd3252-9575-45b5-9822-e43b1df14e5a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b0ea44b4-6b28-4212-9fae-b9c21e55b14f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_f0f81913-c0bb-433a-a015-05d7fa1c773a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fbd3252-9575-45b5-9822-e43b1df14e5a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_f0f81913-c0bb-433a-a015-05d7fa1c773a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_5e1ad9ce-13a5-4dcb-8c79-6a5631a94569" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fbd3252-9575-45b5-9822-e43b1df14e5a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_5e1ad9ce-13a5-4dcb-8c79-6a5631a94569" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_cca4ef0c-7af1-427c-a514-1b935f2ba341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fbd3252-9575-45b5-9822-e43b1df14e5a" xlink:to="loc_us-gaap_SubsequentEventTable_cca4ef0c-7af1-427c-a514-1b935f2ba341" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d5947fa0-902b-4f4d-a16c-3dc4a0aee307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_cca4ef0c-7af1-427c-a514-1b935f2ba341" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d5947fa0-902b-4f4d-a16c-3dc4a0aee307" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d5947fa0-902b-4f4d-a16c-3dc4a0aee307_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d5947fa0-902b-4f4d-a16c-3dc4a0aee307" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d5947fa0-902b-4f4d-a16c-3dc4a0aee307_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_78932273-a4f6-47ec-89f2-14f6049919ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d5947fa0-902b-4f4d-a16c-3dc4a0aee307" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_78932273-a4f6-47ec-89f2-14f6049919ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_60b2b5ca-e301-4ede-a7c9-a840e7c29a46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_78932273-a4f6-47ec-89f2-14f6049919ae" xlink:to="loc_us-gaap_SubsequentEventMember_60b2b5ca-e301-4ede-a7c9-a840e7c29a46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_04bbeb23-7494-40f4-9228-29d749bc73e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_cca4ef0c-7af1-427c-a514-1b935f2ba341" xlink:to="loc_us-gaap_DebtInstrumentAxis_04bbeb23-7494-40f4-9228-29d749bc73e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_04bbeb23-7494-40f4-9228-29d749bc73e3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_04bbeb23-7494-40f4-9228-29d749bc73e3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_04bbeb23-7494-40f4-9228-29d749bc73e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_41381af0-f86c-4366-900e-0d3998b71c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_04bbeb23-7494-40f4-9228-29d749bc73e3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_41381af0-f86c-4366-900e-0d3998b71c1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.00SeniorNotesdueDecember2025Member_5e57aa30-6d0b-4a5b-b73e-d304993f9053" xlink:href="bhc-20220510.xsd#bhc_A9.00SeniorNotesdueDecember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_41381af0-f86c-4366-900e-0d3998b71c1a" xlink:to="loc_bhc_A9.00SeniorNotesdueDecember2025Member_5e57aa30-6d0b-4a5b-b73e-d304993f9053" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NewRestatedCreditAgreementMember_85f56d69-8164-4ab2-adf9-c1105d293e78" xlink:href="bhc-20220510.xsd#bhc_NewRestatedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_41381af0-f86c-4366-900e-0d3998b71c1a" xlink:to="loc_bhc_NewRestatedCreditAgreementMember_85f56d69-8164-4ab2-adf9-c1105d293e78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember_95f84ffc-f7c7-455c-9039-8951fa14ae57" xlink:href="bhc-20220510.xsd#bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_NewRestatedCreditAgreementMember_85f56d69-8164-4ab2-adf9-c1105d293e78" xlink:to="loc_bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember_95f84ffc-f7c7-455c-9039-8951fa14ae57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityNewRestatedCreditAgreementMember_41abfc89-9157-4ffc-a146-41c0fbb936e5" xlink:href="bhc-20220510.xsd#bhc_TermLoanBFacilityNewRestatedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bhc_NewRestatedCreditAgreementMember_85f56d69-8164-4ab2-adf9-c1105d293e78" xlink:to="loc_bhc_TermLoanBFacilityNewRestatedCreditAgreementMember_41abfc89-9157-4ffc-a146-41c0fbb936e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_f0abfe82-abd0-454f-8337-fc663df06cba" xlink:href="bhc-20220510.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_41381af0-f86c-4366-900e-0d3998b71c1a" xlink:to="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_f0abfe82-abd0-454f-8337-fc663df06cba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3d36cfac-2be7-4c62-a5fa-3fd63c1e057e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_cca4ef0c-7af1-427c-a514-1b935f2ba341" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3d36cfac-2be7-4c62-a5fa-3fd63c1e057e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3d36cfac-2be7-4c62-a5fa-3fd63c1e057e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3d36cfac-2be7-4c62-a5fa-3fd63c1e057e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3d36cfac-2be7-4c62-a5fa-3fd63c1e057e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_96cdcc7e-cdaf-4de4-a127-aeb355853256" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3d36cfac-2be7-4c62-a5fa-3fd63c1e057e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_96cdcc7e-cdaf-4de4-a127-aeb355853256" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_ccedd57e-1037-4354-9e69-930eb9231ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_96cdcc7e-cdaf-4de4-a127-aeb355853256" xlink:to="loc_us-gaap_UnsecuredDebtMember_ccedd57e-1037-4354-9e69-930eb9231ece" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_1ada5803-d6ea-415b-996a-600a4316c21c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_96cdcc7e-cdaf-4de4-a127-aeb355853256" xlink:to="loc_us-gaap_SecuredDebtMember_1ada5803-d6ea-415b-996a-600a4316c21c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_3b023c7d-510e-4507-8858-80ecb2ef76fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_cca4ef0c-7af1-427c-a514-1b935f2ba341" xlink:to="loc_us-gaap_CreditFacilityAxis_3b023c7d-510e-4507-8858-80ecb2ef76fa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_3b023c7d-510e-4507-8858-80ecb2ef76fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_3b023c7d-510e-4507-8858-80ecb2ef76fa" xlink:to="loc_us-gaap_CreditFacilityDomain_3b023c7d-510e-4507-8858-80ecb2ef76fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_661ec018-762a-49e6-9f95-eabc4dc46289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_3b023c7d-510e-4507-8858-80ecb2ef76fa" xlink:to="loc_us-gaap_CreditFacilityDomain_661ec018-762a-49e6-9f95-eabc4dc46289" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_005d67a4-55a7-4aaa-b9da-7a7dc4ca85bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_661ec018-762a-49e6-9f95-eabc4dc46289" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_005d67a4-55a7-4aaa-b9da-7a7dc4ca85bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_9325cd24-2f36-4400-9161-dd953a76fb99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_cca4ef0c-7af1-427c-a514-1b935f2ba341" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_9325cd24-2f36-4400-9161-dd953a76fb99" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_9325cd24-2f36-4400-9161-dd953a76fb99_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_9325cd24-2f36-4400-9161-dd953a76fb99" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_9325cd24-2f36-4400-9161-dd953a76fb99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8948017b-a335-443f-a2d4-5fa58fbcc0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_9325cd24-2f36-4400-9161-dd953a76fb99" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8948017b-a335-443f-a2d4-5fa58fbcc0ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_cd0d8e2b-3063-42cc-84ae-83231b7e97eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8948017b-a335-443f-a2d4-5fa58fbcc0ad" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_cd0d8e2b-3063-42cc-84ae-83231b7e97eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_0434641c-c085-49e7-9c51-1362a1c58938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8948017b-a335-443f-a2d4-5fa58fbcc0ad" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_0434641c-c085-49e7-9c51-1362a1c58938" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9bfa9689-bfa7-43d1-add6-d4a325947640" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_cca4ef0c-7af1-427c-a514-1b935f2ba341" xlink:to="loc_srt_RangeAxis_9bfa9689-bfa7-43d1-add6-d4a325947640" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9bfa9689-bfa7-43d1-add6-d4a325947640_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9bfa9689-bfa7-43d1-add6-d4a325947640" xlink:to="loc_srt_RangeMember_9bfa9689-bfa7-43d1-add6-d4a325947640_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b601ccd3-9d71-47e8-a9cd-812ca7ef702f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9bfa9689-bfa7-43d1-add6-d4a325947640" xlink:to="loc_srt_RangeMember_b601ccd3-9d71-47e8-a9cd-812ca7ef702f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9e771b80-686e-4f0d-ade4-8e43f5db3905" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b601ccd3-9d71-47e8-a9cd-812ca7ef702f" xlink:to="loc_srt_MaximumMember_9e771b80-686e-4f0d-ade4-8e43f5db3905" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>bhc-20220510_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:9acca3cc-2386-49dd-bd2b-e67723848b1a,g:d4f0cfd5-5dd4-484a-81ac-21ef5810b617-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_879ab856-2b6f-4693-b2eb-b04eb0de1066_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other payments</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueCommissionersIrelandMember_9a2f57d0-535b-4f95-ac16-53b254845abb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueCommissionersIrelandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Commissioners, Ireland</link:label>
    <link:label id="lab_us-gaap_RevenueCommissionersIrelandMember_label_en-US" xlink:label="lab_us-gaap_RevenueCommissionersIrelandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Commissioners, Ireland [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueCommissionersIrelandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueCommissionersIrelandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueCommissionersIrelandMember" xlink:to="lab_us-gaap_RevenueCommissionersIrelandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_27aae8f5-3d75-4e1d-a21c-60bb2f2c098a_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Major Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_129e5a0b-d6aa-4832-a58a-c1204cdd33e4_terseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEGAL PROCEEDINGS</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_480e0242-da16-48db-9ab7-fca49048158c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial (gain) losses</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_0e019eb3-1eee-462d-8ec1-2064a54d6417_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1364e7f5-a4b9-4fe3-846d-39481c288f5c_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_aac13c5f-7885-4101-a4d9-c0aab0b68143_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock_21388057-0c2e-49d8-a70d-69615cd818bc_terseLabel_en-US" xlink:label="lab_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of pension and postretirement benefit plan assets assumed in connection with the Acquisition</link:label>
    <link:label id="lab_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock_label_en-US" xlink:label="lab_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with Acquisition [Table Text Block]</link:label>
    <link:label id="lab_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock_documentation_en-US" xlink:label="lab_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock" xlink:href="bhc-20220510.xsd#bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock" xlink:to="lab_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_acb0a108-855d-4f01-947b-776bf8eef1ca_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_2077e07b-f8cd-4b6e-a810-ed3e6ec999bd_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_757a269f-067b-43a2-b354-a79aa50ec233_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_9180fec1-ae95-4831-b130-9e2e2341e48b_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA-BC_ac6f471e-7f06-4838-9bbb-9697c1820d88_terseLabel_en-US" xlink:label="lab_stpr_CA-BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">British Columbia</link:label>
    <link:label id="lab_stpr_CA-BC_label_en-US" xlink:label="lab_stpr_CA-BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BRITISH COLUMBIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-BC" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA-BC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA-BC" xlink:to="lab_stpr_CA-BC" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_36f45899-0eae-4024-8607-272e73d72a92_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a097f0f1-d1cd-4e14-8962-ad5872859873_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CollaborativeAgreementMilestonePaymentsAggregate_accdfcb1-ce03-463d-a0f5-c76bf57670fc_terseLabel_en-US" xlink:label="lab_bhc_CollaborativeAgreementMilestonePaymentsAggregate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments in terms of collaboration and license agreements, aggregate</link:label>
    <link:label id="lab_bhc_CollaborativeAgreementMilestonePaymentsAggregate_label_en-US" xlink:label="lab_bhc_CollaborativeAgreementMilestonePaymentsAggregate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone Payments, Aggregate</link:label>
    <link:label id="lab_bhc_CollaborativeAgreementMilestonePaymentsAggregate_documentation_en-US" xlink:label="lab_bhc_CollaborativeAgreementMilestonePaymentsAggregate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amounts required to be paid by the reporting entity, which are contingent upon the achievement of specific development, regulatory or commercial milestones, in connection with the Collaboration Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CollaborativeAgreementMilestonePaymentsAggregate" xlink:href="bhc-20220510.xsd#bhc_CollaborativeAgreementMilestonePaymentsAggregate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CollaborativeAgreementMilestonePaymentsAggregate" xlink:to="lab_bhc_CollaborativeAgreementMilestonePaymentsAggregate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_88b622d2-dd8d-4f49-9417-d45a9fb585f3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of acquisition-related contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_a88a124f-dbb8-43d2-b983-e709a42cbe40_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_ee155e28-af2f-483a-9b1c-bd6e47e08ce1_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherAssetsFixedIncomeSecuritiesMember_7871e14a-bd23-4d45-b9a0-1ff3623ac37d_terseLabel_en-US" xlink:label="lab_bhc_OtherAssetsFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_bhc_OtherAssetsFixedIncomeSecuritiesMember_label_en-US" xlink:label="lab_bhc_OtherAssetsFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Fixed Income Securities [Member]</link:label>
    <link:label id="lab_bhc_OtherAssetsFixedIncomeSecuritiesMember_documentation_en-US" xlink:label="lab_bhc_OtherAssetsFixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Fixed Income Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherAssetsFixedIncomeSecuritiesMember" xlink:href="bhc-20220510.xsd#bhc_OtherAssetsFixedIncomeSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherAssetsFixedIncomeSecuritiesMember" xlink:to="lab_bhc_OtherAssetsFixedIncomeSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromHedgeInvestingActivities_f1491b56-173f-4c1d-8505-10492464c657_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds, cross-currency swaps</link:label>
    <link:label id="lab_us-gaap_ProceedsFromHedgeInvestingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Hedge, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromHedgeInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:to="lab_us-gaap_ProceedsFromHedgeInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SynergyPharmaceuticalsInc.Member_081035c3-2457-4143-8eb1-18b028985631_terseLabel_en-US" xlink:label="lab_bhc_SynergyPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Synergy</link:label>
    <link:label id="lab_bhc_SynergyPharmaceuticalsInc.Member_label_en-US" xlink:label="lab_bhc_SynergyPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Synergy Pharmaceuticals Inc. [Member]</link:label>
    <link:label id="lab_bhc_SynergyPharmaceuticalsInc.Member_documentation_en-US" xlink:label="lab_bhc_SynergyPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Synergy Pharmaceuticals Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SynergyPharmaceuticalsInc.Member" xlink:href="bhc-20220510.xsd#bhc_SynergyPharmaceuticalsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SynergyPharmaceuticalsInc.Member" xlink:to="lab_bhc_SynergyPharmaceuticalsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_760f3f22-1980-469b-8a8f-9307034e88a0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aa80e6c4-f0c1-462f-a5c7-df48ccc3c5a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_731f1831-75aa-4abb-a137-ff13c686882a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_219061f3-10b9-4e3f-96e1-489f9f73aefb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for future grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b04573e5-56af-4d32-8586-01eaddac0c2d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in Cash and cash equivalents and Restricted cash and other settlement deposits</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_45ac82bc-aff4-4a36-99d3-2747ebe0f22e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f9a58e24-1df2-4d20-a04f-504305f38855_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Company share volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember_cf2fa2ad-7700-455e-851c-dd488213b773_terseLabel_en-US" xlink:label="lab_bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Argentina, Brazil, Egypt, Greece, Serbia, South Africa, Turkey, Ukraine, Venezuela and Vietnam</link:label>
    <link:label id="lab_bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember_label_en-US" xlink:label="lab_bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Argentina, Brazil, Egypt, Greece, Serbia, South Africa, Turkey, Ukraine, Venezuela and Vietnam [Member]</link:label>
    <link:label id="lab_bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember_documentation_en-US" xlink:label="lab_bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Argentina, Brazil, Egypt, Greece, Serbia, South Africa, Turkey, Ukraine, Venezuela and Vietnam</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember" xlink:href="bhc-20220510.xsd#bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember" xlink:to="lab_bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_6f1bb7de-8842-41c5-8492-428e52285a21_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_31f6e163-a099-442c-b0ba-e63957150473_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_8296c12a-5b51-47ea-b261-808d27c1a497_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_aa319b49-7a9e-4cb5-b22a-719e3e71a000_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of stock options exercised in the period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_bb249cee-3897-41f9-bc4d-1b587c03650b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration adjustments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IncomeTaxLineItems_fb604c54-df96-4af2-9bd4-012f80d5bfa5_terseLabel_en-US" xlink:label="lab_bhc_IncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Line Items]</link:label>
    <link:label id="lab_bhc_IncomeTaxLineItems_label_en-US" xlink:label="lab_bhc_IncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Line Items]</link:label>
    <link:label id="lab_bhc_IncomeTaxLineItems_documentation_en-US" xlink:label="lab_bhc_IncomeTaxLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxLineItems" xlink:href="bhc-20220510.xsd#bhc_IncomeTaxLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IncomeTaxLineItems" xlink:to="lab_bhc_IncomeTaxLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_518259bc-78e7-42d9-aef6-f2dd3cafc053_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain on sales of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_1451d893-9f55-4d30-a8d1-a0a5dec0ebef_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone achievement, included in net gain (loss) on other sales of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember_f3bec12e-97d4-4a56-ab2a-48826b6227f8_terseLabel_en-US" xlink:label="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Doctors Allergy Formula, LLC Litigation</link:label>
    <link:label id="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember_label_en-US" xlink:label="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Doctors Allergy Formula, LLC Litigation [Member]</link:label>
    <link:label id="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember_documentation_en-US" xlink:label="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Doctors Allergy Formula, LLC Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:href="bhc-20220510.xsd#bhc_DoctorsAllergyFormulaLLCLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:to="lab_bhc_DoctorsAllergyFormulaLLCLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_dc84d74a-6688-40fb-bd9e-586de5da801c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_b9415b91-663e-4c66-a9c6-99792b2a7401_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_b6ba1824-018a-4e0e-a338-6552e8bacc6b_negatedTerseLabel_en-US" xlink:label="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of contingent consideration adjustments, including accretion</link:label>
    <link:label id="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_label_en-US" xlink:label="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Contingent Consideration Liability, Including Accretion, Operating Activities</link:label>
    <link:label id="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_documentation_en-US" xlink:label="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Contingent Consideration Liability, Including Accretion, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" xlink:href="bhc-20220510.xsd#bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" xlink:to="lab_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermLoanBFacilityDueNovember2025Member_3150bd32-92b8-4790-ad5a-389a1bc20987_terseLabel_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due November 2025</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueNovember2025Member_label_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due November 2025 [Member]</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueNovember2025Member_documentation_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due November 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member" xlink:href="bhc-20220510.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermLoanBFacilityDueNovember2025Member" xlink:to="lab_bhc_TermLoanBFacilityDueNovember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_ea4e50c1-0a6d-4cb9-ad33-4581d86b2c3c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product brand intangible assets (estimated useful life 7 years)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_e1171543-61d8-4dcb-9282-85a9785f6716_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_44e4a1e5-b096-48e6-a166-4f454e8b8a78_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentExpectedFaceAmount_535ce30f-f2b8-4a0b-8c05-706082476497_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentExpectedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected aggregate principal amount</link:label>
    <link:label id="lab_bhc_DebtInstrumentExpectedFaceAmount_label_en-US" xlink:label="lab_bhc_DebtInstrumentExpectedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Expected Face Amount</link:label>
    <link:label id="lab_bhc_DebtInstrumentExpectedFaceAmount_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentExpectedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Expected Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentExpectedFaceAmount" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentExpectedFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentExpectedFaceAmount" xlink:to="lab_bhc_DebtInstrumentExpectedFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_df8af49c-2e92-44e8-b84c-6dea940a454e_terseLabel_en-US" xlink:label="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Units Excluding Ortho Dermatologics</link:label>
    <link:label id="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_label_en-US" xlink:label="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Units Excluding Ortho Dermatologics [Member]</link:label>
    <link:label id="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_documentation_en-US" xlink:label="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Units Excluding Ortho Dermatologics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:href="bhc-20220510.xsd#bhc_ReportingUnitsExcludingOrthoDermatologicsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:to="lab_bhc_ReportingUnitsExcludingOrthoDermatologicsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SandozLitigationMember_0a93192d-a5a7-4875-a96d-1a7dde11a9e7_terseLabel_en-US" xlink:label="lab_bhc_SandozLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sandoz Litigation</link:label>
    <link:label id="lab_bhc_SandozLitigationMember_label_en-US" xlink:label="lab_bhc_SandozLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sandoz Litigation [Member]</link:label>
    <link:label id="lab_bhc_SandozLitigationMember_documentation_en-US" xlink:label="lab_bhc_SandozLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sandoz Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SandozLitigationMember" xlink:href="bhc-20220510.xsd#bhc_SandozLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SandozLitigationMember" xlink:to="lab_bhc_SandozLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_33f54040-2f48-42cc-b627-ab49f910943f_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5984d1e9-6f77-4a66-9cac-1c1f35b36182_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excluded from computation of diluted earnings per share, effect anti-dilutive (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_109e2bb2-1dfc-4929-91c4-be8aa7e1c542_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_d131a5ac-65a0-4df0-8887-2b05ef8e8d28_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the components of inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_fd39ecf1-5858-483d-b687-3e73c1bd4d91_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_c1c030cc-6b42-42ca-9f3a-934cd2facc75_terseLabel_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_af7b278b-a4d1-4106-b670-ca7a2bf88d0b_negatedTerseLabel_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_label_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets Excluding Amortization Allocated to Revenues Cost of Good Sold</link:label>
    <link:label id="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_documentation_en-US" xlink:label="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:href="bhc-20220510.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:to="lab_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_27f1c49b-346e-406b-bd44-e7373cced554_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits_0a4f0eec-8c47-4b87-b299-01a77de88956_periodStartLabel_en-US" xlink:label="lab_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and Restricted cash and other settlement deposits, beginning of year</link:label>
    <link:label id="lab_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits_4b7c1603-324d-42bd-a197-083e83c4ce1f_periodEndLabel_en-US" xlink:label="lab_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and Restricted cash and other settlement deposits, end of year</link:label>
    <link:label id="lab_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits_28107acb-8fc1-42f4-a93c-a1a61fd8091f_totalLabel_en-US" xlink:label="lab_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and Restricted cash and other settlement deposits, end of year</link:label>
    <link:label id="lab_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits_label_en-US" xlink:label="lab_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, And Other Settlement Deposits</link:label>
    <link:label id="lab_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits_documentation_en-US" xlink:label="lab_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, And Other Settlement Deposits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" xlink:href="bhc-20220510.xsd#bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" xlink:to="lab_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_411d9bef-dbd6-46f8-b4a6-cdb1d4a2efad_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets net of valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember_e05bb1a9-d763-4989-8bbf-e9cad236a294_terseLabel_en-US" xlink:label="lab_bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.875% Senior Notes due May 2023, May 2019 Refinancing</link:label>
    <link:label id="lab_bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember_label_en-US" xlink:label="lab_bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.875% Senior Notes due May 2023, May 2019 Refinancing [Member]</link:label>
    <link:label id="lab_bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember_documentation_en-US" xlink:label="lab_bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.875% Senior Notes due May 2023, May 2019 Refinancing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember" xlink:href="bhc-20220510.xsd#bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember" xlink:to="lab_bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_1f62e8c9-7d0f-4491-8d60-38cd18ec6942_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_c5f5568d-e17f-44c2-8165-85807952d6a6_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_d54ba9cb-781d-4ba7-a1ea-23b35c8d0692_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_e24c831a-3c03-4ca6-87d9-29d4a82f2073_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fff4556b-bf89-4d36-b565-39a27ae5af85_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_9dd7c154-fe86-4dfb-b51e-d770a12448c9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated aggregate amortization expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_4996446e-9915-4ab5-b3da-f78eaad7de23_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance_f9b75ce7-3e1c-4b68-94f7-9f025559af31_terseLabel_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quality assurance</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance_label_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Quality Assurance</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance_documentation_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Quality Assurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:href="bhc-20220510.xsd#bhc_ResearchAndDevelopmentExpenseQualityAssurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:to="lab_bhc_ResearchAndDevelopmentExpenseQualityAssurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_47145dad-4e56-4a1c-aab4-d395cf70404d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_a1ad8cea-6de1-4f35-9780-adc48b75bd26_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_cf6d93e0-5a52-4b64-a1c9-f252a776dddd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_722a55d7-3274-4f8f-a6f7-5e8e07b9e427_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of net loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_296820d9-dafc-4a95-9b70-175263aa5005_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Possible decrease in unrecognized tax benefits realized in next twelve months</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_d86a6cea-be57-4b1a-84ca-8dbfd5ce9f7e_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanOtherCosts_2ad9f065-6a9b-4f0a-8e32-849a59122880_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanOtherCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanOtherCosts_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanOtherCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Other Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanOtherCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanOtherCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanOtherCosts" xlink:to="lab_us-gaap_DefinedBenefitPlanOtherCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes725DueMay2029Member_8abd30e3-1331-46aa-bc57-f095ca3a9d8f_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes725DueMay2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.250% Senior Notes Due May 2029</link:label>
    <link:label id="lab_bhc_SeniorNotes725DueMay2029Member_label_en-US" xlink:label="lab_bhc_SeniorNotes725DueMay2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 7.25%, Due May 2029 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes725DueMay2029Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes725DueMay2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes 7.25 Percent Due May 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes725DueMay2029Member" xlink:to="lab_bhc_SeniorNotes725DueMay2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_84410bfa-4866-49fd-8af0-da3b410ede2a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest distributions</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherIncomeExpenseNet_1538037b-8c9a-4c8c-8d1a-28f7875aba6c_terseLabel_en-US" xlink:label="lab_bhc_OtherIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_bhc_OtherIncomeExpenseNet_label_en-US" xlink:label="lab_bhc_OtherIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense), Net</link:label>
    <link:label id="lab_bhc_OtherIncomeExpenseNet_documentation_en-US" xlink:label="lab_bhc_OtherIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherIncomeExpenseNet" xlink:href="bhc-20220510.xsd#bhc_OtherIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherIncomeExpenseNet" xlink:to="lab_bhc_OtherIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember_4da15471-f42f-4eba-8881-a6575095c950_terseLabel_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Other Settlement Deposits</link:label>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember_label_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Other Settlement Deposits, Current [Member]</link:label>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember_documentation_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Other Settlement Deposits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember" xlink:href="bhc-20220510.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember" xlink:to="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_01549032-0d91-450e-964c-1351563ab5c0_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_13aebc89-3b62-4be2-a8b6-990a63988dc5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">For Determining Net Periodic (Benefit) Cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_77b78075-aaec-42c3-ba95-18d4313407da_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentAmountAvailableForRestrictedPayments_8fa2d000-8d5d-48d0-acc0-670db4ed78ef_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentAmountAvailableForRestrictedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount available for restricted payments</link:label>
    <link:label id="lab_bhc_DebtInstrumentAmountAvailableForRestrictedPayments_label_en-US" xlink:label="lab_bhc_DebtInstrumentAmountAvailableForRestrictedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Amount Available For Restricted Payments</link:label>
    <link:label id="lab_bhc_DebtInstrumentAmountAvailableForRestrictedPayments_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentAmountAvailableForRestrictedPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Amount Available For Restricted Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAmountAvailableForRestrictedPayments" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentAmountAvailableForRestrictedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentAmountAvailableForRestrictedPayments" xlink:to="lab_bhc_DebtInstrumentAmountAvailableForRestrictedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_09d4e96a-f8c5-4605-bc3c-afaacf8273af_verboseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_dbb7880b-d164-45df-a58e-1859ab1d8085_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">China</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_InvestmentGradeMember_850da460-4824-4812-90f5-89e284b2802b_terseLabel_en-US" xlink:label="lab_bhc_InvestmentGradeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment grade</link:label>
    <link:label id="lab_bhc_InvestmentGradeMember_label_en-US" xlink:label="lab_bhc_InvestmentGradeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Grade [Member]</link:label>
    <link:label id="lab_bhc_InvestmentGradeMember_documentation_en-US" xlink:label="lab_bhc_InvestmentGradeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Grade [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InvestmentGradeMember" xlink:href="bhc-20220510.xsd#bhc_InvestmentGradeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_InvestmentGradeMember" xlink:to="lab_bhc_InvestmentGradeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_410992a4-e6e7-4641-b5e8-7f82a11a7f03_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_46ea63df-5280-448d-8b31-5bd04b1c76d3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of loss before benefit of income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_7cc8744f-1c44-4f6e-90f0-334839d500a5_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_c34678e9-aec2-41db-8d88-3c4d790e620a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax_c2667ff7-0453-4eec-a038-d60af7d7d664_terseLabel_en-US" xlink:label="lab_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, year-over-year increase</link:label>
    <link:label id="lab_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Year-Over-Year Revenue From Contract With Customer, Excluding Assessed Tax</link:label>
    <link:label id="lab_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax_documentation_en-US" xlink:label="lab_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Year-Over-Year Revenue From Contract With Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="bhc-20220510.xsd#bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_3fd3aee0-3f44-4a9b-8088-a79df91f350a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and postretirement benefit plan adjustments:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_1e630ebb-ee30-408b-9d58-7b4f7721faec_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchased face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_abe558b4-70e5-4136-baff-6cea21ed5761_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchased aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_country_DE_36001d53-fb0f-4bca-a4ec-e90ab0c802af_verboseLabel_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Germany</link:label>
    <link:label id="lab_country_DE_782230b2-a33b-4141-9e20-7cbe6c8475fb_terseLabel_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Germany</link:label>
    <link:label id="lab_country_DE_label_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GERMANY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE" xlink:to="lab_country_DE" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_b9cd2e9a-0880-4aac-a914-74d17bd60b6d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended_03f2646d-e7c6-4439-a0d4-0786a40b1e54_terseLabel_en-US" xlink:label="lab_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of defined benefit plans amended</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended_label_en-US" xlink:label="lab_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Number of Defined Benefit Plans Amended</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended_documentation_en-US" xlink:label="lab_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Number of Defined Benefit Plans Amended</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended" xlink:href="bhc-20220510.xsd#bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended" xlink:to="lab_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_dfe32ae7-c6a5-4fd8-b850-95284b7f493a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_39054bf4-cd0b-43f2-8da6-1c132861567a_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit_b13a2ece-c879-4327-800a-b936b6f7c495_terseLabel_en-US" xlink:label="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit_label_en-US" xlink:label="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Noncash Expense (Benefit)</link:label>
    <link:label id="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit_documentation_en-US" xlink:label="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The noncash component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:href="bhc-20220510.xsd#bhc_DeferredIncomeTaxNoncashExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:to="lab_bhc_DeferredIncomeTaxNoncashExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_fbacd17b-a7f7-491c-89b8-b67c795613df_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_7dbcd5c0-7481-4cee-9ab7-6ba292e1ec02_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of short-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SellingGeneralAndAdministrativeExpenseMember_6586de6a-070b-4b3f-84cc-c1cad18fa48b_terseLabel_en-US" xlink:label="lab_bhc_SellingGeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_bhc_SellingGeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_bhc_SellingGeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling General and Administrative Expense [Member]</link:label>
    <link:label id="lab_bhc_SellingGeneralAndAdministrativeExpenseMember_documentation_en-US" xlink:label="lab_bhc_SellingGeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The allocation (or location) of expense to (in) selling, general and administrative expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SellingGeneralAndAdministrativeExpenseMember" xlink:href="bhc-20220510.xsd#bhc_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SellingGeneralAndAdministrativeExpenseMember" xlink:to="lab_bhc_SellingGeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d5dcfd72-6d6a-4f11-87dd-fd307e85b2a7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components and classification of share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_56a45d7a-c8d5-40c1-ab27-2191aacf3136_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic loss per share attributable to Bausch Health Companies Inc. (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NonemployeeDirectorMember_56bf0e7a-1611-47b2-8ea3-d79c3e858c7c_terseLabel_en-US" xlink:label="lab_bhc_NonemployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee Director</link:label>
    <link:label id="lab_bhc_NonemployeeDirectorMember_label_en-US" xlink:label="lab_bhc_NonemployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee Director [Member]</link:label>
    <link:label id="lab_bhc_NonemployeeDirectorMember_documentation_en-US" xlink:label="lab_bhc_NonemployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonemployeeDirectorMember" xlink:href="bhc-20220510.xsd#bhc_NonemployeeDirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NonemployeeDirectorMember" xlink:to="lab_bhc_NonemployeeDirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_e9f03848-aeb7-46cd-bbc0-70c9230b2be1_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sub-lease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3a2bc55e-de97-4dfe-aaf4-569d05e1854e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e80cbdeb-d82b-4d6f-b4b0-cd3cb2c1fd1d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_e0d49c28-76b8-4758-9858-1a178b7161f1_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d9004734-2f41-47e4-967c-efbf1f5e4d2c_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_4efeeb72-4f53-49cd-a042-da5a1ba24d8a_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherLongTermDebtMember_e4a63e20-7cf5-4fc7-8e70-68f4e98e72df_terseLabel_en-US" xlink:label="lab_bhc_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_bhc_OtherLongTermDebtMember_label_en-US" xlink:label="lab_bhc_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Debt [Member]</link:label>
    <link:label id="lab_bhc_OtherLongTermDebtMember_documentation_en-US" xlink:label="lab_bhc_OtherLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents long-term debt obligations not elsewhere enumerated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherLongTermDebtMember" xlink:href="bhc-20220510.xsd#bhc_OtherLongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherLongTermDebtMember" xlink:to="lab_bhc_OtherLongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CA_55b2f4b2-de0f-4e56-9671-da65159804b9_verboseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada</link:label>
    <link:label id="lab_country_CA_22d70d9c-4573-42bd-bd2c-19ff880a1011_terseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada</link:label>
    <link:label id="lab_country_CA_label_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CANADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_f0d26c49-f2dc-4823-962d-7ab96b6ac5d4_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BauschLombMember_392783c9-924d-40c2-a4c7-7cd744d42d7f_terseLabel_en-US" xlink:label="lab_bhc_BauschLombMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb</link:label>
    <link:label id="lab_bhc_BauschLombMember_label_en-US" xlink:label="lab_bhc_BauschLombMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb [Member]</link:label>
    <link:label id="lab_bhc_BauschLombMember_documentation_en-US" xlink:label="lab_bhc_BauschLombMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember" xlink:href="bhc-20220510.xsd#bhc_BauschLombMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BauschLombMember" xlink:to="lab_bhc_BauschLombMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitDomain_d52b1246-7798-453f-af71-5a32e722f4a5_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain" xlink:to="lab_us-gaap_ReportingUnitDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_4268db09-dcfc-4fc0-b92f-e3965d29c27d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PerrigoIsraelPharmaceuticalsLitigationMember_0cb7630b-2bda-46b4-8ff3-e8bfe84f8b9c_terseLabel_en-US" xlink:label="lab_bhc_PerrigoIsraelPharmaceuticalsLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Perrigo Israel Pharmaceuticals Litigation</link:label>
    <link:label id="lab_bhc_PerrigoIsraelPharmaceuticalsLitigationMember_label_en-US" xlink:label="lab_bhc_PerrigoIsraelPharmaceuticalsLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Perrigo Israel Pharmaceuticals Litigation [Member]</link:label>
    <link:label id="lab_bhc_PerrigoIsraelPharmaceuticalsLitigationMember_documentation_en-US" xlink:label="lab_bhc_PerrigoIsraelPharmaceuticalsLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Perrigo Israel Pharmaceuticals Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerrigoIsraelPharmaceuticalsLitigationMember" xlink:href="bhc-20220510.xsd#bhc_PerrigoIsraelPharmaceuticalsLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PerrigoIsraelPharmaceuticalsLitigationMember" xlink:to="lab_bhc_PerrigoIsraelPharmaceuticalsLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_d94b186e-1399-4e94-a1cc-46724bff4713_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_05411d80-6deb-4a92-8c13-46758374475a_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_d6eba2d4-796b-4a55-8739-6856a852aef4_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_3289fc66-38f9-4c05-9f01-bd81682c46eb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod_8affa8ba-33ca-4f49-bb9f-fad72c0a811a_terseLabel_en-US" xlink:label="lab_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future benefit payments period</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod_label_en-US" xlink:label="lab_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Estimated Future Benefit Payments, Period</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod_documentation_en-US" xlink:label="lab_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Estimated Future Benefit Payments, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod" xlink:href="bhc-20220510.xsd#bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod" xlink:to="lab_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember_5699d6ab-419f-49aa-9bf7-bc6f4c0d32a6_terseLabel_en-US" xlink:label="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued And Other Current Liabilities [Member]</link:label>
    <link:label id="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember_documentation_en-US" xlink:label="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued And Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:href="bhc-20220510.xsd#bhc_AccruedAndOtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:to="lab_bhc_AccruedAndOtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax_5e0263cc-574f-498c-9171-7d8b61827df2_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized prior service credits</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans_c28133c2-c279-4b3a-a156-c8eabf204518_terseLabel_en-US" xlink:label="lab_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of defined benefit plans</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans_label_en-US" xlink:label="lab_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Number of Defined Benefit Plans</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans_documentation_en-US" xlink:label="lab_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Number of Defined Benefit Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans" xlink:href="bhc-20220510.xsd#bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans" xlink:to="lab_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_86d10622-2cc0-42f6-96cd-43ffda2a42d3_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_d8244445-d64b-4bc9-a22f-2dfbd1695216_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of revenues by geographic region</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ad2bb1f0-a9d9-4048-8b18-fd121eefef98_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Significant Acquisitions and Disposals [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_56a050ec-0418-493c-bb0b-c80311dd3624_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_419e61da-1fce-480f-9532-f5b5be7cc595_terseLabel_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_label_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain" xlink:to="lab_us-gaap_PlanAssetCategoriesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesAdjustments_4e041541-8040-4722-a6a5-d1837629945c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in variable consideration provision, adjustment</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesAdjustments_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_0e1d9d17-8e2a-4710-ae31-0667c90552d9_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_e583b5e5-45dc-4362-bbe4-d9221bd5c909_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished_b23c0533-2ed9-4e35-93a8-e3dbd75ff95b_terseLabel_en-US" xlink:label="lab_bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business separation and proposed initial public offering, number of companies to be established</link:label>
    <link:label id="lab_bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished_label_en-US" xlink:label="lab_bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Separation And Proposed Initial Public Offering, Number Of Companies To Be Established</link:label>
    <link:label id="lab_bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished_documentation_en-US" xlink:label="lab_bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Separation And Proposed Initial Public Offering, Number Of Companies To Be Established</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished" xlink:href="bhc-20220510.xsd#bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished" xlink:to="lab_bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_d2ae9040-cc90-45a5-9c77-ea7eca5c0e51_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt and other</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_41cfbec2-6f9c-447c-b8dc-39e12b8db685_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GlobalHighYieldMember_a54091d2-b1f3-4c49-9ee2-1de36a2e5bf7_terseLabel_en-US" xlink:label="lab_bhc_GlobalHighYieldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global high yield</link:label>
    <link:label id="lab_bhc_GlobalHighYieldMember_label_en-US" xlink:label="lab_bhc_GlobalHighYieldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global High Yield [Member]</link:label>
    <link:label id="lab_bhc_GlobalHighYieldMember_documentation_en-US" xlink:label="lab_bhc_GlobalHighYieldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global High Yield [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlobalHighYieldMember" xlink:href="bhc-20220510.xsd#bhc_GlobalHighYieldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GlobalHighYieldMember" xlink:to="lab_bhc_GlobalHighYieldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_744281b8-e42a-40a1-bb75-e5049a2f4b04_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_983ac50d-b1de-4db0-840c-e71e134e66ed_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairments</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_cc395ba2-e181-4144-b7f8-f0a2352944d9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected_04e09a06-a4ed-41bb-a55a-74fdfcb3520d_terseLabel_en-US" xlink:label="lab_bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected additional payments</link:label>
    <link:label id="lab_bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected_label_en-US" xlink:label="lab_bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Payments To Acquire Equity Securities, FV-NI, Expected</link:label>
    <link:label id="lab_bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected_documentation_en-US" xlink:label="lab_bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Payments To Acquire Equity Securities, FV-NI, Expected</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected" xlink:href="bhc-20220510.xsd#bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected" xlink:to="lab_bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_78f63abd-c685-448e-9317-e7a4a9ed36ec_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_58cb3c9c-2b09-4d47-84c9-c880254228cd_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CustomerTopTenProductsMember_ac0e087e-461f-46e0-af4c-5344915cbd75_terseLabel_en-US" xlink:label="lab_bhc_CustomerTopTenProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer, Top Ten Products</link:label>
    <link:label id="lab_bhc_CustomerTopTenProductsMember_label_en-US" xlink:label="lab_bhc_CustomerTopTenProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer, Top Ten Products [Member]</link:label>
    <link:label id="lab_bhc_CustomerTopTenProductsMember_documentation_en-US" xlink:label="lab_bhc_CustomerTopTenProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer, Top Ten Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CustomerTopTenProductsMember" xlink:href="bhc-20220510.xsd#bhc_CustomerTopTenProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CustomerTopTenProductsMember" xlink:to="lab_bhc_CustomerTopTenProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_b745ac5a-e8b7-4ee2-9c2d-7f7a1b13988e_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions based on tax positions related to the current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_ad4d86c3-7105-4169-984f-d0e0e6ebc0a9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_911aba00-a244-4113-b2b3-7b76640916b9_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CashDiscountsAndAllowancesSettlementPeriod_3c28c76c-f28a-44bc-b14d-00954e9d1004_terseLabel_en-US" xlink:label="lab_bhc_CashDiscountsAndAllowancesSettlementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement period for cash discounts and allowances</link:label>
    <link:label id="lab_bhc_CashDiscountsAndAllowancesSettlementPeriod_label_en-US" xlink:label="lab_bhc_CashDiscountsAndAllowancesSettlementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Discounts And Allowances, Settlement Period</link:label>
    <link:label id="lab_bhc_CashDiscountsAndAllowancesSettlementPeriod_documentation_en-US" xlink:label="lab_bhc_CashDiscountsAndAllowancesSettlementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Discounts And Allowances, Settlement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CashDiscountsAndAllowancesSettlementPeriod" xlink:href="bhc-20220510.xsd#bhc_CashDiscountsAndAllowancesSettlementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CashDiscountsAndAllowancesSettlementPeriod" xlink:to="lab_bhc_CashDiscountsAndAllowancesSettlementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_bb4c6441-af30-489f-a15a-37e075ff6a12_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount_6eabb0b4-cbdc-49e3-9bbc-921f7b9375cd_negatedTerseLabel_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to tax attributes</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount_label_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Adjustments To Tax Attributes, Amount</link:label>
    <link:label id="lab_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount_documentation_en-US" xlink:label="lab_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Adjustments To Tax Attributes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" xlink:href="bhc-20220510.xsd#bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" xlink:to="lab_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_059ef57e-2cb1-47bd-a496-c5779487062d_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_d2dcff73-4953-47d6-9460-ddba11e421dc_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion of unrecognized tax benefits, if recognized, would affect the Company's effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_f0b460be-74a2-4727-919d-1743c4ce65f5_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_4aeb909b-1a3d-4e31-a6d4-f8400ac2b43a_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_daca256e-097f-465e-beda-d7a7437b82ad_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A5.00SeniorNotesDueJanuary2028Member_7486bebf-f5e7-41ac-a7a4-0248a0aad19f_terseLabel_en-US" xlink:label="lab_bhc_A5.00SeniorNotesDueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Senior Unsecured Notes Due January 2028</link:label>
    <link:label id="lab_bhc_A5.00SeniorNotesDueJanuary2028Member_label_en-US" xlink:label="lab_bhc_A5.00SeniorNotesDueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Senior Notes Due January 2028 [Member]</link:label>
    <link:label id="lab_bhc_A5.00SeniorNotesDueJanuary2028Member_documentation_en-US" xlink:label="lab_bhc_A5.00SeniorNotesDueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Senior Notes Due January 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.00SeniorNotesDueJanuary2028Member" xlink:href="bhc-20220510.xsd#bhc_A5.00SeniorNotesDueJanuary2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A5.00SeniorNotesDueJanuary2028Member" xlink:to="lab_bhc_A5.00SeniorNotesDueJanuary2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_d0ef1ee6-91df-4d2f-9580-22f117f70ec2_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_5f94fd80-fb49-418e-acf3-b41fdc82ac78_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cash proceeds from incurrence of debt</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Percentage of Net Proceeds from Incurrence of Debt Payable as Mandatory Pre-payments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of net cash proceeds from the incurrence of debt payable as mandatory prepayments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:href="bhc-20220510.xsd#bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:to="lab_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpensePolicyTextBlock_b2ca5fed-8008-45f4-8bc8-81a3bd4c51b4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestExpensePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestExpensePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpensePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpensePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpensePolicyTextBlock" xlink:to="lab_us-gaap_InterestExpensePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_e8ba84e8-aee6-4737-8189-279ac6e4ea60_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement loss recognized</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_092b9bf1-b4b5-4074-a11b-9a41d5fccf4a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assets and liabilities measured at fair value on a non-recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_f819cd82-0155-4a6d-8273-e84d79977db4_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_6854715d-9723-4428-bd20-628f81309be1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_eb7c6ab1-cfa1-445b-a25f-df42e4526b84_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_a8f56870-148e-440b-9dca-9fb3c0d25bad_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_61d3876f-98c5-4ef8-ad65-7c687759ef1b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_4e519b56-e82e-4575-a906-d921a679589c_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_country_FR_c2d96bdb-7da6-4eb3-9f95-61a5457e7740_verboseLabel_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">France</link:label>
    <link:label id="lab_country_FR_d2df645c-cc6a-4f39-b543-a115b06d95c9_terseLabel_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">France</link:label>
    <link:label id="lab_country_FR_label_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FRANCE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_FR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_FR" xlink:to="lab_country_FR" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c5abd239-251b-4ccb-b393-07115f25f43d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_49eb0ca5-dede-4b41-9b3a-ca9301df176c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining restructuring liabilities</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_206834e5-5d72-4436-bd53-de705819e66f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages sought</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_8a122931-0600-426b-bcd0-2a3fee92488d_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of stock options that will vest on each of the first, second, third and fourth anniversaries from the date of grant</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation, Arrangement by Share Based Payment Award, Options Vested Percentage</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents percentage of stock options that will vest in the future period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:href="bhc-20220510.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains_d7315523-56af-4205-8354-a1b31427a3a5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized FX on U.S. dollar debt and other financing cost</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Unrealized Currency Transaction Gains</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_485dea39-7e29-44cf-ad78-9bd097161dc3_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and benefit costs</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_a1bec7f5-6140-4049-a473-85c488420d60_terseLabel_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting unit, impairment test, long-term growth rates</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_label_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Long-Term Growth Rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_documentation_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Long-Term Growth Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:href="bhc-20220510.xsd#bhc_ReportingUnitImpairmentTestLongTermGrowthRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:to="lab_bhc_ReportingUnitImpairmentTestLongTermGrowthRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_890e2d1b-4d52-479f-86a5-f960d9764268_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_country_GB_2db638dc-d84b-4416-a441-24e86111e71e_terseLabel_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom</link:label>
    <link:label id="lab_country_GB_label_en-US" xlink:label="lab_country_GB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED KINGDOM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_GB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_GB" xlink:to="lab_country_GB" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A7.25SeniorUnsecuredNotesDue2029Member_453ff9a8-f763-4a0c-8c0d-9d4eb76feec3_terseLabel_en-US" xlink:label="lab_bhc_A7.25SeniorUnsecuredNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.25% Senior Unsecured Notes due 2029</link:label>
    <link:label id="lab_bhc_A7.25SeniorUnsecuredNotesDue2029Member_label_en-US" xlink:label="lab_bhc_A7.25SeniorUnsecuredNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.25% Senior Unsecured Notes Due 2029 [Member]</link:label>
    <link:label id="lab_bhc_A7.25SeniorUnsecuredNotesDue2029Member_documentation_en-US" xlink:label="lab_bhc_A7.25SeniorUnsecuredNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.25% Senior Unsecured Notes Due 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A7.25SeniorUnsecuredNotesDue2029Member" xlink:href="bhc-20220510.xsd#bhc_A7.25SeniorUnsecuredNotesDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A7.25SeniorUnsecuredNotesDue2029Member" xlink:to="lab_bhc_A7.25SeniorUnsecuredNotesDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_82062744-31d9-4036-bb5b-e86256e91c4c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_b778d33a-9589-4c99-8eb8-7a601cd14547_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_4ec44b18-4333-4475-a0f0-24127ca3219d_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Percentage of Net Cash Proceeds of Insurance and Condemnation Proceeds from Property or Asset Losses Payable as Mandatory Prepayments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of net cash proceeds of insurance and condemnation proceeds for property or asset (losses) which is payable as mandatory prepayment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:href="bhc-20220510.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:to="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_fd3b43ed-ab7a-4873-8072-033330c8120d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_c5a45da0-a4ac-4fa1-81ad-9fd42f0e65e0_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest and penalties related to unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_8f999e53-7b7c-4d4a-aae3-423156121563_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_868f6287-1a3b-4d8d-a00d-63bb58a6d5d1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_country_ES_b7b274cc-8154-40bb-ac42-8f70290fa95b_terseLabel_en-US" xlink:label="lab_country_ES" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spain</link:label>
    <link:label id="lab_country_ES_label_en-US" xlink:label="lab_country_ES" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPAIN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_ES"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_ES" xlink:to="lab_country_ES" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract_4fbba83c-310a-409a-9bd6-b707512d4ea5_terseLabel_en-US" xlink:label="lab_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures:</link:label>
    <link:label id="lab_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract_label_en-US" xlink:label="lab_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditure and Depreciation and Amortization [Abstract]</link:label>
    <link:label id="lab_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract_documentation_en-US" xlink:label="lab_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the capital expenditures, depreciation and amortization by segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract" xlink:href="bhc-20220510.xsd#bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract" xlink:to="lab_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_917c79f8-4341-4317-8bb1-a901e6858818_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2fc2f8e0-eb45-419c-9fc6-2b635141c1bb_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_1e946682-dedb-4575-90c7-1020d118bdc0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_1008e47f-e3c7-43a4-b884-dee095bfe44f_terseLabel_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits including interest and penalties</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_label_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Including Interest and Penalties</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_documentation_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The gross amount of unrecognized tax benefits including interest and penalties pertaining to uncertain tax positions taken in tax returns as of the balance sheet date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:href="bhc-20220510.xsd#bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:to="lab_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities_10c3e568-3533-459c-b9de-9bc4aa2eaba7_terseLabel_en-US" xlink:label="lab_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities_label_en-US" xlink:label="lab_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Defined Benefit Plans, Accrued and Other Current Liabilities</link:label>
    <link:label id="lab_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities_documentation_en-US" xlink:label="lab_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Defined Benefit Plans, Accrued and Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" xlink:href="bhc-20220510.xsd#bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" xlink:to="lab_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_25db2594-25ed-48fd-9169-b8577f364536_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expenses [Line Items]</link:label>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_label_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expenses [Line Items]</link:label>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_documentation_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Schedule Of Other Income And Expenses [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:href="bhc-20220510.xsd#bhc_ScheduleOfOtherIncomeAndExpensesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:to="lab_bhc_ScheduleOfOtherIncomeAndExpensesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_1e13268e-3b42-4a95-a51e-34bf419c35d2_terseLabel_en-US" xlink:label="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR Performance-Based Restricted Stock Units</link:label>
    <link:label id="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TSR Performance-Based Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20220510.xsd#bhc_TSRPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_TSRPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_4b733012-244c-42e0-9ec9-efb65bf4a043_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_72bcb6d1-86f9-4f3d-ad49-6556b0cc1007_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_6c34593f-3e96-4865-93a0-fb63c76937c0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of remaining lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_33658b8c-eb64-4432-bf11-84c4107a5a50_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, no par value, unlimited shares authorized, 359,405,748 and 355,422,347&#160;issued and outstanding at December&#160;31, 2021 and 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AmounPharmaceuticalCompanySAEMember_90e93038-7f05-4b63-bdeb-4f467d943a14_terseLabel_en-US" xlink:label="lab_bhc_AmounPharmaceuticalCompanySAEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amoun Pharmaceutical Company S.A.E</link:label>
    <link:label id="lab_bhc_AmounPharmaceuticalCompanySAEMember_label_en-US" xlink:label="lab_bhc_AmounPharmaceuticalCompanySAEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amoun Pharmaceutical Company S.A.E [Member]</link:label>
    <link:label id="lab_bhc_AmounPharmaceuticalCompanySAEMember_documentation_en-US" xlink:label="lab_bhc_AmounPharmaceuticalCompanySAEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amoun Pharmaceutical Company S.A.E</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember" xlink:href="bhc-20220510.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AmounPharmaceuticalCompanySAEMember" xlink:to="lab_bhc_AmounPharmaceuticalCompanySAEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6f36a394-1679-4385-b697-fbf8f576c7cc_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_3c05244e-6ba8-489e-98e0-92c741115c31_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer concentration</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e58f4143-0665-45df-b860-1fdf65808443_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_faf2fff4-091b-4c49-bb1e-49fce15a1b09_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_49446e20-d243-4ffb-a4e4-01207577eb2f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_21076586-2b6f-4ae5-bede-6abde295da21_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of assets and businesses, net of costs to sell</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses, Net of Cash Divested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_8197e17f-1546-44c9-8f48-a69752c73b5e_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_label_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:to="lab_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_6b617cf8-dff2-4fbe-ad8b-3434bc2f708f_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded status, end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Funded (Unfunded) Status of Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:to="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_cf21d71f-818d-4012-967a-1c8a1077e3ae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of weighted-average assumption as of the date of grant using the Black Scholes option-pricing model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_36d2a810-bcc8-4b74-9247-16ee72324e13_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss_4b7588de-8750-4c9e-aab7-6c012961ea2f_terseLabel_en-US" xlink:label="lab_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro-forma operating results</link:label>
    <link:label id="lab_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss_label_en-US" xlink:label="lab_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Operating Income (Loss)</link:label>
    <link:label id="lab_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss_documentation_en-US" xlink:label="lab_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss" xlink:href="bhc-20220510.xsd#bhc_BusinessAcquisitionProFormaOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss" xlink:to="lab_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_e64ffe39-e2c2-4c1e-85ad-1f8727c02022_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_75068cff-bded-482d-a6b3-b3353c9cb9bf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_d5281a96-d95a-47b8-8006-ddc98104fbf4_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax_23130d2a-3c73-4333-a3db-08ef4206bf5a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service credit</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod_bf01a4db-dacf-4b0b-90b7-8920298a926c_terseLabel_en-US" xlink:label="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Highly liquid investments, maturity period (or less)</link:label>
    <link:label id="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod_label_en-US" xlink:label="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Highly Liquid Investments, Maturity Period</link:label>
    <link:label id="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod_documentation_en-US" xlink:label="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Highly Liquid Investments, Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:href="bhc-20220510.xsd#bhc_HighlyLiquidInvestmentsMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:to="lab_bhc_HighlyLiquidInvestmentsMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_country_EG_568a1f21-cba1-4c71-9672-78143cdc64b7_terseLabel_en-US" xlink:label="lab_country_EG" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Egypt</link:label>
    <link:label id="lab_country_EG_label_en-US" xlink:label="lab_country_EG" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EGYPT</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_EG" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_EG"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_EG" xlink:to="lab_country_EG" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_895ca698-69b8-4f11-b535-354e1fd390e8_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_ba87cf4e-eb29-4327-bf21-f65ae011594f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_0b8b0024-9d48-43c5-9c45-80e6c2dfc506_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of open tax years by jurisdiction</link:label>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_ab7b229e-a585-4064-9f5b-9476bfcea690_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_dcf3b5b9-dabe-4987-8402-bfe836f11946_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured leverage ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_0be8dfd5-4f27-4450-ae96-9233da99841f_verboseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured leverage ratio (not greater than)</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Secured Leverage Ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Secured Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:to="lab_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_54179ac1-a703-42da-a7f1-a2c8662ef594_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8aae3fdc-078a-4e79-bc4d-a5603df5f85d_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxYear2013Member_489c547d-7cc6-48c2-acf9-1634a3d24782_terseLabel_en-US" xlink:label="lab_us-gaap_TaxYear2013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2013</link:label>
    <link:label id="lab_us-gaap_TaxYear2013Member_label_en-US" xlink:label="lab_us-gaap_TaxYear2013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2013 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2013Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxYear2013Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxYear2013Member" xlink:to="lab_us-gaap_TaxYear2013Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_e68b7a90-2006-4b08-b1e0-f35185891a3e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_1ab1a21b-532b-413b-8bed-7eb7564cfb41_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_56ac2e4b-00df-40e0-851d-9a068d69d5c8_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f9f2c68a-9bbf-4ece-b4a7-cd66c2a99a9a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price appreciation credits</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_ecfb7bba-bac0-47bd-bcf6-b99fe0323d4e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_0e3c2a29-ab2d-46fc-ad1a-00b0e4a626bc_terseLabel_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation, Non-Class Complaints</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_label_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation, Non-Class Complaints [Member]</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_documentation_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation, Non-Class Complaints [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:href="bhc-20220510.xsd#bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:to="lab_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_ccf9638f-0ee5-4874-af2a-28ea97be5823_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfCommitmentsLineItems_37db74d3-4269-4f13-afcd-54ce234b3aaa_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other commitments</link:label>
    <link:label id="lab_bhc_ScheduleOfCommitmentsLineItems_label_en-US" xlink:label="lab_bhc_ScheduleOfCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Commitments [Line Items]</link:label>
    <link:label id="lab_bhc_ScheduleOfCommitmentsLineItems_documentation_en-US" xlink:label="lab_bhc_ScheduleOfCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfCommitmentsLineItems" xlink:href="bhc-20220510.xsd#bhc_ScheduleOfCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfCommitmentsLineItems" xlink:to="lab_bhc_ScheduleOfCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BrandedandOtherGenericProductsMember_d0832752-f971-44ae-9e59-f7c70ca588a3_terseLabel_en-US" xlink:label="lab_bhc_BrandedandOtherGenericProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Branded and Other Generics</link:label>
    <link:label id="lab_bhc_BrandedandOtherGenericProductsMember_label_en-US" xlink:label="lab_bhc_BrandedandOtherGenericProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Branded and Other Generic Products [Member]</link:label>
    <link:label id="lab_bhc_BrandedandOtherGenericProductsMember_documentation_en-US" xlink:label="lab_bhc_BrandedandOtherGenericProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Branded and Other Generic Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BrandedandOtherGenericProductsMember" xlink:href="bhc-20220510.xsd#bhc_BrandedandOtherGenericProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BrandedandOtherGenericProductsMember" xlink:to="lab_bhc_BrandedandOtherGenericProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_769e4474-e2db-4e9d-9173-d97744a1cf0c_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_22daf997-c6cf-46db-93ae-28363cc6148f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_e39ab023-3e8d-42d6-aa1f-a1100f3bf8ea_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_61481823-612c-4173-bf0d-5b4387c3f173_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_ad6d5e85-4862-4995-b1b0-fd66c921dae8_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_be3d9a39-e96f-4682-830b-b759f90273a2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) recognized in Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_a2505cd2-e3f4-4a3b-af14-82f82e1123da_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_a4979b39-6589-4cdd-b171-83a555148e18_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_b8d85a11-3261-493e-b12d-5eca189da8b7_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes525DueJanuary2030Member_7fa5e65c-6358-4dfc-97bf-29ae91f1ced4_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.250% Senior Notes Due January 2030</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueJanuary2030Member_label_en-US" xlink:label="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.25%, Due January 2030 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueJanuary2030Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Senior Notes Due January 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueJanuary2030Member" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes525DueJanuary2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes525DueJanuary2030Member" xlink:to="lab_bhc_SeniorNotes525DueJanuary2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_99f0ca80-6a38-47e4-b4e1-b5b2238fce0e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_5a21210c-59fd-496c-af90-7bc8da519b66_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7aad1c69-2bc5-4de0-abaa-561593cd9976_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_434d24db-5569-4065-b576-fd878a021610_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_f8fc17ea-db51-448a-a179-e6a75aabb011_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_f59ca55b-949d-4e43-b61e-d9044e3a3bd3_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_ea0f4fd5-6889-4eda-9a27-066fe9147d33_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent_1a8f7a4f-7d5b-4c9d-9452-ea92a3254b35_terseLabel_en-US" xlink:label="lab_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent_label_en-US" xlink:label="lab_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension And Other Postretirement Defined Benefit Plans, Other Assets, Noncurrent</link:label>
    <link:label id="lab_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent_documentation_en-US" xlink:label="lab_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension And Other Postretirement Defined Benefit Plans, Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" xlink:href="bhc-20220510.xsd#bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" xlink:to="lab_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_a2311c90-5853-4f8f-bb41-6d743ad9f997_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027-2031</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_4f80c0bf-7470-4a59-8500-9211ba6d8a38_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amount received</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded from Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PerformanceBasedRestrictedStockUnitsMember_34348252-0a78-4977-a61f-ecf521b9f39b_terseLabel_en-US" xlink:label="lab_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units</link:label>
    <link:label id="lab_bhc_PerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_PerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents stock awards in the form of performance-based restricted stock units (RSUs) to certain directors, officers and other eligible employees pursuant to the company's incentive compensation plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20220510.xsd#bhc_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_PerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_11848f33-afe4-44dd-902b-57982f9741f4_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_02c69d9c-8b51-4169-8b66-b3423bdc047c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue of acquiree since acquisition date</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_InterestSettlementOnCrossCurrencySwaps_640e4b97-a08c-4525-a9da-967ef39a2112_terseLabel_en-US" xlink:label="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements from cross-currency swaps</link:label>
    <link:label id="lab_bhc_InterestSettlementOnCrossCurrencySwaps_label_en-US" xlink:label="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Settlement On Cross-Currency Swaps</link:label>
    <link:label id="lab_bhc_InterestSettlementOnCrossCurrencySwaps_documentation_en-US" xlink:label="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Settlement On Cross-Currency Swaps</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:href="bhc-20220510.xsd#bhc_InterestSettlementOnCrossCurrencySwaps"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:to="lab_bhc_InterestSettlementOnCrossCurrencySwaps" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PharmaceuticalProductsMember_d49bac0f-d42e-46ce-a198-95183aee9f8a_terseLabel_en-US" xlink:label="lab_bhc_PharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceuticals</link:label>
    <link:label id="lab_bhc_PharmaceuticalProductsMember_label_en-US" xlink:label="lab_bhc_PharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Products [Member]</link:label>
    <link:label id="lab_bhc_PharmaceuticalProductsMember_documentation_en-US" xlink:label="lab_bhc_PharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PharmaceuticalProductsMember" xlink:href="bhc-20220510.xsd#bhc_PharmaceuticalProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PharmaceuticalProductsMember" xlink:to="lab_bhc_PharmaceuticalProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueJune2023Member_9ade0413-d229-431a-b461-8d12d3892ddd_terseLabel_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023 Revolving Credit Facility Due June 2023</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueJune2023Member_label_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due June 2023 [Member]</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityDueJune2023Member_documentation_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility Due June 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:href="bhc-20220510.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:to="lab_bhc_RevolvingCreditFacilityDueJune2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IT_e921d564-f44a-4bbb-a72f-ac070e385ffb_terseLabel_en-US" xlink:label="lab_country_IT" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Italy</link:label>
    <link:label id="lab_country_IT_label_en-US" xlink:label="lab_country_IT" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ITALY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IT" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IT"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IT" xlink:to="lab_country_IT" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_5cf8a495-2756-4115-92a5-667080504f62_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible amount of share-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_0f52f31d-a168-411a-8253-404fe1cc95c1_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_90855617-2603-4fde-bbdd-2702224d337c_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_9849e8a4-8e02-47c2-8c77-f0f9d497d981_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of principal amount that can be redeemed</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member_ef5a20de-a706-4998-9154-ce97ced25d01_verboseLabel_en-US" xlink:label="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.750% Senior Notes Due August 2027</link:label>
    <link:label id="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member_label_en-US" xlink:label="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.75% Notes Due August 2027 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.75% Notes Due August 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:href="bhc-20220510.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:to="lab_bhc_SeniorSecured5.75NotesDueAugust2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_33945d6e-00ab-4d78-9b80-d0c8dbd451a1_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentPolicy_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfCommitmentsTable_a86db151-4b76-4df5-847a-15ace0d89442_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Commitments [Table]</link:label>
    <link:label id="lab_bhc_ScheduleOfCommitmentsTable_label_en-US" xlink:label="lab_bhc_ScheduleOfCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Commitments [Table]</link:label>
    <link:label id="lab_bhc_ScheduleOfCommitmentsTable_documentation_en-US" xlink:label="lab_bhc_ScheduleOfCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to commitments of the entity during the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfCommitmentsTable" xlink:href="bhc-20220510.xsd#bhc_ScheduleOfCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfCommitmentsTable" xlink:to="lab_bhc_ScheduleOfCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_e5220858-bbc6-4ace-be47-f69a64a7033f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_47a64593-02ed-471b-b0c7-2cbcbb8bfb39_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_4f890a92-b45e-4315-a1b8-fc792f787850_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_082fe7b9-8978-4fb6-84b0-82d386cdecea_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_9cfa1818-46ea-49c7-a17b-3afdd3f8272c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherRevenuesMember_93c31a85-6edc-4aa0-a29a-88ac07e92106_terseLabel_en-US" xlink:label="lab_bhc_OtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_bhc_OtherRevenuesMember_label_en-US" xlink:label="lab_bhc_OtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues [Member]</link:label>
    <link:label id="lab_bhc_OtherRevenuesMember_documentation_en-US" xlink:label="lab_bhc_OtherRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherRevenuesMember" xlink:href="bhc-20220510.xsd#bhc_OtherRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherRevenuesMember" xlink:to="lab_bhc_OtherRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_d4ffcb05-e9aa-49bf-b10f-6f2bda208c0b_terseLabel_en-US" xlink:label="lab_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Products For Disposal, September 2019</link:label>
    <link:label id="lab_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_label_en-US" xlink:label="lab_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Products For Disposal, September Two Thousand Nineteen [Member]</link:label>
    <link:label id="lab_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_documentation_en-US" xlink:label="lab_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Products For Disposal, September Two Thousand Nineteen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember" xlink:href="bhc-20220510.xsd#bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember" xlink:to="lab_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock_62df3685-7e1a-48e2-872f-8de6b5b28839_terseLabel_en-US" xlink:label="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE</link:label>
    <link:label id="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock_label_en-US" xlink:label="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]</link:label>
    <link:label id="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock_documentation_en-US" xlink:label="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:href="bhc-20220510.xsd#bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:to="lab_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_01152171-902c-42a4-bb95-691ac80095c3_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_99f4fa93-c005-45f9-bbf1-650ee74f3874_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_c46ca72c-3f7d-4009-bd86-b3389e54bc5e_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OrthoDermatologicsReportingUnitMember_6091ac95-5fcf-429a-bc40-d0072bd53f13_terseLabel_en-US" xlink:label="lab_bhc_OrthoDermatologicsReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Reporting Unit</link:label>
    <link:label id="lab_bhc_OrthoDermatologicsReportingUnitMember_label_en-US" xlink:label="lab_bhc_OrthoDermatologicsReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Reporting Unit [Member]</link:label>
    <link:label id="lab_bhc_OrthoDermatologicsReportingUnitMember_documentation_en-US" xlink:label="lab_bhc_OrthoDermatologicsReportingUnitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Reporting Unit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsReportingUnitMember" xlink:href="bhc-20220510.xsd#bhc_OrthoDermatologicsReportingUnitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OrthoDermatologicsReportingUnitMember" xlink:to="lab_bhc_OrthoDermatologicsReportingUnitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_69560999-a35d-48f6-b340-b252ec8b555c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of operating lease future payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_38fc5256-300d-4a02-af95-4b99cb7af0f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of external customers that accounted for 10% or more of total revenues</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit_7ee1feb8-2b22-461e-b809-9eeb3fa5f7a0_terseLabel_en-US" xlink:label="lab_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets held for sale reclassified to goodwill</link:label>
    <link:label id="lab_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Transfers Related To Sale of Business Unit</link:label>
    <link:label id="lab_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit_documentation_en-US" xlink:label="lab_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Transfers Related To Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit" xlink:href="bhc-20220510.xsd#bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit" xlink:to="lab_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_b4b05930-8aeb-4789-8268-49a6da5a2800_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Bausch Health Companies Inc. shareholders&#8217; (deficit) equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_15b9bb0d-a701-4e9e-9f41-d74679dd380e_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_b5c3d405-b344-4979-a34b-8118d59a4807_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage_4b80d3ba-5e25-43ef-b23d-ce9f31f52f95_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual amortization rate, percentage</link:label>
    <link:label id="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage_label_en-US" xlink:label="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Annual Amortization Rate, Percentage</link:label>
    <link:label id="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Annual Amortization Rate, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentAnnualAmortizationRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:to="lab_bhc_DebtInstrumentAnnualAmortizationRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_47f407a0-8121-422c-8420-b89986e3771c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_ac2bab65-cf77-4c26-b735-cda60881c172_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_0f83c0c3-767b-408f-9424-9ef1619e3e7c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Supplemental Cash Flow Disclosures</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_88aa931d-3475-406e-8653-a21f15658b81_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_65c7bf00-d11f-4062-911b-bdf20abb970d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IE_238de95d-e330-46ac-aa60-4fd1b56965ac_terseLabel_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ireland</link:label>
    <link:label id="lab_country_IE_label_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IRELAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IE" xlink:to="lab_country_IE" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A9.00SeniorNotesdueDecember2025Member_f320c96a-1009-4bd5-bbbb-220074c5185c_terseLabel_en-US" xlink:label="lab_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Unsecured Notes due December 2025</link:label>
    <link:label id="lab_bhc_A9.00SeniorNotesdueDecember2025Member_label_en-US" xlink:label="lab_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Notes due December 2025 [Member]</link:label>
    <link:label id="lab_bhc_A9.00SeniorNotesdueDecember2025Member_documentation_en-US" xlink:label="lab_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Notes due December 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:href="bhc-20220510.xsd#bhc_A9.00SeniorNotesdueDecember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:to="lab_bhc_A9.00SeniorNotesdueDecember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes500DueJanuary2028Member_3e8a4283-0b5d-405c-8c58-7ea8c289c2a5_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.000% Senior Notes Due January 2028</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueJanuary2028Member_label_en-US" xlink:label="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.00%, Due January 2028 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueJanuary2028Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.00% Senior Notes Due January 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes500DueJanuary2028Member" xlink:to="lab_bhc_SeniorNotes500DueJanuary2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember_8f8d7836-334e-4964-aee4-c5294601f6bb_terseLabel_en-US" xlink:label="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D not in service</link:label>
    <link:label id="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember_ac07a09c-6f35-43d4-863c-6ba8fae96c2b_verboseLabel_en-US" xlink:label="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D</link:label>
    <link:label id="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in Process Research and Development [Member]</link:label>
    <link:label id="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents intangible assets that the entity has acquired as a result of business acquisition, which is represented through the premium in the purchase price over book value attributed to research and development on new product that is not yet being sold.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember" xlink:href="bhc-20220510.xsd#bhc_AcquiredInProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember" xlink:to="lab_bhc_AcquiredInProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PriceAppreciationCreditMember_b6e89da4-0589-404f-8e13-22d5bff9c1ea_terseLabel_en-US" xlink:label="lab_bhc_PriceAppreciationCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Appreciation Credit</link:label>
    <link:label id="lab_bhc_PriceAppreciationCreditMember_label_en-US" xlink:label="lab_bhc_PriceAppreciationCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Appreciation Credit [Member]</link:label>
    <link:label id="lab_bhc_PriceAppreciationCreditMember_documentation_en-US" xlink:label="lab_bhc_PriceAppreciationCreditMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Appreciation Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PriceAppreciationCreditMember" xlink:href="bhc-20220510.xsd#bhc_PriceAppreciationCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PriceAppreciationCreditMember" xlink:to="lab_bhc_PriceAppreciationCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_6041b84b-d912-4aab-8c11-a613087d0422_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_641d0b87-ab1a-43b0-a63e-e1ff0c80b519_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_c5ed7a91-80bc-41b6-9e3b-0eddbdb8f327_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_8e8d9b91-1f9a-42ec-af4e-e4b9486fd7ca_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_5835afff-0b98-4225-bcea-b36bd14f7467_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_e2f4dac7-7bbf-4093-94db-3914cd4d8014_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember_a48ea362-6a20-451e-b95c-ad980c1f91f5_terseLabel_en-US" xlink:label="lab_bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Slayback Pharma LLC And Slayback Pharma India LLP Litigation</link:label>
    <link:label id="lab_bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember_label_en-US" xlink:label="lab_bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Slayback Pharma LLC And Slayback Pharma India LLP Litigation [Member]</link:label>
    <link:label id="lab_bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember_documentation_en-US" xlink:label="lab_bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Slayback Pharma LLC And Slayback Pharma India LLP Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember" xlink:href="bhc-20220510.xsd#bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember" xlink:to="lab_bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_05236880-d6c3-4663-af3f-04e165e63b5b_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_418d07b2-bf34-414b-96e2-4b3270c4ca38_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_b6ebd9e6-df74-4ec9-99c2-a7008afb7b5e_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_5252b2e7-a81e-49ff-bcaf-7cbad9c1d09b_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic (benefit) cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_baa44faf-659f-4988-aee5-e39e519fa833_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings of short-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A7.00SeniorUnsecuredNotesDue2028Member_6e9ff710-7d12-43c4-b494-592c48bf9e0f_terseLabel_en-US" xlink:label="lab_bhc_A7.00SeniorUnsecuredNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.00% Senior Unsecured Notes due 2028</link:label>
    <link:label id="lab_bhc_A7.00SeniorUnsecuredNotesDue2028Member_label_en-US" xlink:label="lab_bhc_A7.00SeniorUnsecuredNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.00% Senior Unsecured Notes Due 2028 [Member]</link:label>
    <link:label id="lab_bhc_A7.00SeniorUnsecuredNotesDue2028Member_documentation_en-US" xlink:label="lab_bhc_A7.00SeniorUnsecuredNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.00% Senior Unsecured Notes Due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A7.00SeniorUnsecuredNotesDue2028Member" xlink:href="bhc-20220510.xsd#bhc_A7.00SeniorUnsecuredNotesDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A7.00SeniorUnsecuredNotesDue2028Member" xlink:to="lab_bhc_A7.00SeniorUnsecuredNotesDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable_8276bbf2-a01c-468f-ad76-bcd7779d52bb_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expenses [Table]</link:label>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable_label_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expenses [Table]</link:label>
    <link:label id="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable_documentation_en-US" xlink:label="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Income And Expenses [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:href="bhc-20220510.xsd#bhc_ScheduleOfOtherIncomeAndExpensesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:to="lab_bhc_ScheduleOfOtherIncomeAndExpensesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_country_PL_4c3d38a2-b56c-44f7-a53b-01552b1f12c7_terseLabel_en-US" xlink:label="lab_country_PL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Poland</link:label>
    <link:label id="lab_country_PL_label_en-US" xlink:label="lab_country_PL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">POLAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_PL" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_PL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_PL" xlink:to="lab_country_PL" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ConcentrationRiskNumberOfProducts_7e3bc13f-4269-4af0-b666-278af0868e23_terseLabel_en-US" xlink:label="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products represented of total revenue</link:label>
    <link:label id="lab_bhc_ConcentrationRiskNumberOfProducts_label_en-US" xlink:label="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Number Of Products</link:label>
    <link:label id="lab_bhc_ConcentrationRiskNumberOfProducts_documentation_en-US" xlink:label="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Number Of Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskNumberOfProducts" xlink:href="bhc-20220510.xsd#bhc_ConcentrationRiskNumberOfProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ConcentrationRiskNumberOfProducts" xlink:to="lab_bhc_ConcentrationRiskNumberOfProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_5662e979-d7dc-460b-856c-7888ae7443e0_terseLabel_en-US" xlink:label="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of research and development</link:label>
    <link:label id="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_label_en-US" xlink:label="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Research And Development Expense [Table Text Block]</link:label>
    <link:label id="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_documentation_en-US" xlink:label="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Research And Development Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:href="bhc-20220510.xsd#bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:to="lab_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_9917cc54-34db-4c19-bad6-ed129109627b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_657e3583-41e9-49ce-9d40-af51435bbd3f_verboseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Compensation Plan</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_254ad6a3-7bf4-41c9-bf3f-8441b6301111_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_d78476d5-a8b4-425d-91cc-5b47472b03b4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_058a752f-6e1c-4afe-a178-d258f39510a4_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_39160285-a628-4f60-a010-77f4e921aab9_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee, unutilized commitments, percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_9f5a3ba1-0b5b-45a0-89a8-ed8d617a861c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair values of assets acquired and liabilities assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_bd1bcd03-b739-44bf-9a2e-bd4af6f517e1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LiabilitiesLesseeAbstract_c97fca95-e1dd-44b1-a453-3da58424a82c_terseLabel_en-US" xlink:label="lab_bhc_LiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities included in:</link:label>
    <link:label id="lab_bhc_LiabilitiesLesseeAbstract_label_en-US" xlink:label="lab_bhc_LiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Lessee [Abstract]</link:label>
    <link:label id="lab_bhc_LiabilitiesLesseeAbstract_documentation_en-US" xlink:label="lab_bhc_LiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LiabilitiesLesseeAbstract" xlink:href="bhc-20220510.xsd#bhc_LiabilitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LiabilitiesLesseeAbstract" xlink:to="lab_bhc_LiabilitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_95f40c47-6ed3-43fe-8297-d8f2d7e7d035_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period provision</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_5c42133b-31fa-4419-b530-8e384f83dcfd_netLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales return provisions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_bf800926-8757-4073-8167-019eaca8c17a_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged to other accounts</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_c11be236-9a4f-438c-992a-9b853499be63_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underfunded pension benefit plans</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_076c0a90-fd56-48cb-b353-8ec4fb301c61_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_d58580e8-c086-4d89-aefa-0965befb201a_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_25296636-6cce-42d6-ab28-c8a7e33a9005_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_d8cb6354-97a1-448d-9ebf-946df71b7c81_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_a033e67c-cf2e-42ca-93d2-40c36e040d71_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:to="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_5ee3da8a-c8e1-43c3-844a-7755f8690f08_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_72567491-6852-4f6c-b0c4-429c6cfc97b1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_U.S.BroadMarketMember_2d6453d4-5563-4369-ac3f-ac972158aaa1_terseLabel_en-US" xlink:label="lab_bhc_U.S.BroadMarketMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. broad market</link:label>
    <link:label id="lab_bhc_U.S.BroadMarketMember_label_en-US" xlink:label="lab_bhc_U.S.BroadMarketMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Broad Market [Member]</link:label>
    <link:label id="lab_bhc_U.S.BroadMarketMember_documentation_en-US" xlink:label="lab_bhc_U.S.BroadMarketMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Broad Market [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_U.S.BroadMarketMember" xlink:href="bhc-20220510.xsd#bhc_U.S.BroadMarketMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_U.S.BroadMarketMember" xlink:to="lab_bhc_U.S.BroadMarketMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b962a4bb-9ec9-4795-a7f7-9a2e806371a3_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_a46fe6aa-80d3-46a4-b724-bc4f2885cff4_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of groups of investors</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_label_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_documentation_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:href="bhc-20220510.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:to="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes925DueApril2026Member_5e9026e8-8a8f-495b-b5c1-e3cd1454919e_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes925DueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.250% Senior Notes Due April 2026</link:label>
    <link:label id="lab_bhc_SeniorNotes925DueApril2026Member_label_en-US" xlink:label="lab_bhc_SeniorNotes925DueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 9.25%, Due April 2026 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes925DueApril2026Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes925DueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.25% Senior Notes Due April 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes925DueApril2026Member" xlink:to="lab_bhc_SeniorNotes925DueApril2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_29509d6e-9508-4175-88b0-a0854d80b7d2_verboseLabel_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of countries in which entity operates</link:label>
    <link:label id="lab_us-gaap_NumberOfCountriesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Countries in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_46e9f2e3-07d8-4775-bcc1-1d085ca10628_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_afe2e59d-2b5d-4a1b-927e-5b49b7e7e319_terseLabel_en-US" xlink:label="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_label_en-US" xlink:label="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration Fair Value Disclosure</link:label>
    <link:label id="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_documentation_en-US" xlink:label="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement which may include cash and shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:href="bhc-20220510.xsd#bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:to="lab_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_fa10192a-db1f-4bf7-8c18-24d698412bd5_verboseLabel_en-US" xlink:label="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, Time-based RSUs, Performance-based RSUs</link:label>
    <link:label id="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20220510.xsd#bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_437fb5b2-6d4b-4e07-b8f7-b4159c0a3944_negatedLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and credits</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_9ccef1d5-21a9-4e08-a11c-4e3a1bb6b0f9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_30ea15bf-4bad-4999-8ac8-d1b160a6839b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_77b8821c-ffbd-483a-8362-7a304899802e_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Provision for) benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_548a2fb5-b168-44ab-95b6-369bcac178e7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realignment of segment goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_0e30b5eb-bdc7-46cb-9060-4edaf8a7c9d6_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price Per Share</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation, Arrangement by Share Based Payment Award Options Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" xlink:href="bhc-20220510.xsd#bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" xlink:to="lab_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_0e641c4f-6ba4-433e-981e-dd8e1dc1a811_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_94f0756f-656c-451f-a2a0-6668e6c04bb7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net trade receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_ed6eb3eb-f29e-406b-8b42-ace4c3f9c5f0_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_4907c212-5098-494e-aaca-e8759a2c92f9_verboseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember" xlink:to="lab_us-gaap_UnsecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_09f54c18-5807-4d31-9fbe-29dab94e2587_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of cases dismissed</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Dismissed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:to="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_dba88e7d-2425-48bd-874e-34fee4731591_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_c25f6732-37ce-4aea-aa3f-ce2da55d9029_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_51813d0f-cb33-43bc-b10f-f68426e4ccae_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Plan Assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_a8c37ca4-9cbc-4664-a1dd-624b1f72944f_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b511cb27-0f18-453b-b886-ca841144dc42_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_2f93c398-c1f7-40c2-b577-9e187c0ba8d6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_8864809a-0cd3-4fb5-90fd-d76f34fedee8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_MX_ba05507a-4d85-4515-9aff-e3eede98acde_terseLabel_en-US" xlink:label="lab_country_MX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mexico</link:label>
    <link:label id="lab_country_MX_label_en-US" xlink:label="lab_country_MX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MEXICO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_MX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_MX" xlink:to="lab_country_MX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_7a1849c7-4edc-4492-a94c-e0af8bad96fb_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SalixSegmentMember_66fad51f-5104-4d73-8a2f-3629a47315ae_terseLabel_en-US" xlink:label="lab_bhc_SalixSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix</link:label>
    <link:label id="lab_bhc_SalixSegmentMember_3a253217-8a3c-43e9-8e7c-241046b1c48d_verboseLabel_en-US" xlink:label="lab_bhc_SalixSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix</link:label>
    <link:label id="lab_bhc_SalixSegmentMember_label_en-US" xlink:label="lab_bhc_SalixSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix Segment [Member]</link:label>
    <link:label id="lab_bhc_SalixSegmentMember_documentation_en-US" xlink:label="lab_bhc_SalixSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salix Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember" xlink:href="bhc-20220510.xsd#bhc_SalixSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SalixSegmentMember" xlink:to="lab_bhc_SalixSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c4706f34-d570-440b-8f11-082e84ce1e7a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance on Canadian deferred tax assets and tax rate changes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_410e0999-36aa-4fbe-a0b5-81332082f31d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_1a2eb412-9e98-4420-be60-17d561200b32_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_674ea022-2ea4-49da-ad56-6583ba663e30_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of long-term debt and other</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_cfb22010-785f-436c-a0cf-b522322df2bf_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_2f22004f-9877-44c5-a07d-5cfdae2d128b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_b8507933-1c18-4021-95a9-b7a9d053efa9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_country_NL_36431e33-54dc-4d2f-93bc-3de5ae06abf7_terseLabel_en-US" xlink:label="lab_country_NL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Netherlands</link:label>
    <link:label id="lab_country_NL_label_en-US" xlink:label="lab_country_NL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NETHERLANDS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_NL" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_NL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_NL" xlink:to="lab_country_NL" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_06db8fe0-76b1-44be-8a9e-d2052e3a0135_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value of stock options (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_1b27b17b-126f-43a7-ab68-200d00619a68_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6b9cf299-cc8f-4372-aede-1cba19c25456_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025Member_066434d0-ce68-46b3-942d-c8c71befcfd4_verboseLabel_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025Member_a6116578-1e51-4af5-8fd6-bdc359561ddd_terseLabel_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025Member_label_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025 [Member]</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025Member_documentation_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member" xlink:href="bhc-20220510.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermLoanBFacilityDueJune2025Member" xlink:to="lab_bhc_TermLoanBFacilityDueJune2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_85643840-6d2c-443b-9d92-b143abe173da_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_bf456bd3-60f3-45aa-a1e0-a5358e3d0b08_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_0702ba1b-59f3-423f-a38e-f9dc78daa10b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_b1c99308-c267-4516-accc-74ef6135ccf6_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TimeBasedRSUMember_e2bee9df-e0b6-4f6d-8ce8-5269b6441404_terseLabel_en-US" xlink:label="lab_bhc_TimeBasedRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-Based RSUs</link:label>
    <link:label id="lab_bhc_TimeBasedRSUMember_label_en-US" xlink:label="lab_bhc_TimeBasedRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Based RSU [Member]</link:label>
    <link:label id="lab_bhc_TimeBasedRSUMember_documentation_en-US" xlink:label="lab_bhc_TimeBasedRSUMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents stock awards in the form of time-based restricted stock units (RSUs) to certain directors, officers and other eligible employees pursuant to the company's incentive compensation plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TimeBasedRSUMember" xlink:href="bhc-20220510.xsd#bhc_TimeBasedRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TimeBasedRSUMember" xlink:to="lab_bhc_TimeBasedRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_ba1752a3-1d8f-424d-aadf-2774e7e861a3_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_94075e9e-b984-4472-bffd-d6051019bfd5_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GainLossRelatedToLitigationSettlementGross_442347c3-3b6a-4d4b-b989-b8e036c5f42d_negatedTerseLabel_en-US" xlink:label="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to accrued legal settlements</link:label>
    <link:label id="lab_bhc_GainLossRelatedToLitigationSettlementGross_label_en-US" xlink:label="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related To Litigation Settlement, Gross</link:label>
    <link:label id="lab_bhc_GainLossRelatedToLitigationSettlementGross_documentation_en-US" xlink:label="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related To Litigation Settlement, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainLossRelatedToLitigationSettlementGross" xlink:href="bhc-20220510.xsd#bhc_GainLossRelatedToLitigationSettlementGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GainLossRelatedToLitigationSettlementGross" xlink:to="lab_bhc_GainLossRelatedToLitigationSettlementGross" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AssetsLesseeAbstract_66c5842e-97bb-4933-9122-f439532945de_terseLabel_en-US" xlink:label="lab_bhc_AssetsLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets included in:</link:label>
    <link:label id="lab_bhc_AssetsLesseeAbstract_label_en-US" xlink:label="lab_bhc_AssetsLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Lessee [Abstract]</link:label>
    <link:label id="lab_bhc_AssetsLesseeAbstract_documentation_en-US" xlink:label="lab_bhc_AssetsLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetsLesseeAbstract" xlink:href="bhc-20220510.xsd#bhc_AssetsLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AssetsLesseeAbstract" xlink:to="lab_bhc_AssetsLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_cd0e7674-1921-4bd1-b199-b06745784780_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_1b5fdd38-6ef4-4aeb-9df4-171957ceed3d_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of fair value in excess of carrying value</link:label>
    <link:label id="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_label_en-US" xlink:label="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:to="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_1b8954ef-fd69-4ce4-a148-5bf798507455_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_49e5e993-d908-4f45-8e6c-70699444c841_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the components and classification of share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_95e0cae3-120d-4dfc-9fde-7ac1c27afa7f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual asset allocations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForDiscountsAndAllowancesMember_5b607112-12a1-48c3-b5e2-60041a333e00_terseLabel_en-US" xlink:label="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts and Allowances</link:label>
    <link:label id="lab_bhc_ReserveForDiscountsAndAllowancesMember_label_en-US" xlink:label="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Discounts And Allowances [Member]</link:label>
    <link:label id="lab_bhc_ReserveForDiscountsAndAllowancesMember_documentation_en-US" xlink:label="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Discounts And Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDiscountsAndAllowancesMember" xlink:href="bhc-20220510.xsd#bhc_ReserveForDiscountsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForDiscountsAndAllowancesMember" xlink:to="lab_bhc_ReserveForDiscountsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_1e2ff108-3052-4de8-8acc-e3cda92c52c5_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_47bdc2af-b6d8-4f28-8c58-8e741013fbab_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_934468fd-d54b-4341-8e65-8ed59745cf0e_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_7ce5a94e-3bf2-4f3e-8b7b-edb88dadab5e_terseLabel_en-US" xlink:label="lab_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_label_en-US" xlink:label="lab_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards Research and Development</link:label>
    <link:label id="lab_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_documentation_en-US" xlink:label="lab_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The tax effect as of the balance sheet date of the amount of future tax deductions arising from unused research and development tax credit carryforwards; a tax credit carryforward is the amount by which tax credits available for utilization exceed statutory limitations for inclusion in historical filings, and which can only be utilized if sufficient tax-basis income is generated in future periods and providing tax laws continue to allow such utilization.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:href="bhc-20220510.xsd#bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:to="lab_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_3b8ae889-86c0-42d9-b4ed-07dd586e4726_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a3f213bd-e3ff-4cc6-936f-45b8d2cb2cc6_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ba868e5c-3358-4338-a4f8-717f2600241e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_540b6b85-264b-4dbc-85d3-5373acfac840_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_7184f3d4-660a-4ed5-854c-55c42df066e9_netLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods_ae0a9970-a637-4527-9577-93ca21709b9a_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distinct insurance policy periods</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods_label_en-US" xlink:label="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Insurance Policy Periods</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods_documentation_en-US" xlink:label="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Insurance Policy Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:href="bhc-20220510.xsd#bhc_LossContingencyNumberOfInsurancePolicyPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:to="lab_bhc_LossContingencyNumberOfInsurancePolicyPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ACertainInternationalBusinessMember_ae6bf7c2-4525-4c96-a7a7-4f107b4526ea_terseLabel_en-US" xlink:label="lab_bhc_ACertainInternationalBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A Certain International Business</link:label>
    <link:label id="lab_bhc_ACertainInternationalBusinessMember_label_en-US" xlink:label="lab_bhc_ACertainInternationalBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A Certain International Business [Member]</link:label>
    <link:label id="lab_bhc_ACertainInternationalBusinessMember_documentation_en-US" xlink:label="lab_bhc_ACertainInternationalBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A Certain International Business [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ACertainInternationalBusinessMember" xlink:href="bhc-20220510.xsd#bhc_ACertainInternationalBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ACertainInternationalBusinessMember" xlink:to="lab_bhc_ACertainInternationalBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_dc2d11d4-fabd-4a5b-a151-dfee1dc8cd35_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_20fdfca3-b27a-4968-bd87-d61e0a1a07ae_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_512df6b6-3869-4ba3-a561-e75cc0f8a768_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_75da3ee2-9f0d-4dac-81d2-9099acbc25a0_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_821fa975-b835-4d44-bed9-15f95a643d1a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Useful Lives (Years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecuredTermCreditFacilitiesMember_4ff18fe0-4a05-4e65-adf9-a6cb0af4d7d4_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecuredTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities</link:label>
    <link:label id="lab_bhc_SeniorSecuredTermCreditFacilitiesMember_label_en-US" xlink:label="lab_bhc_SeniorSecuredTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Term Credit Facilities [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecuredTermCreditFacilitiesMember_documentation_en-US" xlink:label="lab_bhc_SeniorSecuredTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the Senior Secured Credit Facilities which includes the Revolving Credit Facility, New Term Loan A Facility, and the Delayed Draw Facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredTermCreditFacilitiesMember" xlink:href="bhc-20220510.xsd#bhc_SeniorSecuredTermCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecuredTermCreditFacilitiesMember" xlink:to="lab_bhc_SeniorSecuredTermCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_d4fb46d6-71d9-4498-86f2-6e4314f299f3_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3efcff69-cbd8-405d-97fe-03440339956e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of calculation of loss per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_6b0baa5a-cef2-4952-a4dc-755533520774_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_e7c5f88a-2107-4f07-b88a-154ab71d8e96_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_3bca1dc6-da40-47b3-a7b1-596100123b29_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_78b28515-d870-421c-b85f-6be8513c0770_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_0bf40162-8381-4871-945f-00482f083543_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_2ba20ddf-ee06-41e5-81a6-e3996a664a58_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of non-vested time-based RSU activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_f59b0511-bfd3-4f3c-9ccf-382007468f84_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED AND OTHER CURRENT LIABILITIES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_ff00d1ae-87ac-4229-a3f7-fa45e43ef9e2_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage_d8d7818c-e685-4eb3-9567-765f2a99519f_terseLabel_en-US" xlink:label="lab_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold percentage for amortization of net actuarial gains and losses</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage_label_en-US" xlink:label="lab_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Actuarial Gain (Loss), Amortization Threshold Percentage</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage_documentation_en-US" xlink:label="lab_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Actuarial Gain (Loss), Amortization Threshold Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage" xlink:href="bhc-20220510.xsd#bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage" xlink:to="lab_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NovaliqGmbHMember_f05a5304-d6ae-4f19-9e71-da87f405dfbe_terseLabel_en-US" xlink:label="lab_bhc_NovaliqGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novaliq GmbH</link:label>
    <link:label id="lab_bhc_NovaliqGmbHMember_label_en-US" xlink:label="lab_bhc_NovaliqGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novaliq GmbH [Member]</link:label>
    <link:label id="lab_bhc_NovaliqGmbHMember_documentation_en-US" xlink:label="lab_bhc_NovaliqGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novaliq GmbH [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NovaliqGmbHMember" xlink:href="bhc-20220510.xsd#bhc_NovaliqGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NovaliqGmbHMember" xlink:to="lab_bhc_NovaliqGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_f206ba70-74eb-429d-85ac-9cb1bebdc0c1_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate on debt (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_6707a3ce-e484-4a6b-aebe-e106b0fb9377_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TaxYear2015AndTaxYear2016Member_334c8f5f-ef72-4d88-ab76-f6f305c6d1a8_terseLabel_en-US" xlink:label="lab_bhc_TaxYear2015AndTaxYear2016Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2015 and Tax Year 2016</link:label>
    <link:label id="lab_bhc_TaxYear2015AndTaxYear2016Member_label_en-US" xlink:label="lab_bhc_TaxYear2015AndTaxYear2016Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2015 And Tax Year 2016 [Member]</link:label>
    <link:label id="lab_bhc_TaxYear2015AndTaxYear2016Member_documentation_en-US" xlink:label="lab_bhc_TaxYear2015AndTaxYear2016Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2015 And Tax Year 2016</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaxYear2015AndTaxYear2016Member" xlink:href="bhc-20220510.xsd#bhc_TaxYear2015AndTaxYear2016Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TaxYear2015AndTaxYear2016Member" xlink:to="lab_bhc_TaxYear2015AndTaxYear2016Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_b0140512-5017-4e08-bcf1-befe731c9638_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_154559eb-99d8-44f1-9165-b4dcd396bfe0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0fc2e98d-4e79-4d48-8fb6-c4fa4e818a81_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_8fbc054e-72ce-4fa7-b064-d385672b783f_verboseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_c652a722-b2d6-4bef-b173-4d7512c52bdc_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving credit facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_8ef8d75a-c979-432c-b5c3-057715da0e6f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside basis differences</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Undistributed Foreign Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NumberOfOtherBusinessesAcquired_47fe54f6-fcaf-4a48-b7a1-128738387fff_terseLabel_en-US" xlink:label="lab_bhc_NumberOfOtherBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of other material business combinations</link:label>
    <link:label id="lab_bhc_NumberOfOtherBusinessesAcquired_label_en-US" xlink:label="lab_bhc_NumberOfOtherBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Other Businesses Acquired</link:label>
    <link:label id="lab_bhc_NumberOfOtherBusinessesAcquired_documentation_en-US" xlink:label="lab_bhc_NumberOfOtherBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Other Businesses Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NumberOfOtherBusinessesAcquired" xlink:href="bhc-20220510.xsd#bhc_NumberOfOtherBusinessesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NumberOfOtherBusinessesAcquired" xlink:to="lab_bhc_NumberOfOtherBusinessesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_641d3256-8cc0-44e7-b306-43f695e99888_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherMachineryAndEquipmentMember_48ea3885-19b7-4cae-a855-921d6cba0d9a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherMachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other equipment</link:label>
    <link:label id="lab_us-gaap_OtherMachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OtherMachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherMachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherMachineryAndEquipmentMember" xlink:to="lab_us-gaap_OtherMachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_7eef70e4-a1fb-4e8f-ae94-9fa6343d44d6_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:to="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_ba116a00-f959-4dad-8c39-8100db606288_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of lease expenses</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_6b4c00fe-47f2-4fba-b2c2-4a5031f14209_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_beba3d2b-02ef-4449-b041-4877007ff4d1_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alternate term, principal amount maturity threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_label_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Principal Amount Maturity Threshold</link:label>
    <link:label id="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Alternate Term, Principal Amount Maturity Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:to="lab_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccruedProductRebateCurrent_59e67aaf-db67-4a2d-9187-f8ed9799408e_terseLabel_en-US" xlink:label="lab_bhc_AccruedProductRebateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product rebates</link:label>
    <link:label id="lab_bhc_AccruedProductRebateCurrent_label_en-US" xlink:label="lab_bhc_AccruedProductRebateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Product Rebate Current</link:label>
    <link:label id="lab_bhc_AccruedProductRebateCurrent_documentation_en-US" xlink:label="lab_bhc_AccruedProductRebateCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the current portion of accrued product rebates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductRebateCurrent" xlink:href="bhc-20220510.xsd#bhc_AccruedProductRebateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccruedProductRebateCurrent" xlink:to="lab_bhc_AccruedProductRebateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_989fea85-daa9-4695-b9c3-0f3764c8d68a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest crediting rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_e795a635-eee0-4e8d-b52c-484808025c2b_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_4afc3924-5b49-485a-be2b-bae1f01174d0_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_6415e9d1-fe05-4a96-bac7-6cc7db1e3f04_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_778c0e88-2649-4517-83ca-bfd034fe81d4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_country_RS_b7689d64-0d21-4900-96cf-54a933f1cd99_terseLabel_en-US" xlink:label="lab_country_RS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Serbia</link:label>
    <link:label id="lab_country_RS_label_en-US" xlink:label="lab_country_RS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SERBIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_RS" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_RS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_RS" xlink:to="lab_country_RS" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseMember_3359f018-c0f2-4116-a6ef-56b8e790e832_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember" xlink:to="lab_us-gaap_InterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ForeignCountryStateAndLocalMember_9fd02aea-d80b-47d9-bf6a-5676b92caf1a_terseLabel_en-US" xlink:label="lab_bhc_ForeignCountryStateAndLocalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian Federal and Provincial</link:label>
    <link:label id="lab_bhc_ForeignCountryStateAndLocalMember_label_en-US" xlink:label="lab_bhc_ForeignCountryStateAndLocalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Country State and Local [Member]</link:label>
    <link:label id="lab_bhc_ForeignCountryStateAndLocalMember_documentation_en-US" xlink:label="lab_bhc_ForeignCountryStateAndLocalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The designated tax department of state or local government of a foreign country entitled to levy and collect income taxes from the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ForeignCountryStateAndLocalMember" xlink:href="bhc-20220510.xsd#bhc_ForeignCountryStateAndLocalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ForeignCountryStateAndLocalMember" xlink:to="lab_bhc_ForeignCountryStateAndLocalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_RU_2e74d9ce-54f7-47b3-92dd-94358b60aa40_terseLabel_en-US" xlink:label="lab_country_RU" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Russia</link:label>
    <link:label id="lab_country_RU_label_en-US" xlink:label="lab_country_RU" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RUSSIAN FEDERATION</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_RU" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_RU"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_RU" xlink:to="lab_country_RU" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_328b88d2-7314-4f30-8987-37f73bb4ffde_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_f12aba79-1fa2-4c46-aaea-7b27fe296fd1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign tax rate differences</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorUnsecuredNotesDue2023Member_62e18726-2c1e-4ba4-8911-efcaa63a59b7_terseLabel_en-US" xlink:label="lab_bhc_SeniorUnsecuredNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes due 2023</link:label>
    <link:label id="lab_bhc_SeniorUnsecuredNotesDue2023Member_label_en-US" xlink:label="lab_bhc_SeniorUnsecuredNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due 2023 [Member]</link:label>
    <link:label id="lab_bhc_SeniorUnsecuredNotesDue2023Member_documentation_en-US" xlink:label="lab_bhc_SeniorUnsecuredNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorUnsecuredNotesDue2023Member" xlink:href="bhc-20220510.xsd#bhc_SeniorUnsecuredNotesDue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorUnsecuredNotesDue2023Member" xlink:to="lab_bhc_SeniorUnsecuredNotesDue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_ce760579-df67-42d8-a430-ed62f71736fa_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_69ce283d-f73c-4a55-8484-3576d4a51716_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_1240a8f5-93f7-4cf5-994c-7faf178a5b59_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) recognized in interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_e3c45dc2-f4f7-4606-bc3f-dbcca2e3cf78_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_c4afc0fd-d5d4-455a-bbb0-7546c764178c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, integration, separation and IPO costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_69dbb5dc-7a1c-4572-82f3-5c3fefe6cf5e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NoncashCumulativeForeignCurrencyTranslationLoss_fa0eb4ba-668c-44ea-9977-20141feea82d_terseLabel_en-US" xlink:label="lab_bhc_NoncashCumulativeForeignCurrencyTranslationLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash cumulative foreign currency translation loss</link:label>
    <link:label id="lab_bhc_NoncashCumulativeForeignCurrencyTranslationLoss_label_en-US" xlink:label="lab_bhc_NoncashCumulativeForeignCurrencyTranslationLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Cumulative Foreign Currency Translation Loss</link:label>
    <link:label id="lab_bhc_NoncashCumulativeForeignCurrencyTranslationLoss_documentation_en-US" xlink:label="lab_bhc_NoncashCumulativeForeignCurrencyTranslationLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Cumulative Foreign Currency Translation Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NoncashCumulativeForeignCurrencyTranslationLoss" xlink:href="bhc-20220510.xsd#bhc_NoncashCumulativeForeignCurrencyTranslationLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NoncashCumulativeForeignCurrencyTranslationLoss" xlink:to="lab_bhc_NoncashCumulativeForeignCurrencyTranslationLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_a8475e6f-ba65-410b-bf68-cee57b982143_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TaxYear2005ThroughTaxYear2009Member_2385d822-ebb9-4d1c-a6fe-6dafec2410ff_terseLabel_en-US" xlink:label="lab_bhc_TaxYear2005ThroughTaxYear2009Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2005 through Tax Year 2009</link:label>
    <link:label id="lab_bhc_TaxYear2005ThroughTaxYear2009Member_label_en-US" xlink:label="lab_bhc_TaxYear2005ThroughTaxYear2009Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2005 Through Tax Year 2009 [Member]</link:label>
    <link:label id="lab_bhc_TaxYear2005ThroughTaxYear2009Member_documentation_en-US" xlink:label="lab_bhc_TaxYear2005ThroughTaxYear2009Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2005 Through Tax Year 2009</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaxYear2005ThroughTaxYear2009Member" xlink:href="bhc-20220510.xsd#bhc_TaxYear2005ThroughTaxYear2009Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TaxYear2005ThroughTaxYear2009Member" xlink:to="lab_bhc_TaxYear2005ThroughTaxYear2009Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccretionForTimeValueOfMoneyMember_d85e655b-bbaf-44ca-a74c-6c5541b98d8a_terseLabel_en-US" xlink:label="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion for the time value of money</link:label>
    <link:label id="lab_bhc_AccretionForTimeValueOfMoneyMember_label_en-US" xlink:label="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion For Time Value Of Money [Member]</link:label>
    <link:label id="lab_bhc_AccretionForTimeValueOfMoneyMember_documentation_en-US" xlink:label="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion For Time Value Of Money [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccretionForTimeValueOfMoneyMember" xlink:href="bhc-20220510.xsd#bhc_AccretionForTimeValueOfMoneyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccretionForTimeValueOfMoneyMember" xlink:to="lab_bhc_AccretionForTimeValueOfMoneyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_a0e7264b-fa56-47c2-b5d4-736acf8c4d89_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ireland</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_54535073-4bc4-46b8-9f8d-9fac365f9ade_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes6125DueApril2025Member_34e66202-bb72-476e-9f84-72e979c5123c_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% Senior Notes Due April 2025</link:label>
    <link:label id="lab_bhc_SeniorNotes6125DueApril2025Member_label_en-US" xlink:label="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.125%, Due April 2025 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes6125DueApril2025Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% Senior Notes due April 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes6125DueApril2025Member" xlink:to="lab_bhc_SeniorNotes6125DueApril2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_3fadff45-bba3-43aa-a888-4e068dd216b9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and Acquisition-Related Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_b97a1130-5444-4bb4-aa2d-ca9e91927a58_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_801d0ed1-6e52-4550-944d-20ba9059108f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_3631b35e-6e26-46b3-85c8-0db227a8f1d3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_563e7779-0e31-4516-b1af-3b3acf77384d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_a4a0049b-6e0c-4c13-9201-5a8796ec1b3d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held-for-sale, Long Lived, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:to="lab_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition_89ba9ec5-0ce8-4759-b33e-e7b812bd3048_negatedTerseLabel_en-US" xlink:label="lab_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization or settlement recognition of net loss</link:label>
    <link:label id="lab_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition_label_en-US" xlink:label="lab_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Amortization or Settlement Recognition</link:label>
    <link:label id="lab_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition_documentation_en-US" xlink:label="lab_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Amortization or Settlement Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" xlink:href="bhc-20220510.xsd#bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" xlink:to="lab_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6e1687d6-4b9c-48a6-bb42-4735d1678a2b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_22e7881f-e5d1-4919-9e07-b2c0fc40d0e3_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_0de3a483-5a61-40b9-b4b2-5928f88d4e8a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of intangible assets and other assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_9ede6ec5-b475-4dc5-9910-1f8ea59e011b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_fe5a8769-0f0d-4b35-9a08-20d8c899ad1a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_cd27f8a3-896a-4555-a790-53e4799d6ffa_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent_864b5a57-4474-4e8e-be88-6eb4d8b74e47_terseLabel_en-US" xlink:label="lab_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent_label_en-US" xlink:label="lab_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Sundry Liabilities, Current</link:label>
    <link:label id="lab_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent_documentation_en-US" xlink:label="lab_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Sundry Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent" xlink:href="bhc-20220510.xsd#bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent" xlink:to="lab_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FixedIncomeSecuritiesMember_c9c95428-fcdc-4f36-81ff-d37166b9f8f6_terseLabel_en-US" xlink:label="lab_us-gaap_FixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed income securities</link:label>
    <link:label id="lab_us-gaap_FixedIncomeSecuritiesMember_c205c524-35f9-4b2e-b9d8-042b378c5717_verboseLabel_en-US" xlink:label="lab_us-gaap_FixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed income securities:</link:label>
    <link:label id="lab_us-gaap_FixedIncomeSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_FixedIncomeSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Income Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FixedIncomeSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FixedIncomeSecuritiesMember" xlink:to="lab_us-gaap_FixedIncomeSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b0ca2deb-f109-4781-8895-9e3bc9938518_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndDebtExpense_00eb2414-efe5-484c-b667-a958b3c6cf7c_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestAndDebtExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestAndDebtExpense_label_en-US" xlink:label="lab_us-gaap_InterestAndDebtExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and Debt Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDebtExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndDebtExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndDebtExpense" xlink:to="lab_us-gaap_InterestAndDebtExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dc2e0d86-81de-44c3-9cef-86d345555306_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_193f6cbc-7d97-44e7-9cba-92f270cc3a08_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BauschLombInternationalMember_525c33ed-3504-43a8-895b-184e49f405a3_terseLabel_en-US" xlink:label="lab_bhc_BauschLombInternationalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch + Lomb/ International</link:label>
    <link:label id="lab_bhc_BauschLombInternationalMember_label_en-US" xlink:label="lab_bhc_BauschLombInternationalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch Lomb/International [Member]</link:label>
    <link:label id="lab_bhc_BauschLombInternationalMember_documentation_en-US" xlink:label="lab_bhc_BauschLombInternationalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch Lomb/International [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombInternationalMember" xlink:href="bhc-20220510.xsd#bhc_BauschLombInternationalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BauschLombInternationalMember" xlink:to="lab_bhc_BauschLombInternationalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_02f98d2b-fdbe-4cb3-b9a8-e285f1afa4b3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a1bf2dd1-c1b5-489b-8c1a-761a5220f6e5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ProductBrandsMember_4394f303-0459-4575-bf77-23fe9a06a027_verboseLabel_en-US" xlink:label="lab_bhc_ProductBrandsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product brands</link:label>
    <link:label id="lab_bhc_ProductBrandsMember_21cb41af-6cec-4fce-ba76-4bd739685646_terseLabel_en-US" xlink:label="lab_bhc_ProductBrandsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product brands</link:label>
    <link:label id="lab_bhc_ProductBrandsMember_label_en-US" xlink:label="lab_bhc_ProductBrandsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Brands [Member]</link:label>
    <link:label id="lab_bhc_ProductBrandsMember_documentation_en-US" xlink:label="lab_bhc_ProductBrandsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the rights to non-patented product brands.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember" xlink:href="bhc-20220510.xsd#bhc_ProductBrandsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ProductBrandsMember" xlink:to="lab_bhc_ProductBrandsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_4e89fca2-2fda-4177-8a34-d83ad087050c_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c8fa6ee6-e03f-4499-8f9b-8fae4558ac19_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_4c235ba3-df5c-4654-b543-3c64fd1d10ac_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held For Sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Held-for-sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_01fd29b3-3069-4b49-9e2e-c73a95d9760f_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of entities, exercised opt-out right, pursuing action</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_label_en-US" xlink:label="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_documentation_en-US" xlink:label="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:href="bhc-20220510.xsd#bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:to="lab_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c6dd78d5-805e-4fa5-b3f1-0f811db4a65b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_a49433ee-615a-42d1-8c16-39b8ec954a53_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember_ec2c25a3-69ad-4d23-bdb1-fb57cfe41a46_terseLabel_en-US" xlink:label="lab_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pooled Scientific Research and Experimental Development</link:label>
    <link:label id="lab_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember_label_en-US" xlink:label="lab_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pooled Scientific Research and Experimental Development Expenditures [Member]</link:label>
    <link:label id="lab_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember_documentation_en-US" xlink:label="lab_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the details pertaining to pooled scientific research and experimental development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:href="bhc-20220510.xsd#bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:to="lab_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_5151a31b-6b28-4995-83b0-6e21af659b17_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental credit facility borrowings</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Threshold For Incremental Borrowings</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Threshold For Incremental Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:href="bhc-20220510.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:to="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CanadaBankersAcceptanceRateMember_85718a44-3bbe-4bf4-96f7-4a2fce434cdd_terseLabel_en-US" xlink:label="lab_bhc_CanadaBankersAcceptanceRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada Bankers Acceptance Rate</link:label>
    <link:label id="lab_bhc_CanadaBankersAcceptanceRateMember_label_en-US" xlink:label="lab_bhc_CanadaBankersAcceptanceRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada Bankers Acceptance Rate [Member]</link:label>
    <link:label id="lab_bhc_CanadaBankersAcceptanceRateMember_documentation_en-US" xlink:label="lab_bhc_CanadaBankersAcceptanceRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada Bankers Acceptance Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadaBankersAcceptanceRateMember" xlink:href="bhc-20220510.xsd#bhc_CanadaBankersAcceptanceRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CanadaBankersAcceptanceRateMember" xlink:to="lab_bhc_CanadaBankersAcceptanceRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OutLicensedTechnologyMember_dd4302ad-c903-490a-9c2e-5b8381fa01fe_verboseLabel_en-US" xlink:label="lab_bhc_OutLicensedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out-licensed technology and other</link:label>
    <link:label id="lab_bhc_OutLicensedTechnologyMember_873e709d-c429-4185-ad51-8e9381a175af_terseLabel_en-US" xlink:label="lab_bhc_OutLicensedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology and other</link:label>
    <link:label id="lab_bhc_OutLicensedTechnologyMember_label_en-US" xlink:label="lab_bhc_OutLicensedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out Licensed Technology [Member]</link:label>
    <link:label id="lab_bhc_OutLicensedTechnologyMember_documentation_en-US" xlink:label="lab_bhc_OutLicensedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the rights to receive cash flows under an out-license arrangement (for example, license fees, milestone payments and royalties).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OutLicensedTechnologyMember" xlink:href="bhc-20220510.xsd#bhc_OutLicensedTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OutLicensedTechnologyMember" xlink:to="lab_bhc_OutLicensedTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_9312989c-a840-4219-8976-20356a935676_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of estimated aggregate amortization expense for each of the five succeeding years</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_ae7e9a97-4372-486f-8d3b-8a663e175c31_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_503d3865-e680-4aca-b289-3bdc49395a7c_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_febf9207-5972-4538-99e8-0d2c01b318ac_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_c538b60e-bbdb-4458-85de-d91d3e475896_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_f7f05687-b2ef-417f-a03c-f2d482badf8f_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_3f9fac88-1ca8-4abe-b033-a67179e0f354_periodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of period</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_e62f6122-2281-41c2-b7b1-b178d4cad4a0_periodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of period</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_948ddb62-c69b-4cec-86cc-770b10e90118_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release of foreign currency translation losses upon disposal of assets held for sale</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_83fb4ab9-848e-4769-a9c8-bbb0c15ce308_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">B&amp;L Trademark</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_22eee576-434d-432e-b1a6-9a94b402fce8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected benefit from income taxes at Canadian statutory rate</link:label>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_label_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:to="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_8c03d412-6b98-48a8-b66c-beec6c051420_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_a6cc164e-2bb2-449b-8685-2f25436f7e05_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock_15aa96eb-1b5c-44db-84bb-3506df6e193c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of foreign exchange contracts on the Consolidated Statements of Operations and Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments Included in Trading Activities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_332f01a8-2e0e-4550-b4d6-49843ebac9fc_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bcfb5297-f6af-4a98-86e8-5ced44dbb705_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_d0c94c78-2800-43ec-a0f2-e600486459a3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_bbebac04-84fd-47eb-a810-d5517b842727_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total leverage ratio (not greater than)</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Total Leverage Ratio, Maximum</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Total Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:to="lab_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BaseRateOrPrimeRateMember_82e1fefd-eac7-4d39-87dc-8b4ecd553f67_terseLabel_en-US" xlink:label="lab_bhc_BaseRateOrPrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate or Prime Rate</link:label>
    <link:label id="lab_bhc_BaseRateOrPrimeRateMember_label_en-US" xlink:label="lab_bhc_BaseRateOrPrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate Or Prime Rate [Member]</link:label>
    <link:label id="lab_bhc_BaseRateOrPrimeRateMember_documentation_en-US" xlink:label="lab_bhc_BaseRateOrPrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate Or Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BaseRateOrPrimeRateMember" xlink:href="bhc-20220510.xsd#bhc_BaseRateOrPrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BaseRateOrPrimeRateMember" xlink:to="lab_bhc_BaseRateOrPrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TradeReceivableNetPortionPastDue_2c6d8d0c-bd58-4e68-9b61-c8fd0a82ddcd_terseLabel_en-US" xlink:label="lab_bhc_TradeReceivableNetPortionPastDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion of net trade receivables that is past due</link:label>
    <link:label id="lab_bhc_TradeReceivableNetPortionPastDue_label_en-US" xlink:label="lab_bhc_TradeReceivableNetPortionPastDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Receivable, Net, Portion Past Due</link:label>
    <link:label id="lab_bhc_TradeReceivableNetPortionPastDue_documentation_en-US" xlink:label="lab_bhc_TradeReceivableNetPortionPastDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Receivable, Net, Portion Past Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TradeReceivableNetPortionPastDue" xlink:href="bhc-20220510.xsd#bhc_TradeReceivableNetPortionPastDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TradeReceivableNetPortionPastDue" xlink:to="lab_bhc_TradeReceivableNetPortionPastDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_b2ef8255-837a-4b11-87f0-d71c852aa329_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_ab5be9d8-b315-4f2a-a1f1-08d9aa343079_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_2f311128-d668-4173-aa01-6b2aedb2ce29_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of possible loss, income tax examination (up to)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:to="lab_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c2df8805-6a81-451c-bccb-f4ce462cb95b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant-Date Fair Value Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_57223683-30b4-474d-aaa1-a66d679f3244_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets, beginning of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_0841da8f-f9d2-45eb-9988-0a28e7267f5a_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets, end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_401dfee2-6d0a-4576-8d0f-0533a0ff649b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_5f6f39b5-3325-466f-a912-f1de7a2c72ed_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_890849cb-0702-4671-8f59-f03b1494eefa_terseLabel_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Costs</link:label>
    <link:label id="lab_us-gaap_LegalCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalCostsPolicyTextBlock" xlink:to="lab_us-gaap_LegalCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RevenuePerformanceObligationPaymentTerms_0849c1d2-7953-409e-b684-6324a38cc0f4_terseLabel_en-US" xlink:label="lab_bhc_RevenuePerformanceObligationPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment terms</link:label>
    <link:label id="lab_bhc_RevenuePerformanceObligationPaymentTerms_label_en-US" xlink:label="lab_bhc_RevenuePerformanceObligationPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Payment Terms</link:label>
    <link:label id="lab_bhc_RevenuePerformanceObligationPaymentTerms_documentation_en-US" xlink:label="lab_bhc_RevenuePerformanceObligationPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuePerformanceObligationPaymentTerms" xlink:href="bhc-20220510.xsd#bhc_RevenuePerformanceObligationPaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RevenuePerformanceObligationPaymentTerms" xlink:to="lab_bhc_RevenuePerformanceObligationPaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_df8cd669-4129-45c1-8a0c-8e3cda28c71d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Debt Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDebtSecuritiesMember" xlink:to="lab_us-gaap_OtherDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_c31db668-f03a-45a3-a1be-970d59d098bb_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated company contributions in next fiscal year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_83ac4314-1096-4dfa-b5fd-01d462ee0065_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_6a207d3d-eaf1-43c3-b6b8-81fb29c660f5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeferredTaxAssetsPrepaidExpenses_7c39f855-c7c4-4ade-a169-38cc67ac7072_terseLabel_en-US" xlink:label="lab_bhc_DeferredTaxAssetsPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_bhc_DeferredTaxAssetsPrepaidExpenses_label_en-US" xlink:label="lab_bhc_DeferredTaxAssetsPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Prepaid Expenses</link:label>
    <link:label id="lab_bhc_DeferredTaxAssetsPrepaidExpenses_documentation_en-US" xlink:label="lab_bhc_DeferredTaxAssetsPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsPrepaidExpenses" xlink:href="bhc-20220510.xsd#bhc_DeferredTaxAssetsPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeferredTaxAssetsPrepaidExpenses" xlink:to="lab_bhc_DeferredTaxAssetsPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_43d437d9-ffed-4bfa-a3f3-04a5194e2e73_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable at the end of the period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CardinalHealthIncMember_778a2675-f84f-47a0-aa5c-4d839f30b1ef_terseLabel_en-US" xlink:label="lab_bhc_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health,&#160;Inc.</link:label>
    <link:label id="lab_bhc_CardinalHealthIncMember_label_en-US" xlink:label="lab_bhc_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health Inc [Member]</link:label>
    <link:label id="lab_bhc_CardinalHealthIncMember_documentation_en-US" xlink:label="lab_bhc_CardinalHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the major customer of the entity, Cardinal Health, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CardinalHealthIncMember" xlink:href="bhc-20220510.xsd#bhc_CardinalHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CardinalHealthIncMember" xlink:to="lab_bhc_CardinalHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_3b4fe636-6719-4958-8cbc-4e0028e634ad_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DiscontinuedProductLinesMember_63fba88e-21b8-41ef-b2d7-1a98619bbbdb_terseLabel_en-US" xlink:label="lab_bhc_DiscontinuedProductLinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Product Lines</link:label>
    <link:label id="lab_bhc_DiscontinuedProductLinesMember_label_en-US" xlink:label="lab_bhc_DiscontinuedProductLinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Product Lines [Member]</link:label>
    <link:label id="lab_bhc_DiscontinuedProductLinesMember_documentation_en-US" xlink:label="lab_bhc_DiscontinuedProductLinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Product Lines</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiscontinuedProductLinesMember" xlink:href="bhc-20220510.xsd#bhc_DiscontinuedProductLinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DiscontinuedProductLinesMember" xlink:to="lab_bhc_DiscontinuedProductLinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_931eb7db-092b-4602-adde-7be47e7ed58a_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent_e6e06ca2-9970-4b15-b044-fe8a780aec5f_terseLabel_en-US" xlink:label="lab_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent_label_en-US" xlink:label="lab_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Sundry Liabilities, Noncurrent</link:label>
    <link:label id="lab_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent_documentation_en-US" xlink:label="lab_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Sundry Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent" xlink:href="bhc-20220510.xsd#bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent" xlink:to="lab_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns_9dee3b57-3baf-43d7-a3de-ed81c4932020_terseLabel_en-US" xlink:label="lab_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of subsidiaries file federal income tax returns in Canada, U.S., and other foreign jurisdictions (or more)</link:label>
    <link:label id="lab_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns_label_en-US" xlink:label="lab_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Number Of Subsidiaries File Federal Income Tax Returns</link:label>
    <link:label id="lab_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns_documentation_en-US" xlink:label="lab_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Number Of Subsidiaries File Federal Income Tax Returns</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns" xlink:href="bhc-20220510.xsd#bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns" xlink:to="lab_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_235737f2-3b05-4f90-a026-b6b289ce7211_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_743e0822-bbf0-46bd-902c-be6ad7ad6203_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_2e672eec-6475-4706-a4ea-34083772122a_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance by Deferred Tax Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:to="lab_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_783fcd92-65e9-466f-b7c5-ab5ce400d716_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_3508ad74-821a-4f57-acdd-3e79acaa4c13_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_cb86ce55-831c-47b6-977b-e0377af7d47f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OrthoDermatologicsSegmentMember_a56d2108-4f25-4963-8ea8-a0863248cdac_terseLabel_en-US" xlink:label="lab_bhc_OrthoDermatologicsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics</link:label>
    <link:label id="lab_bhc_OrthoDermatologicsSegmentMember_label_en-US" xlink:label="lab_bhc_OrthoDermatologicsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Segment [Member]</link:label>
    <link:label id="lab_bhc_OrthoDermatologicsSegmentMember_documentation_en-US" xlink:label="lab_bhc_OrthoDermatologicsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ortho Dermatologics Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember" xlink:href="bhc-20220510.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OrthoDermatologicsSegmentMember" xlink:to="lab_bhc_OrthoDermatologicsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_f5a84e71-d256-47c0-8e15-803a178353f2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of non-vested performance-based RSU activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Performance-based Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_eb0ed98a-94f4-40d1-9d94-c26a34483d0d_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_1c506924-2b62-42cc-a3b4-781398750d72_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_f13fe3ec-cb0b-4ab9-b535-f3f95df81c1a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_49fc1005-8196-461a-b924-fc23a28a23fa_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted-average common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_301ea4c6-0c5b-4ec9-9ee1-6b056eeb1e23_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_61feadc6-6f1f-42b5-b8a9-233c8d327c82_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationMember_4855632d-42fa-4e52-a0ae-6944ac303ee9_terseLabel_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationMember_label_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Litigation [Member]</link:label>
    <link:label id="lab_bhc_GlumetzaAntitrustLitigationMember_documentation_en-US" xlink:label="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glumetza Antitrust Class Actions Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationMember" xlink:href="bhc-20220510.xsd#bhc_GlumetzaAntitrustLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GlumetzaAntitrustLitigationMember" xlink:to="lab_bhc_GlumetzaAntitrustLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_7413bd2c-36a5-47dc-812d-d6c5d014740e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_4319979f-5062-4b1b-b8a8-54f38d27b819_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_616c146a-b598-49b6-88f7-7f7268939dae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of stock option activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d4a04dfa-972f-46c1-86a7-53ff15a6ec4a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_d2e87f9a-c9ec-4f77-aba1-f24fd1a9122d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of net periodic benefit cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeparationAndInitialPublicOfferingCostsMember_968587be-0317-4a67-b6db-443e208adf57_terseLabel_en-US" xlink:label="lab_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation and IPO Costs</link:label>
    <link:label id="lab_bhc_SeparationAndInitialPublicOfferingCostsMember_label_en-US" xlink:label="lab_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation And Initial Public Offering Costs [Member]</link:label>
    <link:label id="lab_bhc_SeparationAndInitialPublicOfferingCostsMember_documentation_en-US" xlink:label="lab_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separation And Initial Public Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:href="bhc-20220510.xsd#bhc_SeparationAndInitialPublicOfferingCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:to="lab_bhc_SeparationAndInitialPublicOfferingCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_e6228d07-d6c2-4848-82f7-5197948a0757_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DivestituresOfNoncoreProductsPolicyTextBlock_672aeac6-cc60-4afd-85f9-c5da4ad3ff42_terseLabel_en-US" xlink:label="lab_bhc_DivestituresOfNoncoreProductsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures of Products</link:label>
    <link:label id="lab_bhc_DivestituresOfNoncoreProductsPolicyTextBlock_label_en-US" xlink:label="lab_bhc_DivestituresOfNoncoreProductsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures Of Non-core Products [Policy Text Block]</link:label>
    <link:label id="lab_bhc_DivestituresOfNoncoreProductsPolicyTextBlock_documentation_en-US" xlink:label="lab_bhc_DivestituresOfNoncoreProductsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures of Non-core Products [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DivestituresOfNoncoreProductsPolicyTextBlock" xlink:href="bhc-20220510.xsd#bhc_DivestituresOfNoncoreProductsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DivestituresOfNoncoreProductsPolicyTextBlock" xlink:to="lab_bhc_DivestituresOfNoncoreProductsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_f344a512-68d8-45dc-a970-a7a96709e909_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_f39167bb-0950-4587-a2e2-46cb5617730f_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_13251120-4110-47f3-9c61-e4ad5310e3bb_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_17c3a700-e117-4201-98b6-3a4dd15ecb0b_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4ed38804-1a6a-4fc1-be90-d8c8e5f3eae6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_3d37c45f-a0a8-4f7f-95fb-2c9d0fa26f2d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_d48b8937-b387-4916-ad42-abd0aa773562_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9ad87d26-6e81-4213-b24d-1e387ba6a04c_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts_f0f183be-81f9-4177-be96-294b95bf516a_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Credit Losses</link:label>
    <link:label id="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts_label_en-US" xlink:label="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Allowance for Credit Losses, Policy for Uncollectible Amounts [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts" xlink:to="lab_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CanadaRevenueAgencyMember_8180d263-5d16-4f4a-9cf4-ab6b523b6355_terseLabel_en-US" xlink:label="lab_us-gaap_CanadaRevenueAgencyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada Revenue Agency</link:label>
    <link:label id="lab_us-gaap_CanadaRevenueAgencyMember_label_en-US" xlink:label="lab_us-gaap_CanadaRevenueAgencyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada Revenue Agency [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CanadaRevenueAgencyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CanadaRevenueAgencyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CanadaRevenueAgencyMember" xlink:to="lab_us-gaap_CanadaRevenueAgencyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ff2f16d0-8dc4-4a31-a408-41927a51f66c_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock option life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_04eab509-ea2d-4695-905b-f54f57ea15fc_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_908d0e96-9b97-4df7-b69b-b0272e7d0814_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_75d62cc2-e4ee-4770-980d-7f567c1d226d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of employee withholding taxes related to share-based awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member_a08b74ea-e1e5-4a7f-be20-38909eeaa466_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.500% Senior Notes Due November 2025</link:label>
    <link:label id="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member_label_en-US" xlink:label="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.50% Notes Due November 2025 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 5.50% Notes Due November 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:href="bhc-20220510.xsd#bhc_SeniorSecured5.50NotesDueNovember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:to="lab_bhc_SeniorSecured5.50NotesDueNovember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_8697a2ea-67c0-457b-829d-d19928a796e5_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_8a42047d-f6e6-4d09-8423-b94ffde56c51_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_029b785e-7bc9-40f3-9cfa-f81f606401f5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at the end of the period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_cb8d9a7e-29ad-4e0f-b63a-ae2a054f70a8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of underfunded plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f693b451-7a28-4162-a0ce-61512fe7a340_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember_d1356052-52dd-4f18-9517-fda03f7b2c4a_terseLabel_en-US" xlink:label="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSN Laboratories Private Ltd. Litigation</link:label>
    <link:label id="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember_label_en-US" xlink:label="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSN Laboratories Private Ltd. Litigation [Member]</link:label>
    <link:label id="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember_documentation_en-US" xlink:label="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MSN Laboratories Private Ltd. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:href="bhc-20220510.xsd#bhc_MSNLaboratoriesPrivateLtdLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:to="lab_bhc_MSNLaboratoriesPrivateLtdLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_d8eb5417-1ecc-4d04-9310-cd199ecbf995_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA-QC_49e2b30f-a61d-499e-802f-20a1b75a7b39_terseLabel_en-US" xlink:label="lab_stpr_CA-QC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quebec</link:label>
    <link:label id="lab_stpr_CA-QC_label_en-US" xlink:label="lab_stpr_CA-QC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">QUEBEC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-QC" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA-QC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA-QC" xlink:to="lab_stpr_CA-QC" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_60d427d8-c042-4319-930f-157ae28ae5f4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2bd91e77-1055-484a-8313-8b4a6360c52c_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption of New Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_79f06562-da89-40b5-bc27-5d3f3053d8cf_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_b058be55-902d-47d9-aef3-a5db2077e661_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_7f979142-a951-4e86-a099-8da39a6e1110_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Method and assumptions on valuation of stock options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_MitsubishiTanabePharmaCorporationMember_68528444-dbd6-4ce1-b389-9402c2c6b125_terseLabel_en-US" xlink:label="lab_bhc_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation</link:label>
    <link:label id="lab_bhc_MitsubishiTanabePharmaCorporationMember_label_en-US" xlink:label="lab_bhc_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation [Member]</link:label>
    <link:label id="lab_bhc_MitsubishiTanabePharmaCorporationMember_documentation_en-US" xlink:label="lab_bhc_MitsubishiTanabePharmaCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mitsubishi Tanabe Pharma Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MitsubishiTanabePharmaCorporationMember" xlink:href="bhc-20220510.xsd#bhc_MitsubishiTanabePharmaCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_MitsubishiTanabePharmaCorporationMember" xlink:to="lab_bhc_MitsubishiTanabePharmaCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3822f97e-cc79-4dbc-944b-38589e320347_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining unrecognized compensation expense related to non-vested awards</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_9ca0ac4b-a2ad-4cb1-a195-9131ad67e5db_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_c8df824a-4d91-4819-99e3-4840353a6d0b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of amounts recognized in accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_811a1723-3279-4332-b4d1-965397dab074_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent suits filed</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_3282d8af-4b08-4283-9e66-cb449fc8932e_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PastDuePeriodForAccountsReceivableToBeNegligible_9512cfd6-ec92-4151-9a8f-480d73f8ef7e_terseLabel_en-US" xlink:label="lab_bhc_PastDuePeriodForAccountsReceivableToBeNegligible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Past due period for receivables to be negligible (less than)</link:label>
    <link:label id="lab_bhc_PastDuePeriodForAccountsReceivableToBeNegligible_label_en-US" xlink:label="lab_bhc_PastDuePeriodForAccountsReceivableToBeNegligible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Past Due Period for Accounts Receivable to be Negligible</link:label>
    <link:label id="lab_bhc_PastDuePeriodForAccountsReceivableToBeNegligible_documentation_en-US" xlink:label="lab_bhc_PastDuePeriodForAccountsReceivableToBeNegligible" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the past due period for which accounts receivables are negligible.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PastDuePeriodForAccountsReceivableToBeNegligible" xlink:href="bhc-20220510.xsd#bhc_PastDuePeriodForAccountsReceivableToBeNegligible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PastDuePeriodForAccountsReceivableToBeNegligible" xlink:to="lab_bhc_PastDuePeriodForAccountsReceivableToBeNegligible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_32838862-35ac-430f-9eec-5bb1adab9119_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_d104f4ec-f179-4c2a-89eb-85dba6e01950_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_5a76b0cd-5b2d-4630-83d7-3ed4fe0d945b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss related to settlements</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_bfe13a3f-c64e-4a2d-bac6-0ea375ba39ce_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_2e300b22-7c02-4255-9a17-ee1befc7808e_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_Goodwill_e50ab179-99cb-4ca5-bda7-2ab57e868c13_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_b29baac8-5248-4c7f-9c8c-c0df04601747_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_17b3b797-a37d-4a81-a9f2-eee6bbacc7b5_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_999f8b42-66b1-47d9-adeb-3db4e17fba7a_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes_acecaff3-19bc-4c9a-8050-6fef201f72d8_verboseLabel_en-US" xlink:label="lab_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plant, equipment and technology</link:label>
    <link:label id="lab_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes_label_en-US" xlink:label="lab_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Basis Difference of Convertible Notes</link:label>
    <link:label id="lab_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes_documentation_en-US" xlink:label="lab_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the deferred tax liability recognized for the original basis difference between the principal amount of the Convertible Notes and value allocated to the liability component, which resulted in a corresponding reduction to the valuation allowance recorded against deferred tax assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes" xlink:href="bhc-20220510.xsd#bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes" xlink:to="lab_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OpenTaxYear_529174ed-8ff0-42d3-98c6-de8b7c5249d3_terseLabel_en-US" xlink:label="lab_us-gaap_OpenTaxYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Years</link:label>
    <link:label id="lab_us-gaap_OpenTaxYear_label_en-US" xlink:label="lab_us-gaap_OpenTaxYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Tax Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OpenTaxYear" xlink:to="lab_us-gaap_OpenTaxYear" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A5.875SeniorNotesdueMay2023Member_2156b0a7-6045-42a1-a9b8-f097ea614654_terseLabel_en-US" xlink:label="lab_bhc_A5.875SeniorNotesdueMay2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.875% Senior Unsecured Notes due May 2023</link:label>
    <link:label id="lab_bhc_A5.875SeniorNotesdueMay2023Member_label_en-US" xlink:label="lab_bhc_A5.875SeniorNotesdueMay2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.875% Senior Notes due May 2023 [Member]</link:label>
    <link:label id="lab_bhc_A5.875SeniorNotesdueMay2023Member_documentation_en-US" xlink:label="lab_bhc_A5.875SeniorNotesdueMay2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.875% Senior Notes due May 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.875SeniorNotesdueMay2023Member" xlink:href="bhc-20220510.xsd#bhc_A5.875SeniorNotesdueMay2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A5.875SeniorNotesdueMay2023Member" xlink:to="lab_bhc_A5.875SeniorNotesdueMay2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_f17fbb9c-897f-4298-945f-5214ff384598_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_21c83bea-2194-48a3-b2c3-2d0547edf296_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of changes in the carrying amount of goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b00e8fbb-5770-43d7-8388-773593e4c73e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_b40ff911-c159-410b-b593-db3035ad9c31_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Percentage of Net Cash Proceeds from Asset Sales Outside Ordinary Course of Business Payable as Mandatory Prepayments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of net cash proceeds from asset sales outside ordinary course of business payable as mandatory prepayments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:href="bhc-20220510.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:to="lab_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_e86528f5-e764-4e29-9bd2-9c89d6c4ea17_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PeriodReceivableOutstanding_d76cf55d-b5a1-4155-9da0-c4080309bb58_terseLabel_en-US" xlink:label="lab_bhc_PeriodReceivableOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period net trade receivable balance outstanding (more than)</link:label>
    <link:label id="lab_bhc_PeriodReceivableOutstanding_label_en-US" xlink:label="lab_bhc_PeriodReceivableOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Receivable Outstanding</link:label>
    <link:label id="lab_bhc_PeriodReceivableOutstanding_documentation_en-US" xlink:label="lab_bhc_PeriodReceivableOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The period of time the accounts receivable has been outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PeriodReceivableOutstanding" xlink:href="bhc-20220510.xsd#bhc_PeriodReceivableOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PeriodReceivableOutstanding" xlink:to="lab_bhc_PeriodReceivableOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_30a79051-70a4-46cd-b690-b3ce354358e2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assets and liabilities associated with derivatives, included in the Consolidated Balance Sheets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_db7ebf06-b446-48ee-903c-0084b07cccdc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PadagisLitigationMember_a4726b2c-e984-4c22-8d17-307c22ab6721_terseLabel_en-US" xlink:label="lab_bhc_PadagisLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Padagis Litigation</link:label>
    <link:label id="lab_bhc_PadagisLitigationMember_label_en-US" xlink:label="lab_bhc_PadagisLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Padagis Litigation [Member]</link:label>
    <link:label id="lab_bhc_PadagisLitigationMember_documentation_en-US" xlink:label="lab_bhc_PadagisLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Padagis Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PadagisLitigationMember" xlink:href="bhc-20220510.xsd#bhc_PadagisLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PadagisLitigationMember" xlink:to="lab_bhc_PadagisLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_88ab4dea-2f97-495f-b1a1-58f4d22691d7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_8585030b-3eeb-42bc-b020-e12d0f50c30a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension adjustment, net of tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RevenuesNetMember_e59dc6d6-b04d-4b9a-865b-e3c31040493a_terseLabel_en-US" xlink:label="lab_bhc_RevenuesNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_bhc_RevenuesNetMember_label_en-US" xlink:label="lab_bhc_RevenuesNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues Net [Member]</link:label>
    <link:label id="lab_bhc_RevenuesNetMember_documentation_en-US" xlink:label="lab_bhc_RevenuesNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate net revenues during the period in the normal course of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember" xlink:href="bhc-20220510.xsd#bhc_RevenuesNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RevenuesNetMember" xlink:to="lab_bhc_RevenuesNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member_dbd0570c-13e4-4fa4-a5a2-5b7a5e534944_terseLabel_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025 and November 2025</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member_label_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025 And November 2025 [Member]</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member_documentation_en-US" xlink:label="lab_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility Due June 2025 And November 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member" xlink:href="bhc-20220510.xsd#bhc_TermLoanBFacilityDueJune2025AndNovember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member" xlink:to="lab_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_ccba8459-69e6-411d-af9c-a2e9135a2832_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6f40488d-2bd7-4f5d-b945-00ab295d7136_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AustralianTaxationOfficeMember_c5efb096-a514-4732-a4d4-40838452194d_verboseLabel_en-US" xlink:label="lab_us-gaap_AustralianTaxationOfficeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australian Taxation Office</link:label>
    <link:label id="lab_us-gaap_AustralianTaxationOfficeMember_4b30a53e-ed4d-4639-9509-b1b93bf9d675_terseLabel_en-US" xlink:label="lab_us-gaap_AustralianTaxationOfficeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australia</link:label>
    <link:label id="lab_us-gaap_AustralianTaxationOfficeMember_label_en-US" xlink:label="lab_us-gaap_AustralianTaxationOfficeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australian Taxation Office [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AustralianTaxationOfficeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AustralianTaxationOfficeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AustralianTaxationOfficeMember" xlink:to="lab_us-gaap_AustralianTaxationOfficeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_bb3a31f0-e361-48ab-8820-0b4dc05fa84b_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits_de03dc37-4314-453b-a9b2-5a01c12f8cc0_terseLabel_en-US" xlink:label="lab_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unclaimed investment tax credits and research and development credits</link:label>
    <link:label id="lab_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits_label_en-US" xlink:label="lab_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unclaimed Tax Credits and Research and Development Credits</link:label>
    <link:label id="lab_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits_documentation_en-US" xlink:label="lab_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of unclaimed tax credits and research and development credits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" xlink:href="bhc-20220510.xsd#bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" xlink:to="lab_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes_8c4e40f9-6329-425f-af94-eecf802693ff_terseLabel_en-US" xlink:label="lab_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged to Benefit from income taxes</link:label>
    <link:label id="lab_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes_label_en-US" xlink:label="lab_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances And Reserves, Additions, Charge To Benefit From Income Taxes</link:label>
    <link:label id="lab_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes_documentation_en-US" xlink:label="lab_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances And Reserves, Additions, Charge To Benefit From Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" xlink:href="bhc-20220510.xsd#bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" xlink:to="lab_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_43b33753-1ed9-4f26-9261-e261735c58f6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_565e41ac-9be8-4e5c-b83b-d7afe6a062e9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Canadian statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_c261b676-2270-435c-8d44-ec13313e2119_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_8101b990-7173-4db5-9ba5-33fcddffada2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Per Share Attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_227f19f2-4a06-44c9-9614-24ab4f096788_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_019f665b-bb96-4261-9987-e4eee7422a28_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_51275381-1ad4-445d-bbc3-f5e28a4f7631_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_75397eaa-3c5b-426c-a8fd-d84b660506fc_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_e0f77923-a6cb-48e1-8bf8-ac77d8936f08_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy_5de561ae-66ca-4bd2-8d83-a6e3450895f4_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Plans, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:to="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_def20030-e066-4473-8adc-ab009d18b684_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_a7b6400b-cb7f-414d-8191-059478d667f8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0ec0e489-2e95-4637-9a0d-ce0baa0d421f_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization and Impairments</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_914b75fe-4ff1-4eee-8005-036f3085d78c_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes5.625PercentDueDecember2021Member_dd32dc35-fe34-4bb4-9bf3-0c28d1720abd_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes5.625PercentDueDecember2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.625 % Senior Unsecured Notes due December 2021</link:label>
    <link:label id="lab_bhc_SeniorNotes5.625PercentDueDecember2021Member_label_en-US" xlink:label="lab_bhc_SeniorNotes5.625PercentDueDecember2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes 5.625 Percent Due December 2021 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes5.625PercentDueDecember2021Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes5.625PercentDueDecember2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes 5.625 Percent Due December 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes5.625PercentDueDecember2021Member" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes5.625PercentDueDecember2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes5.625PercentDueDecember2021Member" xlink:to="lab_bhc_SeniorNotes5.625PercentDueDecember2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_537c1165-38f6-4a88-b31d-9b3efa062f8e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of aggregate maturities of long-term debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_8f248cf1-6a85-4f67-b3c3-ab34055b99ff_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NonU.S.OtherAssetsMember_779c279c-ff23-48a7-bc68-4caabea29d52_terseLabel_en-US" xlink:label="lab_bhc_NonU.S.OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_bhc_NonU.S.OtherAssetsMember_label_en-US" xlink:label="lab_bhc_NonU.S.OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. Other Assets [Member]</link:label>
    <link:label id="lab_bhc_NonU.S.OtherAssetsMember_documentation_en-US" xlink:label="lab_bhc_NonU.S.OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. Other Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonU.S.OtherAssetsMember" xlink:href="bhc-20220510.xsd#bhc_NonU.S.OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NonU.S.OtherAssetsMember" xlink:to="lab_bhc_NonU.S.OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CanadianSecuritiesLitigationMember_0f3c043e-b056-49ad-83f4-ec0bcf3abe1d_terseLabel_en-US" xlink:label="lab_bhc_CanadianSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian Securities Litigation</link:label>
    <link:label id="lab_bhc_CanadianSecuritiesLitigationMember_label_en-US" xlink:label="lab_bhc_CanadianSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian Securities Litigation [Member]</link:label>
    <link:label id="lab_bhc_CanadianSecuritiesLitigationMember_documentation_en-US" xlink:label="lab_bhc_CanadianSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian Securities Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadianSecuritiesLitigationMember" xlink:href="bhc-20220510.xsd#bhc_CanadianSecuritiesLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CanadianSecuritiesLitigationMember" xlink:to="lab_bhc_CanadianSecuritiesLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_43271ef7-1daa-477b-8899-f8246b8b8910_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_9e3fa6e7-5b77-45ca-b605-0a485a3866ab_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation, Arrangement by Share Based Payment Award, Options Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:href="bhc-20220510.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_9c2fe16f-d123-49a2-81d5-6a0f05ec69af_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_9d8dae25-4d6d-4aa8-8fce-8ade6ed36b42_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_10cda0d5-561c-4c68-bacb-71f93288ca76_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_523282e0-a25d-4f56-a829-a0f5c2837613_terseLabel_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_label_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Noncurrent Liability</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_documentation_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Noncurrent Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:href="bhc-20220510.xsd#bhc_BusinessCombinationContingentConsiderationNoncurrentLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:to="lab_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage_f41f4258-b4b5-46b7-bc42-e36ad8136e01_negatedTerseLabel_en-US" xlink:label="lab_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, year-over-year decrease, percentage</link:label>
    <link:label id="lab_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage_label_en-US" xlink:label="lab_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Year-Over-Year Revenue From Contract With Customer, Excluding Assessed Tax, Percentage</link:label>
    <link:label id="lab_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage_documentation_en-US" xlink:label="lab_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Year-Over-Year Revenue From Contract With Customer, Excluding Assessed Tax, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage" xlink:href="bhc-20220510.xsd#bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage" xlink:to="lab_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeferredTaxAssetsTaxLossCarryforwards_b4ad6a9c-7c9d-4e04-95c0-c1163f99ed79_terseLabel_en-US" xlink:label="lab_bhc_DeferredTaxAssetsTaxLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax loss carryforwards</link:label>
    <link:label id="lab_bhc_DeferredTaxAssetsTaxLossCarryforwards_label_en-US" xlink:label="lab_bhc_DeferredTaxAssetsTaxLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Loss Carryforwards</link:label>
    <link:label id="lab_bhc_DeferredTaxAssetsTaxLossCarryforwards_documentation_en-US" xlink:label="lab_bhc_DeferredTaxAssetsTaxLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the deferred tax assets on tax loss carryforwards available to the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsTaxLossCarryforwards" xlink:href="bhc-20220510.xsd#bhc_DeferredTaxAssetsTaxLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeferredTaxAssetsTaxLossCarryforwards" xlink:to="lab_bhc_DeferredTaxAssetsTaxLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_d1af3b79-bea4-4d07-8d21-00de6ad512f1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_6c3b44fd-fe93-416b-84f9-2cca246edbd3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_e1fe4e16-0178-4cdf-ab3a-60d445457e8b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_bbcc3ef7-5956-484b-98c0-c1f666af3fd8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds, settlement of cross-currency swaps</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Hedge, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_75f524d0-a5f7-4b68-9735-4fce63debadd_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions_87897f42-eb2d-4055-9fca-659512853a30_terseLabel_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, net increase for tax positions of current year</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Net Increase Resulting From Current Period Tax Positions</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions_documentation_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Net Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions" xlink:href="bhc-20220510.xsd#bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions" xlink:to="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_4daf6815-e5fd-4778-a666-fdbad9c81999_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_81f3e189-d2b5-4733-8a0e-28fab121d0d7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price percentage (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_258f0a89-2a07-46a5-9e40-a3a63afb4531_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of other expense, net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ConcentrationRiskPercentageofNetTradeReceivables_bf9b55fe-229c-4eff-8f96-1e371b4e3055_terseLabel_en-US" xlink:label="lab_bhc_ConcentrationRiskPercentageofNetTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net trade receivables accounted for by largest wholesale customers</link:label>
    <link:label id="lab_bhc_ConcentrationRiskPercentageofNetTradeReceivables_label_en-US" xlink:label="lab_bhc_ConcentrationRiskPercentageofNetTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage of Net Trade Receivables</link:label>
    <link:label id="lab_bhc_ConcentrationRiskPercentageofNetTradeReceivables_documentation_en-US" xlink:label="lab_bhc_ConcentrationRiskPercentageofNetTradeReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage of Net Trade Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskPercentageofNetTradeReceivables" xlink:href="bhc-20220510.xsd#bhc_ConcentrationRiskPercentageofNetTradeReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ConcentrationRiskPercentageofNetTradeReceivables" xlink:to="lab_bhc_ConcentrationRiskPercentageofNetTradeReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8fa94dc6-ae69-464c-8aed-7544ee6b834a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax_984ab577-bdbe-4119-a024-0e65ababfd24_terseLabel_en-US" xlink:label="lab_bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1% change in estimated return rates, Impact on pre-tax earnings</link:label>
    <link:label id="lab_bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax_label_en-US" xlink:label="lab_bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis, Impact Of 1 Percent Change In Estimated Return Rate, Income (Loss) Before Tax</link:label>
    <link:label id="lab_bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax_documentation_en-US" xlink:label="lab_bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis, Impact Of 1 Percent Change In Estimated Return Rate, Income (Loss) Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax" xlink:href="bhc-20220510.xsd#bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax" xlink:to="lab_bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_003acb13-48bd-4bdb-a5b7-a1bb7ab08fe3_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired or forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EyenoviaIncMember_fce9b123-1db9-4c47-a0e8-f40a822e336e_terseLabel_en-US" xlink:label="lab_bhc_EyenoviaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eyenovia, Inc.</link:label>
    <link:label id="lab_bhc_EyenoviaIncMember_label_en-US" xlink:label="lab_bhc_EyenoviaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eyenovia, Inc. [Member]</link:label>
    <link:label id="lab_bhc_EyenoviaIncMember_documentation_en-US" xlink:label="lab_bhc_EyenoviaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eyenovia, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EyenoviaIncMember" xlink:href="bhc-20220510.xsd#bhc_EyenoviaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EyenoviaIncMember" xlink:to="lab_bhc_EyenoviaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_7e995b36-9029-4652-b16e-896a45dba691_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_78f31c72-66d6-43bb-aefe-a1cb85d9cffa_terseLabel_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit concentration</link:label>
    <link:label id="lab_us-gaap_CreditConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CreditConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditConcentrationRiskMember" xlink:to="lab_us-gaap_CreditConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_35170370-8ddf-45b8-8f98-8716b4b0dc70_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_cfeb0abb-9fb4-4f19-8536-98a83d1f64d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AmerisourceBergenCorporationMember_923ba63a-2543-4af4-92eb-82a5d1349b56_terseLabel_en-US" xlink:label="lab_bhc_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Corporation</link:label>
    <link:label id="lab_bhc_AmerisourceBergenCorporationMember_label_en-US" xlink:label="lab_bhc_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amerisource Bergen Corporation [Member]</link:label>
    <link:label id="lab_bhc_AmerisourceBergenCorporationMember_documentation_en-US" xlink:label="lab_bhc_AmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the major customer of the entity, AmerisourceBergen Corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmerisourceBergenCorporationMember" xlink:href="bhc-20220510.xsd#bhc_AmerisourceBergenCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AmerisourceBergenCorporationMember" xlink:to="lab_bhc_AmerisourceBergenCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue_bf6e2472-cbee-4526-99c1-eb4a654863fc_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of stock options vested</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award, Options Vested in Period, Total Fair Value</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the total fair value of stock options vested during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" xlink:href="bhc-20220510.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_e1599935-49d0-461c-ab9a-bab3ed301e47_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable operating lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers_db36c849-b527-4da6-8067-2dab9b45fba6_terseLabel_en-US" xlink:label="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement agreements, number of insurers</link:label>
    <link:label id="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers_label_en-US" xlink:label="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Settlement Agreements, Number Of Insurers</link:label>
    <link:label id="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers_documentation_en-US" xlink:label="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Settlement Agreements, Number Of Insurers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:href="bhc-20220510.xsd#bhc_LossContingencySettlementAgreementsNumberOfInsurers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:to="lab_bhc_LossContingencySettlementAgreementsNumberOfInsurers" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual_5bb2741d-25f6-4dfd-8b35-55f79bb00c77_terseLabel_en-US" xlink:label="lab_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating results of acquiree since acquisition</link:label>
    <link:label id="lab_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual_label_en-US" xlink:label="lab_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Operating Income (Loss) Since Acquisition, Actual</link:label>
    <link:label id="lab_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual_documentation_en-US" xlink:label="lab_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Operating Income (Loss) Since Acquisition, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual" xlink:href="bhc-20220510.xsd#bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual" xlink:to="lab_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_aad71935-8fc2-4308-a9be-31d4787f216e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net actuarial gain (loss) arising during the year</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ebdfe9b6-92d5-48c0-be9c-abd3a287f5ce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_e33482bd-2e2f-49bd-9526-d59ec38a99e0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_0b6086d5-b0d8-4bf9-ac1b-d42330aeb178_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_36470358-e868-4fb4-9567-c16c8aa7009a_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3afe62e8-4f1d-415c-a372-177fe3fa10e2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_13056d50-e5e7-4597-b0a0-050b4166956b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) related to changes in fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_a927bfd6-38e1-46eb-a741-9b9ba1e87401_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_c88b3832-c1db-4644-b6bd-185050b95d1a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_708db778-c0af-47b5-b1a0-446e775e6e09_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.000 % Senior Notes Due March 2024</link:label>
    <link:label id="lab_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_label_en-US" xlink:label="lab_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes 7.00 Percent Due March 2024 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes 7.00 Percent Due March 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member" xlink:href="bhc-20220510.xsd#bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member" xlink:to="lab_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_58c7b1eb-ea6c-4c5d-8097-7c9ae4a2b550_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_b4a382fe-5ae3-4190-a225-849f5b289185_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated goodwill impairment charges to date</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_5f983183-3c0d-49e9-8382-4520f6256e4e_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_db5e3786-e692-4f49-a206-57198817a7e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_a60adaa6-6042-4f6f-8b04-2fa7b54daa30_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underfunded plans having accumulated benefit obligations exceeding the fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_458d5eb4-f735-4275-93b3-807232d038ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_34abd9ea-dc0f-41ad-bf56-48f4c72d327f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_b9954c99-557c-4a3e-9d28-66f2d643a8b5_totalLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_a0fd6eb4-bc5a-45db-90b6-e09d7776b59d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_9f3fb707-0c94-443e-bfa3-df6825004153_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INTANGIBLE ASSETS AND GOODWILL</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7f49764d-af01-4bf0-b278-8f0499a30acd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8c5843bb-83a4-47c4-ad1f-c2824b45a7d3_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_dc48211c-4aba-473d-b4c3-91a090677335_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_82a4a5ab-297c-4380-8d27-cd501ae1f1ef_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_3685d4a5-cd50-4356-a52d-69ab8b75ec19_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_637614d8-8748-423d-b3e7-fe617d8b15ab_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate brands</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_179fe3f8-0f12-4570-979b-6f0e24f4fa01_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a05892ab-8695-4af4-9e9f-1f8fe41f38b1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_81238249-2396-4697-812e-f1fc11f9a9a0_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2c004d56-3842-4c9e-8be0-aed12be1e425_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_37c9d54e-9c13-4eba-b2d9-be17bf11438a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest crediting rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_0eee3a24-2a82-4a52-8383-7ebd2975fac0_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of estimated useful lives of property, plant and equipment</link:label>
    <link:label id="lab_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_label_en-US" xlink:label="lab_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Useful Lives of Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label id="lab_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_documentation_en-US" xlink:label="lab_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of estimated useful lives of major classes of property, plant and equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:href="bhc-20220510.xsd#bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:to="lab_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_394ed314-6290-47c7-b4db-ee471b38ad38_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service credit</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_90dfd937-9589-4294-ae2a-670e41efceed_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of carrying amounts of assets and liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Long Lived Assets Held-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:to="lab_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_4e5c28d0-d6ed-4e46-92bd-ab7eaf3b29a2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, contingent consideration obligations, discount rate</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_f9177da7-5b19-477e-92c8-558f1e64d9de_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of long-lived assets by geographic region</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived Assets by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_0bc10c92-7169-4ad7-b690-31556dc19c7b_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_2589c287-dcf0-4dc3-a2ac-0f29322237db_verboseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_7944ccec-4e20-48de-b4d4-543bae750ed4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_0ba271c4-914e-4c84-bbaf-acbd2db211e2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of tax effect of major items recorded as deferred tax assets and liabilities and valuation allowance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A5.375SeniorNotesdueMarch2020Member_f2f5b6f0-1a09-4718-84ee-a10168b528cc_terseLabel_en-US" xlink:label="lab_bhc_A5.375SeniorNotesdueMarch2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.375% Senior Notes due March 2020</link:label>
    <link:label id="lab_bhc_A5.375SeniorNotesdueMarch2020Member_label_en-US" xlink:label="lab_bhc_A5.375SeniorNotesdueMarch2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.375% Senior Notes due March 2020 [Member]</link:label>
    <link:label id="lab_bhc_A5.375SeniorNotesdueMarch2020Member_documentation_en-US" xlink:label="lab_bhc_A5.375SeniorNotesdueMarch2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.375% Senior Notes due March 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.375SeniorNotesdueMarch2020Member" xlink:href="bhc-20220510.xsd#bhc_A5.375SeniorNotesdueMarch2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A5.375SeniorNotesdueMarch2020Member" xlink:to="lab_bhc_A5.375SeniorNotesdueMarch2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_17631e8a-3086-42fd-9558-93467e6bb91a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of vesting rights</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_9c08c8a8-2130-4e2e-8c27-2e661f6ec4fa_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment included in other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6363cc83-da9a-4294-9ef5-311174bf8b2a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_d9e9bd37-c471-4d2d-b62e-88a3149d63af_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan, percentage of actual plan asset allocations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Target Allocation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a535c96f-0b83-4e26-bda7-971a48768f21_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_7be2ec61-4f40-4ecf-af9c-5ce57772576c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RESEARCH AND DEVELOPMENT</link:label>
    <link:label id="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research, Development, and Computer Software Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:to="lab_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_d7e33325-f0e0-4415-936a-8ba1590c687d_terseLabel_en-US" xlink:label="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of the change in projected benefit obligations, change in plan assets and funded status</link:label>
    <link:label id="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:to="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CrossCurrencyFinalSettlementMember_1943adfb-960e-4299-983f-cd0a60f7357f_terseLabel_en-US" xlink:label="lab_bhc_CrossCurrencyFinalSettlementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross-currency swaps, final settlement</link:label>
    <link:label id="lab_bhc_CrossCurrencyFinalSettlementMember_label_en-US" xlink:label="lab_bhc_CrossCurrencyFinalSettlementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency, Final Settlement [Member]</link:label>
    <link:label id="lab_bhc_CrossCurrencyFinalSettlementMember_documentation_en-US" xlink:label="lab_bhc_CrossCurrencyFinalSettlementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency, Final Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CrossCurrencyFinalSettlementMember" xlink:href="bhc-20220510.xsd#bhc_CrossCurrencyFinalSettlementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CrossCurrencyFinalSettlementMember" xlink:to="lab_bhc_CrossCurrencyFinalSettlementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member_76a0bc10-593c-463d-a47b-0b65ca76a0fe_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 6.125% Notes Due February 2027</link:label>
    <link:label id="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member_label_en-US" xlink:label="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 6.125% Notes Due February 2027 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 6.125% Notes Due February 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:href="bhc-20220510.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:to="lab_bhc_SeniorSecured6125NotesDueFebruary2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_f0ceb584-3911-4cae-b1e8-399d585a1220_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining availability</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_faa1aead-3e7b-4b3f-be5f-13be1524c57b_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForChargebacksMember_92e25428-9475-4c36-bd2e-ac426a244480_terseLabel_en-US" xlink:label="lab_bhc_ReserveForChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks</link:label>
    <link:label id="lab_bhc_ReserveForChargebacksMember_label_en-US" xlink:label="lab_bhc_ReserveForChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Chargebacks [Member]</link:label>
    <link:label id="lab_bhc_ReserveForChargebacksMember_documentation_en-US" xlink:label="lab_bhc_ReserveForChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Chargebacks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForChargebacksMember" xlink:href="bhc-20220510.xsd#bhc_ReserveForChargebacksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForChargebacksMember" xlink:to="lab_bhc_ReserveForChargebacksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_820e9645-93f4-4ede-a79c-1547cc15d60f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of cases</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_94262b2d-2e3f-4173-9733-c9871f7de04d_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_374f4ece-dcb0-47c9-bcb9-5633729b9960_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net pension and postretirement benefit plan adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_eed930dd-9004-40b1-97c2-bd770ec2932a_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government bond funds</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_b1b8f2bf-d79d-4cbc-afaf-16ec3cd630ab_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit_4f06d7f7-bdae-47ea-8a70-a5a739661c64_negatedTerseLabel_en-US" xlink:label="lab_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit on intra-entity transfers</link:label>
    <link:label id="lab_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit_label_en-US" xlink:label="lab_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Deferred Intercompany Profit</link:label>
    <link:label id="lab_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit_documentation_en-US" xlink:label="lab_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the portion of the difference between total income tax expense (benefit) as reported in the income statement and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to deferred intercompany profit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit" xlink:href="bhc-20220510.xsd#bhc_IncomeTaxReconciliationDeferredIntercompanyProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit" xlink:to="lab_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_154da1c4-fe27-4ee1-abfc-bed8b5d263af_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_c3122ffa-0d71-4898-8f26-f4bbc0416f7d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment converted into minor equity interest</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:to="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_b74f4499-21ed-4882-9abb-6333e2b6dd83_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_8bf0d2e2-2b5d-4f6a-847e-fc935771d764_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_0044679a-2411-4170-a48f-23af8bcc74e1_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total identifiable net assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool_e1fa617d-70b9-447b-a053-c32014ecb428_terseLabel_en-US" xlink:label="lab_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scientific Research and Experimental Development pool</link:label>
    <link:label id="lab_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool_label_en-US" xlink:label="lab_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Scientific Research and Experimental Development Pool</link:label>
    <link:label id="lab_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool_documentation_en-US" xlink:label="lab_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the deferred tax assets on scientific research and experimental development pool, of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool" xlink:href="bhc-20220510.xsd#bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool" xlink:to="lab_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_f74fbaf3-5cd3-41aa-a3ff-d19de81fa836_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_1a456bac-fa77-4718-9e64-b435c7a5518f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions recognized</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_856f27d6-eab8-4a07-837f-e55802c0c3f3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_InternationalRxMember_52f25be9-e721-4629-849a-6a1535af9b64_terseLabel_en-US" xlink:label="lab_bhc_InternationalRxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_bhc_InternationalRxMember_label_en-US" xlink:label="lab_bhc_InternationalRxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Rx [Member]</link:label>
    <link:label id="lab_bhc_InternationalRxMember_documentation_en-US" xlink:label="lab_bhc_InternationalRxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Rx</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember" xlink:href="bhc-20220510.xsd#bhc_InternationalRxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_InternationalRxMember" xlink:to="lab_bhc_InternationalRxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_4b541b09-c599-4cbf-b8cf-c148ea5e38cf_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseProductRelated_eccb0c19-4dcc-451d-9c92-517dd8d4e595_terseLabel_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product related research and development</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseProductRelated_label_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Product Related</link:label>
    <link:label id="lab_bhc_ResearchAndDevelopmentExpenseProductRelated_documentation_en-US" xlink:label="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Expense, Product Related</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:href="bhc-20220510.xsd#bhc_ResearchAndDevelopmentExpenseProductRelated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:to="lab_bhc_ResearchAndDevelopmentExpenseProductRelated" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilitiesMember_7ca5c227-ec38-4a7e-834d-7fc7799edb44_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Credit Facilities</link:label>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilitiesMember_label_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecuredCreditFacilitiesMember_documentation_en-US" xlink:label="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Credit Facilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilitiesMember" xlink:href="bhc-20220510.xsd#bhc_SeniorSecuredCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecuredCreditFacilitiesMember" xlink:to="lab_bhc_SeniorSecuredCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_8a9495ed-0aad-452c-9149-f8d0880620a5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based awards tax withholding</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_97c538ce-f92e-4d40-be60-66185e92bcf5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total number of shares approved for grant by the Company under the share-based compensation plans (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_d00c369e-0c6d-4d8f-af5f-39203f28d118_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid from operating cash flows for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_7d0b7d7b-6a18-4282-a6d1-37e375eb567e_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recoveries</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Recovery</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_9729e3e1-f7bd-4cf5-95e7-7668002013b8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_c8a6074e-8d22-48e1-8e97-5ca42acacce9_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_85d3b17d-ea3a-4e4e-a0d2-078c937cd375_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_8e5123a3-cdb9-40b0-9883-3fa79599b3e2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_7301e5ed-8a8f-4df5-8ff2-2bab1df9ad3b_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total gross maturities</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_acf78104-1aff-4aa7-8ef3-d6b9f4e50d25_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in the carrying amount of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitAxis_04a55de4-290e-4ed4-9b4e-945b1504cf27_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis" xlink:to="lab_us-gaap_ReportingUnitAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_0514c137-b369-42c8-95dd-b41114b71e84_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange loss</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_99bcc282-e63d-4470-b565-2958abe0f410_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of groups of investors filing action, remain pending</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_label_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending</link:label>
    <link:label id="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_documentation_en-US" xlink:label="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:href="bhc-20220510.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:to="lab_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6b77980c-88a5-459e-980b-9a2af6686aae_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EmergingMarketsMember_e1b32ac2-578b-4091-80b1-85c78eae331d_verboseLabel_en-US" xlink:label="lab_bhc_EmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging markets</link:label>
    <link:label id="lab_bhc_EmergingMarketsMember_label_en-US" xlink:label="lab_bhc_EmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Emerging Markets [Member]</link:label>
    <link:label id="lab_bhc_EmergingMarketsMember_documentation_en-US" xlink:label="lab_bhc_EmergingMarketsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the Emerging Markets segment of the entity. The segment consists of branded generic pharmaceutical products, as well as OTC products and agency/in-licensing arrangements with other research-based pharmaceutical companies (where the entity distributes and markets branded, patented products under long-term, renewable contracts). Products are sold primarily in Europe (Poland, Serbia, Hungary, Croatia and Russia), Latin America (Mexico, Brazil and exports out of Mexico to other Latin American markets), South East Asia and South Africa.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmergingMarketsMember" xlink:href="bhc-20220510.xsd#bhc_EmergingMarketsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EmergingMarketsMember" xlink:to="lab_bhc_EmergingMarketsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_4d9bb3dc-f752-4d25-a247-3181734a0e7f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and (deficit) equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate_1c5fbf50-b7ae-48e4-be70-5c4804602667_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental borrowings interest rate</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility Threshold For Incremental Borrowings Interest Rate</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility Threshold For Incremental Borrowings Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate" xlink:href="bhc-20220510.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate" xlink:to="lab_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_c2fbf2d3-3141-432d-8178-61621fd2d708_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_a9232ee0-fe2f-4298-9d8e-017df9b7ec6a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0f3c7df6-0f9d-4e44-afd5-84465c17e1b2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_221f614f-f1d5-4035-9465-84c0e0704032_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_cbc14f1a-238e-4db0-884c-eea451343ff1_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4f2bf204-63ad-4fe8-9f1d-df478c54cbf0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_2bc9c24d-9b72-49a9-b21e-ca82c8e95381_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds_a323faf1-32c8-4039-a109-8fdb3df4aaf4_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings</link:label>
    <link:label id="lab_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds_label_en-US" xlink:label="lab_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maximum Redemption Percentage With Equity Offering Proceeds</link:label>
    <link:label id="lab_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maximum Redemption Percentage With Equity Offering Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" xlink:to="lab_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_cf487366-db3f-420d-9571-2844730e4302_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_68c8cf8a-eda3-4d00-b95b-910be2c8da49_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_00de46c7-c3cc-479c-a396-02f1bdeaa99f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_c310de89-1025-44de-af3a-98017f174a86_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit (expense)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NumberOfLargestWholesaleCustomers_58617b65-2aa4-4741-bd98-4bce450e6d04_terseLabel_en-US" xlink:label="lab_bhc_NumberOfLargestWholesaleCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of largest wholesale customers</link:label>
    <link:label id="lab_bhc_NumberOfLargestWholesaleCustomers_label_en-US" xlink:label="lab_bhc_NumberOfLargestWholesaleCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Largest Wholesale Customers</link:label>
    <link:label id="lab_bhc_NumberOfLargestWholesaleCustomers_documentation_en-US" xlink:label="lab_bhc_NumberOfLargestWholesaleCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of largest wholesale customers.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NumberOfLargestWholesaleCustomers" xlink:href="bhc-20220510.xsd#bhc_NumberOfLargestWholesaleCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NumberOfLargestWholesaleCustomers" xlink:to="lab_bhc_NumberOfLargestWholesaleCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_ee21df8e-95a1-4e8d-a309-c6a03267e1db_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_b87ccb9f-2499-47f1-9c2f-372a049d4124_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_f5af2642-4424-4cd1-b1a6-737814a707a5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LOSS PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_d9fd35c2-f104-4006-b22a-86943d975239_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. Plans</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_c2ade4f0-4da4-4179-b3b5-52d741956f65_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_cf15937d-97ba-4a28-82ee-668c912f2863_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_54a80684-43b5-4936-a74c-b61eac9e89d6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b17e3b0b-b082-46eb-a8fc-6fbd32d27463_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherPerformanceBasedRestrictedStockUnitsMember_485d3c2f-6679-4d57-ab1f-e1ea2f269b7b_terseLabel_en-US" xlink:label="lab_bhc_OtherPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Based Restricted Stock Units</link:label>
    <link:label id="lab_bhc_OtherPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_OtherPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_OtherPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_OtherPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherPerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20220510.xsd#bhc_OtherPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_OtherPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses_68f167bb-625a-4456-b9b9-9021a03df22e_negatedTerseLabel_en-US" xlink:label="lab_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses_label_en-US" xlink:label="lab_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Expenses</link:label>
    <link:label id="lab_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses_documentation_en-US" xlink:label="lab_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses" xlink:href="bhc-20220510.xsd#bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses" xlink:to="lab_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_26bc8638-59d6-4bb4-b930-54bf62a1fe42_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes625DueFebruary2029Member_0bb7dde3-36ad-4601-8ea2-f047dd8bb32d_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.250% Senior Notes Due February 2029</link:label>
    <link:label id="lab_bhc_SeniorNotes625DueFebruary2029Member_label_en-US" xlink:label="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.25%, Due February 2029 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes625DueFebruary2029Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 6.25%, Due February 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes625DueFebruary2029Member" xlink:to="lab_bhc_SeniorNotes625DueFebruary2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_d5200de9-8fb4-4942-8ca4-e4e09aa87f07_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c2e3f1b3-bcd4-4cff-9c3c-c0093a60cf3d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired or forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d8887ca7-e19e-4e1b-b44b-2a46934db7c5_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_04a9df27-ecc1-47ca-a562-1d97eb5d2016_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_a9d079fb-1f41-48d5-be96-080332c706f2_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts_a1720abf-676e-4352-9b72-fe85a87516b6_terseLabel_en-US" xlink:label="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, integration, separation and IPO costs</link:label>
    <link:label id="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts_3d37ecde-218c-4e41-8fd3-dc3d72d48475_negatedLabel_en-US" xlink:label="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, integration, separation and IPO costs</link:label>
    <link:label id="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts_label_en-US" xlink:label="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges And Initial Public Offering Costs</link:label>
    <link:label id="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts_documentation_en-US" xlink:label="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges And Initial Public Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:href="bhc-20220510.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:to="lab_bhc_RestructuringChargesAndInitialPublicOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DerivativeGainExcludedComponent_6c89358b-6d47-4e70-bd43-01d01361a760_negatedTerseLabel_en-US" xlink:label="lab_bhc_DerivativeGainExcludedComponent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain excluded from hedge effectiveness</link:label>
    <link:label id="lab_bhc_DerivativeGainExcludedComponent_label_en-US" xlink:label="lab_bhc_DerivativeGainExcludedComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain, Excluded Component</link:label>
    <link:label id="lab_bhc_DerivativeGainExcludedComponent_documentation_en-US" xlink:label="lab_bhc_DerivativeGainExcludedComponent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain, Excluded Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeGainExcludedComponent" xlink:href="bhc-20220510.xsd#bhc_DerivativeGainExcludedComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DerivativeGainExcludedComponent" xlink:to="lab_bhc_DerivativeGainExcludedComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccruedProductReturnCurrent_8ae49774-4859-48fe-9fa9-8c634f06a7dd_terseLabel_en-US" xlink:label="lab_bhc_AccruedProductReturnCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product returns</link:label>
    <link:label id="lab_bhc_AccruedProductReturnCurrent_label_en-US" xlink:label="lab_bhc_AccruedProductReturnCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Product Return Current</link:label>
    <link:label id="lab_bhc_AccruedProductReturnCurrent_documentation_en-US" xlink:label="lab_bhc_AccruedProductReturnCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductReturnCurrent" xlink:href="bhc-20220510.xsd#bhc_AccruedProductReturnCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccruedProductReturnCurrent" xlink:to="lab_bhc_AccruedProductReturnCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_665033cc-be7e-4224-ab2f-05c1d6446b7b_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_6590be21-2a74-4f8e-b811-68d8275dcc7e_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional suits filed, but not served</link:label>
    <link:label id="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_label_en-US" xlink:label="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency New Claims Filed But Not Yet Served Number</link:label>
    <link:label id="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_documentation_en-US" xlink:label="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency New Claims Filed But Not Yet Served Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:href="bhc-20220510.xsd#bhc_LossContingencyNewClaimsFiledButNotYetServedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:to="lab_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1331d6f3-f4a0-4d8b-b9d8-80c583135525_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_fe12daa0-da64-4a7f-9b86-d84112e96abd_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUPPLEMENTAL CASH FLOW DISCLOSURES</link:label>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7a82ab6f-9004-4d47-a94d-1fbc8c251b3d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of businesses, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_35c0a333-4f28-4050-9a59-d926ee4309e1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_55a0a04d-8467-49d4-92ed-c7f6a47773a8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FINANCING ARRANGEMENTS</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_9e3eb6e8-170a-4544-ba4e-ac83d86b63f0_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized as:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForDistributionFeesMember_8111ceba-9466-4081-b472-e844f6b73aa3_terseLabel_en-US" xlink:label="lab_bhc_ReserveForDistributionFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution Fees</link:label>
    <link:label id="lab_bhc_ReserveForDistributionFeesMember_label_en-US" xlink:label="lab_bhc_ReserveForDistributionFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Distribution Fees [Member]</link:label>
    <link:label id="lab_bhc_ReserveForDistributionFeesMember_documentation_en-US" xlink:label="lab_bhc_ReserveForDistributionFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Distribution Fees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDistributionFeesMember" xlink:href="bhc-20220510.xsd#bhc_ReserveForDistributionFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForDistributionFeesMember" xlink:to="lab_bhc_ReserveForDistributionFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_144b8be6-c39f-447b-9ab8-0e8b4cd53e61_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ca079f26-64d7-4842-bd77-f81017163b8d_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHARE-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_2960270c-b61e-481e-8301-2e13fceb8c72_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_2b530c50-4c28-40e1-9e3b-d4d8971e6305_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_124fce84-af2a-4213-8f52-0f89fbd08187_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OvertheCounterProductsMember_967c7823-e0bf-4532-bd5b-5cd80bc4744c_terseLabel_en-US" xlink:label="lab_bhc_OvertheCounterProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC</link:label>
    <link:label id="lab_bhc_OvertheCounterProductsMember_label_en-US" xlink:label="lab_bhc_OvertheCounterProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over the Counter Products [Member]</link:label>
    <link:label id="lab_bhc_OvertheCounterProductsMember_documentation_en-US" xlink:label="lab_bhc_OvertheCounterProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over the Counter Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OvertheCounterProductsMember" xlink:href="bhc-20220510.xsd#bhc_OvertheCounterProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OvertheCounterProductsMember" xlink:to="lab_bhc_OvertheCounterProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_ea2c5588-f3f6-4802-a26c-0238e73ad921_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of revenues by segment and by product category</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ffbc3168-29a7-45ad-a0ab-0ec72d22ed71_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange and other</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_2e3c99f2-ddaa-4f61-b631-4eeb7dcfa850_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of certain assets of Synergy</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_7badea0f-e16f-4a6f-beed-6d7c845efcfe_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_bd0a14f0-fee6-458d-9ced-21fc3b801698_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postretirement Benefit Plan</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_b55df67b-c544-47ad-a5ce-717ac14cb88c_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Postretirement Benefit Plan</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_950ed780-6f91-40c5-bf2e-2c3a184cf420_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Notes&#160;20 and 21)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualRightsMember_f4a3ff30-8a61-4eef-90b3-e2c780a853ed_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product rights/patents</link:label>
    <link:label id="lab_us-gaap_ContractualRightsMember_9c82b126-1cfe-4d84-a3a5-c4d42b64fe98_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product rights/patents</link:label>
    <link:label id="lab_us-gaap_ContractualRightsMember_label_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualRightsMember" xlink:to="lab_us-gaap_ContractualRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_50d5ae37-e200-4fbd-8b6e-3bbdccf4ddca_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_Legalsettlementsandrelatedfees_9ec938b3-39cd-4b1a-a78f-9c594a2f6bf7_terseLabel_en-US" xlink:label="lab_bhc_Legalsettlementsandrelatedfees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal matters and related fees</link:label>
    <link:label id="lab_bhc_Legalsettlementsandrelatedfees_label_en-US" xlink:label="lab_bhc_Legalsettlementsandrelatedfees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal settlements and related fees</link:label>
    <link:label id="lab_bhc_Legalsettlementsandrelatedfees_documentation_en-US" xlink:label="lab_bhc_Legalsettlementsandrelatedfees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal settlements and related fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_Legalsettlementsandrelatedfees" xlink:href="bhc-20220510.xsd#bhc_Legalsettlementsandrelatedfees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_Legalsettlementsandrelatedfees" xlink:to="lab_bhc_Legalsettlementsandrelatedfees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_65e6ef80-914d-4400-b214-d41424a792a8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_522fa5ce-7bde-443a-9bdd-933d6ed8bfa3_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax_0d4e6338-fd48-4df2-81b1-8a6221ca37aa_terseLabel_en-US" xlink:label="lab_bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1% change in volume of product sold through to Medicaid plan participants, Impact on pre-tax earnings</link:label>
    <link:label id="lab_bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax_label_en-US" xlink:label="lab_bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis, Impact Of 1 Percent Change In Volume Of Product Sold Through To Medicaid Plan Participants, Income (Loss) Before Tax</link:label>
    <link:label id="lab_bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax_documentation_en-US" xlink:label="lab_bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sensitivity Analysis, Impact Of 1 Percent Change In Volume Of Product Sold Through To Medicaid Plan Participants, Income (Loss) Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax" xlink:href="bhc-20220510.xsd#bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax" xlink:to="lab_bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_699b86f0-3f68-41a0-bcb7-bb60f39634d7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_19688a64-0405-4f1b-b8eb-54d73df04c10_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_9f0819be-7a61-4339-99ed-f48de6a8ea1c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_d2604cb1-2505-4927-b3a0-b4a247fd1ce9_terseLabel_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting unit, impairment test, estimated cash flows, discount rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_label_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate</link:label>
    <link:label id="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_documentation_en-US" xlink:label="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:href="bhc-20220510.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:to="lab_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_bfb31847-7168-4b10-b995-f40a4fa768a6_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_67d66568-e558-49f5-b7f8-fad64a616d54_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues and long-lived assets by geographic region</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_273f8155-de66-48e9-a724-944cba10105b_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_CedarsSinaiMedicalCenterMember_8f4a1cbf-bbe4-48b5-a466-53421a13e6af_terseLabel_en-US" xlink:label="lab_bhc_CedarsSinaiMedicalCenterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cedars-Sinai Medical Center</link:label>
    <link:label id="lab_bhc_CedarsSinaiMedicalCenterMember_label_en-US" xlink:label="lab_bhc_CedarsSinaiMedicalCenterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cedars-Sinai Medical Center [Member]</link:label>
    <link:label id="lab_bhc_CedarsSinaiMedicalCenterMember_documentation_en-US" xlink:label="lab_bhc_CedarsSinaiMedicalCenterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cedars-Sinai Medical Center</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CedarsSinaiMedicalCenterMember" xlink:href="bhc-20220510.xsd#bhc_CedarsSinaiMedicalCenterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_CedarsSinaiMedicalCenterMember" xlink:to="lab_bhc_CedarsSinaiMedicalCenterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_d536acd7-3a98-4168-9a70-a35300f474b0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible portion of Goodwill impairments</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_c5af7b40-54f5-4c38-99d3-2ea821a3a4ec_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8399201b-f734-44a1-b4ae-1f745bfd236a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_f2e3ee67-038e-4e4c-ab0f-1ab6992e0d0e_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of annual excess cash flow</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Percentage of Consolidated Excess Cash Flow Payable as Mandatory Prepayments</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of annual excess cash flow with any excess amounts after the prepayment of the loans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:href="bhc-20220510.xsd#bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:to="lab_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_8be48f4d-5f0d-4634-880b-211641867d90_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of compensation increase</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions_9713418b-3852-479f-bac8-882cffe71a4c_terseLabel_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, net decrease for tax positions of prior years</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Net Decrease Resulting From Prior Period Tax Positions</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions_documentation_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Net Decrease Resulting From Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions" xlink:href="bhc-20220510.xsd#bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions" xlink:to="lab_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_afcc359d-32df-4317-8634-77bf627d244b_negatedTerseLabel_en-US" xlink:label="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange and other</link:label>
    <link:label id="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_label_en-US" xlink:label="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance For Foreign Exchange And Other</link:label>
    <link:label id="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_documentation_en-US" xlink:label="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance For Foreign Exchange And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:href="bhc-20220510.xsd#bhc_AccountsReceivableAllowanceForForeignExchangeAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:to="lab_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForCustomerReturnsMember_fb53c97a-5e1d-4a67-bad4-94e1491a3214_terseLabel_en-US" xlink:label="lab_bhc_ReserveForCustomerReturnsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_bhc_ReserveForCustomerReturnsMember_label_en-US" xlink:label="lab_bhc_ReserveForCustomerReturnsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Customer Returns [Member]</link:label>
    <link:label id="lab_bhc_ReserveForCustomerReturnsMember_documentation_en-US" xlink:label="lab_bhc_ReserveForCustomerReturnsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Customer Returns [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember" xlink:href="bhc-20220510.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForCustomerReturnsMember" xlink:to="lab_bhc_ReserveForCustomerReturnsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_5d723410-5fd4-4abe-8673-2b836fed08c4_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DefinedBenefitPlanEmployerContributionMaximumAge_20fc78cf-ca9b-4fba-9e7e-d374dc8d0249_terseLabel_en-US" xlink:label="lab_bhc_DefinedBenefitPlanEmployerContributionMaximumAge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer contribution maximum age</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanEmployerContributionMaximumAge_label_en-US" xlink:label="lab_bhc_DefinedBenefitPlanEmployerContributionMaximumAge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Employer Contribution, Maximum Age</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanEmployerContributionMaximumAge_documentation_en-US" xlink:label="lab_bhc_DefinedBenefitPlanEmployerContributionMaximumAge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Employer Contribution, Maximum Age</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanEmployerContributionMaximumAge" xlink:href="bhc-20220510.xsd#bhc_DefinedBenefitPlanEmployerContributionMaximumAge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DefinedBenefitPlanEmployerContributionMaximumAge" xlink:to="lab_bhc_DefinedBenefitPlanEmployerContributionMaximumAge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_b6a400a4-dea5-4de7-81c6-e6fea56a2860_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_eceb56a1-a2b2-4f16-adf8-81ebccc155bc_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_bc14cdd9-0bee-4710-a5a5-f8837942d440_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_6e24c3cb-269f-43d1-a4b7-b78b3624bf63_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_MilestonePaymentRelatedToCertainProductMember_4769df6f-7cc0-43d7-b63c-f7397d65f351_terseLabel_en-US" xlink:label="lab_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Related To Certain Product</link:label>
    <link:label id="lab_bhc_MilestonePaymentRelatedToCertainProductMember_label_en-US" xlink:label="lab_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Related To Certain Product [Member]</link:label>
    <link:label id="lab_bhc_MilestonePaymentRelatedToCertainProductMember_documentation_en-US" xlink:label="lab_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Related To Certain Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:href="bhc-20220510.xsd#bhc_MilestonePaymentRelatedToCertainProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:to="lab_bhc_MilestonePaymentRelatedToCertainProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_10436900-d0f7-4eb4-9fa3-b4fb82a9e003_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_65a763e8-3a91-4233-923c-63ff3f2d3b3b_terseLabel_en-US" xlink:label="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROTC Performance-Based Restricted Stock Units</link:label>
    <link:label id="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROTC Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROTC Performance-Based Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:href="bhc-20220510.xsd#bhc_ROTCPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_371462cc-5d94-41f0-a160-7efd9601fea7_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_bf61dec3-8479-4142-bf48-73096b251e59_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_a07090dc-f4ff-47e1-8537-8338815d7210_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_254738b3-48b4-4a24-9d10-6ff8fedcee91_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes700DueMarch2024Member_1ef076a5-26ee-434e-acb1-230027e5fff1_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes700DueMarch2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 7.00%, Due March 2024</link:label>
    <link:label id="lab_bhc_SeniorNotes700DueMarch2024Member_label_en-US" xlink:label="lab_bhc_SeniorNotes700DueMarch2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 7.00%, Due March 2024 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes700DueMarch2024Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes700DueMarch2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 7.00%, Due March 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueMarch2024Member" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes700DueMarch2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes700DueMarch2024Member" xlink:to="lab_bhc_SeniorNotes700DueMarch2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_4045f174-11e7-4933-bf57-2966e4370c08_netLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestructuringAndIntegrationCostsMember_eb5c0886-97b5-4dee-a673-7423ca1a8e9b_terseLabel_en-US" xlink:label="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Integration Costs</link:label>
    <link:label id="lab_bhc_RestructuringAndIntegrationCostsMember_label_en-US" xlink:label="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Integration Costs [Member]</link:label>
    <link:label id="lab_bhc_RestructuringAndIntegrationCostsMember_documentation_en-US" xlink:label="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Integration Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndIntegrationCostsMember" xlink:href="bhc-20220510.xsd#bhc_RestructuringAndIntegrationCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestructuringAndIntegrationCostsMember" xlink:to="lab_bhc_RestructuringAndIntegrationCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear_1c761173-626b-4f7e-8050-5be4696dfe07_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in NOLs</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Increase (Decrease) in Liability from Prior Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear" xlink:to="lab_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_af7b8e7c-6d33-4f32-b23c-61368f4dfe83_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits_98c6890e-355e-4aa9-8050-432a0e1066bb_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of alleged stockholders filed lawsuits</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits_label_en-US" xlink:label="lab_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Alleged Stockholders, Filed Lawsuits</link:label>
    <link:label id="lab_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits_documentation_en-US" xlink:label="lab_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Alleged Stockholders, Filed Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits" xlink:href="bhc-20220510.xsd#bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits" xlink:to="lab_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_168c7e45-be17-494f-9125-204b78b617a0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_06e5ce13-03d8-4919-ae1a-c43d2ff3bece_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_5c9856d9-4721-447a-8f45-844526ad852d_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_a29d6adc-d603-457e-88fd-541e63b42150_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ede59dba-9e5f-4ee1-b632-85c630aaaa95_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of year</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_e38e949e-3a97-4876-906e-5aad35401bb9_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_0ac9e320-b805-4f9f-8fd6-cd2cf592321b_terseLabel_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition-related contingent consideration</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_label_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements Change in Amount of Contingent Consideration Asset Cash</link:label>
    <link:label id="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_documentation_en-US" xlink:label="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents the cash-flow impact of any change, including any differences arising upon settlement, recognized during the reporting period in the value of an asset or assets, arising from an item of contingent consideration, recognized in a business combination.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:href="bhc-20220510.xsd#bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:to="lab_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecured4875NotesDueJune2028Member_ceb2f09d-48af-4ed8-aa28-ef4fd4830825_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.875% Senior Notes Due June 2028</link:label>
    <link:label id="lab_bhc_SeniorSecured4875NotesDueJune2028Member_label_en-US" xlink:label="lab_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 4.875% Notes Due June 2028 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecured4875NotesDueJune2028Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured 4.875% Notes Due June 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:href="bhc-20220510.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:to="lab_bhc_SeniorSecured4875NotesDueJune2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d222d24a-8cb0-487c-bcea-274ec0840721_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PartnerRelationshipsMember_2bf35a02-6879-4021-a3e1-7ea204be3ffe_terseLabel_en-US" xlink:label="lab_bhc_PartnerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner relationships</link:label>
    <link:label id="lab_bhc_PartnerRelationshipsMember_9971684b-20ef-46dd-95cf-f24e49c5e4af_verboseLabel_en-US" xlink:label="lab_bhc_PartnerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner relationships</link:label>
    <link:label id="lab_bhc_PartnerRelationshipsMember_label_en-US" xlink:label="lab_bhc_PartnerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner Relationships [Member]</link:label>
    <link:label id="lab_bhc_PartnerRelationshipsMember_documentation_en-US" xlink:label="lab_bhc_PartnerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to existing arrangements with various other entities, for which the entity provides regulatory, compliance, sales, marketing and distribution functions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PartnerRelationshipsMember" xlink:href="bhc-20220510.xsd#bhc_PartnerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PartnerRelationshipsMember" xlink:to="lab_bhc_PartnerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_d7e6e524-adb4-4d67-be48-37d91e7a4ef9_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_7e24c4f6-c2b4-4893-abc0-1a9bf5aaf28e_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_bdebf0bc-b8a7-4793-9049-8fe3a3a23703_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments, including loss on assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_a75670c4-c28c-449c-8385-a336ff16adc7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments, including loss on assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_19f8874c-ca80-403a-a15d-37631334da71_negatedLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments, including loss on assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_2734e0e6-90df-4c84-a6fe-16b69d69b317_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LupinPharmaceuticalsIncLitigationMember_8d200b95-c7a6-40bd-8db1-6a9a6301f64f_terseLabel_en-US" xlink:label="lab_bhc_LupinPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lupin Pharmaceuticals, Inc. Litigation</link:label>
    <link:label id="lab_bhc_LupinPharmaceuticalsIncLitigationMember_label_en-US" xlink:label="lab_bhc_LupinPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lupin Pharmaceuticals, Inc. Litigation [Member]</link:label>
    <link:label id="lab_bhc_LupinPharmaceuticalsIncLitigationMember_documentation_en-US" xlink:label="lab_bhc_LupinPharmaceuticalsIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lupin Pharmaceuticals, Inc. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LupinPharmaceuticalsIncLitigationMember" xlink:href="bhc-20220510.xsd#bhc_LupinPharmaceuticalsIncLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LupinPharmaceuticalsIncLitigationMember" xlink:to="lab_bhc_LupinPharmaceuticalsIncLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_e7ae6122-d6c6-43ae-9b9b-b94c2c8c799e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate notional amounts</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_04281259-2019-4433-a496-060aa6e2d80b_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_c247b56b-c102-48b0-85ab-49a9b4735441_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired IPR&amp;D, included in other expense, net</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A8.50SeniorNotesDueJanuary2027Member_70f21f4d-55a1-4bc3-894a-8caa1cafc93e_terseLabel_en-US" xlink:label="lab_bhc_A8.50SeniorNotesDueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8.50% Senior Unsecured Notes Due January 2027</link:label>
    <link:label id="lab_bhc_A8.50SeniorNotesDueJanuary2027Member_label_en-US" xlink:label="lab_bhc_A8.50SeniorNotesDueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8.50% Senior Notes Due January 2027 [Member]</link:label>
    <link:label id="lab_bhc_A8.50SeniorNotesDueJanuary2027Member_documentation_en-US" xlink:label="lab_bhc_A8.50SeniorNotesDueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8.50% Senior Notes Due January 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A8.50SeniorNotesDueJanuary2027Member" xlink:href="bhc-20220510.xsd#bhc_A8.50SeniorNotesDueJanuary2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A8.50SeniorNotesDueJanuary2027Member" xlink:to="lab_bhc_A8.50SeniorNotesDueJanuary2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_1920597e-d7cb-4a73-8a58-5a3f626aa0f7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_459c5cf2-87b8-4bca-83e2-51229c1098f1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ThreeLargestUSWholesalerCustomersMember_3f1c7532-bad7-4b5b-9382-5a3d8b6998a9_terseLabel_en-US" xlink:label="lab_bhc_ThreeLargestUSWholesalerCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three largest U.S. wholesaler customers</link:label>
    <link:label id="lab_bhc_ThreeLargestUSWholesalerCustomersMember_label_en-US" xlink:label="lab_bhc_ThreeLargestUSWholesalerCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Largest US Wholesaler Customers [Member]</link:label>
    <link:label id="lab_bhc_ThreeLargestUSWholesalerCustomersMember_documentation_en-US" xlink:label="lab_bhc_ThreeLargestUSWholesalerCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to the three largest U.S. wholesaler customers.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ThreeLargestUSWholesalerCustomersMember" xlink:href="bhc-20220510.xsd#bhc_ThreeLargestUSWholesalerCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ThreeLargestUSWholesalerCustomersMember" xlink:to="lab_bhc_ThreeLargestUSWholesalerCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PlaintiffsDirectPurchasersMember_077b1a36-072f-47ab-b890-5b690bcec7bd_terseLabel_en-US" xlink:label="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiffs, Direct Purchasers</link:label>
    <link:label id="lab_bhc_PlaintiffsDirectPurchasersMember_label_en-US" xlink:label="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiffs, Direct Purchasers [Member]</link:label>
    <link:label id="lab_bhc_PlaintiffsDirectPurchasersMember_documentation_en-US" xlink:label="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiffs, Direct Purchasers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PlaintiffsDirectPurchasersMember" xlink:href="bhc-20220510.xsd#bhc_PlaintiffsDirectPurchasersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PlaintiffsDirectPurchasersMember" xlink:to="lab_bhc_PlaintiffsDirectPurchasersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_a3936a75-2090-4406-a125-b2cf8f1db62a_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_aad63ac5-1e66-4665-9322-40bb139a97f3_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assumptions used to calculate the fair values of performance-based RSUs</link:label>
    <link:label id="lab_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share Based Payment Award, Equity Instruments Other than Options Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the significant assumptions used during the year to estimate the fair value of equity based payment instruments, excluding stock (or unit) options, including but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:href="bhc-20220510.xsd#bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_d5eb29b6-3d84-40f3-bdfe-cb0f314c4f00_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_e31816fe-2e0f-41a0-b04b-0c41bf136450_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_954c54a3-bed9-4c99-bb5e-4a5049d51cbd_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes850DueJanuary2027Member_b062689f-f3e6-420d-8af7-d1cc4898c1dc_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8.500% Senior Notes Due January 2027</link:label>
    <link:label id="lab_bhc_SeniorNotes850DueJanuary2027Member_label_en-US" xlink:label="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 8.50%, Due January 2027 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes850DueJanuary2027Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8.50% Senior Notes Due January 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes850DueJanuary2027Member" xlink:to="lab_bhc_SeniorNotes850DueJanuary2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_adf1d423-264a-43b1-a914-5b8ee95185fe_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2d884e56-90ea-4dc9-95a3-66fac62877ee_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6ed10df3-8ebe-4656-b088-3b9bf516dd4c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_254ba2cb-6204-42a4-b406-6adc4a78c8b5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_d3827d6a-cd5c-4d5b-817b-431d6851a945_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_1ab01b2c-d940-4f69-b6a9-53c2b437cc5a_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_f025c9f5-4e2d-4231-b05b-e2b20d0d15a0_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember_67d1ef24-aaf8-4133-ac04-2a62ea77d948_terseLabel_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility, New Restated Credit Agreement</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember_label_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility, New Restated Credit Agreement [Member]</link:label>
    <link:label id="lab_bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember_documentation_en-US" xlink:label="lab_bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility, New Restated Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember" xlink:href="bhc-20220510.xsd#bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember" xlink:to="lab_bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes4.502023Member_0fa7de47-5e65-4fec-9065-c327d3775ada_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes4.502023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Senior Unsecured Notes euro-denominated debt Due May 2023</link:label>
    <link:label id="lab_bhc_SeniorNotes4.502023Member_label_en-US" xlink:label="lab_bhc_SeniorNotes4.502023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.50%, 2023 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes4.502023Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes4.502023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 4.50%, 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes4.502023Member" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes4.502023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes4.502023Member" xlink:to="lab_bhc_SeniorNotes4.502023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_ef5e58f4-02b3-45e1-a000-85f6dcb5bfe2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_b5c534dd-3874-4832-9226-46d9949e2b1f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_eb470a48-0b0f-41a0-9aac-0d68d556c3ed_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_e045a5fc-7a3b-45c4-8121-380c187c995d_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments / Settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_30d9b58e-ee8d-4df6-b93d-458e3f3417fa_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_9d941ff7-65f6-4e3c-98f4-5ba4feac465d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average assumptions used to determine net periodic benefit costs and benefit obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_525d76a0-9bed-4c8d-b246-ae91cd4947e1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_65f0ba8a-c888-4c31-bb08-b2dc25977284_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_c85f5da0-d1be-4095-b77c-124df28deaa3_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_51b24676-250a-4f32-93db-5236767533a0_verboseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_817104e5-23db-46eb-8a09-669028b75dba_terseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized interest</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized" xlink:to="lab_us-gaap_InterestCostsCapitalized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EurodollarMember_54ece345-c1e2-4192-93d7-3ec094c539fe_terseLabel_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurodollar</link:label>
    <link:label id="lab_us-gaap_EurodollarMember_label_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurodollar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EurodollarMember" xlink:to="lab_us-gaap_EurodollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_192c1f02-7078-498c-9dcf-e10f906f7fe9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future benefit payments for the pension benefit plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Expected Benefit Payments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_4bf5f7cb-9745-4e26-b5cc-787e325333bc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the components of accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_37b8b714-fe90-4695-ad3a-9c8131124c90_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_b744fc9b-ca6b-4041-819e-85f97b8871cb_terseLabel_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and other settlement deposits</link:label>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_label_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Other Settlement Deposits, Current</link:label>
    <link:label id="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_documentation_en-US" xlink:label="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Other Settlement Deposits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:href="bhc-20220510.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:to="lab_bhc_RestrictedCashAndOtherSettlementDepositsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_8cacdbbc-cb96-4f7f-a6e2-6bc64be2db1b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of the beginning and ending amounts of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities_5fc65ffa-7be8-4035-9bf2-a099f7dc729a_terseLabel_en-US" xlink:label="lab_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum period to classify uncertain tax position liabilities as long term liabilities</link:label>
    <link:label id="lab_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities_label_en-US" xlink:label="lab_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Period to Classify Uncertain Tax Position, Liabilities as Long Term Liabilities</link:label>
    <link:label id="lab_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities_documentation_en-US" xlink:label="lab_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the minimum period to classify uncertain tax position liabilities as long term liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities" xlink:href="bhc-20220510.xsd#bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities" xlink:to="lab_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_7fbe7253-9358-499c-bc6a-f733f04063e5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_a6b01442-b87a-436d-a2f2-727e33a5f833_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_b6e3012d-a119-4795-9c51-af79e06f1787_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCUMULATED OTHER COMPREHENSIVE LOSS</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_b863ff8e-def0-418f-8547-b4d1672dd9d5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A9.25SeniorNotesDueApril2026Member_257c7ac8-7c70-4701-888b-fadcc997b62f_terseLabel_en-US" xlink:label="lab_bhc_A9.25SeniorNotesDueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.25% Senior Unsecured Notes Due April 2026</link:label>
    <link:label id="lab_bhc_A9.25SeniorNotesDueApril2026Member_label_en-US" xlink:label="lab_bhc_A9.25SeniorNotesDueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.25% Senior Notes Due April 2026 [Member]</link:label>
    <link:label id="lab_bhc_A9.25SeniorNotesDueApril2026Member_documentation_en-US" xlink:label="lab_bhc_A9.25SeniorNotesDueApril2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.25% Senior Notes Due April 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.25SeniorNotesDueApril2026Member" xlink:href="bhc-20220510.xsd#bhc_A9.25SeniorNotesDueApril2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A9.25SeniorNotesDueApril2026Member" xlink:to="lab_bhc_A9.25SeniorNotesDueApril2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember_fb9bb47f-42b6-4eda-b83e-396aa5b1061e_terseLabel_en-US" xlink:label="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Weighted-Average Discount Rate</link:label>
    <link:label id="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember_label_en-US" xlink:label="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Weighted-Average Discount Rate [Member]</link:label>
    <link:label id="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember_documentation_en-US" xlink:label="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Weighted-Average Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:href="bhc-20220510.xsd#bhc_MeasurementInputWeightedAverageDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:to="lab_bhc_MeasurementInputWeightedAverageDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_c55cc8b4-e2be-416e-8356-7beb6b7bb8ec_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_926abc88-8fc9-4312-ab1d-62179b6bb7ae_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_d8046161-55a1-4dd3-9d3c-d63d154328b7_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected rate of return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DerivativeLawsuitsMember_9ba8a59f-10ff-4340-a337-357d8fde093e_terseLabel_en-US" xlink:label="lab_bhc_DerivativeLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Lawsuits</link:label>
    <link:label id="lab_bhc_DerivativeLawsuitsMember_label_en-US" xlink:label="lab_bhc_DerivativeLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Lawsuits [Member]</link:label>
    <link:label id="lab_bhc_DerivativeLawsuitsMember_documentation_en-US" xlink:label="lab_bhc_DerivativeLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeLawsuitsMember" xlink:href="bhc-20220510.xsd#bhc_DerivativeLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DerivativeLawsuitsMember" xlink:to="lab_bhc_DerivativeLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_a576a704-c57b-403c-b750-e02ded897ac4_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_baac5ae3-87c1-4df1-836a-54baf8791e6d_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_2765db3d-7e1f-4fe3-97b7-f44e573a6571_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenant, redemption and discharge condition, amount, if circumstances met</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Redemption And Discharge Condition, Amount, If Circumstances Met</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Redemption And Discharge Condition, Amount, If Circumstances Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:to="lab_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_a720c9ec-061e-4a65-a3f7-8df2312800c5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_c9bf5bb4-c93f-4196-a3b5-cad930e67bf9_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember_9654fb51-026a-4259-8e02-2019b7079d33_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured and Unsecured Notes</link:label>
    <link:label id="lab_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember_label_en-US" xlink:label="lab_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes And Senior Unsecured Notes [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember_documentation_en-US" xlink:label="lab_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes And Senior Unsecured Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember" xlink:href="bhc-20220510.xsd#bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember" xlink:to="lab_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_8c3dd126-9473-4bc7-9f2d-e0f867cfde7f_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_7fb8b5aa-0131-4139-84e3-ad3e0d82c653_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes550DueMarch2023Member_f1094f89-dc57-493a-b7e4-9acc6ec2579b_verboseLabel_en-US" xlink:label="lab_bhc_SeniorNotes550DueMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Senior Notes Due March 2023</link:label>
    <link:label id="lab_bhc_SeniorNotes550DueMarch2023Member_label_en-US" xlink:label="lab_bhc_SeniorNotes550DueMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.50%, Due March 2023 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes550DueMarch2023Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes550DueMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Senior Notes due March 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes550DueMarch2023Member" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes550DueMarch2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes550DueMarch2023Member" xlink:to="lab_bhc_SeniorNotes550DueMarch2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_d5c27294-6f3d-4768-b67c-509144cfe55f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_0803a691-94de-479a-b53d-9f55920bb60d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_58ee5a58-ead6-4191-a4b1-8bad05897c14_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_e22bfaa5-3418-4a01-a97c-903cb13a39c8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_51752597-711d-415f-b175-87399413e83b_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of lines of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxYear2012Member_f5532dc7-1e8a-47ed-b2c9-d55925b017ba_terseLabel_en-US" xlink:label="lab_us-gaap_TaxYear2012Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2012</link:label>
    <link:label id="lab_us-gaap_TaxYear2012Member_label_en-US" xlink:label="lab_us-gaap_TaxYear2012Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2012 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2012Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxYear2012Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxYear2012Member" xlink:to="lab_us-gaap_TaxYear2012Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_dc2d93f0-cb52-4636-955d-b79664425700_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed charge coverage ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:to="lab_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A5.25SeniorNotesDueJanuary2030Member_fb8ce41d-56c8-42fc-a289-92d78d6643fc_terseLabel_en-US" xlink:label="lab_bhc_A5.25SeniorNotesDueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Senior Unsecured Notes Due January 2030</link:label>
    <link:label id="lab_bhc_A5.25SeniorNotesDueJanuary2030Member_label_en-US" xlink:label="lab_bhc_A5.25SeniorNotesDueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Senior Notes Due January 2030 [Member]</link:label>
    <link:label id="lab_bhc_A5.25SeniorNotesDueJanuary2030Member_documentation_en-US" xlink:label="lab_bhc_A5.25SeniorNotesDueJanuary2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Senior Notes Due January 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.25SeniorNotesDueJanuary2030Member" xlink:href="bhc-20220510.xsd#bhc_A5.25SeniorNotesDueJanuary2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A5.25SeniorNotesDueJanuary2030Member" xlink:to="lab_bhc_A5.25SeniorNotesDueJanuary2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_be72f6ed-8b4d-441a-98d4-f65c005d78b2_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_00db1e60-25a5-415f-a448-2656be5ba6d1_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_InsuranceCoverageLawsuitMember_6b45279b-a3b6-4375-a15a-45b721d0eb6f_terseLabel_en-US" xlink:label="lab_bhc_InsuranceCoverageLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage Lawsuit</link:label>
    <link:label id="lab_bhc_InsuranceCoverageLawsuitMember_label_en-US" xlink:label="lab_bhc_InsuranceCoverageLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage Lawsuit [Member]</link:label>
    <link:label id="lab_bhc_InsuranceCoverageLawsuitMember_documentation_en-US" xlink:label="lab_bhc_InsuranceCoverageLawsuitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage Lawsuit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InsuranceCoverageLawsuitMember" xlink:href="bhc-20220510.xsd#bhc_InsuranceCoverageLawsuitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_InsuranceCoverageLawsuitMember" xlink:to="lab_bhc_InsuranceCoverageLawsuitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_be927c85-3c7f-47f4-b061-155671bfa291_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d93d8f20-c544-444d-9121-40ca44857901_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total (deficit) equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f5928916-08b9-4253-82ab-30a9f78b094b_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_02416ff3-fb06-44bc-91ab-56e4cc28c959_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_dc760cec-6fd0-4bac-870a-d1d056a6b27c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase to accumulated deficit (less than)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_584a3d86-4346-49f0-8e34-403d177ab899_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_8a8a3ac8-519b-40a4-87bc-dbed3fe69878_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price percentage due to change in control (as a percent)</link:label>
    <link:label id="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_label_en-US" xlink:label="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage, Change in Control</link:label>
    <link:label id="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage, Change in Control</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:to="lab_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_5c96416e-c140-4281-8feb-cfdd07507af2_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_91c6b0e6-d32f-40f3-8d71-c67bf99d50b0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of long-term debt, net of discounts</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_978710eb-146a-471b-9b9c-c8cdc8666ee7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_70b711fe-22af-4446-9833-6ff1088d1792_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_b550ebed-16f2-4786-851d-34cdd9e0da0e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents_fc3e73c1-c65e-45ef-8577-d7231c0473d5_terseLabel_en-US" xlink:label="lab_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum term of original maturity to classify instruments as cash and cash equivalents (less than)</link:label>
    <link:label id="lab_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents_label_en-US" xlink:label="lab_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Term of Original Maturity to Classify Instruments as Cash and Cash Equivalents</link:label>
    <link:label id="lab_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents_documentation_en-US" xlink:label="lab_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the maximum original term of maturity for an instrument to be classified as cash or cash equivalent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents" xlink:href="bhc-20220510.xsd#bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents" xlink:to="lab_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f4149d3e-49dc-4733-95ab-ec16b55aeaa4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_ddf2c517-920a-4eaa-b66b-6e4440cd580f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_9125d0c0-51b7-4827-b29b-20bfad97328b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_1b1d750b-90d5-49ce-8bf4-39cf76552786_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes525DueFebruary2031Member_94bebfb6-7344-42f4-9fd0-0157306315da_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes525DueFebruary2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.250% Senior Notes, Due February 2031</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueFebruary2031Member_label_en-US" xlink:label="lab_bhc_SeniorNotes525DueFebruary2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.25%, Due February 2031 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes525DueFebruary2031Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes525DueFebruary2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.25%, Due February 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes525DueFebruary2031Member" xlink:to="lab_bhc_SeniorNotes525DueFebruary2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_438e924c-3b84-469d-95e2-a1a301852650_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of segment revenues and profit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_abf983fd-40d7-4212-be46-0fd6e6e0ed5d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_7b44c467-1909-425e-84e4-a66ce85d9472_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_07817ac7-6891-473a-83d6-6181ae320b99_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_261c0bfc-ff92-444d-8903-85cf31985019_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_38cfea1b-f122-4d71-b9e6-8af1f367b1ce_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax_9ba84f8c-d748-4c62-bdd2-51ab3478e8e1_terseLabel_en-US" xlink:label="lab_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency impact</link:label>
    <link:label id="lab_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax_label_en-US" xlink:label="lab_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Foreign Currency Adjustment, Net Of Tax</link:label>
    <link:label id="lab_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax_documentation_en-US" xlink:label="lab_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Foreign Currency Adjustment, Net Of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" xlink:href="bhc-20220510.xsd#bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" xlink:to="lab_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_5c1f6101-6118-44d2-8b49-f6ce5ac464ac_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest coverage ratio (not less than)</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:to="lab_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_b8bbb87c-9ef8-4467-9f6f-ed8eed371552_negatedLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_a2693af9-5766-430c-a477-d671992a640e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_160eb4c4-6893-458b-bac2-aa55577191ff_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DefinedBenefitPlanPercentageAllocationofFund_31bfa359-343e-4fb3-b309-ab80c53892c1_terseLabel_en-US" xlink:label="lab_bhc_DefinedBenefitPlanPercentageAllocationofFund" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage allocation of fund</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanPercentageAllocationofFund_label_en-US" xlink:label="lab_bhc_DefinedBenefitPlanPercentageAllocationofFund" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Percentage Allocation of Fund</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanPercentageAllocationofFund_documentation_en-US" xlink:label="lab_bhc_DefinedBenefitPlanPercentageAllocationofFund" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Percentage Allocation of Fund</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanPercentageAllocationofFund" xlink:href="bhc-20220510.xsd#bhc_DefinedBenefitPlanPercentageAllocationofFund"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DefinedBenefitPlanPercentageAllocationofFund" xlink:to="lab_bhc_DefinedBenefitPlanPercentageAllocationofFund" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_106f2927-bd66-419b-ac8f-3a59b3ec151e_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_a9bbfc5c-d190-4b00-b16c-09c0e5cf2bc0_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of capital expenditures, depreciation and amortization by segment</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Other Significant Reconciling Items from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A5.50SeniorNotesdueMarch2023Member_19efd4d3-5b5f-4348-bfd0-b4f5c97c80b2_terseLabel_en-US" xlink:label="lab_bhc_A5.50SeniorNotesdueMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Senior Unsecured Notes due March 2023</link:label>
    <link:label id="lab_bhc_A5.50SeniorNotesdueMarch2023Member_label_en-US" xlink:label="lab_bhc_A5.50SeniorNotesdueMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Senior Notes due March 2023 [Member]</link:label>
    <link:label id="lab_bhc_A5.50SeniorNotesdueMarch2023Member_documentation_en-US" xlink:label="lab_bhc_A5.50SeniorNotesdueMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Senior Notes due March 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.50SeniorNotesdueMarch2023Member" xlink:href="bhc-20220510.xsd#bhc_A5.50SeniorNotesdueMarch2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A5.50SeniorNotesdueMarch2023Member" xlink:to="lab_bhc_A5.50SeniorNotesdueMarch2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_72447475-2001-4be1-8f75-5fcb8a3d0023_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER EXPENSE, NET</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalPeriod_a2864749-aa11-4001-bd9e-8b0268c20585_terseLabel_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stay of the approval period</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalPeriod_label_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Period</link:label>
    <link:label id="lab_bhc_LossContingencyStayOfApprovalPeriod_documentation_en-US" xlink:label="lab_bhc_LossContingencyStayOfApprovalPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Stay Of Approval, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalPeriod" xlink:href="bhc-20220510.xsd#bhc_LossContingencyStayOfApprovalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LossContingencyStayOfApprovalPeriod" xlink:to="lab_bhc_LossContingencyStayOfApprovalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShowertoShowerProductLiabilityLitigationMember_5f2cb5cc-c24d-4f0d-8d54-a4d40d6ea3ed_terseLabel_en-US" xlink:label="lab_bhc_ShowertoShowerProductLiabilityLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower to Shower Product Liability Litigation</link:label>
    <link:label id="lab_bhc_ShowertoShowerProductLiabilityLitigationMember_label_en-US" xlink:label="lab_bhc_ShowertoShowerProductLiabilityLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower to Shower Product Liability Litigation [Member]</link:label>
    <link:label id="lab_bhc_ShowertoShowerProductLiabilityLitigationMember_documentation_en-US" xlink:label="lab_bhc_ShowertoShowerProductLiabilityLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower to Shower Product Liability Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowertoShowerProductLiabilityLitigationMember" xlink:href="bhc-20220510.xsd#bhc_ShowertoShowerProductLiabilityLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShowertoShowerProductLiabilityLitigationMember" xlink:to="lab_bhc_ShowertoShowerProductLiabilityLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_93ab0ac0-850f-4714-a980-e87d9f3a54a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease expense</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3e188988-e271-40ba-8e4e-06b44ce9a7ec_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issued under share-based compensation plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_d4a750c6-8827-462c-930c-9662fae97738_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining mandatory quarterly amortization payments</link:label>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_label_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Quarterly Amortization</link:label>
    <link:label id="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Periodic Payment, Quarterly Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:to="lab_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_31c32358-a49e-489a-a005-ee4171cef3ba_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio_a9b86802-7791-4c84-8a31-6ebdc0593561_terseLabel_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total leverage ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio_label_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Total Leverage Ratio</link:label>
    <link:label id="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio_documentation_en-US" xlink:label="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Total Leverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:to="lab_bhc_DebtInstrumentCovenantTotalLeverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_967452d9-6a90-478a-8d08-c1accf6651c4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_36f47887-4876-42d5-8386-0ef9a6208fdd_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_8026f88e-a2dc-41fd-a9a7-a621d00f634b_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on disposal of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_60aed31d-0872-464e-8079-4082b122275c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_c824b24e-9691-45f2-b8eb-83318436c721_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement, escrow fund included in restricted cash</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_ccb78c15-8b59-4428-bd67-9e8b935e0861_verboseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation, amount agreed to pay</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ec85523d-7142-4ed3-a74c-01fe1a8216a9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issued under share-based compensation plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_ce42fa1e-fb48-475a-b589-9ceeaa49dddb_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States - Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_4437bae3-db24-4575-a569-2c0e89d71a49_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_FairValueAdjustmentsMember_172106f7-8726-4621-b0e9-8404a5004aba_terseLabel_en-US" xlink:label="lab_bhc_FairValueAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustments</link:label>
    <link:label id="lab_bhc_FairValueAdjustmentsMember_label_en-US" xlink:label="lab_bhc_FairValueAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustments [Member]</link:label>
    <link:label id="lab_bhc_FairValueAdjustmentsMember_documentation_en-US" xlink:label="lab_bhc_FairValueAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FairValueAdjustmentsMember" xlink:href="bhc-20220510.xsd#bhc_FairValueAdjustmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_FairValueAdjustmentsMember" xlink:to="lab_bhc_FairValueAdjustmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_a2e5268f-6af1-4bf3-82a1-233e28ec316d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_4b6202d5-7347-416b-abe3-7ace05cb4802_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes500DueFebruary2029Member_adab6118-926e-413a-be09-8e908f903045_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes500DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.000% Senior Note Due February 2029</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueFebruary2029Member_label_en-US" xlink:label="lab_bhc_SeniorNotes500DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.00%, Due February 2029 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes500DueFebruary2029Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes500DueFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 5.00%, Due February 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes500DueFebruary2029Member" xlink:to="lab_bhc_SeniorNotes500DueFebruary2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7bde18e0-52bd-410f-a4b5-f869d524ba96_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_959e7752-617c-457a-81d2-8d0b4a61c2ed_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_0559a73b-dd83-4978-b0e2-0d9b7bff2f7a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance against deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_0777f501-890b-4219-8a97-89e1be1092f0_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_1b344aaa-72dc-4c35-bd1d-83b6d0aad3ec_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customers [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_05550211-08c6-458d-9f37-28717f1bb70e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost-rationalization and integration initiatives</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_485e547b-fe6f-4aa1-bbe4-6037ec17d986_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d0ef0ac2-eaa3-43f4-893c-1cc0d94ca24f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_67ab0d5a-5402-4f6e-b3a6-902f26ba2951_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_eb6a5d22-e6c1-4df2-869c-d722ec80c987_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes700DueJanuary2028Member_91901939-ed11-4123-b88d-7e5ce12bdd18_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.000 % Senior Notes Due January 2028</link:label>
    <link:label id="lab_bhc_SeniorNotes700DueJanuary2028Member_label_en-US" xlink:label="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 7.00%, Due January 2028 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes700DueJanuary2028Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes 7.00 Percent Due January 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes700DueJanuary2028Member" xlink:to="lab_bhc_SeniorNotes700DueJanuary2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_8fb05c26-8820-49ca-8903-26daafe4ed23_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill reclassified to assets held for sale</link:label>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_ad1eee45-5dfa-496f-9896-f982c3e56004_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RICOClassActionsLitigationMember_304656bf-d5c6-4916-bef2-576cb7332a21_terseLabel_en-US" xlink:label="lab_bhc_RICOClassActionsLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RICO Class Actions Litigation</link:label>
    <link:label id="lab_bhc_RICOClassActionsLitigationMember_label_en-US" xlink:label="lab_bhc_RICOClassActionsLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RICO Class Actions Litigation [Member]</link:label>
    <link:label id="lab_bhc_RICOClassActionsLitigationMember_documentation_en-US" xlink:label="lab_bhc_RICOClassActionsLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RICO Class Actions Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RICOClassActionsLitigationMember" xlink:href="bhc-20220510.xsd#bhc_RICOClassActionsLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RICOClassActionsLitigationMember" xlink:to="lab_bhc_RICOClassActionsLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_45cea118-3c9d-4419-8e6a-15dace60988c_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_226188db-7932-4140-b714-6c89b895e60d_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets reclassified, held and used</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_4709a1b5-8674-4b7a-9cb1-336252e2d457_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation and other matters</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_cadd3fab-6c1e-476a-9c1b-38702043cd4c_terseLabel_en-US" xlink:label="lab_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.50% Senior Notes Due March 2022</link:label>
    <link:label id="lab_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_label_en-US" xlink:label="lab_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes 6.50 Percent Due March 2022 [Member]</link:label>
    <link:label id="lab_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_documentation_en-US" xlink:label="lab_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Notes 6.50 Percent Due March 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member" xlink:href="bhc-20220510.xsd#bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member" xlink:to="lab_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_a48de094-0a94-485f-a470-11fce4a428f5_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_cc4985de-18f9-48d1-92d0-7ebfed035661_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_63df9276-5bfe-4a21-9bf1-96b76f76d828_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued_96819f4e-a7bb-469e-afe0-885ffeb134b8_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum common shares issuable upon vesting (in shares)</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation, Arrangement by Share Based Payment Award, Number of Shares that could be Issued</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the maximum number of common shares that could be issued upon vesting of outstanding awards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued" xlink:href="bhc-20220510.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_1c77b0cc-8fde-4959-8358-de8d1e192df7_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DeviceProductsMember_9004025d-b4b5-49df-aba7-d015e5179da0_terseLabel_en-US" xlink:label="lab_bhc_DeviceProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Devices</link:label>
    <link:label id="lab_bhc_DeviceProductsMember_label_en-US" xlink:label="lab_bhc_DeviceProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Products [Member]</link:label>
    <link:label id="lab_bhc_DeviceProductsMember_documentation_en-US" xlink:label="lab_bhc_DeviceProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Device Products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeviceProductsMember" xlink:href="bhc-20220510.xsd#bhc_DeviceProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DeviceProductsMember" xlink:to="lab_bhc_DeviceProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_93a0d0d3-eed2-4813-bddf-930ad76799e3_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_0e69c5e9-0491-4a20-a2bb-46e5d5626f4b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of activity in allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_8a5cb4e8-901a-4326-a299-0245dc3f6c18_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_109e8fde-f504-458d-9af3-627b924b5fe2_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_f0c5309d-dcb9-4b22-87fe-d814d6bae3a8_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff89df38-d84d-4bfe-9979-0b87d3cccfb2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_585ae3c3-1af9-4570-b9be-b08ee0199a6f_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_0ab29a59-61cc-47ec-b0fd-f54bf0d28c40_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_6c0cc74e-1143-4b01-8108-a214721b6b77_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of long-term debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnitedStatesandPuertoRicoMember_a8f6177e-2a2f-4b73-9f59-9bcf32b49d69_terseLabel_en-US" xlink:label="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. and Puerto Rico</link:label>
    <link:label id="lab_bhc_UnitedStatesandPuertoRicoMember_label_en-US" xlink:label="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States and Puerto Rico [Member]</link:label>
    <link:label id="lab_bhc_UnitedStatesandPuertoRicoMember_documentation_en-US" xlink:label="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States and Puerto Rico [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnitedStatesandPuertoRicoMember" xlink:href="bhc-20220510.xsd#bhc_UnitedStatesandPuertoRicoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnitedStatesandPuertoRicoMember" xlink:to="lab_bhc_UnitedStatesandPuertoRicoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_89776881-2982-40ea-8b74-6bdaabecd2ea_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_be56f2c3-50e0-4515-b622-cc7a132aaf14_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payments, included in acquired in-process research and development costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9fb0dc4b-56eb-4489-ab02-13375999b5c0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_1beb4b42-8df2-4a45-a4d4-35250f095410_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_323df55c-7c2b-43ec-b0c1-ad984370ec7b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs</link:label>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_6651d2d4-ac85-4749-9283-46d49d51c254_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DiversifiedProductsSegmentMember_40eab23d-1dee-4474-b47c-4fb66979aa31_terseLabel_en-US" xlink:label="lab_bhc_DiversifiedProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diversified Products</link:label>
    <link:label id="lab_bhc_DiversifiedProductsSegmentMember_f011ec4a-3e71-4a01-ab0d-d1aa81ede558_verboseLabel_en-US" xlink:label="lab_bhc_DiversifiedProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diversified Products</link:label>
    <link:label id="lab_bhc_DiversifiedProductsSegmentMember_label_en-US" xlink:label="lab_bhc_DiversifiedProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diversified Products Segment [Member]</link:label>
    <link:label id="lab_bhc_DiversifiedProductsSegmentMember_documentation_en-US" xlink:label="lab_bhc_DiversifiedProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diversified Products Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember" xlink:href="bhc-20220510.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DiversifiedProductsSegmentMember" xlink:to="lab_bhc_DiversifiedProductsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetAssetLiabilityAbstract_163ab4d2-2d83-4fa2-9d2b-50083feed96c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetAssetLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets:</link:label>
    <link:label id="lab_us-gaap_FairValueNetAssetLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueNetAssetLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Asset (Liability) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetAssetLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetAssetLiabilityAbstract" xlink:to="lab_us-gaap_FairValueNetAssetLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_460263fe-8318-40ec-98d6-ab6ee8b805d5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted-average common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_9f254522-b0bf-4942-b6af-21951042f056_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted loss per share attributable to Bausch Health Companies Inc. (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_3c511df1-2500-4d79-ba72-a924c2516ff3_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_c08d929c-6846-4af8-a824-116dea192452_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and write-off of debt discounts and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity_6aad4c1b-5a39-4229-8e22-d4946499941a_terseLabel_en-US" xlink:label="lab_bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected maximum borrowing capacity</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity_label_en-US" xlink:label="lab_bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Expected Maximum Borrowing Capacity</link:label>
    <link:label id="lab_bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity_documentation_en-US" xlink:label="lab_bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Expected Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity" xlink:href="bhc-20220510.xsd#bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity" xlink:to="lab_bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_ad0c870e-06b0-4070-ae19-06a43441d620_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_8eea7f16-991f-4a87-a9e1-f1574a6b059c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain excluded from assessment of hedge effectiveness</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_4c101d07-a978-42a5-aa86-facc405c58fe_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leaseholds and Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_023194b4-79d5-428d-a7fc-16e34649e8c8_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_cafdde9f-ff65-4ebb-a0bb-f4c9fb9ca4b8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NJ_698fb654-4d93-4f97-b00b-93b904131327_terseLabel_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Jersey</link:label>
    <link:label id="lab_stpr_NJ_label_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW JERSEY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NJ" xlink:to="lab_stpr_NJ" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_c6baa2b7-f1db-4d82-94ab-08ff7cdfe4e7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_03e8a949-98f3-4faa-aae4-f4f84ee31573_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Bausch Health Companies Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_d9235a89-e387-4d8a-bea4-6d498e15cada_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_6bbd770f-0b5b-4cbf-ab21-2f1a73bfe946_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccumulatedLossesAvailableForFederalPurposes_b82e4a27-cb42-463f-8db2-c162b9145095_terseLabel_en-US" xlink:label="lab_bhc_AccumulatedLossesAvailableForFederalPurposes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated losses available for federal and provincial purposes</link:label>
    <link:label id="lab_bhc_AccumulatedLossesAvailableForFederalPurposes_label_en-US" xlink:label="lab_bhc_AccumulatedLossesAvailableForFederalPurposes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Losses Available for Federal Purposes</link:label>
    <link:label id="lab_bhc_AccumulatedLossesAvailableForFederalPurposes_documentation_en-US" xlink:label="lab_bhc_AccumulatedLossesAvailableForFederalPurposes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the details pertaining to accumulated losses available for federal and provincial purposes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccumulatedLossesAvailableForFederalPurposes" xlink:href="bhc-20220510.xsd#bhc_AccumulatedLossesAvailableForFederalPurposes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccumulatedLossesAvailableForFederalPurposes" xlink:to="lab_bhc_AccumulatedLossesAvailableForFederalPurposes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_fb4bd82b-0f20-4618-a3cf-62c9f023cde1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_EquipmentOnOperatingLeaseMember_6e293ef6-76f6-44c5-b937-20c5b299afa2_terseLabel_en-US" xlink:label="lab_bhc_EquipmentOnOperatingLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment on operating lease</link:label>
    <link:label id="lab_bhc_EquipmentOnOperatingLeaseMember_label_en-US" xlink:label="lab_bhc_EquipmentOnOperatingLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment On Operating Lease [Member]</link:label>
    <link:label id="lab_bhc_EquipmentOnOperatingLeaseMember_documentation_en-US" xlink:label="lab_bhc_EquipmentOnOperatingLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment On Operating Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EquipmentOnOperatingLeaseMember" xlink:href="bhc-20220510.xsd#bhc_EquipmentOnOperatingLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_EquipmentOnOperatingLeaseMember" xlink:to="lab_bhc_EquipmentOnOperatingLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_McKessonCorporationMember_e852511d-6009-4433-9bd2-eda1bda56781_terseLabel_en-US" xlink:label="lab_bhc_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation</link:label>
    <link:label id="lab_bhc_McKessonCorporationMember_label_en-US" xlink:label="lab_bhc_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mc Kesson Corporation [Member]</link:label>
    <link:label id="lab_bhc_McKessonCorporationMember_documentation_en-US" xlink:label="lab_bhc_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the major customer of the entity, McKesson Corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_McKessonCorporationMember" xlink:href="bhc-20220510.xsd#bhc_McKessonCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_McKessonCorporationMember" xlink:to="lab_bhc_McKessonCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_cea13472-9606-4aed-a103-03579206cf39_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_c560a68f-d540-43c4-bc39-0638a56b4fe5_terseLabel_en-US" xlink:label="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of variable consideration provisions</link:label>
    <link:label id="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_label_en-US" xlink:label="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Valuation And Qualifying Accounts [Table Text Block]</link:label>
    <link:label id="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_documentation_en-US" xlink:label="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Valuation And Qualifying Accounts [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:href="bhc-20220510.xsd#bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:to="lab_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_295ae5d0-5480-4484-8b07-28966611e377_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2f4b5681-0764-42d6-a6e5-094e57c58194_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of benefit from income taxes from the expected amount calculated by applying the Canadian statutory rate to loss before benefit of income taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_45f16de8-1d5b-4291-861d-eee3df700596_terseLabel_en-US" xlink:label="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairments</link:label>
    <link:label id="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_31f45e8a-d639-479d-94ee-3065afc339bd_verboseLabel_en-US" xlink:label="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairment</link:label>
    <link:label id="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_49351148-a725-4418-a896-12f39d333e37_negatedLabel_en-US" xlink:label="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairments</link:label>
    <link:label id="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_label_en-US" xlink:label="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss, Not Included In Asset Impairment Charges</link:label>
    <link:label id="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_documentation_en-US" xlink:label="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss, Not Included In Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:href="bhc-20220510.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:to="lab_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_103ba4ba-167e-4fbe-921f-ce36e1014018_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_8a0617d8-0a98-424b-a5e0-365360442fe0_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bausch Health Companies&#160;Inc. Shareholders' Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_b41be45f-ccef-4435-a9d5-f1b8d16d668f_verboseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment reporting information</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_b5cfff27-40a6-44b4-bd61-88b30e8ed7bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components and classification of financial assets and liabilities measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember_e65a03a1-0cfa-4562-9a87-64ce2e908a24_terseLabel_en-US" xlink:label="lab_bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.875% Senior Notes due May 2023, March 2019 Refinancing</link:label>
    <link:label id="lab_bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember_label_en-US" xlink:label="lab_bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.875% Senior Notes due May 2023, March 2019 Refinancing [Member]</link:label>
    <link:label id="lab_bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember_documentation_en-US" xlink:label="lab_bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.875% Senior Notes due May 2023, March 2019 Refinancing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember" xlink:href="bhc-20220510.xsd#bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember" xlink:to="lab_bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member_e7b28bc5-aefc-4a78-8ab7-5c25aeb532e4_terseLabel_en-US" xlink:label="lab_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spear Pharmaceuticals, Inc. And Spear Dermatology Products Inc.</link:label>
    <link:label id="lab_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member_label_en-US" xlink:label="lab_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spear Pharmaceuticals, Inc. And Spear Dermatology Products Inc. [Member]</link:label>
    <link:label id="lab_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member_documentation_en-US" xlink:label="lab_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spear Pharmaceuticals, Inc. And Spear Dermatology Products Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member" xlink:href="bhc-20220510.xsd#bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member" xlink:to="lab_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_PaymentForDebtAmortizationPrepaymentCost_386a76f5-0077-4947-b04f-9a2841284fa1_terseLabel_en-US" xlink:label="lab_bhc_PaymentForDebtAmortizationPrepaymentCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment, outstanding debt</link:label>
    <link:label id="lab_bhc_PaymentForDebtAmortizationPrepaymentCost_label_en-US" xlink:label="lab_bhc_PaymentForDebtAmortizationPrepaymentCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Debt Amortization Prepayment Cost</link:label>
    <link:label id="lab_bhc_PaymentForDebtAmortizationPrepaymentCost_documentation_en-US" xlink:label="lab_bhc_PaymentForDebtAmortizationPrepaymentCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Debt Amortization Prepayment Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForDebtAmortizationPrepaymentCost" xlink:href="bhc-20220510.xsd#bhc_PaymentForDebtAmortizationPrepaymentCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_PaymentForDebtAmortizationPrepaymentCost" xlink:to="lab_bhc_PaymentForDebtAmortizationPrepaymentCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0d66da63-7659-4e87-948d-238617de96d7_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_cc881933-85f8-47bb-b643-600f0cb3d502_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_ad41e6e2-7500-44d8-a2c7-ab82309726c7_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4a8538e9-1ba4-4d48-82ae-7aebcabedad4_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnfavorableRegulatoryActionMember_c80779b6-f53f-4347-98aa-8cf2799e69e0_terseLabel_en-US" xlink:label="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable Regulatory Action</link:label>
    <link:label id="lab_us-gaap_UnfavorableRegulatoryActionMember_label_en-US" xlink:label="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfavorable Regulatory Action [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnfavorableRegulatoryActionMember" xlink:to="lab_us-gaap_UnfavorableRegulatoryActionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_61f5773e-1cc1-4965-a741-a6c1313ab537_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_a00f349f-64b6-4cbf-b605-71a1dd7ddc5f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_f76dc850-5b73-4c44-a279-4fd47d1a2974_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_e1bed38e-142e-4f2e-b074-c74a114d94af_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of effect of hedging instruments on financial statements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SoltaMedicalSegmentMember_443c3d05-c344-4369-aaa7-8f7900b16cd2_terseLabel_en-US" xlink:label="lab_bhc_SoltaMedicalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solta Medical</link:label>
    <link:label id="lab_bhc_SoltaMedicalSegmentMember_label_en-US" xlink:label="lab_bhc_SoltaMedicalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solta Medical Segment [Member]</link:label>
    <link:label id="lab_bhc_SoltaMedicalSegmentMember_documentation_en-US" xlink:label="lab_bhc_SoltaMedicalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solta Medical Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember" xlink:href="bhc-20220510.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SoltaMedicalSegmentMember" xlink:to="lab_bhc_SoltaMedicalSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_c34ed6b7-6091-4c0d-aceb-0ef173c67bfd_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant_68bf7bd2-88b5-451b-b20f-7211d86d168e_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate fair market value on awards granted during any calendar year</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Plan Modification, Fair Market Value Limit On Annual Grant</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Plan Modification, Fair Market Value Limit On Annual Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" xlink:href="bhc-20220510.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_eb03a1d3-c5cd-4108-bb9e-ffadccb436ff_terseLabel_en-US" xlink:label="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates, Advertising Credits Portion</link:label>
    <link:label id="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_label_en-US" xlink:label="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates, Advertising Credits Portion [Member]</link:label>
    <link:label id="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_documentation_en-US" xlink:label="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates, Advertising Credits Portion [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:href="bhc-20220510.xsd#bhc_ReserveForRebatesAdvertisingCreditsPortionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:to="lab_bhc_ReserveForRebatesAdvertisingCreditsPortionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_dd11ba4d-e3f2-4a93-9c8e-ce87f62e081b_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash proceeds from divestiture</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8c053e19-69c0-42df-8794-6057092ec7e7_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_706027c0-d0a6-486a-ab15-61f3bcc81e63_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_5f49a957-9a76-47e9-9de5-09f2e7bba687_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_0c38d695-0164-4de8-b78b-c5389fe9a4c8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_18d3ef71-94d4-4267-82dc-f9d3511af9b4_terseLabel_en-US" xlink:label="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and other settlement deposits</link:label>
    <link:label id="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_label_en-US" xlink:label="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Cash Equivalents And Other Settlement Deposits, Fair Value Disclosure</link:label>
    <link:label id="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_documentation_en-US" xlink:label="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash And Cash Equivalents And Other Settlement Deposits, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:href="bhc-20220510.xsd#bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:to="lab_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_1cdf4d22-a297-4f89-921f-30258f2876da_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held For Sale</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_bb325065-aa14-499e-817e-89f80f061170_terseLabel_en-US" xlink:label="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Violation of Canadian Provincial Securities Legislation</link:label>
    <link:label id="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_label_en-US" xlink:label="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Violation of Canadian Provincial Securities Legislation [Member]</link:label>
    <link:label id="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_documentation_en-US" xlink:label="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Violation of Canadian Provincial Securities Legislation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:href="bhc-20220510.xsd#bhc_ViolationofCanadianProvincialSecuritiesLegislationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:to="lab_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_ff16aae5-2923-44d6-b583-0c478abe40cb_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherEquipmentAndLeaseholdImprovementMember_206b5cfe-d8b8-4cdf-99ec-9d9f5ce81038_terseLabel_en-US" xlink:label="lab_bhc_OtherEquipmentAndLeaseholdImprovementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other equipment and leasehold improvements</link:label>
    <link:label id="lab_bhc_OtherEquipmentAndLeaseholdImprovementMember_label_en-US" xlink:label="lab_bhc_OtherEquipmentAndLeaseholdImprovementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Equipment and Leasehold Improvement [Member]</link:label>
    <link:label id="lab_bhc_OtherEquipmentAndLeaseholdImprovementMember_documentation_en-US" xlink:label="lab_bhc_OtherEquipmentAndLeaseholdImprovementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents other equipment and leasehold improvements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherEquipmentAndLeaseholdImprovementMember" xlink:href="bhc-20220510.xsd#bhc_OtherEquipmentAndLeaseholdImprovementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherEquipmentAndLeaseholdImprovementMember" xlink:to="lab_bhc_OtherEquipmentAndLeaseholdImprovementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_28ecd1cd-f312-4484-9377-c02e3fac6051_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal proceedings and other matters</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9294f35a-5fff-4df8-8182-fbb6af6bd9a9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROPERTY, PLANT AND EQUIPMENT</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_e9692804-15f0-4eb6-b43c-e044a66db917_terseLabel_en-US" xlink:label="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for losses on trade receivables and inventories</link:label>
    <link:label id="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_label_en-US" xlink:label="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for Losses on Accounts Receivable and Inventories</link:label>
    <link:label id="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_documentation_en-US" xlink:label="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:href="bhc-20220510.xsd#bhc_AllowancesForLossesOnAccountsReceivableAndInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:to="lab_bhc_AllowancesForLossesOnAccountsReceivableAndInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_3ea93184-6d9c-4b41-8ade-c03b4e65a0d9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_5ce6afbd-8b1c-440b-bfae-b26b1848f8da_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected benefit obligation, beginning of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_44ecdd5f-0c6a-4d7b-80c3-01d46d8a9f33_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected benefit obligation, end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_e599b4e3-f70e-4663-a08a-ce6dbca33d22_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_19f48ec8-ce1e-4c91-9f67-b7d1d80f2add_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other current liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:to="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_51a34592-b724-41d9-bc32-5702b668bc04_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_345b44c8-b47f-4868-b784-c5d3dd463898_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of unamortized debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_a073d576-1fb9-44ac-a589-6f71a19f5cbf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_a01f9efb-6c09-416d-b1f0-efefe4756ee6_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_e8295acb-2a17-48ea-b8ee-a40f08f0a4f2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_6b654d28-51dc-40e3-a4e1-9e5db16f461e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pro-forma revenue</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption_79550c3b-f13f-4684-b469-75bd06fa5e2e_terseLabel_en-US" xlink:label="lab_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label id="lab_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption_label_en-US" xlink:label="lab_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability, Excluding Amount Recognized Upon Adoption</link:label>
    <link:label id="lab_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption_documentation_en-US" xlink:label="lab_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability, Excluding Amount Recognized Upon Adoption</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" xlink:href="bhc-20220510.xsd#bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" xlink:to="lab_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IncomeTaxReconciliationUncertainTaxPositions_08ba78ab-d0cd-45cd-85ee-ecfbdb71af73_negatedTerseLabel_en-US" xlink:label="lab_bhc_IncomeTaxReconciliationUncertainTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in uncertain tax positions</link:label>
    <link:label id="lab_bhc_IncomeTaxReconciliationUncertainTaxPositions_label_en-US" xlink:label="lab_bhc_IncomeTaxReconciliationUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Uncertain Tax Positions</link:label>
    <link:label id="lab_bhc_IncomeTaxReconciliationUncertainTaxPositions_documentation_en-US" xlink:label="lab_bhc_IncomeTaxReconciliationUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to uncertain tax positions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxReconciliationUncertainTaxPositions" xlink:href="bhc-20220510.xsd#bhc_IncomeTaxReconciliationUncertainTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IncomeTaxReconciliationUncertainTaxPositions" xlink:to="lab_bhc_IncomeTaxReconciliationUncertainTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c6dc27a0-feb6-4a30-b9b6-07a6d9266230_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_26d9296a-64ed-4b24-8bf3-26060065335a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">For Determining Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LuxembourgInlandRevenueMember_f160e4fc-e67c-4b77-9d77-c67ce128ff07_terseLabel_en-US" xlink:label="lab_us-gaap_LuxembourgInlandRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Luxembourg</link:label>
    <link:label id="lab_us-gaap_LuxembourgInlandRevenueMember_label_en-US" xlink:label="lab_us-gaap_LuxembourgInlandRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Luxembourg Inland Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LuxembourgInlandRevenueMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LuxembourgInlandRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LuxembourgInlandRevenueMember" xlink:to="lab_us-gaap_LuxembourgInlandRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_55e9df87-a9de-43eb-91b1-92e8fed0f788_terseLabel_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower To Shower Product Liability Litigation Alleging Caused Ovarian Cancer Mesothelioma Or Breast Cancer</link:label>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_label_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower To Shower Product Liability Litigation Alleging Caused Ovarian Cancer Mesothelioma Or Breast Cancer [Member]</link:label>
    <link:label id="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_documentation_en-US" xlink:label="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shower To Shower Product Liability Litigation Alleging Caused Ovarian Cancer Mesothelioma Or Breast Cancer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:href="bhc-20220510.xsd#bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:to="lab_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_SeniorNotes900DueDecember2025Member_ed5178fc-4212-4008-8a12-be3e41d94232_terseLabel_en-US" xlink:label="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.000% Senior Notes Due December 2025</link:label>
    <link:label id="lab_bhc_SeniorNotes900DueDecember2025Member_label_en-US" xlink:label="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes, 9.00%, Due December 2025 [Member]</link:label>
    <link:label id="lab_bhc_SeniorNotes900DueDecember2025Member_documentation_en-US" xlink:label="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">9.00% Senior Notes due December 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes900DueDecember2025Member" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes900DueDecember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_SeniorNotes900DueDecember2025Member" xlink:to="lab_bhc_SeniorNotes900DueDecember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_6913cc80-5431-4a7c-b95a-b1e07ad06b66_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_28ef6511-79b9-43d7-8c92-479589498c42_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_c9816224-757b-4b6e-be25-c836192346fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_a42c6d30-143a-478a-a657-2b7d88df87ba_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_A6.125SeniorNotesdueApril2025Member_c7977e6a-543a-4021-ae34-cbef01a09b43_terseLabel_en-US" xlink:label="lab_bhc_A6.125SeniorNotesdueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% Senior Unsecured Notes due April 2025</link:label>
    <link:label id="lab_bhc_A6.125SeniorNotesdueApril2025Member_label_en-US" xlink:label="lab_bhc_A6.125SeniorNotesdueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% Senior Notes due April 2025 [Member]</link:label>
    <link:label id="lab_bhc_A6.125SeniorNotesdueApril2025Member_documentation_en-US" xlink:label="lab_bhc_A6.125SeniorNotesdueApril2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.125% Senior Notes due April 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A6.125SeniorNotesdueApril2025Member" xlink:href="bhc-20220510.xsd#bhc_A6.125SeniorNotesdueApril2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_A6.125SeniorNotesdueApril2025Member" xlink:to="lab_bhc_A6.125SeniorNotesdueApril2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_c6341391-5f29-4e16-924b-f9fd8416ecf0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Payment for Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NonU.S.DevelopedMarketsMember_26150f98-85ad-4fe5-b427-25736b9ec22f_terseLabel_en-US" xlink:label="lab_bhc_NonU.S.DevelopedMarketsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Worldwide developed markets</link:label>
    <link:label id="lab_bhc_NonU.S.DevelopedMarketsMember_label_en-US" xlink:label="lab_bhc_NonU.S.DevelopedMarketsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. Developed Markets [Member]</link:label>
    <link:label id="lab_bhc_NonU.S.DevelopedMarketsMember_documentation_en-US" xlink:label="lab_bhc_NonU.S.DevelopedMarketsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. Developed Markets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonU.S.DevelopedMarketsMember" xlink:href="bhc-20220510.xsd#bhc_NonU.S.DevelopedMarketsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NonU.S.DevelopedMarketsMember" xlink:to="lab_bhc_NonU.S.DevelopedMarketsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_6a16781d-58c1-4d25-a4c7-cc2e4883c665_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_520c0800-1d9e-41fa-afa3-3e7ab3f1fd9c_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_5136eb20-8a86-4fe0-8b00-e24b979c3f0b_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate_a618b484-4b04-4639-82bc-bf31d857c6a4_terseLabel_en-US" xlink:label="lab_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retrospective effect of application of new accounting standard</link:label>
    <link:label id="lab_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate_label_en-US" xlink:label="lab_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Effect Of Retrospective Application Of Accounting Standards Update</link:label>
    <link:label id="lab_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate_documentation_en-US" xlink:label="lab_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Effect Of Retrospective Application Of Accounting Standards Update</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" xlink:href="bhc-20220510.xsd#bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" xlink:to="lab_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TaxBenefitRecognitionMeasurementPercentage_c24c5f7e-151f-42b6-957d-0ee63252f7e6_terseLabel_en-US" xlink:label="lab_bhc_TaxBenefitRecognitionMeasurementPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit recognition, measurement percentage (greater than)</link:label>
    <link:label id="lab_bhc_TaxBenefitRecognitionMeasurementPercentage_label_en-US" xlink:label="lab_bhc_TaxBenefitRecognitionMeasurementPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Benefit Recognition, Measurement Percentage</link:label>
    <link:label id="lab_bhc_TaxBenefitRecognitionMeasurementPercentage_documentation_en-US" xlink:label="lab_bhc_TaxBenefitRecognitionMeasurementPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Benefit Recognition, Measurement Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaxBenefitRecognitionMeasurementPercentage" xlink:href="bhc-20220510.xsd#bhc_TaxBenefitRecognitionMeasurementPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TaxBenefitRecognitionMeasurementPercentage" xlink:to="lab_bhc_TaxBenefitRecognitionMeasurementPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_c79c8a94-b137-4f84-bb5a-f48121220f0f_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_23af557a-4d76-4432-8271-a25a43cd4457_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of loss before benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_b4100d7d-e69a-4efd-9a25-22a2f7ee4fce_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_NewRestatedCreditAgreementMember_0b5052a0-bbd6-4fb9-a589-db079f4b3113_terseLabel_en-US" xlink:label="lab_bhc_NewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Restated Credit Agreement</link:label>
    <link:label id="lab_bhc_NewRestatedCreditAgreementMember_label_en-US" xlink:label="lab_bhc_NewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Restated Credit Agreement [Member]</link:label>
    <link:label id="lab_bhc_NewRestatedCreditAgreementMember_documentation_en-US" xlink:label="lab_bhc_NewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Restated Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NewRestatedCreditAgreementMember" xlink:href="bhc-20220510.xsd#bhc_NewRestatedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_NewRestatedCreditAgreementMember" xlink:to="lab_bhc_NewRestatedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_66eba0ec-551a-4468-a6e7-c325a3db9d3d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandImprovementsMember_b724f1c4-8d5e-4e23-bce3-5e8fde39e8e2_terseLabel_en-US" xlink:label="lab_us-gaap_LandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land improvements</link:label>
    <link:label id="lab_us-gaap_LandImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandImprovementsMember" xlink:to="lab_us-gaap_LandImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2531c53c-cfc7-4d2d-8b4e-9b6506c33860_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_3860632a-35b2-4ea1-b665-f678921f3a0f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_c61d1c14-a1e1-479a-ae55-27cf1e36ef40_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_d60d5d5f-7253-434a-beb8-4f852b853777_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_e4ede9a2-66ec-46e5-9c91-0fd72b5e1def_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_68bfafb6-aab9-4ebd-b352-c426fe3b66dc_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0d0434f7-b562-4096-b32e-0c8d53c178a5_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_cd2effe3-d50c-4f8d-bc28-8925ed57fe12_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance_44686bd8-7b27-48e3-9a58-c4f287dd9413_terseLabel_en-US" xlink:label="lab_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit accrual, interest percentage earned on cash balance</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance_label_en-US" xlink:label="lab_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Accrual, Interest Percentage Earned On Cash Balance</link:label>
    <link:label id="lab_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance_documentation_en-US" xlink:label="lab_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Accrual, Interest Percentage Earned On Cash Balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance" xlink:href="bhc-20220510.xsd#bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance" xlink:to="lab_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_9750751a-0bc2-44ab-b3b9-501387e4ba3e_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b27d1d3c-bdb5-4008-a025-0f7907ff892b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_67e03a10-d3da-4f2d-8e6d-35843b7d581d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_df66dd94-a622-48e2-8b33-582af99e7aeb_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_891b5293-2e4d-496b-a438-cddcdceb61d1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-offs</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_f17a6a5a-68bf-4398-a2c4-15ef6776c10e_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapse of statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_23b7e724-e005-4873-b16f-d3251bb7d78d_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_0a8ed04e-22e6-4b6d-b72e-6fc959818314_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014Member_d344b6cb-b80f-48c7-bb9c-f4adac98a771_terseLabel_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Incentive Plan 2014</link:label>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014Member_label_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Incentive Plan 2014 [Member]</link:label>
    <link:label id="lab_bhc_OmnibusIncentivePlan2014Member_documentation_en-US" xlink:label="lab_bhc_OmnibusIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Omnibus Incentive Plan 2014 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014Member" xlink:href="bhc-20220510.xsd#bhc_OmnibusIncentivePlan2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OmnibusIncentivePlan2014Member" xlink:to="lab_bhc_OmnibusIncentivePlan2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrencySwapMember_12e0a5ae-efff-4abf-b9c8-222885d9ad25_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross-currency swaps</link:label>
    <link:label id="lab_us-gaap_CurrencySwapMember_d8dfe2ea-2e24-4bb0-9b67-88890025e51c_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross-currency swaps</link:label>
    <link:label id="lab_us-gaap_CurrencySwapMember_label_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencySwapMember" xlink:to="lab_us-gaap_CurrencySwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_OtherCountriesMember_c6fbb96e-54e5-443e-b056-47fe084b6f00_terseLabel_en-US" xlink:label="lab_bhc_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_bhc_OtherCountriesMember_label_en-US" xlink:label="lab_bhc_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:label id="lab_bhc_OtherCountriesMember_documentation_en-US" xlink:label="lab_bhc_OtherCountriesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Countries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherCountriesMember" xlink:href="bhc-20220510.xsd#bhc_OtherCountriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_OtherCountriesMember" xlink:to="lab_bhc_OtherCountriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_003c6b07-86c0-455c-8bd4-0ae8568a7735_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_0fb99889-11ed-41c3-bf23-c64a74eed1d1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Projected Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_3414536f-c95e-4ec4-b2d8-70a55dd9cf1e_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_1caf33ed-7d2d-462d-bbf9-d7a21b7d3c40_verboseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_80ecb714-ed4e-4577-a06c-6bdb05a2c4d7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AllegroOphthalmicsLLCMember_88f0f898-8f48-460d-afc1-6b4e4bf69084_terseLabel_en-US" xlink:label="lab_bhc_AllegroOphthalmicsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allegro</link:label>
    <link:label id="lab_bhc_AllegroOphthalmicsLLCMember_label_en-US" xlink:label="lab_bhc_AllegroOphthalmicsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allegro Ophthalmics, LLC [Member]</link:label>
    <link:label id="lab_bhc_AllegroOphthalmicsLLCMember_documentation_en-US" xlink:label="lab_bhc_AllegroOphthalmicsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allegro Ophthalmics, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllegroOphthalmicsLLCMember" xlink:href="bhc-20220510.xsd#bhc_AllegroOphthalmicsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AllegroOphthalmicsLLCMember" xlink:to="lab_bhc_AllegroOphthalmicsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7fec57bc-697e-428d-81d8-86c6cfd04857_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock_f5c41b2e-5023-4dad-8c18-ea64fe92be97_terseLabel_en-US" xlink:label="lab_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of estimated useful lives of intangible assets</link:label>
    <link:label id="lab_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Useful Lives of Finite Lived Intangible Assets [Table Text Block]</link:label>
    <link:label id="lab_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock_documentation_en-US" xlink:label="lab_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of estimated useful lives of major classes of finite-lived intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="bhc-20220510.xsd#bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_4f9b8f15-4a18-4c63-83c7-b996898a145a_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments to acquire certain assets and assumed liabilities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_LitigationwithFormerSalixCEOMember_c8d391ec-9494-4318-ae7f-fbd338e3220a_terseLabel_en-US" xlink:label="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation with Former Salix CEO</link:label>
    <link:label id="lab_bhc_LitigationwithFormerSalixCEOMember_label_en-US" xlink:label="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation with Former Salix CEO [Member]</link:label>
    <link:label id="lab_bhc_LitigationwithFormerSalixCEOMember_documentation_en-US" xlink:label="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation with Former Salix CEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationwithFormerSalixCEOMember" xlink:href="bhc-20220510.xsd#bhc_LitigationwithFormerSalixCEOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_LitigationwithFormerSalixCEOMember" xlink:to="lab_bhc_LitigationwithFormerSalixCEOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b4485256-95e3-4b1a-8c12-b17b6d4d2f7b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_863dba91-2e31-404a-bcb7-bac9d5b1b92f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange and other</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnutilizedITInfrastructureImprovementProjectMember_9276c53a-9c57-46f4-9a98-c9c5fb36fd54_terseLabel_en-US" xlink:label="lab_bhc_UnutilizedITInfrastructureImprovementProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unutilized IT Infrastructure Improvement Project</link:label>
    <link:label id="lab_bhc_UnutilizedITInfrastructureImprovementProjectMember_label_en-US" xlink:label="lab_bhc_UnutilizedITInfrastructureImprovementProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unutilized IT Infrastructure Improvement Project [Member]</link:label>
    <link:label id="lab_bhc_UnutilizedITInfrastructureImprovementProjectMember_documentation_en-US" xlink:label="lab_bhc_UnutilizedITInfrastructureImprovementProjectMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unutilized IT Infrastructure Improvement Project</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnutilizedITInfrastructureImprovementProjectMember" xlink:href="bhc-20220510.xsd#bhc_UnutilizedITInfrastructureImprovementProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnutilizedITInfrastructureImprovementProjectMember" xlink:to="lab_bhc_UnutilizedITInfrastructureImprovementProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_810c0126-0245-4216-84b3-cd632a874b47_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment reporting information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ReserveForRebatesMember_33654290-28d9-4dea-abfc-47640feb2ac9_terseLabel_en-US" xlink:label="lab_bhc_ReserveForRebatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates</link:label>
    <link:label id="lab_bhc_ReserveForRebatesMember_label_en-US" xlink:label="lab_bhc_ReserveForRebatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates [Member]</link:label>
    <link:label id="lab_bhc_ReserveForRebatesMember_documentation_en-US" xlink:label="lab_bhc_ReserveForRebatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve For Rebates [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesMember" xlink:href="bhc-20220510.xsd#bhc_ReserveForRebatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ReserveForRebatesMember" xlink:to="lab_bhc_ReserveForRebatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_1362a2fa-4f95-47a3-8939-f3ed12984913_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of accrued legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_9565e8c1-8443-4940-98a2-8e3b28309fd4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_05b45738-1439-4525-875d-b7a618e3b185_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ApotexIncLitigationMember_ec85889f-9ff8-4a3c-9c69-9120f8feb5bd_terseLabel_en-US" xlink:label="lab_bhc_ApotexIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apotex Inc. Litigation</link:label>
    <link:label id="lab_bhc_ApotexIncLitigationMember_label_en-US" xlink:label="lab_bhc_ApotexIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apotex Inc. Litigation [Member]</link:label>
    <link:label id="lab_bhc_ApotexIncLitigationMember_documentation_en-US" xlink:label="lab_bhc_ApotexIncLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apotex Inc. Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ApotexIncLitigationMember" xlink:href="bhc-20220510.xsd#bhc_ApotexIncLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ApotexIncLitigationMember" xlink:to="lab_bhc_ApotexIncLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncurrentAssets_37acf94d-150f-40e9-b1db-cff86a205efa_terseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived assets</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets" xlink:to="lab_us-gaap_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_824e4e9b-ac70-4130-9c7f-73ee5b1a032f_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Funds Effective Swap Rate</link:label>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_label_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:to="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_466761eb-a289-40f5-856c-fe401e1c13b5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of compensation increase</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions_226ecbc8-8b8e-4854-be36-bb01aa115640_terseLabel_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, net increase for tax positions of prior years</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Net Increase Resulting From Prior Period Tax Positions</link:label>
    <link:label id="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions_documentation_en-US" xlink:label="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Net Increase Resulting From Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions" xlink:href="bhc-20220510.xsd#bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions" xlink:to="lab_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_b46b767b-5033-4829-b2cb-29e6882e5e32_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expenses</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock_71320b7a-eccc-487a-997d-f444789fe2a5_terseLabel_en-US" xlink:label="lab_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of other operating lease information</link:label>
    <link:label id="lab_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock_label_en-US" xlink:label="lab_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Operating Lease Information, Lessee [Table Text Block]</link:label>
    <link:label id="lab_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock_documentation_en-US" xlink:label="lab_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Operating Lease Information, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock" xlink:href="bhc-20220510.xsd#bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock" xlink:to="lab_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_25ad7500-4ca7-48e8-b260-4731eab1896e_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_AssetsAndLiabilitiesLesseeTableTextBlock_de980d95-cb3d-4fb7-ae90-390a0d309f25_terseLabel_en-US" xlink:label="lab_bhc_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of right-of-use assets and right-of-use liabilities</link:label>
    <link:label id="lab_bhc_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_bhc_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_bhc_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_bhc_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="bhc-20220510.xsd#bhc_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_bhc_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IncomeTaxTable_e63e4739-317c-472f-8cce-a4bf181733bd_terseLabel_en-US" xlink:label="lab_bhc_IncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Table]</link:label>
    <link:label id="lab_bhc_IncomeTaxTable_label_en-US" xlink:label="lab_bhc_IncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax [Table]</link:label>
    <link:label id="lab_bhc_IncomeTaxTable_documentation_en-US" xlink:label="lab_bhc_IncomeTaxTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of information relating to income taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxTable" xlink:href="bhc-20220510.xsd#bhc_IncomeTaxTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IncomeTaxTable" xlink:to="lab_bhc_IncomeTaxTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_30b41e3d-f7ac-4dca-8d19-a9f9f34a0a47_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Other non-current assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_7c70264c-2452-4553-8e35-1c18c0f47784_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized actuarial losses</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ValeantUSSecuritiesLitigationMember_0598f6ad-7f5c-4c45-b4bc-8120e5d5e711_terseLabel_en-US" xlink:label="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valeant US Securities Litigation</link:label>
    <link:label id="lab_bhc_ValeantUSSecuritiesLitigationMember_fb4f573e-f266-42a4-a363-fad26bb15b91_verboseLabel_en-US" xlink:label="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valeant US Securities Litigation</link:label>
    <link:label id="lab_bhc_ValeantUSSecuritiesLitigationMember_label_en-US" xlink:label="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valeant US Securities Litigation [Member]</link:label>
    <link:label id="lab_bhc_ValeantUSSecuritiesLitigationMember_documentation_en-US" xlink:label="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valeant US Securities Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember" xlink:href="bhc-20220510.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ValeantUSSecuritiesLitigationMember" xlink:to="lab_bhc_ValeantUSSecuritiesLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance_ee497cad-832e-4fe8-9a8c-0dfd4e41e44d_negatedTerseLabel_en-US" xlink:label="lab_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance related to foreign tax credits and NOLs</link:label>
    <link:label id="lab_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance_label_en-US" xlink:label="lab_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Change in Operating Losses Valuation Allowance</link:label>
    <link:label id="lab_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance_documentation_en-US" xlink:label="lab_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to change in valuation allowance related to operating losses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" xlink:href="bhc-20220510.xsd#bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" xlink:to="lab_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_9724af03-ace5-41cf-90fc-d7182f7ca984_terseLabel_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation, Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:href="bhc-20220510.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_3df4fff7-336f-4505-b613-209b5f46ec89_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_5d66bf81-d8a5-4ab8-923a-964ee7414f02_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of year</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_a763b6b4-2ca7-4156-95a2-513946706288_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cooperative advertising credits included in rebates</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_fe29d4ae-14f8-4a8a-9f9c-e8f67414e328_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_e46d0ca6-a434-4f53-83c6-0d9978e31734_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_7a38a452-4282-467a-8c03-0e87a6e210a6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_4e18dffe-51e5-464d-81c0-9eb28319b728_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_d2e42137-cf2c-4433-b9e8-30cea96b36d1_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_b5ab8734-4a37-4376-8ab0-c3c869f75af0_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_90cb683d-2e9e-4eae-aa8c-48a5d4053adb_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_5063f688-2679-45f7-b35f-2301dcbba599_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized discounts</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_06e45798-d9b8-49f8-990a-6dddc642401b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetDomain_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetDomain" xlink:to="lab_us-gaap_DeferredTaxAssetDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3a5cfe9f-a7fc-4e62-81ef-66d28803b720_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bhc_TermLoanBFacilityNewRestatedCreditAgreementMember_6fbffc38-174e-4f5e-be89-96bb08b70f54_terseLabel_en-US" xlink:label="lab_bhc_TermLoanBFacilityNewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility, New Restated Credit Agreement</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityNewRestatedCreditAgreementMember_label_en-US" xlink:label="lab_bhc_TermLoanBFacilityNewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility, New Restated Credit Agreement [Member]</link:label>
    <link:label id="lab_bhc_TermLoanBFacilityNewRestatedCreditAgreementMember_documentation_en-US" xlink:label="lab_bhc_TermLoanBFacilityNewRestatedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B Facility, New Restated Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityNewRestatedCreditAgreementMember" xlink:href="bhc-20220510.xsd#bhc_TermLoanBFacilityNewRestatedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bhc_TermLoanBFacilityNewRestatedCreditAgreementMember" xlink:to="lab_bhc_TermLoanBFacilityNewRestatedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201613Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-13 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>bhc-20220510_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:9acca3cc-2386-49dd-bd2b-e67723848b1a,g:d4f0cfd5-5dd4-484a-81ac-21ef5810b617-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.bauschhealth.com/role/Document" xlink:type="simple" xlink:href="bhc-20220510.xsd#Document"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/Document" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_f879e87e-bf39-46f9-ab08-36628960b518" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_6583ff82-02b3-4089-af00-0eb2a18d341f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f879e87e-bf39-46f9-ab08-36628960b518" xlink:to="loc_dei_DocumentType_6583ff82-02b3-4089-af00-0eb2a18d341f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6fafc899-0747-4f15-aabb-1ebd9b3069fd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f879e87e-bf39-46f9-ab08-36628960b518" xlink:to="loc_dei_DocumentPeriodEndDate_6fafc899-0747-4f15-aabb-1ebd9b3069fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_d2e20a7b-ddab-46d9-a453-211640a293e6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f879e87e-bf39-46f9-ab08-36628960b518" xlink:to="loc_dei_EntityRegistrantName_d2e20a7b-ddab-46d9-a453-211640a293e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_27808434-2b4b-45ef-a6f0-cdc9afb734a1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f879e87e-bf39-46f9-ab08-36628960b518" xlink:to="loc_dei_EntityIncorporationStateCountryCode_27808434-2b4b-45ef-a6f0-cdc9afb734a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_bcd027b5-293b-48d2-a06e-75703f6aaf19" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f879e87e-bf39-46f9-ab08-36628960b518" xlink:to="loc_dei_EntityAddressCountry_bcd027b5-293b-48d2-a06e-75703f6aaf19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a90b91fa-d2b3-4a36-b55a-8f6eb04bbe55" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f879e87e-bf39-46f9-ab08-36628960b518" xlink:to="loc_dei_EntityFileNumber_a90b91fa-d2b3-4a36-b55a-8f6eb04bbe55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_fa17f0d9-8dac-47ce-80fb-0a6ac782ea41" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f879e87e-bf39-46f9-ab08-36628960b518" xlink:to="loc_dei_EntityTaxIdentificationNumber_fa17f0d9-8dac-47ce-80fb-0a6ac782ea41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a7473267-c7ab-4575-b2a9-256e4be43bd9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f879e87e-bf39-46f9-ab08-36628960b518" xlink:to="loc_dei_EntityAddressAddressLine1_a7473267-c7ab-4575-b2a9-256e4be43bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_150d5951-1e38-48ed-a11d-4237392b3a2e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f879e87e-bf39-46f9-ab08-36628960b518" xlink:to="loc_dei_EntityAddressCityOrTown_150d5951-1e38-48ed-a11d-4237392b3a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0a13560e-4d80-4e63-8070-79a988bc3b45" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f879e87e-bf39-46f9-ab08-36628960b518" xlink:to="loc_dei_EntityAddressStateOrProvince_0a13560e-4d80-4e63-8070-79a988bc3b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b832154a-979e-4ea0-9fdb-0ef3a76a88fa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f879e87e-bf39-46f9-ab08-36628960b518" xlink:to="loc_dei_EntityAddressPostalZipCode_b832154a-979e-4ea0-9fdb-0ef3a76a88fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_2a7ef4e7-3aa2-48ea-b6ed-47792e2a3ea2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f879e87e-bf39-46f9-ab08-36628960b518" xlink:to="loc_dei_CityAreaCode_2a7ef4e7-3aa2-48ea-b6ed-47792e2a3ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_f1d8163c-c9e9-4ffb-a578-6cb4aba5978d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f879e87e-bf39-46f9-ab08-36628960b518" xlink:to="loc_dei_LocalPhoneNumber_f1d8163c-c9e9-4ffb-a578-6cb4aba5978d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_94efd0b7-c660-43f2-bd22-17ffbd114dd7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f879e87e-bf39-46f9-ab08-36628960b518" xlink:to="loc_dei_WrittenCommunications_94efd0b7-c660-43f2-bd22-17ffbd114dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_39b87b4b-1fa8-4f1b-9978-ee623fa85b9c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f879e87e-bf39-46f9-ab08-36628960b518" xlink:to="loc_dei_SolicitingMaterial_39b87b4b-1fa8-4f1b-9978-ee623fa85b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_331d6ad3-b85a-46cb-819c-29bf393acd42" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f879e87e-bf39-46f9-ab08-36628960b518" xlink:to="loc_dei_PreCommencementTenderOffer_331d6ad3-b85a-46cb-819c-29bf393acd42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_9ac3f352-4cb7-4e2a-9415-439e4d2783cb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f879e87e-bf39-46f9-ab08-36628960b518" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_9ac3f352-4cb7-4e2a-9415-439e4d2783cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_5fb14dfe-0839-4725-a369-81bc30ba2532" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f879e87e-bf39-46f9-ab08-36628960b518" xlink:to="loc_dei_Security12bTitle_5fb14dfe-0839-4725-a369-81bc30ba2532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a6aa9e9c-7f0f-4852-b290-30c7d86b22e4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f879e87e-bf39-46f9-ab08-36628960b518" xlink:to="loc_dei_TradingSymbol_a6aa9e9c-7f0f-4852-b290-30c7d86b22e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_acba32be-0cb4-4aaf-b2d3-94d22e981058" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f879e87e-bf39-46f9-ab08-36628960b518" xlink:to="loc_dei_SecurityExchangeName_acba32be-0cb4-4aaf-b2d3-94d22e981058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_774b2af7-1d94-45f7-8943-236996f0b856" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f879e87e-bf39-46f9-ab08-36628960b518" xlink:to="loc_dei_EntityEmergingGrowthCompany_774b2af7-1d94-45f7-8943-236996f0b856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e74255ac-a05e-4e89-8094-da5ecaf355e1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f879e87e-bf39-46f9-ab08-36628960b518" xlink:to="loc_dei_EntityCentralIndexKey_e74255ac-a05e-4e89-8094-da5ecaf355e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_36f51bc2-aef1-436f-9ddb-f1130a3a6544" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_f879e87e-bf39-46f9-ab08-36628960b518" xlink:to="loc_dei_AmendmentFlag_36f51bc2-aef1-436f-9ddb-f1130a3a6544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bhc-20220510.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_fc619f50-8e50-40e9-a307-72c61a316d68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_0e469f4c-8165-47b1-88d2-4b8bf93cbd21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fc619f50-8e50-40e9-a307-72c61a316d68" xlink:to="loc_us-gaap_AssetsAbstract_0e469f4c-8165-47b1-88d2-4b8bf93cbd21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_d5dca4b6-fb04-4eab-8a8b-12e9f3753dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0e469f4c-8165-47b1-88d2-4b8bf93cbd21" xlink:to="loc_us-gaap_AssetsCurrentAbstract_d5dca4b6-fb04-4eab-8a8b-12e9f3753dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_64fd1222-c138-4786-b217-6b7b3bb9fb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d5dca4b6-fb04-4eab-8a8b-12e9f3753dd2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_64fd1222-c138-4786-b217-6b7b3bb9fb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_13e2d575-6a66-40d7-ab75-82664c7b291c" xlink:href="bhc-20220510.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d5dca4b6-fb04-4eab-8a8b-12e9f3753dd2" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_13e2d575-6a66-40d7-ab75-82664c7b291c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_a28bf6d0-4f05-4e45-a24e-440fdabc06b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d5dca4b6-fb04-4eab-8a8b-12e9f3753dd2" xlink:to="loc_us-gaap_ReceivablesNetCurrent_a28bf6d0-4f05-4e45-a24e-440fdabc06b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_31023a52-a0b1-4db8-8546-4d600d96f30b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d5dca4b6-fb04-4eab-8a8b-12e9f3753dd2" xlink:to="loc_us-gaap_InventoryNet_31023a52-a0b1-4db8-8546-4d600d96f30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ad2f58e3-6362-4b95-9ffa-bd5cf51f4810" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d5dca4b6-fb04-4eab-8a8b-12e9f3753dd2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ad2f58e3-6362-4b95-9ffa-bd5cf51f4810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e9a3a1f3-742a-494b-b621-aa35f33ed975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_d5dca4b6-fb04-4eab-8a8b-12e9f3753dd2" xlink:to="loc_us-gaap_AssetsCurrent_e9a3a1f3-742a-494b-b621-aa35f33ed975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e9d2e606-5117-4c97-8c87-75bce5fb1714" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0e469f4c-8165-47b1-88d2-4b8bf93cbd21" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e9d2e606-5117-4c97-8c87-75bce5fb1714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8f97da25-a78b-49d3-ab74-e410a1e50351" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0e469f4c-8165-47b1-88d2-4b8bf93cbd21" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8f97da25-a78b-49d3-ab74-e410a1e50351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_34bae971-a13a-4ce0-89a2-f1e09e8b4573" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0e469f4c-8165-47b1-88d2-4b8bf93cbd21" xlink:to="loc_us-gaap_Goodwill_34bae971-a13a-4ce0-89a2-f1e09e8b4573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_52eb9be5-67d4-4138-9589-89f13596a0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0e469f4c-8165-47b1-88d2-4b8bf93cbd21" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_52eb9be5-67d4-4138-9589-89f13596a0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_36ef0960-68d6-486d-bbf0-779a1a4e3d11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0e469f4c-8165-47b1-88d2-4b8bf93cbd21" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_36ef0960-68d6-486d-bbf0-779a1a4e3d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_754697df-59a4-44b6-bd0c-4f6c1a4fee4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0e469f4c-8165-47b1-88d2-4b8bf93cbd21" xlink:to="loc_us-gaap_Assets_754697df-59a4-44b6-bd0c-4f6c1a4fee4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_56fd878b-8e82-4e92-9665-d162606c74f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fc619f50-8e50-40e9-a307-72c61a316d68" xlink:to="loc_us-gaap_LiabilitiesAbstract_56fd878b-8e82-4e92-9665-d162606c74f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_8d37f0e9-a9c2-42bc-814a-43dd3f381430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_56fd878b-8e82-4e92-9665-d162606c74f6" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_8d37f0e9-a9c2-42bc-814a-43dd3f381430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7fd71091-24d8-466a-9598-7d4e4cccf8da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8d37f0e9-a9c2-42bc-814a-43dd3f381430" xlink:to="loc_us-gaap_AccountsPayableCurrent_7fd71091-24d8-466a-9598-7d4e4cccf8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_8d8caef9-c37c-49b8-8ec3-3732e2989741" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8d37f0e9-a9c2-42bc-814a-43dd3f381430" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_8d8caef9-c37c-49b8-8ec3-3732e2989741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4b591a33-708e-421b-985c-0f1b1039380e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8d37f0e9-a9c2-42bc-814a-43dd3f381430" xlink:to="loc_us-gaap_LiabilitiesCurrent_4b591a33-708e-421b-985c-0f1b1039380e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_4837a733-182b-44fb-9ac8-61b284382a8c" xlink:href="bhc-20220510.xsd#bhc_BusinessCombinationContingentConsiderationNoncurrentLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_56fd878b-8e82-4e92-9665-d162606c74f6" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability_4837a733-182b-44fb-9ac8-61b284382a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_15ae262e-7570-4c71-89de-a935c7d87a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_56fd878b-8e82-4e92-9665-d162606c74f6" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_15ae262e-7570-4c71-89de-a935c7d87a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_5a15341f-0bbc-41c7-ad61-45d2722bdda7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_56fd878b-8e82-4e92-9665-d162606c74f6" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_5a15341f-0bbc-41c7-ad61-45d2722bdda7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_35c854d6-a51e-4887-9736-6a723953ad4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_56fd878b-8e82-4e92-9665-d162606c74f6" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_35c854d6-a51e-4887-9736-6a723953ad4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d00d722a-0be4-4b2e-b785-2c0fb8b65b89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_56fd878b-8e82-4e92-9665-d162606c74f6" xlink:to="loc_us-gaap_Liabilities_d00d722a-0be4-4b2e-b785-2c0fb8b65b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_215cc8f0-c4f4-40ac-bd09-2fdd3fea67e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fc619f50-8e50-40e9-a307-72c61a316d68" xlink:to="loc_us-gaap_CommitmentsAndContingencies_215cc8f0-c4f4-40ac-bd09-2fdd3fea67e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_ae3bda7e-a813-4ddf-826d-dc6655cd1d62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fc619f50-8e50-40e9-a307-72c61a316d68" xlink:to="loc_us-gaap_StockholdersEquityAbstract_ae3bda7e-a813-4ddf-826d-dc6655cd1d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d0888ca0-97ca-484d-b0e6-2c9345e6d019" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ae3bda7e-a813-4ddf-826d-dc6655cd1d62" xlink:to="loc_us-gaap_CommonStockValue_d0888ca0-97ca-484d-b0e6-2c9345e6d019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6b0d12f5-d887-4b9b-89a0-2fd19601f621" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ae3bda7e-a813-4ddf-826d-dc6655cd1d62" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_6b0d12f5-d887-4b9b-89a0-2fd19601f621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_140964ca-4e97-4ad5-be40-11214f9908a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ae3bda7e-a813-4ddf-826d-dc6655cd1d62" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_140964ca-4e97-4ad5-be40-11214f9908a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_16ea23c3-1654-4d07-933b-f2e3580e757b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ae3bda7e-a813-4ddf-826d-dc6655cd1d62" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_16ea23c3-1654-4d07-933b-f2e3580e757b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1c7dea90-9d8c-4adc-8ff3-d8914cafd050" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ae3bda7e-a813-4ddf-826d-dc6655cd1d62" xlink:to="loc_us-gaap_StockholdersEquity_1c7dea90-9d8c-4adc-8ff3-d8914cafd050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_fe7fcf14-c4de-424a-baa0-cabc9da5dfc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ae3bda7e-a813-4ddf-826d-dc6655cd1d62" xlink:to="loc_us-gaap_MinorityInterest_fe7fcf14-c4de-424a-baa0-cabc9da5dfc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b801eb47-3bf9-43d5-90d0-dc4ceb394404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ae3bda7e-a813-4ddf-826d-dc6655cd1d62" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b801eb47-3bf9-43d5-90d0-dc4ceb394404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_0f8a90d5-6e19-411a-9787-8ac83df55612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fc619f50-8e50-40e9-a307-72c61a316d68" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_0f8a90d5-6e19-411a-9787-8ac83df55612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="bhc-20220510.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c941694e-fa21-4bac-a020-c7cc7f67db84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_cc9f91bd-ca9e-408c-9929-bc3e9acb653a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c941694e-fa21-4bac-a020-c7cc7f67db84" xlink:to="loc_us-gaap_CommonStockSharesIssued_cc9f91bd-ca9e-408c-9929-bc3e9acb653a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_88b33377-2b0e-47eb-8b81-79de8a019479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c941694e-fa21-4bac-a020-c7cc7f67db84" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_88b33377-2b0e-47eb-8b81-79de8a019479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bhc-20220510.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_de0fddf2-d339-4338-be95-50d55b11c984" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_593a1a48-74a2-4dbb-b826-1d14ab942793" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_de0fddf2-d339-4338-be95-50d55b11c984" xlink:to="loc_us-gaap_StatementTable_593a1a48-74a2-4dbb-b826-1d14ab942793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_72db89e6-840c-44f8-80a1-9843b60a8526" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_593a1a48-74a2-4dbb-b826-1d14ab942793" xlink:to="loc_srt_ProductOrServiceAxis_72db89e6-840c-44f8-80a1-9843b60a8526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2fc34700-7185-4f47-8492-548ce407c8a5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_72db89e6-840c-44f8-80a1-9843b60a8526" xlink:to="loc_srt_ProductsAndServicesDomain_2fc34700-7185-4f47-8492-548ce407c8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_6bddd85b-141c-4ce6-8b52-1f07bd8d8adf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2fc34700-7185-4f47-8492-548ce407c8a5" xlink:to="loc_us-gaap_ProductMember_6bddd85b-141c-4ce6-8b52-1f07bd8d8adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_038cd057-ff15-481e-a3fb-d7e0f14d7c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2fc34700-7185-4f47-8492-548ce407c8a5" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_038cd057-ff15-481e-a3fb-d7e0f14d7c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_593a1a48-74a2-4dbb-b826-1d14ab942793" xlink:to="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_071ba504-8e0b-467c-b520-7265412f95b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_RevenuesAbstract_071ba504-8e0b-467c-b520-7265412f95b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e7e436aa-0d4a-4d84-9f62-388897f14ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_071ba504-8e0b-467c-b520-7265412f95b9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e7e436aa-0d4a-4d84-9f62-388897f14ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_9d6db876-b7eb-4396-9d55-eddb2a91f790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_9d6db876-b7eb-4396-9d55-eddb2a91f790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_948c37c5-f368-47b0-a153-a72691aa1ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9d6db876-b7eb-4396-9d55-eddb2a91f790" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_948c37c5-f368-47b0-a153-a72691aa1ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c6bb8a72-30fb-4c8e-96a7-4e113b28d325" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9d6db876-b7eb-4396-9d55-eddb2a91f790" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c6bb8a72-30fb-4c8e-96a7-4e113b28d325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_f4b19837-f67e-4497-94e8-0882042344a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9d6db876-b7eb-4396-9d55-eddb2a91f790" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_f4b19837-f67e-4497-94e8-0882042344a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_152e1f23-12c7-400e-8e1c-786c3a4ea220" xlink:href="bhc-20220510.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9d6db876-b7eb-4396-9d55-eddb2a91f790" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_152e1f23-12c7-400e-8e1c-786c3a4ea220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_44b375d3-c580-4e44-bf3a-e654638d3963" xlink:href="bhc-20220510.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9d6db876-b7eb-4396-9d55-eddb2a91f790" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_44b375d3-c580-4e44-bf3a-e654638d3963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_97019eee-9c7e-42f0-be06-2110ac6871e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9d6db876-b7eb-4396-9d55-eddb2a91f790" xlink:to="loc_us-gaap_AssetImpairmentCharges_97019eee-9c7e-42f0-be06-2110ac6871e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_e2a84e05-f8f3-445e-b60c-81fbb374352b" xlink:href="bhc-20220510.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9d6db876-b7eb-4396-9d55-eddb2a91f790" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_e2a84e05-f8f3-445e-b60c-81fbb374352b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_2d14a558-19a7-41aa-bbf3-38ee962df86d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9d6db876-b7eb-4396-9d55-eddb2a91f790" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_2d14a558-19a7-41aa-bbf3-38ee962df86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a9bae5b5-b438-4078-a4bb-41f024907877" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_9d6db876-b7eb-4396-9d55-eddb2a91f790" xlink:to="loc_us-gaap_CostsAndExpenses_a9bae5b5-b438-4078-a4bb-41f024907877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_83deea0a-615f-4323-a653-1d5a690401d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_OperatingIncomeLoss_83deea0a-615f-4323-a653-1d5a690401d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_6fb3a891-68e4-4c19-a531-7f1dc22ff69b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_InvestmentIncomeInterest_6fb3a891-68e4-4c19-a531-7f1dc22ff69b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_7fb803f4-c02e-4d36-a47f-0c3153adc720" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_InterestExpenseDebt_7fb803f4-c02e-4d36-a47f-0c3153adc720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_dcc2400f-c489-43f3-907e-952f29b0b1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_dcc2400f-c489-43f3-907e-952f29b0b1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2bd82fbe-3172-45b7-9ba9-4293ef80d19f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_2bd82fbe-3172-45b7-9ba9-4293ef80d19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_32f0e39f-fff7-469e-9eda-103b755c4327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_32f0e39f-fff7-469e-9eda-103b755c4327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4f4dac20-8d01-4b2c-aeee-4178e52933cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4f4dac20-8d01-4b2c-aeee-4178e52933cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ba1c197b-1990-4e17-985d-fbebb90e1f88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_ProfitLoss_ba1c197b-1990-4e17-985d-fbebb90e1f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8d7a67ad-73b7-4814-917b-f3712dbbd124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8d7a67ad-73b7-4814-917b-f3712dbbd124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e3a04aae-2b7c-468d-b712-5715884c4874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_NetIncomeLoss_e3a04aae-2b7c-468d-b712-5715884c4874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d8bf0de0-c181-4827-b37f-d5a8c6dedc39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_EarningsPerShareBasic_d8bf0de0-c181-4827-b37f-d5a8c6dedc39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_258376aa-559f-4c21-a89c-3bd8833a96ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_EarningsPerShareDiluted_258376aa-559f-4c21-a89c-3bd8833a96ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5cd49acb-0a1d-4c26-abbe-f972a5fcd215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5cd49acb-0a1d-4c26-abbe-f972a5fcd215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1606e6b6-99b3-42fe-99a1-9c7cd62928c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6a6dccbf-a61f-40cc-9c42-c7c69752a633" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1606e6b6-99b3-42fe-99a1-9c7cd62928c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bhc-20220510.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_eb80f678-f3cc-4143-a9fc-63f2b104f265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7bd23aab-bc92-4403-afe9-99b453fecf30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_eb80f678-f3cc-4143-a9fc-63f2b104f265" xlink:to="loc_us-gaap_ProfitLoss_7bd23aab-bc92-4403-afe9-99b453fecf30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_096b1b1c-eaa2-4eb3-a29a-f19ec5203945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_eb80f678-f3cc-4143-a9fc-63f2b104f265" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_096b1b1c-eaa2-4eb3-a29a-f19ec5203945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_324858e3-80a2-4f01-b84b-66edf5215455" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_096b1b1c-eaa2-4eb3-a29a-f19ec5203945" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_324858e3-80a2-4f01-b84b-66edf5215455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_d0948f3e-0d23-420f-9509-89b30ea312de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_324858e3-80a2-4f01-b84b-66edf5215455" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax_d0948f3e-0d23-420f-9509-89b30ea312de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax_4a05e719-4035-4771-a576-7dd6bb53ed10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_324858e3-80a2-4f01-b84b-66edf5215455" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax_4a05e719-4035-4771-a576-7dd6bb53ed10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition_ef2fc6c5-6c06-4d3f-88bb-cfd13548471e" xlink:href="bhc-20220510.xsd#bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_324858e3-80a2-4f01-b84b-66edf5215455" xlink:to="loc_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition_ef2fc6c5-6c06-4d3f-88bb-cfd13548471e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_f644ceee-67ad-456a-9f89-fc57286e8c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_324858e3-80a2-4f01-b84b-66edf5215455" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_f644ceee-67ad-456a-9f89-fc57286e8c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax_c48f72d5-bd27-42f1-b54f-8aeb7167c3bf" xlink:href="bhc-20220510.xsd#bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_324858e3-80a2-4f01-b84b-66edf5215455" xlink:to="loc_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax_c48f72d5-bd27-42f1-b54f-8aeb7167c3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_cba7775a-9efb-4ddb-be5c-6b84c9672fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract_324858e3-80a2-4f01-b84b-66edf5215455" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_cba7775a-9efb-4ddb-be5c-6b84c9672fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_cfeecf51-9389-4742-a8f1-589c07ca6b49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_096b1b1c-eaa2-4eb3-a29a-f19ec5203945" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_cfeecf51-9389-4742-a8f1-589c07ca6b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_28218b6f-be92-4eb7-908a-9ea463873579" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_096b1b1c-eaa2-4eb3-a29a-f19ec5203945" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_28218b6f-be92-4eb7-908a-9ea463873579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_26fb82c9-f9aa-423d-a6a7-a1ad2a2ac80d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_eb80f678-f3cc-4143-a9fc-63f2b104f265" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_26fb82c9-f9aa-423d-a6a7-a1ad2a2ac80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_11069d64-ff73-4b9d-8e7d-c9d7ce4a5892" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_eb80f678-f3cc-4143-a9fc-63f2b104f265" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_11069d64-ff73-4b9d-8e7d-c9d7ce4a5892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_50773c5c-2e56-4a02-823d-1ce2e1c689b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_eb80f678-f3cc-4143-a9fc-63f2b104f265" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_50773c5c-2e56-4a02-823d-1ce2e1c689b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT" xlink:type="simple" xlink:href="bhc-20220510.xsd#CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_27e87ba3-55ca-435f-ba36-a508fec42b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4ff6ad6a-c747-4375-8c86-c42c71527560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_27e87ba3-55ca-435f-ba36-a508fec42b2d" xlink:to="loc_us-gaap_StatementTable_4ff6ad6a-c747-4375-8c86-c42c71527560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_32082fbd-2457-491c-86bf-39bcfb1a9138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4ff6ad6a-c747-4375-8c86-c42c71527560" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_32082fbd-2457-491c-86bf-39bcfb1a9138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d926c3da-9d71-4308-a8c5-d8b777a2133a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_32082fbd-2457-491c-86bf-39bcfb1a9138" xlink:to="loc_us-gaap_EquityComponentDomain_d926c3da-9d71-4308-a8c5-d8b777a2133a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_e5c8e787-3e6c-4fd5-a26d-df05981cf7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d926c3da-9d71-4308-a8c5-d8b777a2133a" xlink:to="loc_us-gaap_ParentMember_e5c8e787-3e6c-4fd5-a26d-df05981cf7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_72f5188d-270a-411a-ad8c-e8c45384c631" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_e5c8e787-3e6c-4fd5-a26d-df05981cf7e3" xlink:to="loc_us-gaap_CommonStockMember_72f5188d-270a-411a-ad8c-e8c45384c631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_311ca4d8-436e-4ade-b69a-c277af622091" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_e5c8e787-3e6c-4fd5-a26d-df05981cf7e3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_311ca4d8-436e-4ade-b69a-c277af622091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4a3db07d-f769-4a42-a0fd-fccdf76ca2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_e5c8e787-3e6c-4fd5-a26d-df05981cf7e3" xlink:to="loc_us-gaap_RetainedEarningsMember_4a3db07d-f769-4a42-a0fd-fccdf76ca2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7789e0c4-80db-4941-9df0-031c152db20b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_e5c8e787-3e6c-4fd5-a26d-df05981cf7e3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7789e0c4-80db-4941-9df0-031c152db20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_0f214d39-8961-4618-87f3-8f9ee4d3c6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d926c3da-9d71-4308-a8c5-d8b777a2133a" xlink:to="loc_us-gaap_NoncontrollingInterestMember_0f214d39-8961-4618-87f3-8f9ee4d3c6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_9281a176-b740-4d9a-beda-1ea22783e2f3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4ff6ad6a-c747-4375-8c86-c42c71527560" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_9281a176-b740-4d9a-beda-1ea22783e2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_39c3c726-42fd-4352-a669-6804e3c29a67" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_9281a176-b740-4d9a-beda-1ea22783e2f3" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_39c3c726-42fd-4352-a669-6804e3c29a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_0e8948f6-dca8-49e6-bc04-34b9bd2f5420" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_39c3c726-42fd-4352-a669-6804e3c29a67" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_0e8948f6-dca8-49e6-bc04-34b9bd2f5420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9f324018-d10e-4f8a-95a1-f56865e7825d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4ff6ad6a-c747-4375-8c86-c42c71527560" xlink:to="loc_us-gaap_StatementLineItems_9f324018-d10e-4f8a-95a1-f56865e7825d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a9d738e0-eb5c-4c29-8a62-7c7a488b70fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9f324018-d10e-4f8a-95a1-f56865e7825d" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a9d738e0-eb5c-4c29-8a62-7c7a488b70fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_fb77db08-4307-494b-a00a-c4ff34a09e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a9d738e0-eb5c-4c29-8a62-7c7a488b70fc" xlink:to="loc_us-gaap_CommonStockSharesIssued_fb77db08-4307-494b-a00a-c4ff34a09e5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b5afe1e5-385c-4ea8-8f97-23efcaa3af05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a9d738e0-eb5c-4c29-8a62-7c7a488b70fc" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b5afe1e5-385c-4ea8-8f97-23efcaa3af05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_96c22c6a-b902-4aea-a844-4d872d61ad06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a9d738e0-eb5c-4c29-8a62-7c7a488b70fc" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_96c22c6a-b902-4aea-a844-4d872d61ad06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_9f280b08-57cf-464d-9149-f03ead824b04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a9d738e0-eb5c-4c29-8a62-7c7a488b70fc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_9f280b08-57cf-464d-9149-f03ead824b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7f58d391-2bec-4327-9624-cd0d0cfc8b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a9d738e0-eb5c-4c29-8a62-7c7a488b70fc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7f58d391-2bec-4327-9624-cd0d0cfc8b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1f6ba1ce-cb02-4a9a-b960-f1af9702b474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a9d738e0-eb5c-4c29-8a62-7c7a488b70fc" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1f6ba1ce-cb02-4a9a-b960-f1af9702b474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_aaf26c05-9d52-460b-807a-76570833da75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a9d738e0-eb5c-4c29-8a62-7c7a488b70fc" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_aaf26c05-9d52-460b-807a-76570833da75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_53445d67-5ff5-4a83-ae4f-ce57cee4e25a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a9d738e0-eb5c-4c29-8a62-7c7a488b70fc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_53445d67-5ff5-4a83-ae4f-ce57cee4e25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_52997ecb-c7e4-4bcf-ba02-d822975f537e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a9d738e0-eb5c-4c29-8a62-7c7a488b70fc" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_52997ecb-c7e4-4bcf-ba02-d822975f537e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_fbf1b060-5114-4fde-8b5f-aa5828792bef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a9d738e0-eb5c-4c29-8a62-7c7a488b70fc" xlink:to="loc_us-gaap_ProfitLoss_fbf1b060-5114-4fde-8b5f-aa5828792bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_29a37505-cd9d-49fd-ad7e-93fe7b6c616f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a9d738e0-eb5c-4c29-8a62-7c7a488b70fc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_29a37505-cd9d-49fd-ad7e-93fe7b6c616f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b24b67df-b744-482d-b0a1-5a822c860cab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a9d738e0-eb5c-4c29-8a62-7c7a488b70fc" xlink:to="loc_us-gaap_CommonStockSharesIssued_b24b67df-b744-482d-b0a1-5a822c860cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0846aa8b-7a50-486d-b4de-899889f914d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a9d738e0-eb5c-4c29-8a62-7c7a488b70fc" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0846aa8b-7a50-486d-b4de-899889f914d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bhc-20220510.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_1a5c842a-0c08-44d8-9070-3165896e1ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_784f765f-ad88-411b-af5e-d937271ce0a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1a5c842a-0c08-44d8-9070-3165896e1ea7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_784f765f-ad88-411b-af5e-d937271ce0a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_2eea9472-bb84-467f-94eb-300ce2da5c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_784f765f-ad88-411b-af5e-d937271ce0a1" xlink:to="loc_us-gaap_ProfitLoss_2eea9472-bb84-467f-94eb-300ce2da5c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c74258d3-fe9c-4c23-9579-378b37efd4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_784f765f-ad88-411b-af5e-d937271ce0a1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c74258d3-fe9c-4c23-9579-378b37efd4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_104606a4-9787-4b0b-adb8-5cf72ab72272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c74258d3-fe9c-4c23-9579-378b37efd4a9" xlink:to="loc_us-gaap_DepreciationAndAmortization_104606a4-9787-4b0b-adb8-5cf72ab72272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_05c920cf-6202-4337-8b4e-8a50484e8666" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c74258d3-fe9c-4c23-9579-378b37efd4a9" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_05c920cf-6202-4337-8b4e-8a50484e8666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_0d187f62-eec4-465c-8248-f18be966a1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c74258d3-fe9c-4c23-9579-378b37efd4a9" xlink:to="loc_us-gaap_AssetImpairmentCharges_0d187f62-eec4-465c-8248-f18be966a1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_0aae9ef9-591b-4d54-b461-6dd4d36d6480" xlink:href="bhc-20220510.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c74258d3-fe9c-4c23-9579-378b37efd4a9" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_0aae9ef9-591b-4d54-b461-6dd4d36d6480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_36309544-3841-4047-a1f8-4daf5524a50d" xlink:href="bhc-20220510.xsd#bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c74258d3-fe9c-4c23-9579-378b37efd4a9" xlink:to="loc_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash_36309544-3841-4047-a1f8-4daf5524a50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_7d0e8178-33b8-48fa-837f-05356548b9f9" xlink:href="bhc-20220510.xsd#bhc_AllowancesForLossesOnAccountsReceivableAndInventories"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c74258d3-fe9c-4c23-9579-378b37efd4a9" xlink:to="loc_bhc_AllowancesForLossesOnAccountsReceivableAndInventories_7d0e8178-33b8-48fa-837f-05356548b9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_2294cfd2-5bf4-4bb5-9ed5-054b3c0941e8" xlink:href="bhc-20220510.xsd#bhc_DeferredIncomeTaxNoncashExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c74258d3-fe9c-4c23-9579-378b37efd4a9" xlink:to="loc_bhc_DeferredIncomeTaxNoncashExpenseBenefit_2294cfd2-5bf4-4bb5-9ed5-054b3c0941e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_20711dc6-f6d8-4c02-b888-fa8e5ef0ee97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c74258d3-fe9c-4c23-9579-378b37efd4a9" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_20711dc6-f6d8-4c02-b888-fa8e5ef0ee97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GainLossRelatedToLitigationSettlementGross_1715d70c-3253-41c0-a618-445a0a29edbb" xlink:href="bhc-20220510.xsd#bhc_GainLossRelatedToLitigationSettlementGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c74258d3-fe9c-4c23-9579-378b37efd4a9" xlink:to="loc_bhc_GainLossRelatedToLitigationSettlementGross_1715d70c-3253-41c0-a618-445a0a29edbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_5fea73c0-c2fb-48b1-ba34-d58fca359f33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c74258d3-fe9c-4c23-9579-378b37efd4a9" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_5fea73c0-c2fb-48b1-ba34-d58fca359f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_74f31092-e203-4656-bc1c-8a6f5088035f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c74258d3-fe9c-4c23-9579-378b37efd4a9" xlink:to="loc_us-gaap_ShareBasedCompensation_74f31092-e203-4656-bc1c-8a6f5088035f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_9795afe1-65ef-4a0e-b9a4-80b5ae9d0d65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c74258d3-fe9c-4c23-9579-378b37efd4a9" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_9795afe1-65ef-4a0e-b9a4-80b5ae9d0d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeGainExcludedComponent_1ee44938-02a7-4ba8-8e53-a344cd599bd1" xlink:href="bhc-20220510.xsd#bhc_DerivativeGainExcludedComponent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c74258d3-fe9c-4c23-9579-378b37efd4a9" xlink:to="loc_bhc_DerivativeGainExcludedComponent_1ee44938-02a7-4ba8-8e53-a344cd599bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5046703b-faec-43f7-95a5-4b566000280a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c74258d3-fe9c-4c23-9579-378b37efd4a9" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_5046703b-faec-43f7-95a5-4b566000280a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_62e57152-4b9e-4699-8e59-9c4f4fab35aa" xlink:href="bhc-20220510.xsd#bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c74258d3-fe9c-4c23-9579-378b37efd4a9" xlink:to="loc_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities_62e57152-4b9e-4699-8e59-9c4f4fab35aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_8403e229-8fb3-40f1-bdf7-c4ca145d5b71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c74258d3-fe9c-4c23-9579-378b37efd4a9" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_8403e229-8fb3-40f1-bdf7-c4ca145d5b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fbc35a43-853d-41f4-93a5-9979c6f3ed2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c74258d3-fe9c-4c23-9579-378b37efd4a9" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fbc35a43-853d-41f4-93a5-9979c6f3ed2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2806cd36-758f-46cb-a792-f1185332d2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fbc35a43-853d-41f4-93a5-9979c6f3ed2b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2806cd36-758f-46cb-a792-f1185332d2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_3619536c-f62d-4599-aaec-a19a856a0728" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fbc35a43-853d-41f4-93a5-9979c6f3ed2b" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_3619536c-f62d-4599-aaec-a19a856a0728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c1e164d0-8257-4c7b-9f2f-496ad7341abd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fbc35a43-853d-41f4-93a5-9979c6f3ed2b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c1e164d0-8257-4c7b-9f2f-496ad7341abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2a4eb3b4-096f-47f7-a202-2503f177b794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fbc35a43-853d-41f4-93a5-9979c6f3ed2b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2a4eb3b4-096f-47f7-a202-2503f177b794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a12104f4-3492-40fc-a1cf-84e2f57d694c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_784f765f-ad88-411b-af5e-d937271ce0a1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a12104f4-3492-40fc-a1cf-84e2f57d694c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_63cb28d5-f03d-487c-afca-791c96b49174" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1a5c842a-0c08-44d8-9070-3165896e1ea7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_63cb28d5-f03d-487c-afca-791c96b49174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_b3a2a9e9-a38d-481f-8d4f-4327da8d0e06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_63cb28d5-f03d-487c-afca-791c96b49174" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_b3a2a9e9-a38d-481f-8d4f-4327da8d0e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_c2cdd173-9398-4091-8fe5-69777c5341e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_63cb28d5-f03d-487c-afca-791c96b49174" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_c2cdd173-9398-4091-8fe5-69777c5341e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d7ab316f-3e06-41ba-833c-06fbd3fc6133" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_63cb28d5-f03d-487c-afca-791c96b49174" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d7ab316f-3e06-41ba-833c-06fbd3fc6133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_c16fb8f6-9776-4189-9f1a-b300661fe727" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_63cb28d5-f03d-487c-afca-791c96b49174" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_c16fb8f6-9776-4189-9f1a-b300661fe727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_33968811-082f-4181-80f4-79a04c05cc13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_63cb28d5-f03d-487c-afca-791c96b49174" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_33968811-082f-4181-80f4-79a04c05cc13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_3e621c3e-fd6c-4c9d-a8b5-6891d9c55ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_63cb28d5-f03d-487c-afca-791c96b49174" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_3e621c3e-fd6c-4c9d-a8b5-6891d9c55ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InterestSettlementOnCrossCurrencySwaps_a6e2252b-81e3-4b86-9ca8-55ff21f74cea" xlink:href="bhc-20220510.xsd#bhc_InterestSettlementOnCrossCurrencySwaps"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_63cb28d5-f03d-487c-afca-791c96b49174" xlink:to="loc_bhc_InterestSettlementOnCrossCurrencySwaps_a6e2252b-81e3-4b86-9ca8-55ff21f74cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5079f230-cd11-4c35-aa75-d6b0b5ba8f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_63cb28d5-f03d-487c-afca-791c96b49174" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5079f230-cd11-4c35-aa75-d6b0b5ba8f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_51360f28-2cb9-48f8-9251-2b6ad0ba5059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1a5c842a-0c08-44d8-9070-3165896e1ea7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_51360f28-2cb9-48f8-9251-2b6ad0ba5059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d0aa1ef4-336f-4f3c-90f0-f9564047fdf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_51360f28-2cb9-48f8-9251-2b6ad0ba5059" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d0aa1ef4-336f-4f3c-90f0-f9564047fdf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_7dbb07c1-4541-448a-8486-9753332c62c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_51360f28-2cb9-48f8-9251-2b6ad0ba5059" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_7dbb07c1-4541-448a-8486-9753332c62c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_49a8d51d-27a8-4ef8-a5ca-fb692dbb0766" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_51360f28-2cb9-48f8-9251-2b6ad0ba5059" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_49a8d51d-27a8-4ef8-a5ca-fb692dbb0766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_af653780-d932-4a31-8326-f47876714c38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_51360f28-2cb9-48f8-9251-2b6ad0ba5059" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_af653780-d932-4a31-8326-f47876714c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7443af3c-321e-4fc1-b452-0dedd794c879" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_51360f28-2cb9-48f8-9251-2b6ad0ba5059" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7443af3c-321e-4fc1-b452-0dedd794c879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_f253199d-2568-4f46-b832-8abcb08dcb8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_51360f28-2cb9-48f8-9251-2b6ad0ba5059" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_f253199d-2568-4f46-b832-8abcb08dcb8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_5d1093a6-68a3-4e8a-afc5-6fb47c4470dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_51360f28-2cb9-48f8-9251-2b6ad0ba5059" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_5d1093a6-68a3-4e8a-afc5-6fb47c4470dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8a7f33df-ea4d-4b74-a0c1-c0f242024f28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_51360f28-2cb9-48f8-9251-2b6ad0ba5059" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8a7f33df-ea4d-4b74-a0c1-c0f242024f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_37100b57-3dee-4fdb-9731-4e68ef97d580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_51360f28-2cb9-48f8-9251-2b6ad0ba5059" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_37100b57-3dee-4fdb-9731-4e68ef97d580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3fff13cb-44c1-4e66-ac4a-a159a7cf4304" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1a5c842a-0c08-44d8-9070-3165896e1ea7" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3fff13cb-44c1-4e66-ac4a-a159a7cf4304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9478951f-672e-4f75-bf6c-e50ac1a1cd27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1a5c842a-0c08-44d8-9070-3165896e1ea7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9478951f-672e-4f75-bf6c-e50ac1a1cd27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits_141a0691-3d58-4f90-937d-d57fbf413b18" xlink:href="bhc-20220510.xsd#bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1a5c842a-0c08-44d8-9070-3165896e1ea7" xlink:to="loc_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits_141a0691-3d58-4f90-937d-d57fbf413b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits_64072ad5-c0fc-410e-aa3b-09748a6fe683" xlink:href="bhc-20220510.xsd#bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1a5c842a-0c08-44d8-9070-3165896e1ea7" xlink:to="loc_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits_64072ad5-c0fc-410e-aa3b-09748a6fe683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a6495b05-a7da-409d-91ae-1505f34689c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1a5c842a-0c08-44d8-9070-3165896e1ea7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a6495b05-a7da-409d-91ae-1505f34689c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_4e24f054-9564-4a98-9ffe-43db59ba1202" xlink:href="bhc-20220510.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1a5c842a-0c08-44d8-9070-3165896e1ea7" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrent_4e24f054-9564-4a98-9ffe-43db59ba1202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits_d5d5467a-3cc3-49b5-bb8f-8b7c403fab68" xlink:href="bhc-20220510.xsd#bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_1a5c842a-0c08-44d8-9070-3165896e1ea7" xlink:to="loc_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits_d5d5467a-3cc3-49b5-bb8f-8b7c403fab68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="bhc-20220510.xsd#DESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fdb2fcc3-6294-4c8e-8715-48a2e8a8ad13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_8db7c94e-a920-4b95-96bd-58fea0aaee88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_fdb2fcc3-6294-4c8e-8715-48a2e8a8ad13" xlink:to="loc_us-gaap_NatureOfOperations_8db7c94e-a920-4b95-96bd-58fea0aaee88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#DESCRIPTIONOFBUSINESSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e871d1ce-33ed-4fec-888e-2e730fd180d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_b0416884-f9ce-426a-b0af-c8f86307345e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e871d1ce-33ed-4fec-888e-2e730fd180d8" xlink:to="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_b0416884-f9ce-426a-b0af-c8f86307345e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="bhc-20220510.xsd#SIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_903ae91f-049a-4829-9f66-919cc5567d33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2cfa4f8a-3cd1-4faa-8296-1986811551a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_903ae91f-049a-4829-9f66-919cc5567d33" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2cfa4f8a-3cd1-4faa-8296-1986811551a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="bhc-20220510.xsd#SIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_fa618253-2aed-4ab3-b3ed-3e8e78a217fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_fa618253-2aed-4ab3-b3ed-3e8e78a217fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_dd3eec51-c59a-4134-9760-da2456ed2125" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_us-gaap_UseOfEstimates_dd3eec51-c59a-4134-9760-da2456ed2125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_331d71e8-56bc-4abb-983d-f1bc4f41e913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_331d71e8-56bc-4abb-983d-f1bc4f41e913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_a62fae21-dc1a-4acb-8869-e941578ad023" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_a62fae21-dc1a-4acb-8869-e941578ad023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_97a5054f-94f7-4986-8a60-2976acb39154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_97a5054f-94f7-4986-8a60-2976acb39154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_ed5c07ef-9b1e-4fd1-9fdb-286bae50b51f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_ed5c07ef-9b1e-4fd1-9fdb-286bae50b51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_d63e96be-fff5-4fce-a2e0-a8acfac8da35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_d63e96be-fff5-4fce-a2e0-a8acfac8da35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_21ace12d-3828-4728-a448-31b590c975df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_21ace12d-3828-4728-a448-31b590c975df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts_87f328a0-b23f-42e1-83fa-54867954bb39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts_87f328a0-b23f-42e1-83fa-54867954bb39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_8849e8c9-168d-4d57-b6ae-bfc88a0918ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_8849e8c9-168d-4d57-b6ae-bfc88a0918ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3cb2f26c-c7ee-4f35-b3ce-f7ec83f9e428" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_3cb2f26c-c7ee-4f35-b3ce-f7ec83f9e428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_3392e73b-3bb8-40d6-856b-65f10ef4c4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_3392e73b-3bb8-40d6-856b-65f10ef4c4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DivestituresOfNoncoreProductsPolicyTextBlock_54524644-97ba-42b5-a221-f14d7c50296e" xlink:href="bhc-20220510.xsd#bhc_DivestituresOfNoncoreProductsPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_bhc_DivestituresOfNoncoreProductsPolicyTextBlock_54524644-97ba-42b5-a221-f14d7c50296e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_1337749c-6a84-46c5-9bf9-1778c363a5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentPolicy_1337749c-6a84-46c5-9bf9-1778c363a5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_a2c5e73b-3a79-4812-af30-e2f16fa21011" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_a2c5e73b-3a79-4812-af30-e2f16fa21011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_0f753e3d-9b74-4c90-88a1-3aa1b233b418" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_0f753e3d-9b74-4c90-88a1-3aa1b233b418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_7139868d-09e6-430f-b6de-99e0848882f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_7139868d-09e6-430f-b6de-99e0848882f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_02ce5041-3220-49f6-989d-d8aca55f9982" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_02ce5041-3220-49f6-989d-d8aca55f9982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_6f37f99a-5687-48c8-a73b-0fb9d147a62c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_6f37f99a-5687-48c8-a73b-0fb9d147a62c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_0551d7a7-d665-4f00-83a0-e9063a9c1e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_0551d7a7-d665-4f00-83a0-e9063a9c1e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalCostsPolicyTextBlock_afe65e48-4ddf-4e68-9ecd-a0a09a558767" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_us-gaap_LegalCostsPolicyTextBlock_afe65e48-4ddf-4e68-9ecd-a0a09a558767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_93a3599e-64f2-4699-adc3-7edfb0d8ac5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_93a3599e-64f2-4699-adc3-7edfb0d8ac5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2daa8cdd-b869-483f-a3df-474c6b3bf461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2daa8cdd-b869-483f-a3df-474c6b3bf461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpensePolicyTextBlock_5b1befce-7774-439b-b827-bfbc90ca506e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpensePolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_us-gaap_InterestExpensePolicyTextBlock_5b1befce-7774-439b-b827-bfbc90ca506e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_68215554-1aea-4619-b4ce-1753c5c17498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_68215554-1aea-4619-b4ce-1753c5c17498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_8c08a809-8baa-41cb-906f-bac2369c0a91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_8c08a809-8baa-41cb-906f-bac2369c0a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_3401c0dc-aa79-48af-aef4-8e7bda4dbce3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_3401c0dc-aa79-48af-aef4-8e7bda4dbce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_6bdd274b-b95a-49d1-a179-c771c08a0f4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_6bdd274b-b95a-49d1-a179-c771c08a0f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy_6f34f989-208a-4829-8993-6c121b228e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy_6f34f989-208a-4829-8993-6c121b228e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_404bb895-52af-4660-96fc-8b407011057b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_404bb895-52af-4660-96fc-8b407011057b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_9daf1443-e2a1-45d7-9ed4-3c6cd6b4e5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2b86d10b-e1a6-4511-8776-e233732339a4" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_9daf1443-e2a1-45d7-9ed4-3c6cd6b4e5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="bhc-20220510.xsd#SIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4fc9d7f5-9a40-4cdd-b3a9-068dc19b03e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_7af05062-e842-4c32-99d1-94d99aa76229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4fc9d7f5-9a40-4cdd-b3a9-068dc19b03e8" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_7af05062-e842-4c32-99d1-94d99aa76229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_2399c8a8-0e8b-4436-8f56-35101da815e2" xlink:href="bhc-20220510.xsd#bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4fc9d7f5-9a40-4cdd-b3a9-068dc19b03e8" xlink:to="loc_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_2399c8a8-0e8b-4436-8f56-35101da815e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock_fbc548e9-0ff1-48b1-b2eb-fcfb665b4d43" xlink:href="bhc-20220510.xsd#bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4fc9d7f5-9a40-4cdd-b3a9-068dc19b03e8" xlink:to="loc_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock_fbc548e9-0ff1-48b1-b2eb-fcfb665b4d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_0e3321f9-a95c-45b8-9fc9-a41a374a89de" xlink:href="bhc-20220510.xsd#bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4fc9d7f5-9a40-4cdd-b3a9-068dc19b03e8" xlink:to="loc_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock_0e3321f9-a95c-45b8-9fc9-a41a374a89de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_103ec652-cc88-43c0-81bb-eb3c07177d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished_66667a9e-eab8-4a30-b2da-a8aab238af48" xlink:href="bhc-20220510.xsd#bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_103ec652-cc88-43c0-81bb-eb3c07177d5a" xlink:to="loc_bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished_66667a9e-eab8-4a30-b2da-a8aab238af48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_da9a7770-cb56-4e44-8a15-399718c117fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_606973bb-9156-4688-9409-647da0fa3001" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_da9a7770-cb56-4e44-8a15-399718c117fa" xlink:to="loc_us-gaap_ConcentrationRiskTable_606973bb-9156-4688-9409-647da0fa3001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_10deead8-5bbe-4858-aa50-00c9e7b14885" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_606973bb-9156-4688-9409-647da0fa3001" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_10deead8-5bbe-4858-aa50-00c9e7b14885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ce14e89-4b3a-4f64-8b55-8af79197bc53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_10deead8-5bbe-4858-aa50-00c9e7b14885" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ce14e89-4b3a-4f64-8b55-8af79197bc53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_beae0876-9357-4069-a28e-68eeeaf90853" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8ce14e89-4b3a-4f64-8b55-8af79197bc53" xlink:to="loc_us-gaap_AccountsReceivableMember_beae0876-9357-4069-a28e-68eeeaf90853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_07dc1c95-8c9c-4dd8-87d2-b531c2ae15f3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_606973bb-9156-4688-9409-647da0fa3001" xlink:to="loc_srt_MajorCustomersAxis_07dc1c95-8c9c-4dd8-87d2-b531c2ae15f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_55e9f807-e625-4ad8-8e51-9fb43c8edf9b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_07dc1c95-8c9c-4dd8-87d2-b531c2ae15f3" xlink:to="loc_srt_NameOfMajorCustomerDomain_55e9f807-e625-4ad8-8e51-9fb43c8edf9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ThreeLargestUSWholesalerCustomersMember_61ad24e2-1f2a-4cad-9ac6-8e27682d93d4" xlink:href="bhc-20220510.xsd#bhc_ThreeLargestUSWholesalerCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_55e9f807-e625-4ad8-8e51-9fb43c8edf9b" xlink:to="loc_bhc_ThreeLargestUSWholesalerCustomersMember_61ad24e2-1f2a-4cad-9ac6-8e27682d93d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_5d00cd68-44eb-4996-af30-b5baaf92b410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_606973bb-9156-4688-9409-647da0fa3001" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_5d00cd68-44eb-4996-af30-b5baaf92b410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c7dc1137-6e69-4bd8-8638-d2fc07a97026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_5d00cd68-44eb-4996-af30-b5baaf92b410" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c7dc1137-6e69-4bd8-8638-d2fc07a97026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditConcentrationRiskMember_14bf81df-d64e-4209-8450-939d27b4a0b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c7dc1137-6e69-4bd8-8638-d2fc07a97026" xlink:to="loc_us-gaap_CreditConcentrationRiskMember_14bf81df-d64e-4209-8450-939d27b4a0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_64642837-d776-4013-9a0d-5f77ab4af8b9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_606973bb-9156-4688-9409-647da0fa3001" xlink:to="loc_srt_StatementGeographicalAxis_64642837-d776-4013-9a0d-5f77ab4af8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2b0aee8a-1cee-4c58-ab0d-d846d543ba18" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_64642837-d776-4013-9a0d-5f77ab4af8b9" xlink:to="loc_srt_SegmentGeographicalDomain_2b0aee8a-1cee-4c58-ab0d-d846d543ba18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember_a42b31f5-6849-46b1-b6f8-a8cc1fff3a55" xlink:href="bhc-20220510.xsd#bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2b0aee8a-1cee-4c58-ab0d-d846d543ba18" xlink:to="loc_bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember_a42b31f5-6849-46b1-b6f8-a8cc1fff3a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_513a8d52-ee00-4273-9bbc-241e7272b3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_606973bb-9156-4688-9409-647da0fa3001" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_513a8d52-ee00-4273-9bbc-241e7272b3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents_68f0b4b9-8e4e-4482-a4a9-b463fd8e13fb" xlink:href="bhc-20220510.xsd#bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_513a8d52-ee00-4273-9bbc-241e7272b3bd" xlink:to="loc_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents_68f0b4b9-8e4e-4482-a4a9-b463fd8e13fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NumberOfLargestWholesaleCustomers_76e71dae-6a96-4208-a563-f47e75102308" xlink:href="bhc-20220510.xsd#bhc_NumberOfLargestWholesaleCustomers"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_513a8d52-ee00-4273-9bbc-241e7272b3bd" xlink:to="loc_bhc_NumberOfLargestWholesaleCustomers_76e71dae-6a96-4208-a563-f47e75102308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskPercentageofNetTradeReceivables_318dbe7c-b63a-421e-a281-cbb413c4a055" xlink:href="bhc-20220510.xsd#bhc_ConcentrationRiskPercentageofNetTradeReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_513a8d52-ee00-4273-9bbc-241e7272b3bd" xlink:to="loc_bhc_ConcentrationRiskPercentageofNetTradeReceivables_318dbe7c-b63a-421e-a281-cbb413c4a055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4cf492ca-7710-4436-b4c5-5fea22594424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_513a8d52-ee00-4273-9bbc-241e7272b3bd" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4cf492ca-7710-4436-b4c5-5fea22594424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PastDuePeriodForAccountsReceivableToBeNegligible_8a11c1d2-8a14-4e0d-875f-592046aeb060" xlink:href="bhc-20220510.xsd#bhc_PastDuePeriodForAccountsReceivableToBeNegligible"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_513a8d52-ee00-4273-9bbc-241e7272b3bd" xlink:to="loc_bhc_PastDuePeriodForAccountsReceivableToBeNegligible_8a11c1d2-8a14-4e0d-875f-592046aeb060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PeriodReceivableOutstanding_7b08fe9a-6d05-4a54-8e9a-e4975d844fc4" xlink:href="bhc-20220510.xsd#bhc_PeriodReceivableOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_513a8d52-ee00-4273-9bbc-241e7272b3bd" xlink:to="loc_bhc_PeriodReceivableOutstanding_7b08fe9a-6d05-4a54-8e9a-e4975d844fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TradeReceivableNetPortionPastDue_b94ce3ff-a3d3-4f51-98ef-2f45816e7e78" xlink:href="bhc-20220510.xsd#bhc_TradeReceivableNetPortionPastDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_513a8d52-ee00-4273-9bbc-241e7272b3bd" xlink:to="loc_bhc_TradeReceivableNetPortionPastDue_b94ce3ff-a3d3-4f51-98ef-2f45816e7e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_85f70a7c-502c-4ede-9b57-68fefd689ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_d3574fb7-4237-49c4-b714-c4f9081d5179" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_85f70a7c-502c-4ede-9b57-68fefd689ad1" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_d3574fb7-4237-49c4-b714-c4f9081d5179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_d0ab8ef6-3fb5-45f6-bc2f-2553945a6ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_85f70a7c-502c-4ede-9b57-68fefd689ad1" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_d0ab8ef6-3fb5-45f6-bc2f-2553945a6ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_9c001c6f-accd-4af9-bebc-1bd81d7df680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_d0ab8ef6-3fb5-45f6-bc2f-2553945a6ccd" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_9c001c6f-accd-4af9-bebc-1bd81d7df680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate_2b894e3b-03d7-45b6-8ac7-8656f821e61e" xlink:href="bhc-20220510.xsd#bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_d0ab8ef6-3fb5-45f6-bc2f-2553945a6ccd" xlink:to="loc_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate_2b894e3b-03d7-45b6-8ac7-8656f821e61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_bf152ee6-951d-44c7-b951-ea756c0afdb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_d0ab8ef6-3fb5-45f6-bc2f-2553945a6ccd" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_bf152ee6-951d-44c7-b951-ea756c0afdb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_ac874c67-3b19-4818-a4fd-0d7b1557c7c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_d0ab8ef6-3fb5-45f6-bc2f-2553945a6ccd" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_ac874c67-3b19-4818-a4fd-0d7b1557c7c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_b7c0e615-0010-419d-b73b-5c334b0ae7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_d0ab8ef6-3fb5-45f6-bc2f-2553945a6ccd" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_b7c0e615-0010-419d-b73b-5c334b0ae7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_6fd496b8-593c-408a-b387-b45f1eba813b" xlink:href="bhc-20220510.xsd#bhc_AccountsReceivableAllowanceForForeignExchangeAndOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_d0ab8ef6-3fb5-45f6-bc2f-2553945a6ccd" xlink:to="loc_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther_6fd496b8-593c-408a-b387-b45f1eba813b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_ee1615d0-c7c2-4ad9-8418-85bd510b351c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_d0ab8ef6-3fb5-45f6-bc2f-2553945a6ccd" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_ee1615d0-c7c2-4ad9-8418-85bd510b351c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7af9fabf-858c-40d8-b794-280cf218371d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3ce3048a-4c7a-420d-a544-4384bd47e441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7af9fabf-858c-40d8-b794-280cf218371d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3ce3048a-4c7a-420d-a544-4384bd47e441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c6f63d0b-9e4d-4a8d-b3b5-236ae94284eb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3ce3048a-4c7a-420d-a544-4384bd47e441" xlink:to="loc_srt_RangeAxis_c6f63d0b-9e4d-4a8d-b3b5-236ae94284eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cc8226fe-db63-4eaa-bc37-e4e12f7b96f0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c6f63d0b-9e4d-4a8d-b3b5-236ae94284eb" xlink:to="loc_srt_RangeMember_cc8226fe-db63-4eaa-bc37-e4e12f7b96f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_99503b1b-b7da-43fc-9bd7-140730bb2e1a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cc8226fe-db63-4eaa-bc37-e4e12f7b96f0" xlink:to="loc_srt_MinimumMember_99503b1b-b7da-43fc-9bd7-140730bb2e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_463a1b0d-692d-47e8-ad43-d9734297298f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cc8226fe-db63-4eaa-bc37-e4e12f7b96f0" xlink:to="loc_srt_MaximumMember_463a1b0d-692d-47e8-ad43-d9734297298f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d7bebcbd-3c61-4a02-a08c-5061c3c7acbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3ce3048a-4c7a-420d-a544-4384bd47e441" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d7bebcbd-3c61-4a02-a08c-5061c3c7acbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c16ba043-9c3b-4fc2-bf0c-73b47838f5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d7bebcbd-3c61-4a02-a08c-5061c3c7acbb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c16ba043-9c3b-4fc2-bf0c-73b47838f5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandImprovementsMember_47f0343f-8abd-4acb-be1b-f648e18ad085" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c16ba043-9c3b-4fc2-bf0c-73b47838f5c8" xlink:to="loc_us-gaap_LandImprovementsMember_47f0343f-8abd-4acb-be1b-f648e18ad085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_6a715471-afb3-4976-a136-fa13c288007a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c16ba043-9c3b-4fc2-bf0c-73b47838f5c8" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_6a715471-afb3-4976-a136-fa13c288007a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_5db6c40b-9536-4dbe-b5b3-1d26fb1a1b63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c16ba043-9c3b-4fc2-bf0c-73b47838f5c8" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_5db6c40b-9536-4dbe-b5b3-1d26fb1a1b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherMachineryAndEquipmentMember_61d817ab-d9c8-46f7-b710-0ada670c01c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherMachineryAndEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c16ba043-9c3b-4fc2-bf0c-73b47838f5c8" xlink:to="loc_us-gaap_OtherMachineryAndEquipmentMember_61d817ab-d9c8-46f7-b710-0ada670c01c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EquipmentOnOperatingLeaseMember_1c44282f-a212-4328-bfd7-be90b70c6aa6" xlink:href="bhc-20220510.xsd#bhc_EquipmentOnOperatingLeaseMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c16ba043-9c3b-4fc2-bf0c-73b47838f5c8" xlink:to="loc_bhc_EquipmentOnOperatingLeaseMember_1c44282f-a212-4328-bfd7-be90b70c6aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_a0d3642f-cb67-49f7-a51a-b0ca220cc258" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c16ba043-9c3b-4fc2-bf0c-73b47838f5c8" xlink:to="loc_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_a0d3642f-cb67-49f7-a51a-b0ca220cc258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac8d290a-f50f-4779-910c-fb10fb12580d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3ce3048a-4c7a-420d-a544-4384bd47e441" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac8d290a-f50f-4779-910c-fb10fb12580d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_87c6d45e-ab07-4711-956f-3e1830196603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ac8d290a-f50f-4779-910c-fb10fb12580d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_87c6d45e-ab07-4711-956f-3e1830196603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_93a721a3-7a8e-4dc9-9d43-93b0224e27be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_df71809c-beaa-45aa-8fd6-3d2d7e18a548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_93a721a3-7a8e-4dc9-9d43-93b0224e27be" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_df71809c-beaa-45aa-8fd6-3d2d7e18a548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ba23508a-c7ed-45b2-9138-d860b29ac348" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_df71809c-beaa-45aa-8fd6-3d2d7e18a548" xlink:to="loc_srt_RangeAxis_ba23508a-c7ed-45b2-9138-d860b29ac348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_899bbff5-1736-49f5-97f4-52bb97932888" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ba23508a-c7ed-45b2-9138-d860b29ac348" xlink:to="loc_srt_RangeMember_899bbff5-1736-49f5-97f4-52bb97932888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_46d9ae31-b998-4aee-aea9-6014c5bd87b7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_899bbff5-1736-49f5-97f4-52bb97932888" xlink:to="loc_srt_MinimumMember_46d9ae31-b998-4aee-aea9-6014c5bd87b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0942116d-b7b4-40cc-80e8-f61c922f635a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_899bbff5-1736-49f5-97f4-52bb97932888" xlink:to="loc_srt_MaximumMember_0942116d-b7b4-40cc-80e8-f61c922f635a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dc363e23-8a50-44f7-b7dc-fa8db4aed5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_df71809c-beaa-45aa-8fd6-3d2d7e18a548" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dc363e23-8a50-44f7-b7dc-fa8db4aed5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fdbcceca-1e5e-4b92-90c2-f308345e0157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dc363e23-8a50-44f7-b7dc-fa8db4aed5ba" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fdbcceca-1e5e-4b92-90c2-f308345e0157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_70336584-816b-47ac-84c3-c6a112962784" xlink:href="bhc-20220510.xsd#bhc_ProductBrandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fdbcceca-1e5e-4b92-90c2-f308345e0157" xlink:to="loc_bhc_ProductBrandsMember_70336584-816b-47ac-84c3-c6a112962784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_332af8f0-b4d4-4183-8852-976629d04e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fdbcceca-1e5e-4b92-90c2-f308345e0157" xlink:to="loc_us-gaap_TradeNamesMember_332af8f0-b4d4-4183-8852-976629d04e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_8dbb68a9-d0f4-4e04-be24-1cf5023f9dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fdbcceca-1e5e-4b92-90c2-f308345e0157" xlink:to="loc_us-gaap_ContractualRightsMember_8dbb68a9-d0f4-4e04-be24-1cf5023f9dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PartnerRelationshipsMember_ebff2956-b0b1-485c-93ae-042193dbf37a" xlink:href="bhc-20220510.xsd#bhc_PartnerRelationshipsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fdbcceca-1e5e-4b92-90c2-f308345e0157" xlink:to="loc_bhc_PartnerRelationshipsMember_ebff2956-b0b1-485c-93ae-042193dbf37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OutLicensedTechnologyMember_58e95916-4029-4198-8ef6-479f4f1f40f7" xlink:href="bhc-20220510.xsd#bhc_OutLicensedTechnologyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fdbcceca-1e5e-4b92-90c2-f308345e0157" xlink:to="loc_bhc_OutLicensedTechnologyMember_58e95916-4029-4198-8ef6-479f4f1f40f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_caedd051-76f3-4230-a607-49eda891e1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_df71809c-beaa-45aa-8fd6-3d2d7e18a548" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_caedd051-76f3-4230-a607-49eda891e1ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_fc022721-a9ec-42b7-bd18-a39959bb027d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_caedd051-76f3-4230-a607-49eda891e1ac" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_fc022721-a9ec-42b7-bd18-a39959bb027d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_95ba6699-3ee3-4a42-8053-3716eda3605c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_beea758a-e50e-4b78-8497-09562e8d259f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95ba6699-3ee3-4a42-8053-3716eda3605c" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_beea758a-e50e-4b78-8497-09562e8d259f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_d95cfc30-d9bb-49ed-a074-899d44b041a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_beea758a-e50e-4b78-8497-09562e8d259f" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_d95cfc30-d9bb-49ed-a074-899d44b041a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_2cfc3ab4-dcae-4cda-96b0-95d9d72b7ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_d95cfc30-d9bb-49ed-a074-899d44b041a9" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_2cfc3ab4-dcae-4cda-96b0-95d9d72b7ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDiscountsAndAllowancesMember_f635ef6c-41f3-452f-b483-a92d9bb3caf3" xlink:href="bhc-20220510.xsd#bhc_ReserveForDiscountsAndAllowancesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2cfc3ab4-dcae-4cda-96b0-95d9d72b7ec6" xlink:to="loc_bhc_ReserveForDiscountsAndAllowancesMember_f635ef6c-41f3-452f-b483-a92d9bb3caf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember_5ab6c0dc-2db2-402a-ac93-d23e3527a10a" xlink:href="bhc-20220510.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2cfc3ab4-dcae-4cda-96b0-95d9d72b7ec6" xlink:to="loc_bhc_ReserveForCustomerReturnsMember_5ab6c0dc-2db2-402a-ac93-d23e3527a10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesMember_cedf6525-60b4-46d1-9361-f616e9e59fd3" xlink:href="bhc-20220510.xsd#bhc_ReserveForRebatesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2cfc3ab4-dcae-4cda-96b0-95d9d72b7ec6" xlink:to="loc_bhc_ReserveForRebatesMember_cedf6525-60b4-46d1-9361-f616e9e59fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForChargebacksMember_8f8e89d1-4896-43df-b6fb-a596397b41c8" xlink:href="bhc-20220510.xsd#bhc_ReserveForChargebacksMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2cfc3ab4-dcae-4cda-96b0-95d9d72b7ec6" xlink:to="loc_bhc_ReserveForChargebacksMember_8f8e89d1-4896-43df-b6fb-a596397b41c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForDistributionFeesMember_8ce0dd03-a080-4fe1-a14a-563da9ef5106" xlink:href="bhc-20220510.xsd#bhc_ReserveForDistributionFeesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2cfc3ab4-dcae-4cda-96b0-95d9d72b7ec6" xlink:to="loc_bhc_ReserveForDistributionFeesMember_8ce0dd03-a080-4fe1-a14a-563da9ef5106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c63e6faa-93ec-4992-99d2-87b2c2c1eb6c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_beea758a-e50e-4b78-8497-09562e8d259f" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c63e6faa-93ec-4992-99d2-87b2c2c1eb6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5090ad5b-5ccf-40de-8bac-c291b883b22d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c63e6faa-93ec-4992-99d2-87b2c2c1eb6c" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5090ad5b-5ccf-40de-8bac-c291b883b22d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_ce0a17a6-5268-4a57-8777-e38a6ba50157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5090ad5b-5ccf-40de-8bac-c291b883b22d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_ce0a17a6-5268-4a57-8777-e38a6ba50157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_2e6c5e53-5476-40ac-83ba-c175db6cdaa2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5090ad5b-5ccf-40de-8bac-c291b883b22d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_2e6c5e53-5476-40ac-83ba-c175db6cdaa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_eb1ddf90-61cc-4b5b-ad66-ba9b1fd0605b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5090ad5b-5ccf-40de-8bac-c291b883b22d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_eb1ddf90-61cc-4b5b-ad66-ba9b1fd0605b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_c130ecae-f07a-4c6a-9842-0a1219b0a5aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_5090ad5b-5ccf-40de-8bac-c291b883b22d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_c130ecae-f07a-4c6a-9842-0a1219b0a5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c9b001ce-cf60-4cbd-8332-2499a1e9b838" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_58d1a965-44df-43b7-800d-ecd851e8d780" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9b001ce-cf60-4cbd-8332-2499a1e9b838" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_58d1a965-44df-43b7-800d-ecd851e8d780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_cda26ec9-2fd6-400d-aad8-b6f740c67348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_58d1a965-44df-43b7-800d-ecd851e8d780" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_cda26ec9-2fd6-400d-aad8-b6f740c67348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_db364f69-89ec-4708-a890-2caffd4f02af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_cda26ec9-2fd6-400d-aad8-b6f740c67348" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_db364f69-89ec-4708-a890-2caffd4f02af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_46026231-56f6-4884-9cee-fc1464aac429" xlink:href="bhc-20220510.xsd#bhc_ReserveForRebatesAdvertisingCreditsPortionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_db364f69-89ec-4708-a890-2caffd4f02af" xlink:to="loc_bhc_ReserveForRebatesAdvertisingCreditsPortionMember_46026231-56f6-4884-9cee-fc1464aac429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReserveForCustomerReturnsMember_cfedcd79-14e8-4259-815b-5655f980b487" xlink:href="bhc-20220510.xsd#bhc_ReserveForCustomerReturnsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_db364f69-89ec-4708-a890-2caffd4f02af" xlink:to="loc_bhc_ReserveForCustomerReturnsMember_cfedcd79-14e8-4259-815b-5655f980b487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_659ef397-99cc-44d3-b8c4-4d2f371bb9d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_58d1a965-44df-43b7-800d-ecd851e8d780" xlink:to="loc_srt_RangeAxis_659ef397-99cc-44d3-b8c4-4d2f371bb9d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_50832f7f-39b7-4204-b544-28e36969c063" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_659ef397-99cc-44d3-b8c4-4d2f371bb9d7" xlink:to="loc_srt_RangeMember_50832f7f-39b7-4204-b544-28e36969c063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1ce9e934-12a7-4f78-a2d3-76fd5913cddf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_50832f7f-39b7-4204-b544-28e36969c063" xlink:to="loc_srt_MinimumMember_1ce9e934-12a7-4f78-a2d3-76fd5913cddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f6aa81f0-51bb-4bc9-8554-a3e61fe23e23" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_50832f7f-39b7-4204-b544-28e36969c063" xlink:to="loc_srt_MaximumMember_f6aa81f0-51bb-4bc9-8554-a3e61fe23e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5f67fd6a-f76e-4b33-a4de-04f927d3c21f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_58d1a965-44df-43b7-800d-ecd851e8d780" xlink:to="loc_srt_ProductOrServiceAxis_5f67fd6a-f76e-4b33-a4de-04f927d3c21f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_afc21235-62fe-43eb-8ec7-11e76c9baff6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5f67fd6a-f76e-4b33-a4de-04f927d3c21f" xlink:to="loc_srt_ProductsAndServicesDomain_afc21235-62fe-43eb-8ec7-11e76c9baff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PriceAppreciationCreditMember_56c99bde-8ee9-4ded-88cc-f20dab03494a" xlink:href="bhc-20220510.xsd#bhc_PriceAppreciationCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_afc21235-62fe-43eb-8ec7-11e76c9baff6" xlink:to="loc_bhc_PriceAppreciationCreditMember_56c99bde-8ee9-4ded-88cc-f20dab03494a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b54c5fea-39a4-4047-a127-0f537fd62635" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_58d1a965-44df-43b7-800d-ecd851e8d780" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b54c5fea-39a4-4047-a127-0f537fd62635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_250c73a5-35a5-4bc6-93b6-95c3022be964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b54c5fea-39a4-4047-a127-0f537fd62635" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_250c73a5-35a5-4bc6-93b6-95c3022be964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CashDiscountsAndAllowancesSettlementPeriod_3623ce8d-e98f-4c46-b665-adbb529ae620" xlink:href="bhc-20220510.xsd#bhc_CashDiscountsAndAllowancesSettlementPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b54c5fea-39a4-4047-a127-0f537fd62635" xlink:to="loc_bhc_CashDiscountsAndAllowancesSettlementPeriod_3623ce8d-e98f-4c46-b665-adbb529ae620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax_345e1797-995b-4db1-8455-95d88bf32185" xlink:href="bhc-20220510.xsd#bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b54c5fea-39a4-4047-a127-0f537fd62635" xlink:to="loc_bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax_345e1797-995b-4db1-8455-95d88bf32185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_79d717b9-fa96-47b0-a152-b645fecd0b27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b54c5fea-39a4-4047-a127-0f537fd62635" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_79d717b9-fa96-47b0-a152-b645fecd0b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_02220813-5c72-4441-a11a-98ec44871073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b54c5fea-39a4-4047-a127-0f537fd62635" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_02220813-5c72-4441-a11a-98ec44871073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax_68ca22b2-4035-417d-b103-a2afb6f7a174" xlink:href="bhc-20220510.xsd#bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b54c5fea-39a4-4047-a127-0f537fd62635" xlink:to="loc_bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax_68ca22b2-4035-417d-b103-a2afb6f7a174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3279cdb1-8d6a-4545-b353-941a92ed1a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b54c5fea-39a4-4047-a127-0f537fd62635" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3279cdb1-8d6a-4545-b353-941a92ed1a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuePerformanceObligationPaymentTerms_90683dd0-2e0a-47b0-b901-ddab112ce760" xlink:href="bhc-20220510.xsd#bhc_RevenuePerformanceObligationPaymentTerms"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_b54c5fea-39a4-4047-a127-0f537fd62635" xlink:to="loc_bhc_RevenuePerformanceObligationPaymentTerms_90683dd0-2e0a-47b0-b901-ddab112ce760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_891ebbad-a1d8-432c-84c4-b00f5deb5210" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_4f80524f-9777-4d07-903b-e32487c0df4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_891ebbad-a1d8-432c-84c4-b00f5deb5210" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_4f80524f-9777-4d07-903b-e32487c0df4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0c95d262-88c8-49aa-b712-b849cdaa60dc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_4f80524f-9777-4d07-903b-e32487c0df4c" xlink:to="loc_srt_RangeAxis_0c95d262-88c8-49aa-b712-b849cdaa60dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_92e697f0-9e1c-4869-91ca-5cdbf3fe4e0c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0c95d262-88c8-49aa-b712-b849cdaa60dc" xlink:to="loc_srt_RangeMember_92e697f0-9e1c-4869-91ca-5cdbf3fe4e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2da377be-a966-4292-bcc7-3e9489b83ccb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_92e697f0-9e1c-4869-91ca-5cdbf3fe4e0c" xlink:to="loc_srt_MinimumMember_2da377be-a966-4292-bcc7-3e9489b83ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c7f9772c-01ae-4921-9d4a-88087f2617f6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_92e697f0-9e1c-4869-91ca-5cdbf3fe4e0c" xlink:to="loc_srt_MaximumMember_c7f9772c-01ae-4921-9d4a-88087f2617f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a9e76d0a-19b9-4eac-a216-439353ec8353" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_4f80524f-9777-4d07-903b-e32487c0df4c" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_a9e76d0a-19b9-4eac-a216-439353ec8353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9f19292c-989e-44fa-94d0-80a170eb4633" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a9e76d0a-19b9-4eac-a216-439353ec8353" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9f19292c-989e-44fa-94d0-80a170eb4633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_abc60969-014e-4b25-bdee-524a65d14c26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a9e76d0a-19b9-4eac-a216-439353ec8353" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_abc60969-014e-4b25-bdee-524a65d14c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdvertisingCostsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SIGNIFICANTACCOUNTINGPOLICIESAdvertisingCostsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdvertisingCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2791724a-34a7-46fb-8024-3c13dc312f51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_8cc6f568-35ed-4384-ac85-0168a8178f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2791724a-34a7-46fb-8024-3c13dc312f51" xlink:to="loc_us-gaap_AdvertisingExpense_8cc6f568-35ed-4384-ac85-0168a8178f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInterestExpenseDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SIGNIFICANTACCOUNTINGPOLICIESInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_111c069e-91a2-45f4-bd58-c8320423468a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_5f6f505e-8eaa-4b14-9711-c4dcb2e65901" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_111c069e-91a2-45f4-bd58-c8320423468a" xlink:to="loc_us-gaap_InterestCostsCapitalized_5f6f505e-8eaa-4b14-9711-c4dcb2e65901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7280ca0c-5088-4dbb-935a-b3fa7adb7d98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaxBenefitRecognitionMeasurementPercentage_8b146336-508f-43fe-b024-eb9f8b97b199" xlink:href="bhc-20220510.xsd#bhc_TaxBenefitRecognitionMeasurementPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7280ca0c-5088-4dbb-935a-b3fa7adb7d98" xlink:to="loc_bhc_TaxBenefitRecognitionMeasurementPercentage_8b146336-508f-43fe-b024-eb9f8b97b199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities_db559b81-d11c-4596-b5ae-9327c45debde" xlink:href="bhc-20220510.xsd#bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7280ca0c-5088-4dbb-935a-b3fa7adb7d98" xlink:to="loc_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities_db559b81-d11c-4596-b5ae-9327c45debde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESEmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SIGNIFICANTACCOUNTINGPOLICIESEmployeeBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESEmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6eebf587-3cdd-4b8d-baa0-c516a63c8c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage_fdb2205b-2660-4c1b-aea3-87c8914baa43" xlink:href="bhc-20220510.xsd#bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6eebf587-3cdd-4b8d-baa0-c516a63c8c3b" xlink:to="loc_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage_fdb2205b-2660-4c1b-aea3-87c8914baa43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7163bf68-1d44-4654-8daf-82a636c120c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_19f9b51c-bd69-4fef-9c2f-1099f0f4e445" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7163bf68-1d44-4654-8daf-82a636c120c9" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_19f9b51c-bd69-4fef-9c2f-1099f0f4e445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e6eebec9-22a9-4bd3-b36e-e928a9e977c6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_19f9b51c-bd69-4fef-9c2f-1099f0f4e445" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e6eebec9-22a9-4bd3-b36e-e928a9e977c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_eee4026b-3d08-4802-84d5-a285a328d084" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_e6eebec9-22a9-4bd3-b36e-e928a9e977c6" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_eee4026b-3d08-4802-84d5-a285a328d084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_e1b3c62b-63ae-487c-9a87-1f019626e74a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_eee4026b-3d08-4802-84d5-a285a328d084" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_e1b3c62b-63ae-487c-9a87-1f019626e74a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1690d3a6-eb47-42ee-92c2-dac92e4fe758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_19f9b51c-bd69-4fef-9c2f-1099f0f4e445" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1690d3a6-eb47-42ee-92c2-dac92e4fe758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_25f65a11-8952-4f3b-a2a0-b769903520e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1690d3a6-eb47-42ee-92c2-dac92e4fe758" xlink:to="loc_us-gaap_EquityComponentDomain_25f65a11-8952-4f3b-a2a0-b769903520e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4e66bbb5-b255-4c3a-891a-7c6245d38197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_25f65a11-8952-4f3b-a2a0-b769903520e9" xlink:to="loc_us-gaap_RetainedEarningsMember_4e66bbb5-b255-4c3a-891a-7c6245d38197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8fd48d3c-19ec-4839-8be0-ced2ce22d3c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_19f9b51c-bd69-4fef-9c2f-1099f0f4e445" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8fd48d3c-19ec-4839-8be0-ced2ce22d3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4fee4a69-6e00-4bde-b692-b528987d83da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8fd48d3c-19ec-4839-8be0-ced2ce22d3c6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4fee4a69-6e00-4bde-b692-b528987d83da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURE" xlink:type="simple" xlink:href="bhc-20220510.xsd#ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURE"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_f8c39068-7e56-4538-8645-41decd80a8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock_36ae3369-58ed-4ad1-80fa-21586a8b9322" xlink:href="bhc-20220510.xsd#bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_f8c39068-7e56-4538-8645-41decd80a8cd" xlink:to="loc_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock_36ae3369-58ed-4ad1-80fa-21586a8b9322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURETables" xlink:type="simple" xlink:href="bhc-20220510.xsd#ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURETables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e47b1b71-e62a-4fe1-9561-0e1af7b3909f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_d63a8752-6fbb-4d4f-8f99-a8104f3cbe15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e47b1b71-e62a-4fe1-9561-0e1af7b3909f" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_d63a8752-6fbb-4d4f-8f99-a8104f3cbe15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_62c857c0-5c73-4806-8182-d992a250ccdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e47b1b71-e62a-4fe1-9561-0e1af7b3909f" xlink:to="loc_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock_62c857c0-5c73-4806-8182-d992a250ccdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_11b7f11b-eecd-4b2e-b94e-996d17416b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_963db72f-3618-456a-b2e0-932700c50c01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_11b7f11b-eecd-4b2e-b94e-996d17416b3e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_963db72f-3618-456a-b2e0-932700c50c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b5b9a31e-2010-4eb8-a426-6d83ae723ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_963db72f-3618-456a-b2e0-932700c50c01" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b5b9a31e-2010-4eb8-a426-6d83ae723ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c567271-f788-46ce-98f1-e2b45ccc6013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b5b9a31e-2010-4eb8-a426-6d83ae723ed3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c567271-f788-46ce-98f1-e2b45ccc6013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SynergyPharmaceuticalsInc.Member_72a59346-80b8-4473-8c1d-7c7f7b98a61e" xlink:href="bhc-20220510.xsd#bhc_SynergyPharmaceuticalsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c567271-f788-46ce-98f1-e2b45ccc6013" xlink:to="loc_bhc_SynergyPharmaceuticalsInc.Member_72a59346-80b8-4473-8c1d-7c7f7b98a61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_92acf60c-5635-402e-8bea-db596bacb531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_963db72f-3618-456a-b2e0-932700c50c01" xlink:to="loc_us-gaap_AssetAcquisitionAxis_92acf60c-5635-402e-8bea-db596bacb531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_8ec13d68-de52-40ed-9b14-ffa95f544bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_92acf60c-5635-402e-8bea-db596bacb531" xlink:to="loc_us-gaap_AssetAcquisitionDomain_8ec13d68-de52-40ed-9b14-ffa95f544bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AllegroOphthalmicsLLCMember_098c912b-e9f1-4555-8bb3-409990104a9e" xlink:href="bhc-20220510.xsd#bhc_AllegroOphthalmicsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_8ec13d68-de52-40ed-9b14-ffa95f544bfb" xlink:to="loc_bhc_AllegroOphthalmicsLLCMember_098c912b-e9f1-4555-8bb3-409990104a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_a2c3dbe9-1458-4e17-aa89-a61dbba4a94b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_963db72f-3618-456a-b2e0-932700c50c01" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_a2c3dbe9-1458-4e17-aa89-a61dbba4a94b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_1a2287ae-d15f-4f1a-9a00-a29d3f84a2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_a2c3dbe9-1458-4e17-aa89-a61dbba4a94b" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_1a2287ae-d15f-4f1a-9a00-a29d3f84a2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_49a4c223-d19c-4b96-a58c-2c13cca7b68b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_1a2287ae-d15f-4f1a-9a00-a29d3f84a2f9" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_49a4c223-d19c-4b96-a58c-2c13cca7b68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_7e64f341-8324-44cf-aa27-371fcffd00f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_1a2287ae-d15f-4f1a-9a00-a29d3f84a2f9" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_7e64f341-8324-44cf-aa27-371fcffd00f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_0aa8d92f-2a5e-4b11-866c-c71cd81e130f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_1a2287ae-d15f-4f1a-9a00-a29d3f84a2f9" xlink:to="loc_us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember_0aa8d92f-2a5e-4b11-866c-c71cd81e130f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_831abbbf-15dd-4a82-91f5-72713aabdca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_963db72f-3618-456a-b2e0-932700c50c01" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_831abbbf-15dd-4a82-91f5-72713aabdca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e360a342-ebe9-47ae-90a3-970743c91a44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_831abbbf-15dd-4a82-91f5-72713aabdca9" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e360a342-ebe9-47ae-90a3-970743c91a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember_11de04cd-7422-435a-888a-5845235eea63" xlink:href="bhc-20220510.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e360a342-ebe9-47ae-90a3-970743c91a44" xlink:to="loc_bhc_AmounPharmaceuticalCompanySAEMember_11de04cd-7422-435a-888a-5845235eea63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_910d42af-c6ee-41be-abc4-7f23f06185ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_963db72f-3618-456a-b2e0-932700c50c01" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_910d42af-c6ee-41be-abc4-7f23f06185ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_a8d509f0-aa7c-4522-8fd6-8ab5c976a08c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_910d42af-c6ee-41be-abc4-7f23f06185ab" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_a8d509f0-aa7c-4522-8fd6-8ab5c976a08c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_41548330-b8f6-4d80-9c74-d94acdd5ba6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_910d42af-c6ee-41be-abc4-7f23f06185ab" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_41548330-b8f6-4d80-9c74-d94acdd5ba6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_a992836e-db32-45b8-8161-4ea641fce3b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_910d42af-c6ee-41be-abc4-7f23f06185ab" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_a992836e-db32-45b8-8161-4ea641fce3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss_17d63777-6c79-4f13-8d03-5d0d44813696" xlink:href="bhc-20220510.xsd#bhc_BusinessAcquisitionProFormaOperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_910d42af-c6ee-41be-abc4-7f23f06185ab" xlink:to="loc_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss_17d63777-6c79-4f13-8d03-5d0d44813696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual_04b8b03e-c5ff-4e94-bcc2-983a3304004f" xlink:href="bhc-20220510.xsd#bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_910d42af-c6ee-41be-abc4-7f23f06185ab" xlink:to="loc_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual_04b8b03e-c5ff-4e94-bcc2-983a3304004f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_af41b7d4-0ad9-4f88-920e-feee607eb389" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_910d42af-c6ee-41be-abc4-7f23f06185ab" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_af41b7d4-0ad9-4f88-920e-feee607eb389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NumberOfOtherBusinessesAcquired_ea206b54-4de8-4275-98db-f7c364d49620" xlink:href="bhc-20220510.xsd#bhc_NumberOfOtherBusinessesAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_910d42af-c6ee-41be-abc4-7f23f06185ab" xlink:to="loc_bhc_NumberOfOtherBusinessesAcquired_ea206b54-4de8-4275-98db-f7c364d49620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_adeb8a87-4c26-4f7d-8fee-148682c75774" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_910d42af-c6ee-41be-abc4-7f23f06185ab" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_adeb8a87-4c26-4f7d-8fee-148682c75774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_b9753b2d-0842-42fb-be25-8c264406631d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_910d42af-c6ee-41be-abc4-7f23f06185ab" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_b9753b2d-0842-42fb-be25-8c264406631d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected_6650c48c-308e-4519-8601-a11a89dd22a1" xlink:href="bhc-20220510.xsd#bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_910d42af-c6ee-41be-abc4-7f23f06185ab" xlink:to="loc_bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected_6650c48c-308e-4519-8601-a11a89dd22a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_5a631ad3-0712-4355-bad0-4f138c513d20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_910d42af-c6ee-41be-abc4-7f23f06185ab" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_5a631ad3-0712-4355-bad0-4f138c513d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_7640cba3-64a0-4e09-87a7-f21cfb9a4d62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_910d42af-c6ee-41be-abc4-7f23f06185ab" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_7640cba3-64a0-4e09-87a7-f21cfb9a4d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NoncashCumulativeForeignCurrencyTranslationLoss_259b0472-a6f3-4b22-a4e1-68cbcd757494" xlink:href="bhc-20220510.xsd#bhc_NoncashCumulativeForeignCurrencyTranslationLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_910d42af-c6ee-41be-abc4-7f23f06185ab" xlink:to="loc_bhc_NoncashCumulativeForeignCurrencyTranslationLoss_259b0472-a6f3-4b22-a4e1-68cbcd757494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c0387d33-0f72-4810-89fd-73177e8cbc9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d0b79b28-e9cd-4939-a23e-4e4d111eaeb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c0387d33-0f72-4810-89fd-73177e8cbc9a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d0b79b28-e9cd-4939-a23e-4e4d111eaeb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b65d0ead-3e23-4cec-b5f1-a26ba0c4b36b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d0b79b28-e9cd-4939-a23e-4e4d111eaeb5" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b65d0ead-3e23-4cec-b5f1-a26ba0c4b36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e5b5bbe-4fc0-43cc-b830-0e12e7c75f52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b65d0ead-3e23-4cec-b5f1-a26ba0c4b36b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e5b5bbe-4fc0-43cc-b830-0e12e7c75f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SynergyPharmaceuticalsInc.Member_45797853-4ebb-44fa-a8b8-89f94195732f" xlink:href="bhc-20220510.xsd#bhc_SynergyPharmaceuticalsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e5b5bbe-4fc0-43cc-b830-0e12e7c75f52" xlink:to="loc_bhc_SynergyPharmaceuticalsInc.Member_45797853-4ebb-44fa-a8b8-89f94195732f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_70ec8b49-d35b-406d-a75b-b5f2702e1eab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d0b79b28-e9cd-4939-a23e-4e4d111eaeb5" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_70ec8b49-d35b-406d-a75b-b5f2702e1eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_98f0eedd-3361-424a-817c-64182e97361f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70ec8b49-d35b-406d-a75b-b5f2702e1eab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_98f0eedd-3361-424a-817c-64182e97361f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_9969affb-4588-41b6-84c8-93a633b05b56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70ec8b49-d35b-406d-a75b-b5f2702e1eab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_9969affb-4588-41b6-84c8-93a633b05b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_930d4eef-f853-4baf-8c27-81c1db08fb23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70ec8b49-d35b-406d-a75b-b5f2702e1eab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_930d4eef-f853-4baf-8c27-81c1db08fb23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_274a9b57-ec6e-483f-96d0-d45c685a6bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70ec8b49-d35b-406d-a75b-b5f2702e1eab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_274a9b57-ec6e-483f-96d0-d45c685a6bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_e4cfea76-7654-4989-b528-c92f4ffff376" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70ec8b49-d35b-406d-a75b-b5f2702e1eab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_e4cfea76-7654-4989-b528-c92f4ffff376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses_5dcde453-6df8-4ab1-bb78-bcbea43da195" xlink:href="bhc-20220510.xsd#bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70ec8b49-d35b-406d-a75b-b5f2702e1eab" xlink:to="loc_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses_5dcde453-6df8-4ab1-bb78-bcbea43da195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_6720dc50-45dd-45db-90af-37983b94bb98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70ec8b49-d35b-406d-a75b-b5f2702e1eab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_6720dc50-45dd-45db-90af-37983b94bb98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_90c5b3ea-57a3-48b3-a2b2-ff966a45f964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70ec8b49-d35b-406d-a75b-b5f2702e1eab" xlink:to="loc_us-gaap_Goodwill_90c5b3ea-57a3-48b3-a2b2-ff966a45f964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_ecbfc51f-f789-4eed-9cb7-95cdafe7096d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70ec8b49-d35b-406d-a75b-b5f2702e1eab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_ecbfc51f-f789-4eed-9cb7-95cdafe7096d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_879ab176-2fbe-4bd3-8282-b04000e0154c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_70ec8b49-d35b-406d-a75b-b5f2702e1eab" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_879ab176-2fbe-4bd3-8282-b04000e0154c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_18c74c6f-12fd-4c23-9d7b-bc23170e7d32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f67cd9aa-4c3b-4877-8009-ba715b3b8686" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_18c74c6f-12fd-4c23-9d7b-bc23170e7d32" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f67cd9aa-4c3b-4877-8009-ba715b3b8686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6a062929-c553-4efe-b398-f25c233d25e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f67cd9aa-4c3b-4877-8009-ba715b3b8686" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6a062929-c553-4efe-b398-f25c233d25e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2f57c801-0361-4c8a-b35f-b02376617d67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6a062929-c553-4efe-b398-f25c233d25e3" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2f57c801-0361-4c8a-b35f-b02376617d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ACertainInternationalBusinessMember_9e2104f2-3647-4f1d-88ce-1c2d5b8befdd" xlink:href="bhc-20220510.xsd#bhc_ACertainInternationalBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2f57c801-0361-4c8a-b35f-b02376617d67" xlink:to="loc_bhc_ACertainInternationalBusinessMember_9e2104f2-3647-4f1d-88ce-1c2d5b8befdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_d4b39a56-5e2d-4346-a829-786d4f5e9c68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f67cd9aa-4c3b-4877-8009-ba715b3b8686" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_d4b39a56-5e2d-4346-a829-786d4f5e9c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0eae1074-dd7b-4062-88f8-5eed6cff875e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_d4b39a56-5e2d-4346-a829-786d4f5e9c68" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0eae1074-dd7b-4062-88f8-5eed6cff875e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_2d145273-9fbc-41df-afbe-8cadaf8128dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_0eae1074-dd7b-4062-88f8-5eed6cff875e" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_2d145273-9fbc-41df-afbe-8cadaf8128dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5c328517-190b-47b7-86fe-d85e04156033" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f67cd9aa-4c3b-4877-8009-ba715b3b8686" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5c328517-190b-47b7-86fe-d85e04156033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_6635bab6-9047-4a8e-9bc2-395b02331fab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5c328517-190b-47b7-86fe-d85e04156033" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_6635bab6-9047-4a8e-9bc2-395b02331fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_0fa70b84-9e02-41a4-a8e6-ca127e04fb12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_6635bab6-9047-4a8e-9bc2-395b02331fab" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_0fa70b84-9e02-41a4-a8e6-ca127e04fb12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_0f3def9e-072b-4457-b327-a6f1a977da26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_6635bab6-9047-4a8e-9bc2-395b02331fab" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_0f3def9e-072b-4457-b327-a6f1a977da26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_8fb28364-d0f1-47a2-baff-65317bd54812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_6635bab6-9047-4a8e-9bc2-395b02331fab" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_8fb28364-d0f1-47a2-baff-65317bd54812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_ca654fc7-8071-4708-9097-e51dc265f164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_6635bab6-9047-4a8e-9bc2-395b02331fab" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_ca654fc7-8071-4708-9097-e51dc265f164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_1d356c52-1489-403c-a3fa-134b91b3b54d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5c328517-190b-47b7-86fe-d85e04156033" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_1d356c52-1489-403c-a3fa-134b91b3b54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_4b84552e-89c0-4fb8-8833-505998d2158f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_1d356c52-1489-403c-a3fa-134b91b3b54d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_4b84552e-89c0-4fb8-8833-505998d2158f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_3cab0c0b-4aa5-4acb-98f3-171fcf990151" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_1d356c52-1489-403c-a3fa-134b91b3b54d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_3cab0c0b-4aa5-4acb-98f3-171fcf990151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_90397337-014b-4bf4-9fce-80a0f501f20d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_1d356c52-1489-403c-a3fa-134b91b3b54d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_90397337-014b-4bf4-9fce-80a0f501f20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_b995e7ce-8ff7-481b-9c9d-84846cb569a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_1d356c52-1489-403c-a3fa-134b91b3b54d" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_b995e7ce-8ff7-481b-9c9d-84846cb569a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_6d9bf238-3d60-42f3-b9de-bc01c2289b49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5c328517-190b-47b7-86fe-d85e04156033" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_6d9bf238-3d60-42f3-b9de-bc01c2289b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_bc58e447-e352-4559-bc25-5609bc803bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_6d9bf238-3d60-42f3-b9de-bc01c2289b49" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_bc58e447-e352-4559-bc25-5609bc803bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent_04ed6261-f9ec-4250-b373-8e8e27837d1e" xlink:href="bhc-20220510.xsd#bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_6d9bf238-3d60-42f3-b9de-bc01c2289b49" xlink:to="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent_04ed6261-f9ec-4250-b373-8e8e27837d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_ca5bb1b9-6562-4c81-88e5-8887db116d93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_6d9bf238-3d60-42f3-b9de-bc01c2289b49" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_ca5bb1b9-6562-4c81-88e5-8887db116d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_89407fdb-30f4-4ed5-9086-109c98ca4020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5c328517-190b-47b7-86fe-d85e04156033" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_89407fdb-30f4-4ed5-9086-109c98ca4020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_da025681-daa1-4668-90ad-014ea691456f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_89407fdb-30f4-4ed5-9086-109c98ca4020" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_da025681-daa1-4668-90ad-014ea691456f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent_514b1584-ea1e-4faf-9de6-1b3e72a82ac7" xlink:href="bhc-20220510.xsd#bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_89407fdb-30f4-4ed5-9086-109c98ca4020" xlink:to="loc_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent_514b1584-ea1e-4faf-9de6-1b3e72a82ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_2de8c4b1-d812-45c4-bc5b-3bdfb76039e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract_89407fdb-30f4-4ed5-9086-109c98ca4020" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_2de8c4b1-d812-45c4-bc5b-3bdfb76039e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS" xlink:type="simple" xlink:href="bhc-20220510.xsd#RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a4a81860-e6bb-42d4-bbac-ef72d5da2e62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_61130be7-e454-42a3-bb4f-1a8e249bd440" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_a4a81860-e6bb-42d4-bbac-ef72d5da2e62" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_61130be7-e454-42a3-bb4f-1a8e249bd440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_c7fcb3f8-2dc1-467b-b50c-0f91f1019313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_44ab1c4a-ab7e-4ff6-8393-06df2e68bea5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_c7fcb3f8-2dc1-467b-b50c-0f91f1019313" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_44ab1c4a-ab7e-4ff6-8393-06df2e68bea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_a8ceee5c-0d4e-4b71-8566-90a5318a1506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_44ab1c4a-ab7e-4ff6-8393-06df2e68bea5" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_a8ceee5c-0d4e-4b71-8566-90a5318a1506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_bc95fe0f-fc44-4766-95a3-fc18e2e88b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_a8ceee5c-0d4e-4b71-8566-90a5318a1506" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_bc95fe0f-fc44-4766-95a3-fc18e2e88b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringAndIntegrationCostsMember_accfafab-b23e-4496-95d4-67257baa0897" xlink:href="bhc-20220510.xsd#bhc_RestructuringAndIntegrationCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_bc95fe0f-fc44-4766-95a3-fc18e2e88b0c" xlink:to="loc_bhc_RestructuringAndIntegrationCostsMember_accfafab-b23e-4496-95d4-67257baa0897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeparationAndInitialPublicOfferingCostsMember_e0d667aa-7676-4d2d-8574-f39c91d93d58" xlink:href="bhc-20220510.xsd#bhc_SeparationAndInitialPublicOfferingCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_bc95fe0f-fc44-4766-95a3-fc18e2e88b0c" xlink:to="loc_bhc_SeparationAndInitialPublicOfferingCostsMember_e0d667aa-7676-4d2d-8574-f39c91d93d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_d2e8ac34-6ae7-4da7-8301-367892b96597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_44ab1c4a-ab7e-4ff6-8393-06df2e68bea5" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_d2e8ac34-6ae7-4da7-8301-367892b96597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_0f7cebd9-6185-4ed8-9ead-936216684e97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d2e8ac34-6ae7-4da7-8301-367892b96597" xlink:to="loc_us-gaap_RestructuringReserve_0f7cebd9-6185-4ed8-9ead-936216684e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_364830a9-c2be-42db-bd57-70314dfe36df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d2e8ac34-6ae7-4da7-8301-367892b96597" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_364830a9-c2be-42db-bd57-70314dfe36df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_882768da-34f8-49c6-885d-bd3ebef1d868" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d2e8ac34-6ae7-4da7-8301-367892b96597" xlink:to="loc_us-gaap_PaymentsForRestructuring_882768da-34f8-49c6-885d-bd3ebef1d868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_a53c7884-6603-47b0-9a79-cd2f0cf6b2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d2e8ac34-6ae7-4da7-8301-367892b96597" xlink:to="loc_us-gaap_RestructuringCharges_a53c7884-6603-47b0-9a79-cd2f0cf6b2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_fc1f0be8-825f-4add-a1b2-a9711ff44b28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d2e8ac34-6ae7-4da7-8301-367892b96597" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_fc1f0be8-825f-4add-a1b2-a9711ff44b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="bhc-20220510.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8eff67c7-b1c7-4c20-8a9f-9ced7eb1bf00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_47feaaff-d5bf-4065-ac5f-bf4584334c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8eff67c7-b1c7-4c20-8a9f-9ced7eb1bf00" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_47feaaff-d5bf-4065-ac5f-bf4584334c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="bhc-20220510.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d31ce348-052d-4c87-a41d-bf4ee1d76237" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_892e5f50-b503-4bd1-82da-b871b53dd926" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d31ce348-052d-4c87-a41d-bf4ee1d76237" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_892e5f50-b503-4bd1-82da-b871b53dd926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_c358a0a3-5a59-4209-8c83-69d0090dc4e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d31ce348-052d-4c87-a41d-bf4ee1d76237" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_c358a0a3-5a59-4209-8c83-69d0090dc4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_61e8c9e4-3524-430f-bb1a-92e75534d61d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d31ce348-052d-4c87-a41d-bf4ee1d76237" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_61e8c9e4-3524-430f-bb1a-92e75534d61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock_e182822f-8e8c-4b99-bd16-6e91a630e27b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d31ce348-052d-4c87-a41d-bf4ee1d76237" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock_e182822f-8e8c-4b99-bd16-6e91a630e27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_5b26981e-77aa-4173-a2ad-ddbfd9603331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d31ce348-052d-4c87-a41d-bf4ee1d76237" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_5b26981e-77aa-4173-a2ad-ddbfd9603331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_f3da4f5a-ac39-4d37-b775-a625e99e017c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d31ce348-052d-4c87-a41d-bf4ee1d76237" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_f3da4f5a-ac39-4d37-b775-a625e99e017c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5e944049-8773-4146-a5c8-3df9b81901ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fa5a531c-ed24-48ad-bc74-28242447874e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5e944049-8773-4146-a5c8-3df9b81901ab" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fa5a531c-ed24-48ad-bc74-28242447874e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_409c9182-4de7-4d37-9074-9f9c63db9362" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fa5a531c-ed24-48ad-bc74-28242447874e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_409c9182-4de7-4d37-9074-9f9c63db9362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c6e4a89b-b3fd-43df-b034-af1b55b391c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_409c9182-4de7-4d37-9074-9f9c63db9362" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c6e4a89b-b3fd-43df-b034-af1b55b391c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_dddf6227-d030-4f3f-95b1-e37f79f40d31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c6e4a89b-b3fd-43df-b034-af1b55b391c8" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_dddf6227-d030-4f3f-95b1-e37f79f40d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_118afa9d-df01-4a38-b76a-0e0f46d2c1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fa5a531c-ed24-48ad-bc74-28242447874e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_118afa9d-df01-4a38-b76a-0e0f46d2c1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92fd67f3-1c07-4aa4-8d49-d3f6c1c9e82c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_118afa9d-df01-4a38-b76a-0e0f46d2c1bf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92fd67f3-1c07-4aa4-8d49-d3f6c1c9e82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b2d640d1-3d0c-43c8-81c9-f987495e50c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92fd67f3-1c07-4aa4-8d49-d3f6c1c9e82c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b2d640d1-3d0c-43c8-81c9-f987495e50c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2189d3e4-88e7-4f91-8e88-157cfcca6a14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92fd67f3-1c07-4aa4-8d49-d3f6c1c9e82c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2189d3e4-88e7-4f91-8e88-157cfcca6a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9fdc9ed8-d378-4fe6-95c1-de8b58b89452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92fd67f3-1c07-4aa4-8d49-d3f6c1c9e82c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9fdc9ed8-d378-4fe6-95c1-de8b58b89452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_adde38b2-41a2-452f-a409-13e2397831b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fa5a531c-ed24-48ad-bc74-28242447874e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_adde38b2-41a2-452f-a409-13e2397831b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_8a922b11-8b91-4df1-9082-be15dd498751" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_adde38b2-41a2-452f-a409-13e2397831b1" xlink:to="loc_us-gaap_HedgingRelationshipDomain_8a922b11-8b91-4df1-9082-be15dd498751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_a20d7d72-9d5d-44b3-9bb4-163be8998ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_8a922b11-8b91-4df1-9082-be15dd498751" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_a20d7d72-9d5d-44b3-9bb4-163be8998ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4dda6d8c-f67c-4b35-9b35-4f8f30acc779" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fa5a531c-ed24-48ad-bc74-28242447874e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4dda6d8c-f67c-4b35-9b35-4f8f30acc779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4e4392e7-bdcc-40cb-94c5-658c217b249a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4dda6d8c-f67c-4b35-9b35-4f8f30acc779" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4e4392e7-bdcc-40cb-94c5-658c217b249a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_a649004a-e4f4-49aa-a279-283842fa330a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4e4392e7-bdcc-40cb-94c5-658c217b249a" xlink:to="loc_us-gaap_CurrencySwapMember_a649004a-e4f4-49aa-a279-283842fa330a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_47be04a8-2cc6-4f18-beb7-8fc280de68e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4e4392e7-bdcc-40cb-94c5-658c217b249a" xlink:to="loc_us-gaap_ForeignExchangeContractMember_47be04a8-2cc6-4f18-beb7-8fc280de68e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_dbd31134-e1ff-4c14-a92b-98030ab8edd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fa5a531c-ed24-48ad-bc74-28242447874e" xlink:to="loc_us-gaap_HedgingDesignationAxis_dbd31134-e1ff-4c14-a92b-98030ab8edd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_2f1d4d08-86c8-4e44-9083-562f4e5bbff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_dbd31134-e1ff-4c14-a92b-98030ab8edd4" xlink:to="loc_us-gaap_HedgingDesignationDomain_2f1d4d08-86c8-4e44-9083-562f4e5bbff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_cfd7ef53-de4c-483f-8ebd-8153a1491dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_2f1d4d08-86c8-4e44-9083-562f4e5bbff8" xlink:to="loc_us-gaap_NondesignatedMember_cfd7ef53-de4c-483f-8ebd-8153a1491dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_39f051d9-b0be-4a85-b389-ac45723c0878" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_2f1d4d08-86c8-4e44-9083-562f4e5bbff8" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_39f051d9-b0be-4a85-b389-ac45723c0878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a319deaa-e843-4445-b359-87078551bcd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fa5a531c-ed24-48ad-bc74-28242447874e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a319deaa-e843-4445-b359-87078551bcd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_d3c48298-998a-41df-8e04-7150ad9f1e60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a319deaa-e843-4445-b359-87078551bcd7" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_d3c48298-998a-41df-8e04-7150ad9f1e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c88e3f69-0d55-4166-bbda-f6836f16cd70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d3c48298-998a-41df-8e04-7150ad9f1e60" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_c88e3f69-0d55-4166-bbda-f6836f16cd70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_12ba1ced-463d-4016-8b6d-911562174432" xlink:href="bhc-20220510.xsd#bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d3c48298-998a-41df-8e04-7150ad9f1e60" xlink:to="loc_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure_12ba1ced-463d-4016-8b6d-911562174432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_958fffec-2b5f-4cdc-9223-11e73e95e24f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_d3c48298-998a-41df-8e04-7150ad9f1e60" xlink:to="loc_us-gaap_DerivativeAssets_958fffec-2b5f-4cdc-9223-11e73e95e24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_fe05f4c7-194e-4b1b-9e49-da3d70da253e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a319deaa-e843-4445-b359-87078551bcd7" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_fe05f4c7-194e-4b1b-9e49-da3d70da253e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_017009a6-6734-46c8-b04a-7deff28ddf56" xlink:href="bhc-20220510.xsd#bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_fe05f4c7-194e-4b1b-9e49-da3d70da253e" xlink:to="loc_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure_017009a6-6734-46c8-b04a-7deff28ddf56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_560f3445-2274-4f0d-859f-437cfc865d89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_fe05f4c7-194e-4b1b-9e49-da3d70da253e" xlink:to="loc_us-gaap_DerivativeLiabilities_560f3445-2274-4f0d-859f-437cfc865d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a2d722fd-323d-49f2-bee3-610e26519b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7e11dd1a-d247-49aa-9617-8378c9fdaabf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a2d722fd-323d-49f2-bee3-610e26519b2a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7e11dd1a-d247-49aa-9617-8378c9fdaabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_ab8b87d0-4624-4005-ab0c-e16a29be816c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7e11dd1a-d247-49aa-9617-8378c9fdaabf" xlink:to="loc_srt_LitigationCaseAxis_ab8b87d0-4624-4005-ab0c-e16a29be816c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a68ad7c9-a404-4604-81bc-ca9a68ba8eec" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_ab8b87d0-4624-4005-ab0c-e16a29be816c" xlink:to="loc_srt_LitigationCaseTypeDomain_a68ad7c9-a404-4604-81bc-ca9a68ba8eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_236ef1ff-82f1-41d3-afa3-bb60981bf325" xlink:href="bhc-20220510.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_a68ad7c9-a404-4604-81bc-ca9a68ba8eec" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_236ef1ff-82f1-41d3-afa3-bb60981bf325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_331fdc41-de14-4717-8f90-bb2819ca5186" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7e11dd1a-d247-49aa-9617-8378c9fdaabf" xlink:to="loc_srt_StatementGeographicalAxis_331fdc41-de14-4717-8f90-bb2819ca5186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_99b08438-215f-4468-a56d-b4235a9a11c8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_331fdc41-de14-4717-8f90-bb2819ca5186" xlink:to="loc_srt_SegmentGeographicalDomain_99b08438-215f-4468-a56d-b4235a9a11c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_60b2c22a-2666-4c9f-8f18-a254c9a91d3c" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_99b08438-215f-4468-a56d-b4235a9a11c8" xlink:to="loc_stpr_NJ_60b2c22a-2666-4c9f-8f18-a254c9a91d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_f4c03c8b-5806-4311-9bf3-e7ae1d637fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7e11dd1a-d247-49aa-9617-8378c9fdaabf" xlink:to="loc_us-gaap_LitigationStatusAxis_f4c03c8b-5806-4311-9bf3-e7ae1d637fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_10d86143-0824-41a8-8872-c3c852aa0f21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_f4c03c8b-5806-4311-9bf3-e7ae1d637fd3" xlink:to="loc_us-gaap_LitigationStatusDomain_10d86143-0824-41a8-8872-c3c852aa0f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_5959f0c9-dfe5-4e63-b666-53119014ab02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_10d86143-0824-41a8-8872-c3c852aa0f21" xlink:to="loc_us-gaap_SettledLitigationMember_5959f0c9-dfe5-4e63-b666-53119014ab02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_356779b0-7697-4b03-b289-51c4545522ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_7e11dd1a-d247-49aa-9617-8378c9fdaabf" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_356779b0-7697-4b03-b289-51c4545522ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_f9472136-be0b-4d52-8421-d727ca169e4f" xlink:href="bhc-20220510.xsd#bhc_HighlyLiquidInvestmentsMaturityPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_356779b0-7697-4b03-b289-51c4545522ba" xlink:to="loc_bhc_HighlyLiquidInvestmentsMaturityPeriod_f9472136-be0b-4d52-8421-d727ca169e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_c8ba8755-8c7f-4424-b487-3a450d0be675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_356779b0-7697-4b03-b289-51c4545522ba" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_c8ba8755-8c7f-4424-b487-3a450d0be675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d3b944ef-9a49-40d4-b6b7-fbfecc9535cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a6227724-b007-49de-9c48-2154e005989e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d3b944ef-9a49-40d4-b6b7-fbfecc9535cc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a6227724-b007-49de-9c48-2154e005989e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_74edbb9f-f8d8-4cee-9d4b-7f69ba6db725" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a6227724-b007-49de-9c48-2154e005989e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_74edbb9f-f8d8-4cee-9d4b-7f69ba6db725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ffb296c8-28cd-48be-96b9-d79ed4f1542d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_74edbb9f-f8d8-4cee-9d4b-7f69ba6db725" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ffb296c8-28cd-48be-96b9-d79ed4f1542d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_c9926ca2-13b8-47eb-a58f-c47e7ac79334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_ffb296c8-28cd-48be-96b9-d79ed4f1542d" xlink:to="loc_us-gaap_CurrencySwapMember_c9926ca2-13b8-47eb-a58f-c47e7ac79334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CrossCurrencyFinalSettlementMember_25f43906-cfdc-4d53-be66-e4274e345b7f" xlink:href="bhc-20220510.xsd#bhc_CrossCurrencyFinalSettlementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrencySwapMember_c9926ca2-13b8-47eb-a58f-c47e7ac79334" xlink:to="loc_bhc_CrossCurrencyFinalSettlementMember_25f43906-cfdc-4d53-be66-e4274e345b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ea1f1381-f10e-455a-bbe5-bbad8c298371" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a6227724-b007-49de-9c48-2154e005989e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ea1f1381-f10e-455a-bbe5-bbad8c298371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_5fa9d520-ff03-45e9-9d21-f204306fc4a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ea1f1381-f10e-455a-bbe5-bbad8c298371" xlink:to="loc_us-gaap_HedgingRelationshipDomain_5fa9d520-ff03-45e9-9d21-f204306fc4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_9bd88e9a-9861-40b5-ae64-01004a069a11" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_5fa9d520-ff03-45e9-9d21-f204306fc4a5" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_9bd88e9a-9861-40b5-ae64-01004a069a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_622fc8d0-ef9f-43a4-a11e-268e5285d1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a6227724-b007-49de-9c48-2154e005989e" xlink:to="loc_us-gaap_HedgingDesignationAxis_622fc8d0-ef9f-43a4-a11e-268e5285d1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_c5bb8dde-a18b-4fe9-9d2a-4eb0b72a3f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_622fc8d0-ef9f-43a4-a11e-268e5285d1ca" xlink:to="loc_us-gaap_HedgingDesignationDomain_c5bb8dde-a18b-4fe9-9d2a-4eb0b72a3f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_ed6bce50-340f-45a5-b5cd-bc28076b54b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_c5bb8dde-a18b-4fe9-9d2a-4eb0b72a3f6e" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_ed6bce50-340f-45a5-b5cd-bc28076b54b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b0b6dd1-9907-4e5e-9253-5c84180f1df5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a6227724-b007-49de-9c48-2154e005989e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b0b6dd1-9907-4e5e-9253-5c84180f1df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_83a81707-df18-4ded-b6ff-1208dbb98594" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b0b6dd1-9907-4e5e-9253-5c84180f1df5" xlink:to="loc_us-gaap_DerivativeNotionalAmount_83a81707-df18-4ded-b6ff-1208dbb98594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeInvestingActivities_ab7af6b8-ee1f-4deb-86cc-db15da6b86e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromHedgeInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b0b6dd1-9907-4e5e-9253-5c84180f1df5" xlink:to="loc_us-gaap_ProceedsFromHedgeInvestingActivities_ab7af6b8-ee1f-4deb-86cc-db15da6b86e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_06cdc053-d5f8-4cfc-9b1e-43cbd4c4d05f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b0b6dd1-9907-4e5e-9253-5c84180f1df5" xlink:to="loc_us-gaap_InvestmentIncomeInterest_06cdc053-d5f8-4cfc-9b1e-43cbd4c4d05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_688ed763-7b8f-4eeb-b99c-bad193dc57c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2b0b6dd1-9907-4e5e-9253-5c84180f1df5" xlink:to="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_688ed763-7b8f-4eeb-b99c-bad193dc57c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2ea8d1cc-0301-48e1-964f-c7f233b6dfdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b8940a3-f85d-4c91-b068-da4254758969" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2ea8d1cc-0301-48e1-964f-c7f233b6dfdb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b8940a3-f85d-4c91-b068-da4254758969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c898a0be-9d3f-4963-8730-0b6892a0e1af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b8940a3-f85d-4c91-b068-da4254758969" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c898a0be-9d3f-4963-8730-0b6892a0e1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0b917516-b33b-4bdb-b4ec-7f69460d7695" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c898a0be-9d3f-4963-8730-0b6892a0e1af" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0b917516-b33b-4bdb-b4ec-7f69460d7695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_a7c76b75-4273-488a-a6d5-a62ba40922ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0b917516-b33b-4bdb-b4ec-7f69460d7695" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_a7c76b75-4273-488a-a6d5-a62ba40922ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_71086a47-330c-4fa4-b71b-6761a88c731e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0b917516-b33b-4bdb-b4ec-7f69460d7695" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_71086a47-330c-4fa4-b71b-6761a88c731e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4c05da9b-b603-4a28-8aa0-6eedbb3b54cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b8940a3-f85d-4c91-b068-da4254758969" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4c05da9b-b603-4a28-8aa0-6eedbb3b54cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_195a9b0a-591f-4cd3-ac67-bd7675b13156" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4c05da9b-b603-4a28-8aa0-6eedbb3b54cc" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_195a9b0a-591f-4cd3-ac67-bd7675b13156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_a2049c9e-c09f-4156-afdd-f7942851e2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_195a9b0a-591f-4cd3-ac67-bd7675b13156" xlink:to="loc_us-gaap_CurrencySwapMember_a2049c9e-c09f-4156-afdd-f7942851e2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c5dfe78f-36f5-44b6-9cf9-7d498f9576d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b8940a3-f85d-4c91-b068-da4254758969" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c5dfe78f-36f5-44b6-9cf9-7d498f9576d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_52c68974-ec31-43b0-a33f-61d889258617" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_c5dfe78f-36f5-44b6-9cf9-7d498f9576d0" xlink:to="loc_us-gaap_HedgingRelationshipDomain_52c68974-ec31-43b0-a33f-61d889258617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_d5a761d0-c195-4f23-bf42-27c23248c592" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_52c68974-ec31-43b0-a33f-61d889258617" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_d5a761d0-c195-4f23-bf42-27c23248c592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_4efa966b-4fb9-4e79-89ed-7bbe0f032ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b8940a3-f85d-4c91-b068-da4254758969" xlink:to="loc_us-gaap_HedgingDesignationAxis_4efa966b-4fb9-4e79-89ed-7bbe0f032ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_29d40ed8-69e7-408b-a61a-ae01f6383722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_4efa966b-4fb9-4e79-89ed-7bbe0f032ea1" xlink:to="loc_us-gaap_HedgingDesignationDomain_29d40ed8-69e7-408b-a61a-ae01f6383722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b8fb2eb3-c474-42d8-88d0-c52e628cd4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_29d40ed8-69e7-408b-a61a-ae01f6383722" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b8fb2eb3-c474-42d8-88d0-c52e628cd4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f11178db-fc1a-4f38-8ac1-31ec109f9d82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_4b8940a3-f85d-4c91-b068-da4254758969" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f11178db-fc1a-4f38-8ac1-31ec109f9d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_98c32c03-d3e3-4004-aa06-56f27641ce34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f11178db-fc1a-4f38-8ac1-31ec109f9d82" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_98c32c03-d3e3-4004-aa06-56f27641ce34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_86439078-730b-4bb5-a1a1-7350fbd66fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f11178db-fc1a-4f38-8ac1-31ec109f9d82" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_86439078-730b-4bb5-a1a1-7350fbd66fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_5fac646f-d5bd-49b1-8bbe-4890f2e2802b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f11178db-fc1a-4f38-8ac1-31ec109f9d82" xlink:to="loc_us-gaap_DerivativeLiabilities_5fac646f-d5bd-49b1-8bbe-4890f2e2802b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_bad9342b-967d-49b0-8759-9e89f4aeac26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e99b0998-6d6f-452b-8468-274209031f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bad9342b-967d-49b0-8759-9e89f4aeac26" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e99b0998-6d6f-452b-8468-274209031f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_a0e11ae2-9c65-4559-b315-96b0083ac790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e99b0998-6d6f-452b-8468-274209031f1e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_a0e11ae2-9c65-4559-b315-96b0083ac790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b4f0d9da-1f38-4b4e-8457-ec0e6d844e35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a0e11ae2-9c65-4559-b315-96b0083ac790" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b4f0d9da-1f38-4b4e-8457-ec0e6d844e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_1d9e6d8a-93f3-4429-b108-23beb0447518" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b4f0d9da-1f38-4b4e-8457-ec0e6d844e35" xlink:to="loc_us-gaap_CurrencySwapMember_1d9e6d8a-93f3-4429-b108-23beb0447518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CrossCurrencyFinalSettlementMember_354881b3-31d3-4034-b5d0-326386dd298e" xlink:href="bhc-20220510.xsd#bhc_CrossCurrencyFinalSettlementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b4f0d9da-1f38-4b4e-8457-ec0e6d844e35" xlink:to="loc_bhc_CrossCurrencyFinalSettlementMember_354881b3-31d3-4034-b5d0-326386dd298e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ea90e635-3e90-4f1c-81a4-d4029b116339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e99b0998-6d6f-452b-8468-274209031f1e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ea90e635-3e90-4f1c-81a4-d4029b116339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_cd24a93b-7b74-4ec7-9ef9-e24a623c247f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ea90e635-3e90-4f1c-81a4-d4029b116339" xlink:to="loc_us-gaap_HedgingRelationshipDomain_cd24a93b-7b74-4ec7-9ef9-e24a623c247f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_5b9d0139-5521-4bb1-92dc-824e32ec52ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_cd24a93b-7b74-4ec7-9ef9-e24a623c247f" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_5b9d0139-5521-4bb1-92dc-824e32ec52ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_741c8e92-ce3d-447b-8189-c90410d0eda6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e99b0998-6d6f-452b-8468-274209031f1e" xlink:to="loc_us-gaap_HedgingDesignationAxis_741c8e92-ce3d-447b-8189-c90410d0eda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_07eac5c1-6e79-4e7a-85e0-91c2cefc3bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_741c8e92-ce3d-447b-8189-c90410d0eda6" xlink:to="loc_us-gaap_HedgingDesignationDomain_07eac5c1-6e79-4e7a-85e0-91c2cefc3bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b1f3b00a-f7a5-4149-9ac5-bb895743ceff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_07eac5c1-6e79-4e7a-85e0-91c2cefc3bbf" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b1f3b00a-f7a5-4149-9ac5-bb895743ceff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6dae0530-cacf-45ff-a48c-83050008d7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e99b0998-6d6f-452b-8468-274209031f1e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6dae0530-cacf-45ff-a48c-83050008d7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a4e72712-6dd0-4ef1-ac82-8f9e61f1c7bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6dae0530-cacf-45ff-a48c-83050008d7b5" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a4e72712-6dd0-4ef1-ac82-8f9e61f1c7bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_7f88abac-9a8f-4c28-9689-4596910fc568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a4e72712-6dd0-4ef1-ac82-8f9e61f1c7bb" xlink:to="loc_us-gaap_InterestExpenseMember_7f88abac-9a8f-4c28-9689-4596910fc568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_99035930-e492-40a6-a5cc-ec8b1d2c2fac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_e99b0998-6d6f-452b-8468-274209031f1e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_99035930-e492-40a6-a5cc-ec8b1d2c2fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_e973a78f-bf65-43fb-8151-795c519e390b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_99035930-e492-40a6-a5cc-ec8b1d2c2fac" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_e973a78f-bf65-43fb-8151-795c519e390b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_adf1d0a5-55f6-49e5-a42d-142ffec922ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_99035930-e492-40a6-a5cc-ec8b1d2c2fac" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_adf1d0a5-55f6-49e5-a42d-142ffec922ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_d9c8b294-8682-4856-a2e6-4f1ed2e01a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_99035930-e492-40a6-a5cc-ec8b1d2c2fac" xlink:to="loc_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities_d9c8b294-8682-4856-a2e6-4f1ed2e01a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6f1fac72-ff4b-46c7-b1ea-4817bc813654" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85b0ba12-bcf9-44a9-bcf3-f55708726712" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6f1fac72-ff4b-46c7-b1ea-4817bc813654" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85b0ba12-bcf9-44a9-bcf3-f55708726712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_f2089632-ca8a-4145-b4a6-627e40aa25f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85b0ba12-bcf9-44a9-bcf3-f55708726712" xlink:to="loc_us-gaap_HedgingDesignationAxis_f2089632-ca8a-4145-b4a6-627e40aa25f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_0e97efd8-7994-4e7c-a7b6-a9f41f73830b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_f2089632-ca8a-4145-b4a6-627e40aa25f3" xlink:to="loc_us-gaap_HedgingDesignationDomain_0e97efd8-7994-4e7c-a7b6-a9f41f73830b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_df41afe6-d13c-4057-a308-e34888995128" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_0e97efd8-7994-4e7c-a7b6-a9f41f73830b" xlink:to="loc_us-gaap_NondesignatedMember_df41afe6-d13c-4057-a308-e34888995128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_22954db4-8d02-4c9a-b885-f27eb0483225" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85b0ba12-bcf9-44a9-bcf3-f55708726712" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_22954db4-8d02-4c9a-b885-f27eb0483225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a2b1ba0e-bcde-40f4-b552-acf8edd2cf0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_22954db4-8d02-4c9a-b885-f27eb0483225" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a2b1ba0e-bcde-40f4-b552-acf8edd2cf0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_430bb873-78e1-45e2-9adc-0b5b43ed1f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a2b1ba0e-bcde-40f4-b552-acf8edd2cf0b" xlink:to="loc_us-gaap_ForeignExchangeContractMember_430bb873-78e1-45e2-9adc-0b5b43ed1f6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f86e6df0-5b7b-4983-bc3a-888c6726d91b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_85b0ba12-bcf9-44a9-bcf3-f55708726712" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f86e6df0-5b7b-4983-bc3a-888c6726d91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_164e60ad-be92-4d03-86a8-c64e6f6c3de4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f86e6df0-5b7b-4983-bc3a-888c6726d91b" xlink:to="loc_us-gaap_DerivativeNotionalAmount_164e60ad-be92-4d03-86a8-c64e6f6c3de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d2de4c9b-53b7-400a-a6f8-ff4d2cc8da66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01948448-8b47-4038-b1f4-8b9e5ddf80e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d2de4c9b-53b7-400a-a6f8-ff4d2cc8da66" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01948448-8b47-4038-b1f4-8b9e5ddf80e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e02b49cf-189a-4b2d-b7b7-f58adb3b5690" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01948448-8b47-4038-b1f4-8b9e5ddf80e8" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e02b49cf-189a-4b2d-b7b7-f58adb3b5690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_987ba9be-dbe0-4d1d-b66d-841f1606f278" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e02b49cf-189a-4b2d-b7b7-f58adb3b5690" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_987ba9be-dbe0-4d1d-b66d-841f1606f278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember_f7680cb8-a2be-4a34-8e60-be6ac548b95a" xlink:href="bhc-20220510.xsd#bhc_AccruedAndOtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_987ba9be-dbe0-4d1d-b66d-841f1606f278" xlink:to="loc_bhc_AccruedAndOtherCurrentLiabilitiesMember_f7680cb8-a2be-4a34-8e60-be6ac548b95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_2cbb57eb-c452-4491-9a73-088e2197d813" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_987ba9be-dbe0-4d1d-b66d-841f1606f278" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_2cbb57eb-c452-4491-9a73-088e2197d813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_a0ec8043-ded3-4c91-b52f-aac5fc59f6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01948448-8b47-4038-b1f4-8b9e5ddf80e8" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_a0ec8043-ded3-4c91-b52f-aac5fc59f6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4ca01bae-51dc-42fc-aa95-b1aaa4cdeb79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a0ec8043-ded3-4c91-b52f-aac5fc59f6cc" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4ca01bae-51dc-42fc-aa95-b1aaa4cdeb79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_ea536ae8-da48-4968-a99c-a5901dcabe2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4ca01bae-51dc-42fc-aa95-b1aaa4cdeb79" xlink:to="loc_us-gaap_ForeignExchangeContractMember_ea536ae8-da48-4968-a99c-a5901dcabe2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_a0ffca10-c895-40fc-b61c-24bc9f85a205" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01948448-8b47-4038-b1f4-8b9e5ddf80e8" xlink:to="loc_us-gaap_HedgingDesignationAxis_a0ffca10-c895-40fc-b61c-24bc9f85a205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_2676a2e3-5f65-4718-b692-01636f12f268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_a0ffca10-c895-40fc-b61c-24bc9f85a205" xlink:to="loc_us-gaap_HedgingDesignationDomain_2676a2e3-5f65-4718-b692-01636f12f268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_78b3bfd6-4ab0-4e91-bfbe-7f283e2c0092" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_2676a2e3-5f65-4718-b692-01636f12f268" xlink:to="loc_us-gaap_NondesignatedMember_78b3bfd6-4ab0-4e91-bfbe-7f283e2c0092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e1e7444-bdd7-418d-8237-e45ff25d39b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_01948448-8b47-4038-b1f4-8b9e5ddf80e8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e1e7444-bdd7-418d-8237-e45ff25d39b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_e5ca727f-cd06-446b-a06d-bf32925c4b96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e1e7444-bdd7-418d-8237-e45ff25d39b6" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_e5ca727f-cd06-446b-a06d-bf32925c4b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_44db15b8-5dfa-4a41-9275-33e97d4754a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e1e7444-bdd7-418d-8237-e45ff25d39b6" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_44db15b8-5dfa-4a41-9275-33e97d4754a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_7064b722-647e-49eb-b7bd-3c40b07214c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3e1e7444-bdd7-418d-8237-e45ff25d39b6" xlink:to="loc_us-gaap_DerivativeLiabilities_7064b722-647e-49eb-b7bd-3c40b07214c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f3462995-7c88-4380-a250-cea8d6828a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8ab1d6f9-78b6-424e-8639-cb0cc627c646" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f3462995-7c88-4380-a250-cea8d6828a2d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8ab1d6f9-78b6-424e-8639-cb0cc627c646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_38374562-7f31-4728-9256-ca00a29d94ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8ab1d6f9-78b6-424e-8639-cb0cc627c646" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_38374562-7f31-4728-9256-ca00a29d94ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a6ae9e6e-b502-417b-91f6-add259248fed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_38374562-7f31-4728-9256-ca00a29d94ff" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a6ae9e6e-b502-417b-91f6-add259248fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_37458fb2-b5e4-4381-b890-4108ce914498" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a6ae9e6e-b502-417b-91f6-add259248fed" xlink:to="loc_us-gaap_ForeignExchangeContractMember_37458fb2-b5e4-4381-b890-4108ce914498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_7cdb21f5-9d86-4a7a-97bb-a728745d086c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8ab1d6f9-78b6-424e-8639-cb0cc627c646" xlink:to="loc_us-gaap_HedgingDesignationAxis_7cdb21f5-9d86-4a7a-97bb-a728745d086c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_788be721-1448-4443-b017-d1644a8a3a81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_7cdb21f5-9d86-4a7a-97bb-a728745d086c" xlink:to="loc_us-gaap_HedgingDesignationDomain_788be721-1448-4443-b017-d1644a8a3a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_f1967334-0b87-4c6a-8ad9-176843921029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_788be721-1448-4443-b017-d1644a8a3a81" xlink:to="loc_us-gaap_NondesignatedMember_f1967334-0b87-4c6a-8ad9-176843921029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ccb4f676-0fe7-4ab0-a00e-0094c574f441" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8ab1d6f9-78b6-424e-8639-cb0cc627c646" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ccb4f676-0fe7-4ab0-a00e-0094c574f441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_2f180f63-bd01-426a-b650-f36d3766fcc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ccb4f676-0fe7-4ab0-a00e-0094c574f441" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_2f180f63-bd01-426a-b650-f36d3766fcc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_3a63c2c6-dd67-493e-9e00-b9d955fffde5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ccb4f676-0fe7-4ab0-a00e-0094c574f441" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss_3a63c2c6-dd67-493e-9e00-b9d955fffde5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" xlink:type="simple" xlink:href="bhc-20220510.xsd#FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_28053e29-d94e-43ca-8ca4-331a824af651" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d6815b3b-06db-4036-99f8-2d7ed5ee3964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_28053e29-d94e-43ca-8ca4-331a824af651" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d6815b3b-06db-4036-99f8-2d7ed5ee3964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4cb0b8f8-df34-4086-8b52-833ce36b88f9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d6815b3b-06db-4036-99f8-2d7ed5ee3964" xlink:to="loc_srt_RangeAxis_4cb0b8f8-df34-4086-8b52-833ce36b88f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_50cbe6fd-40de-4c01-8d08-7478b9bb45e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4cb0b8f8-df34-4086-8b52-833ce36b88f9" xlink:to="loc_srt_RangeMember_50cbe6fd-40de-4c01-8d08-7478b9bb45e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b2363ed1-3f27-4ffc-9625-e002173f59b0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_50cbe6fd-40de-4c01-8d08-7478b9bb45e8" xlink:to="loc_srt_MinimumMember_b2363ed1-3f27-4ffc-9625-e002173f59b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b0957184-a57f-4e55-9ba5-3d1b03e1e97f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_50cbe6fd-40de-4c01-8d08-7478b9bb45e8" xlink:to="loc_srt_MaximumMember_b0957184-a57f-4e55-9ba5-3d1b03e1e97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_0ea9dd42-3ce1-4bcb-bccc-985688c7bbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d6815b3b-06db-4036-99f8-2d7ed5ee3964" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_0ea9dd42-3ce1-4bcb-bccc-985688c7bbd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_6a6fa0b0-786d-4f7e-b0fb-63c5ef5a2375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_0ea9dd42-3ce1-4bcb-bccc-985688c7bbd5" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_6a6fa0b0-786d-4f7e-b0fb-63c5ef5a2375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_cb11c888-ae86-4463-8466-069fc5eb83ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6a6fa0b0-786d-4f7e-b0fb-63c5ef5a2375" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_cb11c888-ae86-4463-8466-069fc5eb83ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_3d2f9452-d165-4941-8b41-ea8b82c10447" xlink:href="bhc-20220510.xsd#bhc_MeasurementInputWeightedAverageDiscountRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6a6fa0b0-786d-4f7e-b0fb-63c5ef5a2375" xlink:to="loc_bhc_MeasurementInputWeightedAverageDiscountRateMember_3d2f9452-d165-4941-8b41-ea8b82c10447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_308b4bb2-d6dd-4dd5-955c-059ea7d367b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d6815b3b-06db-4036-99f8-2d7ed5ee3964" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_308b4bb2-d6dd-4dd5-955c-059ea7d367b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9829d6d3-1af6-4593-b6f3-c487860b804f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_308b4bb2-d6dd-4dd5-955c-059ea7d367b0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9829d6d3-1af6-4593-b6f3-c487860b804f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a89879ac-abb8-406f-a1b8-e4d29d4d3ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9829d6d3-1af6-4593-b6f3-c487860b804f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a89879ac-abb8-406f-a1b8-e4d29d4d3ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9dd8c312-cf1d-4a6f-abb4-e2a0e5572d50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d6815b3b-06db-4036-99f8-2d7ed5ee3964" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9dd8c312-cf1d-4a6f-abb4-e2a0e5572d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2fde7fb5-3ce3-4004-bc94-677c8ab41d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9dd8c312-cf1d-4a6f-abb4-e2a0e5572d50" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2fde7fb5-3ce3-4004-bc94-677c8ab41d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_3951eb2b-35db-4d36-827c-5421f86095e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2fde7fb5-3ce3-4004-bc94-677c8ab41d2c" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_3951eb2b-35db-4d36-827c-5421f86095e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_da712105-51e5-4f3e-aa81-ea02b8741bab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d6815b3b-06db-4036-99f8-2d7ed5ee3964" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_da712105-51e5-4f3e-aa81-ea02b8741bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_beb3efbb-f6fa-47ba-bdcc-7c2516a95e26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_da712105-51e5-4f3e-aa81-ea02b8741bab" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_beb3efbb-f6fa-47ba-bdcc-7c2516a95e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccretionForTimeValueOfMoneyMember_a7c7f8d0-cab0-4b2e-8b08-ae60d040ccd9" xlink:href="bhc-20220510.xsd#bhc_AccretionForTimeValueOfMoneyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_beb3efbb-f6fa-47ba-bdcc-7c2516a95e26" xlink:to="loc_bhc_AccretionForTimeValueOfMoneyMember_a7c7f8d0-cab0-4b2e-8b08-ae60d040ccd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_FairValueAdjustmentsMember_db33522e-121c-4ceb-9d0e-967fc56eb94e" xlink:href="bhc-20220510.xsd#bhc_FairValueAdjustmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_beb3efbb-f6fa-47ba-bdcc-7c2516a95e26" xlink:to="loc_bhc_FairValueAdjustmentsMember_db33522e-121c-4ceb-9d0e-967fc56eb94e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2e1f4510-47df-4360-8903-d42ac1725eff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d6815b3b-06db-4036-99f8-2d7ed5ee3964" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2e1f4510-47df-4360-8903-d42ac1725eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_6c3a6d9f-adfd-430e-9783-a8ecc28cf51d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2e1f4510-47df-4360-8903-d42ac1725eff" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_6c3a6d9f-adfd-430e-9783-a8ecc28cf51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0b3b44da-a9e6-4ec8-aebc-a2e5e4f60b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2e1f4510-47df-4360-8903-d42ac1725eff" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0b3b44da-a9e6-4ec8-aebc-a2e5e4f60b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_78867297-977e-47fa-aa66-1e02e6fd192a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0b3b44da-a9e6-4ec8-aebc-a2e5e4f60b25" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_78867297-977e-47fa-aa66-1e02e6fd192a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d5a81b87-5667-461c-874b-9009aad7792f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0b3b44da-a9e6-4ec8-aebc-a2e5e4f60b25" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d5a81b87-5667-461c-874b-9009aad7792f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0a52a032-f558-474f-a2b6-fdbca56ee658" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0b3b44da-a9e6-4ec8-aebc-a2e5e4f60b25" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_0a52a032-f558-474f-a2b6-fdbca56ee658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_8950b799-adb7-47b5-a245-6b22887b370e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0b3b44da-a9e6-4ec8-aebc-a2e5e4f60b25" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome_8950b799-adb7-47b5-a245-6b22887b370e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_194abda0-5397-45b3-bd7b-8e9f845d7221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_0b3b44da-a9e6-4ec8-aebc-a2e5e4f60b25" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_194abda0-5397-45b3-bd7b-8e9f845d7221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_b0762731-f522-46bd-937f-5c0c079903aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2e1f4510-47df-4360-8903-d42ac1725eff" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_b0762731-f522-46bd-937f-5c0c079903aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_0c081d55-3a54-48af-99ed-ce59fa6d4298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2e1f4510-47df-4360-8903-d42ac1725eff" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_0c081d55-3a54-48af-99ed-ce59fa6d4298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b545139e-a3b6-46b2-977c-1ff4d2faf711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9aa5bc93-302f-4e50-867e-55b950fbb933" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b545139e-a3b6-46b2-977c-1ff4d2faf711" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9aa5bc93-302f-4e50-867e-55b950fbb933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_73386d82-cd6e-43cf-9947-c5682d484a51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9aa5bc93-302f-4e50-867e-55b950fbb933" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_73386d82-cd6e-43cf-9947-c5682d484a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_66e59ef4-32dd-4ec9-9a98-eac020838643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_73386d82-cd6e-43cf-9947-c5682d484a51" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_66e59ef4-32dd-4ec9-9a98-eac020838643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_24b62518-4f5e-4d5f-9069-072fb39deee8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_66e59ef4-32dd-4ec9-9a98-eac020838643" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_24b62518-4f5e-4d5f-9069-072fb39deee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50dedc3c-5537-4efb-a1d1-adf23c3b74da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9aa5bc93-302f-4e50-867e-55b950fbb933" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50dedc3c-5537-4efb-a1d1-adf23c3b74da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e54d18ed-74ce-426e-acc7-3a2fef190127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50dedc3c-5537-4efb-a1d1-adf23c3b74da" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e54d18ed-74ce-426e-acc7-3a2fef190127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_6a2ceec1-59a2-40ca-b159-397ce8cb8794" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e54d18ed-74ce-426e-acc7-3a2fef190127" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_6a2ceec1-59a2-40ca-b159-397ce8cb8794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_be164b56-4f53-427d-9d0c-54a9dd4f95ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e54d18ed-74ce-426e-acc7-3a2fef190127" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_be164b56-4f53-427d-9d0c-54a9dd4f95ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f18d95f5-b111-4b31-aedd-a61891a50cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e54d18ed-74ce-426e-acc7-3a2fef190127" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f18d95f5-b111-4b31-aedd-a61891a50cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ade77934-6613-4b23-b255-2264804cbe79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9aa5bc93-302f-4e50-867e-55b950fbb933" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ade77934-6613-4b23-b255-2264804cbe79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiabilityAbstract_f258fd2e-eab5-4927-abd6-3d68ab29c766" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetAssetLiabilityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ade77934-6613-4b23-b255-2264804cbe79" xlink:to="loc_us-gaap_FairValueNetAssetLiabilityAbstract_f258fd2e-eab5-4927-abd6-3d68ab29c766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_4066465c-30ba-4242-b931-224dd8386628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetAssetLiabilityAbstract_f258fd2e-eab5-4927-abd6-3d68ab29c766" xlink:to="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_4066465c-30ba-4242-b931-224dd8386628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9fec4f23-9985-4f40-b0c7-99685a2fe3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e63334df-7887-4001-a497-87de803999e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9fec4f23-9985-4f40-b0c7-99685a2fe3ae" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e63334df-7887-4001-a497-87de803999e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_6c186c32-51e1-44b1-9d73-2ad1940fc0c7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e63334df-7887-4001-a497-87de803999e2" xlink:to="loc_srt_ProductOrServiceAxis_6c186c32-51e1-44b1-9d73-2ad1940fc0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_08214808-c6ea-499b-bc86-c5905a34956c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_6c186c32-51e1-44b1-9d73-2ad1940fc0c7" xlink:to="loc_srt_ProductsAndServicesDomain_08214808-c6ea-499b-bc86-c5905a34956c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_e23124bb-44de-4308-abcb-83d88d1c7ec1" xlink:href="bhc-20220510.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_08214808-c6ea-499b-bc86-c5905a34956c" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_e23124bb-44de-4308-abcb-83d88d1c7ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_12117b8e-295f-4460-bd79-0b3c1387e339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e63334df-7887-4001-a497-87de803999e2" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_12117b8e-295f-4460-bd79-0b3c1387e339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_33546501-a737-4d4d-9d9d-9c301d0a2acc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_12117b8e-295f-4460-bd79-0b3c1387e339" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_33546501-a737-4d4d-9d9d-9c301d0a2acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_fa66ede1-9467-41d3-94cc-db3b1736bb4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_33546501-a737-4d4d-9d9d-9c301d0a2acc" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_fa66ede1-9467-41d3-94cc-db3b1736bb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_930e5c36-d133-475c-ac54-68bd1bf38e74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e63334df-7887-4001-a497-87de803999e2" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_930e5c36-d133-475c-ac54-68bd1bf38e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3b8f9fdb-3cfc-40ff-966b-045de43fd2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_930e5c36-d133-475c-ac54-68bd1bf38e74" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3b8f9fdb-3cfc-40ff-966b-045de43fd2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_b36146aa-315f-46f0-86e6-955e492be0c4" xlink:href="bhc-20220510.xsd#bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3b8f9fdb-3cfc-40ff-966b-045de43fd2fa" xlink:to="loc_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_b36146aa-315f-46f0-86e6-955e492be0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fdc821ed-b951-4927-8ce7-30089116feb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e63334df-7887-4001-a497-87de803999e2" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fdc821ed-b951-4927-8ce7-30089116feb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2c94faa4-2db5-413c-a278-db4ed0c68c70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fdc821ed-b951-4927-8ce7-30089116feb6" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2c94faa4-2db5-413c-a278-db4ed0c68c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c6d6781b-5f89-4363-9aa2-b30f3d1fb83b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2c94faa4-2db5-413c-a278-db4ed0c68c70" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c6d6781b-5f89-4363-9aa2-b30f3d1fb83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_21152d4a-21c6-44d5-b0fd-486442ea7a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e63334df-7887-4001-a497-87de803999e2" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_21152d4a-21c6-44d5-b0fd-486442ea7a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d6ae5e4d-5416-404a-b7c9-25c603c83e10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_21152d4a-21c6-44d5-b0fd-486442ea7a6f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d6ae5e4d-5416-404a-b7c9-25c603c83e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_f2175efe-da64-4566-af80-5a6b8620f931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d6ae5e4d-5416-404a-b7c9-25c603c83e10" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_f2175efe-da64-4566-af80-5a6b8620f931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3b8cf0db-668d-449e-a1e8-6e41f0fedf3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e63334df-7887-4001-a497-87de803999e2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3b8cf0db-668d-449e-a1e8-6e41f0fedf3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_016f6396-7b73-4146-b2aa-3fb650a3b00d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3b8cf0db-668d-449e-a1e8-6e41f0fedf3a" xlink:to="loc_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure_016f6396-7b73-4146-b2aa-3fb650a3b00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_a12eee19-e4e5-428f-91b4-aea937f18dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3b8cf0db-668d-449e-a1e8-6e41f0fedf3a" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_a12eee19-e4e5-428f-91b4-aea937f18dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_547e3caf-db95-463b-b061-8fa68afe9db8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3b8cf0db-668d-449e-a1e8-6e41f0fedf3a" xlink:to="loc_us-gaap_Assets_547e3caf-db95-463b-b061-8fa68afe9db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2f844c85-a268-4757-bf6f-1dcf9a40a7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_32f28c3f-ca9f-4b40-873f-68d8e57fb6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2f844c85-a268-4757-bf6f-1dcf9a40a7a0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_32f28c3f-ca9f-4b40-873f-68d8e57fb6a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_85947fae-30f6-4c2b-8254-35bf0e41380a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_32f28c3f-ca9f-4b40-873f-68d8e57fb6a3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_85947fae-30f6-4c2b-8254-35bf0e41380a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e6cff71d-f40c-4635-9db2-4f67a7c8f5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_85947fae-30f6-4c2b-8254-35bf0e41380a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e6cff71d-f40c-4635-9db2-4f67a7c8f5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_06bbd428-4538-478c-b7eb-5757ebce9806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e6cff71d-f40c-4635-9db2-4f67a7c8f5e2" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_06bbd428-4538-478c-b7eb-5757ebce9806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_451c562f-2e44-413a-a181-f3d4c0e9cd32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_32f28c3f-ca9f-4b40-873f-68d8e57fb6a3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_451c562f-2e44-413a-a181-f3d4c0e9cd32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_01ccf604-7e64-47cf-90a4-2c8badc68342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_451c562f-2e44-413a-a181-f3d4c0e9cd32" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_01ccf604-7e64-47cf-90a4-2c8badc68342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0898cfae-0fc4-4021-8b75-30769a21db48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_01ccf604-7e64-47cf-90a4-2c8badc68342" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0898cfae-0fc4-4021-8b75-30769a21db48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9421163b-a1bc-4aa6-84e9-1f6192735777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_32f28c3f-ca9f-4b40-873f-68d8e57fb6a3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9421163b-a1bc-4aa6-84e9-1f6192735777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_4dde5503-44f0-4985-8bc6-5f2c5561e26b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9421163b-a1bc-4aa6-84e9-1f6192735777" xlink:to="loc_us-gaap_DebtInstrumentFairValue_4dde5503-44f0-4985-8bc6-5f2c5561e26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIES" xlink:type="simple" xlink:href="bhc-20220510.xsd#INVENTORIES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_d356112c-b8bd-43f2-9244-29c12d4578a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_b5d08a3a-f960-405a-818d-bdf64d35ff85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_d356112c-b8bd-43f2-9244-29c12d4578a6" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_b5d08a3a-f960-405a-818d-bdf64d35ff85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIESTables" xlink:type="simple" xlink:href="bhc-20220510.xsd#INVENTORIESTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_c748533a-bd6b-49bb-9eb7-3b75c47e9a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_30d58c32-c229-48f2-9ae7-be0fbffe1b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c748533a-bd6b-49bb-9eb7-3b75c47e9a2d" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_30d58c32-c229-48f2-9ae7-be0fbffe1b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#INVENTORIESSummaryofInventoriesNetDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_a2366459-ee6c-4ec7-a73e-f4454f9772ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_c236f06e-5872-4d01-84d8-c47aac19cedb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a2366459-ee6c-4ec7-a73e-f4454f9772ec" xlink:to="loc_us-gaap_InventoryRawMaterials_c236f06e-5872-4d01-84d8-c47aac19cedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_aca31f39-f26f-4765-bb9b-161c96bf919e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a2366459-ee6c-4ec7-a73e-f4454f9772ec" xlink:to="loc_us-gaap_InventoryWorkInProcess_aca31f39-f26f-4765-bb9b-161c96bf919e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_70668886-47e1-4205-bf95-51c1950689b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a2366459-ee6c-4ec7-a73e-f4454f9772ec" xlink:to="loc_us-gaap_InventoryFinishedGoods_70668886-47e1-4205-bf95-51c1950689b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d06585e2-b914-4872-a9c4-3a0a0f733d56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a2366459-ee6c-4ec7-a73e-f4454f9772ec" xlink:to="loc_us-gaap_InventoryNet_d06585e2-b914-4872-a9c4-3a0a0f733d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENT" xlink:type="simple" xlink:href="bhc-20220510.xsd#PROPERTYPLANTANDEQUIPMENT"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_431a9c8e-a59b-4f4d-964e-a5adba298fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_f3775afd-3d37-4385-a931-e0148a457168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_431a9c8e-a59b-4f4d-964e-a5adba298fc8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_f3775afd-3d37-4385-a931-e0148a457168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTTables" xlink:type="simple" xlink:href="bhc-20220510.xsd#PROPERTYPLANTANDEQUIPMENTTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c83d23f6-5213-4cbc-99ce-8f5caab60df4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_694f106c-b098-43d2-837b-68b32390556d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c83d23f6-5213-4cbc-99ce-8f5caab60df4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_694f106c-b098-43d2-837b-68b32390556d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_90d2d80c-d8c1-4edf-80fe-4e863d199003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_15946ffc-4b52-4f29-bebb-cb56286f9a05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_90d2d80c-d8c1-4edf-80fe-4e863d199003" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_15946ffc-4b52-4f29-bebb-cb56286f9a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2396b5a3-8706-4c76-8cf9-19c8f9d3b27f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_15946ffc-4b52-4f29-bebb-cb56286f9a05" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2396b5a3-8706-4c76-8cf9-19c8f9d3b27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d6ee19e5-f8c9-455e-97f3-e61df4fa7125" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2396b5a3-8706-4c76-8cf9-19c8f9d3b27f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d6ee19e5-f8c9-455e-97f3-e61df4fa7125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_7b733a88-fe8a-4bb4-bdc7-748925a1d135" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d6ee19e5-f8c9-455e-97f3-e61df4fa7125" xlink:to="loc_us-gaap_LandMember_7b733a88-fe8a-4bb4-bdc7-748925a1d135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_05aecf2a-f635-4dae-9f7f-42ba05fbdbb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d6ee19e5-f8c9-455e-97f3-e61df4fa7125" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_05aecf2a-f635-4dae-9f7f-42ba05fbdbb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_756f3cc1-6d5f-4544-a0f3-21c476d213cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d6ee19e5-f8c9-455e-97f3-e61df4fa7125" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_756f3cc1-6d5f-4544-a0f3-21c476d213cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherEquipmentAndLeaseholdImprovementMember_77b1dbe6-5ca1-428c-a4f4-889739b4e866" xlink:href="bhc-20220510.xsd#bhc_OtherEquipmentAndLeaseholdImprovementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d6ee19e5-f8c9-455e-97f3-e61df4fa7125" xlink:to="loc_bhc_OtherEquipmentAndLeaseholdImprovementMember_77b1dbe6-5ca1-428c-a4f4-889739b4e866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EquipmentOnOperatingLeaseMember_034741ad-bdc8-46a0-afa5-d9dd8cc881f2" xlink:href="bhc-20220510.xsd#bhc_EquipmentOnOperatingLeaseMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d6ee19e5-f8c9-455e-97f3-e61df4fa7125" xlink:to="loc_bhc_EquipmentOnOperatingLeaseMember_034741ad-bdc8-46a0-afa5-d9dd8cc881f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_b45d86e3-cfcd-4935-b8fd-19efd4302074" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d6ee19e5-f8c9-455e-97f3-e61df4fa7125" xlink:to="loc_us-gaap_ConstructionInProgressMember_b45d86e3-cfcd-4935-b8fd-19efd4302074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bd0a4c54-f18b-4b21-80ca-ee706b14b584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_15946ffc-4b52-4f29-bebb-cb56286f9a05" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bd0a4c54-f18b-4b21-80ca-ee706b14b584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4c4a83a1-f4bf-477e-b91c-aeea60492b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bd0a4c54-f18b-4b21-80ca-ee706b14b584" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4c4a83a1-f4bf-477e-b91c-aeea60492b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_91ddb2d8-e310-4149-b32a-ed470de8065a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bd0a4c54-f18b-4b21-80ca-ee706b14b584" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_91ddb2d8-e310-4149-b32a-ed470de8065a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_eeadcb20-8dc3-4f5a-9151-d397fe899664" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_bd0a4c54-f18b-4b21-80ca-ee706b14b584" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_eeadcb20-8dc3-4f5a-9151-d397fe899664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#PROPERTYPLANTANDEQUIPMENTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_951620bb-0bb6-414a-bde7-bd1636399dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_41973d53-3f5d-4e0a-b42e-fb1d077f9c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_951620bb-0bb6-414a-bde7-bd1636399dfe" xlink:to="loc_us-gaap_Depreciation_41973d53-3f5d-4e0a-b42e-fb1d077f9c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL" xlink:type="simple" xlink:href="bhc-20220510.xsd#INTANGIBLEASSETSANDGOODWILL"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8cf077c4-0805-44d9-8300-860bcfd2904f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_3343c33f-d370-4b9e-a399-ca26bbbaf2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8cf077c4-0805-44d9-8300-860bcfd2904f" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_3343c33f-d370-4b9e-a399-ca26bbbaf2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables" xlink:type="simple" xlink:href="bhc-20220510.xsd#INTANGIBLEASSETSANDGOODWILLTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8a670f5f-7cd6-4405-abd6-ad8186653eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_6ec07180-9946-4fe1-8975-19e64daf3a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8a670f5f-7cd6-4405-abd6-ad8186653eaa" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_6ec07180-9946-4fe1-8975-19e64daf3a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_639a5645-9bbd-492b-84eb-22fd738e9a96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8a670f5f-7cd6-4405-abd6-ad8186653eaa" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_639a5645-9bbd-492b-84eb-22fd738e9a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_ecda1fbd-bcdf-4faf-8157-18b7055547f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8a670f5f-7cd6-4405-abd6-ad8186653eaa" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_ecda1fbd-bcdf-4faf-8157-18b7055547f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_6916aadb-f42c-4258-bbed-b787ae40a621" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8a670f5f-7cd6-4405-abd6-ad8186653eaa" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_6916aadb-f42c-4258-bbed-b787ae40a621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4e5eb06a-2135-4e46-afff-abbe1b7c6fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d78251f5-2464-4a77-bb72-e943fb30f907" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4e5eb06a-2135-4e46-afff-abbe1b7c6fb0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d78251f5-2464-4a77-bb72-e943fb30f907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1369ec7b-4c27-4612-8c9b-129bea4c49ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d78251f5-2464-4a77-bb72-e943fb30f907" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1369ec7b-4c27-4612-8c9b-129bea4c49ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_66a71c3a-56bf-4788-9f1a-9df26c126811" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1369ec7b-4c27-4612-8c9b-129bea4c49ae" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_66a71c3a-56bf-4788-9f1a-9df26c126811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_a5d7f19f-4592-4268-b3b1-49033397eddc" xlink:href="bhc-20220510.xsd#bhc_ProductBrandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_66a71c3a-56bf-4788-9f1a-9df26c126811" xlink:to="loc_bhc_ProductBrandsMember_a5d7f19f-4592-4268-b3b1-49033397eddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_65774df6-2617-44a8-a62c-798942926fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_66a71c3a-56bf-4788-9f1a-9df26c126811" xlink:to="loc_us-gaap_TradeNamesMember_65774df6-2617-44a8-a62c-798942926fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_cbe231b8-6217-4e73-a0f0-455f20c14b86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_66a71c3a-56bf-4788-9f1a-9df26c126811" xlink:to="loc_us-gaap_ContractualRightsMember_cbe231b8-6217-4e73-a0f0-455f20c14b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PartnerRelationshipsMember_907729fa-5b22-4700-80f8-9fc11a3b560e" xlink:href="bhc-20220510.xsd#bhc_PartnerRelationshipsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_66a71c3a-56bf-4788-9f1a-9df26c126811" xlink:to="loc_bhc_PartnerRelationshipsMember_907729fa-5b22-4700-80f8-9fc11a3b560e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OutLicensedTechnologyMember_16607570-623e-4fbb-87d0-9a003ed84058" xlink:href="bhc-20220510.xsd#bhc_OutLicensedTechnologyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_66a71c3a-56bf-4788-9f1a-9df26c126811" xlink:to="loc_bhc_OutLicensedTechnologyMember_16607570-623e-4fbb-87d0-9a003ed84058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8289f89e-ec0c-4db6-89a7-0995308cbf4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d78251f5-2464-4a77-bb72-e943fb30f907" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8289f89e-ec0c-4db6-89a7-0995308cbf4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3564e350-fb3d-4afc-a5d3-56329cae25fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8289f89e-ec0c-4db6-89a7-0995308cbf4e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3564e350-fb3d-4afc-a5d3-56329cae25fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b770c65a-01e1-4ecd-8073-4280fd66d037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8289f89e-ec0c-4db6-89a7-0995308cbf4e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b770c65a-01e1-4ecd-8073-4280fd66d037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_37b1fd48-7e03-4702-8cb3-519b1b7c12c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8289f89e-ec0c-4db6-89a7-0995308cbf4e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_37b1fd48-7e03-4702-8cb3-519b1b7c12c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7728a7a5-01e1-468f-a3a8-6b175a69c35e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8289f89e-ec0c-4db6-89a7-0995308cbf4e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7728a7a5-01e1-468f-a3a8-6b175a69c35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8ddfa4a3-87aa-491e-92c3-8b19768f3774" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4e5eb06a-2135-4e46-afff-abbe1b7c6fb0" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8ddfa4a3-87aa-491e-92c3-8b19768f3774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c188c9f6-f0ba-4d7e-a0fd-45760ad13c54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8ddfa4a3-87aa-491e-92c3-8b19768f3774" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c188c9f6-f0ba-4d7e-a0fd-45760ad13c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c118360b-d3fa-45bf-8883-1bdc56cdc2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_c188c9f6-f0ba-4d7e-a0fd-45760ad13c54" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c118360b-d3fa-45bf-8883-1bdc56cdc2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember_54ad01d6-4291-492c-8b99-9834cb5798ef" xlink:href="bhc-20220510.xsd#bhc_AcquiredInProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c118360b-d3fa-45bf-8883-1bdc56cdc2e1" xlink:to="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember_54ad01d6-4291-492c-8b99-9834cb5798ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_49960772-3c35-4800-818b-2eaefaba1cff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c118360b-d3fa-45bf-8883-1bdc56cdc2e1" xlink:to="loc_us-gaap_TrademarksMember_49960772-3c35-4800-818b-2eaefaba1cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_383015da-3a5f-434e-b408-d4a349130486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_8ddfa4a3-87aa-491e-92c3-8b19768f3774" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_383015da-3a5f-434e-b408-d4a349130486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_47d1004d-4b69-4b29-9651-d0c93fa1830f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_383015da-3a5f-434e-b408-d4a349130486" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_47d1004d-4b69-4b29-9651-d0c93fa1830f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_386f4eb1-532a-4e46-b133-9f8cdd606f0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4e5eb06a-2135-4e46-afff-abbe1b7c6fb0" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_386f4eb1-532a-4e46-b133-9f8cdd606f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_793048d4-a369-48d2-a7f6-9a8598e2924b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4e5eb06a-2135-4e46-afff-abbe1b7c6fb0" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_793048d4-a369-48d2-a7f6-9a8598e2924b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="bhc-20220510.xsd#INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#INTANGIBLEASSETSANDGOODWILLNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_80b4113f-bd9a-4254-b24e-321503483ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_50ea566e-e424-4808-b847-d48e08687c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_80b4113f-bd9a-4254-b24e-321503483ecf" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_50ea566e-e424-4808-b847-d48e08687c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7973174c-9e49-4773-95fa-d7c09765f0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_50ea566e-e424-4808-b847-d48e08687c8d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7973174c-9e49-4773-95fa-d7c09765f0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_10fdd4e5-d99b-4fd4-8dea-82994190b143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7973174c-9e49-4773-95fa-d7c09765f0a9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_10fdd4e5-d99b-4fd4-8dea-82994190b143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ProductBrandsMember_302505d7-e30d-4087-ab0a-ea0c5e32d5bf" xlink:href="bhc-20220510.xsd#bhc_ProductBrandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_10fdd4e5-d99b-4fd4-8dea-82994190b143" xlink:to="loc_bhc_ProductBrandsMember_302505d7-e30d-4087-ab0a-ea0c5e32d5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiscontinuedProductLinesMember_e716d203-7ca4-4b4c-9e97-85b829badac4" xlink:href="bhc-20220510.xsd#bhc_DiscontinuedProductLinesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_10fdd4e5-d99b-4fd4-8dea-82994190b143" xlink:to="loc_bhc_DiscontinuedProductLinesMember_e716d203-7ca4-4b4c-9e97-85b829badac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_ac63632f-4fae-4f37-a90d-fbf2ef013733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_10fdd4e5-d99b-4fd4-8dea-82994190b143" xlink:to="loc_us-gaap_ContractualRightsMember_ac63632f-4fae-4f37-a90d-fbf2ef013733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnutilizedITInfrastructureImprovementProjectMember_40b00212-a426-4e44-b67c-c68a5276a740" xlink:href="bhc-20220510.xsd#bhc_UnutilizedITInfrastructureImprovementProjectMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_10fdd4e5-d99b-4fd4-8dea-82994190b143" xlink:to="loc_bhc_UnutilizedITInfrastructureImprovementProjectMember_40b00212-a426-4e44-b67c-c68a5276a740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_3e38b12b-1d47-484d-be21-5d741998ea1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_50ea566e-e424-4808-b847-d48e08687c8d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_3e38b12b-1d47-484d-be21-5d741998ea1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_19937db1-4d20-412d-8d46-70b73bf30221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_3e38b12b-1d47-484d-be21-5d741998ea1d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_19937db1-4d20-412d-8d46-70b73bf30221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_db574417-1244-4c3d-8ebe-18fc00ba1ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_19937db1-4d20-412d-8d46-70b73bf30221" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_db574417-1244-4c3d-8ebe-18fc00ba1ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_e29e81d0-85fd-4f89-b0e3-06d68ef259a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_19937db1-4d20-412d-8d46-70b73bf30221" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_e29e81d0-85fd-4f89-b0e3-06d68ef259a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_13559b50-5221-41ba-92ee-4aed77a48ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_50ea566e-e424-4808-b847-d48e08687c8d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_13559b50-5221-41ba-92ee-4aed77a48ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1db7fc66-cbb5-41b5-bd00-25f3e2a6e0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_13559b50-5221-41ba-92ee-4aed77a48ea1" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1db7fc66-cbb5-41b5-bd00-25f3e2a6e0c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmounPharmaceuticalCompanySAEMember_619233c6-2510-4bba-9d58-8ea06a7228db" xlink:href="bhc-20220510.xsd#bhc_AmounPharmaceuticalCompanySAEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1db7fc66-cbb5-41b5-bd00-25f3e2a6e0c0" xlink:to="loc_bhc_AmounPharmaceuticalCompanySAEMember_619233c6-2510-4bba-9d58-8ea06a7228db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ACertainInternationalBusinessMember_d61347fc-381e-43b4-8d5e-bf4b4a0c2517" xlink:href="bhc-20220510.xsd#bhc_ACertainInternationalBusinessMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1db7fc66-cbb5-41b5-bd00-25f3e2a6e0c0" xlink:to="loc_bhc_ACertainInternationalBusinessMember_d61347fc-381e-43b4-8d5e-bf4b4a0c2517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_59a2bc81-2ce7-4288-889d-6193ef36e8f4" xlink:href="bhc-20220510.xsd#bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1db7fc66-cbb5-41b5-bd00-25f3e2a6e0c0" xlink:to="loc_bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember_59a2bc81-2ce7-4288-889d-6193ef36e8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ed333307-7069-437b-b669-7bc7391c3a82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_50ea566e-e424-4808-b847-d48e08687c8d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ed333307-7069-437b-b669-7bc7391c3a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_62c5886c-ee84-47d0-88fa-62b0b38059e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ed333307-7069-437b-b669-7bc7391c3a82" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_62c5886c-ee84-47d0-88fa-62b0b38059e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember_9622b12d-04a5-4a1d-ab74-57525f0f1bcf" xlink:href="bhc-20220510.xsd#bhc_AcquiredInProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_62c5886c-ee84-47d0-88fa-62b0b38059e3" xlink:to="loc_bhc_AcquiredInProcessResearchAndDevelopmentMember_9622b12d-04a5-4a1d-ab74-57525f0f1bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_eec86c1b-eed7-4578-85b7-4bc3de9128c2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_50ea566e-e424-4808-b847-d48e08687c8d" xlink:to="loc_srt_RangeAxis_eec86c1b-eed7-4578-85b7-4bc3de9128c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e1319fa8-2d72-49ed-9472-477231472373" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_eec86c1b-eed7-4578-85b7-4bc3de9128c2" xlink:to="loc_srt_RangeMember_e1319fa8-2d72-49ed-9472-477231472373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_50ef58df-a887-4552-90f3-90ca73f08332" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e1319fa8-2d72-49ed-9472-477231472373" xlink:to="loc_srt_MinimumMember_50ef58df-a887-4552-90f3-90ca73f08332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_68ecdcff-9708-4c64-b901-8799d8733c75" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e1319fa8-2d72-49ed-9472-477231472373" xlink:to="loc_srt_MaximumMember_68ecdcff-9708-4c64-b901-8799d8733c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitAxis_943710be-b60b-4411-8cd8-a271d8929dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_50ea566e-e424-4808-b847-d48e08687c8d" xlink:to="loc_us-gaap_ReportingUnitAxis_943710be-b60b-4411-8cd8-a271d8929dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitDomain_3539e330-6d8e-480b-986d-2fc06e5b4726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_943710be-b60b-4411-8cd8-a271d8929dd8" xlink:to="loc_us-gaap_ReportingUnitDomain_3539e330-6d8e-480b-986d-2fc06e5b4726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsReportingUnitMember_cf560f92-811b-4519-9cd7-593eb3fa1fbf" xlink:href="bhc-20220510.xsd#bhc_OrthoDermatologicsReportingUnitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_3539e330-6d8e-480b-986d-2fc06e5b4726" xlink:to="loc_bhc_OrthoDermatologicsReportingUnitMember_cf560f92-811b-4519-9cd7-593eb3fa1fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_3383608a-ab34-4e9e-9697-7074323a1397" xlink:href="bhc-20220510.xsd#bhc_ReportingUnitsExcludingOrthoDermatologicsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_3539e330-6d8e-480b-986d-2fc06e5b4726" xlink:to="loc_bhc_ReportingUnitsExcludingOrthoDermatologicsMember_3383608a-ab34-4e9e-9697-7074323a1397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_56cf4eb9-8a9c-43e6-bcb0-cd3d08430b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_50ea566e-e424-4808-b847-d48e08687c8d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_56cf4eb9-8a9c-43e6-bcb0-cd3d08430b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d0a27e56-46b7-49df-97e7-becedeb519ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_56cf4eb9-8a9c-43e6-bcb0-cd3d08430b5d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d0a27e56-46b7-49df-97e7-becedeb519ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7972ed38-7d7e-4ca0-9137-ee727f1ae7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d0a27e56-46b7-49df-97e7-becedeb519ba" xlink:to="loc_us-gaap_SubsequentEventMember_7972ed38-7d7e-4ca0-9137-ee727f1ae7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_53b48e38-a190-4bb0-ac84-2ac7683deaaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_50ea566e-e424-4808-b847-d48e08687c8d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_53b48e38-a190-4bb0-ac84-2ac7683deaaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_198b8752-4d65-45d5-bf6f-ec5bd4ce1986" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_53b48e38-a190-4bb0-ac84-2ac7683deaaf" xlink:to="loc_us-gaap_SegmentDomain_198b8752-4d65-45d5-bf6f-ec5bd4ce1986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_7541c877-6836-42a6-b410-ee5cf281d16c" xlink:href="bhc-20220510.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_198b8752-4d65-45d5-bf6f-ec5bd4ce1986" xlink:to="loc_bhc_BauschLombMember_7541c877-6836-42a6-b410-ee5cf281d16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_8fd086bc-4772-4aaf-ae79-9d623aff5376" xlink:href="bhc-20220510.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_198b8752-4d65-45d5-bf6f-ec5bd4ce1986" xlink:to="loc_bhc_SalixSegmentMember_8fd086bc-4772-4aaf-ae79-9d623aff5376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_ce72a476-70b1-4007-baed-572fef93df66" xlink:href="bhc-20220510.xsd#bhc_InternationalRxMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_198b8752-4d65-45d5-bf6f-ec5bd4ce1986" xlink:to="loc_bhc_InternationalRxMember_ce72a476-70b1-4007-baed-572fef93df66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_430be8e4-97ec-4bd1-a5f2-1d132962d105" xlink:href="bhc-20220510.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_198b8752-4d65-45d5-bf6f-ec5bd4ce1986" xlink:to="loc_bhc_SoltaMedicalSegmentMember_430be8e4-97ec-4bd1-a5f2-1d132962d105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_42131205-2f0e-424b-802b-dc50f29fb748" xlink:href="bhc-20220510.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_198b8752-4d65-45d5-bf6f-ec5bd4ce1986" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_42131205-2f0e-424b-802b-dc50f29fb748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_50ea566e-e424-4808-b847-d48e08687c8d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_a7adb00c-c13d-47aa-b7bd-2e3c17851172" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_a7adb00c-c13d-47aa-b7bd-2e3c17851172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_685a6d21-46be-4c48-ae80-b918f7e68644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_685a6d21-46be-4c48-ae80-b918f7e68644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_20e50900-2736-436e-86b7-8cdd66332134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_20e50900-2736-436e-86b7-8cdd66332134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_5067de1a-c388-4027-bf86-77359a1c2910" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_5067de1a-c388-4027-bf86-77359a1c2910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fe577782-ed5f-4178-801a-425104e78815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fe577782-ed5f-4178-801a-425104e78815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax_f60f43d0-026c-410b-b6e7-fa9b2c3df87a" xlink:href="bhc-20220510.xsd#bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:to="loc_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax_f60f43d0-026c-410b-b6e7-fa9b2c3df87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage_fbefdd69-caaf-434a-9487-3d9ab4377676" xlink:href="bhc-20220510.xsd#bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:to="loc_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage_fbefdd69-caaf-434a-9487-3d9ab4377676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_cf32a977-a5c1-436a-bd7e-8ad6f5b75857" xlink:href="bhc-20220510.xsd#bhc_ReportingUnitImpairmentTestLongTermGrowthRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:to="loc_bhc_ReportingUnitImpairmentTestLongTermGrowthRate_cf32a977-a5c1-436a-bd7e-8ad6f5b75857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_077167c5-6347-4b59-bc5e-cdfba626bcc8" xlink:href="bhc-20220510.xsd#bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:to="loc_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate_077167c5-6347-4b59-bc5e-cdfba626bcc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_c6bc04e5-72c3-4076-9974-068123b7a163" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:to="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_c6bc04e5-72c3-4076-9974-068123b7a163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_ecfdcc4d-7b76-4fc0-9055-6ff10b96daef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_ecfdcc4d-7b76-4fc0-9055-6ff10b96daef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_06e07eaf-c6bf-450a-871c-06cbfd79ee9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:to="loc_us-gaap_NumberOfReportableSegments_06e07eaf-c6bf-450a-871c-06cbfd79ee9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b1f466f6-e59b-48e2-a992-da07bd97bf2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:to="loc_us-gaap_Goodwill_b1f466f6-e59b-48e2-a992-da07bd97bf2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_be1eb543-ceef-40d2-952f-fa5f81eb92cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0713b661-9960-47e9-bdef-59c56ce3ca67" xlink:to="loc_us-gaap_NumberOfReportingUnits_be1eb543-ceef-40d2-952f-fa5f81eb92cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9e28f3dd-7ed2-4f44-aca8-4015f7c4f7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7ce5d567-be67-40e3-9509-f142c71501c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9e28f3dd-7ed2-4f44-aca8-4015f7c4f7a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7ce5d567-be67-40e3-9509-f142c71501c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1f66883e-e5d3-4bfc-aad7-50ee516b9f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7ce5d567-be67-40e3-9509-f142c71501c5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1f66883e-e5d3-4bfc-aad7-50ee516b9f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9fd9fee6-1adf-40f9-a931-05317177c26c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7ce5d567-be67-40e3-9509-f142c71501c5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9fd9fee6-1adf-40f9-a931-05317177c26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0156e909-c875-4374-b67f-2880a2f6409a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7ce5d567-be67-40e3-9509-f142c71501c5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0156e909-c875-4374-b67f-2880a2f6409a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_122e8876-f8f7-4945-8264-928a6c6c89f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7ce5d567-be67-40e3-9509-f142c71501c5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_122e8876-f8f7-4945-8264-928a6c6c89f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_33a63a80-b0ce-42e0-8ed9-f6b793fe249f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7ce5d567-be67-40e3-9509-f142c71501c5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_33a63a80-b0ce-42e0-8ed9-f6b793fe249f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_cefbd8af-1dc0-4c91-b7b4-d01a5fdbd5be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7ce5d567-be67-40e3-9509-f142c71501c5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_cefbd8af-1dc0-4c91-b7b4-d01a5fdbd5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f5cb806e-80cd-4cd8-b25d-ae93b293ee61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_7ce5d567-be67-40e3-9509-f142c71501c5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f5cb806e-80cd-4cd8-b25d-ae93b293ee61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_52474097-b0a3-4b7e-9e3c-aaf4cf7fddf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_1dadcdc2-d181-43d3-bc2c-b024b1821c9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_52474097-b0a3-4b7e-9e3c-aaf4cf7fddf3" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_1dadcdc2-d181-43d3-bc2c-b024b1821c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_45831985-7b97-484c-83c8-3dd12618bbb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1dadcdc2-d181-43d3-bc2c-b024b1821c9c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_45831985-7b97-484c-83c8-3dd12618bbb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9231340b-4d2c-4d84-ab36-ebe5a391c13b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_45831985-7b97-484c-83c8-3dd12618bbb3" xlink:to="loc_us-gaap_SegmentDomain_9231340b-4d2c-4d84-ab36-ebe5a391c13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombInternationalMember_cb8c1269-de5f-45e6-8c57-dad66e46046b" xlink:href="bhc-20220510.xsd#bhc_BauschLombInternationalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9231340b-4d2c-4d84-ab36-ebe5a391c13b" xlink:to="loc_bhc_BauschLombInternationalMember_cb8c1269-de5f-45e6-8c57-dad66e46046b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_c2e03aed-763f-4df9-9819-cbc6fc07f649" xlink:href="bhc-20220510.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9231340b-4d2c-4d84-ab36-ebe5a391c13b" xlink:to="loc_bhc_BauschLombMember_c2e03aed-763f-4df9-9819-cbc6fc07f649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_cac29ec3-0be9-4edc-8661-730615aca1fa" xlink:href="bhc-20220510.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9231340b-4d2c-4d84-ab36-ebe5a391c13b" xlink:to="loc_bhc_SalixSegmentMember_cac29ec3-0be9-4edc-8661-730615aca1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_b562fa7f-80b2-43a3-b6cd-656ae9d5467c" xlink:href="bhc-20220510.xsd#bhc_InternationalRxMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9231340b-4d2c-4d84-ab36-ebe5a391c13b" xlink:to="loc_bhc_InternationalRxMember_b562fa7f-80b2-43a3-b6cd-656ae9d5467c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_9f9de315-cb61-465e-a03a-5010e2c56f1d" xlink:href="bhc-20220510.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9231340b-4d2c-4d84-ab36-ebe5a391c13b" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_9f9de315-cb61-465e-a03a-5010e2c56f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_8882c7cf-5a48-498d-9852-045411a3766e" xlink:href="bhc-20220510.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9231340b-4d2c-4d84-ab36-ebe5a391c13b" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_8882c7cf-5a48-498d-9852-045411a3766e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_8dd01427-ccf7-439e-9124-436a95a90979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_1dadcdc2-d181-43d3-bc2c-b024b1821c9c" xlink:to="loc_us-gaap_GoodwillLineItems_8dd01427-ccf7-439e-9124-436a95a90979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_05e29c20-6a82-44e9-a45c-f5d16cab4d86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_8dd01427-ccf7-439e-9124-436a95a90979" xlink:to="loc_us-gaap_GoodwillRollForward_05e29c20-6a82-44e9-a45c-f5d16cab4d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_02c1fb95-74cd-4b2c-b082-3eb5b83ea9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_05e29c20-6a82-44e9-a45c-f5d16cab4d86" xlink:to="loc_us-gaap_Goodwill_02c1fb95-74cd-4b2c-b082-3eb5b83ea9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_b265b2ba-d6e2-4512-8ef2-e6288ce542f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_05e29c20-6a82-44e9-a45c-f5d16cab4d86" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_b265b2ba-d6e2-4512-8ef2-e6288ce542f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_721efb8d-9f88-4b64-96be-60b9cf26bc43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_05e29c20-6a82-44e9-a45c-f5d16cab4d86" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_721efb8d-9f88-4b64-96be-60b9cf26bc43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_9701f6c5-74ef-4599-bba2-2862e0d4f20c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_05e29c20-6a82-44e9-a45c-f5d16cab4d86" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_9701f6c5-74ef-4599-bba2-2862e0d4f20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit_13683423-6c3d-4a1f-b3e6-049302e89a65" xlink:href="bhc-20220510.xsd#bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_05e29c20-6a82-44e9-a45c-f5d16cab4d86" xlink:to="loc_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit_13683423-6c3d-4a1f-b3e6-049302e89a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_99fe4118-145a-4e7b-af7f-c625e3377ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_05e29c20-6a82-44e9-a45c-f5d16cab4d86" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_99fe4118-145a-4e7b-af7f-c625e3377ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_cd7919dd-0535-4c55-82a5-3c0b517ce0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_05e29c20-6a82-44e9-a45c-f5d16cab4d86" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_cd7919dd-0535-4c55-82a5-3c0b517ce0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ac2c6ad3-ce97-46ef-8d0e-9b7c706cae8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_05e29c20-6a82-44e9-a45c-f5d16cab4d86" xlink:to="loc_us-gaap_Goodwill_ac2c6ad3-ce97-46ef-8d0e-9b7c706cae8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES" xlink:type="simple" xlink:href="bhc-20220510.xsd#ACCRUEDANDOTHERCURRENTLIABILITIES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_689badef-0050-44e4-a040-69502a945a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_5eee0d56-cefc-48db-835a-ad4797f91079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_689badef-0050-44e4-a040-69502a945a76" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_5eee0d56-cefc-48db-835a-ad4797f91079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables" xlink:type="simple" xlink:href="bhc-20220510.xsd#ACCRUEDANDOTHERCURRENTLIABILITIESTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_782caf3e-0ff3-474c-9199-d63f2a23a45c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c811a73d-edfd-4352-9dfa-12c9555c8872" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_782caf3e-0ff3-474c-9199-d63f2a23a45c" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c811a73d-edfd-4352-9dfa-12c9555c8872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#ACCRUEDANDOTHERCURRENTLIABILITIESDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_b55a47c0-6843-4786-8a9c-64ae943a757b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_Legalsettlementsandrelatedfees_ad1569e5-6f5a-4773-87ee-0ce4608bd496" xlink:href="bhc-20220510.xsd#bhc_Legalsettlementsandrelatedfees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b55a47c0-6843-4786-8a9c-64ae943a757b" xlink:to="loc_bhc_Legalsettlementsandrelatedfees_ad1569e5-6f5a-4773-87ee-0ce4608bd496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductRebateCurrent_515f9502-1c33-4620-96e9-0591c762e958" xlink:href="bhc-20220510.xsd#bhc_AccruedProductRebateCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b55a47c0-6843-4786-8a9c-64ae943a757b" xlink:to="loc_bhc_AccruedProductRebateCurrent_515f9502-1c33-4620-96e9-0591c762e958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccruedProductReturnCurrent_1a28f757-a85e-4cb8-b58a-55a6d60177bd" xlink:href="bhc-20220510.xsd#bhc_AccruedProductReturnCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b55a47c0-6843-4786-8a9c-64ae943a757b" xlink:to="loc_bhc_AccruedProductReturnCurrent_1a28f757-a85e-4cb8-b58a-55a6d60177bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_35671e83-662c-460b-9ef5-64ffd2015046" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b55a47c0-6843-4786-8a9c-64ae943a757b" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_35671e83-662c-460b-9ef5-64ffd2015046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_6f5e7378-3ac0-4dae-a923-04441e7f60e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b55a47c0-6843-4786-8a9c-64ae943a757b" xlink:to="loc_us-gaap_InterestPayableCurrent_6f5e7378-3ac0-4dae-a923-04441e7f60e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_d92fbf4f-b4e5-47d8-a92e-a459629c216b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b55a47c0-6843-4786-8a9c-64ae943a757b" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_d92fbf4f-b4e5-47d8-a92e-a459629c216b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7a66aeaa-ef67-4300-b0bf-bba5b193da7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b55a47c0-6843-4786-8a9c-64ae943a757b" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7a66aeaa-ef67-4300-b0bf-bba5b193da7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5d05245a-641e-462a-b425-fa8adaea4dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b55a47c0-6843-4786-8a9c-64ae943a757b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5d05245a-641e-462a-b425-fa8adaea4dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS" xlink:type="simple" xlink:href="bhc-20220510.xsd#FINANCINGARRANGEMENTS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1042ca06-a165-444a-a9c6-04b91086fcdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1a110c5a-9d6a-4fbd-bbca-6b4545f8734d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1042ca06-a165-444a-a9c6-04b91086fcdc" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1a110c5a-9d6a-4fbd-bbca-6b4545f8734d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables" xlink:type="simple" xlink:href="bhc-20220510.xsd#FINANCINGARRANGEMENTSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_981baacc-8fa5-49db-8b90-d242f7c03204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_0646ccbe-5bbb-40e1-97c3-8e2e7439ec4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_981baacc-8fa5-49db-8b90-d242f7c03204" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_0646ccbe-5bbb-40e1-97c3-8e2e7439ec4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_b7329f9b-a5cd-4919-ab2c-0c76962e03de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_981baacc-8fa5-49db-8b90-d242f7c03204" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_b7329f9b-a5cd-4919-ab2c-0c76962e03de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0f32e095-0fe9-40bf-a4b4-f55c44a532c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_335adb6d-6271-431f-9d76-16240f5ddbac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0f32e095-0fe9-40bf-a4b4-f55c44a532c8" xlink:to="loc_us-gaap_DebtInstrumentTable_335adb6d-6271-431f-9d76-16240f5ddbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_7b5faf71-973d-4f92-a308-82d548e0d831" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_335adb6d-6271-431f-9d76-16240f5ddbac" xlink:to="loc_us-gaap_CreditFacilityAxis_7b5faf71-973d-4f92-a308-82d548e0d831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_dc38d36c-6a07-45a2-9c96-8da38ac306e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_7b5faf71-973d-4f92-a308-82d548e0d831" xlink:to="loc_us-gaap_CreditFacilityDomain_dc38d36c-6a07-45a2-9c96-8da38ac306e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_9fcc30f5-e31b-427e-9f0e-f0862a482346" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_dc38d36c-6a07-45a2-9c96-8da38ac306e4" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_9fcc30f5-e31b-427e-9f0e-f0862a482346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_990c8acd-29f7-43d3-b7c1-9f55ce93ce1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_335adb6d-6271-431f-9d76-16240f5ddbac" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_990c8acd-29f7-43d3-b7c1-9f55ce93ce1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_97d1a98d-b749-48f6-8fda-a8a219ce4a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_990c8acd-29f7-43d3-b7c1-9f55ce93ce1d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_97d1a98d-b749-48f6-8fda-a8a219ce4a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_82f97f7d-7ac8-4981-907c-d4b4a0ad218a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_97d1a98d-b749-48f6-8fda-a8a219ce4a09" xlink:to="loc_us-gaap_SecuredDebtMember_82f97f7d-7ac8-4981-907c-d4b4a0ad218a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_163bc677-4663-41e8-a606-bcfbd7feb565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_97d1a98d-b749-48f6-8fda-a8a219ce4a09" xlink:to="loc_us-gaap_UnsecuredDebtMember_163bc677-4663-41e8-a606-bcfbd7feb565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fe9341ff-9e86-4059-8aa1-7beb7fefb959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_335adb6d-6271-431f-9d76-16240f5ddbac" xlink:to="loc_us-gaap_DebtInstrumentAxis_fe9341ff-9e86-4059-8aa1-7beb7fefb959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_fe9341ff-9e86-4059-8aa1-7beb7fefb959" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_ac8f59e1-d853-4d58-8901-783085cda733" xlink:href="bhc-20220510.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_ac8f59e1-d853-4d58-8901-783085cda733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_b02a7ea3-28de-4aa9-a3fb-09e3d6a5ca75" xlink:href="bhc-20220510.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_b02a7ea3-28de-4aa9-a3fb-09e3d6a5ca75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member_43cb982d-f2da-4492-87c7-0a3e28321e9f" xlink:href="bhc-20220510.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_TermLoanBFacilityDueNovember2025Member_43cb982d-f2da-4492-87c7-0a3e28321e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_2f1bde28-f044-46ed-906f-132a2fa01ded" xlink:href="bhc-20220510.xsd#bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_2f1bde28-f044-46ed-906f-132a2fa01ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_d69ba5bb-8af3-4823-a278-986bf534c5d3" xlink:href="bhc-20220510.xsd#bhc_SeniorSecured5.50NotesDueNovember2025Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_d69ba5bb-8af3-4823-a278-986bf534c5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_d1e32dee-693d-4dc2-ac27-9d5b4baed11b" xlink:href="bhc-20220510.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_d1e32dee-693d-4dc2-ac27-9d5b4baed11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member_30fd0db1-3f11-4678-8d2c-1a6b46095dce" xlink:href="bhc-20220510.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_SeniorSecured4875NotesDueJune2028Member_30fd0db1-3f11-4678-8d2c-1a6b46095dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_1e50d821-697b-4b69-983c-7fff750f8006" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_1e50d821-697b-4b69-983c-7fff750f8006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes900DueDecember2025Member_5fbfa744-fbf2-4c1b-9ae3-42ac6def01b6" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes900DueDecember2025Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_SeniorNotes900DueDecember2025Member_5fbfa744-fbf2-4c1b-9ae3-42ac6def01b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes925DueApril2026Member_4801d733-90e2-4814-9597-892116135b4a" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes925DueApril2026Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_SeniorNotes925DueApril2026Member_4801d733-90e2-4814-9597-892116135b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes850DueJanuary2027Member_44df5156-d812-4635-a8b6-87f25a07ba8f" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes850DueJanuary2027Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_SeniorNotes850DueJanuary2027Member_44df5156-d812-4635-a8b6-87f25a07ba8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueJanuary2028Member_755e2c59-6392-4b95-a14f-5da0e2156e32" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes700DueJanuary2028Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_SeniorNotes700DueJanuary2028Member_755e2c59-6392-4b95-a14f-5da0e2156e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueJanuary2028Member_1c1ce7db-fad3-4c44-adce-28bc9cebc401" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes500DueJanuary2028Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_SeniorNotes500DueJanuary2028Member_1c1ce7db-fad3-4c44-adce-28bc9cebc401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member_1113e18f-dcd0-4601-94cc-ad3bd0a91328" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_SeniorNotes625DueFebruary2029Member_1113e18f-dcd0-4601-94cc-ad3bd0a91328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member_5d636110-2e2b-42f7-b076-0eb738921d76" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_SeniorNotes500DueFebruary2029Member_5d636110-2e2b-42f7-b076-0eb738921d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes725DueMay2029Member_a08e6ed9-f380-4a82-99bd-7e53376b35cb" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes725DueMay2029Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_SeniorNotes725DueMay2029Member_a08e6ed9-f380-4a82-99bd-7e53376b35cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueJanuary2030Member_b12832e1-0e9f-41df-ac47-eea00253766e" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes525DueJanuary2030Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_SeniorNotes525DueJanuary2030Member_b12832e1-0e9f-41df-ac47-eea00253766e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member_df27b0d2-4032-4147-a7f1-2b6ead3a113d" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_SeniorNotes525DueFebruary2031Member_df27b0d2-4032-4147-a7f1-2b6ead3a113d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherLongTermDebtMember_0468b0d5-d2cb-47bc-bf9b-6819d9776b5b" xlink:href="bhc-20220510.xsd#bhc_OtherLongTermDebtMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b3973783-3fa3-46fe-9dc2-855621d02065" xlink:to="loc_bhc_OtherLongTermDebtMember_0468b0d5-d2cb-47bc-bf9b-6819d9776b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_04594dca-7640-4dbc-bec3-3682a0046c87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_335adb6d-6271-431f-9d76-16240f5ddbac" xlink:to="loc_us-gaap_DebtInstrumentLineItems_04594dca-7640-4dbc-bec3-3682a0046c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7ff7ba57-989c-4c10-b6ca-06fcd18f41fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_04594dca-7640-4dbc-bec3-3682a0046c87" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7ff7ba57-989c-4c10-b6ca-06fcd18f41fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_9a3b75a9-d73e-4fb2-9e5c-7267498ea731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_04594dca-7640-4dbc-bec3-3682a0046c87" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_9a3b75a9-d73e-4fb2-9e5c-7267498ea731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_93e4efeb-5773-4e8f-85f8-f909fe8b83c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_04594dca-7640-4dbc-bec3-3682a0046c87" xlink:to="loc_us-gaap_LongTermDebt_93e4efeb-5773-4e8f-85f8-f909fe8b83c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_c4a548ee-e03b-4e1e-a86b-e824ba3f65a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_04594dca-7640-4dbc-bec3-3682a0046c87" xlink:to="loc_us-gaap_LongTermDebtCurrent_c4a548ee-e03b-4e1e-a86b-e824ba3f65a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_2ccc8073-9c4c-49aa-8e86-cb975f018530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_04594dca-7640-4dbc-bec3-3682a0046c87" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_2ccc8073-9c4c-49aa-8e86-cb975f018530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FINANCINGARRANGEMENTSCovenantComplianceDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_34ad5f3c-14b2-4565-abd8-e9934ea206e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6aa30612-3acf-45e6-ba28-b5cb2f8d22e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_34ad5f3c-14b2-4565-abd8-e9934ea206e8" xlink:to="loc_us-gaap_DebtInstrumentTable_6aa30612-3acf-45e6-ba28-b5cb2f8d22e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_c43e1ac1-256c-4218-aff3-767cfeb1e37e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6aa30612-3acf-45e6-ba28-b5cb2f8d22e2" xlink:to="loc_us-gaap_CreditFacilityAxis_c43e1ac1-256c-4218-aff3-767cfeb1e37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_4d646b81-5d4a-4a5a-a14e-fe8639f9e84f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_c43e1ac1-256c-4218-aff3-767cfeb1e37e" xlink:to="loc_us-gaap_CreditFacilityDomain_4d646b81-5d4a-4a5a-a14e-fe8639f9e84f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_04683eca-9ad4-48bf-9e0f-4eb8f77d7967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_4d646b81-5d4a-4a5a-a14e-fe8639f9e84f" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_04683eca-9ad4-48bf-9e0f-4eb8f77d7967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_aac28205-979d-4516-afd2-466a301e57c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6aa30612-3acf-45e6-ba28-b5cb2f8d22e2" xlink:to="loc_us-gaap_DebtInstrumentLineItems_aac28205-979d-4516-afd2-466a301e57c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAmountAvailableForRestrictedPayments_bf3c85ed-ff2e-42ab-ba09-cc7298c02813" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentAmountAvailableForRestrictedPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aac28205-979d-4516-afd2-466a301e57c4" xlink:to="loc_bhc_DebtInstrumentAmountAvailableForRestrictedPayments_bf3c85ed-ff2e-42ab-ba09-cc7298c02813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_d3d87cab-1256-419d-8e3a-a4bf4c6a9d35" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aac28205-979d-4516-afd2-466a301e57c4" xlink:to="loc_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio_d3d87cab-1256-419d-8e3a-a4bf4c6a9d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_b4d249e6-43a7-4cc9-a0b8-d22111b082cd" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aac28205-979d-4516-afd2-466a301e57c4" xlink:to="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_b4d249e6-43a7-4cc9-a0b8-d22111b082cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9cf28d1b-c17a-43e1-bf62-436a0c754fab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e751c116-f164-4903-bdba-b29a4e87a74c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9cf28d1b-c17a-43e1-bf62-436a0c754fab" xlink:to="loc_us-gaap_DebtInstrumentTable_e751c116-f164-4903-bdba-b29a4e87a74c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_270ea6fb-9568-49cf-a577-34415fd1cd0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e751c116-f164-4903-bdba-b29a4e87a74c" xlink:to="loc_us-gaap_CreditFacilityAxis_270ea6fb-9568-49cf-a577-34415fd1cd0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_53276ff6-12d1-4b98-8cf9-afb493f8a774" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_270ea6fb-9568-49cf-a577-34415fd1cd0a" xlink:to="loc_us-gaap_CreditFacilityDomain_53276ff6-12d1-4b98-8cf9-afb493f8a774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_8381898a-6e94-47ea-8cc1-9feeef471d04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_53276ff6-12d1-4b98-8cf9-afb493f8a774" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_8381898a-6e94-47ea-8cc1-9feeef471d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_2726ec4e-cb0b-43f4-925f-104f349ed920" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_53276ff6-12d1-4b98-8cf9-afb493f8a774" xlink:to="loc_us-gaap_LetterOfCreditMember_2726ec4e-cb0b-43f4-925f-104f349ed920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_98fe3871-82f4-4135-8d5f-c44112dafd2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e751c116-f164-4903-bdba-b29a4e87a74c" xlink:to="loc_us-gaap_DebtInstrumentAxis_98fe3871-82f4-4135-8d5f-c44112dafd2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a74eb401-6ef9-49c2-b31f-2ee99ece2c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_98fe3871-82f4-4135-8d5f-c44112dafd2e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a74eb401-6ef9-49c2-b31f-2ee99ece2c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_11b2ba92-81b7-4325-b65c-f23c822c5b38" xlink:href="bhc-20220510.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a74eb401-6ef9-49c2-b31f-2ee99ece2c8f" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_11b2ba92-81b7-4325-b65c-f23c822c5b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_fd4135fe-2640-42da-8a82-740d5163c9a1" xlink:href="bhc-20220510.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a74eb401-6ef9-49c2-b31f-2ee99ece2c8f" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_fd4135fe-2640-42da-8a82-740d5163c9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_37f75754-0bd9-4a7a-b5bc-718781d616e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e751c116-f164-4903-bdba-b29a4e87a74c" xlink:to="loc_us-gaap_DebtInstrumentLineItems_37f75754-0bd9-4a7a-b5bc-718781d616e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_68208265-b2d6-4ac7-9e20-14f77e2311d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_37f75754-0bd9-4a7a-b5bc-718781d616e7" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_68208265-b2d6-4ac7-9e20-14f77e2311d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_174683cd-a829-4e1f-954f-7c14426948f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_37f75754-0bd9-4a7a-b5bc-718781d616e7" xlink:to="loc_us-gaap_DebtInstrumentTerm_174683cd-a829-4e1f-954f-7c14426948f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_d03cf1d2-0d3a-4510-9b6d-e8e204f53dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_37f75754-0bd9-4a7a-b5bc-718781d616e7" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_d03cf1d2-0d3a-4510-9b6d-e8e204f53dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_113319bb-7574-493f-8350-f1d3ff0d885b" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_37f75754-0bd9-4a7a-b5bc-718781d616e7" xlink:to="loc_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold_113319bb-7574-493f-8350-f1d3ff0d885b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_6d788d3d-a11e-493e-baff-ffd4275532f6" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_37f75754-0bd9-4a7a-b5bc-718781d616e7" xlink:to="loc_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold_6d788d3d-a11e-493e-baff-ffd4275532f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c1e7192c-b276-40cb-8fca-41de6508589b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_37f75754-0bd9-4a7a-b5bc-718781d616e7" xlink:to="loc_us-gaap_LongTermDebt_c1e7192c-b276-40cb-8fca-41de6508589b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_1b15a1e0-0f8e-463c-aa9b-7c2a9d665597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_37f75754-0bd9-4a7a-b5bc-718781d616e7" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_1b15a1e0-0f8e-463c-aa9b-7c2a9d665597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_107c6c49-f9c8-4f3d-b9a1-731304847aac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2e641d1e-0b59-49b1-9fe4-a691b15dde3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_107c6c49-f9c8-4f3d-b9a1-731304847aac" xlink:to="loc_us-gaap_DebtInstrumentTable_2e641d1e-0b59-49b1-9fe4-a691b15dde3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_ff1a519f-505b-4407-a437-523339511dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2e641d1e-0b59-49b1-9fe4-a691b15dde3c" xlink:to="loc_us-gaap_VariableRateAxis_ff1a519f-505b-4407-a437-523339511dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_a798bcda-fec1-40b2-a42a-b3e940aad501" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_ff1a519f-505b-4407-a437-523339511dfb" xlink:to="loc_us-gaap_VariableRateDomain_a798bcda-fec1-40b2-a42a-b3e940aad501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_a8303424-e154-4cfc-bf59-aad88992a669" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_a798bcda-fec1-40b2-a42a-b3e940aad501" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_a8303424-e154-4cfc-bf59-aad88992a669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_bc0883a9-9fea-408e-87db-26746b0b8c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_a798bcda-fec1-40b2-a42a-b3e940aad501" xlink:to="loc_us-gaap_EurodollarMember_bc0883a9-9fea-408e-87db-26746b0b8c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadaBankersAcceptanceRateMember_06c6c12c-0df0-406c-b55f-d54fa82ff6cd" xlink:href="bhc-20220510.xsd#bhc_CanadaBankersAcceptanceRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_a798bcda-fec1-40b2-a42a-b3e940aad501" xlink:to="loc_bhc_CanadaBankersAcceptanceRateMember_06c6c12c-0df0-406c-b55f-d54fa82ff6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BaseRateOrPrimeRateMember_855c1f8e-8c00-4ee7-a9e7-0bc2bfb4e689" xlink:href="bhc-20220510.xsd#bhc_BaseRateOrPrimeRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_a798bcda-fec1-40b2-a42a-b3e940aad501" xlink:to="loc_bhc_BaseRateOrPrimeRateMember_855c1f8e-8c00-4ee7-a9e7-0bc2bfb4e689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6eefa541-3e1c-4c33-bb57-6b4c09e3527d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2e641d1e-0b59-49b1-9fe4-a691b15dde3c" xlink:to="loc_us-gaap_DebtInstrumentAxis_6eefa541-3e1c-4c33-bb57-6b4c09e3527d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_862fe0a4-286f-4ca2-b21c-5387488a29e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_6eefa541-3e1c-4c33-bb57-6b4c09e3527d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_862fe0a4-286f-4ca2-b21c-5387488a29e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredCreditFacilitiesMember_8e81487f-3e0b-408c-9210-011263e4ccd8" xlink:href="bhc-20220510.xsd#bhc_SeniorSecuredCreditFacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_862fe0a4-286f-4ca2-b21c-5387488a29e7" xlink:to="loc_bhc_SeniorSecuredCreditFacilitiesMember_8e81487f-3e0b-408c-9210-011263e4ccd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_85cf51ab-b475-4fc6-be70-f5ade38e29c4" xlink:href="bhc-20220510.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_862fe0a4-286f-4ca2-b21c-5387488a29e7" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_85cf51ab-b475-4fc6-be70-f5ade38e29c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredTermCreditFacilitiesMember_70d70593-ec2e-4123-aea9-547c188a901c" xlink:href="bhc-20220510.xsd#bhc_SeniorSecuredTermCreditFacilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_862fe0a4-286f-4ca2-b21c-5387488a29e7" xlink:to="loc_bhc_SeniorSecuredTermCreditFacilitiesMember_70d70593-ec2e-4123-aea9-547c188a901c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025Member_55d44bb4-e338-4b5f-90e5-d5afb928488c" xlink:href="bhc-20220510.xsd#bhc_TermLoanBFacilityDueJune2025Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_862fe0a4-286f-4ca2-b21c-5387488a29e7" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025Member_55d44bb4-e338-4b5f-90e5-d5afb928488c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueNovember2025Member_e712cc85-9d6e-4fab-8e0d-d89a8cd69a38" xlink:href="bhc-20220510.xsd#bhc_TermLoanBFacilityDueNovember2025Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_862fe0a4-286f-4ca2-b21c-5387488a29e7" xlink:to="loc_bhc_TermLoanBFacilityDueNovember2025Member_e712cc85-9d6e-4fab-8e0d-d89a8cd69a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_19c2f186-a226-4211-82ef-8aab26dbfdfa" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2e641d1e-0b59-49b1-9fe4-a691b15dde3c" xlink:to="loc_srt_RangeAxis_19c2f186-a226-4211-82ef-8aab26dbfdfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dd1bbb44-42a5-4c82-a745-2242be94cb96" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_19c2f186-a226-4211-82ef-8aab26dbfdfa" xlink:to="loc_srt_RangeMember_dd1bbb44-42a5-4c82-a745-2242be94cb96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4464b1d5-30a9-474f-bb98-cfc023724267" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_dd1bbb44-42a5-4c82-a745-2242be94cb96" xlink:to="loc_srt_MinimumMember_4464b1d5-30a9-474f-bb98-cfc023724267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_87adc0e4-fb90-486f-bc8b-2a1d3a484040" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_dd1bbb44-42a5-4c82-a745-2242be94cb96" xlink:to="loc_srt_MaximumMember_87adc0e4-fb90-486f-bc8b-2a1d3a484040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_1f579138-ab7a-42b0-b760-da954f2e7726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2e641d1e-0b59-49b1-9fe4-a691b15dde3c" xlink:to="loc_us-gaap_CreditFacilityAxis_1f579138-ab7a-42b0-b760-da954f2e7726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e1a47386-8079-4d9b-8ebb-473cac37a454" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_1f579138-ab7a-42b0-b760-da954f2e7726" xlink:to="loc_us-gaap_CreditFacilityDomain_e1a47386-8079-4d9b-8ebb-473cac37a454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_cf7e649f-3146-42b4-b594-9f8a679a6917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_e1a47386-8079-4d9b-8ebb-473cac37a454" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_cf7e649f-3146-42b4-b594-9f8a679a6917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_f0f4aa02-8a85-4836-b7cd-3573236bb960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2e641d1e-0b59-49b1-9fe4-a691b15dde3c" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_f0f4aa02-8a85-4836-b7cd-3573236bb960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_aa5d3a32-8e74-4db2-aec8-0ca4caa732c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_f0f4aa02-8a85-4836-b7cd-3573236bb960" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_aa5d3a32-8e74-4db2-aec8-0ca4caa732c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_34351aba-fe94-4984-8c41-0844c9a5623b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_aa5d3a32-8e74-4db2-aec8-0ca4caa732c7" xlink:to="loc_us-gaap_SecuredDebtMember_34351aba-fe94-4984-8c41-0844c9a5623b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_2d6b3197-4fd4-4974-b50d-cab96ac4c2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_aa5d3a32-8e74-4db2-aec8-0ca4caa732c7" xlink:to="loc_us-gaap_UnsecuredDebtMember_2d6b3197-4fd4-4974-b50d-cab96ac4c2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2e641d1e-0b59-49b1-9fe4-a691b15dde3c" xlink:to="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ef45e21e-f854-4456-875d-f98d4a62f86f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ef45e21e-f854-4456-875d-f98d4a62f86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_20db5a64-b546-4f8e-bac1-8ceca5954686" xlink:href="bhc-20220510.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments_20db5a64-b546-4f8e-bac1-8ceca5954686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_8f7a1f20-1e5c-4a57-a4bc-e5c2b07b7b12" xlink:href="bhc-20220510.xsd#bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments_8f7a1f20-1e5c-4a57-a4bc-e5c2b07b7b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_a064f233-c938-4d1d-93a7-2a3922a354a9" xlink:href="bhc-20220510.xsd#bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments_a064f233-c938-4d1d-93a7-2a3922a354a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_c5a09950-0808-4951-b882-2d26cb9e3610" xlink:href="bhc-20220510.xsd#bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:to="loc_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments_c5a09950-0808-4951-b882-2d26cb9e3610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_70d25448-67da-4314-93de-2d12df4b6023" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_70d25448-67da-4314-93de-2d12df4b6023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_69767bfc-c64d-4dca-b679-d1fd4e25fcf5" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentAnnualAmortizationRatePercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:to="loc_bhc_DebtInstrumentAnnualAmortizationRatePercentage_69767bfc-c64d-4dca-b679-d1fd4e25fcf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_af2bcd94-b226-485e-8c82-d8a2a7a24209" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:to="loc_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization_af2bcd94-b226-485e-8c82-d8a2a7a24209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_cc2f906e-4863-4ba0-8032-c832b2398e32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_cc2f906e-4863-4ba0-8032-c832b2398e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_8ebcda11-ea32-4db3-95be-78bc34701646" xlink:href="bhc-20220510.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings_8ebcda11-ea32-4db3-95be-78bc34701646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate_a9c7dcba-5af5-4278-b4a3-d57208a5b75d" xlink:href="bhc-20220510.xsd#bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:to="loc_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate_a9c7dcba-5af5-4278-b4a3-d57208a5b75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_c1b2ff3f-3032-44ac-911a-a7a716dd25ed" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:to="loc_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio_c1b2ff3f-3032-44ac-911a-a7a716dd25ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_1e59d570-845f-44d6-a76f-559ab094f1e8" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum_1e59d570-845f-44d6-a76f-559ab094f1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_854f51f4-48b8-466b-a304-94fbebffa13f" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c9753cf6-8e6b-44a3-ab32-df8b22742363" xlink:to="loc_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum_854f51f4-48b8-466b-a304-94fbebffa13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b400698c-1770-4df5-904c-50a2353981d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_859ba741-60db-4459-97ec-0a5843044698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b400698c-1770-4df5-904c-50a2353981d9" xlink:to="loc_us-gaap_DebtInstrumentTable_859ba741-60db-4459-97ec-0a5843044698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_569d9da3-5290-4b91-9a85-73f0c3eafd55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_859ba741-60db-4459-97ec-0a5843044698" xlink:to="loc_us-gaap_DebtInstrumentAxis_569d9da3-5290-4b91-9a85-73f0c3eafd55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0b11e187-6160-41a0-b8cb-d08c74fa67c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_569d9da3-5290-4b91-9a85-73f0c3eafd55" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0b11e187-6160-41a0-b8cb-d08c74fa67c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_ee878083-cefa-419c-9fad-258d0d8d76b3" xlink:href="bhc-20220510.xsd#bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b11e187-6160-41a0-b8cb-d08c74fa67c3" xlink:to="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_ee878083-cefa-419c-9fad-258d0d8d76b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_b097dac6-871e-4697-a6d5-44f6557bc939" xlink:href="bhc-20220510.xsd#bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b11e187-6160-41a0-b8cb-d08c74fa67c3" xlink:to="loc_bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member_b097dac6-871e-4697-a6d5-44f6557bc939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_46fd449b-8581-4b23-9a34-e66b1c31c424" xlink:href="bhc-20220510.xsd#bhc_SeniorSecured5.50NotesDueNovember2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b11e187-6160-41a0-b8cb-d08c74fa67c3" xlink:to="loc_bhc_SeniorSecured5.50NotesDueNovember2025Member_46fd449b-8581-4b23-9a34-e66b1c31c424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_818fd486-6c11-453a-9bdf-c72c84c0cf73" xlink:href="bhc-20220510.xsd#bhc_SeniorSecured5.75NotesDueAugust2027Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b11e187-6160-41a0-b8cb-d08c74fa67c3" xlink:to="loc_bhc_SeniorSecured5.75NotesDueAugust2027Member_818fd486-6c11-453a-9bdf-c72c84c0cf73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A8.50SeniorNotesDueJanuary2027Member_ba820b43-99ec-4e63-b2b0-aa59ce0f1716" xlink:href="bhc-20220510.xsd#bhc_A8.50SeniorNotesDueJanuary2027Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b11e187-6160-41a0-b8cb-d08c74fa67c3" xlink:to="loc_bhc_A8.50SeniorNotesDueJanuary2027Member_ba820b43-99ec-4e63-b2b0-aa59ce0f1716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.875SeniorNotesdueMay2023Member_c140756a-bdb1-434a-ad0f-82f788ebd428" xlink:href="bhc-20220510.xsd#bhc_A5.875SeniorNotesdueMay2023Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b11e187-6160-41a0-b8cb-d08c74fa67c3" xlink:to="loc_bhc_A5.875SeniorNotesdueMay2023Member_c140756a-bdb1-434a-ad0f-82f788ebd428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes5.625PercentDueDecember2021Member_f5048103-f3f3-418b-a2d0-c3b0712c9356" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes5.625PercentDueDecember2021Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b11e187-6160-41a0-b8cb-d08c74fa67c3" xlink:to="loc_bhc_SeniorNotes5.625PercentDueDecember2021Member_f5048103-f3f3-418b-a2d0-c3b0712c9356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember_0ebe669c-5eed-4278-b006-a64ecb171b5d" xlink:href="bhc-20220510.xsd#bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b11e187-6160-41a0-b8cb-d08c74fa67c3" xlink:to="loc_bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember_0ebe669c-5eed-4278-b006-a64ecb171b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured4875NotesDueJune2028Member_1e416db2-59fd-471d-9a96-3b5514e5491a" xlink:href="bhc-20220510.xsd#bhc_SeniorSecured4875NotesDueJune2028Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b11e187-6160-41a0-b8cb-d08c74fa67c3" xlink:to="loc_bhc_SeniorSecured4875NotesDueJune2028Member_1e416db2-59fd-471d-9a96-3b5514e5491a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes700DueMarch2024Member_796df159-d301-4eaf-bbc9-319d80a1a85b" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes700DueMarch2024Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0b11e187-6160-41a0-b8cb-d08c74fa67c3" xlink:to="loc_bhc_SeniorNotes700DueMarch2024Member_796df159-d301-4eaf-bbc9-319d80a1a85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5485b3fa-e146-40aa-8497-3d8ae3ac308d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_859ba741-60db-4459-97ec-0a5843044698" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5485b3fa-e146-40aa-8497-3d8ae3ac308d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_497f1dcb-8a54-4f6a-9d9d-88c47cdad37a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5485b3fa-e146-40aa-8497-3d8ae3ac308d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_497f1dcb-8a54-4f6a-9d9d-88c47cdad37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_25174a8a-f10e-427d-9a5c-6b98972867b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_497f1dcb-8a54-4f6a-9d9d-88c47cdad37a" xlink:to="loc_us-gaap_SecuredDebtMember_25174a8a-f10e-427d-9a5c-6b98972867b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_26e48f1c-3444-4184-8a93-33efd3443d27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_497f1dcb-8a54-4f6a-9d9d-88c47cdad37a" xlink:to="loc_us-gaap_UnsecuredDebtMember_26e48f1c-3444-4184-8a93-33efd3443d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_6e25399a-0b2d-4b10-aaaa-6d26cb1aa5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_859ba741-60db-4459-97ec-0a5843044698" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_6e25399a-0b2d-4b10-aaaa-6d26cb1aa5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_74bdfed3-d781-418a-a4cd-3a505f85399f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_6e25399a-0b2d-4b10-aaaa-6d26cb1aa5b6" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_74bdfed3-d781-418a-a4cd-3a505f85399f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_b896d053-9133-436c-86dc-36b592785e71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_74bdfed3-d781-418a-a4cd-3a505f85399f" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_b896d053-9133-436c-86dc-36b592785e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_459c287b-8882-4e16-81cb-b4f3b9c40170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_74bdfed3-d781-418a-a4cd-3a505f85399f" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_459c287b-8882-4e16-81cb-b4f3b9c40170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a0757de1-afa5-4033-951f-e564058e04e7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_859ba741-60db-4459-97ec-0a5843044698" xlink:to="loc_srt_RangeAxis_a0757de1-afa5-4033-951f-e564058e04e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_975316e8-a4c9-410f-a339-ec1e0fbed89d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a0757de1-afa5-4033-951f-e564058e04e7" xlink:to="loc_srt_RangeMember_975316e8-a4c9-410f-a339-ec1e0fbed89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_58d99adf-af08-486e-aee5-d05e9e80b7e6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_975316e8-a4c9-410f-a339-ec1e0fbed89d" xlink:to="loc_srt_MaximumMember_58d99adf-af08-486e-aee5-d05e9e80b7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c5a492ce-9573-455c-8c3d-cdd9ec8eefbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_859ba741-60db-4459-97ec-0a5843044698" xlink:to="loc_us-gaap_DebtInstrumentLineItems_c5a492ce-9573-455c-8c3d-cdd9ec8eefbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_481ee1ad-6904-47eb-aae1-0f3fbc102a69" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c5a492ce-9573-455c-8c3d-cdd9ec8eefbe" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_481ee1ad-6904-47eb-aae1-0f3fbc102a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_13952f7f-0499-4c20-85ea-bc099df28b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c5a492ce-9573-455c-8c3d-cdd9ec8eefbe" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_13952f7f-0499-4c20-85ea-bc099df28b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a5bede33-9db3-4722-8020-b7f7317e2596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c5a492ce-9573-455c-8c3d-cdd9ec8eefbe" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a5bede33-9db3-4722-8020-b7f7317e2596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_c05a1497-bde9-45e7-b9bd-55ad362e77cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c5a492ce-9573-455c-8c3d-cdd9ec8eefbe" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_c05a1497-bde9-45e7-b9bd-55ad362e77cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6ce536e5-59d3-4768-ab40-a40999842b15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c5a492ce-9573-455c-8c3d-cdd9ec8eefbe" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6ce536e5-59d3-4768-ab40-a40999842b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_104731f3-2ccc-410e-8a95-05abb25b5f53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c5a492ce-9573-455c-8c3d-cdd9ec8eefbe" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_104731f3-2ccc-410e-8a95-05abb25b5f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds_31fecb17-524b-4927-9de0-084600b8ff07" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c5a492ce-9573-455c-8c3d-cdd9ec8eefbe" xlink:to="loc_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds_31fecb17-524b-4927-9de0-084600b8ff07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_2f974ed5-52b3-4959-b375-00d079829636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c5a492ce-9573-455c-8c3d-cdd9ec8eefbe" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_2f974ed5-52b3-4959-b375-00d079829636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_dc04ff55-4a55-479a-83a8-17bad22c98d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f6214da5-1ebf-4c2e-ac99-ca313737046f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_dc04ff55-4a55-479a-83a8-17bad22c98d2" xlink:to="loc_us-gaap_DebtInstrumentTable_f6214da5-1ebf-4c2e-ac99-ca313737046f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a38c87a5-6dbf-4d4a-a803-21e48c9dc16e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f6214da5-1ebf-4c2e-ac99-ca313737046f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a38c87a5-6dbf-4d4a-a803-21e48c9dc16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_064bca09-7809-462c-8186-615dc4b67f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a38c87a5-6dbf-4d4a-a803-21e48c9dc16e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_064bca09-7809-462c-8186-615dc4b67f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_dcb2dcc3-f896-4a75-be9b-bd0c7dbf3d69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_064bca09-7809-462c-8186-615dc4b67f0a" xlink:to="loc_us-gaap_UnsecuredDebtMember_dcb2dcc3-f896-4a75-be9b-bd0c7dbf3d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_5f4526e1-e554-442e-9fb4-c3659428b8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_064bca09-7809-462c-8186-615dc4b67f0a" xlink:to="loc_us-gaap_SecuredDebtMember_5f4526e1-e554-442e-9fb4-c3659428b8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_eea7df83-c5d0-4bba-b50c-65aa0383ae16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f6214da5-1ebf-4c2e-ac99-ca313737046f" xlink:to="loc_us-gaap_DebtInstrumentAxis_eea7df83-c5d0-4bba-b50c-65aa0383ae16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_eea7df83-c5d0-4bba-b50c-65aa0383ae16" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.50SeniorNotesdueMarch2023Member_9234ce4d-5374-4abe-8b6e-79f521585cf7" xlink:href="bhc-20220510.xsd#bhc_A5.50SeniorNotesdueMarch2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_A5.50SeniorNotesdueMarch2023Member_9234ce4d-5374-4abe-8b6e-79f521585cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.375SeniorNotesdueMarch2020Member_fa1381e8-8001-4363-8860-2a6c6b5da764" xlink:href="bhc-20220510.xsd#bhc_A5.375SeniorNotesdueMarch2020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_A5.375SeniorNotesdueMarch2020Member_fa1381e8-8001-4363-8860-2a6c6b5da764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.875SeniorNotesdueMay2023Member_d3d8af89-78f6-4aaa-93ba-a4892c03dbef" xlink:href="bhc-20220510.xsd#bhc_A5.875SeniorNotesdueMay2023Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_A5.875SeniorNotesdueMay2023Member_d3d8af89-78f6-4aaa-93ba-a4892c03dbef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember_8ba68ec8-9477-4af3-a32e-96572b07cce6" xlink:href="bhc-20220510.xsd#bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_A5.875SeniorNotesdueMay2023Member_d3d8af89-78f6-4aaa-93ba-a4892c03dbef" xlink:to="loc_bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember_8ba68ec8-9477-4af3-a32e-96572b07cce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember_ca039c6a-e390-4fc8-9f5a-bb27b6e91eeb" xlink:href="bhc-20220510.xsd#bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_A5.875SeniorNotesdueMay2023Member_d3d8af89-78f6-4aaa-93ba-a4892c03dbef" xlink:to="loc_bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember_ca039c6a-e390-4fc8-9f5a-bb27b6e91eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes4.502023Member_7685340c-3796-47a9-9a55-dd1b8334ef0f" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes4.502023Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_SeniorNotes4.502023Member_7685340c-3796-47a9-9a55-dd1b8334ef0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A6.125SeniorNotesdueApril2025Member_8166b68b-2689-410d-a62d-c4d6283f2e84" xlink:href="bhc-20220510.xsd#bhc_A6.125SeniorNotesdueApril2025Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_A6.125SeniorNotesdueApril2025Member_8166b68b-2689-410d-a62d-c4d6283f2e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorUnsecuredNotesDue2023Member_12243e09-10c8-47b8-a11d-844b7ad909dd" xlink:href="bhc-20220510.xsd#bhc_SeniorUnsecuredNotesDue2023Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_SeniorUnsecuredNotesDue2023Member_12243e09-10c8-47b8-a11d-844b7ad909dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes6125DueApril2025Member_53bbed08-89b9-4079-ac85-396fdd079505" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes6125DueApril2025Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_SeniorNotes6125DueApril2025Member_53bbed08-89b9-4079-ac85-396fdd079505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.00SeniorNotesdueDecember2025Member_f8a8b992-2121-40d3-9fcd-34fafd07393c" xlink:href="bhc-20220510.xsd#bhc_A9.00SeniorNotesdueDecember2025Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_A9.00SeniorNotesdueDecember2025Member_f8a8b992-2121-40d3-9fcd-34fafd07393c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.25SeniorNotesDueApril2026Member_f2635fd8-c893-483a-8999-9c91b6e9fbbc" xlink:href="bhc-20220510.xsd#bhc_A9.25SeniorNotesDueApril2026Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_A9.25SeniorNotesDueApril2026Member_f2635fd8-c893-483a-8999-9c91b6e9fbbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A8.50SeniorNotesDueJanuary2027Member_ff5e5eaa-f618-4e11-8f03-c8f0fefa981a" xlink:href="bhc-20220510.xsd#bhc_A8.50SeniorNotesDueJanuary2027Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_A8.50SeniorNotesDueJanuary2027Member_ff5e5eaa-f618-4e11-8f03-c8f0fefa981a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A7.00SeniorUnsecuredNotesDue2028Member_8018f639-d475-46ff-976f-ce8b124f2267" xlink:href="bhc-20220510.xsd#bhc_A7.00SeniorUnsecuredNotesDue2028Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_A7.00SeniorUnsecuredNotesDue2028Member_8018f639-d475-46ff-976f-ce8b124f2267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A7.25SeniorUnsecuredNotesDue2029Member_8422ff9b-0f6f-4efa-ba50-b9027aea4e5e" xlink:href="bhc-20220510.xsd#bhc_A7.25SeniorUnsecuredNotesDue2029Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_A7.25SeniorUnsecuredNotesDue2029Member_8422ff9b-0f6f-4efa-ba50-b9027aea4e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.00SeniorNotesDueJanuary2028Member_138f9d52-3d1d-4e01-9e51-cf35f98e0551" xlink:href="bhc-20220510.xsd#bhc_A5.00SeniorNotesDueJanuary2028Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_A5.00SeniorNotesDueJanuary2028Member_138f9d52-3d1d-4e01-9e51-cf35f98e0551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A5.25SeniorNotesDueJanuary2030Member_0a1f1337-de51-41af-9bc0-bdac3ba2a857" xlink:href="bhc-20220510.xsd#bhc_A5.25SeniorNotesDueJanuary2030Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_A5.25SeniorNotesDueJanuary2030Member_0a1f1337-de51-41af-9bc0-bdac3ba2a857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes625DueFebruary2029Member_cc79b265-0832-4884-b048-dbec1871b456" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes625DueFebruary2029Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_SeniorNotes625DueFebruary2029Member_cc79b265-0832-4884-b048-dbec1871b456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_31eab49f-054e-4f49-9950-f668b86badb1" xlink:href="bhc-20220510.xsd#bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member_31eab49f-054e-4f49-9950-f668b86badb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member_9333fa8b-1aa8-4597-afb5-07b182aad1fd" xlink:href="bhc-20220510.xsd#bhc_TermLoanBFacilityDueJune2025AndNovember2025Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_TermLoanBFacilityDueJune2025AndNovember2025Member_9333fa8b-1aa8-4597-afb5-07b182aad1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes500DueFebruary2029Member_3328d49b-8011-4fa6-a5c9-0efc4211e772" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes500DueFebruary2029Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_SeniorNotes500DueFebruary2029Member_3328d49b-8011-4fa6-a5c9-0efc4211e772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes525DueFebruary2031Member_4bed9b3c-d48d-4659-8438-bd582c730943" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes525DueFebruary2031Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_SeniorNotes525DueFebruary2031Member_4bed9b3c-d48d-4659-8438-bd582c730943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorNotes550DueMarch2023Member_26e4d75e-1026-4a59-840a-ca2e0f110663" xlink:href="bhc-20220510.xsd#bhc_SeniorNotes550DueMarch2023Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1f4d2670-9fcf-4f83-ab00-1744f54a7773" xlink:to="loc_bhc_SeniorNotes550DueMarch2023Member_26e4d75e-1026-4a59-840a-ca2e0f110663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_38acd062-57af-4b91-b1ac-f187c08057bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f6214da5-1ebf-4c2e-ac99-ca313737046f" xlink:to="loc_us-gaap_LitigationStatusAxis_38acd062-57af-4b91-b1ac-f187c08057bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_197d3de8-92ed-4094-bb98-0e2e07cc4908" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_38acd062-57af-4b91-b1ac-f187c08057bf" xlink:to="loc_us-gaap_LitigationStatusDomain_197d3de8-92ed-4094-bb98-0e2e07cc4908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_41b909f9-60b7-4065-acaf-7f55acb4104c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_197d3de8-92ed-4094-bb98-0e2e07cc4908" xlink:to="loc_us-gaap_SettledLitigationMember_41b909f9-60b7-4065-acaf-7f55acb4104c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_209ab76a-b36c-4871-b262-4b238f1bba9d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f6214da5-1ebf-4c2e-ac99-ca313737046f" xlink:to="loc_srt_StatementGeographicalAxis_209ab76a-b36c-4871-b262-4b238f1bba9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b9695792-53a5-4e59-8c1c-379ada279bdc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_209ab76a-b36c-4871-b262-4b238f1bba9d" xlink:to="loc_srt_SegmentGeographicalDomain_b9695792-53a5-4e59-8c1c-379ada279bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_e96d4572-4481-4d96-a61f-e7eed2f03cb2" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b9695792-53a5-4e59-8c1c-379ada279bdc" xlink:to="loc_stpr_NJ_e96d4572-4481-4d96-a61f-e7eed2f03cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_8b921302-a9af-4812-91ef-b1f632e4183f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f6214da5-1ebf-4c2e-ac99-ca313737046f" xlink:to="loc_srt_LitigationCaseAxis_8b921302-a9af-4812-91ef-b1f632e4183f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_04230d54-6360-461a-932f-0c53eef6312c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_8b921302-a9af-4812-91ef-b1f632e4183f" xlink:to="loc_srt_LitigationCaseTypeDomain_04230d54-6360-461a-932f-0c53eef6312c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_8ea45cb8-a049-400c-b24e-82ff0405a216" xlink:href="bhc-20220510.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_04230d54-6360-461a-932f-0c53eef6312c" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_8ea45cb8-a049-400c-b24e-82ff0405a216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_c5db70a6-3529-4d56-b7d7-fb4898c77249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f6214da5-1ebf-4c2e-ac99-ca313737046f" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_c5db70a6-3529-4d56-b7d7-fb4898c77249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_f851e9c8-b07e-4913-8366-5e257547f0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_c5db70a6-3529-4d56-b7d7-fb4898c77249" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_f851e9c8-b07e-4913-8366-5e257547f0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_1ebf76c4-0121-43a7-aef4-82694e78c6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_f851e9c8-b07e-4913-8366-5e257547f0b2" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_1ebf76c4-0121-43a7-aef4-82694e78c6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_5d27ab5e-def9-4f52-bd5a-21269cc9c894" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_f851e9c8-b07e-4913-8366-5e257547f0b2" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_5d27ab5e-def9-4f52-bd5a-21269cc9c894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6babba29-33a2-4fe7-b633-0d631648129f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f6214da5-1ebf-4c2e-ac99-ca313737046f" xlink:to="loc_us-gaap_DebtInstrumentLineItems_6babba29-33a2-4fe7-b633-0d631648129f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_e60558fb-b312-471c-9224-8eea8a82d3d8" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentRedemptionPricePercentageChangeinControl"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6babba29-33a2-4fe7-b633-0d631648129f" xlink:to="loc_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl_e60558fb-b312-471c-9224-8eea8a82d3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d2c0a366-f62d-4717-99a1-5293292db490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6babba29-33a2-4fe7-b633-0d631648129f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_d2c0a366-f62d-4717-99a1-5293292db490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_45781087-f8f7-4509-b27c-c5d155fc9c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6babba29-33a2-4fe7-b633-0d631648129f" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_45781087-f8f7-4509-b27c-c5d155fc9c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_640238fa-cfdc-4b33-be9e-63e5c9039f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6babba29-33a2-4fe7-b633-0d631648129f" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_640238fa-cfdc-4b33-be9e-63e5c9039f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_21ef2233-c248-4bcc-8505-74a093e38c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6babba29-33a2-4fe7-b633-0d631648129f" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_21ef2233-c248-4bcc-8505-74a093e38c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_5264d6ae-dd86-43c5-97b1-65cccb91ba63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6babba29-33a2-4fe7-b633-0d631648129f" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_5264d6ae-dd86-43c5-97b1-65cccb91ba63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds_fd0f02f5-b376-486f-89d3-a4ed0cc8a874" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6babba29-33a2-4fe7-b633-0d631648129f" xlink:to="loc_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds_fd0f02f5-b376-486f-89d3-a4ed0cc8a874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_13fca7b0-e89f-4614-88e2-58cd09bff2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6babba29-33a2-4fe7-b633-0d631648129f" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_13fca7b0-e89f-4614-88e2-58cd09bff2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_1ab5c4c6-1308-4f6d-90be-a2cf61675352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6babba29-33a2-4fe7-b633-0d631648129f" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_1ab5c4c6-1308-4f6d-90be-a2cf61675352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PaymentForDebtAmortizationPrepaymentCost_851857b3-dbb6-46ed-92c8-9bffa8e3e33f" xlink:href="bhc-20220510.xsd#bhc_PaymentForDebtAmortizationPrepaymentCost"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6babba29-33a2-4fe7-b633-0d631648129f" xlink:to="loc_bhc_PaymentForDebtAmortizationPrepaymentCost_851857b3-dbb6-46ed-92c8-9bffa8e3e33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8be0ba13-e67d-422d-9aa1-89156d66f960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d1dff5e7-4cef-461f-ac29-f08a46213580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8be0ba13-e67d-422d-9aa1-89156d66f960" xlink:to="loc_us-gaap_DebtInstrumentTable_d1dff5e7-4cef-461f-ac29-f08a46213580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2a39b425-5958-4bf2-9249-f0ff33311be4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d1dff5e7-4cef-461f-ac29-f08a46213580" xlink:to="loc_us-gaap_DebtInstrumentAxis_2a39b425-5958-4bf2-9249-f0ff33311be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_587c00f4-aa5c-43d3-bfb0-82f895394c27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2a39b425-5958-4bf2-9249-f0ff33311be4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_587c00f4-aa5c-43d3-bfb0-82f895394c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityDueJune2023Member_5dfec80c-5d17-413f-8878-20f2868b66e4" xlink:href="bhc-20220510.xsd#bhc_RevolvingCreditFacilityDueJune2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_587c00f4-aa5c-43d3-bfb0-82f895394c27" xlink:to="loc_bhc_RevolvingCreditFacilityDueJune2023Member_5dfec80c-5d17-413f-8878-20f2868b66e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.00SeniorNotesdueDecember2025Member_b6b5d002-fd69-4b49-819a-815f3a325c15" xlink:href="bhc-20220510.xsd#bhc_A9.00SeniorNotesdueDecember2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_587c00f4-aa5c-43d3-bfb0-82f895394c27" xlink:to="loc_bhc_A9.00SeniorNotesdueDecember2025Member_b6b5d002-fd69-4b49-819a-815f3a325c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_b2fa26da-21e3-43a3-8aef-465f3d26dc7c" xlink:href="bhc-20220510.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_587c00f4-aa5c-43d3-bfb0-82f895394c27" xlink:to="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_b2fa26da-21e3-43a3-8aef-465f3d26dc7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_69f4ff25-b80c-44f7-8125-4bfeb0e3eabd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d1dff5e7-4cef-461f-ac29-f08a46213580" xlink:to="loc_us-gaap_CreditFacilityAxis_69f4ff25-b80c-44f7-8125-4bfeb0e3eabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_cf2eb12b-1dfa-438a-8f57-841aaae086cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_69f4ff25-b80c-44f7-8125-4bfeb0e3eabd" xlink:to="loc_us-gaap_CreditFacilityDomain_cf2eb12b-1dfa-438a-8f57-841aaae086cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_c156db34-0652-47bf-bacb-a081a844537a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_cf2eb12b-1dfa-438a-8f57-841aaae086cf" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_c156db34-0652-47bf-bacb-a081a844537a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c70d3c76-4139-4018-ace8-aecffa6ee77b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d1dff5e7-4cef-461f-ac29-f08a46213580" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c70d3c76-4139-4018-ace8-aecffa6ee77b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_042596f8-5d7c-4436-a720-2c8ff44ea959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c70d3c76-4139-4018-ace8-aecffa6ee77b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_042596f8-5d7c-4436-a720-2c8ff44ea959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_0f6f65fa-fe2e-4a2a-a7e6-53aba533799f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_042596f8-5d7c-4436-a720-2c8ff44ea959" xlink:to="loc_us-gaap_UnsecuredDebtMember_0f6f65fa-fe2e-4a2a-a7e6-53aba533799f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_fafafb67-02dc-4271-9daf-33ca13bb7e73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_042596f8-5d7c-4436-a720-2c8ff44ea959" xlink:to="loc_us-gaap_SecuredDebtMember_fafafb67-02dc-4271-9daf-33ca13bb7e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0ff527c3-f6c3-4ce3-9b7a-e58e0b291876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d1dff5e7-4cef-461f-ac29-f08a46213580" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0ff527c3-f6c3-4ce3-9b7a-e58e0b291876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_009fee0a-e21d-4964-ae25-623c4e2c41c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0ff527c3-f6c3-4ce3-9b7a-e58e0b291876" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_009fee0a-e21d-4964-ae25-623c4e2c41c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5acc61b2-618b-4f48-ac03-f1f60bab5f75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_009fee0a-e21d-4964-ae25-623c4e2c41c7" xlink:to="loc_us-gaap_SubsequentEventMember_5acc61b2-618b-4f48-ac03-f1f60bab5f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e2b63df0-e72f-4184-8ed6-c76e0e5529b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d1dff5e7-4cef-461f-ac29-f08a46213580" xlink:to="loc_us-gaap_DebtInstrumentLineItems_e2b63df0-e72f-4184-8ed6-c76e0e5529b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_592112e9-7a86-47c5-993a-c41dafedb3e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e2b63df0-e72f-4184-8ed6-c76e0e5529b0" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_592112e9-7a86-47c5-993a-c41dafedb3e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_c063269b-da3e-4bcd-a9a6-346c4b5c59fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e2b63df0-e72f-4184-8ed6-c76e0e5529b0" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_c063269b-da3e-4bcd-a9a6-346c4b5c59fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_fc78c2bb-f534-4b66-b7fd-46c7d07f2b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e2b63df0-e72f-4184-8ed6-c76e0e5529b0" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_fc78c2bb-f534-4b66-b7fd-46c7d07f2b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_888e4ba6-fab6-4b0a-92de-31003803d136" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e2b63df0-e72f-4184-8ed6-c76e0e5529b0" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_888e4ba6-fab6-4b0a-92de-31003803d136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_31ea8548-4070-4c82-a439-4bbe6882a2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e2b63df0-e72f-4184-8ed6-c76e0e5529b0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_31ea8548-4070-4c82-a439-4bbe6882a2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0249c88d-e95a-478b-a8ba-aa4484944fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_53b39218-e92e-4cfd-bfe6-488e55838eef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0249c88d-e95a-478b-a8ba-aa4484944fe0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_53b39218-e92e-4cfd-bfe6-488e55838eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_c7784fe0-d778-4cd9-a365-226044c63c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0249c88d-e95a-478b-a8ba-aa4484944fe0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_c7784fe0-d778-4cd9-a365-226044c63c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_23b9481b-5e5a-46b6-9369-ed0c793670d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0249c88d-e95a-478b-a8ba-aa4484944fe0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_23b9481b-5e5a-46b6-9369-ed0c793670d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_2e6ae454-116f-4cf6-bec3-a3202ab7ef75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0249c88d-e95a-478b-a8ba-aa4484944fe0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_2e6ae454-116f-4cf6-bec3-a3202ab7ef75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_0414fe29-63f3-4149-b82a-9d99b08e53de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0249c88d-e95a-478b-a8ba-aa4484944fe0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_0414fe29-63f3-4149-b82a-9d99b08e53de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_b0608ced-eb51-4454-a51f-c0a9ec4af143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0249c88d-e95a-478b-a8ba-aa4484944fe0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_b0608ced-eb51-4454-a51f-c0a9ec4af143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_2e1d40f2-6d6a-4dcf-885f-3b2e00d6d072" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0249c88d-e95a-478b-a8ba-aa4484944fe0" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_2e1d40f2-6d6a-4dcf-885f-3b2e00d6d072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_f4e75b47-ed64-400a-bc46-18221ef80ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0249c88d-e95a-478b-a8ba-aa4484944fe0" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_f4e75b47-ed64-400a-bc46-18221ef80ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_dfcb1083-f491-435f-80d6-558c8ddd17d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0249c88d-e95a-478b-a8ba-aa4484944fe0" xlink:to="loc_us-gaap_LongTermDebt_dfcb1083-f491-435f-80d6-558c8ddd17d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS" xlink:type="simple" xlink:href="bhc-20220510.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_7e188622-53e7-4ebe-9aae-20d2364b48c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_22d92757-7c6e-4332-b333-fefdf8e270c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_7e188622-53e7-4ebe-9aae-20d2364b48c6" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_22d92757-7c6e-4332-b333-fefdf8e270c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" xlink:type="simple" xlink:href="bhc-20220510.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2c391200-9ea5-476c-8e89-44769c45444b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_9c7b5311-04e5-416f-aefc-638d84a14142" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2c391200-9ea5-476c-8e89-44769c45444b" xlink:to="loc_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_9c7b5311-04e5-416f-aefc-638d84a14142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_71fe4c3f-b449-4265-8d64-57db074a22de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2c391200-9ea5-476c-8e89-44769c45444b" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_71fe4c3f-b449-4265-8d64-57db074a22de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_48d5f503-d96c-485f-b0a7-c6fa7dc1856c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2c391200-9ea5-476c-8e89-44769c45444b" xlink:to="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_48d5f503-d96c-485f-b0a7-c6fa7dc1856c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_47bb0e33-56e9-4b44-8b3e-ea8740518134" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2c391200-9ea5-476c-8e89-44769c45444b" xlink:to="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_47bb0e33-56e9-4b44-8b3e-ea8740518134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_64855071-8011-4dae-9ab4-61c2e765dcab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2c391200-9ea5-476c-8e89-44769c45444b" xlink:to="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_64855071-8011-4dae-9ab4-61c2e765dcab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_eb19a638-baaa-4bdc-bf82-d7cb6a35c9da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2c391200-9ea5-476c-8e89-44769c45444b" xlink:to="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_eb19a638-baaa-4bdc-bf82-d7cb6a35c9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_07465bec-6190-48ed-8fc2-5df22e6464c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2c391200-9ea5-476c-8e89-44769c45444b" xlink:to="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_07465bec-6190-48ed-8fc2-5df22e6464c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock_ae373134-5a21-4eee-97e8-707e16a78bb1" xlink:href="bhc-20220510.xsd#bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2c391200-9ea5-476c-8e89-44769c45444b" xlink:to="loc_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock_ae373134-5a21-4eee-97e8-707e16a78bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a5d1b147-94eb-475c-badc-bb63e8cae3eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_f960eebc-03f8-4f64-8c1f-780ed1a0e273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a5d1b147-94eb-475c-badc-bb63e8cae3eb" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_f960eebc-03f8-4f64-8c1f-780ed1a0e273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_7c976396-959c-4060-b296-61d7119e0677" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_f960eebc-03f8-4f64-8c1f-780ed1a0e273" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_7c976396-959c-4060-b296-61d7119e0677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_ffd9bda9-7b6c-4e5f-808c-5519da5c7066" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7c976396-959c-4060-b296-61d7119e0677" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_ffd9bda9-7b6c-4e5f-808c-5519da5c7066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_f498994e-979b-4ca0-bc30-7709c58ccada" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_ffd9bda9-7b6c-4e5f-808c-5519da5c7066" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_f498994e-979b-4ca0-bc30-7709c58ccada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_934d1ad0-5e46-4b4f-8630-ef80d15fc221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_ffd9bda9-7b6c-4e5f-808c-5519da5c7066" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_934d1ad0-5e46-4b4f-8630-ef80d15fc221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_cb6fe15f-f35b-4579-a2c2-c32f85fe9603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_f960eebc-03f8-4f64-8c1f-780ed1a0e273" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_cb6fe15f-f35b-4579-a2c2-c32f85fe9603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_4096a7be-b9e7-447d-9cbb-7db3577f72cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_cb6fe15f-f35b-4579-a2c2-c32f85fe9603" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_4096a7be-b9e7-447d-9cbb-7db3577f72cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_a07a52c8-6141-495f-b259-50eebf7c59f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_4096a7be-b9e7-447d-9cbb-7db3577f72cd" xlink:to="loc_us-gaap_ForeignPlanMember_a07a52c8-6141-495f-b259-50eebf7c59f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_b1faf7cb-0c3a-4bd1-bbc6-88f4b75a1aa3" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IE"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignPlanMember_a07a52c8-6141-495f-b259-50eebf7c59f2" xlink:to="loc_country_IE_b1faf7cb-0c3a-4bd1-bbc6-88f4b75a1aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_b1cdc84f-faec-4813-b298-195115f7f464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_4096a7be-b9e7-447d-9cbb-7db3577f72cd" xlink:to="loc_us-gaap_DomesticPlanMember_b1cdc84f-faec-4813-b298-195115f7f464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_3eb7059f-9da0-42c3-895b-00b72792ff34" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_b1cdc84f-faec-4813-b298-195115f7f464" xlink:to="loc_country_US_3eb7059f-9da0-42c3-895b-00b72792ff34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_8445c32b-afdf-4b8a-be69-f0f7c44dcf0a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_f960eebc-03f8-4f64-8c1f-780ed1a0e273" xlink:to="loc_srt_StatementScenarioAxis_8445c32b-afdf-4b8a-be69-f0f7c44dcf0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_06ee79f1-91a8-427e-9106-c66e158d3fbd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_8445c32b-afdf-4b8a-be69-f0f7c44dcf0a" xlink:to="loc_srt_ScenarioUnspecifiedDomain_06ee79f1-91a8-427e-9106-c66e158d3fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_fc7b57a5-47ae-4aa4-a004-7258811e9e13" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_06ee79f1-91a8-427e-9106-c66e158d3fbd" xlink:to="loc_srt_ScenarioForecastMember_fc7b57a5-47ae-4aa4-a004-7258811e9e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_8ff04f89-111f-46c4-9d29-91138d3a5103" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_f960eebc-03f8-4f64-8c1f-780ed1a0e273" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_8ff04f89-111f-46c4-9d29-91138d3a5103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance_dd126e3f-f961-4261-8e35-2e6d1c9df1a9" xlink:href="bhc-20220510.xsd#bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_8ff04f89-111f-46c4-9d29-91138d3a5103" xlink:to="loc_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance_dd126e3f-f961-4261-8e35-2e6d1c9df1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans_360713c2-47c1-4198-b9db-e55bcf3b2c85" xlink:href="bhc-20220510.xsd#bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_8ff04f89-111f-46c4-9d29-91138d3a5103" xlink:to="loc_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans_360713c2-47c1-4198-b9db-e55bcf3b2c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended_42c4769a-9ae8-43e0-8116-3e0a28f7ccdb" xlink:href="bhc-20220510.xsd#bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_8ff04f89-111f-46c4-9d29-91138d3a5103" xlink:to="loc_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended_42c4769a-9ae8-43e0-8116-3e0a28f7ccdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanEmployerContributionMaximumAge_eddf6c32-132e-402b-b8ad-25f6a4dd7402" xlink:href="bhc-20220510.xsd#bhc_DefinedBenefitPlanEmployerContributionMaximumAge"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_8ff04f89-111f-46c4-9d29-91138d3a5103" xlink:to="loc_bhc_DefinedBenefitPlanEmployerContributionMaximumAge_eddf6c32-132e-402b-b8ad-25f6a4dd7402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_79af6dc8-083b-4ce4-b4da-de9888548410" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_8ff04f89-111f-46c4-9d29-91138d3a5103" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_79af6dc8-083b-4ce4-b4da-de9888548410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_e9830d93-e34a-4236-bfca-2c8a6794f3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_8ff04f89-111f-46c4-9d29-91138d3a5103" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_e9830d93-e34a-4236-bfca-2c8a6794f3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod_5cd510fc-4f2a-497f-b2ff-c84c341b4724" xlink:href="bhc-20220510.xsd#bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_8ff04f89-111f-46c4-9d29-91138d3a5103" xlink:to="loc_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod_5cd510fc-4f2a-497f-b2ff-c84c341b4724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_ff61a917-bf3f-4f51-afd1-51051f84ed75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_8ff04f89-111f-46c4-9d29-91138d3a5103" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_ff61a917-bf3f-4f51-afd1-51051f84ed75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DefinedBenefitPlanPercentageAllocationofFund_85eabddf-b7d4-4cd2-8931-1bcbe127431d" xlink:href="bhc-20220510.xsd#bhc_DefinedBenefitPlanPercentageAllocationofFund"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_8ff04f89-111f-46c4-9d29-91138d3a5103" xlink:to="loc_bhc_DefinedBenefitPlanPercentageAllocationofFund_85eabddf-b7d4-4cd2-8931-1bcbe127431d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_6a798dc1-90a2-4260-9c13-5d392397f46c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_8ff04f89-111f-46c4-9d29-91138d3a5103" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_6a798dc1-90a2-4260-9c13-5d392397f46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b4e3d055-3e1f-4a17-b749-6e646b997098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_41d453d1-c46f-4e67-afa6-0b8a2089d522" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b4e3d055-3e1f-4a17-b749-6e646b997098" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_41d453d1-c46f-4e67-afa6-0b8a2089d522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_b831d65b-2712-4649-9b13-c6fa039e2078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_41d453d1-c46f-4e67-afa6-0b8a2089d522" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_b831d65b-2712-4649-9b13-c6fa039e2078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_22ba916c-ccd7-4618-a2a3-c393a4f729e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_b831d65b-2712-4649-9b13-c6fa039e2078" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_22ba916c-ccd7-4618-a2a3-c393a4f729e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_82bb7eac-4e0d-418f-93e4-f545334675d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_22ba916c-ccd7-4618-a2a3-c393a4f729e7" xlink:to="loc_us-gaap_DomesticPlanMember_82bb7eac-4e0d-418f-93e4-f545334675d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2b1b6287-ab53-4668-80dd-4d9e91bf5a0a" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_82bb7eac-4e0d-418f-93e4-f545334675d6" xlink:to="loc_country_US_2b1b6287-ab53-4668-80dd-4d9e91bf5a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_fe7c90f4-d1d6-41d7-b31b-e1e6cfcb80fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_22ba916c-ccd7-4618-a2a3-c393a4f729e7" xlink:to="loc_us-gaap_ForeignPlanMember_fe7c90f4-d1d6-41d7-b31b-e1e6cfcb80fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_4e98d54d-52d9-4d9e-a970-60737dbf5a54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_41d453d1-c46f-4e67-afa6-0b8a2089d522" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_4e98d54d-52d9-4d9e-a970-60737dbf5a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_51ad2b2a-b39e-440a-929e-a7a07444dbda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_4e98d54d-52d9-4d9e-a970-60737dbf5a54" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_51ad2b2a-b39e-440a-929e-a7a07444dbda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_b1eb889c-d06b-41ad-816e-0d831e301182" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_51ad2b2a-b39e-440a-929e-a7a07444dbda" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_b1eb889c-d06b-41ad-816e-0d831e301182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_2d9aee09-daa9-46d9-9dc4-ce81db17bc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_51ad2b2a-b39e-440a-929e-a7a07444dbda" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_2d9aee09-daa9-46d9-9dc4-ce81db17bc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_b73e4b90-c329-45d7-8a8b-3e4d9914c477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_41d453d1-c46f-4e67-afa6-0b8a2089d522" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_b73e4b90-c329-45d7-8a8b-3e4d9914c477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_db497d22-e23b-40f5-8f96-02ac63ec4da0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_b73e4b90-c329-45d7-8a8b-3e4d9914c477" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax_db497d22-e23b-40f5-8f96-02ac63ec4da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax_94058b63-1274-49ae-9af9-d5eb343348ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_b73e4b90-c329-45d7-8a8b-3e4d9914c477" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax_94058b63-1274-49ae-9af9-d5eb343348ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f55b75a3-fde5-432a-8eca-b9364380b584" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e5acbcdb-03b3-4ed5-8035-00751f36e2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_f55b75a3-fde5-432a-8eca-b9364380b584" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e5acbcdb-03b3-4ed5-8035-00751f36e2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_c352abca-2d4d-4210-a929-5697d9f476ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e5acbcdb-03b3-4ed5-8035-00751f36e2c9" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_c352abca-2d4d-4210-a929-5697d9f476ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_a687d319-71c1-4718-854e-237a854eaa79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_c352abca-2d4d-4210-a929-5697d9f476ba" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_a687d319-71c1-4718-854e-237a854eaa79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_fa6066ef-e426-4a09-9fec-ba8f7fc513d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_a687d319-71c1-4718-854e-237a854eaa79" xlink:to="loc_us-gaap_DomesticPlanMember_fa6066ef-e426-4a09-9fec-ba8f7fc513d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_035121eb-942e-4b95-9013-68adbf2d2226" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_fa6066ef-e426-4a09-9fec-ba8f7fc513d3" xlink:to="loc_country_US_035121eb-942e-4b95-9013-68adbf2d2226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_158b361d-77d3-4e12-b96e-82cb28e6a24c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_a687d319-71c1-4718-854e-237a854eaa79" xlink:to="loc_us-gaap_ForeignPlanMember_158b361d-77d3-4e12-b96e-82cb28e6a24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_7ed213eb-cc5b-477e-8f9c-dfc78e71829d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e5acbcdb-03b3-4ed5-8035-00751f36e2c9" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_7ed213eb-cc5b-477e-8f9c-dfc78e71829d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_00ae33f6-d0e8-450f-a907-d5a312cd5a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7ed213eb-cc5b-477e-8f9c-dfc78e71829d" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_00ae33f6-d0e8-450f-a907-d5a312cd5a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_0f21ad1a-c8f9-4a2c-94a5-83cc549a9881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_00ae33f6-d0e8-450f-a907-d5a312cd5a4f" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_0f21ad1a-c8f9-4a2c-94a5-83cc549a9881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_cee0ba5d-5a1c-4320-8d12-53e8a0cba9cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_00ae33f6-d0e8-450f-a907-d5a312cd5a4f" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_cee0ba5d-5a1c-4320-8d12-53e8a0cba9cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_19c7016a-a608-4d1d-bb80-2bb8ba517469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_e5acbcdb-03b3-4ed5-8035-00751f36e2c9" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_19c7016a-a608-4d1d-bb80-2bb8ba517469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_564a0e7f-2116-475f-97c0-296abe7af786" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_19c7016a-a608-4d1d-bb80-2bb8ba517469" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_564a0e7f-2116-475f-97c0-296abe7af786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_92d85bcf-b9af-4993-91da-9fc7ed57c2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_19c7016a-a608-4d1d-bb80-2bb8ba517469" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_92d85bcf-b9af-4993-91da-9fc7ed57c2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_1b6fb562-956f-45f9-a213-0ab6483624f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_19c7016a-a608-4d1d-bb80-2bb8ba517469" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_1b6fb562-956f-45f9-a213-0ab6483624f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_27de45d8-eafa-42fa-aaaf-76de58190bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_19c7016a-a608-4d1d-bb80-2bb8ba517469" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_27de45d8-eafa-42fa-aaaf-76de58190bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_80a99580-f902-4af7-9891-461cc2c4aa1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_19c7016a-a608-4d1d-bb80-2bb8ba517469" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_80a99580-f902-4af7-9891-461cc2c4aa1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_a835f12f-e7b9-4c6a-aadf-1160f4756bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_19c7016a-a608-4d1d-bb80-2bb8ba517469" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_a835f12f-e7b9-4c6a-aadf-1160f4756bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanOtherCosts_9e0ab437-abeb-4b93-804d-2e5cf744127e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanOtherCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_19c7016a-a608-4d1d-bb80-2bb8ba517469" xlink:to="loc_us-gaap_DefinedBenefitPlanOtherCosts_9e0ab437-abeb-4b93-804d-2e5cf744127e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e285e3f4-1fde-4330-96a1-351129c41fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_19c7016a-a608-4d1d-bb80-2bb8ba517469" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_e285e3f4-1fde-4330-96a1-351129c41fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_7ee90246-b140-4857-a33e-5df5020db563" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f2b8fc13-1df6-4b42-b352-2f9c1da3e79f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_7ee90246-b140-4857-a33e-5df5020db563" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f2b8fc13-1df6-4b42-b352-2f9c1da3e79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_fb14848c-2893-4d67-94f1-3d2ca297149e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f2b8fc13-1df6-4b42-b352-2f9c1da3e79f" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_fb14848c-2893-4d67-94f1-3d2ca297149e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_cadffd88-22ee-4d85-b3c2-38ce59f5369a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_fb14848c-2893-4d67-94f1-3d2ca297149e" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_cadffd88-22ee-4d85-b3c2-38ce59f5369a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_d38b9f7d-b2d7-4861-a7e1-522c99f53979" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_cadffd88-22ee-4d85-b3c2-38ce59f5369a" xlink:to="loc_us-gaap_DomesticPlanMember_d38b9f7d-b2d7-4861-a7e1-522c99f53979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_fddeb17f-75a0-4ad0-b3a4-ded78c86aeee" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_d38b9f7d-b2d7-4861-a7e1-522c99f53979" xlink:to="loc_country_US_fddeb17f-75a0-4ad0-b3a4-ded78c86aeee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_ff2b07dc-7d62-4b96-a0f1-4c9c6f407071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_cadffd88-22ee-4d85-b3c2-38ce59f5369a" xlink:to="loc_us-gaap_ForeignPlanMember_ff2b07dc-7d62-4b96-a0f1-4c9c6f407071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_bf250bdd-4fba-4d93-a7c1-03e45a4ab0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f2b8fc13-1df6-4b42-b352-2f9c1da3e79f" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_bf250bdd-4fba-4d93-a7c1-03e45a4ab0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_b247ee25-be14-489c-b607-9fac6d461a20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_bf250bdd-4fba-4d93-a7c1-03e45a4ab0a8" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_b247ee25-be14-489c-b607-9fac6d461a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_af588c5f-aac2-48a8-8df5-9a62df0b29c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_b247ee25-be14-489c-b607-9fac6d461a20" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_af588c5f-aac2-48a8-8df5-9a62df0b29c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_85e83372-4742-4dfa-a141-0f0b10e44eae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_b247ee25-be14-489c-b607-9fac6d461a20" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_85e83372-4742-4dfa-a141-0f0b10e44eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d61b6661-19dd-4b12-8229-99c1001da357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_f2b8fc13-1df6-4b42-b352-2f9c1da3e79f" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d61b6661-19dd-4b12-8229-99c1001da357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e2a4d12f-8819-4c00-81bc-92c1d279ea57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d61b6661-19dd-4b12-8229-99c1001da357" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e2a4d12f-8819-4c00-81bc-92c1d279ea57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_9e8bfa4a-85c6-4f86-8cec-8e38db78d454" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e2a4d12f-8819-4c00-81bc-92c1d279ea57" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_9e8bfa4a-85c6-4f86-8cec-8e38db78d454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_da5ecc2f-8305-4261-adc8-e69e7ab3f69c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e2a4d12f-8819-4c00-81bc-92c1d279ea57" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_da5ecc2f-8305-4261-adc8-e69e7ab3f69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_28d48546-f127-401d-8dce-0b3c11b8a771" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e2a4d12f-8819-4c00-81bc-92c1d279ea57" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_28d48546-f127-401d-8dce-0b3c11b8a771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_28f54b81-b661-40bd-ada8-9ad6b86a33df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsBenefitObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e2a4d12f-8819-4c00-81bc-92c1d279ea57" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_28f54b81-b661-40bd-ada8-9ad6b86a33df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_9105b36c-5b79-40ab-ae07-63065580bd4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e2a4d12f-8819-4c00-81bc-92c1d279ea57" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_9105b36c-5b79-40ab-ae07-63065580bd4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_3f2dc7e4-9217-4d94-941a-41b733ceb057" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e2a4d12f-8819-4c00-81bc-92c1d279ea57" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_3f2dc7e4-9217-4d94-941a-41b733ceb057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_2499b4cc-8997-4169-b798-c1ef92e2554f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e2a4d12f-8819-4c00-81bc-92c1d279ea57" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_2499b4cc-8997-4169-b798-c1ef92e2554f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_ebc4a83a-effe-44c6-be9b-65aeb1f7cb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_e2a4d12f-8819-4c00-81bc-92c1d279ea57" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_ebc4a83a-effe-44c6-be9b-65aeb1f7cb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b8218252-ebc8-45b1-b89d-81b3ff647c82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d61b6661-19dd-4b12-8229-99c1001da357" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b8218252-ebc8-45b1-b89d-81b3ff647c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_d22a6a83-851f-4385-b65d-020af9f76bee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b8218252-ebc8-45b1-b89d-81b3ff647c82" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_d22a6a83-851f-4385-b65d-020af9f76bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_45629f40-b85c-443a-8606-8de7d0d64d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b8218252-ebc8-45b1-b89d-81b3ff647c82" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_45629f40-b85c-443a-8606-8de7d0d64d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_5facfaec-e11c-4d79-8279-fbb7e7e74a17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b8218252-ebc8-45b1-b89d-81b3ff647c82" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_5facfaec-e11c-4d79-8279-fbb7e7e74a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_fdb7fcae-1a66-4f99-9a38-77806316dd25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b8218252-ebc8-45b1-b89d-81b3ff647c82" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_fdb7fcae-1a66-4f99-9a38-77806316dd25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_4faf4759-0d18-45db-a515-05830b80a23e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b8218252-ebc8-45b1-b89d-81b3ff647c82" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_4faf4759-0d18-45db-a515-05830b80a23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_f6eb72a7-6ba1-4cbb-85e2-fbf69f940354" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b8218252-ebc8-45b1-b89d-81b3ff647c82" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_f6eb72a7-6ba1-4cbb-85e2-fbf69f940354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_f87aac9f-9e1e-47c6-a09d-f1ca11f597f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_b8218252-ebc8-45b1-b89d-81b3ff647c82" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_f87aac9f-9e1e-47c6-a09d-f1ca11f597f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_cfa49a4b-2450-4534-9291-768e581d529e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d61b6661-19dd-4b12-8229-99c1001da357" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_cfa49a4b-2450-4534-9291-768e581d529e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_2e7b3628-854f-4f90-a8f6-1256802e9c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d61b6661-19dd-4b12-8229-99c1001da357" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_2e7b3628-854f-4f90-a8f6-1256802e9c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent_66a08477-3883-4da8-85f9-05c4cd82a22f" xlink:href="bhc-20220510.xsd#bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_2e7b3628-854f-4f90-a8f6-1256802e9c1f" xlink:to="loc_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent_66a08477-3883-4da8-85f9-05c4cd82a22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities_75b1d0f5-e84d-4fdf-a083-a02014015cad" xlink:href="bhc-20220510.xsd#bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_2e7b3628-854f-4f90-a8f6-1256802e9c1f" xlink:to="loc_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities_75b1d0f5-e84d-4fdf-a083-a02014015cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_82a18af1-0cef-41ee-8ed9-a0a7c4fd1816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_2e7b3628-854f-4f90-a8f6-1256802e9c1f" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent_82a18af1-0cef-41ee-8ed9-a0a7c4fd1816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1" xlink:type="simple" xlink:href="bhc-20220510.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_35e12779-2612-4b02-a125-d5f97e6fd474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_44cea9ea-3a9b-42fe-9072-005531e0b2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_35e12779-2612-4b02-a125-d5f97e6fd474" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_44cea9ea-3a9b-42fe-9072-005531e0b2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_c000eee8-e9c7-4dca-9ab8-dec2edf61f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_44cea9ea-3a9b-42fe-9072-005531e0b2ed" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_c000eee8-e9c7-4dca-9ab8-dec2edf61f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_9c193dc4-28ce-4809-90c0-f3de9ebf808e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_c000eee8-e9c7-4dca-9ab8-dec2edf61f6e" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_9c193dc4-28ce-4809-90c0-f3de9ebf808e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_c078ff49-640f-427a-bed3-9eba5bf24d43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_9c193dc4-28ce-4809-90c0-f3de9ebf808e" xlink:to="loc_us-gaap_DomesticPlanMember_c078ff49-640f-427a-bed3-9eba5bf24d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0f312417-f0cb-4b14-9be4-7801a72ab1fe" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_c078ff49-640f-427a-bed3-9eba5bf24d43" xlink:to="loc_country_US_0f312417-f0cb-4b14-9be4-7801a72ab1fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_38894763-8c74-478d-9cde-9e4960157d76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_9c193dc4-28ce-4809-90c0-f3de9ebf808e" xlink:to="loc_us-gaap_ForeignPlanMember_38894763-8c74-478d-9cde-9e4960157d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4252150f-96d4-4b6a-8b22-68f8b8c9234c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_44cea9ea-3a9b-42fe-9072-005531e0b2ed" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4252150f-96d4-4b6a-8b22-68f8b8c9234c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_4bf2b324-2189-4d72-bf8e-e102103851fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4252150f-96d4-4b6a-8b22-68f8b8c9234c" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_4bf2b324-2189-4d72-bf8e-e102103851fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_57a03bfe-0403-4f3f-9f6a-5f3fc95af4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_4bf2b324-2189-4d72-bf8e-e102103851fd" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_57a03bfe-0403-4f3f-9f6a-5f3fc95af4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_5b2d752d-f04a-4ccc-9fa3-232ee330c5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_4bf2b324-2189-4d72-bf8e-e102103851fd" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_5b2d752d-f04a-4ccc-9fa3-232ee330c5dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_bee71353-8978-41f8-86a3-8cb976a5e627" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_4bf2b324-2189-4d72-bf8e-e102103851fd" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_bee71353-8978-41f8-86a3-8cb976a5e627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_725c30e5-e38c-4a0e-a014-860583a59197" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7bc68ddf-bcc8-4860-a736-51ef47532435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_725c30e5-e38c-4a0e-a014-860583a59197" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7bc68ddf-bcc8-4860-a736-51ef47532435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_68d36885-c845-4d99-897b-5facd339cb76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7bc68ddf-bcc8-4860-a736-51ef47532435" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_68d36885-c845-4d99-897b-5facd339cb76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_72a01d2f-3418-4849-aca8-8f019ad83aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_68d36885-c845-4d99-897b-5facd339cb76" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_72a01d2f-3418-4849-aca8-8f019ad83aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_141047f6-283b-47b5-8b18-3b9c66e27181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_72a01d2f-3418-4849-aca8-8f019ad83aea" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_141047f6-283b-47b5-8b18-3b9c66e27181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_88df3ea4-147b-47de-9fbc-26e2d75856f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_72a01d2f-3418-4849-aca8-8f019ad83aea" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_88df3ea4-147b-47de-9fbc-26e2d75856f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_077fa40f-fe3e-431f-a6bb-323ab10999fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7bc68ddf-bcc8-4860-a736-51ef47532435" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_077fa40f-fe3e-431f-a6bb-323ab10999fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_6a4120ef-cbf1-4f4f-8f3c-cee99d7b7faf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_077fa40f-fe3e-431f-a6bb-323ab10999fb" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_6a4120ef-cbf1-4f4f-8f3c-cee99d7b7faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_6eb8632d-d922-4728-99c7-7cdcbd06af96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_6a4120ef-cbf1-4f4f-8f3c-cee99d7b7faf" xlink:to="loc_us-gaap_DomesticPlanMember_6eb8632d-d922-4728-99c7-7cdcbd06af96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0169cb29-6d72-4487-b58f-4f47d1b021ab" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_6eb8632d-d922-4728-99c7-7cdcbd06af96" xlink:to="loc_country_US_0169cb29-6d72-4487-b58f-4f47d1b021ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_ed95aa34-33c4-4838-9ff1-cbe535a3af31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_6a4120ef-cbf1-4f4f-8f3c-cee99d7b7faf" xlink:to="loc_us-gaap_ForeignPlanMember_ed95aa34-33c4-4838-9ff1-cbe535a3af31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_0e54b61e-b33e-4ac8-8204-1735d56b5ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7bc68ddf-bcc8-4860-a736-51ef47532435" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_0e54b61e-b33e-4ac8-8204-1735d56b5ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_b587b12b-f56d-425e-bcbc-1bfc79abd4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_0e54b61e-b33e-4ac8-8204-1735d56b5ab1" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_b587b12b-f56d-425e-bcbc-1bfc79abd4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_02dbcf8e-c558-4f19-bab8-ad57319acbf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_0e54b61e-b33e-4ac8-8204-1735d56b5ab1" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_02dbcf8e-c558-4f19-bab8-ad57319acbf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_6f7367f4-ae83-4cd8-8c87-45da0acf20f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_0e54b61e-b33e-4ac8-8204-1735d56b5ab1" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_6f7367f4-ae83-4cd8-8c87-45da0acf20f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_fbaf3f80-87e6-404e-a65a-7b3c84f42a52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_0e54b61e-b33e-4ac8-8204-1735d56b5ab1" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_fbaf3f80-87e6-404e-a65a-7b3c84f42a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_58a21ac6-cb63-4944-957c-da8ff16eec66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_0e54b61e-b33e-4ac8-8204-1735d56b5ab1" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_58a21ac6-cb63-4944-957c-da8ff16eec66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_ae3d2320-9036-4f56-971f-3f81bab5e36c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_0e54b61e-b33e-4ac8-8204-1735d56b5ab1" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_ae3d2320-9036-4f56-971f-3f81bab5e36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8de9a053-063c-443a-aaa7-f4873aa396c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_50a282df-a7c1-4e2d-98d5-53bac037b649" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8de9a053-063c-443a-aaa7-f4873aa396c1" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_50a282df-a7c1-4e2d-98d5-53bac037b649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_dd099264-4dd9-483a-9a87-d54f224a43e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_50a282df-a7c1-4e2d-98d5-53bac037b649" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_dd099264-4dd9-483a-9a87-d54f224a43e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_9aa4f797-8835-450f-ab06-1c3b5c0402ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_dd099264-4dd9-483a-9a87-d54f224a43e4" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_9aa4f797-8835-450f-ab06-1c3b5c0402ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_39a0756a-7579-4813-aca2-3ec63de928eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9aa4f797-8835-450f-ab06-1c3b5c0402ba" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_39a0756a-7579-4813-aca2-3ec63de928eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_e6f16dd8-4fd7-4a34-9297-eb417e8a9e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_9aa4f797-8835-450f-ab06-1c3b5c0402ba" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_e6f16dd8-4fd7-4a34-9297-eb417e8a9e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_94e25901-208f-461a-a0e2-a8ea3ac63e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_50a282df-a7c1-4e2d-98d5-53bac037b649" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_94e25901-208f-461a-a0e2-a8ea3ac63e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_140f9c4d-a92a-46a9-a1da-12cd06544d76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_94e25901-208f-461a-a0e2-a8ea3ac63e6e" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_140f9c4d-a92a-46a9-a1da-12cd06544d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_e0f292db-92fb-4d15-847f-1a2cd03583ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_140f9c4d-a92a-46a9-a1da-12cd06544d76" xlink:to="loc_us-gaap_DomesticPlanMember_e0f292db-92fb-4d15-847f-1a2cd03583ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b82bebc8-7d26-43cd-8926-2a3497f801bb" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_e0f292db-92fb-4d15-847f-1a2cd03583ae" xlink:to="loc_country_US_b82bebc8-7d26-43cd-8926-2a3497f801bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_8cd5df5d-89cc-4098-b793-f86294e20c99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_140f9c4d-a92a-46a9-a1da-12cd06544d76" xlink:to="loc_us-gaap_ForeignPlanMember_8cd5df5d-89cc-4098-b793-f86294e20c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ff459615-37a0-415f-aabb-a4b75cfc0c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_50a282df-a7c1-4e2d-98d5-53bac037b649" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ff459615-37a0-415f-aabb-a4b75cfc0c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_6a5b88b0-ee91-4010-805d-c6bf02a87d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ff459615-37a0-415f-aabb-a4b75cfc0c1a" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_6a5b88b0-ee91-4010-805d-c6bf02a87d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_59b71b5e-86b1-414d-b742-54b3c68b8320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_6a5b88b0-ee91-4010-805d-c6bf02a87d1e" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_59b71b5e-86b1-414d-b742-54b3c68b8320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_ddb68331-9879-4b13-8a5a-14344a88d1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_6a5b88b0-ee91-4010-805d-c6bf02a87d1e" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_ddb68331-9879-4b13-8a5a-14344a88d1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_798551ad-6072-414a-a15e-80dcbffbca95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_6a5b88b0-ee91-4010-805d-c6bf02a87d1e" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_798551ad-6072-414a-a15e-80dcbffbca95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_bc6c3a68-73cb-4e49-be98-e45cac239fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_6a5b88b0-ee91-4010-805d-c6bf02a87d1e" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate_bc6c3a68-73cb-4e49-be98-e45cac239fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_a46016f3-8931-4894-9d95-1a93b4b86c65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ff459615-37a0-415f-aabb-a4b75cfc0c1a" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_a46016f3-8931-4894-9d95-1a93b4b86c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_8d321fb1-9aa5-4ab7-adb2-7f1cfea95e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_a46016f3-8931-4894-9d95-1a93b4b86c65" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_8d321fb1-9aa5-4ab7-adb2-7f1cfea95e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_aa6269bb-f11d-47c4-b97b-a9b90e929279" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_a46016f3-8931-4894-9d95-1a93b4b86c65" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_aa6269bb-f11d-47c4-b97b-a9b90e929279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_d9d83d47-69c9-4c73-a0fc-271ee3d85def" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_a46016f3-8931-4894-9d95-1a93b4b86c65" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate_d9d83d47-69c9-4c73-a0fc-271ee3d85def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9791f52a-8c95-461b-8249-c89c1f6fedf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_3d8ce808-3971-4d96-9249-80a7d7d0342a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_9791f52a-8c95-461b-8249-c89c1f6fedf0" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_3d8ce808-3971-4d96-9249-80a7d7d0342a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_7b805b9f-776f-4819-93e7-222559342789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_3d8ce808-3971-4d96-9249-80a7d7d0342a" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_7b805b9f-776f-4819-93e7-222559342789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_f06c5936-be38-4823-b665-8f1064a6b82e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7b805b9f-776f-4819-93e7-222559342789" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_f06c5936-be38-4823-b665-8f1064a6b82e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_88249192-7f91-439d-aa41-6490aef83e77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_f06c5936-be38-4823-b665-8f1064a6b82e" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_88249192-7f91-439d-aa41-6490aef83e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_5fb2600b-b467-4104-b38c-604ebb4dfea6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_3d8ce808-3971-4d96-9249-80a7d7d0342a" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_5fb2600b-b467-4104-b38c-604ebb4dfea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_c0e6efcc-e0a5-4a54-a543-5cbbd9c44efa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_5fb2600b-b467-4104-b38c-604ebb4dfea6" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_c0e6efcc-e0a5-4a54-a543-5cbbd9c44efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_7c584534-c866-4b4e-a0d2-8172cd4e417b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c0e6efcc-e0a5-4a54-a543-5cbbd9c44efa" xlink:to="loc_us-gaap_DomesticPlanMember_7c584534-c866-4b4e-a0d2-8172cd4e417b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ec7a6f9b-0924-4aaf-9c5f-2244fee1a2a9" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_7c584534-c866-4b4e-a0d2-8172cd4e417b" xlink:to="loc_country_US_ec7a6f9b-0924-4aaf-9c5f-2244fee1a2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_ffd45302-908d-48cb-a5c1-360b8c4bf247" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_c0e6efcc-e0a5-4a54-a543-5cbbd9c44efa" xlink:to="loc_us-gaap_ForeignPlanMember_ffd45302-908d-48cb-a5c1-360b8c4bf247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_f7cc2296-9c1e-4d42-8529-4fb6c8e59255" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_3d8ce808-3971-4d96-9249-80a7d7d0342a" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_f7cc2296-9c1e-4d42-8529-4fb6c8e59255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_6ff92a7b-9162-4065-b849-e85dd534241c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_f7cc2296-9c1e-4d42-8529-4fb6c8e59255" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_6ff92a7b-9162-4065-b849-e85dd534241c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_d5aa96b0-27c0-4d5b-a051-e85efee33cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_6ff92a7b-9162-4065-b849-e85dd534241c" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_d5aa96b0-27c0-4d5b-a051-e85efee33cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_2ec6d5a6-6a5b-49cd-b107-11290ce533ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_6ff92a7b-9162-4065-b849-e85dd534241c" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_2ec6d5a6-6a5b-49cd-b107-11290ce533ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeSecuritiesMember_b6bc27ce-53f2-4963-afb2-91679bb56a87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FixedIncomeSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_6ff92a7b-9162-4065-b849-e85dd534241c" xlink:to="loc_us-gaap_FixedIncomeSecuritiesMember_b6bc27ce-53f2-4963-afb2-91679bb56a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_57a8929a-336b-4486-b508-8e4b88007d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_6ff92a7b-9162-4065-b849-e85dd534241c" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_57a8929a-336b-4486-b508-8e4b88007d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_438eb7dd-60cb-464a-92e1-e191044b176e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_3d8ce808-3971-4d96-9249-80a7d7d0342a" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_438eb7dd-60cb-464a-92e1-e191044b176e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_4ef21b86-4504-4923-9c6b-24834408b175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_438eb7dd-60cb-464a-92e1-e191044b176e" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_4ef21b86-4504-4923-9c6b-24834408b175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_bae79e19-6d52-46ee-93d3-c22aa70d4cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2aa567e5-f71c-4ed8-b614-4466ce4afdfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_bae79e19-6d52-46ee-93d3-c22aa70d4cf6" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2aa567e5-f71c-4ed8-b614-4466ce4afdfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_2fb2b777-c0a5-4fb6-aa00-6c202f08f00e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2aa567e5-f71c-4ed8-b614-4466ce4afdfd" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_2fb2b777-c0a5-4fb6-aa00-6c202f08f00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_ea6eaed0-dd9d-49c4-9c1e-b0e92a16a599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_2fb2b777-c0a5-4fb6-aa00-6c202f08f00e" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_ea6eaed0-dd9d-49c4-9c1e-b0e92a16a599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_df9d6605-3728-4879-8987-8bb1b387b265" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_ea6eaed0-dd9d-49c4-9c1e-b0e92a16a599" xlink:to="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_df9d6605-3728-4879-8987-8bb1b387b265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_14c81246-9159-401b-a411-0519b7c4f357" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_ea6eaed0-dd9d-49c4-9c1e-b0e92a16a599" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_14c81246-9159-401b-a411-0519b7c4f357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_U.S.BroadMarketMember_51968391-5fea-4d5c-adf0-e7c1743429fc" xlink:href="bhc-20220510.xsd#bhc_U.S.BroadMarketMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_14c81246-9159-401b-a411-0519b7c4f357" xlink:to="loc_bhc_U.S.BroadMarketMember_51968391-5fea-4d5c-adf0-e7c1743429fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmergingMarketsMember_a35a91ac-bb37-48d9-a147-4a56549bf549" xlink:href="bhc-20220510.xsd#bhc_EmergingMarketsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_14c81246-9159-401b-a411-0519b7c4f357" xlink:to="loc_bhc_EmergingMarketsMember_a35a91ac-bb37-48d9-a147-4a56549bf549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonU.S.DevelopedMarketsMember_75823986-4ac5-445d-987a-fb5d432cc68c" xlink:href="bhc-20220510.xsd#bhc_NonU.S.DevelopedMarketsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_14c81246-9159-401b-a411-0519b7c4f357" xlink:to="loc_bhc_NonU.S.DevelopedMarketsMember_75823986-4ac5-445d-987a-fb5d432cc68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonU.S.OtherAssetsMember_c7860208-56c3-4fc2-a344-be925d8d8c14" xlink:href="bhc-20220510.xsd#bhc_NonU.S.OtherAssetsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_14c81246-9159-401b-a411-0519b7c4f357" xlink:to="loc_bhc_NonU.S.OtherAssetsMember_c7860208-56c3-4fc2-a344-be925d8d8c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FixedIncomeSecuritiesMember_e9fabdf1-9457-430c-9a7b-52a93e408889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FixedIncomeSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_ea6eaed0-dd9d-49c4-9c1e-b0e92a16a599" xlink:to="loc_us-gaap_FixedIncomeSecuritiesMember_e9fabdf1-9457-430c-9a7b-52a93e408889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InvestmentGradeMember_6e74c39b-5db3-437d-9549-a73da25365ce" xlink:href="bhc-20220510.xsd#bhc_InvestmentGradeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FixedIncomeSecuritiesMember_e9fabdf1-9457-430c-9a7b-52a93e408889" xlink:to="loc_bhc_InvestmentGradeMember_6e74c39b-5db3-437d-9549-a73da25365ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlobalHighYieldMember_8da55feb-4fe1-48e7-980c-175a53bc7dbb" xlink:href="bhc-20220510.xsd#bhc_GlobalHighYieldMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FixedIncomeSecuritiesMember_e9fabdf1-9457-430c-9a7b-52a93e408889" xlink:to="loc_bhc_GlobalHighYieldMember_8da55feb-4fe1-48e7-980c-175a53bc7dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_9f07e8b4-3bc8-4f00-bb30-ad1bb1bd9a89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FixedIncomeSecuritiesMember_e9fabdf1-9457-430c-9a7b-52a93e408889" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_9f07e8b4-3bc8-4f00-bb30-ad1bb1bd9a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherAssetsFixedIncomeSecuritiesMember_c9749f10-21db-41b3-9304-633944bbedf8" xlink:href="bhc-20220510.xsd#bhc_OtherAssetsFixedIncomeSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_ea6eaed0-dd9d-49c4-9c1e-b0e92a16a599" xlink:to="loc_bhc_OtherAssetsFixedIncomeSecuritiesMember_c9749f10-21db-41b3-9304-633944bbedf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7ab18cad-fd6c-402f-ad7f-aa4c48ce65bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2aa567e5-f71c-4ed8-b614-4466ce4afdfd" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7ab18cad-fd6c-402f-ad7f-aa4c48ce65bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4d51e755-624d-4abc-8e15-276e1388aa7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7ab18cad-fd6c-402f-ad7f-aa4c48ce65bd" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4d51e755-624d-4abc-8e15-276e1388aa7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_7ca9df74-8d9f-4663-a9d6-a35f21eb9295" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4d51e755-624d-4abc-8e15-276e1388aa7b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_7ca9df74-8d9f-4663-a9d6-a35f21eb9295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_baafa9a0-51ff-4aae-942b-f1345fbd0fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4d51e755-624d-4abc-8e15-276e1388aa7b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_baafa9a0-51ff-4aae-942b-f1345fbd0fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e22990e7-bdcd-44c8-9f32-8735a3e2ed07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4d51e755-624d-4abc-8e15-276e1388aa7b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e22990e7-bdcd-44c8-9f32-8735a3e2ed07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_50995c53-0354-47a9-a8c0-93c7ba9e684c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2aa567e5-f71c-4ed8-b614-4466ce4afdfd" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_50995c53-0354-47a9-a8c0-93c7ba9e684c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_5a9f616d-582c-447c-88fc-51774942f3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_50995c53-0354-47a9-a8c0-93c7ba9e684c" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_5a9f616d-582c-447c-88fc-51774942f3f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_18f7a420-d3bf-4269-8dab-42be1e020c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_5a9f616d-582c-447c-88fc-51774942f3f0" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_18f7a420-d3bf-4269-8dab-42be1e020c1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_39e2fe48-a24a-47aa-b8c4-609a6eba82db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2aa567e5-f71c-4ed8-b614-4466ce4afdfd" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_39e2fe48-a24a-47aa-b8c4-609a6eba82db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_09d7f70d-67e1-45cd-8fcb-fe55324da5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_39e2fe48-a24a-47aa-b8c4-609a6eba82db" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_09d7f70d-67e1-45cd-8fcb-fe55324da5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_22bdd46b-9fa4-414e-925a-035a5b69eee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_09d7f70d-67e1-45cd-8fcb-fe55324da5a7" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_22bdd46b-9fa4-414e-925a-035a5b69eee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_f1a4c208-8aca-4c83-8846-66966b35e6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2aa567e5-f71c-4ed8-b614-4466ce4afdfd" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_f1a4c208-8aca-4c83-8846-66966b35e6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_df0831a6-aebf-451c-8455-3d0a0be1de4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_f1a4c208-8aca-4c83-8846-66966b35e6dc" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_df0831a6-aebf-451c-8455-3d0a0be1de4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_94a0165a-318f-4087-ae5c-06089150bc13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_df0831a6-aebf-451c-8455-3d0a0be1de4b" xlink:to="loc_us-gaap_DomesticPlanMember_94a0165a-318f-4087-ae5c-06089150bc13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_06453b4b-0cec-47eb-a8ff-27a75c7cfb6f" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_94a0165a-318f-4087-ae5c-06089150bc13" xlink:to="loc_country_US_06453b4b-0cec-47eb-a8ff-27a75c7cfb6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_50e55283-96d4-4537-afd5-93d947b8ebae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_df0831a6-aebf-451c-8455-3d0a0be1de4b" xlink:to="loc_us-gaap_ForeignPlanMember_50e55283-96d4-4537-afd5-93d947b8ebae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_b8aedcaa-2800-44aa-a4fd-6724ef6be8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_2aa567e5-f71c-4ed8-b614-4466ce4afdfd" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_b8aedcaa-2800-44aa-a4fd-6724ef6be8b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_c814d3aa-fbe5-4f5b-8acb-fe79edc31808" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_b8aedcaa-2800-44aa-a4fd-6724ef6be8b4" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_c814d3aa-fbe5-4f5b-8acb-fe79edc31808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASES" xlink:type="simple" xlink:href="bhc-20220510.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bc37d91c-8862-44dc-be1f-aa81366f84a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_94d1835d-3231-466a-9d21-4e706e0826b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bc37d91c-8862-44dc-be1f-aa81366f84a8" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_94d1835d-3231-466a-9d21-4e706e0826b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASESTables" xlink:type="simple" xlink:href="bhc-20220510.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f131b1e5-1ed0-492c-9308-2b1aa6305237" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetsAndLiabilitiesLesseeTableTextBlock_19003d6d-585c-45fe-9c91-be285e15a507" xlink:href="bhc-20220510.xsd#bhc_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f131b1e5-1ed0-492c-9308-2b1aa6305237" xlink:to="loc_bhc_AssetsAndLiabilitiesLesseeTableTextBlock_19003d6d-585c-45fe-9c91-be285e15a507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_9c704d8d-cb8c-4510-ad9f-2997e94cacd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f131b1e5-1ed0-492c-9308-2b1aa6305237" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_9c704d8d-cb8c-4510-ad9f-2997e94cacd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock_ec6f1368-ff6d-46ab-9b3e-d9275b896f33" xlink:href="bhc-20220510.xsd#bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f131b1e5-1ed0-492c-9308-2b1aa6305237" xlink:to="loc_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock_ec6f1368-ff6d-46ab-9b3e-d9275b896f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_b391eece-f433-4e6b-8853-df0f76feb3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f131b1e5-1ed0-492c-9308-2b1aa6305237" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_b391eece-f433-4e6b-8853-df0f76feb3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_772750dd-7d35-4c85-af5d-92e001df11cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AssetsLesseeAbstract_e6ab227b-59a5-4ffc-86ee-97d5ec365219" xlink:href="bhc-20220510.xsd#bhc_AssetsLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_772750dd-7d35-4c85-af5d-92e001df11cf" xlink:to="loc_bhc_AssetsLesseeAbstract_e6ab227b-59a5-4ffc-86ee-97d5ec365219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_759e8237-1579-4ae5-a25f-9a5499096aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_AssetsLesseeAbstract_e6ab227b-59a5-4ffc-86ee-97d5ec365219" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_759e8237-1579-4ae5-a25f-9a5499096aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LiabilitiesLesseeAbstract_297c4997-2997-45d6-85f3-fdff4f2af720" xlink:href="bhc-20220510.xsd#bhc_LiabilitiesLesseeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_772750dd-7d35-4c85-af5d-92e001df11cf" xlink:to="loc_bhc_LiabilitiesLesseeAbstract_297c4997-2997-45d6-85f3-fdff4f2af720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_47c6e0fe-55e9-49a9-8f35-c3f55e737ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_LiabilitiesLesseeAbstract_297c4997-2997-45d6-85f3-fdff4f2af720" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_47c6e0fe-55e9-49a9-8f35-c3f55e737ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_0d2dc29c-b5a9-46cf-a310-2c59275c6f32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_LiabilitiesLesseeAbstract_297c4997-2997-45d6-85f3-fdff4f2af720" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_0d2dc29c-b5a9-46cf-a310-2c59275c6f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d0f80f41-50a3-4348-ad05-60fd69679df5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_LiabilitiesLesseeAbstract_297c4997-2997-45d6-85f3-fdff4f2af720" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d0f80f41-50a3-4348-ad05-60fd69679df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_2b2457f9-e9f0-4c87-a0da-f5509a50145d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_LiabilitiesLesseeAbstract_297c4997-2997-45d6-85f3-fdff4f2af720" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_2b2457f9-e9f0-4c87-a0da-f5509a50145d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a319f0bb-b9ce-46fc-beb5-6e6275f09465" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_LiabilitiesLesseeAbstract_297c4997-2997-45d6-85f3-fdff4f2af720" xlink:to="loc_us-gaap_OperatingLeaseLiability_a319f0bb-b9ce-46fc-beb5-6e6275f09465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_81c05534-e0ab-40f3-afda-ce6d04ccc2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_LiabilitiesLesseeAbstract_297c4997-2997-45d6-85f3-fdff4f2af720" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_81c05534-e0ab-40f3-afda-ce6d04ccc2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#LEASESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEASESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d6e774e0-92d5-4338-bf77-d9d5cd272a89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_3737e947-cb78-4f66-9676-60441d5c5d90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d6e774e0-92d5-4338-bf77-d9d5cd272a89" xlink:to="loc_us-gaap_FinanceLeaseLiability_3737e947-cb78-4f66-9676-60441d5c5d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_084cfef6-c0e8-4e1c-93b3-9cd9b98176ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d6e774e0-92d5-4338-bf77-d9d5cd272a89" xlink:to="loc_us-gaap_SubleaseIncome_084cfef6-c0e8-4e1c-93b3-9cd9b98176ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_62e90c1f-deb3-45b8-8629-6188d565c767" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d6e774e0-92d5-4338-bf77-d9d5cd272a89" xlink:to="loc_us-gaap_ShortTermLeaseCost_62e90c1f-deb3-45b8-8629-6188d565c767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASESLeaseExpensesDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#LEASESLeaseExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEASESLeaseExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_983f0398-383e-42c3-b1cd-09af5d392026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_1b441b09-a0c5-4a8b-96a1-6b25f9ad229b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_983f0398-383e-42c3-b1cd-09af5d392026" xlink:to="loc_us-gaap_OperatingLeaseCost_1b441b09-a0c5-4a8b-96a1-6b25f9ad229b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_8eac1c94-8d5b-4337-8c27-43719305e7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_983f0398-383e-42c3-b1cd-09af5d392026" xlink:to="loc_us-gaap_VariableLeaseCost_8eac1c94-8d5b-4337-8c27-43719305e7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#LEASESLeaseAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_45bf82ed-0878-4793-a4dc-21d7dcad6f99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_3afc86f1-9bc9-41cf-a974-25ec4298e6cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_45bf82ed-0878-4793-a4dc-21d7dcad6f99" xlink:to="loc_us-gaap_OperatingLeasePayments_3afc86f1-9bc9-41cf-a974-25ec4298e6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption_0b87462c-118a-4ca6-92ea-e7897af21dc7" xlink:href="bhc-20220510.xsd#bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_45bf82ed-0878-4793-a4dc-21d7dcad6f99" xlink:to="loc_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption_0b87462c-118a-4ca6-92ea-e7897af21dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f5dc2e16-63f8-44eb-8199-84bddaf5785e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_45bf82ed-0878-4793-a4dc-21d7dcad6f99" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f5dc2e16-63f8-44eb-8199-84bddaf5785e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_30e4f8d5-a1c0-471a-a5e8-7588f585cd27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_45bf82ed-0878-4793-a4dc-21d7dcad6f99" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_30e4f8d5-a1c0-471a-a5e8-7588f585cd27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#LEASESLeaseFuturePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3bccc1e2-6b7d-46e5-81ba-22a1fdca3484" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f355038b-47b3-4d38-ac47-56b7b817d767" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3bccc1e2-6b7d-46e5-81ba-22a1fdca3484" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_f355038b-47b3-4d38-ac47-56b7b817d767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7c6ad714-d432-4eca-ba10-e271ec0ae705" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3bccc1e2-6b7d-46e5-81ba-22a1fdca3484" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7c6ad714-d432-4eca-ba10-e271ec0ae705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9218cbc2-1cbe-4d89-8517-d19ec350929a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3bccc1e2-6b7d-46e5-81ba-22a1fdca3484" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9218cbc2-1cbe-4d89-8517-d19ec350929a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c020fb37-d582-42f0-b8d4-d8bad89f731e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3bccc1e2-6b7d-46e5-81ba-22a1fdca3484" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c020fb37-d582-42f0-b8d4-d8bad89f731e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_cbf57489-1c58-4810-9edd-7b0e124a91df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3bccc1e2-6b7d-46e5-81ba-22a1fdca3484" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_cbf57489-1c58-4810-9edd-7b0e124a91df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_2ee0185d-099e-44f4-a3d9-a00b8474a578" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3bccc1e2-6b7d-46e5-81ba-22a1fdca3484" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_2ee0185d-099e-44f4-a3d9-a00b8474a578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e784b955-d14e-448a-8f82-6e07f7b454e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3bccc1e2-6b7d-46e5-81ba-22a1fdca3484" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e784b955-d14e-448a-8f82-6e07f7b454e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1a35475d-5fe2-4044-a557-08ee703f929b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3bccc1e2-6b7d-46e5-81ba-22a1fdca3484" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1a35475d-5fe2-4044-a557-08ee703f929b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_fbe81c64-e0f6-4f7b-ac7a-ef2b51c8e4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3bccc1e2-6b7d-46e5-81ba-22a1fdca3484" xlink:to="loc_us-gaap_OperatingLeaseLiability_fbe81c64-e0f6-4f7b-ac7a-ef2b51c8e4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e0c6aaf2-fd13-4722-8d97-523d355ac224" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3bccc1e2-6b7d-46e5-81ba-22a1fdca3484" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e0c6aaf2-fd13-4722-8d97-523d355ac224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e3a53ec8-2ee6-434f-ba5d-9816ad9f9785" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3bccc1e2-6b7d-46e5-81ba-22a1fdca3484" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e3a53ec8-2ee6-434f-ba5d-9816ad9f9785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1" xlink:type="simple" xlink:href="bhc-20220510.xsd#LEASESLeaseFuturePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION" xlink:type="simple" xlink:href="bhc-20220510.xsd#SHAREBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d6d8a58c-716b-436a-8fc1-c21cc9467990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9985856a-ab1f-4c99-b449-82424d59c6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d6d8a58c-716b-436a-8fc1-c21cc9467990" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9985856a-ab1f-4c99-b449-82424d59c6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="bhc-20220510.xsd#SHAREBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab4a1c1b-ec13-48eb-9e8c-8fa13c5a6530" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_bb9a28f1-e9a7-4513-8296-96b77b8f6af8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab4a1c1b-ec13-48eb-9e8c-8fa13c5a6530" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_bb9a28f1-e9a7-4513-8296-96b77b8f6af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4ad40b97-6e3c-42c6-933a-3a3c582c56bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab4a1c1b-ec13-48eb-9e8c-8fa13c5a6530" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4ad40b97-6e3c-42c6-933a-3a3c582c56bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_14185d02-7ee6-4bb3-91b6-ac0e2e9a1683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab4a1c1b-ec13-48eb-9e8c-8fa13c5a6530" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_14185d02-7ee6-4bb3-91b6-ac0e2e9a1683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_a37286da-6492-4bf9-92f3-aef5d21b877f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab4a1c1b-ec13-48eb-9e8c-8fa13c5a6530" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_a37286da-6492-4bf9-92f3-aef5d21b877f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_26cc5800-fd7b-4e72-a0f2-92db0198ea6f" xlink:href="bhc-20220510.xsd#bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab4a1c1b-ec13-48eb-9e8c-8fa13c5a6530" xlink:to="loc_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_26cc5800-fd7b-4e72-a0f2-92db0198ea6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_76e2c44b-fe8a-43fc-8ed7-911e9b5667f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ab4a1c1b-ec13-48eb-9e8c-8fa13c5a6530" xlink:to="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_76e2c44b-fe8a-43fc-8ed7-911e9b5667f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_178ed0e4-5ae2-466f-88fa-875ba55d4fee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c61be85a-80aa-404c-8a00-c80bb323a632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_178ed0e4-5ae2-466f-88fa-875ba55d4fee" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c61be85a-80aa-404c-8a00-c80bb323a632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_c595073e-9ca8-4f79-aa04-284ab0f19e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c61be85a-80aa-404c-8a00-c80bb323a632" xlink:to="loc_us-gaap_PlanNameAxis_c595073e-9ca8-4f79-aa04-284ab0f19e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b5c646e5-9b11-4679-b67a-7d796d60f867" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_c595073e-9ca8-4f79-aa04-284ab0f19e2a" xlink:to="loc_us-gaap_PlanNameDomain_b5c646e5-9b11-4679-b67a-7d796d60f867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OmnibusIncentivePlan2014Member_b495dadb-d239-49fe-902d-7eeb7f8458b9" xlink:href="bhc-20220510.xsd#bhc_OmnibusIncentivePlan2014Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b5c646e5-9b11-4679-b67a-7d796d60f867" xlink:to="loc_bhc_OmnibusIncentivePlan2014Member_b495dadb-d239-49fe-902d-7eeb7f8458b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_cf40e670-388c-450b-ba0c-b7cbd884798a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c61be85a-80aa-404c-8a00-c80bb323a632" xlink:to="loc_srt_TitleOfIndividualAxis_cf40e670-388c-450b-ba0c-b7cbd884798a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ac1c769d-64eb-4574-a3c4-2b9fd8de8069" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_cf40e670-388c-450b-ba0c-b7cbd884798a" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ac1c769d-64eb-4574-a3c4-2b9fd8de8069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NonemployeeDirectorMember_22445c15-2dc4-46df-ae94-acd00f8939a3" xlink:href="bhc-20220510.xsd#bhc_NonemployeeDirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ac1c769d-64eb-4574-a3c4-2b9fd8de8069" xlink:to="loc_bhc_NonemployeeDirectorMember_22445c15-2dc4-46df-ae94-acd00f8939a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6e7a354-46e4-4201-bdf3-114cad18d3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c61be85a-80aa-404c-8a00-c80bb323a632" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6e7a354-46e4-4201-bdf3-114cad18d3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e0372654-9aa9-4acf-8843-29c334fc4943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6e7a354-46e4-4201-bdf3-114cad18d3e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e0372654-9aa9-4acf-8843-29c334fc4943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0b29049f-3ae9-4498-8063-f8264ae2e202" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6e7a354-46e4-4201-bdf3-114cad18d3e5" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0b29049f-3ae9-4498-8063-f8264ae2e202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b432f1cc-64c9-48c3-90a4-a478f05ea699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6e7a354-46e4-4201-bdf3-114cad18d3e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_b432f1cc-64c9-48c3-90a4-a478f05ea699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant_235ebd7f-58fe-46ce-8960-8c806262f805" xlink:href="bhc-20220510.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6e7a354-46e4-4201-bdf3-114cad18d3e5" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant_235ebd7f-58fe-46ce-8960-8c806262f805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_aa05c965-0882-42fb-af67-4b58164bb4a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_c6e7a354-46e4-4201-bdf3-114cad18d3e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_aa05c965-0882-42fb-af67-4b58164bb4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1e884ef6-7515-4199-a368-1b7ee7b07b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a8f0b622-9d81-4ea7-a28d-b09fface19c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1e884ef6-7515-4199-a368-1b7ee7b07b6e" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a8f0b622-9d81-4ea7-a28d-b09fface19c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_90448cf6-3634-4663-9cc4-cdf71ab73cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a8f0b622-9d81-4ea7-a28d-b09fface19c3" xlink:to="loc_us-gaap_AwardTypeAxis_90448cf6-3634-4663-9cc4-cdf71ab73cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53ff4121-7c0f-41eb-99db-29cd1f23c5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_90448cf6-3634-4663-9cc4-cdf71ab73cb6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53ff4121-7c0f-41eb-99db-29cd1f23c5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_84c9108a-e189-491e-aa4c-a12d5e36b0be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53ff4121-7c0f-41eb-99db-29cd1f23c5e0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_84c9108a-e189-491e-aa4c-a12d5e36b0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_fe5b3dd6-9cd7-4909-b423-5bd1e94bafec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53ff4121-7c0f-41eb-99db-29cd1f23c5e0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_fe5b3dd6-9cd7-4909-b423-5bd1e94bafec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1b8b3504-9e34-4e4d-abbf-46850e21fef1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a8f0b622-9d81-4ea7-a28d-b09fface19c3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1b8b3504-9e34-4e4d-abbf-46850e21fef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_35d1ea5b-ee69-4d97-895e-68a8baef1ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1b8b3504-9e34-4e4d-abbf-46850e21fef1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_35d1ea5b-ee69-4d97-895e-68a8baef1ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2f00596e-a91d-4c23-bf57-24404a18ee49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_35d1ea5b-ee69-4d97-895e-68a8baef1ac6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2f00596e-a91d-4c23-bf57-24404a18ee49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SellingGeneralAndAdministrativeExpenseMember_25616d48-31b2-4bc3-9f09-0a7746775300" xlink:href="bhc-20220510.xsd#bhc_SellingGeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_35d1ea5b-ee69-4d97-895e-68a8baef1ac6" xlink:to="loc_bhc_SellingGeneralAndAdministrativeExpenseMember_25616d48-31b2-4bc3-9f09-0a7746775300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31d61191-2236-412f-8b87-9b4476f01be5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_a8f0b622-9d81-4ea7-a28d-b09fface19c3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31d61191-2236-412f-8b87-9b4476f01be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d27f292c-c094-4948-84f0-54584fd69306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_31d61191-2236-412f-8b87-9b4476f01be5" xlink:to="loc_us-gaap_ShareBasedCompensation_d27f292c-c094-4948-84f0-54584fd69306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SHAREBASEDCOMPENSATIONStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a78caf70-2fe3-44c3-8553-d8c8394ddc05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cd6fa236-3a09-43f3-8443-c0248e17b817" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a78caf70-2fe3-44c3-8553-d8c8394ddc05" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cd6fa236-3a09-43f3-8443-c0248e17b817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_e70f2253-bc28-4de3-8f75-24af6a1f6999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cd6fa236-3a09-43f3-8443-c0248e17b817" xlink:to="loc_us-gaap_VestingAxis_e70f2253-bc28-4de3-8f75-24af6a1f6999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_c8c30275-0c4a-45ee-87ae-3cf19a13bf6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_e70f2253-bc28-4de3-8f75-24af6a1f6999" xlink:to="loc_us-gaap_VestingDomain_c8c30275-0c4a-45ee-87ae-3cf19a13bf6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_b16441d7-c233-438b-aec6-d0fb96717fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_c8c30275-0c4a-45ee-87ae-3cf19a13bf6d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_b16441d7-c233-438b-aec6-d0fb96717fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e895ea6c-fd59-49b3-b063-8d8ce19f532c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_c8c30275-0c4a-45ee-87ae-3cf19a13bf6d" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_e895ea6c-fd59-49b3-b063-8d8ce19f532c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bb3339bb-b5de-486c-a5e5-3f7f140f0db6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cd6fa236-3a09-43f3-8443-c0248e17b817" xlink:to="loc_us-gaap_AwardTypeAxis_bb3339bb-b5de-486c-a5e5-3f7f140f0db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61939580-34a5-4edf-936a-ac82ae30c754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_bb3339bb-b5de-486c-a5e5-3f7f140f0db6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61939580-34a5-4edf-936a-ac82ae30c754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4b3ee6d3-e6cc-4d44-9476-a199f50b0202" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_61939580-34a5-4edf-936a-ac82ae30c754" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4b3ee6d3-e6cc-4d44-9476-a199f50b0202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95ca2795-8500-4064-828a-02d750a1030f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cd6fa236-3a09-43f3-8443-c0248e17b817" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95ca2795-8500-4064-828a-02d750a1030f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_331e480f-4540-4f0c-ab1a-5bfef18e5c2f" xlink:href="bhc-20220510.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95ca2795-8500-4064-828a-02d750a1030f" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage_331e480f-4540-4f0c-ab1a-5bfef18e5c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b268bb25-6af3-4d2e-a173-4478f939a635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95ca2795-8500-4064-828a-02d750a1030f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b268bb25-6af3-4d2e-a173-4478f939a635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_5f7b672b-2ff0-4315-a899-9a616bced5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95ca2795-8500-4064-828a-02d750a1030f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_5f7b672b-2ff0-4315-a899-9a616bced5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_aeb5cd02-f786-457e-aa79-fdc51564cc21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_5f7b672b-2ff0-4315-a899-9a616bced5e7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_aeb5cd02-f786-457e-aa79-fdc51564cc21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_781a32a9-e938-4753-87d9-8f114e8c15bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_5f7b672b-2ff0-4315-a899-9a616bced5e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_781a32a9-e938-4753-87d9-8f114e8c15bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_42dea893-860f-4ae9-97cd-158c4123b3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_5f7b672b-2ff0-4315-a899-9a616bced5e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_42dea893-860f-4ae9-97cd-158c4123b3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3dac2788-e510-4fee-b864-e2ab5bbc2a62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_5f7b672b-2ff0-4315-a899-9a616bced5e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3dac2788-e510-4fee-b864-e2ab5bbc2a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3a463edb-48f5-4ea4-ba42-11fba18b5f45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95ca2795-8500-4064-828a-02d750a1030f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3a463edb-48f5-4ea4-ba42-11fba18b5f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d4222579-70ff-4302-b281-06b5c47aea01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3a463edb-48f5-4ea4-ba42-11fba18b5f45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d4222579-70ff-4302-b281-06b5c47aea01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_21930af5-aaf8-4a86-8002-e5a3d345a494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3a463edb-48f5-4ea4-ba42-11fba18b5f45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_21930af5-aaf8-4a86-8002-e5a3d345a494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_35bf13e4-ecea-4973-aa26-62c9d5924272" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3a463edb-48f5-4ea4-ba42-11fba18b5f45" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_35bf13e4-ecea-4973-aa26-62c9d5924272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_f82dc2bb-1922-471a-a6b3-8692c3146ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3a463edb-48f5-4ea4-ba42-11fba18b5f45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_f82dc2bb-1922-471a-a6b3-8692c3146ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_63bedb3b-da61-4294-bfaa-12f07ba3c394" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3a463edb-48f5-4ea4-ba42-11fba18b5f45" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_63bedb3b-da61-4294-bfaa-12f07ba3c394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1281a542-70d5-4389-bfc6-e7cba0ab7162" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95ca2795-8500-4064-828a-02d750a1030f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1281a542-70d5-4389-bfc6-e7cba0ab7162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_e6118991-fb79-4493-8658-406ab5b6b8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95ca2795-8500-4064-828a-02d750a1030f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_e6118991-fb79-4493-8658-406ab5b6b8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_75bd425a-8573-4978-8979-6d7d4b18b592" xlink:href="bhc-20220510.xsd#bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95ca2795-8500-4064-828a-02d750a1030f" xlink:to="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_75bd425a-8573-4978-8979-6d7d4b18b592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_784de42c-3b84-4887-b8f0-6e347643d9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_75bd425a-8573-4978-8979-6d7d4b18b592" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_784de42c-3b84-4887-b8f0-6e347643d9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_da2a8826-5030-4de5-9c2a-db9b4a3bb8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_75bd425a-8573-4978-8979-6d7d4b18b592" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_da2a8826-5030-4de5-9c2a-db9b4a3bb8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_875b3f3d-8137-4a85-bd5d-ee39b80be02a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_75bd425a-8573-4978-8979-6d7d4b18b592" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_875b3f3d-8137-4a85-bd5d-ee39b80be02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1ea1dcb9-eaf2-4af7-8017-b94ea0b21b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_75bd425a-8573-4978-8979-6d7d4b18b592" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1ea1dcb9-eaf2-4af7-8017-b94ea0b21b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5f0c5062-8bcd-40d8-9b7a-2600c807840d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward_75bd425a-8573-4978-8979-6d7d4b18b592" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5f0c5062-8bcd-40d8-9b7a-2600c807840d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_dbc072e6-6cdb-43e5-9152-1d8e8a679009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95ca2795-8500-4064-828a-02d750a1030f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_dbc072e6-6cdb-43e5-9152-1d8e8a679009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_b18097d8-30d6-47ad-8ee0-4a433550039f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95ca2795-8500-4064-828a-02d750a1030f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_b18097d8-30d6-47ad-8ee0-4a433550039f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_73069328-c4fb-491f-8d8c-1ea77ad2c9c9" xlink:href="bhc-20220510.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95ca2795-8500-4064-828a-02d750a1030f" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_73069328-c4fb-491f-8d8c-1ea77ad2c9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0ae0e50d-17fd-4d3f-b9b5-07d303e0fcdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_73069328-c4fb-491f-8d8c-1ea77ad2c9c9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0ae0e50d-17fd-4d3f-b9b5-07d303e0fcdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_43e2dea6-15b5-4dc7-94be-911774100890" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_73069328-c4fb-491f-8d8c-1ea77ad2c9c9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_43e2dea6-15b5-4dc7-94be-911774100890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_10c2d2c0-02b2-4a9d-b49e-1fb0830c72fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_73069328-c4fb-491f-8d8c-1ea77ad2c9c9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_10c2d2c0-02b2-4a9d-b49e-1fb0830c72fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_e5bb4839-27a9-4369-af5e-8d6d26eeebb6" xlink:href="bhc-20220510.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95ca2795-8500-4064-828a-02d750a1030f" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_e5bb4839-27a9-4369-af5e-8d6d26eeebb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7e3316ba-a2ed-4fb0-8148-1865416940dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_e5bb4839-27a9-4369-af5e-8d6d26eeebb6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7e3316ba-a2ed-4fb0-8148-1865416940dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_63585cdf-cdb3-4150-9163-c08c5f231b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_e5bb4839-27a9-4369-af5e-8d6d26eeebb6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_63585cdf-cdb3-4150-9163-c08c5f231b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_5509e805-d06a-4c89-ae50-2a80ecde59c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_e5bb4839-27a9-4369-af5e-8d6d26eeebb6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_5509e805-d06a-4c89-ae50-2a80ecde59c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_700188e9-8d8c-4412-9bc8-d1280895497e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_95ca2795-8500-4064-828a-02d750a1030f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_700188e9-8d8c-4412-9bc8-d1280895497e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fff182a4-8181-441e-82bf-ed17e71cf086" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_700188e9-8d8c-4412-9bc8-d1280895497e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fff182a4-8181-441e-82bf-ed17e71cf086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_3dcb8797-93a2-419e-9920-7b891d598044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_700188e9-8d8c-4412-9bc8-d1280895497e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_3dcb8797-93a2-419e-9920-7b891d598044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_4f65ac92-a1a2-4b3c-8b25-383a596ca0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_700188e9-8d8c-4412-9bc8-d1280895497e" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_4f65ac92-a1a2-4b3c-8b25-383a596ca0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d54ec739-50e6-4a93-9abd-2ec858c57883" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_700188e9-8d8c-4412-9bc8-d1280895497e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d54ec739-50e6-4a93-9abd-2ec858c57883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_20c2b02d-2b8f-4776-842b-8e8902621761" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_700188e9-8d8c-4412-9bc8-d1280895497e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_20c2b02d-2b8f-4776-842b-8e8902621761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue_c822a81c-c080-46c3-8590-9969015d6212" xlink:href="bhc-20220510.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_700188e9-8d8c-4412-9bc8-d1280895497e" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue_c822a81c-c080-46c3-8590-9969015d6212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SHAREBASEDCOMPENSATIONRSUsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6411ebc2-b8c2-429f-a6e1-4a1f987d0e7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_af511a96-a649-43dc-b2cb-134e07572bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6411ebc2-b8c2-429f-a6e1-4a1f987d0e7b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_af511a96-a649-43dc-b2cb-134e07572bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f23b4a39-8601-4bc5-9c11-750cd47a1a24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_af511a96-a649-43dc-b2cb-134e07572bdf" xlink:to="loc_us-gaap_AwardTypeAxis_f23b4a39-8601-4bc5-9c11-750cd47a1a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1a9a29c5-6b68-4304-aaac-42fc05f380e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f23b4a39-8601-4bc5-9c11-750cd47a1a24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1a9a29c5-6b68-4304-aaac-42fc05f380e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_a7577818-5daa-40c2-a279-8779d9e7f46f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1a9a29c5-6b68-4304-aaac-42fc05f380e7" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_a7577818-5daa-40c2-a279-8779d9e7f46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TimeBasedRSUMember_455af49f-e03d-4b5a-97c0-a102e12efc8e" xlink:href="bhc-20220510.xsd#bhc_TimeBasedRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1a9a29c5-6b68-4304-aaac-42fc05f380e7" xlink:to="loc_bhc_TimeBasedRSUMember_455af49f-e03d-4b5a-97c0-a102e12efc8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_6568d460-f16e-48e2-badc-57db52d524bf" xlink:href="bhc-20220510.xsd#bhc_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1a9a29c5-6b68-4304-aaac-42fc05f380e7" xlink:to="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_6568d460-f16e-48e2-badc-57db52d524bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_96af9e3e-e960-4e62-a642-ef1e20d916a2" xlink:href="bhc-20220510.xsd#bhc_TSRPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_6568d460-f16e-48e2-badc-57db52d524bf" xlink:to="loc_bhc_TSRPerformanceBasedRestrictedStockUnitsMember_96af9e3e-e960-4e62-a642-ef1e20d916a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_a5c00bf1-6922-4ccd-afea-7fad9002eaed" xlink:href="bhc-20220510.xsd#bhc_ROTCPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_6568d460-f16e-48e2-badc-57db52d524bf" xlink:to="loc_bhc_ROTCPerformanceBasedRestrictedStockUnitsMember_a5c00bf1-6922-4ccd-afea-7fad9002eaed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherPerformanceBasedRestrictedStockUnitsMember_a417264e-9096-44a7-9df8-6427d0b938c2" xlink:href="bhc-20220510.xsd#bhc_OtherPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_6568d460-f16e-48e2-badc-57db52d524bf" xlink:to="loc_bhc_OtherPerformanceBasedRestrictedStockUnitsMember_a417264e-9096-44a7-9df8-6427d0b938c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_982d2ca9-5fde-4141-b86f-218917909de9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_af511a96-a649-43dc-b2cb-134e07572bdf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_982d2ca9-5fde-4141-b86f-218917909de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_153d62f2-3574-498e-b05e-0b03a146c512" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_982d2ca9-5fde-4141-b86f-218917909de9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_153d62f2-3574-498e-b05e-0b03a146c512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6e91ca31-5d9d-45d0-a3f0-6c9f111d7f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_982d2ca9-5fde-4141-b86f-218917909de9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6e91ca31-5d9d-45d0-a3f0-6c9f111d7f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1eb166d7-31b5-42e2-ac5d-9a34dfb8f9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_982d2ca9-5fde-4141-b86f-218917909de9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1eb166d7-31b5-42e2-ac5d-9a34dfb8f9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_229ecbe3-5c3e-44b8-bace-3eee3d1282b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_982d2ca9-5fde-4141-b86f-218917909de9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_229ecbe3-5c3e-44b8-bace-3eee3d1282b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ca073d8f-cf7c-447b-b6ff-71ee83105d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_982d2ca9-5fde-4141-b86f-218917909de9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ca073d8f-cf7c-447b-b6ff-71ee83105d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued_5eea834f-dd38-42db-aa25-2622f11b1603" xlink:href="bhc-20220510.xsd#bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_982d2ca9-5fde-4141-b86f-218917909de9" xlink:to="loc_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued_5eea834f-dd38-42db-aa25-2622f11b1603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3cd768b5-f66b-4854-8a01-7137061f8451" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_982d2ca9-5fde-4141-b86f-218917909de9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3cd768b5-f66b-4854-8a01-7137061f8451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_eecc9baf-aca4-4931-9bfa-65f7fefaefae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3cd768b5-f66b-4854-8a01-7137061f8451" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_eecc9baf-aca4-4931-9bfa-65f7fefaefae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f22034cf-aee2-4635-b875-f274877dbeb7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3cd768b5-f66b-4854-8a01-7137061f8451" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f22034cf-aee2-4635-b875-f274877dbeb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7ec9d4ac-3c53-48e9-bb24-94338db4f959" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3cd768b5-f66b-4854-8a01-7137061f8451" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7ec9d4ac-3c53-48e9-bb24-94338db4f959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_25716d8d-3ba9-4acf-812a-5afd987b415f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3cd768b5-f66b-4854-8a01-7137061f8451" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_25716d8d-3ba9-4acf-812a-5afd987b415f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2fd0a053-bd63-4a66-bb27-624917457cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_3cd768b5-f66b-4854-8a01-7137061f8451" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2fd0a053-bd63-4a66-bb27-624917457cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c3736c32-8ea6-4654-b4b5-3895780e92d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_982d2ca9-5fde-4141-b86f-218917909de9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c3736c32-8ea6-4654-b4b5-3895780e92d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c1503271-5020-41be-a883-7bca5018a865" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c3736c32-8ea6-4654-b4b5-3895780e92d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c1503271-5020-41be-a883-7bca5018a865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bb50a22a-0d49-40e7-8436-967cbc2ba634" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c3736c32-8ea6-4654-b4b5-3895780e92d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bb50a22a-0d49-40e7-8436-967cbc2ba634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e9bffba0-0539-4b43-85ef-934812947781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c3736c32-8ea6-4654-b4b5-3895780e92d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_e9bffba0-0539-4b43-85ef-934812947781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d135937b-0075-4289-b387-c2f354af124b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c3736c32-8ea6-4654-b4b5-3895780e92d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d135937b-0075-4289-b387-c2f354af124b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a593541c-396f-4812-9a05-d36b3edc623e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_c3736c32-8ea6-4654-b4b5-3895780e92d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a593541c-396f-4812-9a05-d36b3edc623e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_0642f347-0423-4984-98c8-9b3191546d79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_982d2ca9-5fde-4141-b86f-218917909de9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_0642f347-0423-4984-98c8-9b3191546d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_98704278-72e8-4e93-84b9-71592761c53c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_0642f347-0423-4984-98c8-9b3191546d79" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_98704278-72e8-4e93-84b9-71592761c53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_796cd475-1c93-4671-9715-36732bdbd9d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_0642f347-0423-4984-98c8-9b3191546d79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_796cd475-1c93-4671-9715-36732bdbd9d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3d9b6c6f-cbd7-40ad-a412-d8d2502a3b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_0642f347-0423-4984-98c8-9b3191546d79" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3d9b6c6f-cbd7-40ad-a412-d8d2502a3b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bhc-20220510.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3347fb65-4ff0-4494-a317-4dbcdee2e79e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_7589a95a-419c-416d-99b4-b2f59a537c20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3347fb65-4ff0-4494-a317-4dbcdee2e79e" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_7589a95a-419c-416d-99b4-b2f59a537c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" xlink:type="simple" xlink:href="bhc-20220510.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c9d9da7c-d85c-44fe-aa61-8f7363ec9d61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_ea4b00d2-8899-4bc5-8789-0751541fcba8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c9d9da7c-d85c-44fe-aa61-8f7363ec9d61" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_ea4b00d2-8899-4bc5-8789-0751541fcba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_12d6ca9d-c544-4a20-bae2-e852a9e7b9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_84fffa95-80a3-4946-9a56-6ab23fdfee13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_12d6ca9d-c544-4a20-bae2-e852a9e7b9bd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_84fffa95-80a3-4946-9a56-6ab23fdfee13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9a6df90d-572b-4164-9e99-0d028835c18e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_84fffa95-80a3-4946-9a56-6ab23fdfee13" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9a6df90d-572b-4164-9e99-0d028835c18e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f6507f33-dcb5-4857-84ec-068af07f5862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9a6df90d-572b-4164-9e99-0d028835c18e" xlink:to="loc_us-gaap_EquityComponentDomain_f6507f33-dcb5-4857-84ec-068af07f5862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_7d805300-0827-4799-8efe-824d8f79d843" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f6507f33-dcb5-4857-84ec-068af07f5862" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_7d805300-0827-4799-8efe-824d8f79d843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_f12d5109-7879-43b0-8764-b58157a4b745" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f6507f33-dcb5-4857-84ec-068af07f5862" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_f12d5109-7879-43b0-8764-b58157a4b745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0b58e2f6-7110-4845-8351-94ff9c2d7e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f6507f33-dcb5-4857-84ec-068af07f5862" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0b58e2f6-7110-4845-8351-94ff9c2d7e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_52dc6ee2-36e7-4d93-939a-1227b583483d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_84fffa95-80a3-4946-9a56-6ab23fdfee13" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_52dc6ee2-36e7-4d93-939a-1227b583483d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2929d319-8f6b-4935-8f80-68d3031f78b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_52dc6ee2-36e7-4d93-939a-1227b583483d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2929d319-8f6b-4935-8f80-68d3031f78b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT" xlink:type="simple" xlink:href="bhc-20220510.xsd#RESEARCHANDDEVELOPMENT"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_5a0b645e-394d-4377-9e9c-ad5ceb0afad8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_2bb1c30f-5c18-4d39-84c9-765ac8203ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_5a0b645e-394d-4377-9e9c-ad5ceb0afad8" xlink:to="loc_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock_2bb1c30f-5c18-4d39-84c9-765ac8203ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables" xlink:type="simple" xlink:href="bhc-20220510.xsd#RESEARCHANDDEVELOPMENTTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_935b52d7-1f75-43f8-a202-d66e228b1395" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_e77f460c-0f9b-43a8-8682-7dabb46c2f0e" xlink:href="bhc-20220510.xsd#bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_935b52d7-1f75-43f8-a202-d66e228b1395" xlink:to="loc_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock_e77f460c-0f9b-43a8-8682-7dabb46c2f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_37406a2a-6ecd-4948-8154-f236ed1efcd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_173270d1-2b1a-457a-8a5d-3a5cf8e18c18" xlink:href="bhc-20220510.xsd#bhc_ResearchAndDevelopmentExpenseProductRelated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_37406a2a-6ecd-4948-8154-f236ed1efcd5" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseProductRelated_173270d1-2b1a-457a-8a5d-3a5cf8e18c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_6c080bb3-11f5-47f9-89ae-54c6209cc086" xlink:href="bhc-20220510.xsd#bhc_ResearchAndDevelopmentExpenseQualityAssurance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_37406a2a-6ecd-4948-8154-f236ed1efcd5" xlink:to="loc_bhc_ResearchAndDevelopmentExpenseQualityAssurance_6c080bb3-11f5-47f9-89ae-54c6209cc086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0b63c708-2f2e-464a-b491-3118b333bdb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_37406a2a-6ecd-4948-8154-f236ed1efcd5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0b63c708-2f2e-464a-b491-3118b333bdb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENET" xlink:type="simple" xlink:href="bhc-20220510.xsd#OTHEREXPENSENET"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENET" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_baa8dc68-e2a4-46a9-9273-17398e507d55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_cc931484-921b-4b51-bc16-f8e28bd7633a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_baa8dc68-e2a4-46a9-9273-17398e507d55" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_cc931484-921b-4b51-bc16-f8e28bd7633a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETTables" xlink:type="simple" xlink:href="bhc-20220510.xsd#OTHEREXPENSENETTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENETTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_9afcb8db-7959-4a3f-ad83-b299ab71afca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_d078d53f-ff18-4bd6-ae4d-3938821ffa61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_9afcb8db-7959-4a3f-ad83-b299ab71afca" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_d078d53f-ff18-4bd6-ae4d-3938821ffa61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_cc9d711b-9c46-462a-a455-839e2a00bedb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_bc99601d-f90a-403b-9969-c65884ae5e88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_cc9d711b-9c46-462a-a455-839e2a00bedb" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_bc99601d-f90a-403b-9969-c65884ae5e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_c2f44378-acb1-4276-855f-6f75a466378a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_cc9d711b-9c46-462a-a455-839e2a00bedb" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_c2f44378-acb1-4276-855f-6f75a466378a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_33fe639b-4a31-4ded-af7d-79fcbdfc0028" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_cc9d711b-9c46-462a-a455-839e2a00bedb" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_33fe639b-4a31-4ded-af7d-79fcbdfc0028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_157f5f29-7929-4feb-99db-7d7a3c129806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_cc9d711b-9c46-462a-a455-839e2a00bedb" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_157f5f29-7929-4feb-99db-7d7a3c129806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherIncomeExpenseNet_f2d937b9-b623-4f9d-b499-d7acef2c6d96" xlink:href="bhc-20220510.xsd#bhc_OtherIncomeExpenseNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_cc9d711b-9c46-462a-a455-839e2a00bedb" xlink:to="loc_bhc_OtherIncomeExpenseNet_f2d937b9-b623-4f9d-b499-d7acef2c6d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_013518d0-3839-4d26-a177-6f9a740c7e49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_cc9d711b-9c46-462a-a455-839e2a00bedb" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_013518d0-3839-4d26-a177-6f9a740c7e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#OTHEREXPENSENETNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_ed2549b6-d6f0-4c98-a582-6539fb650313" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_e15d5680-47e6-4af1-92e4-9a2a416fa83e" xlink:href="bhc-20220510.xsd#bhc_ScheduleOfOtherIncomeAndExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_ed2549b6-d6f0-4c98-a582-6539fb650313" xlink:to="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_e15d5680-47e6-4af1-92e4-9a2a416fa83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_65b251f6-ea31-472b-8c5d-573d4c4b6283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_e15d5680-47e6-4af1-92e4-9a2a416fa83e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_65b251f6-ea31-472b-8c5d-573d4c4b6283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a45301c8-e076-4f5e-9374-5fabedbd229e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_65b251f6-ea31-472b-8c5d-573d4c4b6283" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a45301c8-e076-4f5e-9374-5fabedbd229e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MilestonePaymentRelatedToCertainProductMember_1d4042f1-fea9-49ad-afdf-09f024ccbcf5" xlink:href="bhc-20220510.xsd#bhc_MilestonePaymentRelatedToCertainProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a45301c8-e076-4f5e-9374-5fabedbd229e" xlink:to="loc_bhc_MilestonePaymentRelatedToCertainProductMember_1d4042f1-fea9-49ad-afdf-09f024ccbcf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_3c9b6712-9730-4630-9c5b-9301ee1baeb2" xlink:href="bhc-20220510.xsd#bhc_ScheduleOfOtherIncomeAndExpensesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesTable_e15d5680-47e6-4af1-92e4-9a2a416fa83e" xlink:to="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_3c9b6712-9730-4630-9c5b-9301ee1baeb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_615261b8-e328-43f4-b731-b984d646274f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_3c9b6712-9730-4630-9c5b-9301ee1baeb2" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_615261b8-e328-43f4-b731-b984d646274f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_8da6c408-77c6-4a3d-98f2-17fcae45b1c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_3c9b6712-9730-4630-9c5b-9301ee1baeb2" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_8da6c408-77c6-4a3d-98f2-17fcae45b1c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_11a5092a-a589-4283-9de8-2610829883f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfOtherIncomeAndExpensesLineItems_3c9b6712-9730-4630-9c5b-9301ee1baeb2" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_11a5092a-a589-4283-9de8-2610829883f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXES" xlink:type="simple" xlink:href="bhc-20220510.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e44e905d-c524-40ae-8740-cac7dc72b785" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_27842b53-7406-421f-ad88-4bf675643883" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e44e905d-c524-40ae-8740-cac7dc72b785" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_27842b53-7406-421f-ad88-4bf675643883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="bhc-20220510.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_95382507-e5e1-40b3-8291-c636b663bc9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_392ed9ab-76b7-489e-9264-17ea78d17176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_95382507-e5e1-40b3-8291-c636b663bc9b" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_392ed9ab-76b7-489e-9264-17ea78d17176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_23c763d0-edbb-4eba-b940-5648a5978499" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_95382507-e5e1-40b3-8291-c636b663bc9b" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_23c763d0-edbb-4eba-b940-5648a5978499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_11b82855-5142-49f2-a49a-48fd53652183" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_95382507-e5e1-40b3-8291-c636b663bc9b" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_11b82855-5142-49f2-a49a-48fd53652183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2a91dbe2-0a62-4ffe-b0db-f0595ba72929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_95382507-e5e1-40b3-8291-c636b663bc9b" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2a91dbe2-0a62-4ffe-b0db-f0595ba72929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_f372a7ad-e3c4-491c-a783-33abbb155d71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_95382507-e5e1-40b3-8291-c636b663bc9b" xlink:to="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_f372a7ad-e3c4-491c-a783-33abbb155d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_376b287d-16c7-4bb6-9d77-d0cddc1c1189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_95382507-e5e1-40b3-8291-c636b663bc9b" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_376b287d-16c7-4bb6-9d77-d0cddc1c1189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0f4231fd-ec19-4609-bd31-5c75ea88a6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_7ea66d82-baab-4c80-a244-dd502bc7c56c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0f4231fd-ec19-4609-bd31-5c75ea88a6a7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_7ea66d82-baab-4c80-a244-dd502bc7c56c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_3b5fea8e-c84d-41ef-9d98-66d4541d5396" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_7ea66d82-baab-4c80-a244-dd502bc7c56c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_3b5fea8e-c84d-41ef-9d98-66d4541d5396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_5fbdcce1-6058-4344-a453-8cdf9541f026" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_7ea66d82-baab-4c80-a244-dd502bc7c56c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_5fbdcce1-6058-4344-a453-8cdf9541f026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_361b39be-c72c-4346-9e76-3ab7743d5148" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_7ea66d82-baab-4c80-a244-dd502bc7c56c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_361b39be-c72c-4346-9e76-3ab7743d5148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9b75cc4b-7984-4180-8488-7e0b2a9c4fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0f4231fd-ec19-4609-bd31-5c75ea88a6a7" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9b75cc4b-7984-4180-8488-7e0b2a9c4fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_27efccbd-097a-4f77-886c-46e7b40ad406" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9b75cc4b-7984-4180-8488-7e0b2a9c4fb8" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_27efccbd-097a-4f77-886c-46e7b40ad406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_aa5cfa84-007c-4667-89b1-6e3c144b9027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9b75cc4b-7984-4180-8488-7e0b2a9c4fb8" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_aa5cfa84-007c-4667-89b1-6e3c144b9027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_506df5f8-138d-48c9-849b-3c17f3cf8b83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_9b75cc4b-7984-4180-8488-7e0b2a9c4fb8" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_506df5f8-138d-48c9-849b-3c17f3cf8b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_28aedf33-cb60-4e9b-80d7-0dd6fb7a80d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0f4231fd-ec19-4609-bd31-5c75ea88a6a7" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_28aedf33-cb60-4e9b-80d7-0dd6fb7a80d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5c9f10b9-3b2b-4399-810e-8435f33f5e95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_28aedf33-cb60-4e9b-80d7-0dd6fb7a80d0" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5c9f10b9-3b2b-4399-810e-8435f33f5e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_479793fb-8a30-4a63-aec1-4d371c7c3610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_28aedf33-cb60-4e9b-80d7-0dd6fb7a80d0" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_479793fb-8a30-4a63-aec1-4d371c7c3610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b954f03a-99ce-4e35-8654-576fced14f31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_28aedf33-cb60-4e9b-80d7-0dd6fb7a80d0" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b954f03a-99ce-4e35-8654-576fced14f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e3c32c34-4c33-4342-babd-b0d8c7e35cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0f4231fd-ec19-4609-bd31-5c75ea88a6a7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e3c32c34-4c33-4342-babd-b0d8c7e35cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_83e57458-0c9d-40c8-bac5-724337ed34bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7778913f-8aea-4562-b7e8-f3a8c281fd4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_83e57458-0c9d-40c8-bac5-724337ed34bf" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7778913f-8aea-4562-b7e8-f3a8c281fd4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8eda9f45-c93a-4c97-9553-66c027b076a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_83e57458-0c9d-40c8-bac5-724337ed34bf" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8eda9f45-c93a-4c97-9553-66c027b076a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3c140cec-c8cb-45e9-af29-1bbc9ad7dbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_83e57458-0c9d-40c8-bac5-724337ed34bf" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3c140cec-c8cb-45e9-af29-1bbc9ad7dbb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_f3fad3df-cfa6-416a-b2a2-a2bd5bcfdf6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3c140cec-c8cb-45e9-af29-1bbc9ad7dbb1" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_f3fad3df-cfa6-416a-b2a2-a2bd5bcfdf6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_f20282a4-b189-41fa-908d-4968922c8b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3c140cec-c8cb-45e9-af29-1bbc9ad7dbb1" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_f20282a4-b189-41fa-908d-4968922c8b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount_69ae93df-3a24-485d-a6b5-3d26579c9cd6" xlink:href="bhc-20220510.xsd#bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3c140cec-c8cb-45e9-af29-1bbc9ad7dbb1" xlink:to="loc_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount_69ae93df-3a24-485d-a6b5-3d26579c9cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance_e98f2cff-a657-4e82-931e-7e8cb3f8d660" xlink:href="bhc-20220510.xsd#bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3c140cec-c8cb-45e9-af29-1bbc9ad7dbb1" xlink:to="loc_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance_e98f2cff-a657-4e82-931e-7e8cb3f8d660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_dbc710e2-48b7-4dc8-bab2-5abcd5f86548" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3c140cec-c8cb-45e9-af29-1bbc9ad7dbb1" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_dbc710e2-48b7-4dc8-bab2-5abcd5f86548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxReconciliationUncertainTaxPositions_9611f1c3-f571-4da4-b158-3157f58022d4" xlink:href="bhc-20220510.xsd#bhc_IncomeTaxReconciliationUncertainTaxPositions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3c140cec-c8cb-45e9-af29-1bbc9ad7dbb1" xlink:to="loc_bhc_IncomeTaxReconciliationUncertainTaxPositions_9611f1c3-f571-4da4-b158-3157f58022d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_3fffca7d-8f71-4cdb-8a6c-c407f5098310" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3c140cec-c8cb-45e9-af29-1bbc9ad7dbb1" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_3fffca7d-8f71-4cdb-8a6c-c407f5098310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_ff8ae7f0-5dc6-4548-9c21-a34a9eedb6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3c140cec-c8cb-45e9-af29-1bbc9ad7dbb1" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_ff8ae7f0-5dc6-4548-9c21-a34a9eedb6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit_25da5094-c736-4475-ba69-c6beb2eadb64" xlink:href="bhc-20220510.xsd#bhc_IncomeTaxReconciliationDeferredIntercompanyProfit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3c140cec-c8cb-45e9-af29-1bbc9ad7dbb1" xlink:to="loc_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit_25da5094-c736-4475-ba69-c6beb2eadb64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_a9429c71-3552-4204-a378-21254deaec30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3c140cec-c8cb-45e9-af29-1bbc9ad7dbb1" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_a9429c71-3552-4204-a378-21254deaec30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_60c2a3df-0599-49c7-a8b6-2e8f54f5bcce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_3c140cec-c8cb-45e9-af29-1bbc9ad7dbb1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_60c2a3df-0599-49c7-a8b6-2e8f54f5bcce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fbdae842-1821-4f38-9d71-6f1c521580cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_8574499a-e653-43b3-95ce-3adbbc237721" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fbdae842-1821-4f38-9d71-6f1c521580cb" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_8574499a-e653-43b3-95ce-3adbbc237721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsTaxLossCarryforwards_bd76ed9b-d0d6-440b-a319-95c38c0aad67" xlink:href="bhc-20220510.xsd#bhc_DeferredTaxAssetsTaxLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8574499a-e653-43b3-95ce-3adbbc237721" xlink:to="loc_bhc_DeferredTaxAssetsTaxLossCarryforwards_bd76ed9b-d0d6-440b-a319-95c38c0aad67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_489ea70b-38b9-4664-b71d-7f7a34561f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8574499a-e653-43b3-95ce-3adbbc237721" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_489ea70b-38b9-4664-b71d-7f7a34561f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_47b29438-e89a-4604-9351-4932be98d168" xlink:href="bhc-20220510.xsd#bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8574499a-e653-43b3-95ce-3adbbc237721" xlink:to="loc_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment_47b29438-e89a-4604-9351-4932be98d168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool_4a0e78e9-87f5-48ff-a9a3-4fdf7692fe6a" xlink:href="bhc-20220510.xsd#bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8574499a-e653-43b3-95ce-3adbbc237721" xlink:to="loc_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool_4a0e78e9-87f5-48ff-a9a3-4fdf7692fe6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_c6a8fe4a-d05c-44a2-b98f-25b7c289a999" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8574499a-e653-43b3-95ce-3adbbc237721" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_c6a8fe4a-d05c-44a2-b98f-25b7c289a999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_1cf72dab-9a1c-43be-a313-c5656354b9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8574499a-e653-43b3-95ce-3adbbc237721" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_1cf72dab-9a1c-43be-a313-c5656354b9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxAssetsPrepaidExpenses_1b36879f-0a5e-40dc-8665-5ac00d6fbd55" xlink:href="bhc-20220510.xsd#bhc_DeferredTaxAssetsPrepaidExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8574499a-e653-43b3-95ce-3adbbc237721" xlink:to="loc_bhc_DeferredTaxAssetsPrepaidExpenses_1b36879f-0a5e-40dc-8665-5ac00d6fbd55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_5531e814-be4f-40d5-9c11-7c6b3b5111e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8574499a-e653-43b3-95ce-3adbbc237721" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_5531e814-be4f-40d5-9c11-7c6b3b5111e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1cae1c1b-6ccb-4bac-8c26-bf5366581470" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8574499a-e653-43b3-95ce-3adbbc237721" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_1cae1c1b-6ccb-4bac-8c26-bf5366581470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_b51de40c-66d1-4f02-ac3a-40793d21697f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8574499a-e653-43b3-95ce-3adbbc237721" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_b51de40c-66d1-4f02-ac3a-40793d21697f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_773d4a73-0479-4be4-a865-0c197753a68b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8574499a-e653-43b3-95ce-3adbbc237721" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_773d4a73-0479-4be4-a865-0c197753a68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_c5573add-b239-4758-b5ff-a97019658c24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8574499a-e653-43b3-95ce-3adbbc237721" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_c5573add-b239-4758-b5ff-a97019658c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f99642bb-4985-443d-9d41-4afbce89d051" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fbdae842-1821-4f38-9d71-6f1c521580cb" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f99642bb-4985-443d-9d41-4afbce89d051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_cf54957f-1ecd-496b-9eaa-7ca62c15bdb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f99642bb-4985-443d-9d41-4afbce89d051" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_cf54957f-1ecd-496b-9eaa-7ca62c15bdb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes_c48a7d99-7c39-45eb-b62a-eae009e3b014" xlink:href="bhc-20220510.xsd#bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f99642bb-4985-443d-9d41-4afbce89d051" xlink:to="loc_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes_c48a7d99-7c39-45eb-b62a-eae009e3b014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_f87359e4-ac15-49af-9fb7-02911dbc5373" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f99642bb-4985-443d-9d41-4afbce89d051" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_f87359e4-ac15-49af-9fb7-02911dbc5373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains_9a3e02a7-0d11-4786-92eb-43469ba27526" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f99642bb-4985-443d-9d41-4afbce89d051" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains_9a3e02a7-0d11-4786-92eb-43469ba27526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_75f9bc2a-7ef7-486e-993d-a55e0cccecc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_f99642bb-4985-443d-9d41-4afbce89d051" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_75f9bc2a-7ef7-486e-993d-a55e0cccecc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_273f350c-fb29-4238-895b-b6afb0777ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fbdae842-1821-4f38-9d71-6f1c521580cb" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_273f350c-fb29-4238-895b-b6afb0777ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_55b61f40-25d7-4af3-aad1-277266b89769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_ae791976-d80d-4496-b5ed-c186380d0fe6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_55b61f40-25d7-4af3-aad1-277266b89769" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_ae791976-d80d-4496-b5ed-c186380d0fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_57b39963-6726-4ce7-86b5-1503db6d5e32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_ae791976-d80d-4496-b5ed-c186380d0fe6" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_57b39963-6726-4ce7-86b5-1503db6d5e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_e0271214-8000-47be-a538-293be7b5caa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_57b39963-6726-4ce7-86b5-1503db6d5e32" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_e0271214-8000-47be-a538-293be7b5caa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_dbec263b-b376-47f0-89e1-cd2fc1069564" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_e0271214-8000-47be-a538-293be7b5caa3" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_dbec263b-b376-47f0-89e1-cd2fc1069564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a2f9d21b-a34b-4b36-9d72-8e36f672f29d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_ae791976-d80d-4496-b5ed-c186380d0fe6" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a2f9d21b-a34b-4b36-9d72-8e36f672f29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ff099e96-2c54-4d9b-894e-0218c111b780" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_a2f9d21b-a34b-4b36-9d72-8e36f672f29d" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ff099e96-2c54-4d9b-894e-0218c111b780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_9424e68d-12ed-4504-bb3f-f2b3a6563909" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ff099e96-2c54-4d9b-894e-0218c111b780" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_9424e68d-12ed-4504-bb3f-f2b3a6563909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes_9cdc9c72-51ba-4b43-bf38-a532541f3f38" xlink:href="bhc-20220510.xsd#bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ff099e96-2c54-4d9b-894e-0218c111b780" xlink:to="loc_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes_9cdc9c72-51ba-4b43-bf38-a532541f3f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_6fcec8e1-0bed-4b04-a828-7fe4d7d45ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ff099e96-2c54-4d9b-894e-0218c111b780" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_6fcec8e1-0bed-4b04-a828-7fe4d7d45ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_00950fc8-c80b-47b7-bb10-978d1f5bf2b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_ff099e96-2c54-4d9b-894e-0218c111b780" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_00950fc8-c80b-47b7-bb10-978d1f5bf2b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#INCOMETAXESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3dc82f2e-5b07-4720-b991-8c14187fb3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxTable_3bf6b472-a23f-41cc-8110-9806d8a6840c" xlink:href="bhc-20220510.xsd#bhc_IncomeTaxTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3dc82f2e-5b07-4720-b991-8c14187fb3aa" xlink:to="loc_bhc_IncomeTaxTable_3bf6b472-a23f-41cc-8110-9806d8a6840c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_0389e86c-aa18-4643-aa95-00ab569b0f96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxTable_3bf6b472-a23f-41cc-8110-9806d8a6840c" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_0389e86c-aa18-4643-aa95-00ab569b0f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_82ea176c-4937-46a4-a5f0-c9f98da1a76e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0389e86c-aa18-4643-aa95-00ab569b0f96" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_82ea176c-4937-46a4-a5f0-c9f98da1a76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ForeignCountryStateAndLocalMember_072f7bc5-2be8-42e8-a271-1c1b452291bb" xlink:href="bhc-20220510.xsd#bhc_ForeignCountryStateAndLocalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_82ea176c-4937-46a4-a5f0-c9f98da1a76e" xlink:to="loc_bhc_ForeignCountryStateAndLocalMember_072f7bc5-2be8-42e8-a271-1c1b452291bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_4478857e-edc5-4b2a-ab2a-776a6f12e4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_82ea176c-4937-46a4-a5f0-c9f98da1a76e" xlink:to="loc_us-gaap_DomesticCountryMember_4478857e-edc5-4b2a-ab2a-776a6f12e4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_43728d1c-7623-40b2-a5c1-5deee8216fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_82ea176c-4937-46a4-a5f0-c9f98da1a76e" xlink:to="loc_us-gaap_ForeignCountryMember_43728d1c-7623-40b2-a5c1-5deee8216fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_ccf1b727-22d1-4292-834d-dd669cba5c79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceByDeferredTaxAssetAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxTable_3bf6b472-a23f-41cc-8110-9806d8a6840c" xlink:to="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_ccf1b727-22d1-4292-834d-dd669cba5c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetDomain_b9f07f15-1d87-469e-9d7f-f903efb422a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis_ccf1b727-22d1-4292-834d-dd669cba5c79" xlink:to="loc_us-gaap_DeferredTaxAssetDomain_b9f07f15-1d87-469e-9d7f-f903efb422a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember_f96383e0-3d4a-47f6-a4f4-594c64e643e1" xlink:href="bhc-20220510.xsd#bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetDomain_b9f07f15-1d87-469e-9d7f-f903efb422a1" xlink:to="loc_bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember_f96383e0-3d4a-47f6-a4f4-594c64e643e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_e72f5fe1-2df0-49ab-9a0e-5863082efbad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxTable_3bf6b472-a23f-41cc-8110-9806d8a6840c" xlink:to="loc_us-gaap_TaxPeriodAxis_e72f5fe1-2df0-49ab-9a0e-5863082efbad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_7f5ed113-3834-43ab-8b69-593c9ae9f59a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_e72f5fe1-2df0-49ab-9a0e-5863082efbad" xlink:to="loc_us-gaap_TaxPeriodDomain_7f5ed113-3834-43ab-8b69-593c9ae9f59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2012Member_e4323266-a8ff-4176-8917-eb2d0535ba1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxYear2012Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_7f5ed113-3834-43ab-8b69-593c9ae9f59a" xlink:to="loc_us-gaap_TaxYear2012Member_e4323266-a8ff-4176-8917-eb2d0535ba1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2013Member_a971bf8d-9a4a-4e7a-8c1e-dd25de8c913f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxYear2013Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_7f5ed113-3834-43ab-8b69-593c9ae9f59a" xlink:to="loc_us-gaap_TaxYear2013Member_a971bf8d-9a4a-4e7a-8c1e-dd25de8c913f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaxYear2005ThroughTaxYear2009Member_1cc817f6-1f1c-4ca0-83bd-ff211f9c2083" xlink:href="bhc-20220510.xsd#bhc_TaxYear2005ThroughTaxYear2009Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_7f5ed113-3834-43ab-8b69-593c9ae9f59a" xlink:to="loc_bhc_TaxYear2005ThroughTaxYear2009Member_1cc817f6-1f1c-4ca0-83bd-ff211f9c2083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TaxYear2015AndTaxYear2016Member_f3fc83ed-838f-48df-9b0b-46570c8f5d2e" xlink:href="bhc-20220510.xsd#bhc_TaxYear2015AndTaxYear2016Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_7f5ed113-3834-43ab-8b69-593c9ae9f59a" xlink:to="loc_bhc_TaxYear2015AndTaxYear2016Member_f3fc83ed-838f-48df-9b0b-46570c8f5d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_1feaa2fd-aa46-4fef-998d-54f92d57b0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxTable_3bf6b472-a23f-41cc-8110-9806d8a6840c" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_1feaa2fd-aa46-4fef-998d-54f92d57b0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_08cb6573-d68b-40db-9350-1ee95f5208c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_1feaa2fd-aa46-4fef-998d-54f92d57b0ba" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_08cb6573-d68b-40db-9350-1ee95f5208c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueCommissionersIrelandMember_324f29d9-6123-4fb1-a0ff-0672627d1c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueCommissionersIrelandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_08cb6573-d68b-40db-9350-1ee95f5208c4" xlink:to="loc_us-gaap_RevenueCommissionersIrelandMember_324f29d9-6123-4fb1-a0ff-0672627d1c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CanadaRevenueAgencyMember_6fe14649-4dbe-4a96-ac44-0afa24bfb50c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CanadaRevenueAgencyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_08cb6573-d68b-40db-9350-1ee95f5208c4" xlink:to="loc_us-gaap_CanadaRevenueAgencyMember_6fe14649-4dbe-4a96-ac44-0afa24bfb50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AustralianTaxationOfficeMember_238dbed3-9436-46dd-95a1-1b5b29301b63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AustralianTaxationOfficeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_08cb6573-d68b-40db-9350-1ee95f5208c4" xlink:to="loc_us-gaap_AustralianTaxationOfficeMember_238dbed3-9436-46dd-95a1-1b5b29301b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:href="bhc-20220510.xsd#bhc_IncomeTaxLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxTable_3bf6b472-a23f-41cc-8110-9806d8a6840c" xlink:to="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_624b7208-1dca-4beb-bc42-c7230ca17aff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_624b7208-1dca-4beb-bc42-c7230ca17aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AccumulatedLossesAvailableForFederalPurposes_bfb00d34-96c9-4954-93cc-6f8a6b02f51a" xlink:href="bhc-20220510.xsd#bhc_AccumulatedLossesAvailableForFederalPurposes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_bhc_AccumulatedLossesAvailableForFederalPurposes_bfb00d34-96c9-4954-93cc-6f8a6b02f51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits_f550a852-0464-4da6-bc4a-ce635dea1794" xlink:href="bhc-20220510.xsd#bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits_f550a852-0464-4da6-bc4a-ce635dea1794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_ceea6f13-0cb3-4c11-a0e5-6824fe189289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_ceea6f13-0cb3-4c11-a0e5-6824fe189289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_dcb7debc-cdef-492c-89f3-28b22d5b0bac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_dcb7debc-cdef-492c-89f3-28b22d5b0bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_4300c267-81f3-4cba-8712-7aa13c56e7db" xlink:href="bhc-20220510.xsd#bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties_4300c267-81f3-4cba-8712-7aa13c56e7db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_adc899dd-f12c-447f-8211-af1d8c36258d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_adc899dd-f12c-447f-8211-af1d8c36258d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions_6272c3bd-7dae-4339-8b8d-5568be98e97c" xlink:href="bhc-20220510.xsd#bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions_6272c3bd-7dae-4339-8b8d-5568be98e97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions_7b924d81-f7fa-49ec-8619-9a0515084335" xlink:href="bhc-20220510.xsd#bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions_7b924d81-f7fa-49ec-8619-9a0515084335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions_95db29e0-2c43-4fb3-b482-700017a2b78d" xlink:href="bhc-20220510.xsd#bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions_95db29e0-2c43-4fb3-b482-700017a2b78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_baf1c37b-8c3a-4a95-8052-058d2915b8c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_baf1c37b-8c3a-4a95-8052-058d2915b8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_fe77e8a6-70c4-4ac2-82a7-f6749e6742ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_fe77e8a6-70c4-4ac2-82a7-f6749e6742ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns_f895600a-cc22-4eba-86ea-c3d2382f9662" xlink:href="bhc-20220510.xsd#bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns_f895600a-cc22-4eba-86ea-c3d2382f9662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear_5303c1a3-af27-457d-b058-52a46b1ace6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear_5303c1a3-af27-457d-b058-52a46b1ace6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_c56d0bf0-4156-420d-81e9-1f2411e78427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss_c56d0bf0-4156-420d-81e9-1f2411e78427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_5fbe3b14-1181-476e-9108-e9286e32a7c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_IncomeTaxLineItems_cf346fd0-1369-4b23-be08-eed86b1e7491" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_5fbe3b14-1181-476e-9108-e9286e32a7c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_108f52ed-7db7-4cb4-8ca7-1ef249911b03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_b1a427f5-0df8-41d3-a541-1f0b49f672cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_108f52ed-7db7-4cb4-8ca7-1ef249911b03" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_b1a427f5-0df8-41d3-a541-1f0b49f672cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_df4fa3bb-35ef-4c50-a311-e1c759db6c85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_b1a427f5-0df8-41d3-a541-1f0b49f672cc" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_df4fa3bb-35ef-4c50-a311-e1c759db6c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_831af75c-ae94-4634-965f-4fb2bbd74a48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_df4fa3bb-35ef-4c50-a311-e1c759db6c85" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_831af75c-ae94-4634-965f-4fb2bbd74a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_11b358d1-4169-48bf-835a-29f336583222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_831af75c-ae94-4634-965f-4fb2bbd74a48" xlink:to="loc_us-gaap_DomesticCountryMember_11b358d1-4169-48bf-835a-29f336583222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_fea764e0-d7d2-4db2-b06a-6b5d37b4ae21" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_831af75c-ae94-4634-965f-4fb2bbd74a48" xlink:to="loc_country_CA_fea764e0-d7d2-4db2-b06a-6b5d37b4ae21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_e5ec4812-64b6-4d67-a1e9-c0e1559b688a" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DE"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_831af75c-ae94-4634-965f-4fb2bbd74a48" xlink:to="loc_country_DE_e5ec4812-64b6-4d67-a1e9-c0e1559b688a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_fba444ec-5895-49c6-b457-ee40dc7293d6" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_FR"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_831af75c-ae94-4634-965f-4fb2bbd74a48" xlink:to="loc_country_FR_fba444ec-5895-49c6-b457-ee40dc7293d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_b74e151b-e09a-4593-89d2-1941289f91ef" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_831af75c-ae94-4634-965f-4fb2bbd74a48" xlink:to="loc_country_CN_b74e151b-e09a-4593-89d2-1941289f91ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_bd0bc975-5932-4cbc-8fd1-bbb030e8c827" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IE"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_831af75c-ae94-4634-965f-4fb2bbd74a48" xlink:to="loc_country_IE_bd0bc975-5932-4cbc-8fd1-bbb030e8c827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_NL_432fae80-326e-4a67-a2a6-9a53a795642e" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_NL"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_831af75c-ae94-4634-965f-4fb2bbd74a48" xlink:to="loc_country_NL_432fae80-326e-4a67-a2a6-9a53a795642e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AustralianTaxationOfficeMember_a380aa83-c6f5-4984-b575-8d2aa6153eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AustralianTaxationOfficeMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_831af75c-ae94-4634-965f-4fb2bbd74a48" xlink:to="loc_us-gaap_AustralianTaxationOfficeMember_a380aa83-c6f5-4984-b575-8d2aa6153eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LuxembourgInlandRevenueMember_f4c5ea87-c288-4f13-9724-c302a0e3ad97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LuxembourgInlandRevenueMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_831af75c-ae94-4634-965f-4fb2bbd74a48" xlink:to="loc_us-gaap_LuxembourgInlandRevenueMember_f4c5ea87-c288-4f13-9724-c302a0e3ad97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e4ca961a-d2d5-4cbe-a404-8b619de66d10" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_b1a427f5-0df8-41d3-a541-1f0b49f672cc" xlink:to="loc_srt_RangeAxis_e4ca961a-d2d5-4cbe-a404-8b619de66d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_25b1ed42-0f10-4830-aa69-21a083ab5737" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e4ca961a-d2d5-4cbe-a404-8b619de66d10" xlink:to="loc_srt_RangeMember_25b1ed42-0f10-4830-aa69-21a083ab5737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1fbc4189-acf7-4838-a3a7-e92eb8f9b141" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_25b1ed42-0f10-4830-aa69-21a083ab5737" xlink:to="loc_srt_MinimumMember_1fbc4189-acf7-4838-a3a7-e92eb8f9b141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3de848aa-7d62-4fe1-bc16-5ce31ef1bae2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_25b1ed42-0f10-4830-aa69-21a083ab5737" xlink:to="loc_srt_MaximumMember_3de848aa-7d62-4fe1-bc16-5ce31ef1bae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_5e1ebe78-df09-40f1-8468-16a127931ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_b1a427f5-0df8-41d3-a541-1f0b49f672cc" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_5e1ebe78-df09-40f1-8468-16a127931ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear_53c79279-26a3-4476-93c1-bd4673dd6e58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_5e1ebe78-df09-40f1-8468-16a127931ebd" xlink:to="loc_us-gaap_OpenTaxYear_53c79279-26a3-4476-93c1-bd4673dd6e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9a05a3ae-839f-4261-8373-cd0a0658c580" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3599542d-41c3-4a24-bb3b-e218b5a7a37e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9a05a3ae-839f-4261-8373-cd0a0658c580" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3599542d-41c3-4a24-bb3b-e218b5a7a37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_3f6d5009-25d2-4fd4-b0d8-0fe28ae16dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3599542d-41c3-4a24-bb3b-e218b5a7a37e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_3f6d5009-25d2-4fd4-b0d8-0fe28ae16dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_f4510c50-4e82-429e-8781-2696cc9ba64f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3599542d-41c3-4a24-bb3b-e218b5a7a37e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_f4510c50-4e82-429e-8781-2696cc9ba64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_856432b0-c43a-4840-8351-3c83fc019f18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3599542d-41c3-4a24-bb3b-e218b5a7a37e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_856432b0-c43a-4840-8351-3c83fc019f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_87439b02-e161-44f8-a5e3-57f13879623a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3599542d-41c3-4a24-bb3b-e218b5a7a37e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_87439b02-e161-44f8-a5e3-57f13879623a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_30148318-eeca-41e7-aa56-613cd1855b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3599542d-41c3-4a24-bb3b-e218b5a7a37e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_30148318-eeca-41e7-aa56-613cd1855b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_aa351fb8-990f-427d-9a05-1960c23bd7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3599542d-41c3-4a24-bb3b-e218b5a7a37e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_aa351fb8-990f-427d-9a05-1960c23bd7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LOSSPERSHARE" xlink:type="simple" xlink:href="bhc-20220510.xsd#LOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4276eb25-fb97-4694-ac78-f47ba8cc7d82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_e016f8a2-e0a5-4066-853e-ae0591127b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4276eb25-fb97-4694-ac78-f47ba8cc7d82" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_e016f8a2-e0a5-4066-853e-ae0591127b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LOSSPERSHARETables" xlink:type="simple" xlink:href="bhc-20220510.xsd#LOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a1d0aebd-731a-48ae-baf5-c524049e6a56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8fa7971c-5e35-467a-8b45-6ea72d05d614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a1d0aebd-731a-48ae-baf5-c524049e6a56" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8fa7971c-5e35-467a-8b45-6ea72d05d614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_17ca87df-8596-4b9a-aa29-addacbaa9b78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a4825d80-9268-4315-b846-28c2945403af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_17ca87df-8596-4b9a-aa29-addacbaa9b78" xlink:to="loc_us-gaap_NetIncomeLoss_a4825d80-9268-4315-b846-28c2945403af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7d87fcdd-eb59-40f1-914e-625df2d89ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_17ca87df-8596-4b9a-aa29-addacbaa9b78" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7d87fcdd-eb59-40f1-914e-625df2d89ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_741088bc-5bf0-4738-bc68-534fe36d5201" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_17ca87df-8596-4b9a-aa29-addacbaa9b78" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_741088bc-5bf0-4738-bc68-534fe36d5201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d6ae75e0-9f43-4efc-8d77-35e602e907b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_17ca87df-8596-4b9a-aa29-addacbaa9b78" xlink:to="loc_us-gaap_EarningsPerShareBasic_d6ae75e0-9f43-4efc-8d77-35e602e907b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_88bf90ec-2332-42c7-ad51-0018980ef683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_17ca87df-8596-4b9a-aa29-addacbaa9b78" xlink:to="loc_us-gaap_EarningsPerShareDiluted_88bf90ec-2332-42c7-ad51-0018980ef683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#LOSSPERSHARENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6d819cee-9554-43ed-b03f-1781e174f458" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8b7db4c6-37ef-4db5-84ae-44047a2c9c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6d819cee-9554-43ed-b03f-1781e174f458" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8b7db4c6-37ef-4db5-84ae-44047a2c9c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ab78e02f-ef24-4d14-89ec-917bdf58c6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8b7db4c6-37ef-4db5-84ae-44047a2c9c4b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ab78e02f-ef24-4d14-89ec-917bdf58c6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4ceedc95-0d93-4039-993a-9d9611aa07ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ab78e02f-ef24-4d14-89ec-917bdf58c6e9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4ceedc95-0d93-4039-993a-9d9611aa07ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_9be1b6f6-ae1b-4c41-9917-fe5842132b82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4ceedc95-0d93-4039-993a-9d9611aa07ae" xlink:to="loc_us-gaap_StockCompensationPlanMember_9be1b6f6-ae1b-4c41-9917-fe5842132b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_7cedb14b-4162-43a3-810d-05beecf41ec2" xlink:href="bhc-20220510.xsd#bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4ceedc95-0d93-4039-993a-9d9611aa07ae" xlink:to="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_7cedb14b-4162-43a3-810d-05beecf41ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_7ba33bf2-28fd-4ea9-bce2-628b05f15b3b" xlink:href="bhc-20220510.xsd#bhc_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember_7cedb14b-4162-43a3-810d-05beecf41ec2" xlink:to="loc_bhc_PerformanceBasedRestrictedStockUnitsMember_7ba33bf2-28fd-4ea9-bce2-628b05f15b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_63145cda-3f9a-4c09-a17b-df5b39cef7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8b7db4c6-37ef-4db5-84ae-44047a2c9c4b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_63145cda-3f9a-4c09-a17b-df5b39cef7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_aceb7fbb-660b-4504-9d0c-e0f0590c1f66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_63145cda-3f9a-4c09-a17b-df5b39cef7b1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_aceb7fbb-660b-4504-9d0c-e0f0590c1f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURES" xlink:type="simple" xlink:href="bhc-20220510.xsd#SUPPLEMENTALCASHFLOWDISCLOSURES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_fe6ef2cc-98ec-4ff5-91e4-3c4e13b5c8f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_c3e34a21-dd2f-4d47-8a58-406894896140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_fe6ef2cc-98ec-4ff5-91e4-3c4e13b5c8f2" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_c3e34a21-dd2f-4d47-8a58-406894896140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESTables" xlink:type="simple" xlink:href="bhc-20220510.xsd#SUPPLEMENTALCASHFLOWDISCLOSURESTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_5e388923-0844-401e-98fd-7a76c6fd588b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_9923b438-4b43-4eaf-9fd3-c51b276c4665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_5e388923-0844-401e-98fd-7a76c6fd588b" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_9923b438-4b43-4eaf-9fd3-c51b276c4665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_476e8130-2223-415c-b413-78e9b45f2ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_3530e1b3-a258-4f07-9b8f-ad38f33482da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_476e8130-2223-415c-b413-78e9b45f2ca9" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_3530e1b3-a258-4f07-9b8f-ad38f33482da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_b06ab775-d4ae-48bf-94bb-34f094f03e79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3530e1b3-a258-4f07-9b8f-ad38f33482da" xlink:to="loc_us-gaap_InterestPaidNet_b06ab775-d4ae-48bf-94bb-34f094f03e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_e343dabf-3d66-4956-86c9-b0e1e510b4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3530e1b3-a258-4f07-9b8f-ad38f33482da" xlink:to="loc_us-gaap_IncomeTaxesPaid_e343dabf-3d66-4956-86c9-b0e1e510b4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGS" xlink:type="simple" xlink:href="bhc-20220510.xsd#LEGALPROCEEDINGS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0c6dd094-e5bd-41dd-b1e3-795e99c2cab5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_23e718cd-1cd8-4b3b-9f61-53d1a8faa159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0c6dd094-e5bd-41dd-b1e3-795e99c2cab5" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_23e718cd-1cd8-4b3b-9f61-53d1a8faa159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#LEGALPROCEEDINGSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a67dae6a-1574-4035-841b-103d04dfd4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_2e612f62-abb8-4df7-adbe-1795c67eefa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_a67dae6a-1574-4035-841b-103d04dfd4aa" xlink:to="loc_us-gaap_LossContingenciesTable_2e612f62-abb8-4df7-adbe-1795c67eefa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_da840fde-f4a6-4238-b135-fa23d67e542d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_2e612f62-abb8-4df7-adbe-1795c67eefa1" xlink:to="loc_srt_LitigationCaseAxis_da840fde-f4a6-4238-b135-fa23d67e542d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_da840fde-f4a6-4238-b135-fa23d67e542d" xlink:to="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ValeantUSSecuritiesLitigationMember_840af22b-1b83-4874-a7a1-97ba8f238b9e" xlink:href="bhc-20220510.xsd#bhc_ValeantUSSecuritiesLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_ValeantUSSecuritiesLitigationMember_840af22b-1b83-4874-a7a1-97ba8f238b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CanadianSecuritiesLitigationMember_5725aa93-51fa-4d10-9ecf-a351dc1e771e" xlink:href="bhc-20220510.xsd#bhc_CanadianSecuritiesLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_CanadianSecuritiesLitigationMember_5725aa93-51fa-4d10-9ecf-a351dc1e771e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RICOClassActionsLitigationMember_6eb09704-5f8e-401f-a1a2-87318ff32bd2" xlink:href="bhc-20220510.xsd#bhc_RICOClassActionsLitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_RICOClassActionsLitigationMember_6eb09704-5f8e-401f-a1a2-87318ff32bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InsuranceCoverageLawsuitMember_cb729d9e-d72a-411f-b0c5-922d1c1372d4" xlink:href="bhc-20220510.xsd#bhc_InsuranceCoverageLawsuitMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_InsuranceCoverageLawsuitMember_cb729d9e-d72a-411f-b0c5-922d1c1372d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SandozLitigationMember_bc0a7838-f709-4096-b36a-af6b35739202" xlink:href="bhc-20220510.xsd#bhc_SandozLitigationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_SandozLitigationMember_bc0a7838-f709-4096-b36a-af6b35739202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PerrigoIsraelPharmaceuticalsLitigationMember_f9c4f008-aac0-4350-b5ac-f00af346bf33" xlink:href="bhc-20220510.xsd#bhc_PerrigoIsraelPharmaceuticalsLitigationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_PerrigoIsraelPharmaceuticalsLitigationMember_f9c4f008-aac0-4350-b5ac-f00af346bf33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PadagisLitigationMember_1847514f-1324-4a73-8dbe-82aeb9fc4809" xlink:href="bhc-20220510.xsd#bhc_PadagisLitigationMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_PadagisLitigationMember_1847514f-1324-4a73-8dbe-82aeb9fc4809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_f15bed9e-ea86-40b9-ac59-24014b53f565" xlink:href="bhc-20220510.xsd#bhc_MSNLaboratoriesPrivateLtdLitigationMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_MSNLaboratoriesPrivateLtdLitigationMember_f15bed9e-ea86-40b9-ac59-24014b53f565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember_4aab0b71-7520-42cf-bae7-e6f0c3536626" xlink:href="bhc-20220510.xsd#bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember_4aab0b71-7520-42cf-bae7-e6f0c3536626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LupinPharmaceuticalsIncLitigationMember_18f2fb16-92c5-46c8-96eb-19b27ac0ceb5" xlink:href="bhc-20220510.xsd#bhc_LupinPharmaceuticalsIncLitigationMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_LupinPharmaceuticalsIncLitigationMember_18f2fb16-92c5-46c8-96eb-19b27ac0ceb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowertoShowerProductLiabilityLitigationMember_a355adbc-d4ba-41e5-9ccd-c56d1a809592" xlink:href="bhc-20220510.xsd#bhc_ShowertoShowerProductLiabilityLitigationMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_ShowertoShowerProductLiabilityLitigationMember_a355adbc-d4ba-41e5-9ccd-c56d1a809592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_cb43f7e6-613a-4d53-ae6b-36d7ed0a015a" xlink:href="bhc-20220510.xsd#bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ShowertoShowerProductLiabilityLitigationMember_a355adbc-d4ba-41e5-9ccd-c56d1a809592" xlink:to="loc_bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember_cb43f7e6-613a-4d53-ae6b-36d7ed0a015a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_117dd036-0ae7-4422-aa99-7feba8581730" xlink:href="bhc-20220510.xsd#bhc_DoctorsAllergyFormulaLLCLitigationMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_DoctorsAllergyFormulaLLCLitigationMember_117dd036-0ae7-4422-aa99-7feba8581730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LitigationwithFormerSalixCEOMember_ffd99770-edd9-4c3a-a18c-ea023b1c4cf6" xlink:href="bhc-20220510.xsd#bhc_LitigationwithFormerSalixCEOMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_LitigationwithFormerSalixCEOMember_ffd99770-edd9-4c3a-a18c-ea023b1c4cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationMember_38912431-1181-48e6-bf87-03a7c09b00fb" xlink:href="bhc-20220510.xsd#bhc_GlumetzaAntitrustLitigationMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_GlumetzaAntitrustLitigationMember_38912431-1181-48e6-bf87-03a7c09b00fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_7357d7e3-df75-40c0-a2a9-f7a448e9031e" xlink:href="bhc-20220510.xsd#bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_GlumetzaAntitrustLitigationMember_38912431-1181-48e6-bf87-03a7c09b00fb" xlink:to="loc_bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember_7357d7e3-df75-40c0-a2a9-f7a448e9031e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ApotexIncLitigationMember_b3c78c2e-4757-46a7-ae74-ee3b89d6f3f5" xlink:href="bhc-20220510.xsd#bhc_ApotexIncLitigationMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_ApotexIncLitigationMember_b3c78c2e-4757-46a7-ae74-ee3b89d6f3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DerivativeLawsuitsMember_5082a34e-f2fc-4c55-ad56-afe54687d5de" xlink:href="bhc-20220510.xsd#bhc_DerivativeLawsuitsMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_0b4d348f-d606-45ce-a59b-984385b07f48" xlink:to="loc_bhc_DerivativeLawsuitsMember_5082a34e-f2fc-4c55-ad56-afe54687d5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_3a09d78c-4093-4804-b9ef-0da6639a65b8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_2e612f62-abb8-4df7-adbe-1795c67eefa1" xlink:to="loc_srt_StatementGeographicalAxis_3a09d78c-4093-4804-b9ef-0da6639a65b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3289dcde-adf7-45e5-9568-a42b258d0bd7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_3a09d78c-4093-4804-b9ef-0da6639a65b8" xlink:to="loc_srt_SegmentGeographicalDomain_3289dcde-adf7-45e5-9568-a42b258d0bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_1d14e3f6-48a2-4cd4-aeed-c7027cb3d744" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_NJ"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3289dcde-adf7-45e5-9568-a42b258d0bd7" xlink:to="loc_stpr_NJ_1d14e3f6-48a2-4cd4-aeed-c7027cb3d744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_13892afb-901f-44c3-bffd-68a9450a967b" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3289dcde-adf7-45e5-9568-a42b258d0bd7" xlink:to="loc_country_CA_13892afb-901f-44c3-bffd-68a9450a967b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-BC_d641e86f-4977-41be-804b-bca72337b50d" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA-BC"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_country_CA_13892afb-901f-44c3-bffd-68a9450a967b" xlink:to="loc_stpr_CA-BC_d641e86f-4977-41be-804b-bca72337b50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA-QC_52823629-7a6a-4e23-a306-fbd63c16819d" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA-QC"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_country_CA_13892afb-901f-44c3-bffd-68a9450a967b" xlink:to="loc_stpr_CA-QC_52823629-7a6a-4e23-a306-fbd63c16819d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_2deb502f-be31-40ae-877d-3218393343b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_2e612f62-abb8-4df7-adbe-1795c67eefa1" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_2deb502f-be31-40ae-877d-3218393343b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_ee873533-f94e-4d65-83f0-77cd612c8e99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_2deb502f-be31-40ae-877d-3218393343b4" xlink:to="loc_us-gaap_LossContingencyNatureDomain_ee873533-f94e-4d65-83f0-77cd612c8e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnfavorableRegulatoryActionMember_50a16105-58ec-4d46-b83a-5182a3d26294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnfavorableRegulatoryActionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_ee873533-f94e-4d65-83f0-77cd612c8e99" xlink:to="loc_us-gaap_UnfavorableRegulatoryActionMember_50a16105-58ec-4d46-b83a-5182a3d26294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_849abe26-62cd-4e82-a5b0-d5fcf22c6c63" xlink:href="bhc-20220510.xsd#bhc_ViolationofCanadianProvincialSecuritiesLegislationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_ee873533-f94e-4d65-83f0-77cd612c8e99" xlink:to="loc_bhc_ViolationofCanadianProvincialSecuritiesLegislationMember_849abe26-62cd-4e82-a5b0-d5fcf22c6c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_adde6f3e-9343-4d0e-88a6-e2d97bb71bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_2e612f62-abb8-4df7-adbe-1795c67eefa1" xlink:to="loc_us-gaap_LitigationStatusAxis_adde6f3e-9343-4d0e-88a6-e2d97bb71bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_77c82c99-e605-4655-a7d9-fb71ae222ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_adde6f3e-9343-4d0e-88a6-e2d97bb71bf6" xlink:to="loc_us-gaap_LitigationStatusDomain_77c82c99-e605-4655-a7d9-fb71ae222ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_e338e94c-7467-4986-9497-81c49f08d16b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_77c82c99-e605-4655-a7d9-fb71ae222ef7" xlink:to="loc_us-gaap_PendingLitigationMember_e338e94c-7467-4986-9497-81c49f08d16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_f03aa113-5297-4877-88f1-c1f0fd09d10c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_77c82c99-e605-4655-a7d9-fb71ae222ef7" xlink:to="loc_us-gaap_SettledLitigationMember_f03aa113-5297-4877-88f1-c1f0fd09d10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8ecdf1c5-7447-43cc-b192-4adc60d22eab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_2e612f62-abb8-4df7-adbe-1795c67eefa1" xlink:to="loc_srt_CounterpartyNameAxis_8ecdf1c5-7447-43cc-b192-4adc60d22eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95db7d64-8d70-489a-895b-d5bda93547ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8ecdf1c5-7447-43cc-b192-4adc60d22eab" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95db7d64-8d70-489a-895b-d5bda93547ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PlaintiffsDirectPurchasersMember_3c032ea5-20d2-487e-b78b-43d60a7783b2" xlink:href="bhc-20220510.xsd#bhc_PlaintiffsDirectPurchasersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_95db7d64-8d70-489a-895b-d5bda93547ab" xlink:to="loc_bhc_PlaintiffsDirectPurchasersMember_3c032ea5-20d2-487e-b78b-43d60a7783b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fce1ae14-e893-43e3-a631-a0bce3ab956f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_2e612f62-abb8-4df7-adbe-1795c67eefa1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fce1ae14-e893-43e3-a631-a0bce3ab956f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_53b4c750-1bb5-4acb-a351-6661de9a795c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fce1ae14-e893-43e3-a631-a0bce3ab956f" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_53b4c750-1bb5-4acb-a351-6661de9a795c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_513d7223-47aa-4461-adc8-d8547c448a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_53b4c750-1bb5-4acb-a351-6661de9a795c" xlink:to="loc_us-gaap_SubsequentEventMember_513d7223-47aa-4461-adc8-d8547c448a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_58fc3284-a9b8-4874-bcaa-db6c26ecbf34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_2e612f62-abb8-4df7-adbe-1795c67eefa1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_58fc3284-a9b8-4874-bcaa-db6c26ecbf34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_aaef1f5f-1c62-4177-897b-72f2cc7689e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_58fc3284-a9b8-4874-bcaa-db6c26ecbf34" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_aaef1f5f-1c62-4177-897b-72f2cc7689e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember_01a248e9-15fd-4b83-a8ed-e5cbc901cd5d" xlink:href="bhc-20220510.xsd#bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_aaef1f5f-1c62-4177-897b-72f2cc7689e2" xlink:to="loc_bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember_01a248e9-15fd-4b83-a8ed-e5cbc901cd5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_2e612f62-abb8-4df7-adbe-1795c67eefa1" xlink:to="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_Legalsettlementsandrelatedfees_514ca020-83cc-4aa8-85f1-c9d5645c2a75" xlink:href="bhc-20220510.xsd#bhc_Legalsettlementsandrelatedfees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_bhc_Legalsettlementsandrelatedfees_514ca020-83cc-4aa8-85f1-c9d5645c2a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_adcfe675-2eed-41dd-94d5-59708956f887" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_adcfe675-2eed-41dd-94d5-59708956f887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_8ddb5fe4-c911-4662-a2b7-4f1c9730bf0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_8ddb5fe4-c911-4662-a2b7-4f1c9730bf0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_a074ac66-24d5-482a-aabb-f998c4ca1a1b" xlink:href="bhc-20220510.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors_a074ac66-24d5-482a-aabb-f998c4ca1a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_ce8f85b6-82c1-4ec7-9dea-43d1794ebbba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_ce8f85b6-82c1-4ec7-9dea-43d1794ebbba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_7dc26786-de4b-47e6-b98e-9d7c1cd1beff" xlink:href="bhc-20220510.xsd#bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending_7dc26786-de4b-47e6-b98e-9d7c1cd1beff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_b0176889-c878-405f-81ec-5c85508d693f" xlink:href="bhc-20220510.xsd#bhc_LossContingencyNewClaimsFiledButNotYetServedNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber_b0176889-c878-405f-81ec-5c85508d693f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_ba7ca89a-50e9-4f5a-ba6f-7bee42bb9ad4" xlink:href="bhc-20220510.xsd#bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction_ba7ca89a-50e9-4f5a-ba6f-7bee42bb9ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_2cdcd99b-5997-4a32-8266-35f9c7565e05" xlink:href="bhc-20220510.xsd#bhc_LossContingencyNumberOfInsurancePolicyPeriods"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_bhc_LossContingencyNumberOfInsurancePolicyPeriods_2cdcd99b-5997-4a32-8266-35f9c7565e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers_67835862-0146-4af0-ab4f-9ce771572377" xlink:href="bhc-20220510.xsd#bhc_LossContingencySettlementAgreementsNumberOfInsurers"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_bhc_LossContingencySettlementAgreementsNumberOfInsurers_67835862-0146-4af0-ab4f-9ce771572377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_bdd3a85b-80b3-40f5-970b-4ded40ded5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedFromOtherParty_bdd3a85b-80b3-40f5-970b-4ded40ded5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyStayOfApprovalPeriod_a4c39e3a-94f0-4871-8d4f-6e187efe7762" xlink:href="bhc-20220510.xsd#bhc_LossContingencyStayOfApprovalPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_bhc_LossContingencyStayOfApprovalPeriod_a4c39e3a-94f0-4871-8d4f-6e187efe7762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_e0231a05-1fd4-451b-adb6-fb25adc7b258" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_e0231a05-1fd4-451b-adb6-fb25adc7b258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_1683e2d2-8127-4634-89ef-66d9e040793e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_1683e2d2-8127-4634-89ef-66d9e040793e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits_b24e684c-e2da-4260-8f28-55e7440e6cef" xlink:href="bhc-20220510.xsd#bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b9bc74cf-01e3-48d1-95ae-56724742098f" xlink:to="loc_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits_b24e684c-e2da-4260-8f28-55e7440e6cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="bhc-20220510.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_608dad1e-3be7-4d46-847f-d99d16bfca55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6251c0ec-7caa-4153-909d-4a0c1a5bb8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_608dad1e-3be7-4d46-847f-d99d16bfca55" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6251c0ec-7caa-4153-909d-4a0c1a5bb8ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_624a1256-2076-4114-bf37-c11927299bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfCommitmentsTable_5af8cb5c-25ff-4260-acc4-7b99c8bf9200" xlink:href="bhc-20220510.xsd#bhc_ScheduleOfCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_624a1256-2076-4114-bf37-c11927299bfd" xlink:to="loc_bhc_ScheduleOfCommitmentsTable_5af8cb5c-25ff-4260-acc4-7b99c8bf9200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2966e0e8-cb46-4127-a151-b16cb1a28373" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfCommitmentsTable_5af8cb5c-25ff-4260-acc4-7b99c8bf9200" xlink:to="loc_srt_CounterpartyNameAxis_2966e0e8-cb46-4127-a151-b16cb1a28373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_33c13532-e45a-4b77-9a69-9e4bc8a2e5c1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2966e0e8-cb46-4127-a151-b16cb1a28373" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_33c13532-e45a-4b77-9a69-9e4bc8a2e5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member_fff9d7ee-1035-452e-9561-333f999c59c4" xlink:href="bhc-20220510.xsd#bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_33c13532-e45a-4b77-9a69-9e4bc8a2e5c1" xlink:to="loc_bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member_fff9d7ee-1035-452e-9561-333f999c59c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_MitsubishiTanabePharmaCorporationMember_150f3a3c-bae7-4ab1-b848-6426d313077e" xlink:href="bhc-20220510.xsd#bhc_MitsubishiTanabePharmaCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_33c13532-e45a-4b77-9a69-9e4bc8a2e5c1" xlink:to="loc_bhc_MitsubishiTanabePharmaCorporationMember_150f3a3c-bae7-4ab1-b848-6426d313077e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NovaliqGmbHMember_7243b6c9-030f-4d51-bfcc-7682b2095dc9" xlink:href="bhc-20220510.xsd#bhc_NovaliqGmbHMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_33c13532-e45a-4b77-9a69-9e4bc8a2e5c1" xlink:to="loc_bhc_NovaliqGmbHMember_7243b6c9-030f-4d51-bfcc-7682b2095dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CedarsSinaiMedicalCenterMember_9489aa0e-0e0a-4636-981e-32f4ebede059" xlink:href="bhc-20220510.xsd#bhc_CedarsSinaiMedicalCenterMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_33c13532-e45a-4b77-9a69-9e4bc8a2e5c1" xlink:to="loc_bhc_CedarsSinaiMedicalCenterMember_9489aa0e-0e0a-4636-981e-32f4ebede059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_EyenoviaIncMember_852039f6-bf13-437e-968b-169a5f8eeb2f" xlink:href="bhc-20220510.xsd#bhc_EyenoviaIncMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_33c13532-e45a-4b77-9a69-9e4bc8a2e5c1" xlink:to="loc_bhc_EyenoviaIncMember_852039f6-bf13-437e-968b-169a5f8eeb2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ScheduleOfCommitmentsLineItems_49a14cf7-6795-470a-be5e-bb903176560a" xlink:href="bhc-20220510.xsd#bhc_ScheduleOfCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfCommitmentsTable_5af8cb5c-25ff-4260-acc4-7b99c8bf9200" xlink:to="loc_bhc_ScheduleOfCommitmentsLineItems_49a14cf7-6795-470a-be5e-bb903176560a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_0cb912fe-ef4c-414d-9cfc-532c340d4b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfCommitmentsLineItems_49a14cf7-6795-470a-be5e-bb903176560a" xlink:to="loc_us-gaap_ContractualObligation_0cb912fe-ef4c-414d-9cfc-532c340d4b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CollaborativeAgreementMilestonePaymentsAggregate_8d127300-96e4-4ba2-b50f-62d448f23175" xlink:href="bhc-20220510.xsd#bhc_CollaborativeAgreementMilestonePaymentsAggregate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_ScheduleOfCommitmentsLineItems_49a14cf7-6795-470a-be5e-bb903176560a" xlink:to="loc_bhc_CollaborativeAgreementMilestonePaymentsAggregate_8d127300-96e4-4ba2-b50f-62d448f23175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATION" xlink:type="simple" xlink:href="bhc-20220510.xsd#SEGMENTINFORMATION"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1f0f5ec0-1dde-49e5-a8bd-b06e7adf35e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_19e62b43-cd90-4bc6-8e16-fd2f55786f38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1f0f5ec0-1dde-49e5-a8bd-b06e7adf35e8" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_19e62b43-cd90-4bc6-8e16-fd2f55786f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="bhc-20220510.xsd#SEGMENTINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_31212b7f-2cad-4943-928a-b38d9f7932d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_3edf7e02-dfeb-4059-964a-72b0ee37b416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_31212b7f-2cad-4943-928a-b38d9f7932d1" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_3edf7e02-dfeb-4059-964a-72b0ee37b416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_6284b7ec-63f0-4f0c-ba68-0018cb4006ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_31212b7f-2cad-4943-928a-b38d9f7932d1" xlink:to="loc_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock_6284b7ec-63f0-4f0c-ba68-0018cb4006ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_3c7b56bf-5833-4bd8-bbfb-ae3df6e75cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_31212b7f-2cad-4943-928a-b38d9f7932d1" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_3c7b56bf-5833-4bd8-bbfb-ae3df6e75cc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_32e7026b-55b2-4d27-961a-750c2705a591" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_31212b7f-2cad-4943-928a-b38d9f7932d1" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_32e7026b-55b2-4d27-961a-750c2705a591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_6189c36a-e1b9-415c-9973-fe671e9c39fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_31212b7f-2cad-4943-928a-b38d9f7932d1" xlink:to="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_6189c36a-e1b9-415c-9973-fe671e9c39fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_9a0b6182-9a82-4f6b-ab1e-d32142ca1eda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_31212b7f-2cad-4943-928a-b38d9f7932d1" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_9a0b6182-9a82-4f6b-ab1e-d32142ca1eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SEGMENTINFORMATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_25dfc768-4b39-4256-9599-0871f9bfd698" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f93f1487-4d63-4345-be5d-d9c27e7dfef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_25dfc768-4b39-4256-9599-0871f9bfd698" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f93f1487-4d63-4345-be5d-d9c27e7dfef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3bb11057-b588-4fb4-8f09-141951ee6563" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f93f1487-4d63-4345-be5d-d9c27e7dfef7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3bb11057-b588-4fb4-8f09-141951ee6563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b566c296-f1ee-4bdd-aa2a-56f39c3edb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3bb11057-b588-4fb4-8f09-141951ee6563" xlink:to="loc_us-gaap_SegmentDomain_b566c296-f1ee-4bdd-aa2a-56f39c3edb7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OrthoDermatologicsSegmentMember_7da3d316-10c3-48d8-ac46-6f891ced0727" xlink:href="bhc-20220510.xsd#bhc_OrthoDermatologicsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_b566c296-f1ee-4bdd-aa2a-56f39c3edb7f" xlink:to="loc_bhc_OrthoDermatologicsSegmentMember_7da3d316-10c3-48d8-ac46-6f891ced0727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_ba8483af-65fe-449c-beee-60ebea946830" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f93f1487-4d63-4345-be5d-d9c27e7dfef7" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_ba8483af-65fe-449c-beee-60ebea946830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_a2dafbc0-2aad-469d-b807-46c68ad9478c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ba8483af-65fe-449c-beee-60ebea946830" xlink:to="loc_us-gaap_NumberOfReportingUnits_a2dafbc0-2aad-469d-b807-46c68ad9478c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_9c802dca-038a-4da7-908d-b07f21fa899c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b506cbd1-3734-445b-ac50-7926cba2f63b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9c802dca-038a-4da7-908d-b07f21fa899c" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b506cbd1-3734-445b-ac50-7926cba2f63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_84c21100-deee-47a3-b6bb-9a00dac328ae" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b506cbd1-3734-445b-ac50-7926cba2f63b" xlink:to="loc_srt_ConsolidationItemsAxis_84c21100-deee-47a3-b6bb-9a00dac328ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_1a357e8d-2eaf-440f-a596-853e6bf41299" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_84c21100-deee-47a3-b6bb-9a00dac328ae" xlink:to="loc_srt_ConsolidationItemsDomain_1a357e8d-2eaf-440f-a596-853e6bf41299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_d4b9e272-16d9-4a5c-826e-f02fd9015d44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_1a357e8d-2eaf-440f-a596-853e6bf41299" xlink:to="loc_us-gaap_OperatingSegmentsMember_d4b9e272-16d9-4a5c-826e-f02fd9015d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_0ca8ba2f-24aa-44c4-a530-060fede49249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_1a357e8d-2eaf-440f-a596-853e6bf41299" xlink:to="loc_us-gaap_CorporateNonSegmentMember_0ca8ba2f-24aa-44c4-a530-060fede49249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_4c7bd71d-b2b2-4034-8f51-2f7265cf6cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b506cbd1-3734-445b-ac50-7926cba2f63b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_4c7bd71d-b2b2-4034-8f51-2f7265cf6cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_33686b80-7919-472e-8951-98db7a93451e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_4c7bd71d-b2b2-4034-8f51-2f7265cf6cc7" xlink:to="loc_us-gaap_SegmentDomain_33686b80-7919-472e-8951-98db7a93451e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_323e29a6-6e7d-4fd1-ad9d-d604e1261035" xlink:href="bhc-20220510.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_33686b80-7919-472e-8951-98db7a93451e" xlink:to="loc_bhc_BauschLombMember_323e29a6-6e7d-4fd1-ad9d-d604e1261035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_8d7bb267-7e51-4240-b224-9ffa46ed5bad" xlink:href="bhc-20220510.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_33686b80-7919-472e-8951-98db7a93451e" xlink:to="loc_bhc_SalixSegmentMember_8d7bb267-7e51-4240-b224-9ffa46ed5bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_49d6b30a-9fec-4fdb-b601-35a89616bc3b" xlink:href="bhc-20220510.xsd#bhc_InternationalRxMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_33686b80-7919-472e-8951-98db7a93451e" xlink:to="loc_bhc_InternationalRxMember_49d6b30a-9fec-4fdb-b601-35a89616bc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_b6e490d5-60d8-4947-94de-27af3bedf25a" xlink:href="bhc-20220510.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_33686b80-7919-472e-8951-98db7a93451e" xlink:to="loc_bhc_SoltaMedicalSegmentMember_b6e490d5-60d8-4947-94de-27af3bedf25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_ec7cdc16-354d-46b7-89ef-c581293169e7" xlink:href="bhc-20220510.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_33686b80-7919-472e-8951-98db7a93451e" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_ec7cdc16-354d-46b7-89ef-c581293169e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_97e450b6-20e7-452e-8830-04d1ee29de52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_b506cbd1-3734-445b-ac50-7926cba2f63b" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_97e450b6-20e7-452e-8830-04d1ee29de52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4bb6d09a-58fc-445d-80a0-7ddd80da48f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_97e450b6-20e7-452e-8830-04d1ee29de52" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4bb6d09a-58fc-445d-80a0-7ddd80da48f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ef4e04c6-4b3d-4615-adc7-0eb24ee42208" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_97e450b6-20e7-452e-8830-04d1ee29de52" xlink:to="loc_us-gaap_OperatingIncomeLoss_ef4e04c6-4b3d-4615-adc7-0eb24ee42208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_490e00cd-eab5-4250-be26-456da679cc66" xlink:href="bhc-20220510.xsd#bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_97e450b6-20e7-452e-8830-04d1ee29de52" xlink:to="loc_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold_490e00cd-eab5-4250-be26-456da679cc66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_0989a6db-52ff-4cfd-bcbc-1590010854d2" xlink:href="bhc-20220510.xsd#bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_97e450b6-20e7-452e-8830-04d1ee29de52" xlink:to="loc_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges_0989a6db-52ff-4cfd-bcbc-1590010854d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_ab9d7a3b-c7b1-44ab-8f41-75d8413a0902" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_97e450b6-20e7-452e-8830-04d1ee29de52" xlink:to="loc_us-gaap_AssetImpairmentCharges_ab9d7a3b-c7b1-44ab-8f41-75d8413a0902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_51199a46-f758-4ac6-b211-af638eb7c1b9" xlink:href="bhc-20220510.xsd#bhc_RestructuringChargesAndInitialPublicOfferingCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_97e450b6-20e7-452e-8830-04d1ee29de52" xlink:to="loc_bhc_RestructuringChargesAndInitialPublicOfferingCosts_51199a46-f758-4ac6-b211-af638eb7c1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_2bb10c27-73b3-4ff0-816d-129c7e5c54d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_97e450b6-20e7-452e-8830-04d1ee29de52" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_2bb10c27-73b3-4ff0-816d-129c7e5c54d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_244a0215-112d-400c-8bef-2c04afc31b67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_97e450b6-20e7-452e-8830-04d1ee29de52" xlink:to="loc_us-gaap_InvestmentIncomeInterest_244a0215-112d-400c-8bef-2c04afc31b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDebtExpense_48aaa656-54a6-44a6-b949-b2f45c0a4a45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndDebtExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_97e450b6-20e7-452e-8830-04d1ee29de52" xlink:to="loc_us-gaap_InterestAndDebtExpense_48aaa656-54a6-44a6-b949-b2f45c0a4a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_76880df1-a223-4743-9306-1790462aa1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_97e450b6-20e7-452e-8830-04d1ee29de52" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_76880df1-a223-4743-9306-1790462aa1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ca69e6cd-9648-40d2-aefc-5f8f6354456a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_97e450b6-20e7-452e-8830-04d1ee29de52" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ca69e6cd-9648-40d2-aefc-5f8f6354456a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a4723209-8984-48f6-a287-2988a5066876" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_97e450b6-20e7-452e-8830-04d1ee29de52" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a4723209-8984-48f6-a287-2988a5066876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract_85f04cb3-7e8c-4f90-88fb-94cfe8e81716" xlink:href="bhc-20220510.xsd#bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_97e450b6-20e7-452e-8830-04d1ee29de52" xlink:to="loc_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract_85f04cb3-7e8c-4f90-88fb-94cfe8e81716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_56eb8f35-9bba-4fdc-b4f0-3d897547b321" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract_85f04cb3-7e8c-4f90-88fb-94cfe8e81716" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_56eb8f35-9bba-4fdc-b4f0-3d897547b321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ad570ff7-d7d0-4926-869a-bcdbe7d85e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2d86df2a-3dcf-4948-b6d3-7d36169aa567" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ad570ff7-d7d0-4926-869a-bcdbe7d85e1b" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2d86df2a-3dcf-4948-b6d3-7d36169aa567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8bb40399-21b9-41cf-9ba6-bc696eeb85a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2d86df2a-3dcf-4948-b6d3-7d36169aa567" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8bb40399-21b9-41cf-9ba6-bc696eeb85a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9f678cd2-7d22-47ca-aa19-9230000af013" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8bb40399-21b9-41cf-9ba6-bc696eeb85a7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9f678cd2-7d22-47ca-aa19-9230000af013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_d605f214-0179-41f3-8b56-21b1fb6e6dcc" xlink:href="bhc-20220510.xsd#bhc_RevenuesNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9f678cd2-7d22-47ca-aa19-9230000af013" xlink:to="loc_bhc_RevenuesNetMember_d605f214-0179-41f3-8b56-21b1fb6e6dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c1d451b0-5902-464f-ad80-face0dc7a02b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2d86df2a-3dcf-4948-b6d3-7d36169aa567" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c1d451b0-5902-464f-ad80-face0dc7a02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ebd13227-0f33-4cf0-ac67-b258a7e36977" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c1d451b0-5902-464f-ad80-face0dc7a02b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ebd13227-0f33-4cf0-ac67-b258a7e36977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_0cc73ea3-974f-482f-8540-d5a791150e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ebd13227-0f33-4cf0-ac67-b258a7e36977" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_0cc73ea3-974f-482f-8540-d5a791150e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_fe2c3280-5d0f-4956-8f97-964ea6165792" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2d86df2a-3dcf-4948-b6d3-7d36169aa567" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_fe2c3280-5d0f-4956-8f97-964ea6165792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1b135ed5-bc80-4c58-a0f8-7637ce513c70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fe2c3280-5d0f-4956-8f97-964ea6165792" xlink:to="loc_us-gaap_SegmentDomain_1b135ed5-bc80-4c58-a0f8-7637ce513c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BauschLombMember_3497e2d4-8c07-4ecc-943a-7b735af444f4" xlink:href="bhc-20220510.xsd#bhc_BauschLombMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1b135ed5-bc80-4c58-a0f8-7637ce513c70" xlink:to="loc_bhc_BauschLombMember_3497e2d4-8c07-4ecc-943a-7b735af444f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SalixSegmentMember_eac02964-7fad-4ad1-8342-69371f3d862b" xlink:href="bhc-20220510.xsd#bhc_SalixSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1b135ed5-bc80-4c58-a0f8-7637ce513c70" xlink:to="loc_bhc_SalixSegmentMember_eac02964-7fad-4ad1-8342-69371f3d862b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_InternationalRxMember_02d7dabd-90ee-465d-85ce-f80eaabbe262" xlink:href="bhc-20220510.xsd#bhc_InternationalRxMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1b135ed5-bc80-4c58-a0f8-7637ce513c70" xlink:to="loc_bhc_InternationalRxMember_02d7dabd-90ee-465d-85ce-f80eaabbe262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SoltaMedicalSegmentMember_90f8d953-4a58-425f-a3cf-ed140d4bb2b8" xlink:href="bhc-20220510.xsd#bhc_SoltaMedicalSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1b135ed5-bc80-4c58-a0f8-7637ce513c70" xlink:to="loc_bhc_SoltaMedicalSegmentMember_90f8d953-4a58-425f-a3cf-ed140d4bb2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DiversifiedProductsSegmentMember_6a58b7dc-3f15-4167-98e9-a4639807d48b" xlink:href="bhc-20220510.xsd#bhc_DiversifiedProductsSegmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1b135ed5-bc80-4c58-a0f8-7637ce513c70" xlink:to="loc_bhc_DiversifiedProductsSegmentMember_6a58b7dc-3f15-4167-98e9-a4639807d48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_988459cb-066b-4d26-be95-8eb833df34da" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2d86df2a-3dcf-4948-b6d3-7d36169aa567" xlink:to="loc_srt_ProductOrServiceAxis_988459cb-066b-4d26-be95-8eb833df34da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5ba0c06a-d651-43de-a70d-251eec43d37d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_988459cb-066b-4d26-be95-8eb833df34da" xlink:to="loc_srt_ProductsAndServicesDomain_5ba0c06a-d651-43de-a70d-251eec43d37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_PharmaceuticalProductsMember_e7b688d0-cf43-4d2b-a96e-d055c049a49d" xlink:href="bhc-20220510.xsd#bhc_PharmaceuticalProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ba0c06a-d651-43de-a70d-251eec43d37d" xlink:to="loc_bhc_PharmaceuticalProductsMember_e7b688d0-cf43-4d2b-a96e-d055c049a49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DeviceProductsMember_4af2255b-f7fa-4537-861b-d6c98c074ab1" xlink:href="bhc-20220510.xsd#bhc_DeviceProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ba0c06a-d651-43de-a70d-251eec43d37d" xlink:to="loc_bhc_DeviceProductsMember_4af2255b-f7fa-4537-861b-d6c98c074ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OvertheCounterProductsMember_b9a331e3-d405-4e6b-ae29-432992294234" xlink:href="bhc-20220510.xsd#bhc_OvertheCounterProductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ba0c06a-d651-43de-a70d-251eec43d37d" xlink:to="loc_bhc_OvertheCounterProductsMember_b9a331e3-d405-4e6b-ae29-432992294234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_BrandedandOtherGenericProductsMember_3e4d4418-758e-4719-ba03-1f8321ee176f" xlink:href="bhc-20220510.xsd#bhc_BrandedandOtherGenericProductsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ba0c06a-d651-43de-a70d-251eec43d37d" xlink:to="loc_bhc_BrandedandOtherGenericProductsMember_3e4d4418-758e-4719-ba03-1f8321ee176f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherRevenuesMember_c2d09537-c3d7-49f4-b196-2d95a05e7f93" xlink:href="bhc-20220510.xsd#bhc_OtherRevenuesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5ba0c06a-d651-43de-a70d-251eec43d37d" xlink:to="loc_bhc_OtherRevenuesMember_c2d09537-c3d7-49f4-b196-2d95a05e7f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_657242c8-5c85-44ce-a78a-c4a7915a35ac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2d86df2a-3dcf-4948-b6d3-7d36169aa567" xlink:to="loc_srt_MajorCustomersAxis_657242c8-5c85-44ce-a78a-c4a7915a35ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0a0a1204-a918-463e-8f40-287c1ead1356" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_657242c8-5c85-44ce-a78a-c4a7915a35ac" xlink:to="loc_srt_NameOfMajorCustomerDomain_0a0a1204-a918-463e-8f40-287c1ead1356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CustomerTopTenProductsMember_b3c9b1b3-5a45-4f3a-8922-8f6764f39d72" xlink:href="bhc-20220510.xsd#bhc_CustomerTopTenProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_0a0a1204-a918-463e-8f40-287c1ead1356" xlink:to="loc_bhc_CustomerTopTenProductsMember_b3c9b1b3-5a45-4f3a-8922-8f6764f39d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_98526be2-6a87-429c-bbd7-22d48b302ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_2d86df2a-3dcf-4948-b6d3-7d36169aa567" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_98526be2-6a87-429c-bbd7-22d48b302ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_ConcentrationRiskNumberOfProducts_17e4450c-ac73-470d-bdfd-6386c9c283ea" xlink:href="bhc-20220510.xsd#bhc_ConcentrationRiskNumberOfProducts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_98526be2-6a87-429c-bbd7-22d48b302ece" xlink:to="loc_bhc_ConcentrationRiskNumberOfProducts_17e4450c-ac73-470d-bdfd-6386c9c283ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_a09ee8b1-40be-4fc5-b32e-9b5196691964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_98526be2-6a87-429c-bbd7-22d48b302ece" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_a09ee8b1-40be-4fc5-b32e-9b5196691964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1b62b43d-b98a-4dd1-b86b-f0051df249d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_98526be2-6a87-429c-bbd7-22d48b302ece" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1b62b43d-b98a-4dd1-b86b-f0051df249d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SEGMENTINFORMATIONGeographicInformationRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_a626a627-4c7d-4131-ae48-bfcd5d294776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1045f479-d675-4d49-af49-3d796f6b8090" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a626a627-4c7d-4131-ae48-bfcd5d294776" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1045f479-d675-4d49-af49-3d796f6b8090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6ab67be7-35b1-43d2-bf47-8eee165a1429" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1045f479-d675-4d49-af49-3d796f6b8090" xlink:to="loc_srt_StatementGeographicalAxis_6ab67be7-35b1-43d2-bf47-8eee165a1429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_6ab67be7-35b1-43d2-bf47-8eee165a1429" xlink:to="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnitedStatesandPuertoRicoMember_00931089-3428-45fe-98a7-6a42b7ea0495" xlink:href="bhc-20220510.xsd#bhc_UnitedStatesandPuertoRicoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:to="loc_bhc_UnitedStatesandPuertoRicoMember_00931089-3428-45fe-98a7-6a42b7ea0495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_3544fb78-992f-411f-b92a-f9f05b8933f0" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:to="loc_country_CN_3544fb78-992f-411f-b92a-f9f05b8933f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_9ae549b8-ba0d-47e1-b853-9cb7c87a1cb8" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:to="loc_country_CA_9ae549b8-ba0d-47e1-b853-9cb7c87a1cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PL_d86fe157-8775-4687-b524-b6ada867f308" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_PL"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:to="loc_country_PL_d86fe157-8775-4687-b524-b6ada867f308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX_13f3d14d-4139-4069-81be-6624d750ed38" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_MX"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:to="loc_country_MX_13f3d14d-4139-4069-81be-6624d750ed38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_b9ed64b7-789b-4144-b2fc-5c85243c5cf9" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:to="loc_country_JP_b9ed64b7-789b-4144-b2fc-5c85243c5cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_a22af6f5-45ee-403c-8528-95490dc058ea" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_FR"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:to="loc_country_FR_a22af6f5-45ee-403c-8528-95490dc058ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_RU_f0de7d08-7833-4e9d-8130-b681c1655464" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_RU"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:to="loc_country_RU_f0de7d08-7833-4e9d-8130-b681c1655464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_EG_03cb3b90-6917-47c6-a64e-8493da2840fa" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_EG"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:to="loc_country_EG_03cb3b90-6917-47c6-a64e-8493da2840fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_60fd0697-acbb-472e-b14f-6f527cad486f" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DE"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:to="loc_country_DE_60fd0697-acbb-472e-b14f-6f527cad486f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_GB_05d9c539-dd2b-4873-8e6b-c95e16884105" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_GB"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:to="loc_country_GB_05d9c539-dd2b-4873-8e6b-c95e16884105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_ES_c9127d43-ebb8-4942-bf91-e4385c3e5782" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_ES"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:to="loc_country_ES_c9127d43-ebb8-4942-bf91-e4385c3e5782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IT_601f1f4d-5f2e-4c80-abca-613289be82cd" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IT"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:to="loc_country_IT_601f1f4d-5f2e-4c80-abca-613289be82cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherCountriesMember_6d4dbbbd-1118-447e-9d6a-fa6209e62797" xlink:href="bhc-20220510.xsd#bhc_OtherCountriesMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ede7ece8-2d48-433e-8fd7-f6d9bf7630e5" xlink:to="loc_bhc_OtherCountriesMember_6d4dbbbd-1118-447e-9d6a-fa6209e62797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_b72771e1-9dfd-4786-8f3e-ca482dad52d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1045f479-d675-4d49-af49-3d796f6b8090" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_b72771e1-9dfd-4786-8f3e-ca482dad52d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7de8d1de-e160-48ce-b5a2-f91733ebce94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_b72771e1-9dfd-4786-8f3e-ca482dad52d7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7de8d1de-e160-48ce-b5a2-f91733ebce94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4b93a9f9-2040-4951-8e3c-fd06b823596c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_fe4a9b59-8dd5-4d3d-a7eb-dc751f926464" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4b93a9f9-2040-4951-8e3c-fd06b823596c" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_fe4a9b59-8dd5-4d3d-a7eb-dc751f926464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a9021bd9-6e8c-4551-a6b3-f5d39e8ddc5e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_fe4a9b59-8dd5-4d3d-a7eb-dc751f926464" xlink:to="loc_srt_StatementGeographicalAxis_a9021bd9-6e8c-4551-a6b3-f5d39e8ddc5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_564c01d5-a9b5-4291-9f87-cff8937c58c0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_a9021bd9-6e8c-4551-a6b3-f5d39e8ddc5e" xlink:to="loc_srt_SegmentGeographicalDomain_564c01d5-a9b5-4291-9f87-cff8937c58c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_UnitedStatesandPuertoRicoMember_c80b7d8e-2366-45d1-a4ad-4b17675ee26b" xlink:href="bhc-20220510.xsd#bhc_UnitedStatesandPuertoRicoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_564c01d5-a9b5-4291-9f87-cff8937c58c0" xlink:to="loc_bhc_UnitedStatesandPuertoRicoMember_c80b7d8e-2366-45d1-a4ad-4b17675ee26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_ac8831ba-3ab3-4171-9066-21661f493594" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IE"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_564c01d5-a9b5-4291-9f87-cff8937c58c0" xlink:to="loc_country_IE_ac8831ba-3ab3-4171-9066-21661f493594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_e00cb90d-e724-4388-b11f-4d9eb86b8961" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_564c01d5-a9b5-4291-9f87-cff8937c58c0" xlink:to="loc_country_CA_e00cb90d-e724-4388-b11f-4d9eb86b8961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PL_4e39fb8d-25ca-4a7b-af2a-e029ff5c2b54" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_PL"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_564c01d5-a9b5-4291-9f87-cff8937c58c0" xlink:to="loc_country_PL_4e39fb8d-25ca-4a7b-af2a-e029ff5c2b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_1ee9d8c9-7466-43e4-8858-c591b7a9d591" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DE"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_564c01d5-a9b5-4291-9f87-cff8937c58c0" xlink:to="loc_country_DE_1ee9d8c9-7466-43e4-8858-c591b7a9d591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_MX_0541799e-1e92-4637-a240-fab39774f902" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_MX"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_564c01d5-a9b5-4291-9f87-cff8937c58c0" xlink:to="loc_country_MX_0541799e-1e92-4637-a240-fab39774f902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_9591ff25-7552-4a7f-b946-c5506ee59520" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_FR"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_564c01d5-a9b5-4291-9f87-cff8937c58c0" xlink:to="loc_country_FR_9591ff25-7552-4a7f-b946-c5506ee59520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_cffae110-88fc-46be-b7e4-3cd121836fb8" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_564c01d5-a9b5-4291-9f87-cff8937c58c0" xlink:to="loc_country_CN_cffae110-88fc-46be-b7e4-3cd121836fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_RS_40b3bf63-8973-46d8-a1f8-d84a486352c0" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_RS"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_564c01d5-a9b5-4291-9f87-cff8937c58c0" xlink:to="loc_country_RS_40b3bf63-8973-46d8-a1f8-d84a486352c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IT_d5c843ea-b694-4487-a8e7-9470507179b4" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_IT"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_564c01d5-a9b5-4291-9f87-cff8937c58c0" xlink:to="loc_country_IT_d5c843ea-b694-4487-a8e7-9470507179b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_OtherCountriesMember_29c36e50-f9b1-4d8b-bfcd-f2bfd11bb44d" xlink:href="bhc-20220510.xsd#bhc_OtherCountriesMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_564c01d5-a9b5-4291-9f87-cff8937c58c0" xlink:to="loc_bhc_OtherCountriesMember_29c36e50-f9b1-4d8b-bfcd-f2bfd11bb44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_27b1d024-ffe5-4669-ae81-ccac74a36db3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_fe4a9b59-8dd5-4d3d-a7eb-dc751f926464" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_27b1d024-ffe5-4669-ae81-ccac74a36db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_af34d30d-8b3f-4fc7-b00b-7bae3c56fbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_27b1d024-ffe5-4669-ae81-ccac74a36db3" xlink:to="loc_us-gaap_NoncurrentAssets_af34d30d-8b3f-4fc7-b00b-7bae3c56fbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SEGMENTINFORMATIONMajorCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c1febe59-ad9a-46c1-bfb2-7e306f18ac6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_fd83f75e-66c8-491b-9c04-a72432995cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c1febe59-ad9a-46c1-bfb2-7e306f18ac6c" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_fd83f75e-66c8-491b-9c04-a72432995cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_4babe1ed-ee9d-488e-aa57-28686d1b1757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_fd83f75e-66c8-491b-9c04-a72432995cb8" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_4babe1ed-ee9d-488e-aa57-28686d1b1757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6f3194e6-682d-41f0-bd77-6e088dc2cb3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_4babe1ed-ee9d-488e-aa57-28686d1b1757" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6f3194e6-682d-41f0-bd77-6e088dc2cb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_c6717112-610d-4e94-a8eb-89cf9dbfc1a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_6f3194e6-682d-41f0-bd77-6e088dc2cb3c" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_c6717112-610d-4e94-a8eb-89cf9dbfc1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c7db25d8-5866-4745-bcc6-1f1b842a12ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_fd83f75e-66c8-491b-9c04-a72432995cb8" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c7db25d8-5866-4745-bcc6-1f1b842a12ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0e73c552-a0bf-4a34-a073-e537882047e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c7db25d8-5866-4745-bcc6-1f1b842a12ff" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0e73c552-a0bf-4a34-a073-e537882047e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevenuesNetMember_19048ff1-09bd-47cf-8e93-c237c82f0cbb" xlink:href="bhc-20220510.xsd#bhc_RevenuesNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0e73c552-a0bf-4a34-a073-e537882047e7" xlink:to="loc_bhc_RevenuesNetMember_19048ff1-09bd-47cf-8e93-c237c82f0cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_32a22493-b3de-4a1f-a6d4-3b0567d21d9f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_fd83f75e-66c8-491b-9c04-a72432995cb8" xlink:to="loc_srt_MajorCustomersAxis_32a22493-b3de-4a1f-a6d4-3b0567d21d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_9434a810-0f32-495b-a79a-56e6cc520505" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_32a22493-b3de-4a1f-a6d4-3b0567d21d9f" xlink:to="loc_srt_NameOfMajorCustomerDomain_9434a810-0f32-495b-a79a-56e6cc520505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_AmerisourceBergenCorporationMember_350caaac-a8e5-4099-9f83-ca8b4de73059" xlink:href="bhc-20220510.xsd#bhc_AmerisourceBergenCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9434a810-0f32-495b-a79a-56e6cc520505" xlink:to="loc_bhc_AmerisourceBergenCorporationMember_350caaac-a8e5-4099-9f83-ca8b4de73059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_McKessonCorporationMember_aa81e804-1c72-42d7-bf76-7c5d26daa825" xlink:href="bhc-20220510.xsd#bhc_McKessonCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9434a810-0f32-495b-a79a-56e6cc520505" xlink:to="loc_bhc_McKessonCorporationMember_aa81e804-1c72-42d7-bf76-7c5d26daa825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_CardinalHealthIncMember_03a94cb2-0505-43a4-9620-6b5393255d99" xlink:href="bhc-20220510.xsd#bhc_CardinalHealthIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_9434a810-0f32-495b-a79a-56e6cc520505" xlink:to="loc_bhc_CardinalHealthIncMember_03a94cb2-0505-43a4-9620-6b5393255d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_741147bc-e5ae-4e33-a940-6a4864e145c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_fd83f75e-66c8-491b-9c04-a72432995cb8" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_741147bc-e5ae-4e33-a940-6a4864e145c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_782884fd-17d8-4adf-ba8c-25bad9c38516" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_741147bc-e5ae-4e33-a940-6a4864e145c3" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_782884fd-17d8-4adf-ba8c-25bad9c38516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="bhc-20220510.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_158947ad-76d6-4c2e-9b18-60a8dd30bc4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_70aa6034-eea1-4e7c-bd93-fdae7c224597" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_158947ad-76d6-4c2e-9b18-60a8dd30bc4d" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_70aa6034-eea1-4e7c-bd93-fdae7c224597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails" xlink:type="simple" xlink:href="bhc-20220510.xsd#SUBSEQUENTEVENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_f5308c80-a905-44bc-b848-469cb6553037" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_cca4ef0c-7af1-427c-a514-1b935f2ba341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_f5308c80-a905-44bc-b848-469cb6553037" xlink:to="loc_us-gaap_SubsequentEventTable_cca4ef0c-7af1-427c-a514-1b935f2ba341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d5947fa0-902b-4f4d-a16c-3dc4a0aee307" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_cca4ef0c-7af1-427c-a514-1b935f2ba341" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d5947fa0-902b-4f4d-a16c-3dc4a0aee307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_78932273-a4f6-47ec-89f2-14f6049919ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d5947fa0-902b-4f4d-a16c-3dc4a0aee307" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_78932273-a4f6-47ec-89f2-14f6049919ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_60b2b5ca-e301-4ede-a7c9-a840e7c29a46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_78932273-a4f6-47ec-89f2-14f6049919ae" xlink:to="loc_us-gaap_SubsequentEventMember_60b2b5ca-e301-4ede-a7c9-a840e7c29a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_04bbeb23-7494-40f4-9228-29d749bc73e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_cca4ef0c-7af1-427c-a514-1b935f2ba341" xlink:to="loc_us-gaap_DebtInstrumentAxis_04bbeb23-7494-40f4-9228-29d749bc73e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_41381af0-f86c-4366-900e-0d3998b71c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_04bbeb23-7494-40f4-9228-29d749bc73e3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_41381af0-f86c-4366-900e-0d3998b71c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_A9.00SeniorNotesdueDecember2025Member_5e57aa30-6d0b-4a5b-b73e-d304993f9053" xlink:href="bhc-20220510.xsd#bhc_A9.00SeniorNotesdueDecember2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_41381af0-f86c-4366-900e-0d3998b71c1a" xlink:to="loc_bhc_A9.00SeniorNotesdueDecember2025Member_5e57aa30-6d0b-4a5b-b73e-d304993f9053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_NewRestatedCreditAgreementMember_85f56d69-8164-4ab2-adf9-c1105d293e78" xlink:href="bhc-20220510.xsd#bhc_NewRestatedCreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_41381af0-f86c-4366-900e-0d3998b71c1a" xlink:to="loc_bhc_NewRestatedCreditAgreementMember_85f56d69-8164-4ab2-adf9-c1105d293e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember_95f84ffc-f7c7-455c-9039-8951fa14ae57" xlink:href="bhc-20220510.xsd#bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_NewRestatedCreditAgreementMember_85f56d69-8164-4ab2-adf9-c1105d293e78" xlink:to="loc_bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember_95f84ffc-f7c7-455c-9039-8951fa14ae57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_TermLoanBFacilityNewRestatedCreditAgreementMember_41abfc89-9157-4ffc-a146-41c0fbb936e5" xlink:href="bhc-20220510.xsd#bhc_TermLoanBFacilityNewRestatedCreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bhc_NewRestatedCreditAgreementMember_85f56d69-8164-4ab2-adf9-c1105d293e78" xlink:to="loc_bhc_TermLoanBFacilityNewRestatedCreditAgreementMember_41abfc89-9157-4ffc-a146-41c0fbb936e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_f0abfe82-abd0-454f-8337-fc663df06cba" xlink:href="bhc-20220510.xsd#bhc_SeniorSecured6125NotesDueFebruary2027Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_41381af0-f86c-4366-900e-0d3998b71c1a" xlink:to="loc_bhc_SeniorSecured6125NotesDueFebruary2027Member_f0abfe82-abd0-454f-8337-fc663df06cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_3d36cfac-2be7-4c62-a5fa-3fd63c1e057e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_cca4ef0c-7af1-427c-a514-1b935f2ba341" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_3d36cfac-2be7-4c62-a5fa-3fd63c1e057e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_96cdcc7e-cdaf-4de4-a127-aeb355853256" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_3d36cfac-2be7-4c62-a5fa-3fd63c1e057e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_96cdcc7e-cdaf-4de4-a127-aeb355853256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_ccedd57e-1037-4354-9e69-930eb9231ece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_96cdcc7e-cdaf-4de4-a127-aeb355853256" xlink:to="loc_us-gaap_UnsecuredDebtMember_ccedd57e-1037-4354-9e69-930eb9231ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_1ada5803-d6ea-415b-996a-600a4316c21c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_96cdcc7e-cdaf-4de4-a127-aeb355853256" xlink:to="loc_us-gaap_SecuredDebtMember_1ada5803-d6ea-415b-996a-600a4316c21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_3b023c7d-510e-4507-8858-80ecb2ef76fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_cca4ef0c-7af1-427c-a514-1b935f2ba341" xlink:to="loc_us-gaap_CreditFacilityAxis_3b023c7d-510e-4507-8858-80ecb2ef76fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_661ec018-762a-49e6-9f95-eabc4dc46289" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_3b023c7d-510e-4507-8858-80ecb2ef76fa" xlink:to="loc_us-gaap_CreditFacilityDomain_661ec018-762a-49e6-9f95-eabc4dc46289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_005d67a4-55a7-4aaa-b9da-7a7dc4ca85bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_661ec018-762a-49e6-9f95-eabc4dc46289" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_005d67a4-55a7-4aaa-b9da-7a7dc4ca85bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_9325cd24-2f36-4400-9161-dd953a76fb99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_cca4ef0c-7af1-427c-a514-1b935f2ba341" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_9325cd24-2f36-4400-9161-dd953a76fb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8948017b-a335-443f-a2d4-5fa58fbcc0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_9325cd24-2f36-4400-9161-dd953a76fb99" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8948017b-a335-443f-a2d4-5fa58fbcc0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_cd0d8e2b-3063-42cc-84ae-83231b7e97eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8948017b-a335-443f-a2d4-5fa58fbcc0ad" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_cd0d8e2b-3063-42cc-84ae-83231b7e97eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_0434641c-c085-49e7-9c51-1362a1c58938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8948017b-a335-443f-a2d4-5fa58fbcc0ad" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_0434641c-c085-49e7-9c51-1362a1c58938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9bfa9689-bfa7-43d1-add6-d4a325947640" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_cca4ef0c-7af1-427c-a514-1b935f2ba341" xlink:to="loc_srt_RangeAxis_9bfa9689-bfa7-43d1-add6-d4a325947640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b601ccd3-9d71-47e8-a9cd-812ca7ef702f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9bfa9689-bfa7-43d1-add6-d4a325947640" xlink:to="loc_srt_RangeMember_b601ccd3-9d71-47e8-a9cd-812ca7ef702f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9e771b80-686e-4f0d-ade4-8e43f5db3905" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b601ccd3-9d71-47e8-a9cd-812ca7ef702f" xlink:to="loc_srt_MaximumMember_9e771b80-686e-4f0d-ade4-8e43f5db3905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_6fbd3252-9575-45b5-9822-e43b1df14e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_cca4ef0c-7af1-427c-a514-1b935f2ba341" xlink:to="loc_us-gaap_SubsequentEventLineItems_6fbd3252-9575-45b5-9822-e43b1df14e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_e5ae3817-7890-49da-bb57-53f1bfe80095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fbd3252-9575-45b5-9822-e43b1df14e5a" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_e5ae3817-7890-49da-bb57-53f1bfe80095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_4771da95-a9bc-444b-b07d-760570a0553b" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fbd3252-9575-45b5-9822-e43b1df14e5a" xlink:to="loc_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet_4771da95-a9bc-444b-b07d-760570a0553b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentExpectedFaceAmount_a0b649dc-fec8-400b-b14d-458088e05974" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentExpectedFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fbd3252-9575-45b5-9822-e43b1df14e5a" xlink:to="loc_bhc_DebtInstrumentExpectedFaceAmount_a0b649dc-fec8-400b-b14d-458088e05974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity_28100316-df88-44b7-88cc-f716e28d8dd2" xlink:href="bhc-20220510.xsd#bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fbd3252-9575-45b5-9822-e43b1df14e5a" xlink:to="loc_bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity_28100316-df88-44b7-88cc-f716e28d8dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio_b0e315ec-b983-435e-a650-86d39f424e95" xlink:href="bhc-20220510.xsd#bhc_DebtInstrumentCovenantTotalLeverageRatio"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fbd3252-9575-45b5-9822-e43b1df14e5a" xlink:to="loc_bhc_DebtInstrumentCovenantTotalLeverageRatio_b0e315ec-b983-435e-a650-86d39f424e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_26d5b79c-2044-4259-8184-8e0726d19483" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fbd3252-9575-45b5-9822-e43b1df14e5a" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_26d5b79c-2044-4259-8184-8e0726d19483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b0ea44b4-6b28-4212-9fae-b9c21e55b14f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fbd3252-9575-45b5-9822-e43b1df14e5a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_b0ea44b4-6b28-4212-9fae-b9c21e55b14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_f0f81913-c0bb-433a-a015-05d7fa1c773a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fbd3252-9575-45b5-9822-e43b1df14e5a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_f0f81913-c0bb-433a-a015-05d7fa1c773a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_5e1ad9ce-13a5-4dcb-8c79-6a5631a94569" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6fbd3252-9575-45b5-9822-e43b1df14e5a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_5e1ad9ce-13a5-4dcb-8c79-6a5631a94569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373489022632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document<br></strong></div></th>
<th class="th"><div>May 10, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 10,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Bausch Health Companies Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0448205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2150 St. Elz&#233;ar Blvd. West<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Laval<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">QC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">H7L 4A8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">744-6792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, No Par Value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BHC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000885590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373489450872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 582<span></span>
</td>
<td class="nump">$ 605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestrictedCashAndOtherSettlementDepositsCurrent', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">1,537<span></span>
</td>
<td class="nump">1,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">1,775<span></span>
</td>
<td class="nump">1,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">993<span></span>
</td>
<td class="nump">1,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">720<span></span>
</td>
<td class="nump">855<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">5,607<span></span>
</td>
<td class="nump">5,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">1,598<span></span>
</td>
<td class="nump">1,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">6,948<span></span>
</td>
<td class="nump">8,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">12,457<span></span>
</td>
<td class="nump">13,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">2,252<span></span>
</td>
<td class="nump">2,137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">340<span></span>
</td>
<td class="nump">664<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">29,202<span></span>
</td>
<td class="nump">31,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">407<span></span>
</td>
<td class="nump">337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">4,791<span></span>
</td>
<td class="nump">4,576<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,198<span></span>
</td>
<td class="nump">4,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of long-term debt</a></td>
<td class="nump">22,654<span></span>
</td>
<td class="nump">23,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities, net</a></td>
<td class="nump">529<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">653<span></span>
</td>
<td class="nump">1,012<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">29,236<span></span>
</td>
<td class="nump">30,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Notes&#160;20 and 21)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common shares, no par value, unlimited shares authorized, 359,405,748 and 355,422,347&#160;issued and outstanding at December&#160;31, 2021 and 2020, respectively</a></td>
<td class="nump">10,317<span></span>
</td>
<td class="nump">10,227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">462<span></span>
</td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(8,961)<span></span>
</td>
<td class="num">(8,013)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,924)<span></span>
</td>
<td class="num">(2,133)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Bausch Health Companies Inc. shareholders&#8217; (deficit) equity</a></td>
<td class="num">(106)<span></span>
</td>
<td class="nump">535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total (deficit) equity</a></td>
<td class="num">(34)<span></span>
</td>
<td class="nump">605<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and (deficit) equity</a></td>
<td class="nump">$ 29,202<span></span>
</td>
<td class="nump">$ 31,199<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessCombinationContingentConsiderationNoncurrentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Noncurrent Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessCombinationContingentConsiderationNoncurrentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestrictedCashAndOtherSettlementDepositsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash And Other Settlement Deposits, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestrictedCashAndOtherSettlementDepositsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373495671752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">359,405,748<span></span>
</td>
<td class="nump">355,422,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">359,405,748<span></span>
</td>
<td class="nump">355,422,347<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373490443752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 8,434<span></span>
</td>
<td class="nump">$ 8,027<span></span>
</td>
<td class="nump">$ 8,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">2,624<span></span>
</td>
<td class="nump">2,367<span></span>
</td>
<td class="nump">2,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">465<span></span>
</td>
<td class="nump">452<span></span>
</td>
<td class="nump">471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold', window );">Amortization of intangible assets</a></td>
<td class="nump">1,375<span></span>
</td>
<td class="nump">1,645<span></span>
</td>
<td class="nump">1,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges', window );">Goodwill impairments</a></td>
<td class="nump">469<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments, including loss on assets held for sale</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestructuringChargesAndInitialPublicOfferingCosts', window );">Restructuring, integration, separation and IPO costs</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other expense, net</a></td>
<td class="nump">373<span></span>
</td>
<td class="nump">502<span></span>
</td>
<td class="nump">1,426<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total Expenses</a></td>
<td class="nump">7,984<span></span>
</td>
<td class="nump">7,351<span></span>
</td>
<td class="nump">8,804<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="nump">450<span></span>
</td>
<td class="nump">676<span></span>
</td>
<td class="num">(203)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="num">(1,426)<span></span>
</td>
<td class="num">(1,534)<span></span>
</td>
<td class="num">(1,612)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">(62)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange and other</a></td>
<td class="nump">7<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before benefit from income taxes</a></td>
<td class="num">(1,024)<span></span>
</td>
<td class="num">(934)<span></span>
</td>
<td class="num">(1,837)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(937)<span></span>
</td>
<td class="num">(559)<span></span>
</td>
<td class="num">(1,783)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interest</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Bausch Health Companies Inc.</a></td>
<td class="num">$ (948)<span></span>
</td>
<td class="num">$ (560)<span></span>
</td>
<td class="num">$ (1,788)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share attributable to Bausch Health Companies Inc. (in dollars per share)</a></td>
<td class="num">$ (2.64)<span></span>
</td>
<td class="num">$ (1.58)<span></span>
</td>
<td class="num">$ (5.08)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share attributable to Bausch Health Companies Inc. (in dollars per share)</a></td>
<td class="num">$ (2.64)<span></span>
</td>
<td class="num">$ (1.58)<span></span>
</td>
<td class="num">$ (5.08)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average common shares (in shares)</a></td>
<td class="nump">358.9<span></span>
</td>
<td class="nump">355.0<span></span>
</td>
<td class="nump">352.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average common shares (in shares)</a></td>
<td class="nump">358.9<span></span>
</td>
<td class="nump">355.0<span></span>
</td>
<td class="nump">352.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 8,342<span></span>
</td>
<td class="nump">$ 7,924<span></span>
</td>
<td class="nump">$ 8,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues</a></td>
<td class="nump">2,361<span></span>
</td>
<td class="nump">2,202<span></span>
</td>
<td class="nump">2,297<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Impairment Loss, Not Included In Asset Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestructuringChargesAndInitialPublicOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges And Initial Public Offering Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestructuringChargesAndInitialPublicOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373488923352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (937)<span></span>
</td>
<td class="num">$ (559)<span></span>
</td>
<td class="num">$ (1,783)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Pension and postretirement benefit plan adjustments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax', window );">Net actuarial gain (loss) arising during the year</a></td>
<td class="nump">24<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax', window );">Amortization of prior service credit</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition', window );">Amortization or settlement recognition of net loss</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax', window );">Income tax benefit (expense)</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax', window );">Foreign currency impact</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net pension and postretirement benefit plan adjustments</a></td>
<td class="nump">28<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(158)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income</a></td>
<td class="num">(130)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(1,067)<span></span>
</td>
<td class="num">(604)<span></span>
</td>
<td class="num">(1,733)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income attributable to noncontrolling interest</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Bausch Health Companies Inc.</a></td>
<td class="num">$ (1,079)<span></span>
</td>
<td class="num">$ (607)<span></span>
</td>
<td class="num">$ (1,737)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Defined Benefit Plan, Foreign Currency Adjustment, Net Of Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Amortization or Settlement Recognition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL34724391-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373491205640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Bausch Health Companies&#160;Inc. Shareholders' Equity (Deficit)</div></th>
<th class="th">
<div>Bausch Health Companies&#160;Inc. Shareholders' Equity (Deficit) </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Common Shares</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">349,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 2,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,121<span></span>
</td>
<td class="nump">$ 413<span></span>
</td>
<td class="num">$ (5,664)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,137)<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">Accounting Standards Update 2016-13 [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common shares issued under share-based compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common shares issued under share-based compensation plans</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="num">(46)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Share-based awards tax withholding</a></td>
<td class="num">(40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distributions</a></td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">(1,783)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,788)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,788)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2019</a></td>
<td class="nump">1,136<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">1,063<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">$ 10,172<span></span>
</td>
<td class="nump">429<span></span>
</td>
<td class="num">(7,452)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">(2,086)<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common shares issued under share-based compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common shares issued under share-based compensation plans</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Share-based awards tax withholding</a></td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distributions</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">(559)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(560)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(560)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">$ (45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">355,422,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,227<span></span>
</td>
<td class="nump">454<span></span>
</td>
<td class="num">(8,013)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,133)<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Shareholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Common shares issued under share-based compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Common shares issued under share-based compensation plans</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="num">(68)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Share-based awards tax withholding</a></td>
<td class="num">(52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Release of foreign currency translation losses upon disposal of assets held for sale</a></td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest distributions</a></td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">(937)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(948)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(948)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">$ (130)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(131)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(131)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">359,405,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="num">$ (34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (106)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,317<span></span>
</td>
<td class="nump">$ 462<span></span>
</td>
<td class="num">$ (8,961)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,924)<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL122642865-165497<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S65<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124359872&amp;loc=SL124427846-239511<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL120254526-165497<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(1)<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(2)<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(01)<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373489507080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows From Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (937)<span></span>
</td>
<td class="num">$ (559)<span></span>
</td>
<td class="num">$ (1,783)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization of intangible assets</a></td>
<td class="nump">1,552<span></span>
</td>
<td class="nump">1,825<span></span>
</td>
<td class="nump">2,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization and write-off of debt discounts and debt issuance costs</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments, including loss on assets held for sale</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges', window );">Goodwill impairment</a></td>
<td class="nump">469<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AllowancesForLossesOnAccountsReceivableAndInventories', window );">Allowances for losses on trade receivables and inventories</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DeferredIncomeTaxNoncashExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(225)<span></span>
</td>
<td class="num">(475)<span></span>
</td>
<td class="num">(230)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Gain on disposal of assets</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GainLossRelatedToLitigationSettlementGross', window );">Additions to accrued legal settlements</a></td>
<td class="nump">569<span></span>
</td>
<td class="nump">442<span></span>
</td>
<td class="nump">1,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments of accrued legal settlements</a></td>
<td class="num">(351)<span></span>
</td>
<td class="num">(168)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Foreign exchange loss</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DerivativeGainExcludedComponent', window );">Gain excluded from hedge effectiveness</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities', window );">Payments of contingent consideration adjustments, including accretion</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables</a></td>
<td class="num">(229)<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="num">(209)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued and other liabilities</a></td>
<td class="nump">121<span></span>
</td>
<td class="num">(471)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">1,426<span></span>
</td>
<td class="nump">1,111<span></span>
</td>
<td class="nump">1,501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows From Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of businesses, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(180)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisition of intangible assets and other assets</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(269)<span></span>
</td>
<td class="num">(302)<span></span>
</td>
<td class="num">(270)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale of marketable securities</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested', window );">Proceeds from sale of assets and businesses, net of costs to sell</a></td>
<td class="nump">669<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_InterestSettlementOnCrossCurrencySwaps', window );">Settlements from cross-currency swaps</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">409<span></span>
</td>
<td class="num">(261)<span></span>
</td>
<td class="num">(419)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows From Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Issuance of long-term debt, net of discounts</a></td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">3,455<span></span>
</td>
<td class="nump">5,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="num">(3,440)<span></span>
</td>
<td class="num">(5,642)<span></span>
</td>
<td class="num">(4,406)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Borrowings of short-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayments of short-term debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of employee withholding taxes related to share-based awards</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payments of acquisition-related contingent consideration</a></td>
<td class="num">(83)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of financing costs</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">10<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(1,513)<span></span>
</td>
<td class="num">(2,294)<span></span>
</td>
<td class="nump">1,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(19)<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in Cash and cash equivalents and Restricted cash and other settlement deposits</a></td>
<td class="nump">303<span></span>
</td>
<td class="num">(1,428)<span></span>
</td>
<td class="nump">2,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits', window );">Cash and cash equivalents and Restricted cash and other settlement deposits, beginning of year</a></td>
<td class="nump">1,816<span></span>
</td>
<td class="nump">3,244<span></span>
</td>
<td class="nump">723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits', window );">Cash and cash equivalents and Restricted cash and other settlement deposits, end of year</a></td>
<td class="nump">2,119<span></span>
</td>
<td class="nump">1,816<span></span>
</td>
<td class="nump">3,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">582<span></span>
</td>
<td class="nump">605<span></span>
</td>
<td class="nump">3,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestrictedCashAndOtherSettlementDepositsCurrent', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">1,537<span></span>
</td>
<td class="nump">1,211<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits', window );">Cash and cash equivalents and Restricted cash and other settlement deposits, end of year</a></td>
<td class="nump">$ 2,119<span></span>
</td>
<td class="nump">$ 1,816<span></span>
</td>
<td class="nump">$ 3,244<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AllowancesForLossesOnAccountsReceivableAndInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AllowancesForLossesOnAccountsReceivableAndInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the cash-flow impact of any change, including any differences arising upon settlement, recognized during the reporting period in the value of an asset or assets, arising from an item of contingent consideration, recognized in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, And Other Settlement Deposits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DeferredIncomeTaxNoncashExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DeferredIncomeTaxNoncashExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DerivativeGainExcludedComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative, Gain, Excluded Component</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DerivativeGainExcludedComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GainLossRelatedToLitigationSettlementGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) Related To Litigation Settlement, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GainLossRelatedToLitigationSettlementGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Impairment Loss, Not Included In Asset Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_InterestSettlementOnCrossCurrencySwaps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Settlement On Cross-Currency Swaps</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_InterestSettlementOnCrossCurrencySwaps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment For Contingent Consideration Liability, Including Accretion, Operating Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestrictedCashAndOtherSettlementDepositsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash And Other Settlement Deposits, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestrictedCashAndOtherSettlementDepositsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the cash inflow during the period from the sale of a component of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373495148968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">DESCRIPTION OF BUSINESS</a></td>
<td class="text">DESCRIPTION OF BUSINESSBausch Health Companies Inc. (the &#8220;Company&#8221;), formerly known as Valeant Pharmaceuticals International, Inc.,  is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (&#8220;OTC&#8221;) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in approximately 100 countries.  Effective August 9, 2013, the Company continued from the federal jurisdiction of Canada to the Province of British Columbia, meaning that the Company became a company registered under the laws of the Province of British Columbia as if it had been incorporated under the laws of the Province of British Columbia. As a result of this continuance, the legal domicile of the Company became the Province of British Columbia, the Canada Business Corporations Act ceased to apply to the Company and the Company became subject to the British Columbia Business Corporations Act.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373488973016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Use of Estimates </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements have been prepared by the Company in United&#160;States (&#8220;U.S.&#8221;) dollars and in accordance with U.S.&#160;generally accepted accounting principles (&#8220;U.S. GAAP&#8221;), applied on a consistent basis. The Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation of the Bausch + Lomb Eye-Health Business and Initial Public Offering of Solta Medical Business</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, the Company announced its intentions to separate its eye-health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc. (the &#8220;B+L Separation&#8221;). On August 3, 2021, the Company announced its intentions to conduct an initial public offering  (&#8220;IPO&#8221;) of its aesthetic medical device business, Global Solta (the &#8220;Solta IPO&#8221;).  In January 2022, the Company completed the internal organizational design and structure of the new eye-health entity, Bausch + Lomb Corporation  (&#8220;Bausch + Lomb&#8221;), and the new Global Solta entity, Solta Medical Corporation  (&#8220;Solta&#8221;), as previously announced and aims to launch the B+L IPO and the Solta IPO when financial market conditions are favorable (and subject to receipt of regulatory, stock exchange and other approvals). Following the B+L IPO the Company expects to complete the separation of Bausch + Lomb after the expiry of customary lockups related to the B+L IPO and achievement of targeted debt leverage ratios, subject to the receipt of applicable shareholder and other necessary approvals. The B+L Separation and the proposed Solta IPO will establish three separate companies that include: (i) a fully integrated eye-health company which will consist of the Company&#8217;s Bausch + Lomb Global Vision Care, Global Surgical, Global Consumer and Global Ophthalmic Pharmaceuticals businesses, (ii) a global provider of aesthetic medical devices which will consist of the Company&#8217;s Solta business and (iii) a diversified pharmaceutical company which will include the Company&#8217;s Salix, International (formerly International Rx), dentistry, neurology, medical dermatology and generics pharmaceutical businesses. These audited Consolidated Financial Statements do not include any adjustments to give effect to either the B+L Separation or the proposed Solta IPO.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impacts of COVID-19 Pandemic</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unprecedented nature of the COVID-19 pandemic has, and continues to, adversely impact the global economy. The COVID-19 pandemic and the reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have had significant direct and indirect effects on businesses and commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facility closures and production suspensions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which these events may continue to impact the Company's business, financial condition, cash flows and results of operations, in particular, will depend on future developments which are highly uncertain and many of which are outside the Company's control. Such developments include the availability and effectiveness of vaccines for the COVID-19 virus, COVID-19 vaccine immunization rates, the ultimate geographic spread and duration of the pandemic, the extent and duration of a resurgence of the COVID-19 virus and variant strains thereof, such as the delta and omicron variants, new information concerning the severity of the COVID-19 virus, the effectiveness and intensity of measures to contain the COVID-19 virus and the economic impact of the pandemic and the reactions to it. Such developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company's business, financial condition, cash flows and results of operations. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has been able to continue its operations with limited disruptions in supply and manufacturing. Although it is difficult to predict the broad macroeconomic effects that the COVID-19 pandemic will have on industries or individual companies, the Company has assessed the possible effects and outcomes of the pandemic on, among other things, its supply chain, customers and distributors, discounts and rebates, employee base, product sustainability, research and development efforts, product pipeline and consumer demand and currently believes that its estimates are reasonable. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the Company's Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows.  The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include: provisions for product returns, rebates, chargebacks, discounts and allowances and distribution fees paid to certain wholesalers; useful lives of amortizable intangible assets and property, plant and equipment; expected future cash flows used in evaluating intangible assets for impairment, assessing compliance with debt covenants and making going concern assessments; reporting unit fair values for testing goodwill for impairment and allocating goodwill to new reporting unit structure on a relative fair value basis; provisions for loss contingencies; provisions for income taxes, uncertain tax positions and realizability of deferred tax assets; fair value of cross-currency swaps; fair value of foreign currency exchange contracts; and the recognition of the fair value of assets and liabilities acquired in a business combination, including the fair value of contingent consideration. Under certain product manufacturing and supply agreements, management uses information from the Company&#8217;s commercialization counterparties to arrive at estimates for future returns, rebates and chargebacks. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#8217;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#8217;s Consolidated Financial Statements could be materially impacted.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2022, the Company operates in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International, (iv) Solta Medical and (v) Diversified Products. Prior to the first quarter of 2022, the Company operated in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International, (iv) Ortho Dermatologics and (v) Diversified Products. All segment revenues and profits for the periods presented have been recast to conform to the 2022 segment reporting structure. See Note 22, &#8220;SEGMENT INFORMATION&#8221; for additional information.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Consolidated Financial Statements after the date of acquisition.  Acquired in-process research and development (&#8220;IPR&amp;D&#8221;) is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&amp;D has an alternative future use. If the acquired net assets do not constitute a business, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&amp;D with no alternative future use is charged to expense at the acquisition&#160;date and any future contingent consideration is not recorded until it becomes probable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair values of cash and cash equivalents, trade receivables, accounts payable and accrued liabilities approximate their carrying values due to their short maturity periods. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows or Monte Carlo Simulation (when appropriate) analyses and assessment of the probability of occurrence of potential future events. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Derivative Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting for changes in the fair value of a derivative instrument depends on whether the instrument has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Consolidated Statements of Operations during the current period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cross-currency swaps qualified for and had been designated as an accounting hedge of the foreign currency exposure of a net investment in a foreign operation and were remeasured at each reporting date to reflect changes in their fair values.  The fair value was determined via a mark-to-market analysis, using observable (Level&#160;2) inputs. These inputs included: (i)&#160;the foreign currency exchange spot rate between the euro and U.S. dollar, (ii)&#160;the interest rate yield curves in the euro and U.S. dollar and (iii)&#160;the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps is reported as a gain or loss in the Consolidated Statements of Comprehensive Loss as part of Foreign currency translation adjustment to the extent they are effective, and remain in Accumulated other comprehensive loss until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps was ineffective. The Company uses the spot method of assessing hedge effectiveness. The Company had elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as a reduction of Interest expense in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses foreign currency exchange contracts to economically hedge the foreign exchange exposure on certain of the Company&#8217;s intercompany and third party balances. The Company's foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash in bank accounts and highly liquid investments with maturities of three months or less when&#160;purchased.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables, cross-currency swaps and foreign currency exchange contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests its excess cash in high-quality, money market instruments and term deposits with varying maturities, but typically less than three months.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash deposited at banks may exceed the amount of insurance provided on such deposits. Generally, these cash deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate such risks by spreading its risk across multiple counterparties and monitoring the risk profiles of these counterparties.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s trade receivables primarily represent amounts due from wholesale distributors, retail pharmacies, government entities and group purchasing organizations. Outside of the U.S., concentrations of credit risk with respect to trade receivables, which are typically unsecured, are limited due to the number of customers using the Company&#8217;s products, as well as their dispersion across many different geographic regions. The Company performs periodic credit evaluations of customers and does not require collateral. The Company monitors economic conditions, including volatility associated with international economies, and related impacts on the relevant financial markets and its business, especially in light of sovereign credit issues. The credit and economic conditions within Argentina, Brazil, Egypt, Greece, among other members of the European Union, Turkey, Ukraine and Venezuela have been weak in recent years. These conditions have increased, and may continue to increase, the average length of time that it takes to collect on the Company&#8217;s trade receivables outstanding in these countries. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company&#8217;s three largest U.S. wholesaler customers accounted for approximately 44% of net trade receivables. In addition, as of December 31, 2021 and 2020, the Company&#8217;s net trade receivable balance from Argentina, Brazil, Egypt, Greece, Serbia, South Africa, Turkey, Ukraine, Venezuela and Vietnam amounted to $78 million and $166&#160;million, respectively, the majority of which is current or less than 90 days past due. The portion of the net trade receivable from these countries that is past due more than 90&#160;days amounted to $2 million, as of December 31, 2021, a portion of which is comprised of public hospitals.  Based on an analysis of credit risk, including an analysis of bad debt </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">experience and assessment of historical payment patterns for such customers, the Company has established a reserve covering more than half of the balance past due more than 90 days for such countries. Over the three-year period ended December&#160;31, 2021, the Company has not experienced any material losses from uncollectible accounts in excess of the established reserves.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not enter into financial instruments for trading or speculative purposes. Further, the Company has a policy of only entering into contracts with parties that have at least an investment grade credit rating. The Company enters into cross-currency swaps and foreign currency exchange contracts with high credit quality financial institutions. The counter-parties to the Company's cross-currency swaps and foreign currency exchange contracts are major financial institutions, and there is no significant concentration of exposure with any one counter-party. To date, no counterparty has failed to meet its obligations to the Company and management believes the risk of loss associated with these contracts is remote.  See Note 5, &#8220;FAIR VALUE MEASUREMENTS&#8221; for additional details regarding the Company's cross-currency swaps and foreign currency exchange contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allowance for Credit Losses</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.&#160; Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be&#160;collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses. Allowance for credit losses were $35 million, $39 million and $48&#160;million as of December 31, 2021, 2020 and 2019, respectively. The activity in the allowance for credit losses for trade receivables for the years 2021, 2020 and 2019 is as follows.</span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.199%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.965%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retrospective effect of application of new accounting standard</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoveries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories comprise raw materials, work in process and finished goods, which are valued at the lower of cost or net realizable value, on a first-in, first-out basis. The cost value for work in process and finished goods inventories includes materials, direct labor and an allocation of overheads. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on&#160;hand.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are reported at cost, less accumulated depreciation. Costs incurred on assets under construction are capitalized as construction in progress. Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful&#160;lives: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:54.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 30 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 40 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;-&#160;20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;-&#160;10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment on operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of term of lease or 10 years</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reported at cost, less accumulated amortization and impairments. Intangible assets with finite lives are amortized over their estimated useful lives. Amortization is calculated primarily using the straight-line method based on the following estimated useful&#160;lives:</span></div><div style="margin-top:5pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:54.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - 20 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 - 20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 - 15 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 - 9 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Out-licensed technology and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 - 9 years</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Divestitures of Products</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds on the divestiture of products and the carrying amount of the related assets is recorded as a gain/loss on sale within Other expense, net. Any contingent payments that are potentially due to the Company as a result of these divestitures are recorded when realizable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IPR&amp;D </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of IPR&amp;D acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset will be assigned a useful life and&#160;amortized. Acquired IPR&amp;D assets are tested for impairment at least annually or when triggering events are identified.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of an acquired IPR&amp;D intangible asset is typically determined using an income approach. This approach starts with a forecast of the net cash flows expected to be generated by the asset over its estimated useful life. The net cash flows reflect the asset&#8217;s stage of completion, the probability of technical success, the projected costs to complete, expected market competition and an assessment of the asset&#8217;s life-cycle. The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the expected cash flow&#160;streams.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.  If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset, which include the amount and timing of the projected future cash flows. If the expected undiscounted cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash&#160;flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets, which includes acquired IPR&amp;D and the corporate trademark acquired in the acquisition of Bausch &amp; Lomb Holdings Incorporated (the &#8216;&#8216;B&amp;L Trademark&#8217;&#8217;), are tested for impairment annually or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based on a comparison of the fair value of the asset to its carrying value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is recorded with the acquisition of a business and is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment at least annually as of October 1st at the reporting unit level. Goodwill impairment is measured as the amount by which a reporting unit's carrying value exceeds its fair value. A reporting unit is the same as, or one level below, an operating segment. A</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n entity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is permitted to first assess qualitatively whether it is necessary to perform a quantitative impairment test for any of its reporting units. The quantitative impairment test is required only when the Company concludes that it is more likely than not that a reporting unit&#8217;s fair value is less than its carrying amount. In evaluating whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company considers the totality of all relevant events or circumstances that affect the fair value or carrying amount of a reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An interim goodwill impairment test in advance of the annual impairment assessment may be required if events occur that indicate an impairment might be present. For example, a substantial decline in the Company&#8217;s market capitalization, changes in reportable segments, unexpected adverse business conditions, economic factors and unanticipated competitive activities may signal that an interim impairment test is needed. Accordingly, among other factors, the Company monitors </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">changes in its share price between annual impairment tests. The Company considers a decline in its share price that corresponds to an overall deterioration in stock market conditions to be less of an indicator of goodwill impairment than a unilateral decline in its share price reflecting adverse changes in its underlying operating performance, cash flows, financial condition and/or liquidity. In the event that the Company&#8217;s market capitalization does decline below its book value, the Company would consider the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. The Company believes that short-term fluctuations in share prices may not necessarily reflect underlying values.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt discounts, premiums and issuance costs are presented in the Consolidated Balance Sheets as a direct deduction from or addition to the carrying amount of the related debt and are amortized or accreted, using the effective interest method, as interest expense over the contractual lives of the related credit facilities or notes. Deferred financing costs associated with revolving credit facility arrangements are included in the balances of Prepaid expenses and other current assets and Other non-current assets in the Consolidated Balance Sheets and are amortized as interest expense over the contractual life of the related revolving credit facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities of the Company&#8217;s foreign operations having a functional currency other than the U.S.&#160;dollar are translated into U.S.&#160;dollars at the exchange rate prevailing at the balance sheet date, and at the average exchange rate for the reporting period for revenue and expense accounts. The cumulative foreign currency translation adjustment is recorded as a component of Accumulated other comprehensive loss in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange gains and losses on transactions occurring in a currency other than an operation&#8217;s functional currency are recognized as a component of Foreign exchange and other in the Consolidated Statements of Operations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are primarily generated from product sales, primarily in the therapeutic areas of eye-health, gastroenterology  (&#8220;GI&#8221;) and dermatology that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 22, &#8220;SEGMENT INFORMATION&#8221; for the disaggregation of revenues which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when the customer obtains control of promised goods or services and in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services.  To achieve this core principle, the Company applies the five-step revenue model to contracts within its scope: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract with the Company&#8217;s customers exists for each product sale.  Where a contract with a customer contains more than one performance obligation, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The transaction price is adjusted for variable consideration which is discussed below.  The Company generally recognizes revenue for product sales at a point in time, when the customer obtains control of the products.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160; The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers.  Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.&#160;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the activity and ending balances of the Company&#8217;s variable consideration provisions the years 2021 and 2020.</span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:28.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.881%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, January 1, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,050&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(613)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,322)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,273)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(593)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,297)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,013)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,378)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,863&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $36 million and $32 million as of December 31, 2021 and 2020, respectively, which are reflected as a reduction of Trade accounts receivable, net in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company's products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis.  This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#8217;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period.  The Company applies this method consistently for contracts with similar characteristics.  The following describes the major sources of variable consideration in the Company&#8217;s customer arrangements and the methodology, estimates and judgments applied to estimate each type of variable consideration.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Discounts and Allowances</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash discounts are offered for prompt payment and allowances for volume purchases. Provisions for cash discounts and allowances are estimated at the time of sale and recorded as direct reductions to trade receivables and revenue. Management estimates the provisions for cash discounts and allowances based on contractual sales terms with customers, an analysis of unpaid invoices and historical payment experience. Estimated cash discounts and allowances have historically been predictable and less subjective, due to the limited number of assumptions involved, the consistency of historical experience and the fact that these amounts are generally settled within one month of incurring the&#160;liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Returns</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, customers are generally allowed to return a product within a specified period of time before and after its expiration date, excluding European businesses which generally do not provide a right of return. The returns provision is estimated utilizing historical sales and return rates over the period during which customers have a right of return, taking into account available information on competitive products and contract changes. The information utilized to estimate the returns provision includes: (i) historical return and exchange levels, (ii) external data with respect to inventory levels in the wholesale distribution channel, (iii) external data with respect to prescription demand for products, (iv) remaining shelf lives of products at the date of sale and (v) estimated returns liability to be processed by year of sale based on an analysis of lot information related to actual historical returns.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the estimate for returns, management is required to make certain assumptions regarding the timing of the introduction of new products and the potential of these products to capture market share. In addition, certain assumptions with respect to the extent and pattern of decline associated with generic competition are necessary. These assumptions are formulated using market data for similar products, past experience and other available information.  These assumptions are continually reassessed, and changes to the estimates and assumptions are made as new information becomes available. A change of 1% in the estimated return rates would have impacted the Company&#8217;s pre-tax earnings by approximately $81 million for the year 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimate for returns may be impacted by a number of factors, but the principal factor relates to the inventory levels in the distribution channel. When management becomes aware of an increase in such inventory levels, it considers whether the increase may be temporary or other-than-temporary. Temporary increases in wholesaler inventory levels will not warrant revision to the provision for returns. Other-than-temporary increases in wholesaler inventory levels, however, may be an indication that future product returns could be higher than originally anticipated, and, as a result, estimates for returns may need to be adjusted. Factors that suggest increases in wholesaler inventory levels are temporary include: (i) recently implemented or announced price increases for certain products, (ii) new product launches or expanded indications for existing products and (iii) timing of purchases by wholesale customers. Conversely, factors that suggest increases in wholesaler inventory levels are other-than-temporary include: (i) declining sales trends based on prescription demand, (ii) introduction of new products or generic competition, (iii) increasing price competition from generic competitors and (iv) changes to the U.S.&#160;National Drug Codes (&#8220;NDC&#8221;) of products.  Changes in the NDC of products could result in a period of higher returns related to products with the old NDC, as U.S.&#160;customers generally permit only one NDC per product for identification and tracking within their inventory systems.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the last several years, the Company increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving sales return experience, primarily related to branded and generic products. Sales return provisions for 2021 and 2020 were $131&#160;million and $120&#160;million, respectively, and includes reductions in variable consideration for sales return provisions related to past sales of approximately $28 million and $38 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates and Chargebacks</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales made under governmental and managed-care pricing programs in the U.S. are subject to rebates.&#160; The Company participates in state government-managed Medicaid programs, as well as certain other qualifying federal and state government programs whereby rebates are provided to participating government entities. Medicaid rebates are generally billed 45 days to 270&#160;days after the quarter in which the product is dispensed to the Medicaid participant.  As a result, the Medicaid rebate reserve includes an estimate of outstanding claims for end-customer sales that occurred, but for which the related claim has not been billed and/or paid, and an estimate for future claims that will be made when inventory in the distribution channel is sold through to plan participants. The calculation of the Medicaid rebate reserve also requires other estimates, such as estimates of sales mix, to determine which sales are subject to rebates and the amount of such rebates. A change of 1% in the estimated rates used in the Medicaid rebate reserve would have impacted the Company&#8217;s pre-tax earnings by approximately $76 million for 2021. Quarterly, the Medicaid rebate reserve is adjusted based on actual claims paid. Due to the delay in billing, adjustments to actual claims paid may incorporate revisions of that reserve for several periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed Care rebates relate to contractual agreements to sell products to managed care organizations and pharmacy benefit managers at contractual rebate percentages in exchange for volume and/or market&#160;share.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks relate to contractual agreements to sell products to government agencies, group purchasing organizations and other indirect customers at contractual prices that are lower than the list prices the Company charges wholesalers. When these group purchasing organizations or other indirect customers purchase products through wholesalers at these reduced prices, the wholesaler charges the Company for the difference between the prices they paid the Company and the prices at which they sold the products to the indirect customers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In estimating provisions for rebates and chargebacks, management considers relevant statutes with respect to governmental pricing programs and contractual sales terms with managed-care providers and group purchasing organizations. Management estimates the amount of product sales subject to these programs based on historical utilization levels. Changes in the level of utilization of products through private or public benefit plans and group purchasing organizations will affect the amount of rebates and chargebacks that the Company is obligated to pay. Management continually updates these factors based on new contractual or statutory requirements, and any significant changes in sales trends that may impact the percentage of products subject to rebates or&#160;chargebacks.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of Managed Care, Medicaid and other rebates and chargebacks has become more significant as a result of a combination of deeper discounts implemented in each of the last three years, changes in the Company&#8217;s product portfolio due to recent acquisitions and increased Medicaid utilization due to expansion of government funding for these programs.&#160;Management&#8217;s estimate for rebates and chargebacks may be impacted by a number of factors, but the principal factor relates to the level of inventory in the distribution channel.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebate provisions are based on factors such as timing and terms of plans under contract, time to process rebates, product pricing, sales volumes, amount of inventory in the distribution channel and prescription trends. Adjustments to actual for the years 2021 and 2020 were not material to the Company&#8217;s revenues or earnings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient Co-Pay Assistance programs, Consumer Rebates and Loyalty Programs are rebates offered on many of the Company&#8217;s products.  Patient Co-Pay Assistance Programs are patient discount programs offered in the form of coupon cards or point of sale discounts, with which patients receive certain discounts off their prescription at participating pharmacies, as defined by the specific product program. An accrual for these programs is established, equal to management&#8217;s estimate of the discount, rebate and loyalty incentives attributable to a sale.  That estimate is based on historical experience and other relevant factors. The accrual is adjusted throughout each quarter based on actual experience and changes in other factors, if any.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution Fees</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells products primarily to wholesalers, and in some instances to large pharmacy chains such as CVS and Walmart.  The Company has Distribution Services Agreements  (&#8220;DSAs&#8221;) with several large wholesale customers such as McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Specialty.  Under the DSAs, the wholesalers agree to provide services, and the Company pays the contracted DSA distribution service fees for these services based on product volumes.  Additionally, price appreciation credits are generated when the Company increases a product&#8217;s wholesaler acquisition cost (&#8220;WAC&#8221;) under contracts with certain wholesalers. Under such contracts, the Company is entitled to credits from such wholesalers for the impact of that WAC increase on inventory currently on hand at the wholesalers. Such credits are offset against the total distribution service fees paid to each such wholesaler. The variable consideration associated with price appreciation credits is reflected in the transaction price of products sold when it is determined to be probable that a significant reversal will not occur. Included as a reduction of current period provisions for Distribution Fees in the table above are price appreciation credits of $17 million and $15 million for the years 2021 and 2020, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Assets and Contract Liabilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Commissions </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales commissions are generally attributed to periods shorter than one year and therefore are expensed when incurred. Sales commissions are included in selling, general and administrative expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Component</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected not to adjust consideration for the effects of a significant financing component when the period between the transfer of a promised good or service to the customer and when the customer pays for that good or service will be one year or less. The Company's global payment terms are generally between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzM5OTI3_716494a0-facf-44b6-8b49-d8fd0a7992d6">thirty</span> to ninety days.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain facilities, vehicles and equipment principally under multi-year agreements generally having a lease term of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzQwMDc5_7eac39f6-be77-4d3e-9e6c-f409097e05ab">one</span> to twenty years, some of which include termination options and options to extend the lease term from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzQwMTcz_d3eef5e1-5571-4a30-b1f7-7d9902542a6b">one</span> to five years or on a month-to-month basis. The Company includes options that are reasonably certain to be exercised as part of the lease term. The Company may negotiate termination clauses in anticipation of changes in market conditions but generally, these termination options are not exercised. Certain lease agreements also include variable payments that are dependent on usage or may vary month-to-month such as insurance, taxes and maintenance costs. None of the Company's lease agreements contain material residual value guarantees or material restrictive covenants.</span></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to record a right-of-use asset and corresponding lease liability, equal to the present value of the lease payments at the commencement date of each lease. For all asset classes, in determining future lease payments, the Company has elected to aggregate lease components, such as payments for rent, taxes and insurance costs with non-lease components such as maintenance costs, and account for these payments as a single lease component. In limited </span></div><div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">circumstances, when the information necessary to determine the rate implicit in a lease is available, the present value of the lease payments is determined using the rate implicit in that lease. If the information necessary to determine the rate implicit in a lease is not available, the Company uses its incremental borrowing rate at the commencement of the lease, which represents the rate of interest that the Company would incur to borrow on a collateralized basis over a similar term.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All leases must be classified as either an operating lease or finance lease. The classification is determined based on whether substantive control has been transferred to the lessee.  The classification governs the pattern of lease expense recognition. For leases classified as operating leases, total lease expense over the term of the lease is equal to the undiscounted payments due in accordance with the lease arrangement. Fixed lease expense is recognized periodically on a straight-line basis over the term of each lease and includes: (i) imputed interest during the period on the lease liability determined using the effective interest rate method plus (ii) amortization of the right-of-use asset for that period. Amortization of the right-of-use asset during the period is calculated as the difference between the straight-line expense and the imputed interest on the lease liability for that period. Variable lease expense is recognized when the achievement of the specific target is considered probable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to internal research and development programs, including costs associated with the development of acquired IPR&amp;D, are expensed as goods are delivered or services are performed. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Milestone payments made to third parties before a product receives regulatory approval, but after the milestone is determined to be probable, are expensed and included in Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from third parties as reimbursement of development activities conducted under certain research and development arrangements are recognized as a reduction of Research and development expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Costs </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal fees and other costs related to litigation and other legal proceedings or services are expensed as incurred and are included in Selling, general and administrative expenses. Certain legal costs associated with acquisitions are included in Acquisition-related costs and certain legal costs associated with divestitures, legal settlements and other business development activities are included in Litigation and other matters or Net gain on sales of assets within Other expense (income), net, as appropriate. Legal costs expensed are reported net of expected insurance recoveries. A claim for insurance recovery is recognized when realization becomes probable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advertising costs comprise product samples, print media, promotional materials and television advertising and are expensed on the first use of the advertisement. Included in Selling, general and administrative expenses are advertising costs of $515 million, $451 million and $544 million, for 2021, 2020 and 2019, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Compensation </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes all share-based payments to employees, including grants of employee stock options and restricted share units (&#8220;RSUs&#8221;), at estimated fair value. The Company amortizes the fair value of stock option or RSU grants on a straight-line basis over the requisite service period of the individual stock option or RSU grant, which generally equals the vesting period. Stock option and RSU forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Share-based compensation is recorded in Research and development expenses and Selling, general and administrative expenses, as&#160;appropriate. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition-Related Contingent Consideration </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related contingent consideration, which primarily consists of potential milestone payments and royalty obligations, is recorded in the Consolidated Balance Sheets at its acquisition date estimated fair value, in accordance with the acquisition method of accounting. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the Consolidated Statements of Operations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level&#160;3 measurement as defined in fair value measurement accounting.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense includes standby fees, the amortization of debt discounts and deferred financing costs, accretion of debt premiums and the amortization of amounts excluded from the assessment of effectiveness related to the Company's cross-currency swaps. Interest costs are expensed as incurred, except to the extent such interest is related to construction in progress, in which case interest is capitalized. Capitalized interest related to construction in progress as of December 31, 2021 and 2020 was $60 million and $45&#160;million, respectively, and is included in Property, plant and equipment, net. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the temporary differences between the financial statement and income tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. A valuation allowance is provided for the portion of deferred tax assets that is more likely than not to remain unrealized. Deferred tax assets and liabilities are measured using enacted tax rates and&#160;laws.  Deferred tax assets for outside basis differences in investments in subsidiaries are only recognized if the difference will be realized in the foreseeable future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax benefit from an uncertain tax position is recognized only if it is more likely than not that the tax position will be sustained upon examination by the appropriate taxing authority, based on the technical merits of the position. The tax benefits recognized from such position are measured based on the amount for which there is a greater than 50% likelihood of being realized upon settlement. Liabilities associated with uncertain tax positions are classified as long-term unless expected to be paid within one year. Interest and penalties related to uncertain tax positions, if any, are recorded in the provision for income taxes and classified with the related liability on the consolidated balance&#160;sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Per Share Attributable to Bausch Health Companies Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period. Diluted loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period after giving effect to dilutive potential common shares for stock options and RSUs, determined using the treasury stock&#160;method.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss comprises Net loss and Other comprehensive (loss) income. Other comprehensive (loss) income includes items such as foreign currency translation adjustments, unrealized holding gains and losses on available-for-sale and other investments and certain pension and other postretirement benefit plan adjustments. Accumulated other comprehensive loss is recorded as a component of shareholders&#8217; equity.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is subject to loss contingencies, such as claims and assessments arising from litigation and other legal proceedings, contractual indemnities, product and environmental liabilities and tax matters. Accruals for loss contingencies are recorded when the Company determines that it is both probable that a liability has been incurred and the amount of loss can be reasonably estimated. If the estimate of the amount of the loss is a range and some amount within the range appears to be a better estimate than any other amount within the range, that amount is accrued as a liability. If no amount within the range is a better estimate than any other amount, the minimum amount of the range is accrued as a&#160;liability. These accruals are adjusted periodically as assessments change or additional information becomes available.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If no accrual is made for a loss contingency because the amount of loss cannot be reasonably estimated, the Company will disclose contingent liabilities when there is at least a reasonable possibility that a loss or an additional loss may have been incurred. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Benefit Plans </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors various retirement and pension plans, including defined benefit pension plans, defined contribution plans and a participatory defined benefit postretirement plan. The determination of defined benefit pension and postretirement plan obligations and their associated expenses requires the use of actuarial valuations to estimate the benefits employees earn while working, as well as the present value of those benefits. Net actuarial gains and losses that exceed 10 percent of the greater of the plan&#8217;s projected benefit obligations or the market-related value of assets are amortized to earnings over the shorter of the estimated average future service period of the plan participants (or the </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimated average future lifetime of the plan participants if the majority of plan participants are inactive) or the period until any anticipated final plan settlements. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New&#160;Accounting Standards</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board  (&#8220;FASB&#8221;) issued guidance on the impairment of financial instruments requiring an impairment model based on expected losses rather than incurred losses. Under this guidance, an entity recognizes as an allowance its estimate of expected credit losses.  The guidance was effective for the Company beginning January 1, 2020 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit, which resulted in an increase to Accumulated deficit of less than $1&#160;million. The application of this guidance did not have a material effect on the Company's results of operations and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued guidance modifying the disclosure requirements for fair value measurement.  The guidance was effective for the Company beginning January 1, 2020. The application of this guidance did not have a material effect on the Company's disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued guidance modifying the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans.  The guidance was effective for annual periods ending after December 15, 2020. The application of this guidance did not have a material effect on the Company's disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.&#160; The guidance is effective for the Company beginning with annual periods beginning January 1, 2021.&#160; The application of this guidance did not have a material effect on the Company's financial position, results of operations and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued guidance providing optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform.&#160; Optional expedients are provided for contract modification accounting within the areas of receivables, debt, leases, derivatives and hedging.&#160;The optional amendments are effective for all entities as of March 12, 2020, through December 31, 2022. During 2020 and 2021, the Company has not entered into any contract modifications in which the optional expedients were applied.&#160; However, if prior to December 31, 2022, the Company enters into a contract modification in which the optional expedients are applied, the Company will evaluate the impact of adoption of this guidance on its financial position, results of operations and cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373495155112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock', window );">ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE</a></td>
<td class="text">ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition Agreement for Synergy Pharmaceuticals Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 6, 2019, the Company acquired certain assets of Synergy Pharmaceuticals Inc.  (&#8220;Synergy&#8221;) for a cash purchase price of approximately $180 million and the assumption of certain liabilities, pursuant to the terms approved by the U.S. Bankruptcy Court for the Southern District of New York on March 1, 2019. Among the assets acquired are the worldwide rights to the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) product, a once-daily tablet for adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. This acquired business is included in the Company's Salix segment and is expected to result in additional revenues and costs savings associated with business synergies.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets Acquired and Liabilities Assumed</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of certain assets of Synergy has been accounted for as a business combination under the acquisition method of accounting since: (i) substantially all of the fair value of the assets acquired is not&#160;concentrated in a single identifiable asset or group of similar identifiable assets and (ii) substantive inputs and processes were acquired to contribute to the creation of outputs. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed related to the acquisition of certain assets of Synergy as of the acquisition date:</span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:89.795%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.005%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product brand intangible assets (estimated useful life 7 years)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of consideration transferred</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill associated with the acquisition of certain assets of Synergy is not deductible for income tax purposes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue and Operating Results </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues associated with the acquired assets of Synergy during the period March 6, 2019 through December 31, 2019 were $55 million. Operating results associated with the acquired assets of Synergy during the period March 6, 2019 through December 31, 2019 and pro-forma revenues and operating results for the year 2019 were not material. Included in Other expense, net for 2019 are acquisition-related costs of $8 million directly related to the acquisition of certain assets of Synergy, which include expenditures for advisory, legal, valuation, accounting and other similar services.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other material business combinations in 2021, 2020 or 2019. The measurement period for all acquisitions has closed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Option to Purchase All Ophthalmology Assets of Allegro Ophthalmics, LLC  (&#8220;Allegro&#8221;)</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 21, 2020, the Company announced that it had entered into an agreement to acquire an option to purchase all of the ophthalmology assets of Allegro (the &#8220;Option&#8221;), a privately held biopharmaceutical company focused on the development of therapies that regulate integrin functions for the treatment of ocular diseases. Among the assets to be acquired if the Option was exercised, were the worldwide rights to risuteganib (Luminate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), Allegro's lead investigational compound in retina, which is believed to simultaneously act on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases such as intermediate dry Age-related Macular Degeneration.  During the three months ended September 30, 2020, the Company made and expensed as acquired IPR&amp;D included in Other expense, net, an initial upfront payment of $10&#160;million to acquire the Option.  However, on June 23, 2021, Allegro notified the Company that it did not raise the additional funding required under the option agreement.  Pursuant to the terms of the option agreement, the Option thereby terminated, and the Company exercised its right to convert the $10&#160;million upfront payment into a minor equity interest in Allegro.  The Company expects that it will make no additional payments pursuant to this option agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Licensing Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products. These products are sometimes investigational treatments in early stage development that target unique conditions.  The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by regulatory agencies, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain.  The commitment periods under these agreements vary and include customary termination provisions.  Expenses arising from commitments, if any, to fund the development and testing of these products and their promotion are recognized as incurred. Royalties due are recognized when earned and milestone payments are accrued when each milestone has been achieved and payment is probable and can be reasonably estimated.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestiture of Amoun Pharmaceutical Company S.A.E.  (&#8220;Amoun&#8221;)</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2021, the Company announced that it and certain of its affiliates had entered into a definitive agreement to sell all of its equity interests in Amoun for total gross consideration of approximately $740&#160;million (including the assignment to the purchasing entity of an intercompany loan granted by the Company to Amoun), subject to certain adjustments (the &#8220;Amoun Sale&#8221;). The Amoun Sale closed on July 26, 2021. As part of the Amoun Sale, cash generated by Amoun during the period from the locked-box date of January 1, 2021 through closing was for the benefit of the purchasing entity, subject to working capital during such period. Amoun manufactures, markets and distributes branded generics of human and animal health products. The Amoun business was part of the International segment (previously </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included within the former Bausch + Lomb/International segment) and was reclassified as held for sale as of December 31, 2020. As a result of meeting the criteria for held for sale classification, the carrying value of the Amoun business, was adjusted to its estimated fair value, less costs to sell, and the Company recognized an impairment loss of $96&#160;million during the three months ended December 31, 2020 and an additional impairment loss of $88&#160;million during 2021, included within Asset impairments, including loss on assets held for sale in the Consolidated Statements of Operations. In connection with completing the Amoun Sale, the Company recognized an additional loss of $26&#160;million during 2021, included within Other (income) expense, net in the Combined Statements of Operations. The total loss of $210&#160;million includes the release of non-cash cumulative foreign currency translation losses of $340&#160;million, which were included as part of the carrying value of the Amoun business when measuring for impairment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the Consolidated Balance Sheets as of December 31, 2020 are the following carrying amounts of the Amoun business' assets and liabilities held for sale.</span></div><div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:38.353%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.353%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.009%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373489999320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</a></td>
<td class="text">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and integration costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The liability associated with restructuring and integration costs as of December 31, 2021 was $19 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $18&#160;million, $11&#160;million and $31&#160;million of restructuring and integration-related costs and made payments of $19&#160;million, $18&#160;million and $31 million during 2021, 2020 and 2019, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation costs, Separation-related costs, IPO Costs and IPO-related Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred, and will incur, costs associated with activities to effectuate the B+L Separation and the Solta IPO. These activities include: (i) separating the Bausch + Lomb and Solta Medical businesses from the remainder of the Company and (ii) registering the Bausch + Lomb and Solta Medical businesses as independent publicly traded entities. Separation and IPO costs are incremental costs directly related to the B+L Separation and Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing a new board of directors and related board committees for the Bausch + Lomb and Solta Medical entities. Included in Restructuring, integration, separation and IPO costs for the years ended December 31, 2021 and 2020 are Separation and IPO costs of $32&#160;million and $11&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also incurred, and will incur, Separation-related and IPO-related costs which are incremental costs indirectly related to the B+L Separation and Solta IPO. Separation-related and IPO-related costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. Included in Selling, general and administrative for years ended December 31, 2021 and 2020 are Separation-related and IPO-related costs of $132&#160;million and $21&#160;million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent and timing of future charges for these costs cannot be reasonably estimated at this time and could be material.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373495357416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are estimated based on valuation techniques and inputs categorized as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;1&#160;&#8212;&#160;Quoted prices in active markets for identical assets or liabilities;</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;2&#160;&#8212;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;&#160;and </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level&#160;3&#160;&#8212;&#160;Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or&#160;estimation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the&#160;instrument.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis as of: </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:26.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.201%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash and other settlement deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cross-currency swaps</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments, primarily money market funds, with maturities of three months or less when&#160;purchased, and are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, Restricted cash and other settlement deposits includes $1,510&#160;million of payments into escrow funds under the terms of settlement agreements regarding that certain U.S. securities litigation (subject to an objector's appeal of the final court approval) and the Glumetza Antitrust Litigation. These payments are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature.  These payments will remain in escrow until final approval of the settlements as discussed in Note 20, &#8220;LEGAL PROCEEDINGS&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers into or out of Level 3 during 2021 and 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cross-currency Swaps</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into cross-currency swaps, with aggregate notional amounts of $1,250 million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its consolidated financial statements from adverse movements in exchange rates. The euro-denominated net investment being hedged was the Company&#8217;s investment in certain euro-denominated subsidiaries.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During November 2021, the Company entered into a transaction to unwind its cross-currency swaps and received net proceeds of $4&#160;million, which included interest income of $6&#160;million, offset by the amount owed by the Company upon the unwinding of $2&#160;million. The gain arising from the transaction of the swaps has been included as a component of Other comprehensive loss.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with the Company's cross-currency swaps as included in the Consolidated Balance Sheets as of December 31, 2021 and 2020 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.647%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of hedging instruments on the Consolidated Statements of Operations and Consolidated Statements of Comprehensive Loss for 2021 and 2020: </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.647%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in Other comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain excluded from assessment of hedge effectiveness</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location of gain of excluded component</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2021 and 2020, the Company received $27&#160;million and $23&#160;million, respectively, in settlements of its cross-currency swaps which are reported as Investing activities in the Consolidated Statements of Cash Flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Contracts</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021 and 2020, the Company entered into foreign currency exchange contracts.  As of December&#160;31, 2021, these contracts had an aggregate outstanding notional amount of $166&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with the Company's foreign exchange contracts as included in the Consolidated Balance Sheets as of December 31, 2021 and 2020 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.647%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of the Company's foreign exchange contracts on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for 2021 and 2020:</span></div><div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.647%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) related to changes in fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss related to settlements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition-related Contingent Consideration Obligations</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurement of contingent consideration obligations arising from business combinations is determined via a probability-weighted discounted cash flow analysis, using unobservable (Level&#160;3) inputs. These inputs may include: (i)&#160;the estimated amount and timing of projected cash flows, (ii)&#160;the probability of the achievement of the factor(s) on which the contingency is based and (iii)&#160;the risk-adjusted discount rate used to present value the probability-weighted cash&#160;flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly higher or lower fair value measurement. At December&#160;31, 2021, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from 6% to 18%, and a weighted average risk-adjusted discount rate of 7%. The weighted average risk-adjusted discount rate was calculated by weighting each contract's relative fair value at December&#160;31, 2021.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the years 2021 and 2020:</span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:63.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.981%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning balance, January 1, </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to Acquisition-related contingent consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion for the time value of money</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments / Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment included in other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance, December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a non-recurring basis:</span></div><div style="margin-bottom:8pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:24.277%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current assets held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current assets held for sale of $245&#160;million as of December 31, 2020 were remeasured to estimated fair value, less costs to sell, which utilized Level 3 unobservable inputs. See Note 3, &#8220;ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE&#8221; for additional details regarding these assets held for sale.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Long-term Debt</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of long-term debt as of December&#160;31, 2021 and 2020 was $22,689 million and $25,378 million, respectively, and was estimated using the quoted market prices for the same or similar debt issuances (Level 2).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373495357416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIES<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net, as of December 31, 2021 and 2020 consist of: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,094&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373494957864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY, PLANT AND EQUIPMENT</a></td>
<td class="text">PROPERTY, PLANT AND EQUIPMENT<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of property, plant and equipment as of December 31, 2021 and 2020 consist of: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equipment and leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment on operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,820)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,781)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $177 million, $180 million and $178 million for 2021, 2020 and 2019, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373493019352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS AND GOODWILL</a></td>
<td class="text">INTANGIBLE ASSETS AND GOODWILL<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets as of December&#160;31, 2021 and 2020 consist of:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:27.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.984%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Useful<br/>Lives<br/>(Years)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:36pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization and Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization and Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,914)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(404)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,055)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,481&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,741)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired IPR&amp;D not in service</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B&amp;L Trademark</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,128&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,948&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,186&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,741)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,445&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments, including loss on assets held for sale in the Consolidated Statement of Operations.  The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale in 2021 included: (i) impairments of $105&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines, (ii) an $88&#160;million loss on assets held for sale in connection with the Amoun Sale, (iii) impairments of $23&#160;million, in aggregate, related to the discontinuance of certain product lines and (iv) $18&#160;million related to a portion of an IT infrastructure improvement project no longer being utilized.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale in 2020 included impairments of: (i) $96&#160;million to reduce the carrying value of the Amoun business to its estimated fair value less costs to sell due to classifying the business as held for sale as discussed in Note 3, &#8220;ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE&#8221;, (ii) $16&#160;million in aggregate, due to decreases in forecasted sales of certain product lines, (iii) $1&#160;million in aggregate, related to the discontinuance of certain product lines not aligned with the focus of the Company's core businesses and (iv) $1&#160;million related to Acquired IPR&amp;D not in service.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset impairments, including loss on assets held for sale in 2019 included impairments of: (i) $58 million reflecting decreases in forecasted sales of certain product lines due to generic competition and other factors, (ii) $8 million related to assets being classified as held for sale, (iii) $5 million related to certain product/patent assets associated with the discontinuance of specific product lines not aligned with the focus of the Company's core businesses and (iv) $4 million related to Acquired IPR&amp;D not in service. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impairments to assets reclassified as held for sale were measured as the difference of the carrying value of these assets as compared to the estimated fair values of these assets less costs to sell determined using a discounted cash flow analysis which utilized Level 3 unobservable inputs. The other impairments and adjustments to finite-lived intangible assets were measured as the difference of the historical carrying value of these finite-lived assets as compared to the estimated fair value as determined using a discounted cash flow analysis using Level 3 unobservable inputs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodically, the Company&#8217;s products face the expiration of their patent or regulatory exclusivity. The Company anticipates that product sales for such product would decrease shortly following a loss of exclusivity  (&#8220;LOE&#8221;), due to the possible entry of a generic competitor. Where the Company has the rights, it may elect to launch an authorized generic of such product (either as the Company&#8217;s own branded generic or through a third-party).  This may occur prior to, upon or following generic entry, which may mitigate the anticipated decrease in product sales; however, even with launch of an authorized generic, the decline in product sales of such product could still be significant, and the effect on future revenues could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management continually assesses the useful lives related to the Company's long-lived assets to reflect the most current assumptions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense of finite-lived intangible assets for the five years ending December&#160;31 and thereafter are as&#160;follows: </span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:16.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.881%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill during the years ended December 31, 2021, 2020 and 2019 were as follows: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:31.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.408%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + <br/>Lomb/<br/>International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + <br/>Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, January 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,805&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of certain assets of Synergy </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill reclassified to assets held for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,786&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets held for sale reclassified to goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill reclassified to assets held for sale (Note 3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,704)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(578)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,318&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,457&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized but is tested for impairment at least annually on October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment.  The Company performs its annual impairment test by first assessing qualitative factors. Where the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed for that reporting unit (Step 1). </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair values of a reporting unit using a discounted cash flow model which utilizes Level 3 unobservable inputs. The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The quantitative fair value test is performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit's terminal value. </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To forecast a reporting unit's cash flows the Company takes into consideration economic conditions and trends, estimated future operating results, management's and a market participant's view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts are based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected LOE to the Company's product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company&#8217;s control could have a positive or negative impact on achieving its targets.  Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2019</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Annual Goodwill Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2019 by first assessing qualitative factors. Where the qualitative assessment suggested that it was more likely than not that the fair value of a reporting unit was less than its carrying amount, a quantitative fair value test was performed for that reporting unit. In each quantitative fair value test performed, the fair value was greater than the carrying value of the reporting unit.  As a result, there was no impairment to the goodwill of any reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2020</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The negative impacts of the COVID-19 pandemic on the global economy have led to significant volatility in the global equity markets. The Company has been able to continue its operations with limited disruptions and has assessed the potential impact that the COVID-19 pandemic is likely to have on its forecasted cash flows.  In performing its assessment, the Company considered the possible effects and outcomes of the COVID-19 pandemic on, among other things, its supply chain, customers and distributors, employee base, product sustainability, research and development activities, product pipeline and consumer demand and related rebates and discounts and has made adjustments, although not considered to be material, to its long-term forecasts used in its previous goodwill impairment assessments, for these and other matters. After completing this assessment, although not completely insulated from the negative effects of the COVID-19 pandemic, the Company believes that its long-term forecasted cash flows, as adjusted for the possible outcome of the COVID-19 pandemic and other matters, do not indicate that the fair value of any reporting unit may be below its carrying value. </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2020 revenues were most negatively impacted during its second quarter by certain social restrictions and other precautionary measures taken in response to the COVID-19 pandemic. However, as governments began lifting social restrictions, allowing offices of certain health care providers to reopen and certain surgeries and elective medical procedures to proceed, the negative trend in the revenues of certain businesses began to level off and stabilize prior to the third quarter of 2020. Revenues for 2021 and 2020 were $8,434&#160;million and $8,027&#160;million, respectively. The increase of $407&#160;million in revenue represents an improving trend over the decreases in year-over-year revenues for the three month periods ended June 30, 2020, September 30, 2020 and December 31, 2020 of 23%, 3% and less than 1%, respectively. The Company's revenues returned to pre-pandemic levels for many of its businesses and geographies in 2021 and, presuming there continues to be increased availability of effective vaccines and any further resurgence of the COVID-19 virus, the delta and omicron variants and other variant strains thereof do not have a material adverse impact on efforts to contain the COVID-19 virus, the Company anticipates the COVID-19 pandemic to have a minimal impact on its remaining businesses and geographies in 2022. However, the rates of recovery for each business will vary by geography and will be dependent upon, among other things, the availability and effectiveness of vaccines for the COVID-19 virus, government responses, rates of economic recovery, precautionary measures taken by patients and customers, the rate at which remaining social restrictions are lifted and once lifted, the presumption that social restrictions will not be materially reenacted in the event of a resurgence of the virus and other actions taken in response to the COVID-19 pandemic.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Interim Goodwill Impairment Assessment</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the interim periods of 2020, after giving consideration to the nature and timing of the negative impacts of the COVID-19 pandemic on the Company's forecasted cash flows, with the exception of the Ortho Dermatologics reporting unit, no events occurred, or circumstances changed that would indicate that the fair value of any other reporting unit might be below its carrying value and therefore, no impairments were recorded. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2020 and June 30, 2020, the operating results for the Ortho Dermatologics reporting unit were less than forecasted primarily due to certain products experiencing longer launch cycles than originally anticipated as a result of the COVID-19 pandemic. The Company revised its long-term forecasts as of March 31, 2020 and as of June 30, 2020 for these matters. Management believed that these events were indicators that there was less headroom as of March 31, 2020 and June 30, 2020 as compared to the headroom calculated on the date Ortho Dermatologics goodwill was previously tested for impairment. Therefore, a quantitative fair value test for impairment to the goodwill of the Ortho Dermatologics reporting unit was performed at March 31, 2020 and at June 30, 2020. Based on the quantitative fair value tests, the fair value of the Ortho Dermatologics reporting unit continued to be greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit at March 31, 2020 and at June 30, 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2020 Annual Goodwill Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2020 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2020, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2020, the Company considered, among other matters, a range of potential impacts of COVID-19 pandemic related matters and the limited headroom calculated on the date Ortho Dermatologics goodwill was last tested for impairment (June 30, 2020).  The Company believed that these factors may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2020, utilizing a long-term growth rate of 2.0% and a range of discount rates between 9.50% and 9.75%, in estimation of the fair value of this reporting unit.  Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately 10% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2021</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Quarter 2021 - Realignment of Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2021 through the fourth quarter of 2021, the Company operated in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International, (iv) Ortho Dermatologics and (v) Diversified Products. The Bausch + Lomb segment consists of the: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. The Salix segment consists of the Salix reporting unit. The International segment consists of the International (formerly International RX) reporting unit. The Ortho Dermatologics segment consisted of the: (i) Ortho Dermatologics and (ii) Global Solta reporting units. The Diversified Products segment consists of the: (i) Neurology and Other, (ii) Generics and (iii) Dentistry reporting units. This realignment in segment structure resulted in a change in the Company's former International reporting unit, which is now divided between the International Bausch + Lomb reporting unit and International reporting unit. In addition, as part of this realignment of segment structure, certain products historically included in the Generics reporting unit are now included in the U.S. Bausch + Lomb reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of this realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. Goodwill previously reported in the former International reporting unit was reassigned to the International Bausch + Lomb and International reporting units, and a portion of goodwill previously reported in the former Generics reporting unit was reassigned to the U.S. Bausch + Lomb reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the change in reporting units, the Company performed a qualitative fair value assessment for its former: (i) International and (ii) Generics reporting units. Based on the qualitative fair value assessment performed, management believed that it was more likely than not that the carrying values of its former: (i) International and (ii) </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generics reporting units were less than their respective fair values and therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately following the change in reporting units, as a result of the change in composition of the net assets for its current: (i) International Bausch + Lomb, (ii) International and (iii) Generics reporting units, the Company performed a quantitative fair value test. The quantitative fair value test utilized a range of long-term growth rates of 1.0% to 3.0% and a range of discount rates between 11.0% and 12.25%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than 40%, and, therefore, there was no impairment to goodwill. In addition, as the U.S. Bausch + Lomb reporting unit had a change in composition of its net assets related to certain products historically included in the Generics reporting unit now being included in the U.S. Bausch + Lomb reporting unit, the Company performed a qualitative assessment of this reporting unit. Based on the qualitative fair value assessment performed, management believed that it was more likely than not that the carrying value of its current U.S. Bausch + Lomb reporting unit was less than its fair value and therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">March 31, 2021 Impairment to Goodwill </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, management identified launches of certain Ortho Dermatologics products which were not going to achieve their trajectories as forecasted once the social restrictions associated with the COVID-19 pandemic began to ease in the U.S. and offices of health care professionals could reopen. In addition, insurance coverage pressures within the U.S. continued to persist limiting patient access to topical acne and psoriasis products.  In light of these developments, during the first quarter of 2021, the Company began taking steps to: (i) redirect its R&amp;D spend to eliminate projects it has identified as high cost and high risk, (ii) redirect a portion of its marketing and product development outside the U.S. to geographies where there is better patient access and (iii) reduce its cost structure to be more competitive. As a result, during the three months ended March 31, 2021, the Company revised its long-term forecasts for the Ortho Dermatologics reporting unit. Management believed that these events were indicators that there is less headroom as of March 31, 2021 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2020). Therefore, a quantitative fair value test for the Ortho Dermatologics reporting unit was performed. The quantitative fair value test utilized the Company's most recent cash flow projections as revised in the first quarter of 2021 to reflect the business changes previously discussed, including a range of potential outcomes, along with a long-term growth rate of 1.0% and a range of discount rates between 9.0% and 10.0%. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at March 31, 2021, and the Company recognized a goodwill impairment of $469&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Second Quarter 2021 - Realignment of Bausch + Lomb Reporting Units</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the second quarter of 2021, the Company changed the way it reviews the financial information of its Bausch + Lomb segment.  Beginning in the second quarter of 2021, management no longer reviews the financial information of its Bausch + Lomb segment on a geographic basis, but instead reviews this financial information on a business line basis.  This change created a change in the reporting units of the Bausch + Lomb segment. After the change, under its business line view, the Bausch + Lomb segment consists of the global: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units. Prior to the second quarter of 2021, under the geographic view, the Bausch + Lomb segment consisted of the former: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. As a result of this realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. The change in Bausch + Lomb reporting units does not impact the reported revenues and segment profits of the Bausch + Lomb segment for any prior periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immediately prior to the change in its Bausch + Lomb reporting units, the Company performed a qualitative fair value assessment for its former reporting units. Based on the qualitative fair value assessment, management believed that it was more likely than not that the carrying values of its former:  (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units were less than their respective fair values and, therefore, concluded a quantitative assessment was not required.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the change in composition of net assets, the Company performed a quantitative fair value test of its new: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units immediately following the change in the Bausch + Lomb segment. The quantitative fair value test utilized long-term growth rates of 2.0% and 3.0% and a range of discount rates between 7.0% and 10.0%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than 45%, and, therefore, there was no impairment to goodwill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">June 30, 2021 and September 30, 2021 Interim Assessments of Goodwill</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to monitor the market conditions impacting the Ortho Dermatologics reporting unit. The  Company's latest forecasts for the Ortho Dermatologics reporting unit include a range of potential outcomes for, among other matters: (i) the impacts of the COVID-19 pandemic on operations, (ii) the impact of the loss of exclusivity of certain products, (iii) the impact of longer launch cycles for certain new products, (iv) progress of its product pipeline and (v) ongoing pricing pressures, which could negatively impact the reporting unit's results over the long term. The changes in the amounts and timing of revenues and expenses in the latest forecast as compared to the forecast used at March 31, 2021 (the last time goodwill of the Ortho Dermatologics reporting unit was tested), were not substantial enough to materially adversely affect the recoverability of the Ortho Dermatologics reporting unit's assets and are not material enough to indicate that the fair value of the Ortho Dermatologics reporting unit might be below its carrying value as last tested at March 31, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other events occurred or circumstances changed during the period October 1, 2020 (the earliest date goodwill was tested for all other reporting units) through December 31, 2021 that indicated that the fair value of any reporting unit, other than the Ortho Dermatologics reporting unit, might be below its carrying value. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Annual Goodwill Impairment Test</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducted its annual goodwill impairment test as of October 1, 2021 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2021, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2021, the Company considered, among other matters, the limited headroom as a result of the impairment to the goodwill of the Ortho Dermatologics reporting unit when last tested (March 31, 2021) and macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The Company believed that these facts and circumstances may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2021, utilizing a long-term growth rate of 1.0% and a discount rate of 9.0%, in estimation of the fair value of this reporting unit.  Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately 10% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If market conditions deteriorate, if the factors and circumstances regarding the COVID-19 pandemic escalate beyond management&#8217;s current expectations, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and those charges could be material.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated goodwill impairment charges through December 31, 2021 were $4,180 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Realignment of Segment Structure</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2022, the Company has realigned and has begun managing its operations in a manner consistent with the organizational structure of the two separate entities as proposed by the Solta IPO. Under the new reporting structure, the Company has five reportable segments and has allocated goodwill to those segments as follows: (i) $5,318&#160;million to the Bausch + Lomb segment, (ii) $3,159&#160;million to the Salix segment, (iii) $825&#160;million to the International segment, (iv) $115&#160;million to the Solta Medical segment and (v) $3,040&#160;million to the Diversified Products segment. The new segment structure does not impact the Company&#8217;s reporting units but realigns the two reporting units of the former Ortho Dermatologics segment whereby the Ortho Dermatologics reporting unit is now part of the current Diversified Products segment and the Solta reporting unit is now its own operating and reportable segment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373495133400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED AND OTHER CURRENT LIABILITIES</a></td>
<td class="text">ACCRUED AND OTHER CURRENT LIABILITIES<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities as of December 31, 2021 and 2020 consist of: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal matters and related fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefit costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,791&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,576&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373495492408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">FINANCING ARRANGEMENTS</a></td>
<td class="text">FINANCING ARRANGEMENTS<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs as of December 31, 2021 and 2020 consists of the following:</span></div><div style="margin-top:11pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:34.158%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.082%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.082%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.000% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.500% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.750% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.875% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.125%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.000%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.250%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.500%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.000%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.000%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.250%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.000%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.250%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.250%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.250%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,925&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,925&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Covenant Compliance</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Credit Facilities (as defined below) and the indentures governing the Senior Secured Notes and Senior Unsecured Notes contain customary affirmative and negative covenants and specified events of default. These affirmative and negative covenants include, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company&#8217;s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends on capital stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates. As of December&#160;31, 2021, the amount available for restricted payments under the &#8220;builder basket&#8221; in the Company&#8217;s most restrictive indentures (as defined by those indentures) was approximately $13,800&#160;million (although such availability is subject to the Company's compliance with a 2.00:1.00 fixed charge coverage ratio). The 2023 Revolving Credit Facility (as defined below) also contains a financial maintenance covenant that requires the Company to maintain a first lien net leverage ratio of not greater than 4.00:1.00. The financial maintenance covenant may be waived or amended without the consent of the term loan facility lenders and contains a customary term loan facility standstill.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the Company was in compliance with its financial maintenance covenant related to its debt obligations. The Company, based on its current forecast for the next twelve months from the date of issuance of these financial statements, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations over that same period. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to take steps to improve its operating results to ensure continual compliance with its financial maintenance covenant and may take other actions to reduce its debt levels to align with the Company&#8217;s long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the &#8220;Senior Secured Credit Facilities&#8221; under the Company's Fourth Amended and Restated Credit and Guaranty Agreement (the &#8220;Restated Credit Agreement&#8221;), with a syndicate of financial institutions and investors as lenders. The Restated Credit Agreement provides for a revolving credit facility of $1,225 million (the &#8220;2023 Revolving Credit Facility&#8221;) and a seven year Tranche B Term Loan Facility of $4,565 million (the &#8220;June 2025 Term Loan B Facility&#8221;) borrowed by the Company&#8217;s subsidiary, Bausch Health Americas, Inc. (&#8220;BHA&#8221;). </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2023 Revolving Credit Facility matures on the earlier of June 1, 2023 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company or BHA in an aggregate principal amount in excess of $1,000 million. Both the Company and BHA are borrowers with respect to the 2023 Revolving Credit Facility. Borrowings under the 2023 Revolving Credit Facility may be made in U.S. dollars or Canadian dollars (or if an amendment to the Restated Credit Agreement is made to replace LIBOR with an alternative benchmark rate with respect to borrowings under the Revolving Credit Facility denominated in euros, euros).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2021, the Company had $285 million of outstanding borrowings, $54 million of issued and outstanding letters of credit, and remaining availability of $886 million under its 2023 Revolving Credit Facility.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2018, the Company entered into the First Incremental Amendment to the Restated Credit Agreement, which provided an additional seven year Tranche B Term Loan Facility of $1,500&#160;million (the &#8220;November 2025 Term Loan B Facility&#8221;).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Current Description of Senior Secured Credit Facilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Senior Secured Credit Facilities in U.S. dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a base rate determined by reference to the highest of: (a) the prime rate (as defined in the Restated Credit Agreement), (b) the federal funds effective rate plus 1/2 of 1.00% or (c) the eurocurrency rate (as defined in the Restated Credit Agreement) for a period of one month plus 1.00% (or if such eurocurrency rate shall not be ascertainable, 1.00%) or (ii) a eurocurrency rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing adjusted for certain additional costs (provided however, that the eurocurrency rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2023 Revolving Credit Facility in euros, when available, are expected to bear interest at a term benchmark rate determined by reference to the costs of funds for euro deposits for the interest period relevant to such borrowing (provided however, that the eurocurrency rate is at no time expected to be less than 0.00% per annum), plus an applicable margin. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2023 Revolving Credit Facility in Canadian dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a prime rate determined by reference to the higher of: (a) the rate of interest last quoted by The Wall Street Journal as the &#8220;Canadian Prime Rate&#8221; or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Bank of Canada as its prime rate and (b) the 1 month BA rate (as defined below) calculated daily plus 1.00% (provided however, that the prime rate shall at no time be less than 0.00%) or (ii) the bankers&#8217; acceptance rate for Canadian dollar deposits in the Toronto interbank market (the &#8220;BA rate&#8221;) for the interest period relevant to such borrowing (provided however, that the BA rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions and customary baskets set forth in the Restated Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i)&#160;100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii)&#160;100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the Restated Credit Agreement), (iii)&#160;50% of Excess Cash Flow (as&#160;defined in the Restated Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv)&#160;100% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility are 2.00% and 1.75%, respectively, with respect to base rate and prime rate borrowings and 3.00% and 2.75%, </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, with respect to eurocurrency rate and BA rate borrowings. As of December 31, 2021, the stated rates of interest on the Company&#8217;s borrowings under the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility were 3.09% and 2.84% per annum, respectively.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortization rate for both the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility is 5.00% per annum. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of December 31, 2021, there were no remaining mandatory quarterly amortization payments for the Senior Secured Credit Facilities. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The applicable interest rate margins for borrowings under the 2023 Revolving Credit Facility are 1.50%-2.00% with respect to base rate or prime rate borrowings and 2.50%-3.00% with respect to eurocurrency rate or BA rate borrowings.&#160; As of December 31, 2021, the stated rate of interest on the 2023 Revolving Credit Facility was 2.84% per annum. In addition, the Company is required to pay commitment fees of 0.25% - 0.50% per annum with respect to the unutilized commitments under the 2023 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on eurocurrency rate borrowings under the 2023 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency&#160;fees.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restated Credit Agreement permits the incurrence of incremental credit facility borrowings, up to the greater of $1,000 million and 28.5% of Consolidated Adjusted EBITDA (non-GAAP) (as defined in the Restated Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to, in the case of secured debt, a secured leverage ratio of not greater than 3.50:1.00, and, in the case of unsecured debt, either a total leverage ratio of not greater than 6.50:1.00 or an interest coverage ratio of not less than 2.00:1.00.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Secured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes are guaranteed by each of the Company&#8217;s subsidiaries that is a guarantor under the Restated Credit Agreement and existing Senior Unsecured Notes (together, the &#8220;Note Guarantors&#8221;). The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#8217;s obligations under the Restated Credit Agreement under the terms of the indentures governing the Senior Secured Notes. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#8217;s and Note Guarantors&#8217; respective existing and future unsubordinated indebtedness and senior to the Company&#8217;s and Note Guarantors&#8217; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pari passu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#8217;s and the Note Guarantors&#8217; respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company&#8217;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#8217;s debt that is secured by assets that are not collateral.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#8217;s notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">6.500% Senior Secured Notes due 2022 and 7.00% Senior Secured Notes due 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Company issued $1,250&#160;million aggregate principal amount of 6.500% senior secured notes due March 15, 2022 (the &#8220;March 2022 Secured Notes&#8221;) and $2,000&#160;million aggregate principal amount of 7.000% senior secured notes due March 15, 2024 (the &#8220;March 2024 Secured Notes&#8221;), in a private placement. Interest on these notes is payable semi-annually in arrears on each March 15 and September 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The March 2022 Secured Notes were repaid in full as part of the May 2020 Refinancing Transactions (as defined below).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The March 2024 Secured Notes were repaid in full during 2021 with cash on hand and as part of the June 2021 Refinancing Transactions (as defined below).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">5.500% Senior Secured Notes due 2025</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;17, 2017, the Company issued $1,000&#160;million, and, on November 21, 2017, the Company issued $750&#160;million,  aggregate principal amount of 5.500% Senior Secured Notes due November 2025 (the &#8220;November 2025 Secured Notes&#8221;), </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in a private placement. Interest on the November 2025 Secured Notes is payable semi-annually in arrears on each May 1 and November 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The November 2025 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time, at the redemption prices set forth in the indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">5.750% Senior Secured Notes due 2027 - March 2019 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2019, BHA and the Company issued: (i) $1,000 million aggregate principal amount of 8.500% Senior Unsecured Notes due 2027 (the &#8220;January 2027 Unsecured Notes&#8221;) and (ii) $500 million aggregate principal amount of 5.750% Senior Secured Notes due August 2027 (the &#8220;August 2027 Secured Notes&#8221;), respectively, in a private placement. A portion of the proceeds and cash on hand were used to: (i) repurchase $584 million of 5.875% Senior Unsecured Notes due 2023 (the &#8220;May 2023 Unsecured Notes&#8221;), (ii) repurchase $518 million of 5.625% Senior Unsecured Notes due 2021 (the &#8220;December 2021 Unsecured Notes&#8221;), (iii) repurchase $216 million of 5.500% Senior Unsecured Notes due 2023 (the &#8220;March 2023 Unsecured Notes&#8221;) and (iv) pay all fees and expenses associated with these transactions (collectively, the &#8220;March 2019 Refinancing Transactions&#8221;). During April 2019, the Company redeemed $182 million of the December 2021 Unsecured Notes, representing the remaining outstanding principal balance of the December 2021 Unsecured Notes and completing the refinancing of $1,500 million of debt in connection with the March 2019 Refinancing Transactions. The March 2019 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $8 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value. Interest on the August 2027 Secured Notes is payable semi-annually in arrears on each February 15 and August 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The August 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after August 15, 2022, at the redemption prices set forth in the indenture. The Company may redeem some or all of the August 2027 Secured Notes prior to August 15, 2022 at a price equal to 100% of the principal amount thereof plus a &#8220;make-whole&#8221; premium. Prior to August 15, 2022, the Company may redeem up to 40% of the aggregate principal amount of the August 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">4.875% Senior Secured Notes due 2028 - June 2021 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2021, the Company issued $1,600&#160;million aggregate principal amount of 4.875% Senior Secured Notes due June 2028 (the &#8220;June 2028 Secured Notes&#8221;) in a private placement. The proceeds and cash on hand were used to: (i) repurchase a portion and redeem the remainder of $1,600&#160;million of the March 2024 Secured Notes, representing the remaining outstanding principal balance of the March 2024 Secured Notes and (ii) pay all fees and expenses associated with these transactions (collectively, the &#8220;June 2021 Refinancing Transactions&#8221;). The June 2021 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $38&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value. Interest on the June 2028 Secured Notes is payable semi-annually in arrears on each June 1 and December 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2028 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after June 1, 2024, at the redemption prices set forth in the June 2028 Secured Notes indenture. The Company may redeem some or all of the June 2028 Secured Notes prior to June 1, 2024 at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of the redemption plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to June 1, 2024, the Company may redeem up to 40% of the aggregate principal amount of the June 2028 Secured Notes using the net proceeds of certain equity offerings at the redemption price set forth in the June 2028 Secured Notes indenture.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Unsecured Notes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Unsecured Notes issued by the Company are the Company&#8217;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the Senior Secured Credit Facilities. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the Senior Secured Credit Facilities. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">5.500% Senior Unsecured Notes due 2023</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 30, 2015, the Company issued $1,000 million aggregate principal amount of March 2023 Unsecured Notes in a private placement. The March 2023 Unsecured Notes accrued interest at the rate of 5.500% per year, payable semi-annually in arrears. On March 8, 2019 and May 23, 2019, the Company repurchased $216 million and $382 million of March 2023 Unsecured Notes as part of the March 2019 Refinancing Transactions and the May 2019 Refinancing Transactions (as defined below), respectively. Throughout 2020, the Company repurchased, in aggregate, $169&#160;million of March 2023 Unsecured Notes using cash on hand. The Company repurchased the remaining outstanding balance of $233&#160;million in December 2020 as part of the December 2020 Refinancing Transactions (as defined below).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">5.375% Senior Unsecured Notes due 2020, 5.875% Senior Unsecured Notes due 2023, 4.500% Senior Unsecured Notes due 2023 and 6.125% Senior Unsecured Notes due 2025</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2015, VRX Escrow Corp. (the &#8220;VRX Issuer&#8221;), a newly formed wholly owned subsidiary of the Company, issued $2,000 million aggregate principal amount of 5.375% Senior Unsecured Notes due 2020 (the &#8220;March 2020 Unsecured Notes&#8221;), $3,250 million aggregate principal amount of May 2023 Unsecured Notes, &#8364;1,500 million aggregate principal amount of 4.500% Senior Unsecured Notes due 2023 (the &#8220;Euro Notes&#8221;) and $3,250 million aggregate principal amount of 6.125% Senior Unsecured Notes due 2025 (the &#8220;April 2025 Unsecured Notes&#8221; and, together with the March 2020 Unsecured Notes&#8221;), the May 2023 Unsecured Notes and the Euro Notes, the &#8220;VRX Notes&#8221;) in a private placement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The March 2020 Unsecured Notes&#8221;) accrued interest at the rate of 5.375% per year and were repaid in full as part of certain refinancing transactions completed in 2017 and 2018. The May 2023 Unsecured Notes and the Euro Notes accrued interest at the rate of 5.875% and 4.500%  per year, respectively and were each repaid in full as of December 31, 2020, as discussed below. The April 2025 Unsecured Notes accrue interest at the rate of 6.125% per year, payable semi-annually in arrears. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of a refinancing transaction completed in June 2018, the Company repaid the remaining outstanding principal amounts of the March 2020 Unsecured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company repurchased $584 million and $1,118 million of May 2023 Unsecured Notes as part of the March 2019 Refinancing Transactions and the May 2019 Refinancing Transactions (as defined below), respectively, and on October 3, 2019, the Company repaid an additional $100 million of May 2023 Unsecured Notes using cash on hand. On January 16, 2020, the Company redeemed $1,240 million aggregate principal amount of the May 2023 Unsecured Notes as part of the December 2019 Financing and Refinancing Transactions (as defined below). Throughout 2020, the Company repaid, in aggregate, $208&#160;million of the May 2023 Unsecured Notes, with the May 2023 Unsecured Notes having been fully repaid during November 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2020, the Company redeemed the remaining outstanding balance of the Euro Notes as part of the December 2020 Refinancing Transactions, as defined below.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout 2021, the Company repaid, in aggregate, $600&#160;million of the April 2025 Unsecured Notes. The Company may redeem all or a portion of the April 2025 Unsecured Notes at the redemption prices set forth in the applicable indenture, plus accrued and unpaid interest to the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">9.000% Senior Unsecured Notes due 2025</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;18, 2017, the Company issued $1,500 million aggregate principal amount of 9.000% Senior Unsecured Notes due 2025 (the &#8220;December 2025 Unsecured Notes&#8221;) in a private placement, the net proceeds of which were used to repurchase $1,500&#160;million in aggregate principal amount of previously outstanding senior unsecured notes (the &#8220;December 2017 Refinancing Transactions&#8221;). The related fees and expenses were paid using cash on hand. The December 2025 Unsecured Notes accrue interest at the rate of 9.000% per year, payable semi-annually in arrears on each of June 15 and December 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the December 2025 Unsecured Notes at any time prior to December 15, 2021, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to December 15, 2020, the Company may redeem up to 40% of the aggregate principal amount of the outstanding December 2025 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the December 2025 Unsecured Notes indenture. On or after December 15, 2021, the Company may redeem all or a portion of the December 2025 Unsecured Notes at the applicable redemption prices set forth in the December 2025 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">9.250% Senior Unsecured Notes due 2026</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 26, 2018, BHA issued $1,500 million in aggregate principal amount of 9.250% Senior Unsecured Notes due 2026 (the &#8220;April 2026 Unsecured Notes&#8221;) in a private placement, the net proceeds of which, and cash on hand, were used to repurchase $1,500 million in aggregate principal amount of unsecured notes. All fees and expenses associated with these transactions were paid with cash on hand (collectively, the &#8220;March 2018 Refinancing Transactions&#8221;). The April 2026 Unsecured Notes accrue interest at the rate of 9.250% per year, payable semi-annually in arrears on each of April 1 and October 1.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BHA may redeem all or a portion of the April 2026 Unsecured Notes at any time prior to April 1, 2022, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to April 1, 2021, BHA may redeem up to 40% of the aggregate principal amount of the outstanding April 2026 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the April 2026 Unsecured Notes indenture. On or after April 1, 2022, BHA may redeem all or a portion of the April 2026 Unsecured Notes at the applicable redemption prices set forth in the April 2026 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">8.500% Senior Unsecured Notes due 2027</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of a 2018 refinancing transaction, BHA issued $750 million in aggregate principal amount of January 2027 Unsecured Notes in a private placement. The January 2027 Unsecured Notes accrue interest at the rate of 8.500% per year, payable semi-annually in arrears on each of January 31 and July 31. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the March 2019 Refinancing Transactions described above, BHA issued $1,000 million aggregate principal amount of 8.500% Senior Unsecured Notes due January 2027. These are additional notes and form part of the same series as BHA&#8217;s existing January 2027 Unsecured Notes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BHA may redeem all or a portion of the January 2027 Unsecured Notes at any time prior to July 31, 2022, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to July 31, 2021, BHA may redeem up to 40% of the aggregate principal amount of the outstanding January 2027 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the January 2027 Unsecured Notes indenture. On or after July 31, 2022, BHA may redeem all or a portion of the January 2027 Unsecured Notes at the applicable redemption prices set forth in the January 2027 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">7.000% Senior Unsecured Notes due 2028 and 7.250% Senior Unsecured Notes due 2029 - May 2019 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 23, 2019, the Company issued: (i) $750 million aggregate principal amount of 7.000% Senior Unsecured Notes due January 2028 (the &#8220;7.000% January 2028 Unsecured Notes&#8221;) and (ii) $750 million aggregate principal amount of 7.250% Senior Unsecured Notes due May 2029 (the &#8220;May 2029 Unsecured Notes&#8221;), respectively, in a private placement. The proceeds and cash on hand were used to: (i) repurchase $1,118 million of May 2023 Unsecured Notes, (ii) repurchase $382 million of March 2023 Unsecured Notes and (iii) pay all fees and expenses associated with these transactions (collectively, the &#8220;May 2019 Refinancing Transactions&#8221;). The May 2019 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $32 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#8217;s carrying value. Interest on the 7.000% January 2028 Unsecured Notes is payable semi-annually in arrears on each January 15 and July 15. Interest on the May 2029 Unsecured Notes is payable semi-annually in arrears on each May 30 and November 30. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 7.000% January 2028 Unsecured Notes and the May 2029 Unsecured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after January 15, 2023 and May 30, 2024, respectively, at the redemption prices set forth in the respective indenture. The Company may redeem some or all of the 7.000% January 2028 Unsecured Notes or the May 2029 Unsecured Notes prior to January 15, 2023 and May 30, 2024, respectively, at a price equal to 100% of the principal amount thereof plus a &#8220;make-whole&#8221; premium. Prior to July 15, 2022, and May 30, 2022, the Company may redeem up to 40% of the aggregate principal amount of the 7.000% January 2028 Unsecured Notes or the May 2029 Unsecured Notes, respectively, using the proceeds of certain equity offerings at the redemption price set forth in the respective indenture. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">5.000% Senior Unsecured Notes due 2028 and 5.250% Senior Unsecured Notes due 2030 - December 2019 Financing and Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, the Company issued: (i) $1,250 million aggregate principal amount of 5.000% Senior Unsecured Notes due January 2028 (the &#8220;5.000% January 2028 Unsecured Notes&#8221;) and (ii) $1,250 million aggregate principal amount of 5.250% Senior Unsecured Notes due January 2030 (the &#8220;January 2030 Unsecured Notes&#8221;) in a private placement. The proceeds and cash on hand were used to: (i) redeem $1,240 million of May 2023 Unsecured Notes on January 16, 2020, (ii) finance the $1,210 million settlement of certain U.S. Securities litigation as discussed in Note 20, &#8220;LEGAL PROCEEDINGS&#8221; and (iii) pay all fees and expenses associated with these transactions (collectively, the &#8220;December 2019 Financing and Refinancing Transactions&#8221;). The redemption of $1,240&#160;million of May 2023 Unsecured notes was accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $24&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt's carrying value.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on the 5.000% January 2028 Unsecured Notes&#8221;) is payable semi-annually in arrears on each January 30 and July 30. Interest on the January 2030 Unsecured Notes&#8221;) is payable semi-annually in arrears on each January 30 and July 30. The 5.000% January 2028 Unsecured Notes&#8221;) and the January 2030 Unsecured Notes&#8221;) are redeemable at the option of the Company, in whole or in part, at any time on or after January 30, 2023 and January 30, 2025, respectively, at the redemption prices set forth in the respective indenture. The Company may redeem some or all of the 5.000% January 2028 Unsecured Notes&#8221;) or the January 2030 Unsecured Notes&#8221;) prior to January 30, 2023 and January 30, 2025, respectively, at a price equal to 100% of the principal amount thereof plus a &#8220;make-whole&#8221; premium. Prior to January 30, 2023, the Company may redeem up to 40% of the aggregate principal amount of the 5.000% January 2028 Unsecured Notes&#8221;) or the January 2030 Unsecured Notes&#8221;) using the proceeds of certain equity offerings at the redemption price set forth in the respective indenture. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">6.250% Senior Unsecured Notes due 2029 - May 2020 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 26, 2020, the Company issued $1,500&#160;million aggregate principal amount of 6.250% Senior Unsecured Notes due February 2029 (the &#8220;6.250% February 2029 Unsecured Notes&#8221;) in a private placement. The proceeds and cash on hand were used to: (i) repurchase $1,250&#160;million aggregate principal amount of the outstanding March 2022 Secured Notes, (ii) prepay $303&#160;million of mandatory amortization scheduled for payment in 2022 under the Company's June 2025 and November 2025 Term Loan B Facilities and (iii) pay all fees and expenses associated with these transactions (collectively, the &#8220;May 2020 Refinancing Transactions&#8221;). The May 2020 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $27&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt's carrying value. The 6.250% February 2029 Unsecured Notes accrue interest at the rate of 6.250% per year, payable semi-annually in arrears on each of February 15 and August 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the 6.250% February 2029 Unsecured Notes at any time prior to February 15, 2024, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to August 15, 2023, the Company may redeem up to 40% of the aggregate principal amount of the outstanding 6.250% February 2029 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the 6.250% February 2029 Unsecured Notes indenture. On or after February 15, 2024, the Company may redeem all or a portion of the 6.250% February 2029 Unsecured Notes at the applicable redemption prices set forth in the 6.250% February 2029 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">5.000% Senior Unsecured Notes due 2029 and 5.250% Senior Unsecured Notes due 2031 &#8211; December 2020 Refinancing Transactions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2020, the Company issued $1,000&#160;million aggregate principal amount of 5.000% Senior Unsecured Notes due February 2029 (the &#8220;5.000% February 2029 Unsecured Notes&#8221;) and $1,000&#160;million aggregate principal amount of 5.250% Senior Unsecured Notes due February 2031 (the &#8220;February 2031 Unsecured Notes&#8221;) in a private placement. The aggregate proceeds and cash on hand were used to repurchase the remaining outstanding principal amounts of: (i) &#8364;1,500&#160;million of the Euro Notes, (ii) $233&#160;million of the March 2023 Unsecured Notes and (iii) pay all fees and expenses associated with these transactions (collectively, the &#8220;December 2020 Refinancing Transactions&#8221;). The December 2020 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $7&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt's carrying value. The 5.000% February 2029 Unsecured Notes accrue interest at the rate of 5.000% per year, payable semi-annually in arrears on each of February 15 and August 15. The February 2031 Unsecured Notes accrue interest at the rate of 5.250% per year, payable semi-annually in arrears on each of February 15 and August 15.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the 5.000% February 2029 Unsecured Notes at any time prior to February 15, 2024, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to February 15, 2024, the Company may redeem up to 40% of the aggregate principal amount of the outstanding 5.000% February 2029 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the 5.000% February 2029 Unsecured Notes indenture. On or after February 15, 2024, the Company may redeem all or a portion of the 5.000% February 2029 Unsecured Notes at the applicable redemption prices set forth in the 5.000% February 2029 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all or a portion of the February 2031 Unsecured Notes at any time prior to February 15, 2026, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#8220;make-whole&#8221; premium. In addition, at any time prior to February 15, 2024, the Company may redeem up to 40% of the aggregate principal amount of the outstanding February 2031 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the February 2031 Unsecured Notes indenture. On or after February 15, 2026, the Company may redeem all or a portion of the February 2031 Unsecured Notes at the applicable redemption prices set forth in the February 2031 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Stated Rate of Interest</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average stated rate of interest for the Company's outstanding debt obligations as of December 31, 2021 and 2020 was 5.88% and 6.02%, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturities and Mandatory Payments</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities and mandatory payments of debt obligations for the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:88.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross maturities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Restated Credit Agreement, there is no Excess Cash Flow payment due for 2021.</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 11, 2022, the Company repaid its outstanding balance of $285&#160;million under its 2023 Revolving Credit Facility.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As more fully discussed in Note 23, &#8220;SUBSEQUENT EVENTS&#8221;, during January 2022, the Company: (i) issued conditional notices of redemption to redeem in full all of its outstanding April 2025 Unsecured Notes&#8221;  and to redeem $370&#160;million aggregate principal amount of its outstanding December 2025 Unsecured Notes and (ii) issued $1,000&#160;million aggregate principal amount of 6.125% Senior Secured Notes due February 2027.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373495023336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</a></td>
<td class="text">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANSThe Company has defined benefit plans and a participatory defined benefit postretirement medical and life insurance plan, which covers a closed grandfathered group of legacy Bausch &amp; Lomb Holdings Incorporated (&#8216;&#8216;B&amp;L&#8217;&#8217;) U.S. employees and employees in certain other countries. The U.S. defined benefit accruals were frozen as of December 31, 2004 and benefits that were earned up to December 31, 2004 were preserved. Participants continue to earn interest credits on their cash balance at an interest crediting rate that is equal to the greater of: (i) the average annual yield on 10-year treasury bonds in effect for the November preceding the plan year or (ii) 4.50%. The most significant non-U.S. plans are two defined benefit plans in Ireland. In 2011, both Ireland defined benefit plans were closed to future service benefit accruals; however, additional accruals related to annual salary increases continued. In December 2014, one of the Ireland defined benefit plans was amended effective August 2014 to eliminate future benefit accruals related to salary increases. All of the pension benefits accrued through the plan amendment date were preserved. As a result of the plan amendment, there are no active plan participants accruing benefits under the amended Ireland defined benefit plan.  The U.S. postretirement benefit <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plan was amended effective January 1, 2005 to eliminate employer contributions after age 65 for participants who did not meet the minimum requirements of age and service on that date. The employer contributions for medical and prescription drug benefits for participants retiring after March 1, 1989 were frozen effective January 1, 2010. Effective January 1, 2014, the Company no longer offers medical and life insurance coverage to new retirees.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the B&amp;L benefit plans, outside of the U.S., a limited group of the Company's employees are covered by defined benefit pension plans. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses December 31 as the year-end measurement date for all of its defined benefit pension plans and the postretirement benefit plan. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Pension Benefit Plans and Postretirement Benefit Plan </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes in its Consolidated Balance Sheets an asset or liability equal to the over- or under-funded benefit obligation of each defined benefit pension plan and postretirement benefit plan. Actuarial gains or losses and prior service costs or credits that arise during the period but are not recognized as components of net periodic benefit cost are recognized, net of tax, as a component of Other comprehensive income (loss). </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts included in Accumulated other comprehensive loss as of December 31, 2021 and 2020 were as follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:38.413%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.963%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized actuarial losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized prior service credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Periodic (Benefit) Cost</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the components of net periodic (benefit) cost for the Company&#8217;s defined benefit pension plans and postretirement benefit plan in 2021, 2020 and 2019:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:25.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.504%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of prior service credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement loss recognized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Benefit Obligation, Change in Plan Assets and Funded Status </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents components of the change in projected benefit obligation, change in plan assets and funded status for 2021 and 2020: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:40.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.025%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in Projected Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation, beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial (gain) losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets, beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funded status, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Settlement loss recognized and Settlements in the tables above are the costs and payments associated with the conversion of a portion of the Company&#8217;s defined benefit plan in Ireland to a defined contribution plan during the fourth quarter of 2021.</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of the Company&#8217;s pension benefit plans were underfunded as of December 31, 2021 and 2020, having accumulated benefit obligations exceeding the fair value of plan assets. There were no U.S. pension benefit plans that were underfunded as of December 31, 2021, having accumulated benefit obligations exceeding the fair value of plan assets. Information for the underfunded pension benefit plans is as follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:56.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.971%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy for funding its pension benefit plans is to make contributions that meet or exceed the minimum statutory funding requirements. These contributions are determined based upon recommendations made by the actuary under accepted actuarial principles. In 2022, the Company expects to contribute $0, $9 million and $4 million to the U.S. pension benefit plan, the non-U.S. pension benefit plans and the U.S. postretirement benefit plan, respectively. The Company plans to use postretirement benefit plan assets and cash on hand, as necessary, to fund the U.S. postretirement benefit plan benefit payments in 2022.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Benefit Payments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future benefit payments over the next 10 years for the pension benefit plans and the postretirement benefit plan, which reflect expected future service, as appropriate, are expected to be paid as follows: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:54.219%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.337%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.337%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.430%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>&#160;Benefit<br/>&#160;Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assumptions</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used to determine net periodic benefit costs and benefit obligations for 2021, 2020 and 2019 were as follows: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:43.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.427%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement Benefit Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For Determining Net Periodic (Benefit) Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. Plans:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:55.197%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.073%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement Benefit Plan</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For Determining Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected long-term rate of return on plan assets was developed based on a capital markets model that uses expected asset class returns, variance and correlation assumptions. The expected asset class returns were developed starting with current Treasury (for the U.S. pension plan) or Eurozone (for the Ireland pension plans) government yields and then adding corporate bond spreads and equity risk premiums to develop the return expectations for each asset class. The expected asset class returns are forward-looking. The variance and correlation assumptions are also forward-looking. They take into account historical relationships, but are adjusted to reflect expected capital market trends. The expected return on plan assets for the Company&#8217;s U.S. pension plan for 2021 was 5.00%. The expected return on plan assets for the Company&#8217;s Ireland pension plans was 2.75% for 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discount rate used to determine benefit obligations represents the current rate at which the benefit plan liabilities could be effectively settled considering the timing of expected payments for plan participants.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 expected rate of return for the U.S. pension benefit plan will be 4.50%. The 2022 expected rate of return for the Ireland pension benefit plans will be 2.75%. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pension Benefit Plans Assets             </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pension benefit plan assets are invested in several asset categories. The following presents the actual asset allocation as of December 31, 2021 and 2020:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:77.048%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.070%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The investment strategy underlying pension plan asset allocation is to manage the assets of the plan to provide for the non-current liabilities while maintaining sufficient liquidity to pay current benefits. Pension plan assets are diversified to protect against large investment losses and to reduce the probability of excessive performance volatility. Diversification of assets is achieved by allocating funds to various asset classes and investment styles within asset classes, and retaining investment management firm(s) with complementary investment philosophies, styles and approaches.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s pension plan assets are managed by outside investment managers using a total return investment approach, whereby a mix of equity and debt securities investments are used to maximize the long-term rate of return on plan assets. A significant portion of the assets of the U.S. and Ireland pension plans have been invested in equity securities, as equity portfolios have historically provided higher returns than debt and other asset classes over extended time horizons. Correspondingly, equity investments also entail greater risks than other investments. Equity risks are balanced by investing a significant portion of plan assets in broadly diversified fixed income securities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Plan Assets </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measured the fair value of plan assets based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. See Note 5, &#8220;FAIR VALUE MEASUREMENTS&#8221; for details on the Company's fair value measurements based on a three-tier hierarchy.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents total plan assets by investment category as of December 31, 2021 and 2020 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value. There were no transfers between Level 1 and Level 2 during 2021 and 2020.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.062%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans - U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. broad market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide developed markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:31.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.083%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.360%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans - Non-U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide developed markets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global high yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government bond funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consisted primarily of term deposits and money market instruments. The fair value of the term deposits approximates their carrying amounts due to their short term maturities. The money market instruments also have short maturities and are valued using a market approach based on the quoted market prices of identical instruments. </span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commingled funds are not publicly traded. The underlying assets in these funds are publicly traded on the exchanges and have readily available price quotes. The Ireland pension plans held approximately 95% and 96% of the non-U.S. commingled funds in 2021 and 2020, respectively. The commingled funds held by the U.S. and Ireland pension plans are primarily invested in index funds.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The underlying assets in the fixed income funds are generally valued using the net asset value per fund share, which is derived using a market approach with inputs that include broker quotes, benchmark yields, base spreads and reported trades. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defined Contribution Plans </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors defined contribution plans in the U.S., Ireland and certain other countries.&#160;Under these plans, employees are allowed to contribute a portion of their salaries to the plans, and the Company matches a portion of the employee contributions. The Company contributed $44 million, $43 million and $41 million to these plans during the years ended December 31, 2021, 2020 and 2019, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373495489592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES <div style="margin-bottom:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets and lease liabilities associated with the Company's operating leases are included in the Consolidated Balance Sheet as of December 31, 2021 and 2020 as follows:</span></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:82.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.925%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets included in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzItMC0xLTEtOTQ4MzE_4bf2464d-f080-463a-b82a-fe3327a6ffe8"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzItMC0xLTEtOTQ4MzE_ce76341b-5893-4112-b76b-f4aed3b43dcf">Other non-current assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities included in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzQtMC0xLTEtOTQ4MzE_4bf64393-afaa-455f-a448-662b6f9a6f45"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzQtMC0xLTEtOTQ4MzE_4de59f41-dcca-4036-87e1-e7e98c16d228">Accrued and other current liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzUtMC0xLTEtOTQ4MzE_339c676d-41f8-49e5-86a9-b2e8149fc1fd"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzUtMC0xLTEtOTQ4MzE_c6eaab40-e3c8-4b6a-afe4-21b28ab4bf11">Other non-current liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, 2020 and 2019 the Company's finance leases were not material and for the years 2021, 2020 and 2019 sub-lease income and short-term lease expense were not material. Lease expense for the years 2021, 2020 and 2019 include:</span></div><div style="margin-bottom:6.6pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:70.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable operating lease costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to operating leases for 2021, 2020 and 2019 is as follows:</span></div><div style="margin-bottom:6.6pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:70.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid from operating cash flows for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, future payments under noncancelable operating leases for each of the five succeeding years ending December 31 and thereafter are as&#160;follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:91.594%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of remaining lease payments</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373495195832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text">SHARE-BASED COMPENSATIONIn May 2014, shareholders approved the Company&#8217;s 2014 Omnibus Incentive Plan (the &#8220;2014 Plan&#8221;), which replaced the Company&#8217;s 2011 Omnibus Incentive Plan (the &#8220;2011 Plan&#8221;) for future equity awards granted by the Company. The Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan was equal to 18,000,000 common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">surrendered under the 2011 Plan and the Company&#8217;s 2007 Equity Compensation Plan. The Company registered 20,000,000 common shares of common stock for issuance under the 2014 Plan.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 30, 2018, the Company amended and restated the 2014 Plan (the &#8220;Amended and Restated 2014 Plan&#8221;). The Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Amended and Restated 2014 Plan has been increased by an additional 11,900,000 common shares, as approved by the requisite number of shareholders at the Company&#8217;s annual general meeting held on April 30, 2018, (ii) introduction of a $750,000 aggregate fair market value limit on awards (in either equity, cash or other compensation) that can be granted in any calendar year to a participant who is a non-employee director, (iii) housekeeping changes to address recent changes to Section 162(m) of the Internal Revenue Code, (iv) awards are expressly subject to the Company&#8217;s clawback policy and (v) awards not assumed or substituted in connection with a Change of Control (as defined in the Amended and Restated 2014 Plan) will only vest on a pro rata basis.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective April 28, 2020, the Company further amended and restated the Amended and Restated 2014 Plan (the &#8220;Further Amended and Restated 2014 Plan&#8221;). The Further Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Further Amended and Restated 2014 Plan has been increased by an additional 13,500,000 common shares, as approved by the requisite number of shareholders at the Company&#8217;s annual general meeting held on April 28, 2020, (ii) the exercise price of stock options and share appreciation rights (&#8220;SARs&#8221;) will be based on the closing price of the underlying common shares on the date such stock options or SARs are granted (rather than on the last preceding trading date), (iii)&#160;additional provisions clarifying that: (a)&#160;stock options and SARs will not be eligible for the payment of dividend or dividend equivalents and (b)&#160;the Talent and Compensation Committee of the Board of Directors of the Company cannot, without shareholder approval, seek to effect any repricing of any previously granted &#8220;underwater&#8221; stock option or SAR and (iv) other housekeeping and/or clerical changes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 11,593,000 common shares were available for future grants as of December&#160;31, 2021. The Company uses reserved and unissued common shares to satisfy its obligation under its share-based compensation plans.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a long-term incentive program with the objective of aligning the share-based awards granted to senior management with the Company&#8217;s focus on improving its tangible capital usage and allocation, while maintaining focus on improving total shareholder return over the long-term.  The share-based awards granted under this long-term incentive program consist of time-based stock options, time-based RSUs and performance-based RSUs. Performance-based RSUs are comprised of: (i) awards that vest upon achievement of certain share price appreciation conditions that are based on total shareholder return (&#8220;TSR&#8221;), (ii) awards that vest upon attainment of certain performance targets that are based on the Company&#8217;s return on tangible capital (&#8220;ROTC&#8221;) and (iii) vest fully or partially upon attainment of certain goals that are linked to the B+L Separation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components and classification of share-based compensation expense related to stock options and&#160;RSUs for the years 2021, 2020 and 2019 were as follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:67.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.934%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.934%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options granted under the 2011 Plan and the Amended and Restated 2014 Plan generally expire on the fifth or tenth anniversary of the grant date. The exercise price of any stock option granted under the 2011 Plan and the Amended and Restated 2014 Plan will not be less than the closing price per common share on the date of grant. Stock options generally vest 33% and 25% each year over a three-year and four-year period, respectively, on the anniversary of the date of&#160;grant.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of all stock options granted for the years 2021, 2020 and 2019 were estimated as of the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock option life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected stock option life was determined based on historical exercise and forfeiture patterns. The expected volatility was determined based on implied volatility in the market traded options of the Company&#8217;s common stock. The risk-free interest rate was determined based on the rate at the time of grant for zero-coupon U.S. government bonds with maturity dates equal to the expected life of the stock&#160;option. The expected dividend yield was determined based on the stock option&#8217;s exercise price and expected annual dividend rate at the time of&#160;grant.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model used by the Company to calculate stock option values was developed to estimate the fair value of freely tradeable, fully transferable stock options without vesting restrictions, which significantly differ from the Company&#8217;s stock option awards. This model also requires highly subjective assumptions, including future stock price volatility and expected time until exercise, which greatly affect the calculated values.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during 2021: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:56.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.706%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, January&#160;1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired or forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair values of all stock options granted in 2021, 2020 and 2019 were $10.92, $6.60 and $8.45, respectively. The total intrinsic values of stock options exercised in 2021, 2020 and 2019 were $15 million, $2 million and $3 million, respectively. Proceeds received on the exercise of stock options in 2021, 2020 and 2019 were $22 million, $5 million and $5 million,&#160;respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the total remaining unrecognized compensation expense related to non-vested stock options amounted to $10 million, which will be amortized over the weighted-average remaining requisite service period of approximately 1.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years. The total fair value of stock options vested in 2021, 2020 and 2019 were $15 million, $15 million and&#160;$18 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RSUs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs generally vest on the first or third anniversary date from the date of grant or 33% a year over a three-year period. Annual RSUs granted to non-management directors vest immediately prior to the next Annual Meeting of Shareholders. Pursuant to the applicable unit agreement, certain RSUs may be subject to the attainment of any applicable performance goals specified by the Board of Directors. If the vesting of the RSUs is conditional upon the attainment of performance goals, any RSUs that do not vest as a result of a determination that the prescribed performance goals failed to be attained will be forfeited immediately upon such determination. RSUs are credited with dividend equivalents, in the form of additional RSUs, when dividends are paid on the Company&#8217;s common shares. Such additional RSUs will have the same vesting dates and will vest under the same terms as the RSUs in respect of which such additional RSUs are&#160;credited.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent provided for in a RSU agreement, the Company may, in lieu of all or a portion of the common shares which would otherwise be provided to a holder, elect to pay a cash amount equivalent to the market price of the Company&#8217;s </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common shares on the vesting date for each vested RSU. The amount of cash payment will be determined based on the average market price of the Company&#8217;s common shares on the vesting date. The Company&#8217;s current intent is to settle vested RSUs through the issuance of common&#160;shares.   </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Time-Based RSUs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each vested time-based RSU represents the right of a holder to receive one of the Company&#8217;s common shares. The fair value of each RSU granted is estimated based on the trading price of the Company&#8217;s common shares on the date of&#160;grant.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-vested time-based RSU activity during 2021: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:72.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.994%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Time-Based<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, January&#160;1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the total remaining unrecognized compensation expense related to non-vested time-based RSUs amounted to $68 million, which will be amortized over the weighted-average remaining requisite service period of approximately 1.6 years. The total fair value of time-based RSUs vested in 2021, 2020 and 2019 were $69 million, $66 million and $34 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance-Based RSUs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each vested performance-based RSU represents the right of a holder to receive a number of the Company&#8217;s common shares up to a specified maximum. Performance-based RSUs vest upon achievement of certain share price appreciation conditions or attainment of certain performance targets. If the Company&#8217;s performance is below a specified performance level, no common shares will be&#160;paid. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each TSR performance-based RSU granted during 2021, 2020 and 2019 was estimated using a Monte Carlo Simulation model, which utilizes multiple input variables to estimate the probability that the performance condition will be achieved.  The fair value of the ROTC performance-based RSUs is estimated based on the trading price of the Company&#8217;s common shares on the date of grant.  Expense recognized for the ROTC performance-based RSUs in each reporting period reflects the Company&#8217;s latest estimate of the number of ROTC performance-based RSUs that are expected to vest.  If the ROTC performance-based RSUs do not ultimately vest due to the ROTC targets not being met, no compensation expense is recognized and any previously recognized compensation expense is reversed. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of TSR performance-based RSUs granted during 2021, 2020 and 2019 were estimated with the following assumptions:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"/><td style="width:58.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.727%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected Company share volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected company share volatility was determined based on implied volatility in the market traded options of the Company&#8217;s common stock. The risk-free interest rate was determined based on the rate at the time of grant for zero-coupon U.S.&#160;government bonds with maturity dates equal to the contractual term of the performance-based&#160;RSUs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-vested performance-based RSU activity during 2021: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:72.799%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.587%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance-based <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, January&#160;1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company granted approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,035,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance-based RSUs, consisting of approximately 400,000 units of TSR performance-based RSUs with an average grant date fair value of $56.04 per RSU, approximately 413,000 units of ROTC performance-based RSUs with a weighted-average grant date fair value of $31.72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per RSU and approximately 222,000 of other performance-based RSU's with a weighted-average grant date fair value of $28.49. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the total remaining unrecognized compensation expense related to non-vested performance-based RSUs amounted to $32 million, which will be amortized over the weighted-average remaining requisite service period of approximately 1.7 years.  A maximum of approximately 3,476,000 common shares could be issued upon vesting of the performance-based RSUs outstanding as of December 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373495010520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">ACCUMULATED OTHER COMPREHENSIVE LOSS</a></td>
<td class="text">ACCUMULATED OTHER COMPREHENSIVE LOSS<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss as of December&#160;31, 2021 and 2020 consists of: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,905)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,077)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension adjustment, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,924)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,133)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company&#8217;s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to the Company&#8217;s retained earnings for foreign jurisdictions in which the Company is not considered to be permanently reinvested.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373494979544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock', window );">RESEARCH AND DEVELOPMENT</a></td>
<td class="text">RESEARCH AND DEVELOPMENT<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Research and development are costs related to product development and quality assurance programs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards. Research and development costs for the years 2021, 2020 and 2019 consists of:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product related research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 730<br> -URI http://asc.fasb.org/subtopic&amp;trid=2197926<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373495493240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EXPENSE, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">OTHER EXPENSE, NET</a></td>
<td class="text">OTHER EXPENSE, NET<div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net for the years 2021, 2020 and 2019 consists of:</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain on sales of assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,426&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, Litigation and other matters of $356 million includes adjustments related to the Glumetza Antitrust Litigation, partially offset by insurance recoveries related to certain litigation matters. In 2020, Litigation and other matters of $422 million includes net charges related to the U.S. Securities Litigation, the SEC Investigation and the Canadian Securities Litigation and related opt-outs. In 2020, Litigation and other matters also includes an insurance recovery related to a certain litigation matter. In 2019, Litigation and other matters of $1,401 million includes the settlement of a legacy U.S. securities class action matter. Certain of these matters and other significant matters are discussed in further detail in Note 20, &#8220;LEGAL PROCEEDINGS&#8221;.</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020 and 2019, Acquired in-process research and development costs of $32&#160;million and $41&#160;million, primarily consist of costs associated with the upfront payments to enter into certain exclusive licensing agreements. </span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, Net gain on sales of assets includes $20 million related to the achievement of a milestone related to a certain product.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI http://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI http://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373495159384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Loss before benefit from income taxes for 2021, 2020 and 2019 consist of:  </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(323)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,396)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(701)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(524)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,024)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,837)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Benefit from income taxes for 2021, 2020 and 2019 consist of: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Benefit from income taxes differs from the expected amount calculated by applying the Company&#8217;s Canadian statutory rate of 26.9% to Loss before benefit from income taxes for 2021, 2020 and 2019 as follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before benefit from income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,024)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,837)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected benefit from income taxes at Canadian statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible amount of share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to tax attributes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance related to foreign tax credits and NOLs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance on Canadian deferred tax assets and tax rate changes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in uncertain tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible portion of Goodwill impairments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit on intra-entity transfers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities as of December 31, 2021 and 2020 consist of: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific Research and Experimental Development pool</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,252)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets net of valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,065&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,999&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plant, equipment and technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside basis differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized FX on U.S. dollar debt and other financing cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the deferred tax asset valuation allowance for 2021, 2020 and 2019: </span></div><div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,913&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to Benefit from income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to other accounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s U.S. interest expense is subject to limitation rules which limit U.S. interest expense to 30% of adjusted taxable income, defined similar to EBITDA through 2021 and EBIT thereafter.  Disallowed interest can be carried forward indefinitely and any unused interest deduction assessed for recoverability. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) was signed into law.  The CARES Act also amended the annual limitation on the deduction of interest in the following respects: (i) increasing the limitation to 50% of adjusted taxable income (&#8220;ATI&#8221;), (ii) providing a rule for a partnership&#8217;s 2019 section 163(j)-disallowed interest expense and (iii) allowing an election to apply 2019 ATI to the 2020 section 163(j) computation.  For corporations, the increase to 50% of ATI applies to all taxable years beginning in 2019 or 2020 and permits taxpayers whose 2020 income will decrease from its 2019 level, an election to apply their 2019 ATI, rather than their 2020 ATI, to their 2020 computation. The Company considered such provisions and expects to fully utilize any interest carry forwards in future periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has provided for income taxes in accordance with guidance issued by accounting regulatory bodies, the U.S. Internal Revenue Service and state and local governments through the date of the issuance of these Consolidated Financial Statements. Additional guidance and interpretations can be expected and such guidance, if any, could impact future results.  While management continues to monitor these matters, the ultimate impact, if any, as a result of the application of any guidance issued in the future cannot be determined at this time.   </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The realization of deferred tax assets is dependent on the Company generating sufficient domestic and foreign taxable income in the years that the temporary differences become deductible. A valuation allowance has been provided for the portion of the deferred tax assets that the Company determined is more likely than not to remain unrealized based on estimated future taxable income and tax planning strategies.  In 2021, the valuation allowance decreased by $30 million primarily due to book taxable income in Canada, the change in deferred tax assets in Canada and the use of deferred tax assets in the U.S. in connection with internal restructurings. In 2020, the valuation allowance decreased by $579 million as a result of taxable losses in Canada as offset by a reduction of deferred tax assets due to internal restructurings. Given the Company&#8217;s history of pre-tax losses and expected future losses in Canada, the Company maintained that there was insufficient objective evidence to release the valuation allowance against Canadian tax loss carryforwards, International Tax Credits (&#8220;ITC&#8221;) and pooled Scientific Research and Experimental Development Tax Incentive (&#8220;SR&amp;ED&#8221;) expenditures.  The Canadian valuation allowance represents a material portion of the Company's total valuation allowance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, the Company had accumulated taxable losses available to offset future years&#8217; federal and provincial taxable income in Canada of approximately $6,669 million and $6,530 million, respectively.&#160; As of December 31, 2021 and 2020, unclaimed ITCs available to offset future federal taxes in Canada were approximately $31 million and $37 million, respectively, which expire in the years 2022 through 2041.&#160; In addition, as of December 31, 2021 and 2020, pooled SR&amp;ED expenditures available to offset against future taxable income in Canada were approximately $196 million and $206 million, respectively, which may be carried forward indefinitely.  As of December 31, 2021 and 2020, a full valuation allowance against the net Canadian deferred tax assets on the parent company has been provided of $1,965 million and $1,966 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, the Company had accumulated taxable losses available to offset future years' federal taxable income in the U.S. of approximately $266 million and $814 million, respectively, including acquired losses which expire in the years 2022 through 2037. While the remaining taxable losses are subject to multiple annual loss limitations as a result of previous ownership changes, the Company believes that the recoverability of the deferred tax assets associated with these taxable losses are more likely than not to be realized. As of December 31, 2021 and 2020 U.S. research and development credits available to offset future years' federal income taxes in the U.S. were approximately $119 million and $110 million, respectively, which includes acquired research and development credits and which expire in the years 2022 through 2042.  In the U.S. the Company has a capital loss of which is offset by a full valuation allowance since the benefit is not expected to be realized.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, the Company had accumulated taxable losses available to offset future years&#8217; taxable income in Ireland of approximately $10,040 million and $8,387 million, respectively.&#160; As of  December&#160;31, 2021, the Company continues to have a capital loss which is offset by a valuation allowance on the portion of the loss for which a benefit is not expected to be realized.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for income taxes on the unremitted earnings of its direct foreign affiliates except for its direct U.S. subsidiaries.  The Company continues to assert that the unremitted earnings of its U.S.&#160;subsidiaries will be permanently reinvested and not repatriated.  As of December 31, 2021, the Company estimates that there will be no tax liability attributable to unremitted earnings of its U.S. subsidiaries. However, distribution of future earnings could be subject to U.S. withholding tax.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, unrecognized tax benefits (including interest and penalties) were $927 million and $1,025 million, of which $271 million and $414 million would affect the effective income tax rate, respectively. In 2021 and 2020, the remaining unrecognized tax benefits would not impact the effective tax rate as the tax positions are offset against existing tax attributes or are timing in nature. In 2021 and 2020, the Company recognized net increases to unrecognized tax benefits for current year tax positions of $79 million and $66 million, respectively.  The Company recognized a net reduction of $177 million during 2021 and a net reduction of $42 million during 2020 in the unrecognized tax benefits related to tax positions taken in the prior years.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for interest and penalties related to unrecognized tax benefits in the provision for income taxes. As of December 31, 2021 and 2020, accrued interest and penalties related to unrecognized tax benefits were approximately $41 million and $49 million, respectively. In 2021, the Company recognized a net decrease of approximately $8 million and, in 2020, recognized an increase of  $4 million of interest and&#160;penalties, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and one or more of its subsidiaries file federal income tax returns in Canada, the U.S., and other foreign jurisdictions, as well as various provinces and states in Canada and the U.S.&#160;The Company and its subsidiaries have open tax years, primarily from 2012 to 2020, with significant taxing jurisdictions, respectively, including Canada and the U.S.&#160;These open years contain certain matters that could be subject to differing interpretations of applicable tax laws and regulations and tax treaties, as they relate to the amount, timing, or inclusion of revenues and expenses, or the sustainability of income tax positions of the Company and its subsidiaries. Certain of these tax years are expected to remain open indefinitely.</span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"/><td style="width:82.106%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jurisdiction:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Open Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States - Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2012 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2013 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2011 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 - 2020</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Internal Revenue Service (the &#8220;IRS&#8221;) completed its examinations of the Company&#8217;s U.S. consolidated federal income tax returns for the years 2013 and 2014. There were no material adjustments to the Company's taxable income as a result of these examinations.  However, the 2014 tax year remains open to the extent of a 2017 capital loss carried back to that year. Additionally, the IRS has selected for examination the Company's annual tax filings for 2015 and 2016 and the Company's short period tax return for the period ended September 8, 2017, which was filed as a result of the Company's internal restructuring efforts during 2017. In 2017, the Company undertook an internal restructuring in the form of what is commonly known as a Granite Trust transaction, which resulted in a recorded capital loss (the &#8220;2017 Capital Loss&#8221;). Recently, the Company has received a notice of proposed adjustment from the IRS that would disallow the 2017 Capital Loss and expects to receive a notice of proposed tax deficiency from the IRS, after which the Company intends to contest proposed tax deficiency through the IRS administrative appeals process. If the Company were ultimately unsuccessful in defending its position, and all or a substantial portion of the 2017 Capital Loss deduction were disallowed, the Company could be liable for additional taxes (excluding penalties and interest) of up to $2,100&#160;million, which could have an adverse effect on the Company&#8217;s financial condition and results of operations. The Company intends to vigorously defend its position, including through appropriate litigation, if necessary, and ultimately believes it will sustain its deduction of the 2017 Capital Loss, and, accordingly, no income tax provision has been recorded.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is currently under examination by the Canada Revenue Agency (&#8220;CRA&#8221;) for three separate cycles: (a) years 2012 through 2013 (b) years 2014 through 2015, and (c) years 2016 through 2017.  The Company believes that the CRA will open an audit cycle for the years 2018 &#8211; 2019 in 2022.  The Company settled the tax years from 2005 through 2009 </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with the CRA. The Company had previously filed a Notice of Objection related to the assessment of these years and reduced net operating losses with a full valuation allowance by CAD 44&#160;million to close these years.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The adjustment did not result in a material change to the provision for income taxes.  The CRA audits of the 2010 and 2011 tax years were closed in 2016 and resulted in no material adjustments. The Company received an assessment for certain transfer pricing matters in 2012 and 2013 for CAD 85&#160;million and CAD 90&#160;million, respectively.  The Company disagrees with the adjustments and has filed a Notice of Objection for 2012 and 2013.  The Company settled certain transfer pricing matters relating the 2015 and 2016 tax years resulting in a reduction to its NOLs of approximately CAD 21&#160;million for 2015 and will receive a further adjustment for 2016.  The expected adjustment for 2016 will reduce NOLs currently offset by a full valuation allowance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s subsidiaries in Germany are under audit for tax years 2014 through 2016.  At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's Consolidated Financial Statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s subsidiaries in Australia are under audit by the Australian Tax Office for various years beginning in 2010. On August 8, 2017, the Australian Taxation Office issued a notice of assessment for the tax years 2011 through 2017 in the aggregate amount of $117 million, which includes penalties and interest.  The Company disagrees with the assessment and continues to believe that its tax positions are appropriate and supported by the facts, circumstances and applicable laws. The Company intends to defend its tax position in this matter vigorously and has filed a holding objection against the assessment by the Australian Taxation Office and has secured a bank guarantee to cover any potential cash outlays regarding this assessment. The bank guarantee has been reduced over time to now be an immaterial value.  Negotiations with the Australian Tax Office are ongoing and the Company expects to enter into a Settlement Deed in early 2022 with no material adverse results.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company's U.S. affiliates remain under examination for various state tax audits in the U.S. for years 2015 through 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain affiliates of the Company in regions outside of Canada, the U.S., Germany, Luxembourg and Australia are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits.  At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's Consolidated Financial Statements.</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the unrecognized tax&#160;benefits for 2021, 2020 and 2019: </span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions of prior years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes it is reasonably possible that the total amount of unrecognized tax benefits at December 31, 2021 could decrease by approximately $104 million in the next twelve months as a result of the resolution of certain tax and transfer pricing audits and other events.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373495147160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">LOSS PER SHARE</a></td>
<td class="text">LOSS  PER SHARE<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss per share attributable to Bausch Health Companies Inc. for 2021, 2020 and 2019 were calculated as&#160;follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(560)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,788)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic and diluted weighted-average common shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">358.9&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">355.0&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352.1&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.64)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.58)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.08)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, 2020 and 2019, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive.  The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately 4,932,000, 3,154,000 and 5,106,000 common shares for 2021, 2020 and 2019, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in 2021, 2020 and 2019, stock options, time-based RSUs and performance-based RSUs to purchase approximately 3,428,000, 9,551,000 and 2,598,000 common shares of the Company, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During 2021, an additional 156,000 performance-based RSUs were not included in the computation of diluted earnings per share as the required performance conditions had not been met.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373495119224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL CASH FLOW DISCLOSURES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">SUPPLEMENTAL CASH FLOW DISCLOSURES</a></td>
<td class="text">SUPPLEMENTAL CASH FLOW DISCLOSURES <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow disclosures for 2021, 2020 and 2019 are as&#160;follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -URI http://asc.fasb.org/topic&amp;trid=2134446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373495192536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">LEGAL PROCEEDINGS</a></td>
<td class="text">LEGAL PROCEEDINGS<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described below. Going forward, in the Company's subsequent Quarterly Reports on Form 10-Q, the Company will only include a description of these matters to the extent there has been a material update with respect thereto during the applicable quarter or to the extent otherwise required by law.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a quarterly basis, the Company evaluates developments in legal proceedings, potential settlements and other matters that could increase or decrease the amount of the liability accrued. As of December 31, 2021, the Company's Consolidated Balance Sheets includes accrued current loss contingencies of $1,890 million related to matters which the Company believes a potential resolution or settlement is both probable and reasonably estimable. For all other matters, unless otherwise indicated, the Company cannot reasonably predict the outcome of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company&#8217;s business, financial condition and results of operations, and could cause the market value of its common shares and/or debt securities to decline.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental and Regulatory Inquiries</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investigation by the U.S. Attorney's Office for the District of Massachusetts - re OraPharma</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts, requesting materials including documents concerning the sales, marketing, coverage and reimbursement of Arestin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including related support services, and other matters.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is cooperating with this investigation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities and RICO Class Actions and Related Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Securities Litigation </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 16, 2019, the Company announced that it had agreed to settle, subject to final court approval, the consolidated securities class action filed in the U.S. District Court for the District of New Jersey (In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658). On January 31, 2021, the District Court </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued an order granting final approval of this settlement. On February 4, 2021, Timber Hill LLC filed a notice of appeal of the Court&#8217;s final approval order, which overruled its objections to the allocation of settlement proceeds as between common stock and options.  On March 1, 2021, Cathy Lochridge filed a notice of appeal of the Court&#8217;s final approval order, which overruled her objections as to the attorneys&#8217; fees awarded to class counsel. On October 14, 2021, Timber Hill dismissed its appeal of the final approval order. On December 20, 2021, the Third Circuit denied Lochridge&#8217;s appeal. On January 3, 2022, Lochridge filed a petition for rehearing of the appeal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">en banc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which remains pending.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2015, four putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. The allegations related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company&#8217;s business and prospects, including relating to drug pricing, the Company&#8217;s use of specialty pharmacies, and the Company&#8217;s relationship with Philidor. On May 31, 2016, the court entered an order consolidating the four actions under the caption In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658. On December 16, 2019, the Company, the current or former officers and directors, ValueAct, and the underwriters announced that they agreed to resolve the securities action for $1,210 million, subject to final court approval. This settlement received final approval from the court on January 31, 2021 and will resolve and discharge all claims against the Company in the class action.  As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. The settlement remains subject to an appeal of the final court approval (as such appeal is further described above). In order to qualify for a settlement payment all persons and entities that purchased or otherwise acquired the Company securities during the class period must have submitted a proof of claim and release form by May 6, 2020. The settlement payments have been paid into an escrow account in accordance with the payment schedule outlined in the settlement agreement. These payments, less certain settlement expenses and attorneys' fees, will remain in escrow until resolution of the appeal of the final court approval of the settlement agreement. The opt-out litigations discussed below remain ongoing. As of December 31, 2021, Restricted cash and other settlement deposits includes an aggregate $1,210&#160;million of: (i) payments in the escrow fund and (ii) certain disbursements for settlement expenses and attorney's fees. Disbursements for attorney's fees remain refundable until resolution of the appeal of the final court approval of the settlement agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2018, a putative class action was filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. This action, captioned Timber Hill LLC, v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 18-cv-10246) (&#8220;Timber Hill&#8221;), asserts securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons who purchased call options or sold put options on the Company&#8217;s common stock during the period January 4, 2013 through August 11, 2016.  On June 11, 2018, this action was consolidated with In re Valeant Pharmaceuticals International, Inc. Securities Litigation, (Case No. 15-cv-07658).  On January 14, 2019, the defendants filed a motion to dismiss the Timber Hill complaint. Briefing on that motion was completed on February 13, 2019. On August 15, 2019, the Court denied the motion to dismiss the Timber Hill action, holding that this complaint was a legal nullity as a result of the June 11, 2018 consolidation order.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the consolidated putative class action, thirty-seven groups of individual investors in the Company&#8217;s stock and debt securities have chosen to opt out of the consolidated putative class action and filed securities actions in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. These actions are captioned: T. Rowe Price Growth Stock Fund, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-5034); Equity Trustees Limited as Responsible Entity for T. Rowe Price Global Equity Fund v. Valeant Pharmaceuticals International Inc. (Case No. 16-cv-6127); Principal Funds, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-6128); BloombergSen Partners Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7212); Discovery Global Citizens Master Fund, Ltd. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7321); MSD Torchlight Partners, L.P. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7324); BlueMountain Foinaven Master Fund, L.P. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7328) (&#8220;BlueMountain&#8221;); Incline Global Master LP v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7494); VALIC Company I v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7496); Janus Aspen Series v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7497) (&#8220;Janus Aspen&#8221;); Okumus Opportunistic Value Fund, LTD v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-6513) (&#8220;Okumus&#8221;); Lord Abbett Investment Trust- Lord Abbett Short Duration Income Fund, v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-6365) (&#8220;Lord Abbett&#8221;); Pentwater Equity Opportunities Master Fund LTD v. Valeant Pharmaceuticals International, Inc., et al. (Case No. 17-cv-7552) (&#8220;Pentwater&#8221;); Public Employees&#8217; Retirement System of Mississippi v. Valeant Pharmaceuticals International Inc. (Case No. 17-cv-7625) (&#8220;Mississippi&#8221;); The Boeing Company Employee Retirement Plans Master Trust v. Valeant Pharmaceuticals International Inc., et al., (Case No. 17-cv-7636) (&#8220;Boeing&#8221;); State Board of Administration of Florida v. Valeant Pharmaceuticals International Inc. (Case No. 17-cv-12808); The Regents of the University of California v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-13488); GMO Trust v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0089); F&#246;rsta AP Fonden v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-12088); New York City Employees&#8217; Retirement System v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0032) </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;NYCERS&#8221;); Hound Partners Offshore Fund, LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-08705) (&#8220;Hound Partners&#8221;); Blackrock Global Allocation Fund, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0343) (&#8220;Blackrock&#8221;); Colonial First State Investments Limited As Responsible Entity for Commonwealth Global Shares Fund 1 v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0383); Bharat Ahuja v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0846); Brahman Capital Corp. v. Valeant Pharmaceuticals International, Inc (Case No. 18-cv-0893); The Prudential Insurance Company of America v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-01223) (&#8220;Prudential&#8221;); Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) (&#8220;Senzar&#8221;); 2012 Dynasty UC LLC v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-08595) (&#8220;2012 Dynasty&#8221;); Catalyst Dynamic Alpha Fund v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-12673) (&#8220;Catalyst&#8221;); Northwestern Mutual Life Insurance Co., v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-15286) (&#8220;Northwestern Mutual&#8221;); Bahaa Aly, et al. v. Valeant Pharmaceuticals International, Inc., (Case No. 18-cv-17393) (&#8220;Aly&#8221;); Office of the Treasurer as Trustee for the Connecticut Retirement Plans and Trust Funds v. Valeant Pharmaceuticals International, Inc. (Case No. 19-cv-18473) (&#8220;Connecticut&#8221;); Delaware Public Employees&#8217; Retirement System v. Valeant Pharmaceuticals International, Inc. (Case No. 19-cv-18475) (&#8220;Delaware&#8221;); Maverick Neutral Levered Fund v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-02190) (&#8220;Maverick&#8221;), Templeton v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-05478) (&#8220;Templeton&#8221;), USAA Mutual Funds Trust, et al. v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 20-cv-07462) (&#8220;USAA&#8221;), and GIC Private Ltd. v. Valeant Pharmaceuticals International, Inc., (Case No. 20-cv-07460) (&#8220;GIC&#8221;). Sixteen of the thirty-seven opt-out actions have been dismissed; and the total number of remaining opt-out actions pending in the District of New Jersey is twenty-one actions.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These individual shareholder actions assert claims under Sections 10(b), and 20(a) of the Exchange Act. Certain of these individual actions assert additional claims, including claims under Section 18 of the Exchange Act, Sections 11, 12(a)(2), and 15 of the Securities Act, common law fraud, negligent misrepresentation, and claims under the New Jersey Racketeer Influenced and Corrupt Organizations Act. These claims are based on alleged purchases of Company stock, options, and/or debt at various times between January 3, 2013 and August 10, 2016. The allegations in the complaints are similar to those made by plaintiffs in the putative class action. Motions to dismiss have been filed and in most cases decided in many of these individual actions. To date, the Court has dismissed state law claims including New Jersey Racketeer Influenced and Corrupt Organizations Act, common law fraud, and negligent misrepresentation claims in certain cases. On January 7, 2019, the Court entered a stipulation of voluntary dismissal in the Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) opt-out action, closing the case.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 10, 2019, the Court granted defendants&#8217; motion to dismiss all claims in the Bahaa Aly v. Valeant Pharmaceuticals International, Inc. (&#8220;Aly&#8221;) (Case No. 18-cv-17393) opt-out action. On October 9, 2019, the Aly Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Third Circuit. On June 16, 2021, the Court of Appeals granted plaintiffs&#8217; appeal in the Aly action. This action has been remanded to the District Court. On June 19, 2020, the Court entered stipulations of voluntary dismissal in the Catalyst, Mississippi, Connecticut, and Delaware actions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 13, 2020, the Court entered a stipulation of voluntary dismissal in the NYCERS action. On December 30, 2020, the Court entered a stipulation of voluntary dismissal in the BlueMountain action. On February 18, 2021, and March 10, 2021, the Court entered stipulations of voluntary dismissal in the T. Rowe, BloombergSen, Principal Funds, Pentwater, Lord Abbett, Equity Trustees, and UC Regents actions. On April 30, 2021, the Court entered a stipulation of voluntary dismissal in the Florida SBA action.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2021, the Court entered a stipulation of voluntary dismissal in the Janus action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disputes the claims against it in the remaining individual opt-out complaints and intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canadian Securities Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, six putative class actions were filed and served against the Company and certain current or former officers and directors in Canada in the provinces of British Columbia, Ontario and Quebec. These actions are captioned: (a) Alladina v. Valeant, et al. (Case No. S-1594B6) (Supreme Court of British Columbia) (filed November 17, 2015); (b) Kowalyshyn v. Valeant, et al. (CV-15-540593-00CP) (Ontario Superior Court) (filed November 16, 2015); (c) Kowalyshyn et al. v. Valeant, et al. (CV-15-541082-00CP) (Ontario Superior Court) (filed November 23, 2015); (d) O&#8217;Brien v. Valeant et al. (CV-15-543678-00CP) (Ontario Superior Court) (filed December 30, 2015); (e) Catucci v. Valeant, et al. (Court File No. 540-17-011743159, then Court File No. 500-06-000783-163) (Quebec Superior Court) (filed October 26, 2015); and (f) Rousseau-Godbout v. Valeant, et al. (Court File No. 500-06-000770-152) (Quebec Superior Court) (filed October 27, 2015). </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also aware of two additional putative class actions that were filed with the applicable court but which have not been served on the Company. These actions are captioned: (i) Okeley v. Valeant, et al. (Case No. S-159991) (Supreme Court of British Columbia) (filed December 2, 2015); and (ii) Sukenaga v Valeant et al. (CV-15-540567-00CP) (Ontario </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Superior Court) (filed November 16, 2015), and the factual allegations made in these actions are substantially similar to those outlined herein.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The actions generally allege violations of Canadian provincial securities legislation on behalf of putative classes of persons who purchased or otherwise acquired securities of the Company for periods commencing as early as January 1, 2013 and ending as late as November 16, 2015. The alleged violations relate to the same matters described in the U.S. Securities Litigation description above.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these putative class actions, other than the Catucci action in the Quebec Superior Court, was discontinued. In the Catucci action, on August 29, 2017, the judge granted the plaintiffs leave to proceed with their claims under the Quebec Securities Act and authorized the class proceeding.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 26, 2017, the plaintiffs issued their Judicial Application Originating Class Proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After a hearing on November 11, 2019, the court approved a settlement in the Catucci action between the class members and the Company&#8217;s auditors and the action was dismissed as against them. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2020, the Company entered into a settlement agreement with the plaintiffs in Catucci, on behalf of the class, pursuant to which it agreed to resolve the Catucci action for the amount of CAD 94 million plus payment of an additional amount to cover notice and settlement administration costs and disbursements.  As part of the settlement, the Company and the other defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. Court approval of the settlement was granted after a hearing on November 16, 2020. The Catucci action has now been dismissed against the Company, its current and former directors and officers, its underwriters and its insurers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the class proceedings described above, on April 12, 2018, the Company was served with an application for leave filed in the Quebec Superior Court of Justice to pursue an action under the Quebec Securities Act against the Company and certain current or former officers and directors. This proceeding is captioned BlackRock Asset Management Canada Limited et al. v. Valeant, et al. (Court File No. 500-11-054155-185). The allegations in the proceeding are similar to those made by plaintiffs in the Catucci class action.  On June 18, 2018, the same BlackRock entities filed an originating application (Court File No. 500-17-103749-183) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is aware that certain other members of the Catucci class exercised their opt-out rights prior to the June 19, 2018 deadline. On February 15, 2019, one of the entities which exercised its opt-out rights, the California State Teachers' Retirement System (&#8220;CalSTRS&#8221;), served the Company with an application in the Quebec Superior Court of Justice for leave to pursue an action under the Quebec Securities Act against the Company, certain current or former officers and directors of the Company and its auditor. That proceeding is captioned California State Teachers&#8217; Retirement System v. Bausch Health Companies Inc. et al. (Court File No. 500-11-055722-181). The allegations in the proceeding are similar to those made by the plaintiffs in the Catucci class action and in the BlackRock opt-out proceedings. On that same date, CalSTRS also served the Company with proceedings (Court File No. 500-17-106044-186) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2020, the Quebec Superior Court granted the applications of CalSTRS and BlackRock for leave to pursue their respective actions asserting claims under the Quebec Securities Act. On June 16, 2020, the Quebec Court of Appeal granted the defendants leave to appeal that decision. The appeal was heard on September 29, 2021 and, by judgment dated October 29, 2021, the appeals were dismissed.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 8 and 9, 2020, respectively, CalSTRS amended its proceedings to, among other things, include a new alleged misrepresentation concerning the accounting treatment of &#8220;price appreciation credits&#8221; in respect of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> during the period covered by the claims. A hearing was held on February 17, 2021 with respect to whether CalSTRS would be permitted to file the proposed amended proceedings. On June 9, 2021, the Quebec Superior Court granted the Company&#8217;s application to strike the new allegations from its Quebec Securities Act claim, but permitted the amendments to its claim under the Quebec Civil Code. On December 8, 2021, CalSTRS delivered its amended pleadings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2021, four additional opt-outs from the Catucci class issued a Statement of Claim in the Ontario Superior Court of Justice. That proceeding is captioned The Bank of Korea et al. v. Valeant Pharmaceuticals International Inc. et al. (Court File No. 21-00658966-0000). In addition, these plaintiffs also served and filed a motion for leave to pursue claims under the Ontario Securities Act. The allegations in this proceeding are similar to those made by the plaintiffs in the Catucci class action and the plaintiffs in the opt-out actions described above. </span></div><div style="margin-top:7.5pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that it has viable defenses in each of these actions. In each case, the Company intends to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RICO Class Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between May 27, 2016 and September 16, 2016, three actions were filed in the U.S. District Court for the District of New Jersey against the Company and various third-parties (these actions were subsequently consolidated), alleging claims under the federal Racketeer Influenced Corrupt Organizations Act (&#8220;RICO&#8221;) on behalf of a putative class of certain third-party payors that paid claims submitted by Philidor for certain Company-branded drugs between January 2, 2013 and November 9, 2015.&#160; The consolidated complaint alleges, among other things, that the defendants committed predicate acts of mail and wire fraud by submitting or causing to be submitted prescription reimbursement requests that misstated or omitted facts regarding: (1) the identity and licensing status of the dispensing pharmacy; (2) the resubmission of previously denied claims; (3) patient co-pay waivers; (4) the availability of generic alternatives; and (5) the insured&#8217;s consent to renew the prescription.&#160; The complaint further alleges that these acts constitute a pattern of racketeering or a racketeering conspiracy in violation of the RICO statute and caused plaintiffs and the putative class unspecified damages, which may be trebled under the RICO statute.  On August 4, 2021, the Company executed a stipulation of settlement for this action and, on August 17, 2021, the Court preliminarily approved the settlement.  On December 6, 2021 the Special Master overseeing this litigation issued a report and recommendation recommending final approval of the settlement, and on February 22, 2022 the settlement was approved by the district court. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Coverage Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2017, the Company filed a lawsuit against its insurance companies that issued insurance policies covering claims made against the Company, its subsidiaries, and its directors and officers during two distinct policy periods, (i) 2013-14 and (ii) 2015-16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lawsuit is currently pending in the United States District Court for the District of New Jersey (Valeant Pharmaceuticals International, Inc., et al. v. AIG Insurance Company of Canada, et al.; 3:18-CV-00493).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the lawsuit, the Company seeks coverage for: (i) the costs of defending and resolving claims brought by former shareholders and debtholders of Allergan, Inc. in In re Allergan, Inc. Proxy Violation Securities Litigation and Timber Hill LLC, individually and on behalf of all others similarly situated v. Pershing Square Capital Management, L.P., et al. (the &#8220;Allergan Securities Litigation&#8221;) (under the 2013-2014 coverage period), and (ii) costs incurred and to be incurred in connection with the securities class actions and opt-out cases described in this section and the SEC Investigation and certain of the other investigations described under &#8220;Complete or Inactive Matters&#8221; in Note 20, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC and the CSA on February 24, 2021 and under &#8220;Governmental and Regulatory Inquiries&#8221; and &#8220;Complete or Inactive Matters&#8221; in Note 21, &#8220;LEGAL PROCEEDINGS,&#8221; to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC and the CSA on February 19, 2020 (under the 2015-2016 coverage period).</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2021, the Company entered into settlement agreements with the insurers in the 2015-2016 coverage period in which the Company agreed to resolve its claims for insurance coverage in connection with the U.S. Securities Litigation and the Canadian Securities Litigation and related opt-out litigation and related investigations matters described above.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On that same day, the Company entered into settlement agreements with two of its insurers in the 2013-2014 coverage period in which the Company agreed to resolve its claims against those two insurers only for insurance coverage in connection with the Allergan Securities Litigation. As a result of all of the settlement agreements entered into with the insurers on July 20, 2021, the Company has received an aggregate sum of $213&#160;million. The Company&#8217;s insurance claims with respect to the Allergan Securities Litigation against the remaining insurers in the 2013-2014 coverage period remain pending.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hound Partners Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, Hound Partners Offshore Fund, LP, Hound Partners Long Master, LP, and Hound Partners Concentrated Master, LP, filed a lawsuit against the Company in the Superior Court of New Jersey Law Division/Mercer County.  This action is captioned Hound Partners Offshore Fund, LP et al., v. Valeant Pharmaceuticals International, Inc., et al. (No. MER-L-002185-18).  This suit asserts claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act. The Company disputes the claims and intends to vigorously defend this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pricing Antitrust Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's subsidiaries, Oceanside Pharmaceuticals, Inc. (&#8220;Oceanside&#8221;), Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) (&#8220;Bausch Health US&#8221;), and Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International) (&#8220;Bausch Health Americas&#8221;) (for the purposes of this paragraph, collectively, the &#8220;Company&#8221;), are defendants in multidistrict antitrust litigation (&#8220;MDL&#8221;) entitled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Generic Pharmaceuticals Pricing </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, pending in the United States District Court for the Eastern District of Pennsylvania (MDL No. 2724, 16-MD-2724). The lawsuits seek damages under federal and state antitrust laws, state consumer protection and unjust enrichment laws and allege that the Company&#8217;s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals. The lawsuits, which have been brought as putative class actions by direct purchasers, end payers, and indirect resellers, and as direct actions by direct purchasers, end payers, insurers, States, and various Counties, Cities, and Towns, have been consolidated into the MDL. There are also additional, separate complaints which have been consolidated in the same MDL that do not name the Company or any of its subsidiaries as a defendant. There are cases pending in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed in the cases. The cases have been put in deferred status. The Company disputes the claims against it and continues to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, Bausch Health Companies Inc. and certain U.S. and Canadian subsidiaries (for the purposes of this paragraph, collectively &#8220;the Company&#8221;) have been named as defendants in a proposed class proceeding entitled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kathryn Eaton v. Teva Canada Limited, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Federal Court in Toronto, Ontario, Canada (Court File No. T-607-20). The plaintiff seeks to certify a proposed class action on behalf of persons in Canada who purchased generic drugs in the private sector, alleging that the Company and other defendants violated the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Competition Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by conspiring to allocate the market, fix prices, and maintain the supply of generic drugs, and seeking damages under federal law. The proposed class action contains similar allegations to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re: Generic Pharmaceuticals Pricing Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> pending in the United States Court for the Eastern District of Pennsylvania. The Company disputes the claims against it and will defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza State-Law Insurer Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 8, 2021, the insurer plaintiff from the federal </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822-WHA (N.D. Cal.) (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) (discussed in further detail below) filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#8220;State Court Action&#8221;).  The State Court Action alleges that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or grant any other company a license to do so.  The State Court Action alleges that the settlement agreement resulted in higher prices for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. On September 20, 2021, the parties stipulated that the insurer plaintiff&#8217;s direct opt-out claims from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, discussed below, were deemed asserted in the State Court Action.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defendants&#8217; demurrer in the State Court Action was heard on September 22, 2021.  On November 11, 2021, the court denied the motion in part and granted it in part as to certain state law claims, with leave to amend.  The insurer plaintiff did not amend the complaint. Defendants&#8217; answers were filed on February 3, 2022. The Company disputes the claims and intends to vigorously defend this matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Litigation/Paragraph IV Matters</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company (and/or certain of its affiliates) is also party to certain patent infringement proceedings in the United States and Canada, including as arising from claims filed by the Company (or that the Company anticipates filing within the required time periods) in connection with Notices of Paragraph IV Certification (in the United States) and Notices of Allegation (in Canada) received from third-party generic manufacturers respecting their pending applications for generic versions of certain products sold by or on behalf of the Company, including Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 550mg, Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Relistor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Injection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the United States, and Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in Canada or other similar suits.</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2020, the Company and Alfasigma S.p.A.  (&#8220;Alfasigma&#8221;) received a Notice of Paragraph IV Certification from Norwich Pharmaceuticals Inc. (&#8220;Norwich&#8221;), in which Norwich asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Norwich&#8217;s generic rifaximin tablets, 550 mg, for which an Abbreviated New Drug Application (&#8220;ANDA&#8221;) has been filed by Norwich. The Company, through its subsidiaries Salix Pharmaceuticals, Inc. and Bausch Health Ireland Limited, holds the New Drug Application for Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and owns or exclusively licenses (from Alfasigma) these patents.  On March 26, 2020, certain of the Company&#8217;s subsidiaries and Alfasigma filed suit against Norwich in the U.S. District Court for the District of Delaware (Case No. 20-cv-00430) pursuant to the Hatch-Waxman Act, alleging infringement by Norwich of one or more claims of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of Norwich&#8217;s ANDA for rifaximin tablets, 550 mg. Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is protected by 26 patents covering the composition of matter and the use of Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. A 3-day bench trial is scheduled to begin March 21, 2022. The Company </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">remains confident in the strength of the Xifaxan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will continue to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 23, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (now Padagis LLC) (&#8220;Padagis&#8221;), in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA's Orange Book for Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotine) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#8217; generic lotion, for which an ANDA has been filed by Padagis.  On August 28, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA.  On September 3, 2020, this action was consolidated with the action between the Company and Padagis described below, regarding Padagis&#8217; ANDA for generic Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion. The Company remains confident in the strength of the Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related patents and will vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Padagis, in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#8217;s Orange Book for Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#8217; generic halobetasol propionate lotion, for which an ANDA has been filed by Padagis.  On May 1, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA for halobetasol propionate lotion. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described above, regarding Padagis&#8217; ANDA for generic Duobrii</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (halobetasol propionate and tazarotine) lotion. The Company remains confident in the strength of the Bryhali</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, the Company commenced litigation against MSN Laboratories Private Ltd. (&#8220;MSN&#8221;) and Mylan Pharmaceuticals Inc., (&#8220;Mylan&#8221;) alleging patent infringement by MSN&#8217;s and Mylan&#8217;s filing of their ANDA for generic Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (plecanatide) 3mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from each of MSN and Mylan, in which they had each asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> tablets, 3 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of their respective generic plecanatide tablets, 3 mg.  The filing of these suits triggered a 30-month stay of the approval of the MSN and Mylan ANDAs for plecanatide tablets. The Company remains confident in the strength of the Trulance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company commenced litigation against Slayback Pharma LLC and Slayback Pharma India LLP (together, &#8220;Slayback&#8221;) alleging patent infringement by Slayback Pharma LLC&#8217;s filing of its ANDA No. 216361, referencing Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (0.025% brimonidine tartrate ophthalmic solution). This suit had been filed following receipt of a Notice of Paragraph IV Certification from Slayback Pharma LLC, in which it had asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brimonidine tartrate ophthalmic solution, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of its generic brimonidine tartrate solution.  The filing of this suit triggered a 30-month stay of the approval of the Slayback ANDA for its brimonidine tartrate solution.  The Company remains confident in the strength of the Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and intends to vigorously defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2022 the Company commenced litigation against Lupin Pharmaceuticals, Inc. (&#8220;Lupin&#8221;) alleging patent infringement by Lupin&#8217;s filing of its ANDA No. 216716, referencing Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (0.025% brimonidine tartrate ophthalmic solution). This suit had been filed following receipt of a Notice of Paragraph IV Certification from Lupin, in which it had asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#8217;s Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> brimonidine tartrate ophthalmic solution, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of its generic brimonidine tartrate solution.  The filing of this suit triggered a 30-month stay of the approval of the Lupin ANDA for its brimonidine tartrate solution. The Company remains confident in the strength of the Lumify</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> patents and will continue to vigorously pursue this matter and defend its intellectual property.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jublia Patent Litigation</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, patents covering the Company's branded pharmaceutical products may be challenged in proceedings other than court proceedings, including inter partes review (&#8220;IPR&#8221;) at the U.S. Patent &amp; Trademark Office. The proceedings operate under different standards from district court proceedings, and are often completed within 18 months of institution. IPR challenges have been brought against patents covering the Company's branded pharmaceutical products. For example, following Acrux DDS&#8217;s IPR petition, the U.S. Patent and Trial Appeal Board  (&#8220;PTAB&#8221;), in May 2017, instituted inter partes review for an Orange Book-listed patent covering Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(U.S. Patent No. 7,214,506 (the &#8220;&#8216;506 Patent&#8221;)) and, on </span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 6, 2018, issued a written determination invalidating such patent. An appeal of this decision was filed on August 7, 2018. On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings.  As a result of a settlement, a joint motion to terminate the proceedings was filed on November 12, 2020 and, on January 8, 2021, the PTAB granted this motion.   The &#8216;506 Patent, therefore, remains valid and enforceable and expires in 2026. Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is covered by fourteen Orange Book-listed patents owned by the Company or its licensor, which expire in the years 2028 through 2035. In August and September 2018, the Company received notices of the filing of a number of ANDAs with paragraph IV certification, and has timely filed patent infringement suits against these ANDA filers, and, in addition, the Company has also commenced certain patent infringement proceedings in Canada against four separate defendants.  All cases in the U.S. regarding Jublia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been settled. In Canada, two lawsuits remain pending against Apotex Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Products Liability Litigation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2016, the Company has been named in a number of product liability lawsuits involving the Shower to Shower&#174; body powder product acquired in September 2012 from Johnson &amp; Johnson; due to dismissals, twenty-nine (29) of such product liability suits currently remain pending. Potential liability (including its attorneys&#8217; fees and costs) arising out of these remaining suits is subject to full indemnification obligations of Johnson &amp; Johnson owed to the Company and its affiliates, and legal fees and costs will be paid by Johnson &amp; Johnson. Twenty-eight (28) of these lawsuits filed by individual plaintiffs allege that the use of Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> caused the plaintiffs to develop ovarian cancer, mesothelioma or breast cancer. The allegations in these cases include failure to warn, design defect, manufacturing defect, negligence, gross negligence, breach of express and implied warranties, civil conspiracy concert in action, negligent misrepresentation, wrongful death, loss of consortium and/or punitive damages. The damages sought include compensatory damages, including medical expenses, lost wages or earning capacity, loss of consortium and/or compensation for pain and suffering, mental anguish anxiety and discomfort, physical impairment and loss of enjoyment of life. Plaintiffs also seek pre- and post-judgment interest, exemplary and punitive damages, and attorneys&#8217; fees. Additionally, two proposed class actions have been filed in Canada against the Company and various Johnson &amp; Johnson entities (one in the Supreme Court of British Columbia and one in the Superior Court of Quebec), on behalf of persons who have purchased or used Johnson &amp; Johnson&#8217;s Baby Powder or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The class actions allege the use of the product increases certain health risks (British Columbia) or negligence in failing to properly test, failing to warn of health risks, and failing to remove the products from the market in a timely manner (Quebec). The plaintiffs in these actions are seeking awards of general, special, compensatory and punitive damages. On November 17, 2020, the British Columbia court issued a judgment declining to certify a class as to the Company or Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and at this time no appeal of that judgment has been filed. On December 16, 2021, the plaintiff in the British Columbia class action filed a Second Amended Notice of Civil Claim and Application for Certification, removing the Company as a defendant; as a result, the British Columbia class action is concluded as to the Company. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson, through one or more subsidiaries has purported to have completed a Texas divisional merger with respect to any talc liabilities at Johnson &amp; Johnson Consumer, Inc. (&#8220;JJCI&#8221;). LTL Management, LLC (&#8220;LTL&#8221;), the resulting entity of the divisional merger, assumed JJCI&#8217;s talc liabilities and thereafter filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the Western District of North Carolina. Pursuant to a court order, the case was transferred to the United States District Court for the District of New Jersey. Notwithstanding the divisional merger and LTL&#8217;s bankruptcy case, the Company and its affiliates continue to have indemnification claims and rights against Johnson &amp; Johnson and LTL pursuant to the terms of the indemnification agreement entered into between JJCI and its affiliates and the Company and its affiliates, which indemnification agreement remains in effect. As a result, it is the Company's current expectation that it will not incur any material impairments with respect to its indemnification claims as a result of the divisional merger or the bankruptcy. Substantially all cases subject to the indemnification agreement related to Johnson &amp; Johnson&#8217;s talc liability are stayed through February 28, 2022, pursuant to a preliminary injunction issued by the bankruptcy court. Motions to dismiss the LTL bankruptcy, as well as extend the stay beyond February 28, 2022, were argued in the bankruptcy court in February 2022. A decision of the court is pending. To the extent that any cases subject to the indemnification agreement proceed during the pendency of the bankruptcy case, it is the Company's expectation that Johnson &amp; Johnson, in accordance with the indemnification agreement, will continue to vigorously defend the Company in each of the remaining actions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Civil Actions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Proposition 65 Related Matter</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 19, 2019, plaintiffs filed a proposed class action in California state court against Bausch Health US and Johnson &amp; Johnson (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gutierrez, et al. v. Johnson &amp; Johnson, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 37-2019-00025810-CU-NP-CTL), asserting claims for </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">purported violations of the California Consumer Legal Remedies Act, False Advertising Law and Unfair Competition Law in connection with their sale of talcum powder products that the plaintiffs allege violated Proposition 65 and/or the California Safe Cosmetics Act. This lawsuit was served on Bausch Health US in June 2019 and was subsequently removed to the United States District Court for the Southern District of California, where it is currently pending. Plaintiffs seek damages, disgorgement of profits, injunctive relief, and reimbursement/restitution. The Company filed a motion to dismiss Plaintiffs&#8217; claims, which was granted in April 2020 without prejudice. In May 2020, Plaintiffs filed an amended complaint and in June 2020, filed a motion for leave to amend the complaint further, which was granted.  In August 2020, Plaintiffs filed the Fifth Amended Complaint. On January 22, 2021, the Court granted the motion to dismiss with prejudice. On February 19, 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit Court of Appeals. On July 1, 2021, Appellants (Plaintiffs) filed their opening brief; Appellees' response briefs were filed on October 8, 2021. This matter was stayed by the Ninth Circuit on December 7, 2021, due to the preliminary injunction entered by the bankruptcy court in the LTL bankruptcy proceeding. This stay included Appellants&#8217; reply brief deadline, which was previously due to be filed on or before December 2, 2021. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Mexico Attorney General Consumer Protection Action</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US were named in an action brought by State of New Mexico ex rel. Hector H. Balderas, Attorney General of New Mexico, in the County of Santa Fe New Mexico First Judicial District Court (New Mexico ex rel. Balderas v. Johnson &amp; Johnson, et al., Civil Action No. D-101-CV-2020-00013, filed on January 2, 2020), alleging consumer protection claims against Johnson &amp; Johnson and Johnson &amp; Johnson Consumer Companies, Inc., the Company and Bausch Health US related to Shower to Shower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its alleged causal link to mesothelioma and other cancers.  In April 2020, Bausch Health US filed a motion to dismiss, which in September 2020, the Court granted in part as to the New Mexico Medicaid Fraud Act and New Mexico Fraud Against Taxpayers Act claims and denied as to all other claims. The State of New Mexico brings claims against all defendants under the New Mexico Unfair Practices Act and other common law and equitable causes of action, alleging defendants engaged in wrongful marketing, sale and promotion of talcum powder products. The lawsuit seeks to recover the cost of the talcum powder products as well as the cost of treating asbestos-related cancers allegedly caused by those products. Bausch Health US filed its answer on November 16, 2020. On December 30, 2020 Johnson &amp; Johnson filed a Motion for Partial Judgment on the Pleadings and on January 4, 2021, Bausch Health US filed a joinder to that motion, which was denied on March 8, 2021. Trial is scheduled to begin on January 18, 2023.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Doctors Allergy Formula Lawsuit</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, Doctors Allergy Formula, LLC (&#8220;Doctors Allergy&#8221;), filed a lawsuit against Bausch Health Americas in the Supreme Court of the State of New York, County of New York, asserting breach of contract and related claims under a 2015 Asset Purchase Agreement, which purports to include milestone payments that Doctors Allergy alleges should have been paid by Bausch Health Americas.  Doctors Allergy claims its damages are not less than $23 million. Bausch Health Americas has asserted counterclaims against Doctors Allergy. Bausch Health Americas filed a motion seeking an order granting Bausch Health Americas summary judgment on its counterclaims against Plaintiff and dismissing Plaintiff&#8217;s claims against it. The motion was fully briefed as of May 2021. The Court held a hearing on the motion on January 25, 2022. The motion remains pending. Bausch Health Americas disputes the claims against it and will continue to defend itself vigorously.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation with Former Salix CEO</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 28, 2019, former Salix Ltd. CEO and director Carolyn Logan filed a lawsuit in the Delaware Court of Chancery, Case No. 2019-0059, asserting claims for breach of contract and declaratory relief.  On November 19, 2021, Logan amended her complaint to add a claim for breach of the implied covenant of good faith and fair dealing. The lawsuit arises out of the contractual termination of approximately $30 million in unvested equity awards following the determination by the Salix Ltd. Board of Directors that Logan intentionally engaged in wrongdoing that resulted, or would reasonably be expected to result, in material harm to Salix Ltd., or to the business or reputation of Salix Ltd.  Logan seeks the restoration of the unvested equity awards and a declaration regarding certain rights related to indemnification. On June 19, 2019, the Court entered an order staying the claim for declaratory relief pending the final resolution of the breach of contract claim. Trial is scheduled to commence on September 6, 2022. The Company disputes the claims and intends to vigorously defend the matter.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Completed or Inactive Matters</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following matters have concluded, have settled, are the subject of an agreement to settle or have otherwise been closed since January 1, 2021, have been inactive from the Company&#8217;s perspective for several quarters or the Company anticipates that no further material activity will take place with respect thereto. Due to the closure, settlement, inactivity or change in status of the matters referenced below, these matters will no longer appear in the Company's next public reports and disclosures, unless required. With respect to inactive matters, to the extent material activity takes place in subsequent quarters with respect thereto, the Company will provide updates as required or as deemed appropriate.</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glumetza Antitrust Litigation</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between August 2019 and July 2020, eight (8) putative antitrust class actions and four (4) non-class complaints naming Bausch Health Companies Inc., Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., and Santarus, Inc. (for purposes of this subsection, collectively, the &#8220;Company&#8221;), among other defendants, were filed or transferred to the Northern District of California. Three (3) of the class actions were filed by plaintiffs seeking to represent a class of direct purchasers. The purported classes of direct purchasers filed a consolidated first amended complaint and a motion for class certification in April 2020. The court certified a direct purchaser class in August 2020.  The putative class action complaints filed by end payer purchasers have all been voluntarily dismissed. Three (3) of the non-class complaints were filed by direct purchasers. The fourth non-class complaint, asserting claims based on both direct and indirect purchases, was filed by an insurer plaintiff in July 2020 and subsequently amended in September 2020.  In December 2020, the court denied the Company&#8217;s motion to dismiss as to the insurer plaintiff&#8217;s direct claims but dismissed the insurer plaintiff&#8217;s indirect claims. On February 2, 2021, the insurer plaintiff&#8217;s motion for leave to amend its complaint was denied.</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These actions were consolidated and coordinated in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 3:19-cv-05822-WHA (N.D. Cal.) (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The lawsuits alleged that a 2012 settlement of a patent litigation regarding Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or grant any other company a license to do so. The complaints alleged that the settlement agreement resulted in higher prices for Glumetza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic equivalent both prior to and after generic entry. Both the class and non-class plaintiffs sought damages under federal antitrust laws for claims based on direct purchases.</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 26, 2021, the Company reached an agreement in principle and, thereafter, on September 14, 2021, executed a final settlement agreement to resolve the class plaintiffs&#8217; claims for $300&#160;million, subject to court approval. On August 1, 2021, the Company also reached an agreement in principle to resolve the non-class direct purchaser plaintiffs&#8217; claims, described above, for additional consideration.  A final settlement agreement with the non-class direct purchaser plaintiffs was executed on August 6, 2021. As part of the settlements, the Company admitted no liability as to the claims against it and denied all allegations of wrongdoing.  On September 20, 2021, the insurer plaintiff voluntarily dismissed its claims in the consolidated federal action. By stipulation, the insurer plaintiff has asserted its direct opt-out claims in the State Court Action, resulting in the consolidation of all of its opt-out claims in the State Court Action.</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 22, 2021, the court granted preliminary approval of the class settlement agreement and vacated the October 2021 trial date and all other pre-trial deadlines in the consolidated actions. On February 3, 2022, the court granted final  approval of the class settlement and ordered dismissal of the class plaintiffs' claims. Subject to appeal of the final approval of the class settlement, the settlements will resolve and discharge all asserted class and direct purchaser non-class claims against the Company in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Glumetza Antitrust Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Proposition 65 Related Matter</span></div><div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 29, 2020, Plaintiff Jan Graham filed a lawsuit (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Graham v. Bausch Health Companies, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 20STCV03578) in Los Angeles County Superior Court against the Company, Bausch Health US and several other manufacturers, distributors and retailers of talcum powder products, alleging violations of California Proposition 65 by manufacturing and distributing talcum powder products containing chemicals listed under the statue, without a compliant warning on the label. On January 29, 2021, certain defendants including the Company and Bausch Health US filed a Motion for Summary Judgment or in the Alternative Motion for Summary Adjudication, which was granted with prejudice on May 26, 2021; Plaintiff waived the right to appeal.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Lawsuits</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 10, 2019 and September 13, 2019, two alleged stockholders filed derivative lawsuits purportedly on behalf of the Company against former Company board members and executives. On March 7, 2020, a consolidated amended derivative complaint was filed, captioned In re Bausch Health Companies Inc. F/K/A/ Valeant Pharmaceuticals International, Inc. Stockholder Derivative Litigation (Case No. 19-cv-17833). </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plaintiffs asserted claims for breach of fiduciary duty, waste of corporate assets, and unjust enrichment related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company&#8217;s business and prospects, including relating to drug pricing, the Company&#8217;s use of specialty pharmacies, and the Company&#8217;s relationship with Philidor. The consolidated complaint also asserted a claim for contribution and indemnification by the Defendants for any liability the Company ultimately faces as a result of the conduct alleged in the complaint. The claims alleged in these cases were based on the same purported conduct that is at issue in In re Valeant Pharmaceuticals International, Inc. Securities Litigation, all of which occurred prior to 2017. On April 21, 2020, the Defendants filed a motion to dismiss the consolidated amended complaint.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Briefing on this motion concluded on August 3, 2020. On November 24, 2020, the Special Master appointed by the Court issued a report recommending that the motion to dismiss be granted in full.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2021, the District Court adopted the report and recommendation of the Special Master and dismissed the action.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373495188200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has commitments related to capital expenditures of approximately $76 million as of December&#160;31, 2021. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain agreements, the Company may be required to make payments contingent upon the achievement of specific developmental, regulatory, or commercial milestones. As of December&#160;31, 2021, the Company believes it is reasonably possible that it may potentially make milestone and license fee payments, including sales-based milestone payments, of approximately $340 million over time, in the aggregate, to third parties for products currently under development or being marketed, primarily consisting of the following:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of a June 2013 distribution and supply agreement with Mylan Pharmaceuticals Inc. (as assignee of Spear Pharmaceuticals, Inc and Spear Dermatology Products Inc.), the Company may be required to make sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $70 million, in the aggregate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of an April 2019 agreement with Mitsubishi Tanabe Pharma Corporation, the Company has acquired an exclusive license to develop and commercialize&#160;MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate receptor that plays a role in autoimmune diseases, such as Inflammatory Bowel Disease and ulcerative colitis. The Company may be required to make development and sales-based milestone payments over time of up to $60 million, in the aggregate, as well as royalties on future sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of a December 2019 agreement with Novaliq GmbH, the Company has acquired an exclusive license for the commercialization and development in the U.S. and Canada of NOV03 (perfluorohexyloctane), an investigational drug to treat Dry Eye Disease associated with Meibomian gland dysfunction and may be required to make sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $48 million, in the aggregate, as well as royalties on future sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of a November 2019 agreement with Cedars-Sinai Medical Center, to evaluate a new formulation of rifaximin for the treatment of irritable bowel syndrome, the Company may be required to make development and sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $36&#160;million, in the aggregate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of an October 2020 agreement with Eyenovia, Inc., the Company has acquired an exclusive license in the U.S. and Canada for the development and commercialization of an investigational microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression, also known as nearsightedness, in children ages 3-12. Under the terms of the agreement, the Company may be required to make development and sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $35&#160;million, in the aggregate.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the terms of a May 2020 agreement with STADA Arzneimittel AG and its development partner, Xbrane Biopharma AB, to commercialize in the U.S. and Canada a biosimilar candidate to Lucentis (ranibizumab), the Company may be required to make development and sales-based milestone payments.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of these arrangements, the future potential payments related to the attainment of the specified milestones over a period of several years are inherently uncertain. As of December 31, 2021, no accruals related to the aforementioned agreements exist because the milestone targets are not yet probable of being achieved.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into agreements that include indemnification provisions for product liability and other matters. These provisions are generally subject to maximum amounts, specified claim periods and other conditions and limits. In addition, the Company is obligated to indemnify its officers and directors in respect of any legal claims or actions initiated against them in their capacity as officers and directors of the Company in accordance with applicable law. Pursuant to such indemnities, the Company is indemnifying certain former officers and directors in respect of certain litigation and regulatory matters.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021 and 2020, no material amounts were accrued for the Company&#8217;s obligations under these indemnification provisions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373495002088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text">SEGMENT INFORMATION<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the planned separation of its Solta business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., the Company has begun managing its operations in a manner which is consistent with the organizational structure of the two separate entities as proposed by the Solta IPO. As a result, during the first quarter of 2022, the Company&#8217;s Chief Executive Officer  (&#8220;CEO&#8221;), who is the Company&#8217;s Chief Operating Decision Maker, commenced managing the business differently through changes in its operating and reportable segments, which necessitated a realignment of the Company&#8217;s historical segment structure. This realignment is consistent with how the Company&#8217;s CEO currently: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports. Pursuant to these changes, effective in the first quarter of 2022, the Company operates in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International (formerly International Rx), (iv) Solta Medical and (v) Diversified Products. The new segment structure does not impact the Company&#8217;s reporting units but realigns the two reporting units of the former Ortho Dermatologics segment whereby its medical dermatology reporting unit (Ortho Dermatologics) is now part of the current Diversified Products segment and the Solta reporting unit is now the sole reporting unit of the new Solta Medical segment. All segment revenues and segment profits for the periods presented have been recast to conform to the 2022 reportable segment structure.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a brief description of the Company&#8217;s segments:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Bausch + Lomb segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Bausch + Lomb Vision Care, Consumer, Surgical and Ophthalmic Pharmaceuticals products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Salix segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of GI products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The International segment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales, with the exception of sales of Bausch +Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Solta Medical segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of global sales of Solta aesthetic medical devices.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">The Diversified Products segment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products, (iii) Ortho Dermatologics (dermatological) products and (iv) dentistry products. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment profit is based on operating income after the elimination of intercompany transactions.  Certain costs, such as Amortization of intangible assets, Asset impairments, including loss on assets held for sale, Restructuring, integration, separation and IPO costs, and Other expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company&#8217;s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single&#160;segment.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Revenues and Profit</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenues and profits for the years 2021, 2020 and 2019 were as&#160;follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,027&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,601&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profit:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,578&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,835&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(792)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(619)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(609)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,375)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,645)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,897)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(502)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,426)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,534)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before benefit from income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,024)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,837)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to segment revenue and profit in order for the prior years to conform to current year presentation. These reclassifications are not material.</span></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Capital Expenditures</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures by segment for the years 2021, 2020 and 2019 were as&#160;follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total capital expenditures</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenues by Product and by Product Category </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for the Company's top ten products for the years 2021, 2020 and 2019 represented 43%, 41% and 39% of total product sales, respectively. Revenues by segment and product category were as&#160;follows: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"/><td style="width:23.745%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,762&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,596&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,765&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,074&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"/><td style="width:23.745%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,680&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,415&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,027&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"/><td style="width:23.745%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,524&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,718&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,778&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,453&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,601&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are attributed to a geographic region based on the location of the customer for the years 2021, 2020 and 2019 were as&#160;follows:</span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,887&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,164&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,027&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,601&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made and are reflected in the table above.</span></div><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consisting of property, plant and equipment, net of accumulated depreciation, are attributed to geographic regions based on their physical location as of December&#160;31, 2021 and 2020 were as&#160;follows: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:79.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serbia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Customers</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that accounted for 10% or more of total revenues were as&#160;follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health,&#160;Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373488991016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, the Company issued conditional notices of redemption to redeem in full all of its outstanding April 2025 Unsecured Notes&#8221;  and to redeem $370&#160;million aggregate principal amount of its outstanding December 2025 Unsecured Notes. On February 10, 2022, the Company extended these conditional notices of redemption through March 15, 2022. The redemption and discharge of the indenture governing the April 2025 Unsecured Notes&#8221;  will be conditioned upon the completion of the Credit Agreement Refinancing, as defined below. The redemption of the December 2025 Unsecured Notes will be conditioned upon the receipt of aggregate gross proceeds from the B+L IPO, the B+L Debt Financing as defined below, the Credit Agreement Refinancing and the offering of the February 2027 Secured Notes, as defined below, of at least $7,000&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 18, 2022, the Company announced its intention to refinance its existing Restated Credit Agreement with a Fifth Amended Restated Credit Agreement (the &#8220;New Restated Credit Agreement&#8221; and such refinancing, the &#8220;Credit Agreement Refinancing&#8221;). The New Restated Credit Agreement is expected to consist of approximately $2,500&#160;million of term B loans and a $975&#160;million revolving credit facility. The Credit Agreement Refinancing is expected to occur only upon completion of the B+L IPO and a related debt financing by Bausch + Lomb (the &#8220;B+L Debt Financing&#8221;). At the time of the B+L IPO, the Credit Agreement Refinancing will provide that Bausch + Lomb initially be a &#8220;restricted&#8221; subsidiary subject to the terms of the Credit Agreement covenants, however the Credit Agreement Refinancing is expected to permit the Company to designate Bausch + Lomb as an &#8220;unrestricted&#8221; subsidiary under the New Restated Credit Agreement covenants upon achievement of a 7.6x pro forma &#8220;Remainco Total Leverage Ratio.&#8221; Such designation could take place at any time after the B+L IPO (including as soon as the closing of the B+L IPO). The Credit Agreement Refinancing is designed to facilitate the separation and distribution of Bausch + Lomb. The Credit Agreement Refinancing will not be consummated until completion of the B+L IPO and related B+L Debt Financing. There can be no assurance that the Credit Agreement Refinancing will occur on the terms described above, or at all. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2022, the Company issued $1,000&#160;million aggregate principal amount of 6.125% senior secured notes due February 2027 (the &#8220;February 2027 Secured Notes&#8221;). The February 2027 Secured Notes accrue interest at a rate of 6.125% per year, payable semi-annually in arrears on each February and August. The February 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after February 2024, at the redemption prices set forth in the indenture. The Company may redeem some or all of the February 2027 Secured Notes prior to February 2024 at a price equal to 100% of the principal amount thereof plus a &#8220;make-whole&#8221; premium. Prior to February 2024, the Company may redeem up to 40% of the aggregate principal amount of the February 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the B+L IPO does not occur on or prior to August 15, 2022, the Company will be required to redeem the February 2027 Secured Notes at such time at a redemption price equal to the issue price of the February 2027 Secured Notes plus accrued and unpaid interest.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373490114056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation and Use of Estimates The Consolidated Financial Statements have been prepared by the Company in United&#160;States (&#8220;U.S.&#8221;) dollars and in accordance with U.S.&#160;generally accepted accounting principles (&#8220;U.S. GAAP&#8221;), applied on a consistent basis. The Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the Company's Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows.  The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include: provisions for product returns, rebates, chargebacks, discounts and allowances and distribution fees paid to certain wholesalers; useful lives of amortizable intangible assets and property, plant and equipment; expected future cash flows used in evaluating intangible assets for impairment, assessing compliance with debt covenants and making going concern assessments; reporting unit fair values for testing goodwill for impairment and allocating goodwill to new reporting unit structure on a relative fair value basis; provisions for loss contingencies; provisions for income taxes, uncertain tax positions and realizability of deferred tax assets; fair value of cross-currency swaps; fair value of foreign currency exchange contracts; and the recognition of the fair value of assets and liabilities acquired in a business combination, including the fair value of contingent consideration. Under certain product manufacturing and supply agreements, management uses information from the Company&#8217;s commercialization counterparties to arrive at estimates for future returns, rebates and chargebacks. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#8217;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#8217;s Consolidated Financial Statements could be materially impacted.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior year amounts to conform to the current year presentation.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commencing in the first quarter of 2022, the Company operates in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International, (iv) Solta Medical and (v) Diversified Products. Prior to the first quarter of 2022, the Company operated in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International, (iv) Ortho Dermatologics and (v) Diversified Products. All segment revenues and profits for the periods presented have been recast to conform to the 2022 segment reporting structure. See Note 22, &#8220;SEGMENT INFORMATION&#8221; for additional information.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions and Acquisition-Related Contingent Consideration</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisitions </span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Consolidated Financial Statements after the date of acquisition.  Acquired in-process research and development (&#8220;IPR&amp;D&#8221;) is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&amp;D has an alternative future use. If the acquired net assets do not constitute a business, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&amp;D with no alternative future use is charged to expense at the acquisition&#160;date and any future contingent consideration is not recorded until it becomes probable.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition-Related Contingent Consideration </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition-related contingent consideration, which primarily consists of potential milestone payments and royalty obligations, is recorded in the Consolidated Balance Sheets at its acquisition date estimated fair value, in accordance with the acquisition method of accounting. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the Consolidated Statements of Operations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level&#160;3 measurement as defined in fair value measurement accounting.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value of Financial InstrumentsThe estimated fair values of cash and cash equivalents, trade receivables, accounts payable and accrued liabilities approximate their carrying values due to their short maturity periods. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows or Monte Carlo Simulation (when appropriate) analyses and assessment of the probability of occurrence of potential future events.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Fair Value of Derivative Instruments</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Derivative Instruments</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting for changes in the fair value of a derivative instrument depends on whether the instrument has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Consolidated Statements of Operations during the current period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cross-currency swaps qualified for and had been designated as an accounting hedge of the foreign currency exposure of a net investment in a foreign operation and were remeasured at each reporting date to reflect changes in their fair values.  The fair value was determined via a mark-to-market analysis, using observable (Level&#160;2) inputs. These inputs included: (i)&#160;the foreign currency exchange spot rate between the euro and U.S. dollar, (ii)&#160;the interest rate yield curves in the euro and U.S. dollar and (iii)&#160;the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps is reported as a gain or loss in the Consolidated Statements of Comprehensive Loss as part of Foreign currency translation adjustment to the extent they are effective, and remain in Accumulated other comprehensive loss until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps was ineffective. The Company uses the spot method of assessing hedge effectiveness. The Company had elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as a reduction of Interest expense in the Consolidated Statements of Operations.</span></div>The Company uses foreign currency exchange contracts to economically hedge the foreign exchange exposure on certain of the Company&#8217;s intercompany and third party balances. The Company's foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash in bank accounts and highly liquid investments with maturities of three months or less when&#160;purchased.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables, cross-currency swaps and foreign currency exchange contracts.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests its excess cash in high-quality, money market instruments and term deposits with varying maturities, but typically less than three months.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash deposited at banks may exceed the amount of insurance provided on such deposits. Generally, these cash deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate such risks by spreading its risk across multiple counterparties and monitoring the risk profiles of these counterparties.</span></div>The Company&#8217;s trade receivables primarily represent amounts due from wholesale distributors, retail pharmacies, government entities and group purchasing organizations. Outside of the U.S., concentrations of credit risk with respect to trade receivables, which are typically unsecured, are limited due to the number of customers using the Company&#8217;s products, as well as their dispersion across many different geographic regions. The Company performs periodic credit evaluations of customers and does not require collateral. The Company monitors economic conditions, including volatility associated with international economies, and related impacts on the relevant financial markets and its business, especially in light of sovereign credit issues. The credit and economic conditions within Argentina, Brazil, Egypt, Greece, among other members of the European Union, Turkey, Ukraine and Venezuela have been weak in recent years.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts', window );">Allowance for Credit Losses</a></td>
<td class="text">Allowance for Credit LossesAn allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.&#160; Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be&#160;collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories comprise raw materials, work in process and finished goods, which are valued at the lower of cost or net realizable value, on a first-in, first-out basis. The cost value for work in process and finished goods inventories includes materials, direct labor and an allocation of overheads. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on&#160;hand.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are reported at cost, less accumulated depreciation. Costs incurred on assets under construction are capitalized as construction in progress. Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful&#160;lives: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:54.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 30 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 40 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;-&#160;20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;-&#160;10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment on operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of term of lease or 10 years</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reported at cost, less accumulated amortization and impairments. Intangible assets with finite lives are amortized over their estimated useful lives. Amortization is calculated primarily using the straight-line method based on the following estimated useful&#160;lives:</span></div><div style="margin-top:5pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:54.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - 20 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 - 20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 - 15 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 - 9 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Out-licensed technology and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 - 9 years</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DivestituresOfNoncoreProductsPolicyTextBlock', window );">Divestitures of Products</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Divestitures of Products</span></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds on the divestiture of products and the carrying amount of the related assets is recorded as a gain/loss on sale within Other expense, net. Any contingent payments that are potentially due to the Company as a result of these divestitures are recorded when realizable.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">IPR&amp;D</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IPR&amp;D </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of IPR&amp;D acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset will be assigned a useful life and&#160;amortized. Acquired IPR&amp;D assets are tested for impairment at least annually or when triggering events are identified.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of an acquired IPR&amp;D intangible asset is typically determined using an income approach. This approach starts with a forecast of the net cash flows expected to be generated by the asset over its estimated useful life. The net cash flows reflect the asset&#8217;s stage of completion, the probability of technical success, the projected costs to complete, expected market competition and an assessment of the asset&#8217;s life-cycle. The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the expected cash flow&#160;streams.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.  If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset, which include the amount and timing of the projected future cash flows. If the expected undiscounted cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash&#160;flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets, which includes acquired IPR&amp;D and the corporate trademark acquired in the acquisition of Bausch &amp; Lomb Holdings Incorporated (the &#8216;&#8216;B&amp;L Trademark&#8217;&#8217;), are tested for impairment annually or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based on a comparison of the fair value of the asset to its carrying value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is recorded with the acquisition of a business and is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment at least annually as of October 1st at the reporting unit level. Goodwill impairment is measured as the amount by which a reporting unit's carrying value exceeds its fair value. A reporting unit is the same as, or one level below, an operating segment. A</span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n entity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is permitted to first assess qualitatively whether it is necessary to perform a quantitative impairment test for any of its reporting units. The quantitative impairment test is required only when the Company concludes that it is more likely than not that a reporting unit&#8217;s fair value is less than its carrying amount. In evaluating whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company considers the totality of all relevant events or circumstances that affect the fair value or carrying amount of a reporting unit.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An interim goodwill impairment test in advance of the annual impairment assessment may be required if events occur that indicate an impairment might be present. For example, a substantial decline in the Company&#8217;s market capitalization, changes in reportable segments, unexpected adverse business conditions, economic factors and unanticipated competitive activities may signal that an interim impairment test is needed. Accordingly, among other factors, the Company monitors </span></div>changes in its share price between annual impairment tests. The Company considers a decline in its share price that corresponds to an overall deterioration in stock market conditions to be less of an indicator of goodwill impairment than a unilateral decline in its share price reflecting adverse changes in its underlying operating performance, cash flows, financial condition and/or liquidity. In the event that the Company&#8217;s market capitalization does decline below its book value, the Company would consider the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. The Company believes that short-term fluctuations in share prices may not necessarily reflect underlying values.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt discounts, premiums and issuance costs are presented in the Consolidated Balance Sheets as a direct deduction from or addition to the carrying amount of the related debt and are amortized or accreted, using the effective interest method, as interest expense over the contractual lives of the related credit facilities or notes. Deferred financing costs associated with revolving credit facility arrangements are included in the balances of Prepaid expenses and other current assets and Other non-current assets in the Consolidated Balance Sheets and are amortized as interest expense over the contractual life of the related revolving credit facility.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities of the Company&#8217;s foreign operations having a functional currency other than the U.S.&#160;dollar are translated into U.S.&#160;dollars at the exchange rate prevailing at the balance sheet date, and at the average exchange rate for the reporting period for revenue and expense accounts. The cumulative foreign currency translation adjustment is recorded as a component of Accumulated other comprehensive loss in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency exchange gains and losses on transactions occurring in a currency other than an operation&#8217;s functional currency are recognized as a component of Foreign exchange and other in the Consolidated Statements of Operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenues are primarily generated from product sales, primarily in the therapeutic areas of eye-health, gastroenterology  (&#8220;GI&#8221;) and dermatology that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 22, &#8220;SEGMENT INFORMATION&#8221; for the disaggregation of revenues which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when the customer obtains control of promised goods or services and in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services.  To achieve this core principle, the Company applies the five-step revenue model to contracts within its scope: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A contract with the Company&#8217;s customers exists for each product sale.  Where a contract with a customer contains more than one performance obligation, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The transaction price is adjusted for variable consideration which is discussed below.  The Company generally recognizes revenue for product sales at a point in time, when the customer obtains control of the products.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Sales Provisions</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160; The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#8217;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future period.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers.  Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.&#160;</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the activity and ending balances of the Company&#8217;s variable consideration provisions the years 2021 and 2020.</span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:28.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.881%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, January 1, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,050&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(613)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,322)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,273)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(593)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,297)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,013)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,378)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,863&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $36 million and $32 million as of December 31, 2021 and 2020, respectively, which are reflected as a reduction of Trade accounts receivable, net in the Consolidated Balance Sheets.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company's products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis.  This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#8217;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period.  The Company applies this method consistently for contracts with similar characteristics.  The following describes the major sources of variable consideration in the Company&#8217;s customer arrangements and the methodology, estimates and judgments applied to estimate each type of variable consideration.  </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Discounts and Allowances</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash discounts are offered for prompt payment and allowances for volume purchases. Provisions for cash discounts and allowances are estimated at the time of sale and recorded as direct reductions to trade receivables and revenue. Management estimates the provisions for cash discounts and allowances based on contractual sales terms with customers, an analysis of unpaid invoices and historical payment experience. Estimated cash discounts and allowances have historically been predictable and less subjective, due to the limited number of assumptions involved, the consistency of historical experience and the fact that these amounts are generally settled within one month of incurring the&#160;liability.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Returns</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, customers are generally allowed to return a product within a specified period of time before and after its expiration date, excluding European businesses which generally do not provide a right of return. The returns provision is estimated utilizing historical sales and return rates over the period during which customers have a right of return, taking into account available information on competitive products and contract changes. The information utilized to estimate the returns provision includes: (i) historical return and exchange levels, (ii) external data with respect to inventory levels in the wholesale distribution channel, (iii) external data with respect to prescription demand for products, (iv) remaining shelf lives of products at the date of sale and (v) estimated returns liability to be processed by year of sale based on an analysis of lot information related to actual historical returns.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the estimate for returns, management is required to make certain assumptions regarding the timing of the introduction of new products and the potential of these products to capture market share. In addition, certain assumptions with respect to the extent and pattern of decline associated with generic competition are necessary. These assumptions are formulated using market data for similar products, past experience and other available information.  These assumptions are continually reassessed, and changes to the estimates and assumptions are made as new information becomes available. A change of 1% in the estimated return rates would have impacted the Company&#8217;s pre-tax earnings by approximately $81 million for the year 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimate for returns may be impacted by a number of factors, but the principal factor relates to the inventory levels in the distribution channel. When management becomes aware of an increase in such inventory levels, it considers whether the increase may be temporary or other-than-temporary. Temporary increases in wholesaler inventory levels will not warrant revision to the provision for returns. Other-than-temporary increases in wholesaler inventory levels, however, may be an indication that future product returns could be higher than originally anticipated, and, as a result, estimates for returns may need to be adjusted. Factors that suggest increases in wholesaler inventory levels are temporary include: (i) recently implemented or announced price increases for certain products, (ii) new product launches or expanded indications for existing products and (iii) timing of purchases by wholesale customers. Conversely, factors that suggest increases in wholesaler inventory levels are other-than-temporary include: (i) declining sales trends based on prescription demand, (ii) introduction of new products or generic competition, (iii) increasing price competition from generic competitors and (iv) changes to the U.S.&#160;National Drug Codes (&#8220;NDC&#8221;) of products.  Changes in the NDC of products could result in a period of higher returns related to products with the old NDC, as U.S.&#160;customers generally permit only one NDC per product for identification and tracking within their inventory systems.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the last several years, the Company increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving sales return experience, primarily related to branded and generic products. Sales return provisions for 2021 and 2020 were $131&#160;million and $120&#160;million, respectively, and includes reductions in variable consideration for sales return provisions related to past sales of approximately $28 million and $38 million, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates and Chargebacks</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales made under governmental and managed-care pricing programs in the U.S. are subject to rebates.&#160; The Company participates in state government-managed Medicaid programs, as well as certain other qualifying federal and state government programs whereby rebates are provided to participating government entities. Medicaid rebates are generally billed 45 days to 270&#160;days after the quarter in which the product is dispensed to the Medicaid participant.  As a result, the Medicaid rebate reserve includes an estimate of outstanding claims for end-customer sales that occurred, but for which the related claim has not been billed and/or paid, and an estimate for future claims that will be made when inventory in the distribution channel is sold through to plan participants. The calculation of the Medicaid rebate reserve also requires other estimates, such as estimates of sales mix, to determine which sales are subject to rebates and the amount of such rebates. A change of 1% in the estimated rates used in the Medicaid rebate reserve would have impacted the Company&#8217;s pre-tax earnings by approximately $76 million for 2021. Quarterly, the Medicaid rebate reserve is adjusted based on actual claims paid. Due to the delay in billing, adjustments to actual claims paid may incorporate revisions of that reserve for several periods.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed Care rebates relate to contractual agreements to sell products to managed care organizations and pharmacy benefit managers at contractual rebate percentages in exchange for volume and/or market&#160;share.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks relate to contractual agreements to sell products to government agencies, group purchasing organizations and other indirect customers at contractual prices that are lower than the list prices the Company charges wholesalers. When these group purchasing organizations or other indirect customers purchase products through wholesalers at these reduced prices, the wholesaler charges the Company for the difference between the prices they paid the Company and the prices at which they sold the products to the indirect customers.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In estimating provisions for rebates and chargebacks, management considers relevant statutes with respect to governmental pricing programs and contractual sales terms with managed-care providers and group purchasing organizations. Management estimates the amount of product sales subject to these programs based on historical utilization levels. Changes in the level of utilization of products through private or public benefit plans and group purchasing organizations will affect the amount of rebates and chargebacks that the Company is obligated to pay. Management continually updates these factors based on new contractual or statutory requirements, and any significant changes in sales trends that may impact the percentage of products subject to rebates or&#160;chargebacks.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of Managed Care, Medicaid and other rebates and chargebacks has become more significant as a result of a combination of deeper discounts implemented in each of the last three years, changes in the Company&#8217;s product portfolio due to recent acquisitions and increased Medicaid utilization due to expansion of government funding for these programs.&#160;Management&#8217;s estimate for rebates and chargebacks may be impacted by a number of factors, but the principal factor relates to the level of inventory in the distribution channel.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebate provisions are based on factors such as timing and terms of plans under contract, time to process rebates, product pricing, sales volumes, amount of inventory in the distribution channel and prescription trends. Adjustments to actual for the years 2021 and 2020 were not material to the Company&#8217;s revenues or earnings.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient Co-Pay Assistance programs, Consumer Rebates and Loyalty Programs are rebates offered on many of the Company&#8217;s products.  Patient Co-Pay Assistance Programs are patient discount programs offered in the form of coupon cards or point of sale discounts, with which patients receive certain discounts off their prescription at participating pharmacies, as defined by the specific product program. An accrual for these programs is established, equal to management&#8217;s estimate of the discount, rebate and loyalty incentives attributable to a sale.  That estimate is based on historical experience and other relevant factors. The accrual is adjusted throughout each quarter based on actual experience and changes in other factors, if any.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution Fees</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells products primarily to wholesalers, and in some instances to large pharmacy chains such as CVS and Walmart.  The Company has Distribution Services Agreements  (&#8220;DSAs&#8221;) with several large wholesale customers such as McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Specialty.  Under the DSAs, the wholesalers agree to provide services, and the Company pays the contracted DSA distribution service fees for these services based on product volumes.  Additionally, price appreciation credits are generated when the Company increases a product&#8217;s wholesaler acquisition cost (&#8220;WAC&#8221;) under contracts with certain wholesalers. Under such contracts, the Company is entitled to credits from such wholesalers for the impact of that WAC increase on inventory currently on hand at the wholesalers. Such credits are offset against the total distribution service fees paid to each such wholesaler. The variable consideration associated with price appreciation credits is reflected in the transaction price of products sold when it is determined to be probable that a significant reversal will not occur. Included as a reduction of current period provisions for Distribution Fees in the table above are price appreciation credits of $17 million and $15 million for the years 2021 and 2020, respectively.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Assets and Contract Liabilities</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sales Commissions </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales commissions are generally attributed to periods shorter than one year and therefore are expensed when incurred. Sales commissions are included in selling, general and administrative expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Component</span></div>The Company has elected not to adjust consideration for the effects of a significant financing component when the period between the transfer of a promised good or service to the customer and when the customer pays for that good or service will be one year or less.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs related to internal research and development programs, including costs associated with the development of acquired IPR&amp;D, are expensed as goods are delivered or services are performed. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Milestone payments made to third parties before a product receives regulatory approval, but after the milestone is determined to be probable, are expensed and included in Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts due from third parties as reimbursement of development activities conducted under certain research and development arrangements are recognized as a reduction of Research and development expenses.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Legal Costs</a></td>
<td class="text">Legal Costs Legal fees and other costs related to litigation and other legal proceedings or services are expensed as incurred and are included in Selling, general and administrative expenses. Certain legal costs associated with acquisitions are included in Acquisition-related costs and certain legal costs associated with divestitures, legal settlements and other business development activities are included in Litigation and other matters or Net gain on sales of assets within Other expense (income), net, as appropriate. Legal costs expensed are reported net of expected insurance recoveries. A claim for insurance recovery is recognized when realization becomes probable<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text">Advertising CostsAdvertising costs comprise product samples, print media, promotional materials and television advertising and are expensed on the first use of the advertisement.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation The Company recognizes all share-based payments to employees, including grants of employee stock options and restricted share units (&#8220;RSUs&#8221;), at estimated fair value. The Company amortizes the fair value of stock option or RSU grants on a straight-line basis over the requisite service period of the individual stock option or RSU grant, which generally equals the vesting period. Stock option and RSU forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Share-based compensation is recorded in Research and development expenses and Selling, general and administrative expenses, as&#160;appropriate.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpensePolicyTextBlock', window );">Interest Expense</a></td>
<td class="text">Interest Expense Interest expense includes standby fees, the amortization of debt discounts and deferred financing costs, accretion of debt premiums and the amortization of amounts excluded from the assessment of effectiveness related to the Company's cross-currency swaps. Interest costs are expensed as incurred, except to the extent such interest is related to construction in progress, in which case interest is capitalized.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the temporary differences between the financial statement and income tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. A valuation allowance is provided for the portion of deferred tax assets that is more likely than not to remain unrealized. Deferred tax assets and liabilities are measured using enacted tax rates and&#160;laws.  Deferred tax assets for outside basis differences in investments in subsidiaries are only recognized if the difference will be realized in the foreseeable future.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax benefit from an uncertain tax position is recognized only if it is more likely than not that the tax position will be sustained upon examination by the appropriate taxing authority, based on the technical merits of the position. The tax benefits recognized from such position are measured based on the amount for which there is a greater than 50% likelihood of being realized upon settlement. Liabilities associated with uncertain tax positions are classified as long-term unless expected to be paid within one year. Interest and penalties related to uncertain tax positions, if any, are recorded in the provision for income taxes and classified with the related liability on the consolidated balance&#160;sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Share Attributable to Bausch Health Companies Inc.</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Per Share Attributable to Bausch Health Companies Inc.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period. Diluted loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period after giving effect to dilutive potential common shares for stock options and RSUs, determined using the treasury stock&#160;method.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss comprises Net loss and Other comprehensive (loss) income. Other comprehensive (loss) income includes items such as foreign currency translation adjustments, unrealized holding gains and losses on available-for-sale and other investments and certain pension and other postretirement benefit plan adjustments. Accumulated other comprehensive loss is recorded as a component of shareholders&#8217; equity.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is subject to loss contingencies, such as claims and assessments arising from litigation and other legal proceedings, contractual indemnities, product and environmental liabilities and tax matters. Accruals for loss contingencies are recorded when the Company determines that it is both probable that a liability has been incurred and the amount of loss can be reasonably estimated. If the estimate of the amount of the loss is a range and some amount within the range appears to be a better estimate than any other amount within the range, that amount is accrued as a liability. If no amount within the range is a better estimate than any other amount, the minimum amount of the range is accrued as a&#160;liability. These accruals are adjusted periodically as assessments change or additional information becomes available.</span></div>If no accrual is made for a loss contingency because the amount of loss cannot be reasonably estimated, the Company will disclose contingent liabilities when there is at least a reasonable possibility that a loss or an additional loss may have been incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementPlansPolicy', window );">Employee Benefit Plans</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Benefit Plans </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors various retirement and pension plans, including defined benefit pension plans, defined contribution plans and a participatory defined benefit postretirement plan. The determination of defined benefit pension and postretirement plan obligations and their associated expenses requires the use of actuarial valuations to estimate the benefits employees earn while working, as well as the present value of those benefits. Net actuarial gains and losses that exceed 10 percent of the greater of the plan&#8217;s projected benefit obligations or the market-related value of assets are amortized to earnings over the shorter of the estimated average future service period of the plan participants (or the </span></div>estimated average future lifetime of the plan participants if the majority of plan participants are inactive) or the period until any anticipated final plan settlements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Adoption of New Accounting Standards</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New&#160;Accounting Standards</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board  (&#8220;FASB&#8221;) issued guidance on the impairment of financial instruments requiring an impairment model based on expected losses rather than incurred losses. Under this guidance, an entity recognizes as an allowance its estimate of expected credit losses.  The guidance was effective for the Company beginning January 1, 2020 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit, which resulted in an increase to Accumulated deficit of less than $1&#160;million. The application of this guidance did not have a material effect on the Company's results of operations and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued guidance modifying the disclosure requirements for fair value measurement.  The guidance was effective for the Company beginning January 1, 2020. The application of this guidance did not have a material effect on the Company's disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued guidance modifying the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans.  The guidance was effective for annual periods ending after December 15, 2020. The application of this guidance did not have a material effect on the Company's disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.&#160; The guidance is effective for the Company beginning with annual periods beginning January 1, 2021.&#160; The application of this guidance did not have a material effect on the Company's financial position, results of operations and cash flows.</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued guidance providing optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform.&#160; Optional expedients are provided for contract modification accounting within the areas of receivables, debt, leases, derivatives and hedging.&#160;The optional amendments are effective for all entities as of March 12, 2020, through December 31, 2022. During 2020 and 2021, the Company has not entered into any contract modifications in which the optional expedients were applied.&#160; However, if prior to December 31, 2022, the Company enters into a contract modification in which the optional expedients are applied, the Company will evaluate the impact of adoption of this guidance on its financial position, results of operations and cash flows.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text">Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company&#8217;s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single&#160;segment.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DivestituresOfNoncoreProductsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Divestitures of Non-core Products [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DivestituresOfNoncoreProductsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123368208&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for charging off uncollectible financing receivables, including, but not limited to, factors and methodologies used in estimating the allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (a,b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing interest expense, including the method of amortizing debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 10<br> -Section 05<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28365394&amp;loc=d3e23770-108382<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149975-122751<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementPlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66047640&amp;loc=d3e39622-114963<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65877416&amp;loc=d3e29149-114947<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6412939&amp;loc=d3e15145-114933<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementPlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373492276952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Summary of activity in allowance for credit losses</a></td>
<td class="text">The activity in the allowance for credit losses for trade receivables for the years 2021, 2020 and 2019 is as follows.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.199%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.965%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retrospective effect of application of new accounting standard</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-offs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recoveries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock', window );">Schedule of estimated useful lives of property, plant and equipment</a></td>
<td class="text">Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful&#160;lives: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:54.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 - 30 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 40 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;-&#160;20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;-&#160;10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment on operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Up to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of term of lease or 10 years</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of estimated useful lives of intangible assets</a></td>
<td class="text">Amortization is calculated primarily using the straight-line method based on the following estimated useful&#160;lives:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:54.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 - 20 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 - 20 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 - 15 years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 - 9 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Out-licensed technology and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 - 9 years</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock', window );">Summary of variable consideration provisions</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the activity and ending balances of the Company&#8217;s variable consideration provisions the years 2021 and 2020.</span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:28.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.881%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts<br/>and<br/>Allowances</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chargebacks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Distribution<br/>Fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, January 1, 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">691&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,050&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(613)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,322)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,273)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">779&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current period provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(593)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,297)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,013)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,378)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve balance, December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,863&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of estimated useful lives of major classes of finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of estimated useful lives of major classes of property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Valuation And Qualifying Accounts [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373495087176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Estimated fair values of assets acquired and liabilities assumed</a></td>
<td class="text">The following table summarizes the estimated fair values of the assets acquired and liabilities assumed related to the acquisition of certain assets of Synergy as of the acquisition date:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:89.795%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.005%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product brand intangible assets (estimated useful life 7 years)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of consideration transferred</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock', window );">Schedule of carrying amounts of assets and liabilities held for sale</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the Consolidated Balance Sheets as of December 31, 2020 are the following carrying amounts of the Amoun business' assets and liabilities held for sale.</span></div><div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:38.353%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.004%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.353%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.009%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373495329256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of components and classification of financial assets and liabilities measured at fair value on a recurring basis</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis as of: </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:26.200%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.346%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.201%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&#160;(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash and other settlement deposits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,211&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cross-currency swaps</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Schedule of assets and liabilities associated with derivatives, included in the Consolidated Balance Sheets</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with the Company's cross-currency swaps as included in the Consolidated Balance Sheets as of December 31, 2021 and 2020 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.647%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets and liabilities associated with the Company's foreign exchange contracts as included in the Consolidated Balance Sheets as of December 31, 2021 and 2020 are as follows:</span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.647%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of effect of hedging instruments on financial statements</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of hedging instruments on the Consolidated Statements of Operations and Consolidated Statements of Comprehensive Loss for 2021 and 2020: </span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.647%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) recognized in Other comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain excluded from assessment of hedge effectiveness</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Location of gain of excluded component</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Expense</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock', window );">Schedule of foreign exchange contracts on the Consolidated Statements of Operations and Consolidated Statements of Cash Flows</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the effect of the Company's foreign exchange contracts on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for 2021 and 2020:</span></div><div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:70.652%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.646%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.647%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) related to changes in fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss related to settlements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the years 2021 and 2020:</span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:63.534%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.981%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning balance, January 1, </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to Acquisition-related contingent consideration:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion for the time value of money</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments / Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment included in other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance, December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of assets and liabilities measured at fair value on a non-recurring basis</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components and classification of the Company&#8217;s financial assets and liabilities measured at fair value on a non-recurring basis:</span></div><div style="margin-bottom:8pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:24.277%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.359%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current assets held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of gains and losses on derivative instruments included in an entity's trading activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4F<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624186-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 55<br> -Paragraph 184<br> -URI http://asc.fasb.org/extlink&amp;oid=123421605&amp;loc=SL5634876-113961<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for net investment hedges of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373494996920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of the components of inventories</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net, as of December 31, 2021 and 2020 consist of: </span></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,094&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373494982072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property, plant and equipment</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of property, plant and equipment as of December 31, 2021 and 2020 consist of: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other equipment and leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment on operating lease</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,820)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,781)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373491183368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of components of finite-lived intangible assets</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets as of December&#160;31, 2021 and 2020 consist of:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:27.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.984%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Useful<br/>Lives<br/>(Years)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:36pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization and Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization and Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,914)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(404)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,055)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,481&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,741)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired IPR&amp;D not in service</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B&amp;L Trademark</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,128&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,948&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,186&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,741)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,445&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of components of indefinite-lived intangible assets</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The major components of intangible assets as of December&#160;31, 2021 and 2020 consist of:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:27.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.113%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.893%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.984%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Useful<br/>Lives<br/>(Years)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:36pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization and Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization and Impairments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product brands</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,914)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,976&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate brands</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">907&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(404)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product rights/patents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,055)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Technology and other</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,481&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,741)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,740&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired IPR&amp;D not in service</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">B&amp;L Trademark</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,128&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,180)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,948&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,186&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,741)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,445&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of estimated aggregate amortization expense for each of the five succeeding years</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense of finite-lived intangible assets for the five years ending December&#160;31 and thereafter are as&#160;follows: </span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"/><td style="width:16.735%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.562%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.881%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of changes in the carrying amount of goodwill</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of goodwill during the years ended December 31, 2021, 2020 and 2019 were as follows: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:31.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.763%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.611%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.790%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.408%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + <br/>Lomb/<br/>International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Bausch + <br/>Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ortho Dermatologics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, January 1, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,805&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of certain assets of Synergy </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill reclassified to assets held for sale</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,786&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,126&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets held for sale reclassified to goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill reclassified to assets held for sale (Note 3)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,267&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realignment of segment goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,704)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(578)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(118)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,318&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,159&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,457&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373495195832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued and other current liabilities</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued and other current liabilities as of December 31, 2021 and 2020 consist of: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal matters and related fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefit costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,791&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,576&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373488920376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of long-term debt</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs as of December 31, 2021 and 2020 consists of the following:</span></div><div style="margin-top:11pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:34.158%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.082%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.082%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.129%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net of Premiums, Discounts and Issuance Costs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Credit Facilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025 Term Loan B Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Secured Notes:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.000% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.500% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.750% Secured Notes</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.875% Secured Notes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Senior Unsecured Notes:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.125%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.000%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.250%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.500%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.000%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.000%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.250%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.000%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.250%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.250%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2030</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.250%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Various</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,925&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current portion of long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,925&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of aggregate maturities of long-term debt</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maturities and Mandatory Payments</span></div><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities and mandatory payments of debt obligations for the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:</span></div><div style="margin-bottom:8pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:88.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.067%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross maturities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt and other</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373491144472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of amounts recognized in accumulated other comprehensive loss</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts included in Accumulated other comprehensive loss as of December 31, 2021 and 2020 were as follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:38.413%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.963%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized actuarial losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized prior service credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Components of net periodic benefit cost</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the components of net periodic (benefit) cost for the Company&#8217;s defined benefit pension plans and postretirement benefit plan in 2021, 2020 and 2019:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:25.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.951%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.504%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of prior service credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlement loss recognized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net periodic (benefit) cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock', window );">Components of the change in projected benefit obligations, change in plan assets and funded status</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents components of the change in projected benefit obligation, change in plan assets and funded status for 2021 and 2020: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:40.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.025%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>Benefit Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in Projected Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation, beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actuarial (gain) losses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets, beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actual return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Benefits paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funded status, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock', window );">Schedule of underfunded plans</a></td>
<td class="text">Information for the underfunded pension benefit plans is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:56.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.971%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Projected benefit obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated benefit obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock', window );">Future benefit payments for the pension benefit plans</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future benefit payments over the next 10 years for the pension benefit plans and the postretirement benefit plan, which reflect expected future service, as appropriate, are expected to be paid as follows: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:54.219%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.337%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.337%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.430%"/><td style="width:0.1%"/></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S. Postretirement<br/>&#160;Benefit<br/>&#160;Plan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027-2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Weighted-average assumptions used to determine net periodic benefit costs and benefit obligations</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used to determine net periodic benefit costs and benefit obligations for 2021, 2020 and 2019 were as follows: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:43.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.423%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.427%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement Benefit Plan</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For Determining Net Periodic (Benefit) Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.04&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. Plans:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected rate of return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.05&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:55.197%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.073%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension Benefit Plans</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Postretirement Benefit Plan</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For Determining Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-U.S. Plans:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate of compensation increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest crediting rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock', window );">Actual asset allocations</a></td>
<td class="text">The following presents the actual asset allocation as of December 31, 2021 and 2020:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:77.048%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.066%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.070%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-U.S. Plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed income securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock', window );">Fair value of pension and postretirement benefit plan assets assumed in connection with the Acquisition</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents total plan assets by investment category as of December 31, 2021 and 2020 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value. There were no transfers between Level 1 and Level 2 during 2021 and 2020.</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.062%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.290%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans - U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. broad market</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide developed markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:31.624%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.083%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.360%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension Benefit Plans - Non-U.S. Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging markets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide developed markets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed income securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment grade</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global high yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government bond funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with Acquisition [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(b)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans.  This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373495580552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Summary of right-of-use assets and right-of-use liabilities</a></td>
<td class="text"><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets and lease liabilities associated with the Company's operating leases are included in the Consolidated Balance Sheet as of December 31, 2021 and 2020 as follows:</span></div><div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:82.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.925%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets included in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzItMC0xLTEtOTQ4MzE_4bf2464d-f080-463a-b82a-fe3327a6ffe8"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzItMC0xLTEtOTQ4MzE_ce76341b-5893-4112-b76b-f4aed3b43dcf">Other non-current assets</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities included in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzQtMC0xLTEtOTQ4MzE_4bf64393-afaa-455f-a448-662b6f9a6f45"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzQtMC0xLTEtOTQ4MzE_4de59f41-dcca-4036-87e1-e7e98c16d228">Accrued and other current liabilities</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzUtMC0xLTEtOTQ4MzE_339c676d-41f8-49e5-86a9-b2e8149fc1fd"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzUtMC0xLTEtOTQ4MzE_c6eaab40-e3c8-4b6a-afe4-21b28ab4bf11">Other non-current liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of lease expenses</a></td>
<td class="text">Lease expense for the years 2021, 2020 and 2019 include:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:70.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable operating lease costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock', window );">Summary of other operating lease information</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to operating leases for 2021, 2020 and 2019 is as follows:</span></div><div style="margin-bottom:6.6pt;margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:70.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.977%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.405%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.978%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid from operating cash flows for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new operating lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of operating lease future payments</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, future payments under noncancelable operating leases for each of the five succeeding years ending December 31 and thereafter are as&#160;follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:91.594%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Imputed interest</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of remaining lease payments</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Operating Lease Information, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373491139032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of the components and classification of share-based compensation expense</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components and classification of share-based compensation expense related to stock options and&#160;RSUs for the years 2021, 2020 and 2019 were as follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:67.033%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.934%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.934%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.251%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted-average assumption as of the date of grant using the Black Scholes option-pricing model</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of all stock options granted for the years 2021, 2020 and 2019 were estimated as of the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected stock option life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activity</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during 2021: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"><tr><td style="width:1.0%"/><td style="width:56.633%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.016%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.706%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, January&#160;1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired or forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of non-vested time-based RSU activity</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-vested time-based RSU activity during 2021: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:72.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.994%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.452%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Time-Based<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, January&#160;1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used to calculate the fair values of performance-based RSUs</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of TSR performance-based RSUs granted during 2021, 2020 and 2019 were estimated with the following assumptions:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"/><td style="width:58.136%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.727%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contractual term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected Company share volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock', window );">Summary of non-vested performance-based RSU activity</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes non-vested performance-based RSU activity during 2021: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:72.799%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.587%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Performance-based <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant-Date<br/>Fair Value Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, January&#160;1, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested, December&#160;31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of equity based payment instruments, excluding stock (or unit) options, including but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested performance-based units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373495181016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of the components of accumulated other comprehensive loss</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss as of December&#160;31, 2021 and 2020 consists of: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,905)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,077)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension adjustment, net of tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,924)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,133)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373508214600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock', window );">Summary of research and development</a></td>
<td class="text">Research and development costs for the years 2021, 2020 and 2019 consists of:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product related research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Research And Development Expense [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373495035176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EXPENSE, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of other expense, net</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net for the years 2021, 2020 and 2019 consists of:</span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation and other matters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired in-process research and development costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain on sales of assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,426&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373488958472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Components of loss before benefit from income taxes</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Loss before benefit from income taxes for 2021, 2020 and 2019 consist of:  </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(323)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,396)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(701)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(524)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,024)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,837)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of benefit from income taxes</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of Benefit from income taxes for 2021, 2020 and 2019 consist of: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(216)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of benefit from income taxes from the expected amount calculated by applying the Canadian statutory rate to loss before benefit of income taxes</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Benefit from income taxes differs from the expected amount calculated by applying the Company&#8217;s Canadian statutory rate of 26.9% to Loss before benefit from income taxes for 2021, 2020 and 2019 as follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before benefit from income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,024)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,837)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected benefit from income taxes at Canadian statutory rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible amount of share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to tax attributes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance related to foreign tax credits and NOLs</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance on Canadian deferred tax assets and tax rate changes</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in uncertain tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible portion of Goodwill impairments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefit on intra-entity transfers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of tax effect of major items recorded as deferred tax assets and liabilities and valuation allowance</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities as of December 31, 2021 and 2020 consist of: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:78.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.957%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax loss carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific Research and Experimental Development pool</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credit carryforwards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,222)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,252)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets net of valuation allowance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,065&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,999&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plant, equipment and technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside basis differences</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized FX on U.S. dollar debt and other financing cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the deferred tax asset valuation allowance for 2021, 2020 and 2019: </span></div><div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,913&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to Benefit from income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charged to other accounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,222&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Summary of open tax years by jurisdiction</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"/><td style="width:82.106%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jurisdiction:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Open Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States - Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2012 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2013 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2011 - 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Luxembourg</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 - 2020</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of the beginning and ending amounts of unrecognized tax benefits</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the unrecognized tax&#160;benefits for 2021, 2020 and 2019: </span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions of prior years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(169)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373494985272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of calculation of loss per share</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss per share attributable to Bausch Health Companies Inc. for 2021, 2020 and 2019 were calculated as&#160;follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(560)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,788)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic and diluted weighted-average common shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">358.9&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">355.0&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352.1&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic and diluted loss per share attributable to Bausch Health Companies Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.64)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.58)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5.08)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373495136424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL CASH FLOW DISCLOSURES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Supplemental Cash Flow Disclosures</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow disclosures for 2021, 2020 and 2019 are as&#160;follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"/><td style="width:67.849%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.561%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.966%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,419&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,474&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373491026600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of segment revenues and profit</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Segment revenues and profits for the years 2021, 2020 and 2019 were as&#160;follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,415&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,027&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,601&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profit:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,578&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,835&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(792)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(619)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(609)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,375)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,645)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,897)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill impairments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(469)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments, including loss on assets held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, integration, separation and IPO costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(502)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,426)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,426)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,534)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before benefit from income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,024)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,837)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock', window );">Schedule of capital expenditures, depreciation and amortization by segment</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures by segment for the years 2021, 2020 and 2019 were as&#160;follows:</span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bausch + Lomb</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salix</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Solta Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diversified Products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total capital expenditures</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of revenues by segment and by product category</a></td>
<td class="text">Revenues by segment and product category were as&#160;follows: <div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"/><td style="width:23.745%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the year ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,762&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,596&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,144&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,765&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,074&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,121&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"/><td style="width:23.745%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the year ended December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,680&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,313&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,415&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,904&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,274&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,027&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"/><td style="width:23.745%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.548%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.571%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.788%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bausch + Lomb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salix</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Solta Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diversified Products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the year ended December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceuticals</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Devices</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,524&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,718&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Branded and Other Generics </span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,246&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,778&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,453&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,601&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of revenues by geographic region</a></td>
<td class="text"><div style="margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are attributed to a geographic region based on the location of the customer for the years 2021, 2020 and 2019 were as&#160;follows:</span></div><div style="margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,887&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,164&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Russia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Egypt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,434&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,027&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,601&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Schedule of long-lived assets by geographic region</a></td>
<td class="text"><div style="margin-top:3pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consisting of property, plant and equipment, net of accumulated depreciation, are attributed to geographic regions based on their physical location as of December&#160;31, 2021 and 2020 were as&#160;follows: </span></div><div style="margin-top:5pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:79.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. and Puerto Rico</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Serbia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,598&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of external customers that accounted for 10% or more of total revenues</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers that accounted for 10% or more of total revenues were as&#160;follows: </span></div><div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"/><td style="width:68.656%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.954%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AmerisourceBergen Corporation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health,&#160;Inc.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of each significant reconciling item, other than profit (loss), revenues, or assets, in the reconciliation of totals of such items in reportable segments to the entity's corresponding consolidated amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373495131720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>country</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfCountriesInWhichEntityOperates', window );">Number of countries in which entity operates</a></td>
<td class="nump">100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfCountriesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of countries in which the entity operates as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfCountriesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373495011992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>company</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished', window );">Business separation and proposed initial public offering, number of companies to be established</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Separation And Proposed Initial Public Offering, Number Of Companies To Be Established</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373490415816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Concentrations of Credit Risk (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations of Credit Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents', window );">Maximum term of original maturity to classify instruments as cash and cash equivalents (less than)</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ConcentrationRiskPercentageofNetTradeReceivables', window );">Percentage of net trade receivables accounted for by largest wholesale customers</a></td>
<td class="nump">44.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember', window );">Argentina, Brazil, Egypt, Greece, Serbia, South Africa, Turkey, Ukraine, Venezuela and Vietnam</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations of Credit Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Net trade receivable</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">$ 166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_PastDuePeriodForAccountsReceivableToBeNegligible', window );">Past due period for receivables to be negligible (less than)</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_PeriodReceivableOutstanding', window );">Period net trade receivable balance outstanding (more than)</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_TradeReceivableNetPortionPastDue', window );">Portion of net trade receivables that is past due</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Trade receivables | Three largest U.S. wholesaler customers | Credit concentration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentrations of Credit Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_NumberOfLargestWholesaleCustomers', window );">Number of largest wholesale customers | wholesaler</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ConcentrationRiskPercentageofNetTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Percentage of Net Trade Receivables</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ConcentrationRiskPercentageofNetTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum original term of maturity for an instrument to be classified as cash or cash equivalent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_NumberOfLargestWholesaleCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of largest wholesale customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_NumberOfLargestWholesaleCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_PastDuePeriodForAccountsReceivableToBeNegligible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the past due period for which accounts receivables are negligible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_PastDuePeriodForAccountsReceivableToBeNegligible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_PeriodReceivableOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of time the accounts receivable has been outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_PeriodReceivableOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_TradeReceivableNetPortionPastDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trade Receivable, Net, Portion Past Due</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_TradeReceivableNetPortionPastDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_ThreeLargestUSWholesalerCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_ThreeLargestUSWholesalerCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373491001192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Activity in Allowance for Credit Losses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Balance, beginning of period</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate', window );">Retrospective effect of application of new accounting standard</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Write-offs</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries', window );">Recoveries</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther', window );">Foreign exchange and other</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Balance, end of period</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccountsReceivableAllowanceForForeignExchangeAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance For Foreign Exchange And Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccountsReceivableAllowanceForForeignExchangeAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Effect Of Retrospective Application Of Accounting Standards Update</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in allowance for credit loss on accounts receivable, from recovery.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373491104376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Land improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Other equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Land improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">30 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Buildings and improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">40 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Other equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Equipment on operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherMachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bhc_EquipmentOnOperatingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bhc_EquipmentOnOperatingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373488206344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember', window );">Product brands</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate brands</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember', window );">Product rights/patents</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember', window );">Partner relationships</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember', window );">Out-licensed technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Product brands</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Corporate brands</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Product rights/patents</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Partner relationships</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Out-licensed technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Product brands</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Corporate brands</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Product rights/patents</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Partner relationships</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Out-licensed technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">9 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373486944664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Variable Consideration Provisions (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, beginning of year</a></td>
<td class="nump">$ 1,813<span></span>
</td>
<td class="nump">$ 2,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provision</a></td>
<td class="nump">5,428<span></span>
</td>
<td class="nump">5,036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(5,378)<span></span>
</td>
<td class="num">(5,273)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, end of year</a></td>
<td class="nump">1,863<span></span>
</td>
<td class="nump">1,813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDiscountsAndAllowancesMember', window );">Discounts and Allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, beginning of year</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provision</a></td>
<td class="nump">625<span></span>
</td>
<td class="nump">621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(593)<span></span>
</td>
<td class="num">(613)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, end of year</a></td>
<td class="nump">222<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, beginning of year</a></td>
<td class="nump">575<span></span>
</td>
<td class="nump">691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provision</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(224)<span></span>
</td>
<td class="num">(236)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, end of year</a></td>
<td class="nump">482<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesMember', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, beginning of year</a></td>
<td class="nump">779<span></span>
</td>
<td class="nump">927<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provision</a></td>
<td class="nump">2,462<span></span>
</td>
<td class="nump">2,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(2,297)<span></span>
</td>
<td class="num">(2,322)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, end of year</a></td>
<td class="nump">944<span></span>
</td>
<td class="nump">779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForChargebacksMember', window );">Chargebacks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, beginning of year</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provision</a></td>
<td class="nump">1,999<span></span>
</td>
<td class="nump">1,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(2,013)<span></span>
</td>
<td class="num">(1,909)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, end of year</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDistributionFeesMember', window );">Distribution Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, beginning of year</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Current period provision</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and credits</a></td>
<td class="num">(251)<span></span>
</td>
<td class="num">(193)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, end of year</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDiscountsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDiscountsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForChargebacksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForChargebacksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDistributionFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForDistributionFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373489568504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Cooperative advertising credits included in rebates</a></td>
<td class="nump">$ 1,863<span></span>
</td>
<td class="nump">$ 1,813<span></span>
</td>
<td class="nump">$ 2,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CashDiscountsAndAllowancesSettlementPeriod', window );">Settlement period for cash discounts and allowances</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax', window );">1% change in estimated return rates, Impact on pre-tax earnings</a></td>
<td class="nump">$ 81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Sales return provisions</a></td>
<td class="nump">5,428<span></span>
</td>
<td class="nump">5,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax', window );">1% change in volume of product sold through to Medicaid plan participants, Impact on pre-tax earnings</a></td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Price appreciation credits</a></td>
<td class="nump">8,434<span></span>
</td>
<td class="nump">8,027<span></span>
</td>
<td class="nump">8,601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_PriceAppreciationCreditMember', window );">Price Appreciation Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Price appreciation credits</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RevenuePerformanceObligationPaymentTerms', window );">Payment terms</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RevenuePerformanceObligationPaymentTerms', window );">Payment terms</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesAdvertisingCreditsPortionMember', window );">Rebates, Advertising Credits Portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Cooperative advertising credits included in rebates</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Cooperative advertising credits included in rebates</a></td>
<td class="nump">482<span></span>
</td>
<td class="nump">575<span></span>
</td>
<td class="nump">$ 691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Sales return provisions</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesAdjustments', window );">Reduction in variable consideration provision, adjustment</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_CashDiscountsAndAllowancesSettlementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Discounts And Allowances, Settlement Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_CashDiscountsAndAllowancesSettlementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RevenuePerformanceObligationPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Payment Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RevenuePerformanceObligationPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sensitivity Analysis, Impact Of 1 Percent Change In Estimated Return Rate, Income (Loss) Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sensitivity Analysis, Impact Of 1 Percent Change In Volume Of Product Sold Through To Medicaid Plan Participants, Income (Loss) Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_PriceAppreciationCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_PriceAppreciationCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesAdvertisingCreditsPortionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForRebatesAdvertisingCreditsPortionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=bhc_ReserveForCustomerReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373489360744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373489021544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expenses</a></td>
<td class="nump">$ 515<span></span>
</td>
<td class="nump">$ 451<span></span>
</td>
<td class="nump">$ 544<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373492763528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Interest Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Capitalized interest</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373492999864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_TaxBenefitRecognitionMeasurementPercentage', window );">Tax benefit recognition, measurement percentage (greater than)</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities', window );">Minimum period to classify uncertain tax position liabilities as long term liabilities</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the minimum period to classify uncertain tax position liabilities as long term liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_TaxBenefitRecognitionMeasurementPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Benefit Recognition, Measurement Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_TaxBenefitRecognitionMeasurementPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373494990152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Employee Benefit Plans (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage', window );">Threshold percentage for amortization of net actuarial gains and losses</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Actuarial Gain (Loss), Amortization Threshold Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373490481704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES - Adoption of New Accounting Standards (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Increase to accumulated deficit (less than)</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="num">$ (605)<span></span>
</td>
<td class="num">$ (1,136)<span></span>
</td>
<td class="num">$ (2,815)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Increase to accumulated deficit (less than)</a></td>
<td class="nump">$ 8,961<span></span>
</td>
<td class="nump">$ 8,013<span></span>
</td>
<td class="nump">7,452<span></span>
</td>
<td class="nump">$ 5,664<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Increase to accumulated deficit (less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment | Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Increase to accumulated deficit (less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373486586200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 26, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 23, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 06, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>businessCombination</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>businessCombination</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>businessCombination</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combinations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 373,000,000<span></span>
</td>
<td class="nump">$ 502,000,000<span></span>
</td>
<td class="nump">$ 1,426,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_NumberOfOtherBusinessesAcquired', window );">Number of other material business combinations | businessCombination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Upfront payment converted into minor equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected', window );">Expected additional payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Held For Sale | Amoun Pharmaceutical Company S.A.E</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combinations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Amoun Pharmaceutical Company S.A.E</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combinations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Cash proceeds from divestiture</a></td>
<td class="nump">$ 740,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Amoun Pharmaceutical Company S.A.E</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combinations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_NoncashCumulativeForeignCurrencyTranslationLoss', window );">Noncash cumulative foreign currency translation loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=bhc_AllegroOphthalmicsLLCMember', window );">Allegro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combinations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired IPR&amp;D, included in other expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bhc_SynergyPharmaceuticalsInc.Member', window );">Synergy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combinations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash payments to acquire certain assets and assumed liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Revenue of acquiree since acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Pro-forma revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss', window );">Pro-forma operating results</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual', window );">Operating results of acquiree since acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Payments To Acquire Equity Securities, FV-NI, Expected</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessAcquisitionProFormaOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Pro Forma Operating Income (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessAcquisitionProFormaOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Pro Forma Information, Operating Income (Loss) Since Acquisition, Actual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_NoncashCumulativeForeignCurrencyTranslationLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Cumulative Foreign Currency Translation Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_NoncashCumulativeForeignCurrencyTranslationLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_NumberOfOtherBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Other Businesses Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_NumberOfOtherBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=bhc_AllegroOphthalmicsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=bhc_AllegroOphthalmicsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bhc_SynergyPharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bhc_SynergyPharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373488866648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Estimated Fair Value Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 06, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combinations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,457<span></span>
</td>
<td class="nump">$ 13,044<span></span>
</td>
<td class="nump">$ 13,126<span></span>
</td>
<td class="nump">$ 13,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bhc_SynergyPharmaceuticalsInc.Member', window );">Synergy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combinations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventories</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Product brand intangible assets (estimated useful life 7 years)</a></td>
<td class="nump">159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses', window );">Accrued expenses</a></td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="nump">177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total fair value of consideration transferred</a></td>
<td class="nump">$ 180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted- Average Remaining Useful Lives (Years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of inventory recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bhc_SynergyPharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bhc_SynergyPharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373489571704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Assets and Liabilities Held For Sale (Details) - A Certain International Business - Held For Sale<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Prepaid expenses and other current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Trade receivables, net</a></td>
<td class="nump">$ 91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventories, net</a></td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets', window );">Total Prepaid expenses and other current assets</a></td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract', window );"><strong>Other non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent', window );">Property, plant and equipment, net</a></td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent', window );">Goodwill and Intangible assets, net</a></td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets', window );">Deferred tax assets, net</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets', window );">Total Other non-current assets</a></td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Accrued and other current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities', window );">Total Accrued and other current liabilities</a></td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract', window );"><strong>Other non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities', window );">Total Other non-current liabilities</a></td>
<td class="nump">$ 57<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Other Sundry Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Other Sundry Liabilities, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred tax assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2473-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2510-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_ACertainInternationalBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_ACertainInternationalBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373486534936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Cost-rationalization and integration initiatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">$ 2,624<span></span>
</td>
<td class="nump">$ 2,367<span></span>
</td>
<td class="nump">$ 2,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=bhc_RestructuringAndIntegrationCostsMember', window );">Restructuring and Integration Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Cost-rationalization and integration initiatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Remaining restructuring liabilities</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring costs</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Restructuring payments</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=bhc_SeparationAndInitialPublicOfferingCostsMember', window );">Separation and IPO Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Cost-rationalization and integration initiatives</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring, integration, separation and IPO costs</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">$ 132<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=bhc_RestructuringAndIntegrationCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=bhc_RestructuringAndIntegrationCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=bhc_SeparationAndInitialPublicOfferingCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=bhc_SeparationAndInitialPublicOfferingCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373486770072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging | Cross-currency swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">1,537<span></span>
</td>
<td class="nump">1,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Foreign currency exchange contracts</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Net Investment Hedging | Cross-currency swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">1,537<span></span>
</td>
<td class="nump">1,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level 1 | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Foreign currency exchange contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level 1 | Net Investment Hedging | Cross-currency swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;2 | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Foreign currency exchange contracts</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;2 | Net Investment Hedging | Cross-currency swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure', window );">Restricted cash and other settlement deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;3 | Foreign currency exchange contracts | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Foreign currency exchange contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Level&#160;3 | Net Investment Hedging | Cross-currency swaps | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement which may include cash and shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Cash And Cash Equivalents And Other Settlement Deposits, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373490330632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 16, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_HighlyLiquidInvestmentsMaturityPeriod', window );">Highly liquid investments, maturity period (or less)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">Valeant US Securities Litigation | New Jersey | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement, escrow fund included in restricted cash</a></td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="nump">$ 1,510<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_HighlyLiquidInvestmentsMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Highly Liquid Investments, Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_HighlyLiquidInvestmentsMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373490999432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember', window );">Cross-currency swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromHedgeInvestingActivities', window );">Net proceeds, cross-currency swaps</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities', window );">Net proceeds, settlement of cross-currency swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember', window );">Cross-currency swaps | Net Investment Hedging | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Aggregate notional amounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bhc_CrossCurrencyFinalSettlementMember', window );">Cross-currency swaps, final settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities', window );">Net proceeds, settlement of cross-currency swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromHedgeInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromHedgeInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3581-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromHedgeInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bhc_CrossCurrencyFinalSettlementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bhc_CrossCurrencyFinalSettlementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373488141608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Cross-currency Swaps Included in Consolidated Balance Sheets (Details) - Cross-currency swaps - Net Investment Hedging - Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Net fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossLiability', window );">Other non-current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373491035960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember', window );">Cross-currency swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities', window );">Net proceeds, settlement of cross-currency swaps</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember', window );">Cross-currency swaps | Net Investment Hedging | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Gain (loss) recognized in Other comprehensive loss</a></td>
<td class="nump">77<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember', window );">Cross-currency swaps | Net Investment Hedging | Designated as Hedging Instrument | Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Gain excluded from assessment of hedge effectiveness</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bhc_CrossCurrencyFinalSettlementMember', window );">Cross-currency swaps, final settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities', window );">Net proceeds, settlement of cross-currency swaps</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromHedgeInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromHedgeInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bhc_CrossCurrencyFinalSettlementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bhc_CrossCurrencyFinalSettlementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373493011000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Foreign Currency Exchange Contracts, Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument | Foreign currency exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Aggregate notional amounts</a></td>
<td class="nump">$ 166,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373488145336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details) - Foreign currency exchange contracts - Not Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Net fair value</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=bhc_AccruedAndOtherCurrentLiabilitiesMember', window );">Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossLiability', window );">Accrued and other current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=bhc_AccruedAndOtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=bhc_AccruedAndOtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373489450696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details) - Foreign currency exchange contracts - Not Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Gain (loss) related to changes in fair value</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss', window );">Loss related to settlements</a></td>
<td class="num">$ (17)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized loss of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373486752728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level3) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>rate</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 328<span></span>
</td>
<td class="nump">$ 316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Acquisition-related contingent consideration adjustments</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments / Settlements</a></td>
<td class="num">(99)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome', window );">Foreign currency translation adjustment included in other comprehensive loss</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Non-current portion</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_AccretionForTimeValueOfMoneyMember', window );">Accretion for the time value of money</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Acquisition-related contingent consideration adjustments</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_FairValueAdjustmentsMember', window );">Fair value adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Acquisition-related contingent consideration adjustments</a></td>
<td class="num">$ (6)<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=bhc_MeasurementInputWeightedAverageDiscountRateMember', window );">Measurement Input, Weighted-Average Discount Rate | Level&#160;3 | Recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value, contingent consideration obligations, discount rate | rate</a></td>
<td class="nump">0.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Measurement Input, Discount Rate | Level&#160;3 | Recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value, contingent consideration obligations, discount rate | rate</a></td>
<td class="nump">0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Measurement Input, Discount Rate | Level&#160;3 | Recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value, contingent consideration obligations, discount rate | rate</a></td>
<td class="nump">0.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_AccretionForTimeValueOfMoneyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bhc_AccretionForTimeValueOfMoneyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bhc_FairValueAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bhc_FairValueAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=bhc_MeasurementInputWeightedAverageDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=bhc_MeasurementInputWeightedAverageDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373492615784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis (Details) - Fair Value, Nonrecurring - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Other non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure', window );">Non-current assets held for sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Other non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure', window );">Non-current assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Other non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure', window );">Non-current assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Other non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure', window );">Non-current assets held for sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 245<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of assets classified as held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373491011640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis, Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets reclassified, held and used</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,202<span></span>
</td>
<td class="nump">$ 31,199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Non-recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure', window );">Non-current assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | Non-recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure', window );">Non-current assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Held For Sale | Certain Products For Disposal, September 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of assets classified as held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373633675480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Fair Value of Long-term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Non-recurring basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of long-term debt</a></td>
<td class="nump">$ 22,689<span></span>
</td>
<td class="nump">$ 25,378<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373491217320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES - Summary of Inventories, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 279<span></span>
</td>
<td class="nump">$ 286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">602<span></span>
</td>
<td class="nump">665<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">$ 993<span></span>
</td>
<td class="nump">$ 1,094<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373488878920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT - Major Components of Property, Plant, and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 3,418<span></span>
</td>
<td class="nump">$ 3,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(1,820)<span></span>
</td>
<td class="num">(1,781)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">1,598<span></span>
</td>
<td class="nump">1,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">675<span></span>
</td>
<td class="nump">686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">1,678<span></span>
</td>
<td class="nump">1,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bhc_OtherEquipmentAndLeaseholdImprovementMember', window );">Other equipment and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">342<span></span>
</td>
<td class="nump">360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bhc_EquipmentOnOperatingLeaseMember', window );">Equipment on operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 576<span></span>
</td>
<td class="nump">$ 436<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bhc_OtherEquipmentAndLeaseholdImprovementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bhc_OtherEquipmentAndLeaseholdImprovementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bhc_EquipmentOnOperatingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bhc_EquipmentOnOperatingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373495102664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, PLANT AND EQUIPMENT - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 177<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373488036568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 25,430<span></span>
</td>
<td class="nump">$ 25,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(20,180)<span></span>
</td>
<td class="num">(18,741)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">5,250<span></span>
</td>
<td class="nump">6,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">27,128<span></span>
</td>
<td class="nump">27,186<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net (Excluding Goodwill)</a></td>
<td class="nump">6,948<span></span>
</td>
<td class="nump">8,445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=bhc_AcquiredInProcessResearchAndDevelopmentMember', window );">Acquired IPR&amp;D not in service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">B&amp;L Trademark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">$ 1,698<span></span>
</td>
<td class="nump">1,698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember', window );">Product brands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted- Average Remaining Useful Lives (Years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 20,842<span></span>
</td>
<td class="nump">20,890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(16,169)<span></span>
</td>
<td class="num">(14,914)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 4,673<span></span>
</td>
<td class="nump">5,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate brands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted- Average Remaining Useful Lives (Years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 902<span></span>
</td>
<td class="nump">907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(473)<span></span>
</td>
<td class="num">(404)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 429<span></span>
</td>
<td class="nump">503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember', window );">Product rights/patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted- Average Remaining Useful Lives (Years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 3,321<span></span>
</td>
<td class="nump">3,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(3,174)<span></span>
</td>
<td class="num">(3,055)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 147<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember', window );">Partner relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted- Average Remaining Useful Lives (Years)</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 158<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(158)<span></span>
</td>
<td class="num">(168)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember', window );">Technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted- Average Remaining Useful Lives (Years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 207<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization and Impairments</a></td>
<td class="num">(206)<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=bhc_AcquiredInProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=bhc_AcquiredInProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_PartnerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_OutLicensedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373411821976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>reporting_unit </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 469,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,434,000,000<span></span>
</td>
<td class="nump">$ 8,027,000,000<span></span>
</td>
<td class="nump">$ 8,601,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue, year-over-year increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">407,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage', window );">Revenue, year-over-year decrease, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Percentage of fair value in excess of carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated goodwill impairment charges to date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,180,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,044,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,457,000,000<span></span>
</td>
<td class="nump">13,044,000,000<span></span>
</td>
<td class="nump">13,126,000,000<span></span>
</td>
<td class="nump">$ 13,142,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,765,000,000<span></span>
</td>
<td class="nump">3,415,000,000<span></span>
</td>
<td class="nump">3,778,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,318,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,074,000,000<span></span>
</td>
<td class="nump">1,904,000,000<span></span>
</td>
<td class="nump">2,022,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
<td class="nump">3,156,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,166,000,000<span></span>
</td>
<td class="nump">1,181,000,000<span></span>
</td>
<td class="nump">1,154,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308,000,000<span></span>
</td>
<td class="nump">253,000,000<span></span>
</td>
<td class="nump">194,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,121,000,000<span></span>
</td>
<td class="nump">1,274,000,000<span></span>
</td>
<td class="nump">1,453,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,914,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,357,000,000<span></span>
</td>
<td class="nump">2,914,000,000<span></span>
</td>
<td class="nump">2,914,000,000<span></span>
</td>
<td class="nump">$ 2,914,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | reporting_unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,318,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Solta Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,040,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=bhc_OrthoDermatologicsReportingUnitMember', window );">Ortho Dermatologics Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 469,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rates</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Percentage of fair value in excess of carrying value</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=bhc_ReportingUnitsExcludingOrthoDermatologicsMember', window );">Reporting Units Excluding Ortho Dermatologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Ortho Dermatologics Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate', window );">Reporting unit, impairment test, long-term growth rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">12.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Ortho Dermatologics Reporting Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate', window );">Reporting unit, impairment test, estimated cash flows, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">9.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=bhc_AcquiredInProcessResearchAndDevelopmentMember', window );">Acquired IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Amoun Pharmaceutical Company S.A.E</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Held For Sale | Amoun Pharmaceutical Company S.A.E</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Held For Sale | A Certain International Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Held For Sale | Certain Products For Disposal, September 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember', window );">Product brands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,000,000<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="nump">58,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_DiscontinuedProductLinesMember', window );">Discontinued Product Lines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember', window );">Product rights/patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_UnutilizedITInfrastructureImprovementProjectMember', window );">Unutilized IT Infrastructure Improvement Project</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Year-Over-Year Revenue From Contract With Customer, Excluding Assessed Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Year-Over-Year Revenue From Contract With Customer, Excluding Assessed Tax, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ReportingUnitImpairmentTestLongTermGrowthRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reporting Unit, Impairment Test, Long-Term Growth Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ReportingUnitImpairmentTestLongTermGrowthRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of fair value of reporting unit in excess of carrying amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=bhc_OrthoDermatologicsReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=bhc_OrthoDermatologicsReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=bhc_ReportingUnitsExcludingOrthoDermatologicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=bhc_ReportingUnitsExcludingOrthoDermatologicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=bhc_AcquiredInProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=bhc_AcquiredInProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_AmounPharmaceuticalCompanySAEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_ACertainInternationalBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_ACertainInternationalBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_ProductBrandsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_DiscontinuedProductLinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_DiscontinuedProductLinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_UnutilizedITInfrastructureImprovementProjectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bhc_UnutilizedITInfrastructureImprovementProjectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373492714024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Estimated aggregate amortization expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 1,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">1,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2025</a></td>
<td class="nump">795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2026</a></td>
<td class="nump">664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 5,250<span></span>
</td>
<td class="nump">$ 6,740<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373491240440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWILL - Schedule of Goodwill (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Oct. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,044,000,000<span></span>
</td>
<td class="nump">$ 13,126,000,000<span></span>
</td>
<td class="nump">$ 13,142,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisition of certain assets of Synergy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill reclassified to assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(217,000,000)<span></span>
</td>
<td class="num">(18,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(118,000,000)<span></span>
</td>
<td class="nump">117,000,000<span></span>
</td>
<td class="num">(1,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit', window );">Assets held for sale reclassified to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(469,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,457,000,000<span></span>
</td>
<td class="nump">13,044,000,000<span></span>
</td>
<td class="nump">13,126,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombInternationalMember', window );">Bausch + Lomb/ International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,704,000,000<span></span>
</td>
<td class="nump">5,786,000,000<span></span>
</td>
<td class="nump">5,805,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill reclassified to assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(217,000,000)<span></span>
</td>
<td class="num">(18,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">117,000,000<span></span>
</td>
<td class="num">(1,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit', window );">Assets held for sale reclassified to goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,704,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,704,000,000<span></span>
</td>
<td class="nump">5,786,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,395,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,318,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
<td class="nump">3,156,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisition of certain assets of Synergy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
<td class="nump">3,159,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">887,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember', window );">Ortho Dermatologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,267,000,000<span></span>
</td>
<td class="nump">1,267,000,000<span></span>
</td>
<td class="nump">1,267,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(469,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">798,000,000<span></span>
</td>
<td class="nump">1,267,000,000<span></span>
</td>
<td class="nump">1,267,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Change in the carrying amount of goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,914,000,000<span></span>
</td>
<td class="nump">2,914,000,000<span></span>
</td>
<td class="nump">2,914,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Realignment of segment goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(578,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,357,000,000<span></span>
</td>
<td class="nump">$ 2,914,000,000<span></span>
</td>
<td class="nump">$ 2,914,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Transfers Related To Sale of Business Unit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombInternationalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombInternationalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373486742376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED AND OTHER CURRENT LIABILITIES (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_Legalsettlementsandrelatedfees', window );">Legal matters and related fees</a></td>
<td class="nump">$ 1,890<span></span>
</td>
<td class="nump">$ 1,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AccruedProductRebateCurrent', window );">Product rebates</a></td>
<td class="nump">908<span></span>
</td>
<td class="nump">747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AccruedProductReturnCurrent', window );">Product returns</a></td>
<td class="nump">482<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employee compensation and benefit costs</a></td>
<td class="nump">336<span></span>
</td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest</a></td>
<td class="nump">328<span></span>
</td>
<td class="nump">341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">749<span></span>
</td>
<td class="nump">767<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">$ 4,791<span></span>
</td>
<td class="nump">$ 4,576<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccruedProductRebateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the current portion of accrued product rebates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccruedProductRebateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccruedProductReturnCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccruedProductReturnCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_Legalsettlementsandrelatedfees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Legal settlements and related fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_Legalsettlementsandrelatedfees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373414861704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 08, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 03, 2020</div></th>
<th class="th"><div>May 26, 2020</div></th>
<th class="th"><div>Mar. 08, 2019</div></th>
<th class="th"><div>Oct. 17, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 22,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">22,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: Current portion of long-term debt and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of long-term debt</a></td>
<td class="nump">$ 22,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member', window );">Term Loan B Facility Due June 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">3.09%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 2,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 2,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member', window );">Term Loan B Facility Due November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">2.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 7.000 % Senior Notes Due March 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 5.500% Senior Notes Due November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 5.750% Senior Notes Due August 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 4.875% Senior Notes Due June 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">4.875%<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 6.125% Senior Notes Due April 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 2,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 2,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 9.000% Senior Notes Due December 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 9.250% Senior Notes Due April 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">9.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 8.500% Senior Notes Due January 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 7.000 % Senior Notes Due January 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.000% Senior Notes Due January 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 6.250% Senior Notes Due February 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.000% Senior Note Due February 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 7.250% Senior Notes Due May 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.250% Senior Notes Due January 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 1,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.250% Senior Notes, Due February 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Senior Secured Credit Facilities | 2023 Revolving Credit Facility Due June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Long-term debt, net of unamortized debt discount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate on debt (as a percent)</a></td>
<td class="nump">2.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal Amount</a></td>
<td class="nump">$ 285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.50NotesDueNovember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.50NotesDueNovember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.75NotesDueAugust2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.75NotesDueAugust2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes900DueDecember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes900DueDecember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes925DueApril2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes925DueApril2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes850DueJanuary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueFebruary2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueFebruary2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes725DueMay2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes725DueMay2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueJanuary2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueJanuary2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueFebruary2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueFebruary2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_OtherLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_OtherLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373492207304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Covenant Compliance (Details) - Revolving credit facility<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentAmountAvailableForRestrictedPayments', window );">Amount available for restricted payments</a></td>
<td class="nump">$ 13,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio', window );">Fixed charge coverage ratio</a></td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio', window );">Secured leverage ratio</a></td>
<td class="nump">4.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentAmountAvailableForRestrictedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Amount Available For Restricted Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentAmountAvailableForRestrictedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Secured Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373490453272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Nov. 27, 2018</div></th>
<th class="th"><div>Jun. 01, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,654,000,000<span></span>
</td>
<td class="nump">$ 23,925,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member', window );">Term Loan B Facility Due June 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="nump">$ 4,565,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,772,000,000<span></span>
</td>
<td class="nump">3,220,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | 2023 Revolving Credit Facility Due June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold', window );">Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">91 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold', window );">Alternate term, principal amount maturity threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">886,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | 2023 Revolving Credit Facility Due June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Alternate Term, Principal Amount Maturity Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373488041352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Current Description of Senior Secured Credit Facilities (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization', window );">Remaining mandatory quarterly amortization payments</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings', window );">Incremental credit facility borrowings</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate', window );">Incremental borrowings interest rate</a></td>
<td class="nump">28.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio', window );">Secured leverage ratio (not greater than)</a></td>
<td class="nump">4.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum', window );">Interest coverage ratio (not less than)</a></td>
<td class="nump">2.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio', window );">Secured leverage ratio (not greater than)</a></td>
<td class="nump">3.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility | Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum', window );">Total leverage ratio (not greater than)</a></td>
<td class="nump">6.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember', window );">Senior Credit Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member', window );">2023 Revolving Credit Facility Due June 2023 | Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.84%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member', window );">2023 Revolving Credit Facility Due June 2023 | Minimum | Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee, unutilized commitments, percentage</a></td>
<td class="nump">0.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member', window );">2023 Revolving Credit Facility Due June 2023 | Maximum | Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Commitment fee, unutilized commitments, percentage</a></td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredTermCreditFacilitiesMember', window );">Senior Secured Credit Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments', window );">Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments', window );">Percentage of cash proceeds from incurrence of debt</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments', window );">Percentage of annual excess cash flow</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments', window );">Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member', window );">Term Loan B Facility Due June 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">3.09%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentAnnualAmortizationRatePercentage', window );">Annual amortization rate, percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member', window );">Term Loan B Facility Due November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">2.84%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentAnnualAmortizationRatePercentage', window );">Annual amortization rate, percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember', window );">Federal Funds Effective Swap Rate | Senior Secured Credit Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar | Senior Credit Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar | Senior Credit Facilities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar | 2023 Revolving Credit Facility Due June 2023 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar | 2023 Revolving Credit Facility Due June 2023 | Minimum | Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar | 2023 Revolving Credit Facility Due June 2023 | Maximum | Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar | Term Loan B Facility Due June 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember', window );">Eurodollar | Term Loan B Facility Due November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">2.75%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=bhc_CanadaBankersAcceptanceRateMember', window );">Canada Bankers Acceptance Rate | 2023 Revolving Credit Facility Due June 2023</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=bhc_CanadaBankersAcceptanceRateMember', window );">Canada Bankers Acceptance Rate | 2023 Revolving Credit Facility Due June 2023 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=bhc_BaseRateOrPrimeRateMember', window );">Base Rate or Prime Rate | 2023 Revolving Credit Facility Due June 2023 | Minimum | Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=bhc_BaseRateOrPrimeRateMember', window );">Base Rate or Prime Rate | 2023 Revolving Credit Facility Due June 2023 | Maximum | Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=bhc_BaseRateOrPrimeRateMember', window );">Base Rate or Prime Rate | Term Loan B Facility Due June 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableRateAxis=bhc_BaseRateOrPrimeRateMember', window );">Base Rate or Prime Rate | Term Loan B Facility Due November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable interest rate</a></td>
<td class="nump">1.75%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentAnnualAmortizationRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Annual Amortization Rate, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentAnnualAmortizationRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Terms, Secured Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Total Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Periodic Payment, Quarterly Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of annual excess cash flow with any excess amounts after the prepayment of the loans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of net cash proceeds from asset sales outside ordinary course of business payable as mandatory prepayments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of net cash proceeds of insurance and condemnation proceeds for property or asset (losses) which is payable as mandatory prepayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of net cash proceeds from the incurrence of debt payable as mandatory prepayments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Threshold For Incremental Borrowings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility Threshold For Incremental Borrowings Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredTermCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredTermCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueNovember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_CanadaBankersAcceptanceRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_CanadaBankersAcceptanceRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=bhc_BaseRateOrPrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=bhc_BaseRateOrPrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373416487288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Senior Secured Notes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 08, 2021</div></th>
<th class="th"><div>May 26, 2020</div></th>
<th class="th"><div>Jan. 16, 2020</div></th>
<th class="th"><div>May 23, 2019</div></th>
<th class="th"><div>Mar. 08, 2019</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Nov. 21, 2017</div></th>
<th class="th"><div>Oct. 17, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Mar. 27, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage due to change in control (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,440,000,000<span></span>
</td>
<td class="nump">$ 5,642,000,000<span></span>
</td>
<td class="nump">$ 4,406,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">$ 38,000,000<span></span>
</td>
<td class="nump">$ 27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,000,000<span></span>
</td>
<td class="nump">$ 59,000,000<span></span>
</td>
<td class="nump">$ 42,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage due to change in control (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member', window );">6.50% Senior Notes Due March 2022 | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member', window );">7.000 % Senior Notes Due March 2024 | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.50NotesDueNovember2025Member', window );">5.500% Senior Notes Due November 2025 | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.75NotesDueAugust2027Member', window );">5.750% Senior Notes Due August 2027 | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds', window );">Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_A8.50SeniorNotesDueJanuary2027Member', window );">8.50% Senior Unsecured Notes Due January 2027 | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds', window );">Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_A5.875SeniorNotesdueMay2023Member', window );">5.875% Senior Unsecured Notes due May 2023 | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.875%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,240,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes5.625PercentDueDecember2021Member', window );">5.625 % Senior Unsecured Notes due December 2021 | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 518,000,000<span></span>
</td>
<td class="nump">$ 182,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember', window );">Senior Secured and Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member', window );">4.875% Senior Notes Due June 2028 | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member', window );">4.875% Senior Notes Due June 2028 | Senior Secured Notes | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member', window );">4.875% Senior Notes Due June 2028 | Senior Secured Notes | Debt Instrument, Redemption, Period Two | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Maximum percentage of principal amount that can be redeemed</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueMarch2024Member', window );">Senior Notes, 7.00%, Due March 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Maximum Redemption Percentage With Equity Offering Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Percentage, Change in Control</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentRedemptionPricePercentageChangeinControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.50NotesDueNovember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.50NotesDueNovember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.75NotesDueAugust2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured5.75NotesDueAugust2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A8.50SeniorNotesDueJanuary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A8.50SeniorNotesDueJanuary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A5.875SeniorNotesdueMay2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A5.875SeniorNotesdueMay2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes5.625PercentDueDecember2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes5.625PercentDueDecember2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured4875NotesDueJune2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueMarch2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes700DueMarch2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373405765624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">11 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 08, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 03, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 26, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 16, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 16, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 03, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 23, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 08, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 26, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 18, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 03, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 27, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 27, 2015 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jan. 30, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage due to change in control (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,440,000,000<span></span>
</td>
<td class="nump">$ 5,642,000,000<span></span>
</td>
<td class="nump">$ 4,406,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">$ 38,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,000,000<span></span>
</td>
<td class="nump">59,000,000<span></span>
</td>
<td class="nump">42,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember', window );">Settled Litigation | New Jersey | Valeant US Securities Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation, amount agreed to pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,210,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,510,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025AndNovember2025Member', window );">Term Loan B Facility Due June 2025 and November 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_PaymentForDebtAmortizationPrepaymentCost', window );">Repayment, outstanding debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 303,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl', window );">Redemption price percentage due to change in control (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.50% Senior Unsecured Notes due March 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 382,000,000<span></span>
</td>
<td class="nump">$ 216,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 233,000,000<span></span>
</td>
<td class="nump">$ 169,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.375% Senior Notes due March 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.875% Senior Unsecured Notes due May 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.875%<span></span>
</td>
<td class="nump">5.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,240,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.875% Senior Notes due May 2023, March 2019 Refinancing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">584,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.875% Senior Notes due May 2023, May 2019 Refinancing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,118,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 4.50% Senior Unsecured Notes euro-denominated debt Due May 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased face amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 6.125% Senior Unsecured Notes due April 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | Senior Unsecured Notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,240,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 6.125% Senior Notes Due April 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 9.00% Senior Unsecured Notes due December 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 9.00% Senior Unsecured Notes due December 2025 | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 9.00% Senior Unsecured Notes due December 2025 | Debt Instrument, Redemption, Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds', window );">Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 9.25% Senior Unsecured Notes Due April 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds', window );">Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 8.50% Senior Unsecured Notes Due January 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds', window );">Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 7.00% Senior Unsecured Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds', window );">Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 7.25% Senior Unsecured Notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds', window );">Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.00% Senior Unsecured Notes Due January 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds', window );">Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.25% Senior Unsecured Notes Due January 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds', window );">Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 6.250% Senior Notes Due February 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 6.250% Senior Notes Due February 2029 | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 6.250% Senior Notes Due February 2029 | Debt Instrument, Redemption, Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds', window );">Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.000% Senior Note Due February 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds', window );">Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.250% Senior Notes, Due February 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds', window );">Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Senior Unsecured Notes | 5.50% Senior Notes Due March 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 233,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Senior Secured Notes | 6.50% Senior Notes Due March 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Maximum Redemption Percentage With Equity Offering Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentRedemptionPricePercentageChangeinControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Price, Percentage, Change in Control</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentRedemptionPricePercentageChangeinControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_PaymentForDebtAmortizationPrepaymentCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment For Debt Amortization Prepayment Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_PaymentForDebtAmortizationPrepaymentCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025AndNovember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityDueJune2025AndNovember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A5.50SeniorNotesdueMarch2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A5.50SeniorNotesdueMarch2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A5.375SeniorNotesdueMarch2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A5.375SeniorNotesdueMarch2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A5.875SeniorNotesdueMay2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A5.875SeniorNotesdueMay2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes4.502023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes4.502023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A6.125SeniorNotesdueApril2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A6.125SeniorNotesdueApril2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorUnsecuredNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorUnsecuredNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes6125DueApril2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A9.00SeniorNotesdueDecember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A9.00SeniorNotesdueDecember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A9.25SeniorNotesDueApril2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A9.25SeniorNotesDueApril2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A8.50SeniorNotesDueJanuary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A8.50SeniorNotesDueJanuary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A7.00SeniorUnsecuredNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A7.00SeniorUnsecuredNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A7.25SeniorUnsecuredNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A7.25SeniorUnsecuredNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A5.00SeniorNotesDueJanuary2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A5.00SeniorNotesDueJanuary2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A5.25SeniorNotesDueJanuary2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A5.25SeniorNotesDueJanuary2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes625DueFebruary2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueFebruary2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes500DueFebruary2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueFebruary2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes525DueFebruary2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorNotes550DueMarch2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorNotes550DueMarch2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373414779992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Feb. 11, 2022</div></th>
<th class="th"><div>Feb. 10, 2022</div></th>
<th class="th"><div>Jan. 18, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 18, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.88%<span></span>
</td>
<td class="nump">6.02%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member', window );">2023 Revolving Credit Facility Due June 2023 | Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member', window );">2023 Revolving Credit Facility Due June 2023 | Revolving credit facility | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of lines of credit</a></td>
<td class="nump">$ 285,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_A9.00SeniorNotesdueDecember2025Member', window );">9.00% Senior Unsecured Notes due December 2025 | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_A9.00SeniorNotesdueDecember2025Member', window );">9.00% Senior Unsecured Notes due December 2025 | Senior Unsecured Notes | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 370,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member', window );">Senior Secured 6.125% Notes Due February 2027 | Senior Secured Notes | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityDueJune2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A9.00SeniorNotesdueDecember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A9.00SeniorNotesdueDecember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373493324936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FINANCING ARRANGEMENTS - Maturities, Schedule of Maturities and Mandatory Payments of Debt Obligations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2025</a></td>
<td class="nump">9,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2026</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">11,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total gross maturities</a></td>
<td class="nump">22,870<span></span>
</td>
<td class="nump">$ 24,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized discounts</a></td>
<td class="num">(216)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total long-term debt and other</a></td>
<td class="nump">$ 22,654<span></span>
</td>
<td class="nump">$ 23,925<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373486899752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>defined_benefit_plan</div>
</th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>defined_benefit_plan</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod', window );">Future benefit payments period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Contributions recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,000,000<span></span>
</td>
<td class="nump">$ 43,000,000<span></span>
</td>
<td class="nump">$ 41,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Underfunded pension benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Underfunded pension benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 231,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance', window );">Benefit accrual, interest percentage earned on cash balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Estimated company contributions in next fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Percentage of expected return on plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.74%<span></span>
</td>
<td class="nump">2.98%<span></span>
</td>
<td class="nump">3.46%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans', window );">Number of defined benefit plans | defined_benefit_plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended', window );">Number of defined benefit plans amended | defined_benefit_plan</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Percentage of expected return on plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DefinedBenefitPlanPercentageAllocationofFund', window );">Percentage allocation of fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | Ireland | Scenario, Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Percentage of expected return on plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Estimated company contributions in next fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Percentage of expected return on plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="nump">7.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | United States | Scenario, Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Percentage of expected return on plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Benefit Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DefinedBenefitPlanEmployerContributionMaximumAge', window );">Employer contribution maximum age</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">65 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Estimated company contributions in next fiscal year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Percentage of expected return on plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Benefit Accrual, Interest Percentage Earned On Cash Balance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DefinedBenefitPlanEmployerContributionMaximumAge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Employer Contribution, Maximum Age</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DefinedBenefitPlanEmployerContributionMaximumAge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Estimated Future Benefit Payments, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Number of Defined Benefit Plans Amended</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Number of Defined Benefit Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DefinedBenefitPlanPercentageAllocationofFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Percentage Allocation of Fund</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DefinedBenefitPlanPercentageAllocationofFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2919-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373492533272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">U.S. Postretirement Benefit Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax', window );">Unrecognized actuarial losses</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax', window );">Unrecognized prior service credits</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Pension Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax', window );">Unrecognized actuarial losses</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax', window );">Unrecognized prior service credits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Non-U.S. Plans | Pension Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax', window );">Unrecognized actuarial losses</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax', window );">Unrecognized prior service credits</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373487943912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">U.S. Postretirement Benefit Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credit</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlement loss recognized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanOtherCosts', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic (benefit) cost</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Pension Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlement loss recognized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanOtherCosts', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic (benefit) cost</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Non-U.S. Plans | Pension Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of net loss</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credit</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlement loss recognized</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanOtherCosts', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic (benefit) cost</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanOtherCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of defined benefit plan cost (credit), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanOtherCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373488062072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Change in Benefit Obligation, Plan Assets and Funded Status (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">U.S. Postretirement Benefit Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in Projected Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation, beginning of year</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gain) losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Currency translation adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation, end of year</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in Plan Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, beginning of year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Currency translation adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, end of year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status, end of year</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Recognized as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States | Pension Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in Projected Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation, beginning of year</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation', window );">Settlements</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gain) losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Currency translation adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation, end of year</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in Plan Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, beginning of year</a></td>
<td class="nump">231<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Currency translation adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, end of year</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status, end of year</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Recognized as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Non-U.S. Plans | Pension Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in Projected Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation, beginning of year</a></td>
<td class="nump">294<span></span>
</td>
<td class="nump">259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation', window );">Settlements</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gain) losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Currency translation adjustments</a></td>
<td class="num">(18)<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation, end of year</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">294<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in Plan Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, beginning of year</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Currency translation adjustments</a></td>
<td class="num">(13)<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, end of year</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="nump">$ 161<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status, end of year</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Recognized as:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pension And Other Postretirement Defined Benefit Plans, Other Assets, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pension and Other Postretirement Defined Benefit Plans, Accrued and Other Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(6)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(10)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSettlementsBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSettlementsPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373493287048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Underfunded Plans (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Underfunded plans having accumulated benefit obligations exceeding the fair value of plan assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation', window );">Projected benefit obligation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 236,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation', window );">Accumulated benefit obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">236,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">231,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Underfunded plans having accumulated benefit obligations exceeding the fair value of plan assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation', window );">Projected benefit obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">294,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation', window );">Accumulated benefit obligation</a></td>
<td class="nump">$ 219,000,000<span></span>
</td>
<td class="nump">286,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373405733016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Future Benefit Payments for the Pension Benefit Plans (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2023</a></td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2024</a></td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2025</a></td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2026</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2027-2031</a></td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2022</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2023</a></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2024</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2025</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2026</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2027-2031</a></td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">U.S. Postretirement Benefit Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2022</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2023</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2024</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2025</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2026</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2027-2031</a></td>
<td class="nump">$ 11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373490776952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Weighted-Average Assumptions Used to Determine Net Periodic Benefit Costs and Benefit Obligations (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>For Determining Net Periodic (Benefit) Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">3.16%<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="nump">7.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate', window );">Interest crediting rate</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>For Determining Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">2.69%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate', window );">Interest crediting rate</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Benefit Plans | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>For Determining Net Periodic (Benefit) Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate</a></td>
<td class="nump">1.37%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
<td class="nump">2.39%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets</a></td>
<td class="nump">2.74%<span></span>
</td>
<td class="nump">2.98%<span></span>
</td>
<td class="nump">3.46%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">3.05%<span></span>
</td>
<td class="nump">2.89%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate', window );">Interest crediting rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>For Determining Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">1.72%<span></span>
</td>
<td class="nump">1.37%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">2.63%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate', window );">Interest crediting rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">U.S. Postretirement Benefit Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>For Determining Net Periodic (Benefit) Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Discount rate</a></td>
<td class="nump">2.09%<span></span>
</td>
<td class="nump">3.04%<span></span>
</td>
<td class="nump">4.16%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected rate of return on plan assets</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>For Determining Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">2.57%<span></span>
</td>
<td class="nump">2.09%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Rate of compensation increase</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average interest crediting rate used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2919-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average interest crediting rate used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373492802200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Actual Asset Allocations (Details) - Pension Benefit Plans<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">United States | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Defined benefit plan, percentage of actual plan asset allocations</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">United States | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Defined benefit plan, percentage of actual plan asset allocations</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">United States | Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Defined benefit plan, percentage of actual plan asset allocations</a></td>
<td class="nump">69.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Plans | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Defined benefit plan, percentage of actual plan asset allocations</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Plans | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Defined benefit plan, percentage of actual plan asset allocations</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Plans | Fixed income securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Defined benefit plan, percentage of actual plan asset allocations</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Plans | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Defined benefit plan, percentage of actual plan asset allocations</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373414636232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with the Acquisition (Details) - Pension Benefit Plans - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">$ 224<span></span>
</td>
<td class="nump">$ 231<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="nump">$ 161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">223<span></span>
</td>
<td class="nump">229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember', window );">Cash and cash equivalents | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember', window );">Cash and cash equivalents | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember', window );">Cash and cash equivalents | Level 1 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember', window );">Cash and cash equivalents | Level 1 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember', window );">Cash and cash equivalents | Level&#160;2 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember', window );">Cash and cash equivalents | Level&#160;2 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember', window );">Cash and cash equivalents | Level&#160;3 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember', window );">Cash and cash equivalents | Level&#160;3 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_U.S.BroadMarketMember', window );">U.S. broad market | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_U.S.BroadMarketMember', window );">U.S. broad market | Level 1 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_U.S.BroadMarketMember', window );">U.S. broad market | Level&#160;2 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_U.S.BroadMarketMember', window );">U.S. broad market | Level&#160;3 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_EmergingMarketsMember', window );">Emerging markets | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_EmergingMarketsMember', window );">Emerging markets | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_EmergingMarketsMember', window );">Emerging markets | Level 1 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_EmergingMarketsMember', window );">Emerging markets | Level 1 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_EmergingMarketsMember', window );">Emerging markets | Level&#160;2 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_EmergingMarketsMember', window );">Emerging markets | Level&#160;2 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_EmergingMarketsMember', window );">Emerging markets | Level&#160;3 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_EmergingMarketsMember', window );">Emerging markets | Level&#160;3 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.DevelopedMarketsMember', window );">Worldwide developed markets | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.DevelopedMarketsMember', window );">Worldwide developed markets | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.DevelopedMarketsMember', window );">Worldwide developed markets | Level 1 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.DevelopedMarketsMember', window );">Worldwide developed markets | Level 1 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.DevelopedMarketsMember', window );">Worldwide developed markets | Level&#160;2 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.DevelopedMarketsMember', window );">Worldwide developed markets | Level&#160;2 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.DevelopedMarketsMember', window );">Worldwide developed markets | Level&#160;3 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.DevelopedMarketsMember', window );">Worldwide developed markets | Level&#160;3 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.OtherAssetsMember', window );">Other assets | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.OtherAssetsMember', window );">Other assets | Level 1 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.OtherAssetsMember', window );">Other assets | Level&#160;2 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.OtherAssetsMember', window );">Other assets | Level&#160;3 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_InvestmentGradeMember', window );">Investment grade | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_InvestmentGradeMember', window );">Investment grade | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_InvestmentGradeMember', window );">Investment grade | Level 1 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_InvestmentGradeMember', window );">Investment grade | Level 1 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_InvestmentGradeMember', window );">Investment grade | Level&#160;2 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">155<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_InvestmentGradeMember', window );">Investment grade | Level&#160;2 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_InvestmentGradeMember', window );">Investment grade | Level&#160;3 | Recurring basis | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_InvestmentGradeMember', window );">Investment grade | Level&#160;3 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_GlobalHighYieldMember', window );">Global high yield | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_GlobalHighYieldMember', window );">Global high yield | Level 1 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_GlobalHighYieldMember', window );">Global high yield | Level&#160;2 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_GlobalHighYieldMember', window );">Global high yield | Level&#160;3 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Government bond funds | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Government bond funds | Level 1 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Government bond funds | Level&#160;2 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Government bond funds | Level&#160;3 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_OtherAssetsFixedIncomeSecuritiesMember', window );">Other assets | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_OtherAssetsFixedIncomeSecuritiesMember', window );">Other assets | Level 1 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_OtherAssetsFixedIncomeSecuritiesMember', window );">Other assets | Level&#160;2 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_OtherAssetsFixedIncomeSecuritiesMember', window );">Other assets | Level&#160;3 | Recurring basis | Non-U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_U.S.BroadMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_U.S.BroadMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_EmergingMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_EmergingMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.DevelopedMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.DevelopedMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_NonU.S.OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_InvestmentGradeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_InvestmentGradeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_GlobalHighYieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_GlobalHighYieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_OtherAssetsFixedIncomeSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=bhc_OtherAssetsFixedIncomeSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373486711928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Right-of-use Assets and Right-of-use Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AssetsLesseeAbstract', window );"><strong>Right-of-use assets included in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Other non-current assets</a></td>
<td class="nump">$ 247<span></span>
</td>
<td class="nump">$ 259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LiabilitiesLesseeAbstract', window );"><strong>Lease liabilities included in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
<td class="text">Accrued and other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">$ 214<span></span>
</td>
<td class="nump">$ 227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other non-current liabilities<span></span>
</td>
<td class="text">Other non-current liabilities<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of remaining lease payments</a></td>
<td class="nump">$ 264<span></span>
</td>
<td class="nump">$ 279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other non-current assets<span></span>
</td>
<td class="text">Other non-current assets<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AssetsLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets, Lessee [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AssetsLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liabilities, Lessee [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373494961480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance leases</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sub-lease income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373493119992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Lease Expenses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 67<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable operating lease costs</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373486887160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Lease Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid from operating cash flows for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">7 years 2 months 12 days<span></span>
</td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">6.10%<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-of-Use Asset Obtained in Exchange for Operating Lease Liability, Excluding Amount Recognized Upon Adoption</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373489102840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Lease Future Payments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of remaining lease payments</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">$ 279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion</a></td>
<td class="nump">$ 214<span></span>
</td>
<td class="nump">$ 227<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373492505800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Narrative (Details) - Omnibus Incentive Plan 2014 - USD ($)<br></strong></div></th>
<th class="th"><div>Apr. 28, 2020</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Total number of shares approved for grant by the Company under the share-based compensation plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares available for issuance (in shares)</a></td>
<td class="nump">13,500,000<span></span>
</td>
<td class="nump">11,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for future grants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,593,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014Member', window );">Nonemployee Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant', window );">Aggregate fair market value on awards granted during any calendar year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Plan Modification, Fair Market Value Limit On Annual Grant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bhc_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bhc_NonemployeeDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bhc_NonemployeeDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373411739288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 128<span></span>
</td>
<td class="nump">$ 105<span></span>
</td>
<td class="nump">$ 102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=bhc_SellingGeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Components and classification of share-based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 113<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=bhc_SellingGeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=bhc_SellingGeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373405661400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Stock Options (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Method and assumptions on valuation of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected stock option life (years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">50.20%<span></span>
</td>
<td class="nump">38.70%<span></span>
</td>
<td class="nump">46.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning of the period (in shares)</a></td>
<td class="nump">8.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Expired or forfeited (in shares)</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">End of the period (in shares)</a></td>
<td class="nump">8.9<span></span>
</td>
<td class="nump">8.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at the end of the period (in shares)</a></td>
<td class="nump">8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and exercisable at the end of the period (in shares)</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward', window );"><strong>Weighted- Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 25.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">32.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">18.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired or forfeited (in dollars per share)</a></td>
<td class="nump">29.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">End of the period (in dollars per share)</a></td>
<td class="nump">27.65<span></span>
</td>
<td class="nump">$ 25.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest at the end of the period (in dollars per share)</a></td>
<td class="nump">27.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and exercisable at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 27.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted- Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at the end of the period</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest at the end of the period</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable at the end of the period</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at the end of the period</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest at the end of the period</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Vested and exercisable at the end of the period</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of stock options (in dollars per share)</a></td>
<td class="nump">$ 10.92<span></span>
</td>
<td class="nump">$ 6.60<span></span>
</td>
<td class="nump">$ 8.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of stock options exercised in the period</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Remaining unrecognized compensation expense related to non-vested awards</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue', window );">Fair value of stock options vested</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Vesting Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Vesting Period One | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage', window );">Percentage of stock options that will vest on each of the first, second, third and fourth anniversaries from the date of grant</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Vesting Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Vesting Period Two | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage', window );">Percentage of stock options that will vest on each of the first, second, third and fourth anniversaries from the date of grant</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the total fair value of stock options vested during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of stock options that will vest in the future period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373486921560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - RSUs (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting rights</a></td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember', window );">Time-Based RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Remaining unrecognized compensation expense related to non-vested awards</a></td>
<td class="nump">$ 68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value</a></td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning of the period (in shares)</a></td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(3,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">End of the period (in shares)</a></td>
<td class="nump">5,400,000<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant-Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 21.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">31.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">21.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">26.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">End of the period (in dollars per share)</a></td>
<td class="nump">$ 28.16<span></span>
</td>
<td class="nump">$ 21.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_PerformanceBasedRestrictedStockUnitsMember', window );">Performance-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Remaining unrecognized compensation expense related to non-vested awards</a></td>
<td class="nump">$ 32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued', window );">Maximum common shares issuable upon vesting (in shares)</a></td>
<td class="nump">3,476,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning of the period (in shares)</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,035,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(1,000,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">End of the period (in shares)</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant-Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 28.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">40.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">27.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">End of the period (in dollars per share)</a></td>
<td class="nump">$ 33.92<span></span>
</td>
<td class="nump">$ 28.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Method and assumptions on valuation of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual term (years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Company share volatility</a></td>
<td class="nump">52.00%<span></span>
</td>
<td class="nump">38.60%<span></span>
</td>
<td class="nump">46.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_TSRPerformanceBasedRestrictedStockUnitsMember', window );">TSR Performance-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant-Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 56.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_ROTCPerformanceBasedRestrictedStockUnitsMember', window );">ROTC Performance-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">413,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant-Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 31.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bhc_OtherPerformanceBasedRestrictedStockUnitsMember', window );">Other Performance Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">222,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant-Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 28.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum number of common shares that could be issued upon vesting of outstanding awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_TimeBasedRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_TSRPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_TSRPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_ROTCPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_ROTCPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bhc_OtherPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bhc_OtherPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373488157288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Accumulated Other Comprehensive Loss (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="num">$ (34)<span></span>
</td>
<td class="nump">$ 605<span></span>
</td>
<td class="nump">$ 1,136<span></span>
</td>
<td class="nump">$ 2,815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,905)<span></span>
</td>
<td class="num">(2,077)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Pension adjustment, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Accumulated other comprehensive loss</a></td>
<td class="num">$ (1,924)<span></span>
</td>
<td class="num">$ (2,133)<span></span>
</td>
<td class="num">$ (2,086)<span></span>
</td>
<td class="num">$ (2,137)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373493066984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND DEVELOPMENT - Schedule of Research and Development Costs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ResearchAndDevelopmentExpenseProductRelated', window );">Product related research and development</a></td>
<td class="nump">$ 440<span></span>
</td>
<td class="nump">$ 420<span></span>
</td>
<td class="nump">$ 434<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ResearchAndDevelopmentExpenseQualityAssurance', window );">Quality assurance</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 465<span></span>
</td>
<td class="nump">$ 452<span></span>
</td>
<td class="nump">$ 471<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ResearchAndDevelopmentExpenseProductRelated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Product Related</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ResearchAndDevelopmentExpenseProductRelated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ResearchAndDevelopmentExpenseQualityAssurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Quality Assurance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ResearchAndDevelopmentExpenseQualityAssurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373486390008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EXPENSE, NET - Schedule of Other Expense (Income), Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation and other matters</a></td>
<td class="nump">$ 356<span></span>
</td>
<td class="nump">$ 422<span></span>
</td>
<td class="nump">$ 1,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development costs</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Net gain on sales of assets</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition-related contingent consideration</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_OtherIncomeExpenseNet', window );">Other, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="nump">$ 373<span></span>
</td>
<td class="nump">$ 502<span></span>
</td>
<td class="nump">$ 1,426<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_OtherIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Income (Expense), Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_OtherIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373489310056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EXPENSE, NET - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ScheduleOfOtherIncomeAndExpensesLineItems', window );"><strong>Schedule Of Other Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation and other matters</a></td>
<td class="nump">$ 356<span></span>
</td>
<td class="nump">$ 422<span></span>
</td>
<td class="nump">$ 1,401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Upfront payments, included in acquired in-process research and development costs</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Milestone achievement, included in net gain (loss) on other sales of assets</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bhc_MilestonePaymentRelatedToCertainProductMember', window );">Milestone Payment Related To Certain Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ScheduleOfOtherIncomeAndExpensesLineItems', window );"><strong>Schedule Of Other Income And Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Milestone achievement, included in net gain (loss) on other sales of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ScheduleOfOtherIncomeAndExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Schedule Of Other Income And Expenses [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ScheduleOfOtherIncomeAndExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bhc_MilestonePaymentRelatedToCertainProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bhc_MilestonePaymentRelatedToCertainProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373405695496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Components of Benefit from Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Components of loss before benefit of income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (323)<span></span>
</td>
<td class="num">$ (410)<span></span>
</td>
<td class="num">$ (2,396)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(701)<span></span>
</td>
<td class="num">(524)<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before benefit from income taxes</a></td>
<td class="num">(1,024)<span></span>
</td>
<td class="num">(934)<span></span>
</td>
<td class="num">(1,837)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Domestic</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">74<span></span>
</td>
<td class="num">(216)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">51<span></span>
</td>
<td class="num">(224)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Domestic</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">590<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">599<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Provision for) benefit from income taxes</a></td>
<td class="nump">$ 87<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373490769304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of Effective Income Tax Reconciliation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Expected Canadian statutory rate</a></td>
<td class="nump">26.90%<span></span>
</td>
<td class="nump">26.90%<span></span>
</td>
<td class="nump">26.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before benefit from income taxes</a></td>
<td class="num">$ (1,024)<span></span>
</td>
<td class="num">$ (934)<span></span>
</td>
<td class="num">$ (1,837)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Benefit from income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations', window );">Expected benefit from income taxes at Canadian statutory rate</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">251<span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Non-deductible amount of share-based compensation</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount', window );">Adjustments to tax attributes</a></td>
<td class="num">(59)<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="num">(99)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance', window );">Change in valuation allowance related to foreign tax credits and NOLs</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance on Canadian deferred tax assets and tax rate changes</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">687<span></span>
</td>
<td class="num">(142)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncomeTaxReconciliationUncertainTaxPositions', window );">Change in uncertain tax positions</a></td>
<td class="nump">112<span></span>
</td>
<td class="num">(163)<span></span>
</td>
<td class="num">(350)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax rate differences</a></td>
<td class="num">(198)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses', window );">Non-deductible portion of Goodwill impairments</a></td>
<td class="num">(99)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit', window );">Tax benefit on intra-entity transfers</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(338)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">(Provision for) benefit from income taxes</a></td>
<td class="nump">$ 87<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Adjustments To Tax Attributes, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to change in valuation allowance related to operating losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_IncomeTaxReconciliationDeferredIntercompanyProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of the difference between total income tax expense (benefit) as reported in the income statement and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to deferred intercompany profit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_IncomeTaxReconciliationDeferredIntercompanyProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_IncomeTaxReconciliationUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to uncertain tax positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_IncomeTaxReconciliationUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373411807352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Tax Effect of Major Items Recorded as Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DeferredTaxAssetsTaxLossCarryforwards', window );">Tax loss carryforwards</a></td>
<td class="nump">$ 2,973<span></span>
</td>
<td class="nump">$ 2,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Provisions</a></td>
<td class="nump">991<span></span>
</td>
<td class="nump">1,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment', window );">Research and development tax credits</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool', window );">Scientific Research and Experimental Development pool</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryforwards</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DeferredTaxAssetsPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">4,287<span></span>
</td>
<td class="nump">4,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(2,222)<span></span>
</td>
<td class="num">(2,252)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets net of valuation allowance</a></td>
<td class="nump">2,065<span></span>
</td>
<td class="nump">1,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes', window );">Plant, equipment and technology</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings', window );">Outside basis differences</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains', window );">Unrealized FX on U.S. dollar debt and other financing cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">342<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 1,723<span></span>
</td>
<td class="nump">$ 1,609<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DeferredTaxAssetsPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Prepaid Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DeferredTaxAssetsPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the deferred tax assets on scientific research and experimental development pool, of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tax effect as of the balance sheet date of the amount of future tax deductions arising from unused research and development tax credit carryforwards; a tax credit carryforward is the amount by which tax credits available for utilization exceed statutory limitations for inclusion in historical filings, and which can only be utilized if sufficient tax-basis income is generated in future periods and providing tax laws continue to allow such utilization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DeferredTaxAssetsTaxLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the deferred tax assets on tax loss carryforwards available to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DeferredTaxAssetsTaxLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the deferred tax liability recognized for the original basis difference between the principal amount of the Convertible Notes and value allocated to the liability component, which resulted in a corresponding reduction to the valuation allowance recorded against deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on foreign currency transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R121.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373414777544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Schedule of Reconciliation of Deferred Tax Asset Valuation Allowance (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, beginning of year</a></td>
<td class="nump">$ 1,813<span></span>
</td>
<td class="nump">$ 2,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged to other accounts</a></td>
<td class="nump">5,428<span></span>
</td>
<td class="nump">5,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, end of year</a></td>
<td class="nump">1,863<span></span>
</td>
<td class="nump">1,813<span></span>
</td>
<td class="nump">$ 2,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember', window );">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, beginning of year</a></td>
<td class="nump">2,252<span></span>
</td>
<td class="nump">2,831<span></span>
</td>
<td class="nump">2,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes', window );">Charged to Benefit from income taxes</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(773)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Charged to other accounts</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="num">(95)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance, end of year</a></td>
<td class="nump">$ 2,222<span></span>
</td>
<td class="nump">$ 2,252<span></span>
</td>
<td class="nump">$ 2,831<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>SEC Schedule, 12-09, Valuation Allowances And Reserves, Additions, Charge To Benefit From Income Taxes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R122.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373486495848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (Details)<br> $ in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 08, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>subsidiary</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($) </div>
<div>subsidiary</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance against deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties', window );">Unrecognized tax benefits including interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Portion of unrecognized tax benefits, if recognized, would affect the Company's effective tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions', window );">Unrecognized tax benefits, net increase for tax positions of current year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions', window );">Unrecognized tax benefits, net decrease for tax positions of prior years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions', window );">Unrecognized tax benefits, net increase for tax positions of prior years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties related to unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Net increase (decrease) recognized in interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns', window );">Number of subsidiaries file federal income tax returns in Canada, U.S., and other foreign jurisdictions (or more) | subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss', window );">Estimate of possible loss, income tax examination (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Possible decrease in unrecognized tax benefits realized in next twelve months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2013Member', window );">Tax Year 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss', window );">Estimate of possible loss, income tax examination (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=bhc_ForeignCountryStateAndLocalMember', window );">Canadian Federal and Provincial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Decrease in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AccumulatedLossesAvailableForFederalPurposes', window );">Accumulated losses available for federal and provincial purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits', window );">Unclaimed investment tax credits and research and development credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance against deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=bhc_ForeignCountryStateAndLocalMember', window );">Canadian Federal and Provincial | Pooled Scientific Research and Experimental Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">United States - Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AccumulatedLossesAvailableForFederalPurposes', window );">Accumulated losses available for federal and provincial purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits', window );">Unclaimed investment tax credits and research and development credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">United States - Federal | Revenue Commissioners, Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AccumulatedLossesAvailableForFederalPurposes', window );">Accumulated losses available for federal and provincial purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Ireland | Revenue Commissioners, Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AccumulatedLossesAvailableForFederalPurposes', window );">Accumulated losses available for federal and provincial purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Ireland | Australian Taxation Office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss', window );">Estimate of possible loss, income tax examination (up to)</a></td>
<td class="nump">$ 117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Ireland | Tax Year 2012 | Canada Revenue Agency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss', window );">Estimate of possible loss, income tax examination (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Ireland | Tax Year 2005 through Tax Year 2009 | Canada Revenue Agency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear', window );">Reduction in NOLs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Ireland | Tax Year 2015 and Tax Year 2016 | Canada Revenue Agency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear', window );">Reduction in NOLs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AccumulatedLossesAvailableForFederalPurposes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the details pertaining to accumulated losses available for federal and provincial purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AccumulatedLossesAvailableForFederalPurposes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax, Number Of Subsidiaries File Federal Income Tax Returns</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of unclaimed tax credits and research and development credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross amount of unrecognized tax benefits including interest and penalties pertaining to uncertain tax positions taken in tax returns as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Net Decrease Resulting From Prior Period Tax Positions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Net Increase Resulting from Current Period Tax Positions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Net Increase Resulting From Prior Period Tax Positions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated amount of loss resulting from an adverse tax position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount the liability recorded for the income tax examination increased or decreased in the current year/accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=bhc_ForeignCountryStateAndLocalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=bhc_ForeignCountryStateAndLocalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceByDeferredTaxAssetAxis=bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_RevenueCommissionersIrelandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_RevenueCommissionersIrelandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CanadaRevenueAgencyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CanadaRevenueAgencyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=bhc_TaxYear2005ThroughTaxYear2009Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=bhc_TaxYear2005ThroughTaxYear2009Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=bhc_TaxYear2015AndTaxYear2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=bhc_TaxYear2015AndTaxYear2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R123.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373486398360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Federal Income Tax Returns by Jurisdiction (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">United States - Federal | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2015<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">United States - Federal | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_CA', window );">Canada | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2012<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_CA', window );">Canada | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_DE', window );">Germany | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_DE', window );">Germany | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_FR', window );">France | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_FR', window );">France | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_CN', window );">China | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_CN', window );">China | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_IE', window );">Ireland | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_IE', window );">Ireland | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_NL', window );">Netherlands | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=country_NL', window );">Netherlands | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_AustralianTaxationOfficeMember', window );">Australia | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_AustralianTaxationOfficeMember', window );">Australia | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_LuxembourgInlandRevenueMember', window );">Luxembourg | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_LuxembourgInlandRevenueMember', window );">Luxembourg | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Years</a></td>
<td class="text">2020<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=country_NL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=country_NL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_AustralianTaxationOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_AustralianTaxationOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_LuxembourgInlandRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_LuxembourgInlandRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R124.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373490476056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Reconciliation Schedule of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance, beginning of year</a></td>
<td class="nump">$ 1,025<span></span>
</td>
<td class="nump">$ 1,002<span></span>
</td>
<td class="nump">$ 654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current year</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions of prior years</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior years</a></td>
<td class="num">(129)<span></span>
</td>
<td class="num">(209)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapse of statute of limitations</a></td>
<td class="num">(169)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance, end of year</a></td>
<td class="nump">$ 927<span></span>
</td>
<td class="nump">$ 1,025<span></span>
</td>
<td class="nump">$ 1,002<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R125.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373493267576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Bausch Health Companies Inc.</a></td>
<td class="num">$ (948)<span></span>
</td>
<td class="num">$ (560)<span></span>
</td>
<td class="num">$ (1,788)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average common shares (in shares)</a></td>
<td class="nump">358.9<span></span>
</td>
<td class="nump">355.0<span></span>
</td>
<td class="nump">352.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted-average common shares (in shares)</a></td>
<td class="nump">358.9<span></span>
</td>
<td class="nump">355.0<span></span>
</td>
<td class="nump">352.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share attributable to Bausch Health Companies Inc. (in dollars per share)</a></td>
<td class="num">$ (2.64)<span></span>
</td>
<td class="num">$ (1.58)<span></span>
</td>
<td class="num">$ (5.08)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share attributable to Bausch Health Companies Inc. (in dollars per share)</a></td>
<td class="num">$ (2.64)<span></span>
</td>
<td class="num">$ (1.58)<span></span>
</td>
<td class="num">$ (5.08)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R126.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373492644760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER SHARE - Narrative (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Stock Compensation Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Excluded from computation of diluted earnings per share, effect anti-dilutive (in shares)</a></td>
<td class="nump">4,932<span></span>
</td>
<td class="nump">3,154<span></span>
</td>
<td class="nump">5,106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember', window );">Stock options, Time-based RSUs, Performance-based RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Excluded from computation of diluted earnings per share, effect anti-dilutive (in shares)</a></td>
<td class="nump">3,428<span></span>
</td>
<td class="nump">9,551<span></span>
</td>
<td class="nump">2,598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_PerformanceBasedRestrictedStockUnitsMember', window );">Performance-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Excluded from computation of diluted earnings per share, effect anti-dilutive (in shares)</a></td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bhc_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R127.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373490492616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL CASH FLOW DISCLOSURES - Schedule of Supplemental Cash Flow Disclosures (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Other payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 1,419<span></span>
</td>
<td class="nump">$ 1,474<span></span>
</td>
<td class="nump">$ 1,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="nump">$ 162<span></span>
</td>
<td class="nump">$ 172<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R128.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373407554920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEGAL PROCEEDINGS - Narrative (Details)<br> $ in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 02, 2022</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>case</div>
</th>
<th class="th">
<div>Dec. 16, 2021 </div>
<div>case</div>
</th>
<th class="th">
<div>Jul. 26, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 20, 2021 </div>
<div>USD ($) </div>
<div>insured</div>
</th>
<th class="th"><div>Aug. 28, 2020</div></th>
<th class="th">
<div>Aug. 04, 2020 </div>
<div>CAD ($)</div>
</th>
<th class="th"><div>May 01, 2020</div></th>
<th class="th">
<div>Dec. 16, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 28, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 07, 2017 </div>
<div>insurance_policy_period</div>
</th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2015 </div>
<div>case</div>
</th>
<th class="th">
<div>Sep. 16, 2016 </div>
<div>action</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>group </div>
<div>case </div>
<div>action</div>
</th>
<th class="th">
<div>Jul. 30, 2020 </div>
<div>case</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>case</div>
</th>
<th class="th">
<div>Dec. 15, 2021 </div>
<div>case</div>
</th>
<th class="th">
<div>Mar. 17, 2021 </div>
<div>numberOfBusiness</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 13, 2019 </div>
<div>shareholder</div>
</th>
<th class="th">
<div>Sep. 10, 2019 </div>
<div>shareholder</div>
</th>
<th class="th">
<div>Feb. 15, 2019 </div>
<div>entity</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_Legalsettlementsandrelatedfees', window );">Legal matters and related fees | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">Valeant US Securities Litigation | New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors', window );">Number of groups of investors | group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsDismissedNumber', window );">Number of cases dismissed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending', window );">Number of groups of investors filing action, remain pending | group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">Valeant US Securities Litigation | New Jersey | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation, amount agreed to pay | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">Valeant US Securities Litigation | New Jersey | Settled Litigation | Restricted Cash and Other Settlement Deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation, amount agreed to pay | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember', window );">Valeant US Securities Litigation | New Jersey | Unfavorable Regulatory Action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Recent suits filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember', window );">Canadian Securities Litigation | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Recent suits filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember', window );">Canadian Securities Litigation | Canada | Violation of Canadian Provincial Securities Legislation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber', window );">Number of additional suits filed, but not served | action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction', window );">Number of entities, exercised opt-out right, pursuing action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember', window );">Canadian Securities Litigation | Canada | Violation of Canadian Provincial Securities Legislation | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation, amount agreed to pay | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_RICOClassActionsLitigationMember', window );">RICO Class Actions Litigation | New Jersey | Unfavorable Regulatory Action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Recent suits filed | action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember', window );">Insurance Coverage Lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyNumberOfInsurancePolicyPeriods', window );">Number of distinct insurance policy periods | insurance_policy_period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember', window );">Insurance Coverage Lawsuit | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencySettlementAgreementsNumberOfInsurers', window );">Settlement agreements, number of insurers | insured</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Aggregate amount received | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_SandozLitigationMember', window );">Sandoz Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalPeriod', window );">Stay of the approval period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PerrigoIsraelPharmaceuticalsLitigationMember', window );">Perrigo Israel Pharmaceuticals Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalPeriod', window );">Stay of the approval period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_PadagisLitigationMember', window );">Padagis Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalPeriod', window );">Stay of the approval period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_MSNLaboratoriesPrivateLtdLitigationMember', window );">MSN Laboratories Private Ltd. Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalPeriod', window );">Stay of the approval period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember', window );">Slayback Pharma LLC And Slayback Pharma India LLP Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalPeriod', window );">Stay of the approval period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_LupinPharmaceuticalsIncLitigationMember', window );">Lupin Pharmaceuticals, Inc. Litigation | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyStayOfApprovalPeriod', window );">Stay of the approval period</a></td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowertoShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowertoShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | Canada | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowertoShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | British Columbia | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowertoShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | British Columbia | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsDismissedNumber', window );">Number of cases dismissed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowertoShowerProductLiabilityLitigationMember', window );">Shower to Shower Product Liability Litigation | Quebec | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember', window );">Shower To Shower Product Liability Litigation Alleging Caused Ovarian Cancer Mesothelioma Or Breast Cancer | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_DoctorsAllergyFormulaLLCLitigationMember', window );">Doctors Allergy Formula, LLC Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_LitigationwithFormerSalixCEOMember', window );">Litigation with Former Salix CEO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember', window );">Glumetza Antitrust Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Recent suits filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember', window );">Glumetza Antitrust Litigation | Plaintiffs, Direct Purchasers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Recent suits filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember', window );">Glumetza Antitrust Litigation | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation, amount agreed to pay | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember', window );">Glumetza Antitrust Litigation, Non-Class Complaints</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Recent suits filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember', window );">Glumetza Antitrust Litigation, Non-Class Complaints | Plaintiffs, Direct Purchasers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Recent suits filed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_ApotexIncLitigationMember', window );">Apotex Inc. Litigation | Canada | Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bhc_DerivativeLawsuitsMember', window );">Derivative Lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Legal proceedings and other matters</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits', window );">Number of alleged stockholders filed lawsuits | shareholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_Legalsettlementsandrelatedfees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Legal settlements and related fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_Legalsettlementsandrelatedfees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyNewClaimsFiledButNotYetServedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency New Claims Filed But Not Yet Served Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyNewClaimsFiledButNotYetServedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Alleged Stockholders, Filed Lawsuits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyNumberOfInsurancePolicyPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Insurance Policy Periods</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyNumberOfInsurancePolicyPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Plaintiffs, Number of Groups of Investors</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencySettlementAgreementsNumberOfInsurers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Settlement Agreements, Number Of Insurers</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencySettlementAgreementsNumberOfInsurers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LossContingencyStayOfApprovalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Stay Of Approval, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LossContingencyStayOfApprovalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded from other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsDismissedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims dismissed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsDismissedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ValeantUSSecuritiesLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_UnfavorableRegulatoryActionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_CanadianSecuritiesLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=bhc_ViolationofCanadianProvincialSecuritiesLegislationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=bhc_ViolationofCanadianProvincialSecuritiesLegislationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_RICOClassActionsLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_RICOClassActionsLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_InsuranceCoverageLawsuitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_SandozLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_SandozLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_PerrigoIsraelPharmaceuticalsLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_PerrigoIsraelPharmaceuticalsLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_PadagisLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_PadagisLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_MSNLaboratoriesPrivateLtdLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_MSNLaboratoriesPrivateLtdLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_LupinPharmaceuticalsIncLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_LupinPharmaceuticalsIncLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ShowertoShowerProductLiabilityLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ShowertoShowerProductLiabilityLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA-BC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA-BC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA-QC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA-QC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_DoctorsAllergyFormulaLLCLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_DoctorsAllergyFormulaLLCLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_LitigationwithFormerSalixCEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_LitigationwithFormerSalixCEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bhc_PlaintiffsDirectPurchasersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bhc_PlaintiffsDirectPurchasersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_ApotexIncLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_ApotexIncLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bhc_DerivativeLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bhc_DerivativeLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R129.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373493272328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ScheduleOfCommitmentsLineItems', window );"><strong>Other commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Capital expenditures</a></td>
<td class="nump">$ 76,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CollaborativeAgreementMilestonePaymentsAggregate', window );">Milestone payments in terms of collaboration and license agreements, aggregate</a></td>
<td class="nump">340,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member', window );">Spear Pharmaceuticals, Inc. And Spear Dermatology Products Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ScheduleOfCommitmentsLineItems', window );"><strong>Other commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CollaborativeAgreementMilestonePaymentsAggregate', window );">Milestone payments in terms of collaboration and license agreements, aggregate</a></td>
<td class="nump">70,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bhc_MitsubishiTanabePharmaCorporationMember', window );">Mitsubishi Tanabe Pharma Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ScheduleOfCommitmentsLineItems', window );"><strong>Other commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CollaborativeAgreementMilestonePaymentsAggregate', window );">Milestone payments in terms of collaboration and license agreements, aggregate</a></td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bhc_NovaliqGmbHMember', window );">Novaliq GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ScheduleOfCommitmentsLineItems', window );"><strong>Other commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CollaborativeAgreementMilestonePaymentsAggregate', window );">Milestone payments in terms of collaboration and license agreements, aggregate</a></td>
<td class="nump">48,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bhc_CedarsSinaiMedicalCenterMember', window );">Cedars-Sinai Medical Center</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ScheduleOfCommitmentsLineItems', window );"><strong>Other commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CollaborativeAgreementMilestonePaymentsAggregate', window );">Milestone payments in terms of collaboration and license agreements, aggregate</a></td>
<td class="nump">36,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bhc_EyenoviaIncMember', window );">Eyenovia, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ScheduleOfCommitmentsLineItems', window );"><strong>Other commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CollaborativeAgreementMilestonePaymentsAggregate', window );">Milestone payments in terms of collaboration and license agreements, aggregate</a></td>
<td class="nump">$ 35,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_CollaborativeAgreementMilestonePaymentsAggregate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amounts required to be paid by the reporting entity, which are contingent upon the achievement of specific development, regulatory or commercial milestones, in connection with the Collaboration Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_CollaborativeAgreementMilestonePaymentsAggregate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ScheduleOfCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>-- None. No documentation exists for this element. --</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ScheduleOfCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bhc_MitsubishiTanabePharmaCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bhc_MitsubishiTanabePharmaCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bhc_NovaliqGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bhc_NovaliqGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bhc_CedarsSinaiMedicalCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bhc_CedarsSinaiMedicalCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bhc_EyenoviaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bhc_EyenoviaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R130.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373495496024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>reporting_unit</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember', window );">Ortho Dermatologics</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_OrthoDermatologicsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R131.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373416174600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Segment Revenues and Profit, Assets and Capital Expenditures, Depreciation &amp; Amortization of Intangible Assets &amp; Asset Impairments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 08, 2021</div></th>
<th class="th"><div>May 26, 2020</div></th>
<th class="th"><div>Mar. 08, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,434<span></span>
</td>
<td class="nump">$ 8,027<span></span>
</td>
<td class="nump">$ 8,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="nump">676<span></span>
</td>
<td class="num">(203)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,375)<span></span>
</td>
<td class="num">(1,645)<span></span>
</td>
<td class="num">(1,897)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges', window );">Goodwill impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(469)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments, including loss on assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="num">(114)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_RestructuringChargesAndInitialPublicOfferingCosts', window );">Restructuring, integration, separation and IPO costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(373)<span></span>
</td>
<td class="num">(502)<span></span>
</td>
<td class="num">(1,426)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,426)<span></span>
</td>
<td class="num">(1,534)<span></span>
</td>
<td class="num">(1,612)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">$ (38)<span></span>
</td>
<td class="num">$ (27)<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before benefit from income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,024)<span></span>
</td>
<td class="num">(934)<span></span>
</td>
<td class="num">(1,837)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract', window );"><strong>Capital expenditures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Total capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="nump">302<span></span>
</td>
<td class="nump">270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,765<span></span>
</td>
<td class="nump">3,415<span></span>
</td>
<td class="nump">3,778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,074<span></span>
</td>
<td class="nump">1,904<span></span>
</td>
<td class="nump">2,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,166<span></span>
</td>
<td class="nump">1,181<span></span>
</td>
<td class="nump">1,154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,121<span></span>
</td>
<td class="nump">1,274<span></span>
</td>
<td class="nump">1,453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,434<span></span>
</td>
<td class="nump">8,027<span></span>
</td>
<td class="nump">8,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,743<span></span>
</td>
<td class="nump">3,578<span></span>
</td>
<td class="nump">3,835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract', window );"><strong>Capital expenditures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Total capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="nump">289<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,765<span></span>
</td>
<td class="nump">3,415<span></span>
</td>
<td class="nump">3,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">958<span></span>
</td>
<td class="nump">909<span></span>
</td>
<td class="nump">1,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract', window );"><strong>Capital expenditures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Total capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,074<span></span>
</td>
<td class="nump">1,904<span></span>
</td>
<td class="nump">2,022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,493<span></span>
</td>
<td class="nump">1,338<span></span>
</td>
<td class="nump">1,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract', window );"><strong>Capital expenditures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Total capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,166<span></span>
</td>
<td class="nump">1,181<span></span>
</td>
<td class="nump">1,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403<span></span>
</td>
<td class="nump">386<span></span>
</td>
<td class="nump">352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract', window );"><strong>Capital expenditures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Total capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Solta Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract', window );"><strong>Capital expenditures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Total capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,121<span></span>
</td>
<td class="nump">1,274<span></span>
</td>
<td class="nump">1,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">722<span></span>
</td>
<td class="nump">814<span></span>
</td>
<td class="nump">933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract', window );"><strong>Capital expenditures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Total capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(792)<span></span>
</td>
<td class="num">(619)<span></span>
</td>
<td class="num">(609)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract', window );"><strong>Capital expenditures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Total capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the capital expenditures, depreciation and amortization by segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Impairment Loss, Not Included In Asset Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_RestructuringChargesAndInitialPublicOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges And Initial Public Offering Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_RestructuringChargesAndInitialPublicOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R132.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373487322392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Revenues by Product Category (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>product</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>product</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>product</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_ConcentrationRiskNumberOfProducts', window );">Number of products represented of total revenue | product</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 8,434<span></span>
</td>
<td class="nump">$ 8,027<span></span>
</td>
<td class="nump">$ 8,601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember', window );">Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">3,762<span></span>
</td>
<td class="nump">3,680<span></span>
</td>
<td class="nump">4,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_DeviceProductsMember', window );">Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,904<span></span>
</td>
<td class="nump">1,566<span></span>
</td>
<td class="nump">1,718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember', window );">OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,532<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
<td class="nump">1,447<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember', window );">Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,144<span></span>
</td>
<td class="nump">1,248<span></span>
</td>
<td class="nump">1,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bhc_OtherRevenuesMember', window );">Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">3,765<span></span>
</td>
<td class="nump">3,415<span></span>
</td>
<td class="nump">3,778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">514<span></span>
</td>
<td class="nump">506<span></span>
</td>
<td class="nump">623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,596<span></span>
</td>
<td class="nump">1,313<span></span>
</td>
<td class="nump">1,524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,388<span></span>
</td>
<td class="nump">1,311<span></span>
</td>
<td class="nump">1,322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember', window );">Bausch + Lomb | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,074<span></span>
</td>
<td class="nump">1,904<span></span>
</td>
<td class="nump">2,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,066<span></span>
</td>
<td class="nump">1,899<span></span>
</td>
<td class="nump">2,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember', window );">Salix | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,166<span></span>
</td>
<td class="nump">1,181<span></span>
</td>
<td class="nump">1,154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">259<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="nump">268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">737<span></span>
</td>
<td class="nump">775<span></span>
</td>
<td class="nump">730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember', window );">International | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember', window );">Solta Medical | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,121<span></span>
</td>
<td class="nump">1,274<span></span>
</td>
<td class="nump">1,453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">923<span></span>
</td>
<td class="nump">1,020<span></span>
</td>
<td class="nump">1,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | OTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | Branded and Other Generics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">167<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember', window );">Diversified Products | Other revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember', window );">Revenues | Product Concentration Risk | Customer, Top Ten Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">43.00%<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_ConcentrationRiskNumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Number Of Products</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_ConcentrationRiskNumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_DeviceProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_DeviceProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bhc_OtherRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bhc_OtherRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_CustomerTopTenProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_CustomerTopTenProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R133.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373486657304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Geographic Information, Revenue (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 8,434<span></span>
</td>
<td class="nump">$ 8,027<span></span>
</td>
<td class="nump">$ 8,601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember', window );">U.S. and Puerto Rico</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">4,887<span></span>
</td>
<td class="nump">4,791<span></span>
</td>
<td class="nump">5,164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">490<span></span>
</td>
<td class="nump">341<span></span>
</td>
<td class="nump">368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">343<span></span>
</td>
<td class="nump">331<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_PL', window );">Poland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">280<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MX', window );">Mexico</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">256<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">226<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_FR', window );">France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_RU', window );">Russia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_EG', window );">Egypt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">243<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">154<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">116<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_ES', window );">Spain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">88<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IT', window );">Italy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bhc_OtherCountriesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 986<span></span>
</td>
<td class="nump">$ 937<span></span>
</td>
<td class="nump">$ 995<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_PL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_PL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_RU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_RU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_EG">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_EG</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_ES">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_ES</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bhc_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bhc_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R134.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373492556040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Geographical Information, Long-Lived Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 1,598<span></span>
</td>
<td class="nump">$ 1,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember', window );">U.S. and Puerto Rico</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">743<span></span>
</td>
<td class="nump">725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IE', window );">Ireland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">336<span></span>
</td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_PL', window );">Poland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MX', window );">Mexico</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_FR', window );">France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_RS', window );">Serbia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IT', window );">Italy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bhc_OtherCountriesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues and long-lived assets by geographic region</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bhc_UnitedStatesandPuertoRicoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_PL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_PL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_RS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_RS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bhc_OtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bhc_OtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R135.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373489607272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION - Major Customers (Details) - Customer concentration - Revenues<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">AmerisourceBergen Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">McKesson Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Cardinal Health,&#160;Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Segment reporting information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=bhc_RevenuesNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_AmerisourceBergenCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_AmerisourceBergenCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_McKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_McKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bhc_CardinalHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bhc_CardinalHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R136.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140373414791496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Feb. 10, 2022</div></th>
<th class="th"><div>Jan. 18, 2022</div></th>
<th class="th"><div>Dec. 18, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_A9.00SeniorNotesdueDecember2025Member', window );">9.00% Senior Unsecured Notes due December 2025 | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bhc_A9.00SeniorNotesdueDecember2025Member', window );">9.00% Senior Unsecured Notes due December 2025 | Senior Unsecured Notes | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 9.00% Senior Unsecured Notes due December 2025 | Senior Unsecured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Repurchased aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 370,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet', window );">Debt covenant, redemption and discharge condition, amount, if circumstances met</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | New Restated Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentCovenantTotalLeverageRatio', window );">Total leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Revolving Credit Facility, New Restated Credit Agreement | Revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity', window );">Expected maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 975,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Term Loan B Facility, New Restated Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bhc_DebtInstrumentExpectedFaceAmount', window );">Expected aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Senior Secured 6.125% Notes Due February 2027 | Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">6.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Senior Secured 6.125% Notes Due February 2027 | Senior Secured Notes | Debt Instrument, Redemption, Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage (as a percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Senior Secured 6.125% Notes Due February 2027 | Senior Secured Notes | Debt Instrument, Redemption, Period Two | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Maximum percentage of principal amount that can be redeemed</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Redemption And Discharge Condition, Amount, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentCovenantTotalLeverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Total Leverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentCovenantTotalLeverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_DebtInstrumentExpectedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Expected Face Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_DebtInstrumentExpectedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Expected Maximum Borrowing Capacity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bhc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_A9.00SeniorNotesdueDecember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_A9.00SeniorNotesdueDecember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_NewRestatedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_NewRestatedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityNewRestatedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_TermLoanBFacilityNewRestatedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bhc_SeniorSecured6125NotesDueFebruary2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>bhc-20220510_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bhc="http://www.bauschhealth.com/20220510"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bhc-20220510.xsd" xlink:type="simple"/>
    <context id="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2022-05-10</startDate>
            <endDate>2022-05-10</endDate>
        </period>
    </context>
    <context id="id5393601523d4ba3bef1b785065c95b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idc87f78bc74d4e43ab17c35afb0f8079_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie8771372c3b94462beccdbc52f82e2b4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6ff468ead247475a82ce446740f1f83a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i32509de5461547988d9730878e48539c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib332d58601bd454bb89ede6b79782526_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie3a6d276415e419fb9288f1aa64070ba_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9065a4b181534b6ab3a847b07fb47561_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic1d1a33a09fa48859e7e47fd030be3fd_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7651c2a37e9f49e9915cd978a12d1e8f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if72905c016ef4f1494ae44900f94a9fd_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibbcfed5f24544ab594fad1395b2ed82b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7c139d1926cf4e6c9d1ee8a32ee091d3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i18439fe8345c481db53c486667ac6940_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6adf3d44da584f02a9de432de2320ed5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id70a674e2be94ffd85bbca114010b4f0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i15c0150c538f487cb6591cfcbe5f75f1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i261c4af1d70b4e2395fbc9f9f1d94e47_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id967574fda7e4ceabaf0455646739979_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i119d0f73c7f74fc9bb4f33a268f1733a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i473f77fb1af344a29eab4fdfd6d3dd2b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia3596f3678c0497483ac196ed8bec2eb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9a73edc85bf74e808a3aec728f72c249_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9aca61c7e88b46d19ad0b86e6d3a2ecf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia032d22b364945dd81a246b3994295ed_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if43bfad251bd4331a051f408c738cf0b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i10dd5d5cf93949878c6cc5089859a3bd_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2f5bb32797ed4025b477232d70d05dd7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i052b9590a90c45a9b05e3dd474e6d8d6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2d81998e18d049a795cb319c580e68df_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1dca8f6ac26c452fa7d59299882a0097_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5ff42e3612b54f43abc128d492dcd6b7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9eb6e474c66a4666bf7e3a85d9c998a9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3f36a5753643489d88a4e0f82c989bd6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i086e5920df794c1bb867ec98391c2996_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia496362f6d164947b1a2ae170da89d4c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3bcb5947fed543afb53cd6a3b48f336b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if8bec50dbaed4dbea096a71456e733f9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i923a3743995f408db8308a2d12856422_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib105e1aee9db4b46ae7d9e203dadfad7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3206e4462f2f44e9860f3d0294412da9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5b49661c9941455eb0cd3e84d7fac743_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7b938a0322254b5aaab41c8892322507_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if33956ad61204d93933927de0fdb82c7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1a6553baa7a24ea0992e7694bf3ada46_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i28ab1aeb8c054aa1a4603d09d2ee8fc7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i19f72ec10a1846be8c55a1dd70f9a9a2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i11f91c7cdb5e4652b3582c04a13bbd0c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0aec0a6b31ac49f8b1539442f4d1de2a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i69270432269b42208da3ba0a5f6c0c8d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i525200ba6a35425892b9fb1f4c0c7eeb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff498ebdd499404a95f12abea2bd55e9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2e55e9853c474101a26d48d5ad7d46b6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i19c82921041f4fa6b0c1e1a12a9800a1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia62208ce4dc846f1ba9f111c31435582_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:ThreeLargestUSWholesalerCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iedf6d2b80161425e9e29520cc751a2f1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic0a435d217a0443898aeb95a619d60b2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i00e7a4ba81a046a790930dda41d3956b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0043ca6c60b448469dd9c10b6369a160_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic50c129d307b456db8bd6d0a3572b5cf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1c6ea96094f24f6aa4162dcd33584114_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id111070c09c44a9f836bd940a8c401b1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id5d7287ea6164d739cdd4537fbbcf93b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i71d4507094c54c61a828a4ba28c456f8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i300d1bbfb1584998a64def9a1e591494_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherMachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idcb50c382a0f41abb2ebb51d91d43a1c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bhc:EquipmentOnOperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifbd918087d4845c1890cc471931bf4ee_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id51447b7e78f425bafc98f09b85f21fd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i975464f279ce4238b86edce4c77ddbe8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie756de63eaaf4535abb5aeced45c5b18_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia21b8496153c42c087eeb45cea371ca7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i490b2ed3d24b48e583bcdcad19e43866_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibeae95de06d24f9696ad1c74d3eee5f4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic53aa697e1c24a5896e49065797f9b0d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i589f537dbee5471e9bfcdc450bd648fd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2b9398fd67264ccbab689da594b22ed4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i36b171d0ac0f4d8ba4064dc0477f6b5d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie888db196c4b4c7da3187745b2f5d4b8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i25b840b91a804c71b49368c35927a054_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if1c4cad2abfd4049a17a50ff205cdabc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i775805d9c3154ad285c4fa424c1e815b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i43f8e7fcb97b444098dc083e79b1b3cc_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5df68fab41b644118a6a79ca3701e13c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i23a4bf59c23544509ffad0bea04a9270_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i13a9ccb3dbd94a549431fe94a821e396_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib4e09033a34c4a888cda3e4a5656b5bf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1941a9e694f34f33978cf055adb0230f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia3abe2f197384a5faf80cf8970b4f6e1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb7a5a9f654c44d88f30b125fda3dd93_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id38abec1faf94c6a8cb3456db066aea3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if02ec4ff710b412386b75c6474100d94_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i40cfa45466644cff8b8dc0f3298dfb6a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9fc0bea60f3d4043bab8518cf76f48fa_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if231ab941291433d88b5f479ceaaaab9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i056b23d864094b3a8805bbf7eae8f62d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifac9a0ee97354de5ad0790a506ffc752_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7f5af18d5ed449a39d9cf011a2c82598_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i968f181cf55f432d8b88feaea1bfdebb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i024019b8dc9d47e9a40e0391dd2811f6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForCustomerReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic252586b20d24ab2b1f4c1e7d2d0216a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i45c7461bce0f4ce88d5a315b0d9016b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i77cd717b81fc4051b53b2ba09fbc08d7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForDistributionFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3217dc4fc80f4a868a33e3af520f1ca4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3bc559ab6ace4d47880bb10942e52a2d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">bhc:ReserveForRebatesAdvertisingCreditsPortionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if642d30e99ba413e98c7c9fa16c98d58_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie8f30533812f49bdb16ff48c59ebaf7a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PriceAppreciationCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if18ed4a9db4c4141bfff00c96c8d6997_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idb0e80397f6a447584308760a43131cd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie389482f874b41c39bfff2d72239425b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i65c560b8d709448ebce15c3e5d971fa8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib7ab09da936244e1bea7e8bf2554b541_D20190306-20190306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:SynergyPharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-06</startDate>
            <endDate>2019-03-06</endDate>
        </period>
    </context>
    <context id="i3228597eb86549919c150d017affe6c9_I20190306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:SynergyPharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-06</instant>
        </period>
    </context>
    <context id="ieaf743deafab4bc2bccd438cce5fc248_D20190306-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:SynergyPharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-06</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifaffb0ddf4f849c6b6a4167f5b18f584_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bhc:SynergyPharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic9f191dca8cb406ead6fbd0a27981bb3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">bhc:AllegroOphthalmicsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie23b3d96ce1248c98d46a1440bd6d937_D20210623-20210623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-06-23</startDate>
            <endDate>2021-06-23</endDate>
        </period>
    </context>
    <context id="id741d32018d54352affe7795fbf6464e_D20210726-20210726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-26</startDate>
            <endDate>2021-07-26</endDate>
        </period>
    </context>
    <context id="i6e7cb1daba9744fc8e55c867cd1d063f_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id21d49c675e3425b871866e8870406fc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5b13ca98db8c463aaeed70c3abe4f348_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id64abf2e66454ecb8393494a9d2a34a1_D20200101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:AmounPharmaceuticalCompanySAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id9dae4cbf28945e690c15be6b4c2db5e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:ACertainInternationalBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0e08237054f64594815ad5013a5aa9e4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a1258a2943a4cd69dc73c01e660d449_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i405dec7379e74ca38494473ae3975347_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icc79228c9dac48f29a1d9bd8078aa0c4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:RestructuringAndIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i813493bb33fc46b7a7a4c4b6aa9f0252_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationAndInitialPublicOfferingCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i10381b45a049401593f3912db2562a03_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">bhc:SeparationAndInitialPublicOfferingCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3f6583316fc34f2ebde02bee82fce983_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifadbfa9e788b43cba3cad3e76ae5d807_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7aec1240743845078358d61e36c809cf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2abe9143f14849f1bc9dd6da011f2cf4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3319185b216a47d3b6da5be2dc91b570_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia48dede4a3424904945186832465d56a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie64c787ebb9447d0a92c7295f0f6d419_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia04ea7b71bd04c6d9cf8679abe9ec99e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7e44595ee4a14fcabb69571771959535_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i78ba78cf61414c25a16502d502d685c6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i70b47e80f74944c99ac1f1b1f772d335_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie46f9e499c3b4367a00f89844e5b3e05_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia18f0da75a394809a608e7d0eae6fa53_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7ecd69567c0b46f5b506f1e4c711298e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i440fa512b3bd4579bb8d93cc9d65ddd0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if1313267327e41edacf2aecaa695623a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7a6ca21431734f2b82ccc26320d115b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if285ca9b8419448ca0ecfe732b387fab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7727cda61cec499488b86e1b280aba86_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic622a69d05a04c3da2e6c078832136fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff786c33709b42768b27ac83294252fa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia2ec169a70624d1a9715b177b9eed016_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia3c641a323124a5e909b2269cea5b838_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if60700f229f0413882411855a4cc706a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6ad175767e714adb952f1fc81f92fc67_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic25e35c549a54c708a26494e39477c78_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia2313e85fce74e5aae451d3654b4cc63_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="i2543b8697622497798f72858198a9b4e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bhc:CrossCurrencyFinalSettlementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib6236fa286e14aeabadb9f150267531f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2d8c9c1bfdd840429f53aab587d9c839_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7b510358d6854ed28e6f46e5f58ded33_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id6beec5955f640bf84cf335c76410fb7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4ac58aeb82cb4d5da0dc54736de89480_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5cd1bac2236840fd955596ca631b176d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9eb64f96a45e4870872718cc8df9421a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6c82f3651439499c885ddce82e4834ce_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i457c889b626f42869ba8488dbeeb08d6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i22478da08d664decbeccb00e9738fd08_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9dc84dac17cc43a3984fc9929fd5e294_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1e1566b2fa444f9281a88fe587091171_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iad637097d6f449b982fcf6ea6c568da3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0bdd18e14d804d67a4f34d683bfa58ea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if472041674414bdeb5fb73f64f380506_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:AccruedAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib426ea78162c4c489b291c4a5ef1bda1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ida0fa648d576472480251eb6eb22d85b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i71801473f3324db7b4ad384aae92fc76_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3c9863c6c02148b280910bb43a45b30b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0159699620b14a238fdfa5d3fe9aea70_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic984dc5f62ec4772bc9ece326f420058_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i680eb79e17184399ba8ff57eb89e8ab8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iafdb511725c04b449bc18c9f41f1c601_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">bhc:MeasurementInputWeightedAverageDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i98d1e9065dbc434ca6fa39e4ee7397d4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5fa8c12aacc74d6b91c15b886f0f76d8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:AccretionForTimeValueOfMoneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if32e75dc65d54621a38196e180c5052b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if4908569b3b44a878e5d419525405804_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bhc:FairValueAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i15d7424af8b443409563957178d9f029_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8453f3b3b4c743129918b8a8465d47e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica46ac5deb7f4bca98fd1442ab972fe1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i00e41fe3c6f64b2289dbd0cd45fde7ea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0703b0cf397f477687f950dbbe23e831_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9ca97df2856842dfbaf44ca3f738a575_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib66efd6818984bf8b7ee621516776ce1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia03371e98c434dabab65c558c26cca83_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i03f09b98a2794ea19b27978f0c0a73fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i794b0cd648154358b5f12e82f9710bbf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i55bc00875c13421c8e7ef466a6e806e2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5486904f53c94726b49a9232f4dcb0d0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i802908ddd2fd4486afb3bf31d0d9edd9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2600359d03bf4008a75ebdf90c246dfc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5b77fdc1142642a0acda999683173c6e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bhc:OtherEquipmentAndLeaseholdImprovementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i38dbc214d6144a758e35f77291e56b5c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bhc:OtherEquipmentAndLeaseholdImprovementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ida44475894334e22b76c358bb055a53a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bhc:EquipmentOnOperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6649875e397846f2945b7974a238e07a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bhc:EquipmentOnOperatingLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ied26b295528f43e08d519d8a4f061068_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8e5b883341944b8591f5c00136de5e09_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia7db43bf7c3c4b4186ebf9e2d3d12935_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iead8c960de884ed6a2da68f1c9212534_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i118c693b1f954748862447902a5683db_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7a7c179df5a84846a54bcfeb13c293e4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie8d0b9bcbcff47528293434664f12031_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0141b3d37c034975b5525cda87681171_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2c05dc4d9b434c80a5cbd4af3c7c9d01_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie35bf5d8694c4774974b0abc32f8fb13_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idabeb53d68674574be9e8bc3a04fc023_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i03fe969473114a429bbf4edf40c1b1b5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9d77acb3fa444b01a7222031f5d4d6ea_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1b81638d52a34a33a0380c8dc68c21d6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:PartnerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i240a15f4864f40c195868e118ea13730_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5ba67417f7694417880945ef3a458823_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9ac6cd5788244ea0b4e00e55c970a88b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:OutLicensedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4357b8c2815049e2916abd0dd4c84a5e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bhc:AcquiredInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i68da001337c24191a51c93ad8d98f64a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bhc:AcquiredInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6c9e8270f510440cafaaadcad18b83e9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i46550d37e139414ebc038a9317b297af_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibdc79af88d674986aa0a6ba7cb0f5f09_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i846ec01236d9492bac74fd5461000270_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:UnutilizedITInfrastructureImprovementProjectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i80296fd237314f53b6c594ed566c42d6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:ACertainInternationalBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4e1691abab7e45ce93d9c7cf06722945_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i993b35454ff842d7806cb59a463ffa34_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:DiscontinuedProductLinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8d17c5bf6d9841eba3706e1d48dc6848_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bhc:AcquiredInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if5392c04784e4d69b6bc3a708883efda_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bhc:ProductBrandsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i20a958bbcf974985879a206eeec09656_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bhc:CertainProductsForDisposalSeptemberTwoThousandNineteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia3596e67486c490b9d96f6e6a4bf73bb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i525a2c44053046a38066e353d995cc61_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">bhc:AcquiredInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i29a1b1fb5e7d43a0a5704750d1336b1f_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0c3d9b6375104575a0b650fb85f1b280_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i94cb38fd73a64df9bcbf981da8f70e3c_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="id466e6e6ca4d4b5cbde067689c3faef3_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i417dcef94a21464c8f3e70b1b83c913c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iba8428875eb04c3490fd83250b59b893_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if3dfd5b244cf486d987b952dbf744f29_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iba148d40c69f47e983b912769213931c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0f812afa0f2f46a5a00813ce760a5ac1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i53ea644df00c4c18a3c89f1915121a44_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i25de128371b34a1f9d25e80a34d0887d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i305ad186f05a46689ddd955b46c78817_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9106cb312b894b4fb0e6e25a1c2f3229_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4e7e6c0540534603be58b450ccc6ebd2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieb7488e0749d446eabef23fd482eb625_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3cbcad2018a947ad8f38faccb79805c0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i414fba28824c413593139a2e4ef76d21_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ied7527e9c7f3438db93389c0a1768d2a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3a5a9e6c49d742aca8267ceb1bf314d3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3328d4d641274769857018f609cda173_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iea2db51516f74749bd5cb23d69094522_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombInternationalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5bc870f8e27c47c28a8e424dee7145fe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9aac4f4658b94a079f835ab8b92e3d71_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id1d8a07e1c514b0588c2be7cad93ca17_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id5279cba8f1f4e03838c2449f0a36169_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:OrthoDermatologicsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2ccf39e3c6294658af0ff9fe475686ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf7ffc6e85884b44bb020321c2fcfd9b_D20191001-20191001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-01</endDate>
        </period>
    </context>
    <context id="ib12ef9337a854b11b31304b6e0c0205c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i7127e175a3854e52bc0c75d9ff20c0a3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic1987990ae2747de8eb8993bcdd37868_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7cb87466591741d69c11218eca97afee_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:ReportingUnitsExcludingOrthoDermatologicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i98b90ee22470425788f2889f17244951_D20200331-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-31</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i699a9e7d09c64c9c88f463de1d97f137_D20200630-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-30</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i30a1d9b6c3d84763be8ecc3f1d79f317_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="i5d5b8f902e834dda885bb99a7a2bb489_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="i6080875e0e1f4486a08e3dc0c2dc6319_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="i21115bf566934307b8091d4d727aa2c3_D20201001-20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="i86c894299d29409ead4b863813550b86_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9a2dd9a9a7d04b008adc3046b51f7059_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic6202fe446ad4ef9a31cbf50a8342593_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icded4b5feb5b4918af206e2655141f49_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ice067f6010c74048bd8841e74a7cef86_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i47d8b26934ee4498a7ab3ff3fecbfed7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6ea718d72ec4448ba2219818acc2f6f2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibe79965a558440f68c2f201ffc977e8e_D20210331-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-31</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icd4661795c6d477dae3ccd804bc808e8_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5d4cdd25b2984038a1406bacb8cdc3dd_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i90bbe44e848c4111942574f93f21895e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i4b861d276efc40a681c82e2398b819a7_D20210630-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-06-30</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i75ce7fc0f0264a0f904c3a8cde7de3fd_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="idfae6f80e7694be08e982fe5786bd632_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">bhc:OrthoDermatologicsReportingUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="if40967e6d4d3497cb45e304881c2d2d3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i711dcf2b52cb48f98fc1cf3d97a987ec_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i969d616487264ae4b3b65d39984bbeda_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i22c93f5e835048719e869de028b61cc3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ifc44ed8e69bb43ea954db330ec970a6a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie889e70e297a454da84ecd8e61e4957d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i707a0a1b00b141a28c29e5d5fd1faa7a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8fd6185a911a4065809d6e0b5f61c3b9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib49f81a33d864365851ef46a13cca29f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4fd3df09e61d4c56a4826cfa2060c2f1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i537bc84d95f240518063d4d8d3b870e2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1d40e1f7a1c14a28b74752dcba680ada_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic6eb226ab9604bf188531181e371079e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes7.00PercentDueMarch2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3248199cb70749178b2c7c4fb4982735_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes7.00PercentDueMarch2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i06ec3dd3dcb0438eaf3aebc8db3d319e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1a77d52d62824a7cadf4ab72fa8e094b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i557d4dca2ccb47e682e75358f752e842_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i40edb907b7044d23b89c96ffb68d67e9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4fe84f0ae9724529bf29568dbbffd5a3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4bb8d72e3c074630bbceb17545ec7261_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2db39af25b1445a1b1d39932a08c5fc7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibfeed60331fb49708cf75fb16367305e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia3daa9b4fd734cb7af4bf16715ab23b1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5e861b64daed45ebbe70114675bf535f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes900DueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8827aaaa75144f59a8e1bb3dccf8fe3d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iad0d1a99b6ec42b9aaee8785c8cb6f79_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes925DueApril2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5a929eccb9e64e0b88c64d38a28ef190_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9a25feedc2bd4f438e6d127ea650e095_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes850DueJanuary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i03f92fc0786847c3b0c496e8d1603888_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0c0dad67e3784bcdb5a6e6f002cd9ee7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4315b5a6bf3449c790d05b0d6ad5b10b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i43b03fff47d14db7bcc1ddf661a8dc92_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i46a9772e12364383a02b198038550550_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic87200a1dc2742999c99925809369c99_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i55ad7bb0a54347dd9a4596d8be5b8dca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6f0cd0c7bcda47b38d01957e2a3bc327_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5c5faf2607ad4637a05e98dc5c8875c4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i19dcb028ec1d4e60aa66dbeb559a420a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes725DueMay2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0249a1288b1649bdbb249d5ea07218db_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1627b94e1a9a4cca93a1bbe3b864cf4d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueJanuary2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i06254af032384d79944c4fbf0358b2a1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f9e33e485084fff9d0c81867c005c16_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if4e37ee467534e15bb29330c819bd784_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic10baeef95084b95a40fdf0c4c004831_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:OtherLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i27fc8076f1bb4e4fac0065b5495211c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3c884d2a677c46099dc4bf036009410a_I20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-01</instant>
        </period>
    </context>
    <context id="i3e81a6b0b4494ea99594e7ae61d6e7e2_D20180601-20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-01</endDate>
        </period>
    </context>
    <context id="i3ac7b4fdfdf54cca97131f28525e6edc_I20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-01</instant>
        </period>
    </context>
    <context id="i1b48943d62f64d77bf275084b850c10b_D20180601-20180601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-01</endDate>
        </period>
    </context>
    <context id="icca812a26f644f92a7e1f4a986e51c00_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8bba7bbfcfef401787d57a665a8baaab_D20181127-20181127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-27</startDate>
            <endDate>2018-11-27</endDate>
        </period>
    </context>
    <context id="i122eb939c38343d79b07091d8c902050_I20181127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-27</instant>
        </period>
    </context>
    <context id="i0ee961e3429c4173bd50b3e41367ad7c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia998a2f7b86b483b983a8b3498ae44fc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i388ac421c82b49c48346643fa2ca8a0c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredCreditFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i984c72f35f464a9f992e3b3b631f4b0d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6084b059746d44c2acce81065d562b57_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:CanadaBankersAcceptanceRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if7840f0b2e2b48f5833d3f0adc12fa7e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:CanadaBankersAcceptanceRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib2fc98102d394e23ab05be5028d334b8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredTermCreditFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i27aa31be484b4e9b951df5511db3cc35_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateOrPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5d1c850c7eb04b9a9236112505ccf265_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateOrPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i084241e0c0984f30b029369bd43fb499_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0a3693985875498082ba11e282f4e79b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueNovember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1a7a975faf994c36a88b4e0e0eb6800f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6e2ae2d598fc4a64a6dd097539edef68_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateOrPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifd51dd72613243c68aa536db0dc3c70f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">bhc:BaseRateOrPrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i302db430cde9461f934b806767f52349_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9b262c356e2e4aef8c99010988af7e67_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i77d8c4f932f64c7ab48f7c0ff10b8a3a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i76d8b3b4ed87466eab6f101ddcb61ba9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i558d07c8b64a40c8b3072a4379c5db37_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3089f6878ad144f5971f1a990ab34d3a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id9abd9fd4a3d4f839584c60b7f287d72_I20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes6.50PercentDueMarch2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="idd735e6d7a4a49c4a31ba11a3b55d3c5_I20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes7.00PercentDueMarch2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="i449725090bcb4e129cd4dff2677ce289_I20171017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-17</instant>
        </period>
    </context>
    <context id="i17ca0b3ae0a14541b95a0029b74fc81f_I20171121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.50NotesDueNovember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-21</instant>
        </period>
    </context>
    <context id="i426ecf59adef4723a9464ff7dd035235_I20190308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-08</instant>
        </period>
    </context>
    <context id="ic4d5b348d3924c7286e27eb049dcb072_I20190308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A8.50SeniorNotesDueJanuary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-08</instant>
        </period>
    </context>
    <context id="i234da319c3ef47c291bbc91d590a7fc6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5875SeniorNotesDueMay2023March2019RefinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1b7290e999a74c9f84f1e1f0dc4acadf_I20190308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.875SeniorNotesdueMay2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-08</instant>
        </period>
    </context>
    <context id="i60523f26c0cc421995caf64823d36f89_D20190308-20190308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5.625PercentDueDecember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-08</startDate>
            <endDate>2019-03-08</endDate>
        </period>
    </context>
    <context id="i7107764faeb3461fb0c3e1558afa09a0_I20190308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5.625PercentDueDecember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-08</instant>
        </period>
    </context>
    <context id="ia554f95ec9dd4a30af67e386976e2ee4_D20190308-20190308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.50SeniorNotesdueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-08</startDate>
            <endDate>2019-03-08</endDate>
        </period>
    </context>
    <context id="i8c3fe314a07b49f5a24c68a78aa7c617_I20190308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.50SeniorNotesdueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-08</instant>
        </period>
    </context>
    <context id="ia4a78928619a4fbdbb34836a1b0fe3dd_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes5.625PercentDueDecember2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i55f45e1ec8754cce8219f906d738aa2d_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotesAndSeniorUnsecuredNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="iefa733ef7c794dbaaf6199d058362bd6_D20190308-20190308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2019-03-08</startDate>
            <endDate>2019-03-08</endDate>
        </period>
    </context>
    <context id="i64a0081e7f7a480c9031042be2e2e776_D20190308-20190308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured5.75NotesDueAugust2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-08</startDate>
            <endDate>2019-03-08</endDate>
        </period>
    </context>
    <context id="i8eb18dd3d80f4b20be43d6f02dd8ec59_I20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-08</instant>
        </period>
    </context>
    <context id="ide09659430754a848ded8babd4ea06b0_D20210608-20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes700DueMarch2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="i88ac47eb607d48dda7da8b2ce778805a_D20210608-20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="i9c34aa862974483ea57b2b1d0e3c0f03_D20210608-20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="if7d99baf53a5465bbbfe961490f008dc_D20210608-20210608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured4875NotesDueJune2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="i4fc30bcb84e44522a8af652f8f8ce17c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibd5fa5a50ddb47ce943d25e5158d7fa4_I20150130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.50SeniorNotesdueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-01-30</instant>
        </period>
    </context>
    <context id="if6d83e37326d4725bc725486444bd866_D20190523-20190523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.50SeniorNotesdueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-23</startDate>
            <endDate>2019-05-23</endDate>
        </period>
    </context>
    <context id="i6dd5787480294fa2b679e5d4885e9821_D20200101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.50SeniorNotesdueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="idc9c834100a744ec86cca979fb7b31ec_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.50SeniorNotesdueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9fdd4332ca4c43c99f6dab6dd5f1e32f_I20150327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.375SeniorNotesdueMarch2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-27</instant>
        </period>
    </context>
    <context id="ia903bb7aea2a44119bda10563a043e40_I20150327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.875SeniorNotesdueMay2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-27</instant>
        </period>
    </context>
    <context id="iedce2bbbaab64fc79908a3e30f8e6c65_I20150327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes4.502023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-27</instant>
        </period>
    </context>
    <context id="i7040cce3fb9b4eeba357b284b09231e2_I20150327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A6.125SeniorNotesdueApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-27</instant>
        </period>
    </context>
    <context id="id9f599c080f5467ea5baebd9fac485a0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5875SeniorNotesDueMay2023May2019RefinancingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if99807b8eead4d89b01d9fb9a37fc251_D20191003-20191003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorUnsecuredNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-03</startDate>
            <endDate>2019-10-03</endDate>
        </period>
    </context>
    <context id="ic53f9efb99aa4ccda95f61d26890a343_I20200116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorUnsecuredNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-16</instant>
        </period>
    </context>
    <context id="if94fac52f3f54b40b4fdd01288bf1861_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorUnsecuredNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id6298e5d16674dff95b3e998b6c37203_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes6125DueApril2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4177e1b635b74d889574e58be568dee6_I20171218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.00SeniorNotesdueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-18</instant>
        </period>
    </context>
    <context id="i5a8941f15dfb40e2ad916e87ad8d78c1_I20171218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.375SeniorNotesdueMarch2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-18</instant>
        </period>
    </context>
    <context id="i719d98863d0149828286447cfc21c537_D20171218-20171218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.00SeniorNotesdueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-18</startDate>
            <endDate>2017-12-18</endDate>
        </period>
    </context>
    <context id="ib5f75d74fcd94b378a67e51f53cdb29a_D20171218-20171218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.00SeniorNotesdueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-18</startDate>
            <endDate>2017-12-18</endDate>
        </period>
    </context>
    <context id="ic7a91ae9c014412285210f2ad632343e_I20180326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.25SeniorNotesDueApril2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-26</instant>
        </period>
    </context>
    <context id="i2277d8eefa0b44fba997881be7afffec_D20180326-20180326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.25SeniorNotesDueApril2026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-26</startDate>
            <endDate>2018-03-26</endDate>
        </period>
    </context>
    <context id="i177b63c1f7f747e3b7ccc3613e2fcaa8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A8.50SeniorNotesDueJanuary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib4c76c9931404817acf913b8360dbb5e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A8.50SeniorNotesDueJanuary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i797b2df10ff44b2aa71c461fc27b30ef_I20190523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A7.00SeniorUnsecuredNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-23</instant>
        </period>
    </context>
    <context id="ibc2d2ee34b9d4af8aaed19ac1ff2667c_I20190523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A7.25SeniorUnsecuredNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-23</instant>
        </period>
    </context>
    <context id="i9c71c44fc4c34b9bae672a9f56dfd653_D20190523-20190523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-23</startDate>
            <endDate>2019-05-23</endDate>
        </period>
    </context>
    <context id="i2c637f283ab04dfbbbfee6141ea6b782_D20190523-20190523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A7.25SeniorUnsecuredNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-23</startDate>
            <endDate>2019-05-23</endDate>
        </period>
    </context>
    <context id="if78fcb7d67eb418892f72d087ada3247_D20190523-20190523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A7.00SeniorUnsecuredNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-23</startDate>
            <endDate>2019-05-23</endDate>
        </period>
    </context>
    <context id="i8b69c2b55c9f49159ba0241d1da3b1b6_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.00SeniorNotesDueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="i707c6ada63c346a9b3799fb37f228dee_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.25SeniorNotesDueJanuary2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="i11d7dcdeb76f46a1ac2fb260dc29bf23_D20200116-20200116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.875SeniorNotesdueMay2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-16</startDate>
            <endDate>2020-01-16</endDate>
        </period>
    </context>
    <context id="i6ba274da5cb54b1daae13438db70ae34_D20191216-20191216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-16</startDate>
            <endDate>2019-12-16</endDate>
        </period>
    </context>
    <context id="i4f688b41850c4d0fba418cbe194ccfbe_D20191230-20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.25SeniorNotesDueJanuary2030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2019-12-30</endDate>
        </period>
    </context>
    <context id="i2b0d3caab19d43358c37172b00a1d73e_D20191230-20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A5.00SeniorNotesDueJanuary2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2019-12-30</endDate>
        </period>
    </context>
    <context id="i23b34418de5747bc96ac966e1bad4561_I20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-26</instant>
        </period>
    </context>
    <context id="i39f28d2202204cc1b5a777f81170474c_I20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredNotes6.50PercentDueMarch2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-26</instant>
        </period>
    </context>
    <context id="if0649a2ad7e34fdd9c9aaacf95248fea_D20200526-20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityDueJune2025AndNovember2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-26</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="i79078ef3ff22478e8ad56dbe5a19750d_D20200526-20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
        </entity>
        <period>
            <startDate>2020-05-26</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="i80f3eb0d6a794c4dbf060750dbc6dc48_D20200526-20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-26</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="i7a0f2471e7f44074809037b78de94990_D20200526-20200526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes625DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-26</startDate>
            <endDate>2020-05-26</endDate>
        </period>
    </context>
    <context id="i4d4effd4ca8849688cd2273c89e716e3_I20201203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-03</instant>
        </period>
    </context>
    <context id="i374367eeb97946bcb6cacd5888eb32f6_I20201203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-03</instant>
        </period>
    </context>
    <context id="id77d7960c24b4e4a865ddd716f13ec49_I20201203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes4.502023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-03</instant>
        </period>
    </context>
    <context id="idd85aaaa25cc479b99bd4e886b1c3240_I20201203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes550DueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-03</instant>
        </period>
    </context>
    <context id="i356651edb41c4b0a8e39c4bd624b498e_D20201203-20201203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes550DueMarch2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-03</startDate>
            <endDate>2020-12-03</endDate>
        </period>
    </context>
    <context id="id78465b77ff94c179049b8f8da315bc7_D20201203-20201203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes500DueFebruary2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-03</startDate>
            <endDate>2020-12-03</endDate>
        </period>
    </context>
    <context id="i4f524b83d2a14769b88a62af6ce78e47_D20201203-20201203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorNotes525DueFebruary2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-03</startDate>
            <endDate>2020-12-03</endDate>
        </period>
    </context>
    <context id="i85ca12bc72e84e42b58ea2d217fa1aaa_D20220211-20220211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityDueJune2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-11</startDate>
            <endDate>2022-02-11</endDate>
        </period>
    </context>
    <context id="i4e619b455ff146759a2117b1f93fefb2_I20220118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:A9.00SeniorNotesdueDecember2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-18</instant>
        </period>
    </context>
    <context id="ib440abcc71694fa09f8e1ad1955b47b3_I20220210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-10</instant>
        </period>
    </context>
    <context id="i85cf29296fb442daae3551dbbb86810d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecuredTermCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2f9960dff77240d28dd966ea114e1dc3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i09794c3bfd084a82b2a8672bfec8f4ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:IE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0da6a354b78d46da85ab05e0768ba4cf_D20141201-20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:IE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-12-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7fe9a8f118334aab8ff6bd90e126b597_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i14b494ef22db47cbaaccc4668e7c1b84_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icac9bfd5e8d54c0689a02e2e251a39cd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic8813f768a6d40a090aaffec2d906007_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if38262082aca4b1ca51d9de262b48c77_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if6a73441ba534c4aac153b012771c389_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie5d47857632948b3953696f970672168_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9b7fae28641143098c895dc923ecf268_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i60dd7747d8e84735ad54cdac6b306397_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i75033e6771e2462a948d8f02b08289cd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i463e7100cf0447ed909a1b0e9a750265_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i77e60ffa0a7048b3bc6ab71dd3ff10d2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idea50cd734984c47856762240b1f1a02_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9d64985a4d524a32b742dc7857f893e4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a24ca36ef784ec8aca560e12794804b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i56ca37936bae4988b7fe9d7260b0cb9e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i72013f8a77a84d8ab1b6625f3d57d1a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i180a6063ed294b858f6f1b7f8889f355_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:IE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if9fef24732ce40f1b0ecd84c613bcf34_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9ed8db4899e1486f9838d297668a6b15_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:IE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i75d6d22fe7ca49c89901fff21f7ad775_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i69b3efe62ce6415a85977af860ad298b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8c0ee6030b5c47b0a466a9c0070795c1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id92890a272ad4d899e7c6ca96512a97e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i149842c6f40f4c6b98cbccfc257a922e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i564973e386674c78ba408d13105b6bb9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia227b3e9ab7d47569890495351afa79e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iba0dcccaa1ae4b01bba40ab426ba276d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1fd2da8ac3ce4d44bbccc6dac3b7d322_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib00d5eeb7e7c4827bda09db46a2b4b1d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i36fefdbf2cff4913b1f038b13bc2cb55_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id521934ae5cd453d9101134d84a1626d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie612fd61a6d44af9a15649aaa2d9324a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8bc3ec72daa042338987d5ace9cc9c8d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i508b730bcd0045f397f719f04005991d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6e4425ac2c7e4b668baf3cbbb7ae8f68_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i89055898a93c470ba50888d0e49f6b0d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id8ab04904aed47918dfa94bfb170c6d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia2650274c9924895bc8990f8ebdac630_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i06afb70ae6a84cb4ba00bb19a81c46b5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i719bfb4f085d4c0687d6a46f624c525d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i66914e16e0af429cbb73c75ef6994478_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i37752c8772ad4c29a5c583152fb1b1b2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6c903c7579724e20ba48c46c10b81489_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i89938cca48aa4028b0c54c7484178623_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i93955a18cd3641cdb2827cd853fc1b10_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa2bba98ed41466c8eba7b037cea18ab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2a9940f2b3284c0aa162120bf8b40dfe_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5229d9d0142d45cdb60d7849d3a88d6e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia3c37ec3412c46a4893efcd62fe0f8fb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:U.S.BroadMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2c6eb4a0a10d45f7a7eac6ac330e192a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5ada422ea708495daf471908c27e5f60_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9ea389b2765d4a4fafbd53999a35bb35_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i74064a651ca64c52b9baa2296bd46b02_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieac386533ed94ed9a1fef188636cdbb6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1ea8ab4572664d2591c8cb715411dd99_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9bdce432423c43a8a10a88bf483dc5c8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4956f9b1dfe045249f6c89ed5e3c029e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iab7cb7f147434baa9c2c29c45db60a33_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i924b51a174a64385823aa357a0e7d2d6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i86b804a160e24122a58d7bdb3e3fbf73_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife79e98052444bd79079d82129a7420a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4826dfe3433b4c8db9be32ccbebd4288_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i32bbe248bdd14f98b8a37a069861c416_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ica87f2077d3b4d10a04094762892a8b9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ica23a5188b6f4261abc044904c51cb8b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1a607fbcafdf4f8f9686e30cf1341551_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i485c30c6aa2a43eab8ca4aca9b70a7d6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie2fe2902fe4c41e5a9916ee6a7bd0a90_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9547b54812bf44caaa56e89c1c450612_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i23a29524779046dbb6c442615652d8ec_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i734a347aebdf40829771a9719601c1a2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7b1173f2365141c1815363160c16b76b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i26f1f9b48f334ed1a02e13e365598828_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifae30c4aff3d4a04be56aae506f89f0f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idbf7a924becb4619aca1895ebcae9add_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib1912d789a0c46d991c0a3481ca5f6a1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i52de4cf8c1b0450fad0734be23582658_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i573fd8e898604de1858ab39ea3a2f4dd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iac7f5ab099cd40b592114ecfb3acc77b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iac4d46a037ab47089459af1054a64149_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i26d6737e6a7a4e638bdb45c231ed9fd5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i41d69b7357c9455081525dab7d356749_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i64de5046767046de88a2974a3167af0f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iee2f17c2a4204c139a5cb4c3ea8be354_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idd8d218140314ef584532f8f6d286341_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i235dff73cd944ced95f474c54f791c38_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1613dfe248574162a0b44c0c9a6b5c54_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9b79635c2ffe49ca916192dec4f287c6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib51448370c174e5ca94ba98d05fc89d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iac7d05a36d0e406b93de498c08fff242_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5829e60e9724608908829f25ab1d7d2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d0c98de7cf64efd96dfbe09aeb5ee81_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i32e3ecbd002a4e80a35abbbbdc4463e7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i90565c4f71694e28b3ea6de13e2a5891_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie31761652b084de784cd258f75f2ab5c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie5dbb70148a946ea9172055a4c675214_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id2b24c259bf14e85a565ed910de3fe12_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i848b70ed1bbc4567bfd96cad2f56686b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i80d8aa205290445f8909c5d756177c51_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia47563e74c594e7b94af08bf1c408bfa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifd5049ff38de4a8c965af08e2994ca04_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifd8ab02c4da8460891761a7202ea7fbb_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iccd41ef2d6e64a15b9d909ae1d8e22fd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i96121b9d867041058111f2cfd46930a1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1798ff527d09475a9e91083ed73cef87_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:EmergingMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iac0b4c1d18854f90b18c3b8d1b65c5d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i341cd2bb05814777ac5eb1149ac11deb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a3d63af67894f27abf02eb5401cbe40_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id1498ce58934451fa75a98f7dcbb17dd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6a556e59b8bd4005a138e1541662bb46_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iebfe537a4e7b4899829b3ce5a6812386_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i122fb437432445bb8b94f66c1352498c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6d8ae058e10b42b19b2b7a51fe102286_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:NonU.S.DevelopedMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9920661ad081431584fffee6621bedd1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia0debe97407a4a29ac76598d242abe70_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie3f9511b3ce84767b0cd5dda4878a1d8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib0d196db8de044f7b096a26f568bcc2e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie7166c1867db42a59946692d872ca487_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i77e48c2c77094705a53af852b1a9d72f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifef414e1cacc4427af5c130c1dfb7069_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i562a1c1d813143b387a1386991ee371c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:InvestmentGradeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9dd6ff8969cd46219034eaa9f922cc63_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i67a8b38165f445a29651dd0163d7b97e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3fc0e0e6cfd34b848a4329f6b2d4eef1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i85a230e5f81a48c78ac96f0556ba1bcd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i55a8a69189ab41e4a27cb0653b591709_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i01a935b5313744c69b2134f0706843b3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia283fca771744c269e37b513966bcfca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib78c157abc13457fb3c2ffeeabc6887c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:GlobalHighYieldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib31507c35e284e299c5a447d87eb3bad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ief04c0c77f754c4e8773310d3f3f995d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4abe5fa288434acba436f3607616486a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1a1c231876b24515b9cf5290b20d8497_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4091e0935746423e802930a0a249f3ab_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icced8c77467a439ab94442205659b698_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie78131bdf4944cb4b7835bfd51e69c57_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8d6663b8d3354af0836780f9a3ccb7d8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i819974f0d173482a87f6215140f5cd12_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a4ba4ae2f084135b4c3396a39a9e4d5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8a1a9199b6b3495db74904db30ace49f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i90b3621ef3a04a7e80b74c2ea9544924_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic9b498085ab54167830633419e66f3ce_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if783dd84203d4097828a5dfcf36b9360_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3617a1ce43f34e31b97e8612dceb1bc9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1fdf60201168414184b8e02445c9a52f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">bhc:OtherAssetsFixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i38f0c1c6c791466996e0e14977fb3043_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i27c4a253513c4ac885cb55c4a07909d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieabf485ffa9b4b01ac91c9afed822bd0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i991e579e87be40ff91924707db6a6553_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0e76b4972fd740e69b695e357d4e25c2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if13b91c47c564e65a71a7033d532765d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2043342d86cd4a6280d52ee1ce7e996a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic9788e7d7947465a8b5827eb980e4f3c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6361735a69df45b5bec1a681fbc6e116_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:IE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id943b700697244c1a9af35217a5014fc_I20140531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-05-31</instant>
        </period>
    </context>
    <context id="i6006b5cfb8f34c728d0575646bfaa31c_D20180430-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-30</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="ia9c449e903f04beb9f713f2df4efd6ca_D20180430-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bhc:NonemployeeDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-30</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i0d0c600ff58f4f0da9f1d4e553efd25b_D20200428-20200428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-28</startDate>
            <endDate>2020-04-28</endDate>
        </period>
    </context>
    <context id="i5e2ddff148e045819b4c2a2baecf7de3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bhc:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2f3083202c7e4f36ada3cfe487b44863_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i69f7d41ce4b642209bb25ea9c478625f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i00aeb13ceebf48e891b516a2d0c221d3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2c0144ad2365471881ed18f7ced989f8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3dcf40ad82c34f11ac4a925dd47873ab_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4b764cf71454461b9ae558f095cef352_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i169ce44b8b6147b5af92c163ff58f3e3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i25d8a1ce6eb4407f92324a3e68f2013f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifbd1e5635e5040f3a9121f39e9238a50_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bhc:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib100363bb61344be9b5ce0d1f32e9248_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bhc:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ieb7848e770bf4984a2093c22786e7db8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bhc:SellingGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id87fa13c036e497faecb209787ce467e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iecd38b28e9a84d1880313b43be4e32a2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7384f8f25998459682939a04e6a9c33f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if57561008d804ce4b03b997a95d4d41e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9d3ab00f203a4abdb121762625a88c8a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i01666d0d4a034ebbb396a9f3c3378737_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if15c6a218d7d43c38c67bf323a224454_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i45c56aa08db349ad9a3b4168267b7511_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5cd01c5e13964b01922532131f0e6d49_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i89368b0fb9454b688b6e6dde554c44e1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i29af68bd8dac4b57b173b5f3c801e3b7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TimeBasedRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i42196f5311924fb28aae7927e03f4954_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i071c8dec838c4bb88915169735766953_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if5e547542b4b4e4db07d76b12dbfa958_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i403b5b7721914e66b5361779547ecaef_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i54c4a51199e24aa0a3d6a1ec87ede263_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if92bc6c46d244c3788aeab448cab0a64_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:TSRPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4b9e26fe691746ed9f535f3800019b25_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:ROTCPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibf752be0eda64aa790f9f6d3442bf3f5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bhc:OtherPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie3c11e633ca64c359eb1f4e64ed9945e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i76387c207f8f42439a9c69184bef25d1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i66760525c1824001967bb86d988a25bf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8ddbf83e6ad54de686a53b50675cf560_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5cdfe5b964b94b969e2829780c73f7e9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bhc:MilestonePaymentRelatedToCertainProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibffc30cecb9c4ef0b327417dbb601c42_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4f6b4de2972a45b48db5cc52d91b1a88_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if84d1523bc1740e9b7b6df3d57e513ef_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i915068d30e9c465eb1028aff329712ac_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic055386399994346ad881ca91aeba458_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i67ba81224f654cb2b0f2010018455b61_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id379e27a083f4bb1879222afc10f82f9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i187c9f9f5937400ba090ce33c5c46259_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie80a8d41d8154b9fa08ad7c9d7849024_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i27ecb8e5fdeb4e02bde51b102f8143fc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib41b4897f8fc4d62a5af15ed7e0950d0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia1d46f5c753c4613a41c0b24b7215d74_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">bhc:PooledScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i64fcc3a1ff2b47af8fa496e471287739_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">bhc:ForeignCountryStateAndLocalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowanceByDeferredTaxAssetAxis">bhc:PooledScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3a91733048244e1caf9bc10fed86c62d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie95a42cdf2a44bae88536d5e9143a530_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id6d550dbbfda46bf82a16f8ce10ebe0b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:RevenueCommissionersIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i541042590f234b388cebba5a8ab708be_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:RevenueCommissionersIrelandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3981d7a177af492eb4fbd78ea657ad8f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0a701334d8d94a828739c539bfb11dbf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic261bd3e9bfd4d98ae7b58e6abadcb92_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3c2e628003764836a5a04489d83647f6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i90867327964d4767846d8c36adbc2e43_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if4e269c5fff94bdba040ffb57118494d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i65523828a01044e59ade22a5ccb853d2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5c327fe5449c48c48e8d5f0372ae6137_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib902cbf8a7fe4328a5114bf1cab23702_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1c126541a8a74e41a63df4a34dfd968a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i96392c49eef14e5988d30ce53b0250b0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i031396881a4b4914914165e52a669249_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie5eb8fe6d6da478c96fbec9cb03cc330_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie47ed3dfd2114787b382d6779d753245_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">country:NL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i966ab6abce524555a38770e32731ec1b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id73c90871edb496a8acded32a4868495_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5656a30a453e4f61bee5ce805d141aa0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:LuxembourgInlandRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaf6683fc8f2a4c7681664da8552f7c19_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:LuxembourgInlandRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6ad0eba196ab4a07a56009d4610284f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">bhc:TaxYear2005ThroughTaxYear2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3a2b5c5adebc4e62b7d64a5d6bcca25d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5a6621a8c1674dbc9a844087860a0e82_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0bb9780df86a4065b01b2469abd59faf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CanadaRevenueAgencyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">bhc:TaxYear2015AndTaxYear2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if92917964a2f48fc8d583659d90471f8_D20170808-20170808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-08</startDate>
            <endDate>2017-08-08</endDate>
        </period>
    </context>
    <context id="i794db5d83c3641aa853ac4acaa8182e9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i426b648515c34755bb623ee81a4f1ae9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0aaea235b331445aa69d79ccdb7823d4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifd3e00426ff44f65af5c22541ee8cb9a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i84aa0d0a4fea4c29a4fea75d90ed7794_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5998f35e4ed44ab4a12b43f529e4ee2e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i647e97c259b643fcb29ab0bf3ac45e1a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bhc:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i574ece8cc22045c08b39e4da379ec989_D20151001-20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="i546776d7d59544bda0c885c5725afaef_D20211231-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bhc:RestrictedCashAndOtherSettlementDepositsCurrentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0a8688d163da4bddb3dfdc9ef920e0fb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ValeantUSSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i721131c964b147fab4e1a6b8f95b4460_D20150101-20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="i522c83d185a3433eb7ebdb03a1574f39_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3d14d3034bc54cf58ac8ef0977e6b643_D20200804-20200804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-04</startDate>
            <endDate>2020-08-04</endDate>
        </period>
    </context>
    <context id="i0288b667636240ca9edb0931e9570cbf_I20190215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-15</instant>
        </period>
    </context>
    <context id="i7a3cc564cfa54644914c3dd2984b2e99_I20210317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:CanadianSecuritiesLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">bhc:ViolationofCanadianProvincialSecuritiesLegislationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-17</instant>
        </period>
    </context>
    <context id="ic99388c5fb8449b4b2899f64833edd24_D20160527-20160916">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:RICOClassActionsLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:UnfavorableRegulatoryActionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-05-27</startDate>
            <endDate>2016-09-16</endDate>
        </period>
    </context>
    <context id="ib788085ae68b43f5be26854e2e649395_D20171207-20171207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-07</startDate>
            <endDate>2017-12-07</endDate>
        </period>
    </context>
    <context id="ia2292d9d54a74b14a40833c7ee03e2c0_I20210720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-20</instant>
        </period>
    </context>
    <context id="i10b5c7db69ef4006bcb53437d3aa06b8_D20210720-20210720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:InsuranceCoverageLawsuitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-20</startDate>
            <endDate>2021-07-20</endDate>
        </period>
    </context>
    <context id="i8d3399dca8844555b1a0224ee52572bb_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:SandozLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i416608f63c8f48baa9c46a05acc57dba_D20200828-20200828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PerrigoIsraelPharmaceuticalsLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-28</startDate>
            <endDate>2020-08-28</endDate>
        </period>
    </context>
    <context id="i20d7a644460c4ab7b2d3fc7e95d5d3c7_D20200501-20200501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:PadagisLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-01</endDate>
        </period>
    </context>
    <context id="iad566679ccb740d78397815ac12d9b44_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:MSNLaboratoriesPrivateLtdLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="id9d5c1c1399a4c59b08e7d331695b3a6_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie5f2cff0c15c4497abb7c0bb38853653_D20220202-20220202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LupinPharmaceuticalsIncLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-02</startDate>
            <endDate>2022-02-02</endDate>
        </period>
    </context>
    <context id="i1bdbb266b2064e05970e5019800e2253_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ApotexIncLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8167d807dd934310925525373a61a11f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowertoShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9b8fdb21d7d648d59dfb6f5b8647cf38_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7ca0340304c47edaa88616e036f7daf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowertoShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib2a61b2c466048d7a44cf2f37e6f9067_D20211216-20211216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowertoShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-BC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-16</startDate>
            <endDate>2021-12-16</endDate>
        </period>
    </context>
    <context id="i4161ab534a444089a14221908e89ca6b_I20211215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowertoShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-BC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-15</instant>
        </period>
    </context>
    <context id="ic25fde520f434990aec8bc4ef672935d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:ShowertoShowerProductLiabilityLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA-QC</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8cee0c4f1d894fc3aa19e2148d91bb12_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:DoctorsAllergyFormulaLLCLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i2fa7f1086a9a45249ac683ef177587c9_D20190128-20190128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:LitigationwithFormerSalixCEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-28</startDate>
            <endDate>2019-01-28</endDate>
        </period>
    </context>
    <context id="i5c84bf2f503a48bcbda0eee28745f465_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="ic39bb939c10e450dbd36a0e824f2720b_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i7cb1b7f540294b49ad9ef73316d882e6_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i2e52d3146d5a487e9ca0aeaadf2b0915_D20190801-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:PlaintiffsDirectPurchasersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationNonClassComplaintsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i35ef7917c4e846cdb1959043a03d5bca_D20210726-20210726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:GlumetzaAntitrustLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-26</startDate>
            <endDate>2021-07-26</endDate>
        </period>
    </context>
    <context id="iff2a848fa15e484ba0fd1a37bd47732e_I20190910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:DerivativeLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-10</instant>
        </period>
    </context>
    <context id="i6efe4500a1e94445a37235d0071dbc71_I20190913">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bhc:DerivativeLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-13</instant>
        </period>
    </context>
    <context id="i45d0ac640df44b65a4bc4c22c9500429_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5496c79fe37f42a9a6ed6ceefc84608e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:MitsubishiTanabePharmaCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i76cbbad47b514c08a436d4d6576f412a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:NovaliqGmbHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5bdf942d40b54fefaef817509211ad3e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:CedarsSinaiMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if4268c1a55cd4a2e89570ee83827d90d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bhc:EyenoviaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff7c3f276277409b964a030bb9ddf9bc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i899638122b1443aea3cf842ccf65501f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4cd37c585bfd45c29417f050b1fb96e7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9b94206c32884a8fa83f6929a2cb28d7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic6899a304edb44929422d6afaf6cef0a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icda72308df944034b125cc6838172395_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8df850998cb6487c8f0b80f71254800b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i98f0b0d400a84364ac143e0c73a45029_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i42a14ea9b3e84273aeea86db5027a7ef_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iff3b9d2f71d648e191dab78cdfc14a22_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0bcc7f02716c496789da6644b328c014_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i59a5f333092b47d6b10bcf6f866713da_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iabb641d02a434242909814412771e876_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if09045f9cc464856be5eee85d720e168_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if27684da78ec405a8823766a077e4e59_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie8c2fffa98a84f4785e561d53fa2ad78_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i20c9332693f549f3a5029b30f65e69d5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0629a7489a0e43599cf635c5af5d5370_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9327c2fc153040b99cb89cd74f8b0c52_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ied28eb131a9d4f14930f4e4a0f0d7abd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia29f4c57d8b542cbafe1450ba688c6b5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icc8c408b488a4ea2a66ad4c5e2951610_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i72654cd7063243f1a8df8bc3a4f0195d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i85db686e88084b1daeb7d9f72f4f05ad_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CustomerTopTenProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i418a04d4e056401399ccd4b61b80c49e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i208a6bf939c242978d7d9ccc2fc10274_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i183660041cad45ea8dd6de8f87fb3352_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2e9b099c602241aea11206441f010b8a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i85426466f4c3491594754c3f8fc926ab_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ica7446f3b2c9467380385861ab7f846c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i97a39f300bde49ca9fc43dfa11399cca_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if6cb2a068a1c48d2ace685a569e695c1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6dfbabd3f8ad4b34a103357fe12fcfcd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5fb12fface6c4c7e82b18336a7a67376_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iada6d354701043aa8ed66ad26387df2c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iefe6d8b686a343d78914861cca583670_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie68fa27569a84628a38c78ec3c373351_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaee7f42c5a6e468eb8cc29e3ccdff123_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibd994066bcd8437a9238a565a38135fd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9083205e195d456097ba2cf0d7d660c7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7a89853896aa43c787ccc01b19d26a52_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibdef7aa1a0f744b2a4b78007975133bd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9dbb383514c346138c6f03e2442cf299_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9cfbdc3f3475470493bc0b06e113623c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie646b8a4d77c437591b1f253ad1ce98c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2b09688e27584c5c8598014546598fc6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i93bb05eba3ba4b89973b0e8adec86826_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5cd4d9c52b49420b9fd755ecae1f6e34_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i449241e47dc94783a4ce61ebe70a084c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i945b3a4ecfe946f49fd0768311efb98e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1c41e1b8ff6243bea499531336ad49f3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9565df56092f4004881389c04df25c93_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie8a16169eb2d4f67b89fdacefbd0662d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6a0ba16f9629426fbbc2da84a05d2fd5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if72021acf180458a8e22ca22a9fa4b7c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i10c6872a04d24bdd87a47a8fcff435f5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i01141cbdbc294de9a69e8742d0ac0103_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4a2b29c602cd4b958959f3a523a03952_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i30e3835f2cc243289f8661e3a751167e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1fa10e66f5ca4afbb367c4f716dbdb6f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i035f8ab24ddb4f03a63105201f52a080_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8f1a89016aaa44f1b9b7cbf14bcc530f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i07e9e47444534ef380cd91916978cc8e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7ea3465f6a0045f59c3e4d358fade4ea_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic174d4e74321475a84d00d558435391e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7f3a113a586047de86a5ff20c4cad591_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5d52437e494a45f5b5d81fd921f506ea_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iba2bfdb91306432787e6d119f24c9aa6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iccf8163c97e441b695eed7ad4118029e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id931ecb1d5924adc9990fe3880f43991_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2b3b9253b89e4ba5af70da5f568580ee_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0ce0e8c5792746c4898df7b4b795738b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia6b7d530488142ca89ab8ee239e906ac_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i87499fcd581e451e8b4380c27a63aa69_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i090b17bc8edc432898c155379a09ffbc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i675b1f36cfd84e78bd9e49edeea02d3d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i79f443d6034b41279b6e32600dfad1dc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i99f4c2a755d74f6782eeac0e0d29ccd5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7e35c309da054713ba96e1155984e51e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2daf7c9c3709441a96dee7e2be490687_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i827e4d3a675249bd9a863b2b7df083b6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8c401d26917e40768b5d281285429ae5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibe1dab615a544098b3eb8dab58113a92_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icd1357104df74efbb0da5b76bc89c115_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib6331eae27614b90855cfb5b25b9acd0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i92793a91c9c747858dd71f6a9a0a9d23_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ida777483b4584d87a6cf2850e419fdd4_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie7999bb21b9045d28a73afe96f2eb35b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i672bff69a6fc4ef3aebe3725cc29e40e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i626b9ba57ccd4f46b64c17f382055091_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i936342f03a8e4fa2b1e39321ca993106_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i24cd510cf43d4f998e635afc20c956b2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i55bf18e767ee4fbd8771bf6350d26aff_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i00e2f75f8e8a4e30a276c3033c8f9971_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i087b26d2da5842a783ce0a89063cf3f2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7af7813bfb2b41168f468df55e46c835_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic113e26dc8a943e3bcb1595fc30166d4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:PharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia0ca740d21c34ec1a4f67ff1a0624db4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie9186a43c41842cca559fad18f9be2a6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icc4e1ec44690405aa82469ba14ebe09c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i25dddfae7e964bdfac0c22c5bd9b8197_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5f5298b1c6b04825936c29a9867976f9_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if179cdcb08a0401481a1219768254267_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:DeviceProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="if8664af0b79840da9709c1622bb9ddf2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie3e3f60c68704a709d886a22a7a0625c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ieecb00ddf1e346c497a7a3939fd11cb7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i546306a3ad4f430786457eae18ef4185_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0b77d4f86e5b4d38a20c7bda0feef351_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8a4ec44e96e44217afae2275f04e02cb_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OvertheCounterProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i02ace42c02c2429cb5f9a01e0cdfb82c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia05135846e24408ea51ac1a000116fc6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i654644a806dc4e4c810f174fd6c3d5d7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i14f7e763fe5647bc92cbfc644aadf9e5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icdd6fed0918446febaeb315df0545125_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i80e98cb6ebeb4ac595398dcd45214e1a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:BrandedandOtherGenericProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id42bd5ff7402461eae15a600bbe77743_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0c6ab8b8553d4be6bb88ba2a97705892_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SalixSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibd261e8b9f2d458587ab145f0b01027b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i835dafddf9254e80881be0cd65ee190b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i58a96cd4d49841fba044c42410080076_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i16d6de8cde05443f89914d40cf8374a2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bhc:OtherRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0536a549f4e94235a4c555bc2d5aa85d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:BauschLombMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i551031e418e04e92a28afd201e2a7815_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:InternationalRxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0e0b639594e4483fa2e3d9eaa57f0c52_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:SoltaMedicalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia6a213bd75514daebf43eb6d93a109f3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">bhc:DiversifiedProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5464eb24d31a4be0beb852ba387bade8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7ba444e2ab994ca1a3c530ace04d6dc6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibe8e8f4ff47f48599e5fcab4fe291d47_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id15ad738c4a24f2db24b34a5a0710ae4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1c2d9ba589c34635af841f55fabca3a3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id9cd10e388d948f69faaa2a13ee4e9a3_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9548d7cc49134168aac65b53c630d341_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i08b753376f4946ee869fca342eb74772_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibad2ef89232a4629aad3bf5d2c272019_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i21a132fe24e747f0a5b421bc7f0ac7e7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i920bf658665d471ba624c241f037cab0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibbd946703e614d71b6d50b2f7ef7c141_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id50f4cab02f148edb0f275c887c08c1a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2af93ee9adb74fed8865c912c5df1f30_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i54515e5b9a1540f28363106924361f49_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5566c138571140a6b83afaef74940706_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id01f277d70d744e19dc9ac68d075ef8e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia51b7a120b6d4bfaaac2e2f5d62cd956_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i67e2a75f81a2442e98999a9c1a2cd7a8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifb566fc6694e418b911114af24372afe_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6c64023910d940d280c4372028887834_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0cffeeeada484c5982be5b0d0fba6d27_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i36510dcee9304e688d7fe55e6e0cdada_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7458902eaa074c759452bcd57083fefa_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2524acb5669c4f46b137c163c7500bb8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:EG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iea6f1abfde62479a85a276b00644bbda_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:EG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7d19db7ffad34988952acdbe5de7846c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:EG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0667b68241574742a0864172124b2604_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i26ae9e62be7441c196757ba308583044_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i516a86604ef14c82b80390e67af470ba_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4339bb0ca24249ba8ca9d3aacc1e7a0a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8e8cb0908b5141feae7cceed8fb1fbf6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icfa55d1cb36c454c8ec5fda74ab99db4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i47f75495e622462aaff82bf298f1f418_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if8280a4a6ac8459590c2dcaa41f23220_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i530e4f0186a947ecbd4d27d49cb0e1dd_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:ES</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic43dc8234c6a4dceabd306a0a1c1fe32_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i16c4e15aae264f818da6ace454e9fbec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7a5eeb906ad94c799a42264f6d5855ed_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i1fffa5927ecf4eb5b8a70faa07450b99_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib537ff890e5e4cec8f7b9df78020e5c0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9fc8256f50d840ac85eb640d6f16ba43_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8965029593294a24adc5e0c5daccbfbd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1c135788a091404aa9a7b000b712ebb3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:UnitedStatesandPuertoRicoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifc3f5d1fae4241ef94326581b829bff7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idc53a771e452444ea4bc5759cdd083db_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibe7ac3c028a54540be9b808a17416a89_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4ab3fadee1424d2b9a667a9b07eac40a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i34d52e2c9af34f2eba8ae6242e32285b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie7fa6fc30bf5449caf063162224cd090_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if3f2d957c7234a77b712ff75e65b792e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie327497372b349d3a51955d6959df2f5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i69ea4eb4471f4aae9d2a35f42e82ace9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2c536f8e7b6c4bdc94cd38d6eef8e2e3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i872f81fbc9ba4c60a97667b7432c52c3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if846fad239254513bf3cca0ba1935da3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie66e6133905345078ee7cb9899b48d33_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6d19b0b4d54a4b8cad166f0ef7a625c7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icbf66cd972eb4b26b35c2652ab001028_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic83a5702808c4b7889dca0da3411ecf7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:RS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1597a3574967438391767431a634b19a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idde75edf275b41fb8ca106bbac1cc51f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IT</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icb3cfed9c9f746829c13cb94a536f2e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2183ac8cb0c24b26a214e41ab91d3425_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bhc:OtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3630993f4ba446f9a740bd6e81c5a6ad_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i18e3409174504c54b7800e5ee44a1e49_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i18eef1a898514fe0a4faf29152835a3a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:AmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i36636d2e771b4f25a4bb954e3f474155_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i35cef2f6062b462484e17c3d2b33a715_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idad1bbd9ef07469495ba41c98fade794_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaff05b11cfdd4a25ba35f7b6f554d5c4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i23b4bebac662486b914059dbbda7d89e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie831ea955b1b4600b7818bcbb63030ae_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bhc:CardinalHealthIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bhc:RevenuesNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i74d4a550bdbc4a13ac94ac84a9361ccb_I20220118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:TermLoanBFacilityNewRestatedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-18</instant>
        </period>
    </context>
    <context id="i2c8a1f0a665d43229d899da271c970a6_I20220118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:RevolvingCreditFacilityNewRestatedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-18</instant>
        </period>
    </context>
    <context id="if17269c4e45643c89336bb79651ea5eb_D20220118-20220118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:NewRestatedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-18</startDate>
            <endDate>2022-01-18</endDate>
        </period>
    </context>
    <context id="i4d0ad67661d948d99c4ae13e0a3670a2_D20220210-20220210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-10</startDate>
            <endDate>2022-02-10</endDate>
        </period>
    </context>
    <context id="i6c6a7f652a6543c78115ce45b38d0293_D20220210-20220210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000885590</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bhc:SeniorSecured6125NotesDueFebruary2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-10</startDate>
            <endDate>2022-02-10</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="country">
        <measure>bhc:country</measure>
    </unit>
    <unit id="company">
        <measure>bhc:company</measure>
    </unit>
    <unit id="wholesaler">
        <measure>bhc:wholesaler</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="businesscombination">
        <measure>bhc:businessCombination</measure>
    </unit>
    <unit id="rate">
        <measure>bhc:rate</measure>
    </unit>
    <unit id="segment">
        <measure>bhc:segment</measure>
    </unit>
    <unit id="reporting_unit">
        <measure>bhc:reporting_unit</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="defined_benefit_plan">
        <measure>bhc:defined_benefit_plan</measure>
    </unit>
    <unit id="subsidiary">
        <measure>bhc:subsidiary</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="case">
        <measure>bhc:case</measure>
    </unit>
    <unit id="group">
        <measure>bhc:group</measure>
    </unit>
    <unit id="action">
        <measure>bhc:action</measure>
    </unit>
    <unit id="entity">
        <measure>bhc:entity</measure>
    </unit>
    <unit id="numberofbusiness">
        <measure>bhc:numberOfBusiness</measure>
    </unit>
    <unit id="insurance_policy_period">
        <measure>bhc:insurance_policy_period</measure>
    </unit>
    <unit id="insured">
        <measure>bhc:insured</measure>
    </unit>
    <unit id="shareholder">
        <measure>bhc:shareholder</measure>
    </unit>
    <unit id="product">
        <measure>bhc:product</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl80L2ZyYWc6MWUxMTM3MGUzZDY3NDg2ZTllZmVjNjQzZDg5MGJiNjMvdGFibGU6Yjc0OGRhZGFhYmI4NDI0Y2ExYjM5ZTliMjY3Zjc2YzAvdGFibGVyYW5nZTpiNzQ4ZGFkYWFiYjg0MjRjYTFiMzllOWIyNjdmNzZjMF8yLTEtMS0xLTk5MDc5_9005b654-7bce-4584-981d-0c4323d8eedc">0000885590</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl80L2ZyYWc6MWUxMTM3MGUzZDY3NDg2ZTllZmVjNjQzZDg5MGJiNjMvdGFibGU6Yjc0OGRhZGFhYmI4NDI0Y2ExYjM5ZTliMjY3Zjc2YzAvdGFibGVyYW5nZTpiNzQ4ZGFkYWFiYjg0MjRjYTFiMzllOWIyNjdmNzZjMF81LTEtMS0xLTk5MDc5_3af1d405-1deb-4520-b841-edee6ec198fe">false</dei:AmendmentFlag>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzExLTAtMS0xLTk0ODMx_04eaaa0c-20bb-457c-924e-608518b46f23">http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201613Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <bhc:RevenuePerformanceObligationPaymentTerms
      contextRef="if18ed4a9db4c4141bfff00c96c8d6997_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzM5OTI3_716494a0-facf-44b6-8b49-d8fd0a7992d6">P30D</bhc:RevenuePerformanceObligationPaymentTerms>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ie389482f874b41c39bfff2d72239425b_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzQwMDc5_7eac39f6-be77-4d3e-9e6c-f409097e05ab">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ie389482f874b41c39bfff2d72239425b_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzQwMTcz_d3eef5e1-5571-4a30-b1f7-7d9902542a6b">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i85cf29296fb442daae3551dbbb86810d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDMvZnJhZzo1NTQ1ODA5YmYyNzg0YjMwYTgwODYxYWVkZmNiZDIxNS90YWJsZTphMTlkNDc5MmViZmU0YmZiYWEwYzZkODAyN2RhN2I3YS90YWJsZXJhbmdlOmExOWQ0NzkyZWJmZTRiZmJhYTBjNmQ4MDI3ZGE3YjdhXzAtMS0xLTEtOTQ4MzE_80d37567-8b0c-4a46-9755-f1473d16ae0e"
      unitRef="number">0.005</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzItMC0xLTEtOTQ4MzE_4bf2464d-f080-463a-b82a-fe3327a6ffe8">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzItMC0xLTEtOTQ4MzE_ce76341b-5893-4112-b76b-f4aed3b43dcf">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzQtMC0xLTEtOTQ4MzE_4bf64393-afaa-455f-a448-662b6f9a6f45">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzQtMC0xLTEtOTQ4MzE_4de59f41-dcca-4036-87e1-e7e98c16d228">http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzUtMC0xLTEtOTQ4MzE_339c676d-41f8-49e5-86a9-b2e8149fc1fd">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzUtMC0xLTEtOTQ4MzE_c6eaab40-e3c8-4b6a-afe4-21b28ab4bf11">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGV4dHJlZ2lvbjo0NzljNDViN2I5M2E0N2NhYTI2ZmE0N2IyNDkxMzBmM18xNzY1_9c419fe8-5839-43c7-9fb8-fb8fa935e7be">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGV4dHJlZ2lvbjo0NzljNDViN2I5M2E0N2NhYTI2ZmE0N2IyNDkxMzBmM18xNzQ_ec51d375-713a-4a58-903e-f624ccb7f033">2022-05-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGV4dHJlZ2lvbjo0NzljNDViN2I5M2E0N2NhYTI2ZmE0N2IyNDkxMzBmM18xNzYx_9aa51e4c-9c63-47aa-a5b4-e04c004b0878">Bausch Health Companies Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGFibGU6ZDUyMDcxZGIyZjhhNGE5N2I2N2NjMWUxNTU5OWQ3M2MvdGFibGVyYW5nZTpkNTIwNzFkYjJmOGE0YTk3YjY3Y2MxZTE1NTk5ZDczY18wLTAtMS0xLTk5MDc5_6bcb3518-4d6b-422c-ac17-1b3e57220fde">A1</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressCountry
      contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGFibGU6ZDUyMDcxZGIyZjhhNGE5N2I2N2NjMWUxNTU5OWQ3M2MvdGFibGVyYW5nZTpkNTIwNzFkYjJmOGE0YTk3YjY3Y2MxZTE1NTk5ZDczY18wLTItMS0xLTk5MDc5_fc84b31a-36e5-49bd-8006-3fbeaf4f9a00">CA</dei:EntityAddressCountry>
    <dei:EntityFileNumber
      contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGFibGU6ZDUyMDcxZGIyZjhhNGE5N2I2N2NjMWUxNTU5OWQ3M2MvdGFibGVyYW5nZTpkNTIwNzFkYjJmOGE0YTk3YjY3Y2MxZTE1NTk5ZDczY18wLTMtMS0xLTk5MDc5_46ccb226-811f-4a93-a8f6-c7bf4cb8bb7e">001-14956</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGFibGU6ZDUyMDcxZGIyZjhhNGE5N2I2N2NjMWUxNTU5OWQ3M2MvdGFibGVyYW5nZTpkNTIwNzFkYjJmOGE0YTk3YjY3Y2MxZTE1NTk5ZDczY18wLTUtMS0xLTk5MDc5_c38af265-835e-4019-bdd6-b8e0b07a113a">98-0448205</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGV4dHJlZ2lvbjo0NzljNDViN2I5M2E0N2NhYTI2ZmE0N2IyNDkxMzBmM18xNzYy_61c00c47-114a-4889-ac9b-9242b2e683e7">2150 St. Elz&#xe9;ar Blvd. West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGV4dHJlZ2lvbjo0NzljNDViN2I5M2E0N2NhYTI2ZmE0N2IyNDkxMzBmM18xNzY2_848bc109-1b44-4c8e-b913-b95cbc01193a">Laval</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGV4dHJlZ2lvbjo0NzljNDViN2I5M2E0N2NhYTI2ZmE0N2IyNDkxMzBmM18xNzYz_8b5e855b-f39e-40a3-acab-7ba49794374d">QC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry
      contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGV4dHJlZ2lvbjo0NzljNDViN2I5M2E0N2NhYTI2ZmE0N2IyNDkxMzBmM18xNzU3_3e54cff7-909e-4fa9-b3b9-75085bcc597e">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGV4dHJlZ2lvbjo0NzljNDViN2I5M2E0N2NhYTI2ZmE0N2IyNDkxMzBmM18xNzU4_e9f9425f-b6d9-41ec-abbe-1d1576a4db5f">H7L 4A8</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGV4dHJlZ2lvbjo0NzljNDViN2I5M2E0N2NhYTI2ZmE0N2IyNDkxMzBmM18xNzU5_bd8d7e60-8d4e-4a61-be39-532f66b05245">514</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGV4dHJlZ2lvbjo0NzljNDViN2I5M2E0N2NhYTI2ZmE0N2IyNDkxMzBmM18xNzY3_d4375829-914c-4286-b960-165512641df3">744-6792</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGV4dHJlZ2lvbjo0NzljNDViN2I5M2E0N2NhYTI2ZmE0N2IyNDkxMzBmM18xNzY5_5d8a81d9-c962-408a-8407-5740494bf821">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGV4dHJlZ2lvbjo0NzljNDViN2I5M2E0N2NhYTI2ZmE0N2IyNDkxMzBmM18xNzcw_e1424fc0-4ab8-4bfa-bf1f-e240537488f8">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGV4dHJlZ2lvbjo0NzljNDViN2I5M2E0N2NhYTI2ZmE0N2IyNDkxMzBmM18xNzY4_8dc4780a-da17-4080-95b4-e276097f3ad8">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGV4dHJlZ2lvbjo0NzljNDViN2I5M2E0N2NhYTI2ZmE0N2IyNDkxMzBmM18xNzYw_670d22fb-f96b-4104-a295-660a28ea9da6">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGFibGU6ZThjODg2NjQ1YWQ5NGE1N2E2ZTU2MDlkMDIwY2UyN2EvdGFibGVyYW5nZTplOGM4ODY2NDVhZDk0YTU3YTZlNTYwOWQwMjBjZTI3YV8xLTAtMS0xLTk5MDc5_590c7893-1bd8-44cb-a174-e06d3f844e7b">Common Shares, No Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGFibGU6ZThjODg2NjQ1YWQ5NGE1N2E2ZTU2MDlkMDIwY2UyN2EvdGFibGVyYW5nZTplOGM4ODY2NDVhZDk0YTU3YTZlNTYwOWQwMjBjZTI3YV8xLTEtMS0xLTk5MDc5_4bd5dc01-e1d3-43b5-b963-9e3eaf84db9e">BHC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGFibGU6ZThjODg2NjQ1YWQ5NGE1N2E2ZTU2MDlkMDIwY2UyN2EvdGFibGVyYW5nZTplOGM4ODY2NDVhZDk0YTU3YTZlNTYwOWQwMjBjZTI3YV8xLTItMS0xLTk5MDc5_ca4baf7f-f5e8-4b54-8a57-d37ee6efc58e">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510"
      id="id3VybDovL2RvY3MudjEvZG9jOmZmMjhlMTViNTYwMzQyYWI4YTM4ZDFmZGY4ZmI2MjdmL3NlYzpmZjI4ZTE1YjU2MDM0MmFiOGEzOGQxZmRmOGZiNjI3Zl8xL2ZyYWc6NDc5YzQ1YjdiOTNhNDdjYWEyNmZhNDdiMjQ5MTMwZjMvdGV4dHJlZ2lvbjo0NzljNDViN2I5M2E0N2NhYTI2ZmE0N2IyNDkxMzBmM18xNzY0_7cbe8cec-d9aa-45ab-8d52-1e5e6db8b7af">false</dei:EntityEmergingGrowthCompany>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzQtMi0xLTEtOTQ4MzE_9794ada4-cb09-4a10-b6ce-0db69830db03"
      unitRef="usd">582000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzQtNC0xLTEtOTQ4MzE_1389602c-657a-4ba2-ac09-06651910dbfb"
      unitRef="usd">605000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <bhc:RestrictedCashAndOtherSettlementDepositsCurrent
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzUtMi0xLTEtOTQ4MzE_5d847b4f-9a3b-488b-9256-128176ddb57c"
      unitRef="usd">1537000000</bhc:RestrictedCashAndOtherSettlementDepositsCurrent>
    <bhc:RestrictedCashAndOtherSettlementDepositsCurrent
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzUtNC0xLTEtOTQ4MzE_279d634b-1530-4bdf-a60a-68a6997d4407"
      unitRef="usd">1211000000</bhc:RestrictedCashAndOtherSettlementDepositsCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzYtMi0xLTEtOTQ4MzE_686a45ac-366d-4d27-bb60-904c39a81dd3"
      unitRef="usd">1775000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzYtNC0xLTEtOTQ4MzE_24fcd4ac-e357-4e93-ac67-4d6acf4d80eb"
      unitRef="usd">1577000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzctMi0xLTEtOTQ4MzE_549f841a-6413-48db-bc81-5ac9d4514885"
      unitRef="usd">993000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzctNC0xLTEtOTQ4MzE_0163be90-217f-4d98-a4d7-eb908dc43681"
      unitRef="usd">1094000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzgtMi0xLTEtOTQ4MzE_c00ef405-6e32-41fb-b52d-b5c8479436de"
      unitRef="usd">720000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzgtNC0xLTEtOTQ4MzE_1bb23c15-396e-4416-885b-894f25d9bb25"
      unitRef="usd">855000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzktMi0xLTEtOTQ4MzE_5bbbfe07-3e40-41b6-8c57-65889496aaf6"
      unitRef="usd">5607000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzktNC0xLTEtOTQ4MzE_20dc0bbc-708d-40b2-87fa-d179b930766c"
      unitRef="usd">5342000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzEwLTItMS0xLTk0ODMx_c3788717-f3a5-4d5a-b3d8-12ee20e41dd4"
      unitRef="usd">1598000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzEwLTQtMS0xLTk0ODMx_10384676-da77-483f-b2ce-1e6d3332d799"
      unitRef="usd">1567000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzExLTItMS0xLTk0ODMx_999d5cec-4495-40b2-a649-2088b845505d"
      unitRef="usd">6948000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzExLTQtMS0xLTk0ODMx_2e87171d-5e2b-4850-b955-def9bddcd49d"
      unitRef="usd">8445000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzEyLTItMS0xLTk0ODMx_7a6494cd-cfc1-4e87-9ed9-a6e37ca90864"
      unitRef="usd">12457000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzEyLTQtMS0xLTk0ODMx_e985d5a4-1fba-476f-9396-516d8ecc2ed6"
      unitRef="usd">13044000000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzEzLTItMS0xLTk0ODMx_41633dcd-73e3-49b9-9dd0-0e57273b61b4"
      unitRef="usd">2252000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzEzLTQtMS0xLTk0ODMx_57049148-661e-4e03-86b1-420886d3a15a"
      unitRef="usd">2137000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzE0LTItMS0xLTk0ODMx_f7563753-c7bb-4d9a-80d6-3ca5838ec873"
      unitRef="usd">340000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzE0LTQtMS0xLTk0ODMx_15ec21bb-78cb-4b82-98d5-8eb700f0c19a"
      unitRef="usd">664000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzE1LTItMS0xLTk0ODMx_5428772b-3d6a-4578-bde3-c1686cbc23ba"
      unitRef="usd">29202000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzE1LTQtMS0xLTk0ODMx_c0c6028d-b31c-4557-a672-099090591702"
      unitRef="usd">31199000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzE4LTItMS0xLTk0ODMx_576dde1a-5662-4179-b126-0947e736e54c"
      unitRef="usd">407000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzE4LTQtMS0xLTk0ODMx_e4e6f33a-1a60-4c42-853f-07ae86324a1c"
      unitRef="usd">337000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzE5LTItMS0xLTk0ODMx_9e0888fb-cc0a-46b8-9499-a99b384b5cc8"
      unitRef="usd">4791000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzE5LTQtMS0xLTk0ODMx_8d3fdfee-e1aa-44d6-8015-f1c5c2511d9f"
      unitRef="usd">4576000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzIwLTItMS0xLTk0ODMx_1dde74bf-3637-4648-bad2-8b91d0a36602"
      unitRef="usd">5198000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzIwLTQtMS0xLTk0ODMx_6b5dad94-d7d9-4aba-9ad3-ee2623f49088"
      unitRef="usd">4913000000</us-gaap:LiabilitiesCurrent>
    <bhc:BusinessCombinationContingentConsiderationNoncurrentLiability
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzIxLTItMS0xLTk0ODMx_a4d7e1cb-5986-4e5d-8b62-f4cd3f0a4f79"
      unitRef="usd">202000000</bhc:BusinessCombinationContingentConsiderationNoncurrentLiability>
    <bhc:BusinessCombinationContingentConsiderationNoncurrentLiability
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzIxLTQtMS0xLTk0ODMx_4b43f868-fd07-4080-8e25-afa3e454c6ee"
      unitRef="usd">216000000</bhc:BusinessCombinationContingentConsiderationNoncurrentLiability>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzIyLTItMS0xLTk0ODMx_18db40f8-be0c-4ec1-b876-1471f7d4e70e"
      unitRef="usd">22654000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzIyLTQtMS0xLTk0ODMx_99681720-a322-4efb-ac2c-8806215d7d43"
      unitRef="usd">23925000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzIzLTItMS0xLTk0ODMx_1e609a24-c4e3-48bd-8e43-d3e8bc63233c"
      unitRef="usd">529000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzIzLTQtMS0xLTk0ODMx_22b8fcd9-60e5-4079-9aeb-ebbf50e695a3"
      unitRef="usd">528000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzI0LTItMS0xLTk0ODMx_efff87cf-dde6-4f04-9078-2046a5502508"
      unitRef="usd">653000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzI0LTQtMS0xLTk0ODMx_de4496a2-28c1-40e0-a797-b0df63923844"
      unitRef="usd">1012000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzI1LTItMS0xLTk0ODMx_3023989a-98ca-467e-8c1d-d8b7dfc7abc2"
      unitRef="usd">29236000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzI1LTQtMS0xLTk0ODMx_35754e54-ca43-47e7-860f-885b8e7e90a7"
      unitRef="usd">30594000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzI2LTItMS0xLTk0ODMx_9d6a9c1f-58f6-40a6-ac58-92d1714d61f3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzI2LTQtMS0xLTk0ODMx_5931381f-567e-4e22-a9c0-5a19c7745743"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzI4LTAtMS0xLTk0ODMxL3RleHRyZWdpb246ZTRmNDk1NzQ4MGYyNGMzYzllMjJlN2MwZjE5OTliY2JfNjI_12b8e4de-4313-4296-9aad-f6f54ab22add"
      unitRef="shares">359405748</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzI4LTAtMS0xLTk0ODMxL3RleHRyZWdpb246ZTRmNDk1NzQ4MGYyNGMzYzllMjJlN2MwZjE5OTliY2JfNjI_9bf430c4-7210-46d3-9d1f-151e6ca8b723"
      unitRef="shares">359405748</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzI4LTAtMS0xLTk0ODMxL3RleHRyZWdpb246ZTRmNDk1NzQ4MGYyNGMzYzllMjJlN2MwZjE5OTliY2JfNjk_3baac1f1-72cf-4463-bc60-a235eb7b4187"
      unitRef="shares">355422347</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzI4LTAtMS0xLTk0ODMxL3RleHRyZWdpb246ZTRmNDk1NzQ4MGYyNGMzYzllMjJlN2MwZjE5OTliY2JfNjk_4df45541-3b33-4f5e-a32c-a6ff463775ce"
      unitRef="shares">355422347</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzI4LTItMS0xLTk0ODMx_3be2c208-6352-479f-9733-ab0018231782"
      unitRef="usd">10317000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzI4LTQtMS0xLTk0ODMx_e257e637-eab1-42dc-b4b6-1017bbea0a4d"
      unitRef="usd">10227000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzI5LTItMS0xLTk0ODMx_8a3b98ce-3f96-46a6-aeb0-dad46dc16ae8"
      unitRef="usd">462000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzI5LTQtMS0xLTk0ODMx_9ec07e09-ad2c-465f-a45e-2d8ca9adc944"
      unitRef="usd">454000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzMwLTItMS0xLTk0ODMx_e2802f49-c0f5-4f08-88bb-01c2b5150b89"
      unitRef="usd">-8961000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzMwLTQtMS0xLTk0ODMx_7ea3cdfb-e713-472b-b2ac-cfa17c2d4b17"
      unitRef="usd">-8013000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzMxLTItMS0xLTk0ODMx_45a4ba3b-2204-45ab-97f9-4916dbfc3dde"
      unitRef="usd">-1924000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzMxLTQtMS0xLTk0ODMx_59d8d103-940d-4735-98e6-05e3ef1255c9"
      unitRef="usd">-2133000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzMyLTItMS0xLTk0ODMx_ff324f21-06fe-49de-a4f4-8bb7daea38e7"
      unitRef="usd">-106000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzMyLTQtMS0xLTk0ODMx_284f4b8f-5ac2-4aec-9b49-da8e5e6bd68a"
      unitRef="usd">535000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzMzLTItMS0xLTk0ODMx_ff0a8a33-46ee-4a32-ab84-d03d30899128"
      unitRef="usd">72000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzMzLTQtMS0xLTk0ODMx_f3504c7f-71cd-429d-8b7c-0e5807ea5442"
      unitRef="usd">70000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzM0LTItMS0xLTk0ODMx_c9e9af4b-1346-4dad-9d07-2656390ba65c"
      unitRef="usd">-34000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzM0LTQtMS0xLTk0ODMx_3b91614d-1d7b-4ea6-a422-228495474d78"
      unitRef="usd">605000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzM1LTItMS0xLTk0ODMx_ce8d75b8-1df4-4919-9dbc-02b12c08a03f"
      unitRef="usd">29202000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTUvZnJhZzo3MzRiZWRkNDQwMmI0M2ZjYWM0MWQ1ZmY4OThiY2EzNi90YWJsZTo1ZGZlN2U0MzM2OWU0MTYxYjYwNjUxM2E4NTM3ZmEwNi90YWJsZXJhbmdlOjVkZmU3ZTQzMzY5ZTQxNjFiNjA2NTEzYTg1MzdmYTA2XzM1LTQtMS0xLTk0ODMx_421ab523-8665-4d9b-a735-771daf2ad07b"
      unitRef="usd">31199000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc87f78bc74d4e43ab17c35afb0f8079_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzMtMS0xLTEtOTQ4MzE_7803e3ae-4210-45e8-8c81-1e217ad60987"
      unitRef="usd">8342000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8771372c3b94462beccdbc52f82e2b4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzMtMy0xLTEtOTQ4MzE_d29a36bb-2581-447a-9ff3-74ed003644f5"
      unitRef="usd">7924000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ff468ead247475a82ce446740f1f83a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzMtNS0xLTEtOTQ4MzE_301e6723-3f5a-4a8e-9bbe-3717700576d6"
      unitRef="usd">8489000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i32509de5461547988d9730878e48539c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzQtMS0xLTEtOTQ4MzE_3eb50b05-72a3-4a2f-b3fe-acad80b6825a"
      unitRef="usd">92000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib332d58601bd454bb89ede6b79782526_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzQtMy0xLTEtOTQ4MzE_be7272b6-10fa-444e-9f2a-e9dd77638900"
      unitRef="usd">103000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3a6d276415e419fb9288f1aa64070ba_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzQtNS0xLTEtOTQ4MzE_c92ca5f5-71db-44dc-b76d-b72d816c32a3"
      unitRef="usd">112000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzUtMS0xLTEtOTQ4MzE_b90525f9-10a2-4cd0-b3e7-aed1121fb5e0"
      unitRef="usd">8434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzUtMy0xLTEtOTQ4MzE_d63563cd-004a-4bd8-ac7a-6c18c3dafb8b"
      unitRef="usd">8027000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzUtNS0xLTEtOTQ4MzE_dc2d6f87-be78-400f-81b6-6990144ee35c"
      unitRef="usd">8601000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="idc87f78bc74d4e43ab17c35afb0f8079_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzctMS0xLTEtOTQ4MzE_9c696e45-228a-4856-a7a7-eccc24de94f4"
      unitRef="usd">2361000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie8771372c3b94462beccdbc52f82e2b4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzctMy0xLTEtOTQ4MzE_eab2e367-41f6-4883-8fc1-d5467274cb6a"
      unitRef="usd">2202000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6ff468ead247475a82ce446740f1f83a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzctNS0xLTEtOTQ4MzE_e92f9041-591e-4bcf-872c-d2d2960adff4"
      unitRef="usd">2297000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i32509de5461547988d9730878e48539c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzgtMS0xLTEtOTQ4MzE_fed38e0a-97f1-4800-bde7-b15021b39f0a"
      unitRef="usd">33000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib332d58601bd454bb89ede6b79782526_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzgtMy0xLTEtOTQ4MzE_d51bccad-1a5c-4055-858b-7fc22976c942"
      unitRef="usd">47000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie3a6d276415e419fb9288f1aa64070ba_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzgtNS0xLTEtOTQ4MzE_692bc07a-681a-452b-82e0-827d65a09f4d"
      unitRef="usd">53000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzktMS0xLTEtOTQ4MzE_a177e430-ccd9-4ac5-9108-37a9858a3f28"
      unitRef="usd">2624000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzktMy0xLTEtOTQ4MzE_671582a9-a81f-4f33-aea3-7eab9218a778"
      unitRef="usd">2367000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzktNS0xLTEtOTQ4MzE_8c69224d-a1da-4eb9-833b-17a1a24504c8"
      unitRef="usd">2554000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzEwLTEtMS0xLTk0ODMx_e0dc0b6d-765e-43c2-b8ea-406ea2806f7c"
      unitRef="usd">465000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzEwLTMtMS0xLTk0ODMx_9603fde2-7592-4a8f-91ec-9627ea654d42"
      unitRef="usd">452000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzEwLTUtMS0xLTk0ODMx_c34d03dc-deb5-41c7-9c9c-a2c0ec329b84"
      unitRef="usd">471000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzExLTEtMS0xLTk0ODMx_d5f60881-882b-44bf-80c4-df4f12aa6593"
      unitRef="usd">1375000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzExLTMtMS0xLTk0ODMx_a8859627-66a7-4ec2-b49a-bbf0bcf383f7"
      unitRef="usd">1645000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzExLTUtMS0xLTk0ODMx_cde27e80-b7f8-4061-b0c7-1bc92c564621"
      unitRef="usd">1897000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzEyLTEtMS0xLTk0ODMx_f44230fd-aa19-4bf5-97d6-bafc0c17d742"
      unitRef="usd">469000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzEyLTMtMS0xLTk0ODMx_20a531b3-04d5-46d1-aa45-73f2ab2b2fdb"
      unitRef="usd">0</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzEyLTUtMS0xLTk0ODMx_04a2ef35-eeb0-41a9-9639-e5cb2ade050b"
      unitRef="usd">0</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzEzLTEtMS0xLTk0ODMx_358bf3c9-c18b-4d5f-aafb-90ee1b84b940"
      unitRef="usd">234000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzEzLTMtMS0xLTk0ODMx_fbe987db-8996-4bff-810e-d61c98bbdc80"
      unitRef="usd">114000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzEzLTUtMS0xLTk0ODMx_d972c677-90db-45dd-b8bf-5aaff1ed8393"
      unitRef="usd">75000000</us-gaap:AssetImpairmentCharges>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE0LTEtMS0xLTk0ODMx_434c9702-122a-4d83-b52a-3abd603209e1"
      unitRef="usd">50000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE0LTMtMS0xLTk0ODMx_b6601a6b-8afd-4ffe-88e2-56548ff451c4"
      unitRef="usd">22000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE0LTUtMS0xLTk0ODMx_286f0936-0709-434d-9d4c-9cf251271f3f"
      unitRef="usd">31000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE1LTEtMS0xLTk0ODMx_dbcdf5c4-5808-4e18-8ccd-24f303d4583a"
      unitRef="usd">-373000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE1LTMtMS0xLTk0ODMx_d01d36ce-d109-4361-b1be-fe437729a28b"
      unitRef="usd">-502000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE1LTUtMS0xLTk0ODMx_af28a5c6-7d62-4b2b-b5f1-beb34c8cd722"
      unitRef="usd">-1426000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostsAndExpenses
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE2LTEtMS0xLTk0ODMx_f20053d6-e163-4141-9a89-276d62204019"
      unitRef="usd">7984000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE2LTMtMS0xLTk0ODMx_24459a5a-284b-402a-9efc-8e6123c41a38"
      unitRef="usd">7351000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE2LTUtMS0xLTk0ODMx_ce5a8e3f-6f7d-4e9e-8336-6385e44f3fb2"
      unitRef="usd">8804000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE3LTEtMS0xLTk0ODMx_37e961ef-e977-47c5-aaea-28f54c870ff9"
      unitRef="usd">450000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE3LTMtMS0xLTk0ODMx_adddd037-8cf6-45bf-9461-35a848d9252d"
      unitRef="usd">676000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE3LTUtMS0xLTk0ODMx_fb2ee83d-9527-4d4a-b22c-80f6ad570137"
      unitRef="usd">-203000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE4LTEtMS0xLTk0ODMx_327e0e65-9e5b-49c9-9d40-f15f00a93538"
      unitRef="usd">7000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE4LTMtMS0xLTk0ODMx_e38eef94-fe3d-4500-a35c-b147c7697c65"
      unitRef="usd">13000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE4LTUtMS0xLTk0ODMx_c62182d4-6eac-4262-a8d1-b4d18c037266"
      unitRef="usd">12000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseDebt
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE5LTEtMS0xLTk0ODMx_1b0c3a3a-4fa6-434c-a39d-9dfc3aebbc9d"
      unitRef="usd">1426000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE5LTMtMS0xLTk0ODMx_edc67937-8d64-4818-a506-b54878223e83"
      unitRef="usd">1534000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzE5LTUtMS0xLTk0ODMx_1ab50fda-72cc-4f27-b8b4-5abb8464f9da"
      unitRef="usd">1612000000</us-gaap:InterestExpenseDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzIwLTEtMS0xLTk0ODMx_ea02bbbf-aff1-447d-b21d-3aec04e5f3a1"
      unitRef="usd">-62000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzIwLTMtMS0xLTk0ODMx_44a8b6c4-de64-4923-be33-b3e281595987"
      unitRef="usd">-59000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzIwLTUtMS0xLTk0ODMx_f03a88cd-594b-4ceb-bc16-c0eca588dacb"
      unitRef="usd">-42000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzIxLTEtMS0xLTk0ODMx_97f078f2-3922-410e-9ac8-16a6cd568bb2"
      unitRef="usd">7000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzIxLTMtMS0xLTk0ODMx_9c033080-2c4b-460f-9bd3-d15deed68c7b"
      unitRef="usd">-30000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzIxLTUtMS0xLTk0ODMx_63b6d40c-37fc-4330-949b-a11fb8f7ac98"
      unitRef="usd">8000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzIyLTEtMS0xLTk0ODMx_1c4ac6ed-6ed8-4b05-94b8-877bdaee5260"
      unitRef="usd">-1024000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzIyLTMtMS0xLTk0ODMx_84acde4f-e5ef-4b0d-8259-63e5dedd73d8"
      unitRef="usd">-934000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzIyLTUtMS0xLTk0ODMx_5dd578d4-fc93-478e-bbf9-596e6887e287"
      unitRef="usd">-1837000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzIzLTEtMS0xLTk0ODMx_6305edc3-86dd-4dc5-98f1-90acb7d747da"
      unitRef="usd">-87000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzIzLTMtMS0xLTk0ODMx_0701442c-d785-4c6d-931b-c55363d8dd8e"
      unitRef="usd">-375000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzIzLTUtMS0xLTk0ODMx_c0961863-b5ea-4fd7-9f02-485a65dd3fdd"
      unitRef="usd">-54000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzI0LTEtMS0xLTk0ODMx_cc8e9e6c-eec8-463b-ac59-dfe33d594170"
      unitRef="usd">-937000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzI0LTMtMS0xLTk0ODMx_45823ac2-9c2e-4ca8-85d9-5f146891a299"
      unitRef="usd">-559000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzI0LTUtMS0xLTk0ODMx_5b4b35b2-8ce7-4693-b4c6-e9795acedd5b"
      unitRef="usd">-1783000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzI1LTEtMS0xLTk0ODMx_783d9df5-0b2d-4346-805f-1742092ab3b2"
      unitRef="usd">11000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzI1LTMtMS0xLTk0ODMx_1fe94743-e4a7-4048-80bf-7fb891c51850"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzI1LTUtMS0xLTk0ODMx_38a54c30-65c4-4128-bb95-fd53a8668c0a"
      unitRef="usd">5000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzI2LTEtMS0xLTk0ODMx_b5000712-fe80-4137-81fb-64a4f77c5742"
      unitRef="usd">-948000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzI2LTMtMS0xLTk0ODMx_decb28db-2f84-4020-9eca-586e3c49a0d2"
      unitRef="usd">-560000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzI2LTUtMS0xLTk0ODMx_df8aaa3f-449b-4cfe-ab45-9193ac3384c1"
      unitRef="usd">-1788000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzI4LTEtMS0xLTk0ODMx_af1c6f61-5cae-4d7f-9435-d4033c24f650"
      unitRef="usdPerShare">-2.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzI4LTEtMS0xLTk0ODMx_f3ee7061-3fb4-4970-ae54-631555a9baa2"
      unitRef="usdPerShare">-2.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzI4LTMtMS0xLTk0ODMx_dde9f557-1e13-49ee-a7b2-10d16c070965"
      unitRef="usdPerShare">-1.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzI4LTMtMS0xLTk0ODMx_fffeb972-dbc7-46c1-a923-584601c42fd1"
      unitRef="usdPerShare">-1.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzI4LTUtMS0xLTk0ODMx_8c86d686-2659-4f12-bb67-b853a27d08d3"
      unitRef="usdPerShare">-5.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzI4LTUtMS0xLTk0ODMx_dbedc38b-86d2-483d-aea2-925f0693174e"
      unitRef="usdPerShare">-5.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzMwLTEtMS0xLTk0ODMx_2701e3a8-d81d-4782-9165-ce4da81f0a7b"
      unitRef="shares">358900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzMwLTEtMS0xLTk0ODMx_cb0f8c67-bc0d-4ad0-a350-a28f056d9952"
      unitRef="shares">358900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzMwLTMtMS0xLTk0ODMx_255c37d6-4f9e-4511-b578-326f6a6b9269"
      unitRef="shares">355000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzMwLTMtMS0xLTk0ODMx_9ec93fe0-8896-4d07-a063-abf74c47a980"
      unitRef="shares">355000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzMwLTUtMS0xLTk0ODMx_2997b533-f22a-4403-95d9-280971affe40"
      unitRef="shares">352100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8yOTgvZnJhZzplZWQ3MGY5OGRhNjQ0ZmQyYjkzMmI5ZDRjYWI5NmU4YS90YWJsZTplMmU3ZDhjMDJmMjk0YjdjYTRkYmQwM2Q0YTc0NWZjZS90YWJsZXJhbmdlOmUyZTdkOGMwMmYyOTRiN2NhNGRiZDAzZDRhNzQ1ZmNlXzMwLTUtMS0xLTk0ODMx_b630f35d-3c36-453d-8940-8b8ab0a32202"
      unitRef="shares">352100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ProfitLoss
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzItMS0xLTEtOTQ4MzE_eefe108e-982a-45c1-b0c3-6896ba424e73"
      unitRef="usd">-937000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzItMy0xLTEtOTQ4MzE_7c3152b3-110b-46fc-b354-267fdb5c902c"
      unitRef="usd">-559000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzItNS0xLTEtOTQ4MzE_30cd79a8-2610-4b63-b880-31fc45fb1e2e"
      unitRef="usd">-1783000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzUtMS0xLTEtOTQ4MzE_eadba2b4-2ebe-46fe-ae0a-15f7cecf9428"
      unitRef="usd">24000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzUtMy0xLTEtOTQ4MzE_1301463d-b019-4fdc-b418-b14871328240"
      unitRef="usd">-15000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzUtNS0xLTEtOTQ4MzE_905a68d3-a7e7-4f0b-9475-d6a2aa9aec12"
      unitRef="usd">-8000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzYtMS0xLTEtOTQ4MzE_a1375195-6ded-4561-8bad-82f0ae1acacd"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzYtMy0xLTEtOTQ4MzE_628169cd-ad7f-4966-ab02-9e4371ee60cd"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzYtNS0xLTEtOTQ4MzE_e4a9d14a-1dee-40f8-948b-0a956bc693c1"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax>
    <bhc:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzctMS0xLTEtOTQ4MzE_12f8769f-6f16-4609-8326-1b79bb68e983"
      unitRef="usd">-10000000</bhc:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition>
    <bhc:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzctMy0xLTEtOTQ4MzE_097a540f-b101-43c9-9866-a5dc40bdc073"
      unitRef="usd">-1000000</bhc:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition>
    <bhc:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzctNS0xLTEtOTQ4MzE_8c55edeb-42c2-40de-b2ef-e5d3283626dd"
      unitRef="usd">-2000000</bhc:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzgtMS0xLTEtOTQ4MzE_feabce6c-87a3-4e00-864e-4bd619336da7"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzgtMy0xLTEtOTQ4MzE_177896e4-b371-493d-9a53-fd3ed4271709"
      unitRef="usd">2000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzgtNS0xLTEtOTQ4MzE_85d36c1f-d26e-4ff4-b45a-35cad1844d5a"
      unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <bhc:OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzktMS0xLTEtOTQ4MzE_b62c5329-db75-4a27-8607-aa794bb36ca6"
      unitRef="usd">-3000000</bhc:OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax>
    <bhc:OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzktMy0xLTEtOTQ4MzE_e4853c34-ef8b-48ff-9c3d-431a018cfe1a"
      unitRef="usd">0</bhc:OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax>
    <bhc:OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzktNS0xLTEtOTQ4MzE_ff0362eb-f38e-475f-b5b9-bb15c73e2637"
      unitRef="usd">-2000000</bhc:OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzEwLTEtMS0xLTk0ODMx_417d2606-ddc0-4a7e-833c-7fa2675d6461"
      unitRef="usd">-28000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzEwLTMtMS0xLTk0ODMx_ed440ee9-5986-4a95-b6d5-50260193dc1e"
      unitRef="usd">16000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzEwLTUtMS0xLTk0ODMx_b55bbed1-cfc9-435b-8133-c94c3a8eeb69"
      unitRef="usd">14000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzExLTEtMS0xLTk0ODMx_b8c38e1d-c6e5-4f24-b078-849d6c96a1e1"
      unitRef="usd">-158000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzExLTMtMS0xLTk0ODMx_9a305891-003c-4920-ad3f-c772f82ffc6b"
      unitRef="usd">-29000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzExLTUtMS0xLTk0ODMx_d586dc96-72b9-46ba-a4a2-3e0ce8c119df"
      unitRef="usd">64000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzEyLTEtMS0xLTk0ODMx_f72fe79a-9522-437d-8daf-13740bd01650"
      unitRef="usd">-130000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzEyLTMtMS0xLTk0ODMx_0afc2821-8f6b-4a47-8a6f-9ddec5d66827"
      unitRef="usd">-45000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzEyLTUtMS0xLTk0ODMx_e70a705a-8326-4454-8528-d92f6e6aebc3"
      unitRef="usd">50000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzEzLTEtMS0xLTk0ODMx_23812efd-ef11-43cd-b1c5-714fcf67ec3d"
      unitRef="usd">-1067000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzEzLTMtMS0xLTk0ODMx_8285bd35-d917-4a8e-83c2-a00b8a3e971d"
      unitRef="usd">-604000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzEzLTUtMS0xLTk0ODMx_0f577559-542b-4d70-ae33-e81bc9517012"
      unitRef="usd">-1733000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzE0LTEtMS0xLTk0ODMx_82a686bc-b61c-4078-9624-e6eb317bf4e4"
      unitRef="usd">12000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzE0LTMtMS0xLTk0ODMx_fb7eec7b-e652-40b4-be2f-084ba18978a3"
      unitRef="usd">3000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzE0LTUtMS0xLTk0ODMx_c3208496-3cfa-4b92-b3df-1be45c266be1"
      unitRef="usd">4000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzE1LTEtMS0xLTk0ODMx_b0d48c96-17d9-47bd-98db-3b88bbcbe18d"
      unitRef="usd">-1079000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzE1LTMtMS0xLTk0ODMx_0a8b0fba-ce27-4e87-8f3b-ac21f7857881"
      unitRef="usd">-607000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDEvZnJhZzo2YTJhMDY1NzFlNGI0OTY5YWMxYWMyYzk0NjhhZmYxNC90YWJsZTozMWUyY2E4ZDQwOTI0OGExYWZlYTVjZmI1YTZlN2JmNi90YWJsZXJhbmdlOjMxZTJjYThkNDA5MjQ4YTFhZmVhNWNmYjVhNmU3YmY2XzE1LTUtMS0xLTk0ODMx_c29d8544-3701-452b-92ad-f9d984b229ed"
      unitRef="usd">-1737000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9065a4b181534b6ab3a847b07fb47561_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzMtMi0xLTEtOTQ4MzE_e72c8401-e59a-4c63-b49a-537de4db4b05"
      unitRef="shares">349900000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9065a4b181534b6ab3a847b07fb47561_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzMtNC0xLTEtOTQ4MzE_8761d188-3a97-4486-a3eb-4e69ca663de5"
      unitRef="usd">10121000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic1d1a33a09fa48859e7e47fd030be3fd_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzMtNi0xLTEtOTQ4MzE_ea2ffa4c-72cf-4253-b208-2e6a089c42c9"
      unitRef="usd">413000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7651c2a37e9f49e9915cd978a12d1e8f_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzMtOC0xLTEtOTQ4MzE_d21f7a77-fff4-4d71-bfdb-b4a53caa7566"
      unitRef="usd">-5664000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if72905c016ef4f1494ae44900f94a9fd_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzMtMTAtMS0xLTk0ODMx_b9f024e3-9033-408b-8429-312fbb13f723"
      unitRef="usd">-2137000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibbcfed5f24544ab594fad1395b2ed82b_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzMtMTItMS0xLTk0ODMx_da694b4b-dfa6-40d4-a50c-64371512b5e6"
      unitRef="usd">2733000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7c139d1926cf4e6c9d1ee8a32ee091d3_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzMtMTQtMS0xLTk0ODMx_3739edfc-f705-4e26-9293-8291e6b64454"
      unitRef="usd">82000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i18439fe8345c481db53c486667ac6940_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzMtMTYtMS0xLTk0ODMx_c95fc102-0136-4729-95c0-0d4a0cbd012b"
      unitRef="usd">2815000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i6adf3d44da584f02a9de432de2320ed5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzQtMi0xLTEtOTQ4MzE_a3af01d5-748a-4015-bb4e-a96a7c32499b"
      unitRef="shares">2700000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6adf3d44da584f02a9de432de2320ed5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzQtNC0xLTEtOTQ4MzE_f9947940-933f-4af5-975a-14f0a715c33d"
      unitRef="usd">51000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id70a674e2be94ffd85bbca114010b4f0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzQtNi0xLTEtOTQ4MzE_4a50f0ec-c48b-465e-b428-97a316810068"
      unitRef="usd">-46000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i15c0150c538f487cb6591cfcbe5f75f1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzQtMTItMS0xLTk0ODMx_3bae0398-782b-4041-a7b4-0653e276b1b8"
      unitRef="usd">5000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzQtMTYtMS0xLTk0ODMx_17391473-c0cf-4e16-b2c5-02ab1eed2151"
      unitRef="usd">5000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="id70a674e2be94ffd85bbca114010b4f0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzUtNi0xLTEtOTQ4MzE_a78de168-83db-4e7d-9ec0-139815f8c955"
      unitRef="usd">102000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i15c0150c538f487cb6591cfcbe5f75f1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzUtMTItMS0xLTk0ODMx_94340cf5-1329-4dcd-858b-7026ea447a37"
      unitRef="usd">102000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzUtMTYtMS0xLTk0ODMx_e0376acd-852d-4dd4-8b76-224b4eabff0f"
      unitRef="usd">102000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="id70a674e2be94ffd85bbca114010b4f0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzYtNi0xLTEtOTQ4MzE_ecc404f9-92f7-4916-a21d-0bd074a874a2"
      unitRef="usd">40000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i15c0150c538f487cb6591cfcbe5f75f1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzYtMTItMS0xLTk0ODMx_af8bf771-6e0d-4484-aa3f-ca82f49cb247"
      unitRef="usd">40000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzYtMTYtMS0xLTk0ODMx_96bdb609-7511-4764-b69b-350be25bb969"
      unitRef="usd">40000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i261c4af1d70b4e2395fbc9f9f1d94e47_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzctMTQtMS0xLTk0ODMx_b95362c8-5790-42d3-b667-a5c97c8fed2e"
      unitRef="usd">13000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzctMTYtMS0xLTk0ODMx_ccd97c4f-adf4-4086-9853-da819aec3be0"
      unitRef="usd">13000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="id967574fda7e4ceabaf0455646739979_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzgtOC0xLTEtOTQ4MzE_94f39ecf-3192-41ee-a425-a5d9767ac964"
      unitRef="usd">-1788000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i15c0150c538f487cb6591cfcbe5f75f1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzgtMTItMS0xLTk0ODMx_0553b8cc-fe95-4fe0-9fd3-b7627596a7b3"
      unitRef="usd">-1788000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i261c4af1d70b4e2395fbc9f9f1d94e47_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzgtMTQtMS0xLTk0ODMx_9598812b-d9af-46e3-a87a-9cac0b75580e"
      unitRef="usd">5000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzgtMTYtMS0xLTk0ODMx_e1f92176-293a-40e9-a686-18f01302d3c0"
      unitRef="usd">-1783000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i119d0f73c7f74fc9bb4f33a268f1733a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzktMTAtMS0xLTk0ODMx_b2acdede-06cb-4a4a-8cfb-aff8d48f0504"
      unitRef="usd">51000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i15c0150c538f487cb6591cfcbe5f75f1_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzktMTItMS0xLTk0ODMx_57b5e6ed-c96d-4cb5-94da-9d60c1d2bd00"
      unitRef="usd">51000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i261c4af1d70b4e2395fbc9f9f1d94e47_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzktMTQtMS0xLTk0ODMx_d98ffe65-7641-40d6-986c-088355d61884"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzktMTYtMS0xLTk0ODMx_d99ce5f6-86b8-4da0-a0e5-1fa8e7edf211"
      unitRef="usd">50000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i473f77fb1af344a29eab4fdfd6d3dd2b_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEwLTItMS0xLTk0ODMx_601b5aac-959b-4afd-8c6e-2adaabcf8906"
      unitRef="shares">352600000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i473f77fb1af344a29eab4fdfd6d3dd2b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEwLTQtMS0xLTk0ODMx_788e6267-5574-48c7-83c6-c2ebe2c1d79e"
      unitRef="usd">10172000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia3596f3678c0497483ac196ed8bec2eb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEwLTYtMS0xLTk0ODMx_a6ba20ee-c703-4534-b1c5-a548a682787c"
      unitRef="usd">429000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9a73edc85bf74e808a3aec728f72c249_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEwLTgtMS0xLTk0ODMx_33d65fd6-bfae-403d-9a19-e44379d52df9"
      unitRef="usd">-7452000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9aca61c7e88b46d19ad0b86e6d3a2ecf_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEwLTEwLTEtMS05NDgzMQ_788c3cb7-bb2a-4e50-b76f-03e56cf28545"
      unitRef="usd">-2086000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia032d22b364945dd81a246b3994295ed_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEwLTEyLTEtMS05NDgzMQ_43a2707d-05df-44f7-8713-232c70453cb4"
      unitRef="usd">1063000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if43bfad251bd4331a051f408c738cf0b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEwLTE0LTEtMS05NDgzMQ_3a8c4c9d-a492-4383-9026-a552abd67e9a"
      unitRef="usd">73000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEwLTE2LTEtMS05NDgzMQ_3eac9d46-a388-4be2-9aa6-fe1b7227d54c"
      unitRef="usd">1136000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2f5bb32797ed4025b477232d70d05dd7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzExLTgtMS0xLTk0ODMx_506a800c-000d-4d9c-a05b-e19f543af841"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i052b9590a90c45a9b05e3dd474e6d8d6_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzExLTEyLTEtMS05NDgzMQ_394534b7-cb55-4c4f-acc3-edd710166fe6"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2d81998e18d049a795cb319c580e68df_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzExLTE2LTEtMS05NDgzMQ_8d61ebc0-59c7-40f7-9c60-08caddefc620"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i1dca8f6ac26c452fa7d59299882a0097_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEyLTItMS0xLTk0ODMx_59d7604e-3d8e-4ba5-b9f5-c0f676dc72b2"
      unitRef="shares">2800000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1dca8f6ac26c452fa7d59299882a0097_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEyLTQtMS0xLTk0ODMx_82eefb14-6a59-4653-ad69-3b4c810ff428"
      unitRef="usd">55000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5ff42e3612b54f43abc128d492dcd6b7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEyLTYtMS0xLTk0ODMx_3c09421b-d5f1-425f-b282-8d645882460a"
      unitRef="usd">-50000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9eb6e474c66a4666bf7e3a85d9c998a9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEyLTEyLTEtMS05NDgzMQ_292655e6-65d6-4db2-8c53-8c8c4634b3d5"
      unitRef="usd">5000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEyLTE2LTEtMS05NDgzMQ_c3168ed7-77a5-4cd3-b815-fec1e4880ae7"
      unitRef="usd">5000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5ff42e3612b54f43abc128d492dcd6b7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEzLTYtMS0xLTk0ODMx_a08be976-c573-44c5-ad88-75886f10451c"
      unitRef="usd">105000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9eb6e474c66a4666bf7e3a85d9c998a9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEzLTEyLTEtMS05NDgzMQ_7b422d6d-b4df-43e5-9277-45108116eea6"
      unitRef="usd">105000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzEzLTE2LTEtMS05NDgzMQ_8895d1d4-277d-46bd-af11-19b9ae250c69"
      unitRef="usd">105000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i5ff42e3612b54f43abc128d492dcd6b7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE0LTYtMS0xLTk0ODMx_c66e72f0-9fbe-42fa-b033-3628f05eb42d"
      unitRef="usd">30000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i9eb6e474c66a4666bf7e3a85d9c998a9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE0LTEyLTEtMS05NDgzMQ_a6a059e2-f991-4cbc-8c11-7f36a94eb5a0"
      unitRef="usd">30000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE0LTE2LTEtMS05NDgzMQ_b9bc3551-1d97-4ff5-b584-d14fc75c735d"
      unitRef="usd">30000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i3f36a5753643489d88a4e0f82c989bd6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE1LTE0LTEtMS05NDgzMQ_048a9042-9fa9-43c5-a8cf-8f048f809935"
      unitRef="usd">6000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE1LTE2LTEtMS05NDgzMQ_2f9d8af4-ee25-4d90-81aa-4c7023a59112"
      unitRef="usd">6000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="i086e5920df794c1bb867ec98391c2996_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE2LTgtMS0xLTk0ODMx_6c4eaec5-96f7-4f43-a36a-a51a65aa5ce3"
      unitRef="usd">-560000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9eb6e474c66a4666bf7e3a85d9c998a9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE2LTEyLTEtMS05NDgzMQ_aebc66aa-06db-4725-93ed-f872af2edfa7"
      unitRef="usd">-560000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3f36a5753643489d88a4e0f82c989bd6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE2LTE0LTEtMS05NDgzMQ_12511f42-6a60-4c33-8616-0116ac8e225f"
      unitRef="usd">1000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE2LTE2LTEtMS05NDgzMQ_890ec503-5550-4453-8dd1-27d28e49cfad"
      unitRef="usd">-559000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia496362f6d164947b1a2ae170da89d4c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE3LTEwLTEtMS05NDgzMQ_1c992e7c-cfc4-48d8-9d45-3611d64ba863"
      unitRef="usd">-47000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9eb6e474c66a4666bf7e3a85d9c998a9_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE3LTEyLTEtMS05NDgzMQ_8b4d98a1-19d5-4e4d-9850-ee429ef4224b"
      unitRef="usd">-47000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3f36a5753643489d88a4e0f82c989bd6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE3LTE0LTEtMS05NDgzMQ_bb80f1d3-b211-4b47-a919-5fc3e478eef5"
      unitRef="usd">2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE3LTE2LTEtMS05NDgzMQ_86d31e04-d63e-4c3e-aebf-993a3e5e30e2"
      unitRef="usd">-45000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i3bcb5947fed543afb53cd6a3b48f336b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE4LTItMS0xLTk0ODMx_ffacf82c-4a07-46b5-b113-eece69fc1627"
      unitRef="shares">355400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3bcb5947fed543afb53cd6a3b48f336b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE4LTQtMS0xLTk0ODMx_01078642-65d6-42bc-b780-bf88c86e29fd"
      unitRef="usd">10227000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if8bec50dbaed4dbea096a71456e733f9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE4LTYtMS0xLTk0ODMx_03818dd2-664d-4b9d-9929-eaec7ac54198"
      unitRef="usd">454000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i923a3743995f408db8308a2d12856422_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE4LTgtMS0xLTk0ODMx_92fed015-9946-43e7-b7c2-46e4812ecbb9"
      unitRef="usd">-8013000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib105e1aee9db4b46ae7d9e203dadfad7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE4LTEwLTEtMS05NDgzMQ_289dd953-d994-49c9-baa7-fe1e2f3a8e8f"
      unitRef="usd">-2133000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3206e4462f2f44e9860f3d0294412da9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE4LTEyLTEtMS05NDgzMQ_c538656e-df0d-42d8-8e35-2da28b7f6f91"
      unitRef="usd">535000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5b49661c9941455eb0cd3e84d7fac743_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE4LTE0LTEtMS05NDgzMQ_8ce244e1-7939-4054-a494-ae347b85f929"
      unitRef="usd">70000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE4LTE2LTEtMS05NDgzMQ_7e2f543f-fcfd-46d8-aeb4-eadd5b8c5123"
      unitRef="usd">605000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i7b938a0322254b5aaab41c8892322507_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE5LTItMS0xLTk0ODMx_d38916ee-7e9a-4870-8b0b-8da66bc88e2d"
      unitRef="shares">4000000.0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7b938a0322254b5aaab41c8892322507_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE5LTQtMS0xLTk0ODMx_f1dac23f-54ef-45bc-b342-9cb60ee0481e"
      unitRef="usd">90000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if33956ad61204d93933927de0fdb82c7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE5LTYtMS0xLTk0ODMx_5dc9eafa-e135-4dfc-9df7-d6a78fd7aca2"
      unitRef="usd">-68000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i1a6553baa7a24ea0992e7694bf3ada46_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE5LTEyLTEtMS05NDgzMQ_5aef2618-6c09-4965-9a4f-c894a639d916"
      unitRef="usd">22000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzE5LTE2LTEtMS05NDgzMQ_46ecb795-3fac-4ee5-8939-2fbef8afc9ee"
      unitRef="usd">22000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if33956ad61204d93933927de0fdb82c7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzIwLTYtMS0xLTk0ODMx_5c96d5fe-ec54-441f-8682-4decd59527dc"
      unitRef="usd">128000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1a6553baa7a24ea0992e7694bf3ada46_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzIwLTEyLTEtMS05NDgzMQ_e920ae3b-7455-4488-86e8-35fc60d6b7b3"
      unitRef="usd">128000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzIwLTE2LTEtMS05NDgzMQ_228ac2d5-063b-467f-bb63-12aece4eabc4"
      unitRef="usd">128000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if33956ad61204d93933927de0fdb82c7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzIxLTYtMS0xLTk0ODMx_f1e546e9-eab1-4b23-8f2f-9570fa9885b7"
      unitRef="usd">52000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i1a6553baa7a24ea0992e7694bf3ada46_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzIxLTEyLTEtMS05NDgzMQ_300c183f-5190-4671-b9b3-f842df287a72"
      unitRef="usd">52000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzIxLTE2LTEtMS05NDgzMQ_527da8a6-3fa1-43bc-9bef-4991d05e0cd1"
      unitRef="usd">52000000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i28ab1aeb8c054aa1a4603d09d2ee8fc7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzIyLTEwLTEtMS05NDgzMQ_cb34a76e-0809-45c6-b4b1-c8ba75e1952d"
      unitRef="usd">340000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i1a6553baa7a24ea0992e7694bf3ada46_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzIyLTEyLTEtMS05NDgzMQ_a597f5f2-cd1f-4a4a-b820-2f4bcf2978e7"
      unitRef="usd">340000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzIyLTE2LTEtMS05NDgzMQ_33b9f48e-c0b3-4105-836b-ce54d92294a4"
      unitRef="usd">340000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i19f72ec10a1846be8c55a1dd70f9a9a2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzIzLTE0LTEtMS05NDgzMQ_69849f5d-753c-48c8-a358-0c9a9fe8df06"
      unitRef="usd">10000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzIzLTE2LTEtMS05NDgzMQ_fb9aa2f8-39e9-45c0-bd95-6f707eae847c"
      unitRef="usd">10000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:ProfitLoss
      contextRef="i11f91c7cdb5e4652b3582c04a13bbd0c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI0LTgtMS0xLTk0ODMx_5dbdb1ca-c5e6-43f8-8bef-ed4eb28be09a"
      unitRef="usd">-948000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1a6553baa7a24ea0992e7694bf3ada46_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI0LTEyLTEtMS05NDgzMQ_d7a7e0a0-d736-4ff1-9ccc-8e0d14dab3c9"
      unitRef="usd">-948000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i19f72ec10a1846be8c55a1dd70f9a9a2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI0LTE0LTEtMS05NDgzMQ_4ba1a2e0-74c5-4720-9890-b568b5e45cbe"
      unitRef="usd">11000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI0LTE2LTEtMS05NDgzMQ_9a172322-2211-4c08-b9c3-ce9bd867e56a"
      unitRef="usd">-937000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i28ab1aeb8c054aa1a4603d09d2ee8fc7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI1LTEwLTEtMS05NDgzMQ_c5fccc9a-3ace-457c-8c2b-51838e543251"
      unitRef="usd">-131000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1a6553baa7a24ea0992e7694bf3ada46_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI1LTEyLTEtMS05NDgzMQ_fce10e47-056b-4da3-9c6a-69391c3c5758"
      unitRef="usd">-131000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i19f72ec10a1846be8c55a1dd70f9a9a2_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI1LTE0LTEtMS05NDgzMQ_dd07b44e-0124-44b0-a912-6f033e7abeb1"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI1LTE2LTEtMS05NDgzMQ_abf9adcf-a712-4d87-bf6c-e532ad11a8bc"
      unitRef="usd">-130000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0aec0a6b31ac49f8b1539442f4d1de2a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI2LTItMS0xLTk0ODMx_89cacb4b-8dc0-4334-889e-fbee5871e75f"
      unitRef="shares">359400000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0aec0a6b31ac49f8b1539442f4d1de2a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI2LTQtMS0xLTk0ODMx_56cd63d5-bce8-4e2f-86b7-45da0cbf565c"
      unitRef="usd">10317000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i69270432269b42208da3ba0a5f6c0c8d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI2LTYtMS0xLTk0ODMx_79b6deac-529f-4f88-b665-71a371350e9f"
      unitRef="usd">462000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i525200ba6a35425892b9fb1f4c0c7eeb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI2LTgtMS0xLTk0ODMx_55804549-75af-4bf5-a6a9-ad9a723a954c"
      unitRef="usd">-8961000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iff498ebdd499404a95f12abea2bd55e9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI2LTEwLTEtMS05NDgzMQ_b0ad28fe-736c-41ac-a1c4-3a54f7f90858"
      unitRef="usd">-1924000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2e55e9853c474101a26d48d5ad7d46b6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI2LTEyLTEtMS05NDgzMQ_4b4f804b-517f-4d90-adb7-4db153d21c1a"
      unitRef="usd">-106000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i19c82921041f4fa6b0c1e1a12a9800a1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI2LTE0LTEtMS05NDgzMQ_dded9af4-2ada-41c8-8035-bae45cd15807"
      unitRef="usd">72000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDQvZnJhZzo3YzRhYWUwYjZkNzM0YjQ0YjFjZTBkMTNhYmUwNGU5YS90YWJsZTpmOTJmNDEzMGQwZmM0ZWJiYmFjNzEwNjJjNmYwNzY0ZC90YWJsZXJhbmdlOmY5MmY0MTMwZDBmYzRlYmJiYWM3MTA2MmM2ZjA3NjRkXzI2LTE2LTEtMS05NDgzMQ_c4e579ca-4e22-4ebd-9e8a-91c95dbb9cc4"
      unitRef="usd">-34000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzMtMi0xLTEtOTQ4MzE_eefe108e-982a-45c1-b0c3-6896ba424e73"
      unitRef="usd">-937000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzMtNC0xLTEtOTQ4MzE_7c3152b3-110b-46fc-b354-267fdb5c902c"
      unitRef="usd">-559000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzMtNi0xLTEtOTQ4MzE_30cd79a8-2610-4b63-b880-31fc45fb1e2e"
      unitRef="usd">-1783000000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzUtMi0xLTEtOTQ4MzE_05ea3879-7412-45b9-a4f4-95cf56fa314d"
      unitRef="usd">1552000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzUtNC0xLTEtOTQ4MzE_4b605682-34b9-4596-afad-2dedee295c72"
      unitRef="usd">1825000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzUtNi0xLTEtOTQ4MzE_c86eb6d9-077f-4b9d-b277-57cf091b22dc"
      unitRef="usd">2075000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzYtMi0xLTEtOTQ4MzE_9387213f-d9f8-451f-8ad2-fd4386c2bafa"
      unitRef="usd">55000000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzYtNC0xLTEtOTQ4MzE_63fd2de0-dc17-4cf7-b148-0385f1a88772"
      unitRef="usd">61000000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzYtNi0xLTEtOTQ4MzE_5e978029-9029-42f3-a286-c16f5811df96"
      unitRef="usd">63000000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AssetImpairmentCharges
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzctMi0xLTEtOTQ4MzE_358bf3c9-c18b-4d5f-aafb-90ee1b84b940"
      unitRef="usd">234000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzctNC0xLTEtOTQ4MzE_fbe987db-8996-4bff-810e-d61c98bbdc80"
      unitRef="usd">114000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzctNi0xLTEtOTQ4MzE_d972c677-90db-45dd-b8bf-5aaff1ed8393"
      unitRef="usd">75000000</us-gaap:AssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzgtMi0xLTEtOTQ4MzE_f44230fd-aa19-4bf5-97d6-bafc0c17d742"
      unitRef="usd">469000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzgtNC0xLTEtOTQ4MzE_7027c8bb-cf82-466d-bbb4-44b67aa50a51"
      unitRef="usd">0</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzgtNi0xLTEtOTQ4MzE_3123715d-6b25-4f65-88a3-32b992f13cdb"
      unitRef="usd">0</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzktMi0xLTEtOTQ4MzE_c3daab34-d024-4ebf-b7c9-5d630549b580"
      unitRef="usd">11000000</bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash>
    <bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzktNC0xLTEtOTQ4MzE_5e8ef50b-e687-435c-a3cb-faac828b07ab"
      unitRef="usd">48000000</bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash>
    <bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzktNi0xLTEtOTQ4MzE_e3b1b5c9-ccb8-48a8-9e01-aa3d37561718"
      unitRef="usd">12000000</bhc:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash>
    <bhc:AllowancesForLossesOnAccountsReceivableAndInventories
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzEwLTItMS0xLTk0ODMx_012ab480-4f52-4228-84d0-e1b1c9a1dc2d"
      unitRef="usd">60000000</bhc:AllowancesForLossesOnAccountsReceivableAndInventories>
    <bhc:AllowancesForLossesOnAccountsReceivableAndInventories
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzEwLTQtMS0xLTk0ODMx_d2b9a4ea-03f9-4684-96ca-517807350404"
      unitRef="usd">60000000</bhc:AllowancesForLossesOnAccountsReceivableAndInventories>
    <bhc:AllowancesForLossesOnAccountsReceivableAndInventories
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzEwLTYtMS0xLTk0ODMx_ff574830-3155-4e0a-8a64-1c507f07b887"
      unitRef="usd">75000000</bhc:AllowancesForLossesOnAccountsReceivableAndInventories>
    <bhc:DeferredIncomeTaxNoncashExpenseBenefit
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzExLTItMS0xLTk0ODMx_f405f747-2d57-4189-aae2-958e34e297c2"
      unitRef="usd">-225000000</bhc:DeferredIncomeTaxNoncashExpenseBenefit>
    <bhc:DeferredIncomeTaxNoncashExpenseBenefit
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzExLTQtMS0xLTk0ODMx_6feb7912-c065-4ee8-8111-baf3ff5d9222"
      unitRef="usd">-475000000</bhc:DeferredIncomeTaxNoncashExpenseBenefit>
    <bhc:DeferredIncomeTaxNoncashExpenseBenefit
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzExLTYtMS0xLTk0ODMx_4f46d9fb-578b-4c06-9885-ca65e6d24dfb"
      unitRef="usd">-230000000</bhc:DeferredIncomeTaxNoncashExpenseBenefit>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzEyLTItMS0xLTk0ODMx_aa3c1e72-a374-463a-8e5b-253e29511cfd"
      unitRef="usd">2000000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzEyLTQtMS0xLTk0ODMx_221a877f-12f3-40ae-aaac-25f6bfa04b7b"
      unitRef="usd">1000000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzEyLTYtMS0xLTk0ODMx_9451d367-8fbd-4662-a6f7-378db732c8a5"
      unitRef="usd">31000000</us-gaap:GainLossOnDispositionOfAssets>
    <bhc:GainLossRelatedToLitigationSettlementGross
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzEzLTItMS0xLTk0ODMx_a52ea0fd-fe48-49a9-8294-ae6ff1ae074c"
      unitRef="usd">-569000000</bhc:GainLossRelatedToLitigationSettlementGross>
    <bhc:GainLossRelatedToLitigationSettlementGross
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzEzLTQtMS0xLTk0ODMx_4b1b8426-78b2-4c84-8078-07c50dcb12bb"
      unitRef="usd">-442000000</bhc:GainLossRelatedToLitigationSettlementGross>
    <bhc:GainLossRelatedToLitigationSettlementGross
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzEzLTYtMS0xLTk0ODMx_6e54261a-f087-4e55-ac39-f10a2e5f23cd"
      unitRef="usd">-1401000000</bhc:GainLossRelatedToLitigationSettlementGross>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE0LTItMS0xLTk0ODMx_4a5e1458-5b07-4bb3-954e-1452804c74de"
      unitRef="usd">351000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE0LTQtMS0xLTk0ODMx_6a594e7c-8fa3-46d1-a5ee-661797a09470"
      unitRef="usd">168000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE0LTYtMS0xLTk0ODMx_0a9fa05c-e332-43fb-bc1f-d7cef3b6da33"
      unitRef="usd">15000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:ShareBasedCompensation
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE1LTItMS0xLTk0ODMx_3167d0b7-1fff-4afe-934e-0144fec4ba23"
      unitRef="usd">128000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE1LTQtMS0xLTk0ODMx_592f4b8f-de61-4254-a594-288ad8a25b47"
      unitRef="usd">105000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE1LTYtMS0xLTk0ODMx_4cf2d252-3a5a-4821-893d-26ad80bb88d1"
      unitRef="usd">102000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE2LTItMS0xLTk0ODMx_f4745b66-96ae-4250-b489-7b0135915ebf"
      unitRef="usd">-6000000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE2LTQtMS0xLTk0ODMx_18714798-1190-4b1c-ae30-22225d1686d6"
      unitRef="usd">-8000000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE2LTYtMS0xLTk0ODMx_5cb55d1d-039c-4a3c-b814-a0a20e1e8769"
      unitRef="usd">-7000000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <bhc:DerivativeGainExcludedComponent
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE3LTItMS0xLTk0ODMx_142fefb7-48bc-45e8-873f-70c07cbd6905"
      unitRef="usd">20000000</bhc:DerivativeGainExcludedComponent>
    <bhc:DerivativeGainExcludedComponent
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE3LTQtMS0xLTk0ODMx_c15154fe-0607-4b04-b1c8-8125266dc19a"
      unitRef="usd">23000000</bhc:DerivativeGainExcludedComponent>
    <bhc:DerivativeGainExcludedComponent
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE3LTYtMS0xLTk0ODMx_482630c0-d1b0-43f9-a6b3-eb03ce2e75f6"
      unitRef="usd">9000000</bhc:DerivativeGainExcludedComponent>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE4LTItMS0xLTk0ODMx_fc714814-3094-4cae-848a-c1032a658511"
      unitRef="usd">-62000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE4LTQtMS0xLTk0ODMx_a0ba7f51-a93e-416c-8465-63a655ae5a5d"
      unitRef="usd">-59000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE4LTYtMS0xLTk0ODMx_1142d4f2-a651-46d3-a419-d6eadde8aac4"
      unitRef="usd">-42000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE5LTItMS0xLTk0ODMx_27d2d1c8-3d79-493d-b786-1b1be9db6938"
      unitRef="usd">16000000</bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities>
    <bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE5LTQtMS0xLTk0ODMx_94b74dd7-ac16-405e-b6c2-eb4cd505c414"
      unitRef="usd">1000000</bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities>
    <bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzE5LTYtMS0xLTk0ODMx_caad2782-1ec8-4623-9711-17ce631898ad"
      unitRef="usd">1000000</bhc:PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzIwLTItMS0xLTk0ODMx_25f5e648-3f34-45c5-968f-8599fe140475"
      unitRef="usd">41000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzIwLTQtMS0xLTk0ODMx_e02bf204-f3fd-4acd-8cc0-da4a39e5bcad"
      unitRef="usd">18000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzIwLTYtMS0xLTk0ODMx_565f4319-f060-467b-aeca-026c715e5a4c"
      unitRef="usd">-36000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzIyLTItMS0xLTk0ODMx_5d0f73e0-fd03-468b-abb4-b4ebc7615fa6"
      unitRef="usd">229000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzIyLTQtMS0xLTk0ODMx_cd482e1b-43ac-4b72-ab1a-12c285725e26"
      unitRef="usd">-170000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzIyLTYtMS0xLTk0ODMx_1a1fb927-6deb-42a8-84e5-f90a98142b9f"
      unitRef="usd">-39000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzIzLTItMS0xLTk0ODMx_f1377e9b-d276-4be7-9f71-e37bd65ded5d"
      unitRef="usd">16000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzIzLTQtMS0xLTk0ODMx_543645c6-42b5-46aa-ad2f-5f66c04aa1ef"
      unitRef="usd">77000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzIzLTYtMS0xLTk0ODMx_a58089ae-59c7-430b-a29b-eb431b2bf9d9"
      unitRef="usd">209000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzI0LTItMS0xLTk0ODMx_79bff121-be83-4d74-bc1c-0f8f3c92b807"
      unitRef="usd">4000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzI0LTQtMS0xLTk0ODMx_3f3fe161-0d71-4c4f-8fb1-c6c84371ccb2"
      unitRef="usd">-12000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzI0LTYtMS0xLTk0ODMx_eb5d2455-c94e-40f6-907e-62d84e9dbd45"
      unitRef="usd">-1000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzI1LTItMS0xLTk0ODMx_d5403375-7eb6-418c-a76f-d9d1dd5ad4de"
      unitRef="usd">121000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzI1LTQtMS0xLTk0ODMx_7b5123d6-0fbf-468d-872e-5a6d6a451014"
      unitRef="usd">-471000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzI1LTYtMS0xLTk0ODMx_97448d85-fa4a-4035-8d2d-3f57b4a6c591"
      unitRef="usd">-149000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzI2LTItMS0xLTk0ODMx_c604a17e-9ffb-48d2-ae7c-0c51919657df"
      unitRef="usd">1426000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzI2LTQtMS0xLTk0ODMx_fd950edb-0715-4b3b-853d-d7a114423b62"
      unitRef="usd">1111000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzI2LTYtMS0xLTk0ODMx_51560238-e7a2-4bd1-8a01-4c73ee581e42"
      unitRef="usd">1501000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzI4LTItMS0xLTk0ODMx_9918c02e-04d8-4ac5-9da9-610696f291e7"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzI4LTQtMS0xLTk0ODMx_05e1deeb-24f7-4d52-b88b-feffb95328cf"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzI4LTYtMS0xLTk0ODMx_7aaae4ee-d2ce-472b-b18f-3c74b5bb4cfa"
      unitRef="usd">180000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzI5LTItMS0xLTk0ODMx_8adb01ae-f0c5-445f-b320-6e7cbaf125e2"
      unitRef="usd">14000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzI5LTQtMS0xLTk0ODMx_e71a787e-a6b7-4584-843f-3b20f22790a1"
      unitRef="usd">7000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzI5LTYtMS0xLTk0ODMx_788e2357-b146-4441-828c-9634d8ee0140"
      unitRef="usd">8000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzMwLTItMS0xLTk0ODMx_f6f29cec-ea82-4bdd-aa6d-83fe7dcdfb65"
      unitRef="usd">269000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzMwLTQtMS0xLTk0ODMx_b0d0eb0a-be79-4a6a-b66d-b9c2f1c2996c"
      unitRef="usd">302000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzMwLTYtMS0xLTk0ODMx_b67fdf41-1663-4bab-8e90-6ca5d801f2f5"
      unitRef="usd">270000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzMxLTItMS0xLTk0ODMx_632c56c7-6c6b-4580-91eb-1e364b5654ad"
      unitRef="usd">19000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzMxLTQtMS0xLTk0ODMx_4fa9d07f-8bac-41c5-8738-adf62e7f6bba"
      unitRef="usd">4000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzMxLTYtMS0xLTk0ODMx_98ee0fd6-288a-4248-b875-7e00ba7159f3"
      unitRef="usd">16000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzMyLTItMS0xLTk0ODMx_55ac511f-a20d-4f65-a9d3-8d7984943e9a"
      unitRef="usd">15000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzMyLTQtMS0xLTk0ODMx_5acabd3e-a4fd-4069-bc92-5dd767f73338"
      unitRef="usd">8000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzMyLTYtMS0xLTk0ODMx_3e0cc5be-d8e6-4517-8d0e-5874238ad6a6"
      unitRef="usd">10000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzMzLTItMS0xLTk0ODMx_c5c9347f-1308-40a6-ae10-dad7e566f555"
      unitRef="usd">669000000</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzMzLTQtMS0xLTk0ODMx_61ec80c3-47ac-4625-bcfd-1ba365430355"
      unitRef="usd">21000000</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzMzLTYtMS0xLTk0ODMx_fcf152e3-9c1f-4cec-a4d4-0185445af825"
      unitRef="usd">45000000</us-gaap:ProceedsFromDivestitureOfBusinessesNetOfCashDivested>
    <bhc:InterestSettlementOnCrossCurrencySwaps
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzM0LTItMS0xLTk0ODMx_5a6eb238-045c-4a95-90b5-0df3c431a182"
      unitRef="usd">27000000</bhc:InterestSettlementOnCrossCurrencySwaps>
    <bhc:InterestSettlementOnCrossCurrencySwaps
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzM0LTQtMS0xLTk0ODMx_5fc83a47-6099-4c2b-861a-4fb613a79cd8"
      unitRef="usd">23000000</bhc:InterestSettlementOnCrossCurrencySwaps>
    <bhc:InterestSettlementOnCrossCurrencySwaps
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzM0LTYtMS0xLTk0ODMx_0f404b2d-1e7b-49bd-9af5-cbb87b5f28ef"
      unitRef="usd">0</bhc:InterestSettlementOnCrossCurrencySwaps>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzM1LTItMS0xLTk0ODMx_241c9d43-698d-4aba-a2f7-1887e6997ea8"
      unitRef="usd">409000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzM1LTQtMS0xLTk0ODMx_2153097b-46b4-499a-b36b-042724a1dfbe"
      unitRef="usd">-261000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzM1LTYtMS0xLTk0ODMx_d72c86f0-f15c-4ae5-8c98-230a21248c2e"
      unitRef="usd">-419000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzM3LTItMS0xLTk0ODMx_787e2bde-cbea-4690-b0ed-9d3048498cc9"
      unitRef="usd">2100000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzM3LTQtMS0xLTk0ODMx_f4f314c0-a006-4e82-94c2-8df7cec17c80"
      unitRef="usd">3455000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzM3LTYtMS0xLTk0ODMx_3e3633a4-3aaa-4861-8ce5-91ffda957530"
      unitRef="usd">5960000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzM4LTItMS0xLTk0ODMx_2a286964-15bc-45ef-b133-017f0ebbc362"
      unitRef="usd">3440000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzM4LTQtMS0xLTk0ODMx_112e4430-69f9-4ce9-aa60-395f6f95962c"
      unitRef="usd">5642000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzM4LTYtMS0xLTk0ODMx_404d491a-d44d-4869-88e9-48a86b0cc906"
      unitRef="usd">4406000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzM5LTItMS0xLTk0ODMx_2ad8cb49-2c1f-43e8-83f2-8ba20ca98def"
      unitRef="usd">0</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzM5LTQtMS0xLTk0ODMx_80240aec-8c67-4fe1-9f67-a95fdb4d0e55"
      unitRef="usd">1000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzM5LTYtMS0xLTk0ODMx_1284411a-c96c-4694-bd77-6e0378f2585e"
      unitRef="usd">12000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQwLTItMS0xLTk0ODMx_d4aeaf2a-c924-41df-9f54-9051308a34cd"
      unitRef="usd">0</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQwLTQtMS0xLTk0ODMx_e8ccbca7-a7a9-4495-99bd-50bd771778ea"
      unitRef="usd">1000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQwLTYtMS0xLTk0ODMx_f972a0f8-db39-48d6-b8c7-6133e847f934"
      unitRef="usd">12000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQxLTItMS0xLTk0ODMx_cad43166-9bde-4a1c-b7b3-18e320fce6fa"
      unitRef="usd">52000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQxLTQtMS0xLTk0ODMx_e69ccf24-9c70-4457-9c4a-6a3f2a9fefd4"
      unitRef="usd">30000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQxLTYtMS0xLTk0ODMx_5c1603e8-5792-4cb9-b9f4-2bcb4a81fdac"
      unitRef="usd">40000000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQyLTItMS0xLTk0ODMx_95080ca1-f571-4a73-9af6-4680c63143bd"
      unitRef="usd">83000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQyLTQtMS0xLTk0ODMx_dd4a0078-ec12-4940-938c-fe46119c0583"
      unitRef="usd">35000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQyLTYtMS0xLTk0ODMx_18d8589f-005f-45f8-9bc6-bae4bbfd96a7"
      unitRef="usd">35000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQzLTItMS0xLTk0ODMx_ca6c01b1-2670-4aa2-a3f6-c80a50a6c14a"
      unitRef="usd">48000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQzLTQtMS0xLTk0ODMx_651f2f5c-f1cf-47ae-a03c-7a57e58ba0c0"
      unitRef="usd">39000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQzLTYtMS0xLTk0ODMx_65d2c062-254c-42f6-9e6d-e3e0b808755c"
      unitRef="usd">28000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ0LTItMS0xLTk0ODMx_c2276e93-fee2-498f-a1e2-ab4bad9d5e56"
      unitRef="usd">10000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ0LTQtMS0xLTk0ODMx_5337c692-e652-4807-8c0a-6649ba3bd44a"
      unitRef="usd">-3000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ0LTYtMS0xLTk0ODMx_e34ae960-9c97-4a89-865d-30f0c97acf23"
      unitRef="usd">-8000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ1LTItMS0xLTk0ODMx_26711d70-90bc-433f-a01e-bb50448c4105"
      unitRef="usd">-1513000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ1LTQtMS0xLTk0ODMx_0c39831b-a059-4cdd-b02d-bd62d3343086"
      unitRef="usd">-2294000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ1LTYtMS0xLTk0ODMx_6ac63cf0-fe43-4a3c-877b-febe0608571d"
      unitRef="usd">1443000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ2LTItMS0xLTk0ODMx_07e50071-026f-471d-932d-07ed4ffe98ba"
      unitRef="usd">-19000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ2LTQtMS0xLTk0ODMx_257f3944-6557-4e7b-b12e-a0ce48c1c1d0"
      unitRef="usd">16000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ2LTYtMS0xLTk0ODMx_040cdda7-e140-4e77-96c5-46cc4afc3089"
      unitRef="usd">-4000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ3LTItMS0xLTk0ODMx_a0c8f20e-ba31-4ab0-97d9-5ac14a6e5202"
      unitRef="usd">303000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ3LTQtMS0xLTk0ODMx_a5de0651-3403-4def-a96e-01232c574bec"
      unitRef="usd">-1428000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ3LTYtMS0xLTk0ODMx_811fb20e-14cb-44a4-a15d-f3911904825a"
      unitRef="usd">2521000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ4LTItMS0xLTk0ODMx_fee9de61-fed7-4449-a88d-7ecd30c1f4bb"
      unitRef="usd">1816000000</bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits>
    <bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits
      contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ4LTQtMS0xLTk0ODMx_3c4ed8cc-79f6-4e47-836c-40f63365f521"
      unitRef="usd">3244000000</bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits>
    <bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits
      contextRef="i18439fe8345c481db53c486667ac6940_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ4LTYtMS0xLTk0ODMx_c138cf32-3a81-442b-aa9e-ba9ad7038adc"
      unitRef="usd">723000000</bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits>
    <bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ5LTItMS0xLTk0ODMx_ce86acb1-a91b-43a6-8ae7-b6a11b51b13a"
      unitRef="usd">2119000000</bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits>
    <bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ5LTQtMS0xLTk0ODMx_876da0b6-82fa-4b9b-acc9-488d5d17eb12"
      unitRef="usd">1816000000</bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits>
    <bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits
      contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzQ5LTYtMS0xLTk0ODMx_522f163a-df6a-43c7-bb23-6db3f9879fa9"
      unitRef="usd">3244000000</bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzUxLTItMS0xLTk0ODMx_9794ada4-cb09-4a10-b6ce-0db69830db03"
      unitRef="usd">582000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzUxLTQtMS0xLTk0ODMx_1389602c-657a-4ba2-ac09-06651910dbfb"
      unitRef="usd">605000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzUxLTYtMS0xLTk0ODMx_46b0b1d7-0994-4433-a37e-a30a55982050"
      unitRef="usd">3243000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <bhc:RestrictedCashAndOtherSettlementDepositsCurrent
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzUyLTItMS0xLTk0ODMx_5d847b4f-9a3b-488b-9256-128176ddb57c"
      unitRef="usd">1537000000</bhc:RestrictedCashAndOtherSettlementDepositsCurrent>
    <bhc:RestrictedCashAndOtherSettlementDepositsCurrent
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzUyLTQtMS0xLTk0ODMx_279d634b-1530-4bdf-a60a-68a6997d4407"
      unitRef="usd">1211000000</bhc:RestrictedCashAndOtherSettlementDepositsCurrent>
    <bhc:RestrictedCashAndOtherSettlementDepositsCurrent
      contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzUyLTYtMS0xLTk0ODMx_89df046e-ecd1-4af6-a0c6-9b0daa1f7e9f"
      unitRef="usd">1000000</bhc:RestrictedCashAndOtherSettlementDepositsCurrent>
    <bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzUzLTItMS0xLTk0ODMx_25e6d296-abe1-4334-81b5-f46816083858"
      unitRef="usd">2119000000</bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits>
    <bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzUzLTQtMS0xLTk0ODMx_d0234a40-5255-4702-993e-137669a6f110"
      unitRef="usd">1816000000</bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits>
    <bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits
      contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMDcvZnJhZzozN2NjMjc5MjBlOTY0OGJjODdiNDcxMjRkYzFiNDBiMi90YWJsZTowZThjYmU4NTZmODg0ZTk5YTllZjg5OTgwOTJkMDYwNy90YWJsZXJhbmdlOjBlOGNiZTg1NmY4ODRlOTlhOWVmODk5ODA5MmQwNjA3XzUzLTYtMS0xLTk0ODMx_eed12bca-89de-4c33-a8c3-bbf1fc4eb14d"
      unitRef="usd">3244000000</bhc:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits>
    <us-gaap:NatureOfOperations
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTMvZnJhZzplNzU5NWUwMGZiNmM0NjkzYmY3OGQ5NTg4ZWNiZjgyZi90ZXh0cmVnaW9uOmU3NTk1ZTAwZmI2YzQ2OTNiZjc4ZDk1ODhlY2JmODJmXzEwOTI_0b55899e-7683-47bb-8e97-9abebb3d4411">DESCRIPTION OF BUSINESSBausch Health Companies Inc. (the &#x201c;Company&#x201d;), formerly known as Valeant Pharmaceuticals International, Inc.,  is a multinational, specialty pharmaceutical and medical device company that develops, manufactures and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (&#x201c;OTC&#x201d;) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in approximately 100 countries.  Effective August 9, 2013, the Company continued from the federal jurisdiction of Canada to the Province of British Columbia, meaning that the Company became a company registered under the laws of the Province of British Columbia as if it had been incorporated under the laws of the Province of British Columbia. As a result of this continuance, the legal domicile of the Company became the Province of British Columbia, the Canada Business Corporations Act ceased to apply to the Company and the Company became subject to the British Columbia Business Corporations Act.</us-gaap:NatureOfOperations>
    <us-gaap:NumberOfCountriesInWhichEntityOperates
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTMvZnJhZzplNzU5NWUwMGZiNmM0NjkzYmY3OGQ5NTg4ZWNiZjgyZi90ZXh0cmVnaW9uOmU3NTk1ZTAwZmI2YzQ2OTNiZjc4ZDk1ODhlY2JmODJmXzUwNg_058d8c36-8e4f-4b59-9187-3c1474636c60"
      unitRef="country">100</us-gaap:NumberOfCountriesInWhichEntityOperates>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MjQy_fbf277de-b2ad-4ce9-8869-2144f0799866">SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation and Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Consolidated Financial Statements have been prepared by the Company in United&#160;States (&#x201c;U.S.&#x201d;) dollars and in accordance with U.S.&#160;generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;), applied on a consistent basis. The Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Separation of the Bausch + Lomb Eye-Health Business and Initial Public Offering of Solta Medical Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 6, 2020, the Company announced its intentions to separate its eye-health business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc. (the &#x201c;B+L Separation&#x201d;). On August 3, 2021, the Company announced its intentions to conduct an initial public offering  (&#x201c;IPO&#x201d;) of its aesthetic medical device business, Global Solta (the &#x201c;Solta IPO&#x201d;).  In January 2022, the Company completed the internal organizational design and structure of the new eye-health entity, Bausch + Lomb Corporation  (&#x201c;Bausch + Lomb&#x201d;), and the new Global Solta entity, Solta Medical Corporation  (&#x201c;Solta&#x201d;), as previously announced and aims to launch the B+L IPO and the Solta IPO when financial market conditions are favorable (and subject to receipt of regulatory, stock exchange and other approvals). Following the B+L IPO the Company expects to complete the separation of Bausch + Lomb after the expiry of customary lockups related to the B+L IPO and achievement of targeted debt leverage ratios, subject to the receipt of applicable shareholder and other necessary approvals. The B+L Separation and the proposed Solta IPO will establish three separate companies that include: (i) a fully integrated eye-health company which will consist of the Company&#x2019;s Bausch + Lomb Global Vision Care, Global Surgical, Global Consumer and Global Ophthalmic Pharmaceuticals businesses, (ii) a global provider of aesthetic medical devices which will consist of the Company&#x2019;s Solta business and (iii) a diversified pharmaceutical company which will include the Company&#x2019;s Salix, International (formerly International Rx), dentistry, neurology, medical dermatology and generics pharmaceutical businesses. These audited Consolidated Financial Statements do not include any adjustments to give effect to either the B+L Separation or the proposed Solta IPO.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Impacts of COVID-19 Pandemic&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unprecedented nature of the COVID-19 pandemic has, and continues to, adversely impact the global economy. The COVID-19 pandemic and the reactions of governments, private sector participants and the public in an effort to contain the spread of the COVID-19 virus and/or address its impacts have had significant direct and indirect effects on businesses and commerce. This includes, but is not limited to, disruption to supply chains, employee base and transactional activity, facility closures and production suspensions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent to which these events may continue to impact the Company's business, financial condition, cash flows and results of operations, in particular, will depend on future developments which are highly uncertain and many of which are outside the Company's control. Such developments include the availability and effectiveness of vaccines for the COVID-19 virus, COVID-19 vaccine immunization rates, the ultimate geographic spread and duration of the pandemic, the extent and duration of a resurgence of the COVID-19 virus and variant strains thereof, such as the delta and omicron variants, new information concerning the severity of the COVID-19 virus, the effectiveness and intensity of measures to contain the COVID-19 virus and the economic impact of the pandemic and the reactions to it. Such developments, among others, depending on their nature, duration and intensity, could have a significant adverse effect on the Company's business, financial condition, cash flows and results of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has been able to continue its operations with limited disruptions in supply and manufacturing. Although it is difficult to predict the broad macroeconomic effects that the COVID-19 pandemic will have on industries or individual companies, the Company has assessed the possible effects and outcomes of the pandemic on, among other things, its supply chain, customers and distributors, discounts and rebates, employee base, product sustainability, research and development efforts, product pipeline and consumer demand and currently believes that its estimates are reasonable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In preparing the Company's Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows.  The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include: provisions for product returns, rebates, chargebacks, discounts and allowances and distribution fees paid to certain wholesalers; useful lives of amortizable intangible assets and property, plant and equipment; expected future cash flows used in evaluating intangible assets for impairment, assessing compliance with debt covenants and making going concern assessments; reporting unit fair values for testing goodwill for impairment and allocating goodwill to new reporting unit structure on a relative fair value basis; provisions for loss contingencies; provisions for income taxes, uncertain tax positions and realizability of deferred tax assets; fair value of cross-currency swaps; fair value of foreign currency exchange contracts; and the recognition of the fair value of assets and liabilities acquired in a business combination, including the fair value of contingent consideration. Under certain product manufacturing and supply agreements, management uses information from the Company&#x2019;s commercialization counterparties to arrive at estimates for future returns, rebates and chargebacks. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#x2019;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#x2019;s Consolidated Financial Statements could be materially impacted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior year amounts to conform to the current year presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commencing in the first quarter of 2022, the Company operates in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International, (iv) Solta Medical and (v) Diversified Products. Prior to the first quarter of 2022, the Company operated in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International, (iv) Ortho Dermatologics and (v) Diversified Products. All segment revenues and profits for the periods presented have been recast to conform to the 2022 segment reporting structure. See Note 22, &#x201c;SEGMENT INFORMATION&#x201d; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisitions &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Consolidated Financial Statements after the date of acquisition.  Acquired in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&amp;amp;D has an alternative future use. If the acquired net assets do not constitute a business, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&amp;amp;D with no alternative future use is charged to expense at the acquisition&#160;date and any future contingent consideration is not recorded until it becomes probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair values of cash and cash equivalents, trade receivables, accounts payable and accrued liabilities approximate their carrying values due to their short maturity periods. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows or Monte Carlo Simulation (when appropriate) analyses and assessment of the probability of occurrence of potential future events. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting for changes in the fair value of a derivative instrument depends on whether the instrument has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Consolidated Statements of Operations during the current period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cross-currency swaps qualified for and had been designated as an accounting hedge of the foreign currency exposure of a net investment in a foreign operation and were remeasured at each reporting date to reflect changes in their fair values.  The fair value was determined via a mark-to-market analysis, using observable (Level&#160;2) inputs. These inputs included: (i)&#160;the foreign currency exchange spot rate between the euro and U.S. dollar, (ii)&#160;the interest rate yield curves in the euro and U.S. dollar and (iii)&#160;the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps is reported as a gain or loss in the Consolidated Statements of Comprehensive Loss as part of Foreign currency translation adjustment to the extent they are effective, and remain in Accumulated other comprehensive loss until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps was ineffective. The Company uses the spot method of assessing hedge effectiveness. The Company had elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as a reduction of Interest expense in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses foreign currency exchange contracts to economically hedge the foreign exchange exposure on certain of the Company&#x2019;s intercompany and third party balances. The Company's foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of cash in bank accounts and highly liquid investments with maturities of three months or less when&#160;purchased.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables, cross-currency swaps and foreign currency exchange contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company invests its excess cash in high-quality, money market instruments and term deposits with varying maturities, but typically less than three months.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash deposited at banks may exceed the amount of insurance provided on such deposits. Generally, these cash deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate such risks by spreading its risk across multiple counterparties and monitoring the risk profiles of these counterparties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s trade receivables primarily represent amounts due from wholesale distributors, retail pharmacies, government entities and group purchasing organizations. Outside of the U.S., concentrations of credit risk with respect to trade receivables, which are typically unsecured, are limited due to the number of customers using the Company&#x2019;s products, as well as their dispersion across many different geographic regions. The Company performs periodic credit evaluations of customers and does not require collateral. The Company monitors economic conditions, including volatility associated with international economies, and related impacts on the relevant financial markets and its business, especially in light of sovereign credit issues. The credit and economic conditions within Argentina, Brazil, Egypt, Greece, among other members of the European Union, Turkey, Ukraine and Venezuela have been weak in recent years. These conditions have increased, and may continue to increase, the average length of time that it takes to collect on the Company&#x2019;s trade receivables outstanding in these countries. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the Company&#x2019;s three largest U.S. wholesaler customers accounted for approximately 44% of net trade receivables. In addition, as of December 31, 2021 and 2020, the Company&#x2019;s net trade receivable balance from Argentina, Brazil, Egypt, Greece, Serbia, South Africa, Turkey, Ukraine, Venezuela and Vietnam amounted to $78 million and $166&#160;million, respectively, the majority of which is current or less than 90 days past due. The portion of the net trade receivable from these countries that is past due more than 90&#160;days amounted to $2 million, as of December 31, 2021, a portion of which is comprised of public hospitals.  Based on an analysis of credit risk, including an analysis of bad debt &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;experience and assessment of historical payment patterns for such customers, the Company has established a reserve covering more than half of the balance past due more than 90 days for such countries. Over the three-year period ended December&#160;31, 2021, the Company has not experienced any material losses from uncollectible accounts in excess of the established reserves.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not enter into financial instruments for trading or speculative purposes. Further, the Company has a policy of only entering into contracts with parties that have at least an investment grade credit rating. The Company enters into cross-currency swaps and foreign currency exchange contracts with high credit quality financial institutions. The counter-parties to the Company's cross-currency swaps and foreign currency exchange contracts are major financial institutions, and there is no significant concentration of exposure with any one counter-party. To date, no counterparty has failed to meet its obligations to the Company and management believes the risk of loss associated with these contracts is remote.  See Note 5, &#x201c;FAIR VALUE MEASUREMENTS&#x201d; for additional details regarding the Company's cross-currency swaps and foreign currency exchange contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.&#160; Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be&#160;collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses. Allowance for credit losses were $35 million, $39 million and $48&#160;million as of December 31, 2021, 2020 and 2019, respectively. The activity in the allowance for credit losses for trade receivables for the years 2021, 2020 and 2019 is as follows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.199%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retrospective effect of application of new accounting standard&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-offs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories comprise raw materials, work in process and finished goods, which are valued at the lower of cost or net realizable value, on a first-in, first-out basis. The cost value for work in process and finished goods inventories includes materials, direct labor and an allocation of overheads. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on&#160;hand.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are reported at cost, less accumulated depreciation. Costs incurred on assets under construction are capitalized as construction in progress. Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful&#160;lives: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15 - 30 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 40 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;-&#160;20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;-&#160;10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment on operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser of term of lease or 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reported at cost, less accumulated amortization and impairments. Intangible assets with finite lives are amortized over their estimated useful lives. Amortization is calculated primarily using the straight-line method based on the following estimated useful&#160;lives:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4 - 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 - 9 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Out-licensed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8 - 9 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Divestitures of Products&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net proceeds on the divestiture of products and the carrying amount of the related assets is recorded as a gain/loss on sale within Other expense, net. Any contingent payments that are potentially due to the Company as a result of these divestitures are recorded when realizable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IPR&amp;amp;D &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of IPR&amp;amp;D acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset will be assigned a useful life and&#160;amortized. Acquired IPR&amp;amp;D assets are tested for impairment at least annually or when triggering events are identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of an acquired IPR&amp;amp;D intangible asset is typically determined using an income approach. This approach starts with a forecast of the net cash flows expected to be generated by the asset over its estimated useful life. The net cash flows reflect the asset&#x2019;s stage of completion, the probability of technical success, the projected costs to complete, expected market competition and an assessment of the asset&#x2019;s life-cycle. The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the expected cash flow&#160;streams.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.  If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset, which include the amount and timing of the projected future cash flows. If the expected undiscounted cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash&#160;flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets, which includes acquired IPR&amp;amp;D and the corporate trademark acquired in the acquisition of Bausch &amp;amp; Lomb Holdings Incorporated (the &#x2018;&#x2018;B&amp;amp;L Trademark&#x2019;&#x2019;), are tested for impairment annually or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based on a comparison of the fair value of the asset to its carrying value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is recorded with the acquisition of a business and is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment at least annually as of October 1st at the reporting unit level. Goodwill impairment is measured as the amount by which a reporting unit's carrying value exceeds its fair value. A reporting unit is the same as, or one level below, an operating segment. A&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n entity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is permitted to first assess qualitatively whether it is necessary to perform a quantitative impairment test for any of its reporting units. The quantitative impairment test is required only when the Company concludes that it is more likely than not that a reporting unit&#x2019;s fair value is less than its carrying amount. In evaluating whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company considers the totality of all relevant events or circumstances that affect the fair value or carrying amount of a reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An interim goodwill impairment test in advance of the annual impairment assessment may be required if events occur that indicate an impairment might be present. For example, a substantial decline in the Company&#x2019;s market capitalization, changes in reportable segments, unexpected adverse business conditions, economic factors and unanticipated competitive activities may signal that an interim impairment test is needed. Accordingly, among other factors, the Company monitors &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;changes in its share price between annual impairment tests. The Company considers a decline in its share price that corresponds to an overall deterioration in stock market conditions to be less of an indicator of goodwill impairment than a unilateral decline in its share price reflecting adverse changes in its underlying operating performance, cash flows, financial condition and/or liquidity. In the event that the Company&#x2019;s market capitalization does decline below its book value, the Company would consider the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. The Company believes that short-term fluctuations in share prices may not necessarily reflect underlying values.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt discounts, premiums and issuance costs are presented in the Consolidated Balance Sheets as a direct deduction from or addition to the carrying amount of the related debt and are amortized or accreted, using the effective interest method, as interest expense over the contractual lives of the related credit facilities or notes. Deferred financing costs associated with revolving credit facility arrangements are included in the balances of Prepaid expenses and other current assets and Other non-current assets in the Consolidated Balance Sheets and are amortized as interest expense over the contractual life of the related revolving credit facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities of the Company&#x2019;s foreign operations having a functional currency other than the U.S.&#160;dollar are translated into U.S.&#160;dollars at the exchange rate prevailing at the balance sheet date, and at the average exchange rate for the reporting period for revenue and expense accounts. The cumulative foreign currency translation adjustment is recorded as a component of Accumulated other comprehensive loss in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency exchange gains and losses on transactions occurring in a currency other than an operation&#x2019;s functional currency are recognized as a component of Foreign exchange and other in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenues are primarily generated from product sales, primarily in the therapeutic areas of eye-health, gastroenterology  (&#x201c;GI&#x201d;) and dermatology that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 22, &#x201c;SEGMENT INFORMATION&#x201d; for the disaggregation of revenues which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when the customer obtains control of promised goods or services and in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services.  To achieve this core principle, the Company applies the five-step revenue model to contracts within its scope: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A contract with the Company&#x2019;s customers exists for each product sale.  Where a contract with a customer contains more than one performance obligation, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The transaction price is adjusted for variable consideration which is discussed below.  The Company generally recognizes revenue for product sales at a point in time, when the customer obtains control of the products.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160; The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#x2019;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers.  Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the activity and ending balances of the Company&#x2019;s variable consideration provisions the years 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;br/&gt;and&lt;br/&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Distribution&lt;br/&gt;Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balance, January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,909)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(593)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $36 million and $32 million as of December 31, 2021 and 2020, respectively, which are reflected as a reduction of Trade accounts receivable, net in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company's products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis.  This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#x2019;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period.  The Company applies this method consistently for contracts with similar characteristics.  The following describes the major sources of variable consideration in the Company&#x2019;s customer arrangements and the methodology, estimates and judgments applied to estimate each type of variable consideration.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash discounts are offered for prompt payment and allowances for volume purchases. Provisions for cash discounts and allowances are estimated at the time of sale and recorded as direct reductions to trade receivables and revenue. Management estimates the provisions for cash discounts and allowances based on contractual sales terms with customers, an analysis of unpaid invoices and historical payment experience. Estimated cash discounts and allowances have historically been predictable and less subjective, due to the limited number of assumptions involved, the consistency of historical experience and the fact that these amounts are generally settled within one month of incurring the&#160;liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with industry practice, customers are generally allowed to return a product within a specified period of time before and after its expiration date, excluding European businesses which generally do not provide a right of return. The returns provision is estimated utilizing historical sales and return rates over the period during which customers have a right of return, taking into account available information on competitive products and contract changes. The information utilized to estimate the returns provision includes: (i) historical return and exchange levels, (ii) external data with respect to inventory levels in the wholesale distribution channel, (iii) external data with respect to prescription demand for products, (iv) remaining shelf lives of products at the date of sale and (v) estimated returns liability to be processed by year of sale based on an analysis of lot information related to actual historical returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the estimate for returns, management is required to make certain assumptions regarding the timing of the introduction of new products and the potential of these products to capture market share. In addition, certain assumptions with respect to the extent and pattern of decline associated with generic competition are necessary. These assumptions are formulated using market data for similar products, past experience and other available information.  These assumptions are continually reassessed, and changes to the estimates and assumptions are made as new information becomes available. A change of 1% in the estimated return rates would have impacted the Company&#x2019;s pre-tax earnings by approximately $81 million for the year 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimate for returns may be impacted by a number of factors, but the principal factor relates to the inventory levels in the distribution channel. When management becomes aware of an increase in such inventory levels, it considers whether the increase may be temporary or other-than-temporary. Temporary increases in wholesaler inventory levels will not warrant revision to the provision for returns. Other-than-temporary increases in wholesaler inventory levels, however, may be an indication that future product returns could be higher than originally anticipated, and, as a result, estimates for returns may need to be adjusted. Factors that suggest increases in wholesaler inventory levels are temporary include: (i) recently implemented or announced price increases for certain products, (ii) new product launches or expanded indications for existing products and (iii) timing of purchases by wholesale customers. Conversely, factors that suggest increases in wholesaler inventory levels are other-than-temporary include: (i) declining sales trends based on prescription demand, (ii) introduction of new products or generic competition, (iii) increasing price competition from generic competitors and (iv) changes to the U.S.&#160;National Drug Codes (&#x201c;NDC&#x201d;) of products.  Changes in the NDC of products could result in a period of higher returns related to products with the old NDC, as U.S.&#160;customers generally permit only one NDC per product for identification and tracking within their inventory systems.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Over the last several years, the Company increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving sales return experience, primarily related to branded and generic products. Sales return provisions for 2021 and 2020 were $131&#160;million and $120&#160;million, respectively, and includes reductions in variable consideration for sales return provisions related to past sales of approximately $28 million and $38 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rebates and Chargebacks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales made under governmental and managed-care pricing programs in the U.S. are subject to rebates.&#160; The Company participates in state government-managed Medicaid programs, as well as certain other qualifying federal and state government programs whereby rebates are provided to participating government entities. Medicaid rebates are generally billed 45 days to 270&#160;days after the quarter in which the product is dispensed to the Medicaid participant.  As a result, the Medicaid rebate reserve includes an estimate of outstanding claims for end-customer sales that occurred, but for which the related claim has not been billed and/or paid, and an estimate for future claims that will be made when inventory in the distribution channel is sold through to plan participants. The calculation of the Medicaid rebate reserve also requires other estimates, such as estimates of sales mix, to determine which sales are subject to rebates and the amount of such rebates. A change of 1% in the estimated rates used in the Medicaid rebate reserve would have impacted the Company&#x2019;s pre-tax earnings by approximately $76 million for 2021. Quarterly, the Medicaid rebate reserve is adjusted based on actual claims paid. Due to the delay in billing, adjustments to actual claims paid may incorporate revisions of that reserve for several periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Managed Care rebates relate to contractual agreements to sell products to managed care organizations and pharmacy benefit managers at contractual rebate percentages in exchange for volume and/or market&#160;share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks relate to contractual agreements to sell products to government agencies, group purchasing organizations and other indirect customers at contractual prices that are lower than the list prices the Company charges wholesalers. When these group purchasing organizations or other indirect customers purchase products through wholesalers at these reduced prices, the wholesaler charges the Company for the difference between the prices they paid the Company and the prices at which they sold the products to the indirect customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In estimating provisions for rebates and chargebacks, management considers relevant statutes with respect to governmental pricing programs and contractual sales terms with managed-care providers and group purchasing organizations. Management estimates the amount of product sales subject to these programs based on historical utilization levels. Changes in the level of utilization of products through private or public benefit plans and group purchasing organizations will affect the amount of rebates and chargebacks that the Company is obligated to pay. Management continually updates these factors based on new contractual or statutory requirements, and any significant changes in sales trends that may impact the percentage of products subject to rebates or&#160;chargebacks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of Managed Care, Medicaid and other rebates and chargebacks has become more significant as a result of a combination of deeper discounts implemented in each of the last three years, changes in the Company&#x2019;s product portfolio due to recent acquisitions and increased Medicaid utilization due to expansion of government funding for these programs.&#160;Management&#x2019;s estimate for rebates and chargebacks may be impacted by a number of factors, but the principal factor relates to the level of inventory in the distribution channel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rebate provisions are based on factors such as timing and terms of plans under contract, time to process rebates, product pricing, sales volumes, amount of inventory in the distribution channel and prescription trends. Adjustments to actual for the years 2021 and 2020 were not material to the Company&#x2019;s revenues or earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient Co-Pay Assistance programs, Consumer Rebates and Loyalty Programs are rebates offered on many of the Company&#x2019;s products.  Patient Co-Pay Assistance Programs are patient discount programs offered in the form of coupon cards or point of sale discounts, with which patients receive certain discounts off their prescription at participating pharmacies, as defined by the specific product program. An accrual for these programs is established, equal to management&#x2019;s estimate of the discount, rebate and loyalty incentives attributable to a sale.  That estimate is based on historical experience and other relevant factors. The accrual is adjusted throughout each quarter based on actual experience and changes in other factors, if any.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distribution Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sells products primarily to wholesalers, and in some instances to large pharmacy chains such as CVS and Walmart.  The Company has Distribution Services Agreements  (&#x201c;DSAs&#x201d;) with several large wholesale customers such as McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Specialty.  Under the DSAs, the wholesalers agree to provide services, and the Company pays the contracted DSA distribution service fees for these services based on product volumes.  Additionally, price appreciation credits are generated when the Company increases a product&#x2019;s wholesaler acquisition cost (&#x201c;WAC&#x201d;) under contracts with certain wholesalers. Under such contracts, the Company is entitled to credits from such wholesalers for the impact of that WAC increase on inventory currently on hand at the wholesalers. Such credits are offset against the total distribution service fees paid to each such wholesaler. The variable consideration associated with price appreciation credits is reflected in the transaction price of products sold when it is determined to be probable that a significant reversal will not occur. Included as a reduction of current period provisions for Distribution Fees in the table above are price appreciation credits of $17 million and $15 million for the years 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract Assets and Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales Commissions &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales commissions are generally attributed to periods shorter than one year and therefore are expensed when incurred. Sales commissions are included in selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financing Component&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected not to adjust consideration for the effects of a significant financing component when the period between the transfer of a promised good or service to the customer and when the customer pays for that good or service will be one year or less. The Company's global payment terms are generally between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzM5OTI3_716494a0-facf-44b6-8b49-d8fd0a7992d6"&gt;thirty&lt;/span&gt; to ninety days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases certain facilities, vehicles and equipment principally under multi-year agreements generally having a lease term of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzQwMDc5_7eac39f6-be77-4d3e-9e6c-f409097e05ab"&gt;one&lt;/span&gt; to twenty years, some of which include termination options and options to extend the lease term from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzQwMTcz_d3eef5e1-5571-4a30-b1f7-7d9902542a6b"&gt;one&lt;/span&gt; to five years or on a month-to-month basis. The Company includes options that are reasonably certain to be exercised as part of the lease term. The Company may negotiate termination clauses in anticipation of changes in market conditions but generally, these termination options are not exercised. Certain lease agreements also include variable payments that are dependent on usage or may vary month-to-month such as insurance, taxes and maintenance costs. None of the Company's lease agreements contain material residual value guarantees or material restrictive covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to record a right-of-use asset and corresponding lease liability, equal to the present value of the lease payments at the commencement date of each lease. For all asset classes, in determining future lease payments, the Company has elected to aggregate lease components, such as payments for rent, taxes and insurance costs with non-lease components such as maintenance costs, and account for these payments as a single lease component. In limited &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;circumstances, when the information necessary to determine the rate implicit in a lease is available, the present value of the lease payments is determined using the rate implicit in that lease. If the information necessary to determine the rate implicit in a lease is not available, the Company uses its incremental borrowing rate at the commencement of the lease, which represents the rate of interest that the Company would incur to borrow on a collateralized basis over a similar term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All leases must be classified as either an operating lease or finance lease. The classification is determined based on whether substantive control has been transferred to the lessee.  The classification governs the pattern of lease expense recognition. For leases classified as operating leases, total lease expense over the term of the lease is equal to the undiscounted payments due in accordance with the lease arrangement. Fixed lease expense is recognized periodically on a straight-line basis over the term of each lease and includes: (i) imputed interest during the period on the lease liability determined using the effective interest rate method plus (ii) amortization of the right-of-use asset for that period. Amortization of the right-of-use asset during the period is calculated as the difference between the straight-line expense and the imputed interest on the lease liability for that period. Variable lease expense is recognized when the achievement of the specific target is considered probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs related to internal research and development programs, including costs associated with the development of acquired IPR&amp;amp;D, are expensed as goods are delivered or services are performed. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Milestone payments made to third parties before a product receives regulatory approval, but after the milestone is determined to be probable, are expensed and included in Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from third parties as reimbursement of development activities conducted under certain research and development arrangements are recognized as a reduction of Research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Costs &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legal fees and other costs related to litigation and other legal proceedings or services are expensed as incurred and are included in Selling, general and administrative expenses. Certain legal costs associated with acquisitions are included in Acquisition-related costs and certain legal costs associated with divestitures, legal settlements and other business development activities are included in Litigation and other matters or Net gain on sales of assets within Other expense (income), net, as appropriate. Legal costs expensed are reported net of expected insurance recoveries. A claim for insurance recovery is recognized when realization becomes probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Advertising Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Advertising costs comprise product samples, print media, promotional materials and television advertising and are expensed on the first use of the advertisement. Included in Selling, general and administrative expenses are advertising costs of $515 million, $451 million and $544 million, for 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Share-Based Compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes all share-based payments to employees, including grants of employee stock options and restricted share units (&#x201c;RSUs&#x201d;), at estimated fair value. The Company amortizes the fair value of stock option or RSU grants on a straight-line basis over the requisite service period of the individual stock option or RSU grant, which generally equals the vesting period. Stock option and RSU forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Share-based compensation is recorded in Research and development expenses and Selling, general and administrative expenses, as&#160;appropriate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisition-Related Contingent Consideration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquisition-related contingent consideration, which primarily consists of potential milestone payments and royalty obligations, is recorded in the Consolidated Balance Sheets at its acquisition date estimated fair value, in accordance with the acquisition method of accounting. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the Consolidated Statements of Operations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level&#160;3 measurement as defined in fair value measurement accounting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Interest Expense &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense includes standby fees, the amortization of debt discounts and deferred financing costs, accretion of debt premiums and the amortization of amounts excluded from the assessment of effectiveness related to the Company's cross-currency swaps. Interest costs are expensed as incurred, except to the extent such interest is related to construction in progress, in which case interest is capitalized. Capitalized interest related to construction in progress as of December 31, 2021 and 2020 was $60 million and $45&#160;million, respectively, and is included in Property, plant and equipment, net. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the temporary differences between the financial statement and income tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. A valuation allowance is provided for the portion of deferred tax assets that is more likely than not to remain unrealized. Deferred tax assets and liabilities are measured using enacted tax rates and&#160;laws.  Deferred tax assets for outside basis differences in investments in subsidiaries are only recognized if the difference will be realized in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax benefit from an uncertain tax position is recognized only if it is more likely than not that the tax position will be sustained upon examination by the appropriate taxing authority, based on the technical merits of the position. The tax benefits recognized from such position are measured based on the amount for which there is a greater than 50% likelihood of being realized upon settlement. Liabilities associated with uncertain tax positions are classified as long-term unless expected to be paid within one year. Interest and penalties related to uncertain tax positions, if any, are recorded in the provision for income taxes and classified with the related liability on the consolidated balance&#160;sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Loss Per Share Attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period. Diluted loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period after giving effect to dilutive potential common shares for stock options and RSUs, determined using the treasury stock&#160;method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss comprises Net loss and Other comprehensive (loss) income. Other comprehensive (loss) income includes items such as foreign currency translation adjustments, unrealized holding gains and losses on available-for-sale and other investments and certain pension and other postretirement benefit plan adjustments. Accumulated other comprehensive loss is recorded as a component of shareholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingencies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company is subject to loss contingencies, such as claims and assessments arising from litigation and other legal proceedings, contractual indemnities, product and environmental liabilities and tax matters. Accruals for loss contingencies are recorded when the Company determines that it is both probable that a liability has been incurred and the amount of loss can be reasonably estimated. If the estimate of the amount of the loss is a range and some amount within the range appears to be a better estimate than any other amount within the range, that amount is accrued as a liability. If no amount within the range is a better estimate than any other amount, the minimum amount of the range is accrued as a&#160;liability. These accruals are adjusted periodically as assessments change or additional information becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If no accrual is made for a loss contingency because the amount of loss cannot be reasonably estimated, the Company will disclose contingent liabilities when there is at least a reasonable possibility that a loss or an additional loss may have been incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employee Benefit Plans &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors various retirement and pension plans, including defined benefit pension plans, defined contribution plans and a participatory defined benefit postretirement plan. The determination of defined benefit pension and postretirement plan obligations and their associated expenses requires the use of actuarial valuations to estimate the benefits employees earn while working, as well as the present value of those benefits. Net actuarial gains and losses that exceed 10 percent of the greater of the plan&#x2019;s projected benefit obligations or the market-related value of assets are amortized to earnings over the shorter of the estimated average future service period of the plan participants (or the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;estimated average future lifetime of the plan participants if the majority of plan participants are inactive) or the period until any anticipated final plan settlements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adoption of New&#160;Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board  (&#x201c;FASB&#x201d;) issued guidance on the impairment of financial instruments requiring an impairment model based on expected losses rather than incurred losses. Under this guidance, an entity recognizes as an allowance its estimate of expected credit losses.  The guidance was effective for the Company beginning January 1, 2020 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit, which resulted in an increase to Accumulated deficit of less than $1&#160;million. The application of this guidance did not have a material effect on the Company's results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued guidance modifying the disclosure requirements for fair value measurement.  The guidance was effective for the Company beginning January 1, 2020. The application of this guidance did not have a material effect on the Company's disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued guidance modifying the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans.  The guidance was effective for annual periods ending after December 15, 2020. The application of this guidance did not have a material effect on the Company's disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.&#160; The guidance is effective for the Company beginning with annual periods beginning January 1, 2021.&#160; The application of this guidance did not have a material effect on the Company's financial position, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued guidance providing optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform.&#160; Optional expedients are provided for contract modification accounting within the areas of receivables, debt, leases, derivatives and hedging.&#160;The optional amendments are effective for all entities as of March 12, 2020, through December 31, 2022. During 2020 and 2021, the Company has not entered into any contract modifications in which the optional expedients were applied.&#160; However, if prior to December 31, 2022, the Company enters into a contract modification in which the optional expedients are applied, the Company will evaluate the impact of adoption of this guidance on its financial position, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MDI5_10cfbb5c-4ee0-4d3a-a194-b0847ff50de6">Basis of Presentation and Use of Estimates The Consolidated Financial Statements have been prepared by the Company in United&#160;States (&#x201c;U.S.&#x201d;) dollars and in accordance with U.S.&#160;generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;), applied on a consistent basis. The Consolidated Financial Statements include the accounts of the Company and those of its subsidiaries and any variable interest entities for which the Company is the primary beneficiary. All intercompany transactions and balances have been eliminated.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <bhc:BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzE3ODk_053dea0b-63c8-4891-947b-9170c7759599"
      unitRef="company">3</bhc:BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished>
    <us-gaap:UseOfEstimates
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MjE2_b5505187-2963-435a-b1e1-0f925d99a097">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In preparing the Company's Consolidated Financial Statements, management is required to make estimates and assumptions. This includes estimates and assumptions regarding the nature, timing and extent of the impacts that the COVID-19 pandemic will have on its operations and cash flows.  The estimates and assumptions used by the Company affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates made by management include: provisions for product returns, rebates, chargebacks, discounts and allowances and distribution fees paid to certain wholesalers; useful lives of amortizable intangible assets and property, plant and equipment; expected future cash flows used in evaluating intangible assets for impairment, assessing compliance with debt covenants and making going concern assessments; reporting unit fair values for testing goodwill for impairment and allocating goodwill to new reporting unit structure on a relative fair value basis; provisions for loss contingencies; provisions for income taxes, uncertain tax positions and realizability of deferred tax assets; fair value of cross-currency swaps; fair value of foreign currency exchange contracts; and the recognition of the fair value of assets and liabilities acquired in a business combination, including the fair value of contingent consideration. Under certain product manufacturing and supply agreements, management uses information from the Company&#x2019;s commercialization counterparties to arrive at estimates for future returns, rebates and chargebacks. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an ongoing basis, management reviews its estimates to ensure that these estimates appropriately reflect changes in the Company&#x2019;s business and new information as it becomes available. If historical experience and other factors used by management to make these estimates do not reasonably reflect future activity, the Company&#x2019;s Consolidated Financial Statements could be materially impacted.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MTk3_398c7778-029b-49f5-af48-4e5431fd5510">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to prior year amounts to conform to the current year presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commencing in the first quarter of 2022, the Company operates in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International, (iv) Solta Medical and (v) Diversified Products. Prior to the first quarter of 2022, the Company operated in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International, (iv) Ortho Dermatologics and (v) Diversified Products. All segment revenues and profits for the periods presented have been recast to conform to the 2022 segment reporting structure. See Note 22, &#x201c;SEGMENT INFORMATION&#x201d; for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MDI0_9d4eb89c-fd3e-4a4e-be74-666a7749c6b8">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisitions &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Acquired businesses are accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recorded at fair value, with limited exceptions. Transaction costs and costs to restructure the acquired company are expensed as incurred. The operating results of the acquired business are reflected in the Consolidated Financial Statements after the date of acquisition.  Acquired in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) is recognized at fair value and initially characterized as an indefinite-lived intangible asset, irrespective of whether the acquired IPR&amp;amp;D has an alternative future use. If the acquired net assets do not constitute a business, the transaction is accounted for as an asset acquisition and no goodwill is recognized. In an asset acquisition, the amount allocated to acquired IPR&amp;amp;D with no alternative future use is charged to expense at the acquisition&#160;date and any future contingent consideration is not recorded until it becomes probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisition-Related Contingent Consideration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquisition-related contingent consideration, which primarily consists of potential milestone payments and royalty obligations, is recorded in the Consolidated Balance Sheets at its acquisition date estimated fair value, in accordance with the acquisition method of accounting. The fair value of the acquisition-related contingent consideration is remeasured each reporting period, with changes in fair value recorded in the Consolidated Statements of Operations. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level&#160;3 measurement as defined in fair value measurement accounting.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MjI5_a6737dc1-1f73-47c5-8f2e-8ad2cb91eb95">Fair Value of Financial InstrumentsThe estimated fair values of cash and cash equivalents, trade receivables, accounts payable and accrued liabilities approximate their carrying values due to their short maturity periods. The fair value of acquisition-related contingent consideration is based on estimated discounted future cash flows or Monte Carlo Simulation (when appropriate) analyses and assessment of the probability of occurrence of potential future events.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MjMy_589e8572-89fe-4b32-8f82-93db23a6f145">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting for changes in the fair value of a derivative instrument depends on whether the instrument has been designated and qualifies as part of a hedging relationship and on the type of hedging relationship. For derivative instruments designated and qualifying as hedging instruments, the hedging instrument must be designated, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of the foreign currency exposure of a net investment in a foreign operation. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the Consolidated Statements of Operations during the current period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cross-currency swaps qualified for and had been designated as an accounting hedge of the foreign currency exposure of a net investment in a foreign operation and were remeasured at each reporting date to reflect changes in their fair values.  The fair value was determined via a mark-to-market analysis, using observable (Level&#160;2) inputs. These inputs included: (i)&#160;the foreign currency exchange spot rate between the euro and U.S. dollar, (ii)&#160;the interest rate yield curves in the euro and U.S. dollar and (iii)&#160;the credit risk rating for each applicable counterparty. The net change in fair value of cross-currency swaps is reported as a gain or loss in the Consolidated Statements of Comprehensive Loss as part of Foreign currency translation adjustment to the extent they are effective, and remain in Accumulated other comprehensive loss until either the sale or complete, or substantially complete, liquidation of the subsidiary. No portion of the cross-currency swaps was ineffective. The Company uses the spot method of assessing hedge effectiveness. The Company had elected to amortize amounts excluded from the assessment of effectiveness over the term of its cross-currency swaps as a reduction of Interest expense in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;The Company uses foreign currency exchange contracts to economically hedge the foreign exchange exposure on certain of the Company&#x2019;s intercompany and third party balances. The Company's foreign currency exchange contracts are remeasured at each reporting date to reflect changes in their fair values determined using forward rates, which are observable market inputs, multiplied by the notional amount. These contracts have not been designated as an accounting hedge, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Operations as part of Foreign exchange and other.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MTk2_42ded05f-c867-46ec-bd69-24ab9d85fda0">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of cash in bank accounts and highly liquid investments with maturities of three months or less when&#160;purchased.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <bhc:MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzEwNjAy_6739ce57-4ad6-4ffb-8f21-523438a0f96c">P3M</bhc:MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MTkx_86c91f11-6c69-45e7-9e9c-cd63fb080a6d">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, trade receivables, cross-currency swaps and foreign currency exchange contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company invests its excess cash in high-quality, money market instruments and term deposits with varying maturities, but typically less than three months.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash deposited at banks may exceed the amount of insurance provided on such deposits. Generally, these cash deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate such risks by spreading its risk across multiple counterparties and monitoring the risk profiles of these counterparties.&lt;/span&gt;&lt;/div&gt;The Company&#x2019;s trade receivables primarily represent amounts due from wholesale distributors, retail pharmacies, government entities and group purchasing organizations. Outside of the U.S., concentrations of credit risk with respect to trade receivables, which are typically unsecured, are limited due to the number of customers using the Company&#x2019;s products, as well as their dispersion across many different geographic regions. The Company performs periodic credit evaluations of customers and does not require collateral. The Company monitors economic conditions, including volatility associated with international economies, and related impacts on the relevant financial markets and its business, especially in light of sovereign credit issues. The credit and economic conditions within Argentina, Brazil, Egypt, Greece, among other members of the European Union, Turkey, Ukraine and Venezuela have been weak in recent years.</us-gaap:ConcentrationRiskCreditRisk>
    <bhc:MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzExMDYy_0732fe1d-3269-469f-8089-6a8a92678e9d">P3M</bhc:MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents>
    <bhc:NumberOfLargestWholesaleCustomers
      contextRef="ia62208ce4dc846f1ba9f111c31435582_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzEyNjAx_3cd2da7f-1d75-430d-9f21-4dad516d1280"
      unitRef="wholesaler">3</bhc:NumberOfLargestWholesaleCustomers>
    <bhc:ConcentrationRiskPercentageofNetTradeReceivables
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzEyNjY2_27977363-37b8-4886-a702-d100dd3799ea"
      unitRef="number">0.44</bhc:ConcentrationRiskPercentageofNetTradeReceivables>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="iedf6d2b80161425e9e29520cc751a2f1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzEyODY3_4249c8b8-df21-40c8-87e6-2784431264dd"
      unitRef="usd">78000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic0a435d217a0443898aeb95a619d60b2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzEyODc0_88a7500d-0b67-43d4-a72e-1408c38bcbe5"
      unitRef="usd">166000000</us-gaap:AccountsReceivableNetCurrent>
    <bhc:PastDuePeriodForAccountsReceivableToBeNegligible
      contextRef="i00e7a4ba81a046a790930dda41d3956b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzEyOTM4_0ca3c985-a7fa-4a84-8a59-eb3d6a65add8">P90D</bhc:PastDuePeriodForAccountsReceivableToBeNegligible>
    <bhc:PeriodReceivableOutstanding
      contextRef="i00e7a4ba81a046a790930dda41d3956b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzEzMDQ0_b5eb3a06-be2d-4908-8938-916c08285eb2">P90D</bhc:PeriodReceivableOutstanding>
    <bhc:TradeReceivableNetPortionPastDue
      contextRef="iedf6d2b80161425e9e29520cc751a2f1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzEzMDY0_6d408324-220c-4e05-a664-810a5b564e2e"
      unitRef="usd">2000000</bhc:TradeReceivableNetPortionPastDue>
    <bhc:PeriodReceivableOutstanding
      contextRef="i00e7a4ba81a046a790930dda41d3956b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzEzMzcw_d322a533-ad0d-497e-aa79-70b804c65d55">P90D</bhc:PeriodReceivableOutstanding>
    <us-gaap:FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MjM1_088e83b0-b356-4216-a13a-ba1a9f86b26d">Allowance for Credit LossesAn allowance is maintained for potential credit losses. The Company estimates the current expected credit loss on its receivables based on various factors, including historical credit loss experience, customer credit worthiness, value of collaterals (if any), and any relevant current and reasonably supportable future economic factors.&#160; Additionally, the Company generally estimates the expected credit loss on a pool basis when customers are deemed to have similar risk characteristics. Trade receivable balances are written off against the allowance when it is deemed probable that the trade receivable will not be&#160;collected. Trade receivables, net are stated net of certain sales provisions and the allowance for credit losses.</us-gaap:FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzE1MTk1_9e7c1223-0578-4615-b29f-9ce92b2f6393"
      unitRef="usd">35000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzE1MTk5_9f2f2b58-da1c-4a43-8d9c-890a6fea2c99"
      unitRef="usd">39000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzE1MjA2_abaa0baf-3d6a-43c1-83ed-9c59df7e798f"
      unitRef="usd">48000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MTM2_57130331-0679-495b-9c06-3761296b2abd">The activity in the allowance for credit losses for trade receivables for the years 2021, 2020 and 2019 is as follows.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.199%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retrospective effect of application of new accounting standard&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Write-offs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzEtMS0xLTEtOTQ4MzE_824101f1-a0d9-40a9-bc93-f96287c5df31"
      unitRef="usd">39000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzEtMy0xLTEtOTQ4MzE_31fea177-5ec4-4bec-8d2e-a368a10355f3"
      unitRef="usd">48000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i18439fe8345c481db53c486667ac6940_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzEtNS0xLTEtOTQ4MzE_1a97abe7-2d63-4fa5-a31a-e4d155cb997c"
      unitRef="usd">47000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzItMS0xLTEtOTQ4MzE_56e5b909-69dd-427a-ac7e-be2f5ec71bd2"
      unitRef="usd">0</bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate>
    <bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzItMy0xLTEtOTQ4MzE_3a594caa-960f-4cbd-8245-fa610d0ea2be"
      unitRef="usd">1000000</bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate>
    <bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzItNS0xLTEtOTQ4MzE_714247d7-5e1c-43fc-937e-f572aabe02f5"
      unitRef="usd">0</bhc:AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzMtMS0xLTEtOTQ4MzE_80cb4574-3c41-4d25-8b5a-daf8dccff3bb"
      unitRef="usd">-2000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzMtMy0xLTEtOTQ4MzE_97da51b2-d81c-4bcc-81e5-9e8075cd0fd4"
      unitRef="usd">2000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzMtNS0xLTEtOTQ4MzE_4aba4f73-dc44-42e5-bd47-f16b11d01a8b"
      unitRef="usd">10000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzQtMS0xLTEtOTQ4MzE_254c7f18-22d7-48e7-955d-d659ec827203"
      unitRef="usd">3000000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzQtMy0xLTEtOTQ4MzE_cad34110-6372-4095-9d68-adbd0a0a7af4"
      unitRef="usd">12000000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzQtNS0xLTEtOTQ4MzE_ba91a831-a7be-4054-bb13-cc1e8d958854"
      unitRef="usd">10000000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzUtMS0xLTEtOTQ4MzE_3ef1f5e7-4d35-484b-8327-cf7bce69eaf0"
      unitRef="usd">2000000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzUtMy0xLTEtOTQ4MzE_226031e6-4c9c-4ac4-8780-ee5bd613fe75"
      unitRef="usd">3000000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzUtNS0xLTEtOTQ4MzE_ae6baf3d-967a-4253-8ef4-54cff995a6b8"
      unitRef="usd">1000000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
    <bhc:AccountsReceivableAllowanceForForeignExchangeAndOther
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzYtMS0xLTEtOTQ4MzE_65976557-0d6a-48a4-b12f-7d3c8a247c22"
      unitRef="usd">1000000</bhc:AccountsReceivableAllowanceForForeignExchangeAndOther>
    <bhc:AccountsReceivableAllowanceForForeignExchangeAndOther
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzYtMy0xLTEtOTQ4MzE_1d0ead6f-fa8b-4106-8092-baf31561315c"
      unitRef="usd">3000000</bhc:AccountsReceivableAllowanceForForeignExchangeAndOther>
    <bhc:AccountsReceivableAllowanceForForeignExchangeAndOther
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzYtNS0xLTEtOTQ4MzE_942414ab-cf42-4eb8-9e91-1429a28ecfe4"
      unitRef="usd">0</bhc:AccountsReceivableAllowanceForForeignExchangeAndOther>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzctMS0xLTEtOTQ4MzE_9e7c1223-0578-4615-b29f-9ce92b2f6393"
      unitRef="usd">35000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzctMy0xLTEtOTQ4MzE_736d4d6f-c4dc-47bb-a7a6-5d367485a4e5"
      unitRef="usd">39000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiMWRhZjU3NGJkZWM0NGU3YWUzYmJkOTRlZjkxYzk4NC90YWJsZXJhbmdlOmIxZGFmNTc0YmRlYzQ0ZTdhZTNiYmQ5NGVmOTFjOTg0XzctNS0xLTEtOTQ4MzE_f590c2fa-31b9-4754-810a-83c337cd311c"
      unitRef="usd">48000000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MDQ0_ecfc17ff-40a4-48bb-9611-ff67eeb8c0e5">&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories comprise raw materials, work in process and finished goods, which are valued at the lower of cost or net realizable value, on a first-in, first-out basis. The cost value for work in process and finished goods inventories includes materials, direct labor and an allocation of overheads. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates the carrying value of inventories on a regular basis, taking into account such factors as historical and anticipated future sales compared with quantities on hand, the price the Company expects to obtain for products in their respective markets compared with historical cost and the remaining shelf life of goods on&#160;hand.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MDg2_5355b98f-5eaa-4218-9b63-0c41082a4235">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are reported at cost, less accumulated depreciation. Costs incurred on assets under construction are capitalized as construction in progress. Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful&#160;lives: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15 - 30 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 40 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;-&#160;20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;-&#160;10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment on operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser of term of lease or 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <bhc:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MTA1_d5cb6bcb-bdc8-4396-8992-47db42315be3">Depreciation is calculated using the straight-line method, commencing when the assets become available for productive use, based on the following estimated useful&#160;lives: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15 - 30 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 40 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;-&#160;20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;-&#160;10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment on operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Up to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser of term of lease or 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bhc:ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i0043ca6c60b448469dd9c10b6369a160_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpjZmNiNzYwM2ExODE0YTJiYTllZjRjZWE3MTdlYWExNi90YWJsZXJhbmdlOmNmY2I3NjAzYTE4MTRhMmJhOWVmNGNlYTcxN2VhYTE2XzAtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjoxNDA0MmQyODNiNmE0YWY3ODY1MmU5ZTE2NzkyN2RlYl80_3eb0ecea-47c6-4565-8f90-4b9e34a10985">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ic50c129d307b456db8bd6d0a3572b5cf_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpjZmNiNzYwM2ExODE0YTJiYTllZjRjZWE3MTdlYWExNi90YWJsZXJhbmdlOmNmY2I3NjAzYTE4MTRhMmJhOWVmNGNlYTcxN2VhYTE2XzAtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjoxNDA0MmQyODNiNmE0YWY3ODY1MmU5ZTE2NzkyN2RlYl85_23db710b-14fd-4575-9045-fcebe4b1fb22">P30Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i1c6ea96094f24f6aa4162dcd33584114_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpjZmNiNzYwM2ExODE0YTJiYTllZjRjZWE3MTdlYWExNi90YWJsZXJhbmdlOmNmY2I3NjAzYTE4MTRhMmJhOWVmNGNlYTcxN2VhYTE2XzEtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjpiZDcxMDIzMTQ5Zjk0OTFkYmE5ZWY4ZDVkOTc3ZjVmMV8xMA_51bb9843-96be-4da9-ac81-4cdb5a050e3b">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="id111070c09c44a9f836bd940a8c401b1_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpjZmNiNzYwM2ExODE0YTJiYTllZjRjZWE3MTdlYWExNi90YWJsZXJhbmdlOmNmY2I3NjAzYTE4MTRhMmJhOWVmNGNlYTcxN2VhYTE2XzItMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo4MmRjZmJlMTBiYzc0YmEzYjc3MjA1MDE4MDgzYTJiYl80_3c98ef13-b2ec-47eb-80a7-3dbfb7c5806d">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="id5d7287ea6164d739cdd4537fbbcf93b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpjZmNiNzYwM2ExODE0YTJiYTllZjRjZWE3MTdlYWExNi90YWJsZXJhbmdlOmNmY2I3NjAzYTE4MTRhMmJhOWVmNGNlYTcxN2VhYTE2XzItMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo4MmRjZmJlMTBiYzc0YmEzYjc3MjA1MDE4MDgzYTJiYl85_eb66779a-f5c6-4281-826b-3f92ef8c6230">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i71d4507094c54c61a828a4ba28c456f8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpjZmNiNzYwM2ExODE0YTJiYTllZjRjZWE3MTdlYWExNi90YWJsZXJhbmdlOmNmY2I3NjAzYTE4MTRhMmJhOWVmNGNlYTcxN2VhYTE2XzMtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo2MTg4ZDQ3NzIwMDI0MGY5YjY5YjIwMWY4NDdjNWQwYV80_8f709766-2eed-4f68-9df8-e9a120dcf294">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i300d1bbfb1584998a64def9a1e591494_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpjZmNiNzYwM2ExODE0YTJiYTllZjRjZWE3MTdlYWExNi90YWJsZXJhbmdlOmNmY2I3NjAzYTE4MTRhMmJhOWVmNGNlYTcxN2VhYTE2XzMtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo2MTg4ZDQ3NzIwMDI0MGY5YjY5YjIwMWY4NDdjNWQwYV85_f27fa2f2-ae1d-44ac-94e2-b57f702a7c36">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="idcb50c382a0f41abb2ebb51d91d43a1c_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpjZmNiNzYwM2ExODE0YTJiYTllZjRjZWE3MTdlYWExNi90YWJsZXJhbmdlOmNmY2I3NjAzYTE4MTRhMmJhOWVmNGNlYTcxN2VhYTE2XzQtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjphZTA3ODdiODEzNzQ0ZWVlYTcxZWViY2I2YzUyMTYyM18xMA_70345585-7949-4e89-b81b-20882920888d">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ifbd918087d4845c1890cc471931bf4ee_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpjZmNiNzYwM2ExODE0YTJiYTllZjRjZWE3MTdlYWExNi90YWJsZXJhbmdlOmNmY2I3NjAzYTE4MTRhMmJhOWVmNGNlYTcxN2VhYTE2XzUtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjozMzBkYTBjMTY3Yzc0OGU5YWNiY2JjOGQ4MTdhNjQyNl8zMQ_1370791c-3770-4668-8d82-0c056bd3edfb">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MDc0_d00f4199-a020-4135-acbe-755ad1d3a655">&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reported at cost, less accumulated amortization and impairments. Intangible assets with finite lives are amortized over their estimated useful lives. Amortization is calculated primarily using the straight-line method based on the following estimated useful&#160;lives:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4 - 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 - 9 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Out-licensed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8 - 9 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <bhc:ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MjI1_be3f6b13-e10f-45b1-90b7-c1782f285691">Amortization is calculated primarily using the straight-line method based on the following estimated useful&#160;lives:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4 - 15 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7 - 9 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Out-licensed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8 - 9 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</bhc:ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="id51447b7e78f425bafc98f09b85f21fd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTowNTk3MzE4MGEwODE0YWVkYmRlYzk3MDdjNmYzMDM4NC90YWJsZXJhbmdlOjA1OTczMTgwYTA4MTRhZWRiZGVjOTcwN2M2ZjMwMzg0XzAtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo3NjJjOGU5ZmZjM2E0OTE3ODczODc4YzQxYzAzMjg0Nl80_de7a19bd-4c51-459e-b03a-5ca8c4976c2c">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i975464f279ce4238b86edce4c77ddbe8_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTowNTk3MzE4MGEwODE0YWVkYmRlYzk3MDdjNmYzMDM4NC90YWJsZXJhbmdlOjA1OTczMTgwYTA4MTRhZWRiZGVjOTcwN2M2ZjMwMzg0XzAtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo3NjJjOGU5ZmZjM2E0OTE3ODczODc4YzQxYzAzMjg0Nl85_a706822f-f481-4620-9c9d-a9e9b85bc041">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ie756de63eaaf4535abb5aeced45c5b18_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTowNTk3MzE4MGEwODE0YWVkYmRlYzk3MDdjNmYzMDM4NC90YWJsZXJhbmdlOjA1OTczMTgwYTA4MTRhZWRiZGVjOTcwN2M2ZjMwMzg0XzEtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjoxNGUzMjg4YzQzMzQ0MmRmOWI0NGY0Zjg1ZDk0YTFiMF80_02ae2763-9ebb-424b-8685-2dce49bef81f">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ia21b8496153c42c087eeb45cea371ca7_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTowNTk3MzE4MGEwODE0YWVkYmRlYzk3MDdjNmYzMDM4NC90YWJsZXJhbmdlOjA1OTczMTgwYTA4MTRhZWRiZGVjOTcwN2M2ZjMwMzg0XzEtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjoxNGUzMjg4YzQzMzQ0MmRmOWI0NGY0Zjg1ZDk0YTFiMF85_b7029e28-0ffe-42b8-9bfa-65a5d810b2ef">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i490b2ed3d24b48e583bcdcad19e43866_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTowNTk3MzE4MGEwODE0YWVkYmRlYzk3MDdjNmYzMDM4NC90YWJsZXJhbmdlOjA1OTczMTgwYTA4MTRhZWRiZGVjOTcwN2M2ZjMwMzg0XzItMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjpkMzQxOGJmNmU0MWY0MzRhODViYTExNTM3NWQ5ODRlY180_528739f3-6153-4986-b7df-11c132ecc234">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ibeae95de06d24f9696ad1c74d3eee5f4_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTowNTk3MzE4MGEwODE0YWVkYmRlYzk3MDdjNmYzMDM4NC90YWJsZXJhbmdlOjA1OTczMTgwYTA4MTRhZWRiZGVjOTcwN2M2ZjMwMzg0XzItMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjpkMzQxOGJmNmU0MWY0MzRhODViYTExNTM3NWQ5ODRlY185_d720ad75-e8fc-48d9-9a14-6240dd90bd42">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ic53aa697e1c24a5896e49065797f9b0d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTowNTk3MzE4MGEwODE0YWVkYmRlYzk3MDdjNmYzMDM4NC90YWJsZXJhbmdlOjA1OTczMTgwYTA4MTRhZWRiZGVjOTcwN2M2ZjMwMzg0XzMtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjpiZjgyNzE5ZTlhZGM0MjE1YjAzYjUzNGZkYmI5NmI4Yl80_7b821bfb-4922-4621-975d-ef89848eec61">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i589f537dbee5471e9bfcdc450bd648fd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTowNTk3MzE4MGEwODE0YWVkYmRlYzk3MDdjNmYzMDM4NC90YWJsZXJhbmdlOjA1OTczMTgwYTA4MTRhZWRiZGVjOTcwN2M2ZjMwMzg0XzMtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjpiZjgyNzE5ZTlhZGM0MjE1YjAzYjUzNGZkYmI5NmI4Yl85_1ff3668d-20db-4839-b551-5019d4983e88">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i2b9398fd67264ccbab689da594b22ed4_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTowNTk3MzE4MGEwODE0YWVkYmRlYzk3MDdjNmYzMDM4NC90YWJsZXJhbmdlOjA1OTczMTgwYTA4MTRhZWRiZGVjOTcwN2M2ZjMwMzg0XzQtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo3MjI5ODg3OWU2NWY0YjAyOGEwNGRjYzIwZWUxZDAxYV80_5cfd55bf-830f-47fb-91e5-dfbbdce2678a">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i36b171d0ac0f4d8ba4064dc0477f6b5d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTowNTk3MzE4MGEwODE0YWVkYmRlYzk3MDdjNmYzMDM4NC90YWJsZXJhbmdlOjA1OTczMTgwYTA4MTRhZWRiZGVjOTcwN2M2ZjMwMzg0XzQtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo3MjI5ODg3OWU2NWY0YjAyOGEwNGRjYzIwZWUxZDAxYV85_dac9f6b3-d068-479d-9e25-a9b76acc9b9b">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <bhc:DivestituresOfNoncoreProductsPolicyTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MTQ4_7440ad1e-c14d-4681-b892-f2b98ad4cc50">&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Divestitures of Products&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net proceeds on the divestiture of products and the carrying amount of the related assets is recorded as a gain/loss on sale within Other expense, net. Any contingent payments that are potentially due to the Company as a result of these divestitures are recorded when realizable.&lt;/span&gt;&lt;/div&gt;</bhc:DivestituresOfNoncoreProductsPolicyTextBlock>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MTM3_7497380f-48cf-4d40-aa52-d8a25172ff97">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IPR&amp;amp;D &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of IPR&amp;amp;D acquired through a business combination is capitalized as an indefinite-lived intangible asset until the completion or abandonment of the related research and development activities. When the related research and development is completed, the asset will be assigned a useful life and&#160;amortized. Acquired IPR&amp;amp;D assets are tested for impairment at least annually or when triggering events are identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of an acquired IPR&amp;amp;D intangible asset is typically determined using an income approach. This approach starts with a forecast of the net cash flows expected to be generated by the asset over its estimated useful life. The net cash flows reflect the asset&#x2019;s stage of completion, the probability of technical success, the projected costs to complete, expected market competition and an assessment of the asset&#x2019;s life-cycle. The net cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the expected cash flow&#160;streams.&lt;/span&gt;&lt;/div&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MDg4_2ce0463a-61ff-4131-9257-000368c57b1c">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable.  If indicators of impairment are present, the asset is tested for recoverability by comparing the carrying value of the asset to the related estimated undiscounted future cash flows expected to be derived from the asset, which include the amount and timing of the projected future cash flows. If the expected undiscounted cash flows are less than the carrying value of the asset, then the asset is considered to be impaired and its carrying value is written down to fair value, based on the related estimated discounted future cash&#160;flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets, which includes acquired IPR&amp;amp;D and the corporate trademark acquired in the acquisition of Bausch &amp;amp; Lomb Holdings Incorporated (the &#x2018;&#x2018;B&amp;amp;L Trademark&#x2019;&#x2019;), are tested for impairment annually or more frequently if events or changes in circumstances between annual tests indicate that the asset may be impaired. Impairment losses on indefinite-lived intangible assets are recognized based on a comparison of the fair value of the asset to its carrying value.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MDQ1_cc3d0246-bb9d-4063-b8b2-55f358fe5337">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is recorded with the acquisition of a business and is calculated as the difference between the acquisition date fair value of the consideration transferred and the values assigned to the assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment at least annually as of October 1st at the reporting unit level. Goodwill impairment is measured as the amount by which a reporting unit's carrying value exceeds its fair value. A reporting unit is the same as, or one level below, an operating segment. A&lt;/span&gt;&lt;span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n entity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is permitted to first assess qualitatively whether it is necessary to perform a quantitative impairment test for any of its reporting units. The quantitative impairment test is required only when the Company concludes that it is more likely than not that a reporting unit&#x2019;s fair value is less than its carrying amount. In evaluating whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, the Company considers the totality of all relevant events or circumstances that affect the fair value or carrying amount of a reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An interim goodwill impairment test in advance of the annual impairment assessment may be required if events occur that indicate an impairment might be present. For example, a substantial decline in the Company&#x2019;s market capitalization, changes in reportable segments, unexpected adverse business conditions, economic factors and unanticipated competitive activities may signal that an interim impairment test is needed. Accordingly, among other factors, the Company monitors &lt;/span&gt;&lt;/div&gt;changes in its share price between annual impairment tests. The Company considers a decline in its share price that corresponds to an overall deterioration in stock market conditions to be less of an indicator of goodwill impairment than a unilateral decline in its share price reflecting adverse changes in its underlying operating performance, cash flows, financial condition and/or liquidity. In the event that the Company&#x2019;s market capitalization does decline below its book value, the Company would consider the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists. The Company believes that short-term fluctuations in share prices may not necessarily reflect underlying values.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MjEz_704ac726-ee03-47c5-b40b-6874098c4c07">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt discounts, premiums and issuance costs are presented in the Consolidated Balance Sheets as a direct deduction from or addition to the carrying amount of the related debt and are amortized or accreted, using the effective interest method, as interest expense over the contractual lives of the related credit facilities or notes. Deferred financing costs associated with revolving credit facility arrangements are included in the balances of Prepaid expenses and other current assets and Other non-current assets in the Consolidated Balance Sheets and are amortized as interest expense over the contractual life of the related revolving credit facility.&lt;/span&gt;&lt;/div&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MDEz_e3430b2b-6f13-4da3-a963-b6ffcb37de98">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities of the Company&#x2019;s foreign operations having a functional currency other than the U.S.&#160;dollar are translated into U.S.&#160;dollars at the exchange rate prevailing at the balance sheet date, and at the average exchange rate for the reporting period for revenue and expense accounts. The cumulative foreign currency translation adjustment is recorded as a component of Accumulated other comprehensive loss in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency exchange gains and losses on transactions occurring in a currency other than an operation&#x2019;s functional currency are recognized as a component of Foreign exchange and other in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MTA5_e7bd812f-0d3a-422d-a0af-786891d26e75">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenues are primarily generated from product sales, primarily in the therapeutic areas of eye-health, gastroenterology  (&#x201c;GI&#x201d;) and dermatology that consist of: (i) branded pharmaceuticals, (ii) generic and branded generic pharmaceuticals, (iii) OTC products and (iv) medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices). Other revenues include alliance and service revenue from the licensing and co-promotion of products and contract service revenue primarily in the areas of dermatology and topical medication. Contract service revenue is derived primarily from contract manufacturing for third parties and is not material. See Note 22, &#x201c;SEGMENT INFORMATION&#x201d; for the disaggregation of revenues which depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by the economic factors of each category of customer contracts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when the customer obtains control of promised goods or services and in an amount that reflects the consideration to which the Company expects to be entitled to receive in exchange for those goods or services.  To achieve this core principle, the Company applies the five-step revenue model to contracts within its scope: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A contract with the Company&#x2019;s customers exists for each product sale.  Where a contract with a customer contains more than one performance obligation, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The transaction price is adjusted for variable consideration which is discussed below.  The Company generally recognizes revenue for product sales at a point in time, when the customer obtains control of the products.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Sales Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As is customary in the pharmaceutical industry, gross product sales are subject to a variety of deductions in arriving at reported net product sales.&#160; The transaction price for product sales is typically adjusted for variable consideration, which may be in the form of cash discounts, allowances, returns, rebates, chargebacks and distribution fees paid to customers. Provisions for variable consideration are established to reflect the Company&#x2019;s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in the future period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Provisions for these deductions are recorded concurrently with the recognition of gross product sales revenue and include cash discounts and allowances, chargebacks, and distribution fees, which are paid to direct customers, as well as rebates and returns, which can be paid to direct and indirect customers.  Returns provision balances and volume discounts to direct customers are included in Accrued and other current liabilities. All other provisions related to direct customers are included in Trade receivables, net, while provision balances related to indirect customers are included in Accrued and other current liabilities.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the activity and ending balances of the Company&#x2019;s variable consideration provisions the years 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;br/&gt;and&lt;br/&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Distribution&lt;br/&gt;Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balance, January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,909)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(593)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Rebates in the table above are cooperative advertising credits due to customers of approximately $36 million and $32 million as of December 31, 2021 and 2020, respectively, which are reflected as a reduction of Trade accounts receivable, net in the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continually monitors its variable consideration provisions and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results. The Company is required to make subjective judgments based primarily on its evaluation of current market conditions and trade inventory levels related to the Company's products. These judgments include the potential impact of the COVID-19 pandemic on, among other things, unemployment and related changes in customer health insurance levels, customer behaviors during the COVID-19 pandemic and government stimulus bills that focus on ensuring availability and access to lifesaving drugs during a public health crisis.  This evaluation may result in an increase or decrease in the experience rate that is applied to current and future sales, or require an adjustment related to past sales, or both. If the trend in actual amounts of variable consideration varies from the Company&#x2019;s prior estimates, the Company adjusts these estimates when such trend is believed to be sustainable. At that time, the Company would record the necessary adjustments which would affect net product revenue and earnings reported in the current period.  The Company applies this method consistently for contracts with similar characteristics.  The following describes the major sources of variable consideration in the Company&#x2019;s customer arrangements and the methodology, estimates and judgments applied to estimate each type of variable consideration.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash discounts are offered for prompt payment and allowances for volume purchases. Provisions for cash discounts and allowances are estimated at the time of sale and recorded as direct reductions to trade receivables and revenue. Management estimates the provisions for cash discounts and allowances based on contractual sales terms with customers, an analysis of unpaid invoices and historical payment experience. Estimated cash discounts and allowances have historically been predictable and less subjective, due to the limited number of assumptions involved, the consistency of historical experience and the fact that these amounts are generally settled within one month of incurring the&#160;liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consistent with industry practice, customers are generally allowed to return a product within a specified period of time before and after its expiration date, excluding European businesses which generally do not provide a right of return. The returns provision is estimated utilizing historical sales and return rates over the period during which customers have a right of return, taking into account available information on competitive products and contract changes. The information utilized to estimate the returns provision includes: (i) historical return and exchange levels, (ii) external data with respect to inventory levels in the wholesale distribution channel, (iii) external data with respect to prescription demand for products, (iv) remaining shelf lives of products at the date of sale and (v) estimated returns liability to be processed by year of sale based on an analysis of lot information related to actual historical returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the estimate for returns, management is required to make certain assumptions regarding the timing of the introduction of new products and the potential of these products to capture market share. In addition, certain assumptions with respect to the extent and pattern of decline associated with generic competition are necessary. These assumptions are formulated using market data for similar products, past experience and other available information.  These assumptions are continually reassessed, and changes to the estimates and assumptions are made as new information becomes available. A change of 1% in the estimated return rates would have impacted the Company&#x2019;s pre-tax earnings by approximately $81 million for the year 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimate for returns may be impacted by a number of factors, but the principal factor relates to the inventory levels in the distribution channel. When management becomes aware of an increase in such inventory levels, it considers whether the increase may be temporary or other-than-temporary. Temporary increases in wholesaler inventory levels will not warrant revision to the provision for returns. Other-than-temporary increases in wholesaler inventory levels, however, may be an indication that future product returns could be higher than originally anticipated, and, as a result, estimates for returns may need to be adjusted. Factors that suggest increases in wholesaler inventory levels are temporary include: (i) recently implemented or announced price increases for certain products, (ii) new product launches or expanded indications for existing products and (iii) timing of purchases by wholesale customers. Conversely, factors that suggest increases in wholesaler inventory levels are other-than-temporary include: (i) declining sales trends based on prescription demand, (ii) introduction of new products or generic competition, (iii) increasing price competition from generic competitors and (iv) changes to the U.S.&#160;National Drug Codes (&#x201c;NDC&#x201d;) of products.  Changes in the NDC of products could result in a period of higher returns related to products with the old NDC, as U.S.&#160;customers generally permit only one NDC per product for identification and tracking within their inventory systems.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Over the last several years, the Company increased its focus on maximizing operational efficiencies and continues to take actions to reduce product returns, including but not limited to: (i) monitoring and reducing customer inventory levels, (ii) instituting disciplined pricing policies and (iii) improving contracting. These actions have had the effect of improving sales return experience, primarily related to branded and generic products. Sales return provisions for 2021 and 2020 were $131&#160;million and $120&#160;million, respectively, and includes reductions in variable consideration for sales return provisions related to past sales of approximately $28 million and $38 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rebates and Chargebacks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales made under governmental and managed-care pricing programs in the U.S. are subject to rebates.&#160; The Company participates in state government-managed Medicaid programs, as well as certain other qualifying federal and state government programs whereby rebates are provided to participating government entities. Medicaid rebates are generally billed 45 days to 270&#160;days after the quarter in which the product is dispensed to the Medicaid participant.  As a result, the Medicaid rebate reserve includes an estimate of outstanding claims for end-customer sales that occurred, but for which the related claim has not been billed and/or paid, and an estimate for future claims that will be made when inventory in the distribution channel is sold through to plan participants. The calculation of the Medicaid rebate reserve also requires other estimates, such as estimates of sales mix, to determine which sales are subject to rebates and the amount of such rebates. A change of 1% in the estimated rates used in the Medicaid rebate reserve would have impacted the Company&#x2019;s pre-tax earnings by approximately $76 million for 2021. Quarterly, the Medicaid rebate reserve is adjusted based on actual claims paid. Due to the delay in billing, adjustments to actual claims paid may incorporate revisions of that reserve for several periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Managed Care rebates relate to contractual agreements to sell products to managed care organizations and pharmacy benefit managers at contractual rebate percentages in exchange for volume and/or market&#160;share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks relate to contractual agreements to sell products to government agencies, group purchasing organizations and other indirect customers at contractual prices that are lower than the list prices the Company charges wholesalers. When these group purchasing organizations or other indirect customers purchase products through wholesalers at these reduced prices, the wholesaler charges the Company for the difference between the prices they paid the Company and the prices at which they sold the products to the indirect customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In estimating provisions for rebates and chargebacks, management considers relevant statutes with respect to governmental pricing programs and contractual sales terms with managed-care providers and group purchasing organizations. Management estimates the amount of product sales subject to these programs based on historical utilization levels. Changes in the level of utilization of products through private or public benefit plans and group purchasing organizations will affect the amount of rebates and chargebacks that the Company is obligated to pay. Management continually updates these factors based on new contractual or statutory requirements, and any significant changes in sales trends that may impact the percentage of products subject to rebates or&#160;chargebacks.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of Managed Care, Medicaid and other rebates and chargebacks has become more significant as a result of a combination of deeper discounts implemented in each of the last three years, changes in the Company&#x2019;s product portfolio due to recent acquisitions and increased Medicaid utilization due to expansion of government funding for these programs.&#160;Management&#x2019;s estimate for rebates and chargebacks may be impacted by a number of factors, but the principal factor relates to the level of inventory in the distribution channel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rebate provisions are based on factors such as timing and terms of plans under contract, time to process rebates, product pricing, sales volumes, amount of inventory in the distribution channel and prescription trends. Adjustments to actual for the years 2021 and 2020 were not material to the Company&#x2019;s revenues or earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient Co-Pay Assistance programs, Consumer Rebates and Loyalty Programs are rebates offered on many of the Company&#x2019;s products.  Patient Co-Pay Assistance Programs are patient discount programs offered in the form of coupon cards or point of sale discounts, with which patients receive certain discounts off their prescription at participating pharmacies, as defined by the specific product program. An accrual for these programs is established, equal to management&#x2019;s estimate of the discount, rebate and loyalty incentives attributable to a sale.  That estimate is based on historical experience and other relevant factors. The accrual is adjusted throughout each quarter based on actual experience and changes in other factors, if any.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distribution Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sells products primarily to wholesalers, and in some instances to large pharmacy chains such as CVS and Walmart.  The Company has Distribution Services Agreements  (&#x201c;DSAs&#x201d;) with several large wholesale customers such as McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and McKesson Specialty.  Under the DSAs, the wholesalers agree to provide services, and the Company pays the contracted DSA distribution service fees for these services based on product volumes.  Additionally, price appreciation credits are generated when the Company increases a product&#x2019;s wholesaler acquisition cost (&#x201c;WAC&#x201d;) under contracts with certain wholesalers. Under such contracts, the Company is entitled to credits from such wholesalers for the impact of that WAC increase on inventory currently on hand at the wholesalers. Such credits are offset against the total distribution service fees paid to each such wholesaler. The variable consideration associated with price appreciation credits is reflected in the transaction price of products sold when it is determined to be probable that a significant reversal will not occur. Included as a reduction of current period provisions for Distribution Fees in the table above are price appreciation credits of $17 million and $15 million for the years 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract Assets and Contract Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no contract assets for any period presented. Contract liabilities consist of deferred revenue, the balance of which is not material to any period presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sales Commissions &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales commissions are generally attributed to periods shorter than one year and therefore are expensed when incurred. Sales commissions are included in selling, general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financing Component&lt;/span&gt;&lt;/div&gt;The Company has elected not to adjust consideration for the effects of a significant financing component when the period between the transfer of a promised good or service to the customer and when the customer pays for that good or service will be one year or less.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MTE2_a1dacf78-d3d5-4bbb-9ca8-dc56d3d9b8f9">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the activity and ending balances of the Company&#x2019;s variable consideration provisions the years 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.625%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;br/&gt;and&lt;br/&gt;Allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Distribution&lt;br/&gt;Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balance, January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(613)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,909)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(193)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,273)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current period provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(593)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,297)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ie888db196c4b4c7da3187745b2f5d4b8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzEtMi0xLTEtOTQ4MzE_5c786abd-e7c5-4a53-b959-5136c8d4877b"
      unitRef="usd">182000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i25b840b91a804c71b49368c35927a054_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzEtNC0xLTEtOTQ4MzE_3967f2ad-bc91-4ef6-bf69-b4e165423117"
      unitRef="usd">691000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="if1c4cad2abfd4049a17a50ff205cdabc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzEtNi0xLTEtOTQ4MzE_00feb8a0-483f-400b-9caf-cf7fcfd241e4"
      unitRef="usd">927000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i775805d9c3154ad285c4fa424c1e815b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzEtOC0xLTEtOTQ4MzE_f5e49573-dd4a-46b1-9dfe-4799b9dbd264"
      unitRef="usd">168000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i43f8e7fcb97b444098dc083e79b1b3cc_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzEtMTAtMS0xLTk0ODMx_92725c8c-36b7-4a9e-b655-37682b084d06"
      unitRef="usd">82000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzEtMTItMS0xLTk0ODMx_d2bd15ad-8ede-47d6-9d13-cd8d363e0a97"
      unitRef="usd">2050000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i5df68fab41b644118a6a79ca3701e13c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzItMi0xLTEtOTQ4MzE_7ce48200-1e66-4342-b94f-9a2a08342d7e"
      unitRef="usd">621000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i23a4bf59c23544509ffad0bea04a9270_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzItNC0xLTEtOTQ4MzE_5ff39431-c150-4eed-b1f3-842a131b15f5"
      unitRef="usd">120000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i13a9ccb3dbd94a549431fe94a821e396_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzItNi0xLTEtOTQ4MzE_8097d622-11bd-4c4e-9569-3c2443d87d51"
      unitRef="usd">2174000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ib4e09033a34c4a888cda3e4a5656b5bf_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzItOC0xLTEtOTQ4MzE_04da03da-15f4-4f48-a6a1-b783b9ba8c7b"
      unitRef="usd">1925000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i1941a9e694f34f33978cf055adb0230f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzItMTAtMS0xLTk0ODMx_a2e06f53-ff15-4b92-83e2-eac1ab62cc41"
      unitRef="usd">196000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzItMTItMS0xLTk0ODMx_edf2cb45-503d-4f4f-aa1a-076065d8bb51"
      unitRef="usd">5036000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i5df68fab41b644118a6a79ca3701e13c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzMtMi0xLTEtOTQ4MzE_58fee874-f967-481e-aafe-0977556e9324"
      unitRef="usd">613000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i23a4bf59c23544509ffad0bea04a9270_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzMtNC0xLTEtOTQ4MzE_54b30ad8-5988-48f2-babb-4c89bbe74a9b"
      unitRef="usd">236000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i13a9ccb3dbd94a549431fe94a821e396_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzMtNi0xLTEtOTQ4MzE_623c3715-cd48-488f-92f3-b54de627d7d0"
      unitRef="usd">2322000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ib4e09033a34c4a888cda3e4a5656b5bf_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzMtOC0xLTEtOTQ4MzE_1c0bb306-dd1a-42af-a9cf-dd5ccf99b356"
      unitRef="usd">1909000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i1941a9e694f34f33978cf055adb0230f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzMtMTAtMS0xLTk0ODMx_97f041c6-7b97-4ffe-a28e-11f4d6919aaa"
      unitRef="usd">193000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzMtMTItMS0xLTk0ODMx_99073109-0187-4f94-ae3f-bf6b7fd2efc8"
      unitRef="usd">5273000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia3abe2f197384a5faf80cf8970b4f6e1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzQtMi0xLTEtOTQ4MzE_a250845e-9ed1-479e-82b7-d4c2086a1a60"
      unitRef="usd">190000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ifb7a5a9f654c44d88f30b125fda3dd93_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzQtNC0xLTEtOTQ4MzE_1de6c587-d0c2-4a6b-bfaf-87a479a330c1"
      unitRef="usd">575000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id38abec1faf94c6a8cb3456db066aea3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzQtNi0xLTEtOTQ4MzE_70d5594e-76b8-4c35-a0fc-0e2eb962212b"
      unitRef="usd">779000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="if02ec4ff710b412386b75c6474100d94_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzQtOC0xLTEtOTQ4MzE_27ae3fde-46ec-4b73-a160-34912eeb4b3f"
      unitRef="usd">184000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i40cfa45466644cff8b8dc0f3298dfb6a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzQtMTAtMS0xLTk0ODMx_cf435759-b49e-489b-8a4f-8a31762b97b7"
      unitRef="usd">85000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzQtMTItMS0xLTk0ODMx_a8fe9b22-5f43-4a9f-8ba8-d7d547039173"
      unitRef="usd">1813000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i9fc0bea60f3d4043bab8518cf76f48fa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzUtMi0xLTEtOTQ4MzE_6540ac12-07d8-4738-9423-1b9aa262ac45"
      unitRef="usd">625000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="if231ab941291433d88b5f479ceaaaab9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzUtNC0xLTEtOTQ4MzE_1d61f288-5508-4505-b9a7-0e99280fe228"
      unitRef="usd">131000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i056b23d864094b3a8805bbf7eae8f62d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzUtNi0xLTEtOTQ4MzE_cfbfeb44-43c7-4ae5-a9de-8369fd279892"
      unitRef="usd">2462000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ifac9a0ee97354de5ad0790a506ffc752_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzUtOC0xLTEtOTQ4MzE_78738bf2-12ac-4ff6-bf46-fa51cf54c57b"
      unitRef="usd">1999000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i7f5af18d5ed449a39d9cf011a2c82598_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzUtMTAtMS0xLTk0ODMx_39c86854-0ad8-4e88-81d6-ee670df9990e"
      unitRef="usd">211000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzUtMTItMS0xLTk0ODMx_4ed2af62-b427-428e-bfa9-dcc211010b81"
      unitRef="usd">5428000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i9fc0bea60f3d4043bab8518cf76f48fa_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzYtMi0xLTEtOTQ4MzE_0401b0c4-0c4a-480b-be8e-43c4e5ddc878"
      unitRef="usd">593000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="if231ab941291433d88b5f479ceaaaab9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzYtNC0xLTEtOTQ4MzE_2b06dd70-1e3b-47ec-893c-d11791090811"
      unitRef="usd">224000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i056b23d864094b3a8805bbf7eae8f62d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzYtNi0xLTEtOTQ4MzE_37abbe57-5298-40a3-9ff5-f833ac121dc3"
      unitRef="usd">2297000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ifac9a0ee97354de5ad0790a506ffc752_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzYtOC0xLTEtOTQ4MzE_71f72481-5ce4-4a64-89c8-c41f8f6ff55f"
      unitRef="usd">2013000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i7f5af18d5ed449a39d9cf011a2c82598_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzYtMTAtMS0xLTk0ODMx_6e037fd8-c6e1-43d6-86fd-a19c9e73520c"
      unitRef="usd">251000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzYtMTItMS0xLTk0ODMx_ef363e12-8e9e-4d0c-b305-c24ebc1f118f"
      unitRef="usd">5378000000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i968f181cf55f432d8b88feaea1bfdebb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzctMi0xLTEtOTQ4MzE_b2c263f2-4608-462d-a761-8f8201066906"
      unitRef="usd">222000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i024019b8dc9d47e9a40e0391dd2811f6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzctNC0xLTEtOTQ4MzE_6c1c68a7-982d-451a-8948-87b96bab1810"
      unitRef="usd">482000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ic252586b20d24ab2b1f4c1e7d2d0216a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzctNi0xLTEtOTQ4MzE_3c185cc1-9d86-4b68-9755-42206c3415fb"
      unitRef="usd">944000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i45c7461bce0f4ce88d5a315b0d9016b4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzctOC0xLTEtOTQ4MzE_c6f23863-ed17-42d1-ac3e-bc305be7a8d7"
      unitRef="usd">170000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i77cd717b81fc4051b53b2ba09fbc08d7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzctMTAtMS0xLTk0ODMx_68a4a4d5-d50f-4584-9b32-f3bacfa62926"
      unitRef="usd">45000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90YWJsZTpiYmI5ODkyMTVkMDk0NjQwYTBjYTlkOGE3MWY3MjU3Ni90YWJsZXJhbmdlOmJiYjk4OTIxNWQwOTQ2NDBhMGNhOWQ4YTcxZjcyNTc2XzctMTItMS0xLTk0ODMx_25557c24-3793-4bf4-9fc8-e05e7a6530f9"
      unitRef="usd">1863000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i3217dc4fc80f4a868a33e3af520f1ca4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzI2OTQ3_6ec96215-e446-4398-a840-028c6748a916"
      unitRef="usd">36000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i3bc559ab6ace4d47880bb10942e52a2d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzI2OTU0_88372f14-c092-4f9c-aee6-56e7ec25b360"
      unitRef="usd">32000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <bhc:CashDiscountsAndAllowancesSettlementPeriod
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzI5NDUz_5aaeb0f6-1544-485b-ba4f-280f6082433d">P1M</bhc:CashDiscountsAndAllowancesSettlementPeriod>
    <bhc:SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzMxMTU3_c2fd3023-c3b5-4bfe-9728-6e942b82a609"
      unitRef="usd">81000000</bhc:SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="if231ab941291433d88b5f479ceaaaab9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzMzMTc3_ff86c284-4864-43d9-8b53-ffe80fbbd634"
      unitRef="usd">131000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i23a4bf59c23544509ffad0bea04a9270_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzMzMTg0_14f8cd77-6717-4c37-bb2c-c1b6c1f7853d"
      unitRef="usd">120000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="if231ab941291433d88b5f479ceaaaab9_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzMzMzE5_91ec4653-9106-4088-b234-81c2b6d9a3c9"
      unitRef="usd">-28000000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesAdjustments
      contextRef="i23a4bf59c23544509ffad0bea04a9270_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzMzMzI2_a4a30269-529e-4f51-a896-f4d9d5051b02"
      unitRef="usd">-38000000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <bhc:SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzM0NDgy_fef165e2-fba3-41d3-a981-768b3efa8c91"
      unitRef="usd">76000000</bhc:SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if642d30e99ba413e98c7c9fa16c98d58_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzM5MTA5_fbe55789-9ffa-4731-99f1-43f893356dce"
      unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8f30533812f49bdb16ff48c59ebaf7a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzM5MTE2_a7d18a1b-c00e-4330-b1b4-252b88059645"
      unitRef="usd">15000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <bhc:RevenuePerformanceObligationPaymentTerms
      contextRef="idb0e80397f6a447584308760a43131cd_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzM5OTMz_ad7a052c-4da5-45d6-8d51-f5e3cb7bb8b6">P90D</bhc:RevenuePerformanceObligationPaymentTerms>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i65c560b8d709448ebce15c3e5d971fa8_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzQwMDg1_b8999fa2-df7c-4948-8c34-790db0719683">P20Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i65c560b8d709448ebce15c3e5d971fa8_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzQwMTc5_235c9143-3320-4700-9bdc-56da414a78ce">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MDU0_2b515cc6-0b75-4626-a267-6080d6916111">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs related to internal research and development programs, including costs associated with the development of acquired IPR&amp;amp;D, are expensed as goods are delivered or services are performed. Under certain research and development arrangements with third parties, the Company may be required to make payments that are contingent on the achievement of specific developmental, regulatory and/or commercial milestones. Milestone payments made to third parties before a product receives regulatory approval, but after the milestone is determined to be probable, are expensed and included in Research and development expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Milestone payments made to third parties after regulatory approval is received are capitalized and amortized over the estimated useful life of the approved product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts due from third parties as reimbursement of development activities conducted under certain research and development arrangements are recognized as a reduction of Research and development expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LegalCostsPolicyTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MTU0_aadb3aef-e3df-4087-8ba1-4526f194e8af">Legal Costs Legal fees and other costs related to litigation and other legal proceedings or services are expensed as incurred and are included in Selling, general and administrative expenses. Certain legal costs associated with acquisitions are included in Acquisition-related costs and certain legal costs associated with divestitures, legal settlements and other business development activities are included in Litigation and other matters or Net gain on sales of assets within Other expense (income), net, as appropriate. Legal costs expensed are reported net of expected insurance recoveries. A claim for insurance recovery is recognized when realization becomes probable</us-gaap:LegalCostsPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MDU2_911f0789-e23e-4937-a007-82e80ff716e5">Advertising CostsAdvertising costs comprise product samples, print media, promotional materials and television advertising and are expensed on the first use of the advertisement.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzQ0NjU3_cd4f8a9a-91be-4a71-8bcf-75a5328036cd"
      unitRef="usd">515000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzQ0NjYx_7a86cd8c-c696-4dcc-a3b2-9d672e002481"
      unitRef="usd">451000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzQ0NjY4_94da8b62-5926-4324-978f-2bbaeffdee4a"
      unitRef="usd">544000000</us-gaap:AdvertisingExpense>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MTY4_bd1debf3-825c-4835-9d33-8fd913163ee0">Share-Based Compensation The Company recognizes all share-based payments to employees, including grants of employee stock options and restricted share units (&#x201c;RSUs&#x201d;), at estimated fair value. The Company amortizes the fair value of stock option or RSU grants on a straight-line basis over the requisite service period of the individual stock option or RSU grant, which generally equals the vesting period. Stock option and RSU forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Share-based compensation is recorded in Research and development expenses and Selling, general and administrative expenses, as&#160;appropriate.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:InterestExpensePolicyTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MDU4_a37ea6ad-4b20-4af1-95ea-c63bb8f49cc7">Interest Expense Interest expense includes standby fees, the amortization of debt discounts and deferred financing costs, accretion of debt premiums and the amortization of amounts excluded from the assessment of effectiveness related to the Company's cross-currency swaps. Interest costs are expensed as incurred, except to the extent such interest is related to construction in progress, in which case interest is capitalized.</us-gaap:InterestExpensePolicyTextBlock>
    <us-gaap:InterestCostsCapitalized
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzQ2NTky_9cf42469-bf3c-430f-a4d9-cadd6357bfa0"
      unitRef="usd">60000000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzQ2NTk5_38e91051-7ea5-4583-b1bc-502f31a87d17"
      unitRef="usd">45000000</us-gaap:InterestCostsCapitalized>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MTAx_2d9b2d45-da87-4292-9713-f6868ad4a832">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the liability method. Deferred tax assets and liabilities are recognized for the temporary differences between the financial statement and income tax bases of assets and liabilities, and for operating losses and tax credit carryforwards. A valuation allowance is provided for the portion of deferred tax assets that is more likely than not to remain unrealized. Deferred tax assets and liabilities are measured using enacted tax rates and&#160;laws.  Deferred tax assets for outside basis differences in investments in subsidiaries are only recognized if the difference will be realized in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax benefit from an uncertain tax position is recognized only if it is more likely than not that the tax position will be sustained upon examination by the appropriate taxing authority, based on the technical merits of the position. The tax benefits recognized from such position are measured based on the amount for which there is a greater than 50% likelihood of being realized upon settlement. Liabilities associated with uncertain tax positions are classified as long-term unless expected to be paid within one year. Interest and penalties related to uncertain tax positions, if any, are recorded in the provision for income taxes and classified with the related liability on the consolidated balance&#160;sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <bhc:TaxBenefitRecognitionMeasurementPercentage
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzQ3Njgz_9d99d056-c0b6-4fc7-971e-ce08bbc8f0a2"
      unitRef="number">0.50</bhc:TaxBenefitRecognitionMeasurementPercentage>
    <bhc:MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzQ3ODQ2_aeb9eaf1-ab30-47ea-88d0-b0fdc592dd02">P1Y</bhc:MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MjQ1_84785da1-40bc-40b6-9c76-2a463549454b">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Loss Per Share Attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period. Diluted loss per share attributable to Bausch Health Companies Inc. is calculated by dividing Net loss attributable to Bausch Health Companies Inc. by the weighted-average number of common shares outstanding during the reporting period after giving effect to dilutive potential common shares for stock options and RSUs, determined using the treasury stock&#160;method.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MTk0_bd8d1e2e-f9f5-43ad-a602-d6faed618828">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss comprises Net loss and Other comprehensive (loss) income. Other comprehensive (loss) income includes items such as foreign currency translation adjustments, unrealized holding gains and losses on available-for-sale and other investments and certain pension and other postretirement benefit plan adjustments. Accumulated other comprehensive loss is recorded as a component of shareholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MjQ2_e6880480-4aa4-457b-9996-45934ee825c9">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingencies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company is subject to loss contingencies, such as claims and assessments arising from litigation and other legal proceedings, contractual indemnities, product and environmental liabilities and tax matters. Accruals for loss contingencies are recorded when the Company determines that it is both probable that a liability has been incurred and the amount of loss can be reasonably estimated. If the estimate of the amount of the loss is a range and some amount within the range appears to be a better estimate than any other amount within the range, that amount is accrued as a liability. If no amount within the range is a better estimate than any other amount, the minimum amount of the range is accrued as a&#160;liability. These accruals are adjusted periodically as assessments change or additional information becomes available.&lt;/span&gt;&lt;/div&gt;If no accrual is made for a loss contingency because the amount of loss cannot be reasonably estimated, the Company will disclose contingent liabilities when there is at least a reasonable possibility that a loss or an additional loss may have been incurred.</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:PensionAndOtherPostretirementPlansPolicy
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MjU3_ca6564d4-0c86-4b1b-bc24-ef0702964d02">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employee Benefit Plans &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors various retirement and pension plans, including defined benefit pension plans, defined contribution plans and a participatory defined benefit postretirement plan. The determination of defined benefit pension and postretirement plan obligations and their associated expenses requires the use of actuarial valuations to estimate the benefits employees earn while working, as well as the present value of those benefits. Net actuarial gains and losses that exceed 10 percent of the greater of the plan&#x2019;s projected benefit obligations or the market-related value of assets are amortized to earnings over the shorter of the estimated average future service period of the plan participants (or the &lt;/span&gt;&lt;/div&gt;estimated average future lifetime of the plan participants if the majority of plan participants are inactive) or the period until any anticipated final plan settlements.</us-gaap:PensionAndOtherPostretirementPlansPolicy>
    <bhc:DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzUwNTY0_08eea9a7-632b-4045-a32a-137553d3cb14"
      unitRef="number">0.10</bhc:DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzU0MDU5_1701634e-5268-49bb-8714-d655961cb133">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adoption of New&#160;Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board  (&#x201c;FASB&#x201d;) issued guidance on the impairment of financial instruments requiring an impairment model based on expected losses rather than incurred losses. Under this guidance, an entity recognizes as an allowance its estimate of expected credit losses.  The guidance was effective for the Company beginning January 1, 2020 and was applied using a modified retrospective approach through a cumulative-effect adjustment to accumulated deficit, which resulted in an increase to Accumulated deficit of less than $1&#160;million. The application of this guidance did not have a material effect on the Company's results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued guidance modifying the disclosure requirements for fair value measurement.  The guidance was effective for the Company beginning January 1, 2020. The application of this guidance did not have a material effect on the Company's disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued guidance modifying the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans.  The guidance was effective for annual periods ending after December 15, 2020. The application of this guidance did not have a material effect on the Company's disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.&#160; The guidance is effective for the Company beginning with annual periods beginning January 1, 2021.&#160; The application of this guidance did not have a material effect on the Company's financial position, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued guidance providing optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions that reference LIBOR or a reference rate that is expected to be discontinued as a result of reference rate reform.&#160; Optional expedients are provided for contract modification accounting within the areas of receivables, debt, leases, derivatives and hedging.&#160;The optional amendments are effective for all entities as of March 12, 2020, through December 31, 2022. During 2020 and 2021, the Company has not entered into any contract modifications in which the optional expedients were applied.&#160; However, if prior to December 31, 2022, the Company enters into a contract modification in which the optional expedients are applied, the Company will evaluate the impact of adoption of this guidance on its financial position, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2f5bb32797ed4025b477232d70d05dd7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTYvZnJhZzoyMDFmNDc3ZDAwMDI0MzA1ODk4YmZlNzk3YWNmODkyZC90ZXh0cmVnaW9uOjIwMWY0NzdkMDAwMjQzMDU4OThiZmU3OTdhY2Y4OTJkXzUxNTU1_8249bafe-5c63-4cbb-b558-f5a6c95603ef"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzY2Mjg_63f901e2-d0b6-4adb-8e5a-32feef185c2d">ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisition Agreement for Synergy Pharmaceuticals Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 6, 2019, the Company acquired certain assets of Synergy Pharmaceuticals Inc.  (&#x201c;Synergy&#x201d;) for a cash purchase price of approximately $180 million and the assumption of certain liabilities, pursuant to the terms approved by the U.S. Bankruptcy Court for the Southern District of New York on March 1, 2019. Among the assets acquired are the worldwide rights to the Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (plecanatide) product, a once-daily tablet for adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. This acquired business is included in the Company's Salix segment and is expected to result in additional revenues and costs savings associated with business synergies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets Acquired and Liabilities Assumed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition of certain assets of Synergy has been accounted for as a business combination under the acquisition method of accounting since: (i) substantially all of the fair value of the assets acquired is not&#160;concentrated in a single identifiable asset or group of similar identifiable assets and (ii) substantive inputs and processes were acquired to contribute to the creation of outputs. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed related to the acquisition of certain assets of Synergy as of the acquisition date:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product brand intangible assets (estimated useful life 7 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill associated with the acquisition of certain assets of Synergy is not deductible for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue and Operating Results &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues associated with the acquired assets of Synergy during the period March 6, 2019 through December 31, 2019 were $55 million. Operating results associated with the acquired assets of Synergy during the period March 6, 2019 through December 31, 2019 and pro-forma revenues and operating results for the year 2019 were not material. Included in Other expense, net for 2019 are acquisition-related costs of $8 million directly related to the acquisition of certain assets of Synergy, which include expenditures for advisory, legal, valuation, accounting and other similar services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no other material business combinations in 2021, 2020 or 2019. The measurement period for all acquisitions has closed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Option to Purchase All Ophthalmology Assets of Allegro Ophthalmics, LLC  (&#x201c;Allegro&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 21, 2020, the Company announced that it had entered into an agreement to acquire an option to purchase all of the ophthalmology assets of Allegro (the &#x201c;Option&#x201d;), a privately held biopharmaceutical company focused on the development of therapies that regulate integrin functions for the treatment of ocular diseases. Among the assets to be acquired if the Option was exercised, were the worldwide rights to risuteganib (Luminate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), Allegro's lead investigational compound in retina, which is believed to simultaneously act on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases such as intermediate dry Age-related Macular Degeneration.  During the three months ended September 30, 2020, the Company made and expensed as acquired IPR&amp;amp;D included in Other expense, net, an initial upfront payment of $10&#160;million to acquire the Option.  However, on June 23, 2021, Allegro notified the Company that it did not raise the additional funding required under the option agreement.  Pursuant to the terms of the option agreement, the Option thereby terminated, and the Company exercised its right to convert the $10&#160;million upfront payment into a minor equity interest in Allegro.  The Company expects that it will make no additional payments pursuant to this option agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Licensing Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company may enter into select licensing and collaborative agreements for the commercialization and/or development of unique products. These products are sometimes investigational treatments in early stage development that target unique conditions.  The ultimate outcome, including whether the product will be: (i) fully developed, (ii) approved by regulatory agencies, (iii) covered by third-party payors or (iv) profitable for distribution, is highly uncertain.  The commitment periods under these agreements vary and include customary termination provisions.  Expenses arising from commitments, if any, to fund the development and testing of these products and their promotion are recognized as incurred. Royalties due are recognized when earned and milestone payments are accrued when each milestone has been achieved and payment is probable and can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Divestiture of Amoun Pharmaceutical Company S.A.E.  (&#x201c;Amoun&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 31, 2021, the Company announced that it and certain of its affiliates had entered into a definitive agreement to sell all of its equity interests in Amoun for total gross consideration of approximately $740&#160;million (including the assignment to the purchasing entity of an intercompany loan granted by the Company to Amoun), subject to certain adjustments (the &#x201c;Amoun Sale&#x201d;). The Amoun Sale closed on July 26, 2021. As part of the Amoun Sale, cash generated by Amoun during the period from the locked-box date of January 1, 2021 through closing was for the benefit of the purchasing entity, subject to working capital during such period. Amoun manufactures, markets and distributes branded generics of human and animal health products. The Amoun business was part of the International segment (previously &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;included within the former Bausch + Lomb/International segment) and was reclassified as held for sale as of December 31, 2020. As a result of meeting the criteria for held for sale classification, the carrying value of the Amoun business, was adjusted to its estimated fair value, less costs to sell, and the Company recognized an impairment loss of $96&#160;million during the three months ended December 31, 2020 and an additional impairment loss of $88&#160;million during 2021, included within Asset impairments, including loss on assets held for sale in the Consolidated Statements of Operations. In connection with completing the Amoun Sale, the Company recognized an additional loss of $26&#160;million during 2021, included within Other (income) expense, net in the Combined Statements of Operations. The total loss of $210&#160;million includes the release of non-cash cumulative foreign currency translation losses of $340&#160;million, which were included as part of the carrying value of the Amoun business when measuring for impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in the Consolidated Balance Sheets as of December 31, 2020 are the following carrying amounts of the Amoun business' assets and liabilities held for sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.004%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.009%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade receivables, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill and Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ib7ab09da936244e1bea7e8bf2554b541_D20190306-20190306"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzIwNQ_2885afff-24ab-4480-afbc-f087079593ed"
      unitRef="usd">180000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzY1NDQ_5b321517-be35-4901-8faf-8f3b4cbca08b">The following table summarizes the estimated fair values of the assets acquired and liabilities assumed related to the acquisition of certain assets of Synergy as of the acquisition date:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.795%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.005%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product brand intangible assets (estimated useful life 7 years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of consideration transferred&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i3228597eb86549919c150d017affe6c9_I20190306"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTo3NzE1ZGFjM2YwYmM0OWRiYmIzYzliYWRlMzEzNTFkMi90YWJsZXJhbmdlOjc3MTVkYWMzZjBiYzQ5ZGJiYjNjOWJhZGUzMTM1MWQyXzEtMS0xLTEtOTQ4MzE_6c539db0-3a05-412b-9b78-20505dff46a1"
      unitRef="usd">7000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="i3228597eb86549919c150d017affe6c9_I20190306"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTo3NzE1ZGFjM2YwYmM0OWRiYmIzYzliYWRlMzEzNTFkMi90YWJsZXJhbmdlOjc3MTVkYWMzZjBiYzQ5ZGJiYjNjOWJhZGUzMTM1MWQyXzItMS0xLTEtOTQ4MzE_a24e407a-9997-4149-abfb-93685f4dc496"
      unitRef="usd">24000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="i3228597eb86549919c150d017affe6c9_I20190306"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTo3NzE1ZGFjM2YwYmM0OWRiYmIzYzliYWRlMzEzNTFkMi90YWJsZXJhbmdlOjc3MTVkYWMzZjBiYzQ5ZGJiYjNjOWJhZGUzMTM1MWQyXzMtMS0xLTEtOTQ4MzE_226b1ab4-bcb3-4699-ac71-9a14d5ef8dc8"
      unitRef="usd">5000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ib7ab09da936244e1bea7e8bf2554b541_D20190306-20190306"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTo3NzE1ZGFjM2YwYmM0OWRiYmIzYzliYWRlMzEzNTFkMi90YWJsZXJhbmdlOjc3MTVkYWMzZjBiYzQ5ZGJiYjNjOWJhZGUzMTM1MWQyXzQtMC0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo2ODI4ODkwNDgzMWU0YTQ4OGQxODI3MDc1YzMzZmM1OF81OQ_cbb274d1-fba9-4f5f-a37a-c73061ed4580">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i3228597eb86549919c150d017affe6c9_I20190306"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTo3NzE1ZGFjM2YwYmM0OWRiYmIzYzliYWRlMzEzNTFkMi90YWJsZXJhbmdlOjc3MTVkYWMzZjBiYzQ5ZGJiYjNjOWJhZGUzMTM1MWQyXzQtMS0xLTEtOTQ4MzE_b1e58c28-eda3-4c5b-a049-f86d99d4a91f"
      unitRef="usd">159000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i3228597eb86549919c150d017affe6c9_I20190306"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTo3NzE1ZGFjM2YwYmM0OWRiYmIzYzliYWRlMzEzNTFkMi90YWJsZXJhbmdlOjc3MTVkYWMzZjBiYzQ5ZGJiYjNjOWJhZGUzMTM1MWQyXzUtMS0xLTEtOTQ4MzE_c2e228fd-847c-4e16-b7c5-22a631b63774"
      unitRef="usd">1000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <bhc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses
      contextRef="i3228597eb86549919c150d017affe6c9_I20190306"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTo3NzE1ZGFjM2YwYmM0OWRiYmIzYzliYWRlMzEzNTFkMi90YWJsZXJhbmdlOjc3MTVkYWMzZjBiYzQ5ZGJiYjNjOWJhZGUzMTM1MWQyXzYtMS0xLTEtOTQ4MzE_1f413b5e-01ec-4b5b-a53d-046c5e2e4123"
      unitRef="usd">17000000</bhc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="i3228597eb86549919c150d017affe6c9_I20190306"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTo3NzE1ZGFjM2YwYmM0OWRiYmIzYzliYWRlMzEzNTFkMi90YWJsZXJhbmdlOjc3MTVkYWMzZjBiYzQ5ZGJiYjNjOWJhZGUzMTM1MWQyXzctMS0xLTEtOTQ4MzE_5ee43fd6-63f5-4036-99be-cffbe0f9ca24"
      unitRef="usd">177000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="i3228597eb86549919c150d017affe6c9_I20190306"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTo3NzE1ZGFjM2YwYmM0OWRiYmIzYzliYWRlMzEzNTFkMi90YWJsZXJhbmdlOjc3MTVkYWMzZjBiYzQ5ZGJiYjNjOWJhZGUzMTM1MWQyXzgtMS0xLTEtOTQ4MzE_b8406942-fed1-438d-9939-65f2a4141a5e"
      unitRef="usd">3000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i3228597eb86549919c150d017affe6c9_I20190306"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTo3NzE1ZGFjM2YwYmM0OWRiYmIzYzliYWRlMzEzNTFkMi90YWJsZXJhbmdlOjc3MTVkYWMzZjBiYzQ5ZGJiYjNjOWJhZGUzMTM1MWQyXzktMS0xLTEtOTQ4MzE_654119a4-49ed-4f45-9d60-c29cb070e5b4"
      unitRef="usd">180000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
      contextRef="ieaf743deafab4bc2bccd438cce5fc248_D20190306-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzE2MzI_d0cba8d6-e315-45bc-8083-2b0136c95c54"
      unitRef="usd">55000000</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <bhc:BusinessAcquisitionProFormaOperatingIncomeLoss
      contextRef="ifaffb0ddf4f849c6b6a4167f5b18f584_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzE4Mjc_597eb2f8-299f-4e30-9586-cae6c2c18869"
      unitRef="usd">0</bhc:BusinessAcquisitionProFormaOperatingIncomeLoss>
    <bhc:BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual
      contextRef="ieaf743deafab4bc2bccd438cce5fc248_D20190306-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzE4Mjc_5a0288a8-5d0e-46a3-96f1-6f650ba18503"
      unitRef="usd">0</bhc:BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual>
    <us-gaap:BusinessAcquisitionsProFormaRevenue
      contextRef="ifaffb0ddf4f849c6b6a4167f5b18f584_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzE4Mjc_e7a30ac1-1382-4bbf-9b22-fccdad3db981"
      unitRef="usd">0</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ifaffb0ddf4f849c6b6a4167f5b18f584_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzE4OTg_84d27ff6-64be-47db-b29c-5af033fd6b1a"
      unitRef="usd">-8000000</us-gaap:OtherNonoperatingIncomeExpense>
    <bhc:NumberOfOtherBusinessesAcquired
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzIwNzY_4620f66a-30fa-4c71-b76b-b21c1758a579"
      unitRef="businesscombination">0</bhc:NumberOfOtherBusinessesAcquired>
    <bhc:NumberOfOtherBusinessesAcquired
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzIwNzY_b86ce378-ec30-418e-a69c-266151bd20db"
      unitRef="businesscombination">0</bhc:NumberOfOtherBusinessesAcquired>
    <bhc:NumberOfOtherBusinessesAcquired
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzIwNzY_df225f65-44aa-4a4e-99f8-79f53b83ea4c"
      unitRef="businesscombination">0</bhc:NumberOfOtherBusinessesAcquired>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="ic9f191dca8cb406ead6fbd0a27981bb3_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzMxMTA_5278152f-8ebc-48ca-92a2-ab37f1addfcc"
      unitRef="usd">10000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi
      contextRef="ie23b3d96ce1248c98d46a1440bd6d937_D20210623-20210623"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzM0MDU_5fb308a7-835f-4687-a488-b08d317d129d"
      unitRef="usd">10000000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <bhc:AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzM1MDQ_6e5ef7c1-7a74-4d27-8cd6-08e9123b3c77"
      unitRef="usd">0</bhc:AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="id741d32018d54352affe7795fbf6464e_D20210726-20210726"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzQ3NzE_01e91e70-eeac-4920-a93e-78315530b053"
      unitRef="usd">740000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i6e7cb1daba9744fc8e55c867cd1d063f_D20201001-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzU3MTY_c5a3b5fd-89ad-417e-8f90-a62b74f5e0ef"
      unitRef="usd">96000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="id21d49c675e3425b871866e8870406fc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzU4MDQ_7cd8b091-3984-4958-b4ed-8eaac1e1552e"
      unitRef="usd">88000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i5b13ca98db8c463aaeed70c3abe4f348_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzYwMzE_07dda7ad-5be2-4a11-b368-eb52503b9c6e"
      unitRef="usd">26000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="id64abf2e66454ecb8393494a9d2a34a1_D20200101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzYxNTE_7928140c-5466-42b3-bb6c-1bdde88dfcfd"
      unitRef="usd">210000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <bhc:NoncashCumulativeForeignCurrencyTranslationLoss
      contextRef="id64abf2e66454ecb8393494a9d2a34a1_D20200101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzYyMzc_d1f4a03f-0ef1-4aec-97eb-2d8d36b59b8b"
      unitRef="usd">340000000</bhc:NoncashCumulativeForeignCurrencyTranslationLoss>
    <us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90ZXh0cmVnaW9uOmRkNTIzYTZmNGU5NjQ1ZGRiZWZjMWUxNjQwYmU4YzVlXzY1MzY_ee89df11-4628-4c3a-b8f4-5e3814254f89">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in the Consolidated Balance Sheets as of December 31, 2020 are the following carrying amounts of the Amoun business' assets and liabilities held for sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.004%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.353%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.009%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade receivables, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill and Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="id9dae4cbf28945e690c15be6b4c2db5e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTphNTlhNjU4ZTlhZWM0MTk5OWFlNWYyNGRkZGE1YWI2NC90YWJsZXJhbmdlOmE1OWE2NThlOWFlYzQxOTk5YWU1ZjI0ZGRkYTVhYjY0XzItMi0xLTEtOTQ4MzE_e88c6ffe-acdc-41fe-a0df-36352ea972b1"
      unitRef="usd">91000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent
      contextRef="id9dae4cbf28945e690c15be6b4c2db5e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTphNTlhNjU4ZTlhZWM0MTk5OWFlNWYyNGRkZGE1YWI2NC90YWJsZXJhbmdlOmE1OWE2NThlOWFlYzQxOTk5YWU1ZjI0ZGRkYTVhYjY0XzItNi0xLTEtOTQ4MzE_fd2729fb-6fe9-46a8-a04a-41a86230f724"
      unitRef="usd">7000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
      contextRef="id9dae4cbf28945e690c15be6b4c2db5e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTphNTlhNjU4ZTlhZWM0MTk5OWFlNWYyNGRkZGE1YWI2NC90YWJsZXJhbmdlOmE1OWE2NThlOWFlYzQxOTk5YWU1ZjI0ZGRkYTVhYjY0XzMtMi0xLTEtOTQ4MzE_ecbdbf45-f476-4d49-a551-e84e06b28cf1"
      unitRef="usd">63000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
    <bhc:DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent
      contextRef="id9dae4cbf28945e690c15be6b4c2db5e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTphNTlhNjU4ZTlhZWM0MTk5OWFlNWYyNGRkZGE1YWI2NC90YWJsZXJhbmdlOmE1OWE2NThlOWFlYzQxOTk5YWU1ZjI0ZGRkYTVhYjY0XzMtNi0xLTEtOTQ4MzE_0da9ce33-e9c4-4a68-b8ba-18d038318d06"
      unitRef="usd">28000000</bhc:DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent
      contextRef="id9dae4cbf28945e690c15be6b4c2db5e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTphNTlhNjU4ZTlhZWM0MTk5OWFlNWYyNGRkZGE1YWI2NC90YWJsZXJhbmdlOmE1OWE2NThlOWFlYzQxOTk5YWU1ZjI0ZGRkYTVhYjY0XzQtMi0xLTEtOTQ4MzE_0c02eceb-2617-42c4-94f6-b34cd9fa2c81"
      unitRef="usd">8000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities
      contextRef="id9dae4cbf28945e690c15be6b4c2db5e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTphNTlhNjU4ZTlhZWM0MTk5OWFlNWYyNGRkZGE1YWI2NC90YWJsZXJhbmdlOmE1OWE2NThlOWFlYzQxOTk5YWU1ZjI0ZGRkYTVhYjY0XzQtNi0xLTEtOTQ4MzE_121a1529-704c-40f3-887e-19546cd53e9c"
      unitRef="usd">35000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets
      contextRef="id9dae4cbf28945e690c15be6b4c2db5e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTphNTlhNjU4ZTlhZWM0MTk5OWFlNWYyNGRkZGE1YWI2NC90YWJsZXJhbmdlOmE1OWE2NThlOWFlYzQxOTk5YWU1ZjI0ZGRkYTVhYjY0XzUtMi0xLTEtOTQ4MzE_6ab4dbaa-1dae-4faf-b50a-bb0ff7fae8a1"
      unitRef="usd">162000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent
      contextRef="id9dae4cbf28945e690c15be6b4c2db5e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTphNTlhNjU4ZTlhZWM0MTk5OWFlNWYyNGRkZGE1YWI2NC90YWJsZXJhbmdlOmE1OWE2NThlOWFlYzQxOTk5YWU1ZjI0ZGRkYTVhYjY0XzctMi0xLTEtOTQ4MzE_c28325ad-b893-4b87-adc7-58c2293902eb"
      unitRef="usd">68000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities
      contextRef="id9dae4cbf28945e690c15be6b4c2db5e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTphNTlhNjU4ZTlhZWM0MTk5OWFlNWYyNGRkZGE1YWI2NC90YWJsZXJhbmdlOmE1OWE2NThlOWFlYzQxOTk5YWU1ZjI0ZGRkYTVhYjY0XzctNi0xLTEtOTQ4MzE_fcbc54e2-3e3d-4f0f-8971-341c49a6dac2"
      unitRef="usd">36000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent
      contextRef="id9dae4cbf28945e690c15be6b4c2db5e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTphNTlhNjU4ZTlhZWM0MTk5OWFlNWYyNGRkZGE1YWI2NC90YWJsZXJhbmdlOmE1OWE2NThlOWFlYzQxOTk5YWU1ZjI0ZGRkYTVhYjY0XzgtMi0xLTEtOTQ4MzE_23917ab4-09ad-47a9-bb18-bfb2e0f71678"
      unitRef="usd">245000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
    <bhc:DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent
      contextRef="id9dae4cbf28945e690c15be6b4c2db5e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTphNTlhNjU4ZTlhZWM0MTk5OWFlNWYyNGRkZGE1YWI2NC90YWJsZXJhbmdlOmE1OWE2NThlOWFlYzQxOTk5YWU1ZjI0ZGRkYTVhYjY0XzgtNi0xLTEtOTQ4MzE_7c674408-e380-4f64-bc8e-063f336fa702"
      unitRef="usd">21000000</bhc:DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets
      contextRef="id9dae4cbf28945e690c15be6b4c2db5e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTphNTlhNjU4ZTlhZWM0MTk5OWFlNWYyNGRkZGE1YWI2NC90YWJsZXJhbmdlOmE1OWE2NThlOWFlYzQxOTk5YWU1ZjI0ZGRkYTVhYjY0XzktMi0xLTEtOTQ4MzE_085b5774-8db7-4e24-9c4d-7ea42216cea5"
      unitRef="usd">2000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities
      contextRef="id9dae4cbf28945e690c15be6b4c2db5e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTphNTlhNjU4ZTlhZWM0MTk5OWFlNWYyNGRkZGE1YWI2NC90YWJsZXJhbmdlOmE1OWE2NThlOWFlYzQxOTk5YWU1ZjI0ZGRkYTVhYjY0XzktNi0xLTEtOTQ4MzE_bd3a70ed-c55b-404a-baa0-57896d81bb87"
      unitRef="usd">57000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets
      contextRef="id9dae4cbf28945e690c15be6b4c2db5e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMTkvZnJhZzpkZDUyM2E2ZjRlOTY0NWRkYmVmYzFlMTY0MGJlOGM1ZS90YWJsZTphNTlhNjU4ZTlhZWM0MTk5OWFlNWYyNGRkZGE1YWI2NC90YWJsZXJhbmdlOmE1OWE2NThlOWFlYzQxOTk5YWU1ZjI0ZGRkYTVhYjY0XzEwLTItMS0xLTk0ODMx_28b2c95f-ab69-47af-ac9b-1ea5279d04a5"
      unitRef="usd">315000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjIvZnJhZzo2YzE5YWE4MWIzNWQ0YzliOGYyZGQ3MjA0YzMwMWU3Ny90ZXh0cmVnaW9uOjZjMTlhYTgxYjM1ZDRjOWI4ZjJkZDcyMDRjMzAxZTc3XzIzODI_4313ae86-c018-4b43-a632-e9ea95214d2e">RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restructuring and integration costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates opportunities to improve its operating results and implements cost savings programs to streamline its operations and eliminate&#160;redundant processes and expenses. Restructuring and integration costs are expenses associated with the implementation of these cost savings programs and include expenses associated with: (i)&#160;reducing headcount, (ii)&#160;eliminating real estate costs associated with unused or under-utilized facilities and (iii) implementing contribution margin improvement and other cost reduction initiatives. The liability associated with restructuring and integration costs as of December 31, 2021 was $19 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred $18&#160;million, $11&#160;million and $31&#160;million of restructuring and integration-related costs and made payments of $19&#160;million, $18&#160;million and $31 million during 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Separation costs, Separation-related costs, IPO Costs and IPO-related Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred, and will incur, costs associated with activities to effectuate the B+L Separation and the Solta IPO. These activities include: (i) separating the Bausch + Lomb and Solta Medical businesses from the remainder of the Company and (ii) registering the Bausch + Lomb and Solta Medical businesses as independent publicly traded entities. Separation and IPO costs are incremental costs directly related to the B+L Separation and Solta IPO and include, but are not limited to: (i) legal, audit and advisory fees, (ii) talent acquisition costs and (iii) costs associated with establishing a new board of directors and related board committees for the Bausch + Lomb and Solta Medical entities. Included in Restructuring, integration, separation and IPO costs for the years ended December 31, 2021 and 2020 are Separation and IPO costs of $32&#160;million and $11&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has also incurred, and will incur, Separation-related and IPO-related costs which are incremental costs indirectly related to the B+L Separation and Solta IPO. Separation-related and IPO-related costs include, but are not limited to: (i) IT infrastructure and software licensing costs, (ii) rebranding costs and (iii) costs associated with facility relocation and/or modification. Included in Selling, general and administrative for years ended December 31, 2021 and 2020 are Separation-related and IPO-related costs of $132&#160;million and $21&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The extent and timing of future charges for these costs cannot be reasonably estimated at this time and could be material.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i0e08237054f64594815ad5013a5aa9e4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjIvZnJhZzo2YzE5YWE4MWIzNWQ0YzliOGYyZGQ3MjA0YzMwMWU3Ny90ZXh0cmVnaW9uOjZjMTlhYTgxYjM1ZDRjOWI4ZjJkZDcyMDRjMzAxZTc3XzY1OA_9552cd6a-efec-4c63-b686-62e6f6e5adaa"
      unitRef="usd">19000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i8a1258a2943a4cd69dc73c01e660d449_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjIvZnJhZzo2YzE5YWE4MWIzNWQ0YzliOGYyZGQ3MjA0YzMwMWU3Ny90ZXh0cmVnaW9uOjZjMTlhYTgxYjM1ZDRjOWI4ZjJkZDcyMDRjMzAxZTc3XzY4Mw_d116bbcf-99dc-4c57-af34-c6c02ba701b3"
      unitRef="usd">18000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="i405dec7379e74ca38494473ae3975347_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjIvZnJhZzo2YzE5YWE4MWIzNWQ0YzliOGYyZGQ3MjA0YzMwMWU3Ny90ZXh0cmVnaW9uOjZjMTlhYTgxYjM1ZDRjOWI4ZjJkZDcyMDRjMzAxZTc3XzY4Nw_5067a094-f4fc-450e-b17e-8caf23ea6e03"
      unitRef="usd">11000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="icc79228c9dac48f29a1d9bd8078aa0c4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjIvZnJhZzo2YzE5YWE4MWIzNWQ0YzliOGYyZGQ3MjA0YzMwMWU3Ny90ZXh0cmVnaW9uOjZjMTlhYTgxYjM1ZDRjOWI4ZjJkZDcyMDRjMzAxZTc3XzY5NA_e8b67f66-f7e0-47ff-a66b-a398b37237f0"
      unitRef="usd">31000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:PaymentsForRestructuring
      contextRef="i8a1258a2943a4cd69dc73c01e660d449_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjIvZnJhZzo2YzE5YWE4MWIzNWQ0YzliOGYyZGQ3MjA0YzMwMWU3Ny90ZXh0cmVnaW9uOjZjMTlhYTgxYjM1ZDRjOWI4ZjJkZDcyMDRjMzAxZTc3Xzc2NQ_01705965-ac35-49cf-b697-0e103f91dad9"
      unitRef="usd">19000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i405dec7379e74ca38494473ae3975347_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjIvZnJhZzo2YzE5YWE4MWIzNWQ0YzliOGYyZGQ3MjA0YzMwMWU3Ny90ZXh0cmVnaW9uOjZjMTlhYTgxYjM1ZDRjOWI4ZjJkZDcyMDRjMzAxZTc3Xzc2OQ_4927d53c-9e4e-44d9-abbf-2707088065ba"
      unitRef="usd">18000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="icc79228c9dac48f29a1d9bd8078aa0c4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjIvZnJhZzo2YzE5YWE4MWIzNWQ0YzliOGYyZGQ3MjA0YzMwMWU3Ny90ZXh0cmVnaW9uOjZjMTlhYTgxYjM1ZDRjOWI4ZjJkZDcyMDRjMzAxZTc3Xzc3Ng_321405d7-761e-47cb-9e4c-ff53cbb22311"
      unitRef="usd">31000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringCharges
      contextRef="i813493bb33fc46b7a7a4c4b6aa9f0252_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjIvZnJhZzo2YzE5YWE4MWIzNWQ0YzliOGYyZGQ3MjA0YzMwMWU3Ny90ZXh0cmVnaW9uOjZjMTlhYTgxYjM1ZDRjOWI4ZjJkZDcyMDRjMzAxZTc3XzE3MTU_b4280557-5cbc-472b-a583-537770f1d294"
      unitRef="usd">32000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i10381b45a049401593f3912db2562a03_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjIvZnJhZzo2YzE5YWE4MWIzNWQ0YzliOGYyZGQ3MjA0YzMwMWU3Ny90ZXh0cmVnaW9uOjZjMTlhYTgxYjM1ZDRjOWI4ZjJkZDcyMDRjMzAxZTc3XzE3MjI_8ce9eccc-fbe5-4774-ad1a-5db9b3a33c8b"
      unitRef="usd">11000000</us-gaap:RestructuringCharges>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i813493bb33fc46b7a7a4c4b6aa9f0252_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjIvZnJhZzo2YzE5YWE4MWIzNWQ0YzliOGYyZGQ3MjA0YzMwMWU3Ny90ZXh0cmVnaW9uOjZjMTlhYTgxYjM1ZDRjOWI4ZjJkZDcyMDRjMzAxZTc3XzIyMzY_e41b9c6d-a543-4ede-86b8-a20338be061c"
      unitRef="usd">132000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i10381b45a049401593f3912db2562a03_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjIvZnJhZzo2YzE5YWE4MWIzNWQ0YzliOGYyZGQ3MjA0YzMwMWU3Ny90ZXh0cmVnaW9uOjZjMTlhYTgxYjM1ZDRjOWI4ZjJkZDcyMDRjMzAxZTc3XzIyNDM_3119ce75-1cec-4047-b4f5-02a1663f2b34"
      unitRef="usd">21000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzU4MzE_b20e4b4a-4db6-4698-97b5-aa9e2cc852e5">FAIR VALUE MEASUREMENTS&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value measurements are estimated based on valuation techniques and inputs categorized as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;1&#160;&#x2014;&#160;Quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;2&#160;&#x2014;&#160;Observable inputs other than Level&#160;1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;&#160;and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level&#160;3&#160;&#x2014;&#160;Unobservable inputs that are supported by little or no market activity and that are financial instruments whose values are determined using discounted cash flow methodologies, pricing models, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or&#160;estimation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the&#160;instrument.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy table presents the components and classification of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis as of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted cash and other settlement deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of highly liquid investments, primarily money market funds, with maturities of three months or less when&#160;purchased, and are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, Restricted cash and other settlement deposits includes $1,510&#160;million of payments into escrow funds under the terms of settlement agreements regarding that certain U.S. securities litigation (subject to an objector's appeal of the final court approval) and the Glumetza Antitrust Litigation. These payments are reflected in the Consolidated Balance Sheets at carrying value, which approximates fair value due to their short-term nature.  These payments will remain in escrow until final approval of the settlements as discussed in Note 20, &#x201c;LEGAL PROCEEDINGS&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers into or out of Level 3 during 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cross-currency Swaps&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, the Company entered into cross-currency swaps, with aggregate notional amounts of $1,250 million, to mitigate fluctuation in the value of a portion of its euro-denominated net investment in its consolidated financial statements from adverse movements in exchange rates. The euro-denominated net investment being hedged was the Company&#x2019;s investment in certain euro-denominated subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During November 2021, the Company entered into a transaction to unwind its cross-currency swaps and received net proceeds of $4&#160;million, which included interest income of $6&#160;million, offset by the amount owed by the Company upon the unwinding of $2&#160;million. The gain arising from the transaction of the swaps has been included as a component of Other comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities associated with the Company's cross-currency swaps as included in the Consolidated Balance Sheets as of December 31, 2021 and 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of hedging instruments on the Consolidated Statements of Operations and Consolidated Statements of Comprehensive Loss for 2021 and 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized in Other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain excluded from assessment of hedge effectiveness&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Location of gain of excluded component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2021 and 2020, the Company received $27&#160;million and $23&#160;million, respectively, in settlements of its cross-currency swaps which are reported as Investing activities in the Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Exchange Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021 and 2020, the Company entered into foreign currency exchange contracts.  As of December&#160;31, 2021, these contracts had an aggregate outstanding notional amount of $166&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities associated with the Company's foreign exchange contracts as included in the Consolidated Balance Sheets as of December 31, 2021 and 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of the Company's foreign exchange contracts on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) related to changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss related to settlements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisition-related Contingent Consideration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value measurement of contingent consideration obligations arising from business combinations is determined via a probability-weighted discounted cash flow analysis, using unobservable (Level&#160;3) inputs. These inputs may include: (i)&#160;the estimated amount and timing of projected cash flows, (ii)&#160;the probability of the achievement of the factor(s) on which the contingency is based and (iii)&#160;the risk-adjusted discount rate used to present value the probability-weighted cash&#160;flows. Significant increases or decreases in any of those inputs in isolation could result in a significantly higher or lower fair value measurement. At December&#160;31, 2021, the fair value measurements of acquisition-related contingent consideration were determined using risk-adjusted discount rates ranging from 6% to 18%, and a weighted average risk-adjusted discount rate of 7%. The weighted average risk-adjusted discount rate was calculated by weighting each contract's relative fair value at December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the years 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Beginning balance, January 1, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to Acquisition-related contingent consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion for the time value of money&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments / Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment included in other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance, December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components and classification of the Company&#x2019;s financial assets and liabilities measured at fair value on a non-recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.277%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.364%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current assets held for sale of $245&#160;million as of December 31, 2020 were remeasured to estimated fair value, less costs to sell, which utilized Level 3 unobservable inputs. See Note 3, &#x201c;ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE&#x201d; for additional details regarding these assets held for sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value of Long-term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of long-term debt as of December&#160;31, 2021 and 2020 was $22,689 million and $25,378 million, respectively, and was estimated using the quoted market prices for the same or similar debt issuances (Level 2).&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzU4MTM_8fdc2b76-6071-4769-9b84-a39c7a36af37">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy table presents the components and classification of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis as of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.200%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#160;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted cash and other settlement deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3f6583316fc34f2ebde02bee82fce983_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzMtMi0xLTEtOTQ4MzE_a5c155eb-8216-463d-bb51-7999eed32163"
      unitRef="usd">76000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifadbfa9e788b43cba3cad3e76ae5d807_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzMtNC0xLTEtOTQ4MzE_8203bc6f-34b0-4166-8ddf-446f6816e937"
      unitRef="usd">58000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7aec1240743845078358d61e36c809cf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzMtNi0xLTEtOTQ4MzE_d13bc5ac-e1f6-4b76-8fd1-df6f285505c7"
      unitRef="usd">18000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2abe9143f14849f1bc9dd6da011f2cf4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzMtOC0xLTEtOTQ4MzE_266852dd-fd79-41e8-9828-edc5f527450e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3319185b216a47d3b6da5be2dc91b570_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzMtMTAtMS0xLTk0ODMx_c73db9ad-05a9-479d-99f5-f0ae4dd98e0b"
      unitRef="usd">41000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia48dede4a3424904945186832465d56a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzMtMTItMS0xLTk0ODMx_9682b81c-6a1a-41d9-85cb-992d4426e06b"
      unitRef="usd">8000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie64c787ebb9447d0a92c7295f0f6d419_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzMtMTQtMS0xLTk0ODMx_7ac8903f-52d2-48b9-8043-95adb5822a6f"
      unitRef="usd">33000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia04ea7b71bd04c6d9cf8679abe9ec99e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzMtMTYtMS0xLTk0ODMx_d68cff4a-2a73-41af-b3ba-d3dee701d332"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="i3f6583316fc34f2ebde02bee82fce983_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzQtMi0xLTEtOTQ4MzE_9bcf1318-f524-4a5d-8c83-c8ae507e6aa1"
      unitRef="usd">1537000000</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="ifadbfa9e788b43cba3cad3e76ae5d807_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzQtNC0xLTEtOTQ4MzE_b503e69c-9ce6-4cec-893d-ff5d39a2f4a1"
      unitRef="usd">1537000000</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="i7aec1240743845078358d61e36c809cf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzQtNi0xLTEtOTQ4MzE_141d1677-085a-417f-b7b1-857d19a06fcc"
      unitRef="usd">0</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="i2abe9143f14849f1bc9dd6da011f2cf4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzQtOC0xLTEtOTQ4MzE_85e62b12-dde3-4b35-bb91-15bec9ae0d28"
      unitRef="usd">0</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="i3319185b216a47d3b6da5be2dc91b570_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzQtMTAtMS0xLTk0ODMx_c2ab82da-a509-49f2-a76e-3c0eaf78c95f"
      unitRef="usd">1211000000</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="ia48dede4a3424904945186832465d56a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzQtMTItMS0xLTk0ODMx_ef629ab8-68ad-47c8-84d2-182772d68e6f"
      unitRef="usd">1211000000</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="ie64c787ebb9447d0a92c7295f0f6d419_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzQtMTQtMS0xLTk0ODMx_f2afcb89-15b5-453f-a0be-02bc0757d1d5"
      unitRef="usd">0</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure
      contextRef="ia04ea7b71bd04c6d9cf8679abe9ec99e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzQtMTYtMS0xLTk0ODMx_48470e93-b22c-410c-87ca-991d0dc29f5c"
      unitRef="usd">0</bhc:RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure>
    <us-gaap:DerivativeAssets
      contextRef="i7e44595ee4a14fcabb69571771959535_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzUtMi0xLTEtOTQ4MzE_4a5849d2-10ea-4520-8bb2-2f539f35f097"
      unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i78ba78cf61414c25a16502d502d685c6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzUtNC0xLTEtOTQ4MzE_c5e7edf8-b329-4df4-8334-d308b0b50515"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i70b47e80f74944c99ac1f1b1f772d335_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzUtNi0xLTEtOTQ4MzE_37b2c69e-ebc2-4f59-9b15-93299cb3a546"
      unitRef="usd">1000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ie46f9e499c3b4367a00f89844e5b3e05_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzUtOC0xLTEtOTQ4MzE_5812db49-32be-4e3d-8b39-2ac64fa6e975"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ia18f0da75a394809a608e7d0eae6fa53_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzUtMTAtMS0xLTk0ODMx_53f33fc6-14dd-4ca5-9749-2ccfa659d26a"
      unitRef="usd">3000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i7ecd69567c0b46f5b506f1e4c711298e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzUtMTItMS0xLTk0ODMx_9f4c53e8-0817-468b-9b3e-ca630bdebee4"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i440fa512b3bd4579bb8d93cc9d65ddd0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzUtMTQtMS0xLTk0ODMx_d9571f27-b560-4987-8844-f7ea5d05c2c1"
      unitRef="usd">3000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="if1313267327e41edacf2aecaa695623a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzUtMTYtMS0xLTk0ODMx_550c05b2-807f-4815-a11b-7ab23f4f83e0"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i3f6583316fc34f2ebde02bee82fce983_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzctMi0xLTEtOTQ4MzE_a089a2f1-0ef4-4b15-afc7-80adafeda3e5"
      unitRef="usd">241000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="ifadbfa9e788b43cba3cad3e76ae5d807_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzctNC0xLTEtOTQ4MzE_65c725d0-8863-4d7b-894b-6fd6aa00fe2c"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i7aec1240743845078358d61e36c809cf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzctNi0xLTEtOTQ4MzE_7942d034-ba02-44dc-bbb2-5c80fda3384e"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i2abe9143f14849f1bc9dd6da011f2cf4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzctOC0xLTEtOTQ4MzE_4cf8c8b7-e696-4d91-b903-257836a34d7f"
      unitRef="usd">241000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="i3319185b216a47d3b6da5be2dc91b570_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzctMTAtMS0xLTk0ODMx_f80d1d0a-8c83-43ef-860e-1238d22bf149"
      unitRef="usd">328000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="ia48dede4a3424904945186832465d56a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzctMTItMS0xLTk0ODMx_1e65434b-02af-4d94-9d59-2981edf211c9"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="ie64c787ebb9447d0a92c7295f0f6d419_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzctMTQtMS0xLTk0ODMx_426bc45a-d813-4404-8d3c-336f392f6bc3"
      unitRef="usd">0</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure
      contextRef="ia04ea7b71bd04c6d9cf8679abe9ec99e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzctMTYtMS0xLTk0ODMx_29b110f4-04ce-4fd5-a8ec-95cbb545c7d3"
      unitRef="usd">328000000</bhc:BusinessAcquisitionContingentConsiderationFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="i7a6ca21431734f2b82ccc26320d115b4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzgtMi0xLTEtOTQ4MzE_764f2331-a020-4af1-8496-4e42a2efa15f"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="if285ca9b8419448ca0ecfe732b387fab_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzgtNC0xLTEtOTQ4MzE_ea4cc7a6-ccd7-4f51-9bf4-605ccd3affad"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i7727cda61cec499488b86e1b280aba86_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzgtNi0xLTEtOTQ4MzE_1ef2202f-bc05-49ec-b6e4-bf96f453ce97"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ic622a69d05a04c3da2e6c078832136fb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzgtOC0xLTEtOTQ4MzE_0e3b7943-24f4-4b9d-86a6-1c5a9c639625"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="iff786c33709b42768b27ac83294252fa_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzgtMTAtMS0xLTk0ODMx_6a784cb2-cf5e-4c45-9101-25b4f036fdb4"
      unitRef="usd">70000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ia2ec169a70624d1a9715b177b9eed016_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzgtMTItMS0xLTk0ODMx_f4f222fb-dd4e-49ec-835b-919a19642b11"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ia3c641a323124a5e909b2269cea5b838_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzgtMTQtMS0xLTk0ODMx_63ada723-5d21-4a01-8d2c-30dd61f9ba65"
      unitRef="usd">70000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="if60700f229f0413882411855a4cc706a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzgtMTYtMS0xLTk0ODMx_467014da-4a95-462c-a325-2f10e704593a"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i7e44595ee4a14fcabb69571771959535_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzktMi0xLTEtOTQ4MzE_144b6f4e-5d0a-44e9-935b-19ae4c4bc683"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i78ba78cf61414c25a16502d502d685c6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzktNC0xLTEtOTQ4MzE_7e9f815c-6ee3-4528-9561-cb50d268c1b3"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i70b47e80f74944c99ac1f1b1f772d335_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzktNi0xLTEtOTQ4MzE_a3231062-cc63-4500-9824-90adc32e2b26"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ie46f9e499c3b4367a00f89844e5b3e05_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzktOC0xLTEtOTQ4MzE_b9a29cba-f7e3-4999-a015-058cd4d8d277"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ia18f0da75a394809a608e7d0eae6fa53_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzktMTAtMS0xLTk0ODMx_d3fd8ff0-c04e-4c0d-9881-150139c54bcd"
      unitRef="usd">11000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i7ecd69567c0b46f5b506f1e4c711298e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzktMTItMS0xLTk0ODMx_b6081996-afd5-4c83-9c5d-783f72b7de55"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i440fa512b3bd4579bb8d93cc9d65ddd0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzktMTQtMS0xLTk0ODMx_8b732d75-ef10-41ff-8498-969ba963f559"
      unitRef="usd">11000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="if1313267327e41edacf2aecaa695623a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNjEwOGQ4OWU1Y2U0NDE3ODkwNTVkNDU3M2U2ZjZiNi90YWJsZXJhbmdlOmY2MTA4ZDg5ZTVjZTQ0MTc4OTA1NWQ0NTczZTZmNmI2XzktMTYtMS0xLTk0ODMx_90fb1d7d-36d2-4c12-acbe-f857833b836d"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <bhc:HighlyLiquidInvestmentsMaturityPeriod
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzEzODk_e25e18b5-82a6-4082-8b81-7f21d32d8db2">P3M</bhc:HighlyLiquidInvestmentsMaturityPeriod>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i6ad175767e714adb952f1fc81f92fc67_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzE1NzI_e768c93c-282e-4a38-a7fc-103003d5b66a"
      unitRef="usd">1510000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ic25e35c549a54c708a26494e39477c78_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzIyMjE_d98a7a44-11ce-406d-ab03-48caef4fd617"
      unitRef="usd">1250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ProceedsFromHedgeInvestingActivities
      contextRef="ia2313e85fce74e5aae451d3654b4cc63_D20211101-20211130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzI2NDI_c3c33cde-e0f9-4953-b186-47806c16a5f8"
      unitRef="usd">4000000</us-gaap:ProceedsFromHedgeInvestingActivities>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ia2313e85fce74e5aae451d3654b4cc63_D20211101-20211130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzI2ODA_a6c8fe54-723f-49c7-977d-d138f1a5a4a4"
      unitRef="usd">6000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:PaymentsForProceedsFromHedgeInvestingActivities
      contextRef="i2543b8697622497798f72858198a9b4e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzI3NDc_404b5977-489e-416d-aa3d-9db86aaade7a"
      unitRef="usd">2000000</us-gaap:PaymentsForProceedsFromHedgeInvestingActivities>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzU4MTU_a6f8d7b5-2e74-406e-b6fd-ea953fffb41e">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities associated with the Company's cross-currency swaps as included in the Consolidated Balance Sheets as of December 31, 2021 and 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets and liabilities associated with the Company's foreign exchange contracts as included in the Consolidated Balance Sheets as of December 31, 2021 and 2020 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="ib6236fa286e14aeabadb9f150267531f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTowODA1YjgwNjNjY2U0M2JkYTMyMjJmNjVkOWIwY2ZkNS90YWJsZXJhbmdlOjA4MDViODA2M2NjZTQzYmRhMzIyMmY2NWQ5YjBjZmQ1XzEtMS0xLTEtOTQ4MzE_ac4c8309-705a-447b-be7f-41dd9f808302"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="i2d8c9c1bfdd840429f53aab587d9c839_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTowODA1YjgwNjNjY2U0M2JkYTMyMjJmNjVkOWIwY2ZkNS90YWJsZXJhbmdlOjA4MDViODA2M2NjZTQzYmRhMzIyMmY2NWQ5YjBjZmQ1XzEtMy0xLTEtOTQ4MzE_f1c474e9-77fa-4747-ac03-b6c1e9451c06"
      unitRef="usd">79000000</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i7b510358d6854ed28e6f46e5f58ded33_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTowODA1YjgwNjNjY2U0M2JkYTMyMjJmNjVkOWIwY2ZkNS90YWJsZXJhbmdlOjA4MDViODA2M2NjZTQzYmRhMzIyMmY2NWQ5YjBjZmQ1XzItMS0xLTEtOTQ4MzE_ce8c95b6-1091-4f71-83fb-63acb42d67a6"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="id6beec5955f640bf84cf335c76410fb7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTowODA1YjgwNjNjY2U0M2JkYTMyMjJmNjVkOWIwY2ZkNS90YWJsZXJhbmdlOjA4MDViODA2M2NjZTQzYmRhMzIyMmY2NWQ5YjBjZmQ1XzItMy0xLTEtOTQ4MzE_d5fd2f3c-ed92-45df-b49c-f17461e2a194"
      unitRef="usd">9000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeLiabilities
      contextRef="i4ac58aeb82cb4d5da0dc54736de89480_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTowODA1YjgwNjNjY2U0M2JkYTMyMjJmNjVkOWIwY2ZkNS90YWJsZXJhbmdlOjA4MDViODA2M2NjZTQzYmRhMzIyMmY2NWQ5YjBjZmQ1XzMtMS0xLTEtOTQ4MzE_ccb69d2c-9c8c-48be-9306-3dced472f2eb"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i5cd1bac2236840fd955596ca631b176d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTowODA1YjgwNjNjY2U0M2JkYTMyMjJmNjVkOWIwY2ZkNS90YWJsZXJhbmdlOjA4MDViODA2M2NjZTQzYmRhMzIyMmY2NWQ5YjBjZmQ1XzMtMy0xLTEtOTQ4MzE_52841ece-cdd2-4e90-a830-fe2b7c556e0c"
      unitRef="usd">70000000</us-gaap:DerivativeLiabilities>
    <us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzU4MzY_56ca2952-61df-4600-92e5-e585aaa6f534">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of hedging instruments on the Consolidated Statements of Operations and Consolidated Statements of Comprehensive Loss for 2021 and 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) recognized in Other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(57)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain excluded from assessment of hedge effectiveness&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Location of gain of excluded component&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i9eb64f96a45e4870872718cc8df9421a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNDcxMDE5M2I4MmY0NzIyYTZkMjM0ZDMyMzBjYzIxNy90YWJsZXJhbmdlOmY0NzEwMTkzYjgyZjQ3MjJhNmQyMzRkMzIzMGNjMjE3XzEtMS0xLTEtOTQ4MzE_792a52f2-6bad-45a9-a371-e5bae1451409"
      unitRef="usd">77000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i6c82f3651439499c885ddce82e4834ce_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNDcxMDE5M2I4MmY0NzIyYTZkMjM0ZDMyMzBjYzIxNy90YWJsZXJhbmdlOmY0NzEwMTkzYjgyZjQ3MjJhNmQyMzRkMzIzMGNjMjE3XzEtMy0xLTEtOTQ4MzE_aba0aee4-b740-44f9-96d8-bf65abd5cc9f"
      unitRef="usd">-57000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i457c889b626f42869ba8488dbeeb08d6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNDcxMDE5M2I4MmY0NzIyYTZkMjM0ZDMyMzBjYzIxNy90YWJsZXJhbmdlOmY0NzEwMTkzYjgyZjQ3MjJhNmQyMzRkMzIzMGNjMjE3XzItMS0xLTEtOTQ4MzE_e39c298b-f84c-4faf-aa46-a10a04b8b589"
      unitRef="usd">20000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i22478da08d664decbeccb00e9738fd08_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTpmNDcxMDE5M2I4MmY0NzIyYTZkMjM0ZDMyMzBjYzIxNy90YWJsZXJhbmdlOmY0NzEwMTkzYjgyZjQ3MjJhNmQyMzRkMzIzMGNjMjE3XzItMy0xLTEtOTQ4MzE_7a132eff-e86c-443a-860a-7a84e0e9b00a"
      unitRef="usd">23000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:PaymentsForProceedsFromHedgeInvestingActivities
      contextRef="i9dc84dac17cc43a3984fc9929fd5e294_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzMyMTk_aebf6df2-414f-4f4e-beac-dfe467430bd1"
      unitRef="usd">27000000</us-gaap:PaymentsForProceedsFromHedgeInvestingActivities>
    <us-gaap:PaymentsForProceedsFromHedgeInvestingActivities
      contextRef="i1e1566b2fa444f9281a88fe587091171_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzMyMjY_4882c70b-344b-4a16-ae72-0299f3227eb8"
      unitRef="usd">23000000</us-gaap:PaymentsForProceedsFromHedgeInvestingActivities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iad637097d6f449b982fcf6ea6c568da3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzM1NzE_7e26de50-432d-43df-b489-7ddbe1ed79e3"
      unitRef="usd">166000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="i0bdd18e14d804d67a4f34d683bfa58ea_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZToxNmVjMWFlZWVjYWE0ZWI1ODRmMTU3NjgzYWRhOGQ4MC90YWJsZXJhbmdlOjE2ZWMxYWVlZWNhYTRlYjU4NGYxNTc2ODNhZGE4ZDgwXzEtMS0xLTEtOTQ4MzE_936c94ae-8dc6-4a3b-8bff-db541106dbae"
      unitRef="usd">0</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="if472041674414bdeb5fb73f64f380506_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZToxNmVjMWFlZWVjYWE0ZWI1ODRmMTU3NjgzYWRhOGQ4MC90YWJsZXJhbmdlOjE2ZWMxYWVlZWNhYTRlYjU4NGYxNTc2ODNhZGE4ZDgwXzEtMy0xLTEtOTQ4MzE_635da57b-a5bf-4cad-916f-6f6f87bfc6fe"
      unitRef="usd">11000000</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ib426ea78162c4c489b291c4a5ef1bda1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZToxNmVjMWFlZWVjYWE0ZWI1ODRmMTU3NjgzYWRhOGQ4MC90YWJsZXJhbmdlOjE2ZWMxYWVlZWNhYTRlYjU4NGYxNTc2ODNhZGE4ZDgwXzItMS0xLTEtOTQ4MzE_ea689996-37ea-4441-a214-7108b489286c"
      unitRef="usd">1000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ida0fa648d576472480251eb6eb22d85b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZToxNmVjMWFlZWVjYWE0ZWI1ODRmMTU3NjgzYWRhOGQ4MC90YWJsZXJhbmdlOjE2ZWMxYWVlZWNhYTRlYjU4NGYxNTc2ODNhZGE4ZDgwXzItMy0xLTEtOTQ4MzE_5fa84962-cfff-4294-ad87-6adb0195d937"
      unitRef="usd">3000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeLiabilities
      contextRef="iad637097d6f449b982fcf6ea6c568da3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZToxNmVjMWFlZWVjYWE0ZWI1ODRmMTU3NjgzYWRhOGQ4MC90YWJsZXJhbmdlOjE2ZWMxYWVlZWNhYTRlYjU4NGYxNTc2ODNhZGE4ZDgwXzMtMS0xLTEtOTQ4MzE_c85843d1-cfb9-40a5-8cfd-b8c3176a0931"
      unitRef="usd">1000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i71801473f3324db7b4ad384aae92fc76_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZToxNmVjMWFlZWVjYWE0ZWI1ODRmMTU3NjgzYWRhOGQ4MC90YWJsZXJhbmdlOjE2ZWMxYWVlZWNhYTRlYjU4NGYxNTc2ODNhZGE4ZDgwXzMtMy0xLTEtOTQ4MzE_410b5e50-320b-4071-8d6c-0078970582a9"
      unitRef="usd">8000000</us-gaap:DerivativeLiabilities>
    <us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzU4Mzc_ff465a6b-c63f-4296-8b91-aa3bc4abe5f8">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the effect of the Company's foreign exchange contracts on the Consolidated Statements of Operations and the Consolidated Statements of Cash Flows for 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.646%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) related to changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss related to settlements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i3c9863c6c02148b280910bb43a45b30b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo4OWM4ZGQxMTYzN2E0NjFjOTAwNTEzODRiOTRlNGRhYy90YWJsZXJhbmdlOjg5YzhkZDExNjM3YTQ2MWM5MDA1MTM4NGI5NGU0ZGFjXzEtMS0xLTEtOTQ4MzE_a7cf8acb-f419-4d6c-b8c2-ae3e43589bb6"
      unitRef="usd">9000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i0159699620b14a238fdfa5d3fe9aea70_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo4OWM4ZGQxMTYzN2E0NjFjOTAwNTEzODRiOTRlNGRhYy90YWJsZXJhbmdlOjg5YzhkZDExNjM3YTQ2MWM5MDA1MTM4NGI5NGU0ZGFjXzEtMy0xLTEtOTQ4MzE_bc706bb8-7585-48d9-b428-19d92670f7be"
      unitRef="usd">-8000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss
      contextRef="i3c9863c6c02148b280910bb43a45b30b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo4OWM4ZGQxMTYzN2E0NjFjOTAwNTEzODRiOTRlNGRhYy90YWJsZXJhbmdlOjg5YzhkZDExNjM3YTQ2MWM5MDA1MTM4NGI5NGU0ZGFjXzItMS0xLTEtOTQ4MzE_ea23b725-be79-4283-a97f-d5d228363832"
      unitRef="usd">17000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss
      contextRef="i0159699620b14a238fdfa5d3fe9aea70_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo4OWM4ZGQxMTYzN2E0NjFjOTAwNTEzODRiOTRlNGRhYy90YWJsZXJhbmdlOjg5YzhkZDExNjM3YTQ2MWM5MDA1MTM4NGI5NGU0ZGFjXzItMy0xLTEtOTQ4MzE_9c1d93d1-a9f5-4743-b65e-099a87afdd44"
      unitRef="usd">2000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ic984dc5f62ec4772bc9ece326f420058_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzQ3NTY_1a0a8a5c-cf9c-4208-8083-183290dbebee"
      unitRef="rate">0.06</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i680eb79e17184399ba8ff57eb89e8ab8_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzQ3NjI_6db8d513-7376-4c9b-938b-c37845705f14"
      unitRef="rate">0.18</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="iafdb511725c04b449bc18c9f41f1c601_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzQ4MjA_d9c9e95a-81bb-41aa-848e-8bd32b90b43d"
      unitRef="rate">0.07</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzU4MTg_a6ad28bf-039d-4dc3-99ee-a03307054731">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs (Level&#160;3) for the years 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Beginning balance, January 1, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to Acquisition-related contingent consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accretion for the time value of money&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments / Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment included in other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance, December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzEtNC0xLTEtOTQ4MzE_caf9dc76-102b-4cad-bcec-f3bab09bc8c9"
      unitRef="usd">328000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzEtOC0xLTEtOTQ4MzE_30f57215-2d42-4250-bdb2-e05e02c4c20c"
      unitRef="usd">316000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i98d1e9065dbc434ca6fa39e4ee7397d4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzMtMi0xLTEtOTQ4MzE_b0125d9d-4cb2-4afb-ad84-bbf8d4b19521"
      unitRef="usd">17000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i5fa8c12aacc74d6b91c15b886f0f76d8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzMtNi0xLTEtOTQ4MzE_a1122538-f44e-465d-ada0-ebd36372988f"
      unitRef="usd">23000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="if32e75dc65d54621a38196e180c5052b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzQtMi0xLTEtOTQ4MzE_cb6bdddc-e96e-4a02-b89e-54d845e31a59"
      unitRef="usd">-6000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="if4908569b3b44a878e5d419525405804_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzQtNi0xLTEtOTQ4MzE_31da3cda-9e77-4c73-9738-e4526031451a"
      unitRef="usd">25000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzUtNC0xLTEtOTQ4MzE_54cdca53-c77b-4393-9f73-787f9b2791f8"
      unitRef="usd">11000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzUtOC0xLTEtOTQ4MzE_a3da7b8a-3456-463f-bb1a-098ec8b0caca"
      unitRef="usd">48000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzYtNC0xLTEtOTQ4MzE_806982c2-3975-47d0-9973-d850d634f8db"
      unitRef="usd">99000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzYtOC0xLTEtOTQ4MzE_0c77d0d2-fcf6-4401-870f-c59f403f2831"
      unitRef="usd">36000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzctNC0xLTEtOTQ4MzE_cea22eae-ac8d-434d-8c2c-6c1ed2af418e"
      unitRef="usd">1000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzctOC0xLTEtOTQ4MzE_5876cd45-c5d9-405c-b1b2-cc51f792ca30"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzgtNC0xLTEtOTQ4MzE_a43db714-8de6-4b3c-a524-4236c8cbe135"
      unitRef="usd">241000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzgtOC0xLTEtOTQ4MzE_200dc661-508c-44f8-a325-cc34ca34cd2e"
      unitRef="usd">328000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzktNC0xLTEtOTQ4MzE_f2c99a14-bfc3-4889-8388-ae8f5694958e"
      unitRef="usd">39000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzktOC0xLTEtOTQ4MzE_48448c97-739d-43b3-a43b-90269d73dace"
      unitRef="usd">112000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzEwLTQtMS0xLTk0ODMx_b6716af1-6d42-4665-82c7-8c1b5b79f6f1"
      unitRef="usd">202000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo3MmJlNDUwOTc1MjY0YmQwYmYwNjI4YzQ0YmJiMmU0OS90YWJsZXJhbmdlOjcyYmU0NTA5NzUyNjRiZDBiZjA2MjhjNDRiYmIyZTQ5XzEwLTgtMS0xLTk0ODMx_e1f3db8c-f450-49cf-9812-eaf71e95cc2f"
      unitRef="usd">216000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzU4MzU_6f3a4d2a-1e77-400b-980d-1e769e580fe9">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components and classification of the Company&#x2019;s financial assets and liabilities measured at fair value on a non-recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.277%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.364%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure
      contextRef="i15d7424af8b443409563957178d9f029_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo4OWQ0NWI5NjU0YWI0YzliODllZTMzZWRkZWY5YjVmOC90YWJsZXJhbmdlOjg5ZDQ1Yjk2NTRhYjRjOWI4OWVlMzNlZGRlZjliNWY4XzMtMi0xLTEtOTQ4MzE_d6ae8445-bf34-4405-8d98-208032d50c10"
      unitRef="usd">0</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure
      contextRef="i8453f3b3b4c743129918b8a8465d47e3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo4OWQ0NWI5NjU0YWI0YzliODllZTMzZWRkZWY5YjVmOC90YWJsZXJhbmdlOjg5ZDQ1Yjk2NTRhYjRjOWI4OWVlMzNlZGRlZjliNWY4XzMtNC0xLTEtOTQ4MzE_a2443bd3-ff06-430e-b4fb-49ceb9e875cc"
      unitRef="usd">0</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure
      contextRef="ica46ac5deb7f4bca98fd1442ab972fe1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo4OWQ0NWI5NjU0YWI0YzliODllZTMzZWRkZWY5YjVmOC90YWJsZXJhbmdlOjg5ZDQ1Yjk2NTRhYjRjOWI4OWVlMzNlZGRlZjliNWY4XzMtNi0xLTEtOTQ4MzE_fab2b218-c4bc-4074-99bb-f3101f91d5e9"
      unitRef="usd">0</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure
      contextRef="i00e41fe3c6f64b2289dbd0cd45fde7ea_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo4OWQ0NWI5NjU0YWI0YzliODllZTMzZWRkZWY5YjVmOC90YWJsZXJhbmdlOjg5ZDQ1Yjk2NTRhYjRjOWI4OWVlMzNlZGRlZjliNWY4XzMtOC0xLTEtOTQ4MzE_946915f1-c2b6-4896-b1e6-8371cfc140a3"
      unitRef="usd">0</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure
      contextRef="i0703b0cf397f477687f950dbbe23e831_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo4OWQ0NWI5NjU0YWI0YzliODllZTMzZWRkZWY5YjVmOC90YWJsZXJhbmdlOjg5ZDQ1Yjk2NTRhYjRjOWI4OWVlMzNlZGRlZjliNWY4XzMtMTAtMS0xLTk0ODMx_c68c1850-eafc-4550-a228-e98d66559bae"
      unitRef="usd">245000000</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure
      contextRef="i9ca97df2856842dfbaf44ca3f738a575_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo4OWQ0NWI5NjU0YWI0YzliODllZTMzZWRkZWY5YjVmOC90YWJsZXJhbmdlOjg5ZDQ1Yjk2NTRhYjRjOWI4OWVlMzNlZGRlZjliNWY4XzMtMTItMS0xLTk0ODMx_3085f154-4b8f-468f-821a-cda1be598f59"
      unitRef="usd">0</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure
      contextRef="ib66efd6818984bf8b7ee621516776ce1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo4OWQ0NWI5NjU0YWI0YzliODllZTMzZWRkZWY5YjVmOC90YWJsZXJhbmdlOjg5ZDQ1Yjk2NTRhYjRjOWI4OWVlMzNlZGRlZjliNWY4XzMtMTQtMS0xLTk0ODMx_7112899c-6c84-4423-a3d9-c58fe46e80ca"
      unitRef="usd">0</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure
      contextRef="ia03371e98c434dabab65c558c26cca83_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90YWJsZTo4OWQ0NWI5NjU0YWI0YzliODllZTMzZWRkZWY5YjVmOC90YWJsZXJhbmdlOjg5ZDQ1Yjk2NTRhYjRjOWI4OWVlMzNlZGRlZjliNWY4XzMtMTYtMS0xLTk0ODMx_073fff13-69a3-4409-a7a0-4fcd9ac15f8b"
      unitRef="usd">245000000</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure
      contextRef="ia03371e98c434dabab65c558c26cca83_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzU0MDY_073fff13-69a3-4409-a7a0-4fcd9ac15f8b"
      unitRef="usd">245000000</us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ica46ac5deb7f4bca98fd1442ab972fe1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzU2ODg_cb3632c2-75d5-4b19-8ad0-5a40a6d3166e"
      unitRef="usd">22689000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ib66efd6818984bf8b7ee621516776ce1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjUvZnJhZzo2YmUyNjJkMDA0ZWQ0YjZmODg2N2IwZDMyNWU1M2MzNy90ZXh0cmVnaW9uOjZiZTI2MmQwMDRlZDRiNmY4ODY3YjBkMzI1ZTUzYzM3XzU2OTU_eae42820-09f3-4122-b3fb-de0e600f2731"
      unitRef="usd">25378000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjgvZnJhZzpiODdiNTkzOWQ3NGI0NTcwOTgyODU1YzRkZGU5MWM1Mi90ZXh0cmVnaW9uOmI4N2I1OTM5ZDc0YjQ1NzA5ODI4NTVjNGRkZTkxYzUyXzU0_de019526-f2b9-42fe-a1b6-454a4fac229d">INVENTORIES&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, net, as of December 31, 2021 and 2020 consist of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjgvZnJhZzpiODdiNTkzOWQ3NGI0NTcwOTgyODU1YzRkZGU5MWM1Mi90ZXh0cmVnaW9uOmI4N2I1OTM5ZDc0YjQ1NzA5ODI4NTVjNGRkZTkxYzUyXzQ4_50187ff9-e4c1-4d87-810b-ee15b1e8dcf6">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, net, as of December 31, 2021 and 2020 consist of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjgvZnJhZzpiODdiNTkzOWQ3NGI0NTcwOTgyODU1YzRkZGU5MWM1Mi90YWJsZTo4NDBmNWUxYTlkMjk0ZDQyYTljNzdhYWExODY0OWI2My90YWJsZXJhbmdlOjg0MGY1ZTFhOWQyOTRkNDJhOWM3N2FhYTE4NjQ5YjYzXzEtMi0xLTEtOTQ4MzE_07893f60-b98e-46a4-abc3-0351fa9293dd"
      unitRef="usd">279000000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjgvZnJhZzpiODdiNTkzOWQ3NGI0NTcwOTgyODU1YzRkZGU5MWM1Mi90YWJsZTo4NDBmNWUxYTlkMjk0ZDQyYTljNzdhYWExODY0OWI2My90YWJsZXJhbmdlOjg0MGY1ZTFhOWQyOTRkNDJhOWM3N2FhYTE4NjQ5YjYzXzEtNC0xLTEtOTQ4MzE_ebed9ba8-36bd-4699-a020-418526d46881"
      unitRef="usd">286000000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjgvZnJhZzpiODdiNTkzOWQ3NGI0NTcwOTgyODU1YzRkZGU5MWM1Mi90YWJsZTo4NDBmNWUxYTlkMjk0ZDQyYTljNzdhYWExODY0OWI2My90YWJsZXJhbmdlOjg0MGY1ZTFhOWQyOTRkNDJhOWM3N2FhYTE4NjQ5YjYzXzItMi0xLTEtOTQ4MzE_272ff609-f643-4277-bbe8-36917410ffde"
      unitRef="usd">112000000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjgvZnJhZzpiODdiNTkzOWQ3NGI0NTcwOTgyODU1YzRkZGU5MWM1Mi90YWJsZTo4NDBmNWUxYTlkMjk0ZDQyYTljNzdhYWExODY0OWI2My90YWJsZXJhbmdlOjg0MGY1ZTFhOWQyOTRkNDJhOWM3N2FhYTE4NjQ5YjYzXzItNC0xLTEtOTQ4MzE_d71d27e6-2099-484e-8734-6c54289c0fbc"
      unitRef="usd">143000000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjgvZnJhZzpiODdiNTkzOWQ3NGI0NTcwOTgyODU1YzRkZGU5MWM1Mi90YWJsZTo4NDBmNWUxYTlkMjk0ZDQyYTljNzdhYWExODY0OWI2My90YWJsZXJhbmdlOjg0MGY1ZTFhOWQyOTRkNDJhOWM3N2FhYTE4NjQ5YjYzXzMtMi0xLTEtOTQ4MzE_87b55bab-c9ce-4590-a60c-061558fb218f"
      unitRef="usd">602000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjgvZnJhZzpiODdiNTkzOWQ3NGI0NTcwOTgyODU1YzRkZGU5MWM1Mi90YWJsZTo4NDBmNWUxYTlkMjk0ZDQyYTljNzdhYWExODY0OWI2My90YWJsZXJhbmdlOjg0MGY1ZTFhOWQyOTRkNDJhOWM3N2FhYTE4NjQ5YjYzXzMtNC0xLTEtOTQ4MzE_f134079f-7502-49d6-9601-fd85b5709e23"
      unitRef="usd">665000000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjgvZnJhZzpiODdiNTkzOWQ3NGI0NTcwOTgyODU1YzRkZGU5MWM1Mi90YWJsZTo4NDBmNWUxYTlkMjk0ZDQyYTljNzdhYWExODY0OWI2My90YWJsZXJhbmdlOjg0MGY1ZTFhOWQyOTRkNDJhOWM3N2FhYTE4NjQ5YjYzXzQtMi0xLTEtOTQ4MzE_34baf053-ee71-44ce-88b2-d3d3b32ab13c"
      unitRef="usd">993000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMjgvZnJhZzpiODdiNTkzOWQ3NGI0NTcwOTgyODU1YzRkZGU5MWM1Mi90YWJsZTo4NDBmNWUxYTlkMjk0ZDQyYTljNzdhYWExODY0OWI2My90YWJsZXJhbmdlOjg0MGY1ZTFhOWQyOTRkNDJhOWM3N2FhYTE4NjQ5YjYzXzQtNC0xLTEtOTQ4MzE_336cc98a-bd2a-46ed-bcbe-b6dbafc2a61f"
      unitRef="usd">1094000000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90ZXh0cmVnaW9uOjc4N2I2ZWMwNzIyYjQ4YjliMjU1YTliZGU3MTY4YTdhXzE2Mg_8acc374f-6197-46ac-bf7c-9a7eb0622577">PROPERTY, PLANT AND EQUIPMENT&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of property, plant and equipment as of December 31, 2021 and 2020 consist of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other equipment and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment on operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,781)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense was $177 million, $180 million and $178 million for 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90ZXh0cmVnaW9uOjc4N2I2ZWMwNzIyYjQ4YjliMjU1YTliZGU3MTY4YTdhXzE1Mw_53e908ed-cbf4-4cb0-a5b4-e0e2e04c2828">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of property, plant and equipment as of December 31, 2021 and 2020 consist of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other equipment and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment on operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,820)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,781)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i03f09b98a2794ea19b27978f0c0a73fb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzEtMi0xLTEtOTQ4MzE_f4c16bbc-e808-4f17-90f0-e416e4abcf5e"
      unitRef="usd">74000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i794b0cd648154358b5f12e82f9710bbf_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzEtNC0xLTEtOTQ4MzE_5febd3cd-1168-4453-8f67-098d04a77519"
      unitRef="usd">79000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i55bc00875c13421c8e7ef466a6e806e2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzItMi0xLTEtOTQ4MzE_0d4f1c1f-ec68-43e6-932c-a59179f9a8f5"
      unitRef="usd">675000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5486904f53c94726b49a9232f4dcb0d0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzItNC0xLTEtOTQ4MzE_54bd40db-c887-4f52-b997-01ab09c7e8b5"
      unitRef="usd">686000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i802908ddd2fd4486afb3bf31d0d9edd9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzMtMi0xLTEtOTQ4MzE_9e878865-64b7-4c7c-aaf9-3777b51d8564"
      unitRef="usd">1678000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2600359d03bf4008a75ebdf90c246dfc_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzMtNC0xLTEtOTQ4MzE_33257df4-b996-4cdc-8f4d-4a3c4607c7f0"
      unitRef="usd">1722000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5b77fdc1142642a0acda999683173c6e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzQtMi0xLTEtOTQ4MzE_4d7dbcce-fe66-4c90-813f-92af7d2c10ee"
      unitRef="usd">342000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i38dbc214d6144a758e35f77291e56b5c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzQtNC0xLTEtOTQ4MzE_27f03cf5-66f0-42a0-8ced-66cd8f55a899"
      unitRef="usd">360000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ida44475894334e22b76c358bb055a53a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzUtMi0xLTEtOTQ4MzE_56f2490c-fd6d-43f1-8c38-8f382c643e14"
      unitRef="usd">73000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6649875e397846f2945b7974a238e07a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzUtNC0xLTEtOTQ4MzE_72269282-8bba-431c-9c48-36d78200de30"
      unitRef="usd">65000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ied26b295528f43e08d519d8a4f061068_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzYtMi0xLTEtOTQ4MzE_3322b5b8-043c-4b1c-9d3b-a8fb44174eab"
      unitRef="usd">576000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8e5b883341944b8591f5c00136de5e09_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzYtNC0xLTEtOTQ4MzE_9a9625ac-bea8-40c3-a72a-b535791d351b"
      unitRef="usd">436000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzctMi0xLTEtOTQ4MzE_cfe024b2-efa2-4f24-b88b-8ea5bceac56d"
      unitRef="usd">3418000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzctNC0xLTEtOTQ4MzE_a45f93c1-b154-4c5d-978a-48d07b5d4e2d"
      unitRef="usd">3348000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzgtMi0xLTEtOTQ4MzE_3fe43ae8-dce8-4cee-87a2-bcb025362095"
      unitRef="usd">1820000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzgtNC0xLTEtOTQ4MzE_2dc3045e-64f2-4f3f-add8-6ff7913e366c"
      unitRef="usd">1781000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzktMi0xLTEtOTQ4MzE_098622fa-25c4-462d-aff6-67263f8de474"
      unitRef="usd">1598000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90YWJsZTpkMzJkMzM2Nzc3Y2U0YmNlODEyOWY1MGRlODI2MGI4Mi90YWJsZXJhbmdlOmQzMmQzMzY3NzdjZTRiY2U4MTI5ZjUwZGU4MjYwYjgyXzktNC0xLTEtOTQ4MzE_89417b04-b1a9-47f8-a45c-3632e60a5966"
      unitRef="usd">1567000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90ZXh0cmVnaW9uOjc4N2I2ZWMwNzIyYjQ4YjliMjU1YTliZGU3MTY4YTdhXzEwNg_c32a93f8-5da5-43cb-be15-f7a05331879b"
      unitRef="usd">177000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90ZXh0cmVnaW9uOjc4N2I2ZWMwNzIyYjQ4YjliMjU1YTliZGU3MTY4YTdhXzExMA_d5fe4a9e-db56-4ea1-abc4-6c43301d9546"
      unitRef="usd">180000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzEvZnJhZzo3ODdiNmVjMDcyMmI0OGI5YjI1NWE5YmRlNzE2OGE3YS90ZXh0cmVnaW9uOjc4N2I2ZWMwNzIyYjQ4YjliMjU1YTliZGU3MTY4YTdhXzExNw_575d3d90-68a5-4f21-8e54-a3be09b60114"
      unitRef="usd">178000000</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzI0NDMw_0444af87-067c-41f9-b384-b2732afc4183">INTANGIBLE ASSETS AND GOODWILL&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of intangible assets as of December&#160;31, 2021 and 2020 consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.113%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Useful&lt;br/&gt;Lives&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:36pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization and Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization and Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14,914)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D not in service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;B&amp;amp;L Trademark&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. Impairment charges associated with these assets are included in Asset impairments, including loss on assets held for sale in the Consolidated Statement of Operations.  The Company continues to monitor the recoverability of its finite-lived intangible assets and tests the intangible assets for impairment if indicators of impairment are present. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset impairments, including loss on assets held for sale in 2021 included: (i) impairments of $105&#160;million, in aggregate, due to decreases in forecasted sales of certain product lines, (ii) an $88&#160;million loss on assets held for sale in connection with the Amoun Sale, (iii) impairments of $23&#160;million, in aggregate, related to the discontinuance of certain product lines and (iv) $18&#160;million related to a portion of an IT infrastructure improvement project no longer being utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset impairments, including loss on assets held for sale in 2020 included impairments of: (i) $96&#160;million to reduce the carrying value of the Amoun business to its estimated fair value less costs to sell due to classifying the business as held for sale as discussed in Note 3, &#x201c;ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE&#x201d;, (ii) $16&#160;million in aggregate, due to decreases in forecasted sales of certain product lines, (iii) $1&#160;million in aggregate, related to the discontinuance of certain product lines not aligned with the focus of the Company's core businesses and (iv) $1&#160;million related to Acquired IPR&amp;amp;D not in service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset impairments, including loss on assets held for sale in 2019 included impairments of: (i) $58 million reflecting decreases in forecasted sales of certain product lines due to generic competition and other factors, (ii) $8 million related to assets being classified as held for sale, (iii) $5 million related to certain product/patent assets associated with the discontinuance of specific product lines not aligned with the focus of the Company's core businesses and (iv) $4 million related to Acquired IPR&amp;amp;D not in service. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The impairments to assets reclassified as held for sale were measured as the difference of the carrying value of these assets as compared to the estimated fair values of these assets less costs to sell determined using a discounted cash flow analysis which utilized Level 3 unobservable inputs. The other impairments and adjustments to finite-lived intangible assets were measured as the difference of the historical carrying value of these finite-lived assets as compared to the estimated fair value as determined using a discounted cash flow analysis using Level 3 unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Periodically, the Company&#x2019;s products face the expiration of their patent or regulatory exclusivity. The Company anticipates that product sales for such product would decrease shortly following a loss of exclusivity  (&#x201c;LOE&#x201d;), due to the possible entry of a generic competitor. Where the Company has the rights, it may elect to launch an authorized generic of such product (either as the Company&#x2019;s own branded generic or through a third-party).  This may occur prior to, upon or following generic entry, which may mitigate the anticipated decrease in product sales; however, even with launch of an authorized generic, the decline in product sales of such product could still be significant, and the effect on future revenues could be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management continually assesses the useful lives related to the Company's long-lived assets to reflect the most current assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated amortization expense of finite-lived intangible assets for the five years ending December&#160;31 and thereafter are as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the carrying amounts of goodwill during the years ended December 31, 2021, 2020 and 2019 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Bausch + &lt;br/&gt;Lomb/&lt;br/&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Bausch + &lt;br/&gt;Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance, January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquisition of certain assets of Synergy &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill reclassified to assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assets held for sale reclassified to goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill reclassified to assets held for sale (Note 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realignment of segment goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is not amortized but is tested for impairment at least annually on October 1st at the reporting unit level. A reporting unit is the same as, or one level below, an operating segment.  The Company performs its annual impairment test by first assessing qualitative factors. Where the qualitative assessment suggests that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed for that reporting unit (Step 1). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of a reporting unit refers to the price that would be received to sell the unit as a whole in an orderly transaction between market participants. The Company estimates the fair values of a reporting unit using a discounted cash flow model which utilizes Level 3 unobservable inputs. The discounted cash flow model relies on assumptions regarding revenue growth rates, gross profit, projected working capital needs, selling, general and administrative expenses, research and development expenses, capital expenditures, income tax rates, discount rates and terminal growth rates. To estimate fair value, the Company discounts the forecasted cash flows of each reporting unit. The discount rate the Company uses represents the estimated weighted average cost of capital, which reflects the overall level of inherent risk involved in its reporting unit operations and the rate of return a market participant would expect to earn. The quantitative fair value test is performed utilizing long-term growth rates and discount rates applied to the estimated cash flows in estimation of fair value. To estimate cash flows beyond the final year of its model, the Company estimates a terminal value by applying an in-perpetuity growth assumption and discount factor to determine the reporting unit's terminal value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To forecast a reporting unit's cash flows the Company takes into consideration economic conditions and trends, estimated future operating results, management's and a market participant's view of growth rates and product lives, and anticipates future economic conditions. Revenue growth rates inherent in these forecasts are based on input from internal and external market research that compare factors such as growth in global economies, recent industry trends and product life-cycles. Macroeconomic factors such as changes in economies, changes in the competitive landscape including the unexpected LOE to the Company's product portfolio, changes in government legislation, product life-cycles, industry consolidations and other changes beyond the Company&#x2019;s control could have a positive or negative impact on achieving its targets.  Accordingly, if market conditions deteriorate, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2019 Annual Goodwill Impairment Test&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company conducted its annual goodwill impairment test as of October 1, 2019 by first assessing qualitative factors. Where the qualitative assessment suggested that it was more likely than not that the fair value of a reporting unit was less than its carrying amount, a quantitative fair value test was performed for that reporting unit. In each quantitative fair value test performed, the fair value was greater than the carrying value of the reporting unit.  As a result, there was no impairment to the goodwill of any reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The negative impacts of the COVID-19 pandemic on the global economy have led to significant volatility in the global equity markets. The Company has been able to continue its operations with limited disruptions and has assessed the potential impact that the COVID-19 pandemic is likely to have on its forecasted cash flows.  In performing its assessment, the Company considered the possible effects and outcomes of the COVID-19 pandemic on, among other things, its supply chain, customers and distributors, employee base, product sustainability, research and development activities, product pipeline and consumer demand and related rebates and discounts and has made adjustments, although not considered to be material, to its long-term forecasts used in its previous goodwill impairment assessments, for these and other matters. After completing this assessment, although not completely insulated from the negative effects of the COVID-19 pandemic, the Company believes that its long-term forecasted cash flows, as adjusted for the possible outcome of the COVID-19 pandemic and other matters, do not indicate that the fair value of any reporting unit may be below its carrying value. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's 2020 revenues were most negatively impacted during its second quarter by certain social restrictions and other precautionary measures taken in response to the COVID-19 pandemic. However, as governments began lifting social restrictions, allowing offices of certain health care providers to reopen and certain surgeries and elective medical procedures to proceed, the negative trend in the revenues of certain businesses began to level off and stabilize prior to the third quarter of 2020. Revenues for 2021 and 2020 were $8,434&#160;million and $8,027&#160;million, respectively. The increase of $407&#160;million in revenue represents an improving trend over the decreases in year-over-year revenues for the three month periods ended June 30, 2020, September 30, 2020 and December 31, 2020 of 23%, 3% and less than 1%, respectively. The Company's revenues returned to pre-pandemic levels for many of its businesses and geographies in 2021 and, presuming there continues to be increased availability of effective vaccines and any further resurgence of the COVID-19 virus, the delta and omicron variants and other variant strains thereof do not have a material adverse impact on efforts to contain the COVID-19 virus, the Company anticipates the COVID-19 pandemic to have a minimal impact on its remaining businesses and geographies in 2022. However, the rates of recovery for each business will vary by geography and will be dependent upon, among other things, the availability and effectiveness of vaccines for the COVID-19 virus, government responses, rates of economic recovery, precautionary measures taken by patients and customers, the rate at which remaining social restrictions are lifted and once lifted, the presumption that social restrictions will not be materially reenacted in the event of a resurgence of the virus and other actions taken in response to the COVID-19 pandemic.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2020 Interim Goodwill Impairment Assessment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the interim periods of 2020, after giving consideration to the nature and timing of the negative impacts of the COVID-19 pandemic on the Company's forecasted cash flows, with the exception of the Ortho Dermatologics reporting unit, no events occurred, or circumstances changed that would indicate that the fair value of any other reporting unit might be below its carrying value and therefore, no impairments were recorded. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2020 and June 30, 2020, the operating results for the Ortho Dermatologics reporting unit were less than forecasted primarily due to certain products experiencing longer launch cycles than originally anticipated as a result of the COVID-19 pandemic. The Company revised its long-term forecasts as of March 31, 2020 and as of June 30, 2020 for these matters. Management believed that these events were indicators that there was less headroom as of March 31, 2020 and June 30, 2020 as compared to the headroom calculated on the date Ortho Dermatologics goodwill was previously tested for impairment. Therefore, a quantitative fair value test for impairment to the goodwill of the Ortho Dermatologics reporting unit was performed at March 31, 2020 and at June 30, 2020. Based on the quantitative fair value tests, the fair value of the Ortho Dermatologics reporting unit continued to be greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit at March 31, 2020 and at June 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2020 Annual Goodwill Impairment Test&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company conducted its annual goodwill impairment test as of October 1, 2020 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2020, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2020, the Company considered, among other matters, a range of potential impacts of COVID-19 pandemic related matters and the limited headroom calculated on the date Ortho Dermatologics goodwill was last tested for impairment (June 30, 2020).  The Company believed that these factors may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2020, utilizing a long-term growth rate of 2.0% and a range of discount rates between 9.50% and 9.75%, in estimation of the fair value of this reporting unit.  Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately 10% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;First Quarter 2021 - Realignment of Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commencing in the first quarter of 2021 through the fourth quarter of 2021, the Company operated in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International, (iv) Ortho Dermatologics and (v) Diversified Products. The Bausch + Lomb segment consists of the: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. The Salix segment consists of the Salix reporting unit. The International segment consists of the International (formerly International RX) reporting unit. The Ortho Dermatologics segment consisted of the: (i) Ortho Dermatologics and (ii) Global Solta reporting units. The Diversified Products segment consists of the: (i) Neurology and Other, (ii) Generics and (iii) Dentistry reporting units. This realignment in segment structure resulted in a change in the Company's former International reporting unit, which is now divided between the International Bausch + Lomb reporting unit and International reporting unit. In addition, as part of this realignment of segment structure, certain products historically included in the Generics reporting unit are now included in the U.S. Bausch + Lomb reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of this realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. Goodwill previously reported in the former International reporting unit was reassigned to the International Bausch + Lomb and International reporting units, and a portion of goodwill previously reported in the former Generics reporting unit was reassigned to the U.S. Bausch + Lomb reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately prior to the change in reporting units, the Company performed a qualitative fair value assessment for its former: (i) International and (ii) Generics reporting units. Based on the qualitative fair value assessment performed, management believed that it was more likely than not that the carrying values of its former: (i) International and (ii) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generics reporting units were less than their respective fair values and therefore, concluded a quantitative assessment was not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately following the change in reporting units, as a result of the change in composition of the net assets for its current: (i) International Bausch + Lomb, (ii) International and (iii) Generics reporting units, the Company performed a quantitative fair value test. The quantitative fair value test utilized a range of long-term growth rates of 1.0% to 3.0% and a range of discount rates between 11.0% and 12.25%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than 40%, and, therefore, there was no impairment to goodwill. In addition, as the U.S. Bausch + Lomb reporting unit had a change in composition of its net assets related to certain products historically included in the Generics reporting unit now being included in the U.S. Bausch + Lomb reporting unit, the Company performed a qualitative assessment of this reporting unit. Based on the qualitative fair value assessment performed, management believed that it was more likely than not that the carrying value of its current U.S. Bausch + Lomb reporting unit was less than its fair value and therefore, concluded a quantitative assessment was not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;March 31, 2021 Impairment to Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2021, management identified launches of certain Ortho Dermatologics products which were not going to achieve their trajectories as forecasted once the social restrictions associated with the COVID-19 pandemic began to ease in the U.S. and offices of health care professionals could reopen. In addition, insurance coverage pressures within the U.S. continued to persist limiting patient access to topical acne and psoriasis products.  In light of these developments, during the first quarter of 2021, the Company began taking steps to: (i) redirect its R&amp;amp;D spend to eliminate projects it has identified as high cost and high risk, (ii) redirect a portion of its marketing and product development outside the U.S. to geographies where there is better patient access and (iii) reduce its cost structure to be more competitive. As a result, during the three months ended March 31, 2021, the Company revised its long-term forecasts for the Ortho Dermatologics reporting unit. Management believed that these events were indicators that there is less headroom as of March 31, 2021 as compared to the headroom calculated on the date goodwill was last tested for impairment (October 1, 2020). Therefore, a quantitative fair value test for the Ortho Dermatologics reporting unit was performed. The quantitative fair value test utilized the Company's most recent cash flow projections as revised in the first quarter of 2021 to reflect the business changes previously discussed, including a range of potential outcomes, along with a long-term growth rate of 1.0% and a range of discount rates between 9.0% and 10.0%. Based on the quantitative fair value test, the carrying value of the Ortho Dermatologics reporting unit exceeded its fair value at March 31, 2021, and the Company recognized a goodwill impairment of $469&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Second Quarter 2021 - Realignment of Bausch + Lomb Reporting Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commencing in the second quarter of 2021, the Company changed the way it reviews the financial information of its Bausch + Lomb segment.  Beginning in the second quarter of 2021, management no longer reviews the financial information of its Bausch + Lomb segment on a geographic basis, but instead reviews this financial information on a business line basis.  This change created a change in the reporting units of the Bausch + Lomb segment. After the change, under its business line view, the Bausch + Lomb segment consists of the global: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units. Prior to the second quarter of 2021, under the geographic view, the Bausch + Lomb segment consisted of the former: (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units. As a result of this realignment, goodwill was reassigned to each of the aforementioned reporting units using a relative fair value approach. The change in Bausch + Lomb reporting units does not impact the reported revenues and segment profits of the Bausch + Lomb segment for any prior periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immediately prior to the change in its Bausch + Lomb reporting units, the Company performed a qualitative fair value assessment for its former reporting units. Based on the qualitative fair value assessment, management believed that it was more likely than not that the carrying values of its former:  (i) U.S. Bausch + Lomb and (ii) International Bausch + Lomb reporting units were less than their respective fair values and, therefore, concluded a quantitative assessment was not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the change in composition of net assets, the Company performed a quantitative fair value test of its new: (i) Vision Care / Consumer Products, (ii) Ophthalmic Pharmaceuticals and (iii) Surgical reporting units immediately following the change in the Bausch + Lomb segment. The quantitative fair value test utilized long-term growth rates of 2.0% and 3.0% and a range of discount rates between 7.0% and 10.0%, in estimation of the fair value of the reporting units. After completing the testing, the fair value of each of these reporting units exceeded its carrying value by more than 45%, and, therefore, there was no impairment to goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;June 30, 2021 and September 30, 2021 Interim Assessments of Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to monitor the market conditions impacting the Ortho Dermatologics reporting unit. The  Company's latest forecasts for the Ortho Dermatologics reporting unit include a range of potential outcomes for, among other matters: (i) the impacts of the COVID-19 pandemic on operations, (ii) the impact of the loss of exclusivity of certain products, (iii) the impact of longer launch cycles for certain new products, (iv) progress of its product pipeline and (v) ongoing pricing pressures, which could negatively impact the reporting unit's results over the long term. The changes in the amounts and timing of revenues and expenses in the latest forecast as compared to the forecast used at March 31, 2021 (the last time goodwill of the Ortho Dermatologics reporting unit was tested), were not substantial enough to materially adversely affect the recoverability of the Ortho Dermatologics reporting unit's assets and are not material enough to indicate that the fair value of the Ortho Dermatologics reporting unit might be below its carrying value as last tested at March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No other events occurred or circumstances changed during the period October 1, 2020 (the earliest date goodwill was tested for all other reporting units) through December 31, 2021 that indicated that the fair value of any reporting unit, other than the Ortho Dermatologics reporting unit, might be below its carrying value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Annual Goodwill Impairment Test&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company conducted its annual goodwill impairment test as of October 1, 2021 by first assessing qualitative factors. Based on its qualitative assessment as of October 1, 2021, management believed that, with the exception of the Ortho Dermatologics reporting unit, it was more likely than not that the carrying amounts of its reporting units were less than their respective fair values and therefore concluded that a quantitative fair value test for those reporting units was not required.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of its qualitative assessment of the Ortho Dermatologics reporting unit as of October 1, 2021, the Company considered, among other matters, the limited headroom as a result of the impairment to the goodwill of the Ortho Dermatologics reporting unit when last tested (March 31, 2021) and macroeconomic factors such as higher than expected inflation for many commodities, volatility in many of the equity markets and pressures on market interest rates. The Company believed that these facts and circumstances may suggest that it was more likely than not that the fair value of the Ortho Dermatologics reporting unit was less than its carrying amount, and therefore a quantitative fair value test was performed for the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed a quantitative fair value test for the Ortho Dermatologics reporting unit as of October 1, 2021, utilizing a long-term growth rate of 1.0% and a discount rate of 9.0%, in estimation of the fair value of this reporting unit.  Based on the quantitative fair value test, the fair value of the Ortho Dermatologics reporting unit was approximately 10% greater than its carrying value and as a result there was no impairment to the goodwill of the reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If market conditions deteriorate, if the factors and circumstances regarding the COVID-19 pandemic escalate beyond management&#x2019;s current expectations, or if the Company is unable to execute its strategies, it may be necessary to record impairment charges in the future and those charges could be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated goodwill impairment charges through December 31, 2021 were $4,180 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2022 Realignment of Segment Structure&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commencing in the first quarter of 2022, the Company has realigned and has begun managing its operations in a manner consistent with the organizational structure of the two separate entities as proposed by the Solta IPO. Under the new reporting structure, the Company has five reportable segments and has allocated goodwill to those segments as follows: (i) $5,318&#160;million to the Bausch + Lomb segment, (ii) $3,159&#160;million to the Salix segment, (iii) $825&#160;million to the International segment, (iv) $115&#160;million to the Solta Medical segment and (v) $3,040&#160;million to the Diversified Products segment. The new segment structure does not impact the Company&#x2019;s reporting units but realigns the two reporting units of the former Ortho Dermatologics segment whereby the Ortho Dermatologics reporting unit is now part of the current Diversified Products segment and the Solta reporting unit is now its own operating and reportable segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzI0NDMz_9c1c82cf-a162-48ad-a6bb-81cb07090fb6">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of intangible assets as of December&#160;31, 2021 and 2020 consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.113%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Useful&lt;br/&gt;Lives&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:36pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization and Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization and Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14,914)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D not in service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;B&amp;amp;L Trademark&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzI0NDQ5_d9c5fb85-8493-436b-a77c-6563504cafcb">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The major components of intangible assets as of December&#160;31, 2021 and 2020 consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.113%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.893%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.984%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Useful&lt;br/&gt;Lives&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:36pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization and Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization and Impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14,914)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate brands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(404)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Product rights/patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,055)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Partner relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired IPR&amp;amp;D not in service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;B&amp;amp;L Trademark&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;NA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,180)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ia7db43bf7c3c4b4186ebf9e2d3d12935_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzMtMS0xLTEtOTQ4MzE_9f5c909d-270a-4ed5-8277-27a36ce4f592">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iead8c960de884ed6a2da68f1c9212534_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzMtMy0xLTEtOTQ4MzE_6f31c74f-4ab6-44e5-b9c4-deb808a8bdd3"
      unitRef="usd">20842000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iead8c960de884ed6a2da68f1c9212534_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzMtNS0xLTEtOTQ4MzE_f35dce6c-7362-4362-9b6d-7831fb893734"
      unitRef="usd">16169000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iead8c960de884ed6a2da68f1c9212534_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzMtNy0xLTEtOTQ4MzE_10fda4f6-6062-4014-a8fe-a74c9f4ecc7b"
      unitRef="usd">4673000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i118c693b1f954748862447902a5683db_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzMtOS0xLTEtOTQ4MzE_62dc30e2-1684-45c3-90c2-37611dbfb313"
      unitRef="usd">20890000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i118c693b1f954748862447902a5683db_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzMtMTEtMS0xLTk0ODMx_9536681b-e212-4832-82e1-e36059109f9f"
      unitRef="usd">14914000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i118c693b1f954748862447902a5683db_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzMtMTMtMS0xLTk0ODMx_6d6570ee-3738-4d99-adb9-1351697bf57c"
      unitRef="usd">5976000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i7a7c179df5a84846a54bcfeb13c293e4_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzQtMS0xLTEtOTQ4MzE_74328f08-3b3a-411a-985e-46dbe1a5e1ef">P6Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie8d0b9bcbcff47528293434664f12031_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzQtMy0xLTEtOTQ4MzE_a30802c3-7129-430a-b933-4101b1341a68"
      unitRef="usd">902000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie8d0b9bcbcff47528293434664f12031_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzQtNS0xLTEtOTQ4MzE_1578c5fe-63d2-462c-a8c7-a410f7455bce"
      unitRef="usd">473000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie8d0b9bcbcff47528293434664f12031_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzQtNy0xLTEtOTQ4MzE_5c60eb0d-2348-4009-b98f-b3ff8aa49119"
      unitRef="usd">429000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0141b3d37c034975b5525cda87681171_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzQtOS0xLTEtOTQ4MzE_77961ebe-d77f-44ff-9fb6-a074327a57e0"
      unitRef="usd">907000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0141b3d37c034975b5525cda87681171_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzQtMTEtMS0xLTk0ODMx_7afa5f93-c455-4020-8864-50b57005474f"
      unitRef="usd">404000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0141b3d37c034975b5525cda87681171_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzQtMTMtMS0xLTk0ODMx_5b936290-64c6-445d-a9ac-e85a3aa2f3ae"
      unitRef="usd">503000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i2c05dc4d9b434c80a5cbd4af3c7c9d01_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzUtMS0xLTEtOTQ4MzE_27a96377-95a1-43fe-8508-fa2a7c9ee56a">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie35bf5d8694c4774974b0abc32f8fb13_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzUtMy0xLTEtOTQ4MzE_af0a7078-b843-4693-8b0e-ddf2f7f36cbd"
      unitRef="usd">3321000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie35bf5d8694c4774974b0abc32f8fb13_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzUtNS0xLTEtOTQ4MzE_9c72e337-d3fd-4f11-b0bc-4c27e03467cf"
      unitRef="usd">3174000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie35bf5d8694c4774974b0abc32f8fb13_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzUtNy0xLTEtOTQ4MzE_8cd5e86d-8d44-4764-a879-6a797ea4e5e4"
      unitRef="usd">147000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="idabeb53d68674574be9e8bc3a04fc023_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzUtOS0xLTEtOTQ4MzE_a42a60b1-e367-44da-949c-dbb7b2822dcc"
      unitRef="usd">3305000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idabeb53d68674574be9e8bc3a04fc023_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzUtMTEtMS0xLTk0ODMx_d12acb76-c827-4fb6-b7b3-52f679e9e50b"
      unitRef="usd">3055000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="idabeb53d68674574be9e8bc3a04fc023_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzUtMTMtMS0xLTk0ODMx_b123e3e2-1171-475d-a3ad-bbcd86f29415"
      unitRef="usd">250000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i03fe969473114a429bbf4edf40c1b1b5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzYtMS0xLTEtOTQ4MzE_416af604-6ac0-4dec-85e9-6790470abf2e">P0Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9d77acb3fa444b01a7222031f5d4d6ea_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzYtMy0xLTEtOTQ4MzE_b3a1cc68-e952-4532-bca1-293addfe733b"
      unitRef="usd">158000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9d77acb3fa444b01a7222031f5d4d6ea_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzYtNS0xLTEtOTQ4MzE_231281cb-30d8-44cc-9acc-00bb7903bda9"
      unitRef="usd">158000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9d77acb3fa444b01a7222031f5d4d6ea_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzYtNy0xLTEtOTQ4MzE_1b8a48de-fd58-4524-88d5-d825b778a7c7"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1b81638d52a34a33a0380c8dc68c21d6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzYtOS0xLTEtOTQ4MzE_84576f90-596a-4a60-bee1-fa46e6461607"
      unitRef="usd">169000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1b81638d52a34a33a0380c8dc68c21d6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzYtMTEtMS0xLTk0ODMx_ecfd1a68-d94c-4fe7-92c4-26f706f78ac1"
      unitRef="usd">168000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1b81638d52a34a33a0380c8dc68c21d6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzYtMTMtMS0xLTk0ODMx_8291c1c8-3b22-49e6-bdea-740b1a6d9c34"
      unitRef="usd">1000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i240a15f4864f40c195868e118ea13730_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzctMS0xLTEtOTQ4MzE_687431cd-65bb-4e17-84a6-88589f633105">P1Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5ba67417f7694417880945ef3a458823_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzctMy0xLTEtOTQ4MzE_94154dfa-14ec-4102-b594-8ea47090d1a1"
      unitRef="usd">207000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5ba67417f7694417880945ef3a458823_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzctNS0xLTEtOTQ4MzE_d027d420-16ac-4ca9-8605-3e93d4b23027"
      unitRef="usd">206000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5ba67417f7694417880945ef3a458823_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzctNy0xLTEtOTQ4MzE_7a21975b-84a2-45c4-9c14-6564cb5dc283"
      unitRef="usd">1000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i9ac6cd5788244ea0b4e00e55c970a88b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzctOS0xLTEtOTQ4MzE_54d97206-7204-4e96-94eb-53eee880c029"
      unitRef="usd">210000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i9ac6cd5788244ea0b4e00e55c970a88b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzctMTEtMS0xLTk0ODMx_012d21d6-d9b5-4cb5-a15e-ba50a2bb0d43"
      unitRef="usd">200000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i9ac6cd5788244ea0b4e00e55c970a88b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzctMTMtMS0xLTk0ODMx_07f63b13-5a0c-46d3-9e45-fafc63bcc6a0"
      unitRef="usd">10000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzgtMy0xLTEtOTQ4MzE_5e9f2227-91f2-4e90-972e-df551f752299"
      unitRef="usd">25430000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzgtNS0xLTEtOTQ4MzE_8aabf777-3f09-4322-a1c4-b4858552003a"
      unitRef="usd">20180000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzgtNy0xLTEtOTQ4MzE_1cfc9779-eb99-4e51-a3f3-53b7dcee96fc"
      unitRef="usd">5250000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzgtOS0xLTEtOTQ4MzE_63d4d765-ef59-4b09-94ac-884c51897433"
      unitRef="usd">25481000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzgtMTEtMS0xLTk0ODMx_33b58b79-7eab-4bdc-861a-183eb6aab5d9"
      unitRef="usd">18741000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzgtMTMtMS0xLTk0ODMx_d86e7e70-c3f2-4188-8ad5-d1f054d8774a"
      unitRef="usd">6740000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i4357b8c2815049e2916abd0dd4c84a5e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzktMy0xLTEtOTQ4MzE_9a88b054-d4de-48bf-8929-6cc4ad2c883f"
      unitRef="usd">0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i4357b8c2815049e2916abd0dd4c84a5e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzktNy0xLTEtOTQ4MzE_eef95bbd-9ba9-4ab3-9d95-aa285d6b66fd"
      unitRef="usd">0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i68da001337c24191a51c93ad8d98f64a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzktOS0xLTEtOTQ4MzE_8387ffe3-b0fb-4f5c-8e1f-aae14ec8d18b"
      unitRef="usd">7000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i68da001337c24191a51c93ad8d98f64a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzktMTMtMS0xLTk0ODMx_8d793535-83d4-4f46-8a14-66ea83ce8895"
      unitRef="usd">7000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i6c9e8270f510440cafaaadcad18b83e9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzEwLTMtMS0xLTk0ODMx_419bb543-e35b-4cb4-9fb5-ea7dfd2406d4"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i6c9e8270f510440cafaaadcad18b83e9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzEwLTctMS0xLTk0ODMx_8c05a31c-4df1-4afd-bdf0-c1141ce8d587"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i46550d37e139414ebc038a9317b297af_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzEwLTktMS0xLTk0ODMx_6acfb467-4ec6-44fa-a6bc-bdce23171958"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i46550d37e139414ebc038a9317b297af_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzEwLTEzLTEtMS05NDgzMQ_9ced6d83-8e9e-4fcd-9ca7-ad4208021d6a"
      unitRef="usd">1698000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzExLTMtMS0xLTk0ODMx_c3d93440-4ede-4222-85b0-e89959a5d2af"
      unitRef="usd">27128000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzExLTUtMS0xLTk0ODMx_b8e5a5b2-1ed7-4300-803a-57a172950adf"
      unitRef="usd">20180000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzExLTctMS0xLTk0ODMx_d10fbfa9-7ae0-4e2f-8118-832f42d4510f"
      unitRef="usd">6948000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzExLTktMS0xLTk0ODMx_1abbb223-1929-4b75-a0af-6e19340ec24e"
      unitRef="usd">27186000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzExLTExLTEtMS05NDgzMQ_c9f97afe-5dc0-48a3-9d3b-a92a7185973f"
      unitRef="usd">18741000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTo3NjU4ODUxYmMyYjI0MTQzYWQ0MTE3YWM5MjkxMTFhMC90YWJsZXJhbmdlOjc2NTg4NTFiYzJiMjQxNDNhZDQxMTdhYzkyOTExMWEwXzExLTEzLTEtMS05NDgzMQ_8e85bfd5-902c-46f3-90e8-050c918c6e84"
      unitRef="usd">8445000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="ia7db43bf7c3c4b4186ebf9e2d3d12935_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzYwNg_e687bcd6-e54e-48e6-a017-307eb31ff11f"
      unitRef="usd">105000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i5b13ca98db8c463aaeed70c3abe4f348_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzY5NQ_d2489f7b-fb90-4d61-a582-bedc5930ee8e"
      unitRef="usd">88000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="ibdc79af88d674986aa0a6ba7cb0f5f09_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzc4Mw_c41569ee-cca9-450d-a19e-d3fe5b465c23"
      unitRef="usd">23000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i846ec01236d9492bac74fd5461000270_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzg2NQ_ac29c259-8e49-4087-8a4c-76592384c1a3"
      unitRef="usd">18000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i80296fd237314f53b6c594ed566c42d6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzk5OQ_837014c5-7333-4666-a261-84a0d8a3e60b"
      unitRef="usd">96000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i4e1691abab7e45ce93d9c7cf06722945_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzExNzQ_287fc4a3-e41d-4d12-9adf-e1d7e29dffaa"
      unitRef="usd">16000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i993b35454ff842d7806cb59a463ffa34_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzEyNjA_a70c7789-8733-42c1-bd82-0d5581c87c5d"
      unitRef="usd">1000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i8d17c5bf6d9841eba3706e1d48dc6848_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE0MDE_db79e87c-ff0c-4768-99a7-ef5a7b6cd8b8"
      unitRef="usd">1000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="if5392c04784e4d69b6bc3a708883efda_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE0ODY_f57f456a-ac7c-4973-95c4-b76362f0d8ca"
      unitRef="usd">58000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="i20a958bbcf974985879a206eeec09656_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE2MDY_0aebb381-dbea-4e0d-a49d-2e473c8b0a34"
      unitRef="usd">8000000</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="ia3596e67486c490b9d96f6e6a4bf73bb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE2Njg_492ebeda-9048-47da-82b6-6f3230f9df64"
      unitRef="usd">5000000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i525a2c44053046a38066e353d995cc61_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE4NDI_3aae49ea-4085-4fb4-8baa-e2b2aa653944"
      unitRef="usd">4000000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzI0NDQy_a1a719c1-050e-47c5-a657-b9a0ee3ebf9f">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated amortization expense of finite-lived intangible assets for the five years ending December&#160;31 and thereafter are as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.735%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.881%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTowYTBmN2JjZTdhNjA0YmRjOThmNGM4ZDI2MTQxOTBiZC90YWJsZXJhbmdlOjBhMGY3YmNlN2E2MDRiZGM5OGY0YzhkMjYxNDE5MGJkXzEtMi0xLTEtOTQ4MzE_1d4f47ec-adaa-4374-9cf5-3cda280188da"
      unitRef="usd">1181000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTowYTBmN2JjZTdhNjA0YmRjOThmNGM4ZDI2MTQxOTBiZC90YWJsZXJhbmdlOjBhMGY3YmNlN2E2MDRiZGM5OGY0YzhkMjYxNDE5MGJkXzEtNC0xLTEtOTQ4MzE_179aafdb-b621-47fe-b0d2-dc22ef545da5"
      unitRef="usd">1026000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTowYTBmN2JjZTdhNjA0YmRjOThmNGM4ZDI2MTQxOTBiZC90YWJsZXJhbmdlOjBhMGY3YmNlN2E2MDRiZGM5OGY0YzhkMjYxNDE5MGJkXzEtNi0xLTEtOTQ4MzE_fa7ce9fe-6e32-4d20-90ea-1c1dac44a091"
      unitRef="usd">902000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTowYTBmN2JjZTdhNjA0YmRjOThmNGM4ZDI2MTQxOTBiZC90YWJsZXJhbmdlOjBhMGY3YmNlN2E2MDRiZGM5OGY0YzhkMjYxNDE5MGJkXzEtOC0xLTEtOTQ4MzE_422482a9-a263-42ce-90d5-4893fd5c699a"
      unitRef="usd">795000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTowYTBmN2JjZTdhNjA0YmRjOThmNGM4ZDI2MTQxOTBiZC90YWJsZXJhbmdlOjBhMGY3YmNlN2E2MDRiZGM5OGY0YzhkMjYxNDE5MGJkXzEtMTAtMS0xLTk0ODMx_a7c17f1d-efd6-4b85-ba7b-291f3848345c"
      unitRef="usd">664000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTowYTBmN2JjZTdhNjA0YmRjOThmNGM4ZDI2MTQxOTBiZC90YWJsZXJhbmdlOjBhMGY3YmNlN2E2MDRiZGM5OGY0YzhkMjYxNDE5MGJkXzEtMTItMS0xLTk0ODMx_41a35abc-c718-4425-81fe-579ed3531d6a"
      unitRef="usd">682000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTowYTBmN2JjZTdhNjA0YmRjOThmNGM4ZDI2MTQxOTBiZC90YWJsZXJhbmdlOjBhMGY3YmNlN2E2MDRiZGM5OGY0YzhkMjYxNDE5MGJkXzEtMTQtMS0xLTk0ODMx_d8711f68-5e3b-4e6a-bb42-50a0b3875f03"
      unitRef="usd">5250000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzI0NDQ2_f594bce6-406e-42a6-a186-0e786145c275">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the carrying amounts of goodwill during the years ended December 31, 2021, 2020 and 2019 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.763%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.790%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Bausch + &lt;br/&gt;Lomb/&lt;br/&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Bausch + &lt;br/&gt;Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Ortho Dermatologics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance, January 1, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:4.5pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquisition of certain assets of Synergy &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill reclassified to assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Assets held for sale reclassified to goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill reclassified to assets held for sale (Note 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realignment of segment goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(118)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i29a1b1fb5e7d43a0a5704750d1336b1f_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEtMi0xLTEtOTQ4MzE_fb0d3acc-7fb4-4005-bb6a-8cccc05a5193"
      unitRef="usd">5805000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0c3d9b6375104575a0b650fb85f1b280_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEtNi0xLTEtOTQ4MzE_57a64689-c619-4363-ac0a-7cce662e9665"
      unitRef="usd">3156000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i94cb38fd73a64df9bcbf981da8f70e3c_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEtMTAtMS0xLTk0ODMx_40b8cc7d-413e-472f-88e0-441092ca840b"
      unitRef="usd">1267000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="id466e6e6ca4d4b5cbde067689c3faef3_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEtMTItMS0xLTk0ODMx_12f2b128-df2d-4a86-b37e-7ca226a938ee"
      unitRef="usd">2914000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i18439fe8345c481db53c486667ac6940_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEtMTQtMS0xLTk0ODMx_7846e121-1015-4c01-a2e7-03e0896ccbcb"
      unitRef="usd">13142000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i417dcef94a21464c8f3e70b1b83c913c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzItNi0xLTEtOTQ4MzE_1d8fb209-e961-4c3a-8c9b-32f8c721415c"
      unitRef="usd">3000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzItMTQtMS0xLTk0ODMx_24eedca8-560c-47ee-bc9b-e8c539e38dbe"
      unitRef="usd">3000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="iba8428875eb04c3490fd83250b59b893_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzMtMi0xLTEtOTQ4MzE_d69461b1-d1fc-4b33-ae6d-81019ae8c901"
      unitRef="usd">18000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzMtMTQtMS0xLTk0ODMx_d49b5573-c117-4fbf-bdd1-8ee2746052a4"
      unitRef="usd">18000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="iba8428875eb04c3490fd83250b59b893_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzQtMi0xLTEtOTQ4MzE_117d8852-db8c-45af-893a-913cefd28df2"
      unitRef="usd">-1000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzQtMTQtMS0xLTk0ODMx_be9221e5-fc43-4389-9614-882660182aeb"
      unitRef="usd">-1000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="if3dfd5b244cf486d987b952dbf744f29_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzUtMi0xLTEtOTQ4MzE_aa7b0024-4999-41f7-9977-f8f29a657fd4"
      unitRef="usd">5786000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="iba148d40c69f47e983b912769213931c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzUtNi0xLTEtOTQ4MzE_0c23dcc8-2575-462e-aa03-f7538d87a7fe"
      unitRef="usd">3159000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0f812afa0f2f46a5a00813ce760a5ac1_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzUtMTAtMS0xLTk0ODMx_716193d8-01b0-4e9b-a06f-6e022c7bc563"
      unitRef="usd">1267000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i53ea644df00c4c18a3c89f1915121a44_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzUtMTItMS0xLTk0ODMx_3cf606b2-c8d7-4038-8e02-d1463c947a58"
      unitRef="usd">2914000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzUtMTQtMS0xLTk0ODMx_d7d95163-6c95-40b1-b509-3addaffcb434"
      unitRef="usd">13126000000</us-gaap:Goodwill>
    <bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit
      contextRef="i25de128371b34a1f9d25e80a34d0887d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzYtMi0xLTEtOTQ4MzE_5877de6e-35d2-4e1c-84b0-6b6920b67e82"
      unitRef="usd">18000000</bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit>
    <bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzYtMTQtMS0xLTk0ODMx_1bbdad06-bde5-49f4-8a71-61940eb2146c"
      unitRef="usd">18000000</bhc:GoodwillTransfersRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i25de128371b34a1f9d25e80a34d0887d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzctMi0xLTEtOTQ4MzE_985928d7-10f8-4e16-81e1-ed61c34d6a9b"
      unitRef="usd">217000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzctMTQtMS0xLTk0ODMx_2bc4ec48-e6a2-422e-8e31-129109581049"
      unitRef="usd">217000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i25de128371b34a1f9d25e80a34d0887d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzgtMi0xLTEtOTQ4MzE_d676ec4a-a31a-4917-92a4-b1f02f00e5f4"
      unitRef="usd">117000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzgtMTQtMS0xLTk0ODMx_5b385009-7c39-42b4-bb82-eefe4f6a29f5"
      unitRef="usd">117000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i305ad186f05a46689ddd955b46c78817_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzktMi0xLTEtOTQ4MzE_a5b7027c-32f6-433c-8a9c-3efe27b5ce00"
      unitRef="usd">5704000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i9106cb312b894b4fb0e6e25a1c2f3229_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzktNi0xLTEtOTQ4MzE_a647b0a1-82c7-4be6-b7c5-60156c8fea9e"
      unitRef="usd">3159000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i4e7e6c0540534603be58b450ccc6ebd2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzktMTAtMS0xLTk0ODMx_c3875ffb-0cfe-48bc-a838-a0cd9a0797f4"
      unitRef="usd">1267000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ieb7488e0749d446eabef23fd482eb625_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzktMTItMS0xLTk0ODMx_68c18c76-4fee-4bc4-a541-3b6c66b57aa5"
      unitRef="usd">2914000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzktMTQtMS0xLTk0ODMx_5cd9aacd-cd71-4292-b58e-b4b699c1b81b"
      unitRef="usd">13044000000</us-gaap:Goodwill>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i3cbcad2018a947ad8f38faccb79805c0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEwLTItMS0xLTk0ODMx_bd171c30-de31-49cb-a1f6-11236bf19d27"
      unitRef="usd">-5704000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i414fba28824c413593139a2e4ef76d21_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEwLTQtMS0xLTk0ODMx_07f00c98-8568-490a-9c03-1cb4cdaa9493"
      unitRef="usd">5395000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ied7527e9c7f3438db93389c0a1768d2a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEwLTgtMS0xLTk0ODMx_894a382c-a960-45a1-9015-31789bb1aecb"
      unitRef="usd">887000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i3a5a9e6c49d742aca8267ceb1bf314d3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEwLTEyLTEtMS05NDgzMQ_4604c6e0-057e-4109-b400-692defc8a221"
      unitRef="usd">-578000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEwLTE0LTEtMS05NDgzMQ_48cece26-901e-44b3-8a7e-d18ea2c591a5"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i3cbcad2018a947ad8f38faccb79805c0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzExLTItMS0xLTk0ODMx_7dcd3c5a-c27a-4faa-8fe7-7c04c686a04d"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i3328d4d641274769857018f609cda173_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzExLTEwLTEtMS05NDgzMQ_b8d34063-01ec-47e1-b974-fb6488fffa89"
      unitRef="usd">469000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzExLTE0LTEtMS05NDgzMQ_be37f6a0-ee6b-4a1b-ae8f-3c9331ca48c2"
      unitRef="usd">469000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i3cbcad2018a947ad8f38faccb79805c0_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEyLTItMS0xLTk0ODMx_78d40e9f-4915-49bf-b867-4a16610d6f79"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i414fba28824c413593139a2e4ef76d21_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEyLTQtMS0xLTk0ODMx_d30d0907-604a-4f61-96b5-71ac12705055"
      unitRef="usd">-77000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ied7527e9c7f3438db93389c0a1768d2a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEyLTgtMS0xLTk0ODMx_ac1df28b-ed09-4d2c-a76d-8965949dc05c"
      unitRef="usd">-62000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i3a5a9e6c49d742aca8267ceb1bf314d3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEyLTEyLTEtMS05NDgzMQ_ce51623c-9c14-4fc8-bdae-d3ceb40806f7"
      unitRef="usd">21000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEyLTE0LTEtMS05NDgzMQ_0d424611-b3e6-41cf-a4e8-627fb51394f9"
      unitRef="usd">-118000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="iea2db51516f74749bd5cb23d69094522_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEzLTItMS0xLTk0ODMx_36831202-69a2-48b6-8d39-755b85100a6f"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5bc870f8e27c47c28a8e424dee7145fe_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEzLTQtMS0xLTk0ODMx_41993544-bfa1-46ae-8f0e-1a68f4b227ea"
      unitRef="usd">5318000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i9aac4f4658b94a079f835ab8b92e3d71_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEzLTYtMS0xLTk0ODMx_672e45de-be73-4eb2-b807-4758c5bf211d"
      unitRef="usd">3159000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="id1d8a07e1c514b0588c2be7cad93ca17_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEzLTgtMS0xLTk0ODMx_87108737-77bd-4beb-bc7b-100beb5e3d77"
      unitRef="usd">825000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="id5279cba8f1f4e03838c2449f0a36169_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEzLTEwLTEtMS05NDgzMQ_00a84818-8795-4c5c-91fb-a1d6ee243be8"
      unitRef="usd">798000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2ccf39e3c6294658af0ff9fe475686ff_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEzLTEyLTEtMS05NDgzMQ_a207ce1f-daa9-4e61-9ac9-e32d07ca7554"
      unitRef="usd">2357000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90YWJsZTpmZmIwNWJlNTI0NzI0NzY2YjEzMjk2M2JlMzBlN2YxMS90YWJsZXJhbmdlOmZmYjA1YmU1MjQ3MjQ3NjZiMTMyOTYzYmUzMGU3ZjExXzEzLTE0LTEtMS05NDgzMQ_940b7e7a-a396-44b4-97b5-382f2be93568"
      unitRef="usd">12457000000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="idf7ffc6e85884b44bb020321c2fcfd9b_D20191001-20191001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzY5Mzc_ca3e7c77-e22f-4736-a58c-40db4ae6e038"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzg3MTY_11953966-5649-4981-9e46-445bd8261b25"
      unitRef="usd">8434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzg3MjM_3fcc9e3a-b8cb-4f45-bc58-6556353b8201"
      unitRef="usd">8027000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <bhc:IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzg3NTc_42c471d1-c9e5-4398-877c-cda20e34b886"
      unitRef="usd">407000000</bhc:IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax>
    <bhc:IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage
      contextRef="ib12ef9337a854b11b31304b6e0c0205c_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzg5NDA_f12170a2-f042-4e2d-91bc-ef54cc88e0e4"
      unitRef="number">-0.23</bhc:IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage>
    <bhc:IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage
      contextRef="i7127e175a3854e52bc0c75d9ff20c0a3_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzg5NDQ_39255933-b8d2-4829-8568-77a7e1a4be77"
      unitRef="number">-0.03</bhc:IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage>
    <bhc:IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage
      contextRef="ic1987990ae2747de8eb8993bcdd37868_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzg5NjE_e3fe7817-a50f-4bb8-a9ac-be2dd4513c3b"
      unitRef="number">-0.01</bhc:IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i7cb87466591741d69c11218eca97afee_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzEwNDgy_6d53d587-7a95-49b0-9acf-d2727e6a309a"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i98b90ee22470425788f2889f17244951_D20200331-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzExNDk0_00753941-efca-4f9d-b6ea-608bc6712d1c"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i699a9e7d09c64c9c88f463de1d97f137_D20200630-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzExNDk0_944d2b71-f51b-4436-8ec0-7fe93e021c50"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i30a1d9b6c3d84763be8ecc3f1d79f317_I20201001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzEyODc5_a5f8ec8e-07b2-4b33-be90-5fe0b129cf82"
      unitRef="number">0.020</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i5d5b8f902e834dda885bb99a7a2bb489_I20201001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzEyOTIw_36ff7d06-fbbe-4424-b713-6f26839426f3"
      unitRef="number">0.0950</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i6080875e0e1f4486a08e3dc0c2dc6319_I20201001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzEyOTI3_ddb1e198-cd44-4cdc-9125-5b9219ff57a7"
      unitRef="number">0.0975</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i30a1d9b6c3d84763be8ecc3f1d79f317_I20201001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzEzMTA2_8dee9861-a846-4009-82e8-6ebb98e61134"
      unitRef="number">0.10</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i21115bf566934307b8091d4d727aa2c3_D20201001-20201001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzEzMTY3_526eb8ff-1a2c-4419-bbd4-e1bbabf175ff"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i86c894299d29409ead4b863813550b86_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE1Njg3_40bb0a36-ee42-4717-a5b6-0ee80ba469eb"
      unitRef="number">0.010</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i9a2dd9a9a7d04b008adc3046b51f7059_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE1Njkz_698f0d50-ee7c-4b38-8ef5-8ecfb6fd8b59"
      unitRef="number">0.030</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i86c894299d29409ead4b863813550b86_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE1NzM0_51d13418-166f-4640-8d44-14ebae97cc9d"
      unitRef="number">0.110</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i9a2dd9a9a7d04b008adc3046b51f7059_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE1NzQx_4da77f05-9461-4f6e-b3f0-89658d3c7b3e"
      unitRef="number">0.1225</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="ic6202fe446ad4ef9a31cbf50a8342593_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE1OTIw_5580adc7-2f06-4024-a1b3-16c5cf660ec1"
      unitRef="number">0.40</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="icded4b5feb5b4918af206e2655141f49_D20210331-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE1OTUw_7995e29e-b24f-437a-86ba-7bba849e2e63"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="ice067f6010c74048bd8841e74a7cef86_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE4MTk4_7df2c569-b2b5-493f-863b-d3ff4e4e5384"
      unitRef="number">0.010</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i47d8b26934ee4498a7ab3ff3fecbfed7_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE4MjM5_e5aed00f-3517-4c2a-b29a-a0b6a8c4347b"
      unitRef="number">0.090</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i6ea718d72ec4448ba2219818acc2f6f2_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE4MjQ2_369e07a8-6aca-4b6b-97b1-0947ac6815c3"
      unitRef="number">0.100</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ibe79965a558440f68c2f201ffc977e8e_D20210331-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE4NDQ5_d1c46927-ad80-431d-8c38-cecbef5b1382"
      unitRef="usd">469000000</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="icd4661795c6d477dae3ccd804bc808e8_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzIwNTAw_ad2b2ac5-43bf-4f9e-8a57-6792eff31d4e"
      unitRef="number">0.020</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i5d4cdd25b2984038a1406bacb8cdc3dd_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzIwNTA3_5f89e579-1e13-4d31-acc6-8c74b7b07307"
      unitRef="number">0.030</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="icd4661795c6d477dae3ccd804bc808e8_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzIwNTQ4_c364856c-30a9-4915-b076-bbd3c2e77427"
      unitRef="number">0.070</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i5d4cdd25b2984038a1406bacb8cdc3dd_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzIwNTU1_45c66b8f-36bb-4989-9e30-bc700a54a013"
      unitRef="number">0.100</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i90bbe44e848c4111942574f93f21895e_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzIwNzM0_181b3f2c-ba57-4ed8-a18e-06c52e774db7"
      unitRef="number">0.45</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i4b861d276efc40a681c82e2398b819a7_D20210630-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzIwNzY0_e66d42f6-6850-48ce-b26a-cb89e114115a"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <bhc:ReportingUnitImpairmentTestLongTermGrowthRate
      contextRef="i75ce7fc0f0264a0f904c3a8cde7de3fd_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzIzNzEx_33a5407d-2fa5-400c-abb0-9f8c811a7228"
      unitRef="number">0.010</bhc:ReportingUnitImpairmentTestLongTermGrowthRate>
    <bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate
      contextRef="i75ce7fc0f0264a0f904c3a8cde7de3fd_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzIzNzM3_908d9262-b42d-439e-a311-53397f24c650"
      unitRef="number">0.090</bhc:ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i75ce7fc0f0264a0f904c3a8cde7de3fd_I20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzIzOTE2_1ef5f657-40e4-46b1-b44a-ee6bcfd802d9"
      unitRef="number">0.10</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="idfae6f80e7694be08e982fe5786bd632_D20211001-20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzIzOTc3_b0382a22-c585-44f8-b21c-5206c20c8584"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzI0NDA2_0d419d8b-8a00-4391-b137-fce4709bc723"
      unitRef="usd">4180000000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:NumberOfReportableSegments
      contextRef="if40967e6d4d3497cb45e304881c2d2d3_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE2NDkyNjc0NjgzODI_d79ff47a-9f0f-485f-aaed-466a5dbe510e"
      unitRef="segment">5</us-gaap:NumberOfReportableSegments>
    <us-gaap:Goodwill
      contextRef="i711dcf2b52cb48f98fc1cf3d97a987ec_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE2NDkyNjc0NjgzMDc_64416579-3f77-4dea-8ffe-4c7b81625535"
      unitRef="usd">5318000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i969d616487264ae4b3b65d39984bbeda_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE2NDkyNjc0NjgzNTM_625e3039-4f9a-4531-8a2e-ac3953faf34f"
      unitRef="usd">3159000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i22c93f5e835048719e869de028b61cc3_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE2NDkyNjc0NjgzNjk_3af9e7dc-8fd6-40c6-8710-deafa0fea35b"
      unitRef="usd">825000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ifc44ed8e69bb43ea954db330ec970a6a_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE2NDkyNjc0NjgzMjM_5ff78fe3-cf56-4823-98fd-df36ed94f552"
      unitRef="usd">115000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie889e70e297a454da84ecd8e61e4957d_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzE2NDkyNjc0NjgzMzc_18e5fd51-bd98-44e0-aa76-bca85603bfb3"
      unitRef="usd">3040000000</us-gaap:Goodwill>
    <us-gaap:NumberOfReportingUnits
      contextRef="if40967e6d4d3497cb45e304881c2d2d3_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzQvZnJhZzpkNzZlZTI4NjRhNjc0Zjc0ODVhNDQxZmY0M2VjYTEwMi90ZXh0cmVnaW9uOmQ3NmVlMjg2NGE2NzRmNzQ4NWE0NDFmZjQzZWNhMTAyXzk4OTU2MDQ2NzcwODg_26ff550b-c60a-4f92-93ed-619a03ebe12c"
      unitRef="reporting_unit">2</us-gaap:NumberOfReportingUnits>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90ZXh0cmVnaW9uOjgxNjY1NDkyNjJhMjQzZWNiM2QwMTVmMjYxNzlkMmY2Xzcy_89d7ebbe-6384-4850-ada7-1c609baaedaf">ACCRUED AND OTHER CURRENT LIABILITIES&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities as of December 31, 2021 and 2020 consist of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal matters and related fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90ZXh0cmVnaW9uOjgxNjY1NDkyNjJhMjQzZWNiM2QwMTVmMjYxNzlkMmY2XzY5_a90d4e0b-d53f-4105-a8dc-9f37b7965783">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued and other current liabilities as of December 31, 2021 and 2020 consist of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal matters and related fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <bhc:Legalsettlementsandrelatedfees
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzEtMi0xLTEtOTQ4MzE_6632df50-e56e-4967-a221-cc14bdea41e8"
      unitRef="usd">1890000000</bhc:Legalsettlementsandrelatedfees>
    <bhc:Legalsettlementsandrelatedfees
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzEtNC0xLTEtOTQ4MzE_e6bcd93a-d61a-42cc-aa60-f088a074ef47"
      unitRef="usd">1672000000</bhc:Legalsettlementsandrelatedfees>
    <bhc:AccruedProductRebateCurrent
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzItMi0xLTEtOTQ4MzE_25cce1be-446b-4586-ad00-68cd69ae4ec3"
      unitRef="usd">908000000</bhc:AccruedProductRebateCurrent>
    <bhc:AccruedProductRebateCurrent
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzItNC0xLTEtOTQ4MzE_9036809c-648e-4fd6-a0ed-c7ec44a32d85"
      unitRef="usd">747000000</bhc:AccruedProductRebateCurrent>
    <bhc:AccruedProductReturnCurrent
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzMtMi0xLTEtOTQ4MzE_38305d81-f587-42aa-aa37-d8f6e225140a"
      unitRef="usd">482000000</bhc:AccruedProductReturnCurrent>
    <bhc:AccruedProductReturnCurrent
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzMtNC0xLTEtOTQ4MzE_2310fc2f-0c2f-4a50-8018-0871dde2f006"
      unitRef="usd">575000000</bhc:AccruedProductReturnCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzQtMi0xLTEtOTQ4MzE_a2bb8dee-1ec4-4ab0-8cf2-14f9f171eca3"
      unitRef="usd">336000000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzQtNC0xLTEtOTQ4MzE_56730ebd-557f-4d8c-a64e-a5ad57a33cac"
      unitRef="usd">316000000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzUtMi0xLTEtOTQ4MzE_f6e12278-8021-42e7-806a-ca3d08587b42"
      unitRef="usd">328000000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzUtNC0xLTEtOTQ4MzE_0590a5dc-a026-4ca3-9735-b2f45b22c175"
      unitRef="usd">341000000</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzYtMi0xLTEtOTQ4MzE_07724153-ee7d-43bd-bda3-03d046205804"
      unitRef="usd">98000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzYtNC0xLTEtOTQ4MzE_90a6fa7e-9edf-421a-b634-dd5931385045"
      unitRef="usd">158000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzctMi0xLTEtOTQ4MzE_7a44fce4-59f1-45fb-8fa8-2789947eadeb"
      unitRef="usd">749000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzctNC0xLTEtOTQ4MzE_36dbdd45-063b-4dcf-8122-5a32914f9567"
      unitRef="usd">767000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzgtMi0xLTEtOTQ4MzE_aca1f9d4-ed9d-488c-a192-61cac79985b1"
      unitRef="usd">4791000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zMzcvZnJhZzo4MTY2NTQ5MjYyYTI0M2VjYjNkMDE1ZjI2MTc5ZDJmNi90YWJsZTo1OTg4ZTcxNTgzZTQ0NGIxOTQxYWJlZWM4MWRiOTIzNy90YWJsZXJhbmdlOjU5ODhlNzE1ODNlNDQ0YjE5NDFhYmVlYzgxZGI5MjM3XzgtNC0xLTEtOTQ4MzE_e12e3c72-1df2-486c-996f-e716b6735fed"
      unitRef="usd">4576000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzM0MjUx_3201fc25-88f7-4fd0-ad31-cee5a68c5f89">FINANCING ARRANGEMENTS&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs as of December 31, 2021 and 2020 consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.158%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.033%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Credit Facilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023 Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.000% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.500% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.750% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.875% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Unsecured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.125%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.000%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.500%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.000%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.000%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.000%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Covenant Compliance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Credit Facilities (as defined below) and the indentures governing the Senior Secured Notes and Senior Unsecured Notes contain customary affirmative and negative covenants and specified events of default. These affirmative and negative covenants include, among other things, and subject to certain qualifications and exceptions, covenants that restrict the Company&#x2019;s ability and the ability of its subsidiaries to: incur or guarantee additional indebtedness; create or permit liens on assets; pay dividends on capital stock or redeem, repurchase or retire capital stock or subordinated indebtedness; make certain investments and other restricted payments; engage in mergers, acquisitions, consolidations and amalgamations; transfer and sell certain assets; and engage in transactions with affiliates. As of December&#160;31, 2021, the amount available for restricted payments under the &#x201c;builder basket&#x201d; in the Company&#x2019;s most restrictive indentures (as defined by those indentures) was approximately $13,800&#160;million (although such availability is subject to the Company's compliance with a 2.00:1.00 fixed charge coverage ratio). The 2023 Revolving Credit Facility (as defined below) also contains a financial maintenance covenant that requires the Company to maintain a first lien net leverage ratio of not greater than 4.00:1.00. The financial maintenance covenant may be waived or amended without the consent of the term loan facility lenders and contains a customary term loan facility standstill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the Company was in compliance with its financial maintenance covenant related to its debt obligations. The Company, based on its current forecast for the next twelve months from the date of issuance of these financial statements, expects to remain in compliance with its financial maintenance covenant and meet its debt service obligations over that same period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to take steps to improve its operating results to ensure continual compliance with its financial maintenance covenant and may take other actions to reduce its debt levels to align with the Company&#x2019;s long-term strategy, including divesting other businesses, refinancing debt and issuing equity or equity-linked securities as deemed appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Secured Credit Facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 1, 2018, the Company and certain of its subsidiaries as guarantors entered into the &#x201c;Senior Secured Credit Facilities&#x201d; under the Company's Fourth Amended and Restated Credit and Guaranty Agreement (the &#x201c;Restated Credit Agreement&#x201d;), with a syndicate of financial institutions and investors as lenders. The Restated Credit Agreement provides for a revolving credit facility of $1,225 million (the &#x201c;2023 Revolving Credit Facility&#x201d;) and a seven year Tranche B Term Loan Facility of $4,565 million (the &#x201c;June 2025 Term Loan B Facility&#x201d;) borrowed by the Company&#x2019;s subsidiary, Bausch Health Americas, Inc. (&#x201c;BHA&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2023 Revolving Credit Facility matures on the earlier of June 1, 2023 and the date that is 91 calendar days prior to the scheduled maturity of indebtedness for borrowed money of the Company or BHA in an aggregate principal amount in excess of $1,000 million. Both the Company and BHA are borrowers with respect to the 2023 Revolving Credit Facility. Borrowings under the 2023 Revolving Credit Facility may be made in U.S. dollars or Canadian dollars (or if an amendment to the Restated Credit Agreement is made to replace LIBOR with an alternative benchmark rate with respect to borrowings under the Revolving Credit Facility denominated in euros, euros).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2021, the Company had $285 million of outstanding borrowings, $54 million of issued and outstanding letters of credit, and remaining availability of $886 million under its 2023 Revolving Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 27, 2018, the Company entered into the First Incremental Amendment to the Restated Credit Agreement, which provided an additional seven year Tranche B Term Loan Facility of $1,500&#160;million (the &#x201c;November 2025 Term Loan B Facility&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Current Description of Senior Secured Credit Facilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the Senior Secured Credit Facilities in U.S. dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a base rate determined by reference to the highest of: (a) the prime rate (as defined in the Restated Credit Agreement), (b) the federal funds effective rate plus 1/2 of 1.00% or (c) the eurocurrency rate (as defined in the Restated Credit Agreement) for a period of one month plus 1.00% (or if such eurocurrency rate shall not be ascertainable, 1.00%) or (ii) a eurocurrency rate determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing adjusted for certain additional costs (provided however, that the eurocurrency rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the 2023 Revolving Credit Facility in euros, when available, are expected to bear interest at a term benchmark rate determined by reference to the costs of funds for euro deposits for the interest period relevant to such borrowing (provided however, that the eurocurrency rate is at no time expected to be less than 0.00% per annum), plus an applicable margin. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the 2023 Revolving Credit Facility in Canadian dollars bear interest at a rate per annum equal to, at the Company's option, either: (i) a prime rate determined by reference to the higher of: (a) the rate of interest last quoted by The Wall Street Journal as the &#x201c;Canadian Prime Rate&#x201d; or, if The Wall Street Journal ceases to quote such rate, the highest per annum interest rate published by the Bank of Canada as its prime rate and (b) the 1 month BA rate (as defined below) calculated daily plus 1.00% (provided however, that the prime rate shall at no time be less than 0.00%) or (ii) the bankers&#x2019; acceptance rate for Canadian dollar deposits in the Toronto interbank market (the &#x201c;BA rate&#x201d;) for the interest period relevant to such borrowing (provided however, that the BA rate shall at no time be less than 0.00% per annum), in each case plus an applicable margin.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to certain exceptions and customary baskets set forth in the Restated Credit Agreement, the Company is required to make mandatory prepayments of the loans under the Senior Secured Credit Facilities under certain circumstances, including from: (i)&#160;100% of the net cash proceeds of insurance and condemnation proceeds for property or asset losses (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold), (ii)&#160;100% of the net cash proceeds from the incurrence of debt (other than permitted debt as described in the Restated Credit Agreement), (iii)&#160;50% of Excess Cash Flow (as&#160;defined in the Restated Credit Agreement) subject to decrease based on leverage ratios and subject to a threshold amount and (iv)&#160;100% of net cash proceeds from asset sales (subject to reinvestment rights, decrease based on leverage ratios and net proceeds threshold). These mandatory prepayments may be used to satisfy future amortization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The applicable interest rate margins for the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility are 2.00% and 1.75%, respectively, with respect to base rate and prime rate borrowings and 3.00% and 2.75%, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respectively, with respect to eurocurrency rate and BA rate borrowings. As of December 31, 2021, the stated rates of interest on the Company&#x2019;s borrowings under the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility were 3.09% and 2.84% per annum, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortization rate for both the June 2025 Term Loan B Facility and the November 2025 Term Loan B Facility is 5.00% per annum. The Company may direct that prepayments be applied to such amortization payments in order of maturity. As of December 31, 2021, there were no remaining mandatory quarterly amortization payments for the Senior Secured Credit Facilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The applicable interest rate margins for borrowings under the 2023 Revolving Credit Facility are 1.50%-2.00% with respect to base rate or prime rate borrowings and 2.50%-3.00% with respect to eurocurrency rate or BA rate borrowings.&#160; As of December 31, 2021, the stated rate of interest on the 2023 Revolving Credit Facility was 2.84% per annum. In addition, the Company is required to pay commitment fees of 0.25% - 0.50% per annum with respect to the unutilized commitments under the 2023 Revolving Credit Facility, payable quarterly in arrears. The Company also is required to pay: (i) letter of credit fees on the maximum amount available to be drawn under all outstanding letters of credit in an amount equal to the applicable margin on eurocurrency rate borrowings under the 2023 Revolving Credit Facility on a per annum basis, payable quarterly in arrears, (ii) customary fronting fees for the issuance of letters of credit and (iii) agency&#160;fees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Restated Credit Agreement permits the incurrence of incremental credit facility borrowings, up to the greater of $1,000 million and 28.5% of Consolidated Adjusted EBITDA (non-GAAP) (as defined in the Restated Credit Agreement), subject to customary terms and conditions, as well as the incurrence of additional incremental credit facility borrowings subject to, in the case of secured debt, a secured leverage ratio of not greater than 3.50:1.00, and, in the case of unsecured debt, either a total leverage ratio of not greater than 6.50:1.00 or an interest coverage ratio of not less than 2.00:1.00.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Notes are guaranteed by each of the Company&#x2019;s subsidiaries that is a guarantor under the Restated Credit Agreement and existing Senior Unsecured Notes (together, the &#x201c;Note Guarantors&#x201d;). The Senior Secured Notes and the guarantees related thereto are senior obligations and are secured, subject to permitted liens and certain other exceptions, by the same first priority liens that secure the Company&#x2019;s obligations under the Restated Credit Agreement under the terms of the indentures governing the Senior Secured Notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Secured Notes and the guarantees rank equally in right of repayment with all of the Company&#x2019;s and Note Guarantors&#x2019; respective existing and future unsubordinated indebtedness and senior to the Company&#x2019;s and Note Guarantors&#x2019; respective future subordinated indebtedness. The Senior Secured Notes and the guarantees related thereto are effectively &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;pari passu&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; with the Company&#x2019;s and the Note Guarantors&#x2019; respective existing and future indebtedness secured by a first priority lien on the collateral securing the Senior Secured Notes and effectively senior to the Company&#x2019;s and the Note Guarantors&#x2019; respective existing and future indebtedness that is unsecured, including the existing Senior Unsecured Notes, or that is secured by junior liens, in each case to the extent of the value of the collateral. In addition, the Senior Secured Notes are structurally subordinated to: (i) all liabilities of any of the Company&#x2019;s subsidiaries that do not guarantee the Senior Secured Notes and (ii) any of the Company&#x2019;s debt that is secured by assets that are not collateral.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the occurrence of a change in control (as defined in the indentures governing the Senior Secured Notes), unless the Company has exercised its right to redeem all of the notes of a series, holders of the Senior Secured Notes may require the Company to repurchase such holder&#x2019;s notes, in whole or in part, at a purchase price equal to 101% of the principal amount thereof plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;6.500% Senior Secured Notes due 2022 and 7.00% Senior Secured Notes due 2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2017, the Company issued $1,250&#160;million aggregate principal amount of 6.500% senior secured notes due March 15, 2022 (the &#x201c;March 2022 Secured Notes&#x201d;) and $2,000&#160;million aggregate principal amount of 7.000% senior secured notes due March 15, 2024 (the &#x201c;March 2024 Secured Notes&#x201d;), in a private placement. Interest on these notes is payable semi-annually in arrears on each March 15 and September 15.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The March 2022 Secured Notes were repaid in full as part of the May 2020 Refinancing Transactions (as defined below).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The March 2024 Secured Notes were repaid in full during 2021 with cash on hand and as part of the June 2021 Refinancing Transactions (as defined below).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;5.500% Senior Secured Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October&#160;17, 2017, the Company issued $1,000&#160;million, and, on November 21, 2017, the Company issued $750&#160;million,  aggregate principal amount of 5.500% Senior Secured Notes due November 2025 (the &#x201c;November 2025 Secured Notes&#x201d;), &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in a private placement. Interest on the November 2025 Secured Notes is payable semi-annually in arrears on each May 1 and November 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The November 2025 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time, at the redemption prices set forth in the indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;5.750% Senior Secured Notes due 2027 - March 2019 Refinancing Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 8, 2019, BHA and the Company issued: (i) $1,000 million aggregate principal amount of 8.500% Senior Unsecured Notes due 2027 (the &#x201c;January 2027 Unsecured Notes&#x201d;) and (ii) $500 million aggregate principal amount of 5.750% Senior Secured Notes due August 2027 (the &#x201c;August 2027 Secured Notes&#x201d;), respectively, in a private placement. A portion of the proceeds and cash on hand were used to: (i) repurchase $584 million of 5.875% Senior Unsecured Notes due 2023 (the &#x201c;May 2023 Unsecured Notes&#x201d;), (ii) repurchase $518 million of 5.625% Senior Unsecured Notes due 2021 (the &#x201c;December 2021 Unsecured Notes&#x201d;), (iii) repurchase $216 million of 5.500% Senior Unsecured Notes due 2023 (the &#x201c;March 2023 Unsecured Notes&#x201d;) and (iv) pay all fees and expenses associated with these transactions (collectively, the &#x201c;March 2019 Refinancing Transactions&#x201d;). During April 2019, the Company redeemed $182 million of the December 2021 Unsecured Notes, representing the remaining outstanding principal balance of the December 2021 Unsecured Notes and completing the refinancing of $1,500 million of debt in connection with the March 2019 Refinancing Transactions. The March 2019 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $8 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#x2019;s carrying value. Interest on the August 2027 Secured Notes is payable semi-annually in arrears on each February 15 and August 15.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The August 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after August 15, 2022, at the redemption prices set forth in the indenture. The Company may redeem some or all of the August 2027 Secured Notes prior to August 15, 2022 at a price equal to 100% of the principal amount thereof plus a &#x201c;make-whole&#x201d; premium. Prior to August 15, 2022, the Company may redeem up to 40% of the aggregate principal amount of the August 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;4.875% Senior Secured Notes due 2028 - June 2021 Refinancing Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 8, 2021, the Company issued $1,600&#160;million aggregate principal amount of 4.875% Senior Secured Notes due June 2028 (the &#x201c;June 2028 Secured Notes&#x201d;) in a private placement. The proceeds and cash on hand were used to: (i) repurchase a portion and redeem the remainder of $1,600&#160;million of the March 2024 Secured Notes, representing the remaining outstanding principal balance of the March 2024 Secured Notes and (ii) pay all fees and expenses associated with these transactions (collectively, the &#x201c;June 2021 Refinancing Transactions&#x201d;). The June 2021 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $38&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#x2019;s carrying value. Interest on the June 2028 Secured Notes is payable semi-annually in arrears on each June 1 and December 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The June 2028 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after June 1, 2024, at the redemption prices set forth in the June 2028 Secured Notes indenture. The Company may redeem some or all of the June 2028 Secured Notes prior to June 1, 2024 at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest to, but not including, the date of the redemption plus a &#x201c;make-whole&#x201d; premium. In addition, at any time prior to June 1, 2024, the Company may redeem up to 40% of the aggregate principal amount of the June 2028 Secured Notes using the net proceeds of certain equity offerings at the redemption price set forth in the June 2028 Secured Notes indenture.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Unsecured Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Senior Unsecured Notes issued by the Company are the Company&#x2019;s senior unsecured obligations and are jointly and severally guaranteed on a senior unsecured basis by each of its subsidiaries that is a guarantor under the Senior Secured Credit Facilities. The Senior Unsecured Notes issued by BHA are senior unsecured obligations of BHA and are jointly and severally guaranteed on a senior unsecured basis by the Company and each of its subsidiaries (other than BHA) that is a guarantor under the Senior Secured Credit Facilities. Future subsidiaries of the Company and BHA, if any, may be required to guarantee the Senior Unsecured Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company experiences a change in control, the Company may be required to make an offer to repurchase each series of Senior Unsecured Notes, in whole or in part, at a purchase price equal to 101% of the aggregate principal amount of the Senior Unsecured Notes repurchased, plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;5.500% Senior Unsecured Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 30, 2015, the Company issued $1,000 million aggregate principal amount of March 2023 Unsecured Notes in a private placement. The March 2023 Unsecured Notes accrued interest at the rate of 5.500% per year, payable semi-annually in arrears. On March 8, 2019 and May 23, 2019, the Company repurchased $216 million and $382 million of March 2023 Unsecured Notes as part of the March 2019 Refinancing Transactions and the May 2019 Refinancing Transactions (as defined below), respectively. Throughout 2020, the Company repurchased, in aggregate, $169&#160;million of March 2023 Unsecured Notes using cash on hand. The Company repurchased the remaining outstanding balance of $233&#160;million in December 2020 as part of the December 2020 Refinancing Transactions (as defined below).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;5.375% Senior Unsecured Notes due 2020, 5.875% Senior Unsecured Notes due 2023, 4.500% Senior Unsecured Notes due 2023 and 6.125% Senior Unsecured Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 27, 2015, VRX Escrow Corp. (the &#x201c;VRX Issuer&#x201d;), a newly formed wholly owned subsidiary of the Company, issued $2,000 million aggregate principal amount of 5.375% Senior Unsecured Notes due 2020 (the &#x201c;March 2020 Unsecured Notes&#x201d;), $3,250 million aggregate principal amount of May 2023 Unsecured Notes, &#x20ac;1,500 million aggregate principal amount of 4.500% Senior Unsecured Notes due 2023 (the &#x201c;Euro Notes&#x201d;) and $3,250 million aggregate principal amount of 6.125% Senior Unsecured Notes due 2025 (the &#x201c;April 2025 Unsecured Notes&#x201d; and, together with the March 2020 Unsecured Notes&#x201d;), the May 2023 Unsecured Notes and the Euro Notes, the &#x201c;VRX Notes&#x201d;) in a private placement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The March 2020 Unsecured Notes&#x201d;) accrued interest at the rate of 5.375% per year and were repaid in full as part of certain refinancing transactions completed in 2017 and 2018. The May 2023 Unsecured Notes and the Euro Notes accrued interest at the rate of 5.875% and 4.500%  per year, respectively and were each repaid in full as of December 31, 2020, as discussed below. The April 2025 Unsecured Notes accrue interest at the rate of 6.125% per year, payable semi-annually in arrears. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of a refinancing transaction completed in June 2018, the Company repaid the remaining outstanding principal amounts of the March 2020 Unsecured Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, the Company repurchased $584 million and $1,118 million of May 2023 Unsecured Notes as part of the March 2019 Refinancing Transactions and the May 2019 Refinancing Transactions (as defined below), respectively, and on October 3, 2019, the Company repaid an additional $100 million of May 2023 Unsecured Notes using cash on hand. On January 16, 2020, the Company redeemed $1,240 million aggregate principal amount of the May 2023 Unsecured Notes as part of the December 2019 Financing and Refinancing Transactions (as defined below). Throughout 2020, the Company repaid, in aggregate, $208&#160;million of the May 2023 Unsecured Notes, with the May 2023 Unsecured Notes having been fully repaid during November 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 3, 2020, the Company redeemed the remaining outstanding balance of the Euro Notes as part of the December 2020 Refinancing Transactions, as defined below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Throughout 2021, the Company repaid, in aggregate, $600&#160;million of the April 2025 Unsecured Notes. The Company may redeem all or a portion of the April 2025 Unsecured Notes at the redemption prices set forth in the applicable indenture, plus accrued and unpaid interest to the date of redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;9.000% Senior Unsecured Notes due 2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;18, 2017, the Company issued $1,500 million aggregate principal amount of 9.000% Senior Unsecured Notes due 2025 (the &#x201c;December 2025 Unsecured Notes&#x201d;) in a private placement, the net proceeds of which were used to repurchase $1,500&#160;million in aggregate principal amount of previously outstanding senior unsecured notes (the &#x201c;December 2017 Refinancing Transactions&#x201d;). The related fees and expenses were paid using cash on hand. The December 2025 Unsecured Notes accrue interest at the rate of 9.000% per year, payable semi-annually in arrears on each of June 15 and December 15.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may redeem all or a portion of the December 2025 Unsecured Notes at any time prior to December 15, 2021, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#x201c;make-whole&#x201d; premium. In addition, at any time prior to December 15, 2020, the Company may redeem up to 40% of the aggregate principal amount of the outstanding December 2025 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the December 2025 Unsecured Notes indenture. On or after December 15, 2021, the Company may redeem all or a portion of the December 2025 Unsecured Notes at the applicable redemption prices set forth in the December 2025 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;9.250% Senior Unsecured Notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 26, 2018, BHA issued $1,500 million in aggregate principal amount of 9.250% Senior Unsecured Notes due 2026 (the &#x201c;April 2026 Unsecured Notes&#x201d;) in a private placement, the net proceeds of which, and cash on hand, were used to repurchase $1,500 million in aggregate principal amount of unsecured notes. All fees and expenses associated with these transactions were paid with cash on hand (collectively, the &#x201c;March 2018 Refinancing Transactions&#x201d;). The April 2026 Unsecured Notes accrue interest at the rate of 9.250% per year, payable semi-annually in arrears on each of April 1 and October 1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;BHA may redeem all or a portion of the April 2026 Unsecured Notes at any time prior to April 1, 2022, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#x201c;make-whole&#x201d; premium. In addition, at any time prior to April 1, 2021, BHA may redeem up to 40% of the aggregate principal amount of the outstanding April 2026 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the April 2026 Unsecured Notes indenture. On or after April 1, 2022, BHA may redeem all or a portion of the April 2026 Unsecured Notes at the applicable redemption prices set forth in the April 2026 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;8.500% Senior Unsecured Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of a 2018 refinancing transaction, BHA issued $750 million in aggregate principal amount of January 2027 Unsecured Notes in a private placement. The January 2027 Unsecured Notes accrue interest at the rate of 8.500% per year, payable semi-annually in arrears on each of January 31 and July 31. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the March 2019 Refinancing Transactions described above, BHA issued $1,000 million aggregate principal amount of 8.500% Senior Unsecured Notes due January 2027. These are additional notes and form part of the same series as BHA&#x2019;s existing January 2027 Unsecured Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;BHA may redeem all or a portion of the January 2027 Unsecured Notes at any time prior to July 31, 2022, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#x201c;make-whole&#x201d; premium. In addition, at any time prior to July 31, 2021, BHA may redeem up to 40% of the aggregate principal amount of the outstanding January 2027 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the January 2027 Unsecured Notes indenture. On or after July 31, 2022, BHA may redeem all or a portion of the January 2027 Unsecured Notes at the applicable redemption prices set forth in the January 2027 Unsecured Notes indenture, plus accrued and unpaid interest to the date of redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;7.000% Senior Unsecured Notes due 2028 and 7.250% Senior Unsecured Notes due 2029 - May 2019 Refinancing Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 23, 2019, the Company issued: (i) $750 million aggregate principal amount of 7.000% Senior Unsecured Notes due January 2028 (the &#x201c;7.000% January 2028 Unsecured Notes&#x201d;) and (ii) $750 million aggregate principal amount of 7.250% Senior Unsecured Notes due May 2029 (the &#x201c;May 2029 Unsecured Notes&#x201d;), respectively, in a private placement. The proceeds and cash on hand were used to: (i) repurchase $1,118 million of May 2023 Unsecured Notes, (ii) repurchase $382 million of March 2023 Unsecured Notes and (iii) pay all fees and expenses associated with these transactions (collectively, the &#x201c;May 2019 Refinancing Transactions&#x201d;). The May 2019 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $32 million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt&#x2019;s carrying value. Interest on the 7.000% January 2028 Unsecured Notes is payable semi-annually in arrears on each January 15 and July 15. Interest on the May 2029 Unsecured Notes is payable semi-annually in arrears on each May 30 and November 30. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 7.000% January 2028 Unsecured Notes and the May 2029 Unsecured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after January 15, 2023 and May 30, 2024, respectively, at the redemption prices set forth in the respective indenture. The Company may redeem some or all of the 7.000% January 2028 Unsecured Notes or the May 2029 Unsecured Notes prior to January 15, 2023 and May 30, 2024, respectively, at a price equal to 100% of the principal amount thereof plus a &#x201c;make-whole&#x201d; premium. Prior to July 15, 2022, and May 30, 2022, the Company may redeem up to 40% of the aggregate principal amount of the 7.000% January 2028 Unsecured Notes or the May 2029 Unsecured Notes, respectively, using the proceeds of certain equity offerings at the redemption price set forth in the respective indenture. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;5.000% Senior Unsecured Notes due 2028 and 5.250% Senior Unsecured Notes due 2030 - December 2019 Financing and Refinancing Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 30, 2019, the Company issued: (i) $1,250 million aggregate principal amount of 5.000% Senior Unsecured Notes due January 2028 (the &#x201c;5.000% January 2028 Unsecured Notes&#x201d;) and (ii) $1,250 million aggregate principal amount of 5.250% Senior Unsecured Notes due January 2030 (the &#x201c;January 2030 Unsecured Notes&#x201d;) in a private placement. The proceeds and cash on hand were used to: (i) redeem $1,240 million of May 2023 Unsecured Notes on January 16, 2020, (ii) finance the $1,210 million settlement of certain U.S. Securities litigation as discussed in Note 20, &#x201c;LEGAL PROCEEDINGS&#x201d; and (iii) pay all fees and expenses associated with these transactions (collectively, the &#x201c;December 2019 Financing and Refinancing Transactions&#x201d;). The redemption of $1,240&#160;million of May 2023 Unsecured notes was accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $24&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt's carrying value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on the 5.000% January 2028 Unsecured Notes&#x201d;) is payable semi-annually in arrears on each January 30 and July 30. Interest on the January 2030 Unsecured Notes&#x201d;) is payable semi-annually in arrears on each January 30 and July 30. The 5.000% January 2028 Unsecured Notes&#x201d;) and the January 2030 Unsecured Notes&#x201d;) are redeemable at the option of the Company, in whole or in part, at any time on or after January 30, 2023 and January 30, 2025, respectively, at the redemption prices set forth in the respective indenture. The Company may redeem some or all of the 5.000% January 2028 Unsecured Notes&#x201d;) or the January 2030 Unsecured Notes&#x201d;) prior to January 30, 2023 and January 30, 2025, respectively, at a price equal to 100% of the principal amount thereof plus a &#x201c;make-whole&#x201d; premium. Prior to January 30, 2023, the Company may redeem up to 40% of the aggregate principal amount of the 5.000% January 2028 Unsecured Notes&#x201d;) or the January 2030 Unsecured Notes&#x201d;) using the proceeds of certain equity offerings at the redemption price set forth in the respective indenture. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;6.250% Senior Unsecured Notes due 2029 - May 2020 Refinancing Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 26, 2020, the Company issued $1,500&#160;million aggregate principal amount of 6.250% Senior Unsecured Notes due February 2029 (the &#x201c;6.250% February 2029 Unsecured Notes&#x201d;) in a private placement. The proceeds and cash on hand were used to: (i) repurchase $1,250&#160;million aggregate principal amount of the outstanding March 2022 Secured Notes, (ii) prepay $303&#160;million of mandatory amortization scheduled for payment in 2022 under the Company's June 2025 and November 2025 Term Loan B Facilities and (iii) pay all fees and expenses associated with these transactions (collectively, the &#x201c;May 2020 Refinancing Transactions&#x201d;). The May 2020 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $27&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt's carrying value. The 6.250% February 2029 Unsecured Notes accrue interest at the rate of 6.250% per year, payable semi-annually in arrears on each of February 15 and August 15.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may redeem all or a portion of the 6.250% February 2029 Unsecured Notes at any time prior to February 15, 2024, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#x201c;make-whole&#x201d; premium. In addition, at any time prior to August 15, 2023, the Company may redeem up to 40% of the aggregate principal amount of the outstanding 6.250% February 2029 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the 6.250% February 2029 Unsecured Notes indenture. On or after February 15, 2024, the Company may redeem all or a portion of the 6.250% February 2029 Unsecured Notes at the applicable redemption prices set forth in the 6.250% February 2029 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;5.000% Senior Unsecured Notes due 2029 and 5.250% Senior Unsecured Notes due 2031 &#x2013; December 2020 Refinancing Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 3, 2020, the Company issued $1,000&#160;million aggregate principal amount of 5.000% Senior Unsecured Notes due February 2029 (the &#x201c;5.000% February 2029 Unsecured Notes&#x201d;) and $1,000&#160;million aggregate principal amount of 5.250% Senior Unsecured Notes due February 2031 (the &#x201c;February 2031 Unsecured Notes&#x201d;) in a private placement. The aggregate proceeds and cash on hand were used to repurchase the remaining outstanding principal amounts of: (i) &#x20ac;1,500&#160;million of the Euro Notes, (ii) $233&#160;million of the March 2023 Unsecured Notes and (iii) pay all fees and expenses associated with these transactions (collectively, the &#x201c;December 2020 Refinancing Transactions&#x201d;). The December 2020 Refinancing Transactions were accounted for as an extinguishment of debt and the Company incurred a loss on extinguishment of debt of $7&#160;million representing the difference between the amount paid to settle the extinguished debt and the extinguished debt's carrying value. The 5.000% February 2029 Unsecured Notes accrue interest at the rate of 5.000% per year, payable semi-annually in arrears on each of February 15 and August 15. The February 2031 Unsecured Notes accrue interest at the rate of 5.250% per year, payable semi-annually in arrears on each of February 15 and August 15.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may redeem all or a portion of the 5.000% February 2029 Unsecured Notes at any time prior to February 15, 2024, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;redemption, plus a &#x201c;make-whole&#x201d; premium. In addition, at any time prior to February 15, 2024, the Company may redeem up to 40% of the aggregate principal amount of the outstanding 5.000% February 2029 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the 5.000% February 2029 Unsecured Notes indenture. On or after February 15, 2024, the Company may redeem all or a portion of the 5.000% February 2029 Unsecured Notes at the applicable redemption prices set forth in the 5.000% February 2029 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may redeem all or a portion of the February 2031 Unsecured Notes at any time prior to February 15, 2026, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the date of redemption, plus a &#x201c;make-whole&#x201d; premium. In addition, at any time prior to February 15, 2024, the Company may redeem up to 40% of the aggregate principal amount of the outstanding February 2031 Unsecured Notes with the net proceeds of certain equity offerings at the redemption price set forth in the February 2031 Unsecured Notes indenture. On or after February 15, 2026, the Company may redeem all or a portion of the February 2031 Unsecured Notes at the applicable redemption prices set forth in the February 2031 Unsecured Notes indenture, plus accrued and unpaid interest to, but not including, the date of redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Stated Rate of Interest&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average stated rate of interest for the Company's outstanding debt obligations as of December 31, 2021 and 2020 was 5.88% and 6.02%, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Maturities and Mandatory Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities and mandatory payments of debt obligations for the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross maturities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Restated Credit Agreement, there is no Excess Cash Flow payment due for 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 11, 2022, the Company repaid its outstanding balance of $285&#160;million under its 2023 Revolving Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As more fully discussed in Note 23, &#x201c;SUBSEQUENT EVENTS&#x201d;, during January 2022, the Company: (i) issued conditional notices of redemption to redeem in full all of its outstanding April 2025 Unsecured Notes&#x201d;  and to redeem $370&#160;million aggregate principal amount of its outstanding December 2025 Unsecured Notes and (ii) issued $1,000&#160;million aggregate principal amount of 6.125% Senior Secured Notes due February 2027.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzM0MjYy_8309ef5f-9884-4695-a8b1-56007e0b258a">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Principal amounts of debt obligations and principal amounts of debt obligations net of premiums, discounts and issuance costs as of December 31, 2021 and 2020 consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:11pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.158%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.033%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.082%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.129%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Principal Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net of Premiums, Discounts and Issuance Costs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Credit Facilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023 Revolving Credit Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025 Term Loan B Facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Secured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.000% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;March 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.500% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;November 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.750% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.875% Secured Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Senior Unsecured Notes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.125%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.000%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.500%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.000%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.000%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.000%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.250%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i707a0a1b00b141a28c29e5d5fd1faa7a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzMtNC0xLTEtOTQ4MzE_e5bf967a-94ad-4b7d-8934-d01269a81287"
      unitRef="usd">285000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i707a0a1b00b141a28c29e5d5fd1faa7a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzMtNi0xLTEtOTQ4MzE_9853262b-681f-4536-9338-66a08a38f8c5"
      unitRef="usd">285000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8fd6185a911a4065809d6e0b5f61c3b9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzMtOC0xLTEtOTQ4MzE_0d66a31b-2594-4e8d-b1e7-874d0ce6a8f0"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i8fd6185a911a4065809d6e0b5f61c3b9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzMtMTAtMS0xLTk0ODMx_5666a8b8-78b8-43ed-953d-7afd5023281a"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ib49f81a33d864365851ef46a13cca29f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzQtNC0xLTEtOTQ4MzE_e21e90ae-0db0-44a5-9575-30e1d23a0a9d"
      unitRef="usd">2829000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ib49f81a33d864365851ef46a13cca29f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzQtNi0xLTEtOTQ4MzE_a8a41cb4-fb3e-404a-8cc5-a35d74814fb1"
      unitRef="usd">2772000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4fd3df09e61d4c56a4826cfa2060c2f1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzQtOC0xLTEtOTQ4MzE_e818ba7d-4c73-40fe-bcac-2524dd5bb39e"
      unitRef="usd">3298000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i4fd3df09e61d4c56a4826cfa2060c2f1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzQtMTAtMS0xLTk0ODMx_36669060-2e9a-46ac-b829-1b1ffff5f90a"
      unitRef="usd">3220000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i537bc84d95f240518063d4d8d3b870e2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzUtNC0xLTEtOTQ4MzE_0c367710-d873-4d7f-a65d-f58cae8fc9d3"
      unitRef="usd">994000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i537bc84d95f240518063d4d8d3b870e2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzUtNi0xLTEtOTQ4MzE_055ece72-e281-4628-8edf-14f4e32be70a"
      unitRef="usd">984000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1d40e1f7a1c14a28b74752dcba680ada_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzUtOC0xLTEtOTQ4MzE_a2153145-c20a-4da2-ace2-e10ce9a4e727"
      unitRef="usd">1125000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i1d40e1f7a1c14a28b74752dcba680ada_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzUtMTAtMS0xLTk0ODMx_ea64cf77-a5fa-437c-99c0-5552eabe61b6"
      unitRef="usd">1112000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic6eb226ab9604bf188531181e371079e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzctMC0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjpkMWZjZTdhNmRlYmI0ODFiOGVjMWZiMWUzMGRiNmQxMl80_4e2c51c5-da05-4f51-839f-cf895300c87d"
      unitRef="number">0.07000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic6eb226ab9604bf188531181e371079e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzctNC0xLTEtOTQ4MzE_fa4f838e-f292-409d-9407-8d2dd8851e89"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ic6eb226ab9604bf188531181e371079e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzctNi0xLTEtOTQ4MzE_edaea50d-dc04-4880-9041-b3f489846d82"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3248199cb70749178b2c7c4fb4982735_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzctOC0xLTEtOTQ4MzE_be931920-2888-427c-9053-2c32c10a4e00"
      unitRef="usd">2000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i3248199cb70749178b2c7c4fb4982735_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzctMTAtMS0xLTk0ODMx_c189bdcf-f38a-426f-b221-1e3e6b98454c"
      unitRef="usd">1987000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i06ec3dd3dcb0438eaf3aebc8db3d319e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzgtMC0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjpiOGRkMWY2YWVmYmU0YmUyYTBiNDhlNzQ4M2M2MDM5Yl80_d95b9b75-dc00-4ce7-b014-bf7773ae2618"
      unitRef="number">0.05500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i06ec3dd3dcb0438eaf3aebc8db3d319e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzgtNC0xLTEtOTQ4MzE_8b0ea2af-e4ec-48b3-868f-93d269613b95"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i06ec3dd3dcb0438eaf3aebc8db3d319e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzgtNi0xLTEtOTQ4MzE_c4c40cda-3407-4cda-a41e-5e0c2c5060bf"
      unitRef="usd">1739000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1a77d52d62824a7cadf4ab72fa8e094b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzgtOC0xLTEtOTQ4MzE_913c013a-4a5e-4b47-810f-61641335197b"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i1a77d52d62824a7cadf4ab72fa8e094b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzgtMTAtMS0xLTk0ODMx_64857746-7c95-40c9-bf15-abc40af9644d"
      unitRef="usd">1736000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i557d4dca2ccb47e682e75358f752e842_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzktMC0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo4ZWEyNWM0NDZjYmM0MzExYjA3NzA4MGI4NjdlYTNmZF80_478a7805-236b-4909-8d88-02ab60a904ce"
      unitRef="number">0.05750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i557d4dca2ccb47e682e75358f752e842_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzktNC0xLTEtOTQ4MzE_4faeef3d-2265-4717-bad6-03e47f93a51a"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i557d4dca2ccb47e682e75358f752e842_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzktNi0xLTEtOTQ4MzE_6cd7501f-610d-4a0c-8bec-05f2bdd179ee"
      unitRef="usd">495000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i40edb907b7044d23b89c96ffb68d67e9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzktOC0xLTEtOTQ4MzE_6350d5fd-9245-4d2c-97d8-745eecb07d37"
      unitRef="usd">500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i40edb907b7044d23b89c96ffb68d67e9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzktMTAtMS0xLTk0ODMx_5f04e9d0-79d1-4cd1-88a7-01da5b4d9a03"
      unitRef="usd">494000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4fe84f0ae9724529bf29568dbbffd5a3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzEwLTAtMS0xLTk0ODMxL3RleHRyZWdpb246NjYwZmUxNGJmMDMwNGYwYmE4NmYzMTcwY2QzNWJiMGNfNA_0794558a-cb41-4e3b-8239-dc3a6051a52d"
      unitRef="number">0.04875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4fe84f0ae9724529bf29568dbbffd5a3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzEwLTQtMS0xLTk0ODMx_7f61cf1c-2e35-45d3-bbb0-fa60eacfbeae"
      unitRef="usd">1600000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i4fe84f0ae9724529bf29568dbbffd5a3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzEwLTYtMS0xLTk0ODMx_bd90ad36-82ae-43b9-82d0-a7477a1cb079"
      unitRef="usd">1580000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4bb8d72e3c074630bbceb17545ec7261_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzEwLTgtMS0xLTk0ODMx_ab0b07e0-334c-4f58-8de7-022f58dbf5e4"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i4bb8d72e3c074630bbceb17545ec7261_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzEwLTEwLTEtMS05NDgzMQ_abaaa23c-8335-4738-b07a-c0ada75be6ef"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i2db39af25b1445a1b1d39932a08c5fc7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzEyLTAtMS0xLTk0ODMxL3RleHRyZWdpb246YTExNzE3YTAwZGEzNGNmN2IyM2Q3OTIwNmY5N2JjZTNfNA_10e38569-9cf8-433d-9169-59cbf0bddad2"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i2db39af25b1445a1b1d39932a08c5fc7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzEyLTQtMS0xLTk0ODMx_258f4646-2255-470c-9023-2288fb14277a"
      unitRef="usd">2650000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i2db39af25b1445a1b1d39932a08c5fc7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzEyLTYtMS0xLTk0ODMx_2c0aedd8-e12a-4416-adf5-c24faacfa51c"
      unitRef="usd">2640000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ibfeed60331fb49708cf75fb16367305e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzEyLTgtMS0xLTk0ODMx_23b66636-5fa2-4613-bdd1-4944bd164605"
      unitRef="usd">3250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ibfeed60331fb49708cf75fb16367305e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzEyLTEwLTEtMS05NDgzMQ_a5bb9504-d470-4576-91fd-67d8080c3d9e"
      unitRef="usd">3234000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia3daa9b4fd734cb7af4bf16715ab23b1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzEzLTAtMS0xLTk0ODMxL3RleHRyZWdpb246NzIwY2ZjYzg2MTBmNDY4YzlmMjcyNDQ2NmRkNGNiYmNfNA_80241282-1a55-4448-b62e-7d3449d3adc0"
      unitRef="number">0.09000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ia3daa9b4fd734cb7af4bf16715ab23b1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzEzLTQtMS0xLTk0ODMx_0b044bba-2123-4201-9390-403af9a7c037"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ia3daa9b4fd734cb7af4bf16715ab23b1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzEzLTYtMS0xLTk0ODMx_b9237258-891d-4443-bc67-6bbaa0f279bc"
      unitRef="usd">1482000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5e861b64daed45ebbe70114675bf535f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzEzLTgtMS0xLTk0ODMx_caa2e104-7a33-4a06-8f09-e0bb0efb0be6"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i5e861b64daed45ebbe70114675bf535f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzEzLTEwLTEtMS05NDgzMQ_4d64b925-16e9-4000-a6a1-459ff95b8f3b"
      unitRef="usd">1478000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8827aaaa75144f59a8e1bb3dccf8fe3d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE0LTAtMS0xLTk0ODMxL3RleHRyZWdpb246ZGQ4MTg2NWQyNDExNDRmOTgwNjM4MGYzYTllN2M3MzdfNA_ee452e09-5f38-4309-a960-289847e06c3e"
      unitRef="number">0.09250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i8827aaaa75144f59a8e1bb3dccf8fe3d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE0LTQtMS0xLTk0ODMx_dd629759-6eae-4180-a55e-fc3066dd7645"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i8827aaaa75144f59a8e1bb3dccf8fe3d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE0LTYtMS0xLTk0ODMx_1fc31b23-f2e2-43f7-a488-e79e967b305f"
      unitRef="usd">1489000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="iad0d1a99b6ec42b9aaee8785c8cb6f79_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE0LTgtMS0xLTk0ODMx_7f5389b8-f0dc-42cb-910b-c4412f1a1d27"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="iad0d1a99b6ec42b9aaee8785c8cb6f79_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE0LTEwLTEtMS05NDgzMQ_19bf7612-e192-4577-996a-157c5f01d4e7"
      unitRef="usd">1487000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5a929eccb9e64e0b88c64d38a28ef190_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE1LTAtMS0xLTk0ODMxL3RleHRyZWdpb246Mzg1Zjk0ODQ5OWRlNGZjNGIzNjMxYmExZTFmOTYzN2RfNA_0acfa3f0-30df-48d6-a7d3-f0797d728f50"
      unitRef="number">0.08500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5a929eccb9e64e0b88c64d38a28ef190_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE1LTQtMS0xLTk0ODMx_72ecab66-da9e-4704-a55d-d0244de2d402"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i5a929eccb9e64e0b88c64d38a28ef190_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE1LTYtMS0xLTk0ODMx_0d18ba87-ed94-4b23-b2c4-2f0623f4009e"
      unitRef="usd">1754000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i9a25feedc2bd4f438e6d127ea650e095_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE1LTgtMS0xLTk0ODMx_448e3489-cb1c-4b8b-b8e7-97319ecfa3d5"
      unitRef="usd">1750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i9a25feedc2bd4f438e6d127ea650e095_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE1LTEwLTEtMS05NDgzMQ_9fe055c1-148c-4e6c-8cdb-5011cc0625f8"
      unitRef="usd">1755000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i03f92fc0786847c3b0c496e8d1603888_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE2LTAtMS0xLTk0ODMxL3RleHRyZWdpb246YzQ5ZjBiMmE2NzFmNDczZTg4OTU0MTM3ZjQzNmQ3ZWFfNA_9b111029-0b9d-4371-ace9-59bd01c6199b"
      unitRef="number">0.07000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i03f92fc0786847c3b0c496e8d1603888_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE2LTQtMS0xLTk0ODMx_3a3069f6-a53f-420b-a8b1-97f1f2cb88f2"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i03f92fc0786847c3b0c496e8d1603888_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE2LTYtMS0xLTk0ODMx_fcd524bf-d7a6-4c06-8c36-48ccf9c509ea"
      unitRef="usd">743000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0c0dad67e3784bcdb5a6e6f002cd9ee7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE2LTgtMS0xLTk0ODMx_aac31b37-4789-458f-82fa-94ce185094e1"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i0c0dad67e3784bcdb5a6e6f002cd9ee7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE2LTEwLTEtMS05NDgzMQ_4fa09e72-fb95-4dd0-8e84-6f5e71c32117"
      unitRef="usd">742000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4315b5a6bf3449c790d05b0d6ad5b10b_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE3LTAtMS0xLTk0ODMxL3RleHRyZWdpb246YWRiYTAxOGMzNWE3NDBlY2E2NGEzMmE3ZWE3NWFjZTdfNA_94e7b346-cb5b-435d-b222-895ae23cce3e"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i4315b5a6bf3449c790d05b0d6ad5b10b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE3LTQtMS0xLTk0ODMx_f078d879-e7df-41ac-8f04-65816152e4ab"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i4315b5a6bf3449c790d05b0d6ad5b10b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE3LTYtMS0xLTk0ODMx_3389963d-d4fc-4eff-a900-b0e39befb825"
      unitRef="usd">1238000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i43b03fff47d14db7bcc1ddf661a8dc92_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE3LTgtMS0xLTk0ODMx_a4444fa4-988d-4eb2-8c79-7233ae5ef578"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i43b03fff47d14db7bcc1ddf661a8dc92_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE3LTEwLTEtMS05NDgzMQ_e9f68ecc-7256-44b3-aadf-7fa220bb2e88"
      unitRef="usd">1236000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i46a9772e12364383a02b198038550550_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE4LTAtMS0xLTk0ODMxL3RleHRyZWdpb246N2RhZjk2ZGE1MWNiNGFjNmI2MGQxYjQ3MWQ2NzFmYjdfNA_80a3cbef-0cbd-407f-ba20-3bc522e3a9d0"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i46a9772e12364383a02b198038550550_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE4LTQtMS0xLTk0ODMx_98ad2d69-b9db-4037-8a9d-a5bc1f2489ee"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i46a9772e12364383a02b198038550550_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE4LTYtMS0xLTk0ODMx_2ea3860a-39dd-438d-b757-bd643f11b02d"
      unitRef="usd">1483000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic87200a1dc2742999c99925809369c99_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE4LTgtMS0xLTk0ODMx_11b6a21f-fd40-4dab-8e41-aaa918f5f950"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ic87200a1dc2742999c99925809369c99_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE4LTEwLTEtMS05NDgzMQ_d7fe91f4-4340-4cd8-bab1-57b7ee0e0bf6"
      unitRef="usd">1480000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i55ad7bb0a54347dd9a4596d8be5b8dca_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE5LTAtMS0xLTk0ODMxL3RleHRyZWdpb246ZDVlMzc1YzBlZjVkNGMxZWJhMDM5MDBhNzRmM2RhNTZfNA_4b7d362d-4837-468b-865d-a952020ea858"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i55ad7bb0a54347dd9a4596d8be5b8dca_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE5LTQtMS0xLTk0ODMx_c8ba464d-fa04-4db2-abce-5a9973c06aba"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i55ad7bb0a54347dd9a4596d8be5b8dca_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE5LTYtMS0xLTk0ODMx_f7470c92-b62a-4915-ad9c-acbe173d785d"
      unitRef="usd">990000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6f0cd0c7bcda47b38d01957e2a3bc327_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE5LTgtMS0xLTk0ODMx_7a49125c-c445-4650-9b01-36b27867c3c7"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i6f0cd0c7bcda47b38d01957e2a3bc327_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzE5LTEwLTEtMS05NDgzMQ_8454b9b8-cbfb-49c5-ace1-512fe132551f"
      unitRef="usd">988000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5c5faf2607ad4637a05e98dc5c8875c4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIwLTAtMS0xLTk0ODMxL3RleHRyZWdpb246NTE1NzkxZjBjNDMyNGIxNGJmMDdiOGZlZTEyN2VkYmRfNA_b27316b5-f164-49e8-88da-c82c61a4e775"
      unitRef="number">0.07250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i5c5faf2607ad4637a05e98dc5c8875c4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIwLTQtMS0xLTk0ODMx_fb23d92c-76aa-4992-87d3-d015f1d98236"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i5c5faf2607ad4637a05e98dc5c8875c4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIwLTYtMS0xLTk0ODMx_84ab0d0f-ba22-46bc-877a-317a75f3e369"
      unitRef="usd">742000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i19dcb028ec1d4e60aa66dbeb559a420a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIwLTgtMS0xLTk0ODMx_101346e7-cd19-4c5a-a3a5-f6bcaade744b"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i19dcb028ec1d4e60aa66dbeb559a420a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIwLTEwLTEtMS05NDgzMQ_92be6b1d-32de-4bf3-9322-46823358943b"
      unitRef="usd">741000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0249a1288b1649bdbb249d5ea07218db_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIxLTAtMS0xLTk0ODMxL3RleHRyZWdpb246MGQ5YTlhNGU4NDQyNGY4YWEwYTZkOTU0MjVhOGMxNzdfNA_eaaf607a-624b-4bcb-ac6f-ed4a3ad5a620"
      unitRef="number">0.05250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0249a1288b1649bdbb249d5ea07218db_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIxLTQtMS0xLTk0ODMx_0688d24e-18aa-4dcc-a000-8d0c9cc2c917"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i0249a1288b1649bdbb249d5ea07218db_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIxLTYtMS0xLTk0ODMx_03fe1d39-7ea5-4dae-8dd8-d8491bbbfd3c"
      unitRef="usd">1237000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i1627b94e1a9a4cca93a1bbe3b864cf4d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIxLTgtMS0xLTk0ODMx_4488d3b5-6951-425c-8f0e-a46009028e3e"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i1627b94e1a9a4cca93a1bbe3b864cf4d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIxLTEwLTEtMS05NDgzMQ_9e6a187f-c2c4-4e78-b4f7-9577bcba0ac2"
      unitRef="usd">1235000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i06254af032384d79944c4fbf0358b2a1_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIyLTAtMS0xLTk0ODMxL3RleHRyZWdpb246YTFmYTljYmYzNmYzNGVmM2I0ODg0NWQ5OTE4MjEzYjdfNA_824b5aea-4783-40c9-89fc-f7a5cd654d89"
      unitRef="number">0.05250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i06254af032384d79944c4fbf0358b2a1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIyLTQtMS0xLTk0ODMx_eee00ad4-b749-424b-af34-604e6ddc3190"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i06254af032384d79944c4fbf0358b2a1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIyLTYtMS0xLTk0ODMx_dc9794cd-e9bd-4185-be0d-72757337cc1e"
      unitRef="usd">989000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i7f9e33e485084fff9d0c81867c005c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIyLTgtMS0xLTk0ODMx_fa964be7-4ed1-49f8-964c-73fff6270d91"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i7f9e33e485084fff9d0c81867c005c16_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIyLTEwLTEtMS05NDgzMQ_fb7327b9-c9ca-4dba-bdf8-825c75b1a088"
      unitRef="usd">988000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="if4e37ee467534e15bb29330c819bd784_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIzLTQtMS0xLTk0ODMx_7ce6c019-335b-46ac-8a93-1849d89434f9"
      unitRef="usd">12000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="if4e37ee467534e15bb29330c819bd784_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIzLTYtMS0xLTk0ODMx_6f3fd2d4-e2f6-40ab-8040-e56ea159f7a6"
      unitRef="usd">12000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic10baeef95084b95a40fdf0c4c004831_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIzLTgtMS0xLTk0ODMx_37279e27-0f16-4b97-9866-a2d82d784ced"
      unitRef="usd">12000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="ic10baeef95084b95a40fdf0c4c004831_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzIzLTEwLTEtMS05NDgzMQ_3a8e4064-c0b4-43a7-a10e-f9661083e24c"
      unitRef="usd">12000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzI0LTQtMS0xLTk0ODMx_a22ca8c7-c4b1-45ce-96fc-40908b9d2f0e"
      unitRef="usd">22870000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzI0LTYtMS0xLTk0ODMx_18644bca-6373-4833-b48e-967eddd0745c"
      unitRef="usd">22654000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzI0LTgtMS0xLTk0ODMx_2665b15d-66fc-45fc-8923-e37a93bb3f53"
      unitRef="usd">24185000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebt
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzI0LTEwLTEtMS05NDgzMQ_6c097a0d-b423-4027-9f88-3014655b6a67"
      unitRef="usd">23925000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzI1LTYtMS0xLTk0ODMx_d053f199-82c5-4783-9856-a54c5c932685"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzI1LTEwLTEtMS05NDgzMQ_8734d831-7a50-4060-bb85-e809689e2a22"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzI2LTYtMS0xLTk0ODMx_7489527c-0865-4d81-bce4-9fff8b227580"
      unitRef="usd">22654000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZTo4ZGYyNmE4NWViMzI0ODM5YTI1ZTJkNGZkNzkwZDFiZS90YWJsZXJhbmdlOjhkZjI2YTg1ZWIzMjQ4MzlhMjVlMmQ0ZmQ3OTBkMWJlXzI2LTEwLTEtMS05NDgzMQ_99681720-a322-4efb-ac2c-8806215d7d43"
      unitRef="usd">23925000000</us-gaap:LongTermDebtNoncurrent>
    <bhc:DebtInstrumentAmountAvailableForRestrictedPayments
      contextRef="i27fc8076f1bb4e4fac0065b5495211c5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzExODQ_8e049cc5-edfb-40e2-a3e2-1176d7db8c58"
      unitRef="usd">13800000000</bhc:DebtInstrumentAmountAvailableForRestrictedPayments>
    <bhc:DebtInstrumentCovenantTermsFixedChargeCoverageRatio
      contextRef="i27fc8076f1bb4e4fac0065b5495211c5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEyNjE_5d68a941-f4aa-4f78-820c-966e1c8a2084"
      unitRef="number">2.00</bhc:DebtInstrumentCovenantTermsFixedChargeCoverageRatio>
    <bhc:DebtInstrumentCovenantTermsSecuredLeverageRatio
      contextRef="i27fc8076f1bb4e4fac0065b5495211c5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE0OTA_d1e703b0-5162-4265-8e7f-dc7dbc8cc302"
      unitRef="number">4.00</bhc:DebtInstrumentCovenantTermsSecuredLeverageRatio>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i3c884d2a677c46099dc4bf036009410a_I20180601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI4MTk_9404d8ad-b49b-4eba-ba4e-96e79272d2cc"
      unitRef="usd">1225000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm
      contextRef="i3e81a6b0b4494ea99594e7ae61d6e7e2_D20180601-20180601"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzM0MjU5_427b6f5f-1efc-42f0-9258-e1b0c26d2483">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i3ac7b4fdfdf54cca97131f28525e6edc_I20180601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI5MDc_253b7642-490e-4e86-bcaa-fa030c33290d"
      unitRef="usd">4565000000</us-gaap:DebtInstrumentFaceAmount>
    <bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold
      contextRef="i1b48943d62f64d77bf275084b850c10b_D20180601-20180601"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMxMjE_4772bc4f-ec15-40a6-96fc-7b6202e80d83">P91D</bhc:DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold>
    <bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold
      contextRef="i3c884d2a677c46099dc4bf036009410a_I20180601"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMyNzM_36acbb61-f204-483a-b91f-427573695e27"
      unitRef="usd">1000000000</bhc:DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold>
    <us-gaap:LongTermDebt
      contextRef="i707a0a1b00b141a28c29e5d5fd1faa7a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzM3MDA_52e0709c-c5f0-4ed8-ae5c-2419fd960b17"
      unitRef="usd">285000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="icca812a26f644f92a7e1f4a986e51c00_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzM3MzA_fedeadcf-0cc3-4beb-8206-1247b4db4e7b"
      unitRef="usd">54000000</us-gaap:LongTermDebt>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i707a0a1b00b141a28c29e5d5fd1faa7a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzM4MDg_6f6c6a8f-ab34-4aa6-a834-a85618eb8e9b"
      unitRef="usd">886000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm
      contextRef="i8bba7bbfcfef401787d57a665a8baaab_D20181127-20181127"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzM0Mjc4_fbc79a40-b403-446f-91b6-52a520bbdb65">P7Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i122eb939c38343d79b07091d8c902050_I20181127"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzQwMzU_5c0b06ac-1c7a-4e5b-b10b-433bac75754a"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i0ee961e3429c4173bd50b3e41367ad7c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzQ1Njg_1659c4ce-dafd-4b62-b84b-6b235558f553"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia998a2f7b86b483b983a8b3498ae44fc_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzQ2Mjk_54417f87-8653-4723-906b-9cbfbb042822"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i388ac421c82b49c48346643fa2ca8a0c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzQ4OTc_629f9de6-72ad-4977-b25b-e48c03bdc6fe"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i984c72f35f464a9f992e3b3b631f4b0d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzUyODU_78e21b45-b16f-41df-9b14-0c974c209ff9"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i6084b059746d44c2acce81065d562b57_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzU4NDI_e6253f5f-c860-4d78-bd94-9055b07bfecc"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="if7840f0b2e2b48f5833d3f0adc12fa7e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzU5MTQ_e9086449-5bd2-49af-b030-8a313bf93c72"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="if7840f0b2e2b48f5833d3f0adc12fa7e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzYxNDk_d09d6dbd-4547-4168-a063-49d1e2fda141"
      unitRef="number">0.0000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments
      contextRef="ib2fc98102d394e23ab05be5028d334b8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzY0NTk_cd799bef-1289-471a-ad71-83e253a552c6"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments
      contextRef="ib2fc98102d394e23ab05be5028d334b8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzY2NTY_2cdb61b6-293e-48db-8356-3d67c7d7df63"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments
      contextRef="ib2fc98102d394e23ab05be5028d334b8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzY3OTM_aa15e4f2-5640-4ca4-b21c-f6f2c846a5ec"
      unitRef="number">0.50</bhc:LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments>
    <bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments
      contextRef="ib2fc98102d394e23ab05be5028d334b8_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzY5NTA_30cec9eb-d51f-4968-bb35-fb0a26a6a58a"
      unitRef="number">1</bhc:LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i27aa31be484b4e9b951df5511db3cc35_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzcyNTQ_d29a4a7e-7be0-491b-9450-79d25fb4fdf0"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i5d1c850c7eb04b9a9236112505ccf265_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzcyNjE_d55486b5-7857-4d2a-a257-958c24609f2c"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i084241e0c0984f30b029369bd43fb499_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzczMzU_62cea398-8fc1-4e24-b362-9d5db498711b"
      unitRef="number">0.0300</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i0a3693985875498082ba11e282f4e79b_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzczNDI_d92d8c95-e131-4cea-9620-c4590f0c211f"
      unitRef="number">0.0275</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib49f81a33d864365851ef46a13cca29f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzc1NDA_2a5dd090-35e0-4324-81ad-b39e287ee449"
      unitRef="number">0.0309</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i537bc84d95f240518063d4d8d3b870e2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzc1NDc_1cbdeafb-7edf-4420-a16a-4292f3b4dc14"
      unitRef="number">0.0284</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bhc:DebtInstrumentAnnualAmortizationRatePercentage
      contextRef="ib49f81a33d864365851ef46a13cca29f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzc2NTk_10996344-f68b-41ef-8c02-6c584f069a41"
      unitRef="number">0.0500</bhc:DebtInstrumentAnnualAmortizationRatePercentage>
    <bhc:DebtInstrumentAnnualAmortizationRatePercentage
      contextRef="i537bc84d95f240518063d4d8d3b870e2_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzc2NTk_b787cb51-0a62-4bdd-9d4a-6c234fe9ee10"
      unitRef="number">0.0500</bhc:DebtInstrumentAnnualAmortizationRatePercentage>
    <bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization
      contextRef="i1a7a975faf994c36a88b4e0e0eb6800f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzc3OTE_81cdf3af-6e50-43af-9472-f9fff05b5a2f"
      unitRef="usd">0</bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i6e2ae2d598fc4a64a6dd097539edef68_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzc5ODY_b9273739-f737-4ccb-aa3a-e89a7078270c"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ifd51dd72613243c68aa536db0dc3c70f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzc5ODk_16a90161-2167-40d1-8c92-6ac86b63a70e"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i302db430cde9461f934b806767f52349_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzgwNDc_fe0ba08b-bc90-47ec-899e-757e5422ccbc"
      unitRef="number">0.0250</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i9b262c356e2e4aef8c99010988af7e67_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzgwNTA_7d42946d-97e6-4013-a75c-5bba21a7972e"
      unitRef="number">0.0300</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i707a0a1b00b141a28c29e5d5fd1faa7a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzgxODU_24ad8271-5893-426e-88e4-1fafac58c2d4"
      unitRef="number">0.0284</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i77d8c4f932f64c7ab48f7c0ff10b8a3a_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzgyNjI_e934835a-9018-456d-bff8-2631a575d615"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="i76d8b3b4ed87466eab6f101ddcb61ba9_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzgyNjc_41be03ee-6f85-4337-a89b-24b9c9e0f0ab"
      unitRef="number">0.0050</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <bhc:LineOfCreditFacilityThresholdForIncrementalBorrowings
      contextRef="i27fc8076f1bb4e4fac0065b5495211c5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzg5MTg_23ba630c-98ab-4fde-8219-cfae83722069"
      unitRef="usd">1000000000</bhc:LineOfCreditFacilityThresholdForIncrementalBorrowings>
    <bhc:LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate
      contextRef="i1a7a975faf994c36a88b4e0e0eb6800f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzg5MjU_bab4c450-f040-40df-951a-4bdf4e608f6c"
      unitRef="number">0.285</bhc:LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate>
    <bhc:DebtInstrumentCovenantTermsSecuredLeverageRatio
      contextRef="i558d07c8b64a40c8b3072a4379c5db37_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzkyMjY_f42dd547-7518-4579-8ff8-985a7615cdcc"
      unitRef="number">3.50</bhc:DebtInstrumentCovenantTermsSecuredLeverageRatio>
    <bhc:DebtInstrumentCovenantTotalLeverageRatioMaximum
      contextRef="i3089f6878ad144f5971f1a990ab34d3a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzkzMjE_ccff3b1d-179e-4081-9bb9-4a4f79271cf3"
      unitRef="number">6.50</bhc:DebtInstrumentCovenantTotalLeverageRatioMaximum>
    <bhc:DebtInstrumentCovenantInterestCoverageRatioMinimum
      contextRef="i27fc8076f1bb4e4fac0065b5495211c5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzkzNzY_af1976fd-2ecd-405a-900d-d84d92d49271"
      unitRef="number">2.00</bhc:DebtInstrumentCovenantInterestCoverageRatioMinimum>
    <bhc:DebtInstrumentRedemptionPricePercentageChangeinControl
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzExMzU1_c0d14a2b-4ff0-480c-9cad-cb92c4b475a6"
      unitRef="number">1.01</bhc:DebtInstrumentRedemptionPricePercentageChangeinControl>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id9abd9fd4a3d4f839584c60b7f287d72_I20170331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzExNDI0_a3582fa9-9771-40ab-88d3-39bc205cf6c2"
      unitRef="number">0.06500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idd735e6d7a4a49c4a31ba11a3b55d3c5_I20170331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzExNDYx_bfc56ce8-6206-4f15-9801-828a7b96c368"
      unitRef="number">0.0700</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id9abd9fd4a3d4f839584c60b7f287d72_I20170331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzExNTI5_b23a52c4-cc72-4827-98ff-3111ed706409"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id9abd9fd4a3d4f839584c60b7f287d72_I20170331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzExNTYy_a3582fa9-9771-40ab-88d3-39bc205cf6c2"
      unitRef="number">0.06500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="idd735e6d7a4a49c4a31ba11a3b55d3c5_I20170331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzExNjQy_50900620-3850-432c-ad51-229f59b9d334"
      unitRef="usd">2000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idd735e6d7a4a49c4a31ba11a3b55d3c5_I20170331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzExNjc1_bfc56ce8-6206-4f15-9801-828a7b96c368"
      unitRef="number">0.07000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i449725090bcb4e129cd4dff2677ce289_I20171017"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEyMTQy_4d0ce25d-dd77-4997-bef8-5b795d08b746"
      unitRef="number">0.05500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i449725090bcb4e129cd4dff2677ce289_I20171017"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEyMjE1_cf7b8035-983c-4a36-85db-102d7b5c2aed"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i17ca0b3ae0a14541b95a0029b74fc81f_I20171121"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEyMjY1_96222aed-d108-45e3-8c8f-a8ec59061b0d"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i449725090bcb4e129cd4dff2677ce289_I20171017"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEyMzAw_4d0ce25d-dd77-4997-bef8-5b795d08b746"
      unitRef="number">0.05500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i426ecf59adef4723a9464ff7dd035235_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEyNjc3_16a59dce-31d1-4551-b079-66379bdb647f"
      unitRef="number">0.05750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic4d5b348d3924c7286e27eb049dcb072_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEyNzk4_69a00a55-4fe7-4bb1-bc9b-a6cd0d10a9be"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic4d5b348d3924c7286e27eb049dcb072_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEyODMx_79d899c1-b890-44a4-91b7-982abb15e63e"
      unitRef="number">0.08500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i426ecf59adef4723a9464ff7dd035235_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEyOTEy_87b5db2c-910a-4715-9bf5-6c56ddbcf1ee"
      unitRef="usd">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i426ecf59adef4723a9464ff7dd035235_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEyOTQ1_0218e345-3a79-4e3b-aa73-77b97e4c75a1"
      unitRef="number">0.05750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i234da319c3ef47c291bbc91d590a7fc6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEzMTMw_ad149e92-1d00-4991-be97-c1557077de86"
      unitRef="usd">584000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1b7290e999a74c9f84f1e1f0dc4acadf_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEzMTM2_5344af66-9549-44cb-983e-a6747b2727df"
      unitRef="number">0.05875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i60523f26c0cc421995caf64823d36f89_D20190308-20190308"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEzMjIx_dc7577b7-cf1c-4073-b2a1-090c5e6e270f"
      unitRef="usd">518000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7107764faeb3461fb0c3e1558afa09a0_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEzMjI3_7a9290e5-8980-4028-b3d3-db99c0b2870c"
      unitRef="number">0.05625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ia554f95ec9dd4a30af67e386976e2ee4_D20190308-20190308"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEzMzE4_28604139-8b05-4d1e-af08-e4baf1fb690a"
      unitRef="usd">216000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8c3fe314a07b49f5a24c68a78aa7c617_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEzMzI0_7ab4bcd2-a9ab-45ab-92bc-85803813446a"
      unitRef="number">0.05500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ia4a78928619a4fbdbb34836a1b0fe3dd_D20190401-20190430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEzNTYz_61824fd3-87b5-4500-85bf-180adb5d2552"
      unitRef="usd">182000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i55f45e1ec8754cce8219f906d738aa2d_I20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEzNzMy_c2945191-9a36-4cd8-a393-23517317e821"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="iefa733ef7c794dbaaf6199d058362bd6_D20190308-20190308"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzEzOTE5_d7fbb717-73d1-4fdd-837d-5993abddbbc9"
      unitRef="usd">-8000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i64a0081e7f7a480c9031042be2e2e776_D20190308-20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE0NDY2_28984433-2035-405b-b377-3e24d2668a27"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds
      contextRef="i64a0081e7f7a480c9031042be2e2e776_D20190308-20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE0NTg1_20a6b576-f3ac-4c56-b431-1017f92552d9"
      unitRef="number">0.40</bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8eb18dd3d80f4b20be43d6f02dd8ec59_I20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE0NzU0_6c040f76-fe8b-401a-b6a5-8de578e9b40a"
      unitRef="number">0.04875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i8eb18dd3d80f4b20be43d6f02dd8ec59_I20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE0ODYw_870400e9-3f80-4829-a1b9-6329e17b003f"
      unitRef="usd">1600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8eb18dd3d80f4b20be43d6f02dd8ec59_I20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE0ODkz_6c040f76-fe8b-401a-b6a5-8de578e9b40a"
      unitRef="number">0.04875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ide09659430754a848ded8babd4ea06b0_D20210608-20210608"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE1MDg0_b63385f0-1b72-4a51-a3cb-d39f8fba47a2"
      unitRef="usd">1600000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i88ac47eb607d48dda7da8b2ce778805a_D20210608-20210608"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE1NDg1_2c7c903b-f49c-48ef-b124-f8e8c731780a"
      unitRef="usd">-38000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i9c34aa862974483ea57b2b1d0e3c0f03_D20210608-20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE2MDQw_942adf78-bd7b-4c7e-b9eb-ba62c0a24d47"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="if7d99baf53a5465bbbfe961490f008dc_D20210608-20210608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE2MjY1_650a8c0b-22ac-4f85-b975-96bf0e87cc9b"
      unitRef="number">0.40</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <bhc:DebtInstrumentRedemptionPricePercentageChangeinControl
      contextRef="i4fc30bcb84e44522a8af652f8f8ce17c_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE3MzIw_1e603f67-c841-4510-864f-ade814342ea7"
      unitRef="number">1.01</bhc:DebtInstrumentRedemptionPricePercentageChangeinControl>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibd5fa5a50ddb47ce943d25e5158d7fa4_I20150130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE3NDM0_5f2de05f-829e-4c8f-8925-b0f856a4b879"
      unitRef="number">0.05500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ibd5fa5a50ddb47ce943d25e5158d7fa4_I20150130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE3NTA5_d8f6175b-b82c-49e0-9bcf-55850b2a5960"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibd5fa5a50ddb47ce943d25e5158d7fa4_I20150130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE3NjU2_5f2de05f-829e-4c8f-8925-b0f856a4b879"
      unitRef="number">0.05500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ia554f95ec9dd4a30af67e386976e2ee4_D20190308-20190308"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE3NzYy_28604139-8b05-4d1e-af08-e4baf1fb690a"
      unitRef="usd">216000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="if6d83e37326d4725bc725486444bd866_D20190523-20190523"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE3NzY5_302ab4e8-d6ef-433d-851a-f13f771519eb"
      unitRef="usd">382000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i6dd5787480294fa2b679e5d4885e9821_D20200101-20201130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE3ODk3_c8aaeb18-552b-47f4-89ff-3082e7765252"
      unitRef="usd">169000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="idc9c834100a744ec86cca979fb7b31ec_D20201201-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE4MDEx_d5ece080-ad15-43e1-97d7-f50a2607d7aa"
      unitRef="usd">233000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9fdd4332ca4c43c99f6dab6dd5f1e32f_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE4MTA1_dedf23c6-0fe5-41fa-bb48-8441ea834f9e"
      unitRef="number">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia903bb7aea2a44119bda10563a043e40_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE4MTQx_ff18696a-d0fc-40cb-9828-d2339cf208db"
      unitRef="number">0.05875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iedce2bbbaab64fc79908a3e30f8e6c65_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE4MTc3_899b1f37-6184-4d58-b5d0-58990e43cd44"
      unitRef="number">0.04500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7040cce3fb9b4eeba357b284b09231e2_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE4MjE2_d29ef6f2-ba50-4ef4-aa44-7a25424167cf"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9fdd4332ca4c43c99f6dab6dd5f1e32f_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE4MzY5_e32693f0-3164-43cd-a8a2-ecd4eb423207"
      unitRef="usd">2000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9fdd4332ca4c43c99f6dab6dd5f1e32f_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE4NDAy_2f8d00c6-5dbe-4d74-8aa1-c166b9f6adc6"
      unitRef="number">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia903bb7aea2a44119bda10563a043e40_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE4NDcz_c776e1b4-063f-40a7-a613-ed2c1c833e8f"
      unitRef="usd">3250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iedce2bbbaab64fc79908a3e30f8e6c65_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE4NTMy_adb57aa8-e0f8-4feb-83be-d3893c8939ac"
      unitRef="eur">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iedce2bbbaab64fc79908a3e30f8e6c65_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE4NTY1_d018ada1-a7a5-4609-8338-f933b58dff79"
      unitRef="number">0.04500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7040cce3fb9b4eeba357b284b09231e2_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE4NjIz_bf49642d-66a8-40d3-a534-365dde1d181b"
      unitRef="usd">3250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7040cce3fb9b4eeba357b284b09231e2_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE4NjU2_427feabc-6c0b-4a97-a63f-f1a4e329d9cf"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9fdd4332ca4c43c99f6dab6dd5f1e32f_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE4ODU5_3f68eee7-0380-48e0-8332-87b21e8e96a3"
      unitRef="number">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia903bb7aea2a44119bda10563a043e40_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE5MDI1_8082628a-19da-419c-8637-73b66c3cf5bb"
      unitRef="number">0.05875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iedce2bbbaab64fc79908a3e30f8e6c65_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE5MDMy_1527a76a-6615-4237-8238-6d76ca553667"
      unitRef="number">0.04500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7040cce3fb9b4eeba357b284b09231e2_I20150327"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE5MTk1_55f16d3e-f4b6-4576-8786-51eca8b387ba"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i234da319c3ef47c291bbc91d590a7fc6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE5NDM5_ad149e92-1d00-4991-be97-c1557077de86"
      unitRef="usd">584000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="id9f599c080f5467ea5baebd9fac485a0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE5NDQ2_4c918951-cc70-4db4-81fc-af12c419bb2f"
      unitRef="usd">1118000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="if99807b8eead4d89b01d9fb9a37fc251_D20191003-20191003"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE5NTc1_cbab03ec-c437-4d01-a4ff-96d68c16d97e"
      unitRef="usd">100000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="ic53f9efb99aa4ccda95f61d26890a343_I20200116"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE5NjQ2_f6f29e27-7d8f-4787-90b4-f4455fd862ff"
      unitRef="usd">1240000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="if94fac52f3f54b40b4fdd01288bf1861_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzE5ODI1_5603c123-c23b-4474-a551-241862cbbc43"
      unitRef="usd">208000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="id6298e5d16674dff95b3e998b6c37203_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIwMTYw_d79abc04-aa99-468f-9261-e99cf5a4dc12"
      unitRef="usd">600000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4177e1b635b74d889574e58be568dee6_I20171218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIwMzk2_2e6fc31b-df8a-45a9-b322-0407682735f9"
      unitRef="number">0.09000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4177e1b635b74d889574e58be568dee6_I20171218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIwNDcz_9d54d596-a2d9-4367-8e63-5a1da9f67637"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4177e1b635b74d889574e58be568dee6_I20171218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIwNTA2_a0f6c992-ed83-4325-a880-5d0ce3675401"
      unitRef="number">0.09000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i5a8941f15dfb40e2ad916e87ad8d78c1_I20171218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIwNjUz_e90ad480-eae9-4b9b-8773-6f6a6fac4ef9"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4177e1b635b74d889574e58be568dee6_I20171218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIwODgx_6ce58f17-a70d-4158-9cf5-af40b14c29d6"
      unitRef="number">0.09000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i719d98863d0149828286447cfc21c537_D20171218-20171218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIxMTAw_838bb1d8-02f5-45ab-8a32-f46778ac1ca8"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds
      contextRef="ib5f75d74fcd94b378a67e51f53cdb29a_D20171218-20171218"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIxMzE2_9cade36b-6040-4b7c-b971-d83fb2530992"
      unitRef="number">0.40</bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic7a91ae9c014412285210f2ad632343e_I20180326"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIxNzk2_9f0dca8c-e3bd-43de-b3c6-f0aeca631ed7"
      unitRef="number">0.09250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic7a91ae9c014412285210f2ad632343e_I20180326"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIxODYx_722fe2c7-8f73-4849-946d-970e1b508a39"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic7a91ae9c014412285210f2ad632343e_I20180326"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIxODk3_9f0dca8c-e3bd-43de-b3c6-f0aeca631ed7"
      unitRef="number">0.09250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="ic7a91ae9c014412285210f2ad632343e_I20180326"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIyMDYw_8ce0993d-fdfb-4337-ab02-27b26da77dfa"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ic7a91ae9c014412285210f2ad632343e_I20180326"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIyMzE5_9f0dca8c-e3bd-43de-b3c6-f0aeca631ed7"
      unitRef="number">0.09250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i2277d8eefa0b44fba997881be7afffec_D20180326-20180326"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIyNTIx_685536f0-5f46-4e99-90ea-d2e98d7ad4b5"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds
      contextRef="i2277d8eefa0b44fba997881be7afffec_D20180326-20180326"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIyNzI1_452f7531-e359-4f0f-afe9-056ba5de198b"
      unitRef="number">0.40</bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i177b63c1f7f747e3b7ccc3613e2fcaa8_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIzMTgx_ac813477-de11-45f7-ae76-f4765066d548"
      unitRef="number">0.08500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i177b63c1f7f747e3b7ccc3613e2fcaa8_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIzMjcw_1c649a78-25f7-4c4a-998c-a1c7c562b4a0"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i177b63c1f7f747e3b7ccc3613e2fcaa8_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIzNDIz_ac813477-de11-45f7-ae76-f4765066d548"
      unitRef="number">0.08500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic4d5b348d3924c7286e27eb049dcb072_I20190308"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIzNTUx_69a00a55-4fe7-4bb1-bc9b-a6cd0d10a9be"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i177b63c1f7f747e3b7ccc3613e2fcaa8_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIzNTg0_ac813477-de11-45f7-ae76-f4765066d548"
      unitRef="number">0.08500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ib4c76c9931404817acf913b8360dbb5e_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzIzODYw_a26b93b3-8ae9-41ed-a63c-3f0dc0479c1b"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds
      contextRef="ib4c76c9931404817acf913b8360dbb5e_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI0MDY0_1e3f1881-52e7-4d2a-8b68-8d3817a149c3"
      unitRef="number">0.40</bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i797b2df10ff44b2aa71c461fc27b30ef_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI0NTI4_9f4b7735-0a06-4590-b947-e56e49267136"
      unitRef="number">0.07000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibc2d2ee34b9d4af8aaed19ac1ff2667c_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI0NTY3_a4c85980-5c1a-4d00-863e-16772573b60e"
      unitRef="number">0.07250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i797b2df10ff44b2aa71c461fc27b30ef_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI0Njc5_9544e3ec-cf87-4491-9c17-92f3e8c55fe6"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i797b2df10ff44b2aa71c461fc27b30ef_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI0NzEy_9f4b7735-0a06-4590-b947-e56e49267136"
      unitRef="number">0.07000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i797b2df10ff44b2aa71c461fc27b30ef_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI0NzYx_a712cfca-43d3-4b1b-acf0-5c747af2579d"
      unitRef="number">0.07000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ibc2d2ee34b9d4af8aaed19ac1ff2667c_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI0ODA0_414e4ded-39f7-4488-887d-9d552cac3de9"
      unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibc2d2ee34b9d4af8aaed19ac1ff2667c_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI0ODM3_a4c85980-5c1a-4d00-863e-16772573b60e"
      unitRef="number">0.07250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="id9f599c080f5467ea5baebd9fac485a0_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI1MDA3_4c918951-cc70-4db4-81fc-af12c419bb2f"
      unitRef="usd">1118000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="if6d83e37326d4725bc725486444bd866_D20190523-20190523"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI1MDU1_302ab4e8-d6ef-433d-851a-f13f771519eb"
      unitRef="usd">382000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i9c71c44fc4c34b9bae672a9f56dfd653_D20190523-20190523"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI1MzMy_816a167e-fbe4-4b2c-8686-4e24ce094e7a"
      unitRef="usd">-32000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i797b2df10ff44b2aa71c461fc27b30ef_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI1NDc5_20801ae9-d0e8-49ef-bfb9-ee6eaffab1c1"
      unitRef="number">0.07000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i797b2df10ff44b2aa71c461fc27b30ef_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI1Njkz_c708cfbb-fd9b-400b-bae3-dac97678aeaf"
      unitRef="number">0.07000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i797b2df10ff44b2aa71c461fc27b30ef_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI2MDAz_def56d2a-5f2e-4beb-8e13-493847060733"
      unitRef="number">0.07000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i2c637f283ab04dfbbbfee6141ea6b782_D20190523-20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI2MTQ1_78bc22e5-71b0-4878-8fc4-cc1becbd04fc"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="if78fcb7d67eb418892f72d087ada3247_D20190523-20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI2MTQ1_895fa434-a7ca-4ee1-ab36-3bd0d9f8759c"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds
      contextRef="if78fcb7d67eb418892f72d087ada3247_D20190523-20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI2Mjgw_91adab12-9d39-4d74-b7a3-013b82b13177"
      unitRef="number">0.40</bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds>
    <bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds
      contextRef="i2c637f283ab04dfbbbfee6141ea6b782_D20190523-20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI2Mjgw_a5ef3700-8594-4e40-992a-e31d46ca66d9"
      unitRef="number">0.40</bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i797b2df10ff44b2aa71c461fc27b30ef_I20190523"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI2MzI0_8cb1d3c3-f21d-4547-b10a-738741289ae3"
      unitRef="number">0.07000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8b69c2b55c9f49159ba0241d1da3b1b6_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI2NTE0_629806e7-0bbd-4c49-8c8c-cb89d2df3f33"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i707c6ada63c346a9b3799fb37f228dee_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI2NTUz_e3f2fa2c-75e5-46ea-b1d8-00a89170d3dc"
      unitRef="number">0.05250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i8b69c2b55c9f49159ba0241d1da3b1b6_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI2Njg5_05c7066e-c198-4b5f-9baf-e71a17232e23"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8b69c2b55c9f49159ba0241d1da3b1b6_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI2NzIy_52a833f0-f124-4039-94c4-b14c273656a4"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8b69c2b55c9f49159ba0241d1da3b1b6_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI2Nzcx_b5b81aea-e5a1-4658-9d34-d9e895449e78"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i707c6ada63c346a9b3799fb37f228dee_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI2ODE0_501ff417-aed9-4d40-8001-0ed3f2aa1739"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i707c6ada63c346a9b3799fb37f228dee_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI2ODQ3_9211a149-b2f7-4788-9f69-7563d5afd0e6"
      unitRef="number">0.05250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i11d7dcdeb76f46a1ac2fb260dc29bf23_D20200116-20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI3MDA2_ca8bc690-15c6-4ec1-9c2d-8800bebc0053"
      unitRef="usd">1240000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i6ba274da5cb54b1daae13438db70ae34_D20191216-20191216"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI3MDc1_e0ac410a-911e-4855-8b78-b9dac1dcb563"
      unitRef="usd">1210000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i11d7dcdeb76f46a1ac2fb260dc29bf23_D20200116-20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI3MzEx_6642d215-c81e-4799-817a-552c63d1f014"
      unitRef="usd">1240000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i11d7dcdeb76f46a1ac2fb260dc29bf23_D20200116-20200116"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI3NDUw_7b8a94c2-1088-4f5e-8b1f-6d98bf738c54"
      unitRef="usd">-24000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8b69c2b55c9f49159ba0241d1da3b1b6_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI3NTk3_b5b81aea-e5a1-4658-9d34-d9e895449e78"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8b69c2b55c9f49159ba0241d1da3b1b6_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI3NzYy_b5b81aea-e5a1-4658-9d34-d9e895449e78"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8b69c2b55c9f49159ba0241d1da3b1b6_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI4MDI4_b5b81aea-e5a1-4658-9d34-d9e895449e78"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i4f688b41850c4d0fba418cbe194ccfbe_D20191230-20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI4MTI2_6f433409-67d4-47ca-a13e-d1ae30afb674"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i2b0d3caab19d43358c37172b00a1d73e_D20191230-20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI4MTI2_db747253-52c6-47b7-8e2b-4aa13c1fec0e"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds
      contextRef="i2b0d3caab19d43358c37172b00a1d73e_D20191230-20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI4MjQ2_07e3403a-489a-488d-bd75-43f42cd35d48"
      unitRef="number">0.40</bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds>
    <bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds
      contextRef="i4f688b41850c4d0fba418cbe194ccfbe_D20191230-20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI4MjQ2_92059197-0a0d-4ec2-9a1a-4ded70d5c7c2"
      unitRef="number">0.40</bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8b69c2b55c9f49159ba0241d1da3b1b6_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI4Mjkw_b5b81aea-e5a1-4658-9d34-d9e895449e78"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i23b34418de5747bc96ac966e1bad4561_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI4NDE3_810619d3-98a8-4001-94e5-482f8f99f66a"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i23b34418de5747bc96ac966e1bad4561_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI4NTI0_219af690-8ec1-4af7-ae3a-e5abf7df91c9"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i23b34418de5747bc96ac966e1bad4561_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI4NTU3_810619d3-98a8-4001-94e5-482f8f99f66a"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i23b34418de5747bc96ac966e1bad4561_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI4NjA3_810619d3-98a8-4001-94e5-482f8f99f66a"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i39f28d2202204cc1b5a777f81170474c_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI4NzI1_7ae4b391-7de3-4bf9-a226-3640cd6bb9a9"
      unitRef="usd">1250000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <bhc:PaymentForDebtAmortizationPrepaymentCost
      contextRef="if0649a2ad7e34fdd9c9aaacf95248fea_D20200526-20200526"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI4ODEy_761df073-5c79-4da7-91f7-c59f3dd8d03f"
      unitRef="usd">303000000</bhc:PaymentForDebtAmortizationPrepaymentCost>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i79078ef3ff22478e8ad56dbe5a19750d_D20200526-20200526"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI5MjE3_a3609d8f-d9d0-46c6-be0c-1f37cbcabe96"
      unitRef="usd">-27000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i23b34418de5747bc96ac966e1bad4561_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI5MzUy_810619d3-98a8-4001-94e5-482f8f99f66a"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i23b34418de5747bc96ac966e1bad4561_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI5NDE2_810619d3-98a8-4001-94e5-482f8f99f66a"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i23b34418de5747bc96ac966e1bad4561_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI5NTQ3_810619d3-98a8-4001-94e5-482f8f99f66a"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i80f3eb0d6a794c4dbf060750dbc6dc48_D20200526-20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI5NjQw_748f8e60-c549-4408-97f6-44f5a89b4933"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds
      contextRef="i7a0f2471e7f44074809037b78de94990_D20200526-20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI5ODU0_78b336d3-a913-4046-81d5-1b5be8598c43"
      unitRef="number">0.40</bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i23b34418de5747bc96ac966e1bad4561_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzI5OTEw_810619d3-98a8-4001-94e5-482f8f99f66a"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i23b34418de5747bc96ac966e1bad4561_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMwMDM0_810619d3-98a8-4001-94e5-482f8f99f66a"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i23b34418de5747bc96ac966e1bad4561_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMwMTU2_810619d3-98a8-4001-94e5-482f8f99f66a"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i23b34418de5747bc96ac966e1bad4561_I20200526"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMwMjQy_810619d3-98a8-4001-94e5-482f8f99f66a"
      unitRef="number">0.06250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4d4effd4ca8849688cd2273c89e716e3_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMwMzY2_14e45b67-28ca-4572-bc98-a4d862cb11ed"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i374367eeb97946bcb6cacd5888eb32f6_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMwNDA1_dea2ea85-8f33-4050-b3c7-0d393ccaaf06"
      unitRef="number">0.05250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i4d4effd4ca8849688cd2273c89e716e3_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMwNTIx_88b35f2f-54be-4ce6-9b2c-7286ff6c78f3"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4d4effd4ca8849688cd2273c89e716e3_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMwNTU0_14e45b67-28ca-4572-bc98-a4d862cb11ed"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4d4effd4ca8849688cd2273c89e716e3_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMwNjA0_14e45b67-28ca-4572-bc98-a4d862cb11ed"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i374367eeb97946bcb6cacd5888eb32f6_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMwNjQz_dfd71b7b-2fc6-4088-8c78-3e423b0225b5"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i374367eeb97946bcb6cacd5888eb32f6_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMwNjc2_dea2ea85-8f33-4050-b3c7-0d393ccaaf06"
      unitRef="number">0.05250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="id77d7960c24b4e4a865ddd716f13ec49_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMwODk4_04fcf269-9562-4fcf-b95c-a6c7957a6f50"
      unitRef="eur">1500000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="idd85aaaa25cc479b99bd4e886b1c3240_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMwOTI1_3b5c584c-6edf-4c0d-80f1-a88f77a936d1"
      unitRef="usd">233000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i356651edb41c4b0a8e39c4bd624b498e_D20201203-20201203"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMxMjQ3_691090c3-7186-412d-9981-c1e77521268a"
      unitRef="usd">-7000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4d4effd4ca8849688cd2273c89e716e3_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMxMzgy_14e45b67-28ca-4572-bc98-a4d862cb11ed"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4d4effd4ca8849688cd2273c89e716e3_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMxNDQ2_14e45b67-28ca-4572-bc98-a4d862cb11ed"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i374367eeb97946bcb6cacd5888eb32f6_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMxNTk1_dea2ea85-8f33-4050-b3c7-0d393ccaaf06"
      unitRef="number">0.05250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4d4effd4ca8849688cd2273c89e716e3_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMxNzI2_14e45b67-28ca-4572-bc98-a4d862cb11ed"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="id78465b77ff94c179049b8f8da315bc7_D20201203-20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMxODE5_80fed3f2-b5d1-4365-842d-a3e855b00b7b"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds
      contextRef="id78465b77ff94c179049b8f8da315bc7_D20201203-20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMyMDM1_15391621-7b89-4d66-9d6b-0bf68376ce39"
      unitRef="number">0.40</bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4d4effd4ca8849688cd2273c89e716e3_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMyMDkx_14e45b67-28ca-4572-bc98-a4d862cb11ed"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4d4effd4ca8849688cd2273c89e716e3_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMyMjE1_9d72a58c-1c76-487e-b30b-3d6edd8ff930"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4d4effd4ca8849688cd2273c89e716e3_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMyMzM3_14e45b67-28ca-4572-bc98-a4d862cb11ed"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4d4effd4ca8849688cd2273c89e716e3_I20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMyNDIz_7cf92c41-8e1f-4853-939c-ee6721922ddc"
      unitRef="number">0.05000</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i4f524b83d2a14769b88a62af6ce78e47_D20201203-20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMyNjg0_17ed9b4d-6b62-45e4-b4b3-152fcc08c3f3"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds
      contextRef="i4f524b83d2a14769b88a62af6ce78e47_D20201203-20201203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMyOTAw_6d56c6a2-9484-4d88-8b96-3c58b7204698"
      unitRef="number">0.40</bhc:DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMzNTQw_f8a0ba4a-ba7b-479b-a5f6-db1c2cdbf592"
      unitRef="number">0.0588</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMzNTQ3_ed3c517b-58ac-487f-be51-6a31d2a2353e"
      unitRef="number">0.0602</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzM0MjY2_b4a77843-064f-4949-8c31-6a844def3e7a">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Maturities and Mandatory Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities and mandatory payments of debt obligations for the five succeeding years ending December&#160;31 and thereafter are as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:88.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.067%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross maturities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZToyNDhiYWNjNzA0MGM0OGYyYjdmNDU5MTEyYmQyYTNkNC90YWJsZXJhbmdlOjI0OGJhY2M3MDQwYzQ4ZjJiN2Y0NTkxMTJiZDJhM2Q0XzEtMS0xLTEtOTQ4MzE_845fddb6-158b-41ec-beef-f407344986a2"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZToyNDhiYWNjNzA0MGM0OGYyYjdmNDU5MTEyYmQyYTNkNC90YWJsZXJhbmdlOjI0OGJhY2M3MDQwYzQ4ZjJiN2Y0NTkxMTJiZDJhM2Q0XzItMS0xLTEtOTQ4MzE_f1e27b30-df86-469e-8e31-938376f46ac1"
      unitRef="usd">285000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZToyNDhiYWNjNzA0MGM0OGYyYjdmNDU5MTEyYmQyYTNkNC90YWJsZXJhbmdlOjI0OGJhY2M3MDQwYzQ4ZjJiN2Y0NTkxMTJiZDJhM2Q0XzMtMS0xLTEtOTQ4MzE_5bb124ee-5618-4d9e-b8c0-1f950d295748"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZToyNDhiYWNjNzA0MGM0OGYyYjdmNDU5MTEyYmQyYTNkNC90YWJsZXJhbmdlOjI0OGJhY2M3MDQwYzQ4ZjJiN2Y0NTkxMTJiZDJhM2Q0XzQtMS0xLTEtOTQ4MzE_09ae58db-486e-4074-828a-556658544bd8"
      unitRef="usd">9723000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZToyNDhiYWNjNzA0MGM0OGYyYjdmNDU5MTEyYmQyYTNkNC90YWJsZXJhbmdlOjI0OGJhY2M3MDQwYzQ4ZjJiN2Y0NTkxMTJiZDJhM2Q0XzUtMS0xLTEtOTQ4MzE_13fac832-1a4b-4cc6-a842-cfa72c71cb6e"
      unitRef="usd">1500000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZToyNDhiYWNjNzA0MGM0OGYyYjdmNDU5MTEyYmQyYTNkNC90YWJsZXJhbmdlOjI0OGJhY2M3MDQwYzQ4ZjJiN2Y0NTkxMTJiZDJhM2Q0XzYtMS0xLTEtOTQ4MzE_dc378bd1-9f80-40e4-a977-5cd05d291520"
      unitRef="usd">11362000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZToyNDhiYWNjNzA0MGM0OGYyYjdmNDU5MTEyYmQyYTNkNC90YWJsZXJhbmdlOjI0OGJhY2M3MDQwYzQ4ZjJiN2Y0NTkxMTJiZDJhM2Q0XzctMS0xLTEtOTQ4MzE_9a94e3cb-b4e0-4e57-bedc-5839afde3f9c"
      unitRef="usd">22870000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZToyNDhiYWNjNzA0MGM0OGYyYjdmNDU5MTEyYmQyYTNkNC90YWJsZXJhbmdlOjI0OGJhY2M3MDQwYzQ4ZjJiN2Y0NTkxMTJiZDJhM2Q0XzgtMS0xLTEtOTQ4MzE_a3301d9b-6921-4818-9a43-311d97fbb27c"
      unitRef="usd">216000000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90YWJsZToyNDhiYWNjNzA0MGM0OGYyYjdmNDU5MTEyYmQyYTNkNC90YWJsZXJhbmdlOjI0OGJhY2M3MDQwYzQ4ZjJiN2Y0NTkxMTJiZDJhM2Q0XzktMS0xLTEtOTQ4MzE_18644bca-6373-4833-b48e-967eddd0745c"
      unitRef="usd">22654000000</us-gaap:LongTermDebt>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="i85ca12bc72e84e42b58ea2d217fa1aaa_D20220211-20220211"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzMzODkx_7797c5f4-1cb5-44db-925f-abf81c654c54"
      unitRef="usd">285000000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i4e619b455ff146759a2117b1f93fefb2_I20220118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzM0MTA0_a5f7f32e-eb93-4667-898c-f205fe522558"
      unitRef="usd">370000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib440abcc71694fa09f8e1ad1955b47b3_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzM0MTcy_a162e295-ca06-4715-9f7d-0a898ba35a97"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib440abcc71694fa09f8e1ad1955b47b3_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDAvZnJhZzphMTg0NGY1OTZmMTQ0ZDkyODVhMTg1NTFkOTM4NWI4ZS90ZXh0cmVnaW9uOmExODQ0ZjU5NmYxNDRkOTI4NWExODU1MWQ5Mzg1YjhlXzM0MjA1_588a6e93-7f54-42ca-a25e-29812b915be0"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzkzODc_20e82d07-658e-4c4d-8d4f-9375014538d2">PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANSThe Company has defined benefit plans and a participatory defined benefit postretirement medical and life insurance plan, which covers a closed grandfathered group of legacy Bausch &amp;amp; Lomb Holdings Incorporated (&#x2018;&#x2018;B&amp;amp;L&#x2019;&#x2019;) U.S. employees and employees in certain other countries. The U.S. defined benefit accruals were frozen as of December 31, 2004 and benefits that were earned up to December 31, 2004 were preserved. Participants continue to earn interest credits on their cash balance at an interest crediting rate that is equal to the greater of: (i) the average annual yield on 10-year treasury bonds in effect for the November preceding the plan year or (ii) 4.50%. The most significant non-U.S. plans are two defined benefit plans in Ireland. In 2011, both Ireland defined benefit plans were closed to future service benefit accruals; however, additional accruals related to annual salary increases continued. In December 2014, one of the Ireland defined benefit plans was amended effective August 2014 to eliminate future benefit accruals related to salary increases. All of the pension benefits accrued through the plan amendment date were preserved. As a result of the plan amendment, there are no active plan participants accruing benefits under the amended Ireland defined benefit plan.  The U.S. postretirement benefit &lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;plan was amended effective January 1, 2005 to eliminate employer contributions after age 65 for participants who did not meet the minimum requirements of age and service on that date. The employer contributions for medical and prescription drug benefits for participants retiring after March 1, 1989 were frozen effective January 1, 2010. Effective January 1, 2014, the Company no longer offers medical and life insurance coverage to new retirees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the B&amp;amp;L benefit plans, outside of the U.S., a limited group of the Company's employees are covered by defined benefit pension plans. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses December 31 as the year-end measurement date for all of its defined benefit pension plans and the postretirement benefit plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Pension Benefit Plans and Postretirement Benefit Plan &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes in its Consolidated Balance Sheets an asset or liability equal to the over- or under-funded benefit obligation of each defined benefit pension plan and postretirement benefit plan. Actuarial gains or losses and prior service costs or credits that arise during the period but are not recognized as components of net periodic benefit cost are recognized, net of tax, as a component of Other comprehensive income (loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amounts included in Accumulated other comprehensive loss as of December 31, 2021 and 2020 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement&lt;br/&gt;Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrecognized actuarial losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrecognized prior service credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Periodic (Benefit) Cost&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the components of net periodic (benefit) cost for the Company&#x2019;s defined benefit pension plans and postretirement benefit plan in 2021, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement&lt;br/&gt;Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of prior service credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlement loss recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net periodic (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Benefit Obligation, Change in Plan Assets and Funded Status &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents components of the change in projected benefit obligation, change in plan assets and funded status for 2021 and 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement&lt;br/&gt;Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Change in Projected Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Actuarial (gain) losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Change in Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Company contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Funded status, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Recognized as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Settlement loss recognized and Settlements in the tables above are the costs and payments associated with the conversion of a portion of the Company&#x2019;s defined benefit plan in Ireland to a defined contribution plan during the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A number of the Company&#x2019;s pension benefit plans were underfunded as of December 31, 2021 and 2020, having accumulated benefit obligations exceeding the fair value of plan assets. There were no U.S. pension benefit plans that were underfunded as of December 31, 2021, having accumulated benefit obligations exceeding the fair value of plan assets. Information for the underfunded pension benefit plans is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s policy for funding its pension benefit plans is to make contributions that meet or exceed the minimum statutory funding requirements. These contributions are determined based upon recommendations made by the actuary under accepted actuarial principles. In 2022, the Company expects to contribute $0, $9 million and $4 million to the U.S. pension benefit plan, the non-U.S. pension benefit plans and the U.S. postretirement benefit plan, respectively. The Company plans to use postretirement benefit plan assets and cash on hand, as necessary, to fund the U.S. postretirement benefit plan benefit payments in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Estimated Future Benefit Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future benefit payments over the next 10 years for the pension benefit plans and the postretirement benefit plan, which reflect expected future service, as appropriate, are expected to be paid as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.337%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.337%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement&lt;br/&gt;&#160;Benefit&lt;br/&gt;&#160;Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027-2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used to determine net periodic benefit costs and benefit obligations for 2021, 2020 and 2019 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;For Determining Net Periodic (Benefit) Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Plans:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-U.S. Plans:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.197%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;For Determining Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Plans:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-U.S. Plans:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected long-term rate of return on plan assets was developed based on a capital markets model that uses expected asset class returns, variance and correlation assumptions. The expected asset class returns were developed starting with current Treasury (for the U.S. pension plan) or Eurozone (for the Ireland pension plans) government yields and then adding corporate bond spreads and equity risk premiums to develop the return expectations for each asset class. The expected asset class returns are forward-looking. The variance and correlation assumptions are also forward-looking. They take into account historical relationships, but are adjusted to reflect expected capital market trends. The expected return on plan assets for the Company&#x2019;s U.S. pension plan for 2021 was 5.00%. The expected return on plan assets for the Company&#x2019;s Ireland pension plans was 2.75% for 2021.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The discount rate used to determine benefit obligations represents the current rate at which the benefit plan liabilities could be effectively settled considering the timing of expected payments for plan participants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2022 expected rate of return for the U.S. pension benefit plan will be 4.50%. The 2022 expected rate of return for the Ireland pension benefit plans will be 2.75%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pension Benefit Plans Assets             &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pension benefit plan assets are invested in several asset categories. The following presents the actual asset allocation as of December 31, 2021 and 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.048%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fixed income securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fixed income securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The investment strategy underlying pension plan asset allocation is to manage the assets of the plan to provide for the non-current liabilities while maintaining sufficient liquidity to pay current benefits. Pension plan assets are diversified to protect against large investment losses and to reduce the probability of excessive performance volatility. Diversification of assets is achieved by allocating funds to various asset classes and investment styles within asset classes, and retaining investment management firm(s) with complementary investment philosophies, styles and approaches.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s pension plan assets are managed by outside investment managers using a total return investment approach, whereby a mix of equity and debt securities investments are used to maximize the long-term rate of return on plan assets. A significant portion of the assets of the U.S. and Ireland pension plans have been invested in equity securities, as equity portfolios have historically provided higher returns than debt and other asset classes over extended time horizons. Correspondingly, equity investments also entail greater risks than other investments. Equity risks are balanced by investing a significant portion of plan assets in broadly diversified fixed income securities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Plan Assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measured the fair value of plan assets based on the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. See Note 5, &#x201c;FAIR VALUE MEASUREMENTS&#x201d; for details on the Company's fair value measurements based on a three-tier hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents total plan assets by investment category as of December 31, 2021 and 2020 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value. There were no transfers between Level 1 and Level 2 during 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans - U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commingled funds:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. broad market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment grade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans - Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commingled funds:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment grade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Global high yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government bond funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consisted primarily of term deposits and money market instruments. The fair value of the term deposits approximates their carrying amounts due to their short term maturities. The money market instruments also have short maturities and are valued using a market approach based on the quoted market prices of identical instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commingled funds are not publicly traded. The underlying assets in these funds are publicly traded on the exchanges and have readily available price quotes. The Ireland pension plans held approximately 95% and 96% of the non-U.S. commingled funds in 2021 and 2020, respectively. The commingled funds held by the U.S. and Ireland pension plans are primarily invested in index funds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The underlying assets in the fixed income funds are generally valued using the net asset value per fund share, which is derived using a market approach with inputs that include broker quotes, benchmark yields, base spreads and reported trades. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Defined Contribution Plans &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors defined contribution plans in the U.S., Ireland and certain other countries.&#160;Under these plans, employees are allowed to contribute a portion of their salaries to the plans, and the Company matches a portion of the employee contributions. The Company contributed $44 million, $43 million and $41 million to these plans during the years ended December 31, 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <bhc:DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance
      contextRef="i2f9960dff77240d28dd966ea114e1dc3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzY3Mg_1d60d66f-a725-493c-9058-2293d90ab9b0"
      unitRef="number">0.0450</bhc:DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance>
    <bhc:DefinedBenefitPlanNumberofDefinedBenefitPlans
      contextRef="i09794c3bfd084a82b2a8672bfec8f4ff_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzcxNg_1a043f3c-6eba-492c-8e29-97e7a7bb0057"
      unitRef="defined_benefit_plan">2</bhc:DefinedBenefitPlanNumberofDefinedBenefitPlans>
    <bhc:DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended
      contextRef="i0da6a354b78d46da85ab05e0768ba4cf_D20141201-20141231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzkzOA_6aec1255-96a3-471f-8aed-1a6fa59bbdc1"
      unitRef="defined_benefit_plan">1</bhc:DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended>
    <bhc:DefinedBenefitPlanEmployerContributionMaximumAge
      contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzE0MjM_0a25672f-32c3-426e-a8f1-e62b6ca45ab3">P65Y</bhc:DefinedBenefitPlanEmployerContributionMaximumAge>
    <us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2Xzk0MjE_afccc8f6-3d94-44a4-8927-02ee0f306f9d">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amounts included in Accumulated other comprehensive loss as of December 31, 2021 and 2020 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement&lt;br/&gt;Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrecognized actuarial losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrecognized prior service credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax
      contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTMwOWMyODhjOTc0OWIxOTVhOWFhZTgyYTJjNDY0My90YWJsZXJhbmdlOmQ1MzA5YzI4OGM5NzQ5YjE5NWE5YWFlODJhMmM0NjQzXzMtMi0xLTEtOTQ4MzE_b6dfbfed-c1ef-44e8-82aa-309f4b01248e"
      unitRef="usd">-18000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax
      contextRef="i7fe9a8f118334aab8ff6bd90e126b597_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTMwOWMyODhjOTc0OWIxOTVhOWFhZTgyYTJjNDY0My90YWJsZXJhbmdlOmQ1MzA5YzI4OGM5NzQ5YjE5NWE5YWFlODJhMmM0NjQzXzMtNC0xLTEtOTQ4MzE_489495ab-9f29-423e-a2c1-55cb96df5c69"
      unitRef="usd">-21000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax
      contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTMwOWMyODhjOTc0OWIxOTVhOWFhZTgyYTJjNDY0My90YWJsZXJhbmdlOmQ1MzA5YzI4OGM5NzQ5YjE5NWE5YWFlODJhMmM0NjQzXzMtNi0xLTEtOTQ4MzE_40461b73-b0f3-480b-8512-20063c4bf854"
      unitRef="usd">-42000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax
      contextRef="icac9bfd5e8d54c0689a02e2e251a39cd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTMwOWMyODhjOTc0OWIxOTVhOWFhZTgyYTJjNDY0My90YWJsZXJhbmdlOmQ1MzA5YzI4OGM5NzQ5YjE5NWE5YWFlODJhMmM0NjQzXzMtOC0xLTEtOTQ4MzE_8f99add9-d34a-44cd-a226-97ae69926d78"
      unitRef="usd">-76000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax
      contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTMwOWMyODhjOTc0OWIxOTVhOWFhZTgyYTJjNDY0My90YWJsZXJhbmdlOmQ1MzA5YzI4OGM5NzQ5YjE5NWE5YWFlODJhMmM0NjQzXzMtMTAtMS0xLTk0ODMx_48dbec28-0404-446e-af87-c669517756d0"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax
      contextRef="if38262082aca4b1ca51d9de262b48c77_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTMwOWMyODhjOTc0OWIxOTVhOWFhZTgyYTJjNDY0My90YWJsZXJhbmdlOmQ1MzA5YzI4OGM5NzQ5YjE5NWE5YWFlODJhMmM0NjQzXzMtMTItMS0xLTk0ODMx_661947cf-2a3e-421c-b05d-fcebd24db860"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax
      contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTMwOWMyODhjOTc0OWIxOTVhOWFhZTgyYTJjNDY0My90YWJsZXJhbmdlOmQ1MzA5YzI4OGM5NzQ5YjE5NWE5YWFlODJhMmM0NjQzXzQtMi0xLTEtOTQ4MzE_7b90e87b-6136-46b0-bced-98a7f3ca1acb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax
      contextRef="i7fe9a8f118334aab8ff6bd90e126b597_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTMwOWMyODhjOTc0OWIxOTVhOWFhZTgyYTJjNDY0My90YWJsZXJhbmdlOmQ1MzA5YzI4OGM5NzQ5YjE5NWE5YWFlODJhMmM0NjQzXzQtNC0xLTEtOTQ4MzE_f4c611e1-55e1-485b-9f76-6b2041521a82"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax
      contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTMwOWMyODhjOTc0OWIxOTVhOWFhZTgyYTJjNDY0My90YWJsZXJhbmdlOmQ1MzA5YzI4OGM5NzQ5YjE5NWE5YWFlODJhMmM0NjQzXzQtNi0xLTEtOTQ4MzE_b7e245cf-1167-4849-a34a-8199f61175e4"
      unitRef="usd">-25000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax
      contextRef="icac9bfd5e8d54c0689a02e2e251a39cd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTMwOWMyODhjOTc0OWIxOTVhOWFhZTgyYTJjNDY0My90YWJsZXJhbmdlOmQ1MzA5YzI4OGM5NzQ5YjE5NWE5YWFlODJhMmM0NjQzXzQtOC0xLTEtOTQ4MzE_4f30173b-859e-4d31-9e66-af90e8526477"
      unitRef="usd">-27000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax
      contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTMwOWMyODhjOTc0OWIxOTVhOWFhZTgyYTJjNDY0My90YWJsZXJhbmdlOmQ1MzA5YzI4OGM5NzQ5YjE5NWE5YWFlODJhMmM0NjQzXzQtMTAtMS0xLTk0ODMx_5e6240fc-4ee5-4170-a059-492a2a676a98"
      unitRef="usd">-8000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax
      contextRef="if38262082aca4b1ca51d9de262b48c77_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTMwOWMyODhjOTc0OWIxOTVhOWFhZTgyYTJjNDY0My90YWJsZXJhbmdlOmQ1MzA5YzI4OGM5NzQ5YjE5NWE5YWFlODJhMmM0NjQzXzQtMTItMS0xLTk0ODMx_0b284a75-0fef-43cc-a04e-f32176c49668"
      unitRef="usd">-11000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2Xzk0MjY_53741ddc-889b-4014-9dfb-33a8564c03f3">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the components of net periodic (benefit) cost for the Company&#x2019;s defined benefit pension plans and postretirement benefit plan in 2021, 2020 and 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.951%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement&lt;br/&gt;Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of prior service credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlement loss recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net periodic (benefit) cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzMtMi0xLTEtOTQ4MzE_7a818f45-208f-4e23-bdd5-4470307cb891"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzMtNC0xLTEtOTQ4MzE_1b8e4e84-bd87-4b85-b7f4-ccce884d43be"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ie5d47857632948b3953696f970672168_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzMtNi0xLTEtOTQ4MzE_f4de1a0e-190b-495a-be08-61f334952fed"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzMtOC0xLTEtOTQ4MzE_6e7865f6-fdfe-4245-a18a-cd85e87fce9f"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzMtMTAtMS0xLTk0ODMx_136a2658-19ba-4349-ae1b-7f9d7a15377f"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i60dd7747d8e84735ad54cdac6b306397_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzMtMTItMS0xLTk0ODMx_4622373a-b94a-4b5c-b20d-9a948cab712d"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzMtMTQtMS0xLTk0ODMx_fd16fc9f-3329-4369-b356-3767a9a87143"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzMtMTYtMS0xLTk0ODMx_6e60a1b2-28e0-42c7-86ed-11c9a832e1bb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i75033e6771e2462a948d8f02b08289cd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzMtMTgtMS0xLTk0ODMx_18f10f55-4eb3-4356-b519-2b8c79a09403"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzQtMi0xLTEtOTQ4MzE_547ab516-4f86-4b44-8fa8-b7a1b48f5729"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzQtNC0xLTEtOTQ4MzE_76ca2839-d91b-4759-a931-c9842db28c00"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ie5d47857632948b3953696f970672168_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzQtNi0xLTEtOTQ4MzE_5444d618-eabe-4831-b834-02ffd984a2a2"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzQtOC0xLTEtOTQ4MzE_c0ea6482-6b27-43af-aabc-e58c5f32b792"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzQtMTAtMS0xLTk0ODMx_3209e87b-3c74-439a-a6c9-01e0d1deb35e"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i60dd7747d8e84735ad54cdac6b306397_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzQtMTItMS0xLTk0ODMx_5e22b4e1-8161-4e0d-ba3a-d644473063da"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzQtMTQtMS0xLTk0ODMx_265a206f-f259-4c1f-ac5b-1dae5b94f09a"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzQtMTYtMS0xLTk0ODMx_288719f7-33f7-429d-a405-fd8b681a9368"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i75033e6771e2462a948d8f02b08289cd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzQtMTgtMS0xLTk0ODMx_c31e9f79-257a-4dce-8ea1-bdb1b4a38ec4"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzUtMi0xLTEtOTQ4MzE_d2dad0d1-ea6a-46bc-b435-7b37044a2732"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzUtNC0xLTEtOTQ4MzE_81f8ddad-8a1e-4b7b-ad7b-21ffc5ec98bc"
      unitRef="usd">13000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ie5d47857632948b3953696f970672168_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzUtNi0xLTEtOTQ4MzE_2f660d10-4dca-407d-b4fe-9154e0d09b1b"
      unitRef="usd">13000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzUtOC0xLTEtOTQ4MzE_a965104c-afd5-4d41-9bd3-29536bdf0753"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzUtMTAtMS0xLTk0ODMx_4ae6cd29-79ec-4cc0-a4eb-ae7c5aef4efe"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i60dd7747d8e84735ad54cdac6b306397_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzUtMTItMS0xLTk0ODMx_57bb4a53-5d47-4df7-b451-e75e6e60dcba"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzUtMTQtMS0xLTk0ODMx_fa4b3790-36e6-4f27-b65b-cae646f166fc"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzUtMTYtMS0xLTk0ODMx_fdd7e16b-9bfe-47bd-8ad7-543ee01dc695"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i75033e6771e2462a948d8f02b08289cd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzUtMTgtMS0xLTk0ODMx_9497cebf-4626-40b4-8653-627c91512158"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzYtMi0xLTEtOTQ4MzE_1e6ad9a1-cb0b-4473-ae41-817df9519226"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzYtNC0xLTEtOTQ4MzE_88be7e78-d264-4ebd-be9a-27f5164f2a65"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ie5d47857632948b3953696f970672168_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzYtNi0xLTEtOTQ4MzE_133c082a-bb29-455f-8242-c68a044a1ad6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzYtOC0xLTEtOTQ4MzE_6330015a-b93a-4bef-aa92-4e79a5989e26"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzYtMTAtMS0xLTk0ODMx_ec79e97d-a06e-4fd3-ac3f-ecf02191477c"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i60dd7747d8e84735ad54cdac6b306397_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzYtMTItMS0xLTk0ODMx_63f20367-330c-4cce-bea0-2d1c1f075441"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzYtMTQtMS0xLTk0ODMx_25aff60d-9e3f-4cc1-910a-b665f7f19818"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzYtMTYtMS0xLTk0ODMx_4efafa4b-6c43-40a1-b605-d33e083045f5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i75033e6771e2462a948d8f02b08289cd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzYtMTgtMS0xLTk0ODMx_65dd63db-08c9-4d6f-9b9d-751c95d43360"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzctMi0xLTEtOTQ4MzE_06e516f4-0049-4293-a224-74a9bdf2664a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzctNC0xLTEtOTQ4MzE_a26934e7-0f9e-4212-b095-0645f6179a55"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ie5d47857632948b3953696f970672168_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzctNi0xLTEtOTQ4MzE_66278974-99ba-41a8-b311-ab18824249b5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzctOC0xLTEtOTQ4MzE_110c514b-098c-4275-99a2-0d3e8c41f308"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzctMTAtMS0xLTk0ODMx_298ae707-132d-4e5c-999b-120bd81c0f6a"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i60dd7747d8e84735ad54cdac6b306397_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzctMTItMS0xLTk0ODMx_42ce521d-f1a4-4562-b336-d1c532276718"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzctMTQtMS0xLTk0ODMx_2cb374ef-9fb9-4309-845c-fb6577a7c467"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzctMTYtMS0xLTk0ODMx_3a84b45a-f3a0-460c-9840-9f27e52c31f3"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i75033e6771e2462a948d8f02b08289cd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzctMTgtMS0xLTk0ODMx_7bdd5e72-7a07-4475-b583-1c9ada6eb3ec"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzgtMi0xLTEtOTQ4MzE_0e8f10fa-9f6f-4e81-8473-aa94ca39d1a4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzgtNC0xLTEtOTQ4MzE_36e34b7f-64a9-435e-a188-ae6318b84eb0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="ie5d47857632948b3953696f970672168_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzgtNi0xLTEtOTQ4MzE_f7a04b76-36b5-4b01-83f7-6f03eec0ac21"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzgtOC0xLTEtOTQ4MzE_e498f9ce-fe7f-4e0e-846d-843520c57624"
      unitRef="usd">-8000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzgtMTAtMS0xLTk0ODMx_be193e92-48b9-4d8a-a9cd-6dda86a6fbb2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i60dd7747d8e84735ad54cdac6b306397_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzgtMTItMS0xLTk0ODMx_581baeec-1f9e-494e-8a1b-d37aaf297644"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzgtMTQtMS0xLTk0ODMx_683dbbbf-2e06-4a59-8ef0-b9242c417f7d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzgtMTYtMS0xLTk0ODMx_3045915e-8665-4c48-888a-aff25f162c88"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="i75033e6771e2462a948d8f02b08289cd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzgtMTgtMS0xLTk0ODMx_c8abadeb-338d-4b64-824e-c51bc6d9dd3f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanOtherCosts
      contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzktMi0xLTEtOTQ4MzE_c3133afe-ac07-4d18-aee8-bc0211830342"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanOtherCosts>
    <us-gaap:DefinedBenefitPlanOtherCosts
      contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzktNC0xLTEtOTQ4MzE_9a8a2e1b-972f-4470-be2f-d52b44517867"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanOtherCosts>
    <us-gaap:DefinedBenefitPlanOtherCosts
      contextRef="ie5d47857632948b3953696f970672168_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzktNi0xLTEtOTQ4MzE_e937c7a2-e1fd-45af-a9c0-b538d89a07d2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanOtherCosts>
    <us-gaap:DefinedBenefitPlanOtherCosts
      contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzktOC0xLTEtOTQ4MzE_c79f172c-de6e-479c-9348-d7c5063356f6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanOtherCosts>
    <us-gaap:DefinedBenefitPlanOtherCosts
      contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzktMTAtMS0xLTk0ODMx_67bbd354-b9fb-4206-844b-2475bb8ef7db"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanOtherCosts>
    <us-gaap:DefinedBenefitPlanOtherCosts
      contextRef="i60dd7747d8e84735ad54cdac6b306397_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzktMTItMS0xLTk0ODMx_f4151f6e-f43d-48ef-b7c9-4948cb753f06"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanOtherCosts>
    <us-gaap:DefinedBenefitPlanOtherCosts
      contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzktMTQtMS0xLTk0ODMx_87dbd5e2-8858-496f-abca-17d5a24fa2bd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanOtherCosts>
    <us-gaap:DefinedBenefitPlanOtherCosts
      contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzktMTYtMS0xLTk0ODMx_a5630b5d-1acc-4c8b-ad5d-da1c05ded3f6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanOtherCosts>
    <us-gaap:DefinedBenefitPlanOtherCosts
      contextRef="i75033e6771e2462a948d8f02b08289cd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzktMTgtMS0xLTk0ODMx_2ab879ae-e107-4cb7-9779-575a42f9eaba"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanOtherCosts>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzEwLTItMS0xLTk0ODMx_bea87601-cbbd-4094-bf06-e11a2daa67d4"
      unitRef="usd">-6000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzEwLTQtMS0xLTk0ODMx_b6abdf94-af1e-447d-9814-375c7b537d6d"
      unitRef="usd">-6000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ie5d47857632948b3953696f970672168_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzEwLTYtMS0xLTk0ODMx_b12a3c40-e6ac-4b57-926e-2e38d999f4a7"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzEwLTgtMS0xLTk0ODMx_dcd4ef21-7c12-4028-9252-c6cbc1695b89"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzEwLTEwLTEtMS05NDgzMQ_dfd086ec-df24-4165-a60d-bd8171021577"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i60dd7747d8e84735ad54cdac6b306397_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzEwLTEyLTEtMS05NDgzMQ_783c17f8-907c-4754-a628-6afa14cf01a1"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzEwLTE0LTEtMS05NDgzMQ_757556e0-c587-4ecd-9ac8-123801adb0d8"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzEwLTE2LTEtMS05NDgzMQ_9aa485b4-f265-4477-895a-cd820b9e8f21"
      unitRef="usd">-2000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i75033e6771e2462a948d8f02b08289cd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxM2ZjN2Y5ZWM4OGI0MmIyYTZjMTExZDJjMGEyYmNiMC90YWJsZXJhbmdlOjEzZmM3ZjllYzg4YjQyYjJhNmMxMTFkMmMwYTJiY2IwXzEwLTE4LTEtMS05NDgzMQ_37ff8d95-91a2-4034-a828-eefcdad0bc85"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2Xzk0MTY_76457e0b-f571-424d-81dd-22de01c22b83">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents components of the change in projected benefit obligation, change in plan assets and funded status for 2021 and 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement&lt;br/&gt;Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 4.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Change in Projected Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Actuarial (gain) losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Change in Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Actual return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Company contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Benefits paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Funded status, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Recognized as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i7fe9a8f118334aab8ff6bd90e126b597_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzQtMi0xLTEtOTQ4MzE_8c2db1e4-5838-4cbf-8b9c-68d7cb3c3f55"
      unitRef="usd">236000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i463e7100cf0447ed909a1b0e9a750265_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzQtNC0xLTEtOTQ4MzE_c9593702-a13a-448a-81fc-9e67acb6eb13"
      unitRef="usd">227000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="icac9bfd5e8d54c0689a02e2e251a39cd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzQtNi0xLTEtOTQ4MzE_2f5d240a-2f7f-4daf-b9b4-642baa37a16e"
      unitRef="usd">294000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i77e60ffa0a7048b3bc6ab71dd3ff10d2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzQtOC0xLTEtOTQ4MzE_1fcc679f-aafb-4c7b-bd8b-e92702b28b79"
      unitRef="usd">259000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="if38262082aca4b1ca51d9de262b48c77_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzQtMTAtMS0xLTk0ODMx_d0a7009c-320e-492b-b51a-4c76929fa350"
      unitRef="usd">39000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="idea50cd734984c47856762240b1f1a02_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzQtMTItMS0xLTk0ODMx_c5dff500-c098-4901-83a5-08d075e45413"
      unitRef="usd">41000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzUtMi0xLTEtOTQ4MzE_84b39927-1a42-4f25-a6f4-6d1a44b36a3c"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzUtNC0xLTEtOTQ4MzE_3f745688-9610-44d2-a3a1-e7b7aaef7ab9"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzUtNi0xLTEtOTQ4MzE_06e85864-42bd-483b-a9f4-2b8b410a901d"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzUtOC0xLTEtOTQ4MzE_71be263e-2e03-41ad-98ac-ede10b1d05ba"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzUtMTAtMS0xLTk0ODMx_fb34b2f1-aa3f-49c7-a5a8-01fb44b2a707"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzUtMTItMS0xLTk0ODMx_8deee005-1424-42e2-8723-612a10d795d5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzYtMi0xLTEtOTQ4MzE_e042c060-c968-415d-b31b-0e8c6870f919"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzYtNC0xLTEtOTQ4MzE_9c27023f-5dd7-4aba-9ea3-0ce525fd8b43"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzYtNi0xLTEtOTQ4MzE_7a5b4f64-00ba-4be7-8a1d-d1465129a4f4"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzYtOC0xLTEtOTQ4MzE_e729c062-42df-49e7-b4f9-48a8947780f2"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzYtMTAtMS0xLTk0ODMx_3c572434-591b-4d91-a56d-995fb1d41357"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzYtMTItMS0xLTk0ODMx_3ceef61d-724c-42ca-854b-ea81e3fa5a80"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzgtMi0xLTEtOTQ4MzE_1b94de1e-a337-468a-b69f-92ddd51a3e69"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzgtNC0xLTEtOTQ4MzE_4ebb69ab-fc62-4032-85e5-851c78bd0559"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzgtNi0xLTEtOTQ4MzE_2ed4b22b-5aab-4d7e-b717-770540a72d04"
      unitRef="usd">43000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzgtOC0xLTEtOTQ4MzE_90d36e6e-441e-4e3a-ae9c-18cf5c8cb39e"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzgtMTAtMS0xLTk0ODMx_920f1df2-b8d1-4bd9-b521-f16a48da808c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzgtMTItMS0xLTk0ODMx_fc1bb800-f273-4a70-a690-58e6362bf036"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzktMi0xLTEtOTQ4MzE_2ebd6b06-ab99-4ba3-9fe3-565045690019"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzktNC0xLTEtOTQ4MzE_143fc5cd-9e89-4e97-982e-d415ed66d5b5"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzktNi0xLTEtOTQ4MzE_119fa506-ff1b-4651-9065-04dd76461d91"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzktOC0xLTEtOTQ4MzE_d0f0f3e6-06c5-44be-ab40-211ea4814aed"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzktMTAtMS0xLTk0ODMx_60f1c9ce-c9e1-4e4b-8f35-02181ccbb4f0"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzktMTItMS0xLTk0ODMx_233dcd1e-75cb-40ea-ba7c-25ddcd03e3ea"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzEwLTItMS0xLTk0ODMx_013ade28-62e0-480b-b56a-cd79eb8093a1"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzEwLTQtMS0xLTk0ODMx_7349c10b-b693-4647-92c3-229d6796246b"
      unitRef="usd">-17000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzEwLTYtMS0xLTk0ODMx_9c7dbf4c-6e29-442a-a650-ff6c6d7da09e"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzEwLTgtMS0xLTk0ODMx_0964fcad-7cb7-4f8d-a9f4-e205eb389b51"
      unitRef="usd">-13000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzEwLTEwLTEtMS05NDgzMQ_d36cbe6d-e2a0-43e3-8ecb-752495df3935"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzEwLTEyLTEtMS05NDgzMQ_9fca6a33-67a5-40a8-96fd-e71972092ae3"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzExLTItMS0xLTk0ODMx_e91b3cd8-52aa-48e3-aecd-46e0398c60b4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzExLTQtMS0xLTk0ODMx_95fe4209-a7d9-4c3e-98a7-fe4ffc9eeb88"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzExLTYtMS0xLTk0ODMx_153f2e9d-5e29-49f3-b341-b6ecf8f49411"
      unitRef="usd">-18000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzExLTgtMS0xLTk0ODMx_34475cde-4fb9-4cb6-a19d-7899c40ec1ee"
      unitRef="usd">22000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzExLTEwLTEtMS05NDgzMQ_4ad47a59-3320-4e79-b31d-26ca7053640b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzExLTEyLTEtMS05NDgzMQ_eb7e35b1-d4a1-48a4-a9d6-80834f7304e4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzEyLTItMS0xLTk0ODMx_a12e2823-5c44-4829-9317-f9c5367e3100"
      unitRef="usd">220000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i7fe9a8f118334aab8ff6bd90e126b597_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzEyLTQtMS0xLTk0ODMx_69209c55-7fee-4459-83fa-9c847160c5b3"
      unitRef="usd">236000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzEyLTYtMS0xLTk0ODMx_a578ac6a-7ecf-4120-b284-de15d7e71fd6"
      unitRef="usd">228000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="icac9bfd5e8d54c0689a02e2e251a39cd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzEyLTgtMS0xLTk0ODMx_0ec75ba7-4b0d-470b-aa5a-0a8119cdc1cf"
      unitRef="usd">294000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzEyLTEwLTEtMS05NDgzMQ_4941e9fd-f46b-421e-bb8e-1c08239765aa"
      unitRef="usd">35000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="if38262082aca4b1ca51d9de262b48c77_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzEyLTEyLTEtMS05NDgzMQ_f3e035bf-328a-4f75-ab49-dd856494858f"
      unitRef="usd">39000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7fe9a8f118334aab8ff6bd90e126b597_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE1LTItMS0xLTk0ODMx_256f0282-e9a0-4c5a-ad87-4f7953958f8d"
      unitRef="usd">231000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i463e7100cf0447ed909a1b0e9a750265_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE1LTQtMS0xLTk0ODMx_e0634efe-85ea-42c7-82e1-03058df523ff"
      unitRef="usd">216000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icac9bfd5e8d54c0689a02e2e251a39cd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE1LTYtMS0xLTk0ODMx_bdcb4d05-3126-4297-b18f-0d73aee229a1"
      unitRef="usd">189000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i77e60ffa0a7048b3bc6ab71dd3ff10d2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE1LTgtMS0xLTk0ODMx_41bb7314-e2d4-45a4-8878-b94c5f0a4b26"
      unitRef="usd">161000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if38262082aca4b1ca51d9de262b48c77_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE1LTEwLTEtMS05NDgzMQ_e2402ad3-b63b-462e-bfa1-d2ba006995e2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idea50cd734984c47856762240b1f1a02_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE1LTEyLTEtMS05NDgzMQ_9dbefc94-37b1-42fb-935c-cee566157017"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE2LTItMS0xLTk0ODMx_109bbe19-2056-48e8-bb14-53e7ade70d8e"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE2LTQtMS0xLTk0ODMx_c8d72abb-d887-4871-9dc3-ce1976c11ec3"
      unitRef="usd">29000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE2LTYtMS0xLTk0ODMx_2cd563c6-9d69-4a54-aecf-ad2a29c2de59"
      unitRef="usd">18000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE2LTgtMS0xLTk0ODMx_2f510673-f87f-445c-84a9-7d506b483e2b"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE2LTEwLTEtMS05NDgzMQ_5b738b52-b26c-4306-9583-0c86a954c24b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE2LTEyLTEtMS05NDgzMQ_2e987288-3193-49b3-8382-c24ed5f018ef"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE4LTItMS0xLTk0ODMx_8d40e7fb-a061-48bc-ab54-265598f022fd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE4LTQtMS0xLTk0ODMx_99f1dc2b-5f64-4126-b658-1c248d6bdc7f"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE4LTYtMS0xLTk0ODMx_2c2a5ee0-1b79-4edc-8bd7-2c2ea5ac7dec"
      unitRef="usd">28000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE4LTgtMS0xLTk0ODMx_2f9bef7b-3823-40d8-9366-c28ff2884339"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE4LTEwLTEtMS05NDgzMQ_1353a317-19a3-4f1c-95c3-85094db6d534"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE4LTEyLTEtMS05NDgzMQ_ccfdb5b7-33bd-46f1-9e67-dd5b3fdf8495"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE5LTItMS0xLTk0ODMx_b3015e06-489a-4df6-b286-83ca2cb52b63"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE5LTQtMS0xLTk0ODMx_019fd3df-43b7-4e83-be7c-d4d1a006d5b7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE5LTYtMS0xLTk0ODMx_09564187-ff7d-4ab9-abcb-5f573354d84b"
      unitRef="usd">43000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE5LTgtMS0xLTk0ODMx_7cdbf7e3-4896-4fef-9401-3f0c5071de6a"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE5LTEwLTEtMS05NDgzMQ_aaada47f-91d4-4bf6-9b2d-f8b9ef6aa08e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzE5LTEyLTEtMS05NDgzMQ_3dfa5576-0f04-4a4b-87a8-3082239eb6b3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIwLTItMS0xLTk0ODMx_5452d54a-fcb7-4167-8dba-5bed1fb9cf2b"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIwLTQtMS0xLTk0ODMx_07834555-e581-4e1e-8287-63609108e9c8"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIwLTYtMS0xLTk0ODMx_c7221b26-bf55-4893-b5df-3d3bf1c0a9e5"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIwLTgtMS0xLTk0ODMx_1d2e2cd3-f02e-49a1-907e-705506a8da32"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIwLTEwLTEtMS05NDgzMQ_704fa223-61da-4ab0-ba24-77b4f396fc73"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIwLTEyLTEtMS05NDgzMQ_8e96bb9e-7b4e-4a7d-91e6-0be776d966b1"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIxLTItMS0xLTk0ODMx_a7300ae3-ce07-47db-b093-9af2a87e9780"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIxLTQtMS0xLTk0ODMx_7f73339c-de66-4861-b099-733e9e10c05f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIxLTYtMS0xLTk0ODMx_8813416c-3132-4d2e-8fe2-18d6586f8490"
      unitRef="usd">-13000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIxLTgtMS0xLTk0ODMx_e6d79a87-9ae9-4599-9d3d-29ad0ea8c455"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIxLTEwLTEtMS05NDgzMQ_d9b30931-6de0-4d4a-a80c-9dad3e863b73"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIxLTEyLTEtMS05NDgzMQ_e190d9e5-f585-4054-ac84-200912125756"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIyLTItMS0xLTk0ODMx_a25937f3-0145-421f-ab2c-3d548177d6a5"
      unitRef="usd">224000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7fe9a8f118334aab8ff6bd90e126b597_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIyLTQtMS0xLTk0ODMx_b836fcec-7363-473e-9cec-3221d3bc9216"
      unitRef="usd">231000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIyLTYtMS0xLTk0ODMx_3da70e9d-5983-4aff-8e0c-e256885fe031"
      unitRef="usd">175000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icac9bfd5e8d54c0689a02e2e251a39cd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIyLTgtMS0xLTk0ODMx_4d3f4fff-4175-4cf6-a2bd-1d0df4fc4398"
      unitRef="usd">189000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIyLTEwLTEtMS05NDgzMQ_65bad12e-f43b-45f7-a499-e79ad8d50bbd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if38262082aca4b1ca51d9de262b48c77_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIyLTEyLTEtMS05NDgzMQ_661d9d0b-814e-4459-b2bd-7d6c843960b8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIzLTItMS0xLTk0ODMx_2cd85f9f-00eb-4229-89f9-d958f0522f61"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i7fe9a8f118334aab8ff6bd90e126b597_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIzLTQtMS0xLTk0ODMx_20b4f5b2-8ae9-41ff-a765-df283eb78bff"
      unitRef="usd">-5000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIzLTYtMS0xLTk0ODMx_45984456-0495-4774-8404-03ebc37f3790"
      unitRef="usd">-53000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="icac9bfd5e8d54c0689a02e2e251a39cd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIzLTgtMS0xLTk0ODMx_fd41eacd-ed5b-4236-b9d7-17ae0db52263"
      unitRef="usd">-105000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIzLTEwLTEtMS05NDgzMQ_0ba78659-8aad-42e0-b202-fa16a7912361"
      unitRef="usd">-35000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="if38262082aca4b1ca51d9de262b48c77_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzIzLTEyLTEtMS05NDgzMQ_d6997f3e-92b4-43ea-a682-a959ff5ce339"
      unitRef="usd">-39000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent
      contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI2LTItMS0xLTk0ODMx_216e3be7-079a-40bd-ad69-220d7d7ba035"
      unitRef="usd">4000000</bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent>
    <bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent
      contextRef="i7fe9a8f118334aab8ff6bd90e126b597_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI2LTQtMS0xLTk0ODMx_2c4cc346-cfe4-47a7-b6a4-f12540a5816f"
      unitRef="usd">0</bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent>
    <bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent
      contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI2LTYtMS0xLTk0ODMx_01f313a0-3f72-4f78-8f5f-0959a4608255"
      unitRef="usd">0</bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent>
    <bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent
      contextRef="icac9bfd5e8d54c0689a02e2e251a39cd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI2LTgtMS0xLTk0ODMx_52c01acb-2d8e-4270-8346-4b0274a05b6d"
      unitRef="usd">0</bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent>
    <bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent
      contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI2LTEwLTEtMS05NDgzMQ_750d0b9f-24d7-46a0-9e92-aa3cbbb17cdc"
      unitRef="usd">0</bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent>
    <bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent
      contextRef="if38262082aca4b1ca51d9de262b48c77_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI2LTEyLTEtMS05NDgzMQ_9909563d-ecaf-4521-8a52-b2efa64923aa"
      unitRef="usd">0</bhc:PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent>
    <bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities
      contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI3LTItMS0xLTk0ODMx_fb698997-5ec2-4bb5-996e-18d8d32a2e4a"
      unitRef="usd">0</bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities>
    <bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities
      contextRef="i7fe9a8f118334aab8ff6bd90e126b597_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI3LTQtMS0xLTk0ODMx_284788d3-a6e3-486e-9f37-0c8a99daffe7"
      unitRef="usd">0</bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities>
    <bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities
      contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI3LTYtMS0xLTk0ODMx_8a5aa689-35fc-4c79-b6a6-194e1a07885f"
      unitRef="usd">2000000</bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities>
    <bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities
      contextRef="icac9bfd5e8d54c0689a02e2e251a39cd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI3LTgtMS0xLTk0ODMx_7d15d5f6-b962-4626-a71d-9419bd0ac5f6"
      unitRef="usd">2000000</bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities>
    <bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities
      contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI3LTEwLTEtMS05NDgzMQ_350aa1c9-97fa-4156-ab5e-43c9beb29176"
      unitRef="usd">4000000</bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities>
    <bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities
      contextRef="if38262082aca4b1ca51d9de262b48c77_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI3LTEyLTEtMS05NDgzMQ_bfde52d7-f6b4-4880-bd13-7ac80e716e9a"
      unitRef="usd">4000000</bhc:PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent
      contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI4LTItMS0xLTk0ODMx_5e87994e-7bff-42e5-8475-e4124af458c4"
      unitRef="usd">0</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent
      contextRef="i7fe9a8f118334aab8ff6bd90e126b597_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI4LTQtMS0xLTk0ODMx_27305402-6a39-4eaf-a58a-3355edcc3e2b"
      unitRef="usd">5000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent
      contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI4LTYtMS0xLTk0ODMx_cc06e466-8e9b-44d5-b8a6-024b3f69d7f8"
      unitRef="usd">51000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent
      contextRef="icac9bfd5e8d54c0689a02e2e251a39cd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI4LTgtMS0xLTk0ODMx_79f48d35-67b1-44ea-adec-7c602a2d4b41"
      unitRef="usd">103000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent
      contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI4LTEwLTEtMS05NDgzMQ_d111027b-ad84-4c06-9369-1bbe95889878"
      unitRef="usd">31000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent
      contextRef="if38262082aca4b1ca51d9de262b48c77_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkOGViZmMwOGJhN2I0ZGE4ODAzNjY3ZjQ1YTNmYzhjOC90YWJsZXJhbmdlOmQ4ZWJmYzA4YmE3YjRkYTg4MDM2NjdmNDVhM2ZjOGM4XzI4LTEyLTEtMS05NDgzMQ_871c02d3-7769-4f66-8d72-40d06240ba7f"
      unitRef="usd">35000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i9d64985a4d524a32b742dc7857f893e4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzM0OTU_2ce9bc95-9133-47d0-bef9-cc00f349a709"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2Xzk0MTU_78512fbd-8123-4880-894e-d996323ce3cc">Information for the underfunded pension benefit plans is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated benefit obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="i9d64985a4d524a32b742dc7857f893e4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxZGU2OTljZWU5MWM0YzcwODI5NTI3NTVjYzQ5ZTMwYi90YWJsZXJhbmdlOjFkZTY5OWNlZTkxYzRjNzA4Mjk1Mjc1NWNjNDllMzBiXzItMi0xLTEtOTQ4MzE_2cc56b1e-55ab-4bfc-9353-1f9b469eccbf"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="i4a24ca36ef784ec8aca560e12794804b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxZGU2OTljZWU5MWM0YzcwODI5NTI3NTVjYzQ5ZTMwYi90YWJsZXJhbmdlOjFkZTY5OWNlZTkxYzRjNzA4Mjk1Mjc1NWNjNDllMzBiXzItNC0xLTEtOTQ4MzE_de02f972-4c9f-413a-a4f5-9c2b438ce341"
      unitRef="usd">236000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxZGU2OTljZWU5MWM0YzcwODI5NTI3NTVjYzQ5ZTMwYi90YWJsZXJhbmdlOjFkZTY5OWNlZTkxYzRjNzA4Mjk1Mjc1NWNjNDllMzBiXzItNi0xLTEtOTQ4MzE_a578ac6a-7ecf-4120-b284-de15d7e71fd6"
      unitRef="usd">228000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="i56ca37936bae4988b7fe9d7260b0cb9e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxZGU2OTljZWU5MWM0YzcwODI5NTI3NTVjYzQ5ZTMwYi90YWJsZXJhbmdlOjFkZTY5OWNlZTkxYzRjNzA4Mjk1Mjc1NWNjNDllMzBiXzItOC0xLTEtOTQ4MzE_84c06578-2e42-4edf-88ea-fa9fd7872a4a"
      unitRef="usd">294000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i9d64985a4d524a32b742dc7857f893e4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxZGU2OTljZWU5MWM0YzcwODI5NTI3NTVjYzQ5ZTMwYi90YWJsZXJhbmdlOjFkZTY5OWNlZTkxYzRjNzA4Mjk1Mjc1NWNjNDllMzBiXzMtMi0xLTEtOTQ4MzE_df3b2605-31fd-4237-9a82-79be94ce249e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i4a24ca36ef784ec8aca560e12794804b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxZGU2OTljZWU5MWM0YzcwODI5NTI3NTVjYzQ5ZTMwYi90YWJsZXJhbmdlOjFkZTY5OWNlZTkxYzRjNzA4Mjk1Mjc1NWNjNDllMzBiXzMtNC0xLTEtOTQ4MzE_1816c029-b53d-42de-ada0-c0e1a56c82b3"
      unitRef="usd">236000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i72013f8a77a84d8ab1b6625f3d57d1a7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxZGU2OTljZWU5MWM0YzcwODI5NTI3NTVjYzQ5ZTMwYi90YWJsZXJhbmdlOjFkZTY5OWNlZTkxYzRjNzA4Mjk1Mjc1NWNjNDllMzBiXzMtNi0xLTEtOTQ4MzE_6015b639-2080-426e-a3f9-bfae228e87a5"
      unitRef="usd">219000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i56ca37936bae4988b7fe9d7260b0cb9e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxZGU2OTljZWU5MWM0YzcwODI5NTI3NTVjYzQ5ZTMwYi90YWJsZXJhbmdlOjFkZTY5OWNlZTkxYzRjNzA4Mjk1Mjc1NWNjNDllMzBiXzMtOC0xLTEtOTQ4MzE_ac2c8ec6-bff7-456a-8f32-e507764c2cd3"
      unitRef="usd">286000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i9d64985a4d524a32b742dc7857f893e4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxZGU2OTljZWU5MWM0YzcwODI5NTI3NTVjYzQ5ZTMwYi90YWJsZXJhbmdlOjFkZTY5OWNlZTkxYzRjNzA4Mjk1Mjc1NWNjNDllMzBiXzQtMi0xLTEtOTQ4MzE_181e68d9-1478-49f3-8e78-5672c4fd7127"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i4a24ca36ef784ec8aca560e12794804b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxZGU2OTljZWU5MWM0YzcwODI5NTI3NTVjYzQ5ZTMwYi90YWJsZXJhbmdlOjFkZTY5OWNlZTkxYzRjNzA4Mjk1Mjc1NWNjNDllMzBiXzQtNC0xLTEtOTQ4MzE_5b26824e-5580-41a1-80b9-1f0d2208ca1b"
      unitRef="usd">231000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxZGU2OTljZWU5MWM0YzcwODI5NTI3NTVjYzQ5ZTMwYi90YWJsZXJhbmdlOjFkZTY5OWNlZTkxYzRjNzA4Mjk1Mjc1NWNjNDllMzBiXzQtNi0xLTEtOTQ4MzE_3da70e9d-5983-4aff-8e0c-e256885fe031"
      unitRef="usd">175000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i56ca37936bae4988b7fe9d7260b0cb9e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToxZGU2OTljZWU5MWM0YzcwODI5NTI3NTVjYzQ5ZTMwYi90YWJsZXJhbmdlOjFkZTY5OWNlZTkxYzRjNzA4Mjk1Mjc1NWNjNDllMzBiXzQtOC0xLTEtOTQ4MzE_16802146-055c-4489-bd1b-bcccd358a160"
      unitRef="usd">189000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzQwMzE_c1c11ebe-24a1-49f6-85e7-8b7506f5231a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzQwMzU_5f496e86-97d3-43bb-9b44-8368d3fe2e7d"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzQwNDI_9202ec5d-aab9-4ae7-b0d1-f213ac8fe65f"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2Xzk0MTc_27d1d2ab-fd43-44d4-aae9-3c0aa922ff6b">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future benefit payments over the next 10 years for the pension benefit plans and the postretirement benefit plan, which reflect expected future service, as appropriate, are expected to be paid as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.337%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.337%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement&lt;br/&gt;&#160;Benefit&lt;br/&gt;&#160;Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027-2031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock>
    <bhc:DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzQ0MDM_8580cfa8-68d7-4a30-9952-8d4b813ce650">P10Y</bhc:DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzItMi0xLTEtOTQ4MzE_2e065094-2b1a-4473-8c20-d6664088b652"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzItNC0xLTEtOTQ4MzE_434aca7c-c37f-474a-8ff0-bfa19bf9c23f"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzItNi0xLTEtOTQ4MzE_473a1a71-5819-47d0-a7bf-adc2ba5ab237"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzMtMi0xLTEtOTQ4MzE_7fb41768-8c5e-4b79-a5ea-11f56711d279"
      unitRef="usd">19000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzMtNC0xLTEtOTQ4MzE_fb2935c3-4b11-4389-bcee-da7730b19b84"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzMtNi0xLTEtOTQ4MzE_e39aba81-0763-47fe-b65c-9b24e607ae09"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzQtMi0xLTEtOTQ4MzE_d0915a60-f9ad-4ace-99f4-e94268b11499"
      unitRef="usd">17000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzQtNC0xLTEtOTQ4MzE_39fe23ec-d032-46bf-9538-78b3564f5708"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzQtNi0xLTEtOTQ4MzE_ab1cebf1-830f-4410-b7d1-945241db7c85"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzUtMi0xLTEtOTQ4MzE_66ab520d-cde2-4449-8248-f06ba150c3b2"
      unitRef="usd">17000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzUtNC0xLTEtOTQ4MzE_74cd438e-bc59-4677-bc0f-ef961f485298"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzUtNi0xLTEtOTQ4MzE_044f3cf7-1187-412b-bb96-716c9419bbb7"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzYtMi0xLTEtOTQ4MzE_bcf518fe-0315-4643-a2b6-b8233593701b"
      unitRef="usd">16000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzYtNC0xLTEtOTQ4MzE_3d0d33aa-8560-46a4-b344-f052539d45ec"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzYtNi0xLTEtOTQ4MzE_2d7fd0e1-f57a-4b81-90c5-4a8ce360ab0f"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzctMi0xLTEtOTQ4MzE_86d81549-69a4-4bbd-9042-f88bbe6863be"
      unitRef="usd">73000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzctNC0xLTEtOTQ4MzE_805f2075-d0d5-4898-816b-f4e90f269382"
      unitRef="usd">42000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZToyZTMzMWZkNzBhYTk0MmQ4YWNiYjVhYmEzNDFhNWQwNC90YWJsZXJhbmdlOjJlMzMxZmQ3MGFhOTQyZDhhY2JiNWFiYTM0MWE1ZDA0XzctNi0xLTEtOTQ4MzE_a277af45-fef8-4da4-bb5d-e05a521b519d"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2Xzk0MTg_01fd3f9b-fdf2-403e-86e2-aaf5757072ed">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used to determine net periodic benefit costs and benefit obligations for 2021, 2020 and 2019 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.192%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.423%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;For Determining Net Periodic (Benefit) Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Plans:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-U.S. Plans:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.197%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.073%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Postretirement Benefit Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;For Determining Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Plans:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-U.S. Plans:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rate of compensation increase&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest crediting rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzQtMi0xLTEtOTQ4MzE_db05aa52-f1f1-415f-8559-b0afb2cd5867"
      unitRef="number">0.0225</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzQtNC0xLTEtOTQ4MzE_3d016d4c-4e3d-4a03-a3b4-9fd6c8dd57ff"
      unitRef="number">0.0316</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="ie5d47857632948b3953696f970672168_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzQtNi0xLTEtOTQ4MzE_1641a2e4-54b2-42bf-be43-195cdfca3ec4"
      unitRef="number">0.0425</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzQtOC0xLTEtOTQ4MzE_0a982eeb-d4cb-4268-916e-1f565d5ec0d8"
      unitRef="number">0.0209</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzQtMTAtMS0xLTk0ODMx_f9709a36-6452-4fae-8800-da437398b128"
      unitRef="number">0.0304</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i75033e6771e2462a948d8f02b08289cd_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzQtMTItMS0xLTk0ODMx_513b667a-8e2f-4652-af14-f916929cf161"
      unitRef="number">0.0416</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzUtMi0xLTEtOTQ4MzE_1d8bb7c0-20bf-4dd4-8b60-06e2e2e71020"
      unitRef="number">0.0500</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzUtNC0xLTEtOTQ4MzE_758a4bd7-f9c9-41dd-a203-309eed93df03"
      unitRef="number">0.0625</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="ie5d47857632948b3953696f970672168_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzUtNi0xLTEtOTQ4MzE_e7e4ac48-214c-4132-8000-c1d5feba8185"
      unitRef="number">0.0725</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzUtOC0xLTEtOTQ4MzE_f9298377-3dcf-4f38-89fe-cd7852a25a0b"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzUtMTAtMS0xLTk0ODMx_5ed04096-0bd7-45c8-ad0f-380a0c9b7042"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i75033e6771e2462a948d8f02b08289cd_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzUtMTItMS0xLTk0ODMx_cb99388c-6de0-4373-a939-e29f8cf2c34b"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzYtMi0xLTEtOTQ4MzE_989dac3a-e7a7-4cd5-9a35-7535ffd43176"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzYtNC0xLTEtOTQ4MzE_4e280dac-607f-45fb-b0e0-88ba3c2430e2"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="ie5d47857632948b3953696f970672168_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzYtNi0xLTEtOTQ4MzE_0b53fb91-020a-44de-872c-085d678b66ee"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i35e34787aea44b2c84b3316d8752b209_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzYtOC0xLTEtOTQ4MzE_b4dcc522-56b2-4f32-b70b-0da06de2f641"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i1b89847b8a7448c58984a5ac74bb239e_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzYtMTAtMS0xLTk0ODMx_3ef62917-c0a9-402e-809e-96da2f8041bb"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i75033e6771e2462a948d8f02b08289cd_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzYtMTItMS0xLTk0ODMx_36476697-94fd-4136-91a6-eeed78b02149"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzctMi0xLTEtOTQ4MzE_4b6beb85-69f6-415e-b546-1cbbbbaec1aa"
      unitRef="number">0.0475</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="if6a73441ba534c4aac153b012771c389_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzctNC0xLTEtOTQ4MzE_f5b6439a-257b-48b1-8ccd-e388ff13d3ee"
      unitRef="number">0.0475</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="ie5d47857632948b3953696f970672168_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzctNi0xLTEtOTQ4MzE_34208d6a-c5ec-4c08-853a-4317cc4534da"
      unitRef="number">0.0500</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzktMi0xLTEtOTQ4MzE_0e07aa89-6bc3-4ef9-a0d4-622c6e5742f3"
      unitRef="number">0.0137</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzktNC0xLTEtOTQ4MzE_aab695dc-9a6b-452b-8b87-01bd3ed66599"
      unitRef="number">0.0168</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i60dd7747d8e84735ad54cdac6b306397_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzktNi0xLTEtOTQ4MzE_64fae372-8de5-4021-aa65-255df1c5cab4"
      unitRef="number">0.0239</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzEwLTItMS0xLTk0ODMx_68cac582-103c-471f-afba-c0d03a1d8763"
      unitRef="number">0.0274</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzEwLTQtMS0xLTk0ODMx_8e9a2d24-3868-427c-bd45-1ef7afa8fa1f"
      unitRef="number">0.0298</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i60dd7747d8e84735ad54cdac6b306397_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzEwLTYtMS0xLTk0ODMx_42b4fd5e-7dec-4db7-92e8-a2ea27b7e119"
      unitRef="number">0.0346</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzExLTItMS0xLTk0ODMx_d05ad309-eea9-4110-82a7-6b33c19fa25d"
      unitRef="number">0.0260</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzExLTQtMS0xLTk0ODMx_b1fb640f-b5e4-418e-a408-665df1f0ce07"
      unitRef="number">0.0305</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i60dd7747d8e84735ad54cdac6b306397_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzExLTYtMS0xLTk0ODMx_ce9b3d8c-1464-43da-8596-a4320426e9bc"
      unitRef="number">0.0289</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="i9b7fae28641143098c895dc923ecf268_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzEyLTItMS0xLTk0ODMx_84f83602-bf31-44fb-971e-b033464717e7"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="ib4b5263a88f44844907d9c12e8c85064_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzEyLTQtMS0xLTk0ODMx_a03a67e0-3358-4965-af81-bc5767ddb480"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate
      contextRef="i60dd7747d8e84735ad54cdac6b306397_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTozYzk4ZGI5YmY4N2Y0ZjM4ODU3ZTA4MWEzNzE0OGNjNS90YWJsZXJhbmdlOjNjOThkYjliZjg3ZjRmMzg4NTdlMDgxYTM3MTQ4Y2M1XzEyLTYtMS0xLTk0ODMx_7da361b8-f7ae-47eb-af3e-9da6741b83eb"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzUtMi0xLTEtOTQ4MzE_e1dce046-0c8e-4e4d-b742-a314e7dd04a5"
      unitRef="number">0.0269</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i7fe9a8f118334aab8ff6bd90e126b597_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzUtNC0xLTEtOTQ4MzE_053ae44e-ec19-4bc9-9f07-a9de54d39320"
      unitRef="number">0.0225</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzUtNi0xLTEtOTQ4MzE_bd53900d-13ae-4b2d-b144-f8ca7ac7a221"
      unitRef="number">0.0257</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="if38262082aca4b1ca51d9de262b48c77_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzUtOC0xLTEtOTQ4MzE_8dc686f5-5aeb-440c-b654-ab5343ddf816"
      unitRef="number">0.0209</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzYtMi0xLTEtOTQ4MzE_ea4a4fea-dc5e-40e5-9120-5d836d37a445"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i7fe9a8f118334aab8ff6bd90e126b597_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzYtNC0xLTEtOTQ4MzE_9c66cc61-9308-4ada-82f6-f1ece91bc7fd"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="ic8813f768a6d40a090aaffec2d906007_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzYtNi0xLTEtOTQ4MzE_63b1bd76-5fb3-4cbf-8097-cdd4f4fcc367"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="if38262082aca4b1ca51d9de262b48c77_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzYtOC0xLTEtOTQ4MzE_c57a5724-a73b-4884-a133-7d89cfe1dc48"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="ibb7c373f0d534f23860c5b73ad7fc6df_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzctMi0xLTEtOTQ4MzE_b7953aaf-1f5d-4904-9577-21669eaef917"
      unitRef="number">0.0475</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="i7fe9a8f118334aab8ff6bd90e126b597_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzctNC0xLTEtOTQ4MzE_00cba627-d840-4efe-8dd1-451880b711e8"
      unitRef="number">0.0475</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzktMi0xLTEtOTQ4MzE_16e89c1a-d689-403b-84b9-4f3cdfd6c9d5"
      unitRef="number">0.0172</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="icac9bfd5e8d54c0689a02e2e251a39cd_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzktNC0xLTEtOTQ4MzE_a2fd86f7-7fce-4602-ac96-0aa824012ad4"
      unitRef="number">0.0137</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzEwLTItMS0xLTk0ODMx_1b672fe8-805a-4b64-8894-a08dcac7a28c"
      unitRef="number">0.0263</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="icac9bfd5e8d54c0689a02e2e251a39cd_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzEwLTQtMS0xLTk0ODMx_e1324ee8-5043-4c9c-8a8b-20dcfbc4597e"
      unitRef="number">0.0260</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="i14b494ef22db47cbaaccc4668e7c1b84_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzExLTItMS0xLTk0ODMx_bc4b4c92-f713-4d2f-bdd7-8cfd744fd254"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate
      contextRef="icac9bfd5e8d54c0689a02e2e251a39cd_I20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkNTY1NTkwNjE5NTU0MTE4YjlkMWZiNzcwODhiYTVmOC90YWJsZXJhbmdlOmQ1NjU1OTA2MTk1NTQxMThiOWQxZmI3NzA4OGJhNWY4XzExLTQtMS0xLTk0ODMx_fc406ff4-b481-48df-938b-7c024ed53a9e"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzU0OTI_1d8bb7c0-20bf-4dd4-8b60-06e2e2e71020"
      unitRef="number">0.0500</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i180a6063ed294b858f6f1b7f8889f355_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzU1NzU_0f8af5df-54f6-4c67-886a-9e8e66c47a6a"
      unitRef="number">0.0275</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="if9fef24732ce40f1b0ecd84c613bcf34_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzU4Nzg_2da0aad5-919d-4e36-a7f0-c75a945db4e5"
      unitRef="number">0.0450</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i9ed8db4899e1486f9838d297668a6b15_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzU5NTk_4a433342-0574-41d2-81af-5d2359e88a23"
      unitRef="number">0.0275</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2Xzk0MDg_22cc0734-c820-4686-8c5d-50ec959f584e">The following presents the actual asset allocation as of December 31, 2021 and 2020:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:77.048%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.066%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fixed income securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fixed income securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i75d6d22fe7ca49c89901fff21f7ad775_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTo2MzFiZjA1NmIyOTk0NDNjOTAyMDI0NTQxYmJlMmEwZC90YWJsZXJhbmdlOjYzMWJmMDU2YjI5OTQ0M2M5MDIwMjQ1NDFiYmUyYTBkXzItMi0xLTEtOTQ4MzE_00a1045d-ff04-417f-8605-cda73eb8164f"
      unitRef="number">0.01</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i69b3efe62ce6415a85977af860ad298b_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTo2MzFiZjA1NmIyOTk0NDNjOTAyMDI0NTQxYmJlMmEwZC90YWJsZXJhbmdlOjYzMWJmMDU2YjI5OTQ0M2M5MDIwMjQ1NDFiYmUyYTBkXzItNC0xLTEtOTQ4MzE_f5239707-0874-4240-9ec3-5ae3e9acb44f"
      unitRef="number">0.01</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i8c0ee6030b5c47b0a466a9c0070795c1_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTo2MzFiZjA1NmIyOTk0NDNjOTAyMDI0NTQxYmJlMmEwZC90YWJsZXJhbmdlOjYzMWJmMDU2YjI5OTQ0M2M5MDIwMjQ1NDFiYmUyYTBkXzMtMi0xLTEtOTQ4MzE_7397c4f5-446b-4385-ab95-ff52b5126173"
      unitRef="number">0.30</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="id92890a272ad4d899e7c6ca96512a97e_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTo2MzFiZjA1NmIyOTk0NDNjOTAyMDI0NTQxYmJlMmEwZC90YWJsZXJhbmdlOjYzMWJmMDU2YjI5OTQ0M2M5MDIwMjQ1NDFiYmUyYTBkXzMtNC0xLTEtOTQ4MzE_44b1a67a-f9d6-4131-a352-8860091635fc"
      unitRef="number">0.39</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i149842c6f40f4c6b98cbccfc257a922e_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTo2MzFiZjA1NmIyOTk0NDNjOTAyMDI0NTQxYmJlMmEwZC90YWJsZXJhbmdlOjYzMWJmMDU2YjI5OTQ0M2M5MDIwMjQ1NDFiYmUyYTBkXzQtMi0xLTEtOTQ4MzE_6bdcbf70-c75f-4536-853d-560ce3a16bcb"
      unitRef="number">0.69</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i564973e386674c78ba408d13105b6bb9_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTo2MzFiZjA1NmIyOTk0NDNjOTAyMDI0NTQxYmJlMmEwZC90YWJsZXJhbmdlOjYzMWJmMDU2YjI5OTQ0M2M5MDIwMjQ1NDFiYmUyYTBkXzQtNC0xLTEtOTQ4MzE_c5803675-4b21-4fb1-9d28-297ed8de7135"
      unitRef="number">0.60</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="ia227b3e9ab7d47569890495351afa79e_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTo2MzFiZjA1NmIyOTk0NDNjOTAyMDI0NTQxYmJlMmEwZC90YWJsZXJhbmdlOjYzMWJmMDU2YjI5OTQ0M2M5MDIwMjQ1NDFiYmUyYTBkXzYtMi0xLTEtOTQ4MzE_7b33db5b-49c8-48ed-9add-20ac370924e4"
      unitRef="number">0.09</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="iba0dcccaa1ae4b01bba40ab426ba276d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTo2MzFiZjA1NmIyOTk0NDNjOTAyMDI0NTQxYmJlMmEwZC90YWJsZXJhbmdlOjYzMWJmMDU2YjI5OTQ0M2M5MDIwMjQ1NDFiYmUyYTBkXzYtNC0xLTEtOTQ4MzE_1cefa379-35d7-4902-823c-8071ba8560b4"
      unitRef="number">0.03</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i1fd2da8ac3ce4d44bbccc6dac3b7d322_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTo2MzFiZjA1NmIyOTk0NDNjOTAyMDI0NTQxYmJlMmEwZC90YWJsZXJhbmdlOjYzMWJmMDU2YjI5OTQ0M2M5MDIwMjQ1NDFiYmUyYTBkXzctMi0xLTEtOTQ4MzE_ffd7f5fc-92aa-4690-8ce9-70ace45b3751"
      unitRef="number">0.31</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="ib00d5eeb7e7c4827bda09db46a2b4b1d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTo2MzFiZjA1NmIyOTk0NDNjOTAyMDI0NTQxYmJlMmEwZC90YWJsZXJhbmdlOjYzMWJmMDU2YjI5OTQ0M2M5MDIwMjQ1NDFiYmUyYTBkXzctNC0xLTEtOTQ4MzE_bfe28f9a-e4c9-457f-8acb-31814c889c11"
      unitRef="number">0.28</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i36fefdbf2cff4913b1f038b13bc2cb55_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTo2MzFiZjA1NmIyOTk0NDNjOTAyMDI0NTQxYmJlMmEwZC90YWJsZXJhbmdlOjYzMWJmMDU2YjI5OTQ0M2M5MDIwMjQ1NDFiYmUyYTBkXzgtMi0xLTEtOTQ4MzE_48039839-d48c-4d29-a294-107537ef262b"
      unitRef="number">0.39</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="id521934ae5cd453d9101134d84a1626d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTo2MzFiZjA1NmIyOTk0NDNjOTAyMDI0NTQxYmJlMmEwZC90YWJsZXJhbmdlOjYzMWJmMDU2YjI5OTQ0M2M5MDIwMjQ1NDFiYmUyYTBkXzgtNC0xLTEtOTQ4MzE_a5f42b09-317f-499f-a8c8-81a15b779bef"
      unitRef="number">0.58</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="ie612fd61a6d44af9a15649aaa2d9324a_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTo2MzFiZjA1NmIyOTk0NDNjOTAyMDI0NTQxYmJlMmEwZC90YWJsZXJhbmdlOjYzMWJmMDU2YjI5OTQ0M2M5MDIwMjQ1NDFiYmUyYTBkXzktMi0xLTEtOTQ4MzE_c728c794-3234-43ba-90db-fb6e0d5f3952"
      unitRef="number">0.21</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i8bc3ec72daa042338987d5ace9cc9c8d_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTo2MzFiZjA1NmIyOTk0NDNjOTAyMDI0NTQxYmJlMmEwZC90YWJsZXJhbmdlOjYzMWJmMDU2YjI5OTQ0M2M5MDIwMjQ1NDFiYmUyYTBkXzktNC0xLTEtOTQ4MzE_f7055487-1df9-43e4-bf0f-0f03dc1395fc"
      unitRef="number">0.11</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <bhc:ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2Xzk0MjQ_ee56a2dc-3436-4743-ad56-9735858c970d">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents total plan assets by investment category as of December 31, 2021 and 2020 and the classification of each investment category within the fair value hierarchy with respect to the inputs used to measure fair value. There were no transfers between Level 1 and Level 2 during 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.233%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans - U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commingled funds:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. broad market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment grade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="45" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pension Benefit Plans - Non-U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commingled funds:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Emerging markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide developed markets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed income securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment grade&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Global high yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government bond funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bhc:ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i508b730bcd0045f397f719f04005991d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzMtMi0xLTEtOTQ4MzE_b566e599-1bf1-48d8-8789-3cdb1f828c17"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6e4425ac2c7e4b668baf3cbbb7ae8f68_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzMtNC0xLTEtOTQ4MzE_314a84a2-b4a5-49c9-a9c2-41bd7624d45d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i89055898a93c470ba50888d0e49f6b0d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzMtNi0xLTEtOTQ4MzE_7d9ee1c8-8d0e-4d96-9492-82241e601d37"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id8ab04904aed47918dfa94bfb170c6d0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzMtOC0xLTEtOTQ4MzE_aaad0104-895c-416e-ab80-c86809c63956"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia2650274c9924895bc8990f8ebdac630_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzMtMTAtMS0xLTk0ODMx_c83a6511-7254-4f94-b7bf-f525b38d2a0b"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i06afb70ae6a84cb4ba00bb19a81c46b5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzMtMTItMS0xLTk0ODMx_7738af3c-65bd-4159-8a4b-cb5b038e5562"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i719bfb4f085d4c0687d6a46f624c525d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzMtMTQtMS0xLTk0ODMx_92996633-2175-4b3c-bd2b-6380973cd818"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i66914e16e0af429cbb73c75ef6994478_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzMtMTYtMS0xLTk0ODMx_c1ec0308-b6dd-448d-950d-9c0744bf7930"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i37752c8772ad4c29a5c583152fb1b1b2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzYtMi0xLTEtOTQ4MzE_9cc289f2-c8d4-4c62-bf90-49dfee91df2c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6c903c7579724e20ba48c46c10b81489_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzYtNC0xLTEtOTQ4MzE_9723fe4a-1ee8-415b-a35d-d66e6bd3c2f5"
      unitRef="usd">36000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i89938cca48aa4028b0c54c7484178623_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzYtNi0xLTEtOTQ4MzE_e1d2e245-8979-4bc6-b5a7-6ca11b52c275"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i93955a18cd3641cdb2827cd853fc1b10_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzYtOC0xLTEtOTQ4MzE_d8704c4a-d161-4901-b08b-6c4fbefe6f6d"
      unitRef="usd">36000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifa2bba98ed41466c8eba7b037cea18ab_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzYtMTAtMS0xLTk0ODMx_2e2bf84c-cff0-4e80-bace-1f7458f9b80e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2a9940f2b3284c0aa162120bf8b40dfe_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzYtMTItMS0xLTk0ODMx_7858fb32-0215-4fbd-a136-d61d8f3aaf29"
      unitRef="usd">48000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5229d9d0142d45cdb60d7849d3a88d6e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzYtMTQtMS0xLTk0ODMx_6651767f-cc93-4648-bf37-dfd6963e109e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia3c37ec3412c46a4893efcd62fe0f8fb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzYtMTYtMS0xLTk0ODMx_ffd751f5-d49d-4867-b17f-110a9fe4d03e"
      unitRef="usd">48000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2c6eb4a0a10d45f7a7eac6ac330e192a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzctMi0xLTEtOTQ4MzE_f191c56e-8b1a-4447-8353-ff6bd5ce6029"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5ada422ea708495daf471908c27e5f60_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzctNC0xLTEtOTQ4MzE_10b8d940-6e2b-4e7b-a5a8-fcf379dd9607"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9ea389b2765d4a4fafbd53999a35bb35_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzctNi0xLTEtOTQ4MzE_3d250f76-e9e1-4087-8964-ae061191985f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i74064a651ca64c52b9baa2296bd46b02_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzctOC0xLTEtOTQ4MzE_57391942-cc98-407c-8da0-78c7f846f879"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ieac386533ed94ed9a1fef188636cdbb6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzctMTAtMS0xLTk0ODMx_d55d8d10-d817-4f9b-a310-2f06badebfba"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1ea8ab4572664d2591c8cb715411dd99_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzctMTItMS0xLTk0ODMx_dc6a9958-cd4f-47f0-9680-1dcfb383ea9b"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9bdce432423c43a8a10a88bf483dc5c8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzctMTQtMS0xLTk0ODMx_db516e71-4200-41fe-9950-9738eb5e68a2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4956f9b1dfe045249f6c89ed5e3c029e_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzctMTYtMS0xLTk0ODMx_83e95fa0-f991-4c0e-8dc4-948da377200a"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iab7cb7f147434baa9c2c29c45db60a33_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzgtMi0xLTEtOTQ4MzE_0c4f4900-5434-4c4c-94c5-f5fbe346c76b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i924b51a174a64385823aa357a0e7d2d6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzgtNC0xLTEtOTQ4MzE_a629db5f-8af0-4c28-9e83-6aa6ee4b2b3e"
      unitRef="usd">16000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i86b804a160e24122a58d7bdb3e3fbf73_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzgtNi0xLTEtOTQ4MzE_36feeb1a-6a81-4cb7-849f-829c8e1c9133"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ife79e98052444bd79079d82129a7420a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzgtOC0xLTEtOTQ4MzE_17299f8b-90a5-4a1c-83e3-b7dc09343da8"
      unitRef="usd">16000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4826dfe3433b4c8db9be32ccbebd4288_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzgtMTAtMS0xLTk0ODMx_cb91605f-36c3-48dd-83f1-9300cee4a61e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i32bbe248bdd14f98b8a37a069861c416_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzgtMTItMS0xLTk0ODMx_90f32a46-ac7a-4b43-98c3-6be1384f1abe"
      unitRef="usd">20000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ica87f2077d3b4d10a04094762892a8b9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzgtMTQtMS0xLTk0ODMx_5fb8747a-ff8e-49ce-8210-a8f80685dfd1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ica23a5188b6f4261abc044904c51cb8b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzgtMTYtMS0xLTk0ODMx_016867cc-c359-4d2d-9fd7-3736eb0c8e77"
      unitRef="usd">20000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1a607fbcafdf4f8f9686e30cf1341551_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzktMi0xLTEtOTQ4MzE_90c6d8a9-6d39-4365-b9bd-05d61a626f60"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i485c30c6aa2a43eab8ca4aca9b70a7d6_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzktNC0xLTEtOTQ4MzE_d30a4167-1ccf-4e7f-b892-4ca134ec6a12"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie2fe2902fe4c41e5a9916ee6a7bd0a90_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzktNi0xLTEtOTQ4MzE_50b52736-47b1-41d6-9090-3daac70c6d3b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9547b54812bf44caaa56e89c1c450612_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzktOC0xLTEtOTQ4MzE_2b3af8df-4613-4d17-90a9-ea4650f65457"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i23a29524779046dbb6c442615652d8ec_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzktMTAtMS0xLTk0ODMx_2b3719b9-d511-48eb-b96e-b087d9311e43"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i734a347aebdf40829771a9719601c1a2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzktMTItMS0xLTk0ODMx_c48d6720-9003-476a-b2bd-e7fc3bd2b949"
      unitRef="usd">14000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7b1173f2365141c1815363160c16b76b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzktMTQtMS0xLTk0ODMx_376a6ecb-e067-4c92-a68c-19b9ff7c3e72"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i26f1f9b48f334ed1a02e13e365598828_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzktMTYtMS0xLTk0ODMx_9aed5523-b479-4a9e-9f0c-e57ee81ed502"
      unitRef="usd">14000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifae30c4aff3d4a04be56aae506f89f0f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzExLTItMS0xLTk0ODMx_ce0ae7d5-a594-4c93-bdbb-7786b8a8119e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idbf7a924becb4619aca1895ebcae9add_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzExLTQtMS0xLTk0ODMx_61358a54-a89e-415a-8a2c-16e942519409"
      unitRef="usd">155000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib1912d789a0c46d991c0a3481ca5f6a1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzExLTYtMS0xLTk0ODMx_0687caef-399f-4e4b-a822-a1634a51cedf"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i52de4cf8c1b0450fad0734be23582658_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzExLTgtMS0xLTk0ODMx_56f04e6c-ff17-4e60-92bd-d9fe63635d05"
      unitRef="usd">155000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i573fd8e898604de1858ab39ea3a2f4dd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzExLTEwLTEtMS05NDgzMQ_461758fb-38aa-4a46-a740-e546de736cfc"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iac7f5ab099cd40b592114ecfb3acc77b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzExLTEyLTEtMS05NDgzMQ_64047ad8-bd4c-4ac2-af94-2f13638cfc17"
      unitRef="usd">138000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iac4d46a037ab47089459af1054a64149_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzExLTE0LTEtMS05NDgzMQ_31dc704d-0b96-40fe-83e9-8e7c89e151ae"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i26d6737e6a7a4e638bdb45c231ed9fd5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzExLTE2LTEtMS05NDgzMQ_d2506fe2-721c-44ca-938c-b052379c3744"
      unitRef="usd">138000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i41d69b7357c9455081525dab7d356749_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzEyLTItMS0xLTk0ODMx_4fd2e646-5de6-46ba-9003-f66e44336937"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i64de5046767046de88a2974a3167af0f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzEyLTQtMS0xLTk0ODMx_ec0380ae-4bbe-469d-8a90-28968f2e8eca"
      unitRef="usd">223000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iee2f17c2a4204c139a5cb4c3ea8be354_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzEyLTYtMS0xLTk0ODMx_f7396cbc-92f4-45bf-933e-42d2ca8a07ee"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idd8d218140314ef584532f8f6d286341_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzEyLTgtMS0xLTk0ODMx_12eda5bb-cabc-4a61-b330-2741cf013a0f"
      unitRef="usd">224000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i235dff73cd944ced95f474c54f791c38_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzEyLTEwLTEtMS05NDgzMQ_77a68ddd-9166-4ddf-8b80-a2cd648758bd"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1613dfe248574162a0b44c0c9a6b5c54_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzEyLTEyLTEtMS05NDgzMQ_c386bea9-1605-49ef-b80f-80f1f45b9122"
      unitRef="usd">229000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9b79635c2ffe49ca916192dec4f287c6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzEyLTE0LTEtMS05NDgzMQ_4eaa2da4-95f3-4d8f-bedc-56abf74bb02e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib51448370c174e5ca94ba98d05fc89d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpkN2ZkNTViZGU2ZDg0NmQzYjljNWU5ZmQzZTc5MGU3OC90YWJsZXJhbmdlOmQ3ZmQ1NWJkZTZkODQ2ZDNiOWM1ZTlmZDNlNzkwZTc4XzEyLTE2LTEtMS05NDgzMQ_cea2ab62-9ca0-4808-afe8-c56733377664"
      unitRef="usd">231000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iac7d05a36d0e406b93de498c08fff242_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzMtMi0xLTEtOTQ4MzE_df41d189-be7c-46f8-afcf-5bb25b10381d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if5829e60e9724608908829f25ab1d7d2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzMtNC0xLTEtOTQ4MzE_d556c09a-267e-46c2-a22d-3f7931cc2061"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8d0c98de7cf64efd96dfbe09aeb5ee81_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzMtNi0xLTEtOTQ4MzE_087c4c7f-fe54-400e-92c8-b278628c6cc5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i32e3ecbd002a4e80a35abbbbdc4463e7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzMtOC0xLTEtOTQ4MzE_caf99ed6-7a03-4473-b0df-f687478fbc6c"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i90565c4f71694e28b3ea6de13e2a5891_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzMtMTAtMS0xLTk0ODMx_fd784408-56b3-4ff9-9422-9af29e3891af"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie31761652b084de784cd258f75f2ab5c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzMtMTItMS0xLTk0ODMx_f0650695-5dce-4958-9b52-870633f7c04f"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie5dbb70148a946ea9172055a4c675214_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzMtMTQtMS0xLTk0ODMx_df192321-01b0-4fa1-97fb-8a1c8d95ba03"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id2b24c259bf14e85a565ed910de3fe12_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzMtMTYtMS0xLTk0ODMx_126d4ad3-0d5d-4006-93d8-edf6e32637b7"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i848b70ed1bbc4567bfd96cad2f56686b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzYtMi0xLTEtOTQ4MzE_48901672-5036-4100-baa3-748507d2eadc"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i80d8aa205290445f8909c5d756177c51_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzYtNC0xLTEtOTQ4MzE_482126bf-2403-4144-84ee-bba82f78bdf3"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia47563e74c594e7b94af08bf1c408bfa_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzYtNi0xLTEtOTQ4MzE_10b01292-59d2-40b7-979f-47adb0925df4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifd5049ff38de4a8c965af08e2994ca04_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzYtOC0xLTEtOTQ4MzE_d91c656f-a7aa-4082-ad77-6986bd45f76d"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifd8ab02c4da8460891761a7202ea7fbb_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzYtMTAtMS0xLTk0ODMx_5eff9612-cb89-42d0-a5b8-3fb51c7154ee"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iccd41ef2d6e64a15b9d909ae1d8e22fd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzYtMTItMS0xLTk0ODMx_414b2dca-e396-4b68-8bc2-e61ebc2e2700"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i96121b9d867041058111f2cfd46930a1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzYtMTQtMS0xLTk0ODMx_d6823d18-a098-4467-afb3-a0d5f5aaba86"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1798ff527d09475a9e91083ed73cef87_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzYtMTYtMS0xLTk0ODMx_fed96d14-d3d2-4861-850c-e9db845ba45b"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iac0b4c1d18854f90b18c3b8d1b65c5d1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzctMi0xLTEtOTQ4MzE_ef02473b-e2a2-4edc-b333-dc646c865792"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i341cd2bb05814777ac5eb1149ac11deb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzctNC0xLTEtOTQ4MzE_67c67421-b901-4ca4-991b-6f2f6b1c7d51"
      unitRef="usd">51000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3a3d63af67894f27abf02eb5401cbe40_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzctNi0xLTEtOTQ4MzE_e9cf23b3-13c6-4ff3-9723-1a2ce1651ad6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id1498ce58934451fa75a98f7dcbb17dd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzctOC0xLTEtOTQ4MzE_f160c152-3520-41ec-ba21-7531fdc236e0"
      unitRef="usd">51000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6a556e59b8bd4005a138e1541662bb46_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzctMTAtMS0xLTk0ODMx_59e9f8fe-a5d3-4137-abff-be7f5c529d23"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iebfe537a4e7b4899829b3ce5a6812386_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzctMTItMS0xLTk0ODMx_c370fde7-2384-4019-a63f-b8984149f512"
      unitRef="usd">51000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i122fb437432445bb8b94f66c1352498c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzctMTQtMS0xLTk0ODMx_6209481e-8914-4888-9b49-ac3643906979"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6d8ae058e10b42b19b2b7a51fe102286_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzctMTYtMS0xLTk0ODMx_0ab9f803-4de3-420d-acc5-d6a80c78dce3"
      unitRef="usd">51000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9920661ad081431584fffee6621bedd1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzktMi0xLTEtOTQ4MzE_16001a0f-45cc-4bb7-ab71-11dc89a27601"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia0debe97407a4a29ac76598d242abe70_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzktNC0xLTEtOTQ4MzE_40d73968-fb56-42ed-9fb3-e1ddef0e2203"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie3f9511b3ce84767b0cd5dda4878a1d8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzktNi0xLTEtOTQ4MzE_5c66803d-2741-43eb-b7d0-69ddfe3e27e1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib0d196db8de044f7b096a26f568bcc2e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzktOC0xLTEtOTQ4MzE_6c4e0494-2b8c-4416-b543-afc6b5e6a2bc"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie7166c1867db42a59946692d872ca487_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzktMTAtMS0xLTk0ODMx_51b583f2-5ea6-4e4b-85d0-81012d8f6401"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i77e48c2c77094705a53af852b1a9d72f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzktMTItMS0xLTk0ODMx_ecb5ef79-f1f4-4b33-bd3b-4c565821c5fc"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifef414e1cacc4427af5c130c1dfb7069_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzktMTQtMS0xLTk0ODMx_006c2db1-a18d-4785-8ceb-59b9312c422c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i562a1c1d813143b387a1386991ee371c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzktMTYtMS0xLTk0ODMx_b0a8f011-b141-44aa-9c01-844330b66254"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9dd6ff8969cd46219034eaa9f922cc63_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEwLTItMS0xLTk0ODMx_db2bebc5-310c-4d54-8476-90f0d77b6dd4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i67a8b38165f445a29651dd0163d7b97e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEwLTQtMS0xLTk0ODMx_4fea558c-3851-4b43-b27c-d68bdd0e8806"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3fc0e0e6cfd34b848a4329f6b2d4eef1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEwLTYtMS0xLTk0ODMx_142b22c6-2632-4cfe-a5ac-aad7fa066439"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i85a230e5f81a48c78ac96f0556ba1bcd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEwLTgtMS0xLTk0ODMx_1fbe6116-acbd-4c83-b349-48ee3121bb87"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i55a8a69189ab41e4a27cb0653b591709_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEwLTEwLTEtMS05NDgzMQ_78475e6c-8406-4867-a184-57e1787d5d6c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i01a935b5313744c69b2134f0706843b3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEwLTEyLTEtMS05NDgzMQ_42c09db4-f856-4aa2-a0fa-78f012c2a1bf"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia283fca771744c269e37b513966bcfca_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEwLTE0LTEtMS05NDgzMQ_1763dd0c-4cc8-417d-9895-00e59875ee49"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib78c157abc13457fb3c2ffeeabc6887c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEwLTE2LTEtMS05NDgzMQ_1e5c4b4b-a776-4330-817b-6709a5346078"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib31507c35e284e299c5a447d87eb3bad_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzExLTItMS0xLTk0ODMx_8adff5a0-5b87-4a8a-9860-f2799c624714"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ief04c0c77f754c4e8773310d3f3f995d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzExLTQtMS0xLTk0ODMx_1fa339b6-f39f-4bbe-8878-5a9611bc5dae"
      unitRef="usd">65000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4abe5fa288434acba436f3607616486a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzExLTYtMS0xLTk0ODMx_5340981c-37a1-4ac7-89a8-32223970f2ba"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1a1c231876b24515b9cf5290b20d8497_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzExLTgtMS0xLTk0ODMx_dbbf24ae-ece7-408a-8247-8ae3041b6cfe"
      unitRef="usd">66000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4091e0935746423e802930a0a249f3ab_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzExLTEwLTEtMS05NDgzMQ_7308133d-b4d5-4ae9-8784-c0b835b3f5d1"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="icced8c77467a439ab94442205659b698_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzExLTEyLTEtMS05NDgzMQ_57bb143c-84ca-4bd8-9c52-78d5db8a1aaf"
      unitRef="usd">102000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie78131bdf4944cb4b7835bfd51e69c57_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzExLTE0LTEtMS05NDgzMQ_9c05e36b-d569-4f05-9699-1c1e6d449c41"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8d6663b8d3354af0836780f9a3ccb7d8_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzExLTE2LTEtMS05NDgzMQ_53855344-5def-4ab1-bb30-bfafb21be744"
      unitRef="usd">103000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i819974f0d173482a87f6215140f5cd12_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEyLTItMS0xLTk0ODMx_01ba7108-1ce3-430e-bc0d-955d15281001"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3a4ba4ae2f084135b4c3396a39a9e4d5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEyLTQtMS0xLTk0ODMx_4a9614a2-3bbb-4445-a8c6-77de4a0a99f9"
      unitRef="usd">35000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8a1a9199b6b3495db74904db30ace49f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEyLTYtMS0xLTk0ODMx_7b2763f0-2696-4329-a6ce-c65dd50cee36"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i90b3621ef3a04a7e80b74c2ea9544924_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEyLTgtMS0xLTk0ODMx_9662d827-68ec-443f-8fd3-0bde9c53c272"
      unitRef="usd">37000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic9b498085ab54167830633419e66f3ce_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEyLTEwLTEtMS05NDgzMQ_e238b4d2-40f2-4428-9531-7470d98ace46"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if783dd84203d4097828a5dfcf36b9360_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEyLTEyLTEtMS05NDgzMQ_923209e6-a943-46c5-8dd0-c08b3d840a4b"
      unitRef="usd">20000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3617a1ce43f34e31b97e8612dceb1bc9_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEyLTE0LTEtMS05NDgzMQ_86e580a4-464a-4d6b-bf61-105aebca33fb"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1fdf60201168414184b8e02445c9a52f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEyLTE2LTEtMS05NDgzMQ_8c1ea66c-33e7-4f8c-af55-a360a2a313d2"
      unitRef="usd">22000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i38f0c1c6c791466996e0e14977fb3043_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEzLTItMS0xLTk0ODMx_32351ebf-8d56-45cd-964b-1ad239c8f08e"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i27c4a253513c4ac885cb55c4a07909d1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEzLTQtMS0xLTk0ODMx_d7bca388-c928-480b-8361-5bd74dcf32cf"
      unitRef="usd">172000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ieabf485ffa9b4b01ac91c9afed822bd0_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEzLTYtMS0xLTk0ODMx_eeddf07b-b01d-4078-a040-906e5637087b"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i991e579e87be40ff91924707db6a6553_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEzLTgtMS0xLTk0ODMx_28dd52eb-e5c7-4748-8a9e-0eb16cc8818d"
      unitRef="usd">175000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0e76b4972fd740e69b695e357d4e25c2_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEzLTEwLTEtMS05NDgzMQ_fd28fb30-ef21-4901-a046-fc27c404cdc5"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if13b91c47c564e65a71a7033d532765d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEzLTEyLTEtMS05NDgzMQ_5d80319e-7439-4c09-b516-10c2ba4b719a"
      unitRef="usd">186000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2043342d86cd4a6280d52ee1ce7e996a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEzLTE0LTEtMS05NDgzMQ_6dbd433b-08db-47f6-a514-6afda1951220"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic9788e7d7947465a8b5827eb980e4f3c_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90YWJsZTpmYjAxZWYwOTM2Mjg0OGUyOWM1ZTVmZWIwMDdkZDYzNS90YWJsZXJhbmdlOmZiMDFlZjA5MzYyODQ4ZTI5YzVlNWZlYjAwN2RkNjM1XzEzLTE2LTEtMS05NDgzMQ_37141cd9-35aa-40e4-86cf-b3df083f6cd1"
      unitRef="usd">189000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <bhc:DefinedBenefitPlanPercentageAllocationofFund
      contextRef="i180a6063ed294b858f6f1b7f8889f355_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2Xzg1OTE_9cb5c86c-0076-4bd2-9c07-a4a6494cbb2a"
      unitRef="number">0.95</bhc:DefinedBenefitPlanPercentageAllocationofFund>
    <bhc:DefinedBenefitPlanPercentageAllocationofFund
      contextRef="i6361735a69df45b5bec1a681fbc6e116_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2Xzg1OTg_7ad289d1-6b81-457f-b31c-9d974568f800"
      unitRef="number">0.96</bhc:DefinedBenefitPlanPercentageAllocationofFund>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzkzMjI_0a706106-dcd6-4758-a0d9-fcf4c8bbe946"
      unitRef="usd">44000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzkzMjY_00831136-3483-4b06-8080-1d5401b38c5f"
      unitRef="usd">43000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDYvZnJhZzpiYTQ4MmM2Nzc5MDk0YTBiOTdjZjZkMDY5Yzg1YTAyNi90ZXh0cmVnaW9uOmJhNDgyYzY3NzkwOTRhMGI5N2NmNmQwNjljODVhMDI2XzkzMzM_d62e9b28-8286-4734-becd-2dee8c905f6d"
      unitRef="usd">41000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90ZXh0cmVnaW9uOjQyNTNmNzM2ZmM3YzRkMDk4NzhlYzM3ZjdhMTMwZDU0XzYwNA_a93a077d-726e-4f82-b46b-bd9f4cf58e11">LEASES &lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets and lease liabilities associated with the Company's operating leases are included in the Consolidated Balance Sheet as of December 31, 2021 and 2020 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets included in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzItMC0xLTEtOTQ4MzE_4bf2464d-f080-463a-b82a-fe3327a6ffe8"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzItMC0xLTEtOTQ4MzE_ce76341b-5893-4112-b76b-f4aed3b43dcf"&gt;Other non-current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities included in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzQtMC0xLTEtOTQ4MzE_4bf64393-afaa-455f-a448-662b6f9a6f45"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzQtMC0xLTEtOTQ4MzE_4de59f41-dcca-4036-87e1-e7e98c16d228"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzUtMC0xLTEtOTQ4MzE_339c676d-41f8-49e5-86a9-b2e8149fc1fd"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzUtMC0xLTEtOTQ4MzE_c6eaab40-e3c8-4b6a-afe4-21b28ab4bf11"&gt;Other non-current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, 2020 and 2019 the Company's finance leases were not material and for the years 2021, 2020 and 2019 sub-lease income and short-term lease expense were not material. Lease expense for the years 2021, 2020 and 2019 include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6.6pt;margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to operating leases for 2021, 2020 and 2019 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6.6pt;margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid from operating cash flows for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, future payments under noncancelable operating leases for each of the five succeeding years ending December 31 and thereafter are as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:91.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <bhc:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90ZXh0cmVnaW9uOjQyNTNmNzM2ZmM3YzRkMDk4NzhlYzM3ZjdhMTMwZDU0XzYwNQ_f9e7ac6d-64ec-41fc-9d5d-51900c261610">&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets and lease liabilities associated with the Company's operating leases are included in the Consolidated Balance Sheet as of December 31, 2021 and 2020 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets included in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzItMC0xLTEtOTQ4MzE_4bf2464d-f080-463a-b82a-fe3327a6ffe8"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzItMC0xLTEtOTQ4MzE_ce76341b-5893-4112-b76b-f4aed3b43dcf"&gt;Other non-current assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liabilities included in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzQtMC0xLTEtOTQ4MzE_4bf64393-afaa-455f-a448-662b6f9a6f45"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzQtMC0xLTEtOTQ4MzE_4de59f41-dcca-4036-87e1-e7e98c16d228"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzUtMC0xLTEtOTQ4MzE_339c676d-41f8-49e5-86a9-b2e8149fc1fd"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzUtMC0xLTEtOTQ4MzE_c6eaab40-e3c8-4b6a-afe4-21b28ab4bf11"&gt;Other non-current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bhc:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzItMS0xLTEtOTQ4MzE_2d90aff0-8db6-4079-ac85-15791442a7b9"
      unitRef="usd">247000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzItMy0xLTEtOTQ4MzE_29e8847b-c267-4a55-aaeb-34255f77b7f9"
      unitRef="usd">259000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzQtMS0xLTEtOTQ4MzE_4b103433-bee7-4f79-b6ef-3325957af88a"
      unitRef="usd">50000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzQtMy0xLTEtOTQ4MzE_2a4d6d7b-3833-4354-bffc-2df084b93120"
      unitRef="usd">52000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzUtMS0xLTEtOTQ4MzE_3849e584-7582-46b9-9b46-f4fb0af28b8a"
      unitRef="usd">214000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzUtMy0xLTEtOTQ4MzE_f0c247c7-eebe-45a5-b02f-fca1d907f98b"
      unitRef="usd">227000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzYtMS0xLTEtOTQ4MzE_85085fb1-fe6d-4b76-9f74-da21592b845b"
      unitRef="usd">264000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpmNjI1N2ZiNTVjMTQ0Yzk4ODRiYzg5MjkwYTM2NGNmZS90YWJsZXJhbmdlOmY2MjU3ZmI1NWMxNDRjOTg4NGJjODkyOTBhMzY0Y2ZlXzYtMy0xLTEtOTQ4MzE_4ae857e5-52be-472b-b157-731209605604"
      unitRef="usd">279000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90ZXh0cmVnaW9uOjQyNTNmNzM2ZmM3YzRkMDk4NzhlYzM3ZjdhMTMwZDU0XzIxNQ_19b66785-c1f5-4c39-9c2d-211243263736"
      unitRef="usd">0</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90ZXh0cmVnaW9uOjQyNTNmNzM2ZmM3YzRkMDk4NzhlYzM3ZjdhMTMwZDU0XzIxNQ_7c74e893-4c1e-449b-bc0f-6f0b18c56e4a"
      unitRef="usd">0</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90ZXh0cmVnaW9uOjQyNTNmNzM2ZmM3YzRkMDk4NzhlYzM3ZjdhMTMwZDU0XzIxNQ_e1d19bd4-dfa1-4547-a0c4-b081b30aa1b4"
      unitRef="usd">0</us-gaap:FinanceLeaseLiability>
    <us-gaap:SubleaseIncome
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90ZXh0cmVnaW9uOjQyNTNmNzM2ZmM3YzRkMDk4NzhlYzM3ZjdhMTMwZDU0XzMxMQ_1ea98294-fbe5-493b-b504-95a7c6826ac2"
      unitRef="usd">0</us-gaap:SubleaseIncome>
    <us-gaap:ShortTermLeaseCost
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90ZXh0cmVnaW9uOjQyNTNmNzM2ZmM3YzRkMDk4NzhlYzM3ZjdhMTMwZDU0XzMxMQ_22f3b3f6-4cb1-49e7-a8c3-d7beb4cf1c60"
      unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90ZXh0cmVnaW9uOjQyNTNmNzM2ZmM3YzRkMDk4NzhlYzM3ZjdhMTMwZDU0XzMxMQ_25a182a3-14fa-4bec-a352-937298eb25b6"
      unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90ZXh0cmVnaW9uOjQyNTNmNzM2ZmM3YzRkMDk4NzhlYzM3ZjdhMTMwZDU0XzMxMQ_c71c640e-cfc1-45f6-ae92-ffa6ae51ea52"
      unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90ZXh0cmVnaW9uOjQyNTNmNzM2ZmM3YzRkMDk4NzhlYzM3ZjdhMTMwZDU0XzMxMQ_cf15973f-2f03-4d64-99b5-decbf4b3fe8a"
      unitRef="usd">0</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90ZXh0cmVnaW9uOjQyNTNmNzM2ZmM3YzRkMDk4NzhlYzM3ZjdhMTMwZDU0XzMxMQ_d48b7a78-33a3-4b68-aa05-2d8be1473694"
      unitRef="usd">0</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90ZXh0cmVnaW9uOjQyNTNmNzM2ZmM3YzRkMDk4NzhlYzM3ZjdhMTMwZDU0XzYwNg_80067e09-2481-480b-9855-f28fc5c1c0b6">Lease expense for the years 2021, 2020 and 2019 include:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpiMmMyNjc2NmYzZjY0YWIzOGFmOGM0NzUyZTQ0N2RkNS90YWJsZXJhbmdlOmIyYzI2NzY2ZjNmNjRhYjM4YWY4YzQ3NTJlNDQ3ZGQ1XzEtMS0xLTEtOTQ4MzE_f875c358-1851-4ef0-bbed-14727e57c680"
      unitRef="usd">67000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpiMmMyNjc2NmYzZjY0YWIzOGFmOGM0NzUyZTQ0N2RkNS90YWJsZXJhbmdlOmIyYzI2NzY2ZjNmNjRhYjM4YWY4YzQ3NTJlNDQ3ZGQ1XzEtMy0xLTEtOTQ4MzE_520c4a44-c303-4cbc-bf97-1f63b9ac8be3"
      unitRef="usd">65000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpiMmMyNjc2NmYzZjY0YWIzOGFmOGM0NzUyZTQ0N2RkNS90YWJsZXJhbmdlOmIyYzI2NzY2ZjNmNjRhYjM4YWY4YzQ3NTJlNDQ3ZGQ1XzEtNS0xLTEtOTQ4MzE_21c05f49-012e-4a90-8243-1dcca4302da9"
      unitRef="usd">62000000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpiMmMyNjc2NmYzZjY0YWIzOGFmOGM0NzUyZTQ0N2RkNS90YWJsZXJhbmdlOmIyYzI2NzY2ZjNmNjRhYjM4YWY4YzQ3NTJlNDQ3ZGQ1XzItMS0xLTEtOTQ4MzE_0a2826a6-a836-4c5d-bd60-64a1915eb8e2"
      unitRef="usd">12000000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpiMmMyNjc2NmYzZjY0YWIzOGFmOGM0NzUyZTQ0N2RkNS90YWJsZXJhbmdlOmIyYzI2NzY2ZjNmNjRhYjM4YWY4YzQ3NTJlNDQ3ZGQ1XzItMy0xLTEtOTQ4MzE_5b4b41b9-0f54-4ef0-acc5-8dbf3818f578"
      unitRef="usd">12000000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpiMmMyNjc2NmYzZjY0YWIzOGFmOGM0NzUyZTQ0N2RkNS90YWJsZXJhbmdlOmIyYzI2NzY2ZjNmNjRhYjM4YWY4YzQ3NTJlNDQ3ZGQ1XzItNS0xLTEtOTQ4MzE_e047bb5b-4b6e-4638-8c9a-2d15d8c5e68a"
      unitRef="usd">16000000</us-gaap:VariableLeaseCost>
    <bhc:AdditionalOperatingLeaseInformationLesseeTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90ZXh0cmVnaW9uOjQyNTNmNzM2ZmM3YzRkMDk4NzhlYzM3ZjdhMTMwZDU0XzYwNw_b41bedd2-8e88-4476-8d7b-cbc4860890d4">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to operating leases for 2021, 2020 and 2019 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6.6pt;margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.458%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.977%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.405%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.978%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid from operating cash flows for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bhc:AdditionalOperatingLeaseInformationLesseeTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpjOGY5MzRjNmYwODI0Njg1YTRlY2Y5MzE1ZWQwZmYyNS90YWJsZXJhbmdlOmM4ZjkzNGM2ZjA4MjQ2ODVhNGVjZjkzMTVlZDBmZjI1XzEtMS0xLTEtOTQ4MzE_bc28460c-d3a4-4fb9-8842-63b2129eec8c"
      unitRef="usd">76000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpjOGY5MzRjNmYwODI0Njg1YTRlY2Y5MzE1ZWQwZmYyNS90YWJsZXJhbmdlOmM4ZjkzNGM2ZjA4MjQ2ODVhNGVjZjkzMTVlZDBmZjI1XzEtMy0xLTEtOTQ4MzE_b2c85188-c53b-4e31-80eb-b3bc4887a4bc"
      unitRef="usd">74000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpjOGY5MzRjNmYwODI0Njg1YTRlY2Y5MzE1ZWQwZmYyNS90YWJsZXJhbmdlOmM4ZjkzNGM2ZjA4MjQ2ODVhNGVjZjkzMTVlZDBmZjI1XzEtNS0xLTEtOTQ4MzE_a793bc17-c8bc-43e3-86af-01716e52f0a9"
      unitRef="usd">73000000</us-gaap:OperatingLeasePayments>
    <bhc:RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpjOGY5MzRjNmYwODI0Njg1YTRlY2Y5MzE1ZWQwZmYyNS90YWJsZXJhbmdlOmM4ZjkzNGM2ZjA4MjQ2ODVhNGVjZjkzMTVlZDBmZjI1XzItMS0xLTEtOTQ4MzE_0e03c663-7fe0-4df4-8ed5-fd35a5108771"
      unitRef="usd">46000000</bhc:RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption>
    <bhc:RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpjOGY5MzRjNmYwODI0Njg1YTRlY2Y5MzE1ZWQwZmYyNS90YWJsZXJhbmdlOmM4ZjkzNGM2ZjA4MjQ2ODVhNGVjZjkzMTVlZDBmZjI1XzItMy0xLTEtOTQ4MzE_43a1a45c-a69e-4575-ab50-101def537b0e"
      unitRef="usd">39000000</bhc:RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption>
    <bhc:RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpjOGY5MzRjNmYwODI0Njg1YTRlY2Y5MzE1ZWQwZmYyNS90YWJsZXJhbmdlOmM4ZjkzNGM2ZjA4MjQ2ODVhNGVjZjkzMTVlZDBmZjI1XzItNS0xLTEtOTQ4MzE_2c99d6c4-6d58-4d9d-8019-3008b81a282b"
      unitRef="usd">47000000</bhc:RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpjOGY5MzRjNmYwODI0Njg1YTRlY2Y5MzE1ZWQwZmYyNS90YWJsZXJhbmdlOmM4ZjkzNGM2ZjA4MjQ2ODVhNGVjZjkzMTVlZDBmZjI1XzMtMS0xLTEtOTQ4MzE_1624ff9e-e460-4c93-b75f-fc34b59cdc90">P7Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpjOGY5MzRjNmYwODI0Njg1YTRlY2Y5MzE1ZWQwZmYyNS90YWJsZXJhbmdlOmM4ZjkzNGM2ZjA4MjQ2ODVhNGVjZjkzMTVlZDBmZjI1XzMtMy0xLTEtOTQ4MzE_8dfb050f-99e3-4fbf-97c1-22891f945b0c">P7Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpjOGY5MzRjNmYwODI0Njg1YTRlY2Y5MzE1ZWQwZmYyNS90YWJsZXJhbmdlOmM4ZjkzNGM2ZjA4MjQ2ODVhNGVjZjkzMTVlZDBmZjI1XzMtNS0xLTEtOTQ4MzE_fa8cc74f-9e78-4871-8988-8f991653f395">P8Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpjOGY5MzRjNmYwODI0Njg1YTRlY2Y5MzE1ZWQwZmYyNS90YWJsZXJhbmdlOmM4ZjkzNGM2ZjA4MjQ2ODVhNGVjZjkzMTVlZDBmZjI1XzQtMS0xLTEtOTQ4MzE_cdf9e059-47d3-41a7-94ba-53430f2bb978"
      unitRef="number">0.061</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpjOGY5MzRjNmYwODI0Njg1YTRlY2Y5MzE1ZWQwZmYyNS90YWJsZXJhbmdlOmM4ZjkzNGM2ZjA4MjQ2ODVhNGVjZjkzMTVlZDBmZjI1XzQtMy0xLTEtOTQ4MzE_fa33b715-1859-45c1-9c02-8a2705c6ea85"
      unitRef="number">0.062</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTpjOGY5MzRjNmYwODI0Njg1YTRlY2Y5MzE1ZWQwZmYyNS90YWJsZXJhbmdlOmM4ZjkzNGM2ZjA4MjQ2ODVhNGVjZjkzMTVlZDBmZjI1XzQtNS0xLTEtOTQ4MzE_a3005621-b7ef-4187-b087-375ae955d8da"
      unitRef="number">0.062</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90ZXh0cmVnaW9uOjQyNTNmNzM2ZmM3YzRkMDk4NzhlYzM3ZjdhMTMwZDU0XzYwOA_9fc482f5-5714-4be3-ab0e-d660ee06851f">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, future payments under noncancelable operating leases for each of the five succeeding years ending December 31 and thereafter are as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:91.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTo5MGNmZjU2MTJlNjU0MzhkODJkNTBjNjUwNTY2N2IzMy90YWJsZXJhbmdlOjkwY2ZmNTYxMmU2NTQzOGQ4MmQ1MGM2NTA1NjY3YjMzXzEtMi0xLTEtOTQ4MzE_8d6e6f83-f4c1-4906-89f8-c97b300f1dc6"
      unitRef="usd">64000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTo5MGNmZjU2MTJlNjU0MzhkODJkNTBjNjUwNTY2N2IzMy90YWJsZXJhbmdlOjkwY2ZmNTYxMmU2NTQzOGQ4MmQ1MGM2NTA1NjY3YjMzXzItMi0xLTEtOTQ4MzE_5caa0bef-372d-423b-87cf-836c35366840"
      unitRef="usd">53000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTo5MGNmZjU2MTJlNjU0MzhkODJkNTBjNjUwNTY2N2IzMy90YWJsZXJhbmdlOjkwY2ZmNTYxMmU2NTQzOGQ4MmQ1MGM2NTA1NjY3YjMzXzMtMi0xLTEtOTQ4MzE_91b7e9fb-a319-49cb-b4a1-d8f792ed9eb4"
      unitRef="usd">41000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTo5MGNmZjU2MTJlNjU0MzhkODJkNTBjNjUwNTY2N2IzMy90YWJsZXJhbmdlOjkwY2ZmNTYxMmU2NTQzOGQ4MmQ1MGM2NTA1NjY3YjMzXzQtMi0xLTEtOTQ4MzE_40ec6c2d-0706-4bd1-a11e-3a24f90913a2"
      unitRef="usd">38000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTo5MGNmZjU2MTJlNjU0MzhkODJkNTBjNjUwNTY2N2IzMy90YWJsZXJhbmdlOjkwY2ZmNTYxMmU2NTQzOGQ4MmQ1MGM2NTA1NjY3YjMzXzUtMi0xLTEtOTQ4MzE_2c4ce14c-da4c-47bb-bd71-55f5c9266290"
      unitRef="usd">34000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTo5MGNmZjU2MTJlNjU0MzhkODJkNTBjNjUwNTY2N2IzMy90YWJsZXJhbmdlOjkwY2ZmNTYxMmU2NTQzOGQ4MmQ1MGM2NTA1NjY3YjMzXzYtMi0xLTEtOTQ4MzE_b549ecbf-b99e-41f8-9978-0e8ca3881950"
      unitRef="usd">100000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTo5MGNmZjU2MTJlNjU0MzhkODJkNTBjNjUwNTY2N2IzMy90YWJsZXJhbmdlOjkwY2ZmNTYxMmU2NTQzOGQ4MmQ1MGM2NTA1NjY3YjMzXzctMi0xLTEtOTQ4MzE_13703995-d687-40cd-8ca9-df9a94301bf2"
      unitRef="usd">330000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTo5MGNmZjU2MTJlNjU0MzhkODJkNTBjNjUwNTY2N2IzMy90YWJsZXJhbmdlOjkwY2ZmNTYxMmU2NTQzOGQ4MmQ1MGM2NTA1NjY3YjMzXzgtMi0xLTEtOTQ4MzE_9334f7a2-b574-4479-9045-29f5fc07188a"
      unitRef="usd">66000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTo5MGNmZjU2MTJlNjU0MzhkODJkNTBjNjUwNTY2N2IzMy90YWJsZXJhbmdlOjkwY2ZmNTYxMmU2NTQzOGQ4MmQ1MGM2NTA1NjY3YjMzXzktMi0xLTEtOTQ4MzE_2ec4db40-b910-4682-a5a7-7b48ec9da43d"
      unitRef="usd">264000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTo5MGNmZjU2MTJlNjU0MzhkODJkNTBjNjUwNTY2N2IzMy90YWJsZXJhbmdlOjkwY2ZmNTYxMmU2NTQzOGQ4MmQ1MGM2NTA1NjY3YjMzXzEwLTItMS0xLTk0ODMx_9b2019dc-1dd0-4135-85ce-c293a59b6a6b"
      unitRef="usd">50000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNDkvZnJhZzo0MjUzZjczNmZjN2M0ZDA5ODc4ZWMzN2Y3YTEzMGQ1NC90YWJsZTo5MGNmZjU2MTJlNjU0MzhkODJkNTBjNjUwNTY2N2IzMy90YWJsZXJhbmdlOjkwY2ZmNTYxMmU2NTQzOGQ4MmQ1MGM2NTA1NjY3YjMzXzExLTItMS0xLTk0ODMx_3ae75631-3993-4793-be3c-afa743d1d8d1"
      unitRef="usd">214000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzExMjI2_593321c3-c3eb-4653-bee6-3cd8e1ffc850">SHARE-BASED COMPENSATIONIn May 2014, shareholders approved the Company&#x2019;s 2014 Omnibus Incentive Plan (the &#x201c;2014 Plan&#x201d;), which replaced the Company&#x2019;s 2011 Omnibus Incentive Plan (the &#x201c;2011 Plan&#x201d;) for future equity awards granted by the Company. The Company transferred the common shares available under the 2011 Plan to the 2014 Plan. The maximum number of common shares that may be issued to participants under the 2014 Plan was equal to 18,000,000 common shares, plus the number of common shares under the 2011 Plan reserved but unissued and not underlying outstanding awards and the number of common shares becoming available for reuse after awards are terminated, forfeited, cancelled, exchanged or &lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;surrendered under the 2011 Plan and the Company&#x2019;s 2007 Equity Compensation Plan. The Company registered 20,000,000 common shares of common stock for issuance under the 2014 Plan.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective April 30, 2018, the Company amended and restated the 2014 Plan (the &#x201c;Amended and Restated 2014 Plan&#x201d;). The Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Amended and Restated 2014 Plan has been increased by an additional 11,900,000 common shares, as approved by the requisite number of shareholders at the Company&#x2019;s annual general meeting held on April 30, 2018, (ii) introduction of a $750,000 aggregate fair market value limit on awards (in either equity, cash or other compensation) that can be granted in any calendar year to a participant who is a non-employee director, (iii) housekeeping changes to address recent changes to Section 162(m) of the Internal Revenue Code, (iv) awards are expressly subject to the Company&#x2019;s clawback policy and (v) awards not assumed or substituted in connection with a Change of Control (as defined in the Amended and Restated 2014 Plan) will only vest on a pro rata basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective April 28, 2020, the Company further amended and restated the Amended and Restated 2014 Plan (the &#x201c;Further Amended and Restated 2014 Plan&#x201d;). The Further Amended and Restated 2014 Plan includes the following amendments: (i) the number of common shares authorized for issuance under the Further Amended and Restated 2014 Plan has been increased by an additional 13,500,000 common shares, as approved by the requisite number of shareholders at the Company&#x2019;s annual general meeting held on April 28, 2020, (ii) the exercise price of stock options and share appreciation rights (&#x201c;SARs&#x201d;) will be based on the closing price of the underlying common shares on the date such stock options or SARs are granted (rather than on the last preceding trading date), (iii)&#160;additional provisions clarifying that: (a)&#160;stock options and SARs will not be eligible for the payment of dividend or dividend equivalents and (b)&#160;the Talent and Compensation Committee of the Board of Directors of the Company cannot, without shareholder approval, seek to effect any repricing of any previously granted &#x201c;underwater&#x201d; stock option or SAR and (iv) other housekeeping and/or clerical changes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximately 11,593,000 common shares were available for future grants as of December&#160;31, 2021. The Company uses reserved and unissued common shares to satisfy its obligation under its share-based compensation plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a long-term incentive program with the objective of aligning the share-based awards granted to senior management with the Company&#x2019;s focus on improving its tangible capital usage and allocation, while maintaining focus on improving total shareholder return over the long-term.  The share-based awards granted under this long-term incentive program consist of time-based stock options, time-based RSUs and performance-based RSUs. Performance-based RSUs are comprised of: (i) awards that vest upon achievement of certain share price appreciation conditions that are based on total shareholder return (&#x201c;TSR&#x201d;), (ii) awards that vest upon attainment of certain performance targets that are based on the Company&#x2019;s return on tangible capital (&#x201c;ROTC&#x201d;) and (iii) vest fully or partially upon attainment of certain goals that are linked to the B+L Separation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components and classification of share-based compensation expense related to stock options and&#160;RSUs for the years 2021, 2020 and 2019 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.033%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.934%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.934%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options granted under the 2011 Plan and the Amended and Restated 2014 Plan generally expire on the fifth or tenth anniversary of the grant date. The exercise price of any stock option granted under the 2011 Plan and the Amended and Restated 2014 Plan will not be less than the closing price per common share on the date of grant. Stock options generally vest 33% and 25% each year over a three-year and four-year period, respectively, on the anniversary of the date of&#160;grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of all stock options granted for the years 2021, 2020 and 2019 were estimated as of the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock option life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected stock option life was determined based on historical exercise and forfeiture patterns. The expected volatility was determined based on implied volatility in the market traded options of the Company&#x2019;s common stock. The risk-free interest rate was determined based on the rate at the time of grant for zero-coupon U.S. government bonds with maturity dates equal to the expected life of the stock&#160;option. The expected dividend yield was determined based on the stock option&#x2019;s exercise price and expected annual dividend rate at the time of&#160;grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes option-pricing model used by the Company to calculate stock option values was developed to estimate the fair value of freely tradeable, fully transferable stock options without vesting restrictions, which significantly differ from the Company&#x2019;s stock option awards. This model also requires highly subjective assumptions, including future stock price volatility and expected time until exercise, which greatly affect the calculated values.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, January&#160;1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable, December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average fair values of all stock options granted in 2021, 2020 and 2019 were $10.92, $6.60 and $8.45, respectively. The total intrinsic values of stock options exercised in 2021, 2020 and 2019 were $15 million, $2 million and $3 million, respectively. Proceeds received on the exercise of stock options in 2021, 2020 and 2019 were $22 million, $5 million and $5 million,&#160;respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the total remaining unrecognized compensation expense related to non-vested stock options amounted to $10 million, which will be amortized over the weighted-average remaining requisite service period of approximately 1.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;years. The total fair value of stock options vested in 2021, 2020 and 2019 were $15 million, $15 million and&#160;$18 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs generally vest on the first or third anniversary date from the date of grant or 33% a year over a three-year period. Annual RSUs granted to non-management directors vest immediately prior to the next Annual Meeting of Shareholders. Pursuant to the applicable unit agreement, certain RSUs may be subject to the attainment of any applicable performance goals specified by the Board of Directors. If the vesting of the RSUs is conditional upon the attainment of performance goals, any RSUs that do not vest as a result of a determination that the prescribed performance goals failed to be attained will be forfeited immediately upon such determination. RSUs are credited with dividend equivalents, in the form of additional RSUs, when dividends are paid on the Company&#x2019;s common shares. Such additional RSUs will have the same vesting dates and will vest under the same terms as the RSUs in respect of which such additional RSUs are&#160;credited.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To the extent provided for in a RSU agreement, the Company may, in lieu of all or a portion of the common shares which would otherwise be provided to a holder, elect to pay a cash amount equivalent to the market price of the Company&#x2019;s &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;common shares on the vesting date for each vested RSU. The amount of cash payment will be determined based on the average market price of the Company&#x2019;s common shares on the vesting date. The Company&#x2019;s current intent is to settle vested RSUs through the issuance of common&#160;shares.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Time-Based RSUs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each vested time-based RSU represents the right of a holder to receive one of the Company&#x2019;s common shares. The fair value of each RSU granted is estimated based on the trading price of the Company&#x2019;s common shares on the date of&#160;grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes non-vested time-based RSU activity during 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Time-Based&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested, January&#160;1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested, December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the total remaining unrecognized compensation expense related to non-vested time-based RSUs amounted to $68 million, which will be amortized over the weighted-average remaining requisite service period of approximately 1.6 years. The total fair value of time-based RSUs vested in 2021, 2020 and 2019 were $69 million, $66 million and $34 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance-Based RSUs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each vested performance-based RSU represents the right of a holder to receive a number of the Company&#x2019;s common shares up to a specified maximum. Performance-based RSUs vest upon achievement of certain share price appreciation conditions or attainment of certain performance targets. If the Company&#x2019;s performance is below a specified performance level, no common shares will be&#160;paid. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each TSR performance-based RSU granted during 2021, 2020 and 2019 was estimated using a Monte Carlo Simulation model, which utilizes multiple input variables to estimate the probability that the performance condition will be achieved.  The fair value of the ROTC performance-based RSUs is estimated based on the trading price of the Company&#x2019;s common shares on the date of grant.  Expense recognized for the ROTC performance-based RSUs in each reporting period reflects the Company&#x2019;s latest estimate of the number of ROTC performance-based RSUs that are expected to vest.  If the ROTC performance-based RSUs do not ultimately vest due to the ROTC targets not being met, no compensation expense is recognized and any previously recognized compensation expense is reversed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of TSR performance-based RSUs granted during 2021, 2020 and 2019 were estimated with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.136%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.727%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contractual term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected Company share volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected company share volatility was determined based on implied volatility in the market traded options of the Company&#x2019;s common stock. The risk-free interest rate was determined based on the rate at the time of grant for zero-coupon U.S.&#160;government bonds with maturity dates equal to the contractual term of the performance-based&#160;RSUs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes non-vested performance-based RSU activity during 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.799%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.798%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Performance-based &lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested, January&#160;1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested, December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, the Company granted approximately&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,035,000&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;performance-based RSUs, consisting of approximately 400,000 units of TSR performance-based RSUs with an average grant date fair value of $56.04 per RSU, approximately 413,000 units of ROTC performance-based RSUs with a weighted-average grant date fair value of $31.72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;per RSU and approximately 222,000 of other performance-based RSU's with a weighted-average grant date fair value of $28.49. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the total remaining unrecognized compensation expense related to non-vested performance-based RSUs amounted to $32 million, which will be amortized over the weighted-average remaining requisite service period of approximately 1.7 years.  A maximum of approximately 3,476,000 common shares could be issued upon vesting of the performance-based RSUs outstanding as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="id943b700697244c1a9af35217a5014fc_I20140531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzQyMw_30d16b86-be77-4084-9419-3681c549db1d"
      unitRef="shares">18000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="id943b700697244c1a9af35217a5014fc_I20140531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzc4Mw_d5b518ce-e12b-48cf-8c8c-56b139aecf38"
      unitRef="shares">20000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i6006b5cfb8f34c728d0575646bfaa31c_D20180430-20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzExNjg_b1c971d0-65a8-4f12-9aa6-b24091cbd275"
      unitRef="shares">11900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant
      contextRef="ia9c449e903f04beb9f713f2df4efd6ca_D20180430-20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzEzMjU_e489f5ab-7b8a-4ac8-8070-e5f315997dd4"
      unitRef="usd">750000</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i0d0c600ff58f4f0da9f1d4e553efd25b_D20200428-20200428"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzIyMTQ_1a12a6b1-62e9-4cb4-9a46-1942d1c1c499"
      unitRef="shares">13500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i5e2ddff148e045819b4c2a2baecf7de3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzMwMjE_59de7295-b1d6-4ffb-8efd-c67e6dad76c8"
      unitRef="shares">11593000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzExMjEy_3a86113c-a882-4f39-ae2f-458be43276d9">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components and classification of share-based compensation expense related to stock options and&#160;RSUs for the years 2021, 2020 and 2019 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.033%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.934%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.934%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.251%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzEtMi0xLTEtOTQ4MzE_650098d4-1996-4b4c-bd6b-5a39a4dadadd"
      unitRef="usd">15000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2f3083202c7e4f36ada3cfe487b44863_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzEtNC0xLTEtOTQ4MzE_cbba8c9b-3417-4352-a61e-e5a95a18572c"
      unitRef="usd">15000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i69f7d41ce4b642209bb25ea9c478625f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzEtNi0xLTEtOTQ4MzE_4845aafe-8c94-45ed-b59e-c62f086e367f"
      unitRef="usd">21000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i00aeb13ceebf48e891b516a2d0c221d3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzItMi0xLTEtOTQ4MzE_5d378fb9-44a2-4548-9a18-d983a49b1b2a"
      unitRef="usd">113000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2c0144ad2365471881ed18f7ced989f8_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzItNC0xLTEtOTQ4MzE_b48faedf-70b3-403e-9815-fb89bd8eae18"
      unitRef="usd">90000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i3dcf40ad82c34f11ac4a925dd47873ab_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzItNi0xLTEtOTQ4MzE_68d2c2f9-dbdb-4618-8740-4158a17b3624"
      unitRef="usd">81000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzMtMi0xLTEtOTQ4MzE_a0acef1e-aad6-41e8-b9c2-2c559f098909"
      unitRef="usd">128000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzMtNC0xLTEtOTQ4MzE_e2e9e578-fe6c-4b4b-b64a-110d43abcf63"
      unitRef="usd">105000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzMtNi0xLTEtOTQ4MzE_b0e27eda-b937-4fbc-9d37-74e5009f18ce"
      unitRef="usd">102000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i4b764cf71454461b9ae558f095cef352_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzUtMi0xLTEtOTQ4MzE_3491dafc-93f7-4736-89cf-a17dfde0f3ef"
      unitRef="usd">10000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i169ce44b8b6147b5af92c163ff58f3e3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzUtNC0xLTEtOTQ4MzE_f79d0921-0492-4e9d-82e3-2896a7e28df2"
      unitRef="usd">11000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i25d8a1ce6eb4407f92324a3e68f2013f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzUtNi0xLTEtOTQ4MzE_cdc21aea-a185-43d3-9dc2-8539ff2bd232"
      unitRef="usd">9000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ifbd1e5635e5040f3a9121f39e9238a50_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzYtMi0xLTEtOTQ4MzE_07e99f25-d0fa-48bb-ae7a-5277d5131019"
      unitRef="usd">118000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ib100363bb61344be9b5ce0d1f32e9248_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzYtNC0xLTEtOTQ4MzE_d770af6a-86e7-4535-965e-9c0d5792c179"
      unitRef="usd">94000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ieb7848e770bf4984a2093c22786e7db8_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzYtNi0xLTEtOTQ4MzE_fc27e080-1a07-4d7c-a909-6c6d8731fe94"
      unitRef="usd">93000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzctMi0xLTEtOTQ4MzE_4d14c92a-a89e-4655-a632-e82f9d6582b4"
      unitRef="usd">128000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzctNC0xLTEtOTQ4MzE_46f2292e-cb1a-4ffa-8766-c7f44817828d"
      unitRef="usd">105000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTpjYmU4NTg2OTgwYjM0ZDRmOWQzNTJkOWFlMmFmYTViNS90YWJsZXJhbmdlOmNiZTg1ODY5ODBiMzRkNGY5ZDM1MmQ5YWUyYWZhNWI1XzctNi0xLTEtOTQ4MzE_03d66f13-5095-4d85-a193-3a7d51f35241"
      unitRef="usd">102000000</us-gaap:ShareBasedCompensation>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage
      contextRef="id87fa13c036e497faecb209787ce467e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzQ1OTg_4adca589-10af-48fd-95d7-27bfe9d15c14"
      unitRef="number">0.33</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage
      contextRef="iecd38b28e9a84d1880313b43be4e32a2_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzQ2MDU_3e15c71b-6cb5-4a84-8e49-60a072e1ee61"
      unitRef="number">0.25</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7384f8f25998459682939a04e6a9c33f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzExMjU5_008af08b-e30f-4572-afda-a8a4642b5ebe">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="if57561008d804ce4b03b997a95d4d41e_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzExMjIw_ff144dce-8c2e-4e1d-992f-105fc228f77c">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzExMjIx_85aa30c8-0d84-4c01-8bf2-99184273029c">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of all stock options granted for the years 2021, 2020 and 2019 were estimated as of the date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected stock option life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo4YzQzMTJjOTViMjI0YmIxOTFmNGVkOGVjNmI3NDEwNC90YWJsZXJhbmdlOjhjNDMxMmM5NWIyMjRiYjE5MWY0ZWQ4ZWM2Yjc0MTA0XzEtMi0xLTEtOTQ4MzE_dad0dff6-aaac-4183-b4e0-78a02d97e5a4">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i2f3083202c7e4f36ada3cfe487b44863_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo4YzQzMTJjOTViMjI0YmIxOTFmNGVkOGVjNmI3NDEwNC90YWJsZXJhbmdlOjhjNDMxMmM5NWIyMjRiYjE5MWY0ZWQ4ZWM2Yjc0MTA0XzEtNC0xLTEtOTQ4MzE_141a1c81-1ab6-457e-9c3e-d1282fa52507">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i69f7d41ce4b642209bb25ea9c478625f_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo4YzQzMTJjOTViMjI0YmIxOTFmNGVkOGVjNmI3NDEwNC90YWJsZXJhbmdlOjhjNDMxMmM5NWIyMjRiYjE5MWY0ZWQ4ZWM2Yjc0MTA0XzEtNi0xLTEtOTQ4MzE_5e0c0a63-8bc2-4b25-a8be-cd2823ac912c">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo4YzQzMTJjOTViMjI0YmIxOTFmNGVkOGVjNmI3NDEwNC90YWJsZXJhbmdlOjhjNDMxMmM5NWIyMjRiYjE5MWY0ZWQ4ZWM2Yjc0MTA0XzItMi0xLTEtOTQ4MzE_1d4deba2-b582-458c-a6cd-7bf551ccf8d6"
      unitRef="number">0.502</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i2f3083202c7e4f36ada3cfe487b44863_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo4YzQzMTJjOTViMjI0YmIxOTFmNGVkOGVjNmI3NDEwNC90YWJsZXJhbmdlOjhjNDMxMmM5NWIyMjRiYjE5MWY0ZWQ4ZWM2Yjc0MTA0XzItNC0xLTEtOTQ4MzE_649d26d9-cb2f-472d-a05a-24de0a980941"
      unitRef="number">0.387</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i69f7d41ce4b642209bb25ea9c478625f_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo4YzQzMTJjOTViMjI0YmIxOTFmNGVkOGVjNmI3NDEwNC90YWJsZXJhbmdlOjhjNDMxMmM5NWIyMjRiYjE5MWY0ZWQ4ZWM2Yjc0MTA0XzItNi0xLTEtOTQ4MzE_4cb9089c-9672-44b0-af64-bab91742c29d"
      unitRef="number">0.465</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo4YzQzMTJjOTViMjI0YmIxOTFmNGVkOGVjNmI3NDEwNC90YWJsZXJhbmdlOjhjNDMxMmM5NWIyMjRiYjE5MWY0ZWQ4ZWM2Yjc0MTA0XzMtMi0xLTEtOTQ4MzE_86c2f65a-5153-449d-b8e9-a568af712cd2"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i2f3083202c7e4f36ada3cfe487b44863_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo4YzQzMTJjOTViMjI0YmIxOTFmNGVkOGVjNmI3NDEwNC90YWJsZXJhbmdlOjhjNDMxMmM5NWIyMjRiYjE5MWY0ZWQ4ZWM2Yjc0MTA0XzMtNC0xLTEtOTQ4MzE_295b0131-902b-4f1d-9488-615e6bea751a"
      unitRef="number">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i69f7d41ce4b642209bb25ea9c478625f_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo4YzQzMTJjOTViMjI0YmIxOTFmNGVkOGVjNmI3NDEwNC90YWJsZXJhbmdlOjhjNDMxMmM5NWIyMjRiYjE5MWY0ZWQ4ZWM2Yjc0MTA0XzMtNi0xLTEtOTQ4MzE_20d4265f-5995-4c12-9d0e-c0cd8617453b"
      unitRef="number">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo4YzQzMTJjOTViMjI0YmIxOTFmNGVkOGVjNmI3NDEwNC90YWJsZXJhbmdlOjhjNDMxMmM5NWIyMjRiYjE5MWY0ZWQ4ZWM2Yjc0MTA0XzQtMi0xLTEtOTQ4MzE_74aecb7b-a79e-463d-b5e2-bd3a0a22e7fb"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i2f3083202c7e4f36ada3cfe487b44863_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo4YzQzMTJjOTViMjI0YmIxOTFmNGVkOGVjNmI3NDEwNC90YWJsZXJhbmdlOjhjNDMxMmM5NWIyMjRiYjE5MWY0ZWQ4ZWM2Yjc0MTA0XzQtNC0xLTEtOTQ4MzE_3a9414b3-fdf0-4d5e-b49f-ab1c573a3c86"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i69f7d41ce4b642209bb25ea9c478625f_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo4YzQzMTJjOTViMjI0YmIxOTFmNGVkOGVjNmI3NDEwNC90YWJsZXJhbmdlOjhjNDMxMmM5NWIyMjRiYjE5MWY0ZWQ4ZWM2Yjc0MTA0XzQtNi0xLTEtOTQ4MzE_8a37e203-bc2c-4b62-b23d-69ea53568400"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzExMjY1_bcdf91ff-842a-4bee-bf74-ddadcd01c105">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, January&#160;1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable, December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9d3ab00f203a4abdb121762625a88c8a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzEtMi0xLTEtOTQ4MzE_a92061ca-eb55-400b-a0fa-9f1157638e9f"
      unitRef="shares">8700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9d3ab00f203a4abdb121762625a88c8a_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzEtNC0xLTEtOTQ4MzE_52447dc3-ba4d-4b2a-9f25-32c6163a7a9a"
      unitRef="usdPerShare">25.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzItMi0xLTEtOTQ4MzE_0140f4a2-7c6d-4b68-a005-3b0cfc61c097"
      unitRef="shares">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzItNC0xLTEtOTQ4MzE_1d7af709-05a7-48d5-9553-ce0f74e6b0ed"
      unitRef="usdPerShare">32.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzMtMi0xLTEtOTQ4MzE_a9553a83-25f2-4660-b97a-54393d0c9083"
      unitRef="shares">1200000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzMtNC0xLTEtOTQ4MzE_3cc6abea-7048-45b2-82e3-0a823be594ab"
      unitRef="usdPerShare">18.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzQtMi0xLTEtOTQ4MzE_89377c24-b5eb-4bec-8fe1-c802928397da"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzQtNC0xLTEtOTQ4MzE_8fd13a20-4888-4654-9155-e0ec58af43f7"
      unitRef="usdPerShare">29.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i01666d0d4a034ebbb396a9f3c3378737_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzUtMi0xLTEtOTQ4MzE_08d57cc1-ddc1-47c9-9ce1-871f998877c4"
      unitRef="shares">8900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i01666d0d4a034ebbb396a9f3c3378737_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzUtNC0xLTEtOTQ4MzE_24973307-94e5-45f9-9e6b-5c94125b9531"
      unitRef="usdPerShare">27.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzUtNi0xLTEtOTQ4MzE_529725ed-0a1a-485f-81b5-bf7fe1adb7d0">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i01666d0d4a034ebbb396a9f3c3378737_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzUtOC0xLTEtOTQ4MzE_c03540a9-7b44-4268-9674-52b703e293e9"
      unitRef="usd">36000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i01666d0d4a034ebbb396a9f3c3378737_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzYtMi0xLTEtOTQ4MzE_090fe84f-05ca-4c8b-b0ee-941a0a96ee70"
      unitRef="shares">8500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i01666d0d4a034ebbb396a9f3c3378737_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzYtNC0xLTEtOTQ4MzE_74a5036d-8eb5-42ae-b98a-032c23ca2ed2"
      unitRef="usdPerShare">27.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzYtNi0xLTEtOTQ4MzE_286ab90b-f479-45c1-98d4-324cb1e78c90">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i01666d0d4a034ebbb396a9f3c3378737_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzYtOC0xLTEtOTQ4MzE_f252452a-6264-4148-84c1-bc191d4fbe4c"
      unitRef="usd">35000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i01666d0d4a034ebbb396a9f3c3378737_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzctMi0xLTEtOTQ4MzE_62890023-a52f-4853-bbaa-f1727eb05c6a"
      unitRef="shares">5500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i01666d0d4a034ebbb396a9f3c3378737_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzctNC0xLTEtOTQ4MzE_be91e431-a9e3-457e-921a-5becca9e83ab"
      unitRef="usdPerShare">27.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzctNi0xLTEtOTQ4MzE_8e8d7c84-6dc3-4d1c-8194-30877b44cc14">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i01666d0d4a034ebbb396a9f3c3378737_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NGI5Njg3OWQ3YjI0Njk2OWI4ZWFhMGFhMGE5M2NiZi90YWJsZXJhbmdlOjc0Yjk2ODc5ZDdiMjQ2OTY5YjhlYWEwYWEwYTkzY2JmXzctOC0xLTEtOTQ4MzE_68c4db26-6a1e-4ed0-bbbb-20c56af61fb6"
      unitRef="usd">30000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzYwNzI_d85b981b-65ac-44ea-adab-60869cc30943"
      unitRef="usdPerShare">10.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2f3083202c7e4f36ada3cfe487b44863_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzYwNzY_56048a78-5c1a-4e0c-99dd-8ae8231e4c63"
      unitRef="usdPerShare">6.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i69f7d41ce4b642209bb25ea9c478625f_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzYwODM_ee21e3b5-afc8-4fde-8f02-3a24f690e6e7"
      unitRef="usdPerShare">8.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzYxNjY_1824f523-b503-42c0-b050-e607212f8278"
      unitRef="usd">15000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i2f3083202c7e4f36ada3cfe487b44863_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzYxNzA_aac11a73-97fd-408d-95c3-b2a2de99702b"
      unitRef="usd">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i69f7d41ce4b642209bb25ea9c478625f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzYxNzc_2be7d821-6e96-4c32-8993-62674f6e049c"
      unitRef="usd">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzYyNTc_b2ea46c2-5323-4ebf-996c-9c73aa7cdf32"
      unitRef="usd">22000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i2f3083202c7e4f36ada3cfe487b44863_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzYyNjE_a6873f3e-603a-4f58-8fd2-af6ab09e4af7"
      unitRef="usd">5000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i69f7d41ce4b642209bb25ea9c478625f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzYyNjg_b8b89af1-d18c-4b77-9a9f-cd94935b2e86"
      unitRef="usd">5000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i01666d0d4a034ebbb396a9f3c3378737_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzYzOTI_19df01ac-fd23-46fc-9a52-1de2625a9a11"
      unitRef="usd">10000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzY0OTg_f349024c-c351-4d1d-9f98-1a1d12845b8a">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue
      contextRef="i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzY1NjQ_a4c01200-23b8-4b2d-87e1-8d243d0c3e30"
      unitRef="usd">15000000</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue
      contextRef="i2f3083202c7e4f36ada3cfe487b44863_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzY1Njg_1e348f48-6e3d-4ab9-bcf4-26f2ccc5d289"
      unitRef="usd">15000000</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue
      contextRef="i69f7d41ce4b642209bb25ea9c478625f_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzY1NzU_9c48ab42-30f2-4e14-81b1-5f1455df2c09"
      unitRef="usd">18000000</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i00aeb13ceebf48e891b516a2d0c221d3_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzY2ODM_cf7ac52f-7a0e-414c-a1c2-287732251aff"
      unitRef="number">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i00aeb13ceebf48e891b516a2d0c221d3_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzExMjQ3_8eebbd2b-6ac4-4cb7-a162-90389f205961">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzExMjI5_421b2022-d83e-480b-b8d9-5ebd200586ca">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes non-vested time-based RSU activity during 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.452%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Time-Based&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested, January&#160;1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested, December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="if15c6a218d7d43c38c67bf323a224454_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTozNzFkMTllZWJiYWY0ZjM0ODM2NGIzYTFhNTA3N2Y1MC90YWJsZXJhbmdlOjM3MWQxOWVlYmJhZjRmMzQ4MzY0YjNhMWE1MDc3ZjUwXzEtMi0xLTEtOTQ4MzE_d6f05561-72f1-4e83-a57e-2407fa6765bd"
      unitRef="shares">5700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="if15c6a218d7d43c38c67bf323a224454_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTozNzFkMTllZWJiYWY0ZjM0ODM2NGIzYTFhNTA3N2Y1MC90YWJsZXJhbmdlOjM3MWQxOWVlYmJhZjRmMzQ4MzY0YjNhMWE1MDc3ZjUwXzEtNC0xLTEtOTQ4MzE_b136646e-16b1-4149-ac3f-4874f6b14874"
      unitRef="usdPerShare">21.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i45c56aa08db349ad9a3b4168267b7511_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTozNzFkMTllZWJiYWY0ZjM0ODM2NGIzYTFhNTA3N2Y1MC90YWJsZXJhbmdlOjM3MWQxOWVlYmJhZjRmMzQ4MzY0YjNhMWE1MDc3ZjUwXzItMi0xLTEtOTQ4MzE_d06237c7-98a0-4b02-ac46-5e2abdae2590"
      unitRef="shares">3400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i45c56aa08db349ad9a3b4168267b7511_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTozNzFkMTllZWJiYWY0ZjM0ODM2NGIzYTFhNTA3N2Y1MC90YWJsZXJhbmdlOjM3MWQxOWVlYmJhZjRmMzQ4MzY0YjNhMWE1MDc3ZjUwXzItNC0xLTEtOTQ4MzE_13b07e9c-3323-4017-ae4b-b33e059f8218"
      unitRef="usdPerShare">31.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i45c56aa08db349ad9a3b4168267b7511_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTozNzFkMTllZWJiYWY0ZjM0ODM2NGIzYTFhNTA3N2Y1MC90YWJsZXJhbmdlOjM3MWQxOWVlYmJhZjRmMzQ4MzY0YjNhMWE1MDc3ZjUwXzMtMi0xLTEtOTQ4MzE_75457dd8-2c6a-4038-b3e3-8376a4a68dda"
      unitRef="shares">3300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i45c56aa08db349ad9a3b4168267b7511_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTozNzFkMTllZWJiYWY0ZjM0ODM2NGIzYTFhNTA3N2Y1MC90YWJsZXJhbmdlOjM3MWQxOWVlYmJhZjRmMzQ4MzY0YjNhMWE1MDc3ZjUwXzMtNC0xLTEtOTQ4MzE_30ad54b9-a01a-4d19-bf03-5c7f5d76e1fc"
      unitRef="usdPerShare">21.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i45c56aa08db349ad9a3b4168267b7511_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTozNzFkMTllZWJiYWY0ZjM0ODM2NGIzYTFhNTA3N2Y1MC90YWJsZXJhbmdlOjM3MWQxOWVlYmJhZjRmMzQ4MzY0YjNhMWE1MDc3ZjUwXzQtMi0xLTEtOTQ4MzE_5f991abb-5f4e-48e0-a2c5-ba8176fcabda"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i45c56aa08db349ad9a3b4168267b7511_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTozNzFkMTllZWJiYWY0ZjM0ODM2NGIzYTFhNTA3N2Y1MC90YWJsZXJhbmdlOjM3MWQxOWVlYmJhZjRmMzQ4MzY0YjNhMWE1MDc3ZjUwXzQtNC0xLTEtOTQ4MzE_d96f727e-6644-4a1f-8e88-406be8498a0c"
      unitRef="usdPerShare">26.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i5cd01c5e13964b01922532131f0e6d49_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTozNzFkMTllZWJiYWY0ZjM0ODM2NGIzYTFhNTA3N2Y1MC90YWJsZXJhbmdlOjM3MWQxOWVlYmJhZjRmMzQ4MzY0YjNhMWE1MDc3ZjUwXzUtMi0xLTEtOTQ4MzE_b956a90b-56c5-4d9a-8b67-c59a4aee96c6"
      unitRef="shares">5400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i5cd01c5e13964b01922532131f0e6d49_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTozNzFkMTllZWJiYWY0ZjM0ODM2NGIzYTFhNTA3N2Y1MC90YWJsZXJhbmdlOjM3MWQxOWVlYmJhZjRmMzQ4MzY0YjNhMWE1MDc3ZjUwXzUtNC0xLTEtOTQ4MzE_0f200ccc-0241-45ff-8e6b-0abe1c9a285f"
      unitRef="usdPerShare">28.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i5cd01c5e13964b01922532131f0e6d49_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzg0OTU_c03bd8be-7ac2-40d1-b4ee-81d1c4a987a8"
      unitRef="usd">68000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i45c56aa08db349ad9a3b4168267b7511_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzg2MDE_7395218b-db52-44d7-933c-abc269f1f812">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i45c56aa08db349ad9a3b4168267b7511_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzg2Njk_a2bf112a-fda7-46f9-8260-0fb9e2efb634"
      unitRef="usd">69000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i89368b0fb9454b688b6e6dde554c44e1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzg2NzM_26c81986-1e26-42b6-9785-6da39d81a339"
      unitRef="usd">66000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i29af68bd8dac4b57b173b5f3c801e3b7_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzg2ODA_2afe8003-e7cc-42b5-b45b-aa29a5a7209e"
      unitRef="usd">34000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <bhc:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzExMjI0_51f147a1-cdb5-46c5-9a63-33e66caf3134">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of TSR performance-based RSUs granted during 2021, 2020 and 2019 were estimated with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.136%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.727%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contractual term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected Company share volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bhc:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i42196f5311924fb28aae7927e03f4954_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo1NzhiNGNjMTk0MTg0Yjg5OWZlZTE3YTZkYzRkZmU3OC90YWJsZXJhbmdlOjU3OGI0Y2MxOTQxODRiODk5ZmVlMTdhNmRjNGRmZTc4XzEtMi0xLTEtOTQ4MzE_93187aa8-a7a5-4be9-a1e8-13f15879cafe">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i071c8dec838c4bb88915169735766953_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo1NzhiNGNjMTk0MTg0Yjg5OWZlZTE3YTZkYzRkZmU3OC90YWJsZXJhbmdlOjU3OGI0Y2MxOTQxODRiODk5ZmVlMTdhNmRjNGRmZTc4XzEtNC0xLTEtOTQ4MzE_e2a15963-a696-44ab-bc25-c1403ed27be5">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if5e547542b4b4e4db07d76b12dbfa958_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo1NzhiNGNjMTk0MTg0Yjg5OWZlZTE3YTZkYzRkZmU3OC90YWJsZXJhbmdlOjU3OGI0Y2MxOTQxODRiODk5ZmVlMTdhNmRjNGRmZTc4XzEtNi0xLTEtOTQ4MzE_9358d5ef-811f-4918-a7fb-6e4ded7824f6">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i42196f5311924fb28aae7927e03f4954_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo1NzhiNGNjMTk0MTg0Yjg5OWZlZTE3YTZkYzRkZmU3OC90YWJsZXJhbmdlOjU3OGI0Y2MxOTQxODRiODk5ZmVlMTdhNmRjNGRmZTc4XzItMi0xLTEtOTQ4MzE_12907647-d9e2-4bfa-bd94-6cb131899166"
      unitRef="number">0.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i071c8dec838c4bb88915169735766953_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo1NzhiNGNjMTk0MTg0Yjg5OWZlZTE3YTZkYzRkZmU3OC90YWJsZXJhbmdlOjU3OGI0Y2MxOTQxODRiODk5ZmVlMTdhNmRjNGRmZTc4XzItNC0xLTEtOTQ4MzE_d54b7b64-a41c-4b1a-9574-793b6fbdaa75"
      unitRef="number">0.386</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if5e547542b4b4e4db07d76b12dbfa958_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo1NzhiNGNjMTk0MTg0Yjg5OWZlZTE3YTZkYzRkZmU3OC90YWJsZXJhbmdlOjU3OGI0Y2MxOTQxODRiODk5ZmVlMTdhNmRjNGRmZTc4XzItNi0xLTEtOTQ4MzE_01a28984-7126-4151-b034-43f0c58442bb"
      unitRef="number">0.465</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i42196f5311924fb28aae7927e03f4954_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo1NzhiNGNjMTk0MTg0Yjg5OWZlZTE3YTZkYzRkZmU3OC90YWJsZXJhbmdlOjU3OGI0Y2MxOTQxODRiODk5ZmVlMTdhNmRjNGRmZTc4XzMtMi0xLTEtOTQ4MzE_d2864922-7a63-4724-8a0d-4acda08d070d"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i071c8dec838c4bb88915169735766953_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo1NzhiNGNjMTk0MTg0Yjg5OWZlZTE3YTZkYzRkZmU3OC90YWJsZXJhbmdlOjU3OGI0Y2MxOTQxODRiODk5ZmVlMTdhNmRjNGRmZTc4XzMtNC0xLTEtOTQ4MzE_6f54454e-0632-4e78-9c62-a20bae1ff75d"
      unitRef="number">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if5e547542b4b4e4db07d76b12dbfa958_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo1NzhiNGNjMTk0MTg0Yjg5OWZlZTE3YTZkYzRkZmU3OC90YWJsZXJhbmdlOjU3OGI0Y2MxOTQxODRiODk5ZmVlMTdhNmRjNGRmZTc4XzMtNi0xLTEtOTQ4MzE_6e842b66-af9c-4294-8c31-c027fd3818f4"
      unitRef="number">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzExMjYz_a437f2fe-5f29-4d96-9b69-80b639def481">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes non-vested performance-based RSU activity during 2021: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.799%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.798%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.587%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Performance-based &lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested, January&#160;1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested, December&#160;31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i403b5b7721914e66b5361779547ecaef_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NzA3OGE4ODE0MTQ0YzM1OTQwYzIzNDI5MjY3ZGZmYi90YWJsZXJhbmdlOjc3MDc4YTg4MTQxNDRjMzU5NDBjMjM0MjkyNjdkZmZiXzEtMi0xLTEtOTQ4MzE_659b461a-1c5a-4127-b4af-b18d3a64dd21"
      unitRef="shares">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i403b5b7721914e66b5361779547ecaef_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NzA3OGE4ODE0MTQ0YzM1OTQwYzIzNDI5MjY3ZGZmYi90YWJsZXJhbmdlOjc3MDc4YTg4MTQxNDRjMzU5NDBjMjM0MjkyNjdkZmZiXzEtNC0xLTEtOTQ4MzE_ec9d5f6c-a47d-47bd-8641-7059b839c780"
      unitRef="usdPerShare">28.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i42196f5311924fb28aae7927e03f4954_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NzA3OGE4ODE0MTQ0YzM1OTQwYzIzNDI5MjY3ZGZmYi90YWJsZXJhbmdlOjc3MDc4YTg4MTQxNDRjMzU5NDBjMjM0MjkyNjdkZmZiXzItMi0xLTEtOTQ4MzE_daf529af-6e2b-4c4f-bf3b-ac38fc33c25b"
      unitRef="shares">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i42196f5311924fb28aae7927e03f4954_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NzA3OGE4ODE0MTQ0YzM1OTQwYzIzNDI5MjY3ZGZmYi90YWJsZXJhbmdlOjc3MDc4YTg4MTQxNDRjMzU5NDBjMjM0MjkyNjdkZmZiXzItNC0xLTEtOTQ4MzE_f63aec26-ec32-4ab7-b8db-57418a3555b2"
      unitRef="usdPerShare">40.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i42196f5311924fb28aae7927e03f4954_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NzA3OGE4ODE0MTQ0YzM1OTQwYzIzNDI5MjY3ZGZmYi90YWJsZXJhbmdlOjc3MDc4YTg4MTQxNDRjMzU5NDBjMjM0MjkyNjdkZmZiXzMtMi0xLTEtOTQ4MzE_bf846ed0-48a6-47bc-bdf7-485cdf55f6c7"
      unitRef="shares">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i42196f5311924fb28aae7927e03f4954_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NzA3OGE4ODE0MTQ0YzM1OTQwYzIzNDI5MjY3ZGZmYi90YWJsZXJhbmdlOjc3MDc4YTg4MTQxNDRjMzU5NDBjMjM0MjkyNjdkZmZiXzMtNC0xLTEtOTQ4MzE_4405773e-f129-4630-afbf-4939aec62e55"
      unitRef="usdPerShare">27.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i54c4a51199e24aa0a3d6a1ec87ede263_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NzA3OGE4ODE0MTQ0YzM1OTQwYzIzNDI5MjY3ZGZmYi90YWJsZXJhbmdlOjc3MDc4YTg4MTQxNDRjMzU5NDBjMjM0MjkyNjdkZmZiXzQtMi0xLTEtOTQ4MzE_9d2f5f9d-6e88-4c85-ac84-b371007cb8d5"
      unitRef="shares">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i54c4a51199e24aa0a3d6a1ec87ede263_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90YWJsZTo3NzA3OGE4ODE0MTQ0YzM1OTQwYzIzNDI5MjY3ZGZmYi90YWJsZXJhbmdlOjc3MDc4YTg4MTQxNDRjMzU5NDBjMjM0MjkyNjdkZmZiXzQtNC0xLTEtOTQ4MzE_f986b387-fdea-4514-8173-ee757699f28e"
      unitRef="usdPerShare">33.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i42196f5311924fb28aae7927e03f4954_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzEwNDg3_2ea188b8-e12a-4a88-890c-740e9c326e13"
      unitRef="shares">1035000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="if92bc6c46d244c3788aeab448cab0a64_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzEwNTQy_af3e6b16-250c-4663-b791-391cb62cef54"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if92bc6c46d244c3788aeab448cab0a64_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzEwNjIy_37ae5cfb-5726-4be1-b15c-ad1e15b71833"
      unitRef="usdPerShare">56.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i4b9e26fe691746ed9f535f3800019b25_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzEwNjQ4_87160cb6-bbe7-414d-9cd6-2aa17476f0d3"
      unitRef="shares">413000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4b9e26fe691746ed9f535f3800019b25_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzEwNzM3_234b4f3d-6124-4439-a953-5529db2b6db2"
      unitRef="usdPerShare">31.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ibf752be0eda64aa790f9f6d3442bf3f5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzEwNzY2_ce3953c0-1301-47a7-aaf0-ab05ff0aa4dd"
      unitRef="shares">222000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibf752be0eda64aa790f9f6d3442bf3f5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzEwODUy_fac74819-7fe6-406e-a5a3-007db4e6f4ff"
      unitRef="usdPerShare">28.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i54c4a51199e24aa0a3d6a1ec87ede263_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzEwOTcy_9ad6a846-757b-4cb2-b9d2-d6b152362f43"
      unitRef="usd">32000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i42196f5311924fb28aae7927e03f4954_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzExMDc4_4f20400a-e10f-495d-b9fa-7f2ca4268f00">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued
      contextRef="i54c4a51199e24aa0a3d6a1ec87ede263_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTIvZnJhZzphYjE2ZThiZGNlODA0ODBiYTA3ZGY0ZWUwNDMzMTUyMi90ZXh0cmVnaW9uOmFiMTZlOGJkY2U4MDQ4MGJhMDdkZjRlZTA0MzMxNTIyXzExMTE2_f5b5d4eb-26cd-4789-9597-a6e69c2488ca"
      unitRef="shares">3476000</bhc:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTUvZnJhZzphNWI3NGZhOTNkY2E0NDA5ODg3NTMzODE5ZjIzNzZiNy90ZXh0cmVnaW9uOmE1Yjc0ZmE5M2RjYTQ0MDk4ODc1MzM4MTlmMjM3NmI3XzQxOQ_53bc77da-d72b-4d37-af4d-d029fe7b4544">ACCUMULATED OTHER COMPREHENSIVE LOSS&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss as of December&#160;31, 2021 and 2020 consists of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,905)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension adjustment, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are not provided for foreign currency translation adjustments arising on the translation of the Company&#x2019;s operations having a functional currency other than the U.S. dollar, except to the extent of translation adjustments related to the Company&#x2019;s retained earnings for foreign jurisdictions in which the Company is not considered to be permanently reinvested.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTUvZnJhZzphNWI3NGZhOTNkY2E0NDA5ODg3NTMzODE5ZjIzNzZiNy90ZXh0cmVnaW9uOmE1Yjc0ZmE5M2RjYTQ0MDk4ODc1MzM4MTlmMjM3NmI3XzQyNA_f892e612-cbef-45d8-b7ca-dcfc729ab3a0">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss as of December&#160;31, 2021 and 2020 consists of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,905)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension adjustment, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,924)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie3c11e633ca64c359eb1f4e64ed9945e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTUvZnJhZzphNWI3NGZhOTNkY2E0NDA5ODg3NTMzODE5ZjIzNzZiNy90YWJsZTozNGNjMDA4Y2YwZTU0NmIwYjAwZmVkN2UwNjFkYmMxYi90YWJsZXJhbmdlOjM0Y2MwMDhjZjBlNTQ2YjBiMDBmZWQ3ZTA2MWRiYzFiXzEtMi0xLTEtOTQ4MzE_c6b7a91b-c36d-4321-9534-1eb97d682702"
      unitRef="usd">-1905000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i76387c207f8f42439a9c69184bef25d1_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTUvZnJhZzphNWI3NGZhOTNkY2E0NDA5ODg3NTMzODE5ZjIzNzZiNy90YWJsZTozNGNjMDA4Y2YwZTU0NmIwYjAwZmVkN2UwNjFkYmMxYi90YWJsZXJhbmdlOjM0Y2MwMDhjZjBlNTQ2YjBiMDBmZWQ3ZTA2MWRiYzFiXzEtNC0xLTEtOTQ4MzE_4c0b57b7-1d32-4fbc-8eac-f6ce0dc28516"
      unitRef="usd">-2077000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i66760525c1824001967bb86d988a25bf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTUvZnJhZzphNWI3NGZhOTNkY2E0NDA5ODg3NTMzODE5ZjIzNzZiNy90YWJsZTozNGNjMDA4Y2YwZTU0NmIwYjAwZmVkN2UwNjFkYmMxYi90YWJsZXJhbmdlOjM0Y2MwMDhjZjBlNTQ2YjBiMDBmZWQ3ZTA2MWRiYzFiXzItMi0xLTEtOTQ4MzE_97c4e386-1ead-4e4b-9e9a-9c4abce0967b"
      unitRef="usd">-19000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8ddbf83e6ad54de686a53b50675cf560_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTUvZnJhZzphNWI3NGZhOTNkY2E0NDA5ODg3NTMzODE5ZjIzNzZiNy90YWJsZTozNGNjMDA4Y2YwZTU0NmIwYjAwZmVkN2UwNjFkYmMxYi90YWJsZXJhbmdlOjM0Y2MwMDhjZjBlNTQ2YjBiMDBmZWQ3ZTA2MWRiYzFiXzItNC0xLTEtOTQ4MzE_078abc69-e5a0-4d83-8fb3-6843e0a57515"
      unitRef="usd">-56000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iff498ebdd499404a95f12abea2bd55e9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTUvZnJhZzphNWI3NGZhOTNkY2E0NDA5ODg3NTMzODE5ZjIzNzZiNy90YWJsZTozNGNjMDA4Y2YwZTU0NmIwYjAwZmVkN2UwNjFkYmMxYi90YWJsZXJhbmdlOjM0Y2MwMDhjZjBlNTQ2YjBiMDBmZWQ3ZTA2MWRiYzFiXzMtMi0xLTEtOTQ4MzE_e43fe811-1d4e-4ebc-ba04-69fd43bbfae5"
      unitRef="usd">-1924000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib105e1aee9db4b46ae7d9e203dadfad7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTUvZnJhZzphNWI3NGZhOTNkY2E0NDA5ODg3NTMzODE5ZjIzNzZiNy90YWJsZTozNGNjMDA4Y2YwZTU0NmIwYjAwZmVkN2UwNjFkYmMxYi90YWJsZXJhbmdlOjM0Y2MwMDhjZjBlNTQ2YjBiMDBmZWQ3ZTA2MWRiYzFiXzMtNC0xLTEtOTQ4MzE_102ca691-948e-416d-a5c3-dad4d45862f2"
      unitRef="usd">-2133000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTgvZnJhZzo1ODQyNjcyNDQyNjg0N2Y2OWQ1YjA3MDY1OGRiMzA2ZS90ZXh0cmVnaW9uOjU4NDI2NzI0NDI2ODQ3ZjY5ZDViMDcwNjU4ZGIzMDZlXzI4OQ_f4831b35-b1f3-48d2-9eff-21cc626135c2">RESEARCH AND DEVELOPMENT&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in Research and development are costs related to product development and quality assurance programs. Quality assurance are the costs incurred to meet evolving customer and regulatory standards. Research and development costs for the years 2021, 2020 and 2019 consists of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product related research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Quality assurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock>
    <bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTgvZnJhZzo1ODQyNjcyNDQyNjg0N2Y2OWQ1YjA3MDY1OGRiMzA2ZS90ZXh0cmVnaW9uOjU4NDI2NzI0NDI2ODQ3ZjY5ZDViMDcwNjU4ZGIzMDZlXzI4OA_0683eed8-bb32-4215-8185-e6588ddde073">Research and development costs for the years 2021, 2020 and 2019 consists of:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product related research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Quality assurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock>
    <bhc:ResearchAndDevelopmentExpenseProductRelated
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTgvZnJhZzo1ODQyNjcyNDQyNjg0N2Y2OWQ1YjA3MDY1OGRiMzA2ZS90YWJsZTo0OWE3YzJkZmNlMzU0MjJlODRiYWJmZTNiMzcwN2ZmYi90YWJsZXJhbmdlOjQ5YTdjMmRmY2UzNTQyMmU4NGJhYmZlM2IzNzA3ZmZiXzEtMi0xLTEtOTQ4MzE_ae777afb-7fed-4679-a270-b7a758edb24e"
      unitRef="usd">440000000</bhc:ResearchAndDevelopmentExpenseProductRelated>
    <bhc:ResearchAndDevelopmentExpenseProductRelated
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTgvZnJhZzo1ODQyNjcyNDQyNjg0N2Y2OWQ1YjA3MDY1OGRiMzA2ZS90YWJsZTo0OWE3YzJkZmNlMzU0MjJlODRiYWJmZTNiMzcwN2ZmYi90YWJsZXJhbmdlOjQ5YTdjMmRmY2UzNTQyMmU4NGJhYmZlM2IzNzA3ZmZiXzEtNC0xLTEtOTQ4MzE_b90cb8ed-65ea-415a-9e22-4ab0f460a1cc"
      unitRef="usd">420000000</bhc:ResearchAndDevelopmentExpenseProductRelated>
    <bhc:ResearchAndDevelopmentExpenseProductRelated
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTgvZnJhZzo1ODQyNjcyNDQyNjg0N2Y2OWQ1YjA3MDY1OGRiMzA2ZS90YWJsZTo0OWE3YzJkZmNlMzU0MjJlODRiYWJmZTNiMzcwN2ZmYi90YWJsZXJhbmdlOjQ5YTdjMmRmY2UzNTQyMmU4NGJhYmZlM2IzNzA3ZmZiXzEtNi0xLTEtOTQ4MzE_8efa0c51-9431-4cd1-b2c7-2b3c83a2b3c7"
      unitRef="usd">434000000</bhc:ResearchAndDevelopmentExpenseProductRelated>
    <bhc:ResearchAndDevelopmentExpenseQualityAssurance
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTgvZnJhZzo1ODQyNjcyNDQyNjg0N2Y2OWQ1YjA3MDY1OGRiMzA2ZS90YWJsZTo0OWE3YzJkZmNlMzU0MjJlODRiYWJmZTNiMzcwN2ZmYi90YWJsZXJhbmdlOjQ5YTdjMmRmY2UzNTQyMmU4NGJhYmZlM2IzNzA3ZmZiXzItMi0xLTEtOTQ4MzE_45f61b26-790a-40fb-b760-13072779ac0a"
      unitRef="usd">25000000</bhc:ResearchAndDevelopmentExpenseQualityAssurance>
    <bhc:ResearchAndDevelopmentExpenseQualityAssurance
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTgvZnJhZzo1ODQyNjcyNDQyNjg0N2Y2OWQ1YjA3MDY1OGRiMzA2ZS90YWJsZTo0OWE3YzJkZmNlMzU0MjJlODRiYWJmZTNiMzcwN2ZmYi90YWJsZXJhbmdlOjQ5YTdjMmRmY2UzNTQyMmU4NGJhYmZlM2IzNzA3ZmZiXzItNC0xLTEtOTQ4MzE_bb4a3109-35b7-4035-8e1e-24e5e366e530"
      unitRef="usd">32000000</bhc:ResearchAndDevelopmentExpenseQualityAssurance>
    <bhc:ResearchAndDevelopmentExpenseQualityAssurance
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTgvZnJhZzo1ODQyNjcyNDQyNjg0N2Y2OWQ1YjA3MDY1OGRiMzA2ZS90YWJsZTo0OWE3YzJkZmNlMzU0MjJlODRiYWJmZTNiMzcwN2ZmYi90YWJsZXJhbmdlOjQ5YTdjMmRmY2UzNTQyMmU4NGJhYmZlM2IzNzA3ZmZiXzItNi0xLTEtOTQ4MzE_b08cdee1-209b-418d-ad57-e4362f2bf796"
      unitRef="usd">37000000</bhc:ResearchAndDevelopmentExpenseQualityAssurance>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTgvZnJhZzo1ODQyNjcyNDQyNjg0N2Y2OWQ1YjA3MDY1OGRiMzA2ZS90YWJsZTo0OWE3YzJkZmNlMzU0MjJlODRiYWJmZTNiMzcwN2ZmYi90YWJsZXJhbmdlOjQ5YTdjMmRmY2UzNTQyMmU4NGJhYmZlM2IzNzA3ZmZiXzMtMi0xLTEtOTQ4MzE_3864b27f-4078-476c-8e5d-953015d2a160"
      unitRef="usd">465000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTgvZnJhZzo1ODQyNjcyNDQyNjg0N2Y2OWQ1YjA3MDY1OGRiMzA2ZS90YWJsZTo0OWE3YzJkZmNlMzU0MjJlODRiYWJmZTNiMzcwN2ZmYi90YWJsZXJhbmdlOjQ5YTdjMmRmY2UzNTQyMmU4NGJhYmZlM2IzNzA3ZmZiXzMtNC0xLTEtOTQ4MzE_4405a517-dadc-4657-9873-8fda4bcf9db7"
      unitRef="usd">452000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNTgvZnJhZzo1ODQyNjcyNDQyNjg0N2Y2OWQ1YjA3MDY1OGRiMzA2ZS90YWJsZTo0OWE3YzJkZmNlMzU0MjJlODRiYWJmZTNiMzcwN2ZmYi90YWJsZXJhbmdlOjQ5YTdjMmRmY2UzNTQyMmU4NGJhYmZlM2IzNzA3ZmZiXzMtNi0xLTEtOTQ4MzE_a72f3192-4f07-4d6d-8998-36219172cd18"
      unitRef="usd">471000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90ZXh0cmVnaW9uOjBlMWIzNGI5OGIwYTQyYzU5YWZhOTY2YTA4MDQ4Y2NlXzk4OQ_50f86dfc-4c3b-42e6-a4fd-e51ae6bfaa51">OTHER EXPENSE, NET&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expense, net for the years 2021, 2020 and 2019 consists of:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Litigation and other matters&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired in-process research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gain on sales of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, Litigation and other matters of $356 million includes adjustments related to the Glumetza Antitrust Litigation, partially offset by insurance recoveries related to certain litigation matters. In 2020, Litigation and other matters of $422 million includes net charges related to the U.S. Securities Litigation, the SEC Investigation and the Canadian Securities Litigation and related opt-outs. In 2020, Litigation and other matters also includes an insurance recovery related to a certain litigation matter. In 2019, Litigation and other matters of $1,401 million includes the settlement of a legacy U.S. securities class action matter. Certain of these matters and other significant matters are discussed in further detail in Note 20, &#x201c;LEGAL PROCEEDINGS&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020 and 2019, Acquired in-process research and development costs of $32&#160;million and $41&#160;million, primarily consist of costs associated with the upfront payments to enter into certain exclusive licensing agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, Net gain on sales of assets includes $20 million related to the achievement of a milestone related to a certain product.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90ZXh0cmVnaW9uOjBlMWIzNGI5OGIwYTQyYzU5YWZhOTY2YTA4MDQ4Y2NlXzk4NQ_5c0be3ba-b857-4464-a830-f838044fc2ea">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other expense, net for the years 2021, 2020 and 2019 consists of:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Litigation and other matters&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired in-process research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net gain on sales of assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition-related contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzItMi0xLTEtOTQ4MzE_dee9c137-e4f1-4d12-8223-3e2ba1f6373f"
      unitRef="usd">-356000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzItNC0xLTEtOTQ4MzE_28bef38e-5572-4df9-ae91-f8015e63fac1"
      unitRef="usd">-422000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzItNi0xLTEtOTQ4MzE_e93c3ea3-9e42-48e9-83b7-28ffd77b657e"
      unitRef="usd">-1401000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzMtMi0xLTEtOTQ4MzE_c1b6d87f-4a67-4a36-85cb-747935da7dc1"
      unitRef="usd">8000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzMtNC0xLTEtOTQ4MzE_e510e9da-be33-46ed-92c7-d34bea4c94f0"
      unitRef="usd">32000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzMtNi0xLTEtOTQ4MzE_acef8e2d-5ac8-40a3-b9da-b6d2c8e70ded"
      unitRef="usd">41000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzQtMi0xLTEtOTQ4MzE_f0338fd5-0b05-4e46-9948-98395da8e8d0"
      unitRef="usd">2000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzQtNC0xLTEtOTQ4MzE_e1c5df5e-9e4e-44fb-9590-33ada62ae62b"
      unitRef="usd">1000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzQtNi0xLTEtOTQ4MzE_29d3f304-a94c-44a8-a089-cb990fb9baab"
      unitRef="usd">31000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzUtMi0xLTEtOTQ4MzE_fc7cdfcf-a2d4-4bac-aa36-24b426d1c7b4"
      unitRef="usd">11000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzUtNC0xLTEtOTQ4MzE_e4f0d6fd-edca-4b8c-9405-368495c8a33a"
      unitRef="usd">48000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzUtNi0xLTEtOTQ4MzE_d4526288-678f-4c33-b362-f1386ac0f4d2"
      unitRef="usd">20000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <bhc:OtherIncomeExpenseNet
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzYtMi0xLTEtOTQ4MzE_e8b526e4-65d9-4978-8cf4-4e3f8f166d2a"
      unitRef="usd">0</bhc:OtherIncomeExpenseNet>
    <bhc:OtherIncomeExpenseNet
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzYtNC0xLTEtOTQ4MzE_404be505-aa2a-4245-8ffa-14a2bb3683e9"
      unitRef="usd">1000000</bhc:OtherIncomeExpenseNet>
    <bhc:OtherIncomeExpenseNet
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzYtNi0xLTEtOTQ4MzE_83828aba-fb99-4be6-8b1e-361655fbfa24"
      unitRef="usd">-5000000</bhc:OtherIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzctMi0xLTEtOTQ4MzE_68788be2-61cd-4481-9b55-1bacc6d36a05"
      unitRef="usd">-373000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzctNC0xLTEtOTQ4MzE_d200a98b-ee9b-435d-80f2-dc72bf9e8f6a"
      unitRef="usd">-502000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90YWJsZTo2MDIzYzM3YWUwY2I0YTQyODQxN2IxYzEzYjNjNmJiNy90YWJsZXJhbmdlOjYwMjNjMzdhZTBjYjRhNDI4NDE3YjFjMTNiM2M2YmI3XzctNi0xLTEtOTQ4MzE_c5b0303e-764d-4335-984c-718eb14ca543"
      unitRef="usd">-1426000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90ZXh0cmVnaW9uOjBlMWIzNGI5OGIwYTQyYzU5YWZhOTY2YTA4MDQ4Y2NlXzcw_dee9c137-e4f1-4d12-8223-3e2ba1f6373f"
      unitRef="usd">-356000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90ZXh0cmVnaW9uOjBlMWIzNGI5OGIwYTQyYzU5YWZhOTY2YTA4MDQ4Y2NlXzI2MQ_28bef38e-5572-4df9-ae91-f8015e63fac1"
      unitRef="usd">-422000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90ZXh0cmVnaW9uOjBlMWIzNGI5OGIwYTQyYzU5YWZhOTY2YTA4MDQ4Y2NlXzU2Ng_e93c3ea3-9e42-48e9-83b7-28ffd77b657e"
      unitRef="usd">-1401000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90ZXh0cmVnaW9uOjBlMWIzNGI5OGIwYTQyYzU5YWZhOTY2YTA4MDQ4Y2NlXzc2MA_e510e9da-be33-46ed-92c7-d34bea4c94f0"
      unitRef="usd">32000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90ZXh0cmVnaW9uOjBlMWIzNGI5OGIwYTQyYzU5YWZhOTY2YTA4MDQ4Y2NlXzc2Nw_acef8e2d-5ac8-40a3-b9da-b6d2c8e70ded"
      unitRef="usd">41000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i5cdfe5b964b94b969e2829780c73f7e9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjEvZnJhZzowZTFiMzRiOThiMGE0MmM1OWFmYTk2NmEwODA0OGNjZS90ZXh0cmVnaW9uOjBlMWIzNGI5OGIwYTQyYzU5YWZhOTY2YTA4MDQ4Y2NlXzkxMQ_c0618355-398a-4536-9090-4fa16b4c40e6"
      unitRef="usd">20000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzEyNzg4_81794c93-e49b-4a82-8272-78a796c983e1">INCOME TAXES &lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of Loss before benefit from income taxes for 2021, 2020 and 2019 consist of:  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(701)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(524)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of Benefit from income taxes for 2021, 2020 and 2019 consist of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(224)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Benefit from income taxes differs from the expected amount calculated by applying the Company&#x2019;s Canadian statutory rate of 26.9% to Loss before benefit from income taxes for 2021, 2020 and 2019 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Loss before benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected benefit from income taxes at Canadian statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible amount of share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to tax attributes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance related to foreign tax credits and NOLs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance on Canadian deferred tax assets and tax rate changes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax rate differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible portion of Goodwill impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit on intra-entity transfers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities as of December 31, 2021 and 2020 consist of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Scientific Research and Experimental Development pool&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plant, equipment and technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside basis differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized FX on U.S. dollar debt and other financing cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of the deferred tax asset valuation allowance for 2021, 2020 and 2019: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charged to Benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charged to other accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s U.S. interest expense is subject to limitation rules which limit U.S. interest expense to 30% of adjusted taxable income, defined similar to EBITDA through 2021 and EBIT thereafter.  Disallowed interest can be carried forward indefinitely and any unused interest deduction assessed for recoverability. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (&#x201c;CARES Act&#x201d;) was signed into law.  The CARES Act also amended the annual limitation on the deduction of interest in the following respects: (i) increasing the limitation to 50% of adjusted taxable income (&#x201c;ATI&#x201d;), (ii) providing a rule for a partnership&#x2019;s 2019 section 163(j)-disallowed interest expense and (iii) allowing an election to apply 2019 ATI to the 2020 section 163(j) computation.  For corporations, the increase to 50% of ATI applies to all taxable years beginning in 2019 or 2020 and permits taxpayers whose 2020 income will decrease from its 2019 level, an election to apply their 2019 ATI, rather than their 2020 ATI, to their 2020 computation. The Company considered such provisions and expects to fully utilize any interest carry forwards in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has provided for income taxes in accordance with guidance issued by accounting regulatory bodies, the U.S. Internal Revenue Service and state and local governments through the date of the issuance of these Consolidated Financial Statements. Additional guidance and interpretations can be expected and such guidance, if any, could impact future results.  While management continues to monitor these matters, the ultimate impact, if any, as a result of the application of any guidance issued in the future cannot be determined at this time.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The realization of deferred tax assets is dependent on the Company generating sufficient domestic and foreign taxable income in the years that the temporary differences become deductible. A valuation allowance has been provided for the portion of the deferred tax assets that the Company determined is more likely than not to remain unrealized based on estimated future taxable income and tax planning strategies.  In 2021, the valuation allowance decreased by $30 million primarily due to book taxable income in Canada, the change in deferred tax assets in Canada and the use of deferred tax assets in the U.S. in connection with internal restructurings. In 2020, the valuation allowance decreased by $579 million as a result of taxable losses in Canada as offset by a reduction of deferred tax assets due to internal restructurings. Given the Company&#x2019;s history of pre-tax losses and expected future losses in Canada, the Company maintained that there was insufficient objective evidence to release the valuation allowance against Canadian tax loss carryforwards, International Tax Credits (&#x201c;ITC&#x201d;) and pooled Scientific Research and Experimental Development Tax Incentive (&#x201c;SR&amp;amp;ED&#x201d;) expenditures.  The Canadian valuation allowance represents a material portion of the Company's total valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021 and 2020, the Company had accumulated taxable losses available to offset future years&#x2019; federal and provincial taxable income in Canada of approximately $6,669 million and $6,530 million, respectively.&#160; As of December 31, 2021 and 2020, unclaimed ITCs available to offset future federal taxes in Canada were approximately $31 million and $37 million, respectively, which expire in the years 2022 through 2041.&#160; In addition, as of December 31, 2021 and 2020, pooled SR&amp;amp;ED expenditures available to offset against future taxable income in Canada were approximately $196 million and $206 million, respectively, which may be carried forward indefinitely.  As of December 31, 2021 and 2020, a full valuation allowance against the net Canadian deferred tax assets on the parent company has been provided of $1,965 million and $1,966 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021 and 2020, the Company had accumulated taxable losses available to offset future years' federal taxable income in the U.S. of approximately $266 million and $814 million, respectively, including acquired losses which expire in the years 2022 through 2037. While the remaining taxable losses are subject to multiple annual loss limitations as a result of previous ownership changes, the Company believes that the recoverability of the deferred tax assets associated with these taxable losses are more likely than not to be realized. As of December 31, 2021 and 2020 U.S. research and development credits available to offset future years' federal income taxes in the U.S. were approximately $119 million and $110 million, respectively, which includes acquired research and development credits and which expire in the years 2022 through 2042.  In the U.S. the Company has a capital loss of which is offset by a full valuation allowance since the benefit is not expected to be realized.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021 and 2020, the Company had accumulated taxable losses available to offset future years&#x2019; taxable income in Ireland of approximately $10,040 million and $8,387 million, respectively.&#160; As of  December&#160;31, 2021, the Company continues to have a capital loss which is offset by a valuation allowance on the portion of the loss for which a benefit is not expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides for income taxes on the unremitted earnings of its direct foreign affiliates except for its direct U.S. subsidiaries.  The Company continues to assert that the unremitted earnings of its U.S.&#160;subsidiaries will be permanently reinvested and not repatriated.  As of December 31, 2021, the Company estimates that there will be no tax liability attributable to unremitted earnings of its U.S. subsidiaries. However, distribution of future earnings could be subject to U.S. withholding tax.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021 and 2020, unrecognized tax benefits (including interest and penalties) were $927 million and $1,025 million, of which $271 million and $414 million would affect the effective income tax rate, respectively. In 2021 and 2020, the remaining unrecognized tax benefits would not impact the effective tax rate as the tax positions are offset against existing tax attributes or are timing in nature. In 2021 and 2020, the Company recognized net increases to unrecognized tax benefits for current year tax positions of $79 million and $66 million, respectively.  The Company recognized a net reduction of $177 million during 2021 and a net reduction of $42 million during 2020 in the unrecognized tax benefits related to tax positions taken in the prior years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides for interest and penalties related to unrecognized tax benefits in the provision for income taxes. As of December 31, 2021 and 2020, accrued interest and penalties related to unrecognized tax benefits were approximately $41 million and $49 million, respectively. In 2021, the Company recognized a net decrease of approximately $8 million and, in 2020, recognized an increase of  $4 million of interest and&#160;penalties, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and one or more of its subsidiaries file federal income tax returns in Canada, the U.S., and other foreign jurisdictions, as well as various provinces and states in Canada and the U.S.&#160;The Company and its subsidiaries have open tax years, primarily from 2012 to 2020, with significant taxing jurisdictions, respectively, including Canada and the U.S.&#160;These open years contain certain matters that could be subject to differing interpretations of applicable tax laws and regulations and tax treaties, as they relate to the amount, timing, or inclusion of revenues and expenses, or the sustainability of income tax positions of the Company and its subsidiaries. Certain of these tax years are expected to remain open indefinitely.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.931%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jurisdiction:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Open Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States - Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2015 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2012 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2013 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2016 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2016 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Netherlands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Australia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2011 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Luxembourg&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Internal Revenue Service (the &#x201c;IRS&#x201d;) completed its examinations of the Company&#x2019;s U.S. consolidated federal income tax returns for the years 2013 and 2014. There were no material adjustments to the Company's taxable income as a result of these examinations.  However, the 2014 tax year remains open to the extent of a 2017 capital loss carried back to that year. Additionally, the IRS has selected for examination the Company's annual tax filings for 2015 and 2016 and the Company's short period tax return for the period ended September 8, 2017, which was filed as a result of the Company's internal restructuring efforts during 2017. In 2017, the Company undertook an internal restructuring in the form of what is commonly known as a Granite Trust transaction, which resulted in a recorded capital loss (the &#x201c;2017 Capital Loss&#x201d;). Recently, the Company has received a notice of proposed adjustment from the IRS that would disallow the 2017 Capital Loss and expects to receive a notice of proposed tax deficiency from the IRS, after which the Company intends to contest proposed tax deficiency through the IRS administrative appeals process. If the Company were ultimately unsuccessful in defending its position, and all or a substantial portion of the 2017 Capital Loss deduction were disallowed, the Company could be liable for additional taxes (excluding penalties and interest) of up to $2,100&#160;million, which could have an adverse effect on the Company&#x2019;s financial condition and results of operations. The Company intends to vigorously defend its position, including through appropriate litigation, if necessary, and ultimately believes it will sustain its deduction of the 2017 Capital Loss, and, accordingly, no income tax provision has been recorded.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is currently under examination by the Canada Revenue Agency (&#x201c;CRA&#x201d;) for three separate cycles: (a) years 2012 through 2013 (b) years 2014 through 2015, and (c) years 2016 through 2017.  The Company believes that the CRA will open an audit cycle for the years 2018 &#x2013; 2019 in 2022.  The Company settled the tax years from 2005 through 2009 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with the CRA. The Company had previously filed a Notice of Objection related to the assessment of these years and reduced net operating losses with a full valuation allowance by CAD 44&#160;million to close these years.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The adjustment did not result in a material change to the provision for income taxes.  The CRA audits of the 2010 and 2011 tax years were closed in 2016 and resulted in no material adjustments. The Company received an assessment for certain transfer pricing matters in 2012 and 2013 for CAD 85&#160;million and CAD 90&#160;million, respectively.  The Company disagrees with the adjustments and has filed a Notice of Objection for 2012 and 2013.  The Company settled certain transfer pricing matters relating the 2015 and 2016 tax years resulting in a reduction to its NOLs of approximately CAD 21&#160;million for 2015 and will receive a further adjustment for 2016.  The expected adjustment for 2016 will reduce NOLs currently offset by a full valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s subsidiaries in Germany are under audit for tax years 2014 through 2016.  At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s subsidiaries in Australia are under audit by the Australian Tax Office for various years beginning in 2010. On August 8, 2017, the Australian Taxation Office issued a notice of assessment for the tax years 2011 through 2017 in the aggregate amount of $117 million, which includes penalties and interest.  The Company disagrees with the assessment and continues to believe that its tax positions are appropriate and supported by the facts, circumstances and applicable laws. The Company intends to defend its tax position in this matter vigorously and has filed a holding objection against the assessment by the Australian Taxation Office and has secured a bank guarantee to cover any potential cash outlays regarding this assessment. The bank guarantee has been reduced over time to now be an immaterial value.  Negotiations with the Australian Tax Office are ongoing and the Company expects to enter into a Settlement Deed in early 2022 with no material adverse results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company's U.S. affiliates remain under examination for various state tax audits in the U.S. for years 2015 through 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain affiliates of the Company in regions outside of Canada, the U.S., Germany, Luxembourg and Australia are currently under examination by relevant taxing authorities, and all necessary accruals have been recorded, including uncertain tax benefits.  At this time, the Company does not expect that proposed adjustments, if any, would be material to the Company's Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of the unrecognized tax&#160;benefits for 2021, 2020 and 2019: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes it is reasonably possible that the total amount of unrecognized tax benefits at December 31, 2021 could decrease by approximately $104 million in the next twelve months as a result of the resolution of certain tax and transfer pricing audits and other events.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzEyNzkz_48a0afec-5bbb-4a3a-ba64-810767af43f0">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of Loss before benefit from income taxes for 2021, 2020 and 2019 consist of:  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(701)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(524)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo3OGU2MGJhZDNmMjg0MmY2OTM4Mjk0NTE1YTRiOGIxMS90YWJsZXJhbmdlOjc4ZTYwYmFkM2YyODQyZjY5MzgyOTQ1MTVhNGI4YjExXzEtMi0xLTEtOTQ4MzE_44a58e39-77c8-490c-bbce-40e2e83c956e"
      unitRef="usd">-323000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo3OGU2MGJhZDNmMjg0MmY2OTM4Mjk0NTE1YTRiOGIxMS90YWJsZXJhbmdlOjc4ZTYwYmFkM2YyODQyZjY5MzgyOTQ1MTVhNGI4YjExXzEtNC0xLTEtOTQ4MzE_077ee069-7bcd-4d11-ae81-b755303d5a19"
      unitRef="usd">-410000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo3OGU2MGJhZDNmMjg0MmY2OTM4Mjk0NTE1YTRiOGIxMS90YWJsZXJhbmdlOjc4ZTYwYmFkM2YyODQyZjY5MzgyOTQ1MTVhNGI4YjExXzEtNi0xLTEtOTQ4MzE_07684475-8cec-4adf-a16e-7cf77d0ed5b9"
      unitRef="usd">-2396000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo3OGU2MGJhZDNmMjg0MmY2OTM4Mjk0NTE1YTRiOGIxMS90YWJsZXJhbmdlOjc4ZTYwYmFkM2YyODQyZjY5MzgyOTQ1MTVhNGI4YjExXzItMi0xLTEtOTQ4MzE_e208f7c9-2ed3-4bd1-80e3-dbcb398a7c85"
      unitRef="usd">-701000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo3OGU2MGJhZDNmMjg0MmY2OTM4Mjk0NTE1YTRiOGIxMS90YWJsZXJhbmdlOjc4ZTYwYmFkM2YyODQyZjY5MzgyOTQ1MTVhNGI4YjExXzItNC0xLTEtOTQ4MzE_e675393a-5406-4a77-8e14-09f892b1db4c"
      unitRef="usd">-524000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo3OGU2MGJhZDNmMjg0MmY2OTM4Mjk0NTE1YTRiOGIxMS90YWJsZXJhbmdlOjc4ZTYwYmFkM2YyODQyZjY5MzgyOTQ1MTVhNGI4YjExXzItNi0xLTEtOTQ4MzE_e3f2a5da-7bd7-405a-bfa3-78978c54d41f"
      unitRef="usd">559000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo3OGU2MGJhZDNmMjg0MmY2OTM4Mjk0NTE1YTRiOGIxMS90YWJsZXJhbmdlOjc4ZTYwYmFkM2YyODQyZjY5MzgyOTQ1MTVhNGI4YjExXzMtMi0xLTEtOTQ4MzE_1c77bc36-b682-4933-820f-de684a4b8593"
      unitRef="usd">-1024000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo3OGU2MGJhZDNmMjg0MmY2OTM4Mjk0NTE1YTRiOGIxMS90YWJsZXJhbmdlOjc4ZTYwYmFkM2YyODQyZjY5MzgyOTQ1MTVhNGI4YjExXzMtNC0xLTEtOTQ4MzE_85e471b9-c468-470b-a7fd-79afa2893e3d"
      unitRef="usd">-934000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo3OGU2MGJhZDNmMjg0MmY2OTM4Mjk0NTE1YTRiOGIxMS90YWJsZXJhbmdlOjc4ZTYwYmFkM2YyODQyZjY5MzgyOTQ1MTVhNGI4YjExXzMtNi0xLTEtOTQ4MzE_e0eca1f6-f1aa-4b8d-b6c7-bd1dff1d6157"
      unitRef="usd">-1837000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzEyNzg0_58dacd67-1a85-48a5-9552-3a5f5dee9cd6">&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of Benefit from income taxes for 2021, 2020 and 2019 consist of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(224)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzItMi0xLTEtOTQ4MzE_a097bcde-e53f-4d22-84f9-09f1f561a24b"
      unitRef="usd">23000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzItNC0xLTEtOTQ4MzE_928708af-faa5-4bfc-9a0a-29acb7702c25"
      unitRef="usd">8000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzItNi0xLTEtOTQ4MzE_41b77ac4-0aa1-4a70-b12e-21c381768a68"
      unitRef="usd">12000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzMtMi0xLTEtOTQ4MzE_56590b3f-d011-438d-854b-2919558cb59d"
      unitRef="usd">-74000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzMtNC0xLTEtOTQ4MzE_a0cba2ac-669b-40a3-8137-11686653b403"
      unitRef="usd">216000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzMtNi0xLTEtOTQ4MzE_5ff8e665-7aed-4fdc-82ca-124d82b72dbc"
      unitRef="usd">116000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzQtMi0xLTEtOTQ4MzE_80c1820a-91c9-4378-9b47-7f95e7a2dfd8"
      unitRef="usd">-51000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzQtNC0xLTEtOTQ4MzE_533bca2f-f728-4685-9371-0c7bbf3ebf4a"
      unitRef="usd">224000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzQtNi0xLTEtOTQ4MzE_208cbfc7-fdb8-4a69-92ca-8bcc3bcd8ebb"
      unitRef="usd">128000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzYtMi0xLTEtOTQ4MzE_c1d30500-5886-4ffd-bf39-36bd3603b431"
      unitRef="usd">-20000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzYtNC0xLTEtOTQ4MzE_881ea8c8-070e-4296-ba38-54777a1023cb"
      unitRef="usd">-9000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzYtNi0xLTEtOTQ4MzE_a6f29de1-43fe-4232-9c7d-16f428f9a66b"
      unitRef="usd">5000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzctMi0xLTEtOTQ4MzE_1d539bbc-4d5b-4bef-b2f7-e8288c876fc3"
      unitRef="usd">-16000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzctNC0xLTEtOTQ4MzE_f924f007-de81-4e67-97d0-0104fe20cbe9"
      unitRef="usd">-590000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzctNi0xLTEtOTQ4MzE_f22e6930-f0c3-4cc4-9551-14549f9fbe92"
      unitRef="usd">-187000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzgtMi0xLTEtOTQ4MzE_5e1ebe03-68cd-4ddb-bab2-d6ab5d6b471d"
      unitRef="usd">-36000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzgtNC0xLTEtOTQ4MzE_bd9195a0-302a-46f2-bc02-1130795d3da2"
      unitRef="usd">-599000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzgtNi0xLTEtOTQ4MzE_3e94fd29-73b6-445d-880a-dac2ef0c8de4"
      unitRef="usd">-182000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzktMi0xLTEtOTQ4MzE_3c8b5cf7-e519-4bdc-bc7c-f63d4bc29be7"
      unitRef="usd">-87000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzktNC0xLTEtOTQ4MzE_90daf8de-441f-4dbd-b7ed-c87bc6a84efa"
      unitRef="usd">-375000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyMmU0ODFkNTVhZTk0ZTMwYjk5MTJkYTVjM2I0MTkwYy90YWJsZXJhbmdlOjIyZTQ4MWQ1NWFlOTRlMzBiOTkxMmRhNWMzYjQxOTBjXzktNi0xLTEtOTQ4MzE_71abe0b2-fb21-4cfc-84f8-cba658c6d71a"
      unitRef="usd">-54000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzEyNzg1_e7d5f433-3f17-428d-892a-7b3cb1963131">&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Benefit from income taxes differs from the expected amount calculated by applying the Company&#x2019;s Canadian statutory rate of 26.9% to Loss before benefit from income taxes for 2021, 2020 and 2019 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Loss before benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected benefit from income taxes at Canadian statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible amount of share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments to tax attributes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance related to foreign tax credits and NOLs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt;text-indent:-4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance on Canadian deferred tax assets and tax rate changes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax rate differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible portion of Goodwill impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefit on intra-entity transfers&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzIyMw_137620d8-b047-4d43-ac44-a78ac9db5963"
      unitRef="number">0.269</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzIyMw_2feea97e-e592-41cc-98bb-8a7beabf0288"
      unitRef="number">0.269</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzIyMw_fbc79e19-6ee6-4728-86d8-06b83e313bbe"
      unitRef="number">0.269</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzEtMi0xLTEtOTQ4MzE_434eed2b-bfd0-4adf-8140-d45c4dc679e0"
      unitRef="usd">-1024000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzEtNC0xLTEtOTQ4MzE_83274b80-127d-4848-a027-27d30de8110b"
      unitRef="usd">-934000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzEtNi0xLTEtOTQ4MzE_587c1855-5487-427d-8efe-410e065325de"
      unitRef="usd">-1837000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzMtMi0xLTEtOTQ4MzE_71276c10-8ad9-4b60-85d2-30d97f75e124"
      unitRef="usd">-275000000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzMtNC0xLTEtOTQ4MzE_ecab016d-73db-4e12-bba6-6bb7c1c18991"
      unitRef="usd">-251000000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzMtNi0xLTEtOTQ4MzE_1ab61b82-d00f-4663-9944-471314fcc92d"
      unitRef="usd">-494000000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzQtMi0xLTEtOTQ4MzE_09fecb4a-c139-4e20-848c-13fcdcd150ca"
      unitRef="usd">9000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzQtNC0xLTEtOTQ4MzE_e856f76f-d5b3-4de8-8a7b-817399a54b42"
      unitRef="usd">9000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzQtNi0xLTEtOTQ4MzE_71d456ff-04eb-44c8-a8e0-01979c08f883"
      unitRef="usd">7000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <bhc:EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzUtMi0xLTEtOTQ4MzE_0d9d17e0-06ab-4593-81ec-e81b409e1a40"
      unitRef="usd">59000000</bhc:EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount>
    <bhc:EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzUtNC0xLTEtOTQ4MzE_d17f7c4b-dcf4-40a7-afbc-431f82ca9ac2"
      unitRef="usd">-26000000</bhc:EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount>
    <bhc:EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzUtNi0xLTEtOTQ4MzE_35b5c7cc-3c0e-4b0a-b198-5d9c1ce9bee1"
      unitRef="usd">99000000</bhc:EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount>
    <bhc:IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzYtMi0xLTEtOTQ4MzE_9097cbcd-86a9-4b32-a997-d1eedccdcd6a"
      unitRef="usd">-28000000</bhc:IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance>
    <bhc:IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzYtNC0xLTEtOTQ4MzE_24f6ed05-2a42-4d25-9caf-f10d89534a67"
      unitRef="usd">-62000000</bhc:IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance>
    <bhc:IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzYtNi0xLTEtOTQ4MzE_2bf619a7-236f-4944-8853-48c559fdbadf"
      unitRef="usd">-21000000</bhc:IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzctMi0xLTEtOTQ4MzE_353614ca-668e-4d9a-b9bd-60c5067d42b0"
      unitRef="usd">-40000000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzctNC0xLTEtOTQ4MzE_75744d6f-4eee-4ec8-b2cd-b6a5ba313ccf"
      unitRef="usd">-687000000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzctNi0xLTEtOTQ4MzE_76b530e9-f2fb-46a6-ab6d-8a5c20dd90a6"
      unitRef="usd">142000000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <bhc:IncomeTaxReconciliationUncertainTaxPositions
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzgtMi0xLTEtOTQ4MzE_c7a10253-0427-4875-8c66-59226381897b"
      unitRef="usd">-112000000</bhc:IncomeTaxReconciliationUncertainTaxPositions>
    <bhc:IncomeTaxReconciliationUncertainTaxPositions
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzgtNC0xLTEtOTQ4MzE_2ca9dacf-e800-47b7-8ed4-95dd75799456"
      unitRef="usd">163000000</bhc:IncomeTaxReconciliationUncertainTaxPositions>
    <bhc:IncomeTaxReconciliationUncertainTaxPositions
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzgtNi0xLTEtOTQ4MzE_694d36c1-0c99-4cb0-9125-1ceeb01416de"
      unitRef="usd">350000000</bhc:IncomeTaxReconciliationUncertainTaxPositions>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzktMi0xLTEtOTQ4MzE_2934e825-1a72-4c77-9326-cb8809fda1de"
      unitRef="usd">198000000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzktNC0xLTEtOTQ4MzE_bebc2ba0-8734-4da2-aa4b-d18f5a85530b"
      unitRef="usd">128000000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzktNi0xLTEtOTQ4MzE_a947e25e-7ed9-4cc1-8c67-cd6e7dd76b18"
      unitRef="usd">-186000000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzEwLTItMS0xLTk0ODMx_307706cb-9e77-400b-820b-99745dccb82a"
      unitRef="usd">99000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzEwLTQtMS0xLTk0ODMx_1e45e6e8-662e-4861-a7fe-ba9785463f6b"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzEwLTYtMS0xLTk0ODMx_c4a4c0ca-645d-428b-8527-bd468f06ebaf"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <bhc:IncomeTaxReconciliationDeferredIntercompanyProfit
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzExLTItMS0xLTk0ODMx_4f79a88d-5d69-41d5-8b45-5b9edceb83f3"
      unitRef="usd">0</bhc:IncomeTaxReconciliationDeferredIntercompanyProfit>
    <bhc:IncomeTaxReconciliationDeferredIntercompanyProfit
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzExLTQtMS0xLTk0ODMx_a970e31b-76d7-48ad-9545-a1d521b9e6d1"
      unitRef="usd">338000000</bhc:IncomeTaxReconciliationDeferredIntercompanyProfit>
    <bhc:IncomeTaxReconciliationDeferredIntercompanyProfit
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzExLTYtMS0xLTk0ODMx_d817f659-e1e2-4293-ab01-4c946a4b6d9c"
      unitRef="usd">0</bhc:IncomeTaxReconciliationDeferredIntercompanyProfit>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzEyLTItMS0xLTk0ODMx_f051ca52-8e55-42b1-839f-13a2de3cd513"
      unitRef="usd">3000000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzEyLTQtMS0xLTk0ODMx_85c25e2c-7c2b-4740-8a27-4f13dc749b5c"
      unitRef="usd">13000000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzEyLTYtMS0xLTk0ODMx_a896a901-8f69-4fdd-b917-cff57245c87b"
      unitRef="usd">49000000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzEzLTItMS0xLTk0ODMx_b3885901-b88d-4d31-b211-1e7fb390f743"
      unitRef="usd">-87000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzEzLTQtMS0xLTk0ODMx_4ce276db-1f4e-47e3-9e50-7ccf8d3562ac"
      unitRef="usd">-375000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZToyNTU5ODg2MTRiOTU0ZmFhYmQyYWRjYzUxODczY2NkYy90YWJsZXJhbmdlOjI1NTk4ODYxNGI5NTRmYWFiZDJhZGNjNTE4NzNjY2RjXzEzLTYtMS0xLTk0ODMx_efba7445-665a-41a1-8471-5e6a8bb5a0df"
      unitRef="usd">-54000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzEyNzk1_a36f5c09-507f-4878-b48e-45043177cd8f">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities as of December 31, 2021 and 2020 consist of: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Scientific Research and Experimental Development pool&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets net of valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plant, equipment and technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside basis differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized FX on U.S. dollar debt and other financing cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of the deferred tax asset valuation allowance for 2021, 2020 and 2019: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charged to Benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charged to other accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <bhc:DeferredTaxAssetsTaxLossCarryforwards
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzItMi0xLTEtOTQ4MzE_8483eae4-8e3c-48d6-8312-ef8627d3dff7"
      unitRef="usd">2973000000</bhc:DeferredTaxAssetsTaxLossCarryforwards>
    <bhc:DeferredTaxAssetsTaxLossCarryforwards
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzItNC0xLTEtOTQ4MzE_7884ec59-145e-4b09-91cd-a6db8c15b6c3"
      unitRef="usd">2924000000</bhc:DeferredTaxAssetsTaxLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzMtMi0xLTEtOTQ4MzE_1448a6a8-e652-44c4-a5cc-0fae3b62ebd7"
      unitRef="usd">991000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzMtNC0xLTEtOTQ4MzE_8f1ff2ac-6888-41d4-9b24-430d2a18d381"
      unitRef="usd">1004000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <bhc:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzQtMi0xLTEtOTQ4MzE_5c0b75cc-68d6-454d-968b-2a361299d4c0"
      unitRef="usd">173000000</bhc:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment>
    <bhc:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzQtNC0xLTEtOTQ4MzE_4ed9e4cf-9cef-434a-91d2-a3a67f8ae0a0"
      unitRef="usd">172000000</bhc:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment>
    <bhc:DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzUtMi0xLTEtOTQ4MzE_9bb77961-bdef-4d56-9a45-fb44941224c5"
      unitRef="usd">52000000</bhc:DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool>
    <bhc:DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzUtNC0xLTEtOTQ4MzE_cdce10d4-6112-40bc-9312-b0636b7b85a5"
      unitRef="usd">55000000</bhc:DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzYtMi0xLTEtOTQ4MzE_df2c39fc-128f-4355-a4ee-322bdb2eeeb9"
      unitRef="usd">14000000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzYtNC0xLTEtOTQ4MzE_98f0763d-f6f2-4688-bf1a-8a8f5f5bc5a0"
      unitRef="usd">20000000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzctMi0xLTEtOTQ4MzE_2c65af03-3332-473f-bfcc-beb3a7a111da"
      unitRef="usd">3000000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzctNC0xLTEtOTQ4MzE_dfbe5117-5457-4b5c-ba69-13ae57a00e61"
      unitRef="usd">9000000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <bhc:DeferredTaxAssetsPrepaidExpenses
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzgtMi0xLTEtOTQ4MzE_3868a2b0-1bad-43ea-9b4b-48d687abf81e"
      unitRef="usd">26000000</bhc:DeferredTaxAssetsPrepaidExpenses>
    <bhc:DeferredTaxAssetsPrepaidExpenses
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzgtNC0xLTEtOTQ4MzE_e9908c3e-63bc-44e9-8409-b598d32c757c"
      unitRef="usd">27000000</bhc:DeferredTaxAssetsPrepaidExpenses>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzktMi0xLTEtOTQ4MzE_b49ac937-4cd8-4895-9a8a-e9e63db931b0"
      unitRef="usd">17000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzktNC0xLTEtOTQ4MzE_9dcb8d86-237c-40f1-a791-d26bc50f6697"
      unitRef="usd">16000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzEwLTItMS0xLTk0ODMx_c2850bb7-1d82-4785-b650-672347480c0b"
      unitRef="usd">38000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzEwLTQtMS0xLTk0ODMx_69fabca9-fb87-4e35-b4fb-0137efc3259f"
      unitRef="usd">24000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzExLTItMS0xLTk0ODMx_34b0732a-2574-4878-a2d5-22ad6cf3ea33"
      unitRef="usd">4287000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzExLTQtMS0xLTk0ODMx_4e09c117-b4a9-4e07-8835-e293ba85b721"
      unitRef="usd">4251000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzEyLTItMS0xLTk0ODMx_9c554600-ddc9-4175-ba32-9fae8bfe0031"
      unitRef="usd">2222000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzEyLTQtMS0xLTk0ODMx_d3bfa287-cb63-414f-b079-1ea08570b7ae"
      unitRef="usd">2252000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzEzLTItMS0xLTk0ODMx_6356e9e4-ddca-45c4-a8e4-ecea99ef332e"
      unitRef="usd">2065000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzEzLTQtMS0xLTk0ODMx_ffaa8845-ab4f-4e7a-846f-485739d9f9ab"
      unitRef="usd">1999000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzE1LTItMS0xLTk0ODMx_1404ee48-df0a-41c8-8203-4a70e66ac2b6"
      unitRef="usd">188000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzE1LTQtMS0xLTk0ODMx_11c0214d-f29a-4ffa-9e33-e31e04274f65"
      unitRef="usd">228000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <bhc:DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzE2LTItMS0xLTk0ODMx_febc9b55-7a4a-464a-8b34-2996a37ff37d"
      unitRef="usd">44000000</bhc:DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes>
    <bhc:DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzE2LTQtMS0xLTk0ODMx_11e96dd0-b994-4b29-91d0-4f8e5cb936cc"
      unitRef="usd">89000000</bhc:DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzE3LTItMS0xLTk0ODMx_af0102c4-23cf-4464-aa33-aa045b133948"
      unitRef="usd">110000000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzE3LTQtMS0xLTk0ODMx_2c8def22-c357-4494-a756-4c91deda4245"
      unitRef="usd">71000000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzE4LTItMS0xLTk0ODMx_c65daf2c-4335-49ba-8e2c-4768478d3281"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains>
    <us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzE4LTQtMS0xLTk0ODMx_584524c6-cd51-43e1-801f-0f7afeda270b"
      unitRef="usd">2000000</us-gaap:DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzE5LTItMS0xLTk0ODMx_be9defe1-6bd1-41e7-9c16-7b5156b7d1f6"
      unitRef="usd">342000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzE5LTQtMS0xLTk0ODMx_0e9d90be-a923-485b-8147-843b3019e787"
      unitRef="usd">390000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzIwLTItMS0xLTk0ODMx_3e102fae-3308-4791-8a86-800327133134"
      unitRef="usd">1723000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTpiMzAyMDVjYjQzNjk0NmM2OWU3YzkzYTJjZWU2N2FkMS90YWJsZXJhbmdlOmIzMDIwNWNiNDM2OTQ2YzY5ZTdjOTNhMmNlZTY3YWQxXzIwLTQtMS0xLTk0ODMx_35d081b9-a850-4e6c-b607-0785aca16f5a"
      unitRef="usd">1609000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ibffc30cecb9c4ef0b327417dbb601c42_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo0YTMzYjZmM2U3YzE0NzQyYjQxMzhmYTlhOTAzN2YxYi90YWJsZXJhbmdlOjRhMzNiNmYzZTdjMTQ3NDJiNDEzOGZhOWE5MDM3ZjFiXzEtMi0xLTEtOTQ4MzE_e781b92f-7785-4dc8-afa6-8e6e10992074"
      unitRef="usd">2252000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i4f6b4de2972a45b48db5cc52d91b1a88_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo0YTMzYjZmM2U3YzE0NzQyYjQxMzhmYTlhOTAzN2YxYi90YWJsZXJhbmdlOjRhMzNiNmYzZTdjMTQ3NDJiNDEzOGZhOWE5MDM3ZjFiXzEtNC0xLTEtOTQ4MzE_4ccf618c-9699-41a6-be45-861cd1fe91cc"
      unitRef="usd">2831000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="if84d1523bc1740e9b7b6df3d57e513ef_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo0YTMzYjZmM2U3YzE0NzQyYjQxMzhmYTlhOTAzN2YxYi90YWJsZXJhbmdlOjRhMzNiNmYzZTdjMTQ3NDJiNDEzOGZhOWE5MDM3ZjFiXzEtNi0xLTEtOTQ4MzE_6bacef1f-7980-4c43-95ef-0ad382029c1a"
      unitRef="usd">2913000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <bhc:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes
      contextRef="i915068d30e9c465eb1028aff329712ac_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo0YTMzYjZmM2U3YzE0NzQyYjQxMzhmYTlhOTAzN2YxYi90YWJsZXJhbmdlOjRhMzNiNmYzZTdjMTQ3NDJiNDEzOGZhOWE5MDM3ZjFiXzItMi0xLTEtOTQ4MzE_1b50c7d5-adea-4c53-9d37-0b778b512acb"
      unitRef="usd">-63000000</bhc:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes>
    <bhc:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes
      contextRef="ic055386399994346ad881ca91aeba458_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo0YTMzYjZmM2U3YzE0NzQyYjQxMzhmYTlhOTAzN2YxYi90YWJsZXJhbmdlOjRhMzNiNmYzZTdjMTQ3NDJiNDEzOGZhOWE5MDM3ZjFiXzItNC0xLTEtOTQ4MzE_8b8d4be8-63da-4020-ab37-bb3492bbb07f"
      unitRef="usd">-773000000</bhc:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes>
    <bhc:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes
      contextRef="i67ba81224f654cb2b0f2010018455b61_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo0YTMzYjZmM2U3YzE0NzQyYjQxMzhmYTlhOTAzN2YxYi90YWJsZXJhbmdlOjRhMzNiNmYzZTdjMTQ3NDJiNDEzOGZhOWE5MDM3ZjFiXzItNi0xLTEtOTQ4MzE_fa1fa240-43e9-40a1-8e65-357bbdefbd04"
      unitRef="usd">13000000</bhc:SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i915068d30e9c465eb1028aff329712ac_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo0YTMzYjZmM2U3YzE0NzQyYjQxMzhmYTlhOTAzN2YxYi90YWJsZXJhbmdlOjRhMzNiNmYzZTdjMTQ3NDJiNDEzOGZhOWE5MDM3ZjFiXzMtMi0xLTEtOTQ4MzE_be03e754-8df8-4648-83bc-07bcfb64b2fe"
      unitRef="usd">33000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="ic055386399994346ad881ca91aeba458_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo0YTMzYjZmM2U3YzE0NzQyYjQxMzhmYTlhOTAzN2YxYi90YWJsZXJhbmdlOjRhMzNiNmYzZTdjMTQ3NDJiNDEzOGZhOWE5MDM3ZjFiXzMtNC0xLTEtOTQ4MzE_67adb9c4-0ff7-4bd3-8d45-36c6beeabb68"
      unitRef="usd">194000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="i67ba81224f654cb2b0f2010018455b61_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo0YTMzYjZmM2U3YzE0NzQyYjQxMzhmYTlhOTAzN2YxYi90YWJsZXJhbmdlOjRhMzNiNmYzZTdjMTQ3NDJiNDEzOGZhOWE5MDM3ZjFiXzMtNi0xLTEtOTQ4MzE_a344f7fc-2f2b-43c6-8ca3-5bb911133da7"
      unitRef="usd">-95000000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id379e27a083f4bb1879222afc10f82f9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo0YTMzYjZmM2U3YzE0NzQyYjQxMzhmYTlhOTAzN2YxYi90YWJsZXJhbmdlOjRhMzNiNmYzZTdjMTQ3NDJiNDEzOGZhOWE5MDM3ZjFiXzQtMi0xLTEtOTQ4MzE_f0b64635-b1de-4aed-b08a-5193712877ea"
      unitRef="usd">2222000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ibffc30cecb9c4ef0b327417dbb601c42_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo0YTMzYjZmM2U3YzE0NzQyYjQxMzhmYTlhOTAzN2YxYi90YWJsZXJhbmdlOjRhMzNiNmYzZTdjMTQ3NDJiNDEzOGZhOWE5MDM3ZjFiXzQtNC0xLTEtOTQ4MzE_7d6c1102-b191-4a9d-9766-9756bd722da7"
      unitRef="usd">2252000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i4f6b4de2972a45b48db5cc52d91b1a88_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo0YTMzYjZmM2U3YzE0NzQyYjQxMzhmYTlhOTAzN2YxYi90YWJsZXJhbmdlOjRhMzNiNmYzZTdjMTQ3NDJiNDEzOGZhOWE5MDM3ZjFiXzQtNi0xLTEtOTQ4MzE_440e421a-1a7c-4323-95bf-e2598af58cc2"
      unitRef="usd">2831000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i187c9f9f5937400ba090ce33c5c46259_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzI2MDE_6f0d0a5d-6229-4703-9ab2-1fce0608170b"
      unitRef="usd">-30000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ie80a8d41d8154b9fa08ad7c9d7849024_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzI4MzM_5e8f61a7-344e-4500-9f8f-1aa85d4faa93"
      unitRef="usd">-579000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <bhc:AccumulatedLossesAvailableForFederalPurposes
      contextRef="i27ecb8e5fdeb4e02bde51b102f8143fc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzM1Nzg_7f80fda3-375e-41a0-be2d-08ece0850c2d"
      unitRef="usd">6669000000</bhc:AccumulatedLossesAvailableForFederalPurposes>
    <bhc:AccumulatedLossesAvailableForFederalPurposes
      contextRef="ib41b4897f8fc4d62a5af15ed7e0950d0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzM1ODU_a7f1f04f-fbfb-4f0d-978d-780f84ca5905"
      unitRef="usd">6530000000</bhc:AccumulatedLossesAvailableForFederalPurposes>
    <bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits
      contextRef="i27ecb8e5fdeb4e02bde51b102f8143fc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzM2OTk_ad20e31c-da1e-4029-9829-8f57e449f541"
      unitRef="usd">31000000</bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits>
    <bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits
      contextRef="ib41b4897f8fc4d62a5af15ed7e0950d0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzM3MDY_ee153585-ac58-4a5f-88b4-287805af81ad"
      unitRef="usd">37000000</bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ia1d46f5c753c4613a41c0b24b7215d74_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzM4OTg_656f69d6-0c38-4102-8483-e6ded75f4bd8"
      unitRef="usd">196000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i64fcc3a1ff2b47af8fa496e471287739_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzM5MDU_600c0d1e-f0c7-4a46-b58d-2ce394c6751e"
      unitRef="usd">206000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i27ecb8e5fdeb4e02bde51b102f8143fc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzQwOTI_1f62dab4-66df-4ba4-bff8-58d0e96aff74"
      unitRef="usd">1965000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="ib41b4897f8fc4d62a5af15ed7e0950d0_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzQwOTk_1305c4be-d5f2-4dd4-982d-0d7fa55d0080"
      unitRef="usd">1966000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <bhc:AccumulatedLossesAvailableForFederalPurposes
      contextRef="i3a91733048244e1caf9bc10fed86c62d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzQyNTY_60763c3b-c189-4ec9-be34-f4329734ea35"
      unitRef="usd">266000000</bhc:AccumulatedLossesAvailableForFederalPurposes>
    <bhc:AccumulatedLossesAvailableForFederalPurposes
      contextRef="ie95a42cdf2a44bae88536d5e9143a530_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzQyNjM_868368b6-f9ec-4bb5-8200-82926588a1e1"
      unitRef="usd">814000000</bhc:AccumulatedLossesAvailableForFederalPurposes>
    <bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits
      contextRef="i3a91733048244e1caf9bc10fed86c62d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzQ3NjE_78f9a2e8-a4e6-4bf6-abe3-d4bdf702f420"
      unitRef="usd">119000000</bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits>
    <bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits
      contextRef="ie95a42cdf2a44bae88536d5e9143a530_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzQ3Njg_3b385be3-ab83-4baf-84f3-b7383853bbc6"
      unitRef="usd">110000000</bhc:UnclaimedTaxCreditsAndResearchAndDevelopmentCredits>
    <bhc:AccumulatedLossesAvailableForFederalPurposes
      contextRef="id6d550dbbfda46bf82a16f8ce10ebe0b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzUxNjc_adbd8ec4-690d-4f04-b560-af8ed29a3a1f"
      unitRef="usd">10040000000</bhc:AccumulatedLossesAvailableForFederalPurposes>
    <bhc:AccumulatedLossesAvailableForFederalPurposes
      contextRef="i541042590f234b388cebba5a8ab708be_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzUxNzQ_be320d95-1cd0-4768-a6f9-38e0371a1b60"
      unitRef="usd">8387000000</bhc:AccumulatedLossesAvailableForFederalPurposes>
    <bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzU5MzE_5d261528-1833-4a33-abad-80f440dc2752"
      unitRef="usd">927000000</bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties>
    <bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzU5Mzg_8eb568e0-f312-41dd-a6a0-a9c01a6323b2"
      unitRef="usd">1025000000</bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzU5NTE_26011e86-f35d-4edb-a2c1-37869efc7665"
      unitRef="usd">271000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzU5NTg_5e945755-fe86-41a8-b40d-b04babe1f1bd"
      unitRef="usd">414000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <bhc:UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzYzMTY_e6b68821-0450-4f93-880f-a9557cbf8218"
      unitRef="usd">79000000</bhc:UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions>
    <bhc:UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzYzMjM_d707663f-df01-4430-a7f2-2d1582b07d06"
      unitRef="usd">66000000</bhc:UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions>
    <bhc:UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzYzODQ_a1a92004-cab2-4e64-afe0-419ca3b502cf"
      unitRef="usd">177000000</bhc:UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions>
    <bhc:UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzY0MjA_6233cace-b1a0-4d71-8654-269d5d4e0571"
      unitRef="usd">42000000</bhc:UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzY3MzQ_f2ec2f4e-b758-4969-8278-f37850b10c48"
      unitRef="usd">41000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzY3NDE_35bd3e8c-b44d-4216-9ad8-3a6577651d0f"
      unitRef="usd">49000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzY4MjE_9be89a15-53f0-4c4e-b656-57f008b6b8c7"
      unitRef="usd">-8000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzY4NjM_055661c2-e86c-4d9d-9e8d-399162f0a447"
      unitRef="usd">4000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <bhc:IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzY5MjM_91896c3d-7e26-4700-9c2c-4fbb079887d5"
      unitRef="subsidiary">1</bhc:IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzEyNzky_c40f39e0-23dd-4a41-aa59-9665c9ec53c3">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.931%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jurisdiction:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Open Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States - Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2015 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2012 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2013 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2016 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2016 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Netherlands&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Australia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2011 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Luxembourg&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 - 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:OpenTaxYear
      contextRef="i3981d7a177af492eb4fbd78ea657ad8f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzEtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjpkYzViNDAxODNmZDE0NGQwOWQ3OGM0NTAxZjdmODI0OF80_a78413a0-0978-4f3c-b8d8-9e10617430d8">2015</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="i0a701334d8d94a828739c539bfb11dbf_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzEtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjpkYzViNDAxODNmZDE0NGQwOWQ3OGM0NTAxZjdmODI0OF85_e9a79cc0-dfa7-41f4-93e2-c4b5bde19af2">2020</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="ic261bd3e9bfd4d98ae7b58e6abadcb92_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzItMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjowMmU5YjRhNTUwODQ0N2M1YTJkMjk1MjU4ZTY1NmEzMF80_a9140a37-0e74-4e45-89ca-8b594b45cd19">2012</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="i3c2e628003764836a5a04489d83647f6_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzItMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjowMmU5YjRhNTUwODQ0N2M1YTJkMjk1MjU4ZTY1NmEzMF85_482f6e1b-5214-4c39-8ebe-3c811d461cad">2020</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="i90867327964d4767846d8c36adbc2e43_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzMtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjoxYTZmMjhjNWQ1Yjg0MDBiODFlNmVlMTQ5YzkzYTUzZl80_4302c183-31dc-4d98-8bf4-2baa75fb45d0">2014</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="if4e269c5fff94bdba040ffb57118494d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzMtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjoxYTZmMjhjNWQ1Yjg0MDBiODFlNmVlMTQ5YzkzYTUzZl85_a8145d07-4442-41b5-9e64-40859d6b7866">2020</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="i65523828a01044e59ade22a5ccb853d2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzQtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjplNjdlNzczYzU3ODE0ZmZiODIzNDVmMjVlNDlkY2NkMl80_c7c7fa71-e905-4c61-bcfb-060c9be98643">2013</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="i5c327fe5449c48c48e8d5f0372ae6137_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzQtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjplNjdlNzczYzU3ODE0ZmZiODIzNDVmMjVlNDlkY2NkMl85_573a4d24-b81a-4e44-a70a-cd71cd5bf2c5">2020</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="ib902cbf8a7fe4328a5114bf1cab23702_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzUtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo3ZTgxZDgyYzg0OWQ0ZGFjOTU5MDcwMGUwNGI3NGU2Y180_e0588f5a-55ad-4871-8b39-dbf94dbb1521">2016</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="i1c126541a8a74e41a63df4a34dfd968a_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzUtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo3ZTgxZDgyYzg0OWQ0ZGFjOTU5MDcwMGUwNGI3NGU2Y185_a5b6bee7-b9df-4428-99c3-c8aa028ac944">2020</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="i96392c49eef14e5988d30ce53b0250b0_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzYtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjowZGVhY2ExYjMwNDA0MzQ1YTE1MWFhYmU4NWRmZGNhMV80_43f6b47e-20a6-449c-aa00-e3e9f870d11f">2016</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="i031396881a4b4914914165e52a669249_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzYtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjowZGVhY2ExYjMwNDA0MzQ1YTE1MWFhYmU4NWRmZGNhMV85_55663b89-c38c-4818-9996-f60b51f5a740">2020</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="ie5eb8fe6d6da478c96fbec9cb03cc330_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzctMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjowNWU2YWJiYTA4NGY0NTQwOWJlMzA0ZDQxNDhmYjE0Zl80_8fd1619a-27f6-4ad3-9efa-0ff7f456f4e9">2017</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="ie47ed3dfd2114787b382d6779d753245_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzctMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjowNWU2YWJiYTA4NGY0NTQwOWJlMzA0ZDQxNDhmYjE0Zl85_5847044e-3e59-4506-ba7c-091aa1930bb5">2020</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="i966ab6abce524555a38770e32731ec1b_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzgtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo0OWY0MjAwOWU3YTU0MmM5YjczNWU2Nzk1YzcyYWQyM180_0f53a362-adfc-4c8a-93b8-30f6169a1215">2011</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="id73c90871edb496a8acded32a4868495_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzgtMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo0OWY0MjAwOWU3YTU0MmM5YjczNWU2Nzk1YzcyYWQyM185_4fadd04b-dc63-482e-aea9-ea80cfd36ee8">2020</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="i5656a30a453e4f61bee5ce805d141aa0_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzktMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo2ZjE3MjMyYjFjYTE0YzBmYmU2MDQwMjQ4Yjg4ZGIwNV80_33de5765-410c-4700-b26c-e5c788b55576">2017</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="iaf6683fc8f2a4c7681664da8552f7c19_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTozODE4YzViYjhiZDI0MDVmYmE3MTQwMGViODc2NGUzMy90YWJsZXJhbmdlOjM4MThjNWJiOGJkMjQwNWZiYTcxNDAwZWI4NzY0ZTMzXzktMi0xLTEtOTQ4MzEvdGV4dHJlZ2lvbjo2ZjE3MjMyYjFjYTE0YzBmYmU2MDQwMjQ4Yjg4ZGIwNV85_5d10930d-3266-48ea-a758-aea4241f4a99">2020</us-gaap:OpenTaxYear>
    <us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzkwNDM_e64df7d0-b34c-4f36-b6b8-564695786d44"
      unitRef="usd">2100000000</us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss>
    <us-gaap:IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear
      contextRef="i6ad0eba196ab4a07a56009d4610284f7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzk5MzI_fd5e7106-c46d-4e7f-90de-17aaf4adc491"
      unitRef="cad">-44000000</us-gaap:IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear>
    <us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss
      contextRef="i3a2b5c5adebc4e62b7d64a5d6bcca25d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzEwMjQ5_a7f7ee04-0411-45b0-ae02-029696402cbd"
      unitRef="cad">85000000</us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss>
    <us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss
      contextRef="i5a6621a8c1674dbc9a844087860a0e82_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzEwMjYw_047f61b7-019c-4549-975a-91aadfcc04a0"
      unitRef="cad">90000000</us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss>
    <us-gaap:IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear
      contextRef="i0bb9780df86a4065b01b2469abd59faf_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzEwNTI2_7e3d89fa-75bb-4602-873e-3c0884149cd9"
      unitRef="cad">-21000000</us-gaap:IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear>
    <us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss
      contextRef="if92917964a2f48fc8d583659d90471f8_D20170808-20170808"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzExMTg1_1fb169f9-0abb-41c8-8d6a-a56cc6acdf4f"
      unitRef="usd">117000000</us-gaap:IncomeTaxExaminationEstimateOfPossibleLoss>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzEyODI3_98b60f16-523c-4402-bae3-a8934c3d269e">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of the unrecognized tax&#160;benefits for 2021, 2020 and 2019: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(169)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzEtMi0xLTEtOTQ4MzE_8eb0b134-ab96-4587-b3df-4886e3314d73"
      unitRef="usd">1025000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzEtNC0xLTEtOTQ4MzE_74cf11ec-df82-4e04-ad26-816941a1156a"
      unitRef="usd">1002000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i18439fe8345c481db53c486667ac6940_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzEtNi0xLTEtOTQ4MzE_a3149cd6-3567-4916-9438-bfef327d136a"
      unitRef="usd">654000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzItMi0xLTEtOTQ4MzE_824d7b79-1245-4021-b222-e2e846c143ff"
      unitRef="usd">79000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzItNC0xLTEtOTQ4MzE_376b4b1e-c904-4582-8ddc-c4a78981657a"
      unitRef="usd">66000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzItNi0xLTEtOTQ4MzE_dd996837-c101-46f6-b787-7aedb053826e"
      unitRef="usd">361000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzMtMi0xLTEtOTQ4MzE_97278474-baf1-4b22-b7d6-f941959ee621"
      unitRef="usd">121000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzMtNC0xLTEtOTQ4MzE_948c5e13-f719-4d79-a384-6cd4fe2d86b4"
      unitRef="usd">171000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzMtNi0xLTEtOTQ4MzE_22bea28f-2268-494c-9df4-aefa30e201fd"
      unitRef="usd">63000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzQtMi0xLTEtOTQ4MzE_72b4c01f-f779-4db8-bb25-557447e29094"
      unitRef="usd">129000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzQtNC0xLTEtOTQ4MzE_5a8d0423-2cea-4c31-bdd4-1818bbcb497e"
      unitRef="usd">209000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzQtNi0xLTEtOTQ4MzE_6da063ef-810f-4e34-8833-abf6e8aebbfd"
      unitRef="usd">58000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzUtMi0xLTEtOTQ4MzE_c485ccb1-f28f-4c63-b715-b1e6602744d1"
      unitRef="usd">169000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzUtNC0xLTEtOTQ4MzE_9d726a10-a696-4cbd-bf34-d383ca26dbef"
      unitRef="usd">5000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzUtNi0xLTEtOTQ4MzE_bafe5534-79c8-4961-8a4b-a061e017158f"
      unitRef="usd">18000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzYtMi0xLTEtOTQ4MzE_2e76882a-9463-4f3f-8f80-8a2752705564"
      unitRef="usd">927000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzYtNC0xLTEtOTQ4MzE_550ded15-6fcc-4403-a98d-1e6fd7939108"
      unitRef="usd">1025000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i10dd5d5cf93949878c6cc5089859a3bd_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90YWJsZTo5ZDhlZDZmMTc1NzU0MjIyODdhYmI3OGNkNjk5MjdhNy90YWJsZXJhbmdlOjlkOGVkNmYxNzU3NTQyMjI4N2FiYjc4Y2Q2OTkyN2E3XzYtNi0xLTEtOTQ4MzE_fc0b85c6-2c1b-43c7-a4c1-d18b6a0f8ffc"
      unitRef="usd">1002000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjQvZnJhZzpkNDBkZDYyMzNkYjA0ZGEzYTZiNzU0ZTYyMmNjNmY0Zi90ZXh0cmVnaW9uOmQ0MGRkNjIzM2RiMDRkYTNhNmI3NTRlNjIyY2M2ZjRmXzEyNjYz_99e65db3-73d1-40a7-b7ce-6d29f8387bdb"
      unitRef="usd">104000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90ZXh0cmVnaW9uOjQ5Yjk3YTVjMDMzODQ5NDZiYmRiNjkwOGJmZWQyMzA0XzEwMzI_6372277e-2345-4cc8-8d16-b4acdd3f995a">LOSS  PER SHARE&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss per share attributable to Bausch Health Companies Inc. for 2021, 2020 and 2019 were calculated as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(948)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,788)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic and diluted weighted-average common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;358.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;355.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;352.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic and diluted loss per share attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, 2020 and 2019, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive.  The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately 4,932,000, 3,154,000 and 5,106,000 common shares for 2021, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, in 2021, 2020 and 2019, stock options, time-based RSUs and performance-based RSUs to purchase approximately 3,428,000, 9,551,000 and 2,598,000 common shares of the Company, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method. During 2021, an additional 156,000 performance-based RSUs were not included in the computation of diluted earnings per share as the required performance conditions had not been met.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90ZXh0cmVnaW9uOjQ5Yjk3YTVjMDMzODQ5NDZiYmRiNjkwOGJmZWQyMzA0XzEwMjk_3f5b82a4-2637-4401-bfc3-09a776fe4720">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss per share attributable to Bausch Health Companies Inc. for 2021, 2020 and 2019 were calculated as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(948)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,788)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic and diluted weighted-average common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;358.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;355.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;352.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic and diluted loss per share attributable to Bausch Health Companies Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90YWJsZTo0YTZlYzg1ZDg5NWY0YjY3YTc0YWMwMTJmNjAyZjMyOC90YWJsZXJhbmdlOjRhNmVjODVkODk1ZjRiNjdhNzRhYzAxMmY2MDJmMzI4XzEtMi0xLTEtOTQ4MzE_426ce37d-433f-4a0d-9166-023b8f653063"
      unitRef="usd">-948000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90YWJsZTo0YTZlYzg1ZDg5NWY0YjY3YTc0YWMwMTJmNjAyZjMyOC90YWJsZXJhbmdlOjRhNmVjODVkODk1ZjRiNjdhNzRhYzAxMmY2MDJmMzI4XzEtNC0xLTEtOTQ4MzE_a678243c-c163-4200-b111-38c17983091b"
      unitRef="usd">-560000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90YWJsZTo0YTZlYzg1ZDg5NWY0YjY3YTc0YWMwMTJmNjAyZjMyOC90YWJsZXJhbmdlOjRhNmVjODVkODk1ZjRiNjdhNzRhYzAxMmY2MDJmMzI4XzEtNi0xLTEtOTQ4MzE_2f1df46b-7da3-4041-b670-0956e8164a04"
      unitRef="usd">-1788000000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90YWJsZTo0YTZlYzg1ZDg5NWY0YjY3YTc0YWMwMTJmNjAyZjMyOC90YWJsZXJhbmdlOjRhNmVjODVkODk1ZjRiNjdhNzRhYzAxMmY2MDJmMzI4XzItMi0xLTEtOTQ4MzE_2701e3a8-d81d-4782-9165-ce4da81f0a7b"
      unitRef="shares">358900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90YWJsZTo0YTZlYzg1ZDg5NWY0YjY3YTc0YWMwMTJmNjAyZjMyOC90YWJsZXJhbmdlOjRhNmVjODVkODk1ZjRiNjdhNzRhYzAxMmY2MDJmMzI4XzItMi0xLTEtOTQ4MzE_cb0f8c67-bc0d-4ad0-a350-a28f056d9952"
      unitRef="shares">358900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90YWJsZTo0YTZlYzg1ZDg5NWY0YjY3YTc0YWMwMTJmNjAyZjMyOC90YWJsZXJhbmdlOjRhNmVjODVkODk1ZjRiNjdhNzRhYzAxMmY2MDJmMzI4XzItNC0xLTEtOTQ4MzE_255c37d6-4f9e-4511-b578-326f6a6b9269"
      unitRef="shares">355000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90YWJsZTo0YTZlYzg1ZDg5NWY0YjY3YTc0YWMwMTJmNjAyZjMyOC90YWJsZXJhbmdlOjRhNmVjODVkODk1ZjRiNjdhNzRhYzAxMmY2MDJmMzI4XzItNC0xLTEtOTQ4MzE_9ec93fe0-8896-4d07-a063-abf74c47a980"
      unitRef="shares">355000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90YWJsZTo0YTZlYzg1ZDg5NWY0YjY3YTc0YWMwMTJmNjAyZjMyOC90YWJsZXJhbmdlOjRhNmVjODVkODk1ZjRiNjdhNzRhYzAxMmY2MDJmMzI4XzItNi0xLTEtOTQ4MzE_2997b533-f22a-4403-95d9-280971affe40"
      unitRef="shares">352100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90YWJsZTo0YTZlYzg1ZDg5NWY0YjY3YTc0YWMwMTJmNjAyZjMyOC90YWJsZXJhbmdlOjRhNmVjODVkODk1ZjRiNjdhNzRhYzAxMmY2MDJmMzI4XzItNi0xLTEtOTQ4MzE_b630f35d-3c36-453d-8940-8b8ab0a32202"
      unitRef="shares">352100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90YWJsZTo0YTZlYzg1ZDg5NWY0YjY3YTc0YWMwMTJmNjAyZjMyOC90YWJsZXJhbmdlOjRhNmVjODVkODk1ZjRiNjdhNzRhYzAxMmY2MDJmMzI4XzMtMi0xLTEtOTQ4MzE_d6832e65-792b-4c6e-b6bb-2bb1f92a61a1"
      unitRef="usdPerShare">-2.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90YWJsZTo0YTZlYzg1ZDg5NWY0YjY3YTc0YWMwMTJmNjAyZjMyOC90YWJsZXJhbmdlOjRhNmVjODVkODk1ZjRiNjdhNzRhYzAxMmY2MDJmMzI4XzMtMi0xLTEtOTQ4MzE_db472fbd-a24b-4172-93cb-5cfa14a4edba"
      unitRef="usdPerShare">-2.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90YWJsZTo0YTZlYzg1ZDg5NWY0YjY3YTc0YWMwMTJmNjAyZjMyOC90YWJsZXJhbmdlOjRhNmVjODVkODk1ZjRiNjdhNzRhYzAxMmY2MDJmMzI4XzMtNC0xLTEtOTQ4MzE_46aefd65-8938-4ed4-9cc1-3615a5fb510f"
      unitRef="usdPerShare">-1.58</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90YWJsZTo0YTZlYzg1ZDg5NWY0YjY3YTc0YWMwMTJmNjAyZjMyOC90YWJsZXJhbmdlOjRhNmVjODVkODk1ZjRiNjdhNzRhYzAxMmY2MDJmMzI4XzMtNC0xLTEtOTQ4MzE_c10946fa-ff85-454d-acf6-ef71e1f4dad1"
      unitRef="usdPerShare">-1.58</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90YWJsZTo0YTZlYzg1ZDg5NWY0YjY3YTc0YWMwMTJmNjAyZjMyOC90YWJsZXJhbmdlOjRhNmVjODVkODk1ZjRiNjdhNzRhYzAxMmY2MDJmMzI4XzMtNi0xLTEtOTQ4MzE_20db63a1-337a-432b-8291-66985ae5c4ea"
      unitRef="usdPerShare">-5.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90YWJsZTo0YTZlYzg1ZDg5NWY0YjY3YTc0YWMwMTJmNjAyZjMyOC90YWJsZXJhbmdlOjRhNmVjODVkODk1ZjRiNjdhNzRhYzAxMmY2MDJmMzI4XzMtNi0xLTEtOTQ4MzE_a5d3571f-9265-4ab6-8e60-4c016555b5fa"
      unitRef="usdPerShare">-5.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i794db5d83c3641aa853ac4acaa8182e9_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90ZXh0cmVnaW9uOjQ5Yjk3YTVjMDMzODQ5NDZiYmRiNjkwOGJmZWQyMzA0XzQ5MA_337e9138-aa97-4e10-801a-3f99f2271959"
      unitRef="shares">4932000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i426b648515c34755bb623ee81a4f1ae9_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90ZXh0cmVnaW9uOjQ5Yjk3YTVjMDMzODQ5NDZiYmRiNjkwOGJmZWQyMzA0XzQ5NA_f298bbce-9d18-452b-bc6b-78ff4e65693e"
      unitRef="shares">3154000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0aaea235b331445aa69d79ccdb7823d4_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90ZXh0cmVnaW9uOjQ5Yjk3YTVjMDMzODQ5NDZiYmRiNjkwOGJmZWQyMzA0XzUwMQ_3be0f562-7726-4b2c-8565-d8bac17be7c5"
      unitRef="shares">5106000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifd3e00426ff44f65af5c22541ee8cb9a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90ZXh0cmVnaW9uOjQ5Yjk3YTVjMDMzODQ5NDZiYmRiNjkwOGJmZWQyMzA0XzY0NQ_781a3560-7317-41f6-b73f-940c188526c5"
      unitRef="shares">3428000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i84aa0d0a4fea4c29a4fea75d90ed7794_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90ZXh0cmVnaW9uOjQ5Yjk3YTVjMDMzODQ5NDZiYmRiNjkwOGJmZWQyMzA0XzY0OQ_02005b7a-fdf8-4b65-90e8-3d561ad8e055"
      unitRef="shares">9551000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5998f35e4ed44ab4a12b43f529e4ee2e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90ZXh0cmVnaW9uOjQ5Yjk3YTVjMDMzODQ5NDZiYmRiNjkwOGJmZWQyMzA0XzY1Ng_7f9e5389-77e0-4218-b946-33d4907cde5a"
      unitRef="shares">2598000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i647e97c259b643fcb29ab0bf3ac45e1a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNjcvZnJhZzo0OWI5N2E1YzAzMzg0OTQ2YmJkYjY5MDhiZmVkMjMwNC90ZXh0cmVnaW9uOjQ5Yjk3YTVjMDMzODQ5NDZiYmRiNjkwOGJmZWQyMzA0Xzg3OQ_da9a3ae2-f222-4774-932a-ca419ea8b188"
      unitRef="shares">156000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzAvZnJhZzoxNTYzMDI1Nzg3NTc0NWVkOGZkYzQ3OGY5ZGY5OTA2OS90ZXh0cmVnaW9uOjE1NjMwMjU3ODc1NzQ1ZWQ4ZmRjNDc4ZjlkZjk5MDY5XzY2_f70577ee-f0e9-49a4-b4e5-863c39a881b6">SUPPLEMENTAL CASH FLOW DISCLOSURES &lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow disclosures for 2021, 2020 and 2019 are as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income taxes paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzAvZnJhZzoxNTYzMDI1Nzg3NTc0NWVkOGZkYzQ3OGY5ZGY5OTA2OS90ZXh0cmVnaW9uOjE1NjMwMjU3ODc1NzQ1ZWQ4ZmRjNDc4ZjlkZjk5MDY5XzY4_0ccacab2-c16a-4f4b-8503-b9606cb19363">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow disclosures for 2021, 2020 and 2019 are as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.849%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.561%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.944%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.970%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income taxes paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:InterestPaidNet
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzAvZnJhZzoxNTYzMDI1Nzg3NTc0NWVkOGZkYzQ3OGY5ZGY5OTA2OS90YWJsZTpmM2NjMzgxNzE5MzQ0Y2UzOTc1MjcwOGMxYTNkOTYxMC90YWJsZXJhbmdlOmYzY2MzODE3MTkzNDRjZTM5NzUyNzA4YzFhM2Q5NjEwXzItMi0xLTEtOTQ4MzE_58f10011-9b7a-464b-8b81-a93f08635e6d"
      unitRef="usd">1419000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzAvZnJhZzoxNTYzMDI1Nzg3NTc0NWVkOGZkYzQ3OGY5ZGY5OTA2OS90YWJsZTpmM2NjMzgxNzE5MzQ0Y2UzOTc1MjcwOGMxYTNkOTYxMC90YWJsZXJhbmdlOmYzY2MzODE3MTkzNDRjZTM5NzUyNzA4YzFhM2Q5NjEwXzItNC0xLTEtOTQ4MzE_b45b8254-aebd-4e7b-8130-cc7ecf68d4af"
      unitRef="usd">1474000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzAvZnJhZzoxNTYzMDI1Nzg3NTc0NWVkOGZkYzQ3OGY5ZGY5OTA2OS90YWJsZTpmM2NjMzgxNzE5MzQ0Y2UzOTc1MjcwOGMxYTNkOTYxMC90YWJsZXJhbmdlOmYzY2MzODE3MTkzNDRjZTM5NzUyNzA4YzFhM2Q5NjEwXzItNi0xLTEtOTQ4MzE_8e7fb822-352f-4397-b334-cd62e769c4f1"
      unitRef="usd">1537000000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzAvZnJhZzoxNTYzMDI1Nzg3NTc0NWVkOGZkYzQ3OGY5ZGY5OTA2OS90YWJsZTpmM2NjMzgxNzE5MzQ0Y2UzOTc1MjcwOGMxYTNkOTYxMC90YWJsZXJhbmdlOmYzY2MzODE3MTkzNDRjZTM5NzUyNzA4YzFhM2Q5NjEwXzMtMi0xLTEtOTQ4MzE_8f77d593-b8c3-4deb-ac3f-62d588c5a384"
      unitRef="usd">240000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzAvZnJhZzoxNTYzMDI1Nzg3NTc0NWVkOGZkYzQ3OGY5ZGY5OTA2OS90YWJsZTpmM2NjMzgxNzE5MzQ0Y2UzOTc1MjcwOGMxYTNkOTYxMC90YWJsZXJhbmdlOmYzY2MzODE3MTkzNDRjZTM5NzUyNzA4YzFhM2Q5NjEwXzMtNC0xLTEtOTQ4MzE_61482c14-56bd-45af-bfdf-fe19ea469a0c"
      unitRef="usd">162000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzAvZnJhZzoxNTYzMDI1Nzg3NTc0NWVkOGZkYzQ3OGY5ZGY5OTA2OS90YWJsZTpmM2NjMzgxNzE5MzQ0Y2UzOTc1MjcwOGMxYTNkOTYxMC90YWJsZXJhbmdlOmYzY2MzODE3MTkzNDRjZTM5NzUyNzA4YzFhM2Q5NjEwXzMtNi0xLTEtOTQ4MzE_6c056d82-bd14-47b6-81cd-6b7985db27fa"
      unitRef="usd">172000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzU2MjQx_bc5c5ef6-a1ce-4365-834f-0ed2fdd640f6">LEGAL PROCEEDINGS&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company becomes involved in various legal and administrative proceedings, which include product liability, intellectual property, commercial, tax, antitrust, governmental and regulatory investigations, related private litigation and ordinary course employment-related issues. From time to time, the Company also initiates actions or files counterclaims. The Company could be subject to counterclaims or other suits in response to actions it may initiate. The Company believes that the prosecution of these actions and counterclaims is important to preserve and protect the Company, its reputation and its assets. Certain of these proceedings and actions are described below. Going forward, in the Company's subsequent Quarterly Reports on Form 10-Q, the Company will only include a description of these matters to the extent there has been a material update with respect thereto during the applicable quarter or to the extent otherwise required by law.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On a quarterly basis, the Company evaluates developments in legal proceedings, potential settlements and other matters that could increase or decrease the amount of the liability accrued. As of December 31, 2021, the Company's Consolidated Balance Sheets includes accrued current loss contingencies of $1,890 million related to matters which the Company believes a potential resolution or settlement is both probable and reasonably estimable. For all other matters, unless otherwise indicated, the Company cannot reasonably predict the outcome of these legal proceedings, nor can it estimate the amount of loss, or range of loss, if any, that may result from these proceedings. An adverse outcome in certain of these proceedings could have a material adverse effect on the Company&#x2019;s business, financial condition and results of operations, and could cause the market value of its common shares and/or debt securities to decline.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Governmental and Regulatory Inquiries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investigation by the U.S. Attorney's Office for the District of Massachusetts - re OraPharma&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, the Company received a subpoena from the U.S. Attorney's Office for the District of Massachusetts, requesting materials including documents concerning the sales, marketing, coverage and reimbursement of Arestin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, including related support services, and other matters.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is cooperating with this investigation.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company cannot predict the outcome or the duration of this investigation or any other legal proceedings or any enforcement actions or other remedies that may be imposed on the Company arising out of this investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Securities and RICO Class Actions and Related Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. Securities Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 16, 2019, the Company announced that it had agreed to settle, subject to final court approval, the consolidated securities class action filed in the U.S. District Court for the District of New Jersey (In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658). On January 31, 2021, the District Court &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;issued an order granting final approval of this settlement. On February 4, 2021, Timber Hill LLC filed a notice of appeal of the Court&#x2019;s final approval order, which overruled its objections to the allocation of settlement proceeds as between common stock and options.  On March 1, 2021, Cathy Lochridge filed a notice of appeal of the Court&#x2019;s final approval order, which overruled her objections as to the attorneys&#x2019; fees awarded to class counsel. On October 14, 2021, Timber Hill dismissed its appeal of the final approval order. On December 20, 2021, the Third Circuit denied Lochridge&#x2019;s appeal. On January 3, 2022, Lochridge filed a petition for rehearing of the appeal &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;en banc&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which remains pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2015, four putative securities class actions were filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. The allegations related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company&#x2019;s business and prospects, including relating to drug pricing, the Company&#x2019;s use of specialty pharmacies, and the Company&#x2019;s relationship with Philidor. On May 31, 2016, the court entered an order consolidating the four actions under the caption In re Valeant Pharmaceuticals International, Inc. Securities Litigation, Case No. 15-cv-07658. On December 16, 2019, the Company, the current or former officers and directors, ValueAct, and the underwriters announced that they agreed to resolve the securities action for $1,210 million, subject to final court approval. This settlement received final approval from the court on January 31, 2021 and will resolve and discharge all claims against the Company in the class action.  As part of the settlement, the Company and the other settling defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. The settlement remains subject to an appeal of the final court approval (as such appeal is further described above). In order to qualify for a settlement payment all persons and entities that purchased or otherwise acquired the Company securities during the class period must have submitted a proof of claim and release form by May 6, 2020. The settlement payments have been paid into an escrow account in accordance with the payment schedule outlined in the settlement agreement. These payments, less certain settlement expenses and attorneys' fees, will remain in escrow until resolution of the appeal of the final court approval of the settlement agreement. The opt-out litigations discussed below remain ongoing. As of December 31, 2021, Restricted cash and other settlement deposits includes an aggregate $1,210&#160;million of: (i) payments in the escrow fund and (ii) certain disbursements for settlement expenses and attorney's fees. Disbursements for attorney's fees remain refundable until resolution of the appeal of the final court approval of the settlement agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 6, 2018, a putative class action was filed in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. This action, captioned Timber Hill LLC, v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 18-cv-10246) (&#x201c;Timber Hill&#x201d;), asserts securities fraud claims under Sections 10(b) and 20(a) of the Exchange Act on behalf of a putative class of persons who purchased call options or sold put options on the Company&#x2019;s common stock during the period January 4, 2013 through August 11, 2016.  On June 11, 2018, this action was consolidated with In re Valeant Pharmaceuticals International, Inc. Securities Litigation, (Case No. 15-cv-07658).  On January 14, 2019, the defendants filed a motion to dismiss the Timber Hill complaint. Briefing on that motion was completed on February 13, 2019. On August 15, 2019, the Court denied the motion to dismiss the Timber Hill action, holding that this complaint was a legal nullity as a result of the June 11, 2018 consolidation order.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the consolidated putative class action, thirty-seven groups of individual investors in the Company&#x2019;s stock and debt securities have chosen to opt out of the consolidated putative class action and filed securities actions in the U.S. District Court for the District of New Jersey against the Company and certain current or former officers and directors. These actions are captioned: T. Rowe Price Growth Stock Fund, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-5034); Equity Trustees Limited as Responsible Entity for T. Rowe Price Global Equity Fund v. Valeant Pharmaceuticals International Inc. (Case No. 16-cv-6127); Principal Funds, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-6128); BloombergSen Partners Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7212); Discovery Global Citizens Master Fund, Ltd. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7321); MSD Torchlight Partners, L.P. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7324); BlueMountain Foinaven Master Fund, L.P. v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7328) (&#x201c;BlueMountain&#x201d;); Incline Global Master LP v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7494); VALIC Company I v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7496); Janus Aspen Series v. Valeant Pharmaceuticals International, Inc. (Case No. 16-cv-7497) (&#x201c;Janus Aspen&#x201d;); Okumus Opportunistic Value Fund, LTD v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-6513) (&#x201c;Okumus&#x201d;); Lord Abbett Investment Trust- Lord Abbett Short Duration Income Fund, v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-6365) (&#x201c;Lord Abbett&#x201d;); Pentwater Equity Opportunities Master Fund LTD v. Valeant Pharmaceuticals International, Inc., et al. (Case No. 17-cv-7552) (&#x201c;Pentwater&#x201d;); Public Employees&#x2019; Retirement System of Mississippi v. Valeant Pharmaceuticals International Inc. (Case No. 17-cv-7625) (&#x201c;Mississippi&#x201d;); The Boeing Company Employee Retirement Plans Master Trust v. Valeant Pharmaceuticals International Inc., et al., (Case No. 17-cv-7636) (&#x201c;Boeing&#x201d;); State Board of Administration of Florida v. Valeant Pharmaceuticals International Inc. (Case No. 17-cv-12808); The Regents of the University of California v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-13488); GMO Trust v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0089); F&#xf6;rsta AP Fonden v. Valeant Pharmaceuticals International, Inc. (Case No. 17-cv-12088); New York City Employees&#x2019; Retirement System v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0032) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;NYCERS&#x201d;); Hound Partners Offshore Fund, LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-08705) (&#x201c;Hound Partners&#x201d;); Blackrock Global Allocation Fund, Inc. v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0343) (&#x201c;Blackrock&#x201d;); Colonial First State Investments Limited As Responsible Entity for Commonwealth Global Shares Fund 1 v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0383); Bharat Ahuja v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-0846); Brahman Capital Corp. v. Valeant Pharmaceuticals International, Inc (Case No. 18-cv-0893); The Prudential Insurance Company of America v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-01223) (&#x201c;Prudential&#x201d;); Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) (&#x201c;Senzar&#x201d;); 2012 Dynasty UC LLC v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-08595) (&#x201c;2012 Dynasty&#x201d;); Catalyst Dynamic Alpha Fund v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-12673) (&#x201c;Catalyst&#x201d;); Northwestern Mutual Life Insurance Co., v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-15286) (&#x201c;Northwestern Mutual&#x201d;); Bahaa Aly, et al. v. Valeant Pharmaceuticals International, Inc., (Case No. 18-cv-17393) (&#x201c;Aly&#x201d;); Office of the Treasurer as Trustee for the Connecticut Retirement Plans and Trust Funds v. Valeant Pharmaceuticals International, Inc. (Case No. 19-cv-18473) (&#x201c;Connecticut&#x201d;); Delaware Public Employees&#x2019; Retirement System v. Valeant Pharmaceuticals International, Inc. (Case No. 19-cv-18475) (&#x201c;Delaware&#x201d;); Maverick Neutral Levered Fund v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-02190) (&#x201c;Maverick&#x201d;), Templeton v. Valeant Pharmaceuticals International, Inc. (Case No. 20-cv-05478) (&#x201c;Templeton&#x201d;), USAA Mutual Funds Trust, et al. v. Valeant Pharmaceuticals International, Inc., et al., (Case No. 20-cv-07462) (&#x201c;USAA&#x201d;), and GIC Private Ltd. v. Valeant Pharmaceuticals International, Inc., (Case No. 20-cv-07460) (&#x201c;GIC&#x201d;). Sixteen of the thirty-seven opt-out actions have been dismissed; and the total number of remaining opt-out actions pending in the District of New Jersey is twenty-one actions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These individual shareholder actions assert claims under Sections 10(b), and 20(a) of the Exchange Act. Certain of these individual actions assert additional claims, including claims under Section 18 of the Exchange Act, Sections 11, 12(a)(2), and 15 of the Securities Act, common law fraud, negligent misrepresentation, and claims under the New Jersey Racketeer Influenced and Corrupt Organizations Act. These claims are based on alleged purchases of Company stock, options, and/or debt at various times between January 3, 2013 and August 10, 2016. The allegations in the complaints are similar to those made by plaintiffs in the putative class action. Motions to dismiss have been filed and in most cases decided in many of these individual actions. To date, the Court has dismissed state law claims including New Jersey Racketeer Influenced and Corrupt Organizations Act, common law fraud, and negligent misrepresentation claims in certain cases. On January 7, 2019, the Court entered a stipulation of voluntary dismissal in the Senzar Healthcare Master Fund LP v. Valeant Pharmaceuticals International, Inc. (Case No. 18-cv-02286) opt-out action, closing the case.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 10, 2019, the Court granted defendants&#x2019; motion to dismiss all claims in the Bahaa Aly v. Valeant Pharmaceuticals International, Inc. (&#x201c;Aly&#x201d;) (Case No. 18-cv-17393) opt-out action. On October 9, 2019, the Aly Plaintiffs filed a notice of appeal to the United States Court of Appeals for the Third Circuit. On June 16, 2021, the Court of Appeals granted plaintiffs&#x2019; appeal in the Aly action. This action has been remanded to the District Court. On June 19, 2020, the Court entered stipulations of voluntary dismissal in the Catalyst, Mississippi, Connecticut, and Delaware actions.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 13, 2020, the Court entered a stipulation of voluntary dismissal in the NYCERS action. On December 30, 2020, the Court entered a stipulation of voluntary dismissal in the BlueMountain action. On February 18, 2021, and March 10, 2021, the Court entered stipulations of voluntary dismissal in the T. Rowe, BloombergSen, Principal Funds, Pentwater, Lord Abbett, Equity Trustees, and UC Regents actions. On April 30, 2021, the Court entered a stipulation of voluntary dismissal in the Florida SBA action.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 20, 2021, the Court entered a stipulation of voluntary dismissal in the Janus action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disputes the claims against it in the remaining individual opt-out complaints and intends to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Canadian Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015, six putative class actions were filed and served against the Company and certain current or former officers and directors in Canada in the provinces of British Columbia, Ontario and Quebec. These actions are captioned: (a) Alladina v. Valeant, et al. (Case No. S-1594B6) (Supreme Court of British Columbia) (filed November 17, 2015); (b) Kowalyshyn v. Valeant, et al. (CV-15-540593-00CP) (Ontario Superior Court) (filed November 16, 2015); (c) Kowalyshyn et al. v. Valeant, et al. (CV-15-541082-00CP) (Ontario Superior Court) (filed November 23, 2015); (d) O&#x2019;Brien v. Valeant et al. (CV-15-543678-00CP) (Ontario Superior Court) (filed December 30, 2015); (e) Catucci v. Valeant, et al. (Court File No. 540-17-011743159, then Court File No. 500-06-000783-163) (Quebec Superior Court) (filed October 26, 2015); and (f) Rousseau-Godbout v. Valeant, et al. (Court File No. 500-06-000770-152) (Quebec Superior Court) (filed October 27, 2015). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also aware of two additional putative class actions that were filed with the applicable court but which have not been served on the Company. These actions are captioned: (i) Okeley v. Valeant, et al. (Case No. S-159991) (Supreme Court of British Columbia) (filed December 2, 2015); and (ii) Sukenaga v Valeant et al. (CV-15-540567-00CP) (Ontario &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Superior Court) (filed November 16, 2015), and the factual allegations made in these actions are substantially similar to those outlined herein.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The actions generally allege violations of Canadian provincial securities legislation on behalf of putative classes of persons who purchased or otherwise acquired securities of the Company for periods commencing as early as January 1, 2013 and ending as late as November 16, 2015. The alleged violations relate to the same matters described in the U.S. Securities Litigation description above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each of these putative class actions, other than the Catucci action in the Quebec Superior Court, was discontinued. In the Catucci action, on August 29, 2017, the judge granted the plaintiffs leave to proceed with their claims under the Quebec Securities Act and authorized the class proceeding.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 26, 2017, the plaintiffs issued their Judicial Application Originating Class Proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After a hearing on November 11, 2019, the court approved a settlement in the Catucci action between the class members and the Company&#x2019;s auditors and the action was dismissed as against them. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 4, 2020, the Company entered into a settlement agreement with the plaintiffs in Catucci, on behalf of the class, pursuant to which it agreed to resolve the Catucci action for the amount of CAD 94 million plus payment of an additional amount to cover notice and settlement administration costs and disbursements.  As part of the settlement, the Company and the other defendants admitted no liability as to the claims against it and deny all allegations of wrongdoing. Court approval of the settlement was granted after a hearing on November 16, 2020. The Catucci action has now been dismissed against the Company, its current and former directors and officers, its underwriters and its insurers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the class proceedings described above, on April 12, 2018, the Company was served with an application for leave filed in the Quebec Superior Court of Justice to pursue an action under the Quebec Securities Act against the Company and certain current or former officers and directors. This proceeding is captioned BlackRock Asset Management Canada Limited et al. v. Valeant, et al. (Court File No. 500-11-054155-185). The allegations in the proceeding are similar to those made by plaintiffs in the Catucci class action.  On June 18, 2018, the same BlackRock entities filed an originating application (Court File No. 500-17-103749-183) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is aware that certain other members of the Catucci class exercised their opt-out rights prior to the June 19, 2018 deadline. On February 15, 2019, one of the entities which exercised its opt-out rights, the California State Teachers' Retirement System (&#x201c;CalSTRS&#x201d;), served the Company with an application in the Quebec Superior Court of Justice for leave to pursue an action under the Quebec Securities Act against the Company, certain current or former officers and directors of the Company and its auditor. That proceeding is captioned California State Teachers&#x2019; Retirement System v. Bausch Health Companies Inc. et al. (Court File No. 500-11-055722-181). The allegations in the proceeding are similar to those made by the plaintiffs in the Catucci class action and in the BlackRock opt-out proceedings. On that same date, CalSTRS also served the Company with proceedings (Court File No. 500-17-106044-186) against the same defendants asserting claims under the Quebec Civil Code in respect of the same alleged misrepresentations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 3, 2020, the Quebec Superior Court granted the applications of CalSTRS and BlackRock for leave to pursue their respective actions asserting claims under the Quebec Securities Act. On June 16, 2020, the Quebec Court of Appeal granted the defendants leave to appeal that decision. The appeal was heard on September 29, 2021 and, by judgment dated October 29, 2021, the appeals were dismissed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 8 and 9, 2020, respectively, CalSTRS amended its proceedings to, among other things, include a new alleged misrepresentation concerning the accounting treatment of &#x201c;price appreciation credits&#x201d; in respect of Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; during the period covered by the claims. A hearing was held on February 17, 2021 with respect to whether CalSTRS would be permitted to file the proposed amended proceedings. On June 9, 2021, the Quebec Superior Court granted the Company&#x2019;s application to strike the new allegations from its Quebec Securities Act claim, but permitted the amendments to its claim under the Quebec Civil Code. On December 8, 2021, CalSTRS delivered its amended pleadings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 17, 2021, four additional opt-outs from the Catucci class issued a Statement of Claim in the Ontario Superior Court of Justice. That proceeding is captioned The Bank of Korea et al. v. Valeant Pharmaceuticals International Inc. et al. (Court File No. 21-00658966-0000). In addition, these plaintiffs also served and filed a motion for leave to pursue claims under the Ontario Securities Act. The allegations in this proceeding are similar to those made by the plaintiffs in the Catucci class action and the plaintiffs in the opt-out actions described above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7.5pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that it has viable defenses in each of these actions. In each case, the Company intends to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RICO Class Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between May 27, 2016 and September 16, 2016, three actions were filed in the U.S. District Court for the District of New Jersey against the Company and various third-parties (these actions were subsequently consolidated), alleging claims under the federal Racketeer Influenced Corrupt Organizations Act (&#x201c;RICO&#x201d;) on behalf of a putative class of certain third-party payors that paid claims submitted by Philidor for certain Company-branded drugs between January 2, 2013 and November 9, 2015.&#160; The consolidated complaint alleges, among other things, that the defendants committed predicate acts of mail and wire fraud by submitting or causing to be submitted prescription reimbursement requests that misstated or omitted facts regarding: (1) the identity and licensing status of the dispensing pharmacy; (2) the resubmission of previously denied claims; (3) patient co-pay waivers; (4) the availability of generic alternatives; and (5) the insured&#x2019;s consent to renew the prescription.&#160; The complaint further alleges that these acts constitute a pattern of racketeering or a racketeering conspiracy in violation of the RICO statute and caused plaintiffs and the putative class unspecified damages, which may be trebled under the RICO statute.  On August 4, 2021, the Company executed a stipulation of settlement for this action and, on August 17, 2021, the Court preliminarily approved the settlement.  On December 6, 2021 the Special Master overseeing this litigation issued a report and recommendation recommending final approval of the settlement, and on February 22, 2022 the settlement was approved by the district court. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Insurance Coverage Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 7, 2017, the Company filed a lawsuit against its insurance companies that issued insurance policies covering claims made against the Company, its subsidiaries, and its directors and officers during two distinct policy periods, (i) 2013-14 and (ii) 2015-16.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lawsuit is currently pending in the United States District Court for the District of New Jersey (Valeant Pharmaceuticals International, Inc., et al. v. AIG Insurance Company of Canada, et al.; 3:18-CV-00493).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the lawsuit, the Company seeks coverage for: (i) the costs of defending and resolving claims brought by former shareholders and debtholders of Allergan, Inc. in In re Allergan, Inc. Proxy Violation Securities Litigation and Timber Hill LLC, individually and on behalf of all others similarly situated v. Pershing Square Capital Management, L.P., et al. (the &#x201c;Allergan Securities Litigation&#x201d;) (under the 2013-2014 coverage period), and (ii) costs incurred and to be incurred in connection with the securities class actions and opt-out cases described in this section and the SEC Investigation and certain of the other investigations described under &#x201c;Complete or Inactive Matters&#x201d; in Note 20, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC and the CSA on February 24, 2021 and under &#x201c;Governmental and Regulatory Inquiries&#x201d; and &#x201c;Complete or Inactive Matters&#x201d; in Note 21, &#x201c;LEGAL PROCEEDINGS,&#x201d; to the Company's Consolidated Financial Statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC and the CSA on February 19, 2020 (under the 2015-2016 coverage period).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 20, 2021, the Company entered into settlement agreements with the insurers in the 2015-2016 coverage period in which the Company agreed to resolve its claims for insurance coverage in connection with the U.S. Securities Litigation and the Canadian Securities Litigation and related opt-out litigation and related investigations matters described above.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On that same day, the Company entered into settlement agreements with two of its insurers in the 2013-2014 coverage period in which the Company agreed to resolve its claims against those two insurers only for insurance coverage in connection with the Allergan Securities Litigation. As a result of all of the settlement agreements entered into with the insurers on July 20, 2021, the Company has received an aggregate sum of $213&#160;million. The Company&#x2019;s insurance claims with respect to the Allergan Securities Litigation against the remaining insurers in the 2013-2014 coverage period remain pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hound Partners Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, Hound Partners Offshore Fund, LP, Hound Partners Long Master, LP, and Hound Partners Concentrated Master, LP, filed a lawsuit against the Company in the Superior Court of New Jersey Law Division/Mercer County.  This action is captioned Hound Partners Offshore Fund, LP et al., v. Valeant Pharmaceuticals International, Inc., et al. (No. MER-L-002185-18).  This suit asserts claims for common law fraud, negligent misrepresentation, and violations of the New Jersey Racketeer Influenced and Corrupt Organizations Act. The Company disputes the claims and intends to vigorously defend this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Antitrust&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Generic Pricing Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's subsidiaries, Oceanside Pharmaceuticals, Inc. (&#x201c;Oceanside&#x201d;), Bausch Health US, LLC (formerly Valeant Pharmaceuticals North America LLC) (&#x201c;Bausch Health US&#x201d;), and Bausch Health Americas, Inc. (formerly Valeant Pharmaceuticals International) (&#x201c;Bausch Health Americas&#x201d;) (for the purposes of this paragraph, collectively, the &#x201c;Company&#x201d;), are defendants in multidistrict antitrust litigation (&#x201c;MDL&#x201d;) entitled &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re: Generic Pharmaceuticals Pricing &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, pending in the United States District Court for the Eastern District of Pennsylvania (MDL No. 2724, 16-MD-2724). The lawsuits seek damages under federal and state antitrust laws, state consumer protection and unjust enrichment laws and allege that the Company&#x2019;s subsidiaries entered into a conspiracy to fix, stabilize, and raise prices, rig bids and engage in market and customer allocation for generic pharmaceuticals. The lawsuits, which have been brought as putative class actions by direct purchasers, end payers, and indirect resellers, and as direct actions by direct purchasers, end payers, insurers, States, and various Counties, Cities, and Towns, have been consolidated into the MDL. There are also additional, separate complaints which have been consolidated in the same MDL that do not name the Company or any of its subsidiaries as a defendant. There are cases pending in the Court of Common Pleas of Philadelphia County against the Company and other defendants related to the multidistrict litigation, but no complaint has been filed in the cases. The cases have been put in deferred status. The Company disputes the claims against it and continues to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, Bausch Health Companies Inc. and certain U.S. and Canadian subsidiaries (for the purposes of this paragraph, collectively &#x201c;the Company&#x201d;) have been named as defendants in a proposed class proceeding entitled &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Kathryn Eaton v. Teva Canada Limited, et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the Federal Court in Toronto, Ontario, Canada (Court File No. T-607-20). The plaintiff seeks to certify a proposed class action on behalf of persons in Canada who purchased generic drugs in the private sector, alleging that the Company and other defendants violated the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Competition Act&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; by conspiring to allocate the market, fix prices, and maintain the supply of generic drugs, and seeking damages under federal law. The proposed class action contains similar allegations to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re: Generic Pharmaceuticals Pricing Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; pending in the United States Court for the Eastern District of Pennsylvania. The Company disputes the claims against it and will defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Glumetza State-Law Insurer Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 8, 2021, the insurer plaintiff from the federal &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 3:19-cv-05822-WHA (N.D. Cal.) (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;) (discussed in further detail below) filed an action asserting its indirect (state law) claims in the Superior Court of Alameda County, California against the Company and others (the &#x201c;State Court Action&#x201d;).  The State Court Action alleges that a 2012 settlement of a patent litigation regarding Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or grant any other company a license to do so.  The State Court Action alleges that the settlement agreement resulted in higher prices for Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and its generic equivalent both prior to and after generic entry. On September 20, 2021, the parties stipulated that the insurer plaintiff&#x2019;s direct opt-out claims from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, discussed below, were deemed asserted in the State Court Action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Defendants&#x2019; demurrer in the State Court Action was heard on September 22, 2021.  On November 11, 2021, the court denied the motion in part and granted it in part as to certain state law claims, with leave to amend.  The insurer plaintiff did not amend the complaint. Defendants&#x2019; answers were filed on February 3, 2022. The Company disputes the claims and intends to vigorously defend this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intellectual Property&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Patent Litigation/Paragraph IV Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company (and/or certain of its affiliates) is also party to certain patent infringement proceedings in the United States and Canada, including as arising from claims filed by the Company (or that the Company anticipates filing within the required time periods) in connection with Notices of Paragraph IV Certification (in the United States) and Notices of Allegation (in Canada) received from third-party generic manufacturers respecting their pending applications for generic versions of certain products sold by or on behalf of the Company, including Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 550mg, Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and Relistor&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Injection&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the United States, and Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in Canada or other similar suits.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 17, 2020, the Company and Alfasigma S.p.A.  (&#x201c;Alfasigma&#x201d;) received a Notice of Paragraph IV Certification from Norwich Pharmaceuticals Inc. (&#x201c;Norwich&#x201d;), in which Norwich asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#x2019;s Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; tablets, 550 mg, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Norwich&#x2019;s generic rifaximin tablets, 550 mg, for which an Abbreviated New Drug Application (&#x201c;ANDA&#x201d;) has been filed by Norwich. The Company, through its subsidiaries Salix Pharmaceuticals, Inc. and Bausch Health Ireland Limited, holds the New Drug Application for Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and owns or exclusively licenses (from Alfasigma) these patents.  On March 26, 2020, certain of the Company&#x2019;s subsidiaries and Alfasigma filed suit against Norwich in the U.S. District Court for the District of Delaware (Case No. 20-cv-00430) pursuant to the Hatch-Waxman Act, alleging infringement by Norwich of one or more claims of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patents, thereby triggering a 30-month stay of the approval of Norwich&#x2019;s ANDA for rifaximin tablets, 550 mg. Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; is protected by 26 patents covering the composition of matter and the use of Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; listed in the FDA&#x2019;s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. A 3-day bench trial is scheduled to begin March 21, 2022. The Company &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;remains confident in the strength of the Xifaxan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents and will continue to vigorously pursue this matter and defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 23, 2020, the Company received a Notice of Paragraph IV Certification from Perrigo Israel Pharmaceuticals, Ltd. (now Padagis LLC) (&#x201c;Padagis&#x201d;), in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA's Orange Book for Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate and tazarotine) lotion, are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#x2019; generic lotion, for which an ANDA has been filed by Padagis.  On August 28, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA.  On September 3, 2020, this action was consolidated with the action between the Company and Padagis described below, regarding Padagis&#x2019; ANDA for generic Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate) lotion. The Company remains confident in the strength of the Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related patents and will vigorously defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 20, 2020, the Company received a Notice of Paragraph IV Certification from Padagis, in which Padagis asserted that certain U.S. patents, each of which is listed in the FDA&#x2019;s Orange Book for Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate) lotion, 0.01% are either invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of Padagis&#x2019; generic halobetasol propionate lotion, for which an ANDA has been filed by Padagis.  On May 1, 2020, the Company filed suit against Padagis pursuant to the Hatch-Waxman Act, alleging infringement by Padagis of one or more claims of the Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patents, thereby triggering a 30-month stay of the approval of the Padagis ANDA for halobetasol propionate lotion. On September 3, 2020, this action was consolidated with the action between the Company and Padagis described above, regarding Padagis&#x2019; ANDA for generic Duobrii&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (halobetasol propionate and tazarotine) lotion. The Company remains confident in the strength of the Bryhali&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Patents and intends to vigorously pursue this matter and defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, the Company commenced litigation against MSN Laboratories Private Ltd. (&#x201c;MSN&#x201d;) and Mylan Pharmaceuticals Inc., (&#x201c;Mylan&#x201d;) alleging patent infringement by MSN&#x2019;s and Mylan&#x2019;s filing of their ANDA for generic Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (plecanatide) 3mg tablets. This suit had been filed following receipt of a Notice of Paragraph IV Certification from each of MSN and Mylan, in which they had each asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#x2019;s Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; tablets, 3 mg, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of their respective generic plecanatide tablets, 3 mg.  The filing of these suits triggered a 30-month stay of the approval of the MSN and Mylan ANDAs for plecanatide tablets. The Company remains confident in the strength of the Trulance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents and intends to vigorously pursue this matter and defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, the Company commenced litigation against Slayback Pharma LLC and Slayback Pharma India LLP (together, &#x201c;Slayback&#x201d;) alleging patent infringement by Slayback Pharma LLC&#x2019;s filing of its ANDA No. 216361, referencing Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (0.025% brimonidine tartrate ophthalmic solution). This suit had been filed following receipt of a Notice of Paragraph IV Certification from Slayback Pharma LLC, in which it had asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#x2019;s Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; brimonidine tartrate ophthalmic solution, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of its generic brimonidine tartrate solution.  The filing of this suit triggered a 30-month stay of the approval of the Slayback ANDA for its brimonidine tartrate solution.  The Company remains confident in the strength of the Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents and intends to vigorously defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 2, 2022 the Company commenced litigation against Lupin Pharmaceuticals, Inc. (&#x201c;Lupin&#x201d;) alleging patent infringement by Lupin&#x2019;s filing of its ANDA No. 216716, referencing Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (0.025% brimonidine tartrate ophthalmic solution). This suit had been filed following receipt of a Notice of Paragraph IV Certification from Lupin, in which it had asserted that the U.S. patents listed in the FDA's Orange Book for the Company&#x2019;s Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; brimonidine tartrate ophthalmic solution, were either invalid, unenforceable and/or would not be infringed by the commercial manufacture, use or sale of its generic brimonidine tartrate solution.  The filing of this suit triggered a 30-month stay of the approval of the Lupin ANDA for its brimonidine tartrate solution. The Company remains confident in the strength of the Lumify&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; patents and will continue to vigorously pursue this matter and defend its intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Jublia Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, patents covering the Company's branded pharmaceutical products may be challenged in proceedings other than court proceedings, including inter partes review (&#x201c;IPR&#x201d;) at the U.S. Patent &amp;amp; Trademark Office. The proceedings operate under different standards from district court proceedings, and are often completed within 18 months of institution. IPR challenges have been brought against patents covering the Company's branded pharmaceutical products. For example, following Acrux DDS&#x2019;s IPR petition, the U.S. Patent and Trial Appeal Board  (&#x201c;PTAB&#x201d;), in May 2017, instituted inter partes review for an Orange Book-listed patent covering Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(U.S. Patent No. 7,214,506 (the &#x201c;&#x2018;506 Patent&#x201d;)) and, on &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 6, 2018, issued a written determination invalidating such patent. An appeal of this decision was filed on August 7, 2018. On March 13, 2020, the Court of Appeals for the Federal Circuit reversed this decision and remanded the matter back to the PTAB for further proceedings.  As a result of a settlement, a joint motion to terminate the proceedings was filed on November 12, 2020 and, on January 8, 2021, the PTAB granted this motion.   The &#x2018;506 Patent, therefore, remains valid and enforceable and expires in 2026. Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;is covered by fourteen Orange Book-listed patents owned by the Company or its licensor, which expire in the years 2028 through 2035. In August and September 2018, the Company received notices of the filing of a number of ANDAs with paragraph IV certification, and has timely filed patent infringement suits against these ANDA filers, and, in addition, the Company has also commenced certain patent infringement proceedings in Canada against four separate defendants.  All cases in the U.S. regarding Jublia&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; have been settled. In Canada, two lawsuits remain pending against Apotex Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Liability &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Products Liability Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since 2016, the Company has been named in a number of product liability lawsuits involving the Shower to Shower&#xae; body powder product acquired in September 2012 from Johnson &amp;amp; Johnson; due to dismissals, twenty-nine (29) of such product liability suits currently remain pending. Potential liability (including its attorneys&#x2019; fees and costs) arising out of these remaining suits is subject to full indemnification obligations of Johnson &amp;amp; Johnson owed to the Company and its affiliates, and legal fees and costs will be paid by Johnson &amp;amp; Johnson. Twenty-eight (28) of these lawsuits filed by individual plaintiffs allege that the use of Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; caused the plaintiffs to develop ovarian cancer, mesothelioma or breast cancer. The allegations in these cases include failure to warn, design defect, manufacturing defect, negligence, gross negligence, breach of express and implied warranties, civil conspiracy concert in action, negligent misrepresentation, wrongful death, loss of consortium and/or punitive damages. The damages sought include compensatory damages, including medical expenses, lost wages or earning capacity, loss of consortium and/or compensation for pain and suffering, mental anguish anxiety and discomfort, physical impairment and loss of enjoyment of life. Plaintiffs also seek pre- and post-judgment interest, exemplary and punitive damages, and attorneys&#x2019; fees. Additionally, two proposed class actions have been filed in Canada against the Company and various Johnson &amp;amp; Johnson entities (one in the Supreme Court of British Columbia and one in the Superior Court of Quebec), on behalf of persons who have purchased or used Johnson &amp;amp; Johnson&#x2019;s Baby Powder or Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The class actions allege the use of the product increases certain health risks (British Columbia) or negligence in failing to properly test, failing to warn of health risks, and failing to remove the products from the market in a timely manner (Quebec). The plaintiffs in these actions are seeking awards of general, special, compensatory and punitive damages. On November 17, 2020, the British Columbia court issued a judgment declining to certify a class as to the Company or Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and at this time no appeal of that judgment has been filed. On December 16, 2021, the plaintiff in the British Columbia class action filed a Second Amended Notice of Civil Claim and Application for Certification, removing the Company as a defendant; as a result, the British Columbia class action is concluded as to the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson, through one or more subsidiaries has purported to have completed a Texas divisional merger with respect to any talc liabilities at Johnson &amp;amp; Johnson Consumer, Inc. (&#x201c;JJCI&#x201d;). LTL Management, LLC (&#x201c;LTL&#x201d;), the resulting entity of the divisional merger, assumed JJCI&#x2019;s talc liabilities and thereafter filed for Chapter 11 bankruptcy protection in the United States Bankruptcy Court for the Western District of North Carolina. Pursuant to a court order, the case was transferred to the United States District Court for the District of New Jersey. Notwithstanding the divisional merger and LTL&#x2019;s bankruptcy case, the Company and its affiliates continue to have indemnification claims and rights against Johnson &amp;amp; Johnson and LTL pursuant to the terms of the indemnification agreement entered into between JJCI and its affiliates and the Company and its affiliates, which indemnification agreement remains in effect. As a result, it is the Company's current expectation that it will not incur any material impairments with respect to its indemnification claims as a result of the divisional merger or the bankruptcy. Substantially all cases subject to the indemnification agreement related to Johnson &amp;amp; Johnson&#x2019;s talc liability are stayed through February 28, 2022, pursuant to a preliminary injunction issued by the bankruptcy court. Motions to dismiss the LTL bankruptcy, as well as extend the stay beyond February 28, 2022, were argued in the bankruptcy court in February 2022. A decision of the court is pending. To the extent that any cases subject to the indemnification agreement proceed during the pendency of the bankruptcy case, it is the Company's expectation that Johnson &amp;amp; Johnson, in accordance with the indemnification agreement, will continue to vigorously defend the Company in each of the remaining actions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;General Civil Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;California Proposition 65 Related Matter&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 19, 2019, plaintiffs filed a proposed class action in California state court against Bausch Health US and Johnson &amp;amp; Johnson (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Gutierrez, et al. v. Johnson &amp;amp; Johnson, et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 37-2019-00025810-CU-NP-CTL), asserting claims for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;purported violations of the California Consumer Legal Remedies Act, False Advertising Law and Unfair Competition Law in connection with their sale of talcum powder products that the plaintiffs allege violated Proposition 65 and/or the California Safe Cosmetics Act. This lawsuit was served on Bausch Health US in June 2019 and was subsequently removed to the United States District Court for the Southern District of California, where it is currently pending. Plaintiffs seek damages, disgorgement of profits, injunctive relief, and reimbursement/restitution. The Company filed a motion to dismiss Plaintiffs&#x2019; claims, which was granted in April 2020 without prejudice. In May 2020, Plaintiffs filed an amended complaint and in June 2020, filed a motion for leave to amend the complaint further, which was granted.  In August 2020, Plaintiffs filed the Fifth Amended Complaint. On January 22, 2021, the Court granted the motion to dismiss with prejudice. On February 19, 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit Court of Appeals. On July 1, 2021, Appellants (Plaintiffs) filed their opening brief; Appellees' response briefs were filed on October 8, 2021. This matter was stayed by the Ninth Circuit on December 7, 2021, due to the preliminary injunction entered by the bankruptcy court in the LTL bankruptcy proceeding. This stay included Appellants&#x2019; reply brief deadline, which was previously due to be filed on or before December 2, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New Mexico Attorney General Consumer Protection Action&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Bausch Health US were named in an action brought by State of New Mexico ex rel. Hector H. Balderas, Attorney General of New Mexico, in the County of Santa Fe New Mexico First Judicial District Court (New Mexico ex rel. Balderas v. Johnson &amp;amp; Johnson, et al., Civil Action No. D-101-CV-2020-00013, filed on January 2, 2020), alleging consumer protection claims against Johnson &amp;amp; Johnson and Johnson &amp;amp; Johnson Consumer Companies, Inc., the Company and Bausch Health US related to Shower to Shower&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and its alleged causal link to mesothelioma and other cancers.  In April 2020, Bausch Health US filed a motion to dismiss, which in September 2020, the Court granted in part as to the New Mexico Medicaid Fraud Act and New Mexico Fraud Against Taxpayers Act claims and denied as to all other claims. The State of New Mexico brings claims against all defendants under the New Mexico Unfair Practices Act and other common law and equitable causes of action, alleging defendants engaged in wrongful marketing, sale and promotion of talcum powder products. The lawsuit seeks to recover the cost of the talcum powder products as well as the cost of treating asbestos-related cancers allegedly caused by those products. Bausch Health US filed its answer on November 16, 2020. On December 30, 2020 Johnson &amp;amp; Johnson filed a Motion for Partial Judgment on the Pleadings and on January 4, 2021, Bausch Health US filed a joinder to that motion, which was denied on March 8, 2021. Trial is scheduled to begin on January 18, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Bausch Health US dispute the claims against them and intend to defend this lawsuit vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Doctors Allergy Formula Lawsuit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, Doctors Allergy Formula, LLC (&#x201c;Doctors Allergy&#x201d;), filed a lawsuit against Bausch Health Americas in the Supreme Court of the State of New York, County of New York, asserting breach of contract and related claims under a 2015 Asset Purchase Agreement, which purports to include milestone payments that Doctors Allergy alleges should have been paid by Bausch Health Americas.  Doctors Allergy claims its damages are not less than $23 million. Bausch Health Americas has asserted counterclaims against Doctors Allergy. Bausch Health Americas filed a motion seeking an order granting Bausch Health Americas summary judgment on its counterclaims against Plaintiff and dismissing Plaintiff&#x2019;s claims against it. The motion was fully briefed as of May 2021. The Court held a hearing on the motion on January 25, 2022. The motion remains pending. Bausch Health Americas disputes the claims against it and will continue to defend itself vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation with Former Salix CEO&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 28, 2019, former Salix Ltd. CEO and director Carolyn Logan filed a lawsuit in the Delaware Court of Chancery, Case No. 2019-0059, asserting claims for breach of contract and declaratory relief.  On November 19, 2021, Logan amended her complaint to add a claim for breach of the implied covenant of good faith and fair dealing. The lawsuit arises out of the contractual termination of approximately $30 million in unvested equity awards following the determination by the Salix Ltd. Board of Directors that Logan intentionally engaged in wrongdoing that resulted, or would reasonably be expected to result, in material harm to Salix Ltd., or to the business or reputation of Salix Ltd.  Logan seeks the restoration of the unvested equity awards and a declaration regarding certain rights related to indemnification. On June 19, 2019, the Court entered an order staying the claim for declaratory relief pending the final resolution of the breach of contract claim. Trial is scheduled to commence on September 6, 2022. The Company disputes the claims and intends to vigorously defend the matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Completed or Inactive Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following matters have concluded, have settled, are the subject of an agreement to settle or have otherwise been closed since January 1, 2021, have been inactive from the Company&#x2019;s perspective for several quarters or the Company anticipates that no further material activity will take place with respect thereto. Due to the closure, settlement, inactivity or change in status of the matters referenced below, these matters will no longer appear in the Company's next public reports and disclosures, unless required. With respect to inactive matters, to the extent material activity takes place in subsequent quarters with respect thereto, the Company will provide updates as required or as deemed appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Glumetza Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Between August 2019 and July 2020, eight (8) putative antitrust class actions and four (4) non-class complaints naming Bausch Health Companies Inc., Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc., and Santarus, Inc. (for purposes of this subsection, collectively, the &#x201c;Company&#x201d;), among other defendants, were filed or transferred to the Northern District of California. Three (3) of the class actions were filed by plaintiffs seeking to represent a class of direct purchasers. The purported classes of direct purchasers filed a consolidated first amended complaint and a motion for class certification in April 2020. The court certified a direct purchaser class in August 2020.  The putative class action complaints filed by end payer purchasers have all been voluntarily dismissed. Three (3) of the non-class complaints were filed by direct purchasers. The fourth non-class complaint, asserting claims based on both direct and indirect purchases, was filed by an insurer plaintiff in July 2020 and subsequently amended in September 2020.  In December 2020, the court denied the Company&#x2019;s motion to dismiss as to the insurer plaintiff&#x2019;s direct claims but dismissed the insurer plaintiff&#x2019;s indirect claims. On February 2, 2021, the insurer plaintiff&#x2019;s motion for leave to amend its complaint was denied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These actions were consolidated and coordinated in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 3:19-cv-05822-WHA (N.D. Cal.) (the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;). The lawsuits alleged that a 2012 settlement of a patent litigation regarding Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; delayed generic entry in exchange for an agreement not to launch an authorized generic of Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; or grant any other company a license to do so. The complaints alleged that the settlement agreement resulted in higher prices for Glumetza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and its generic equivalent both prior to and after generic entry. Both the class and non-class plaintiffs sought damages under federal antitrust laws for claims based on direct purchases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 26, 2021, the Company reached an agreement in principle and, thereafter, on September 14, 2021, executed a final settlement agreement to resolve the class plaintiffs&#x2019; claims for $300&#160;million, subject to court approval. On August 1, 2021, the Company also reached an agreement in principle to resolve the non-class direct purchaser plaintiffs&#x2019; claims, described above, for additional consideration.  A final settlement agreement with the non-class direct purchaser plaintiffs was executed on August 6, 2021. As part of the settlements, the Company admitted no liability as to the claims against it and denied all allegations of wrongdoing.  On September 20, 2021, the insurer plaintiff voluntarily dismissed its claims in the consolidated federal action. By stipulation, the insurer plaintiff has asserted its direct opt-out claims in the State Court Action, resulting in the consolidation of all of its opt-out claims in the State Court Action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 22, 2021, the court granted preliminary approval of the class settlement agreement and vacated the October 2021 trial date and all other pre-trial deadlines in the consolidated actions. On February 3, 2022, the court granted final  approval of the class settlement and ordered dismissal of the class plaintiffs' claims. Subject to appeal of the final approval of the class settlement, the settlements will resolve and discharge all asserted class and direct purchaser non-class claims against the Company in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In re Glumetza Antitrust Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;California Proposition 65 Related Matter&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 29, 2020, Plaintiff Jan Graham filed a lawsuit (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Graham v. Bausch Health Companies, Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 20STCV03578) in Los Angeles County Superior Court against the Company, Bausch Health US and several other manufacturers, distributors and retailers of talcum powder products, alleging violations of California Proposition 65 by manufacturing and distributing talcum powder products containing chemicals listed under the statue, without a compliant warning on the label. On January 29, 2021, certain defendants including the Company and Bausch Health US filed a Motion for Summary Judgment or in the Alternative Motion for Summary Adjudication, which was granted with prejudice on May 26, 2021; Plaintiff waived the right to appeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivative Lawsuits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 10, 2019 and September 13, 2019, two alleged stockholders filed derivative lawsuits purportedly on behalf of the Company against former Company board members and executives. On March 7, 2020, a consolidated amended derivative complaint was filed, captioned In re Bausch Health Companies Inc. F/K/A/ Valeant Pharmaceuticals International, Inc. Stockholder Derivative Litigation (Case No. 19-cv-17833). &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Plaintiffs asserted claims for breach of fiduciary duty, waste of corporate assets, and unjust enrichment related to, among other things, allegedly false and misleading statements and/or failures to disclose information about the Company&#x2019;s business and prospects, including relating to drug pricing, the Company&#x2019;s use of specialty pharmacies, and the Company&#x2019;s relationship with Philidor. The consolidated complaint also asserted a claim for contribution and indemnification by the Defendants for any liability the Company ultimately faces as a result of the conduct alleged in the complaint. The claims alleged in these cases were based on the same purported conduct that is at issue in In re Valeant Pharmaceuticals International, Inc. Securities Litigation, all of which occurred prior to 2017. On April 21, 2020, the Defendants filed a motion to dismiss the consolidated amended complaint.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Briefing on this motion concluded on August 3, 2020. On November 24, 2020, the Special Master appointed by the Court issued a report recommending that the motion to dismiss be granted in full.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 20, 2021, the District Court adopted the report and recommendation of the Special Master and dismissed the action.&lt;/span&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <bhc:Legalsettlementsandrelatedfees
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzEyNjY_6632df50-e56e-4967-a221-cc14bdea41e8"
      unitRef="usd">1890000000</bhc:Legalsettlementsandrelatedfees>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i574ece8cc22045c08b39e4da379ec989_D20151001-20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzM3MjY_aa46ab29-07f7-4cbd-b76e-53b2cddcb660"
      unitRef="case">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i574ece8cc22045c08b39e4da379ec989_D20151001-20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzQyNjc_182648f3-8cf7-4c70-9b65-9b47be6b283f"
      unitRef="case">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i6ba274da5cb54b1daae13438db70ae34_D20191216-20191216"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzQ1Njc_e0ac410a-911e-4855-8b78-b9dac1dcb563"
      unitRef="usd">1210000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i546776d7d59544bda0c885c5725afaef_D20211231-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzU2OTM_2dad565c-e3ff-4460-9f0f-adf868414324"
      unitRef="usd">1210000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors
      contextRef="i0a8688d163da4bddb3dfdc9ef920e0fb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzcwNjc_59fb786d-26df-4412-ab31-5b86fcc26866"
      unitRef="group">37</bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors>
    <us-gaap:LossContingencyClaimsDismissedNumber
      contextRef="i0a8688d163da4bddb3dfdc9ef920e0fb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzExNzE2_fcdc282f-b32a-4935-b918-ce267321c631"
      unitRef="case">16</us-gaap:LossContingencyClaimsDismissedNumber>
    <bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors
      contextRef="i0a8688d163da4bddb3dfdc9ef920e0fb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzExNzI2_59fb786d-26df-4412-ab31-5b86fcc26866"
      unitRef="group">37</bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors>
    <bhc:LossContingencyPlaintiffsNumberofGroupsofInvestorsPending
      contextRef="i0a8688d163da4bddb3dfdc9ef920e0fb_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzExODU3_1f65c35a-7736-4813-a61f-336d916f236b"
      unitRef="group">21</bhc:LossContingencyPlaintiffsNumberofGroupsofInvestorsPending>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i721131c964b147fab4e1a6b8f95b4460_D20150101-20151231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzE0NDA4_3a1669ad-3abf-4e32-bbcf-7566097f8352"
      unitRef="case">6</us-gaap:LossContingencyNewClaimsFiledNumber>
    <bhc:LossContingencyNewClaimsFiledButNotYetServedNumber
      contextRef="i522c83d185a3433eb7ebdb03a1574f39_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzE1Mzc1_4da8c2fc-18aa-49ba-bbf6-16a65311bc20"
      unitRef="action">2</bhc:LossContingencyNewClaimsFiledButNotYetServedNumber>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i3d14d3034bc54cf58ac8ef0977e6b643_D20200804-20200804"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzE3MDM4_1db2b7ab-40ff-4ca7-8bbd-9613177f7790"
      unitRef="cad">94000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction
      contextRef="i0288b667636240ca9edb0931e9570cbf_I20190215"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzE4NDY0_f8aac46e-4d34-4b59-ae0b-6477175c35bc"
      unitRef="entity">1</bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction>
    <bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction
      contextRef="i7a3cc564cfa54644914c3dd2984b2e99_I20210317"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzIwNDUw_749ba614-d108-4b98-9914-afdad924e890"
      unitRef="numberofbusiness">4</bhc:LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="ic99388c5fb8449b4b2899f64833edd24_D20160527-20160916"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzIxMTk5_fb7b2580-3098-4547-8398-b13004f38669"
      unitRef="action">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <bhc:LossContingencyNumberOfInsurancePolicyPeriods
      contextRef="ib788085ae68b43f5be26854e2e649395_D20171207-20171207"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzIzMDEz_6eb28166-4542-4b30-a299-5bd6c3984e0c"
      unitRef="insurance_policy_period">2</bhc:LossContingencyNumberOfInsurancePolicyPeriods>
    <bhc:LossContingencySettlementAgreementsNumberOfInsurers
      contextRef="ia2292d9d54a74b14a40833c7ee03e2c0_I20210720"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzI0OTc4_63dd2055-3a41-4e84-8c9d-8bbaddc5802c"
      unitRef="insured">2</bhc:LossContingencySettlementAgreementsNumberOfInsurers>
    <bhc:LossContingencySettlementAgreementsNumberOfInsurers
      contextRef="ia2292d9d54a74b14a40833c7ee03e2c0_I20210720"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzI1MDk0_cc6d1513-403d-427f-b7f8-f7eae0a6870d"
      unitRef="insured">2</bhc:LossContingencySettlementAgreementsNumberOfInsurers>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty
      contextRef="i10b5c7db69ef4006bcb53437d3aa06b8_D20210720-20210720"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzI1MzMx_af664376-a160-4038-af98-92909c57a39e"
      unitRef="usd">213000000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <bhc:LossContingencyStayOfApprovalPeriod
      contextRef="i8d3399dca8844555b1a0224ee52572bb_D20190901-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzMyMDgy_538512f7-0f0e-450f-a83b-31d3fc5baad9">P30M</bhc:LossContingencyStayOfApprovalPeriod>
    <bhc:LossContingencyStayOfApprovalPeriod
      contextRef="i416608f63c8f48baa9c46a05acc57dba_D20200828-20200828"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzMzMjY2_e99dd0ba-a747-4aa4-b881-353dcd248238">P30M</bhc:LossContingencyStayOfApprovalPeriod>
    <bhc:LossContingencyStayOfApprovalPeriod
      contextRef="i20d7a644460c4ab7b2d3fc7e95d5d3c7_D20200501-20200501"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzM0Mjg0_67da5d03-e833-4ca3-a2d7-b0c02d941737">P30M</bhc:LossContingencyStayOfApprovalPeriod>
    <bhc:LossContingencyStayOfApprovalPeriod
      contextRef="iad566679ccb740d78397815ac12d9b44_D20210401-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzM1NDMx_96181824-8fa3-4baf-84aa-087eb5acc71b">P30M</bhc:LossContingencyStayOfApprovalPeriod>
    <bhc:LossContingencyStayOfApprovalPeriod
      contextRef="id9d5c1c1399a4c59b08e7d331695b3a6_D20210901-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzM2NDA1_7962c290-73de-44d9-8d8d-b5f220aeedcb">P30M</bhc:LossContingencyStayOfApprovalPeriod>
    <bhc:LossContingencyStayOfApprovalPeriod
      contextRef="ie5f2cff0c15c4497abb7c0bb38853653_D20220202-20220202"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzM3MzAx_22b73222-aaf9-40fe-bb8c-0e74ac0bc253">P30M</bhc:LossContingencyStayOfApprovalPeriod>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i1bdbb266b2064e05970e5019800e2253_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzM5MzQ3_7c16e61e-f98c-4510-92dc-409314519d84"
      unitRef="case">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i8167d807dd934310925525373a61a11f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzM5Njc3_c586af71-0bae-45cd-be32-6ce58bce0bf0"
      unitRef="case">29</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i9b8fdb21d7d648d59dfb6f5b8647cf38_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzQwMDIw_86156626-add2-4b00-a5e6-068778bf7cdb"
      unitRef="case">28</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ic7ca0340304c47edaa88616e036f7daf_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzQwODY3_abaefb6f-ac93-4878-8e63-c6fb78c34cfc"
      unitRef="case">2</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyClaimsDismissedNumber
      contextRef="ib2a61b2c466048d7a44cf2f37e6f9067_D20211216-20211216"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzQwOTc5_77aa1899-c0bb-4888-808f-4c0d1a49b2f8"
      unitRef="case">1</us-gaap:LossContingencyClaimsDismissedNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i4161ab534a444089a14221908e89ca6b_I20211215"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzQwOTc5_d700276a-cf85-490f-94c7-dc3fe5da5315"
      unitRef="case">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="ic25fde520f434990aec8bc4ef672935d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzQxMDI3_7b0e98cf-f7d5-4162-a1de-21b5809cf45d"
      unitRef="case">1</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i8cee0c4f1d894fc3aa19e2148d91bb12_D20180401-20180430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzQ3ODgy_b233e803-35c1-418f-b7b8-df2fc5efa5b1"
      unitRef="usd">23000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i2fa7f1086a9a45249ac683ef177587c9_D20190128-20190128"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzQ4ODI2_a294b7d4-8d9d-4098-be6e-f62aacd7a2de"
      unitRef="usd">30000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i5c84bf2f503a48bcbda0eee28745f465_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzUwMzI4_f9d14f5e-e5a1-47aa-8771-575c10829ed1"
      unitRef="case">8</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="ic39bb939c10e450dbd36a0e824f2720b_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzUwMzc1_8ed6bc53-eea6-49a8-8783-1cfb99863d5e"
      unitRef="case">4</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i7cb1b7f540294b49ad9ef73316d882e6_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzUwNjc1_2131434d-047a-4df3-9cca-51f09745f235"
      unitRef="case">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i2e52d3146d5a487e9ca0aeaadf2b0915_D20190801-20200730"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzUxMDg5_ee0e5988-a7e5-460d-b5de-1c973420bb71"
      unitRef="case">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i35ef7917c4e846cdb1959043a03d5bca_D20210726-20210726"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzUyNDc2_d0fe508c-7dd9-4441-b4e4-0475250aea8d"
      unitRef="usd">300000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <bhc:LossContingencyNumberOfAllegedStockholdersFiledLawsuits
      contextRef="iff2a848fa15e484ba0fd1a37bd47732e_I20190910"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzU0NjUw_51c6042b-18c7-4b48-98a1-72deaf0e3b7e"
      unitRef="shareholder">2</bhc:LossContingencyNumberOfAllegedStockholdersFiledLawsuits>
    <bhc:LossContingencyNumberOfAllegedStockholdersFiledLawsuits
      contextRef="i6efe4500a1e94445a37235d0071dbc71_I20190913"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzMvZnJhZzozZTYyMDM3NmQ4NTI0ZTE5ODA2ODQ1Yjg2NmJkMjQ3Yy90ZXh0cmVnaW9uOjNlNjIwMzc2ZDg1MjRlMTk4MDY4NDViODY2YmQyNDdjXzU0NjUw_c862e7a2-465e-40db-bf48-2d9e8bbdb859"
      unitRef="shareholder">2</bhc:LossContingencyNumberOfAllegedStockholdersFiledLawsuits>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzYvZnJhZzoyYmMyNDgwOTYzZDE0N2M2ODUxYzJiOWNkZDRiM2VmOS90ZXh0cmVnaW9uOjJiYzI0ODA5NjNkMTQ3YzY4NTFjMmI5Y2RkNGIzZWY5XzQ0MDU_30f818ee-b020-446b-a9b3-5776fdef845c">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has commitments related to capital expenditures of approximately $76 million as of December&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under certain agreements, the Company may be required to make payments contingent upon the achievement of specific developmental, regulatory, or commercial milestones. As of December&#160;31, 2021, the Company believes it is reasonably possible that it may potentially make milestone and license fee payments, including sales-based milestone payments, of approximately $340 million over time, in the aggregate, to third parties for products currently under development or being marketed, primarily consisting of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Under the terms of a June 2013 distribution and supply agreement with Mylan Pharmaceuticals Inc. (as assignee of Spear Pharmaceuticals, Inc and Spear Dermatology Products Inc.), the Company may be required to make sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $70 million, in the aggregate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Under the terms of an April 2019 agreement with Mitsubishi Tanabe Pharma Corporation, the Company has acquired an exclusive license to develop and commercialize&#160;MT-1303 (amiselimod), a late-stage oral compound that targets the sphingosine 1-phosphate receptor that plays a role in autoimmune diseases, such as Inflammatory Bowel Disease and ulcerative colitis. The Company may be required to make development and sales-based milestone payments over time of up to $60 million, in the aggregate, as well as royalties on future sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Under the terms of a December 2019 agreement with Novaliq GmbH, the Company has acquired an exclusive license for the commercialization and development in the U.S. and Canada of NOV03 (perfluorohexyloctane), an investigational drug to treat Dry Eye Disease associated with Meibomian gland dysfunction and may be required to make sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $48 million, in the aggregate, as well as royalties on future sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Under the terms of a November 2019 agreement with Cedars-Sinai Medical Center, to evaluate a new formulation of rifaximin for the treatment of irritable bowel syndrome, the Company may be required to make development and sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $36&#160;million, in the aggregate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Under the terms of an October 2020 agreement with Eyenovia, Inc., the Company has acquired an exclusive license in the U.S. and Canada for the development and commercialization of an investigational microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression, also known as nearsightedness, in children ages 3-12. Under the terms of the agreement, the Company may be required to make development and sales-based milestone payments. The Company believes it is reasonably possible that these payments over time may approximate $35&#160;million, in the aggregate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Under the terms of a May 2020 agreement with STADA Arzneimittel AG and its development partner, Xbrane Biopharma AB, to commercialize in the U.S. and Canada a biosimilar candidate to Lucentis (ranibizumab), the Company may be required to make development and sales-based milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the nature of these arrangements, the future potential payments related to the attainment of the specified milestones over a period of several years are inherently uncertain. As of December 31, 2021, no accruals related to the aforementioned agreements exist because the milestone targets are not yet probable of being achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Indemnification Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company enters into agreements that include indemnification provisions for product liability and other matters. These provisions are generally subject to maximum amounts, specified claim periods and other conditions and limits. In addition, the Company is obligated to indemnify its officers and directors in respect of any legal claims or actions initiated against them in their capacity as officers and directors of the Company in accordance with applicable law. Pursuant to such indemnities, the Company is indemnifying certain former officers and directors in respect of certain litigation and regulatory matters.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021 and 2020, no material amounts were accrued for the Company&#x2019;s obligations under these indemnification provisions.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ContractualObligation
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzYvZnJhZzoyYmMyNDgwOTYzZDE0N2M2ODUxYzJiOWNkZDRiM2VmOS90ZXh0cmVnaW9uOjJiYzI0ODA5NjNkMTQ3YzY4NTFjMmI5Y2RkNGIzZWY5Xzg2_29144e87-d681-42b0-92ad-d0a64c95a8ce"
      unitRef="usd">76000000</us-gaap:ContractualObligation>
    <bhc:CollaborativeAgreementMilestonePaymentsAggregate
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzYvZnJhZzoyYmMyNDgwOTYzZDE0N2M2ODUxYzJiOWNkZDRiM2VmOS90ZXh0cmVnaW9uOjJiYzI0ODA5NjNkMTQ3YzY4NTFjMmI5Y2RkNGIzZWY5XzQ0OQ_884238e9-9a55-45a4-a964-7376ab2918b0"
      unitRef="usd">340000000</bhc:CollaborativeAgreementMilestonePaymentsAggregate>
    <bhc:CollaborativeAgreementMilestonePaymentsAggregate
      contextRef="i45d0ac640df44b65a4bc4c22c9500429_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzYvZnJhZzoyYmMyNDgwOTYzZDE0N2M2ODUxYzJiOWNkZDRiM2VmOS90ZXh0cmVnaW9uOjJiYzI0ODA5NjNkMTQ3YzY4NTFjMmI5Y2RkNGIzZWY5XzkzNg_b86dab81-a141-4dc4-9ffc-07d97e0355df"
      unitRef="usd">70000000</bhc:CollaborativeAgreementMilestonePaymentsAggregate>
    <bhc:CollaborativeAgreementMilestonePaymentsAggregate
      contextRef="i5496c79fe37f42a9a6ed6ceefc84608e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzYvZnJhZzoyYmMyNDgwOTYzZDE0N2M2ODUxYzJiOWNkZDRiM2VmOS90ZXh0cmVnaW9uOjJiYzI0ODA5NjNkMTQ3YzY4NTFjMmI5Y2RkNGIzZWY5XzE0MjE_2117ceab-1c81-417d-8432-bb7b96a81c35"
      unitRef="usd">60000000</bhc:CollaborativeAgreementMilestonePaymentsAggregate>
    <bhc:CollaborativeAgreementMilestonePaymentsAggregate
      contextRef="i76cbbad47b514c08a436d4d6576f412a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzYvZnJhZzoyYmMyNDgwOTYzZDE0N2M2ODUxYzJiOWNkZDRiM2VmOS90ZXh0cmVnaW9uOjJiYzI0ODA5NjNkMTQ3YzY4NTFjMmI5Y2RkNGIzZWY5XzE5MzY_30c24375-e0d4-49f8-9c13-f10a28eaba35"
      unitRef="usd">48000000</bhc:CollaborativeAgreementMilestonePaymentsAggregate>
    <bhc:CollaborativeAgreementMilestonePaymentsAggregate
      contextRef="i5bdf942d40b54fefaef817509211ad3e_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzYvZnJhZzoyYmMyNDgwOTYzZDE0N2M2ODUxYzJiOWNkZDRiM2VmOS90ZXh0cmVnaW9uOjJiYzI0ODA5NjNkMTQ3YzY4NTFjMmI5Y2RkNGIzZWY5XzIzNDI_aa8abf5b-8db5-4630-88b8-29f4c11bb8ac"
      unitRef="usd">36000000</bhc:CollaborativeAgreementMilestonePaymentsAggregate>
    <bhc:CollaborativeAgreementMilestonePaymentsAggregate
      contextRef="if4268c1a55cd4a2e89570ee83827d90d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzYvZnJhZzoyYmMyNDgwOTYzZDE0N2M2ODUxYzJiOWNkZDRiM2VmOS90ZXh0cmVnaW9uOjJiYzI0ODA5NjNkMTQ3YzY4NTFjMmI5Y2RkNGIzZWY5XzI5NjI_9f172d5a-2c64-499f-90ca-3f2d70375d39"
      unitRef="usd">35000000</bhc:CollaborativeAgreementMilestonePaymentsAggregate>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90ZXh0cmVnaW9uOjJmNDdlODBjMTIyNDQ0ZGQ5NzM3ZDQ1YzUzMWMzOTFkXzM0NTg_3cc0f96e-8213-47dd-9322-0c8585ce7b7a">SEGMENT INFORMATION&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reportable Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the planned separation of its Solta business into an independent publicly traded entity from the remainder of Bausch Health Companies Inc., the Company has begun managing its operations in a manner which is consistent with the organizational structure of the two separate entities as proposed by the Solta IPO. As a result, during the first quarter of 2022, the Company&#x2019;s Chief Executive Officer  (&#x201c;CEO&#x201d;), who is the Company&#x2019;s Chief Operating Decision Maker, commenced managing the business differently through changes in its operating and reportable segments, which necessitated a realignment of the Company&#x2019;s historical segment structure. This realignment is consistent with how the Company&#x2019;s CEO currently: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports. Pursuant to these changes, effective in the first quarter of 2022, the Company operates in the following reportable segments: (i) Bausch + Lomb, (ii) Salix, (iii) International (formerly International Rx), (iv) Solta Medical and (v) Diversified Products. The new segment structure does not impact the Company&#x2019;s reporting units but realigns the two reporting units of the former Ortho Dermatologics segment whereby its medical dermatology reporting unit (Ortho Dermatologics) is now part of the current Diversified Products segment and the Solta reporting unit is now the sole reporting unit of the new Solta Medical segment. All segment revenues and segment profits for the periods presented have been recast to conform to the 2022 reportable segment structure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a brief description of the Company&#x2019;s segments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The Bausch + Lomb segment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consists of global sales of Bausch + Lomb Vision Care, Consumer, Surgical and Ophthalmic Pharmaceuticals products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The Salix segment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consists of sales in the U.S. of GI products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The International segment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consists of sales, with the exception of sales of Bausch +Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The Solta Medical segment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consists of global sales of Solta aesthetic medical devices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;The Diversified Products segment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consists of sales in the U.S. of: (i) pharmaceutical products in the areas of neurology and certain other therapeutic classes, (ii) generic products, (iii) Ortho Dermatologics (dermatological) products and (iv) dentistry products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment profit is based on operating income after the elimination of intercompany transactions.  Certain costs, such as Amortization of intangible assets, Asset impairments, including loss on assets held for sale, Restructuring, integration, separation and IPO costs, and Other expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company&#x2019;s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single&#160;segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Revenues and Profit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment revenues and profits for the years 2021, 2020 and 2019 were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment profit:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(619)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,897)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairments, including loss on assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring, integration, separation and IPO costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(502)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Loss before benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to segment revenue and profit in order for the prior years to conform to current year presentation. These reclassifications are not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Capital Expenditures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capital expenditures by segment for the years 2021, 2020 and 2019 were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital expenditures:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenues by Product and by Product Category &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues for the Company's top ten products for the years 2021, 2020 and 2019 represented 43%, 41% and 39% of total product sales, respectively. Revenues by segment and product category were as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Geographic Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are attributed to a geographic region based on the location of the customer for the years 2021, 2020 and 2019 were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Poland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Russia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Egypt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Italy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made and are reflected in the table above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets consisting of property, plant and equipment, net of accumulated depreciation, are attributed to geographic regions based on their physical location as of December&#160;31, 2021 and 2020 were as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.751%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Poland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Serbia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Italy &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Major Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customers that accounted for 10% or more of total revenues were as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health,&#160;Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportingUnits
      contextRef="i3328d4d641274769857018f609cda173_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90ZXh0cmVnaW9uOjJmNDdlODBjMTIyNDQ0ZGQ5NzM3ZDQ1YzUzMWMzOTFkXzYwNDczMTM5NjIzNTc_975093b7-0787-44d9-a9da-32e6f99345b8"
      unitRef="reporting_unit">2</us-gaap:NumberOfReportingUnits>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90ZXh0cmVnaW9uOjJmNDdlODBjMTIyNDQ0ZGQ5NzM3ZDQ1YzUzMWMzOTFkXzM0NTQ_acd0ce3b-b07a-48ea-953b-f89b7debfac5">Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of the Company&#x2019;s businesses and incurs certain expenses, gains and losses related to the overall management of the Company, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single&#160;segment.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90ZXh0cmVnaW9uOjJmNDdlODBjMTIyNDQ0ZGQ5NzM3ZDQ1YzUzMWMzOTFkXzM0MjU_7af8863b-9013-42f8-b59d-6a964f63bb24">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Segment revenues and profits for the years 2021, 2020 and 2019 were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment profit:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(792)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(619)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,375)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,897)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill impairments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(469)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairments, including loss on assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(75)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring, integration, separation and IPO costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(373)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(502)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Loss before benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,024)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(934)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,837)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff7c3f276277409b964a030bb9ddf9bc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzItMS0xLTEtOTQ4MzE_4357dfd2-0344-4973-8edb-c2794adf37b2"
      unitRef="usd">3765000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i899638122b1443aea3cf842ccf65501f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzItMy0xLTEtOTQ4MzE_a510040a-798d-4e7c-b8c0-d92a9b072cd0"
      unitRef="usd">3415000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4cd37c585bfd45c29417f050b1fb96e7_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzItNS0xLTEtOTQ4MzE_bfb8bd3c-0465-4a70-9eb5-50857eea5279"
      unitRef="usd">3778000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b94206c32884a8fa83f6929a2cb28d7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzMtMS0xLTEtOTQ4MzE_2349c5da-5a76-4e77-b875-353f2fa02176"
      unitRef="usd">2074000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6899a304edb44929422d6afaf6cef0a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzMtMy0xLTEtOTQ4MzE_d1b296b1-746d-4e00-8640-a3c84828fb1f"
      unitRef="usd">1904000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icda72308df944034b125cc6838172395_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzMtNS0xLTEtOTQ4MzE_9602ac59-6a32-4da3-9f9b-73d4af61dc41"
      unitRef="usd">2022000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8df850998cb6487c8f0b80f71254800b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzQtMS0xLTEtOTQ4MzE_2dd3d18f-ce41-48ea-acd6-7c1c44aff1e8"
      unitRef="usd">1166000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98f0b0d400a84364ac143e0c73a45029_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzQtMy0xLTEtOTQ4MzE_fe75a9d6-641f-4d8c-aa4a-9448ec43cacb"
      unitRef="usd">1181000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i42a14ea9b3e84273aeea86db5027a7ef_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzQtNS0xLTEtOTQ4MzE_b2bf76c1-c754-49fc-85cc-a1bd725a6687"
      unitRef="usd">1154000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff3b9d2f71d648e191dab78cdfc14a22_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzUtMS0xLTEtOTQ4MzE_ae2f99cc-bd77-4048-b5a1-29e0aca7ca22"
      unitRef="usd">308000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0bcc7f02716c496789da6644b328c014_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzUtMy0xLTEtOTQ4MzE_33aff332-8a5c-4430-b55f-69571662a23b"
      unitRef="usd">253000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59a5f333092b47d6b10bcf6f866713da_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzUtNS0xLTEtOTQ4MzE_c95c56b9-f4a5-4f1f-acb4-0f9dd6ec2ff7"
      unitRef="usd">194000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iabb641d02a434242909814412771e876_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzYtMS0xLTEtOTQ4MzE_90441763-32c3-4e09-b37b-17c5f38468fc"
      unitRef="usd">1121000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if09045f9cc464856be5eee85d720e168_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzYtMy0xLTEtOTQ4MzE_b0eaaab8-7613-4ffb-9d8c-0daa88f647f4"
      unitRef="usd">1274000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if27684da78ec405a8823766a077e4e59_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzYtNS0xLTEtOTQ4MzE_e19d2800-3ae2-4616-90f6-f178fdfdfaee"
      unitRef="usd">1453000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8c2fffa98a84f4785e561d53fa2ad78_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzctMS0xLTEtOTQ4MzE_d1b792db-bb77-4f31-9163-18530cfcb82a"
      unitRef="usd">8434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20c9332693f549f3a5029b30f65e69d5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzctMy0xLTEtOTQ4MzE_a1e1fd3d-95b8-4a1a-9a76-1e4187064c21"
      unitRef="usd">8027000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0629a7489a0e43599cf635c5af5d5370_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzctNS0xLTEtOTQ4MzE_4b2fe399-997b-4b92-ba2f-199a5f986541"
      unitRef="usd">8601000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="iff7c3f276277409b964a030bb9ddf9bc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzktMS0xLTEtOTQ4MzE_3e9d2b93-b92d-4c7d-be53-6fc52f0c3128"
      unitRef="usd">958000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i899638122b1443aea3cf842ccf65501f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzktMy0xLTEtOTQ4MzE_970a7047-f9f5-4355-8e29-7d242b12a2f2"
      unitRef="usd">909000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4cd37c585bfd45c29417f050b1fb96e7_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzktNS0xLTEtOTQ4MzE_7f26ac45-2fd5-4612-8d37-48e99c881d56"
      unitRef="usd">1117000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9b94206c32884a8fa83f6929a2cb28d7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzEwLTEtMS0xLTk0ODMx_8e742cbe-04ae-4109-b31a-c7411efd023a"
      unitRef="usd">1493000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic6899a304edb44929422d6afaf6cef0a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzEwLTMtMS0xLTk0ODMx_bf5b1ff8-a44e-470f-bf95-12a61ac6473e"
      unitRef="usd">1338000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icda72308df944034b125cc6838172395_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzEwLTUtMS0xLTk0ODMx_b23ecf54-f383-4fef-a7fa-84d34895638e"
      unitRef="usd">1349000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8df850998cb6487c8f0b80f71254800b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzExLTEtMS0xLTk0ODMx_62c50723-750d-4895-85fd-8f0c9fe0d4fb"
      unitRef="usd">403000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i98f0b0d400a84364ac143e0c73a45029_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzExLTMtMS0xLTk0ODMx_1ae1ce54-6872-48e2-9d7f-9e757cfbfe32"
      unitRef="usd">386000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i42a14ea9b3e84273aeea86db5027a7ef_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzExLTUtMS0xLTk0ODMx_7d1e59d8-4e58-4b68-8507-c667a1b9b84e"
      unitRef="usd">352000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iff3b9d2f71d648e191dab78cdfc14a22_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzEyLTEtMS0xLTk0ODMx_8decf672-6d88-48f4-a26c-af1809193889"
      unitRef="usd">167000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0bcc7f02716c496789da6644b328c014_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzEyLTMtMS0xLTk0ODMx_83d739b3-587e-4176-9c9e-bd98030416b4"
      unitRef="usd">131000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i59a5f333092b47d6b10bcf6f866713da_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzEyLTUtMS0xLTk0ODMx_092ce28a-004a-4e56-a8d9-421931fb2536"
      unitRef="usd">84000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iabb641d02a434242909814412771e876_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzEzLTEtMS0xLTk0ODMx_048d4303-c749-41d8-bd6b-6023cb87dbc8"
      unitRef="usd">722000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if09045f9cc464856be5eee85d720e168_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzEzLTMtMS0xLTk0ODMx_b1239a28-65bb-41d7-b995-f74fc5ead140"
      unitRef="usd">814000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if27684da78ec405a8823766a077e4e59_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzEzLTUtMS0xLTk0ODMx_7f238c69-d78c-4b6a-884a-7c1e466e5405"
      unitRef="usd">933000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie8c2fffa98a84f4785e561d53fa2ad78_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE0LTEtMS0xLTk0ODMx_c0a4edf4-6591-46c7-a012-5ca037f87950"
      unitRef="usd">3743000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i20c9332693f549f3a5029b30f65e69d5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE0LTMtMS0xLTk0ODMx_afec34ad-8d2e-4d68-b8bc-2a03443803f8"
      unitRef="usd">3578000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0629a7489a0e43599cf635c5af5d5370_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE0LTUtMS0xLTk0ODMx_5753d38b-d7bc-4140-b5c5-18f6a806ab50"
      unitRef="usd">3835000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9327c2fc153040b99cb89cd74f8b0c52_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE1LTEtMS0xLTk0ODMx_75b476e8-58d9-420f-be5b-47fc02d8d510"
      unitRef="usd">-792000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ied28eb131a9d4f14930f4e4a0f0d7abd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE1LTMtMS0xLTk0ODMx_77fe29e2-2e8c-4969-be9f-4e8695debca4"
      unitRef="usd">-619000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia29f4c57d8b542cbafe1450ba688c6b5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE1LTUtMS0xLTk0ODMx_8c1d0eb6-20d8-4499-98d6-49bdca1691a9"
      unitRef="usd">-609000000</us-gaap:OperatingIncomeLoss>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE2LTEtMS0xLTk0ODMx_b7facf5a-aadd-484d-8ee6-cdd35f008eb9"
      unitRef="usd">1375000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE2LTMtMS0xLTk0ODMx_7421f041-65cc-4ccd-bae7-7755a9330595"
      unitRef="usd">1645000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE2LTUtMS0xLTk0ODMx_344091d9-9144-4dcf-a70e-76bc24594133"
      unitRef="usd">1897000000</bhc:AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE3LTEtMS0xLTk0ODMx_d159a2d4-4faf-4345-8b13-568ce5e3cff5"
      unitRef="usd">469000000</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE3LTMtMS0xLTk0ODMx_f08da81c-343a-4069-a9d3-cc3d9e5df0f6"
      unitRef="usd">0</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE3LTUtMS0xLTk0ODMx_09c6e2ca-c0a7-44fe-828e-18316dfd1686"
      unitRef="usd">0</bhc:GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE4LTEtMS0xLTk0ODMx_32cd3aff-7ab7-499d-a48a-007baefc149f"
      unitRef="usd">234000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE4LTMtMS0xLTk0ODMx_c44fbafa-e5ac-44dd-abfe-b44f472a6648"
      unitRef="usd">114000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE4LTUtMS0xLTk0ODMx_e39a1a0f-34e6-4258-8ebf-e96a35bc1a6c"
      unitRef="usd">75000000</us-gaap:AssetImpairmentCharges>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE5LTEtMS0xLTk0ODMx_543bc79e-37eb-4c61-a7a1-00517c0af12d"
      unitRef="usd">50000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE5LTMtMS0xLTk0ODMx_ef40161d-f6f1-415e-9e57-0ac8bdf5c552"
      unitRef="usd">22000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <bhc:RestructuringChargesAndInitialPublicOfferingCosts
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzE5LTUtMS0xLTk0ODMx_627f9b31-8c77-4ffc-9760-d3f30a4082fd"
      unitRef="usd">31000000</bhc:RestructuringChargesAndInitialPublicOfferingCosts>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzIwLTEtMS0xLTk0ODMx_bade4f17-c5ae-486e-a7b0-544f07fc0f0f"
      unitRef="usd">-373000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzIwLTMtMS0xLTk0ODMx_03dc9c35-d183-42c9-ab4c-9af691897561"
      unitRef="usd">-502000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzIwLTUtMS0xLTk0ODMx_c3bfaddb-1a7d-4e70-a59b-70ad41e922ff"
      unitRef="usd">-1426000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzIxLTEtMS0xLTk0ODMx_b7c2440b-8790-42b7-a506-0f5d666a9520"
      unitRef="usd">450000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzIxLTMtMS0xLTk0ODMx_1b5764e0-dce8-46ad-b999-03ef8be9cf77"
      unitRef="usd">676000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzIxLTUtMS0xLTk0ODMx_6bbb55ad-7929-4133-8367-1861092387da"
      unitRef="usd">-203000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzIyLTEtMS0xLTk0ODMx_6307ef24-ae88-41fd-9e7d-f1a6d6a591f7"
      unitRef="usd">7000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzIyLTMtMS0xLTk0ODMx_d2aeadac-f909-4b69-9c07-f66540689347"
      unitRef="usd">13000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzIyLTUtMS0xLTk0ODMx_e6567242-38a6-4ea6-acf6-c4d2073c0c80"
      unitRef="usd">12000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestAndDebtExpense
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzIzLTEtMS0xLTk0ODMx_33ce6458-1218-4818-8946-64edf92d0239"
      unitRef="usd">1426000000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzIzLTMtMS0xLTk0ODMx_571fc66c-887c-47b7-a126-cea59d357492"
      unitRef="usd">1534000000</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzIzLTUtMS0xLTk0ODMx_223b4e39-3fde-4634-887e-e9f019c012fc"
      unitRef="usd">1612000000</us-gaap:InterestAndDebtExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzI0LTEtMS0xLTk0ODMx_8553c2c5-506a-405a-b9e5-ff888acac8ce"
      unitRef="usd">-62000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzI0LTMtMS0xLTk0ODMx_2aa73fd2-79dc-4085-a73f-f64f2310c36f"
      unitRef="usd">-59000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzI0LTUtMS0xLTk0ODMx_bb489af2-77d9-4447-b0a5-54b91d6b2790"
      unitRef="usd">-42000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzI1LTEtMS0xLTk0ODMx_4b95da98-6cc4-4225-a72d-e8bc81be3cdf"
      unitRef="usd">7000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzI1LTMtMS0xLTk0ODMx_c5660489-41be-44d3-8e4b-edec13e49f11"
      unitRef="usd">-30000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzI1LTUtMS0xLTk0ODMx_fa991619-b482-4a85-8583-0a4eee1aed43"
      unitRef="usd">8000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzI2LTEtMS0xLTk0ODMx_c81b35d4-646b-4ce6-a73e-dcc8559890c2"
      unitRef="usd">-1024000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzI2LTMtMS0xLTk0ODMx_07cbe54b-d28d-4657-8c4e-e7b4a67e3cad"
      unitRef="usd">-934000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZToyYTdmMTU0Y2M0ZmQ0ZTk1YmM5Nzg3YzI5YzE4Zjc1MS90YWJsZXJhbmdlOjJhN2YxNTRjYzRmZDRlOTViYzk3ODdjMjljMThmNzUxXzI2LTUtMS0xLTk0ODMx_1d9fbd0c-586c-40b2-b1d2-0a19846801b5"
      unitRef="usd">-1837000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90ZXh0cmVnaW9uOjJmNDdlODBjMTIyNDQ0ZGQ5NzM3ZDQ1YzUzMWMzOTFkXzM0MzI_6f3ddb2a-3b3c-4bd1-8f53-0e3265d0d431">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capital expenditures by segment for the years 2021, 2020 and 2019 were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital expenditures:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total capital expenditures&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="iff7c3f276277409b964a030bb9ddf9bc_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzItMS0xLTEtOTQ4MzE_da692d23-fc6b-42c0-93bc-36e01d253db3"
      unitRef="usd">201000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i899638122b1443aea3cf842ccf65501f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzItMy0xLTEtOTQ4MzE_4fbb6255-8ee7-422e-a5ce-4dec5578592e"
      unitRef="usd">253000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i4cd37c585bfd45c29417f050b1fb96e7_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzItNS0xLTEtOTQ4MzE_30427701-0dfa-4058-b599-768fcf9d3f3f"
      unitRef="usd">186000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i9b94206c32884a8fa83f6929a2cb28d7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzMtMS0xLTEtOTQ4MzE_b5529e84-074a-49fb-b10a-f59e9289e6ca"
      unitRef="usd">2000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ic6899a304edb44929422d6afaf6cef0a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzMtMy0xLTEtOTQ4MzE_845fe6d0-85a1-4ff1-ac69-b2e992e1e1da"
      unitRef="usd">3000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="icda72308df944034b125cc6838172395_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzMtNS0xLTEtOTQ4MzE_e08e86b1-fdfa-4c49-bf65-4967b276121f"
      unitRef="usd">2000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i8df850998cb6487c8f0b80f71254800b_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzQtMS0xLTEtOTQ4MzE_7eea3ede-f0c6-4139-a669-addde6fea0d1"
      unitRef="usd">22000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i98f0b0d400a84364ac143e0c73a45029_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzQtMy0xLTEtOTQ4MzE_506567b2-1224-4404-ba4c-88ba83b471ab"
      unitRef="usd">29000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i42a14ea9b3e84273aeea86db5027a7ef_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzQtNS0xLTEtOTQ4MzE_53a1eb9e-36b4-48fa-ba16-24a85c4daccf"
      unitRef="usd">39000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="iff3b9d2f71d648e191dab78cdfc14a22_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzUtMS0xLTEtOTQ4MzE_235464b5-2d7e-453c-a627-b8a8a7d6a123"
      unitRef="usd">1000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i0bcc7f02716c496789da6644b328c014_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzUtMy0xLTEtOTQ4MzE_40e0b780-d138-415c-bcc8-0a582558327f"
      unitRef="usd">2000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i59a5f333092b47d6b10bcf6f866713da_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzUtNS0xLTEtOTQ4MzE_d4a3749e-c69f-457c-8eda-7e5e943747d2"
      unitRef="usd">1000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="iabb641d02a434242909814412771e876_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzYtMS0xLTEtOTQ4MzE_47335e51-9195-41bc-9c94-055b46f86dea"
      unitRef="usd">1000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="if09045f9cc464856be5eee85d720e168_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzYtMy0xLTEtOTQ4MzE_9ab802d9-22b4-4c87-860a-657ca00e74a5"
      unitRef="usd">2000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="if27684da78ec405a8823766a077e4e59_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzYtNS0xLTEtOTQ4MzE_bf8490ac-88bf-4c2c-ac2c-f6064d5deada"
      unitRef="usd">2000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ie8c2fffa98a84f4785e561d53fa2ad78_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzctMS0xLTEtOTQ4MzE_73a0e880-75ab-4422-9ea6-a82be77169e8"
      unitRef="usd">227000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i20c9332693f549f3a5029b30f65e69d5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzctMy0xLTEtOTQ4MzE_b6271279-a032-4fad-8b51-5a36ea5e701a"
      unitRef="usd">289000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i0629a7489a0e43599cf635c5af5d5370_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzctNS0xLTEtOTQ4MzE_4cf04078-3715-4a3f-a74e-9edae0e0e71f"
      unitRef="usd">230000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i9327c2fc153040b99cb89cd74f8b0c52_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzgtMS0xLTEtOTQ4MzE_02c1259e-eae3-49c4-a4c2-b468bf9f3171"
      unitRef="usd">42000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ied28eb131a9d4f14930f4e4a0f0d7abd_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzgtMy0xLTEtOTQ4MzE_61ddfbba-4566-4ba2-a74d-d0ee61ee5d8a"
      unitRef="usd">13000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ia29f4c57d8b542cbafe1450ba688c6b5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzgtNS0xLTEtOTQ4MzE_9901ea77-49ab-4726-a83a-9913b8715a0d"
      unitRef="usd">40000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzktMS0xLTEtOTQ4MzE_f92ceb1c-bd46-4284-a60c-fcbf07ccf285"
      unitRef="usd">269000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzktMy0xLTEtOTQ4MzE_fdc33a7a-4c14-4bac-bbf6-6b89673ee2a6"
      unitRef="usd">302000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplZDZmODMyOWNhMjg0NTljODk2MGViNTVhZTEzY2Q1Ny90YWJsZXJhbmdlOmVkNmY4MzI5Y2EyODQ1OWM4OTYwZWI1NWFlMTNjZDU3XzktNS0xLTEtOTQ4MzE_fd0d8ec8-78dc-4ff5-a937-a6b461112b50"
      unitRef="usd">270000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <bhc:ConcentrationRiskNumberOfProducts
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90ZXh0cmVnaW9uOjJmNDdlODBjMTIyNDQ0ZGQ5NzM3ZDQ1YzUzMWMzOTFkXzI3NDQ_3b9bccfa-aa7a-4cac-acad-64cf96800d0c"
      unitRef="product">10</bhc:ConcentrationRiskNumberOfProducts>
    <bhc:ConcentrationRiskNumberOfProducts
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90ZXh0cmVnaW9uOjJmNDdlODBjMTIyNDQ0ZGQ5NzM3ZDQ1YzUzMWMzOTFkXzI3NDQ_5345d9bf-6f95-4612-88a7-5cbaf7003ba1"
      unitRef="product">10</bhc:ConcentrationRiskNumberOfProducts>
    <bhc:ConcentrationRiskNumberOfProducts
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90ZXh0cmVnaW9uOjJmNDdlODBjMTIyNDQ0ZGQ5NzM3ZDQ1YzUzMWMzOTFkXzI3NDQ_d7da40fe-f8c8-4259-b2df-2442a84b963a"
      unitRef="product">10</bhc:ConcentrationRiskNumberOfProducts>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icc8c408b488a4ea2a66ad4c5e2951610_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90ZXh0cmVnaW9uOjJmNDdlODBjMTIyNDQ0ZGQ5NzM3ZDQ1YzUzMWMzOTFkXzI3ODU_12463edb-5f15-4efb-ac60-5f72a3dc7f70"
      unitRef="number">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i72654cd7063243f1a8df8bc3a4f0195d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90ZXh0cmVnaW9uOjJmNDdlODBjMTIyNDQ0ZGQ5NzM3ZDQ1YzUzMWMzOTFkXzI3ODk_c713d8bc-4762-42c9-a695-5635d86ec36b"
      unitRef="number">0.41</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i85db686e88084b1daeb7d9f72f4f05ad_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90ZXh0cmVnaW9uOjJmNDdlODBjMTIyNDQ0ZGQ5NzM3ZDQ1YzUzMWMzOTFkXzI3OTY_ea6b772f-3f5c-4ec9-8b8d-467784226c3f"
      unitRef="number">0.39</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90ZXh0cmVnaW9uOjJmNDdlODBjMTIyNDQ0ZGQ5NzM3ZDQ1YzUzMWMzOTFkXzM0NTA_2440d7ce-cf9a-40b8-8056-059212c3144c">Revenues by segment and product category were as&#160;follows: &lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the year ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the year ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.745%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.571%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Bausch + Lomb&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Salix&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Solta Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Diversified Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the year ended December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceuticals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Branded and Other Generics &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i418a04d4e056401399ccd4b61b80c49e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzItMS0xLTEtOTQ4MzE_99085bc9-c3f3-4b00-8669-129d68cb3143"
      unitRef="usd">514000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i208a6bf939c242978d7d9ccc2fc10274_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzItMy0xLTEtOTQ4MzE_4305dc96-c211-4e8f-9896-278a6432e7d7"
      unitRef="usd">2066000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i183660041cad45ea8dd6de8f87fb3352_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzItNS0xLTEtOTQ4MzE_520ae44b-2efa-46e9-9324-b34457901046"
      unitRef="usd">259000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e9b099c602241aea11206441f010b8a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzItNy0xLTEtOTQ4MzE_c7464bcc-0b2b-45d3-a227-c786fb422c93"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85426466f4c3491594754c3f8fc926ab_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzItOS0xLTEtOTQ4MzE_43b1c645-fc51-4bae-a7ea-c9b415cf8963"
      unitRef="usd">923000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ica7446f3b2c9467380385861ab7f846c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzItMTEtMS0xLTk0ODMx_52140414-18cf-4fb6-907f-7e16384501d8"
      unitRef="usd">3762000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i97a39f300bde49ca9fc43dfa11399cca_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzMtMS0xLTEtOTQ4MzE_8e543822-692d-47b1-9209-4810e841aab7"
      unitRef="usd">1596000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6cb2a068a1c48d2ace685a569e695c1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzMtMy0xLTEtOTQ4MzE_940658ef-171c-47aa-8ed4-a5b4aa237d56"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6dfbabd3f8ad4b34a103357fe12fcfcd_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzMtNS0xLTEtOTQ4MzE_a382f980-0e1a-4b3c-ba78-322b577e3f95"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5fb12fface6c4c7e82b18336a7a67376_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzMtNy0xLTEtOTQ4MzE_6fb436e8-7870-4b39-a53b-35922163b215"
      unitRef="usd">308000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iada6d354701043aa8ed66ad26387df2c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzMtOS0xLTEtOTQ4MzE_d49d4d94-0063-4c99-9174-abe50215004b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iefe6d8b686a343d78914861cca583670_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzMtMTEtMS0xLTk0ODMx_b852d9ed-f745-4d7f-b6e2-128abac09f1a"
      unitRef="usd">1904000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie68fa27569a84628a38c78ec3c373351_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzQtMS0xLTEtOTQ4MzE_47fe5ed7-4f44-4c77-adc9-bc53549903d4"
      unitRef="usd">1388000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaee7f42c5a6e468eb8cc29e3ccdff123_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzQtMy0xLTEtOTQ4MzE_0d8cf900-b1f0-478b-9d28-282f872d354b"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd994066bcd8437a9238a565a38135fd_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzQtNS0xLTEtOTQ4MzE_7e2ff5f2-cfb2-4f95-830a-1d0a02580c8c"
      unitRef="usd">136000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9083205e195d456097ba2cf0d7d660c7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzQtNy0xLTEtOTQ4MzE_bdffe16c-859d-45c9-96fa-61621ff1039c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a89853896aa43c787ccc01b19d26a52_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzQtOS0xLTEtOTQ4MzE_fcf8a682-3fb3-482e-b9eb-14e46f273983"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibdef7aa1a0f744b2a4b78007975133bd_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzQtMTEtMS0xLTk0ODMx_f53579bb-e8d0-4860-a99d-143cb08fc1f9"
      unitRef="usd">1532000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9dbb383514c346138c6f03e2442cf299_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzUtMS0xLTEtOTQ4MzE_6e001629-961d-4dc8-8e75-acc2a5c88c93"
      unitRef="usd">240000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9cfbdc3f3475470493bc0b06e113623c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzUtMy0xLTEtOTQ4MzE_bd95d3c7-0609-49c1-b0c9-633cf043f71d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie646b8a4d77c437591b1f253ad1ce98c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzUtNS0xLTEtOTQ4MzE_d084ec7a-c743-4965-912d-03fffc64e01a"
      unitRef="usd">737000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b09688e27584c5c8598014546598fc6_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzUtNy0xLTEtOTQ4MzE_638cf024-e9cb-4941-9dc9-e2bba7981782"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i93bb05eba3ba4b89973b0e8adec86826_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzUtOS0xLTEtOTQ4MzE_6ce2fcdb-8efb-4068-92d0-9ceaf090d89c"
      unitRef="usd">167000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5cd4d9c52b49420b9fd755ecae1f6e34_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzUtMTEtMS0xLTk0ODMx_1ad70f85-0195-4fc8-adad-c489c5d7d5de"
      unitRef="usd">1144000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i449241e47dc94783a4ce61ebe70a084c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzYtMS0xLTEtOTQ4MzE_03e9e5a1-1427-4156-9ce1-d515304573db"
      unitRef="usd">27000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i945b3a4ecfe946f49fd0768311efb98e_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzYtMy0xLTEtOTQ4MzE_af7ac0ed-4eb6-4474-b044-432190dcfedb"
      unitRef="usd">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c41e1b8ff6243bea499531336ad49f3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzYtNS0xLTEtOTQ4MzE_10b00ec7-6047-4d70-aa5e-7026dc9135e8"
      unitRef="usd">34000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9565df56092f4004881389c04df25c93_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzYtNy0xLTEtOTQ4MzE_fb316d71-d4bc-4d1f-8a94-f874aa94e4c6"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8a16169eb2d4f67b89fdacefbd0662d_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzYtOS0xLTEtOTQ4MzE_a7c6d37a-9262-4879-bc33-8e0c226ec769"
      unitRef="usd">23000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a0ba16f9629426fbbc2da84a05d2fd5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzYtMTEtMS0xLTk0ODMx_d4a74a1f-12c7-4f76-80d7-508c8d3e747a"
      unitRef="usd">92000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i414fba28824c413593139a2e4ef76d21_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzctMS0xLTEtOTQ4MzE_3a20ad0f-64d2-4e3c-9d77-24feb1be5481"
      unitRef="usd">3765000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if72021acf180458a8e22ca22a9fa4b7c_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzctMy0xLTEtOTQ4MzE_83710c9e-863a-4258-b004-41df10bcad1a"
      unitRef="usd">2074000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied7527e9c7f3438db93389c0a1768d2a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzctNS0xLTEtOTQ4MzE_fdcc1b15-8e74-46e9-89ea-2f296fcebbf6"
      unitRef="usd">1166000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10c6872a04d24bdd87a47a8fcff435f5_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzctNy0xLTEtOTQ4MzE_1e3dbdaa-fadd-4dd6-a0e9-517f29b10758"
      unitRef="usd">308000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a5a9e6c49d742aca8267ceb1bf314d3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzctOS0xLTEtOTQ4MzE_a51278cf-f590-421d-b441-988f4d2a98a5"
      unitRef="usd">1121000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTpkMmViODg4ZjdhMmM0ODlkYTNmMDRmMzM2YTI0OTUzZC90YWJsZXJhbmdlOmQyZWI4ODhmN2EyYzQ4OWRhM2YwNGYzMzZhMjQ5NTNkXzctMTEtMS0xLTk0ODMx_6ef34a92-a5df-4238-bace-1e6e3b1e1b6f"
      unitRef="usd">8434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i01141cbdbc294de9a69e8742d0ac0103_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzItMS0xLTEtOTQ4MzE_c93127f0-b57b-4992-90bd-f29917ee923b"
      unitRef="usd">506000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a2b29c602cd4b958959f3a523a03952_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzItMy0xLTEtOTQ4MzE_98a074ce-d78c-4ea1-a229-a8cb9777dd3c"
      unitRef="usd">1899000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i30e3835f2cc243289f8661e3a751167e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzItNS0xLTEtOTQ4MzE_57398410-19d1-4543-abcb-2955e891eff5"
      unitRef="usd">255000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1fa10e66f5ca4afbb367c4f716dbdb6f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzItNy0xLTEtOTQ4MzE_e1786e67-e358-461c-8b26-e4928596ec3d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i035f8ab24ddb4f03a63105201f52a080_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzItOS0xLTEtOTQ4MzE_1b68c9dc-bbf3-4757-aca4-1e81347f2496"
      unitRef="usd">1020000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f1a89016aaa44f1b9b7cbf14bcc530f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzItMTEtMS0xLTk0ODMx_0549f4d6-1aa4-44b6-bf23-9b86303daeeb"
      unitRef="usd">3680000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07e9e47444534ef380cd91916978cc8e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzMtMS0xLTEtOTQ4MzE_13634bb1-9974-4f64-bca8-576945c3eb58"
      unitRef="usd">1313000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ea3465f6a0045f59c3e4d358fade4ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzMtMy0xLTEtOTQ4MzE_d5addd11-2f56-42d5-97bf-507d387295ac"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic174d4e74321475a84d00d558435391e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzMtNS0xLTEtOTQ4MzE_8cc124b5-cb0f-4d8f-98d8-cc53aa6f3837"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7f3a113a586047de86a5ff20c4cad591_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzMtNy0xLTEtOTQ4MzE_5b219622-2a26-4423-96be-6916edb39232"
      unitRef="usd">253000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d52437e494a45f5b5d81fd921f506ea_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzMtOS0xLTEtOTQ4MzE_f7111ed7-f7fb-4263-b502-5c7d14ea4c63"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba2bfdb91306432787e6d119f24c9aa6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzMtMTEtMS0xLTk0ODMx_dca457b8-d3fb-49c8-b59a-4ef8f146afe2"
      unitRef="usd">1566000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iccf8163c97e441b695eed7ad4118029e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzQtMS0xLTEtOTQ4MzE_6df16169-deea-4582-b389-ca7c977c5f7c"
      unitRef="usd">1311000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id931ecb1d5924adc9990fe3880f43991_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzQtMy0xLTEtOTQ4MzE_52f43661-77ce-4f8d-9609-7b3dd3dae2bf"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b3b9253b89e4ba5af70da5f568580ee_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzQtNS0xLTEtOTQ4MzE_36786e46-2ff6-4462-b9b7-92a78ca8ede0"
      unitRef="usd">112000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ce0e8c5792746c4898df7b4b795738b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzQtNy0xLTEtOTQ4MzE_4078afa7-204d-40bc-8026-6f3dc5b3dab0"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia6b7d530488142ca89ab8ee239e906ac_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzQtOS0xLTEtOTQ4MzE_e508aff3-0ba9-4abb-8daa-cc883c8c2d99"
      unitRef="usd">7000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87499fcd581e451e8b4380c27a63aa69_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzQtMTEtMS0xLTk0ODMx_51da16e6-5243-4d0b-8dc0-b28d94240ca3"
      unitRef="usd">1430000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i090b17bc8edc432898c155379a09ffbc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzUtMS0xLTEtOTQ4MzE_1a21dab9-1343-4a1d-9aad-77b5c950a33a"
      unitRef="usd">254000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i675b1f36cfd84e78bd9e49edeea02d3d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzUtMy0xLTEtOTQ4MzE_2acb1902-4767-49e4-9587-0d3a950da81f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79f443d6034b41279b6e32600dfad1dc_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzUtNS0xLTEtOTQ4MzE_f6dfbe64-f7f6-403a-801e-7aecc0ab66cc"
      unitRef="usd">775000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99f4c2a755d74f6782eeac0e0d29ccd5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzUtNy0xLTEtOTQ4MzE_ab51c859-97e5-4348-b41f-336038c8c6c4"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e35c309da054713ba96e1155984e51e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzUtOS0xLTEtOTQ4MzE_f94beee9-2831-4365-add7-448bd0163315"
      unitRef="usd">219000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2daf7c9c3709441a96dee7e2be490687_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzUtMTEtMS0xLTk0ODMx_cb11f061-17b7-410b-a4bf-15fe9f183b16"
      unitRef="usd">1248000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i827e4d3a675249bd9a863b2b7df083b6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzYtMS0xLTEtOTQ4MzE_2d3a4418-a14d-4b65-9f1c-831e469aa81d"
      unitRef="usd">31000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c401d26917e40768b5d281285429ae5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzYtMy0xLTEtOTQ4MzE_cc6ae831-9719-4509-ba56-68d92a8b5f9a"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe1dab615a544098b3eb8dab58113a92_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzYtNS0xLTEtOTQ4MzE_68644d4d-7cd1-413d-8275-0635a97239a0"
      unitRef="usd">39000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd1357104df74efbb0da5b76bc89c115_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzYtNy0xLTEtOTQ4MzE_ebdc0e10-46ed-4b91-b936-b7fa9f7ebbb6"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6331eae27614b90855cfb5b25b9acd0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzYtOS0xLTEtOTQ4MzE_9b44a839-b7c8-4ba7-8c83-b43c3e9003fc"
      unitRef="usd">28000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92793a91c9c747858dd71f6a9a0a9d23_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzYtMTEtMS0xLTk0ODMx_522a23d5-2e65-4913-9a67-d751b59a175d"
      unitRef="usd">103000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida777483b4584d87a6cf2850e419fdd4_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzctMS0xLTEtOTQ4MzE_ad5a3f67-ff99-4ea7-a6e9-03f201a1e138"
      unitRef="usd">3415000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7999bb21b9045d28a73afe96f2eb35b_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzctMy0xLTEtOTQ4MzE_58bf45d1-3e8d-4af1-b7f3-29e722fc8ca2"
      unitRef="usd">1904000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i672bff69a6fc4ef3aebe3725cc29e40e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzctNS0xLTEtOTQ4MzE_9b0dc1c7-1501-4264-a404-f6030eb8574e"
      unitRef="usd">1181000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i626b9ba57ccd4f46b64c17f382055091_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzctNy0xLTEtOTQ4MzE_473e3e28-d5c3-4a6c-8931-a7a693a7bcb5"
      unitRef="usd">253000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i936342f03a8e4fa2b1e39321ca993106_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzctOS0xLTEtOTQ4MzE_956aff85-3b9f-41b8-bdbd-0e44a4100604"
      unitRef="usd">1274000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTphMjEzYjdmNTRiOTg0N2E0OTc2YTk5OTIyMmViNzc3Yi90YWJsZXJhbmdlOmEyMTNiN2Y1NGI5ODQ3YTQ5NzZhOTk5MjIyZWI3NzdiXzctMTEtMS0xLTk0ODMx_59ec633f-75a4-4c62-8ffb-b59f8149cf3a"
      unitRef="usd">8027000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24cd510cf43d4f998e635afc20c956b2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzItMS0xLTEtOTQ4MzE_840cc8bc-6142-4b15-bbce-0c06589ca37b"
      unitRef="usd">623000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i55bf18e767ee4fbd8771bf6350d26aff_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzItMy0xLTEtOTQ4MzE_b86d5bcb-e76f-4eec-b783-0ed485d6cbb0"
      unitRef="usd">2022000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00e2f75f8e8a4e30a276c3033c8f9971_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzItNS0xLTEtOTQ4MzE_8df414d8-5c66-4efa-a759-62f9173cf114"
      unitRef="usd">268000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i087b26d2da5842a783ce0a89063cf3f2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzItNy0xLTEtOTQ4MzE_2086a2c8-1585-4144-ab99-ae6e7a2b84bb"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7af7813bfb2b41168f468df55e46c835_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzItOS0xLTEtOTQ4MzE_9d0b7018-a477-4f53-ab8e-bcb7e8246b5c"
      unitRef="usd">1165000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic113e26dc8a943e3bcb1595fc30166d4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzItMTEtMS0xLTk0ODMx_51100e84-e4f9-4cc2-b9dd-68abc44e631f"
      unitRef="usd">4078000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0ca740d21c34ec1a4f67ff1a0624db4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzMtMS0xLTEtOTQ4MzE_37be65ef-62f7-4939-bce2-b9a47ff98a50"
      unitRef="usd">1524000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9186a43c41842cca559fad18f9be2a6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzMtMy0xLTEtOTQ4MzE_a85028d0-4f02-4b2f-98a5-6e58d5dbb87d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc4e1ec44690405aa82469ba14ebe09c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzMtNS0xLTEtOTQ4MzE_001cbe4d-cf7a-4ac3-b654-65d5f751d3d0"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i25dddfae7e964bdfac0c22c5bd9b8197_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzMtNy0xLTEtOTQ4MzE_f22291a6-6d00-49ca-a085-a05aa777e983"
      unitRef="usd">194000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f5298b1c6b04825936c29a9867976f9_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzMtOS0xLTEtOTQ4MzE_98861ac9-3d82-4376-902f-423b237470ef"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if179cdcb08a0401481a1219768254267_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzMtMTEtMS0xLTk0ODMx_2eec6e2d-271a-4c63-936a-f7b54d4d1213"
      unitRef="usd">1718000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8664af0b79840da9709c1622bb9ddf2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzQtMS0xLTEtOTQ4MzE_d064e35a-7805-4283-b8db-17b2e5dcbd29"
      unitRef="usd">1322000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3e3f60c68704a709d886a22a7a0625c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzQtMy0xLTEtOTQ4MzE_374955f5-20f9-4cc5-ae85-a25e481e302c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieecb00ddf1e346c497a7a3939fd11cb7_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzQtNS0xLTEtOTQ4MzE_6b72f697-6a85-458c-81cd-c7efd90dde13"
      unitRef="usd">119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i546306a3ad4f430786457eae18ef4185_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzQtNy0xLTEtOTQ4MzE_e4772f21-bf8b-403d-8343-86281d5cf154"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b77d4f86e5b4d38a20c7bda0feef351_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzQtOS0xLTEtOTQ4MzE_6749f4b4-d801-437e-8d7b-2df44ea27cb1"
      unitRef="usd">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a4ec44e96e44217afae2275f04e02cb_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzQtMTEtMS0xLTk0ODMx_3d0fe4ac-b1c2-4907-8b3a-acc7122bc605"
      unitRef="usd">1447000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02ace42c02c2429cb5f9a01e0cdfb82c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzUtMS0xLTEtOTQ4MzE_94fc5fec-4b0f-4886-833f-6e226eeba25b"
      unitRef="usd">260000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia05135846e24408ea51ac1a000116fc6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzUtMy0xLTEtOTQ4MzE_055e5ba9-5248-46fc-a719-8db9a14553f0"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i654644a806dc4e4c810f174fd6c3d5d7_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzUtNS0xLTEtOTQ4MzE_548e5ca0-9181-4663-a657-66418c62ae4b"
      unitRef="usd">730000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14f7e763fe5647bc92cbfc644aadf9e5_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzUtNy0xLTEtOTQ4MzE_864878f6-b04c-4877-ac15-92104e8a31ba"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icdd6fed0918446febaeb315df0545125_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzUtOS0xLTEtOTQ4MzE_105f77b8-aa5c-46ac-85e4-35a3d29ff337"
      unitRef="usd">256000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80e98cb6ebeb4ac595398dcd45214e1a_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzUtMTEtMS0xLTk0ODMx_898a6948-2fe3-4c7c-91d7-a412754f9eef"
      unitRef="usd">1246000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id42bd5ff7402461eae15a600bbe77743_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzYtMS0xLTEtOTQ4MzE_0ad428ee-228e-40fe-9a76-f1a9a74eb4dc"
      unitRef="usd">49000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c6ab8b8553d4be6bb88ba2a97705892_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzYtMy0xLTEtOTQ4MzE_9288c9c8-9628-4895-99e0-39872311f0da"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd261e8b9f2d458587ab145f0b01027b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzYtNS0xLTEtOTQ4MzE_01b83f39-132c-4b80-a086-ff23568a533b"
      unitRef="usd">37000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i835dafddf9254e80881be0cd65ee190b_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzYtNy0xLTEtOTQ4MzE_c4cf7873-2d82-4c2d-a2b8-824c3f4ac409"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58a96cd4d49841fba044c42410080076_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzYtOS0xLTEtOTQ4MzE_1a89eec8-36c8-4368-89a5-c15191d49294"
      unitRef="usd">26000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16d6de8cde05443f89914d40cf8374a2_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzYtMTEtMS0xLTk0ODMx_8337b56c-0ec6-4fee-9e6f-108fe05198f7"
      unitRef="usd">112000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0536a549f4e94235a4c555bc2d5aa85d_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzctMS0xLTEtOTQ4MzE_625a6780-c173-4ab0-94af-460931151404"
      unitRef="usd">3778000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i417dcef94a21464c8f3e70b1b83c913c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzctMy0xLTEtOTQ4MzE_bd9cbab5-fb76-46c0-8f78-51a99016f00a"
      unitRef="usd">2022000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i551031e418e04e92a28afd201e2a7815_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzctNS0xLTEtOTQ4MzE_248bce84-0a54-4f21-b1a1-71fc1bd1abb8"
      unitRef="usd">1154000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e0b639594e4483fa2e3d9eaa57f0c52_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzctNy0xLTEtOTQ4MzE_1c6380be-e30f-42dd-a1f8-c19e38cd67d7"
      unitRef="usd">194000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia6a213bd75514daebf43eb6d93a109f3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzctOS0xLTEtOTQ4MzE_16a1867e-a3a5-47f9-b377-a2cf13e47c46"
      unitRef="usd">1453000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo5ZGMxMDNhMjUyZmE0MjUwYWIyNjcwMWYxYzdlMjVmYi90YWJsZXJhbmdlOjlkYzEwM2EyNTJmYTQyNTBhYjI2NzAxZjFjN2UyNWZiXzctMTEtMS0xLTk0ODMx_454bf8a5-5d43-4172-ada8-28384e34bb6b"
      unitRef="usd">8601000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90ZXh0cmVnaW9uOjJmNDdlODBjMTIyNDQ0ZGQ5NzM3ZDQ1YzUzMWMzOTFkXzM0NTM_51a41ea7-72bc-4de7-90d1-fede6cbba799">&lt;div style="margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are attributed to a geographic region based on the location of the customer for the years 2021, 2020 and 2019 were as&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Poland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Russia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Egypt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United Kingdom&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Spain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Italy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5464eb24d31a4be0beb852ba387bade8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzEtMS0xLTEtOTQ4MzE_d4b5978e-f461-4207-941b-62de2c8725b0"
      unitRef="usd">4887000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ba444e2ab994ca1a3c530ace04d6dc6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzEtMy0xLTEtOTQ4MzE_c02b3143-d1b2-492d-b400-1160dbeef69d"
      unitRef="usd">4791000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe8e8f4ff47f48599e5fcab4fe291d47_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzEtNS0xLTEtOTQ4MzE_eb0530fd-1de9-4396-959e-bcc3c70d7764"
      unitRef="usd">5164000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id15ad738c4a24f2db24b34a5a0710ae4_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzItMS0xLTEtOTQ4MzE_5b295a79-af25-41b8-a4a4-9aa8886311b3"
      unitRef="usd">490000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c2d9ba589c34635af841f55fabca3a3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzItMy0xLTEtOTQ4MzE_ff51d5c4-d877-480b-8041-c8267cf19be4"
      unitRef="usd">341000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9cd10e388d948f69faaa2a13ee4e9a3_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzItNS0xLTEtOTQ4MzE_7bdc3b06-f38e-4927-ad39-d50015867e8c"
      unitRef="usd">368000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9548d7cc49134168aac65b53c630d341_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzMtMS0xLTEtOTQ4MzE_8d4aff22-b38d-44b5-909f-7276969f30b7"
      unitRef="usd">343000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08b753376f4946ee869fca342eb74772_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzMtMy0xLTEtOTQ4MzE_19e0f85a-1756-44c6-9a7f-abd6ebdff95e"
      unitRef="usd">331000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibad2ef89232a4629aad3bf5d2c272019_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzMtNS0xLTEtOTQ4MzE_f44bf0ae-f182-48d8-8435-b7910a248c3e"
      unitRef="usd">339000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21a132fe24e747f0a5b421bc7f0ac7e7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzQtMS0xLTEtOTQ4MzE_223774e5-b003-496c-a25e-21fc8d77b3a8"
      unitRef="usd">280000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i920bf658665d471ba624c241f037cab0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzQtMy0xLTEtOTQ4MzE_47980a55-d5a0-480d-adcc-3df6f4366c66"
      unitRef="usd">238000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibbd946703e614d71b6d50b2f7ef7c141_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzQtNS0xLTEtOTQ4MzE_9ac5e097-bee7-4fa5-9f68-39370492243b"
      unitRef="usd">231000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id50f4cab02f148edb0f275c887c08c1a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzUtMS0xLTEtOTQ4MzE_d43a8a94-1643-4cdd-ae83-abe1a9b0dc68"
      unitRef="usd">256000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2af93ee9adb74fed8865c912c5df1f30_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzUtMy0xLTEtOTQ4MzE_028a39c1-61b2-45d0-b954-6330f1ec4507"
      unitRef="usd">225000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i54515e5b9a1540f28363106924361f49_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzUtNS0xLTEtOTQ4MzE_26f525cb-d900-4279-bce5-d6bf0549b410"
      unitRef="usd">228000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5566c138571140a6b83afaef74940706_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzYtMS0xLTEtOTQ4MzE_8db5a6cf-7656-4fbc-a7dc-e78fe5eff6a3"
      unitRef="usd">230000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id01f277d70d744e19dc9ac68d075ef8e_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzYtMy0xLTEtOTQ4MzE_7b5c6671-377c-4c08-9ddf-8185b46732d5"
      unitRef="usd">226000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia51b7a120b6d4bfaaac2e2f5d62cd956_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzYtNS0xLTEtOTQ4MzE_f9408b72-9360-40e6-afba-17f6090fd077"
      unitRef="usd">241000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i67e2a75f81a2442e98999a9c1a2cd7a8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzctMS0xLTEtOTQ4MzE_91115ff6-3fe3-4f32-80c3-25cea6080f64"
      unitRef="usd">208000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb566fc6694e418b911114af24372afe_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzctMy0xLTEtOTQ4MzE_fbcb6519-0870-41f8-b50d-5fb04fb440a9"
      unitRef="usd">179000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c64023910d940d280c4372028887834_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzctNS0xLTEtOTQ4MzE_a49cf8d9-cfb1-49c5-a917-d27d105ffaf8"
      unitRef="usd">201000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0cffeeeada484c5982be5b0d0fba6d27_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzgtMS0xLTEtOTQ4MzE_4d8a6425-294a-4833-ac90-438ef4c93ba9"
      unitRef="usd">160000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36510dcee9304e688d7fe55e6e0cdada_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzgtMy0xLTEtOTQ4MzE_f3233cc2-e5fd-4a71-946d-84dd2bd7ee84"
      unitRef="usd">137000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7458902eaa074c759452bcd57083fefa_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzgtNS0xLTEtOTQ4MzE_ace274ba-f116-46a1-bae7-fed180a4917c"
      unitRef="usd">180000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2524acb5669c4f46b137c163c7500bb8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzktMS0xLTEtOTQ4MzE_cbdf7296-828e-40b0-bdc6-bab463d7db25"
      unitRef="usd">156000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea6f1abfde62479a85a276b00644bbda_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzktMy0xLTEtOTQ4MzE_98a75a3e-bfaa-441a-95ba-20517cc24c79"
      unitRef="usd">243000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d19db7ffad34988952acdbe5de7846c_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzktNS0xLTEtOTQ4MzE_35693f93-1aba-4231-87f2-ef15aa26f140"
      unitRef="usd">218000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0667b68241574742a0864172124b2604_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzEwLTEtMS0xLTk0ODMx_9dd9d1f6-8d81-4f89-aedd-95f35598136f"
      unitRef="usd">154000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26ae9e62be7441c196757ba308583044_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzEwLTMtMS0xLTk0ODMx_50f9afe5-99bb-4002-8248-538fdf4c6bba"
      unitRef="usd">144000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i516a86604ef14c82b80390e67af470ba_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzEwLTUtMS0xLTk0ODMx_6ba1cded-be9a-47e4-b57b-4a99fb74440b"
      unitRef="usd">150000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4339bb0ca24249ba8ca9d3aacc1e7a0a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzExLTEtMS0xLTk0ODMx_2926b3f5-e8db-4a3c-ae73-66acc005ae97"
      unitRef="usd">116000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e8cb0908b5141feae7cceed8fb1fbf6_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzExLTMtMS0xLTk0ODMx_168c305c-95c0-48be-82b5-268c07efaaab"
      unitRef="usd">86000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icfa55d1cb36c454c8ec5fda74ab99db4_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzExLTUtMS0xLTk0ODMx_09ec5ce9-5b05-486b-a694-697ed101130b"
      unitRef="usd">115000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47f75495e622462aaff82bf298f1f418_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzEyLTEtMS0xLTk0ODMx_7938de04-245c-41f0-aa0f-abc151517e26"
      unitRef="usd">88000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8280a4a6ac8459590c2dcaa41f23220_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzEyLTMtMS0xLTk0ODMx_66c64918-bacb-4819-ae13-8fd2dc179b09"
      unitRef="usd">78000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i530e4f0186a947ecbd4d27d49cb0e1dd_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzEyLTUtMS0xLTk0ODMx_d4543bed-9515-4408-a98b-74ce4a652e95"
      unitRef="usd">86000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic43dc8234c6a4dceabd306a0a1c1fe32_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzEzLTEtMS0xLTk0ODMx_bb52985c-03ee-4d1a-bf4d-63b1f5d4f4a8"
      unitRef="usd">80000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16c4e15aae264f818da6ace454e9fbec_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzEzLTMtMS0xLTk0ODMx_faa653f6-6676-4b3a-8d41-dd3dc89d5a9c"
      unitRef="usd">71000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a5eeb906ad94c799a42264f6d5855ed_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzEzLTUtMS0xLTk0ODMx_560deddd-fefe-45f1-afc7-a8f9cb94286c"
      unitRef="usd">85000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1fffa5927ecf4eb5b8a70faa07450b99_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzE0LTEtMS0xLTk0ODMx_7cfe829e-478a-4107-bc4e-c584e49fa01d"
      unitRef="usd">986000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib537ff890e5e4cec8f7b9df78020e5c0_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzE0LTMtMS0xLTk0ODMx_56e35605-042c-46f4-bb04-37cb7a6c12e4"
      unitRef="usd">937000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9fc8256f50d840ac85eb640d6f16ba43_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzE0LTUtMS0xLTk0ODMx_c2413109-f99b-44e4-956b-ac52c972259b"
      unitRef="usd">995000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzE1LTEtMS0xLTk0ODMx_758c7c18-31df-4347-bc08-405818a85d9c"
      unitRef="usd">8434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibcd9ef98167340e2855d818e1e859e77_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzE1LTMtMS0xLTk0ODMx_ebe72e38-1944-4fe4-83c1-c189b0b65fe4"
      unitRef="usd">8027000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTplM2FkYTQxM2Y5NjI0NTRiOGUxYTUxMWE5NWJiOTYwNS90YWJsZXJhbmdlOmUzYWRhNDEzZjk2MjQ1NGI4ZTFhNTExYTk1YmI5NjA1XzE1LTUtMS0xLTk0ODMx_99e4af40-43ce-4f4a-9517-8a5cb50cbb1c"
      unitRef="usd">8601000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90ZXh0cmVnaW9uOjJmNDdlODBjMTIyNDQ0ZGQ5NzM3ZDQ1YzUzMWMzOTFkXzM0Njg_dc964a36-3760-4d82-870e-86ccad8b73b3">&lt;div style="margin-top:3pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets consisting of property, plant and equipment, net of accumulated depreciation, are attributed to geographic regions based on their physical location as of December&#160;31, 2021 and 2020 were as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.751%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.956%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. and Puerto Rico&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Poland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mexico&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;France&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;China&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Serbia&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Italy &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:NoncurrentAssets
      contextRef="i8965029593294a24adc5e0c5daccbfbd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzEtMS0xLTEtOTQ4MzE_60e431ad-b186-4506-a733-734a2cc227fe"
      unitRef="usd">743000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i1c135788a091404aa9a7b000b712ebb3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzEtMy0xLTEtOTQ4MzE_942d4f86-c5b7-46d6-b2b5-65109b52fb92"
      unitRef="usd">725000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ifc3f5d1fae4241ef94326581b829bff7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzItMS0xLTEtOTQ4MzE_ef63eb1a-daf7-4b8f-9ce3-bd4c7f6f46c7"
      unitRef="usd">336000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="idc53a771e452444ea4bc5759cdd083db_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzItMy0xLTEtOTQ4MzE_006bf58a-50d0-4f62-8f4f-670ce7ba58f6"
      unitRef="usd">328000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ibe7ac3c028a54540be9b808a17416a89_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzMtMS0xLTEtOTQ4MzE_9112f4da-0717-4051-b109-f4e397d0b064"
      unitRef="usd">123000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i4ab3fadee1424d2b9a667a9b07eac40a_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzMtMy0xLTEtOTQ4MzE_beecc5e3-766a-4e88-bcae-964d05024222"
      unitRef="usd">110000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i34d52e2c9af34f2eba8ae6242e32285b_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzQtMS0xLTEtOTQ4MzE_64bea86c-bdcf-4cbf-a448-f4003b580986"
      unitRef="usd">75000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ie7fa6fc30bf5449caf063162224cd090_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzQtMy0xLTEtOTQ4MzE_abfe80f5-2b42-4e56-85f3-aec3e04212e8"
      unitRef="usd">83000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="if3f2d957c7234a77b712ff75e65b792e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzUtMS0xLTEtOTQ4MzE_08a5c085-bcf9-438d-8681-d74c7e561462"
      unitRef="usd">87000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ie327497372b349d3a51955d6959df2f5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzUtMy0xLTEtOTQ4MzE_3495b80a-b642-4d30-a1f9-5d05444c4fd4"
      unitRef="usd">80000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i69ea4eb4471f4aae9d2a35f42e82ace9_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzYtMS0xLTEtOTQ4MzE_8153c164-5b5b-4d07-b6ed-c25b20a0068b"
      unitRef="usd">45000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i2c536f8e7b6c4bdc94cd38d6eef8e2e3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzYtMy0xLTEtOTQ4MzE_59afcb51-d539-48d0-a160-9df5d246240b"
      unitRef="usd">49000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i872f81fbc9ba4c60a97667b7432c52c3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzctMS0xLTEtOTQ4MzE_69966e64-d31d-4a83-9cc0-928513df6804"
      unitRef="usd">39000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="if846fad239254513bf3cca0ba1935da3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzctMy0xLTEtOTQ4MzE_57e25b4b-4510-4aaa-8aa2-e8df42f7ae13"
      unitRef="usd">34000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ie66e6133905345078ee7cb9899b48d33_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzgtMS0xLTEtOTQ4MzE_e8ff066b-d828-4cb5-ac86-0d9f24baadd3"
      unitRef="usd">30000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i6d19b0b4d54a4b8cad166f0ef7a625c7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzgtMy0xLTEtOTQ4MzE_301173cd-77f6-4fe5-958b-dc3b2886c845"
      unitRef="usd">31000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="icbf66cd972eb4b26b35c2652ab001028_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzktMS0xLTEtOTQ4MzE_198a0114-bba7-458c-8c1c-22011e0a169c"
      unitRef="usd">25000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ic83a5702808c4b7889dca0da3411ecf7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzktMy0xLTEtOTQ4MzE_2bffd16a-c76e-4893-906c-3736d5837337"
      unitRef="usd">30000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i1597a3574967438391767431a634b19a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzEwLTEtMS0xLTk0ODMx_fd18f7b4-7e87-4e25-9e39-05873d895ab1"
      unitRef="usd">21000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="idde75edf275b41fb8ca106bbac1cc51f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzEwLTMtMS0xLTk0ODMx_4741c00f-d6d4-4ceb-8abb-11be4e3cabe2"
      unitRef="usd">23000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="icb3cfed9c9f746829c13cb94a536f2e8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzExLTEtMS0xLTk0ODMx_916c3a87-466e-445a-8fe0-e290d4037eb0"
      unitRef="usd">74000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i2183ac8cb0c24b26a214e41ab91d3425_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzExLTMtMS0xLTk0ODMx_024465b3-d8ab-4b87-a825-4ec802deebf2"
      unitRef="usd">74000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="id5393601523d4ba3bef1b785065c95b7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzEyLTEtMS0xLTk0ODMx_d33a5bda-ac5e-4629-8807-072a42888338"
      unitRef="usd">1598000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i16f569f1ea44497cbf30cc6291ac9a0b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTozYzdiM2RkZjQxZTM0MGY4OTU5MzZhZjU0OWM2Zjk3My90YWJsZXJhbmdlOjNjN2IzZGRmNDFlMzQwZjg5NTkzNmFmNTQ5YzZmOTczXzEyLTMtMS0xLTk0ODMx_03b7ba57-80d6-42fc-b17c-63a1eabf46fb"
      unitRef="usd">1567000000</us-gaap:NoncurrentAssets>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90ZXh0cmVnaW9uOjJmNDdlODBjMTIyNDQ0ZGQ5NzM3ZDQ1YzUzMWMzOTFkXzM0MzQ_2daef25f-a72b-4523-8d03-980ae925d09a">&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customers that accounted for 10% or more of total revenues were as&#160;follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:13pt;padding-left:18pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.954%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.939%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cardinal Health,&#160;Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3630993f4ba446f9a740bd6e81c5a6ad_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo1YTFlODg3NzZiMDk0YzNkYTJhZjRjODIyMzMwZDM3Yi90YWJsZXJhbmdlOjVhMWU4ODc3NmIwOTRjM2RhMmFmNGM4MjIzMzBkMzdiXzEtMS0xLTEtOTQ4MzE_5211187a-0696-4c1f-8580-5d22d36a4262"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i18e3409174504c54b7800e5ee44a1e49_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo1YTFlODg3NzZiMDk0YzNkYTJhZjRjODIyMzMwZDM3Yi90YWJsZXJhbmdlOjVhMWU4ODc3NmIwOTRjM2RhMmFmNGM4MjIzMzBkMzdiXzEtMy0xLTEtOTQ4MzE_e7618e48-efd9-432e-9da2-d9015df6ff9f"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i18eef1a898514fe0a4faf29152835a3a_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo1YTFlODg3NzZiMDk0YzNkYTJhZjRjODIyMzMwZDM3Yi90YWJsZXJhbmdlOjVhMWU4ODc3NmIwOTRjM2RhMmFmNGM4MjIzMzBkMzdiXzEtNS0xLTEtOTQ4MzE_8517283a-bb8f-4878-be74-40a2ccbc30c6"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i36636d2e771b4f25a4bb954e3f474155_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo1YTFlODg3NzZiMDk0YzNkYTJhZjRjODIyMzMwZDM3Yi90YWJsZXJhbmdlOjVhMWU4ODc3NmIwOTRjM2RhMmFmNGM4MjIzMzBkMzdiXzItMS0xLTEtOTQ4MzE_7f30ce58-9487-4309-a194-0ba1e9cd5b58"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i35cef2f6062b462484e17c3d2b33a715_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo1YTFlODg3NzZiMDk0YzNkYTJhZjRjODIyMzMwZDM3Yi90YWJsZXJhbmdlOjVhMWU4ODc3NmIwOTRjM2RhMmFmNGM4MjIzMzBkMzdiXzItMy0xLTEtOTQ4MzE_e5382aa1-dc83-4458-bed9-35ec0ac9b3af"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idad1bbd9ef07469495ba41c98fade794_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo1YTFlODg3NzZiMDk0YzNkYTJhZjRjODIyMzMwZDM3Yi90YWJsZXJhbmdlOjVhMWU4ODc3NmIwOTRjM2RhMmFmNGM4MjIzMzBkMzdiXzItNS0xLTEtOTQ4MzE_31649801-1fb0-4028-b9b6-87864aae2f71"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iaff05b11cfdd4a25ba35f7b6f554d5c4_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo1YTFlODg3NzZiMDk0YzNkYTJhZjRjODIyMzMwZDM3Yi90YWJsZXJhbmdlOjVhMWU4ODc3NmIwOTRjM2RhMmFmNGM4MjIzMzBkMzdiXzMtMS0xLTEtOTQ4MzE_158a10eb-2223-4ef1-8009-9cf8eafda937"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i23b4bebac662486b914059dbbda7d89e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo1YTFlODg3NzZiMDk0YzNkYTJhZjRjODIyMzMwZDM3Yi90YWJsZXJhbmdlOjVhMWU4ODc3NmIwOTRjM2RhMmFmNGM4MjIzMzBkMzdiXzMtMy0xLTEtOTQ4MzE_af176261-c79e-4f5f-9067-af8f5c7fad75"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie831ea955b1b4600b7818bcbb63030ae_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zNzkvZnJhZzoyZjQ3ZTgwYzEyMjQ0NGRkOTczN2Q0NWM1MzFjMzkxZC90YWJsZTo1YTFlODg3NzZiMDk0YzNkYTJhZjRjODIyMzMwZDM3Yi90YWJsZXJhbmdlOjVhMWU4ODc3NmIwOTRjM2RhMmFmNGM4MjIzMzBkMzdiXzMtNS0xLTEtOTQ4MzE_8095df51-5700-426f-bb20-db2172555a48"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zODIvZnJhZzozMDUwZjFhZDIxMGY0NjM2OGNhNDI3NzU0MzY1NzgyZS90ZXh0cmVnaW9uOjMwNTBmMWFkMjEwZjQ2MzY4Y2E0Mjc3NTQzNjU3ODJlXzIyNTk_152e8085-797f-4e72-a095-bcd4694eaec5">SUBSEQUENT EVENTS&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 18, 2022, the Company issued conditional notices of redemption to redeem in full all of its outstanding April 2025 Unsecured Notes&#x201d;  and to redeem $370&#160;million aggregate principal amount of its outstanding December 2025 Unsecured Notes. On February 10, 2022, the Company extended these conditional notices of redemption through March 15, 2022. The redemption and discharge of the indenture governing the April 2025 Unsecured Notes&#x201d;  will be conditioned upon the completion of the Credit Agreement Refinancing, as defined below. The redemption of the December 2025 Unsecured Notes will be conditioned upon the receipt of aggregate gross proceeds from the B+L IPO, the B+L Debt Financing as defined below, the Credit Agreement Refinancing and the offering of the February 2027 Secured Notes, as defined below, of at least $7,000&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 18, 2022, the Company announced its intention to refinance its existing Restated Credit Agreement with a Fifth Amended Restated Credit Agreement (the &#x201c;New Restated Credit Agreement&#x201d; and such refinancing, the &#x201c;Credit Agreement Refinancing&#x201d;). The New Restated Credit Agreement is expected to consist of approximately $2,500&#160;million of term B loans and a $975&#160;million revolving credit facility. The Credit Agreement Refinancing is expected to occur only upon completion of the B+L IPO and a related debt financing by Bausch + Lomb (the &#x201c;B+L Debt Financing&#x201d;). At the time of the B+L IPO, the Credit Agreement Refinancing will provide that Bausch + Lomb initially be a &#x201c;restricted&#x201d; subsidiary subject to the terms of the Credit Agreement covenants, however the Credit Agreement Refinancing is expected to permit the Company to designate Bausch + Lomb as an &#x201c;unrestricted&#x201d; subsidiary under the New Restated Credit Agreement covenants upon achievement of a 7.6x pro forma &#x201c;Remainco Total Leverage Ratio.&#x201d; Such designation could take place at any time after the B+L IPO (including as soon as the closing of the B+L IPO). The Credit Agreement Refinancing is designed to facilitate the separation and distribution of Bausch + Lomb. The Credit Agreement Refinancing will not be consummated until completion of the B+L IPO and related B+L Debt Financing. There can be no assurance that the Credit Agreement Refinancing will occur on the terms described above, or at all. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 10, 2022, the Company issued $1,000&#160;million aggregate principal amount of 6.125% senior secured notes due February 2027 (the &#x201c;February 2027 Secured Notes&#x201d;). The February 2027 Secured Notes accrue interest at a rate of 6.125% per year, payable semi-annually in arrears on each February and August. The February 2027 Secured Notes are redeemable at the option of the Company, in whole or in part, at any time on or after February 2024, at the redemption prices set forth in the indenture. The Company may redeem some or all of the February 2027 Secured Notes prior to February 2024 at a price equal to 100% of the principal amount thereof plus a &#x201c;make-whole&#x201d; premium. Prior to February 2024, the Company may redeem up to 40% of the aggregate principal amount of the February 2027 Secured Notes using the proceeds of certain equity offerings at the redemption price set forth in the indenture.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the B+L IPO does not occur on or prior to August 15, 2022, the Company will be required to redeem the February 2027 Secured Notes at such time at a redemption price equal to the issue price of the February 2027 Secured Notes plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="i4e619b455ff146759a2117b1f93fefb2_I20220118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zODIvZnJhZzozMDUwZjFhZDIxMGY0NjM2OGNhNDI3NzU0MzY1NzgyZS90ZXh0cmVnaW9uOjMwNTBmMWFkMjEwZjQ2MzY4Y2E0Mjc3NTQzNjU3ODJlXzE0MQ_a5f7f32e-eb93-4667-898c-f205fe522558"
      unitRef="usd">370000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <bhc:DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet
      contextRef="i4e619b455ff146759a2117b1f93fefb2_I20220118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zODIvZnJhZzozMDUwZjFhZDIxMGY0NjM2OGNhNDI3NzU0MzY1NzgyZS90ZXh0cmVnaW9uOjMwNTBmMWFkMjEwZjQ2MzY4Y2E0Mjc3NTQzNjU3ODJlXzcyNA_493e256e-9ed8-4b2a-97c8-d448f75f3347"
      unitRef="usd">7000000000</bhc:DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet>
    <bhc:DebtInstrumentExpectedFaceAmount
      contextRef="i74d4a550bdbc4a13ac94ac84a9361ccb_I20220118"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zODIvZnJhZzozMDUwZjFhZDIxMGY0NjM2OGNhNDI3NzU0MzY1NzgyZS90ZXh0cmVnaW9uOjMwNTBmMWFkMjEwZjQ2MzY4Y2E0Mjc3NTQzNjU3ODJlXzEwNTQ_fbeaf781-8d15-464a-975a-eee1886c58e0"
      unitRef="usd">2500000000</bhc:DebtInstrumentExpectedFaceAmount>
    <bhc:LineOfCreditFacilityExpectedMaximumBorrowingCapacity
      contextRef="i2c8a1f0a665d43229d899da271c970a6_I20220118"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zODIvZnJhZzozMDUwZjFhZDIxMGY0NjM2OGNhNDI3NzU0MzY1NzgyZS90ZXh0cmVnaW9uOjMwNTBmMWFkMjEwZjQ2MzY4Y2E0Mjc3NTQzNjU3ODJlXzEwNzk_5fe08cc4-3211-43f8-b467-fbb6a18fe7d8"
      unitRef="usd">975000000</bhc:LineOfCreditFacilityExpectedMaximumBorrowingCapacity>
    <bhc:DebtInstrumentCovenantTotalLeverageRatio
      contextRef="if17269c4e45643c89336bb79651ea5eb_D20220118-20220118"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zODIvZnJhZzozMDUwZjFhZDIxMGY0NjM2OGNhNDI3NzU0MzY1NzgyZS90ZXh0cmVnaW9uOjMwNTBmMWFkMjEwZjQ2MzY4Y2E0Mjc3NTQzNjU3ODJlXzExMTE_87b59f03-07de-4115-b2d8-f3ab4d925b6a"
      unitRef="number">0.076</bhc:DebtInstrumentCovenantTotalLeverageRatio>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib440abcc71694fa09f8e1ad1955b47b3_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zODIvZnJhZzozMDUwZjFhZDIxMGY0NjM2OGNhNDI3NzU0MzY1NzgyZS90ZXh0cmVnaW9uOjMwNTBmMWFkMjEwZjQ2MzY4Y2E0Mjc3NTQzNjU3ODJlXzExNjA_a162e295-ca06-4715-9f7d-0a898ba35a97"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib440abcc71694fa09f8e1ad1955b47b3_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zODIvZnJhZzozMDUwZjFhZDIxMGY0NjM2OGNhNDI3NzU0MzY1NzgyZS90ZXh0cmVnaW9uOjMwNTBmMWFkMjEwZjQ2MzY4Y2E0Mjc3NTQzNjU3ODJlXzExOTM_588a6e93-7f54-42ca-a25e-29812b915be0"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib440abcc71694fa09f8e1ad1955b47b3_I20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zODIvZnJhZzozMDUwZjFhZDIxMGY0NjM2OGNhNDI3NzU0MzY1NzgyZS90ZXh0cmVnaW9uOjMwNTBmMWFkMjEwZjQ2MzY4Y2E0Mjc3NTQzNjU3ODJlXzEzMzM_588a6e93-7f54-42ca-a25e-29812b915be0"
      unitRef="number">0.06125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i4d0ad67661d948d99c4ae13e0a3670a2_D20220210-20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zODIvZnJhZzozMDUwZjFhZDIxMGY0NjM2OGNhNDI3NzU0MzY1NzgyZS90ZXh0cmVnaW9uOjMwNTBmMWFkMjEwZjQ2MzY4Y2E0Mjc3NTQzNjU3ODJlXzE3MTE_c84b65ba-636f-4b60-a2fa-8e98fa4c055b"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="i6c6a7f652a6543c78115ce45b38d0293_D20220210-20220210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgyNTZmMjI1ZjA3ZDQ5NDA5YzMxZjc0NDNhZGZmZGJmL3NlYzo4MjU2ZjIyNWYwN2Q0OTQwOWMzMWY3NDQzYWRmZmRiZl8zODIvZnJhZzozMDUwZjFhZDIxMGY0NjM2OGNhNDI3NzU0MzY1NzgyZS90ZXh0cmVnaW9uOjMwNTBmMWFkMjEwZjQ2MzY4Y2E0Mjc3NTQzNjU3ODJlXzE4Mjg_0f74805a-8ed2-4461-b96b-4b6dc46da484"
      unitRef="number">0.40</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>147
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M6\U0RC>LRLQ7^?B1MQ,*K+]$9KK^%SVVMMX,)94V,F\'@X)<%,U?]M0&8F\
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M=TMQSF9[USFSYC*P,_7,[2L$&MKUD:[RD^C=,[DKK\1=7O_OF1Q;BYV89T\
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M-997UW^[T@-)=66WJ-[S 4UJ=T<T_R> +M,R]0( &(=KZ'N92PA&L/X4:P;
MG+I8%\2$_ AB0@IB0GX2,2%58I)E8UV("F)"?B Q(56Z0/1G$"TP8U*E)GU]
MX0/T=&VW)AP%-2&/1TT(0"B(J[O; C0Y "K[4E 3\A34A "$0M^1#-N )@=
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MM*.7,0XK^A1!$S;0>J&UZR<AP/!QL_P;4$L#!!0    ( *B.JE3@XGTY@"H
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M^O7DQ>,LK\O2-(Z64B )SNLFA^DL8'F[RO#9;&DKVYBRW.%MN\$A33BA35/
MZC9E;X;L_<7%M4XSR<QF4Q;P(NXZF\/V"M?"1I!>"W=XSTW#1&676]JFK("
M&F\;-]*N:H9J ?==-W-%7I@&L0COXE-;^-/,2@M#MA:.I,U@@J+%1X"-9C>K
M8KY*H>GH3]@L<D: ?&47@)CP^V%V498\SEP>!CRMG"&FQE/.3(DPC8_-E@4P
M"]SK8?8%3Y!10G;SVG3 W;._91_J]2Q[N[,'?[>FA -YW3E /<?#7L'Y(HBN
MNQE02?9IL; -'@D,\J4N6Y/]:O-B#@_XMSY5V46W!*:5/25J/9[T@%<!4.<
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M<"7'D[1("30?O2T(9>'1>KT3Y6LPHM(E&)*BR<#DRQK&JP@0$U2&MDB(#N
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M6._$2")(HZH.(P'1;DHC$AKQF^CUA9CL $S1=2*63F@!"[!@Z7:&8#>< N&
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MS =*($AT@)G;L/>$G5_6.Y ]K/RZV  &J5(*<:**Q8P=A 0)E>3%RGHD$LF
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MS]JT.GD'J(H49Q"M)11YVS+%;B'JD$/N 8K<M6P&!7XL7).C($&I&VT:AOB
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M=(D:__0[BS^B-JZ8BT L$#/  $EJ:@7LK]6AL[F33NAQ+!R)3UN7.QT9/]Q
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MOV)!MFWP ;B_J$'-E#]P BP+I^6]^C]02P,$%     @ J(ZJ5/A;T4\P#0
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M#MR!;=@<E)!()<*O6GXCY*^,(T2X\X#"-OY<L6"(LCO&'A??;H-+*PY'U)8
M:6-U@'F<J9'6@\J)%\BM92; ?E0QAV,/0X'P6;)[?!S#9MR3R@:I_F_"A 1^
MR1W#$'O-EE2Q(E)D]70A1U  6N#6F$I^6P\^<TB' !MQ(-$9_F8[</?+F)P>
M\J'<[EE;\5/HG=3 Q#^9P2/Q@ J8Q5KE)4+%::!9*)TK[8S%PEPM93[B<.8(
M'O6QNDO3")A$T<!8/(A!HV"0L"I:Y=$B0:63.3$SXP,1#./AL%#203JNG,&E
M+"?E3:>TX\J4Y CTE,+(IYP1MY%.G6/]YRJK,YD7)C<(E?/6-GBG4 #:]SH!
M8;JY^=#RM;"@Y6M@AS-5U3Z"HM@;%+$L8:N$/)1)5/8: @)A4#&Y2 $"L43(
MEI'29Q_6]-RT"K1\L%<$S4 /N:7''BT*HGM31,F),H%8KCR7S%0.!@-:-."J
MY!E686'0R4%8X^E,BI3(3<72>D&LK#17)2AHU;*AB"35( 0<NH#ZWC4Q6VHJ
M>7$_#J>P2;6#@YFO;+)%:#_O);OVR@??/DAB4,HFV)^.?+0]Q2BM=BB\2UGJ
MN=B[:0H*NY9:PB;!;B!JN9+DG!55DJ4,/(SL 5]R'EN%\)=M%A$9RK5:^41$
M*@ =9*E,XXBV$$'VMJ-*998*/'2$4Q:Y1$E'$5QS'A6Z-DEF0#DI04"-Y-SD
MH*G$5A_D&ME15/@<F4RT&(@!1)".+6Y1U0DE18I#SY>J!9&/TMOY4N'Z4(O&
MXK*#22"B0I;Y3E=1I]N+[<.#QV*[D*DO(@'/4N9_T4_7MW??RZ)Z<SD@Q-L
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M8?_7PQXSX1$5!DZ7_N$2:X?/(/])%R,P)(#KF=:N&9""]B5[^B]02P,$%
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M7\FOOG5:W4ZG]O_A&-0WJ%Y205"J-%H)]2."=T_)H"GG1EZK*;5QU=MX57/
M,]&/  Y4!^0OK4J85&D)V(\VAJ\.V<-Z=]D6W8/U^A9/>MV3#<_IR< :YUZ6
M>W)+N7 ;AJ_[=KR_^?+7 /O5E>Y9I7'YP*48(\=A/T/%F1#OXS%E]#LX#],H
MLS R@,;3.>)Q5:2#29[&>$HTAEM9;GV <6!:I6@P57"4GY2CC*!2L<@1[<1:
M+?9&2@PHG*FJ5K1H".G4F43';-!SF2">E1A14>HH:"-I[8IBE .W%1A>+A;6
M_."*Q=7C.L:?ISS<<C/DMY><0U-26!&[D<(/(KSUS.#1:93D8&VQC>#I[!=4
M0+(7<N73D4ZA"!$[\AQC)_#!%8GBO,Z:U(3+*5#T4ZV:2AO3IIG2(V4S')'$
M;7O4QHRH@)XB8^K]?0<%Q%? 2INGU,(7QO[A""D%^@G\27R9P ]RFWD, =MN
M2/!*O$^0!+*?4O015L@(<)6K<HTV\3J2?+G!O]Z:]Q1:P@K0B(Z3I$[ 'C6'
M3L+&BRT7<%3P,_M3C9([YW=SC=H0SM'RU=7^JZOA^_Z5^'3S<3 <7EQ>OQ_Q
M_<XK5@-0+.D#U1-".'4398,'4,F8<\@5C!_GG',XLQ#RE%#:]QEGQ(QS40SM
MG+;J^4] 8V593RP1K2&K$*AR.B5GRD@S,B)A,*<RC+T/WML]++VWQ76-MS<\
M)<FC+-3_P;8A=4Z0.JER# Y/\:!R:UZB=#=<<$&O%(11D0H)T(%_2N>H4C<J
MWRP886+-7,CX#O 1H]RI(I8JEJ1RVC'H3RX[5H3>3,53/%M*M[:$:*I9Q-H#
MT52AZUB#&&GU8)AKTI"(Q)/(1@M)[Q72=Q-P(T]1&\4>E'6IAOP"Y8G"^<CO
M"GX;*15[LQU4)O,!%/B(5\.JCK:">HJ-M7U4C3:3"5R>"GX^4; G"!22<7&K
MT#Y?A#+3*TI[)5'=0I3'?TI( 1$N\-ET3&ZUK19QQIM")H!)5%JIBQNR*OQH
M]$?F7+IEU8SZ-W=4ZKI@\ U%'FX;>!*9B;V^MI,_-@'LZJ ]35WK\T89OTR&
M]4-PLT#DL3S.[R]%#>,5RAH;:10-I^*350N)]*Q^+ !%.'W[K%3,#HC4)YZ*
M:]4H=N^5(LWR?$TEKB832B54)2!T:%#]F&76H#6J(IALN AEF%?XD9&#AIVO
M8"<^Q36@W8SE>W*_'?*.70H6@U//3V_.35Y$ %"INW-XO.NG@U:\$WCF 9K.
M%4<C)HZ !B2DB@5TJ9CK]J!M=33A0,#_4EKETY=%1 Z]$:G^8P!72B)'*&IX
M/>)835(I*6&[>UP6'31T&PJ548[E%E[E9-4B..II+C#VVJ (V9CS>N@-P*<O
MF2#)#4)'0/OVS1->P-7G.XJ&=EGS#HKUA@6;#\J:]V)-6GR$4B=/E]&/E'L9
M5PY5P3V3,=5-5;I$SJ:&##/?O=3I,^?149,+?XN:BDVL.0+\5035CR*;D^$?
M4,TFHL*9XSE$Q8>OAQ3EC[3/X*9?1O+9A/7+COW[9.6/KU2[L;8<3PTX3HFE
M3G8])];&UT,9(SK@,?SK[JX]'@^JX_&@<3S^.$Y"51^Z-1O;0QM/V*8FHE$"
MC*G?1U0)#AR'_INCME2M)7BG)161UHR]2ZU>+OD5"!ZM[1-*1-\*1]=6:";F
M]<;F3BBL=T./KC@7A([=7*Z*2"+K['HW*MO=(:;9[GH>"AUH]E5%#1VP]HX.
MLVN*E]W9:*;57:.K-I%T!-N!O0%7U9@L$05GE4T]6A[B@WS ^>VEC+_B %9#
MA"O?L@$9HB)8[9Y6%9R5_FTQJO4%@8B%I14?V&-57% ]EX9-F0I#JM\1#M[R
M4":AZM3E"9?,LMYP3%;<6D#@4R, I:7=X%P@YVP#,V^8P<$GG],%XB/9@T[T
M(^@BU!".I2L?O2"D.R<O0OM"E+!*G%#D]'%+0=OC%SXY/&L>'50BF41Y4KPX
M\--)+04_*ZGMC\ ,5-W4()-K<&T_SJS<"S4XC8'CBYKFER*_;*^N;:AZO.OM
MZ'S-&XDJ?B>-TN@7B?5<P6"I7Y138DO\4Z:YM"N!S1>-OE[G2/09;^]*L.MS
M&HIGG!<5[[_0$G11.Q/[7AGRV+$O#VLOVV1MW9TCZ'[XO&9F?3Z2[<&)^%2T
M//;$J)80=DY/=\5.#TL\:#+RH2RY+Z]18IA-17/U"F_H"Z(2Z*:?'71\[S1D
M_*)'T#N%UEV<E:LS3_&(JNDN?9)UGO_B@40^_O+A_^(]0\I&;H3&[[QE&!2]
MLTVO$IX<\/#P*</;A^L']W#Z <OSNTF9J W=Y_7M]<-'GCRY$+<9,+ \W:PM
M;/<]MU-B"+ASL[5(ZI4%6KX;'1GG@]ZI)"FZ)GD&Z]&)L<!G#3LA:RKE>X&]
MLA78'_QY>SFZ_'SY\7K4$E>7@^'UZ/+ZO>B_OQF&=^W]ZPMQ<?EE./I\^?GV
M9AAZA;Q-&<<Z'"B0FZ1.F@U?*EW6(=-NN/\$E6$Z]>W0"S7.[I=Q&)"4 V(:
M\.0)@?+.=K?;.CHYO7>V/&SUCD\VG2]I"$VMT/>T3V$47K"'-PBU]^S<%))S
M57_%RUIJYW+BEC(M='?;ZWY;L5?[V<I<V2G_.(?LC#3J?\%2WBU__]/W/WNI
MAOL?#WV0%AG$P5$FF+K?/C[<0G[F'^3XB\PL^$<P8Y-E9LY?9TJ"GFD GD\,
M=ADN:('R5U%O_PM02P,$%     @ J(ZJ5%'D^=-A @  !@4  !D   !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&ULG51-;]LP#/TKA+'#!@3U5YHV01*@Z0?6
MP[HBW=K#L(-B,[%06?)$I6[__2@Y\3)@S6$7F9+X'A]I4M/6V&>J$!V\UDK3
M+*J<:R9Q3$6%M: 3TZ#FF[6QM7"\M9N8&HNB#*!:Q5F2C.):2!W-I^'LWLZG
M9NN4U'AO@;9U+>S; I5I9U$:[0^6<E,Y?Q#/IXW8X .Z[\V]Y5W<LY2R1DW2
M:+"XGD47Z60Q]/[!X5%B2P<V^$Q6QCS[S6TYBQ(O"!46SC,(_KS@)2KEB5C&
MKQUGU(?TP$-[SWX3<N=<5H+PTJ@G6;IJ%IU'4.):;)5;FO8S[O(Y]7R%4116
M:#O?/(N@V)(S]0[,"FJINZ]XW=7A '">O /(=H LZ.X"!957PHGYU)H6K/=F
M-F^$5 .:Q4GM?\J#LWPK&>?FMW>/UW??OBYOKQ^FL6-"?QP7._"B V?O@-,,
MOACM*H)K76+Y-T',2GHYV5[.(CO*>(7%">3I +(D2X_PY7UZ>>#+WTM/OZ!V
MQK[!E:1"&=I:A!\7*W*6^^'GD0C#/L(P1!C^7P&/@OW$3:@1!<XB'BE"^X+1
M(2/L]4ND 6AT Q $9@U<)ZQ7:/M:@="E-Q(H#$\,.?::P$>IN6F4XOZG3YU?
M\%F*EIO(H95"$7R [&SLU_,1//$, :,::PHD@I3_<3K,X49JR5U6PL:8DF"4
M9# :G3)H/,YY30?)> C_*F=\T)LUVDV80&*56^VZ-NU/^R&_Z'K[CWOW0GP1
M=B,U@<(U0Y.3L],(;#=UW<:9)G3ZRCB>FV!6_%"A]0Y\OS;&[3<^0/_TS7\#
M4$L#!!0    ( *B.JE0=%;=[ P,  'H&   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$T+GAM;*U5WT_;,!#^5T[1'H84D9]- FHKM=!I2 ,Z!INF:0]NXC;>
M'#O8#H7_?F>GS3HT>-E>;)]]]]WW7>S+>"O53UU3:N"QX4)/O-J8]C0(=%G3
MANACV5*!)VNI&F+05)M MXJ2R@4U/(C#, L:PH0W';N]I9J.96<X$W2I0'=-
M0]33G'*YG7B1M]^X89O:V(U@.F[)AGZBYJY=*K2" :5B#16:20&*KB?>+#J=
MI];?.7QF=*L/UF"5K*3\:8V+:N*%EA#EM#06@>#T0,\HYQ8(:=SO,+TAI0T\
M7._1WSGMJ&5%-#V3_ NK3#WQ"@\JNB8=-S=R^Y[N](PL7BFY=B-L>]\4,Y:=
M-K+9!:/=,-'/Y'%7AX. (GPA(-X%Q(YWG\BQ/">&3,=*;D%9;T2S"R?512,Y
M)NQ'^604GC*,,]/ES?5R<7/[U8?EA]G5+<RNSF'Q\>YB>;FXNAT'!E-8QZ#<
MP<U[N/@%N"B&2RE,K6$A*EK]"1 @MX%@O"<XCU]%/*?E,221#W$81Z_@)8/@
MQ.$E+PE6>*&5>4+!G @#1%2PN.]8BS?-P+?92AN%5^7[*ZG2(57J4J7_J[;_
M  >W-<5[\4,J*&732H%J-,@UM(/>=M!+![W$^6"-:;.B:JBS\\)%B&#X_K1!
MKU-XRP1>0<[Q->FCWL_Y?+#>;R!/[7 "\X[QBHF-=BBL008/M'%\LGP$69'!
M)2EK5*>>GM&)_"PO<,SC&*Y-C8P.J*(GI_@ :\F?P29I#$D6'GQ'?.]6-C'(
MHX^"/(%L!&?(W:BN;PFH!U$VBFH-HSR#-,D@\=.HP#%)"YB59==TG!A:X4O'
MIE<RX@+?1GX1AT=VSHOH"'5'_NBDZ.<LQX(>.--'[*!(8(O%?A/E^;Z&/EI%
MN+></CPNA@WLN*[(?E_E_I-$)S[V0MU2U\WXT_'?[FEPT \:JC:NZVG\EITP
M?6L8=H?&.NO[R6_WOBM?$K5A0F,-UQ@:'N<C#U3?Z7K#R-9UEY4TV*O<LL:?
M U76 <_74IJ]81,,OYOI+U!+ P04    " "HCJI4PB:A1H<=  "A<0  &0
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MVDV\!4L"WHYG^_%V/)N)#Y*"9(O\5')!+QTW#VD\A VGX"+L0&=GGM[#X]-
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M>AS-M+8<V1T;7&[":X\Y"@@\DII;$E3[QM]I,V3;ZL30B!M?8[1M;<AV/9!
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M0A7%'G0$P8!_'-CC9J?C%]X[I]B!K$ KZ2QO 7X@R8(95+5I"AS%60:U'=-
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M<VU 1NY\AL/GDW/C]1E,A=?5J1?%&M0>3H2U89?I^4S^GCK3P6(^JTY0E%O
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M1^BEK11!(IR4,L<;1"CU:,V<+(?160[GW,'(BC+(+*B<*R>+NJD#RU1$I :
MMCBZ&CHPI>0V+@7$ 6H@'*ML' B/\+V,7A!4L?@.U+D1$;#\EJ/$59ILZ;.
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MI;(1_]VC'6 " DWM )2#WENYB.VU.;)'/Y ;S+HW.%,;D/L>E\K,;JQ0<\O
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M5CI^<E7E]35O\J"&%,'!TUQA%E2#P/[Z'8ULM0@H8[@LV1(41BS7C*-NB:^
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MU0(36F#ROZ3R[[S$_5J)CVF\D<E6K&6.H@P@0[%@"HA-))-<R"044FQD5NA
M;V219MO=D2E0JB9AK$(=R(BF1GJIA$[R,I-)H CF0#RN=; 60?J@,EA !%&:
M [05# F7LEBKC.[2<B/2I8C42@9;<2%+,$CBCS+>O!6?TW@A_I)&H4Y6N;A.
M@C3;I)DL8-[A'_\P][W96_-U01,^T]WI6_-U)+X/[X9"Q9LHW2K%FZSO="("
ME15@T$2*V "F95)D6N5#@42CR6T:R"#(2AGEXA'0%\LL_:G Y.2X Y!6%2\
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M^X$#XS14$4<HU.NI5N*>1Q!)2D)P#<CB'C!*H#8^>L8TH_8L>?S:& Z;&'?
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M8[I<@XBI# ? [\L4!-+<X +5B_ ?_@U02P,$%     @ J(ZJ5+&.:3A(!
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MW"5(7' 6E\X62/.5<RPX:F/I'.2A46^VCC7#"O=GB2TQ4.# O(=DCU=IU3+
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M0K=JJ_4#WU_(A6M_="0N4D-K@R[TG!5W'I[9RL?/;_=<#GX/4+]IX::%H]
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ME85"JQ6G.@0:8N[W-_J=-3=<+H&.2<$+F--+1V/2Q.3VP[O3N-W[1&DK4'N
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M91?>JKCPZ#U3IG+?M0RIJJ5MGG9[VC;&2=,/_L*;KGK'=,ZE 8%K,HTZE_T
M=-.IFHU5E>\.*V7IL_AE0<T=M0/0_5HI>]@X!^WO8OP'4$L#!!0    ( *B.
MJE1L)45Z2@0  "P*   9    >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;*56
M;4_C1A#^*R,752"%Q';"RT&(%$*.0^(X1.[:2E4_+.N)O;WU;FYW34A_?6?7
MQ@D%(MI^B&-[9YZ9YYD9[PZ7VGRW!:*#QU(J>Q85SBU.>CW+"RR9[>H%*EJ9
M:U,R1X\F[]F%098%IU+VTC@^[)5,J&@T#.]NS6BH*R>%PEL#MBI+9E;G*/7R
M+$JBIQ=W(B^<?]$;#1<LQQFZ;XM;0T^]%B43)2HKM *#\[-HG)R<#[Q],/A%
MX-)NW(-G<J_U=_]PE9U%L4\()7+G$1C]/> $I?1 E,:/!C-J0WK'S?LG](^!
M.W&Y9Q8G6OXJ,E><1<<19#AGE71W>OD)&SX''H]K:<,5EK5M_R@"7EFGR\:9
M,BB%JO_98Z/#AL-Q_(9#VCBD(>\Z4,CR@CDV&AJ]!..M"<W?!*K!FY(3RA=E
MY@RM"O)SHR]?/TWO8/K;[?1F-NW S?3KL.<(UZ_V>(-Q7F.D;V D*7S6RA46
MIBK#[#E CQ)JLTJ?LCI/MR)>(.]"/^E &J?)%KQ^R[(?\/IOL70%&KA27)<(
M3&4P?:2NMFCA]_&]=89ZXX\M809MF$$(,_A?8OY;#*BSQSKE#B@:59I&H+>P
M0F9L4"EH%0=R:9Q\ *YI<*RSH.<GL"L4-8^4- =V+YC7UL'R6CB1LWI&R%N'
M:-3O#@EZ!_H'AW0=I"E=D\X@3F#,?U3"8 9"[2^,YF@MS:>E5'@1(#)\H&E?
MT.PZRL,G<0S]% 8)W%#N.7TJ@()9)M&G!\Q:))O== ]V$_KUZ1)B6.&SVC<H
MF:-P1,D)E=>HQ"Y#4Z>=)# X)C*U4K5"/_]TG";I*22P>[#WFH3$[*A/UX.X
M898>4H<T6F[5A%+>\:HTBI(,7%89<6'9GS2QGK87I$[:Z5"H2UF5Z/YB,"8.
MSI#91HP.+)AQ@DFY(O YJ0'W*X*UE6&*(V%Q_8!&X#-8CL9Y*>4ZUR;#;D,D
M?@<17]@71+P^O& FQQ=$OG5G79@AKPPAT_(F"[\^FTXH^@/:9W']RH0IE@FF
M7O<.9D^Q],+MTP[R;B),6KU1!O52N]4F#_:V=DW$Y,,[I*NGX85XGBN5T$D,
M ^ ;'"3FC*]J\>R:/I?4^V%GVDA@TN1&C@1E<<VRS<**7(FYX(SPVU6#D E+
M>X8-HPGSR@3C# E.^C<WVB%X,?UPI/'I]?1R? VW=U\FT^G%U<WE++Q/3EO9
MV\])Y[\,?9B3=7=YHYU!*Q@UO1%T$!#4],W'RGO4KB2+YB+4:RE<$32M%G-#
M7P":E54]8E1)^B>&0FV, SY2'2QM]51<[D\/*@>6&PS5L!OUW?8M:HNY0R(\
M$?C')#!>".*\+C+94=MKA:_W&JF65=QU7]MH>AL[>(DT=_Z<0OVA*^7JS;Q]
MVQZ%QO4)8&U>GZ,^T]A2^U/+S<DU[AX=1&#JLTG]X/0BG ?NM:/31;@MZ#B'
MQAO0^EQ3FS0//D![0!S]#5!+ P04    " "HCJI4C927;>,5  #)0P  &0
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M!]_4?%'C!R_?OEF)N;R2]:^KRQ)^>VE'2=52YI4J\JB4LY]>3(:OWAW@\_3
M;TJN*^_G"%<R+8H;_.4B_>G%  &2F4QJ'$' ?[?R3&89#@1@_*['?&&GQ!?]
MG\WH'VCML):IJ.19D?U#I?7BIQ<G+Z)4SD23U=^*]<]2K^<0QTN*K*)_HS4_
M>SAZ$25-51=+_3) L%0Y_R_N-!Z\%TX&6UX8Z1=&!#=/1%">BUJ\?5,6ZZC$
MIV$T_(&62F\#<"K'3;FJ2_A6P7OUVT_O/TX^19??OIZ]?W]^\>7CU9N7-0R+
M7[Y,]!#O>(C1EB&&H^ASD=>+*GJ?IS(-!W@)\%B@1@:H=Z-[1SR7R7XT'L;1
M:# :WC/>V"YR3..-MXQW5BR7J@92JJM(Y&ET!N"J?"[S1,DJ.E=5DA554\KH
MOR;3JBZ!4O[[GED/[*P'-.O!<U#[Q"&B#V6QC&I@BZ@NZ/\XJA<25K1<B7P3
M3652+&%-*K\MLEN9P@_1K2A5T511)N<BH_6+%"A)X4J1):)56212IH"1*H[6
M"Y4LX+4D:U+Z*FV2.LJ4F*I,U9L8OJJ!AX"I&A@-OE_)$C^&>9>R3)3( ")Q
M%\-$M:I+H. XFA>WLLP1_QJ 4LZ;3-1%N4%(956KN4 FA?E+"5\ X*M2W<(/
M,+/YDMXL2H 3I ?,UY25C.1RE14;''K/O*FJJI'5_D.H$EE5P.PP/+Q5D7@
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MQW61W#!CD_%6T:H^BQ+FLV@[$_5B$WTJDD6I4I H_XHE(2-Z2Q)N55J,5GK
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MSV0RSAWY*U5'DY*&AL'+9HX>=D+*N6\\M)Z0;V$8T/I@]:]8*"JC>OM>XBD
M-0NU8HU[N0"?(2U*S<A&_*'B8.F.&RA1OOIBSPE]8U$0P1BR:/)4\I8G@IV\
M?ZG\WG]8Y^G5/)*28H2TD:" '2II36N B)\.-"A\O_'T)_DNMVS<>JQC="',
M#F[2:&C=I <U+5)VH$R</=D20=:FY &*KEJC!9%/;L#DI5<);,J<^"?2\8D^
MQM1L[HL!\C-7HK2>J(.S;7<P*G7@!9\B*U7.0 X)8K-TJ6KDV+SP_5DKW5N
M@1 EX"5%B[* ]P&6=0DLGQ8DX:X#N*P$]! /Q-TGW<.=B'8$O@0R5#\+VS*#
M!W!!+J "4N!6[I)897Z!X7]O1*9F&]I^$:A;L6%#$Q8 UG!E3#YTA&MK9ZX:
MT+&"3,S2<UU%HL,5/IX]FO/B(+QE,(,J0,JAFT*^'V! XUR@6$)_;<9XUJY
M1O$&Y!=TF%!$$(.-!AVDZI54/#"%:U9"H6I@]")^BC5&$LC]53G]6*84;]#V
MO[3XP/1&"LH^TID*JV*\&8GGV+JZ9@=7@Q!'Y.,;%>*](N] ZU7:VK;6PE_)
M3H@-8R!QX'0:8H!6A2&)0+G>1R\=EFC!C(;4'NH,%T:MB!L;LCDH-&<  FIF
M8MX:U_DF6<-BG$94"\\%\P!()?@J*HCMP$[, :PY!BA"V003O8IVU*[;7+T+
M&C6S!M$(?W<4/&3P#0NP_F-%)/_0#H#;BSM MD/KU=8C!ANEQ+DI!/2OVA\T
MP)I<,L$/3V)D$6,3!?[-6E3_I\P@92"+C08&T%JN1AS=[C]%(\>11"$%_^\X
M)7R"2G@X&!T<[48[:&:,!J^]>>B3X>O=F$+4&"?V9-.L%$UJ1#J;#%?&H!\.
M=J:[M*[18$?LFFUZ?P="$ -E$XY-3>5"9"2Q.CL#GQEINEX4GOQ,*"2XLEX]
M$$V*+[O/^F->@0ODR54M48V>)2=B.(:ORJ*9+TQ(:*C-*D=4^I.3F#U%CY("
MEYKDX@\SGW8>]G_9#3+VDZ><C<.Q+ A2-H'1-V+?QJ,N0-4*MA59Z%VIY(S\
MD5P'3 IOG?"8K#EL8EWCX9CG)Z ,]@Y#FP[92;M/%$%\$"+##0O8;-XX,MM4
MY6 ED(0."N5-9DP/86*OF@:#S?,MX2(W'N %1F-U,-18+OZ>]@H1HH.RWNQ5
M\A8TYQS(9T5DC.'I6Y5B-H]C1\#DK>R,)5+GH+>#I:23DP4X+ 03$+N+2CT&
M/!J42:!CTU;_1\1>D&XKI9-]KZ+K_>A;L9;198DQB(^@NH"MK@A;'T#V:*YY
MFD3TN>D(N>EP,#[8?1V]!YL,:.<:<ZN2&! L+&2="A4T)AD5:JWW:."Q0=B"
M+BNFL-EZ& 3OT8#UPW4T'!T#7#!ZGJ@5/(5C5C]FS3#V"8S]+BL*9+?Y%=#7
M)3@#.>X0P?[I\KES'(^&(Y@#ZP P!+0Q&#H#(OP#; D,BV->CW?R4YT^>U7'
MX]$09OQ\=1Y=%Z Y,JP=L>N".?8O?\0<!X2Y1GY&@QBI_0,8> +9/US1CYGM
MQ.EH?U*CI%_CBVAI&_1J&'[ _AV<XDI_FWRZ.+-,?O$#1CV"45%O56 2@U$)
M6H_2/,\?^-BARAO?8>KK30,N5/25<AX-EFJHA(,&9LNNSY\!QC%QUN%P[,#@
M&1T$GT#71)/I% Q7G=8BZY6$SE[P[=4"\S+G)C$"<V&^A,%\+HCCHT,'HC>I
M@_,2H%IC;LK(,XLS4B >G7\'SHQ-V@'L^/!PY "S,'A@-=,,MNP]5:> D#;A
MXF^R5B4[ E<; &U)63<P*?#/:J6^7Q(S7$<C#V'>N XR= K?%1*M%,,J!DH?
MNLM,.,%'N_XTT'K->0WCV+/F&10'WA4&10%  7N-F4&O4HD=KP]948(A\4Q$
M@589G&AL?)-S<@:UK?)KKC!'C;0$GYQA6 7\0_7X&;<0\W!\<()3?OS\]8D(
M[0Y(?M%@<'(*XWWXRY_ /WI=5K6()I<@XL'5R9\-[&A P*(E]9]%>8.Z</,8
M<G[VFL8>8WWYS[/WWZX<<?Q<(!];]?]U-JM ^%B9^!Q%PK.?' \\_@FG<V"\
MRT1R4Z)MIS79Q.6Z?HBUQ\",#\:^1M5S.C#.BJS(L33B@X+-UYSC9+4S#"=;
M#<,S<CK74F1@KNK%7'%1!(G,X?,7<3)&C,&KX!%-%LT_G\-'>I,.4"^_*\5B
M*7)@T)7"HHRSHEP]$><]0Y^.M5"X+)M4UPI=Y!4H-PPB&H&)@@E<!1CWV8L9
MCD;>+KM9/8DH\S\$^)FT20GZ'8%2>S[1CT8GGD#FZ=STX(:.HO--#G-NHE_/
M*(O\[!T\//78S)_!HVX!NPHRA;Y9@BZ=9*N%>)J[LF7^X>CHV$.ZF<G-_04L
MB,5:(I;!5&ZHTO63FLF %/:?8]XP'(<!YGMF]62.6 B0[]G&VB1/-64ZLQ^/
M3STLP-">_<DE0EHC7F.-6E,"R8&+J=U.ZW>?%7F.8;4$O/V._8 N-.LZ<@F?
M@;!3 OGD(-@X-[4#_5QFF(Z73S#!?@!4'CD; !Q(G\'E F%Q ]JT 4L&:$G>
M4L+S><0\&C#[#D\'GLVGYW*AT6M)8;#B&3:!GNGPX-CS\>RX;JI?KR83PR^\
MX==< /Z=)-LU(34DQP='GIF TWJA8,#I1W $+W4!^7?XZ_TS>EB&\<V$^]&5
MNJLQ&:6Y)0BSF?2+"1NYU)4M_'AM$Y=U45-LD.**,!IG(BBZV1I&5U:8N-B6
MV)>JHGH-=+[9*W(;N3*!+"_L1V60&+J4+L?. ?7[PN?Q_?'SGG)Q;\K6-":<
M*4QRV"]<Z(,!9%C?I+$'XS".AB, ;F>D01T>FE>\Z#6]I&/OP+><-8BC7,XS
MA6X!%FR4DDKG\UI'N2E^Z .%8WIX_P:FF@22*(&89N"S4R:?SYV49;.JHZ_E
M7.3J#YV.(V3QII@$-(BOJ= %?[J*Q*88R%&QN5@,,<8FMQ 'I:RBMD<_\/2#
MJ[8*JGZ&8P+-1,(')H_0+G8QF7D3SV8H*S Q,Z'KW0NJLD\E)G+Y(046NGFS
M-^R['WTN;-F8B:X[)M$Y@9P27\L" $P( ZE,5,KIL*4VR+:1&*P$1@9!X ?W
ML=[?55Y1(0[MOCDY86GO6;O:1UCXPCW$Y2!P$6I<<9!".>YF*VP)#2Q&K9K,
MNLNW189A.'A+KY?"_)H+_BV&92B[ "=94=FB 7B#EG8E5[6NKQET5T=ED#+U
MLD5&F7=3,UZ!B5ZG-9V>O*"N:;3-B@H7&=3]G?KK02@N'6MLK5W4:9U?<W+@
MR+6K-#+0^:"'*FN#!85_7@KP*#R0T7K;8-6QJL&J*3[)+<QF75[NUQV:03V5
MZ_K';E&K!\\I5W;T$:Y'MM4#=&OL]=@/G,6^(<IL9BU!*PD(D,SD /L!>0H'
M<7S"WW17-#'X,5,$X7MO(I?//#&;C&O6M;*#[L9_!Z)UVB@.LB]Q-\]CXY^Q
M'QB.VXDJAA!<2!-P\_=ELBI59K#6"_A3L&:"A%?O)C[2:/-'/V@.#MP[QG#A
M 7@4E)VLMM24Z?>==><I+2-'?#5+VJ^6:$[3D124@5@M+#. 3\V+$C1\M@%[
M2^0B52+?4KA_D>OBVTK=]2OCH. 6IZ7C@ND/RZ'BR@E(86V"LK@%8F*;YAW"
M7"TPK@4FL!(Q;%F-!@R-\O=&3O%8\+UI6+1%)UF&];5^:*8GCG\%WO?IP3MT
MOZ^:%?J#3D"V 8%G&"=?BENMI%@%'X)SAX4D?RO6*)$6F[Q_TM]@LKW#@\'A
MZ7AO,#B[A '-TF!R+/ H>?:>F8[<3$DP4\>GZDXX')R,GCKA:.PF3'>CKUHG
M8*%%X$&VYQH?'9\\<JZ6D.2YY"X*]B9)5/^2:',^P/NT?8!,4+U[@^'P^& ,
M.TG,G$?MIP:#O<$10#4X/AGO#8\P=L!TM TT6Z;NT$[59[-=$(58,R>:O8]%
M2F78CP'3 7 \P'C/XP$P%-8YU43GEEFQH=F[+GSO:0M?4SV*Q]RV&M([O<J5
M:U-8&%?QDQ6.QZ%(QVM1$!8O/<2-"NCG1F9R\PA>/#T=/HD7W1F(<*>P3O"J
MN9$Y2*WH=BNY#@Z/CK^;%UW9]DSP.7C?4R(7B 5<"S=XQ!E/8RMX?-/UG6PE
M*IXR5EJIF/=!9<J2WF.'$$1_X:EQ*_RU2.4CP%8/P!NJ,FK-+VP+"4;>4]C6
M7QCLS6'/VS"IHG'*Q6M<W(:G>$'9@=$H!1YUAA]L39CGB.K(!GR+AROP_P[^
M/><4(/#PP <RC!E:B:4[]>VJI_U:HGY-Z1\?IUKK_>B]P/-!]IQK+Y?%]OB'
ML(8JR3-M+^N)>_D_IO(P+,RE(\]TO/JB;Y08M\^< V77XI@MF7\V>&S'&/6D
M79VC 4QP*[D) )V^LA) E=U0AH$PB))P.6T#E%JJ/_0$NN;;GG ,_!XM0C5T
M?CR #[GQY+^ GTW$.F%)1)CZ6JJYROGT!Q]6O Q.(\_02Q61/8N4>S0R]-TM
MOQJ7S3OOI'?O)ID8B5O>D@:NMAYZ ;=>D75C'O!*+5V,003G'99^]>%!Z"GH
M4__:(N7B]MX"8J^F/0BVZ!7%(:/;!<7(TU6CFT+H=A_UEO,E+>P8A].=,#^;
MG$>G![:<>Y4UE2VQ1W<V][63?HVZ9=S"9FFWETU-M\ PYY\456T,2:]V^SN/
MA?Q;3H.</50$CK1A.%7<1\W!68C69J#_G1?K5CBYSUKGSA[&3*=*2[;3G6E.
MI?S::N?'6R>2^("BRBD15/47H;;$0=4^L\+"BSR]X<B5)WO-//#X"UL:1-Q\
M:,;*!20_EF1!-7RO1$6L_])41&!UP30O:4#&WH/B[L?6RSNLT,ET6S5/>?UO
M6$LPP2XKX,"#X<)$HETED\6_S][O6IW#(>9KAH>'>\,38T3VA',]L)X8SC7$
M&$9S;:CGQ-]>TL1NI?;HD?$T 8E.X/L;WKNRX[WA8'Q\< HK X/>WR>:Q^=P
MRBYT<@C>II^!XXVU VRQF38OAF%Q.&-F=$*UW7X#;)1S:Q63^R"A8U2(L9 "
MU,D[;)M468UH0@ EUH0BX2C73\8+HPU/8*4BY?8404#(%K-CUD=/:5'.\M[-
M28>W@QDU1[JZ)RXLN99@ L$B_MJ30'69].SJVA7LQ(:7 Q;OX>O'\K'C_Q_$
MT?'38Q@M*]?V2&(K &E"U%NY?2M6[TU.OQ--!9O&@7H],[<;2?8?E &'QZ,1
M<,KP^3*@:VELDP,F8\,!3,/VALR"SC)?];D-9EU*TV@J8D=W&P7Y6F:KE#@:
M'!S VH_^=Z6$SYQ!X+F?WGT+WF,2[>5IU.2^YNAC"Y8E&E1T5<*,ZWVK#=FF
MDTX(@6]E%0+H/1Q;\$Q^ _<<LWB5C9[J;] $0%.(8@TN+<2^#I\OCI$:T=WA
M\X9TJ,1Z':=^=%?H5 >%/JR)%+@I)X1,FYEP&,-2&XMOF"G5TM*GO&TG_UTK
MLERNMQ-'NV^./KI*OY92U,:*UN)U1<<WT*S$0_D\ +:JJ4UM8HLZ/V;-4M9_
M"--7IWNJC,QP[D;F+%ZPK*TQRKN1M8Y0'>N]"'NCH3,A"0T&;6O3)P^FT[8V
M'4'/I!$\W-;&H+<M&8CL@@U]F&4Z[IFG9[#Y3%VJ&Y[>;HWF+SK<CCO<KSX(
M.3$%R+SED#,$T'/%)4Q EC:=;[Y'C(2Y(IO!,7A+9:9X8TBU&.SHQA%!5Y1C
M\RYW2'"^EI:VE3NS'TIJTVJ&%9&AM#."7(ON_KB8IY ?T';7E'S-;_"-OQ5
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M<#S4G9AEO5GUJUC;%=6S,A+J\\O=8R4W7<0=HI4OA<IT<Q(D%CH<#NO2BZ3
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M[TT5?Y:"PW4:@.\+ ]5K'VB![F+YZ ]02P,$%     @ J(ZJ5*_*),%=#0
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M/;BJE[PF]].+"6$W6H$/)J48O0+I&557?IYY:B<OSR%6VJ_9+H1: $TMV:1
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MTYTG9AL_=+2+%Q)KBGDB/DL;)6)X6 KMB6\0VEK&%L8*M4_:.;$(5JJ@27L
M%'-S2U:S!?Q\N\,6\(Z8MO!A09$'./PPRU,*:BM%YQ"@O!C#E90Q7:]HIK2$
M._6\*Z3C>J-8QI2KZ0/PE92-SMT,R6*KRD/(5@&=6^,<PFHBHMB)F3596#QY
M^4E\O/S:;6[>T]2+#S7@!WB[6VTL"9:PXV=D^4%E4L,&F'0DKML&/?1+-\#W
M(B7IO-@[Z@X&#4][VQ-+:@W:1I#&K%4:1%OE40F5PBNZ4\XSR"L"L3TV/+!M
MH7PB)'PRP_]Q5E+VZ>7/&4?@SN#=%W2T)U>V$](5(+1M$Z4E99.W*R$O2AYM
MU(=J W-SM%(*%0#D<3 ^.#H',^X4&B2E2[$WZAZNO!W"1S83$Y$:J5W *\7>
MFZ/#9HFE6Y/>LANC4NE,1BI5?EG"VDB7>ZA,!%X(HX$C,/IA@E64K7!82H.U
M,?-V)76Z%!-9H :(E^*3R:9K87G(\Y4;QSXH\9A:[BG<@?HA+^'*6Q5#1 +^
MKH-0&MF*RKWDY)4U'(N(6<4.J"GAT.Q4K)C?N/P'SF'7!%R(A'NRU$0H;<#B
MD5")61#JW';,]_R?0X'R:\F$IS$Y-==<2-8-DDR'VHY";[2D0.*4>#;3M#&B
M)(",$@5+PBNFJCCJO;YC)XLPSM;*KXC'U\B(;\:C@7QBXS&1BBL)[O1J.-><
M9[4Q*M"K2&&W_(&>ETH4!<0LV,SQES-?(:XY]QPJTB*N*J,SC,^5C2 UKE7L
MJ@TO=DN $E$9@"IUV-<LR%$NK6SW-7AX6M0)L1:.'90%AJ*[5MTCS/$<!?1X
MM,'-R5:GVL/T"8K16B.0 8*U@5=<84.5#6FP6^;4N=]B.CP3P5YHE5/P FW!
MAA"EZ2X31C5?[0W;[6/+F/.Z-QP=/H/?M8*NNN_JT'?CXGX;:Y>5#0UNO4QO
M6 BZ1[:@T+(XFX*QPC+8%3;DJ%B2M%V1RZ6<ILR23+U"TRM"<<&,*"V.=]:Q
M,PD9M%+)@1P7<YQ*=L!BJ9H3@Y(JCF9M4*E<W66EB\1@&;R&:[#6=]>RB??8
M*J?:6@^ZM>36&(3(\/SG<*1%FJ/Q*KT^QE5<KP*=R64]T3J3!0S5@+QE\F!%
M6(R\6X-4NCV $#AU@"!8,1P,GM4B'S#'<P+@99X6;E7:,Q265\$M=07"L3M3
M1=83EX\J7N=ORZPBY[4'*P2;6;S-[,+5 W S$V)71-:CBK+):-[-!.>>"M#&
M^'Q<KR"Q@5JN/$V6P_S&^R4EFYE^W0WUN&L9EZ7V^66;G0 >9JNRGH=<NF]#
M$]^ GRM&]6(7]H1HAY2-0VH5.I<J;M*W]]C1M-\ZZF>$,PI_T'#<BK0O3_W-
MT^:;R;C\5+!:7GYPP4EHKC"3I33#UD'OZ+ C;/D1H[SQ)@\?#J;&>Y.%RX0D
M&C$OP/N9@1W5#2MHOB2=_0M02P,$%     @ J(ZJ5'^OH1T\.   8L4  !D
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M!-/-W1"SDBU(9H &1#'*K>$HM;V!6528&"2+EG2XY-1'88HX8)J$3+D8;(?
ME<(95 6'J5FBZ$[9E2]4"*A/$:<FW^:HIC);]3YRF&K%08B(08:L,QSJ%K@/
M'#< "B"#ZF4C3EV/(#1_3JXVF5?=LB%IJL^$.6<*[;DKQ]#!4Z"]#A<$AT4^
M=%@-)2&Q2QU/3@*QJ!HV-L]#DR?2",=C;)TBR9!0NCB9)*+S$OTL%>8(CI+@
MO=].[-^D#N? 1>KTUD?& 0J8\9QPSL5*,P0PM-& IDG>_T:]U0@K0O!,G?
M" ZU8G0)M1&$H6:X%$Z]QX1<%)X]RLN9_%5U4<(EC<#D0TF/=ZZ*Q*1NSJ?H
MF8UE>8VJ0I%>B8&<ECY;B!545&ZO,0V]QV4X(TJY3.059-D6)I94HDV'I" 9
M'BWG/0%[JU318R&AR1+H8PA\AI<&9)/O4N/Q8_RCH%RMT@TDOV:&PL0@IK.9
M9H*N7$3\3.0DJ*HKPF>3TF;,;A.C8CVB/Z5EB'A$(84(&3A%D:]=L0;M=4W
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MLJE8GE&&;^U\^BN;#I7]W?=.\0EC9*<!#6-DCF9L+5(EW(,-,4!23<2>03?
MIC^,%A3W:ZG$>4 ER+;?BL]9E'@]1X6H9.^>*;T#)SV*$M 5F5G<*X'W;ER?
M#S.,_;XITX3/V1MP47LDKG^1NOAT] Q3<_(!)T;.O6?V#3>LZ_3+"^3_9R7*
M+D,:V'(Z<>N3'/BGT!EDE-0>/,IH14.H<*^=B>,%KS )&>T"0ID0,_.<@ =!
ME>Y<![H)#L26D]N[HVN7%NWU#,Z[:>L*Y5W-(30M!_[IW-<!<Q! "_7WK+R$
MM%TN"J!@'X8<KU-X<D534HX)Y?C3LG$-V%Q+GM3OQMZ 5SY^/HM#7=0V8"M-
M#S)WDZ.,>(R,.,4<%I(/F*<&Z%JM*-E$OZMVU[#F I4V,/DVW*HCY"L@&P F
M#\8 -B&0D9_,19SX@U!G'*CHW-2'FJV 18^))<H-O!^/PY/:DV5582'VME);
M/MJ8RI+!8(/C]$=HCX/L\XJB% (>3:DX,"PEC+';,<Q "_<KB;O*,!_,ZRRQ
M"9EBQFLZT5<U2&"?19-N-M@>3*'C0<Z6>.9@<]A-#RB6XB;2.\Q;5J&'F&\K
MQ-:4Y=$]9R>;3R&Z,E#KD5 PAH/6RJ:J.0O:YS6.IR5[9N;I-]B]_EU.-N)V
M24!T@@[;O/%I6UA@P6<6NOV5JC0.(Q4]UTTUT@[/Y#J!D44>A8+=")SN1\:4
MY[)\,MB3;[ >V"]F;%WGL#W$"=P&,RAN*AA;(]Q%D%>YAEF.FM;M/&BV5>8*
M:<7!T-0(-/4!7($08=XBL;Q]I'D];IYH8$U!*\PF>EP<'FS%AF)PI2@=3;F.
M#_)I^J3O"D )9-*\1*OVQQ]2=?^>4_NV)QY[8N1Y3!T(N,1)?$$-C-1P>>2!
M6>8^T^*2DN1.PW3>OS@HHO.YK.X+%=K[ZBDK9BA<C 34&S&-J8-0G%PJI!-0
M@?[H2GL8(Y!M#H.65H1=XP#EV@.#!A<RNZ]$#4,70I86N)C&%86TPUQ)>'$X
M&\9R-;:(P/!M*&.2DU!"0V9FUU"?)_3JQ<PA)!N/L G;38_3&LGGM:MR+BL$
M'H<-3>[#3"0FY/O_6#2X"+FZIY02P@.A<U"P,I;&Z*^!)^H]: J4H=];8^U"
MO0GP!0*0TZ9M8@X3PE.C,-''?1J5)+N$ 0^=PQ Z463^'F>D\1X-66BF$Z>F
M<5%%\!&$%H6SZ=Z&R1T=#)6BYA;R$YA$]7L-NJ8XC=>4@XY1[!79ICYU7;UT
MWKMP0#*PO])+@2C4ANRO,4$!HG ^ES#N@=7W+?GA00KX.5V3*AMFJDOT7T;D
MT 1S?)6\R/V21^\XCE/?TZC<"6FL;@B9>_!I8RM-B='8)#Y?GGV8BC<<<M2*
MY-[9MIS<%/ _2FU"OS=[)] KKKRXUVYPC-BL,J.Z:(RX2=Q>L]>%<Q15;>*Z
M8JWXLSSRDD/I%O@E_F\[^7G2X#$ V.3"C8?AY?;'G(,!1"^'\@%3_P"OW%1%
MMW5F;R,+&[B/3J6)Q=!+9+P6W$F,?S:U"^JYN<\\XY42!(?"C>W(##Z$Q==N
MXW.4J\G^;-\PA<-^W"60?11EQBT6@W=MC*4<(&T#*'R+TS"Q/3B-#7\<ST$U
M*K$=3X%//3&^6SWI3X(Z9X9_OK,(^1D#(? 8A4EUI;/DO\ 800G%#<F/DV^2
MQ:LE_/OB]0+^?;U\B=^\> 7_TM?+V?'S8W%E:=< <R8O8,T+&&4Y6[Q\!F.^
M7CY/%J]?),]GQR<OD@O;1(A==V!DOEB</$D>+T]>X+^SD^42_H<WCU_C_Z_Q
MM^>SY4OX?[#V=X C6PQ3GNCJ%Z^/D^<OGR<O7[Z&?3Q+7L'TLU>+DZD5PR,G
M"UCQLQ=+7/'KU\ERL8 5/UN^.K#BY[2JY?(9K7CY^B7]?\S[>+Z@%9^\?'6/
M%2.,ETL$[#,"[^MGSQ#>+_$<GCW'/V>O7IQ@6H/'7SUH%0/<9.:JNG&<NU^)
M>P@_8Z@%E-G@*?5-90)]8 0KM*(!MOD-G)1@&FW[FY-E^-QP9Y/^+A1/9Z:@
M T,J@?^%1FS#0FVF>%^3'$A_)CT@[G:Z65V04VDYG.U#-KCWN\F/:#DJOPD*
M0"?]Z,;[#H[U+SWUOL?&)W%J#TV68V9JQDQ1NHQJ@MU2UZEW9PQCE2CVXR22
M\::I)M-+'I?.<*8(\*EM+TOM]7JEP2/MRT5'Q<%^ZS*.^(G:8ZJ<V5C0^#"?
MNT[LDQ@U$,AN%\(*+7;:<T0_XO:&Q?ZU,6KY9X)M6(S-] IUGMR2U;/J00=T
MU&MM2!"-YPW',K>[HMI[_Y:/[9B\'S4AV!5HRI%Y%Z:*\\JA^QY1U+1E&:X&
M)]I@A(0SD1$KNZ(#0 ->"2*L*QB4&CGA;&0/,"Y*;(@;45$@O:*X2L-Q@ZSN
M-GYV,(LZ4)!7NO)5G4N-7!X='V*3I)RS!P6 7&L12N;D;^TO$K P)(1R+B]=
MA$ ,*52BV@HT2N@0G"-'3?#G&TS880Y+>/X*3LRGY[4PKESJ0!$ET]?] $.X
MX?L1#C9OYOZWGC/TC&Q:8",$'M@'F9=4AB<+0@NC0%>/)O4U\!ZH[<([-#V"
M;%,[P2VU%V:55Y1YS4%)+<,AULL/2SJ#-0FC"$M:EY0^YXU']:(<[@YDW$^4
M[T.5+N$N"W1Z5G7/^>1K=H?ENI&VE;D&T.Y*./ V_0U]9%57BV9UT$":=+ST
M8J.2=\4+)U_OK'>'0> ?!DWU$7:4:$NL\15)VX(XSGX:&O2?]>P+JD!94Y:G
MV.3;G:\&Z9D?;.>R&J^--X:&\*0%H_:P)'UJ43/@&VZ):E:8NX60F2C7=;"^
MD OW]75YC?!KGOP<.G+'=>"[AZS5F]$V-LRF&QO5W(#16%6E;\F$V^E*LIQ
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M69!YJ@W85HRGIB4?6PTP #GRU9\QY(B"I=)W$!TI8+/FNX+*ZA'O"/_TDMA
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MX2QD:*TX>3Z\;O3A29P)E\DL[[CZA2\J^IQ^.6"&WO_U1#ZT](%ZZ:W\71S
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MSVN7 LSP ?A]756M?L )T M#R_OAOP%02P,$%     @ J(ZJ5(R,]_.=!0
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M9L:@PK'7;OUT00H2V0]OM!?C 6J-.FJ-#E,+3^>L5H*<".LDGD\B@]J*9:U
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MRE(S\<N&NC=J!Z#[G5+VM'$.QO_!XE]02P,$%     @ J(ZJ5,[C8Q$"!@
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M+ T#O]W2]$7M'.A^K90]'!S!<9Z/_P!02P,$%     @ J(ZJ5(+H :KO!
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MOW,%1R] .:>M*/4_CTHW%:?3:D7EU(_5BFHOFY8[8PN>INBJ04YOC&;H=-P
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M3Z=!5=Z9RP\C"W=/?9"&;KUNN$26HK($M#Z7TFP_K(+ZCXO1OU!+ P04
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MP<!*3K$T.LB&'6;"K5[H.+WP-VD3[9RN_>M<"H0[3<#_4ZW=JD,*UE>K)W\
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M7%N>@-_OC6F6#ZR@_[)]]G]02P,$%     @ J(ZJ5$^<3.D; @  %@0  !D
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MA 'H[PGGZF5B E0M_.P/4$L#!!0    ( *B.JE1@2NU580,  "\0   9
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MEMUI.= B*SK")Z%-?UE<)J:C)]).,,^G0NCEP":H?B/H_0502P,$%     @
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M\/A?"Z=^S:E?<NIW<+HA:?&8,S"E\R3+DFP.V"MXIX2;$KB+-2AC%0ZR&<$
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M#F$ -??%(455%9"]*D0+PN=2@;,WJP*5>2/_\RA0>36R>_4'%:A[,0RT=!A
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MI?#B5P;P\X?%/-*+?<U#AU1JC/")/PFXE&3<+,E+:L="NQ3LN$@D(P^<0F"
MLC!MDJB ;YM^_6/^Y%N5J^5Q/'(?S;PU-M[@@(53.2"(J%RG!RT*TK69_8LN
MGA:'.9/T"./@^0VZFF9',F68[(1H3N2:Q0HX79F0[F7? )+9H4MVH\4V/89X
M$%J+*+W<4&)J8@W,[RLA]/.-35 <?8W_!5!+ P04    " "HCJI4-<EQ C4"
M  !^!@  &0   'AL+W=O<FMS:&5E=',O<VAE970U."YX;6RU5=UOFS 0_U<L
MGC8I"X1\5P0I(6N'E*91TVX/TQX<<@E6;<QL9Z3__6Q#4"8-.FG;"_CL^WV<
M#QU!P<6+3 $4.C.:R9F3*I7?N*Y,4F!8=GD.F3XY<,&PTJ$XNC(7@/<6Q*CK
M>][(99AD3AC8O8T( WY2E&2P$4B>&,/B=0&4%S.GYUPV'LDQ56;##8,<'V$+
MZCG?"!VY-<N>,,@DX1D2<)@Y\][-8FKR;<)G H6\6B-3R8[S%Q/$^YGC&4-
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M?6SG&#:[<:_&B9G,]U@<2281A8.F\KIC_86(<MJ5@>*YG3 [KO2\LLM4_R!
MF 1]?N!<70(SM.I?3O@34$L#!!0    ( *B.JE3@/04D9@(  +L%   9
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M-Y2:]#Z3)M,V=[MPN@X-M=:.VC-,*WH/T?@ .M]H[?8+3]"]L)._4$L#!!0
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M$#+]ZIA>:!$E'XN60FL1)C\WE/A4F@7P?"6$?KTPWY_R;[_#?P!02P,$%
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M1]+T<HL? :#=!'R^5LJ^#=RY-/NL&/X-4$L#!!0    ( *B.JE3K*\]?3@,
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M$XEN+DX36+7WS;I5EEK?#TOZUZ!V";2^4\J> M?_W=\K_0]02P,$%     @
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M4'&$4&!L'0*C98T]%,(!$8T_6\R@O-(%[N]WZ/<^=\IES@SVE/C)$YNV@ML
M$ERP7-B)VCS@-A]/,%;"^"=LMKZ5 .+<6)5M@XE!QF6QLM>M#GL!U>LC =$V
M(/H84#\24-L&U'RB!3.?5I]9UFYJM0'MO G-;;PV/IJRX=)5<6HUO>449]OW
MG>$$GCNCV0#&@\YT-AF,!X\_IG )I!)I(&'P&J=,+A%Z2EI-LAL8RECD"29
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M+$TROTWI7X/:.=#[A5)V=W 7E'^O]E]02P,$%     @ J(ZJ5)=Q0OS1!
M6Q,  !D   !X;"]W;W)K<VAE971S+W-H965T-S8N>&ULU5A1;]LV$/XK!Z\8
M6B")1#IVG,XQ8#LI%B N F=I'XH]T!)M<Z5(CZ3L!MB/'TDIDBU+2A^ZKLU#
M3,K'N^_N._&C.=Q)]5FO*37P)>%"7W76QFS>!H&.UC0A^DQNJ+#?+*5*B+%3
MM0KT1E$2^T4)#W 8]H.$,-$9#?VS>S4:RM1P)NB] ITF"5%/$\KE[JJ#.L\/
MYFRU-NY!,!INR(H^4/.XN5=V%A1>8I90H9D4H.CRJC-&;Z>XYQ9XBP^,[O3>
M&%PJ"RD_N\EM?-4)'2+*:62<"V(_MG1*.7>>+(Z_<Z>=(J9;N#]^]O[.)V^3
M61!-IY)_9+%97W4&'8CIDJ3<S.7N=YHGY %&DFO_'W:Y;=B!*-5&)OEBBR!A
M(OLD7_)"["VPB=8OP/D"7%V &A9T\P5=GVB&S*=U30P9#97<@7+6UIL;^-KX
MU38;)AR-#T;9;YE=9T;OQK=S^#"^>[R!V<WXX7%^,[MY_\<#G,)8:VHT$!'#
M'2,+QIEA5,.,$ITJ&@,Q\(XP!1\(3RDX1F!.HU0I)E8P(9II>-1N_,!6@BU9
M1(2!1R$7FJHM67 *MV*3V@BO[^B6\NX;>'U-#6%<OX%7P 3,&.>6:3T,C$W4
MP0VB/*E)EA1N2 IAF$EAUAIN1$SC0P>!K5!1)OQ<I@EN]7A-HS/HHA/ (4:/
M#]?P^M4;10RMP3;]>D]A[JD%8+?@L>O==IMX+*@XJ:?+$E2AYZ2&#6<C1617
M$_>6G<"4\"CE?@*?YI)SL&_/CJCXSQ;0YP7H<P_ZO 'TA*Z8$ [0@G BHKIR
M3C(7/>_";4K;41</AL%VO^0U-JA?V!Q@ZQ78>JW8QM'?*=/,)7ZJJ*V K:$M
MC;%HJ6UD.]0LIBJK#(G_LJ^JW=U,;;=FD?I[\!"J9'!L<CZH3Z!?)-!O3>">
M/'E $(#=C VGC?#Z1[%/+R\K^&ILN@T5OB@ 7K0"M(UD-UD!KBFIB)[ *"(T
MKU;4;@413^UK[/8$:=94V>(G5K/63DRV%+C4M6E='%>]DM2Q15B?TJ!(:=":
MDMUN7NCFP5%(?%Z%=6RSW_$'P"X+8)>MP*:^Q@8V4KGRUB&[/(Y:;8)C$X1P
M/3 4E@(4MD)[;U^PZ&5XN9>#RH6X K#.J&DC0'L2B5[8"B)%?5?:8Q/8#@1C
M3S*PS81O"8D4]*EE.T2XC(1_GET<E=J#NM]MK\Q#'339197F8QO<;6"YU"+4
M+D:^]AFGC1 /79=2@GH_$:VE@*!V!?FFM/:/)/JT7Z7UV ;W&F@M10:UJTQ>
M8Z\DOHHG\-&?[6E\.MY:]"L*UTQ',K4&<YLC_ /^0/KK+Z@?_M:UTY*:A:.F
MK;:E4*#!5[?$2R?M@^YP5G;+5)6C]J<[&P!N#4UT*_FE8*!VQ2A?AY-FTN6"
MLY4?VH:-GZNHLBHVG(\G>>#+?=D]"R_"@S]4SSLN906WR\J,"9:DB<51TP'?
MC'!<B@A&/R+AN-0>C/\GPO/ %<(;9!F7JH/;56=&OGP/ADL!P><_),.E#.'V
MGS3_(<.]&H91]<P:[%U3)%2M_.V-!A\A^RE>/"UNB,;^7J3R?(+>3K-[GM)-
M=NTT(\K^I-3 Z=*Z#,\N+#"5W>1D$R,W_C)D(8V1B1^N*;'9.P/[_5)*\SQQ
M 8K[M-&_4$L#!!0    ( *B.JE0-U$U=I@(  +T(   9    >&PO=V]R:W-H
M965T<R]S:&5E=#<W+GAM;*U6VV[B,!3\E:-LM6JEMKD!O2P@4:#:2J5;P=)]
M-N1 K#HV:SO0_?NUG30%M:1]X(7X<F:8F<@^:6^$?%8IHH:7C''5\5*M5]>^
MK^8I9D2=BQ5RL[,0,B/:3.725RN))'&@C/E1$+3\C%#N==MN[5%VVR+7C')\
ME*#R+"/RWPTRL>EXH?>Z,*;+5-L%O]M>D25.4$]7C]+,_(HEH1ER104'B8N.
MUPNO^V%D :[BB>)&;8W!6ID)\6PG=TG'"ZPB9#C7EH*8QQK[R)AE,CK^EJ1>
M]9\6N#U^9;]UYHV9&5'8%^P/373:\2X]2'!!<J;'8O,32T--RS<73+E?V)2U
M@0?S7&F1E6"C(*.\>)*7,H@M0-C8 XA*0/150%P"8F>T4.9L#8@FW;84&Y"V
MVK#9@<O&H8T;RNUKG&AI=JG!Z>YM[VX,3[W[Z1!&P]YD.AZ.A@^_)W &/:50
M*R \@7M*9I1135'!"(G*)29@WP$\"'XVQGDN)>5+N"&**C@>H":4J1-#<DNH
MA"?"<CRUM;(J/8/I9 #'1R=P!)3#B#)FWJIJ^]J8LM+\>6G@IC 0[3$PP/DY
MQ.$I1$$4?@#O?QT>[,)]$V659U3E&3F^> _?+YVB!&YBL4Z1:R NQ^L:[KCB
MCAUW8P_WPSM62)$E8 XS*,+PH_ *QJ9CM$=ZW34NU]OYO*^(&LVJ9D=HHQ+:
MJ!5ZCVMD$-98;E9,S8/'V:JX6P>/LV!LU<195[$C\Z*2>?%YF-^_A:W@1U3C
M^K*BNSQXHE<5]]7!$[WZ--&ZBAV98?!VZ05?S32N\1UNW:+AP5,-W^Z4,#IX
MKB5EW<G_H.3]T?>W>HMM[",BEY0K8+@PJ.#\PL!ET2N+B18KUVYF0IOFY8:I
M^;Y :0O,_D((_3JQ':SZ8NG^!U!+ P04    " "HCJI4GAMV,U4#  #S"@
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M:[+!.5.W?/<WJ3;DFW@19[+X!;O*UK% E$O%D\I9(TAH6O[C7Q41+0?H'7%
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MCE7J AM,ZO*<K?<]*>7SXC68 -,\[.;53W6W>M4V+%XP.=I\\Y[N>\CG<29
M0F=JJ/LE4('YYM77YD*R9?'VZ)%)R=+BXX*&$>6Y@?I^QIA\O<@#5"\@!_\!
M4$L#!!0    ( *B.JE0GPI$^/0H  +9    9    >&PO=V]R:W-H965T<R]S
M:&5E=#@T+GAM;,5<6W/;NA'^*QA/VSF=.A;!.T\=S]B6XRBU)8V5]#QT.AV:
M@B3V\** I.UT^N,+4I16%,$EI21L'A)1VEU@+_AVL0!S^1KSWY,58REY"X,H
M>7^V2M/UKX-!XJU8Z"87\9I%XI=%S$,W%8]\.4C6G+GS@BD,!JJBF(/0]:.S
MJ\OBNRF_NHRS-/ C-N4DR<+0Y=]N6!"_OC^C9]LOGOSE*LV_&%Q=KMTEF['T
MRWK*Q=-@)V7NARQ*_#@BG"W>GUW37Z>.G3,4%'_WV6NR]YGDJCS'\>_YPVC^
M_DS)9\0"YJ6Y"%?\\\)N61#DDL0\OI9"SW9CYHS[G[?2/Q3*"V6>W83=QL%O
M_CQ=O3^SS\B<+=PL2)_BUX^L5,C(Y7EQD!1_D]>25CDC7I:D<5@RBQF$?K3Y
MUWTK#;''H-(&!K5D4+LR:"6#UI5!+QGTK@Q&R6!T93!+!K,K@U4R6%T9[)+!
M/F#0U08&IV1PNHY E:WGE ,6JC>Q[)Q]Z.UFEJV[:6=_TZW#:6>/TZW+:6>?
MTZW3:6>OTZW;:>'WP6:1%"MLZ*;NU26/7PG/Z86\_$.Q3 M^L;#\*$>46<K%
MK[[@2Z]&X\_7X_O1S<,=N9[-[C[/R/5X2.XGD^%OHX<'\HZ,7<[=?-637X8L
M=?T@^?/E(!4CY_P#KQSE9C.*VC#*Q$LOB$+/B:JH],ML2'[Y@TS*+2[E4Q9=
M$$UIDS+$I3RZ7$AIG<M==XV49BD?NFN$2+GOKA$BY6-GC:C3+&74?2YJ*86S
M=<Q3/UK^*XO\-&%+D9%2B>A/N.@A\[JH^3=<RHRMP>02]H<C/"9A?^RN Q)\
MXQ]BB4EG*9C#I]VEV%(I P%).UQ2=[BD%F*U!K$??!$J[-V# )XY&46I&RW]
MYX"1ZR1A:4+^\2#HR2AE8?)/9#1M-YI6C*8WC'8?Q_-7/PB('ZY=G^?QF<CP
M:2/%**3DM=K+E8B!EWWL::7XV$KQ6*?034<I_NPH*VKJ.S5U5,TG]L*BC,E4
M>]QPFGN#VKJF'XRZ"4Z]-C];42T9Z41":BH4T\78Z6)TT>6<?&,N?Q>_,/XN
M_T3\R!.5=<)D.AHU'77E<-Z5R9B[R9@G36;.-I,Y)VO&/1%5HDB7 1\NG5XH
MRA]E2(>S:0UL#SB;*N&K&,7:&<5"!4UW*I-X019B79$7-\B8<!%A;QY+DOQ[
M3]07WT1NV/PF6W3X*+K1H.:PA4]I4=/>J6FC@JX]+PNSP$T%4"WK.$*\E<N7
M+"%I3.:"2!:7=CTNJ:U@@>GL)N=T C99T#FUM4DU19<N^4>G-D.JZH9TS8\E
MM$UR)S):JIHRVJELOE17,3-1!<I@!374C9N)W3KY"WF(PV<D*NA>84U[R& 4
M$B953P;WDG7?SIIE&E+WR6AU*J6=2.5:-NH2R,FT6U*6*J35!C8TB@\,69+B
M:7+F!OX;YA/(4=3H(P8@#=%.>4@> V;-9*IBR3.\A)8ZBGP)2^6J^+*$%$)Q
ME,;PJV2M!!\U#@NE4OGNM.,C:"='T$[EM(=85S44)"&*9R$17(Q';MZE<P,L
MEB!S4*>'V%4!@54<@;'8+5DK\4A-:9H82VGMPYISXSXIK7$8YU6%( &H]&3\
M*EDKY;9ZB+'5<?=V3G@BF,5!ZI)'-O<]-!140&)5ZR,4 (#5T_<I:GVCHBF'
MP%]&0IU4-31Y(-1)J8/' 20!%=^I#(79>.(O?&&\*8_GF7>XN:P*!K17S3[<
M F"LXF",NJ4.;I2JTE4WEM&J\DPTD='J-2=6%0+05''0Q+*+6B_*58?*JV,9
MK=90'1\A=W($[;2D-7#:JJ$@%ZCX-F*6/2?L:Y9O9^Y>:LV[:LL% %]3^FCQ
M !YK.!Z/L_"9\7S/N6E(NOE@93<R(?\ES8W)D5:':T-N4PU@6L-A^G Z^1ZX
MZ(^*J50[IM(9U2MOM6%&>TTPO. ^]+*82-=MD0;8KNE]>!W05\/1%UGCHY)U
M?\VT[2(T0&<-K\4EUFS;6&@ Q9K5AQ4!*;63D7*DU5%*4@-7!P;DT8Y#'F'%
MKJ6N#DBD]X%$.B"1?G)E.-*/K@QU@!R]I3*4A&3'8E$'%-'[*!;UO9XV7BRB
MQI24=;561G5< !8=!Q:),8^L]'3 $KV/2D\'>-%/WG:/2M9]T-2VK8$FHP+.
MZ#C.3'BZBLF0Y7=%XB!>^EY"GG;I\4LM&5:' 531^]C;&@ P!KZW[7B^=%.*
MP0Z8)"3UTZ'-"7:[M _M)/<H2=4> ( &#H!/E8KG?+]=GK)$?!'$T?*=@/F0
M+(7P=$6XFTHW'C<M(S6=G0Q/Y+MKX5-;3A4, &NCK9_;8B/QEQ\6QPZ>FZS(
M(HA?DW,R]Q,OS@01EQ\VW+0,Z[0I (G P,O)'W3^<],R#)4<Y)2N.IZQJBKD
M(*.M8;$/40FY>_.";)X_2P -&W'O]+./SK(!&<C J]F."#8VZMW@)K2 ;&3@
MV>A1Z!IF(:8')!C#[L-ND&D,O'[]<4AWVS*2!'E*I,/Y)$A7/0.'+&>V=7!_
M"F+=M@QK-2G>PD=;-8=\9N*H7T:H* &_JX Q(3F8?5R/,0'+31PK?Y)KARW#
M2I+1!MI;^0S<LX#L)H[LC^Y;"_:8@-EF'YAM[EU*:3L-_&'8TS)2TU63X?%\
M55TA1YAMO>F?A#WXL(W%Q["-4;U0#51U2&DFOF<J0_2[P0=RFMG'[LF"O&+]
M7_+*L&78YL*RA=&YL%#76I!7+#RO7'M?,Y_G5IX^_<D-UW\=8F(A>UA]9 \+
MLH>%P_$('"8J?C^:L\5F!D$Q Q]FX!8SD!665OW&A_Q,5T*(GH)8D LL/!<,
M_60=)VY [GF<K<_)YEDH()1Z_I9W=]DY&<=I_H,71R)B,_'C9,UXT:S,&_O7
MH8A(,EVY8HEZ+$OSKANYC85](B'@XOKB#C,X9!JKCTQC0::Q<!P_='"[/Q^M
M^D;!1COOUMZ]0QQ;J[,IDMPFT)#9U(\9:[?0JK,!>+9P>/[(@CGY$/,B/KX[
M! "DK3Y V@:0MG'0.][HG^QZ9\E!C6X#<-HX<-:,3FX93UT_JIX>D)LL$9P)
MMB>W 5;M/F#5!EBUCX'5+B8?VW5P;#$YH*.-H^.AR;<&WS;"B]^V$'I.9FPM
M+)&?@.:O'V#V -2S^T ]&U#//@;UNMA_8DM0#S4_@)[=<MMZ8V;RS-UHCL;S
MWL7F/GHE-D"6C7<B3L@BMN0"L2*_URHCE=X@FT@H#=1+#J"D@Z-DI3+8NBRW
M(^8Q!V#/Z>/.L0.(Y^#-XA,\YD@N+DCO9(U+2@.I^*K3!N!T6CK3I>%Y_KIQ
M,EB+_4&MG5D5#2CH]'&]P0',<_!3R.,],'$DMQY0NP(@.C@@?HE$.1/X_\E5
M_RRT7W W2;FP=,:%TN&:QR^LF*IPP+^9A^U&'0 ^IX^K$ Z@HM-RT_:$F*_?
MS6JX93+8>Y,W?Z/_T>5+7^P< K80K,I%7O?SS4ORFX<T7A<O]S[':1J'Q<<5
M<^>,YP3B]T4<I]N'_'WAW7]5</4_4$L#!!0    ( *B.JE2P4"_6C0(  !D'
M   9    >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;(V5;5/B,!#'OTJFXPN=
MN;//!1SH# +G,:/HB)ZO(RQMQK3ADB!ZG_XV:>UP1Q'?T#SL?W^[2[+I;X5\
M43F )F\%+]7 R;5>7[BN6N104'4NUE#BSDK(@FJ<RLQ5:PET:44%=P//2]R"
MLM))^W;M3J9]L=&<E7 GB=H4!97OE\#%=N#XSL?"/<MR;1;<M+^F&<Q!/Z[O
M),[<QLN2%5 J)DHB835PAO[%J&?LK<$O!ENU,R8FDV<A7LQDNAPXG@D(."RT
M\4#Q\PHCX-PXPC!^USZ=!FF$N^,/[S]L[IC+,U4P$OR)+74^<+H.6<**;KB^
M%]N?4.<3&W\+P97])=O:UG/(8J.T*&HQ1E"PLOK2M[H..P(_.B (:D'P54%8
M"T*;:!6936M,-4W[4FR)--;HS0QL;:P:LV&E^1?G6N(N0YU.I[.'X>QJ>GD]
M(</Y?/(P)\/9F%S=WHZ?IM?7Y#L9%D)J]H?:HD_>\/0H(*=CT)1Q=88&C_,Q
M.3TY(R>$E>2&<8Z&JN]J#,X@W$4=R&452' @D#$LSDGH?R.!%_@M\M'7Y=Z_
M<A=+TM0E:.H26'_A 7\3I1D>$E@2FF42,AP2NEL*J$KQ"2IL4*%%10=0&''0
M5J]*%5N5N8ROJ>]WL32O+:RH847'6&$;JU(ENRPO2-I9<<.*C[&B-E:\Q^IY
M03LJ:5#),53<ADKV4)U>W([J-*C.,532ANKLH9(D:D=U&U3W4]1##MB85QID
M&["[#^P>*&.O ?8^!<[PU1A1*=]9F9F+OREU&[FW=S#C(/8:='5=]XV23N3]
M%Y^[T[C,HW%#9<9*13BL4.:==U OJT9<3;18VU[V+#1V1CO,\>T":0QP?R6$
M_IB8]MB\ANE?4$L#!!0    ( *B.JE2R"_DDN@4  %$@   9    >&PO=V]R
M:W-H965T<R]S:&5E=#@V+GAM;+6:;5/;.!#'OXHF<R_:N2NV).>I$S(#A.:X
MH85IVNMKX2B)I[:5DQ4"W_[D!ZP$R8L)A!=@)[O2KK3Z_2V9T5;(W]F*<X4>
MDCC-3CLKI=:?/2\+5SQAV8E8\U1_LQ R84K?RJ67K25G\\(IB3WB^STO85':
M&8^*SV[E>"0V*HY2?BM1MDD2)A_/>2RVIQW<>?K@>[1<J?P#;SQ:LR6?<?5S
M?2OUG5>W,H\2GF:12)'DB]/.&?X\#;JY0V'Q;\2WV<XURE.Y$^)W?G,U/^WX
M>40\YJ'*FV#ZSSV_X'&<MZ3C^*]JM%/WF3ON7C^U_J5(7B=SQS)^(>)?T5RM
M3CN##IKS!=O$ZKO8_LVKA(H 0Q%GQ6^T+6W[00>%FTR)I'+6$2116OYE#]5
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M7+F60BGX -W=!ZAE%XD;<R5JVT5RS94H. '=MQ-0RRX2IT:YMETDXO ""EY
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M*TL#Y,V<7BS4+H#.-TK9-\=-4?<&)K\!4$L#!!0    ( *B.JE3N?9.UWP,
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M_OF0#R3;F//QG$EUVC:W:_7)1;@V4.^7C,G#0!^YRX^X_G]02P,$%     @
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M@]NFB3V])4U 0QJWDB8@(L6KLCVE"1_$<U1^%/A*7;4?WH9A@P QZ4$;I@=
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M+@+"13B:-O?9$<CE<P2,BW 8+?F\6QN.Z0"41;05[P%1$5YO;>$]'LA5MD4
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M0-1U)@%L$YR1ZY/TI@(J ;0FK335?>!C?U]-M2.0R_0^$+6/@W 'TS>MIOK
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MV7DX_<,;\<EQJ]L"(_9*DRE_"N=7+#>(I/+<<!IG_\$\'VNU@)O$//1SL-#
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M^/M#+%9B^2'_=M/EUU<?_!]02P,$%     @ J(ZJ5'VHEK?1 P  &@\  !D
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M)AQ-Y#"83*U+LZTG=AN>G(J ::Z[9M.]C>D>:/HZ$3SCN;"Z[FF>O(9KIR*
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M 2BIMTFQ",,LJA*9O$QDW.W0$=/60KI1=&PQJDB$,1BO[_DDG271O])LF)]
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M)K2;B\F@\2QKB2AP$!@<AVRKB#OQ "5UJXH9Y#W'7XX="='9@+'FVB!JQK3
M6)-M'!1F"/O0-),HK! XT7AOFDGT- -KZ#6)/&;I%(4I F-JWU23Z+CI-XT:
MB&39<Q(%).+(37;--8D[(3%(+&<85&&'PMAQQ&YJ.-]JQFZ#QK*@J4(*A9'B
MC-W4 !4M=AM%EMA-%5<HS)5#XB+5*=(<75!2MZHP0V',')YN4ITH&&LC;Q U
MUW]@$MG6/]UZL>(X(=LKZ:3N5,8@:=NFBN(2]3\FXZ2*!A1..O;)."ET.%4U
M&WI_4K>HL$)AK!R<<5+WR18HJ?M5+*$P2_;..*G[98E!8IM-BB449LFM=+A^
M:5DDE@<DG+["@M_]O0FGKT*]#X?ZCWAUJ<=Y?-R<Z2:1;^&[KV#@PS!P)9R^
MX>5$TYA3$H"2NG/%!A]F@S/A]/7 K?6I4Q(8)):%X*O@[\/!W[%I\0VAG&J]
M;A#9^G3K+3R<ASBW+;Z>(6C[*5A3=Z:PX</8V"/A]'4DM)M[98/&L_6>XH8/
M<^.0C96O\Z#M:6X-*8CEP,97U/#?<U#FV)#XIM,OS;8I(='6ET%D#6L*-?[Q
MA^:<3)&%'?P&9*=8SPQOT_O-BRHF$;-=55&D8C"I]LTYF4X<;6J:-#:C"DK,
MD:'LFG0RG2O:+#1H+">&3+&'P>QQ!'!F./+2 KA)9%G43)&%P61Q!G!F8DO3
M&:BI.U-H83!:#@F.S$ 23^M'763+D=G6M2X8-X<GGLQ EE[S_:!)U P" =,O
M?MF#@((4<YR9[95X,@.>?&T$3 SKVL9  8KU/R;Y9 H+#,Y ]DD^F?M "Y34
MK^8IOO1<E[<.3#Y[.C.:-[E 2=VO@DH/ALK>R6=5W_:T]K7KA;K&ZS;W9YVM
MV]$+GLW*6^:YA,8J$>L[P9M?-S?9+\K[VXW?+[V38'T?756SOAY_$V82Z3F*
M^9.LLGO4DXZR]8WS]1>1+LL[V.-4B'11?ISS<,JS0B#__I2FXNU+\8#-O?_S
M_P%02P,$%     @ J(ZJ5/MW6939 @  .0D  !H   !X;"]W;W)K<VAE971S
M+W-H965T,3 P+GAM;,V676_:,!2&_XH5[:*5-O(%%"I HI!J2"V-"&S:I4E.
MB-<D9K8#W;^?[:0I+9#VHA?C(MC)>=\\Y_@DSF!/V2-/  1ZRM*<#XU$B.VU
M:?(P@0SS%MU"+J_$E&58R"G;F'S+ $=:E*6F8UE=,\,D-T8#?<YGHP$M1$IR
M\!GB199A]O<&4KH?&K;Q?&)!-HE0)\S18(LW$(!8;7TF9V;M$I$,<DYHCAC$
M0V-L7T]L+= 1/PCL^<$8J536E#ZJR2P:&I8B@A1"H2RP_-O!!-)4.4F./Y6I
M4=]3"0_'S^ZW.GF9S!ISF-#T)XE$,C1Z!HH@QD4J%G3_':J$.LHOI"G71[2O
M8BT#A047-*O$DB C>?F/GZI"' CL]AF!4PF<CPK<2N#J1$LRG=84"SP:,+I'
M3$5+-S70M=%JF0W)U3(&@LFK1.K$R/?FP>QACL;S*?(?@N7"6\X6WKTW7R+O
MWK][^.5YZ,:;>[>S)?+OQO, ?4.K/ (6%_(8(3_%.4<74Q"8I/Q270VFZ.++
MY< 4$D_=Q PKE)L2Q3F#,H6PA5S[*W(LQSXAGWQ<;KV6F[(H=66<NC*.]FN?
M\5OE1,@$ X$%\ 8_M_9SM9][UN^E:EM=M03O2+Z1G1P669%B=;<UY! 3@>@Z
M)1NL&ITC> H!(A4I$D Q)@SM<%H HK$V0IAS$$V([1JQW9BRS^AO^7B=Y#BU
MGJ5;1[NI]\5N) N_.URRXPC'[5KZ5T>^0NW4J)U&U'%CT4[!EG[=!MCCB'=@
MNS5LMQ'V]F-K5G)VW^4\CG!<NXGSJN:\:N2<T_S;JA6TRJ>ZH:%ZM6'O?^WY
M?HW8_\R>G_2/B]]O-Q7?MEY>Q=8G]W1E^.KYLOMO:*J7IW4,WFOL;OM@#[$_
MK;\GE=<AL]U[RUR"F ?[FOJHN,=L0V1WI!!+K=6ZDB:LW*?+B:!;O=6MJ9 ;
MIQXF\ML&F J0UV-*Q?-$[9[UU]+H'U!+ P04    " "HCJI4H+X@DX #  #V
M#0  &@   'AL+W=O<FMS:&5E=',O<VAE970Q,#$N>&ULS9==;]L@%(;_"K)V
ML4EK;,A74R61FL75(K6IU:2;IFD7-"$-*C89D*:3]N,'MFN[-<15KW:3&,S+
M<SCFO(+A@8L'N25$@:>8)7+D;97:G?F^7&U)C&6+[TBBWVRXB+'237'ORYT@
M>)V*8N:C(.CY,::)-QZF?9$8#_E>,9J02 "YCV,L_DP(XX>1![WGCAMZOU6F
MPQ\/=_B>+(BZW45"M_QBEC6-22(I3X @FY%W#L\FJ&L$Z8AOE!QDY1F8I=QQ
M_F :L_7("TQ$A)&5,E-@_?=(OA#&S$PZCM_YI%[!-,+J\_/L%^GB]6+NL"1?
M./M.UVH[\DX]L"8;O&?JAA^^DGQ!:8 KSF3Z"P[YV, #J[U4/,[%.H*8)MD_
M?LH341$@Z!"@7(#2N#-0&N44*SP>"GX PHS6LYF'=*FI6@='$_-5%DKHMU3K
MU#@*YXO9]1R<SZ<@NEXL;\+E[":\"N=+$%Y%E]<_PA!,PGEX,5N"Z/)\O@ G
MX&*O]H* "4G(ABH0X3_Z,RD)]!X!:DM E'^T8@##B00?IT1ARN0G\ '0!%Q1
MQO0@.?257H8)QE_E(4^RD)$CY"E9M4 ;?@8H0/!V,04?/WQZ.8NODU!D A69
M0.FT'5<FK%'_!;<)560-%@HK(H]PV@6GG7+:SO WNF?]BH.3-;C6R1,@XE()
MHJ@@)JNOABWQ'2-@29[T"\97#^#GI9X,S!2)Y:\CP76*X#I'DZ!3BFQ?)%-U
M4Y4I],<Q[ []1PNI6Y"Z3:2VC92I>E72P$[J%:1>$ZEC(_7JI+Z=U"](_292
MUT;JOYET6I!.FT@]&^FT3NK928."-&@B]4]0T(8VW*"&Z[?M.!B4AA2\JP[G
M/#FY;2U:6<>1O0XKW@?_OU*$I2'!XX[D*L9<5DV[HQAA:4JP_:YRS&55EF-#
MP=)C8*/)6 LRE[W83@Y6Z3*PT6:L)0GK/N-BE3X#&XW&6I2P[C0N5NDTL-%J
MW&4)ZX;300YBZ3CPN.5DM>>NB&-;OC0;./C_*A*5WH2.>Y.K(G/9BX3;\XU*
M<T+P7169R]["JAQ]&IW&6I&H[C0.?T>ETZ!&I[%6)*H[C8M5.@UJ=!IK1:*Z
MT[A8I=.@1J=Q5V2N?7& @J^(?N44;VY$5UC<4[VM&=EH4=#J:[7(+AE90_%=
M>K"_XTI?$]+'K;Z8$6$&Z/<;SM5SP]P5BJO>^!]02P,$%     @ J(ZJ5'^0
MUO.V!   *!H  !H   !X;"]W;W)K<VAE971S+W-H965T,3 R+GAM;+U9:V^C
M.!3]*Q;22C/2%K AKRJ-E!1&6VF:1DT[H_E(@Y-8 SAK.Y..M#]^S2,06K";
M-)TO"3B<<WV/[_4),-Q1]I.O,1;@.8X2?F6LA=A<6A9?K'$<<)-N<")_65(6
M!T*>LI7%-PP'80:*(PO9=M>* Y(8HV$V-F.C(=V*B"1XQ@#?QG' ?D]P1'=7
M!C3V _=DM1;I@#4:;H(5GF/QN)DQ>6:5+"&)<<()30##RRMC#"\]QTX!V17?
M"-[Q@V.0IO)$Z<_TY":\,NQT1CC""Y%2!/+K%[[&490RR7G\6Y :9<P4>'B\
M9_^2)2^3>0HXOJ;1=Q**]971-T"(E\$V$O=T]P\N$NJD? L:\>P3[(IK;0,L
MMES0N #+&<0DR;^#YT*( P#LM@!0 4 O 6X+P"D SEL!;@%P,V7R5#(=O$ $
MHR&C.\#2JR5;>I")F:%E^B1)UWTNF/R52)P8S?SI_.9N"L93#\SNY@_W_L/-
MO7_K3Q^ ?SO[>O?#]\'$G_I?;A[ [.MX.@<7X'LF)@XOQK\PD\4!QER6S29=
M1PX>.0Z!H,## C,Y80RFLGIGF!$:D@68X 0OB0#7E L.@B0L1^Z>(K(*<I)/
M$AV0B'\>6D(FF4[56A0)3?*$4$M"$(%;FH@U!WX2XK!.8$EU2HG07J()4C)Z
M>&$"!_X-D(U@PX2NWPZW&^#>F^%PH,C&*1?<R?C<M@4O>G8O^RP*I.#_@<>$
MR"4%<Q$(S!5QW#*.F\5Q6N+(KBQK@"2K>A5\*J)_SNI $:U31NLHL_((7]!M
M(@"3TV\J&C4<F:CS5]/2JF&.";M-,$\-<U]'JR7=+9/N*GG\YXW</>6BI4D#
MNI3[L-BR!,C5W<A5!0'G6/ F-=2\'=.V&]50P[HM(GIJ6$^C1J]4HZ?DN2]$
M6-!8FB+/=A) DH5T0]Y8$FHZNTV$TV#>T;":"/U2A+Z2YR:1'8>Y #+MD(BT
M\=HZ0DWDFKWFCC@-YJEA#1572W]0IC\X:M-Y[2V*(-"N/--^WVZCP2.S.V@4
M5XM3MPH\<'UXWF;1\+5VR_&X>D:HR@B=J_(U3*VE?SRNGDMET? TCY[2Y.+1
MG)OY@"I4Y=+P3]@TK'P:OM.H-7AH.KWFQ='ANOW&C4F#0Z;SLE7KF5=F#3_*
MK37$R.RYS9+H<(,62=0XQW1?_NNI2U(Y-CRS96OXY+[:L@NI<8YI-[N6-EY?
M71R5;<.S^;:&J7TG/@WG'8^K:U!Y-_Q \T:5>:-WFK<&#\T>:A18BWNU<]4S
MJ,P;G=F\-7RR;9SFC+0XY=*CRKS1V<Q;P]1:_L?CZKE4YHW4YIT;M/1+N;\3
MAF,L2^W0R%5!*MM&?\*V467;Z)VVK<$CTV[^QZO!R9VYT=L\#<Y]?6=>S[RR
M;?11MJTA;J_4TW#>\;BZ))5MHS/;MH:O78D3[[6/Q]65J&P;]3_0LBIG1(-W
M=I\:C\Q.\Y]F+>Y5U]:?.5:FZZC-[^B2T?"UELSQN#PCZ^ 1>HS9*GL5P4$F
M>_ZHN!PM7W>,LX?\+\8G\-++7UI4-/D[E-N K8B\CXOP4E+:\F[1 "Q_+9&?
M"+K)'M0_42%HG!VN<1!BEEX@?U]2*O8G:8#RY=#H?U!+ P04    " "HCJI4
MEH)_Q($#  "#$0  &@   'AL+W=O<FMS:&5E=',O<VAE970Q,#,N>&ULS5AM
M;]HZ&/TK5J1)F[21."F43H!$::HAM30J=-/5U3Z8Y*%8=6)FF]%)]\=?.Z0)
M78E3KG17OA []GG>SI,<G-Z&BP>Y!%#H,669[#M+I5:?75?&2TB);/$59'IE
MP45*E)Z*>U>N!) D!Z7,]3VOXZ:$9LZ@E]^+Q*#'UXK1#"*!Y#I-B?AU#HQO
M^@YVGF[<TONE,C?<06]%[F$*ZFX5"3US2RL)32&3E&=(P*+O#/'GD>\;0+[C
M*X6-W!DCD\J<\P<S&2=]QS,1 8-8&1-$7W[""!@SEG0</PJC3NG3 '?'3]8O
M\^1U,G,B8<39-YJH9=_I.BB!!5DS=<LW7Z!(J&WLQ9S)_!=MBKV>@^*U5#PM
MP#J"E&;;*WDL"K$#P"<U +\ ^*\%! 4@R!/=1I:G=4$4&?0$WR!A=FMK9I#7
M)D?K;&AF:)PJH5>IQJE!%$ZFXYL)&DXN4'0SG=V&L_%M>!U.9BB\CJYN_@I#
M=!Y.PLOQ#$57P\D4?4+#6*T)0T,I=9L-&>,Q,91(]/X"%*%,?M";HH+J<\A@
M016*&,EDSU4Z9N/9C8OXSK?Q^37Q74#<0@'^B'S/QWO@H]?#O>=P5U>J+)=?
MELO/[9W4V+O+J(($3151(-$_:$3D$I$L0;$9P(\U_4D89$I:? 6EKR#W%=3&
MOM!WDN<5S)W=J"4(%'&I!"@J0#]6ZK=M,S)G@&;PJ!<T00_H[RMM#(T5I/*[
M);B3,K@3:R&>@IL77E?:ZT>T A'K6/3SC_C"/**F3\P2(GFSD*I9]K6"W25N
M>=Z[?2UP,.Q9QNTRX_9!U(>:;/4+28C7@BH*-LH[I8_.\5%^6@9W^N<IM[L,
MO#K.&W!G#:1WRYR[!Y%^21_UE&8Q3^%UU)^5GLZ.CWKL53+A_7GR&WQV]K!8
MO/0;@'O:YGG>._*(K:8F//MTUYJVBD+_MS<^KN0%^T?8!94BX> -NL#NL[X)
M[+B@J0<JJ<-V!7G1 X>\^G&E+[A]A-Q7TH0[;\"]W6=0J_D-0+_;Q'ZE>MBN
M)2_8/UP#<"4WN'N$/5!I%#Y[@QZP^]RGY44/V('MIA[P*_7S[8+RH@=R-FRF
M*X'Q\?$Q[N^<=^P'GO^%\0:??NU3WP#$M?_UW9T3LOD\<4W$/=4%9+#0EKS6
MJ7XUB^V)?SM1?)4?FN=<Z2-X/EP"24"8#7I]P;EZFIAS>/G=9? O4$L#!!0
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M0(P?F*@'(2,Q!#KUH&"$'D3&M/)$O6# 4KSON: ]T$0L'YBH#"$S,00ZE:%
M\3"@3L=4!/6>@T>^8A@P%N][,&@//!&]!R9J0\A3#(%.;2CH?AI6^['L=,PZ
MSQGZ[,'JHR(_1Y4K-V>)>"S'6(=5J\W6'[ZX_J9(G^N/([Q/BR)=UE\N1#07
M6150_OPQ38OM-]4G'.X^ _/D_U!+ P04    " "HCJI4"]!#]A #  "S"@
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MG4 [!SQ?*&5W&Q>@O>^R?U!+ P04    " "HCJI4GS.32&4"  !:!@  &@
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MPOA?6%>QK0"2E;&JJ,"40<%E^<^>*Q^V %%O!R"J -%[0'<'H%,!.H?.T*T
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MJN"R"W)9MN9RHD5NN]M<:.B5=KB!ZPR39@%\7PFAWR>F8=87I-$_4$L#!!0
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M=',O<VAE970Q,3,N>&ULS9IM4]LX$(#_BB;3FZ$SC6-+=EXZP P0>NT'"D.
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MFACW[S+ KQE ?,@ RV</1NI=OB]WS1_4YN\2 AE@2>S!*-6-VHSQ?6SHUVT
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ME 7@][64YC"Q >K6;?8+4$L#!!0    ( *B.JE0.(7C?- ,  $@)   :
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M2J4!P.]+(?3;PFQ0_>MB]B]02P,$%     @ J(ZJ5 >IL3YS!   *Q   !H
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M>\OP<Q)BZU!9?*=P5)TQLE*>A/AA)U^RN1=81L @U1:"F,<!UL"813(\_FE
MO79/Z]@=OZ#_4HDW8IZ(@K5@?]!,%W-OXJ$,<K)G^E$<?X5&T,CBI8*IZA\=
M&]O 0^E>:5$VSH9!27G]),]-(#H.87S& 3<.N.\P/.,0-0[1M0[#QF%81::6
M4L4A(9HL9E(<D;36!LT.JF!6WD8^Y3;O&RW-6VK\].++;^O?[^_0U^6?=QMT
M@S:FKK(] R1R] BIX"EEE%09,BL)Y" E9.@K>49+I4Q9?B=L7[]?,E-#A*>
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MS5GR2L#GR2"]? +V3OKT\@%PH'PE4!,2OZW?\Q745](YNANDGT_ WTF??CX
M/J6OJ'/,7 B]J0_3#5JI4MKFQ+E]VA[87S?'U#"\.>U_Y'J328-RL7;0^&+B
M^-'- 7IS8]6N/K1>*FM545]N!4^%K@:X[]=*V;>;:H+VWQCS?P!02P,$%
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MTSF7A@C(;.AP\,5FUTV3- :JRA?F2:$M<S\L[+L"VCG8]4PIO!@N0?=2Q7\
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M--$,)UW,']8Q$T_,OZ^*MRA*CA")" ;,S\+FU^D_B(C6.@*LSU^RKIY_'(\
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M:&5E=',O<VAE970Q,S(N>&ULO9M=;]LX%H;_"F', C/8;LTO4=(@"=!8G9D
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MHY+(*NF/&MCIV=EY6@+G%D%>YVL5%P;: ^9YTPVTI]M>U2X8).K3#(-D* %
M3L].SINL#4SSU7B<VN( 5/-<&&8/J.=--\R>P>02[?9K5 5J 6I4>0.&60!$
MA1VBO01\5T4D 'G"A7D6P#XQW3P+W?!23REU%D:1NAQ,(C'P;$\ 1X6=HVH^
MQLLB ;03+FRR  2*Z399Z.96O2>,2R*KI#_JSK?*=I"J&;"71P)0)URX8@$@
M%--=L=#=+&$JETPB0M4,F$0#QE@ 5(4=JFH.)A5+/D#0=^&>?0"B/]T]^[KC
M]9GZQ,(D\E5 &7L:6!X^P-6WPU5;'N>63CXPT'?AH'W@HC_=0?NZZ]5VP)@T
MJGLV:0:^E?8!L/Z(=\[3*D:W<M7<JVVA /CY+IRSW]EP,]TY^[KG95BM6PTB
MZJE?-AA$)!PHG7P K#_BG[O1_Z[2R0<0^BX\=0 D#*9[ZF#<4X]+(JND/VK@
M:3#BJ95,C!=- ? N<&&D X!?,-U(!X;OD[4581#I*\(@&EP1 8 T&+'32A[L
MI5, G M<>.D *!A,]]*!S04?,C JB:R2_JB!I8&=I6KT)Q5-06?WH@NC'0 *
M@^E&.]#-L9:444EDE?0W2@)00SM0M25Q;KD4 OU"%_8Z!"*&T^UUJ)MB-1'C
MDL@JZ8\:N!K:N1HEK[(HD^>D7A&'K?[6\ /T0A>N.@08AM-==:C[X=JR$34#
M!A55OZ"+3"K>N9'TAP]L#>UL->7ANXJG$( 8NG#<(1 QG.ZX0]TGAY2IB3&8
M:4RUU6&RW)T=:OW1=_9TCVSJ-B?FG+W>W<W>3G9[X\YV;_P#^[VQ;I%57)VA
MB>P:9>B=K=[8#MJ!C(QL <>=/>#8R29PW-D%CG]@&SC6/;):W)HTZED3DV9H
MRS'N[ #'=NX.9&/:SG#<V1J.G>P-QYW-X?@'=H=C@Y<6ZO,IDXH2]9F(4>4-
MIJJS/1S;03RT<,[>-HX[^\:Q"X=.N@=FR'2/?FS;/6FEW6:,(FWKODDTE)O>
M\9OS>-S<\X\G+O-L*;.J:!\JHOND_%+_\QC!=^@QWZ)'F9U3M9'N01KBPMB3
M[I$;8B]!^_,LZGF^0UM9-._%+]*<3GN/G+W'^&^F(Y^C+<E RVBL)0OUEON0
MS#O'<^L0OK3'G$NTS'=9M3_;>GKW=);Z0WN 6'G_NCECW1[[A6[V![1OX^(E
MR4J4RN>Z2_R^>4!:[(\\[U]4^;8]!/R45W4>VS_7,E[)HA'4_W_.\^KXHKG
MZ>3YU?\!4$L#!!0    ( *B.JE3![GZVX00  +P:   :    >&PO=V]R:W-H
M965T<R]S:&5E=#$S,RYX;6R]F5]SHCH8QK]*QMF+W9G=0OZ(V+'.M-KV=,_8
M=NIV]SJ55)F%Q .QMM_^!*1$0T@[7G"C@,_[)ODE/O"2T59D?_,58Q*\I@G/
MSWHK*=>GGI<O5BRE^8E8,ZY^>1992J4ZS99>OLX8C<J@-/&0[P=>2F/>&X_*
M:_?9>"0V,HDYN\] ODE3FKU=L$1LSWJP]W[A(5ZN9''!&X_6=,GF3#ZN[S-U
MYM59HCAE/(\%!QE[/NN=P],I"8J 4O$[9MM\[Q@40WD2XF]Q<A.=]?RB1RQA
M"UFDH.KKA4U8DA295#_^JY+VZC:+P/WC]^Q7Y>#58)YHSB8B^1-'<G76"WL@
M8L]TD\@'L?V'50/J%_D6(LG+3["MM'X/+#:Y%&D5K'J0QGSW35\K$'L!,&@)
M0%4 ,@-(2P"N O!G T@50$HRNZ&4'*94TO$H$UN0%6J5K3@H89;1:O@Q+^9]
M+C/U:ZSBY'A^>3V[O/T%;FZO[AYFY[]N[F[!#W#-Q#*CZU6\ #=\M[C4)'T'
M#^R%\0T#7Z=,TCC)ORGMXWP*OG[Y!KZ F(-9G"1*F8\\J3I7-.$MJHY<[#J"
M6CH"$9@)+E<YN.01BPX3>&I4]=#0^] ND#/CE"U. (;? ?(1M'1H\OEPWQ(^
M_70X'#I&@^N)PF4^W)*O0I\#RB.0"+[\D:@_3 1HGC.9@Z<WL-23EK&EF@5'
MJZ1NE92MD@]:M<WG+K)?1A;V\C(."28C[V6?L47DH\&A:&H1!3ZL10<][]<]
M[SM[_G@R/RE9W6]8)@5XB!?" 22HTP8=3L.@;G5P]#3L(H,]>"0,#<(3BV@P
MA,8T-$5]&!#[-(1UST-GSR>KF%,'@6&=9]@A=^AK>_2/)E^%'E =^@9YBP@3
MD[Q-%(1V\G#/VJ&;/>4T<L&'2*="7>+7I@?Q\?BQA2PV\5M$N('?)AJVX-?6
M"=W>>2\21<N%07L9['>)7YL=#([''S2@H;"Q^BTB')KX;:(6^X?:,J';,V?L
MU6WY4'L8#+O$KST/#H_'/VQ"ZP<F?HL(]4W\-E&+^2!MG,AMG#_IFKHH(&UC
M"'9('VG/0^AH^E7HX9(U%[]-A(PIFMI$I&7Q(^V;R.V;5QGE"^;"H&T,D2[Q
M:\]#[@<X)_Y^$YH?FOB;(C@8FOAMF=KP:]]$'_CF)L]CUYT7:1M#@R[Q:\]#
M[@<W)_ZP239HK'Z+")M/_C;1WDWDL._:-Y';-R^7;VOIJKFTBV&_0_I8>QYV
M/[JYZ%>A!\P:SF\1(?/A:&H3P1;GQ]HWL=LWKUF64O[FXK!7]'99]6)M>OCX
MNK<*/>1OUKTV$2$F?UNFEM6/M7'B#RI?'DN%Z-^8+R.1NG!H/\-=5KU8FQ\^
MON[%S7(5PL;?H"D*S3NP-5&_91:T?V*W?\[7-'9"T&Z&NRQ]B?8^<GSI2YH%
M:VC>?RV:@?GH;\L3V-$3;9[$;9XWDB8N^R':RDB792_1MD>.+WM)LUAME%T6
MS< L>FUY6E8]V7M=Z/;-.[EBF0N!=C'29<E+M-61XTO>*G3_1>70M).)3=1X
M[K&)AB9];^^U?LJR9;D]DH.%V'"Y>PU>7ZVW8,[+C0?C^@4\G>XV4G2:W;[.
MC&;+F.<@8<\JI7\R4#W*=ELENQ,IUN7FP9.04J3EX8K1B&6%0/W^+(1\/RD:
MJ#>LQO\#4$L#!!0    ( *B.JE2$WM*\WP,  -,3   :    >&PO=V]R:W-H
M965T<R]S:&5E=#$S-"YX;6R]F&UOFSH4Q[^*A?:BD[: ;?(T)9&Z=.V-U+11
MLM[[V@$GH!F<:YRF_?8S#\6,@!>I%6\"AG..S_G%_/TP.7'Q*PDHE> E8G$R
MM0(I#]]L._$"&I&DQP\T5F]V7$1$JJ;8V\E!4.)G3A&SD>,,[(B$L36;9,]6
M8C;A1\G"F*X$2(Y11,3K=\KX:6I!Z^W!.MP',GU@SR8'LJ<;*I\.*Z%:=AG%
M#R,:)R&/@:"[J74-O\WQ('7(+/X-Z2FIW(.TE"WGO]+&PI]:3IH19=23:0BB
M+L]T3AE+(ZD\_B^"6F6?J6/U_BWZ;5:\*F9+$CKG[+_0E\'4&EG ISMR9'+-
M3__0HJ!^&L_C+,E^P:FP=2S@'1/)H\)991"%<7XE+P6(B@-T6QQ0X8 N=<"%
M \X*S3/+RKHADLPF@I^ 2*U5M/0F8Y-YJVK"./T;-U*HMZ'RD[/-C[OECX>?
M8/%P^[A>7O]</#Z K^".\KT@AR#T" .+.!\MBOH7<,_C_==[1=X'UTE"90*N
M;J@D(4L^*[^GS0VX^O09? )A#)8A8\HGF=A2)9IV9WM%4M_SI%!+4C?4ZP$,
MOP#D(-C@/K_<W?G3W59X2D:H9(2R>+@EWIH^T_A($T!B'[ 4 ,L D!S ]A7L
M2UYJ:.]5T89><=DKSGIU6WJ]KW?4Q#$/T<]"I%_L\PSVQZ.)_5REU60T&)9&
M?V3GEMFYQNR>>IM>QF-UI$)RL X];BBZ7X;M=XAZ4/8Z>#_J/,2@0G'HXAKI
M!AO4;P8]+',;&G-;",H4#$.5HS+2J$.VX[+7\?O9CL^X83RHL6VP0:-FMM#1
MZN<8LYN3F/C$4":L""GL$"_4X@31^P$7,:KT(*J/WB8CZ+0@UC(&S3JVXG\9
MOU!K#G2[1*Q%"?8_ ''__./OUPF?VXQP"V M7M"L7G=4S<[QJZE2+39PV"5A
M+4UP] &$1^?TAG7"#39M0UA+&#1KV)*^F*<WI 4'.1T"1EJ=$'P_X")&%9Y;
M'\)--N-FP*BRP#)KV*T@L4=-A6JY0;A+P%J;D'E!=!E@]WP2&]<!-]BX+8"U
M@B&S@LV#,#9-<TBK#1ITR5<K$S*O@R[C.SQGY]3Y-MC %KY:OY!9OS94;$,C
M8"TV:-SE;D,K$S8OA2[;;SAG\%!=(1IL<(L$8ZU?V*Q?"TF8:8K#6FMPI[NY
MRG;N(_9S^)POK/-ML&E91& M7]@L7X\RH,)4IY8:W.46#FMAPA^PB2MB5/?"
M0[?.UVB39V=73ES2XZXE$?LP3@"C.^7D](;*6^0G2'E#\D-V"+/E4O(HNPTH
M\:E(#=3['>?RK9&>ZY3G>+/?4$L#!!0    ( *B.JE3AS6Y1VP(  .P)   :
M    >&PO=V]R:W-H965T<R]S:&5E=#$S-2YX;6RU5FUOVC 0_BM6IDV;U)(7
M4J =(/'2%S315K3;/KO)D7A-[,QV2O?O9SLAA8X$)K5?$OOLY_'=/8GO^BO&
M'T4,(-%SFE QL&(ILS/;%D$,*18ME@%5*TO&4RS5E$>VR#C@T(#2Q/8<IV.G
MF%!KV#>V6S[LLUPFA,(M1R)/4\S_C"%AJX'E6FO#@D2QU 9[V,]P!'<@OV>W
M7,WLBB4D*5!!&$4<E@-KY)Y-70,P.WX06(F-,=*A/##VJ">S<& YVB-(()":
M JO7$TP@2323\N-W26I59VK@YGC-?F&"5\$\8 $3EOPDH8P'5L]"(2QQGL@%
M6UU!&=")Y@M8(LP3K<J]CH6"7$B6EF#E04IH\<;/92(V &ZG!N"5 .\UP*\!
MM$M ^U" 7P)\DYDB%).'*99XV.=LA;C>K=CTP"33H%7XA&K=[R17JT3AY/#N
M_')^?GV/9M<7-XOYZ'YV<XV.T1S_8AQ-S/' !?H\!8E)(KZHM;45!8P&0"7'
M1L!CM( GH#F(OBV58YK>#DHGQH437HT3KH?FC,I8H',:0KA-8*N(JK"\=5AC
MKY%Q"D$+M=TCY#F>N\.AR>%P9P=\>C#</6V(IEV)U#9\?@W?2*6;");S ,;
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " "HCJI4R)JZZA,)  "#60  #P
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M*C$N\OU3FCW4'R._Q97R-9HXO/P\!/%]\7_"F&\VZ4H,\]5^)[+J$,=";&O
MK'Q,G\H.RY*=N.Z\O*7^2O)_!.O#UZLDEQ*LXGTJ7RB"=4-(1^//PG@V"8;>
M@@_9C3?Q0I^S^);S1:P =@%@MS5 ]FZ>*) ] -E[0\AX(7],>2@!9R,VF_-(
M@>P#R'YKD/YL.E<@!P!RT!ID?.NID;0 I-5>)+WX5H&T :1-"SGDL1\%\T4P
M"VNPFV4<A#Q6>[4#X!Q:N#@8A\$H\+UPP3S?GRW#11".V5Q&U0^X"ND"2)<6
MTO/_6@9Q4$<POF"2C(=Q3>F-(RY;7!W #32"&[28$8\7T=)?+",)=\&"<,''
MD5=37["8J_W:A*(A-LW("R)VYTV6G$VY%R^C0Z=1\9!F3&+/!.&=Q)E%^M5G
M(JF8Q%:91[4\%G]?L/FDZ2CAD'%Y2<[KP*F02"HFL57DY>:%X^!FPID7Q[65
M:\SQ;#;\%$PF*B6RBDFL%3G&1$LY6-=LL\4MCYB_C"(91MFMO9M Q41>,8G%
M,@I".;]IQI@HDF%]W4604$QBH\SK\4_:I [B?"8'';X(#KV8\>E<:VND%I/8
M+1,YNNB=&#G$))9(/6OAES<2:=A,LV0,F[%9G5TC>W2)[2%[QG*ZG#13F>>>
M(2DC?ELW]ITJN2ZR1Y?8'E)RW(O\V^;B&_([/ID=#X-=F*40Z^,0.OZY;E]^
MP4*ND2&+=(DM$H2R03E;>)^U3M%%TN@22V,RBV,FW=;,Z;5K#$FB2RR)>#F?
M3YKQS)LT$WDVFLP^L6$0^Q)XJ6(B272))3'A8\DG)P<^YT/I"JU5D1^ZQ'Z0
MU]DT6!Q2H;J;RC2IGM7S\&A*WT5VZ%)G'GS<&"L(1[-H^FHH1JKH4JMB>1/+
M^5WCT[LC\?>0(WK$CH#9VGU7Q42.Z!$[ F/V5$RDBAZQ*F!:J4<3WM(B]L:9
M?(V]6R02I%0QD4IZY/G'K[SM!>T/E0T)I4<L%)C L7<J)A)*CU@H.(5C*B;2
M2X]8+S"'T_L-$DR/6#"G<[B3UR:238]8-C"9TZ+91^KI$ZOGD,R=BEX?J:9/
MK9HS6=TSJ(J)5-,G5PU([O1&1JKI$ZOF7')W(IIP_818-:]SO)/7)3).G]@X
M:K)W$@YYID^=N&A9WTD\Y)<^L5]@^J=W%N27_MLG,"=#B>32)Y;+F;4G=LG"
MI"C41=L!DLN@U;RFKV(BV0Q:S6L&*B:2S8!8-AC34C&1; ;$LL&8MHJ)9#,@
ME@W&=%1,N%Q/?<\,8KHJ)E+/@%@]"/.^6;W]A8D4-*!6$,0T54RDH$&+J_?W
MIFK* ;+0@/I^&L14[P=9R$)6BQ:Z-U4+6<A"5HL6NC=5"UG(0E:+%KHW50M9
MR$(6L87P34#MVD06LH@MA#&U:Q-9R")?WD>8VK4)MXT16PCNU-$R# M9R"*V
MT+D[OY?,*TNA;ERUD(4LZAMM"%./)K*016RA\YA^D9?J?70;6<@FMA#$U*)I
M(PO9[>PB>\94QTT;6<@FMM!YS%%>B%3%1!:R6UKC:3#U1D<6LHDMA#&U1D<6
MLHDMA <D#1-9R*;>9 8Q5:?;</MRFQ;2G&XC"]FM66B4I(6Z>&8C"]G$%E*7
M22]9O-_MDN('RS<LR+[JAU$<9"&'V$)XQ?12Q406<H@M!#&U<=-!%G+(]S2#
MA5T=$UG((=^AAC#5<=-!%G+:W.FLC9L.LI!#O@2$,-5QTT$6<H@MA%?SM49'
M%G*H+71Z-?]E"%4QX7&:=C8=R%EQ+H=W=<'%019RJ'.AL]$469JKT721A5SJ
M7.AL-/=%(3(5$UG(I<Z%4#2UX=U%%G*I<R&(J?9T%UG(I<Z%SF%^$NG#HSI#
M<I&%7.I<Z!SF-*GVA9I9NLA"+O76-[B]2&MT9"&7V$(84W6ZBRSDMGGR1G.Z
MBRSD$EL(8ZKWWEUXK+/5K6_J"K!IX(.=U-D0!'4T4'BTTZ#.AR"HJX'"0YX&
ML8L0J+X.;!KPZ*=!??83@IH:*#S^:5 ?Y3ELT+QD46W)RWQSN2_%8:&@9$FF
M@<(3H :QD7Z!-EN0ZN(@[-U05$FZU?9-F08\ &J0'^YYIIR(1,:1?Y>?58KR
M!54#A6=!#6(E'8%ZZW5:OR?9LB#;:%-YTX"G08TW.0[Z"W2TE],DP>;)C_KO
M2J:!PH.B1DLG19\O6144UQN@+C@ 0.NL6 /%%0?:VJ4M0:M\I8%"+5$7'P"@
M4;PL-5"H)>J2!'A#>4\#A5JB+DMP=DNY;'KY\1HHU!)U98(3F\H/B.O]5K!<
M X5FHJY-<!+TMTLU4&@FZC(%VA[X^@[8[BG/FK$^W[ ;O>FAF:@+%1R!_F[T
M#>.;C0X*S41=P^ (=)%\;P!758TZ5>\NFK"6@4E=S !$-!(KK3/!:@8F=3F#
M(]#C*:D&BJOBD"\A:: CL19%,\=;Y3O!M"HTL,J!^99E#FIMRN;.5NDV;=[)
M8@T4FNEM:Q\<7:6^WIF@F:C+(;P"U:]2#12:B;H@ CZXHTU*8'T$D[I PJO*
M#7I0-5!H)NHB";"2@[8,;\**"29YR803AZ&4F*J@L(*"25Y"X21H+![JOV.1
M!@K-1%Y$X21H)+Z*;"_T=!E643"IRRB<!AV+_*%(GAXUA<(Z"B9U(04(JBW3
MF;"2@DE=2N$TZ#3Y)R^8O]>R4%A6P:2NJ_"J4,KY<1065C /E16NFK>7'S^L
MQ2;-Q#J4_Z24SZ^2[6I>L/K'\[QA4,_#-_OMUI?/S;))GJQ?:@B_U#_^^!]0
M2P,$%     @ J(ZJ5(/U682N P  NT\  !H   !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<\W<2TX;012%X:T@+R!=M]X5 :-,F$;9@ 7-0P%LN3M*LOL@
M,H!SE4$FJ/^1U4:4S\2?D.G?YU_GQ_WZ<'A>[A^.R]FOI\?GY6)WOZ['S].T
M7-_/3_OET^$X/[_\Y/9P>MJO+Y>GN^FXO_Z^OYNG&$*=3N_/V%V>OS_S[-OO
MX_P_)QYN;Q^NYR^'ZQ]/\_/ZCX.GGX?3]^5^GM?=V;?]Z6Y>+W;3K\>WIY?I
M]<$^O9R\.[NZN=B=KFYL-VT]*,J@N/V@)(/2]H.R#,K;#RHRJ&P_J,J@NOV@
M)H/:]H.Z#.K;#QHR:&P_R(+*& "3'-8 K4VY-H#7IF ;0&Q3L@U@MBG:!E#;
ME&T#N&T*MP'D-J7; ':;XFT O:/J'0%Z1]4[ O2.[H]M@-Y1]8X O:/J'0%Z
M1]4[ O2.JG<$Z!U5[PC0.ZK>$:!W5+TC0.^D>B> WDGU3@"]D^J= 'HG]V$)
M0.^D>B> WDGU3@"]D^J= 'HGU3L!]$ZJ=P+HG53O!- [J]X9H'=6O3- [ZQZ
M9X#>6?7. +VS^[ ;H'=6O3- [ZQZ9X#>6?7. +VSZIT!>F?5.P/T+JIW >A=
M5.\"T+NHW@6@=U&]"T#OHGH7@-[%_;,2H'=1O0M [Z)Z%X#>1?4N +V+ZET
M>E?5NP+TKJIW!>A=5>\*T+NJWA6@=U6]*T#OJGI7@-[5W6P"T+NJWA6@=U6]
M*T#OJGI7@-Y-]6X O9OJW0!Z-]6[ ?1NJG<#Z-U4[P;0NZG>#:!W4[T;0._F
M;A8$Z-U4[P;0NZG>#:!W5[T[0.^N>G> WEWU[@"]N^K= 7IWU;L#].ZJ=P?H
MW57O#M"[J]X=H'=W-WL#].ZJ=P?H/53O =![J-X#H/=0O0= [Z%Z#X#>0_4>
M +V'ZCT >@_5>P#T'JKW .@]5.\!T'NX6 >@MP6?ZP#\MN""G0 0W()+=@+
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M_V0IZFY^ E!+ 0(4 Q0    ( *B.JE0'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ J(ZJ5,PTA!?N
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ J(ZJ5)E<G",0!@  G"<  !,              ( !S $  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "HCJI4%14CNT($  #%$
M&               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ J(ZJ5&+)JZ%,!@  MQ@  !@              ("!A0P  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( *B.JE3P. #M/ (
M $\%   8              " @0<3  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    " "HCJI4FA7!L-4&   C'@  &               @(%Y
M%0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ J(ZJ5,HQ
M<T5H!   BP\  !@              ("!A!P  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    ( *B.JE2@L9I18 <  /\E   8
M  " @2(A  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "H
MCJI4WD]$Y-()  "T+@  &               @(&X*   >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ J(ZJ5#7%$G7Z P  Z @  !@
M         ("!P#(  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   ( *B.JE3@XGTY@"H  -N%   8              " @? V  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " "HCJI4^%O13S -   U(@
M&0              @(&F80  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    ( *B.JE3Z_O[O;04  -4.   9              " @0UO  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ J(ZJ5'7Q&L56
M#   (24  !D              ("!L70  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    " "HCJI44>3YTV$"   &!0  &0
M@($^@0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( *B.
MJE0=%;=[ P,  'H&   9              " @=:#  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ J(ZJ5,(FH4:''0  H7$  !D
M         ("!$(<  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    " "HCJI4#@$3#L\"  #L!0  &0              @('.I   >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( *B.JE0-HSE[41P  '&'
M   9              " @=2G  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ J(ZJ5(3G'!=@$P  %#\  !D              ("!7,0
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "HCJI4L8YI
M.$@$  !Z"@  &0              @('SUP  >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    ( *B.JE1-^7V1T!   #<X   9
M  " @7+<  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
MJ(ZJ5+HV=R$D P  "0<  !D              ("!>>T  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    " "HCJI4/!,G4K@"   Z!@  &0
M            @('4\   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    ( *B.JE1L)45Z2@0  "P*   9              " @</S  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ J(ZJ5(V4EVWC%0
MR4,  !D              ("!1/@  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    " "HCJI4Q\]YO/T#  #:"0  &0              @(%>
M#@$ >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( *B.JE3/
MKSGP>@(  &D%   9              " @9(2 0!X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ J(ZJ5"]EM/,7)P  >8<  !D
M     ("!0Q4! 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *B.JE2,C/?SG04  ) -   9              "
M@<"1 0!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ J(ZJ
M5!VQIK@B!   '@H  !D              ("!E)<! 'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    " "HCJI4C'IT%4(&  !L%@  &0
M        @('MFP$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   ( *B.JE23#@7B? (  "$%   9              " @6:B 0!X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ J(ZJ5.0KE]?P @  &P8
M !D              ("!&:4! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    " "HCJI4SN-C$0(&  #L$@  &0              @(% J $
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( *B.JE0:.K%1
MX0(  -L%   9              " @7FN 0!X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ J(ZJ5(+H :KO!   @0P  !D
M ("!D;$! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " "H
MCJI4PXGHU]()  !>(P  &0              @(&WM@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( *B.JE0^4S/-; 0  .L+   9
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M970T-2YX;6Q02P$"% ,4    " "HCJI4)(KKH9<'  !F%0  &0
M    @(&OTP$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (
M *B.JE3DTR$SM0(   $&   9              " @7W; 0!X;"]W;W)K<VAE
M971S+W-H965T-#<N>&UL4$L! A0#%     @ J(ZJ5)A0#FR) @  6P4  !D
M             ("!:=X! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"
M% ,4    " "HCJI4#2!7*6L(  #E%@  &0              @($IX0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( *B.JE1/G$SI&P(
M !8$   9              " @<OI 0!X;"]W;W)K<VAE971S+W-H965T-3 N
M>&UL4$L! A0#%     @ J(ZJ5"UB1RHD @  '@0  !D              ("!
M'>P! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " "HCJI4
MN.+UP]T#  !Q"P  &0              @(%X[@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4R+GAM;%!+ 0(4 Q0    ( *B.JE2B8Y,EK@,  ,X+   9
M      " @8SR 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%
M  @ J(ZJ5&!*[55A P  +Q   !D              ("!<?8! 'AL+W=O<FMS
M:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " "HCJI49]<>OQ<$  !R&
M&0              @($)^@$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+
M 0(4 Q0    ( *B.JE098X,H) 4  /(8   9              " @5?^ 0!X
M;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ J(ZJ5+:BDW?:
M!   !A,  !D              ("!L@," 'AL+W=O<FMS:&5E=',O<VAE970U
M-RYX;6Q02P$"% ,4    " "HCJI4-<EQ C4"  !^!@  &0
M@('#" ( >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( *B.
MJE3@/04D9@(  +L%   9              " @2\+ @!X;"]W;W)K<VAE971S
M+W-H965T-3DN>&UL4$L! A0#%     @ J(ZJ5+<O[>)5 @  ) 4  !D
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M=#8T+GAM;%!+ 0(4 Q0    ( *B.JE1U%-X>UP,  #L,   9
M  " @6\> @!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @
MJ(ZJ5);"UR.6 P  8@P  !D              ("!?2(" 'AL+W=O<FMS:&5E
M=',O<VAE970V-BYX;6Q02P$"% ,4    " "HCJI4ZRO/7TX#   4"P  &0
M            @(%*)@( >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4
M Q0    ( *B.JE2K_$O.V04  +HC   9              " @<\I @!X;"]W
M;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ J(ZJ5/*]2%/* @
MZ@8  !D              ("!WR\" 'AL+W=O<FMS:&5E=',O<VAE970V.2YX
M;6Q02P$"% ,4    " "HCJI4KS!)^I #  "P#   &0              @('@
M,@( >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( *B.JE0L
M?E_IY (  (P(   9              " @:<V @!X;"]W;W)K<VAE971S+W-H
M965T-S$N>&UL4$L! A0#%     @ J(ZJ5&0$[X1L P  ] H  !D
M     ("!PCD" 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *B.JE0-U$U=I@(  +T(   9              "
M@4]+ @!X;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ J(ZJ
M5)X;=C-5 P  \PH  !D              ("!+$X" 'AL+W=O<FMS:&5E=',O
M<VAE970W."YX;6Q02P$"% ,4    " "HCJI4G.(8H%P"   O!0  &0
M        @(&X40( >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0
M   ( *B.JE11*WKL;P(  $$&   9              " @4M4 @!X;"]W;W)K
M<VAE971S+W-H965T.# N>&UL4$L! A0#%     @ J(ZJ5 3>BARB P  !P\
M !D              ("!\58" 'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q0
M2P$"% ,4    " "HCJI4!W1+BVD"  "[!0  &0              @('*6@(
M>&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    ( *B.JE30/:MA
MO04  (P<   9              " @6I= @!X;"]W;W)K<VAE971S+W-H965T
M.#,N>&UL4$L! A0#%     @ J(ZJ5"?"D3X]"@  MD   !D
M ("!7F," 'AL+W=O<FMS:&5E=',O<VAE970X-"YX;6Q02P$"% ,4    " "H
MCJI4L% OUHT"   9!P  &0              @('2;0( >&PO=V]R:W-H965T
M<R]S:&5E=#@U+GAM;%!+ 0(4 Q0    ( *B.JE2R"_DDN@4  %$@   9
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M970Y,"YX;6Q02P$"% ,4    " "HCJI4C(<.QS\'   F+0  &0
M    @(&FB0( >&PO=V]R:W-H965T<R]S:&5E=#DQ+GAM;%!+ 0(4 Q0    (
M *B.JE2;)FU +0<  &DJ   9              " @1R1 @!X;"]W;W)K<VAE
M971S+W-H965T.3(N>&UL4$L! A0#%     @ J(ZJ5+NS'8+O"P  REH  !D
M             ("!@)@" 'AL+W=O<FMS:&5E=',O<VAE970Y,RYX;6Q02P$"
M% ,4    " "HCJI4?:B6M]$#   :#P  &0              @(&FI ( >&PO
M=V]R:W-H965T<R]S:&5E=#DT+GAM;%!+ 0(4 Q0    ( *B.JE0-M& O\P(
M '$(   9              " @:ZH @!X;"]W;W)K<VAE971S+W-H965T.34N
M>&UL4$L! A0#%     @ J(ZJ5++^]EB0!0  [!P  !D              ("!
MV*L" 'AL+W=O<FMS:&5E=',O<VAE970Y-BYX;6Q02P$"% ,4    " "HCJI4
MPK5Y##(#  #)"@  &0              @(&?L0( >&PO=V]R:W-H965T<R]S
M:&5E=#DW+GAM;%!+ 0(4 Q0    ( *B.JE1%K<6O] 0  )T9   9
M      " @0BU @!X;"]W;W)K<VAE971S+W-H965T.3@N>&UL4$L! A0#%
M  @ J(ZJ5*8U.7@/"    S   !D              ("!,[H" 'AL+W=O<FMS
M:&5E=',O<VAE970Y.2YX;6Q02P$"% ,4    " "HCJI4^W=9E-D"   Y"0
M&@              @(%YP@( >&PO=V]R:W-H965T<R]S:&5E=#$P,"YX;6Q0
M2P$"% ,4    " "HCJI4H+X@DX #  #V#0  &@              @(&*Q0(
M>&PO=V]R:W-H965T<R]S:&5E=#$P,2YX;6Q02P$"% ,4    " "HCJI4?Y#6
M\[8$   H&@  &@              @(%"R0( >&PO=V]R:W-H965T<R]S:&5E
M=#$P,BYX;6Q02P$"% ,4    " "HCJI4EH)_Q($#  "#$0  &@
M    @($PS@( >&PO=V]R:W-H965T<R]S:&5E=#$P,RYX;6Q02P$"% ,4
M" "HCJI4^--JQGL+   /<P  &@              @('IT0( >&PO=V]R:W-H
M965T<R]S:&5E=#$P-"YX;6Q02P$"% ,4    " "HCJI4"]!#]A #  "S"@
M&@              @(&<W0( >&PO=V]R:W-H965T<R]S:&5E=#$P-2YX;6Q0
M2P$"% ,4    " "HCJI4K/*QT7<"  #[!@  &@              @('DX (
M>&PO=V]R:W-H965T<R]S:&5E=#$P-BYX;6Q02P$"% ,4    " "HCJI4GS.3
M2&4"  !:!@  &@              @(&3XP( >&PO=V]R:W-H965T<R]S:&5E
M=#$P-RYX;6Q02P$"% ,4    " "HCJI4P@0 N1\#   L"0  &@
M    @($PY@( >&PO=V]R:W-H965T<R]S:&5E=#$P."YX;6Q02P$"% ,4
M" "HCJI4D;E2?^("   L"0  &@              @(&'Z0( >&PO=V]R:W-H
M965T<R]S:&5E=#$P.2YX;6Q02P$"% ,4    " "HCJI4)FA5=4$#  !<"0
M&@              @(&A[ ( >&PO=V]R:W-H965T<R]S:&5E=#$Q,"YX;6Q0
M2P$"% ,4    " "HCJI4:U08;$8#  "8#   &@              @($:\ (
M>&PO=V]R:W-H965T<R]S:&5E=#$Q,2YX;6Q02P$"% ,4    " "HCJI4\(:!
M.D4'  !-(P  &@              @(&8\P( >&PO=V]R:W-H965T<R]S:&5E
M=#$Q,BYX;6Q02P$"% ,4    " "HCJI4?/(*&^<&  #7(@  &@
M    @($5^P( >&PO=V]R:W-H965T<R]S:&5E=#$Q,RYX;6Q02P$"% ,4
M" "HCJI4FI>QJB$#   ("P  &@              @($T @, >&PO=V]R:W-H
M965T<R]S:&5E=#$Q-"YX;6Q02P$"% ,4    " "HCJI4%#4W:+0"  !J!P
M&@              @(&-!0, >&PO=V]R:W-H965T<R]S:&5E=#$Q-2YX;6Q0
M2P$"% ,4    " "HCJI4!TBS:4\#  #&"0  &@              @(%Y" ,
M>&PO=V]R:W-H965T<R]S:&5E=#$Q-BYX;6Q02P$"% ,4    " "HCJI4#B%X
MWS0#  !("0  &@              @($ # , >&PO=V]R:W-H965T<R]S:&5E
M=#$Q-RYX;6Q02P$"% ,4    " "HCJI4NVB:DY<#   @#0  &@
M    @(%L#P, >&PO=V]R:W-H965T<R]S:&5E=#$Q."YX;6Q02P$"% ,4
M" "HCJI4=9T9P+ $  #&$   &@              @($[$P, >&PO=V]R:W-H
M965T<R]S:&5E=#$Q.2YX;6Q02P$"% ,4    " "HCJI4!ZFQ/G,$   K$
M&@              @($C& , >&PO=V]R:W-H965T<R]S:&5E=#$R,"YX;6Q0
M2P$"% ,4    " "HCJI4 WI@XGD#  "M"P  &@              @('.' ,
M>&PO=V]R:W-H965T<R]S:&5E=#$R,2YX;6Q02P$"% ,4    " "HCJI4H@<J
M:>P&  ".'P  &@              @(%_( , >&PO=V]R:W-H965T<R]S:&5E
M=#$R,BYX;6Q02P$"% ,4    " "HCJI4_X;C+SH$  #2&   &@
M    @(&C)P, >&PO=V]R:W-H965T<R]S:&5E=#$R,RYX;6Q02P$"% ,4
M" "HCJI4UQZ/+&D#  !5"@  &@              @($5+ , >&PO=V]R:W-H
M965T<R]S:&5E=#$R-"YX;6Q02P$"% ,4    " "HCJI4=Y?I,S<#  #W"0
M&@              @(&V+P, >&PO=V]R:W-H965T<R]S:&5E=#$R-2YX;6Q0
M2P$"% ,4    " "HCJI4P#L<>R0#  !B"@  &@              @($E,P,
M>&PO=V]R:W-H965T<R]S:&5E=#$R-BYX;6Q02P$"% ,4    " "HCJI4U0\K
M+90"  "'!@  &@              @(&!-@, >&PO=V]R:W-H965T<R]S:&5E
M=#$R-RYX;6Q02P$"% ,4    " "HCJI4\$HT).8*  !-0   &@
M    @(%-.0, >&PO=V]R:W-H965T<R]S:&5E=#$R."YX;6Q02P$"% ,4
M" "HCJI4"ZHO&BL#  #,"P  &@              @(%K1 , >&PO=V]R:W-H
M965T<R]S:&5E=#$R.2YX;6Q02P$"% ,4    " "HCJI4HM0;DB4"  "U!
M&@              @('.1P, >&PO=V]R:W-H965T<R]S:&5E=#$S,"YX;6Q0
M2P$"% ,4    " "HCJI4#%3R#FP(  #N+P  &@              @($K2@,
M>&PO=V]R:W-H965T<R]S:&5E=#$S,2YX;6Q02P$"% ,4    " "HCJI4Y&6X
M,.L(  "%/@  &@              @('/4@, >&PO=V]R:W-H965T<R]S:&5E
M=#$S,BYX;6Q02P$"% ,4    " "HCJI4P>Y^MN$$  "\&@  &@
M    @('R6P, >&PO=V]R:W-H965T<R]S:&5E=#$S,RYX;6Q02P$"% ,4
M" "HCJI4A-[2O-\#  #3$P  &@              @($+80, >&PO=V]R:W-H
M965T<R]S:&5E=#$S-"YX;6Q02P$"% ,4    " "HCJI4X<UN4=L"  #L"0
M&@              @($B90, >&PO=V]R:W-H965T<R]S:&5E=#$S-2YX;6Q0
M2P$"% ,4    " "HCJI4K-F9QI0$   _%   &@              @($U: ,
M>&PO=V]R:W-H965T<R]S:&5E=#$S-BYX;6Q02P$"% ,4    " "HCJI4@]Z]
M%2P#   *$@  #0              @ $!;0, >&PO<W1Y;&5S+GAM;%!+ 0(4
M Q0    ( *B.JE27BKL<P    !,"   +              "  5AP P!?<F5L
M<R\N<F5L<U!+ 0(4 Q0    ( *B.JE3(FKKJ$PD  (-9   /
M  "  4%Q P!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "HCJI4@_59A*X#
M  "[3P  &@              @ &!>@, >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    " "HCJI48!O&JLP"   K3   $P
M@ %G?@, 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     D "0 ,PG  !D@0,
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>924</ContextCount>
  <ElementCount>633</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>255</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>24</UnitCount>
  <MyReports>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010001 - Document - Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/Document</Role>
      <ShortName>Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050006 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>210011001 - Disclosure - DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS</Role>
      <ShortName>DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>210031002 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>210191003 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURE</Role>
      <ShortName>ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>210241004 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS</Role>
      <ShortName>RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>210261005 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>210401006 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INVENTORIES</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>210431007 - Disclosure - PROPERTY, PLANT AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENT</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>210471008 - Disclosure - INTANGIBLE ASSETS AND GOODWILL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>210531009 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES</Role>
      <ShortName>ACCRUED AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>210561010 - Disclosure - FINANCING ARRANGEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS</Role>
      <ShortName>FINANCING ARRANGEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>210661011 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>210771012 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>210841013 - Disclosure - SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION</Role>
      <ShortName>SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>210901014 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>210931015 - Disclosure - RESEARCH AND DEVELOPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT</Role>
      <ShortName>RESEARCH AND DEVELOPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>210961016 - Disclosure - OTHER EXPENSE, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/OTHEREXPENSENET</Role>
      <ShortName>OTHER EXPENSE, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>211001017 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>211091018 - Disclosure - LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LOSSPERSHARE</Role>
      <ShortName>LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>211131019 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURES</Role>
      <ShortName>SUPPLEMENTAL CASH FLOW DISCLOSURES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>211161020 - Disclosure - LEGAL PROCEEDINGS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGS</Role>
      <ShortName>LEGAL PROCEEDINGS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>211181021 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>211201022 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATION</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>211281023 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>220042001 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>230053001 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>230203002 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURETables</Role>
      <ShortName>ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURE</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>230273003 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>230413004 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INVENTORIESTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/INVENTORIES</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>230443005 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTTables</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENT</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>230483006 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>230543007 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables</Role>
      <ShortName>ACCRUED AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>230573008 - Disclosure - FINANCING ARRANGEMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables</Role>
      <ShortName>FINANCING ARRANGEMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>230673009 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>230783010 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/LEASES</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>230853011 - Disclosure - SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables</Role>
      <ShortName>SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>230913012 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>230943013 - Disclosure - RESEARCH AND DEVELOPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables</Role>
      <ShortName>RESEARCH AND DEVELOPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>230973014 - Disclosure - OTHER EXPENSE, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/OTHEREXPENSENETTables</Role>
      <ShortName>OTHER EXPENSE, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/OTHEREXPENSENET</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>231013015 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/INCOMETAXES</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>231103016 - Disclosure - LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LOSSPERSHARETables</Role>
      <ShortName>LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/LOSSPERSHARE</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>231143017 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESTables</Role>
      <ShortName>SUPPLEMENTAL CASH FLOW DISCLOSURES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURES</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>231213018 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/SEGMENTINFORMATION</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>240024001 - Disclosure - DESCRIPTION OF BUSINESS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails</Role>
      <ShortName>DESCRIPTION OF BUSINESS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>240064002 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>240074003 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Concentrations of Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Concentrations of Credit Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>240084004 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Activity in Allowance for Credit Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Activity in Allowance for Credit Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>240094005 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>240104006 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>240114007 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Variable Consideration Provisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Variable Consideration Provisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>240124008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>240134009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>240144010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdvertisingCostsDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>240154011 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInterestExpenseDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>240164012 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>240174013 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESEmployeeBenefitPlansDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>240184014 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Adoption of New Accounting Standards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES - Adoption of New Accounting Standards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>240214015 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails</Role>
      <ShortName>ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURETables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>240224016 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Estimated Fair Value Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Estimated Fair Value Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>240234017 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Assets and Liabilities Held For Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails</Role>
      <ShortName>ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Assets and Liabilities Held For Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>240254018 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails</Role>
      <ShortName>RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>240284019 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>240294020 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>240304021 - Disclosure - FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>240314022 - Disclosure - FAIR VALUE MEASUREMENTS - Cross-currency Swaps Included in Consolidated Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Cross-currency Swaps Included in Consolidated Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>240324023 - Disclosure - FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>240334024 - Disclosure - FAIR VALUE MEASUREMENTS - Foreign Currency Exchange Contracts, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Foreign Currency Exchange Contracts, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>240344025 - Disclosure - FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>240354026 - Disclosure - FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>240364027 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level3) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level3) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>240374028 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>240384029 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>240394030 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value of Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Fair Value of Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>240424031 - Disclosure - INVENTORIES - Summary of Inventories, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails</Role>
      <ShortName>INVENTORIES - Summary of Inventories, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>240454032 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Major Components of Property, Plant, and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT - Major Components of Property, Plant, and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>240464033 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails</Role>
      <ShortName>PROPERTY, PLANT AND EQUIPMENT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>240494034 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>240504035 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>240514036 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>240524037 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWILL - Schedule of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>240554038 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails</Role>
      <ShortName>ACCRUED AND OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>240584039 - Disclosure - FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>240594040 - Disclosure - FINANCING ARRANGEMENTS - Covenant Compliance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Covenant Compliance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>240604041 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>240614042 - Disclosure - FINANCING ARRANGEMENTS - Current Description of Senior Secured Credit Facilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Current Description of Senior Secured Credit Facilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>240624043 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Senior Secured Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>240634044 - Disclosure - FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>240644045 - Disclosure - FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>240654046 - Disclosure - FINANCING ARRANGEMENTS - Maturities, Schedule of Maturities and Mandatory Payments of Debt Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails</Role>
      <ShortName>FINANCING ARRANGEMENTS - Maturities, Schedule of Maturities and Mandatory Payments of Debt Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>240684047 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>240694048 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>240704049 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>240714050 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Change in Benefit Obligation, Plan Assets and Funded Status (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Change in Benefit Obligation, Plan Assets and Funded Status (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>240724051 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Underfunded Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Underfunded Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>240734052 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Future Benefit Payments for the Pension Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Future Benefit Payments for the Pension Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>240744053 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Weighted-Average Assumptions Used to Determine Net Periodic Benefit Costs and Benefit Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Weighted-Average Assumptions Used to Determine Net Periodic Benefit Costs and Benefit Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>240754054 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Actual Asset Allocations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Actual Asset Allocations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>240764055 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with the Acquisition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails</Role>
      <ShortName>PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with the Acquisition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>240794056 - Disclosure - LEASES - Right-of-use Assets and Right-of-use Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails</Role>
      <ShortName>LEASES - Right-of-use Assets and Right-of-use Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>240804057 - Disclosure - LEASES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEASESNarrativeDetails</Role>
      <ShortName>LEASES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>240814058 - Disclosure - LEASES - Lease Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEASESLeaseExpensesDetails</Role>
      <ShortName>LEASES - Lease Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>240824059 - Disclosure - LEASES - Lease Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails</Role>
      <ShortName>LEASES - Lease Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>240834060 - Disclosure - LEASES - Lease Future Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails</Role>
      <ShortName>LEASES - Lease Future Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>240864061 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>240874062 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>240884063 - Disclosure - SHARE-BASED COMPENSATION - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>240894064 - Disclosure - SHARE-BASED COMPENSATION - RSUs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - RSUs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>240924065 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Accumulated Other Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Accumulated Other Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>240954066 - Disclosure - RESEARCH AND DEVELOPMENT - Schedule of Research and Development Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails</Role>
      <ShortName>RESEARCH AND DEVELOPMENT - Schedule of Research and Development Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>115</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>240984067 - Disclosure - OTHER EXPENSE, NET - Schedule of Other Expense (Income), Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails</Role>
      <ShortName>OTHER EXPENSE, NET - Schedule of Other Expense (Income), Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>240994068 - Disclosure - OTHER EXPENSE, NET - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails</Role>
      <ShortName>OTHER EXPENSE, NET - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>117</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>241024069 - Disclosure - INCOME TAXES - Components of Benefit from Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES - Components of Benefit from Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>118</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>241034070 - Disclosure - INCOME TAXES - Schedule of Effective Income Tax Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails</Role>
      <ShortName>INCOME TAXES - Schedule of Effective Income Tax Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>119</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>241044071 - Disclosure - INCOME TAXES - Tax Effect of Major Items Recorded as Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>INCOME TAXES - Tax Effect of Major Items Recorded as Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>120</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R121.htm</HtmlFileName>
      <LongName>241054072 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Deferred Tax Asset Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails</Role>
      <ShortName>INCOME TAXES - Schedule of Reconciliation of Deferred Tax Asset Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>121</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R122.htm</HtmlFileName>
      <LongName>241064073 - Disclosure - INCOME TAXES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails</Role>
      <ShortName>INCOME TAXES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>122</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R123.htm</HtmlFileName>
      <LongName>241074074 - Disclosure - INCOME TAXES - Federal Income Tax Returns by Jurisdiction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails</Role>
      <ShortName>INCOME TAXES - Federal Income Tax Returns by Jurisdiction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>123</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R124.htm</HtmlFileName>
      <LongName>241084075 - Disclosure - INCOME TAXES - Reconciliation Schedule of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>INCOME TAXES - Reconciliation Schedule of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>124</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R125.htm</HtmlFileName>
      <LongName>241114076 - Disclosure - LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails</Role>
      <ShortName>LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>125</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R126.htm</HtmlFileName>
      <LongName>241124077 - Disclosure - LOSS PER SHARE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails</Role>
      <ShortName>LOSS PER SHARE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>126</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R127.htm</HtmlFileName>
      <LongName>241154078 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES - Schedule of Supplemental Cash Flow Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails</Role>
      <ShortName>SUPPLEMENTAL CASH FLOW DISCLOSURES - Schedule of Supplemental Cash Flow Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>127</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R128.htm</HtmlFileName>
      <LongName>241174079 - Disclosure - LEGAL PROCEEDINGS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails</Role>
      <ShortName>LEGAL PROCEEDINGS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>128</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R129.htm</HtmlFileName>
      <LongName>241194080 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>129</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R130.htm</HtmlFileName>
      <LongName>241224081 - Disclosure - SEGMENT INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails</Role>
      <ShortName>SEGMENT INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>130</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R131.htm</HtmlFileName>
      <LongName>241234082 - Disclosure - SEGMENT INFORMATION - Segment Revenues and Profit, Assets and Capital Expenditures, Depreciation &amp; Amortization of Intangible Assets &amp; Asset Impairments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails</Role>
      <ShortName>SEGMENT INFORMATION - Segment Revenues and Profit, Assets and Capital Expenditures, Depreciation &amp; Amortization of Intangible Assets &amp; Asset Impairments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>131</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R132.htm</HtmlFileName>
      <LongName>241244083 - Disclosure - SEGMENT INFORMATION - Revenues by Product Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails</Role>
      <ShortName>SEGMENT INFORMATION - Revenues by Product Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>132</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R133.htm</HtmlFileName>
      <LongName>241254084 - Disclosure - SEGMENT INFORMATION - Geographic Information, Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails</Role>
      <ShortName>SEGMENT INFORMATION - Geographic Information, Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>133</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R134.htm</HtmlFileName>
      <LongName>241264085 - Disclosure - SEGMENT INFORMATION - Geographical Information, Long-Lived Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails</Role>
      <ShortName>SEGMENT INFORMATION - Geographical Information, Long-Lived Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>134</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R135.htm</HtmlFileName>
      <LongName>241274086 - Disclosure - SEGMENT INFORMATION - Major Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails</Role>
      <ShortName>SEGMENT INFORMATION - Major Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>135</Position>
    </Report>
    <Report instance="bhc-20220510.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R136.htm</HtmlFileName>
      <LongName>241294087 - Disclosure - SUBSEQUENT EVENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails</Role>
      <ShortName>SUBSEQUENT EVENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>136</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="bhc-20220510.htm">bhc-20220510.htm</File>
    <File doctype="8-K" original="bhc-20220510_d2.htm">bhc-20220510_d2.htm</File>
    <File>bhc-20220510.xsd</File>
    <File>bhc-20220510_cal.xml</File>
    <File>bhc-20220510_def.xml</File>
    <File>bhc-20220510_lab.xml</File>
    <File>bhc-20220510_pre.xml</File>
    <File>bhc5422-ex991.htm</File>
    <File>bhc8-k542022ex23.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="2250">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>153
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bhc-20220510.htm bhc-20220510_d2.htm": {
   "axisCustom": 0,
   "axisStandard": 53,
   "contextCount": 924,
   "dts": {
    "calculationLink": {
     "local": [
      "bhc-20220510_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bhc-20220510_def.xml"
     ]
    },
    "inline": {
     "local": [
      "bhc-20220510.htm",
      "bhc-20220510_d2.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bhc-20220510_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bhc-20220510_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bhc-20220510.xsd",
      "reference-2009-12-16.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 1130,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 10,
    "http://www.bauschhealth.com/20220510": 1,
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 13
   },
   "keyCustom": 125,
   "keyStandard": 508,
   "memberCustom": 145,
   "memberStandard": 102,
   "nsprefix": "bhc",
   "nsuri": "http://www.bauschhealth.com/20220510",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510.htm",
      "contextRef": "i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000010001 - Document - Document",
     "role": "http://www.bauschhealth.com/role/Document",
     "shortName": "Document",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510.htm",
      "contextRef": "i22c093f3e8154981a72b21abdd0b2d02_D20220510-20220510",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210191003 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE",
     "role": "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURE",
     "shortName": "ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i9d64985a4d524a32b742dc7857f893e4_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240724051 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Underfunded Plans (Details)",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Underfunded Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i9d64985a4d524a32b742dc7857f893e4_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ibb7c373f0d534f23860c5b73ad7fc6df_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240734052 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Future Benefit Payments for the Pension Benefit Plans (Details)",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Future Benefit Payments for the Pension Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ibb7c373f0d534f23860c5b73ad7fc6df_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240744053 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Weighted-Average Assumptions Used to Determine Net Periodic Benefit Costs and Benefit Obligations (Details)",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Weighted-Average Assumptions Used to Determine Net Periodic Benefit Costs and Benefit Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i959101704be3480b96cd3bb9b5fbca32_D20210101-20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i75d6d22fe7ca49c89901fff21f7ad775_I20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240754054 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Actual Asset Allocations (Details)",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Actual Asset Allocations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i75d6d22fe7ca49c89901fff21f7ad775_I20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ibb7c373f0d534f23860c5b73ad7fc6df_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240764055 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with the Acquisition (Details)",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with the Acquisition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "idd8d218140314ef584532f8f6d286341_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240794056 - Disclosure - LEASES - Right-of-use Assets and Right-of-use Liabilities (Details)",
     "role": "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails",
     "shortName": "LEASES - Right-of-use Assets and Right-of-use Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FinanceLeaseLiability",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240804057 - Disclosure - LEASES - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/LEASESNarrativeDetails",
     "shortName": "LEASES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FinanceLeaseLiability",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinanceLeaseLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240814058 - Disclosure - LEASES - Lease Expenses (Details)",
     "role": "http://www.bauschhealth.com/role/LEASESLeaseExpensesDetails",
     "shortName": "LEASES - Lease Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:AdditionalOperatingLeaseInformationLesseeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240824059 - Disclosure - LEASES - Lease Additional Information (Details)",
     "role": "http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails",
     "shortName": "LEASES - Lease Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:AdditionalOperatingLeaseInformationLesseeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R109": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240834060 - Disclosure - LEASES - Lease Future Payments (Details)",
     "role": "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails",
     "shortName": "LEASES - Lease Future Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210241004 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS",
     "role": "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS",
     "shortName": "RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R110": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id943b700697244c1a9af35217a5014fc_I20140531",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240864061 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "SHARE-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id943b700697244c1a9af35217a5014fc_I20140531",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R111": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240874062 - Disclosure - SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails",
     "shortName": "SHARE-BASED COMPENSATION - Summary of Share-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i4b764cf71454461b9ae558f095cef352_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R112": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240884063 - Disclosure - SHARE-BASED COMPENSATION - Stock Options (Details)",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails",
     "shortName": "SHARE-BASED COMPENSATION - Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i8d74ea6015bc42bb9fc512a0ab35c9c1_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R113": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i00aeb13ceebf48e891b516a2d0c221d3_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240894064 - Disclosure - SHARE-BASED COMPENSATION - RSUs (Details)",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
     "shortName": "SHARE-BASED COMPENSATION - RSUs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i00aeb13ceebf48e891b516a2d0c221d3_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R114": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240924065 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Accumulated Other Comprehensive Loss (Details)",
     "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of Accumulated Other Comprehensive Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie3c11e633ca64c359eb1f4e64ed9945e_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R115": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ResearchAndDevelopmentExpenseProductRelated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240954066 - Disclosure - RESEARCH AND DEVELOPMENT - Schedule of Research and Development Costs (Details)",
     "role": "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails",
     "shortName": "RESEARCH AND DEVELOPMENT - Schedule of Research and Development Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ResearchAndDevelopmentExpenseProductRelated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R116": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240984067 - Disclosure - OTHER EXPENSE, NET - Schedule of Other Expense (Income), Net (Details)",
     "role": "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails",
     "shortName": "OTHER EXPENSE, NET - Schedule of Other Expense (Income), Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationAcquisitionRelatedCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R117": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240994068 - Disclosure - OTHER EXPENSE, NET - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails",
     "shortName": "OTHER EXPENSE, NET - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i5cdfe5b964b94b969e2829780c73f7e9_D20190101-20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GainLossOnDispositionOfAssets1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R118": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241024069 - Disclosure - INCOME TAXES - Components of Benefit from Income Taxes (Details)",
     "role": "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails",
     "shortName": "INCOME TAXES - Components of Benefit from Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R119": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241034070 - Disclosure - INCOME TAXES - Schedule of Effective Income Tax Reconciliation (Details)",
     "role": "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails",
     "shortName": "INCOME TAXES - Schedule of Effective Income Tax Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210261005 - Disclosure - FAIR VALUE MEASUREMENTS",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R120": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DeferredTaxAssetsTaxLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241044071 - Disclosure - INCOME TAXES - Tax Effect of Major Items Recorded as Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "INCOME TAXES - Tax Effect of Major Items Recorded as Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DeferredTaxAssetsTaxLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R121": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i16f569f1ea44497cbf30cc6291ac9a0b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241054072 - Disclosure - INCOME TAXES - Schedule of Reconciliation of Deferred Tax Asset Valuation Allowance (Details)",
     "role": "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails",
     "shortName": "INCOME TAXES - Schedule of Reconciliation of Deferred Tax Asset Valuation Allowance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "if84d1523bc1740e9b7b6df3d57e513ef_I20181231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R122": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241064073 - Disclosure - INCOME TAXES - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails",
     "shortName": "INCOME TAXES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "bhc:UnrecognizedTaxBenefitsIncludingInterestAndPenalties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R123": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i3981d7a177af492eb4fbd78ea657ad8f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OpenTaxYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241074074 - Disclosure - INCOME TAXES - Federal Income Tax Returns by Jurisdiction (Details)",
     "role": "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
     "shortName": "INCOME TAXES - Federal Income Tax Returns by Jurisdiction (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i3981d7a177af492eb4fbd78ea657ad8f_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OpenTaxYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R124": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i16f569f1ea44497cbf30cc6291ac9a0b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241084075 - Disclosure - INCOME TAXES - Reconciliation Schedule of Unrecognized Tax Benefits (Details)",
     "role": "http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails",
     "shortName": "INCOME TAXES - Reconciliation Schedule of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i18439fe8345c481db53c486667ac6940_I20181231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R125": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241114076 - Disclosure - LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details)",
     "role": "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails",
     "shortName": "LOSS PER SHARE - Schedule of Calculation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R126": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i794db5d83c3641aa853ac4acaa8182e9_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241124077 - Disclosure - LOSS PER SHARE - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails",
     "shortName": "LOSS PER SHARE - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i794db5d83c3641aa853ac4acaa8182e9_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R127": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaidNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241154078 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES - Schedule of Supplemental Cash Flow Disclosures (Details)",
     "role": "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails",
     "shortName": "SUPPLEMENTAL CASH FLOW DISCLOSURES - Schedule of Supplemental Cash Flow Disclosures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaidNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R128": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:Legalsettlementsandrelatedfees",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241174079 - Disclosure - LEGAL PROCEEDINGS - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails",
     "shortName": "LEGAL PROCEEDINGS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i0a8688d163da4bddb3dfdc9ef920e0fb_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "bhc:LossContingencyPlaintiffsNumberofGroupsofInvestors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "group",
      "xsiNil": "false"
     }
    },
    "R129": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractualObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241194080 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractualObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210401006 - Disclosure - INVENTORIES",
     "role": "http://www.bauschhealth.com/role/INVENTORIES",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R130": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i3328d4d641274769857018f609cda173_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "reporting_unit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241224081 - Disclosure - SEGMENT INFORMATION - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
     "shortName": "SEGMENT INFORMATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i3328d4d641274769857018f609cda173_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "reporting_unit",
      "xsiNil": "false"
     }
    },
    "R131": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241234082 - Disclosure - SEGMENT INFORMATION - Segment Revenues and Profit, Assets and Capital Expenditures, Depreciation & Amortization of Intangible Assets & Asset Impairments (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails",
     "shortName": "SEGMENT INFORMATION - Segment Revenues and Profit, Assets and Capital Expenditures, Depreciation & Amortization of Intangible Assets & Asset Impairments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:InterestAndDebtExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R132": {
     "firstAnchor": {
      "ancestors": [
       "bhc:ConcentrationRiskNumberOfProducts",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ConcentrationRiskNumberOfProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241244083 - Disclosure - SEGMENT INFORMATION - Revenues by Product Category (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
     "shortName": "SEGMENT INFORMATION - Revenues by Product Category (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "bhc:ConcentrationRiskNumberOfProducts",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:ConcentrationRiskNumberOfProducts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     }
    },
    "R133": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241254084 - Disclosure - SEGMENT INFORMATION - Geographic Information, Revenue (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
     "shortName": "SEGMENT INFORMATION - Geographic Information, Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i5464eb24d31a4be0beb852ba387bade8_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R134": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NoncurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241264085 - Disclosure - SEGMENT INFORMATION - Geographical Information, Long-Lived Assets (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails",
     "shortName": "SEGMENT INFORMATION - Geographical Information, Long-Lived Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NoncurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R135": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i3630993f4ba446f9a740bd6e81c5a6ad_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241274086 - Disclosure - SEGMENT INFORMATION - Major Customers (Details)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
     "shortName": "SEGMENT INFORMATION - Major Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i3630993f4ba446f9a740bd6e81c5a6ad_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R136": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i4177e1b635b74d889574e58be568dee6_I20171218",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "241294087 - Disclosure - SUBSEQUENT EVENTS - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails",
     "shortName": "SUBSEQUENT EVENTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i4e619b455ff146759a2117b1f93fefb2_I20220118",
      "decimals": "INF",
      "lang": "en-US",
      "name": "bhc:DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210431007 - Disclosure - PROPERTY, PLANT AND EQUIPMENT",
     "role": "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENT",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210471008 - Disclosure - INTANGIBLE ASSETS AND GOODWILL",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210531009 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES",
     "role": "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES",
     "shortName": "ACCRUED AND OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210561010 - Disclosure - FINANCING ARRANGEMENTS",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS",
     "shortName": "FINANCING ARRANGEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210661011 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210771012 - Disclosure - LEASES",
     "role": "http://www.bauschhealth.com/role/LEASES",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210841013 - Disclosure - SHARE-BASED COMPENSATION",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION",
     "shortName": "SHARE-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210901014 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS",
     "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210931015 - Disclosure - RESEARCH AND DEVELOPMENT",
     "role": "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT",
     "shortName": "RESEARCH AND DEVELOPMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210961016 - Disclosure - OTHER EXPENSE, NET",
     "role": "http://www.bauschhealth.com/role/OTHEREXPENSENET",
     "shortName": "OTHER EXPENSE, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211001017 - Disclosure - INCOME TAXES",
     "role": "http://www.bauschhealth.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211091018 - Disclosure - LOSS PER SHARE",
     "role": "http://www.bauschhealth.com/role/LOSSPERSHARE",
     "shortName": "LOSS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211131019 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES",
     "role": "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURES",
     "shortName": "SUPPLEMENTAL CASH FLOW DISCLOSURES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211161020 - Disclosure - LEGAL PROCEEDINGS",
     "role": "http://www.bauschhealth.com/role/LEGALPROCEEDINGS",
     "shortName": "LEGAL PROCEEDINGS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211181021 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211201022 - Disclosure - SEGMENT INFORMATION",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATION",
     "shortName": "SEGMENT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "211281023 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://www.bauschhealth.com/role/SUBSEQUENTEVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "220042001 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230053001 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230203002 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE (Tables)",
     "role": "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURETables",
     "shortName": "ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230273003 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230413004 - Disclosure - INVENTORIES (Tables)",
     "role": "http://www.bauschhealth.com/role/INVENTORIESTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230443005 - Disclosure - PROPERTY, PLANT AND EQUIPMENT (Tables)",
     "role": "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTTables",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230483006 - Disclosure - INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230543007 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Tables)",
     "role": "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables",
     "shortName": "ACCRUED AND OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230573008 - Disclosure - FINANCING ARRANGEMENTS (Tables)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables",
     "shortName": "FINANCING ARRANGEMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostsAndExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230673009 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230783010 - Disclosure - LEASES (Tables)",
     "role": "http://www.bauschhealth.com/role/LEASESTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:AssetsAndLiabilitiesLesseeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230853011 - Disclosure - SHARE-BASED COMPENSATION (Tables)",
     "role": "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables",
     "shortName": "SHARE-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230913012 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)",
     "role": "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables",
     "shortName": "ACCUMULATED OTHER COMPREHENSIVE LOSS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230943013 - Disclosure - RESEARCH AND DEVELOPMENT (Tables)",
     "role": "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables",
     "shortName": "RESEARCH AND DEVELOPMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:SummaryOfResearchAndDevelopmentExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "230973014 - Disclosure - OTHER EXPENSE, NET (Tables)",
     "role": "http://www.bauschhealth.com/role/OTHEREXPENSENETTables",
     "shortName": "OTHER EXPENSE, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "231013015 - Disclosure - INCOME TAXES (Tables)",
     "role": "http://www.bauschhealth.com/role/INCOMETAXESTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "231103016 - Disclosure - LOSS PER SHARE (Tables)",
     "role": "http://www.bauschhealth.com/role/LOSSPERSHARETables",
     "shortName": "LOSS PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "231143017 - Disclosure - SUPPLEMENTAL CASH FLOW DISCLOSURES (Tables)",
     "role": "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESTables",
     "shortName": "SUPPLEMENTAL CASH FLOW DISCLOSURES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "231213018 - Disclosure - SEGMENT INFORMATION (Tables)",
     "role": "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables",
     "shortName": "SEGMENT INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040005 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfCountriesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240024001 - Disclosure - DESCRIPTION OF BUSINESS - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails",
     "shortName": "DESCRIPTION OF BUSINESS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfCountriesInWhichEntityOperates",
      "reportCount": 1,
      "unique": true,
      "unitRef": "country",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished",
      "reportCount": 1,
      "unique": true,
      "unitRef": "company",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240064002 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished",
      "reportCount": 1,
      "unique": true,
      "unitRef": "company",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240074003 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Concentrations of Credit Risk (Details)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Concentrations of Credit Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240084004 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Activity in Allowance for Credit Losses (Details)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Activity in Allowance for Credit Losses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i18439fe8345c481db53c486667ac6940_I20181231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i0043ca6c60b448469dd9c10b6369a160_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240094005 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment (Details)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i0043ca6c60b448469dd9c10b6369a160_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ia7db43bf7c3c4b4186ebf9e2d3d12935_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240104006 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets (Details)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id51447b7e78f425bafc98f09b85f21fd_D20210101-20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i16f569f1ea44497cbf30cc6291ac9a0b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240114007 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Variable Consideration Provisions (Details)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Variable Consideration Provisions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesDeductions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bhc:SummaryOfValuationAndQualifyingAccountsTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240124008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "bhc:CashDiscountsAndAllowancesSettlementPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i65c560b8d709448ebce15c3e5d971fa8_I20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240134009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i65c560b8d709448ebce15c3e5d971fa8_I20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240144010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdvertisingCostsDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Advertising Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdvertisingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i9065a4b181534b6ab3a847b07fb47561_I20181231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050006 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT",
     "shortName": "CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i9065a4b181534b6ab3a847b07fb47561_I20181231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestCostsCapitalized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240154011 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Interest Expense (Details)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInterestExpenseDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestCostsCapitalized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:IncomeTaxPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:TaxBenefitRecognitionMeasurementPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240164012 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Income Taxes (Details)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:IncomeTaxPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:TaxBenefitRecognitionMeasurementPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PensionAndOtherPostretirementPlansPolicy",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240174013 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Employee Benefit Plans (Details)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESEmployeeBenefitPlansDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Employee Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PensionAndOtherPostretirementPlansPolicy",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240184014 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Adoption of New Accounting Standards (Details)",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Adoption of New Accounting Standards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240214015 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
     "shortName": "ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "bhc:NumberOfOtherBusinessesAcquired",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "bhc:NumberOfOtherBusinessesAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "businesscombination",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240224016 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Estimated Fair Value Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Estimated Fair Value Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i3228597eb86549919c150d017affe6c9_I20190306",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id9dae4cbf28945e690c15be6b4c2db5e_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240234017 - Disclosure - ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Assets and Liabilities Held For Sale (Details)",
     "role": "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails",
     "shortName": "ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE - Assets and Liabilities Held For Sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id9dae4cbf28945e690c15be6b4c2db5e_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240254018 - Disclosure - RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails",
     "shortName": "RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i0e08237054f64594815ad5013a5aa9e4_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "iad637097d6f449b982fcf6ea6c568da3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240284019 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i3f6583316fc34f2ebde02bee82fce983_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:HighlyLiquidInvestmentsMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240294020 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:HighlyLiquidInvestmentsMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240304021 - Disclosure - FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ia2313e85fce74e5aae451d3654b4cc63_D20211101-20211130",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromHedgeInvestingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i4ac58aeb82cb4d5da0dc54736de89480_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240314022 - Disclosure - FAIR VALUE MEASUREMENTS - Cross-currency Swaps Included in Consolidated Balance Sheets (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Cross-currency Swaps Included in Consolidated Balance Sheets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ib6236fa286e14aeabadb9f150267531f_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetFairValueGrossLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i9dc84dac17cc43a3984fc9929fd5e294_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForProceedsFromHedgeInvestingActivities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240324023 - Disclosure - FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Cross-currency Swaps, Effect of Hedging Instruments on Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i9eb64f96a45e4870872718cc8df9421a_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "iad637097d6f449b982fcf6ea6c568da3_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240334024 - Disclosure - FAIR VALUE MEASUREMENTS - Foreign Currency Exchange Contracts, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Foreign Currency Exchange Contracts, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "iad637097d6f449b982fcf6ea6c568da3_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "iad637097d6f449b982fcf6ea6c568da3_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240344025 - Disclosure - FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included in Consolidated Balance Sheets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i0bdd18e14d804d67a4f34d683bfa58ea_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssetFairValueGrossLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i3c9863c6c02148b280910bb43a45b30b_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240354026 - Disclosure - FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Foreign Exchange Contracts Included on Consolidated Statements of Operations and Consolidated Statements of Cash Flows (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i3c9863c6c02148b280910bb43a45b30b_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i16f569f1ea44497cbf30cc6291ac9a0b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240364027 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level3) (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details",
     "shortName": "FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level3) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i10dd5d5cf93949878c6cc5089859a3bd_I20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i15d7424af8b443409563957178d9f029_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240374028 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i8453f3b3b4c743129918b8a8465d47e3_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AssetsHeldForSaleLongLivedFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240384029 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis, Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured on a Non-Recurring Basis, Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ica46ac5deb7f4bca98fd1442ab972fe1_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240394030 - Disclosure - FAIR VALUE MEASUREMENTS - Fair Value of Long-term Debt (Details)",
     "role": "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails",
     "shortName": "FAIR VALUE MEASUREMENTS - Fair Value of Long-term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ica46ac5deb7f4bca98fd1442ab972fe1_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210011001 - Disclosure - DESCRIPTION OF BUSINESS",
     "role": "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS",
     "shortName": "DESCRIPTION OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240424031 - Disclosure - INVENTORIES - Summary of Inventories, Net (Details)",
     "role": "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails",
     "shortName": "INVENTORIES - Summary of Inventories, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240454032 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Major Components of Property, Plant, and Equipment (Details)",
     "role": "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT - Major Components of Property, Plant, and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240464033 - Disclosure - PROPERTY, PLANT AND EQUIPMENT - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails",
     "shortName": "PROPERTY, PLANT AND EQUIPMENT - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240494034 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details)",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Schedule of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i4b861d276efc40a681c82e2398b819a7_D20210630-20210630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240504035 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "bhc:IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240514036 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i16f569f1ea44497cbf30cc6291ac9a0b_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240524037 - Disclosure - INTANGIBLE ASSETS AND GOODWILL - Schedule of Goodwill (Details)",
     "role": "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWILL - Schedule of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i8cbe5627d66d43e0ab4433d90d6be6f6_D20190101-20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:Legalsettlementsandrelatedfees",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240554038 - Disclosure - ACCRUED AND OTHER CURRENT LIABILITIES (Details)",
     "role": "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails",
     "shortName": "ACCRUED AND OTHER CURRENT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "bhc:AccruedProductRebateCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240584039 - Disclosure - FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
     "shortName": "FINANCING ARRANGEMENTS - Summary of Consolidated Long-term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i27fc8076f1bb4e4fac0065b5495211c5_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentAmountAvailableForRestrictedPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240594040 - Disclosure - FINANCING ARRANGEMENTS - Covenant Compliance (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
     "shortName": "FINANCING ARRANGEMENTS - Covenant Compliance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i27fc8076f1bb4e4fac0065b5495211c5_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentAmountAvailableForRestrictedPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "210031002 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240604041 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
     "shortName": "FINANCING ARRANGEMENTS - Senior Secured Credit Facilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i8bba7bbfcfef401787d57a665a8baaab_D20181127-20181127",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i1a7a975faf994c36a88b4e0e0eb6800f_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240614042 - Disclosure - FINANCING ARRANGEMENTS - Current Description of Senior Secured Credit Facilities (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
     "shortName": "FINANCING ARRANGEMENTS - Current Description of Senior Secured Credit Facilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i1a7a975faf994c36a88b4e0e0eb6800f_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentPeriodicPaymentQuarterlyAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentRedemptionPricePercentageChangeinControl",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240624043 - Disclosure - FINANCING ARRANGEMENTS - Senior Secured Notes (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
     "shortName": "FINANCING ARRANGEMENTS - Senior Secured Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "idd735e6d7a4a49c4a31ba11a3b55d3c5_I20170331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "bhc:DebtInstrumentRedemptionPricePercentageChangeinControl",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240634044 - Disclosure - FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
     "shortName": "FINANCING ARRANGEMENTS - Senior Unsecured Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "if0649a2ad7e34fdd9c9aaacf95248fea_D20200526-20200526",
      "decimals": "-6",
      "lang": "en-US",
      "name": "bhc:PaymentForDebtAmortizationPrepaymentCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtWeightedAverageInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240644045 - Disclosure - FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
     "shortName": "FINANCING ARRANGEMENTS - Weighted Average Stated Rate of Interest (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtWeightedAverageInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240654046 - Disclosure - FINANCING ARRANGEMENTS - Maturities, Schedule of Maturities and Mandatory Payments of Debt Obligations (Details)",
     "role": "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails",
     "shortName": "FINANCING ARRANGEMENTS - Maturities, Schedule of Maturities and Mandatory Payments of Debt Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "id5393601523d4ba3bef1b785065c95b7_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240684047 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Narrative (Details)",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ie9639c1bfc224d709201fbe65fcb7a42_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bhc:DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ic8813f768a6d40a090aaffec2d906007_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240694048 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details)",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Amounts Recognized in Accumulated Other Comprehensive Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "ic8813f768a6d40a090aaffec2d906007_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i35e34787aea44b2c84b3316d8752b209_D20210101-20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240704049 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Components of Net Periodic Benefit Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i35e34787aea44b2c84b3316d8752b209_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "if38262082aca4b1ca51d9de262b48c77_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanBenefitObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "240714050 - Disclosure - PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Change in Benefit Obligation, Plan Assets and Funded Status (Details)",
     "role": "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
     "shortName": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS - Change in Benefit Obligation, Plan Assets and Funded Status (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bhc-20220510_d2.htm",
      "contextRef": "i35e34787aea44b2c84b3316d8752b209_D20210101-20211231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanSettlementsBenefitObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 255,
   "tag": {
    "bhc_A5.00SeniorNotesDueJanuary2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.00% Senior Notes Due January 2028 [Member]",
        "label": "5.00% Senior Notes Due January 2028 [Member]",
        "terseLabel": "5.00% Senior Unsecured Notes Due January 2028"
       }
      }
     },
     "localname": "A5.00SeniorNotesDueJanuary2028Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A5.25SeniorNotesDueJanuary2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.25% Senior Notes Due January 2030 [Member]",
        "label": "5.25% Senior Notes Due January 2030 [Member]",
        "terseLabel": "5.25% Senior Unsecured Notes Due January 2030"
       }
      }
     },
     "localname": "A5.25SeniorNotesDueJanuary2030Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A5.375SeniorNotesdueMarch2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.375% Senior Notes due March 2020 [Member]",
        "label": "5.375% Senior Notes due March 2020 [Member]",
        "terseLabel": "5.375% Senior Notes due March 2020"
       }
      }
     },
     "localname": "A5.375SeniorNotesdueMarch2020Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A5.50SeniorNotesdueMarch2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.50% Senior Notes due March 2023 [Member]",
        "label": "5.50% Senior Notes due March 2023 [Member]",
        "terseLabel": "5.50% Senior Unsecured Notes due March 2023"
       }
      }
     },
     "localname": "A5.50SeniorNotesdueMarch2023Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A5.875SeniorNotesdueMay2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.875% Senior Notes due May 2023 [Member]",
        "label": "5.875% Senior Notes due May 2023 [Member]",
        "terseLabel": "5.875% Senior Unsecured Notes due May 2023"
       }
      }
     },
     "localname": "A5.875SeniorNotesdueMay2023Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A5875SeniorNotesDueMay2023March2019RefinancingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.875% Senior Notes due May 2023, March 2019 Refinancing",
        "label": "5.875% Senior Notes due May 2023, March 2019 Refinancing [Member]",
        "terseLabel": "5.875% Senior Notes due May 2023, March 2019 Refinancing"
       }
      }
     },
     "localname": "A5875SeniorNotesDueMay2023March2019RefinancingMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A5875SeniorNotesDueMay2023May2019RefinancingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.875% Senior Notes due May 2023, May 2019 Refinancing",
        "label": "5.875% Senior Notes due May 2023, May 2019 Refinancing [Member]",
        "terseLabel": "5.875% Senior Notes due May 2023, May 2019 Refinancing"
       }
      }
     },
     "localname": "A5875SeniorNotesDueMay2023May2019RefinancingMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A6.125SeniorNotesdueApril2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.125% Senior Notes due April 2025 [Member]",
        "label": "6.125% Senior Notes due April 2025 [Member]",
        "terseLabel": "6.125% Senior Unsecured Notes due April 2025"
       }
      }
     },
     "localname": "A6.125SeniorNotesdueApril2025Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A7.00SeniorUnsecuredNotesDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "7.00% Senior Unsecured Notes Due 2028 [Member]",
        "label": "7.00% Senior Unsecured Notes Due 2028 [Member]",
        "terseLabel": "7.00% Senior Unsecured Notes due 2028"
       }
      }
     },
     "localname": "A7.00SeniorUnsecuredNotesDue2028Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A7.25SeniorUnsecuredNotesDue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "7.25% Senior Unsecured Notes Due 2029 [Member]",
        "label": "7.25% Senior Unsecured Notes Due 2029 [Member]",
        "terseLabel": "7.25% Senior Unsecured Notes due 2029"
       }
      }
     },
     "localname": "A7.25SeniorUnsecuredNotesDue2029Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A8.50SeniorNotesDueJanuary2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "8.50% Senior Notes Due January 2027 [Member]",
        "label": "8.50% Senior Notes Due January 2027 [Member]",
        "terseLabel": "8.50% Senior Unsecured Notes Due January 2027"
       }
      }
     },
     "localname": "A8.50SeniorNotesDueJanuary2027Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A9.00SeniorNotesdueDecember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "9.00% Senior Notes due December 2025 [Member]",
        "label": "9.00% Senior Notes due December 2025 [Member]",
        "terseLabel": "9.00% Senior Unsecured Notes due December 2025"
       }
      }
     },
     "localname": "A9.00SeniorNotesdueDecember2025Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_A9.25SeniorNotesDueApril2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "9.25% Senior Notes Due April 2026 [Member]",
        "label": "9.25% Senior Notes Due April 2026 [Member]",
        "terseLabel": "9.25% Senior Unsecured Notes Due April 2026"
       }
      }
     },
     "localname": "A9.25SeniorNotesDueApril2026Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ACertainInternationalBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A Certain International Business [Member]",
        "label": "A Certain International Business [Member]",
        "terseLabel": "A Certain International Business"
       }
      }
     },
     "localname": "ACertainInternationalBusinessMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AccountsReceivableAllowanceForForeignExchangeAndOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Allowance For Foreign Exchange And Other",
        "label": "Accounts Receivable, Allowance For Foreign Exchange And Other",
        "negatedTerseLabel": "Foreign exchange and other"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForForeignExchangeAndOther",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Effect Of Retrospective Application Of Accounting Standards Update",
        "label": "Accounts Receivable, Effect Of Retrospective Application Of Accounting Standards Update",
        "terseLabel": "Retrospective effect of application of new accounting standard"
       }
      }
     },
     "localname": "AccountsReceivableEffectOfRetrospectiveApplicationOfAccountingStandardsUpdate",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AccretionForTimeValueOfMoneyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accretion For Time Value Of Money [Member]",
        "label": "Accretion For Time Value Of Money [Member]",
        "terseLabel": "Accretion for the time value of money"
       }
      }
     },
     "localname": "AccretionForTimeValueOfMoneyMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AccruedAndOtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued And Other Current Liabilities",
        "label": "Accrued And Other Current Liabilities [Member]",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedAndOtherCurrentLiabilitiesMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AccruedProductRebateCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the current portion of accrued product rebates.",
        "label": "Accrued Product Rebate Current",
        "terseLabel": "Product rebates"
       }
      }
     },
     "localname": "AccruedProductRebateCurrent",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AccruedProductReturnCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for product returns. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Product Return Current",
        "terseLabel": "Product returns"
       }
      }
     },
     "localname": "AccruedProductReturnCurrent",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AccumulatedLossesAvailableForFederalPurposes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the details pertaining to accumulated losses available for federal and provincial purposes.",
        "label": "Accumulated Losses Available for Federal Purposes",
        "terseLabel": "Accumulated losses available for federal and provincial purposes"
       }
      }
     },
     "localname": "AccumulatedLossesAvailableForFederalPurposes",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AcquiredInProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents intangible assets that the entity has acquired as a result of business acquisition, which is represented through the premium in the purchase price over book value attributed to research and development on new product that is not yet being sold.",
        "label": "Acquired in Process Research and Development [Member]",
        "terseLabel": "Acquired IPR&amp;D not in service",
        "verboseLabel": "Acquired IPR&amp;D"
       }
      }
     },
     "localname": "AcquiredInProcessResearchAndDevelopmentMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]",
        "label": "Acquisitions, Licensing Agreements, And Assets Held For Sale Disclosures [Text Block]",
        "terseLabel": "ACQUISITIONS, LICENSING AGREEMENTS AND DIVESTITURE"
       }
      }
     },
     "localname": "AcquisitionsLicensingAgreementsAndAssetsHeldForSaleDisclosuresTextBlock",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_AdditionalOperatingLeaseInformationLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Operating Lease Information, Lessee [Table Text Block]",
        "label": "Additional Operating Lease Information, Lessee [Table Text Block]",
        "terseLabel": "Summary of other operating lease information"
       }
      }
     },
     "localname": "AdditionalOperatingLeaseInformationLesseeTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Payments To Acquire Equity Securities, FV-NI, Expected",
        "label": "Additional Payments To Acquire Equity Securities, FV-NI, Expected",
        "terseLabel": "Expected additional payments"
       }
      }
     },
     "localname": "AdditionalPaymentsToAcquireEquitySecuritiesFVNIExpected",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AllegroOphthalmicsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allegro Ophthalmics, LLC",
        "label": "Allegro Ophthalmics, LLC [Member]",
        "terseLabel": "Allegro"
       }
      }
     },
     "localname": "AllegroOphthalmicsLLCMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AllowancesForLossesOnAccountsReceivableAndInventories": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the current period expense charged against operations (1) for the purpose of reducing receivables to an amount that approximates their net realizable value and (2) the charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.",
        "label": "Allowances for Losses on Accounts Receivable and Inventories",
        "terseLabel": "Allowances for losses on trade receivables and inventories"
       }
      }
     },
     "localname": "AllowancesForLossesOnAccountsReceivableAndInventories",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AmerisourceBergenCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the major customer of the entity, AmerisourceBergen Corporation.",
        "label": "Amerisource Bergen Corporation [Member]",
        "terseLabel": "AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "AmerisourceBergenCorporationMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible asset amortization expense excluding amortization allocated to alliance and royalty revenue and cost of goods sold during the period.",
        "label": "Amortization of Intangible Assets Excluding Amortization Allocated to Revenues Cost of Good Sold",
        "negatedTerseLabel": "Amortization of intangible assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssetsExcludingAmortizationAllocatedToRevenuesCostOfGoodSold",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_AmounPharmaceuticalCompanySAEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amoun Pharmaceutical Company S.A.E",
        "label": "Amoun Pharmaceutical Company S.A.E [Member]",
        "terseLabel": "Amoun Pharmaceutical Company S.A.E"
       }
      }
     },
     "localname": "AmounPharmaceuticalCompanySAEMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ApotexIncLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Apotex Inc. Litigation",
        "label": "Apotex Inc. Litigation [Member]",
        "terseLabel": "Apotex Inc. Litigation"
       }
      }
     },
     "localname": "ApotexIncLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Argentina, Brazil, Egypt, Greece, Serbia, South Africa, Turkey, Ukraine, Venezuela and Vietnam",
        "label": "Argentina, Brazil, Egypt, Greece, Serbia, South Africa, Turkey, Ukraine, Venezuela and Vietnam [Member]",
        "terseLabel": "Argentina, Brazil, Egypt, Greece, Serbia, South Africa, Turkey, Ukraine, Venezuela and Vietnam"
       }
      }
     },
     "localname": "ArgentinaBrazilEgyptGreeceSerbiaSouthAfricaTurkeyUkraineVenezuelaAndVietnamMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Summary of right-of-use assets and right-of-use liabilities"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_AssetsLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets, Lessee [Abstract]",
        "label": "Assets, Lessee [Abstract]",
        "terseLabel": "Right-of-use assets included in:"
       }
      }
     },
     "localname": "AssetsLesseeAbstract",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_BaseRateOrPrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Base Rate Or Prime Rate [Member]",
        "label": "Base Rate Or Prime Rate [Member]",
        "terseLabel": "Base Rate or Prime Rate"
       }
      }
     },
     "localname": "BaseRateOrPrimeRateMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BauschLombInternationalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bausch Lomb/International [Member]",
        "label": "Bausch Lomb/International [Member]",
        "terseLabel": "Bausch + Lomb/ International"
       }
      }
     },
     "localname": "BauschLombInternationalMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BauschLombMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bausch + Lomb",
        "label": "Bausch + Lomb [Member]",
        "terseLabel": "Bausch + Lomb"
       }
      }
     },
     "localname": "BauschLombMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BrandedandOtherGenericProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Branded and Other Generic Products [Member]",
        "label": "Branded and Other Generic Products [Member]",
        "terseLabel": "Branded and Other Generics"
       }
      }
     },
     "localname": "BrandedandOtherGenericProductsMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_BusinessAcquisitionContingentConsiderationFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, as of the balance sheet date, of potential payments under the contingent consideration arrangement which may include cash and shares.",
        "label": "Business Acquisition, Contingent Consideration Fair Value Disclosure",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationFairValueDisclosure",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_BusinessAcquisitionProFormaOperatingIncomeLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Pro Forma Operating Income (Loss)",
        "label": "Business Acquisition, Pro Forma Operating Income (Loss)",
        "terseLabel": "Pro-forma operating results"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaOperatingIncomeLoss",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the cash-flow impact of any change, including any differences arising upon settlement, recognized during the reporting period in the value of an asset or assets, arising from an item of contingent consideration, recognized in a business combination.",
        "label": "Business Combination, Contingent Consideration Arrangements Change in Amount of Contingent Consideration Asset Cash",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAssetCash",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_BusinessCombinationContingentConsiderationNoncurrentLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration, Noncurrent Liability",
        "label": "Business Combination, Contingent Consideration, Noncurrent Liability",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationNoncurrentLiability",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Pro Forma Information, Operating Income (Loss) Since Acquisition, Actual",
        "label": "Business Combination, Pro Forma Information, Operating Income (Loss) Since Acquisition, Actual",
        "terseLabel": "Operating results of acquiree since acquisition"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationOperatingIncomeLossSinceAcquisitionActual",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Expenses",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Expenses",
        "negatedTerseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedAccruedExpenses",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Separation And Proposed Initial Public Offering, Number Of Companies To Be Established",
        "label": "Business Separation And Proposed Initial Public Offering, Number Of Companies To Be Established",
        "terseLabel": "Business separation and proposed initial public offering, number of companies to be established"
       }
      }
     },
     "localname": "BusinessSeparationAndProposedInitialPublicOfferingNumberOfCompaniesToBeEstablished",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_CanadaBankersAcceptanceRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Canada Bankers Acceptance Rate [Member]",
        "label": "Canada Bankers Acceptance Rate [Member]",
        "terseLabel": "Canada Bankers Acceptance Rate"
       }
      }
     },
     "localname": "CanadaBankersAcceptanceRateMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_CanadianSecuritiesLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Canadian Securities Litigation",
        "label": "Canadian Securities Litigation [Member]",
        "terseLabel": "Canadian Securities Litigation"
       }
      }
     },
     "localname": "CanadianSecuritiesLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_CapitalExpenditureAndDepreciationAndAmortizationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the capital expenditures, depreciation and amortization by segment.",
        "label": "Capital Expenditure and Depreciation and Amortization [Abstract]",
        "terseLabel": "Capital expenditures:"
       }
      }
     },
     "localname": "CapitalExpenditureAndDepreciationAndAmortizationAbstract",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_CardinalHealthIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the major customer of the entity, Cardinal Health, Inc.",
        "label": "Cardinal Health Inc [Member]",
        "terseLabel": "Cardinal Health,\u00a0Inc."
       }
      }
     },
     "localname": "CardinalHealthIncMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, And Other Settlement Deposits",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, And Other Settlement Deposits",
        "periodEndLabel": "Cash and cash equivalents and Restricted cash and other settlement deposits, end of year",
        "periodStartLabel": "Cash and cash equivalents and Restricted cash and other settlement deposits, beginning of year",
        "totalLabel": "Cash and cash equivalents and Restricted cash and other settlement deposits, end of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_CashDiscountsAndAllowancesSettlementPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Discounts And Allowances, Settlement Period",
        "label": "Cash Discounts And Allowances, Settlement Period",
        "terseLabel": "Settlement period for cash discounts and allowances"
       }
      }
     },
     "localname": "CashDiscountsAndAllowancesSettlementPeriod",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_CedarsSinaiMedicalCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cedars-Sinai Medical Center",
        "label": "Cedars-Sinai Medical Center [Member]",
        "terseLabel": "Cedars-Sinai Medical Center"
       }
      }
     },
     "localname": "CedarsSinaiMedicalCenterMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_CertainProductsForDisposalSeptemberTwoThousandNineteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certain Products For Disposal, September Two Thousand Nineteen [Member]",
        "label": "Certain Products For Disposal, September Two Thousand Nineteen [Member]",
        "terseLabel": "Certain Products For Disposal, September 2019"
       }
      }
     },
     "localname": "CertainProductsForDisposalSeptemberTwoThousandNineteenMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_CollaborativeAgreementMilestonePaymentsAggregate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amounts required to be paid by the reporting entity, which are contingent upon the achievement of specific development, regulatory or commercial milestones, in connection with the Collaboration Agreement.",
        "label": "Collaborative Agreement Milestone Payments, Aggregate",
        "terseLabel": "Milestone payments in terms of collaboration and license agreements, aggregate"
       }
      }
     },
     "localname": "CollaborativeAgreementMilestonePaymentsAggregate",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ConcentrationRiskNumberOfProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk, Number Of Products",
        "label": "Concentration Risk, Number Of Products",
        "terseLabel": "Number of products represented of total revenue"
       }
      }
     },
     "localname": "ConcentrationRiskNumberOfProducts",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_ConcentrationRiskPercentageofNetTradeReceivables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk, Percentage of Net Trade Receivables",
        "label": "Concentration Risk, Percentage of Net Trade Receivables",
        "terseLabel": "Percentage of net trade receivables accounted for by largest wholesale customers"
       }
      }
     },
     "localname": "ConcentrationRiskPercentageofNetTradeReceivables",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_CrossCurrencyFinalSettlementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cross Currency, Final Settlement",
        "label": "Cross Currency, Final Settlement [Member]",
        "terseLabel": "Cross-currency swaps, final settlement"
       }
      }
     },
     "localname": "CrossCurrencyFinalSettlementMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_CustomerTopTenProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer, Top Ten Products",
        "label": "Customer, Top Ten Products [Member]",
        "terseLabel": "Customer, Top Ten Products"
       }
      }
     },
     "localname": "CustomerTopTenProductsMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold",
        "label": "Debt Instrument, Alternate Term, Number Of Days Prior To Scheduled Maturity In Excess Of Principal Amount Threshold",
        "terseLabel": "Alternate term, number of days prior to scheduled maturity in excess of principal amount threshold"
       }
      }
     },
     "localname": "DebtInstrumentAlternateTermNumberOfDaysPriorToScheduledMaturityInExcessOfPrincipalAmountThreshold",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Alternate Term, Principal Amount Maturity Threshold",
        "label": "Debt Instrument, Alternate Term, Principal Amount Maturity Threshold",
        "terseLabel": "Alternate term, principal amount maturity threshold"
       }
      }
     },
     "localname": "DebtInstrumentAlternateTermPrincipalAmountMaturityThreshold",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentAmountAvailableForRestrictedPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Amount Available For Restricted Payments",
        "label": "Debt Instrument, Amount Available For Restricted Payments",
        "terseLabel": "Amount available for restricted payments"
       }
      }
     },
     "localname": "DebtInstrumentAmountAvailableForRestrictedPayments",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentAnnualAmortizationRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Annual Amortization Rate, Percentage",
        "label": "Debt Instrument, Annual Amortization Rate, Percentage",
        "terseLabel": "Annual amortization rate, percentage"
       }
      }
     },
     "localname": "DebtInstrumentAnnualAmortizationRatePercentage",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentCovenantInterestCoverageRatioMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "label": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "terseLabel": "Interest coverage ratio (not less than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantInterestCoverageRatioMinimum",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Redemption And Discharge Condition, Amount, If Circumstances Met",
        "label": "Debt Instrument, Covenant, Redemption And Discharge Condition, Amount, If Circumstances Met",
        "terseLabel": "Debt covenant, redemption and discharge condition, amount, if circumstances met"
       }
      }
     },
     "localname": "DebtInstrumentCovenantRedemptionAndDischargeConditionAmountIfCircumstancesMet",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentCovenantTermsFixedChargeCoverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio",
        "label": "Debt Instrument, Covenant Terms, Fixed Charge Coverage Ratio",
        "terseLabel": "Fixed charge coverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTermsFixedChargeCoverageRatio",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCovenantTermsSecuredLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Terms, Secured Leverage Ratio",
        "label": "Debt Instrument, Covenant Terms, Secured Leverage Ratio",
        "terseLabel": "Secured leverage ratio",
        "verboseLabel": "Secured leverage ratio (not greater than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTermsSecuredLeverageRatio",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentCovenantTotalLeverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Total Leverage Ratio",
        "label": "Debt Instrument, Covenant, Total Leverage Ratio",
        "terseLabel": "Total leverage ratio"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTotalLeverageRatio",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentCovenantTotalLeverageRatioMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Compliance, Total Leverage Ratio",
        "label": "Debt Instrument, Covenant, Total Leverage Ratio, Maximum",
        "terseLabel": "Total leverage ratio (not greater than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantTotalLeverageRatioMaximum",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bhc_DebtInstrumentExpectedFaceAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Expected Face Amount",
        "label": "Debt Instrument, Expected Face Amount",
        "terseLabel": "Expected aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentExpectedFaceAmount",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Maximum Redemption Percentage With Equity Offering Proceeds",
        "label": "Debt Instrument, Maximum Redemption Percentage With Equity Offering Proceeds",
        "terseLabel": "Maximum percentage of the aggregate principal amount that may be redeemed with the net proceeds of certain equity offerings"
       }
      }
     },
     "localname": "DebtInstrumentMaximumRedemptionPercentageWithEquityOfferingProceeds",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DebtInstrumentPeriodicPaymentQuarterlyAmortization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Periodic Payment, Quarterly Amortization",
        "label": "Debt Instrument, Periodic Payment, Quarterly Amortization",
        "terseLabel": "Remaining mandatory quarterly amortization payments"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentQuarterlyAmortization",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DebtInstrumentRedemptionPricePercentageChangeinControl": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption Price, Percentage, Change in Control",
        "label": "Debt Instrument, Redemption Price, Percentage, Change in Control",
        "terseLabel": "Redemption price percentage due to change in control (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageChangeinControl",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DeferredIncomeTaxNoncashExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The noncash component of income tax expense for the period representing the increase (decrease) in the entity's deferred tax assets and liabilities pertaining to continuing operations.",
        "label": "Deferred Income Tax Noncash Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxNoncashExpenseBenefit",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DeferredTaxAssetsPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Prepaid Expenses",
        "label": "Deferred Tax Assets, Prepaid Expenses",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetsPrepaidExpenses",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the deferred tax assets on scientific research and experimental development pool, of the entity.",
        "label": "Deferred Tax Assets, Scientific Research and Experimental Development Pool",
        "terseLabel": "Scientific Research and Experimental Development pool"
       }
      }
     },
     "localname": "DeferredTaxAssetsScientificResearchAndExperimentalDevelopmentPool",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tax effect as of the balance sheet date of the amount of future tax deductions arising from unused research and development tax credit carryforwards; a tax credit carryforward is the amount by which tax credits available for utilization exceed statutory limitations for inclusion in historical filings, and which can only be utilized if sufficient tax-basis income is generated in future periods and providing tax laws continue to allow such utilization.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards Research and Development",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopment",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DeferredTaxAssetsTaxLossCarryforwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the deferred tax assets on tax loss carryforwards available to the entity.",
        "label": "Deferred Tax Assets, Tax Loss Carryforwards",
        "terseLabel": "Tax loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxLossCarryforwards",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the deferred tax liability recognized for the original basis difference between the principal amount of the Convertible Notes and value allocated to the liability component, which resulted in a corresponding reduction to the valuation allowance recorded against deferred tax assets.",
        "label": "Deferred Tax Liabilities, Basis Difference of Convertible Notes",
        "verboseLabel": "Plant, equipment and technology"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesBasisDifferenceOfConvertibleNotes",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Actuarial Gain (Loss), Amortization Threshold Percentage",
        "label": "Defined Benefit Plan, Actuarial Gain (Loss), Amortization Threshold Percentage",
        "terseLabel": "Threshold percentage for amortization of net actuarial gains and losses"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialGainLossAmortizationThresholdPercentage",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESEmployeeBenefitPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Benefit Accrual, Interest Percentage Earned On Cash Balance",
        "label": "Defined Benefit Plan, Benefit Accrual, Interest Percentage Earned On Cash Balance",
        "terseLabel": "Benefit accrual, interest percentage earned on cash balance"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitAccrualInterestPercentageEarnedOnCashBalance",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DefinedBenefitPlanEmployerContributionMaximumAge": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Employer Contribution, Maximum Age",
        "label": "Defined Benefit Plan, Employer Contribution, Maximum Age",
        "terseLabel": "Employer contribution maximum age"
       }
      }
     },
     "localname": "DefinedBenefitPlanEmployerContributionMaximumAge",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Estimated Future Benefit Payments, Period",
        "label": "Defined Benefit Plan, Estimated Future Benefit Payments, Period",
        "terseLabel": "Future benefit payments period"
       }
      }
     },
     "localname": "DefinedBenefitPlanEstimatedFutureBenefitPaymentsPeriod",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Number of Defined Benefit Plans Amended",
        "label": "Defined Benefit Plan, Number of Defined Benefit Plans Amended",
        "terseLabel": "Number of defined benefit plans amended"
       }
      }
     },
     "localname": "DefinedBenefitPlanNumberOfDefinedBenefitPlansAmended",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_DefinedBenefitPlanNumberofDefinedBenefitPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Number of Defined Benefit Plans",
        "label": "Defined Benefit Plan, Number of Defined Benefit Plans",
        "terseLabel": "Number of defined benefit plans"
       }
      }
     },
     "localname": "DefinedBenefitPlanNumberofDefinedBenefitPlans",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_DefinedBenefitPlanPercentageAllocationofFund": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Percentage Allocation of Fund",
        "label": "Defined Benefit Plan, Percentage Allocation of Fund",
        "terseLabel": "Percentage allocation of fund"
       }
      }
     },
     "localname": "DefinedBenefitPlanPercentageAllocationofFund",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_DerivativeGainExcludedComponent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative, Gain, Excluded Component",
        "label": "Derivative, Gain, Excluded Component",
        "negatedTerseLabel": "Gain excluded from hedge effectiveness"
       }
      }
     },
     "localname": "DerivativeGainExcludedComponent",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DerivativeLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Lawsuits [Member]",
        "label": "Derivative Lawsuits [Member]",
        "terseLabel": "Derivative Lawsuits"
       }
      }
     },
     "localname": "DerivativeLawsuitsMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DeviceProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Device Products [Member]",
        "label": "Device Products [Member]",
        "terseLabel": "Devices"
       }
      }
     },
     "localname": "DeviceProductsMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DiscontinuedProductLinesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discontinued Product Lines",
        "label": "Discontinued Product Lines [Member]",
        "terseLabel": "Discontinued Product Lines"
       }
      }
     },
     "localname": "DiscontinuedProductLinesMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Other Sundry Liabilities, Current",
        "label": "Disposal Group, Including Discontinued Operation, Other Sundry Liabilities, Current",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesCurrent",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Other Sundry Liabilities, Noncurrent",
        "label": "Disposal Group, Including Discontinued Operation, Other Sundry Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherSundryLiabilitiesNoncurrent",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_DiversifiedProductsSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Diversified Products Segment [Member]",
        "label": "Diversified Products Segment [Member]",
        "terseLabel": "Diversified Products",
        "verboseLabel": "Diversified Products"
       }
      }
     },
     "localname": "DiversifiedProductsSegmentMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_DivestituresOfNoncoreProductsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divestitures of Non-core Products [Policy Text Block]",
        "label": "Divestitures Of Non-core Products [Policy Text Block]",
        "terseLabel": "Divestitures of Products"
       }
      }
     },
     "localname": "DivestituresOfNoncoreProductsPolicyTextBlock",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_DoctorsAllergyFormulaLLCLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Doctors Allergy Formula, LLC Litigation [Member]",
        "label": "Doctors Allergy Formula, LLC Litigation [Member]",
        "terseLabel": "Doctors Allergy Formula, LLC Litigation"
       }
      }
     },
     "localname": "DoctorsAllergyFormulaLLCLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Adjustments To Tax Attributes, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Adjustments To Tax Attributes, Amount",
        "negatedTerseLabel": "Adjustments to tax attributes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAdjustmentsToTaxAttributesAmount",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_EmergingMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Emerging Markets segment of the entity. The segment consists of branded generic pharmaceutical products, as well as OTC products and agency/in-licensing arrangements with other research-based pharmaceutical companies (where the entity distributes and markets branded, patented products under long-term, renewable contracts). Products are sold primarily in Europe (Poland, Serbia, Hungary, Croatia and Russia), Latin America (Mexico, Brazil and exports out of Mexico to other Latin American markets), South East Asia and South Africa.",
        "label": "Emerging Markets [Member]",
        "verboseLabel": "Emerging markets"
       }
      }
     },
     "localname": "EmergingMarketsMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]",
        "label": "Employee Stock Options, Time-Based Restricted Stock Units, and Performance-Based Restricted Stock Units [Member]",
        "verboseLabel": "Stock options, Time-based RSUs, Performance-based RSUs"
       }
      }
     },
     "localname": "EmployeeStockOptionsTimeBasedRestrictedStockUnitsandPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_EquipmentOnOperatingLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment On Operating Lease",
        "label": "Equipment On Operating Lease [Member]",
        "terseLabel": "Equipment on operating lease"
       }
      }
     },
     "localname": "EquipmentOnOperatingLeaseMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_EyenoviaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eyenovia, Inc.",
        "label": "Eyenovia, Inc. [Member]",
        "terseLabel": "Eyenovia, Inc."
       }
      }
     },
     "localname": "EyenoviaIncMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_FairValueAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Adjustments",
        "label": "Fair Value Adjustments [Member]",
        "terseLabel": "Fair value adjustments"
       }
      }
     },
     "localname": "FairValueAdjustmentsMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ForeignCountryStateAndLocalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The designated tax department of state or local government of a foreign country entitled to levy and collect income taxes from the entity.",
        "label": "Foreign Country State and Local [Member]",
        "terseLabel": "Canadian Federal and Provincial"
       }
      }
     },
     "localname": "ForeignCountryStateAndLocalMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_GainLossRelatedToLitigationSettlementGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) Related To Litigation Settlement, Gross",
        "label": "Gain (Loss) Related To Litigation Settlement, Gross",
        "negatedTerseLabel": "Additions to accrued legal settlements"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlementGross",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_GlobalHighYieldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global High Yield [Member]",
        "label": "Global High Yield [Member]",
        "terseLabel": "Global high yield"
       }
      }
     },
     "localname": "GlobalHighYieldMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_GlumetzaAntitrustLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glumetza Antitrust Class Actions Litigation [Member]",
        "label": "Glumetza Antitrust Litigation [Member]",
        "terseLabel": "Glumetza Antitrust Litigation"
       }
      }
     },
     "localname": "GlumetzaAntitrustLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_GlumetzaAntitrustLitigationNonClassComplaintsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glumetza Antitrust Litigation, Non-Class Complaints [Member]",
        "label": "Glumetza Antitrust Litigation, Non-Class Complaints [Member]",
        "terseLabel": "Glumetza Antitrust Litigation, Non-Class Complaints"
       }
      }
     },
     "localname": "GlumetzaAntitrustLitigationNonClassComplaintsMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill, Impairment Loss, Not Included In Asset Impairment Charges",
        "label": "Goodwill, Impairment Loss, Not Included In Asset Impairment Charges",
        "negatedLabel": "Goodwill impairments",
        "terseLabel": "Goodwill impairments",
        "verboseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLossNotIncludedInAssetImpairmentCharges",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_GoodwillTransfersRelatedToSaleOfBusinessUnit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill, Transfers Related To Sale of Business Unit",
        "label": "Goodwill, Transfers Related To Sale of Business Unit",
        "terseLabel": "Assets held for sale reclassified to goodwill"
       }
      }
     },
     "localname": "GoodwillTransfersRelatedToSaleOfBusinessUnit",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_HighlyLiquidInvestmentsMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Highly Liquid Investments, Maturity Period",
        "label": "Highly Liquid Investments, Maturity Period",
        "terseLabel": "Highly liquid investments, maturity period (or less)"
       }
      }
     },
     "localname": "HighlyLiquidInvestmentsMaturityPeriod",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_IncomeTaxLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Income Tax [Line Items]",
        "terseLabel": "Income Tax [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxLineItems",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax, Number Of Subsidiaries File Federal Income Tax Returns",
        "label": "Income Tax, Number Of Subsidiaries File Federal Income Tax Returns",
        "terseLabel": "Number of subsidiaries file federal income tax returns in Canada, U.S., and other foreign jurisdictions (or more)"
       }
      }
     },
     "localname": "IncomeTaxNumberOfSubsidiariesFileFederalIncomeTaxReturns",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to change in valuation allowance related to operating losses.",
        "label": "Income Tax Reconciliation Change in Operating Losses Valuation Allowance",
        "negatedTerseLabel": "Change in valuation allowance related to foreign tax credits and NOLs"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInOperatingLossesValuationAllowance",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_IncomeTaxReconciliationDeferredIntercompanyProfit": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the portion of the difference between total income tax expense (benefit) as reported in the income statement and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to deferred intercompany profit.",
        "label": "Income Tax Reconciliation Deferred Intercompany Profit",
        "negatedTerseLabel": "Tax benefit on intra-entity transfers"
       }
      }
     },
     "localname": "IncomeTaxReconciliationDeferredIntercompanyProfit",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_IncomeTaxReconciliationUncertainTaxPositions": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the difference between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to uncertain tax positions.",
        "label": "Income Tax Reconciliation, Uncertain Tax Positions",
        "negatedTerseLabel": "Change in uncertain tax positions"
       }
      }
     },
     "localname": "IncomeTaxReconciliationUncertainTaxPositions",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_IncomeTaxTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information relating to income taxes.",
        "label": "Income Tax [Table]",
        "terseLabel": "Income Tax [Table]"
       }
      }
     },
     "localname": "IncomeTaxTable",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Year-Over-Year Revenue From Contract With Customer, Excluding Assessed Tax",
        "label": "Increase (Decrease) In Year-Over-Year Revenue From Contract With Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue, year-over-year increase"
       }
      }
     },
     "localname": "IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Year-Over-Year Revenue From Contract With Customer, Excluding Assessed Tax, Percentage",
        "label": "Increase (Decrease) In Year-Over-Year Revenue From Contract With Customer, Excluding Assessed Tax, Percentage",
        "negatedTerseLabel": "Revenue, year-over-year decrease, percentage"
       }
      }
     },
     "localname": "IncreaseDecreaseInYearOverYearRevenueFromContractWithCustomerExcludingAssessedTaxPercentage",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_InsuranceCoverageLawsuitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Insurance Coverage Lawsuit [Member]",
        "label": "Insurance Coverage Lawsuit [Member]",
        "terseLabel": "Insurance Coverage Lawsuit"
       }
      }
     },
     "localname": "InsuranceCoverageLawsuitMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_InterestSettlementOnCrossCurrencySwaps": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Settlement On Cross-Currency Swaps",
        "label": "Interest Settlement On Cross-Currency Swaps",
        "terseLabel": "Settlements from cross-currency swaps"
       }
      }
     },
     "localname": "InterestSettlementOnCrossCurrencySwaps",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_InternationalRxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International Rx",
        "label": "International Rx [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "InternationalRxMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_InvestmentGradeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment Grade [Member]",
        "label": "Investment Grade [Member]",
        "terseLabel": "Investment grade"
       }
      }
     },
     "localname": "InvestmentGradeMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_Legalsettlementsandrelatedfees": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal settlements and related fees",
        "label": "Legal settlements and related fees",
        "terseLabel": "Legal matters and related fees"
       }
      }
     },
     "localname": "Legalsettlementsandrelatedfees",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_LiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities, Lessee [Abstract]",
        "label": "Liabilities, Lessee [Abstract]",
        "terseLabel": "Lease liabilities included in:"
       }
      }
     },
     "localname": "LiabilitiesLesseeAbstract",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_LineOfCreditFacilityExpectedMaximumBorrowingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Expected Maximum Borrowing Capacity",
        "label": "Line of Credit Facility, Expected Maximum Borrowing Capacity",
        "terseLabel": "Expected maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityExpectedMaximumBorrowingCapacity",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of annual excess cash flow with any excess amounts after the prepayment of the loans.",
        "label": "Line of Credit Facility, Percentage of Consolidated Excess Cash Flow Payable as Mandatory Prepayments",
        "terseLabel": "Percentage of annual excess cash flow"
       }
      }
     },
     "localname": "LineOfCreditFacilityPercentageOfConsolidatedExcessCashFlowPayableAsMandatoryPrepayments",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of net cash proceeds from asset sales outside ordinary course of business payable as mandatory prepayments.",
        "label": "Line of Credit Facility, Percentage of Net Cash Proceeds from Asset Sales Outside Ordinary Course of Business Payable as Mandatory Prepayments",
        "terseLabel": "Percentage of cash proceeds from asset sales outside the ordinary course of business payable as mandatory prepayments"
       }
      }
     },
     "localname": "LineOfCreditFacilityPercentageOfNetCashProceedsFromAssetSalesOutsideOrdinaryCourseOfBusinessPayableAsMandatoryPrepayments",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of net cash proceeds of insurance and condemnation proceeds for property or asset (losses) which is payable as mandatory prepayment.",
        "label": "Line of Credit Facility, Percentage of Net Cash Proceeds of Insurance and Condemnation Proceeds from Property or Asset Losses Payable as Mandatory Prepayments",
        "terseLabel": "Percentage of net cash proceeds of insurance and condemnation proceeds for property or asset losses"
       }
      }
     },
     "localname": "LineOfCreditFacilityPercentageOfNetCashProceedsOfInsuranceAndCondemnationProceedsFromPropertyOrAssetLossesPayableAsMandatoryPrepayments",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of net cash proceeds from the incurrence of debt payable as mandatory prepayments.",
        "label": "Line of Credit Facility, Percentage of Net Proceeds from Incurrence of Debt Payable as Mandatory Pre-payments",
        "terseLabel": "Percentage of cash proceeds from incurrence of debt"
       }
      }
     },
     "localname": "LineOfCreditFacilityPercentageOfNetProceedsFromIncurrenceOfDebtPayableAsMandatoryPrepayments",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LineOfCreditFacilityThresholdForIncrementalBorrowings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Threshold For Incremental Borrowings",
        "label": "Line Of Credit Facility, Threshold For Incremental Borrowings",
        "terseLabel": "Incremental credit facility borrowings"
       }
      }
     },
     "localname": "LineOfCreditFacilityThresholdForIncrementalBorrowings",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility Threshold For Incremental Borrowings Interest Rate",
        "label": "Line Of Credit Facility Threshold For Incremental Borrowings Interest Rate",
        "terseLabel": "Incremental borrowings interest rate"
       }
      }
     },
     "localname": "LineOfCreditFacilityThresholdForIncrementalBorrowingsInterestRate",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_LitigationwithFormerSalixCEOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation with Former Salix CEO [Member]",
        "label": "Litigation with Former Salix CEO [Member]",
        "terseLabel": "Litigation with Former Salix CEO"
       }
      }
     },
     "localname": "LitigationwithFormerSalixCEOMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_LossContingencyNewClaimsFiledButNotYetServedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency New Claims Filed But Not Yet Served Number",
        "label": "Loss Contingency New Claims Filed But Not Yet Served Number",
        "terseLabel": "Number of additional suits filed, but not served"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledButNotYetServedNumber",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyNumberOfAllegedStockholdersFiledLawsuits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Alleged Stockholders, Filed Lawsuits",
        "label": "Loss Contingency, Number Of Alleged Stockholders, Filed Lawsuits",
        "terseLabel": "Number of alleged stockholders filed lawsuits"
       }
      }
     },
     "localname": "LossContingencyNumberOfAllegedStockholdersFiledLawsuits",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action",
        "label": "Loss Contingency, Number Of Entities, Exercised Opt-Out Right, Pursuing Action",
        "terseLabel": "Number of entities, exercised opt-out right, pursuing action"
       }
      }
     },
     "localname": "LossContingencyNumberOfEntitiesExercisedOptOutRightPursuingAction",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyNumberOfInsurancePolicyPeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Insurance Policy Periods",
        "label": "Loss Contingency, Number Of Insurance Policy Periods",
        "terseLabel": "Number of distinct insurance policy periods"
       }
      }
     },
     "localname": "LossContingencyNumberOfInsurancePolicyPeriods",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyPlaintiffsNumberofGroupsofInvestors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Plaintiffs, Number of Groups of Investors",
        "label": "Loss Contingency, Plaintiffs, Number of Groups of Investors",
        "terseLabel": "Number of groups of investors"
       }
      }
     },
     "localname": "LossContingencyPlaintiffsNumberofGroupsofInvestors",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyPlaintiffsNumberofGroupsofInvestorsPending": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending",
        "label": "Loss Contingency, Plaintiffs, Number of Groups of Investors, Pending",
        "terseLabel": "Number of groups of investors filing action, remain pending"
       }
      }
     },
     "localname": "LossContingencyPlaintiffsNumberofGroupsofInvestorsPending",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencySettlementAgreementsNumberOfInsurers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Settlement Agreements, Number Of Insurers",
        "label": "Loss Contingency, Settlement Agreements, Number Of Insurers",
        "terseLabel": "Settlement agreements, number of insurers"
       }
      }
     },
     "localname": "LossContingencySettlementAgreementsNumberOfInsurers",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_LossContingencyStayOfApprovalPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Stay Of Approval, Period",
        "label": "Loss Contingency, Stay Of Approval, Period",
        "terseLabel": "Stay of the approval period"
       }
      }
     },
     "localname": "LossContingencyStayOfApprovalPeriod",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_LupinPharmaceuticalsIncLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lupin Pharmaceuticals, Inc. Litigation",
        "label": "Lupin Pharmaceuticals, Inc. Litigation [Member]",
        "terseLabel": "Lupin Pharmaceuticals, Inc. Litigation"
       }
      }
     },
     "localname": "LupinPharmaceuticalsIncLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_MSNLaboratoriesPrivateLtdLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MSN Laboratories Private Ltd. Litigation",
        "label": "MSN Laboratories Private Ltd. Litigation [Member]",
        "terseLabel": "MSN Laboratories Private Ltd. Litigation"
       }
      }
     },
     "localname": "MSNLaboratoriesPrivateLtdLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum original term of maturity for an instrument to be classified as cash or cash equivalent.",
        "label": "Maximum Term of Original Maturity to Classify Instruments as Cash and Cash Equivalents",
        "terseLabel": "Maximum term of original maturity to classify instruments as cash and cash equivalents (less than)"
       }
      }
     },
     "localname": "MaximumTermOfOriginalMaturityToClassifyInstrumentsAsCashAndCashEquivalents",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_McKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the major customer of the entity, McKesson Corporation.",
        "label": "Mc Kesson Corporation [Member]",
        "terseLabel": "McKesson Corporation"
       }
      }
     },
     "localname": "McKessonCorporationMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_MeasurementInputWeightedAverageDiscountRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Weighted-Average Discount Rate [Member]",
        "label": "Measurement Input, Weighted-Average Discount Rate [Member]",
        "terseLabel": "Measurement Input, Weighted-Average Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputWeightedAverageDiscountRateMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_MilestonePaymentRelatedToCertainProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment Related To Certain Product [Member]",
        "label": "Milestone Payment Related To Certain Product [Member]",
        "terseLabel": "Milestone Payment Related To Certain Product"
       }
      }
     },
     "localname": "MilestonePaymentRelatedToCertainProductMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the minimum period to classify uncertain tax position liabilities as long term liabilities.",
        "label": "Minimum Period to Classify Uncertain Tax Position, Liabilities as Long Term Liabilities",
        "terseLabel": "Minimum period to classify uncertain tax position liabilities as long term liabilities"
       }
      }
     },
     "localname": "MinimumPeriodToClassifyUncertainTaxPositionLiabilitiesAsLongTermLiabilities",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_MitsubishiTanabePharmaCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mitsubishi Tanabe Pharma Corporation [Member]",
        "label": "Mitsubishi Tanabe Pharma Corporation [Member]",
        "terseLabel": "Mitsubishi Tanabe Pharma Corporation"
       }
      }
     },
     "localname": "MitsubishiTanabePharmaCorporationMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NewRestatedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Restated Credit Agreement",
        "label": "New Restated Credit Agreement [Member]",
        "terseLabel": "New Restated Credit Agreement"
       }
      }
     },
     "localname": "NewRestatedCreditAgreementMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NonU.S.DevelopedMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-U.S. Developed Markets [Member]",
        "label": "Non-U.S. Developed Markets [Member]",
        "terseLabel": "Worldwide developed markets"
       }
      }
     },
     "localname": "NonU.S.DevelopedMarketsMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NonU.S.OtherAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-U.S. Other Assets [Member]",
        "label": "Non-U.S. Other Assets [Member]",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "NonU.S.OtherAssetsMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NoncashCumulativeForeignCurrencyTranslationLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Cumulative Foreign Currency Translation Loss",
        "label": "Noncash Cumulative Foreign Currency Translation Loss",
        "terseLabel": "Noncash cumulative foreign currency translation loss"
       }
      }
     },
     "localname": "NoncashCumulativeForeignCurrencyTranslationLoss",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_NonemployeeDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nonemployee Director [Member]",
        "label": "Nonemployee Director [Member]",
        "terseLabel": "Nonemployee Director"
       }
      }
     },
     "localname": "NonemployeeDirectorMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NovaliqGmbHMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novaliq GmbH [Member]",
        "label": "Novaliq GmbH [Member]",
        "terseLabel": "Novaliq GmbH"
       }
      }
     },
     "localname": "NovaliqGmbHMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_NumberOfLargestWholesaleCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of largest wholesale customers.",
        "label": "Number of Largest Wholesale Customers",
        "terseLabel": "Number of largest wholesale customers"
       }
      }
     },
     "localname": "NumberOfLargestWholesaleCustomers",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_NumberOfOtherBusinessesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Other Businesses Acquired",
        "label": "Number Of Other Businesses Acquired",
        "terseLabel": "Number of other material business combinations"
       }
      }
     },
     "localname": "NumberOfOtherBusinessesAcquired",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bhc_OmnibusIncentivePlan2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Omnibus Incentive Plan 2014 [Member]",
        "label": "Omnibus Incentive Plan 2014 [Member]",
        "terseLabel": "Omnibus Incentive Plan 2014"
       }
      }
     },
     "localname": "OmnibusIncentivePlan2014Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OrthoDermatologicsReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ortho Dermatologics Reporting Unit [Member]",
        "label": "Ortho Dermatologics Reporting Unit [Member]",
        "terseLabel": "Ortho Dermatologics Reporting Unit"
       }
      }
     },
     "localname": "OrthoDermatologicsReportingUnitMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OrthoDermatologicsSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ortho Dermatologics Segment [Member]",
        "label": "Ortho Dermatologics Segment [Member]",
        "terseLabel": "Ortho Dermatologics"
       }
      }
     },
     "localname": "OrthoDermatologicsSegmentMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherAssetsFixedIncomeSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Assets, Fixed Income Securities [Member]",
        "label": "Other Assets, Fixed Income Securities [Member]",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsFixedIncomeSecuritiesMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Foreign Currency Adjustment, Net Of Tax",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Foreign Currency Adjustment, Net Of Tax",
        "terseLabel": "Foreign currency impact"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDefinedBenefitPlanForeignCurrencyAdjustmentNetOfTax",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Amortization or Settlement Recognition",
        "label": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Amortization or Settlement Recognition",
        "negatedTerseLabel": "Amortization or settlement recognition of net loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansAmortizationorSettlementRecognition",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_OtherCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Countries [Member]",
        "label": "Other Countries [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCountriesMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherEquipmentAndLeaseholdImprovementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents other equipment and leasehold improvements.",
        "label": "Other Equipment and Leasehold Improvement [Member]",
        "terseLabel": "Other equipment and leasehold improvements"
       }
      }
     },
     "localname": "OtherEquipmentAndLeaseholdImprovementMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Income (Expense), Net",
        "label": "Other Income (Expense), Net",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherIncomeExpenseNet",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_OtherLongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents long-term debt obligations not elsewhere enumerated.",
        "label": "Other Long Term Debt [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLongTermDebtMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Performance Based Restricted Stock Units",
        "label": "Other Performance Based Restricted Stock Units [Member]",
        "terseLabel": "Other Performance Based Restricted Stock Units"
       }
      }
     },
     "localname": "OtherPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OtherRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Revenues [Member]",
        "label": "Other Revenues [Member]",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "OtherRevenuesMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OutLicensedTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the rights to receive cash flows under an out-license arrangement (for example, license fees, milestone payments and royalties).",
        "label": "Out Licensed Technology [Member]",
        "terseLabel": "Technology and other",
        "verboseLabel": "Out-licensed technology and other"
       }
      }
     },
     "localname": "OutLicensedTechnologyMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_OvertheCounterProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Over the Counter Products [Member]",
        "label": "Over the Counter Products [Member]",
        "terseLabel": "OTC"
       }
      }
     },
     "localname": "OvertheCounterProductsMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PadagisLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Padagis Litigation",
        "label": "Padagis Litigation [Member]",
        "terseLabel": "Padagis Litigation"
       }
      }
     },
     "localname": "PadagisLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PartnerRelationshipsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to existing arrangements with various other entities, for which the entity provides regulatory, compliance, sales, marketing and distribution functions.",
        "label": "Partner Relationships [Member]",
        "terseLabel": "Partner relationships",
        "verboseLabel": "Partner relationships"
       }
      }
     },
     "localname": "PartnerRelationshipsMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PastDuePeriodForAccountsReceivableToBeNegligible": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the past due period for which accounts receivables are negligible.",
        "label": "Past Due Period for Accounts Receivable to be Negligible",
        "terseLabel": "Past due period for receivables to be negligible (less than)"
       }
      }
     },
     "localname": "PastDuePeriodForAccountsReceivableToBeNegligible",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment For Contingent Consideration Liability, Including Accretion, Operating Activities",
        "label": "Payment For Contingent Consideration Liability, Including Accretion, Operating Activities",
        "negatedTerseLabel": "Payments of contingent consideration adjustments, including accretion"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityIncludingAccretionOperatingActivities",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_PaymentForDebtAmortizationPrepaymentCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment For Debt Amortization Prepayment Cost",
        "label": "Payment For Debt Amortization Prepayment Cost",
        "terseLabel": "Repayment, outstanding debt"
       }
      }
     },
     "localname": "PaymentForDebtAmortizationPrepaymentCost",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pension And Other Postretirement Defined Benefit Plans, Other Assets, Noncurrent",
        "label": "Pension And Other Postretirement Defined Benefit Plans, Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansOtherAssetsNoncurrent",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pension and Other Postretirement Defined Benefit Plans, Accrued and Other Current Liabilities",
        "label": "Pension and Other Postretirement Defined Benefit Plans, Accrued and Other Current Liabilities",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "PensionandOtherPostretirementDefinedBenefitPlansAccruedandOtherCurrentLiabilities",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_PerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents stock awards in the form of performance-based restricted stock units (RSUs) to certain directors, officers and other eligible employees pursuant to the company's incentive compensation plan.",
        "label": "Performance Based Restricted Stock Units [Member]",
        "terseLabel": "Performance-Based Restricted Stock Units"
       }
      }
     },
     "localname": "PerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PeriodReceivableOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time the accounts receivable has been outstanding.",
        "label": "Period Receivable Outstanding",
        "terseLabel": "Period net trade receivable balance outstanding (more than)"
       }
      }
     },
     "localname": "PeriodReceivableOutstanding",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_PerrigoIsraelPharmaceuticalsLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Perrigo Israel Pharmaceuticals Litigation",
        "label": "Perrigo Israel Pharmaceuticals Litigation [Member]",
        "terseLabel": "Perrigo Israel Pharmaceuticals Litigation"
       }
      }
     },
     "localname": "PerrigoIsraelPharmaceuticalsLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PharmaceuticalProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical Products [Member]",
        "label": "Pharmaceutical Products [Member]",
        "terseLabel": "Pharmaceuticals"
       }
      }
     },
     "localname": "PharmaceuticalProductsMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PlaintiffsDirectPurchasersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plaintiffs, Direct Purchasers [Member]",
        "label": "Plaintiffs, Direct Purchasers [Member]",
        "terseLabel": "Plaintiffs, Direct Purchasers"
       }
      }
     },
     "localname": "PlaintiffsDirectPurchasersMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PooledScientificResearchAndExperimentalDevelopmentExpendituresMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the details pertaining to pooled scientific research and experimental development.",
        "label": "Pooled Scientific Research and Experimental Development Expenditures [Member]",
        "terseLabel": "Pooled Scientific Research and Experimental Development"
       }
      }
     },
     "localname": "PooledScientificResearchAndExperimentalDevelopmentExpendituresMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_PriceAppreciationCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price Appreciation Credit [Member]",
        "label": "Price Appreciation Credit [Member]",
        "terseLabel": "Price Appreciation Credit"
       }
      }
     },
     "localname": "PriceAppreciationCreditMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ProductBrandsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the rights to non-patented product brands.",
        "label": "Product Brands [Member]",
        "terseLabel": "Product brands",
        "verboseLabel": "Product brands"
       }
      }
     },
     "localname": "ProductBrandsMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RICOClassActionsLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RICO Class Actions Litigation",
        "label": "RICO Class Actions Litigation [Member]",
        "terseLabel": "RICO Class Actions Litigation"
       }
      }
     },
     "localname": "RICOClassActionsLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ROTCPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ROTC Performance-Based Restricted Stock Units [Member]",
        "label": "ROTC Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "ROTC Performance-Based Restricted Stock Units"
       }
      }
     },
     "localname": "ROTCPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate",
        "label": "Reporting Unit, Impairment Test, Estimated Cash Flows, Discount Rate",
        "terseLabel": "Reporting unit, impairment test, estimated cash flows, discount rate"
       }
      }
     },
     "localname": "ReportingUnitImpairmentTestEstimatedCashFlowsDiscountRate",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_ReportingUnitImpairmentTestLongTermGrowthRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reporting Unit, Impairment Test, Long-Term Growth Rate",
        "label": "Reporting Unit, Impairment Test, Long-Term Growth Rate",
        "terseLabel": "Reporting unit, impairment test, long-term growth rates"
       }
      }
     },
     "localname": "ReportingUnitImpairmentTestLongTermGrowthRate",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_ReportingUnitsExcludingOrthoDermatologicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reporting Units Excluding Ortho Dermatologics",
        "label": "Reporting Units Excluding Ortho Dermatologics [Member]",
        "terseLabel": "Reporting Units Excluding Ortho Dermatologics"
       }
      }
     },
     "localname": "ReportingUnitsExcludingOrthoDermatologicsMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ResearchAndDevelopmentExpenseProductRelated": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Expense, Product Related",
        "label": "Research And Development Expense, Product Related",
        "terseLabel": "Product related research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseProductRelated",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ResearchAndDevelopmentExpenseQualityAssurance": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Expense, Quality Assurance",
        "label": "Research And Development Expense, Quality Assurance",
        "terseLabel": "Quality assurance"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseQualityAssurance",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ReserveForChargebacksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Chargebacks [Member]",
        "label": "Reserve For Chargebacks [Member]",
        "terseLabel": "Chargebacks"
       }
      }
     },
     "localname": "ReserveForChargebacksMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForCustomerReturnsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Customer Returns [Member]",
        "label": "Reserve For Customer Returns [Member]",
        "terseLabel": "Returns"
       }
      }
     },
     "localname": "ReserveForCustomerReturnsMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForDiscountsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Discounts And Allowances [Member]",
        "label": "Reserve For Discounts And Allowances [Member]",
        "terseLabel": "Discounts and Allowances"
       }
      }
     },
     "localname": "ReserveForDiscountsAndAllowancesMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForDistributionFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Distribution Fees [Member]",
        "label": "Reserve For Distribution Fees [Member]",
        "terseLabel": "Distribution Fees"
       }
      }
     },
     "localname": "ReserveForDistributionFeesMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForRebatesAdvertisingCreditsPortionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Rebates, Advertising Credits Portion [Member]",
        "label": "Reserve For Rebates, Advertising Credits Portion [Member]",
        "terseLabel": "Rebates, Advertising Credits Portion"
       }
      }
     },
     "localname": "ReserveForRebatesAdvertisingCreditsPortionMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ReserveForRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve For Rebates [Member]",
        "label": "Reserve For Rebates [Member]",
        "terseLabel": "Rebates"
       }
      }
     },
     "localname": "ReserveForRebatesMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash And Cash Equivalents And Other Settlement Deposits, Fair Value Disclosure",
        "label": "Restricted Cash And Cash Equivalents And Other Settlement Deposits, Fair Value Disclosure",
        "terseLabel": "Restricted cash and other settlement deposits"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAndOtherSettlementDepositsFairValueDisclosure",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_RestrictedCashAndOtherSettlementDepositsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash And Other Settlement Deposits, Current",
        "label": "Restricted Cash And Other Settlement Deposits, Current",
        "terseLabel": "Restricted cash and other settlement deposits"
       }
      }
     },
     "localname": "RestrictedCashAndOtherSettlementDepositsCurrent",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_RestrictedCashAndOtherSettlementDepositsCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash And Other Settlement Deposits, Current",
        "label": "Restricted Cash And Other Settlement Deposits, Current [Member]",
        "terseLabel": "Restricted Cash and Other Settlement Deposits"
       }
      }
     },
     "localname": "RestrictedCashAndOtherSettlementDepositsCurrentMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RestructuringAndIntegrationCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring And Integration Costs",
        "label": "Restructuring And Integration Costs [Member]",
        "terseLabel": "Restructuring and Integration Costs"
       }
      }
     },
     "localname": "RestructuringAndIntegrationCostsMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RestructuringChargesAndInitialPublicOfferingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 7.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring Charges And Initial Public Offering Costs",
        "label": "Restructuring Charges And Initial Public Offering Costs",
        "negatedLabel": "Restructuring, integration, separation and IPO costs",
        "terseLabel": "Restructuring, integration, separation and IPO costs"
       }
      }
     },
     "localname": "RestructuringChargesAndInitialPublicOfferingCosts",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_RevenuePerformanceObligationPaymentTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Payment Terms",
        "label": "Revenue, Performance Obligation, Payment Terms",
        "terseLabel": "Payment terms"
       }
      }
     },
     "localname": "RevenuePerformanceObligationPaymentTerms",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bhc_RevenuesNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net revenues during the period in the normal course of business.",
        "label": "Revenues Net [Member]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenuesNetMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RevolvingCreditFacilityDueJune2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolving Credit Facility Due June 2023 [Member]",
        "label": "Revolving Credit Facility Due June 2023 [Member]",
        "terseLabel": "2023 Revolving Credit Facility Due June 2023"
       }
      }
     },
     "localname": "RevolvingCreditFacilityDueJune2023Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RevolvingCreditFacilityNewRestatedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolving Credit Facility, New Restated Credit Agreement",
        "label": "Revolving Credit Facility, New Restated Credit Agreement [Member]",
        "terseLabel": "Revolving Credit Facility, New Restated Credit Agreement"
       }
      }
     },
     "localname": "RevolvingCreditFacilityNewRestatedCreditAgreementMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability, Excluding Amount Recognized Upon Adoption",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability, Excluding Amount Recognized Upon Adoption",
        "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityExcludingAmountRecognizedUponAdoption",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SEC Schedule, 12-09, Valuation Allowances And Reserves, Additions, Charge To Benefit From Income Taxes",
        "label": "SEC Schedule, 12-09, Valuation Allowances And Reserves, Additions, Charge To Benefit From Income Taxes",
        "terseLabel": "Charged to Benefit from income taxes"
       }
      }
     },
     "localname": "SECSchedule1209ValuationAllowancesAndReservesAdditionsChargeToBenefitFromIncomeTaxes",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_SalixSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Salix Segment [Member]",
        "label": "Salix Segment [Member]",
        "terseLabel": "Salix",
        "verboseLabel": "Salix"
       }
      }
     },
     "localname": "SalixSegmentMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SandozLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sandoz Litigation [Member]",
        "label": "Sandoz Litigation [Member]",
        "terseLabel": "Sandoz Litigation"
       }
      }
     },
     "localname": "SandozLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ScheduleOfCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Schedule of Commitments [Line Items]",
        "terseLabel": "Other commitments"
       }
      }
     },
     "localname": "ScheduleOfCommitmentsLineItems",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_ScheduleOfCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to commitments of the entity during the reporting period.",
        "label": "Schedule of Commitments [Table]",
        "terseLabel": "Schedule of Commitments [Table]"
       }
      }
     },
     "localname": "ScheduleOfCommitmentsTable",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of estimated useful lives of major classes of finite-lived intangible assets.",
        "label": "Schedule of Estimated Useful Lives of Finite Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of estimated useful lives of intangible assets"
       }
      }
     },
     "localname": "ScheduleOfEstimatedUsefulLivesOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of estimated useful lives of major classes of property, plant and equipment.",
        "label": "Schedule of Estimated Useful Lives of Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of estimated useful lives of property, plant and equipment"
       }
      }
     },
     "localname": "ScheduleOfEstimatedUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_ScheduleOfOtherIncomeAndExpensesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Schedule Of Other Income And Expenses [Table]",
        "label": "Schedule Of Other Income And Expenses [Line Items]",
        "terseLabel": "Schedule Of Other Income And Expenses [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfOtherIncomeAndExpensesLineItems",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_ScheduleOfOtherIncomeAndExpensesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Other Income And Expenses [Table]",
        "label": "Schedule Of Other Income And Expenses [Table]",
        "terseLabel": "Schedule Of Other Income And Expenses [Table]"
       }
      }
     },
     "localname": "ScheduleOfOtherIncomeAndExpensesTable",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of equity based payment instruments, excluding stock (or unit) options, including but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share Based Payment Award, Equity Instruments Other than Options Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions used to calculate the fair values of performance-based RSUs"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with Acquisition [Table Text Block]",
        "label": "Schedule of Fair Value of Pension and Postretirement Benefit Plan Assets Assumed in Connection with Acquisition [Table Text Block]",
        "terseLabel": "Fair value of pension and postretirement benefit plan assets assumed in connection with the Acquisition"
       }
      }
     },
     "localname": "ScheduleofFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwithAcquisitionTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_SellingGeneralAndAdministrativeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The allocation (or location) of expense to (in) selling, general and administrative expense.",
        "label": "Selling General and Administrative Expense [Member]",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpenseMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes4.502023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 4.50%, 2023 [Member]",
        "label": "Senior Notes, 4.50%, 2023 [Member]",
        "terseLabel": "4.50% Senior Unsecured Notes euro-denominated debt Due May 2023"
       }
      }
     },
     "localname": "SeniorNotes4.502023Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes5.625PercentDueDecember2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes 5.625 Percent Due December 2021 [Member]",
        "label": "Senior Notes 5.625 Percent Due December 2021 [Member]",
        "terseLabel": "5.625 % Senior Unsecured Notes due December 2021"
       }
      }
     },
     "localname": "SeniorNotes5.625PercentDueDecember2021Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes500DueFebruary2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 5.00%, Due February 2029",
        "label": "Senior Notes, 5.00%, Due February 2029 [Member]",
        "terseLabel": "5.000% Senior Note Due February 2029"
       }
      }
     },
     "localname": "SeniorNotes500DueFebruary2029Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes500DueJanuary2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.00% Senior Notes Due January 2028 [Member]",
        "label": "Senior Notes, 5.00%, Due January 2028 [Member]",
        "terseLabel": "5.000% Senior Notes Due January 2028"
       }
      }
     },
     "localname": "SeniorNotes500DueJanuary2028Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes525DueFebruary2031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 5.25%, Due February 2031",
        "label": "Senior Notes, 5.25%, Due February 2031 [Member]",
        "terseLabel": "5.250% Senior Notes, Due February 2031"
       }
      }
     },
     "localname": "SeniorNotes525DueFebruary2031Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes525DueJanuary2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.25% Senior Notes Due January 2030 [Member]",
        "label": "Senior Notes, 5.25%, Due January 2030 [Member]",
        "terseLabel": "5.250% Senior Notes Due January 2030"
       }
      }
     },
     "localname": "SeniorNotes525DueJanuary2030Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes550DueMarch2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.50% Senior Notes due March 2023 [Member]",
        "label": "Senior Notes, 5.50%, Due March 2023 [Member]",
        "verboseLabel": "5.50% Senior Notes Due March 2023"
       }
      }
     },
     "localname": "SeniorNotes550DueMarch2023Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes6125DueApril2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.125% Senior Notes due April 2025 [Member]",
        "label": "Senior Notes, 6.125%, Due April 2025 [Member]",
        "terseLabel": "6.125% Senior Notes Due April 2025"
       }
      }
     },
     "localname": "SeniorNotes6125DueApril2025Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes625DueFebruary2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 6.25%, Due February 2029",
        "label": "Senior Notes, 6.25%, Due February 2029 [Member]",
        "terseLabel": "6.250% Senior Notes Due February 2029"
       }
      }
     },
     "localname": "SeniorNotes625DueFebruary2029Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes700DueJanuary2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes 7.00 Percent Due January 2028 [Member]",
        "label": "Senior Notes, 7.00%, Due January 2028 [Member]",
        "terseLabel": "7.000 % Senior Notes Due January 2028"
       }
      }
     },
     "localname": "SeniorNotes700DueJanuary2028Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes700DueMarch2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes, 7.00%, Due March 2024",
        "label": "Senior Notes, 7.00%, Due March 2024 [Member]",
        "terseLabel": "Senior Notes, 7.00%, Due March 2024"
       }
      }
     },
     "localname": "SeniorNotes700DueMarch2024Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes725DueMay2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes 7.25 Percent Due May 2029 [Member]",
        "label": "Senior Notes, 7.25%, Due May 2029 [Member]",
        "terseLabel": "7.250% Senior Notes Due May 2029"
       }
      }
     },
     "localname": "SeniorNotes725DueMay2029Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes850DueJanuary2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "8.50% Senior Notes Due January 2027 [Member]",
        "label": "Senior Notes, 8.50%, Due January 2027 [Member]",
        "terseLabel": "8.500% Senior Notes Due January 2027"
       }
      }
     },
     "localname": "SeniorNotes850DueJanuary2027Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes900DueDecember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "9.00% Senior Notes due December 2025 [Member]",
        "label": "Senior Notes, 9.00%, Due December 2025 [Member]",
        "terseLabel": "9.000% Senior Notes Due December 2025"
       }
      }
     },
     "localname": "SeniorNotes900DueDecember2025Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorNotes925DueApril2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "9.25% Senior Notes Due April 2026 [Member]",
        "label": "Senior Notes, 9.25%, Due April 2026 [Member]",
        "verboseLabel": "9.250% Senior Notes Due April 2026"
       }
      }
     },
     "localname": "SeniorNotes925DueApril2026Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured4875NotesDueJune2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 4.875% Notes Due June 2028",
        "label": "Senior Secured 4.875% Notes Due June 2028 [Member]",
        "terseLabel": "4.875% Senior Notes Due June 2028"
       }
      }
     },
     "localname": "SeniorSecured4875NotesDueJune2028Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured5.50NotesDueNovember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 5.50% Notes Due November 2025 [Member]",
        "label": "Senior Secured 5.50% Notes Due November 2025 [Member]",
        "terseLabel": "5.500% Senior Notes Due November 2025"
       }
      }
     },
     "localname": "SeniorSecured5.50NotesDueNovember2025Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured5.75NotesDueAugust2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 5.75% Notes Due August 2027 [Member]",
        "label": "Senior Secured 5.75% Notes Due August 2027 [Member]",
        "verboseLabel": "5.750% Senior Notes Due August 2027"
       }
      }
     },
     "localname": "SeniorSecured5.75NotesDueAugust2027Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecured6125NotesDueFebruary2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured 6.125% Notes Due February 2027",
        "label": "Senior Secured 6.125% Notes Due February 2027 [Member]",
        "terseLabel": "Senior Secured 6.125% Notes Due February 2027"
       }
      }
     },
     "localname": "SeniorSecured6125NotesDueFebruary2027Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecuredCreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured Credit Facilities [Member]",
        "label": "Senior Secured Credit Facilities [Member]",
        "terseLabel": "Senior Credit Facilities"
       }
      }
     },
     "localname": "SeniorSecuredCreditFacilitiesMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecuredNotes6.50PercentDueMarch2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured Notes 6.50 Percent Due March 2022 [Member]",
        "label": "Senior Secured Notes 6.50 Percent Due March 2022 [Member]",
        "terseLabel": "6.50% Senior Notes Due March 2022"
       }
      }
     },
     "localname": "SeniorSecuredNotes6.50PercentDueMarch2022Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecuredNotes7.00PercentDueMarch2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured Notes 7.00 Percent Due March 2024 [Member]",
        "label": "Senior Secured Notes 7.00 Percent Due March 2024 [Member]",
        "terseLabel": "7.000 % Senior Notes Due March 2024"
       }
      }
     },
     "localname": "SeniorSecuredNotes7.00PercentDueMarch2024Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecuredNotesAndSeniorUnsecuredNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Secured Notes And Senior Unsecured Notes [Member]",
        "label": "Senior Secured Notes And Senior Unsecured Notes [Member]",
        "terseLabel": "Senior Secured and Unsecured Notes"
       }
      }
     },
     "localname": "SeniorSecuredNotesAndSeniorUnsecuredNotesMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorSecuredTermCreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Senior Secured Credit Facilities which includes the Revolving Credit Facility, New Term Loan A Facility, and the Delayed Draw Facility.",
        "label": "Senior Secured Term Credit Facilities [Member]",
        "terseLabel": "Senior Secured Credit Facilities"
       }
      }
     },
     "localname": "SeniorSecuredTermCreditFacilitiesMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SeniorUnsecuredNotesDue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due 2023 [Member]",
        "label": "Senior Unsecured Notes Due 2023 [Member]",
        "terseLabel": "Senior Unsecured Notes due 2023"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDue2023Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sensitivity Analysis, Impact Of 1 Percent Change In Estimated Return Rate, Income (Loss) Before Tax",
        "label": "Sensitivity Analysis, Impact Of 1 Percent Change In Estimated Return Rate, Income (Loss) Before Tax",
        "terseLabel": "1% change in estimated return rates, Impact on pre-tax earnings"
       }
      }
     },
     "localname": "SensitivityAnalysisImpactOf1PercentChangeInEstimatedReturnRateIncomeLossBeforeTax",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sensitivity Analysis, Impact Of 1 Percent Change In Volume Of Product Sold Through To Medicaid Plan Participants, Income (Loss) Before Tax",
        "label": "Sensitivity Analysis, Impact Of 1 Percent Change In Volume Of Product Sold Through To Medicaid Plan Participants, Income (Loss) Before Tax",
        "terseLabel": "1% change in volume of product sold through to Medicaid plan participants, Impact on pre-tax earnings"
       }
      }
     },
     "localname": "SensitivityAnalysisImpactOf1PercentChangeInVolumeOfProductSoldThroughToMedicaidPlanParticipantsIncomeLossBeforeTax",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_SeparationAndInitialPublicOfferingCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Separation And Initial Public Offering Costs",
        "label": "Separation And Initial Public Offering Costs [Member]",
        "terseLabel": "Separation and IPO Costs"
       }
      }
     },
     "localname": "SeparationAndInitialPublicOfferingCostsMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum number of common shares that could be issued upon vesting of outstanding awards.",
        "label": "Share Based Compensation, Arrangement by Share Based Payment Award, Number of Shares that could be Issued",
        "terseLabel": "Maximum common shares issuable upon vesting (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesThatCouldBeIssued",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Share Based Compensation, Arrangement by Share Based Payment Award, Options Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the total fair value of stock options vested during the period.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options Vested in Period, Total Fair Value",
        "terseLabel": "Fair value of stock options vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of stock options that will vest in the future period.",
        "label": "Share Based Compensation, Arrangement by Share Based Payment Award, Options Vested Percentage",
        "terseLabel": "Percentage of stock options that will vest on each of the first, second, third and fourth anniversaries from the date of grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Share Based Compensation, Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted- Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Plan Modification, Fair Market Value Limit On Annual Grant",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Plan Modification, Fair Market Value Limit On Annual Grant",
        "terseLabel": "Aggregate fair market value on awards granted during any calendar year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationFairMarketValueLimitOnAnnualGrant",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Share Based Compensation, Arrangement by Share Based Payment Award Options Weighted Average Exercise Price [Roll Forward]",
        "terseLabel": "Weighted- Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageExercisePriceRollForward",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bhc_ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shower To Shower Product Liability Litigation Alleging Caused Ovarian Cancer Mesothelioma Or Breast Cancer",
        "label": "Shower To Shower Product Liability Litigation Alleging Caused Ovarian Cancer Mesothelioma Or Breast Cancer [Member]",
        "terseLabel": "Shower To Shower Product Liability Litigation Alleging Caused Ovarian Cancer Mesothelioma Or Breast Cancer"
       }
      }
     },
     "localname": "ShowerToShowerProductLiabilityLitigationAllegingCausedOvarianCancerMesotheliomaOrBreastCancerMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ShowertoShowerProductLiabilityLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shower to Shower Product Liability Litigation [Member]",
        "label": "Shower to Shower Product Liability Litigation [Member]",
        "terseLabel": "Shower to Shower Product Liability Litigation"
       }
      }
     },
     "localname": "ShowertoShowerProductLiabilityLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Slayback Pharma LLC And Slayback Pharma India LLP Litigation",
        "label": "Slayback Pharma LLC And Slayback Pharma India LLP Litigation [Member]",
        "terseLabel": "Slayback Pharma LLC And Slayback Pharma India LLP Litigation"
       }
      }
     },
     "localname": "SlaybackPharmaLLCAndSlaybackPharmaIndiaLLPLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SoltaMedicalSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Solta Medical Segment",
        "label": "Solta Medical Segment [Member]",
        "terseLabel": "Solta Medical"
       }
      }
     },
     "localname": "SoltaMedicalSegmentMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Spear Pharmaceuticals, Inc. And Spear Dermatology Products Inc. [Member]",
        "label": "Spear Pharmaceuticals, Inc. And Spear Dermatology Products Inc. [Member]",
        "terseLabel": "Spear Pharmaceuticals, Inc. And Spear Dermatology Products Inc."
       }
      }
     },
     "localname": "SpearPharmaceuticalsInc.AndSpearDermatologyProductsInc.Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_SummaryOfResearchAndDevelopmentExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Research And Development Expense [Table Text Block]",
        "label": "Summary Of Research And Development Expense [Table Text Block]",
        "terseLabel": "Summary of research and development"
       }
      }
     },
     "localname": "SummaryOfResearchAndDevelopmentExpenseTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_SummaryOfValuationAndQualifyingAccountsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Valuation And Qualifying Accounts [Table Text Block]",
        "label": "Summary Of Valuation And Qualifying Accounts [Table Text Block]",
        "terseLabel": "Summary of variable consideration provisions"
       }
      }
     },
     "localname": "SummaryOfValuationAndQualifyingAccountsTableTextBlock",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bhc_SynergyPharmaceuticalsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Synergy Pharmaceuticals Inc. [Member]",
        "label": "Synergy Pharmaceuticals Inc. [Member]",
        "terseLabel": "Synergy"
       }
      }
     },
     "localname": "SynergyPharmaceuticalsInc.Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TSRPerformanceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TSR Performance-Based Restricted Stock Units [Member]",
        "label": "TSR Performance-Based Restricted Stock Units [Member]",
        "terseLabel": "TSR Performance-Based Restricted Stock Units"
       }
      }
     },
     "localname": "TSRPerformanceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TaxBenefitRecognitionMeasurementPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Benefit Recognition, Measurement Percentage",
        "label": "Tax Benefit Recognition, Measurement Percentage",
        "terseLabel": "Tax benefit recognition, measurement percentage (greater than)"
       }
      }
     },
     "localname": "TaxBenefitRecognitionMeasurementPercentage",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bhc_TaxYear2005ThroughTaxYear2009Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Year 2005 Through Tax Year 2009",
        "label": "Tax Year 2005 Through Tax Year 2009 [Member]",
        "terseLabel": "Tax Year 2005 through Tax Year 2009"
       }
      }
     },
     "localname": "TaxYear2005ThroughTaxYear2009Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TaxYear2015AndTaxYear2016Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Year 2015 And Tax Year 2016",
        "label": "Tax Year 2015 And Tax Year 2016 [Member]",
        "terseLabel": "Tax Year 2015 and Tax Year 2016"
       }
      }
     },
     "localname": "TaxYear2015AndTaxYear2016Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermLoanBFacilityDueJune2025AndNovember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B Facility Due June 2025 And November 2025",
        "label": "Term Loan B Facility Due June 2025 And November 2025 [Member]",
        "terseLabel": "Term Loan B Facility Due June 2025 and November 2025"
       }
      }
     },
     "localname": "TermLoanBFacilityDueJune2025AndNovember2025Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermLoanBFacilityDueJune2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B Facility Due June 2025 [Member]",
        "label": "Term Loan B Facility Due June 2025 [Member]",
        "terseLabel": "Term Loan B Facility Due June 2025",
        "verboseLabel": "Term Loan B Facility Due June 2025"
       }
      }
     },
     "localname": "TermLoanBFacilityDueJune2025Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermLoanBFacilityDueNovember2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B Facility Due November 2025 [Member]",
        "label": "Term Loan B Facility Due November 2025 [Member]",
        "terseLabel": "Term Loan B Facility Due November 2025"
       }
      }
     },
     "localname": "TermLoanBFacilityDueNovember2025Member",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TermLoanBFacilityNewRestatedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B Facility, New Restated Credit Agreement",
        "label": "Term Loan B Facility, New Restated Credit Agreement [Member]",
        "terseLabel": "Term Loan B Facility, New Restated Credit Agreement"
       }
      }
     },
     "localname": "TermLoanBFacilityNewRestatedCreditAgreementMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ThreeLargestUSWholesalerCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the three largest U.S. wholesaler customers.",
        "label": "Three Largest US Wholesaler Customers [Member]",
        "terseLabel": "Three largest U.S. wholesaler customers"
       }
      }
     },
     "localname": "ThreeLargestUSWholesalerCustomersMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TimeBasedRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents stock awards in the form of time-based restricted stock units (RSUs) to certain directors, officers and other eligible employees pursuant to the company's incentive compensation plan.",
        "label": "Time Based RSU [Member]",
        "terseLabel": "Time-Based RSUs"
       }
      }
     },
     "localname": "TimeBasedRSUMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_TradeReceivableNetPortionPastDue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trade Receivable, Net, Portion Past Due",
        "label": "Trade Receivable, Net, Portion Past Due",
        "terseLabel": "Portion of net trade receivables that is past due"
       }
      }
     },
     "localname": "TradeReceivableNetPortionPastDue",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_U.S.BroadMarketMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. Broad Market [Member]",
        "label": "U.S. Broad Market [Member]",
        "terseLabel": "U.S. broad market"
       }
      }
     },
     "localname": "U.S.BroadMarketMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_UnclaimedTaxCreditsAndResearchAndDevelopmentCredits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of unclaimed tax credits and research and development credits.",
        "label": "Unclaimed Tax Credits and Research and Development Credits",
        "terseLabel": "Unclaimed investment tax credits and research and development credits"
       }
      }
     },
     "localname": "UnclaimedTaxCreditsAndResearchAndDevelopmentCredits",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_UnitedStatesandPuertoRicoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United States and Puerto Rico [Member]",
        "label": "United States and Puerto Rico [Member]",
        "terseLabel": "U.S. and Puerto Rico"
       }
      }
     },
     "localname": "UnitedStatesandPuertoRicoMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_UnrecognizedTaxBenefitsIncludingInterestAndPenalties": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross amount of unrecognized tax benefits including interest and penalties pertaining to uncertain tax positions taken in tax returns as of the balance sheet date.",
        "label": "Unrecognized Tax Benefits, Including Interest and Penalties",
        "terseLabel": "Unrecognized tax benefits including interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncludingInterestAndPenalties",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Net Decrease Resulting From Prior Period Tax Positions",
        "label": "Unrecognized Tax Benefits, Net Decrease Resulting From Prior Period Tax Positions",
        "terseLabel": "Unrecognized tax benefits, net decrease for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsNetDecreaseResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Net Increase Resulting from Current Period Tax Positions",
        "label": "Unrecognized Tax Benefits, Net Increase Resulting From Current Period Tax Positions",
        "terseLabel": "Unrecognized tax benefits, net increase for tax positions of current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsNetIncreaseResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Net Increase Resulting From Prior Period Tax Positions",
        "label": "Unrecognized Tax Benefits, Net Increase Resulting From Prior Period Tax Positions",
        "terseLabel": "Unrecognized tax benefits, net increase for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsNetIncreaseResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bhc_UnutilizedITInfrastructureImprovementProjectMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unutilized IT Infrastructure Improvement Project",
        "label": "Unutilized IT Infrastructure Improvement Project [Member]",
        "terseLabel": "Unutilized IT Infrastructure Improvement Project"
       }
      }
     },
     "localname": "UnutilizedITInfrastructureImprovementProjectMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ValeantUSSecuritiesLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valeant US Securities Litigation [Member]",
        "label": "Valeant US Securities Litigation [Member]",
        "terseLabel": "Valeant US Securities Litigation",
        "verboseLabel": "Valeant US Securities Litigation"
       }
      }
     },
     "localname": "ValeantUSSecuritiesLitigationMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bhc_ViolationofCanadianProvincialSecuritiesLegislationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Violation of Canadian Provincial Securities Legislation [Member]",
        "label": "Violation of Canadian Provincial Securities Legislation [Member]",
        "terseLabel": "Violation of Canadian Provincial Securities Legislation"
       }
      }
     },
     "localname": "ViolationofCanadianProvincialSecuritiesLegislationMember",
     "nsuri": "http://www.bauschhealth.com/20220510",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "Canada",
        "verboseLabel": "Canada"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China",
        "verboseLabel": "China"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_DE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GERMANY",
        "terseLabel": "Germany",
        "verboseLabel": "Germany"
       }
      }
     },
     "localname": "DE",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_EG": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EGYPT",
        "terseLabel": "Egypt"
       }
      }
     },
     "localname": "EG",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_ES": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SPAIN",
        "terseLabel": "Spain"
       }
      }
     },
     "localname": "ES",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_FR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FRANCE",
        "terseLabel": "France",
        "verboseLabel": "France"
       }
      }
     },
     "localname": "FR",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_GB": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED KINGDOM",
        "terseLabel": "United Kingdom"
       }
      }
     },
     "localname": "GB",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IRELAND",
        "terseLabel": "Ireland"
       }
      }
     },
     "localname": "IE",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_IT": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ITALY",
        "terseLabel": "Italy"
       }
      }
     },
     "localname": "IT",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_MX": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MEXICO",
        "terseLabel": "Mexico"
       }
      }
     },
     "localname": "MX",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_NL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NETHERLANDS",
        "terseLabel": "Netherlands"
       }
      }
     },
     "localname": "NL",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_PL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "POLAND",
        "terseLabel": "Poland"
       }
      }
     },
     "localname": "PL",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_RS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SERBIA",
        "terseLabel": "Serbia"
       }
      }
     },
     "localname": "RS",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_RU": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RUSSIAN FEDERATION",
        "terseLabel": "Russia"
       }
      }
     },
     "localname": "RU",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/Document"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/Document"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/Document"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/Document"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/Document"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/Document"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/Document"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/Document"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/Document"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r930"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/Document"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r930"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/Document"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/Document"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/Document"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r930"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/Document"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r930"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/Document"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/Document"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r932"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/Document"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r933"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/Document"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r929"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/Document"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r931"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/Document"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r934"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/Document"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/Document"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r935"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.bauschhealth.com/role/Document"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r173",
      "r236",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r262",
      "r266",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r395",
      "r397",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r173",
      "r236",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r262",
      "r266",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r395",
      "r397",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r84",
      "r86",
      "r170",
      "r171",
      "r404",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r2",
      "r185",
      "r193",
      "r199",
      "r291",
      "r603",
      "r604",
      "r605",
      "r653",
      "r654",
      "r738",
      "r741",
      "r743",
      "r744",
      "r938"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r2",
      "r185",
      "r193",
      "r199",
      "r291",
      "r603",
      "r604",
      "r605",
      "r653",
      "r654",
      "r738",
      "r741",
      "r743",
      "r744",
      "r938"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r2",
      "r185",
      "r193",
      "r199",
      "r291",
      "r603",
      "r604",
      "r605",
      "r653",
      "r654",
      "r738",
      "r741",
      "r743",
      "r744",
      "r938"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r274",
      "r455",
      "r458",
      "r893"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Major Customers [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r403",
      "r438",
      "r554",
      "r560",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r833",
      "r890",
      "r894",
      "r926",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r403",
      "r438",
      "r554",
      "r560",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r833",
      "r890",
      "r894",
      "r926",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r274",
      "r455",
      "r458",
      "r893"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Name of Major Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r269",
      "r455",
      "r456",
      "r838",
      "r889",
      "r891"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r269",
      "r455",
      "r456",
      "r838",
      "r889",
      "r891"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r403",
      "r438",
      "r490",
      "r554",
      "r560",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r833",
      "r890",
      "r894",
      "r926",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r403",
      "r438",
      "r490",
      "r554",
      "r560",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r833",
      "r890",
      "r894",
      "r926",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r85",
      "r86",
      "r170",
      "r171",
      "r404",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r194",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Scenario, Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r194",
      "r199",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r270",
      "r271",
      "r455",
      "r457",
      "r892",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r270",
      "r271",
      "r455",
      "r457",
      "r892",
      "r910",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r194",
      "r199",
      "r369",
      "r555",
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r276",
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r178",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA-BC": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BRITISH COLUMBIA",
        "terseLabel": "British Columbia"
       }
      }
     },
     "localname": "CA-BC",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CA-QC": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "QUEBEC",
        "terseLabel": "Quebec"
       }
      }
     },
     "localname": "CA-QC",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NJ": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW JERSEY",
        "terseLabel": "New Jersey"
       }
      }
     },
     "localname": "NJ",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r186",
      "r187",
      "r188",
      "r189",
      "r282",
      "r283",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r384",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r653",
      "r654",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r814",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "ACCRUED AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r60",
      "r818"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r911"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Trade receivables"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r23",
      "r41",
      "r277",
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Net trade receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r27",
      "r28",
      "r64"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Employee compensation and benefit costs"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r35",
      "r848",
      "r871"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r93",
      "r99",
      "r109",
      "r110",
      "r111",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Pension adjustment, net of tax"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r57",
      "r341"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r44",
      "r96",
      "r98",
      "r99",
      "r874",
      "r902",
      "r906"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r109",
      "r110",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r95",
      "r99",
      "r109",
      "r110",
      "r111",
      "r182",
      "r183",
      "r184",
      "r698",
      "r897",
      "r898",
      "r940"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "verboseLabel": "AOCI Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r90",
      "r99",
      "r109",
      "r110",
      "r111",
      "r698",
      "r781",
      "r782",
      "r783",
      "r784",
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r603",
      "r604",
      "r605",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Share-based awards tax withholding"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r562",
      "r564",
      "r609",
      "r610"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Costs"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r613"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expenses"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdvertisingCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r280",
      "r294",
      "r295",
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of period",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries": {
     "auth_ref": [
      "r298"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in allowance for credit loss on accounts receivable, from recovery.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Recovery",
        "terseLabel": "Recoveries"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRecoveries",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "negatedTerseLabel": "Write-offs"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r153",
      "r423",
      "r433",
      "r434",
      "r794"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization and write-off of debt discounts and debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Excluded from computation of diluted earnings per share, effect anti-dilutive (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "verboseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r153",
      "r336"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "negatedLabel": "Asset impairments, including loss on assets held for sale",
        "terseLabel": "Asset impairments, including loss on assets held for sale",
        "verboseLabel": "Asset impairments, including loss on assets held for sale"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r165",
      "r244",
      "r257",
      "r264",
      "r287",
      "r385",
      "r386",
      "r387",
      "r389",
      "r390",
      "r391",
      "r392",
      "r394",
      "r396",
      "r398",
      "r399",
      "r692",
      "r699",
      "r766",
      "r816",
      "r818",
      "r846",
      "r870"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Assets reclassified, held and used",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r24",
      "r25",
      "r79",
      "r165",
      "r287",
      "r385",
      "r386",
      "r387",
      "r389",
      "r390",
      "r391",
      "r392",
      "r394",
      "r396",
      "r398",
      "r399",
      "r692",
      "r699",
      "r766",
      "r816",
      "r818"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsHeldForSaleLongLivedFairValueDisclosure": {
     "auth_ref": [
      "r746"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of assets classified as held for sale.",
        "label": "Assets Held-for-sale, Long Lived, Fair Value Disclosure",
        "terseLabel": "Non-current assets held for sale"
       }
      }
     },
     "localname": "AssetsHeldForSaleLongLivedFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]",
        "terseLabel": "Prepaid expenses and other current assets:"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent [Abstract]",
        "terseLabel": "Other non-current assets:"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AustralianTaxationOfficeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Australia.",
        "label": "Australian Taxation Office [Member]",
        "terseLabel": "Australia",
        "verboseLabel": "Australian Taxation Office"
       }
      }
     },
     "localname": "AustralianTaxationOfficeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r566",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r711",
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Buildings and improvements",
        "verboseLabel": "Buildings and improvements"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r549",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r549",
      "r556",
      "r672",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "auth_ref": [
      "r670",
      "r671"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisition, Pro Forma Revenue",
        "terseLabel": "Pro-forma revenue"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r668"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition-related contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r679",
      "r680"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details": {
       "order": 1.0,
       "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "verboseLabel": "Current portion"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r751"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Fair value, contingent consideration obligations, discount rate"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r679",
      "r680"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details": {
       "order": 2.0,
       "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Non-current portion"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": {
     "auth_ref": [
      "r669"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.",
        "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual",
        "terseLabel": "Revenue of acquiree since acquisition date"
       }
      }
     },
     "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r675"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r675"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r675"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedTerseLabel": "Accounts payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r675"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Product brand intangible assets (estimated useful life 7 years)"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "auth_ref": [
      "r674",
      "r675"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of inventory recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r674",
      "r675"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Total identifiable net assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r675"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Total fair value of consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Acquisitions and Acquisition-Related Contingent Consideration"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CanadaRevenueAgencyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Canada.",
        "label": "Canada Revenue Agency [Member]",
        "terseLabel": "Canada Revenue Agency"
       }
      }
     },
     "localname": "CanadaRevenueAgencyMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r21",
      "r54",
      "r155"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "bhc_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndOtherSettlementDeposits",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r31",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r146",
      "r779"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in Cash and cash equivalents and Restricted cash and other settlement deposits"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "terseLabel": "SUPPLEMENTAL CASH FLOW DISCLOSURES"
       }
      }
     },
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans.",
        "label": "Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]",
        "terseLabel": "Components of the change in projected benefit obligations, change in plan assets and funded status"
       }
      }
     },
     "localname": "ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r69",
      "r368",
      "r854",
      "r880"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Notes\u00a020 and 21)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r378",
      "r912"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r381",
      "r913"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r182",
      "r183",
      "r743"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r40",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r40",
      "r818"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common shares, no par value, unlimited shares authorized, 359,405,748 and 355,422,347\u00a0issued and outstanding at December\u00a031, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r104",
      "r106",
      "r107",
      "r119",
      "r860",
      "r885"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Bausch Health Companies Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r104",
      "r106",
      "r118",
      "r690",
      "r691",
      "r703",
      "r859",
      "r884"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Comprehensive income attributable to noncontrolling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r104",
      "r106",
      "r117",
      "r689",
      "r703",
      "r858",
      "r883"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r116",
      "r129",
      "r857",
      "r882"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r224",
      "r225",
      "r274",
      "r763",
      "r764",
      "r911"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r224",
      "r225",
      "r274",
      "r763",
      "r764",
      "r908",
      "r911"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r224",
      "r225",
      "r274",
      "r763",
      "r764",
      "r908",
      "r911"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r218",
      "r867"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r224",
      "r225",
      "r274",
      "r763",
      "r764"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r221",
      "r224",
      "r225",
      "r226",
      "r763",
      "r765",
      "r911"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r224",
      "r225",
      "r274",
      "r763",
      "r764",
      "r911"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Capital expenditures"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualRightsMember": {
     "auth_ref": [
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights that arise from a contractual arrangement with a third party (not including franchise rights and license agreements).",
        "label": "Contractual Rights [Member]",
        "terseLabel": "Product rights/patents",
        "verboseLabel": "Product rights/patents"
       }
      }
     },
     "localname": "ContractualRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r266",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r124",
      "r838"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r122"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total Expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "auth_ref": [
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.",
        "label": "Credit Concentration Risk [Member]",
        "terseLabel": "Credit concentration"
       }
      }
     },
     "localname": "CreditConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESConcentrationsofCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrencySwapMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.",
        "label": "Currency Swap [Member]",
        "terseLabel": "Cross-currency swaps",
        "verboseLabel": "Cross-currency swaps"
       }
      }
     },
     "localname": "CurrencySwapMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r166",
      "r647",
      "r657"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "negatedTerseLabel": "Domestic"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r166",
      "r647"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "negatedTerseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r166",
      "r647",
      "r657",
      "r659"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r222",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer concentration"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r163",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r417",
      "r424",
      "r425",
      "r427",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "FINANCING ARRANGEMENTS"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r164",
      "r173",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r407",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r431",
      "r432",
      "r433",
      "r434",
      "r795",
      "r847",
      "r851",
      "r869"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Variable interest rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r36",
      "r428",
      "r851",
      "r869"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Principal Amount",
        "totalLabel": "Total gross maturities"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r400",
      "r431",
      "r432",
      "r793",
      "r795",
      "r796"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Aggregate principal amount",
        "verboseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r415",
      "r431",
      "r432",
      "r762"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value of long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r66",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate",
        "verboseLabel": "Stated interest rate on debt (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]",
        "verboseLabel": "Long-term debt, net of unamortized debt discount"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r67",
      "r164",
      "r173",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r407",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r431",
      "r432",
      "r433",
      "r434",
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r865"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r865"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r865"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period One"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r865"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Debt Instrument, Redemption, Period Two"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r865"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption price percentage (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of principal amount of debt redeemed.",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "terseLabel": "Maximum percentage of principal amount that can be redeemed"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of the original debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchased Face Amount",
        "terseLabel": "Repurchased face amount",
        "verboseLabel": "Repurchased aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r67",
      "r164",
      "r173",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r407",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r426",
      "r431",
      "r432",
      "r433",
      "r434",
      "r441",
      "r442",
      "r443",
      "r444",
      "r792",
      "r793",
      "r795",
      "r796",
      "r866"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r413",
      "r792",
      "r796"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Unamortized discounts"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Weighted average interest rate"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r627"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Possible decrease in unrecognized tax benefits realized in next twelve months"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Debt Discounts and Premiums, Issuance Costs and Deferred Financing Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r166",
      "r648",
      "r657"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Domestic"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r166",
      "r648",
      "r657"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r620",
      "r621"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r153",
      "r166",
      "r648",
      "r657",
      "r658",
      "r659"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r37",
      "r38",
      "r638",
      "r849",
      "r868"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r620",
      "r621"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetDomain": {
     "auth_ref": [
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the deferred tax asset for which a valuation reserve exists.",
        "label": "Deferred Tax Asset [Domain]",
        "terseLabel": "Deferred Tax Asset [Domain]"
       }
      }
     },
     "localname": "DeferredTaxAssetDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r645",
      "r646"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r639"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r641"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r641"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r645",
      "r646"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r644",
      "r645",
      "r646"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r645",
      "r646"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r645",
      "r646"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Provisions"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r640"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance",
        "terseLabel": "Valuation allowance against deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r645",
      "r646"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": {
     "auth_ref": [
      "r645"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.",
        "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings",
        "terseLabel": "Outside basis differences"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains": {
     "auth_ref": [
      "r645",
      "r646"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on foreign currency transactions.",
        "label": "Deferred Tax Liabilities, Unrealized Currency Transaction Gains",
        "terseLabel": "Unrealized FX on U.S. dollar debt and other financing cost"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTaxEffectofMajorItemsRecordedasDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax": {
     "auth_ref": [
      "r99",
      "r511"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Accumulated Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Tax",
        "terseLabel": "Unrecognized actuarial losses"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax": {
     "auth_ref": [
      "r99",
      "r511"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Tax",
        "negatedLabel": "Unrecognized prior service credits"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": {
     "auth_ref": [
      "r480",
      "r540"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.",
        "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)",
        "terseLabel": "Actual return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLoss": {
     "auth_ref": [
      "r472"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)",
        "negatedTerseLabel": "Actuarial (gain) losses"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r465",
      "r506",
      "r534",
      "r540",
      "r541"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedTerseLabel": "Amortization of net loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r465",
      "r507",
      "r535",
      "r540",
      "r541"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Amortization of prior service credit"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]",
        "terseLabel": "Recognized as:"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase",
        "terseLabel": "Rate of compensation increase"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average interest crediting rate used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Weighted-Average Interest Crediting Rate",
        "terseLabel": "Interest crediting rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationWeightedAverageInterestCreditingRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": {
     "auth_ref": [
      "r515",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets",
        "terseLabel": "Percentage of expected return on plan assets",
        "verboseLabel": "Expected rate of return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase",
        "terseLabel": "Rate of compensation increase"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average interest crediting rate used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, cash balance and other defined benefit plans with promised interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Weighted-Average Interest Crediting Rate",
        "terseLabel": "Interest crediting rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostWeightedAverageInterestCreditingRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "periodEndLabel": "Projected benefit obligation, end of year",
        "periodStartLabel": "Projected benefit obligation, beginning of year"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": {
     "auth_ref": [
      "r474",
      "r546"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid",
        "negatedLabel": "Benefits paid"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": {
     "auth_ref": [
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r518",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]"
       }
      }
     },
     "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalent in which defined benefit plan asset is invested.",
        "label": "Defined Benefit Plan, Cash and Cash Equivalents [Member]",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DefinedBenefitPlanCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]",
        "terseLabel": "Change in Projected Benefit Obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]",
        "terseLabel": "Change in Plan Assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r482",
      "r491",
      "r493",
      "r538",
      "r540",
      "r541"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Company contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanEquitySecuritiesMember": {
     "auth_ref": [
      "r491",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security representing ownership in corporation or other legal entity for which ownership is represented by share of stock, in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.",
        "label": "Defined Benefit Plan, Equity Securities [Member]",
        "terseLabel": "Equity securities",
        "verboseLabel": "Equity securities:"
       }
      }
     },
     "localname": "DefinedBenefitPlanEquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": {
     "auth_ref": [
      "r500"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years",
        "terseLabel": "2027-2031"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": {
     "auth_ref": [
      "r500"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": {
     "auth_ref": [
      "r500"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": {
     "auth_ref": [
      "r500"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": {
     "auth_ref": [
      "r500"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": {
     "auth_ref": [
      "r500"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": {
     "auth_ref": [
      "r501",
      "r541"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year",
        "terseLabel": "Estimated company contributions in next fiscal year"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r465",
      "r505",
      "r533",
      "r540",
      "r541"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedTerseLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "auth_ref": [
      "r479",
      "r491",
      "r493",
      "r494",
      "r540"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.",
        "label": "Defined Benefit Plan, Plan Assets, Amount",
        "periodEndLabel": "Fair value of plan assets, end of year",
        "periodStartLabel": "Fair value of plan assets, beginning of year",
        "terseLabel": "Fair value of plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": {
     "auth_ref": [
      "r473"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Currency translation adjustments"
       }
      }
     },
     "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": {
     "auth_ref": [
      "r463",
      "r488",
      "r540"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.",
        "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan",
        "totalLabel": "Funded status, end of year"
       }
      }
     },
     "localname": "DefinedBenefitPlanFundedStatusOfPlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r465",
      "r470",
      "r504",
      "r532",
      "r540",
      "r541"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r502",
      "r530",
      "r540",
      "r541"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "totalLabel": "Net periodic (benefit) cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanOtherCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of defined benefit plan cost (credit), classified as other.",
        "label": "Defined Benefit Plan, Other Cost (Credit)",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DefinedBenefitPlanOtherCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]",
        "terseLabel": "Underfunded plans having accumulated benefit obligations exceeding the fair value of plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": {
     "auth_ref": [
      "r526",
      "r527",
      "r540"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation",
        "terseLabel": "Accumulated benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": {
     "auth_ref": [
      "r526",
      "r527",
      "r540"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets",
        "terseLabel": "Fair value of plan assets",
        "verboseLabel": "Underfunded pension benefit plans"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation": {
     "auth_ref": [
      "r526"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation",
        "terseLabel": "Projected benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": {
     "auth_ref": [
      "r484",
      "r546"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Plan Assets, Benefits Paid",
        "negatedTerseLabel": "Benefits paid"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r481"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Currency translation adjustments"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": {
     "auth_ref": [
      "r490",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.",
        "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage",
        "terseLabel": "Defined benefit plan, percentage of actual plan asset allocations"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": {
     "auth_ref": [
      "r466",
      "r509",
      "r537"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement",
        "negatedTerseLabel": "Settlement loss recognized"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r468",
      "r503",
      "r531",
      "r540",
      "r541"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanSettlementsBenefitObligation": {
     "auth_ref": [
      "r469"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement.",
        "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanSettlementsBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": {
     "auth_ref": [
      "r487"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.",
        "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanSettlementsPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]",
        "terseLabel": "For Determining Benefit Obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]",
        "terseLabel": "For Determining Net Periodic (Benefit) Cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r524",
      "r525",
      "r528",
      "r529",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans.",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r547"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Contributions recognized"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r153",
      "r339"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r153",
      "r339"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization of intangible assets"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueGrossLiability": {
     "auth_ref": [
      "r81",
      "r88",
      "r713"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Asset, Fair Value, Gross Liability",
        "terseLabel": "Accrued and other current liabilities",
        "verboseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "DerivativeAssetFairValueGrossLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r82",
      "r83",
      "r86",
      "r762"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Foreign currency exchange contracts"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r80",
      "r86",
      "r87",
      "r713",
      "r832"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r86",
      "r712",
      "r714",
      "r720",
      "r726"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r709",
      "r712",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r709",
      "r712",
      "r720",
      "r726",
      "r727",
      "r730",
      "r734"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r719",
      "r721"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Gain (loss) related to changes in fair value"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss": {
     "auth_ref": [
      "r719",
      "r721"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized loss of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Loss",
        "negatedTerseLabel": "Loss related to settlements"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r82",
      "r83",
      "r86",
      "r762"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Derivative liabilities",
        "totalLabel": "Net fair value"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r705",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Aggregate notional amounts"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r172",
      "r704",
      "r706",
      "r709",
      "r710",
      "r729"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Derivative Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss).",
        "label": "Disclosure of Long Lived Assets Held-for-sale [Table Text Block]",
        "terseLabel": "Schedule of carrying amounts of assets and liabilities held for sale"
       }
      }
     },
     "localname": "DisclosureOfLongLivedAssetsHeldForSaleTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails",
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails",
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r337",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r334",
      "r337",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that either has been sold or is classified as held-for-sale. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupHeldForSaleOrDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r17",
      "r334",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Held-for-sale, Not Discontinued Operations [Member]",
        "terseLabel": "Held For Sale"
       }
      }
     },
     "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails",
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": {
     "auth_ref": [
      "r6",
      "r7",
      "r15",
      "r345"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r15",
      "r338",
      "r345"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets": {
     "auth_ref": [
      "r6",
      "r7",
      "r15",
      "r345"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as deferred tax assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Deferred Tax Assets",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities": {
     "auth_ref": [
      "r6",
      "r7",
      "r15",
      "r345"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities",
        "terseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r15",
      "r333",
      "r345"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent",
        "terseLabel": "Goodwill and Intangible assets, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r15",
      "r338",
      "r345"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Inventory, Current",
        "terseLabel": "Inventories, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets": {
     "auth_ref": [
      "r6",
      "r7",
      "r15",
      "r338",
      "r345"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets, Current",
        "totalLabel": "Total Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities": {
     "auth_ref": [
      "r6",
      "r7",
      "r15",
      "r338",
      "r345"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Current",
        "totalLabel": "Total Accrued and other current liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets": {
     "auth_ref": [
      "r6",
      "r7",
      "r15",
      "r333",
      "r345"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent",
        "totalLabel": "Total Other non-current assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities": {
     "auth_ref": [
      "r6",
      "r7",
      "r15",
      "r333",
      "r345"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent",
        "totalLabel": "Total Other non-current liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r15",
      "r338",
      "r345"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r15",
      "r333",
      "r345"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r549",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails",
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "United States - Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r548",
      "r552",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r120",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r200",
      "r202",
      "r204",
      "r205",
      "r206",
      "r210",
      "r211",
      "r744",
      "r745",
      "r861",
      "r886"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic loss per share attributable to Bausch Health Companies Inc. (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r120",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r202",
      "r204",
      "r205",
      "r206",
      "r210",
      "r211",
      "r744",
      "r745",
      "r861",
      "r886"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted loss per share attributable to Bausch Health Companies Inc. (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r207",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss Per Share Attributable to Bausch Health Companies Inc."
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r207",
      "r208",
      "r209",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r779"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r168",
      "r623",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Expected Canadian statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Components and classification of share-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r596"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Remaining unrecognized compensation expense related to non-vested awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average remaining requisite service period over which unrecognized compensation cost is expected to be amortized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]",
        "verboseLabel": "Segment reporting information"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r109",
      "r110",
      "r111",
      "r182",
      "r183",
      "r184",
      "r187",
      "r196",
      "r198",
      "r214",
      "r291",
      "r440",
      "r445",
      "r603",
      "r604",
      "r605",
      "r653",
      "r654",
      "r743",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r786",
      "r897",
      "r898",
      "r899",
      "r940"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EurodollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.",
        "label": "Eurodollar [Member]",
        "terseLabel": "Eurodollar"
       }
      }
     },
     "localname": "EurodollarMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "verboseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r746",
      "r747",
      "r748",
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r746",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.",
        "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]",
        "terseLabel": "Schedule of assets and liabilities measured at fair value on a non-recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r415",
      "r431",
      "r432",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r540",
      "r747",
      "r823",
      "r824",
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r746",
      "r747",
      "r750",
      "r751",
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r415",
      "r491",
      "r493",
      "r498",
      "r540",
      "r747",
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r415",
      "r431",
      "r432",
      "r491",
      "r493",
      "r498",
      "r540",
      "r747",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "netLabel": "Level 2",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r415",
      "r431",
      "r432",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r540",
      "r747",
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r752",
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of contingent consideration obligations measured on a recurring basis using significant unobservable inputs"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r753"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Acquisition-related contingent consideration adjustments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome": {
     "auth_ref": [
      "r754"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)",
        "verboseLabel": "Foreign currency translation adjustment included in other comprehensive loss"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r755"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedLabel": "Payments / Settlements"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r752"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r415",
      "r431",
      "r432",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r540",
      "r823",
      "r824",
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r746",
      "r747",
      "r750",
      "r751",
      "r756",
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Fair Value, Nonrecurring [Member]",
        "terseLabel": "Non-recurring basis",
        "verboseLabel": "Fair Value, Nonrecurring"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSFairValueofLongtermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r757",
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetAssetLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Net Asset (Liability) [Abstract]",
        "terseLabel": "Other non-current assets:"
       }
      }
     },
     "localname": "FairValueNetAssetLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r760",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "auth_ref": [
      "r732"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.",
        "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]",
        "terseLabel": "Federal Funds Effective Swap Rate"
       }
      }
     },
     "localname": "FederalFundsEffectiveSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r798",
      "r811"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for charging off uncollectible financing receivables, including, but not limited to, factors and methodologies used in estimating the allowance for credit loss.",
        "label": "Financing Receivable, Allowance for Credit Losses, Policy for Uncollectible Amounts [Policy Text Block]",
        "terseLabel": "Allowance for Credit Losses"
       }
      }
     },
     "localname": "FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Weighted- Average Remaining Useful Lives (Years)",
        "verboseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r325"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization and Impairments"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "netLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r319",
      "r322",
      "r325",
      "r328",
      "r839",
      "r843"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Estimated aggregate amortization expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r325",
      "r843"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r319",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r325",
      "r839"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLAmortizationExpenseDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FixedIncomeSecuritiesMember": {
     "auth_ref": [
      "r491",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment that provides a return in the form of fixed periodic payments and eventual return of principal at maturity.",
        "label": "Fixed Income Securities [Member]",
        "terseLabel": "Fixed income securities",
        "verboseLabel": "Fixed income securities:"
       }
      }
     },
     "localname": "FixedIncomeSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Ireland"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r775",
      "r776",
      "r777",
      "r778"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign exchange and other"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r154",
      "r777",
      "r778"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Foreign exchange loss"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r788"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r86",
      "r491",
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign currency exchange contracts"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r166"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.",
        "label": "Foreign Income Tax Expense (Benefit), Continuing Operations",
        "negatedTerseLabel": "Expected benefit from income taxes at Canadian statutory rate"
       }
      }
     },
     "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r548",
      "r552",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "Non-U.S. Plans"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r153",
      "r337",
      "r343"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "negatedLabel": "Gain on disposal of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedTerseLabel": "Net gain on sales of assets",
        "terseLabel": "Milestone achievement, included in net gain (loss) on other sales of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails",
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r368"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedLabel": "Litigation and other matters"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails",
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r153",
      "r435",
      "r436"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on extinguishment of debt",
        "terseLabel": "Loss on extinguishment of debt",
        "verboseLabel": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r304",
      "r306",
      "r818",
      "r845"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance at the end of the period",
        "periodStartLabel": "Balance at the beginning of the period",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "verboseLabel": "Acquisition of certain assets of Synergy"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "INTANGIBLE ASSETS AND GOODWILL"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILL"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r311"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Foreign exchange and other"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r307",
      "r313"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Accumulated goodwill impairment charges to date"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r153",
      "r305",
      "r310",
      "r316"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "negatedTerseLabel": "Impairment",
        "terseLabel": "Goodwill impairments"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Realignment of segment goodwill"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Change in the carrying amount of goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Written off Related to Sale of Business Unit",
        "negatedTerseLabel": "Goodwill reclassified to assets held for sale"
       }
      }
     },
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r709",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r153",
      "r329"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived",
        "verboseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r153",
      "r329"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "Impairment of indefinite-lived intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r153",
      "r335"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "verboseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r332",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r58",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r167",
      "r660"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r114",
      "r244",
      "r256",
      "r260",
      "r263",
      "r266",
      "r844",
      "r855",
      "r862",
      "r887"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Loss before benefit from income taxes",
        "totalLabel": "Loss before benefit from income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r167",
      "r660"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]",
        "terseLabel": "Components of loss before benefit of income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r549",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails",
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredonaNonRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "verboseLabel": "Assets Held For Sale"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r7",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r16",
      "r18",
      "r19",
      "r20",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Schedule of Significant Acquisitions and Disposals [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r344",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r629",
      "r635",
      "r637",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r168",
      "r624",
      "r636",
      "r643",
      "r655",
      "r662",
      "r664",
      "r665",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationEstimateOfPossibleLoss": {
     "auth_ref": [
      "r627"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated amount of loss resulting from an adverse tax position.",
        "label": "Income Tax Examination, Estimate of Possible Loss",
        "terseLabel": "Estimate of possible loss, income tax examination (up to)"
       }
      }
     },
     "localname": "IncomeTaxExaminationEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear": {
     "auth_ref": [
      "r635"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount the liability recorded for the income tax examination increased or decreased in the current year/accounting period.",
        "label": "Income Tax Examination, Increase (Decrease) in Liability from Prior Year",
        "negatedTerseLabel": "Reduction in NOLs"
       }
      }
     },
     "localname": "IncomeTaxExaminationIncreaseDecreaseInLiabilityFromPriorYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r169",
      "r197",
      "r198",
      "r242",
      "r622",
      "r656",
      "r663",
      "r888"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Benefit from income taxes",
        "negatedTotalLabel": "(Provision for) benefit from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/INCOMETAXESComponentsofBenefitfromIncomeTaxesDetails",
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Benefit from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r108",
      "r618",
      "r619",
      "r636",
      "r637",
      "r642",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r623"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "negatedTerseLabel": "Change in valuation allowance on Canadian deferred tax assets and tax rate changes"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r623"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "negatedTerseLabel": "Foreign tax rate differences"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses": {
     "auth_ref": [
      "r623"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount",
        "negatedTerseLabel": "Non-deductible portion of Goodwill impairments"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r623"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount",
        "negatedTerseLabel": "Non-deductible amount of share-based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r623"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofEffectiveIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r148",
      "r157"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "verboseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r152"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r152"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r152"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r152"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Shareholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r320",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r320",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r160",
      "r324",
      "r835",
      "r836",
      "r837",
      "r839"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r318",
      "r323"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Intangible Assets, Net (Excluding Goodwill)"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndDebtExpense": {
     "auth_ref": [
      "r791"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity.",
        "label": "Interest and Debt Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestAndDebtExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestCostsCapitalized": {
     "auth_ref": [
      "r790"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest capitalized during the period.",
        "label": "Interest Costs Capitalized",
        "terseLabel": "Capitalized interest"
       }
      }
     },
     "localname": "InterestCostsCapitalized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r127",
      "r421",
      "r430",
      "r433",
      "r434"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestExpensePolicyTextBlock": {
     "auth_ref": [
      "r789"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing interest expense, including the method of amortizing debt issuance costs.",
        "label": "Interest Expense, Policy [Policy Text Block]",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpensePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r142",
      "r147",
      "r157"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "verboseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r28",
      "r29",
      "r64"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r22",
      "r77",
      "r818"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories, net",
        "totalLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r30",
      "r78",
      "r161",
      "r213",
      "r301",
      "r302",
      "r303",
      "r834"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESSummaryofInventoriesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r126",
      "r237"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandImprovementsMember": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to real estate held.",
        "label": "Land Improvements [Member]",
        "terseLabel": "Land improvements"
       }
      }
     },
     "localname": "LandImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of lease expenses"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets held by a lessee under a capital lease and any addition or improvement to assets held under a lease arrangement (including addition or improvement to assets held by lessee under an operating lease arrangement).",
        "label": "Leaseholds and Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalCostsPolicyTextBlock": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.",
        "label": "Legal Costs, Policy [Policy Text Block]",
        "terseLabel": "Legal Costs"
       }
      }
     },
     "localname": "LegalCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "terseLabel": "LEGAL PROCEEDINGS"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of operating lease future payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r811"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r811"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r811"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r811"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r811"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r811"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r811"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r811"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r801"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r801"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r63",
      "r165",
      "r258",
      "r287",
      "r385",
      "r386",
      "r387",
      "r390",
      "r391",
      "r392",
      "r394",
      "r396",
      "r398",
      "r399",
      "r693",
      "r699",
      "r700",
      "r766",
      "r816",
      "r817"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r47",
      "r165",
      "r287",
      "r766",
      "r818",
      "r853",
      "r877"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and (deficit) equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r65",
      "r165",
      "r287",
      "r385",
      "r386",
      "r387",
      "r390",
      "r391",
      "r392",
      "r394",
      "r396",
      "r398",
      "r399",
      "r693",
      "r699",
      "r700",
      "r766",
      "r816",
      "r817",
      "r818"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]",
        "terseLabel": "Accrued and other current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Other non-current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREAssetsandLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Remaining availability"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "terseLabel": "Commitment fee, unutilized commitments, percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded from other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded from Other Party",
        "terseLabel": "Aggregate amount received"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedFromOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Settlement, escrow fund included in restricted cash",
        "verboseLabel": "Litigation, amount agreed to pay"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.",
        "label": "Long-lived Assets by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of long-lived assets by geographic region"
       }
      }
     },
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r36",
      "r414",
      "r429",
      "r431",
      "r432",
      "r851",
      "r873"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt",
        "totalLabel": "Total long-term debt and other"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "verboseLabel": "Less: Current portion of long-term debt and other"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r173",
      "r382",
      "r419"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r173",
      "r382",
      "r419"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r173",
      "r382",
      "r419"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r173",
      "r382",
      "r419"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r173",
      "r382",
      "r419"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r173",
      "r382",
      "r419"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSMaturitiesScheduleofMaturitiesandMandatoryPaymentsofDebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Non-current portion of long-term debt",
        "verboseLabel": "Non-current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r67",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r376",
      "r379",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Legal proceedings and other matters"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r376",
      "r379",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyClaimsDismissedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims dismissed.",
        "label": "Loss Contingency, Claims Dismissed, Number",
        "terseLabel": "Number of cases dismissed"
       }
      }
     },
     "localname": "LossContingencyClaimsDismissedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r368",
      "r371",
      "r375"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Damages sought"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r376",
      "r379",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Recent suits filed"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Number of cases"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LuxembourgInlandRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Luxembourg.",
        "label": "Luxembourg Inland Revenue [Member]",
        "terseLabel": "Luxembourg"
       }
      }
     },
     "localname": "LuxembourgInlandRevenueMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Measurement Input, Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r749"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisUsingSignificantUnobservableInputsLevel3Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r73",
      "r165",
      "r287",
      "r385",
      "r390",
      "r391",
      "r392",
      "r398",
      "r399",
      "r766",
      "r852",
      "r876"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r445"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Noncontrolling interest distributions"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r215",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "DESCRIPTION OF BUSINESS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash Flows From Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash Flows From Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r146",
      "r150",
      "r154"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash Flows From Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r20",
      "r102",
      "r105",
      "r111",
      "r115",
      "r154",
      "r165",
      "r186",
      "r191",
      "r192",
      "r193",
      "r194",
      "r197",
      "r198",
      "r203",
      "r244",
      "r256",
      "r260",
      "r263",
      "r266",
      "r287",
      "r385",
      "r386",
      "r387",
      "r390",
      "r391",
      "r392",
      "r394",
      "r396",
      "r398",
      "r399",
      "r745",
      "r766",
      "r856",
      "r881"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss attributable to Bausch Health Companies Inc.",
        "verboseLabel": "Net loss attributable to Bausch Health Companies Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r102",
      "r105",
      "r111",
      "r197",
      "r198",
      "r695",
      "r702"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Net income attributable to noncontrolling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r193",
      "r199",
      "r210",
      "r282",
      "r283",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r384",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r651",
      "r652",
      "r653",
      "r654",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r814",
      "r840",
      "r841",
      "r842",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Adoption of New Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r445",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncurrentAssets": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.",
        "label": "Long-Lived Assets",
        "terseLabel": "Long-lived assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignCurrencyExchangeContractsNarrativeDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedonConsolidatedStatementsofOperationsandConsolidatedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfCountriesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of countries in which the entity operates as of balance sheet date.",
        "label": "Number of Countries in which Entity Operates",
        "verboseLabel": "Number of countries in which entity operates"
       }
      }
     },
     "localname": "NumberOfCountriesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/DESCRIPTIONOFBUSINESSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format.",
        "label": "Open Tax Year",
        "terseLabel": "Open Years"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESFederalIncomeTaxReturnsbyJurisdictionDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r244",
      "r256",
      "r260",
      "r263",
      "r266"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating income (loss)",
        "totalLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r803",
      "r812"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r798"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Present value of remaining lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails",
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r798"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Less: Current portion",
        "verboseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails",
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r799"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r798"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current portion",
        "verboseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseFuturePaymentsDetails",
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r799"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r800",
      "r807"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid from operating cash flows for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r797"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r799"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESRightofuseAssetsandRightofuseLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r809",
      "r812"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r808",
      "r812"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r64"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax [Abstract]",
        "terseLabel": "Pension and postretirement benefit plan adjustments:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r92",
      "r96",
      "r510"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax",
        "terseLabel": "Net actuarial gain (loss) arising during the year"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r689",
      "r690",
      "r697"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Release of foreign currency translation losses upon disposal of assets held for sale"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax": {
     "auth_ref": [
      "r96",
      "r100",
      "r101",
      "r510"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, after Tax",
        "terseLabel": "Amortization of prior service credit"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": {
     "auth_ref": [
      "r91",
      "r96",
      "r718",
      "r723",
      "r733"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax",
        "terseLabel": "Gain excluded from assessment of hedge effectiveness"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r722"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Gain (loss) recognized in Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r103",
      "r106",
      "r109",
      "r110",
      "r112",
      "r116",
      "r440",
      "r780",
      "r785",
      "r786",
      "r857",
      "r882"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss)",
        "totalLabel": "Other comprehensive (loss) income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive (loss) income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r94",
      "r96"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedTotalLabel": "Net pension and postretirement benefit plan adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax": {
     "auth_ref": [
      "r94",
      "r97",
      "r689"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax",
        "terseLabel": "Income tax benefit (expense)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherDebtSecuritiesMember": {
     "auth_ref": [
      "r285",
      "r300",
      "r491",
      "r757"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in debt securities classified as other.",
        "label": "Other Debt Obligations [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r460",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "OTHER EXPENSE, NET"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENET"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherMachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other tangible personal property, nonconsumable in nature, with finite lives used to produce goods and services.",
        "label": "Other Machinery and Equipment [Member]",
        "terseLabel": "Other equipment"
       }
      }
     },
     "localname": "OtherMachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r154"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other expense, net",
        "negatedTotalLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails",
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 8.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "negatedTerseLabel": "Other expense, net",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r462",
      "r463",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r513",
      "r515",
      "r516",
      "r518",
      "r521",
      "r525",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Postretirement Benefit Plan",
        "verboseLabel": "U.S. Postretirement Benefit Plan"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Bausch Health Companies\u00a0Inc. Shareholders' Equity (Deficit)"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Payments of acquisition-related contingent consideration"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "negatedLabel": "Payments of accrued legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromHedgeInvestingActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.",
        "label": "Payments for (Proceeds from) Hedge, Investing Activities",
        "terseLabel": "Net proceeds, settlement of cross-currency swaps"
       }
      }
     },
     "localname": "PaymentsForProceedsFromHedgeInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsEffectofHedgingInstrumentsonFinancialInstrumentsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r143",
      "r354"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "terseLabel": "Restructuring payments"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Payments of financing costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Payment of employee withholding taxes related to share-based awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r132",
      "r681"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash payments to acquire certain assets and assumed liabilities"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisition of businesses, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": {
     "auth_ref": [
      "r144",
      "r286"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.",
        "label": "Payments to Acquire Equity Securities, FV-NI",
        "terseLabel": "Upfront payment converted into minor equity interest"
       }
      }
     },
     "localname": "PaymentsToAcquireEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Acquisition of intangible assets and other assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r284"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r133",
      "r683",
      "r684",
      "r685"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Total capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r133"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r490",
      "r492",
      "r498",
      "r517",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r540",
      "r542",
      "r545",
      "r547",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "PENSION AND POSTRETIREMENT EMPLOYEE BENEFIT PLANS"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r464",
      "r488",
      "r850",
      "r872"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans.",
        "label": "Liability, Defined Benefit Plan",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementPlansPolicy": {
     "auth_ref": [
      "r524",
      "r543",
      "r544",
      "r547",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.",
        "label": "Pension and Other Postretirement Plans, Policy [Policy Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementPlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r461",
      "r463",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r513",
      "r515",
      "r516",
      "r518",
      "r521",
      "r525",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r547",
      "r548",
      "r556",
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Pension Benefit Plans"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanAssetCategoriesDomain": {
     "auth_ref": [
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r518",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]"
       }
      }
     },
     "localname": "PlanAssetCategoriesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r566",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r24",
      "r52",
      "r53"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsIncludedinConsolidatedBalanceSheetsDetails",
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSForeignExchangeContractsIncludedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r130"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "verboseLabel": "Cash proceeds from divestiture"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity.",
        "label": "Proceeds from Divestiture of Businesses, Net of Cash Divested",
        "terseLabel": "Proceeds from sale of assets and businesses, net of costs to sell"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromHedgeInvestingActivities": {
     "auth_ref": [
      "r131",
      "r151"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.",
        "label": "Proceeds from Hedge, Investing Activities",
        "terseLabel": "Net proceeds, cross-currency swaps"
       }
      }
     },
     "localname": "ProceedsFromHedgeInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSCrosscurrencySwapsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Issuance of long-term debt, net of discounts"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r136",
      "r141"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sale of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r135"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-term Debt",
        "terseLabel": "Borrowings of short-term debt"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r134",
      "r598"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Product Concentration Risk"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r20",
      "r102",
      "r105",
      "r111",
      "r145",
      "r165",
      "r186",
      "r197",
      "r198",
      "r244",
      "r256",
      "r260",
      "r263",
      "r266",
      "r287",
      "r385",
      "r386",
      "r387",
      "r390",
      "r391",
      "r392",
      "r394",
      "r396",
      "r398",
      "r399",
      "r689",
      "r694",
      "r696",
      "r702",
      "r703",
      "r745",
      "r766",
      "r862"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net (loss) income",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r57",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r350",
      "r914",
      "r915",
      "r916"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY, PLANT AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r56",
      "r340"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, plant and equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r32",
      "r33",
      "r342",
      "r818",
      "r864",
      "r879"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r55",
      "r342",
      "r914",
      "r915"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r32",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r32",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "verboseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r121",
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESActivityinAllowanceforCreditLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r41",
      "r48",
      "r818",
      "r878",
      "r909"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r258",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of each significant reconciling item, other than profit (loss), revenues, or assets, in the reconciliation of totals of such items in reportable segments to the entity's corresponding consolidated amount.",
        "label": "Reconciliation of Other Significant Reconciling Items from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Schedule of capital expenditures, depreciation and amortization by segment"
       }
      }
     },
     "localname": "ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r138",
      "r164"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit",
        "terseLabel": "Repayments of lines of credit"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayments of long-term debt",
        "terseLabel": "Repayments of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-term Debt",
        "negatedLabel": "Repayments of short-term debt"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReportingUnitAxis": {
     "auth_ref": [
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by reporting unit.",
        "label": "Reporting Unit [Axis]",
        "terseLabel": "Reporting Unit [Axis]"
       }
      }
     },
     "localname": "ReportingUnitAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Level of reporting at which goodwill is tested for impairment.",
        "label": "Reporting Unit [Domain]",
        "terseLabel": "Reporting Unit [Domain]"
       }
      }
     },
     "localname": "ReportingUnitDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fair value of reporting unit in excess of carrying amount.",
        "label": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount",
        "terseLabel": "Percentage of fair value in excess of carrying value"
       }
      }
     },
     "localname": "ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Abstract]",
        "terseLabel": "Research and Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "auth_ref": [
      "r321"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off",
        "terseLabel": "Acquired IPR&amp;D, included in other expense, net"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r615"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development",
        "totalLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENTScheduleofResearchandDevelopmentCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development costs",
        "verboseLabel": "Upfront payments, included in acquired in-process research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails",
      "http://www.bauschhealth.com/role/OTHEREXPENSENETScheduleofOtherExpenseIncomeNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": {
     "auth_ref": [
      "r928"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.",
        "label": "Research, Development, and Computer Software Disclosure [Text Block]",
        "terseLabel": "RESEARCH AND DEVELOPMENT"
       }
      }
     },
     "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESEARCHANDDEVELOPMENT"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r352",
      "r354",
      "r357",
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "RESTRUCTURING, INTEGRATION, SEPARATION AND IPO COSTS"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "auth_ref": [
      "r353",
      "r356",
      "r360",
      "r362"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "verboseLabel": "Restructuring costs"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r153",
      "r351",
      "r358",
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring, integration, separation and IPO costs"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r353",
      "r354",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Cost-rationalization and integration initiatives"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r354",
      "r359"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "terseLabel": "Remaining restructuring liabilities"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r43",
      "r445",
      "r606",
      "r818",
      "r875",
      "r901",
      "r906"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r182",
      "r183",
      "r184",
      "r187",
      "r196",
      "r198",
      "r291",
      "r603",
      "r604",
      "r605",
      "r653",
      "r654",
      "r743",
      "r897",
      "r899"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r513",
      "r514",
      "r515",
      "r516",
      "r518",
      "r521",
      "r526",
      "r527",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r548",
      "r552",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r513",
      "r514",
      "r515",
      "r516",
      "r518",
      "r521",
      "r526",
      "r527",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r548",
      "r552",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r461",
      "r462",
      "r463",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r513",
      "r515",
      "r516",
      "r518",
      "r521",
      "r525",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r556",
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r461",
      "r462",
      "r463",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r513",
      "r515",
      "r516",
      "r518",
      "r521",
      "r525",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r556",
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSActualAssetAllocationsDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSAmountsRecognizedinAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFutureBenefitPaymentsforthePensionBenefitPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSNarrativeDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueCommissionersIrelandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Ireland.",
        "label": "Revenue Commissioners, Ireland [Member]",
        "terseLabel": "Revenue Commissioners, Ireland"
       }
      }
     },
     "localname": "RevenueCommissionersIrelandMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r235",
      "r236",
      "r255",
      "r261",
      "r262",
      "r269",
      "r270",
      "r274",
      "r454",
      "r455",
      "r838"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Price appreciation credits",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r162",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues and long-lived assets by geographic region"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving credit facility",
        "verboseLabel": "Senior Secured Credit Facilities"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCovenantComplianceDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Summary of activity in allowance for credit losses"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued and other current liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCRUEDANDOTHERCURRENTLIABILITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r99",
      "r785",
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of the components of accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans.  This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.",
        "label": "Schedule of Allocation of Plan Assets [Table Text Block]",
        "terseLabel": "Actual asset allocations"
       }
      }
     },
     "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the net gain (loss) and net prior service cost or credit recognized in other comprehensive income (loss) for the period for pension plans and/or other employee benefit plans, and reclassification adjustments of other comprehensive income (loss) for the period, as those amounts, including amortization of the net transition asset or obligation, are recognized as components of net periodic benefit cost.",
        "label": "Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of amounts recognized in accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ScheduleOfAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions [Table Text Block]",
        "terseLabel": "Weighted-average assumptions used to determine net periodic benefit costs and benefit obligations"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r526",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of underfunded plans"
       }
      }
     },
     "localname": "ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r672",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITUREEstimatedFairValueAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Cash Flow Disclosures"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Summary of the components and classification of share-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Components of benefit from income taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of long-term debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of tax effect of major items recorded as deferred tax assets and liabilities and valuation allowance"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r524",
      "r525",
      "r528",
      "r529",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSChangeinBenefitObligationPlanAssetsandFundedStatusDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSComponentsofNetPeriodicBenefitCostDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSUnderfundedPlansDetails",
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSWeightedAverageAssumptionsUsedtoDetermineNetPeriodicBenefitCostsandBenefitObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of assets and liabilities associated with derivatives, included in the Consolidated Balance Sheets"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock": {
     "auth_ref": [
      "r728",
      "r731"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of gains and losses on derivative instruments included in an entity's trading activities.",
        "label": "Schedule of Derivative Instruments Included in Trading Activities [Table Text Block]",
        "terseLabel": "Schedule of foreign exchange contracts on the Consolidated Statements of Operations and Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsIncludedInTradingActivitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of calculation of loss per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of benefit from income taxes from the expected amount calculated by applying the Canadian statutory rate to loss before benefit of income taxes"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r564",
      "r595",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of revenues by segment and by product category"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONMajorCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.",
        "label": "Schedule of Expected Benefit Payments [Table Text Block]",
        "terseLabel": "Future benefit payments for the pension benefit plans"
       }
      }
     },
     "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r746",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of components and classification of financial assets and liabilities measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r319",
      "r324",
      "r839"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r319",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of components of finite-lived intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r314",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r314",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of changes in the carrying amount of goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Components of loss before benefit from income taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r327",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r327",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of components of indefinite-lived intangible assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r30",
      "r49",
      "r50",
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of the components of inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INVENTORIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of aggregate maturities of long-term debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "terseLabel": "Components of net periodic benefit cost"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for net investment hedges of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Net Investment Hedges, Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of effect of hedging instruments on financial statements"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.",
        "label": "Schedule of Nonvested Performance-based Units Activity [Table Text Block]",
        "terseLabel": "Summary of non-vested performance-based RSU activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Summary of non-vested time-based RSU activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of other expense, net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r57",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule of Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PROPERTYPLANTANDEQUIPMENTMajorComponentsofPropertyPlantandEquipmentDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Estimated fair values of assets acquired and liabilities assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACQUISITIONSLICENSINGAGREEMENTSANDDIVESTITURETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r353",
      "r354",
      "r355",
      "r356",
      "r360",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "terseLabel": "Schedule of external customers that accounted for 10% or more of total revenues"
       }
      }
     },
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "auth_ref": [
      "r123",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]",
        "terseLabel": "Schedule of revenues by geographic region"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r113",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicInformationRevenueDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONGeographicalInformationLongLivedAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r244",
      "r247",
      "r259",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r244",
      "r247",
      "r259",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of segment revenues and profit"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r566",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r571",
      "r583",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of weighted-average assumption as of the date of grant using the Black Scholes option-pricing model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r635",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Reconciliation of the beginning and ending amounts of unrecognized tax benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of estimated aggregate amortization expense for each of the five succeeding years"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Senior Secured Notes",
        "verboseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r231",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r274",
      "r356",
      "r362",
      "r889"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r231",
      "r233",
      "r234",
      "r244",
      "r248",
      "r260",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r273",
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "SEGMENT INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment reporting information"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]",
        "terseLabel": "Settled Litigation"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisNarrativeDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r152"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "End of the period (in shares)",
        "periodStartLabel": "Beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "End of the period (in dollars per share)",
        "periodStartLabel": "Beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted- Average Grant-Date Fair Value Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r585"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Method and assumptions on valuation of stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected Company share volatility",
        "verboseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Total number of shares approved for grant by the Company under the share-based compensation plans (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for future grants (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Additional disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r585"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of stock options exercised in the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Expired or forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired or forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value of stock options (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r597"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding at the end of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r573",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "End of the period (in shares)",
        "periodStartLabel": "Beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "End of the period (in dollars per share)",
        "periodStartLabel": "Beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r588"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Vested and exercisable at the end of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Vested and exercisable at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Vested and exercisable at the end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r586"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest at the end of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest at the end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r563",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONSummaryofSharebasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Vesting Period One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Vesting Period Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r566",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Percentage of vesting rights"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r590",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Contractual term (years)",
        "verboseLabel": "Expected stock option life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONRSUsDetails",
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding at the end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and exercisable at the end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest at the end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r804",
      "r812"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease expense"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r159",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r8",
      "r231",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r255",
      "r256",
      "r257",
      "r258",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r274",
      "r314",
      "r346",
      "r356",
      "r362",
      "r889"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofGoodwillDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONNarrativeDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONRevenuesbyProductCategoryDetails",
      "http://www.bauschhealth.com/role/SEGMENTINFORMATIONSegmentRevenuesandProfitAssetsandCapitalExpendituresDepreciationAmortizationofIntangibleAssetsAssetImpairmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r71",
      "r109",
      "r110",
      "r111",
      "r182",
      "r183",
      "r184",
      "r187",
      "r196",
      "r198",
      "r214",
      "r291",
      "r440",
      "r445",
      "r603",
      "r604",
      "r605",
      "r653",
      "r654",
      "r743",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r786",
      "r897",
      "r898",
      "r899",
      "r940"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r214",
      "r838"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-based Payment Arrangement [Member]",
        "verboseLabel": "Stock Compensation Plan"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LOSSPERSHARENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r39",
      "r40",
      "r440",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Common shares issued under share-based compensation plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r39",
      "r40",
      "r440",
      "r445",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r39",
      "r40",
      "r445",
      "r565",
      "r584"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Common shares issued under share-based compensation plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r40",
      "r45",
      "r46",
      "r165",
      "r281",
      "r287",
      "r766",
      "r818"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Bausch Health Companies Inc. shareholders\u2019 (deficit) equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r2",
      "r3",
      "r110",
      "r165",
      "r182",
      "r183",
      "r184",
      "r187",
      "r196",
      "r287",
      "r291",
      "r445",
      "r603",
      "r604",
      "r605",
      "r653",
      "r654",
      "r687",
      "r688",
      "r701",
      "r743",
      "r766",
      "r780",
      "r781",
      "r786",
      "r898",
      "r899",
      "r940"
     ],
     "calculation": {
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Increase to accumulated deficit (less than)",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Accumulated other comprehensive loss",
        "totalLabel": "Total (deficit) equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/ACCUMULATEDOTHERCOMPREHENSIVELOSSScheduleofAccumulatedOtherComprehensiveLossDetails",
      "http://www.bauschhealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITYDEFICIT",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESAdoptionofNewAccountingStandardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r806",
      "r812"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "terseLabel": "Sub-lease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r787",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r787",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r787",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r787",
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLNarrativeDetails",
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r819",
      "r822"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r626",
      "r635",
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Summary of open tax years by jurisdiction"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Other payments"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SUPPLEMENTALCASHFLOWDISCLOSURESScheduleofSupplementalCashFlowDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r644"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxYear2012Member": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2012.",
        "label": "Tax Year 2012 [Member]",
        "terseLabel": "Tax Year 2012"
       }
      }
     },
     "localname": "TaxYear2012Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxYear2013Member": {
     "auth_ref": [
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2013.",
        "label": "Tax Year 2013 [Member]",
        "terseLabel": "Tax Year 2013"
       }
      }
     },
     "localname": "TaxYear2013Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Corporate brands"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "B&amp;L Trademark"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INTANGIBLEASSETSANDGOODWILLScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/OTHEREXPENSENETNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r353",
      "r354",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/RESTRUCTURINGINTEGRATIONSEPARATIONANDIPOCOSTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r491",
      "r863",
      "r907"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "Government bond funds"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/PENSIONANDPOSTRETIREMENTEMPLOYEEBENEFITPLANSFairValueofPensionandPostretirementBenefitPlanAssetsAssumedinConnectionwiththeAcquisitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnfavorableRegulatoryActionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A enacted or proposed action, ruling or regulation that is likely to or possibly will have an adverse effect on the entity's financial position or results of operations, excluding tax matters.",
        "label": "Unfavorable Regulatory Action [Member]",
        "terseLabel": "Unfavorable Regulatory Action"
       }
      }
     },
     "localname": "UnfavorableRegulatoryActionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEGALPROCEEDINGSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r617",
      "r630"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance, end of year",
        "periodStartLabel": "Balance, beginning of year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r631"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Reductions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r625"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and penalties related to unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r625"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Net increase (decrease) recognized in interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r632"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to the current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r631"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Additions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r633"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedLabel": "Lapse of statute of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESReconciliationScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r634"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Portion of unrecognized tax benefits, if recognized, would affect the Company's effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnsecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
        "label": "Unsecured Debt [Member]",
        "terseLabel": "Senior Unsecured Notes",
        "verboseLabel": "Unsecured Debt"
       }
      }
     },
     "localname": "UnsecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorSecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSeniorUnsecuredNotesDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSSummaryofConsolidatedLongtermDebtDetails",
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSWeightedAverageStatedRateofInterestDetails",
      "http://www.bauschhealth.com/role/SUBSEQUENTEVENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r216",
      "r217",
      "r219",
      "r220",
      "r227",
      "r228",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceByDeferredTaxAssetAxis": {
     "auth_ref": [
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of deferred tax consequences attributable to deductible temporary differences.",
        "label": "Valuation Allowance by Deferred Tax Asset [Axis]",
        "terseLabel": "Valuation Allowance by Deferred Tax Asset [Axis]"
       }
      }
     },
     "localname": "ValuationAllowanceByDeferredTaxAssetAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r641"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedLabel": "Decrease in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": {
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r178",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.",
        "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset"
       }
      }
     },
     "localname": "ValuationAllowanceOfDeferredTaxAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesAdjustments": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment",
        "negatedTerseLabel": "Reduction in variable consideration provision, adjustment"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r174",
      "r179"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance, end of year",
        "periodStartLabel": "Balance, beginning of year",
        "terseLabel": "Cooperative advertising credits included in rebates"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": {
     "auth_ref": [
      "r177"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account",
        "netLabel": "Sales return provisions",
        "terseLabel": "Charged to other accounts",
        "verboseLabel": "Current period provision"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r178"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedLabel": "Payments and credits"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r178",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r178",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/INCOMETAXESScheduleofReconciliationofDeferredTaxAssetValuationAllowanceDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionNarrativeDetails",
      "http://www.bauschhealth.com/role/SIGNIFICANTACCOUNTINGPOLICIESRevenueRecognitionVariableConsiderationProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r805",
      "r812"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable operating lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/LEASESLeaseExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/FINANCINGARRANGEMENTSCurrentDescriptionofSeniorSecuredCreditFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r201",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted weighted-average common shares (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r200",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic weighted-average common shares (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.bauschhealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.bauschhealth.com/role/LOSSPERSHAREScheduleofCalculationofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 24
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3444-108585"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3581-108585"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "230",
   "URI": "http://asc.fasb.org/topic&trid=2134446"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8475-108599"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "b",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a,b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2510-110228"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2599-110228"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2611-110228"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2443-110228"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2473-110228"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=27011672&loc=d3e149975-122751"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "http://asc.fasb.org/topic&trid=49130413"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(b)(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6412939&loc=d3e15145-114933"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=66047640&loc=d3e39622-114963"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=d3e29149-114947"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.15)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "http://asc.fasb.org/topic&trid=2122503"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "184",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5634876-113961"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=28365394&loc=d3e23770-108382"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r875": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r876": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r877": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r878": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r879": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313"
  },
  "r880": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r881": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r882": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r883": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r884": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r885": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r886": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r887": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r888": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r889": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r890": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r891": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r892": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r893": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r894": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r895": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r896": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r897": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r898": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r899": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r900": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r901": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r902": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r903": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r904": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r905": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r906": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r907": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r908": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r909": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(dd)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r910": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r911": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r912": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r913": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r914": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r915": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r916": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r917": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r918": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r919": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r920": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r921": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r922": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r923": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r924": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r925": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r926": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r927": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r928": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "730",
   "Topic": "985",
   "URI": "http://asc.fasb.org/subtopic&trid=2197926"
  },
  "r929": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r930": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r931": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r932": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r933": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r934": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r935": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r936": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r937": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r938": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r939": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r940": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>154
<FILENAME>0000885590-22-000027-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000885590-22-000027-xbrl.zip
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M2T9-+D%3+5ORG@PV@CQW>@*IL?&FB&^\-M#<8I[/"]#A+S3B!^,[=#*:T>%
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M2E%GPY:_\3*J2A"SV,R:G5'"4(NW6$,V$C.OL*S\RH&S7"FW2-5%-7/7*'%
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M-<0-(8GK>S;.:V+L3AXK/*/Z'F*_3/K3DY.)U-$<Y3.8UC%7DSYS&[S/UC7
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M)H>AF189+ Z*0!O9L00/9$ HE60+&ZBQUS3+,6$7(U(1!S#AN)$=2R50$H"
M032(66B52HD8DDW)HK[LPZ!TZZJ$L+MZ_U_0;/1"2=H'V_JW/!I-GW]P+<<3
M&3T=WWM5#_H>S3O'9^W#%W41_R/\M$]QRU2_Y",3^#O'8SY_3W@@(CGE0KT3
M1[1@H;I -@;CN/\;<Z@#*!6W8>OR5-_7;3JF0))L6NJSS:H-J-IFBVTI.?8#
M<_1?D]0<EAVOH^D(Q(8"B-47\#&1,2UC!I!0O)BOQ'0&*+(WIK-LTR&;FV%*
M@3Q"-DC19$ELA"0V"@/H_[-AZZJS=9')<%]Q&6*J*I9B"Z57_[?2&\=;AWE8
MHRD;MF[2BYLS'0"C_MRZX@M#2%A*9O2U(L? S,.:OMJD%ZMJQ^MH.LUZZUU,
MWB4!*TRU.9)*U$.1\\.:1=RD%QO3N4'!1K&2L^!MZFLU2W:U5A>],VQM&$*;
M@X]18_H3C<8/CZ?3VZ_/07LDAV=;TPY&)Q^@)K,'XQ<RG?4/GA]]4XRY^Y8N
MMZ;GQ[[[$3=K.W?48+MU/WY))\-S)*N2K3>70R4L&6RO=%K)2&VB@:GXG!JM
M<)'9C3EMS&DUL\)5L>V47*I,T5:I@ @YEQS%%I<-%<H#F#I=9=M>J>1QXVB^
MLKA=HW.:+;+I^].J9W(2JTDY>V=];)NXO73;7EAVN['MK\RV6TLY5N^3P0(N
MQ5Q<HJJ6W=L^N#: T:%5MNV-.0W"G!:X8-I)M1$IF>B +6&RH=B4"HJPL7%C
M3AMS&H YK5&*NT#;]C6"):_&ZX""H(9,YR)6H5"RSQO;7C:3-BGNT!S-JMAV
MBR89TYS#9L#ZG!U8J_9'4*O&\HT,7KIM;U+<C6U_GFU'8IM"BDF2!>*"FM?:
M5K-MZ%J-0^D>^G T&ST]JWA&T_=J*2D^HG?FM\>/.RYZD$S?'?JEK.E?_+86
MZD]R_'1")P>]./!YR[_9R>2'G9^_G)7OKKA_V^GT,@T?RVQV*'SEG_49S%M^
M#;#J@OA0 R %T*"3R45 $(^04DWYK&W=*K)S""%H/;W^%[G8#TL5?M&PA[=>
M<FA5$D@@$@B6?0Q05$#%L_IUUKYUL79UVW>M D8?."/["<[(+J:#EPO@2XZ8
MHG. *6%NR>60+6;"\K83U2K'S*L!VB/HG8GZIPM$[X_&='@6<*Y@^H.,-"4Z
M'QNY/D$/)%2Z*&HV&!=3\'8 U<@VD>9O+N+]LO4/CS]68']W=B"3G>-QG?-^
M]G!$970X5X_K&>T668R-<\5J2V/.8,!A"YZHA)P8:_8#**NSL9^-_2QQ674)
MULPK8.8 PBY+;! EM-#KG?D!E,!=9?OY>^K^,I$3&O&]5R?Z69G>&O.<S&=,
MFLW[URZ,Q"MAS2MF28N+1!R+2 T80HM@2LM0F_>AI@C6M)(VD6AC2>ML20O<
M8$HU9)*^Q:< !R;#-4#RD27WT@*;F+3A[JI&@5#9%JI.LWK-1QIK. @8*T5O
MBTV1-U%@P]U5];LH)4+#2! $<C(YN61SK9D;@K,T\('&#8E7C,3+'WV--;OF
M8[#@L1?]4B(R5\E.^>^ARH!Z_6P8/S3&+Z7E$82D+,<276S@<L1"&7)FS5V+
MR1PW/G[#^"__Y@\:]WX\89]WVM7;?YZQKV-\<0Y2UOQ5#2L"2RU2:S%&,/G<
MV.1-?-E8VUI:VU)B&W+-P%1MJA4\><S0*J+#QD$<PL!CV]<GSZW8$&-QC0 T
M,7794LY-@N:F:&VR W>?7Y_Z)(Y]=VMB%9^ !7NCS1:%8@U1X^1 9QN_XOI>
MBQLX-8799K' V0#'1-"\_LV^- I9:/6I\==35'UAVZU:)Z<J0"Y/2RUMJ<*&
MH9_,T ;)&; Q 5@H+"6TDGR+2M1L@AG ?N(-0U>1H8L;P"_@-)BF;*.K4"%C
M<6AKWQ_;;&&R0_:ARYCFWQ#UNM;*D&D4(7-(4;TJ9.."E1*E.,<YE"&[T@U1
MET[4!2Z/M-E8T"COO0,NJ0"QST D?;]B&D#,WU#CFJCA*^;H:ZSJ&"'WXHIH
M32G@"4+QIJS=:--Z<V3YHUW&!HR(T9EB@5R?(=#4EWT3)%5U9NU&N[XB0BUE
MM$T=%' -+3JID)(K%:6*G\_\&A/RZJ<#[Y4ZF)>?V'M](I=!_/"(NZ-I/3Y5
MMND]6Q215J)D1M_]_ZB;R?EN?WVZ/1J/CDZ/KN%GKG0UBB]*0T['HS/KF"A!
MWM+^Z.Q'S(=!^AL7'[YX_>)Y__1'32UF(R6A6!6,X+&OJF@M)"D9)5-985/[
M&*_HU2)YM3'BK]/4+L_\-"[!VN1"-5#ZY$^UN6(#VVR-9@!#4RM%H+^VJ>["
M/GSW#Y59!WWUPPN]W*=RS>;UE3 :,UM!$P.7"AXJQ48>!422Q\1#6FW0E;?>
M>/V0/IKJ&2=SN7S[]65:]0D"Z6^H<-_3L\PAW&W;QV-YO8X)66B4JW5$M2;@
M6-!6&TK.L9F6(@]I]=;J([R4#*EY)REP52,.$)TEGRU&L=G48((;TAC.%1%^
MZWIO\;/3L\5X?S<*/4C;;8 FAXC%J]B@G+($!HO!!=#,U\#ZV>X2D%V*S=K
M"1Q0RXJL!X,A>@S)ILS8C,-!*<G/U$H[Q^/)P.12AN";[^:HP=1;AVASR91!
M?2\D&<#2KQN%[4;3DJ$TMJH$D6I@*:E!J82YL05P5#"Y)E])$KE"G8<'Z(>,
M$;!-?(TM0G$N(Q<VE2$TEC2$=88K-1#Q=7(H&5],;9KG-T@IYM0P&"Y%G)?L
M[>JO"A@0; O<WZX1(W'O?!HS.&Z%&D EWY+/%%+8P+:N$F2!2RQCE,8QVXP9
MBN8@220Z&VQ4/U!E6*:_D2!+X1 9[Y,5S'W<F*E0B:&&D*N+M5+V7P>'OD8)
MLC@.&=],WT!%+B$(62SZ(.5FJJ'DA] '])?)L?[>V>M?#O46W!KSO?^<CD[Z
M.=X?V+HX^"&-A[*V6?%0;<@1L@W@0RZA62?9-4Q]?6!;?>M>+6069S,AE*KW
M*X5J/3A;L^9[#6*D*-E$<6MF,[=/1WK6\5,][N+A@Z.3R?$+N::QX>LIJ 8Y
MHH$6?$5(+A9 0N== Z[%L%DS<UHF:(NSM&P<FLS,KC$H@-2*+\U;-HS"/( Q
M^D\";9OJP6@LD]?O'S@0^W+1&!^0C0($>B<I!2G<T%0'D5M=,_NZ>:@6&+]*
M2HVKM> B.#)4F1 Q9F^3KU'6Q*KZ9.9\J]3;=_7(ARK7Y>#XD-_SA@.Q,)^Y
M5&>!HP50\\KB0TO)H9402U@7"UL-V!9G;=R+CBA:"-Z#.%=2K%W.%Q,"!3^
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MK)AG.2L<8FNP4$S(N;HB23-"])7.QR"'CLNUZ\GK@485/]9"N=D&8GSVB@T
M-D,^VCB @@BKI1ZNITM8[=W.Q=?HL'LW:J8U; (IQ!Q;6PN0EC3&M4!3:JFU
M&B6K?X,"4(IQQKL^BE\;X_FJ?FLN5NCH@^N&ZQ/E;I]/-%=? //^H5^RLLDZ
M:>A]HAR@6%N\]09*%%/U!H9Z/O4(YU./)GJS8O>MS^S!E6?V3-SR9@'W+6GF
M)S8%\GK?)+A234V!L377^Q#[\_N6+NX;KN1]2U>_;[B8^U8MYH1H2'KFS)*E
MY+YIN#+[E./YQM%S.[V9J8-/OV]7M=,%SB2G6G*"& /:!%:ST:HAQV:IU*OQ
MB QHB< C.3F>].9=OXU'LW<AZ-++TWNOSC>V_5D^K.-" =0TR8@X!\F Z[4%
MF\M]I4[J>C#8<WB]/W<G?G#P_AG'2P=>/ZC^/:3^QM?YQ8 :$0DEL<$:H6)5
M4"%Z%LN8FO7I'%0-J3<66]<-U/>C^<T$?F_(]LU+U7.&%'W1$%:K;Y83-O]V
M2<\-Z,NA8WEYKOO]D/HE8X,<2FYHG&0/S*2WKQ2UPT2N%,BXNO!,)[,?'M'X
MZ7EKOOYT>S0>'9T>+6J_^5H#'TTV?8.&$=OF?==-%L^JRAW7Z.W @*=7&^"O
M.CYCK>TM7&+LW:Y,*MF@9>#D$I&K_L.,8@49L&HX?4&ZLZ!AB1QK1G"([! ,
M"C&4''VV/@2CC\X&W591!G^V&__2D;1+JO6+YG$<LPI74N$*16\-<>U%%$JP
M+9F P[KU5W*DJW+K:]33-0&(RG=I2-Y6]6R&5,NX@/[F;OW2[@!+W]3<I(0"
M:#.U7GW(Q1 L:%R_*&5[G@>ORJWX<-7"55--N[!4L_8]X"UJ=*L)#.3"N==E
M2T"I2EME?[EJL>]:: V)<W%=H(A:-V9-1XIOS3=1^Q9.JPO/5YF5+ [X*)1L
M5BTJ%30K*>2<Q:Q^K5;78G/# G[MLY+% 5\D(<9 (60 TWIS+0UEMK6**4F6
M)02RH7OF%8BRO?:*31AJ9$B)27RMG%4FUVRRY'-K7L%QW.5E)>\/NW[1N!Y4
M9A>*PPR]%84%$PO5DJNF)\S#NO4WDY4LZ-:C*455BV3(%:RUV">HH*%OSF:\
M:*"T(BL#KN4.]+$'RRY%:14,Q6QK=N(\YI*M)LKGSOQ\(F=5;L6'_O*J<R5V
M<8LD0I74JFG&12#3L!?/(;5822R^G1OM9D3N$VF]J)%3;B2Q92.][V 1C6"8
M79.0<BP<O3NC]<7(Z0:G3[>Y*X^<VH6-G#8P&).H0&$/F&J!(-Y 5I_EV)UO
M.W(7"T7<*@O/QZ=E*O\YU0_=>Z'_V7M](I=+V7YPP#7#Z:Z^,,1]B>0\56;.
ML3R_TK?P' GU(M!S9I^_=W&*B[<NGO=S?-PE6\NUN1*<,B,WS*W:VCQC(LQ)
MYM645IP5"]P[,2 JOA<!W.+&^B-RM!%RZ@%:H/@2 WM4C:V:CVD ;%@L,(MD
MX8WM%5D<'YRK*NN#9!\T9"2+DI4A8EPNT=;J-WP8R!Z5Q5%",QX0SA*Q%/!"
M&("+]T;F[8[CQD5\D8LX/IS1MO"H]CX,0_(4DC-*,M*;@8)2@C)([32Q A@2
M;V@QO-TX7\2.MZIU<I%A_;N_]%'Q>OF03]>P)I$A6XPI%BRY7!U*X-#8-J)$
MJ[\CZZZ4V8-Q;V'9/_C^&O@7QX<O],;<F:A3F-VG.CK4Z[Y[*C^?CD5_E5\4
M"R]_P67B_\55#&0G6&XJ:7,@M); Q)"-:EPQ)325,+X,H*#;AAT?LF.!O9(!
M6[;D/><(7MD1K/3RM=;72@X'L)OSK]BQ)Y.CA\<TOOUG7H2!F"XT]MP,JHI@
MJ"$29!=KZQW(3'7-#M=TEP;.XBPG^%1J!L;0')A@LXF>@3/[DKL07"_+V>DM
MI?4\ [(>M9F^^#V1K194%94$*3BNA6(V=#Z8LS;6<V, +<Z">N%2YR(5C 9*
MLWH#O;79BD_6)!Q W9J'Q^.G,P6C _61A$FJZG?N;RY*B/P5(Q[+>'0\.?_"
MG>.93--WQOPBDZJ'*3NV>Z\SO9LP$-OU#K)%K"7U6JHVY>)JJM!4KF27_  *
MJ6ZH<4U>PT3I"UR\.G(#/@LU3Z*1F(MG;X?@-:Z$5/@NF#E:G^;;;YR?J^(Q
M+*7$&MZCRZZO\B9N0"6Y1ED,0EE]C[&AQ76H])!4E&LJ6VN!)#$[2<&'W%0*
M2H8!J/35#"3ANQ0N>'CK].GI=*;W,0W$5VA>P 5-4G4!P$X3-JP86RLQ<TPR
M@"&Q#2D6WV"AJ3]HA@23@^"P-(=!"5%*:QS(K[ZGN!)&D-]A=#[BDM<K>"S0
M3Y0RWZOBJV8AT9M2>KWJ%"!(32X.>/SM*Z/$XKR$TS0#J;E0+$#HG;7[\B#O
MR.0:6AU ]=#_CLAOX^E-!X\Y]:)UH4>-D\GH<$!CC*6)<.S3^GUH(BD)5%BV
M8J./R9OSO0 K[2$V=%B@=R#/1%B@MPR'6A*U/JX9DPU45&8.H.;S:M(!C5$V
MW)4ZM#F((#G:$H%)PVR04B09:R&F7J'%A[;Q#X,@Q.(\1,Z]# ]1"JH?6D#*
M8DOQ7&O+33QO/,1G$N)2O(@#<0_$ABTAEB@57$$BD9QRJ+F6V-+@!R*^!C8L
M<*R2T*'46E BB"DY5XT</I/+TBR:C6_X/#;DT(/%SS0^I<GK 0U3(KG0\XOJ
M"D/K<UV1>YEMBL&(P<%/@GX=?%C@S*=OZ%HUO2XXI.J+J8!1,EO-0'/.&__P
M>7Q(YC(?_F[P:U7\@ZF&J4]8^)2A5"Z!HL1FC*N,(@/HIKWAPT)G,+P-G0.E
M>0"L"0V;4 Q'XE"L*1O_\'E\" /U#Z 1PK?6(+$%+JG4:IE;C)8R5QQ R_ -
M'Q;J'R)A2DX4\:AJTI-QQ6)6[1""T?]O_,-G#E;/L\W[4B;GA,"!.(B:DS.]
M?G]UJ1<7QJK_NKY#R,?^>.,@!D&(1:Z6(DZE& K@-6HP$@2,G(N$HB%C #L)
M5Y,09Q%C@!Y"LXG*IJIT8()4?&9C,21QY$OU;I-B#(,0"_00-31J+II$#-$G
M,D%074.H.:=08>,A/C/GG(>,;1J2<[#8U^"[+)I6@$1#%",7*8H8@3,#V&#U
MM7-A@6.3#I"LR[G8V)O$EZ(O<! RR=G,F[&'SPT4<RZ\S36]&8IOB"X5!+&D
MOJ!60D^V%/$E1Z@->.,;AL"'1>[:<@&H&>]\!DZ( 'T[G[X0<G&T61GU17QX
M)R2]'8B#2 W%>X$<3(;6&FJ:D6V.J1H3JHT;!S$(0BS.0S00GT3ZVCBO<2.H
M@D#O.RE43J2\R2P^A1"[LP.9].O9.[^>@7B%:DTAD8;=*Q0,!*9Q,Q74*T#V
M ]AQ\=628(%[+%*KV:385#&"0",%/X82 (,Z@!I6WQ.L6KVH!19FJ%GUFZ.8
M4H5H$+E"5W'1& 1[EO/W4CBK6QI]4TWL W;8W!L<+*2"OI=L*193 #3W(\2@
M?Q+U^E51DLPKZ)^Q8VNH-+G9RE7O%US_$*?_4G#]PT._I+\WU=0WM.@_89[(
M)^MM<UEUID3A.ER#7U8-L@7:F^TMO,%S="UJ5IU*<VFNG#2KZE)J#>SM*W/+
MRS=XM?%L';FHE(*&CE+O($Z8HP2K2FS8ZNNAS%2=[[:S8ZY;@7\Q>5=%]N52
M*)72:I,&QJ:<."2*,5 N1'3N:)05:>OBP:JR8S7"P0=V;M5!IZO9^:5#O\#.
MK7-2T&/UV6L(25A,ZIWB<T5-YLY6@VV0_,3 ?@F<+QDN%\%HQ8/#"C;YPL$4
M+V!]3,2IGG=8LQ>MJ%;8&_].DQ&50WFD/+WLB^^=3H[Y^/"0)C<S/GI>;>*2
M+Q[)]'J-N[>/NVJ;I _\]1<8MZ9>F5Q+)4>5B+Y@]NJI?6^U+!K5-_RY_%W7
MW]5YP\R+?#)GJN!ZQ\@"ZMPT^,0(OI%3W4EF2,S<8'JQ43%#3:[YT"!JIM 0
MG?C>.\MKYE ,KP&F-Y>&KK2_&R0]8Q\1,0$31 :HCFJ5;$T,'*(K(6WH^47T
M[-]_A\;$=)O&SV4RO:7W]T25;YT?M(Z,:BF#::8X<;UK9,C>LV^&N%K7*,F&
M42LANC9<[27*7*NH[LZQ1Q#G25UAD6!<9N^AY#7@ZB7!U;/_KT%T]3I"WA8!
M#6X@6#!8;B%8R\77ZL. </VXG=ZFZ?R5W<DO$_W,%>SSBXFTO#' Y7 HL.9A
MP=0DQ4!!0N>C,B684&MS<4@<NJ9>*3?.X4'R2 6V RNF&DT%FS?%N+Z%M+ F
M]IKEXX!XM K#E5^;&S*D9/&80TX!,)OL"EDK+KL&DK!LZ+/B[:&63R%+B3#U
MO8F(4'VDG%45&?VGQ&Q,&Q"%5FX=PI)&;<21. Z86P6*^G]FHQ![%)86UR%O
M68<<>_%LW4BN*PU!L>9[W+L0> >^QDP4?.1BN/J:!N'P/D9.>G43LVY#7E2V
M,8\K33,:QP6\J2P(T3;L0UTFIIA:<!Z&E)$LG\0K/26UT56?9AE87'35!]57
M B0M5T2U \R96I(XA-FPKR%PW&0BN;&,LRW)B7,%#15]-7U-U*?V4C6M65,R
M>1J 92R?OQL_?E-L[779? 'AG"!&H1*5J)H3U!)MH2$HG*_!CV_8>EY9,+-)
M-9<(!$;_>I,<@4]8 Q<_^+YIU]!R<R68<SV;B$W&%G/*Q&==<))MO0V*H>*!
M_:;,Y-=%!T8JC(V!/$/+'D.&&DU)S>7$:5ZGVJ;>9&^8=%A6.]ZS6K3?!?.+
M3*H>-B\J-ZD'"IZ[3FK8M&7\@JC!R0>)G$C#!E;H*U[(6O(E!/9GI2 VU/A,
M:J3OS$>H 0.A!@ F%PR:4E4$6X>5@5MSO3*%N(QGU%#Y.[C]:Q_TU [FHCGO
M=:Q;68D&O4H+:[;L(G;.V53)%$]BR$( VXL(&>.P)&@UVW9."^M6UF-L:/$^
M+31[78BW<%%J[[?(TB Y3P@16DO,Q@?GSP()&E6FJTJ+U0PDX;MWO<-OG3X]
MG<[<-3?4LMA#B,D+($4%#IIQ9/;H^@ZF',7-ET+."QN?"\\!D^)&JXW=RNJ2
MWBM$>',MUA;("*?YIVI,K+Z[B>K0EE+1LL)&J=4XKW. YX-J%C<IZM6HT1?V
M7:;&675K?RXZ+3Z2-AK3N&H.>[W#7YTL5QS^TD,7MCRM)(=&$)$25&P9FA7;
M#&M*4XG;QM-\$IV^N\PG?L>G8;B9:%1S:*I23>U[H1%#I18A.\\^MHSG;D;I
ML+7AQ2<*D[,JN-]%%][EMN\U"K^&<K@?NI?W2?+?W<NE0[]D+LB:E%3/DJB<
MB;85HP',AI"ID4$R&_<R !I=BZ>A$*!AD(K<QU>-NIDD/D=,??V'P,;3?&8$
MNJ1U^=WPV36$H.7[EUQ]$V^!3"J +9"F2S%3RD2I1ILV_F5ER7,]7@44>]1\
MV2)!Z]U>-(OVD6PQRA/F<Z\"YVF2 6\VQ%C9P/.A?X$KIT=ZJ#<+\"\A- AB
MI?8-8+TZAVKBAB9R\NIB')_[EQ6FT=5G76Z-^>S%M]R:OWS=EO\^4E]@^=(H
M>2\MU83 A51/:/K")JCYN\)Q"7IB$!$T:NPTV4IJB2";JG?&&G!%19@3U>YK
MH\/6?2!Z^53*4FQF]IQ-@^),D5X!NAG'G*6&LZZ]UL359="5 (7\#M#S17E_
MUVC[QBG\15ZY+\2+B]%C+ 9C0(V/&C\I0V;A7*@P")E8S/E:T#CW+D/FQMFZ
MA7GSU&M<K_#A<LEX-1O_\- OL?%>)#%)B2:I(3!38LK%50T5.9M 2P!T$/<-
MJP>B'!TFT(Q$**3BBF4COIIF_-H8PH"<Y&?^XD?"<G0RTR-^F>-_^>O_^[&[
MXQO8U'CS[&Z)$0NUX"E #*64ULM$ RJU3>8Z '8O;\G_QF[^_MB]E\?K:#?0
MJN_+!#,(0'".LJ:MP;7<<A4[J&KJBQNN6@"22RAFR*%1H&"8"Z0JO?F-"Q)L
MR)P:S9M$VF#LZ@X4K=!XX](&HD.GSD*&HUID57D^>1<9D@NEZG\@1P HG./%
ML$IP?NOBP888*T:,#T=4PI;S5QQ1>?_0+QF<8PXI)\C&(31R)2:4H"(A!\'L
M[#P^F(OX8.S&O:PVBYRY>FPR?8GQ0B8QN&+-'JPQI,FGU!SG[?*PE52\E3.5
M8:R[8-%7H3*&S2*5+5=FT:+*<S1F\-Y5@@J^(FJ(H](]5+/B73M7.'YUVS*M
M%GG\GU<*GK''7+?$\8MI!45H?"F)A!P!V-X-G:P)T9,!+V VA!C TM'%T4&X
MBBNED#H%S6L3HLFD$MBT++'&L*'#YTTJ@(:9 =$@&3"UBF\%"X@4\GVDN_<Y
M0=45XC8T^!2O$+^S[@.O<.MD,CJ\GFJYBR+$Z7ATQ@8YG;Q%^4AHJO?MQ]'T
M&)Q-/]S[[='%QR_>NGC>/_]Q)8LM(%:330L0DU H)'V+/E7(@<QF%\RB=\&\
M_@KVP#3$;%+)(L3 &8NQ2JF"Y%.K+M@S5FGZ=#96TQ]L6'7%$'9Y+9DRZT:&
M:JSFV5<<JKETZ)=TIPZ^H2AKD#1!JDP86K3L8D9#'OQ\\8LQUL8-=U:+.^\M
M?)D/S]BXB/'?/EY7@VO_C[TWW8[KR+6$GTAWQ8!  /7/EEUUW<ME^[-<=WW]
MZRX @9#9ER)5'%3E?OJ.X*#)EDU92>4YF<>#=,@\S$PF]@:P(Q! 'I%*(2@,
M^1QB(M(>"7^U<K=%JL7AXA,6[G84F!HF)B\M(M;90H2+9A_!2M%R3:^+1HYK
M>W"7V@I'=OW5HZ;4^]^9A%BK1\5<=("(B$L%+Z1>D)H[WO4=27%Q)1D+Q,X7
M_!_AO47?MXY /*XDJQ,2<1=5F46((?986A^AR9,TCNA4I5&K9'&#Q"J6<G<'
MB!JY,1'FD:( 4QK_(D"U(7_B2&QO6F_? N+)AHR]E@>NSX.](\W>@^SO2;/W
M;OV4VIS2:VFSS59CT%Q)L'J)O61KFE@V="^EB&]#]Y]8>*C"49QMN&Z(*5$9
MDJ"/F(XY9<A^$\PIY+0M/#P(/^F]I=![<8"/&LOI9KU]%RL/*<UQ >Y=@@)T
M%>9*%-6K]-YOJSUN\?!D \9"@?&.5WD/&K_G5=Z[]5/Z0M4Z)*/%7GN%ZEFK
MF66,V5,W$;KU*MN*P]([T-'.FF$K6$5CSA$"4*QBG6-6RAB::O$[OW*W][9!
M8YG0>-^S/'2WC78W'H2KIM9'CM(!-(G4:+,UE*6J.?A]Q[FM(/I!\*FO\]W?
M6A7_HZ-#G^9;WJMS_A3?8JDE]PS*#:23B+?(,L)/3XC5EH^)WS'0?=[P6P;B
M70%DK\=O'@43;-,Q#-$.-G&AXEB3<"_8>L.2C_($Q:=OC>_A%$,RS'-D1A8-
MT/K-Z5#'"-$%M5):D26/FN;[1U*OU$UKP^H*D8A3KZF%N7,A.4%=$9*..HG8
M/Y)(D2UI*<8=.)817T*"V.( DD:]W16=!82+/5#U._M1X8.*XC.=)?^<^<;4
M);LXL5E#-1Q^!//(-U!8<V7N.B-7FAOERT?$DEQ*^=5RV6L0YL?=%=T=(F)L
MM5ESK=@'(J)8ZIHP-$NL/>7[&JZ(3[;:OF6>=/EU#5=\R$+J^[=^RA%>E52A
M23$MH".\B,<,F9K6($/QWA47IQL0W5XL#42S%\JW)U<GSV7NY3V52W]CS?^2
M4Q_T^L>SF_8AXR:_?'/KIT)IOO"SJ_'!SS?Z-S]_?B$O?SXQ.;WKT7+U\N(O
MW_VO'02SU^]XOMKUY?N-4:ZN3KT]^-?Z]'QH;@T^:+W_O5L_J1,)$LV<N@2#
M%KK*N#;UR&#6U>]AFL.3+0PN-@S^&D=O N$?GZ78Q5GSI*%E$]'(\[1P(<LU
MUO'=(".:YC7AZ(@3[ 7@*&N&X8*:EPI5C5'&_^A1I4'!>'><HFR;UQ]9\7Q3
M\/Q7UXL[P/[1TM0G)>,SCRJ[*6O(W(<,2W-$;!@A*6J16FNG&&N "K9V0!S;
M+-X=0J,'!)8DK8Y\NK?&QB)S>[HDH.YRI]-*NM-I"\;(ATSVT\#-M^=R]N7]
M!.TW[0'+%V?M(P9M[D!$E8=5H[Q_ZR?M&8=*WG/O*<&X(FD%FWJ1R+6$M@<+
MK^)SH]"SCXP,I8X\'IH.JH3Y@:EA,Z 5,>- PNF??/%E]YS=CT^0T(<SF),+
M ,+LD<8A5ZTC961@#ANVCP#;C]\7=B_8A@;>>P,3(F DLI'YUFS$7B/ZW6'R
MF+9&!!\YO>BF0?]G5#^S3]LNBF%RA8S577D$<E13-+%6B,@UIXX;(/XD(-[S
M<?E1QR?N$!"MUE89@R50<!#"TEH;SJ''[ :\ 6*YW;9V"8-&96A=2<4,*BOS
M'*U"A!HMI]L>?!L,_H1?*&]/<ED+&G)!+-&;0C30(.29QT7#Z228_'6CU_QD
M@\4B8?$;;5X?4ACU_JV?TG.DTIS@46OO#!8K!V"E3DURG%W,-PRM( ?=/XR@
ME^%T*+<D$2H.")%@DH[FE1PV&*TA<]T_C*B8Q#2')_B<D9*TD$MJ*=8N<>0]
M-S"ZZ7WTY/YBJ3#ZD$U_]%?GIZ].SIX_'2 ZN?KU O\?A9D'OX-GUWKI_[P>
MK_[UJ_'';^Q!O7O#KE[WW5_LW9?\P&__R%@>Z$Q/XH,:,;UWZZ>X1,?("J7T
M'@%K81EHK1H[Y^Y=;SKCICG$8>L^L7_,+J;!Q%M"(=T4)>ZBWX\"!%&S&G'V
M*0S<R:.TR*4H5,UW4$QQ=<4Y[^QMS_9N]R4Z;R5<?W2L=D=\>(0=_1VSX9/A
M.#SC+@JM1Y3OB1-C'\!,LT0VEQ*;JA)2O-O>74>?PP?A<N[FOQ/O3OYPS/J#
MW\!_R<6)Z*G_.*+4N]CXJS>_D-._7I^URZ]G)Y"KDU?^[%_R<M[ZR %W+YT/
M4V?&T'JO-4%HB5J;)602(WAL=NOE%HVF'_WJY.*F^OF'4SG[-=U_N/V!^>#E
M5[-)M[<O_6Q</"[SX\Z:2H2YGV%9>PL$0DF3$-:D YW4H?>UF>C9R_.SR_.+
M;\_MIE+\UEIV?GUV=?'+7[[Y^M/I?8B(>#TNH-V^X?_6VW?\WR_';_&K^0'3
MF_[6C?=/_N!A J$)2BXP2P8 FU 1#<5#15(!ZS>ERG W%FM>;"!<( C?*56&
M!P_&NKUU)V$F%\]0:0Y"F@U-C$!SCMBHEN'/ J\H>_DCPWY_];-?_' ^TIO7
M-]X9]K/;>D]C7K5:KKF'5C+TE F#%:U96NV&[;#BU3^>'9:K>)0,IG9GH1XC
MY0PB2KVC-@X>$VKA>K\#NR%BV8@(.T-$G)NMX#VEFU'0*F)F@$A>+2K!0?B(
MUZ+R_,)/GM]8:U<*=J$ V9W+,#$>BJ<XM0(6D%A"\O%OB9+9VD&XC.,#R.X\
MB!'%W(<.$6P0)' 0F0LV:<05#*&NS8,L+I%\%%KW3 E3H"0FH-&DQ,;-Q_<4
MR.KJ,H$E6VUW7./"0YG5 #I4' 5EM)9564M7DYQ6J]Z.*I';OS+L*'6>6%89
MRM"&$K!8L@ZZUQHM$Z]HX->&HSW._/+2H%*IF!,#:>:2D;%S#5A31%K1B-,-
M1WL<:LI:N_B<XQ,CY,!DQ*49I^S6TRV.#B>N'8G:V'^84]"2, M1!R  #K6Q
MQ>0#7R4@'%:8.T98[27J86BM5IB#2PAJ+C)71IH8:@Z8N1Y6U#M"6.TG"$8E
M'GA2DCJ\E97YE12Q"JHILZ_66RU.F^_?A=02<G8<<LL38)*1/3?J(6F@1'-5
M=:TN9-&VW@^O ;/7&(+U %"]<6")&IQEH"!A>=VK=R4F/BIM]*M>O3O9AJV.
MH7<)4L.4S6HH6F-KN?<86CH(1!Q)WO H &DN)5BK&48.8'.)!2NF!$%CCQ)6
M!Y#%185'L1HW'/8J JTDD)RT0FHVU\<Z<?;#V$M_@*-?RAX72 *3C-XK@1N)
M2<%9ZU)'NA5 U[;'M1][[&[WJN"P1N6,*CZ(0CK+D5I-&#28LA^$/3X^["W%
M/'5\]KD/]5F%H)',R2*82L^MU!9E=1OYBS#/[KQ9I" 8AI9HB4&I4,<>!X6(
MB'LNY;#6R(^A GQ/>[_<??8BS,D<0I]*U-K(,C$.'=)O9SS,D[VW.$I+Q-$[
MHQ:>F9_)^.WOQBS,A^Z^,SEN<KFS XU'+(/?/Y#^4-BFW6T1>J.F0,P>@; S
M91J>L.(L/--85@#;S^S^%L&28X=M+0U;2MVK"; -^(;8>T^Q5VFUEH-(JE;A
M]1[\#MY]UOE"7_XR__SB\M*OG@X</#^_./'WYNX\E<N?OSAK\Z^O_WE]\DI.
MQV_P1^>DEY):(FOV[C@R H18A H/$= )@PP72T<CE#>0+EB>D@5W##EH,:@:
M!!"%+80:*A>+FR?=!41^_4,3*5>_O)F8=HAYPJ-XU<:).$BJ21JTF;A60Q/&
M$I-P/8SEK@VP^P;L+L\",D$R[! Z&"J3J5FW5*IP2KYYV,-( _YZ\F]OWYS9
M^0M_,$N6XE0+ M?LF1 K6)W-+P*UF&,HBJJ\.=4-H_OVHY)2'8**16N#6I!I
M]B4NN43I4ODP_.@:RSL.3EWMSJ^JA&9F(E$<-$2=CE44TLU(:-R.>6^879R?
MC;VE)B26S:$!Z,A6#=OX>CC>G-+F9S>]M6B?&T(K[EJ]&M#(&9H$;@HH24'C
MYG,W_"[:_V;LWIOV9+T#QZRQATPZZPB2:3F,O:TM9]B_--OAFFQ)D3.(%VM0
M<IOM-&*&1B 1TY;F;I!=G)=UC*DWC+.]$DAGB7,-;(Y1:YP3R.9E'P$P-\<3
M9GOTHTD+=N=C22V[U=D:/T#*F9AJ*V+.9FRT^=@-L,ORL"60UAS46@A0>N;:
M:^0>((3"?*?#UNYA#VM/X:]R<O%?<GKM7_[R]]L6ZO/=_/7B9IR(O3>VZ?7-
M;]UZ^>/DR<7)V?.%J=$_M2+W9SZWUY?_.: WAT3^\JV_\M,/?'3?G+V\OKJ\
MN>-QIP[OL*K- =*(.\FJ@^)LE-^SJ6H5IXZT?%KOPEKI<<+ YF..S<<LA=;$
MH<S>*,+9H :5$;Z)6G#@CAI6$*UW0>N=S5G<:+W1>@FTG@=. W  \0:5([4N
M#-HUUF#8PO)IO3%I8](2F"0)2T@5C#D!<=&;4T>=7&>/NAP.8OUE8](!,^F
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M7[K,O4N0WG,#":!>4,1+P$[<0U_^LLS1@?2C'<0W9Z_\\FJ^Y;]=2//UD>6
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M&5R$.Z=DAGE;TCDX[OSM]%SE]#]/GO_\OT_\M*V/.P<D2W=8K5^%1NB+6#I
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M-:G>%6/Q73'6T.RK0M S.6OG__=SF7!*47YPW=.X->_"A! 1 W7,1AU(1=@
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M?<CJ'N2P@MBA0V@O8<R:U)0#3;T)L[-H3,5FB<S0F^F^?]#!A+$#A]!^ MG
M#I7 3#;G0U:C'I1"KP-)0"&LH=O\1T#HFZFASVX,+J<__OL 4;2?6,83-J%!
M"$*0AYRW"-F#U2Q00EK3>-$-1?M394DBN+!F'VI^8,==")L.!%6IMU-C#B><
M'3Z*]C2XM&?EED8(FX=1?>"DB5:RUH=3DI16$-$>PY8[S<3.3Z_D;@_@80G9
M*J-:4+/:A_.):,!8B9L@ NA0_1;B&D:5;DA:1&0K+*7GG ,GA=I0X\!6QTZ(
M->8F*XAL&Y(6$=U$ATZ++22!# D2!Z8($%.MT:GB"J+;1QCUJY-7?G$Y7Z?=
ME\P<[@+ ?H)<#QR@=#:#D2X55"_N3J75%#PBK2#(;8!:4JR;&_L$32JY02A"
ME')%E%"K@Q=>0:S; +6DD.=DJ?<N3$+0H5+Q@K&5W"5)J[2"D+= 6^XGVJ1@
MG'-"SKT ]RQS=5!SZ%@<N9451)LEVG(OCCY@8JE +,$A%^:A:'*Q(KT,<M:P
M D>_0%ONJ9XAISJ\K,62 P0=ME1B:Q4Z:;!R*(MF]V7=_MWYV0$O7'E+Y!IS
M%&[0(_!PL. @H<_>W]H.Q,M^?FONQ<]*X@ZSZ3YI@60JW2.4H()$AKJ&7?Y%
M6O.S>=K7A]Q>WBJ$WSS@=O?8_5,\? Z:T9!9I$ DX",C'E*K#;AXXA(QAA5X
M[C<(.+/Q$[?';GX\N?R?+W_YTL_LYQ=R\3]O34;S5WYV[9??^4XDUM_E_YQ?
M/+V^O#I_,83<6Z<=[K[UT_G+G_SL7MOM:D'S-W[57S?/OGO17]U[B"&K)BPP
M$HZ .4'N469ABEH6Z(-]90TA:X/QHF"\EUA-I2D2^ISK!QJ;N-;&O:8^<%RD
MK2!6;S!>$HSW(P<AD@1H<Z( 0I@#2<P:*$:E8,"^HJ3BLY^/N,/)]Q?/_.+5
MB;W=H>6=L^$/!/$JHWD*)*A]=@>;>Y25VO""9C<K#"%56 %^'L&4N\3L1Q1#
MKQ)!D3)B"!!MJ)GB(QULV)PZU:XYKV9!:L$(^KCZPU6"*#EK&+$+Y_#)*"X#
M)P$!XM 404DV$*VNZF9/!XX+) 3$#I:!8V&H0ZWF3MTXH:SAE,3"@?2G]]%7
MB2>3"H ]:S(&K)E"ID*S?W_MLYW=<>)IE:;D*IE[#D&; YMP-\BMCU!SHYK6
M'V.^\OGU'ES"@V79*G'3T31)0))H0"T-LB 5*<B.7"QNN-FDT0?:&;:NHFUD
M'T,::0:)82BBVCT.>=VM;<C9)-&'3R)T'3#IT]L86'5*.J1V1JDR\I!5U(\O
M%#Q'(H6D";9<H(8Y5ER$O,T=YX29:NMI_:GKW@!T7!+(NV.CN5DF>23,E3C"
M4$ C8RZ4L:ZA;F&'.%JG"9&ZI#I25AFB-9%DLEGUGRW7D9&L(85=X"[1]\,+
M7/WL=PT?#QD_XCY["5L1=$!R);/$GLU:[P,M*\#/(YARDT(?,:BU,4- 5&L$
MN0JG3$-"E^&)8BY]_5)H[P@Z DG$@7(*Q6>9&10,7%62S5+ID=D&6T,OOX6#
MZ$BD415B*ID812"/5*B:68@:><@C6<6>]6)./F[YT8QNWJM(E- K@"8!K11"
MY5IBSGJDT6V5IN2FFBG/T0P9, ZAA#UD3S#2WYZ85V#*!4JE+R_DK'D;?WP_
M8'3Q-S\;%K&#QI%U;99[G@4(-0!GM: !/<:,*:]_]>V33+I)IX]9O %4$FBU
MVI!.A4>>TE/)TJ(YTX:D34)]1*&=!D8B3[406#$J3"%" 1P7W=:_J[08,!V)
ME!IQ38<D5\DZLEYBKEF#DS0W0DH;H/8OXU:)JSG[J;&5I# '."CW5DMQ$X\=
M/:__8,+QI<1S=@)$A]J,H5(6,,?HZC5(&-%H!29=H+2Z0<_]X;Y#A U#T8$5
MM^X,V&%X@E"1<HS>E6D-1]QV9\%-.'W$R20;WB8J]8X)LKH <\EQUE"UV=)J
M \ZFDS[H= J6UN<>4^H0 A#%3&P!VI#>QAMV-EGT!ZT0)6)$=DT-.M:AC'H3
M&Q&K!<2TAAV!->PP'7KN@Q)T *DSSJECV%4M-2&04%KJ=UT8EPVC([=@K_/I
MQ'JD (6$/"63E(3[W"4\,-%S\"EE,*2:9LN-!-H:58$JU*UWR*6O@8];K'[?
MJ"%&B*9-YWC9YBPC;%.%U(+8,&5>44>K!:U+[.5@Z7ZF84G2=-.[8+;>X4)<
M;AHFIRPA\UTUT;+QL_ SYY\QK.P%03GXK#GIR2Q!3D,K$&+T++7$B-4W!*UK
MR6(O((I=8G#$7DQ AE3(6 UZC=A&;,.^@6A]^=!^VL4/3T2B"5I3Z"$+YAC*
M0$PO(_.EL %IM5NY^VFU.9O$<H@H(@ ]*@_=JSV"FI4<CM0QK=*4H3H[5  H
M&;QG"M8X<D2N9$;K3U0.OX?*7G!373)@Z2AASC K;-FAY4)=FH/+AIM-&GV@
M 5>LL[UM';(H0BU"T$)HI1#DDCEN'F>31+_C=GJ>[;VD$ :HS0FE])Z"@4DK
M'#?P;%+H]ZL06TF0JP.#S+BEI5'LC=/00@&WN+5)H <>$)2DO2G'''!$LDK5
ML<7(/8&Q"!X7CE9I0K-.$;/Q\ 80%;FXMRH-8J20> V)R )WB?9RL'0O^&F<
MHYO&D7<DD&;,'+IGHM A\P'D(OMO7G#@4BAI5DXE*[&#2I%>0QL);4$J%'P-
M'FCA"#H"213,@Y.5RJD"&A!3ZU5!*Y>:23<0;=+H04 2U-KF$%JB",F$6)3<
M4V;G@&(K -(:*ER/)C^B"LS=6J'H4**3PMQ>2%4P#X7$*\#39LJ[&,-!8U4C
M;W93SD(62\F5)7#O>F"NX2AZJ.P%1UB+QI[1>B/P2MI&XLO>W"6DEM<P:G0E
M9\L/73I5[@"Y8<B@$%-E1<\)0VA=6FQK\$@K0=(12"B>4]Z3U%):G6>[* V'
M9,%#2W/Z9MG M$FICZR.R,5RX":A0(U9A6>?L&'L$?;* >QQ+P90Q[7KE)KT
M:FRY!@:( U4C=:J>=&11 :D>-ZY6:5)*=19.R4B-$_!(B(4P:]+:>J"L:]A(
M7*"T^IRG4/<#&X,06T*. SZS>XJ6EBBF.2Z3Q=>?LAQ!#Y7]%"YX;*(8BQ2
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MS!J6UQ:X2[2/$_U[DD#9<\>;X4<!9("GT9!$*4F=XKFL/Y'=?]>8 Y="[B.
MA.%KHN?9=XCKP$[FS+W%:+K^(+)W!!V!)"J .:!DF;5).51"*-7%(WF'2.M?
MW-\[B(Y$&HU$J X,$7I1:)DD!:O:)'3WGLL:]JS7<+3@:/*C6?E@ ,[H "E6
MZ>(IU=(#>$BF*\#39LH[UY#$')(-LR5(;%HZ2X@>K'6EM(94=X%2:9\G]?>U
MVUAB+@3H"2"02XEB48:A8\1NZ]\U6DQ3CT.73CC27@"A@,W P2B&'BOTAI9;
M:>N73HM!TA%(J B]>L7<O2!4-1[9R?!& U_2.OOZ)=1BP'0D4LI:P^XM<"2
M<:7BFF-I/10H,6V VK^,6R6N*#B3*;JZ@ECADIF:-2@I@D<Y;ERMTJ0-DK;2
M>X60 &=KAU@$0U#U>< [K\"D"Y16G_'X_YX4N:$HZ;!A;J".JD0J2;C64(C7
ML'FYT#XR!RZ<M"6<C>2YIQ$VJ% 5C5!ZT &65 ]@5>X8FE?M*?W(I4EO0Q.E
M D[#I%'G&B 6]X&9#3N;+/K]K4H2QI&M-F""V%4"@$&"."P<0EW#\M\:=I@.
M/?>)V+ Y6?,AIR%W8HX#4\$ZY0IR7+G/*BT82D8IP!V<(>4B8*44M=3F>8#2
M5F#![230ZV8),>3H$,G#,&>21"-'&"_A\\AR7,-:UY;EO4-.#XJ9"X,#4.Z2
M/#=VD5)[L+(&][JE7N\;55!2S-KJH"LT<>V07;%QEABX']@RTW&M"L^M4-<$
M+4>!(<C4E4I2R5151J)TT\HJWK>RBDNT[<R'7MOU;W[^_$)>_CPI^<:F_S@[
MN?)V<].EG+4?KOWBZOS'$SM_7).F^/ .5G%W'1M4 &!$4&4&DRC92@YB(\2.
MW-?6T)ULP2;=4]=X<NK0.]0.5)B]=!.%[HEC@[54+"S3I'O:NXE%6LUD0W1"
M3VWX8,T@14*-01S6[WAMUC9>_/*7I]\=EG^-0VK.EI[$EN&F.>!<D"JEBYID
M64O_Z_U:;C]]K]E:#)Z)&@-UY"XB26)V'^I3UI#([MUR^_&67(!:-0..&2*2
MB&'1D@US:.,[!^0MOS@L;QE(:\FY8@<&=*?!NN$F(;E6J'4M V_V:[G]))W2
MDG?BE), )A9I67MIR5*=Y#X@;_EHEMM3IY,X8EH:X@!\<*P'*0HIJLU+JUX/
MQUO^\.UA>4M.03L60BQ#UD453&!II)<AUR'XUC"B9_^6VX^WU)%38@W9,4(;
MIL-6@J9>O5>+L(83D'NWW)Z4> D=)KE2CT#>-/14BQ%5"V2WA;&'X2W__O\?
MEK=,TGEH-Y8V<LGNLX=&L4$M*ZW_O_:^OJEM7>OWJW@X<Y]#S\6I)4NV1/?M
M#(6TFW,*M)#N_< _C%Z):1)S[*20?OJ[9#LA =*F;4)>FLZTA<0ODM9OO6JM
M)63#-9*6<Z3<0J2E*V6@QIT[AR@!?F-AY [.X)B$$0)/87VDY?PHMZ@M^RA2
M*&0T1H@$(I(L=,79-@;W+HBKLT_60EK^^\-Z24L=(%!LL8X#'1-B$->*"Q4Q
M'<04_+Q5.%MJ\91;B+04%,E8(/ -(DVD"UHJ;#"XXA%6FM-5R'U<..465&H<
MNTPF:AD2F!!L...<"PY6)5 N%FNPO3Z@W-O3]9*65H*BLRJ*7"H38I(C^$.$
M!0LE!KMSC:3E'"FWF"/W5$0"''(4@$<>:,P"Y6@68 8N'0M7I2W]0BFWJ,(T
M:XTQ0@O"B**<80D^0J #*T6D\1K%+4\_K9>T#",*[*; %P\#8B+&=&P-I29R
M)3Y S_61EG.DW$*D94PHXP$V0@0Q43'EA&*I-(T#%EIC5Z4L?*&46U0_>TR$
M<F8*5\71LBB,%8I"(*(K 5\CV[+^;KVDI1&114):;2),8BX8=6?\R2"(")%R
MG:3E'"FW&&FI$=<RME;HD'#&.,5":;!2M(D9B5:AF=W"*;<@VS**8ADQ3!"-
M24RP"%A$4(P1)A)'P1KE6Q[4UTM:XD@8#I)2FI@0I!"/8AI+$0:,,K VR?I(
MRSE2;C&[/"@2+ +F,A81!=X<"T(>F"@6EL2!7"/;<GZ46XRT)&'(I0R4P 03
M+@53@NM0"*60B46P1GOB[]ZLE[1DABD9\(!)B@BR1IA8@5^NF97(2KL&U3_/
M0+F%2$ME!:4:*1E&BE"0ET91JT5,7"'7ZARGN5#*+4A:QC:FA%,P4C")L!#6
M@K*SF#.+W#D*ZR,MZV?K)2V!3BP01$1",4(Y+*;"6@D!DA.'&*]1!M$<*;<8
MVS(,#+&!.TF6D]@HJ8G&L28<M)]!>A7:@"R<<@MJ<$M"#<Y 2%0DB%9&2.T.
MH0D$^';6A'A]I.5A8[VD)0+#Q+48%09'Q#+$M!.<!HP5PZTT:GVDY1PIMYBX
MI:#&2 YLICE1,>>"8$?#2%-86K-&TG)^E%M0PS)KP2_@&%2<)492R40<V&*W
MC@;@&*R^M!QV+2L.P\F2>;<M6XSLE#2,P2W@@:&&**.8C277-F; YH:J-; T
MGYV."Y&DW(+M0B-+ \U( &X#-3(B@8XLBJ18B9[;2T;'!?6CY1$-,'A\(>:N
M!8?0BII 42V4DE;JR\,5%J?/V$DEZ0"]X-K'PG+PS<\H/85"&C,F HY(0(3@
M(I:PB#)&V$@9%L1951FY&.($,R..5:&E&EEA7/M=8SD)<409D@QS:6V\LIPS
M-"%GNIDS%P8!816*.$;@>V'7[$L0J6A,N=(Z8*&6*\L@<Z?![/A FEBH4 68
M"0HN<" -ERQ@ L7$[7ORE>>#V;9%F L?$"%#*[0Q"&21QI*+*(H%ET%LA +S
M;.7Y8&XTF!T?A$13;+#BPH;$@GX63+C$-FQ"C!F5*\\'LRUXGPL?F-B*"!1S
M("TEA"MA@RA$$<:8*!WP8.7Y8&XTF*%=%%JL.8U5C$,"RMD9JV .41-1&7-L
M5IX/9IOD,A\^"'%,>!S&6(;$9:Q0Q"G5$?AYVF)+5YX/YD:#V?%!Q,$<-9*0
M&%EPW0S76(34@CY@[BCHU;>+9EO2/Q<^P. ?1):96$:*2*TXJ(&0Z<BX0F]0
MS"O/!W.CP>SX@,78,F2EXE(0%06"QRX'.09W65&LPI7G@]F6'\Z%#RPC$?@'
M.'2G3E$42ALJ)0(I$'?G4:T^'\R-!K/C Q-%)D)AR ,:$AK$S)A825<)+PG3
MX>KSP6R;K<Z%#R*-P"F6X*D102130J,HLH&QL8@P5?'*\\'<:# [/E#21I'2
M/ 87V=6<R) J'%$LI-OVPVSE^>!TIHE*<^$#Q< EB&&Q P9V4<P8UZ .0!$0
MA(RRJ\\'<Z/![/@ 41Z#0P!^6@2V$ LYBMT/2$0AD8B+E>>#V::@S&?_0)N8
M&NT:'4IWFB)H!!1$4@J%E*+(KCP?S(T&L]0'H;)&<\5M3"*&N4(AV$5$.-<-
MG.65Y8/G2""8C]>,0#TH5S^CBJI0@9%K_B,D1SHD>'6C1\],D1GN+41AP'EH
MB3O3*+)<Q"20.C(,*2HBH5<@^VUP]-A^VE%P1U:<_W>:Y)_?]-^8CFJV1?;Y
MGDJ#DSN/3?<[)/J5%S?Z-]61H<.+>GDW;3N /+CX5T?AD'DDKM-L\(:1H];V
MX-<D3WN9,F],=F4Z^VEVDY;O7L<<0,1,2 *P=\ -)HHZ S1P^8"&$(%,V?5T
MR7, -VA>1C0O)!,2T&PL$HPSBH@U@2!66,P1Q2RD(ER%ZNX-FI<0S8O)!PVC
M*(PT-G&,)+&8"B(EI\2 [1$31.G&TEAE-!^I_Y@\3]?=P BI,A;;*(BP)!$F
MC!@4JU!C&88B+L_3WA@8&Q OM5VAA4;N-!5C@YA$G' *SA]2G+E$OYBO0A^$
M#8B7!\0+.C/=VH!*A)35F@@,$ ZIC65D*26:JE5H-[8!\400[XM,)QW1^M.(
M5K=YV%'K:$S@4!)II%"1LR0BZ4IQ*->N066L&5^%#N@;""\-A!=B2A@6(B,X
M!4D,]K"K'V.(225E% 9A(,S&E-A >,D-B9B _4!I(+541*!0*$Y<LR+!PP@I
M5597P!L16U;DGO5D;O[;@YOJ ,[N8_ \N&!6P#TPLGO8R;M9SPWX'C8-D[7?
MIZ+SYJU020M6ZMC<GIK<[9[I_<SHI+MWE9EB)VVNNV38P0FQ6>Q;*B:0#41Q
M:FB(,0?US+7 ,7A-,7R\_!B91"N09VGK2]*Y*@GSRQ1;>M".SW/\E1,68T5
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M]NCZS?5%XS \_PO&^+"PE/) Q8R'/I*:^80HZ0L4NQ8'D0XM(\3$<NNU\U.
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MZ@Z[INVQ6H FBNN3PHPOCAO):U/:O&S<Y'VPLUF=9C&V!F'T#$LPP0J^4P8
M PY+5BK4P1%"1=.56U"1H"G_VTN*\"@8@_";A4L[RKBZC=(KV.]EF=M(/RU[
M((-B'!9Y@"?!P Q]-?B@^!6]>@&:6%=:ON4..@,]WDRD:[PJNET!QH#VW(A
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M'QT7[FB;ZWSZ:@PVLB<\FR!G<AFX,AQ559_F361#OL!-S=@T-"9+6* E1RM
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MW2EF>NDP!5C^P7REKF=.36J$N5RE')OR<0HL;DA?'>LU<A"%S-FC;QCQ1 .
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MO\IOI2'IU%!VM (TSW'6HH89V%3>$[+\>"46&^9WM.;$G=$)T;^73@G)&*+
MDC8U"/K6LHBY8*?+N ]\8+L_J#_"-8AV%Z65D3*@WOV<WJTW736J]!\H.5@!
M*H>:1BQ0><<C<8>(ZU:JJ,B&*^KG''9:?6!%4!V8SELZ(U$^3@'21C1![RI^
M[N4M)^O+=XZ^A&[T."L#A0@<)FZ:(\=M/'3&I6B^RK %1$6Y=[UZH>6 _0,*
M_]CQB=6EHA4#SJID^4,1 !4TY[0%(/[:U'4W0%V/I]_'&G^;N#8^.H&NO'M.
MD0KV12WH"N0(-:\B'3'5+ER6"EENK +"[7G4Z_(R40=5_@%KS$&[OE%6A%<
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M /2U!#7"A$#;9-^L3V.GVM(>"EAU.-@.8;^Y\3_3[(KM/(6K\7P'/+Z:6LV
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ML<+WXU&\"M,/R2,IUVLD5'%%T(OPC*$LLXJ!Y8*!Y#2GG)$ZOL[$[2=>T:4
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MCO- /$U(]#X%V5.T=ND&:L^2JQH+FT-MC!90_W]3G&=&A>\78S><N%"VM/2
M0%?9L>QHZ0UB! =A(P.K?00I6$Q2*B%E6X-B4XJ[=#VU=]A596<+\,W5]1+-
MI3> -=I1,JNQ9.@?T=)DP-, G% >#.Y.UFWZ2SU#6/5UE\5R&WCV<9;*($!$
MM%2<U1)<HCHG:65*;:MTEZGIHG59 R5/G)?M.-&N\&)9)%B92P(J4J1,&8WL
M(E@?'"1&-),NHBW;9A30^M[;@;MD[0,D.[.FG> L2_0VNYQR )-%*=S+M*1&
M94#SU<DR4Y3F>" !4F&%OXY'DTE/\D2LC@:"15X*4S*_<I1 -,FE)Y!BHFWY
MT5UZ.BTF-\7$L[)Q<Q:T _R*9 8T48167$'0I2^18@9,.8Y<4VV03JI5<Q=H
MEUR4P\G*ZDC9D3OM8#.'<(PL2((:G494 <);@JO.$4E3PCLG?-Z7I%PA1;8.
M-\V?6-03/O.U&X^_Y]'X=S>.Z%)$)7A*97H$+W,D9AW4F 4:1)+(=FWLO<SH
MYX)+C[^LTS)Q<_X_$D2JM-GMD(X_7'^VN-DJW3['7]/D:!B/0AA?N<&D1T@(
M,7D+EI<$L.@9>!LIZ*PD$LX"RVVZ^F]';Q?#E!6PM4<FUHYQW]#Y&G_O3^^<
MA-7M97&'HBI-)H!S-!N$3H5<FH 9KQ2J ZO(.LGP.Q'1Q1AD0R'5ACEML'0>
M^B4=+/?#$HD%_>-^H= -ELA]/QH->B'R; R1H,N\.<'1<C'*:I"X?\8GKZ/?
M2KEM2D@7 XRM,-6424V5XHJCT,LN<"XX6KQH!*, #:69J2>@%;'"&D9":M,6
M>$T"NY3)OB>UMRN;VF'H;C2H%Z6VE J)</;E@EEY5,/XJQ>&&FU)#J)-[YQG
M".M2)OL^,+,#6]KHL??C=.GZUW;;I,<UX9)9!M0P-M>LQC$'Y4+'4V-]"NLD
M;C[WGB[EEK?60KML\3X]K^4J5M23BQ3#R1-EK@;?XZ1U4'J2H ])$@H]PX K
M*G-$@XPU3M>JN9HN99P?QFMK"X!V4)YEK/:DU%J'C+8;(ZAW*3?@%36024;-
MJW(T8D_7L#-ZNI2)O@\X;<Z$-7.%%Y^7?W@$X5_^\/\ 4$L#!!0    ( *B.
MJE0D[F9_$%@$ .Z$,0 3    8FAC+3(P,C(P-3$P7V0R+FAT;>R]:5?<2+8V
M^OW]%;J<ON>XUB6P%(,4X:KF713&5=0QX#*XJ^TOM6(2R,Z!EC)MXU]_=X2D
M3.7 G(  U3EM(%-##'L_L>?]R__]WN\%7VU>9,/!/]>BC7 M^+^;O_P_"/W[
MU_=O@]=#/>[;P2C8SJT<61-\RT8GP5_&%E^"-!_V@[^&^9?LJT3(W[,]/#W+
ML^.348!#C.>^S%\)J;4D6B-,>(RH, 8I@Q6R<9+ 1Y2K2*X?OS(T#75J&&+&
M4$0YE8A'$NZ*;,IX%*HX2M;-*XY9G&+,TC Q5-!0:!*E":5$FC0U*G6O/1G!
M[&"&@^*?:R>CT>FKER^_??NV\8UL#//CEY$0XN5W=\U:>=$K8[/)A=]5WMLH
MK-XX'GY]"5^\A#E%_Z'UI>[K;.:I_@;W7!R&Y&4V*$9RH.WD^EXV^'+^*-RW
M]:5Z.!Z,\K/E(ZF^]*.I;UAX].Q0W-=*%M.A%-FR@<"UT<M_[[T]U">V+]'\
M!,8%.I;R=')G*@OE[ZN^\"-"881(U%PC,[>BU9OBE^67]:79]_,F$+FUA"E8
M1Y'3RT<(5F3FGGJ%IE>_'.5R4*3#O"]'0-_N80R%O#'"K!A2'"47[6-Y1>/%
MRR^^Z*TX1"%&$:X?4N2CQ66$#Y<L83$ZS9<3@OMFA@K4R>QZ*#DN],F)E;W1
MR88>]MW%.&11Z&]XU9.#XW^NV0'Z<+@&G&*EV?RE;T<R<(] ]C_C[.L_U[:'
M@Q'P/SHZ.P5"T.5?_UP;V>^CEYYQ7F[^G__S?WX99:.>W80!H/H=?QO\R\OR
MXU]>E@]70W.V^8O)O@:9^>=:=AG__HV3" ;V$FXH[RI&9SW[S[5^-D GUJ',
M*XHW$G8Z^OE;9D8GKZ(P_'_7_*6;OQ2G<E#?H(>]8?[JOT+_W\\IS &ELI_U
MSE[]SU'6MT6P;[\%[X=].?B?]0)V#@@KS]+RPB+[8>'!\ [_Y[?JO? <M]OU
M."+LWAS ?[^\=&^N1[TP=C7,C<U1-:+4__=S]:&_Y%4Q[&6F_JB<5[@1N@&<
M2F.RP7$]Z8"*#1:ZG[-_K\TNELR/8;W4<#0:]E]Q>$SUR6AX^LHMG=M))'O9
M\>"51^ZUNUZ[9.G:[7P_R50V"H38P+-K>.YDV(63T4"G-G^PV9P"=\G1,#\+
M]H<C>[,9\=D9?1X7HRP]*S_*!@8F^(K$IW>_8\NI_6 0;(V/84P!67?'?;0>
MC$YLL#WLPV#. CD8P$&E063(1D60>=P ,"R"T=#!B!GK$5P#7V2C3/:"T['J
M93H8IBF,9G <!"_^^[\X(,G/N^\._&_1SS_!M_YATA;PIA%<WK<FTW"WL5\S
M;0,U+F"81;$>_-8;*OC\<-@#/*L?Y?^:/.R%&VWSFZ#QJHW@T%J_=0%>GURU
M^]O^[IO=[:W]HV!K>_O@P_[1[OYOP;N#M[O;NSN' 0I^E456N&&^RVT!$_;X
M#],TP8?"NL]W8 OA5(!=0/"&4YF75\ W;C2_>L ._K_@[;"O@ITSBW[WX!W\
M6DW,/VJW6K)WY9(=U$L&#RGGL5>M2GU7-2FW\L-Q'LBQR9PH!]#NP<;+=6^R
M 9SU[K&',&KK9#ZW:[HW-O#MB<UM-@C@2 O2<0Y#S6')1S+K%4%NCV7N<,G/
M8+*0&\$5:9X_)IK?'3C:'5CM=\W+PF[6CMD'L$S%S(XZ4BW7HZ9+QP;#DNJ-
M/;5^.A7E]\X"D!K<6CL^&9V5TK5[> ZRF+L^=\^L**0BBY+7,IC?[D!OS/+?
MB2P"98_'@P!F+8_=!KD!#4]M.4(WF$"Z+P?PZ&\G&3P6:!>F!R3LF'4Z/1!.
MX"T__&U (,4H!^8=Y[8FV]&W83UU6P[?#0G>?YH/3X<%S$F=S5/'%EP 4RO&
MO=%Z8,9Y34!IE@.B_&<L\U$Y8R=/S,S,47.4_%P$VR>9!8[Z;O5XE'VUCA$
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MW8'3P(B_7,'D8KBXT=,*@EE-XKI)XDN=F,NW:-VY\$MOOLXS'RW@ B% )LJ
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MZO&$Q*Q*1EEA,-^YWJ,G#GNKDEXZO+M+O-M=+.06&6,3JE)$8I* V$(Y4M*
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MIQ@CC#D5C";4)*Y&>_C<#"^/3&AJ%'[V2=$K$:(NT?JN6.VR7)U7!-;4#,?
MS)/MOAV,MFXG_G'#<J"K6* G<[[<0>WLK8%99K+OPA56=JPL%M36EIN$*0['
M2DI=&)( ^5*!MHU5A'7(94C2LJ#VROJPKXZ;'MB:UN%JAZNME=L[7+U?7)T3
MURF.I(*S$?$X9J"W"X6DBP5+DLC(%$O0X17H[=%Z)%;5NO'A<=6+]"^](E@7
M]8%_ZH'W97Z<#>K7WS\G8M\);A H>R)[:3!,@]&)#7X=RMR\FJU$M'S0S _:
MSVZR%^6*PN![\K2PK^I??C99<=J39Z^R@1^"O^GGZEG5!CE]96XU_6J77__\
M+3.CDU=";'!&'()4FE+UXO+;:,.#RQR!E-_1>"-)DG._#C>B<[^[Z+%D(Z)L
MY4_U@^57>NPE:N,%;GEMG3&B5>?"R^)ER>M_'!SNO/L]V-X(WFV]V[J"$GB-
M\KJ/=$G>?S@\W'GKEN3]P:\[[X\.#_:O55WW&F!W^9+ 8QYH/?X8%O;TQ%.&
M/)77H(PK2HP/-[.KUYA^(EOY?EP4MN<I>JA@4,5P<!V*?EQ\O'V2V338^6[U
MV!7["P[2--,V7ST!MZWJ]]/8/)GEIZ K# ?KP=;89"-OK'R?%5^"LI7#R-I%
MVKU,]*LD'PYC:,A59-ERW-W$_1-?N0HDF;Z"P'@$,J+4VB<(G+GHN8%K61/(
M'#X>^%"ZX]R7DLI'E4A96*?1>93RF91I-I #G<%%Q0@^\$TP-N9*7\XO6#4$
MBC<2)R>>#@M?0N55;GO2L5,E'E;:9>/&:HG#Z2U2P5#&H_-ON<>UOW"EWZ!D
MV:I,U\9KHARS.,68I6%BJ*"AT"1*$TJ)-&EJ5/HW%GRMONLDG_+?L44JM_(+
MDBG,\97L?9-GQ=K+63H%DIQ;^OE5>YBU">"_2TAFJHLLZH0ES7N2K#^J)>O0
M#:!&IVK2 14;+'0_J[])[*][:+I9Z.[AU^;7K0^'V[\'O^]LO3T"$?I@[]W6
M_N[.80G-N_O;&^<J=VV9P?;!_N'!V]W76T<[KX/#(_BQM[-_=!@<O D.WNV\
MWSK:A0M:/XL7V2" Q_8 =(KUP'[7%B@'#I$RG:K<#MD?C@'^?FJMOAUO\#B^
MB;X=)QL16;UFS#=(=/Z=%SWUXC>RF#[[L5YMMVXNE;>N#](ETFK$6B^N+I_7
M1ROS(M@9&)"V%@J0KTC%>FR;>5?J\X/.V;F45S7CJS2F>E(K%W8K=[.5B\2#
MMO5ZB$F_MU_M8'S#YO0WB"!KR6*LO!G>?;?X[):S6\[GD=/Z+A^:L8:-D[U%
MF+IU;EOKIGOMV)JG&1UC-$_2A"N=4$,M)5)%B29,IBI,>9B(OU\[$3&$_T-7
M"S^L#KHW^;#ONA*[(?R5C4ZVQP6LA\UWOE>Q[EM%8>'_S2,JH'1<1<Z<]C[]
M]2?9^^TC._CM_<G^YS_#3_T_SSY^_O)CK[_+/KU^__GC7[MLO_^!?CRL(V=.
M>WLN^N7UR>>]UW_ &+^$'S^;SQ^/WG_YV/_SVQZ\^^,1C/&O3Y\_'<Y%SO0_
MG'TZ,E\.?MO[MM?_".-XG^WC_9/]WV!<K[=^P/M.]G^XB)W]WK]_[%51,SLC
MF O=^['S=\)#8HFTB/IV?,QRQ#6/4&1QE$@3AX+[PI"$/L'\W ZWGBAN69XD
M$4FP)DI0&F-EM39*,YQR;+&B'K?"&K>N$-[7X=9#X];9+&X9+"2)E4*8 5I1
MFD@DTI2@A%H3AB2F-&5KF\G2RHX=;G6XU4[<\HTBN94&TX0F3'*L+>!70L,T
M2CF1#K<B4>%6)#K<:CUN[<_)6R2,;)Q@@DC*)**26R24LH@D49*$(4MB$SMY
MB_)5Q2FWJ.)"JR'(%W,-\LLL<4^S.\ U,(I@%@IC&8TC1A/!N1$)"7G"+>6,
M"'T_.F$'0]> H3\7U#YB%0M5R%"")0$8PBE2)+5(:FEXJ&*.F5S;%+?6^;HV
M'^UE9$4(-HS'8:0,950I+JRQL4I$ MN/X_M1DCI&OAXCS^E!RB8XP;[5:0KR
M!*4@3Z18(BN,29*8<!&&KNSK8O7KCI.?#"=;(F.#DYA&S-)(I$I@SM-(RIB&
M2:CN26WH./E:G#RO&6B!M60I',F14<#)KH<Q: /P#S8\BC6!DQHX.6K3F7Q;
MS]=M"B8^XV)#5L0@:$<JU1A3DX0"N#I5-F:I5HFDN'/+/"XP^+ @GRL1,LQ2
M <>ZQ(AJ$X)\;A,DK8'MA,UF-O1F@B6ER&Z5SMSZ*A =1%Q-N-=&V%3 P9$0
M&EK,&8-3A-O(<B9LDG0>D$<'$?,>D)BPF&B#PI""Y*\,!^T]D2C6$=?$R%1Q
MY5OZX:2#B XB%B&":V59C!,3QX82&TI%*2%&A"8&62*-.V?#8X.(>97":&SB
ME"=(V80C()@4\4C%*!:PK91:2UPU4[X>AXNM?%L*$4_+$[$\&GCG^ZD=%/<0
M#7R;@,Y["PI]?(-<9:G-I#6T>D[J^K#PB=C'PZ$IW.*8X(6M@3Z0?5>S]H?T
M1Y%+:<_ZIS++?4ZVNRL;C.3@.',IAQ).A&:F8M="X:YC,=W6':2_N8US)<ML
M_C73MCB$+>Q.Y=6=RGI!MQ<Z%K&ES-42!L&=LQC)1";(:JTQ-5;0E+J6E21>
MU:G\2&7SI\W/*X]1[/CYGOAY3A&W4F%+X@31*(V!GSE!/-41,HS&"4ZH5K%T
M_+RZDJX=/[>0GU<>N]?Q\_WP\[S6; 5.14@CQ$1D$54:M&: :62PP2(.7>$;
M?SYCL2K#6HL4XT>E= R[D+V'"=F[")HZ]+D&^APO: >I-83;4"*1I!%($V&(
ME+$)4A&#K5%$I"%($TNZV7?Q/$^&7U<>F=?QZ^KX==X-QR*EM30HDDPC&C*&
M..,*)2XX0R2Q%JY_(KVUJ-#Q:WOY=>7Q=QV_KHQ?YZ7[6&"E0^<GYY%$E&&%
M.+8A_).8F,E0I-2XCNHMXM?GY$\XM+Z1W7IP; ?657IU7@-I^MD@*T:Y+\;:
MN0CN+2ZPVHW?RKT *-J:V8G*4=F9(U8'6%\6% (9)8FE)$1:&X&HU R)*.2(
M)%* I"%)ZMJGX_7X*68Z=[Q]9P%]'6\_ &_/*0]Q$C&.I4"21RFB*2%(6DE0
M8B7(D!&72<)+5V";3(T=;[<]$J_C[?OG[7E%@VM0-4 ,0S(RH&A8)1 G1*$H
MD9'$E(54>]YFK$WG]G-R([RWA96Y/O$ZAK%?;6]XZD*3.D?"/28>E5L $/5Z
MN@$5/DT#AO5_QEENS>[@73[4MBB<?:0#J&L!U,XW!TXS31-M:'2H8H.2F%E$
MB<9(<0M8%<968A[&::+7-FF\JA[GG>VRA2Q]!XE"'4O?'TOOS;*TB$.2&HM1
MP@1VY852)"*KD0#ITLJ84>.]$:Q-2<0=2[==G>A8^CY9^L-<RWA"34B,!L5,
M,40CG2"AA482Z]!J@H7BU#D8;QTLW'DL;L286\T<AV4Y#9V_XL[5"76B7S7W
MX2#=G>S"EM^$*4HU+MOJ]8;:-0T\&M8=&*:>UR[0<L70]GU! 3$LC4/.(\0Y
M=B5/5(IXJ"DR*4TC+$%>$:[DR3I);JV"=.;/]L+ RE20#@8>!PS,*2V2PSZ#
MO(KB6":(6F>'H$(BI=)0Z91PDB8.!F+:P< 3AH&5J2T=##P.&)A7=(S%B>4A
M4DGJJA7$$5(A:#N1<J716$QC'#D8X%W>Q0,QLV.$;UFOUTSC[IPE]Z+=U$N_
M.UGYM\.BV!^.=@<.RIS5Q4/;]/OM$YD?VZ+#I>OATMF"EI)2BDF8&B1E)! H
M*0P).*20DJD.=928Q-M4XUL7;.]LJNUEYI7J*+=@YJ8$DF;?K4$_;#[LF/S:
M3#ZG@^!0,A(I@D)J&**QB8#=*4,)2;%46.'4*-?\C^,(_]PQ^M-E])5J(1VC
M/SRCSVD9(978IH0A:U6(:"0%<G(:LDPK+(T-6=A*1G]6+A7'$TTE8SW(!G5-
MJ1YP4.#*27E-/CBQ/>.8Q7<F[5PM]Q:YU6D;J\"G'PO:!F%<I40+I".N$ @C
M*0@BJ4(BM#92G"I!P[5-O+*ZSYTIM(7<NO*@K(Y;5\2M<VH#0*C@B5&("Q$[
MVX"KL!I:9.)("ZZ4T=RU7XDZ;GW"W+KR>*N.6U?$K7.ROQ$)UG&2P&'J6JPP
M8Y""TQ8Q.&'3R!I.7+Q!JX(-GI-[X;TM1OE8C\:YSP#/@,6.<^^:6P\*>RKS
M:1W9W7<'L!Q%YWZX)_?#S-94>+0U,+OP^DSVWHU5+],':6K]UVY?.K"Z'EB%
M"XH )52+),0HPEB"(L )4@Q^(U*9."0X%#9:VV1ABVP4G3&RK7I Q\/WP\-S
MZH&*XS"2,:@',C6(PN(BSBU&+&:4IREED7:E)+MLC"?,PRMU*'0\?/<\/*<T
M8!ZGH2 Q"D&&0G J&R0,U4CH%+,()U%*TK5-TJ5?/&3;=EOF(JT' WNS].UG
M8:A8@4I0P'SAMWF+A=^%@U/K5+3!\>Y #_MUE8E]VR6!71.$HL5,"9 $4Z8I
M8CSDB-J((ZZU09BF)"2&,DY<5=CDUF7K.CMC>]EW!=I Q[[WP[YS>H )(T-B
M;9&)O SA0ILC95%J*4D2+"1VO1I9UR#B*;/O"A2!&[)OE[:P2MZ>TP]DBKED
M.D:PL1A1A152+ 4&MXI0S;5),'9I"Q3'+>+NV_H5;J/O/^.>JRL/P_%*_M;
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M?B9_T0ZO1,?N*V#W#_,)1]A:3@P2#,.9;JA$"F.->)C&TK DC$BRMHG#Q4"
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M3 >E@N"1H!."\V!)4%G72<TX.VK/*8?:&U+.9G3&VA ^:JE G/B@+9I,0)2
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M=?=KF>Z,QYB?;0);F1'SPTR4)R6T>Y"N>TOAT=)SK%+D0A3YYYRQXWE =%Q
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MF)P&85QF-%GZO6B>0!-/M'=!62*WMEE'&D94L'8U8:F"=15@;1D2GDHJ18I
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M..M9HIY9J\IL*#+?0:2"]SZ =_561 7O\L#;,B><TBFD;$10I7@^>=&!B9:
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MFZ?\=27A]4+*!^E%EO%1%O'3+.$ZWG*)>B"?<P:5IL3,A0A9J\=L#%H"CL0
M-G BC+#&>YOMP$=YJW0HTZ;BNJ/!Z8KK=>&Z/=!:)$Z%)X"$*!#1,+#",S A
M:1\]U=Z0K6W^2,@N9=!57'<T>%UQO2Y<SY7I<<4Y"N"(^;PVBH+Q48*E*06T
M4DN><2T?6=6E\_I>>6BN1N7K>'K>$F?>2JD)L1O52/"+*"NUK8S:YD>J,F1&
M626 2N=!R)C 4<Z!4)U(=,YSQ1J5172D26I%<O="RQ7)ZT!RR_C('!NSHDE
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M 80I#J;'<5QC#IM43?%U)=@%63T?C1M)5C?&K4EK?AAJ%IQ6T7)(,1:OI$F
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M&$5KMNE -1N[/1CX2NQ@B@QVYB< 5P.^-0"9EFZA"128_W(!P@-;34;N*VM
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M$,$GYW3W*0 E1I-&;4H "H4 R,/28VTK/!"OO='O@BU.6)XXJVGCCP9AB7A
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MR<0=>M0?^K<Z=!4=,R:*##"+1!*CRJFF &2)(3$%G21E4DF3/7D:Y_G:J?N
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M")?TY&&M/WK<ZX_YTOJO865L:(GWV\:Z"?LK98RUO_X0//Z%B_[-.V2V!M*
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M&#%?VN+._YY6BQ)^)X;(RH@/1%B8[B]B>"$NZR?_7D[@*L=D91=7-^!NECF
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M$Y$651B-,SZ=X8^J+:KWOA3C%LZJ_2QD<;9E0!T<50*A,-3_7)T&O JFC79
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M5[.%FQ*(,5#:X=V;!UUDC/MLM> %P.P:+88XF=H,G7O"#>O=!>MOPZN7S55
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MB9>,+.80[82X:]\E]^AY<BQB+90M&-&IS@B54A*N!/RILAP^XI)9_@5QI'N
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MF-LLYS8V@E+*"R7!7E<J3W@L%!>1O&5>[^,2MPD$*W$)P:SA,DE(!HB ]=@
M R2V^RQT1HLHY7&18K( VY"8^X-BP2.X>'"KM8D>=6SV!K#'K<)\Y1RT&JP+
MGDHA618S98O<4F;%QB[$_:W).T6\-VNABCRCD5!Q0J)",T*+E!%.DY3$D@N1
MY(E0-,/:1%^M^O19%C\L)UM@32$YC4%EH6FJ&9,@_@JNC(#_)WG/R3\B)Z\'
M(O+8)HR1+(N D[,H(\##!8D,YPF+K$D2!JI+>EL-37I._O$X.<IRF0 #YS3B
M5*:"L2B3TA9&&&;S1'\G3NY-E%MD\Q6!K:RT1E)*:*JP8K3)B.#:$):"#:J3
M@C.>X#T%FM]6T>B>T7\\1K?.M6 ,+U*\GY()'14\$EF46ZN*+.D9_=XQ^FH
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M^R$P]G?V]_>,_6T8>\W'']LBH2PFF3(4+P]2D->*$45C"X -/)Y9UPKQJ^J
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M)P8V2,YK6$5=FT;@[&:DIT[?=(P";18C9X/&5_H)>M72_UQW_ 0%XXZOS6=
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MNS2=-0T50T]]J.J(SG7E'%DK +L1;AR.C8P3>4/CH9E-_34,84$NX,%9$6$
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MET+5B 2-!3#$WCG)W(EWR*R=<./-[HVTL.'3#GWDEJM)$@YUHZ-&+T5N!-G
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M@HLLD335S&+>('Q-QX+%L=&<LV4.U-MZSX=^839TX=XM[);'(O0/5V578!/
M#@L[N3(X6&@$-/%2N)HXQ]/0(ZL)?0AELK$FAF]O*'JC-^RGQ;J@1-NRJF>H
MM+3*2OB2-SVOB;7?OB8#<Z\7*PN^8H+QC57*7H,5P0 UI(J>$;H5[7[$+J]
MRX7@@O!8 HJ(/ 8Y5EF2IR*E21'13.E'C]-S<D4WKG3B4FEN+"_B+*<L,DF1
MIKJ("Q.;(N4FSZ^</3R<^%5._/W7@UP4<*:%(BKC&6%:*2*H3 C769Z8*$I8
M$3]ZS-)S&OM>-66\4-*D69+K+-.,FDA(AFV8>*0SN.PVPT./>3CTF ^'?L.'
MS@XXTZ*064)2GL"ATX01GA>6)%*"$FNU,4S -6?LG&O>E*W?\-72?#YXS!](
M/OAM2KAOL2K[7^A31TLZD+-CSGLN)G1KHK>;LEO8O*'^=7UM^T#(4L?:2$M!
MS$T5805- ;@H_&HUCVF<46.B9:DWHSKE1<YBD)19S#G0F59IP:1A29[(%;N+
M.P[BSF/4/Y!?V0ASX1XN1+.V6G+MHD5=UP'B@T8Z7]!T9$ 8GIX:L^ 4.\0X
M8"=)-A_##H">MY!BT<0%PX!N<,=]NO;$;]Z^:VMH;8QZ!>GTR(JR\I%7BT'?
MC1O QPMT3SEG5._]:+Z X=MI7AB=X;QA=3EK2U;U.AXW!>L_^U#H,]_3Q$MU
MJ5LN*L7/U1EQL)A@B#YXVQ\%-PN' ?"VQIMZO.;0;DB(L'(%.[&2J^NR[O?X
M,T:@N^IX;1C9AF\5+VN80%>KJ'85]-H*F^V;?-A%XT"8UMU[L7)4CRI4_YH%
M,TMU6?>8^^ JR@L:D'PMVKX5:8UVM!)@L7HQ<EH(0/W<Q#IC2::YC4#2B32-
MDUA3PQ^.J[]O<'P3#(Y/.C_NDX5<]0<)C>M-KNT.+&3K-U>VJS48*I_XHKG3
M&;+TOL^Z%V>.ER^4W)RV"=((DHL7P[O>)RXZV,WEKU ZY>V1,3ZHWQ5EZY6E
M<S']Z\!PXZP MOZW0W"7"TAP07!-K^LEO%SZWH5[Y1=V;$0]1^.ZBV/SEML.
MUT()UEZ:3>^=Y^[*6VR=YW<6YK;7]".O5V8>)N"PI5^XM%]BH9R<S&<^/G8J
M$=!=G%=X;4C\\?%C\[H?WBI&+Q&Y/.K0A5?U"K\NKFKAH6[#AVX'UTTXB(>$
M@UM..+@P@6"YVP$O@(GJ1!O*62$83Y*,,P.ZK$ZRA&4/A[O^8!5S.\2P+@1L
M_N(^%'8@:&Y$)C1A$A-7A8T)3XT@*J-2%I9QI?)EDHR5$IE,8\YDQE*:R8*R
MPA0V+C)E"EXL:Y/-SC<1D;^R%GGAWG6[U09--PF_KI^K/'5N_HVF.])"B+@V
M<M8KPN[5A9!WT"^-Y'/]E*K,PC>!5Q^7\^.%_J0+XXL0$V6^!I])T&M\+'I=
M-X%0;6S\Q'<^:",0%G-D536M:^*+OJK34?U%G-281Q@V(/CLSXA V,!9F).F
MSY4O-##SR8UMO'JY\'84N8 DO;6VG/B(5)CA1M>N5[F<A][7>\%RZ_2C)[U8
MNBX/X.)7NMP,.WH*6J5KWT&]4;'?BP&>N%5/4G,.SNW96^=@:#[#T)SL[G\Z
M/>#*,N#+G$A+%6$TLD0PS8D"J,IHFDLKHD>/L^CFG LW[E$:3OX:)Y\>T,+P
M.$IC BP5"U05%(O.*I)&B:6Q*'(=Y^A76CEYKQ.U;H:^-R$4Y*\7@HM>59C6
MA6GNV'IFME@%R04(+9<"_=&B%8;][(NO@U"UL[_U]2#17"::I43#H1.6\(3P
M/*;$9D56",U$09.'F@[C:6&TCW4)'J1<%Q88"B]4IC%,H#0TK4*(MTN2:]/C
MO-5H$[A]DP,JOC;!?JZ[3*\Z\%*X=U/Q<F:.L5]%==I+Y*L7,OF"?.>,Z,'<
MT^19A/DZ>TX_T'#IW1YK\(V]K-%IW=B7<01?1A^[!56G\. 7[!J$08-HK@G1
MCN/Q](LSH)5UTP"C6X:S:#42Y^IFN.P8^)YK'S<N/V'?>5?'-A0%!?D48R;G
M$Q]T:*ZPIZUMS6=PFHEOMH'?JIJ>31Z'Q^(+MLY8-[#;F_D,[7;!R=$_C=+W
MCFA:;@4W0:E+436SF$[&I_WC+9N>0VUR9E,FM%EAKU^3J8UQQC9?7>2^.YK/
M+@GC:#5TCG4:AL S;VL:P:>-\6TI(-5M+^QI>0X5-0GU"\,TNU[#VH5/],6N
M6.:K: L4A994/7\)#N%BT>9PO2M7=J:UF/H[JXXFKML3LMU9W1B&F[=Z\VMO
ML0MKZ7J8M+-<H..%5X6><4B?;8OHRE=>&(&^(=J"T&>*E;Z-X,WJ%-N[S_O%
M3X$G_.47^J;+7=_I3+ROVA:XK2Q)DE].AGA-=S\>?CO@FG,=I1E1D<P(LRI'
M&<(09:)"2E782"2/'J>K:L3_\21?'DV]HT(:5Y2B@1-'UUV,^V:_=/]*?/SZ
M2^>A;+'.P'@*<.+2\.<3+&W0Q9F'1$!L<!,"VW^0-(HDME-.RN/Y\2OG,-F?
M/O%S/'W7K,/)J'X5O75OU2]A^EC;KO?'H<S= E'N/7V=' @CN4$;H9 4R]P9
M08I"1T1&5JN4)UI'B:M1Z*K<K=3?[4P[KF<E\."Q([N>O>0,BFL:U&VT\E'?
MV=7V"0II"WT!#3-!.DIMG7K-*SLA+2"IZCO.0B<&+Q?4SJ=X03+=CU6TGH56
MFT#?+G9@T+?@\_B@8'F1:LP]BT#=9@B87.49203+:,HX2YE\J/K62Q#01T /
M/IADM+74E?(O,:]!'/"-[8+I%:\<=KA[D/+C7R"6*Z>VH-L\Q$8M]^H\;U>6
MRJ=(U+A B4$FBDE;;N0KC1<$1S]KHXG 7H:'IM>X&1/XD2OC7&NG8*"E']_8
M*^ZR' X JD\Y=M59?H'%ANSVP]*5Z_;N!5?/"[<  YNZ<)+%\9$AK ;/873<
MQOJR/K/*":2G_EO!,N?U]]M$?MSFRAR920VK]28(#_X#"]C9_Q0=2%WHV"2&
M6&Y3PJ@ TLNBA.C,"J.SN"B2%;_D_8.\LSIS]6ACA SA02+[XC(=-#79974/
MK>!Z[X7TY_[SO^&GOP?A<//B1SJW:SDSQUW15+3#P%Z,6J^EJ^TV#L:OKN/Z
M1L]*-3J:CGUDK^N9ZQM*.[L:?J<I,DA@:.+:VG89PWU[4C^I&=VAB[G%("K/
MT)T;HJ4:\PDZ"/K3VAQM*34_#G@_7;,+;A?[<7:NXD373@>C@1%;<4VFJD,;
M6.=_F"TG/_QTC#PN_3*W)KH-S,3FX@-*PN?)@<F*(F(%!GH(1EB:2\(YYD"E
MG#)C,*. KV3,6BU2FVAK"LF*!"3LB.8T48K1B&?\P=;U6J"?AQG-N^U5W@G:
M.5!PPEHVSF04BAVL]%JNY_)CD+P"_O;VJ*M3[4H(>,#JXD+0:N0399UE\W*U
M*#;:9HL86%].M#F>!%]%DU#LG)^3SV4UG812K NF_^"X"*47'/Q5+G$ )</5
M12S:%U;Z8+<B8^.K\'&R4]=Y>;$7<F=9:,N +A3/Z)EML;:GFXF8!--_4\>_
M#51N2]LV?VFCC-LAG,\I@+<8N0I"[D6N=4=X+%C@?*E9]\#)B6MPZJUT CU*
M*&BW;W%&8URY/Z SAMD(B_:?XOMQEQO>T>Z$6\1D>N9DW,0O-8.-4'O,6?N6
M]J ;JS>)X-KI9K+O*IN+AAI\,C=>Q^7JHZ)>(&(??HVY*:+MK;Y0;[BI@='R
M]8=6?NE*)0,N8AZ/ T7X<W!>&ZQNYEJJ+E]/+*VGL/W$&7<'W3MG7)]%)'/>
M'@R3&T_KA4I\?>1H[GYPH_@2TS-7?"N,[SPY=1EN>7/M<3*N(6R?0-Q?L3C@
M$2C$BV!PJ:R;'R@UO?*B)$A,3B9^M2!'_N+YEJX^@,C2C&E&(E6 I"1C2:1*
M&#$VRJ.$PT=1LB(ST3PS!8\,5X891B4<D#!Y'N5QSFD:/529Z5F3KQC\?"-'
M/P]3>.JG3F(?DGH*;!2;T$Q=WDNKB057AU/74!M;2/5LTEY:=6WQP>9C)P2A
M#:[]S M7OAJA:\*#%1]71EO4"?&+WN?<B#&]P.'U\W"37QVEGY35"#-EU7<?
MMIF)H12J3]0,=5F<..>ZV[1Q(SX;MN/YIO.)MSFR(Y!47)PN(.^7:?7))3L"
M>_YB7#^6LSH+(,8W@VTZ0T'W_A6%W*$X!A9C%Y-;])4_]0<2[A%>HZUFTB]@
MSFCDZ=<'WS^"=:-&WO>A7R98\Q=TL+_[LKO_/CJ("F,$%SG):"()BUA*!$T$
MB6F>IE13)6/VZ'&\)D[WQ.]Q(V\V\15-= ><53"*N "HC]X-WMRL_LT)05$^
M::[-$6Q)MXEFJDRO1"M>D^ %[#*LFY[?TT4= 1 BF-]#/Z+U^=?N1K=(@D+N
M;V%FYTNN0YK=66EVR9!F=]M]?1Y@VMR5%*^+)-#'9X($EGIN:B&LAX<0M7@L
M/KJP-Y?.O?*0KXCI2F2:WQNH"\"#>;QCI]2W301#AM+8C]0KPGG;^A$<TU:;
M>ORJFDZF\]#0IQX\<&TF87H0YU&<469(FF0%85Q*4N0Q(SI+4Y[%P$XI?:AZ
MSY9N2I98'-(;FSJJP03\B<98Z0>I"6U/1O^>3PS6PLJ\H>5Y&XN^;A-&?TWA
MGU%;J^;YUMN_FEHUH[*NT69W."]]&880EE6"HE5637YA%^M>NO0Z;YKSJH:O
M#MG_PO%4FW$7+]M&)@:1OQ+.L.CLC*V%UG_6-(F8'95U.R4,DQ]AL,%LL<Q/
M[6P^7?@[JBX]8VW[VA!#W[S!*63M<C'KK^LLU(3--WJF-$ 2KL'DOP6 (:A\
M_5ID7WQ1X''9!C1@/UGM(]] @ZNF35Z1CV(6+DZXFLX/C]##Y[V"\"D)\16=
MV] UJ.SY#5%=5.6L:V)6S\>^IO#(;V+E&\M.%[R-X5N^E55=^QV_2J);8E,I
M:9+SW&@6):ED>9[0!'!=1ZG6.;8T7E\\#PM8P$\K9<<PQB,X,I\Y!^9VHYJ_
M\ID*_7BJ_>GN=!)Z>V&EG2::<4B+.X,Q?-W=?Q<?% DP V&!,:B,$J: ,<@T
M+8A-1:9XFD746%"TSL^*\W8+1]VJUQ&K=RU'NM0NPM^96$7703=0\W3!D_.?
M=:!:%Y4_;4NB>"^[J(]&%B[RI1OMWCO WIH?8I,\N"]%@&P X17P=>AQVH1&
M!8OYO&H;W'3=:-<7;;DA=/L!A]^M93CCRYYQ,,15P4H6C)YGV@XQ5VI=:(JS
M7UY,&6(R08]04U[-^!A!'P?8ILW'Z4 AWT$A[3[Z,J9GTH@_;]<IU9;!EMO5
M8UJ-NI>G(X.]H"<^B;")6O(%&QIK[ZQ__DLU(EKYQ \]JT30'%TR'LA8*I08
M<WJH"\^$73OTG0B;@%9\]<*T&O$$3_ZXC2P-OOA>/\V5],2^7_#<'$!/AQ,X
MH'9EKDE];^^$$\+:9+"E;;38<.$("Z9W^0M-KF*O\I>;E/CB3(AM^B+&751G
M'I"+4_.L-5Q@SP!]W]MZ9D[(_*3)J C9HJ6;)O950Y?IIN?(BQ>WO!RB^VX>
MBU?Z++R/^R^ZT3O=Z0V-67'CUQ8#=EQ92430<VZ_S^+%<_):+FXP*#.Z;,,2
M>Q?;03><F>,H[S;?;HY>;&V]"J507"1/O3$Z,OK09Z7YP,GZJ#P)Z<>>9:PC
MUB9#]N7V7WMOG(N]]\<JA(JXZ).EW#-7$">X9YO^68[RX<B71JBP%=YQ0W][
MZY9;F<6TYF990=4*I-J[?+TP%X%ZD7\M]F-#I<)Y^>1LH^W/"[H(?#)S_?=P
M0\)>A3GAE6A/ 729B>ZZA"WQS_'8:ZFA6QF\U9]VG&RT)^Z5O^4J-,GFZ*F/
MQ>_5N<:RU_V[C5%->/><J=U7OYDZD][:#:F[$CNS_A)Z._L%0RV"_MJ<P']/
MOYC/IG+I7R> &J[G]<IT%R?F)E2'^9QQ/!=.1G1S61,[8KS?TK2F">6;5/;,
M0(M A:^<W1C^7.R(081RVF:1I)E-DM1&N6:<15S1V.8, ^2MU=(>T!@+M-X8
MKF&(WF3V!\&_W)(QCOZDAHWKWKZT+=%FVK@H?E#":Z\@:_VR5"AZ3PZW#BMC
MFCCH+>=%_&\SUL^GU5LQ-D\[P?;N&*T_!=O$R:</3]^=[B3/X+MOQGO[[Z/=
M?]Y\>G_\]_'[;\_'._#[SHM_C_=>[,0?WB[9)H[??-K=W_[V'N:Y^^)=NOOQ
M=?SA!8S_SX>/._^\^PJ_?WE__(Z]__;W^'^^O4]V/AX>9-3R*#8)T2[)6FA)
M"I,*0A-KC(V+5"5Z.;9'Y33BJ31<YRGC>5QD-A41DYQ++HK$K'00>O+ZW?;;
M[?WMO=VW&\"\GCS;?;N]^V*T]>+-LV<[SW;WWXZV=I^.GF[__>SM_O;^NS?/
MSB^/M];=<_&DE@K"1RE<?,Y,RBV+M!$Z$BK/B@(6SN(TOE>F>>]*=$6JU-6J
M.(_:F^)8YMO3B:E B7AU)*ICH<Q\AC&@#SA9<J^1 +.-G@K8%H1O>BXW^EL(
M2 !.==Y.=8;]\%1KV_=1G8ZMG<SAM<+UA<* !&2>J/)]=>;R\>G5ZI_E0D9<
M"TZSA#$32R-R4TB;I"F3*8M#<Q4:9:3YX?SZ9Z]"'>K]Z9;?@K]"0+RI7V#)
MPOMB\/W9H+K]9??U05(4J;#6DH0)21AFFP@K%;%1D4<Y3SDU^M'CN+B@ %XH
M*CD_;B6JMJ%COV(1T%$]%Y.V"B3&M=5=A^*0CNKTD+_$Y%,U/YFI4Z#P>35K
MM=6WH,Z#TC$9/2U]3X7@QAN]GU:?4'0+<K._(YNCK>-IL)8U$3K-14&IT:6_
M3JLQJ,P:% J\;:VY8[^:NX("/T1 R5#8N/#2KXG!0: BU'W;-14"\@WHA#XS
M'. 1&N-S]N>M=L+^[61LE$"3DC:_-^D?H#3""2E#M, *\\Y/XT]6:"=6AYKI
MU70"DA=HL=,3 :*Y\H4Y,?"@(;BRJDJ?XRQ!Z1B/ZM.)KM!VY$?H/8Y&GK)W
MZFUOT*4R?8NV!Q"]RJ^CVAQVE;D6-=6>.:8+'*] _0&N'10"5Q"U%I]=]-=R
ML99V&K6#W?(>VRW/Y.AG="7PUW"KO8:P5_VR-EN((T;?U]VX, RYWZ&@!Y2K
M[+K-1%JL6>=L(BWYJ.FQ;$*#NVIV%W5!&,&WE?EC]%OYNRM[-A,N'1\3:$!A
M#L;.-4T2EA"T=$8%K_VKJ6O[5(G&M8SO.,1F ZAC@C+O;JL; <U!A]5T?N+2
M4TO89U&M><Q?H]_*_AP_FZ:E@0MVQMPS%Q;@S1'-O!K[%?J"30/GZ.9N-AUX
M" ZR^:.J&[4N:W5D -G,GGW3U@K;#@LU0=EK+@)H?PM5CMPMV'>N[%]7\8MA
M#@>II FH.3F1AJ:$@1)("BLL_(=*IJ0242&7=293J%S:5-LLX: CY9+2G"IX
M.)*6,JJ7%3_76V.*\2#.N>:H$$X >Z$T39;6]2&IS[H:*U4-_7FNN$XN"P:B
MYX-8[(_RQ_D:Z!#W>U;<+QWB?F\Y[O="P\;2I9;&LL+FDLLL9992D:621485
M690E(A-7,(3$]/*2PMJY7P@PC_^?@"++VSP6)[7YH_GA3UW6)V-Q^D<Y<<?G
MOO3GXMS7"/MNHO[C0&H\VZ0L16J;5?!_W;PX$.*F(\1_S?3J9P7?!%7OS(^C
MS?C,S\X=%FCD<J/^R\W8SQKV!<GU_WU$'W5WT%-9<O)U%"\>$I[<BA[D=N6F
M<:6XNKCK[OYO .=!5:Y_;Z]BV)%S%AOA4B^Y05*H3RA0371SC94R!J[QG=BY
MBZ$J\I:^T BC<[<M;]=5EAN-[L.B_^_O6F)_:<YV<:?6=@6C($V2(N6YD04
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MW@_BXYN=BP>+2+18LN3'^+&MH &CT!;F++I+$/;?('$ U:%0\"NW>M[Y]O[
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M1(HA+<0\T$+,!UKXT;20[FX=F$)FN<TR8G,3$99;"\I=)HF@O) T!ZG$1FA
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MN@O<;N?I5O0!.>?'#\=[3P^3W63[RX>G.S#>NW@GV?FVAG.6'_:WDYWCUU^
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MO_A<!WH=Y@J"UZ5&O: PV)UHWI9?).9&7@5?5P'HG#6=71LVOLSZO?_QY^Q
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MS% N8!@33T$2E2TF%=,6LQH9R]4,[4=#\P*&J7WB!R=#8S8R)4,; ')AJV.
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M0YSEW.3!''*90@<>9%WNNKFRU-;E7@DQQ;HLGW7Y/!7\)+@/W@J&O%(.<6;
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M=:5Q;S7NW)M[8]>%%O\>UDC/#57S+N1%Z$15QTY<;X'Z1(V&AX]^0X_A]4Z
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M"R_,J7=; ;)Y -EDDG)T,1AG-6+2!0 R8Y"%Y4"<:$%EX%+KO/FL']R2[:F
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MFHCQ1(?FKML+L8<&W>,W>77ZW78K5./9?=%8&00S3&(B:-XKLLS%1)S2 DN
M2^%4*4BV>%"Z/[6%+Z))E%*%#$DT>RP8@0<344A"D*0$I29[+&*5LP>CZ:PJ
MLT2Q,R\,!F8JO?#X.%!*+SP!,DP>#FAK75)*(99P[GE%*;A"GB/'M=!"@ _$
M;-WDF^B'>$,%%)8%%!8+$TJ'VGGK_V2*BD_@]BJ#HC.@_U$09%D"EXLY%4#
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MLR ^%^W4P>@DN;VK[SR[8A<%GDF!IVI(,:U2B@PYG!SB27BD(TF@P#$GT.I
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MX;T]JE7RW#(4.0E HPE%QH:$(@DJ4A-2LCDS\&>B/V\?;4;9,H8Y)KC@*6G
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MN>U?M"J;F9A2RS5'XX)7%@&8[[D7Z9IM+'$D.1%5X,QB*Q3F2N! &)/P1@X
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MG%(YI==[2C_8DU$,@!]N $SZ,UPTE)(H4/*<(<ZT0482CK2F4F*BJ8UN92R
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M*I-:IE2,Z">&RLG<&DNQ\I$DE)L$@QF=,\6M-R@R&N =JX3@>3@*$TN>A53
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M6^=GG2YLV:#U>R4N&'R]YV _OV;Q#>L^/1\NY)9+ 89U\D).,L2?'Y_F)QO
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ML$3[YZ?7VFJ^2BTD8JVEGO;.@-P[3=S!CPB#Z:?,_OY&=/3JA^O58F"F1P7
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M^?,EYY.2G/_$R?EW)MM/).<K@P6EEG(&_W()XI,R%1AQF&K"*7E6R?D+Y_6
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MU^EB[].O\%!_Y6?:/MGZGEM>O$^_-&K0FTH+>M7D>0E_TWT=8C1:$F1UKNK
MV"!-\UCH"&)!1TD(XVN;9!88_1!7*B6$")>$E(9Q!D)48T,"#XHJ:ZEGDTF*
MI?Y^J12RQ_8%!5K0*2$"^PT"BQCD7. H$N>L2T2)E.Y3@#_#@GBN!L0R"_#)
MJ]B$M<U?*\?7AZ:ZL,H51:V/L5KLT GQ1]UF=_!<M^36#0"C\KB)L@X[+55;
M,EYP27($N2JMKC[1RTFODQ\9][?4@>/K5,'4&Q:KUMQ6=1QH&A@/?FK]O?,/
M4!;.!_ZP];];O_>.W3J\!*_] 7OTO?H9?MFN>Y)5293=_.+7?\Q4$#+D_QW>
M>]O)F;&=E)L!_KL)+-=1W[%;#9=1^X@&5QDS]:K^W/AC8^+SU?6G%C3QH0G?
M7GW?ZG%NNE_S[JQFD>,WNNG[XY_Z>^4DR'U*QU__^)]_S+S'K)V<N%/6Y4:V
MYL:]SWOSKFX_\4<O9SS/W(Q9QW/[6;3C>3_?J$[;?9]%>4,G[W(OT9'[PTMO
MLP^OZK VX^Z5LGK-Y;D(NKDQ? ,6<EZEAV2%H29AVV0H#<EY+&<JMUT8W^-)
M/W6=N5MU%_\&%G2NQ@Y7IO/TT=U&2=43WG:WJM51!IRZ^9R]]K6>33XVO#;U
MV.O3N1CPM;->/]>"5\T4&E=WLQ-7.S^Y3-C!_+23GY_!3R]$_M[E\A[/2!D_
MBO5QSV^N0\AE+77"0)4)W_"XS8[2_ TXW*JUQW@$8=@O>)CP/&I254827&KC
M.EPVDL=17VD4L.^DZQE+O8N6[R+>8;O+JL-B8VP>S+_:FXAQ]D)?*2EN'^?.
M#K6I/-9JX1KBI@[E[&;_<W>&23\2Q:D"%V=#G*QQ?)P"KD7&[-,;3"?IW''/
MD39N-T4>%PP=7K?HGO-92NG"?*4+M)0N/''IPIVE"!.E"RD0Q[ *TG+,J74Z
MAP^\2]3+:%[47(&;\.C^F0+K(ZD"$\&[$?B:2@-X\6+HVCJ\0P[-2.R]_G1.
M<VTP\+H8HDYK:1*7*_]@KD$X.9N%WK,LT)GX?HNPNE56WNC_GJ,O?C/A82P8
M=T-3_(6#LEIZ;3@U)E##L8DV<*<ETX0)@>&G>A39+1FB)2B[B$N3M(\.V#['
MSN4IP2C&W(M!51753B(<H\;. A3'7$<],R@+&MMB)VPL#<%88U7 W&&L;? ,
M<^D$20H+4TYXV2?\Y7)?&IUP$!A.6/D<=M=(QR1RQFAR,@7MA%G;9#\L[/[8
M;%["L+<0Q.4.WA<D$,:)1D3*A+CD&.D<D"4\.AN-\MX$8/G9/+]XV/VQF;Z<
M]VWG_>'[/@]6J80%,EP2Q),$,X8E.'0CA0[,*\=BGABY0>\?=Y]*(YW9*K56
M(JJY2],7&7$PS<A*S9FY,30IQA/157=16]#W:?PB@?A2!),#8"@F8QD!*T)@
MJQFGPK#9Q%GB[DNBSRH-2 B- 1,4H@GGN#OER()U!_#DA4]2XNA);G4VBSBK
MGBHCELV] NL>Z(H[D:(3CANB;:)81BJ%()PD;IH^>4V-TFU050+K]R"!/[_M
M*V-$I : B7(024Q9I*6S2#EG-3>11LGF":P/O;33X8>Y7*VM0QO&HBP3QES&
MGA%C;IA[/:MT]%[ABARJ<+$.@RX8L)C/.SJ9V#XC76HUO)S#W6[LY#F.;CK/
M>W3!K]C_L6 RPEAQ%QFM90(ROXK9/-?-6%:M.ADC]TYN^%3'D.OR\/&VT[-"
MU%= 44=E*V=>)K>#7K6$7C,A*S9^O;.^S0,M>W6#[+$F&55WI;SFF9V8!M6K
MU<S&89'3=!')53/LJLOL*.14G9.N&WM/-/1.N5(KNZ0&S?"ONJ_W!/KFSO?]
MW&&C5?6ARN,B<P.HNO=47M7H#<>*E$]S:'YP5A>SY'UI&E3!YOB*U7OPWVG5
M']SZ9@;!Z0 VR0XZUUM<SVOH5@TYKO3+D;D&N9W]]<G/S#R9;,!?;9>M!HO"
M&9SFE=2N/  *  M?M^7_^+_L\>F_WK8&N258M;WY04YRQ4(SH#3/QZ[F'XQ0
MD,W"X^"P'JE9S4?(O^41F8TS\.H>8P'*:OYC-5^C"KZ.S+ ;'>'0.S_+%4C7
M^YV%YDAOM&_#Z4NY!4!EX>==F-CV:_\C+.7<UX,ZJN5>YRTT8QKJPK2KF7<;
MXV.(PD(,-WH$=W5*F+_J9 E=$3IS-$4@]VF!,'<AUD3-S#\6;7UPG^8&BWB+
MQ[-5JF$(S?#%Z^F_#4LTL'5]PK<FA/6&(V:K#UTUZAM.+1P)UF??U7ENI+D^
M,FYQ9KW=<!Q+GFV0:_0JX%Q:Z9&/6*HD,<%><<RU"UIS$A6WRL=4O-Q+MB_X
MSNX7OJ]"HEY( _:%R_UZ6 +[@CD46$H\\BB8YC=YN1_#!\I5T([F/.X8.3?:
M*NM@*2Q%[U(,JOC$'I$@CG;$?A0V!HP38H(HQ#VU0!K&(HN=M-ISQI7+I2A+
MJCR*5A$=%(V><V!Y2RDQFFB0IS3)1,MQ/^9Q?Z#[3)J(E=5(VMP#Q4F'C'($
M8<.5]5(3X5DN[9AUW@MTYUF_P9*=4[R.^3A'K=>S*5UH6.9]K0_YWL%)$YF=
MU7IAP=$1+BICI+!":,YQDAH(-4^/2-XH%76\PR4V/7%D'H]8F0%Q3;9P/;$?
MB.?24(5LT!AQ1@+2GFGD04S$)!QAN6(6/G+[$(C7XKKXHQZ@=7LAQ;@3Z0I4
M6QE57TMUQ<2DL9E&[G4SS.Q/O\B&:E:F8S/$/H$=>U+Y&SHG-0^/V*$S*QMR
M)6:$+3N98R$COI63WK#SWL-N7TT=O[9U?1Z"V $=WYWGS'NPJFP8N0.8=#?<
M(E_ERLZH)A]6%ZJ:7W2&ED?+5P6!82IE?S*LU0B'&S:L#J%=YQ>MMZH"J;&&
M\_4:\KK7;[[45)5&/9>S]EG\U<E.G-8OV:GS3SC_9H;CL!JB\3J\/ST$D[>;
MW47_/K2P'3Z">>>S[^?:'_#'.3"%GTZHWH"KC>3XWG3L]=-5Z[L^ISD?[:HL
M9"PQ=FF%,RN5.K\[EG%VZ\I;H1=K1_;5&-0A%5:W;\8=5+/OF@W-CKV[:+/R
M&E21ANI<F];!SU;0/#15?1IU'BUY_:%YZ8^<C;Y,KELTQ74L$ORJ8CR+5?W<
MDJYZ'=V\7PKI=93TVP\3+H!L=R?QWB)EYW=C+BO3U0<N)5%&>!FX4L%&YCVH
M^-QYC774C3_@YL:9Q0>X@#&U_:V]^^;;O@W44>OS,#V7<A_4B+05"DEE:$P)
MC"L>;VL_M&AS(>Y#H,)1HSEFVA*.I;/>:1\\"Z$<\=*/F.V+I$T4RB 2"4,\
M,(*L]Q*,9L6=<E@QK'YDJNMC\WGQ^]U&$!_XOF>2:R$]8MCFD;U$(* "F;MV
M,$^C4IP"0:AGPO/EN&\[[C_)/@=&DTXGQ*1S>4*S028RC)Q7&%O!+28WNGE?
M>**KP<Y%SJ/FVG-"B,G-V$$(LD2)-B+.ILV2Z+HL\LR)]T03!_OMD<MZ!X]!
M(TMR/T3I105&P0$:\9E9V$M)=,V%%B10)6/R'%NIB=<T4F:TT\18U7CUF\[M
MMR%5272]!PGLX?TH01.@22*I!4; BSGE55H$,L)$0H SQ9V#8\8274N)]WPE
MWJR4>#]QB?>+*ME>,#(UVBB[&@0[/0^=7$VCNYX\5[D6AA#[(GU3HRVEQT;A
M'O= C#69:75:8S5FH%/GA]6^[*&N-4^27[[12 I:SK6K<]\63A@<YN;?GCR6
M+SBSR7OM%LNWFF<T7C/Z"IZY\91=?W'XO6ZOGA<;\\3H0>=K,RYXLB)AV+]L
M_ (SAUKEO1A^_21^&[O$UW_D7P_ZS9#:K*0.\TQ/.Z>Q"D8-6Y_!M:MLYM-^
MQ]=_-UF_PUY4==+P<%9@+I28C%$,-[T:S5S/_LHYQ,V#Y_.'DQH-B R&SK[A
MG(7QV81C 8\\WBL/S1U^98(H9F5L7KUW/I@QWHFT_EY?)V=J IO<=X!4G>7Y
MC_7KM/#!N<M3"BL2BR=U$[S>Z%C<9@!S_JD:)-SL89UQ?3U$>KY%_/=@6.)2
M>46:-5P->[Y>P%WC$>=\YCF&)8[GOTYM_,OTW+=[#79,S*Z\>73E2$9U'9.;
M&K1246BT_6XGT_ITFO%(AK'-A'LV/=QRD%&D[L3X-OI&B@TYH(XD-701;B*,
M.F=IO(!I."2[CO3,-7KE3L)YOI,8%A]$1,H@H@</(B*//HB(E$%$91#1#Q]$
M-)G<==<@HDJ-F1PA-*/OT7)F9A[&DS'Q_O=QX?Z/BL".K>_W<N)0+^O&PTE"
M@W/X8%,R-90>6:^K4> D=6L+-%/9<?WDQ\>];$9D+?1K+[]=Z4:@ E;O-ZO.
M) >OUI;'H"FG&M:L]4Z&)DDU.CM3<14EVIAK_E%]M7'Q7>8A/4?&'3WM'S4/
MB3S*/"0E?%3)XX2IY!8G@[EG5OL058@L-9&K,@]I2;[@R_;EUO=]QJS@6 5$
MDQ5YWH1'UN5)XDE[38A5E.K;BY+&@M2K=^HE7GD;!>RP?8-U,%12Y#@-B#,3
MD66$(,&848ER+_,<UYE52"]\'L[]2+.$*Y=$G>]WM^@^B4DDF2.5.'+$I2-
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M^<O.I]^ZL[KC1>&2D<HBPVU W*F M,FE89A0::PF5"M 4OW@[GBK5\%98*?
MSBVP\WOOY& W]H\S_!28611F)O*:C1:,2NJ0U"0A+IA$AC&-I+186Z:3]J+
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MK+H%E9"5(N3YO-Y&G;P);&W3&+Y"_O3"J*O)J"7_YR&,.3DG0HCHHZ(H4DU
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M3WEP.0O($/A5&.\2=B'80-<VY<:L+O!_*U& Q=-H3_N=;BF ?VSSY7Y05L(
M3XEK$V$ *G3BDDM$J<@6#<[MLRB#7[5.<*Q4*9O;9\E2@5<8N80!GI!Q)\(
MU&,;0] H$FH1YT0B&U*>,\.3M3Y907S%N+PP[LME7)=B#!(S1G*K.P7LFI0
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MFY(L]W(9UVM%,;;D_['WIDUM)=FZ\%]1^+W]GJH(TB?GH2K"$:["5<<=!=2
MNZ_/%T6.6#8@6H+"\.OO6GMK1D(#$L9X=T?96$C:>V<^ZUE#KB%%;B1WSD7X
MCRM+G=#X<Q.U>WJ"/!.U U'5GK-"2I*4R.0#L5DR\/^]8[:HXK"#3:.!&T%N
MHG9?5G#O1.V2*=FQ(D']HNC&9,&S#XPH$TS.---0=*V#GY+H-JEV:S>64SZ9
M$*A7L-$F)>>E<CK9D%6P*?HF:O?EY5,MG06Q#Y^[C>S][4^G__OQ7W!M6)]_
M__/# =S/P?Y/'PYO_SP[X']^@+7$J)T,)@G-P;2VF.6N+:AEK< Q=@J9.'NK
M;)-J]Y2B=LT!X8H-J39BL\9G^)+4-A.UBS9XJ64"*%&P/E+@Q(>8B?+.&1&I
M]L&CX3&/G)J3_D:0F_J;+<KF; VKD89&QW'@NR?2,45\<I'X&#(S(AFKTHM7
MSC62^7PE4Q<:$XTFQ.2E"<(FRIPRF7L1HN!;JF%M5.PVQ7AVWH,'T>4JXH '
M!?:_HL0%RHC0@1NK3131-"JV$>2FQ/419/-.Y,U*)0-.8XFA!%"R46$'*484
MXR4SP95B!92L?4H9ZTVVW-IQMZB*+UQ3XY/4PGBJL@/+5D5KC8JRB;M]<>E\
M>[TT6^[X#8-KP9K\]/%P_^#F\->WGP]A30[V4^?HU_\]_=_C-S>'_%^?WI]5
M QU NPJF@R*%:7!M7;;$VN1)M#QJYF4V1F%ON"9;;CL2>>";1+G=>^H;$5G3
MTV;'Q#5;P1JX2(Y'8K1'SQU\>(NS9,#F4X4E9[G034^;1E*;F-K.)7,FIF:E
M#S31*G&>@S,>(DBF\40PXXTJ(@OMGEI'FT8RMRN9S*48*+<YXL ^3;W7.H4<
ME')><NJ;OG!?1%)GL]DH$U)G0V)BCLBH//'"@S4/,NM]RD;*T.C01E*;H-G.
M)?/N2 4>L@XL$<%3)C(409RH]"E8MD)9)P7*IF1/2#:;9+6U!RIPZ3SCU@:F
MI0LI!'@AJ>RIX<RFIB_<$Y#.STNGH/[Z!USW],/AK^\D/.,-/(=\_^\WU^^/
M__=3-53AX[\^'/UZ\/GPMBHQS=X7=%F(YC* 9,= ?-2%Y"1!^R;E-:>8K+;M
MH-FWFJPV[@LG:).KMLL6LQN167.0_B69;2:J1K6UB<M,F,6H6HJ1>( 7L8E&
M%R./CIFF*TTCR$V%Z9<6W-DIJ*)DEH0C)GML(^TSR&RR)%GI6 BA)!'KGC2F
M$=QG*[A,<Q.PF[\'YSU&[X2'S<\B6"UCD:E)97MZ@GQW"JI-(BBBG6)$8E*;
M+303+S6E#@,U(C<:N!'DIL+T2PONW9!=UIY94TC$^>,R&TN"+(8X90QX^9[Z
MR&L=W$Q!_:J#=IHKZ0L57%B9C'-21ED"O*!LX)XU0;LO+Y\W2X<Y'/]R]O[X
M]./[L_>WA_C?K_\Z.^!X/_!,__Y#'1V_@75Y<SOL"\=E4#Y['*$DB 1OF%A7
M(BG&JYBTDLFZ703MOM5,MXD*4\&:=+==.OL;L5GC,WQ):IN)VN6<*?5)DF"D
M Y]!!N*+D$13F75*43!'MU3^TISD/WM!;D[R'R2;,X&Y%)UQ,B:2'3:495:1
MD&DBAAMEA# QLHS%+ZZ1S&<KF::X+$265E$KP6]SB4;+L"Z14A69;L)R3T^,
M9\)RQ3LM0S;@UB=&I"N6P N1&.S>K[FAR;%&Q3:"W"3+/8)LWHF\E6 $!DQ)
M=!&/K8,G(8&(6JZB48%YBA,9ME!A^A4GRWT!R3JZ_)![.TVY>6ZY2O_RO4[W
MJM^D*>V0Q(O,PN0LM5%"9J9"X$X()'*PT(UMZON^ *G?WHEIF)AUI,P1(7!Z
MKL8)E=X)PJQT";.?97%@<#VXB*@Y!'WV@MI86P\2S)F ABZB))XDR;QH(BFV
MP*:2DJQT]DRY8KQN!/-9"V9D-'@PA!VZ0<$I+VE)A48);I"T@C75?5]$4&="
M%L)PXS(WA!8&@AJ<(<YJ33Q/EB-_QIP:06T$M8E7[%HP[\0KA+=94BU)I $;
MTGM#/*.9%*<UHU9D+N,3$\W'3A/Z H)UW+WTIZU3P#JY!+"#1(3+EC]/K>[&
M<8S'2=]X:@LY'Z7;6+!EGPO=7LH]<MF]^ &!WN^>=E)K^+Q+J?ZIK>/_63<N
MN?KC/Q<-EY1P0E.FN$@R>!%R8<%81;6*3@739*\\,75([T1Z/.?1VVA(E($1
MJ6(F3I<(KJ6C-KC$"\TO7G&^9\VVSM96EI.OZ.#M8=37<$"3++]+F9\)(C&K
MI0S1$RV,P*DM@@1I4?!-3BE1 S10R;Q6\AN3^<;$:4R<F5J@HK0K+'LII3,Q
M%$%CU-PQ'YVGH<D>>GIT-Q.*XUJKP%0BNC)L%/QA'1<D"^.="$$4)8#NY!ZS
M#RX-^LKHKC%Q'I,#&A-G=S)_)\JG(W7&TP2F#<>:(6Z(*]8209G42@7MM0&I
M%WN.?S52/S<,Z)Y5UM)ON=__H?7S5:\':K)UT>U5PMDMVXT,;C'#:6+3!6QK
MZEZ%TWQGU[>10]4<M#RB"SI X#1-E\[GG,AM[G4;AEZ/H=G=T@RJ1&'.$<NC
MJ@L[G56:>"4C;)O@VBH,9EO.^(]/Z"BFH9AOD6)V80(V%+-MBKD[_,@(F:Q@
MQ'A%P0C4E(1@%<F6.FU=YI[SIT@RW\!Y[V'WG,1E9EYS[/L$CGV;!=M-$+E^
M^'DJO8DR;VM]GHO]L0L7!Q@XSC-!FF#4@^P0?L?5,=(ZQ4TDU&IL#VD9"3%+
MXL!<L(%SHRS=S7G;%D3HJ42HO_!W-)S></I7X%,VG+XK3K_;<! \2&8X);Z:
M#)(+3A+@D5A+-6<JF23%;@X8OB"K5X[I?U]ZN.BHHUK]:(=79R P<:K%X)GO
MG73.A_=K08 &KPQ"6<-;JGL0,CO->1^O^I>=<K-M.69T1I#-K"!S%.2?NW_G
M<P_.Z<_=LXO3CC^/>;J3W*K/:9_*<]XAK.HYCS_DUE_YO-/MP5_ '3FU?H8_
M.I>M7WSLG'8N.W"M[WP?**C AU,KY-/N]??5 <PE?+9SGH!MX'/]U@DL6>\<
MGK/ZQ<R7'G8OX2WXJ<$OWIWWIWZ%W.@[YZT(RP&/U;MI^5(Z2&&=OW/UP?-\
M4O\C#O:F_K[^!9!:Z< 797@97NP6O%E_=7KYL@6/U\^K?%/G/)Y>I;S7\F?
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MLZ<%XH%A]5MN %P!&.[G=3NQ;*@(E"BFP2GC6A&;32$I O-%&Z.@_,4KN1#
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M-=,P'<0$T=DYOZH^-@=P@QV4O!HB\.-%M[;)?ZA6&V3DQ^M.NOPP#)!-?'
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MIFJG9Q7%_GKW4/.<LZ53,,;P3!(!<EC%;(_*/GCCO_? &#ON_@74DJY.<SK
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M@RH)8:V/DK-H>9 @GF ":RU%\3B6PM,&[[O!NSPZCFW-77$I:V*X!T)TQI#
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MHFA#HI78\8518K4LQ*=LF1229V^6C.9:;HXL8,LQ*--R$_UETP%OM0YXKNF
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MJ-1:*"85QV*5E#=OSMSTT=<V,_,:QGQT++S;(6/^DD-O:.^X!^1S-[!X;%C
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M&!AE_X^]=VUJ*TFV0/^*PG'BQDR$DZGWPWVN(]QMNZ\[&K"[Z>[!7QSU-,*
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M)],8Y[L,SOD 29H@,V=>6U:]XG5&[ (RZ2IB;Q/'ME/I.".V*9;*@Q8(6>O
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MLJ^%['8N#Z4D2"H\E+%$"ZXE8MPQ()$G$P3-G%RJ?EV/\J\#G.\OCZ?"N9O
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M!?8?;&U>B<RNNLVYRF2V@ 7VV6#6<.+:K+4[M\*>B&"!* +!*H/AA(S@.?5
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MQY[JATWCDW,73GTS\O42YT># [3BW[QD3CGBGCRTER!DJZ/._=P;?I4>>9_
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M&/<C37ZN 7^-4JR2Y#OOWV%W1IYMD23/# 3A"8Q*#) :I9:::);B%23)5T"
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M3^OOG5FJ7?QR]I6'L[H!I[\Z+24FY9]Z^?2A!Q"VK&Q_G__WW$$_.POGY&+
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M?OR+?O[JJ>4^RFV]S?=]^G;[U8]JY_%WP^?[OYQP'U[_Y]W3"X?:I20E@;V
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MN=KY[5^O7SQ[\7KW\8]\_<Z0^ZE>/!OM\\^CMFW,U\-E%4BB=:[PFQ$J5B4
M,PKT&(1).:J*&I/RJZOF=!WS<MT0]$YLG=AND-A< ="6DDZ^0'0.(U638HR>
M"E:'*R>V66!ZJ\C^Q]'#6;"H>%<FXTYXUR2\Y7,U1@$AD!81R+;\H4%02%J
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M>CBBDX?#@QFL9A=]O4^3E\.#TQ%H.9^6NCN[X?SCK]\.\]'>P^"VI-4-BXO
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M5^B40"N3*"%'!!N)_[]9-GB584:W86/\M_%DE-\.<V' O"FC\6')G[5'?M7
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ME63Y?A4%\V9>=3PGG?OBFB"",MA#10-E&Y<'_T/D:H2UT%ILPZ=_)^^5L#9
M" $2W.IH ])=<CGG=Y8\2[_3 >$TV>YO_,<"-2B?.$AY3FZ?/TIYUA2?*,YX
M7B2;_U@B")8+MA-!6>#.,A=S_)866 IOA%/SEE<8]Q45PO8P?>K&PC6P0@<-
M:\+:'\=9FP:#;4H8Z>!D+D=CD/5:(")R(4M.K7(&]#K^#-NH5,CS3)&'R"2D
M221:SKE1WB6&O9?4Y.I8%KMY4QPJY%DJ\EQ,((^)6G/ED*=2(6YS&6L;'6*<
M"I&4<BJW2:3BWED-*U3,>AU Y%]3_M0',&9G))6LH#4[[R@K<[:RK>:#P?>S
MS%G)05-&-N7D+H ^!&)+(RFID\F /<M%M>3+7?(0A4F<H.!]SJ=C$FD5"<KI
MX]H3&2C5&UO;WG=RZ'0^UQG$F0[,VA%LK&S;%ZEA/HQM.SSCOGA3$EJE8MZ5
MT3].8BO!C#.&7"S:I8!QZV1,B#%0*X6R26N[L26>86>R"GF>*?(\C&U;(<]]
MD6?2N+4\R #&+=, /YP)CEQ*'M&<L<^=8237.Q'/J5%39<2\%'+_-*51,V:\
M5#+D&#2-N(D":6E!VM*H"3?)DQ2J)5_JDGL9K74<H\@\++F3%BS(R!$ECFKX
MPB5"9IW)S6V\^'GZ),[ @*?ND[AVVOY!N^4KL;L84TPH_$QG[-$<*:$IXM(9
M9%PN<<N3PS91[;+"3\ET MYBE7)6J%18Q:Z/I")7[+HXNTYHR0E[RI57*$87
M$1=6((=I0LE;$@Q6R>C<"X7>^_!YB>SZPGS]1^V>;4S'V-_50'DVA0H?RENQ
M_I4*UT[OJN#[3O!]/*5MP4YHD1Q!*6;3SRF)3%(<!4N),-1I+C)\RWMK6TOG
MD17WSE9H6:'EJJF]%5K>%2TGE%UNHQ8J"B1H5G85=<@1H9#*OF CL9"8 UJJ
M9<4[/3U:WJV*ZPJGGF[/3OF<J+4QD6>:ZJTB:W209?HC=N+UM1$?CIW?EL.8
M9.;1XBU%$3ET&3OM*R;':\KDBR=4[_T\>']"C),2-$SD21*(>V:0\32@K&5R
M1B533#Z)"EOMXAUV47G%8Y&IX@D@+3> M!XG)!-V1'LA([=W$ZTX!!&$3X89
M;K327GH/RJ_1PL">%OUZYBFL5.WB'78QD@#L&,"<2#;7)^4*6>PY<E@3Q["U
MQ(&\;+6GQ.7M'Q25J$$4V$8!WK#^(X659B%[M^]0Z0,9E-JT1<',=J>'BHK8
MY7?Q9ZY2&N\,]4LOX/4QRWD8T5XQV(K I@AL_^<^@'VT1E/#48+E1]PP@ F!
M.3+"*B\UE=;3.\'$TLOQ?<P4=@0$5B!&KK]6[>7LO:0T,<>2!,AWN;=A!+#0
MGJ&@7'3<)^(EOM->+I\GJ[V<=R^%)9I:A@A/%G$7/;),4&28HD9'1X6[FQ*V
M]$JIU5[.NY=> ><!%B*??!;BN>]3-!2E9*6- B!8/#7&5K)RGGU,1!C%$J()
M@UX=)(A)XT2N]^D2!^2-^FXJ]?)YLMK'.?8Q< W+JS1BS.;JM%(C:[% -&@7
M"0?SUBRJ5-]+#]^L/7C=P0%25W7COIYHC*6*V"#*<^L'C1T"4U:@1'7RPA./
M0<).%!QD"CYW7.$8"'>8.,F-M6 &,VXHL7&JX."8272[B35(,GQ]<X7"ZTNH
M;2Y>1&UFV<-;Y[L^Q=<4WN1SEAZ[TV,WC5(+/?7F[SA>?O&U=1MK52BN*A07
M7U*AN!<W?V)>7*&\P_'*JS#/;F_^2+*[%)M[CJ$/=Y[_LXEL6+JM.![B4/IO
MGD=T0WV_N7]Q<.;I0?,8[CV&S_<N#]^];1Z^V\<'EY\NOAR]QT6[V:GHAKV+
MX\L]>G!Y#&,%:^+LP^GQV3X__GS,CR_?LX.C/QLP5O8%WO>_E[M3L6!)*^&9
MT(AH 29%3!@Y!T8WV)1419$=ZGAC2RXKDG=E(KV6T\"[0K.7@V9+]V!6:'9_
M-)N(U1(4>VXY1YYE=Z=W'KED%")),F>LURXR0+/I%J@5FE5H]J+0;.GGI!6:
MW1O-#B9K?!*/1>(&@3")B%N#D::<(9+K'W&&:; &T.S>Q0@>"\V6E(*UTMCS
MM^W4"_=R^UY&<U7N9;WA=>FF[Y"N*G1=#%VG*RAC2W.LF$16LQQ_) )R06(D
MN05Y)Z+3D>9&;RM4ZJ4J,E6ASJ.:J!7JW!MU)BU4QQTG#G2Z)'CI;\N'T[F,
M>V*P5TDH7:%.A3I//;>G-"4KU+DOZDQ:DA%SY9QP.7(LYMX[&FEO+**!@(3P
M(LH<!DCD"J'.>!+B-1VO'["!*<P@O\DVQAT;>ZTR0!&^JOJ9EG%I/TZR1(LA
M4*2CUHAS)4&>Y0X!SG,ML08HX//W,YV_$?0JY)B6E=KJO\BB5O18CR%W@I_J
M69KCZ69&T747:3]ZC]BY*@9NK>+*UFFL50S<;R$S4"=WX*ABX9YQ+%@5"_<0
ML7"%NB@V9U58*_ZNMP(LQFO$-V?(GB<UFM[8[FGMW-9#+77:S1'I[_,7*<OV
M0@.P35B%\6ZS191]$Y2$?B<V<[W7=KI'];;J7/>EGNL^<,S=7_8B4V?WN5CD
M9X?OCL7^Y0>PJ8]_'.[LX8.SK^3XZ$/CF.;/=\F7S^]_?&D>7TQ;Y/O\R]FW
MRX-W8"6=;<.8W]/#G;]/#][]?98_WS_ZN_%EYP\8R=[,N#OGJ>82>Q28Y8@G
M9Y#6G"+)'"74Q.BUW]A2][;(JTB5"M'6&]$>..ZN0K1%$6WB9,-1KP71&GG!
M'.*1$:1Q=,BQ[ 72('Q<1K1EE?"N$*U"M%6:^.K$WE6(MB"B39Z:6&4 NXA"
M7CN/8*=8[HZ2$":*R"AHPCG^3K%U0;27$']7='M&[83Z8#K;W/"Y6VN[GH4+
M"S,[_O2GMO6US&QOP3LGX_3N42S].:/ULS[!7IK1G$\."PIL7_4;/QP07[VU
M.R ]H+QK:O7"%8U^7M_MPD'T(?KVUQ9,.7PZ;[>V0_L\3Z2"]3O!^HS OXB9
MEY(AE2)&/"2.= P"I<"$%01KI<C&%E^EP_ J!*<"L$>QD2L 6T4 FZQ(SBRQ
M7'ADI<GM=Y1 U@F,8'M#3((IA^/&%EM60?(*P"H 6QN3N *P%02PJ<0V;TR0
MGB,9A 8-S 2D85<1PU@[37)BA@,-[-Y%!U:OR^Y*8]'GXH\8D(516;"1.[$)
MG//+-LXUL^>(>%AD,586O68&E]ZE/<!-KKKABF^7"_YAN-[%E[E0+1DKB)E[
M[[X._4ZNQE=!SQS0LS]E_!%)>4J@-D4NP?CSAB&G1&Y=R+@3Q@=O\,:6VJ23
M]0S+$HC+H/XY H&>/P?=I4U*Q4%/RD$3UH<.R6&!$S(FLARY +\I#WH9U88D
MPX7#^9QO4U8<]+ <=(?F)A4'/24'3:J_R6KO%0>^B0K47ZT(@EW32"=CB!0L
M,2,VMO1<,N@EG.E,Z:6AWO79/*L!&<=K >6FAMKS^@M6%A*FC>I6/S<Y6TH?
M*W8GQ-@9[,8'V(R_8L>/=MA&M,*(.3#B_92>Z@,HJ5@8Q%4 *4NL0@8V$ G&
M&4[4.9/SA.4F60T;^2DXX3\74B5N\3!6Z''O7H85>CP^>EQ,:AB,.45$KNH)
M$") /3<>4Z0M55AX&:T6&3U6I,Q A1[/$CT6ZKY8H<>CH\=4W!O#6$A*D%,Q
M@>ZA56[>J!!3PD:3CY:#K=!CT@B[N6'R0W?)R:4(KCG3VK>]?@=^OOA*!8?;
M)R9YKFD22"C"<X\ZAJS#$04I<8Q8:D'2')4*UJ NP;6]KU,?R"'6S@=1P@#B
M ;X'XO2YQVUC5O'",FLQ6G^:GYDS%5/]>ZQU^]FGEA=@T!\HMHH_1EY:5#C(
M%1*B33WXQ'9R5&8)$_-6.UCUR@98T$4J&QBR*0R?-P-_AG8RG )L75PD5Q\
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M5CXAS:1G@DFI.=[8$O=.TZNB">\*2_R!86E>C;""I;O"TFDGQ@J8[@1,^U/
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M.^';E[,/C2]'VP!1^S_A71<95F N]$08QBCQ#'D6'1BY(D-)E(CYH"-)R8,
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M85EXHC!5AA\-2VE@_$NG&$ZZQLVFP/GG^-_72?A;)?:$A-=$ FIKZA/1W"N
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M/^0\GO8P&9RBY@EAX4$#\]HAAV,$0XR ,FYDC IG#].][:X[\U=UR%T=<K\
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M!"S[MYAGD5VI@[=/$MWX+F:LS *Q#CA6",_IW1TL%Z>;2N2];'<+.GE='"N
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ML0+@"H#O ,".8!&)C=$$QQV7-JI@(L4LV)!L4)73\AD \*163S#U5AJ"#-<
MP$0&9(5G"/:<!RZTI(EFIR5ATV7WUA" 7TXIJC*F,?LQX9FY:6VKW:N==]K?
MZP',!6"I_/]Y(@KRW?5N$>[=*M.P1BX;1( /RES]UW]H2M3OW5K[/':*"[JU
M4_N]" "OI7ZK(!O;^/7&TFKIG=KRR9\V/VX"230:MG/5=;?7+KZ"986Q%.^[
M9I0CN5ZSAM2)/0N+%&K1=G+>37=L#<[Z,,=0]^68ZZU!1L]H":]ZMUC"(M /
MB+1\DRNBWV&S8 B-"WA)?9 >L]3(=OW<(MO%"XML_Q"[0';^="=^CXWV>9'J
MTBKR8OH@Y#ZV4^\'L.A.O>O!9N]W5B@"^>M JK7)X<[[BX,S?W%0_/R*#^@Q
M/?S\GH"48OL[Q^3PW8?Z_N4V_?)Q(@+Y[!,_V-FC!Y=[./^$Y[ O9\?BR\[?
M(*4\2+9/_,N[O<O]G2^-_[W<XX?O3Q+7C#@FD".)(:X#10;D!Z+$>TDE8<+3
MR9!W&S7S2G@)^\0UUXXK,!NY8YS0Z#"?C%C^L/MQ=_O#F_^I;1_LU'9V_][]
MU^%?^[L'1PN$N=_ZZC4-CRZU-0 ZP,,A!1<1S^$7&1>BQ;>[XP ,<B;T?6_\
M0KCQWWV85^^B9KM Y3E?*%_YM6.;W<W:^ZGO\J,S I>/K[<*L5$\OQECKQ:_
MMQN%;/&P2B#K.L4K.O%K=HFU.Q>U(OLH9RENWI@Z>0_^+O+<^DW8THO#-%PB
MX.P1/M\M4Y%7++'@"=AZ^P1+S6+,Z00N'Y!3(I F6B!8:JU#"!$K-B.318-"
MJAPE@=N@=>0^*BY"X)I$&:;8^CHZ+8DHR_Q,4D7*Y""UO(C?+P/YB1D+Y+\9
M"QY 4;PNB^;F)7B"# $LZ"(9 E)M:KY8?/PM&0)RL3MOB;J7\B$R!/CR\P[6
M;*SJ^F^K;(:7%\U?93.\Z/GG6) 7ELWQUT!!'NK,G6O4EBJ=HPI8?HA>$Y/9
M'(N80+-J&66#Z$8[:$#X'TJZ7R'W_6(6T<!]CP\_[[+CRS^_?6D>-/8O/^']
MLS\;ASL?ZO!]\\O1 5P/%A&=U1#BO3@^"F?[S0_-8_KI,E=IWF^"9?7NS]/C
MYI?&/LU'!3#?HB'$=$:&C4HIFUPN(180E\H@2Q5&L&M*Z!@<Y6 4<7[O[MI5
M4D:%<>N-<<X'$Y/11"K&<:1:B*")CB1J88"-"HS#0XR;><Y98=QC8-SD$:4S
MV#O ,B1%;GI#A$4FTJ*K-DY<8DN\!XRC%<95&/?",4Y[%X6D*D@9BJA<QSEC
MP> @09M+,F,<,0.,(Z;"N"?#N D]3L=DL1<Y#(,1Q'T@R%&O$'7,:V;S#P48
MQZ:CX%84XUY"^MC4B565,?8\C-3!QFX/][6"MSO!VW1.&!=)$D<E4@:#"H?!
M8'5*%H79%57*6(_MQA:=KAKP=$T+*_9=6_NK8M][LN^4!>:X900;Q(13P+Y,
MH+QOB/(H(I,R"H9G5LBNV/?9L._CF185^]Z7?2>DK\/:AQCSQAB'.-$!V2 4
MBCP7MZ<N*2.!?:>K4CQQR^!G?@9X7:C2_V?ORYO:2+)]OXJ"^]Z],Q%.)O?%
M'4$$;; ?$XUHV[A[\#]$KB 0$E<2QO#IW\FJDM#")B- 0+D[ "U5E<LYO[/D
M6>J4S>5U)KW^C*'G,,BFPZ2O%0N;/ZO<H77_OV>M7@Q;G3][71_[_=QSHA82
M<PF)V4Q,IB5W5"50[Y1&7,E<O4B$7. -$Q&H!5&PLL;E@VVTI<D%JJ&UAM9E
MA=:%&<LUM#X]M,X4AN-86$%43JK,7;=!]39:Y?(IP7+GDPDN._?%@^WG&EIK
M:*VA]:D<&36T/@.T3L>_*9H8,;G<)E:(!QF0-D8C)BELG:(^$ W0JLBK@=;)
M#/:9M.(%I!M+\MK2C>4;2S<N.AR5!0  E(I7%1PM88IQ?DZ)/.??=S\"4GQI
M[>P>MK8_;>+MDVVR\_?'D[W=8]H\R5USU_'.I^;1;"[B[^WMOP$I/FV)G4];
MYWN (GN7W\3>W[D(QQ[=VUTOFN?MT6;[/Y?'.<58X*1E2*".>>80IU$BRU-
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M(I:(0ISF8G&&6J0<\X[ GI"\SJ^W9=G-3<I""XBHUR\_&<!7(Z@#?A!#PYZ
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MGX2_1* (S$2CDA*14+ZR1A>6@?*"+,(:H)9I;DOA\ZH!ZM$!:MJ5%;UUF,B
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MHDPFQ',@F=:"(:Z]$"8%9T,"J?W@:-?E.YUY:Q80O!AE8X6J\U]YU@.L59E
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M:/FJ7KK-ID>[G7__@.?D)*:JP%I5@[ H/GU=D<^K8)UIJIX9>A'VV#V-9=7
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M+'O4SBLI_5(G=OINS$^YPWZ;CPW(=O4*;*(SU3E+6]J;<AOG?A[1@1*U'M0
MAF,CW;C8F@O%69;X6TB8AK"-.DBPT3+FK,9BC-H@E5$?-*=&^,=.??A?VV2$
M.D_+?&QF;>7 -YDU U@X>K-M)FV0>N^>)E>AIWK3^MQBHMJGAM<'7U54:TI+
M]9PTF8>6SVFL8=M+EL[K3&".5U)3HR5':A\QACG/3PL(\:OQXLE.ZX9,/#MT
M0GE.)ZLK-I[J)%Q72; Y34[DN:[OLB0DJ4NBC*9$N#1,XRP)4BS:4P08IGE<
ML'GZ>R# N'E:"<:\34Y\ZH9A0KGMTS2SB? ].TU99D=!&#I)E,5^X+UX7>5?
MKZ#)6<N-@VI"-J?A]P:F1TTEMQNM0_"RN !+KE((;W#W56<(CH#%S^D(C/(,
M\P7R+K_/12K8-7A\3/ULC\=(A=,^WU\!Z#RRW2 A;_ ,]V@^Q4/%QBWO#P2^
MH^9DO[C0H9&*>(-7OUA8*/>_Q27ZP6>+R>J'_@D/LP/B8 -CQ]DYA!N:5X.'
M8P%;J9Z^XDEA\R36>=+2P=SR UTG]C9]H.<W#^2OK ,=B6 96><8LO\L/XSB
M&SZKYZ&J9XE7&$[,&<M7OY)<'%0-<OE@,B'@LQW7C8@/*RD=BHG5_Y;CV$X(
MHW*BV+?=$ ^@E1RM&UI-(]9,NZP8SEZ!XL52=SJW?RVX9$RZR3"; 40.@@9N
M/@ C85O/DVBW[=]@((NMOU2,"!MPK5U2O_>+^SV/Q3YWXX#ZQ/=%&HF4IPYH
MQR BF9_<Z0BD:Y7>S&?[Q>R3F!U)S3@8J:N,E O?<T\(IS'S,F:[,<4CVI2"
MD<I"V(TT#'S739GGX-E'L>+0HTG"K[%7LHJT9;1J<HY6#S!519_"AE6$AS*9
MB[SL,F.B35RWZ/@Z*Y.#7OPBQF)Q QN3).Y&-J8ASNQJ(.0L.)I_$1.PQM;%
M6C7L!&'45\,#KOIFN&IWP%7_8%SUM3CI'J[:CPC(>Y;1T V)G\!N<U@0!T$<
M!:[CA=[SP57?V$]LB. RJCJ"M@_-Y&F8<KY[^@V;/6)?RAR^OE@^1JO)C;#?
M8OZ,DRYF3L#ZBU+.A3KOM"[RHI6SK-,&.H11S1#K# )<D5<FE=4FRN@:,G$%
M4<9J_JS6,VKR:.5%X1&$(L-09!G8SW!RBKA/0;'I(_Q0,TRTSEDU*@4^1=Y1
M_'=)IEIGKS""UCPHKE)SV%"!#U7WSVM(QMI%W*L[2;2;@TI*LN<I76\I$GC7
M/>Y6>C2CFNV5UD<L,B;2GK">S)4QQ$@2:" GE]&1DMEM^2XC%$G3=4L=BD4J
M(_MYCKS:YCA*1NC-$1DX'!="M:V5_.BUMY67R^@#,\(.L$'1*,U!HY0P;[Q-
M]U:WM?FYL^2]^%,O2QN[H/CWU:S_-N>YU#S;RMV5(G)0YK A%,NM:F-SV&K!
M^"QWUC8Z8A:U:N;W24N)N>U3WS:EECIS:+7L7+GC#$:ED=5S>>-J+6$QA561
MZ2[SA1:U4(/QH!WBRO-G&N8W#$*D>QBINP[KLQ_%O+B2VJQ%N-A!\.AE&G7-
M:[U*([2DU5PWVM8MU&=KN&][2VX.\YO^ISO;NU<ER_MT@SYW"?<=GZ0L("P+
M8LIBD3E)%(DP!4=59B0<)W:(;7X8Z 8?/B'APS/(B<M3+XUH:A,'^089C>PX
M3;F=A*[O1E$618GSXG5"UK<+GH[G54W_B4B123M5H:5&-J"_  6D$24JG][(
M=[?"G175S&3+6Z2"M^6L_2Y4M3O7T1.BPC.^!+U*17>(6GN;$;$MD^*R!\!>
M=28Q4BUY]6&$)!92IQ'- 83D&=5G$^KK/;9LU>,DG\B:J6=J+5<1B?6<L*I/
M$JQ<1@F0<+V&-Z^1/UQKG4N3"ENQ%-=.":I4Y3]V>!I7^K$H2;_A##'E;:(>
M%_*&1O%>XV3>+Y-C,RNR^V7-YRC+>C]B*?$V2.3,VH.(\%0)OC[D,D6\5YW4
M+)\7N"Z6:[E!8+LQIO_7X%Y;P]H0]VHV6(\<N\:&Q>WUE4%=\ZHUV;,Y)(19
M;-S-]HJO?+7(=AT_(@F\FO^JLU#R.6VU)7'82VCKUJKOY!<YU@ZKA :8\ZE@
MC9K$VYF(=0G4^DPW=O],11ZGR!1YW6%=6@?CP)H$0D<>Q%=1LKRJ8PR#("GQ
M0;@;<)]JM='"$KHQK![ELLMY%QQ6,T>N=:"D4"WZA2U>'*=AB+0Q'G$8301/
MG<1W11)$#DNSD_=X5\=S@PT.<^1YS4'V5DOQ6_.N!]/9P7SV$5_Q$-4-?'];
M'S4-9SNK7"GXVR?G)(LI9204-GB[Q"9ID-A4.*D=DBAR(RQY2=F+URL+6K3L
MU?I$>>B-\,F6;1W1T_:F(>91K G'@C(0ZNH?*ZJ#FS+Q\=%QPT8Q,I:J8\!6
M6*V;6JG&NMV3O1IMCJWH90.-*Z.#430C=+;6EJV=U2LKK]_0>06+IO#Z^LGX
M4A*R?9V%"R+/ S/@WMW"+<>&ZZR<*=Q0J%9CTXR8M=P?J<*DYE1V259K:"E2
M9]7K)*CM0ZTU@:%#"+Q[.)C !\@WU):G@[!>O8?;F<[6QM<9?KW<D[:OMVJK
M*T.IIQ]3NMUBLJM6L*L*E@H&NH/OU0UT1M^2FWIXIH(!Y1A-9*4+!VJV>73:
M,2"3Y]]-X8?*":L>+"/<89@65BT9))-KG:1,VFA>JHL9Y'%\':@]6S$SDQ!+
M :GK*1HI0+Z/6H9@]KBV:FT-L:[)F^YX@?4H,."UFQ@])C %$U.]I#N6R%]+
M06<F0:'-X%3RP&+ COW7U VP-_W,$"3UM,BOX_FYF'VC#Y(3C[;B&TSU"NP!
MBH=-MC"A?X&["WPP+1-8H8@W>(%](2+RRP_MKKE,42_30=@K9=%*O&Q9VW5.
M1&W'<8^-/=*;49H7LSHRIRFDS!@9NRSF8VS$@H_3*1_9IVDLC#6%N<283<MB
MW]Q)O=/9T=?KS*74=\MYPE[HLS+_HAY?R[%6L+(#%&Z'U3Z1G)R11.VT7D?F
M9&'TBB,+'B 3/K('T!6VL5L54]>JF'GC(#-J8:2_9&9'-U1\OG92U^E$9C[6
MAF<37?MOND'V@>'49RP("<MH0$)"$I<PGW,OB4GJB23!0,W#?HC1$*A]]T#M
M_>7^[A^7)Q'B[D*7V-QU8@C4DMA.8)ULFG'*$X^(.%G;4;65VM:><M7T;^MZ
MV:8YN HBC/61^$GC=J^&!K>"J6LBE6-91CKY@E?\;P%&;E."HBNC$P\B$R<,
MXB24H%U']48S,S R1_=-L-&.!1HJ^[I%QRIO<<D5K*>DYPNN#(NZ"<G[C(M6
M?[W/8M++"U]_;(G*,-H*'K<Z;&?.4K 'XL+TL\M5;?Y%+K&DTLM&U [V7.O
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MZ0J:]GIJ2>$*'QN;@@1/L)H?!  Q%[)E!7Q&U-WH!4R2@?C W22&/6>P$#H
M K=6EQ,%^@TDTH6WNBQ.,+NH '*8LU&IHV;VNLMN5MJTEM8K7B]NI=</;PL3
M-<?UQ+>0/,G(EFAVCEX_VOT+7C;-X4^RH7<-/#<S*\VJG.R9PE?A\G=H=)K
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M^:S<DJ<W>S]TWE8Y9NJ$_+=Y"A[MTYO.1R",#9X$G4:9835( 8EY7!\P/^+
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M&I(H!UWC9U5$OJ2D-20?7DLBGU68)1=-MWOO9!+ &YCF\(YHI.&AX=9@5^]
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MI(/C4'^UVR;U/V!U!-B9=KO4?5@/D&]:%K#4=,LZ;)$5&]4L4:SJW=&WE3C
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MD(SYE+J)\%P2\\1-4]?#&A$WUKWB\ =L"=( P^WP&ESXKAKED0P\_J3CN>C
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M&^"8Y*(4R3ME^<UK!=R)?SX_$4=I?SH-+ZI9F(GXS_W:BUYOX,$!"\>#I@?
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M(Y<&_.=UJ:<7(&\@D*7%#J"<C*2&4YF<\S18S2T6@:8@"I W$,A+<?? +6S
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M-M8%M,:D._?,*FTFZ4"^[#D 8PO64FK4%BC($%1J>S:<)6( ?X=M8]U=?SW
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M8C50-24,V&J[:S):!YNZN[\20OEU>4$$$F%PF>5\K@)RJ@(! KM[*4VR0<;
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M 6T@$H,[#Y&62>(8XL_",!Z]CXS7R1?8&.JSITE=Y:Q(7=HY/_8;Q+TD@$J
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MNYID8CP;[W1NKYM$=34^XJ*WK,4-Q-:R]GY#25U=+]TRYQ05GGGB3<1]1>1
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M@FMB&CSRB.ZM@C8T,&I??!6L@'EH%@:_CD?7GUX.8#+I9S14;G@,/.#9ELK
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M^65"UWD8;_,1;\>3HG_TS>HG-^UG5Z]S9M58P<![GPE3,1()EA/'LB(E)B\
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M! \[%*(7R7"P'(+IPMS=YU7#GCFY3Y4>@-U[B_SNZ\5CL@'7@8<1*ZYDD&B
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M*E>GKF(=HN>>IK )W]:7Z^V@I0J>W/OQ**04)V]0=B5G,\T3=XHL J*=#VP
M;R!K;TE*+!>,OJ2'!A(]4Q'P+W2JX]DU0?<]LZIU[54P\6XSP4Z'>.:E,J=Y
MC#_I41UBH"5I7&5D?L@!K5F62ILZ'V60D:HZ*2SK$'W/3&I%2Q6:?KV'K_-F
M9Z-Q([)K:U,T:,$:;Y'L"<GNG0O$0V1.Q*!,J.,X; CT>^9:39U6"%RU%]*#
MTM_<E)Q#6H3F(@HMR%D 6"9*E;/NQ[R@ R/K?K2_[Z2]1NTKC$S%0LTDVUB.
MAH0+BM(3D[7SH*,W]U,U?K07:ILGF[07VD1?77>,:8+M1WNA+76Y2>N8;131
M-5ER]MR5^D1N0R32XAOJM'<D&I>BS/B>\'@D)-FEO5 UCFPB_V[:"P7GN [
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M$=B9B:!\+, I&  51*K?I(6B':8Z"] THBO;ANCI/S'WLH\.4\5[ZZG!A?O
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MYF-^Q_^>SEY,OWR=3JJXIN6/V92<D,6W/RYPLL!)^O7?E^=?JRAWSWD-N/A
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M*^0%.=HSC(M+O'A__NGS33E)#'60=J!X4%18V<I:,<!JRJD(%KD*K@U9R19
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MX6[0\MZ/UW<-\/HRG)^%S'/02D+,M"/%D@"O18&"NCCZ*R\:$3UOQG."%C"
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ME ?::K*5E]W54L?*HQ!ERIX+%SMY5_13;QTU]&_KQ\R=94_45]I=M .2,MV
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MS$66$#D3N-Y,U:'3ONOJA\[8[V8)V[OMFTB]P776@V612Z]%L068\A301<'
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M#87@1"E,,1W$[8$W&Z/N6WS5L*]S/_J8MQ-F\YU"&U<Z)YVC9<& U((HS-I
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MA(85@?$LZ"%7=4N)4QY"JKW1A7$?LI,!AYAA-LY)!4T0T47BAYA4P-?]K,6
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M!E<XH\O:1">&2.*,LZ2@"2*Z2/P0)06.'#[/?2WFKXUBTF<(07$PRK. Q9$
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M1?.PQ4'H\IU'"82F@NTY._#[+)T%LO0J-E\11*>KJR?W;DGXY9]/BM8L."V
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M);B4E?QG-/>)%0H(=UD(K:S@O$U/LQ>?Y-.'K4Y)/GU$7='4# L0@[,W@YS
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M7%U]//]T]2]O/IU7Z)N^\^,J19QUA[S>.5TR&BDN(Z"L9*EY+;W)PC"K658
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M:12^W,+D[_.%$4ST7*$/H&QY.#.R=!T,FK#,O)4<&,^[DDFK6BH/D/W37*G
M6,70@NWX5NB6JZD+ON,:+FL(7XSU<@"O3RI-!5*.8<>LXZ3)B%">%('Z3"0(
M7#34"/1+A;&64VG2L1RG8RA-?XOFB#K3AXO*0:&KN/C+M&I=RQR5-F>DSOE2
MQBMD8I,3)'!A@N69!M\E#/31![\ 2^0@N8]K":VB\;&E[8;@P+G$X7UIPB2!
M90(Z2B(\5=I$SJ+K9&J<0+^B8Q@4%5BH&.&VNWE'%U#_8-V)>O'4J4G-/D(^
M6G<B)X4$RRBA67#4<.51N1T0I9,.0>$NOK,XRHMFOE]WHOK$]Y%MY8/\#:(8
M3L=WDY#>ILEU&IV-)[C#S<^^54=$10, A.(7*R*I<^6]'@\IL%Y&/ NI<AU.
M]J='>BF=BGK1,6XFRXH'?D'W6_@_:3H=;P %.-ED\;1BP>!\>32DE+0@)JC(
M=<1?\RYUH[<.\-IYK2.YVFW%8!*'([CYEWG QOM16)6O%N!D\)R4V1 I0!*G
M.27:*^$$5RJZ+JMUR\>_=BIK2&WKG4W]**+?WUZ=_^OOYY>?S_\-OUQ=PJ2H
MW[=#6H8]]9&UXH9Z05\+&%)",6E*C)CEDNODC 4K=5 "%(V>#9[\] .C'^[\
M-/WG'9KWY^@&S"[NG^%+20G4!DZ<*C6/E5?$6<Y+R2S/8F8RJ5T5&0\(:=B"
MZ-#[GG?)S]Z/IK/)77%FT+G!P^L+3%/\!4)Z<UN"[08EY$!8-B\\2W&M12#>
M*T.4R,QGW/[H>EN!2I/N .[XMP-5=&/]JJ<V#95-AX?PSL8X<2@P8[K].I?V
M*+X;XB8 :/2<C4=Q0<$<]OM\-D1/_'8Z@U$H49NS@32&17#S^,] I)2>>&HB
M,9HJ0X$J);K<%%4%]<KUZ'E)JFS9/)S(^9]?4Y@]6 E O4;]#R2G<ME22O[X
M>4%S9:FU"4UH(WLKT.-Q3DXG#A1EQ;>J@JW,[D,^FR341$0TO!G.OJ\0_@9_
M#F_O;M^.)Y/Q'\/1]1E\Q;^8?1]PM/FH8)K$;$OE/&^(M0'A&Z83M]'&]9I;
M&ZG?9^P34(?F(J]X'[E]2_L\GL'-1?J6)G"=/A5W;.!I$DRE0+Q#9UH*E0AH
M18G54;@LN4R=.A]U'>\$5*&):"LF[FZVC'[:N="]5MZXPJ*4Z'J7<DO,2H*;
MEL'?,2=MFRC];8A>N5)4%7C%3.#-N-Z/9FF2IC/4T30OJA)_!,\7E07<IR1Z
M[Z6#%V<HB P)-3APEI0J9<6/H!J[,)ZDLE0CI6)"\C8/:V45?YP,0_H)9J;9
M,L<$";14H1<""%"F"%719&#!&-'&P^\(\"05IPX=%=.A>\+\D/$'HS#\"C>+
MS;+\9;I-<: 2*^DZB3 !I11@\,0&XX@&I04#)Y5N$]]Y*/)_+#VK0V#%O.XM
M0ED$&X0 ,F4:B(',<"LU@8!BDC#OA,K<@Y"[*M!4NX4\:J94$_4X6+PO)==I
M?2*KL/JHG,2-DA)'2W..TC0 F Y$Q""!0DJ"M@G7VP+HV6)\#B;Z"<W91^ -
MXC<WP%J^F'4!UC3J=RNTYPGWK4+@TTIQ@/2/JA[&.L&Y$01D+H&JZ/!;ESE!
MJUQ3Z1QST*G@\TM7BR<">H^K%7V$WEX;5LU)J.>^%-?#.>&NB(80 1,< 2MI
M,H$[D&TJ &R$\^QVZ+YT[5:"/63=(/GHH74\5W0JO4^>"V)DJ8=#LR2.H\/.
M7<2?^&!$.L:UVDG9"@>*N4&.T$-$)<QF%=K> 5=3*V$;LN<Q$@YE;J<B'"CV
M!@?"5GR2"<L@4Y(M'GJRE*AVE"9"HW#.>L,".\:M6&MU>,(X.)8V])%V[7!@
M]Q=*K])H.)Y<CF=I&N_2NQ3FAQ4RI);'EDK*  A*=*1H#8'RQ.-,213E&!39
M4;5V2&R.".XRV/$-@#J\C%L*M7)\SV7ZXU.:SF_L%X_#;ZXG:7Y!L<1F558Z
MSCO%:U1S\)Q S(X$QJB*W(ED; ?"GQKG!+BN*LKZ27OCFV_E;?]!!,"3D)W*
M5N9<GOR#*>TL LI"X R<8AF8A+1>+&=;:M\^PQ]/*>KS-SZN\"OKR^<TN;T8
MP^AM9["2@<_!.N*80K %-D)$7XD%FCV:RCIUB</H/?")Z$A;@5>.WUH<:%<I
MW"$RS;B:GVWO[M(OR4_N8/(=:35+F)E""5%%,?A(48EE)E8(0W+06L1,=?#0
M02]Z#'D"1TDK 3?P)TL;M!DJ;Y'!_9V9B$*'#,BC3ZB;02,ZE8&('+4(+%%E
MVEPI;D)S,I<)!XNZ8HS>-DRK?-8.J)I>)FS&]3Q7"8?S]H0B'"#T!E<)6] Y
M'6(()I$0H33;21+/*VX()"^4LDIPU>9R^9BJ\,0UPK$TH8^L&VC [Z/IXN@J
ML%;%MD**$6="&,7#20HEB4MH)SE!DW=<,'2+F]"_ <SQ+80:/(WK"KE%Z>!'
M@!A$4)8*$G4"-$V5)\YI()I2D(+IP%F; HB/H)P$YX<)N$71J <>[6([\Y2+
M8")!\SVA/4K-HMV3I2EXGK+1N<V%\6,L)V/Y'2CF!L'Y#Q&M#) .F-J6E]N
MZIE*RAW(V$X%.$#<S?> 5=U.C6<-9988S7%?PE.(N.P42>"#C$%J;AM5-SV:
M"CQ5(.X(&M!'R@V8WW*QN2JL0%74!B11"M 8 0#B2^JR 8/0 ECEVYS].V$]
M0U&Y@YD;MQ)[\\"2G\*NTV0XCO-E4*IJA,@EX5EH(B6EQ#'-2(Q."<!%X-?K
ME+2.C+_'=C(60V4:FF=UK2-<&<L=,!XQ*&4SRI<0H'(XP[T4Z !ZF@>O;,%J
MG;24E:;!0BC$*C(!'G&;S.A 91\"A7AB*M0KJ.5Y-*@/*T?7G ^CM+I8B33:
MQ#T15 O<BD,@5D(B5G#!O$G.)/\,RG,/\+G?O&JPVTM]]J/FZ/;.YS_&*[-,
M"JDE"R10JXK!9X@+BA$FT !D05DGVK3$Z@CP'TZ#]J.F<M'53S"Z7KP".)_!
M:>L(_ENN;B,C$*,F40+NP4X:+7?UWNU79/5^V%=O[^XOQ(J9YO<@5H$['6!4
M+YG\$X#C%TG>DX)U$@^07XN%N83C-64A1$%<-*PD?U@"+D1B&0]@4C:4URN.
MWIS&'16/Z[+81VR5V5M6-%JI4S*&>4N)MCH1F6G$R:12O@2/$Q6]<!7K5S\8
M^K@U4_<6_KB&Y+;:5GO61GUD\<S%D%*\_>MYJ1DZ'>*9<3["LWU1E_=B.)UU
M*(O:PZHJ T[7.2X ^E5*K3"1^R*IA]FJ;Z;3-)N^\6@206AS7[(VQ('&];SO
M]^(C+\>C<#>9E(3Y%K@WCW1TFW@S0^N&[4ZQ-/!Q+H;@RQ7S,$W/%H,UU:$=
MPQTXD3<A3.Y2?#Q F[6P=;3CQR(\R>"ZCCTIJK[[_?+'Y8N':?K?_^W_ U!+
M P04    " "HCJI4=/:;7FU+ @#3EA< %    &)H8RTR,#(R,#4Q,%]L86(N
M>&ULY+U[<^-(DB?X_WZ*N%X;VRH[1A4> 2#0-C-K2N6C=9N9TBI5W3-6=D:+
M%R1,48 : )6I_O07@0<)4B08 0(0>J]M)DL2083[SP$/=P]__.O__/&X L\B
MR^,T^;<_V;]8?P(B82F/D_M_^]-O=Q\A_M/__/?_]M_^]?^"\#_>W7X&[U.V
M?A1) 2XS00K!P?>X> !_XR+_ T19^@C^EF9_Q,\$PG\OOW29/KUD\?U# 1S+
M<?8_S?X<$L:(RQAT7.Q#%'(.*7<H%'X0R#\A3&VRN/\S1Y'%(NY!CW,$$48$
M8IO(;]DB\K!M4=\.RINNXN2//ZM_*,D%D,PE>?GKO_WIH2B>_OSKK]^_?__E
M!\U6OZ39_:^.9;F_-E?_J;[\QZOKO[OEU788AK^6GVXNS>-#%\K;VK_^QY?/
MW]B#>"0P3O*")$PMD,=_SLL_?DX9*4K,3](%CEZA?H/-95#]"=H.=.U??N3\
M3__^WP"HX,C2E;@5$5#__>WVZNB2X:_JBE\3<:\D>R.R..7?"I(5GPD5*TE]
M>;?BY4G\VY_R^/%I)9J_/60B.GS;59;MW%51&2HJ;5]1^=^/+?;K&>0/1&_Q
MFM8!B"O9_3H4C5V8?AV,W#NI'\3X!+>6.9ODZH'ZD/"IGMW-4F>3/C[%0ST6
M:4%6$SP6VV5:)*_4'S[+G^IEU(TZE&FY3JVZ6Z2*'X5(N*BTY<ZM0<S_[4_R
MI^4ZA_>$/"V_K9\D5VKO(ZM+DC]\7*7?KY(HS1Y+17Y!\R(CK%CB("04>SYT
MJ!]!Y(<NI(Z@D%I(4(L+V_+]9;%YU)<B@;]]:Z@JE^ZU[I\,<"B.O,^9R--U
MQK8[X>/JT/8F=S:U%^)?$_(H\B=2?T$2KXR&BI]_ORX>1 :>R(NB//_77[?L
M#0?UZJT 7(V+79MBH$@&BF;0(AK\WI#]_QZ%-F4[!*Z4Q9%F^T"EK"]0VQ<[
MESR6*$4DIR6;]2TE9([]JU@5>?,7J/X"+;NV4OZ[Z=J_OGIZ+K*&3Y*Q$\*K
MK_B5I=(<>RK@CAR5^7H6($5ZUH-7B4F2^">09EQDTAP_P.ZKE^56/(MD+2[3
MQ\<X5V:\?+FO,B$?*/Y%/%*1+4/B1%[ +>BY'H4H"CU(F.W+7ZGC25O:(Y2:
M:*23*\Y-%]4$@QV*%Z"FV4PWG89;3RL-"N+(^J@;/_![1?" FD@;G$%UT.E5
M)]4^VB#LZQW]+YIIG#PKEE_E8W(=?2'_E6:7Z[Q('T7V/GTD<;)T D($CCSH
M\L"#2-@<$L=FT+<H=2*'62$F.EJF<Y6Y:19%*$@C4)(*&EK![Q6UQ]\( UR[
MU<E@:(VL0O2AT5866JQW*0AY@Y9RD+_M*X;N%291!EI,-@I [^)^9L9GZ8RM
MOI!"O547";],DR).[D7"8I'?23?JG:3VCZ7MA,(C%H7<)P0B[#J0>)A 9CL6
M8IR[KD FIH;6JG-3"I\_?+KX#&YNKR\_?'A_]?73-S,+0P]I/2MC</Q&5A,E
MO: F&"CC8H=D\+LB&I14#VAN&*$TJ,FAM_*D9H<1&/NFA]F7^VFB]R**$\'?
MB43^4-S(Y^>"%6N2Q63U2>JYSVF>+Q&VA.4@!W(B'1V$.84AH0&,&$&AA;#M
M8;9\%78\^3II+*WU,NF%5X=\L39T@I_N):4_@Y6D51C&9720U]-+0P$YC5:J
MJ04UN4#1N]C\=DU7\7WIT2_ %F;%!OA),?+S<(K* +9!U93.NI,J*0,@]E64
MR5?[FDI*_UU'EYG@<5%'!:0^LD-!76@+(2#R'0ZQ8+9$W$?$0]Q'=F!F&;U>
M9':&4$FC\H\J*DWMH ,PZIH]YX$SNI6SB\L($90N! :V8 XL-+'!<IS5U_9)
MQ[7]WO9O#R03[T@NI+7S^"22O KN9IF4>!G\??>RO>2F.@^Y^$XR_N'OZ[AX
MN4KR(BM3*O+RR.3N@2373^H6^5]%+JV#JZ0Z8%S:KH]$$'F0(!I"% D78N1S
MZ(;2GF$.QI&WL6DTCY8F(KV'332R9JKH S_)/3I7''9LTF\K=,TCKCD)<J(S
M,L4/5(DORD?<,@U:7 /Z MK7U9R#DO4%J)@'+>Y!=6I92/Y!#< "U,^*?%0J
M$ 8\<)M8;,.>V$U%_+1'?A.+Y-69X=3K]]OTKA*6/HH[\N/##T6DJ*WIRM]?
M2Y?_^DED)>GYYM);H600K^+=0WQ"F.TR+X(!QAY$MGS2".(A9!8AU*(^MI%K
M8A@/1]K<S.G&X2SS+..2=E"0'Z9>_("RT]N=WD8B(^\_'Z)(L")^%J"B&4BB
MP:TT7< NZ0MP\9BNY:8S1L;&\,@.ND4,2-ZDF\#PL.ZK^1%6,%/D]($M57HR
M7Z]$&GTD<?97LEK+'V\D.?+V).$WJ5Q!%'%6[3NM>$F>BR*7_\J-AL>))#I1
MKT*:J%SP"R8WHCQ6O]X1NA+;$PO'=C&VO !:S!$JU1M#$E@<^J%O>XQC&U.F
MH^BG)WUN&X'B&3PKIE4,X:EBNSPM>=IA'-!ZQWB27P>DY%W]1S&O[%FV8;]*
MXY<6 VB!H+>MO,&3U+WMS/OY&-LMJAE7#T;YF/RU>4QN6H_)+O\[<6U000 N
MMH_)Y=YCTL(!_%XB 72.Y=[ZJ>%UZ4JI/O])GYX='OY_^11IVTAO)\C*AI+K
M*[O(L3S;*JVB-R!H$JOI[8!NK*HWI*"?^_QNG<>)R'/IX],XJ>RY[5*W8J5"
MH)>2Y'Q)&+6(;6&(/8]#%$DK.T0!A4'@TP@+$=E,*ZW.?.FY63TM,F%6T:DL
MF"K!H% _YC&OK68SC]A ''H>[S@@CVPZ-$2#%M6+'35=$PY*RH?S8LW1&M1+
M-5A^4B_4')9]+[/''7JFY,2Y]#S(ZE.6KI^DP[I:JP)B^=?J_5P+OO%GR[#D
MY3K+Y#O[.294^K-%+/*E8P6!L*1BBS"3>H[Z A)L6U!P5_B"A6%(^;+8E(*=
MSC YFR0C_7>D%&[(][.L@Y/O(\LD\:4!EI:G%:RB'*RVI!NF]9PO/<VLGTEE
M,G924,T,*+E9@ T_H,T0V'"TJ ^76MPL0,WA@!E"@T$\; +1^61-FU\T&(RO
MTH^&NW/?],DL?B8J<MU^@0,O((X?1M#RI0Y&+G$@=3T$21 2XEF".:[1*<S!
M5>9F46Z)/$-Y'H0SM+$5J?0N(D)/Y<';D-JN!4/A",=%MD"8&NUF9\,YP0;U
M510@VH0FAX!1<ULY%YRQ=XKM8]80^#)D3F@']P-G@1Y::>*\SPYF7V=Z=EUL
M6/M6/&7+RPOX[E)ZY'Z$ EO (+)4;KF+84@IA:$?!LS&CL4QUBITV]QR;GKQ
M72:ARA^DG[=:2\^!:):Q;2'J?F_[,3ZV]WM[=7?U[2_@\OKS;U_>75T,4)_V
MBLT#;V,NV"_WZ?.OZN+J350_E6]@58*VO<DT]6:OB-X4E[W^Q.P5XB)>?A/2
M6Y'J[\,/]J R6E2UVM*5[Y.'PQ!:@@B(+ =![%L!= )'!"X/'!(Z.B_4L07F
M]GHU-(*&2*"HU'O)CH+8_<H- <W8)U=FJ&B_AJ=8[W@IY5?+=_+O2/T(JQ_+
MU_+H32=Y24^QU+RR)Z^;6\;SQS2+1%RLY7/U-Z&ZQ@E^\2R]H7OQ2=Z\>$\*
ML8GN+XD5RATXLB&W5<1(V%)MA+X#"?=PX& OQ(&1RS(/MN:FK&K:ZV1IGJY6
M),N!=%&KQ.G9Y$T;/3IZ?L4\B)V3BIXLY[H%T (T$($:(U""!!1*K=/I?X:T
M[#YR_R=)VC9B[?^0E.X^XIPNX;L7=>99A)=J2Z!I5CK:%_>9**G^$J]$7J2)
MJ$G.+^[E1ZJT1_K/C$>,VI )RX7(=SDD5N1!IDZTO< /K$@[#]!T\;GMKAM*
M-YWR5*J,7/DQ5]DV;,M>G7.SBIG*%P6DX57J1])PIY]Z92RT[AUS;%&,O*_M
MD XVM(.M=!KJ%^!B K#U,]7&!'VB7+-;\21O5S[Z*O^4E-GR.<B$U&^9W/2+
M%%#U>L1<F1;JDDP\I9E*^P#R6U('+L#WAY@] *DEVPDAZR?YSI2W9 ^Q>*Y$
M*E^J_$FP.(H9X/*/J_1)_7TA;WJ_7BG#X$5J/GF;QT>1,57(_]B *85_)&?V
M<N<UW8CAEV&2V/K*N",-S?B6DR62]66VG0K6^Q[]W.'Z?G*[W;0[48G\VV2D
M3=#_8YR0A,DK+E3E2'7$@3'U'8<[D'.L\KM0"$-D!Y CCX01]; 7N695O6?1
MHZ4@)BW5;<2E7ETR6@K8>4+4\R?'%\PTVV7CTD6JY=T6_1U6MB==TIEKN %;
M=H;SU@9!=5 GZSR*)O6-!@%OWZ49YJ;]E'&=/)'<?Q;28=KS>VZ%:H37?'@G
MK6Q[23 FMH,BR"G%$+E2$],0NU $5DB0PZA EDD4T92 N7DD#<60U,&6K*$9
MK!31I7-BIEN-9:*G3L=$>F0-NB$=E.0="'%MZ*^N '==J!OKS+[0#:HFC8F8
M5#/VA6A?&?:^3S_])Y6N7"*ILL;8RUU&DIR4[HKJQU?^NJKJ2F_252POV)1'
M"6%[GG P))$3J;0& D-J,TBY+U @+,R$;:((>U,R-XU8,P(:3D"+=C-%V%\X
M>AIQ$LA'5HV'T:ZY*$-@;3Y Q0CXO?[O*.U!SX9U4+79GYI)]>?9H.TKTO-O
M:![;+D/J5878Q_B'ZIZB:O'K(W5IK-9-Z0(<V,)&1(TN<R&2KKNT(8D%[2AR
M?<<ES VX;D1;;\FYZ<CJ#*^J,-</C&K">SKV/#QH8QN )5X5Q<I!EC0W?42V
M5)]N"]@74?T \_#(3A16'@AAHTBM&5@=\5G-&TT6E35CK!V+-?QFSPALEC(A
M>/Y1$OT7P>_%5?(L\F(W1A?9*+2IYT,[<*5]RVP.L6=YT+90Z" ?,=\S:L"J
ML^C<U+3*T'^JZ5X *?X\AZPQM/+OY,FP^$$+>,W@Z,!PCAT#K<FMFG&5!*L2
ML)KD<0*=!@@-&\_467C:L*4!%*^BDR;?[=%4Z241V?W+S0/)'N6CLRYB1E:J
MB=,O32-H;%NNQUSH("^ R$8NQ(+:T,;4<G"(/=_5\K-U%IN;_JGI-6@1<PK-
MT[;AD!B-K%1J4L$>K<IN^:6',7@2/(... .".%4/F[/ -&LSHXE.5V.84[>8
MKI6+)C,[S5=TOV->,?*A3/&XX#PK&QFLDR)[60:^%;F1XT [Q)::L4HA)CB"
MH6L%EHL$QD3KT.;8 G/3FQ6-H"9R 6HR]4M&#J+8K3N'P&9D?6D*BU'-2!?O
MO6M&#MYTLIJ1+I;:-2.=U_6L&:G;,UU')Q->\V,9KV4+IB4AV!(^0S"RF*T&
M:420>"R /$*8,>8RCQB-&!N,LKDIC783-YW,_;PS=;_NT:9I?@PO=CTO\DV$
M.;95.*T<S<LEAL9\V(J'P:B;MFAA:%!?U1T,OL"Y[4A>'7H&KAW9JG5&X*EA
MDH122&PW@%%DN\S'/L:.4>N[XTO-377O]MQL]8]HE7OT[:_1\VQY&/!&5I4M
M(A>3' V?1F6D#AQO>[A[FNWCO3@&.IX]NW[JZUIYIK7ZRR^>2;Q2ZNQCFI7E
M44O'#BW?CEQH6VK<DG"E>^D+:7'B, JCP"4BHI.4%Y\@=&ZZJR*W++0H"0:D
MH;A,&([6JB(-W"O2\S<8P'1*[)IVY@R$.;;9>7ZQ[_91J-@%%SN/0LGQ#,IV
M-64RCT+<4\3^<Y36:D(^6+&L[GK]]J!+DC^H_U<EN<]DI:RS6R$-M9BI_JKR
M@XN$[_ZA=64UC^DJ89G* 7TOJO]N.@,V?3O4:)EJYLR26L@+7.%!SR<11-QU
M(/:P+Y\R03@GS&*.4:O4:<DWVJ\FZEH7U^2#GWC-P,]ERWK):IERR-0/8LMT
M^<<M)-7GVXZLN2B*5:4@N7A*\]C46I_X@=+;\^;[F(R\$RI6%M7#T.)HT7X
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MEIBC4#>W36K#X )4+$JMI)A<@(K-!:@8E?]5K(**UP6HN%V FE\U(+[FN/0
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M(D$)Q!C;D/A>X*GP0>AIQ1I[4S WA7AH=M4 8\GZ2>>T3AT=\Y%U[C[<G9/
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M)<:6]$)($/(HM"/7LXS*9D:D=6[;_(WB+TW*-B+2TRPR4<19/1RS/NIXDE\
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M<9=1A]D1MWG]/'Q(-,_X9_PT-#R,Z%8F_)_O*=#<Z>8HUPD#L&VNVU%80%_
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MX?H.I%0@R$/'L2GWY-MK].:>7'%NKW-%\)_-WN+3N.J]VH.B-?+[WO@VVX8
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M+_^P.7P@)7^&J=;GB$TO_CJ5,$;>)'?E\.K,1YV?[XGFIPT[H.'GYP%3N@>
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MIY]8?&-'[5O30.MV@0U+2C8;IDIYMMD")5]UAMTX1NN04(\S9/0<PMYF&ND
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MJ:F/;#O8/7 @VW6UF1XH2_:SE^7'VR5S>.A33F' B2\- NI*]R#TH&\33VH
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MS;?*]!BH0<!8F'<T!1A\R<D: 8P%5KOX?[0USC[4_+SUIE5^!5FI[(K+JO7
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M"1(N(BACA2"B,8-4A0CB2.%(AF$4"Z>CNI<=3(W'&_E,-LQ^)8\.(+3CV4N
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MDZ%,2&-S&0\#XSBZ+&29#JN\O'[7\B%XMRHV\X3K'20B"8RR)(4H#!-((IK
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M* +4MO3'>ZR]2!W=&'L,CYV)-S#H Q-_)?T,[.0'I0*SW8[R:08:)0;=65X
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M8XV*_2'-:*,ST@G./C_"#-#RU'US+P&CBS*-:'$OY08(/7-F9?J$U<90)5V
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M/-7S^CTO'E<%7?RR7FT?B^LE7VR%7GKUGWEUYR_%_LK_LWY#ZKTN3O2BB%$
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M-,82*B)XA@6E8>#D\>_0]]3(]W@)NU:I.CVO*P6>],36"EQ<1>+TL%A:K,.
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MSX \DV)NSL7436"S5E;DOYIP&1TW#DH%[&:MJSC.B\>B0KDT%YNDN%)?6BS
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MNXF?C, 36NK:K3[;L+3[?>H@KX,M034XNCJ^@><"M%ZW!B)=:TW_^@*T8+H
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M!Y9Z["CL<2;A0-#V2 /W/*M7S].=[*M^#B++$Y+&"11"!/HTGD.:1 PBC'"
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MO>UDD.0R"#%D@0XM#<,4DE2H[RBE6&2YLAQBJVZWG:-,[=/:NO)K*=V6_,-
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M,\R"F*,P@BG-,428*",H31FD0K"4!4F(HL"MI=NA8:9F#S7"@7LMG6O?MH-
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M_U:4ZQD/6(Y8INP?' 10F3P,DD!&4*1!@'"*DIS$3G%\_F2;VLYYJQHPNEV
MK7:Z/5VCW\5N\UM7@ZAT!(V2X/>=FD#KZ9BEZ'/V[5:V=YK3@5>O(:;S\T)M
MD"JOB,<=\P#X^PV/\RC?N,%O_H%]$]HVP!#NQ0UUXOEN__YQ^2S42.L[T[!'
M5 O4C7YK?R,_B\?-XXQ2O?4-$,1(<H@R02'!80!YDH09Q2C*(NOBY8YC3XWU
MC:!@7DL*S,<-?EDLU^!^)=34K=2NABPL=RY]YJ*;HP=&>& .UI*W_)(Z-*42
M_@)4N#?R Z/ !:A5& YM^TJ  Z(^4G7 H^B;W=R\J%*W#DV$GV)^/1'L*/#G
M^L31BO[U5+5="+#O(]Q7"[V[T35UKU;7NK=&N^YX)$(IU)(@",L@XG$.<<89
MQ!0)IA:'6*;6Z\+14::V FA!JXK.RQ4PLCH6&C^.YVEN]X+2P"R^ ^BJ#5"/
M&JW'D;+G92^(C<3 O9%SXMF3B'0PZO%[1^/.D^*W6?+TQ>Y\: +/=WF:W\6Z
M3B^Y)N7ZTT;,(I9RS ,&*4\P1"+%,*=I"!F6/" XXIQ9MV,X-=C4V+')(E.;
MXX58ZW1%+NKRPEI^77B8K$%1@B<E/^ ;!]X\B?MI^O2)YL L:D1]E>:MI-UE
MZ6F!P2>O\-ESJD\81Z+6<^%T8EA;?#J(]N0C1N-;6V7:M&M]3S^/]\=EN2[K
M=F^+4I3;RFRZQ R.$MU;+2,0T3!4!JD,(,]"AI.(D#C*7=S7QP::&NLV\KFY
MCH_":.<']@'.P"1J1-RV^-1"#E+@[A027MVK1P<;U5=Z2N5]Q^?)ZWO6H-*E
M#B[9/S=%Y2+]M'PDQ6)&:$)%SC&D<9A )","2:B;SV.>*Q) <9 Y\<#A8:;&
M D9*T!(3_%X)ZGBD= 14.U8X'ZJ!.:$'2N[E<CI!\%L>Y_!0XY;#Z53W3?F;
M[JO[YJ!ML]W(8[&HBIW7S12NY/6RK,Y-=!G&2,9A&$88\E3MS%"8Q9 0!6Q*
M(R(XC9AP,Q+LAYX:8312FEI<M9RFJLQ%*TO7]'BIU0*_;)[ >ND8F.4P-W8<
M,PSB _/.JR3<K=@7H#T)C>B>JW>YX^4Y1\YZ^)'SYEQA>9M+Y_R$D>.?=<7/
M]4LK6-L45[E[((LZ1NG[<O$LRK7@>Q%*OZI'KS\I/;Z08O57,M^(F^5\_F6Y
MTD^=L8A+C(,$ID37-4Q"!BEC%$K$!$HC1O.$.F763$N_J1%U(SO<AD :\:&6
M'V@%@-%@5\=[I,C9@=XNNU5@8E)/:*GQ$(E;8?0J2:@J1*;#&W9QNEND#D3I
M&K3 _BLZQ/Y[HF_"-.)[!]+QWR,.>-@)]A8O/+"8_6R.3T(6"\'KNB&ZA/AV
M$&7;J']63:9F219%<8IC& <4090AKO93)(0D37F:Y3*.4(\RTY:CN[#N>#E/
MAN^>#=_IK97Z6UV4<Z_RM.[2Y[94VTY*@%'("990YESW?Q$4*J$Q#$B$11:E
MF4R(:\;28%,R?,91QX34M:B'FPH4A%P*$<&4!T1-199"S ,)@R2.22!EBG(G
M6WF :1BE#L:Q*1@&=3L;<@ L![;M:HE!+;+IO5%UX-BVE+Q\U*6D_9E7CB!Y
M-7MLQQ[5''$$9-],<+V]Y_)=5X3^=;7</%4IVFK54;]E504PP;<E&XRUL8M!
M;\+2"Z$6=YG*.*<)C.,H@2A-)21Y&$$9<I&1B&61X+.UB3JT^^!\2.5$;5O9
M!@PN,#&QU?YHL5S 6F(PWXGL2')>YLZ2 L>>D:$)LJF$;A2Z %N50%NG7;V2
MBWKB6MJT,WX\TJA/H/V2K!?)QJ5@GV"^(6BO#^]'W]_$/9F;4_/KY;Q@+[L:
M-CA7QGW.* RR0)GV:19"+),<RB"F(<J1$)*XV)-'1YJ:!6D$!492-SH]CJ4=
M17I!:&#::X&CP]JTF.#W^O\'*=QS$A2O%'5\M%%IYZ32^U1R^@;W .0;\2P4
M"5V+E5RN'G5:SA6=%_>D"K S7B7=7M8X 7(6JOU_EB<Q1$$N($TQ@FD<(1)C
MQ@*); .1;0>=&FDT?FW=]MB2-IPP[F:0H9 ;F$QJD2] 2VBPD_IB>UIP-Q"J
M]K'(0Z [4DRR)Y2=0I-=X>H(4;9^U&BARJ[*M4.6G>\]HRV7SMV[%<ID-(9B
MD](D,>-IFD,41NH_"5-F'0D8Q")FG$289:%5ULC)D:;&T$;0'OVI#J)H9]!Y
MP69@#JYVI28I=_<F#M%3Y"08_ILG'1QM_$9'74H?;$K4>8.O4[:F;<:7S7JS
M$I\?G^;+%]T/:5$U+S+'@<J*_**VHV3^/X*L9BP..=7!C&H+J$\82 Q)2 7,
MLX G.0]R3,\\87"6:6HDTT1E<<"6CT]D\5(5MVV$UX5/%WJ7)(T&7DZ#W.>Q
M[YG%H+/S+N<9V]8QE4J@T0F\4DHG<:DYJ_0"_],U9QX./7JC//"!B+M<[WQ8
MTAO(TP<I_1_MQM[E:CW[J$_9Q.J)K-8OW]4;?OFS*&<X)@S%(8)AD*<0<4D@
M3217$\E1&@D1!*E5JX-C TR-5]LR BTD^%V+:9EQ<A3&;B;T <[ M.:,BS5!
MG5*^BVW4O2VF4?_:9YFC#Q^%,DZIUGS_)Z_K9XI=KY9,"%Y^40+=DKFX7/#?
MR%H;>R]7\C>R^H<PG2-W!N L)5&0\5@70)$A1#&+(4TIACB4-,I9F@;2J;&)
MLP13HX-&@:K5FVX\K(,]'K>2@W(KNIMYY3XW=L;4H(@/S#&OP=;2FU371GZ-
M_$X#<'L:>6<CJ3=Z7DTB=RE&-8!Z@[1O[O1_4)\2@5*L5H+?D9]5-,KU2CR1
M8IN_.\M8G$N<))!E#$%$N%![SC2'^E@AS0C+@BRRKPG8/=CT6,Z(!X13VKT5
MK*>/$WR"-?S>SHAJDMZ:Z+0&/+>:!5;@N53K\P?B:.7YS@'3L1*?'3J=I?=.
M/&+$6GMVRKPNKF=YS_MT,_FK206HJRGH[>[=4O^J+BJNUX#+^_N5:?3[5>]\
M%V7!3'CA#,4<Q1G/H92"0T35]I3$,H8!(DF8(Q&)S*F^][MI,K4EH5+$V%]B
M)[SN;ZR[7(C]AA?C=K;H_[[8&='_%F_!P&N=S^X7K9=IZPA=+\VO+T +E0NP
MQ05L@:GR[":07.=K<J>11G>V-O\>"7.^)LUW*XWS!7+? WU4PQ<+,O^+(//U
MP]<%J\^8LPR3*,T2*#&2$&4D@(3H!I,<JSU1'-!02-NMSY$QIK:\-6*"2LZ+
M__Q?81K\MQ+WS_;F^S$X3V]Y/( TM+OW-3XZZ+Q'O=MC"-GO:SP@-5KPTY-Z
MG$DLUV;1(_G[<@78IEPO'\6J,9;4GTT#COW7#W2^>4Y[G1.(=6QQCMTYVL[F
MA.CM#<VI2]W(D6G?^^IE]N-V%E,D11JG,,W"'*(\P1 SJKA0!$&$U5\0L8I:
MVCUR:M3W8U%L>]A:.BM:^'236S^M!^:R']^_WGW^!&[O+N\^WY[_D;W5\8!!
M5PKVY_OE\W_5%U?V7/T/8\J9KZ[UJ%$^LK>B-]_4@;_T\+&V$DJN5TN^8>MO
MQ6(;RI;&DA*,!8Q"JNN4"0EIQ#,8DARG84XIY591/:>'FMHG]RI1JQ87&'D=
MG(7=X%KX6;U!-K27]2A:/4R0$[ Y>%B]P3>6?]7]I7-SJEH!TN52[7[ > Y5
M*T5>N5/M[NCG3/U-D'*S,GO(KXNGS=H,IMBYU2TBCT-!,TYAD$<4HC2((.%<
MP(P*E(E,\ 0[9<R='G)JC-J2&!B1+T CM$/W$@?([1R'?H$<F&=/83A :+8]
M/EZ=9!;#CNK-LH=AW^WD<&<O^\TI3?AVL^"KEU:*\"YO>"92$:2,1##/LT!7
MKD\@#1""4F"2X8 (EEC[E#S*-34>\U!CP??,65F2[S$?PYN=O>HL5-HYEUL8
M= Z=S-KWF,OQ;. QY]35?O:-?+>Q[6VT,2USWQ#MF?'>'^^^ZFYK+G_?Z/7[
M2MYN:%GP@JS4"%^*N?@BU(/(?'O=C5AO5HMREG,A8IID,*9$0A3S#))8[0($
MQR%#>:S>@<!VB>TKQ-36TTI\[6XO6PH J30 LE*A70I^56FALZ4^D@7AY +\
M^//MGR_,4?724(%<KD1QOP!_WZR*DA>L2J_Z9;D"C^HO#HUQ>\_SZ05YC-D;
M>/7=59-73%M-XI4$;3V 5@34FH!6]?E:F1%FPGY9'6-&1EI#!YP9I_7R7$@[
M%L?>CQYM)3Q7^?:R=_:S^B8&MQO\WJ@Q'DTHQ+4)(+M:-)Z6*$ZR.).16M8"
MW>LH#R )HE0GHD0X9R*+PM M^==JW*FM9&^Z5^\D-P4VE.Q ">^:U&LW!W;>
MK@&0'7J/9P?J )XO1ZP\I]C:C3UR&JT3(&]39=UN[]N8\?%QN;A=+]D_/I*G
M8DWF)JBKO!&E6#T+_F6YJC)SOY;E1M=8F64H%@&.(DBI#"!**8=Y$#%(14IX
M1G@:!4X!R<X23(W'*G'!JI97V]- 5DGP12TR^$79WZ6YSK$3D_O\V#';H*@/
MS'&5[, (KR.-C/B@GH:;]C34M0@:'7SVC^P)G^?&DJY2C-QQLB=(;UM1]GU0
M/U+48:A5M.M\OOQ#/_##RWZ"B4EZCT2:14(PF*),67)9D$*"!($Q"G"<*3LN
MBIR.*6T'GAH%;N4&6\%UY/S;!"BG6@/.TV%'?4. /##C></7F>A<P?+*;]:#
MCTIKKI#LLYGS_7W+$9-VA^@,QY+Q/()I(O*J+#S-6 ()39A 0<"S,'6K04PF
MW%Z[DLZF=94-=G:\TA^1@=G#'HP>)84/Z>RYCC!YMY[9A]5[6S'XX%5GML7=
M+WP=)P%6&RP$<102B&220<(XA['(<L((02QTVG<=&VAJG_+.V^I:@>0HE';?
MLP^ 1CQ3&*."^"E(AFE"^Z[UPT^I?+3!K)_JX<UC+QG;/&[FNAZB.:G5.7DK
M\2 69?$LJC%UT]IOQ4)\78O'<L8H3IE($HCCD*FM"4UAGF44BD!M3(C,.,JL
MPI/Z"C U&FG)7X= O-*@.=3Y12OQ)_"[U@,811Q-!^>)LB.C(>$?F*0&0-Z9
MN/K"YY70G(48E>CZ0K1/@+V?XQY8<K5:/RP_B=6CFOWY\KY@Y:VXU][R^I"'
M)"F/P@ K:TFWPLK3&&)!,"0!U@T5,..$V<:/G!AK:G1GQ 6OY+4/'SB%:S=E
M>49K8'8Z !2H9>V1C',*.?OX"H\(CA1&<1:23H$2EMATQ$.<>L)H80^6JK2C
M&VQOZ5GIB#T(OIF+*[GM8-SJL&"*/>C\VO*2K8OG8OURIRLY[+96,B$8B2R$
M/$I297:R0%%NJ*S0("9AAN,DEE9%YOR(,S56OMT\/I*5J?.H(^(K?72!H4:A
MNLS,S>T/0&J-' L/G3=]=L;H>),R,/DWBN@)V:K2;NY2SX?1!C3J@-^-0L-L
ML?U@Z[<"SWDBC5M&QPM\;VKA^'FJA[:P'^>D+ M9,+.8?UH^DD+9$300/,<$
MYD@BB (>PISG"+(H)3%"..:!4R.:DR-.C5=?9T& UR*#WRNA'3?RIV&W(TNO
M8 [,AV?B>%Z#U2YLAFN>>G#4]VN,V@5"9]/3SAO=B(>+8O;9U/&YY%R]7N7U
MLER3^?]7/'U<<C$+61*D>81@1-,(HH@Q2&**8(;#.,=9$G"[.L+=PTR-8BI)
M02VJ=K=K88&2%FAQ[;CE!++=A.(/KX%9I"]4UO1AAT1'T1KU $,7_T3Z1UC]
M:#CBQ*-'(08[]1HVL+RZG^U1]]C3]<M-2Q:U*?E;L7[X6%?]VC]8DV$L12P8
M9#2@$!&:0YK$"92QS!,N<<A"IW@HM^&G1AFU].!&L.6],@\5+[N9(([HV]DC
MPV$Z,*TT<)K>"8WHX \E.VB$'_;TLQ]R7DT71Q%&M6/ZP;-OU/1\2C]Z^YLH
M[A]TE=)GL2+WHDD7^E3,-^JW59#IU6:M^'2A$V=G*)<L#(($XE#WBDI# JFV
MA"2+8A)A$L5NC=P=QY\:P=5R@C]J-2"I]- =^W2$=A7QWC_XW75Z[ AP0- '
M9L!&<E"+#G;)P'7T>TMN7>O&:.2/ 'LBYY4!7648E0)[ K3/@7T?<T[$F3Z3
M;4BW6&S48[>E <H/0N>(;R-;1*FVEZ)<%VP6!Z$@B*4P8(DR^ 3+82Y$"%,:
M)*D0-!11CZ"T7K),CAQKN?K$K/6;##OZ&PGB@:GP==#(UB2L5-F5.RD!-<J
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M,(ADED%"20AEA"0/21Y&D5-^E>6X4Z,IO8@L%Z8!M$Y@%6N=N5HL><$ K90
M3&G1.V&U<PY<[3YOR YMW+534!6DM=# 2#U6IJD-5D.EE':._5ZYHS: ="2)
M6MWN?D9Y*YY(=01ZN>!?=48!F5]OZ+Q@5U*J3W%Q;\9K>FBF.,$9%3"(PPPB
MDF:0IIQ"A&(1Z5IR,LELSRN=1IX:;^V$KX)%KJ^JK\O^V,T-^--'F(/!.319
M[9"\-&$W1G)0B0X:V1ON<C[==(/9_J1S,+A'.O5T@=W/:6<OQ#I./MV>-]HI
M:"\UVR>B_1[0TUI5KYEQ^%S)CZ1\^#)?_K$K42O2*,(\R/1Q: 011ACB2*JM
M=)AG.<(DR.S(WF:PR?%[(ZNVH;2TP(C;N_IO)]"6=J@G^(;F\_[(N9N;%I#X
MM3&[!AS7L+10_8TU:7-/GP[(NGQ)H9LEE*::"5NN1-WAO=Q/*$VSB C"4LA8
M&B@+4G*($YE#EG"""(^E1%:!R*X#3XU@VK+K+Z41VZ7UK0/LI^W'H< <VD/7
MQO'*E%R"6O(MH$[YN^>![-) >!BP1^L0_/KE/0]TQP; [LAU=OAU>-R(+7S=
ME7S=H[?'_3TMR(/G0:VCQ \ONTOJD\;+/\B*UZ=%?S65KY2E^_GGDV#JQ[NE
M_M7GGV+%BE)[.:I4Q9F,$2))&,$4<PQ1PADD>19 DI$\S8)<Y(%3 ,Y8@D]M
MX:GD-EX+L9,5D#58/P@@= M?:7ZL'+'],ZU'>S,LS><)SO>(A_QMI=LG_;KG
MS\%@ *UZ$P907H#6:],  -9+\^L+T *A:7?KT<@?>>+\;AC&$G[<S<?(4_)F
M(S/V^#T;8:X$+]9?"-.=[U],T*.,\S#-*(5!GJCM3X(S2"(1Z4 %FJ1AEL6!
M4PN%MT-,;;VI) 2-B+WB1P\ :4?ZY\$S,#T[(N/>4/*H\GX[1KX=9MR6D$?5
M?-/S\?B5?9-+N)#%HEB+;\KBYOM)A!]>?B-_7ZY,-M&W;7..,(Z2,(S4UQ^&
MZC^9C&'.TA *1'@2AX&(*75+.G$78FHDL=,!SK42;W-YSVB?TFN6[/AE:.P'
M9B!?L/=(=NF/F^<DF!Z"C)P<TQ^JMTDS9SRK'T5^7ZHQR^)^H9NWU*>L8<9B
MD@4!%*&.(HC4M.28IC FB/,P$;K2HPL#'AAC:@3W?;D&G[8R E*"OPA^KT]8
M=S%I;JQV"%@[TCH3KH$YR08ICWFX%J!X)9Q#XXS*)QV*[M-%UZ7]V.#+<?+9
M4<]W]7;4Y="1X#'& 8(A276#2A9"*O( <LRP2&0LB'#J,.LX_M18I!(??CN\
M5E\ HT.=O:ZUZ%FFWG66[&AG0.P'IB3_L#O34T_PO%*7JPRCTEI/@/8IK^]C
MSJR&7_^?-KK"6<SCC*%$ZE(PNL]<)F&>2 HCEO- DBB5=J'AG:-,C=KV"[S7
M/P"S_;A:]"V&_PK8;I[R!M? ;-0;J?ZU\ \AX:<4_JLGOT\E_$/*'2V$?_#B
MOG7PU\7*>*NOU?S>/BT7Y7+U;?FJ'0Q'F.(\SB"-L=HIY6$*"4<1))0'A&19
MG*1.9?LLQIP:,>Q$!EIF4 L-&JE[VC@VZ-O9-9XQ'9@]SH>S1XU[:X \%[8_
M/>[(U>RM@7A;PM[^UK.[@7\23RO!BNK9XFDNZF#DR\?E:EW\R_S^>K5\$JOU
MBQ9GK4_2_KDIGK1\LYQPG/$HA:G (411&$,:(0Y#H3B,JGU<@-AL(>[U2':L
MY4LTJ\\PKS[#MH##?8WM/M:\I5KO_N#G39T=X8TZ'>/W$V_K= &V6IG0A[9>
M%Z#1[,)0Z?JBBHYHU!NDT[@7P(?J0'Z><._5F=P+I!T=R_T\O[>_C2Q8L;B_
M$4P4SSJRX7(^7_ZA6TQ^4;M9<R"JJUJ+.BQ0_?+'@BWG<\'69NO[N-PLUN5,
M!C+$,140AS*'*,PR[8A+890CFB=4)F'J5%;!EV!3LU:W2@"I74+5"7^EA[,/
MSL_,63OG1I^/X;UVE4I@IY/:+1^?(-U5S@0MZ[^\4@[4V@W;"\KW'/AV_OD1
M;FROH%=(#[@+_3Z_9Z 961!.ZC97E_=BP5[J$T$<XD#9XC%,>)A")!&!.9,(
M$IK2)(II&B>)4[S9L9&F1L25H*!I\%:)ZAAU=A15.T[U@M7 )'D0I@&.5T]B
MX3<D[>AHXT:FG5+Z38#:R1O.2-*@I^-EZ7Z\[!=2K/Y*YAM]!+)YK()GMS&S
M8O48SJ2,9)CR &+.$$0D#B%! 58F8AYE) EEFK+9LUC1I5-BQB#"NGQW;9$'
M].4WH?2O"B'."RG +R^"K'KE7 PST0$2A"9!#@71_0K2/(%YD% H$R233) P
MD<PY_^;=IWF<&D=5S\D-F0-3*G9J4VNWG$UCP@9>#SVDS&AU@=$7M!2^V*7-
M:)T]I\<,.BW^$V*&$7?\%)A!83^8]#+LB#WKI1>$ZHCZ0I0?ZY95>8!YH/U#
M.<TSB+C4=:)R"FD099'(>(!#-%LOUV1NMUB\'<*)Y+<##4<<=WH,4/<,4BOX
M5E['2NEOL;1CY_,0&IA56\)=@(^^&W(=5]UO<?2WPXQ;&OVHFF\*HQ^_LM\7
M7K-)>2.,1_MN>4=^Z@[:#\NY[JCU9;DZG)$WRQ*>1HQ%4" A(,JR .8XX#"3
M29JQD$=1RMW. ON*,KVSO\9L6$H@'I_FRQ<A3.?Y6A.PUDTDP:K24^?:EBV;
M@VAB=^26WK-HQT"#SLPX/%6K<&$ZOK1DOSAL[^V67G]D=BZ*7BFOMS"C$N.Y
MD.W3Y]G/ZU.%<U&HQPIE/PB>_#D)OB_7HORT$=^7S\8!I"8HJ9V/), T4YMQ
M*$*10$0R":F( ACC/,B%( 2E5C'QCN-.;5>MI0W^ U0: ",W4(*#1G*@17>I
M$VD_ ]U\.""N0V]^*RQKL8&6^S^.(=NK%*<]Q"Z%. >!>K0RG#XA=ZS'Z0Q<
M9S5.^Z>-6(O36<77E3C=;^^[A6Z:'NH:?9NR#D#%:9Z12%&],I9UM8B,0ASE
M''+U7D689'DJG$[O#@\S-69O]=NLQ.P9XGL$5-O]]+E0#;ZG=D:IQ\ZZ"P3/
MN^N#0XV\P^Y2]^TNN_/JOKT'R_*CZ4ZM3__4!MX4>I]A@J( 91S*5*00\2"'
M&$4QI#F2DHLD94GHUGWPT#"3(P(E)7@E9MV\P+G]X$%0+8G@;*B&)@)WE'IT
M(.P"P7,/PH-#C=R%L$O=MWT(.Z^>5%W%J\VZ7).%WL=>WM^OC*/KZV*]*A9E
MP<PAP2R(<IKA1,",LARBP-2GD01*',HT2%'PO[E[V^:V<61M^*_@R]:=J3+F
MY@OX]GQS'&?6=V7B',>S6Z?F@PJO-G=ERH>4G'A__0. I$1)M@10!,4Y5;L9
M)R:)[JO)!M#HOMH75HN.LVDR-7>VQ;RXH=!35)WOTB].@G+1X*6Q.$*>^JLP
M_1-F,U+&#BH78(T+6 -3GU%/GJ?1W+A_!>)& VW^-S YFAMM)&I'"X%.[?O6
MM&FZ)?-F>U#=%-<_*:^J6[$^BK\5JM2C)A;8Z4I&2<HRG' 89)A!Q#T!21QB
MB'F O0B)Q,-IO\YP)THVM?FTV^9L54A3"?4G \_R*LNCL>&L9S@1GL,FCB>V
M3XI:3,+?=IM3(M>5<?I84U7+_:N>HMHK-DJ#O "UUKH7@KJGY9\;I5O=0%9P
MU,_N5.G.U/%N(%#?[XDWU !]6Q*7^8L<]H5OB,FJWW!>J/W@Q]>&M4P?(BK1
M'O/GCZ\W!5T\\74?EK: ^^/K6P^[RZM_UY$*$6<A09$/$QRHU.HX@-BC',9^
MY >")SA$GEU3X[%$G]J<L1&V0R<G5])*>?!!J?]+OQC3B&^#V10S31L[GX-.
M-V^/9LUC(SUPN^?1Q!^Y8?389MEO.3VZ!/:I)[]__RI][J)4+WG.JV]Z%/YE
MR3;G&^V9O!]&L1<%, J8W)@(/X59Y"=0,.R%(B$!148UX%:C3FT"D8*#KN2@
M$1U(V7\%&^G-TR+,#7 \[\0)K(Y]MBFB/3).+-YMXWP3)Q"/E&UR\LMKE6!B
MC=2!]!+S9XV67&*M7C>UQ/[F$QN\UDM'EG(2(>FS?4ZI.D=&, M]#U*54<(I
M$5EF=[:S]?BI^>I-*])>2_H=[ PC.[T1<7WN8 Q&_S:L[A:I.T.<I]7JP<7>
M.U?9?;;5\KF<75W"_[J:H8P')/0$Q+$O5UOR\X2I%P@)$/9)$N&$A$;][C:/
MG-KG^5\K3C@U^R8[P!S^#ONIZ_C;^Z\_KC]>7YW^P>TK=X"%55U<?V#J)_UA
MZ4^J\Y!1/J-]H=M/YXW?] W%Z=!S$P]4\;YOO*@4KY8Z"E"Y^QT^KD-1PTVH
M<'U*=.C.6>PQ%"0LA=1# 42AG\GY5'ZS?I1@'J281P+9!>;.H\C47$.7CX\T
MIP6+M;2VD;DSO1RF<;KIF_S,)T?=M\'B[.CBR(U#1@#/:\.!XX%G4F;DZ.!Y
M3;8?*SRS/#W;._$?\NF*PRPO'KZ5BT+^2/4RN"$\V^V1'A"6^3R1.U OBB!*
M$89IZ(<P)0C'8>S1*+"BD;$58'(S'6M(?U0;=?X#;)11:?T%LR_SM3:)V3SE
M$FC'\\L.KMO"KUD?G7([]D5OV-Y3MD*,VYBJ)T1[7:OZ/J?WWH.7)6?W^&?M
M=F^7C[R<)9GPXB@.(,.IRJ(F$20T2&#$0A%Z4<A2:M7H]^UAIN;-M%#6R_.W
M\#->/)^(BONEK190,PJTR]+#*/59?1X 8>BUX5M#C;UR.Z#N&^NJ0U</%6]H
MLTT_KY:KDK>_:(@$_IOC\G/^PF?$BU+"(\6<ISCT$I9!S$4(<<1(X"4)CV.K
M,JZ><DS-:\B7+3YU3V]F@+Y;\L%A/<N.>ETC4*NQ^6U+>Z(T 4H5EUMC*RP=
M[VS-9#GSQM0*L./[2KO'C5R]]A97W67!?N?+QP5;S!</KY>DTFR:LT1D2>:K
M9EA9Y$/$TQAB+\M@RG"8X9C[OF^5%#F"S%-SO+6(NGX(;V0'<C?Z(O7![;ZT
M2TYKFU@_PHM@># [+?.Z/NUUQ6.J7Y:.[N#/5OLA#Y3'L]4TBL8LY/YKE(?9
M&V*P0K >0_?(FLR7U8KDU6-^CPOYVV]2E"=\M2B?54[/)J\L3J,@10A!1E@,
M$>6^:N68P0QY 0UH3/S *.'&8LS)33)KL4$M-Z@%!QW)+5+Z#($_/"DX@M.Q
M4S=!LD^6I"&D%CF2PT,[5H;D(!#;I4G:@74H2=+P2>.E2-JIMI4@:7EKOWW*
M=4.\^IV7+SGE;\\Y7Q?%2UU5K$E7-=-S]_=7BVKY=;'\;[Z\XW3Q4.3_X6P6
MID$@-R@<4IID$#%"I<]'!(9IE&8\#+P0)3:[$V>23FVZN..*1DF=TZR*<BTE
MH-U%K*+/*"K>)<<M%@5\:>@0>G#CNGL1S'8GDS#OB'N2-SAT+\!:OW8+HA12
M;(C@E2_!1J>+IA_;<!L.Y_ /NLUP)^VHFPOGH.]N*=P/V/<X@2P[15V<\7K;
M\DU3 #6TA1G%'J9R!L&!HH6@Q(?85TUX_-#'+$YXQ(C=V<'Q0:<V-RB9.X6=
M%V C]@6H!>_)%6ED M/3@V&!=7Y4, "F/8X%S$$:^ S 8."1 _[F4.Q']RWN
M/978INE5N7%[-X4^3%7>L>2/*EU-%:>J^E55X+I+:Y,RD08(R[5PYD.4JE1I
MN1!6*6!>&(4X9IZ5_QI(KJFYN"ZI#6ZZSG:6P7D!<">I=:'TU&OCM:)@+G7L
MRWYSFHD- _'C&\[UPK9CL[93\-V6S;1:8$LO4"NVS4K@FN=F$,0=L=R<)MN9
M.&X& ?1]AIMA'C\$%?'K5_[C:H[SI^IS/N?LZZII+^QC/PE"& 8JRA&& 22(
M^3"+HS!+&"9>8E7_8C#FU!RVZOPL-[+5*I=?O5!RGD)._#;,9HYU8/ <.\T=
MVN+7"YW^7$L,M,CR7[30KFB,#R+DD-/X[7'/2'!\$(C#;,>';[4L?BV7LSL5
M#;K\F5>S,$@#EF(!$5'MA(,TA!F/8T@)0IF@:18&W*C^M?O4J3D/532<5\N<
MXCGXG>-J538EVDI8PRWL-FR'745O,%ROH/KA8%XX^Y;>ASYQ>4/G\Y9_V_VT
MMY\X3B'M6TJL:VG?_*7]P?8W7"T_K7B]@?R\*)M4>K4$X?F+7E\L/O*O_&&>
M/^2*%B&+_( *%D-.LP B/Y*S/T[E9YMZ+ E%RD5B])WV&7QJG[.2'[!52]X-
MQ*)4F[=&]DJ=4Q .BK7\X,-<E2TN'W%AV VZEXF.GX6[!-ZQZ]"8JUY)WS:8
MM^*#C?P-]AL5'.)M?E#N$O>13LSON-R)5"IWM*:M?^,3^/&8TT<5MUB',]9?
M!"Z[W\.OPYRH]T7UP-&Z]2-'.V/OJVSWL+WW,WJ&%%>DXO^SDN_,]8O\HTDO
MD0N^,$WC (81IG(OZ0FYX.,41H3X6&XE,]\W(CPY.,K49HR-D$!+:1FX>Q-(
MPS#<J?"X7A+N(#-@UHT1!,-&N=X<:=R8U2%E]R)0!R_N]]5_SHM\R;_D+RJ*
MM92F5IZDKLGZRI<SYGM((/F]"U^%DFB 89IQ M.($1QSS\\BSZ9E_.'AK/S
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M#:<,(<BI'X9^R /?MW+#;P\S-<^JA%-5=\^U>':.]!TDS7SCZ?@X=G=K 2]
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M^;D;2UN<M)_=XB,MI2$$<CO-?Y5_@JTA ?^95\L*"#DY+A_S"O"Y5OQ7 .%
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M.SF_HQ?X0\\)&\W>R-&_ &LKWAVRXA!-ETY#W'5/II[2G;METVF@&G1T.G&
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ME7M3/*^6,\0C&J3,@RSF#"*.8I@%A$%,$HY%2((,6W4E&T"FJ3G2S^LF(Q>
MKG51/VZ4Z?8HN=";T9Z53$/8U,ROCFPIQ[ZVU09TU+G8' ZKXX*.1A=@K=,%
MZ&@%M%K#^=T!,1[4%P\AUZC^>4 @=WWVD(_NV1YV>Z;X^/H;7SR4^/DQIY<J
M@7 G["<R/TD83F!$?+G.31(N739-812EPN<Q8AFS:R%K-?S4O'-WF3M7+>GG
M>HG5K&[)*WA8:P-*_B#-:-F4ULXX9K[7'>2.W>R7#<*7:X0WP@,MO=.E;#_H
MANV5:R?"N/UT>\&SUW.WWU-Z<N]P*ITI4Z4D37FA1ZCOT2R B1]+#X=9 DF<
M>=(.410SZF<TL:K.W!MA<DZ,%W4(3<L)OBZ6W#)!>1_$($HSN;1/(*/"@XC1
M$.( 4^B)( N#( @31F8OO"2+46#LCN02R!I!)>.I )JY\I- <7W0V4'#09GK
MNZH/RZ"R-\JX#"CO*;G'8/+NA8/M[N\X73P4^7\XNV%R[9F+'*^)=MNF!)<%
M^[()Y^EL%-6IX$5>ORA?9TF&$*6<RJU^(+U"RK@Z5T(P0B'!/(D\SM")^_W3
MI9R:>VX%RVV]LAL;]M[?CVN9L^SX-RJ"KH[M:G7=ST6%O3MZ@D;1"[!6U6D4
M8#A+N(X+#"#IN2,%PX%M$#L8<+">R^EUVD-;;GB/?S;C;XV[F^%'<)#X%,',
M1QPBFB)("!804\("1@+?YU:1X)YR3,WW=^,+2_P3<"$X76Y2B?(E?ZI *:U>
M,AUW *Q15U_^SBF;^KL**=?!8SR?+WY@^7I;+EE[6MIP8>O>?JZ7OQW3M3H
MJ40[&>S. 2[#%B>B.>R*NJ<LXZZ[3P-L;W5^XN/L,Z\OHU_#)*IW]GI#SU;\
M=]5<3%K%:[:8(A 1B>7V7)$"0Y3X*4P1YQ#[GA^G) I22DVSJ@W&FYIOU1+_
M#331#RTTD%(#+390<ILGU9K ?=CQ.0#1L8,[CM_Q77\O(,TSCP<&=*2LXB&
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M*O^:L2B-L"^-8\56:#7\U*:"M:0 O^!\WN0V6C(2VAG + #C#E;',X 27 5
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MN$<VMYDKG:X172=-**T@46J!KNJ@H[ONX-NYKM$?:  NVA2Q#@:@9G)82A1
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MJ^2E%*<"(B:W[*D0BFH<$Y^)#,N)S89[=S!81R/2?2C52N]I38 S(+B&L\Y
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MIQ++BW[YM:7<DX^5(U:+N7I"+A^?SU_58?#UJEP\<_#AVT):0H[S77J)'%^
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MVI_P;GB1K\KOJS6OY#GLRX9_Y:3<X/)9+E76=DLE)&&,AS",5;.46"Y@RG$
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M.O]^<WI[<?G=,HIPY"(9QA*F@WYL:_L> 7B'(WRD@*<;_-S&!8Z4:=KH@!L
MW\0(' T[S,!^Q7GY=U5'>E$\;M;5-_[$EV%S) NRV L2CT(2^UP:3_F/-)2+
M&' _%)23E"96A'\]<\W-,&K9_N?_\&/O?X=VQK /4#-#YPBFD8V8DA)H,4]
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M V)5ZC\_MHK45')21_#,<6EQ(G&TM(?/FM,OV,B;QHNU4M>]G[=KI;A]6ZW
M5BV@] ):L::CM?[:5K?)%\W\U#C]XDUT2)QN$:V.@6[Q[CGU.9IHLD.>6V"Z
M9SK'(]MOLDT_X^J:4YX_Z5/B4IX8%2W%UU794."TU#>G1<T\O<""TC#*& P#
M)B *_02FZH26)$3$0<("A(A%EM1@06::&]7R3/%&7'T7K?GOS:WML(4YO"..
MA_-DA/=U<&RG@#PTM2HHBJ\MS5>K!9!JU.3X8\-OOK>-O@P3;67C+(?5MG44
ME#V[U+!Q)]N4CE*[NP<=-] 0)I&*ET]J[+8JZIJO-V6Q;0%*HI!F"881]QE$
M.$[D@8VINB7NH\S'8> ;E7H:S#6WDU@CG V51#^6A_<#APB-;/D;2;5-:64%
MC; #"AL.06?#M>$,PLENJ8Z!TI(RPPB<7F*,_A$FI+\P4N4ER8795P9FU6IJ
MRO4VK;?)W6U.$76[YHT\.C3Y(O*DL*5RB%@2A,CW8"2D:45R>.G!)R$,2!K&
M@C,OI5;U],-%F9L-;C3YJV6Z[?"E,+L/F0;@D4UXHT2W7*'1 WQJ-/GE!.R4
M 3MMG))WN /5;?KN<'&FS>D]&K8WB;['CVCOB+Z]\CA_>%RNGE5KK6)=YF2C
M9OH=_\P?-@^G=WP1>((F*160XHRHULD89CSAD(4)8C1E7H",F>QL)Y^;F6RE
M!;0C+GBHY07XSH(/S7H=#GNU8Z+[(=?"6[B[\I^ 1@-P.BK>YJ[PF+A/Y!L[
MQ]_*71X*8(__;#WD9 [U4&6['O;@,096BS3)UCE7),Y=ME6Y=RTW3.Y1FJM.
M;UB<;?>K9H/;<<_%&'D>1I!Q'$'$> )3G\:02^<;1S$.TM@JO<F17'/;94XI
M+3>*SJK8-I!M7,CE3F%+5]W5$IKY[1^P,&-O4"^8H'7KI5H/T%5DY[KORE-R
M56#<G@'&\.<=@^VV5,61;-,6K[@%]$TYB^/ACVN[\7557G,YXH:N-Z6<>L$I
M)](6^Q ')% ]-V*(F4BEI>:$4NI'$;&J1]XWT=RL[@OA@%W!P4%0S<RF"ZA&
MMH/;#ALJ+^J%D.Z;:^R#893.&F\F^Y"V&OM4WM=38^_GA]+I/3RLBIOUBOZS
MN1 @U$>4L0QZA'.($M^#.)+.FTC3,,E0P!"R<MG>S# W,U +"&[N<6G/I_<:
M/<,HYS&8C!V\;.!0PCF\)#FHNF-6O=>S3$RKMT?)M[QZ^SXXE!/JB=>=^>H8
MXT53G+Z(>8!H2 D,XDRE,C&YVR/5[#!)21@'B(C8J)_]H8GF]G*W<JGB$"FF
M+4'3'C3-WG(7&(W\LN]$;"XKU#GG )_! &ZD?AP<$Q_MF6QB5J-^E=]2%AWX
MO'W8__=\*0=8%;SQ'*[Y4B<&KLYXN<9YT;1P;?8ME,09$[& ":6>L@_2-,0A
M5;P?6<+B2(21;QKSMYIY;@9C*SQHI >-^*HU<Z- V[K9/!9MMQB' _^C03RR
MO;%!=T"RBQW,YO'^T>">*-CO%G:K2/\@Z'K"_';C31;C'Z1F-\ _;(!CF$,5
MXYW*MG_OVKGNU+V]I^95DQ^Y\#T4QIGG0>:)!").$,P$#B%!@J0!SKC$S<Z/
M'"K*W#:.1JPA%*"#5L+4!YT"W]&]5)U'4W>MKOM/O)\\0[0NG;P;%8D_M# #
MN3Z/P70$JL]!XGP T^<QL+U/]'G4B /RNB]OSZYX*<=]4+GCGW'%F8[(Y53:
M:WV45ZV^VOS:.,))'/)4,2W[$ 5A"+- .M9Q*$0H A:2D!BG>5M-/3<#J:0'
M'?&AEA_L%&AB3EH%BP1GN_4X[%N/A_+(9M(*X"&IY'9(6V26CX;X5(GF;I&W
MRSP?!%Y?(KK=@-/EI0]2]$6:^K 1ACG96_;"W2ZU"!,?Q0&E,&(9@L@7'L1^
M[,&$"Y;%GB\X3FQZ%;TSAY75GZ!=T8[$,V^\N*7RXNS<Y/>P)"+V&:<A3%&2
M22Q1 (E *4Q"+XM)$/D\,LI2=87E!#OH:%B:G26.1&CDW6\'SHOC@CNWOT=]
MI_[\>_-,ZJCW*/K: ^_[Z)%F\R7I:Y,*L\!>XF4>HU @(2!*N _3*$Q@&H9I
MZJMR']];//&2K*S?^W<GM'G N]..]YP;Y0H.- GO8QY$* E3$JIN7*J(2C77
M8[X'8R%2P1GE/#.Z&W"/^'1LWVTZ7], QBF^EM;W:-0F,\1O:;L;:4<PRKVH
MC&.?WY_R8TQUK_I[K7;_M^QC(S>\R%?E]]6:5XGG?=GPW^77[R6.J#D3^EQX
M28PC&,0JN2A$'&)*?!B$GA<D/!)"&%\S'IIL;H:DEA=H@4] \JOG_<<)D&(#
M+3=0@IN?Q0\B?3C.X1*_D4V* 70#XAD',32/8+C$<J*8Q3&/HU6 PA2;GI#$
MP2$F"T*8*M,-.QA_9YC'_#4O\C77K98OY%-3W.6:!%DU73Y]4.[*O_63U-2:
M_B?'Y>V/U0)Y*!)^@J#O\P2B+ SE\3E*8)#%,4=AXE$O711\;>;2#9+!Z*78
MTEJM1S;/<CU".[=N&/!FWMYX@$YCL6OYFU;P.PWJKO GNAQ>QT6[RIP I0>0
MBKCS#X_"T:G;.$R22;W)H\!Z[60>-]@@OJ5=5OQIH2;E=TT=C>I>W>SIG$32
MLJ4QS!*B*Q*E!ZH801(4A!3[..69^7V<T91S\T-?EKVH,$)';J %MZ(7,D'=
MX-;-.99CW[:]@/'T/1B'T369X&G%VN08U^G(FP[AZXRZR0*A?@8GDX&F)'*R
M4.P5GY/--X_L7WW^$S_DQ0L^]986]J+81B>VQ+!JJUCX-(E]7]KM.(@51TG"
M8>I%'HP(1W$6,\&]Y)@&U@-DLG-G)V-IO:Y[WNK^&.#[Y;>A3:J'K)*9KSLZ
MZ)-FJ=5L3UM%3K9-*L"G5IE?U%)L]:D3VFK6:Z72"$VICP!VG*[40P3ZF+;4
M1T"WMR_U,6,.L[5_X^Q.59GS*K^K)S[]F5<+U8<ZY0F%,9/G?R3" !*=G.:'
ML>I*)'AJE<W[_C1S<X ;*4%'3/"G$M303SL JIG1.QZJD<W9 )2L#50_"$Y-
MSYZI)C4J_>J^-A<'/CV@R^FJJNHDV3M>T.?O&^7$78K3Y9+?->E/]ZNE'*OZ
MFB\Y^X9_5)M\72VRE,9IYG$81A&'"..L]K50&&"/^UX<$^,C\T 9YF9":KEU
ML\-:<E!U1 ="R0Z6C? 6+2P'KM#AX_4$N(]LCY0&H*/""6@6X5* 1@W0U>,$
M:$W M\E6P:)1Z/BK,=$I?;15L>OL>1R>?9T[!XX\76?.XU1_T7GSR*&&N:::
M=T.GXG8;JRW\.*4)1Q$DW%?W4TC S \BN4)(<1;$?H*M:$C>GV9N^XJ6$A*=
M/=[M;6GGF.Z!U,PQ/1ZHL9,!.ABUY:RG9:G:-JB?I062;XUJ.MQ<+;AS5_NA
M<>JN[IEJ4G>U7]W7[NJ!3P\S#J\#D4U5["E=YT\ZT5'QIBU7U:;DM_SG^K,4
M_Y\++^81Y7X(O9"ETG3X&<3<QY"BD 5"A(13;F,ZA@@Q-\-R?7YS>_W'V>T?
MUQ???SL!%]]OSW^[/KV]N/Q^ F[.KT[KG\'I]R_@XNH2G%W>W-[8&9U!2V5F
MDL9>@$EOBM2%6UM]O], [%0 ?RHE@-;"X5G[&!"=FK9!@DQJ^(Z!ZK59/&JL
M@;W*S1DF%>],H3JEM[G($<W2*&891(E</(02#%,AO; 4H2B(,4NC@%GU(Q\N
MR]Q,:"N?IG<MN"'[BXM%,;.2$T$]LK&TI]W=*C-">KD#3-VV_#Y"GFG;>A\/
MW)O6W0Z&'$B2*4\3TG2K?YW_:Y,_X:5BXCQ=G^&R?)8R_!TO-WR!@XQ)"TDA
MB[T0HDA=2:>"P0CY/ X)"OS(CCC39-:Y&4DEK79Q] F,[^2V)-8T0IPS'F5,
MMR>)!$2<^XJT+(!I1./0P_)_6;1XU'UDSPOV0:B_G/\#D#\!7)6*"=V]?(QE
M,-N>G ,[\D:TQ5/_<-[%$Z]!*S708CND1[5!R2UEJM',T]*HVH#QAEK5ZLL#
M/6W^6'*:-P'_,.49RKAB>DD@2I,89E[,880Q"R/D^818%:1W!Y^;F>_*!OB!
M.-MAZ P=W(& C.VQ=L1RZ'F^HZQ;5[([P;2^X3NJO7'VWON,_97WYTV5%UQ=
M:SR0)N-F>\.A^JU5.6M<QDX$N3K3/8 OBM,'U3'X4NS[BDIF5_9EX6&:\3#P
M($F]""*1"7EJ9C&D+* BRH(P\(UOR*<1>6X&Y91*&UWE2D98-M$QNM5!_;A3
MPOPF=Z+E/WS]/K]%'=DHM@J#CL8GNXOB-7BA0??^1GZE[I^>%Z!67/FN^[^I
ME-<^VNP>"_-\@/D]'A.E#]S>YQ7@2ZT/*)7-K_0CL+[G^AP#Q7+U ^0/\NOZ
M,<#%,Z@[M)\H#IPF,J1^RW(AN#SK4UX!7$I3(G^_>90/B%1^O6QN!N66LKHK
M\G]+X\+J:+R:2,ZKZI%4#QA]5E-/GOK]D_(0ZUD!UH_9JJQ_4&> 9@Z=O"L_
MD*_Y@_KL/J/U8G(Y 0:D?47H;M5_=9,/,>WSU),^,9$@DV5;3 ML-SECXIF'
M<C_<<+HI.9.GGT@7/'_9\/^S*;A\,-*F=(ER$@@O8_*$A%70AJ40XR"%7" A
MOQ=Z:1#944 <G'-NS@[Z58KZ'Z!;@:\K[Y74JO ^M>4P.(SZ81=E!"S'3@2I
M\6M$!@VJ[\ YF!OB,*ZV%!%.\9V6*>(PSB[Y(HR!.D@;<7BDB=DCC%5[2R)A
M_M5A :WNWG%:L.^K N]^<RM_JK"N)=O6H09!P *$84J)IV)>%!+*,0P2Q*F7
M(B\)K*C!+.>?FV$_6RVE-BNUJ3[Q[J%&!Y*[_WVIF=O6<GL&+[_TYY?5 \X+
MRU(4VW4S"[B-N!IC!^\G6 CKD-Y .)U&_6QEF#0P.!"@U['#H</8^[Q7N%P7
MO-0Y/6K ^_RQ?<,"(L((>P&,4T5/JU8#A]R'"<<JA9F'\KAJZN;NGV9N!K"1
M%)1=4<V]KAX\LRSQXQ01^6!S>6R(&8-91 44 >(HHQ%'6)@1?[I#=!K"S_$P
M/7PH<(/3R,:^!>B%E -\_AZDS-U\-XA-QK'Q(N*6%YH:7<=5'^NV0SI&M@+\
M9U[I"!GN!FI_Y.M[\(3+?+6I&BY:^?NF ;IJ%_SC/J?W>FC]^V?P6*Z><B;/
M#26_VRQQG;6E"AV6N6)D/P$57JHO/^#RGWS=ILNR7'&TDXT63&R*VGH[BI4=
M7K">$T;/ER<[5!Q6H'N.,/CTD70>O+K".5NPA,<\"A#$3+$&LSB!A*,4A@G+
M?)Y@Q$5FQ]3\:H;Y6>J& 6*M) 2/4L2!5!L-@F9.^A&HC&R7NVV8P%4?',.9
M+5XJ/0Y913/'Q_!/O%1P+Z7$JX_9O<*,YXNKDJMFQ.H"1;<AK:H-+V]YP50)
MH)!;8*(Z"",10QJH]SG-0H@)]:"/,R(BC$60&CFT)I/-SJTM.:0=@4$M,:A%
M!EIFLW?=".K^%]\U@&-[9\=@9VP8;$!YQTI4G/YZMWKZBQQ&&XA_(?4CK'_4
M5L%H@DE,A(VJK;VP^L[ T*&Z0[IXD-M>J88_N\?E':\6A'$B/$(A27$"42+-
M1N:A#*:"ASC$09AXH9T;\/Y$\_,&ZLR$?"MHU;VR5HU;P*JY5Z[ /5\R[3$K
M_]<R]/<^[CB)XL2C2)KKE$(DC\@P#=,(XC",A?!5HGIB%9D]&O5)TH@^%',_
M$VF:( HI3CV(O!!#[$=,NKQQZ(<A8CCQ6U*ZT5%_R33W_S3NAM'LHY_@D7?*
M&L2=A* 1T6$$NA<"MX'F]Z>:-I[<J^Z;L''_I\=H9W2SEN^FFNQ2?,T+7- <
M+Z]6=1KD^<\U+RI%FOPMK]:+( D1][C**6<"(IK*@W4L./1C$F<LSDCH6]ES
M5X+-;0<PZ#YS K;JJ8RMK8*@U1#\N=,1*"4M;^.<+;J98?N(I1S9%#I?Q?-B
M\] D.SF\T7.-_(1]BBR$FU%'(WM([7H?#1A_  _?YC$OKN3V\B ?_LTZIWA9
M713TFYSE3C^AS:5#RB2 )(L@37 LW4G"8,J(#V.<X3CT?!$C8<R[9S;GW*RY
M%AN\DEL7A?\*=K);4+L90G_X9FP$0$>VJ698#K@W,P75@A_//;A3\>$=]\#:
ML=[9H=3'<F<XTG2L=G:JO6"QL_SJT,K/,G_2B4+?5VI0O*Q3K!<\P3SV@P"R
MF$JC'6(.,Y(12#)$ YK2),NLR*?V330W2WUZ=U?J4 ,H&CD!UH):5O[O!=;,
M%W8!U\AV>">BHJIKL*JE=%D^VH^#XU+2/9--7%;:K_+;$M,#GQ]J&41></:9
M%_*']95<^N;'2[)L+%#SB_J6UT-!Z@=1)L'U,XA0&$*,LAAZL8=QS .6>L0N
M:&@IP?RBB:UT ^[0;=$WM2KN$9W*V&C)02,>4+*?;/]K)_[V=ZYOZ@="Y]@^
MV<DPL=D:!-!;:S9LF,&\G%PUL3PMV!?^Q)>K1^5;ZPBJKN0N.=.)U;?WN+B]
M+U>;N_MW"MC^4>9K>::^%&)! Y20*":0^EZ@&HU[,(TP@2C#&4%)&"%D54C@
M6L#9N5N-$N#BZOI_XH?'__VEO7&IRTN;;+R:F6, 79WS!38SM!^Y;"-;XE8U
MG='84:ZI8-\N:*<@H=$0O%],WV@)5T(X90D=90%<,XBZ%7)J=M%1('Z'>72<
M>>PCGJ?IKY'7:8.LRM9PL<'ELUSAI D/)9X(?($8C"+L0T1H"--,EY9A[%,L
M:!8:5TR83#@WDZY$WA8%_R'-=EUNV:FSK#50I9:)>73."/O#\4[7B(YL;5^
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M3U5H6PNM*D(;L<'5%F0M^8E&^?P@RM9&TAXPIP;18OI)C9\]+*\-W8 1[ ,
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M4SP?ASW<F:WZR.:YN^!:7Z 5!HW&0*M\ FJE04?K;L)9HSC8:@XZJH,_M?+
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M)R#RL0>)APCT*/*)\,,8V75\=RO>W.S@55\ZSH 2)<>+:6@Y/VR)QC:OC6)
M:Z89*QH7O*L<V&IW\CKSYV7BCRIM;[5T:'U'0=^MB78KXK1V?!1XWQC[<689
MMB.T!% YKQ99A&B$L/13.<L@HED&"8DX1#CR4,8BGZJ+Z=4:+\W,>6=L*UN\
MG6'$4(":0QZJMP+:F=XN:F9V<R 6(QN];P8 6!NI=U1U:F&ZXT]J'MY1[/6[
M_=Y'AK82U<4M:>2]6V1%O#B(TTQ $?(8HL!C,,4B@<RG%*592GU&[;J(]DTW
M-U=*50 =*L&R[779"[=!M-TIB&,'RSO G0!=SW;BHC[0 $G;AJ&N$/U_MC;0
M'*:#G4)[!YFX2:B)0F_[@QI]:W#DCTN/B]WBGW6\Y3M?GY)J76*Z7F F?(:"
M$ 8QPA"%Q(<X\Q&,2,IY%OEI9-;MSF2RN1GC5E;5]Z?A./^K=7AO/[3&$3TG
M@(T?Q*NQDG)NPW925/!G*ZS#!!(33%R'Y_9/.'5$[J#J[P3A#G]GF.WXFA?Y
MFG_+GSB[D%M0<:=8=.M)3A]6Y3K_M]Z6SFNZFN_\Y_KV!U\^\=_EB?"^6@0L
M31&/%/<YE]:%T0QFD3RGQ;' - [2).'<KH?(<0+9O%#3]!I1&YJ=S3ER2<RL
MTG0PCVRW:D6@U@3L5*E-V DX;V^(NUJ=@/]4U^67Q?XF%]8FS0V@3HW>D2)-
M:A;=P/?:<#H:=9AIW5T4JWM&.4%]_=MIT_GY^?W+Y.;*^#?YR75U45SQ,E^Q
M?_#\[EX^R:?2;N$[?OZ3ES2O^%694[Z(.?,])D*8<L(ABJ5%)EZ:PI"H%G!^
MS!BB=G9X0NGG9[2U[-)H?,H+P%3O\;)2J7=U[LE^?H$/?PS,;/],EW;LR(+2
MJ$F:[.K=[3FOKZ:['WR5HW?9ID'5""@ZOQJ#$]"B !H80(L#T$"XVV@^8/6<
M[DI3RC_I%O8!"_-ZO_L($4;:' \(>KE95W)#5_=3%RH?H:ARJE*L^"*($,$!
M)3 ./ 11@!$DJKA&]=5#.$EI2B*;@,=HDLXM6M(1%.!UDW3)VOS+1_U$.-[Z
M!B^RHXUNBJ6;P;9FNJMU]%5I!HW&.N=\R@WLV%69=KL:+.V\-J=C0;?>BHZ>
M\&,VGK_S2NV(!6LC"[<K]:MF;U0)O;T>.@O3(&$QAI1%%"(6$9CZ"8$H]%F<
M1C[.T*2[TW'JS&T+J[6I\]=V&NS=S:8YWXW[0$VS$T[WF/PWVBX[3]LVS+A>
MZ5^?@ XT<SH<3K+.L]J CU3IO]4N[6;Y7&_ECJ2RV^^K<JTJK:O5,F=:WHLU
M?Z@T X"/B>>3@$*6(0\B$6>0Q#B#44@#@L*$TLB(>6'_%'/;%U](";285NP*
M/6#V[S]N(!IY3QB CK%A/@Q G[&4W^X82OE?KXUDS_"3&*[#ZK7&Q."3PQSZ
MWSE6!;/*Z%P4CYOUENA#>$%$,Q%!Q ,&41#ZD'C2W^8!"3SF,3_"5C4@^R::
MV\O>D1-H08>SJ>S%ULSK=('8R._^,+"L_;)#2#CUF/9.-JDO<TCEUU[&P<_;
M9RM?\Z?5\BDO[LY*SO+U5TQU2?EW_N-:^A^*]+C^P^E=R?7$329HG#"?BP!!
MC$4*D:\:_U$/P0#' <=)(OV&U#2%>: ,<S,J6S5 +2YH%5%)8C] JTO[UZTV
MYAFZ0Q>KWQ1-M 0C6ZFAZ ](E!ZZ#.;9TQ,LQV3\JHY?"JOTZB-Q[,FY'CKR
M9(G81ZK>S<X^=JBC:FC0KY$GT0];_E6!$\91 B,>2[=5< HS3_Y$PR!A89)$
MF!D=3'MGF=O.@OJ::_%-N8*,%ZL'U?1,$;UPLM9U"[]C7;,0#BH!>87[X2W$
M"9ICAS9?E,Z@NG1&27I<N<PKK 95R0S';")+?@1V0TMBWL?$K!+FU7<_H@#F
M??'WU+WL^?!0:M6'AU5QHQBJ=-BQNJBJ#6<++B(>I0)!+R A1!'W(?8\U:U6
MQ(R2B @>V!&JOCO/W.QG+6;-V'72L&.!7(NJ[[?JWUA>:NW#F$0T"A%C,$P3
M!%$:!C + L4"R;(,93P@OEC4EVLW:URN)T/Z]9SCX?V9W^6%)L__C)>*B-$]
MRIR@Q,,HA1YIV4LRC"GT6)RR*(II*#]4:WQ>&/8.<H9Q.^-X")_7.4BCP6L6
MO'( V.AQ:_WFW]1O_DW#BU>+Z9+LMQ<'QQ2_[\\U,;%OK\)OZ7S[/SZP+@OG
MI4YWZ83%_I&O[_\H5J3BY9.Z-=-ALNJ:*[WDH46[2-?*?5:LD)]QE5=MT?_S
M#5^OEW4&Z()[*,*1H##!(9'[)$4P]>5RA*E'_32A618QN[YDXPEK]+9-V\>L
M[;3U%]"1T[+":[S%-;-M'[Q@$U6&*?93K>4)Z(;Y?TA%05?3.O!?@9>ZGH"M
MMD"K>P*V"I\8K;U]#=GHR^*VOFP\<:>M/1L=]C=U:>//.#H-GR8XK1MMUJWK
MJT7HL8Q$*8><IPPB)F)(LE#^)'\7BA#YB< V-$U'26-U3IN,V.FJY(\X9YJY
MN%#=,%7VV$KS?#>T60U1P6B,>^^LF]FF,=EJC+POV//IU3SL6R[3#^3.VP_L
M1U'EO2/17)GQ]H-W!!%>SZ #$]2W3-,=IN@_*L7^\()3/V,9\H5(8!Q).XMX
M2&&FHE\1P4AP3%$<&35KLYQW;N&O-G40XB:U]KV>&HPK,OJ\X(K+M$G^SBD@
M#6$Q757KVA*WOUF197Z'!_!!FZZ>F<D=84W&-J[O<D$/[%5AG_YLAY?;/&7#
MN:=-*+8#Y$WFK^77[2P>X_GB7+=U.&5,/H35F?SQLKQ=_2@641"Q)%:!3R+?
M;42E/TD"%$/,,Y\RE*&$^R;6K6>.N5FR6DS0R"G]#-W]H@1*5C,CU =HO\%Q
M!-/(QF400L9&Q "#=PQ&Q>FO=ZNGO\AO:UOQ+Z1^A/6/VD#TC3N),3!0K'WQ
M33XZS*WY#>=%]6TE/:3JLCC_J3JN;/+J7AU:+\473M8+Z<=X!*<8TC1-Y2NO
M\G6)E\KWGM$@RI(D2)&-0W-PQKD9 "4K6!7R;-B5596LJ:P'.S_D,-PTC43$
MI(5EOJ*,\;((DB2AT _DP3U(&<<XM L#NP%\TFCNM)!'OMK#DA@&D8<A$NKV
M-&0$1D$H?YM$88@].Y8>I\_X--PZTT)NYF<[A7'D35#)"CXI87]1,)Z_@?%+
M'XS6+K4Q-$Z=Z<.S3NI&&X/PVH$V_^*P7?6BD!L3K]9GZ@1[AA_S-5[F_^9L
MD?J)[R$>P4 9&!1S E/L93".,R](21(Q8M5=>-]$<]M#.Z*!O)'9SJ;LA=3,
ME+@ :F0+THH(M(R@(Z0[LW$(!J?68N]DDQJ)0RJ_M@T'/S_,))QORE7-:=!D
M;$:(4QZB"%*?!Q#YF?8Z$AARZF6(1F%FQP#]>H*YF8"=?'8O_AO@S%[X8^ 8
M^[R\%<UA&NLAO9V^V6\FF?2-WJ?BZS=Y[^>.O0%H"^;;]FM-[LFK6+)\HZDO
MO  F7B(/SEE*8<:H@-SW1.;%(A$\&W838#3_W-[_KYNU:J#;AO(?VX0=U?"U
MYGXI*E7HO?V _/;@*+_9"ME&^YWC/K*AZ;:XWE*A;*\ V@68)O)OA=U(-P!F
M,GS038 50/MO!.R&.?HNE-+-PV:I0D+UC>OJX;'D]^I5?N(7!5T]<'7,>O7>
M(2(BD5 "LP1I'H 8DHA2F*0)#X,H#$-BU(O(D3QSLY3=UU991BGUXZK0[ZK\
M#=ZIV&:H=)4$2ZG?X,O10<MI?6DZ]B)-:%8[NC3Y*"^T ;4Z;6!HHDO68_ =
MZ_)UD$P?=2E[#( ]E[5'#3O,5%_S=5XG,JHK_RU12)B0E"0^@M(']2"*LPAB
M%F*8T=0/?3] -+,B87E_FKD9UIV4=1OLP00L>U U,X3'8S6R?1L"D[6YZD?!
MJ17:,]6DQJ5?W=<VX\"GAU"N5.LR5W[A&:[N3XO: .T2E+_PQU65KZLF8VY!
M$H0$S0BD."80><B'J9]Q5;292=.1)CXEYE0K5G//SVBTX@,JY>]D!E=;%0!K
M=+ A]+!;D7[;,C+.HQN<+<1*="!E;YRIG?2@%?]PIN_16-N0IHR&^61D*4ZQ
MMZ1*&81>+T6*W8@34J,,4O4E)<JP(8X]X_]1E)RN[@IU"7*+?S:!A>IZM5Q^
M796*4/35>3"EF#)"**0DBR$2B8 XY@&,"8T1X0$COM'F<;PH\]M+NF5#[?F>
M;$O7-4-VT^KA8;5I3OR;CM:Z9V83(AU\S+=>4=L3_ICK-.'AOJN&;L#9*@*4
M)J!19:)3_5!,1SK06XOS06?YH;#M/\8/'M'>;?\]+_*'S4/=]N=V=;;$596+
MYS\D!N4:YX6<_DK9?&E,.HWD3ZMOJ^+NEI</G5\N(D'C2 @,$\)3Z=*'$<R(
M""#VLDPDC"9!9LQBY5"NN9GH1K6V%<%Z!6BCG;3#C7K:"#\V"H+E3AF *["4
M.@)5U]+]@[FOZG+)#Y\9/F@A1[;A[1I>;=>P50QL-=/VO-5M5T/>+*+2#R@%
MNW_XF$4T/XQ\T&).=E!YE,/I6Q#E-#V,\I[^ZN9@,\)*]!QZ7,XVV8%H!(BZ
MAZ4QAC_V('51,%6&MZ_UK?8:%HD@/ FB$&9AI+)&,@KEL0E#D82A\) 7A]RN
M$Y'5]'/;C;O>^$[^/6VEVU0&RV"^Y0+9GH5<PS[A^<<!XD<<>&R &^F08R3"
M!QUL;.#9?YBQ&F68 6P(XV[N.5]_4^NONM2HZS(<$\]'*( D33!$8<P@#N2)
M) D2'H8X$FD8VIBZ?1/-S:BU#'I:4-!*.N@B<B^V9E;*!6(CVZ-A8%F;G4-(
M.#4P>R>;U)0<4OFUT3CX^<&\L:^S(!0Y[2[X2&(>>GX@C8/O9Q E600S&OD0
MBR3C7BS\)$TL"61[)YR;N3@]._OC]S^^G=Z>?P&7MW\[OP9GE[]?79__[?S[
MS<7?S\&WRYL;:P;.?LC-K(=+($>V(GU)64IFZ<>,$;TU1<@U6V?_I%/3=AI!
M\ Y_I]GWW!%Y?BWYOS:\H,]?5@_RB+@@:1P*D7(H720/(C\5,(U0 @EB?IP$
MC&7,ZBAF,.?<;$^7H'$K*OBS%M;25S&!W,SP. 9R[&CD, R=T%3N065TOLG7
M\WXX<>0>($P8(/=]U?XZYS3[-8@Z_/M?-OSTL<R7$MBX*6X+HH0FF*90_DO:
MG$3"G:8I@0(S2K,L(7$@3&]I#D\W-W.C!-[;=$2U%]'RJPX0L7DPW@#UPQ<E
M;K$<V>*\@/$]\ :T'C% T?RFPBV:$UU .$#5ZA+!'*2>NP&#028+^9LKU(WD
M6WQKP 7[J^Z&KSH>:VK)3;&^QFO>/.2"9(2@1$ 4$,7OR# D:<AAF,481\3W
M8M^H;'O0['.SUV_:=.YZJL.VIWJK!5!J6%RA6J^,P6WWF'A/Z$4:03W QMMC
M;G$Y/2;V$^T (ZR!W;7R4 S[+H^MQYSNBGBHNB\N@@</,I"JG0M>ENHF184L
M;O'/\YI2O$D3.ZN9BO/B;DM57)V2:EUBNE[0**(T)4CUPN80^3&':1C%*F.+
MQ"0A).56=;%'R#*WG:95Y:^6!.Q'K(99+&(BC$?>75HMVM"H2HYJ% &?&E5^
M.0$[;78\[!7XLU7(83## :QNJ=>/D&=:XO7C@7M#N^Y@R,'&5-%6MUP&\I%]
M17A\AI=45=3*R;_S]57#(+X5K%JW= AM7L\U7V_*XK)H6BQD08P)35.8"II!
M%/H!Q,1G, [\)),VER38BH1I;('G9I:E E3Y77<Z7X2W'".E%EKQ("H6EV&M
M,\9>>I9Z*/9C'T81]B%B+(09"RED<<C\"(6*CL^.]7-.BS\-:>B65*94SJY\
M OX[++SQOCZ;Q1Q_\S_0'$#I"SH* ZDQ:%7>?D\I?;(C&E)Z0YU@>]T\'=?;
MIT/7E9_V/QU#?(9)ELRU8S&NT%-['Y,LP3LNRC3SVH<8O\BYGN3$3](8_Z@V
M^;IJ8B>98E6/,@%]3PCI>R /XC!,8!@E+!6,>UEH'$G<-\G<_(6=G* 5U#P\
MM1?)PY$_%_B,;H7?0#,@A+<7(_-(G0NL)@K(#<+,*N1V"(R>R-K>KTX60#LD
M?#=.=O"SPTYP*L6J/B#>\8+FO/K\_!TK(LA+L?OU<YT.'"4Q3CP$:90HSA'I
MBY,D\B#W L99FB686C6:,)]Z;E92<_%W9 2UW(,RA"T6P,PQ'@?6D8WK0$2M
M75![<)PZDQ;33^H6VL/RVL$;,,+ :H5-)3U)-=D#R8NVO6M3[GW!Y)Z6BQQO
M"R1.Z;\V><G9;ZL5^Y$OEZ<%>U%/)IU0SJ3'N2 8TPCS$*8)5>$&X<,TC#&,
M$,$B33*?Q\RF">M(<EJ9PLG:LPK5,_I)Y66I8Z1\Z*J<-:%&L"YQ4=4!2LO:
MB9%6VLR,SF#]1K:YK8:@HZ+NWMTR:G2U;.O)6CU/0*OIB69%Z=9G-]J>J"B$
MPPJ0<1?$;0')2+).6W\R+N!ORE=&GFY(9("L+XIJ7>JCTMGJB1>X6%]SQNO
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MNN!?0<3&[+HC"GWY I+@W4^R+/=HKFUI;/><G>@/"KS*-;=4U"&KW-;\^@5
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M;(9"&B-$"(&9J3QG<0(I#SG$,4UY0 B/[<CL#]]^;J^_D1#L1'3:8AX!L-\
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M62C,H7*;&0Q3$>N0K\#,J37?R1'G9IKV M<IL(Y6Z33"=N;(*VXCVZ%7D"U
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M ]4_3<7T!55?(&QSIVR@X"G-8!KD(40LX%#-.(6!D&$6LS2CDKNX]-8CS\U
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M%C(+88ZX,HI1FD$<<09ESN,D#(G,J77K!Z^2S<T3VRL'F [S:U^CKBVN=NH
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M..9TC%QXZD74-ZY5]0GWZ?)6KZ,-9(+=_A(/5+UN]]=K)1%O3F8;7F09IH%
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MNX ':O<J,TB35#?WRU-E'R,! X9Y$K,PPR1Q2FFW'7EN1E%+#,1>9,>\=FO
M[4S?*#".;.\,@CJEP7SHB'VD9X''!'A7M/QFPUN//FUJO"LHK_+DG6\P-&%"
M&;SKJMH*_F%;+M?WMZ)<%OS;#Z*>3O/'FT>=&EQ=_1(E6U:"WS$>:;:F&/(D
M8#KHIKPZ%F&(\R@1/,FD"*.6(-LV:\)5"*LW[SE-]L@F;"<:>+=<@\J(;DF?
M<<9<V*9)C(+O5.W%E920$@VM/D,7ZZII%%V6ZGMU$@5] MWOM93:%W^3DB]
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MV0\_;5*2,RVO<I3<GS# Q*X>HY]]O:^!_;:M( D.!$D@9[& 2+$,4DD"&).
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M9MHN8 ?%?-4'[/"5 ^OAF9RD8F62EM;/\YB:; "64(8SL_% ]?>/XBR%F+(
M\ICCE*@LH<JJ@X'M@'-3! U>T$T'=*USU\>QG5+PR=S(*J(ES6 =HVR=)1-^
MB]7U#3IMB3I+"EX5IK.];Z!+8M";R 2CFV[S];\NGO3C^?<'6O[K_%>^7I"
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M^0[9M1AYZO!=>S+>".5UN/G0]]&=V6O]T]__UOZ+_H/1M?S[W_X/4$L#!!0
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M &5KZK;_P1@_L0F@]RRX-B28XC@IHP@&5(YPI9/T20KTIH<]/6XOWPL@MG6
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M,,6HX!5<3/'TO,781'L:&<]XV!<_3GKG2UH3+9:5.4U9UK7JE[]+V]A/M55
M-;!*&K!*'],:IO,4W\!RCB?VZBB$R_/+69E$BO%HZ5HY89(Z+<N>20XY@J@(
M>HB4,,:9S,Y1"W42ZK]/V]A.5160#:R2!D!VBX,N,BT-B);I+,U7T\]I<]WQ
M;K$JEQS'^02^3)A.P$40A&F%#F-$7\$)X4GF22A+DU&F4A+2\P@=V_>J8^,J
M*JL!+-Z7VH0%$Q,X] RB#64W!6)S%FC!'<--EB-5=1)3[M,R[C54)43M*?(&
M+AM^F\X7RVXZ(0(QK3"D22:'S"2&M+&\1TH@'O"4#^"#BZ!B#G4"P;N4C'L?
M50DP>XF[21N#=G-3G/)AL>R4LUXOI_YR75)L3A;E>G8Q7R,5^(FGUUQ[2UGR
MTA#ALRLOYXHX&BF*4(;DA9.2UJE,&X;^<7-Y#V;+JJNV ?MW^]YY'A^PYS1;
MM.;(A4X,^6&L3+O!^,="L")FI32K8P^_1]G8!^H!,X;W5LQ@0#MD7[\/G2+.
MTGH:8/8M)_LU^?OV@^MW_'N"D4.V_PM.,NUD(AEPPTG?-0/E>-2:$$S6)GI;
MZ]"IW_[OUD7-IS.4]ZIKHA\G(;CLF(_H4)01711]4N>X(SZ(Y"!XK42=Q.)'
M"!K[1G9@G#QQ-[NS&AIP\^ZQ<7RY7JUA7IR!B;5>"&$,X;[,!C3)$^LM(\;%
M9($R)TWUV_U[5(U]*7MH7.VJD 'O_RN?A9].\,_?WKP_^73\R_&'-Q^/3M[B
MW^YY#C[RH57.P#X,#'3^;2ZOKE%XTQ<ET8Q! "=1E [*0ECBDU.DS']5GK'@
M*AUYCQ"T?_BY_<"3$H-,E!.EX-02(\L@PN@]\1CO$!:9!.\D-ZY..X%OZ1CW
M3!M"]_=CP9WE/.+IM5JN2U>6>!G6Q\M/:?EY&M+1E^EJ8CC:5I<TL;)4J,IL
MB:7 "$I >$W!*MZKT!,7N(41_.XN/AZCH!&O9P=M+@84;1O0Z,+)#0>KUXMS
MF,XG/ <A#:7$,*N(S!*C2.DX4=*&)*D)/=\!GX./^V2, Y)A-'L?)GN*N0$G
M>,O(;ZF;>*I]C-$J3YADH?190<%XQ0G+U/AHHX58ISO)-V2,CI%]U7J_B=:.
M,FX'(#<2Z5X5M[Q084.DRI"<RZ ZRQ(!D3V)!L]E)J,)O$YQRE-4C1,E58?/
M_AIH $W7IS1&'>DM?KF::- Q!)\):)8)FN% 7)"\1(S:&<5!B\K^[34MC<37
MNWLP XFY :!\3)_3_/)6GCPUS(.BDMA$/9':!()6$S<4UTHRGIVJULGZ6TH:
M<7-WU.R]9*4]Q-P.3'Y!.96D]<+"']/UV:O+U1KCQ>5U4\'2SP?_/Y:,EV22
M%!J T%@JFJ.5Q&7-B;#6.H-&,X4ZY4L[$#LNV/9#Q\-0JZ:J)I)^7RU6W?&_
M[<]\(SD7-48:1A-?;BZE<)JXJ!1),7H.CF7CZB0I/491(V?=,&9L$+$W8,X*
M'\>YM+V\[4-^6LSBQ*&G*$Q0) M=9IMX2DI!*0'<>XX!X,:L,]?K<9K&-4[#
MZ/P!( V@@ :@]"EU*2N_IGE:P@R9.8KGT_FTR&@]_9RV4IL$[;U%%HB@&#7(
M8!-Q&LKX<<:$YS8*7B<[O!]]XUJI*A"KH)@&X/81-8,$E+DZK_&@GRVZ+N%;
M9F[.]O#?E].N1AZ#VM!U]BCI@=(S9P7&L-J4,2G.$">3)=1:3B474D*=!YP]
MB!ZW=*$*, ^EPI$G;QV=ET2_?W2Z.LYW.Y'?\'GKUXYFW4>B3[JX<HEO#HKN
M<&"*)Y:Y((P'W*.4)G2162#&ZB! )N#\CGOW8-^?&K2-6^4P*%*;4-_(\+WJ
MB?[V_ *FR\Z%+N4<B_4FD;5LS$X4-W__Z@R6IVDUD=(+HZ(@05E:YE+),G,8
M2,+830L\4)P6/3"Z,P'CYG(.#L3#***!H_T1+IRAS*6$;DDH)I]G2GRBFG#&
M* 1M#4MUN@KM@:YJE115#N0!!#_JI<CUU,7+L+Y<HE'><H!R>CN?KDOZV*6?
M3<-Q1L+*7Q<A3A('*Q/%.,MF@:Z$2L1K6OH/9H_[1@K%?0\S]>R%QZUW&-P\
MU15\ V:I>P4[ON@: );2C)(@M)5>:;?%RS.)4I8P5Z(F#-!+_WY!A$W):1ZS
MK32?]VFZ>J',O@B455#$\V'E-K":I]/.P1OT)NZVI";@/"3E%?&RS!:FQA*0
M'F7%,N72X?>FSG%WEY)>"'(O"D%[";N!^JH[X"]^X,2*F!)0()JIC/+ X *T
MP@@C*M".2LHJ39A_@)BQ^RP,>M>_K[ ;P$L9"+OJNFUM>+BN*]39"[".$6U+
M$[? ' $E&#&9Q<!YSMK5&[_[$$5CMT@8%#F#B+T!S^>*[JVY+,UK)R9[2T66
M)%".04$4&BVFR80&P4I7R&#N7D -AIQ[Q#12M#D4:/83]KXNS2"(^16F\U6Q
ME&EU/'_SI5C/R^GJ;%/,T[&$\N&2TDR"M"61'ATT/&8QQE0\<^>I9U!G3-!W
M21N[1<*@:!I6$0W8HE\6RS0]G6\:_8>O)TN8K] =1.T45@NG/Z>,OU.R.;B/
MEF>?$ *&$ZF\(>CG(9/<B90MC<S5R2Y^!I%C=ST8%&VUE-, [FZ<OZN$HNG\
M$G?3UCM<S+>L77?C3BO<;DM #4[GL/S:"?>1[@Z"9YJ$RR3GC!&K=KC[4@3"
MJ/!&J8#^99U0KR)3X]X[#'XFMZ'\)D*)+8M;_^3G-$]YNI[(+",$3HF-M-3A
M\D"@W!E+9FQ2N*=%"!4Q?(^@<6\MJN!O/Z&W<]7U8;E XKLXV@/#X,=XPIPK
M+U/,E#D]D>"YX+VCB65;)\GLAH9^267TA2!E1]DV8%C>I_6-F>W5%,E& ]I
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M[3YS,1[L!K[I\7M3#>^T9YX%DJ!TZ$AHK8$[()FY%!2GPLDZ>VP@!AHI 3\
M6L?0> /^X6-LESE$\Q2WSQ8?9C!?'<7_NMSD1EW+(RVGBS+->)F@Y+UL_GLM
M"L&E53:)TB\-19$1I=Y*3[1.,2OTDZ4Z+/@'8&I<\ST*2'MNE$,CYF5M'A3
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M<D[H]VELTGD=%:'#J+--J/X&R[^GKJ??IQ0NEQN?/"!+O@SYQ1U7V+*.N,R
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M:".E@.) ",X2NA)HX;U4G%#4231.!FLJW4[N2'&3M^P'M96'4'5+H.Y1P_J
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M:Z]]811"Y((:%!KR\*O5U20CS[BB8+/-N*('".H+//OH^J=ETX<+O@/\C%L
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M!=%F@,QI%">Z$'DVQ0.%S.1PB;J5QT@/*;*4C+!UTVVWP6+OQ8E#L-=P L0
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MD3>S.5X@SJ^*N:3ARH1 >*P.I"FUO %-766(RHN(+-VY(>Y-%!Q"0T?N3"N
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MNN."HET7,RA9!'A!GJ/PB8NLM'6A37;B$:(.;UK_Z:,_DBB?T[_YQUG4F;E
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MM(,8D3BSS@94+!C19B#((T1-6RTUA=$]3"\G&AS=',F?Y'S 8+4#ONX8(=5
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M:#O<ND!/43EG$2DP9Q&4XC3WE!T$87EV7OB<71<8]#[\/)A*)UB8$PT5QC%
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MP0@-0.D#?L?%);XF_>U(5?_C?//EY>5ZL_R*JY]+I6J._B]_"G^=%=366B<
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M/Z\$;)NS1+*PVH+ UA[HBEE#6K8*F'%<R&@#-]-PH R?<[<+=79RD#VR-1O
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MP"B;714$ZTN"-_5Y@=^O[QS7+3V<TKS/N1-[I ,MT "4MO>E#R\7=M+88$S
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M4[!=*-.>'ZFEX_4(<!E9M;/>T3PFS[OE]ZTDMV12,D7O1(8B*-13RI.F;++
M@D3AI.!XOS5U9[@\'*VE(&8BR!RHXKF;[>#B?+FZ/OZ]6VYP;?_!V.^X2J0Q
MDNXWFMD7$DU=BR8*CYF$@,*4JJQ,F8Z%I@"7(H@2&*^/QL^CI^>P\]:"C0ZC
M*97>$I[T/S3;BK=_F63C:[Y_I&"PTDDX(2$(Z\ [$XN6*NG<)=KI,>2\E6#3
MXFA$9;>%(:MW8KVX_'RYWI!0=B<41RDR(AA?'_FJSD(2EK2GHXH!,^==>@!V
M'G#>"K"I\3.2HF</A.Z(I=R-6-?1G;L62K*268YTKBZ\=D:BU>!JDQT>3%2&
M>9U3EVY"'8>;M]!K6NR,I.0F_,Y6#L.%KNO@V^K\XI83Y:A9=H+3,K"Q4K[7
M+HHR@2VE6,V*8ZP+^<JS \U;Q#415L92;#LH\8R1++]BNK_9ZA)+L!2KT7\%
MJ,0C^("D,A&2R5@8CSUQ\MA0G9#B3Q$IHRBW(:S<P;W9G10=!>]62HKG:Q,3
MQQ5X[2TX+S@W7-+NVJFQZ3/C=+OH8R<)DX/UVDB\LI7&Z0KZ?PN+R[#Z<2O^
M4BH7S;6![#C)8Z2&X*(!9XO0@=D8[I-,/X>31T;JAI33N1,>6;?M^!/+[DJS
MB[>LUK6KIP<C/4E36VX%K@KH'&@ID)@4R/=#RB,C=4/*Z5P'CZS;=I"B'Y&&
M)Y[0Y@BELJRK1#MJH& <A(O))XQ),=X/*8^,U TIIW,+/+)NVT&*V>ZEKS&N
MKL7Q.W$XE\A=@9PRJ[14'+Q*B622,;/@N11=> 4[#-4-*Z=VU3N>=ML!RQ7T
M]XBCLY&&<P8"14UL+A8BLP881BMK );O<_-W\RM#P7)J][GC:;<=L-@M]G\+
MMR4)S*'![*%(1["OK4*\CQDL:BFMB5*G[I>WCXW2#2*G=F4[BD[;08?>2O)S
M%Y5L]_S.ZVLI<@*W+Z!X+A"2LH 8&!.Z:[OWYT?JAI)3NYP=3;>M(>7&+4J^
M>Z HPD:6*2IGDKYPDB38PD%$@[2/!MIBN[]+/SE4-ZR<Y.7L*-J=&2Q775-N
M<1Q<B\"4<22"ABP2[9LV)HB5ZL X[K.WY!MUE]WFD8_O!HK3N8<=0XO-Y>R^
M_=GMGBGM54X!K%&5)+6*@8FT9)P@]Z=,<M.TBWQD0BWEMXR=ZSU,ZTU4/-X5
M9$>X^R%L\..FTFA<9^R$SWAF2[$Q: O>^50?)1A$0Z*R2D)&9SO%RS0L-]WG
MV%*V[T!0/ FTT>S3(/9>AM7JQ_GB\XNOM6W8F0\R6AT\9"NQDM11F(\Z@17&
M*N\PV(FH(IZ:54OIP5/@ZP ;-+ 5WM[,S[Q$1=.(H&NG$X6N4$10'!3/?$$7
MG4S3X.?V+%K*#1X'+X-U/!HQ[3CXV''K)A4J5P8",DG1'G*$X$P$=$+%((O1
M89K*ICV3:2E$&A\M0S3>Q#9U6XAWRT6ZED.DE!PCW/ND:+OU(8"KM5\I>JL+
MXT[+:?IH[Y]/2WF_XX-GH-Y'Q,^Q./Q>+K_C(M!6O/SZ[>(\+!*.3-KW^ #3
MLO1U%&Q:6CZI0M9%)N"*@AFEC880LP/T7BH,@AD\=5H^$X)DAHO:':60B&@@
M!E';-Z4HBLM"X#3M/T^%EJ\/!KK0\O51> -1\AXBL:0D\I X"&W(I0KN(-3V
MI];81.$=1VFG.=F? BU?+_,^3\O71]?-H>7ZRE5EHTQT''16 2B>"S5)"(%B
M?B-]\>A4.0)>6J ".-3"76CY^JB[ <@\S0E7K]<E4D3H0U:@7*R4"8P6%D97
MK,W6FVGNI4^-EJ^7U7O1\O4Q00-X>NQL$4(2CH)=\-9G<LS<T#JK#WC&D,?F
MJ&V:KHG!T!>.HU+S';)UC:'UF=])[]&T;.\T7WRG(T=5SNOEZ@/2GYVG>HL>
M?FQ;)I]%B@N=Q@RE"*SE%I$TQCRD9(5WB0G'N]3K]A^YI;AGH+&71]-\4[C:
MG6OK5<7Z]?E?F%]^":O/6'^_"I_Q0[7B69;9V41"<8H*0'%2IT,9*B%X4<D$
MGV47!I,!0[?DEL9&UOBZ;Q=:UW6H;_&V:%%EH3SY]=I<#E1*'@*+#LBU<\XC
M<R)UR0GJ.6R;SQH30.I@G9]>"Y';-<]WHL=S7(_=/J3+6!.W#NDM[L2-N5(1
M+O,(B5L*^ND@";$8PK T@26K50G3= 0^WOTD6LT3I\59N*'3AV<28HX!HO!!
MH;/!JG_MMB%],-#E?K*/PALX[NVY41&683 E@M>F$O72829H:T$JQ77)/&4V
M#2OR*=Q/]C+O\_>3?73='%JNKTZT%-:48BC@R[P6,3IPJ= V7:+RLKA@[;]P
MVY!>%NYR/]E'W0U YNG+,2<==]X%,.AI.5D,),R6E1X1B[(\3]0:\]3N)WM9
MO=?]9!\3-("GM[BA#WM?KF39\=E986I;2TB11=JZBP(O= '.5)%T>LA>3)0=
MLF<V\UX!C(Z>@Q7> &CV4$A[5U ZR\$)FKSB4H/+)$$BOTQ:JF?98^17M]EE
MYI HYT!=-X>66\4O)#9&128U2(N']G(!L18R"$3O,:%(]TE3_M6(V7M9NBLQ
M>Q^UGPHQ.^=1Q%!Y?'FL[7B$AFAT@B)D<D(D'647 H03)V;O9=DAQ.Q]U-P^
M,7O)=445!+'-[ZQ<T*Y69%O%LN9&)A^Z$*R<+#'[4+B,K-KFMJB;6WEIB]56
M*V QDX:"I3U;QP26.^MX-MQ@>W6(1^TY,UYH,TSK#8"G3GP7S_\\#(:_SK]>
M?OUEN5HM_ZR.-7RC/]G\.#-.,"<,^4V1#<F6+'A:.,!5L1:%Y#Q/D^#:9Y8M
M;6\#87'_U#65C1K W[UE2<[YC-N:)94RD,_UM4RE@->J@$U<*6&\<F6: _S#
MN;2T]XV#I0/UW1QB:#W@=<UD9C(50C>P+$-]A6;@:Y$Y.L*_*EKF=(ST^YL9
MM;3A38&>@;IO*M'CQ05]ZB)LL"Z%=Y<U_GM??@T_UK^OSI>K3\N/Z0OFRPO,
MOX7-Y8H<[)O%J[\2KM?O"_V-13K_%BZN=/"),+7^LKS(=-"0DOL8@?1<PPI9
MP$G-*,K(LA26G>O$!C+Y1-NL>AR"S_;LVB[([XFWD_]&3).M<UG2?L Y5C$1
M8B@%"IV+A-5:BM*%8N^ *;1943D!,$>U10-[\YT:]<31<B\21:*V-F9,$5Q)
MH=*!H=',:>>GR:CIS0-P)(:^D4X#0W7< C[VG&0^8+W/H2/,P[,,CUP'C@Q8
M<5C)LQ.$X,G_)A%\-D9K/\T-1K]YMM1\9;H3YTAV.KF\S&OVA%]QG5;GW^HP
MRW+,7,W!XT]<5#Z*6J;-Z>3,)I.4A^)KF_E"^VCTM36PY)(IIVP(TR4\'B>G
M4Z A7T^Q 8NZ7H/';;*&@F!\794YH_S7SNGL@X$N.9U]%-[ COOO875>YUUY
MRZ[:91<>-/<%--,1E&(6@I(6M)!2>LUY+M-$9?=G,C]:#C+M<D0]-X:3GR]L
MWL64 Q1,G&++*$@"05&$1*]8"%G?;^$P 5):R&TXS+9/ &6 HAN RFLD=8>+
MUY>+O'Y5:,Z;\^_X\<_PK8JTHPIWDDDE%""G"%2E4JE<:5&1,,YY+X(Q?A+L
M=)A<.V :8O_EM,9H %^O+E?+O+RX"*L=FWABSLG@JS>FHRVC,X:K[4\J%Z*)
M+#K:WB<!T_V9S/L<-#)R#E+SS->;+\,BY/!+6/P7?=R+E/#;IM):W<(\,Q3U
M<9& Y<)(&$.8U[I KD4\3I1B.I5G/CO0O&\\(T%B?)7.C(]?PGH[\_>KWU?G
M7V\+X;1.O-Y2N,1("$3:NCU]83&)6*)"XWP'7#PZP+QO*B/B81P5-K"=[,E,
M-8@E:$7^'GGE:Y828M063%2)>91:V#S)AG(*^=Z'G((.U'5S:+F5;^B,*,B"
M N%,(3F"@"A((BV=5<X%X8^23==POG<O2W?-]^ZC]B8ZR3QR^[GSG>BX<K:0
MCFJM#',)O.",S,Z%D:A2RMU[W3TY5$OP&&K/QSK"CZ#<4ZD-<#H5S2LEC[(:
M5$D&(EH&10=RQ Z%OT^U-7UMP/&3O8>B9A(UM^1FZD/P(ZO!LFR9]A(P55HG
M+B0$I-.=5C9QTIEG//5U-8\/UU*NV]CN9B0EMU]3HG56*D8%**4#%>EPYQEJ
M.N&%$KUPI+$ND!FIIN3X?5B'HF5DU38(E'?+[ULY;DF$EHN4G :?36U10L[3
M(<N0G0\N9>-#IZJU;J.UE!$V$6 .5/&,H%FO-F<?PN+SU>,(]TD4[@P$(4PE
MX:T%H%C A1"%R;'DTHDRAC[UUB&)?KI_0+HS;$O[S_!S]'!-MF#^73_'S"-Y
M.E6I)"F62DY L$J#$$I$]"I%;\8%P)PGG@-,=M_H _0WL]E_.U_4*J3KB2ME
M5.19@V04 BFK"L1*+Y%*HDC;TO2[$4QW,OR=H6<V_1##+<?0XMSFORI"VYVA
M;,B)D8>C@(:!JCMB3"Z""#S+H)QBJE/=5C?SWQYZGE/K:.8?K,4&[DOWL%SQ
MHJWG%.6&6%GT1&00K6&00RTK$VBMZ.3_#^0 ZQP5'+7UZ2&WZP?JNCFT7 ?1
MR(.RDO9,QRRI)/L:Y<;: %BFD*0-2O\+<\;ULG 7SK@^ZFX ,D\3EJ5B:4'Y
M0J95-=ZB S:M*T5KR@5C?5U5_]O3HK?5>W'&]3%! WBJY3.;Z_*93_1OKA+Z
M6%$A,%%Y/FCK=M+0(DL9I+922$/QEYFNH^#]V;1TUW'XIG6POAO$S"ZU(F@*
MR21)@;4>--?4"DP.6 HJA4"BI(G*D_;.9UZO<[B=GP'. *4W )WK)X0JQ+6_
ME$K6EZ::D%,Y-KU3X)(B,SNED@_:"#E- OZ#J;0%F"'V78ZI["9:WOZQ6#\0
M0F03)?<65*E=H[RM.RS+D *MGY!4$F4:JL$]DYGW@7@"S!RJ\"90\U@-:/)6
MRU0HZD-3"Q6"I&,$Z2D7%X6PBGRPG 0YAU" ':D:>^QLMV%:;V"+NBO&+V%]
MOOY(<PGY_>)V/BD_PZ(T"M)5<;6.0&F2T.H,Q;NL@A'%F6-0GCX^PY9RG@;"
MX4F(C62;F=^7W^XI+O\=5ZG:ZC/]R3O<O SK+[^OE@DQK]\74L#EJB:COUCD
ME\M%QJ^+K5%W?^,UF8*^_X:KS8_WJQ?K-6[>+NGK^O?PHVKHQ?JWL,AU1C]^
M7^&W7=\SP7+4P53?7@^N-:,YUN:A+F$*VM,O71>>DT;$:2ESZS#L-Z347AAI
M?UG=5L:;1=I6\"?ZHVJ]I_7@B@V\5!I!U*FV1*T5CS$!_20BL]%&+L99*X/G
MV%(&P%$6P'&LV3BJ::VOEQ?G)"/F*P*OZA=>7RS_?%H%@1E5A)20?,W'RCR#
MKTWE1)!>T!>M0I<ZH(FFU]*[U?18/H8-&X?QO?VL+NGM'O4Q7.#Z_>5F?9[Q
M_2J?+\+JQ\OE)4WI??GE<DV?NGYF!TLZ,.\U ^98[3FD.43G!(@L3(H>I>%L
M_"AG/ %:N@T_>EPS$PZ:.Y2^6= GXWI3SSH?-]5/W"BMYF +K90#8W/MVL<5
MN8&,)!D7N:AHF#C&)<=3<VSIWF.*@^EH]FF+-G.QN-Q2,ZXVY_^SM5:5[Y9D
MQEMC8TF0C,JT :4 T5@/F9>L4.B22O_6TL^-VB;;W%"'.*'&F\(2R7"^S.?I
MNNOZ_W<95C3,Q8_;LIZ%(F+*GDZ;V^Q1IVN--?GH[(((-@@E6)>@M/_(G3#E
M3A-3HVN^@=UQ7QCQQ^)RC7G'R?AR^?7K^6;+THVW%U!*HGA6JPF<D:!B8. 8
MZ30Y*:*0WJ$\7@N'3E/NA$U_"M@\KO4://'\Y#5^O5R]6:055@G#Q4]"T?69
MP\I5P3E@?<Y3.4KP.B)8%Y-4EG&CAM[)/CMXM]<#=@I(.XX!3A%AMR/5L^"3
MS2D&T*%H4,(ZB%6_65O!7-#1ZBXD00=/I!OR3N+AZOB&:2K,>[G\CHMPU5AE
M?9V.\A:_XXJ\]X=JT;/$HRA%%I#5<9-2$WC. U"48;G)=%3"+ICK.6PWA)W,
M\]"42I\UH>,)X9:T7.Y(=5TW<L91>UH8% HH74BX;$@N4T!K'R+SJG#L4HC;
M<]ANB#J9]Y8IE=ZDA]KYV_KSC717E6AG3JNB>>W:ZJ(#94B503(%)%?$6$K@
ML@R&U%,C=T/5R;Q\3*SZD^/2OT.K\6ZY&9TL__$!IF7#[RC8M'3W43%FO$O
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MK0Q6($CI 1-'5B)FYSO=1YYBY[]>)GND\U\?_375^DV[3)%@INF62B[F#$+
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M7$0?(6:6+"E*YOMOC#-7+1R[SJ67C3M4+?11> .8>5BJHXO2PB 'U-O&V^2
M?8D*DC3:*^&BB]/<Q@^KBSIVE<LA>#E,V0V@90]O)F*PN51*0ITK;V8,$#5+
M8'0(3%*TA_?ICN9EHSUJP>XAP<R!NFX.+;=JX'E161C+".NIU";DE7V>,3H6
M*%4T^4Q[GUWM7XV-MI>EN[+1]E'[_-19=ZC \@W?P8[BR0NI$JH,6EIRG?3O
MP46#8'W1@FNG4^ER\?W\2"V!8Z@UEY.I=GZ@R(=48%?BL!V+4^#2<73@6&7&
MD$:"<X:!"":9J'.PI@L=:(>A6MJ!QH'*J,J='RO/T,;E2HA @3L%=Z4&[R&
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M;P]&NP>4D)+A48#A+M:F)C7Z8Z0I7@R+(>IBIZDLV3N=YN SQ-1/ VB WAL
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MH"V%]<_[TEHY9;>Y)J'V%0P* F,*K-#.<8X>>:>+G%Y(N3N'&6$RCF'W0.4
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MT)YY^9P&Q)KHPK''RUS74;^^W- 1>I_/6=>N.*_IE!TN*A'T&<DF6?824*I
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MD6>*"!79DQ8>5 DFNJP]9;Y'*IL^2F1O%V/'CKQ;Z;,#J#[ QM7>JU*\0!O
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M@V X>2=E3,P*2RJIG\#K=-NF=T%DF[;I733=94#U>+U;4+X=K+40U[=])1A
M9 Q,)/ 5Y@ICQ\H>#KO$ZBMT.@Q"!UQB[:+/#J#Z>*$@H\F8$X.4?*JE1G5Y
M)1/JTTWD!G6C.;POX!)K)Q!L?8FUBT8Z@-9]@3U]H5)\,H;5L1BB]AI;2MR]
ML^!"X$$Z&\31)I&<XD773N!XUK\-IJE.)\ ]<KW"571<* .>:U_'%M6I+)Q
MH[D/-JHB];'F39W6Y=>PZ!M .Z/BCM+VR>__\?$_?EK,,?V*BW_DJS</1*EQ
MTG/0)6.]-8Z J3#(-G*KI!*^W+E=O5<">/3#>SL>A]#B?$B!CG@F5@9>?\V+
MS]/9YTOZK\2!4J/G&"$$:<F9ICK"7]5U5MIHY4/1=Q?!/HB(!S^\MV<? R/B
M<(&.[B7>S6<5US_G;_E\_D=./[)BM1/2UZ(K1@HCE:X3]RU""3HI*6(T;AMO
M\>27]-:@.#!&AA/PR-YCP\@Z[;VL:FYXB-89)I@#;:*D7",*0*E4'68H='+)
M1:ZV!\F]S^_M8K -/@X3:P?)UE-='MD7#*EP\$J3'Y0L@J\= %J@EUDQYQH]
MUS_!3IM# MFA=##ZJ?1V]BTO5[6D]I<%IKQAP62KHO1$<PID$=*2LZ2S%-#*
MA$)+H^-SUU>/?OBXL>M@BIL/*<.1#YR_G,\#GO]U^OG+?TWS>;IZM)U04Z@=
MR"/F.A,K6SHQ22;<:M0R1)ON;F=[$ 0/?OBXX6H+$!PNPPZ.EM\_?JKS_"X6
MW\]FZ2]S<C*S"NL-,[XPFUU0(.O2.548JX$WHRR,UW)0\MCH<'F2K'&/EZ&A
M-+PF1O8MM\*MIV05O56^< :")[(63B[32Z; 2.F5"B&GXK9P-MM]6Z\-F_M$
M)(UDW($SNF[_^.G[]6__.LT+(NK+]U]JEG<Y#0<#=Q$3E&3J*D-1R QL';2M
MHG(Q&QW:M 9L1U]OA9EC7Z@VT&)/V/QU[:37(ES>YV]CURIIGJW68(1*=;IT
M!)>Y!F%-YM(YQ$8#%'8B<^3 O %.'H/BX$KK"9%O9W]<K)9KB?'KD03H4[$*
M7/)U;WE]^^&3 92Z")Z#%XTV%SU!5"=H&QX*CX'N0+UT"C%Q];P(L:!'!IJ7
M4L=69(IZ19T'+I4N(;&2W-$@)KI(,D>%V#YZZ11B\BJ=$L)[1AET2)%$I"CS
M\44*<%9JE%E0X-SH%>'C1(V<?(X*L7WTT@'$'AFJJ9GW.FH)3&J*;&W=K^XB
MHPPIVH ^&Z?:/(8^8-!MY\-$#DD;!M!2EUC;V*)&7PPW";03)!IER19=B>2E
M+>7H2A39:&#Z20VZW4G;VPZZW47T'4#HV=FJW!6+2C!(,M )+XRG<!(#_2YD
MGIE@L=%>JQ,==+N3_G<==+N+,CH UZVD^U8(\6:1_^<BS^+WM1%*GT7)R@$*
MA=4($>HT,3#,H\D!G4B-BQ>/$]=;Q\*(Q;5!]-<3)!]B:&/"S"=;+$M <N.@
M-(6=9,&4U&2M)06WJ+%Q)O X<9W4-88"Q!8EM$.TTRG@EA_JW<FB-AQNAO&(
MD)(R@3(;5'5G,Z710F,-3% 'XW/.;09Q;4-=)Y ;"A+;5&T/T4\'F'M^*G7A
MJ&+M27,8R4BCDQ2E* /&>&."U-FD8Z2C^PZ8UR_WS!U6=[V#<6/ J3 G.1K
M7.-:35)S2FN0B2&CT#9EU28(? $#YG>"PQX#YG?130=P>V!DME?(N"%W+2E_
M L6<)5YT!&:8\URS$+EL@JY3'#"_D[J?'S"_B^S[&##/C-)U*2>PF,EYVQP
M72D@+%H=;2S!/+5:]>0'S.^DL?L#YG<17P?NXOZ8<\TH:A3D1;U)=&1K2?R7
MI.N@"J]L<)3"M"EXG>" ^4.<Q6&2[P Z@P[B"@YSBI0K"\<8!8KT.U2E9C1"
MY6)";<=L<T8=>_2?>;FQ^VB(Z-(:KC/K]^5F@-8D.JZ2Q/HR+M>!%CK4P+7F
MZM83OW3HL#:='%L2V-O;YV,AZ%DH'Z[.GJ?Y_?+Z[./KCS]2NM4<O<U_.-@$
MNX<(&6AVW"\9EWEY,XPK2IM\/;)=G=^K4@0ZLFNOH^/2F.(4MK'$'^DXU/'\
MD@F)^?T?>8%UH_WEAU]; X6SB3NI$T@A>6V"0_")R%+9,I.9$R:T>57R-%WC
MNID#D'#740PH_O[]P]K3[C-M\X?_?&!?\1!1;3Q&X9('3GZ>UU<DRHM87W@X
M$($C&LFTD&TNQH;Q&/4MRV:,YRS],L4P/5^_7[F$\(^GZ(1[@E=:W^-3\JMT
MR>"CYV08PNG,->J[[8 /OAC:]ONZ\@>[Z/GV0Z$FPNT@MEV+YQ7%7W?8\-$R
ME5R"&%QE@]<G<KZ \-YFKR+&U*;Q_1&"QBT8# "B(04^\L/$LY36PX#Q_,>S
M\>VLS!=?+QW^0Z:1HR')&0>ED'TH@P%\D!F2%U8'YTV1<AN_L]_7C]L7.I0;
M.H+HN_!*]R.O*\?[_5=<U=>9W^^P&*3G.<<,14E)09BA=,UI":FP8DW)029^
MM&CX&6+'[;X:U)NU553_<?.'Z><OJWFY6.;+$ %GZ>:/;@4+^X^SW^][!H[$
M#V*S3<AN+?DNEA+8)'6]'=: I0ZG$IDQG@KG\:G;K'Y"]DLCNN8KDW<6HDX[
M\.NYN(62U_4X<9MTCM)HP;<9=O?09W<5BN^BO_NA^ %"Z^" ^]%CKBWI??E]
M8UP3JWUVY'6!:^M!(?EF%+H L::\9]Y@;M,S\B19XX!G&(W?W=$UF/A''T-U
M+Q^]%I#P-A*]=IU"4$:1##A=))14BBH"BQ5L"S_RZ!=TE9+MZTR&$5]W'N4Z
M!GMUL:C2G"@;368E@]:9,.W1@RLDJ2@+_8F5%G.;2]BGZ1K/IPRD^"<=RT%:
MZ&(H^-/\?"15K:_LWI<WTQG.XA3/?YM?;@IZ76.^Y90B_U^FR]6$)9&B\!&"
M)J:5B050UH$Z4=<4E-)3V:8-?"@.QO%V8R&UD6;[]9/OYK.X,=+$BF-%<= ,
MZ_C!^MXC,0V&E62\L3Z5-J7/9TD;IX1U= SNJ8N>'>8-2SM8E@A":5L\9%]8
MC6DL($L(=%8PBD49)VF/ \2!W>;@E:X1(=M(O_UZS@EY>Z(_! @^9CH 2KUB
M#V2CV9#_+\RK1CMI'B%HG&<V1X?<3G+?'S[S%9ZW+WGL8#6.1Z:U5)!9?1[.
M2EW'3E83LTE,Q1@%'L,K[LW .)VDQX+G<?3:_[7 .UQ4J7S+A];][WW0P(7]
MIPEM4[E/)ENK,@,ODJ:H3CH(Q5I(/NF8A!6MQB$/VYYWB>A\QRU+2N.S5Q9B
ML'7"L#% @:JAD%4I3OSIY-L,J'F0G*XJ_KOH_?[>@$.%W4$(]?&"O-WZNKZ.
M&9XPIV+)Q4!DF:C/O-Z\UMG",?G@';?F[K* @:#R(QU=%7(/P<@!XNT!'%_F
MB]6GO/AZW2(T,2)[%GF!E.LF!!T<.",\&.Y<TD9':]IT)=ZGI:OVF8- <IB8
M^P\]UGR]_K-NKCZ\[>#!#QLX!'F>X#9AB'>R,.D=2"<I@1)10N Q 27?12?I
M21QMEL@/&X;\&("O <T#'7^!>4!65W:A"W0L(@<3A"X>DQ#^&!?(6_N-8P4@
MNVC\Z3QG9S%W<,#\#1?3VHIUPX#+&'GT=8RR#M6/6G!1U(T;EGO)=+9W=T<,
MA)-[I'05@QP"D\.$?"*GRTT;ZJW&TT&.FB<_N<6YLSTK;0XABC:*$YG Y6H&
M8[T$K*^4!$\V14RF--H@W_(0^@V_KX=-3226Z$Q=Y!.B!\7KY:"W"H3.40GO
MLHG'*-9=T=/58;2+YI\^C/82]\B/"#;=HU>%PO>!+&Z6TW3V^L_X!6>?,QGC
M(Y5O^HGS"_K)SV=?ZW".#SG./\^F_YO3[W^0(M/\CZK0"0O.*B,B<.[J\" T
MM1D((5OG+1:2<MSFE5-K.KLZ^/:!9'?*["#2^I'7O^<JGIS.OM&??J93MPX8
MN?K+FHGR"845461NP,A"@E<Y@./>@U,A)0HZK--M*D&[4MI5&6 X#SJPBGJ'
M8!T-LK8V7.7?\B+65@O)LBH4H@+RR$B8' %U=F"U<Z4^9DRB3:UI5TJ[>CS3
M#(*'JNA$,HDW%ZN+Q74 ,T@*\?!'ML@=MB"^3=(@0XR19P$FV/J<+VOR10%!
M".2%8">5:]/-VWZ^Q75@<"W6B_R.I/CIG_G\6_YU/EM]64Z*U)I)1]FTK07;
M)!U@5!8TR2,X;E.KNOB^%'>5>.R"GIT>_ VEL@Z.SVWY_*^,BT__G$]L-)@L
M5Y"4%*!R1 C(&61A>8X,LV6MWLOO1&A7Z<8Q@+B/@DX-?P2H//&"NQBB !Y#
M)@-S%)IJ;B%QGZ/4S N/XR.PDMI5#G$T#.ZLI!-#X9OYQ6(2F6 E2&)(.[(R
M41@$E\CH7$!BMEC9:*7.KI1VE40<"X,[J^C4(#C]EB<Q4"ZNR+!XU)21.?+Q
M/M>'@8%E+A1ZGEH]"]^-TG'7 8P%P5U5=$(0/"OTG==,BIP9=[K>&GIR]:HH
M0)GJ73$+3EF%VK::0;@'N>/.MQT!C/LKZX00.<G6J>"UI@!#5;X<@BOD]DUF
MMMB@M,HC#,6Y1>%6N+,O"'<[J:2#9QM/\O7[+&W*E#F]_C/2CU[>XDPX2JTL
MV9,N)$[%%-F3UA:8RY1HR>);-2#M1>Y6('2G#L)!E-6!\WOL/50)V?%HZ@.2
M8D"1+0%&BY"+")I'EQ4>H^EMM]9[?P*H&D+@'7BR9V8S9!8-8A%0$I>@K!#@
MDK>@A4Q2:XQ"]#LA@YTNC/:1?[]>Z-;;]2Q1RQP=4'!IZMOU @'K2!K'31WM
MZ:WK>8X /X7KB&&U<,IWII,[0>,@MZ83?KQ[T[L,7-^<_N<A8OOXU[,/KW^B
M;_[YU?M??WO][N/9I[?OW^TAJD<^:##Q;$/H0)?)-XMAWI=7\Z_UW<6:Z _Y
M'"DVK$W+RX]?R)0#Z2I=J>G6XYOD4+L(EIO:SVQJ A,Y1,%C],I8W^B!XV%T
M'[P%9MMO_^GVM]\:\.R==IJ$A8$74-%["$IY<$()E;2GTZ]-:?Q PD?>&G,\
MK-[;$W-$A?=\\CSLF?;>%_'DQS5VIPWW21P(5 P*>>0!<JS1K\L!?";<NH)<
M1HU&RY?H5#_&+SE=G-_Y[OJE;^:+>\9UMEC49N)+"L[/-PO[WI>;'[S[*<N?
MOM>-3G<G4 >/PA4.V6,==T$2=\+7I^/!VN"*P4;/GD9A]Z0=^"YV<>^E;_?@
MZB"/O1'2?8G\$Q?IXXJ8>K_NPE_6'6F7P%DN+[Y>_MD=[A4FQ0*E[2;+6)_.
M$>-2(D@D;3D1M0EMBG##\C%NFU07-G-T.'1J#+<5<)O[L[B:?KN_W8"K>H_(
M!-AUO2'4>1,\&,#(LB"7P(UKLY'[<-K'[<OJ#/0-U=X5T-_-9]_RD@3\@7Y=
M3"/];LWN[[/IZC%F45KA3$(PR@MBMGCPHL[KRD4GP8.SMDV+S4%DC]ORU06\
M6RM[Y#>ESQU>K__G@OA[.R/>+];B76^?_?0%9]N?:,)$.KD8@Y)LJ+L>!2 K
MHDZB"8Q[E]&49S+@(Y$Z;G_9"'CO$0)]^OK?\F(]ZV 6+R7TE/U;DT54JNX]
MKD]O9=VSD9.EXXUG'[0QMK2I3!Q&]\@+V[OR]JW4?7I5RP'&<F[YP8TKF4<9
MVWD@BKDEY+"L0&/M*S*F@",$@[,ZH-9)E3SRC4?CFN9K@M/\>\X?\^+;-.:'
MDXO;M::;Z0=DLM/Y):5K YU$PT-VFJ3'$&N3%MDETAD4':-D0T@TC19H-&'G
MI&N2N^#Z<>\\%C@ZB$AJU?0=?LUG?TZ7DZB]9E;6-<E81[A:#XA,@7 * RO<
M9]'FW=IM*L;%8P>@F ^DH8[0]?.\#O&8!!W-NJG(!\ZA7OE",!;!)NM-,JRX
M1F_%?Z1C7(3MK\]'@+&'<$<N#KS_.IN&B^7;61VE08%3Y40PKG[-7T->3(+R
M.F$*D(2LJ[GJWG8F4JWG!5N<TBYLLW7SZ6_I P3[Z&[>1) C0F*Y6$T^35?5
MZ;Z=)<J$T@6>7YI'42P;RT"Z]29V%B @BQ!L#,DY9;W;ZD"B;[CE+.C?[CJ*
M1TD8]_:IG]-H&!WU!K*_3U=?UI%F+2U]F?[Q:?Z:[&CU?6.6=5BH-3Z!J2.F
ME+;U*5HD[QQ\22YEQ\Q6 R'W@]_3Q(WCOP:"P5.@&E G(Q]S[^:SO#';GZ>+
M'.DG-XY9"*5TY!I$(M*5204P>^(D)D;.WDN/<HL3[M$OZ @<0ZIS/K1L.PB1
MAW'LOTQG^>TJ?R4[--G61V2U>Y]^H6@ 0BH2.%<1$W=)YC9/'09F9-P;\'X.
MWAYPTH&9/,+O3:/83]\?OF5Z=U&]PN8.:GEVL?HR7U2A3#*35A@2@,>Z+!5C
M+1TI"<)'*56)RJM&W2%#LS)N*C,J,.\M%!D3)1V8";']==,D\PK_F*[P_)*C
M#X2)Q;><WLP7ER]^WBZ7%_42:L*"\(Q20Y!8]V K[\@[&0G%":,PBTPH;F(&
M.Y,Z;BK6$\S;:KD#&!]LQS>K!.Y9=%!2%!XC19QU,+N+$CQ#B@^5=87IC*;1
ME/^&3(T;+/5D&KT@9^SVJWW%4"N(O\[3M$POE?4&IXM?<?&/O*K=./F7Z=?I
MZOWL;#:CU.XO]&FKB9 ZAV0+:%?J[MN8P7G#P%%4:X01Q=T=M_EP%];1*!ZW
M^; '8^D8(2_A\-DXCF\X/:]I'YW&EW) 9#IZHX&YRW%_ ; 8"RIHQXT*06&;
M)6>M.!JWK;$'2^H*,Z?7 _;QXNM77'R?EYL6C]ORVRPB'+I!;+=O;=P]=H (
M.FDMRY00U]6N5G,-JN[A0&D<\&!SMH'98/[=6K9MA1 ID Q&"/#)<5 9+:!P
M"0+SI6#,W,?63Y;^W5JV.ZZ/TUJV"S@ZB*/6Y]LG^N'U_:!GBC(F$J<TLAZQ
MIBY_C@IB*I9CL#*&-L'/#V2\Q.:RG6 Q'TI''0#LV:!K^5C4=</V+-UIQ=&R
M%,4)23:R0F9?^_U]"K7@FW@1,NK<Z(U% V[&A?L!X-HUO&ZMZ0[0?NTR;E[
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M'>OGM74L>Y$:[C/L1Q!;6;?KSKI/I@S;#)0O.A'=7GR3R#63PG+03##2?\B
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M'+\XF-JZ/<[K(G0\KVO0+W=QQ.^?%CA;DCA)IW_!:7VZBC(S@776,B=A6F?
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MZ\6W>9TN1]LP8TDJ\":2&+VN(WYIL9I"BS0P433O,O5VEW>.H+SG,!@U%?+
M"<8_9_$2IU?KE7 S$G5[DPP?S(?>?#XI6C-T6@ C=X^\/31U=2#$;*1.M2K/
M=^DWO\>K1W X?CB46HM\!'OBE\?FZVYL:\RYUN%*8#%0R%FG^R'+&HRC6#1S
MYX5K4X[X#%$CR$[VL]/U)?@18*C+\*P4@TTY1(@ID]?I!7F=OD@0+@B1=$V]
MM8GZ^QIJUM8U[P=3?2MB\!UOD>/\8E8[T!-+VZ&D)+3+ZS2=7;R;T7OR<D6&
M^&.>X>6Z=;B2C$5A+ 4UI:Z=@. L%V 1N8S:9)NZW/39Y]W#3,ON?<]K+/01
M&*PG>/SR%5?_.;^^3.^NOF%<G9628[T*3K_RB=S)":;HO$\)"A=UZ+PMX$2U
MS84G%Z41VK7)BN]'[S CN1N8M2.H:YR6[CRO2)2+C,M,3N<UK;791>VZ<S..
M8W5SUEX/W>?+FPX]% Y;$6N%A$V804GIP85ZQ*6-"]F[[&V7Z_5]T3/,0.WC
M6,2VRADM(-_F1WC^2+PN'N'8!B]4<AR*+4C.1B9GPW!?*U UU\R1#/1!<-R%
MFF&&:Q\-C,T4,UHH/KK\GN+8ZQ2$SPQ$5.OS4Q*X<N2B,,:X11'L_<V[#\MX
M"!3['](]K&'L0S/C=1YOY7KK%=_,O+QQEF-<7.<T">1[1&D#N/6,\MJCP;&:
M*R)71'BN@XMM+IH?0/1 ([^/YT?VKKE7"M+U+;%EGI1L;79H: %&1:Q&07XS
M6BB&A)OIBVATN^H H@<:)#X2D.ZCN8%W]5M^SJ]KW<"'\ODZ+*=IB@MB[;?I
M9=Z<U-S^WJ>\NE[,ZG!,KPUC"#$* 2K75(/)]*U,0CI1O#&BPSZ^[_N[ 6WL
M!QM'D?X(S. M_6=_X=5TMM;3UC?9^LOO9MOY<#]NO91:;S[1DLG(40(684%I
MFR"0N0<M4)%P,683FMC!0ZCNAL_7<$!R--T=6A;PI2E<SY:KZ16]YD,ACWE9
MYU?74^U)U":Q4&]T<FU "9; \>R!%Z$X"=8IT<:3[$YC-RB^AG.51GH9@8'\
MN9">\CN6G^CS^0S#Y8\MHQ-=0I:!*^#<U:F_=3PKK[+T@G8#22Y';-/T:"]R
MN^%PS.<RQ]-6;Y!LVUCX"?<D_/BWZ\5TF:;K"=6]-!W>Z4TM&A+OS^H1FA43
MC(JNTRQL"K:>^RF*CRG@X)G,G?><!]:F]+I!L^('CSZ=SVKJ:CWW?%TY2WX#
M6>^B@:7BR, G<B^TXF3;65"^3JZ);6H8GB1I)+=A#D3&D]OM01H8P>[Z1+O6
M5%1!&0)(74LPHF: DG/(/%KM4S#1Z;8X&D$?Y)Z5W:TM\BZ2'R5^MAT5)<=B
M=03,7H$RZP)676KR7(20K$+ECH2@<=[YW%W;G=LB[R#Z$4#H\<ZK9'ZE=K6Q
M':].J L%G-0(PA<IC792B#9#C_=O>#M T^1=--VIX>TN8A\0._&&Z,GIR:1D
MM$9E!LDF4:\+"@C,()B@D[1!81;/-8]<YOBWB_GW?]D\\08GFV_6$%F#X^?[
MQG83\P D["G$0>_$;6E^>S;).D?EN "C@B&:C06L>8S(,M?:!^/<<XTI=E/\
MV[.Q79;L0?$["G$4BO_MTZ0$5$KE"-IY#<I' T%I"SDKEJ(57J;GAG3LIOC?
M/@W;L*:)XG<4XB@4?WH^"581*GF S#R"TEZ"\V2ON%=<.%\\A6[]F?KS88KN
MVYKZW80X"L6_.YN$Q$+T5M>V3**&ZA%<(2<E!(K167;1/7N4L)OBWW4S];UG
M8YLJ?D<ACL"U.W\_45(4S(Z!%*8V@:B;DT #'K5$6V?)WV](=H#:S]\/4XW>
M5.T["G$$T> +S1M0.H;H)$13ZK;E% 1-F'9)(!JN90YM$E,]=-+HO8J\:7S8
MHR)& *OWUW\1W?/KQ<6[66U9M.DYL^W6IZ+.Z"Q$X1Q)ATOP5BB(D@ED66+R
M;8ZJGR5KF&KPIJ#J3PT#8FJY6$T^U18/-]VK541O.$(22==M-0,JIFH;2>Y3
M-B;Q3B?-]-1?<$/?W<?,G=>.) W12T9\?WF. 03;KD(Z\)R4 %8X ^4D [*#
M'@1'YB22;92=3$AW& R9F3Q 9?>5OH?\!E;[']/9].KZ:ILQ+2$J[CQ@++82
M[@#)L:JU"SFXX@-7G8;7=%+\G5</K/I]%#?O0XI#JQ__^H5PF;)3#A%L,J)V
M[*2 *G(#.F9)D30/F#N=4W13_Z^O'F8+Z$W]>TMQ!-[D8_O?^]OZ*9UY#MDZ
M2(5Y4"08<,HXX :YL)X8"FUN)SQ+UDCRUVW.T _6PPA ]>%;KJ'6IC@X6D\T
M@C HZ\5P4YL^T:)(REB9DLFZS>GY+T2,Y,SS<-7.^Y'S*RD\_)3C?!:G%+C7
M!W^.7W.ZOLSS\D0]9B\EB'N^LT4Q8A_L'Z$LL=YB)@<G@Y.>0F=A",#22HB)
M(3/:1>W:U"<W+$N\*_H/3XG\[*]-GY:;5E++CWE!.IC1#[[,;ZK7U[^^J2+]
M-+^\_.VF]=1$:N^U$JFV!*75BD)!"#) %MP%C1:E;3,;J35G(S&U!^+T8<?P
M$>%A!!O\$_Q/9#%),]K'A*[%%R41&RPY\JBS<)BY2:E-J=,3! V+QG&AIMO5
MUYU4N#<2OZT;$WQ>X6+5^ ;V^@K'LF//F*+((ZB5BRH[4>?0DK&PCI-+Y4V,
M/J!1;5H0]T/_L)G4UXCVE@ 9KYE^G.NG.H8X;904@4%4M1F#4W4LF"8(1R=+
M9-P7WB: ZX/Z85,%_SQ+H@]PC'=!;*_Z=>39*ND#$T";(:=(NSA G25H6[AT
MUALAVXP1ZX/Z84L 7^.": >.05ODO\#UIYRNU[<=[[+]'K\M\X=R\NW;Y336
MI"?Y<*OK>C'[_?1J>@,D\B$95T[R>L^VS@G@V0*B-F"XC(D[K8,[JA]U"#/#
MEDZ^Q@5S-.B,>?U,$&D?+,&!]ZRF&VQ:]_L#[@V+0H9D2YL,SR&A<+-*T->(
MXYU4>& H?#9+;=/J[S]\_OSQ[-/G?SWY=+9'AOS.G_>6['Z:J)[RUF>XJ."I
M./K\%7])!I(R30Y"0PG>@C)> 4;KH"@;T,5HDVN3J'J*HD/-T/WG?B$)OJ%?
M^/LD,UX'K)!'PE"#8L: TS(#9J8]Y\(&UZ8B\$F2ALW*]8*)^R:D'_&/^5SN
MU[6Z/N[>YZ#MD8<T,2:/$=C:I"!/#'-M."UY#84Q0\"B(6JA6.T(2&[,JS(I
MVQ/'#^7^&][@<AKK1)[IY77MR56E_1/QKJ#UED>@N(<0;RR""TJ#R6A%8CH9
MWF9.\IX$C]0<[8*G^^;H&*I[+<;JY\'Y*5[&.JN,7C!_()C]JP<.>%D3XW<(
MPZV-)+<1G4V%]D!O0 6/%-X)#Y@2QH#H@VV33&YE)&_Z;\^O;AK2H7)")\?
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M6Z)/R0][V+2719,2F0?(.M3>+BE!X)EV-*^S]Y$VM$9#TG8B\^"17OD"+__
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M-H?59F5,E$-$HPUHA:;N[V1[O?)D@(O2D:%"U:;O_^/T= *3?\5@.E@)H]@
M?\?I;%GCD;S\,#O[J\KJ>KK\6H7WH53.)M8XQU*A35P(,K>V=M^1S "WGBDC
M$'FC=J(ODM8M@\M>+<;ZU<TH$K:_S1=Y>C$[O::WS^*/+PN<+3%6D55F*Z]O
M,DDQUVQT1..SB:DV\"5GDB4!F.L\C>+(G=1*:=.FD=8.1':#X.L]16BEKU%L
MH]N<]?:,9#J[)AEN',_Y;,/:S>\1@WE):W"!I-3I#!<_UL(]G].GLQ61=KD6
M_\:C0&6%%,R#\TZ!(OYIA3H+PCN'FAGC;)L&X@V9Z@;UUWN8,18\[+\TYBN\
M/'PTT(.KP6L7YY?+P;-T)XV^O4GI=&$J4D1FLZOU5Y[",E<">!5+=MEQ>[]I
M_N,C@O9\?S=XOL[3C:/H9 0F>3O^Z,O\)/[7]721-^4\=5;2^B!GHDT.KD@-
M/@2L17X1@BH,9'+>:F6#%&T*#%XD;;A!9\=!Q[REJEY7IXOM<6'8-B,_I7#L
M8K[XT6=3BA=?TK!_Q&X,MF[U@$E;5HJ%9!,#Y84!9SQ"B"EDFYS.O%&7@^:M
M'L[ZZ7^_KE\3R9E4!-("BZ46OSH()M'B3M+4V::H&Z43F[ SKNJLO;#8?.S!
MSFH?P19/?G7,M1QMS?)T^?<W/]Y09/GU"A=_O[D 'X)BTGL0-PW#B2D?:AHM
M&F\R;2D:V\#X)<K&TG1B,/ \'(+:GR9'B<PM-YOR=%^,=3$)DHX0H&Q$0.0>
MO)",_@\+XVT. U^B;%AD]HN#%T%V@%(&+C?<>E7G>7LO(1FFB^"*=&ZK9(H$
M%[2I@N(EF&Q2C"\XCH\^>&R .$1G\[X$.$H3\^,+_>EZE42>E.:!@?:,A&)4
M 4R.0<&868H6F6CCY3Y#U%C:"HQXR]M+?V.$8F5DLSYS2%P*88&5.D4K4M".
MT5@(0CNT61IOC^2"_21J;"9M3\6_!*@]M3 "0&TS!?<YNFT"$ZW,*,%;$I!R
MHH#3BD&BS=]SKEE6J0FFGJ=K9+#:5_WWDW/]Z6($R'J^'TC)HG9%H^676+7G
MM/N[XNNP,Y61++JVOM$MR(,;\ASA^N-8=L[^=#@&0-ZYM4RNIM0Y:8IGB ,5
MM0-DQ8$UTL:LN8RV:3/W,>R//:KWV98]N\AZ="U[E+=9) 4NUG[?.4;P2B+8
M8*7&HI0J]SH8OKJ6/3NIY]F6/3O(:NA>'@];T&2,3!"XP9;:XQT3!R>5 ..E
MI1"5S.C]4.X5MNS95]<'RFM@;3_>>H:)9!.&!)[5IJVFWIO6,4-Q+".&>FFP
MR^6YT3?LV5?GATMMZ$7^9,L93_PGKV7MC>KJ'5&*_B2Y1SEQQ9(*00379:V_
MAH8]>R_Y7J0W]H8]AE@(-D60A6M0G&(U[[('5$9ZQVQ2KHO5?TT->_8%1*^R
M'+B_^8:!#XM-L+3V>+US2OL8@!D3ZO!M R%[#2X')V4J4G6; =RIM_EC% QL
M-D83?_:BH7$@[%>!;-:?#L@B,PC)U%Z',F5 RQ*(.G<OTO?2=DJJ[0*SAV0,
MUPK]<,T^A,F!8AYXE_KX%6F1Q7R]JIOMEJ6MGVV#<2XQB$7)*ID Z$V&Q+2.
M3'E4ODLKT>?>,3@6#E7?O($LA_9<<I7&/?H5%B&T#E HZ *EI05G>" 915^#
M;H6!=_%6'GGV<(WM^\? P;(;>DXI.5JKK_ET?EU#L'M\!(]2\BPA*49>5JZ#
M[;/P)![AO1!>"=DE(_7<.X:)7MM@H3=9#IV97& MUZ4OZXOVO^=97DSC/7YD
M5DDI3KZ\=G4.#?= 8I/ BY."Y,2M*1VPT>5=P_BJ;3#2NVR'MA^5BVW=S8;\
M*!+SU>A%F2SYX45!X-Z H$@>F<ZV>-G%;#Q\]#"Q;2-K<:#D!@XZ_L#_-5_<
M1F5KQ]IH*Y2(#G1TNLYQJ9)P"%'58V.-4F.GD8N=HHV'[Q\X\3&JD/9 [0R,
MK7.\(CG>X6&SV!@RY((I\J7)/"HC<^U1Q4 X&WG&Q*7N=&^V$\2>)&.X(.90
MO<[[%O+ V\^6\B_S;U_R[+[+):,//$C0J$@R12(X<K6(&6,-?>N3[7+J\MP[
MAD-"3^J;-Y#E""HP=K7![W]>P75:F) %&*P#XT4=Z1UH,Q:BYI0E$SFVZ6:R
M-\D#-Y@;S;YW7-T/;?CNE^YMQ\EO13KA-BNE602,MK9^(9<TI)+ 2&>BC\+)
MW&52R(LO&K:^Y$C*GK>2_ ALY0.&/N9%_0%>9#Y!YG-VM1\H"Q2*EJ@A2)'!
M!TV!B?'TI<U8U>>H&K;,Y;B0ZUU+(T#</J,'># B4#0-P:_GL"<.P9D A9&Y
MHJU"^=1F/FNKR1'-2G*&P6=KG?;8G>PH/2!^S_.+!7[[.HT/M=!G&X@N[VG8
M"6)G-ILW@S#"T/\(OK$.<^22 ^;J/I:8=!)>V4:=M=HW@]@F"Q]UILF%?C^?
M7;R??L_IIL'*C2?-F=)%60_)6 K<DO* A;[(9+TI=9J6;U1]?A#=HZA:/@Q=
M3[=W:*[(@?-WM]7^/ZT#7MXDJS 8&[(%J<,Z62Y(=,J"RSESHY'3IM-;_NY)
M,L;2J:$]#N9]*V5H9-TLS%]9V%Z'2]F2>^*@^BK$Q#KK1;Y+,<F'8HUDN5-W
MXV[(>HJ,X?*!/:EWWK>L!\Z3_#F;KG):"V>)L_3Q.B]6\T_3.-_6F#,O.7.T
M?)0@5G2AH,FA)0]8B6 S,N6[S,E^X34#PJ(?)<[;2'1 <,1:I;'X,3D]G]36
MLR58!]Z+0ILZ+Q20"(3B"]/!>2G+<R[2,L>_7<R__\OFB3?68_/-VGBL4?+S
M?<.5/_4+ACTE. :=GTP\9JU\<+6P@APYFVOHJ27X&&QT%GF\?RWC$)V?#%?F
MU$CGNTEP!#K_^'Z2G"F9:]KY;/6<C+,0M% 0#"9TQA;Y[.#'W73^\?UP94MM
M=+ZC!$>@\S_^QX3+(A-7ZUC-@V+&@^,A@S%"):M93K(_G?_Q/X8K4&JC\QTE
M. *=_]O'2? Y&14L6.<#D:U4':\1UP420LFH8WDNR-Q-Y__V<9CSUW8ZWU&"
M(]#Y;Y\F* 064\@HZ7I7E,D(1"HY)+1'L129=O=/.P_0^6^?AAFPU4[G.TIP
M!#K_].>D,.(X,4<HK1UPLD]DF22CW<CQ2)&M5L^>3>ZF\T]_#C/]JIW.=Y3@
M"'1^]ON$8!ED\ R,Y[:V!C2 1A'7RLN$PBE6^EOG9[\/,Z2JG<YWE. (=/[V
M;&)82>1V6, 8:#>R(D/@J@ 9*V$CDA3N7S4X0.=OSP::&M5.Z3N*< 1*__W-
MA.GDHR:/,]6K<\I9":Y>FHE>9VZ<4YP]E\_=3>F_OQEH3E,[I>\HPA$H_>SS
M)'HN;%(2<@BNEOW55+7GD)5T.LJLK7NN5]N.UOWS0!.+&IKWW40X J6_^T*V
MB1=>*,#4A<R2JITB,$0$PZ6@\",[$9^[I+Z;TM]]&6@.4#NE[RC",5P86U^1
M7$QO[SV9I%(((0'GM61=V0P^&82"1C"?C;#^7D/9IV^,W7MV-W6_@C1<+\(;
M3_%?UT/O][?5:<$*:WGFQ%VI"6=7NP22Y"(J)Q(F+5*;KL/[4CR6[MA'*S,X
MJHK' ^6=:AYMRB[QE(%<,$9.621/7*, VJ,MV8$0LV]34-VJCK59G<QQ4-1#
M&>LN*GV]9:QX^>O(PKNR;U/0VN6-1REMW9GUUD6N*GB)OGB2I:I3IC2GR$Y&
MJ$%^<$)J;SK=M/YG*7(M6:$/VH-+J6Y6,@':'"!%JWGQPCR?"?[?1:Y[HZOG
M(M==%#ET*>*3!7?H"2PA>3#KL9F:Y(<F2"@Z24];18JZTQ72_Q\7N>Z$@TY%
MKKLH96AD/1DW:J,BXR21*IQZ08=\G.(LQ%*<ES9J%SL5\__S%;GNI-Y.1:Z[
MR'KD1:[1L6"3RR"D,22<1,)1M9-VX):BNYR%Z=)Y]A46N>ZDQ!V*7'>1Z!BR
MK&<3C,Y)'A DTK)0W)(DF*F3T(SA%-C3KM[?8?F[;H=H1\ZL[P.&/24X IV?
MGDPR8S%XEB!;H4!)YR#4VER5?*X7+9TWSPU#_V<H<CU$YSM*< 0Z__A^HK+T
M);C:?RPB*+0!L#;2R$SX4G040?>WSL=9Y'J(SG>4X AT_O9LPG/VR44/5M7=
M2&8%SFD'47L>+/I$_QZ[0.+(1:Z'Z'Q'"?:8PCNHM)EIVH.\S\"SKW,%I044
MJLX5#-);JPJYQ,<N;3YRF>LA6M]1@B-8Z;]]FGC"82E"@]5:5-M4+]HH0SC5
MS.2LO1;]754:9YGK(3K?48*C6.FGYQ-B#3/GC&Q2H>#6A S!DHF2,7'!G32E
MS\M*W2ZH';G0]2 _;C<)CD+KGSY/% LR%"/!^=I&RB0'R(N#Y!0J9Z06SR9[
M=BQO[E8,=>12UT.TOJ,$1V#?WWV9)!T=>1\(P7B*-Q3QBBY;\,HRS2SM5J''
M*+UC+=212UT/"M-W$^$8:Z&$C])D35Z(K]?UDPOK[B)01"B)\Q#4_4'(/=="
MO9(4W<'"&T\!R>XE#L(&GIA04$JN%S&-!\R.0XP8K4)I4I#/V(G_70O5_#3J
MJ"H> 93/Y[-XO:C*N&%D@G60DF0)7)"E]B2T$!@+8 -F&35Y7*G-W.W[E+S2
M*J:=]#_O41F]@>DH!4IW.Z+W68CT^),;%AQU8*5U85'D)0<*@@&31P)=Y+1_
M!@$V2V8*=QA?;6'1S[:8FR7YYL==@;_Y<?OV[73RC?E/3A:KZY7W6*]4\  ^
MUO[J5JRG]^CG>X7T45VT-_$C+3':!6=/EQ@=1Z4CV%P?-/]]\^,+_>FZ\D$%
M^GV>$]04-BCG,B!J"\(99Q(/W.HV9?'/$#66VJ,C >2E5LU[:FN,P*N,; (W
M4R3W*ALP3M3N((5!2-:"R<RY%$4,LLU>\0Q1PP*O-\6_!*@]M3 &0&U6W@.6
MMH4UQG++N0##:U>I[%7-W@1P/A:?*);GV*;-]PN$C0Q8^P+@/K!ZU,88P/5P
M_;W)L_CU"A=_7R_":%,0.CG0KA[S6E4GDT<#O/#@E$ NRG.=!'K=*^]0-I;T
MR&@VS/WU-DH<;KG9CFC*EJ)N+0!9H' <)<F)60E92^N<8,KF8_EL=RD;F9D[
M" <O@NP I0Q\<+!-*IWGU<92<\^4*X5T[D.]\Q8+N.PE1"%M=**P&+J4^#YX
M\-@ <8C.YGT)<'RC-Z5 (121&^K\486\ )JD0 :FC4V")]]I8VLY>K/9P).A
MMJ\>=#':09M>286.,V!%BGH'+) H/((VV<2HR6H\VW[GGW'0YDYZ[31H<Q<A
M#[SCG!#5T^7\>A'SF[RXR+/3^8(6TEH7VZG5FD5$C#5$T*"8]_4@ERPHNJ 2
M&6JF?8<MZ.4WC7'HYDZJG#>3Z\ H^2/^OWFYG#_"!))PLB.#RJ,E^8ADH38Z
M 1MU$B;1QZ)+G_TG7S#<?9/^,=&/%(<>4(F+-)WAY;^NC[W>S>)V/(!$KV(0
M4+D')5&!-X*!"5IZ*;1.OHN5>.+QPUU!Z1\&?4AP!,'P Y_LCHQ^GG=;Q;FR
M(9+OCK2]9BF!^&1U;H0S*G.E8YN2EHX$#G/396@?MZ46!RVT[317TSKAG"H)
MN$TD,4P% CHR1SI@\E$ZS=L,DSMX^ND1!N[V"(1=9IWNHI-1E[+\^>;SV;__
M>7;^Y>P_Z,OG?6I6[C^BO^*49XGKJPKE.BSS?UT3E6??JY6ZK0[@VGEE,8$U
MR8"*ZTFVW(%AZ%*2+,3[);!]%5P\0='!52CWGON%)/B&?N'O$\L0#9,*<D9.
MR\1&"(EBS)*0_IOB37V_\V$C5F])&OCLO@],/*@8Z47\K\F8G..B6L_OAXR:
M?>F1S8S-\\2W-CY%2^;6'51]=:\5;6'!U2Z=QL=@-'TJC[,B&QF?&U\P1E2Y
ML @6"P%?$/!1<PHL@Y>ZB(!2/7=EN#<NQU"DU@<27C YNPM]!)';?1ZVI2Q)
MDR4NR,"SVE>\]AU&;B+(%!4RS%FRHZR0D52;':SI%Z"SC]C'B9Y-0L0Z+X6P
M%!"H4D]Q<P3GBP!.WS+E/??8J3]:'_@9P[%W+PI_&41[2']\,-KVO&9!A-J>
M@V10_;:4 6WT@$ZQZKAY5(VFO#]&SNC@LX^JGP?0'G(? 7C>YK!Z-Z/M_+JF
MP=:+BJD0<A 2K*K70UE1X(5P('RBGX1H96Z39GQ(R\!%7WWO6P<*>W1PJ1G]
MS4)27#J.A4%Q9']5[?GF&<O DO3>!<LC?V[J5%^@^4G1L!;G4$T_"YP]Q3[T
M^;C_&V.?\VPZ7YS/5WF9KBEZC6NC2:K5&_.IL[:(DH%)C'9TU $"20:2K.98
M%HHS[AF?QX_(N[QL3!#95Z?SE@(>&#'G^1^?\K)VF$RG].;IZN1BD=?-33>\
M.%VT2>MQJX:6% 8!F(J'R#G327B9K>L EI?>,^PNU#M.>A7K\&6>\\OOT]G%
M#2>_89Q>3E<_7F31Z^)4*1&*C;8VPXTD.TD<>\T+<H7Y_I6PIXI!]WG],(:G
M?]W/CZN(@;'V)2^NWL]Q]J8S<XIC*-%Y\'4B^)I-8HGB#!Y9">0PFMREI&?G
M%P]CL)KBJZWP!T;6S:;].<=K>J_A0J_W[[?7^;<<%M>X^$&0L!NV"B.VLB.Q
MA<1HP:@"3DH+)1HC4V$F!NR J1U>.6SI<N_;7RMACR ZJYTRZ&E756:W.3*9
MI(D%"0,ATSJ(AKC1!4&69&3DF6G;)I?X&#4#E\'W'= ?+/ 1@F9;DV=BBM%F
MB EK-^>LR'P*"YB#U-II*72;_.'C] P;JQVNYQ> LX?01P"=/V?+&S-:V=A>
MB(TY)>(<."-#J:16X#/M]UZR'+R0G$+2)KAYA)AQ@68?'<_[%?@(,//Y 0,<
M$VK')"23D=PS'<![@V 80R6YB8*WZJBS#UZ:!?H-\'*8L$> EKO1Y(W9#4S(
M:!.0.YO))V/VIA&Y8SD&D8LUI4VF^2$M Q<\]^W-'"CLT<%EV_[!D EDW($U
M@B!/QA%\\1HRUHJXJ(QPC1IF/$+-P+>%#]3PLX#90]PC@,P3B:OM31*FD[&H
M0&NDS141(?B$M+HLL1+1Z=!F;WJ6K#&!:!^M/VP VI,*1H"GN_F*3SGEJV]5
M,Q_S8CI/ZR57KR#%)!2((@THQ1AX;CBDY+5$6G#A_@6O)F>EC]$VS."2(QVX
M'ZR,T<-KLQB=5X[Q.I5'REJ6*0N@2+2""OE^)<3(L,WM@"[4C>G4]7!$[ 2X
M/=0S>LA]F.5M()I8<ED$D,Q(6J@Q@E.8P4D*0H/-WN8P .IN"1PS\/9!QD[0
MVT]-HT??EW]LYTTR)951/$)D3E<'Q(*/F@.7Y)#PJ)V7;5K0=B1P3$4$1T??
M?FH:N/7+)YQ=W&1Z?2CHC?- _]846YUEFI*!I)#V"J^L4?T-%;Y][3#CQ'KW
MQ?87Y1CTOX%M,(S'F"3X9'FM$W: /B9P7$2T%"4ST5_WJ%]>/%PCESU5=E_I
M>\AO\-YA?TVOKJ^V]2G96AX< ^-,!E58(N;K[,-,YE&G('V/79[NO'I@U>^C
MN'D?4AR!SW'/]KV_O;)?IT 0Y@5X;6GWTD&#=T( L1%X*EQEW2;W_!1%PXP?
M/-;%KOT$/P( W?>&OETOXE=<YO0;QGQR54<R36K7!^FX!>L\(T\H(82@+6A9
M>"TZ8<QWLBP'.ZR/$#>JZSI[HN %!_50E0S:FJ76,=UEZ'1.HL)?/>^367H[
M71*/BXM\.I^EZ?J':T;?E=/I(EY?+5<XBW4RV&JBR$ G].L98Y%\?Q4@,%M[
M"3!M&3*M99?NJ+T2-:K;/X>A<%B%#5S>>)?QL[^^Y;BZL^Z0!4.K+4+)M>U2
M';L4N$HD6\><RTQ[JW8&W\/WC*KXK&\\'2C6@2%2I?&AW#W_V7*T<27?S!>+
M^3_J*1%^H]]8_9@(QXD,3I%(<:YV'ZA'E[&6DG.3A4LNW9^?]BAL]GGWJ$[^
M#X=2<_&/R@)M3>^7^0HOWV?:D/$B?ZK:FP26)=<Y0O!.UF*J#&@T V>2]$4)
ME>\[93ML@P_?-ZKCME8[W(%B'IT[_XN%%2;I8'U%@%(4Z]0!F-S5N)99^HQ[
MY8YQ57K'+>Y8.<,6CON>PA\=B-[-Z,EYN:+UD#^O;['\[.!7EP>2/55@@B#+
M*C@)KF"FU1(%SUK3+MYF"$MW&D>5>&@!M-X4-#KH_7(XLYC&_ M;A17'/9<0
M60ADEB4",JZ!Z60+\FBM/,8E_B<)[ 0Z]XI!UX]J7@_B/A3ZP2Q.O^'EC5&O
MOYFO<IKHS&NOT@Q<8ATH'0.X:#T8U$9R]$J;(]=(=:2\$T;]/R-&^U%F^QZ2
MFP_JEX#+_/_\'_\?4$L#!!0    ( *B.JE163_'*J9T! %5&#P 1    8FAC
M-30R,BUE>#DY,2YH=&WLO6MWVU:2-OK]_ J\Z:3;7D,IHB3?DIY>2Y9D1SVV
MY;:49&:^S *!31)M$&!PD<S\^E-/5>T+0%*V93NR%,XY;\<B06!C[]JUZ_+4
M4W__?T>GA^?_\_HXFC:S/'K]\],7)X?1-UO??__KWN'WWQ^='T4_G;]\$>UO
M[PRC\RHNZJS)RB+.O__^^-4WT3?3IIG_\/WWEY>7VY=[VV4U^?[\S?>XU?[W
M>5G69CMMTF_^\7=\0O]KXO0?_]_?_]_65G14)NW,%$V45"9N3!JU=59,HE]3
M4[^-MK;TJL-ROJBRR;2)=G=V=Z-?R^IM=A'+]TW6Y.8?]CY__U[^_OOW_)"_
MC\IT\8^_I]E%E*7_^4VV,WJPOQ_O)SNC<;K_,-D=#1\\CN-AO/?$/!X_WAO^
MWY-'-,KOZ7KY4=TL<O.?W\RR8FMJ,( ?]G>W'SV8-S]>9FDS_6&XL_/=-WSI
M/_X^+NDU] =)F9?5#W_9X?_[$=]LC>-9EB]^^-MY-C-U],I<1F_*65S\;5#3
M9&[5ILK&<F&=_6[HQO0,_O-2GTOWR;/"V'$,=_'DB/[O[]_C.COJI;&/RBHU
MU9:.:,S_]Z-^R)?\4)=YEMJ/Y+UVMG<P@'F<IK0<]J6C_2?;#W;PW^[?WW0G
M*ZXF-%^CLFG*V0^/Z3;Z25/.?\#4->9=LQ7GV:3X@1?UFR\]=X]6SMWQNVDV
MRIKHR9/M87<.U[[,@RM?)B'Y,]6-O<T\CXNX*:M%]*ILS >^46]Y'G??Z-]M
MW63CA7R4%2F]X ][#^=??L562_MI$1VT$QI3M#> )A@.HF9J2#O,YG&QB.*B
M*-LB(262-764T6(4T%%UU)114A9IFS1T#7U!JBO.HWD[RK,D*L=C&@WIG'M_
M_<OCW=V='T]>G_*_AC_>IR_Y7K&IZ4$-73TS:9;0CU-SD24F&D%=F;H>1,_S
M<D2?GY5Y$[M;\5_N9O<PV/";*'C4=G1F#/\_>X69QU6,%\ H\-.G<5LGT^@_
MHA?E;!0=+\S63R;.FVGT5$=!;Y?RE7+WESI6^[4^*AJ9O+R,QF45C=N*+J_H
M;9HXR^NH,I.XPHX/[D)CW([NHC2=%)"*PB0\QY<9323>&MNH(!FJ._,/*9#Y
ML$L. 2M%GE(S-_PZ*E/Y(FJJ.*6;0 *;132NRAG?O#*S&-=7N*>NIRZB2'%&
M[W=2)-M=R9[&-:W:I"TB>NMX@@7"@,JYD1%B,%&,+PNZ]>4TH]MF-5ZOSFIL
M _]Z=#334WZ/Y?2F.:]H6[25L4+67);VU8T,'T.BY\^K<DX'>1J-%GWI.* +
MZ-7J-F\&4=I65H#&645[];<VKAIY8YS>G3>#2 X?_5A'A]/,C*/C=R9IF^S"
M1*?C,>VORNVDPV.W4P;T@B5>;_U]3F5B:!A')LEJK.'+^*VI!C0E,S(3H"/<
M3.(V;E'3#.J WAMK.*W*=C*-DFE<3 S/<3#K]$MLM\K,RZJ)1[FA:9O !*D'
MN@(D6G3+K&&[!A/$VX"M'9WL_NBGM%IEQ9M6;^87:#LZIZ\[=UFQQ%/:V2OG
MY?@T2MI*WNRO?WGP^,?H7G:?UK4V^/^#EZ)_D&J@V2'U5A8\[DF;QU4TBNE)
M _H9_6Y&LXFQU&5;T75QGI>)[)54)UR4$5U,5Y,Q1T.F:>"?S#'D49:+9-%,
MX+72K**-J+-9;T>OVZIN8WHKVF/T/K6QJS"(#*U0PD)""_)A8J:O)VO(/REI
MQ)=XW17KYZ>GHW'UU<]H_M\-],U.<.(7=C/=P\29BD2G^_F;=_?Q@XO[/<7,
M,T2?'M'+5'4VSDA.7E<E#JH:RVU(A"Z7)2%*2WJ3HB0!H+>C65NUX/)>>,.V
M@-2.VL;*3NTV>O\B%4MYC>B4#H>2=A )0T,Z>9(EM1O,)1T;AC0!?N7/1'OE
MHG?GZ-Z*>]V'_!8DKZ1LW(Y0&5TY)>[AW6.N]RB]*;XGP];TO];G8&*[BZ$W
MWXZB@]QOO\I<F*(U(LWV0U*%8[PXCE ^,N@ *E.H2!+4 KM]&I-XCHPIZ 9)
M7#=J@F!B5:+%DUF6OF##W\5#U]I8C9E%C[9)*Y,2-GAO)[A'69VT->MLS/D!
M;: %*1XLW+.L(+4$V^V0S#EV0/F:-WST\"6G_DAD??C&-%59SU5AG.D<'ZI&
M5V& *1D]P]H,=[;^RYI)M6FPPG035AHTA-!CT#.95_@BP[GH#OD_[AWM4+,B
MR5O8&S32U]A-)R=6S%0O_*VFIQ0ME!&+'%2[>V,GR M#>AZF3(J#T\Q&I 7V
MAF)K=\S7E3-V'\^LS#@731Y.?#R?DUW4L6:Q _W>],I-#E7>-'2XA$=BI5.P
MO)="-:F;D)^U_0>NQ6>4-S'0(6!0\ATA"V88F@F#@/E^0;^8\^$5U>VH-K^U
M1L[.9V94T<&XB';%9=)S,85UUTQC4N0X/W.3KA@8J4+Z-UD J9\B>@-]+B;B
MB@?+P9QC;?EA*U]]0-:VB6LH:;*Z[,_4". GE.R?9+S:(CY]NUA&[^S;,[(@
M*S5:Z??'[\1NP$]FF2XSO?7EY79MDNU)><&7N9\?DH"D&5GUP7T.TAGYC"2A
M\*YK[)RSXZ.#-_X^:5QMDV$9D0V9Z+3BG0>Z+ZV1Z;?BO\16(4-A>3?^R^W&
MW]Q5<L#HSGP95V23Z+;<U?=G"Y=._^'#G1^'._+5]GLB0[V(%EGW+.(_5":/
M(;Y+,2X?4N*#9\?_)![16=LVRS_YNL)B?@H^+!HXW'OHPH'3RK[%G%3(UHB,
MJ;=;\9@6Z(<XOXP7]3>;D.$7"1FN-FAN*,R&@T1VV:-M^6_XOU_C\;)L17ZH
M[#]9&0I_SU+=U+J\.G]S>O3SX?G)Z:LO9C?O[K,,?[E7E,V5-32$Y .V,@<$
MU,+Y ZQ,9_&V\Y1C&C9 8HT,V036TN ;VK,L, ZZEJ%:,X%A: TY/;C9\9J6
M;9[2P^'"LI5+!N"_VZ(7NHOIK,6XZ)U80?$@_:N>(1(S<\:+F!HY7T1VEF&W
MF 97>G/:Y+5A3]>Y .N-:''8R4BA$Z&V)I.8Y'_<$M&T-#&FQU3\7YK^R[A*
MM_*R?"MFMIL"S)I&0V8F+O MW?),UV+WT8%=C] 22MB!'C[9HS4F:8AG;)(,
M>&#NI\/C%3]UAIB_Q_[R/=AVFL4++'5_[*$1N&+PJ1EGB-NV'%Y5AP..M3/I
M:C^:/+ZLHWNT<W,1PWPQL*OT3!_[0A_KI:8;JO_0RV$F8IP&UNQ8I,@;U-MD
M7:::2D5PDLW:X$V[-B3]%/)FS3P8T/11?!%G.;]J:)I:+;A25>T^&H__0%4E
M6C0U22GR^@,O$J[ZYA\=$_K*0?_A^E4\$!&SG[?/],#_  \#KK*U"R29<WSH
MG.1+,R*KF;15(Y?<KH5BG^GK6B8-V4GH,%F01BE;5O*DM\T[Q -4#_LU3&GG
MQU4](&V1(^S/;N8E>=A\$J0K0F\?:#3M[UYA--VLB73ZR_&;7TZ.?_URR;PO
M;A]=*09KTFFRX,BIN632I='-Z)1^6_<_*=O**G Q83K[.8BV\YZ&%HXFD@*V
M6OQR6I(\6960<=PJF\VK\@(1XW*>&V<&Y'0$J87/,2]YA00"/'?Y@%^-C;<,
MD+QJQ[$/F-$ZO37-@*[.Z)\TMS;1 ;F.YZ9%[IIN%[/=8!:8.CQC$$WBFLPQ
M1BY(Y-Y.TO,3]W82ZG'!?3JJHU%5DB%6L>(KQSYC,J*/8#G-IS%=G_"#X]RF
MC2:FH+5-^(;V2OO9JE_03VBVJBUZ"_)&6PS2C>_TW*M4.TF:<[JXW\O3\UE/
MEA&9'KDI:F21LJ*IXC+AS);]K)Q/R0#)9S2:NB7!QPW(:,WF+NO@@ "UO?-]
MF^W#8LDRT$M).HN6H43PROV%+.V<!ON.5JDAHX,,QYV(7ZPB2?V":?:;W9DD
MN;S*;&J[C I< P%QT/_N\/3N[@R?#""AWSX>[._MT^;)<S:"Z&\Z"NW??"U]
M]'!GZ"]!9M$:<]O1*6TCF.AC\@-*W-&)R#C.<TW>C^& O#>=^_6D VL_*!:W
MCI,A& [\"_"?")%>9WP\?WG\ZCPZ>?7L],W+ [C(5K71)$#A?+#C)$Z.SYZR
MWAM5R+FGIDZJ;!YZ<OV<9'=&/T':-<BTE9NQ9+/>)_];PR]Z[JXU6%:?Q#S[
M#Z\V_/[@076G=+B_S=KB? EU9)WS+SSV*]6)8A[X*-,SMXYSB7]U1_N+8#\.
M:;,,6+C;&4 @9U:Y8\>=>J7_NGL$!6?O1E1O@ZBR+K8B^L=(Z.I9^VJVA^R+
MS+NP^/#YB9?LC6#?!L'NV@]_J("OB8PL"=G AV'-N\0X.V!),[-B[ACL8@6M
MP]C"+F^;.DN-%6+^T>O65&2]O,D2-N]6^QWN.8/WN!MR$IP?WL6-\7X\SFW9
M!BL!6U^-KNV;(N\1ZSLD87=9]5X)1/Q:1&_5,>_=UC4ZT5[OPD*%:34&!&UH
M4TB"P GC2$G.L.%>3,>K6O&%5Z%'[Z7!GW&^*G #>0769O%9K.^O.BS"X"J?
M_>FBK."6K\26UT8.PN#R+^OSKZP4D:Q(;5:-\1.BYP^N SGX0]$A'ZGK$(=Z
M5M)"8<9^B?/VRQ5F[>YNWYPLGQ0(WCT< $]8048*KGD ,-.XHH[&Q#-;G3*;
MYRQ>?-FLS9MLB]&G*+_1@@&!.S8H-F6PIT2-.5'=-M$%)A.B#V'62)/FX'MW
MRPH4ER),ADO'NAH#Y(EP+Y9K!-/+BFW-2C2GJA\?143,>%S%#JDZ(-573D@K
MT@O17<MF3F-K!E$2SR$>?4AK5K^5FA.C,/,SCQ9L:"EXZCQN7&=-PY*(7F<%
MO2]-B'S#R5Z\#RI:LD9V:F>ZNJ5QJ0O!RLQQU8X/(#+D=*#)\V9Y$OWHFO@M
M#2].M+0.PP\G$GGY2>T@%/X42I'CX!<JRF(K*3$O].@F*"E1(#"-D8X'N@5^
M("^6V7>M?*V."4M,]-<S6N>V8FU$ZS>II$Y+TRXB.=7R M%B2'15?DXWGN!-
MV[ L9IR;=U*U(K,Y)Q%LM>X*&114SB@:$LO0%GF9O)7SU:MXD5GZFN$---GV
MQ1"Z)ALC"5Z.$SZT+)FYL%+"8_2H6'D>T-6Z&)>X=_FV*P;!]AC("DY-/I>]
MI7N!KO"E9 +$L(FJ-?,ET[4T@#BORZ *HM6<%NW!<HY]A J,13 ]\Y)K--W,
MQ$E5UC*@3O!>! 659[8J3Y>R:]H,@LR6X(9(*#B+YJ>57P];.<PZ( EQ:1B!
M#=4"@#F7HP/A1,?ME!1=3LO>T*P*:@G5-"DR>Z1*41H5K-H!/9Q147ZSVV6L
M=0EY<=RB97D>J+6^M P$E42+4$!JBA*302+N=(?)K($6/?V/%U%8-EIU"_7T
M40!C):A,&[><+DA+WG?E!B[\R7#A_<<;N/"?#2[\D0;AYR_KOIL&I:_U?R@)
M8M;0OL2?M3^LNR:H5\:'P1'@JGK55U:,(Z[J3KH6[W?21?J9SQK9"O\P>:2?
M79%#"JR5#R\8'_3&]_$%Y)UJK>ZYX&&,=U-R#@1O"9O:KK85&QS&WI*=HZBJ
M;&N:?3,C2P(/40BJU)&2$03?%@5-:G_!Y*'1^#WL*N3I6+TT0*&)L81;:4B<
M$1_D&T! <[("JEA1S?(M'\60XN#DUYN0F3*6*Z=D<A?&,$ZV@8E%UFQJ(A/3
M\BO'@$=!JY7*0&8G:;!?I$K;.(,.#^7@CU2"P3H@&\\4DP;/H__)2,PN"T8T
MF49,/7N&V_!15@7(BPBKP;&D4:B[G&$<CA=1A9IDA\29[?5)55XV4S8M*T-?
M&C7))-H13J*;XMB!HMV\BDZM.UY"?\T .H[>&IZA6?R.;+C?H1D^R 1EX[&&
M+]@(^$$05XNH'/U;YT!ECI438G/NP6S16Q/92E[=*)0>?A0M0#F7V<7TT&R1
MV6C+QSYT"A1R7P?T#?T9N(1%.3*X,ZM&TB<F#:LC5<_4XB$8AX+M/M=5G*S=
M%1@8R@;\4SKNK*WEY._H]37+=2&H;K[]^CD@:YD$LU-E1R9Y1SZQ#DX2;;FC
M]:DJHYY*:-A[/R4SOL [=*-CJ0: I'O$WJK%YNH,@7+K>66Y$?#6X@Y'!\"J
M]@X-][BS[8/M8P];Y&L]-4T1_;,E =I]J/6Y+)KQ*J>^-EHERZ7K">F16@I)
MY_'"Q7E3,R+OATZCB:SM=G32\-JQQ-KW8,\)!?N#I3>:@[+!7,6PHSOCZL2(
M7[ .BXXU>SZ,3<>"\KHF0Y\^:*6+[?VE@>A==H?'K 1S@ZI.5I10II?P<+O.
MOB@1B_.'X[@EBJVK$2>9QA<N"U/5TVS.HLZ_9F4X=G%8UCLJNUP$P_!28 T1
M"QG'%R7"':S+)"JP=EX3:Q_<U8-? FJZWE9C]'QBGV^6!<;Z3^(PW,::#LA=
M[&E5^-T2#HD73..4JYI@']!"T1)8"1%C/9.<?>Y/AEH987!<(/@2)SBH)<Q@
M,)Y:(8A2DU3W/(6R<ZIM1Q#>,"XX*VG;D<(2$"HS7JDF9+65<;5\'M/<3-W,
M("K0]2XX3@"Q]R*XXH:!Z)GH'DT#7E%T2F*R.5?X"&\,",GHQ&RP0<R[H*9+
MI14*G<2^)G/TI_(29]A5$8^8]QN/[]+(1K2S;@,AO*ZPF_@\W8Y^IAG*$?*8
M^C!K9]KXT%NV&N(<,3VGX5/. YJN42#@::PTG L8;!V8=#>AMI1(LYB);A27
MPX-KPT%\)''$D(X,,RUS>B#)PC.'R Q6EE_5O)OKTKB)DB*[4+BZWL:X<S.Z
M00;[AC0@;?B2C1VHNW9>.U'5POU0HN3<-H[MB-2((*-QS#A;A8> I):7(/%R
MG!0%A5S!*P<3ZO>4DZ4 $A]([9?C4[E1K?>KJ)J"5\$>]>Z8=X[C"CW8W?36
M(!C81: 79 ^5S.&,IA^H?V;K\/E)\TZ=:BRJ;EMP JV*MJ\R57OG[P<,TCH^
M061YI?$F[D6>_=9FJ?I"=<O?7L.;Z&T/ZZ(O1V34L_'%I1],]N:L%4>$$;O*
M7OVEV(BNJ)#]QYSM@Y8<74FU%3']LYV7A=WL89BI,[>!M@WBU*OM\D8IH>K5
MMUJQ3&PRU5 =M <XAQ45+;/)8$<'9GYO\EV&0:SW*I6YP&(QCMX[UUK<@NB\
M=3;NH%DS?/"=@K#?-^,L"W0*D:+,ZJG.C(N+.=-/HQN2G./<W&="(>WO;#]X
M_SS>?:3;1V.,.KKE1B&=6[1+QVW.94J-F7"US@!>'9O"BS"P:DO<1FV6-S8V
MD)'"(*^CJRP9=BE*%>:4L#FQ-9&1G7ZA <D'3W[\7!#[C2!>4Q [1]F-"V)N
M8H[H**CR/4[MHA^G"HBIEHLE@98+)9"1*<FT8%B:U9'6TO!/5J7K8' C4QC0
M (KXTK<;"?XJ5*D82C<NP6D '.TA,%V%,$Q8*^F=P&6_*O=*QS+K5 ?TZF@%
M$B6F*#^F.Q27/%!/ND(-?&_PH<<+B]Z..%6D#>OXVD;.&UN(,^B6+0P\M#-X
M@<%*]E '5P)H-(QYW#D+S[IP@1>T$B BW(>2<_EX2$J]3.D\6(-/ :($61HO
MHX(9&1D0VS@I%:<?I<VD)5L.?UE@'7/"]I%:B'A7#!7R 0T)C XDDNE8?5<E
MJACY)P/0< V>$>2=[(7(D2$T]DS@JH-5\^DBM]:*UDB!AD@0V\*G'OI5><:=
MI82;Q"#44W.VDO72YL948=SUKF"#[LK&.RFB?Y)QP,$C$@9/ELE$F19.9S,D
M#O-8"D8NR"Q@FI<S3)C3@:X?R5N2ES6368+%*IG: (D+C?6<X??DUBP(SXEU
MOR"<MY6O"F<*5!54KLC>[=O<&\37!KOUY\)N73E[+UST$)O]4$^8-\IY+^$Y
M;*+N=4>(;[NOR.?=(K&9\<=A[$[J-?9\O<;/3\^.__4S2C:.?Z'_/;L^0X,_
M9>A8@&I?&<7TB3 ;O0QS'_"4&-3-T5(-V)EE)'"]A"(8>)HRX99V9/6XAE07
MH.N<+-= 9VV@)"U-(+U;DC5. 887CEHPSQ2+D,=MY:N5U:JX;*:6$*CUUI B
M&RQ55G34[VJEW(T\=N.FYJ+,+XP<$9<@Z^>W9\11+"QU@J1!-DH*9YB*I/!Q
MS16&C9_Q[<^9][M^SH\=Z8_,^PV"M(V_JI,#O+-VAK7=;';EJK2#9,5Z]J8U
M]K .=KLYQ'XG\^47+<3&+*WH((!]6=$7^4/IQXSSTN1,: 5*OU%,SU0-G[1J
M:0<BX>X#8/D9G5/&%2?5A2.)2W!XCP>YO@OHR@I$3)56I(4TD3Y!.)"L1\;V
M+UOG7 HIVGL-!Z2\6B<Y7;5<SA[F((M%F(<LY[2%=7_]]2_[CWZDS4<_XKH7
M?JSN7T?!;Q^.A_&0Q@:+![,,"":R -_19)JXL=E2R59WG!:FX%JAGV@Z.3D3
MK]!4+#TK-9;R^)!IB!6%%J8?U>.%0-#&JH5XQD-Y E=5CH$@'LQ2W$\S]3T8
MAK%%J.9">0N@E,IECLL9H5DQ&HX3WU.R4#EA628@\V/1TRQ^;P=!=#S (FAI
MU)/5R[)Z.W!0 7B'G4QX)RWEG:NZ,?.ZLSOFQC-!NMVQW#LI?/-[66_(HT9#
M,#*YRWM$@Y.\$/:Z8.Z%8&D$"-VHO##W2?@!DV0\ PG7LH8?=%/^RSDD*[S!
M3]=U=7H?)$,1MXKR6A8-;L*S4D+DY,_H?TFXZX'SRD.Z5\N^ZZT*<4$P2:6(
M>7!/I!Y)IG(,Q[IV4!86?%(O+Y8K%A._;B$[T#9^TB'1&+7A3K<- 5LO_@7[
MV38-W;A,?,*(\EG\WJD96!4'::OH5-[^%,ZLK[H4&H2ZGEI]>. :=[Q!V>0S
M*<ZT9K5<Q-^\"<1@6<8=@>.X+S[C;NDUBC/KCDQ]2)K[^G7.#X;O9PG]NHM8
M&IZHG^=,M&?QJC1O/PL4\@Y7.I^7'L].QQ"Y+Q=F-0I4X>N*0_:QTDXUHBU&
MJ.&QB2F-A_&0KD*ANP25M]F#$E4YWSMM4KH),H_Q4G@J1V<K:Q1*O@ )80GJ
M2N!?+[4ENOS::;S8X C^T"&L3GX)GIRI[#O5U1T@#1V'5;=!X-]J#B!>B$FL
MEE4_>"\4^&%@4X66@;.* 1.'T-=SA$4C)E709Z\^Q96DN_)C>.MH_9@9DNDK
M/?9+A0E>P"#JD*I^NS\ KZHE"\V*+O+='L2UL37I[%=;$):"8\1(L*EB@>F'
MD'/YY"S.C4.D.Q"76XL^1G\5/I_3QYO=<[.[9Q:GYN.H!\)M9:&%D$??,]"J
M2U'6AA-+/;M#K^@6G5P:5]@8X-W*PD%_>T/9"-#7(D#78Y^ 3K *%6*2+>FS
MX<Z WDC,WD"K]2MVHGO0<UU7=E1"XR,T,7"\^)41FT&+L<R[L$G9M\/![M K
M3[4NO%O'\8N@!<(+^L]$T9MD%0JI2U_'W0^[ OL @,V],07T\&%D^\DL]QZ$
ML$_6()L#)<XL5GUVD22NIP'_M 08.I07(>-%RC$#CFGK0H6D+5K3I2=$?YD&
M>\&QPY'0>;P0+7+ETKCI"=Z51TVWF7(!RLIWZ(Y_J<++35!X5-U!J-)7R3[W
MT0H$O93S"^E+[2()WDC+S21.%E'N=YOM-%22O\ Q01*:49PP^POMI@=Z[F1E
MU>]#."OKIA.2LS>G_^1ZW\'U-_L@O'>.5L!IFTA<6*I%;$4!?EBU<R_"DAE
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M8_\'ID-OVBX+6EBI:=8QK)C0R]M4QR^WP)1Z#W!WR1I-7!M!@0FPK&R-T3L
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MW-X 15<"13\FR/SDFPV\]!; 2V]-'-\F=DY<4N;NZCY-_)9MG2.(SV%%&/)
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M+GE3DET(7[MS"6;E?Z"Y^6B@RUXLR'X<M=6D<]DO&58(A!:WT_PY+^5(8GU
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M"XAN1F9_89I>*I'..[*B8/(KV=8[IO$BV^_;(<? A8L]R$/F93'90N&([(J
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ML06NH'I.[$UUNGAK"^X.;A!<[HT#BSH:03EM-1# [A<V&1\Y;I,RCX&M;>9
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M&_Q'%>#[Y!%S.-NHI_)A@W1EN%!8.+RDL=72WO\$3V+O=GL2>BJ\S(ILULX
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M*I;POW ']9EN*[Q8!Y5N-"C-X7TLZ@X.0)>+FZWP6%56C=1/^[ALJ011H":
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M*^S."J"* 5-Z7[:]-(ICW[IVR/(.+14$>9'(5O#'[VH_O61 J26Q/"G(%'9
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M&F>GJ^8CUF@VNBM.QMYAM]M;TXUWV-UZ[)XV3EN.=_<5N\?K=B9SN-UZW!Z
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MBM$HD2.AX6F0=#L.!F,X'H #7AC'M_1"). DLN&)"9@Y&5!Q,-&8R0&322:
M;&;60HP7D8Z]81C?,JN)X5 .<&_]&2TJ 5HQTA0"*DZ8?01\'1 @1W%"ZPU
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M42II4X 0-P+8K,\?@??)K"3$6(K=^J1@ B7>+'8W("6'1/Q=RJF73QGIO!%
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M16!.2 7*D&DFP.*F^*?FBKJ]SA+.@&6TKFX\)XM.>[<M/0 88D;9RS"^87_
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M7.&T-=[T><7*N2R*6<^IF'5O17*E:%>%\8$A,A3 -ZI:3EF!0)]Y:CKH98G
MI0YQ65#K(#A\+O&"OP:)AX6.$Z)IX#4,?=%R#9VDP: H]T+DEH=-[Q/%_Y2Q
M3($I>@HW1@$PJDBUEJJF5%3(\;]2JBL[Q&=\?2P2C<-0EYR00&?;*"-3?#(E
MJV5O=6^5P.>JM;F&N=WHGE3,V';C^&CI:U\H]WQIYRA.6N4<Q3%8LF3*FL?N
M-F4QV3^SZ&]^XU%,^ :ZZTOKPA*'B+AP8D^1:AHWGIK&C9>?OYU__G#YZ\<+
M[_SZ^N+;M7?^^9WWX>KJW>^7'S^NW;<1T7Y'QT95'_:$]?];HRGPDAREB2^+
MZP]/1UZ=YN:HRYPT8'.HX"O,-:-I"!(>?D+:*.Z"H.$82D$51EJ 9ZJ26U=<
MYZ!=N$P-#+Z(*PN#"=7(\@>+U? ;7#!](RQ+BM<N?9:T!/U3E?8D& C%2$HP
M]##G@';G8$#6M<@H,T_9#O2\BV4F" !\6W6(A@U6-QZDJFIQ@I1.4BV.I"J[
M,U<.+-/)U!.BV!O"E]3-(*S'JRX.2@JOX"J--J6KOK3?6UU9#<ZT),VF\C+J
MHD:0L5=*%WD)8K %#+[A30LLTN;NN.9"$5>?L/^,MF=4K8[0ZIM/6VR;>\V&
M867GJ;(,A&E"CUE8D8(Q 1#!S+\,M2U*U?)_PDH?"69=6"#N8_$L7S2)IOG^
MWA[Z,$_D103IK*QZ6R\V5/"NR/)FXT2BP19EXQ0<'DS]?*(T2+?-*?6&2AQS
M$@8WSS6-W,=0ECK&UL5YBH)@(D[CVH]BV@+Z]F.J!&2S%I@)G5^ZP8<LA[4#
M0.=4WQD-.)1;&P^KE,K47V4QCKRN=<#'?FM>-SD*@FV]^42J:)B*RS&-"L*/
MLK&%?XF! .Q2;<H7,7JB@\Z4(J8; >8>E!4.HP^6DL,@S+ $G6,RU)Q;N:""
M,MLDL&*ZN0B_B51V-P4@B30H0 RF'^PG)!EKXAB6IYXV[/S^,$C@B^4H2+M<
M7:# ):CT&G P34N%+=@6 <NOJ&>Z#C-AV)/.)/$P$>H $] (,JX**Z@(?L(K
M;7P!FN[DX$])D'XW-5+J&X)"B]J^SM*BP$_GNN=2AKH>S\ <PT4J6T]AL+'D
MY  6EV&4)T-(5$!?%+6HJ@G\-FVWJ/7"9N8JL4^I@"Q  4+A%IUN+X%^"::S
MT8"A6=V:GGPOK, VG%&4.]>Q7UF-E+Q 58)K+A$@M2A-3ERJ=#C>1=)/,*!"
MA OF-9(XGB * 2/E_5<[\N/NS M Q8.<C5LU58 N3AG[Y)8NA*79 @OHX K$
M Q;<\[=:KTFQ@F8'>#3X,B-05Z8J-0M[@&R=Y4'%CA/?F, R$%3>=RZMU*Y?
M<9;)%T:K OUNH[ 52RC156 X6LR:52=;!]!-:*X^A%^$=($4\4&ZEP!N3821
M?>010!3=5[7JSRTR4]4CB;K;UFZV.-)NK5:9BZ-MH#/]:+L%_[+NNV3W@)*I
M'V1O,N/;$,J<6Q)QIG"%1CD42P,)5[E,!RP+3AO$HXBP*&H-9G2ZP9 HW=_8
M5UOJ^?S?I>86X))U*!'J>E33U4VXNHF77#>Q:E >PTBVGV3KBA ;9?']"@P"
MCF7HFV$I^^H5?9P+:]='Z^O-$C F(\Q-F6!(Z6KO($@&^01K208R+:(CVJZJ
M479" 9_B+>@P]<UM??3CFU:$S%R;JG&"4A/(55<H3'G?'/ZU]5&2UT9*XYZN
M] RD2C"C-/Y(S2NRVPM8=P)))Q-$%:CG(\ZDE"4:MI34G/M[!?#!T+94>1*1
MT0V)%6K:4[)=GX_5S8ENY=Y$NWWT@,J:CLE(-.=);.FMF>^6.W\=\) JNS'.
MJW:K5S+'&A2>&XW0J,BDN:BJ$R*F6X^**BP:0N=12KNX(?'JM')K]\[]4XN+
M*%+EZB8B45Q=:!0CMTJGZ73O/$PE)T>6-^?RYN^1%*=03NS-:X!6Y12E/C"6
MAPTGGK_3Q#.^6!PH#V8N/Z3=H*;W</2W:M OO%=GQ^4S%#V@K'%KBUT(1H)Q
MG[!K%&R@R*=:+@-YNEPYJ./!BIP&X*&F( BT2V^6$Y6S* IZU3Y^8BJECSP%
M\5!V H6?'5M3(_*&%6]W@#$0^U9%07@+Z>Y\H#,)T2%\F:(N"ZNQ<3.!Z07A
M7"^7>GS$*Q]*T-&EX<LHDZ-$7:*O7"6]_')%#=WVM6ZE HK !D4Z#PIU49>L
MB5ZK<@GS 56ZQ8S%73;>%I+A$K!7-><&_ SJW87%G2<OI4=1_W*''>I)@H$]
M=0-.&2&DM.<*Z'3KQ%")-P[4"ZRA3,VE(]+E&=#9A&JKK(5T9;7)7;#20I,"
M^]*0U3,H-%MQ47$)K)$S8M4XS^>KS+Y-'1$[</6'L*XC+%S6F$W%.:A2&V/Q
M%+)EZX3_J@_-X,0QMSA67M^<J&XXCZC&%W@:0".30Q/^KMR7,F8N'\T,ERUW
M52N9ED5M^X"#YT63/EB7@G5[F\!>AI!4]_"*):]\M_(O5Y:Y)^70]F(W7W/H
M/(/>S5HJ^3<KM7VQ"7P4QGTL;+'ZS5@]J*;8N,:/E5E*77)*Q=3ES!G&3HH/
M8ER!9C,77X8%,M6D(\T.]8!G7<F7E)%1C!,F"YAJ>!O6Y2* GUT-W"_*IW>8
M6E=47S66TC[K+"O_K]VJ9=LG-)Z@M8FM%'SNY: Z#-W1NT4KCSON =D\=7=?
M%]Z]V?O<P/G2978NBL\Y$EI[,@)HT;CEFYE$KA8IW<?#\( V3Y5;7FX]5\#J
MD_2IFL)R54T'5,"$0.)**NYMT3@6NX=1FZW5OT+ \R4625 4!:?6#KB(#%&&
MHHH;G2YBI 7T\E!JN;_%C6J>1*ZE;N 0I'A%$CL=Z;;&(N3:"7#I.5FV9&L;
MM#4 %.F8,]5X#:,?B\3G_'(B54]4NIO)!^0_#^()M5FTNK[=AXTE8$P:UGO5
M[3Q<Q>ZPZ+\[[,R)"TEU4RJ=?LOM=-.\CYD.=7,0ZT!"F:G""-/G,N[_P2!*
MBRYO5)'.YN,=,J%,OYH<++_4&,X%WS6]WXM^'':60A5JXO6?H#!21##!A]2L
M7KT/_<F24*+$CVHQ%M!M_^J"?8D5%E[1Z_L  $2Q4XI6#F0P55<I]:5C\+*S
M>/ =*QDHA61W(J-^@R),7S>]W^ X(?=0-CT+2V?DCB]56-B5'G3?;"R2B1C(
MG$8M63<XL;$N1G^QJRV&1R/D?]^47L V(YDG],_25650-%-:#76<_DI1[\8L
MJ\.U?74M+[/-,HZ^ZCZO*6Q0CN,0/KVW=K]G0GY')N3W]>+ZV]??WG[[[>OE
MYP\-[_+SMXL/7\^_75Y];GC7%U_.^=\4!Z2(U-7UM^M'#@3JNHS,*-Z::SRN
MU,*56KA2B[M&71%7*3N[43/E9V_$6,U)Y^PC3S7<-NDCT#;<FY:,S?L@@W"H
MS,K#XDJ9P)'Y7ML<B89BFLI?]#_>@&,S#<7LER"B ]!+;\IPKQD^2-_C/RLV
M/3MKGO:ZR*E9 O_S]8<5$S>)B?^6^?-_.SEIGK:/%_ZYU6RO^;=>M[/6FW=M
M]K1YTCK;G;VVE]O/WPAGC#>@C!0\O+__U/VI$. LHSK3'UZ[3&TX?W!N,B71
MQ6,SW=GJ01C2' ?8YH[=$VM>G(+('8=MX5%_6NK1&K@P%SX/9.Z?,4B 0+GS
MPL_?*IW_'JK'L<:C),XC7VOVP4!*T.Q;P0[WZR Z]$>P'$>%N\A>"?@L@)QT
M"6*X%P95*KGO/:6'4&_!BQ[919X&@PW8EK<+X'U5A>'CG=\^=X*?W*J#=WNJ
MA.?) (!_71$0CI =(:]Z\*-.9TL)>67UI!S/75)/*Y6[E7-GJ_!Z!3(+39O.
M:M"M9>WM(_'3%0F\GHZ>5!B_; 1U5Q5!CXBAEV $?Y:9-Z*F<E%1/"S*S;8>
MT718BEIKP+@CU'K0F7.C5R263=IU^XZ<]D:0\V)L%<[$6,4K5,6G^LAA@P5.
MNSHK967PZE("9Z9L*X:.-FA(O@0SA?)%E"=R5LG*P,-<?[OS9CU?WMDGSR;E
M-X>@1[)1Z-LGNR!*2JGGI[!([GM/A<A4&KD+L//C')/2&@ O-HCZ^ #:;K;O
MGG37LQT>#T(;M@T=KSA>60XRO=::X<#-\PJIV+]1#='>57/=E4DW=5T-TZ3!
M:L0PUSW^0YA/9/:G\,ZQ^CZ!Q[QB]?I!,T4[3=5&)I"J1T8QOL?^C.Y>$!:[
M5GMM%M6U6)ZORFL_7GPX_^A]^7KU]N+BW>7G#T];.ZNWLJ>%?\N02NM^4A&1
M=WWQ%AZ[P8)SM6 0E4<0\+T5ACM.[.*R8L#2.)ARP?F7<0 (@Z]^_0&HIU81
M:</[^/%M@]X3 [K\2HU6$RQJUM.^IX!GG$_+C_'E'+H'%<;<Q77^; =\BZN\
M8YYQ<NOUL0\BD',62O^U=X!G4,2'I[RTWU'$]]K<,*".I=<X8HJO.E4@3/ 0
MD? #A-G"QS1LXVEVB/U0D8%P;&FS^F#Y5"),8PM9T3PSSLJM8Q8RWV9YSQJM
M\QALV-UV-EP]N6P-A[#K<NMO:5$S].DPP9--Q8PQ@!?YL/*-^51#7/X XDGQ
M?F$Q_%R,$LEHVY5!-W>6=7^.H\,KTX'@,J)K/@AD-=-T-XZX8BT[]D7!>]'Z
MD/M:R6[.J2(*"_@DT(\9=O!S;$-<&0CCRSXVCY"3()]@&V[5,3=5/#F4-)0R
M2--<]0^GY2.Z*]H']J/64CE?2L7+5-@6>VXT;11GUA"NZA;$A+](C(EW3<V%
M5VNX [4^]T=Z7A6P+WU9SQWRJ"7P?->G)$[30S4,<>:EMV*ZO[-^Y@A#C?8Y
MZAQ71_OT*JWUS,ULG!Y)S:!+2**[U FV1D0CV)#- F)15PZIGX8BQE>]RG2A
MX_:RW7>:WMRY="\R/$KKM#1GZ.3GAA[_4VWUS4O;H__H+B+/KT,+)%/3V>&1
M"$=CA!Y/D%3SWCT&/MZ:5SWTJ0N);SI0&X[CQN/OY$!.L!UXT7M<WS-!Q/2:
MIZ=J-&2SU?GY9=S--197N["XWE]^/O_\%DPM[_SKU_//'RX^77Q^W.N"NZ+3
M5U1X'U6CPHL?J.;S(!UK2?D.N'-/*4@?6LX=FD12(E57U51U$@1M08-PB^[O
M2@61W)J*0 W404_(6I0F,O:S0FG5=VS4GL;<B^#%W+U1DLW'G;)4[)TMWY/,
M&IU6L86UH9O(0A);HX#4T 2:B82B$9TN&L6WMXK129U'E#KOXP1^1*ECM0#@
M%->>DH\^<4W3@UN:O352CGRE1Y7%PV5+1*@>L_!&MU7E^!:."BE:,N!%5?59
M>O[$/%^U9(J&*,3L''FBO:5__<O1R1O\IE2V.Q@J Q6R"F,1:3%7C'(/ VZ-
M;35+>TT2#]<SRVD;:J@@9 QM RKJJ(:S?W>D-><]'B8YTM_$#[F_;:/HB!D>
MD2? #O10MZ'NJ$=TH EDIB; -L'H4/8_O&QW3"^14B+M42:Z,4XQG7Z1PB[:
MF*2F[[MR7-1^P5A/[6+BZK>Y(Q1U[C"1$<42W'_MAW9>2=7#@[<B\=/Z<W$#
M$![BU*=15_;&L6L@15!-]WIL/!/X@4@T$.(H+ UU"885>X5[5U%K?1'JJ:9\
M)QT-'$G"@3N]-;U?P1D>HMN-CG-@HY#,C-.3LIEASWHUSM+B-GQYM% <=4XM
M]VOQ,%=E*NE>?J5^WO@WU[7#=>UXR5T[[H1>$<WBQI;$QMB7@@)R@A1\5D1?
M+"G%O(V]ZFGT5)I:;HOF14PGU:UK9BA?1O.#WQ;LI8C+]&<ET^9NR8!]^ ?D
M&?7C^#L>0,T#)3D&&Z%LDFAHP0._67!:?I!D6<['6_"@26/5C$,PC<!*33;5
M#$,6D>@;W ^ WLG9RA#0AU>:R3I\72*Z_.Z"C:MNCMR'F/6(:5R;:D^G!D[[
M&H.ZXIY?A4.GK5>*XVD-G/$@3YIJQ[$$5'U9C(T-R5; SK QSI9@U4NJE @6
M/.F(^P\;)"I/&R#_!^ D]?5L4&U" /(TZ<Z/)[SGNT/NLZ8^?H#T6/H*A3'!
M0GFMYS&;W"Q:4CEV=3,1S,YQ\XSFM*L/I3S7^,[7N'\G#E16>R(K;3%,X81^
MS 8;'R$U2]1 R$S"M#Z+[]*Z/$\O7;0]_9P:/%_ <>'F*ENAR(B]'_REGA:K
MS$BIQV1C<'J@LLY]H &:B$P#0DM5 '-(Y5 40E]ORZ"2*>BUH:@JM>QMP.9R
MSBA%&64R/P4%,/*L%JD%]@U!6"Y"PD-?%_K-:C 49^@!S'4R'D-ZJD\GN0%,
M#U&)I/%=S?RIH8Q&X47;SQ8D1Z>@N!.-.2>K?Q+\X,J()")A#E*_1)%%^U(]
M.261V*$2]%"F XXZ((A?564&MK5>E$LH4(C7]H2P/++?UY8T]E7MOZY,H/P-
MQV?Y' 2AX)AF*!H'/QC(*:5/["(72K7@+= #%9A#M<PK?#@__V**3_2 1?CL
MX/4B5<<^WH%?VC_"!2@RHCH W=HX6NB^68X7E9.P*&!/"\>N!K&_MZKQ=TW_
M(+SN,C876 SE(4=!PMYB.7#.I51*Z/&$>ZD'_B*ST*SB,/@NL?4P()%D*X\Q
MUIXPV:2^Q(QO$'&/SKKMU)V .I'J@4K,:BJ* 9]0@P(TKE/XLQJZK45(K/?
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MET8Z^MW;6W:!OV"+";-S7?XN?6E<OXKYAA.GOQ-CG_9@JCU0G 6L7K!@@(+
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M4NB(?DE_AP-IYRE_FB5'\*Z($D_SSR$'#,6%GO C7M>"^S/;C9$YA#G4)XC
M;GZ[_XF"T)ZNY$>V.X'=OS9[[4&?8'O@W9KD8<Y%N7\9B-D"EA?[F>R!!^P'
MLOP9+,.Q/9=Q=X(?@1I./IIZ/C,[\ Q^![]T6C! L!06%O<ZJQ;C;"(L7_!
M,&\*;_>[\;LM!N\:YH]MAFM*GL)Y)SZ\[;+QZJ?O^\-K=F&_RHYCN\P5N%"
M\1^PA:5O6T!N-/Y@E Y_8:^]=^\YT4*NY*J?VQ<\#$^'L!)[L>16B,\ TO$V
MW#""+=%#$SNP ,*V&W&L8@YHH&3&PD8V+1,W"+\#T0!VV01 '7IL#B@2/@NX
M U--!**$)H!!O,AGOP@7T&W)57SRP[G'W@A_P4.@FAE^/HX"0'40L,BUPV!]
M)6KC^;EY&/KV.")"QT7D=S^3<P+G+Y8BI+)M!J];P+H<1ES&A*.6^%%$/JYF
M)==(N:-X52T61-8<W_[5GOG<Y<ZQBM#-9A:A$^NVV+^$R_\X8@E_LZ'WJUC.
M5Z%WM#8OS8;>^R!:PJ(U\/8!WMT*I*[FV_V =QNARM+@VPM\I(W?B 6\KL&W
M#_4Y7A R\<URP):YM\-5.W\"K*IC,*R!8T COK9#6()58>^E;L*=<A/@@ZD=
M-A<63W.2EK1[Z2,-3#/O(0V-_?VCD9EWCXP?Z<V"SQ"[1V2Q9\W\.$G88O2"
MN+>]*, WP'&)@D!,6FS)@=FX Q]ZTVD #@H,DW>2@/L<=%3$MZ5P X#J@QW.
ME96_S?<HX0Q[\M_?V9UQO]?C/:LSGDYZ5Y8Y-OI#S@W>'8GA=-@U_L\<FMWO
M-A/19I)Y<?(8E)('XI'=@EO$?2 .A Z@UAB=*#/< '& Q^>(24Q&2-A K$A\
M*\']2P\XY1)_8]:<NS,1Q-\2C%SPXH>F,;@.B &0_B,'>,G* 3"<<_(Z$9#,
MXD#= I@G MJ'_\&5Q#',SO6OX#S.!/)@,NB;=%'(*C?@7:X"F];PSG:Y:P&U
MPTK<B7)AX9DO:@GPR*>E\)4S3^OX(D+?BQDTD7:W^7W1/MYY_H(9G<O_I:49
MU\@Z;[_-[3$(AM&H;>##R#+TW/#R?]F48 A+^)6O6*]%<D%ZZE//<;P'BF&X
MP)@88P 7&\6-"@,\S&WPG^<<EC06@OC<!FYF4]];T(KJ#1=0GA-8[3X PKB$
M+Z:.H#- V37PY1+T&*TQGM\%BO?%T@,)![ ,0A^$=N0+!3[/LB+?E^O IZ>V
M#ZK]]P@$(A 8T1Z(<H2#+RP.7^'BYG80>CY:)\4(F0S&2$T0X#(!;5/<BHJD
MX&)2?2$"^)?'092%!ZN:1DY6-,?+4I3^]MO2 :3"Y"OVT0M%#$U@$WQJ+$"
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M,=(32+ES5?G#4YT:'V@L!]&_00<&[&TNIB?!UC5:SP&Y417*J2%@9)7)+LU
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M7/RES.(&ATN>S9XINYCU/,V:;9 X@SCSU'/ K:30$NE\U=> 0C^L%#9K]2/
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M_AMVNO"0E4'ZB6]+ >(N*+# &O(5+'LFX;!$&#S8DW"N I79%Q6Y=-)7^#@
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M;W0>L_!-NCN9343(;4=,&&S=BH+ ]EQ,J85S06FU2P]L[4O\+3TU*[^]]18
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M<"5NN5EXD<ON<,:$!^XR%A8MR/*](+A4ELJ*!0]\J83R8+LL_!SYH%("R74
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M\@S*Y6YRW=A&[MT4CL@%;//QU=,MROCDRH@T4:TQS M_\A15&24&!(&\T!,
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M27+ K;@3W^-K+L!?GCTKEF&#] (A@-*\$(:AMGQJ'Y&[=2=I6GH[F682V4@
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M5&Y*F@%W,_=^WZ"RL#P#+ ;372@UYY.VHF[.C3$OALPV\LLR@RWZ,)W?A8V
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M>DG [B!>9.D+V<[K]K(:O3*V#R0HB<4ZP;V@,7\NF9DR3"@*^;,Y,/6!BW[
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M^F48.?(@TOH/.PB.(7-%H_L8)Y:8VQ='W#[C*+\I#A=MI"^(RO5#8_=SRPP
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ML3]F;$IY<JI.]*%8"R\>"4RQME/_OF[SWQ1,@!$ VHHW$6PJ[R^<4(B>,P/
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ME6%<> S 1S+^DI]^::*2E'XKR&6Z5L4<96UZ726W[)[0+$!V3J@+UOC+IF_
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M%E"^ ",S=>'W'$F[(6*.89-8]P/#0/I)Y,@[0^H-TDU1OTCC?-/&Q_TFG,K
MA'<AWQV(Q33#PJ#<0@?!-D$H(7940.Q@ %BEDTF]VK5#[%]7>I1]0(Z0V#>N
MVS+COJ]:DRQ T%J0%$V6UI/+Q!/](^]?N<*H+]%)1S2 WMEWO9>-%C724SE'
M=7WIO.N^@W2=TGX 5%0Z"=!M_2+A,1+R*Q%-Y -B%.&L6&$;QR$H*4>JX[K&
M/=/P+DFM,.P/P**Q]W9=*@-F,X'#2F7;U^,$26,/&R2Y)+HV;O#)U%#<'\-,
MMQ")OJ:T1L;\^$A!5UO0BM]!,63*66B"-Z/*F7F&8-+E)=*;R^,[7/WN+=QR
MG:)S_2=%O!%SFG,M3@BGM@Z]S*0<P%6%N[V$,?"#,;8<%CX;HPR'M9-M8/O-
M$6GM84YWOQNT5ZH8=4-D[Z0E.3?@91I+XV"BI:H+:>&T*T,H/F!QN*IPP<E1
MP1!4U/9]@XTXK1AHNP]*[(RD2+^(*3FA,]C[V)>WO<XRH0 OJ?CCHC7#[^0R
M+]/]PNW$P@5FF=[BO5\U39[2BOWZ$?M09\:6:P0-5\'0\QR/2!1:1IR. V6E
M;GL+]6?&L6>L$]*D?C@HL./$)RQ3,_K%O0C=N0AU I*<O4I"8)(RW&"#X]HV
M*X2CY1QP:+,"6729T!:-&WA C2]KB#JO#S_,L%N#56_-$ AK,!27RJ\THCWT
M@@<J51NZWLQRZKH'<ONVJJ_QQ'D7$>@VH[-R<F@)2KG(<I1P<*&'?#P>(]\?
MF5@X]<R\QU81T^[)_<=O'><>1FO^*Y^!:UW""??CT[^,'M3X3T2"/QP]>_9H
MM !##LTJ9SIV.QEIA:;T', /RL(\Z4=M2/?LK:Z[WT_B:;#@2V"/:A'R23(:
MYU4#XE"DM6] 9?@D=4<"$[3;/IKT'BI:Z[\R$$5SYZ 8]A7M3;IB6E&A)V71
M&66%(YRF;8K&'\46<]O@>S&[<S'KED;A/,&T)0+3P^#%A.ILDQ%V5<BD7TZ;
MS1ECY4J$N=MQHX4PLU512,NQ7F<SU5H>EYPX[9V$!A8!#[C)%Y_7%OF6L4X#
M'C'QR"]AZ]J#(79#]HBG)R<<G% [L=J2>O*J[JY=MZ[+"YKUZ[.F7_&C2U<?
M7J#=FC95R51FQ#HU**B)[\'7C^)M?%74#B56L$8THTAZG$6*?_I DJ7B*B7H
MY';2R0@VH41&J8XHH4'PC^5-T.P]^GZ/OM])]/T=Z45$SD2%4Z5V)T)"0\_0
M@\:7LJ>$?NU"Z",=,S1.AADI3%%A(SG"G:.[D^&IU*%]&E0?^W/ISL^E6S0:
MM&9WQE-UF]:#:3W.6Y<@\!!P:FV[K+(2BZQ0A#R%I:/HGN;<$PPFHPR4I$@J
M'P7/N=]$:"&G%OM*6E6$GG8KOH^[V6ESHSUS^VZ(8L?B*;-Y1=W_.G291DHY
MP8:'H;9<D3UA<3VF9Y BW G-?OUW;?UME1?+JF0R,:34578A9N;'O@X1YX!T
M#Y9*C[Q6PB+I6/R@$:46^"^QJ5F.7:$.V/F:>MA]E'P7\>%@$[UHW?'J*%TJ
M#:"E&A4N7^^EZ^ZEBUUPZ\X-(@!+@ZRVZQXPW*C>*RQ(RHC 77I.BC!D4S*1
M]NMZ]^MJ*5HE&Z! .F_O;G5;66D690,!!>)84NW^#5L9;!;&C2;]_*[\KL(2
M4DH,.S7DBXVK-#Z,T.?4M040D 3(QUZL[EZLHN7? ) A1MRB8NN2KB.Z5G W
M:VH,N%_'NU_'+;6S!I_+AM5_S!]"?D.@/>H6VX&_4Z,:V9/N[_RZ,PV,='NY
M+KL+7S46F9Q4!\898_C-_>+>^>)V*,A(#Z^*65X47*WJMB)KZM_2 FNS2[ &
M#D>^7667:JB:)2X,76?2Z3Y@,_RC'=80O VM.L,&GI60-$C;3BF:389J93<V
MO'L8;(M0YN(@O(:L[7UM!]>[%]@[%]AN,B>;:,MVPXQXT;@=$IP1)C$HG!+0
M^V-I9P5!T=8,((C,#B91GJ0KC,12_1NFXK*Y8(WY]R7H%X)BY^7O*X$7:RR>
MSSCDQ<C2J00\@U<BX!A42OQ&D!\5R4F1YI(6G*:+5)BT%+F&+1\*CK>@>L'&
M1A1^<8 )K77A8 M+XU[:=D+:0DMF6+^KJEB!NB&4.RYJO*:]0(B5,.E!Z9J^
M1.[0OGA^MQ:]4PV;#"$*)+[J#R&X;IK]?86>;%XVJYKL#.3*J4$G1&#6+D,6
M@1=KOBM IBAP7Y%18_W62'Z"OE$EE(<Z$*P\RH1:A)G%_=D8!D9U5,7LP'[9
M"]^="Q^U!4'BHI*ZVADADF\X%77N"#WWN,T>W3I;<^).*6082U)D5YBJ)@AU
M5I,T6)':@CO82SQ_WUIF9P0B0KY1P<L2:V>8#?:FY#.>*$++-9B_R\JKO*Y*
MMHXWLY,9D;1K"IV,_DIT$*.3M$RG:3(Z72%>&B3R%QP> I)&QW,*]"IP^?27
MN%>XHE*C5FLQRC^Y,>^X*1^=:!>&5@#+*1+63@-%G]+ZA5Q5A/X6^-\21D'G
MO:+!$X<D4XQM!TK>"X;EY0P]#LFIUF:6QK_/#*38AZ!C?ATM0QKHW@_9C6WI
MNA%+@($8M])9)H5J&6Y;)"MK6MA8&6T?(\V)XQ:V"?9KNQ-KZZ)CH&\G<*-1
MC]H_6DZC*[LV<2FY>$-@ZJ<^=)C&IAJ*SNW,@<HN:*'=)*VS$8-5!8J:_R/F
MV>YV AB@/NTSB'>Z'W7"@.%1^\Y$WYO<=IIT@>DO[J8[L6#AX"BW;HNC107&
MA588B0QDG_(FXFD7($:0[%ZO+&^<$JH>#O=Y24_&SBF?" (7R#Z%/'ZG9.9?
MDSBJ<XXQF^:"*_H9)VB]_CBDVI,%K*V<545>^7 ^_%!0"E=<CTF6+QE.IMK/
M7@HZ"DRY<3KY&,(E8%\&Y&R$:#3FF(?)AFZ&3/^BK+8S['XQ04%$:?T=XWM\
M'Y/3KVKPV?<Z[OO1<0Q0I'(,92HS<LH-W27WK0;VQ0[?;;'#7A]LUP=3LLTS
M:[WK&9M9,6#(GB&KF[K/6A>" &B9AB2V@\*.! 6;>(S<=<8%K&6%]VC34H')
M[4^,.Y<0E_&7Z)4B&L5O&^08XZA2EV3L@:P[F"G".D=+KXMN+%X/*0%)W #2
M-5UDSKT:_DJ162=7@1,IX1@<,ZZ.B')5@FBS.EUQ@X%TO&HR":@%/B2VF:2+
MZ%7F^)%T#(X S3=T\AUY'<WY@\UA0=EK:(E5=3&]QHZ\$7<3#:I#*$6T'J\%
M"WI2$=A[],Y>=SP)63**+,+*Z67R#7KSN]6X +/NG.@AT).&>Z.Q#-!&N12,
ML(+@&*.;0DA4DKX=FBF)#.97&-AA,9FL:JI3#U14^WU_Y_M^H#?$.T83(2&I
M185A 8\I,DQPGQ/<:2!'%$E)00BFH>>%Q;L%>7(*IP=+Q'N4M$D.6H;^><S@
MY<>/CAZQL!B&@)Y('H5$J=V6+;)YWK"UV0UW>S509\CB;N?=5DK4;3%];COI
M(Y!YB9Y[SD7)LK?W<KQ#<JQEH YO3UD^%@A84[S4Q @Q^*S<ZE614>%?I,+F
MJWQ*IR*;/U2,(\_04XIR%VVSB15!S[BLA,%I7 COP]A01086-XVYS9CH:?&8
MJ(!6/[T>'B+FS.,15OL>%CLKO4YR9QE85/Z$78+W-5E'?&!$7,ZD8,)A#D_[
M"6E'1ND4.7X;*9#=+_2=+W1><*:VRZF+3AAGR AU,,OR=H2Y#L_RN]^ON[.,
MO@ S&5% :%I=LWK&?TTNY>0AH H>/0(^T39ZZU&S;MIL$7H5[5?T+E>42Z]@
MQ<Y@449'QX?J2;Y'&.UKS@^J&\DXZ@9]++CVT<'?#K]\\6Y8JL=/*79V1XMU
M'!JT>RE.Q]6J%==<4Z?L:\OO(3U@98EU1$E/!U6QSK7W%CS[.JVG!T55?:0?
MD="4D2IRRLTH3Y<537:-3D%_#1(Y_6ZS@ PW\2;2#Y8*)IK")O!A79R>!%_[
M I[[&_)'UQF/7IB)MHR?DB4??>>SKI/AAJ$4%CJCC&09-9>"V@8S5JB9RB;7
MLQYK1N<5)93<8O#G=+*=D9^%9:)M<SCZP NY^1-@I"DVK4#R,7,3L5< ?-DT
M@QEQ1@A%^"*TW6I)EY(1?I4W3"?%#]G^6O*_9HCRD:'B,R9Y/5DMFE;ZCV(0
M/@R'GBI"P5 @E RXC?_A'I@R=$@[*F"I+%;GX/=);I8\6K"[Z/,FZ4KX'%/V
M>N%\SAOBY0/CO<F)]*I2T!G9VT+[AC"F@"K4!3+[3:R^S;.0=):XR!LR$K'5
M9-T./C/ERF!A4=$4H@PW^W29HIX1_UDD"_\RSDRLD%@GT'_98,AS@<\)(B05
MJ_"@2- .]XFDP432_QA7TS7\SV6[*/[W_P=02P,$%     @ J(ZJ5.+5*4VB
M P  ! H  !0   !B:&,X+6LU-#(P,C)E>#(S+FAT;<U6;6_;-A#^OE]Q=;&U
M RQ+EFW9<5P#JU]:KXEC."Z"?1HHZ61QD42!I*.XOWY'4>ZRI>F*H=OJ#P0I
MWAV?Y[D[FI-G\ZO9[I?- E*=9[!Y__IB-8.6X[HWO9GKSG=S>+N[O(!^Q^O"
M3K)"<<U%P3+77:Q;T$JU+L>N6U55I^IUA-R[NZUK0O7=3 B%G5C'K>G$?*$1
M63S];O+,<6 NHD..A89((M,8PT'Q8@\W,:I;<)S&:B;*H^3[5(/O^3[<"'G+
M[YC=UUQG.#W%F;AV/7'K0R:AB(_32<SO@,>O6CR,L-\/^[$7!G&_&PQ8;SCP
MS[I)$ 48H3?XM4L@73*W/DH?,WS5RGGAI&C.'P_]4I]7/-;IN.MYW[=JN^DD
M$86FPR0YVZF-\3@2DWL*%@JM13X>4*SFBQ9EO=1XKQV6\7TQK@FW;.R3?R0R
M(<?/O?IW;G:<A.4\.XY?['B."M98P5;DK'C15I0D1Z'DB354_ ,2:#JD7E8-
M(8J3\0)/!+N^8;6X3WG(2>[>GPG]0RH190;E_\1E=K6^7JQW<+6$U7J^V"QH
MH.5V\69UO5ML%_-3M?\TFUV]7^]6ZS>P7&TOOS[S3U3(Q^KY]U3I_U65KD^J
MW""D*#$\0B0*93I0"] I B\B(4LAF>EOH'V)"1D6D=FJ+;:XYTHW!M>:VK;N
M8%HLA<SAVAG!R[50'>CU>H[?&WFC?MO._6 X"NR\>Q90>IKY,/"]03,/1OZ@
M_W$>^&=M8$5LU[U1<#8$IH#1B3'&;:@,"6!EF?&(A1G^""*!U^R@HA3>(LMT
M2I='7K*"DW2K(NJ8?7&0Q(HX:HCK2V>)H3PP>:1Z;]=73!OP/L)20\4I@D15
M8E0K9%Q%R0M#75@YC'XBXS92P@M61)QEE,]&&$6Z*9$P:8!33TG,:$>=](Y2
M5NQK;2,"*NR]:E!:A(84*-S;2#%7T4$I.HCLUT(CT'7(OQ!'VP"@4ZN4DSK&
MQ=@"5W#)CM#U+'6+SUS"#<!/4C(I,9N8)*0,O\,"E3*HN:EW^E\P<+04&8@[
ME ]B6%84OMW@H-PAD\JR("RS@Y2FG+8V0:>J&CGO.E^E(W\[*,V3XV=;\DOC
M?EM]7=]V/SSO#\]5/<)&\@@KRIE,Q4'A3(@22>F+B\TW G9)QZ0LAPV3M^TZ
MZ,\$$(]/)N3)//[7R!]VS!-B?KZT'KXG3ET_MJUWAX]>&">OIA*]/UQ82$U_
MT(]=_N91THSV?52_U*:_ U!+ 0(4 Q0    ( *B.JE27=CW*?J8  #KP"  0
M              "  0    !B:&,M,C R,C U,3 N:'1M4$L! A0#%     @
MJ(ZJ5'Y((1_!,@  F3(" !               ( !K*8  &)H8RTR,#(R,#4Q
M,"YX<V102P$"% ,4    " "HCJI4_ L$*O$\  "E=0( %
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M#P 1              "  :QD"@!B:&,U-#(R+65X.3DQ+FAT;5!+ 0(4 Q0
M   ( *B.JE3BU2E-H@,   0*   4              "  80"# !B:&,X+6LU
C-#(P,C)E>#(S+FAT;5!+!08     "0 ) $8"  !8!@P    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
